PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Dennis, M; Forbes, J; Graham, C; Hackett, M; Hankey, GJ; House, A; Lewis, S; Lundstrom, E; Sandercock, P; Mead, G; Anderson, R; Buchanan, D; Deary, A; Drever, J; Fraser, R; Innes, K; McGill, C; McGrath, A; Perry, D; Walker, P; Williams, C; Chun, Y; Dinsmore, L; Maschauer, E; Fraser, G; Lawrence, K; Shaw, A; Barugh, A; Mikhail, S; Blair, G; Hoeritzauer, I; Scott, M; Lewis, S; Williamson, J; Murray, V; French, R; Stott, D; Burgess, D; Emberson, J; Ellis, G; Tyrrell, P; Brady, M; MacLeod, M; Milligan, H; Sullivan, F; van Wijck, F; Watkins, C; Anderson, C; Morales, D; Langhorne, P; Reid, F; Rodgers, H				Dennis, Martin; Forbes, John; Graham, Catriona; Hackett, Maree; Hankey, Graeme J.; House, Allan; Lewis, Stephanie; Lundstrom, Erik; Sandercock, Peter; Mead, Gillian; Anderson, Rosemary; Buchanan, David; Deary, Ann; Drever, Jonathan; Fraser, Ruth; Innes, Karen; McGill, Connor; McGrath, Aileen; Perry, David; Walker, Pauli; Williams, Carol; Chun, Yvonne; Dinsmore, Lynn; Maschauer, Emma; Fraser, Greig; Lawrence, Katherine; Shaw, Alison; Barugh, Amanda; Mikhail, Shadia; Blair, Gordon; Hoeritzauer, Ingrid; Scott, Maggie; Lewis, Steff; Williamson, Judith; Murray, Veronica; French, Ray; Stott, David; Burgess, David; Emberson, Jonathan; Ellis, Graham; Tyrrell, Pippa; Brady, Marian; MacLeod, Malcolm; Milligan, Hazel; Sullivan, Frank; van Wijck, Frederike; Watkins, Caroline; Anderson, Craig; Morales, D.; Langhorne, Peter; Reid, Fiona; Rodgers, Helen		FOCUS Trial Collaboration	Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial	LANCET			English	Article							ISCHEMIC-STROKE; IMPACT SCALE; TELEPHONE; CLASSIFICATION; DEPRESSION; VALIDATION; VALIDITY; VERSION	Background Results of small trials indicate that fluoxetine might improve functional outcomes after stroke. The FOCUS trial aimed to provide a precise estimate of these effects. Methods FOCUS was a pragmatic, multicentre, parallel group, double-blind, randomised, placebo-controlled trial done at 103 hospitals in the UK. Patients were eligible if they were aged 18 years or older, had a clinical stroke diagnosis, were enrolled and randomly assigned between 2 days and 15 days after onset, and had focal neurological deficits. Patients were randomly allocated fluoxetine 20 mg or matching placebo orally once daily for 6 months via a web-based system by use of a minimisation algorithm. The primary outcome was functional status, measured with the modified Rankin Scale (mRS), at 6 months. Patients, carers, health-care staff, and the trial team were masked to treatment allocation. Functional status was assessed at 6 months and 12 months after randomisation. Patients were analysed according to their treatment allocation. This trial is registered with the ISRCTN registry, number ISRCTN83290762. Findings Between Sept 10,2012, and March 31,2017,3127 patients were recruited. 1564 patients were allocated fluoxetine and 1563 allocated placebo. mRS data at 6 months were available for 1553 (99.3%) patients in each treatment group. The distribution across mRS categories at 6 months was similar in the fluoxetine and placebo groups (common odds ratio adjusted for minimisation variables 0.951 [95% CI 0.839-1.079]; p=0.439). Patients allocated fluoxetine were less likely than those allocated placebo to develop new depression by 6 months (210 [13.43%] patients vs 269 [17.21%]; difference 3.78% [95% CI 1.26-6.30]; p=0.0033), but they had more bone fractures (45 [2.88%] vs 23 [1.47%]; difference 1.41% [95% CI 0.38-2.43]; p=0.0070). There were no significant differences in any other event at 6 or 12 months. Interpretation Fluoxetine 20 mg given daily for 6 months after acute stroke does not seem to improve functional outcomes. Although the treatment reduced the occurrence of depression, it increased the frequency of bone fractures. These results do not support the routine use of fluoxetine either for the prevention of post-stroke depression or to promote recovery of function. Copyright (C) 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.	[Dennis, Martin; Sandercock, Peter; Mead, Gillian] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH16 4SB, Midlothian, Scotland; [Forbes, John] Univ Limerick, Hlth Res Inst, Limerick, Ireland; [Graham, Catriona] Univ Edinburgh, Edinburgh Clin Res Facil, Edinburgh, Midlothian, Scotland; [Hackett, Maree] Univ New South Wales, George Inst Global Hlth, Kensington, NSW, Australia; [Hackett, Maree] Univ Cent Lancashire, Fac Hlth & Wellbeing, Preston, Lancs, England; [Hankey, Graeme J.] Univ Western Australia, Med Sch, Perth, WA, Australia; [House, Allan] Univ Leeds, Inst Hlth Sci, Leeds, W Yorkshire, England; [Lewis, Stephanie] Univ Edinburgh, Edinburgh Clin Trials Unit, Edinburgh, Midlothian, Scotland; [Lundstrom, Erik] Karolinska Inst, Dept Clin Neurosci, Solna, Sweden; [Lundstrom, Erik] Uppsala Univ, Dept Neurosci, Neurol, Uppsala, Sweden; [Brady, Marian] Glasgow Caledonian Univ, Glasgow, Scotland	University of Edinburgh; University of Limerick; University of Edinburgh; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; University of Central Lancashire; University of Western Australia; University of Leeds; University of Edinburgh; Karolinska Institutet; Uppsala University; Glasgow Caledonian University	Dennis, M (corresponding author), Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH16 4SB, Midlothian, Scotland.	martin.dennis@ed.ac.uk	Hackett, Maree L/O-8752-2016; Sullivan, Frank/L-8286-2019; Hankey, Graeme J/H-4968-2014; Lundstrom, Erik/AAQ-5629-2020; LundstrÃm, Erik/HGC-1847-2022; Brady, Marian C/ABA-4241-2021; Brady, marian C/AHB-3737-2022; Strain, William/Y-9858-2019; Macleod, Malcolm Robert/B-2052-2010	Hackett, Maree L/0000-0003-1211-9087; Sullivan, Frank/0000-0002-6623-4964; Hankey, Graeme J/0000-0002-6044-7328; Lundstrom, Erik/0000-0002-5313-9052; Brady, marian C/0000-0002-4589-7021; Strain, William/0000-0002-6826-418X; SKOTNICKA, AGNIESZKA/0000-0003-3452-8754; Bell, Simon/0000-0002-2781-6478; Hoeritzauer, Anne Ingrid/0000-0001-6742-7197; zhang, liqun/0000-0001-6983-7915; Nagaratnam, Kiruba/0000-0003-1455-2773; Emsley, Hedley/0000-0003-0129-4488; HAQUE, MOHAMMAD/0000-0003-0852-6368; Macleod, Mary Joan/0000-0003-2115-8184; Chatterjee, Kausik/0000-0002-3093-1469; Cohen, David/0000-0001-7318-8567; Majid, Arshad/0000-0002-1144-039X; Ford, Gary A/0000-0001-8719-4968; Randall, Marc/0000-0002-3196-182X; Marigold, Richard/0000-0003-1924-1616; Macleod, Malcolm Robert/0000-0001-9187-9839; James, Martin/0000-0001-6065-6018; House, Allan/0000-0001-8721-8026	UK Stroke Association [TSA 2011101]; NIHR Health Technology Assessment Programme [13/04/30]; NIHR; NHS Research Scotland (NRS)	UK Stroke Association; NIHR Health Technology Assessment Programme(National Institute for Health Research (NIHR)); NIHR(National Institute for Health Research (NIHR)); NHS Research Scotland (NRS)	The start-up phase of the FOCUS trial was funded by the UK Stroke Association (TSA 2011101) and the main phase funded by the NIHR Health Technology Assessment Programme (project number 13/04/30). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the NIHR Health Technology Assessment Programme. Recruitment and follow-up was supported by the NIHR-funded UK Stroke Research Network and the Scottish Stroke Research Network, which was supported by NHS Research Scotland (NRS).	ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Altman DG, 2005, BRIT MED J, V330, P843, DOI 10.1136/bmj.330.7495.843; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Bray BD, 2016, LANCET, V388, P170, DOI 10.1016/S0140-6736(16)30443-3; Bruno A, 2011, STROKE, V42, P2276, DOI 10.1161/STROKEAHA.111.613273; Bruno A, 2010, STROKE, V41, P1048, DOI 10.1161/STROKEAHA.109.571562; Chollet F, 2011, LANCET NEUROL, V10, P123, DOI 10.1016/S1474-4422(10)70314-8; Counsell C, 2002, STROKE, V33, P1041, DOI 10.1161/hs0402.105909; Dennis M, 2012, STROKE, V43, P851, DOI 10.1161/STROKEAHA.111.639708; Duncan P, 2005, MED CARE, V43, P507, DOI 10.1097/01.mlr.0000160421.42858.de; Duncan PW, 2003, ARCH PHYS MED REHAB, V84, P950, DOI 10.1016/S0003-9993(03)00035-2; Duncan PW, 2002, CLIN REHABIL, V16, P493, DOI 10.1191/0269215502cr510oa; Duncan PW, 1999, STROKE, V30, P2131, DOI 10.1161/01.STR.30.10.2131; Graham C, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2385-6; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Hoeymans Nancy, 2004, Health Qual Life Outcomes, V2, P23; Kwon S, 2006, QUAL LIFE RES, V15, P367, DOI 10.1007/s11136-005-2292-2; McCabe CJ, 1996, BRIT J PSYCHIAT, V169, P517, DOI 10.1192/bjp.169.4.516; Mead G, 2007, STROKE, V38, P2090, DOI 10.1161/STROKEAHA.106.478941; Mead G, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0864-1; Mead GE, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009286.pub2; Mead GE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016988; National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995, NEW ENGL J MED, V333, P1581; NHS National Services Scotland, 2017, SCOTT STROK IMPR PRO; Salter KL, 2013, J STROKE CEREBROVASC, V22, P1243, DOI 10.1016/j.jstrokecerebrovasdis.2012.03.013; Sansone Randy A, 2012, Innov Clin Neurosci, V9, P41; Schambra H, 2015, PM&R, V7, P1294, DOI 10.1016/j.pmrj.2015.11.007; Tsivgoulis G, 2017, THER ADV NEUROL DISO, V10, P241, DOI 10.1177/1756285617699588; Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]; Wadhwa Ravisha, 2017, Osteoporos Sarcopenia, V3, P75, DOI 10.1016/j.afos.2017.05.002; White R, 2010, HDB DRUG ADM VIA ENT; Whooley MA, 1997, J GEN INTERN MED, V12, P439, DOI 10.1046/j.1525-1497.1997.00076.x	32	153	155	6	51	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 19	2019	393	10168					265	274		10.1016/S0140-6736(18)32823-X	http://dx.doi.org/10.1016/S0140-6736(18)32823-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH8RN	30528472	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000456000000029
J	Woyach, JA; Ruppert, AS; Heerema, NA; Zhao, W; Booth, AM; Ding, W; Bartlett, NL; Brander, DM; Barr, PM; Rogers, KA; Parikh, SA; Coutre, S; Hurria, A; Brown, JR; Lozanski, G; Blachly, JS; Ozer, HG; Major-Elechi, B; Fruth, B; Nattam, S; Larson, RA; Erba, H; Litzow, M; Owen, C; Kuzma, C; Abramson, JS; Little, RF; Smith, SE; Stone, RM; Mandrekar, SJ; Byrd, JC				Woyach, J. A.; Ruppert, A. S.; Heerema, N. A.; Zhao, W.; Booth, A. M.; Ding, W.; Bartlett, N. L.; Brander, D. M.; Barr, P. M.; Rogers, K. A.; Parikh, S. A.; Coutre, S.; Hurria, A.; Brown, J. R.; Lozanski, G.; Blachly, J. S.; Ozer, H. G.; Major-Elechi, B.; Fruth, B.; Nattam, S.; Larson, R. A.; Erba, H.; Litzow, M.; Owen, C.; Kuzma, C.; Abramson, J. S.; Little, R. F.; Smith, S. E.; Stone, R. M.; Mandrekar, S. J.; Byrd, J. C.			Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; BRUTONS TYROSINE KINASE; OPEN-LABEL; RITUXIMAB; BTK; CYCLOPHOSPHAMIDE; FLUDARABINE; MIGRATION; SURVIVAL; ADHESION	BACKGROUND Ibrutinib has been approved by the Food and Drug Administration for the treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has not been compared with chemoimmunotherapy. We conducted a phase 3 trial to evaluate the efficacy of ibrutinib, either alone or in combination with rituximab, relative to chemoimmunotherapy. METHODS Patients 65 years of age or older who had untreated CLL were randomly assigned to receive bendamustine plus rituximab, ibrutinib, or ibrutinib plus rituximab. The primary end point was progression-free survival. The Alliance Data and Safety Monitoring Board made the decision to release the data after the protocol-specified efficacy threshold had been met. RESULTS A total of 183 patients were assigned to receive bendamustine plus rituximab, 182 to receive ibrutinib, and 182 to receive ibrutinib plus rituximab. Median progression-free survival was reached only with bendamustine plus rituximab. The estimated percentage of patients with progression-free survival at 2 years was 74% with benda-mustine plus rituximab and was higher with ibrutinib alone (87%; hazard ratio for disease progression or death, 0.39; 95% confidence interval [CI], 0.26 to 0.58; P<0.001) and with ibrutinib plus rituximab (88%; hazard ratio, 0.38; 95% CI, 0.25 to 0.59; P<0.001). There was no significant difference between the ibrutinib-plus-rituximab group and the ibrutinib group with regard to progression-free survival (hazard ratio, 1.00; 95% CI, 0.62 to 1.62; P = 0.49). With a median follow-up of 38 months, there was no significant difference among the three treatment groups with regard to overall survival. The rate of grade 3, 4, or 5 hematologic adverse events was higher with bendamustine plus rituximab (61%) than with ibrutinib or ibrutinib plus rituximab (41% and 39%, respectively), whereas the rate of grade 3, 4, or 5 non-hematologic adverse events was lower with bendamustine plus rituximab (63%) than with the ibrutinib-containing regimens (74% with each regimen). CONCLUSIONS Among older patients with untreated CLL, treatment with ibrutinib was superior to treatment with bendamustine plus rituximab with regard to progression-free survival. There was no significant difference between ibrutinib and ibrutinib plus rituximab with regard to progression-free survival.	[Woyach, J. A.; Ruppert, A. S.; Heerema, N. A.; Zhao, W.; Rogers, K. A.; Lozanski, G.; Blachly, J. S.; Ozer, H. G.; Byrd, J. C.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Ruppert, A. S.; Booth, A. M.; Major-Elechi, B.; Fruth, B.; Mandrekar, S. J.] Alliance Stat & Data Ctr, Rochester, MN USA; [Ding, W.; Parikh, S. A.; Litzow, M.] Mayo Clin, Rochester, MN USA; [Bartlett, N. L.] Washington Univ, Sch Med, St Louis, MO USA; [Brander, D. M.; Erba, H.] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA; [Kuzma, C.] First Hlth Carolinas Canc Ctr, Pinehurst, NC USA; [Barr, P. M.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA; [Coutre, S.] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Hurria, A.] City Hope Comprehens Canc Ctr, Duarte, CA USA; [Brown, J. R.; Stone, R. M.] Dana Farber Partners CancerCare, Boston, MA USA; [Abramson, J. S.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA; [Nattam, S.] Ft Wayne Med Oncol & Hematol, Ft Wayne, IN USA; [Larson, R. A.] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA; [Smith, S. E.] Loyola Univ, Chicago, IL 60611 USA; [Owen, C.] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada; [Little, R. F.] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Mayo Clinic; Washington University (WUSTL); Duke University; University of Rochester; Stanford University; City of Hope; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; Robert H. Lurie Comprehensive Cancer Center; University of Chicago; Loyola University Chicago; Tom Baker Cancer Clinic; University of Calgary; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Woyach, JA (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Div Hematol, Columbus, OH 43212 USA.	jennifer.woyach@osumc.edu	Barr, Paul/V-2574-2019; Larson, Richard A./AAE-7223-2019	Barr, Paul/0000-0002-9733-401X; Larson, Richard A./0000-0001-9168-3203; Bartlett, Nancy/0000-0001-8470-394X; Ding, Wei/0000-0001-9811-4601; Coutre, Steven/0000-0001-8420-5748	National Cancer Institute (NCI) of the National Institutes of Health [U10CA180821, U10CA180882, UG1CA189823, U10CA180790, U10CA180833, U10CA180836, U10CA180850, U10CA180857, U10CA180867, P30CA033572, UG1CA189858, U10CA180820, U10CA180888, K23CA178183, R01CA197870, R35CA197734]; Pharmacyclics; NATIONAL CANCER INSTITUTE [U10CA180863, UG1CA189823, U10CA180820, U10CA180867, U10CA180836, R01CA197870, U10CA180821, U10CA180888, U24CA196171, K23CA178183, R01CA183444, U10CA180790, R35CA197734, P30CA016058, P30CA033572, U10CA180857, U10CA180882, UG1CA232760, U10CA180850, U10CA180833, UG1CA189858] Funding Source: NIH RePORTER	National Cancer Institute (NCI) of the National Institutes of Health; Pharmacyclics; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by the following awards from the National Cancer Institute (NCI) of the National Institutes of Health: U10CA180821 and U10CA180882, to the Alliance for Clinical Trials in Oncology (Alliance); UG1CA189823, to the Alliance NCI Community Oncology Research Program Research Base; U10CA180790, U10CA180833, U10CA180836, U10CA180850, U10CA180857, U10CA180867, P30CA033572, UG1CA189858, U10CA180820, U10CA180790, and U10CA180888, to the Eastern Cooperative Oncology Group and Southwest Oncology Group; K23CA178183, to Dr. Woyach; R01CA197870, to Drs. Woyach and Byrd; and R35CA197734, to Dr. Byrd. The trial was supported in part by Pharmacyclics (a subsidiary of AbbVie).	Barr PM, 2018, HAEMATOLOGICA, V103, P1502, DOI 10.3324/haematol.2018.192328; Burger JA, 2015, NEW ENGL J MED, V373, P2425, DOI 10.1056/NEJMoa1509388; Byrd JC, 2016, NEW ENGL J MED, V374, P323, DOI 10.1056/NEJMoa1509981; Claus R, 2012, J CLIN ONCOL, V30, P2483, DOI 10.1200/JCO.2011.39.3090; de Gorter DJJ, 2007, IMMUNITY, V26, P93, DOI 10.1016/j.immuni.2006.11.012; de Rooij MFM, 2012, BLOOD, V119, P2590, DOI 10.1182/blood-2011-11-390989; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Eichhorst B, 2016, LANCET ONCOL, V17, P928, DOI 10.1016/S1470-2045(16)30051-1; Goede V, 2014, NEW ENGL J MED, V370, P1101, DOI 10.1056/NEJMoa1313984; Guha A, 2018, J AM COLL CARDIOL, V72, P697, DOI 10.1016/j.jacc.2018.06.002; Haferlach C, 2007, LEUKEMIA, V21, P2442, DOI 10.1038/sj.leu.2404935; Hallek M, 2010, LANCET, V376, P1164, DOI 10.1016/S0140-6736(10)61381-5; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Herman SEM, 2015, CLIN CANCER RES, V21, P4642, DOI 10.1158/1078-0432.CCR-15-0781; Herman SEM, 2014, BLOOD, V123, P3286, DOI 10.1182/blood-2014-02-548610; Herman SEM, 2011, BLOOD, V117, P6287, DOI 10.1182/blood-2011-01-328484; Kil LP, 2013, AM J BLOOD RES, V3, P71; Leong DP, 2016, BLOOD, V128, P138, DOI 10.1182/blood-2016-05-712828; O'Brien S, 2018, BLOOD, V131, P1910, DOI 10.1182/blood-2017-10-810044; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Ponader S, 2012, BLOOD, V119, P1182, DOI 10.1182/blood-2011-10-386417; Rai KR., 1987, CHRONIC LYMPHOCYTIC, P253; ROGERS KA, 2017, BLOOD S1, V130; Seymour JF, 2018, NEW ENGL J MED, V378, P1107, DOI 10.1056/NEJMoa1713976; Tam C, 2015, BLOOD, V126; Woyach JA, 2014, BLOOD, V123, P1810, DOI 10.1182/blood-2013-09-527853; Woyach JA, 2014, BLOOD, V123, P1207, DOI 10.1182/blood-2013-07-515361	27	503	508	0	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 27	2018	379	26					2517	2528		10.1056/NEJMoa1812836	http://dx.doi.org/10.1056/NEJMoa1812836			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF6MK	30501481	Bronze, Green Accepted			2023-01-03	WOS:000454351100007
J	Lu, C; Lei, Z; Wu, HB; Lu, HD				Lu, Chi; Lei, Zhang; Wu, Hongbin; Lu, Hongda			Evaluating risk factors of radiation pneumonitis after stereotactic body radiation therapy in lung tumor: Meta-analysis of 9 observational studies	PLOS ONE			English	Article							ELDERLY-PATIENTS; RADIOTHERAPY; CANCER; TOXICITY; CARCINOMA	Background In this study, we assessed the association of SBRT (stereotactic body radiotherapy) dose and volume with radiation pneumonitis (RP) risk in lung tumor. Methods Relevant articles were identified up to April 2018, using following databases; Medline, EMBASE, Cochrane Library, and China National Knowledge Infrastructure (CNKI). The pooled OR (odds ratio) with 95% CI (confidence interval) data [mean +/- SD (standard deviation)] obtained from different studies was analyzed by statistical analysis using a fixed-effects model or a random-effects model when appropriate. Results The analysis was based on nine observational studies, which were identified based on the study selection criteria. Between RP and non-RP patients, no difference was observed based on age, but significant differences were observed based on planning target volume (PTV), mean ipsilateral lung dose (MLD), total MLD, and V5, V10, V20 and V40 (the percentage of lung volume exceeding 5, 10, 20 and 40 Gy). In addition, PTV >145 cm(3), total MLD >= 4.7 Gy, V5 >= 26.8%, V10 >12% and V20 >= 5.8 were associated with RP risk. Overall, the grade assessments of V5 and V20 revealed moderate quality evidence. Conclusion The present study indicated V5 and V20 as major risk factors for RP after SBRT treatment in lung tumor. In addition, it was observed that lung DVH (Dose Volume Histogram) patterns should be assessed more carefully, while predicting RP incidence after SBRT.	[Lu, Chi; Lei, Zhang; Wu, Hongbin; Lu, Hongda] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Dept Oncol, Wuhan, Hubei, Peoples R China; [Lu, Chi; Lei, Zhang; Wu, Hongbin; Lu, Hongda] Canc Res Inst Wuhan, Wuhan, Hubei, Peoples R China	Huazhong University of Science & Technology	Lu, HD (corresponding author), Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Dept Oncol, Wuhan, Hubei, Peoples R China.; Lu, HD (corresponding author), Canc Res Inst Wuhan, Wuhan, Hubei, Peoples R China.	phlonda66@hotmail.com	lu, chi/AAE-5659-2019		Foundation of Health and Family Planning Commission of Wuhan Municipality, China [WX13B02]; National Natural Science Foundation of China [81372931]	Foundation of Health and Family Planning Commission of Wuhan Municipality, China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was funded by Grant WX13B02 from the Foundation of Health and Family Planning Commission of Wuhan Municipality, China, and by Grant 81372931 from the National Natural Science Foundation of China.	Aibe N, 2014, J RADIAT RES, V55, P575, DOI 10.1093/jrr/rrt146; Barriger RB, 2012, INT J RADIAT ONCOL, V82, P457, DOI 10.1016/j.ijrobp.2010.08.056; Bi N, 2016, INT J RADIAT ONCOL, V95, P1378, DOI 10.1016/j.ijrobp.2016.04.016; Bledsoe TJ, 2017, CLIN CHEST MED, V38, P201, DOI 10.1016/j.ccm.2016.12.004; BLOMGREN H, 1995, ACTA ONCOL, V34, P861, DOI 10.3109/02841869509127197; Bongers EM, 2013, RADIOTHER ONCOL, V109, P95, DOI 10.1016/j.radonc.2013.10.011; Borst GR, 2009, RADIOTHER ONCOL, V91, P307, DOI 10.1016/j.radonc.2009.02.003; Ettinger DS, 2017, J NATL COMPR CANC NE, V15, P504, DOI 10.6004/jnccn.2017.0050; Guckenberger M, 2010, RADIOTHER ONCOL, V97, P65, DOI 10.1016/j.radonc.2010.04.027; Julian P.T.H., 2011, MANUAL COCHRANE REVI; Matsuo Y, 2012, INT J RADIAT ONCOL, V83, pE545, DOI 10.1016/j.ijrobp.2012.01.018; Mirimanoff RO, 2015, CHIN CLIN ONCOL, V4, DOI 10.3978/j.issn.2304-3865.2015.11.02; More JM, 2014, J THORAC ONCOL, V9, P957, DOI 10.1097/JTO.0000000000000182; Nakamura M, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20160560; Nanda RH, 2015, CANCER-AM CANCER SOC, V121, P4222, DOI 10.1002/cncr.29640; Nishimura S, 2014, J THORAC ONCOL, V9, P1370, DOI 10.1097/JTO.0000000000000260; Ohashi T, 2005, INT J RADIAT ONCOL, V62, P1003, DOI 10.1016/j.ijrobp.2004.12.050; Ong CL, 2010, RADIOTHER ONCOL, V97, P431, DOI 10.1016/j.radonc.2010.10.003; Onimaru R, 2015, RADIOTHER ONCOL, V116, P276, DOI 10.1016/j.radonc.2015.07.008; Onishi H, 2004, CANCER-AM CANCER SOC, V101, P1623, DOI 10.1002/cncr.20539; Palma DA, 2012, INT J RADIAT ONCOL, V84, P1058, DOI 10.1016/j.ijrobp.2012.07.2353; Ricardi U, 2009, ACTA ONCOL, V48, P571, DOI 10.1080/02841860802520821; Roach MC, 2015, J THORAC ONCOL, V10, P1261, DOI 10.1097/JTO.0000000000000610; Rowe BP, 2012, J THORAC ONCOL, V7, P1394, DOI 10.1097/JTO.0b013e3182614bf3; Stauder MC, 2011, RADIOTHER ONCOL, V99, P166, DOI 10.1016/j.radonc.2011.04.002; Yamashita H, 2007, RADIAT ONCOL, V2, DOI 10.1186/1748-717X-2-21; Zhao J, 2016, INT J RADIAT ONCOL, V95, P1357, DOI 10.1016/j.ijrobp.2016.03.024	27	14	17	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 6	2018	13	12							e0208637	10.1371/journal.pone.0208637	http://dx.doi.org/10.1371/journal.pone.0208637			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD1YF	30521600	gold, Green Published, Green Submitted			2023-01-03	WOS:000452307600100
J	Wang, YH; Wiesnoski, DH; Helmink, BA; Gopalakrishnan, V; Choi, K; DuPont, HL; Jiang, ZD; Abu-Sbeih, H; Sanchez, CA; Chang, CC; Parra, ER; Francisco-Cruz, A; Raju, GS; Stroehlein, JR; Campbell, MT; Gao, JJ; Subudhi, SK; Maru, DM; Blando, JM; Lazar, AJ; Allison, JP; Sharma, P; Tetzlaff, MT; Wargo, JA; Jenq, RR				Wang, Yinghong; Wiesnoski, Diana H.; Helmink, Beth A.; Gopalakrishnan, Vancheswaran; Choi, Kati; DuPont, Hebert L.; Jiang, Zhi-Dong; Abu-Sbeih, Hamzah; Sanchez, Christopher A.; Chang, Chia-Chi; Parra, Edwin R.; Francisco-Cruz, Alejandro; Raju, Gottumukkala S.; Stroehlein, John R.; Campbell, Matthew T.; Gao, Jianjun; Subudhi, Sumit K.; Maru, Dipen M.; Blando, Jorge M.; Lazar, Alexander J.; Allison, James P.; Sharma, Padmanee; Tetzlaff, Michael T.; Wargo, Jennifer A.; Jenq, Robert R.			Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis	NATURE MEDICINE			English	Article							CYTOTOXIC T-CELLS; ADVERSE EVENTS; BLOCKADE; IMMUNOTHERAPY; IPILIMUMAB; CANCER	We report the first case series of immune checkpoint inhibitors (ICI)-associated colitis successfully treated with fecal microbiota transplantation, with reconstitution of the gut microbiome and a relative increase in the proportion of regulatory T-cells within the colonic mucosa. These preliminary data provide evidence that modulation of the gut microbiome may abrogate ICI-associated colitis.	[Wang, Yinghong; Abu-Sbeih, Hamzah; Raju, Gottumukkala S.; Stroehlein, John R.] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Div Internal Med, Houston, TX 77030 USA; [Wiesnoski, Diana H.; Sanchez, Christopher A.; Chang, Chia-Chi; Wargo, Jennifer A.; Jenq, Robert R.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Div Canc Med, Houston, TX 77030 USA; [Helmink, Beth A.; Gopalakrishnan, Vancheswaran; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Div Surg, Dept Surg Oncol, Houston, TX 77030 USA; [Choi, Kati] Baylor Coll Med, Dept Internal Med, Houston, TX 77030 USA; [DuPont, Hebert L.; Jiang, Zhi-Dong] Univ Texas Houston, Ctr Infect Dis, Sch Publ Hlth, Houston, TX USA; [DuPont, Hebert L.] Kelsey Res Fdn, Houston, TX USA; [Parra, Edwin R.; Francisco-Cruz, Alejandro; Tetzlaff, Michael T.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Div Pathol Lab Med, Houston, TX 77030 USA; [Campbell, Matthew T.; Gao, Jianjun; Subudhi, Sumit K.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Div Canc Med, Houston, TX 77030 USA; [Maru, Dipen M.; Lazar, Alexander J.; Tetzlaff, Michael T.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Div Pathol Lab Med, Houston, TX 77030 USA; [Blando, Jorge M.; Allison, James P.; Sharma, Padmanee] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Div Basic Sci Res, Houston, TX 77030 USA; [Jenq, Robert R.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Wang, YH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Div Internal Med, Houston, TX 77030 USA.	ywang59@mdanderson.org	DuPont, Herbert/AAH-6776-2021; Lazar, Alexander J/A-3416-2008; Abu-Sbeih, Hamzah/M-8472-2018; Francisco-Cruz, Alejandro/AIC-9273-2022; Gopalakrishnan, Vancheswaran/S-9550-2019	Lazar, Alexander J/0000-0002-6395-4499; Abu-Sbeih, Hamzah/0000-0003-3577-6741; Gopalakrishnan, Vancheswaran/0000-0002-8704-035X; Helmink, Beth/0000-0002-8206-0351	MD Anderson Cancer Center's Melanoma Moon Shot Program [710499-80-111538-19]; American Association for Cancer Research Stand Up to Cancer [SU2C-AACR-IRG-19-17]; National Institutes of Health [R01 CA219896-01A1, R01 HL124112]; Cancer Prevention and Research Institute of Texas [RR160089]; NATIONAL CANCER INSTITUTE [R01CA219896, T32CA009599] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL124112] Funding Source: NIH RePORTER	MD Anderson Cancer Center's Melanoma Moon Shot Program; American Association for Cancer Research Stand Up to Cancer; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We are grateful for the following funding support: Andrew Sabin Family Fellows Program (private donation to J.A.W); MD Anderson Cancer Center's Melanoma Moon Shot Program (grant no. 710499-80-111538-19, to J.A.W.); American Association for Cancer Research Stand Up to Cancer (grant no. SU2C-AACR-IRG-19-17, to J.A.W.); National Institutes of Health (grant no. R01 CA219896-01A1, to J.A.W.); National Institutes of Health (grant no. R01 HL124112, to R.R.J.); Cancer Prevention and Research Institute of Texas (grant no. RR160089, to R.R.J.).	Abu-Sbeih H., 2018, J IMMUNOTHER CANCER, V6, P1; Beck KE, 2006, J CLIN ONCOL, V24, P2283, DOI 10.1200/JCO.2005.04.5716; Bertrand A, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0455-8; Borody TJ, 2012, NAT REV GASTRO HEPAT, V9, P88, DOI 10.1038/nrgastro.2011.244; Caporaso JG, 2012, ISME J, V6, P1621, DOI 10.1038/ismej.2012.8; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Chaput N, 2017, ANN ONCOL, V28, P1368, DOI 10.1093/annonc/mdx108; Chen JH, 2017, AM J SURG PATHOL, V41, P643, DOI 10.1097/PAS.0000000000000829; Cramer Peyton, 2017, Curr Gastroenterol Rep, V19, P3, DOI 10.1007/s11894-017-0540-6; Dadu R, 2016, CANCER J, V22, P121, DOI 10.1097/PPO.0000000000000186; Dubin K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10391; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Horvat TZ, 2015, J CLIN ONCOL, V33, P3193, DOI 10.1200/JCO.2015.60.8448; Jenq RR, 2015, BIOL BLOOD MARROW TR, V21, P1373, DOI 10.1016/j.bbmt.2015.04.016; Johnston RL, 2009, DIGEST DIS SCI, V54, P2538, DOI 10.1007/s10620-008-0641-z; Kappeler A, 2000, HISTOL HISTOPATHOL, V15, P167, DOI 10.14670/HH-15.167; Litvak Y, 2017, CURR OPIN MICROBIOL, V39, P1, DOI 10.1016/j.mib.2017.07.003; Lozupone C, 2011, ISME J, V5, P169, DOI 10.1038/ismej.2010.133; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016; Minor DR, 2009, CANCER BIOTHER RADIO, V24, P321, DOI 10.1089/cbr.2008.0607; Nancey S, 2006, GASTROENTEROLOGY, V131, P485, DOI 10.1053/j.gastro.2006.05.018; Png CW, 2010, AM J GASTROENTEROL, V105, P2420, DOI 10.1038/ajg.2010.281; Rognes T, 2016, PEERJ, V4, DOI 10.7717/peerj.2584; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Stack EC, 2014, METHODS, V70, P46, DOI 10.1016/j.ymeth.2014.08.016; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Wang F, 2018, P NATL ACAD SCI USA, V115, P157, DOI 10.1073/pnas.1712901115	30	327	344	12	103	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2018	24	12					1804	+		10.1038/s41591-018-0238-9	http://dx.doi.org/10.1038/s41591-018-0238-9			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	HD3DA	30420754	Green Accepted			2023-01-03	WOS:000452392200007
J	Silva-Cardoso, L; Dias, FA; Fampa, P; Pereira, MG; Atella, GC				Silva-Cardoso, Livia; Dias, Felipe A.; Fampa, Patricia; Pereira, Miria G.; Atella, Georgia C.			Evaluating the effects of anticoagulants on Rhodnius prolixus artificial blood feeding	PLOS ONE			English	Article							INFESTANS KLUG HET; TRIATOMA-INFESTANS; TRYPANOSOMA-CRUZI; EGG-PRODUCTION; LIVE HOST; LIFE-SPAN; IN-VITRO; REDUVIIDAE; HEMIPTERA; AMPLIFICATION	Blood-sucking insects are responsible for the transmission of several important disease-causing organisms such as viruses, bacteria, and protozoans. The hematophagous hemipteran Rhodnius prolixus is one of the most important vectors of Trypanosoma cruzi, the etiological agent of Chagas disease. Due to the medical importance of this insect, it has been used as a study model in physiology and biochemistry since the 1930s. Artificial feeding has been recognized as a feasible and a more ethical alternative method of feeding these hematophagous insects. To prevent clotting after blood collection defibrination or treatment with anticoagulants are necessary. Although anticoagulants have been routinely used for stabilizing the collected blood, there is a gap in demonstration of the effects of using anticoagulants on the feeding and development of the hematophagous insect Rhodnius prolixus. In this study, we compared the survival rate, molting efficiency, fertility, and infection development between insects that were fed on blood containing three different anticoagulants (citrate, EDTA, and heparin). We observed that fifth instar nymphs that were fed on blood containing EDTA and citrate could not perform digestion properly, which resulted in molting inefficiency. Adult insects that were fed on EDTA-containing blood laid lower number of eggs, and also had a diminished egg hatch percentage. When we delivered T. cruzi parasites in blood containing citrate or EDTA to the insects, a lower number of parasites and metacyclic trypomastigotes was observed in the intestine compared to the group fed on heparin-containing blood. Since heparin could potentially inhibit DNA polymerase activity in DNA samples extracted from the intestine, we analyzed different heparin concentrations to determine which one is the best for use as an anticoagulant. Concentrations ranging between 2.5 and 5 U/mL were able to inhibit coagulation without severely impairing DNA polymerase activity, thus indicating that this should be considered as the range of use for feeding experiments. Our results suggest that among the three anticoagulants tested, heparin can be recommended as the anticoagulant of choice for R. prolixus feeding experiments.	[Silva-Cardoso, Livia; Dias, Felipe A.; Atella, Georgia C.] Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo de Meis, Rio De Janeiro, RJ, Brazil; [Fampa, Patricia] Univ Fed Rural Rio de Janeiro, Dept Ciencias Farmaceut, Inst Ciencias Biol & Saude, Seropedica, RJ, Brazil; [Pereira, Miria G.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Rio De Janeiro, RJ, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal Rural do Rio de Janeiro (UFRRJ); Universidade Federal do Rio de Janeiro	Atella, GC (corresponding author), Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo de Meis, Rio De Janeiro, RJ, Brazil.	atella@bioqmed.ufrj.br	Lima, Patricia F N/A-5165-2014; Pereira, Miria G/AAJ-9998-2021; Atella, Georgia/AAK-7897-2020; Fampa, Patricia/AAA-2515-2019	Fampa, Patricia/0000-0003-3440-1622	Fundacao Carlos Chagas de Amparo a Pesquisa do Estado do Rio de Janeiro; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico; FAPERJ; CNPq; Coordenacao de Aperfeicoamento de Pessoas de Nivel Superior	Fundacao Carlos Chagas de Amparo a Pesquisa do Estado do Rio de Janeiro; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPERJ(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoas de Nivel Superior	This research was funded by Fundacao Carlos Chagas de Amparo a Pesquisa do Estado do Rio de Janeiro and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico. Furthermore, Livia Silva Cardoso received fellowships from FAPERJ and CNPq, during the research time; Felipe A. Dias received a fellowship from FAPERJ; and Miria G. Pereira received a joint fellowship from CNPq together with Coordenacao de Aperfeicoamento de Pessoas de Nivel Superior. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aak A, 2014, MED VET ENTOMOL, V28, P50, DOI 10.1111/mve.12015; Achee NL, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-164; Aldana E, 2001, REV BIOL TROP, V49, P689; Azambuja P. de, 1997, The molecular biology of insect disease vectors: a methods manual., P56; Bauerfeind SS, 2007, J INSECT PHYSIOL, V53, P964, DOI 10.1016/j.jinsphys.2007.01.013; BENZON GL, 1987, J AM MOSQUITO CONTR, V3, P322; BEUTLER E, 1990, BIOTECHNIQUES, V9, P166; BUXTON P. A., 1930, TRANS ENT SOC LONDON, V78, P227; CamargO E. P., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P93; Chapman T, 1998, P ROY SOC B-BIOL SCI, V265, P1879, DOI 10.1098/rspb.1998.0516; Chiyaka C, 2013, SCIENCE, V339, P909, DOI 10.1126/science.1229509; Chorna T, 2012, BBA-GEN SUBJECTS, V1820, P1269, DOI 10.1016/j.bbagen.2011.11.002; Coelho HSL, 1997, ARCH INSECT BIOCHEM, V35, P301, DOI 10.1002/(SICI)1520-6327(199705)35:3<301::AID-ARCH4>3.0.CO;2-W; Coura JR, 2010, NATURE, V465; De Beer CJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168799; De Beer CJ, 2012, QUALITY CONTROL EXPA, P140; DESOUZAGARCIA E, 1975, AN ACAD BRAS CIENC, V47, P537; Dias FD, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004186; FRIEND W. G., 1963, CANADIAN ENTOMOL, V95, P362; FRIEND W G, 1987, Memorias do Instituto Oswaldo Cruz, V82, P11, DOI 10.1590/S0074-02761987000700005; FRIEND WG, 1982, J INSECT PHYSIOL, V28, P371, DOI 10.1016/0022-1910(82)90050-6; FRIEND WG, 1977, ANNU REV ENTOMOL, V22, P309, DOI 10.1146/annurev.en.22.010177.001521; FRIEND WG, 1965, CAN J ZOOLOG, V43, P125, DOI 10.1139/z65-010; GARCIA ES, 1985, BRAZ J MED BIOL RES, V18, P195; GARDINER BO, 1972, B ENTOMOL RES, V61, P505, DOI 10.1017/S0007485300047350; GOMES JEPL, 1990, MEM I OSWALDO CRUZ, V85, P299, DOI 10.1590/S0074-02761990000300006; Guarneri AA, 2000, J INSECT PHYSIOL, V46, P1121, DOI 10.1016/S0022-1910(99)00222-X; Guarneri AA, 2017, J INSECT PHYSIOL, V97, P66, DOI 10.1016/j.jinsphys.2016.07.005; Gullan P. J., 2005, INSECTS OUTLINE ENTO, P1; HOLODNIY M, 1991, J CLIN MICROBIOL, V29, P676, DOI 10.1128/JCM.29.4.676-679.1991; HUEBNER E, 1994, CAN J ZOOL, V72, P2244, DOI 10.1139/z94-299; Issmer AE, 2008, ALTERNATIVES ANIMAL, P125; IZRAELI S, 1991, NUCLEIC ACIDS RES, V19, P6051; LANGLEY PA, 1969, NATURE, V221, P855, DOI 10.1038/221855a0; Lehane MJ, 2005, BIOL BLOOD SUCKING I, V2; Mans BJ, 2008, J BIOL CHEM, V283, P18721, DOI 10.1074/jbc.M800188200; Mesquita RD, 2015, P NATL ACAD SCI USA, V112, P14936, DOI 10.1073/pnas.1506226112; MEWS AR, 1976, B ENTOMOL RES, V65, P631, DOI 10.1017/S0007485300006325; Molleman F, 2008, ENTOMOL EXP APPL, V129, P54, DOI 10.1111/j.1570-7458.2008.00752.x; Nattero J, 2011, ACTA TROP, V119, P183, DOI 10.1016/j.actatropica.2011.05.015; NUNEZ JA, 1990, J APPL ENTOMOL, V109, P87, DOI 10.1111/j.1439-0418.1990.tb00023.x; Nunez JA, 1996, J APPL ENTOMOL, V120, P541, DOI 10.1111/j.1439-0418.1996.tb01649.x; Orchard I, 2006, COMP BIOCHEM PHYS A, V144, P316, DOI 10.1016/j.cbpa.2005.11.010; PATTERSON JW, 1979, J INSECT PHYSIOL, V25, P311, DOI 10.1016/0022-1910(79)90018-0; Peterson JK, 2015, AM J TROP MED HYG, V93, P564, DOI 10.4269/ajtmh.15-0218; PIMENTA PFP, 1994, P NATL ACAD SCI USA, V91, P9155, DOI 10.1073/pnas.91.19.9155; Ribeiro JMC, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002594; SCHAUB GA, 1988, T ROY SOC TROP MED H, V82, P94, DOI 10.1016/0035-9203(88)90273-8; SCHAUB GA, 1989, EXP PARASITOL, V68, P260, DOI 10.1016/0014-4894(89)90108-2; Schofield CJ, 1996, P INT WORKSH POP GEN, P45; SMITH JJB, 1979, J EXP BIOL, V82, P93; Solarte Y, 2007, AM J TROP MED HYG, V77, P242, DOI 10.4269/ajtmh.2007.77.242; TERRA WR, 1994, COMP BIOCHEM PHYS B, V109, P1, DOI 10.1016/0305-0491(94)90141-4; Nguyen TH, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1174-x; UBIERGO GO, 1982, J MED ENTOMOL, V19, P109, DOI 10.1093/jmedent/19.1.109; VALLE D, 1987, J INSECT PHYSIOL, V33, P249, DOI 10.1016/0022-1910(87)90045-X; VOIGT WP, 1993, PARASITOLOGY, V107, P257, DOI 10.1017/S0031182000079233; WALADDE SM, 1993, PARASITOLOGY, V107, P249, DOI 10.1017/S0031182000079221; Walker K, 2007, MED VET ENTOMOL, V21, P2, DOI 10.1111/j.1365-2915.2007.00674.x; Wigglesworth VB, 1943, QJ MICROSC SCI, V77, P191; WILLEMS M, 1993, J VIROL METHODS, V42, P127, DOI 10.1016/0166-0934(93)90184-S; Winskill P, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004156	62	4	4	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2018	13	11							e0206979	10.1371/journal.pone.0206979	http://dx.doi.org/10.1371/journal.pone.0206979			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC4HL	30496298	Green Submitted, gold, Green Published			2023-01-03	WOS:000451763800019
J	Ferreira, GF; Stefani, KC; Haje, DD; Nogueira, MP				Ferreira, Gabriel Ferraz; Stefani, Kelly Cristina; Haje, Davi de Podesta; Nogueira, Monica Paschoal			The Ponseti method in children with clubfoot after walking age - Systematic review and metanalysis of observational studies	PLOS ONE			English	Review							NEGLECTED CLUBFOOT; IDIOPATHIC CLUBFOOT; MANAGEMENT; CLUBFEET; FEET	Background The prevalence of untreated congenital clubfoot among children older than walking age is higher in developing countries due to limited resources for early care after birth. The Ponseti method represents an intervention option for older, untreated children. Methods A metanalysis was conducted of observational studies selected through a systematic review of articles included in electronic databases (Medline, Scopus, Embase, Lilacs, and the Cochrane Library) until June 2017. A pooling analysis of proportions with 95% confidence intervals (CIs) and a publication bias assessment were performed as routine. Estimates of success, recurrence, and complication rates were weighted and pooled using the random effects model. Results Twelve studies, including 654 feet diagnosed with congenital clubfoot in children older than walking age (older than 1 year old), were included for analysis. The rate of satisfactory outcomes found via a cluster metanalysis of proportions using the random effects model was 89% (95% CI = 0.82-0.94, p < 0.01), relative to the total analysed. The recurrence rate was 18% (95% CI = 0.14-0.24, p = 0.015), and the rate of casting complications was 7% (95% CI = 0.03-0.15, p = 0.19). Conclusion Application of the Ponseti method in children with untreated idiopathic clubfoot older than walking age leads to satisfactory outcomes, has a low cost, and avoids surgical procedures likely to cause complications. The results obtained exhibited considerable heterogeneity.	[Ferreira, Gabriel Ferraz; Stefani, Kelly Cristina] State Hosp Sao Paulo, Orthopaed & Traumatol Unit, Foot & Ankle Surg Grp, Sao Paulo, SP, Brazil; [Haje, Davi de Podesta] Ctr Clin Orthopectus, Brasilia, DF, Brazil; [Haje, Davi de Podesta] Hosp Base, Brasilia, DF, Brazil; [Nogueira, Monica Paschoal] State Hosp Sao Paulo, Orthopaed & Traumatol Unit, Childrens Orthopaed & Reconstruct Grp, Sao Paulo, SP, Brazil		Ferreira, GF (corresponding author), State Hosp Sao Paulo, Orthopaed & Traumatol Unit, Foot & Ankle Surg Grp, Sao Paulo, SP, Brazil.	ortopediaff@gmail.com	STEFANI, KELLY CRISTINA/P-4547-2015; FERREIRA, GABRIEL/X-9289-2018; Nogueira, Monica Paschoal/M-1682-2016	STEFANI, KELLY CRISTINA/0000-0003-1534-9654; FERREIRA, GABRIEL/0000-0001-8032-3077; Nogueira, Monica Paschoal/0000-0001-5892-2532; Haje, Davi/0000-0003-3231-6512				Ayana B, 2014, ACTA ORTHOP, V85, P641, DOI 10.3109/17453674.2014.957085; Banskota B, 2013, BONE JOINT J, V95B, P1721, DOI 10.1302/0301-620X.95B12.32173; Bashi RHZ, 2016, J PEDIATR ORTHOP B, V25, P99, DOI 10.1097/BPB.0000000000000266; Canale ST., 2007, CAMPBELLS OPERATIVE, V11; Celebi L, 2006, J PEDIATR ORTHOP B, V15, P34, DOI 10.1097/01202412-200601000-00007; Chang Y L, 1991, J Formos Med Assoc, V90, P1186; Chien PFW, 2012, BJOG-INT J OBSTET GY, V119, P903, DOI 10.1111/j.1471-0528.2011.03242.x; Cummings RJ, 2002, J BONE JOINT SURG AM, V84A, P290, DOI 10.2106/00004623-200202000-00018; DELAHUERTA F, 1994, CLIN ORTHOP RELAT R, P89; DIMEGLIO A, 1995, J PEDIATR ORTHOP B, V4, P129, DOI 10.1097/01202412-199504020-00002; Dobbs MB, 2006, J BONE JOINT SURG AM, V88A, P986, DOI 10.2106/JBJS.E.00114; Ettl V, 2009, INT ORTHOP, V33, P515, DOI 10.1007/s00264-007-0495-6; Faizan M, 2015, J FOOT ANKLE SURG, V54, P967, DOI 10.1053/j.jfas.2014.05.009; Ferreira RC, 2006, FOOT ANKLE INT, V27, P266, DOI 10.1177/107110070602700407; GRILL F, 1987, J BONE JOINT SURG BR, V69, P593, DOI 10.1302/0301-620X.69B4.3611163; Haft GF, 2007, J BONE JOINT SURG AM, V89A, P487, DOI 10.2106/JBJS.F.00169; Hassan MK, 2013, CURR ORTHOP PRACT, V24, P295, DOI 10.1097/BCO.0b013e31828ab8b2; Khan SA, 2010, J PEDIATR ORTHOP B, V19, P385, DOI 10.1097/BPB.0b013e3283387cc8; KITE JH, 1972, CLIN ORTHOP RELAT R, P29; Lehman WB, 2003, J PEDIATR ORTHOP B, V12, P133, DOI 10.1097/01.bpb.0000049579.53117.4a; Lourenco AF, 2007, J BONE JOINT SURG BR, V89B, P378, DOI 10.1302/0301-620X.89B3.18313; Mehrafshan M, 2009, J BONE JOINT SURG BR, V91B, P949, DOI 10.1302/0301-620X.91B7.22474; Mehtani A, 2018, J PEDIATR ORTHOP B, V27, P61, DOI 10.1097/BPB.0000000000000450; Moher D, 2015, STATEMENT SYST REV, V4, DOI [10.1186/2046-4053-4-1, DOI 10.1186/2046-4053-4-1, 10.1186/s13643-015-0163-7, DOI 10.14306/RENHYD.20.2.223]; Nogueira MP, 2018, J LIMB LENGTHEN RECO, V4, P49; Penny JN, 2005, TECH ORTHOP, V20, P153, DOI 10.1097/01.bto.0000162987.08300.5e; Pirani S, 1992, J BONE JOINT SURG AM, V74, P448; PONSETI IV, 1992, J BONE JOINT SURG AM, V74A, P448, DOI 10.2106/00004623-199274030-00021; Qureshi AR, PAK J MED SCI, V7, P730; R Core Team, 2021, R LANG ENV STAT COMP; Sinha A, 2016, INDIAN J ORTHOP, V50, P529, DOI 10.4103/0019-5413.189597; Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x; Spiegel DA, 2009, CLIN ORTHOP RELAT R, V467, P1164, DOI 10.1007/s11999-008-0600-1; Verma A, 2012, J PEDIATR ORTHOP B, V21, P79, DOI 10.1097/BPB.0b013e328347a329; Yagmurlu MF, 2011, PEDIATR INT, V53, P85, DOI 10.1111/j.1442-200X.2010.03201.x	35	11	12	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2018	13	11							e0207153	10.1371/journal.pone.0207153	http://dx.doi.org/10.1371/journal.pone.0207153			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB1IJ	30457993	Green Published, Green Submitted, gold			2023-01-03	WOS:000450775300013
J	Pederson, DB; Dong, YQ; Blue, LB; Smith, SV; Cao, M				Pederson, Daniel B.; Dong, Yuqing; Blue, Levi B.; Smith, Sara, V; Cao, Min			Water-soluble cranberry extract inhibits Vibrio cholerae biofilm formation possibly through modulating the second messenger 3 ', 5 ' - Cyclic diguanylate level	PLOS ONE			English	Article							O1 EL-TOR; C-DI-GMP; SIGNAL-TRANSDUCTION SYSTEMS; URINARY-TRACT-INFECTIONS; RUGOSE COLONY MORPHOLOGY; VPS BIOSYNTHESIS GENES; BIOACTIVE COMPOUNDS; POLYSACCHARIDE PRODUCTION; PORPHYROMONAS-GINGIVALIS; PSEUDOMONAS-AERUGINOSA	Quorum sensing (QS) and nucleotide-based second messengers are vital signaling systems that regulate bacterial physiology in response to changing environments. Disrupting bacterial signal transduction is a promising direction to combat infectious diseases, and QS and the second messengers are undoubtedly potential targets. In Vibrio cholerae, both QS and the second messenger 3', 5'-cyclic diguanylate (c-di-GMP) play a central role in controlling motility, motile-to-sessile life transition, and virulence. In this study, we found that water-soluble extract from the North American cranberry could significantly inhibit V. cholerae biofilm formation during the development/maturation stage by reducing the biofilm matrix production and secretion. The anti-biofilm effect by water-soluble cranberry extract was possibly through modulating the intracellular c-di-GMP level and was independent of QS and the QS master regulator HapR. Our results suggest an opportunity to explore more functional foods to fight stubborn infections through interference with the bacterial signaling systems.	[Pederson, Daniel B.; Dong, Yuqing; Blue, Levi B.; Smith, Sara, V; Cao, Min] Clemson Univ, Dept Biol Sci, Clemson, SC 29634 USA; [Dong, Yuqing; Cao, Min] Clemson Univ, Inst Engaged Aging, Clemson, SC 29634 USA	Clemson University; Clemson University	Cao, M (corresponding author), Clemson Univ, Dept Biol Sci, Clemson, SC 29634 USA.; Cao, M (corresponding author), Clemson Univ, Inst Engaged Aging, Clemson, SC 29634 USA.	mcao@clemson.edu		Cao, Min/0000-0003-1592-8111				ALBERT MJ, 1993, LANCET, V341, P704; Ali A, 2000, INFECT IMMUN, V68, P1967, DOI 10.1128/IAI.68.4.1967-1974.2000; Babu J, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/590384; Berk V, 2012, SCIENCE, V337, P236, DOI 10.1126/science.1222981; Beyhan S, 2007, MOL MICROBIOL, V63, P995, DOI 10.1111/j.1365-2958.2006.05568.x; Beyhan S, 2006, J BACTERIOL, V188, P3600, DOI 10.1128/JB.188.10.3600-3613.2006; Bodet C, 2008, CRIT REV FOOD SCI, V48, P672, DOI 10.1080/10408390701636211; Boyd CD, 2012, ANNU REV CELL DEV BI, V28, P439, DOI 10.1146/annurev-cellbio-101011-155705; Burger O, 2002, CRIT REV FOOD SCI, V42, P279, DOI 10.1080/10408390209351916; Casper-Lindley C, 2004, J BACTERIOL, V186, P1574, DOI 10.1128/JB.186.5.1574-1578.2004; Conner JG, 2017, CURR OPIN MICROBIOL, V36, P20, DOI 10.1016/j.mib.2017.01.002; Cote J, 2010, CRIT REV FOOD SCI, V50, P872, DOI 10.1080/10408390903042069; Cote J, 2010, CRIT REV FOOD SCI, V50, P666, DOI 10.1080/10408390903044107; Daglia M, 2012, CURR OPIN BIOTECH, V23, P174, DOI 10.1016/j.copbio.2011.08.007; DAHLBACK B, 1981, ARCH MICROBIOL, V128, P267, DOI 10.1007/BF00422527; Dinh J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103290; Feldman M, 2009, CURR MICROBIOL, V59, P469, DOI 10.1007/s00284-009-9462-3; Fong JCN, 2006, J BACTERIOL, V188, P1049, DOI 10.1128/JB.188.3.1049-1059.2006; Fong JCN, 2007, J BACTERIOL, V189, P2319, DOI 10.1128/JB.01569-06; Fong JCN, 2010, MICROBIOL-SGM, V156, P2757, DOI 10.1099/mic.0.040196-0; Galperin MY, 2001, FEMS MICROBIOL LETT, V203, P11, DOI 10.1111/j.1574-6968.2001.tb10814.x; Hammer BK, 2003, MOL MICROBIOL, V50, P101, DOI 10.1046/j.1365-2958.2003.03688.x; Harjai K, 2014, INDIAN J MED RES, V139, P446; Hollenbeck EC, 2014, BIOPHYS J, V107, P2245, DOI 10.1016/j.bpj.2014.10.015; Howell AB, 2005, PHYTOCHEMISTRY, V66, P2281, DOI 10.1016/j.phytochem.2005.05.022; Howell AB, 2007, MOL NUTR FOOD RES, V51, P732, DOI 10.1002/mnfr.200700038; Jenal U, 2006, ANNU REV GENET, V40, P385, DOI 10.1146/annurev.genet.40.110405.090423; Jenal U, 2017, NAT REV MICROBIOL, V15, P271, DOI 10.1038/nrmicro.2016.190; Jones CJ, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005068; Kalia VC, 2013, BIOTECHNOL ADV, V31, P224, DOI 10.1016/j.biotechadv.2012.10.004; Kim D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145844; Koo H, 2006, CARIES RES, V40, P20, DOI 10.1159/000088901; Krasteva PV, 2010, SCIENCE, V327, P866, DOI 10.1126/science.1181185; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Labrecque J, 2006, J ANTIMICROB CHEMOTH, V58, P439, DOI 10.1093/jac/dkl220; Leshem R, 2011, INVEST OPHTH VIS SCI, V52, P4929, DOI 10.1167/iovs.10-5335; Lim B, 2006, MOL MICROBIOL, V60, P331, DOI 10.1111/j.1365-2958.2006.05106.x; Liu Z, 2007, INFECT IMMUN, V75, P122, DOI 10.1128/IAI.01190-06; Lutz C, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00375; Maisuria VB, 2016, SCI REP-UK, V6, DOI 10.1038/srep30169; Nakayama S, 2011, J AM CHEM SOC, V133, P4856, DOI 10.1021/ja1091062; Opoku-Temeng C, 2016, CHEM COMMUN, V52, P9327, DOI 10.1039/c6cc03439j; Pappas E, 2009, CRIT REV FOOD SCI, V49, P741, DOI 10.1080/10408390802145377; Prabu GR, 2006, J APPL MICROBIOL, V101, P487, DOI 10.1111/j.1365-2672.2006.02912.x; RAMAMURTHY T, 1993, LANCET, V341, P703, DOI 10.1016/0140-6736(93)90480-5; Rampioni G, 2014, BIOORG CHEM, V55, P60, DOI 10.1016/j.bioorg.2014.04.005; Rane HS, 2014, J ANTIMICROB CHEMOTH, V69, P428, DOI 10.1093/jac/dkt398; Romling U, 2013, MICROBIOL MOL BIOL R, V77, P1, DOI 10.1128/MMBR.00043-12; Ryjenkov DA, 2005, J BACTERIOL, V187, P1792, DOI 10.1128/JB.187.5.1792-1798.2005; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shikuma NJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002719; Slobodnikova L, 2016, MOLECULES, V21, DOI 10.3390/molecules21121717; Srivastava D, 2013, MOL MICROBIOL, V90, P1262, DOI 10.1111/mmi.12432; Srivastava D, 2011, J BACTERIOL, V193, P6331, DOI 10.1128/JB.05167-11; Steinberg D, 2004, J ANTIMICROB CHEMOTH, V54, P86, DOI 10.1093/jac/dkh254; Tapiainen T, 2012, EUR J CLIN MICROBIOL, V31, P655, DOI 10.1007/s10096-011-1355-2; Thelin KH, 1996, INFECT IMMUN, V64, P2853, DOI 10.1128/IAI.64.7.2853-2856.1996; Tischler AD, 2004, MOL MICROBIOL, V53, P857, DOI 10.1111/j.1365-2958.2004.04155.x; Ulrey RK, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-499; van der Mei H.C., 1991, MICROBIAL CELL SURFA; Vance RE, 2003, INFECT IMMUN, V71, P2571, DOI 10.1128/IAI.71.5.2571-2576.2003; Walker EB, 1997, J FAM PRACTICE, V45, P167; Watnick PI, 1999, MOL MICROBIOL, V34, P586, DOI 10.1046/j.1365-2958.1999.01624.x; Wojnicz D, 2016, INT J FOOD SCI NUTR, V67, P1005, DOI 10.1080/09637486.2016.1211996; Yamanaka A, 2007, J PERIODONTAL RES, V42, P589, DOI 10.1111/j.1600-0765.2007.00982.x; Yamanaka A, 2004, ORAL MICROBIOL IMMUN, V19, P150, DOI 10.1111/j.0902-0055.2004.00130.x; Yildiz FH, 2004, MOL MICROBIOL, V53, P497, DOI 10.1111/j.1365-2958.2004.04154.x; Yildiz FH, 1999, P NATL ACAD SCI USA, V96, P4028, DOI 10.1073/pnas.96.7.4028; Yildiz FH, 2001, J BACTERIOL, V183, P1716, DOI 10.1128/JB.183.5.1716-1726.2001; Zhu J, 2003, DEV CELL, V5, P647, DOI 10.1016/S1534-5807(03)00295-8; Zhu J, 2002, P NATL ACAD SCI USA, V99, P3129, DOI 10.1073/pnas.052694299	71	8	8	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2018	13	11							e0207056	10.1371/journal.pone.0207056	http://dx.doi.org/10.1371/journal.pone.0207056			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ4PQ	30403745	gold, Green Published, Green Submitted			2023-01-03	WOS:000449379500099
J	Bousquet, PJ; Lefeuvre, D; Tuppin, P; BenDiane, MK; Rocchi, M; Bouee-Benhamiche, E; Viguier, J; Le Bihan-Benjamin, C				Bousquet, Philippe Jean; Lefeuvre, Delphine; Tuppin, Philippe; BenDiane, Marc Karim; Rocchi, Mathieu; Bouee-Benhamiche, Elsa; Viguier, Jerome; Le Bihan-Benjamin, Christine			Cancer care and public health policy evaluations in France: Usefulness of the national cancer cohort	PLOS ONE			English	Article							ADMINISTRATIVE DATABASE; COLORECTAL-CANCER; LUNG; ALGORITHMS; BREAST; COLON; PROSTATE; SNIIRAM	Background In the context of the national Cancer Plans of France that have changed the healthcare landscape, it has become necessary to better document and assess the related actions, and to promote research and understanding. The national cancer cohort, an exhaustive population-based cohort, was set up on the basis of the National Health Data System (SNDS) by the French National Cancer Institute. Objectives The aim is to describe the French national cancer cohort. Methods All people living in France (67 million population) with universal insurance coverage and diagnosed, treated or followed up for a cancer, such as survivors, are included and will be followed up for 25 years. It contains all healthcare consumptions and reimbursements (i.e. hospitalization, outpatient care, medication...) since 2010. Every year, around 650 000 new cases are included. Results From 2010 to 2015, 6.2 million subjects have been included. Most subjects were entered in 2010, in 2015 it concerned 0.6 million. In 2015, the median age was 65 [54-76]; 51% were women. The primary cancer organ could be attributed with certitude to 87% of the people. The most frequent locations were skin (16%), breast (15%), prostate (12%), colon-rectum (11%) and lung (9%). In 2015, 40% of included subjects underwent surgery for cancer, 16% chemotherapy at hospital and 11% at least one session of radiotherapy. Conclusion Based on SNDS, the cancer cohort has been designed to study cancer care use in the short-, medium- and long-term, and evaluate healthcare and public health policies.	[Bousquet, Philippe Jean; Lefeuvre, Delphine; Rocchi, Mathieu; Bouee-Benhamiche, Elsa; Le Bihan-Benjamin, Christine] French Natl Canc Inst INCa, Publ Hlth & Healthcare Div, Survey Monitoring & Assessment Dept, Inst Natl Canc, Boulogne Billancourt, France; [Bousquet, Philippe Jean; BenDiane, Marc Karim] Fac Med, Econ & Social Sci Hlth Care Syst & Soc, Marseille, France; [Tuppin, Philippe] DEPP, Caisse Natl Assurance Malad Travailleurs Salaries, Paris, France; [Viguier, Jerome] French Natl Canc Inst INCa, Publ Hlth & Healthcare Div, Inst Natl Canc, Boulogne Billancourt, France	Institut National du Cancer (INCA) France; UDICE-French Research Universities; Aix-Marseille Universite; Institut National du Cancer (INCA) France	Bousquet, PJ (corresponding author), French Natl Canc Inst INCa, Publ Hlth & Healthcare Div, Survey Monitoring & Assessment Dept, Inst Natl Canc, Boulogne Billancourt, France.; Bousquet, PJ (corresponding author), Fac Med, Econ & Social Sci Hlth Care Syst & Soc, Marseille, France.	pjbousquet@institutcancer.fr	Bendiane, Marc-Karim/M-7060-2019; Bendiane, Marc-Karim K/F-5414-2010; Bousquet, Philippe Jean/AAW-8608-2021; Bousquet, Jean/O-4221-2019	Bendiane, Marc-Karim K/0000-0003-4329-8807; Bousquet, Philippe Jean/0000-0002-0217-5483; 	French national cancer institute	French national cancer institute(Institut National du Cancer (INCA) France)	The study and the Cancer cohort are self-funded by the French national cancer institute.	Ajrouche A, 2017, PHARMACOEPIDEM DR S, V26, P935, DOI 10.1002/pds.4225; Bousquet PJ, 2017, REV EPIDEMIOL SANTE, V65, pS236, DOI 10.1016/j.respe.2017.04.057; Cnamts, 2017, METH REP PATH REP DE; Colonna M, 2014, ESTIMATION PREVALENC; Cowppli-Bony A, 2016, SURVIE PERSONNES A 1; Creighton N, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011161; Doat S, 2016, REV EPIDEMIOL SANTE, V64, P145, DOI 10.1016/j.respe.2015.12.020; Goldsbury D, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-017-0417-5; INCa, 2003, PLAN CANC 2003 2007; INCa, 2013, CONS TRAIT CANC PRES; INCA, 2013, ALG SEL HOSP LIEES P; INCa, 2009, PLAN CANC 2009 2013; INCa, 2014, PROGR NAT RED TAB 20; Institut National du Cancer (INCa), 2015, PLAN CANC 2014 2019; Jehannin-Ligier K, 2017, PROJECTION INCIDENCE; Kehl KL, 2015, J GERIATR ONCOL, V6, P202, DOI 10.1016/j.jgo.2015.01.005; Kern DM, 2017, PRAGMAT OBS RES, V8, P149, DOI 10.2147/POR.S140579; Kudjawu YC, 2016, LUNG CANCER, V95, P44, DOI 10.1016/j.lungcan.2016.02.016; Kudjawu YC, 2015, CANCER EPIDEMIOL, V39, P877, DOI 10.1016/j.canep.2015.10.002; Le Bihan-Benjamin C, 2017, PRESERVATION FERTILI; Lefeuvre Delphine, 2017, Clin Breast Cancer, V17, pe191, DOI 10.1016/j.clbc.2017.01.008; Maroun R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162864; Monnereau A., 2016, SURVIE PERSONNES A 2; Neumann A, 2012, DIABETOLOGIA, V55, P1953, DOI 10.1007/s00125-012-2538-9; Nordstrom BL, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00018; Rey G, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-33; Tuppin P, 2017, REV EPIDEMIOL SANTE, V65, pS149, DOI 10.1016/j.respe.2017.05.004; Tuppin P, 2014, PROG UROL, V24, P572, DOI 10.1016/j.purol.2014.03.004; Tuppin P, 2017, B CANCER, V104, P524, DOI 10.1016/j.bulcan.2017.01.010; Tuppin P, 2014, BMC UROL, V14, DOI 10.1186/1471-2490-14-48; Warren JL, 2002, MED CARE, V40, P3; Whyte JL, 2015, MED CARE, V53, pe49, DOI 10.1097/MLR.0b013e318289c3fb	32	9	9	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2018	13	10							e0206448	10.1371/journal.pone.0206448	http://dx.doi.org/10.1371/journal.pone.0206448			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY7VH	30379946	Green Published, Green Submitted, gold			2023-01-03	WOS:000448823700117
J	Troy, DM; Attwood, AS; Maynard, OM; Scott-Samuel, NE; Hickman, M; Woods, A; Munafo, MR				Troy, David M.; Attwood, Angela S.; Maynard, Olivia M.; Scott-Samuel, Nicholas E.; Hickman, Matthew; Woods, Andy; Munafo, Marcus R.			Effect of glass shape on the pouring accuracy of liquid volume	PLOS ONE			English	Article							ALCOHOL; CONSUMPTION; JUDGMENTS; DIMENSIONS; PERCEPTION; HEALTH	Background The shape of glassware may exacerbate or counteract biases in perceived volume, which may lead people to misjudge the pouring of alcoholic drinks. The aim of these studies was to investigate the effect of glass shape on the pouring accuracy of liquid volume. Methods In Study 1, using an online computerised task, participants (n = 211) were asked to pour liquid in glasses in a within-subjects design with factors of glass shape (straight, curved) and requested percentage fullness (10, 20, 25, 30, 40, 50, 60, 70, 75, 80, 90%). Curve estimations were carried out to determine if errors followed a linear or non-linear relationship. In Study 2, in a real world experimental study, participants (n = 96) were asked to pour water to the midpoint of pint glasses in a within-subjects design with one factor of glass shape (straight, curved, tulip, inverted). Differences between poured amounts were analysed using one-way repeated measures ANOVA. Results In Study 1, participants under-poured in curved glasses compared to straight glasses at all requested amounts. In Study 2, participants under-poured in curved (p < 0.001, dz = 1.51) and tulip (p < 0.001, dz = 0.59) glasses compared to straight glasses. Findings were inconclusive as to whether or not a difference was present between pourings in inverted and straight glasses. Participants displayed a tendency to under-pour in all glasses relative to requested amounts in both studies. Conclusions The shape of glassware appears to influence the pouring accuracy of liquid. Pouring in tulip and curved glasses was more inaccurate compared to straight glasses, possibly due to the height of liquid within the glass and volume changing in a non-linear relationship.	[Troy, David M.; Hickman, Matthew] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England; [Attwood, Angela S.; Maynard, Olivia M.; Munafo, Marcus R.] Univ Bristol, MRC IEU, Bristol, Avon, England; [Attwood, Angela S.; Maynard, Olivia M.; Munafo, Marcus R.] Univ Bristol, UK Ctr Tobacco & Alcohol Studies, Bristol, Avon, England; [Attwood, Angela S.; Maynard, Olivia M.; Scott-Samuel, Nicholas E.; Munafo, Marcus R.] Univ Bristol, Sch Psychol Sci, Bristol, Avon, England; [Woods, Andy] Univ Oxford, Dept Expt Psychol, Crossmodal Res Lab, Oxford, England	University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Oxford	Troy, DM (corresponding author), Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England.	david.troy@bristol.ac.uk	Attwood, Angela S/F-7071-2011; Hickman, Matthew/Y-2400-2019; Munafo, Marcus/AAE-2306-2020	Attwood, Angela S/0000-0003-3696-4349; Hickman, Matthew/0000-0001-9864-459X; Munafo, Marcus/0000-0002-4049-993X; Troy, David/0000-0003-0897-2704; Scott-Samuel, Nicholas/0000-0002-8270-8437; Maynard, Olivia/0000-0002-9048-6627	Medical Research Council [MC_UU_12013/6]; National Institute for Health Research School of Public Health Research [IS-SPH-0211-10031]; NIHR; British Heart Foundation; Cancer Research UK; Economic and Social Research Council; National Institute for Health Research, under UK Clinical Research Collaboration; Medical Research Council; MRC [G0800612, MR/K023233/1, MC_UU_12013/6, MR/L022206/1, MC_UU_00011/7, G0802736] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research School of Public Health Research; NIHR(National Institute for Health Research (NIHR)); British Heart Foundation(British Heart Foundation); Cancer Research UK(Cancer Research UK); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); National Institute for Health Research, under UK Clinical Research Collaboration(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Medical Research Council (https://www.mrc.ac.uk/, MC_UU_12013/6) received by MRM and the National Institute for Health Research School of Public Health Research (http://sphr.nihr.ac.uk/, IS-SPH-0211-10031) received by MRM and MH. The SPHR is funded by the NIHR. SPHR is a partnership between the Universities of Sheffield, Bristol, Cambridge, Exeter, University College London; the London School for Hygiene and Tropical Medicine; the LiLaC collaboration between the Universities of Liverpool and Lancaster and Fuse; the Centre for Translational Research in Public Health, a collaboration between Newcastle, Durham, Northumbria, Sunderland and Teeside Universities. DMT, OMM, ASA and MRM are members of the UK Centre for Tobacco and Alcohol Studies, a UKCRC Public Health Research: Centre of Excellence. Funding from British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, and the National Institute for Health Research, under the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Attwood AS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043007; British Medical Association, 2008, ALC MIS TACKL UK EP; Chandon P, 2009, J MARKETING RES, V46, P739, DOI 10.1509/jmkr.46.6.739; FRAYMAN BJ, 1981, PERCEPT PSYCHOPHYS, V29, P56, DOI 10.3758/BF03198840; Gueguen N, 2004, PERCEPT MOTOR SKILL, V99, P34, DOI 10.2466/PMS.99.5.34-38; Hollands GJ, 2017, NAT HUM BEHAV, V1, DOI 10.1038/s41562-017-0140; Hollands JG, 2000, PSYCHOL REV, V107, P500, DOI 10.1037/0033-295X.107.3.500; HUANG CD, 2003, ECONOMETRIC MODELS A; Kersbergen I, 2018, ADDICTION, V113, P1598, DOI 10.1111/add.14228; Lanier SA, 2005, PHYSIOL BEHAV, V83, P821, DOI 10.1016/j.physbeh.2004.10.004; PEARSON R G, 1964, Percept Mot Skills, V18, P889; Pechey R, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3068-z; Pechey R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144536; PIAGET J, 1967, CONTEMP PSYCHOL, V12, P532, DOI 10.1037/007869; PIAGET J, 1968, SCIENCE, V162, P976, DOI 10.1126/science.162.3857.976; Piaget J., 1960, CHILDS CONCEPTION GE; PIAGET J., 1969, MECHS PERCEPTION; Raghubir P, 1999, J MARKETING RES, V36, P313, DOI 10.2307/3152079; Room R, 2005, LANCET, V365, P519, DOI 10.1016/S0140-6736(05)70276-2; Stafford LD, 2017, J PUBLIC HEALTH-HEID, V25, P147, DOI 10.1007/s10389-016-0770-3; Stafford LD, 2012, FOOD QUAL PREFER, V24, P218, DOI 10.1016/j.foodqual.2011.10.012; Troy DM, 2017, EUR J PUBLIC HEALTH, V27, P352, DOI 10.1093/eurpub/ckw142; Troy David M, 2015, Pilot Feasibility Stud, V1, P27; VAREY CA, 1990, J EXP PSYCHOL HUMAN, V16, P613, DOI 10.1037/0096-1523.16.3.613; World Health Organization, 2012, EUR ACT PLAN RED HAR; Yang S, 2005, J RETAILING, V81, P269, DOI 10.1016/j.jretai.2004.11.003	26	7	7	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2018	13	10							e0204562	10.1371/journal.pone.0204562	http://dx.doi.org/10.1371/journal.pone.0204562			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GX8WQ	30352072	Green Published, gold, Green Submitted			2023-01-03	WOS:000448076200004
J	Dumane, VA; Bakst, R; Green, S				Dumane, Vishruta A.; Bakst, Richard; Green, Sheryl			Dose to organs in the supraclavicular region when covering the Internal Mammary Nodes (IMNs) in breast cancer patients: A comparison of Volumetric Modulated Arc Therapy (VMAT) versus 3D and VMAT	PLOS ONE			English	Article							RADIATION PNEUMONITIS; HEART-DISEASE; RADIOTHERAPY; LUNG; COMPLICATIONS; IRRADIATION; RECURRENCE; SURGERY; WOMEN	During breast/chest wall and regional nodal irradiation (RNI), standard 3D conformal techniques can fail to meet the dosimetric constraints for the heart and ipsilateral lung. VMAT can improve the dosimetric sparing of the heart and lungs. However the unnecessary increase in dose to the organs in the supraclavicular region as a result of using VMAT can be avoided. In this work we investigate potential dosimetric advantages of combining 3D with VMAT to improve sparing of these organs. Ten breast cancer patients requiring radiation therapy to the breast/chest wall and RNI including the IMNs, and who did not have a viable 3D conformal plan were chosen for the study. Each patient was planned with VMAT and with a combination of 3D for the supraclavicular region and VMAT for the breast/chest wall followed by a dosimetric comparison. Prescription dose was 50.4 Gy in 28 fractions. For similar coverage to the PTV and IMNs, doses to the esophagus and cord were reduced by 17.8 Gy and 15.5 Gy while mean dose to the thyroid and larynx were also reduced by 16.5 Gy and 11.7 Gy respectively. Maximum brachial plexus dose was the same in both techniques. The ipsilateral lung V-20Gy increased by 3.1% but was still < 30%. No significant differences were noted in doses to the heart, total lung and contralateral breast. However V-5Gy to the contralateral lung was reduced by 8.5% with the combined plan. Using 3D conformal planning for the supraclavicular region and VMAT over the breast/chest wall improves sparing of the esophagus, cord, thyroid and larynx while reducing low dose exposure to the contralateral lung and does not compromise doses to the heart, ipsilateral lung and total lung.	[Dumane, Vishruta A.; Bakst, Richard; Green, Sheryl] Icahn Sch Med Mt Sinai, Dept Radiat Oncol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Dumane, VA (corresponding author), Icahn Sch Med Mt Sinai, Dept Radiat Oncol, New York, NY 10029 USA.	vishruta.dumane@mountsinai.org	DUMANE, VISHRUTA/Q-8669-2019	DUMANE, VISHRUTA/0000-0002-3405-0052				Abe O, 2005, LANCET, V366, P2087; Amdur RJ, 2007, INT J RADIAT ONCOL, V69, pS46, DOI 10.1016/j.ijrobp.2007.04.091; Asakura H, 2010, RADIOTHER ONCOL, V95, P240, DOI 10.1016/j.radonc.2010.02.006; Chung E, 2013, INT J RADIAT ONCOL, V85, P959, DOI 10.1016/j.ijrobp.2012.08.002; Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825; Goldman UB, 2014, J RADIOTHER PRACT, V13, P211, DOI 10.1017/S1460396913000228; Kong FM, 2002, INT J RADIAT ONCOL, V54, P963, DOI 10.1016/S0360-3016(02)03741-0; Li JG, 2005, MED DOSIM, V30, P135, DOI 10.1016/j.meddos.2005.03.007; Lind PARM, 2001, BREAST CANCER RES TR, V68, P199, DOI 10.1023/A:1012292019599; MARKS LB, 1994, INT J RADIAT ONCOL, V29, P903, DOI 10.1016/0360-3016(94)90584-3; McGale P, 2014, LANCET, V383, P2127, DOI 10.1016/S0140-6736(14)60488-8; OVERGAARD M, 1987, RADIOTHER ONCOL, V9, P1, DOI 10.1016/S0167-8140(87)80213-X; Pierce LJ, 2002, INT J RADIAT ONCOL, V52, P1220, DOI 10.1016/S0360-3016(01)02760-2; Poortmans PM, 2015, NEW ENGL J MED, V373, P317, DOI 10.1056/NEJMoa1415369; Popescu CC, 2010, INT J RADIAT ONCOL, V76, P287, DOI 10.1016/j.ijrobp.2009.05.038; Radiation Therapy Oncology Group, RTOG BREAST CANC CON; ROTHWELL RI, 1985, RADIOTHER ONCOL, V4, P9, DOI 10.1016/S0167-8140(85)80056-6; Whelan TJ, 2015, NEW ENGL J MED, V373, P307, DOI 10.1056/NEJMoa1415340	18	11	11	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2018	13	10							e0205770	10.1371/journal.pone.0205770	http://dx.doi.org/10.1371/journal.pone.0205770			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX5DH	30339705	gold, Green Published, Green Submitted			2023-01-03	WOS:000447761400021
J	Moon, CY; Nam, OH; Kim, M; Lee, HS; Kaushik, SN; Walma, DAC; Jun, HW; Cheon, K; Choi, SC				Moon, Chan-Yang; Nam, Ok Hyung; Kim, Misun; Lee, Hyo-Seol; Kaushik, Sagar N.; Walma, David A. Cruz; Jun, Ho-Wook; Cheon, Kyounga; Choi, Sung Chul			Effects of the nitric oxide releasing biomimetic nanomatrix gel on pulp-dentin regeneration: Pilot study	PLOS ONE			English	Article							MINERAL TRIOXIDE AGGREGATE; IMMATURE PERMANENT TEETH; PLATELET-RICH PLASMA; NEWLY FORMED TISSUES; STEM-CELLS; CALCIUM HYDROXIDE; IN-VITRO; ENDODONTIC REGENERATION; ANTIBACTERIAL EFFICACY; APICAL PERIODONTITIS	Successful disinfection alongside complete endodontic tissue regeneration and revascularization are the most desired clinical outcomes of regenerative endodontics. Despite reported clinical successes, significant limitations to the current regenerative endodontic procedure (REP) have been elucidated. To improve the current REP, an antibiotics and nitric oxide (NO) releasing biomimetic nanomatrix gel was developed. The study evaluates antibacterial effects of an antibiotics and NO releasing biomimetic nanomatrix gel on multispecies endodontic bacteria. Antibiotics, ciprofloxacin (CF) and metronidazole (MN) were mixed and encapsulated within the NO releasing biomimetic nanomatrix gel. The gel was synthesized and self-assembled from peptide amphiphiles containing various functional groups. Antibacterial effects of the antibiotics and NO releasing biomimetic nanomatrix gel were evaluated using bacterial viability assays involving endodontic microorganisms including clinical samples. Pulp-dentin regeneration was evaluated via animal-model experiments. The antibiotics and NO releasing biomimetic nanomatrix gel demonstrated a concentration dependent antibacterial effect. In addition, NO alone demonstrated a concentration dependent antibacterial effect on endodontic microorganism. An in vivo analysis demonstrated the antibiotics and NO releasing biomimetic nanomatrix gel promoted tooth revascularization with maturation of root canals. An optimal concentration of and NO releasing nanomatrix gel is suggested for its potential as a root treatment material for REP and an appropriate protocol for human trials. Further investigation is required to obtain a larger sample size and decide upon ideal growth factor incorporation.	[Moon, Chan-Yang; Nam, Ok Hyung; Kim, Misun; Lee, Hyo-Seol; Choi, Sung Chul] Kyung Hee Univ, Dept Pediat Dent, Seoul, South Korea; [Kaushik, Sagar N.; Jun, Ho-Wook] Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA; [Walma, David A. Cruz; Cheon, Kyounga] Univ Alabama Birmingham, Dept Pediat Dent, Birmingham, AL 35294 USA	Kyung Hee University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Choi, SC (corresponding author), Kyung Hee Univ, Dept Pediat Dent, Seoul, South Korea.; Cheon, K (corresponding author), Univ Alabama Birmingham, Dept Pediat Dent, Birmingham, AL 35294 USA.	kcheon@uab.edu; pedochoi@khu.ac.kr	CHOI, SUNG CHUL/B-4574-2019; Nam, Ok Hyung/Q-9862-2019; NAM, OK HYUNG/A-9769-2019	CHOI, SUNG CHUL/0000-0001-7221-2000; Nam, Ok Hyung/0000-0002-6386-803X; NAM, OK HYUNG/0000-0002-6386-803X; Kaushik, Sagar/0000-0002-5891-5049; Kim, Mi Sun/0000-0001-8338-1838	National Institute of Dental and Craniofacial Research [KDE027401A];  [NRF-2016R1D1A1B03931063];  [2017M3A9E4048170]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL125391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K08DE027401] Funding Source: NIH RePORTER	National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by KDE027401A (National Institute of Dental and Craniofacial Research); NRF-2016R1D1A1B03931063 and 2017M3A9E4048170. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AAE, 2017, TREATM PROC AM ASS 2; AAE, 2013, REG END END COLL EXC, P1; Albuquerque MTP, 2014, J DENT RES, V93, P1222, DOI 10.1177/0022034514549809; Altaii M, 2017, DENT TRAUMATOL, V33, P235, DOI 10.1111/edt.12338; Anderson JM, 2009, ACS NANO, V3, P3447, DOI 10.1021/nn900884n; Andreasen JO, 2002, DENT TRAUMATOL, V18, P134, DOI 10.1034/j.1600-9657.2002.00097.x; Andukuri A, 2011, ACTA BIOMATER, V7, P225, DOI 10.1016/j.actbio.2010.08.013; Backlund CJ, 2014, J DENT RES, V93, P1089, DOI 10.1177/0022034514529974; Bakland LK, 2012, DENT TRAUMATOL, V28, P25, DOI 10.1111/j.1600-9657.2011.01049.x; Ban K, 2014, ACS NANO, V8, P10815, DOI 10.1021/nn504617g; Banchs F, 2004, J ENDODONT, V30, P196, DOI 10.1097/00004770-200404000-00003; Bose R, 2009, J ENDODONT, V35, P1343, DOI 10.1016/j.joen.2009.06.021; BUTLER WT, 1992, MATRIX, V12, P343, DOI 10.1016/S0934-8832(11)80030-2; Carpenter AW, 2012, CHEM SOC REV, V41, P3742, DOI 10.1039/c2cs15273h; Carrotte P, 2004, BRIT DENT J, V197, P735, DOI 10.1038/sj.bdj.4811897; Chen MYH, 2012, INT ENDOD J, V45, P294, DOI 10.1111/j.1365-2591.2011.01978.x; Chuensombat S, 2013, J ENDODONT, V39, P813, DOI 10.1016/j.joen.2012.11.041; CVEK M, 1992, ENDOD DENT TRAUMATOL, V8, P45; Dabbagh B, 2012, PEDIATR DENT, V34, P414; de Avila ED, 2015, BIOMATERIALS, V67, P84, DOI 10.1016/j.biomaterials.2015.07.030; Dimmeler S, 1999, CELL DEATH DIFFER, V6, P964, DOI 10.1038/sj.cdd.4400581; DSOUZA RN, 1995, J DENT RES, V74, P702, DOI 10.1177/00220345950740021301; Egusa H, 2012, J PROSTHODONT RES, V56, P151, DOI 10.1016/j.jpor.2012.06.001; Farges JC, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00185; Felippe WT, 2006, INT ENDOD J, V39, P2, DOI 10.1111/j.1365-2591.2005.01037.x; Galler K M, 2011, Adv Dent Res, V23, P333, DOI 10.1177/0022034511405326; Galler KM, 2008, TISSUE ENG PT A, V14, P2051, DOI 10.1089/ten.tea.2007.0413; Galler KM, 2012, TISSUE ENG PT A, V18, P176, DOI [10.1089/ten.tea.2011.0222, 10.1089/ten.TEA.2011.0222]; Galler KM, 2011, J ENDODONT, V37, P1536, DOI 10.1016/j.joen.2011.08.027; GRUETTER CA, 1979, J CYCLIC NUCL PROT, V5, P211; Hargreaves KM, 2013, J ENDODONT, V39, pS30, DOI 10.1016/j.joen.2012.11.025; Harichane Y, 2011, Adv Dent Res, V23, P307, DOI 10.1177/0022034511405322; Hetrick EM, 2008, ACS NANO, V2, P235, DOI 10.1021/nn700191f; Hoshino E, 1996, INT ENDOD J, V29, P125, DOI 10.1111/j.1365-2591.1996.tb01173.x; Hotwani Kavita, 2014, Restor Dent Endod, V39, P1, DOI 10.5395/rde.2014.39.1.1; Huang GTJ, 2009, REGEN MED, V4, P697, DOI 10.2217/RME.09.45; Huang George T-J, 2011, Front Biosci (Elite Ed), V3, P788, DOI 10.2741/e286; Iwaya S, 2001, DENT TRAUMATOL, V17, P185, DOI 10.1034/j.1600-9657.2001.017004185.x; Kaushik Sagar N, 2016, Biomater Res, V20, P14, DOI 10.1186/s40824-016-0061-7; Kaushik Sagar N, 2015, Biomater Res, V19, P9, DOI 10.1186/s40824-015-0032-4; Kim JO, 2015, INT J BIOL MACROMOL, V79, P217, DOI 10.1016/j.ijbiomac.2015.04.073; Kim ST, 2000, INT ENDOD J, V33, P233, DOI 10.1046/j.1365-2591.2000.00277.x; Kimura H, 2003, ACTA BIOCHIM POL, V50, P49; KUO PC, 1995, ANN SURG, V221, P220, DOI 10.1097/00000658-199503000-00003; Kushwaha M, 2010, BIOMATERIALS, V31, P1502, DOI 10.1016/j.biomaterials.2009.10.051; Labban N, 2014, DENT TRAUMATOL, V30, P429, DOI 10.1111/edt.12108; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; Marconyak LJ, 2016, J ENDODONT, V42, P470, DOI 10.1016/j.joen.2015.10.013; McFarland J, 1907, J AMER MED ASSOC, V49, P1176; Mei YF, 2007, CELL TISSUE RES, V328, P117, DOI 10.1007/s00441-005-0003-5; Mitsiadis TA, 2012, NANOMEDICINE-UK, V7, P1743, DOI [10.2217/NNM.12.146, 10.2217/nnm.12.146]; Mujoo K, 2008, P NATL ACAD SCI USA, V105, P18924, DOI 10.1073/pnas.0810230105; Murray PE, 2007, J ENDODONT, V33, P377, DOI 10.1016/j.joen.2006.09.013; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Nosrat A, 2012, J ENDODONT, V38, P1428, DOI 10.1016/j.joen.2012.06.025; OSTBY B N, 1961, Acta Odontol Scand, V19, P324; Privett BJ, 2010, MOL PHARMACEUT, V7, P2289, DOI 10.1021/mp100248e; Rafter M, 2005, DENT TRAUMATOL, V21, P1, DOI 10.1111/j.1600-9657.2004.00284.x; Reynolds K, 2009, INT ENDOD J, V42, P84, DOI 10.1111/j.1365-2591.2008.01467.x; Rombouts C, 2017, J DENT RES, V96, P137, DOI 10.1177/0022034516671688; Rosenberg B, 2007, DENT TRAUMATOL, V23, P26, DOI 10.1111/j.1600-9657.2006.00453.x; Ruparel NB, 2012, J ENDODONT, V38, P1372, DOI 10.1016/j.joen.2012.06.018; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Sharin VG, 2011, STEM CELLS DEV, V20, P1287, DOI 10.1089/scd.2010.0411; Sharma Bandana, 2013, Patholog Res Int, V2013, P243168, DOI 10.1155/2013/243168; Shi S, 2005, Orthod Craniofac Res, V8, P191, DOI 10.1111/j.1601-6343.2005.00331.x; Shimizu E, 2012, J ENDODONT, V38, P1293, DOI 10.1016/j.joen.2012.06.017; Simon S, 2007, INT ENDOD J, V40, P186, DOI 10.1111/j.1365-2591.2007.01214.x; Siqueira JF, 1999, INT ENDOD J, V32, P361, DOI 10.1046/j.1365-2591.1999.00275.x; SMITH AJ, 1995, INT J DEV BIOL, V39, P273; Sun B, 2012, BIOMACROMOLECULES, V13, P3343, DOI 10.1021/bm301109c; Thomson A, 2010, AUST DENT J, V55, P446, DOI 10.1111/j.1834-7819.2010.01268.x; Torabinejad M, 2011, J ENDODONT, V37, P265, DOI 10.1016/j.joen.2010.11.004; Trevino EG, 2011, J ENDODONT, V37, P1109, DOI 10.1016/j.joen.2011.05.013; Trope M, 2008, PEDIATR DENT, V30, P206; Wang XJ, 2010, J ENDODONT, V36, P56, DOI 10.1016/j.joen.2009.09.039; Wigler R, 2013, J ENDODONT, V39, P319, DOI 10.1016/j.joen.2012.11.014; Witherspoon DE, 2008, J ENDODONT, V34, P1171, DOI 10.1016/j.joen.2008.07.005; Wu R, 2011, J BIOL CHEM, V286, P34923, DOI 10.1074/jbc.M111.239350; Yamauchi N, 2011, J ENDODONT, V37, P1636, DOI 10.1016/j.joen.2011.08.025; Yassen GH, 2013, J ENDODONT, V39, P269, DOI 10.1016/j.joen.2012.09.020; YATES JA, 1988, INT ENDOD J, V21, P313, DOI 10.1111/j.1365-2591.1988.tb01141.x; Zhu XF, 2014, J ENDODONT, V40, P1573, DOI 10.1016/j.joen.2014.05.010	84	16	17	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2018	13	10							e0205534	10.1371/journal.pone.0205534	http://dx.doi.org/10.1371/journal.pone.0205534			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW7TO	30308037	gold, Green Published, Green Submitted			2023-01-03	WOS:000447173500100
J	Fang, Y; Xu, PR; Yang, JL; Qin, YF				Fang, Yun; Xu, Peirong; Yang, Jialiang; Qin, Yufang			A quantile regression forest based method to predict drug response and assess prediction reliability	PLOS ONE			English	Article							CANCER; SENSITIVITY	Drug response prediction is a critical step for personalized treatment of cancer patients and ultimately leads to precision medicine. A lot of machine-learning based methods have been proposed to predict drug response from different types of genomic data. However, currently available methods could only give a "point" prediction of drug response value but fail to provide the reliability and distribution of the prediction, which are of equal interest in clinical practice. In this paper, we proposed a method based on quantile regression forest and applied it to the CCLE dataset. Through the out-of-bag validation, our method achieved much higher prediction accuracy of drug response than other available tools. The assessment of prediction reliability by prediction intervals and its significance in personalized medicine were illustrated by several examples. Functional analysis of selected drug response associated genes showed that the proposed method achieves more biologically plausible results.	[Fang, Yun; Xu, Peirong] Shanghai Normal Univ, Dept Math, Shanghai, Peoples R China; [Yang, Jialiang] Hainan Normal Univ, Sch Math & Stat, Haikou, Hainan, Peoples R China; [Yang, Jialiang] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Qin, Yufang] Shanghai Ocean Univ, Coll Informat Technol, Shanghai, Peoples R China	Shanghai Normal University; Hainan Normal University; Icahn School of Medicine at Mount Sinai; Shanghai Ocean University	Yang, JL (corresponding author), Hainan Normal Univ, Sch Math & Stat, Haikou, Hainan, Peoples R China.; Yang, JL (corresponding author), Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA.; Qin, YF (corresponding author), Shanghai Ocean Univ, Coll Informat Technol, Shanghai, Peoples R China.	jialiang.yang@mssm.edu; yfqin@shou.edu.cn			National Natural Science Foundation of China [11201306, 61572327, 61702325, 11501099]; Innovation Program of Shanghai Municipal Education Commission [13YZ065]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Program of Shanghai Municipal Education Commission(Innovation Program of Shanghai Municipal Education Commission)	This work was supported by the National Natural Science Foundation of China (11201306 (YF), 61572327(XZ), 61702325(YQ) and 11501099 (PX)), the Innovation Program of Shanghai Municipal Education Commission (13YZ065(YF)).	Barnes ML, 2002, SSRN ELECT J; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Dry JR, 2010, CANCER RES, V70, P2264, DOI 10.1158/0008-5472.CAN-09-1577; Fan JQ, 2008, J R STAT SOC B, V70, P849, DOI 10.1111/j.1467-9868.2008.00674.x; Fang Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120408; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Geeleher P, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r47; Gobel G, 1900, CANCER GENOM PROTEOM, V10, P81; Gong ZJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110674; Hadley KE, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-334; Hall P, 2009, J COMPUT GRAPH STAT, V18, P533, DOI 10.1198/jcgs.2009.08041; Hastie T., 2016, ELEMENTS STAT LEARNI; Haura EB, 2011, WIPO Patent Application, Patent No. [WO/2011/034919, 2011034919]; Hyvonen N., COMPUTATIONAL METHOD; James G., 2017, INTRO STAT LEARNING; KOENKER R, 1978, ECONOMETRICA, V46, P33, DOI 10.2307/1913643; Lee JK, 2007, P NATL ACAD SCI USA, V104, P13086, DOI 10.1073/pnas.0610292104; Levene H., 1960, CONTRIBUTIONS PROBAB, P279; Li GR, 2012, ANN STAT, V40, P1846, DOI 10.1214/12-AOS1024; Li RZ, 2012, J AM STAT ASSOC, V107, P1129, DOI 10.1080/01621459.2012.695654; Lipsitz SR, 1997, J R STAT SOC C-APPL, V46, P463, DOI 10.1111/1467-9876.00084; Liu JY, 2015, SCI CHINA MATH, V58, P2033, DOI 10.1007/s11425-015-5062-9; Manning G, 2002, TRENDS BIOCHEM SCI, V27, P514, DOI 10.1016/S0968-0004(02)02179-5; Meinshausen N, 2006, J MACH LEARN RES, V7, P983; Montenegro C, 2016, ESTUD ECONOMIA, V25, P71; Morlacchi P, 2014, FUTURE MED CHEM, V6, P1909, DOI 10.4155/fmc.14.120; Nowotarski J, 2015, COMPUTATION STAT, V30, P791, DOI 10.1007/s00180-014-0523-0; Riddick G, 2011, BIOINFORMATICS, V27, P220, DOI 10.1093/bioinformatics/btq628; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012; Roth JV, 2009, J CLIN MONIT COMPUT, V23, P181, DOI 10.1007/s10877-009-9165-0; Sen T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048770; Sharma PS, 2009, CURR PHARM DESIGN, V15, P758, DOI 10.2174/138161209787582219; Tsai IC, 2012, J INT FINANC MARK I, V22, P609, DOI 10.1016/j.intfin.2012.04.005; Wan Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101183; Wang L, 2012, J AM STAT ASSOC, V107, P518, DOI 10.1080/01621459.2012.665198; Wei W, 2013, J CLIN INVEST, V123, P4435, DOI 10.1172/JCI70625; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343	37	13	15	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2018	13	10							e0205155	10.1371/journal.pone.0205155	http://dx.doi.org/10.1371/journal.pone.0205155			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW0HY	30289891	Green Published, gold, Green Submitted			2023-01-03	WOS:000446545500052
J	Choi, CH; Park, SY; Park, JM; Wu, HG; Kim, JH; Kim, JI				Choi, Chang Heon; Park, So-Yeon; Park, Jong Min; Wu, Hong-Gyun; Kim, Jin-Ho; Kim, Jung-in			Comparison of the IPSA and HIPO algorithms for interstitial tongue high-dose-rate brachytherapy	PLOS ONE			English	Article							RATE PROSTATE BRACHYTHERAPY; OPTIMIZATION ALGORITHMS; AMERICAN BRACHYTHERAPY; HDR BRACHYTHERAPY; CANCER; RADIOTHERAPY; PERFORMANCE	Purpose This study aimed to compare the inverse planning simulated annealing (IPSA) stochastic algorithm with the hybrid inverse planning and optimization (HIPO) algorithm for interstitial tongue high-dose-rate (HDR) brachytherapy. Methods Twenty patients who received radiotherapy for tongue cancer using interstitial HDR brachy-therapy were retrospectively selected for this study. Oncentra Brachy v. 4.3 was used for IPSA and HIPO planning. Four to eight fixed catheter configurations were determined according to the target shape. During the optimization process, predetermined constrain values were used for each IPSA and HIPO plan. The dosimetric parameters and dwell time were analyzed to evaluate the performances of the plans. Results The total dwell time using IPSA was 4 seconds longer than that of HIPO. The number of active positions per catheter for the IPSA plans were approximately 2.5 fewer than those of the HIPO plans. The dose-volumetric parameters related to the clinical target volume with IPSA were lower than those with HIPO. In terms of the dose-volumetric parameters related to normal tissue, HIPO tended to associate with slightly higher values than IPSA, without statistical significance. After GrO, the target coverages were satisfied to clinical goal for all patients. The total dwell times was approximately increased by 10%. Conclusions The IPSA and HIPO dose optimization algorithms generate similar dosimetric results. In terms of the dwell time, HIPO appears to be more beneficial.	[Choi, Chang Heon; Park, So-Yeon; Park, Jong Min; Wu, Hong-Gyun; Kim, Jin-Ho; Kim, Jung-in] Seoul Natl Univ Hosp, Dept Radiat Oncol, Seoul, South Korea; [Choi, Chang Heon; Park, So-Yeon; Park, Jong Min; Wu, Hong-Gyun; Kim, Jin-Ho; Kim, Jung-in] Seoul Natl Univ, Coll Med, Biomed Res Inst, Seoul, South Korea; [Choi, Chang Heon; Park, So-Yeon; Park, Jong Min; Wu, Hong-Gyun; Kim, Jin-Ho; Kim, Jung-in] Seoul Natl Univ, Med Res Ctr, Inst Radiat Med, Seoul, South Korea; [Park, Jong Min] Adv Inst Convergence Technol, Ctr Convergence Res Robot, Suwon, South Korea; [Wu, Hong-Gyun] Seoul Natl Univ, Coll Med, Dept Radiat Oncol, Seoul, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Kim, JH; Kim, JI (corresponding author), Seoul Natl Univ Hosp, Dept Radiat Oncol, Seoul, South Korea.; Kim, JH; Kim, JI (corresponding author), Seoul Natl Univ, Coll Med, Biomed Res Inst, Seoul, South Korea.; Kim, JH; Kim, JI (corresponding author), Seoul Natl Univ, Med Res Ctr, Inst Radiat Med, Seoul, South Korea.	jinho.kim.md@gmail.com; madangin@gmail.com		Kim, Jung-in/0000-0002-0305-5969	National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea [1631200]; National Research Foundation of Korea (NRF) grant - Korean government (MSIP) [2017R1C1B1006636]	National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); National Research Foundation of Korea (NRF) grant - Korean government (MSIP)	This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (No. 1631200) to JK and by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (No. 2017R1C1B1006636) to CHC.	Balvert M, 2015, PHYS MED BIOL, V60, P537, DOI 10.1088/0031-9155/60/2/537; Bansal A, 2016, J CONTEMP BRACHYTHER, V8, P56, DOI 10.5114/jcb.2016.58082; Choi Chang Heon, 2017, [PROGRESS in MEDICAL PHYSICS, 의학물리], V28, P39, DOI 10.14316/pmp.2017.28.2.39; Choi CH, 2017, BRIT J RADIOL, V90, DOI 10.1259/bjr.20160652; Dinkla AM, 2015, BRACHYTHERAPY, V14, P279, DOI 10.1016/j.brachy.2014.09.006; Erickson BA, 2017, BRACHYTHERAPY, V16, P75, DOI 10.1016/j.brachy.2016.05.006; Farrus B, 1996, RADIOTHER ONCOL, V38, P145, DOI 10.1016/0167-8140(95)01685-6; FRIEDRICH RE, 1995, J CRANIO MAXILL SURG, V23, P238, DOI 10.1016/S1010-5182(05)80214-8; Hsu I-Chow J, 2004, Brachytherapy, V3, P147, DOI 10.1016/j.brachy.2004.05.007; Inoue T, 2001, INT J RADIAT ONCOL, V51, P171, DOI 10.1016/S0360-3016(01)01561-9; Jacob D, 2008, INT J RADIAT ONCOL, V72, P820, DOI 10.1016/j.ijrobp.2008.02.009; Jamema SV, 2011, BRACHYTHERAPY, V10, P306, DOI 10.1016/j.brachy.2010.08.011; Katimoto N, 2003, RADIOTHER ONCOL, V68, P123, DOI 10.1016/S0167-8140(03)00055-0; Leung TW, 2002, HEAD NECK-J SCI SPEC, V24, P274, DOI 10.1002/hed.10021; Mavroidis Panayiotis, 2010, J Contemp Brachytherapy, V2, P117; Morton GC, 2008, BRACHYTHERAPY, V7, P12, DOI 10.1016/j.brachy.2007.10.001; Panettieri V, 2014, J APPL CLIN MED PHYS, V15, P256, DOI 10.1120/jacmp.v15i6.5055; Peppa V, 2017, PHYS MED; Poder J, 2016, J CONTEMP BRACHYTHER, V8, P203, DOI 10.5114/jcb.2016.60499; Pokharel S, 2013, J APPL CLIN MED PHYS, V14, P96, DOI 10.1120/jacmp.v14i4.4198; Poulin E, 2016, BRACHYTHERAPY, V15, P102, DOI 10.1016/j.brachy.2015.09.010; Pouliot J, 2004, INT J RADIAT ONCOL, V59, P1196, DOI 10.1016/j.ijrobp.2004.02.055; Takacsi-Nagy Z, 2017, BRACHYTHERAPY, V16, P44, DOI 10.1016/j.brachy.2016.07.005; Trnkova Petra, 2010, J Contemp Brachytherapy, V2, P163; Trnkova P, 2009, RADIOTHER ONCOL, V93, P331, DOI 10.1016/j.radonc.2009.10.004; Umeda M, 2000, ORAL SURG ORAL MED O, V90, P667, DOI 10.1067/moe.2000.110087; Vargo JA, 2014, WORLD J CLIN ONCOL, V5, P921, DOI 10.5306/wjco.v5.i5.921; Yamazaki H, 2004, INT J RADIAT ONCOL, V58, P139, DOI 10.1016/S0360-3016(03)01459-7; Yamazaki H, 2013, J RADIAT RES, V54, P1, DOI 10.1093/jrr/rrs103; Yoshida K, 2017, J CONTEMP BRACHYTHER, V9, P66, DOI 10.5114/jcb.2017.65163	30	5	5	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2018	13	10							e0205229	10.1371/journal.pone.0205229	http://dx.doi.org/10.1371/journal.pone.0205229			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV8IQ	30286187	Green Published, gold, Green Submitted			2023-01-03	WOS:000446383500100
J	Playe, B; Azencott, CA; Stoven, V				Playe, Benoit; Azencott, Chloe-Agathe; Stoven, Veronique			Efficient multi-task chemogenomics for drug specificity prediction	PLOS ONE			English	Article							TARGET INTERACTION PREDICTION; HOSPITALIZED-PATIENTS; HOMOLOGY DETECTION; CHEMICAL GENOMICS; CROSS-VALIDATION; KERNELS; SUPPORT; INFORMATION; DISCOVERY	Adverse drug reactions, also called side effects, range from mild to fatal clinical events and significantly affect the quality of care. Among other causes, side effects occur when drugs bind to proteins other than their intended target. As experimentally testing drug specificity against the entire proteome is out of reach, we investigate the application of chemogenomics approaches. We formulate the study of drug specificity as a problem of predicting interactions between drugs and proteins at the proteome scale. We build several benchmark datasets, and propose NN-MT, a multi-task Support Vector Machine (SVM) algorithm that is trained on a limited number of data points, in order to solve the computational issues or proteome-wide SVM for chemogenomics. We compare NN-MTto different state-of-the-art methods, and show that its prediction performances are similar or better, at an efficient calculation cost. Compared to its competitors, the proposed method is particularly efficient to predict (protein, ligand) interactions in the difficult double-orphan case, i.e. when no interactions are previously known for the protein nor for the ligand. The NN-MTalgorithm appears to be a good default method providing state-of-the-art or better performances, in a wide range of prediction scenario that are considered in the present study: proteome-wide prediction, protein family prediction, test (protein, ligand) pairs dissimilar to pairs in the train set, and orphan cases.	[Playe, Benoit; Azencott, Chloe-Agathe; Stoven, Veronique] PSL Res Univ, Mines ParisTech, Ctr Computat Biol, Paris, France; [Playe, Benoit; Azencott, Chloe-Agathe; Stoven, Veronique] Inst Curie, F-75248 Paris, France; [Playe, Benoit; Azencott, Chloe-Agathe; Stoven, Veronique] INSERM, U900, F-75248 Paris, France	UDICE-French Research Universities; PSL Research University Paris; MINES ParisTech; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm)	Playe, B (corresponding author), PSL Res Univ, Mines ParisTech, Ctr Computat Biol, Paris, France.; Playe, B (corresponding author), Inst Curie, F-75248 Paris, France.; Playe, B (corresponding author), INSERM, U900, F-75248 Paris, France.	benoit.playe@mines-paristech.fr		Azencott, Chloe-Agathe/0000-0003-1003-301X; Playe, Benoit/0000-0003-3836-2683				Allenby GM, 1999, J ECONOMETRICS, V89, P57; Arora N, 1998, MARKET SCI, V17, P29, DOI 10.1287/mksc.17.1.29; Azencott CA, 2007, J CHEM INF MODEL, V47, P965, DOI 10.1021/ci600397p; Bakker B, 2003, J MACHINE LEARNING R, V4, P83; Bleakley K, 2009, BIOINFORMATICS, V25, P2397, DOI 10.1093/bioinformatics/btp433; Bolton EE, 2010, ANN REP COMP CHEM, V4, P217, DOI 10.1016/S1574-1400(08)00012-1; Caruana R, 1998, LEARNING TO LEARN, P95, DOI 10.1007/978-1-4615-5529-2_5; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018; DiMasi JA, 2016, J HEALTH ECON, V47, P20, DOI 10.1016/j.jhealeco.2016.01.012; Erhan D, 2006, J CHEM INF MODEL, V46, P626, DOI 10.1021/ci050367t; Eskin E, 2002, NIPS, P1417; Faulon JL, 2008, BIOINFORMATICS, V24, P225, DOI 10.1093/bioinformatics/btm580; Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777; GOLUB GH, 1979, TECHNOMETRICS, V21, P215, DOI 10.1080/00401706.1979.10489751; Gonen M, 2012, BIOINFORMATICS, V28, P2304, DOI 10.1093/bioinformatics/bts360; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hastie T., 2009, ELEMENTS STAT LEARNI; Hattori M, 2003, J AM CHEM SOC, V125, P11853, DOI 10.1021/ja036030u; Hizukuri Y, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0158-1; Hue M, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-144; Jaakkola T, 2000, J COMPUT BIOL, V7, P95, DOI 10.1089/10665270050081405; Jacob L, 2008, BIOINFORMATICS, V24, P2149, DOI 10.1093/bioinformatics/btn409; Jacob L, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-363; Johnson C. C., 2014, P ADV NEUR INF PROC, V27, P1; JOHNSON SC, 1967, PSYCHOMETRIKA, V32, P241, DOI 10.1007/BF02289588; Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; Kashima H, 2003, PROC INT C MACH LEAR, P321; Kellenberger E, 2008, J CHEM INF MODEL, V48, P1014, DOI 10.1021/ci800023x; Kramer C, 2010, J CHEM INF MODEL, V50, P1961, DOI 10.1021/ci100264e; Kuang Rui, 2005, Journal of Bioinformatics and Computational Biology, V3, P527, DOI 10.1142/S021972000500120X; Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LESLIE C, 2002, P PSB, V7, P566; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Liu Y, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004760; Mahe P, 2005, J CHEM INF MODEL, V45, P939, DOI 10.1021/ci050039t; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Martinez-Lopez Y, 2017, CURR TOP MED CHEM, V17, P2957, DOI 10.2174/1568026617666170821123856; Mei JP, 2013, BIOINFORMATICS, V29, P238, DOI 10.1093/bioinformatics/bts670; Miguel A, 2012, PHARMACOEPIDEM DR S, V21, P1139, DOI 10.1002/pds.3309; Napolitano F, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-30; Nascimento AC RB, 2016, BMC BIOINFORMATICS, V17, P1, DOI [10.1186/s12859-016-0890-3, DOI 10.1186/S12859-016-0890-3]; Okuno Y, 2008, NUCLEIC ACIDS RES, V36, pD907, DOI 10.1093/nar/gkm948; Onakpoya IJ, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0553-2; Pahikkala T, 2015, BRIEF BIOINFORM, V16, P325, DOI 10.1093/bib/bbu010; Paul N, 2004, PROTEINS, V54, P671, DOI 10.1002/prot.10625; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; RAGHAVAN VV, 1989, ACM T INFORM SYST, V7, P205, DOI 10.1145/65943.65945; Rakotomamonjy A, 2008, J MACH LEARN RES, V9, P2491; Saigo H, 2004, BIOINFORMATICS, V20, P1682, DOI 10.1093/bioinformatics/bth141; Scheiber J, 2009, J CHEM INF MODEL, V49, P308, DOI 10.1021/ci800344p; Scholkopf B, 2001, NEURAL COMPUT, V13, P1443, DOI 10.1162/089976601750264965; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Swamidass SJ, 2005, BIOINFORMATICS, V21, pI359, DOI 10.1093/bioinformatics/bti1055; Takarabe M, 2012, BIOINFORMATICS, V28, pI611, DOI 10.1093/bioinformatics/bts413; van Laarhoven T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066952; van Laarhoven T, 2011, BIOINFORMATICS, V27, P3036, DOI 10.1093/bioinformatics/btr500; Vert JP, 2008, COMB CHEM HIGH T SCR, V11, P677, DOI 10.2174/138620708785739899; Warmuth MK, 2003, J CHEM INF COMP SCI, V43, P667, DOI 10.1021/ci025620t; Xia Z, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-S2-S6; Xu Xianjin, 2018, Biophys Rep, V4, P1, DOI 10.1007/s41048-017-0045-8; Yamanishi Y, 2008, BIOINFORMATICS, V24, pI232, DOI 10.1093/bioinformatics/btn162; Yamanishi Y, 2013, MOL INFORM, V32, P991, DOI 10.1002/minf.201300079; Yamanishi Y, 2010, BIOINFORMATICS, V26, pi246, DOI 10.1093/bioinformatics/btq176; Yuan QJ, 2016, BIOINFORMATICS, V32, P18, DOI 10.1093/bioinformatics/btw244; Zheng XD, 2013, 19TH ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING (KDD'13), P1025	67	4	4	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2018	13	10							e0204999	10.1371/journal.pone.0204999	http://dx.doi.org/10.1371/journal.pone.0204999			34	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV8IQ	30286165	Green Submitted, Green Published, gold			2023-01-03	WOS:000446383500072
J	Donohue, JM; Guclu, H; Gellad, WF; Chang, CCH; Huskamp, HA; Choudhry, NK; Zhang, RX; Lo-Ciganic, WH; Junker, SP; Anderson, T; Richards-Shubik, S				Donohue, Julie M.; Guclu, Hasan; Gellad, Walid F.; Chang, Chung-Chou H.; Huskamp, Haiden A.; Choudhry, Niteesh K.; Zhang, Ruoxin; Lo-Ciganic, Wei-Hsuan; Junker, Stefanie P.; Anderson, Timothy; Richards-Shubik, Seth			Influence of peer networks on physician adoption of new drugs	PLOS ONE			English	Article							PATIENT-SHARING NETWORKS; PRIMARY-CARE; SOCIAL NETWORKS; DIFFUSION; BEHAVIOR; CENTRALITY; INNOVATION; CONTAGION; MEDICARE; DECISION	Although physicians learn about new medical technologies from their peers, the magnitude and source of peer influence is unknown. We estimate the effect of peer adoption of three first-in-class medications (dabigatran, sitigliptin, and aliskiren) on physicians' own adoption of those medications. We included 11,958 physicians in Pennsylvania prescribing anticoagulant, antidiabetic, and antihypertensive medications. We constructed 4 types of peer networks based on shared Medicare and Medicaid patients, medical group affiliation, hospital affiliation, and medical school/residency training. Instrumental variables analysis was used to estimate the causal effect of peer adoption (fraction of peers in each network adopting the new drug) on physician adoption (prescribing at least the median number prescriptions within 15 months of the new drug's introduction). We illustrate how physician network position can inform targeting of interventions to physicians by computing a social multiplier. Dabigatran was adopted by 25.2%, sitagliptin by 24.5% and aliskiren by 8.3% of physicians. A 10-percentage point increase in peer adoption in the patient-sharing network led to a 5.90% (SE = 1.50%, p<0.001) increase in physician adoption of dabigatran, 8.32% (SE = 1.51%, p<0.001) increase in sitagliptin, and 7.84% increase in aliskiren adoption (SE = 2.93%, p<0.001). Peer effects through shared hospital affiliation were positive but not significant, and medical group and training network effects were not reliably estimated. Physicians in the top decile of patient-sharing network peers were estimated to have nearly 2-fold stronger influence on their peers' adoption compared to physicians in the top decile of prescribing volume. Limitations include lack of detailed clinical information and pharmaceutical promotion, variables which may influence physician adoption but which are unlikely to bias our peer effect estimates. Peer adoption, especially by those with whom physicians share patients, strongly influenced physician adoption of new drugs. Our study shows the potential for using information on physician peer networks to improve technology diffusion.	[Donohue, Julie M.; Junker, Stefanie P.] Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA; [Guclu, Hasan] Istanbul Medeniyet Univ, Sch Engn & Nat Sci, Dept Stat, Istanbul, Turkey; [Guclu, Hasan] Istanbul Medeniyet Univ, Sch Med, Dept Biostat & Med Informat, Istanbul, Turkey; [Gellad, Walid F.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Hlth Policy Inst, Pittsburgh, PA USA; [Gellad, Walid F.; Chang, Chung-Chou H.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; [Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA; [Chang, Chung-Chou H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA USA; [Huskamp, Haiden A.] Harvard Univ, Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA; [Choudhry, Niteesh K.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA; [Choudhry, Niteesh K.] Harvard Med Sch, Boston, MA USA; [Zhang, Ruoxin] Permanente Med Grp Inc, Qual & Operat Support, Oakland, CA USA; [Lo-Ciganic, Wei-Hsuan] Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Tucson, AZ 85721 USA; [Anderson, Timothy] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Richards-Shubik, Seth] Lehigh Univ, Coll Business & Econ, Dept Econ, Bethlehem, PA 18015 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Istanbul Medeniyet University; Istanbul Medeniyet University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Permanente Medical Groups; University of Arizona; University of California System; University of California San Francisco; Lehigh University	Donohue, JM (corresponding author), Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA.	jdonohue@pitt.edu	Guclu, Hasan/B-7080-2008; Guclu, Hasan/HJB-1612-2022	Guclu, Hasan/0000-0003-3582-9460; Guclu, Hasan/0000-0003-3582-9460; Donohue, Julie/0000-0003-2418-6017	National Heart, Lung, and Blood Institute [R01HL119246]; Permanente Medical Group, Inc.; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL119246] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Permanente Medical Group, Inc.; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by a grant from the National Heart, Lung, and Blood Institute (R01HL119246). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. One of our authors (RZ) is now employed by The Permanente Medical Group, Inc. She was employed solely by the University of Pittsburgh when the analyses for this manuscript were conducted. The Permanente Medical Group, Inc. provided support in the form of salary for author RZ when this work was submitted to PLOS ONE, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of this author are articulated in the 'author contributions' section.	Altalib HH, 2017, EPILEPSY BEHAV, V73, P31, DOI 10.1016/j.yebeh.2017.05.026; Banerjee A, 2013, SCIENCE, V341, P363, DOI 10.1126/science.1236498; Barnett ML, 2012, MED CARE, V50, P152, DOI 10.1097/MLR.0b013e31822dcef7; Barnett ML, 2011, HEALTH SERV RES, V46, P1592, DOI 10.1111/j.1475-6773.2011.01262.x; Becker G., 2000, SOCIAL ECONOMICS; Bhatia T, 2011, INT J RES MARK, V28, P51, DOI 10.1016/j.ijresmar.2010.10.002; Blume L.E., 2011, HDB SOCIAL EC, V1B; BONACICH P, 1987, AM J SOCIOL, V92, P1170, DOI 10.1086/228631; Brin S, 1998, COMPUT NETWORKS ISDN, V30, P107, DOI 10.1016/S0169-7552(98)00110-X; Casalino LP, 2015, MED CARE, V53, P534, DOI 10.1097/MLR.0000000000000365; Centola D, 2011, SCIENCE, V334, P1269, DOI 10.1126/science.1207055; Chambers D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041911; Christakis NA, 2010, CONTAGION PRESCRIBIN; COLEMAN J, 1957, SOCIOMETRY, V20, P253, DOI 10.2307/2785979; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Csardi G., 2006, IGRAPH SOFTWARE PACK; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; Desai NR, 2012, AM J MED, V125, DOI 10.1016/j.amjmed.2011.07.033; Fattore G, 2009, HEALTH POLICY, V92, P141, DOI 10.1016/j.healthpol.2009.03.005; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Flodgren G, 2011, COCHRANE DATABASE SY, V8; Gaviria A, 2001, REV ECON STAT, V83, P257, DOI 10.1162/00346530151143798; Grimshaw JM, 2001, MED CARE, V39, pII2; Institute of Medicine, 2013, VARIATION HLTH CARE, DOI [10.17226/18393, DOI 10.17226/18393]; Institute of Medicine, 2013, BUSINESS MODELS RESP; Iyengar R, 2011, MARKET SCI, V30, P195, DOI 10.1287/mksc.1100.0566; Kaiser Family Foundation, HLTH INS COV TOT POP; Kang CH, 2016, ARTIF INTELL, V239, P70, DOI 10.1016/j.artint.2016.06.008; Keating NL, 2007, J GEN INTERN MED, V22, P794, DOI 10.1007/s11606-007-0190-8; Keating NL, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx009; Landon BE, 2012, JAMA-J AM MED ASSOC, V308, P265, DOI 10.1001/jama.2012.7615; Lewis JM, 2008, SOC SCI MED, V67, P280, DOI 10.1016/j.socscimed.2008.03.046; Liu QH, 2018, CHAOS INTERDISCIPLIN, V28; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; Manchanda P, 2008, MARKET SCI, V27, P961, DOI 10.1287/mksc.1070.0354; MANSKI CF, 1993, REV ECON STUD, V60, P531, DOI 10.2307/2298123; Mascia D, 2011, SOC SCI MED, V72, P798, DOI 10.1016/j.socscimed.2010.12.011; McGettigan P, 2001, BRIT J CLIN PHARMACO, V51, P184; McPherson M, 2001, ANNU REV SOCIOL, V27, P415, DOI 10.1146/annurev.soc.27.1.415; Meltzer D, 2010, SOC SCI MED, V71, P1119, DOI 10.1016/j.socscimed.2010.05.012; Menchik DA, 2010, J HEALTH SOC BEHAV, V51, P137, DOI 10.1177/0022146510372231; Moen EL, 2016, HEALTH SERV OUTCOME, V16, P132, DOI 10.1007/s10742-016-0152-x; Moffitt R.A., 2001, SOCIAL DYNAMICS, P45; Morris ZS, 2011, J ROY SOC MED, V104, P510, DOI 10.1258/jrsm.2011.110180; Nair HS, 2010, J MARKETING RES, V47, P883, DOI 10.1509/jmkr.47.5.883; Neumann PJ, 2005, NEW ENGL J MED, V353, P1516, DOI 10.1056/NEJMsb050564; Norris S., 2010, DRUG CLASS REV DIREC; Pollack CE, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw330; Pollack CE, 2012, HEALTH SERV RES, V47, P380, DOI 10.1111/j.1475-6773.2011.01331.x; Prosser H, 2006, SOC SCI MED, V62, P1565, DOI 10.1016/j.socscimed.2005.08.035; Prosser H, 2003, FAM PRACT, V20, P61, DOI 10.1093/fampra/20.1.61; Scott J, 2005, ANN FAM MED, V3, P443, DOI 10.1370/afm.344; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; Stock J.H., 2005, NBER TECHNICAL WORKI; Valente TW, 2012, SCIENCE, V337, P49, DOI 10.1126/science.1217330; Valente TW, 1999, ANN AM ACAD POLIT SS, V566, P55, DOI 10.1177/0002716299566001005; Van den Bulte C, 2001, AM J SOCIOL, V106, P1409, DOI 10.1086/320819; Van Hoof TJ, 2015, AM HEALTH DRUG BENEF, V8, P414; Wasserman S., 1994, STRUCTURAL ANAL SOCI, DOI [10.1017/CBO9780511815478, DOI 10.1017/CBO9780511815478]; Wooldridge JM, 2010, ECONOMETRIC ANALYSIS OF CROSS SECTION AND PANEL DATA, 2ND EDITION, P1; Yeh JS, 2016, AM HEALTH DRUG BENEF, V9, P42; Yusuf S, 2008, NEW ENGL J MED, V358, P1547, DOI 10.1056/NEJMoa0801317; Zheng K, 2010, J AM MED INFORM ASSN, V17, P328, DOI 10.1136/jamia.2009.000877	63	25	25	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2018	13	10							e0204826	10.1371/journal.pone.0204826	http://dx.doi.org/10.1371/journal.pone.0204826			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GV5EV	30273368	Green Published, gold, Green Submitted			2023-01-03	WOS:000446124700037
J	Aung, K				Aung, KoKo			Review: Liberal oxygen increases mortality in acutely ill adults compared with conservative oxygen therapy	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Aung, KoKo] Paul L Foster Sch Med, El Paso, TX 79905 USA		Aung, K (corresponding author), Paul L Foster Sch Med, El Paso, TX 79905 USA.		Aung, KoKo/I-1236-2019	Aung, KoKo/0000-0002-3152-0610				Bhandari V, 2006, FREE RADICAL BIO MED, V41, P4, DOI 10.1016/j.freeradbiomed.2006.01.027; Cornet AD, 2013, CRIT CARE, V17, DOI 10.1186/cc12554; Damiani E, 2018, CURR OPIN ANESTHESIO, V31, P129, DOI 10.1097/ACO.0000000000000559	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 18	2018	169	6					JC29	JC29		10.7326/ACPJC-2018-169-6-029	http://dx.doi.org/10.7326/ACPJC-2018-169-6-029			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT7CZ	30242402				2023-01-03	WOS:000444679800005
J	Siyoum, M; Astatkie, A; Mekonnen, S; Bekele, G; Taye, K; Tenaw, Z; Yohannes, Z; Kassaye, Z				Siyoum, Melese; Astatkie, Ayalew; Mekonnen, Shewangizaw; Bekele, Gezahegn; Taye, Kefyalew; Tenaw, Zelalem; Yohannes, Zemenu; Kassaye, Zerai			Home birth and its determinants among antenatal care-booked women in public hospitals in Wolayta Zone, southern Ethiopia	PLOS ONE			English	Article							DELIVERY; MORTALITY; PLACE	Introduction Antenatal care (ANC), health facility birth and postnatal care services are proved to reduce maternal and newborn morbidity and mortality. In Ethiopia, even though antenatal care coverage is good, still home birth is high. This study aimed to assess the prevalence and determinants of home birth among women who were booked for ANC in public hospitals in Wolaita zone, southern Ethiopia. Methods A cohort study was conducted from February to May 2017 among 554 third trimester pregnant mothers who visited public hospitals of Wolaita Zone, southern Ethiopia for ANC service. All women were interviewed twice: the first interview was done face-to-face in the health facility in which they were having ANC follow up to gather information about basic socio-demographic and obstetric characteristics; the second interview was done via telephone after they gave birth to get information about the place of birth. Epi-Data version 3.1 was used for data entry and the Statistical Package for the Social Sciences (SPSS) version 22 was used for data analysis. Results A total of 68 (13.5%; 95% Confidence Interval (CI): 10.5%-16.6%) women who were booked for ANC gave birth at home. Being uneducated (AOR = 2.46, 95% CI: [1.10-5.10]), starting ANC visit late (>16weeks) (AOR = 2.27, 95% CI: [1.14-4.50]), time taken to reach at health facility for ANC service (>30minutes) (AOR = 8.94, 95% CI: [4.50-17.72]), waiting time of greater than 30 minutes for ANC in health facilities (AOR = 1.18, 95% CI: [1.06-2.30]) and lack of knowledge about danger signs of pregnancy (AOR = 4.18, 95% CI: [1.80-9.70]) were significantly associated with home birth. Conclusions Home birth among ANC booked women is low compared to other studies. Yet, giving attention to women with no education and those coming from far areas while providing advice on birth preparedness and pregnancy danger signs may be useful to further reduce the rate of home birth. Advising mothers to start ANC early and trying to reduce ANC waiting time could also be of importance.	[Siyoum, Melese; Mekonnen, Shewangizaw; Bekele, Gezahegn; Tenaw, Zelalem; Yohannes, Zemenu] Hawassa Univ, Sch Nursing & Midwifery, Coll Med & Hlth Sci, Hawassa, Ethiopia; [Astatkie, Ayalew] Hawassa Univ, Sch Publ & Environm Hlth, Coll Med & Hlth Sci, Hawassa, Ethiopia; [Taye, Kefyalew; Kassaye, Zerai] Hawassa Univ, Sch Med, Coll Med & Hlth Sci, Hawassa, Ethiopia	Hawassa University; Hawassa University; Hawassa University	Siyoum, M (corresponding author), Hawassa Univ, Sch Nursing & Midwifery, Coll Med & Hlth Sci, Hawassa, Ethiopia.	melesesiyoum755@gmail.com	Astatkie, Ayalew/I-1167-2019	Astatkie, Ayalew/0000-0002-4840-9601; Siyoum, Melese/0000-0001-5451-5665; Dadi, Gezahegn Bekele/0000-0003-4119-3526	Save Newborn Life Phase-III Project of Save the Children Ethiopia, SNNPR branch	Save Newborn Life Phase-III Project of Save the Children Ethiopia, SNNPR branch	We extend our heartfelt gratitude to the Save Newborn Life Phase-III Project of Save the Children Ethiopia, SNNPR branch for financial support. The College of Medicine and Health Sciences of Hawassa University, Hawassa, Ethiopia also deserves thanks for initiating the collaboration with Save the Children Ethiopia. We are indebted to Professor Yemane Berhane for his comments and guidance in designing this study. We also remain thankful to Dr. Fitsum Woldegebriel (from Hawassa University), data collectors, study participants, and officials of Wolayta Zone Health Department and public hospitals in Wolayta zone who helped us one way or another in accomplishing this study.	Abebe Fantu, 2012, BMC Res Notes, V5, P653, DOI 10.1186/1756-0500-5-653; Abeje G, 2014, REPROD HLTH, V11, P1, DOI [10.1186/1742-4755-11-1, DOI 10.1186/1742-4755-11-1]; Amano A, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-105; Bedilu Kucho, 2017, Journal of Public Health and Epidemiology, V9, P177, DOI 10.5897/JPHE2017.0921; Berhan Y, 2014, ETHIOP J HEALTH SCI, V24, P69, DOI 10.4314/ejhs.v24i0.7S; Birmeta K, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-256; Carroli G, 2001, PAEDIATR PERINAT EP, V15, P1; Central Statistical Agency (CSA), 2012, ETH DEM HLTH SURV 20; Central Statistical Agency (CSA) [Ethiopia] ICF, 2016, ETHIOPIA DEMOGRAPHIC; Chinkhumba J, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1014; CSA, 2014, ETH MIN DEM HLTH SUR; Desalegn E., 2014, J GYNECOLOGY OBSTET, V2, P1, DOI [DOI 10.11648/j.jgo.20140201.11, DOI 10.11648/J.JG0.20140201.11]; Ekele BA, 2007, ACTA OBSTET GYN SCAN, V86, P627, DOI 10.1080/00016340601134622; Faye A, 2010, REV EPIDEMIOL SANTE, V58, P323, DOI 10.1016/j.respe.2010.05.004; Fedral Minstry Of Health Ethiopia (FMOH), 2010, MAN PROT SEL OBST TO; Iyaniwura C, 2009, AFRICAN J REPROD HLT, V13; Karkee R, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-193; Kasaye HK, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1409-2; Mengesha ZB, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-130; Mills S, 2008, MATERN CHILD HLTH J, V12, P509, DOI 10.1007/s10995-007-0288-y; Montagu D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017155; Nduka I., 2014, Journal of Medical Investigations and Practice, V9, P102; Shiferaw S, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-5; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Tadese F., 2014, CLIN MOTHER CHILD HL, V11, P164; Teferra AS, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-74; Tsegay R, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4159-1; Tsegay Y, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-30; UNFPA, 2012, TRENDS MAT HLTH ETH; Wagle Rajendra Raj, 2004, BMC Pregnancy Childbirth, V4, P8, DOI 10.1186/1471-2393-4-8; Workineh S., 2015, HLTH SCI J, V9, P1; Zegeye K, 2014, PRIMARY HLTH CARE, V4, P2167, DOI [10.4172/2167-1079.1000152, DOI 10.4172/2167-1079.1000152]	32	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2018	13	9							e0203609	10.1371/journal.pone.0203609	http://dx.doi.org/10.1371/journal.pone.0203609			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT0BU	30192861	Green Published, Green Submitted, gold			2023-01-03	WOS:000444093600117
J	Fittler, A; Vida, RG; Radics, V; Botz, L				Fittler, Andras; Vida, Robert Gyorgy; Radics, Valter; Botz, Lajos			A challenge for healthcare but just another opportunity for illegitimate online sellers: Dubious market of shortage oncology drugs	PLOS ONE			English	Article							PRESCRIPTION DRUGS; PATIENT SAFETY; UNITED-STATES; AVAILABILITY; PHARMACIES; IMPACT; MONEY; CALL	Introduction Drug shortages mean a challenge to healthcare systems. Exposed patients or health care providers may seek alternative resources for these products online. The purpose of our study was to analyze the online availability of oncology shortage drugs at national and at international levels in 2014 and 2016. Methods We tested the online accessibility of oncology shortage drugs by simulating the Internet search method of patients. Search results were evaluated according to operational, distributional, and patient safety characteristics. Results In 2014 and 2016 all (100%) antineoplastic agents affected by shortages were available on the Internet without medical prescription. The number of relevant websites among search engine results has decreased from 112 to 98, while online vendors actually offering oncology shortage drugs for sale has risen from 66.1% to 80.6% within relevant websites in the two evaluated years. None of the online sellers were classified as legitimate or accredited by LegitScript and VIPPS online pharmacy verification databases. Conclusion According to our findings shortage oncology drugs are widely available online. To manage shortages and illegal Internet trade national and international standardized shortage reporting and information systems, regularly updated Internet pharmacy verification databases are needed. As well, institutional procurement and medication use review policies are required.	[Fittler, Andras] Univ Pecs, Fac Pharm, Dept Pharmaceut, Pecs, Hungary; Univ Pecs, Fac Pharm, Cent Clin Pharm, Pecs, Hungary	University of Pecs; University of Pecs	Fittler, A (corresponding author), Univ Pecs, Fac Pharm, Dept Pharmaceut, Pecs, Hungary.	fittler.andras@pte.hu	Vida, Róbert György/AAC-5740-2019; Fittler, András/O-1768-2019	Vida, Róbert György/0000-0003-1176-0251; Fittler, András/0000-0002-8243-6179	European Union; European Social Fund	European Union(European Commission); European Social Fund(European Social Fund (ESF))	The project has been supported by the European Union, co-financed by the European Social Fund within the framework of Comprehensive Development for Implementing Smart Specialization Strategies at the University of PeAcs.	Alsheikh Mona, 2016, Hosp Pharm, V51, P370, DOI 10.1310/hpj5105-370; Alwon BM, 2015, INT J CLIN PHARM-NET, V37, P148, DOI 10.1007/s11096-014-0056-1; Anna Gu, 2011, INNOVATIONS PHARM, V2; ASHP Expert Panel on Drug Product Shortages, 2009, Am J Health Syst Pharm, V66, P1399, DOI 10.2146/ajhp090026; Bauters T, 2016, J ONCOL PHARM PRACT, V22, P766, DOI 10.1177/1078155215610915; Blackstone EA, 2014, AM HEALTH DRUG BENEF, V7, P216; Butterfield Lindsay, 2015, J Pediatr Pharmacol Ther, V20, P149, DOI 10.5863/1551-6776-20.2.149; Cancer medicines shortages in Europe, 2017, REP EC INT UNIT SUPP; Caulder Celeste R, 2015, Hosp Pharm, V50, P279, DOI 10.1310/hpj5004-279; Center for Drug Evaluation and Research FDA, 2006, MAN POL PROC DRUG SH, P2; de Lemos ML, 2016, J ONCOL PHARM PRACT, V22, P566, DOI 10.1177/1078155215589980; De Weerdt E, 2017, APPL HEALTH ECON HEA, V15, P441, DOI 10.1007/s40258-016-0264-z; De Weerdt E, 2015, FRONT PHARMACOL, V6, DOI [10.3329/fphar.2015.00253, 10.3389/fphar.2015.00253]; European Association of Hospital Pharmacists, 2012, EAHP STAT MED SHORT; European Association of Hospital Pharmacists, 2014, EAHPS 2014 SURV MED; European Association of Hospital Pharmacists, 2013, MED SHORT EUR HOSP; European Federation of Pharmaceutical Industries and Associations, 2014, EFPIA GOOD PRACT REV; European Medicines Agency, 2012, EMA5907452012; Fittler A, 2014, EUROPEAN J HOSP PHAR, V21, pA67; Fittler A, 2013, J MED INTERNET RES, V15, P227, DOI 10.2196/jmir.2606; Food and Drug Administration, FDA ACTS PREV MOR DR; Food and Drug Administration, FDA DRUG SHORT CURR; Fox ER, 2014, MAYO CLIN PROC, V89, P361, DOI 10.1016/j.mayocp.2013.11.014; Gabay Michael, 2015, Hosp Pharm, V50, P681, DOI 10.1310/hpj5008-681; GAO, 2016, GAO16595; Gatesman ML, 2011, NEW ENGL J MED, V365, P1653, DOI 10.1056/NEJMp1109772; Goldsack JC, 2014, AM J HEALTH-SYST PH, V71, P571, DOI 10.2146/ajhp130569; Gray A, 2012, B WORLD HEALTH ORGAN, V90, P158, DOI 10.2471/BLT.11.101303; Hawley KL, 2016, ACAD EMERG MED, V23, P63, DOI 10.1111/acem.12838; Holloway Kathleen, DRUG THERAPEUTICS PR, P1; Hughes Kaitlin M, 2015, J Pediatr Pharmacol Ther, V20, P453, DOI 10.5863/1551-6776-20.6.453; Huys Isabelle, 2013, Int J Pharm Pract, V21, P1, DOI 10.1111/ijpp.12012; IMS Institute for Healthcare Informatics, 2011, DRUG SHORT CLOS LOOK; Institute for Safe Medication Practices, 2014, DRUG SHORT SUMM; Institute for Safe Medication Practices (ISMP), 2010, ISMP MED SAFETY ALER, V15, P1; International Pharmaceutical Federation, 2013, REP INT SUMM MED SHO; International Pharmaceutical Federation, 2011, FIP CALLS ATT MED SH; INTERPOL, OP PANG COMB SAL ILL; ISPE, 2013, REP ISPE DRUG SHORT; Iyengar S, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0674-7; Kaposy C, 2014, J BIOETHIC INQ, V11, P85, DOI 10.1007/s11673-013-9494-z; Kehl KL, 2015, J ONCOL PRACT, V11, pE154, DOI 10.1200/JOP.2014.000380; Lagan BM, 2014, PHARMACOEPIDEM DR S, V23, P411, DOI 10.1002/pds.3565; Levaggi R, 2012, HEALTH POLICY, V106, P241, DOI 10.1016/j.healthpol.2012.05.003; Levaggi R, 2009, HEALTH POLICY, V92, P187, DOI 10.1016/j.healthpol.2009.03.010; Liang BA, 2012, NAT REV UROL, V9, P480, DOI 10.1038/nrurol.2012.148; Liang BA, 2012, J MED INTERNET RES, V14, DOI 10.2196/jmir.1999; Liang BA, 2012, VACCINE, V30, P105, DOI 10.1016/j.vaccine.2011.11.016; Liang BA, 2009, AM J LAW MED, V35, P125, DOI 10.1177/009885880903500104; Link MP, 2012, J CLIN ONCOL, V30, P692, DOI 10.1200/JCO.2011.41.0936; Mackey Tim K, 2016, Br Med Bull, V118, P110, DOI 10.1093/bmb/ldw016; Mackey T, 2015, INT J CLIN PHARM-NET, V37, P1076, DOI 10.1007/s11096-015-0154-8; Mackey TK, 2012, J ONCOL PRACT, V8, P341, DOI 10.1200/JOP.2012.000579; Mackey TK, 2011, J PHARM SCI-US, V100, P4571, DOI 10.1002/jps.22679; Malone C, 2016, Ulster Med J, V85, P174; Mazer-Amirshahi M, 2017, J CRIT CARE, V41, P283, DOI 10.1016/j.jcrc.2017.06.005; McKeever AE, 2013, CLIN J ONCOL NURS, V17, P490, DOI 10.1188/13.CJON.490-495; McLaughlin M, 2013, J MANAGE CARE PHARM, V19, P783, DOI 10.18553/jmcp.2013.19.9.783; McLaughlin MM, 2014, AM J HEALTH-SYST PH, V71, P2074, DOI 10.2146/ajhp140116; Monteith S, 2016, J AFFECT DISORDERS, V193, P59, DOI 10.1016/j.jad.2015.12.043; National Association of Boards of Pharmacy, 2016, PHARM GEN TOP LEV DO; National Institute of Pharmacy and Nutrition, TEMP DUG SHORT; Nyaka Bernadett, 2016, J HUNGARIAN INTERDIS, V15, P42; Orizio G, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1795; Orizio G, 2009, EUR J PUBLIC HEALTH, V19, P375, DOI 10.1093/eurpub/ckn146; Parsons HM, 2016, J ONCOL PRACT, V12, pE289, DOI 10.1200/JOP.2015.007237; Pauwels K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119322; Pauwels K, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-438; Quadri F, 2015, CLIN INFECT DIS, V60, P1737, DOI 10.1093/cid/civ201; Reed BN, 2016, AM HEART J, V175, P130, DOI 10.1016/j.ahj.2016.02.004; Ridley DB, 2016, HEALTH AFFAIR, V35, P235, DOI 10.1377/hlthaff.2015.0420; Romito Bryan, 2015, Hosp Pharm, V50, P798, DOI 10.1310/hpj5009-798; Schweitzer SO, 2013, AM J PUBLIC HEALTH, V103, pE10, DOI 10.2105/AJPH.2013.301239; Stephens Martin, 2011, HOSP PHARM 11 STRAT, P181; Taylor Phil, 2012, DRUG SHORTAGES RAISI; US Government Accountability Office, 2014, GAO14194; Valgus J, 2013, J ONCOL PRACT, V9, pE21, DOI 10.1200/JOP.2012.000779; Verified Internet Pharmacy Practice Sites (VIPPS) National Association of Boards of Pharmacy, VIPPS ACCR PHARM LIS; Vida RG, 2017, INT J CLIN PHARM-NET, V39, P78, DOI 10.1007/s11096-016-0398-y; Woodcock J, 2013, CLIN PHARMACOL THER, V93, P170, DOI 10.1038/clpt.2012.220; Yang CJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165183	81	11	11	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2018	13	8							e0203185	10.1371/journal.pone.0203185	http://dx.doi.org/10.1371/journal.pone.0203185			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GR8TH	30153304	Green Published, gold, Green Submitted			2023-01-03	WOS:000443001700049
J	Schneller, LM; Bansal-Travers, M; Goniewicz, ML; McIntosh, S; Ossip, D; O'Connor, RJ				Schneller, Liane M.; Bansal-Travers, Maansi; Goniewicz, Maciej L.; McIntosh, Scott; Ossip, Deborah; O'Connor, Richard J.			Use of flavored electronic cigarette refill liquids among adults and youth in the US-Results from Wave 2 of the Population Assessment of Tobacco and Health Study (2014-2015)	PLOS ONE			English	Article							PRODUCT USE; NICOTINE; PREFERENCES; REASONS; SMOKERS	Introduction Flavored e-cigarettes are enticing to new users and established cigarette smokers using e-cigarettes to quit smoking due to the wide variety of flavor options. However, specific flavor combinations that are popular among e-cigarette users are understudied. Recently, the Deeming rule extended the US Food and Drug Administration's authority over all tobacco products, including e-cigarettes. Methods The Population Assessment of Tobacco and Health Study Wave 2 data were analyzed to assess the prevalence of self-reported flavor categories that are used individually and in combination with other flavor categories among past 30-day youth and adult e-cigarette users in the US. Results Most youth and adult participants reported using a flavored e-cigarette. Reporting an individual flavor category was more common than reporting a combination of flavor categories. Fruit flavor was the most common flavor category reported among youth, and 'menthol/mint' was most common among adults. Fruit and candy/other sweets were the most common flavor categories reported together among both youth and adult past 30-day e-cigarette users. Conclusions The use of flavored e-cigarettes is very popular among youth and adults. Most consumers reported using a single flavor category, although some consumers did use a combination of flavor categories. Preference for menthol/mint among adults may represent from associations with tobacco cigarettes. Typically, sweeter flavors, such as fruit, were among the most popular flavor categories reported, both individually and in combination with other flavors, while more bitter flavors (i.e.: clove/spice) were less common.	[Schneller, Liane M.; Bansal-Travers, Maansi; Goniewicz, Maciej L.; O'Connor, Richard J.] Roswell Pk Comprehens Canc Ctr, Dept Hlth Behav, Buffalo, NY 14203 USA; [McIntosh, Scott; Ossip, Deborah] Univ Rochester, Med Ctr, Dept Publ Hlth Sci, Rochester, NY 14642 USA	University of Rochester	O'Connor, RJ (corresponding author), Roswell Pk Comprehens Canc Ctr, Dept Hlth Behav, Buffalo, NY 14203 USA.	Richard.OConnor@Roswellpark.org	Bansal-Travers, Maansi/AFM-0150-2022; Bansal-Travers, Maansi/AAH-2486-2022; Goniewicz, Maciej L/D-8986-2012; Goniewicz, Maciej Lukasz/Z-1604-2019	Bansal-Travers, Maansi/0000-0002-7944-3570; Bansal-Travers, Maansi/0000-0002-7944-3570; Goniewicz, Maciej Lukasz/0000-0001-6748-3068	Roswell Park Cancer Institute; National Cancer Institute (NCI) [P30CA016056]; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	Roswell Park Cancer Institute; National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Roswell Park Cancer Institute and National Cancer Institute (NCI) grant P30CA016056. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	[Anonymous], [No title captured]; Arrozola RA, 2015, MMWR-MORBID MORTAL W, V64, P381; Audrain-McGovern J, 2016, DRUG ALCOHOL DEPEN, V166, P263, DOI 10.1016/j.drugalcdep.2016.06.030; Berg CJ, 2016, INT J PUBLIC HEALTH, V61, P225, DOI 10.1007/s00038-015-0764-x; Berridge KC, 2009, CURR OPIN PHARMACOL, V9, P65, DOI 10.1016/j.coph.2008.12.014; Coleman BN, 2017, TOB CONTROL, V26, pe117, DOI 10.1136/tobaccocontrol-2016-053462; Dai HY, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-2513; Dawkins L, 2013, ADDICTION, V108, P1115, DOI 10.1111/add.12150; Fairchild AL, 2014, NEW ENGL J MED, V370, P293, DOI 10.1056/NEJMp1313940; Gindi R.M., 2015, ELECT CIGARETTE USE; Hoffman AC, 2016, TOB CONTROL, V25, pii32, DOI 10.1136/tobaccocontrol-2016-053192; Kasza KA, 2017, NEW ENGL J MED, V376, P342, DOI 10.1056/NEJMsa1607538; Kim H, 2016, TOB CONTROL, V25, pii55, DOI 10.1136/tobaccocontrol-2016-053221; Kowitt SD, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14040338; Leigh NJ, 2016, TOB CONTROL, V25, pii81, DOI 10.1136/tobaccocontrol-2016-053205; Morean ME, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189015; Pesko MF, 2016, ADDICTION, V111, P734, DOI 10.1111/add.13257; Soule EK, 2016, DRUG ALCOHOL DEPEN, V166, P168, DOI 10.1016/j.drugalcdep.2016.07.007; United States Department of Health and Human Services. National Institutes of Health. National Institute on Drug Abuse and United States Department of Health and Human Services. Food and Drug Administration. Center for Tobacco Products, 2017, POP ASS TOB HLTH PAT; Villanti AC, 2017, AM J PREV MED, V53, P139, DOI 10.1016/j.amepre.2017.01.026; Yingst JM, 2017, NICOTINE TOB RES, V19, P1381, DOI 10.1093/ntr/ntw383; Zhu SH, 2014, TOB CONTROL, V23, P3, DOI 10.1136/tobaccocontrol-2014-051670	22	35	35	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2018	13	8							e0202744	10.1371/journal.pone.0202744	http://dx.doi.org/10.1371/journal.pone.0202744			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GR6TZ	30138412	Green Submitted, gold, Green Published			2023-01-03	WOS:000442800100116
J	Pardo, R; Vila, M; Cervela, L; de Marco, M; Gama-Perez, P; Gonzalez-Franquesa, A; Statuto, L; Vilallonga, R; Simo, R; Garcia-Roves, PM; Villena, JA				Pardo, Rosario; Vila, Maria; Cervela, Luis; de Marco, Marina; Gama-Perez, Pau; Gonzalez-Franquesa, Alba; Statuto, Lucia; Vilallonga, Ramon; Simo, Rafael; Garcia-Roves, Pablo M.; Villena, Josep A.			Calorie restriction prevents diet-induced insulin resistance independently of PGC-1-driven mitochondrial biogenesis in white adipose tissue	FASEB JOURNAL			English	Article						oxidative metabolism; adipocytes; glucose homeostasis; mitochondria	TRANSCRIPTIONAL CONTROL; PGC-1 COACTIVATORS; SKELETAL-MUSCLE; WEIGHT-LOSS; FAT DIET; INFLAMMATION; MICE; METABOLISM; OBESITY; EXPRESSION	Calorie restriction (CR) exerts remarkable, beneficial effects on glucose homeostasis by mechanisms that are not fully understood. Given the relevance of white adipose tissue (WAT) in glucose homeostasis, we aimed at identifying the main cellular processes regulated in WAT in response to CR in a pathologic context of obesity. For this, a gene-expression profiling study was first conducted in mice fed ad libitum or subjected to 40% CR. We found that the gene network related to mitochondria was the most highly upregulated in WAT by CR. To study the role that increased mitochondrial biogenesis plays on glucose homeostasis following CR, we generated a mouse model devoid of the coactivators peroxisome proliferator-activated receptor coactivator 1 (PGC-1) and PGC-1 specifically in adipocytes. Our results show that mice lacking PGC-1s in adipocytes are unable to increase mitochondrial biogenesis in WAT upon CR. Despite a blunted induction of mitochondrial biogenesis in response to calorie deprivation, mice lacking adipose PGC-1s still respond to CR by improving their glucose homeostasis. Our study demonstrates that PGC-1 coactivators are major regulators of CR-induced mitochondrial biogenesis in WAT and that increased mitochondrial biogenesis and oxidative function in adipose tissue are not required for the improvement of glucose homeostasis mediated by CR.Pardo, R., Vila, M., Cervela, L., de Marco, M., Gama-Perez, P., Gonzalez-Franquesa, A., Statuto, L., Vilallonga, R., Simo, R., Garcia-Roves, P. M., Villena, J. A. Calorie restriction prevents diet-induced insulin resistance independently of PGC-1-driven mitochondrial biogenesis in white adipose tissue.	[Pardo, Rosario; Vila, Maria; Cervela, Luis; de Marco, Marina; Statuto, Lucia; Vilallonga, Ramon; Villena, Josep A.] Univ Autonoma Barcelona, Lab Metab & Obes, Barcelona, Spain; [Simo, Rafael] Univ Autonoma Barcelona, Vall dHebron Inst Recerca, Unit Diabet & Metab, Barcelona, Spain; [Gama-Perez, Pau; Gonzalez-Franquesa, Alba; Garcia-Roves, Pablo M.] Univ Barcelona, Hosp Llobregat, Inst Invest Biomed Bellvitge, Dept Physiol Sci, Barcelona, Spain; [Vilallonga, Ramon] Vall dHebron Univ Hosp, European Accreditat Council Bariatr Surg, Ctr Excellence, Metab & Bariatr Surg Unit, Barcelona, Spain; [Simo, Rafael; Villena, Josep A.] Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Barcelona, Spain; [Gonzalez-Franquesa, Alba] Univ Copenhagen, Novo Nordisk Ctr Basic Metab Res, Copenhagen, Denmark	Autonomous University of Barcelona; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Hospital Universitari Vall d'Hebron; CIBER - Centro de Investigacion Biomedica en Red; CIBERDEM; Instituto de Salud Carlos III; University of Copenhagen	Villena, JA (corresponding author), Vall dHebron Inst Recerca, Unit Diabet & Metab, Lab Metab & Obes, Passeig Vall dHebron 119-129, Barcelona 08035, Spain.	josep.villena@vhir.org	Vilà-Rovira, Maria/GLT-6460-2022; Roves, Pablo Garcia/A-7113-2015; , VILALLONGA/AAO-5437-2020; Gonzalez-Franquesa, Alba/G-1691-2015; Cervela Cardona, Luis Manuel/AAP-3192-2021; Garcia-Roves, Pablo M./X-4585-2018	Gonzalez-Franquesa, Alba/0000-0001-9081-753X; Villena, Josep A/0000-0002-2200-2985; Cervela Cardona, Luis Manuel/0000-0002-7293-4473; Garcia-Roves, Pablo M./0000-0002-8371-2067; Simo Canonge, Rafael/0000-0003-0475-3096	Ministerio de Economia y competitividad (MINECO/FEDER; Spain) [SAF2011-23886, SAF2012-39484]; Instituto de Salud Carlos III (ISCIII) [PI15/00701]	Ministerio de Economia y competitividad (MINECO/FEDER; Spain); Instituto de Salud Carlos III (ISCIII)(Instituto de Salud Carlos IIIEuropean Commission)	The authors thank Anastasia Kralli (Johns Hopkins University, Baltimore, MD, USA) for the Ppargc1a<SUP>flox/flox</SUP> and Ppargc1b<SUP>flox/flox</SUP> mice and helpful discussions. This work was supported by Grants SAF2011-23886 and SAF2012-39484 from Ministerio de Economia y competitividad (MINECO/FEDER; Spain) to J.A.V. and Grant PI15/00701 from Instituto de Salud Carlos III (ISCIII) to P.M.G.-R. The authors declare no conflicts of interest.	[Anonymous], 2015, IDF DIABETES ATLAS; Barger JL, 2017, AGING CELL, V16, P750, DOI 10.1111/acel.12608; Barquissau V, 2018, CELL REP, V22, P1079, DOI 10.1016/j.celrep.2017.12.102; Boden G, 2005, DIABETES, V54, P880, DOI 10.2337/diabetes.54.3.880; Bogacka I, 2005, DIABETES, V54, P1392, DOI 10.2337/diabetes.54.5.1392; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Bruce CR, 2003, J CLIN ENDOCR METAB, V88, P5444, DOI 10.1210/jc.2003-030791; Canto Carles, 2015, Curr Protoc Mouse Biol, V5, P135, DOI 10.1002/9780470942390.mo140061; Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071; Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076; Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780; Eguchi J, 2011, CELL METAB, V13, P249, DOI 10.1016/j.cmet.2011.02.005; Enguix N, 2013, MOL METAB, V2, P215, DOI 10.1016/j.molmet.2013.05.004; Fabbiano S, 2016, CELL METAB, V24, P434, DOI 10.1016/j.cmet.2016.07.023; Feige JN, 2008, CELL METAB, V8, P347, DOI 10.1016/j.cmet.2008.08.017; Finley LWS, 2012, P NATL ACAD SCI USA, V109, P2931, DOI 10.1073/pnas.1115813109; Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633; Guilherme A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; Hancock CR, 2011, FASEB J, V25, P785, DOI 10.1096/fj.10-170415; Henegar C, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r14; Higami Y, 2003, FASEB J, V17, P415, DOI 10.1096/fj.03-0678fje; HIMMSHAGEN J, 1985, INT J OBESITY, V9, P17; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Kang K, 2008, CELL METAB, V7, P485, DOI 10.1016/j.cmet.2008.04.002; Kelly TJ, 2009, J BIOL CHEM, V284, P19945, DOI 10.1074/jbc.M109.015164; Khan T, 2009, MOL CELL BIOL, V29, P1575, DOI 10.1128/MCB.01300-08; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lasheras J, 2016, MOL CELL ENDOCRINOL, V430, P77, DOI 10.1016/j.mce.2016.04.004; Lopez-Lluch G, 2006, P NATL ACAD SCI USA, V103, P1768, DOI 10.1073/pnas.0510452103; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; Meydani SN, 2016, AGING-US, V8, P1416, DOI 10.18632/aging.100994; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Nedergaard J, 2013, BBA-MOL CELL BIOL L, V1831, P943, DOI 10.1016/j.bbalip.2013.01.009; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Pardo R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026989; Park CY, 2017, BIOCHEM BIOPH RES CO, V490, P636, DOI 10.1016/j.bbrc.2017.06.090; Pasarica M, 2009, J CLIN ENDOCR METAB, V94, P5155, DOI 10.1210/jc.2009-0947; Pellegrinelli V, 2016, DIABETOLOGIA, V59, P1075, DOI 10.1007/s00125-016-3933-4; Pope BD, 2016, TRENDS CELL BIOL, V26, P745, DOI 10.1016/j.tcb.2016.05.005; REAVEN E, 1983, DIABETES, V32, P175, DOI 10.2337/diabetes.32.2.175; Reilly SM, 2017, NAT REV ENDOCRINOL, V13, P633, DOI 10.1038/nrendo.2017.90; Rong JX, 2007, DIABETES, V56, P1751, DOI 10.2337/db06-1135; ROTHWELL NJ, 1982, BIOSCIENCE REP, V2, P543, DOI 10.1007/BF01314214; Sun K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4485; Uldry M, 2006, CELL METAB, V3, P333, DOI 10.1016/j.cmet.2006.04.002; VILLARROYA F, 1986, BIOSCIENCE REP, V6, P669, DOI 10.1007/BF01114762; Villena JA, 2007, P NATL ACAD SCI USA, V104, P1418, DOI 10.1073/pnas.0607696104; Villena JA, 2015, FEBS J, V282, P647, DOI 10.1111/febs.13175; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Wetter TJ, 1999, AM J PHYSIOL-ENDOC M, V276, pE728; Wilson-Fritch L, 2004, J CLIN INVEST, V114, P1281, DOI 10.1172/JCI200421752; Zamora M, 2014, CURR PHARM DESIGN, V20, P5527, DOI 10.2174/1381612820666140306102514	55	16	17	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2019	33	2					2343	2358		10.1096/fj.201800310R	http://dx.doi.org/10.1096/fj.201800310R			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HJ6KJ	30277821	Green Submitted			2023-01-03	WOS:000457296600065
J	Zanotto, T; Mercer, TH; van der Linden, ML; Traynor, JP; Petrie, CJ; Doyle, A; Chalmers, K; Allan, N; Price, J; Oun, H; Shilliday, I; Koufaki, P				Zanotto, Tobia; Mercer, Thomas H.; van der Linden, Marietta L.; Traynor, Jamie P.; Petrie, Colin J.; Doyle, Arthur; Chalmers, Karen; Allan, Nicola; Price, Jonathan; Oun, Hadi; Shilliday, Ilona; Koufaki, Pelagia			Baroreflex function, haemodynamic responses to an orthostatic challenge, and falls in haemodialysis patients	PLOS ONE			English	Article							BLOOD-PRESSURE; EFFECTIVENESS INDEX; RISK-FACTORS; MORTALITY; SENSITIVITY; ASSOCIATION; PREVENTION; DIAGNOSIS; ACCURACY; INJURIES	Background Stage 5 chronic kidney disease patients on haemodialysis (HD) often present with dizziness and pre-syncopal events as a result of the combined effect of HD therapy and cardiovascular disease. The dysregulation of blood pressure (BP) during orthostasis may be implicated in the aetiology of falls in these patients. Therefore, we explored the relationship between baroreflex function, the haemodynamic responses to a passive orthostatic challenge, and falls in HD patients. Methods Seventy-six HD patients were enrolled in this cross-sectional study. Participants were classified as "fallers" and "non-fallers" and completed a passive head up tilting to 60 degrees (HUT-60 degrees) test on an automated tilt table. ECG signals, continuous and oscillometric BP measurements and impedance cardiography were recorded. The following variables were derived from these measurements: heart rate (HR) stroke volume (SV), cardiac output (CO), total peripheral resistance (TPR), number of baroreceptor events, and baroreceptor effectiveness index (BEI). Results The forty-four participants who were classified as fallers (57.9%) had a lower number of baroreceptor events (6.5 +/- 8.5 vs 14 +/- 16.7, p = .027) and BEI (20.8 +/- 24.2% vs 33.4 +/- 23.3%, p = .025). In addition, fallers experienced a significantly larger drop in systolic (-6.4 +/- 10.9 vs -0.4 +/- 7.7 mmHg, p = .011) and diastolic (-2.7 +/- 7.3 vs 1.8 +/- 6 mmHg, p = .027) oscillometric BP from supine to HUT-60 degrees compared with non-fallers. None of the variables taken for the analysis were significantly associated with falls in multivariate logistic regression analysis. Conclusions This cross-sectional comparison indicates that, at rest, HD patients with a positive history of falls present with a lower count of baroreceptor sequences and BEI. Short-term BP regulation warrants further investigation as BP drops during a passive orthostatic challenge may be implicated in the aetiology of falls in HD.	[Zanotto, Tobia; Mercer, Thomas H.; van der Linden, Marietta L.; Koufaki, Pelagia] Queen Margaret Univ, Ctr Hlth Act & Rehabil Res, Edinburgh, Midlothian, Scotland; [Traynor, Jamie P.] Queen Elizabeth Univ Hosp, Renal & Transplant Unit, Glasgow, Lanark, Scotland; [Petrie, Colin J.] Monklands Hosp, Dept Cardiol, Airdrie, Scotland; [Doyle, Arthur; Chalmers, Karen; Allan, Nicola] Victoria Hosp, Renal Unit, Kirkcaldy, Scotland; [Price, Jonathan; Oun, Hadi; Shilliday, Ilona] Monklands Hosp, Renal Unit, Airdrie, Scotland	Queen Margaret University; Queen Elizabeth University Hospital (QEUH); Monklands Hospital; Monklands Hospital	Zanotto, T (corresponding author), Queen Margaret Univ, Ctr Hlth Act & Rehabil Res, Edinburgh, Midlothian, Scotland.	TZanotto@qmu.ac.uk		Zanotto, Tobia/0000-0002-6571-4763	British Kidney Patient Association - British Renal Society joint grant (BKPA-BRS) [16-003]	British Kidney Patient Association - British Renal Society joint grant (BKPA-BRS)	This work was supported by a British Kidney Patient Association - British Renal Society joint grant (BKPA-BRS grant number 16-003). PK, TZ, KC, and NA received funding from this grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Rahman EM, 2011, NEPHRON CLIN PRACT, V118, pC278, DOI 10.1159/000322275; Angelousi A, 2014, J HYPERTENS, V32, P1562, DOI 10.1097/HJH.0000000000000235; Brignole M, 2004, EUR HEART J, V25, P2054, DOI 10.1016/j.ehj.2004.09.004; Brittain JM, 2018, CLIN PHYSIOL FUNCT I, V38, P384, DOI 10.1111/cpf.12425; Cook WL, 2006, CLIN J AM SOC NEPHRO, V1, P1197, DOI 10.2215/CJN.01650506; Cooke J, 2009, QJM-INT J MED, V102, P335, DOI 10.1093/qjmed/hcp020; CUMMINGS SR, 1988, J AM GERIATR SOC, V36, P613, DOI 10.1111/j.1532-5415.1988.tb06155.x; Desmet C, 2005, AM J KIDNEY DIS, V45, P148, DOI 10.1053/j.ajkd.2004.09.027; Di Rienzo M, 2001, AM J PHYSIOL-REG I, V280, pR744, DOI 10.1152/ajpregu.2001.280.3.R744; Fisher VL, 2017, DIABET METAB SYND OB, V10, P419, DOI 10.2147/DMSO.S129797; Ganz DA, 2005, J AM GERIATR SOC, V53, P2190, DOI 10.1111/j.1532-5415.2005.00509.x; Gratze G, 1998, COMPUT BIOL MED, V28, P121, DOI 10.1016/S0010-4825(98)00005-5; Hauer K, 2006, AGE AGEING, V35, P5, DOI 10.1093/ageing/afi218; Hildreth CM, 2012, FRONT PHYSIOL, V2, P1, DOI DOI 10.3389/fphys.2011.00121; Hinghofer-Szalkay H, 2011, EUR J APPL PHYSIOL, V111, P163, DOI 10.1007/s00421-010-1646-9; Ilies C, 2012, BRIT J ANAESTH, V108, P202, DOI 10.1093/bja/aer394; Jeleazcov C, 2010, BRIT J ANAESTH, V105, P264, DOI 10.1093/bja/aeq143; Lopez-Soto PJ, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0173-7; Johansson M, 2007, J HYPERTENS, V25, P163, DOI 10.1097/01.hjh.0000254377.18983.eb; Khurana RK, 1996, CLIN AUTON RES, V6, P335, DOI 10.1007/BF02556304; Lamb SE, 2005, J AM GERIATR SOC, V53, P1618, DOI 10.1111/j.1532-5415.2005.53455.x; Li M, 2008, NEPHROL DIAL TRANSPL, V23, P1396, DOI 10.1093/ndt/gfm778; Mattace-Raso FUS, 2007, J HYPERTENS, V25, P1421, DOI 10.1097/HJH.0b013e32811d6a07; McAdams-DeMarco MA, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-224; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; Pasma JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106808; Penaz J, 1976, Z Gesamte Inn Med, V31, P1030; Pinna GD, 2000, EUR HEART J, V21, P1522, DOI 10.1053/euhj.1999.1948; Pitzalis M, 2003, J AM COLL CARDIOL, V41, P1167, DOI 10.1016/S0735-1097(03)00050-0; Polinder-Bos HA, 2014, NETH J MED, V72, P509; Roberts R, 2007, INT UROL NEPHROL, V39, P275, DOI 10.1007/s11255-006-9088-3; Roberts Russell G., 2003, International Urology and Nephrology, V35, P415, DOI 10.1023/B:UROL.0000022866.07751.4a; Schwartz CE, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00461; Shaw BH, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0168-z; Tang ZH, 2014, EUR J MED RES, V19, DOI 10.1186/2047-783X-19-8; Tinetti ME, 2014, JAMA INTERN MED, V174, P588, DOI 10.1001/jamainternmed.2013.14764; UK RENAL REGISTRY. UKRR, 2016, UK REN REG REP 19 AN; Wong AKW, 2014, J AM GERIATR SOC, V62, P1534, DOI 10.1111/jgs.12931; World Health Organization, 2008, GLOBAL REPORT FALLS	39	10	11	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 6	2018	13	12							e0208127	10.1371/journal.pone.0208127	http://dx.doi.org/10.1371/journal.pone.0208127			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HD1YF	30521545	Green Submitted, Green Published, gold			2023-01-03	WOS:000452307600027
J	Braun, I; Tulsky, J				Braun, Ilana; Tulsky, James			Reconciling the Discrepancies in Medicine's Relationship to Medical Marijuana	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Braun, Ilana; Tulsky, James] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA; [Braun, Ilana; Tulsky, James] Harvard Med Sch, Boston, MA USA; [Braun, Ilana; Tulsky, James] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, 450 Brookline Ave,D2005, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Braun, I (corresponding author), Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, 450 Brookline Ave,D2005, Boston, MA 02215 USA.	ibraun@partners.org						Aggarwal Sunil K, 2009, J Opioid Manag, V5, P153; Allan GM, 2018, CAN FAM PHYSICIAN, V64, P111; American Medical Association House of Delegates, 2009, CLIN IMPL POL CONS C; Braun IM, 2017, PSYCHO-ONCOLOGY, V26, P1087, DOI 10.1002/pon.4365; Braun IM, 2018, J CLIN ONCOL, V36, P1957, DOI 10.1200/JCO.2017.76.1221; Marijuana Policy Project, 2018, MED MAR PAT NUMB; Ryan J, 2017, J NEUROSCI NURS, V49, P185, DOI 10.1097/JNN.0000000000000283; Taylor T, 2016, SUPP RES THER ROL MA; The National Academies of Sciences Engineering and Medicine, 2017, HLTH EFF CANN CANN	9	2	4	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 6	2018	169	9					646	+		10.7326/M18-1883	http://dx.doi.org/10.7326/M18-1883			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ4UP	30285072				2023-01-03	WOS:000449399700009
J	Bar-On, Y; Gruell, H; Schoofs, T; Pai, JA; Nogueira, L; Butler, AL; Millard, K; Lehmann, C; Suarez, I; Oliveira, TY; Karagounis, T; Cohen, YZ; Wyen, C; Scholten, S; Handl, L; Belblidia, S; Dizon, JP; Vehreschild, JJ; Witmer-Pack, M; Shimeliovich, I; Jain, K; Fiddike, K; Seaton, KE; Yates, NL; Horowitz, J; Gulick, RM; Pfeifer, N; Tomaras, GD; Seaman, MS; Fatkenheuer, G; Caskey, M; Klein, F; Nussenzweig, MC				Bar-On, Yotam; Gruell, Henning; Schoofs, Till; Pai, Joy A.; Nogueira, Lilian; Butler, Allison L.; Millard, Katrina; Lehmann, Clara; Suarez, Isabelle; Oliveira, Thiago Y.; Karagounis, Theodora; Cohen, Yehuda Z.; Wyen, Christoph; Scholten, Stefan; Handl, Lisa; Belblidia, Shiraz; Dizon, Juan P.; Vehreschild, Joerg J.; Witmer-Pack, Maggi; Shimeliovich, Irina; Jain, Kanika; Fiddike, Kerstin; Seaton, Kelly E.; Yates, Nicole L.; Horowitz, Jill; Gulick, Roy M.; Pfeifer, Nico; Tomaras, Georgia D.; Seaman, Michael S.; Faetkenheuer, Gerd; Caskey, Marina; Klein, Florian; Nussenzweig, Michel C.			Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals	NATURE MEDICINE			English	Article							CD4(+) T-CELLS; MONOCLONAL-ANTIBODY; ANTI-HIV-1 ANTIBODIES; PASSIVE IMMUNOTHERAPY; ANTIRETROVIRAL DRUGS; SUPPRESSES VIREMIA; IMMUNE-RESPONSES; DURABLE CONTROL; HUMANIZED MICE; THERAPY	Monotherapy of HIV-1 infection with single antiretroviral agents is ineffective because error-prone HIV-1 replication leads to the production of drug-resistant viral variants(1,2). Combinations of drugs can establish long-term control, however, antiretroviral therapy (ART) requires daily dosing, can cause side effects and does not eradicate the infection(3,4). Although anti-HIV-1 antibodies constitute a potential alternative to ART(5,6), treatment of viremic individuals with a single antibody also results in emergence of resistant viral variants(7-9). Moreover, combinations of first-generation anti-HIV-1 broadly neutralizing antibodies (bNAbs) had little measurable effect on the infection(10-12). Here we report on a phase 1b clinical trial (NCT02825797) in which two potent bNAbs, 3BNC117(13) and 10-1074(14), were administered in combination to seven HIV-1 viremic individuals. Infusions of 30 mg kg(-1) of each of the antibodies were well-tolerated. In the four individuals with dual antibody-sensitive viruses, immunotherapy resulted in an average reduction in HIV-1 viral load of 2.05 log(10) copies per ml that remained significantly reduced for three months following the first of up to three infusions. In addition, none of these individuals developed resistance to both antibodies. Larger studies will be necessary to confirm the efficacy of antibody combinations in reducing HIV-1 viremia and limiting the emergence of resistant viral variants.	[Bar-On, Yotam; Schoofs, Till; Pai, Joy A.; Nogueira, Lilian; Butler, Allison L.; Millard, Katrina; Oliveira, Thiago Y.; Karagounis, Theodora; Cohen, Yehuda Z.; Belblidia, Shiraz; Dizon, Juan P.; Witmer-Pack, Maggi; Shimeliovich, Irina; Horowitz, Jill; Caskey, Marina; Nussenzweig, Michel C.] Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA; [Gruell, Henning; Schoofs, Till; Jain, Kanika; Klein, Florian] Univ Hosp Cologne, Lab Expt Immunol, Inst Virol, Cologne, Germany; [Gruell, Henning; Lehmann, Clara; Suarez, Isabelle; Wyen, Christoph; Vehreschild, Joerg J.; Fiddike, Kerstin; Faetkenheuer, Gerd] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany; [Gruell, Henning; Lehmann, Clara; Suarez, Isabelle; Vehreschild, Joerg J.; Faetkenheuer, Gerd; Klein, Florian] German Ctr Infect Res, Partner Site Bonn Cologne, Cologne, Germany; [Lehmann, Clara; Suarez, Isabelle; Klein, Florian] Univ Cologne, CMMC, Cologne, Germany; [Wyen, Christoph] Praxis Ebertpl, Cologne, Germany; [Scholten, Stefan] Praxis Hohenstaufenring, Cologne, Germany; [Handl, Lisa; Pfeifer, Nico] Univ Tubingen, Methods Med Informat, Dept Comp Sci, Tubingen, Germany; [Seaton, Kelly E.; Yates, Nicole L.; Tomaras, Georgia D.] Duke Univ, Duke Human Vaccine Inst, Durham, NC USA; [Gulick, Roy M.] Weill Cornell Med, Div Infect Dis, New York, NY USA; [Pfeifer, Nico] Univ Tubingen, Med Fac, Tubingen, Germany; [Pfeifer, Nico] German Ctr Infect Res, Partner Site Tubingen, Tubingen, Germany; [Pfeifer, Nico] Max Planck Inst Informat, Saarbrucken, Germany; [Tomaras, Georgia D.] Duke Univ, Dept Surg, Durham, NC USA; [Tomaras, Georgia D.] Duke Univ, Dept Immunol, Durham, NC USA; [Tomaras, Georgia D.] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC USA; [Seaman, Michael S.] Harvard Med Sch, Ctr Virol & Vaccine Res, Beth Israel Deaconess Med Ctr, Boston, MA USA; [Nussenzweig, Michel C.] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; University of Cologne; University of Cologne; German Center for Infection Research; University of Cologne; University of Cologne; Eberhard Karls University of Tubingen; Duke University; Cornell University; Eberhard Karls University of Tubingen; German Center for Infection Research; Max Planck Society; Duke University; Duke University; Duke University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Howard Hughes Medical Institute; Rockefeller University	Caskey, M; Nussenzweig, MC (corresponding author), Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.; Klein, F (corresponding author), Univ Hosp Cologne, Lab Expt Immunol, Inst Virol, Cologne, Germany.; Klein, F (corresponding author), German Ctr Infect Res, Partner Site Bonn Cologne, Cologne, Germany.; Klein, F (corresponding author), Univ Cologne, CMMC, Cologne, Germany.; Nussenzweig, MC (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.	mcaskey@rockefeller.edu; florian.klein@uk-koeln.de; nussen@rockefeller.edu	Oliveira, Thiago Y/ABF-5186-2020; Nussenzweig, Michel/AAE-7292-2019; Oliveira, Thiago Y/HGA-3848-2022; Pfeifer, Nico/G-1559-2016; Vehreschild, Jorg Janne/G-6764-2013	Oliveira, Thiago Y/0000-0002-2654-0879; Oliveira, Thiago Y/0000-0002-2654-0879; Pfeifer, Nico/0000-0002-4647-8566; Grull, Henning/0000-0002-0725-7138; Seaton, Kelly/0000-0002-2009-3270; Cohen, Yehuda/0000-0001-6987-1478; Vehreschild, Jorg Janne/0000-0002-5446-7170; Eisenberg, Lisa/0000-0002-1041-7948; Karagounis, Theodora/0000-0003-1481-9589	Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD) [OPP1092074, OPP1124068, CAVIMC OPP1146996]; NIH [1UM1 AI100663, R01AI-129795]; Heisenberg-Program of the DFG [KL 2389/2-1]; European Research Council [ERC-StG639961]; German Center for Infection Research (DZIF); Einstein-Rockefeller-CUNY Center for AIDS Research [1P30AI124414-01A1]; BEAT-HIV Delaney grant [UM1 AI126620]; Robertson fund; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI129795, P30AI124414, UM1AI100663, UM1AI126620] Funding Source: NIH RePORTER	Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Heisenberg-Program of the DFG(German Research Foundation (DFG)); European Research Council(European Research Council (ERC)European Commission); German Center for Infection Research (DZIF); Einstein-Rockefeller-CUNY Center for AIDS Research; BEAT-HIV Delaney grant; Robertson fund; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank all study participants who devoted time to our research; members of the Klein and Nussenzweig laboratories for helpful discussions, especially P. Mendoza, C.-L. Lu, J. C. C. Lorenzi, L. Cohn and M. Jankovic; R. Levin, G. Kremer and D. Weiland for study coordination; the Rockefeller University Hospital Clinical Research Support Office and nursing staff as well as C. Golder, E. Thomas, M. Platten, S. Margane and T. Kummerle for help with recruitment and study implementation; C. Ruping and M. Schlotz for help with sample processing; S. Kiss for ophthalmologic assessments; T. Keler and the Celldex Therapeutics team for 3BNC117 and 10-1074 manufacturing and regulatory support; C. Conrad for regulatory support; U. Kerkweg for pharmaceutical services; H. Janicki, M. Ercanoglu, P. Schommers and R. Kaiser for help with virus cultures; P. Fast and H. Park for clinical monitoring; S. McMillan, S. Mosher, S. Sawant, D. Beaumont, M. Sarzotti-Kelsoe, K. Greene, H. Gao and D. Montefiori for help with PK assay development, validation, reporting and/or project management; and S. Schlesinger for input on study design. This work was supported by The Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD) grants OPP1092074, OPP1124068 (M.C.N.), CAVIMC OPP1146996 (G.D.T., M.S.S.); the NIH grants 1UM1 AI100663 and R01AI-129795 (M.C.N.); the Heisenberg-Program of the DFG (KL 2389/2-1), the European Research Council (ERC-StG639961) and the German Center for Infection Research (DZIF) (F.K.); the Einstein-Rockefeller-CUNY Center for AIDS Research (1P30AI124414-01A1); BEAT-HIV Delaney grant UM1 AI126620 (M.C.); and the Robertson fund. M.C.N. is a Howard Hughes Medical Institute Investigator.	Armbruster C, 2004, J ANTIMICROB CHEMOTH, V54, P915, DOI 10.1093/jac/dkh428; Bailey J, 2004, CURR OPIN IMMUNOL, V16, P470, DOI 10.1016/j.coi.2004.05.005; Caskey M, 2017, NAT MED, V23, P185, DOI 10.1038/nm.4268; Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411; Cohen YZ, 2018, J VIROL, V92, DOI 10.1128/JVI.01883-17; Diskin R, 2013, J EXP MED, V210, P1235, DOI 10.1084/jem.20130221; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Gaudinski MR, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002493; Gautam R, 2018, NAT MED, V24, P610, DOI 10.1038/s41591-018-0001-2; Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010; Horwitz JA, 2013, P NATL ACAD SCI USA, V110, P16538, DOI 10.1073/pnas.1315295110; Hraber P, 2015, VIRUSES-BASEL, V7, P5443, DOI 10.3390/v7102881; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Keizer RJ, 2010, CLIN PHARMACOKINET, V49, P493, DOI 10.2165/11531280-000000000-00000; Kirchherr JL, 2007, J VIROL METHODS, V143, P104, DOI 10.1016/j.jviromet.2007.02.015; Klein F, 2014, J EXP MED, V211, P2361, DOI 10.1084/jem.20141050; Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144; Klein F, 2012, NATURE, V492, P118, DOI 10.1038/nature11604; Ko SY, 2014, NATURE, V514, P642, DOI 10.1038/nature13612; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lynch RM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad5752; Lynch RM, 2015, J VIROL, V89, P4201, DOI 10.1128/JVI.03608-14; Mehandru S, 2007, J VIROL, V81, P11016, DOI 10.1128/JVI.01340-07; Mendoza P, 2018, NATURE, V561, P479, DOI 10.1038/s41586-018-0531-2; Mouquet H, 2012, P NATL ACAD SCI USA, V109, pE3268, DOI 10.1073/pnas.1217207109; Ndung'u T, 2012, AIDS, V26, P1255, DOI 10.1097/QAD.0b013e32835461b5; Nishimura Y, 2017, NATURE, V543, P559, DOI 10.1038/nature21435; Robbie GJ, 2013, ANTIMICROB AGENTS CH, V57, P6147, DOI 10.1128/AAC.01285-13; Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P131, DOI 10.1016/j.jim.2013.11.022; Scheid JF, 2016, NATURE, V535, P556, DOI 10.1038/nature18929; Scheid JF, 2011, SCIENCE, V333, P1633, DOI 10.1126/science.1207227; Schoofs T, 2016, SCIENCE, V352, P997, DOI 10.1126/science.aaf0972; Shingai M, 2013, NATURE, V503, P277, DOI 10.1038/nature12746; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033; Trkola A, 2005, NAT MED, V11, P615, DOI 10.1038/nm1244; Walker BD, 2013, NAT REV IMMUNOL, V13, P487, DOI 10.1038/nri3478; Walker LM, 2018, NAT REV IMMUNOL, V18, P297, DOI 10.1038/nri.2017.148; Zhou TQ, 2013, IMMUNITY, V39, P245, DOI 10.1016/j.immuni.2013.04.012	39	145	145	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2018	24	11					1701	+		10.1038/s41591-018-0186-4	http://dx.doi.org/10.1038/s41591-018-0186-4			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	GZ4VS	30258217	Green Accepted			2023-01-03	WOS:000449404200022
J	Dunning, J; Butts, R; Henry, N; Mourad, F; Brannon, A; Rodriguez, H; Young, I; Arias-Buria, JL; Fernandez-de-las-Penas, C				Dunning, James; Butts, Raymond; Henry, Nathan; Mourad, Firas; Brannon, Amy; Rodriguez, Hector; Young, Ian; Arias-Buria, Jose L.; Fernandez-de-las-Penas, Cesar			Electrical dry needling as an adjunct to exercise, manual therapy and ultrasound for plantar fasciitis: A multi-center randomized clinical trial	PLOS ONE			English	Article							EXTREMITY FUNCTIONAL SCALE; NECK DISABILITY INDEX; FOOT FUNCTION INDEX; HEEL PAIN; PHYSICAL-THERAPY; CORTICOSTEROID INJECTION; PERIOSTEAL STIMULATION; KNEE OSTEOARTHRITIS; CONNECTIVE-TISSUE; STEROID INJECTION	Study Design Randomized, single-blinded, multi-center, parallel-group trial. Objectives To compare the effects of adding electrical dry needling into a program of manual therapy, exercise and ultrasound on pain, function and related-disability in individuals with plantar fasciitis (PF). Background The isolated application of electrical dry needling, manual therapy, exercise, and ultrasound has been found to be effective for PF. However, no previous study has investigated the combined effect of these interventions in this population. Methods One hundred and eleven participants (n = 111) with plantar fasciitis were randomized to receive electrical dry needling, manual therapy, exercise and ultrasound (n = 58) or manual therapy, exercise and ultrasound (n = 53). The primary outcome was first-step pain in the morning as measured by the Numeric Pain Rating Scale (NPRS). Secondary outcomes included resting foot pain (NPRS), pain during activity (NPRS), the Lower Extremity Functional Scale (LEFS), the Foot Functional Index (FFI), medication intake, and the Global Rating of Change (GROC). The treatment period was 4 weeks with follow-up assessments at 1 week, 4 weeks, and 3 months after the first treatment session. Both groups received 6 sessions of impairment-based manual therapy directed to the lower limb, self-stretching of the plantar fascia and the Achilles tendon, strengthening exercises for the intrinsic muscles of the foot, and therapeutic ultrasound. In addition, the dry needling group also received 6 sessions of electrical dry needling using a standardized 8-point protocol for 20 minutes. The primary aim was examined with a 2-way mixed-model analysis of covariance (ANCOVA) with treatment group as the between-subjects variable and time as the within-subjects variable after adjusting for baseline outcomes. Results The 2X4 ANCOVA revealed that individuals with PF who received electrical dry needling, manual therapy, exercise and ultrasound experienced significantly greater improvements in first-step morning pain (F = 22.021; P<0.001), resting foot pain (F = 23.931; P<0.001), pain during activity (F = 7.629; P = 0.007), LEFS (F = 13.081; P<0.001), FFI Pain Subscale (F = 13.547; P<0.001), FFI Disability Subscale (F = 8.746; P = 0.004), and FFI Total Score (F = 10.65; P<0.001) than those who received manual therapy, exercise and ultrasound at 3 months. No differences in FFI Activity Limitation Subscale (F = 2.687; P = 0.104) were observed. Significantly (X-2 = 9.512; P = 0.023) more patients in the electrical dry needling group completely stopped taking medication for their pain compared to the manual therapy, exercise and ultrasound group at 3 months. Based on the cutoff score of >=+5 on the GROC, significantly (X-2 = 45.582; P<0.001) more patients within the electrical dry needling group (n = 45, 78%) achieved a successful outcome compared to the manual therapy, exercise and ultrasound group (n =11, 21%). Effect sizes ranged from medium to large (0.53<SMD<0.85) at 3 months in favor of the electrical dry needling group. Conclusion The inclusion of electrical dry needling into a program of manual therapy, exercise and ultrasound was more effective for improving pain, function and related-disability than the application of manual therapy, exercise and ultrasound alone in individuals with PF at mid-term (3 months).	[Dunning, James; Mourad, Firas; Arias-Buria, Jose L.; Fernandez-de-las-Penas, Cesar] Univ Rey Juan Carlos, Dept Phys Therapy Occupat Therapy Rehabil & Phys, Alcorcon, Spain; [Dunning, James; Butts, Raymond; Henry, Nathan; Young, Ian] Amer Acad Manipulat Therapy Fellowship Orthopaed, Montgomery, AL 36117 USA; [Butts, Raymond] Res Phys Therapy Specialists, Columbia, SC USA; [Henry, Nathan] Troop Med Clin, Eglin Air Force Base, FL USA; [Mourad, Firas] Univ Roma Tor Vergata, Rome, Italy; [Brannon, Amy] TOPS Phys Therapy & Orthopaed, Phoenix, AZ USA; [Rodriguez, Hector] Manual Phys Therapy Specialists, El Paso, TX USA; [Young, Ian] CORA Phys Therapy, Savannah, GA USA	Universidad Rey Juan Carlos; University of Rome Tor Vergata	Dunning, J (corresponding author), Univ Rey Juan Carlos, Dept Phys Therapy Occupat Therapy Rehabil & Phys, Alcorcon, Spain.; Dunning, J (corresponding author), Amer Acad Manipulat Therapy Fellowship Orthopaed, Montgomery, AL 36117 USA.	j.dunning.2016@alumnos.urjc.es	Mourad, Firas/W-4867-2017; Mourad, Firas/AAK-1269-2021; Mourad, Firas/AAZ-4026-2021	Mourad, Firas/0000-0002-8981-2085; Mourad, Firas/0000-0002-8981-2085; Dunning, James/0000-0002-1194-0108				Acevedo JI, 1998, FOOT ANKLE INT, V19, P91, DOI 10.1177/107110079801900207; Ahsin S, 2009, PAIN, V147, P60, DOI 10.1016/j.pain.2009.08.004; Ang TWA, 2015, SINGAP MED J, V56, P423, DOI 10.11622/smedj.2015118; Arias-Buria JL, 2017, J PAIN, V18, P11, DOI 10.1016/j.jpain.2016.08.013; Arslan A, 2016, J FOOT ANKLE SURG, V55, P767, DOI 10.1053/j.jfas.2016.03.009; Assad S, 2016, CUREUS, V8, DOI 10.7759/cureus.913; Barrett SL, 1999, AM FAM PHYSICIAN, V59, P2200; Binkley JM, 1999, PHYS THER, V79, P371; Budiman-Mak E, 2013, J FOOT ANKLE RES, V6, DOI 10.1186/1757-1146-6-5; BUDIMANMAK E, 1991, J CLIN EPIDEMIOL, V44, P561, DOI 10.1016/0895-4356(91)90220-4; Bullock CM, 2013, CURR PAIN HEADACHE R, V17, DOI 10.1007/s11916-013-0375-2; Butts R, 2016, INTERNATIONAL JOURNA, V216; Carlesso LC, 2010, J ORTHOP SPORT PHYS, V40, P455, DOI 10.2519/jospt.2010.3229; Casanueva B, 2014, RHEUMATOL INT, V34, P861, DOI 10.1007/s00296-013-2759-3; Celik D, 2016, FOOT ANKLE INT, V37, P150, DOI 10.1177/1071100715607619; Chen CM, 2013, AM J PHYS MED REHAB, V92, P597, DOI 10.1097/PHM.0b013e318278a831; Chen HY, 2013, J ORTHOP SPORT PHYS, V43, P727, DOI 10.2519/jospt.2013.4774; Chen N, 2017, AM J CHINESE MED, V45, P965, DOI 10.1142/S0192415X17500513; Chiew SK, 2016, J RES MED SCI, V21; Cleland JA, 2008, ARCH PHYS MED REHAB, V89, P69, DOI 10.1016/j.apmr.2007.08.126; Cleland JA, 2009, J ORTHOP SPORT PHYS, V39, P573, DOI 10.2519/jospt.2009.3036; Cotchett MP, 2014, PHYS THER, V94, P1083, DOI 10.2522/ptj.20130255; Cotchett MP, 2011, ACUPUNCT MED, V29, P193, DOI 10.1136/aim.2010.003145; Crawford F, 2003, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD000416; Crawford Fay, 2005, Clin Evid, P1533; Drake M, 2011, J ORTHOP SPORT PHYS, V41, P221, DOI 10.2519/jospt.2011.3348; Dunning J, 2014, PHYS THER REV, V19, P252, DOI 10.1179/108331913X13844245102034; Dunning JR, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-0912-3; Ebrahim A, 2007, SCI J AL AZHAR MED U, V28, P1; Erin N, 2009, REGUL PEPTIDES, V152, P108, DOI 10.1016/j.regpep.2008.10.006; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Fernandez-de-las Penas C, 2015, J PAIN, V16, P1087, DOI 10.1016/j.jpain.2015.07.012; Fraser JJ, 2017, J ORTHOP SPORT PHYS, V47, P49, DOI 10.2519/jospt.2017.6999; Goff JD, 2011, AM FAM PHYSICIAN, V84, P676; Grasel RP, 1999, AM J ROENTGENOL, V173, P699, DOI 10.2214/ajr.173.3.10470906; Grecco MV, 2013, CLINICS, V68, P1089, DOI 10.6061/clinics/2013(08)05; Grieve R, 2017, PHYSIOTHERAPY, V103, P193, DOI 10.1016/j.physio.2016.02.002; GUNN CC, 1980, SPINE, V5, P279, DOI 10.1097/00007632-198005000-00011; Hammerman M, 2014, J APPL PHYSIOL, V116, P54, DOI 10.1152/japplphysiol.00741.2013; Hawke F, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006801.pub2; He CH, 2017, J PAIN RES, V10, P1933, DOI 10.2147/JPR.S141607; Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016; Huang Jian, 2007, Zhen Ci Yan Jiu, V32, P115; Huffer D, 2017, PHYS THER SPORT, V24, P44, DOI 10.1016/j.ptsp.2016.08.008; Imamura M, 1998, J MUSCULOSKELETAL PA; Irving DB, 2006, J SCI MED SPORT, V9, P11, DOI 10.1016/j.jsams.2006.02.004; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; Johnson RJ, 2010, CURR SPORT MED REP, V9, P191, DOI 10.1249/JSR.0b013e3181e7cb75; Kalaci A, 2009, J AM PODIAT MED ASSN, V99, P108, DOI 10.7547/0980108; Kamonseki DH, 2016, MANUAL THER, V23, P76, DOI 10.1016/j.math.2015.10.006; Kim E, 2014, PM&R, V6, P152, DOI 10.1016/j.pmrj.2013.07.003; Kim M, 2016, ULTRASOUND Q, V32, P327, DOI 10.1097/RUQ.0000000000000233; Kiter E, 2006, J AM PODIAT MED ASSN, V96, P293, DOI 10.7547/0960293; Kong J, 2007, J ALTERN COMPLEM MED, V13, P1059, DOI 10.1089/acm.2007.0524; Kumnerddee W, 2012, AM J CHINESE MED, V40, P1167, DOI 10.1142/S0192415X12500863; Labovitz Jonathan M, 2011, Foot Ankle Spec, V4, P141, DOI 10.1177/1938640010397341; Landorf KB, 2006, FOOT ANKLE INT, V27, P867, DOI 10.1177/107110070602701020; Landorf KB, 2008, FOOT, V18, P15, DOI [10.1016/j.foot.2007.06.006, DOI 10.1016/J.FOOT.2007.06.006]; LANDORF KB, 2010, J FOOT ANKLE RES, V3, P15660; Langevin HM, 2007, J ALTERN COMPLEM MED, V13, P355, DOI 10.1089/acm.2007.6351; Langevin HM, 2015, J ALTERN COMPLEM MED, V21, P113, DOI 10.1089/acm.2014.0186; Langevin HM, 2006, J CELL PHYSIOL, V207, P767, DOI 10.1002/jcp.20623; Langevin HM, 2005, AM J PHYSIOL-CELL PH, V288, pC747, DOI 10.1152/ajpcell.00420.2004; Langevin HM, 2001, FASEB J, V15, P2275, DOI 10.1096/fj.01-0015hyp; Lemont H, 2003, J AM PODIAT MED ASSN, V93, P234, DOI 10.7547/87507315-93-3-234; LEWIT K, 1979, PAIN, V6, P83, DOI 10.1016/0304-3959(79)90142-8; Li SM, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/164714; Li ZH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092671; Liu Xianxiang, 2004, J Tradit Chin Med, V24, P144; Looney B, 2011, J MANIP PHYSIOL THER, V34, P138, DOI 10.1016/j.jmpt.2010.12.003; Lundeberg T, 2013, ACUPUNCT MED, V31, P7, DOI 10.1136/acupmed-2013-010313; Manheimer E, 2005, ANN INTERN MED, V142, P651, DOI 10.7326/0003-4819-142-8-200504190-00014; Manheimer E, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001977.pub2; Martin RL, 2007, J ORTHOP SPORT PHYS, V37, P72, DOI 10.2519/jospt.2007.2403; Martin RL, 2013, J ORTHOP SPORT PHYS, V43, pA1, DOI 10.2519/jospt.2013.0305; McClinton SM, 2015, FOOT ANKLE INT, V36, P408, DOI 10.1177/1071100714558508; Mcindoe A., 1995, ACUPUNCTURE MED, V13; McMillan AM, 2013, J ORTHOP SPORT PHYS, V43, P875, DOI 10.2519/jospt.2013.4810; McPoil TG, 2008, J ORTHOP SPORT PHYS, V38, pA1, DOI 10.2519/jospt.2008.0302; Menz HB, 2005, J ORTHOP SPORT PHYS, V35, P477, DOI 10.2519/jospt.2005.0108; Mischke JJ, 2017, J MAN MANIP THER, V25, P3, DOI 10.1080/10669817.2015.1106818; Myburgh C, 2008, ARCH PHYS MED REHAB, V89, P1169, DOI 10.1016/j.apmr.2007.12.033; Neal BS, 2012, ACUPUNCT MED, V30, P346, DOI 10.1136/acupmed-2012-010208; Orchard J, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6603; Perez-Millan R, 2001, MED ACUPUNCT, V13, P1; Petraglia F, 2017, MLTJ-MUSCLE LIGAMENT, V7, P107, DOI 10.11138/mltj/2017.7.1.107; Prajapati RT, 2000, WOUND REPAIR REGEN, V8, P226, DOI 10.1046/j.1524-475x.2000.00226.x; Rathleff MS, 2015, SCAND J MED SCI SPOR, V25, pe292, DOI 10.1111/sms.12313; RAUD J, 1991, BIOCHEM BIOPH RES CO, V180, P1429, DOI 10.1016/S0006-291X(05)81356-7; Renan-Ordine R, 2011, J ORTHOP SPORT PHYS, V41, P43, DOI 10.2519/jospt.2011.3504; Riddle DL, 2004, FOOT ANKLE INT, V25, P303, DOI 10.1177/107110070402500505; Roxas M, 2005, ALTERN MED REV, V10, P83; Salaffi F, 2004, EUR J PAIN, V8, P283, DOI 10.1016/j.ejpain.2003.09.004; Schmitt J, 2015, J ORTHOP SPORT PHYS, V45, P106, DOI 10.2519/jospt.2015.5247; SELLMAN JR, 1994, FOOT ANKLE INT, V15, P376, DOI 10.1177/107110079401500706; Shashua A, 2015, J ORTHOP SPORT PHYS, V45, P265, DOI 10.2519/jospt.2015.5155; Singh D, 1997, BMJ-BRIT MED J, V315, P172, DOI 10.1136/bmj.315.7101.172; Sweeting D, 2011, J FOOT ANKLE RES, V4, DOI 10.1186/1757-1146-4-19; Tahririan MA, 2012, J RES MED SCI, V17, P799; Thomas JL, 2010, J FOOT ANKLE SURG, V49, pS1, DOI 10.1053/j.jfas.2010.01.001; Tillu A, 1998, ACUPUNCT MED, V16, P66, DOI DOI 10.1136/AIM.16.2.66; Tong Kuo Bianchini, 2010, Am J Orthop (Belle Mead NJ), V39, P227; Twarowska N, 2015, POSTEPY REHABILITACJ, V2, P63; Watson CJ, 2005, J ORTHOP SPORT PHYS, V35, P136, DOI 10.2519/jospt.2005.35.3.136; Wearing SC, 2006, SPORTS MED, V36, P585, DOI 10.2165/00007256-200636070-00004; Weiner DK, 2007, J AM GERIATR SOC, V55, P1541, DOI 10.1111/j.1532-5415.2007.01314.x; Weiner DK, 2013, CLIN THER, V35, P1703, DOI 10.1016/j.clinthera.2013.09.025; Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x; Wu YT, 2017, ARCH PHYS MED REHAB, V98, P964, DOI 10.1016/j.apmr.2017.01.016; Young B, 2004, J ORTHOP SPORT PHYS, V34, P725, DOI 10.2519/jospt.2004.34.11.725; Young IA, 2010, AM J PHYS MED REHAB, V89, P831, DOI 10.1097/PHM.0b013e3181ec98e6; Yu HN, 2016, J ORTHOP SPORT PHYS, V46, P523, DOI 10.2519/jospt.2016.6521; Yucel U, 2013, PROSTHET ORTHOT INT, V37, P471, DOI 10.1177/0309364613478328; Zhang ZJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429412; Zhou W, 2014, J ACUPUNCT MERIDIAN, V7, P186, DOI 10.1016/j.jams.2014.02.008; Zijlstra FJ, 2003, MEDIAT INFLAMM, V12, P59, DOI 10.1080/0962935031000114943; Zwarenstein M, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2390	118	21	21	2	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2018	13	10							e0205405	10.1371/journal.pone.0205405	http://dx.doi.org/10.1371/journal.pone.0205405			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY7VH	30379937	Green Submitted, Green Published, gold			2023-01-03	WOS:000448823700046
J	Perla, V; Nadimi, M; Reddy, R; Hankins, GR; Nimmakayala, P; Harris, RT; Valluri, J; Sirbu, C; Reddy, UK				Perla, Venu; Nadimi, Marjan; Reddy, Rishi; Hankins, Gerald R.; Nimmakayala, Padma; Harris, Robert T.; Valluri, Jagan; Sirbu, Cristian; Reddy, Umesh K.			Effect of ghost pepper on cell proliferation, apoptosis, senescence and global proteomic profile in human renal adenocarcinoma cells	PLOS ONE			English	Article							DNA-DAMAGE; MASS-SPECTROMETRY; CANCER; PROTEIN; COMPLEX; EXPRESSION; CALCIUM; CAPSICUM; PATHWAY; KINASE	Chili peppers are an important constituent of many foods and contain medicinally valuable compounds, such as capsaicin and dihydrocapsaicin. As various dietary botanicals have anticancer properties, this study was aimed to examine the effect of Ghost pepper (Bhut Jolo-kia), one of the hottest chili peppers in the world, on cell proliferation, apoptosis, senescence and the global proteomic profile in human renal cell adenocarcinoma in vitro. 769-P human renal adenocarcinoma cells were cultured on RPMI 1640 media supplemented with fetal bovine serum (10%) and antibiotic-antimycotic solution (1%). Treatment stock solutions were prepared in ethanol. Cell proliferation was tested with phenol red-free media with capsaicin (0-400 mu M), dihydrocapsaicin (0-400 mu M), capsaicin + dihydrocapsaicin (5:1), and dry Ghost peppers (0-3 g L-1) for 24, 48 and 72 h. Polycaspase and senescence associated-betagalactosidase (SA-beta-gal) activities were tested with capsaicin (400 mu M), dihydrocapsaicin (400 mu M), capsaicin (400 mu M) + dihydrocapsaicin (80 mu M), and ghost pepper (3 g L-1) treatments. Global proteomic profile of cells in control and ghost pepper treatment (3 g L-1) was analyzed after 6 h by a shotgun proteomic approach using tandem mass spectrometry. At 24 h after treatment (24 HAT), relative to control, cell proportion with capsaicin (400 mu M), dihydrocapsaicin (400 mu M), capsaicin (400 mu M) + dihydrocapsaicin (80 mu M), and ghost pepper (3 g L-1) treatments was reduced to 36%, 18%, 33% and 20%, respectively, and further reduced at 48 and 72 HAT. All treatments triggered an early polycaspase response. SA-beta-gal activity was normal or suppressed with all treatments. About 68,220 protein isoforms were identified by shotgun proteomic approach. Among these, about 8.2% were significantly affected by ghost pepper. Ghost pepper regulated various proteins involved in intrinsic and extrinsic apoptotic pathways, Ras, Rb/E2F, p53, TGF-beta, WNT-beta catenin, and calcium induced cell death pathways. Ghost pepper also induced changes in proteins related to methylation, acetylation, genome stability, cell cycle check points, carbohydrate, protein and other metabolism and cellular mechanisms. Ghost pepper exhibited antiproliferation activity by inducing apoptosis through a complex network of proteins in human renal cell adenocarcinoma in vitro.	[Perla, Venu; Nadimi, Marjan; Reddy, Rishi; Hankins, Gerald R.; Nimmakayala, Padma; Harris, Robert T.; Reddy, Umesh K.] West Virginia State Univ, Gus R Douglass Land Grant Inst, Institute, WV 25112 USA; [Perla, Venu; Nadimi, Marjan; Reddy, Rishi; Hankins, Gerald R.; Nimmakayala, Padma; Harris, Robert T.; Reddy, Umesh K.] West Virginia State Univ, Dept Biol, Institute, WV 25112 USA; [Valluri, Jagan] Marshall Univ, Dept Biol Sci, One John Marshall Dr, Huntington, WV USA; [Sirbu, Cristian] Charleston Area Med Ctr, Ctr Canc Res, Charleston, WV USA	West Virginia State University; West Virginia State University; Marshall University	Hankins, GR; Nimmakayala, P; Reddy, UK (corresponding author), West Virginia State Univ, Gus R Douglass Land Grant Inst, Institute, WV 25112 USA.; Hankins, GR; Nimmakayala, P; Reddy, UK (corresponding author), West Virginia State Univ, Dept Biol, Institute, WV 25112 USA.	ghankins@wvstateu.edu; padma@wvstateu.edu; ureddy@wvstateu.edu		Reddy, Umesh/0000-0003-4611-7143	USDA-NIFA [2017-38821-26432]; WV-INBRE Center for Natural Products Research (NIH) [P1400846]; NIH [5P20GM103434-13]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103434] Funding Source: NIH RePORTER	USDA-NIFA(United States Department of Agriculture (USDA)); WV-INBRE Center for Natural Products Research (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by USDA-NIFA (Contract No. 2017-38821-26432) and a grant from WV-INBRE Center for Natural Products Research (NIH), sub-award No. P1400846 and NIH Prime award No. 5P20GM103434-13. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We are thankful to BioProximity, LLC, Chantilly, VA for shotgun proteomic analysis. This work was supported by USDA-NIFA (Contract No. 2017-38821-26432) and a grant from WV-INBRE Center for Natural Products Research (NIH), sub-award No. P1400846 and NIH Prime award No. 5P20GM103434-13.	Acharya U, 2003, SCIENCE, V299, P1740, DOI 10.1126/science.1080549; Aits S, 2013, LYSOSOMAL CELL DEATH; Almeida A, 2010, P NATL ACAD SCI USA, V107, P738, DOI 10.1073/pnas.0913668107; Amin ARMR, 2009, J CLIN ONCOL, V27, P2712, DOI 10.1200/JCO.2008.20.6235; Avdic V, 2011, STRUCTURE, V19, P101, DOI 10.1016/j.str.2010.09.022; Bazrgar M, 2014, EUR J OBSTET GYN R B, V175, P152, DOI 10.1016/j.ejogrb.2014.01.010; Bazwinsky-Wutschke I, 2014, J PINEAL RES, V56, P439, DOI 10.1111/jpi.12135; Bjornson RD, 2008, J PROTEOME RES, V7, P293, DOI 10.1021/pr0701198; Bley K, 2012, TOXICOL PATHOL, V40, P847, DOI 10.1177/0192623312444471; Brini M, 2009, PHYSIOL REV, V89, P1341, DOI 10.1152/physrev.00032.2008; Budanov Andrei V, 2014, Subcell Biochem, V85, P337, DOI 10.1007/978-94-017-9211-0_18; Budhavarapu VN, 2012, CELL CYCLE, V11, P2030, DOI 10.4161/cc.20643; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chambers MC, 2012, NAT BIOTECHNOL, V30, P918, DOI 10.1038/nbt.2377; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Colombo SL, 2011, P NATL ACAD SCI USA, V108, P21069, DOI 10.1073/pnas.1117500108; Craig R, 2004, BIOINFORMATICS, V20, P1466, DOI 10.1093/bioinformatics/bth092; Daniel M, 2015, J EXP BIOL, V218, P59, DOI 10.1242/jeb.107110; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Doostzadeh-Cizeron J, 2000, J BIOL CHEM, V275, P25336, DOI 10.1074/jbc.M000793200; Eliezer Y, 2014, J BIOL CHEM, V289, P8182, DOI 10.1074/jbc.M113.532739; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Geer LY, 2004, J PROTEOME RES, V3, P958, DOI 10.1021/pr0499491; GOVINDARAJAN VS, 1991, CRIT REV FOOD SCI, V29, P435, DOI 10.1080/10408399109527536; Green DR, 2014, SCIENCE, V345, P1466, DOI 10.1126/science.1250256; Grullich C, 2000, J BIOL CHEM, V275, P8650, DOI 10.1074/jbc.275.12.8650; Guinness Book of World Records, 2006, HOTT SPIC; Guo HS, 2014, BIOCHEM BIOPH RES CO, V450, P1370, DOI 10.1016/j.bbrc.2014.06.134; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Henrich KO, 2011, CANCER RES, V71, P3142, DOI 10.1158/0008-5472.CAN-10-3014; HOFFMAN PG, 1983, J AGR FOOD CHEM, V31, P1326, DOI 10.1021/jf00120a044; Howlader N, 2014, SEER CANC STAT REV; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Itahana K., 2007, METHOD MOL BIOL, V2007, P21, DOI DOI 10.1385/1-59745-361-7:21; Johnson W, 2007, INT J TOXICOL, V26, P3, DOI 10.1080/10915810601163939; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; Kasof GM, 1999, MOL CELL BIOL, V19, P4390; Kim JH, 2008, MOL CELL, V31, P510, DOI 10.1016/j.molcel.2008.08.001; Kinnaird A, 2015, J MOL MED, V93, P127, DOI 10.1007/s00109-014-1250-2; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kumar AV, 2014, INT J CANCER, V135, P2579, DOI 10.1002/ijc.28921; Lai D, 2012, BIOSCIENCE REP, V32, P361, DOI 10.1042/BSR20110125; Lam AKM, 2013, FEBS LETT, V587, P3782, DOI 10.1016/j.febslet.2013.10.031; Lauden L, 2014, J INVEST DERMATOL, V134, P1675, DOI 10.1038/jid.2014.20; Lessene G, 2008, NAT REV DRUG DISCOV, V7, P989, DOI 10.1038/nrd2658; Li BY, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-239; Lin H- K, CYTOPLASMIC PML FUNC, P205, DOI [10.1038/nature02783, DOI 10.1038/NATURE02783]; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Lin-Moshier Y, 2013, J BIOL CHEM, V288, P355, DOI 10.1074/jbc.M112.405761; Lovejoy CA, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002772; Ma B, 2013, J BIOL CHEM, V288, P17552, DOI 10.1074/jbc.M113.453985; MacLean B, 2006, BIOINFORMATICS, V22, P2830, DOI 10.1093/bioinformatics/btl379; Mallilankaraman K, 2012, CELL, V151, P630, DOI 10.1016/j.cell.2012.10.011; MARCUS F, 1986, BIOCHEM BIOPH RES CO, V135, P374, DOI 10.1016/0006-291X(86)90005-7; Mathur R, 2000, CURR SCI INDIA, V79, P287; Mayilyan KR, 2012, PROTEIN CELL, V3, P487, DOI 10.1007/s13238-012-2924-6; Meghvansi MK, 2010, J ETHNOPHARMACOL, V132, P1, DOI 10.1016/j.jep.2010.08.034; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nguyen TB, 2002, J BIOL CHEM, V277, P41960, DOI 10.1074/jbc.M203951200; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Phan RT, 2007, NAT IMMUNOL, V8, P1132, DOI 10.1038/ni1508; Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308; Potting C, 2013, CELL METAB, V18, P287, DOI 10.1016/j.cmet.2013.07.008; Ramzi CS CK, 1998, ROBBINS PATHOLOGIC B; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261; Reddy UK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086393; Rishi AK, 2003, J BIOL CHEM, V278, P33422, DOI 10.1074/jbc.M303173200; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sanatombi K, 2008, NOT BOT HORTI AGROBO, V36, P89; Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Slotta DJ, 2010, PROTEOMICS, V10, P3035, DOI 10.1002/pmic.200900370; Sun Y, 2014, BIOCHEM BIOPH RES CO, V450, P1, DOI 10.1016/j.bbrc.2014.05.045; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Tang TD, 2009, J BIOL CHEM, V284, P5414, DOI 10.1074/jbc.M807797200; Tao X, 2002, NEURON, V33, P383, DOI 10.1016/S0896-6273(01)00561-X; Tautenhahn R, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-504; Verone AR, 2013, CARCINOGENESIS, V34, P1737, DOI 10.1093/carcin/bgt126; Vicencio JM, 2008, GERONTOLOGY, V54, P92, DOI 10.1159/000129697; Vogler M, 2009, CELL DEATH DIFFER, V16, P360, DOI 10.1038/cdd.2008.137; Wang J, 2009, NAT STRUCT MOL BIOL, V16, P987, DOI 10.1038/nsmb.1645; Wang X, 2001, CANCER RES, V61, P7417; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Wu CC, 2006, MUTAT RES-FUND MOL M, V601, P71, DOI 10.1016/j.mrfmmm.2006.06.015; Wutka A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095605; Xiao W, 1998, NUCLEIC ACIDS RES, V26, P3908, DOI 10.1093/nar/26.17.3908; Xie Q, 2005, J BIOL CHEM, V280, P19673, DOI 10.1074/jbc.M409517200; Zhao WH, 2008, NATURE, V451, P587, DOI 10.1038/nature06515; Zhou YN, 2005, WORLD J GASTROENTERO, V11, P3468, DOI 10.3748/wjg.v11.i22.3468; Zhou Z, 2013, J BIOL CHEM, V288, P18134, DOI 10.1074/jbc.M113.456962; Zimmerman ZF, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008086; Zois CE, 2014, BIOCHEM PHARMACOL, V92, P3, DOI 10.1016/j.bcp.2014.09.001	98	9	9	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2018	13	10							e0206183	10.1371/journal.pone.0206183	http://dx.doi.org/10.1371/journal.pone.0206183			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY7VH	30379886	Green Published, Green Submitted, gold			2023-01-03	WOS:000448823700094
J	Majeed, YA; Awadalla, SS; Patton, JL				Majeed, Yazan Abdel; Awadalla, Saria S.; Patton, James L.			Regression techniques employing feature selection to predict clinical outcomes in stroke	PLOS ONE			English	Article							MOTOR FUNCTION-TEST; RECOVERY; RELIABILITY; GUIDELINES; VALIDITY	It is not fully clear which measurable factors can reliably predict chronic stroke patients' recovery of motor ability. In this analysis, we investigate the impact of patient demographic characteristics, movement features, and a three-week upper-extremity intervention on the post-treatment change in two widely used clinical outcomes-the Upper Extremity portion of the Fugl-Meyer and the Wolf Motor Function Test. Models based on LASSO, which in validation tests account for 65% and 86% of the variability in Fugl-Meyer and Wolf, respectively, were used to identify the set of salient demographic and movement features. We found that age, affected limb, and several measures describing the patient's ability to efficiently direct motions with a single burst of speed were the most consequential in predicting clinical recovery. On the other hand, the upper-extremity intervention was not a significant predictor of recovery. Beyond a simple prognostic tool, these results suggest that focusing therapy on the more important features is likely to improve recovery. Such validation-intensive methods are a novel approach to determining the relative importance of patient-specific metrics and may help guide the design of customized therapy.	[Majeed, Yazan Abdel; Patton, James L.] Shirley Ryan Abil Lab, Arms & Hands Lab, Chicago, IL 60611 USA; [Majeed, Yazan Abdel; Patton, James L.] Univ Illinois, Coll Engn, Richard & Loan Hill Dept Bioengineering, Chicago, IL 60607 USA; [Majeed, Yazan Abdel; Patton, James L.] Univ Illinois, Coll Med, Chicago, IL 60607 USA; [Awadalla, Saria S.] Univ Illinois, Sch Publ Hlth, Epidemiol & Biostat, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Patton, JL (corresponding author), Shirley Ryan Abil Lab, Arms & Hands Lab, Chicago, IL 60611 USA.; Patton, JL (corresponding author), Univ Illinois, Coll Engn, Richard & Loan Hill Dept Bioengineering, Chicago, IL 60607 USA.; Patton, JL (corresponding author), Univ Illinois, Coll Med, Chicago, IL 60607 USA.	pattonj@uic.edu		Patton, James/0000-0001-7541-3561	NIDILRR MARS3 Grant [90RE5010-01-01]	NIDILRR MARS3 Grant	This work was made possible with funding from NIDILRR (https://www.acl.gov/node/861) MARS3 Grant 90RE5010-01-01. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdollahi Farnaz, 2011, IEEE Int Conf Rehabil Robot, V2011, P5975504, DOI 10.1109/ICORR.2011.5975504; Adams HP, 2007, STROKE, V38, P1655, DOI 10.1161/STROKEAHA.107.181486; Barber PA, 1998, NEUROLOGY, V51, P418, DOI 10.1212/WNL.51.2.418; BARTO AG, 1983, IEEE T SYST MAN CYB, V13, P834, DOI 10.1109/TSMC.1983.6313077; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; DUNCAN PW, 1992, STROKE, V23, P1084, DOI 10.1161/01.STR.23.8.1084; DUNCAN PW, 1983, PHYS THER, V63, P1606, DOI 10.1093/ptj/63.10.1606; Duncan PW, 2000, NEUROPHARMACOLOGY, V39, P835, DOI 10.1016/S0028-3908(00)00003-4; Efron B, 2004, ANN STAT, V32, P407, DOI 10.1214/009053604000000067; Friedman J., 2001, ELEMENTS STAT LEARNI, V1, DOI DOI 10.1007/978-0-387-21606-5_1; HOERL AE, 1970, TECHNOMETRICS, V12, P55, DOI 10.1080/00401706.1970.10488634; JARZEM PF, 1993, J PEDIATR ORTHOPED, V13, P761, DOI 10.1097/01241398-199311000-00014; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kyung M, 2010, BAYESIAN ANAL, V5, P369, DOI 10.1214/10-BA607; Majeed YA, 2015, IEEE ENG MED BIO, P1425, DOI 10.1109/EMBC.2015.7318637; Marshall RS, 2009, ANN NEUROL, V65, P596, DOI 10.1002/ana.21636; Morris DM, 2001, ARCH PHYS MED REHAB, V82, P750, DOI 10.1053/apmr.2001.23183; Mostafavi SM, 2015, INT C REHAB ROBOT, P211, DOI 10.1109/ICORR.2015.7281201; Mostafavi SM, 2014, IEEE ENG MED BIO, P5296, DOI 10.1109/EMBC.2014.6944821; Mostafavi SM, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0104-7; Mostafavi SM, 2014, IEEE ENG MED BIO, P2517, DOI 10.1109/EMBC.2014.6944134; Mostafavi SM, 2013, P IEEE INT C REH ROB, P1; Patton JL, 2006, EXP BRAIN RES, V168, P368, DOI 10.1007/s00221-005-0097-8; Platz T, 2005, CLIN REHABIL, V19, P404, DOI 10.1191/0269215505cr832oa; Reuben DB, 2013, NEUROLOGY, V80, pS65, DOI 10.1212/WNL.0b013e3182872e01; Riley JD, 2011, STROKE, V42, P421, DOI 10.1161/STROKEAHA.110.599340; Rohrer B, 2004, MOTOR CONTROL, V8, P472, DOI 10.1123/mcj.8.4.472; Rohrer B, 2002, J NEUROSCI, V22, P8297; Salthouse TA, 2009, NEUROBIOL AGING, V30, P507, DOI 10.1016/j.neurobiolaging.2008.09.023; Sandri M, 2006, STUD CLASS DATA ANAL, P263, DOI 10.1007/3-540-35978-8_30; Schiemanck SK, 2006, STROKE, V37, P1050, DOI 10.1161/01.STR.0000206462.09410.6f; Siroky DS, 2009, STAT SURV, V3, P147, DOI 10.1214/07-SS033; Stinear C, 2010, LANCET NEUROL, V9, P1228, DOI 10.1016/S1474-4422(10)70247-7; Stinear CM, 2017, LANCET NEUROL, V16, P826, DOI 10.1016/S1474-4422(17)30283-1; Stinear CM, 2017, STROKE, V48, P1011, DOI 10.1161/STROKEAHA.116.015790; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Uswatte G, 2005, STROKE, V36, P2493, DOI 10.1161/01.STR.0000185928.90848.2e; van de Port IGL, 2006, J REHABIL MED, V38, P218, DOI 10.1080/16501970600582930; Wolf SL, 2001, STROKE, V32, P1635, DOI 10.1161/01.STR.32.7.1635; Zarahn E, 2011, CEREB CORTEX, V21, P2712, DOI 10.1093/cercor/bhr047; Zemke AC, 2003, STROKE, V34, pE23, DOI 10.1161/01.STR.0000065827.35634.5E; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	43	11	11	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2018	13	10							e0205639	10.1371/journal.pone.0205639	http://dx.doi.org/10.1371/journal.pone.0205639			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX5DH	30339669	Green Submitted, Green Published, gold			2023-01-03	WOS:000447761400018
J	Lam, MB; Figueroa, JF; Feyman, Y; Reimold, KE; Orav, EJ; Jha, AK				Lam, Miranda B.; Figueroa, Jose F.; Feyman, Yevgeniy; Reimold, Kimberly E.; Orav, E. John; Jha, Ashish K.			Association between patient outcomes and accreditation in US hospitals: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-CARE; MEDICARE BENEFICIARIES; READMISSION RATES; MORTALITY; STROKE; IMPROVEMENT; IMPACT	OBJECTIVES To determine whether patients admitted to US hospitals that are accredited have better outcomes than those admitted to hospitals reviewed through state surveys, and whether accreditation by The Joint Commission (the largest and most well known accrediting body with an international presence) confers any additional benefits for patients compared with other independent accrediting organizations. DESIGN Observational study. SETTING 4400 hospitals in the United States, of which 3337 were accredited (2847 by The Joint Commission) and 1063 underwent state based review between 2014 and 2017. Participants 4 242 684 patients aged 65 years and older admitted for 15 common medical and six common surgical conditions and survey respondents of the Hospital Consumer Assessment of Healthcare Provider and Systems (HCAHPS). MAIN OUTCOME MEASURES Risk adjusted mortality and readmission rates at 30 days and HCAHPS patient experience scores. Hospital admissions were identified from Medicare inpatient files for 2014, and accreditation information was obtained from the Centers for Medicare and Medicaid Services and The Joint Commission. RESULTS Patients treated at accredited hospitals had lower 30 day mortality rates (although not statistically significant lower rates, based on the prespecified P value threshold) than those at hospitals that were reviewed by a state survey agency (10.2% v 10.6%, difference 0.4% (95% confidence interval 0.1% to 0.8%), P=0.03), but nearly identical rates of mortality for the six surgical conditions (2.4% v 2.4%, 0.0% (-0.3% to 0.3%), P=0.99). Readmissions for the 15 medical conditions at 30 days were significantly lower at accredited hospitals than at state survey hospitals (22.4% v 23.2%, 0.8% (0.4% to 1.3%), P<0.001) but did not differ for the surgical conditions (15.9% v 15.6%, 0.3% (-1.2% to 1.6%), P=0.75). No statistically significant differences were seen in 30 day mortality or readmission rates (for both the medical or surgical conditions) between hospitals accredited by The Joint Commission and those accredited by other independent organizations. Patient experience scores were modestly better at state survey hospitals than at accredited hospitals (summary star rating 3.4 v 3.2, 0.2 (0.1 to 0.3), P<0.001). Among accredited hospitals, The Joint Commission did not have significantly different patient experience scores compared to other independent organizations (3.1 v 3.2, 0.1 (-0.003 to 0.2), P=0.06). CONCLUSIONS US hospital accreditation by independent organizations is not associated with lower mortality, and is only slightly associated with reduced readmission rates for the 15 common medical conditions selected in this study. There was no evidence in this study to indicate that patients choosing a hospital accredited by The Joint Commission confer any healthcare benefits over choosing a hospital accredited by another independent accrediting organization.	[Lam, Miranda B.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA; [Lam, Miranda B.; Feyman, Yevgeniy; Reimold, Kimberly E.; Jha, Ashish K.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Figueroa, Jose F.; Jha, Ashish K.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Figueroa, Jose F.; Jha, Ashish K.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med, 75 Francis St, Boston, MA 02115 USA; [Orav, E. John] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Jha, AK (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.; Jha, AK (corresponding author), Harvard Med Sch, Dept Med, Boston, MA 02115 USA.; Jha, AK (corresponding author), Brigham & Womens Hosp, Dept Med, Div Gen Internal Med, 75 Francis St, Boston, MA 02115 USA.	ajha@hsph.harvard.edu	Feyman, Yevgeniy/AAX-1606-2020; Lam, Miranda/L-2377-2019	Feyman, Yevgeniy/0000-0001-7372-7671; Reimold, Kimberly/0000-0002-4067-7222	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001100] Funding Source: NIH RePORTER	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))		Adams R., 2017, BUZZFEED NEWS; Armour S., HOUSE PANEL PROBES O; Armour S., 2017, WALL STREET J; Azagury D, 2016, J AM COLL SURGEONS, V223, P469, DOI 10.1016/j.jamcollsurg.2016.06.014; Barnett ML, 2017, JAMA INTERN MED, V177, P693, DOI 10.1001/jamainternmed.2016.9685; Bogh SB, 2016, INT J QUAL HEALTH C, V28, P715, DOI 10.1093/intqhc/mzw099; Bogh SB, 2015, INT J QUAL HEALTH C, V27, P336, DOI 10.1093/intqhc/mzv053; Brubakk K, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0933-x; Burke LG, 2017, JAMA-J AM MED ASSOC, V317, P2105, DOI 10.1001/jama.2017.5702; Castellucci M., JOINT COMMISSION ACC; Centers for Medicare & Medicaid Services, 2013, COND COV CFCS COND P; Centers for Medicare & Medicaid Services, STAT OP MAN CHAPT 2; Chen J, 2003, HEALTH AFFAIR, V22, P243, DOI 10.1377/hlthaff.22.2.243; Falstie-Jensen AM, 2015, INT J QUAL HEALTH C, V27, P451, DOI 10.1093/intqhc/mzv070; Falstie-Jensen AM, 2015, INT J QUAL HEALTH C, V27, P165, DOI 10.1093/intqhc/mzv023; Figueroa JF, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2214; Gratwohl A, 2014, HAEMATOLOGICA, V99, P908, DOI 10.3324/haematol.2013.096461; Greenfield D, 2008, INT J QUAL HEALTH C, V20, P172, DOI 10.1093/intqhc/mzn005; Greenfield D, 2009, QUAL SAF HEALTH CARE, V18, P162, DOI 10.1136/qshc.2009.032359; Griffith John R, 2002, Qual Manag Health Care, V10, P29; Heuer Albert J, 2004, J Healthc Qual, V26, P46; Ingeman A, 2008, MED CARE, V46, P63, DOI 10.1097/MLR.0b013e3181484b91; Jha AK, 2012, NEW ENGL J MED, V366, P1606, DOI 10.1056/NEJMsa1112351; Joint Commission, FACTS ON SIT SURV PR; Joshi MS, 2003, J CLIN OUTCOMES MANA, V10, P473; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Kristensen PK, 2016, INT J QUAL HEALTH C, V28, P698, DOI 10.1093/intqhc/mzw093; Lichtman JH, 2011, NEUROLOGY, V76, P1976, DOI 10.1212/WNL.0b013e31821e54f3; Lichtman JH, 2011, STROKE, V42, P3387, DOI 10.1161/STROKEAHA.111.622613; Lichtman JH, 2009, STROKE, V40, P3574, DOI 10.1161/STROKEAHA.109.561472; Lutfiyya MN, 2009, INT J QUAL HEALTH C, V21, P112, DOI 10.1093/intqhc/mzp003; McKinney M., 2010, REBOUND JOINT COMMIS; Menachemi N, 2008, JT COMM J QUAL PATIE, V34, P546, DOI 10.1016/S1553-7250(08)34069-0; Merkow RP, 2014, ANN SURG, V259, P1091, DOI 10.1097/SLA.0000000000000542; Morton JM, 2014, ANN SURG, V260, P504, DOI 10.1097/SLA.0000000000000891; Mumford V, 2013, INT J QUAL HEALTH C, V25, P606, DOI 10.1093/intqhc/mzt059; Rosenberg BL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166762; Sack C, 2011, INT J QUAL HEALTH C, V23, P278, DOI 10.1093/intqhc/mzr011; Sack C, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-120; Schmaltz SP, 2011, J HOSP MED, V6, P454, DOI 10.1002/jhm.905; Sekimoto M, 2008, AM J INFECT CONTROL, V36, P212, DOI 10.1016/j.ajic.2007.04.276; The Joint Commission, 2015, FEE EX JOINT COMM BE; Tsai TC, 2013, NEW ENGL J MED, V369, P1134, DOI 10.1056/NEJMsa1303118; Wagner Laura M, 2012, Policy Polit Nurs Pract, V13, P8, DOI 10.1177/1527154412443990	44	49	51	1	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 18	2018	363								k4011	10.1136/bmj.k4011	http://dx.doi.org/10.1136/bmj.k4011			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY1FN	30337294	hybrid, Green Published			2023-01-03	WOS:000448270700002
J	Patterson, JA; Nippita, T; Randall, DA; Irving, DO; Ford, JB				Patterson, Jillian A.; Nippita, Tanya; Randall, Deborah A.; Irving, David O.; Ford, Jane B.		Obstet Transfusion Steering Grp	Outcomes of subsequent pregnancy following obstetric transfusion in a first birth	PLOS ONE			English	Article							SEVERE POSTPARTUM HEMORRHAGE; BLOOD-TRANSFUSION; RISK-FACTORS; RECURRENCE; ALLOIMMUNIZATION; VALIDATION; ANTIBODIES; PLACENTA; COHORT; CELL	Background Increasing rates of postpartum haemorrhage and obstetric transfusion mean that more women are entering subsequent pregnancies with a history of blood transfusion. This study investigates subsequent pregnancy outcomes of women with a prior obstetric red cell transfusion, compared to women without a transfusion. Methods All women with a first pregnancy resulting in a liveborn singleton infant of at least 20 weeks gestation delivering in hospitals in New South Wales, Australia, between 2003 and 2012 were included in the study, with followup for second births until June 2015. Linked hospital and births data were used to identify women with a transfusion and/or postpartum haemorrhage in their first birth, time to second pregnancy and adverse birth outcomes (including transfusion, postpartum haemorrhage and severe morbidity) in their subsequent birth. Results There were 358,384 singleton births to primiparous women, with 1.4% receiving an obstetric blood transfusion. Sixty-three percent of women had at least one subsequent birth. The relative risk (RR) of requiring a transfusion in a second birth was 4.9 (95% CI 4.1,6.1) for women with a previous transfusion compared with women without. The risk (RR) of severe morbidity in a second birth was 4.1 times higher (95% CI 2.2,7.4) for those receiving a transfusion without haemorrhage in their first birth compared with women with neither haemorrhage nor transfusion. Conclusion It is important to consider a woman's history of transfusion and/or haemorrhage as part of her obstetric history to ensure management in a manner that minimises risk in subsequent pregnancies.	[Patterson, Jillian A.; Nippita, Tanya; Randall, Deborah A.; Ford, Jane B.] Kolling Inst, Northern Sydney Local Hlth Dist, Clin & Populat Perinatal Hlth Res, St Leonards, NSW, Australia; [Patterson, Jillian A.; Nippita, Tanya; Randall, Deborah A.; Ford, Jane B.] Univ Sydney, Northern Clin Sch, St Leonards, NSW, Australia; [Nippita, Tanya] Royal North Shore Hosp, Dept Obstet & Gynaecol, Northern Sydney Local Hlth Dist, St Leonards, NSW, Australia; [Irving, David O.] Australian Red Cross Blood Serv, Res & Dev, Sydney, NSW, Australia	University of Sydney; Kolling Institute of Medical Research; University of Sydney; Royal North Shore Hospital; Australian Red Cross Blood Service	Patterson, JA (corresponding author), Kolling Inst, Northern Sydney Local Hlth Dist, Clin & Populat Perinatal Hlth Res, St Leonards, NSW, Australia.; Patterson, JA (corresponding author), Univ Sydney, Northern Clin Sch, St Leonards, NSW, Australia.	jillian.patterson@sydney.edu.au	Patterson, Jillian/A-7384-2015; Irving, David/AAS-9892-2021; Peek, Michael/D-5991-2016	Peek, Michael/0000-0001-6055-5129; Patterson, Jillian/0000-0002-9888-9818; Randall, Deborah/0000-0002-5075-0227	Australian National Health and Medical Research Centre (NHMRC) [1094822]; Australian Research Council Future Fellowship [120100069]	Australian National Health and Medical Research Centre (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council Future Fellowship(Australian Research Council)	This work was supported by an Australian National Health and Medical Research Centre (NHMRC) Partnership grant (#1094822; https://www.nhmrc.gov.au/). JF is supported by an Australian Research Council Future Fellowship (#120100069; http://www.arc.gov.au/). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Ananth CV, 2017, AM J OBSTET GYNECOL, V217, P167, DOI 10.1016/j.ajog.2017.04.016; Baldwin HJ, 2017, ACTA OBSTET GYN SCAN, V96, P1373, DOI 10.1111/aogs.13201; Chen JS, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-68; Copen C.E., 2015, NATL VITAL STAT REPO, V64, P1; Dajak S, 2013, BLOOD TRANSFUS-ITALY, V11, P528, DOI 10.2450/2013.0193-12; Egbor M, 2012, BEST PRACT RES CL OB, V26, P119, DOI 10.1016/j.bpobgyn.2011.10.004; Ford JB, 2007, MED J AUSTRALIA, V187, P391, DOI 10.5694/j.1326-5377.2007.tb01308.x; Ford JB, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0788-5; Ford JB, 2013, AUST HEALTH REV, V37, P495, DOI 10.1071/AH12017; Ford JB, 2012, MATERN CHILD HLTH J, V16, P1542, DOI 10.1007/s10995-011-0919-1; Fullerton G, 2013, BJOG-INT J OBSTET GY, V120, P621, DOI 10.1111/1471-0528.12120; Gardosi J, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f108; Gottvall K, 2002, BJOG-INT J OBSTET GY, V109, P254, DOI 10.1016/S1470-0328(02)01200-4; Holm C, 2012, BJOG-INT J OBSTET GY, V119, P596, DOI 10.1111/j.1471-0528.2011.03267.x; James AH, 2008, J WOMENS HEALTH, V17, P1279, DOI 10.1089/jwh.2007.0605; Knight M, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-55; Koelewijn JM, 2009, BJOG-INT J OBSTET GY, V116, P655, DOI 10.1111/j.1471-0528.2008.01984.x; Kramer MS, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.07.007; Lain SJ, 2008, AUST NZ J OBSTET GYN, V48, P481, DOI 10.1111/j.1479-828X.2008.00910.x; Liumbruno GM, 2010, BLOOD TRANSFUS-ITALY, V8, P8, DOI 10.2450/2009.0108-09; Mehrabadi A, 2014, J OBSTET GYNAECOL CA, V36, P21, DOI 10.1016/S1701-2163(15)30680-0; National Blood Authority, 2015, PAT BLOOD MAN GUID M; Oberg AS, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.10.872; Pal M, 2015, PATHOLOGY, V47, P151, DOI 10.1097/PAT.0000000000000225; Patterson JA, 2015, VOX SANG, V108, P37, DOI 10.1111/vox.12186; Patterson JA, 2014, OBSTET GYNECOL, V123, P126, DOI 10.1097/AOG.0000000000000054; Prick BW, 2014, BJOG-INT J OBSTET GY, V121, P1005, DOI 10.1111/1471-0528.12531; Rn L, 2013, ACTA OBSTET GYN SCAN, V92, P210, DOI [10.1111/aogs.12034, DOI 10.1111/AOGS.12034]; Roberts CL, 2008, MED CARE, V46, P786, DOI 10.1097/MLR.0b013e318178eae4; Roberts CL, 2012, AUST NZ J OBSTET GYN, V52, P483, DOI 10.1111/j.1479-828X.2012.01470.x; Roberts CL, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-7; Seeho SK, AM J OBSTET GYNECOLO; Smith Heather M, 2013, Immunohematology, V29, P127; The Royal Australian and New Zealand College of Obstetricians and Gynaecologists, 2016, MAN POSTP HAEM PPH; Thompson JF, 2011, AUST NZ J OBSTET GYN, V51, P365, DOI 10.1111/j.1479-828X.2011.01317.x; Wikkelso AJ, 2014, J MATERN-FETAL NEO M, V27, P1661, DOI 10.3109/14767058.2013.872095	36	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2018	13	9							e0203195	10.1371/journal.pone.0203195	http://dx.doi.org/10.1371/journal.pone.0203195			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV3OT	30265674	gold, Green Published, Green Submitted			2023-01-03	WOS:000446005500006
J	Eisenstein, M				Eisenstein, Michael			The battle for the brain	NATURE			English	Editorial Material																		Batich KA, 2017, CLIN CANCER RES, V23, P1898, DOI 10.1158/1078-0432.CCR-16-2057; Brown MC, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan4220; Cloughesy TF, 2018, NEURO-ONCOLOGY, V20, P1383, DOI 10.1093/neuonc/noy075; Desjardins A, 2018, NEW ENGL J MED, V379, P150, DOI 10.1056/NEJMoa1716435; Liau LM, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1507-6; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; O'Rourke DM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaa0984	7	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 27	2018	561	7724					S42	S44		10.1038/d41586-018-06705-6	http://dx.doi.org/10.1038/d41586-018-06705-6			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GU8WA	30258155	Bronze			2023-01-03	WOS:000445622500010
J	Jeremias, HF; Lousa, D; Hollmann, A; Coelho, AC; Baltazar, CS; Seixas, JD; Marques, AR; Santos, NC; Romao, CC; Soares, CM				Jeremias, Helia F.; Lousa, Diana; Hollmann, Axel; Coelho, Ana C.; Baltazar, Carla S.; Seixas, Joao D.; Marques, Ana R.; Santos, Nuno C.; Romao, Carlos C.; Soares, Claudio M.			Study of the interactions of bovine serum albumin with a molybdenum(II) carbonyl complex by spectroscopic and molecular simulation methods	PLOS ONE			English	Article							MONOXIDE-RELEASING MOLECULES; CRYSTAL-STRUCTURE; CO-RMS; BINDING; FLUORESCENCE; INCLUSION; DRUGS	Therapy with inhaled carbon monoxide (CO) is being tested in human clinical trials, yet the alternative use of prodrugs, CO-Releasing Molecules (CORMs), is conceptually advantageous. These molecules are designed to release carbon monoxide in specific tissues, in response to some locally expressed stimulus, where CO can trigger a cytoprotective response. The design of such prodrugs, mostly metal carbonyl complexes, must consider their ADMET profiles, including their interaction with transport plasma proteins. However, the molecular details of this interaction remain elusive. To shed light into this matter, we focused on the CORM prototype [Mo(eta(5)-Cp)(CH2COOH)(CO)(3)] (ALF414) and performed a detailed molecular characterization of its interaction with bovine serum albumin (BSA), using spectroscopic and computational methods. The experimental results show that ALF414 partially quenches the intrinsic fluorescence of BSA without changing its secondary structure. The interaction between BSA and ALF414 follows a dynamic quenching mechanism, indicating that no stable complex is formed between the protein Trp residues and ALF414. The molecular dynamics simulations are in good agreement with the experimental results and confirm the dynamic and unspecific character of the interaction between ALF414 and BSA. The simulations also provide important insights into the nature of the interactions of this CORM prototype with BSA, which are dominated by hydrophobic contacts, with a contribution from hydrogen bonding. This kind of information is useful for future CORM design.	[Jeremias, Helia F.; Lousa, Diana; Coelho, Ana C.; Baltazar, Carla S.; Romao, Carlos C.; Soares, Claudio M.] Univ Nova Lisboa, ITQB NOVA, Inst Tecnol Quim & Biol Antonio Xavier, Oeiras, Portugal; [Hollmann, Axel; Santos, Nuno C.] Univ Lisbon, Inst Med Mol, Fac Med, Lisbon, Portugal; [Seixas, Joao D.; Marques, Ana R.; Romao, Carlos C.] Alfama Lda, Inst Biol Expt & Tecnol, Oeiras, Portugal	Universidade Nova de Lisboa; Universidade de Lisboa	Romao, CC; Soares, CM (corresponding author), Univ Nova Lisboa, ITQB NOVA, Inst Tecnol Quim & Biol Antonio Xavier, Oeiras, Portugal.; Romao, CC (corresponding author), Alfama Lda, Inst Biol Expt & Tecnol, Oeiras, Portugal.	ccr@itqb.unl.pt; claudio@itqb.unl.pt	Soares, Claudio M/E-2675-2012; Lousa, Diana/S-7808-2016; Santos, Nuno/N-7248-2013	Soares, Claudio M/0000-0003-1154-556X; Lousa, Diana/0000-0002-2309-0980; Santos, Nuno/0000-0002-0580-0475; Hollmann, Axel/0000-0002-8060-2997	Fundacao para a Ciencia e a Tecnologia, Portugal [PTDC/QUI-BIQ/117799/2010, Pest-OE/EQB/LA0004/2011]; FEDER funds through COMPETE2020 - Programa Operacional Competitividade e Internacionalizacao (POCI) [LISBOA-01-0145-FEDER-007660]; FCT - Fundacao para a Ci00EAncia e a Tecnologia; FCT [SFRH/BPD/92537, SFRH/BPD/92537/2013, SFRH/BPD/70163/2010]; Alfama Lda; ITQB institutional funds; FCT - Fundacao para a Ciencia e a Tecnologia, Portugal [PTDC/QUI-BIQ/117799/2010, Pest-OE/EQB/LA0004/2011]; FEDER funds through COMPETE2020-Programa Operacional Competitividade e Internacionalizacao (POCI) [LISBOA-01-0145-FEDER-007660]; FCT - Fundacao para a Ciencia e a Tecnologia; Fundação para a Ciência e a Tecnologia [PTDC/QUI-BIQ/117799/2010] Funding Source: FCT	Fundacao para a Ciencia e a Tecnologia, Portugal(Portuguese Foundation for Science and Technology); FEDER funds through COMPETE2020 - Programa Operacional Competitividade e Internacionalizacao (POCI); FCT - Fundacao para a Ci00EAncia e a Tecnologia; FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); Alfama Lda; ITQB institutional funds; FCT - Fundacao para a Ciencia e a Tecnologia, Portugal(Portuguese Foundation for Science and Technology); FEDER funds through COMPETE2020-Programa Operacional Competitividade e Internacionalizacao (POCI); FCT - Fundacao para a Ciencia e a Tecnologia(Portuguese Foundation for Science and Technology); Fundação para a Ciência e a Tecnologia	This work was financially supported by Fundacao para a Ciencia e a Tecnologia, Portugal, through projects PTDC/QUI-BIQ/117799/2010 and Pest-OE/EQB/LA0004/2011. This work was also financially supported by Project LISBOA-01-0145-FEDER-007660 (Microbiologia Molecular, Estrutural e Celular) funded by FEDER funds through COMPETE2020 - Programa Operacional Competitividade e Internacionalizacao (POCI) and by national funds through FCT - Fundacao para a Ci00EAncia e a Tecnologia. DL was supported by FCT post-doc fellowship SFRH/BPD/92537 The funder Alfama Lda, owned by Alfama Inc. provided support in the form of salaries for authors [CCR, JDS, ARM] as well as costs for the chemistry [JDS] and biological research [ARM] and initial spectroscopic research at IMM (NCS, AH]. JDS and ARM left Alfama Lda in 2011 when it closed all research activities. CCR resumed his academic position at ITQB in July 2011 and remained as probono manager of Alfama Lda and Board member of Alfama Inc until it was acquired by Proterris Inc in 2017, becoming Proterris (Portugal) Lda. This research was continued at ITQB [CCR, ACC, HFJ spectroscopy; CMS, DL, HFJ, CSB, computational studies] and IMM [NCS, AH, spectroscopic studies] using existing ALF414 stock samples and exclusively financed by Fundacao para a Ciencia e a Tecnologia, Portugal [project PTDC/QUI-BIQ/117799/2010 and Pest-OE/EQB/LA0004/2011] as well as ITQB institutional funds. Since 2011 neither Alfama Lda nor Proterris Inc played any further financial, scientific or commercial role in this research, which was carried out at the academic level with specific. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.r This work was financially supported by FCT - Fundacao para a Ciencia e a Tecnologia, Portugal, through projects PTDC/QUI-BIQ/117799/2010 and Pest-OE/EQB/LA0004/2011. This work was also financially supported by Project LISBOA-01-0145-FEDER-007660 (Microbiologia Molecular, Estrutural e Celular) funded by FEDER funds through COMPETE2020-Programa Operacional Competitividade e Internacionalizacao (POCI) and by national funds through FCT - Fundacao para a Ciencia e a Tecnologia. DL was supported by FCT post-doc fellowship SFRH/BPD/92537/2013. ACC was supported by FCT post-doc fellowship SFRH/BPD/70163/2010.	Adler AJ, 1973, CIRCULAR DICHROISM O, P675; ARIYARAT.JK, 1969, J CHEM SOC A, P1309, DOI 10.1039/j19690001309; Baptista AM, 1999, BIOPHYS J, V76, P2978, DOI 10.1016/S0006-3495(99)77452-7; Baptista AM, 2001, J PHYS CHEM B, V105, P293, DOI 10.1021/jp002763e; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Bertucci C, 2002, CURR MED CHEM, V9, P1463, DOI 10.2174/0929867023369673; Binkley SL, 2010, CHEM COMMUN, V46, P1203, DOI 10.1039/b923688k; Braga SS, 2006, INORG CHIM ACTA, V359, P4757, DOI 10.1016/j.ica.2006.03.017; Chaves-Ferreira M, 2015, ANGEW CHEM INT EDIT, V54, P1172, DOI 10.1002/anie.201409344; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Dorr M, 2014, CURR OPIN CHEM BIOL, V19, P76, DOI 10.1016/j.cbpa.2014.01.005; Fairlamb IJS, 2007, DALTON T, P3603, DOI 10.1039/b707377a; Garcia-Gallego S, 2014, ANGEW CHEM INT EDIT, V53, P9712, DOI 10.1002/anie.201311225; Ghosh S, 2015, J PHYS CHEM B, V119, P7804, DOI 10.1021/acs.jpcb.5b00965; Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600; Heinemann SH, 2014, CHEM COMMUN, V50, P3644, DOI 10.1039/c3cc49196j; HERMANS J, 1984, BIOPOLYMERS, V23, P1513, DOI 10.1002/bip.360230807; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Hewison L, 2010, DALTON T, V39, P8967, DOI 10.1039/c0dt00203h; Hu YJ, 2005, J MOL STRUCT, V750, P174, DOI 10.1016/j.molstruc.2005.04.032; Jiang XJ, 2015, CHEM-EUR J, V21, P13065, DOI 10.1002/chem.201501348; Kautz AC, 2016, DALTON T, V45, P18045, DOI 10.1039/c6dt03515a; Kim HP, 2006, ANNU REV PHARMACOL, V46, P411, DOI 10.1146/annurev.pharmtox.46.120604.141053; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; Lovering F, 2009, J MED CHEM, V52, P6752, DOI 10.1021/jm901241e; Marques AR, 2012, ORGANOMETALLICS, V31, P5810, DOI 10.1021/om300360c; MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805; Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256; Motterlini R, 2010, NAT REV DRUG DISCOV, V9, P728, DOI 10.1038/nrd3228; Otterbein LE, 2009, RESP CARE, V54, P925, DOI 10.4187/002013209793800394; Patra M, 2012, CHEMBIOCHEM, V13, P1232, DOI 10.1002/cbic.201200159; Peters Jr. T., 1995, ALL ALBUMIN BIOCH GE; Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055; Razavet M, 2007, CHEM COMMUN, P2805, DOI 10.1039/b703887a; Romao CC, 2012, CHEM SOC REV, V41, P3571, DOI 10.1039/c2cs15317c; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; Santos NC, 1998, BIOCHEMISTRY-US, V37, P8674, DOI 10.1021/bi9803933; Santos-Silva T, 2011, J AM CHEM SOC, V133, P1192, DOI 10.1021/ja108820s; Scapens D, 2007, DALTON T, P4962, DOI 10.1039/b704832g; Schmid N, 2011, EUR BIOPHYS J BIOPHY, V40, P843, DOI 10.1007/s00249-011-0700-9; Seixas JD, 2013, DALTON T, V42, P5985, DOI 10.1039/c2dt32174b; Steiger C, 2017, EUR J PHARM BIOPHARM, V118, P3, DOI 10.1016/j.ejpb.2016.11.002; Szabo C, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000721; Timerbaev AR, 2006, CHEM REV, V106, P2224, DOI 10.1021/cr040704h; Wu LY, 2005, PHARMACOL REV, V57, P585, DOI 10.1124/pr.57.4.3; Yamasaki K, 2013, BBA-GEN SUBJECTS, V1830, P5435, DOI 10.1016/j.bbagen.2013.05.005; Yang F, 2014, INT J MOL SCI, V15, P3580, DOI 10.3390/ijms15033580; Zhang WQ, 2011, ORGANOMETALLICS, V30, P4643, DOI 10.1021/om200495h; Zobi F, 2012, DALTON T, V41, P370, DOI 10.1039/c1dt10649j	50	10	10	2	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 27	2018	13	9							e0204624	10.1371/journal.pone.0204624	http://dx.doi.org/10.1371/journal.pone.0204624			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV2HB	30261022	Green Published, Green Submitted, gold			2023-01-03	WOS:000445907400082
J	Willyard, C				Willyard, Cassandra			Lighting up the brain To combat brain cancer, neurosurgeons and oncologists will have to get creative. The latest innovations rely on light and electricity to fight the disease	NATURE			English	Editorial Material																			0	3	3	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 27	2018	561	7724					S59	S61		10.1038/d41586-018-06713-6	http://dx.doi.org/10.1038/d41586-018-06713-6			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GU8WA	30258164	Bronze			2023-01-03	WOS:000445622500018
J	Lastrucci, V; D'Arienzo, S; Collini, F; Lorini, C; Zuppiroli, A; Forni, S; Bonaccorsi, G; Gemmi, F; Vannucci, A				Lastrucci, Vieri; D'Arienzo, Sara; Collini, Francesca; Lorini, Chiara; Zuppiroli, Alfredo; Forni, Silvia; Bonaccorsi, Guglielmo; Gemmi, Fabrizio; Vannucci, Andrea			Diagnosis-related differences in the quality of end-of-life care: A comparison between cancer and non-cancer patients	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; PALLIATIVE CARE; HEART-FAILURE; LUNG-CANCER; SEVERE COPD; RESPIRATORY-DISEASES; PREFERRED PLACE; DEATH; INDICATORS; GUIDELINES	Background Cancer, chronic heart failure (CHF), and chronic obstructive pulmonary disease (COPD) in the advanced stages have similar symptom burdens and survival rates. Despite these similarities, the majority of the attention directed to improving the quality of end-of-life (EOL) care has focused on cancer. Aim To assess the extent to which the quality of EOL care received by cancer, CHF, and COPD patients in the last month of life is diagnosis-sensitive. Methods This is a retrospective observational study based on administrative data. The study population includes all Tuscany region residents aged 18 years or older who died with a clinical history of cancer, CHF, or COPD. Decedents were categorized into two mutually exclusive diagnosis categories: cancer (CA) and cardiopulmonary failure (CPF). Several EOL care quality outcome measures were adopted. Multivariable generalized linear model for each outcome were performed. Results The sample included 30,217 decedents. CPF patients were about 1.5 times more likely than cancer patients to die in an acute care hospital (RR 1.59, 95% C.I.: 1.54-1.63). CPF patients were more likely to be hospitalized or admitted to the emergency department (RR 1.09, 95% C.I.: 1.07-1.10; RR 1.15, 95% C.I.: 1.13-1.18, respectively) and less likely to use hospice services (RR 0.08, 95% C.I.: 0.07-0.09) than cancer patients in the last month of life. CPF patients had a four- and two-fold higher risk of intensive care unit admission or of undergoing life-sustaining treatments, respectively, than cancer patients (RR 3.71, 95% C.I.: 3.40-4.04; RR 2.43, 95% C.I.: 2.27-2.60, respectively). Conclusion The study has highlighted the presence of significant differences in the quality of EOL care received in the last month of life by COPD and CHF compared with cancer patients. Further studies are needed to better elucidate the extent and the avoidability of these diagnosis-related differences in the quality of EOL care.	[Lastrucci, Vieri; Lorini, Chiara; Bonaccorsi, Guglielmo] Univ Florence, Dept Hlth Sci, Florence, Italy; [D'Arienzo, Sara; Collini, Francesca; Zuppiroli, Alfredo; Forni, Silvia; Gemmi, Fabrizio; Vannucci, Andrea] Tuscan Reg Hlth Agcy, Florence, Italy	University of Florence	Lastrucci, V (corresponding author), Univ Florence, Dept Hlth Sci, Florence, Italy.	vieri.lastrucci@gmail.com	Gemmi, Fabrizio/AAS-9311-2020; Gemmi, Fabrizio/ABB-4101-2020; Lastrucci, Vieri/AEY-0086-2022	Gemmi, Fabrizio/0000-0002-1266-8433; Lastrucci, Vieri/0000-0003-0762-6666; bonaccorsi, guglielmo/0000-0002-5171-4308				Allen LA, 2012, CIRCULATION, V125, P1928, DOI 10.1161/CIR.0b013e31824f2173; [Anonymous], 1990, World Health Organ Tech Rep Ser, V804, P1; Au DH, 2006, ARCH INTERN MED, V166, P326, DOI 10.1001/archinte.166.3.326; Barnato AE, 2015, J PAIN SYMPTOM MANAG, V49, P521, DOI 10.1016/j.jpainsymman.2014.06.017; Beccaro M, 2006, J EPIDEMIOL COMMUN H, V60, P412, DOI 10.1136/jech.2005.043646; Billingham MJ, 2013, BMJ SUPPORT PALLIAT, V3, P144, DOI 10.1136/bmjspcare-2012-000292; Chou WC, 2013, J PALLIAT CARE, V29, P29, DOI 10.1177/082585971302900105; Claessens MT, 2000, J AM GERIATR SOC, V48, pS146, DOI 10.1111/j.1532-5415.2000.tb03124.x; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592; Coventry PA, 2005, AGE AGEING, V34, P218, DOI 10.1093/ageing/afi054; Curtis JR, 2008, EUR RESPIR J, V32, P796, DOI 10.1183/09031936.00126107; Curtis JR, 2004, EUR RESPIR J, V24, P200, DOI 10.1183/09031936.04.00010104; De Roo ML, 2013, J PAIN SYMPTOM MANAG, V46, P556, DOI 10.1016/j.jpainsymman.2012.09.013; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Earle CC, 2005, INT J QUAL HEALTH C, V17, P505, DOI 10.1093/intqhc/mzi061; Earle CC, 2003, J CLIN ONCOL, V21, P1133, DOI 10.1200/JCO.2003.03.059; Edmonds P, 2001, PALLIATIVE MED, V15, P287, DOI 10.1191/026921601678320278; Fang JC, 2015, J CARD FAIL, V21, P519, DOI 10.1016/j.cardfail.2015.04.013; Goodlin SJ, 2009, J AM COLL CARDIOL, V54, P386, DOI 10.1016/j.jacc.2009.02.078; Goodridge D M, 2009, Can Respir J, V16, pe51; Gore JM, 2000, THORAX, V55, P1000, DOI 10.1136/thorax.55.12.1000; Hanratty B, 2002, BRIT MED J, V325, P581, DOI 10.1136/bmj.325.7364.581; Hanson LC, 1996, ARCH INTERN MED, V156, P785, DOI 10.1001/archinte.156.7.785; HIGGINSON I, 1993, J PUBLIC HEALTH MED, V15, P3, DOI 10.1093/oxfordjournals.pubmed.a042817; Higginson I J, 2000, J Palliat Med, V3, P287, DOI 10.1089/jpm.2000.3.287; Hyasat K, 2016, AM J HOSP PALLIAT ME, V33, P717, DOI 10.1177/1049909115586395; Istituto nazionale di statistica (Istat) [Italian National Institute of Statistics], 2017, BIL DEM ANN 2016 POP; Janssen DJA, 2011, CHEST, V139, P1081, DOI 10.1378/chest.10-1753; Kavalieratos D, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000544; Kontis V, 2017, LANCET, V389, P1323, DOI 10.1016/S0140-6736(16)32381-9; Lanken PN, 2008, AM J RESP CRIT CARE, V177, P912, DOI 10.1164/rccm.200605-587ST; LAWRENCE VA, 1987, ARCH INTERN MED, V147, P1637, DOI 10.1001/archinte.147.9.1637; Lopez-Campos JL, 2016, RESPIROLOGY, V21, P14, DOI 10.1111/resp.12660; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Lynn J, 2003, LIVING WELL END LIFE; McMurray JJ, 2000, HEART, V83, P596, DOI 10.1136/heart.83.5.596; Mizuno A, 2017, J CARDIOL, V70, P335, DOI 10.1016/j.jjcc.2017.02.010; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9; Nates JL, 2016, CRIT CARE MED, V44, P1553, DOI 10.1097/CCM.0000000000001856; Pritt BS, 2005, ARCH PATHOL LAB MED, V129, P1476; Ravakhah K, 2006, SOUTH MED J, V99, P728, DOI 10.1097/01.smj.0000224337.77074.57; Rodriguez KL, 2007, J PALLIAT MED, V10, P99, DOI 10.1089/jpm.2006.0155; Saunders C, 2000, PATIENT EDUC COUNS, V41, P7, DOI 10.1016/S0738-3991(00)00110-5; Sehdev AES, 2001, ARCH INTERN MED, V161, P277, DOI 10.1001/archinte.161.2.277; Siouta N, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0089-4; Skorstengaard MH, 2017, J PALLIAT MED, V20, P1217, DOI 10.1089/jpm.2017.0082; Small N, 2010, PALLIATIVE MED, V24, P740, DOI 10.1177/0269216310375861; Smith AK, 2012, HEALTH AFFAIR, V31, P1277, DOI 10.1377/hlthaff.2011.0922; Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007; Steinhauser KE, 2011, J PAIN SYMPTOM MANAG, V42, P331, DOI 10.1016/j.jpainsymman.2010.11.006; Stewart S, 2001, EUR J HEART FAIL, V3, P315, DOI 10.1016/S1388-9842(00)00141-0; Stjernsward J, 1996, J PAIN SYMPTOM MANAG, V12, P65, DOI 10.1016/0885-3924(96)00109-1; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; Wachterman MW, 2016, JAMA INTERN MED, V176, P1095, DOI 10.1001/jamainternmed.2016.1200; World Health Organization, 2016, PROJ MORT CAUS DEATH; Wysham NG, 2015, ANN AM THORAC SOC, V12, P1294, DOI 10.1513/AnnalsATS.201503-180OC; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; Ziaeian B, 2016, NAT REV CARDIOL, V13, P368, DOI 10.1038/nrcardio.2016.25	60	16	16	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2018	13	9							e0204458	10.1371/journal.pone.0204458	http://dx.doi.org/10.1371/journal.pone.0204458			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GU9BO	30252912	gold, Green Published			2023-01-03	WOS:000445639700053
J	Beom, JH; Kim, JH; Chung, HS; Kim, SM; Ko, DR; Cho, J				Beom, Jin Ho; Kim, Ji Hoon; Chung, Hyun Soo; Kim, Su Mi; Ko, Dong Ryul; Cho, Junho			Flipped-classroom training in advanced cardiopulmonary life support	PLOS ONE			English	Article							MEDICINE; PERFORMANCE; CLERKSHIP; MODEL	Background The effects of the flipped classroom have been demonstrated in various fields of education in recent years. Training in emergency medicine is also beginning to gradually implement the flipped classroom; however, its practical effect in emergency medicine contexts is not yet clear. Objective The present study investigates the effects of the flipped classroom on advanced cardiopulmonary life support (ACLS) training implemented among practicum students in emergency medicine. Methods The study randomly assigned into control and experimental conditions 108 fourth year students in the College of Medicine at Yonsei University, in Seoul, who were scheduled to take clinical practice in emergency medicine between March and July 2017. Students were taught about ACLS in either a traditional lecture-based classroom (control condition) or a flipped classroom (experimental condition); then, simulation training with ACLS scenarios was carried out. Finally, each student was rated on performance using a rating form developed in advance. Results ACLS simulation scores of the students in the flipped classroom were 70.9 +/- 10.9, which was higher than those of the students in the traditional classroom (67.1 +/- 11.3); however, this difference was not statistically significant (p = 0.339). In addition, the difference in student satisfaction as measured on a survey was statistically insignificant (p = 0.655). Conclusions Competency assessment after simulation-based training in ACLS undergone by senior medical students randomly assigned to flipped and traditional classrooms showed no statistical difference in competency between the two groups.	[Beom, Jin Ho; Kim, Ji Hoon; Chung, Hyun Soo; Ko, Dong Ryul; Cho, Junho] Yonsei Univ, Dept Emergency Med, Coll Med, Seoul, South Korea; [Kim, Su Mi] Yonsei Univ, Coll Med, Clin Simulat Ctr, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Cho, J (corresponding author), Yonsei Univ, Dept Emergency Med, Coll Med, Seoul, South Korea.	emjh@yuhs.ac		Cho, Junho/0000-0003-2240-3989; Chung, Hyun Soo/0000-0001-6110-1495; Kim, Ji Hoon/0000-0002-0070-9568				Belfi LM, 2015, ACAD RADIOL, V22, P794, DOI 10.1016/j.acra.2014.11.003; Bliuc Ana-Maria, 2007, The Internet and Higher Education, V10, P231, DOI 10.1016/j.iheduc.2007.08.001; Boysen-Osborn M, 2016, J EDUC EVAL HEALTH P, V13, DOI 10.3352/jeehp.2016.13.11; Chen F, 2017, MED EDUC, V51, P585, DOI 10.1111/medu.13272; Cooper Avraham Z, 2017, J Grad Med Educ, V9, P392, DOI 10.4300/JGME-D-16-00827.1; Corrias A, 2015, IEEE ENG MED BIO, P3985, DOI 10.1109/EMBC.2015.7319267; DeRuisseau LR, 2016, ADV PHYSIOL EDUC, V40, P522, DOI 10.1152/advan.00033.2016; Fox J, 2017, SOUTH MED J, V110, P319, DOI 10.14423/SMJ.0000000000000649; Heitz C, 2015, WEST J EMERG MED, V16, P851, DOI 10.5811/westjem.2015.9.27256; Holmboe ES, 2010, MED TEACH, V32, P676, DOI 10.3109/0142159X.2010.500704; Khanova J, 2015, AM J PHARM EDUC, V79, DOI 10.5688/ajpe799140; Lew EK, 2016, INT J EMERG MED, V9, DOI 10.1186/s12245-016-0123-6; Liebert CA, 2016, AM J SURG, V211, P451, DOI 10.1016/j.amjsurg.2015.10.004; Lin Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174829; Makhdoom N, 2013, J TAIBAH UNIV MED SC, V8, P12, DOI 10.1016/j.jtumed.2013.01.002; McDonald K, 2013, J CONTIN EDUC NURS, V44, P437, DOI 10.3928/00220124-20130925-19; Mehta NB, 2013, ACAD MED, V88, P1418, DOI 10.1097/ACM.0b013e3182a36a07; MILLER GE, 1990, ACAD MED, V65, pS63, DOI 10.1097/00001888-199009000-00045; Morgan H, 2015, CLIN TEACH, V12, P155, DOI 10.1111/tct.12328; Ojennus DD, 2016, BIOCHEM MOL BIOL EDU, V44, P20, DOI 10.1002/bmb.20926; Park SE, 2015, J DENT EDUC, V79, P563; Rose E, 2016, J EMERG MED, V51, P284, DOI 10.1016/j.jemermed.2016.05.033; Tan E, 2015, EMERG MED AUSTRALAS, V27, P444, DOI 10.1111/1742-6723.12454; Whillier S, 2015, J CHIPROPR EDUC, V29, P127, DOI 10.7899/JCE-14-28; Zeng R, 2017, BMC MED EDUC, V17, DOI 10.1186/s12909-017-0881-8	25	10	10	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 5	2018	13	9							e0203114	10.1371/journal.pone.0203114	http://dx.doi.org/10.1371/journal.pone.0203114			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS6HC	30183739	Green Submitted, Green Published, gold			2023-01-03	WOS:000443789900046
J	Cass, KS				Cass, Keith S.			Twitter helped me decide that I'm not for resuscitation	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material														Taubert, Mark/0000-0003-0454-5609					0	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 5	2018	362								k2784	10.1136/bmj.k2784	http://dx.doi.org/10.1136/bmj.k2784			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT4WB	30185527	Bronze			2023-01-03	WOS:000444505300001
J	Naskalska, A; Dabrowska, A; Nowak, P; Szczepanski, A; Jasik, K; Milewska, A; Ochman, M; Zeglen, S; Rajfur, Z; Pyrc, K				Naskalska, Antonina; Dabrowska, Agnieszka; Nowak, Paulina; Szczepanski, Artur; Jasik, Krzysztof; Milewska, Aleksandra; Ochman, Marek; Zeglen, Slawomir; Rajfur, Zenon; Pyrc, Krzysztof			Novel coronavirus-like particles targeting cells lining the respiratory tract	PLOS ONE			English	Article							VIRUS-LIKE PARTICLES; SIZE-EXCLUSION CHROMATOGRAPHY; MEMBRANE-PROTEIN GENE; STRUCTURAL PROTEINS; SPIKE PROTEINS; SARS-COV; ADENOVIRUS DODECAHEDRON; EXPRESSION SYSTEM; SEQUENCE-ANALYSIS; PURIFICATION	Virus like particles (VLPs) produced by the expression of viral structural proteins can serve as versatile nanovectors or potential vaccine candidates. In this study we describe for the first time the generation of HCoV-NL63 VLPs using baculovirus system. Major structural proteins of HCoV-NL63 have been expressed in tagged or native form, and their assembly to form VLPs was evaluated. Additionally, a novel procedure for chromatography purification of HCoV-NL63 VLPs was developed. Interestingly, we show that these nanoparticles may deliver cargo and selectively transduce cells expressing the ACE2 protein such as ciliated cells of the respiratory tract. Production of a specific delivery vector is a major challenge for research concerning targeting molecules. The obtained results show that HCoV-NL63 VLPs may be efficiently produced, purified, modified and serve as a delivery platform. This study constitutes an important basis for further development of a promising viral vector displaying narrow tissue tropism.	[Naskalska, Antonina; Milewska, Aleksandra; Pyrc, Krzysztof] Jagiellonian Univ, Malopolska Ctr Biotechnol, Krakow, Poland; [Dabrowska, Agnieszka; Nowak, Paulina; Szczepanski, Artur; Milewska, Aleksandra; Pyrc, Krzysztof] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Microbiol Dept, Krakow, Poland; [Jasik, Krzysztof] Med Univ Silesia, Sch Pharm, Dept Skin Struct Studies, Div Lab Med, Sosnowiec, Poland; [Ochman, Marek; Zeglen, Slawomir] Silesian Ctr Heart Dis, Dept Cardiac Surg & Transplantol, Zabrze, Poland; [Rajfur, Zenon] Jagiellonian Univ, Inst Phys, Fac Phys Astron & Appl Comp Sci, Krakow, Poland	Jagiellonian University; Jagiellonian University; Medical University Silesia; Silesian Center for Heart Diseases; Jagiellonian University	Naskalska, A; Pyrc, K (corresponding author), Jagiellonian Univ, Malopolska Ctr Biotechnol, Krakow, Poland.; Pyrc, K (corresponding author), Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Microbiol Dept, Krakow, Poland.	antonina.naskalska@uj.edu.pl; K.A.Pyrc@uj.edu.pl	Szczepański, Artur/AAP-1071-2020; JASIK, KRZYSZTOF PIOTR/F-9859-2018	Szczepański, Artur/0000-0003-0421-9520; JASIK, KRZYSZTOF PIOTR/0000-0003-3974-6507; ZEGLEN, SLAWOMIR/0000-0002-7708-4340; Pyrc, Krzysztof/0000-0002-3867-7688; Naskalska, Antonina/0000-0002-5868-1000; Ochman, Marek/0000-0002-1410-5845; Nowak, Paulina/0000-0001-5786-2339; Dabrowska, Agnieszka/0000-0003-1499-4950	National Science Center in Poland within the FUGA grant [UMO-2013/08/S/NZ6/00730]; National Science Center in Poland within the Sonata Bis grant [UMO-2012/07/E/NZ6/01712]; National Centre for Research and Development, Poland [Lider/27/55/L-2/10/2011]; European Union [POIG.02.01.00-12-064/08]; Ministry of Science and Higher Education of the Republic of Poland	National Science Center in Poland within the FUGA grant; National Science Center in Poland within the Sonata Bis grant; National Centre for Research and Development, Poland(National Centre for Research & Development, Poland); European Union(European Commission); Ministry of Science and Higher Education of the Republic of Poland(Ministry of Science and Higher Education, Poland)	This work was supported by the National Science Center in Poland within the FUGA grant (UMO-2013/08/S/NZ6/00730) and Sonata Bis grant (UMO-2012/07/E/NZ6/01712), https://www.ncn.gov.pl/. Part of the work was also supported by the National Centre for Research and Development, Poland (Lider/27/55/L-2/10/2011), http://www.ncbr.gov.pl/. The Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University is a beneficiary of the structural funds from the European Union (grant No: POIG.02.01.00-12-064/08-"Molecular biotechnology for health"). Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University is a partner of the Leading National Research Center supported by the Ministry of Science and Higher Education of the Republic of Poland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arndt AL, 2010, J VIROL, V84, P11418, DOI 10.1128/JVI.01131-10; Baudoux P, 1998, J VIROL, V72, P8636, DOI 10.1128/JVI.72.11.8636-8643.1998; Boscarino JA, 2008, J VIROL, V82, P2989, DOI 10.1128/JVI.01906-07; Bosch BJ, 2004, J VIROL, V78, P7369, DOI 10.1128/JVI.78.14.7369-7378.2004; Burden CS, 2012, J CHROMATOGR B, V880, P82, DOI 10.1016/j.jchromb.2011.10.044; CAVANAGH D, 1983, J GEN VIROL, V64, P1187, DOI 10.1099/0022-1317-64-5-1187; Chen SC, 2009, VIRUS GENES, V38, P365, DOI 10.1007/s11262-009-0341-6; Corse E, 2000, J VIROL, V74, P4319, DOI 10.1128/JVI.74.9.4319-4326.2000; Corse E, 2003, VIROLOGY, V312, P25, DOI 10.1016/S0042-6822(03)00175-2; de Haan CAM, 2000, J VIROL, V74, P4967, DOI 10.1128/JVI.74.11.4967-4978.2000; de Haan CAM, 1998, J VIROL, V72, P6838, DOI 10.1128/JVI.72.8.6838-6850.1998; Du P, 2017, J CHROMATOGR B, V1049, P16, DOI 10.1016/j.jchromb.2016.12.033; Effio CL, 2016, VACCINE, V34, P1259, DOI 10.1016/j.vaccine.2016.01.035; Fender P, 2003, J VIROL, V77, P4960, DOI 10.1128/JVI.77.8.4960-4964.2003; Fernandes F, 2013, EXPERT REV VACCINES, V12, P225, DOI [10.1586/erv.12.153, 10.1586/ERV.12.153]; Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757; Gelhaus S, 2014, VIROLOGY, V464, P397, DOI 10.1016/j.virol.2014.07.035; Ho Y, 2004, BIOCHEM BIOPH RES CO, V318, P833, DOI 10.1016/j.bbrc.2004.04.111; Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102; HOGUE BG, 1990, ADV EXP MED BIOL, V276, P121; Hsieh PK, 2005, J VIROL, V79, P13848, DOI 10.1128/JVI.79.22.13848-13855.2005; Hsieh YC, 2008, J BIOMED SCI, V15, P707, DOI 10.1007/s11373-008-9278-3; Hu Yongwu, 2003, Genomics Proteomics & Bioinformatics, V1, P118; Huang Y, 2004, J VIROL, V78, P12557, DOI 10.1128/JVI.78.22.12557-12565.2004; JOUVENNE P, 1990, VIROLOGY, V174, P608, DOI 10.1016/0042-6822(90)90115-8; Kim HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035893; Kuo LL, 2016, VIROLOGY, V494, P100, DOI 10.1016/j.virol.2016.04.009; Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083; Lai ZW, 2011, BIOCHEMISTRY-US, V50, P5182, DOI 10.1021/bi200525y; Lambert DW, 2005, J BIOL CHEM, V280, P30113, DOI 10.1074/jbc.M505111200; Lander GC, 2012, STRUCTURE, V20, P498, DOI 10.1016/j.str.2012.01.007; Lapps W, 1987, Adv Exp Med Biol, V218, P123; Lee YN, 2005, J VIROL METHODS, V129, P152, DOI 10.1016/j.jviromet.2005.05.022; Liu FX, 2013, PROTEIN EXPRES PURIF, V90, P104, DOI 10.1016/j.pep.2013.05.009; Liu GM, 2013, VACCINE, V31, P5524, DOI 10.1016/j.vaccine.2013.09.024; Liu JJ, 2016, YONSEI MED J, V57, P790, DOI 10.3349/ymj.2016.57.3.790; Lu BJ, 2010, IMMUNOLOGY, V130, P254, DOI 10.1111/j.1365-2567.2010.03231.x; Lu XY, 2007, IMMUNOLOGY, V122, P496, DOI 10.1111/j.1365-2567.2007.02676.x; Milewska A, 2014, J VIROL, V88, P13221, DOI 10.1128/JVI.02078-14; Milewska A, 2013, ANTIVIR RES, V97, P112, DOI 10.1016/j.antiviral.2012.11.006; Mortola E, 2004, FEBS LETT, V576, P174, DOI 10.1016/j.febslet.2004.09.009; MOUNIR S, 1992, J GEN VIROL, V73, P2731, DOI 10.1099/0022-1317-73-10-2731; Muller MA, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-6; Nakauchi M, 2008, MICROBIOL IMMUNOL, V52, P625, DOI 10.1111/j.1348-0421.2008.00079.x; Narayanan K, 2000, J VIROL, V74, P8127, DOI 10.1128/JVI.74.17.8127-8134.2000; Nasimuzzaman M, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.71; Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021; NIEMANN H, 1984, EMBO J, V3, P665, DOI 10.1002/j.1460-2075.1984.tb01864.x; Pyrc K, 2004, VIROL J, V1, DOI 10.1186/1743-422X-1-7; RISCO C, 1995, J VIROL, V69, P5269, DOI 10.1128/JVI.69.9.5269-5277.1995; Ruch TR, 2012, VIRUSES-BASEL, V4, P363, DOI 10.3390/v4030363; Siu YL, 2008, J VIROL, V82, P11318, DOI 10.1128/JVI.01052-08; Steppert P, 2017, J CHROMATOGR A, V1487, P89, DOI 10.1016/j.chroma.2016.12.085; Szurgot I, 2015, MOL BIOTECHNOL, V57, P565, DOI 10.1007/s12033-015-9850-9; Thorp EB, 2006, J VIROL, V80, P1280, DOI 10.1128/JVI.80.3.1280-1289.2006; Tseng YT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064013; Ujike M, 2015, VIRUSES-BASEL, V7, P1700, DOI 10.3390/v7041700; Urbas L, 2011, J CHROMATOGR A, V1218, P2451, DOI 10.1016/j.chroma.2011.01.032; van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024; Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x; Wang C, 2017, ONCOTARGET, V8, P12686, DOI 10.18632/oncotarget.8475; Wang CL, 2017, VIRUS GENES, V53, P548, DOI 10.1007/s11262-017-1450-2; Xu PW, 2016, BIOTECHNOL LETT, V38, P299, DOI 10.1007/s10529-015-1973-3; Ye Y, 2007, J VIROL, V81, P3597, DOI 10.1128/JVI.01472-06; Yu YTC, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0234-7; Zaveckas M, 2015, J CHROMATOGR B, V991, P21, DOI 10.1016/j.jchromb.2015.04.004; Zeltins A, 2013, MOL BIOTECHNOL, V53, P92, DOI 10.1007/s12033-012-9598-4; Zheng Q, 2006, BIOCHEMISTRY-US, V45, P15205, DOI 10.1021/bi061686w	68	26	27	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 5	2018	13	9							e0203489	10.1371/journal.pone.0203489	http://dx.doi.org/10.1371/journal.pone.0203489			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS6HC	30183777	Green Published, Green Submitted, gold			2023-01-03	WOS:000443789900065
J	Reinhold, T; Giannitsis, E; Mockel, M; Frankenstein, L; Vafaie, M; Vollert, JO; Slagman, A				Reinhold, Thomas; Giannitsis, Evangelos; Moeckel, Martin; Frankenstein, Lutz; Vafaie, Mehrshad; Vollert, Joern O.; Slagman, Anna			Cost analysis of early discharge using combined copeptin/cardiac troponin testing versus serial cardiac troponin testing in patients with suspected acute coronary syndrome	PLOS ONE			English	Article							HEALTH ECONOMIC-EVALUATION	Background Symptoms indicating acute coronary syndrome are commonly seen in emergency rooms, but only 10% of patients are actually diagnosed with acute myocardial infarction (AMI). The Guidelines for the diagnosis of patients with suspected AMI include either multiple testing of cardiac troponin (cTN) or a single combined test of cTN and copeptin, which facilitates earlier diagnosis or exclusion of AMI. The aim of the present analysis was to investigate the impact of combined copeptin/cTN testing on health care resource consumption and related costs both during and after initial hospital treatment. Methods and results The analysis was based on the BIC-8 trial and financial data of participating study sites. A cost analysis was carried out primarily from the hospital perspective and secondarily from the perspective of German statutory health insurers. The underlying assumptions of the investigation were tested for robustness in additional sensitivity analyses. In total, the data of 713 patients (n = 359 combined copeptin/cTN testing, n = 354 serial cTN testing) were evaluated. From a hospital perspective, the combined copeptin/cTN testing showed a reduced number of medical procedures and a lower frequency of inpatient admissions. The average staff time was significantly reduced by a mean of 49 minutes (95% confidence interval (CI) 46 to 53) per patient, accompanied by a significant mean reduction of 131 minutes (95%Cl 104 to 158) in the time patients stayed in the emergency room. The initial hospital treatment was less cost-intensive. Over the entire study period, no significant cost differences were observed between the groups for health insurance. Conclusion The combined copeptin/cTN testing has the potential to save costs and staff time in acute care and for the entire hospital stay. The primary explanations for these findings are early identification and ruling out patients without AMI along with the associated reduced need for acute medical treatment.	[Reinhold, Thomas] Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Giannitsis, Evangelos; Frankenstein, Lutz; Vafaie, Mehrshad] Univ Hosp Heidelberg, Dept Angiol Cardiol & Pneumol, Heidelberg, Germany; [Moeckel, Martin; Slagman, Anna] Charite Univ Med Berlin, Dept Cardiol, Div Emergency Med, Berlin, Germany; [Moeckel, Martin; Slagman, Anna] Charite Univ Med Berlin, Dept Cardiol, CPU, Berlin, Germany; [Moeckel, Martin] JCU, Cairns, Australia; [Vollert, Joern O.] ThermoSci BRAHMS GmbH, Hennigsdorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls University Heidelberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Reinhold, T (corresponding author), Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany.	thomas.reinhold@charite.de	Mockel, Martin/AAC-2600-2019	Mockel, Martin/0000-0002-7691-3709; Slagman, Anna/0000-0003-2608-0347; Reinhold, Thomas/0000-0001-5169-7029	Thermo Fisher Scientific BRAHMS GmbH	Thermo Fisher Scientific BRAHMS GmbH	This work is an investigator initiated analysis and was financially supported by Thermo Fisher Scientific BRAHMS GmbH (https://www.brahms.de). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambavane A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187662; Bock JO, 2015, GESUNDHEITSWESEN, V77, P53, DOI 10.1055/s-0034-1374621; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; Cheng QL, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009746; Deutsche Krankenhausgesellschaft, 2016, DKG NT BAND TAR DTSC; Domenico C, 2013, LIGANDASSAY, V18, P68; Julicher P, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013653; Kaambwa B, 2017, INT J CARDIOL, V238, P144, DOI 10.1016/j.ijcard.2017.02.141; Krauth C, 2005, GESUNDHEITSWESEN, V67, P736, DOI 10.1055/s-2005-858698; Mockel M, 2013, EUR J EMERG MED, V20, P103, DOI 10.1097/MEJ.0b013e328351e609; Mockel M, 2015, EUR HEART J, V36, P369, DOI 10.1093/eurheartj/ehu178; Reinhold T, 2010, J PUBLIC HEALTH-HEID, V18, P327, DOI 10.1007/s10389-010-0315-0; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; Schwabe U, 2014, ARZNEIMITTELVERORDNU; Shortt C, 2017, CLIN CHEM, V63, P593, DOI 10.1373/clinchem.2016.261776; Streiner DL, 2011, CHEST, V140, P16, DOI 10.1378/chest.11-0523; Vaidya A, 2014, BMC CARDIOVASC DISOR, V14, DOI 10.1186/1471-2261-14-77	17	13	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2018	13	8							e0202133	10.1371/journal.pone.0202133	http://dx.doi.org/10.1371/journal.pone.0202133			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR6TZ	30138394	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000442800100041
J	Roth, D; Chiang, AJ; Hu, WD; Gugiu, GB; Morra, CN; Versalovic, J; Kalkum, M				Roth, Daniel; Chiang, Abby J.; Hu, Weidong; Gugiu, Gabriel B.; Morra, Christina N.; Versalovic, James; Kalkum, Markus			Two-carbon folate cycle of commensal Lactobacillus reuteri 6475 gives rise to immunomodulatory ethionine, a source for histone ethylation	FASEB JOURNAL			English	Article						ethenyltetrahydrofolate; probiotic bacteria; microbiome; posttranslational modification; lysine ethylation	CHAIN FATTY-ACIDS; CROHNS-DISEASE; METABOLISM; METHIONINE; PROTEIN; PROBIOTICS; MICROBIOTA; BACTERIA; INFLAMMATION; REMISSION	Colonization of the gut by certain probiotic Lactobacillus reuteri strains has been associated with reduced risk of inflammatory diseases and colorectal cancer. Previous studies pointed to a functional link between immunomodulation, histamine production, and folate metabolism, the central 1-carbon pathway for the transfer of methyl groups. Using mass spectrometry and NMR spectroscopy, we analyzed folate metabolites of L. reuteri strain 6475 and discovered that the bacterium produces a 2-carbon-transporting folate in the form of 5,10-ethenyl-tetrahydrofolyl polyglutamate. Isotopic labeling permitted us to trace the source of the 2-carbon unit back to acetate of the culture medium. We show that the 2C folate cycle of L. reuteri is capable of transferring 2 carbon atoms to homocysteine to generate the unconventional amino acid ethionine, a known immunomodulator. When we treated monocytic THP-1 cells with ethionine, their transcription of TNF- was inhibited and cell proliferation reduced. Mass spectrometry of THP-1 histones revealed incorporation of ethionine instead of methionine into proteins, a reduction of histone-methylation, and ethylation of histone lysine residues. Our findings suggest that the microbiome can expose the host to ethionine through a novel 2-carbon transporting variant of the folate cycle and modify human chromatin via ethylation.Roth, D., Chiang, A. J., Hu, W., Gugiu, G. B., Morra, C. N., Versalovic, J., Kalkum, M. The two-carbon folate cycle of commensal Lactobacillus reuteri 6475 gives rise to immunomodulatory ethionine, a source for histone ethylation.	[Roth, Daniel; Chiang, Abby J.; Hu, Weidong; Gugiu, Gabriel B.; Kalkum, Markus] Beckman Res Inst City Hope, Dept Mol Imaging & Therapy, Duarte, CA USA; [Chiang, Abby J.; Kalkum, Markus] Beckman Res Inst City Hope, Irell & Manella Grad Sch Biol Sci, Duarte, CA USA; [Hu, Weidong] Beckman Res Inst City Hope, Nucl Magnet Resonance Core, Duarte, CA USA; [Gugiu, Gabriel B.; Kalkum, Markus] Beckman Res Inst City Hope, Mass Spectrometry & Prote Core, Duarte, CA USA; [Morra, Christina N.] Baylor Coll Med, IMBS, Houston, TX 77030 USA; [Morra, Christina N.; Versalovic, James] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Versalovic, James] Texas Childrens Hosp, Dept Pathol, Houston, TX 77030 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Kalkum, M (corresponding author), Beckman Res Inst City Hope, 1500 East Duarte Rd, Duarte, CA 91010 USA.	mkalkum@coh.org	Roeth, Daniel/AAS-3185-2021	Roeth, Daniel/0000-0002-1190-3219; Kalkum, Markus/0000-0002-9506-671X	U.S. National Institutes of Health (NIH), National Cancer Institute [U01 CA170930]; NIH, National Cancer Institute [P30 CA33572]; NATIONAL CANCER INSTITUTE [U01CA170930, P30CA033572] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH), National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	D.R., A.J.C., C.N.M., J.V., and M.K. were supported by U.S. National Institutes of Health (NIH), National Cancer Institute Grant U01 CA170930 (to J.V.). The use of the City of Hope Mass Spectrometry and Proteomics core facility was partially supported by NIH, National Cancer Institute Grant P30 CA33572. The authors declare no conflicts of interest.	ALIX JH, 1982, MICROBIOL REV, V46, P281, DOI 10.1128/MMBR.46.3.281-295.1982; ASCHKENASY A, 1975, ANN NUTR ALIMENT, V29, P137; ASWAD DW, 1975, J MOL BIOL, V97, P207, DOI 10.1016/S0022-2836(75)80035-0; Bailey LB, 1999, J NUTR, V129, P779, DOI 10.1093/jn/129.4.779; Bibiloni R, 2005, AM J GASTROENTEROL, V100, P1539, DOI 10.1111/j.1572-0241.2005.41794.x; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; Brosnan ME, 2015, BIOCHEM J, V472, P135, DOI 10.1042/BJ20150837; BROWN JL, 1973, BIOCHIM BIOPHYS ACTA, V294, P527, DOI 10.1016/0005-2787(73)90108-1; Bystrov V. F., 1976, Progress in Nuclear Magnetic Resonance Spectroscopy, V10, P41, DOI 10.1016/0079-6565(76)80001-5; COX R, 1984, CANCER RES, V44, P4938; Cummings JH, 1997, JPEN-PARENTER ENTER, V21, P357, DOI 10.1177/0148607197021006357; Dahl WJ, 2017, J AM COLL NUTR, V36, P127, DOI 10.1080/07315724.2016.1188737; De Man J. C., 2008, J APPL BACTERIOL, V23, P130; de Paiva E.P., 2015, SCI CHROMATOGR, V7, P199, DOI [10.4322/sc.2016.004, DOI 10.4322/SC.2016.004]; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; den Besten G, 2013, J LIPID RES, V54, P2325, DOI 10.1194/jlr.R036012; FISHER JF, 1961, J GEN PHYSIOL, V45, P1, DOI 10.1085/jgp.45.1.1; Food and Agriculture Organization of the United Nations World Health Organization, 2006, PROB FOOD HLTH NUTR; Fuller MF, 1998, ANNU REV NUTR, V18, P385, DOI 10.1146/annurev.nutr.18.1.385; Ganesh BP, 2018, MUCOSAL IMMUNOL, V11, P380, DOI 10.1038/mi.2017.58; Ganji-Arjenaki M, 2018, J CELL PHYSIOL, V233, P2091, DOI 10.1002/jcp.25911; Gao CX, 2015, MBIO, V6, DOI 10.1128/mBio.01358-15; Gupta P, 2000, J PEDIATR GASTR NUTR, V31, P453, DOI 10.1097/00005176-200010000-00024; GUYNN RW, 1982, ARCH BIOCHEM BIOPHYS, V217, P181, DOI 10.1016/0003-9861(82)90492-1; Hayashi H, 2005, J MED MICROBIOL, V54, P1093, DOI 10.1099/jmm.0.45935-0; Hollister EB, 2014, GASTROENTEROLOGY, V146, P1449, DOI 10.1053/j.gastro.2014.01.052; HOLLOWAY CT, 1970, J BACTERIOL, V104, P734, DOI 10.1128/JB.104.2.734-747.1970; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jones SE, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-35; Kay Lewis E, 2011, J Magn Reson, V213, P423, DOI 10.1016/j.jmr.2011.09.004; LaBaume L B, 1985, Prog Clin Biol Res, V183, P189; Lichtenstein L, 2016, BEST PRACT RES CL GA, V30, P81, DOI 10.1016/j.bpg.2016.02.002; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; LOERCH JD, 1963, ARCH BIOCHEM BIOPHYS, V103, P272, DOI 10.1016/0003-9861(63)90405-3; MAW GA, 1966, ARCH BIOCHEM BIOPHYS, V115, P291, DOI 10.1016/0003-9861(66)90277-3; MOORE GE, 1967, J AMER MED ASSOC, V199, P519, DOI 10.1001/jama.199.8.519; O'Mahony L, 2011, J ALLERGY CLIN IMMUN, V128, P1153, DOI 10.1016/j.jaci.2011.06.051; RABINOVITZ M, 1957, J BIOL CHEM, V227, P217; RADIX PM, 1983, J NUTR, V113, P159, DOI 10.1093/jn/113.1.159; Reuter G, 2001, Curr Issues Intest Microbiol, V2, P43; Rossi M, 2011, NUTRIENTS, V3, P118, DOI 10.3390/nu3010118; Saarela M, 2002, INT J FOOD MICROBIOL, V78, P99, DOI 10.1016/S0168-1605(02)00235-0; Santos F, 2008, APPL ENVIRON MICROB, V74, P3291, DOI 10.1128/AEM.02719-07; Scarpato E, 2018, J CLIN GASTROENTEROL, V52, pS7, DOI [10.1097/MCG.0000000000001095, 10.1097/mcg.0000000000001095]; Domingo JJS, 2017, GASTROENT HEPAT-BARC, V40, P417, DOI 10.1016/j.gastrohep.2016.12.003; Thomas CM, 2016, MICROBIOLOGYOPEN, V5, P802, DOI 10.1002/mbo3.371; Thomas CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031951; Topping DL, 2001, PHYSIOL REV, V81, P1031, DOI 10.1152/physrev.2001.81.3.1031; van der Wielen N, 2017, J NUTR, V147, P1493, DOI 10.3945/jn.117.248187; Vigsnaes LK, 2012, BENEF MICROBES, V3, P287, DOI 10.3920/BM2012.0018; VILLANUEVA VR, 1966, BIOCHIM BIOPHYS ACTA, V130, P329, DOI 10.1016/0304-4165(66)90228-5; Walter J, 2005, APPL ENVIRON MICROB, V71, P979, DOI 10.1128/AEM.71.2.979-986.2005; Wlostowski M, 2010, TETRAHEDRON LETT, V51, P5977, DOI 10.1016/j.tetlet.2010.08.097; ZABOS P, 1978, BIOCHIM BIOPHYS ACTA, V520, P139, DOI 10.1016/0005-2787(78)90015-1; Zella GC, 2011, INFLAMM BOWEL DIS, V17, P1092, DOI 10.1002/ibd.21460	55	15	15	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2019	33	3					3536	3548		10.1096/fj.201801848R	http://dx.doi.org/10.1096/fj.201801848R			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HM9HS	30452879	Green Published, Bronze			2023-01-03	WOS:000459794800036
J	Horwitz, S; O'Connor, OA; Pro, B; Illidge, T; Fanale, M; Advani, R; Bartlett, NL; Christensen, JH; Morschhauser, F; Domingo-Domenech, E; Rossi, G; Kim, WS; Feldman, T; Lennard, A; Belada, D; Illes, A; Tobinai, K; Tsukasaki, K; Yeh, SP; Shustov, A; Huttmann, A; Savage, KJ; Yuen, S; Iyer, S; Zinzani, PL; Hua, ZW; Little, M; Rao, S; Woolery, J; Manley, T; Trumper, L; Aboulafia, D; Alpdogan, O; Ando, K; Arcaini, L; Baldini, L; Bellam, N; Bartlett, N; Ben Yehuda, D; Benedetti, F; Borchman, P; Bordessoule, D; Brice, P; Briones, J; Caballero, D; Carella, AM; Chang, H; Cheong, JW; Cho, SG; Choi, I; Choquet, S; Colita, A; Congui, AG; D'amore, F; Dang, N; Davison, K; De Guibert, S; Brown, PD; Delwail, V; Demeter, J; di Raimondo, F; Do, YR; Domingo, E; Douvas, M; Dreyling, M; Ernst, T; Fay, K; Ferrero, SF; Flinn, IW; Forero-Torres, A; Fox, C; Friedberg, J; Fukuhara, N; Garcia-Marco, J; Cruz, JG; Codina, JG; Gressin, R; Grigg, A; Gurion, R; Haioun, C; Hajek, R; Hanel, M; Hatake, K; Hensen, R; Horowitz, N; Huttmann, A; Ishizawa, K; Islas-Ohlmayer, M; Jacobsen, E; Janakiram, M; Jurczak, W; Kaminski, M; Kato, K; Kirgner, I; Kuo, CY; Lazaroiu, MC; Le Du, K; Lee, JS; Legouill, S; Larosee, P; Levi, I; Link, B; Maisonneuve, H; Maruyama, D; Mayer, J; McCarty, J; McKay, P; Minami, Y; Mocikova, H; Morra, E; Munoz, J; Nagai, H; O'Connor, O; Opat, S; Pettengell, R; Pezzutto, A; Pfreundschuh, M; Pluta, A; Porcu, P; Quach, H; Rambaldi, A; Renwick, W; Reyes, R; Izquierdo, AR; Ruan, J; Rusconi, C; Salles, G; Santoro, A; Sarriera, J; Savage, K; Shibayama, H; Suh, C; Sureda, A; Tanimoto, M; Taniwaki, M; Tilly, H; Trneny, M; Trumper, L; Tsukamoto, N; Vitolo, U; Walewski, J; Weidmann, E; Wilhelm, M; Witzens-Harig, M; Yacoub, A; Yamamoto, K; Yoon, SS; Yun, HJ; Zain, J; Zinzan, PL				Horwitz, Steven; O'Connor, Owen A.; Pro, Barbara; Illidge, Tim; Fanale, Michelle; Advani, Ranjana; Bartlett, Nancy L.; Christensen, Jacob Haaber; Morschhauser, Franck; Domingo-Domenech, Eva; Rossi, Giuseppe; Kim, Won Seog; Feldman, Tatyana; Lennard, Anne; Belada, David; Illes, Arpad; Tobinai, Kensei; Tsukasaki, Kunihiro; Yeh, Su-Peng; Shustov, Andrei; Huttmann, Andreas; Savage, Kerry J.; Yuen, Sam; Iyer, Swaminathan; Zinzani, Pier Luigi; Hua, Zhaowei; Little, Meredith; Rao, Shangbang; Woolery, Joseph; Manley, Thomas; Trumper, Lorenz; Aboulafia, David; Alpdogan, Onder; Ando, Kiyoshi; Arcaini, Luca; Baldini, Luca; Bellam, Naresh; Bartlett, Nancy; Ben Yehuda, Dina; Benedetti, Fabio; Borchman, Peter; Bordessoule, Dominique; Brice, Pauline; Briones, Javier; Caballero, Dolores; Carella, Angelo Michele; Chang, Hung; Cheong, June Weon; Cho, Seok-Goo; Choi, Ilseung; Choquet, Sylvain; Colita, Andrei; Congui, Angela Giovanna; D'amore, Francesco; Dang, Nam; Davison, Kelly; De Guibert, Sophie; Brown, Peter de Nully; Delwail, Vincent; Demeter, Judit; di Raimondo, Francesco; Do, Young Rok; Domingo, Eva; Douvas, Michael; Dreyling, Martin; Ernst, Thomas; Fay, Keith; Ferrero, Silvia Fernandez; Flinn, Ian Winchester; Forero-Torres, Andres; Fox, Christopher; Friedberg, Jonathan; Fukuhara, Noriko; Garcia-Marco, Jose; Cruz, Jorge Gayoso; Codina, Jose Gomez; Gressin, Remy; Grigg, Andrew; Gurion, Ronit; Haioun, Corinne; Hajek, Roman; Hanel, Mathias; Hatake, Kiyohiko; Hensen, Robert; Horowitz, Netanel; Huttmann, Andreas; Ishizawa, Kenichi; Islas-Ohlmayer, Miguel; Jacobsen, Eric; Janakiram, Murali; Jurczak, Wojciech; Kaminski, Mark; Kato, Koji; Kirgner, Ilya; Kuo, Ching-Yuan; Lazaroiu, Mihaela Cornelia; Le Du, Katell; Lee, Jong-Seok; Legouill, Steven; Larosee, Paul; Levi, Itai; Link, Brian; Maisonneuve, Herve; Maruyama, Dai; Mayer, Jiri; McCarty, John; McKay, Pam; Minami, Yosuke; Mocikova, Heidi; Morra, Enrica; Munoz, Javier; Nagai, Hirokazu; O'Connor, Owen; Opat, Stephen; Pettengell, Ruth; Pezzutto, Antonio; Pfreundschuh, Michael; Pluta, Andrzej; Porcu, Pierluigi; Quach, Hang; Rambaldi, Alessandro; Renwick, William; Reyes, Ruben; Izquierdo, Antonia Rodriguez; Ruan, Jia; Rusconi, Chiara; Salles, Gilles; Santoro, Armando; Sarriera, Jose; Savage, Kerry; Shibayama, Hirohiko; Suh, Cheolwon; Sureda, Anna; Tanimoto, Mitsune; Taniwaki, Masafumi; Tilly, Herve; Trneny, Marek; Trumper, Lorenz; Tsukamoto, Norifumi; Vitolo, Umberto; Walewski, Jan; Weidmann, Eckhart; Wilhelm, Martin; Witzens-Harig, Mathias; Yacoub, Abdulraheem; Yamamoto, Kazuhito; Yoon, Sung-Soo; Yun, Hwan Jung; Zain, Jasmine; Zinzan, Pier Luigi		ECHELON 2 Study Grp	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial	LANCET			English	Article							PREVIOUSLY UNTREATED PATIENTS; NON-HODGKINS-LYMPHOMAS; CD30 EXPRESSION; CYCLOPHOSPHAMIDE; TRANSPLANTATION; VINCRISTINE; PREDNISONE; THERAPY; MULTICENTER; COMBINATION	Background Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas. Methods ECHELON-2 is a double-blind, double-dummy, randomised, placebo-controlled, active-comparator phase 3 study. Eligible adults from 132 sites in 17 countries with previously untreated CD30-positive peripheral T-cell lymphomas (targeting 75% with systemic anaplastic large cell lymphoma) were randomly assigned 1:1 to receive either A+CHP or CHOP for six or eight 21-day cycles. Randomisation was stratified by histological subtype according to local pathology assessment and by international prognostic index score. All patients received cyclophosphamide 750 mg/m(2) and doxorubicin 50 mg/m(2) on day 1 of each cycle intravenously and prednisone 100 mg once daily on days 1 to 5 of each cycle orally, followed by either brentuximab vedotin 1.8 mg/kg and a placebo form of vincristine intravenously (A+CHP group) or vincristine 1.4 mg/m(2) and a placebo form of brentuximab vedotin intravenously (CHOP group) on day 1 of each cycle. The primary endpoint, progression-free survival according to blinded independent central review, was analysed by intent-to-treat. This trial is registered with ClinicalTrials.gov, number NCT01777152. Findings Between Jan 24, 2013, and Nov 7, 2016, 601 patients assessed for eligibility, of whom 452 patients were enrolled and 226 were randomly assigned to both the A+CHP group and the CHOP group. Median progression free survival was 48.2 months (95% CI 35.2 not evaluable) in the A+CHP group and 20.8 months (12.7-47.6) in the CHOP group (hazard ratio 0.71 [95% CI 0.54-0.93], p=0.0110). Adverse events, including incidence and severity of febrile neutropenia (41 [18%] patients in the A+CHP group and 33 [15%] in the CHOP group) and peripheral neuropathy (117 [52%] in the A+CHP group and 124 [55%] in the CHOP group), were similar between groups. Fatal adverse events occurred in seven (3%) patients in the A+CHP group and nine (4%) in the CHOP group. Interpretation Front-line treatment with A+CHP is superior to CHOP for patients with CD30-positive peripheral T-cell lymphomas as shown by a significant improvement in progression-free survival and overall survival with a manageable safety profile. Copyright (C) 2018 Elsevier Ltd. All rights reserved.	[Horwitz, Steven] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA; [O'Connor, Owen A.] Columbia Univ, Med Ctr, New York, NY USA; [Pro, Barbara] Northwestern Univ, Feinberg Sch Med, Div Hematol & Oncol, Dept Med, Chicago, IL 60611 USA; [Illidge, Tim] Univ Manchester, NIH, Div Canc Sci, Fac Biol Med & Hlth, Manchester, Lancs, England; [Illidge, Tim] Christie Hosp Natl Hlth Serv Fdn Trust, Manchester Acad Hlth Sci Ctr, Res Biomed Res Ctr, Manchester, Lancs, England; [Fanale, Michelle; Iyer, Swaminathan] Univ Texas Houston, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Advani, Ranjana] Stanford Canc Ctr, Blood & Marrow Transplant Program, Stanford, CA USA; [Bartlett, Nancy L.] Washington Univ, Sch Med, St Louis, MO USA; [Christensen, Jacob Haaber] Odense Univ Hosp, Odense, Denmark; [Morschhauser, Franck] Univ Lille, Ctr Hosp Univ Lille, Grp Rech Formes Injectables & Technol Assodees, Lille, France; [Domingo-Domenech, Eva] Inst Catala Oncol, Barcelona, Spain; [Rossi, Giuseppe] Azienda Osped Spedali Civili Brescia, Brescia, Italy; [Kim, Won Seog] Samsung Med Ctr, Seoul, South Korea; [Feldman, Tatyana] Hackensack Univ, Med Ctr, Hackensack, NJ USA; [Lennard, Anne] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Belada, David] Charles Univ Prague, Dept Internal Med Haematol 4, Hosp & Fac Med, Hradec Kralove, Czech Republic; [Illes, Arpad] Univ Debrecen, Fac Med, Dept Hematol, Debrecen, Hungary; [Tobinai, Kensei] Natl Canc Ctr, Tokyo, Japan; [Tsukasaki, Kunihiro] Saitama Med Univ, Int Med Ctr, Saitama, Japan; [Yeh, Su-Peng] China Med Univ Hosp, Taichung, Taiwan; [Shustov, Andrei] Univ Washington, Med Ctr, Seattle, WA 98195 USA; [Huttmann, Andreas] Univ Klinikum Essen, Nordrhein Westfalen, Germany; [Savage, Kerry J.] Univ British Columbia, Vancouver, BC, Canada; [Savage, Kerry J.] British Columbia Canc Ctr Lymphoid Canc, Dept Med Oncol, Vancouver, BC, Canada; [Yuen, Sam] Calvary Mater Newcastle Hosp, Waratah, NSW, Australia; [Zinzani, Pier Luigi] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy; [Hua, Zhaowei; Little, Meredith] Millennium Pharmaceut Inc, Cambridge, MA USA; [Fanale, Michelle; Rao, Shangbang; Woolery, Joseph; Manley, Thomas] Seattle Genet Inc, Bothell, WA USA; [Trumper, Lorenz] Univ Med Gottingen, Gottingen, Germany	Memorial Sloan Kettering Cancer Center; Columbia University; Northwestern University; Feinberg School of Medicine; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; Stanford Cancer Institute; Stanford University; Washington University (WUSTL); University of Southern Denmark; Odense University Hospital; Universite de Lille - ISITE; CHU Lille; Universite de Lille; Catalan Institute of Oncology; Hospital Spedali Civili Brescia; Sungkyunkwan University (SKKU); Samsung Medical Center; Hackensack University Medical Center; Newcastle Freeman Hospital; Newcastle University - UK; Charles University Prague; University Hospital Hradec Kralove; University of Debrecen; National Cancer Center - Japan; Saitama Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan; University of Washington; University of Washington Seattle; University of British Columbia; Calvary Mater Newcastle Hospital; University of Bologna; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Seattle Genetics; University of Gottingen	Horwitz, S (corresponding author), Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.	horwitzs@mskcc.org	Walewski, Jan/ABC-9523-2020; Iyer, Swaminathan/GRS-9668-2022; Opat, Stephen/AFR-0783-2022; Rambaldi, Alessandro/M-6172-2019; Quach, Hang/AAB-8516-2020; Yoon, Sung-Soo/J-2773-2012; Santoro, Armando/J-9594-2018; Belada, David/P-9728-2017; Rambaldi, Alessandro/P-2603-2018; Hüttmann, Andreas/W-6106-2019; Salles, Gilles/Z-2336-2019; Savage, Kerry/HCH-5539-2022; Jurczak, Wojciech/ABB-2136-2020; choquet, sylvain/O-7952-2017; Arcaini, Luca/P-8913-2015; Colita, Andrei/AAA-3642-2020; Hajek, Roman/I-6639-2017; Haenel, Mathias Hänel/AAF-2220-2021; Huettmann, Andreas/AAH-6483-2019; Iyer, Swaminathan Padmanabhan/AAB-6709-2020; ILLIDGE, Tim M/M-3659-2015; ZINZANI, PIER LUIGI/J-9182-2016; Di Raimondo, Francesco/K-7965-2016	Opat, Stephen/0000-0002-0308-6458; Rambaldi, Alessandro/0000-0002-3739-7502; Santoro, Armando/0000-0003-1709-9492; Belada, David/0000-0002-4981-6188; Rambaldi, Alessandro/0000-0002-3739-7502; Hüttmann, Andreas/0000-0003-2230-3873; Salles, Gilles/0000-0002-9541-8666; Jurczak, Wojciech/0000-0003-1879-8084; choquet, sylvain/0000-0002-7791-0470; Arcaini, Luca/0000-0002-9504-991X; Hajek, Roman/0000-0001-6955-6267; Iyer, Swaminathan Padmanabhan/0000-0002-1646-813X; ILLIDGE, Tim M/0000-0003-3191-7324; Bartlett, Nancy/0000-0001-8470-394X; QUACH, HANG/0000-0002-4796-3352; Briones Meijide, Javier/0000-0003-2750-3735; Link, Brian/0000-0001-5084-0698; DOMINGO DOMENECH, Eva/0000-0001-8907-090X; Baldini, Luca/0000-0003-2964-9981; Yun, Hwan Jung/0000-0003-0696-1235; Advani, Ranjana/0000-0002-3219-2292; vitolo, umberto/0000-0001-7772-2747; ZINZANI, PIER LUIGI/0000-0002-2112-2651; Demeter, Judit/0000-0001-8745-0757; Delwail, Vincent/0000-0003-0680-1418; le gouill, steven/0000-0001-9840-2128; Colita, Andrei/0000-0002-6531-7717; Di Raimondo, Francesco/0000-0002-7749-0293	Seattle Genetics Inc; Millennium Pharmaceuticals Inc; National Institutes of Health National Cancer Institute Cancer Center; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Seattle Genetics Inc; Millennium Pharmaceuticals Inc(Takeda Pharmaceutical Company Ltd); National Institutes of Health National Cancer Institute Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Seattle Genetics Inc, Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda Pharmacuetical Company Limited, and National Institutes of Health National Cancer Institute Cancer Center.	Advani RH, 2016, BRIT J HAEMATOL, V172, P535, DOI 10.1111/bjh.13855; Anderson JR, 1998, ANN ONCOL, V9, P717, DOI 10.1023/A:1008265532487; Bossard C, 2014, BLOOD, V124, P2983, DOI 10.1182/blood-2014-07-584953; Carson KR, 2017, CANCER-AM CANCER SOC, V123, P1174, DOI 10.1002/cncr.30416; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; d'Amore F, 2015, ANN ONCOL, V26, pV108, DOI 10.1093/annonc/mdv201; D'Amore F, 2009, HAEMATOL-HEMATOL J, V94, P437; d'Amore F, 2012, J CLIN ONCOL, V30, P3093, DOI 10.1200/JCO.2011.40.2719; Dupuis J, 2015, LANCET HAEMATOL, V2, pE160, DOI 10.1016/S2352-3026(15)00023-X; Ellin F, 2014, BLOOD, V124, P1570, DOI 10.1182/blood-2014-04-573089; Fanale MA, 2018, BLOOD, V131, P2120, DOI 10.1182/blood-2017-12-821009; Federico M, 2018, BRIT J HAEMATOL, V181, P760, DOI 10.1111/bjh.15258; Foss FM, 2013, LEUKEMIA LYMPHOMA, V54, P1373, DOI 10.3109/10428194.2012.742521; Giulia P, 2014, SEMIN HEMATOL, V51, P59, DOI 10.1053/j.seminhematol.2013.11.002; Gleeson M, 2018, LANCET HAEMATOL, V5, pE190, DOI 10.1016/S2352-3026(18)30039-5; Horwitz SM, 2016, J NATL COMPR CANC NE, V14, P1067, DOI 10.6004/jnccn.2016.0117; Horwitz SM, 2014, BLOOD, V123, P3095, DOI 10.1182/blood-2013-12-542142; Jantunen E, 2013, BLOOD, V121, P2529, DOI 10.1182/blood-2012-11-466839; Kluin-Nelemans HC, 2011, ANN ONCOL, V22, P1595, DOI 10.1093/annonc/mdq635; Mahadevan D, 2013, CANCER-AM CANCER SOC, V119, P371, DOI 10.1002/cncr.27733; Pro B, 2017, BLOOD, V130, P2709, DOI 10.1182/blood-2017-05-780049; Pro B, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.4144.4144; Reimer P, 2009, J CLIN ONCOL, V27, P106, DOI 10.1200/JCO.2008.17.4870; Sabattini E, 2013, HAEMATOLOGICA, V98, pE81, DOI 10.3324/haematol.2013.084913; Savage KJ, 2008, BLOOD, V111, P5496, DOI 10.1182/blood-2008-01-134270; Savage KJ, 2004, ANN ONCOL, V15, P1467, DOI 10.1093/annonc/mdh392; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; Schmitz N, 2010, BLOOD, V116, P3418, DOI 10.1182/blood-2010-02-270785; Simon A, 2010, BRIT J HAEMATOL, V151, P159, DOI 10.1111/j.1365-2141.2010.08329.x; Vose JM, 2008, J CLIN ONCOL, V26, P4124, DOI 10.1200/JCO.2008.16.4558; Weisenburger DD, 2011, BLOOD, V117, P3402, DOI 10.1182/blood-2010-09-310342	32	329	345	2	59	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 19	2019	393	10168					229	240		10.1016/S0140-6736(18)32984-2	http://dx.doi.org/10.1016/S0140-6736(18)32984-2			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HH8RN	30522922	Green Accepted, Green Submitted			2023-01-03	WOS:000456000000026
J	Staff, RT; Hogan, MJ; Williams, DS; Whalley, LJ				Staff, Roger T.; Hogan, Michael J.; Williams, Daniel S.; Whalley, L. J.			Intellectual engagement and cognitive ability in later life (the "use it or lose it" conjecture): longitudinal, prospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VERBAL-LEARNING TEST; FLUID INTELLIGENCE; PERFORMANCE; EDUCATION; DECLINE; MEMORY; AGE; HEALTHY; RISK; SPEED	OBJECTIVES To examine the association between intellectual engagement and cognitive ability in later life, and determine whether the maintenance of intellectual engagement will offset age related cognitive decline. DESIGN Longitudinal, prospective, observational study. SETTING Non-clinical volunteers in late middle age (all born in 1936) living independently in northeast Scotland. PARTICIPANTS Sample of 498 volunteers who had taken part in the Scottish Mental Health Survey of 1947, from one birth year (1936). MAIN OUTCOME MEASURES Cognitive ability and trajectory of cognitive decline in later life. Typical intellectual engagement was measured by a questionnaire, and repeated cognitive measurements of information processing speed and verbal memory were obtained over a 15 year period (recording more than 1200 longitudinal data points for each cognitive test). RESULTS Intellectual engagement was significantly associated with level of cognitive performance in later life, with each point on a 24 point scale accounting for 0.97 standardised cognitive performance (IQ-like) score, for processing speed and 0.71 points for memory (both P<0.05). Engagement in problem solving activities had the largest association with life course cognitive gains, with each point accounting for 0.43 standardised cognitive performance score, for processing speed and 0.36 points for memory (both P<0.05). However, engagement did not influence the trajectory of age related decline in cognitive performance. Engagement in intellectual stimulating activities was associated with early life ability, with correlations between engagement and childhood ability and education being 0.35 and 0.22, respectively (both P<0.01). CONCLUSION These results show that self reported engagement is not associated with the trajectory of cognitive decline in late life, but is associated with the acquisition of ability during the life course. Overall, findings suggest that high performing adults engage and those that engage more being protected from relative decline.	[Staff, Roger T.] NHS Grampian, Aberdeen, Scotland; [Hogan, Michael J.] Natl Univ Ireland, Dept Psychol, Galway, Ireland; [Williams, Daniel S.] Univ Aberdeen, Dept Psychol, Aberdeen, Scotland; [Whalley, L. J.] Univ Aberdeen, Inst Appl Hlth Sci, Aberdeen, Scotland	Ollscoil na Gaillimhe-University of Galway; University of Aberdeen; University of Aberdeen	Staff, RT (corresponding author), Aberdeen Royal Infirm, Aberdeen AB25 2ZH, Scotland.	r.staff@abdn.ac.uk	Hogan, Michael/AAW-6943-2021; whalley, lawrence j/E-9019-2011		Henry Smith Charity; Biology and Biotechnology Science Research Council; Medical Research Council; Wellcome Trust; Chief Scientist's office of the Scottish Government Health Department; Alzheimer Research UK	Henry Smith Charity; Biology and Biotechnology Science Research Council; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Chief Scientist's office of the Scottish Government Health Department; Alzheimer Research UK(Alzheimer's Research UK (ARUK))	The Aberdeen Birth Cohort Studies were initiated in 1998 by a grant from the Henry Smith Charity and later supported by the Biology and Biotechnology Science Research Council, the Medical Research Council, Wellcome Trust, Chief Scientist's office of the Scottish Government Health Department, and Alzheimer Research UK. The study sponsor was the University of Aberdeen. The funders and sponsor played no role in the design, data collection, interpretation of the data, writing of the report, and the decision to submit the article for publication.	Andersson C, 2006, DEMENT GERIATR COGN, V21, P251, DOI 10.1159/000091398; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; Bielak AAM, 2010, GERONTOLOGY, V56, P507, DOI 10.1159/000264918; Cespon J, 2018, AGEING RES REV, V43, P81, DOI 10.1016/j.arr.2018.03.001; Chamorro-Premuzic T, 2006, J PERS ASSESS, V87, P261, DOI 10.1207/s15327752jpa8703_07; Christensen H, 1997, INT J GERIATR PSYCH, V12, P323, DOI 10.1002/(SICI)1099-1166(199703)12:3<323::AID-GPS492>3.0.CO;2-N; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; GOFF M, 1992, J EDUC PSYCHOL, V84, P537, DOI 10.1037/0022-0663.84.4.537; Hong SI, 2010, SOC SCI MED, V71, P414, DOI 10.1016/j.socscimed.2010.04.009; Hultsch DF, 1999, PSYCHOL AGING, V14, P245, DOI 10.1037/0882-7974.14.2.245; Jopp D, 2007, PSYCHOL AGING, V22, P811, DOI 10.1037/0882-7974.22.4.811; Joy S, 2003, ASSESSMENT, V10, P56, DOI 10.1177/0095399702250335; Leibovici D, 1996, AGE AGEING, V25, P392, DOI 10.1093/ageing/25.5.392; Ngandu T, 2015, LANCET, V385, P2255, DOI 10.1016/S0140-6736(15)60461-5; Parisi JM, 2009, AGING NEUROPSYCHOL C, V16, P485, DOI 10.1080/13825580902866653; Powell C, 2016, PERS INDIV DIFFER, V95, P147, DOI 10.1016/j.paid.2016.02.037; Rabbitt P, 2008, J GERONTOL B-PSYCHOL, V63, pP271, DOI 10.1093/geronb/63.5.P271; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rohwedder S, 2010, J ECON PERSPECT, V24, P119, DOI 10.1257/jep.24.1.119; Rowe JW, 1997, GERONTOLOGIST, V37, P433, DOI 10.1093/geront/37.4.433; SCHAIE KW, 1984, INT J BEHAV DEV, V7, P463, DOI 10.1177/016502548400700405; Solomon A, 2013, ADV ALZH DIS, V3, P465, DOI [10.3233/978-1-61499-154-0-465, 10.3233/JAD-2012-129021]; Staff RT, 2018, AGE AGEING, V47, P847, DOI 10.1093/ageing/afy111; Staff RT, 2016, SOC SCI MED, V151, P130, DOI 10.1016/j.socscimed.2016.01.019; Staff RT, 2014, INTELLIGENCE, V47, P194, DOI 10.1016/j.intell.2014.09.013; Stanovich K. E., 1998, GLOBAL PROSPECTS ED, P253, DOI [DOI 10.1037/10294-009, 10.1037/10294-009]; STANOVICH KE, 1995, DEV PSYCHOL, V31, P811, DOI 10.1037/0012-1649.31.5.811; Stanovich KE, 1988, GLOBAL PROSPECTS ED, P253; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Tranter LJ, 2008, AGING NEUROPSYCHOL C, V15, P184, DOI 10.1080/13825580701322163; Van der Elst W, 2005, J INT NEUROPSYCH SOC, V11, P290, DOI 10.1017/S1355617705050344; van Oijen M, 2007, ALZHEIMERS DEMENT, V3, P92, DOI 10.1016/j.jalz.2007.01.011; Verghese J, 2003, NEW ENGL J MED, V348, P2508, DOI 10.1056/NEJMoa022252; von Stumm S, 2012, PSYCHOL AGING, V27, P761, DOI 10.1037/a0026527; von Stumm S, 2011, PERSPECT PSYCHOL SCI, V6, P574, DOI 10.1177/1745691611421204; Wesnes K, 2002, LANCET NEUROL, V1, P473, DOI 10.1016/S1474-4422(02)00236-3; Whalley LJ, 2011, MATURITAS, V69, P365, DOI 10.1016/j.maturitas.2011.05.010	37	26	26	2	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 10	2018	363								k4925	10.1136/bmj.k4925	http://dx.doi.org/10.1136/bmj.k4925			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HE8IS	30530522	Green Published, hybrid			2023-01-03	WOS:000453690500005
J	Yusefzadeh, H; Didarloo, A; Nabilou, B				Yusefzadeh, Hasan; Didarloo, Alireza; Nabilou, Bahram			Provider knowledge and performance in medication injection safety in anesthesia: A mixed method prospective crosses sectional study	PLOS ONE			English	Article							HEALTH-CARE WORKERS; HEPATITIS-B; NEEDLESTICK INJURIES; PRECAUTIONS; EXPOSURE	Objectives Injection safety during anesthesia is a challenging health care issue in Iranian hospitals. Anesthesia is one of the most medication-intensive procedures in healthcare and injecting patients are an integral part of that care. The present study aimed to assess the status of medication injection safety practice in a teaching center. Design, setting, participants A prospective cross-sectional study was done in 2014-2015 at a 500-bed secondary level teaching hospital affiliated with Urmia University of Medical Sciences, Iran. The study population included providers of anesthesia in two groups of operating rooms (ORs) with different types of surgeries at the center. Data were collected using valid and reliable observation and a questionnaire instruments in two consecutive phases. Mann-Whitney U, Kruskal-Wallis, and Spearman correlation tests were used for data analyses. Results A total of 345 injections were observed and recorded during the study period, 53% in group A ORs, and 47% in group B ORs. Eighty-two questionnaires were completed (96.5% response rate) to determine hospital injection practices and personal knowledge of injection safety. Adherence to safety requirements was observed in 58.5% of injections. Fifty five percent of respondents knew that hepatitis B, C, and HIV are blood borne diseases. Observed compliance with injection safety requirements was determined significant by OR groups (P = 0.00). Correlation was significant between observed injection safety practices by age and work experience (P = 0.00). The Kruskal-Wallis test showed a significant difference (P = 0.000) in observed safe injection practices among four job groups but not in reported adherence. Knowledge of respondents was significant by job groups about blood borne diseases and receiving three doses of hepatitis B vaccine. Conclusions The study revealed that some of safe injection procedures were well carried out in our ORs, but that others were not. The reported adherence of staff was acceptable but their actual practices were unsafe. It is suggested to implement audits, provide safer supplies, and complete Hepatitis B vaccination of injection providers.	[Yusefzadeh, Hasan] Urmia Univ Med Sci, Sch Publ Hlth, Dept Publ Hlth, Orumiyeh, Iran; [Didarloo, Alireza] Urmia Univ Med Sci, Social Determinants Hlth Res Ctr, Sch Publ Hlth, Dept Publ Hlth, Orumiyeh, Iran; [Nabilou, Bahram] Urmia Univ Med Sci, Patient Safety Res Ctr, Sch Publ Hlth, Dept Publ Hlth, Orumiyeh, Iran	Urmia University of Medical Sciences; Urmia University of Medical Sciences; Urmia University of Medical Sciences	Nabilou, B (corresponding author), Urmia Univ Med Sci, Patient Safety Res Ctr, Sch Publ Hlth, Dept Publ Hlth, Orumiyeh, Iran.	bnabil@umsu.ac.ir	Didarloo, Alireza/G-7434-2017; yusefzadeh, hasan/F-9850-2017; Didarloo, Alireza/AAF-9651-2021; nabilou, bahram/ABI-4723-2020; nabilou, bahram/G-7659-2017	Didarloo, Alireza/0000-0002-4541-6654; yusefzadeh, hasan/0000-0001-9919-0235; nabilou, bahram/0000-0001-7188-9992; nabilou, bahram/0000-0001-7188-9992				Abdi MH, 2009, JAHROM MED J, V7, P30, DOI DOI 10.29252/JMJ.7.3.30; Abkar MAA, 2013, J INFECT PUBLIC HEAL, V6, P252, DOI 10.1016/j.jiph.2013.01.003; Adejumo P. O., 2013, INT J INFECT CONTROL, V9, P1, DOI DOI 10.3396/ijic.v9i1.004.13; Adib-Hajbaghery M, 2013, TRAUMA MON, V18, P75, DOI 10.5812/traumamon.12779; Amosu A. M., 2011, Current Research Journal of Biological Sciences, V3, P586; [Anonymous], 2000, ERR IS HUMAN BUILDIN; Azami M, 2017, HEPAT MON, V17, DOI 10.5812/hepatmon.37781; Azami-Aghdash Saber, 2015, Med J Islam Repub Iran, V29, P251; Batra V, 2015, ANN GASTROENTEROL, V28, P276; Bobby Paul, 2011, Turk Silahli Kuvvetleri,  Koruyucu Hekimlik Bulteni, V10, P681; Brown L. B, 2014, AANA J, V82; Ford K, 2013, AANA J, V81; Frandzel S, 2012, ANESTHESIOL NEWS, V38; Gholami A., 2013, INT J HOSP RES, V2, P31; Giard M, 2016, AM J INFECT CONTROL, V44, P8, DOI 10.1016/j.ajic.2015.07.034; Gounder P, 2013, J CLIN ANESTH, V25, P521, DOI 10.1016/j.jclinane.2013.04.013; Hanafi M. I., 2011, Eastern Mediterranean Health Journal, V17, P26; Hashemi SH, 2012, HAMADAN U MED SCI, V18, P41; Hutin YJF, 2003, BMJ-BRIT MED J, V327, P1075, DOI 10.1136/bmj.327.7423.1075; Joint Commission, 2014, Sentinel Event Alert, P1; Kaphle H. P., 2014, International Journal of Medical and Health Sciences, V3, P301; Kesieme E. B., 2011, HEPATITIS RES TREATM, V2011; MEMON A.R, 2007, IFECT DIS J, V16, P105; Merali R, 2008, HEALTHCARE Q, V11; Moghri J, 2013, J CLIN RES GOVERNANC, V2, P47; Mohammadi N, 2011, HEPAT MON, V11, P186; Motamed N., 2006, Eastern Mediterranean Health Journal, V12, P653; Mwachofi A, 2011, INT J HEALTH CARE Q, V24, P274, DOI 10.1108/09526861111125589; Nabilou B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135610; Ogoina Dimie, 2015, J Infect Prev, V16, P16, DOI 10.1177/1757177414558957; Olatosi J O, 2016, J West Afr Coll Surg, V6, P88; Omorogbe V. E., 2012, ANN AFRICAN MED, V11; Shah S, 2007, PAK J MED SCI, V23, P538; Shiva F., 2008, Pejouhesh dar Pezeshki, V32, pPe247; Shrestha Sanjaya Kumar, 2006, J Coll Physicians Surg Pak, V16, P108; Talaat M, 2003, AM J INFECT CONTROL, V31, P469, DOI 10.1016/j.ajic.2003.03.003; Taylor DL, 2006, AORN J, V83, P833, DOI DOI 10.1016/S0001-2092(06)60004-5; Vaziri Siavash, 2008, Indian J Med Sci, V62, P292; Vong S, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-56; World Health Organization, 2008, REV INJ SAF ASS TOOL	40	0	1	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2018	13	12							e0207572	10.1371/journal.pone.0207572	http://dx.doi.org/10.1371/journal.pone.0207572			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD0QO	30517128	Green Published, gold, Green Submitted			2023-01-03	WOS:000452212400044
J	Zhu, D; Wu, MD; Cao, Y; Lin, SH; Xuan, NX; Zhu, C; Li, W; Shen, HH				Zhu, Ding; Wu, Mindan; Cao, Yuan; Lin, Shihua; Xuan, Nanxia; Zhu, Chen; Li, Wen; Shen, Huahao			Heated humidification did not improve compliance of positive airway pressure and subjective daytime sleepiness in obstructive sleep apnea syndrome: A meta-analysis	PLOS ONE			English	Article							QUALITY-OF-LIFE; NASAL SYMPTOMS; MOUTH LEAK; ADHERENCE; CPAP; RISK; DEPRESSION; THERAPY	Introduction We performed a meta-analysis on whether heated humidification during positive airway pressure (PAP) could improve compliance and subjective daytime sleepiness in obstructive sleep apnea syndrome (OSAS) patients. Materials and methods We searched PubMed, EMBASE, Medline, Cochrane Library, Clinical Trials, Web of Science and Scopus from inception to Oct 29, 2017. We made meta-analysis on the all available randomized controlled trials (RCTs) which assessed effects of heated humidification intervention on PAP compliance and subjective daytime sleepiness, by subgroups of automatic adjusting positive airway pressure/ continuous positive airway pressure (APAP/CPAP) usage and patients with/without upper airway symptoms prior to PAP therapy. Results A total of nine RCTs were evaluated finally in this meta-analysis. When all the studies were pooled, heated humidification did not improve PAP usage time [weighted mean difference (WMD) = 13.28, 95% confidence interval(CI): -5.85 to 32.41, P = 0.17] or Epworth sleepiness scale (ESS) score (WMD = -0.63, 95% CI: -1.32 to 0.07, P = 0.08). In terms of PAP usage time, heated humidification failed to enhance compliance in both APAP (WMD = 22.34, 95%CI: -21.08 to 65.77, P = 0.31) or CPAP subgroup (WMD = 11.09, 95%CI: -10.21 to 32.40, P = 0.31) and it was also ineffective among patients with upper airway symptoms prior to PAP therapy (WMD = 22.74, 95% CI: -7.77 to 53.24, P = 0.14) or without (WMD = 13.22, 95`)/X1: -35.84 to 62.29, P = 0.60). In terms of ESS score, heated humidification did not reduce ESS scores in both APAP (WMD = -1.59, 95% CI: -3.81 to 0.64, P = 0.16) or CPAP subgroup (WMD = -0.39, 95% Cl: -1.16 to 0.37, P = 0.32) and it was also helpless among patients with upper airway symptoms prior to PAP therapy (WMD = -1.17, 95% CI: -3.10 to 0.75, P = 0.23) or without (WMD = -0.30, 95`)/X1: -2.25 to 1.66, P = 0.76). Conclusion Heated humidification during PAP therapy improves neither the compliance nor ESS scores in OSAS patients, no matter what types of PAP or whether the patients had upper airway symptoms prior to PAP therapy. But to the population with upper airway symptoms and the APAP users, the conclusions were limited because of small sample size and possible selection bias. More attentions should be paid to these potentially possible benefited subgroups.	[Zhu, Ding; Wu, Mindan; Cao, Yuan; Lin, Shihua; Xuan, Nanxia; Zhu, Chen; Li, Wen; Shen, Huahao] Zhejiang Univ, Key Lab Resp Dis Zhejiang Prov, Dept Resp & Crit Care Med, Affiliated Hosp 2,Sch Med, Hangzhou, Zhejiang, Peoples R China	Zhejiang University	Li, W; Shen, HH (corresponding author), Zhejiang Univ, Key Lab Resp Dis Zhejiang Prov, Dept Resp & Crit Care Med, Affiliated Hosp 2,Sch Med, Hangzhou, Zhejiang, Peoples R China.	liwen@zju.edu.cn; huahaoshen@zju.edu.cn						Al Ashry HS, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/715434; Almendros I, 2008, SLEEP, V31, P127, DOI 10.1093/sleep/31.1.127; Black J, 2003, RESP PHYSIOL NEUROBI, V136, P211, DOI 10.1016/S1569-9048(03)00083-1; Budweiser S, 2009, J SEX MED, V6, P3147, DOI 10.1111/j.1743-6109.2009.01372.x; Constantinidis J, 2000, ACTA OTO-LARYNGOL, V120, P432; Cruz AA, 2006, J ALLERGY CLIN IMMUN, V117, P1351, DOI 10.1016/j.jaci.2006.01.054; Devulapally K, 2009, HEART FAIL REV, V14, P155, DOI 10.1007/s10741-008-9101-2; Engleman HM, 2003, SLEEP MED REV, V7, P81, DOI 10.1053/smrv.2001.0197; Engleman HM, 2000, SLEEP, V23, pS102; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Garbarino S, 2016, SLEEP, V39, P1211, DOI 10.5665/sleep.5834; Hayes D, 2012, AM J RESP CRIT CARE, V185, P1190, DOI 10.1164/rccm.201201-0088OC; HAYES MJ, 1995, THORAX, V50, P1179, DOI 10.1136/thx.50.11.1179; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Ip S, 2012, SYST REV, V1, DOI 10.1186/2046-4053-1-20; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Koutsourelakis I, 2011, EUR RESPIR J, V37, P587, DOI 10.1183/09031936.00036910; Kushida CA, 2006, SLEEP, V29, P375, DOI 10.1093/sleep/29.3.375; Mador MJ, 2005, CHEST, V128, P2151, DOI 10.1378/chest.128.4.2151; Massie CA, 1999, CHEST, V116, P403, DOI 10.1378/chest.116.2.403; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Neill AM, 2003, EUR RESPIR J, V22, P258, DOI 10.1183/09031936.03.00035603; Nilius G, 2016, SLEEP BREATH, V20, P43, DOI 10.1007/s11325-015-1182-2; Rakotonanahary D, 2001, CHEST, V119, P460, DOI 10.1378/chest.119.2.460; Richards GN, 1996, AM J RESP CRIT CARE, V154, P182, DOI 10.1164/ajrccm.154.1.8680678; Ruhle KH, 2011, SLEEP BREATH, V15, P479, DOI 10.1007/s11325-010-0363-2; Ryan S, 2009, J CLIN SLEEP MED, V5, P422; Salgado Sara Moreira da Silva Trindade, 2008, J. bras. pneumol., V34, P690, DOI 10.1590/S1806-37132008000900009; Soudorn C, 2016, RESP CARE, V61, P1151, DOI 10.4187/respcare.04536; Sullivan SS, 2008, CHEST, V134, P854, DOI 10.1378/chest.08-0822; Tregear S, 2009, J CLIN SLEEP MED, V5, P573; Weaver Terri E, 2008, Proc Am Thorac Soc, V5, P173, DOI 10.1513/pats.200708-119MG; Wells RD, 2007, PSYCHOSOM MED, V69, P449, DOI 10.1097/psy.0b013e318068b2f7; Wild MR, 2004, EUR RESPIR J, V24, P461, DOI 10.1183/09031936.04.00114603; Worsnop CJ, 2010, INTERN MED J, V40, P650, DOI 10.1111/j.1445-5994.2009.01969.x; Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104; Yosunkaya S, 2016, NIGER J CLIN PRACT, V19, P573, DOI 10.4103/1119-3077.188703; Zozula R, 2001, Curr Opin Pulm Med, V7, P391, DOI 10.1097/00063198-200111000-00005	39	9	9	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2018	13	12							e0207994	10.1371/journal.pone.0207994	http://dx.doi.org/10.1371/journal.pone.0207994			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD0QO	30517168	gold, Green Submitted, Green Published			2023-01-03	WOS:000452212400075
J	Akache, B; Stark, FC; Jia, YM; Deschatelets, L; Dudani, R; Harrison, BA; Agbayani, G; Williams, D; Jamshidi, MP; Krishnan, L; McCluskie, MJ				Akache, Bassel; Stark, Felicity C.; Jia, Yimei; Deschatelets, Lise; Dudani, Renu; Harrison, Blair A.; Agbayani, Gerard; Williams, Dean; Jamshidi, Mohammad P.; Krishnan, Lakshmi; McCluskie, Michael J.			Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice	PLOS ONE			English	Article							HEPATITIS-B-VACCINE; T-CELL RESPONSES; ANTIGEN; RECOGNITION; IMMUNOGENICITY; IMMUNIZATION; INDUCTION; LIPOSOMES; INFECTION; IMMUNITY	Archaeosomes are liposomes traditionally comprised of total polar lipids (TPL) or semi-synthetic glycerolipids of ether-linked isoprenoid phytanyl cores with varied glyco- and aminohead groups. As adjuvants, they induce robust, long-lasting humoral and cell-mediated immune responses and enhance protection in murine models of infectious disease and cancer. Traditional total polar lipid (TPL) archaeosome formulations are relatively complex and first generation semi-synthetic archaeosomes involve many synthetic steps to arrive at the final desired glycolipid composition. We have developed a novel archaeosome formulation comprising a sulfated disaccharide group covalently linked to the free sn-1 hydroxyl backbone of an archaeal core lipid (sulfated S-lactosylarchaeol, SLA) that can be more readily synthesized yet retains strong immunostimulatory activity for induction of cell-mediated immunity following systemic immunization. Herein, we have evaluated the immunostimulatory effects of SLA archaeosomes when used as adjuvant with ovalbumin (OVA) and hepatitis B surface antigen (HBsAg) and compared this to various other adjuvants including TLR3/4/9 agonists, oil-in-water and water-in-oil emulsions and aluminum hydroxide. Overall, we found that semi-synthetic sulfated glycolipid archaeosomes induce strong Ag-specific IgG titers and CD8 T cells to both antigens. In addition, they induce the expression of a number of cytokines/chemokines including IL-6, G-CSF, KC & MIP-2. SLA archaeosome formulations demonstrated strong adjuvant activity, superior to many of the other tested adjuvants.	[Akache, Bassel; Stark, Felicity C.; Jia, Yimei; Deschatelets, Lise; Dudani, Renu; Harrison, Blair A.; Agbayani, Gerard; Williams, Dean; Jamshidi, Mohammad P.; Krishnan, Lakshmi; McCluskie, Michael J.] Natl Res Council Canada, Ottawa, ON, Canada; [Agbayani, Gerard; Krishnan, Lakshmi] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada	National Research Council Canada; University of Ottawa	McCluskie, MJ (corresponding author), Natl Res Council Canada, Ottawa, ON, Canada.	Michael.McCluskie@nrc-cnrc.gc.ca	Jia, Yimei/AAS-1318-2021; Stark, Felicity/AAT-2342-2021; Jia, Yimei/ABD-4509-2021	Stark, Felicity/0000-0002-7547-8493; Akache, Bassel/0000-0002-5377-7193	National Research Council Canada	National Research Council Canada	Research was funded internally by the National Research Council Canada.	Akache B., 2018, HUM VACC IMMUNOTHER, V16, P1; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Ammi R, 2015, PHARMACOL THERAPEUT, V146, P120, DOI 10.1016/j.pharmthera.2014.09.010; Ascarateil S, J IMMUNOTHERAPY C S2, V3, P428; Awate S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00114; Barber DL, 2003, J IMMUNOL, V171, P27, DOI 10.4049/jimmunol.171.1.27; Bergfors E, 2013, EUR J PEDIATR, V172, P171, DOI 10.1007/s00431-012-1841-2; Bijker MS, 2007, J IMMUNOL, V179, P5033, DOI 10.4049/jimmunol.179.8.5033; Bonam SR, 2017, TRENDS PHARMACOL SCI, V38, P771, DOI 10.1016/j.tips.2017.06.002; Calabro S, 2011, VACCINE, V29, P1812, DOI 10.1016/j.vaccine.2010.12.090; Cantisani R, 2015, J IMMUNOL, V194, P1717, DOI 10.4049/jimmunol.1400623; Conlan JW, 2001, VACCINE, V19, P3509, DOI 10.1016/S0264-410X(01)00041-X; Del Giudice G, 2006, CLIN VACCINE IMMUNOL, V13, P1010, DOI 10.1128/CVI.00191-06; Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; Fisman DN, 2002, CLIN INFECT DIS, V35, P1368, DOI 10.1086/344271; Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635; Gelman AE, 2004, J IMMUNOL, V172, P6065, DOI 10.4049/jimmunol.172.10.6065; Gurnani K, 2004, J IMMUNOL, V173, P566, DOI 10.4049/jimmunol.173.1.566; Hailemichael Y, 2013, NAT MED, V19, P465, DOI 10.1038/nm.3105; Haq K, 2016, EXPERT REV VACCINES, V15, P1557, DOI 10.1080/14760584.2016.1195265; Hofmeyer KA, 2016, CLIN VACCINE IMMUNOL, V23, P785, DOI 10.1128/CVI.00251-16; Hopkins RJ, 2016, VACCINE, V34, P2096, DOI 10.1016/j.vaccine.2016.03.006; Jackson S, 2018, VACCINE, V36, P668, DOI 10.1016/j.vaccine.2017.12.038; James SF, 2018, ANN PHARMACOTHER, V52, P673, DOI 10.1177/1060028018758431; Kato H, 2008, J EXP MED, V205, P1601, DOI 10.1084/jem.20080091; Knudsen NPH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19570; Krieg AM, 2012, NUCLEIC ACID THER, V22, P77, DOI 10.1089/nat.2012.0340; Krishnan L, 2000, INFECT IMMUN, V68, P54, DOI 10.1128/IAI.68.1.54-63.2000; Krishnan L, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/578432; Lindemann M, 2017, SCAND J IMMUNOL, V85, P51, DOI 10.1111/sji.12497; Llopiz D, 2008, CANCER IMMUNOL IMMUN, V57, P19, DOI 10.1007/s00262-007-0346-8; Longhi MP, 2009, J EXP MED, V206, P1589, DOI 10.1084/jem.20090247; Makinen SR, 2016, INT IMMUNOL, V28, P453, DOI 10.1093/intimm/dxw017; Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510; Mata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963; McCluskie MJ, 2017, HUM VACC IMMUNOTHER, V13, P2772, DOI 10.1080/21645515.2017.1316912; McCluskie MJ, 2006, ANTIVIR RES, V69, P77, DOI 10.1016/j.antiviral.2005.10.007; Miles AP, 2005, VACCINE, V23, P2530, DOI 10.1016/j.vaccine.2004.08.049; O'Hagan DT, 2012, VACCINE, V30, P4341, DOI 10.1016/j.vaccine.2011.09.061; Pye D, 1997, VACCINE, V15, P1017, DOI 10.1016/S0264-410X(96)00289-7; ROBINSON RA, 1976, JNCI-J NATL CANCER I, V57, P599, DOI 10.1093/jnci/57.3.599; ROTZSCHKE O, 1991, EUR J IMMUNOL, V21, P2891, DOI 10.1002/eji.1830211136; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; Sprott GD, 2003, METHOD ENZYMOL, V373, P155; Sprott GD, 2012, ARCHAEA, V2012, DOI 10.1155/2012/513231; Whitfield DM, 2010, CARBOHYD RES, V345, P214, DOI 10.1016/j.carres.2009.10.011; Whitfield DM, 2016, National Research Council of Canada. Patent, Patent No. [2016/ 004512, 2016004512]; Wild J, 1999, J IMMUNOL, V163, P1880; WISMANS PJ, 1991, J MED VIROL, V35, P216, DOI 10.1002/jmv.1890350313	51	23	22	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2018	13	12							e0208067	10.1371/journal.pone.0208067	http://dx.doi.org/10.1371/journal.pone.0208067			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD0NQ	30513093	Green Submitted, Green Published, gold			2023-01-03	WOS:000452204800022
J	Kao, PC; Srivastava, S				Kao, Pei-Chun; Srivastava, Shraddha			Mediolateral footpath stabilization during walking in people following stroke	PLOS ONE			English	Article							JOINT COORDINATION; GAIT; STABILITY; BALANCE	Community dwelling stroke survivors most often fall while walking. Understanding how post-stroke individuals control mediolateral footpath during walking may help elucidate the mechanisms that contribute to walking instability. By applying the Uncontrolled Manifold (UCM) approach, we investigated (1) how post-stroke individuals coordinate lower-extremity joint motions to stabilize mediolateral footpath of the swing leg, and (2) how the inter-joint coordination in footpath stabilization correlates to their walking stability. Nine stroke subjects and nine healthy controls walked on a treadmill at four different speeds. UCM analysis partitions the variance of kinematic configurations across gait cycles into "good variance" (i.e., the variance component leading to a consistent footpath) or "bad variance" (i.e., the variance component leading to an inconsistent footpath). We found that both groups had a significantly greater "good" than "bad" variance (p<0.05) for most of the swing phase, suggesting that mediolateral footpath is an important variable stabilized by the central nervous system during walking. Stroke subjects had significantly greater relative variance difference (Delta V) (i.e. normalized difference between "good" and "bad" variance) (p<0.05), indicating a stronger kinematic synergy in footpath stabilization, than the controls. In addition, the kinematic synergy in mediolateral footpath stabilization is strongest during mid-swing but weakest during late swing in healthy gait. However, this phase-dependent strategy is preserved for mid-swing but not for late swing in stroke gait. Moreover, stroke and healthy subjects demonstrated different relationships between UCM and walking stability measures. A stronger kinematic synergy in healthy gait is associated with better walking stability whereas having more "good variance" or stronger kinematic synergy in stroke gait is associated with less walking stability. The current findings suggest that walking with too much "good variance" in people following stroke, despite no effect on the footpath, may adversely affect their walking stability to some extent.	[Kao, Pei-Chun] Univ Massachusetts, Dept Phys Therapy, Lowell, MA 01854 USA; [Srivastava, Shraddha] Med Univ South Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA	University of Massachusetts System; University of Massachusetts Lowell; Medical University of South Carolina	Kao, PC (corresponding author), Univ Massachusetts, Dept Phys Therapy, Lowell, MA 01854 USA.	PeiChun_Kao@uml.edu		Kao, Pei-Chun/0000-0001-8603-3898				Asaka T, 2008, EXP BRAIN RES, V184, P323, DOI 10.1007/s00221-007-1101-2; Bakeman R, 2005, BEHAV RES METHODS, V37, P379, DOI 10.3758/BF03192707; Balasubramanian CK, 2010, CLIN BIOMECH, V25, P483, DOI 10.1016/j.clinbiomech.2010.02.003; Balasubramanian CK, 2009, GAIT POSTURE, V29, P408, DOI 10.1016/j.gaitpost.2008.10.061; Batchelor FA, 2012, INT J STROKE, V7, P482, DOI 10.1111/j.1747-4949.2012.00796.x; Bauby CE, 2000, J BIOMECH, V33, P1433, DOI 10.1016/S0021-9290(00)00101-9; Black DP, 2007, EXP BRAIN RES, V183, P511, DOI 10.1007/s00221-007-1066-1; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J., 1988, STAT POWER ANAL BEHA, V567; De Bujanda Eva, 2004, J Stroke Cerebrovasc Dis, V13, P58; de Freitas SMSF, 2007, NEUROSCI LETT, V417, P66, DOI 10.1016/j.neulet.2007.02.037; Donelan JM, 2004, J BIOMECH, V37, P827, DOI 10.1016/j.jbiomech.2003.06.002; Ellis RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141694; Hyndman D, 2002, ARCH PHYS MED REHAB, V83, P165, DOI 10.1053/apmr.2002.28030; Kao PC, 2014, GAIT POSTURE, V40, P457, DOI 10.1016/j.gaitpost.2014.05.014; Krishnamoorthy V, 2005, EXP BRAIN RES, V164, P1, DOI 10.1007/s00221-004-2205-6; Krishnan V, 2013, GAIT POSTURE, V38, P923, DOI 10.1016/j.gaitpost.2013.04.023; Kuo AD, 1999, INT J ROBOT RES, V18, P917, DOI 10.1177/02783649922066655; Lamontagne A, 2007, CLIN NEUROPHYSIOL, V118, P717, DOI 10.1016/j.clinph.2006.12.013; Latash ML, 2002, EXERC SPORT SCI REV, V30, P26, DOI 10.1097/00003677-200201000-00006; Milanese C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192046; O'Connor SM, 2009, J NEUROPHYSIOL, V102, P1411, DOI 10.1152/jn.00131.2009; Papi E, 2015, J BIOMECH, V48, P324, DOI 10.1016/j.jbiomech.2014.11.024; Rankin BL, 2014, J NEUROPHYSIOL, V112, P374, DOI 10.1152/jn.00138.2014; Reisman DS, 2003, BRAIN, V126, P2510, DOI 10.1093/brain/awg246; Robert T, 2009, EXP BRAIN RES, V197, P185, DOI 10.1007/s00221-009-1904-4; Scholz JP, 1999, EXP BRAIN RES, V126, P289, DOI 10.1007/s002210050738; Srivastava S, 2016, EXP BRAIN RES, V234, P1903, DOI 10.1007/s00221-016-4593-9; Verrel J, 2010, EXP BRAIN RES, V207, P13, DOI 10.1007/s00221-010-2424-y; WINTER DA, 1992, PHYS THER, V72, P45, DOI 10.1093/ptj/72.1.45; Wu YH, 2014, EXERC SPORT SCI REV, V42, P37, DOI 10.1249/JES.0000000000000002; Wu YH, 2013, EXP BRAIN RES, V226, P273, DOI 10.1007/s00221-013-3433-4; Young PMM, 2012, J BIOMECH, V45, P1053, DOI 10.1016/j.jbiomech.2011.12.027; Young PMM, 2012, GAIT POSTURE, V35, P472, DOI 10.1016/j.gaitpost.2011.11.010; Zeni JA, 2010, CLIN BIOMECH, V25, P383, DOI 10.1016/j.clinbiomech.2009.11.002	36	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2018	13	11							e0208120	10.1371/journal.pone.0208120	http://dx.doi.org/10.1371/journal.pone.0208120			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC4HL	30496257	gold, Green Published, Green Submitted			2023-01-03	WOS:000451763800095
J	Candela, E; Marin, F; Rivera-Caravaca, JM; Ibarra, NV; Carrillo, L; Esteve-Pastor, MA; Lozano, T; Macias, MJ; Pernias, V; Sandin, M; Orenes-Pinero, E; Quintana-Giner, M; Hortelano, I; Villamia, B; Veliz, A; Valdes, M; Martinez-Martinez, JG; Ruiz-Nodar, JM				Candela, Elena; Marin, Francisco; Miguel Rivera-Caravaca, Jose; Vicente Ibarra, Nuria; Carrillo, Luna; Asuncion Esteve-Pastor, Maria; Lozano, Teresa; Jesus Macias, Manuel; Pernias, Vicente; Sandin, Miriam; Orenes-Pinero, Esteban; Quintana-Giner, Miriam; Hortelano, Ignacio; Villamia, Beatriz; Veliz, Andrea; Valdes, Mariano; Martinez-Martinez, Juan G.; Ruiz-Nodar, Juan M.			Conservatively managed patients with non-ST-segment elevation acute coronary syndrome are undertreated with indicated medicines	PLOS ONE			English	Article							MEDICAL-MANAGEMENT; UNSTABLE ANGINA; CLOPIDOGREL; TRENDS	Introduction and aims Patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) are often managed conservatively. Clinical practice guidelines recommend treating these patients with the same pharmacological drugs as those who receive invasive treatment. We analyze the use of new antiplatelet drugs (NADs) and other recommended treatments in people discharged following an NSTE-ACS according to the treatment strategy used, comparing the medium-term prognosis between groups. Methods Prospective observational multicenter registry study in 1717 patients discharged from hospital following an ACS; 1143 patients had experienced an NSTE-ACS. We analyzed groups receiving the following treatment: No cardiac catheterization (NO CATH): n = 134; 11.7%; Cardiac catheterization without revascularization (CATH-NO REVASC): n = 256; 22.4%; percutaneous coronary intervention (PCI): n = 629; 55.0%; and coronary artery bypass graft (CABG): n = 124; 10.8%. We assessed major adverse cardiovascular events (MACE), all-cause mortality, and hemorrhagic complications at one year. Results NO CATH was the oldest, had the most comorbidities, and was at the highest risk for ischemic and hemorrhagic events. Few patients who were not revascularized with PCI received NADs (NO CATH: 3.7%; CATH-NO REVASC: 10.6%; PCI: 43.2%; CABG: 3.2%; p<0.001). Non-revascularized patients also received fewer beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB), and statins (p<0.001). At one year, MACE incidence in NO CATH group was three times that of the other groups (30.1%, p<0.001), and all-cause mortality was also much higher (26.3%, p<0.001). There were no significant differences in hemorrhagic events. Belonging to NO CATH group was an independent predictor for MACE at one year in the multivariate analysis (HR 2.72, 95% CI 1.29-5.73; p = 0.008). Conclusions Despite current invasive management of NSTE-ACS, patients not receiving catheterization are at very high risk for under treatment with recommended drugs, including NADs. Their medium-term prognosis is poor, with high mortality. Patients treated with PCI receive better pharmacological management, with high use of NADs.	[Candela, Elena; Carrillo, Luna; Lozano, Teresa; Jesus Macias, Manuel; Sandin, Miriam; Hortelano, Ignacio; Villamia, Beatriz; Martinez-Martinez, Juan G.; Ruiz-Nodar, Juan M.] Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Dept Cardiol, Alicante, Spain; [Marin, Francisco; Miguel Rivera-Caravaca, Jose; Asuncion Esteve-Pastor, Maria; Orenes-Pinero, Esteban; Quintana-Giner, Miriam; Veliz, Andrea; Valdes, Mariano] Hosp Clin Univ Virgen de la Arrixaca, Dept Cardiol, IMIB Arrixaca CIBER CV, Murcia, Spain; [Vicente Ibarra, Nuria; Pernias, Vicente] Hosp Gen Univ Elche, Dept Cardiol, Alicante, Spain	General University Hospital of Alicante; Universidad Miguel Hernandez de Elche; Universitat d'Alacant; Instituto de Investigacion Sanitaria y Biomedica de Alicante (ISABIAL); Hospital Clinico Universitario Virgen de la Arrixaca	Ruiz-Nodar, JM (corresponding author), Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Dept Cardiol, Alicante, Spain.	ruiz_jmi@gva.es	Orenes-Piñero, Esteban/AAG-8752-2019; Rivera-Caravaca, José Miguel/O-5611-2016; Marin, Francisco/AAD-9429-2022; Martinez, Juan Gabriel/A-6956-2018	Orenes-Piñero, Esteban/0000-0003-3979-6678; Rivera-Caravaca, José Miguel/0000-0003-0492-6241; Marin, Francisco/0000-0001-7246-7708; Martinez, Juan Gabriel/0000-0003-2255-3530; Esteve-Pastor, Maria Asuncion/0000-0003-3104-3460; Candela Sanchez, Elena Maria/0000-0002-1697-020X				Amsterdam EA, 2014, J AM COLL CARDIOL, V64, pE139, DOI [10.1016/j.jacc.2014.09.016, 10.1016/j.jacc.2014.09.017]; Amsterdam EA, 2009, AM HEART J, V158, P748, DOI 10.1016/j.ahj.2009.09.008; Esteve-Pastor MA, 2018, J CARDIOVASC PHARM T, V23, P57, DOI 10.1177/1074248417724869; Blatt A, 2016, AM J CARDIOL, V118, P1, DOI 10.1016/j.amjcard.2016.03.054; Bueno H, 2017, REV ESP CARDIOL, V70, P817, DOI [10.1016/j.recesp.2016.11.046, 10.1016/j.rec.2016.12.031]; Chan MY, 2008, JACC-CARDIOVASC INTE, V1, P369, DOI 10.1016/j.jcin.2008.03.019; James SK, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3527; Mehran R, 2011, CIRCULATION, V123, P2736, DOI 10.1161/CIRCULATIONAHA.110.009449; Mohr FW, 2013, LANCET, V381, P629, DOI 10.1016/S0140-6736(13)60141-5; Ohman EM, 2014, J AM COLL CARDIOL, V63, P2258, DOI 10.1016/j.jacc.2014.03.009; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; Solomon MD, 2014, J AM COLL CARDIOL, V63, P2249, DOI 10.1016/j.jacc.2014.02.586; Valgimigli M, 2018, EUR HEART J, V39, P213, DOI 10.1093/eurheartj/ehx419; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482; Yusuf S, 2000, EUR HEART J, V21, P2033	17	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2018	13	11							e0208069	10.1371/journal.pone.0208069	http://dx.doi.org/10.1371/journal.pone.0208069			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC4EO	30485352	Green Published, Green Submitted, gold			2023-01-03	WOS:000451755800103
J	Pettersson, M; Hoglund, AT; Hedstrom, M				Pettersson, Mona; Hoglund, Anna T.; Hedstrom, Mariann			Perspectives on the DNR decision process: A survey of nurses and physicians in hematology and oncology	PLOS ONE			English	Article							RESUSCITATE ORDERS; MORAL DISTRESS; LIFE; END	Introduction In cancer care, do-not-resuscitate (DNR) decisions are made frequently; i.e., decisions not to start the heart in the event of a cardiac arrest. A DNR decision can be a complex process involving nurses and physicians with a wide variety of experiences and perspectives. Previous studies have shown different perceptions of the DNR decision process among nurses and physicians, e.g. concerning patient involvement and information. DNR decisions have also been reported to be unclear and documentation inconsistent. Objective The aim was to investigate how important and how likely to happen nurses and physicians considered various aspects of the DNR decision process, regarding participation, information and documentation, as well as which attributes they found most important in relation to DNR decisions. Methods A descriptive correlational study using a web survey was conducted, including 132 nurses and 84 physicians working in hematology and oncology. Results Almost half of the respondents reported it not likely that the patient would be involved in the decision on DNR, and 21% found it unimportant to inform patients of the DNR decision. Further, 57% reported that providing information to the patient was important, but only 21% stated that this was likely to happen. There were differences between nurses and physicians, especially regarding participation by and information to patients and relatives. The attributes deemed most important for both nurses and physicians pertained more to medical viewpoints than to ethical values, but a difference was found, as nurses chose patient autonomy as the most important value, while physicians rated non-maleficence as the most important value in relation to DNR decisions. Conclusion Nurses and physicians need to be able to talk openly about their different perspectives on DNR decisions, so that they can develop a deeper understanding of the decisions, especially in cases where they disagree. They should also be aware that what they think is important is not always likely to happen. The organization needs to support such discussions through providing an environment that allows ethical discussions on regular basis. Patients and relatives will also benefit from receiving the same information from all caregivers.	[Pettersson, Mona; Hoglund, Anna T.; Hedstrom, Mariann] Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden	Uppsala University	Pettersson, M (corresponding author), Uppsala Univ, Dept Publ Hlth & Caring Sci, Uppsala, Sweden.	mona.pettersson@pubcare.uu.se		Hedstrom, Mariann/0000-0001-6296-0160				[Anonymous], 2011, 20117 SOSFS NAT BOAR; Baruch Y, 2008, HUM RELAT, V61, P1139, DOI 10.1177/0018726708094863; Becerra M, 2011, GERONTOLOGY, V57, P414, DOI 10.1159/000319422; Beckstrand RL, 2012, ONCOL NURS FORUM, V39, pE398, DOI 10.1188/12.ONF.E398-E406; Brown M, 2014, INTERN MED J, V44, P93, DOI 10.1111/imj.12328; Burns JP, 2016, NEW ENGL J MED, V375, P504, DOI 10.1056/NEJMp1605597; Clements M, 2014, RESUSCITATION, V85, P606, DOI 10.1016/j.resuscitation.2014.02.005; Cook DA, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.6318; Corley MC, 2001, J ADV NURS, V33, P250, DOI 10.1046/j.1365-2648.2001.01658.x; Cunningham CT, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0016-z; Duplan KL, 2016, INTENS CRIT CARE NUR, V37, P75, DOI 10.1016/j.iccn.2016.06.005; Ebert JF, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.8353; Jameton A, 2013, J BIOETHIC INQ, V10, P297, DOI 10.1007/s11673-013-9466-3; Jensen HI, 2013, J BIOETHIC INQ, V10, P93, DOI 10.1007/s11673-012-9416-5; Levin Tomer T, 2008, Palliat Support Care, V6, P341, DOI 10.1017/S1478951508000540; Liao K, 2017, OTOLARYNG HEAD NECK, V156, P46, DOI 10.1177/0194599816667712; Mahon Margaret M, 2010, Oncol Nurs Forum, V37, pE141, DOI 10.1188/10.ONF.E141-E150; Martins Y, 2012, BRIT J CANCER, V106, P1021, DOI 10.1038/bjc.2012.28; Meehan A., 2016, UNIVERS J PUBLIC HLT, V4, P55; Mockford C, 2015, RESUSCITATION, V88, P99, DOI 10.1016/j.resuscitation.2014.11.016; Nakagawa S, 2004, BEHAV ECOL, V15, P1044, DOI 10.1093/beheco/arh107; Olver I, 2008, PSYCHO-ONCOL, V17, P347, DOI 10.1002/pon.1246; Olver IN, 2016, CANCERS, V8, DOI 10.3390/cancers8100089; Osinski A, 2017, SUPPORT CARE CANCER, V25, P677, DOI 10.1007/s00520-016-3459-9; Pettersson M, 2018, BMC MED ETHICS, V19, DOI 10.1186/s12910-018-0300-7; Pettersson M, 2014, NURS ETHICS, V21, P902, DOI 10.1177/0969733014533238; Pfeil TA, 2015, ONCOLOGIST, V20, P56, DOI 10.1634/theoncologist.2014-0031; Polit D.F., 2008, NURSING RES GENERATI; Prentice TM, 2018, ARCH DIS CHILD-FETAL, V103, pF441, DOI 10.1136/archdischild-2017-313539; Silen M, 2008, NURS ETHICS, V15, P160, DOI 10.1177/0969733007086014; Socialstyrelsen, 2018, STAT PER SUBJ; Socialstyrelsen, 2016, STAT PER SUBJ; Svantesson Mia, 2003, Intensive Crit Care Nurs, V19, P241, DOI 10.1016/S0964-3397(03)00055-7; Swedish Resuscitation Council, 2017, CARD ARR HOSP TREATM; Swedish Society of Medicine (Svenska Lakaresallskapet), ETH COD; Swedish Society of Medicine Swedish Society of Nursing and Swedish Resuscitaion Council (Svenska Lakaresallskapet Svensk Sjukskoterskeforening and Svenska Radet for Hjart-lungraddning), 2013, ETH CPR; Trivedi S, 2013, REP PRACT ONCOL RADI, V18, P53, DOI 10.1016/j.rpor.2012.12.002; Udo C, 2018, EUR J CANCER CARE, V27, DOI 10.1111/ecc.12728; WHO, 2018, HLTH STAT INF SYST; World Medical Association (WMA), 2013, ETH PRINC MED RES IN; Young A, 2017, PALLIATIVE MED, V31, P853, DOI 10.1177/0269216316682894; Yuen JK, 2011, J GEN INTERN MED, V26, P791, DOI 10.1007/s11606-011-1632-x	42	18	19	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2018	13	11							e0206550	10.1371/journal.pone.0206550	http://dx.doi.org/10.1371/journal.pone.0206550			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HB4VL	30462673	Green Published, gold, Green Submitted			2023-01-03	WOS:000451054800020
J	Bozelli, JC; Jennings, W; Black, S; Hou, YH; Lameire, D; Chatha, P; Kimura, T; Berno, B; Khondker, A; Rheinstadter, MC; Epand, RM				Bozelli, Jose Carlos, Jr.; Jennings, William; Black, Stephanie; Hou, Yu Heng; Lameire, Darius; Chatha, Preet; Kimura, Tomohiro; Berno, Bob; Khondker, Adree; Rheinstadter, Maikel C.; Epand, Richard M.			Membrane curvature allosterically regulates the phosphatidylinositol cycle, controlling its rate and acyl-chain composition of its lipid intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						phosphatidylinositol signaling; membrane biophysics; membrane enzyme; membrane lipid; endoplasmic reticulum (ER); plasma membrane; diacylglycerol kinase (DGK; DAGK); diacylglycerol; lipid signaling; lipid trafficking; phosphatidylinositol cycle; membrane shape; regulation of enzyme by membrane curvature; PM-ER junctions; contact sites; negative Gaussian curvature; membrane trafficking; allostery; membrane protein	DIACYLGLYCEROL KINASE-EPSILON; LATERAL PRESSURE PROFILE; CELL-MEMBRANE; PROTEIN FUNCTION; ELASTIC STRESS; CONTACT SITES; CUBIC PHASES; PHOSPHOINOSITIDES; FUSION; ROLES	Signaling events at membranes are often mediated by membrane lipid composition or membrane physical properties. These membrane properties could act either by favoring the membrane binding of downstream effectors or by modulating their activity. Several proteins can sense/generate membrane physical curvature (i.e. shape). However, the modulation of the activity of enzymes by a membrane's shape has not yet been reported. Here, using a cell-free assay with purified diacylglycerol kinase E (DGKE) and liposomes, we studied the activity and acyl-chain specificity of an enzyme of the phosphatidylinositol (PI) cycle, DGKE. By systematically varying the model membrane lipid composition and physical properties, we found that DGKE has low activity and lacks acyl-chain specificity in locally flat membranes, regardless of the lipid composition. On the other hand, these enzyme properties were greatly enhanced in membrane structures with a negative Gaussian curvature. We also found that this is not a consequence of preferential binding of the enzyme to those structures, but rather is due to a curvature-mediated allosteric regulation of DGKE activity and acyl-chain specificity. Moreover, in a fine-tuned interplay between the enzyme and the membrane, DGKE favored the formation of structures with greater Gaussian curvature. DGKE does not bear a regulatory domain, and these findings reveal the importance of membrane curvature in regulating DGKE activity and acyl-chain specificity. Hence, this study highlights that a hierarchic coupling of membrane physical property and lipid composition synergistically regulates membrane signaling events. We propose that this regulatory mechanism of membrane-associated enzyme activity is likely more common than is currently appreciated.	[Bozelli, Jose Carlos, Jr.; Jennings, William; Black, Stephanie; Hou, Yu Heng; Lameire, Darius; Chatha, Preet; Kimura, Tomohiro; Epand, Richard M.] McMaster Univ, Hlth Sci Ctr, Dept Biochem & Biomed Sci, Hamilton, ON L8S 4K1, Canada; [Berno, Bob; Epand, Richard M.] McMaster Univ, Dept Chem, Hamilton, ON L8S 4L8, Canada; [Khondker, Adree; Rheinstadter, Maikel C.] McMaster Univ, Dept Phys & Astron, Hamilton, ON L8S 4L8, Canada; [Khondker, Adree; Rheinstadter, Maikel C.] McMaster Univ, Origins Inst, Hamilton, ON L8S 4L8, Canada	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; McMaster University; McMaster University	Epand, RM (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8S 4K1, Canada.	epand@mcmaster.ca	Kimura, Tomohiro/AEJ-1621-2022; , Richard/R-2316-2019; Rheinstadter, Maikel C/D-5322-2009	, Richard/0000-0002-9602-9558; Rheinstadter, Maikel C/0000-0002-0558-7475; Bozelli Jr, Jose Carlos/0000-0001-9533-0886; Hou, Yu Heng/0000-0001-7886-8772; Kimura, Tomohiro/0000-0002-4192-7852; Khondker, Adree/0000-0003-3246-4662	Canadian Natural Sciences and Engineering Research Council [RGPIN-2018-05585, RGPIN-2016-06450]; Canada Foundation for Innovation (CFI); CIHR; Ontario Ministry of Economic Development and Innovation; McMaster University	Canadian Natural Sciences and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canada Foundation for Innovation (CFI)(Canada Foundation for Innovation); CIHR(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Economic Development and Innovation; McMaster University	This work was supported by Canadian Natural Sciences and Engineering Research Council grant RGPIN-2018-05585 (to R. M. E.) and RGPIN-2016-06450 (to M. C. R.). This work was also supported by the Canada Foundation for Innovation (CFI), CIHR, and the Ontario Ministry of Economic Development and Innovation (to M. C. R.) and a University Scholar Award from McMaster University (to M. C. R.). The authors declare that they have no conflicts of interest with the contents of this article.	Almsherqi ZA, 2009, INT REV CEL MOL BIO, V274, P275, DOI 10.1016/S1937-6448(08)02006-6; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI DOI 10.1016/0076-6879(66)08014-5; Andersen OS, 2007, ANNU REV BIOPH BIOM, V36, P107, DOI 10.1146/annurev.biophys.36.040306.132643; Attard GS, 2000, P NATL ACAD SCI USA, V97, P9032, DOI 10.1073/pnas.160260697; Balla T, 2013, PHYSIOL REV, V93, P1019, DOI 10.1152/physrev.00028.2012; Besprozvannaya M, 2018, ELIFE, V7, DOI 10.7554/eLife.31019; Bohnert M, 2018, NAT REV MOL CELL BIO, V19, P483, DOI 10.1038/s41580-018-0022-1; Bone LN, 2017, MOL BIOL CELL, V28, P161, DOI 10.1091/mbc.E16-09-0668; Brown MF, 2012, BIOCHEMISTRY-US, V51, P9782, DOI 10.1021/bi301332v; Cantor RS, 1997, BIOCHEMISTRY-US, V36, P2339, DOI 10.1021/bi9627323; Cho H, 2006, MOL CELLS, V22, P97; Colotto A, 1996, BIOCHEMISTRY-US, V35, P980, DOI 10.1021/bi951991+; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; D'Souza K, 2012, J MOL BIOL, V416, P619, DOI 10.1016/j.jmb.2012.01.008; de Turco EBR, 2001, P NATL ACAD SCI USA, V98, P4740, DOI 10.1073/pnas.081536298; Decaffmeyer M, 2008, J MOL BIOL, V383, P797, DOI 10.1016/j.jmb.2008.08.076; Demurtas D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9915; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Ding W, 2015, J PHYS CHEM B, V119, P15263, DOI 10.1021/acs.jpcb.5b06604; Doignon F, 2016, MOL CELL BIOL, V36, P765, DOI 10.1128/MCB.00843-15; DUZGUNES N, 1983, BIOCHIM BIOPHYS ACTA, V732, P289, DOI 10.1016/0005-2736(83)90214-6; Epand RM, 2007, METHOD ENZYMOL, V434, P293, DOI 10.1016/S0076-6879(07)34016-0; Fuhrmans M, 2009, J AM CHEM SOC, V131, P9166, DOI 10.1021/ja903224q; Goni FM, 1999, PROG LIPID RES, V38, P1, DOI 10.1016/S0163-7827(98)00021-6; Graber ZT, 2017, PHYS CHEM CHEM PHYS, V19, P15285, DOI 10.1039/c7cp00718c; Haider A, 2018, DEV CELL, V45, P481, DOI 10.1016/j.devcel.2018.04.012; Hozumi Y, 2017, CELL TISSUE RES, V368, P441, DOI 10.1007/s00441-017-2579-y; Hozumi Y, 2015, CELL TISSUE RES, V362, P295, DOI 10.1007/s00441-015-2199-3; Iversen L, 2015, NAT CHEM BIOL, V11, P822, DOI 10.1038/nchembio.1941; Jarsch IK, 2016, J CELL BIOL, V214, P375, DOI 10.1083/jcb.201604003; Jennings W, 2017, BIOCHEMISTRY-US, V56, P1337, DOI 10.1021/acs.biochem.6b01193; Khondker A, 2018, ACS INFECT DIS, V4, P926, DOI 10.1021/acsinfecdis.7b00156; Kimura T, 2016, PROG LIPID RES, V62, P75, DOI 10.1016/j.plipres.2016.02.001; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kobayashi N, 2007, EUR J CELL BIOL, V86, P433, DOI 10.1016/j.ejcb.2007.05.002; Kollmitzer B, 2013, SOFT MATTER, V9, P10877, DOI 10.1039/c3sm51829a; Lees JA, 2017, SCIENCE, V355, DOI 10.1126/science.aah6171; Li MQ, 2017, BBA-BIOENERGETICS, V1858, P763, DOI 10.1016/j.bbabio.2017.06.003; Luzzati V, 1997, CURR OPIN STRUC BIOL, V7, P661, DOI 10.1016/S0959-440X(97)80075-9; Marsh D, 2007, BIOPHYS J, V93, P3884, DOI 10.1529/biophysj.107.107938; McMahon HT, 2005, NATURE, V438, P590, DOI 10.1038/nature04396; Milne SB, 2008, BIOCHEMISTRY-US, V47, P9372, DOI 10.1021/bi800492c; Mujalli A, 2018, BBA-MOL CELL BIOL L, V1863, P1121, DOI 10.1016/j.bbalip.2018.06.009; Natalini PM, 2013, EXP EYE RES, V112, P139, DOI 10.1016/j.exer.2013.04.012; NIEVA JL, 1995, FEBS LETT, V368, P143, DOI 10.1016/0014-5793(95)00631-I; Phillips R, 2009, NATURE, V459, P379, DOI 10.1038/nature08147; RAND RP, 1985, BIOPHYS J, V47, P483, DOI 10.1016/S0006-3495(85)83941-2; Rappolt M, 2003, BIOPHYS J, V84, P3111, DOI 10.1016/S0006-3495(03)70036-8; Renne MF, 2018, FEBS LETT, V592, P1330, DOI 10.1002/1873-3468.12944; Rohacs T, 1999, J BIOL CHEM, V274, P36065, DOI 10.1074/jbc.274.51.36065; Saheki Y, 2017, ANNU REV BIOCHEM, V86, P659, DOI 10.1146/annurev-biochem-061516-044932; Salditt T, 2016, SEMIN CELL DEV BIOL, V60, P65, DOI 10.1016/j.semcdb.2016.06.014; Salvador-Gallego R, 2017, CELL, V171, P1224, DOI 10.1016/j.cell.2017.11.005; Sato Y, 2016, BBA-PROTEINS PROTEOM, V1864, P1170, DOI 10.1016/j.bbapap.2016.06.012; Schlame M, 2012, NAT CHEM BIOL, V8, P862, DOI 10.1038/NCHEMBIO.1064; Shai N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03957-8; Shulga YV, 2011, J MOL BIOL, V409, P101, DOI 10.1016/j.jmb.2011.03.071; Soubias O, 2010, BIOPHYS J, V99, P817, DOI 10.1016/j.bpj.2010.04.068; Stefan CJ, 2013, CURR OPIN CELL BIOL, V25, P434, DOI 10.1016/j.ceb.2013.02.020; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; Tyler AII, 2015, SOFT MATTER, V11, P3279, DOI 10.1039/c5sm00311c; van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330; Xie S., 2015, CELL LOGIST, V5, DOI [10.1080/21592799.2015.1078431, DOI 10.1080/21592799.2015.1078431]; Yao HW, 2015, P NATL ACAD SCI USA, V112, P10926, DOI 10.1073/pnas.1501430112; Zimmerberg J, 2006, NAT REV MOL CELL BIO, V7, P9, DOI 10.1038/nrm1784	65	30	31	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 16	2018	293	46					17780	17791		10.1074/jbc.RA118.005293	http://dx.doi.org/10.1074/jbc.RA118.005293			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA6SG	30237168	Green Published, hybrid			2023-01-03	WOS:000450409500010
J	Peter, J; Tran, US; Michalski, M; Moser, G				Peter, Johannes; Tran, Ulrich S.; Michalski, Maria; Moser, Gabriele			The structure of resilience in irritable bowel syndrome and its improvement through hypnotherapy: Cross-sectional and prospective longitudinal data	PLOS ONE			English	Article							GUT-DIRECTED HYPNOTHERAPY; QUALITY-OF-LIFE; EMOTION REGULATION; SELF-EFFICACY; STRESS; HYPNOSIS; HEALTH; SCALE; PAIN; NEUROBIOLOGY	Background Resilience refers to a class of variables that are highly relevant to wellbeing and coping with stress, trauma, and chronic adversity. Despite its significance for health, resilience suffers from poor conceptual integration. Irritable bowel syndrome (IBS) is a functional disorder with altered psychological stress reactivity and a brain-gut-microbiota axis, which causes high levels of chronic strain. Gut-directed Hypnotherapy (GHT) is a standardized treatment for IBS aimed at improving resilience. An improvement of resilience as a result of GHT has been hypothesized but requires further investigation. The aims of the study were to validate the construct and develop an integrational measure of various resilience domains by dimensional reduction, and to investigate changes in resilience in IBS patients after GHT. Method A total of N= 74 gastroenterology outpatients with IBS (Rome III criteria) were examined in 7 resilience domains, quality of life, psychological distress and symptom severity. Of these, n = 53 participated in 7 to 10 G HT group sessions (Manchester protocol). Post-treatment examinations were performed on average 10 months after last G HT session. Results Resilience factors proved to be unidimensional in the total sample. Greater resilience (composite score of resilience domains) and quality of life, and lower symptom severity and psychological distress were found after treatment (n = 16). Similar differences were present in cross-sectional comparisons of n = 37 treated vs. n = 37 untreated patients. Conclusion Resilience factors share a common psychological dimension and are functionally connected. The absence of maladaptive behaviours contributes to resilience. Improvements in resilience after hypnotherapy with parallel increases in quality of life and reduced psychological distress and symptom severity were observed. Independent replications with larger sample sizes and randomized controlled trials are needed.	[Peter, Johannes; Michalski, Maria; Moser, Gabriele] Med Univ Vienna, Gastroenterol & Hepatol Div, Dept Internal Med 3, Vienna, Austria; [Tran, Ulrich S.] Univ Vienna, Sch Psychol, Dept Basic Psychol Res & Res Methods, Vienna, Austria	Medical University of Vienna; University of Vienna	Tran, US (corresponding author), Univ Vienna, Sch Psychol, Dept Basic Psychol Res & Res Methods, Vienna, Austria.	ulrich.tran@univie.ac.at		Tran, Ulrich/0000-0002-6589-3167	2014 Marianne Ringler Award for research in psychotherapy and psychosomatics	2014 Marianne Ringler Award for research in psychotherapy and psychosomatics	The study was supported by the 2014 Marianne Ringler Award for research in psychotherapy and psychosomatics, www.marianneringlerpreis.eu, to JP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aldinger M, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0210-2; Almedom AM, 2005, J LOSS TRAUMA, V10, P253, DOI 10.1080/15325020590928216; ANTONOVSKY A, 1993, SOC SCI MED, V36, P725, DOI 10.1016/0277-9536(93)90033-Z; Ben-Ezra M, 2015, ISR J PSYCHIATR REL, V52, P54; Betz C, 2013, Z GASTROENTEROL, V51, P1171, DOI 10.1055/s-0033-1335260; Bryant RA, 2007, J CONSULT CLIN PSYCH, V75, P812, DOI 10.1037/0022-006X.75.5.812; Bryant-Davis T, 2013, AM PSYCHOL, V68, P675, DOI 10.1037/a0034380; Burns AB, 2008, PERS INDIV DIFFER, V44, P360, DOI 10.1016/j.paid.2007.08.015; Canavan C, 2014, ALIMENT PHARM THER, V40, P1023, DOI 10.1111/apt.12938; Carretero-Dios H, 2011, J RES PERS, V45, P153, DOI 10.1016/j.jrp.2010.12.007; Carver CS, 2014, TRENDS COGN SCI, V18, P293, DOI 10.1016/j.tics.2014.02.003; Charuvastra A, 2008, ANNU REV PSYCHOL, V59, P301, DOI 10.1146/annurev.psych.58.110405.085650; Davydov DM, 2010, CLIN PSYCHOL REV, V30, P479, DOI 10.1016/j.cpr.2010.03.003; Edwards KR, 2014, EUR J PSYCHOL, V10, P505, DOI 10.5964/ejop.v10i3.759; Ford AC, 2014, AM J GASTROENTEROL, V109, P1350, DOI 10.1038/ajg.2014.148; Frank L, 2002, CLIN THER, V24, P675, DOI 10.1016/S0149-2918(02)85143-8; Fydrich T., 2009, Z MEDIZINISCHE PSYCH, V18, P43; Gonsalkorale WM, 2006, INT J CLIN EXP HYP, V54, P27, DOI 10.1080/00207140500323030; Gonsalkorale WM, 2004, J PSYCHOSOM RES, V56, P271, DOI 10.1016/S0022-3999(03)00076-X; Gorgen SM, 2015, Z PSYCHIAT PSYCHOL P; Hegberg NJ, 2015, MENT HEALTH PHYS ACT, V8, P1, DOI 10.1016/j.mhpa.2014.10.001; Herrmann-Lingen C., 2011, HOSP ANXIETY DEPRESS; Hinz A, 2006, DIAGNOSTICA, V52, P26, DOI 10.1026/0012-1924.52.1.26; Hinz A, 2011, J PSYCHOSOM RES, V71, P74, DOI 10.1016/j.jpsychores.2011.01.005; Iani L, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/1477-7525-12-84; Jerusalem M., 1999, SKALEN ERFASSUNG LEH; Kalisch R, 2015, BEHAV BRAIN SCI, V38, DOI 10.1017/S0140525X1400082X; Karreman A, 2012, PERS INDIV DIFFER, V53, P821, DOI 10.1016/j.paid.2012.06.014; Kennedy PJ, 2017, NEUROPHARMACOLOGY, V112, P399, DOI 10.1016/j.neuropharm.2016.07.002; Kennedy PJ, 2014, PSYCHOL MED, V44, P3123, DOI 10.1017/S003329171400052X; Kennedy P, 2016, REHABIL PSYCHOL, V61, P92, DOI 10.1037/rep0000066; Kennedy PJ, 2012, NEUROSCI BIOBEHAV R, V36, P310, DOI 10.1016/j.neubiorev.2011.07.001; Kleiman EM, 2017, COGNITION EMOTION, V31, P269, DOI 10.1080/02699931.2015.1108284; Koenen KC, 2009, AM J PSYCHIAT, V166, P50, DOI 10.1176/appi.ajp.2008.08030343; Lea R, 2003, ALIMENT PHARM THER, V17, P635, DOI 10.1046/j.1365-2036.2003.01486.x; Ledoux JE, 2001, AM J PSYCHIAT, V158, P1953, DOI 10.1176/appi.ajp.158.12.1953; Leppin AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111420; Lindfors P, 2013, NEUROGASTROENT MOTIL, V25, P169, DOI 10.1111/nmo.12022; LITT MD, 1988, J PERS SOC PSYCHOL, V54, P149, DOI 10.1037/0022-3514.54.1.149; Loch N, 2011, Z KL PSYCH PSYCHOTH, V40, P94, DOI 10.1026/1616-3443/a000079; Lowen MBO, 2013, ALIMENT PHARM THER, V37, P1184, DOI 10.1111/apt.12319; Mawdsley JE, 2008, AM J GASTROENTEROL, V103, P1460, DOI 10.1111/j.1572-0241.2008.01845.x; Mayer EA, 2014, GASTROENTEROLOGY, V146, P1500, DOI 10.1053/j.gastro.2014.02.037; McEwen BS, 2015, NEUROBIOL STRESS, V1, P1, DOI 10.1016/j.ynstr.2014.09.001; Moffitt TE, 2011, P NATL ACAD SCI USA, V108, P2693, DOI 10.1073/pnas.1010076108; Moloney RD, 2016, CNS NEUROSCI THER, V22, P102, DOI 10.1111/cns.12490; Moser G, 2013, AM J GASTROENTEROL, V108, P602, DOI 10.1038/ajg.2013.19; Olden Kevin W., 2003, Curr Treat Options Gastroenterol, V6, P311, DOI 10.1007/s11938-003-0023-8; Osorio C, 2017, BEHAV MED, V43, P307, DOI 10.1080/08964289.2016.1170661; Palsson OS, 2002, DIGEST DIS SCI, V47, P2605, DOI 10.1023/A:1020545017390; Park SH, 2018, NEUROGASTROENT MOTIL, V30, DOI 10.1111/nmo.13155; Penedo FJ, 2005, CURR OPIN PSYCHIATR, V18, P189, DOI 10.1097/00001504-200503000-00013; Peters SL, 2015, ALIMENT PHARM THER, V41, P1104, DOI 10.1111/apt.13202; Porcelli P, 2017, COMPR PSYCHIAT, V73, P127, DOI 10.1016/j.comppsych.2016.11.010; Pulvers K, 2013, CURR PAIN HEADACHE R, V17, DOI 10.1007/s11916-013-0330-2; Rammstedt B, 2005, DIAGNOSTICA, V51, P195, DOI 10.1026/0012-1924.51.4.195; Richardson GE, 2002, J CLIN PSYCHOL, V58, P307, DOI 10.1002/jclp.10020; Ruch W, 1996, HUMOR, V9, P303, DOI 10.1515/humr.1996.9.3-4.303; Ryff CD, 2014, PSYCHOTHER PSYCHOSOM, V83, P10, DOI 10.1159/000353263; Sarubin N, 2015, Z GESUNDHEITSPSYCHOL, V23, P112, DOI 10.1026/0943-8149/a000142; Schaefert R, 2014, PSYCHOSOM MED, V76, P389, DOI 10.1097/PSY.0000000000000039; Schwarzer R., 2014, SELF EFFICACY THOUGH; Sheppes G, 2015, ANNU REV CLIN PSYCHO, V11, P379, DOI 10.1146/annurev-clinpsy-032814-112739; Spiegel B, 2009, GASTROENTEROLOGY, V137, P1944, DOI 10.1053/j.gastro.2009.08.047; Spiller R, 2007, GUT, V56, P1770, DOI 10.1136/gut.2007.119446; Stahl JE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140212; Stanculete MF, 2015, J GASTROINTEST LIVER, V24, P159, DOI 10.15403/jgld.2014.1121.242.strt; Stewart DE, 2011, PSYCHOSOMATICS, V52, P199, DOI 10.1016/j.psym.2011.01.036; Thompson RW, 2011, TRAUMA VIOLENCE ABUS, V12, P220, DOI 10.1177/1524838011416375; Tran US, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-47; Nguyen V, 2016, GASTROENTEROLOGY, V150, pS731, DOI 10.1016/S0016-5085(16)32487-8; Vlieger AM, 2012, AM J GASTROENTEROL, V107, P627, DOI 10.1038/ajg.2011.487; Weinland SR, 2010, AM J GASTROENTEROL, V105, P1397, DOI 10.1038/ajg.2009.748; Whitehead WE, 2002, GASTROENTEROLOGY, V122, P1140, DOI 10.1053/gast.2002.32392; Whorwell PJ, 2008, J PSYCHOSOM RES, V64, P621, DOI 10.1016/j.jpsychores.2008.02.022; Windle G, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-8; Wu G, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00010; ZWICK WR, 1986, PSYCHOL BULL, V99, P432, DOI 10.1037/0033-2909.99.3.432	78	6	6	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2018	13	11							e0202538	10.1371/journal.pone.0202538	http://dx.doi.org/10.1371/journal.pone.0202538			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HA0PF	30419026	Green Published, Green Submitted, gold			2023-01-03	WOS:000449909200001
J	Elliott, SM; Erickson, ML; Krall, AL; Adams, BA				Elliott, Sarah M.; Erickson, Melinda L.; Krall, Aliesha L.; Adams, Byron A.			Concentrations of pharmaceuticals and other micropollutants in groundwater downgradient from large on-site wastewater discharges	PLOS ONE			English	Article							ORGANIC CONTAMINANTS; TREATMENT SYSTEMS; SEPTIC SYSTEMS; DOMESTIC WELLS; NEW-YORK; FATE; EFFLUENT; CHEMICALS; REMOVAL	Large subsurface treatment systems (LSTS) and rapid infiltration basins (RIB) are preferred onsite wastewater treatments compared to direct discharge of treated wastewater to streams and adjacent facilities. Discharge of these wastewater treatments may result in contaminant loading to aquifers that also serve as drinking water sources downgradient from the discharge site. Until recently, few studies have characterized the contribution of micropollutants (e.g. pharmaceuticals, fragrances, flame retardants, etc.) to receiving aquifers. We conducted a pilot project to characterize the occurrence of micropollutants in groundwater downgradient from 7 on-site treatment systems in Minnesota, USA: 5 community LSTS and 2 municipal RIB. One downgradient monitoring well was sampled three times at each facility over one year. Of 223 micropollutants analyzed, 35 were detected. Total sample concentrations ranged from 90 to 4,039 ng/L. Sulfamethoxazole (antibiotic) was detected in all samples at concentrations from 7 to 965 ng/L. Other pharmaceuticals (0.12-1,000 ng/L), organophosphorus flame retardants (10-500 ng/L), and other anthropogenic chemicals (4-775 ng/L) were also detected. The numbers and concentrations of micropollutants detected were inversely related to dissolved oxygen and depth to water. Ratios of pharmaceutical concentrations to human-health screening values were <0.10 for most samples. However, concentrations of carbamazepine and sulfamethoxazole exceeded screening values at two sites. Study results illustrate that large on-site wastewater systems designed to discharge to permeable soil or shallow groundwater effectively deliver pharmaceuticals and other micropollutants to groundwater aquifers and could contribute micropollutants to drinking water via water supply wells.	[Elliott, Sarah M.; Erickson, Melinda L.; Krall, Aliesha L.] US Geol Survey, Mounds View, MN 55112 USA; [Adams, Byron A.] Minnesota Pollut Control Agcy, St Paul, MN USA	United States Department of the Interior; United States Geological Survey	Elliott, SM (corresponding author), US Geol Survey, Mounds View, MN 55112 USA.	selliott@usgs.gov		Diekoff, Aliesha/0000-0003-2521-5043	State of Minnesota Clean Water fund via the Minnesota Pollution Control Agency; USGS Cooperative Matching Fund	State of Minnesota Clean Water fund via the Minnesota Pollution Control Agency; USGS Cooperative Matching Fund	Funding for this study was provided by the State of Minnesota Clean Water fund via the Minnesota Pollution Control Agency and the USGS Cooperative Matching Fund.; Funding for this study was provided by the State of Minnesota Clean Water Fund via the Minnesota Pollution Control Agency and the USGS Cooperative Matching Fund. We would like to thank the facility owners and operators for their cooperation and participation in this study. We thank our colleague Patrick Phillips, whose comprehensive review greatly improved this manuscript. Any use of trade, firm, or product names is for descriptive purposes only and does not imply endorsement by the U.S. Government.	[Anonymous], 2007, 20075021 US GEOL SUR, DOI DOI 10.3133/SIR20075021; [Anonymous], 2000, 4500NO3F SM; Barber LB, 2009, ENVIRON SCI TECHNOL, V43, P4843, DOI 10.1021/es803292v; Barnes KK, 2008, SCI TOTAL ENVIRON, V402, P192, DOI 10.1016/j.scitotenv.2008.04.028; Blum KM, 2017, SCI TOTAL ENVIRON, V575, P265, DOI 10.1016/j.scitotenv.2016.09.135; Brausch JM, 2011, CHEMOSPHERE, V82, P1518, DOI 10.1016/j.chemosphere.2010.11.018; Bremer JE, 2012, HYDROL EARTH SYST SC, V16, P2453, DOI 10.5194/hess-16-2453-2012; Byron Adams, 2011, BEST MANAGEMENT PRAC; Carrara C, 2008, ENVIRON SCI TECHNOL, V42, P2805, DOI 10.1021/es070344q; Conn KE, 2006, ENVIRON SCI TECHNOL, V40, P7358, DOI 10.1021/es0605117; Conn KE, 2010, ENVIRON ENG SCI, V27, P347, DOI 10.1089/ees.2009.0364; Elliott SM, 2016, CHEM EMERGING CONCER, DOI [10.5066/F7M906RN, DOI 10.5066/F7M906RN]; Valdes ME, 2014, SCI TOTAL ENVIRON, V472, P389, DOI 10.1016/j.scitotenv.2013.10.124; Fairbairn DJ, 2016, SCI TOTAL ENVIRON, V551, P605, DOI 10.1016/j.scitotenv.2016.02.056; Ferrell GM, 2014, J ENVIRON HEALTH, V76, P18; Ferrey M, 2011, WASTEWATER TREATMENT; Fisher IJ, 2016, MAR POLLUT BULL, V107, P509, DOI 10.1016/j.marpolbul.2016.04.038; Foreman W.T., 2012, BOOK B, V5, DOI DOI 10.3133/TM5B9; Furlong E.T., 2014, US GEOLOGICAL SURVEY, V5, DOI [10.3133/tm5B10, DOI 10.3133/TM5B10]; Garcia SN, 2013, CHEMOSPHERE, V92, P38, DOI 10.1016/j.chemosphere.2013.03.007; Godfrey E, 2007, GROUND WATER, V45, P263, DOI 10.1111/j.1745-6584.2006.00288.x; Hinkle S. R., 2005, 20055055 US GEOL SUR; Hobbs H. C., 1982, S 01 GEOLOGIC MAP MI; Lapworth DJ, 2012, ENVIRON POLLUT, V163, P287, DOI 10.1016/j.envpol.2011.12.034; Li WC, 2014, ENVIRON POLLUT, V187, P193, DOI 10.1016/j.envpol.2014.01.015; Minnesota Department of Health, 2017, MINN WELL IND MWI; Phillips PJ, 2015, SCI TOTAL ENVIRON, V512, P43, DOI 10.1016/j.scitotenv.2014.12.067; Schaider LA, 2017, ENVIRON SCI TECHNOL, V51, P7304, DOI 10.1021/acs.est.6b04778; Schaider LA, 2016, SCI TOTAL ENVIRON, V547, P470, DOI 10.1016/j.scitotenv.2015.12.081; Diaz-Cruz MS, 2008, CHEMOSPHERE, V72, P333, DOI 10.1016/j.chemosphere.2008.02.031; Standard Methods Online, 1997, 4500FC SM; Subedi B, 2015, WATER RES, V72, P28, DOI 10.1016/j.watres.2014.10.049; Suchomel A., 2015, PHARM WATER SCREENIN; Swartz CH, 2006, ENVIRON SCI TECHNOL, V40, P4894, DOI 10.1021/es052595+; United States Environmental Protection Agency (USEPA), 1994, 2007 USEPA; United States Environmental Protection Agency (USEPA), 1993, 3501 USEPA; USEPA, 2013, ANN REP 2013 DEC WAS; USEPA, 1999, CLASS 5 UND INJ CONT, V16; USEPA, 2012, CAS STUD IND CLUST D; USEPA, 1997, 3001 US EPA; USGS, US GEOLOGICAL SURVEY, V9; Vatovec C, 2016, SCI TOTAL ENVIRON, V572, P906, DOI 10.1016/j.scitotenv.2016.07.199; Verstraeten IM, 2005, GROUND WATER MONIT R, V25, P107, DOI 10.1111/j.1745-6592.2005.0015.x; Zaugg S.D., 2006, DETERMINATION WASTEW, DOI 10.3133/tm5B4	44	20	20	5	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2018	13	11							e0206004	10.1371/journal.pone.0206004	http://dx.doi.org/10.1371/journal.pone.0206004			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ4PQ	30403721	Green Published, gold, Green Submitted			2023-01-03	WOS:000449379500045
J	Laborde, ND; Leslie, J; Krogstad, E; Morar, N; Mutero, P; Etima, J; Woodrow, K; van der Straten, A				Laborde, Nicole D.; Leslie, Jonah; Krogstad, Emily; Morar, Neetha; Mutero, Prisca; Etima, Juliane; Woodrow, Kim; van der Straten, Ariane			Perceptions of the "Fabric" - An exploratory study of a novel multi-purpose technology among women in Sub Saharan Africa	PLOS ONE			English	Article							CLINICAL-TRIAL; HIV PREVENTION; DRUG-DELIVERY; ACCEPTABILITY; ADHERENCE; TENOFOVIR; FIBERS; CONDOM	Background HIV and pregnancy prevention are dual health priorities for women, and particularly in sub-Saharan Africa. Drug-eluting fibers offer a dosage form that combines HIV prevention and contraception, but early understanding of end-user perspectives is critical to avoid misalignment between products being developed and preferred product attributes. Methods Focus group discussions (FGDs) were conducted in South Africa, Uganda and Zimbabwe, among 55 women who had used vaginal products in previous trials. Participants were given the opportunity to feel a sample of electrospun nanofiber (the fabric), see how it dissolves, and give feedback on shape, size and other attributes. Women were also asked to compare the fabric to vaginal gel and film. Results Three key themes regarding the acceptability of the fabric emerged: 1) look and feel of the product undissolved vs. undissolved, 2) expected effect on sex, and 3) convenience and ease of use. Upon being presented with the fabric, women were initially distrustful, seeing it as undesirable for vaginal insertion. Women generally approved of the product once they saw it dissolve. However, they stressed the importance of the product not interfering with sex by altering the vaginal environment. Women also reacted favorably to the perceived convenience of the fabric, particularly with regards to storage and transport, perceived ease of insertion and use, and dosing regimen. Conclusion Multipurpose prevention technologies, and nanofibers in particular, should be developed with an eye to minimizing impact on sex while maximizing convenience, and presented in such a way as to emphasize non-abrasiveness and ease of dissolution.	[Laborde, Nicole D.; Leslie, Jonah; Krogstad, Emily; van der Straten, Ariane] RTI Int, Womens Global Hlth Imperat, San Francisco, CA 94104 USA; [Krogstad, Emily; Woodrow, Kim] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Morar, Neetha] South Africa Med Res Council, Durban, South Africa; [Mutero, Prisca] UZ UCSF Collaborat Res Programme, Harare, Zimbabwe; [Etima, Juliane] Makerere Univ Johns Hopkins Univ Res Unit, Kampala, Uganda; [van der Straten, Ariane] Univ Calif San Francisco, Dept Med, Ctr AIDS Prevent Studies, San Francisco, CA 94122 USA	Research Triangle Institute; University of Washington; University of Washington Seattle; University of Zimbabwe; University of California System; University of California San Francisco	van der Straten, A (corresponding author), RTI Int, Womens Global Hlth Imperat, San Francisco, CA 94104 USA.; van der Straten, A (corresponding author), Univ Calif San Francisco, Dept Med, Ctr AIDS Prevent Studies, San Francisco, CA 94122 USA.	ariane@rti.org		Mudzingwa, Emily/0000-0003-2736-8350; van der Straten, Ariane/0000-0001-8536-648X	Bill and Melinda Gates Foundation [OPP1110945]; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH062246] Funding Source: NIH RePORTER	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This study was funded by the Bill and Melinda Gates Foundation (OPP1110945, P.I. Kim Woodrow). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2018, DED VERS 7 5 WEB APP; Ariane van der Straten AM, 2018, MTN ANN M WASH DC; Ball C, 2015, DRUG DELIVERY AND DEVELOPMENT OF ANTI-HIV MICROBICIDES, P459; Ball C, 2014, ANTIMICROB AGENTS CH, V58, P4855, DOI 10.1128/AAC.02564-14; Ballard C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037410; Blakney AK, 2014, INT J NANOMED, V9, P2967, DOI 10.2147/IJN.S61664; Blakney AK, 2013, ANTIVIR RES, V100, pS9, DOI 10.1016/j.antiviral.2013.09.022; Brady M, 2014, BJOG-INT J OBSTET GY, V121, P70, DOI 10.1111/1471-0528.12844; Chimbiri AM, 2007, SOC SCI MED, V64, P1102, DOI 10.1016/j.socscimed.2006.10.012; Corneli A, 2016, JAIDS-J ACQ IMM DEF, V71, P452, DOI 10.1097/QAI.0000000000000880; Fernandez-Romero JA, 2015, TRENDS MICROBIOL, V23, P429, DOI 10.1016/j.tim.2015.02.006; HIV/ AIDS JUNPo, 2014, GAP REP GEN; Krogstad EA, 2014, INT J PHARMACEUT, V475, P282, DOI 10.1016/j.ijpharm.2014.08.039; Laborde ND, 2018, AIDS BEHAV, V22, P437, DOI 10.1007/s10461-017-1977-1; Luecke EH, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20875; MacPhail C, 2001, SOC SCI MED, V52, P1613, DOI 10.1016/S0277-9536(00)00272-0; Minnis AM, 2018, AIDS BEHAV, V22, P2662, DOI 10.1007/s10461-018-2078-5; Minnis AM, 2013, AIDS BEHAV, V17, P737, DOI 10.1007/s10461-012-0333-8; Morrow KM, 2014, ARCH SEX BEHAV, V43, P1459, DOI 10.1007/s10508-013-0235-5; Romano JW, 2014, BJOG-INT J OBSTET GY, V121, P15, DOI 10.1111/1471-0528.12850; Sedgh G AL, 2016, UNMET NEED CONTRACEP; Straten Avd, 2016, HIV PREP FORMULATION; Tolley EE, 2013, ANTIVIR RES, V100, pS54, DOI 10.1016/j.antiviral.2013.09.029; van der Straten A, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25094; van der Straten A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089118; Weinrib R, 2018, AIDS BEHAV, V22, P133, DOI 10.1007/s10461-017-1911-6; Woodsong C, 2015, ADV DRUG DELIV REV, DOI [10.1016/j, DOI 10.1016/J]	27	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2018	13	10							e0204821	10.1371/journal.pone.0204821	http://dx.doi.org/10.1371/journal.pone.0204821			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GY7VH	30379839	Green Published, Green Submitted, gold			2023-01-03	WOS:000448823700020
J	Dosso, JA; Kingstone, A				Dosso, Jill A.; Kingstone, Alan			Social modulation of object-directed but not image-directed actions	PLOS ONE			English	Article							PERIPERSONAL SPACE; REAL; ATTENTION; BRAIN; INFORMATION; INTENTIONS; PERCEPTION; MEMORY; 2D	There has recently been an increased research focus on the influence of social factors on human cognition, attention, and action. While this represents an important step towards an ecologically valid description of real-world behaviour, this work has primarily examined dyads interacting with virtual stimuli i.e. on-screen images of objects. Though differences between actions to images and real items are known, their relative sensitivity to social factors is largely unknown. We argue that because images and real items elicit different neural representations, patterns of attention, and hand actions, a direct comparison between the magnitude of social effects while interacting with images and real objects is demanded. We examined patterns of reaching as individuals performed a shape-matching game. Images and real objects were used as stimuli, and social context was manipulated via the proximity of an observer. We found that social context interacted with stimulus type to modulate behaviour. Specifically, there was a delay in reaching for distant objects when a participant was facing another individual but this social effect only occurred when the stimuli were real objects. Our data suggest that even when images and real objects are arranged to share the affordance of reachability, they differ in their sensitivity to social influences. Therefore, the measurement of social effects using on-screen stimuli may poorly predict the social effects of actions directed towards real objects. Accordingly, generalizations between these two domains should be treated with caution.	[Dosso, Jill A.; Kingstone, Alan] Univ British Columbia, Dept Psychol, Vancouver, BC, Canada	University of British Columbia	Dosso, JA (corresponding author), Univ British Columbia, Dept Psychol, Vancouver, BC, Canada.	jill.dosso@psych.ubc.ca		Dosso, Jill/0000-0003-1570-9496	Natural Sciences and Engineering Research Council of Canada (NSERC) [RGPIN-2016-04319]; Social Sciences and Humanities Research Council (SSHRC) [435-2013-2200]	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Social Sciences and Humanities Research Council (SSHRC)(Social Sciences and Humanities Research Council of Canada (SSHRC))	This work was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant (RGPIN-2016-04319) to AK., http://www.nserc-crsng.gc.ca/index_eng.asp; Social Sciences and Humanities Research Council (SSHRC) Insight Grant to AK (435-2013-2200), http://www.sshrc-crsh.gc.ca/home-accueil-eng.aspx.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ansuini C, 2015, NEUROSCIENTIST, V21, P126, DOI 10.1177/1073858414533827; Ansuini C, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00815; Becchio C, 2008, CONSCIOUS COGN, V17, P557, DOI 10.1016/j.concog.2007.03.003; Becchio C, 2010, CURR DIR PSYCHOL SCI, V19, P183, DOI 10.1177/0963721410370131; Brennan AA, 2015, PSYCHON B REV, V22, P1076, DOI 10.3758/s13423-014-0765-4; Brodeur MB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010773; Bushong B, 2010, AM ECON REV, V100, P1556, DOI 10.1257/aer.100.4.1556; Chainay H, 2001, COGNITIVE NEUROPSYCH, V18, P175, DOI 10.1080/02643290042000062; Chen J, 2015, PSYCHOL SCI, V26, P58, DOI 10.1177/0956797614556776; Clery J, 2015, NEUROPSYCHOLOGIA, V70, P313, DOI 10.1016/j.neuropsychologia.2014.10.022; DAVIDOFF J, 1994, BRAIN COGNITION, V24, P1, DOI 10.1006/brcg.1994.1001; di Pellegrino G, 2015, NEUROPSYCHOLOGIA, V66, P126, DOI 10.1016/j.neuropsychologia.2014.11.011; Eskenazi T, 2013, Q J EXP PSYCHOL, V66, P1026, DOI 10.1080/17470218.2012.725058; Ferri F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015855; Freud E, 2018, CORTEX, V98, P34, DOI 10.1016/j.cortex.2017.02.020; Freud E, 2015, PSYCHON B REV, V22, P1377, DOI 10.3758/s13423-015-0803-x; Gallivan JP, 2011, J NEUROSCI, V31, P9599, DOI 10.1523/JNEUROSCI.0080-11.2011; Georgiou I, 2007, COGNITION, V102, P415, DOI 10.1016/j.cognition.2006.01.008; Gerhard TM, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00827; Gianelli C, 2013, PSYCHOL RES-PSYCH FO, V77, P40, DOI 10.1007/s00426-011-0401-0; Gobel MS, 2015, COGNITION, V136, P359, DOI 10.1016/j.cognition.2014.11.040; Gomez MA, 2018, PSYCHOL SCI, V29, P206, DOI 10.1177/0956797617730599; Graziano MSA, 1997, J NEUROPHYSIOL, V77, P2268, DOI 10.1152/jn.1997.77.5.2268; Hayward DA, 2017, CAN J EXP PSYCHOL, V71, P212, DOI 10.1037/cep0000117; HENRY FM, 1960, RES QUART, V31, P448, DOI 10.1080/10671188.1960.10762052; Holmes SA, 2013, BRAIN COGNITION, V82, P18, DOI 10.1016/j.bandc.2013.02.005; Hosang S, 2016, EXP BRAIN RES, V234, P945, DOI 10.1007/s00221-015-4521-4; Inkpen KM, 2002, COLLABORATION TABLET; Karl JM, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00208; Karlinsky A., 2017, P 39 ANN C COGN SCI, P2377; Kirk D., 2012, P SIGCHI C HUM FACT, P159, DOI DOI 10.1145/2207676.2207699; Laidlaw KEW, 2011, P NATL ACAD SCI USA, V108, P5548, DOI 10.1073/pnas.1017022108; LATANE B, 1981, AM PSYCHOL, V36, P343, DOI 10.1037/0003-066X.36.4.343; Maister L, 2015, NEUROPSYCHOLOGIA, V70, P455, DOI 10.1016/j.neuropsychologia.2014.10.027; Manera V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054949; Manera V, 2011, EXP BRAIN RES, V211, P547, DOI 10.1007/s00221-011-2649-4; Morris M. R., 2004, Computer Supported Cooperative Work Conference Proceedings, P262, DOI 10.1145/1031607.1031648; Muller H, 2013, INT J RES MARK, V30, P304, DOI 10.1016/j.ijresmar.2013.03.001; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Oliva M, 2017, I-PERCEPTION, V8, DOI 10.1177/2041669517692814; Ozana A, 2018, ATTEN PERCEPT PSYCHO, V80, P564, DOI 10.3758/s13414-017-1443-1; Peirce JW, 2007, J NEUROSCI METH, V162, P8, DOI 10.1016/j.jneumeth.2006.11.017; Pellencin E, 2018, CORTEX, V104, P163, DOI 10.1016/j.cortex.2017.08.033; Perani D, 2001, NEUROIMAGE, V14, P749, DOI 10.1006/nimg.2001.0872; Pesquita A, 2016, P NATL ACAD SCI USA, V4-9; Saccone EJ, 2018, ATTEN PERCEPT PSYCHO, V80, P54, DOI 10.3758/s13414-017-1413-7; Sebanz N, 2003, COGNITION, V88, pB11, DOI 10.1016/S0010-0277(03)00043-X; Snow JC, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00837; Snow JC, 2011, SCI REP-UK, V1, DOI 10.1038/srep00130; Squires SD, 2016, EXP BRAIN RES, V234, P963, DOI 10.1007/s00221-015-4518-z; Sun HM, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00443; Szpak A, 2016, COGN NEUROSCI-UK, V7, P45, DOI 10.1080/17588928.2015.1048677; Szpak A, 2015, NEUROPSYCHOLOGIA, V70, P462, DOI 10.1016/j.neuropsychologia.2014.10.008; Teneggi C, 2013, CURR BIOL, V23, P406, DOI 10.1016/j.cub.2013.01.043; Terrenghi L, 2007, CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, VOLS 1 AND 2, P1157; Truong G, 2017, J EXP PSYCHOL HUMAN, V43, P192, DOI 10.1037/xhp0000295; Truong G, 2013, COGN AFFECT BEHAV NE, V13, P803, DOI 10.3758/s13415-013-0174-6; Wahn B, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00669; Whalen T, 2006, P 1 IEEE INT WORK HO, P177, DOI [10.1109/TABLETOP.2006.10, DOI 10.1109/TABLETOP.2006.10]; Wild KS, 2012, J AUTISM DEV DISORD, V42, P1739, DOI 10.1007/s10803-011-1417-4; Yu AB, 2014, J EXP PSYCHOL HUMAN, V40, P1861, DOI 10.1037/a0037397	61	3	3	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2018	13	10							e0205830	10.1371/journal.pone.0205830	http://dx.doi.org/10.1371/journal.pone.0205830			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GX8WQ	30352061	Green Published, Green Submitted, gold			2023-01-03	WOS:000448076200018
J	Gilbert, J; Lovibond, K; Mooney, A; Dudley, J				Gilbert, James; Lovibond, Kate; Mooney, Andrew; Dudley, Jan		Guideline Comm	Renal replacement therapy: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CARE		[Gilbert, James; Lovibond, Kate] Royal Coll Physicians, Natl Guideline Ctr, London, England; [Mooney, Andrew] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England; [Mooney, Andrew] Univ Leeds, Leeds, W Yorkshire, England; [Dudley, Jan] Bristol Royal Hosp Children, Bristol, Avon, England	Royal College of Physicians; University of Leeds; University of Leeds; Bristol Royal Hospital For Children	Gilbert, J (corresponding author), Royal Coll Physicians, Natl Guideline Ctr, London, England.	James.Gilbert@rcplondon.ac.uk	Shroff, Rukshana C/C-7347-2008; Shroff, Rukshana/AAG-5383-2019	Shroff, Rukshana C/0000-0001-8501-1072; Shroff, Rukshana/0000-0001-8501-1072	NICE	NICE	JG and KL are employees of the National Guideline Centre. The guideline discussed in this article was developed by the National Guideline Centre which received funding from NICE. No authors received specific funding to write this summary.	Cooper BA, 2010, NEW ENGL J MED, V363, P609, DOI 10.1056/NEJMoa1000552; Khan SS, 2005, KIDNEY INT, V67, P1038, DOI 10.1111/j.1523-1755.2005.00168.x; Kidney Research UK, 2018, DIAL DEC AID MAK RIG; National Institute for Health and Care Excellence, 2018, REN REPL THER CONS M; NHS, 2018, WAIT LIST KIDN TRANS; Renal Association, 2018, UK REN REG 20 ANN RE; Stack AG, 2003, AM J KIDNEY DIS, V41, P310, DOI 10.1053/ajkd.2003.50038	7	7	9	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 19	2018	363								k4303	10.1136/bmj.k4303	http://dx.doi.org/10.1136/bmj.k4303			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY1FS	30341093				2023-01-03	WOS:000448271300002
J	Dong, X; Yan, LY; Huang, L; Guan, XY; Dong, CH; Tao, HM; Wang, T; Qin, XX; Wan, Q				Dong, Xin; Yan, Lanyun; Huang, Lin; Guan, Xinying; Dong, Changhong; Tao, Huimin; Wang, Teng; Qin, Xiaoxuan; Wan, Qi			Repetitive transcranial magnetic stimulation for the treatment of Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials	PLOS ONE			English	Review							DOUBLE-BLIND	Background Several studies have demonstrated that repetitive transcranial magnetic stimulation (rTMS) may have a beneficial effect in Alzheimer's disease (AD). Nevertheless, the clinical benefit of rTMS for AD remains inconclusive. Objective This systematic review and meta-analysis aimed to evaluate the efficacy and safety of rTMS in AD. Methods We searched PubMed, Embase and Cochrane for randomized controlled trials (RCTs) of rTMS for AD. We calculated pooled estimates of mean difference (MD) with 95% confidence intervals (CI). The protocol was registered at International Prospective Register of Systematic Reviews (PROSPERO) (number CRD42018089990). Results Five RCTs involving 148 participants were included in this review. Compared with sham stimulation, high-frequency rTMS led to a significant improvement in cognition as measured by ADAS-cog (MD =-3.65, 95% CI-5.82 to-1.48, p = 0.001), but not MMSE (MD = 0.49, 95% CI -1.45 to 2.42, p = 0.62). High-frequency rTMS also improved the global impression in comparison to the placebo (MD =-0.79, 95% CI-1.24 to-0.34, p = 0.0006). There was no significant difference in mood (MD =-1.36, 95% CI-3.93 to 1.21, p = 0.30) and functional performance (MD = 0.59, 95% CI-1.21 to 2.38, p = 0.52) between high-frequency rTMS and sham groups. Only one trial included low-frequency rTMS reported no significant improvement in cognition, mood and functional performance. Few mild adverse events were observed in both the rTMS and sham groups. Conclusions RTMS is relatively well tolerated, with some promise for cognitive improvement and global impression in patients with AD. Our findings also indicate the variability between ADAS-cog and MMSE in evaluating global cognitive impairment.	[Dong, Xin; Yan, Lanyun; Huang, Lin; Tao, Huimin; Wang, Teng; Qin, Xiaoxuan; Wan, Qi] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurol, Nanjing, Jiangsu, Peoples R China; [Guan, Xinying] First Peoples Hosp Lianyungang, Dept Special Med, Lianyungang, Jiangsu, Peoples R China; [Dong, Changhong] Xuzhou Med Univ, Dept Clin Med, Xuzhou, Jiangsu, Peoples R China	Nanjing Medical University; Xuzhou Medical University	Wan, Q (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Neurol, Nanjing, Jiangsu, Peoples R China.	qi_wan@126.com		Dong, Xin/0000-0002-5400-1872	National Natural Science Foundation of China [81600970]; Nanjing Medical Science and Technology Development Project [YKK17257]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Nanjing Medical Science and Technology Development Project	This work was supported by the National Natural Science Foundation of China (No. 81600970) and Nanjing Medical Science and Technology Development Project (YKK17257). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed MA, 2012, J NEUROL, V259, P83, DOI 10.1007/s00415-011-6128-4; Alcala-Lozano R, 2018, BRAIN STIMUL, V11, P625, DOI 10.1016/j.brs.2017.12.011; Anand A, 2017, EUR J PHARMACOL, V815, P364, DOI 10.1016/j.ejphar.2017.09.043; Anderkova L, 2015, J ALZHEIMERS DIS, V48, P251, DOI 10.3233/JAD-150067; Balsis S, 2015, CLIN NEUROPSYCHOL, V29, P1002, DOI 10.1080/13854046.2015.1119312; BARKER AT, 1985, LANCET, V1, P1106; Bestmann S, 2004, EUR J NEUROSCI, V19, P1950, DOI 10.1111/j.1460-9568.2004.03277.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475; Cappa SF, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00108; Cotelli M, 2011, J NEUROL NEUROSUR PS, V82, P794, DOI 10.1136/jnnp.2009.197848; Eliasova I, 2014, J NEUROL SCI, V346, P318, DOI 10.1016/j.jns.2014.08.036; Esser SK, 2006, BRAIN RES BULL, V69, P86, DOI 10.1016/j.brainresbull.2005.11.003; Gangitano M, 2002, CLIN NEUROPHYSIOL, V113, P1249, DOI 10.1016/S1388-2457(02)00109-8; Guo Q, 2017, NEUROSCI BULL, V33, P747, DOI 10.1007/s12264-017-0185-3; Hayashi T, 2004, ANN NEUROL, V56, P77, DOI 10.1002/ana.20151; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Iimori T, 2019, PROG NEURO-PSYCHOPH, V88, P31, DOI 10.1016/j.pnpbp.2018.06.014; Khoury R, 2018, THER ADV DRUG SAF, V9, P171, DOI 10.1177/2042098617750555; Koch G, 2018, NEUROIMAGE, V169, P302, DOI 10.1016/j.neuroimage.2017.12.048; Lee J, 2016, J CLIN NEUROL, V12, P57, DOI 10.3988/jcn.2016.12.1.57; Lefaucheur JP, 2014, CLIN NEUROPHYSIOL, V125, P2150, DOI 10.1016/j.clinph.2014.05.021; Liao X, 2015, J ALZHEIMERS DIS, V48, P463, DOI 10.3233/JAD-150346; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Qizilbash N, 1998, JAMA-J AM MED ASSOC, V280, P1777, DOI 10.1001/jama.280.20.1777; Rabey JM, 2013, J NEURAL TRANSM, V120, P813, DOI 10.1007/s00702-012-0902-z; Rutherford GA, 2014, ALZHEIMERS DEMENT, V10, P453; Sampath D, 2017, NEUROPSYCH DIS TREAT, V13, P1509, DOI 10.2147/NDT.S136122; Stedman MR, 2011, INT J EPIDEMIOL, V40, P1732, DOI 10.1093/ije/dyp345; Valero-Cabre A, 2017, NEUROSCI BIOBEHAV R, V83, P381, DOI 10.1016/j.neubiorev.2017.10.006; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4; Wu Yue, 2015, Shanghai Arch Psychiatry, V27, P280, DOI 10.11919/j.issn.1002-0829.215107	34	38	40	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2018	13	10							e0205704	10.1371/journal.pone.0205704	http://dx.doi.org/10.1371/journal.pone.0205704			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX0UN	30312319	Green Submitted, Green Published, gold			2023-01-03	WOS:000447427300048
J	Hallifax, RJ; Goldacre, R; Landray, MJ; Rahman, NM; Goldacre, MJ				Hallifax, Rob J.; Goldacre, Raph; Landray, Martin J.; Rahman, Najib M.; Goldacre, Michael J.			Trends in the Incidence and Recurrence of Inpatient-Treated Spontaneous Pneumothorax, 1968-2016	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TUBE DRAINAGE; SIMPLE ASPIRATION; CHEST TUBE; EPIDEMIOLOGY; TETRACYCLINE; MANAGEMENT; RISK	IMPORTANCE Spontaneous pneumothorax is a common disease known to have an unusual epidemiological profile, but there are limited contemporary population-based data. OBJECTIVE To estimate the incidence of hospital admissions for spontaneous pneumothorax, its recurrence and trends over time using large, longstanding hospitalization data sets in England. DESIGN, SETTING, AND PARTICIPANTS A population-based epidemiological study was conducted using an English national data set and an English regional data set, each spanning 1968 to 2016, and including 170 929 hospital admission records of patients 15 years and older. Final date of the study period was December 31, 2016. EXPOSURES Calendar year (for incidence) and readmission to hospital for spontaneous pneumothorax (for recurrence). MAIN OUTCOMES AND MEASURES Primary outcomes were rates of hospital admissions for spontaneous pneumothorax and recurrence, defined as a subsequent hospital readmission with spontaneous pneumothorax. Record-linkage was used to identify multiple admissions per person and comorbidity. Risk factors for recurrence over 5 years of follow-up were assessed using cumulative time-to-failure analysis and Cox proportional hazards regression. RESULTS From 1968 to 2016, there were 170 929 hospital admissions for spontaneous pneumothorax (median age, 44 years [IQR, 26-88]; 73.0% male). In 2016, there were 14.1 spontaneous pneumothorax admissions per 100 000 population 15 years and older (95% CI, 13.7-14.4), a significant increase compared with earlier years, up from 9.1 (95% CI, 8.1-10.1) in 1968. The population-based rate per 100 000 population 15 years and older was higher for males (20.8 [95% CI, 20.2-21.4]) than for females (7.6 [95% CI, 7.2-7.9]). Of patients with spontaneous pneumothorax, 60.8%(95% CI, 59.5%-62.0%) had chronic lung disease. Record-linkage analysis demonstrated that the overall increase in admissions over time could be due in part to an increase in repeat admissions, but there were also significant increases in the annual rate of first-known spontaneous pneumothorax admissions in some population subgroups, for example in women 65 years and older (annual percentage change from 1968 to 2016, 4.08 [95% CI, 3.33-4.82], P < .001). The probability of recurrence within 5 years was similar by sex (25.5%[95% CI, 25.1%-25.9%] for males vs 26.0% [95% CI, 25.3%-26.7%] for females), but there was variation by age group and presence of chronic lung disease. For example, the probability of readmission within 5 years among males aged 15 to 34 years with chronic lung disease was 39.2%(95% CI, 37.7%-40.7%) compared with 19.6%(95% CI, 18.2%-21.1%) in men 65 years and older without chronic lung disease. CONCLUSIONS AND RELEVANCE This study provides contemporary information regarding the trends in incidence and recurrence of inpatient-treated spontaneous pneumothorax.	[Hallifax, Rob J.; Rahman, Najib M.] Oxford Univ Hosp Natl Hlth Serv Fdn Trust, Oxford Ctr Resp Med, Oxford, England; [Goldacre, Raph; Landray, Martin J.; Goldacre, Michael J.] Univ Oxford, Li Ka Shing Ctr Hlth Informat & Discovery, Nuffield Dept Populat Hlth, Unit Hlth Care Epidemiol,Big Data Inst, Oxford, England; [Landray, Martin J.] Univ Oxford, MRC, Nuffield Dept Populat Hlth, Populat Hlth Res Unit, Oxford, England; [Landray, Martin J.; Rahman, Najib M.] Univ Oxford, Oxford Natl Inst Hlth Res, Biomed Res Ctr, Oxford, England	Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Oxford; University of Oxford	Hallifax, RJ (corresponding author), Univ Oxford, Churchill Hosp, Oxford Ctr Resp Med, Oxford OX3 7LJ, England.	robert.hallifax@ndm.ox.ac.uk		Hallifax, Rob/0000-0002-9467-668X; Rahman, Najib M/0000-0003-1195-1680; Landray, Martin/0000-0001-6646-827X	Medical Research Council [MR/L017091/1]; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre; Public Health England; Li Ka Shing Foundation; Robertson Foundations; Medical Research Council; British Heart Foundation; NIHR Oxford Biomedical Research Centre; UK Medical Research Council; MRC [MR/L017091/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research (NIHR) Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Public Health England; Li Ka Shing Foundation; Robertson Foundations; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by Clinical Training Fellowship (MR/L017091/1) from the Medical Research Council (Dr Hallifax), the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (Dr Rahman and Mr R. Goldacre), and Public Health England (Mr R. Goldacre). The Big Data Institute has received funding from the Li Ka Shing Foundation and Robertson Foundations, the Medical Research Council, British Heart Foundation, and is supported by the NIHR Oxford Biomedical Research Centre. The Medical Research Council Population Health Research Unit is funded by the UK Medical Research Council.	ALFAGEME I, 1994, CHEST, V106, P347, DOI 10.1378/chest.106.2.347; ANDRIVET P, 1995, CHEST, V108, P335, DOI 10.1378/chest.108.2.335; Ayed AK, 2006, EUR RESPIR J, V27, P477, DOI 10.1183/09031936.06.00091505; BENSE L, 1987, CHEST, V92, P1009, DOI 10.1378/chest.92.6.1009; Bintcliffe OJ, 2015, LANCET RESP MED, V3, P578, DOI 10.1016/S2213-2600(15)00220-9; Bobbio A, 2015, THORAX, V70, P653, DOI 10.1136/thoraxjnl-2014-206577; Chen JS, 2013, LANCET, V381, P1277, DOI 10.1016/S0140-6736(12)62170-9; Flume PA, 2005, CHEST, V128, P720, DOI 10.1378/chest.128.2.720; Gupta D, 2000, THORAX, V55, P666, DOI 10.1136/thorax.55.8.666; HARVEY J, 1994, BRIT MED J, V309, P1338, DOI 10.1136/bmj.309.6965.1338; Holland J, 2016, J ROY SOC MED, V109, P59, DOI 10.1177/0141076815617651; Legras A, 2014, CHEST, V145, P354, DOI 10.1378/chest.13-1284; LIGHT RW, 1990, JAMA-J AM MED ASSOC, V264, P2224, DOI 10.1001/jama.264.17.2224; LIPPERT HL, 1991, EUR RESPIR J, V4, P324; MacDuff A, 2010, THORAX, V65, P18, DOI 10.1136/thx.2010.136986; MELTON LJ, 1979, AM REV RESPIR DIS, V120, P1379; Noppen M, 2002, AM J RESP CRIT CARE, V165, P1240, DOI 10.1164/rccm.200111-078OC; Olesen WH, 2016, WORLD J SURG, V40, P2163, DOI 10.1007/s00268-016-3508-z; OROURKE JP, 1989, CHEST, V96, P1302, DOI 10.1378/chest.96.6.1302; PRIMROSE WR, 1984, SCOT MED J, V29, P15, DOI 10.1177/003693308402900105; RUCKLEY CV, 1966, THORAX, V21, P139, DOI 10.1136/thx.21.2.139; Sadikot RT, 1997, THORAX, V52, P805, DOI 10.1136/thx.52.9.805; SEREMETIS MG, 1970, CHEST, V57, P65, DOI 10.1378/chest.57.1.65; Sousa Cristiana, 2011, J Clin Med Res, V3, P111, DOI 10.4021/jocmr560w; Visouli AN, 2014, J THORAC DIS, V6, pS448, DOI 10.3978/j.issn.2072-1439.2014.08.49; World Health Organization, 2011, WORLD HLTH STAT 2011	26	62	64	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	2018	320	14					1471	1480		10.1001/jama.2018.14299	http://dx.doi.org/10.1001/jama.2018.14299			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW3IX	30304427	Bronze, Green Published			2023-01-03	WOS:000446792500017
J	Romaniuk, M; Evans, J; Kidd, C				Romaniuk, Madeline; Evans, Justine; Kidd, Chloe			Evaluation of an equine-assisted therapy program for veterans who identify as 'wounded, injured or ill' and their partners	PLOS ONE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; AUSTRALIAN VIETNAM VETERANS; OF-LIFE ENJOYMENT; MENTAL-HEALTH; GULF-WAR; SATISFACTION QUESTIONNAIRE; MILITARY SERVICE; COMBAT VETERANS; DEPRESSION; QUALITY	The aim of this study was to evaluate outcomes of an equine-assisted therapy program for Defence Force veterans and their partners across the psychological domains of depression, anxiety, stress, posttraumatic stress, happiness, and quality of life, as well as compare the outcomes of an Individual and Couples program. A non-controlled, within-subjects longitudinal design was utilized with assessment at three time points (pre-intervention, post-intervention, and three months follow-up). Between-subjects analysis with two groups was also conducted to compare the outcomes of the Individual and Couples programs. Participants were recruited from ten programs in 2016 with a total of 47 veterans and partners from both an Individual program (n = 25; veterans only) and a Couples program (n = 22). Outcome measures included the Depression Anxiety Stress Scale-21, Posttraumatic Stress Disorder Checklist for DSM-5, Oxford Happiness Questionnaire, and Quality-of-Life Enjoyment and Satisfaction Questionnaire-Short Form. Paired samples t-tests revealed that within both the Individual and Couples programs, there were significantly fewer psychological symptoms and significantly greater levels of happiness and quality of life at post-intervention compared to pre-intervention. Reduced psychological symptoms were maintained at the three months follow-up for participants of the Couples program only. Independent samples t-tests revealed participants in the Couples program reported significantly less symptoms of depression, stress, and posttraumatic stress disorder (PTSD) at follow-up compared to participants in the Individual program. These results indicate there may only be meaningful benefits for equine-assisted therapy in the reduction of depression, stress, and PTSD symptoms for veterans, if partners are integrated into the intervention.	[Romaniuk, Madeline; Evans, Justine; Kidd, Chloe] Greenslopes Private Hosp, Gallipoli Med Res Inst, Vet Mental Hlth Initiat, Brisbane, Qld, Australia; [Romaniuk, Madeline] Univ Queensland, Fac Hlth & Behav Sci, Brisbane, Qld, Australia; [Romaniuk, Madeline] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia; [Romaniuk, Madeline] Univ Southern Queensland, Inst Resilient Reg, Springfield Cent, Qld, Australia	University of Queensland; Queensland University of Technology (QUT); University of Southern Queensland	Romaniuk, M (corresponding author), Greenslopes Private Hosp, Gallipoli Med Res Inst, Vet Mental Hlth Initiat, Brisbane, Qld, Australia.; Romaniuk, M (corresponding author), Univ Queensland, Fac Hlth & Behav Sci, Brisbane, Qld, Australia.; Romaniuk, M (corresponding author), Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia.; Romaniuk, M (corresponding author), Univ Southern Queensland, Inst Resilient Reg, Springfield Cent, Qld, Australia.	romaniukm@ramsayhealth.com.au		Romaniuk, Madeline/0000-0002-0621-8372	Queensland Branch of the Returned and Services League of Australia as part of the Veteran Mental Health Initiative at the Gallipoli Medical Research Institute	Queensland Branch of the Returned and Services League of Australia as part of the Veteran Mental Health Initiative at the Gallipoli Medical Research Institute	The Queensland Branch of the Returned and Services League of Australia funded this study as part of the Veteran Mental Health Initiative at the Gallipoli Medical Research Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amato PR, 2015, FAMILY MATTERS, P5; Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; Blevins CA, 2015, J TRAUMA STRESS, V28, P489, DOI 10.1002/jts.22059; Bovin MJ, 2016, PSYCHOL ASSESSMENT, V28, P1379, DOI 10.1037/pas0000254; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J., 2013, STAT POWER ANAL BEHA; Duncan C, 2017, CANADIAN MILITARY J, V17, P45; Duncan C.R., 2014, CAN MIL J, V14, P64; Earles JL, 2015, J TRAUMA STRESS, V28, P149, DOI 10.1002/jts.21990; ENDICOTT J, 1993, PSYCHOPHARMACOL BULL, V29, P321; Ferruolo DM, 2016, SOC WORK, V61, P53, DOI 10.1093/sw/swv054; Glynn SM, 1999, J CONSULT CLIN PSYCH, V67, P243, DOI 10.1037/0022-006X.67.2.243; Hills P, 2002, PERS INDIV DIFFER, V33, P1073, DOI 10.1016/S0191-8869(01)00213-6; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holmes CMP, 2012, CHILD ADOLESC SOC WO, V29, P111, DOI 10.1007/s10560-011-0251-z; Holt-Lunstad J, 2008, ANN BEHAV MED, V35, P239, DOI 10.1007/s12160-008-9018-y; Ikin JF, 2016, J AFFECT DISORDERS, V189, P77, DOI 10.1016/j.jad.2015.09.016; Ikin JF, 2010, J AFFECT DISORDERS, V125, P279, DOI 10.1016/j.jad.2009.12.005; Johnson RA, 2018, MILITARY MED RES, V5, DOI 10.1186/s40779-018-0149-6; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Kelsall HL, 2014, PAIN, V155, P685, DOI 10.1016/j.pain.2013.12.025; Kirby M., 2016, PSYCHOTHERAPY MODEL; Klontz BT, 2007, SOC ANIM, V15, P257, DOI 10.1163/156853007X217195; Kuehn BM, 2009, JAMA-J AM MED ASSOC, V301, P1111, DOI 10.1001/jama.2009.342; Kulesza Magdalena, 2015, Mil Behav Health, V3, P230; Lanning BA, 2018, HUMAN ANIMAL INTERAC; Lanning BA, 2017, OCCUP THER MENT HEAL, V33, P259, DOI 10.1080/0164212X.2017.1283282; Lanning BA, 2013, J REHABIL RES DEV, V50, pXV, DOI 10.1682/JRRD.2013.07.0159; Lee PT, 2016, HEALTH SOC CARE COMM, V24, P225, DOI 10.1111/hsc.12201; Lefkowitz C, 2005, SOC ANIM, V13, P275, DOI 10.1163/156853005774653654; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; Manguno-Mire G, 2007, J NERV MENT DIS, V195, P144, DOI 10.1097/01.nmd.0000254755.53549.69; Masini A, 2010, J PSYCHOSOC NURS MEN, V48, P30, DOI 10.3928/02793695-20100831-08; Matuszek S, 2010, HOLIST NURS PRACT, V24, P187, DOI 10.1097/HNP.0b013e3181e90197; McKenzie DP, 2004, PSYCHOL MED, V34, P1419, DOI 10.1017/S0033291704002818; McLeay SC, 2017, MED J AUSTRALIA, V206, P251, DOI 10.5694/mja16.00935; Mills KL, 2006, AM J PSYCHIAT, V163, P652, DOI 10.1176/appi.ajp.163.4.652; O'Toole BI, 2015, J PSYCHIATR RES, V65, P30, DOI 10.1016/j.jpsychires.2015.02.003; O'Toole BI, 2009, AM J EPIDEMIOL, V170, P318, DOI 10.1093/aje/kwp146; Outram S, 2009, AUST PSYCHOL, V44, P128, DOI 10.1080/00050060802630353; Palley LS, 2010, ILAR J, V51, P199, DOI 10.1093/ilar.51.3.199; Pietrzak RH, 2009, PSYCHIAT SERV, V60, P1118, DOI 10.1176/ps.2009.60.8.1118; Robbins M, 2010, CURR PSYCHOL, V29, P89, DOI 10.1007/s12144-010-9076-8; Russell E, 2013, CAN MED ASSOC J, V185, P1205, DOI 10.1503/cmaj.109-4578; Schottenbauer MA, 2008, PSYCHIATRY, V71, P134, DOI 10.1521/psyc.2008.71.2.134; SHAFFER JP, 1995, ANNU REV PSYCHOL, V46, P561, DOI 10.1146/annurev.ps.46.020195.003021; Sherman MD, 2015, COUPLE FAM PSYCHOL, V4, P136, DOI 10.1037/cfp0000040; Stevanovic D, 2011, J PSYCHIATR MENT HLT, V18, P744, DOI 10.1111/j.1365-2850.2011.01735.x; Tsantefski M, 2017, HEALTH SOC CARE COMM, V25, P1247, DOI 10.1111/hsc.12427; Weathers F.W., 2013, PTSD CHECKLIST DSM 5; Weiss RB, 2015, J PSYCHOPATHOL BEHAV, V37, P217, DOI 10.1007/s10862-014-9461-y; Westerink J, 1999, AUST NZ J PSYCHIAT, V33, P841, DOI 10.1046/j.1440-1614.1999.00638.x; Wortmann JH, 2016, PSYCHOL ASSESSMENT, V28, P1392, DOI 10.1037/pas0000260	54	18	19	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 27	2018	13	9							e0203943	10.1371/journal.pone.0203943	http://dx.doi.org/10.1371/journal.pone.0203943			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GV2HB	30260975	Green Published, Green Submitted, gold			2023-01-03	WOS:000445907400019
J	Iversen, L; Fielding, S; Lidegaard, O; Morch, LS; Skovlund, CW; Hannaford, PC				Iversen, Lisa; Fielding, Shona; Lidegaard, Ojvind; Morch, Lina S.; Skovlund, Charlotte W.; Hannaford, Philip C.			Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEPOT-MEDROXYPROGESTERONE ACETATE; INTRAUTERINE SYSTEM; RISK	OBJECTIVES To investigate the association between contemporary combined hormonal contraceptives (including progestogen types in combined preparations and all progestogen-only products) and overall and specific types of ovarian cancer. DESIGN Prospective, nationwide cohort study. SETTING Denmark, 1995-2014. PARTICIPANTS All women aged 15-49 years during 1995-2014 were eligible. Women were excluded if they immigrated after 1995, had cancer (except non-melanoma skin cancer), had venous thrombosis, or were treated for infertility before entry (final study population included 1 879 227 women). Women were categorised as never users (no record of being dispensed hormonal contraception), current or recent users (<= 1 year after stopping use), or former users (>1 year after stopping use) of different hormonal contraceptives. MAIN OUTCOME MEASURES Poisson regression was used to calculate relative risk of ovarian cancer among users of any contemporary combined hormonal contraceptives and by progestogen type in combined preparations and all progestogen-only products, including non-oral preparations. Separate analyses examined women followed up to their first contraception type switch and those with full contraceptive histories. Duration, time since last use, and tumour histology were examined and the population prevented fraction were calculated. RESULTS During 21.4 million person years, 1249 incident ovarian cancers occurred. Among ever users of hormonal contraception, 478 ovarian cancers were recorded over 13 344 531 person years. Never users had 771 ovarian cancers during 8150 250 person years. Compared with never users, reduced risks of ovarian cancer occurred with current or recent use and former use of any hormonal contraception (relative risk 0.58 (95% confidence interval 0.49 to 0.68) and 0.77 (0.66 to 0.91), respectively). Relative risks among current or recent users decreased with increasing duration (from 0.82 (0.59 to 1.12) with <= 1 year use to 0.26 (0.16 to 0.43) with >10 years' use; P<0.001 for trend). Similar results were achieved among women followed up to their first switch in contraceptive type. Little evidence of major differences in risk estimates by tumour type or progestogen content of combined oral contraceptives was seen. Use of progestogen-only products were not associated with ovarian cancer risk. Among ever users of hormonal contraception, the reduction in the age standardised absolute rate of ovarian cancer was 3.2 per 100 000 person years. Based on the relative risk for the never use versus ever use categories of hormonal contraception (0.66), the population prevented fraction was estimated to be 21%-that is, use of hormonal contraception, prevented 21% of ovarian cancers in the study population. CONCLUSIONS Use of contemporary combined hormonal contraceptives is associated with a reduction in ovarian cancer risk in women of reproductive age-an effect related to duration of use, which diminishes after stopping use. These data suggest no protective effect from progestogen-only products.	[Iversen, Lisa; Hannaford, Philip C.] Univ Aberdeen, Acad Primary Care, Inst Appl Hlth Sci, Aberdeen AB25 2ZD, Scotland; [Fielding, Shona] Univ Aberdeen, Inst Appl Hlth Sci, Med Stat Team, Aberdeen, Scotland; [Lidegaard, Ojvind; Morch, Lina S.; Skovlund, Charlotte W.] Univ Copenhagen, Dept Gynaecol, Juliane Marie Ctr, Rigshosp, Copenhagen, Denmark	University of Aberdeen; University of Aberdeen; Rigshospitalet; University of Copenhagen	Iversen, L (corresponding author), Univ Aberdeen, Acad Primary Care, Inst Appl Hlth Sci, Aberdeen AB25 2ZD, Scotland.	l.iversen@abdn.ac.uk		Morch, Lina/0000-0001-6506-2569; Iversen, Lisa/0000-0002-2524-5229	Novo Nordisk Foundation [11645]	Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited)	Supported by a grant (No 11645) from the Novo Nordisk Foundation. The funder had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the paper; or in the decision to submit the paper for publication.	Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9; Bethea TN, 2017, CANCER CAUSE CONTROL, V28, P385, DOI 10.1007/s10552-016-0840-4; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Doherty JA, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx144; Fritz A., 2000, INT CLASSIFICATION D; Gapstur SM, 2015, LANCET, V385, P1835, DOI 10.1016/S0140-6736(14)61687-1; GLOBOCAN, 2012, EST CANC INC MORT PR; Gottschau M, 2016, ACTA OBSTET GYN SCAN, V95, P1181, DOI 10.1111/aogs.12948; Iversen L, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2017.02.002; Kumle M, 2004, BRIT J CANCER, V90, P1386, DOI 10.1038/sj.bjc.6601715; Lidegaard O, 2012, NEW ENGL J MED, V366, P2257, DOI 10.1056/NEJMoa1111840; Malvezzi M, 2016, ANN ONCOL, V27, P725, DOI 10.1093/annonc/mdw022; McCluggage WG, 2011, PATHOLOGY, V43, P420, DOI 10.1097/PAT.0b013e328348a6e7; Moorman PG, 2016, ANN EPIDEMIOL, V26, P654, DOI 10.1016/j.annepidem.2016.07.004; Morch LS, 2017, NEW ENGL J MED, V377, P2228, DOI 10.1056/NEJMoa1700732; Morch LS, 2009, JAMA-J AM MED ASSOC, V302, P298, DOI 10.1001/jama.2009.1052; Mutch DG, 2014, GYNECOL ONCOL, V133, P401, DOI 10.1016/j.ygyno.2014.04.013; Nielsen LH, 2008, PHARMACOEPIDEM DR S, V17, P384, DOI 10.1002/pds.1549; Owens G, 2015, UICC MANUAL CLIN ONC; Shafrir AL, 2017, CANCER CAUSE CONTROL, V28, P371, DOI 10.1007/s10552-017-0876-0; SHEPHERD JH, 1989, BRIT J OBSTET GYNAEC, V96, P889, DOI 10.1111/j.1471-0528.1989.tb03341.x; Soini T, 2016, ACTA ONCOL, V55, P1281, DOI 10.1080/0284186X.2016.1175660; Soini T, 2014, OBSTET GYNECOL, V124, P292, DOI 10.1097/AOG.0000000000000356; THOMAS DB, 1991, INT J CANCER, V49, P191; Tsilidis KK, 2011, BRIT J CANCER, V105, P1436, DOI 10.1038/bjc.2011.371; United Nations Department of Economic and Social Affairs Population Division., 2015, STESASERA349 UN DEP; Urban M, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001182; Vessey M, 2013, CONTRACEPTION, V88, P678, DOI 10.1016/j.contraception.2013.08.008; Wentzensen N, 2016, J CLIN ONCOL, V34, P2888, DOI 10.1200/JCO.2016.66.8178; Wilailak S, 2012, BJOG-INT J OBSTET GY, V119, P672, DOI 10.1111/j.1471-0528.2012.03298.x; World Health Organization, 1992, INT STAT CLASS DIS H	31	44	44	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	2018	362								k3609	10.1136/bmj.k3609	http://dx.doi.org/10.1136/bmj.k3609			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV6MJ	30257920	Green Published, hybrid			2023-01-03	WOS:000446225200001
J	Karki, P; Prabandari, YS; Probandari, A; Banjara, MR				Karki, Prativa; Prabandari, Yayi Suryo; Probandari, Ari; Banjara, Megha Raj			Feasibility of school-based health education intervention to improve the compliance to mass drug administration for lymphatic Filariasis in Lalitpur district, Nepal: A mixed methods among students, teachers and health program manager	PLOS ONE			English	Article							ELIMINATION; PREVENTION; PROMOTION; CAMPAIGN; CHILDREN	Background Ensuring reduction in transmission of lymphatic Filariasis (LF) and addressing the compliance of people to mass drug administration (MDA) has led to renewed efforts in the field. School-based health education (SBHE) intervention, considered a cost-effective strategy with potential to reach the wider public through young people, was adopted as a strategy for social mobilization. This study assessed SBHE perceptions, implementation barriers, and factors in the supporting environment as well as its efficiency to successfully change LF MDA-related knowledge and practice. Methods This mixed methods study was conducted in four sites of Lalitpur district, Nepal. Classroom-based interactive health education sessions were used as the main intervention strategy in the study. In total, 572 students were assigned to intervention and control groups. Questionnaires were distributed before and after the intervention. Mann-Whitney and McNemar tests were used for analysis. Focus-group discussions with teachers and students and in-depth interviews with the district LF program manager as well as Education Office and school management authorities were conducted. Qualitative thematic analysis approach was adopted. Results Intervention curriculum played a significant role in increasing children's knowledge and practice (p<0.001). Barriers for school-based interventions were budget constraints, human resource deficiencies, lack of opportunities to conduct practical classes under the curriculum, and lack of collaboration with parents. Supportive factors were training provision, monitoring and evaluation practice, adequate facilities and equipment, positive parental attitudes, presence of interested teachers and students, and prioritization by program implementers. Conclusion Effective program planning practices such as proper fiscal management, human resource management, training mechanisms, and efforts to promote practical classes and coordination with parents are required to develop and institutionalize the intervention. Effective learning and a supportive school environment appear to be important components to support implementation. The SBHE intervention is a feasible and promising intervention for accelerating compliance towards MDA to eliminate LF.	[Karki, Prativa; Prabandari, Yayi Suryo] Univ Gadjah Mada, Dept Publ Hlth, Yogyakarta, Indonesia; [Probandari, Ari] Univ Sebelas Maret, Fac Med, Dept Publ Hlth, Surakarta, Indonesia; [Probandari, Ari] Univ Gadjah Mada, Ctr Trop Med, Yogyakarta, Indonesia; [Banjara, Megha Raj] Tribhuvan Univ, Cent Dept Microbiol, Kathmandu, Nepal	Gadjah Mada University; Sebelas Maret University; Gadjah Mada University; Tribhuvan University	Karki, P (corresponding author), Univ Gadjah Mada, Dept Publ Hlth, Yogyakarta, Indonesia.	prativa_karki2003@yahoo.com	Prabandari, Yayi/L-1887-2019; Budhathoki, Shyam Sundar/X-5167-2018	Budhathoki, Shyam Sundar/0000-0002-8614-1087	TDR, the Special Programme for Research and Training in Tropical Diseases based at the World Health Organization in Geneva, Switzerland; WHO/TDR special program for implementation research	TDR, the Special Programme for Research and Training in Tropical Diseases based at the World Health Organization in Geneva, Switzerland; WHO/TDR special program for implementation research	This work was funded provided by TDR, the Special Programme for Research and Training in Tropical Diseases based at the World Health Organization in Geneva, Switzerland. The first author (Prativa) received specific funding for this work from WHO/TDR special program for implementation research. As a part of the funding the author received $4500 as a fund. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adhikari R K, 2014, J Nepal Health Res Counc, V12, P124; Adhikari RK, 2015, J COMMUN HEALTH, V40, P34, DOI 10.1007/s10900-014-9891-1; Amarillo MLE, 2008, PHILIPPINES, V12, P1; Bhatia M, 2014, ASIAN PAC J HEAL SCI, V1, P63; Bockarie MJ, 2009, EXPERT REV ANTI-INFE, V7, P595, DOI [10.1586/eri.09.36, 10.1586/ERI.09.36]; Brown T, 2008, SYSTEMATIC REV SCH B, P110; Byanju R, 2012, J NAT HIST MUS, V26, P136; CDA, 2013, ANN REP 2011 2013; Central Bureau of Statistics Nepal, 2012, NAT POP HOUS CENS 20; Envision, 2016, NEP WORK PLAN FY16; Fawole IO, 1999, HEALTH EDUC RES, V14, P675, DOI 10.1093/her/14.5.675; Feldstein AC, 2008, JT COMM J QUAL PATIE, V34, P228, DOI 10.1016/S1553-7250(08)34030-6; Fielden Amy L, 2011, Int J Qual Stud Health Well-being, V6, DOI 10.3402/qhw.v6i3.7170; Gao XH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044881; Government of Nepal, 2013, DISTR PROF; Hall WJ, 2014, TRANSL BEHAV MED, V4, P131, DOI 10.1007/s13142-013-0226-z; Haque SE, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004607; He FJ, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h770; Hesketh K, 2005, HEALTH PROMOT INT, V20, P19, DOI 10.1093/heapro/dah503; Hussain MA, 2014, INFECT DIS POVERTY, V3, DOI 10.1186/2049-9957-3-31; King JD, 2010, IMPROVING COMMUNITY, P548; Krentel A, 2006, TROP MED INT HEALTH, V11, P1731, DOI 10.1111/j.1365-3156.2006.01720.x; Krentel A, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005027; Krentel A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002447; LaBeaud AD, 2009, J PEDIATR-US, V155, P590, DOI 10.1016/j.jpeds.2009.03.009; Lammie PJ, 2006, TRENDS PARASITOL, V22, P313, DOI 10.1016/j.pt.2006.05.009; Ministry of Education, 2015, NEP ED FIG 2015 AT A; Moshki M, 2017, PLOS ONE; Nandha B, 2007, HEALTH EDUC RES, V22, P539, DOI 10.1093/her/cyl116; Ottesen EA, 2000, TROP MED INT HEALTH, V5, P591, DOI 10.1046/j.1365-3156.2000.00620.x; Rai C, 2009, IMPROVING CHILDREN S, V3; Renju J, 2010, HEALTH EDUC RES, V25, P903, DOI 10.1093/her/cyq041; Roofe NL, 2010, THESIS; Shenoy RK, 2011, PARASITOLOGY, V138, P1559, DOI 10.1017/S003118201100117X; Shrestha RM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166001; Thi L, 2013, GLOABAL HEAL ACTION, V6; Vijayapushpam T, 2010, PUBLIC HEALTH NUTR, V13, P131, DOI 10.1017/S1368980009990255; Webster JP, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0434; WHO, 2007, PROM PHYS ACY SCH IM; WHO, 2010, GPEL PROGR REP 2000; World Health Organization, 2010, REG STRAT PLAN EL LY	41	4	4	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2018	13	9							e0203547	10.1371/journal.pone.0203547	http://dx.doi.org/10.1371/journal.pone.0203547			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GT7EG	30216390	Green Published, gold, Green Submitted			2023-01-03	WOS:000444683700019
J	Petrone, J; DeFrancesco, L				Petrone, Justin; DeFrancesco, Laura			Small molecules get the message	NATURE BIOTECHNOLOGY			English	Editorial Material								A cadre of new biotechs have set their sights on targeting RNA with small-molecule drugs. Justin Petrone and Laura DeFrancesco report.										Mustoe AM, 2018, CELL, V173, P181, DOI 10.1016/j.cell.2018.02.034; Palacino J, 2015, NAT CHEM BIOL, V11, P511, DOI [10.1038/nchembio.1837, 10.1038/NCHEMBIO.1837]; Rizvi NF, 2018, ACS CHEM BIOL, V13, P820, DOI 10.1021/acschembio.7b01013; Rzuczek SG, 2017, NAT CHEM BIOL, V13, P188, DOI [10.1038/NCHEMBIO.2251, 10.1038/nchembio.2251]; Seiler M, 2018, NAT MED, V24, P497, DOI 10.1038/nm.4493; Tran T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2119; Wang JX, 2018, P NATL ACAD SCI USA, V115, pE4604, DOI 10.1073/pnas.1800260115; Welch EM, 2007, NATURE, V447, P87, DOI 10.1038/nature05756	8	8	8	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2018	36	9					787	790		10.1038/nbt.4241	http://dx.doi.org/10.1038/nbt.4241			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	GS8TJ	30188529				2023-01-03	WOS:000443986000012
J	Pellegrini, JAS; Boniatti, MM; Boniatti, VC; Zigiotto, C; Viana, MV; Nedel, WL; Marques, LD; dos Santos, MC; de Almeida, CB; Dal'Pizzol, CP; Ziegelmann, PK; Vieira, SRR				Santos Pellegrini, Jose Augusto; Boniatti, Marcio Manozzo; Boniatti, Viviane Correa; Zigiotto, Crislene; Viana, Marina Vercoza; Nedel, Wagner Luiz; Marques, Leonardo da Silva; dos Santos, Moreno Calcagnotto; de Almeida, Clarissa Balbao; Dal'Pizzol, Claudia Pellizzer; Ziegelmann, Patricia Klarmann; Rios Vieira, Silvia Regina			Pressure-support ventilation or T-piece spontaneous breathing trials for patients with chronic obstructive pulmonary disease - A randomized controlled trial	PLOS ONE			English	Article							REQUIRING MECHANICAL VENTILATION; ACUTE RESPIRATORY-FAILURE; CRITICALLY-ILL ADULTS; GENDER-DIFFERENCES; WEANING PATIENTS; EXTUBATION; DURATION; COPD; METAANALYSIS; LIBERATION	Background Little is known about the best strategy for weaning patients with chronic obstructive pulmonary disease (COPD) from mechanical ventilation. Spontaneous breathing trials (SBT) using a T-piece or pressure-support ventilation (PSV) have a central role in this process. Our aim was to compare T-piece and PSV SBTs according to the duration of mechanical ventilation (MV) in patients with COPD. Methods Patients with COPD who had at least 48 hours of invasive MV support were randomized to 30 minutes of T-piece or PSV at 10 cm H2O after being considered able to undergo a SBT. All patients were preemptively connected to non-invasive ventilation after extubation. Tracheostomized patients were excluded. The primary outcome was total invasive MV duration. Time to liberation from MV was assessed as secondary outcome. Results Between 2012 and 2016, 190 patients were randomized to T-piece (99) or PSV (91) groups. Extubation at first SBT was achieved in 78% of patients. The mean total MV duration was 10.82 +/- 9.1 days for the T-piece group and 7.31 +/- 4.9 days for the PSV group (p < 0.001); however, the pre-SBT duration also differed (7.35 +/- 3.9 and 5.84 +/- 3.3, respectively; p = 0.002). The time to liberation was 8.36 +/- 11.04 days for the T-piece group and 4.06 +/- 4.94 for the PSV group (univariate mean ratio = 2.06 [1.29-3.27], p = 0.003) for the subgroup of patients with difficult or prolonged weaning. The study group was independently associated with the time to liberation in this subgroup. Conclusions The SBT technique did not influence MV duration for patients with COPD. For the difficult/prolonged weaning subgroup, the T-piece may be associated with a longer time to liberation, although this should be clarified by further studies.	[Santos Pellegrini, Jose Augusto; Boniatti, Marcio Manozzo; Viana, Marina Vercoza; Nedel, Wagner Luiz; dos Santos, Moreno Calcagnotto; Rios Vieira, Silvia Regina] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Dept Crit Care Med, Porto Alegre, RS, Brazil; [Boniatti, Viviane Correa; Zigiotto, Crislene; Viana, Marina Vercoza; Nedel, Wagner Luiz; Marques, Leonardo da Silva; dos Santos, Moreno Calcagnotto] Hosp Nossa Senhora da Conceicao, Intens Care Unit, Porto Alegre, RS, Brazil; [dos Santos, Moreno Calcagnotto; de Almeida, Clarissa Balbao; Dal'Pizzol, Claudia Pellizzer] Hosp Montenegro, Intens Care Unit, Montenegro, Brazil; [Ziegelmann, Patricia Klarmann] Univ Fed Rio Grande do Sul, Stat Dept, Porto Alegre, RS, Brazil; [Ziegelmann, Patricia Klarmann] Univ Fed Rio Grande do Sul, Postgrad Program Epidemiol, Porto Alegre, RS, Brazil	Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio Grande do Sul	Pellegrini, JAS (corresponding author), Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Dept Crit Care Med, Porto Alegre, RS, Brazil.	jpellegrini@hcpa.edu.br	Boniatti, Marcio/AAA-4195-2020; Viana, Marina Verçoza/Y-9848-2019; Viana, Marina/R-8017-2017	Viana, Marina Verçoza/0000-0001-9564-4885; Viana, Marina/0000-0001-9564-4885; Boniatti, Marcio Manozzo/0000-0001-9921-0785				Boles JM, 2007, EUR RESPIR J, V29, P1033, DOI 10.1183/09031936.00010206; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; Cabello B, 2010, INTENS CARE MED, V36, P1171, DOI 10.1007/s00134-010-1870-0; Caracta CF, 2003, MT SINAI J MED, V70, P215; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteban A, 1997, AM J RESP CRIT CARE, V156, P459, DOI 10.1164/ajrccm.156.2.9610109; Esteban A, 2008, AM J RESP CRIT CARE, V177, P170, DOI 10.1164/rccm.200706-893OC; Esteban A, 2013, AM J RESP CRIT CARE, V188, P220, DOI 10.1164/rccm.201212-2169OC; Gadre SK, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010487; Haberthur C, 2002, ACTA ANAESTH SCAND, V46, P973, DOI 10.1034/j.1399-6576.2002.460808.x; Jubran A, 2013, JAMA-J AM MED ASSOC, V309, P671, DOI 10.1001/jama.2013.159; Koksal GM, 2004, CRIT CARE, V8, pR31, DOI 10.1186/cc2413; Lee P, 2002, CLEV CLIN J MED, V69, P928, DOI 10.3949/ccjm.69.12.928; Lee P, 2002, CLEV CLIN J MED, V69, P36; Lee P, 2002, CLEV CLIN J MED, V69, P33; Lourenco IS, 2013, REV BRAS CIR CARDIOV, V28, P455, DOI 10.5935/1678-9741.20130075; Matic I, 2007, CROAT MED J, V48, P51; Millum J, 2013, JAMA-J AM MED ASSOC, V310, P2143, DOI 10.1001/jama.2013.281632; Molina-Saldarriaga FJ, 2010, MED INTENSIVA, V34, P453, DOI 10.1016/j.medin.2010.03.007; Nemer SN, 2011, J BRAS PNEUMOL, V37, P669, DOI 10.1590/S1806-37132011000500016; Ongel EA, 2014, INT J CHRONIC OBSTR, V9, P1187, DOI 10.2147/COPD.S70257; Ouellette DR, 2017, CHEST, V151, P166, DOI 10.1016/j.chest.2016.10.036; Pellegrini JAS, 2016, RESP CARE, V61, P1693, DOI 10.4187/respcare.04816; Penuelas O, 2011, AM J RESP CRIT CARE, V184, P430, DOI 10.1164/rccm.201011-1887OC; Rello J, 2006, EUR RESPIR J, V27, P1210, DOI 10.1183/09031936.06.00139305; Rose L, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0755-6; Sklar MC, 2017, AM J RESP CRIT CARE, V195, P1477, DOI 10.1164/rccm.201607-1338OC; Tanios MA, 2006, CRIT CARE MED, V34, P2530, DOI 10.1097/01.CCM.0000236546.98861.25; Teixeira C, 2012, J BRAS PNEUMOL, V38, P364, DOI 10.1590/S1806-37132012000300012; Tonnelier A, 2011, RESP CARE, V56, P583, DOI 10.4187/respcare.00842; Vallverdu I, 1998, AM J RESP CRIT CARE, V158, P1855, DOI 10.1164/ajrccm.158.6.9712135; Varkey AB, 2004, CURR OPIN PULM MED, V10, P98, DOI 10.1097/00063198-200403000-00003; Vitacca M, 2001, AM J RESP CRIT CARE, V164, P225, DOI 10.1164/ajrccm.164.2.2008160; Walkey Allan J, 2013, Ann Am Thorac Soc, V10, P10, DOI 10.1513/AnnalsATS.201206-034OC; Wibbenmeyer LA, 2003, J TRAUMA, V55, P1162, DOI 10.1097/01.TA.0000057149.42968.1D	36	8	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2018	13	8							e0202404	10.1371/journal.pone.0202404	http://dx.doi.org/10.1371/journal.pone.0202404			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR6TZ	30138422	Green Published, gold, Green Submitted			2023-01-03	WOS:000442800100061
J	Weissman, GE; Kerlin, MP; Yuan, YH; Gabler, NB; Groeneveld, PW; Werner, RM; Halpern, SD				Weissman, Gary E.; Kerlin, Meeta Prasad; Yuan, Yihao; Gabler, Nicole B.; Groeneveld, Peter W.; Werner, Rachel M.; Halpern, Scott D.			Population Trends in Intensive Care Unit Admissions in the United States Among Medicare Beneficiaries, 2006-2015	ANNALS OF INTERNAL MEDICINE			English	Letter									[Weissman, Gary E.; Kerlin, Meeta Prasad; Halpern, Scott D.] Univ Penn, Perelman Sch Med, Palliat & Adv Illness Res Ctr, Philadelphia, PA 19104 USA; [Weissman, Gary E.; Kerlin, Meeta Prasad; Groeneveld, Peter W.; Werner, Rachel M.; Halpern, Scott D.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Yuan, Yihao; Gabler, Nicole B.; Groeneveld, Peter W.; Werner, Rachel M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Groeneveld, Peter W.; Werner, Rachel M.] Corporal Michael J Crescenz Vet Affairs Med Ctr, Philadelphia, PA USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Weissman, GE (corresponding author), Univ Penn, Perelman Sch Med, Palliat & Adv Illness Res Ctr, Philadelphia, PA 19104 USA.; Weissman, GE (corresponding author), Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.			Weissman, Gary/0000-0001-9588-3819; Groeneveld, Peter/0000-0002-7374-4292; Werner, Rachel/0000-0003-3435-4221; Halpern, Scott/0000-0002-3603-4769	National Institutes of Health/National Heart, Lung, and Blood Institute [T32-HL098054, K23-HL141639]; National Institutes of Health/National Institute on Aging [K24-AG047908]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL143289, K23HL141639, T32HL098054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K24AG047908] Funding Source: NIH RePORTER	National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health/National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	By National Institutes of Health/National Heart, Lung, and Blood Institute grants T32-HL098054 and K23-HL141639 (Dr. Weissman) and in part by National Institutes of Health/National Institute on Aging grant K24-AG047908 (Dr. Werner and Ms. Yuan).	Halpern SD, 2011, CURR OPIN CRIT CARE, V17, P648, DOI 10.1097/MCC.0b013e32834c7a53; Wallace David J, 2017, Crit Care Med, V45, pe67; Wallace DJ, 2015, AM J RESP CRIT CARE, V191, P410, DOI 10.1164/rccm.201409-1746OC; Weissman GE, 2017, CRIT CARE MED, V45, pE758, DOI 10.1097/CCM.0000000000002374; Wunsch H, 2008, CRIT CARE MED, V36, P2787, DOI 10.1097/CCM.0b013e318186aec8	5	11	11	2	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 5	2019	170	3					213	+		10.7326/M18-1425	http://dx.doi.org/10.7326/M18-1425			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK2IZ	30326008	Green Accepted			2023-01-03	WOS:000457735100016
J	Coccurello, R; Nazio, F; Rossi, C; De Angelis, F; Vacca, V; Giacovazzo, G; Procacci, P; Magnaghi, V; Ciavardelli, D; Marinelli, S				Coccurello, Roberto; Nazio, Francesca; Rossi, Claudia; De Angelis, Federica; Vacca, Valentina; Giacovazzo, Giacomo; Procacci, Patrizia; Magnaghi, Valerio; Ciavardelli, Domenico; Marinelli, Sara			Effects of caloric restriction on neuropathic pain, peripheral nerve degeneration and inflammation in normometabolic and autophagy defective prediabetic Ambra1 mice	PLOS ONE			English	Article							SCHWANN-CELL AUTOPHAGY; INSULIN-RESISTANCE; ACYLCARNITINE PROFILES; PLASMA ACYLCARNITINES; ACTIVATION; EXPRESSION; OBESITY; STRESS; LIFE; RAT	There is a growing interest on the role of autophagy in diabetes pathophysiology, where development of neuropathy is one of the most frequent comorbidities. We have previously demonstrated that neuropathic pain after nerve damage is exacerbated in autophagy-defective heterozygous Ambra1 mice. Here, we show the existence of a prediabetic state in Ambra1 mice, characterized by hyperglycemia, intolerance to glucose and insulin resistance. Thus, we further investigate the hypothesis that prediabetes may account for the exacerbation of allodynia and chronic pain and that counteracting the autophagy deficit may relieve the neuropathic condition. We took advantage from caloric restriction (CR) able to exert a double action: a powerful increase of autophagy and a control on the metabolic status. We found that CR ameliorates neuropathy throughout anti-inflammatory and metabolic mechanisms both in Ambra1 and in WT animals subjected to nerve injury. Moreover, we discovered that nerve lesion represents, per se, a metabolic stressor and CR reinstates glucose homeostasis, insulin resistance, incomplete fatty acid oxidation and energy metabolism. As autophagy inducer, CR promotes and anticipates Schwann cell autophagy via AMP-activated protein kinase (AMPK) that facilitates remyelination in peripheral nerve. In summary, we provide new evidence for the role of autophagy in glucose metabolism and identify in energy depletion by dietary restriction a therapeutic approach in the fight against neuropathic pain.	[Coccurello, Roberto; Vacca, Valentina; Giacovazzo, Giacomo; Marinelli, Sara] CNR, Natl Res Council, Inst Cell Biol & Neurobiol, Rome, Italy; [Coccurello, Roberto; Nazio, Francesca; De Angelis, Federica; Vacca, Valentina; Giacovazzo, Giacomo; Marinelli, Sara] IRCCS S Lucia Fdn, Rome, Italy; [Rossi, Claudia] G dAnnunzio Univ Chieti Pescara, Dept Med Oral & Biotechnol Sci, Chieti, Italy; [Rossi, Claudia; Ciavardelli, Domenico] Ctr Sci Invecchiamento & Med Traslaz CeSI MeT, Chieti, Italy; [Procacci, Patrizia] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy; [Magnaghi, Valerio] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy; [Ciavardelli, Domenico] Kore Univ Enna, Sch Human & Social Sci, Enna, Italy; [Nazio, Francesca] IRCCS Bambino Gesu Childrens Hosp, Dept Pediat Hematol & Oncol, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia Cellulare e Neurobiologia (IBCN-CNR); IRCCS Santa Lucia; G d'Annunzio University of Chieti-Pescara; University of Milan; University of Milan; Universita Kore di ENNA; IRCCS Bambino Gesu	Marinelli, S (corresponding author), CNR, Natl Res Council, Inst Cell Biol & Neurobiol, Rome, Italy.	sara.marinelli@cnr.it	Marinelli, Sara/L-7738-2019; Coccurello, Roberto/F-8460-2015; de angelis, federica/AAG-3425-2020; Nazio, Francesca/K-5272-2014; Vacca, Valentina/J-6643-2018; De Angelis, Federica/P-6426-2018	Marinelli, Sara/0000-0001-5393-4796; Nazio, Francesca/0000-0002-3039-4448; Giacovazzo, Giacomo/0000-0001-7430-2835; Vacca, Valentina/0000-0003-2657-0450; De Angelis, Federica/0000-0001-5773-3414	Italian Ministry of Health - Young Researchers grant [GR-2011-02346912]	Italian Ministry of Health - Young Researchers grant	This work was supported by Italian Ministry of Health - Young Researchers grant GR-2011-02346912. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams SH, 2009, J NUTR, V139, P1073, DOI 10.3945/jn.108.103754; Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Bhatheja K, 2006, INT J BIOCHEM CELL B, V38, P1995, DOI 10.1016/j.biocel.2006.05.007; Bonomini M, 2013, AM J KIDNEY DIS, V62, P929, DOI 10.1053/j.ajkd.2013.04.007; Coccurello R, 2017, EUR J NUTR, V56, P1; Delaney CL, 2001, J NEUROPATH EXP NEUR, V60, P147, DOI 10.1093/jnen/60.2.147; Di Liberato L, 2014, J NEPHROL, V27, P699, DOI 10.1007/s40620-014-0076-x; Dodd KM, 2012, AM J PHYSIOL-ENDOC M, V302, pE1329, DOI 10.1152/ajpendo.00525.2011; Dubovy P, 2011, ANN ANAT, V193, P267, DOI 10.1016/j.aanat.2011.02.011; Eldin WS, 2008, INT J CLIN PRACT, V62, P642, DOI 10.1111/j.1742-1241.2008.01705.x; Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168; Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925; Giacovazzo G, 2018, PURINERG SIGNAL, V14, P299, DOI 10.1007/s11302-018-9610-y; Giesbertz P, 2016, CURR OPIN CLIN NUTR, V19, P48, DOI 10.1097/MCO.0000000000000235; Gomez-Sanchez JA, 2015, J CELL BIOL, V210, P153, DOI 10.1083/jcb.201503019; Gonzalez CD, 2011, AUTOPHAGY, V7, P2, DOI 10.4161/auto.7.1.13044; Hao W, 2015, J BIOL CHEM, V290, P17106, DOI 10.1074/jbc.M114.631291; Heimburger DC, 2006, HDB CLIN NUTR, V17, P371; Inman CF, 2005, J IMMUNOL METHODS, V302, P156, DOI 10.1016/j.jim.2005.05.005; Jung HS, 2008, CELL METAB, V8, P318, DOI 10.1016/j.cmet.2008.08.013; Kaniuk NA, 2007, DIABETES, V56, P930, DOI 10.2337/db06-1160; Kidd GJ, 2013, HAND CLINIC, V115, P55, DOI 10.1016/B978-0-444-52902-2.00005-9; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kobayakawa K, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009430; LECLERCQMEYER V, 1985, ENDOCRINOLOGY, V116, P1168, DOI 10.1210/endo-116-3-1168; Luvisetto S, 2007, NEUROSCIENCE, V145, P1, DOI 10.1016/j.neuroscience.2006.12.004; MacEwan DJ, 2002, BRIT J PHARMACOL, V135, P855, DOI 10.1038/sj.bjp.0704549; Madeo F, 2015, J CLIN INVEST, V125, P85, DOI 10.1172/JCI73946; Marinelli S, 2014, PAIN, V155, P93, DOI 10.1016/j.pain.2013.09.013; Mihalik SJ, 2010, OBESITY, V18, P1695, DOI 10.1038/oby.2009.510; Newgard CB, 2009, CELL METAB, V9, P311, DOI 10.1016/j.cmet.2009.02.002; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Parkitna JR, 2006, J PHYSIOL PHARMACOL, V57, P401; Quan W, 2012, DIABETOLOGIA, V55, P392, DOI 10.1007/s00125-011-2350-y; Sag D, 2008, J IMMUNOL, V181, P8633, DOI 10.4049/jimmunol.181.12.8633; Sandhir R, 2011, NEUROCHEM RES, V36, P856, DOI 10.1007/s11064-011-0414-5; Sirolli V, 2012, BLOOD TRANSFUS-ITALY, V10, pS78, DOI 10.2450/2012.012S; Stino AM, 2017, J DIABETES INVEST, V8, P646, DOI 10.1111/jdi.12650; Stockli J, 2017, J BIOL CHEM, V292, P19135, DOI 10.1074/jbc.M117.818351; Stohr R, 2014, ATHEROSCLEROSIS, V235, P438, DOI 10.1016/j.atherosclerosis.2014.05.946; Su XD, 2015, NAT IMMUNOL, V16, P838, DOI 10.1038/ni.3205; Sun L, 2016, DIABETES CARE, V39, P1563, DOI 10.2337/dc16-0232; Tremblay F, 2005, DIABETES, V54, P2674, DOI 10.2337/diabetes.54.9.2674; Um SH, 2006, CELL METAB, V3, P393, DOI 10.1016/j.cmet.2006.05.003; Unger RH, 2012, J CLIN INVEST, V122, P4, DOI 10.1172/JCI60016; Veroni C, 2010, MOL CELL NEUROSCI, V45, P234, DOI 10.1016/j.mcn.2010.06.014; Wu J, 2013, ENDOCRINE, V44, P87, DOI 10.1007/s12020-012-9826-5; Xia JG, 2009, NUCLEIC ACIDS RES, V37, pW652, DOI 10.1093/nar/gkp356; Yagihashi S, 2016, INT REV NEUROBIOL, V127, P121, DOI 10.1016/bs.irn.2016.03.006; Zhang XY, 2014, DIABETES RES CLIN PR, V104, P376, DOI 10.1016/j.diabres.2014.04.013; Zhao X, 2008, AM J PHYSIOL-LUNG C, V295, pL497, DOI 10.1152/ajplung.90210.2008	53	20	20	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2018	13	12							e0208569	10.1371/journal.pone.0208596	http://dx.doi.org/10.1371/journal.pone.0208596			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD6JR	30532260	Green Published, Green Submitted, gold			2023-01-03	WOS:000452644700034
J	Fuchs, AL; Weaver, AJ; Tripet, BP; Ammons, MCB; Teintze, M; Copie, V				Fuchs, Amanda L.; Weaver, Alan J., Jr.; Tripet, Brian P.; Ammons, Mary Cloud B.; Teintze, Martin; Copie, Valerie			Characterization of the antibacterial activity of Bald's eyesalve against drug resistant Staphylococcus aureus and Pseudomonas aeruginosa	PLOS ONE			English	Article							QUORUM-SENSING ACTIVITY; METHICILLIN-RESISTANT; NATURAL-PRODUCTS; ALLICIN; BIOFILM; L.; MEMBRANE; SULFIDES; ETHANOL	Bald's eyesalve is an Anglo-Saxon medicinal remedy that has been used through ancient times to treat eye sty infections and may represent a source of ancientbiotics. This study assessed the efficacy of Bald's eyesalve against several strains of Staphylococcus aureus and Pseudomonas aeruginosa, including a multi-drug resistant phenotype, and identified the principal compound conveying antibacterial activity. Bald's eyesalve formulations were produced by combining garlic, onion or leek, wine, bovine bile, and brass, with specific ingredient omissions in several formulations, followed by incubation at 4 degrees C for 9 days. Bald's eyesalve formulation ES-GBBr exhibited the greatest antibacterial activity against S. aureus and P. aeruginosa. Fractionation of ES-GBBr using molecular size exclusion and organic solvent partitioning isolated its antibacterial activity to the small molecule nonpolar fraction, and 1D H-1 NMR revealed the identity of the antibacterial agent to be allicin. Depletion of allicin from this fraction by addition of exogenous cysteine established that all observable growth inhibition originated from allicin. Quantification of allicin demonstrated that its concentration was significantly greater in ES-GBBr compared to the ES-O formulation; however, this was not due to greater yield. The antibacterial activity of allicin against S. aureus was antagonized by other ingredients within Bald's eyesalve, whereas they were additive or synergistic against P. aeruginosa. These results suggest that neither leek nor onion is necessary for the antibacterial efficacy of Bald's eyesalve against S. aureus or P. aeruginosa, and while allicin was identified as the principal antibacterial agent present, its activity is influenced differentially in the presence of additional Bald's eyesalve ingredients when used against S. aureus compared to P. aeruginosa. Ancientbiotics may provide a source of promising antibacterials; however, identifying the source of activity and assessing distinct formulations for cooperative effects are essential to using ancient remedies, such as Bald's eyesalve, effectively against drug resistant pathogens.	[Fuchs, Amanda L.; Weaver, Alan J., Jr.; Tripet, Brian P.; Ammons, Mary Cloud B.; Teintze, Martin; Copie, Valerie] Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA; [Weaver, Alan J., Jr.] US Army, Dent & Craniofacial Trauma Res & Tissue Regenerat, Inst Surg Res, Jbsa Ft Sam Houston, TX USA; [Ammons, Mary Cloud B.] Idaho Vet Res & Educ Fdn, Boise Vet Med Ctr, Boise, ID USA	Montana State University System; Montana State University Bozeman	Fuchs, AL; Copie, V (corresponding author), Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA.	afuchs03143@gmail.com; vcopie@montana.edu	Copie, Valerie/GLT-8476-2022; Copie, Valerie/GPW-9767-2022	Copie, Valerie/0000-0002-2778-1463; Copie, Valerie/0000-0002-2778-1463; Fuchs, Amanda/0000-0002-7085-0727; Ammons, Mary Cloud/0000-0002-9717-0844	Montana Research Initiative [51040-MUSRI2015-03]; NSF [MCB-1714556]; NIH [1KO1GM103821-04]; NIH Shared Instrumentation Grant (SIG) program [1S10RR13878, 1S10RR026659]; National Science Foundation [NSF-MRI: DBI-1532078]; Murdock Charitable Trust Foundation [2015066: MNL]; MSU's Vice President for Research and Economic Development's office; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K01GM103821, P20GM109007] Funding Source: NIH RePORTER	Montana Research Initiative; NSF(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Shared Instrumentation Grant (SIG) program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Murdock Charitable Trust Foundation; MSU's Vice President for Research and Economic Development's office; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was funded, in part, by the Montana Research Initiative Grant No. 51040-MUSRI2015-03 (VC, ALF, BPT), NSF Grant No. MCB-1714556 (VC, ALF), and NIH Grant No. 1KO1GM103821-04 (MCBA). The 1D 1H NMR spectra included in this manuscript were recorded at Montana State University's NMR Center on a Bruker AVANCE III 600 NMR spectrometer. Funding for the instrument and corresponding upgrade was provided by the NIH Shared Instrumentation Grant (SIG) program (Grant No. 1S10RR13878 and 1S10RR026659). Support for MSU's NMR Center and new NMR spectrometer has been provided by the National Science Foundation (Grant No. NSF-MRI: DBI-1532078), the Murdock Charitable Trust Foundation (Grant No. 2015066: MNL), and MSU's Vice President for Research and Economic Development's office. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abel U, 2002, CURR OPIN CHEM BIOL, V6, P453, DOI 10.1016/S1367-5931(02)00338-1; Abidi SH, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-57; Ammons MCB, 2014, J PROTEOME RES, V13, P2973, DOI 10.1021/pr500120c; [Anonymous], 2015, M07 A10 METHODS DILU; Atanasov AG, 2015, BIOTECHNOL ADV, V33, P1582, DOI 10.1016/j.biotechadv.2015.08.001; Barrera NP, 2005, TRENDS PHARMACOL SCI, V26, P526, DOI 10.1016/j.tips.2005.08.003; Borlinghaus J, 2014, MOLECULES, V19, P12591, DOI 10.3390/molecules190812591; BOWLES LK, 1985, APPL ENVIRON MICROB, V50, P1165, DOI 10.1128/AEM.50.5.1165-1170.1985; Cavallito CJ, 1944, J AM CHEM SOC, V66, P1950, DOI 10.1021/ja01239a048; Chhabria S, 2018, SAUDI J BIOL SCI, V25, P1429, DOI 10.1016/j.sjbs.2016.01.003; Cockayne TO, 1864, ROLLS SERIES 35; Corral MJ, 2014, ANTIMICROB AGENTS CH, V58, P1596, DOI 10.1128/AAC.00710-13; Cutler RR, 2004, BRIT J BIOMED SCI, V61, P71, DOI 10.1080/09674845.2004.11732646; Diep BA, 2006, LANCET, V367, P731, DOI 10.1016/S0140-6736(06)68231-7; Eldridge GR, 2002, ANAL CHEM, V74, P3963, DOI 10.1021/ac025534s; FEROCI G, 1995, ANAL CHEM, V67, P4077, DOI 10.1021/ac00118a008; FREEMAN F, 1995, J AGR FOOD CHEM, V43, P2332, DOI 10.1021/jf00057a004; FRIED VA, 1973, J BACTERIOL, V114, P239, DOI 10.1128/JB.114.1.239-248.1973; Fujisawa H, 2008, J AGR FOOD CHEM, V56, P4229, DOI 10.1021/jf8000907; Gruhlke MCH, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6010001; Harrison F, 2015, MBIO, V6, DOI 10.1128/mBio.01129-15; HUANG L, 1986, APPL ENVIRON MICROB, V51, P1230, DOI 10.1128/AEM.51.6.1230-1234.1986; Ilic D, 2012, SCI WORLD J, DOI 10.1100/2012/561823; Inui T, 2012, FITOTERAPIA, V83, P1218, DOI 10.1016/j.fitote.2012.06.012; James GA, 2008, WOUND REPAIR REGEN, V16, P37, DOI 10.1111/j.1524-475X.2007.00321.x; Kim JW, 2004, FOOD SCI BIOTECHNOL, V13, P235; Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038/nrd1657; Lanzotti V, 2013, PHYTOCHEM REV, V12, P751, DOI 10.1007/s11101-013-9295-3; Lee JH, 2013, BIOFOULING, V29, P491, DOI 10.1080/08927014.2013.788692; Li XZ, 2015, CLIN MICROBIOL REV, V28, P337, DOI 10.1128/CMR.00117-14; Liu Zhijun, 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P112, DOI 10.2174/187153008784534358; Man A, 2017, REV ROMANA MED LAB, V25, P335, DOI 10.1515/rrlm-2017-0028; Marshakov IK, 2005, PROT MET+, V41, P205, DOI 10.1007/s11124-005-0031-2; Mazzola PG, 2009, BRAZ J PHARM SCI, V45, P241, DOI 10.1590/S1984-82502009000200008; Mnayer D, 2014, MOLECULES, V19, P20034, DOI 10.3390/molecules191220034; Muller A, 2016, J BIOL CHEM, V291, P11477, DOI 10.1074/jbc.M115.702308; Musthafa KS, 2010, CHEMOTHERAPY, V56, P333, DOI 10.1159/000320185; Natesan M, 2008, SCI TECHNOL ADV MAT, V9, DOI 10.1088/1468-6996/9/4/045002; O'Callaghan RJ, 2018, PATHOGENS, V7, DOI 10.3390/pathogens7010009; O'Neill J., 2016, REV ANTIMICROBIAL RE; Qiu F, 2013, J NAT PROD, V76, P413, DOI 10.1021/np3007809; Rahal JJ, 2006, CLIN INFECT DIS, V43, pS95, DOI 10.1086/504486; Santas J, 2010, INT J FOOD SCI TECH, V45, P403, DOI 10.1111/j.1365-2621.2009.02169.x; Sharifi-Rad J, 2014, ANN MED HEALTH SCI R, V4, P863, DOI 10.4103/2141-9248.144883; Silhavy TJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000414; Silveira MG, 2004, APPL ENVIRON MICROB, V70, P2748, DOI 10.1128/AEM.70.5.2748-2755.2004; Stewart PS, 2015, ANTIMICROB AGENTS CH, V59, P3838, DOI 10.1128/AAC.00433-15; Torella JP, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000796; Tsao SM, 2001, J MED MICROBIOL, V50, P646, DOI 10.1099/0022-1317-50-7-646; Tsaoa SM, 2001, J ANTIMICROB CHEMOTH, V47, P665, DOI 10.1093/jac/47.5.665; Vandeputte OM, 2011, MICROBIOL-SGM, V157, P2120, DOI 10.1099/mic.0.049338-0; Vasavi HS, 2016, J MICROBIOL IMMUNOL, V49, P8, DOI 10.1016/j.jmii.2014.03.012; Wagner H, 2009, PHYTOMEDICINE, V16, P97, DOI 10.1016/j.phymed.2008.12.018; Watkins F, 2011, DRUG DISCOV TODAY, V16, P1069, DOI 10.1016/j.drudis.2011.07.002; Wu XQ, 2015, FOOD SCI NUTR, V3, P158, DOI 10.1002/fsn3.199	55	9	9	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2018	13	11							e0208108	10.1371/journal.pone.0208108	http://dx.doi.org/10.1371/journal.pone.0208108			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC4EO	30485362	Green Published, Green Submitted, gold			2023-01-03	WOS:000451755800108
J	Dehghan, M; Mente, A; Rangarajan, S; Sheridan, P; Mohan, V; Iqbal, R; Gupta, R; Lear, S; Wentzel-Viljoen, E; Avezum, A; Lopez-Jaramillo, P; Mony, P; Varma, RP; Kumar, R; Chifamba, J; Alhabib, KF; Mohammadifard, N; Oguz, A; Lanas, F; Rozanska, D; Bostrom, KB; Yusoff, K; Tsolkile, LP; Dans, A; Yusufali, A; Orlandini, A; Poirier, P; Khatib, R; Hu, B; Wei, L; Yin, L; Deeraili, A; Yeates, K; Yusuf, R; Ismail, N; Mozaffarian, D; Teo, K; Anand, SS; Yusuf, S				Dehghan, Mahshid; Mente, Andrew; Rangarajan, Sumathy; Sheridan, Patrick; Mohan, Viswanathan; Iqbal, Romaina; Gupta, Rajeev; Lear, Scott; Wentzel-Viljoen, Edelweiss; Avezum, Alvaro; Lopez-Jaramillo, Patricio; Mony, Prem; Varma, Ravi Prasad; Kumar, Rajesh; Chifamba, Jephat; Alhabib, Khalid F.; Mohammadifard, Noushin; Oguz, Aytekin; Lanas, Fernando; Rozanska, Dorota; Bostrom, Kristina Bengtsson; Yusoff, Khalid; Tsolkile, Lungiswa P.; Dans, Antonio; Yusufali, AfzalHussein; Orlandini, Andres; Poirier, Paul; Khatib, Rasha; Hu, Bo; Wei, Li; Yin, Lu; Deeraili, Ai; Yeates, Karen; Yusuf, Rita; Ismail, Noorhassim; Mozaffarian, Dariush; Teo, Koon; Anand, Sonia S.; Yusuf, Salim		Prospective Urban Rural Epide	Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study	LANCET			English	Article							ALL-CAUSE; METAANALYSIS; CONSUMPTION; RISK; FLAVONOIDS; PRODUCTS; CALCIUM	Background Dietary guidelines recommend minimising consumption of whole-fat dairy products, as they are a source of saturated fats and presumed to adversely affect blood lipids and increase cardiovascular disease and mortality. Evidence for this contention is sparse and few data for the effects of dairy consumption on health are available from low-income and middle-income countries. Therefore, we aimed to assess the associations between total dairy and specific types of dairy products with mortality and major cardiovascular disease. Methods The Prospective Urban Rural Epidemiology (PURE) study is a large multinational cohort study of individuals aged 35-70 years enrolled from 21 countries in five continents. Dietary intakes of dairy products for 136 384 individuals were recorded using country-specific validated food frequency questionnaires. Dairy products comprised milk, yoghurt, and cheese. We further grouped these foods into whole-fat and low-fat dairy. The primary outcome was the composite of mortality or major cardiovascular events (defined as death from cardiovascular causes, non-fatal myocardial infarction, stroke, or heart failure). Hazard ratios (HRs) were calculated using multivariable Cox frailty models with random intercepts to account for clustering of participants by centre. Findings Between Jan 1, 2003, and July 14, 2018, we recorded 10 567 composite events (deaths [n=6796] or major cardiovascular events [n=5855]) during the 9.1 years of follow-up. Higher intake of total dairy (>2 servings per day compared with no intake) was associated with a lower risk of the composite outcome (HR 0.84, 95% CI 0.75-0.94; p(trend) 0.0004), total mortality (0.83, 0.72-0.96; p(trend) 0.0052), non-cardiovascular mortality (0.86, 0.72-1.02; p(trend)=0.046), cardiovascular mortality (0.77, 0.58-1.01; p(trend)=0.029), major cardiovascular disease (0.78, 0.67-0.90; p(trend)=0.0001), and stroke (0.66, 0.53-0.82; p(trend)=0.0003). No significant association with myocardial infarction was observed (HR 0.89, 95% CI 0.71-1.11;p(trend)=0.163). Higher intake (>1 serving vs no intake) of milk (HR 0.90, 95% CI 0.82-0.99; p(trend)=0.0529) and yogurt (0.86, 0.75-0.99; p(trend)=0.0051) was associated with lower risk of the composite outcome, whereas cheese intake was not significantly associated with the composite outcome (0.88, 0.76-1.02; p(trend)=0.1399). Butter intake was low and was not significantly associated with clinical outcomes (HR 1.09, 95% CI 0.90-1.33; p(trend)=0.4113). Interpretation Dairy consumption was associated with lower risk of mortality and major cardiovascular disease events in a diverse multinational cohort. Copyright (c) 2018 Elsevier Ltd. All rights reserved.	[Dehghan, Mahshid; Mente, Andrew; Rangarajan, Sumathy; Sheridan, Patrick; Teo, Koon; Anand, Sonia S.; Yusuf, Salim] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada; [Mente, Andrew] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Mohan, Viswanathan] Madras Diabet Res Fdn, Madras, Tamil Nadu, India; [Iqbal, Romaina] Aga Khan Univ, Hlth Sci & Med, Dept Community, Karachi, Pakistan; [Gupta, Rajeev] Eternal Heart Care Ctr & Res Inst, Dept Med, Jaipur, Rajasthan, India; [Lear, Scott] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada; [Wentzel-Viljoen, Edelweiss] North West Univ, Ctr Excellence Nutr, Potchefstroom Campus, Potchefstroom, South Africa; [Avezum, Alvaro] Dante Pazzanese Inst Cardiol, Sao Paulo, Brazil; [Lopez-Jaramillo, Patricio] Univ Santander, Med Sch, Fdn Oftalmol Santander, Res Dept, Floridablanca Santander, Colombia; [Mony, Prem] St Johns Med Coll & Res Inst, Div Epidemiol & Populat Hlth, Bangalore, Karnataka, India; [Varma, Ravi Prasad] Achutha Menon Ctr Hlth Sci Studies Hlth Act Peopl, Fac Hlth Sci, Thiruvananthapuram, Kerala, India; [Kumar, Rajesh] PGIMER, Sch Publ Hlth, Chandigarh, India; [Chifamba, Jephat] Univ Zimbabwe, Physiol Dept, Coll Hlth Sci, Harare, Zimbabwe; [Alhabib, Khalid F.] King Saud Univ, Dept Cardiac Sci, King Fahad Cardiac Ctr, Coll Med, Riyadh, Saudi Arabia; [Mohammadifard, Noushin] Isfahan Univ Med Sci, Cardiovasc Res Inst, Isfahan Cardiovasc Res Ctr, Esfahan, Iran; [Oguz, Aytekin] Istanbul Medeniyet Univ, Fac Med, Dept Internal Med, Istanbul, Turkey; [Lanas, Fernando] Univ La Frontera, Dept Med, Francisco Salazar, Temuco, Chile; [Rozanska, Dorota] Wroclaw Med Univ, Dept Dietet, Wroclaw, Poland; [Bostrom, Kristina Bengtsson] Univ Gothenburg, Narhalsan R& Ctr Skaraborg Primary Care Skovde, Gothenburg, Sweden; [Bostrom, Kristina Bengtsson] Univ Gothenburg, Dept Publ Hlth & Community Med, Primary Hlth Care, Sahlgrenska Acad, Gothenburg, Sweden; [Yusoff, Khalid] Univ Teknol MARA, Dept Med, Sungai Buloh, Selangor, Malaysia; [Yusoff, Khalid] UCSI Univ, Dept Med, Cheras, Selangor, Malaysia; [Tsolkile, Lungiswa P.] Univ Western Cape, Sch Publ Hlth, Cape Town, Western Cape Pr, South Africa; [Dans, Antonio] Univ Philippines, Dept Med, Manila, Philippines; [Yusufali, AfzalHussein] Dubai Med Univ, Hatta Hosp, Dubai Hlth Author, Dubai, U Arab Emirates; [Orlandini, Andres] Estudios Clin Latinoamer, Rosario, Santa Fe, Argentina; [Poirier, Paul] Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada; [Khatib, Rasha] Northwestern Univ, Dept Neurol, Feinberg Sch Med, Chicago, IL 60611 USA; [Hu, Bo; Wei, Li] Fuwai Hosp, Natl Ctr Cardiovasc Dis, Peking Union Med Coll, State Key Lab Cardiovasc Dis, Beijing, Peoples R China; [Hu, Bo; Wei, Li] Chinese Acad Med Sci, Beijing, Peoples R China; [Deeraili, Ai] Ctr Dis Control & Prevent Xinjiang Hetian, Xinjiang, Peoples R China; [Yeates, Karen] Queens Univ, Dept Med, Kingston, ON, Canada; [Yusuf, Rita] Independent Univ Bashundhara, Sch Life Sci, Dhaka, Bangladesh; [Ismail, Noorhassim] Univ Kebangsaan Malaysia, Med Ctr, Dept Community Hlth, Kuala Lumpur, Malaysia; [Mozaffarian, Dariush] Tufts Univ, Friedman Sch Nutr Sci & Policy, Medford, MA 02155 USA	McMaster University; Population Health Research Institute; McMaster University; Madras Diabetes Research Foundation; Aga Khan University; Eternal Heart Care Centre & Research Institute; Simon Fraser University; North West University - South Africa; Instituto Dante Pazzanese de Cardiologia; Universidad Industrial de Santander; St. John's National Academy of Health Sciences; St. John's Medical College; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; University of Zimbabwe; King Saud University; Isfahan University Medical Science; Istanbul Medeniyet University; Universidad de La Frontera; Wroclaw Medical University; University of Gothenburg; University of Gothenburg; Universiti Teknologi MARA; UCSI University; University of the Western Cape; University of the Philippines System; University of the Philippines Manila; Laval University; Northwestern University; Feinberg School of Medicine; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Queens University - Canada; Independent University Bangladesh (IUB); Universiti Kebangsaan Malaysia; Tufts University	Dehghan, M (corresponding author), McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada.	mahshid.dehghan@phri.ca	Khatib, Rasha/GXV-8883-2022; Mohammadifard, Noushin/M-2244-2018; Chifamba, Jephat/AHE-4535-2022; Varma, Ravi Prasad/CAF-5363-2022; Mony, Prem K./GRF-4752-2022; Lanas, Fernando/AAE-8842-2022; Mozaffarian, Dariush/ABC-2822-2020; Varma, Ravi Prasad/AAV-3234-2020; Oguz, Aytekin/AAJ-2732-2021; Różańska, Dorota/ABD-3220-2021; Avezum, Alvaro/AAP-7687-2020; ISMAIL, ROSNAH/V-2910-2017; Rozanska, Dorota/S-5239-2018	Mohammadifard, Noushin/0000-0003-1776-1060; Chifamba, Jephat/0000-0001-8166-1182; Varma, Ravi Prasad/0000-0002-1147-9622; Mony, Prem K./0000-0002-1399-0520; Oguz, Aytekin/0000-0002-2595-5167; ISMAIL, ROSNAH/0000-0002-8178-3822; Teo, Koon/0000-0002-3731-0956; Yusufali, Afzalhussein/0000-0003-3378-2646; Regulska-Ilow, Bozena/0000-0002-5941-1715; Zatonska, Katarzyna/0000-0002-3772-5588; Yusuf, Salim/0000-0003-4776-5601; Lanas, Fernando/0000-0003-3595-9759; Alhabib, Khalid/0000-0002-6692-3874; Dehghan, Mahshid/0000-0003-2149-847X; Ismail, Noor Hassim/0000-0003-1547-7904; Rozanska, Dorota/0000-0002-0561-2749; Szuba, Andrzej/0000-0002-7555-6201; Lopez-Jaramillo, Patricio/0000-0002-9122-8742; AVEZUM, ALVARO/0000-0002-3073-6890; Wolyniec, Maria/0000-0003-2054-1691	Heart and Stroke Foundation of Ontario; Population Health Research Institute; Canadian Institutes of Health Research (CIHR); CIHR's Strategy for Patient Oriented Research (SPOR) through the Ontario SPOR Support Unit; Ontario Ministry of Health and Long-Term Care; AstraZeneca (Canada); Sanofi-Aventis (France); Sanofi-Aventis (Canada); Boehringer Ingelheim (Germany); Boehringer Ingelheim (Canada); Servier; GlaxoSmithKline; Novartis; King Pharma; Canada: Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network, Canadian Institutes of Health Research (Catalyst Grant: eHealth Innovations) [126524]; Chile: Universidad de La Frontera (Internal Registry) [DI13-PE11]; Colombia: Colciencias [6566-04-18062]; Malaysia: Ministry of Science, Technology and Innovation of Malaysia [100-IRDC/BIOTEK 16/6/21 (13/2007), 07-05-IFN-BPH 010]; Ministry of Higher Education of Malaysia [600-RMI/LRGS/5/3 (2/2011)]; Peru: National Heart, Lung and Blood Institute [HHSN268200900033C]; National Cancer Institute [1P20CA217231]; Wellcome [103994/Z/14/Z]; Poland: Polish Ministry of Science and Higher Education [290/W-PURE/2008/0]; Saudi Arabia: Saudi Heart Association, The Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia [RG-1436-013]; Swedish state; Swedish Heart and Lung Foundation; Swedish Research Council; Swedish Council for Health, Working Life and Welfare; King Gustaf V's and Queen Victoria Freemason's Foundation; AFA Insurance	Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); Population Health Research Institute; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR's Strategy for Patient Oriented Research (SPOR) through the Ontario SPOR Support Unit(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario); AstraZeneca (Canada)(AstraZeneca); Sanofi-Aventis (France)(Sanofi-Aventis); Sanofi-Aventis (Canada)(Sanofi-Aventis); Boehringer Ingelheim (Germany)(Boehringer Ingelheim); Boehringer Ingelheim (Canada)(Boehringer Ingelheim); Servier(Servier); GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); King Pharma; Canada: Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network, Canadian Institutes of Health Research (Catalyst Grant: eHealth Innovations)(Canadian Institutes of Health Research (CIHR)); Chile: Universidad de La Frontera (Internal Registry); Colombia: Colciencias; Malaysia: Ministry of Science, Technology and Innovation of Malaysia; Ministry of Higher Education of Malaysia(Ministry of Education, Malaysia); Peru: National Heart, Lung and Blood Institute; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome; Poland: Polish Ministry of Science and Higher Education; Saudi Arabia: Saudi Heart Association, The Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia; Swedish state; Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Council for Health, Working Life and Welfare; King Gustaf V's and Queen Victoria Freemason's Foundation; AFA Insurance	SY is supported by the Mary W Burke endowed chair of the Heart and Stroke Foundation of Ontario. The PURE Study is an investigator-initiated study that is funded by the Population Health Research Institute, the Canadian Institutes of Health Research (CIHR), Heart and Stroke Foundation of Ontario, support from CIHR's Strategy for Patient Oriented Research (SPOR) through the Ontario SPOR Support Unit, as well as the Ontario Ministry of Health and Long-Term Care and through unrestricted grants from several pharmaceutical companies, with major contributions from AstraZeneca (Canada), Sanofi-Aventis (France and Canada), Boehringer Ingelheim (Germany and Canada), Servier, and GlaxoSmithKline, and additional contributions from Novartis and King Pharma and from various national or local organisations in participating countries. These include Argentina: Fundacion ECLA; Bangladesh: Independent University, Bangladesh and Mitra and Associates; Brazil: Unilever Health Institute, Brazil; Canada: Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network, Canadian Institutes of Health Research (Catalyst Grant: eHealth Innovations grant number: 126524); Chile: Universidad de La Frontera (Internal Registry DI13-PE11); China: National Center for Cardiovascular Diseases; Colombia: Colciencias, grant number: 6566-04-18062; India: Indian Council of Medical Research; Malaysia: Ministry of Science, Technology and Innovation of Malaysia grant number 100-IRDC/BIOTEK 16/6/21 (13/2007), grant number 07-05-IFN-BPH 010, Ministry of Higher Education of Malaysia grant number 600-RMI/LRGS/5/3 (2/2011), Universiti Teknologi MARA, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur Malaysia; CRIM, University Kebangsaan Malaysia; Occupied Palestinian territory: The United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA), occupied Palestinian territory; International Development Research Centre (IDRC), Canada; Peru: National Heart, Lung and Blood Institute (HHSN268200900033C), National Cancer Institute (1P20CA217231), Wellcome (103994/Z/14/Z); Philippines: Philippine Council for Health Research & Development (PCHRD); Poland: Polish Ministry of Science and Higher Education grant number 290/W-PURE/2008/0, Wroclaw Medical University, Wroclaw Medical University; Saudi Arabia: Saudi Heart Association, The Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia (Research group number: RG-1436-013); South Africa: The North-West University, SANPAD (SA and Netherlands Programme for Alternative Development), National Research Foundation, Medical Research Council of SA, The SA Sugar Association (SASA), Faculty of Community and Health Sciences (UWC); Sweden: Grants from the Swedish state under the Agreement concerning research and education of doctors; the Swedish Heart and Lung Foundation; the Swedish Research Council; the Swedish Council for Health, Working Life and Welfare, King Gustaf V's and Queen Victoria Freemason's Foundation, AFA Insurance; Tanzania: Pamoja Tunaweza Health Research Centre (Tanzania), Queen's University, Department of Medicine; Turkey: Metabolic Syndrome Society, Astra Zeneca, Turkey; UAE: Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences and Dubai Health Authority, Dubai UAE.	Alexander DD, 2016, BRIT J NUTR, V115, P737, DOI 10.1017/S0007114515005000; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Aune D, 2015, AM J CLIN NUTR, V101, P87, DOI 10.3945/ajcn.113.067157; Benatar JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076480; Bernstein AM, 2010, CIRCULATION, V122, P876, DOI 10.1161/CIRCULATIONAHA.109.915165; Choi HJ, 2011, DIABETES CARE, V34, P147; Corsi DJ, 2013, AM HEART J, V166, P636, DOI 10.1016/j.ahj.2013.04.019; de Goede J, 2015, NUTR REV, V73, P259, DOI 10.1093/nutrit/nuu060; Dehghan M, 2017, LANCET, V390, P2050, DOI [10.1016/s0140-6736(17)32252-3, 10.1016/S0140-6736(17)32252-3]; Ding M, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j1000; Farvid MS, 2017, AM J EPIDEMIOL, V185, P697, DOI 10.1093/aje/kww139; Forouhi NG, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2139; Forouhi NG, 2014, LANCET DIABETES ENDO, V2, P810, DOI 10.1016/S2213-8587(14)70146-9; Freeman AM, 2018, J AM COLL CARDIOL, V72, P553, DOI 10.1016/j.jacc.2018.05.030; Gholami F, 2017, J CARDIOVASC THORAC, V9, P1, DOI 10.15171/jcvtr.2017.01; Lear SA, 2017, LANCET, V390, P2643, DOI 10.1016/S0140-6736(17)31634-3; Merchant AT, 2006, NUTR J, V5, DOI 10.1186/1475-2891-5-2; Miller V, 2017, LANCET, V390, P2037, DOI [10.1016/S0140-6736(17)32253-5, 10.1016/s0140-6736(17)32253-5]; Mozaffarian D., DIETARY POLICY PRIOR; Mozaffarian D, 2018, CIRC RES, V122, P369, DOI 10.1161/CIRCRESAHA.117.309008; Otto MCD, 2018, AM J CLIN NUTR, V108, P476, DOI 10.1093/ajcn/nqy117; Otto MCD, 2012, AM J CLIN NUTR, V96, P397, DOI 10.3945/ajcn.112.037770; Pimpin L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158118; Porsti I, 2004, KIDNEY INT, V66, P2155, DOI 10.1111/j.1523-1755.2004.66006.x; Qin LQ, 2015, ASIA PAC J CLIN NUTR, V24, P90, DOI 10.6133/apjcn.2015.24.1.09; Soedamah-Muthu SS, 2012, HYPERTENSION, V60, P1131, DOI 10.1161/HYPERTENSIONAHA.112.195206; Tognon G, 2018, EUR J NUTR, V57, P2869, DOI 10.1007/s00394-017-1556-2; Tognon G, 2017, AM J CLIN NUTR, V105, P1502, DOI 10.3945/ajcn.116.140798; Warner EF, 2016, J NUTR, V146, P465, DOI 10.3945/jn.115.217943; Yusuf S, 2014, NEW ENGL J MED, V371, P818, DOI 10.1056/NEJMoa1311890	30	209	216	6	135	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 24	2018	392	10161					2288	2297		10.1016/S0140-6736(18)31812-9	http://dx.doi.org/10.1016/S0140-6736(18)31812-9			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB4ZY	30217460				2023-01-03	WOS:000451067600027
J	Dolgin, E				Dolgin, Elie			A life-changing innovation How the success of one targeted therapy ushered in a new era of lymphoma treatment	NATURE			English	Editorial Material							PCI-32765											Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906; Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107; Phelan JD, 2018, NATURE, V560, P387, DOI 10.1038/s41586-018-0290-0	3	0	0	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 15	2018	563	7731					S46	S47		10.1038/d41586-018-07363-4	http://dx.doi.org/10.1038/d41586-018-07363-4			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HA2EY	30429566				2023-01-03	WOS:000450048400018
J	Smith, FM; Cresswell, K; Myint, AS; Renehan, AG				Smith, Fraser M.; Cresswell, Katharine; Myint, Arthur Sun; Renehan, Andrew G.			Is "watch-and-wait" after chemoradiotherapy safe in patients with rectal cancer?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CLINICAL COMPLETE RESPONDERS; CHEMORADIATION; MANAGEMENT; SURGERY; THERAPY		[Smith, Fraser M.] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Dept Surg, Liverpool, Merseyside, England; [Cresswell, Katharine] Manchester Univ NHS Fdn Trust, Publ Programmes Team, NIHR Biomed Res Ctr Patient & Publ Canc Res Advis, Manchester, Lancs, England; [Cresswell, Katharine] Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England; [Myint, Arthur Sun] Clatterbridge Canc Ctr, Wirral, Merseyside, England; [Smith, Fraser M.; Myint, Arthur Sun] Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England; [Renehan, Andrew G.] Univ Manchester, Fac Biol Med & Hlth, Manchester Canc Res Ctr,Sch Med Sci, NIHR Manchester Biomed Res Ctr,Div Canc Sci, Manchester, Lancs, England; [Renehan, Andrew G.] Christie NHS Fdn Trust, Colorectal & Peritoneal Oncol Ctr, Manchester, Lancs, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Manchester; Clatterbridge Cancer Centre; University of Liverpool; University of Manchester; Christie NHS Foundation Trust	Smith, FM (corresponding author), Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Dept Surg, Liverpool, Merseyside, England.; Smith, FM (corresponding author), Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England.	fraser.smith@rlbuht.nhs.uk	Myint, Arthur Sun/AAO-7695-2020	Myint, Arthur Sun/0000-0001-5323-5696	NIHR Manchester Biomedical Research Centre	NIHR Manchester Biomedical Research Centre(National Institute for Health Research (NIHR))	This research was supported by the NIHR Manchester Biomedical Research Centre.	Breugom AJ, 2015, LANCET ONCOL, V16, P875, DOI 10.1016/S1470-2045(15)00015-7; Cancer Council Australia, 2017, WATCH WAIT APPR CLIN; Chadi SA, 2018, LANCET GASTROENTEROL, V3, P825, DOI 10.1016/S2468-1253(18)30301-7; Dossa F, 2017, LANCET GASTROENTEROL, V2, P501, DOI 10.1016/S2468-1253(17)30074-2; Glynne-Jones R, 2018, ANN ONCOL, V29, P263, DOI 10.1093/annonc/mdy161; Glynne-Jones R, 2012, BRIT J SURG, V99, P897, DOI 10.1002/bjs.8732; Gollins S, 2017, COLORECTAL DIS, V19, P37, DOI 10.1111/codi.13705; Habr-Gama A, 2010, DIS COLON RECTUM, V53, P1692, DOI 10.1007/DCR.0b013e3181f42b89; Kong JC, 2017, DIS COLON RECTUM, V60, P335, DOI 10.1097/DCR.0000000000000754; Maas M, 2011, J CLIN ONCOL, V29, P4633, DOI 10.1200/JCO.2011.37.7176; Maas M, 2010, LANCET ONCOL, V11, P835, DOI 10.1016/S1470-2045(10)70172-8; Martens MH, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw171; Monson JRT, 2013, DIS COLON RECTUM, V56, P535, DOI 10.1097/DCR.0b013e31828cb66c; Myint AS, 2018, INT J RADIAT ONCOL, V100, P565, DOI 10.1016/j.ijrobp.2017.10.022; National Institute for Health and Clinical Excellence, 2012, NON TRADITIONAL REF; Renehan AG, 2017, LANCET GASTROENTEROL, V2, P627, DOI 10.1016/S2468-1253(17)30218-2; Renehan AG, 2016, LANCET ONCOL, V17, P174, DOI 10.1016/S1470-2045(15)00467-2; Smith FM, 2010, BRIT J SURG, V97, P1752, DOI 10.1002/bjs.7251; Smith FM, 2014, DIS COLON RECTUM, V57, P311, DOI 10.1097/DCR.0b013e3182a84eba; van der Valk MJM, 2018, LANCET, V391, P2537, DOI 10.1016/S0140-6736(18)31078-X	20	13	14	2	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2018	363								k4472	10.1136/bmj.k4472	http://dx.doi.org/10.1136/bmj.k4472			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB0RO	30425053				2023-01-03	WOS:000450725200001
J	Erythropel, HC; Kong, G; deWinter, TM; O'Malley, SS; Jordt, SE; Anastas, PT; Zimmerman, JB				Erythropel, Hanno C.; Kong, Grace; deWinter, Tamara M.; O'Malley, Stephanie S.; Jordt, Sven E.; Anastas, Paul T.; Zimmerman, Julie B.			Presence of High-Intensity Sweeteners in Popular Cigarillos of Varying Flavor Profiles	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Erythropel, Hanno C.; deWinter, Tamara M.; Zimmerman, Julie B.] Yale Univ, Dept Chem & Environm Engn, 17 Hillhouse Ave, New Haven, CT 06511 USA; [Kong, Grace; O'Malley, Stephanie S.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Jordt, Sven E.] Duke Univ, Sch Med, Dept Anesthesiol, Durham, NC USA; [Anastas, Paul T.] Yale Univ, Sch Med, Sch Publ Hlth, New Haven, CT USA	Yale University; Yale University; Duke University; Yale University	Zimmerman, JB (corresponding author), Yale Univ, Dept Chem & Environm Engn, 17 Hillhouse Ave, New Haven, CT 06511 USA.	julie.zimmerman@yale.edu	Jordt, Sven-Eric/ABE-6517-2020; Erythropel, Hanno/T-5737-2017; Anastas, Paul/L-3258-2013	Jordt, Sven-Eric/0000-0001-6171-5622; Erythropel, Hanno/0000-0003-3443-9794; Anastas, Paul/0000-0003-4777-5172; Zimmerman, Julie/0000-0002-5392-312X	National Institute on Drug Abuse of the National Institutes of Health (NIH) [P50DA036151]; Center for Tobacco Products of the US Food and Drug Administration (FDA) (Yale Tobacco Center of Regulatory Science); NATIONAL INSTITUTE ON DRUG ABUSE [P50DA036151] Funding Source: NIH RePORTER	National Institute on Drug Abuse of the National Institutes of Health (NIH); Center for Tobacco Products of the US Food and Drug Administration (FDA) (Yale Tobacco Center of Regulatory Science); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by grant P50DA036151 from the National Institute on Drug Abuse of the National Institutes of Health (NIH) and the Center for Tobacco Products of the US Food and Drug Administration (FDA) (Yale Tobacco Center of Regulatory Science).	Giovenco DP, 2018, DRUG ALCOHOL DEPEN, V185, P347, DOI 10.1016/j.drugalcdep.2017.12.011; Kong G, 2018, TOB REGUL SCI, V4, P50, DOI 10.18001/TRS.4.5.5; Kong Grace, 2017, Tob Regul Sci, V3, pS48, DOI 10.18001/TRS.3.2(Suppl1).6; Miao S, 2016, NICOTINE TOB RES, V18, P2169, DOI 10.1093/ntr/ntw141; National Center for Chronic Disease Prevention and Health Promotion, 2012, PREV TOB UYOUTH YO; Rosbrook K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185334	6	11	11	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2018	320	13					1380	1383		10.1001/jama.2018.11187	http://dx.doi.org/10.1001/jama.2018.11187			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV5LJ	30285168	Green Published, Bronze			2023-01-03	WOS:000446143400021
J	Almeer, RS; El-Khadragy, MF; Abdelhabib, S; Moneim, AEA				Almeer, Rafa S.; El-Khadragy, Manal F.; Abdelhabib, Semlali; Moneim, Ahmed E. Abdel			Ziziphus spina-christi leaf extract ameliorates schistosomiasis liver granuloma, fibrosis, and oxidative stress through downregulation of fibrinogenic signaling in mice	PLOS ONE			English	Article							HEPATIC STELLATE CELLS; MATRIX METALLOPROTEINASES; MANSONI INFECTION; GROWTH-FACTOR; L. WILLD; PROTECTS; EXPRESSION; APOPTOSIS; INJURY; TISSUE	Schistosomiasis is a widespread parasitic infection that affects humans, as well as wild and domestic animals. It ranks second after malaria, with a significant health and socio-economic impact in the developing countries. The objective of this study was to assess the anti-schistosomal impact of Ziziphus spina-christi leaf extract (ZLE) on Schistosoma mansoni-induced liver fibrosis in CD-1 Swiss male albino mice. S. mansoni infection was achieved by dipping of mouse tails in schistosomal cercariae. ZLE treatment was initiated at 46 days post-infection by administering a dose of the extract on a daily basis for 10 consecutive days. S. mansoni infection resulted in liver granuloma and fibrosis, with a drastic elevation in liver function factors, nitric oxide, and lipid peroxidation, which were associated with a reduction in glutathione content and substantial inhibition of antioxidant enzyme activities compared to those of the control. Induction of hepatic granuloma, oxidative stress, and fibrosis in the liver was controlled by ZLE administration, which also produced inhibition of matrix metalloproteinase-9, alpha-smooth muscle actin, transforming growth factor-beta, and tissue inhibitors of metalloproteinases expressions. In addition, the S. mansoni-infected group exhibited an increase in Box and caspase-3 levels and a decrease in Bcl-2 level. However, treatment with ZLE mainly mitigated apoptosis in the liver. Thus, the findings of this study revealed that Ziziphus spina-christi had anti-apoptotic, anti-fibrotic, antioxidant, and protective effects on S. mansoni-induced liver wounds. The benefits of Ziziphus spina-christi extract on S. mansoni were partly partially mediated by enhancing anti-fibrinogenic and nuclear factor erythroid 2-related factor 2 (Nrf2) pathways.	[Almeer, Rafa S.; El-Khadragy, Manal F.] King Saud Univ, Coll Sci, Dept Zool, Riyadh, Saudi Arabia; [El-Khadragy, Manal F.; Moneim, Ahmed E. Abdel] Helwan Univ, Fac Sci, Dept Zool & Entomol, Cairo, Egypt; [Abdelhabib, Semlali] King Saud Univ, Coll Sci, Dept Biochem, Genome Res Chair, Riyadh, Saudi Arabia	King Saud University; Egyptian Knowledge Bank (EKB); Helwan University; King Saud University	Almeer, RS (corresponding author), King Saud Univ, Coll Sci, Dept Zool, Riyadh, Saudi Arabia.; Moneim, AEA (corresponding author), Helwan Univ, Fac Sci, Dept Zool & Entomol, Cairo, Egypt.	ralmeer@ksu.edu.sa; aest1977@hotmail.com	Moneim, Ahmed E. Abdel/C-7461-2012; Semlali, Abdelhabib/AAP-7043-2020	Moneim, Ahmed E. Abdel/0000-0002-2654-2591; Semlali, Abdelhabib/0000-0002-1643-0377	Deanship of Scientific Research at King Saud University [R6-17-03-55]	Deanship of Scientific Research at King Saud University(King Saud University)	The authors extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for its funding of this work through the Research Project No. R6-17-03-55.	Abdel Moneim AE, 2013, CNS NEUROL DISORD DR; Adenowo AF, 2015, BRAZ J INFECT DIS, V19, P196, DOI 10.1016/j.bjid.2014.11.004; AEBI H, 1984, METHOD ENZYMOL, V105, P121; Aguiar DD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167135; Al-Olayan EM, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1389-1; Al-Olayan E, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/381413; Almeer RS, 2018, FOOD CHEM TOXICOL, V115, P49, DOI 10.1016/j.fct.2018.03.002; Aly HF, 2013, PARASITOL INT, V62, P380, DOI 10.1016/j.parint.2013.04.002; Amin A, 2009, FOOD CHEM TOXICOL, V47, P2111, DOI 10.1016/j.fct.2009.05.038; Anthony BJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068479; Benammar C, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-54; de Oliveira RB, 2013, INT J PARASITOL, V43, P371, DOI 10.1016/j.ijpara.2012.12.006; Dkhil MA, 2018, INFLAMMOPHARMACOLOGY, V26, P779, DOI 10.1007/s10787-017-0439-8; Dkhil MA, 2018, BIOMED PHARMACOTHER, V102, P64, DOI 10.1016/j.biopha.2018.03.032; Dkhil MA, 2014, PAK J ZOOL, V46, P763; Dooley S, 2012, CELL TISSUE RES, V347, P245, DOI 10.1007/s00441-011-1246-y; Du WD, 1999, WORLD J GASTROENTERO, V5, P397; Duarte S, 2015, MATRIX BIOL, V44-46, P147, DOI 10.1016/j.matbio.2015.01.004; El-Lakkany NM, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-9; Elaloui M, 2017, NAT PROD RES, V31, P1209, DOI 10.1080/14786419.2016.1226830; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fabre V, 2011, J INFECT DIS, V203, P707, DOI 10.1093/infdis/jiq099; Factor VM, 1998, J BIOL CHEM, V273, P15846, DOI 10.1074/jbc.273.25.15846; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hamada T, 2008, HEPATOLOGY, V47, P186, DOI 10.1002/hep.21922; Hams E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00089; Han HX, 2013, PARASITOL INT, V62, P100, DOI 10.1016/j.parint.2012.09.008; Kadioglu O, 2016, PHYTOMEDICINE, V23, P293, DOI 10.1016/j.phymed.2016.01.004; Khandoga A, 2006, J LEUKOCYTE BIOL, V79, P1295, DOI 10.1189/jlb.0805468; Lee EF, 2014, TRENDS PARASITOL, V30, P75, DOI 10.1016/j.pt.2013.12.005; Lee EF, 2011, P NATL ACAD SCI USA, V108, P6999, DOI 10.1073/pnas.1100652108; Li L, 2015, PARASITOLOGY, V142, P341, DOI 10.1017/S0031182014001115; Liang YJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023908; Liu Y, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00116; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lundy SK, 2001, INFECT IMMUN, V69, P271, DOI 10.1128/IAI.69.1.271-280.2001; Michel CG, 2011, J ETHNOPHARMACOL, V133, P53, DOI 10.1016/j.jep.2010.09.001; Moneim AEA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158965; Nabavi SF, 2016, CRIT REV CL LAB SCI, V53, P293, DOI 10.3109/10408363.2015.1129530; Naik SR, 2007, LIVER INT, V27, P393, DOI 10.1111/j.1478-3231.2007.01463.x; NISHIKIMI M, 1972, BIOCHEM BIOPH RES CO, V46, P849, DOI 10.1016/S0006-291X(72)80218-3; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Parola M, 2001, J HEPATOL, V35, P297, DOI 10.1016/S0168-8278(01)00142-8; Pearce EJ, 2005, PARASITE IMMUNOL, V27, P265, DOI 10.1111/j.1365-3024.2005.00765.x; Pradere JP, 2013, HEPATOLOGY, V58, P1461, DOI 10.1002/hep.26429; REITMAN S, 1957, AM J CLIN PATHOL, V28, P56, DOI 10.1093/ajcp/28.1.56; Shaker Y, 2014, J CLIN TRANSL HEPATO, V2, P212, DOI 10.14218/JCTH.2014.00018; de Almeida LMS, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/9521349; Singh KP, 2004, IMMUNOLOGY, V111, P343, DOI 10.1111/j.0019-2805.2004.01817.x; Sobhy MMK, 2018, EXP PARASITOL, V185, P115, DOI 10.1016/j.exppara.2018.01.013; Stetler-Stevenson WG, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127re6; Wang M, 2014, FREE RADICAL BIO MED, V71, P109, DOI 10.1016/j.freeradbiomed.2014.03.015; Wang Q, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00377-4; WHO, 2014, WHO TECH REP SER; Xu WH, 2008, LAB INVEST, V88, P1068, DOI 10.1038/labinvest.2008.75; Zhu DD, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0640-9	57	25	25	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2018	13	10							e0204923	10.1371/journal.pone.0204923	http://dx.doi.org/10.1371/journal.pone.0204923			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV5EV	30273397	gold, Green Published, Green Submitted			2023-01-03	WOS:000446124700048
J	Elwood, PC; Pickering, JE; Morgan, G; Galante, J; Weightman, AL; Morriss, D; Longley, M; Mason, M; Adame, R; Dolwani, S; Chia, WKJ; Lanas, A				Elwood, Peter C.; Pickering, Janet E.; Morgan, Gareth; Galante, Julieta; Weightman, Alison L.; Morriss, Delyth; Longley, Marcus; Mason, Malcolm; Adame, Richard; Dolwani, Sunil; Chia, John W. K.; Lanas, Angel			Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients?	PLOS ONE			English	Review							LOW-DOSE ASPIRIN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROTON PUMP INHIBITORS; BREAST-CANCER; COLORECTAL-CANCER; PROSTATE-CANCER; SECONDARY PREVENTION; REGULAR ASPIRIN; NSAID USE; SURVIVAL	Background Evidence is growing that low-dose aspirin used as an adjuvant treatment of cancer is associated with an increased survival and a reduction in metastatic spread. We therefore extended up to August 2017 an earlier systematic search and meta-analyses of published studies of low-dose aspirin taken by patients with a diagnosis of cancer. Methods Searches were completed in Medline and Embase to August 2017 using a pre-defined search strategy to identify reports of relevant studies. References in all the selected papers were scanned. Two reviewers independently applied pre-determined eligibility criteria and extracted data on cause-specific cancer deaths, overall mortality and the occurrence of metastatic spread. Meta-analyses were then conducted for different cancers and heterogeneity and publication bias assessed. Sensitivity analyses and attempts to reduce heterogeneity were conducted. Results Analyses of 29 studies reported since an earlier review up to April 2015 are presented in this report, and these are then pooled with the 42 studies in our earlier publication. Overall metaanalyses of the 71 studies are presented, based on a total of over 120 thousand patients taking aspirin. Ten of the studies also give evidence on the incidence of metastatic cancer spread. There are now twenty-nine observational studies describing colorectal cancer (CRC) and post-diagnostic aspirin. Pooling the estimates of reduction by aspirin which are reported as hazard ratios (HR), gives an overall HR for aspirin and CRC mortality 0.72(95% CI 0.64-0.80). Fourteen observational studies have reported on aspirin and breast cancer mortality and pooling those that report the association with aspirin as a hazard ratio gives HR 0.69 (0.53-0.90). Sixteen studies report on aspirin and prostate cancer mortality and a pooled estimate yields an HR of 0.87 (95% CI 0.73-1.05). Data from 12 reports relating to other cancers are also listed. Ten studies give evidence of a reduction in metastatic spread; four give a pooled HR 0.31 (95% CI 0.18, 0.54) and five studies which reported odds ratio of metastatic spread give OR 0.79 (0.66 to 0.95). Conclusion Being almost entirely from observational studies, the evidence of benefit from aspirin is limited. There is heterogeneity between studies and the results are subject to important biases, only some of which can be identified. Nevertheless, the evidence would seem to merit wide discussion regarding whether or not it is adequate to justify the recommendation of low-dose therapeutic aspirin, and if it is, for which cancers?	[Elwood, Peter C.; Pickering, Janet E.] Cardiff Univ, Cochrane Inst Primary Care & Publ Hlth, Cardiff, S Glam, Wales; [Pickering, Janet E.] Univ Reading, Inst Food Nutr & Hlth, Reading, Berks, England; [Morgan, Gareth] Hywel Dda Univ Hlth Board, Llanelli, Wales; [Galante, Julieta] Univ Cambridge, Dept Psychiat, Cambridge, England; [Weightman, Alison L.; Morriss, Delyth] Cardiff Univ, Specialist Unit Review Evidence, Cardiff, S Glam, Wales; [Longley, Marcus] Univ South Wales, Hlth Policy, Pontypridd, M Glam, Wales; [Mason, Malcolm] Cardiff Univ, Sch Med, Div Canc & Genet, Cardiff, S Glam, Wales; [Adame, Richard] Cardiff Univ, Inst Canc & Genet, Cardiff, S Glam, Wales; [Dolwani, Sunil] Cardiff Univ, Sch Med, Div Populat Med, Cardiff, S Glam, Wales; [Chia, John W. K.] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore; [Lanas, Angel] Univ Zaragoza, IIS Aragon, CIBERehd, Zaragoza, Spain	Cardiff University; University of Reading; University of Cambridge; Cardiff University; University of South Wales; Cardiff University; Cardiff University; Cardiff University; National Cancer Centre Singapore (NCCS); CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD	Elwood, PC (corresponding author), Cardiff Univ, Cochrane Inst Primary Care & Publ Hlth, Cardiff, S Glam, Wales.	ElwoodPC@cf.ac.uk	Mason, Malcolm D/H-6979-2013; Weightman, Alison/A-4680-2010	Weightman, Alison/0000-0001-5210-3798; Morris, Delyth/0000-0001-8529-1270; Adams, Richard/0000-0003-3915-7243; Galante, Julieta/0000-0002-4108-5341				Abraham N., 2016, AM J GASTROENTEROL S, V3, P2, DOI DOI 10.1038/AJGSUP.2016.2; Abraham NS, 2010, J AM COLL CARDIOL, V56, P2051, DOI 10.1016/j.jacc.2010.09.010; Algra AM, 2012, LANCET ONCOL, V13, P518, DOI 10.1016/S1470-2045(12)70112-2; Ali R, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-261; [Anonymous], 2014, Gastroenterol Hepatol (N Y), V10, P61; Assayag J, 2015, J UROLOGY, V193, P1220, DOI 10.1016/j.juro.2014.11.018; Baigent C, 2016, ANN INTERN MED, V164, P846, DOI 10.7326/M16-0576; Bains SJ, 2016, J CLIN ONCOL, V34, P2501, DOI 10.1200/JCO.2015.65.3519; Bar D, 2016, EUR J OBSTET GYN R B, V207, P227, DOI 10.1016/j.ejogrb.2016.09.005; Barbera L, 2008, LANCET ONCOL, V9, P54, DOI 10.1016/S1470-2045(07)70409-6; Barron TI, 2015, CANCER EPIDEM BIOMAR, V24, P898, DOI 10.1158/1055-9965.EPI-14-1415; Battistoni A, 2015, CLIN CARDIOL, V38, P387, DOI 10.1002/clc.22394; Biondi-Zoccai GGL, 2006, EUR HEART J, V27, P2667, DOI 10.1093/eurheartj/ehl334; Blair CK, 2007, BREAST CANCER RES TR, V101, P191, DOI 10.1007/s10549-006-9277-x; Bothwell PM, 2018, LANCET, V392, P387, DOI [10.1016/S0140-6736(18)31133-4, 10.1016/s0140-6736(18)31133-4]; Brighton TA, 2012, NEW ENGL J MED, V367, P1979, DOI 10.1056/NEJMoa1210384; Burn J, 2013, FAM CANCER, V12, P707, DOI 10.1007/s10689-013-9650-y; Burn J, 2011, LANCET, V378, P2081, DOI 10.1016/S0140-6736(11)61049-0; Caine GJ, 2002, NEOPLASIA, V4, P465, DOI 10.1038/sj.neo.7900263; Cardwell CR, 2014, CANCER CAUSE CONTROL, V25, P33, DOI 10.1007/s10552-013-0306-x; Chae Y, 2013, PIK3CA MUTATIONS ASP; Chae YK, 2014, BLOOD, V123, P1424, DOI 10.1182/blood-2013-07-517102; Chan AT, 2009, JAMA-J AM MED ASSOC, V302, P649, DOI 10.1001/jama.2009.1112; Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1; Coyle C, 2016, CONTEMP CLIN TRIALS, V51, P56, DOI 10.1016/j.cct.2016.10.004; CREAGAN ET, 1991, J CLIN ONCOL, V9, P2104, DOI 10.1200/JCO.1991.9.12.2104; Downer MK, 2017, EUR UROL, V72, P821, DOI 10.1016/j.eururo.2017.01.044; Egger M, 2001, SYSTEMATIC REV HLTH; Elwood P, 2010, J EPIDEMIOL COMMUN H, V64, P761, DOI 10.1136/jech.2009.087767; Elwood PC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166166; Elwood PC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152402; Elwood PC, 2009, LANCET, V373, P1301, DOI 10.1016/S0140-6736(09)60243-9; Fontaine E, 2010, EUR J CARDIO-THORAC, V38, P21, DOI 10.1016/j.ejcts.2010.01.015; Fraser DM, 2014, BRIT J CANCER, V111, P623, DOI 10.1038/bjc.2014.264; Frouws MA, 2017, BRIT J CANCER, V116, P405, DOI 10.1038/bjc.2016.425; Frouws MA, 2017, CANCER TREAT REV, V55, P120, DOI 10.1016/j.ctrv.2016.12.008; GASIC GJ, 1984, CANCER METAST REV, V3, P99, DOI 10.1007/BF00047657; GASIC GJ, 1973, INT J CANCER, V11, P704, DOI 10.1002/ijc.2910110322; GASIC GJ, 1968, P NATL ACAD SCI USA, V61, P46, DOI 10.1073/pnas.61.1.46; Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004; Giampieri R, 2017, CLIN COLORECTAL CANC, V16, P38, DOI 10.1016/j.clcc.2016.07.011; Gray RT, 2017, CLIN TRANSL GASTROEN, V8, DOI 10.1038/ctg.2017.18; Hamada T, 2017, J CLIN ONCOL, V35, P1836, DOI 10.1200/JCO.2016.70.7547; Hippisley-Cox J, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2497; Hua XW, 2017, J CLIN ONCOL, V35, P2806, DOI 10.1200/JCO.2017.72.3569; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1895, DOI 10.1056/NEJM199406303302611; Kim SA, 2018, INT J CLIN ONCOL, V23, P52, DOI 10.1007/s10147-017-1165-3; Langley RE, 2011, BRIT J CANCER, V105, P1107, DOI 10.1038/bjc.2011.289; LEBEAU B, 1993, CANCER, V71, P1741, DOI 10.1002/1097-0142(19930301)71:5<1741::AID-CNCR2820710507>3.0.CO;2-Q; Leitzmann MF, 2002, CANCER EPIDEM BIOMAR, V11, P1108; Li JH, 2016, AM J CANCER RES, V6, P2109; Liebman HA, 2016, THROMB RES, V140, pS18, DOI 10.1016/S0049-3848(16)30093-7; LIPTON A, 1982, J MED, V13, P419; Liu JF, 2009, ANN SURG ONCOL, V16, P1397, DOI 10.1245/s10434-009-0382-z; Ljung R, 2014, INT J CANCER, V135, P238, DOI 10.1002/ijc.28671; Lyman GH, 2007, J CLIN ONCOL, V25, P5490, DOI 10.1200/JCO.2007.14.1283; Macfarlane TV, 2015, CANCER EPIDEMIOL, V39, P1015, DOI 10.1016/j.canep.2015.10.030; Maddison P, 2017, LUNG CANCER, V106, P67, DOI 10.1016/j.lungcan.2017.01.018; Matsuo K, 2016, OBSTET GYNECOL, V128, P127, DOI 10.1097/AOG.0000000000001491; Maulaz AB, 2005, ARCH NEUROL-CHICAGO, V62, P1217, DOI 10.1001/archneur.62.8.1217; Mc Menamin UC, 2017, CANCER EPIDEMIOL, V47, P20, DOI 10.1016/j.canep.2016.12.008; McCarthy AM, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.1521; Mills EJ, 2012, AM J MED, V125, P560, DOI 10.1016/j.amjmed.2012.01.017; Mo C, 2015, WORLD J GASTROENTERO, V21, P5382, DOI 10.3748/wjg.v21.i17.5382; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Murphy C, 2017, INTERN MED J, V47, P88, DOI 10.1111/imj.13312; Nagle CM, 2015, CANCER EPIDEMIOL, V39, P196, DOI 10.1016/j.canep.2014.12.010; O'Brien J, 2000, LANCET, V355, P1295; OConnell D, 2011, NEWCASTLE OTTAWAY SC; Osborn VW, 2016, TUMORI, V102, P65, DOI 10.5301/tj.5000424; Pastore AL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1152-x; Ratnasinghe LD, 2004, ANTICANCER RES, V24, P3177; Restivo A, 2015, BRIT J CANCER, V113, P1133, DOI 10.1038/bjc.2015.336; Rosenberg L, 1998, CANCER-AM CANCER SOC, V82, P2326, DOI 10.1002/(SICI)1097-0142(19980615)82:12<2326::AID-CNCR5>3.0.CO;2-Q; Rothwell PM, 2016, LANCET, V388, P365, DOI 10.1016/S0140-6736(16)30468-8; Rothwell PM, 2012, LANCET, V379, P1591, DOI 10.1016/S0140-6736(12)60209-8; Rothwell PM, 2012, LANCET, V379, P1602, DOI 10.1016/S0140-6736(11)61720-0; Sansbury LB, 2005, AM J EPIDEMIOL, V162, P548, DOI 10.1093/aje/kwi248; Schmoll HJ, 2018, LANCET GASTROENTEROL, V3, P143, DOI 10.1016/S2468-1253(17)30402-8; Shaw G, 2018, EUROPEAN J SURG ONCO, V44, pS13, DOI [10.1016/j.ejso.2017.10.126, DOI 10.1016/J.EJSO.2017.10.126]; Shiao J, 2017, BREAST CANCER RES TR, V161, P463, DOI 10.1007/s10549-016-4081-8; Shimoike N., 2016, J GASTROEN HEPATOL, V5, P1962, DOI [DOI 10.17554/j.issn.2224-3992.2016.05.605, 10.17554/j.issn.2224-3992.2016.05.605, DOI 10.17554/J.ISSN.2224-3992.2016.05.605]; Smith SG, 2017, FAM CANCER, V16, P509, DOI 10.1007/s10689-017-9986-9; Sokol DK, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1481; Soriano LC, 2019, CLIN GASTROENTEROL H, V17, P887, DOI 10.1016/j.cgh.2018.05.061; Veitonmaki T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153413; Veitonmaki T, 2015, PROSTATE, V75, P1394, DOI 10.1002/pros.23020; Ventura L, 2016, EUR J CANC PREV; Vreeburg EM, 1999, GUT, V44, P331, DOI 10.1136/gut.44.3.331; Zhou CK, 2017, CANCER PREV RES, V10, P410, DOI 10.1158/1940-6207.CAPR-17-0033	90	24	26	3	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2018	13	9							e0203957	10.1371/journal.pone.0203957	http://dx.doi.org/10.1371/journal.pone.0203957			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GU9BO	30252883	Green Accepted, Green Published, gold			2023-01-03	WOS:000445639700020
J	Gouvea, GR; Bulgareli, JV; David, LL; Ambrosano, GMB; Cortellazzi, KL; Guerra, LM; Frias, AC; Meneghim, MD; Pereira, AC				Gouvea, Giovana Renata; Bulgareli, Jaqueline Vilela; David, Luciene Luvizotto; Bovi Ambrosano, Glaucia Maria; Cortellazzi, Karine Laura; Guerra, Luciane Miranda; Frias, Antonio Carlos; Meneghim, Marcelo de Castro; Pereira, Antonio Carlos			Variables associated with the oral impact on daily performance of adults in the state of Sao Paulo: A population-based study	PLOS ONE			English	Article							QUALITY-OF-LIFE; DENTAL-HEALTH; EDUCATION; PERIODONTITIS; DISEASE; INCOME; PAIN	Objective: This study aimed to assess the oral impact on daily performance and its association with sociodemographic characteristics, tooth pain, need for prosthesis, and periodontal disease of adults in the state of Sao Paulo, Brazil. Methods: This was a cross-sectional epidemiological study with secondary data obtained from the Oral Health Conditions Project-2015 conducted in 163 municipalities in the state of Sao Paulo with the participation of 17,560 individuals. This study evaluated adults in the age-range between 35-44 years (n = 5,855), selected by means of probabilistic cluster sampling in two stages. The outcome variable was the OIDP (Oral Impacts on Daily Performances), obtained by using this instrument to assess daily activities (eating, speaking, oral hygiene, relaxation, sports practice, smile, study/work, social contact, and sleep). The independent variables were collected and grouped into three blocks: Block 1 (sex, age group, and ethnic group); Block 2 (household income and education); and Block 3 (tooth pain, need for prosthesis, bleeding, calculus, and periodontal pockets). A hierarchical multiple logistic regression analysis was performed considering the complex cluster sampling plan. Each observation was assigned a specific weight, depending on the location, which resulted in weighted frequencies adjusted for the effect of outlining. Results: the female sex (p<0.0001), ethnic group black/mulatto (p<0.0001), low household income (p = 0.0112), up to 8 years of education (p<0.0001), tooth pain (p<0.0001), presence of bleeding (p<0.0001), and presence of periodontal pockets (p<0.0001) had greater oral impact on daily performance. Conclusion: sociodemographic characteristics, tooth pain, and presence of periodontal disease were associated with oral impact on daily performance of the adult population in the state of Sao Paulo, Brazil.	[Gouvea, Giovana Renata; Bulgareli, Jaqueline Vilela; David, Luciene Luvizotto; Bovi Ambrosano, Glaucia Maria; Cortellazzi, Karine Laura; Guerra, Luciane Miranda; Meneghim, Marcelo de Castro; Pereira, Antonio Carlos] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Community Dent, Piracicaba, SP, Brazil; [Frias, Antonio Carlos] Univ Sao Paulo, Dent Sch, Dept Community Dent, Sao Paulo, SP, Brazil	Universidade Estadual de Campinas; Universidade de Sao Paulo	Gouvea, GR (corresponding author), Univ Estadual Campinas, Piracicaba Dent Sch, Dept Community Dent, Piracicaba, SP, Brazil.	gigouvea@hotmail.com	Cortellazzi, Karine Laura/D-4066-2015	Ambrosano, Glaucia Maria Bovi/0000-0001-5950-6370; Guerra, Luciane Miranda/0000-0002-7542-7717; Pereira, Antonio Carlos/0000-0003-1703-8171; Frias, Antonio Carlos/0000-0002-4017-2195; Gouvea, Giovana/0000-0003-0313-607X	FAPESP (Sao Paulo Research Foundation)/Brazil [2014/50119-1]	FAPESP (Sao Paulo Research Foundation)/Brazil(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This work was supported by a granted from the FAPESP (Sao Paulo Research Foundation)/Brazil - Process # 2014/50119-1. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adulyanon S, 1996, COMMUNITY DENT ORAL, V24, P385, DOI 10.1111/j.1600-0528.1996.tb00884.x; Andrade FR, 2013, REV SAUDE PUBLICA S3, V47, P154; [Anonymous], 2010, PESQ NAC SAUD BUC RE, P2012; Astrom AN, 2005, EUR J ORAL SCI, V113, P289, DOI 10.1111/j.1600-0722.2005.00225.x; Badley E M, 1987, Int Disabil Stud, V9, P122; Benyamini Y, 2004, SOC SCI MED, V59, P1109, DOI 10.1016/j.socscimed.2003.12.021; Bernabe E, 2010, J CLIN PERIODONTOL, V37, P968, DOI 10.1111/j.1600-051X.2010.01627.x; Borges TD, 2013, J PERIODONTOL, V84, P325, DOI 10.1902/jop.2012.120069; Brennan F, 2007, ANESTH ANALG, V105, P205, DOI 10.1213/01.ane.0000268145.52345.55; Chaffee BW, 2017, COMMUNITY DENT ORAL, V45, P216, DOI 10.1111/cdoe.12279; Cortes MID, 2002, COMMUNITY DENT ORAL, V30, P193; Currie CC, 2015, J ORAL REHABIL, V42, P883, DOI 10.1111/joor.12333; Edman K, 2018, INT J DENT HYG, V16, P257, DOI 10.1111/idh.12269; Frias AC., 2016, PESQUISA ESTADUAL SA; Geyer S, 2010, COMMUNITY DENT ORAL, V38, P120, DOI 10.1111/j.1600-0528.2009.00520.x; Goes PSA, 2001, THESIS; Grytten J, 2017, COMMUNITY DENT ORAL, V45, P485, DOI 10.1111/cdoe.12319; Guarnizo-Herreno CC, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-827; Herd P, 2007, J HEALTH SOC BEHAV, V48, P223, DOI 10.1177/002214650704800302; Kassebaum NJ, 2014, J DENT RES, V93, P1045, DOI 10.1177/0022034514552491; Lawrence HP, 2008, COMMUNITY DENT ORAL, V36, P305, DOI 10.1111/j.1600-0528.2007.00395.x; Listl S, 2016, COMMUNITY DENT ORAL, V44, P409, DOI 10.1111/cdoe.12231; Locker D, 2011, COMMUNITY DENT ORAL, V39, P3, DOI 10.1111/j.1600-0528.2010.00597.x; Masalu JR, 2003, COMMUNITY DENT ORAL, V31, P7, DOI 10.1034/j.1600-0528.2003.00011.x; Mathers CD, 2003, POPUL HEALTH METR, V1, P6, DOI [DOI 10.1186/1478-7954-1-6, 10.1186/1478-7954-1-6]; Merdad L, 2017, BMC ORAL HEALTH, V17, DOI 10.1186/s12903-017-0338-9; Nagarajappa R, 2018, INT J DENT HYG, V16, P279, DOI 10.1111/idh.12284; Peres KG, 2013, REV SAUDE PUBL, V47, P19, DOI 10.1590/S0034-8910.2013047004361; Sanders AE, 2009, COMMUNITY DENT ORAL, V37, P171, DOI 10.1111/j.1600-0528.2008.00457.x; Sischo L, 2011, J DENT RES, V90, P1264, DOI 10.1177/0022034511399918; Vazquez FD, 2015, QUAL LIFE RES, V24, P661, DOI 10.1007/s11136-014-0795-4; Watt RG, 2016, J DENT RES, V95, P245, DOI 10.1177/0022034515622198; Wellapuli N, 2016, INT DENT J, V66, P337, DOI 10.1111/idj.12255; World Health Organization, 1997, WHO OR HLTH SURV BAS, V4th	34	5	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2018	13	9							e0203777	10.1371/journal.pone.0203777	http://dx.doi.org/10.1371/journal.pone.0203777			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GT5KH	30212507	Green Published, gold, Green Submitted			2023-01-03	WOS:000444545800070
J	Dahrouge, S; Kaczorowski, J; Dolovich, L; Paterson, M; Thabane, L; Tu, K; Younger, J; Chambers, L				Dahrouge, Simone; Kaczorowski, Janusz; Dolovich, Lisa; Paterson, Michael; Thabane, Lehana; Tu, Karen; Younger, Jaime; Chambers, Larry			Long term outcomes of cluster randomized trial to improve cardiovascular health at population level: The Cardiovascular Health Awareness Program (CHAP)	PLOS ONE			English	Article							BLOOD-PRESSURE CONTROL; ALL-CAUSE MORTALITY; RISK-FACTORS; SYSTEMATIC ANALYSIS; DISEASE; HYPERTENSION; PREVENTION; BURDEN; ASSOCIATION; PREVALENCE	Study question The Cardiovascular Health Awareness Program (CHAP) cardiovascular risk reduction program consisted of sessions run by local volunteers in local pharmacies during which cardiovascular risk was assessed, healthy lifestyle and preventive care was promoted, and the participants were oriented to local resources to support changes in modifiable risk factors. A clustered randomized trial implemented in September 2006 across 39 communities targeting community-dwelling individuals 65 years and older showed a significant reduction in hospitalization one year after its implementation (rate ratio of 91 [95% confidence interval (CI): 86%-97%]). This study explores the impact of CHAP in the first five years. Methods Using health administrative data housed at the Institute for Clinical Evaluative Sciences, we established a closed cohort consisting of all individuals eligible in these communities at the study onset whom we followed over time. We assessed hospitalizations and survival using a negative binomial model for count data and Cox regression to assess time to first event, accounting for the clustered design. The primary outcome was the rate of cardiovascular related hospitalizations defined as congestive heart failure, stroke or acute myocardial infarction. Results Most estimates pointed to an advantage for the intervention arm, but only all-cause mortality reached statistical significance (hazard ratio [95% CI] = 0.955 [0.914-0.999]). The hospitalization cardiovascular-related hospitalization rate ratio was (0.958, 95% CI: 0.898-1.022) in favour of the intervention communities, translating to an estimated 408 averted hospitalizations over the five-year period. There was no evidence of the effect of time from start of intervention. Conclusions The consistent direction of the outcomes in favour of the intervention arms suggests that CHAP likely had a meaningful impact on reducing cardiovascular-related morbidity and mortality. Given the low cost of the intervention, further development of CHAP should be pursued.	[Dahrouge, Simone] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada; [Dahrouge, Simone; Chambers, Larry] Bruyere Res Inst, Ottawa, ON, Canada; [Dahrouge, Simone] Inst Clin Evaluat Sci, Ottawa, ON, Canada; [Kaczorowski, Janusz] Univ Montreal, Dept Family & Emergency Med, Montreal, PQ, Canada; [Kaczorowski, Janusz] CRCHUM, Montreal, PQ, Canada; [Dolovich, Lisa; Paterson, Michael; Thabane, Lehana; Younger, Jaime] McMaster Univ, Dept Family Med, Hamilton, ON, Canada; [Dolovich, Lisa] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada; [Paterson, Michael; Chambers, Larry] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Paterson, Michael] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Tu, Karen] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Tu, Karen] Univ Hlth Network, Western Hosp Family Hlth Team, Toronto, ON, Canada; [Chambers, Larry] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Chambers, Larry] York Univ, Fac Hlth, Toronto, ON, Canada	University of Ottawa; University of Ottawa; Universite de Montreal; Universite de Montreal; McMaster University; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; McMaster University; York University - Canada	Dahrouge, S (corresponding author), Univ Ottawa, Dept Family Med, Ottawa, ON, Canada.; Dahrouge, S (corresponding author), Bruyere Res Inst, Ottawa, ON, Canada.; Dahrouge, S (corresponding author), Inst Clin Evaluat Sci, Ottawa, ON, Canada.	sdahrouge@bruyere.org	Chambers, Larry W/AAI-4959-2020	Tu, Karen/0000-0003-0883-4934; Dahrouge, Simone/0000-0001-6488-8086	Canadian Institute of Health Research (CIHR); Institute for Clinical Evaluative Sciences (ICES) - Ontario Ministry of Health and Long-Term Care (MOHLTC); Department of Family and Community Medicine at the University of Toronto	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Institute for Clinical Evaluative Sciences (ICES) - Ontario Ministry of Health and Long-Term Care (MOHLTC)(Ministry of Health and Long-Term Care, Ontario); Department of Family and Community Medicine at the University of Toronto	This study was funded by the Canadian Institute of Health Research (CIHR) and the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). Dr. Karen Tu is supported by a research scholar award from the Department of Family and Community Medicine at the University of Toronto. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abegunde DO, 2007, LANCET, V370, P1929, DOI 10.1016/S0140-6736(07)61696-1; [Anonymous], 2004, Indian J Med Sci, V58, P405; [Anonymous], 2011, DAT QUAL DOC EXT US; Beckett NS, 2008, NEW ENGL J MED, V358, P1887, DOI 10.1056/NEJMoa0801369; Bray GA, 2009, LANCET, V374, P1677, DOI 10.1016/S0140-6736(09)61457-4; Brown RE, 2013, AM J HYPERTENS, V26, P1005, DOI 10.1093/ajh/hpt063; Byberg L, 2009, BRIT J SPORT MED, V43, P482, DOI 10.1136/bmj.b688; Carter M, 2009, HEALTH PROMOT INT, V24, P325, DOI 10.1093/heapro/dap030; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Desveaux L, 2014, MED CARE, V52, P216, DOI 10.1097/MLR.0000000000000065; Dickinson HO, 2006, J HYPERTENS, V24, P215, DOI 10.1097/01.hjh.0000199800.72563.26; Dobbins M, 1999, EFFECTIVENESS COMMUN; Dunneram Y, 2015, HEALTH PROMOT PERSPE, V5, P116, DOI 10.15171/hpp.2015.014; Ekpu VU, 2015, TOB USE INSIGHTS, V8, P1, DOI 10.4137/TUI.S15628; Gellert C, 2012, ARCH INTERN MED, V172, P837, DOI 10.1001/archinternmed.2012.1397; Goeree R, 2013, VALUE HEALTH, V16, P39, DOI 10.1016/j.jval.2012.09.002; Gupta Sangeeta, 2014, Del Med J, V86, P77; Heidenreich PA, 2011, CIRCULATION, V123, P933, DOI 10.1161/CIR.0b013e31820a55f5; Hemmelgarn BR, 2008, CAN J CARDIOL, V24, P507, DOI 10.1016/S0828-282X(08)70627-5; Humphries KH, 2000, J CLIN EPIDEMIOL, V53, P343, DOI 10.1016/S0895-4356(99)00188-2; Joffres MR, 2007, CAN J CARDIOL, V23, P437, DOI 10.1016/S0828-282X(07)70780-8; Kaczorowski J, 2008, PREV MED, V46, P537, DOI 10.1016/j.ypmed.2008.02.005; Kaczorowski J, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d442; Leenen FHH, 2008, CAN MED ASSOC J, V178, P1441, DOI 10.1503/cmaj.071340; LeFevre ML, 2014, ANN INTERN MED, V161, P587, DOI 10.7326/M14-1796; Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Mackay J, 2004, ATLAS HEART DIS STRO; Mathers C, 2009, GLOBAL HLTH RISKS MO; Ministry of Health and Long Term Care, 2006, ONT HLTH PLANN DAT G; Parati G, 2003, J HYPERTENS, V21, P481, DOI 10.1097/00004872-200303000-00008; Pearson TA, 2001, SCAND J PUBLIC HEALT, P69; Pennant M, 2010, AM J EPIDEMIOL, V172, P501, DOI 10.1093/aje/kwq171; Pickering Thomas G, 2007, J Clin Hypertens (Greenwich), V9, P807; Porterfield DS, 2012, AM J PREV MED S71, V42; Powers MA, 2015, DIABETES CARE, V38, P1372, DOI 10.2337/dc15-0730; Public Health Agency of Canada, 2007, HYP FACTS FIG; Quinones AR, 2014, PATIENT EDUC COUNS, V95, P3, DOI 10.1016/j.pec.2013.12.021; Reboldi G, 2014, HYPERTENSION, V63, P475, DOI 10.1161/HYPERTENSIONAHA.113.02089; Stone E, 1997, ANN EPIDEMIOL S, VS7, pS124; Vanstone M, 2013, Ont Health Technol Assess Ser, V13, P1; Vasan RS, 2002, JAMA-J AM MED ASSOC, V287, P1003, DOI 10.1001/jama.287.8.1003; Wagner EH, 2010, J GEN INTERN MED S8, V25; WHO, 2003, PREV REC HEART ATT S; Wilkins Kathryn, 2010, Health Rep, V21, P37; Williams JI, 1996, PATTERNS HEALTHCARE, V2nd; Yazdanyar A, 2009, CLIN GERIATR MED, V25, P563, DOI 10.1016/j.cger.2009.07.007; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	49	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2018	13	9							e0201802	10.1371/journal.pone.0201802	http://dx.doi.org/10.1371/journal.pone.0201802			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT1KN	30188912	Green Submitted, Green Published, gold			2023-01-03	WOS:000444228700001
J	Knezevic, A; Stajic, M; Sofrenic, I; Stanojkovic, T; Milovanovic, I; Tesevic, V; Vukojevic, J				Knezevic, Aleksandar; Stajic, Mirjana; Sofrenic, Ivana; Stanojkovic, Tatjana; Milovanovic, Ivan; Tesevic, Vele; Vukojevic, Jelena			Antioxidative, antifungal, cytotoxic and antineurodegenerative activity of selected Trametes species from Serbia	PLOS ONE			English	Article							RAPID COLORIMETRIC ASSAY; IN-VITRO; GROWTH; MUSHROOM; EXTRACT; CELLS; LEUKEMIA; FUNGI	In a last few decades mushrooms are increasingly attracting attention as functional food and sources of biologically active compounds. Several Trametes species have been used for centuries in traditional medicine of East Asia cultures, but only T. versicolorwas studied sufficiently while there are less substantial data about medicinal properties of other species. Trametes versicolor, T. hirsuta and T. gibbosa were the species tested for biological activities. Antifungal potentials of extracts were assessed for clinical strains of selected Candida and Aspergillus species. ABTS and FRAP assays were used to evaluate antioxidant capacities of studied extracts. Cytotoxic activity was determined against human cervix and lung adenocarcinoma and colon carcinoma cell lines. Antineurodegenerative activity was assessed by determining the rate of acetylcholinesterase and tyrosinase activity. The presence of metabolites in extracts of mycelia and basidiocarps of studied Trametes species was analyzed by H-1 NMR spectroscopy. Studied extracts showed low antifungal potential in comparison with ketoconazole. Basidiocarp extracts were more effective ABTS(+) scavengers and Fe2+ reducers than mycelium ones but less effective in comparison with L-ascorbic acid. Results showed that mycelium extracts had stronger cytotoxic effects against three cancer cell lines than basidiocarp ones, and that cervix adenocarcinoma cells were the most sensitive to the extracts and commercial cytostatics. T. versicolor mycelium extract was the most effective inhibitor of acetylcholinesterase activity but double weaker than galantamine, and T. gibbosa mycelium extract was significantly better inhibitor of tyrosinase activity than kojic acid for 40.9%. Chemical analysis indicated strong synergistic action of triterpenes, sugars and polyphenols in applied assays. The results suggest that tested Trametes species have significant medicinal potentials which could be attributed to antioxidative and cytotoxic activity. Additionally both, basidiocarps and mycelia extracts can strongly inhibit activity of acetylcholinesterase and tyrosinase.	[Knezevic, Aleksandar; Stajic, Mirjana; Milovanovic, Ivan; Vukojevic, Jelena] Univ Belgrade, Fac Biol, Belgrade, Serbia; [Sofrenic, Ivana; Tesevic, Vele] Univ Belgrade, Fac Chem, Studentski Trg, Belgrade, Serbia; [Stanojkovic, Tatjana] Inst Oncol & Radiol Serbia, Belgrade, Serbia	University of Belgrade; University of Belgrade; Institute for Oncology & Radiology of Serbia (IORS)	Knezevic, A (corresponding author), Univ Belgrade, Fac Biol, Belgrade, Serbia.	knezevica@bio.bg.ac.rs	Stanojkovic, Tatjana/AHA-7955-2022; Sofrenić, Ivana/W-2421-2018; Tesevic, Vele/Q-6093-2016	Sofrenić, Ivana/0000-0002-9799-670X; Knezevic, Aleksandar/0000-0002-2776-9675; Tesevic, Vele/0000-0001-7060-9055; Milovanovic, Ivan/0000-0002-5772-4355	Ministry of Education, Science and Technological Development (Republic of Serbia) [173032, 172053]	Ministry of Education, Science and Technological Development (Republic of Serbia)	This work was supported by Ministry of Education, Science and Technological Development (Republic of Serbia), Grant No. 173032, AK, MS, IM, JV; Ministry of Education, Science and Technological Development (Republic of Serbia), Grant No. 172053, IS, VT.	Abd El Hady F., 2014, INT J PHARM SCI REV, V26, P338; Alves MJ, 2013, J APPL MICROBIOL, V115, P346, DOI 10.1111/jam.12196; Andrews JM, 2001, J ANTIMICROB CHEMOTH, V48, P5, DOI 10.1093/jac/48.suppl_1.5; [Anonymous], 1998, M38P NCCLS; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Brakhage AA, 2005, MED MYCOL, V43, pS75, DOI 10.1080/13693780400028967; Cheng K.F., 2008, CANC THER, V6, P117; Courtecuisse R, 1999, MUSHROOMS BRITAIN EU; Cowan MM, 1999, CLIN MICROBIOL REV, V12, P564, DOI 10.1128/CMR.12.4.564; Daglia M, 2012, CURR OPIN BIOTECH, V23, P174, DOI 10.1016/j.copbio.2011.08.007; de Billerbeck VG, 2001, CAN J MICROBIOL, V47, P9, DOI 10.1139/cjm-47-1-9; El-Hady F.K.A., 2014, INT J PHARM SCI REV, V26, P301; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Ferreira ICFR, 2009, CURR MED CHEM, V16, P1543, DOI 10.2174/092986709787909587; Gan C. H., 2013, International Food Research Journal, V20, P1095; Harhaji L, 2008, FOOD CHEM TOXICOL, V46, P1825, DOI 10.1016/j.fct.2008.01.027; Hleba L., 2014, Scientific Papers: Animal Science and Biotechnologies, V47, P89; Hsieh TC, 2002, J ALTERN COMPLEM MED, V8, P591, DOI 10.1089/107555302320825101; Jamila N, 2015, J ENZYM INHIB MED CH, V30, P133, DOI 10.3109/14756366.2014.895720; Janjusevic L, 2018, NAT PROD RES, V32, P963, DOI 10.1080/14786419.2017.1366484; Janjusevic L, 2017, J ENZYM INHIB MED CH, V32, P355, DOI 10.1080/14756366.2016.1252759; Johnsy G., 2011, Journal of Pharmacy Research, V4, P3939; Karaman M, 2010, PHYTOTHER RES, V24, P1473, DOI 10.1002/ptr.2969; Kim Seong-Eun, 2012, Mycobiology, V40, P134, DOI 10.5941/MYCO.2012.40.2.134; Knezevic A, 2015, BOOK OF ABSTRACTS OF, P198; Knezevic Aleksandar, 2015, ScientificWorldJournal, V2015, P146378, DOI 10.1155/2015/146378; Lau CBS, 2004, LIFE SCI, V75, P797, DOI 10.1016/j.lfs.2004.04.001; Likhitwitayawuid K, 2001, J NAT PROD, V64, P1457, DOI 10.1021/np0101806; Lindequist U, 2005, EVID-BASED COMPL ALT, V2, P285, DOI 10.1093/ecam/neh107; Mau JL, 2002, J AGR FOOD CHEM, V50, P6072, DOI 10.1021/jf0201273; MILLER NJ, 1993, CLIN SCI, V84, P407, DOI 10.1042/cs0840407; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mossier DB, 1993, DERMATOLOGY GEN MED, P949; Ng TB, 1998, GEN PHARMACOL, V30, P1, DOI 10.1016/S0306-3623(97)00076-1; OHNO M, 1991, J IMMUNOL METHODS, V145, P199, DOI 10.1016/0022-1759(91)90327-C; Otsuka Y., 2013, INT J NUTR FOOD SCI, V2, P85, DOI DOI 10.11648/j.ijnfs.20130202.19; PACKER L, 2004, OXIDAT STRESS DIS, pR7; Palacios I, 2011, FOOD CHEM, V128, P674, DOI 10.1016/j.foodchem.2011.03.085; Park YK, 1997, ARQ BIOL TECNOL, V40, P97; Patoka J., 2012, MILIT MED SCI LETT, V81, P40; Phillips R., 1981, FOLIA GEOBOT; Picman AK, 1995, BIOCHEM SYST ECOL, V23, P683, DOI 10.1016/0305-1978(95)00081-X; Pop RM, 2018, NOT BOT HORTI AGROBO, V46, P343, DOI 10.15835/nbha46211132; Ren G, 2006, FITOTERAPIA, V77, P408, DOI 10.1016/j.fitote.2006.05.004; Samson R. A., 2010, CBS LAB MANUAL SERIE, V2; Sarker SD, 2007, METHODS, V42, P321, DOI 10.1016/j.ymeth.2007.01.006; Scarpari M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171412; Senol FS, 2010, FOOD CHEM, V120, P34, DOI 10.1016/j.foodchem.2009.09.066; Sheikh I.A., 2014, INT J PHARM PHARM SC, V6, P679; Shnyreva AV, 2018, INT J MED MUSHROOMS, V20, P1, DOI 10.1615/IntJMedMushrooms.2018025250; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; Sivaprakasam E., 2011, International Journal of Pharmaceutical Sciences and Drug Research, V3, P219; Souza NAB, 2010, BRAZ J PHARM SCI, V46, P499, DOI 10.1590/S1984-82502010000300013; Stajic M, 2013, CURR TOP MED CHEM, V13, P2660, DOI 10.2174/15680266113136660192; TAKEUCHI T, 1969, J ANTIBIOT, V22, P215, DOI 10.7164/antibiotics.22.215; Wasser Solomon P, 2014, Biomed J, V37, P345, DOI 10.4103/2319-4170.138318; Wheeler M H, 1988, Curr Top Med Mycol, V2, P338; Yamac M, 2006, PHARM BIOL, V44, P660, DOI 10.1080/13880200601006897	58	17	18	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2018	13	8							e0203064	10.1371/journal.pone.0203064	http://dx.doi.org/10.1371/journal.pone.0203064			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS2JK	30169542	Green Published, gold, Green Submitted			2023-01-03	WOS:000443374400019
J	Macala, KF; Khadaroo, RG; Panahi, S; Gragasin, FS; Bourque, SL				Macala, Kimberly F.; Khadaroo, Rachel G.; Panahi, Sareh; Gragasin, Ferrante S.; Bourque, Stephane L.			Low dose Intralipid resuscitation improves survival compared to ClinOleic in propranolol overdose in rats	PLOS ONE			English	Article							INTRAVENOUS LIPID EMULSION; LOCAL-ANESTHETIC TOXICITY; BUPIVACAINE TOXICITY; PARENTERAL-NUTRITION; FAT EMULSION; INFUSION; THERAPY; BINDING; PHARMACOTOXICITY; HEMODYNAMICS	Background Medication overdose is a prevalent issue and despite mixed reports of efficacy, the use of intravenous lipid emulsions, notably Intralipid (R), for the management of toxicity from lipid-soluble drugs is becoming increasingly prevalent. Whether alternative lipid emulsion formulations have similar efficacy for resuscitation compared to Intralipid is not known. Here, we compared the efficacy of Intralipid and ClinOleic (R) for resuscitation following overdose with the lipid-soluble beta-adrenergic antagonist propranolol. Methods Male Sprague-Dawley rats (age 3-4 months) were anesthetized with isoflurane and instrumented for direct hemodynamic assessments. In Study One, rats (n = 22) were pre-treated with Intralipid 20% (n = 12) or ClinOleic 20% (n = 10) to determine whether the hemodynamic effects of propranolol could be prevented. In Study Two, rats were randomly assigned to Intralipid 20% (1, 2, or 3 mUkg IV, n = 21) or ClinOleic 20% (1, 2, or 3 mUkg IV, n = 20) resuscitation groups following propranolol overdose (15 mg/kg IV). In Study Three the effect of Intralipid 20% (1 mL/kg IV, n = 3) and ClinOleic 20% (1 mL/kg IV, n = 3) in the absence of propranolol was investigated. The primary endpoint in all studies was survival time (up to a maximum of 120 minutes), and secondary endpoints were time to achieve 50%, 75%, and 90% of baseline hemodynamic parameters. Results In Study One, pre-treatment with Intralipid prior to propranolol administration resulted in prolonged survival compared to pre-treatment with ClinOleic at low doses (1 mL/kg; P = 0.002), but provided no benefit at higher doses (3 mL/kg; P = 0.95). In Study Two, Intralipid conferred a survival advantage over ClinOleic, with 18/21 rats surviving 120 minutes in the Intralipid group and only 4/20 survivors in the ClinOleic group (P<0.0001). Median survival times (with interquartile ranges) for rats treated with Intralipid, and ClinOleic, and saline were 120 (80.5-120) min, 21.5 (3.25-74.5) min, and 1 (0.25-2.5) min respectively (P<0.001). Only 3/21 rats in the Intralipid group survived less than 30 minutes, whereas 12/ 20 ClinOleic treated rats had survival times of less than 30 minutes. The number of rats achieving 75%, and 90% of baseline mean arterial pressure was also greater in the Intralipid group (P<0.05 for both values). Treatment in Study Three did not alter survival times. Conclusions Low-dose Intralipid (1, 2, or 3 mL/kg IV) confers a survival advantage up to 120 minutes post-propranolol overdose (the end-point of the experiment) and better hemodynamic recovery compared to ClinOleic (1, 2, or 3 mL/kg IV) in rats with propranolol overdose. As health care centres choose alternate intravenous lipid emulsions, limited availability of Intralipid could impact efficacy and success of overdose treatment for lipid-soluble drugs.	[Macala, Kimberly F.; Khadaroo, Rachel G.] Univ Alberta, Dept Crit Care Med, Edmonton, AB, Canada; [Macala, Kimberly F.; Panahi, Sareh; Gragasin, Ferrante S.; Bourque, Stephane L.] Univ Alberta, Dept Anesthesiol & Pain Med, Edmonton, AB, Canada; [Macala, Kimberly F.; Khadaroo, Rachel G.] Univ Alberta, Dept Surg, Edmonton, AB, Canada; [Bourque, Stephane L.] Univ Alberta, Dept Pharmacol, Edmonton, AB, Canada	University of Alberta; University of Alberta; University of Alberta; University of Alberta	Bourque, SL (corresponding author), Univ Alberta, Dept Anesthesiol & Pain Med, Edmonton, AB, Canada.; Bourque, SL (corresponding author), Univ Alberta, Dept Pharmacol, Edmonton, AB, Canada.	sborque@ualberta.ca		Bourque, Stephane/0000-0001-6375-7404	Canadian Institutes of Health Research [MOP 142396, MOP 142446]; Stollery Children's Hospital Foundation; Lois Hole Hospital for Women through the Women and Children's Health Research Institute; Canadian Critical Care Trials Group; Canadian Institutes for Health Research New Investigator Salary Award	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Stollery Children's Hospital Foundation; Lois Hole Hospital for Women through the Women and Children's Health Research Institute; Canadian Critical Care Trials Group; Canadian Institutes for Health Research New Investigator Salary Award	This work was supported by funding from the Canadian Institutes of Health Research (http://www.cihr-irsc.gc.ca/e/193.html) (MOP 142396 to S.L.B and MOP 142446 to F.S.G) and the generous support of the Stollery Children's Hospital Foundation and the Lois Hole Hospital for Women through the Women and Children's Health Research Institute (http://www.wchri.org/). K.M. is supported by a fellowship from the Canadian Critical Care Trials Group (http://www.ccctg.ca/); S. L.B is supported by a Canadian Institutes for Health Research New Investigator Salary Award.	Agarwala R, 2014, J MED TOXICOL, V10, P210, DOI 10.1007/s13181-013-0353-4; Amer Coll Med Toxicology, 2017, J MED TOXICOL, V13, P124, DOI 10.1007/s13181-016-0550-z; Cao DZ, 2015, J EMERG MED, V48, P387, DOI 10.1016/j.jemermed.2014.10.009; Cave G, 2006, J MED TOXICOL, V2, P4, DOI 10.1007/BF03161005; Cave G, 2009, J MED TOXICOL, V5, P50, DOI 10.1007/BF03160983; Cave G, 2009, ACAD EMERG MED, V16, P815, DOI 10.1111/j.1553-2712.2009.00499.x; Chenoweth JA, 2017, AM J EMERG MED, V35, DOI 10.1016/j.ajem.2017.07.023; Dureau P, 2016, ANESTHESIOLOGY, V125, P474, DOI 10.1097/ALN.0000000000001230; Evans JA, 2013, ANAESTH INTENS CARE, V41, P618, DOI 10.1177/0310057X1304100507; Fettiplace MR, 2017, CLIN TOXICOL, V55, P1021, DOI 10.1080/15563650.2017.1325490; Fettiplace MR, 2015, J CONTROL RELEASE, V198, P62, DOI 10.1016/j.jconrel.2014.11.018; Fettiplace MR, 2014, ANESTHESIOLOGY, V120, P915, DOI 10.1097/ALN.0000000000000142; Fettiplace MR, 2013, CRIT CARE MED, V41, pE156, DOI 10.1097/CCM.0b013e318287f874; Flood P, 2015, STOELTINGS PHARM PHY; Gosselin S, 2016, CLIN TOXICOL, V54, P899, DOI 10.1080/15563650.2016.1214275; Hayes BD, 2016, CLIN TOXICOL, V54, P365, DOI 10.3109/15563650.2016.1151528; Hoegberg LCG, 2016, CLIN TOXICOL, V54, P167, DOI 10.3109/15563650.2015.1121270; Lampropoulos KM, 2012, HELL J CARDIOL, V53, P101; Lavonas EJ, 2015, CIRCULATION, V132, pS501, DOI 10.1161/CIR.0000000000000264; Levine M, 2014, J MED TOXICOL, V10, P10, DOI 10.1007/s13181-013-0356-1; Li ZQ, 2011, ANESTHESIOLOGY, V115, P1219, DOI 10.1097/ALN.0b013e318238be73; Macala K, 2014, ACAD EMERG MED, V21, P1220, DOI 10.1111/acem.12511; Mazoit JX, 2009, ANESTHESIOLOGY, V110, P380, DOI 10.1097/ALN.0b013e318194b252; Mowry JB, 2014, CLIN TOXICOL, V52, P1032, DOI 10.3109/15563650.2014.987397; Partownavid P, 2012, CRIT CARE MED, V40, P2431, DOI 10.1097/CCM.0b013e3182544f48; Ruan WM, 2012, ANESTHESIOLOGY, V116, P334, DOI 10.1097/ALN.0b013e318242a5f1; Ruhm CJ, 2017, SSM-POPUL HLTH, V3, P219, DOI 10.1016/j.ssmph.2017.01.009; Siqueira J, 2011, J CLIN ENDOCR METAB, V96, P3207, DOI 10.1210/jc.2011-0480; St-Onge M, 2014, CLIN TOXICOL, V52, P926, DOI 10.3109/15563650.2014.965827; Stehr SN, 2007, ANESTH ANALG, V104, P186, DOI 10.1213/01.ane.0000248220.01320.58; Takahashi H, 2002, CLIN EXP PHARMACOL P, V29, P198, DOI 10.1046/j.1440-1681.2002.03629.x; Tang W, 2016, ANESTH ANALG, V123, P1116, DOI 10.1213/ANE.0000000000001410; VAGO T, 1984, BIOCHEM BIOPH RES CO, V121, P346, DOI 10.1016/0006-291X(84)90729-0; Vinnars E, 2003, JPEN-PARENTER ENTER, V27, P225, DOI 10.1177/0148607103027003225; Weinberg G, 2003, REGION ANESTH PAIN M, V28, P198, DOI 10.1053/rapm.2003.50041; Weinberg GL, 2012, ANESTHESIOLOGY, V117, P180, DOI 10.1097/ALN.0b013e31825ad8de; Young AC, 2009, RESUSCITATION, V80, P591, DOI 10.1016/j.resuscitation.2009.01.023	37	3	3	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2018	13	8							e0202871	10.1371/journal.pone.0202871	http://dx.doi.org/10.1371/journal.pone.0202871			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS2NZ	30161186	Green Published, Green Submitted, gold			2023-01-03	WOS:000443388900047
J	Abdelhafez, OH; Fawzy, MA; Fahim, JR; Desoukey, SY; Krischke, M; Mueller, MJ; Abdelmohsen, UR				Abdelhafez, Omnia Hesham; Fawzy, Michael Atef; Fahim, John Refaat; Desoukey, Samar Yehia; Krischke, Markus; Mueller, Martin J.; Abdelmohsen, Usama Ramadan			Hepatoprotective potential of Malvaviscus arboreus against carbon tetrachloride-induced liver injury in rats	PLOS ONE			English	Article							INDIAN MEDICINAL-PLANTS; ANTIOXIDANT ACTIVITY; CAFFEIC ACID; L.; HEPATOTOXICITY; EXTRACT; DAMAGE; GLYCOSIDES; PHENOLICS; FLOWERS	Malvaviscus arboreus Cav. is a medicinal plant belonging to family Malvaceae with both ethnomedical and culinary value; however, its phytochemical and biological profiles have been scarcely studied. Accordingly, this work was designed to explore the chemical composition and the hepatoprotective potential of M. arboreus against carbon tetrachloride (CCl4)-induced hepatotoxicity. The total extract of the aerial parts and its derived fractions (petroleum ether, dichloromethane, ethyl acetate, and aqueous) were orally administered to rats for six consecutive days, followed by injection of CCl4 (1:1 v/v, in olive oil, 1.5 ml/kg, i.p.) on the next day. Results showed that the ethyl acetate and dichloromethane fractions significantly alleviated liver injury in rats as indicated by the reduced levels of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), total bilirubin (TB), and malondialdehyde (MDA), along with enhancement of the total antioxidant capacities of their livers, with the maximum effects were recorded by the ethyl acetate fraction. Moreover, the protective actions of both fractions were comparable to those of silymarin (100 mg/kg), and have been also substantiated by histopathological evaluations. On the other hand, liquid chromatography-high resolution electrospray ionization mass spectrometry (LC-HR-ESI-MS) metabolomic profiling of the crude extract of M. arboreus aerial parts showed the presence of a variety of phytochemicals, mostly phenolics, whereas the detailed chemical analysis of the most active fraction (i.e. ethyl acetate) resulted in the isolation and identification of six compounds for the first time in the genus, comprising four phenolic acids; beta-resorcylic, caffeic, protocatechuic, and 4-hydroxyphenylacetic acids, in addition to two flavonoids; trifolin and astragalin. Such phenolic principles, together with their probable synergistic antioxidant and liver-protecting properties, seem to contribute to the observed hepatoprotective potential of M. arboreus.	[Abdelhafez, Omnia Hesham] Deraya Univ, Fac Pharm, Dept Pharmacognosy, New Minia, Egypt; [Fawzy, Michael Atef] Minia Univ, Fac Pharm, Dept Biochem, Al Minya, Egypt; [Fahim, John Refaat; Desoukey, Samar Yehia; Abdelmohsen, Usama Ramadan] Minia Univ, Fac Pharm, Dept Pharmacognosy, Al Minya, Egypt; [Krischke, Markus; Mueller, Martin J.] Univ Wurzburg, Julius von Sachs Inst Biosci Bioctr Pharmaceut Bi, Wurzburg, Germany; [Abdelmohsen, Usama Ramadan] Univ Wurzburg, Julius von Sachs Inst Biol Sci, Dept Bot 2, Wurzburg, Germany	Deraya University; Egyptian Knowledge Bank (EKB); Minia University; Egyptian Knowledge Bank (EKB); Minia University; University of Wurzburg; University of Wurzburg	Abdelmohsen, UR (corresponding author), Minia Univ, Fac Pharm, Dept Pharmacognosy, Al Minya, Egypt.; Mueller, MJ (corresponding author), Univ Wurzburg, Julius von Sachs Inst Biosci Bioctr Pharmaceut Bi, Wurzburg, Germany.; Abdelmohsen, UR (corresponding author), Univ Wurzburg, Julius von Sachs Inst Biol Sci, Dept Bot 2, Wurzburg, Germany.	martin.mueller@biozentrum.uni-wuerzburg.de; usama.ramadan@mu.edu.eg	Desoukey, Samar Yehia/ABB-3317-2020; Abdelmohsen, Usama Ramadan/AAX-9874-2020; mueller, martin j/C-7616-2019; Desoukey, Samar/ABF-3565-2020	Abdelmohsen, Usama Ramadan/0000-0002-1014-6922; fawzy, michael/0000-0002-0456-9021; Fahim, John/0000-0002-2425-0819	German Research Foundation (DFG); University of Wuerzburg	German Research Foundation (DFG)(German Research Foundation (DFG)); University of Wuerzburg	This publication was funded by the German Research Foundation (DFG) and the University of Wuerzburg in the funding programme Open Access Publishing. The author(s) received no specific funding for this work.	Abdelmohsen UR, 2014, MAR DRUGS, V12, P1220, DOI 10.3390/md12031220; ACHARI B, 1984, J NAT PROD, V47, P751, DOI 10.1021/np50034a047; Achyilla GS, 2003, INDIAN J PHARM, V35, P311; Akindele AJ, 2010, J ETHNOPHARMACOL, V129, P46, DOI 10.1016/j.jep.2010.02.024; Al-Rejaie SS, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-136; Ali H, 2014, PHYTOMEDICINE, V21, P131, DOI 10.1016/j.phymed.2013.08.019; ARMENDARIZBORUNDA J, 1991, HEPATOLOGY, V14, P895, DOI 10.1002/hep.1840140523; Bishayee A, 2010, LIVER INT, V30, P1103, DOI 10.1111/j.1478-3231.2010.02295.x; Bork PM, 1997, FEBS LETT, V402, P85, DOI 10.1016/S0014-5793(96)01502-5; CACERES A, 1990, J ETHNOPHARMACOL, V30, P55, DOI 10.1016/0378-8741(90)90017-N; Carini R, 1992, BIOCHEM PHARMACOL, V38, P2859; Cheng N, 2013, FOOD CHEM TOXICOL, V55, P234, DOI 10.1016/j.fct.2012.11.022; Choi J, 2013, ARCH PHARM RES, V36, P912, DOI 10.1007/s12272-013-0090-x; Delange DM, 2012, ANAL CHEM LETT, V2, P171; DOMINGUEZ XA, 1985, J ETHNOPHARMACOL, V13, P139, DOI 10.1016/0378-8741(85)90002-9; Eidi A, 2012, EXCLI J, V11, P495; Ezzat Shahira M, 2016, Pharm Biol, V54, P3172, DOI 10.1080/13880209.2016.1214739; Garber J, 2010, GUIDE CARE USE LAB A, P220; Gulcin I, 2006, TOXICOLOGY, V217, P213, DOI 10.1016/j.tox.2005.09.011; Hafez MM, 2015, BIOL RES, V48, DOI [10.1186/s40659-015-0022-y, 10.1186/S40659-015-0022-Y]; Jaeschke H., 2008, CASARETT DOULLS TOXI, P557, DOI [10.1036/0071470514, DOI 10.1036/0071470514]; Jeong CH, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-25; Jia Lu, 2011, Zhongguo Zhong Yao Za Zhi, V36, P891; Jia L, 2011, J ASIAN NAT PROD RES, V13, P907, DOI 10.1080/10286020.2011.599802; Kaisoon O, 2011, J FUNCT FOODS, V3, P88, DOI 10.1016/j.jff.2011.03.002; Lim T.K., 2014, EDIBLE MED NONMEDICI, V8, P405; MABRY TJ, 1970, SYSTEMATIC IDENTIFIC, P4; Markham K.R, 1982, TECHNIQUES FLAVONOID; Navarro VJ, 2006, NEW ENGL J MED, V354, P731, DOI 10.1056/NEJMra052270; Ohtani K, 2011, Z NATURFORSCH C, V66, P31; Piazzon A, 2010, J AGR FOOD CHEM, V58, P10677, DOI 10.1021/jf101975q; Pietta PG, 2000, J NAT PROD, V63, P1035, DOI 10.1021/np9904509; Ranawat L, 2010, J ETHNOPHARMACOL, V127, P777, DOI 10.1016/j.jep.2009.10.019; Refaat J., 2015, J MED HERBS, V5, P193, DOI [10.3233/JHD-180291, DOI 10.3233/JHD-180291]; Refaat J, 2015, MED CHEM RES, V24, P2939, DOI 10.1007/s00044-015-1342-8; Shen BD, 2015, J ETHNOPHARMACOL, V164, P46, DOI 10.1016/j.jep.2015.01.044; Shi GF, 2006, NEUROSCI LETT, V403, P206, DOI 10.1016/j.neulet.2006.02.057; Shimokawa S, 2015, NAT PROD COMMUN, V10, P451; Smith I, 1960, CHROMATOGR ELECTROPH, P1; Sofowora A, 1993, PHYTOCHEMICAL SCREEN, P270; Somasundaram A, 2010, J ETHNOPHARMACOL, V127, P555, DOI 10.1016/j.jep.2009.11.014; Soon Y. Y., 2002, SMJ Singapore Medical Journal, V43, P077; Stahl E, 1970, THIN LAYER CHROMATOG, P810, DOI DOI 10.1002/STAR.19700221110; Suresh DR, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-61; Syafni N, 2012, INDONES J CHEM, V12, P273, DOI 10.22146/ijc.21342; Takac Milena Jadrijevic-Mladar, 2004, Acta Pharmaceutica (Zagreb), V54, P177; Tambde GM, 2016, TAIWANIA, V61, P243, DOI 10.6165/tai.2016.61.243; Trease G. E., 1989, TXB PHARMACOGNOSY, V12, P343; Wang ML, 2012, J AGR FOOD CHEM, V60, P6620, DOI 10.1021/jf301654y; Wang Y, 2011, PHARMAZIE, V66, P445, DOI 10.1691/ph.2011.0844; WAYNER DDM, 1987, BIOCHIM BIOPHYS ACTA, V924, P408, DOI 10.1016/0304-4165(87)90155-3; Weber LWD, 2003, CRIT REV TOXICOL, V33, P105, DOI 10.1080/713611034; Wu YH, 2007, FOOD CHEM TOXICOL, V45, P1349, DOI 10.1016/j.fct.2007.01.011; YAMADA K, 1995, PHYTOCHEMISTRY, V39, P1031, DOI 10.1016/0031-9422(95)00159-5; Yang SY, 2013, FOOD CHEM TOXICOL, V55, P92, DOI 10.1016/j.fct.2012.12.042; Yeasmin Z., 2014, DHAKA U J PHARM SCI, V13, P143, DOI [10.3329/dujps.v13i2.21892, DOI 10.3329/DUJPS.V13I2.21892]; You Y, 2010, FOOD CHEM TOXICOL, V48, P1632, DOI 10.1016/j.fct.2010.03.037; ZAMORA M, 1992, ETHNOPHARMACOLOGY, V35, P229; Zhang YJ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0105725, 10.1371/journal.pone.0088491, 10.1371/journal.pone.0093458, 10.1371/journal.pone.0109159]; Zhong K., 2014, J FOOD NUTR RES, V2, P349, DOI [10.12691/jfnr-2-7-4, DOI 10.12691/JFNR-2-7-4]	60	34	35	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2018	13	8							e0202362	10.1371/journal.pone.0202362	http://dx.doi.org/10.1371/journal.pone.0202362			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR6TZ	30138328	Green Submitted, Green Published, gold			2023-01-03	WOS:000442800100055
J	Lee, J; McDonald, C				Lee, Joy; McDonald, Christine			Review: Immunotherapy improves some symptoms and reduces long-term medication use in mild to moderate asthma	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Lee, Joy; McDonald, Christine] Austin Hlth, Melbourne, Vic, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health	Lee, J (corresponding author), Austin Hlth, Melbourne, Vic, Australia.		McDonald, Christine Faye/AAU-9083-2021					[Anonymous], GLOB STRAT ASTHM MAN; EAACI GUIDELINE ALLE	2	1	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 21	2018	169	4					JC17	JC17		10.7326/ACPJC-2018-169-4-017	http://dx.doi.org/10.7326/ACPJC-2018-169-4-017			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR4LO	30128507				2023-01-03	WOS:000442580400007
J	Stotzer, US; Pisani, GFD; Canevazzi, GHR; Shiguemoto, GE; Duarte, ACGD; Perez, SED; Selistre-de-Araujo, HS				Stotzer, Uliana Sbeguen; Deriggi Pisani, Graziele Fernanda; Rigo Canevazzi, Gustavo Henrique; Shiguemoto, Gilberto Eiji; de Oliveira Duarte, Ana Claudia Garcia; de Andrade Perez, Sergio Eduardo; Selistre-de-Araujo, Heloisa Sobreiro			Benefits of resistance training on body composition and glucose clearance are inhibited by long-term low carbohydrate diet in rats	PLOS ONE			English	Article							FATTY-ACID SYNTHESIS; INSULIN-RESISTANCE; KETOGENIC DIET; VISCERAL OBESITY; ADIPOSE-TISSUE; WEIGHT-LOSS; FREE MASS; EXERCISE; LIVER; MUSCLE	Background/Objectives Regular exercise training is effective to altering many markers of metabolic syndrome and its effects are strongly influenced by the type of consumed diet. Nowadays, resistance training (RT) has been frequently associated with low-carbohydrate high-fat diet (LCD). After long term these diets causes body weight (BW) regain with deleterious effects on body composition and metabolic risk factors. The effects of RT associated with long-term LCD on these parameters remain unexplored. We aimed to investigate the effects of RT when associated with long-term LCD on BW, feed efficiency, body composition, glucose homeostasis, liver parameters and serum biochemical parameters during BW regain period in rats. Subjects/Methods Male Sprague-Dawley rats were fed with LCD (LC groups) or standard diet (STD) (ST groups). After 10 weeks-diet animals were separated into sedentary (Sed-LC and Sed-ST) and resistance-trained (RT-LC and RT-ST) groups (N = 8/group). RT groups performed an 11-week climbing program on a ladder with progressive load. Dual x-ray absorptiometry, glucose tolerance tests and insulin tolerance tests were performed at weeks 10 and 20. Liver and serum were collected at week 21. Results RT reduced feed efficiency, BW gain, liver fat and total and LDL cholesterol, and improved body composition and glucose clearance in animals fed on STD. In those fed with LCD, RT reduced caloric intake, BW regain, liver fat and serum triglycerides levels. However, improvement in body composition was inhibited and bone mineral density and glucose clearance was further impaired in this association. Conclusions The LCD nullifies the beneficial effects of RT on body composition, glucose homeostasis and impairs some health parameters. Our results do not support the association of RT with LCD in a long term period.	[Stotzer, Uliana Sbeguen; Deriggi Pisani, Graziele Fernanda; Rigo Canevazzi, Gustavo Henrique; Shiguemoto, Gilberto Eiji; de Andrade Perez, Sergio Eduardo; Selistre-de-Araujo, Heloisa Sobreiro] Univ Fed Sao Carlos, Dept Physiol Sci, Sao Carlos, SP, Brazil; [de Oliveira Duarte, Ana Claudia Garcia] Univ Fed Sao Carlos, Dept Phys Educ & Human Motr, Sao Carlos, SP, Brazil	Universidade Federal de Sao Carlos; Universidade Federal de Sao Carlos	Stotzer, US (corresponding author), Univ Fed Sao Carlos, Dept Physiol Sci, Sao Carlos, SP, Brazil.	ulianass@hotmail.com	Stotzer, Uliana S/H-3413-2018	Stotzer, Uliana S/0000-0003-3325-5539; Duarte, Ana Claudia/0000-0002-7667-9481	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [13/00798-2]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [403144/2014-0]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior [001]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was supported by the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (13/00798-2 - USS; HSSA), by the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (403144/2014-0 - USS) and by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (001 - USS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexandraki I, 2015, SOUTH MED J, V108, P401, DOI 10.14423/SMJ.0000000000000308; Aoi W, 2012, PHYSIOL RES, V61, P81, DOI 10.33549/physiolres.932239; Asrih M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126364; Astrup A, 2004, LANCET, V364, P897, DOI 10.1016/S0140-6736(04)16986-9; Axen KV, 2010, OBESITY, V18, P1538, DOI 10.1038/oby.2009.466; Bidinotto P.M., 1997, Boletim Tecnico do CEPTA, V10, P53; Bielohuby M, 2013, AM J PHYSIOL-ENDOC M, V305, pE1059, DOI 10.1152/ajpendo.00208.2013; Brazil Ministrio da Cincia Tecnologia e Inovao Conselho Nacional de Controle de Experimentao Animal, 2016, GUIA BRAS PROD MAN U; Carroll S, 2004, SPORTS MED, V34, P371, DOI 10.2165/00007256-200434060-00004; Caton SJ, 2012, PHYSIOL BEHAV, V106, P185, DOI 10.1016/j.physbeh.2012.02.003; Cleasby ME, 2016, J ENDOCRINOL, V229, pR67, DOI 10.1530/JOE-15-0533; Rodrigues MFC, 2013, CLINICS, V68, P1247, DOI 10.6061/clinics/2013(09)12; Domingos MM, 2012, EUR J APPL PHYSIOL, V112, P1437, DOI 10.1007/s00421-011-2098-6; Duffy PH, 2002, J NUTR, V132, P101, DOI 10.1093/jn/132.1.101; Dulloo AG, 2015, OBES REV, V16, P1, DOI 10.1111/obr.12250; Dulloo AG, 2015, OBES REV, V16, P25, DOI 10.1111/obr.12253; Ellenbroek JH, 2014, AM J PHYSIOL-ENDOC M, V306, pE552, DOI 10.1152/ajpendo.00453.2013; Erlanson-Albertsson C, 2005, INT J OBESITY, V29, pS26, DOI 10.1038/sj.ijo.0803086; Handa K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104948; Holland AM, 2016, AM J PHYSIOL-REG I, V311, pR337, DOI 10.1152/ajpregu.00156.2016; Honors MA, 2009, NUTR METAB, V6, DOI 10.1186/1743-7075-6-46; Hornberger TA, 2004, CAN J APPL PHYSIOL, V29, P16, DOI 10.1139/h04-002; Hunter GR, 2010, OBESITY, V18, P690, DOI 10.1038/oby.2009.316; Jabekk PT, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-17; Jornayvaz FR, 2010, AM J PHYSIOL-ENDOC M, V299, pE808, DOI 10.1152/ajpendo.00361.2010; Leite RD, 2009, APPL PHYSIOL NUTR ME, V34, P1079, DOI 10.1139/H09-116; Mann S, 2014, SPORTS MED, V44, P211, DOI 10.1007/s40279-013-0110-5; Marliss EB, 2002, DIABETES, V51, pS271, DOI 10.2337/diabetes.51.2007.S271; Prestes J, 2012, INT J SPORTS MED, V33, P550, DOI 10.1055/s-0032-1304646; Roberts MD, 2016, J APPL PHYSIOL, V120, P1173, DOI 10.1152/japplphysiol.00837.2015; Rodriguez-Huguet M, 2017, AM J PHYS MED REHAB, V00, P1; Samuel VT, 2010, LANCET, V375, P2267, DOI 10.1016/S0140-6736(10)60408-4; Schwingshackl L, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-130; Sene-Fiorese M, 2008, OBESITY, V16, P2217, DOI 10.1038/oby.2008.339; Shiroma EJ, 2017, MED SCI SPORT EXER, V49, P40, DOI 10.1249/MSS.0000000000001063; Sitnick M, 2009, J PHYSIOL-LONDON, V587, P5753, DOI 10.1113/jphysiol.2009.180174; STANSBIE D, 1976, BIOCHEM J, V160, P413, DOI 10.1042/bj1600413; Stotzer US, 2015, INT J SPORTS MED, V36, P226, DOI 10.1055/s-0034-1390494; Strasser B, 2012, OBES REV, V13, P578, DOI 10.1111/j.1467-789X.2012.00988.x; Suk MinHwa, 2015, J Exerc Nutrition Biochem, V19, P289, DOI 10.5717/jenb.2015.15122303; Tchernof A, 2013, PHYSIOL REV, V93, P359, DOI 10.1152/physrev.00033.2011; Tinsley GM, 2016, INT J SPORT NUTR EXE, V26, P78, DOI 10.1123/ijsnem.2015-0070; Tirapegui J, 2012, NUTRIENTS, V4, P1328, DOI 10.3390/nu4091328; Tobias DK, 2015, LANCET DIABETES ENDO, V3, P968, DOI 10.1016/S2213-8587(15)00367-8; Verheggen RJHM, 2016, OBES REV, V17, P664, DOI 10.1111/obr.12406; Vina J, 2012, BRIT J PHARMACOL, V167, P1, DOI 10.1111/j.1476-5381.2012.01970.x; Warner SO, 2010, J CLIN HYPERTENS, V12, P64, DOI 10.1111/j.1751-7176.2009.00209.x; Wei JW, 2014, J CLIN INVEST, V124, P1781, DOI 10.1172/JCI72323; Wood RJ, 2012, METAB SYNDR RELAT D, V10, P167, DOI 10.1089/met.2011.0104; Xiao J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147062; Zengin A, 2016, EUR J NUTR, V55, P2307, DOI 10.1007/s00394-015-1040-9	51	4	4	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2018	13	12							e0207951	10.1371/journal.pone.0207951	http://dx.doi.org/10.1371/journal.pone.0207951			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD6IO	30532163	Green Published, Green Submitted, gold			2023-01-03	WOS:000452640900006
J	Humphries, C; Jaganathan, S; Panniyammakal, J; Singh, S; Goenka, S; Dorairaj, P; Gill, P; Greenfield, S; Lilford, R; Manaseki-Holland, S				Humphries, Claire; Jaganathan, Suganthi; Panniyammakal, Jeemon; Singh, Sanjeev; Goenka, Shifalika; Dorairaj, Prabhakaran; Gill, Paramjit; Greenfield, Sheila; Lilford, Richard; Manaseki-Holland, Semira			Investigating clinical handover and healthcare communication for outpatients with chronic disease in India: A mixed-methods study	PLOS ONE			English	Article							TRANSITIONAL CARE; INCOME COUNTRIES; QUALITY; RECORDS	Objectives Research concentrating on continuity of care for chronic, non-communicable disease (NCD) patients in resource-constrained settings is currently limited and focusses on inpatients. Outpatient care requires attention as this is where NCD patients often seek treatment and optimal handover of information is essential. We investigated handover, healthcare communication and barriers to continuity of care for chronic NCD outpatients in India. We also explored potential interventions for improving storage and exchange of healthcare information. Methods A mixed-methods design was used across five healthcare facilities in Kerala and Himachal Pradesh states. Questionnaires from 513 outpatients with cardiovascular disease, chronic respiratory disease, or diabetes covered the form and comprehensiveness of information exchange between healthcare professionals (HCPs) and between HCPs and patients. Semi-structured interviews with outpatients and HCPs explored handover, healthcare communication and intervention ideas. Barriers to continuity of care were identified through triangulation of all data sources. Results Almost half (46%) of patients self-referred to hospital outpatient clinics (OPCs). Patient-held healthcare information was often poorly recorded on unstructured sheets of paper; 24% of OPC documents contained the following: diagnosis, medication, long-term care and follow-up information. Just 55% of patients recalled receiving verbal follow-up and medication instructions during OPC appointments. Qualitative themes included patient preference for hospital visits, system factors, inconsistent doctor-patient communication and attitudes towards medical documents. Barriers were hospital time constraints, inconsistent referral practices and absences of OPC medical record-keeping, structured patient-held medical documents and clinical handover training. Patients and HCPs were in favour of the introduction of patient-held booklets for storing and transporting medical documents. Conclusions Deficiencies in communicative practices are compromising the continuity of chronic NCD outpatient care. Targeted systems-based interventions are urgently required to improve information provision and exchange. Our findings indicate that well-designed patient -held booklets are likely to be an acceptable, affordable and effective part of the solution.	[Humphries, Claire; Greenfield, Sheila; Manaseki-Holland, Semira] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England; [Jaganathan, Suganthi; Panniyammakal, Jeemon; Goenka, Shifalika; Dorairaj, Prabhakaran] Publ Hlth Fdn India, Delhi, India; [Jaganathan, Suganthi; Panniyammakal, Jeemon; Goenka, Shifalika; Dorairaj, Prabhakaran] Ctr Chron Dis Control, Delhi, India; [Panniyammakal, Jeemon] Sree Chitra Tirunal Inst Med Sci & Technol, Trivandrum, Kerala, India; [Singh, Sanjeev] Amrita Inst Med Sci, Hosp Adm, Kochi, Kerala, India; [Gill, Paramjit] Univ Warwick, Acad Unit Primary Care, Coventry, W Midlands, England; [Lilford, Richard] Univ Warwick, Ctr Appl Hlth Res & Delivery, Coventry, W Midlands, England	University of Birmingham; Public Health Foundation of India; Department of Science & Technology (India); Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST); Amrita Vishwa Vidyapeetham; Amrita Vishwa Vidyapeetham Kochi; University of Warwick; University of Warwick	Manaseki-Holland, S (corresponding author), Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England.	S.ManasekiHolland@bham.ac.uk	Manaseki-Holland, Semira/AFX-1728-2022; JAGANATHAN, SUGANTHI/AAU-7807-2020; Manaseki-Holland, Semira/I-7303-2017	Manaseki-Holland, Semira/0000-0001-5827-8855; JAGANATHAN, SUGANTHI/0000-0001-6422-1329; Manaseki-Holland, Semira/0000-0001-5827-8855; Goenka, Shifalika/0000-0001-6993-2883; Humphries, Claire/0000-0001-9784-5218; Jeemon, Panniyammakal/0000-0003-4172-4307; Lilford, Richard/0000-0002-0634-984X	National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care West Midlands (NIHR CLAHRC WM); Department For International Development [MR/M00287X/1]; Economic and Social Research Council; Medical Research Council; Wellcome Trust; MRC [MR/M00287X/1] Funding Source: UKRI	National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care West Midlands (NIHR CLAHRC WM)(National Institute for Health Research (NIHR)); Department For International Development; Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This research was supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care West Midlands (NIHR CLAHRC WM). This research was supported by a joint-funded grant (Ref No: MR/M00287X/1) from the following funders: The Department For International Development, The Economic and Social Research Council, The Medical Research Council, and the Wellcome Trust. The funders had no role in study design, data collection, analysis, decision to publish, or reporting of this manuscript.	Aarons GA, 2011, ADM POLICY MENT HLTH, V38, P4, DOI 10.1007/s10488-010-0327-7; Alberti H, 2006, PUBLIC HEALTH, V120, P650, DOI 10.1016/j.puhe.2005.05.011; Australian Commission on Safety and Quality in Healthcare, 2005, NON TRADITIONAL REF, P10; Bradley S, 2014, J CLIN NURS, V23, P1927, DOI 10.1111/jocn.12403; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; British Medical Association, 2004, NON TRADITIONAL REF, V7; Campanella P, 2016, EUR J PUBLIC HEALTH, V26, P60, DOI 10.1093/eurpub/ckv122; Coleman EA, 2003, J AM GERIATR SOC, V51, P549, DOI 10.1046/j.1532-5415.2003.51185.x; Corbin J., 1998, BASICS QUALITATIVE R; Creswell J. W., 2018, DESIGNING CONDUCTING, V3rd; Das J, 2014, ANNU REV ECON, V6, P525, DOI 10.1146/annurev-economics-080213-041350; Davies M, 2001, GUIDELINES PRACTICE, V4; Government of Kerala, EHEALTH KER; Greenhalgh T, 2004, MILBANK Q, V82, P581, DOI 10.1111/j.0887-378X.2004.00325.x; Gulliford Martin, 2006, J Health Serv Res Policy, V11, P248, DOI 10.1258/135581906778476490; Gyedu A, 2015, INT J SURG, V15, P74, DOI 10.1016/j.ijsu.2015.01.033; Hekmatpou D, 2010, INT J NURS PRACT, V16, P389, DOI 10.1111/j.1440-172X.2010.01856.x; Hesselink G, 2012, ANN INTERN MED, V157, P417, DOI 10.7326/0003-4819-157-6-201209180-00006; Ibiyemi O, 2012, ACTA ODONTOL SCAND, V70, P165, DOI 10.3109/00016357.2011.600712; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Kumar P, 2015, INT J RES FDN, V3, P33; Labbadia LL, 2004, ACTA PAUL ENFERM, V17, P55; LILFORD RJ, 1992, BMJ-BRIT MED J, V305, P1181, DOI 10.1136/bmj.305.6863.1181; Majothi S, 2014, NON TRADITIONAL REF, DOI [10.15124/CRD42014009309, DOI 10.15124/CRD42014009309]; Merten H, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4328; Mudany MA, 2015, J TROP PEDIATRICS, V61, P442, DOI 10.1093/tropej/fmv055; Naidu DVN, 2008, INT J EMERG MED, V1, P321, DOI 10.1007/s12245-008-0077-4; Nakamura Y, 2010, JPN MED ASS J, V53, P259; Osaki K, 2013, GLOBAL HEALTH ACTION, V6, P1, DOI 10.3402/gha.v6i0.20429; Palys T., 2008, SAGE ENCY QUALITATIV, P697, DOI DOI 10.4135/9781412963909.N349; Perez R.C., 2016, GLOB PEDIAT HLTH, V3, P1; Philibert I, 2012, BMJ QUAL SAF, V21, P1, DOI 10.1136/bmjqs-2012-001598; Pichitpornchai W, 1999, INT J NURS STUD, V36, P355, DOI 10.1016/S0020-7489(99)00043-7; Piette JD, 2012, B WORLD HEALTH ORGAN, V90, P365, DOI 10.2471/BLT.11.099069; Ramanayake R P J C, 2013, J Family Med Prim Care, V2, P145, DOI 10.4103/2249-4863.117404; SHAH PM, 1993, B WORLD HEALTH ORGAN, V71, P535; Turner Kathleen E, 2011, Online J Public Health Inform, V3, DOI 10.5210/ojphi.v3i2.3631; University of Birmingham, HAND IND WORK INT PR; van Walraven C, 2002, J GEN INTERN MED, V17, P186, DOI 10.1046/j.1525-1497.2002.10741.x; van Walraven C, 1999, AM J MED QUAL, V14, P160, DOI 10.1177/106286069901400403; Walton S, 2006, BRIT MED J, V332, P269, DOI 10.1136/bmj.332.7536.269; WHO, 2014, NON TRADITIONAL REF; Williams Faustine, 2008, Inform Prim Care, V16, P139; World Health Organisation, 1978, NON TRADITIONAL REF; World Health Organization, WHO RES POL, DOI [10.1016/j.respol.2016.03.011, DOI 10.1016/J.RESPOL.2016.03.011]; World Health Organization, 2007, PROM SAF MED CHILDR, P1	46	11	11	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2018	13	12							e0207511	10.1371/journal.pone.0207511	http://dx.doi.org/10.1371/journal.pone.0207511			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HD0QO	30517130	Green Published, Green Submitted, gold			2023-01-03	WOS:000452212400038
J	Rossettini, G; Palese, A; Geri, T; Fiorio, M; Colloca, L; Testa, M				Rossettini, Giacomo; Palese, Alvisa; Geri, Tommaso; Fiorio, Mirta; Colloca, Luana; Testa, Marco			Physical therapists' perspectives on using contextual factors in clinical practice: Findings from an Italian national survey	PLOS ONE			English	Article							LOW-BACK-PAIN; PLACEBO INTERVENTIONS; STANDARDIZED PATIENTS; THERAPEUTIC ALLIANCE; PATIENT EXPECTATIONS; QUESTIONNAIRE SURVEY; INFORMED-CONSENT; MANUAL THERAPY; PRIMARY-CARE; MANAGEMENT	Background Contextual factors (CFs) represent a potential therapeutic tool to boost physiotherapy outcomes, triggering placebo effects. Nevertheless, no evidence about the use of CFs among physical therapists is currently available. Objective To investigate the use of CFs and the opinion of Italian physical therapists specialized in Orthopaedic Manual Therapy (OMTs) on their therapeutic benefits. Design An exploratory cross-sectional online survey. Methods A 17-item questionnaire and 2 clinical vignettes assessed the perspective of OMTs on the adoption of CFs in daily clinical practice. The target population was composed of 906 OMTs. An online survey was performed in 2016 using SurveyMonkey Software. Data were analyzed by descriptive and inferential statistics. Results A total of 558 volunteers (61.6% of the target OMT population) participated in the study. Half of the participants (52.0%) claimed to use CFs frequently in their practice. More of 50% of OMTs valued the therapeutic significance of CFs for different health problems as determined by a combined psychological and physiological effect. OMTs considered the use of CFs ethically acceptable when they exert beneficial therapeutic effects and their effectiveness has emerged in previous clinical experiences (30.6%). They disagreed on the adoption of CFs when they are deceptive (14.1%). Moreover, OMTs did not communicate the adoption of CFs to patients (38.2%), and CFs were usually used in addition to other interventions to optimize clinical responses (19.9%). Psychological mechanisms, patient's expectation and conditioning were believed to be the main components behind CFs (7.9%). Limitations Considering that the data collected were self-reported and retrospective, recall and response biases may limit the internal and external validity of the findings. Conclusions OMTs used CFs in their clinical practice and believed in their therapeutic effect. The knowledge of CFs, placebo and nocebo mechanisms and their clinical effects should be included in physical therapists' university studies.	[Rossettini, Giacomo; Geri, Tommaso; Testa, Marco] Univ Genova Campus Savona, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Savona, Italy; [Palese, Alvisa] Univ Udine, Dept Med & Biol Sci, Udine, Italy; [Fiorio, Mirta] Univ Verona, Dept Neurosci Biomed & Movement Sci, Verona, Italy; [Colloca, Luana] Univ Maryland, Sch Nursing, Dept Pain Translat Symptom Sci, Baltimore, MD 21201 USA; [Colloca, Luana] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Colloca, Luana] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA; [Colloca, Luana] Univ Maryland, Ctr Adv Chron Pain Res, Baltimore, MD 21201 USA	University of Udine; University of Verona; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Testa, M (corresponding author), Univ Genova Campus Savona, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Savona, Italy.	marco.testa@unige.it	Palese, Alvisa/J-9427-2015; Geri, Tommaso/AAJ-2669-2021	Palese, Alvisa/0000-0002-3508-844X; Geri, Tommaso/0000-0001-9198-900X; Testa, Marco/0000-0001-8643-7200; Fiorio, Mirta/0000-0002-6356-0211; Rossettini, Giacomo/0000-0002-1623-7681				A.I.FI, 2017, ECCO CENSIMENTO AIFI; A.I.FI, 2008, FORMAZIONE CORE FISI; Babel P, 2013, MED PRIN PRACT, V22, P484, DOI 10.1159/000351563; Baghcheghi N, 2011, NURS ETHICS, V18, P364, DOI 10.1177/0969733011398093; Baldwin MJ, 2016, BMC SURG, V16, DOI 10.1186/s12893-016-0142-5; Beeton K, 2008, ED STANDARDS ORTHOPA; Bentley M, 2016, J ADV NURS, V72, P1991, DOI 10.1111/jan.12929; Berthelot JM, 2001, JOINT BONE SPINE, V68, P65, DOI 10.1016/S1297-319X(00)00225-6; Bialosky JE, 2017, J MAN MANIP THER, V25, P115, DOI 10.1080/10669817.2017.1309344; Bialosky JE, 2014, J PAIN, V15, P136, DOI 10.1016/j.jpain.2013.10.005; Bishop MD, 2015, PAIN MANAG, V5, P455, DOI 10.2217/pmt.15.39; Bishop MD, 2013, J ORTHOP SPORT PHYS, V43, P457, DOI 10.2519/jospt.2013.4492; Bishop MD, 2011, J MAN MANIP THER, V19, P20, DOI 10.1179/106698110X12804993426929; Blease C, 2016, BIOETHICS, V30, P407, DOI 10.1111/bioe.12245; Bologna Working Group, 2005, FRAM QUAL EUR HIGH E; Brunner E, 2016, CLIN REHABIL, V30, P85, DOI 10.1177/0269215515570499; Carlino E, 2016, NEUROSCIENCE, V338, P19, DOI 10.1016/j.neuroscience.2016.01.053; Carlino E, 2014, NAT REV RHEUMATOL, V10, P348, DOI 10.1038/nrrheum.2014.17; Carvalho C, 2016, PAIN, V157, P2766, DOI 10.1097/j.pain.0000000000000700; Colloca L, 2015, AM J BIOETHICS, V15, P17, DOI 10.1080/15265161.2015.1074314; Converse L, 2015, J GEN INTERN MED, V30, P586, DOI 10.1007/s11606-015-3365-8; de Leeuw E. D., 2008, INT HDB SURVEY METHO; Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6; Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34; Fassler M, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-15; Fassler M, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-144; Fan WM, 2010, COMPUT HUM BEHAV, V26, P132, DOI 10.1016/j.chb.2009.10.015; Ferreira PH, 2013, PHYS THER, V93, P470, DOI 10.2522/ptj.20120137; Fuentes J, 2014, PHYS THER, V94, P477, DOI 10.2522/ptj.20130118; Hall AM, 2010, PHYS THER, V90, P1099, DOI 10.2522/ptj.20090245; Hammond R, 2016, PHYSIOTHERAPY, V102, P71, DOI 10.1016/j.physio.2015.04.002; Harris CS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142804; Hassan Tabinda, 2011, Int J Health Sci (Qassim), V5, P45; Horing B, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01079; Howick J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058247; Hrobjartsson A, 2003, EVAL HEALTH PROF, V26, P153, DOI 10.1177/0163278703026002002; Hush JM, 2011, PHYS THER, V91, P25, DOI 10.2522/ptj.20100061; Kampermann L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178719; Kermen R, 2010, FAM MED, V42, P636; Ladeira CE, 2017, J ORTHOP SPORT PHYS, V47, P347, DOI 10.2519/jospt.2017.6561; Lau C, 2016, PHYS THER, V96, P469, DOI 10.2522/ptj.20150117; Li LC, 2001, PHYS THER, V81, P1018, DOI 10.1093/ptj/81.4.1018; Linde K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092938; Lipsitt DR, 2015, HARVARD REV PSYCHIAT, V23, P438, DOI 10.1097/HRP.0000000000000055; Lorenzetti RC, 2013, AM FAM PHYSICIAN, V87, P419; Lucassen P, 2016, SCAND J PRIM HEALTH, V34, P428, DOI 10.1080/02813432.2016.1249065; Meissner K, 2012, FAM PRACT, V29, P79, DOI 10.1093/fampra/cmr045; Miciak Maxi, 2018, Arch Physiother, V8, P3, DOI 10.1186/s40945-018-0044-1; Miciak M, 2012, SCAND J CARING SCI, V26, P394, DOI 10.1111/j.1471-6712.2011.00923.x; National Statistical Service, 2017, SAMPL SIZ CALC; Nitzan U, 2004, BMJ-BRIT MED J, V329, P944, DOI 10.1136/bmj.38236.646678.55; O'Keeffe M, 2016, PHYS THER, V96, P609, DOI 10.2522/ptj.20150240; Ortiz R, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-011012; Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202; Peabody JW, 2000, JAMA-J AM MED ASSOC, V283, P1715, DOI 10.1001/jama.283.13.1715; Peek K, 2017, DISABIL REHABIL, V39, P1932, DOI 10.1080/09638288.2016.1212281; Petrilli CM, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006578; Philbrick Jodi L., 2015, Medical Reference Services Quarterly, V34, P181, DOI 10.1080/02763869.2015.1019324; R Development Core Team, 2015, LANG ENV STAT COMP; Raz A, 2011, CAN J PSYCHIAT, V56, P198, DOI 10.1177/070674371105600403; Revelle William, 2020, CRAN; Riley SP, 2015, MANUAL THER, V20, P469, DOI 10.1016/j.math.2014.11.011; Rossettini G, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-1943-8; Rossettini G, 2016, WORK, V54, P159, DOI 10.3233/WOR-162289; Sahoo D, 2016, INT J HEALTH CARE Q, V29, P600, DOI 10.1108/IJHCQA-05-2015-0068; Schmidt WC, 1997, BEHAV RES METH INS C, V29, P274, DOI 10.3758/BF03204826; Scholte M, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-266; Shah Kartik N, 2009, Indian J Med Sci, V63, P472, DOI 10.4103/0019-5359.57640; Shermon R, 2008, J GEN INTERN MED, V23, P7, DOI 10.1007/s11606-007-0332-z; Siminoff LA, 2011, PATIENT EDUC COUNS, V82, P318, DOI 10.1016/j.pec.2011.01.021; Testa M, 2016, MANUAL THER, V24, P65, DOI 10.1016/j.math.2016.04.006; Tilburt JC, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1938; Unver S, 2013, AGRI, V25, P156, DOI 10.5505/agri.2013.82621; Veloski J, 2005, AM J MED QUAL, V20, P151, DOI 10.1177/1062860605274520; Vijapura S, 2016, ACAD PSYCHIATR, V40, P783, DOI 10.1007/s40596-015-0470-2; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Wager TD, 2015, NAT REV NEUROSCI, V16, P403, DOI 10.1038/nrn3976; Wartolowska K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091699; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Zadeh R, 2015, HERD-HEALTH ENV RES, V8, P58, DOI 10.1177/1937586715586393	80	22	22	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2018	13	11							e0208159	10.1371/journal.pone.0208159	http://dx.doi.org/10.1371/journal.pone.0208159			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HC6AO	30500838	Green Published, gold			2023-01-03	WOS:000451883700025
J	Davies, N; Manthorpe, J; Sampson, EL; Lamahewa, K; Wilcock, J; Mathew, R; Iliffe, S				Davies, Nathan; Manthorpe, Jill; Sampson, Elizabeth L.; Lamahewa, Kethakie; Wilcock, Jane; Mathew, Rammya; Iliffe, Steve			Guiding practitioners through end of life care for people with dementia: The use of heuristics	PLOS ONE			English	Article							PALLIATIVE CARE; HEALTH-CARE; OF-LIFE; QUALITY; EXPERIENCE; PATIENT; DESIGN; DEATH	Background End of life care (EOLC) for people with dementia can present a multitude of challenges and difficult decisions for practitioners. These challenges may include assessment and management of difficulties with eating and swallowing, responding to agitation, treating pain, and managing recurrent infections. Practitioners sometimes lack both confidence in making end of life decisions and guidance. This study developed an alternative to lengthy guidelines, in the form of heuristics which were tested in clinical settings. The aim of this study was to test the usability and acceptability of a set of heuristics which could be used by practitioners providing EOLC for people with dementia in a variety of clinical and care settings. Methods A three phase co-design process was adopted: 1) Synthesis of evidence and outputs from interviews and focus groups with family carers and practitioners, by a co-design group, to develop heuristics; 2) Testing of the heuristics in five clinical or care settings for six months; 3) Evaluation of the heuristics at three and six months using qualitative individual and group interviews. Results Four heuristics were developed covering: eating and swallowing difficulties, agitation and restlessness, reviewing treatment and interventions at the end of life, and providing routine care. The five sites reported that the heuristics were simple and easy to use, comprehensive, and made implicit, tacit knowledge explicit. Four themes emerged from the qualitative evaluation: authority and permission; synthesis of best practice; providing a structure and breaking down complexity; and reassurance and instilling confidence. Conclusion Use of heuristics is a novel approach to end of life decision making in dementia which can be useful to both experienced and junior members of staff making decisions. Heuristics are a practical tool which could overcome a lack of care pathways and direct guidance in end of life care for people with dementia.	[Davies, Nathan; Lamahewa, Kethakie; Wilcock, Jane; Mathew, Rammya; Iliffe, Steve] UCL, Res Dept Primary Care & Populat Hlth, London, England; [Davies, Nathan; Sampson, Elizabeth L.] UCL, Div Psychiat, Marie Curie Palliat Care Res Dept, Ctr Dementia Palliat Care Res, London, England; [Manthorpe, Jill] Kings Coll London, Social Care Workforce Res Unit, London, England; [Sampson, Elizabeth L.] North Middlesex Univ Hosp, Barnet Enfield & Haringey Mental Hlth Trust Liais, London, England	University of London; University College London; University of London; University College London; University of London; King's College London	Davies, N (corresponding author), UCL, Res Dept Primary Care & Populat Hlth, London, England.; Davies, N (corresponding author), UCL, Div Psychiat, Marie Curie Palliat Care Res Dept, Ctr Dementia Palliat Care Res, London, England.	n.m.davies@ucl.ac.uk	Wilcock, Jane/AAD-9385-2020; Sampson, Elizabeth L/B-8647-2009; Davies, Nathan/W-6693-2019	Wilcock, Jane/0000-0002-9779-7073; Sampson, Elizabeth L/0000-0001-8929-7362; Davies, Nathan/0000-0001-7757-5353; Manthorpe, Jill/0000-0001-9006-1410	Marie Curie Research Grants Scheme [C52233/A18873]; Alzheimer's Society [AS-PG-2013-026]; Clinical Research Networks of the National Institute for Health Research (NIHR)	Marie Curie Research Grants Scheme; Alzheimer's Society; Clinical Research Networks of the National Institute for Health Research (NIHR)	This work was supported by the Marie Curie Research Grants Scheme, grant C52233/A18873. This research was supported by funding from Alzheimer's Society (grant number AS-PG-2013-026). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This project was supported by the Clinical Research Networks of the National Institute for Health Research (NIHR). The views and opinions expressed here are those of the authors and do not necessarily reflect those of the NIHR or the English Department of Health.	Alzheimer's Disease International, 2016, BIBL REF NAT PLANS; Banerjee S, 2009, LIVING WELL DEMENTIA; Barclay S, 2014, BRIT J GEN PRACT, V64, pE576, DOI 10.3399/bjgp14X681397; Bate P, 2006, QUAL SAF HEALTH CARE, V15, P307, DOI 10.1136/qshc.2005.016527; Birch D, 2008, J CLIN NURS, V17, P1144, DOI 10.1111/j.1365-2702.2007.02220.x; Blumenthal-Barby JS, 2015, MED DECIS MAKING, V35, P539, DOI 10.1177/0272989X14547740; Bodemer N, 2015, INTERN EMERG MED, V10, P195, DOI 10.1007/s11739-014-1143-y; Boyd H, 2012, NEW ZEAL MED J, V125, P76; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Brush JE, 2015, DECISION MAKING SHOR; Davies N, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008832; Davies N, 2016, PALLIATIVE MED; DAVIES N, 2016, BMC PALLIAT CARE, V15; Davies N, 2016, BMJ, V353; Dening KH, 2012, BMJ SUPPORT PALLIAT, V2, P103, DOI 10.1136/bmjspcare-2011-000178; Department of Health and Social Care, 2018, CAR ACT PLAN 2018 20; Fetherstonhaugh D, 1741, DID I MAKE RIGHT DEC; Gigerenzer G, 2011, ANNU REV PSYCHOL, V62, P451, DOI 10.1146/annurev-psych-120709-145346; Grande G, 2011, PALLIATIVE MED, V25, P737, DOI 10.1177/0269216311425641; Grol R, 2001, JAMA-J AM MED ASSOC, V286, P2578, DOI 10.1001/jama.286.20.2578; Harbison J, 2003, STROKE, V34, P71, DOI 10.1161/01.STR.0000044170.46643.5E; Hendriks SA, 2014, J PAIN SYMPTOM MANAG, V47, P710, DOI 10.1016/j.jpainsymman.2013.05.015; Kaulio MA, 1998, TOTAL QUAL MANAGE, V9, P141, DOI 10.1080/0954412989333; Koopmans RTCM, 2007, INT J GERIATR PSYCH, V22, P350, DOI 10.1002/gps.1680; Marewski Julian N, 2012, Dialogues Clin Neurosci, V14, P77; Mathew R, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010416; Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50; MCCARTNEY M, 2012, BRIT MED J, V345; Mitchell SL, 2009, NEW ENGL J MED, V361, P1529, DOI 10.1056/NEJMoa0902234; Murphy E, 1998, Health Technol Assess, V2, piii; National Institute for Health and Care Excellence, 2004, IMPR SUPP PALL CAR A; National Institute for Health and Care Excellence (NICE), 2010, DEM QUAL STAND; Neuberger J., 2013, MORE CARE LESS PATHW; Office for National Statistics, 2016, DEATHS REG ENGL W DR; Paton N, 2013, AUSTRALAS PSYCHIATRY, V21, P78, DOI 10.1177/1039856212465347; Piper D, 2012, HEALTH SERV MANAG RE, V25, P162, DOI 10.1177/0951484812474247; Sachs GA, 2004, J GEN INTERN MED, V19, P1057, DOI 10.1111/j.1525-1497.2004.30329.x; Saini G, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0127-2; Sampson EL, 2015, BMJ SUPPORT PALLIAT, V5, P301, DOI 10.1136/bmjspcare-2014-000813; Stanley E, 2014, GET TO GRIPS WITH EX; Thune-Boyle IC., 2010, DEMENTIA, V9, P259, DOI DOI 10.1177/1471301209354026; TORJESEN I, 2013, BMJ BRIT MED J, V346; van der Steen JT, 2014, PALLIATIVE MED, V28, P197, DOI 10.1177/0269216313493685	43	12	12	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2018	13	11							e0206422	10.1371/journal.pone.0206422	http://dx.doi.org/10.1371/journal.pone.0206422			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HA3GQ	30427873	gold, Green Published, Green Submitted			2023-01-03	WOS:000450138500051
J	van Elten, TM; Karsten, MDA; Geelen, A; van Oers, AM; van Poppel, MNM; Groen, H; Gemke, RJBJ; Mol, B; Mutsaerts, MAQ; Roseboom, TJ; Hoek, A				van Elten, Tessa M.; Karsten, Matty D. A.; Geelen, Anouk; van Oers, Anne M.; van Poppel, Mireille N. M.; Groen, Henk; Gemke, Reinoud J. B. J.; Mol, Ben Willem; Mutsaerts, Meike A. Q.; Roseboom, Tessa J.; Hoek, Annemieke		LIFEstyle Study Grp	Effects of a preconception lifestyle intervention in obese infertile women on diet and physical activity; A secondary analysis of a randomized controlled trial	PLOS ONE			English	Article							SOCIAL DESIRABILITY; PREGNANT-WOMEN; WEIGHT-LOSS; RISK; OVERWEIGHT; STRESS; HEALTH; ASSOCIATION; PATTERNS; EXERCISE	Background Lifestyle changes are notoriously difficult. Since women who intend to become pregnant are more susceptible to lifestyle advice, interventions during this time window might be more effective than interventions during any other period in life. We here report the effects of the first large preconception lifestyle intervention RCT on diet and physical activity in obese infertile women. Methods In total, 577 women were randomized between a six-month lifestyle intervention program (intervention group; N = 290) or prompt infertility treatment (control group; N = 287). Self-reported dietary behaviors and physical activity were assessed at baseline, three, six and twelve months after randomization. Mixed models were used to analyze differences between groups. Results Compared to the control group, the intervention group reduced their intake of sugary drinks at three months (-0.5 glasses/day [95% C.I. = -0.9;-0.2]), of savory snacks at three (-2.4 handful/week [-3.4;-1.4]) and at six months (-1.4 handful/week [-2.6;-0.2]), and of sweet snacks at three (-2.2 portion/week [-3.3;-1.0]) and twelve months after randomization (-1.9 portion/week [-3.5;-0.4]). Also, the intervention group was more moderate to vigorous physically active at three months after randomization compared to the control group (169.0 minutes/week [6.0; 332.1]). Conclusion Our study showed that obese infertile women who followed a six-month preconception lifestyle intervention program decreased their intake of high caloric snacks and beverages, and increased their physical activity. These changes in lifestyle may not only improve women's health but their offspring's health too.	[van Elten, Tessa M.; van Poppel, Mireille N. M.; Gemke, Reinoud J. B. J.] Vrije Univ Amsterdam, Amsterdam UMC, Vrije Univ Amsterdam, Dept Publ & Occupat Hlth,Med Ctr, Amsterdam, Netherlands; [van Elten, Tessa M.; Karsten, Matty D. A.; Roseboom, Tessa J.] Univ Amsterdam, Amsterdam UMC, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, Amsterdam, Netherlands; [van Elten, Tessa M.; Karsten, Matty D. A.; Roseboom, Tessa J.] Univ Amsterdam, Amsterdam UMC, Acad Med Ctr, Dept Obstet & Gynecol, Amsterdam, Netherlands; [van Elten, Tessa M.; Karsten, Matty D. A.; van Poppel, Mireille N. M.; Gemke, Reinoud J. B. J.; Roseboom, Tessa J.] Amsterdam Publ Hlth Res Inst, Amsterdam, Netherlands; [van Elten, Tessa M.; Karsten, Matty D. A.; Gemke, Reinoud J. B. J.; Roseboom, Tessa J.] Amsterdam Reprod & Dev, Amsterdam, Netherlands; [Karsten, Matty D. A.; van Oers, Anne M.; Mutsaerts, Meike A. Q.; Hoek, Annemieke] Univ Groningen, Univ Med Ctr Groningen, Dept Obstet & Gynecol, Groningen, Netherlands; [Geelen, Anouk] Wageningen Univ & Res, Div Human Nutr, Wageningen, Netherlands; [van Poppel, Mireille N. M.] Karl Franzens Univ Graz, Inst Sport Sci, Graz, Austria; [Groen, Henk] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [Gemke, Reinoud J. B. J.] Vrije Univ Amsterdam, Emma Childrens Hosp, Dept Pediat, Amsterdam UMC, Amsterdam, Netherlands; [Mol, Ben Willem] Monash Univ, Dept Obstet & Gynecol, Melbourne, Vic, Australia	University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Groningen; Wageningen University & Research; University of Graz; University of Groningen; Emma Children's Hospital; University of Amsterdam; Vrije Universiteit Amsterdam; Monash University	van Elten, TM (corresponding author), Vrije Univ Amsterdam, Amsterdam UMC, Vrije Univ Amsterdam, Dept Publ & Occupat Hlth,Med Ctr, Amsterdam, Netherlands.; van Elten, TM (corresponding author), Univ Amsterdam, Amsterdam UMC, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, Amsterdam, Netherlands.; van Elten, TM (corresponding author), Univ Amsterdam, Amsterdam UMC, Acad Med Ctr, Dept Obstet & Gynecol, Amsterdam, Netherlands.; van Elten, TM (corresponding author), Amsterdam Publ Hlth Res Inst, Amsterdam, Netherlands.; van Elten, TM (corresponding author), Amsterdam Reprod & Dev, Amsterdam, Netherlands.	t.vanelten@vumc.nl	Groen, Henk/B-2163-2013; Van Poppel, Mireille/AAL-8228-2020	Groen, Henk/0000-0002-6629-318X; Van Poppel, Mireille/0000-0001-5694-4324; Roseboom, Tessa/0000-0003-0564-5994; van Elten, Tessa Monique/0000-0002-7677-8973	ZonMw, the Dutch Organization for Health Research and Development [50-50110-96-518]; Dutch Heart Foundation [2013T085]; European Commission (Horizon2020 project) [633595]	ZonMw, the Dutch Organization for Health Research and Development(Netherlands Organization for Health Research and Development); Dutch Heart Foundation(Netherlands Heart Foundation); European Commission (Horizon2020 project)(European Commission)	The LIFEstyle study was funded by ZonMw, the Dutch Organization for Health Research and Development, grant number: 50-50110-96-518. TvE is supported by grants from the Dutch Heart Foundation (2013T085) and the European Commission (Horizon2020 project 633595 DynaHealth). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams SA, 2005, AM J EPIDEMIOL, V161, P389, DOI 10.1093/aje/kwi054; Altfeld S, 1997, WOMEN HEALTH, V26, P29; [Anonymous], 2008, CBO GUIDELINE RICHTL; Bain E, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010443.pub2; Barker M, 2018, LANCET, V391, P1853, DOI [10.1016/s0140-6736(18)30313-1, 10.1016/S0140-6736(18)30313-1]; Cousineau TM, 2007, BEST PRACT RES CL OB, V21, P293, DOI 10.1016/j.bpobgyn.2006.12.003; Crutzen R, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-31; Csemiczky G, 2000, ACTA OBSTET GYN SCAN, V79, P113, DOI 10.1034/j.1600-0412.2000.079002113.x; Curioni CC, 2005, INT J OBESITY, V29, P1168, DOI 10.1038/sj.ijo.0803015; Cwikel J, 2004, EUR J OBSTET GYN R B, V117, P126, DOI 10.1016/j.ejogrb.2004.05.004; Dodd JM, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0161-y; Fleming TP, 2018, LANCET, V391, P1842, DOI [10.1016/s0140-6736(18)30312-x, 10.1016/S0140-6736(18)30312-X]; Flynn AC, 2016, INT J BEHAV NUTR PHY, V13, DOI 10.1186/s12966-016-0450-2; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Hayes L, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0479-2; Health Council of the Netherlands, 2006, GUIDELINES FOR A HEA; Hebert JR, 2008, J NUTR, V138, p226S, DOI 10.1093/jn/138.1.226S; HEBERT JR, 1995, INT J EPIDEMIOL, V24, P389, DOI 10.1093/ije/24.2.389; Hotham E, 2008, AUST NZ J OBSTET GYN, V48, P248, DOI 10.1111/j.1479-828X.2008.00827.x; Huxley R, 2010, EUR J CLIN NUTR, V64, P16, DOI 10.1038/ejcn.2009.68; Jensen, 2014, CIRCULATION, V129, pS139, DOI 10.1161/CIR.0000000000000070; Karsten MDA, 2019, EUR J NUTR, V58, P2463, DOI 10.1007/s00394-018-1798-7; Kim SY, 2007, OBESITY, V15, P986, DOI 10.1038/oby.2007.621; Kristal AR, 1998, J AM DIET ASSOC, V98, P40, DOI 10.1016/S0002-8223(98)00012-1; Moran LJ, 2017, OBESITY, V25, P1022, DOI 10.1002/oby.21848; Muktabhant B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007145.pub3; Mutsaerts MAQ, 2016, NEW ENGL J MED, V374, P1942, DOI 10.1056/NEJMoa1505297; Mutsaerts MAQ, 2010, BMC WOMENS HEALTH, V10, DOI 10.1186/1472-6874-10-22; Oteng-Ntim E, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-47; Phelan S, 2010, AM J OBSTET GYNECOL, V202, DOI [10.1016/j.ajog.2009.06.008, 10.1016/j.ajog.2010.06.051]; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Ramlau-Hansen CH, 2007, HUM REPROD, V22, P1634, DOI 10.1093/humrep/dem035; Russo LM, 2015, OBSTET GYNECOL, V125, P576, DOI 10.1097/AOG.0000000000000691; Simmons D, 2017, J CLIN ENDOCR METAB, V102, P903, DOI 10.1210/jc.2016-3455; Stephenson J, 2018, LANCET, V391, P1830, DOI [10.1016/S0140-6736(18)30311-8, 10.1016/s0140-6736(18)30311-8]; Streuling I, 2010, AM J CLIN NUTR, V92, P678, DOI 10.3945/ajcn.2010.29363; Tanentsapf I, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-81; The Netherlands Nutrition Centre, EETMETER MIJN VOEDIN; Torres SJ, 2007, NUTRITION, V23, P887, DOI 10.1016/j.nut.2007.08.008; Turner K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063743; Valkama A, 2016, EUR J CLIN NUTR, V70, P912, DOI 10.1038/ejcn.2015.205; van den Brink C, RIVM RAPPORT 2608540; Vandepitte L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194599; Wendel-Vos GCW, 2003, J CLIN EPIDEMIOL, V56, P1163, DOI 10.1016/S0895-4356(03)00220-8; Wijndaele K, 2007, PSYCHOL SPORT EXERC, V8, P425, DOI 10.1016/j.psychsport.2006.08.001; Wu T, 2009, OBES REV, V10, P313, DOI 10.1111/j.1467-789X.2008.00547.x; Yilmaz N, 2009, J WOMENS HEALTH, V18, P633, DOI 10.1089/jwh.2008.1057; Zelissen P M J, 2004, Ned Tijdschr Geneeskd, V148, P2060	48	17	17	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2018	13	11							e0206888	10.1371/journal.pone.0206888	http://dx.doi.org/10.1371/journal.pone.0206888			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GZ4PQ	30403756	Green Submitted, gold, Green Published			2023-01-03	WOS:000449379500079
J	Fortes, LS; Costa, MC; Ferreira, MEC; Nascimento, JRA; Fiorese, L; Lima, DRAA; Cyrino, ES				Fortes, Leonardo S.; Costa, Manoel C.; Ferreira, Maria E. C.; Nascimento-Junior, Jose R. A.; Fiorese, Lenamar; Lima-Junior, Dalton R. A. A.; Cyrino, Edilson S.			Frequency of resistance training does not affect inhibitory control or improve strength in well-trained young adults	PLOS ONE			English	Article							EXECUTIVE FUNCTIONS; OLDER WOMEN; EXERCISE; SYSTEMS	The objective of the current study was to compare the effects of resistance training frequency on cognitive inhibitory control in young adults with previous experience in the modality. Male participants (N= 36) were randomly placed into one of three experimental groups. Participants performed resistance training 1 (F1), 2 (F2), and 3 (F3) times per week for 24 weeks. The three groups performed exercises of equal intensity, volume-load, and rest duration. Cognitive inhibitory control (via Stroop test) was tested 72 h before (pre-experiment) and 72 h after (post-experiment) the resistance training program. No time vs. group interaction effects were noted for accuracy (F-(4,F-29) = 3.57, p = 0.18) or response time (F-(4,F-29) = 2.61, p = 0.06) on the Stroop test. These results indicate that increased resistance training frequency, when volume-load is kept constant, does not appear to potentiate cognitive inhibitory control.	[Fortes, Leonardo S.; Lima-Junior, Dalton R. A. A.] Univ Fed Pernambuco, Grad Program Phys Educ, Recife, PE, Brazil; [Costa, Manoel C.] Univ Pernambuco, Super Sch Phys Educ, Recife, PE, Brazil; [Ferreira, Maria E. C.] Univ Fed Juiz de Fora, Grad Program Phys Educ, Juiz De Fora, Brazil; [Nascimento-Junior, Jose R. A.] Fed Univ Vale Sao Francisco, Grad Program Phys Educ, Petrolina, Brazil; [Fiorese, Lenamar] Univ Estadual Maringa, Grad Program Phys Educ, Maringa, Parana, Brazil; [Cyrino, Edilson S.] Univ Estadual Londrina, Grad Program Phys Educ, Londrina, Brazil	Universidade Federal de Pernambuco; Universidade de Pernambuco (UPE); Universidade Federal de Juiz de Fora; Universidade Estadual de Maringa; Universidade Estadual de Londrina	Fortes, LS (corresponding author), Univ Fed Pernambuco, Grad Program Phys Educ, Recife, PE, Brazil.	leodesousafortes@hotmail.com	do Nascimento, José Roberto Andrade/L-2068-2017; de Lima-Junior, Dalton/E-9792-2019; da Cunha Costa, Manoel/I-4632-2014; Fortes, Leonardo de Sousa/Q-3378-2016; Fiorese, Lenamar/AAW-3972-2020; CYRINO, EDILSON/F-7196-2012; Ferreira, Maria Elisa Caputo/D-3496-2019	do Nascimento, José Roberto Andrade/0000-0003-3836-6967; de Lima-Junior, Dalton/0000-0003-1542-604X; da Cunha Costa, Manoel/0000-0001-8815-8846; Fortes, Leonardo de Sousa/0000-0002-0778-769X; CYRINO, EDILSON/0000-0001-9016-8779; Ferreira, Maria Elisa Caputo/0000-0002-3294-7560; Fiorese, Lenamar/0000-0003-1610-7534				Bruce J, 2016, APPL NEUROPSYCH-ADUL, V23, P336, DOI 10.1080/23279095.2015.1064002; Brush CJ, 2016, J SPORT EXERCISE PSY, V38, P396, DOI 10.1123/jsep.2016-0027; Chupel MU, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00377; Deslandes A, 2009, NEUROPSYCHOBIOLOGY, V59, P191, DOI 10.1159/000223730; Fonseca RM, 2014, J STRENGTH COND RES, V28, P3085, DOI 10.1519/JSC.0000000000000539; Hanson NJ, 2018, EXP BRAIN RES, V236, P1643, DOI 10.1007/s00221-018-5247-x; Huang T, 2014, SCAND J MED SCI SPOR, V24, P1, DOI 10.1111/sms.12069; Liu-Ambrose T, 2010, ARCH INTERN MED, V170, P170, DOI 10.1001/archinternmed.2009.494; Portugal EMM, 2013, NEUROPSYCHOBIOLOGY, V68, P1, DOI 10.1159/000350946; Northey JM, 2018, BR J SPORTS MED; Parsons TD, 2011, STUD HEALTH TECHNOL, V163, P433, DOI 10.3233/978-1-60750-706-2-433; Ratamess NA, 2009, MED SCI SPORT EXER, V41, P687, DOI 10.1249/MSS.0b013e3181915670; Rhea MR, 2004, J STRENGTH COND RES, V18, P918, DOI 10.1519/00124278-200411000-00040; Ribeiro AS, 2017, J STRENGTH COND RES, V31, P1888, DOI 10.1519/JSC.0000000000001653; Ribeiro AS, 2016, EXP GERONTOL, V79, P8, DOI 10.1016/j.exger.2016.03.007; Schoenfeld BJ, 2018, SPORTS MED; Schoenfeld BJ, 2016, J SPORT SCI MED, V15, P715; Verburgh L, 2014, BRIT J SPORT MED, V48, P973, DOI 10.1136/bjsports-2012-091441; Weinberg L, 2014, ACTA PSYCHOL, V153, P13, DOI 10.1016/j.actpsy.2014.06.011	19	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2018	13	11							e0206784	10.1371/journal.pone.0206784	http://dx.doi.org/10.1371/journal.pone.0206784			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ3MD	30388181	Green Published, gold, Green Submitted			2023-01-03	WOS:000449289800057
J	Hie, B; Cho, H; Berger, B				Hie, Brian; Cho, Hyunghoon; Berger, Bonnie			Realizing private and practical pharmacological collaboration	SCIENCE			English	Article							DRUG-DISCOVERY; PRODUCTIVITY; INFORMATION	Although combining data from multiple entities could power life-saving breakthroughs, open sharing of pharmacological data is generally not viable because of data privacy and intellectual property concerns. To this end, we leverage modern cryptographic tools to introduce a computational protocol for securely training a predictive model of drug-target interactions (DTIs) on a pooled dataset that overcomes barriers to data sharing by provably ensuring the confidentiality of all underlying drugs, targets, and observed interactions. Our protocol runs within days on a real dataset of more than 1 million interactions and is more accurate than state-of-the-art DTI prediction methods. Using our protocol, we discover previously unidentified DTIs that we experimentally validated via targeted assays. Our work lays a foundation for more effective and cooperative biomedical research.	[Hie, Brian; Cho, Hyunghoon; Berger, Bonnie] MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Berger, Bonnie] MIT, Dept Math, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Berger, B (corresponding author), MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Berger, B (corresponding author), MIT, Dept Math, Cambridge, MA 02139 USA.	bab@mit.edu		Hie, Brian/0000-0003-3224-8142; Cho, Hyunghoon/0000-0002-2713-0150	NIH [R01GM081871]; Kwanjeong Educational Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081871] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Kwanjeong Educational Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	B.H. and H.C. are partially supported by NIH grant R01GM081871 (to B.B.). H.C. is also partially supported by the Kwanjeong Educational Foundation.	Abadi M, 2016, CCS'16: PROCEEDINGS OF THE 2016 ACM SIGSAC CONFERENCE ON COMPUTER AND COMMUNICATIONS SECURITY, P308, DOI 10.1145/2976749.2978318; Ben-Or M., 1988, 20 STOC, P1, DOI 10.1145/62212.62213; Bonawitz K, 2017, CCS'17: PROCEEDINGS OF THE 2017 ACM SIGSAC CONFERENCE ON COMPUTER AND COMMUNICATIONS SECURITY, P1175, DOI 10.1145/3133956.3133982; Buzdar A, 2002, BREAST CANCER RES TR, V73, P161, DOI 10.1023/A:1015229630260; Catrina O, 2010, LECT NOTES COMPUT SC, V6052, P35, DOI 10.1007/978-3-642-14577-3_6; Cho H, 2018, NAT BIOTECHNOL, V36, P547, DOI 10.1038/nbt.4108; Cobanoglu MC, 2013, J CHEM INF MODEL, V53, P3399, DOI 10.1021/ci400219z; Cramer R., 2015, SECURE MULTIPARTY CO; Cressey D, 2011, NATURE, V471, P17, DOI 10.1038/471017a; Damgard I, 2012, LECT NOTES COMPUT SC, V7417, P643; Dwork C, 2006, LECT NOTES COMPUT SC, V3876, P265, DOI 10.1007/11681878_14; Glorot X, 2011, P 14 INT C ART INT S, P315, DOI DOI 10.1002/ECS2.1832; Hitaj B., 2017, ARXIV170207464CSCR; Hunter J., 2014, DRUG DISCOVERY WORLD; Khanna I, 2012, DRUG DISCOV TODAY, V17, P1088, DOI 10.1016/j.drudis.2012.05.007; Knox C, 2011, NUCLEIC ACIDS RES, V39, pD1035, DOI 10.1093/nar/gkq1126; LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539; Levy J., 2015, AGE COLLABORATION WH; Luo YA, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00680-8; Matsushima S, 2011, BIOCHEM BIOPH RES CO, V407, P557, DOI 10.1016/j.bbrc.2011.03.061; Mei JP, 2013, BIOINFORMATICS, V29, P238, DOI 10.1093/bioinformatics/bts670; Mohassel P, 2017, P IEEE S SECUR PRIV, P19, DOI 10.1109/SP.2017.12; Nikolaenko V., 2013, P 2013 ACM SIGSAC C, P801, DOI 10.1145/2508859.2516751; Paul SM, 2010, NAT REV DRUG DISCOV, V9, P203, DOI 10.1038/nrd3078; Reardon S., 2014, NATURE, DOI [10.1038/nature.2014.14672, DOI 10.1038/NATURE.2014.14672]; Shokri R, 2015, ANN ALLERTON CONF, P909, DOI 10.1109/ALLERTON.2015.7447103; Simmons S, 2016, CELL SYST, V3, P54, DOI 10.1016/j.cels.2016.04.013; Szklarczyk D, 2016, NUCLEIC ACIDS RES, V44, pD380, DOI 10.1093/nar/gkv1277; Tocchini-Valentini G, 2004, J MED CHEM, V47, P1956, DOI 10.1021/jm0310582; Wang WH, 2014, BIOINFORMATICS, V30, P2923, DOI 10.1093/bioinformatics/btu403; Wilhelm M., 2017, WIRED; Xia Z, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-S2-S6; Zheng XD, 2013, 19TH ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING (KDD'13), P1025	33	29	30	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 19	2018	362	6412					347	350		10.1126/science.aat4807	http://dx.doi.org/10.1126/science.aat4807			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX4EJ	30337410	Green Accepted, Green Published			2023-01-03	WOS:000447680100050
J	Ehler, E; Sterling, D; Dusenbery, K; Lawrence, J				Ehler, Eric; Sterling, David; Dusenbery, Kathryn; Lawrence, Jessica			Workload implications for clinic workflow with implementation of three-dimensional printed customized bolus for radiation therapy: A pilot study	PLOS ONE			English	Article							PHOTON-BEAM RADIOTHERAPY; PATIENT-SPECIFIC BOLUS; MEGAVOLTAGE PHOTON; ELECTRON-BEAMS; WET GAUZE; AIR-GAP; PERTURBATION	Bolus is commonly used in radiation therapy to improve radiation dose distribution to the target volume, but commercially available products do not always conform well to the patient surface. Tumor control may be compromised, particularly for superficial tumors, if bolus does not conform well and air gaps exist between the patient surface and the bolus. Three-dimensional (3D) printing technology allows the creation of highly detailed, variable shaped objects, making it an attractive and affordable option for customized, patient-specific bolus creation. The use of 3D printing in the clinical setting remains limited. Therefore, the objective of this study was to assess the implications on time and clinical fit using a workflow for 3D printing of customized bolus in companion animals with spontaneous tumors treated with radiation therapy. The primary aim of this study was to evaluate the time required to create a clinical 3D printed bolus. The secondary aims were to evaluate the clinical fit of the bolus and to verify the skin surface dose. Time to segmentation and 3D printing were documented, while the clinical fit of the bolus was assessed in comparison to the bolus created in the treatment planner. The mean and median time from segmentation to generation of 3D printed boluses was 6.15 h and 5.25 h, respectively. The 3D printed bolus was significantly less deviated from the planned bolus compared to the conventional bolus (p = 0.0078) with measured dose under the bolus within 5% agreement of expected dose in 88% of the measurements. Clinically acceptable 3D printed customized bolus was successfully created for treatment within one working day. The most significant impact on time is the 3D printing itself, which therefore has minimal implications on personnel and staffing. Quality assurance steps are recommended when implementing a 3D printing workflow to the radiotherapy clinic.	[Ehler, Eric; Sterling, David; Dusenbery, Kathryn] Univ Minnesota, Med Sch, Dept Radiat Oncol, Minneapolis, MN 55455 USA; [Lawrence, Jessica] Univ Minnesota, Coll Vet Med, Dept Vet Clin Sci, St Paul, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Lawrence, J (corresponding author), Univ Minnesota, Coll Vet Med, Dept Vet Clin Sci, St Paul, MN 55455 USA.	jlawrenc@umn.edu	Lawrence, Jessica/AAD-8460-2019	Lawrence, Jessica/0000-0002-8315-1909; Ehler, Eric/0000-0003-1151-8481	Department of Radiation Oncology at the University of Minnesota	Department of Radiation Oncology at the University of Minnesota	This work was supported by internal funds awarded to EE from the Department of Radiation Oncology at the University of Minnesota. The Department (funder) did not have direct role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Behrens CF, 2006, PHYS MED BIOL, V51, P5937, DOI 10.1088/0031-9155/51/22/015; Benoit J, 2009, VET RADIOL ULTRASOUN, V50, P555, DOI 10.1111/j.1740-8261.2009.01573.x; Butson MJ, 2000, RADIAT MEAS, V32, P201, DOI 10.1016/S1350-4487(99)00276-0; Canters RA, 2016, RADIOTHER ONCOL, V121, P148, DOI 10.1016/j.radonc.2016.07.011; Chiu T, 2018, PRACT RADIAT ONCOL, V8, pE167, DOI 10.1016/j.prro.2017.11.001; Craft DF, 2018, MED PHYS, V45, P1614, DOI 10.1002/mp.12839; Dancewicz OL, 2017, PHYS MEDICA, V38, P111, DOI 10.1016/j.ejmp.2017.05.051; Fujimoto K, 2017, PHYS MEDICA, V38, P1, DOI 10.1016/j.ejmp.2017.04.023; Giannopoulos AA, 2016, J THORAC IMAG, V31, P253, DOI 10.1097/RTI.0000000000000217; Kim SW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110746; Kong M, 2007, AUSTRALAS PHYS ENG S, V30, P111, DOI 10.1007/BF03178415; Lewis D, 2012, MED PHYS, V39, P3741, DOI 10.1118/1.4735223; Lukowiak M, 2017, J APPL CLIN MED PHYS, V18, P76, DOI 10.1002/acm2.12013; Madamesila J, 2016, PHYS MEDICA, V32, P242, DOI 10.1016/j.ejmp.2015.09.013; Matsumoto JS, 2015, RADIOGRAPHICS, V35, P1990, DOI 10.1148/rg.2015140260; Mitsouras D, 2015, RADIOGRAPHICS, V35, P1966, DOI 10.1148/rg.2015140320; Morrison RJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010825; Nagata K, 2012, VET RADIOL ULTRASOUN, V53, P96, DOI 10.1111/j.1740-8261.2011.01866.x; Park JW, 2016, CANCER RADIOTHER, V20, P205, DOI 10.1016/j.canrad.2015.11.003; Park JW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177562; Ricotti R, 2017, PHYS MEDICA, V39, P25, DOI 10.1016/j.ejmp.2017.06.004; Rustgi A K, 1997, Med Dosim, V22, P95, DOI 10.1016/S0958-3947(97)00001-0; SHARMA SC, 1993, MED PHYS, V20, P377, DOI 10.1118/1.597079; Su S., 2014, J APPL CLIN MED PHYS, V15, P4831, DOI [DOI 10.1120/JACMP.V15I4.4831, 10.1120/jacmp.v15i4.4831]; Vyas V, 2013, MED DOSIM, V38, P268, DOI 10.1016/j.meddos.2013.02.007; Yoon J, 2018, J APPL CLIN MED PHYS, V19, P137, DOI 10.1002/acm2.12269; Zhao YZ, 2017, MED DOSIM, V42, P150, DOI 10.1016/j.meddos.2017.03.001	27	9	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2018	13	10							e0204944	10.1371/journal.pone.0204944	http://dx.doi.org/10.1371/journal.pone.0204944			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV5EV	30273403	gold, Green Published, Green Submitted			2023-01-03	WOS:000446124700053
J	Kumar, S; Gupte, HA; Isaakidis, P; Mishra, JK; Munjattu, JF				Kumar, Samresh; Gupte, Himanshu A.; Isaakidis, Petros; Mishra, J. K.; Munjattu, Joseph Francis			"They don't like us....": Barriers to antiretroviral and opioid substitution therapy among homeless HIV positive people who inject drugs in Delhi: A mixed method study	PLOS ONE			English	Article							USERS; CARE	Background Provision of Anti-Retroviral Therapy (ART) and Opioid Substitution Therapy (OST) are important components of the targeted intervention (TI) programme for people who inject drugs (PWID). Homeless HIV positive PWIDs in Delhi is a key population experiencing gaps in uptake of these services, especially the ART uptake which is reportedly far from 90%, UNAIDS' 90-90-90 target to end the AIDS epidemic. Objective To assess the gaps and barriers in accessing the ART and OST services uptake among HIV positive homeless PWID in Delhi and to explore experiences and perspectives of the PWIDs and service providers. Methodology We used a convergent parallel mixed methods design which included a cross-sectional quantitative survey and a qualitative study. Two hundred thirty five homeless HIV positive PWID were interviewed and in-depth interviews were conducted with five PWIDs and nine health providers. Results While only 12% of PWIDs were on ART, 80% were availing OST services. The top individual, health system related and structural barriers for ART service access were insufficient and incorrect knowledge (63%), long waiting time (86%) and lack of family support (44%) respectively. Inconvenient timings, stringent registration requirements and negative attitude of health providers were expressed as major barriers of accessing ART services during the interviews while these were not a concern in OST services. Homelessness, poverty, stigma were common barriers for both services. Integrated, 'single window' service and provision of additional support like nutrition and shelter were suggested as measures to improve access by both health providers and the PWIDs themselves. Conclusion There is an urgent need for structural and health systems changes to improve access to ART and OST services. These include integrated service delivery, flexibility in timing of the centers, accelerated ART initiation, simplification of bureaucratic procedures, nutritional and social support to all homeless HIV positive PWIDs.	[Kumar, Samresh] IHAT, Tech Support Unit, Delhi, India; [Gupte, Himanshu A.] Narotam Sekhsaria Fdn, Bombay, Maharashtra, India; [Isaakidis, Petros] Med Sans Frontieres, Operat Res Unit, Luxembourg, Luxembourg; [Mishra, J. K.] DSACS, Delhi, India; [Munjattu, Joseph Francis] IHAT, Tech Support Unit, Bengaluru, India	Doctors Without Borders	Kumar, S (corresponding author), IHAT, Tech Support Unit, Delhi, India.	samreshkumar10@gmail.com		Gupte, Himanshu/0000-0002-6290-2419; Isaakidis, Petros/0000-0002-7881-1554	Department for International Development (DFID), UK; La Fondation Veuve Emile Metz-Tesch (Luxembourg)	Department for International Development (DFID), UK; La Fondation Veuve Emile Metz-Tesch (Luxembourg)	The training programme and open access publication costs were funded by the Department for International Development (DFID), UK and La Fondation Veuve Emile Metz-Tesch (Luxembourg). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal A, 2015, QUALITY ASSURANCE IM; [Anonymous], 2015, NHMRC STAT EV WIND H; [Anonymous], 2015, NAT INT BIOL BEH SUR; Chakarpani V, 2015, BARRIERS ANTIRETROVI, V26, P835; Chakrapani MD, 2012, BARRIERS OPPORTUNITI; Chakrapani V, 2012, ACCESS COMPREHENSIVE; Chakrapani V, 2014, AIDS CARE, V26, P835, DOI 10.1080/09540121.2013.861573; Creswell JW, 2013, DBER SPEAK SER, P54; DSACS, DELH STAT AIDS CONTR; International Harm Reduction Development Program (IHRD), OPEN SOC I PUBLIC HE; Joshi V, 2012, DIRECTORATE CENSUS O, P2; Latkin C, RELATIONSHIP DRUG US; Mathers BM, 2010, LANCET, V375, P1014, DOI 10.1016/S0140-6736(10)60232-2; National AIDS Control Organization, HIV SENT SURV REP; National AIDS Control Organization, OST OV PERF FY 2016; Rao R, 2017, INDIAN J PSYCHIAT, V59, P457; Reid G, 2014, J PUBLIC HEALTH RES, V3, P1, DOI 10.4081/jphr.2014.204; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; UNAIDS, 90 90 90 AMB TREATM; UNAIDS, FACT SHEET PEOPL LIV; UNAIDS, 2016, 2016 PREV GAP REP, P6; UNAIDS (Joint United Nations Programme on HIV/AIDS), 2014, FAST TRACK END AIDS, P1; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; Wolfe D, 2010, LANCET, V376, P355, DOI 10.1016/S0140-6736(10)60832-X; World Health Organization, 2016, CONS GUID US ANT DRU	25	12	12	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2018	13	8							e0203262	10.1371/journal.pone.0203262	http://dx.doi.org/10.1371/journal.pone.0203262			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GS2NZ	30161255	gold, Green Published, Green Submitted			2023-01-03	WOS:000443388900096
J	Seghieri, C; Calovi, M; Ferre, F				Seghieri, Chiara; Calovi, Martina; Ferre, Francesca			Proximity and waiting times in choice models for outpatient cardiological visits in Italy	PLOS ONE			English	Article							HEALTH-CARE; PATIENT CHOICE; ACCESS; EQUITY	We apply mixed logit regression to investigate patients' choice of non-emergency outpatient cardiovascular specialists in Tuscany, Italy. We focused on the effects of travel time and waiting time. Results reveal that patients prefer clinics nearby and with shorter waiting times. Differences in patient choice depend on age and socioeconomic conditions, thus confirming equity concerns in the access of non-acute services. Our results could be used to optimize the allocation of resources, reduce inequities and increase the efficiency and responsiveness of outpatient systems considering patient preferences.	[Seghieri, Chiara; Calovi, Martina; Ferre, Francesca] Scuola Super Sant Anna, Inst Management, Lab Management & Sanita, Pisa, Italy; [Calovi, Martina] Penn State Univ, Dept Geog, Geoinformat & Earth Observat Lab, University Pk, PA 16802 USA; [Calovi, Martina] Penn State Univ, Inst CyberSci, University Pk, PA 16802 USA	Scuola Superiore Sant'Anna; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ferre, F (corresponding author), Scuola Super Sant Anna, Inst Management, Lab Management & Sanita, Pisa, Italy.	francesca.ferre@santannapisa.it	ferre, francesca/L-7614-2014	ferre, francesca/0000-0001-5781-517X	regional administration-Direzione Diritti di cittadinanza e coesione sociale-of Tuscany	regional administration-Direzione Diritti di cittadinanza e coesione sociale-of Tuscany	This study was supported by the regional administration-Direzione Diritti di cittadinanza e coesione sociale-of Tuscany. The authors acknowledge Professor Sabina Nuti and all researchers from Laboratorio Management e Sanita, Institute of Management, Sant'Anna School of Advances Studies, for their constant support and useful comments.	Aggarwal A, 2016, MED CARE RES REV; Akinci F., 2004, HLTH MARK Q, V22, P3, DOI DOI 10.1300/J026V22N01_02; [Anonymous], [No title captured]; [Anonymous], SANITA SALUTE TOSCAN; ARS T, 2013, RAPP CRIS EC STAT SA; Balia Silvia, 2014, Dev Health Econ Public Policy, V12, P133; Barsanti S, 2014, INT J HEALTH PLAN M, V29, pE233, DOI 10.1002/hpm.2195; Berkowitz E. N., 1981, J HEALTH CARE MARKET, V1, P25; Bevan GA, HEAL EC POLICY LAW; Boo G, 2015, ISPRS ANN PHOTO REM, VII-3, P263, DOI 10.5194/isprsannals-II-3-W5-263-2015; Boscarino J, 1982, J HLTH CARE MARK, P23; Brekke K., 2014, DEV HLTH EC PUBLIC P, V12; Briggs DJ, 2007, REMOTE SENS ENVIRON, V108, P451, DOI 10.1016/j.rse.2006.11.020; Cooper Z, 2011, ECON J, V121, pF228, DOI 10.1111/j.1468-0297.2011.02449.x; Coulter A., 2010, BMJ, V341; Dixon A, 2010, HEALTH ECON POLICY L, V5, P295, DOI 10.1017/S1744133110000058; Exworthy M, 2006, SOC POLICY ADMIN, V40, P267, DOI 10.1111/j.1467-9515.2006.00489.x; Ferre F, 2014, HEALT SYST TRANSIT, V16, P1; Fotaki M, 2007, PUBLIC ADMIN, V85, P1059, DOI 10.1111/j.1467-9299.2007.00682.x; France G, 2005, J HEALTH POLIT POLIC, V30, P169, DOI 10.1215/03616878-30-1-2-169; Gesler MW, 1989, METHODOLOGICAL ADV H; Glorioso V, 2014, HEALTH SERV RES, V49, P950, DOI 10.1111/1475-6773.12128; Hole AR, 2008, J HEALTH ECON, V27, P1078, DOI 10.1016/j.jhealeco.2007.11.006; Lane PM, 1994, HLTH CARE MARKETING; Magnussen J, 2009, NORDIC HLTH CARE SYS; Masseria C, 2010, EUR J PUBLIC HEALTH, V20, P504, DOI 10.1093/eurpub/ckq029; Ministero della salute, 2012, PIAN NAZ GOV LIST AT; Nuti S., 2016, Medical practice variations, P433; PENCHANSKY R, 1981, MED CARE, V19, P127, DOI 10.1097/00005650-198102000-00001; RisaHole Arne, 2016, ECONPAPERS; Shah J, 2010, J CLIN UROL, V3, P25, DOI 10.1016/j.bjmsu.2009.10.003; Siciliani L, 2013, OECD HLTH POLICY STU, P1; Sivey P, 2012, HEALTH ECON, V21, P444, DOI 10.1002/hec.1720; WOLINSKY FD, 1984, HOSP HEALTH SERV ADM, V29, P58	34	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2018	13	8							e0203018	10.1371/journal.pone.0203018	http://dx.doi.org/10.1371/journal.pone.0203018			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GS2NZ	30161181	gold, Green Published, Green Submitted			2023-01-03	WOS:000443388900065
J	Minick, SG; May, SB; Amico, KR; Cully, J; Davila, JA; Kallen, MA; Giordano, TP				Minick, Sophie G.; May, Sarah B.; Amico, K. Rivet; Cully, Jeffrey; Davila, Jessica A.; Kallen, Michael A.; Giordano, Thomas P.			Participants' perspectives on improving retention in HIV care after hospitalization: A post-study qualitative investigation of the MAPPS study	PLOS ONE			English	Article							BEHAVIORAL SKILLS MODEL; ANTIRETROVIRAL THERAPY; VIRAL SUPPRESSION; RANDOMIZED-TRIAL; INTERVENTION; ADHERENCE; INFORMATION; MOTIVATION; PROGRAM	Few interventions have been shown to improve retention in HIV care. We recently completed a randomized, controlled trial of a peer mentoring intervention, which failed to increase retention in care or HIV suppression. We sought to gain insight into this negative result and elicit suggestions for future interventions. We conducted semi-structured one-on-one interviews with a sub-sample of participants and all available interventionists after completion of the primary study. Interviews were coded by two researchers and thematically analyzed. Participants in the intervention arm (N = 16) reported good rapport with and benefit from peer mentoring and found the mentors helpful in facilitating the transition from hospital to out-patient clinic. Control arm participants (N = 9) reported similar emotional and social support benefits from the health educators. In both arms, ongoing challenges including completing paperwork, securing transportation, and rescheduling missed appointments were cited, along with internalized stigma and lack of will to seek care, despite the mentors' best efforts. Suggested improvements to the intervention included: more frequent contact with interventionists; additional support for mental health problems; and targeting overall health rather than a more selective focus on HIV. Mentors and health educators agreed with the participant-reported barriers and added that some participants were too sick to meaningfully participate in the intervention, while others appeared unwilling to engage with the interventionists in a meaningful way. Mentoring was highly acceptable and felt to be impactful, however it was not sufficient to overcome structural barriers or stigma and low motivation in some participants. The attention control intervention may have had an unintended positive impact. Future interventions should focus on broad aspects of health and well-being.	[Minick, Sophie G.; May, Sarah B.; Davila, Jessica A.; Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Minick, Sophie G.; May, Sarah B.; Cully, Jeffrey; Davila, Jessica A.; Giordano, Thomas P.] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety IQuESt, Houston, TX 77030 USA; [Amico, K. Rivet] Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA; [Cully, Jeffrey] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; [Kallen, Michael A.] Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA	Baylor College of Medicine; Baylor College of Medicine; University of Michigan System; University of Michigan; Baylor College of Medicine; Northwestern University; Feinberg School of Medicine	Giordano, TP (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.; Giordano, TP (corresponding author), Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety IQuESt, Houston, TX 77030 USA.	tpg@bcm.edu	/AAE-4700-2020	Amico, K Rivet/0000-0002-4458-6934; May, Sarah/0000-0003-1489-8053	National Institutes of Health [R01MH085527]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH085527] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by the National Institutes of Health (grant number R01MH085527; T.P.G.) and the facilities and resources of the Harris Health System and the Michael E. DeBakey VA Medical Center. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by the National Institutes of Health (grant number R01MH085527; T.P.G.) and the facilities and resources of Baylor College of Medicine, Harris Health System and the Michael E. DeBakey VA Medical Center.	Cully JA, 2012, AIDS PATIENT CARE ST, V26, P165, DOI 10.1089/apc.2011.0248; Doshi RK, 2015, CLIN INFECT DIS, V60, P117, DOI 10.1093/cid/ciu722; El-Sadr WM, 2017, JAMA INTERN MED, V177, P1083, DOI 10.1001/jamainternmed.2017.2158; Fisher JD, 2006, HEALTH PSYCHOL, V25, P462, DOI 10.1037/0278-6133.25.4.462; Fisher Jeffrey D, 2008, Curr HIV/AIDS Rep, V5, P193, DOI 10.1007/s11904-008-0028-y; Gardner LI, 2014, CLIN INFECT DIS, V59, P725, DOI 10.1093/cid/ciu357; Giordano TP, 2016, CLIN INFECT DIS, V63, P678, DOI 10.1093/cid/ciw322; Giordano Thomas P, 2011, Top Antivir Med, V19, P12; Golin CE, 2006, JAIDS-J ACQ IMM DEF, V42, P42, DOI 10.1097/01.qai.0000219771.97303.0a; Kamb ML, 1998, JAMA-J AM MED ASSOC, V280, P1161, DOI 10.1001/jama.280.13.1161; Krippendorff K, 1989, CONTENT ANAL; Metsch LR, 2016, JAMA-J AM MED ASSOC, V316, P156, DOI 10.1001/jama.2016.8914; Mugavero MJ, 2012, JAIDS-J ACQ IMM DEF, V59, P86, DOI 10.1097/QAI.0b013e318236f7d2; Smith LR, 2012, AIDS PATIENT CARE ST, V26, P344, DOI 10.1089/apc.2011.0388	14	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2018	13	8							e0202917	10.1371/journal.pone.0202917	http://dx.doi.org/10.1371/journal.pone.0202917			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GR6UK	30148868	Green Published, gold, Green Submitted			2023-01-03	WOS:000442804200032
J	Tawbi, HA; Forsyth, PA; Algazi, A; Hamid, O; Hodi, FS; Moschos, SJ; Khushalani, NI; Lewis, K; Lao, CD; Postow, MA; Atkins, MB; Ernstoff, MS; Reardon, DA; Puzanov, I; Kudchadkar, RR; Thomas, RP; Tarhini, A; Pavlick, AC; Jiang, J; Avila, A; Demelo, S; Margolin, K				Tawbi, Hussein A.; Forsyth, Peter A.; Algazi, Alain; Hamid, Omid; Hodi, F. Stephen; Moschos, Stergios J.; Khushalani, Nikhil I.; Lewis, Karl; Lao, Christopher D.; Postow, Michael A.; Atkins, Michael B.; Ernstoff, Marc S.; Reardon, David A.; Puzanov, Igor; Kudchadkar, Ragini R.; Thomas, Reena P.; Tarhini, Ahmad; Pavlick, Anna C.; Jiang, Joel; Avila, Alexandre; Demelo, Sheena; Margolin, Kim			Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DABRAFENIB PLUS TRAMETINIB; OPEN-LABEL; SURVIVAL; MONOTHERAPY; MULTICENTER; DIAGNOSIS	BACKGROUND Brain metastases are a common cause of disabling neurologic complications and death in patients with metastatic melanoma. Previous studies of nivolumab combined with ipilimumab in metastatic melanoma have excluded patients with untreated brain metastases. We evaluated the efficacy and safety of nivolumab plus ipilimumab in patients with melanoma who had untreated brain metastases. METHODS In this open-label, multicenter, phase 2 study, patients with metastatic melanoma and at least one measurable, nonirradiated brain metastasis (tumor diameter, 0.5 to 3 cm) and no neurologic symptoms received nivolumab (1 mg per kilogram of body weight) plus ipilimumab (3 mg per kilogram) every 3 weeks for up to four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks until progression or unacceptable toxic effects. The primary end point was the rate of intracranial clinical benefit, defined as the percentage of patients who had stable disease for at least 6 months, complete response, or partial response. RESULTS Among 94 patients with a median follow-up of 14.0 months, the rate of intracranial clinical benefit was 57% (95% confidence interval [ CI], 47 to 68); the rate of complete response was 26%, the rate of partial response was 30%, and the rate of stable disease for at least 6 months was 2%. The rate of extracranial clinical benefit was 56% (95% CI, 46 to 67). Treatment-related grade 3 or 4 adverse events were reported in 55% of patients, including events involving the central nervous system in 7%. One patient died from immune-related myocarditis. The safety profile of the regimen was similar to that reported in patients with melanoma who do not have brain metastases. CONCLUSIONS Nivolumab combined with ipilimumab had clinically meaningful intracranial efficacy, concordant with extracranial activity, in patients with melanoma who had untreated brain metastases.	[Tawbi, Hussein A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Forsyth, Peter A.; Khushalani, Nikhil I.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Algazi, Alain] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Hamid, Omid] Angeles Clin & Res Inst, Los Angeles, CA USA; [Thomas, Reena P.] Stanford Univ Hosp, Palo Alto, CA USA; [Margolin, Kim] City Hope Natl Med Ctr, Dept Med Oncol, Duarte, CA USA; [Hodi, F. Stephen; Reardon, David A.] Dana Farber Canc Inst, Boston, MA USA; [Moschos, Stergios J.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Lewis, Karl] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA; [Lao, Christopher D.] Univ Michigan, Ann Arbor, MI 48109 USA; [Postow, Michael A.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Postow, Michael A.] Weill Cornell Med Coll, New York, NY USA; [Ernstoff, Marc S.; Puzanov, Igor] Roswell Pk Canc Inst, Buffalo, NY 14263 USA; [Pavlick, Anna C.] NYU, Lake Success, NY USA; [Atkins, Michael B.] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA; [Kudchadkar, Ragini R.] Emory Univ, Winship Canc Ctr, Atlanta, GA 30322 USA; [Tarhini, Ahmad] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; [Jiang, Joel; Avila, Alexandre; Demelo, Sheena] Bristol Myers Squibb Co, Princeton, NJ USA; [Tarhini, Ahmad] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA	University of Texas System; UTMD Anderson Cancer Center; H Lee Moffitt Cancer Center & Research Institute; University of California System; University of California San Francisco; Angeles Clinic & Research Institute; Stanford University; City of Hope; Harvard University; Dana-Farber Cancer Institute; University of North Carolina; University of North Carolina Chapel Hill; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Michigan System; University of Michigan; Memorial Sloan Kettering Cancer Center; Cornell University; Roswell Park Cancer Institute; New York University; Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Bristol-Myers Squibb; Cleveland Clinic Foundation	Tawbi, HA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Div Canc Med, 1400 Holcombe Blvd, Houston, TX 77030 USA.	htawbi@mdanderson.org	PUZANOV, IGOR/AAP-2966-2020	PUZANOV, IGOR/0000-0002-9803-3497; Margolin, Kim/0000-0002-5248-4356	Bristol-Myers Squibb; National Cancer Institute [NCT02320058]; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Bristol-Myers Squibb(Bristol-Myers Squibb); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by Bristol-Myers Squibb and the National Cancer Institute;	Agarwala SS, 2004, J CLIN ONCOL, V22, P2101, DOI 10.1200/JCO.2004.11.044; Cagney DN, 2017, NEURO-ONCOLOGY, V19, P1511, DOI 10.1093/neuonc/nox077; Davies MA, 2017, LANCET ONCOL, V18, P863, DOI 10.1016/S1470-2045(17)30429-1; Davies MA, 2011, CANCER-AM CANCER SOC, V117, P1687, DOI 10.1002/cncr.25634; Di Giacomo AM, 2012, LANCET ONCOL, V13, P879, DOI 10.1016/S1470-2045(12)70324-8; Goldberg SB, 2016, LANCET ONCOL, V17, P976, DOI 10.1016/S1470-2045(16)30053-5; Hodi FS, 2016, LANCET ONCOL, V17, P1558, DOI 10.1016/S1470-2045(16)30366-7; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214; Long GV, 2017, ANN ONCOL, V28, P1631, DOI 10.1093/annonc/mdx176; Long GV, 2018, LANCET ONCOL, V19, P672, DOI 10.1016/S1470-2045(18)30139-6; Margolin K, 2012, LANCET ONCOL, V13, P459, DOI 10.1016/S1470-2045(12)70090-6; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Sloan AE, 2009, CANCER CONTROL, V16, P248, DOI 10.1177/107327480901600307; Specht HM, 2016, J NEUROSURG SCI, V60, P357; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684	17	676	692	5	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 23	2018	379	8					722	730		10.1056/NEJMoa1805453	http://dx.doi.org/10.1056/NEJMoa1805453			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR3GS	30134131	Green Accepted, Bronze			2023-01-03	WOS:000442478600006
J	Gao, H; Duan, YH; Fu, XX; Xie, HY; Liu, Y; Yuan, HP; Zhou, MY; Xie, CG				Gao, Hong; Duan, Yuhong; Fu, Xiaoxu; Xie, Hongyan; Liu, Ya; Yuan, Haipo; Zhou, Mingyang; Xie, Chunguang			Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules	PLOS ONE			English	Article							DIET-INDUCED OBESITY; BETA-CELL; UPDATED RESOURCE; GENE; VARIANTS; MOUSE; IDENTIFICATION; INFLAMMATION; NEPHROPATHY; ASSOCIATION	Atherosclerosis-predominant vasculopathy is a common complication of diabetes with high morbidity and high mortality, which is ruining the patient's daily life. As is known to all, traditional Chinese medicine (TCM) SHENQI compound and western medicine rosiglitazone play an important role in the treatment of diabetes. In particular, SHENQI compound has a significant inhibitory effect on vascular lesions. Here, to explore and compare the therapeutic mechanism of SHENQI compound and rosiglitazone on diabetic vasculopathy, we first built 7 groups of mouse models. The behavioral, physiological and pathological morphological characteristics of these mice showed that SHENQI compound has a more comprehensive curative effect than rosiglitazone and has a stronger inhibitory effect on vascular lesions. While rosiglitazone has a more effective but no significant effect on hypoglycemic. Further, based on the gene expression of mice in each group, we performed differential expression analysis. The functional enrichment analysis of these differentially expressed genes (DEGs) revealed the potential pathogenesis and treatment mechanisms of diabetic angiopathy. In addition, we found that SHENQI compound mainly exerts comprehensive effects by regulating MCM8, IRF7, CDK7, NEDD4L by pivot regulator analysis, while rosiglitazone can rapidly lower blood glucose levels by targeting PSMD3, UBA52. Except that, we also identified some pivot TFs and ncRNAs for these potential disease-causing DEG modules, which may the mediators bridging drugs and modules. Finally, similar to pivot regulator analysis, we also identified the regulation of some drugs (e.g. bumetanide, disopyramide and glyburide etc.) which have been shown to have a certain effect on diabetes or diabetic angiopathy, proofing the scientific and objectivity of this study. Overall, this study not only provides an in-depth comparison of the efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy, but also provides clinicians and drug designers with valuable theoretical guidance.	[Gao, Hong; Fu, Xiaoxu; Xie, Hongyan; Liu, Ya; Yuan, Haipo; Zhou, Mingyang; Xie, Chunguang] Chengdu Univ Tradit Chinese Med, Teaching Hosp, Sch Clin Med, Chengdu, Sichuan, Peoples R China; [Duan, Yuhong] Shaanxi Univ Tradit Chinese Med, Teaching Hosp, Dept Two Endocrinol, Xianyang, Peoples R China	Chengdu University of Traditional Chinese Medicine; Shaanxi University of Chinese Medicine	Xie, CG (corresponding author), Chengdu Univ Tradit Chinese Med, Teaching Hosp, Sch Clin Med, Chengdu, Sichuan, Peoples R China.	xcg899@163.com			National Natural Science Foundation of China [81102589]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Science Foundation of China (http://www.nsfc.gov.cn/) (81102589 to H.G.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alkanani AK, 2014, VIROLOGY, V468, P19, DOI 10.1016/j.virol.2014.07.041; Baseler WA, 2012, AM J PHYSIOL-CELL PH, V303, pC1244, DOI 10.1152/ajpcell.00137.2012; Becher PM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193844; Coto E, 2018, HUM IMMUNOL, V79, P494, DOI 10.1016/j.humimm.2018.03.008; Cui TY, 2018, NUCLEIC ACIDS RES, V46, pD371, DOI 10.1093/nar/gkx1025; Cui W, 2015, INFLAMMATION, V38, P835, DOI 10.1007/s10753-014-9993-z; Dihazi H, 2007, CLIN CHEM, V53, P1636, DOI 10.1373/clinchem.2007.088260; Gautam A, 2017, WORLD J DIABETES, V8, P66, DOI 10.4239/wjd.v8.i2.66; Gong GM, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/8076796; Gurzov EN, 2016, FEBS J, V283, P3002, DOI 10.1111/febs.13709; Han H, 2018, NUCLEIC ACIDS RES, V46, pD380, DOI 10.1093/nar/gkx1013; Hasstedt SJ, 2013, J HUM GENET, V58, P378, DOI 10.1038/jhg.2013.21; Hindy G, 2016, GENES NUTR, V11, DOI 10.1186/s12263-016-0524-4; Ke BL, 2015, DIABETES, V64, P3355, DOI 10.2337/db15-0242; Ke B, 2017, AM J TRANSL RES, V9, P2195; Komers R, 2013, LAB INVEST, V93, P543, DOI 10.1038/labinvest.2013.47; Kunz J, 2012, PATHOLOGE, V33, P192, DOI 10.1007/s00292-011-1554-8; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068; Li YH, 2015, NUCLEIC ACIDS RES, V43, pD578, DOI 10.1093/nar/gku903; Liu Ya, 2010, Zhongguo Zhong Xi Yi Jie He Za Zhi, V30, P640; Lu JP, 2015, J HUAZHONG U SCI-MED, V35, P42, DOI 10.1007/s11596-015-1386-5; Makeeva OA, 2015, ACTA NATURAE, V7, P89, DOI 10.32607/20758251-2015-7-3-89-99; Malik AN, 2007, BIOCHEM BIOPH RES CO, V357, P237, DOI 10.1016/j.bbrc.2007.03.132; Migdalis IN, 2001, DIABETES RES CLIN PR, V54, P129, DOI 10.1016/S0168-8227(01)00275-3; Mu CZ, 2016, CELL BIOL INT, V40, P515, DOI 10.1002/cbin.10586; Negishi M, 2009, DIABETIC MED, V26, P76, DOI 10.1111/j.1464-5491.2008.02619.x; Nelaeva A A, 2013, Angiol Sosud Khir, V19, P9; Peng YP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164150; Qian JY, 2015, ENDOCRINOLOGY, V156, P4426, DOI 10.1210/en.2015-1516; Rafehi H, 2017, EPIGENETICS-US, V12, P991, DOI 10.1080/15592294.2017.1371892; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Serrano C, 2012, ANN ONCOL, V23, P897, DOI 10.1093/annonc/mdr348; Sherman BT, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-426; Smart NG, 2006, PLOS BIOL, V4, P200, DOI 10.1371/journal.pbio.0040039; Smyth GK., 2004, STAT APPL GENET MOL, V3, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Takahashi HK, 2014, BIOCHEM J, V460, P411, DOI 10.1042/BJ20131361; Tamura Hiroshi, 2006, Nihon Rinsho, V64, P2119; Tatsumi Fuminori, 2010, Nihon Rinsho, V68, P892; Topper JN, 1997, J CLIN INVEST, V99, P2941, DOI 10.1172/JCI119489; Wang B, 2011, DIABETES, V60, P280, DOI 10.2337/db10-0892; Wang Ming-Rui, 2018, Zhongguo Zhong Yao Za Zhi, V43, P1276, DOI 10.19540/j.cnki.cjcmm.2018.0050; Wang XA, 2013, AM J PHYSIOL-ENDOC M, V305, pE485, DOI 10.1152/ajpendo.00505.2012; Wong CK, 2018, DIABETES, V67, P412, DOI 10.2337/db17-0237; Wu D, 2015, AUTOPHAGY, V11, P1917, DOI 10.1080/15548627.2015.1089375; Xia D, 1999, Zhongguo Zhong Xi Yi Jie He Za Zhi, V19, P90; Xiong Y, 2010, DIABETES, V59, P2505, DOI 10.2337/db10-0315; Xu XH, 2013, J INT MED RES, V41, P13, DOI 10.1177/0300060513477004; Yamagishi Sho-ichi, 2015, Nihon Rinsho, V73, P479; Yi Y, 2017, NUCLEIC ACIDS RES, V45, pD115, DOI 10.1093/nar/gkw1052; Zhang T, 2017, NUCLEIC ACIDS RES, V45, pD135, DOI 10.1093/nar/gkw728; Zhao YH, 2011, DIABETES, V60, P1907, DOI 10.2337/db10-1262; Zheng JS, 2013, J NUTR, V143, P354, DOI 10.3945/jn.112.168401; Zheng Y, 2015, LAB INVEST, V95, P1387, DOI 10.1038/labinvest.2015.112	55	8	8	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 6	2018	13	12							e0207683	10.1371/journal.pone.0207683	http://dx.doi.org/10.1371/journal.pone.0207683			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD1YF	30521536	Green Published, Green Submitted, gold			2023-01-03	WOS:000452307600017
J	Robinson, RJ; Eddingsaas, NC; DiFrancesco, AG; Jayasekera, S; Hensel, EC				Robinson, Risa J.; Eddingsaas, Nathan C.; DiFrancesco, A. Gary; Jayasekera, Shehan; Hensel, Edward C., Jr.			A framework to investigate the impact of topography and product characteristics on electronic cigarette emissions	PLOS ONE			English	Article							NICOTINE; AEROSOL; FORMALDEHYDE; LIQUID	Significance Protocols for testing and reporting emissions of Harmful and Potentially Harmful Constituents (HPHCs) from electronic cigarettes (e-cigs) are lacking. The premise of this study is that multi-path relationships may be developed to describe interactions between product characteristics, use behavior and emissions to develop appropriate protocols for tobacco product regulatory compliance testing. Methods This study proposes a framework consisting of three component terms: HPHC mass concentration, HPHC mass ratio and total particulate mass (TPM) concentration. The framework informs experiments to investigate dependence of aerosol emissions from five electronic cigarettes spanning several design generations and three e-liquids for six repeated trials at each of ten flow conditions. Results Results are reported for TPM concentration as a function of flow conditions spanning the range of natural environment topography observed in prior studies. An empirical correlation describing TPM concentration as a function of flow conditions and coil power setting (6, 7.5 and 10 watts) for the Innokin iTaste MVP 2.0 vaporizer with Innokin iClear 30 dual coil tank is presented. Additional results document the impact of flow conditions and wick and coil design on TPM concentration through comparison of the Innokin iClear 30 (upper coil, capillary action wick) and the Innokin iClear X.I (lower coil, gravity fed wick) operated at 7.5 watts. The impact of e-liquid on TPM concentration is illustrated by comparing emissions from an NJOY Vape Pen filled with AVAIL Arctic Blast, Tobacco Row, and Mardi Gras e-liquids. TPM concentration is shown to depend upon flow conditions across a range of e-cigarette product designs including cig-a-like, pen-style, box-mod and emergent disposable-cartridge style devices. Conclusions A framework provides a foundation for reporting emissions across a variety of e-cigs, e-liquids and research laboratories. The study demonstrates TPM concentration is a function of topography behavior (i.e. puff flow rate and puff duration) for varying device operating power and product characteristics.	[Robinson, Risa J.; DiFrancesco, A. Gary; Jayasekera, Shehan; Hensel, Edward C., Jr.] Rochester Inst Technol, Dept Mech Engn, Rochester, NY 14623 USA; [Eddingsaas, Nathan C.] Rochester Inst Technol, Sch Chem & Mat Sci, Rochester, NY 14623 USA	Rochester Institute of Technology; Rochester Institute of Technology	Robinson, RJ (corresponding author), Rochester Inst Technol, Dept Mech Engn, Rochester, NY 14623 USA.	rjreme@rit.edu	Hensel, Edward/Q-6753-2019	Hensel, Edward/0000-0002-2682-0766; Robinson, Risa/0000-0001-8488-5448	Rochester Institute of Technology	Rochester Institute of Technology	This work was internally funded by Rochester Institute of Technology.	Baassiri M, 2017, AEROSOL SCI TECH, V51, P1231, DOI 10.1080/02786826.2017.1341040; El-Hellani A, 2016, NICOTINE CARBONYL EM; El-Hellani A, 2015, CHEM RES TOXICOL, V28, P1532, DOI 10.1021/acs.chemrestox.5b00107; Farsalinos KE, 2017, FOOD CHEM TOXICOL, V109, P90, DOI 10.1016/j.fct.2017.08.044; Farsalinos KE, 2015, INT J ENV RES PUB HE, V12, P9046, DOI 10.3390/ijerph120809046; Farsalinos KE, 2015, ADDICTION, V110, P1352, DOI 10.1111/add.12942; Goniewicz ML, 2014, ADDICTION, V109, P500, DOI 10.1111/add.12410; Goniewicz ML, 2013, NICOTINE TOB RES, V15, P158, DOI 10.1093/ntr/nts103; Goniewicz ML, 2014, TOB CONTROL, V23, P133, DOI 10.1136/tobaccocontrol-2012-050859; Jensen RP, 2015, NEW ENGL J MED, V372, P392, DOI 10.1056/NEJMc1413069; Kim KH, 2016, ANAL METHODS-UK, V8, P2305, DOI 10.1039/c5ay03385c; Korzun T, 2018, ACS OMEGA, V3, P30, DOI 10.1021/acsomega.7b01521; Kosmider L, 2014, CARBONYL COMPOUNDS E, DOI [10.1093/ntr/ntu078, DOI 10.1093/NTR/NTU078]; KoSmider L, 2017, COMPENSATORY PUFFING, DOI DOI 10.1093/NTENTX162; Kosmider L., 2016, INFLUENCE ELECT CIGA; Margham J, 2016, CHEM RES TOXICOL, V29, P1662, DOI 10.1021/acs.chemrestox.6b00188; Pagano DT, 2015, DETERMINATION NICOTI; Pankow JF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173055; Robinson RJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164038; Robinson R J, 2015, PLoS One, V10, pe0129296, DOI 10.1371/journal.pone.0129296; Sala C, 2017, EUR J MASS SPECTROM, V23, P64, DOI 10.1177/1469066717699078; Sleiman M, 2016, ENVIRON SCI TECHNOL, V50, P9644, DOI 10.1021/acs.est.6b01741; Talih S, 2017, CHEM RES TOXICOL, V30, P1791, DOI 10.1021/acs.chemrestox.7b00212; Talih S, 2015, NICOTINE TOB RES, V17, P150, DOI 10.1093/ntr/ntu174; Tayyarah R, 2014, REGUL TOXICOL PHARM, V70, P704, DOI 10.1016/j.yrtph.2014.10.010; Trehy ML, 2011, J LIQ CHROMATOGR R T, V34, P1442, DOI 10.1080/10826076.2011.572213	26	19	19	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2018	13	11							e0206341	10.1371/journal.pone.0206341	http://dx.doi.org/10.1371/journal.pone.0206341			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ3MT	30395620	Green Published, Green Submitted, gold			2023-01-03	WOS:000449291400020
J	Jiang, ZD; Jenq, RR; Ajami, NJ; Petrosino, JF; Alexander, AA; Ke, S; Iqbal, T; DuPont, AW; Muldrew, K; Shi, YS; Peterson, C; Do, KA; DuPont, HL				Jiang, Zhi-Dong; Jenq, Robert R.; Ajami, Nadim J.; Petrosino, Joseph F.; Alexander, Ashley A.; Ke, Shi; Iqbal, Tehseen; DuPont, Andrew W.; Muldrew, Kenneth; Shi, Yushu; Peterson, Christine; Do, Kim-Anh; DuPont, Herbert L.			Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: A randomized clinical trial	PLOS ONE			English	Article							TRANSPLANTATION; METAANALYSIS; COLONOSCOPY; RESOLUTION; DIVERSITY; FRESH	Background Fecal microbiota transplantation (FMT) via colonoscopy or enema has become a commonly used treatment of recurrent C. difficile infection (CDI). Aims To compare the safety and preliminary efficacy of orally administered lyophilized microbiota product compared with frozen product by enema. Methods In a single center, adults with > 3 episodes of recurrent CDI were randomized to receive encapsulated lyophilized fecal microbiota from 100-200 g of donor feces (n = 31) or frozen FMT from 100 g of donor feces (n = 34) by enema. Safety during the three months post FMT was the primary study objective. Prevention of CDI recurrence during the 60 days after FMT was a secondary objective. Fecal microbiome changes were examined in first 39 subjects studied. Results Adverse experiences were commonly seen in equal frequency in both groups and did not appear to relate to the route of delivery of FMT. CDI recurrence was prevented in 26 of 31 (84%) subjects randomized to capsules and in 30 of 34 (88%) receiving FMT by enema (p = 0.76). Both products normalized fecal microbiota diversity while the lyophilized orally administered product was less effective in repleting Bacteroidia and Verrucomicrobia classes compared to frozen product via enema. Conclusions The route of delivery, oral or rectal, did not influence adverse experiences in FMT. In preliminary evaluation, both routes appeared to show equivalent efficacy, although the dose may need to be higher for lyophilized product. Spore-forming bacteria appear to be the most important engrafting organisms in FMT by the oral route using lyophilized product.	[Jiang, Zhi-Dong; Ke, Shi; Iqbal, Tehseen; DuPont, Herbert L.] Univ Texas Houston, Sch Publ Hlth, Houston, TX 77204 USA; [Jenq, Robert R.; Shi, Yushu; Peterson, Christine; Do, Kim-Anh; DuPont, Herbert L.] Univ Texas Houston, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Ajami, Nadim J.; Petrosino, Joseph F.; DuPont, Herbert L.] Baylor Coll Med, Dept Mol Virol & Microbiol, Alkek Ctr Metagen & Microbiome Res, Houston, TX 77030 USA; [Alexander, Ashley A.; DuPont, Herbert L.] Kelsey Res Fdn, Houston, TX 77005 USA; [DuPont, Andrew W.; DuPont, Herbert L.] Univ Texas Houston, McGovern Med Sch, Houston, TX 77204 USA; [Muldrew, Kenneth; DuPont, Herbert L.] St Lukes Med Ctr, CHI St Lukes Hlth Baylor, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston	DuPont, HL (corresponding author), Univ Texas Houston, Sch Publ Hlth, Houston, TX 77204 USA.; DuPont, HL (corresponding author), Univ Texas Houston, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.; DuPont, HL (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Alkek Ctr Metagen & Microbiome Res, Houston, TX 77030 USA.; DuPont, HL (corresponding author), Kelsey Res Fdn, Houston, TX 77005 USA.; DuPont, HL (corresponding author), Univ Texas Houston, McGovern Med Sch, Houston, TX 77204 USA.; DuPont, HL (corresponding author), St Lukes Med Ctr, CHI St Lukes Hlth Baylor, Houston, TX 77030 USA.	Herbert.L.DuPont@uth.tmc.edu	DuPont, Herbert/AAH-6776-2021; Petrosino, Joseph F./AAF-1621-2019	Peterson, Christine/0000-0003-3316-0468	Roderick MacDonald Research Fund at Baylor St. Luke's Medical Center; University of Texas Health Science Center; Kelsey Research Foundation; Public Health Service [DK 56338]; Texas Gulf Coast Digestive Diseases Center; U.S. Food and Drug Administration [17059]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056338] Funding Source: NIH RePORTER	Roderick MacDonald Research Fund at Baylor St. Luke's Medical Center; University of Texas Health Science Center; Kelsey Research Foundation; Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Texas Gulf Coast Digestive Diseases Center; U.S. Food and Drug Administration; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was funded by grants from the Roderick MacDonald Research Fund at Baylor St. Luke's Medical Center, from grants from the University of Texas Health Science Center (McGovern Medical School and the School of Public Health) and from the Kelsey Research Foundation. This work was supported in part by grants from Public Health Service (grant DK 56338) which funds the Texas Gulf Coast Digestive Diseases Center and is part of IND #17059 with the U.S. Food and Drug Administration.; This study was funded by grants from the Roderick MacDonald Research Fund at Baylor St. Luke's Medical Center, from grants from the University of Texas Health Science Center (McGovern Medical School and the School of Public Health) and from the Kelsey Research Foundation. This work was supported in part by grants from Public Health Service (grant DK 56338) which funds the Texas Gulf Coast Digestive Diseases Center and is part of IND #17059 with the U.S. Food and Drug Administration. The authors thank Dr. Linda Piller for help with data interpretation and Dr. Javier Adachi, Dr. Lu-Yu Hwang and Dr. Kevin Garey who served on the Data Safety Monitoring Board for the study.	Caporaso JG, 2012, ISME J, V6, P1621, DOI 10.1038/ismej.2012.8; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Cohen SH, 2010, INFECT CONT HOSP EP, V31, P431, DOI 10.1086/651706; Costello SP, 2015, ALIMENT PHARM THER, V42, P1011, DOI 10.1111/apt.13366; Garneau JR, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-29; Hamilton MJ, 2012, AM J GASTROENTEROL, V107, P761, DOI 10.1038/ajg.2011.482; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Jiang ZD, 2017, ALIMENT PHARM THER, V45, P899, DOI 10.1111/apt.13969; Jiang ZD, 2017, ANAEROBE, V48, P110, DOI 10.1016/j.anaerobe.2017.08.003; Kao D, 2017, JAMA-J AM MED ASSOC, V318, P1985, DOI 10.1001/jama.2017.17077; Khanna S, 2016, J INFECT DIS, V214, P173, DOI 10.1093/infdis/jiv766; Lee CH, 2016, JAMA-J AM MED ASSOC, V315, P142, DOI 10.1001/jama.2015.18098; Li YT, 2016, ALIMENT PHARM THER, V43, P445, DOI 10.1111/apt.13492; Methe BA, 2012, NATURE, V486, P215, DOI 10.1038/nature11209; Quraishi MN, 2017, ALIMENT PHARM THER, V46, P479, DOI 10.1111/apt.14201; Rognes T, 2016, PEERJ, V4, DOI 10.7717/peerj.2584; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Staley C, 2017, AM J GASTROENTEROL, V112, P940, DOI 10.1038/ajg.2017.6; Staley C, 2016, MBIO, V7, DOI 10.1128/mBio.01965-16; Wong RG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161196; Youngster I, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0680-9	21	53	56	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2018	13	11							e0205064	10.1371/journal.pone.0205064	http://dx.doi.org/10.1371/journal.pone.0205064			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ3MD	30388112	gold, Green Published			2023-01-03	WOS:000449289800010
J	Gould, NJ; Lorencatto, F; During, C; Rowley, M; Glidewell, L; Walwyn, R; Michie, S; Foy, R; Stanworth, SJ; Grimshaw, JM; Francis, JJ				Gould, Natalie J.; Lorencatto, Fabiana; During, Camilla; Rowley, Megan; Glidewell, Liz; Walwyn, Rebecca; Michie, Susan; Foy, Robbie; Stanworth, Simon J.; Grimshaw, Jeremy M.; Francis, Jill J.			How do hospitals respond to feedback about blood transfusion practice? A multiple case study investigation	PLOS ONE			English	Article							IMPLEMENTATION	National clinical audits play key roles in improving care and driving system-wide change. However, effects of audit and feedback depend upon both reach (e.g. relevant staff receiving the feedback) and response (e.g. staff regulating their behaviour accordingly). This study aimed to investigate which hospital staff initially receive feedback and formulate a response, how feedback is disseminated within hospitals, and how responses are enacted (including barriers and enablers to enactment). Using a multiple case study approach, we purposively sampled four UK hospitals for variation in infrastructure and resources. We conducted semi-structured interviews with staff from transfusion-related roles and observed Hospital Transfusion Committee meetings. Interviews and analysis were based on the Theoretical Domains Framework of behaviour change. We coded interview transcripts into theoretical domains, then inductively identified themes within each domain to identify barriers and enablers. We also analysed data to identify which staff currently receive feedback and how dissemination is managed within the hospital. Members of the hospital's transfusion team initially received feedback in all cases, and were primarily responsible for disseminating and responding, facilitated through the Hospital Transfusion Committee. At each hospital, key individuals involved in prescribing transfusions reported never having received feedback from a national audit. Whether audits were discussed and actions explicitly agreed in Committee meetings varied between hospitals. Key enablers of action across all cases included clear lines of responsibility and strategies to remind staff about recommendations. Barriers included difficulties disseminating to relevant staff and needing to amend feedback to make it appropriate for local use. Appropriate responses by hospital staff to feedback about blood transfusion practice depend upon supportive infrastructures and role clarity. Hospitals could benefit from support to disseminate feedback systematically, particularly to frontline staff involved in the behaviours being audited, and practical tools to support strategic decision-making (e.g. action-planning around local response to feedback).	[Gould, Natalie J.; Lorencatto, Fabiana; During, Camilla; Francis, Jill J.] City Univ London, Sch Hlth Sci, London, England; [Lorencatto, Fabiana; Michie, Susan] UCL, Ctr Behav Change, London, England; [Rowley, Megan] Royal Infirm Edinburgh NHS Trust, Scottish Natl Blood Transfus Serv, Edinburgh, Midlothian, Scotland; [Glidewell, Liz; Foy, Robbie] Univ Leeds, Leeds Inst Hlth Sci, Leeds, W Yorkshire, England; [Glidewell, Liz] Univ York, Dept Hlth Sci, York, N Yorkshire, England; [Walwyn, Rebecca] Univ Leeds, Clin Trials Res Unit, Leeds, W Yorkshire, England; [Stanworth, Simon J.] NHS Blood & Transplant, Transfus Med, Oxford, England; [Stanworth, Simon J.] Oxford Univ Hosp NHS Fdn Trust, Dept Haematol, Oxford, England; [Stanworth, Simon J.] Univ Oxford, Radcliffe Dept Med, Oxford, England; [Grimshaw, Jeremy M.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Grimshaw, Jeremy M.] Univ Ottawa, Dept Med, Ottawa, ON, Canada	City University London; University of London; University College London; Royal Infirmary of Edinburgh; University of Edinburgh; University of Leeds; University of York - UK; University of Leeds; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Francis, JJ (corresponding author), City Univ London, Sch Hlth Sci, London, England.	jill.francis.1@city.ac.uk	Francis, Jill/AHE-6998-2022; Glidewell, Liz/G-7338-2011	Glidewell, Liz/0000-0003-2519-2654; Foy, Robbie/0000-0003-0605-7713; Francis, Jill/0000-0001-5784-8895	National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme [RP-PG-1210-12010]	National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme(National Institute for Health Research (NIHR))	This paper summarises independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Grant Reference Number RP-PG-1210-12010) led by Dr Simon J Stanworth. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.	Baxter P, 2008, QUAL REP, V13, P544; Brehaut JC, 2016, ANN INTERN MED, V164, P435, DOI 10.7326/M15-2248; Carver C. S., 1998, SELF REGULATION BEHA, DOI DOI 10.1017/CBO9781139; Christina V, 2016, J NURS MANAGE, V24, P1080, DOI 10.1111/jonm.12409; D'Lima DM, 2015, J HEALTH SERV RES PO, V20, P26, DOI 10.1177/1355819614557299; Dyson J., 2011, Journal of Infection Prevention, V12, P17, DOI 10.1177/1757177410384300; Francis JJ, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18250; Francis JJ, 2014, BRIT J HEALTH PSYCH, V19, P274, DOI 10.1111/bjhp.12066; Francis JJ, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-35; Francis JJ, 2009, BRIT J HEALTH PSYCH, V14, P625, DOI 10.1348/135910708X397025; Glidewell L, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-118; Gould NJ, 2014, IMPLEMENT SCI, V9, DOI 10.1186/s13012-014-0092-1; Graham-Rowe E, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0309-2; Grol R, 2004, MED J AUSTRALIA, V180, pS57, DOI 10.5694/j.1326-5377.2004.tb05948.x; Hartley S, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0614-8; Ivers N, 2012, COCHRANE LIB, V7; Ivers NM, 2016, LANCET, V388, P547, DOI 10.1016/S0140-6736(16)31256-9; Ivers NM, 2014, IMPLEMENT SCI, V9, DOI [10.1186/1748-5908-9-14, 10.1186/1748-5908-9-51]; Michie S, 2005, QUAL SAF HEALTH CARE, V14, P26, DOI 10.1136/qshc.2004.011155; Patey A, 2012, IMPLEMENT SCI, V7, P1; Sinuff T, 2015, BMJ QUAL SAF; Tuti T, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0590-z; Vahidi RG, 2013, J PAKISTAN MED STUDE, V3	23	9	9	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 1	2018	13	11							e0206676	10.1371/journal.pone.0206676	http://dx.doi.org/10.1371/journal.pone.0206676			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ0DG	30383792	Green Published, Green Accepted, gold			2023-01-03	WOS:000449027600083
J	Alkarakooly, Z; Al-Anbaky, QA; Kannan, K; Ali, N				Alkarakooly, Zeiyad; Al-Anbaky, Qudes A.; Kannan, Krishnaswamy; Ali, Nawab			Metabolic reprogramming by Dichloroacetic acid potentiates photodynamic therapy of human breast adenocarcinoma MCF-7 cells	PLOS ONE			English	Article							5-AMINOLEVULINIC ACID; ATP SECRETION; CANCER; DEATH; APOPTOSIS; RADIOTHERAPY; IMMUNOTHERAPY; CYTOTOXICITY; INCREASES; CARCINOMA	Aberrant glycolytic metabolism is one of the hallmarks of carcinogenesis and therefore reversal of metabolic transformation is a promising drug target in cancer treatment strategies. Dichloroacetic acid (DCA) is known to target the glycolytic pathway in cancer cells and facilitates reversal of metabolic transformation from aerobic cytosolic accumulation of pyruvic acid, "the Warburg effect", to mitochondrial oxidative phosphorylation. Recently, combination therapy particularly involving photodynamic therapy (PDT) has received considerable attention in oncology. We hypothesized that if DCA and PDT are combined, they might potentiate mitochondrial dysfunction and induce apoptosis by a reactive oxygen species (ROS) dependent pathway. We used MCF-7 cells as our in vitro model and 5-aminolevulinic acid (5-ALA) dependent PDT therapy to test our hypothesis. We found that combinatorial treatment of MCF-7 cells with PDT and DCA not only increased cell growth inhibition, but also affected mitochondrial membrane integrity perhaps via production of ROS, and enhanced apoptosis. Further, our results on ATP release during the combined treatment demonstrate that immunogenic cell death (ICD) is likely to be a potential mechanism by which PDT and DCA induce cancer cell death. Taken together, our study suggests a novel way of sensitizing MCF-7 cells for accelerated induction of apoptosis and ICD in these cells. The findings included in this study might have direct relevance in breast cancer treatment strategies.	[Alkarakooly, Zeiyad; Al-Anbaky, Qudes A.] Univ Diyala, Coll Sci, Dept Biol, Diyala, Iraq; [Alkarakooly, Zeiyad; Al-Anbaky, Qudes A.; Kannan, Krishnaswamy; Ali, Nawab] Univ Arkansas, Dept Biol, Coll Arts Letters & Sci, Little Rock, AR 72204 USA	University of Diyala; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock	Ali, N (corresponding author), Univ Arkansas, Dept Biol, Coll Arts Letters & Sci, Little Rock, AR 72204 USA.	nali@ualr.edu		Ali, Nawab/0000-0002-0995-4965	Center for Advanced Surface Engineering (CASE, Tunable Team), under the National Science Foundation [IIA-1457888]; Arkansas EPSCoR Program; Arkansas Space Grant Consortium, NASA-EPSCoR	Center for Advanced Surface Engineering (CASE, Tunable Team), under the National Science Foundation; Arkansas EPSCoR Program; Arkansas Space Grant Consortium, NASA-EPSCoR	The authors are thankful for the partial financial support by the Center for Advanced Surface Engineering (CASE, Tunable Team), under the National Science Foundation Grant No. IIA-1457888 and the Arkansas EPSCoR Program. A partial support from Arkansas Space Grant Consortium, NASA-EPSCoR is also gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-anbaky Q, 2016, INT J TOXICOL, V35, P672, DOI 10.1177/1091581816659661; Ayyanathan K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039949; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Bloy N, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.954929; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Brix N, 2017, IMMUNOL REV, V280, P249, DOI 10.1111/imr.12573; Chen G, 2013, CANCER IMMUNOL IMMUN, V62, P203, DOI 10.1007/s00262-012-1388-0; Dai YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092962; Date M, 2004, LIVER INT, V24, P142, DOI 10.1111/j.1478-3231.2004.00902.x; Demaria S, 2004, INT J RADIAT ONCOL, V58, P862, DOI 10.1016/j.ijrobp.2003.09.012; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; ESTAQUIER J, 1995, J EXP MED, V182, P1759, DOI 10.1084/jem.182.6.1759; Galluzzi L, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26536; Galluzzi L, 2012, EMBO J, V31, P1055, DOI 10.1038/emboj.2012.2; Garg AD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00588; Garg AD, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1386829; Garg AD, 2014, PHOTOCH PHOTOBIO SCI, V13, P474, DOI 10.1039/c3pp50333j; Garg AD, 2012, EMBO J, V31, P1062, DOI 10.1038/emboj.2011.497; Golden EB, 2012, FRONT ONCOL, V2, P1, DOI [10.3389/fonc.2012.00088, 10.3389/fonc.2012.00153]; Golding JP, 2013, BRIT J CANCER, V109, P976, DOI 10.1038/bjc.2013.391; GOMER CJ, 1989, RADIAT RES, V120, P1, DOI 10.2307/3577632; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hodge JW GC, 1984, ONCOLOGY WILLISTON P, V22; IDZIOREK T, 1995, J IMMUNOL METHODS, V185, P249, DOI 10.1016/0022-1759(95)00172-7; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kalbasi A, 2013, J CLIN INVEST, V123, P2756, DOI 10.1172/JCI69219; Kannan A, 2016, ONCOTARGET, V7, P6576, DOI 10.18632/oncotarget.5878; Kepp O, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.955691; Kilaparty SP, 2016, CELL STRESS CHAPERON, V21, P593, DOI 10.1007/s12192-016-0684-6; Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380; Kuangda Lu CH, 2018, NATURE BIOMEDICAL EN, V1, P1; Kwitniewski M, 2009, INT J CANCER, V125, P1721, DOI 10.1002/ijc.24488; Lamberti MJ, 2013, PHYTOMEDICINE, V20, P1007, DOI 10.1016/j.phymed.2013.04.018; Lu KD, 2018, NAT BIOMED ENG, V2, P600, DOI 10.1038/s41551-018-0203-4; Mahoney KM, 2015, NAT REV DRUG DISCOV, V14, P561, DOI 10.1038/nrd4591; Martins I, 2014, CELL DEATH DIFFER, V21, P79, DOI 10.1038/cdd.2013.75; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Mokdad AH, 2017, JAMA-J AM MED ASSOC, V317, P388, DOI 10.1001/jama.2016.20324; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Ngiow SF, 2015, CANCER CELL, V27, P437, DOI 10.1016/j.ccell.2015.03.015; Ohashi T, 2013, INT J CANCER, V133, P1107, DOI 10.1002/ijc.28114; Osborn O, 2012, NAT MED, V18, P363, DOI 10.1038/nm.2627; Papandreou I, 2011, INT J CANCER, V128, P1001, DOI 10.1002/ijc.25728; Peng Q, 1997, CANCER-AM CANCER SOC, V79, P2282; Penkert J, 2016, ONCOTARGET, V7, P67626, DOI 10.18632/oncotarget.11759; Raju I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067126; Ribas A, 2015, NEW ENGL J MED, V373, P1490, DOI 10.1056/NEJMp1510079; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Sharman WM, 1999, DRUG DISCOV TODAY, V4, P507, DOI 10.1016/S1359-6446(99)01412-9; Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Vatner RE, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00325; Verbrugge I, 2012, CANCER RES, V72, P3163, DOI 10.1158/0008-5472.CAN-12-0210; WARBURG O, 1956, SCIENCE, V124, P269; Weichselbaum RR, 2017, NAT REV CLIN ONCOL, V14, P365, DOI 10.1038/nrclinonc.2016.211; Wong JYY, 2008, GYNECOL ONCOL, V109, P394, DOI 10.1016/j.ygyno.2008.01.038	60	7	8	9	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 23	2018	13	10							e0206182	10.1371/journal.pone.0206182	http://dx.doi.org/10.1371/journal.pone.0206182			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX8WQ	30352078	Green Published, Green Submitted, gold			2023-01-03	WOS:000448076200035
J	Brown, JC; Rhim, AD; Manning, SL; Brennan, L; Mansour, AI; Rustgi, AK; Damjanov, N; Troxel, AB; Rickels, MR; Ky, B; Zemel, BS; Courneya, KS; Schmitz, KH				Brown, Justin C.; Rhim, Andrew D.; Manning, Sara L.; Brennan, Luke; Mansour, Alexandra I.; Rustgi, Anil K.; Damjanov, Nevena; Troxel, Andrea B.; Rickels, Michael R.; Ky, Bonnie; Zemel, Babette S.; Courneya, Kerry S.; Schmitz, Kathryn H.			Effects of exercise on circulating tumor cells among patients with resected stage I-III colon cancer	PLOS ONE			English	Article							SURROGATE END-POINTS; COLORECTAL-CANCER; PHYSICAL-ACTIVITY; INSULIN-RESISTANCE; GROWTH-FACTOR; SHEAR-STRESS; BLOOD-FLOW; MORTALITY; SURVIVORS; OBESITY	Background Physical activity is associated with a lower risk of disease recurrence among colon cancer patients. Circulating tumor cells (CTC) are prognostic of disease recurrence among stage I-III colon cancer patients. The pathways through which physical activity may alter disease outcomes are unknown, but may be mediated by changes in CTCs. Methods Participants included 23 stage I-III colon cancer patients randomized into one of three groups: usual-care control, 150 min-wk-1 of aerobic exercise (low-dose), and 300 min-wk-1 of aerobic exercise (high-dose) for six months. CTCs from venous blood were quantified in a blinded fashion using an established microfluidic antibody-mediated capture device. Poisson regression models estimated the logarithmic counts of CTCs. Results At baseline, 78% (18/23) of patients had >= 1 CTC. At baseline, older age (-0.12+/- 0.06; P=0.04), lymphovascular invasion (0.63+/-0.25; P=0.012), moderate/poor histology (1.09 +/-0.34; P=0.001), body mass index (0.07+/-0.02; P=0.001), visceral adipose tissue (0.08 +/-0.04; P=0.036), insulin (0.06+/-0.02; P=0.011), sICAM-1 (0.04+/-0.02; P=0.037), and sVCAM-1 (0.06+/-0.03; P=0.045) were associated with CTCs. Over six months, significant decreases in CTCs were observed in the low-dose (-1.34+/-0.34; P<0.001) and high-dose (-1.18+/-0.40; P=0.004) exercise groups, whereas no significant change was observed in the control group (-0.59+/-0.56; P=0.292). Over six months, reductions in body mass index (-0.07+/-0.02; P=0.007), insulin (-0.08+/-0.03; P=0.014), and sICAM-1 (-0.07+/-0.03; P=0.005) were associated with reductions in CTCs. The main limitations of this proof-of-concept study are the small sample size, heterogenous population, and per-protocol statistical analysis. Conclusion Exercise may reduce CTCs among stage I-III colon cancer patients. Changes in host factors correlated with changes in CTCs. Exercise may have a direct effect on CTCs and indirect effects through alterations in host factors. This hypothesis-generating observation derived from a small pilot study warrants further investigation and replication.	[Brown, Justin C.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Rhim, Andrew D.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Manning, Sara L.; Brennan, Luke; Mansour, Alexandra I.] Univ Michigan, Med Sch, Ann Arbor, MI 48109 USA; [Rustgi, Anil K.; Damjanov, Nevena; Rickels, Michael R.; Ky, Bonnie; Zemel, Babette S.] Univ Penn, Philadelphia, PA 19104 USA; [Troxel, Andrea B.] NYU, New York, NY USA; [Zemel, Babette S.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Courneya, Kerry S.] Univ Alberta, Edmonton, AB, Canada; [Schmitz, Kathryn H.] Penn State Coll Med, Hershey, PA USA	Harvard University; Dana-Farber Cancer Institute; University of Texas System; UTMD Anderson Cancer Center; University of Michigan System; University of Michigan; University of Pennsylvania; New York University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Alberta; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Brown, JC (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.	justinc_brown@dfci.harvard.edu	Courneya, Kerry/AAJ-2712-2021; Rickels, Michael/D-1380-2009; Zemel, Babette S./D-1117-2009	Rickels, Michael/0000-0002-9253-838X; Zemel, Babette S./0000-0002-6164-7348; Mansour, Alexandra/0000-0001-8572-4419; Schmitz, Kathryn/0000-0003-2400-2935; Brennan, Luke/0000-0002-5616-7913	National Institutes of Health [K99-CA218603, F31-CA192560, R21-CA182767, U54-CA155850, UL1-TR0000003]; NATIONAL CANCER INSTITUTE [F31CA192560, K99CA218603] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was funded by the National Institutes of Health K99-CA218603 (Brown), F31-CA192560 (Brown), R21-CA182767 (Schmitz), U54-CA155850 (Schmitz), and UL1-TR0000003 (Fitzgerald). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexiou D, 2001, EUR J CANCER, V37, P2392, DOI 10.1016/S0959-8049(01)00318-5; Amemori Sadahiro, 2007, Am J Physiol Gastrointest Liver Physiol, V292, pG923; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Ben Sahra I, 2010, MOL CANCER THER, V9, P1092, DOI 10.1158/1535-7163.MCT-09-1186; Bork U, 2015, BRIT J CANCER, V112, P1306, DOI 10.1038/bjc.2015.88; Brown JC, 2018, ENDOCR-RELAT CANCER, V25, P11, DOI 10.1530/ERC-17-0377; Brown JC, 2018, CLIN COLORECTAL CANC, V17, P32, DOI 10.1016/j.clcc.2017.06.001; Brown JC, 2017, BRIT J CANCER, V117, P1614, DOI 10.1038/bjc.2017.339; Brown JC, 2016, J CLIN ONCOL, V34, P4217, DOI 10.1200/JCO.2016.66.8699; Brown JC, 2016, CONTEMP CLIN TRIALS, V47, P366, DOI 10.1016/j.cct.2016.03.001; Buyse M, 2010, NAT REV CLIN ONCOL, V7, P309, DOI 10.1038/nrclinonc.2010.43; Doyle SL, 2012, P NUTR SOC, V71, P181, DOI 10.1017/S002966511100320X; Fan R, 2016, SCI REP-UK, V6, DOI 10.1038/srep27073; Galizia G, 2013, J GASTROINTEST SURG, V17, P1809, DOI 10.1007/s11605-013-2258-6; Gho YS, 2001, CANCER RES, V61, P4253; Howard K, 2014, J SURG RES, V187, P19, DOI 10.1016/j.jss.2013.11.001; Huffman DM, 2013, CANCER PREV RES, V6, P177, DOI 10.1158/1940-6207.CAPR-12-0414; Iinuma H, 2011, J CLIN ONCOL, V29, P1547, DOI 10.1200/JCO.2010.30.5151; Jain RK, 2014, ANNU REV BIOMED ENG, V16, P321, DOI 10.1146/annurev-bioeng-071813-105259; Je Y, 2013, INT J CANCER, V133, P1905, DOI 10.1002/ijc.28208; Joosse SA, 2015, EMBO MOL MED, V7, P1, DOI 10.15252/emmm.201303698; Kirby BJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035976; Leinonen E, 2003, ATHEROSCLEROSIS, V166, P387, DOI 10.1016/S0021-9150(02)00371-4; Lu CY, 2013, BRIT J CANCER, V108, P791, DOI 10.1038/bjc.2012.595; Maheswaran S, 2010, CURR OPIN GENET DEV, V20, P96, DOI 10.1016/j.gde.2009.12.002; Mitchell MJ, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00044; Mitchell MJ, 2013, NEW J PHYS, V15, DOI 10.1088/1367-2630/15/1/015008; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; Parkinson DR, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-138; Pleis John R, 2009, Vital Health Stat 10, P1; Rhim AD, 2014, GASTROENTEROLOGY, V146, P647, DOI 10.1053/j.gastro.2013.12.007; Rosner B., 2015, FUNDAMENTALS BIOSTAT; Schmid D, 2014, ANN ONCOL, V25, P1293, DOI 10.1093/annonc/mdu012; Sinicrope FA, 2013, CANCER-AM CANCER SOC, V119, P1528, DOI 10.1002/cncr.27938; Tanaka H, 2006, MED SCI SPORT EXER, V38, P81, DOI 10.1249/01.mss.0000191166.81789.de; Taylor CA, 2002, ANN BIOMED ENG, V30, P402, DOI 10.1114/1.1476016; Tran TT, 1996, CANCER EPIDEM BIOMAR, V5, P1013; Uppal A, 2014, THEOR BIOL MED MODEL, V11, DOI 10.1186/1742-4682-11-17; Volkova E, 2014, ONCOL LETT, V7, P311, DOI 10.3892/ol.2013.1710; Wang F.H., 2003, NONFERROUS METALS MI, V8, P12, DOI DOI 10.3978/J.ISSN; Wolpin BM, 2009, J CLIN ONCOL, V27, P176, DOI 10.1200/JCO.2008.17.9945; Xiao J, 2018, EUR J CANCER CARE, V27, DOI 10.1111/ecc.12611	42	20	21	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2018	13	10							e0204875	10.1371/journal.pone.0204875	http://dx.doi.org/10.1371/journal.pone.0204875			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX3PM	30332430	Green Published, gold, Green Submitted			2023-01-03	WOS:000447638200039
J	Katz, S; Backeris, P; Merck, C; Suprun, M; D'Souza, S; Bishop, DF; Desnick, RJ; Moore, K; Ubarretxena-Belandia, I; Lemischka, IR				Katz, Suzanna; Backeris, Peter; Merck, Christopher; Suprun, Maria; D'Souza, Sunita; Bishop, David F.; Desnick, Robert J.; Moore, Kateri; Ubarretxena-Belandia, Iban; Lemischka, Ihor R.			Design and validation of an open-source modular Microplate Photoirradiation System for high-throughput photobiology experiments	PLOS ONE			English	Article							INDUCED PROTOPORPHYRIN IX; PHOTODYNAMIC THERAPY; 5-AMINOLEVULINIC ACID; METHYL AMINOLEVULINATE; ACTINIC KERATOSES; LIGHT; PORPHYRINS; SKIN; INACTIVATION; EXPRESSION	Research in photobiology is currently limited by a lack of devices capable of delivering precise and tunable irradiation to cells in a high-throughput format. This limits researchers to using expensive commercially available or custom-built light sources which make it difficult to replicate, standardize, optimize, and scale experiments. Here we present an open-source Microplate Photoirradiation System (MPS) developed to enable high-throughput light experiments in standard 96 and 24-well microplates for a variety of applications in photobiology research. This open-source system features 96 independently controlled LEDs (4 LEDs per well in 24-well), Wi-Fi connected control and programmable graphical user interface (GUI) for control and programming, automated calibration GUI, and modular control and LED boards for maximum flexibility. A web-based GUI generates light program files containing irradiation parameters for groups of LEDs. These parameters are then uploaded wirelessly, stored and used on the MPS to run photoirradiation experiments inside any incubator. A rapid and semi-quantitative porphyrin metabolism assay was also developed to validate the system in wild-type fibroblasts. Protoporphyrin IX (PpIX) fluorescence accumulation was induced by incubation with 5-aminolevulinic acid (ALA), a photosensitization method leveraged clinically to destroy malignant cell types in a process termed photodynamic therapy (PDT), and cells were irradiated with 405nm light with varying irradiance, duration and pulsation parameters. Immediately after light treatment with the MPS, subsequent photobleaching was measured in live, adherent cells in both 96-well and a 24-well microplates using a microplate reader. Results demonstrate the utility and reliability of the Microplate Photoirradiation System to irradiate cells with precise irradiance and timing parameters in order to measure PpIx photobleaching kinetics in live adherent cells and perform comparable experiments with both 24 and 96 well microplate formats. The high-throughput capability of the MPS enabled measurement of enough irradiance conditions in a single microplate to fit PpIX fluorescence to a bioexponential decay model of photobleaching, as well as reveal a dependency of photobleaching on duty-cycle-but not frequency-in a pulsed irradiance regimen.	[Katz, Suzanna; D'Souza, Sunita; Moore, Kateri; Lemischka, Ihor R.] Icahn Sch Med Mt Sinai, Black Family Stem Cell Inst, Dept Cell Dev & Regenerat Biol, New York, NY 10029 USA; [Backeris, Peter] Icahn Sch Med Mt Sinai, Dept Neurosurg, Sinai Biodesign, New York, NY 10029 USA; [Merck, Christopher] Merck Engn LLC, Hamburg, NJ 07495 USA; [Suprun, Maria] Icahn Sch Med Mt Sinai, Dept Pediat Allergy & Immunol, New York, NY 10029 USA; [Bishop, David F.; Desnick, Robert J.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Ubarretxena-Belandia, Iban; Lemischka, Ihor R.] Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY 10029 USA; [Ubarretxena-Belandia, Iban] Univ Basque Country, UPV EHU, CSIC, Biofisika Inst, Leioa, Spain	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika	Backeris, P (corresponding author), Icahn Sch Med Mt Sinai, Dept Neurosurg, Sinai Biodesign, New York, NY 10029 USA.	peter.backeris@mssm.edu	Bishop, David F./X-4102-2019; Ubarretxena-Belandia, Iban/AAA-8939-2019; Suprun, Maria/ABE-8323-2020; Suprun, Maria/AAE-5507-2022	Suprun, Maria/0000-0001-9161-4021; Bishop, David/0000-0003-1958-8601	Graduate School of Biological Sciences; Black Family Stem Cell Institute at Icahn School of Medicine	Graduate School of Biological Sciences; Black Family Stem Cell Institute at Icahn School of Medicine	We thank the Graduate School of Biological Sciences and the Black Family Stem Cell Institute at Icahn School of Medicine for providing financial support for the project. Chris Merck is affiliated with his own LLC (Merck Engineering LLC). Merck Engineering LLC did not contribute funding to the development of the MPS or its biological validation and has no pecuniary interest in this study. Chris Merck worked as a volunteer collaborator not representing any company or institution. Merck Engineering LLC did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.	Ajioka RS, 2006, BBA-MOL CELL RES, V1763, P723, DOI 10.1016/j.bbamcr.2006.05.005; Akilov O.E., 2006, MED LASER APPL, V21, P251, DOI [DOI 10.1016/J.MLA.2006.07.002, 10.1016/j.mla.2006.07.002]; Alexiades-Armenakas Macrene, 2006, J Drugs Dermatol, V5, P45; Issa MCA, 2010, DERMATOL SURG, V36, P39, DOI 10.1111/j.1524-4725.2009.01385.x; Bagdonas S, 2000, PHOTOCHEM PHOTOBIOL, V72, P186, DOI 10.1562/0031-8655(2000)072<0186:POAAIP>2.0.CO;2; Boere IA, 2003, PHOTOCHEM PHOTOBIOL, V78, P271, DOI 10.1562/0031-8655(2003)078<0271:MISDAP>2.0.CO;2; Chen DX, 2012, ADV DIFFER EQU-NY, P1, DOI 10.1186/1687-1847-2012-33; Clements IP, 2016, PROC SPIE, V9690, DOI 10.1117/12.2213708; Curnow A, 2000, J PHOTOCH PHOTOBIO B, V58, P149, DOI 10.1016/S1011-1344(00)00120-2; Dragieva G, 2004, BRIT J DERMATOL, V151, P196, DOI 10.1111/j.1365-2133.2004.06054.x; GEBRIL M, 1990, NEPHRON, V55, P159, DOI 10.1159/000185945; Georgakoudi I, 1997, PHOTOCHEM PHOTOBIOL, V65, P135, DOI 10.1111/j.1751-1097.1997.tb01889.x; Georgakoudi I, 1998, PHOTOCHEM PHOTOBIOL, V67, P612, DOI 10.1111/j.1751-1097.1998.tb09463.x; Gerhardt KP, 2016, SCI REP-UK, V6, DOI 10.1038/srep35363; GUTNIAK O, 1966, ANAL BIOCHEM, V16, P20, DOI 10.1016/0003-2697(66)90076-5; Hadis MA, 2017, J BIOPHOTONICS, V10, P1514, DOI 10.1002/jbio.201600273; Haj-Hosseini N, 2009, PROC SPIE, V7161, DOI 10.1117/12.808156; Hamblin MR, 2004, PHOTOCH PHOTOBIO SCI, V3, P436, DOI 10.1039/b311900a; Hannanta-anan P, 2016, CELL SYST, V2, P283, DOI 10.1016/j.cels.2016.03.010; Quintanar LFH, 2016, PHOTOMED LASER SURG, V34, P108, DOI 10.1089/pho.2015.4030; Hodgkinson N, 2017, CERVICAL CANC CELLS; Issa M, 2010, ANAIS BRASILEIROS DE; Issa MCA, 2009, BRIT J DERMATOL, V161, P647, DOI 10.1111/j.1365-2133.2009.09326.x; Jori G, 2004, PHOTOCH PHOTOBIO SCI, V3, P403, DOI 10.1039/b311904c; Kaestner L, 2004, PHOTOCH PHOTOBIO SCI, V3, P981, DOI 10.1039/b403127j; Karrer S, 2000, TOPICAL PHOTODYNAMIC; Kasermann F, 1997, ANTIVIR RES, V34, P65, DOI 10.1016/S0166-3542(96)01207-7; Katsambas A, 2008, DERMATOL THER, V21, P86, DOI 10.1111/j.1529-8019.2008.00175.x; Krishnamohan M, 2006, ENVIRON TOXICOL, V1, P192; Martinelli ALC, 1999, J CLIN GASTROENTEROL, V29, P327, DOI 10.1097/00004836-199912000-00006; Meier Daniela, 2014, J Vis Exp, DOI 10.3791/51213; Moan J, 1997, INT J CANCER, V70, P90, DOI 10.1002/(SICI)1097-0215(19970106)70:1<90::AID-IJC14>3.0.CO;2-H; Muller P J, 1996, J Clin Laser Med Surg, V14, P263; Nakai Y, 2015, PHOTODIAGN PHOTODYN, V12, P282, DOI 10.1016/j.pdpdt.2014.12.010; Niu TH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138754; Oleinick N.L., 2011, BASIC PHOTOSENSITIZA; Orenstein A, 1997, FEMS IMMUNOL MED MIC, V19, P307, DOI 10.1016/S0928-8244(97)00097-7; Piacquadio DJ, 2004, ARCH DERMATOL, V140, P41, DOI 10.1001/archderm.140.1.41; Pieslinger A., 2006, MED LASER APPL, V21, P277; Pogue BW, 2008, PROTOPORPHYRIN 9 FLU, V13, DOI [10.1117/1.2937, 10.1117/1.2937476, DOI 10.1117/1.2937476]; Pollock B, 2004, BRIT J DERMATOL, V151, P616, DOI 10.1111/j.1365-2133.2004.06110.x; Reis SA, 2016, NAT CHEM BIOL, V12, P317, DOI [10.1038/NCHEMBIO.2042, 10.1038/nchembio.2042]; Rick K, 1997, J PHOTOCH PHOTOBIO B, V40, P313, DOI 10.1016/S1011-1344(97)00076-6; RIMINGTON C, 1960, BIOCHEM J, V75, P620, DOI 10.1042/bj0750620; Robinson DJ, 1999, PHOTOCHEM PHOTOBIOL, V69, P61, DOI 10.1111/j.1751-1097.1999.tb05307.x; Robinson DJ, 1998, PHOTOCHEM PHOTOBIOL, V67, P140, DOI 10.1562/0031-8655(1998)067<0140:FPOAIP>2.3.CO;2; Roeder B, 1990, LASERS MED SCI; Stringer MR, 2006, PHOTODIAGN PHOTODYN, V3, P19, DOI 10.1016/S1572-1000(05)00155-9; Sudworth CD, 2003, APPL SPECTROSC, V57, P682, DOI 10.1366/000370203322005382; Szeimies RM, 2007, DERMATOL CLIN, V25, P89, DOI 10.1016/j.det.2006.09.008; Wainwright M, 2000, INT J ANTIMICROB AG, V16, P381, DOI 10.1016/S0924-8579(00)00207-7; Wainwright M, 2002, CHEM SOC REV, V31, P128, DOI 10.1039/b101905h; Wainwright M, 2002, CURR MED CHEM, V9, P127, DOI 10.2174/0929867023371355; White B, 2016, 5 AMINOLEVULINIC ACI, DOI DOI 10.1089/PH0.2016.4091; Wilson BC, 1997, LASERS MED SCI; Yin L, 2013, CONTROLLING DELICATE; Yin L, 2013, CONTROLLING THE DELI; Zhang SJ, 2004, PHOTOCHEM PHOTOBIOL, V79, P545, DOI 10.1562/MU-03-32.1; Zhao JZ, 2013, CHEM SOC REV, V42, P5323, DOI 10.1039/c3cs35531d; Zhu TC, 2005, MED PHYS	60	3	3	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2018	13	10							e0203597	10.1371/journal.pone.0203597	http://dx.doi.org/10.1371/journal.pone.0203597			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW0HY	30289930	Green Published, gold, Green Submitted			2023-01-03	WOS:000446545500005
J	Gebremariam, B; Hagos, G; Abay, M				Gebremariam, Brhane; Hagos, Gebremedhin; Abay, Mebrahtu			Assessment of community led total sanitation and hygiene approach on improvement of latrine utilization in Laelay Maichew District, North Ethiopia. A comparative cross-sectional study	PLOS ONE			English	Article								Background Lack of latrines remain a widespread health and environmental hazard in many developing countries. Low latrine utilization mostly affects the poor, rural and marginalized communities as the majority of those who do not use improved latrines live in rural areas where 90% of all open defecation takes place. The counterpart to this problem, Community-Led Total Sanitation, and hygiene (CLTSH) is an approach that involves facilitating a process to inspire and empower communities to stop open defecation and to build and use latrines in a participatory manner. Objective This study was aimed at assessing the Community Led Total Sanitation and Hygiene approach on improvement of latrine utilization in Laelay Maichew District of Central Zone, Northern Ethiopia. Methods A comparative cross-sectional study was conducted in Laelay Maichew District of Central Zone, Northern Ethiopia from November 2016 to January 2017. The study subjects were randomly selected 388 households from CLTSH implemented kebeles and 388 households from CLTSH non-implemented kebeles. Systematic random sampling technique was used to select households among proportionally allocated sample frame of households. Then, Interview of household heads using semi-structured questionnaire was conducted to collect data. Finally, data were entered and analyzed using SPSS version 20.0. Bivariate Logistic regressions model was used to identify candidates of multiple logistic regressions. Those P-values < 0.25 were considered as candidates to multiple logistic regressions to determine independent factors of latrine utilization. Variables with Odds Ratio at 95% CI and P-value < 0.05 was considered statistically significant. The study obtained approval from Aksum University Institutional Review Board before its commencement. Result This study indicated that the level of latrine utilization and latrine availability in CLTSH implemented kebeles were greater than that of CLTSH Non-implemented kebeles. The finding of this study revealed that the rate of latrine utilization in the rural community of Laelay-matches district was about 47.4%, 95% CI (42.9%-51.8%). The majority (71.1%) of household in CLTSH implemented kebeles and (93.5%) of households in CLTSH non-implemented kebeles did not have hand washing facility near the latrine. Households which had no fresh excreta in around latrine were significantly 11.5 times higher than [AOR: 11.5, 95% CI (0.18, 50.2)] utilizing their latrine in CLTSH implemented kebeles. Conclusion The study showed that the level of latrine utilization in CLTSH implemented and that of CLTSH non-implemented kebeles was low. Therefore, concerted efforts should be made by local and national governmental and non-governmental organization to should be used to promote behavioral change in the communities to implement community-led total sanitation and hygiene for improving latrine utilization.	[Gebremariam, Brhane; Abay, Mebrahtu] Aksum Univ, Coll Hlth Sci, Dept Publ Hlth, Aksum, Ethiopia; [Hagos, Gebremedhin] Aksum Univ, Dept Biomed Sci, Coll Hlth Sci, Aksum, Ethiopia		Gebremariam, B (corresponding author), Aksum Univ, Coll Hlth Sci, Dept Publ Hlth, Aksum, Ethiopia.	gebremariambrhane@gmail.com		Abay, Mebrahtu/0000-0002-3307-0588				Admasu A, 2011, BASELINE SURVEY REPO; [Anonymous], PROGR DRINK WAT SAN; Anteneh A, 2010, ETHIOPIAN J HLTH DEV, V24; Ashebir Yemane, 2013, International Journal of Environmental Studies, V70, P629, DOI 10.1080/00207233.2013.835533; Awoke W, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-99; Bongartz P., 2010, PARTICIPATORY LEARNI, V61, P27; Debesay N., 2015, J COMMUNITY MED HLTH, V05, P338, DOI [10.4172/21610711.100033, DOI 10.4172/21610711.100033, 10.4172/21610711.1000338, DOI 10.4172/21610711.1000338]; Ejemot-Nwadiaro R. I., 2008, COCHRANE DATABASE SY; Eshete N, 2015, SCI J PUBLIC HLTH, V3, P669, DOI DOI 10.11648/j.sjph.20150305.22; Gebresilassie W., 2007, MAINSTREAMING HYGIEN; Kar K., 2005, SUBSIDY SELF RESPECT; Kar K, 2008, HDB COMMUNITY LED TO; Snel M, 2012, PAN AFRICAN CLTS PRO; Tefera W, 2008, TECHNICAL ISSUES SAN; United Nations Children's Fund (UNICEF), 2009, COMM APPR TOT SAN BA	15	16	16	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2018	13	9							e0203458	10.1371/journal.pone.0203458	http://dx.doi.org/10.1371/journal.pone.0203458			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT0BU	30192803	gold, Green Submitted, Green Published			2023-01-03	WOS:000444093600077
J	Bridges, D; Kawamura, H; Kanai, T				Bridges, Daniel; Kawamura, Hidemasa; Kanai, Tatsuaki			Probabilistic dose distribution from interfractional motion in carbon ion radiation therapy for prostate cancer shows rectum sparing with moderate target coverage degradation	PLOS ONE			English	Article							RADIOTHERAPY	Purpose This observational study investigates the influence of interfractional motion on clinical target volume (CTV) coverage, planning target volume (PTV) margins, and rectum tissue sparing in carbon ion radiation therapy (CIRT). It reports dose coverage to target structures and organs at risk in the presence of interfractional motion, investigates rectal tissue sparing, and provides recommendations for lowering the rate of toxicity. We also propose probabilistic DVH based on cone-beam computed tomography (CBCT) table shifts from photon therapy for consideration in bone-matching CIRT treatment planning to represent probable dose to our CIRT patient population. Methods At Gunma University Hospital intensity-modulated x-ray therapy (IMXT, aka IMRT) prostate cancer patients are positioned on a table which is shifted twice based on CBCT to align bones and then align prostate tissue to isocenter. These shifts thereby contain interfractional motion. A total of 1306 such table shifts from 85 patients were collected. Normal probability distributions were fit to the difference between bone-matching and prostate-matching CBCT-to-planning CT table shifts (i.e. interfractional motion). Between 2011 and 2016 CIRT prostate patients were treated with three beams to PTV1 (lateral-opposing and anterior) one per day for 9 fractions and two beams for a boost PTV2 (lateral-opposing) one per day for 7 fractions for a prescribed total of 57.6 Gy(RBE) as follows: PTV1 extends the prostate contour by 10/10, 5/10, 6/6 mm in the right/left, posterior/anterior, and superior/inferior directions, respectively, and the proximal seminal vesicles contour by 5 mm superiorly and inferiorly, 3 mm right and left. PTV2 reduces PTV1 posteriorly along a straight line to exclude the rectum and reduces the superior and inferior margins by 6 mm. Probable interfractional motion for 40 patients was simulated using each patient's own beam data as follows: The previously fit normal probability distributions were randomly sampled 2000 times per patient, and the five beams were shifted and summed with the same relative weighting as in the 16fraction regimen. The resulting dose distribution was then scaled back down by 16/2000 to match the prescribed number of fractions. We then analyzed the resulting doses to contoured structures. Results Probable dose to rectum is substantially less than planned: For example, mean+-standard deviation D2% for planned and probable DVH is 51+-1.9 and 45+-2.4, respectively. Cumulative DVH show mean CTV fraction receiving a given probable dose is less than the mean fraction receiving the corresponding planned dose for doses larger than 52 Gy(RBE), up to 19% less at 57.4 Gy(RBE). Our PTV1 margins generally cover 95% of interfractional motion but seminal vesicles and inferior prostate receive less dose than planned due to insufficient PTV2 margins. Conclusion Assuming rigidly shifting interfractional motion around the prostate region and neglecting minor changes in soft tissue stopping power, interfractional motion resulted in target underdosing but better tissue sparing in all cases. Given our low rates of relapse and recurrence, it appears less curative dose is needed than previously thought or else current planning target margins may be excessive: Planning target volumes should be reconsidered with the adoption of dose verification methods. Our probable dose distributions quantify expected dose for future dose verification studies.	[Bridges, Daniel; Kawamura, Hidemasa; Kanai, Tatsuaki] Gunma Univ, Grad Sch Med, Maebashi, Gunma, Japan; [Kawamura, Hidemasa] Gunma Univ, Heavy Ion Med Ctr, Maebashi, Gunma, Japan; [Kanai, Tatsuaki] Osaka Heavy Ion Therapy Ctr, Osaka, Osaka, Japan	Gunma University; Gunma University	Bridges, D (corresponding author), Gunma Univ, Grad Sch Med, Maebashi, Gunma, Japan.	m14702069@gunma-u.ac.jp		, Daniel/0000-0002-5840-0299	Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Daniel Bridges received a scholarship from the Ministry of Education, Culture, Sports, Science and Technology of Japan (accessible at http://www.mext.go.jp/en/) from April 2014 through September 2018. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aubry JF, 2004, INT J RADIAT ONCOL, V60, P30, DOI 10.1016/j.ijrobp.2004.02.045; Dong L, 2013, PROTON CARBON ION TH, P127; Elmpt W, 2018, PHYS IMAGING RAD ONC, V6, P12; Ishikawa H, 2015, ANTICANCER RES, V35, P5559; Jakel O, 2001, PHYS MED BIOL, V46, P1101, DOI 10.1088/0031-9155/46/4/314; Jakel O., 2012, ION BEAM THERAPY FUN; Jelen U, 2012, INT J RADIAT ONCOL, V84, pE257, DOI 10.1016/j.ijrobp.2012.03.058; Kanematsu N, 2003, PHYS MED BIOL, V48, P1053, DOI 10.1088/0031-9155/48/8/307; Kershaw L, 2017, INT J RADIAT ONCOL, V100, P68, DOI [10.1016/j.ijrobp.2017.08.044, DOI 10.1016/J.IJR0BP.2017.08.044]; Koide A, 2017, NUCL INSTRUM METHO A; Krimmer J, 2018, NUCL INSTRUM METH A, V878, P58, DOI 10.1016/j.nima.2017.07.063; Kubota Y, 2016, PLOS ONE; Kubota Y, 2018, J APPL CLIN MED PHYS, V19, P144, DOI 10.1002/acm2.12261; Kubota Y, 2015, J APPL CLIN MED PHYS, V16, P100, DOI 10.1120/jacmp.v16i4.5400; Lomax T., 2013, PROTON CARBON ION TH, P151; Marchant TE, 2018, PHYS MED BIOL, V63, DOI 10.1088/1361-6560/aab0f0; Mettler Fred A. Jr., 2000, Journal of Radiological Protection, V20, P353, DOI 10.1088/0952-4746/20/4/301; Nakahara R, 2018, INT J MED PHYS CLIN, V07, P47; Nomiya T, 2016, RADIOTHER ONCOL, V121, P288, DOI 10.1016/j.radonc.2016.10.009; Paganetti H, 2012, PHYS MED BIOL, V57, pR99, DOI 10.1088/0031-9155/57/11/R99; Tondel H, 2018, RADIOTHER ONCOL, V126, P229, DOI 10.1016/j.radonc.2017.10.029; Yan D, 2005, SEMIN RADIAT ONCOL, V15, P168, DOI 10.1016/j.semradonc.2005.01.007; Yang Y, 2007, PHYS MED BIOL, V52, P685, DOI 10.1088/0031-9155/52/3/011	23	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2018	13	8							e0203289	10.1371/journal.pone.0203289	http://dx.doi.org/10.1371/journal.pone.0203289			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS2JK	30169520	Green Published, gold, Green Submitted			2023-01-03	WOS:000443374400033
J	Landes, R; Illanes, A; Goeppner, D; Gollnick, H; Friebe, M				Landes, Rainer; Illanes, Alfredo; Goeppner, Daniela; Gollnick, Harald; Friebe, Michael			A study of concentration changes of Protoporphyrin IX and Coproporphyrin III in mixed samples mimicking conditions inside cancer cells for Photodynamic Therapy	PLOS ONE			English	Article							DOSE ESTIMATION; MLL CELLS	Photodynamic Therapy (PDT) using Aminolevulinic acid (ALA) could be an effective and minimally invasively applicable way to treat many different types of tumors without radiation and large incisions by just applying a light pulse. However the PDT process is difficult to observe, control and optimize and the dynamical relationships between the variables involved in the process is complex and still hardly understood. One of the main variables affecting the outcome of the process is the determination of the interval of time between ALA inoculation and starting of light delivery. This interval, better known as drug-light interval, should ensure that enough Protoporphyrin IX (PPIX) is located in the vicinity of functional structures inside the cells for the greatest damage during the PDT procedure. One route to better estimate this time interval would be by predicting PPIX from the dynamical changes of its precursors. For that purpose, in this work a novel optical setup (OS) is proposed for differentiating fluorescence emitted by Coproporphyrin III (CPIII) and PPIX itself in samples composed of mixed solutions. The OS is tested using samples with different concentrations in mixed solutions of PPIX and the precursor CPIII as well as with a Polymethyl methacrylate test sample as additional reference. Results show that emitted fluorescence of the whole process can be measured independently for PPIX and its precursor, which can enable future developments on PPIX prediction from the dynamical changes of its precursor for subject-dependent drug-light interval assessment.	[Landes, Rainer; Illanes, Alfredo; Friebe, Michael] Otto Von Guericke Univ, Inst Med Tech, Magdeburg, Saxony Anhalt, Germany; [Goeppner, Daniela] Justus Liebig Univ, Clin Dermatol & Allergol, Giessen, Hesse, Germany; [Gollnick, Harald] Univ Hosp Magdeburg, Magdeburg, Saxony Anhalt, Germany	Otto von Guericke University; Justus Liebig University Giessen; University Hospital Magdeburg	Landes, R (corresponding author), Otto Von Guericke Univ, Inst Med Tech, Magdeburg, Saxony Anhalt, Germany.	rainer.landes@ovgu.de	Friebe, Michael/E-3187-2015	Friebe, Michael/0000-0002-8624-0800; Illanes, Alfredo/0000-0002-0118-0483				Cohen DK, 2016, CANCERS, V8, DOI 10.3390/cancers8100090; Dysart JS, 2006, PHOTOCH PHOTOBIO SCI, V5, P73, DOI 10.1039/b511807g; Dysart JS, 2005, PHYS MED BIOL, V50, P2597, DOI 10.1088/0031-9155/50/11/011; Hillemanns P, 2000, CANCER, V88, P2275, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2275::AID-CNCR11>3.0.CO;2-B; Hindmarsh JT, 1999, CLIN BIOCHEM, V32, P609, DOI 10.1016/S0009-9120(99)00067-3; Huang W, 2010, TALANTA, V82, P1516, DOI 10.1016/j.talanta.2010.07.034; Inoue H, 2007, J NEURO-ONCOL, V83, P223, DOI 10.1007/s11060-006-9325-8; Ji ZY, 2006, J PHOTOCH PHOTOBIO B, V84, P213, DOI 10.1016/j.jphotobiol.2006.03.006; Landes R, 2018, RESULTS PHYS, V8, P1232, DOI 10.1016/j.rinp.2018.01.059; Morton C, 2015, EUR J DERMATOL, V25, P296, DOI 10.1684/ejd.2015.2570; Nakayama T, 2016, SCI REP-UK, V6, DOI 10.1038/srep36478; Pilny A J, 2015, BIOPROTOCOL, V5; Rapozzi V, 2014, RESISTANCE TO TARGET, P3, DOI [10.1007/978-3-319-12730-9_1, DOI 10.1007/978-3-319-12730-9_1]; Sailer R, 2007, PHOTOCH PHOTOBIO SCI, V6, P145, DOI 10.1039/b611715e; Swietach P, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0099	15	2	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2018	13	8							e0202349	10.1371/journal.pone.0202349	http://dx.doi.org/10.1371/journal.pone.0202349			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS2JK	30169536	Green Submitted, Green Published, gold			2023-01-03	WOS:000443374400011
J	Wu, XD; Chen, SS; Li, SZ; Zhang, J; Luan, D; Zhao, SC; Chu, ZH; Xu, Y				Wu, Xiaodong; Chen, Shuangshuang; Li, Shizun; Zhang, Ji; Luan, Di; Zhao, Shoucai; Chu, Zhaohu; Xu, Yang			Oxygen therapy in patients with retinal artery occlusion: A meta-analysis	PLOS ONE			English	Article							HYPERBARIC-OXYGEN; VEIN OCCLUSION; VISUAL-LOSS; MANAGEMENT	Background Oxygen therapy has been widely used for RAO (retinal artery occlusion) patients; however, inconsistent results have been reported. Methods PubMed, Web of Science, EMBASE, Medline (OvidSP), Cochrane, China National Knowledge Infrastructure (CNKI), and Wanfang Database were examined. The primary endpoint was visual acuity (VA), and RevMan software 5.3 was used to statistically analyze the outcomes. Results Seven randomized controlled trials (RCTs) met the inclusion criteria. Patients who received oxygen therapy exhibited probability of visual improvement about 5.61 times compared with the control group who did not receive oxygen therapy (OR = 5.61; 95% CI, 3.60-8.73; p < 0.01). No statistically significant difference was observed between oxygen inhalation methods (Chi 2 = 0.18, df = 1, p = 0.67), combined therapy (Chi 2 = 0.21, df = 1, p = 0.64), or RAO type (Chi 2 = 0.06, df = 1, p = 0.81). Conversely, 100% oxygen (Chi 2 = 4.55, df = 1, p < 0.05) and hyperbaric oxygen (Chi 2 = 4.55, df = 1, p < 0.05) significantly improved VA in RAO patients. Better effect was showed in period within 3 months (Chi 2 = 5.76, df = 1, p < 0.05). The most effective treatment length was over 9 hours (Chi 2 = 6.58, df = 1, p < 0.05). Conclusion Oxygen therapy demonstrated beneficial effects in improving VA in RAO patients, particularly when patients were treated with 100% hyperbaric oxygen and for over 9 hours.	[Wu, Xiaodong; Chen, Shuangshuang; Li, Shizun; Zhang, Ji; Luan, Di; Zhao, Shoucai; Chu, Zhaohu; Xu, Yang] Yijishan Hosp, Affiliated Hosp 1, Wannan Med Coll, Dept Neurol, Wuhu, Peoples R China; [Xu, Yang] Yijishan Hosp, Affiliated Hosp 1, Wannan Med Coll, Cent Lab, Wuhu, Peoples R China	Wannan Medical College; Wannan Medical College	Chu, ZH; Xu, Y (corresponding author), Yijishan Hosp, Affiliated Hosp 1, Wannan Med Coll, Dept Neurol, Wuhu, Peoples R China.; Xu, Y (corresponding author), Yijishan Hosp, Affiliated Hosp 1, Wannan Med Coll, Cent Lab, Wuhu, Peoples R China.	chuzhaohu878@163.com; southtv@163.com	Yang, Xu/AGR-8189-2022	Yang, Xu/0000-0001-8778-3885; Wu, Xiaodong/0000-0001-8407-8398	National Natural Science Foundation of China [81701161]; Scientifc Research Fund Project for Talent Introduction of Yijishan Hospital, Wannan Medical College, Anhui, China [YR201802]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientifc Research Fund Project for Talent Introduction of Yijishan Hospital, Wannan Medical College, Anhui, China	This study was funded by the National Natural Science Foundation of China (81701161) and the Scientifc Research Fund Project for Talent Introduction of Yijishan Hospital, Wannan Medical College, Anhui, China (Grant Nos. YR201802).	Agarwal N, 2016, VASC ENDOVASC SURG, V50, P579, DOI 10.1177/1538574416682158; Aisenbrey S, 2000, OPHTHALMOLOGE, V97, P461, DOI 10.1007/s003470070075; Atebara NH, 1995, OPHTHALMOLOGY, V102, P2029, DOI 10.1016/S0161-6420(95)30758-0; Beiran I, 2001, EUR J OPHTHALMOL, V11, P345, DOI 10.1177/112067210101100405; Beiran I, 1993, Eur J Ophthalmol, V3, P89; Canan H, 2014, J MED CASE REPORTS, V8, P1; Celebi ARC, 2016, DIVING HYPERB MED, V46, P50; Chen YY, 2014, CHINESE MED J-PEKING, V127, P1434, DOI 10.3760/cma.j.issn.0366-6999.20133254; Chen YC, 2018, FACIAL PLAST SURG, V34, pE1, DOI 10.1055/s-0038-1656550; Cope A, 2011, DIVING HYPERB MED, V41, P135; Dattilo M, 2017, NEUROL CLIN, V35, P83, DOI 10.1016/j.ncl.2016.08.013; Dumitrascu OM, 2017, NEUROLOGIST, V22, P153, DOI 10.1097/NRL.0000000000000129; Elkordy Alaa Mohammed, 2016, NMC Case Rep J, V3, P71, DOI 10.2176/nmccrj.cr.2015-0243; Fraser SG, 2009, COCHRANE DB SYST REV, V1; Gaydar V, 2011, INVEST OPHTH VIS SCI, V52, P7514, DOI 10.1167/iovs.11-7574; Gokce G, 2014, HIGH ALT MED BIOL, V15, P84, DOI 10.1089/ham.2013.1086; Graefe AV, ARCH OPHTHALMOLOGIE, V5, P136; Green HS, 2008, N-S ARCH PHARMACOL, V5, pS38; Hayreh SS, 2009, OPHTHALMOLOGY, V116, P1928, DOI 10.1016/j.ophtha.2009.03.006; Hayreh SS, 2009, OPHTHALMOLOGY, V116, P1188, DOI 10.1016/j.ophtha.2009.01.015; Hayreh SS, 2005, AM J OPHTHALMOL, V140, P376, DOI 10.1016/j.ajo.2005.03.038; He Y., 2009, WORLD HLTH DIGEST, V6, P61; Hertzog LM, 1992, CENTRAL RETINAL ARTE; Hong JH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177663; Hsiao SF, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-120; Hwang K., 2016, J CRANIOFAC SURG, V27, P1, DOI [10.1097/SCS.0000000000002387, DOI 10.1097/SCS.0000000000002387]; Jung Young Ho, 2016, Korean J Ophthalmol, V30, P352; Lemos JA, 2015, CASE REP OPHTHALM, V6, P462, DOI 10.1159/000442788; Li HK, 1996, OPHTHALMOLOGY, V103, P2091, DOI 10.1016/S0161-6420(96)30384-9; Lu CH, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1401-6; Man V, 2017, GRAEF ARCH CLIN EXP, V255, P1869, DOI 10.1007/s00417-017-3777-8; Menzel-Severing J, 2012, AM J OPHTHALMOL, V153, P454, DOI 10.1016/j.ajo.2011.08.009; Murphy-Lavoie H, 2012, UNDERSEA HYPERBAR M, V39, P943; PERKINS SA, 1987, ANN OPHTHALMOL, V19, P3; Soares A, 2017, BMJ CASE REP, V2017; STONE R, 1977, ANN OPHTHALMOL, V9, P445; WALLYN CR, 1985, INVEST OPHTH VIS SCI, V26, P1155; Wang L., 2016, CHINA HLTH CARE NUTR, V26; Weinberger AWA, 2002, KLIN MONATSBL AUGENH, V219, P728, DOI 10.1055/s-2002-35687; Weiss JN, 2009, UNDERSEA HYPERBAR M, V36, P401; Zhang X., 2000, CHINESE J CRITICAL C, V20, P32	41	21	21	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2018	13	8							e0202154	10.1371/journal.pone.0202154	http://dx.doi.org/10.1371/journal.pone.0202154			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR9JD	30157206	gold, Green Published, Green Submitted			2023-01-03	WOS:000443071400040
J	Aguilera-Manrique, G; Marquez-Hernandez, VV; Alcaraz-Cordoba, T; Granados-Gamez, G; Gutierrez-Puertas, V; Gutierrez-Puertas, L				Aguilera-Manrique, Gabriel; Marquez-Hernandez, Veronica V.; Alcaraz-Cordoba, Tania; Granados-Gamez, Genoveva; Gutierrez-Puertas, Vanesa; Gutierrez-Puertas, Lorena			The relationship between nomophobia and the distraction associated with smartphone use among nursing students in their clinical practicum	PLOS ONE			English	Article							SOCIAL MEDIA; ADDICTION; NURSES; QUESTIONNAIRE; PHONE; WORK; PREVALENCE; VALIDATION; SETTINGS; USAGE	Background The increasing concern about the adverse effects of overuse of smartphones during clinical practicum implies the need for policies restricting smartphone use while attending to patients. It is important to educate health personnel about the potential risks that can arise from the associated distraction. Objective The aim of this study was to analyze the relationship between the level of nomophobia and the distraction associated with smartphone use among nursing students during their clinical practicum. Methods A cross-sectional study was carried out on 304 nursing students. The nomophobia questionnaire (NMP-Q) and a questionnaire about smartphone use, the distraction associated with it, and opinions about phone restriction policies in hospitals were used. Results A positive correlation between the use of smartphones and the total score of nomophobia was found. In the same way, there was a positive correlation between opinion about smartphone restriction polices with each of the dimensions of nomophobia and the total score of the questionnaire. Conclusions Nursing students who show high levels of nomophobia also regularly use their smartphones during their clinical practicum, although they also believe that the implementation of policies restricting smartphone use while working is necessary.	[Aguilera-Manrique, Gabriel; Marquez-Hernandez, Veronica V.; Alcaraz-Cordoba, Tania; Granados-Gamez, Genoveva; Gutierrez-Puertas, Vanesa; Gutierrez-Puertas, Lorena] Univ Almeria, Fac Hlth Sci, Dept Nursing Physiotherapy & Med, Almeria, Spain; [Aguilera-Manrique, Gabriel; Marquez-Hernandez, Veronica V.; Granados-Gamez, Genoveva] Univ Almeria, Res Grp Hlth Sci CTS 451, Almeria, Spain	Universidad de Almeria; Universidad de Almeria	Marquez-Hernandez, VV (corresponding author), Univ Almeria, Fac Hlth Sci, Dept Nursing Physiotherapy & Med, Almeria, Spain.; Marquez-Hernandez, VV (corresponding author), Univ Almeria, Res Grp Hlth Sci CTS 451, Almeria, Spain.	vmh380@ual.es	Márquez-Hernández, Verónica V./ABE-7896-2020; Gutiérrez-Puertas, Lorena/ABG-4135-2020; Aguilera Manrique, Gabriel/M-7347-2015	Márquez-Hernández, Verónica V./0000-0003-1163-4394; Gutiérrez-Puertas, Lorena/0000-0003-3565-7881; Gutierrez-Puertas, Vanesa/0000-0001-7580-4474; Aguilera Manrique, Gabriel/0000-0002-1945-9626				Aggarwal M., 2012, J PSYCHOL, V15, P50; Alsos OA, 2012, INT J MED INFORM, V81, P12, DOI 10.1016/j.ijmedinf.2011.09.004; Argumosa-Villar L, 2017, J ADOLESCENCE, V56, P127, DOI 10.1016/j.adolescence.2017.02.003; Arpaci I, 2019, INFORM DEV, V35, P96, DOI 10.1177/0266666917730119; Ayar D, 2018, CIN-COMPUT INFORM NU, V36, P589, DOI 10.1097/CIN.0000000000000458; Barton AJ, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-46; Bautista JR, 2016, INT J MED INFORM, V95, P71, DOI 10.1016/j.ijmedinf.2016.09.002; Cagan O, 2014, PROCD SOC BEHV, V114, P831, DOI 10.1016/j.sbspro.2013.12.793; Cho S, 2016, NURS EDUC TODAY, V40, P128, DOI 10.1016/j.nedt.2016.02.021; Cho S, 2015, CIN-COMPUT INFORM NU, V33, P216, DOI 10.1097/CIN.0000000000000132; Cohen TN, 2018, PERIOPER CARE OPERAT, V10, P10, DOI [10.1016/j.pcorm.2017.12.001, DOI 10.1016/J.PCORM.2017.12.001]; Flynn GAH, 2018, CIN-COMPUT INFORM NU, V36, P120, DOI 10.1097/CIN.0000000000000400; Gill PS, 2012, RISK MANAG HEALTHC P, V5, P105, DOI 10.2147/RMHP.S34813; Gokcearslan S, 2016, COMPUT HUM BEHAV, V63, P639, DOI 10.1016/j.chb.2016.05.091; Griffiths M. D., 2005, J SUBST USE, V10, P191, DOI [10.1080/14659890500114359, DOI 10.1080/14659890500114359]; Gutierrez-Puertas L, 2016, CIN-COMPUT INFORM NU, V34, P470, DOI 10.1097/CIN.0000000000000268; Haug S, 2015, J BEHAV ADDICT, V4, P299, DOI 10.1556/2006.4.2015.037; International Telecommunications Union, MEAS INF SOC REP INT; Jones C, 2013, J CLIN NURS, V22, P1495, DOI 10.1111/jocn.12239; Junco R, 2012, COMPUT HUM BEHAV, V28, P2236, DOI 10.1016/j.chb.2012.06.031; Katz-Sidlow RJ, 2012, J HOSP MED, V7, P595, DOI 10.1002/jhm.1950; Kaur A, 2015, INT J PSYCHIAT NURS, V1, P1, DOI DOI 10.5958/2395-180X.2015.00051.1; King Anna Lucia Spear, 2014, Clin Pract Epidemiol Ment Health, V10, P28, DOI 10.2174/1745017901410010028; Kung YM, 2014, CIN-COMPUT INFORM NU, V32, P64, DOI 10.1097/CIN.0000000000000033; Kwon M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056936; Lee S, 2017, APPL COGNITIVE PSYCH, V31, P360, DOI 10.1002/acp.3323; Lin SC, 2013, J ADV NURS, V69, P374, DOI 10.1111/j.1365-2648.2012.06016.x; McBride DL, 2015, J ADV NURS, V71, P2020, DOI 10.1111/jan.12674; McBride DL, 2015, JMIR MHEALTH UHEALTH, V3, DOI 10.2196/mhealth.4001; McBride DL, 2012, J PEDIATR NURS, V27, P275, DOI 10.1016/j.pedn.2012.02.002; McNally G, 2017, NURSE EDUC PRACT, V23, P1, DOI 10.1016/j.nepr.2016.12.004; Mobasheri M.H., 2015, BMJ INNOV, V1, P174, DOI [DOI 10.1136/BMJINNOV-2015-000062, 10.1136/bmjinnov-2015-000062]; Oulasvirta A, 2012, PERS UBIQUIT COMPUT, V16, P105, DOI 10.1007/s00779-011-0412-2; Polit D.F., 2008, NURSING RES GENERATI; Przybylski AK, 2013, COMPUT HUM BEHAV, V29, P1841, DOI 10.1016/j.chb.2013.02.014; Sebri I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165714; SecurEnvoy, 2012, 66 POP SUFF NOM FEAR; Sergeeva A, 2016, HEALTH INFORM J, V22, P1101, DOI 10.1177/1460458215598637; Smith T, 2011, PERFUSION-UK, V26, P375, DOI 10.1177/0267659111409969; Yildirim C, 2016, INFORM DEV, V32, P1322, DOI 10.1177/0266666915599025; Yildirim C, 2015, COMPUT HUM BEHAV, V49, P130, DOI 10.1016/j.chb.2015.02.059	41	52	53	3	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2018	13	8							e0202953	10.1371/journal.pone.0202953	http://dx.doi.org/10.1371/journal.pone.0202953			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GR6UK	30148870	Green Published, gold, Green Submitted			2023-01-03	WOS:000442804200037
J	Sacks, CA; Lee, CC; Kesselheim, AS; Avorn, J				Sacks, Chana A.; Lee, ChangWon C.; Kesselheim, Aaron S.; Avorn, Jerry			Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANGIOTENSIN RECEPTOR BLOCKERS; PRESCRIPTION DRUGS; UNITED-STATES; ADHERENCE; MANAGEMENT; METAANALYSIS; HYPERTENSION; GUIDELINES; QUINIDINE; EFFICACY	IMPORTANCE Brand-name combination drugs can be more expensive than the sum of their components, especially when the constituent products are available as generic medications. The potential savings that could be achieved using generic components is not known. OBJECTIVE To estimate the additional cost to Medicare of prescribing brand-name combination medications instead of generic constituents. DESIGN, SETTING, AND PARTICIPANTS Retrospective analysis for 2011 through 2016 using the Medicare data set of Part D beneficiaries prescribed any of the 1500 medications that accounted for the highest total spending in 2015. Brand-name combination drugs that had identical or therapeutically equivalent generic constituents were included. EXPOSURES Brand-name, oral combination medications with constituents available either as generic drugs or therapeutically equivalent generic substitutes. MAIN OUTCOMES AND MEASURES The estimated difference between the amount spent by Medicare on brand-name combination drugs and the estimated amount that would have been spent on substitutable generic components. RESULTS Among the 1500 medications evaluated, 29 brand-name combination medications were separated into 3 mutually exclusive categories: constituents available as generic medications at identical doses (n = 20), generic constituents at different doses (n = 3), and therapeutically equivalent generic substitutes (n = 6). For the constituents available as generic medications at identical doses category, total spending by Medicare in 2016 on the brand-name combination products was $303 million and the estimated spending for the generic constituents would have been $68 million, which is an estimated difference of $235 million. For the generic constituents at different doses category, total spending by Medicare in 2016 on the brand-name combination products was $232 million and the estimated spending for the generic constituents would have been $13 million, which is an estimated difference of $219 million. For the therapeutically equivalent generic substitutes category, total spending by Medicare in 2016 on the brand-name combination products was $491 million and the estimated spending for the generic constituents would have been $20 million, which is an estimated difference of $471 million. In 2016, the estimated spending for the generic constituents for these 29 drugs would have been $925 million less than the estimated spending for the brand-name combinations. For the 10 most costly combination products available during the entire study period, the listed Medicare spending could have been an estimated $2.7 billion lower between 2011 and 2016 if the generic constituents had been prescribed. CONCLUSIONS AND RELEVANCE In 2016, the difference between the amount that the Medicare drug benefit program reported spending on brand-name combination medications and the estimated spending for generic constituents for the same number of doses was $925 million. Promoting generic substitution and therapeutic interchange through prescriber education and more rational substitution policies may offer important opportunities to achieve substantial savings in the Medicare drug benefit program.	Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law, 75 Francis St, Boston, MA 02115 USA; [Sacks, Chana A.] Harvard Med Sch, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sacks, CA (corresponding author), Harvard Med Sch, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.; Sacks, CA (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	csacks@partners.org		Lee, ChangWon/0000-0001-7534-0526	Laura and John Arnold Foundation; Engelberg Foundation; Harvard Program in Therapeutic Science	Laura and John Arnold Foundation; Engelberg Foundation; Harvard Program in Therapeutic Science	This study was funded by the Laura and John Arnold Foundation as well as by the Engelberg Foundation and the Harvard Program in Therapeutic Science.	Abraham HMA, 2015, DRUG SAFETY, V38, P33, DOI 10.1007/s40264-014-0239-7; Arora S, 2017, AM J MANAG CARE, V23, P410; Avorn J, 2015, NEW ENGL J MED, V372, P1877, DOI 10.1056/NEJMp1500848; Bahiru E, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009868.pub3; Bozic B, 2018, MINI-REV MED CHEM, V18, P468, DOI 10.2174/1389557517666170707110450; Castellano JM, 2014, J AM COLL CARDIOL, V64, P2071, DOI 10.1016/j.jacc.2014.08.021; Centers for Medicare & Medicaid Services, MED D DRUG SPEND DAS; Centers for Medicare & Medicaid Services, 2014, MED D REB SUMM; Choudhry NK, 2016, ANN INTERN MED, V164, P41, DOI 10.7326/M14-2427; Choudhry NK, 2011, NEW ENGL J MED, V365, P2088, DOI 10.1056/NEJMsa1107913; Choudhry NK, 2010, HEALTH AFFAIR, V29, P1995, DOI 10.1377/hlthaff.2010.0336; Cummings JL, 2015, JAMA-J AM MED ASSOC, V314, P1242, DOI 10.1001/jama.2015.10214; Dezsi CA, 2016, AM J CARDIOVASC DRUG, V16, P255, DOI 10.1007/s40256-016-0165-4; Gottwald-Hostalek U, 2017, CLIN PHARM DRUG DEV, V6, P9, DOI 10.1002/cpdd.309; Gralnek IM, 2006, CLIN GASTROENTEROL H, V4, P1452, DOI 10.1016/j.cgh.2006.09.013; Hakim A, 2017, JAMA INTERN MED, V177, P305, DOI 10.1001/jamainternmed.2016.8423; Halo Pharma, HALO PHARM PARTN PHA; Hao J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140708; Henry J., MEDICARE D PRESCRIPT; Johansen ME, 2016, JAMA INTERN MED, V176, P769, DOI 10.1001/jamainternmed.2016.1704; Kanavos P, 2013, HEALTH AFFAIR, V32, P753, DOI 10.1377/hlthaff.2012.0920; Katz PO, 2013, AM J GASTROENTEROL, V108, P308, DOI 10.1038/ajg.2012.444; Kesselheim AS, 2016, JAMA-J AM MED ASSOC, V316, P858, DOI 10.1001/jama.2016.11237; Keyhani S, 2006, HEALTH AFFAIR, V25, P461, DOI 10.1377/hlthaff.25.2.461; Makani H, 2014, EUR HEART J, V35, P1732, DOI 10.1093/eurheartj/eht333; McVary KT, MANAGEMENT BENIGN PR; Pan F, 2008, J GEN INTERN MED, V23, P611, DOI 10.1007/s11606-008-0544-x; Papanicolas I, 2018, JAMA-J AM MED ASSOC, V319, P1024, DOI 10.1001/jama.2018.1150; Pollack A., DRUG MAKERS SIDESTEP; Rabbani A, 2008, AM J HYPERTENS, V21, P509, DOI 10.1038/ajh.2008.31; Reinke Thomas, 2017, Manag Care, V26, P17; Sarpatwari A, 2018, JAMA-J AM MED ASSOC, V319, P2373, DOI 10.1001/jama.2018.7424; Wang B, 2015, AM HEART J, V169, P379, DOI 10.1016/j.ahj.2014.12.014	33	36	36	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	2018	320	7					650	656		10.1001/jama.2018.11439	http://dx.doi.org/10.1001/jama.2018.11439			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR1XH	30140875	Green Published, Bronze			2023-01-03	WOS:000442348100012
J	Getahun, WT; Solomon, AA; Kassie, FY; Kasaye, HK; Denekew, HT				Getahun, Worku Taye; Solomon, Abayneh Aklilu; Kassie, Fisseha Yetewale; Kasaye, Habtamu Kebebe; Denekew, Habtamu Temesgen			Uterine rupture among mothers admitted for obstetrics care and associated factors in referral hospitals of Amhara regional state, institution-based cross-sectional study, Northern Ethiopia, 2013-2017	PLOS ONE			English	Article							PREVALENCE; WOMEN	Background Maternal morbidity and mortality have been one of the most challenging health problems that concern the globe over the years. Uterine rupture is one of the peripartum complications, which cause nearly about one out of thirteen maternal deaths. This study aimed to assess the prevalence and associated factors of uterine rupture among obstetric case in referral hospitals of Amhara Regional State, Northern Ethiopia. Methods Institution based cross sectional study was conducted from Dec 5-2017-Jan 5-2018 on uterine rupture. During the study randomly selected 750 charts were included by using simple random sampling method. Data were checked, coded and entered into Epi info version 7.2 and then exported to SPSS Version 20 for Analysis. Binary Logistic regression was used to identify the predictors of uterine rupture and 95% Confidence Interval of odds ratio at p-value less than 0.05 was taken as a significance level. Result The overall prevalence of uterine rupture was 16.68% (95% CI: 14%, 19.2%). Distance from health facility > 10km (Adjusted Odds Ratio (AOR) = 2.44; 95% CI: 1.13,5.28), parity between II and IV (AOR = 7.26; 95% (3.06,17.22)) and. V (AOR = 12.55; 95% CI 3.64,43.20), laboring for > 24hours(AO = 3.44; 95% CI: 1.49,7.92), with referral paper(AOR = 2.94; 95% CI: 1.28,6.55) diagnosed with obstructed labor (AOR = 4.88; 95% CI: 2.22,10.70), precipitated labor (AOR = 3.59; 95% CI: 1.10,11.77), destructive delivery (AOR = 5.18; 95%: 1.22,20.08), No partograph (AOR = 5.21; 95% CI: 2.72,9.97), CPD(AOR = 4.08; 95% CI: 1.99,8.33), morbidly adherent placenta (AOR = 9.00; 95%: 2.46,27.11), gestational diabetic militias (AOR = 5.78; 95% CI:1. 12,20.00), history of myomectomy(AOR = 5.00; 95% CI: 1.33,18.73), induction and augmentation of labor (AOR = 2.34;95%: 1.15,4.72) obstetric procedure (AOR = 2.54;95%: 1.09,5.91), previous caesarian deliveries 4.90 (2.13,11.26) were found to be significantly associated with uterine rupture. Conclusion This finding showed that the prevalence of uterine rupture is higher. A more vigilant approach to prevent prolonged and obstructed labor, use of partograph, quick referral to a well-equipped center and prevention of other obstetrics complications need to be focused on.	[Getahun, Worku Taye] Debremarkos Referral Hosp, Dept Midwifery, Debremarkos, Ethiopia; [Solomon, Abayneh Aklilu; Kassie, Fisseha Yetewale] Univ Gondar, Sch Midwifery, Gondar, Ethiopia; [Kasaye, Habtamu Kebebe] Wollega Univ, Inst Hlth Sci, Dept Midwifery, Nekemte, Ethiopia; [Denekew, Habtamu Temesgen] Debremarkos Univ, Dept Human Nutr, Debremarkos, Ethiopia	University of Gondar	Getahun, WT (corresponding author), Debremarkos Referral Hosp, Dept Midwifery, Debremarkos, Ethiopia.	worku384@gmail.com	Kasaye, Habtamu Kebebe/U-5762-2019	Kasaye, Habtamu Kebebe/0000-0003-3759-2604; taye, worku/0000-0003-4641-4105; Yetwale, Fisseha/0000-0002-7503-8447; Temesgen, Habtamu/0000-0001-5510-9204	University of Gondar	University of Gondar	The financial support for this research project obtained from University of Gondar (http://www.uog.edu.et/en/).The funder had no role in design of the study and collection, analysis, and interpretation of data and in writing the manuscript.; We would like to express our deepest and heartfelt appreciation to University of Gondar for providing the financial support. We are also glad to say thanks to Amhara Region Referral Hospitals administrative and community for their cooperativeness and their valuable information to do this work. Last but not least, we express our gratitude data collectors and supervisors for their contribution.	Adegbola O, 2017, J CLIN SCI, V14, P13; Al-Zirqi I, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2016.10.017; Alemayehu W, 2013, BJOG-INT J OBSTET GY, V120, P505, DOI 10.1111/1471-0528.12098; Aliyu S., 2016, INTERNAL MED, V6, P1000222; Astatikie G, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1302-z; Berhan Y, 2014, ETHIOP J HEALTH SCI, V24, P15, DOI 10.4314/ejhs.v24i0.3S; Egbe Thomas Obinchemti, 2016, BMC Res Notes, V9, P492; Fitzpatrick KE, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001184; Guise JM, 2004, BMJ-BRIT MED J, V329, P19, DOI 10.1136/bmj.329.7456.19; Gyamfi-Bannerman C, 2012, OBSTET GYNECOL, V120, P1332, DOI [10.1097/AOG.0b013e318273695b, http://10.1097/AOG.0b013e318273695b]; Handady SO, 2015, ACTA MED, V2; Hofmeyr GJ, 2005, BJOG-INT J OBSTET GY, V112, P1221, DOI 10.1111/j.1471-0528.2005.00725.x; Kadowa I, 2010, SINGAP MED J, V51, P35; Legese T, 2016, AM J PUBLIC HLTH RES, V4, P120; Marie BT, 2017, OBSTET GYNECOLOGY IN, V2017; Mengistie H, 2016, MOJ WOMENS HLTH, V2; Motomura K, 2017, SCI REP-UK, V7, DOI 10.1038/srep44093; Mukasa PK, 2013, REPROD HEALTH, V10, DOI 10.1186/1742-4755-10-29; Osemwenkha PA, 2016, NIGERIAN J SURG SCI, V26, P1, DOI DOI 10.4103/1116-5898.196256; Population Census Commission, 2007, NON TRADITIONAL REF; Shick S., 2015, OBSTET GYNECOL CASES, V2, P5; WHO, 2014, WORLD HLTH STAT 2014; WHO, 2013, HLTH STAT STAT 2013; Wilmoth JR, 2012, STAT POLITICS POLICY, V3	24	9	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2018	13	12							e0208470	10.1371/journal.pone.0208470	http://dx.doi.org/10.1371/journal.pone.0208470			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD0NQ	30513120	Green Published, gold, Green Submitted			2023-01-03	WOS:000452204800034
J	Moritz, C				Moritz, Chet			A giant step for spinal cord injury research	NATURE NEUROSCIENCE			English	Editorial Material								The combination of spinal epidural stimulation and physical therapy is restoring walking function to people with spinal cord injury. With intensive rehabilitation, some participants are able to walk in their communities during stimulation and even regain control over previously paralyzed movement in the absence of stimulation.	[Moritz, Chet] Univ Washington, Dept Elect & Comp Engn, Seattle, WA 98195 USA; [Moritz, Chet] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Moritz, Chet] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Moritz, C (corresponding author), Univ Washington, Dept Elect & Comp Engn, Seattle, WA 98195 USA.; Moritz, C (corresponding author), Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.; Moritz, C (corresponding author), Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA.	ctmoritz@uw.edu						Angeli CA, 2018, NEW ENGL J MED, V379, P1244, DOI 10.1056/NEJMoa1803588; Formento E, 2018, NAT NEUROSCI, V21, P1728, DOI 10.1038/s41593-018-0262-6; Gad P, 2018, J NEUROTRAUM, V35, P2145, DOI 10.1089/neu.2017.5461; Gill ML, 2018, NAT MED, V24, P1677, DOI 10.1038/s41591-018-0175-7; Inanici F, 2018, IEEE T NEUR SYS REH, V26, P1272, DOI 10.1109/TNSRE.2018.2834339; Moritz CT, 2018, NEUROTHERAPEUTICS, V15, P628, DOI 10.1007/s13311-018-0637-0; Rejc E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14003-w; Taccola G, 2018, PROG NEUROBIOL, V160, P64, DOI 10.1016/j.pneurobio.2017.10.004; Wagner FB, 2018, NATURE, V563, P65, DOI 10.1038/s41586-018-0649-2	9	8	8	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	DEC	2018	21	12					1647	1648		10.1038/s41593-018-0264-4	http://dx.doi.org/10.1038/s41593-018-0264-4			2	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HB8GE	30382195				2023-01-03	WOS:000451324700002
J	Bakaki, PM; Horace, A; Dawson, N; Winterstein, A; Waldron, J; Staley, J; Knight, EMP; Meropol, SB; Liu, RJ; Johnson, H; Golchin, N; Feinstein, JA; Bolen, SD; Kleinman, LC				Bakaki, Paul M.; Horace, Alexis; Dawson, Neal; Winterstein, Almut; Waldron, Jennifer; Staley, Jennifer; Knight, Elia M. Pestana; Meropol, Sharon B.; Liu, Rujia; Johnson, Hannah; Golchin, Negar; Feinstein, James A.; Bolen, Shari D.; Kleinman, Lawrence C.			Defining pediatric polypharmacy: A scoping review	PLOS ONE			English	Review							PSYCHOTROPIC MEDICATION USE; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; INTENSIVE-CARE-UNIT; ANTIPSYCHOTIC POLYPHARMACY; DRUG UTILIZATION; 2ND-GENERATION ANTIPSYCHOTICS; HOSPITALIZED CHILDREN; ANTIEPILEPTIC DRUGS; CHILDHOOD EPILEPSY; ENROLLED CHILDREN	Objectives Lack of consensus regarding the semantics and definitions of pediatric polypharmacy challenges researchers and clinicians alike. We conducted a scoping review to describe definitions and terminology of pediatric polypharmacy. Methods Medline, PubMed, EMBASE, CINAHL, PsycINFO, Cochrane CENTRAL, and the Web of Science Core Collection databases were searched for English language articles with the concepts of "polypharmacy" and "children". Data were extracted about study characteristics, polypharmacy terms and definitions from qualifying studies, and were synthesized by disease conditions. Results Out of 4,398 titles, we included 363 studies: 324 (89%) provided numeric definitions, 131 (36%) specified duration of polypharmacy, and 162 (45%) explicitly defined it. Over 81% (n = 295) of the studies defined polypharmacy as two or more medications or therapeutic classes. The most common comprehensive definitions of pediatric polypharmacy included: two or more concurrent medications for >= 1 day (n = 41), two or more concurrent medications for >= 31 days (n = 15), and two or more sequential medications over one year (n = 12). Commonly used terms included polypharmacy, polytherapy, combination pharmacotherapy, average number, and concomitant medications. The term polypharmacy was more common in psychiatry literature while epilepsy literature favored the term polytherapy. Conclusions Two or more concurrent medications, without duration, for >= 1 day, >= 31 days, or sequentially for one year were the most common definitions of pediatric polypharmacy. We recommend that pediatric polypharmacy studies specify the number of medications or therapeutic classes, if they are concurrent or sequential, and the duration of medications. We propose defining pediatric polypharmacy as "the prescription or consumption of two or more distinct medications for at least one day". The term "polypharmacy" should be included among key words and definitions in manuscripts.	[Bakaki, Paul M.; Dawson, Neal; Liu, Rujia; Johnson, Hannah; Bolen, Shari D.] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA; [Horace, Alexis] Univ Louisiana, Monroe Coll Pharm, Dept Clin Sci, Monroe, LA USA; [Dawson, Neal; Bolen, Shari D.] MetroHlth Med Ctr, Dept Med, Cleveland, OH USA; [Dawson, Neal; Bolen, Shari D.] MetroHlth, Ctr Hlth Care Res & Policy, Cleveland, OH USA; [Winterstein, Almut] Univ Florida, Dept Pharmaceut Outcomes & Policy, Gainesville, FL USA; [Winterstein, Almut] Univ Florida, Dept Epidemiol & Biostat, Gainesville, FL USA; [Waldron, Jennifer] Rainbow Babies & Childrens Hosp, Univ Hosp, Div Pediat Neurol & Epilepsy, 2101 Adelbert Rd, Cleveland, OH 44106 USA; [Waldron, Jennifer; Meropol, Sharon B.; Kleinman, Lawrence C.] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA; [Staley, Jennifer; Meropol, Sharon B.; Kleinman, Lawrence C.] Rainbow Babies & Childrens Hosp, Univ Hosp, 2101 Adelbert Rd, Cleveland, OH 44106 USA; [Knight, Elia M. Pestana] Cleveland Clin, Neurol Inst, Epilepsy Ctr, Cleveland, OH 44106 USA; [Meropol, Sharon B.; Kleinman, Lawrence C.] Univ Hosp, Rainbow Ctr Child Hlth & Policy, Cleveland, OH USA; [Golchin, Negar] Univ Washington, Sch Pharm, Seattle, WA 98195 USA; [Feinstein, James A.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA	Case Western Reserve University; University of Louisiana System; University of Louisiana Monroe; MetroHealth System; MetroHealth System; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Cleveland Clinic Foundation; University Hospitals of Cleveland; University of Washington; University of Washington Seattle; University of Colorado System; University of Colorado Anschutz Medical Campus	Bakaki, PM (corresponding author), Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA.	pmb18@case.edu	winterstein, almut/ABH-1838-2020; Kleinman, Lawrence/AAS-6934-2021; Feinstein, James Aaron/I-6373-2013; Golchin, Negar/AAP-1163-2020; winterstein, Almut/A-3017-2014	Feinstein, James Aaron/0000-0003-3074-8805; Golchin, Negar/0000-0003-0775-9004; winterstein, Almut/0000-0002-6518-5961	National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH roadmap for Medical Research [KL2TR000440]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K23HD091295] Funding Source: NIH RePORTER	National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH roadmap for Medical Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	PMB. This publication was made possible by the Clinical and Translational Science Collaborative of Cleveland, KL2TR000440 from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. (https://www.ncbi.nlm.nih.gov/books/NBK169203/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allaire BT, 2016, CHILD YOUTH SERV REV, V67, P27, DOI 10.1016/j.childyouth.2016.05.019; American Hospital Formulary Service, 2018, AM HOSP FORM SERV DR; Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [10.1080/1364557032000119616, https://doi.org/10.1080/1364557032000119616, DOI 10.1080/1364557032000119616]; Baeza I, 2014, J CLIN PSYCHOPHARM, V34, P613, DOI 10.1097/JCP.0000000000000190; Bakaki PM, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0560-4; Bali V, 2015, J ATTEN DISORD; Ballardini N, 2016, ALLERGY, V71, P342, DOI 10.1111/all.12798; Bassili A, 2002, INT J QUAL HEALTH C, V14, P277, DOI 10.1093/intqhc/14.4.277; Betts KA, 2014, J CHILD ADOL PSYCHOP, V24, P260, DOI 10.1089/cap.2013.0107; Bhowmik D, 2013, J AFFECT DISORDERS, V150, P424, DOI 10.1016/j.jad.2013.04.034; Carpay HA, 1998, ARCH NEUROL-CHICAGO, V55, P668, DOI 10.1001/archneur.55.5.668; Chandrayan SK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0080014; Chatterjee S, 2007, PHARMACOEPIDEM DR S, V16, P1141, DOI 10.1002/pds.1469; Chen H, 2011, PSYCHIAT SERV, V62, P1450, DOI 10.1176/appi.ps.000642011; Cho YS, 2015, PEDIATR DRUGS, V17, P487, DOI 10.1007/s40272-015-0147-z; Choure MK, 2017, ASIAN J PHARM CLIN R, V10, P102, DOI [10.22159/ajpcr.2017. v10i4.16111, DOI 10.22159/AJPCR.2017.V10I4.16111]; Colquhoun HL, 2014, J CLIN EPIDEMIOL, V67, P1291, DOI 10.1016/j.jclinepi.2014.03.013; Comer JS, 2010, J AM ACAD CHILD PSY, V49, P1001, DOI 10.1016/j.jaac.2010.07.007; Connor DF, 1997, J AM ACAD CHILD PSY, V36, P248, DOI 10.1097/00004583-199702000-00016; Constantine RJ, 2010, CLIN THER, V32, P949, DOI 10.1016/j.clinthera.2010.04.021; Coppola G, 2012, SEIZURE-EUR J EPILEP, V21, P340, DOI 10.1016/j.seizure.2012.02.011; Cornblatt BA, 2007, J CLIN PSYCHIAT, V68, P546, DOI 10.4088/JCP.v68n0410; DANIELL AJ, 1989, AUST PAEDIATR J, V25, P207; Daudt HML, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-48; de Souza AS, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0551-8; Goncalves ACD, 2015, INT J CLIN PHARM-NET, V37, P645, DOI 10.1007/s11096-015-0109-0; dosReis S, 2005, J CHILD ADOL PSYCHOP, V15, P68, DOI 10.1089/cap.2005.15.68; dosReis S, 2011, PEDIATRICS, V128, pE1459, DOI 10.1542/peds.2010-2970; Du W, 2006, AM J PERINAT, V23, P279, DOI 10.1055/s-2006-946719; Feinstein J, 2015, PEDIATRICS, V135, pE99, DOI 10.1542/peds.2014-2015; Feinstein JA, 2015, PHARMACOEPIDEM DR S, V24, P1049, DOI 10.1002/pds.3843; Feudtner C, 2012, ARCH PEDIAT ADOL MED, V166, P9, DOI 10.1001/archpediatrics.2011.161; Fincke BG, 2005, PHARMACOEPIDEM DR S, V14, P121, DOI 10.1002/pds.966; Fleischhacker WW, 2014, INT J NEUROPSYCHOPH, V17, P1083, DOI 10.1017/S1461145712000399; Fontanella CA, 2014, PSYCHIAT SERV, V344, P1173; Fontanella CA, 2009, ANN PHARMACOTHER, V43, P1939, DOI 10.1345/aph.1M326; FRIEND DG, 1959, NEW ENGL J MED, V260, P1015, DOI 10.1056/NEJM195905142602005; Gallego JA, 2012, EXPERT OPIN DRUG SAF, V11, P527, DOI 10.1517/14740338.2012.683523; Gnjidic D, 2012, J CLIN EPIDEMIOL, V65, P989, DOI 10.1016/j.jclinepi.2012.02.018; Gyllenberg D, 2012, NORD J PSYCHIAT, V66, P336, DOI 10.3109/08039488.2011.644809; Helal S. I., 2013, Macedonian Journal of Medical Sciences, V6, P174; HEMMINKI E, 1977, ACTA PSYCHIAT SCAND, V56, P347, DOI 10.1111/j.1600-0447.1977.tb06676.x; Hincapie-Castillo JM, 2017, PSYCHIAT SERV; Horace AE, 2015, INTEGR PHARM RES PRA, V4, P113, DOI 10.2147/IPRP.S64535; HOVSTADIUS B, 2009, BMC CLIN PHARM, V9, P1, DOI DOI 10.1186/1472-6904-9-1; Hovstadius Bo, 2010, BMC Clin Pharmacol, V10, P16, DOI 10.1186/1472-6904-10-16; Jameel F, 2012, J CLIN DIAGNOSTIC RE, V6, P1; Jerrell JM, 2008, HUM PSYCHOPHARM CLIN, V23, P283, DOI 10.1002/hup.932; Jurgens Valerie, 2014, Hosp Pediatr, V4, P153, DOI 10.1542/hpeds.2013-0094; Kalilani L, 2017, EPILEPSY BEHAV, V72, P51, DOI 10.1016/j.yebeh.2017.04.017; Kamble P, 2015, PSYCHIAT SERV, V66, P404, DOI 10.1176/appi.ps.201300391; Kanta C, 2014, J PHARM SCI RES, V6, P373; Khalil H, 2016, WORLDV EVID-BASED NU, V13, P118, DOI 10.1111/wvn.12144; Kieran EA, 2014, ACTA PAEDIATR, V103, pE139, DOI 10.1111/apa.12541; Kumar P, 2008, J PEDIATR, V152, P412, DOI 10.1016/j.jpeds.2007.07.050; Lake JK, 2014, J CHILD ADOL PSYCHOP, V24, P486, DOI 10.1089/cap.2014.0011; Landmark CJ, 2007, SEIZURE-EUR J EPILEP, V16, P356, DOI 10.1016/j.seizure.2007.02.006; Larson AM, 2012, EPILEPSIA, V53, P1162, DOI 10.1111/j.1528-1167.2012.03515.x; Lass J, 2011, EUR J CLIN PHARMACOL, V67, P1263, DOI 10.1007/s00228-011-1072-x; Lee BS, 2016, J HLTH CARE FINANCE, P2; Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69; Logan SL, 2015, J CHILD ADOL PSYCHOP, V25, P323, DOI 10.1089/cap.2013.0119; Mandell DS, 2008, PEDIATRICS, V121, pE441, DOI 10.1542/peds.2007-0984; Martin A, 2003, PSYCHIATR SERV, V54, P72, DOI 10.1176/appi.ps.54.1.72; Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2; McIntyre RS, 2008, ARCH PEDIAT ADOL MED, V162, P929, DOI 10.1001/archpedi.162.10.929; McIntyre RS, 2009, J CLIN PSYCHIAT, V70, P240, DOI 10.4088/JCP.08m04212; Mirza NY, 2009, BANGL J PHARMACOL, V4, P39, DOI 10.3329/bjp.v4i1.1062; Morrato EH, 2007, CLIN THER, V29, P183, DOI 10.1016/j.clinthera.2007.01.002; Neubert A, 2010, EUR J CLIN PHARMACOL, V66, P87, DOI 10.1007/s00228-009-0722-8; Ng E, 2002, ANN PHARMACOTHER, V36, P1150, DOI 10.1345/aph.1A328; Novak PH, 2005, BRIT J CLIN PHARMACO, V59, P712, DOI 10.1111/j.1365-2125.2004.02237.x; O'Leary SD, 2006, CHILD NEUROPSYCHOL, V12, P173, DOI 10.1080/09297040500276844; Osama A, 2016, EGYPT J NEUROL PSYCH, V53, P188, DOI 10.4103/1110-1083.192641; Osunsanmi S, 2016, J CHILD ADOL PSYCHOP, V26, P828, DOI 10.1089/cap.2014.0139; Pandey Anuja A, 2010, Indian J Community Med, V35, P70, DOI 10.4103/0970-0218.62564; Pappadopulos E, 2002, SCHIZOPHRENIA BULL, V28, P111, DOI 10.1093/oxfordjournals.schbul.a006913; Peters MDJ, 2015, INT J EVID-BASED HEA, V13, P141, DOI 10.1097/XEB.0000000000000050; Pham MT, 2014, RES SYNTH METHODS, V5, P371, DOI 10.1002/jrsm.1123; Poudel P, 2016, IRAN J CHILD NEUROL, V10, P48; Procyshyn RM, 2014, J CLIN PSYCHOPHARM, V34, P17, DOI 10.1097/JCP.0b013e3182a607dd; Rashed AN, 2012, EUR J CLIN PHARMACOL, V68, P801, DOI 10.1007/s00228-011-1183-4; Rasu RS, 2014, CLINICOECONOMIC OUTC, V6, P515, DOI 10.2147/CEOR.S67424; Reilly C, 2015, EPILEPSIA, V55, P1910; Reilly C, 2014, PEDIATRICS, V133, pE1586, DOI 10.1542/peds.2013-3787; Rizkalla NA, 2013, PEDIAT CRIT CARE MED, V14; Rubin D, 2012, CHILD YOUTH SERV REV, V34, P1492, DOI 10.1016/j.childyouth.2012.04.006; Rubin DM, 2009, PEDIATRICS, V124, pE305, DOI 10.1542/peds.2008-3713; Rushton JL, 2001, ARCH PEDIAT ADOL MED, V155, P560, DOI 10.1001/archpedi.155.5.560; Saldana SN, 2014, PHARMACOTHERAPY, V34, P836, DOI 10.1002/phar.1453; Sammons HM, 2016, CHILDREN-BASEL, V3, DOI 10.3390/children3010001; Schall CA, 2002, FOCUS AUTISM OTHER D, V17, P229; Schubart JR, 2014, AUTISM, V18, P631, DOI 10.1177/1362361313497537; Sharma S, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1512-4; Spencer D, 2013, PEDIATRICS, V132, P833, DOI 10.1542/peds.2012-3774; Stone BL, 2010, ARCH DIS CHILD, V95, P250, DOI 10.1136/adc.2009.167528; Thomas J., 2010, EPPIREVIEWER 4 SOFTW; Thome-Souza S, 2003, PEDIATR NEUROL, V28, P360, DOI 10.1016/S0887-8994(03)00014-6; van Bennekom MWHL, 2013, J PSYCHOPHARMACOL, V27, P327, DOI 10.1177/0269881113477709; Viktil KK, 2007, BRIT J CLIN PHARMACO, V63, P187, DOI 10.1111/j.1365-2125.2006.02744.x; Wang Y, 2016, INT J PHARMACOL, V12, P496, DOI 10.3923/ijp.2016.496.504; Warrier I, 2006, J CLIN PHARMACOL, V46, P449, DOI 10.1177/0091270005285456; Winterstein AG, 2017, J CLIN PSYCHIAT, V78, pE774, DOI 10.4088/JCP.16m10884; Yoon EY, 2012, PEDIATRICS, V129, pE1, DOI 10.1542/peds.2011-0877; Zito JM, 2008, PEDIATRICS, V121, pE157, DOI 10.1542/peds.2007-0212; Zoega H, 2009, J CHILD ADOL PSYCHOP, V19, P757, DOI 10.1089/cap.2009.0003	107	31	33	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2018	13	11							e0208047	10.1371/journal.pone.0208047	http://dx.doi.org/10.1371/journal.pone.0208047			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HC4HL	30496322	Green Submitted, Green Published, gold			2023-01-03	WOS:000451763800084
J	Park, SH; Lim, YD; Jung, YH; Jeung, KW				Park, Se-hyeok; Lim, Yong Deok; Jung, Yong Hun; Jeung, Kyung Woon			Relationship between hemodynamic parameters and severity of ischemia-induced left ventricular wall thickening during cardiopulmonary resuscitation of consistent quality	PLOS ONE			English	Article							HEART-ASSOCIATION GUIDELINES; TIDAL CARBON-DIOXIDE; 2,3-BUTANEDIONE MONOXIME; CARDIAC RESUSCITATION; PIG MODEL; FIBRILLATION; CONTRACTURE; COMPRESSION; PRESSURE; OUTPUT	Ischemia-induced left ventricular (LV) wall thickening compromises the hemodynamic effectiveness of cardiopulmonary resuscitation (CPR). However, accurate assessment of the severity of ischemia-induced LV wall thickening during CPR is challenging. We investigated, in a swine model, whether hemodynamic parameters, including end-tidal carbon dioxide (ETCO2) level, are linearly associated with the severity of ischemia-induced LV wall thickening during CPR of consistent quality. We retrospectively analyzed 96 datasets for ETCO2 level, arterial pressure, LV wall thickness, and the percent of measured end-diastolic volume (%EDV) relative to EDV at the onset of ventricular fibrillation from eight pigs. Animals underwent advanced cardiovascular life support based on resuscitation guidelines. During CPR, LV wall thickness progressively increased while %EDV progressively decreased. Systolic and diastolic arterial pressure and ETCO2 level were significantly correlated with LV wall thickness and % EDV. Linear mixed effect models revealed that, after adjustment for significant covariates, systolic and diastolic arterial pressure were not associated with LV wall thickness or %EDV. ETCO2 level had a significant linear relationship with %EDV (P = 0.004). However, it could explain only 28.2% of the total variance of %EDV in our model. In conclusion, none of the hemodynamic parameters examined in this study appeared to provide sufficient information on the severity of ischemia-induced LV wall thickening.	[Park, Se-hyeok; Lim, Yong Deok; Jung, Yong Hun; Jeung, Kyung Woon] Chonnam Natl Univ Hosp, Dept Emergency Med, Gwangju, South Korea	Chonnam National University; Chonnam National University Hospital	Jeung, KW (corresponding author), Chonnam Natl Univ Hosp, Dept Emergency Med, Gwangju, South Korea.	neoneti@hanmail.net			National Research Foundation of Korea (NRF) - Korean government (MSIT) [NRF-2018R1A2B6001388]	National Research Foundation of Korea (NRF) - Korean government (MSIT)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF-2018R1A2B6001388). The funding source had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ayoub IM, 2003, CIRCULATION, V107, P1804, DOI 10.1161/01.CIR.0000058704.45646.0D; Ayoub IM, 2007, CRIT CARE MED, V35, P2329, DOI 10.1097/01.CCM.0000280569.87413.74; Bakdash JZ, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00456; Berg RA, 2005, CIRCULATION, V111, P1136, DOI 10.1161/01.CIR.0000157147.26869.31; Cho YC, 2011, EMERG MED J, V28, P40, DOI 10.1136/emj.2010.099911; CRILEY JM, 1976, JAMA-J AM MED ASSOC, V236, P1246, DOI 10.1001/jama.236.11.1246; Gazmuri RJ, 2001, CIRCULATION, V104, P234, DOI 10.1161/01.CIR.104.2.234; GUDIPATI CV, 1988, CIRCULATION, V77, P234, DOI 10.1161/01.CIR.77.1.234; Heradstveit BE, 2012, RESUSCITATION, V83, P813, DOI 10.1016/j.resuscitation.2012.02.021; Jaeger BC, 2017, J APPL STAT, V44, P1086, DOI 10.1080/02664763.2016.1193725; Klouche K, 2002, CHEST, V122, P1006, DOI 10.1378/chest.122.3.1006; KLOUCHE K, 2000, CRIT CARE MED S, V28; KORETSUNE Y, 1990, AM J PHYSIOL, V258, pH9, DOI 10.1152/ajpheart.1990.258.1.H9; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; Lah K, 2011, CRIT CARE, V15, DOI 10.1186/cc9417; Lee BK, 2016, AM J EMERG MED, V34, P1053, DOI 10.1016/j.ajem.2016.03.025; Lee BK, 2015, RESUSCITATION, V87, P26, DOI 10.1016/j.resuscitation.2014.11.011; Link MS, 2015, CIRCULATION, V132, pS444, DOI 10.1161/CIR.0000000000000261; MAIER GW, 1984, CIRCULATION, V70, P86, DOI 10.1161/01.CIR.70.1.86; MORIMOTO Y, 1993, CRIT CARE MED, V21, P1572, DOI 10.1097/00003246-199310000-00028; Neumar RW, 2010, CIRCULATION, V122, pS729, DOI 10.1161/CIRCULATIONAHA.110.970988; NIEMANN JT, 1981, CIRCULATION, V64, P985, DOI 10.1161/01.CIR.64.5.985; NIEMANN JT, 1985, ANN EMERG MED, V14, P521, DOI 10.1016/S0196-0644(85)80774-5; ORNATO JP, 1989, ANN EMERG MED, V18, P732, DOI 10.1016/S0196-0644(89)80005-8; Pfaffenberger S, 2013, CIRC-CARDIOVASC IMAG, V6, P1073, DOI 10.1161/CIRCIMAGING.113.000690; RUDIKOFF MT, 1980, CIRCULATION, V61, P345, DOI 10.1161/01.CIR.61.2.345; SANDERS AB, 1985, ANN EMERG MED, V14, P948, DOI 10.1016/S0196-0644(85)80235-3; Sheak KR, 2015, RESUSCITATION, V89, P149, DOI 10.1016/j.resuscitation.2015.01.026; Takino M, 1996, RESUSCITATION, V33, P101, DOI 10.1016/S0300-9572(96)00995-1; WEIL MH, 1985, CRIT CARE MED, V13, P907, DOI 10.1097/00003246-198511000-00011	31	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2018	13	11							e0208140	10.1371/journal.pone.0208140	http://dx.doi.org/10.1371/journal.pone.0208140			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC4EO	30485382	Green Published, gold, Green Submitted			2023-01-03	WOS:000451755800113
J	Paz-Ares, L; Luft, A; Vicente, D; Tafreshi, A; Gumus, M; Mazieres, J; Hermes, B; Senler, FC; Csoszi, T; Fulop, A; Rodriguez-Cid, J; Wilson, J; Sugawara, S; Kato, T; Lee, KH; Cheng, Y; Novello, S; Halmos, B; Li, X; Lubiniecki, GM; Piperdi, B; Kowalski, DM				Paz-Ares, L.; Luft, A.; Vicente, D.; Tafreshi, A.; Gumus, M.; Mazieres, J.; Hermes, B.; Senler, F. Cay; Csoszi, T.; Fulop, A.; Rodriguez-Cid, J.; Wilson, J.; Sugawara, S.; Kato, T.; Lee, K. H.; Cheng, Y.; Novello, S.; Halmos, B.; Li, X.; Lubiniecki, G. M.; Piperdi, B.; Kowalski, D. M.		KEYNOTE-407 Investigators	Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OPEN-LABEL; STAGE IV; THERAPY; CARBOPLATIN; NIVOLUMAB; DOCETAXEL; CRITERIA; PHASE-3; TRENDS	BACKGROUND Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on >= 50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC. METHODS In this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]-paclitaxel for the first 4 cycles. Primary end points were overall survival and progression-free survival. RESULTS After a median follow-up of 7.8 months, the median overall survival was 15.9 months (95% confidence interval [CI], 13.2 to not reached) in the pembrolizumab-combination group and 11.3 months (95% CI, 9.5 to 14.8) in the placebo-combination group (hazard ratio for death, 0.64; 95% CI, 0.49 to 0.85; P<0.001). The overall survival benefit was consistent regardless of the level of PD-Li expression. The median progression-free survival was 6.4 months (95% CI, 6.2 to 8.3) in the pembrolizumabcombination group and 4.8 months (95% CI, 4.3 to 5.7) in the placebo-combination group (hazard ratio for disease progression or death, 0.56; 95% CI, 0.45 to 0.70; P<0.001). Adverse events of grade 3 or higher occurred in 69.8% of the patients in the pembrolizumab-combination group and in 68.2% of the patients in the placebocombination group. Discontinuation of treatment because of adverse events was more frequent in the pembrolizumab-combination group than in the placebo-combination group (13.3% vs. 6.4%). CONCLUSIONS In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone.	[Paz-Ares, L.] Univ Complutense, Spanish Natl Canc Res Ctr, Hosp Univ Octubre 12, Madrid, Spain; [Paz-Ares, L.] Ciberonc, Madrid, Spain; [Vicente, D.] Hosp Univ Virgen Macarena, Seville, Spain; [Luft, A.] Leningrad Reg Clin Hosp, St Petersburg, Russia; [Tafreshi, A.] Wollongong Oncol, Wollongong, NSW, Australia; [Tafreshi, A.] Wollongong Private Hosp, Wollongong, NSW, Australia; [Gumus, M.] Istanbul Medeniyet Univ Hosp, Istanbul, Turkey; [Senler, F. Cay] Ankara Univ, Ankara, Turkey; [Mazieres, J.] Univ Paul Sabatier, Ctr Hosp Univ Toulouse, Toulouse, France; [Hermes, B.] Univ Klinikum Tubingen, Tubingen, Germany; [Csoszi, T.] Jasz Nagykun Szolnok Cty Hosp, Szolnok, Hungary; [Fulop, A.] Orszagos Koranyi TBC & Pulmonol Intezet, Budapest, Hungary; [Rodriguez-Cid, J.] Med Sur Hosp, Ctr Oncol, Mexico City, DF, Mexico; [Wilson, J.] Humber River Reg Hosp, Toronto, ON, Canada; [Sugawara, S.] Sendai Kousei Hosp, Sendai, Miyagi, Japan; [Kato, T.] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan; [Lee, K. H.] Chungbuk Natl Univ, Coll Med, Chungbuk Natl Univ Hosp, Cheongju, South Korea; [Cheng, Y.] Jilin Canc Hosp, Changchun, Jilin, Peoples R China; [Novello, S.] Univ Turin, Orbassano, Italy; [Halmos, B.] Montefiore Med Ctr, Albert Einstein Coll Med, New York, NY USA; [Li, X.; Lubiniecki, G. M.; Piperdi, B.] Merck, Kenilworth, NJ USA; [Kowalski, D. M.] Maria Sklodowska Curie Inst Oncol, Warsaw, Poland	Centro Nacional de Investigaciones Oncologicas (CNIO); Complutense University of Madrid; Hospital Universitario 12 de Octubre; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Hospital Universitario Virgen Macarena; Ankara University; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Sendai Kousei Hospital; Kanagawa Prefectural Cancer Center; Chungbuk National University; Chungbuk National University Hospital; University of Turin; Montefiore Medical Center; Yeshiva University; Merck & Company; Maria Sklodowska-Curie National Research Institute of Oncology	Paz-Ares, L (corresponding author), Hosp Univ 12 Octubre, Dept Med Oncol, Ave Cordoba, Madrid 28041, Spain.	lpazaresr@seom.org	MAZIERES, JULIEN/M-3986-2014; Şenler, Filiz Çay/AAI-1824-2019; van den Heuvel, Michel M/D-9491-2017; Paz-Ares, Luis/AAH-2750-2019; Gumus, Mahmut/C-7135-2008; novello, silvia/K-6335-2016; Provencio, Mariano/ABE-8586-2020	van den Heuvel, Michel M/0000-0002-6372-2153; Provencio, Mariano/0000-0001-9053-9197; Cheng, Ying/0000-0001-9908-597X; Kowalski, Dariusz/0000-0002-9452-3229; Rybkin, Igor/0000-0002-8434-1093; CAY SENLER, FILIZ/0000-0002-7156-4650; Lee, Ki Hyeong/0000-0002-7830-5950; Trigo, Jose/0000-0002-4489-2683; Provencio Pulla, Mariano/0000-0001-6315-7919; SOTO PARRA, HECTOR/0000-0001-7966-4472; Castonguay, Vincent/0000-0001-8053-4026; Kollmeier, Jens/0000-0002-8048-3895; MORO-SIBILOT, Denis/0000-0001-6776-8610; Piperdi, Bilal/0000-0002-1315-3175	Merck Sharp Dohme	Merck Sharp Dohme(Merck & Company)	Supported by Merck Sharp & Dohme.	BORGHAEI H, 2018, J CLIN ONCOL S, V36; Borghaei H, 2018, J THORAC ONCOL; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Cheng TYD, 2016, J THORAC ONCOL, V11, P1653, DOI 10.1016/j.jtho.2016.05.021; Cutica I, 2014, EUR J INTERN MED, V25, P685, DOI 10.1016/j.ejim.2014.07.002; Edge S.B., 2010, AJCC CANC STAGING MA, V649; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Govindan R, 2017, J CLIN ONCOL, V35, P3449, DOI 10.1200/JCO.2016.71.7629; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Jotte RM, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.18_suppl.LBA9000; Langer CJ, 2016, LANCET ONCOL, V17, P1497, DOI 10.1016/S1470-2045(16)30498-3; Lopes G, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.18_suppl.LBA4; Lortet-Tieulent J, 2014, LUNG CANCER, V84, P13, DOI 10.1016/j.lungcan.2014.01.009; Marrone K, 2017, J THORAC ONCOL, V12, pS893, DOI 10.1016/j.jtho.2016.11.1219; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Roach C, 2016, APPL IMMUNOHISTO M M, V24, P392, DOI 10.1097/PAI.0000000000000408; Socinski MA, 2018, J THORAC ONCOL, V13, P165, DOI 10.1016/j.jtho.2017.11.111; Soldera SV, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00050; Thatcher N, 2015, LANCET ONCOL, V16, P763, DOI 10.1016/S1470-2045(15)00021-2	25	1815	1885	15	151	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 22	2018	379	21					2040	2051		10.1056/NEJMoa1810865	http://dx.doi.org/10.1056/NEJMoa1810865			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB1VX	30280635	Bronze, Green Published			2023-01-03	WOS:000450816900009
J	Turner, NC; Slamon, DJ; Ro, J; Bondarenko, I; Im, SA; Masuda, N; Colleoni, M; DeMichele, A; Loi, S; Verma, S; Iwata, H; Harbeck, N; Loibl, S; Andre, F; Puyana Theall, K; Huang, X; Giorgetti, C; Huang Bartlett, C; Cristofanilli, M				Turner, N. C.; Slamon, D. J.; Ro, J.; Bondarenko, I; Im, S-A; Masuda, N.; Colleoni, M.; DeMichele, A.; Loi, S.; Verma, S.; Iwata, H.; Harbeck, N.; Loibl, S.; Andre, F.; Puyana Theall, K.; Huang, X.; Giorgetti, C.; Huang Bartlett, C.; Cristofanilli, M.			Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOCRINE THERAPY; COMBINATION; ABEMACICLIB; PROGRESSION; LETROZOLE; WOMEN; PLUS	BACKGROUND The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We report the results of a prespecified analysis of overall survival. METHODS We randomly assigned patients with hormone-receptor-positive, HER2-negative advanced breast cancer who had progression or relapse during previous endocrine therapy to receive palbociclib plus fulvestrant or placebo plus fulvestrant. We analyzed overall survival; the effect of palbociclib according to the prespecified stratification factors of presence or absence of sensitivity to endocrine therapy, presence or absence of visceral metastatic disease, and menopausal status; the efficacy of subsequent therapies after disease progression; and safety. RESULTS Among 521 patients who underwent randomization, the median overall survival was 34.9 months (95% confidence interval (CI), 28.8 to 40.0) in the palbociclib-fulvestrant group and 28.0 months (95% CI, 23.6 to 34.6) in the placebo-fulvestrant group (hazard ratio for death, 0.81; 95% CI, 0.64 to 1.03; P=0.09; absolute difference, 6.9 months). CDK416 inhibitor treatment after the completion of the trial regimen occurred in 16% of the patients in the placebo-fulvestrant group. Among 410 patients with sensitivity to previous endocrine therapy, the median overall survival was 39.7 months (95% CI, 34.8 to 45.7) in the palbociclib-fulvestrant group and 29.7 months (95% CI, 23.8 to 37.9) in the placebo-fulvestrant group (hazard ratio, 0.72; 95% CI, 0.55 to 0.94; absolute difference, 10.0 months). The median duration of subsequent therapy was similar in the two groups, and the median time to the receipt of chemotherapy was 17.6 months in the palbociclib-fulvestrant group, as compared with 8.8 months in the placebo-fulvestrant group (hazard ratio, 0.58; 95% CI, 0.47 to 0.73; P<0.001). No new safety signals were observed with 44.8 months of follow-up. CONCLUSIONS Among patients with hormone-receptor-positive, HER2-negative advanced breast cancer who had sensitivity to previous endocrine therapy, treatment with palbociclib-fulvestrant resulted in longer overall survival than treatment with placebo-fulvestrant. The differences in overall survival in the entire trial group were not significant.	[Turner, N. C.] Inst Canc Res, Fulham Rd, London SW3 6JJ, England; [Turner, N. C.] Royal Marsden Hosp, Fulham Rd, London SW3 6JJ, England; [Slamon, D. J.] Univ Calif Los Angeles, David Geffen Sch Med, Santa Monica, CA USA; [Huang, X.] Pfizer Oncol, San Diego, CA USA; [Ro, J.] Natl Canc Ctr, Goyang Si, Gyeonggi Do, South Korea; [Im, S-A] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul Natl Univ Hosp, Seoul, South Korea; [Bondarenko, I] Dnipropetrovsk Med Acad, City Multiple Discipline Clin Hosp 4, Dnepropetrovsk, Ukraine; [Masuda, N.] Natl Hosp Org Osaka Natl Hosp, Osaka, Japan; [Iwata, H.] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan; [Colleoni, M.] Ist Europeo Oncol, Milan, Italy; [Giorgetti, C.] Pfizer Oncol, Milan, Italy; [DeMichele, A.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Huang Bartlett, C.] Pfizer Oncol, Collegeville, PA USA; [Loi, S.] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Verma, S.] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada; [Harbeck, N.] Brustzentrum Univ Munchen, Munich, Germany; [Loibl, S.] German Breast Grp, Neu Isenburg, Germany; [Andre, F.] Inst Gustave Roussy, Villejuif, France; [Puyana Theall, K.] Pfizer Oncol, Cambridge, MA USA; [Cristofanilli, M.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Pfizer; National Cancer Center - Korea (NCC); Seoul National University (SNU); Seoul National University Hospital; Dnipro State Medical University; Osaka National Hospital; Aichi Cancer Center; IRCCS European Institute of Oncology (IEO); Pfizer; University of Pennsylvania; Pennsylvania Medicine; Pfizer; Peter Maccallum Cancer Center; University of Melbourne; Tom Baker Cancer Clinic; University of Calgary; University of Munich; German Breast Group; UNICANCER; Gustave Roussy; Pfizer; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Turner, NC (corresponding author), Inst Canc Res, Fulham Rd, London SW3 6JJ, England.; Turner, NC (corresponding author), Royal Marsden Hosp, Fulham Rd, London SW3 6JJ, England.	nick.turner@icr.ac.uk	Loi, Sherene/H-1979-2016; MASUDA, NORIKAZU/AAM-2417-2021; Bondarenko, Igor/W-9412-2019; ANDRE, Fabrice/AAL-2683-2020; Bondarenko, Igor N/GQP-1497-2022	Loi, Sherene/0000-0001-6137-9171; MASUDA, NORIKAZU/0000-0002-7302-0278; Bondarenko, Igor/0000-0002-7071-2471; ANDRE, Fabrice/0000-0001-5795-8357; Bondarenko, Igor N/0000-0002-7071-2471; Turner, Nicholas/0000-0001-8937-0873	Pfizer	Pfizer(Pfizer)	Supported by Pfizer.	[Anonymous], 2018, N Engl J Med, V379, P2582, DOI 10.1056/NEJMx180043; Broglio KR, 2009, JNCI-J NATL CANCER I, V101, P1642, DOI 10.1093/jnci/djp369; Cardoso F, 2017, BREAST, V31, P244, DOI 10.1016/j.breast.2016.10.001; Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0; Dmitrienko A, 2018, NEW ENGL J MED, V378, P2115, DOI 10.1056/NEJMra1709701; Finn RS, 2016, NEW ENGL J MED, V375, P1925, DOI 10.1056/NEJMoa1607303; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Glimm E, 2010, STAT MED, V29, P219, DOI 10.1002/sim.3748; Goetz MP, 2017, J CLIN ONCOL, V35, P3638, DOI 10.1200/JCO.2017.75.6155; Hortobagyi GN, 2018, ANN ONCOL, V29, P1541, DOI 10.1093/annonc/mdy155; Howlader N, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju055; Loibl S, 2017, ONCOLOGIST, V22, P1028, DOI 10.1634/theoncologist.2017-0072; O'Leary B, 2018, CANC DISCOV; O'Leary B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03215-x; O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26; ROBINS JM, 1991, COMMUN STAT THEORY, V20, P2609, DOI 10.1080/03610929108830654; Rugo HS, 2016, J CLIN ONCOL, V34, P3069, DOI 10.1200/JCO.2016.67.1487; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Slamon DJ, 2018, J CLIN ONCOL, V36, P2465, DOI 10.1200/JCO.2018.78.9909; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sledge GW, 2017, J CLIN ONCOL, V35, P2875, DOI 10.1200/JCO.2017.73.7585; Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270; Watkins C, 2013, PHARM STAT, V12, P348, DOI 10.1002/pst.1602	24	531	544	1	54	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 15	2018	379	20					1926	1936		10.1056/NEJMoa1810527	http://dx.doi.org/10.1056/NEJMoa1810527			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA2FL	30345905	Bronze			2023-01-03	WOS:000450049800007
J	Starbuck, KD; Szender, JB; Duncan, WD; Morrell, K; Etter, JL; Zsiros, E; Odunsi, K; Moysich, K; Eng, KH				Starbuck, Kristen D.; Szender, J. Brian; Duncan, William D.; Morrell, Kayla; Etter, John Lewis; Zsiros, Emese; Odunsi, Kunle; Moysich, Kirsten; Eng, Kevin H.			Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer	PLOS ONE			English	Article							DEBULKING SURGERY; SURVIVAL; DELAY	Objective We aimed to investigate the prognostic impact of duration of first-line chemotherapy administration in patients with epithelial ovarian cancer (EOC). Methods Chemotherapy records were abstracted from the electronic medical record. Patients with on-time completion (105 days) were compared to patients finishing early (<105 days), delays of 1-4 weeks, or >4 weeks. For 222 women with stage IIIC/IV, stage-stratified estimates of progression-free survival (PFS) and overall survival (OS) were compared. A delay sub-study was performed with outliers removed. Each week of delay was correlated with the change in PFS and OS to identify time points associated with change in outcome. Results Most women had on-time completion of chemotherapy (23.6%) or a treatment delay of <= 4 weeks (21.8%); 21.6% of women experienced a delay longer than 4 weeks. R0 resection at initial debulking (OR = 1.99, 95%CI: 1.18-3.36, p = 0.010) and RECIST complete response (OR = 4.88, 95%CI: 2.47-10.63, p<0.001) were strongly associated with on-time completion. Patients with on-time completion and < 1 month delay had similar median survivals of 43.1 months (lower 95% CI bound 33.7 months) and 44.5 months (lower bound 37.0, p = 0.93). Women with >1 month delay had decreased median survival of 18.1 months (14.7-24.9 months), while women with short intervals survived 35.0 months (95%CI: 21.8-49.8 months). Short-term delays lead to progressively decreasing OS. This was significantly different from the on-schedule survival estimate after 6 weeks of delay. Conclusions On-time completion of chemotherapy correlates with increased survival and higher complete response rates. Increasing delays in chemotherapy completion were associated with decreased survival.	[Starbuck, Kristen D.; Szender, J. Brian; Zsiros, Emese; Odunsi, Kunle] Roswell Pk Comprehens Canc Ctr, Dept Gynecol Oncol, Buffalo, NY USA; [Duncan, William D.; Morrell, Kayla; Eng, Kevin H.] Roswell Pk Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY 14203 USA; [Etter, John Lewis; Moysich, Kirsten] Roswell Pk Comprehens Canc Ctr, Dept Canc Prevent & Control, Buffalo, NY USA; [Szender, J. Brian] START Ctr Canc Care, San Antonio, TX USA; [Etter, John Lewis] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Eng, KH (corresponding author), Roswell Pk Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY 14203 USA.	kevin.eng@roswellpark.org	Zsiros, Emese/AAM-4469-2021	Starbuck, Kristen/0000-0003-2294-2915; Zsiros, Emese/0000-0003-0142-7375; Duncan, William/0000-0001-9625-1899	Roswell Park Alliance Foundation; National Institute of Health [1K01LM012100, T32CA108456]; RPCI-UPCI Ovarian Cancer [SPORE P50CA159981-01A1]; National Cancer Institute [P30CA016056]; Roswell Park Comprehensive Cancer Center; Pathology Resource Network; Clinical Data Network; NATIONAL CANCER INSTITUTE [T32CA108456, P30CA016056, P50CA159981] Funding Source: NIH RePORTER	Roswell Park Alliance Foundation; National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RPCI-UPCI Ovarian Cancer; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Roswell Park Comprehensive Cancer Center; Pathology Resource Network; Clinical Data Network; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Roswell Park Alliance Foundation, National Institute of Health grants 1K01LM012100 to KHE, T32CA108456 to KDS, and RPCI-UPCI Ovarian Cancer SPORE P50CA159981-01A1 to KO. This work was also supported by National Cancer Institute grant P30CA016056. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by Roswell Park Comprehensive Cancer Center's shared resources including the Pathology Resource Network and Clinical Data Network.	Alletti SG, 2016, GYNECOL ONCOL, V143, P516, DOI 10.1016/j.ygyno.2016.10.017; Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390; Corrado G, 2015, INT J GYNECOL CANCER, V25, P1253, DOI 10.1097/IGC.0000000000000491; Eilers PHC, 1996, STAT SCI, V11, P89, DOI 10.1214/ss/1038425655; Eng KH, 2015, ONCOTARGET, V6, P36308, DOI 10.18632/oncotarget.6121; Joseph N., 2015, J GENIT SYST DISORD, V4, P4, DOI DOI 10.4172/2325-9728.1000144; Melamed A, 2016, GYNECOL ONCOL, V143, P236, DOI 10.1016/j.ygyno.2016.09.002; Nagel CI, 2012, GYNECOL ONCOL, V124, P221, DOI 10.1016/j.ygyno.2011.10.003; Seagle BLL, 2017, GYNECOL ONCOL, V144, P260, DOI 10.1016/j.ygyno.2016.11.022; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Szender JB, 2017, GYNECOL ONCOL, V146, P491, DOI 10.1016/j.ygyno.2017.06.008; Szender JB, 2017, GYNECOL ONCOL, V145, P420, DOI 10.1016/j.ygyno.2017.03.509; Tewari KS, 2016, ANN ONCOL, V27, P114, DOI 10.1093/annonc/mdv500; Wright JD, 2012, OBSTET GYNECOL, V120, P871, DOI 10.1097/AOG.0b013e31826981de	14	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2018	13	11							e0206913	10.1371/journal.pone.0206913	http://dx.doi.org/10.1371/journal.pone.0206913			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA0PF	30418985	Green Submitted, Green Published, gold			2023-01-03	WOS:000449909200024
J	Spada, TC; Silva, JMRD; Francisco, LS; Marcal, LJ; Antonangelo, L; Zanetta, DMT; Yu, L; Burdmann, EA				Spada, Tania C.; Silva, Jose M. R. D.; Francisco, Lucila S.; Marcal, Lia J.; Antonangelo, Leila; Zanetta, Dirce M. T.; Yu, Luis; Burdmann, Emmanuel A.			High intensity resistance training causes muscle damage and increases biomarkers of acute kidney injury in healthy individuals	PLOS ONE			English	Article							EXERCISE-INDUCED RHABDOMYOLYSIS; PHYSICAL-ACTIVITY; ANAEROBIC CAPACITY; KNOWLEDGE; RECOVERY; SEPSIS; PANEL	Purpose High-intensity interval resistance training (HIIRT) is an increasingly popular exercise program that provides positive results with short sessions. This study aimed to evaluate whether an HIIRT session causes muscle and kidney damage. Methods Fifty-eight healthy volunteers (median age 24 years, 50% women) participated in this study and performed a HIIRT session. The Borg CR10 scale for pain (CR1OP) and blood and urine samples were collected before (baseline) and 2 and 24 hours after the HIIRT session. Blood samples were analyzed for serum creatinine (SCr), creatine kinase (CK) and myoglobin. Urine samples were assessed for creatinine, neutrophil gelatinase-associated lipocalin, interleukin 18, calbindin, microalbuminuria, trefoil factor-3 and beta-2 microglobulin. Results CR10P had a significant increase at 2 and 24 hours post-workout, and CK increased significantly at 2 hours and increased further at 24 hours. Myoglobin increased significantly at 2 hours and remained elevated at 24 hours. SCr increased modestly but significantly at 24 hours only in men. Three men met the KDIGO diagnostic criteria for acute kidney injury. The urinary kidney injury biomarkers increased significantly at 2 hours and returned to the baseline values 24 hours after HIIRT. Conclusions A single HIIRT session caused early and significant elevations in CK, myoglobin, SCr, microalbuminuria and urinary biomarkers indicative of kidney tubular injury, suggesting the occurrence of muscle and kidney damage.	[Spada, Tania C.; Yu, Luis; Burdmann, Emmanuel A.] Univ Sao Paulo, Med Sch, Div Nephrol, Sao Paulo, Brazil; [Spada, Tania C.; Yu, Luis; Burdmann, Emmanuel A.] Univ Sao Paulo, Med Sch, LIM 12, Sao Paulo, Brazil; [Spada, Tania C.; Yu, Luis; Burdmann, Emmanuel A.] Hosp Clin Sao Paulo, Sao Paulo, Brazil; [Silva, Jose M. R. D.] Sao Paulo State Univ, Sch Sci, Bauru, Brazil; [Francisco, Lucila S.] Univ Guarulhos, Div Sports, Guarulhos, Brazil; [Marcal, Lia J.; Antonangelo, Leila] Univ Sao Paulo, Med Sch, Hosp Clin, Dept Pathol,Clin Lab, Sao Paulo, Brazil; [Marcal, Lia J.; Antonangelo, Leila] Univ Sao Paulo, Med Sch, Hosp Clin, LIM 3, Sao Paulo, Brazil; [Zanetta, Dirce M. T.] Univ Sao Paulo, Sch Publ Hlth, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade Estadual Paulista; Universidade Guarulhos; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo	Burdmann, EA (corresponding author), Univ Sao Paulo, Med Sch, Div Nephrol, Sao Paulo, Brazil.; Burdmann, EA (corresponding author), Univ Sao Paulo, Med Sch, LIM 12, Sao Paulo, Brazil.; Burdmann, EA (corresponding author), Hosp Clin Sao Paulo, Sao Paulo, Brazil.	burdmann@usp.br	Zanetta, Dirce M T/G-4950-2013; Antonangelo, Leila/H-9998-2012; Burdmann, Emmanuel/AAY-1966-2020; Burdmann, Emmanuel/B-7023-2009; Yu, Luis/E-8735-2012	Antonangelo, Leila/0000-0002-8634-5100; Burdmann, Emmanuel/0000-0002-7644-8579; Yu, Luis/0000-0001-9102-0063; Zanetta, Dirce Maria/0000-0002-7273-5087	"Conselho Nacional de Desenvolvimento Cientifico e Tecnologico" (CNPq - National Counsel of Technological and Scientific Development), Brazil [CNPq 133977/2015-3, CNPq 305858/2013-0]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo Research Foundation), Sao Paulo, Brazil [FAPESP 2014/19286-4]	"Conselho Nacional de Desenvolvimento Cientifico e Tecnologico" (CNPq - National Counsel of Technological and Scientific Development), Brazil; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo Research Foundation), Sao Paulo, Brazil(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	Tania C. Spada was a recipient of a master degree grant, CNPq 133977/2015-3, from "Conselho Nacional de Desenvolvimento Cientifico e Tecnologico" (CNPq - National Counsel of Technological and Scientific Development), Brazil from 2015 to 2017. Emmanuel A. Burdmann is a recipient of the following research grants: CNPq 305858/2013-0 from "Conselho Nacional de Desenvolvimento Cientifico e Tecnologico" (CNPq - National Counsel of Technological and Scientific Development), Brazil and FAPESP 2014/19286-4 from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo Research Foundation), Sao Paulo, Brazil. There was no specific funding for this study. The authors declare that they have no other relevant financial interests.	Aalborg C, 2016, TIDSSKR NORSKE LAEGE, V136, P1532, DOI 10.4045/tidsskr.15.1207; Almada C, 2013, J PHYSIOL BIOCHEM, V69, P85, DOI 10.1007/s13105-012-0191-x; An RP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168175; Apeland Terje, 2017, BMJ Open Sport Exerc Med, V3, pe000241, DOI 10.1136/bmjsem-2017-000241; Argyropoulos CP, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00073; Arulkumaran N, 2017, CRIT CARE MED, V45, pE821, DOI 10.1097/CCM.0000000000002381; Astor BC, 2011, AM J NEPHROL, V34, P291, DOI 10.1159/000330699; Bhakthavatsalam R K, 2016, Indian J Nephrol, V26, P449; Bird Stephen R, 2016, BMJ Open Sport Exerc Med, V2, pe000143, DOI 10.1136/bmjsem-2016-000143; Borg G., 2000, ESCALAS BORG DOR ESF; Cervellin G, 2017, CLIN BIOCHEM, V50, P656, DOI 10.1016/j.clinbiochem.2017.02.016; Charlton JR, 2014, NEPHROL DIAL TRANSPL, V29, P1301, DOI 10.1093/ndt/gft510; Chugh Atul, 2007, J Clin Hypertens (Greenwich), V9, P196, DOI 10.1111/j.1524-6175.2007.06445.x; Coons SJ, 2009, CLIN THER, V31, P2572, DOI 10.1016/j.clinthera.2009.11.035; Deferrari G, 2018, NEPHROL DIAL TRANSPL, V33, P813, DOI 10.1093/ndt/gfx210; Dieterle F, 2010, NAT BIOTECHNOL, V28, P463, DOI 10.1038/nbt.1622; Du TY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080271; Endre ZH, 2014, NEPHRON CLIN PRACT, V127, P101, DOI 10.1159/000363678; Fardal H, 2016, TIDSSKR NORSKE LAEGE, V136, P1537, DOI 10.4045/tidsskr.16.0042; Feng MC, 2016, J CLIN LAB ANAL, V30, P1037, DOI 10.1002/jcla.21977; Foster C, 2015, J SPORT SCI MED, V14, P747; Gibala MJ, 2008, EXERC SPORT SCI REV, V36, P58, DOI 10.1097/JES.0b013e318168ec1f; Gleason Patrick T, 2017, Curr Treat Options Cardiovasc Med, V19, P79, DOI 10.1007/s11936-017-0578-7; Pitanga FJG, 2017, SAO PAULO MED J, V135, P391, DOI 10.1590/1516-3180.2017.0023190317; Henstridge DC, 2016, J APPL PHYSIOL, V120, P683, DOI 10.1152/japplphysiol.00811.2015; Hoffmann D, 2010, TOXICOLOGY, V277, P49, DOI 10.1016/j.tox.2010.08.013; Honda S, 2017, INTERNAL MED, V56, P1175, DOI 10.2169/internalmedicine.56.7636; Huynh A, 2016, INTERN MED J, V46, P602, DOI 10.1111/imj.13055; Kashani K, 2017, CLIN CHEM LAB MED, V55, P1074, DOI 10.1515/cclm-2016-0973; Kirwan JP, 2017, CLEV CLIN J MED, V84, pS15, DOI 10.3949/ccjm.84.s1.03; Lazzeri C, 2012, SCAND CARDIOVASC J, V46, P324, DOI 10.3109/14017431.2012.702919; Mansour SG, 2017, AM J KIDNEY DIS, V70, P252, DOI 10.1053/j.ajkd.2017.01.045; Nejat M, 2012, KIDNEY INT, V81, P1254, DOI 10.1038/ki.2012.23; Paoli A, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-237; Pennemans V, 2013, CLIN CHEM LAB MED, V51, P1795, DOI 10.1515/cclm-2013-0157; Rinnert M, 2010, CELL TISSUE RES, V339, P639, DOI 10.1007/s00441-009-0913-8; SHAIKH Q A, 1991, JPMA (Journal of the Pakistan Medical Association), V41, P314; Shephard RJ, 2016, J SPORT MED PHYS FIT, V56, P1060; Smith LP, 2014, SOC SCI MED, V120, P126, DOI 10.1016/j.socscimed.2014.09.010; Tabata I, 1996, MED SCI SPORT EXER, V28, P1327, DOI 10.1097/00005768-199610000-00018; Warburton DER, 2017, CURR OPIN CARDIOL, V32, P541, DOI 10.1097/HCO.0000000000000437; Zhao CH, 2017, NEUROPSYCH DIS TREAT, V13, P91, DOI 10.2147/NDT.S124630	42	23	25	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2018	13	11							e0205791	10.1371/journal.pone.0205791	http://dx.doi.org/10.1371/journal.pone.0205791			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ4NU	30399190	Green Submitted, Green Published, gold			2023-01-03	WOS:000449374000003
J	Francisco, CD; Bhatawadekar, SA; Babineau, J; Reid, WD; Yadollahi, A				Francisco, Cristina de Oliveira; Bhatawadekar, Swati Anil; Babineau, Jessica; Reid, W. Darlene; Yadollahi, Azadeh			Effects of physical exercise training on nocturnal symptoms in asthma: Systematic review	PLOS ONE			English	Review							QUALITY-OF-LIFE; PULMONARY REHABILITATION PROGRAM; DECREASED STEROID RESPONSIVENESS; OBESE ADULTS; WEIGHT-LOSS; AEROBIC EXERCISE; SLEEP QUALITY; GLOBAL BURDEN; CHILDREN; INFLAMMATION	Introduction Nocturnal worsening of asthma symptoms is a common feature of asthma. Physical exercise training improves general asthma control; however, there is no evidence showing the effects of physical exercise on nocturnal asthma symptoms. Indeed, asthma patients with daytime and nighttime symptoms are physiologically different, and thus the effects of physical exercise on asthma may also be different in these two groups. The objective of this systematic review is to explore the effects of physical exercise on nocturnal asthma symptoms. Methods Searches were conducted in MEDLINE, Embase, Cochrane Central Register of Controlled Trials, CINAHL and SPORTdiscus (last search on November 2017). Authors from studies that did not report nocturnal symptoms but used questionnaires and/or diaries were contacted for detailed information. Studies that provided results on nocturnal symptoms before and after physical activity intervention were included. Prevalence of nocturnal symptoms was calculated for each study from the percentage of study participants with nocturnal symptoms before and after intervention. Results Eleven studies were included (5 with children and 6 with adults). The prevalence of nocturnal symptoms at baseline ranged from 0% to 63% among children and from 50-73% among adults. In children and adults with nocturnal asthma, aerobic physical exercise reduced the prevalence and frequency of nocturnal symptoms. Conclusions Aerobic physical exercise improves nocturnal asthma in children and adults by reducing the prevalence and frequency of nocturnal symptoms. Physical exercise training could be used with conventional treatments to improve quality of life and asthma control in patients with nocturnal worsening of asthma.	[Francisco, Cristina de Oliveira; Bhatawadekar, Swati Anil; Babineau, Jessica; Yadollahi, Azadeh] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON, Canada; [Reid, W. Darlene] Univ Toronto, Dept Phys Therapy, Toronto, ON, Canada; [Yadollahi, Azadeh] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto Rehabilitation Institute; University of Toronto; University of Toronto	Yadollahi, A (corresponding author), Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON, Canada.; Yadollahi, A (corresponding author), Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada.	Azadeh.Yadollahi@uhn.ca	; Babineau, Jessica/H-5449-2015	Francisco, Cristina/0000-0002-3173-3149; Babineau, Jessica/0000-0002-4770-0579; Bhatawadekar, Swati/0000-0002-2980-055X; Yadollahi, Azadeh/0000-0002-3216-8997	Canadian Research Respiratory Network (CRRN); Allergen NCE; CIHR-Institute of Circulatory and Respiratory Health; Canadian Lung Association (CLA)/Canadian Thoracic Society (CTS)	Canadian Research Respiratory Network (CRRN); Allergen NCE; CIHR-Institute of Circulatory and Respiratory Health(Canadian Institutes of Health Research (CIHR)); Canadian Lung Association (CLA)/Canadian Thoracic Society (CTS)	This work was supported by grants from Canadian Research Respiratory Network (CRRN) and Allergen NCE. CRRN is supported by grants from CIHR-Institute of Circulatory and Respiratory Health and the Canadian Lung Association (CLA)/Canadian Thoracic Society (CTS). The funders had no role in the study design, data collection and analysis, or preparation of the manuscript.	Latorre-Roman PA, 2014, J ASTHMA, V51, P544, DOI 10.3109/02770903.2014.888573; Aronow WS, 2011, CIRCULATION, V123, pE616, DOI [10.1161/CIR.0b013e31821daaf6, 10.1161/CIR.0b013e318222d03f]; Bahadori Katayoun, 2009, BMC Pulm Med, V9, P24, DOI 10.1186/1471-2466-9-24; Ballard RD, 2005, PRIMARY CARE, V32, P511, DOI 10.1016/j.pop.2005.03.002; BARNES PJ, 1988, AM J MED, V85, P64, DOI 10.1016/0002-9343(88)90245-8; Basaran S, 2006, J REHABIL MED, V38, P130, DOI 10.1080/16501970500476142; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bellia V, 2000, J ASTHMA, V37, P595, DOI 10.3109/02770900009090815; Bhatawadekar SA, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.01012; Bhatawadekar SA, 2017, J APPL PHYSIOL, V122, P809, DOI 10.1152/japplphysiol.00969.2016; Bingol Karakoc G, 2000, Allergol Immunopathol (Madr), V28, P12; Bohadana AB, 2002, J ASTHMA, V39, P85, DOI 10.1081/JAS-120002190; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; Boyd AW, 2011, J ALLERGY CLIN IMMUN, V127, pAB223, DOI 10.1016/j.jaci.2010.12.887; Boyd A, 2012, ALLERGY ASTHMA CL IM, V8, DOI 10.1186/1710-1492-8-13; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Buysse D J, 1989, Psychiatry Res, V28, P193; Calhoun WJ, 2003, CHEST, V123, p399S, DOI 10.1378/chest.123.3_suppl.399S; Carson KV, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001116.pub4; Colice Gene L, 2004, Clin Med Res, V2, P155; Colice GL, 1999, AM J RESP CRIT CARE, V160, P1962, DOI 10.1164/ajrccm.160.6.9902112; Colice GL, 2002, CURR OPIN PULM MED, V8, P4, DOI 10.1097/00063198-200201000-00002; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; COX NJM, 1993, LUNG, V171, P235, DOI 10.1007/BF00203723; de Andrade LB, 2014, RESP MED, V108, P1438, DOI 10.1016/j.rmed.2014.07.009; Gomes ELDD, 2015, WORLD J CLIN CASES, V3, P301, DOI 10.12998/wjcc.v3.i3.301; DESJARDIN JA, 1995, AM J RESP CRIT CARE, V152, P193, DOI 10.1164/ajrccm.152.1.7599823; Diette GB, 2000, ARCH PEDIAT ADOL MED, V154, P923, DOI 10.1001/archpedi.154.9.923; Dogra S, 2011, EUR RESPIR J, V37, P318, DOI 10.1183/09031936.00182209; Dogra S, 2010, J ASTHMA, V47, P972, DOI 10.1080/02770903.2010.508857; Eichenberger PA, 2013, SPORTS MED, V43, P1157, DOI 10.1007/s40279-013-0077-2; Fanelli A, 2007, MED SCI SPORT EXER, V39, P1474, DOI 10.1249/mss.0b013e3180d099ad; FITCH KD, 1976, ARCH DIS CHILD, V51, P190, DOI 10.1136/adc.51.3.190; FITZPATRICK MF, 1991, THORAX, V46, P569, DOI 10.1136/thx.46.8.569; Foglio K, 1999, EUR RESPIR J, V13, P125, DOI 10.1183/09031936.99.13112599; Franca-Pinto A, 2015, THORAX, V70, P732, DOI 10.1136/thoraxjnl-2014-206070; Freitas PD, 2017, AM J RESP CRIT CARE, V195, P32, DOI [10.1164/rccm.201603-0446OC, 10.1164/rccm.201603-0446oc]; Gomes ELFD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135433; Gonçalves RC, 2008, Braz. J. Phys. Ther., V12, P127, DOI 10.1590/S1413-35552008000200009; Haines MS, 2013, AM J HEALTH EDUC, V44, P156, DOI 10.1080/19325037.2013.779905; Hallstrand TS, 2000, CHEST, V118, P1460, DOI 10.1378/chest.118.5.1460; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; HOLZER FJ, 1984, AUST PAEDIATR J, V20, P297; HUDGEL DW, 1984, J APPL PHYSIOL, V57, P1319, DOI 10.1152/jappl.1984.57.5.1319; Irvin CG, 2000, AM J RESP CRIT CARE, V161, P50, DOI 10.1164/ajrccm.161.1.9804053; Juniper EF, 2010, EUR RESPIR J, V36, P1410, DOI 10.1183/09031936.00117509; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; Kraft M, 2001, AM J RESP CRIT CARE, V163, P1219, DOI 10.1164/ajrccm.163.5.2002058; Kraft M, 1999, J ALLERGY CLIN IMMUN, V103, P66, DOI 10.1016/S0091-6749(99)70527-0; Kraft M, 2001, AM J RESP CRIT CARE, V163, P1551, DOI 10.1164/ajrccm.163.7.2008013; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Ma J, 2015, ANN AM THORAC SOC, V12, P1, DOI 10.1513/AnnalsATS.201406-271OC; Majewski M, 2015, ADV CLIN EXP MED, V24, P1079, DOI 10.17219/acem/31679; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Matsumoto I, 1999, THORAX, V54, P196, DOI 10.1136/thx.54.3.196; Mendelson M, 2016, EUR RESPIR J, V48, P142, DOI 10.1183/13993003.01897-2015; Mendes FAR, 2010, CHEST, V138, P331, DOI 10.1378/chest.09-2389; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Moreira A, 2008, EUR RESPIR J, V32, P1570, DOI 10.1183/09031936.00171707; MULLER N, 1979, J APPL PHYSIOL, V47, P279, DOI 10.1152/jappl.1979.47.2.279; MULLER NL, 1980, AM REV RESPIR DIS, V121, P463, DOI 10.1164/arrd.1980.121.3.463; Neder JA, 1999, THORAX, V54, P202, DOI 10.1136/thx.54.3.202; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Pastva A, 2004, J IMMUNOL, V172, P4520, DOI 10.4049/jimmunol.172.7.4520; Prasad B, 2014, SLEEP MED REV, V18, P165, DOI 10.1016/j.smrv.2013.04.004; Raherison C, 2006, J ASTHMA, V43, P199, DOI 10.1080/02770900600566744; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Refaat A, 2015, EGYPT J CHEST DIS TU, V64, P761, DOI 10.1016/j.ejcdt.2015.07.004; ROBINSON DM, 1992, NEW ZEAL MED J, V105, P253; Mendes FAR, 2011, MED SCI SPORT EXER, V43, P197, DOI 10.1249/MSS.0b013e3181ed0ea3; SCHNALL R, 1982, AUST PAEDIATR J, V18, P23; Scott HA, 2013, CLIN EXP ALLERGY, V43, P36, DOI 10.1111/cea.12004; Scott HA, 2015, RESPIROLOGY, V20, P243, DOI 10.1111/resp.12423; Singh B, 2017, RESP PHYSIOL NEUROBI, V240, P1, DOI 10.1016/j.resp.2017.02.008; Skloot GS, 2002, MT SINAI J MED, V69, P140; Stores G, 1998, ARCH DIS CHILD, V78, P413, DOI 10.1136/adc.78.5.413; SZENTAGOTHAI K, 1987, PEDIATR PULM, V3, P166, DOI 10.1002/ppul.1950030310; To T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-204; Turk Y, 2017, J CARDIOPULM REHABIL, V37, P214, DOI 10.1097/HCR.0000000000000249; Turner S, 2011, RESPIRATION, V81, P302, DOI 10.1159/000315142; Wang JS, 2009, RESPIROLOGY, V14, P838, DOI 10.1111/j.1440-1843.2009.01567.x; Weisgerber MC, 2003, J ASTHMA, V40, P453, DOI 10.1081/JAS-120018706; Weisgerber M, 2008, PEDIATR PULM, V43, P1175, DOI 10.1002/ppul.20895; Westergren T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009721; Zolaktaf V, 2013, INT J PREVENTIVE MED, V4, pS126	91	20	26	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 22	2018	13	10							e0204953	10.1371/journal.pone.0204953	http://dx.doi.org/10.1371/journal.pone.0204953			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX7HS	30346958	Green Submitted, gold, Green Published			2023-01-03	WOS:000447938400005
J	Amankwaa, I; Boateng, D; Quansah, DY; Akuoko, CP; Evans, C				Amankwaa, Isaac; Boateng, Daniel; Quansah, Dan Yedu; Akuoko, Cynthia Pomaa; Evans, Catrin			Effectiveness of short message services and voice call interventions for antiretroviral therapy adherence and other outcomes: A systematic review and meta-analysis	PLOS ONE			English	Review							BEHAVIOR-CHANGE; HIV TREATMENT; CELL PHONE; HEALTH; PREVENTION; IMPACT; TRIAL	Background The potential of using mobile phone technologies to improve antiretroviral therapy (ART) adherence has provided a new facet to human immunodeficiency virus (HIV) research. The quality of evidence and the strength of recommendations of existing reviews, however, do not adequately support large-scale adoption of the intervention. This review adopted broad selection criteria to include all mobile phone-based interventions designed to improve patient's adherence to ART. Methods We performed a systematic review and meta-analysis of randomized controlled trials and quasi-experimental studies. PUBMED, MEDLINE, EMBASE, PsychINFO, Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, AMED and Web of Science were searched. Online abstracts archives of relevant conference proceedings and trial registries were also searched. Thirty-Five (35) full-text articles were assessed for eligibility. Included studies were conducted in high, low and middle-income countries and reported ART adherence interventions delivered by mobile phones (standard or smartphones) in the form of voice calls, interactive voice response calls (IVR), and short message service (SMS). Results Thirteen (13) studies met the inclusion criteria, and 11 were used in the meta-analysis. Intervention characteristics of included studies ranged from mobile phone functionalities to provision of study phones to participants. SMS and voice call contents were tailored to participants' specific adherence needs. Mobile SMS interventions improved adherence to ART compared with control conditions (OR, 95% CI = 1.59, 1.27-1.98). In subgroup analysis, only scheduled SMS was significant whereas triggered SMS had no effect on adherence to ART. Mobile voice calls did not significantly increase adherence to ART. The interventions were highly rated by > 90% of participants in the studies that reported on the experiences and satisfaction with the intervention. Conclusion Scheduled mobile phone text-messaging have demonstrated significant improvement in adherence to ART. Mobile SMS adherence interventions that allow for two-way communication may, however, be more acceptable than standalone SMS reminders, which are seen to be intrusive, producing habituation and response fatigue. Voice calls and triggered SMS functionalities do not have a significant effect on adherence to ART although there is a higher preference for voice functionality over SMS especially in limited-resource and low-literacy settings. Further exploration of the mobile voice functionality and its possible combination with scheduled SMS functionality is recommended. Evidence provided in this study will guide the implementation of mobile phone intervention to improve adherence to ART, by addressing practical challenges that could militate against scalability especially in resource limited settings.	[Amankwaa, Isaac] Victoria Univ Wellington, Wellington Reg Hosp, Fac Hlth, Grad Sch Nursing Midwifery & Hlth, Wellington, New Zealand; [Boateng, Daniel] Univ Utrecht, Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Julius Global Hlth, Utrecht, Netherlands; [Boateng, Daniel] Kwame Nkrumah Univ Sci & Technol, Sch Publ Hlth, Kumasi, Ghana; [Quansah, Dan Yedu] Lausanne Univ Hosp, Serv Endocrinol Diabet & Metab, Lausanne, Switzerland; [Quansah, Dan Yedu] Univ Cape Coast, Dept Biomed Sci, Cape Coast, Ghana; [Akuoko, Cynthia Pomaa] Christian Serv Univ Coll, Kumasi, Ghana; [Akuoko, Cynthia Pomaa] Queensland Univ Technol, Sch Nursing, Brisbane, Qld, Australia; [Evans, Catrin] Univ Nottingham, Sch Hlth Sci, Queens Med Ctr, Nottingham, England	Victoria University Wellington; Utrecht University; Utrecht University Medical Center; Kwame Nkrumah University Science & Technology; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Cape Coast; Queensland University of Technology (QUT); University of Nottingham	Boateng, D (corresponding author), Univ Utrecht, Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Julius Global Hlth, Utrecht, Netherlands.; Boateng, D (corresponding author), Kwame Nkrumah Univ Sci & Technol, Sch Publ Hlth, Kumasi, Ghana.	Daniel.dboateng@gmail.com	Evans, Catrin/AAE-4794-2019; Boateng, Daniel/H-2918-2019; Amankwaa, Isaac/AAL-1702-2020; Quansah, Dan Yedu/B-8499-2018; Akuoko, Cynthia/W-1519-2019	Boateng, Daniel/0000-0001-7568-7298; Amankwaa, Isaac/0000-0002-7879-4731; Quansah, Dan Yedu/0000-0002-3091-9400; Akuoko, Cynthia/0000-0002-3661-8625				Abdulrahman SA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177698; Ammassari A, 2011, JAIDS-J ACQ IMM DEF, V58, pE113, DOI 10.1097/QAI.0b013e3182359d2a; Anscombe J, 2012, IMPROVING THE EVIDEN, V27; Atun Sarin, 2006, ROLE MOBILE MOBILE P; Bain-Brickley D, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009513; Belzer ME, 2014, AIDS BEHAV, V18, P686, DOI 10.1007/s10461-013-0661-3; Blake H., 2008, BR J COMMUNITY NURS, V13, P160, DOI [DOI 10.12968/BJCN.2008.13.4.29024, 10.12968/bjcn.2008.13.4.29024]; Chinn S, 2000, STAT MED, V19, P3127, DOI 10.1002/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M; Cohen MS, 2012, CURR OPIN HIV AIDS, V7, P99, DOI 10.1097/COH.0b013e32834f5cf2; Cole-Lewis H, 2010, EPIDEMIOL REV, V32, P56, DOI 10.1093/epirev/mxq004; da Costa TM, 2012, INT J MED INFORM, V81, P257, DOI 10.1016/j.ijmedinf.2011.10.002; De Geest S, 2003, EUR J CARDIOVASC NUR, V2, P323, DOI [DOI 10.1016/S1474-5151(03)00091-4, 10.1016/S1474-5151(03)00091-4]; DeSouza SI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104895; Dongsheng Huang, 2013, AIDS RES TREAT, V2013, P1; Dowshen N, 2012, J MED INTERNET RES, V14, DOI 10.2196/jmir.2015; Finitsis DJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088166; Haberer JE, 2016, AIDS, V30, P1294, DOI 10.1097/QAD.0000000000001021; Hall AK, 2015, ANNU REV PUBL HEALTH, V36, P393, DOI 10.1146/annurev-publhealth-031914-122855; Hardon A, 2006, TANZANIA UGANDA, V301, P1; He N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077981; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins JP, 2021, COCHRANE HDB SYSTEMA, DOI 10.1002/9780470712184. ch4; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Horvath T, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009756; ITU [International Telecommunications Union], 2016, ICT FACTS FIGURES 20; Joanna Briggs Institute, 2015, J BRIGGS I REV MAN 2; Kalichman SC, 2011, AIDS PATIENT CARE ST, V25, P303, DOI 10.1089/apc.2010.0367; Kaplan WA, 2006, GLOBALIZATION HEALTH, V2, DOI 10.1186/1744-8603-2-9; Kripalani S, 2007, ARCH INTERN MED, V167, P540, DOI 10.1001/archinte.167.6.540; Lemaire J., 2011, SCALING MOBILE HLTH, P1; Leora Klapper, 2016, CURR SCI, V110, P127, DOI [10.1111/ner.12182, DOI 10.1111/NER.12182]; Lester RT, 2010, LANCET, V376, P1838, DOI 10.1016/S0140-6736(10)61997-6; Lewis MA, 2013, HEALTH PSYCHOL, V32, P248, DOI 10.1037/a0028109; Lewis T, 2012, B WORLD HEALTH ORGAN, V90, P332, DOI 10.2471/BLT.11.099820; Maduka O, 2013, NIGER J CLIN PRACT, V16, P302, DOI 10.4103/1119-3077.113451; Mannheimer SB, 2006, JAIDS-J ACQ IMM DEF, V43, pS41, DOI 10.1097/01.qai.0000245887.58886.ac; MANTEL N, 1959, J NATL CANCER I, V22, P719; Mbuagbaw L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046909; Mechael P, 2010, P COL U EARTH I CTR, V54, P1; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Momin Kazi A., 2017, ROLE MOBILE PHONE BA; Oberhauser O., 2013, MITTEILUNGEN VEREINI, V67, P174; Patrick K, 2008, AM J PREV MED, V35, P177, DOI 10.1016/j.amepre.2008.05.001; Pearson A, 2006, EVIDENCE BASED CLIN, DOI [10.1002/9781444316544, DOI 10.1002/9781444316544]; Perera AI, 2014, AIDS PATIENT CARE ST, V28, P579, DOI 10.1089/apc.2014.0156; Pop-Eleches C, 2011, AIDS, V25, P825, DOI 10.1097/QAD.0b013e32834380c1; Rb H, 2008, COCHRANE DB SYST REV, P2; Ryan P, 2009, CLIN NURSE SPEC, V23, P161, DOI 10.1097/NUR.0b013e3181a42373; Sabin Lora L., 2015, J ACQ IMMUN DEF SYND, V33, P395; Sharma P, 2012, MOBILE PHONE TEXT ME; SHET A, 2014, BMJ, V349; TechTargete, WHAT IS INT VOIC RES; The Joanna Briggs Institute, 2016, CRIT APPR TOOLS JBI; Tolf C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049002; Wand H, 2012, AIDS BEHAV, V16, P360, DOI 10.1007/s10461-011-9969-z; Wang L, 2013, CHINESE MED J-PEKING, V126, P3694, DOI 10.3760/cma.j.issn.0366-6999.20123311; Wang L, 2010, JAIDS-J ACQ IMM DEF, V55, P232, DOI 10.1097/QAI.0b013e3181e9b6b7; WHO, 2002, WHO TRADITIONAL MED; World Health Organization, 2016, CONSOLIDATED GUIDELI, V2nd ed; World Health Organization, 2011, GLOBAL PREVALENCE AN, Vfourth, P1; Wu AW, 2006, AIDS PATIENT CARE ST, V20, P773, DOI 10.1089/apc.2006.20.773; Zurovac D, 2011, LANCET, V378, P795, DOI 10.1016/S0140-6736(11)60783-6	62	44	45	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2018	13	9							e0204091	10.1371/journal.pone.0204091	http://dx.doi.org/10.1371/journal.pone.0204091			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GU5MM	30240417	gold, Green Published			2023-01-03	WOS:000445329700024
J	Shankar, R; Wilcock, M				Shankar, Rohit; Wilcock, Mike			Improving knowledge of psychotropic prescribing in people with Intellectual Disability in primary care	PLOS ONE			English	Article							LEARNING-DISABILITY; GENERAL-PRACTICE; PITFALLS	Purpose People with Intellectual disability (ID) are likely to be prescribed psychotropic medication particularly antipsychotics without a clear clinical indication. This has given rise to a national initiative in the UK to stop overprescribing medication in this vulnerable population. While the goals are simple it is unclear if specialist ID services or primary care services in the UK should look to lead. Further, it is uncertain if primary care practitioners (GPs) can be systematically educated of the latest good practice developments and concerns in this specialised area. This study surveyed the knowledge level of a sample of GPs in Cornwall UK (county of 538,000) post a structured tutorial on psychotropic medication and people with ID. Methods A 21 item questionnaire was delivered in meetings organised for all the county GPs a year after a talk given to the same demographic. The questionnaire conducted an assessment of the knowledge of national guidance on use of psychotropic medication in ID based on the subjects covered in the tutorial. Results Of the 60 expected GP participants the tutorial was attended by 44 GPs (73%) and the follow up meeting by 42 (70%). Ninety percent GPs in the follow up meeting filled the questionnaire. For 16 questions, more than 80% GPs gave correct responses whereas five questions attracted a correct answer from less than 80%. Majority of the GPs felt psychotropic medication management in people with ID should be specialist led. Conclusions GPs' knowledge of issues relevant to prescribing in people with ID benefitted from the tutorial. However a clear need for the psychotropic medication management to be delivered via specialist care emerged. This raises issues of resource allocation and debate on whether people with ID require specialist provision due to lack of ability in main stream primary care to manage their needs.	[Shankar, Rohit] Cornwall Partnership NHS Fdn Trust, Truro, England; [Shankar, Rohit] Univ Exeter, Med Sch, Exeter, Devon, England; [Wilcock, Mike] Royal Cornwall Hosp Trust, Truro, England	University of Exeter; Royal Cornwall Hospital	Shankar, R (corresponding author), Cornwall Partnership NHS Fdn Trust, Truro, England.; Shankar, R (corresponding author), Univ Exeter, Med Sch, Exeter, Devon, England.	Rohit.shankar@nhs.net	Shankar, Rohit/I-9028-2019; Shankar, Rohit/HGU-4155-2022	Shankar, Rohit/0000-0002-1183-6933; Shankar, Rohit/0000-0002-1183-6933				Alexander RT, 2017, BRIT J GEN PRACT, V67, P372, DOI 10.3399/bjgp17X692081; Althubaiti A, 2016, J MULTIDISCIP HEALTH, V9, P211, DOI 10.2147/JMDH.S104807; [Anonymous], 2010, ESTIMATED PREVALENCE; Bakker-van Gijssel EJ, 2017, BRIT J GEN PRACT, V67, pE41, DOI 10.3399/bjgp16X688585; de Kuijper GM, 2017, J INTELL DISABIL RES, V61, P899, DOI 10.1111/jir.12385; Emerson E, 2011, HLTH INEQUALITIES PE; Emerson E., 2012, HLTH INEQUALITIES PE; Emerson E, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0296-x; Faculty of Psychiatry of Intellectual Disability, 2016, PSYCH DRUG PRESCR PE; Glover G., 2015, PRESCRIBING PSYCHOTR; Kerr MP, 2009, EPILEPSY BEHAV, V15, pS26, DOI 10.1016/j.yebeh.2009.03.020; Mastebroek M, 2016, BRIT J GEN PRACT, V66, pE720, DOI 10.3399/bjgp16X686593; McNamara R, 2017, HEALTH TECHNOL ASSES, V21, P1, DOI 10.3310/hta21470; National Collaborating Centre for Mental Health (UK), 2015, CHALLENGING BEHAVIOU; NHS Digital, 2017, HLTH CARE PEOPL LEAR; NHS England, 2016, STOPP MED PEOPL LEAR; Ring H, 2013, ADV CLIN NEUROSCI RE, V13, P13; Russell AM, 2017, BRIT J GEN PRACT, V67, pE842, DOI 10.3399/bjgp17X693461; SHEEHAN R, 2015, BMJ-BRIT MED J, V351, DOI DOI 10.1136/BMJ.H4326; Sheehan R, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3896	20	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2018	13	9							e0204178	10.1371/journal.pone.0204178	http://dx.doi.org/10.1371/journal.pone.0204178			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT7EG	30216381	Green Published, gold, Green Submitted			2023-01-03	WOS:000444683700050
J	McNairy, ML; Jannat-Khah, D; Pape, JW; Marcelin, A; Joseph, P; Mathon, JE; Koenig, S; Wells, M; Fitzgerald, DW; Evans, A				McNairy, Margaret L.; Jannat-Khah, Deanna; Pape, Jean W.; Marcelin, Adias; Joseph, Patrice; Mathon, Jean Edward; Koenig, Serena; Wells, Martin; Fitzgerald, Daniel W.; Evans, Arthur			Predicting death and lost to follow-up among adults initiating antiretroviral therapy in resource-limited settings: Derivation and external validation of a risk score in Haiti	PLOS ONE			English	Article							ELECTRONIC MEDICAL-RECORD; ADVANCED HIV-INFECTION; SUB-SAHARAN AFRICA; TREATMENT OUTCOMES; MORTALITY; CARE; TUBERCULOSIS; AIDS; PREVENTION; IMPACT	Background Over 18 million adults have initiated life-saving antiretroviral therapy (ART) in resource-poor settings; however, mortality and lost-to-follow-up rates continue to be high among patients in their first year after treatment start. Clinical decision tools are needed to identify patients at high risk for poor outcomes in order to provide individualized risk assessment and intervention. This study aimed to develop and externally validate risk prediction tools that estimate the probability of dying or of being lost to follow-up (LTF) during the year after starting ART. Methods We used a derivation cohort of 7,031 adults age 15-70 years initiating ART from 2007 to 2013 at 6 clinics in Haiti; 242 (3.5%) had documented death and 1,521 (21.6%) were LTF at 1 year after starting ART. The following routinely collected data were used as predictors in two logistic regression models (one to predict death and another to predict LTF): age, gender, weight, CD4 count, WHO Stage, and diagnosis of tuberculosis (TB). The validation cohort consisted of 1,835 adults initiating ART at a different HIV clinic in Haiti during 2012. We assessed model discrimination by measuring the C-statistic, and measured model calibration by how closely the predicted probabilities approximated actual probabilities of the two outcomes. We derived a nomogram and a point-based risk score from the predictive models. Findings The model predicting death within the year after starting ART had a C-statistic of 0.75 (95% CI 0.74 to 0.81). There was no evidence for significant overfitting and the predictions were well calibrated. The strongest predictors of 1-year mortality were male gender, low weight, low CD4 count, advanced WHO stage, and the absence of TB. In the validation cohort, the C-statistic was 0.69 (95% CI 0.59 to 0.77). A point-based risk score for death had a C-statistic 0.73 (95% CI 0.69 to 0.76) and categorizes patients as low risk (< 2% risk of death), average risk (3-4%), and high-risk (8-10%) and very high-risk (14-19%) with likelihood ratios to be used in settings where the baseline risk is different from our study population. The model predicting LTF did not discriminate well (C-statistic 0.59). Conclusions A simple risk-score using routinely collected data can predict 1-year mortality after ART initiation for HIV-positive adults in Haiti. However, predicting lost to follow-up using routinely collected data was not as successful. The next step is to assess whether use of this risk score can identify patients who need tailored services to reduce mortality in resource-poor settings such as Haiti.	[McNairy, Margaret L.; Jannat-Khah, Deanna; Evans, Arthur] Weill Cornell Med, Div Gen Internal Med, New York, NY 10065 USA; [McNairy, Margaret L.; Fitzgerald, Daniel W.] Weill Cornell Med, Ctr Global Hlth, New York, NY 10065 USA; [Pape, Jean W.; Marcelin, Adias; Joseph, Patrice; Mathon, Jean Edward] Haitian Grp Study Kaposis Sarcoma & Opportunist I, Port Au Prince, Haiti; [Koenig, Serena] Harvard Med Sch, Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA USA; [Wells, Martin] Cornell Univ, Dept Stat Sci, Ithaca, NY USA	Cornell University; Cornell University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cornell University	McNairy, ML (corresponding author), Weill Cornell Med, Div Gen Internal Med, New York, NY 10065 USA.; McNairy, ML (corresponding author), Weill Cornell Med, Ctr Global Hlth, New York, NY 10065 USA.	mam9365@med.cornell.edu	Jannat-Khah, Deanna/L-9701-2019	Jannat-Khah, Deanna/0000-0002-1091-379X; Wells, Martin/0000-0002-9750-9529	FIC NIH HHS [D43 TW010062] Funding Source: Medline; NIAID NIH HHS [K24 AI098627] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI098627] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal M, 2016, JAIDS-J ACQ IMM DEF, V73, pE33, DOI 10.1097/QAI.0000000000001117; Balkus JE, 2016, JAIDS-J ACQ IMM DEF, V72, P333, DOI 10.1097/QAI.0000000000000974; Bassett IV, 2010, CLIN INFECT DIS, V51, P823, DOI 10.1086/656282; Bengtson AM, 2016, AIDS CARE, V28, P1035, DOI 10.1080/09540121.2016.1144869; Boulle A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001718; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Brown ST, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092606; Duncombe C, 2015, TROP MED INT HEALTH, V20, P430, DOI 10.1111/tmi.12460; Ellman T, 2015, NEW ENGL J MED, V372, P303, DOI 10.1056/NEJMp1414730; Fitzgerald DW, 2000, LANCET, V356, P1470, DOI 10.1016/S0140-6736(00)02870-1; Geng Elvin H, 2010, Curr HIV/AIDS Rep, V7, P234, DOI 10.1007/s11904-010-0061-5; Hakim J, 2017, NEW ENGL J MED, V377, P233, DOI 10.1056/NEJMoa1615822; Harrell Frank E., 2001, REGRESSION MODELING; Horton NJ, 2007, AM STAT, V61, P79, DOI 10.1198/000313007X172556; Irungu EM, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1899-y; Justice AC, 2013, JAIDS-J ACQ IMM DEF, V62, P149, DOI 10.1097/QAI.0b013e31827df36c; Kahle EM, 2013, JAIDS-J ACQ IMM DEF, V62, P339, DOI 10.1097/QAI.0b013e31827e622d; Koenig SP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146903; Koenig SP, 2012, JAIDS-J ACQ IMM DEF, V59, pE60, DOI 10.1097/QAI.0b013e318245d3c1; Koenig SP, 2009, CLIN INFECT DIS, V48, P829, DOI 10.1086/597098; Lawn SD, 2006, AIDS, V20, P1605, DOI 10.1097/01.aids.0000238406.93249.cd; Leger P, 2009, NEW ENGL J MED, V361, P828, DOI 10.1056/NEJMc0809485; Marcelin A, 2015, STUD HEALTH TECHNOL, V216, P883, DOI 10.3233/978-1-61499-564-7-883; Matheson AI, 2012, INT J MED INFORM, V81, P244, DOI 10.1016/j.ijmedinf.2012.01.011; McNairy ML, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002278; McNairy ML, 2015, JAIDS-J ACQ IMM DEF, V70, pE44, DOI 10.1097/QAI.0000000000000745; McNairy ML, 2012, AIDS, V26, P1735, DOI 10.1097/QAD.0b013e328355d67b; Mfinanga S, 2015, LANCET, V385, P2173, DOI 10.1016/S0140-6736(15)60164-7; Mocroft A, 2007, AIDS, V21, P1867, DOI 10.1097/QAD.0b013e328270b877; Moons KGM, 2006, J CLIN EPIDEMIOL, V59, P1092, DOI 10.1016/j.jclinepi.2006.01.009; Moons KGM, 2015, ANN INTERN MED, V162, pW1, DOI 10.7326/M14-0698; Moore D, 2007, AIDS, V21, P713, DOI 10.1097/QAD.0b013e328013f632; Mugavero MJ, 2012, JAIDS-J ACQ IMM DEF, V61, P574, DOI 10.1097/QAI.0b013e318273762f; Pierre S, 2016, NEW ENGL J MED, V374, P397, DOI 10.1056/NEJMc1508934; Puttkammer N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112261; Reilly BM, 2006, ANN INTERN MED, V144, P201, DOI 10.7326/0003-4819-144-3-200602070-00009; Robbins GK, 2010, CLIN INFECT DIS, V50, P779, DOI 10.1086/650537; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Rosen S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001056; Severe P, 2005, NEW ENGL J MED, V353, P2325, DOI 10.1056/NEJMoa051908; Sullivan LM, 2004, STAT MED, V23, P1631, DOI 10.1002/sim.1742; Tate JP, 2013, AIDS, V27, P563, DOI 10.1097/QAD.0b013e32835b8c7f; UNAIDS, 2014, UNAIDS COUNTR REP; von Hippel PT, 2007, SOCIOL METHODOL, V37, P83, DOI 10.1111/j.1467-9531.2007.00180.x; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; WHO, 2006, AN THER HIV INT AD A; World Health Organization, 2015, CONS GUID US ANT DRU; World Health Organization, 2009, RAP ADV ANT THER HIV	48	9	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2018	13	8							e0201945	10.1371/journal.pone.0201945	http://dx.doi.org/10.1371/journal.pone.0201945			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR9JD	30157197	gold, Green Published, Green Submitted			2023-01-03	WOS:000443071400021
J	Renziehausen, A; Wang, HX; Rao, B; Weir, L; Lo Nigro, C; Lattanzio, L; Merlano, M; Vega-Rioja, A; Fernandez-Carranco, MD; Hajji, N; Matin, R; Harwood, C; Li, S; Sim, VR; O'Neill, K; Evans, A; Thompson, A; Szlosarek, P; Fleming, C; Stebbing, J; Proby, C; Tzakos, AG; Syed, N; Crook, T				Renziehausen, Alexander; Wang, Hexiao; Rao, Bhavya; Weir, Lynda; Lo Nigro, Cristiana; Lattanzio, Laura; Merlano, Marco; Vega-Rioja, Antonio; del Carmen Fernandez-Carranco, Maria; Hajji, Nabil; Matin, Rubeta; Harwood, Catherine; Li, Su; Sim, Van Ren; O'Neill, Kevin; Evans, Alan; Thompson, Alastair; Szlosarek, Peter; Fleming, Colin; Stebbing, Justin; Proby, Charlotte; Tzakos, Andreas G.; Syed, Nelofer; Crook, Tim			The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention	ONCOGENE			English	Article							CONVERTING-ENZYME-INHIBITORS; II TYPE-1 RECEPTOR; IMPROVED SURVIVAL; BREAST-CANCER; SERUM; TUMOR; ANGIOGENESIS; ANTAGONIST; BIOMARKER; AGTR1	Despite emergence of new systemic therapies, metastatic melanoma remains a challenging and often fatal form of skin cancer. The renin-angiotensin system (RAS) is a major physiological regulatory pathway controlling salt-water equilibrium, intravascular volume and blood pressure. Biological effects of the RAS are mediated by the vasoactive hormone angiotensin II (AngII) via two receptor subtypes, AT1R (encoded by AGTR1) and AT2R (encoded by AGTR2). We report decreasing expression and increasing CpG island methylation of AGTR1 in metastatic versus primary melanoma and detection in serum of methylated genomic DNA from the AGTR1 CpG island in metastatic melanoma implying that AGTR1 encodes a tumour suppressor function in melanoma. Consistent with this hypothesis, antagonism of AT1R using losartan or shRNA-mediated knockdown in melanoma cell lines expressing AGTR1 resulted in acquisition of the ability to proliferate in serum-free conditions. Conversely, ectopic expression of AGTR1 in cell lines lacking endogenous expression inhibits proliferation irrespective of the presence of AngII implying a ligand-independent suppressor function for AT1R. Treatment of melanoma cell lines expressing endogenous AT2R with either AngII or the AT2R-selective agonist Y6AII induces proliferation in serum-free conditions whereas the AT2R-specific antagonists PD123319 and EMA401 inhibit melanoma growth and angiogenesis and potentiate inhibitors of BRAF and MEK in cells with BRAF V600 mutations. Our results demonstrate that the RAS has both oncogenic and tumour suppressor functions in melanoma. Pharmacological inhibition of AT2R may provide therapeutic opportunities in melanomas expressing this receptor and AGTR1 CpG island methylation in serum may serve as a novel biomarker of metastatic melanoma.	[Renziehausen, Alexander; Hajji, Nabil; Syed, Nelofer] Imperial Coll London, Div Brain Sci, John Fulcher Neurooncol Lab, London, England; [Wang, Hexiao] China Med Univ, Dept Dermatol, Hosp 1, Shenyang, Liaoning, Peoples R China; [Rao, Bhavya; Weir, Lynda; Proby, Charlotte] Ninewells Hosp, Med Res Inst, Dundee, Scotland; [Rao, Bhavya; Weir, Lynda; Proby, Charlotte] Med Sch, Dundee, Scotland; [Lo Nigro, Cristiana; Lattanzio, Laura; Merlano, Marco] Osped San Croce & Carle, Dept Oncol, Cuneo, Italy; [Vega-Rioja, Antonio; del Carmen Fernandez-Carranco, Maria] Hosp Univ Virgen Macarena, Seville, Spain; [Matin, Rubeta; Harwood, Catherine] Barts & London Queen Marys Sch Med & Dent, London, England; [Li, Su] Royal Marsden Hosp, Fulham Rd, London, England; [Sim, Van Ren] Maidstone Hlth Author, Kent Oncol Ctr, Maidstone ME16 9QQ, Kent, England; [O'Neill, Kevin] Charing Cross Hosp, Dept Neurosurg, London, England; [Evans, Alan] Ninewells Hosp, Dept Pathol, Dundee, Scotland; [Thompson, Alastair] MD Anderson Canc Ctr, Breast Surg Oncol, Houston, TX USA; [Szlosarek, Peter] Barts Canc Ctr, Dept Med Oncol, London, England; [Fleming, Colin; Proby, Charlotte] Ninewells Hosp, Dept Dermatol, Dundee, Scotland; [Stebbing, Justin] Imperial Coll, London, England; [Tzakos, Andreas G.] Univ Ioannina, Dept Chem, Ioannina, Greece; [Crook, Tim] St Lukes Canc Ctr, Guildford, Surrey, England	Imperial College London; China Medical University; University of Dundee; University of Dundee; Hospital Universitario Virgen Macarena; University of London; Queen Mary University London; Royal Marsden NHS Foundation Trust; Imperial College London; University of Dundee; University of Texas System; UTMD Anderson Cancer Center; University of Dundee; Imperial College London; University of Ioannina	Syed, N (corresponding author), Imperial Coll London, Div Brain Sci, John Fulcher Neurooncol Lab, London, England.; Crook, T (corresponding author), St Lukes Canc Ctr, Guildford, Surrey, England.	N.syed@imperial.ac.uk; timothycrook@nhs.net	hajji, nabil/AAV-1435-2020; merlano, marco/HHS-9397-2022; tzakos, Andreas/V-9624-2019; Matin, Rubeta/AAB-1515-2019; Renziehausen, Alexander/AAE-4907-2020	Matin, Rubeta/0000-0002-9695-5412; Tzakos, Andreas/0000-0001-6391-0288; Stebbing, Justin/0000-0002-1117-6947; Vega Rioja, Antonio/0000-0003-4698-9697	Anonymous Trust; Tenovus Scotland; Melanoma Focus; Leng Foundation; Brain Tumour Research Campaign; Economica y Competitividad [SAF2014-60649-JN]; Fondo Europeo de Regional-FEDER	Anonymous Trust; Tenovus Scotland; Melanoma Focus; Leng Foundation; Brain Tumour Research Campaign; Economica y Competitividad; Fondo Europeo de Regional-FEDER	The work was supported by They The Anonymous Trust, Tenovus Scotland (to Dr. T.C.), Melanoma Focus (to C.P.), The Leng Foundation (to C.P.) and The Brain Tumour Research Campaign (to N.S.). Antonio Vega-Rioja is under contract Proyectos I + D + I para jovenes investigadores from de Economica y Competitividad (SAF2014-60649-JN) and co-funded by Fondo Europeo de Regional-FEDER. Tim Crook is a Scottish Senior Clinical Fellow in Medical Oncology.	Anand U, 2013, EUR J PAIN, V17, P1012, DOI 10.1002/j.1532-2149.2012.00269.x; Ateeq B, 2009, CELL CYCLE, V8, P3794, DOI 10.4161/cc.8.23.9976; Bar J, 2015, CLIN LUNG CANCER, V16, pE189, DOI 10.1016/j.cllc.2015.05.002; Beaumont KA, 2014, HEALTHCARE-BASEL, V2, P27, DOI 10.3390/healthcare2010027; Brunner D, 2010, ALTEX-ALTERN ANIM EX, V27, P53; Campbell DJ, 1996, CLIN EXP PHARMACOL P, V23, pS125, DOI 10.1111/j.1440-1681.1996.tb03073.x; Carpentier AF, 2012, EUR J NEUROL, V19, P1337, DOI 10.1111/j.1468-1331.2012.03766.x; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen XS, 2013, CANCER LETT, V328, P318, DOI 10.1016/j.canlet.2012.10.006; Corkery DP, 2011, BRIT J HAEMATOL, V153, P786, DOI 10.1111/j.1365-2141.2011.08661.x; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty Keith T, 2011, F1000 Med Rep, V3, P8, DOI 10.3410/M3-8; Guo RD, 2015, IUBMB LIFE, V67, P42, DOI 10.1002/iub.1342; Hanaizi Z, 2012, EUR J CANCER, V48, P237, DOI 10.1016/j.ejca.2011.09.018; Hatzimichael E, 2014, EXPERT REV MOL DIAGN, V14, P639, DOI 10.1586/14737159.2014.928204; Hesselink JMK, 2017, J PAIN RES, V10, P439, DOI 10.2147/JPR.S128520; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoshimoto S, 2012, J INVEST DERMATOL, V132, P1689, DOI 10.1038/jid.2012.36; Karnik SS, 2015, PHARMACOL REV, V67, P754, DOI 10.1124/pr.114.010454; Lo Nigro C, 2013, J INVEST DERMATOL, V133, P1278, DOI 10.1038/jid.2012.493; Magnani F, 2014, ACS CHEM BIOL, V9, P1420, DOI 10.1021/cb500063y; Miura S, 2005, J BIOL CHEM, V280, P18237, DOI 10.1074/jbc.M500639200; Moreno BH, 2015, SEMIN ONCOL, V42, P466, DOI 10.1053/j.seminoncol.2015.02.008; Moreno-Munoz D, 2015, EUR J CLIN INVEST, V45, P1325, DOI 10.1111/eci.12557; Nussberger J, 2002, HYPERTENSION, V39, pE1, DOI 10.1161/hy0102.102293; Otake AH, 2010, CANCER CHEMOTH PHARM, V66, P79, DOI 10.1007/s00280-009-1136-0; Patton EE, 2010, PIGM CELL MELANOMA R, V23, P314, DOI 10.1111/j.1755-148X.2010.00693.x; Reis IM, 2015, BRIT J CANCER, V113, P460, DOI 10.1038/bjc.2015.240; Rhodes DR, 2009, P NATL ACAD SCI USA, V106, P10284, DOI 10.1073/pnas.0900351106; Shah R, 2009, BRIT J CANCER, V100, P1687, DOI 10.1038/sj.bjc.6605042; Sullivan RJ, 2015, CLIN CANCER RES, V21, P2424, DOI 10.1158/1078-0432.CCR-14-1650; Syed N, 2006, BLOOD, V107, P250, DOI 10.1182/blood-2005-03-1194; Wolchok JD, 2015, CELL, V162, P937, DOI 10.1016/j.cell.2015.07.045; Yoon C, 2011, CAN MED ASSOC J, V183, pE1073, DOI 10.1503/cmaj.101497; Zou YZ, 2004, NAT CELL BIOL, V6, P499, DOI 10.1038/ncb1137	35	26	26	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2320	2336		10.1038/s41388-018-0563-y	http://dx.doi.org/10.1038/s41388-018-0563-y			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30478450	Green Accepted			2023-01-03	WOS:000462588000007
J	Beskow, LM; Hammack, CM; Brelsford, KM				Beskow, Laura M.; Hammack, Catherine M.; Brelsford, Kathleen M.			Thought leader perspectives on benefits and harms in precision medicine research	PLOS ONE			English	Article							RESEARCH PARTICIPANTS; INFORMED-CONSENT; PRIVACY; BIOBANKS; CURRENTS; RETURN	Precision medicine research is underway to identify targeted approaches to improving health and preventing disease. However, such endeavors raise significant privacy and confidentiality concerns. The objective of this study was to elucidate the potential benefits and harms associated with precision medicine research through in-depth interviews with a diverse group of thought leaders, including primarily U.S.-based experts and scholars in the areas of ethics, genome research, health law, historically-disadvantaged populations, informatics, and participant-centric perspectives, as well as government officials and human subjects protections leaders. The results suggest the prospect of an array of individual and societal benefits, as well as physical, dignitary, group, economic, psychological, and legal harms. Relative to the way risks and harms are commonly described in consent forms for precision medicine research, the thought leaders we interviewed arguably emphasized a somewhat different set of issues. The return of individual research results, harm to socially-identifiable groups, the value-dependent nature of many benefits and harms, and the risks to the research enterprise itself emerged as important cross-cutting themes. Our findings highlight specific challenges that warrant concentrated care during the design, conduct, dissemination, and translation of precision medicine research and in the development of consent materials and processes.	[Beskow, Laura M.; Hammack, Catherine M.; Brelsford, Kathleen M.] Vanderbilt Univ, Med Ctr, Ctr Biomed Eth & Soc, 221 Kirkland Hall, Nashville, TN 37235 USA	Vanderbilt University	Beskow, LM (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Biomed Eth & Soc, 221 Kirkland Hall, Nashville, TN 37235 USA.	laura.m.beskow@vanderbilt.edu		Brelsford, Kathleen/0000-0002-9423-681X; Beskow, Laura/0000-0002-9314-1915; Hammack-Aviran, Catherine/0000-0002-1410-6231	National Human Genome Research Institute [R01-HG-007733]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG007733] Funding Source: NIH RePORTER	National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This work was supported by a grant to L. M.B. from the National Human Genome Research Institute (R01-HG-007733). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Human Genome Research Institute or the National Institutes of Health. The funder played no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Angrist M, 2013, NATURE, V494, P7, DOI 10.1038/494007a; Bernard H.R., 2010, ANAL QUALITATIVE DAT; Beskow Laura M., 2018, BIG DATA HLTH LAW BI; Boeije H, 2002, QUAL QUANT, V36, P391, DOI 10.1023/A:1020909529486; Brehaut JC, 2010, CONTEMP CLIN TRIALS, V31, P218, DOI 10.1016/j.cct.2010.02.002; Brehaut JC, 2008, IMPLEMENT SCI, V3, DOI 10.1186/1748-5908-3-38; Brenner SE, 2013, NATURE, V498, P139, DOI 10.1038/498139a; Budin-Ljosne I, 2016, BIOPRESERV BIOBANK, V14, P241, DOI 10.1089/bio.2015.0115; Burke W, 2018, J LAW MED ETHICS, V46, P79, DOI 10.1177/1073110518766023; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Corbin J.M., 2008, BASICS QUALITATIVE R, Vthird, DOI DOI 10.4135/9781452230153.N8; Fabsitz RR, 2010, CIRC-CARDIOVASC GENE, V3, P574, DOI 10.1161/CIRCGENETICS.110.958827; Guest G, 2011, APPL THEMATIC ANAL, DOI [10.4135/9781483384436, DOI 10.4135/9781483384436]; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Hayden EC, 2013, NATURE, V502, P26, DOI 10.1038/502026a; Henderson GE, 2014, J LAW MED ETHICS, V42, P344, DOI 10.1111/jlme.12151; Hudson KL, 2017, NEW ENGL J MED, V376, P111, DOI 10.1056/NEJMp1615745; Jarvik GP, 2014, AM J HUM GENET, V94, P818, DOI 10.1016/j.ajhg.2014.04.009; Kaufman DJ, 2009, AM J HUM GENET, V85, P643, DOI 10.1016/j.ajhg.2009.10.002; Khan A, 2014, CLIN GENET, V86, P199, DOI 10.1111/cge.12384; Knoppers BM, 2013, EUR J HUM GENET, V21, P245, DOI 10.1038/ejhg.2012.152; Landau S, 2015, SCIENCE, V347, P504, DOI 10.1126/science.aaa4961; Langstrom N, 2015, INT J EPIDEMIOL, V44, P713, DOI 10.1093/ije/dyv029; McClellan M, 2018, ANNU REV MED, V69, P41, DOI 10.1146/annurev-med-061516-112359; McEwen JE, 2013, TRENDS GENET, V29, P375, DOI 10.1016/j.tig.2013.02.001; Meslin EM, 2010, PUBLIC HEALTH GENOM, V13, P378, DOI 10.1159/000319473; Namey Emily E., 2015, PUBLIC HLTH RES METH, P443; *NAT BIOETH ADV CO, 2001, ETH POL ISS RES INV, V1; National Institutes of Health, ALL US RES PROGR 201; O'Doherty KC, 2011, SOC SCI MED, V73, P367, DOI 10.1016/j.socscimed.2011.05.046; Oliphant EN, 2016, GENET TEST MOL BIOMA, V20, P339, DOI 10.1089/gtmb.2016.29017.sjt; Piffer D, 2015, INTELLIGENCE, V53, P43, DOI 10.1016/j.intell.2015.08.008; Pullman D, 2012, GENET MED, V14, P229, DOI [10.1038/GIM.0b013e31822e578f, 10.1038/gim.0b013e31822e578f]; Rodriguez LL, 2013, SCIENCE, V339, P275, DOI 10.1126/science.1234593; Rothstein MA, 2007, J LAW MED ETHICS, V35, P59, DOI 10.1111/j.1748-720X.2007.00154.x; Rothstein MA, 2016, J LAW MED ETHICS, V44, P352, DOI 10.1177/1073110516654128; Rothstein MA, 2015, J LAW MED ETHICS, V43, P425, DOI 10.1111/jlme.12258; Schadt EE, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.47; Sulmasy DP, 2015, GENET MED, V17, P331, DOI 10.1038/gim.2014.111; Tiihonen J, 2015, MOL PSYCHIATR, V20, P786, DOI 10.1038/mp.2014.130; Underhill K, 2018, HASTINGS CENT REP, V48, P8, DOI 10.1002/hast.805; Weil CJ, 2013, GENET MED, V15, P997, DOI 10.1038/gim.2013.40; Wolf SM, 2012, GENET MED, V14, P361, DOI 10.1038/gim.2012.23	44	11	11	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 26	2018	13	11							e0207842	10.1371/journal.pone.0207842	http://dx.doi.org/10.1371/journal.pone.0207842			32	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HB8GM	30475858	Green Submitted, gold, Green Published			2023-01-03	WOS:000451325700079
J	van Rijt, AM; Dik, JWH; Lokate, M; Postma, MJ; Friedrich, AW				van Rijt, Antonius M.; Dik, Jan-Willem H.; Lokate, Mariette; Postma, Maarten J.; Friedrich, Alex W.			Cost analysis of outbreaks with Methicillin-resistant Staphylococcus aureus (MRSA) in Dutch long-term care facilities (LTCF)	PLOS ONE			English	Article							INFECTION PREVENTION; NURSING-HOMES; INTEGRATED STEWARDSHIP; LOW-PREVALENCE; SETTINGS; SPREAD	Objectives Highly resistant microorganisms (HRMOs) are of high concern worldwide and are becoming increasingly less susceptible for antibiotics. To study the cost effectiveness of infection prevention measures in long-term care, it is essential to first fully understand the impact of HRMOs. The objective of this study is to identify the costs associated with outbreaks caused by Methicillin-resistant Staphylococcus aureus (MRSA) in Dutch long-term care facilities (LTCF). Methods After an outbreak of MRSA, Dutch LTCF can submit a reimbursement form to the Dutch Healthcare Authority ("Nederlandse Zorgautoriteit"; NZa) to get a part of the total costs reimbursed. In this study, we requested NZa forms for financial impact analysis. Details regarding the costs of the outbreak have been extracted from these forms and additionally specific LTCF have been visited in person to validate the data. Results 34 complete reimbursement forms from the period between 2011 and 2016 were received from the NZa and have been included. The median cost per patient per day was estimated at (sic)83.80, varying between (sic)16.89 and (sic)1,820.09. We validated five reimbursement forms by visiting the facility and recalculating the costs. We found a non-significant positive difference of (sic)26.07 compared with the original data (p = 0.068). Conclusions This study is to our knowledge the first to give a national overview of total costs associated with an MRSA outbreak in LTCF in the Netherlands. Overall, costs per patient per day seem lower than in a hospital setting, although total costs are much higher due to the long term of care.	[van Rijt, Antonius M.; Dik, Jan-Willem H.; Lokate, Mariette; Friedrich, Alex W.] Univ Med Ctr Groningen, Dept Med Microbiol, Groningen, Netherlands; [Postma, Maarten J.] Univ Groningen, Fac Med Sci, Groningen, Netherlands	University of Groningen; University of Groningen	Friedrich, AW (corresponding author), Univ Med Ctr Groningen, Dept Med Microbiol, Groningen, Netherlands.	alex.friedrich@umcg.nl	Friedrich, Alex/ABG-9823-2020	van Rijt, Antonius Mattheus/0000-0003-0662-7616; Postma, Maarten/0000-0002-6306-3653	INTERREG V A [202085]; European Commission; Dutch Ministry of Health, Welfare and Sport (VWS); Ministry of Economy, Innovation, Digitalisation and Energy of the German Federal State of North Rhine-Westphalia; German Federal State of Lower Saxony	INTERREG V A; European Commission(European CommissionEuropean Commission Joint Research Centre); Dutch Ministry of Health, Welfare and Sport (VWS); Ministry of Economy, Innovation, Digitalisation and Energy of the German Federal State of North Rhine-Westphalia; German Federal State of Lower Saxony	The work presented in this thesis, was performed at the Department of Medical Microbiology of the University of Groningen and the University Medical Center Groningen. It was supported by the INTERREG V A (202085) funded project EurHealth-1Health (http://www.eurhealth-1health.eu), part of a Dutch-German cross-border network supported by the European Commission, the Dutch Ministry of Health, Welfare and Sport (VWS), the Ministry of Economy, Innovation, Digitalisation and Energy of the German Federal State of North Rhine-Westphalia and the German Federal State of Lower Saxony. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2016, TACKLING DRUG RESIST; Batina NG, 2016, ANTIMICROB RESIST IN, V5, DOI 10.1186/s13756-016-0130-7; Bode LGM, 2011, J HOSP INFECT, V79, P198, DOI 10.1016/j.jhin.2011.05.009; Brink van den R, 2013, END ANTIBIOTICS; Capitano B, 2003, J AM GERIATR SOC, V51, P10, DOI 10.1034/j.1601-5215.2002.51003.x; Centraal Bureau voor de Statistiek (CBS), 2017, DUTCH CONS PRIC IND; Cohen CC, 2016, NURS ECON, V34, P16; Dik JH, 2017, J CLIN MICROBIOL, V55, P3306, DOI 10.1128/JCM.01283-17; Dik JWH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149226; Dik JWH, 2016, FUTURE MICROBIOL, V11, P93, DOI 10.2217/fmb.15.99; ECDC, 2017, SURV ANT RES EUR 201; Greenland K, 2011, J AM GERIATR SOC, V59, P768, DOI 10.1111/j.1532-5415.2011.03325.x; Hakkaart-van Roijen L., 2015, KOSTENHANDLEIDING ME; Hoogendoorn M, 2013, J AM MED DIR ASSOC, V14, P336, DOI 10.1016/j.jamda.2012.11.001; Hubner NO, 2017, J HOSP INFECT, V97, P234, DOI 10.1016/j.jhin.2017.08.002; Lee BY, 2013, MED CARE, V51, P205, DOI 10.1097/MLR.0b013e3182836dc2; Leendert van der Werff Hans Frederik, 2008, Tidsskr Nor Laegeforen, V128, P2734; Manzur A, 2009, CLIN MICROBIOL INFEC, V15, P26, DOI 10.1111/j.1469-0691.2009.03093.x; March A, 2010, CLIN MICROBIOL INFEC, V16, P934, DOI 10.1111/j.1469-0691.2009.03024.x; Millington K., 2007, EXCHANGE RATES EURO; Nederland Zorginstituut, 2016, RICHTL UITV EC EV GE; Pittet D, 2000, LANCET, V10, p[356, 1290]; Pogorzelska-Maziarz M, 2017, AM J INFECT CONTROL, V45, P597, DOI 10.1016/j.ajic.2017.03.020; Roberts RR, 2009, CLIN INFECT DIS, V49, P1175, DOI 10.1086/605630; Travers J, 2015, GERIATR NURS, V36, P355, DOI 10.1016/j.gerinurse.2015.05.001; van den Dool C, 2016, INFECT CONT HOSP EP, V37, P761, DOI 10.1017/ice.2016.59; van der Bij Akke K, 2015, Ned Tijdschr Geneeskd, V159, pA8585; Werkgroep Infectiepreventie (WIP), 2012, RICHTL MET RES STAPH; Werkgroep Infectiepreventie (WIP), 2004, INF VERPL WOONZ AND; Werkgroep Infectiepreventie (WIP), 2007, MRSA VERZ; Werkgroep Infectiepreventie (WIP), 2007, MRSA VERPL; Willemsen I, 2014, ANTIMICROB RESIST IN, V3, DOI 10.1186/2047-2994-3-26; 2012, EV THREAT ANT REOP, P1	33	2	2	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 26	2018	13	11							e0208092	10.1371/journal.pone.0208092	http://dx.doi.org/10.1371/journal.pone.0208092			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HB8GM	30475904	Green Published, Green Submitted, gold			2023-01-03	WOS:000451325700104
J	Min, KL; Son, ES; Kim, JS; Kim, SH; Jung, SM; Chang, MJ				Min, Kyoung Lok; Son, Eun Sun; Kim, Jae Song; Kim, Soo Hyun; Jung, Sun Mi; Chang, Min Jung			Risk factors of colistin safety according to administration routes: Intravenous and aerosolized colistin	PLOS ONE			English	Article							VENTILATOR-ASSOCIATED PNEUMONIA; COLISTIMETHATE SODIUM; NEBULIZED COLISTIN; NEPHROTOXICITY; PHARMACOKINETICS; INFECTIONS; IV	Background Nephrotoxicity of intravenous (IV) colistin has impeded its clinical use; aerosolized (AS) colistin may be an alternative, but safety data are lacking. Therefore, this study aimed to evaluate the incidence of acute kidney injury (AKI) and risk factors associated with IV and AS colistin administration. Methods A retrospective study was performed in a tertiary referral hospital. Data were collected before and after colistin administration between October 2012 and April 2016. Exclusion criteria were as follows: age less than 18 years, previous colistin administration, concurrent use of IV and AS colistin, dialysis before colistin use, and colistin use for less than 3 days. We compared AKI incidence following administration of IV versus AS colistin and analyzed risk factors for colistin-associated nephrotoxicity. Results A total of 464 patients were enrolled (n = 311, IV group; n = 153, AS group). Incidence of AKI was significantly higher in the IV group (IV vs AS, 20.26% vs 7.84%, p-value < 0.001). Duration of colistin use (OR 1.033, 95% CI 1.009-1.058, p-value 0.008) and presence of chronic kidney disease (OR 2.710, 95% CI 1.348-5.448, p-value 0.005) were associated with nephrotoxicity. There were no significant risk factors associated with AS colistin. Conclusions Although AS colistin was not associated with any significant risk factors for nephrotoxicity, duration of colistin use and baseline kidney function may affect AS colistin-associated nephrotoxicity.	[Min, Kyoung Lok; Chang, Min Jung] Yonsei Univ, Coll Med & Pharm, Dept Pharmaceut Med & Regulatory Sci, Incheon, South Korea; [Son, Eun Sun; Kim, Jae Song; Kim, Soo Hyun; Jung, Sun Mi] Yonsei Univ Hlth Syst, Severance Hosp, Dept Pharm, Seoul, South Korea; [Chang, Min Jung] Yonsei Univ, Coll Pharm, Dept Pharm, Incheon, South Korea; [Chang, Min Jung] Yonsei Univ, Coll Pharm, Yonsei Inst Pharmaceut Sci, Incheon, South Korea; [Chang, Min Jung] Yonsei Univ, Coll Pharm, Dept Ind Pharmaceut Sci, Incheon, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University; Yonsei University	Chang, MJ (corresponding author), Yonsei Univ, Coll Med & Pharm, Dept Pharmaceut Med & Regulatory Sci, Incheon, South Korea.; Chang, MJ (corresponding author), Yonsei Univ, Coll Pharm, Dept Pharm, Incheon, South Korea.; Chang, MJ (corresponding author), Yonsei Univ, Coll Pharm, Yonsei Inst Pharmaceut Sci, Incheon, South Korea.; Chang, MJ (corresponding author), Yonsei Univ, Coll Pharm, Dept Ind Pharmaceut Sci, Incheon, South Korea.	mjchang@yonsei.ac.kr		Chang, Min Jung/0000-0002-8408-5907	National Research Foundation of Korea (NRF) - Korea government (Ministry of Science, ICT & Future Planning) [2017R1C1B5016737]	National Research Foundation of Korea (NRF) - Korea government (Ministry of Science, ICT & Future Planning)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (Ministry of Science, ICT & Future Planning) (No. 2017R1C1B5016737). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	DeRyke CA, 2010, ANTIMICROB AGENTS CH, V54, P4503, DOI 10.1128/AAC.01707-09; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Falagas ME, 2010, INT J ANTIMICROB AG, V35, P194, DOI 10.1016/j.ijantimicag.2009.10.005; Falagas ME, 2005, CLIN INFECT DIS, V40, P1333, DOI 10.1086/429323; Gauthier TP, 2012, ANTIMICROB AGENTS CH, V56, P2392, DOI 10.1128/AAC.00028-12; Hartzell JD, 2009, CLIN INFECT DIS, V48, P1724, DOI 10.1086/599225; Imberti R, 2010, CHEST, V138, P1333, DOI 10.1378/chest.10-0463; Jang JY, 2017, J CRIT CARE, V40, P251, DOI 10.1016/j.jcrc.2017.04.004; Javan AO, 2015, EUR J CLIN PHARMACOL, V71, P801, DOI 10.1007/s00228-015-1865-4; Kalin G, 2012, J INFECT CHEMOTHER, V18, P872, DOI 10.1007/s10156-012-0430-7; Kim J, 2009, INT J ANTIMICROB AG, V34, P434, DOI 10.1016/j.ijantimicag.2009.06.028; Kofteridis DP, 2010, CLIN INFECT DIS, V51, P1238, DOI 10.1086/657242; Kwon KH, 2015, INT J ANTIMICROB AG, V45, P605, DOI 10.1016/j.ijantimicag.2015.01.011; Lee YJ, 2015, CRIT CARE MED, V43, P1187, DOI 10.1097/CCM.0000000000000931; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Lewis JR, 2004, AM J PHYSIOL-CELL PH, V286, pC913, DOI 10.1152/ajpcell.00437.2003; Li J, 2006, LANCET INFECT DIS, V6, P589, DOI 10.1016/S1473-3099(06)70580-1; Martis N, 2014, J INFECTION, V69, P1, DOI 10.1016/j.jinf.2014.03.001; Michalopoulos AS, 2010, EXPERT REV ANTI-INFE, V8, P1009, DOI [10.1586/eri.10.88, 10.1586/ERI.10.88]; Naesens R, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-317; Pai MP, 2000, ANN PHARMACOTHER, V34, P1066, DOI 10.1345/aph.19381; Palmer LB, 1998, CRIT CARE MED, V26, P31, DOI 10.1097/00003246-199801000-00013; Paul M, 2010, J ANTIMICROB CHEMOTH, V65, P1019, DOI 10.1093/jac/dkq069; Perez-Pedrero MJ, 2011, MED INTENSIVA, V35, P226, DOI 10.1016/j.medin.2011.01.013; Pogue JM, 2011, CLIN INFECT DIS, V53, P879, DOI 10.1093/cid/cir611; Ratjen F, 2006, J ANTIMICROB CHEMOTH, V57, P306, DOI 10.1093/jac/dki461; Rattanaumpawan P, 2011, J INFECTION, V62, P187, DOI 10.1016/j.jinf.2010.11.013; Rattanaumpawan P, 2010, J ANTIMICROB CHEMOTH, V65, P2645, DOI 10.1093/jac/dkq360; Spapen H, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-14; Tumbarello M, 2013, CHEST, V144, P1768, DOI 10.1378/chest.13-1018; Tuon FF, 2014, INT J ANTIMICROB AG, V43, P349, DOI 10.1016/j.ijantimicag.2013.12.002; Valachis A, 2015, CRIT CARE MED, V43, P527, DOI 10.1097/CCM.0000000000000771; Yapa SWS, 2014, ANTIMICROB AGENTS CH, V58, P2570, DOI 10.1128/AAC.01705-13	33	15	16	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2018	13	11							e0207588	10.1371/journal.pone.0207588	http://dx.doi.org/10.1371/journal.pone.0207588			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB4VL	30462703	Green Published, Green Submitted, gold			2023-01-03	WOS:000451054800068
J	Kim, W; Jang, SY; Lee, TH; Lee, JE; Park, EC				Kim, Woorim; Jang, Suk-Yong; Lee, Tae-Hoon; Lee, Joo Eun; Park, Eun-Cheol			Association between continuity of care and subsequent hospitalization and mortality in patients with mood disorders: Results from the Korea National Health Insurance cohort	PLOS ONE			English	Article							MAJOR DEPRESSIVE DISORDER; MENTAL-DISORDERS; SYMPTOMS; SUICIDE; COMMUNITY; PHYSICIAN; OUTCOMES; BURDEN; RISK	Concerns have been raised about the loss of treatment continuity in unipolar and bipolar depressive disorder patients as continuity of care (COC) may be associated with patient outcomes. This study aimed to examine the relationship between COC and subsequent hospitalization, all-cause mortality, and suicide mortality in individuals with unipolar and bipolar disorder. Data were from the National Health Insurance (NHI) cohort, 2002 to 2013. Study participants included individuals first diagnosed with unipolar depressive disorder or bipolar affective disorder. The independent variable was COC for the first year of outpatient visits after diagnosis, measured using the usual provider of care (UPC) index. The dependent variables were hospitalization in the year after COC measurement, all-cause mortality, and suicide mortality. Analysis was conducted using logistic regression and Cox proportional hazards survival regression. A total of 48,558 individuals were analyzed for hospitalization and 48,947 for all-cause and suicide mortality. Compared to the low COC group, the medium [odds ratio (OR) 0.30, 95 percent confidence interval (95% CI) 0.19-0.47] and the high COC group (OR 0.14, 95% CI 0.09-0.21) showed statistically significant decreased odds of hospitalization. Additionally, lower likelihoods of suicide death were found in the high (HR 0.35, 95% CI 0.16-0.74) compared to the low COC group. The results infer an association between COC after first diagnosis of unipolar or bipolar depressive disorder and hospitalization and suicide mortality, suggesting the potential importance of treatment continuity in improving patient outcomes.	[Kim, Woorim] Yonsei Univ, Grad Sch, Dept Publ Hlth, Seoul, South Korea; [Kim, Woorim; Park, Eun-Cheol] Yonsei Univ, Inst Hlth Serv Res, Seoul, South Korea; [Jang, Suk-Yong] Eulji Univ, Dept Prevent Med, Coll Med, Daejeon, South Korea; [Lee, Tae-Hoon] Hlth Insurance Review & Assessment Serv, Wonju, South Korea; [Lee, Joo Eun] Ajou Univ, Sch Med, Suwon, Gyeonggi Do, South Korea; [Park, Eun-Cheol] Yonsei Univ, Dept Prevent Med, Coll Med, Seoul, South Korea	Yonsei University; Yonsei University; Eulji University; Ajou University; Yonsei University; Yonsei University Health System	Park, EC (corresponding author), Yonsei Univ, Inst Hlth Serv Res, Seoul, South Korea.; Park, EC (corresponding author), Yonsei Univ, Dept Prevent Med, Coll Med, Seoul, South Korea.	ecpark@yuhs.ac	Park, Eun-Cheol/O-5644-2019	Park, Eun-Cheol/0000-0002-2306-5398; Jang, Suk-Yong/0000-0003-0558-1505; Kim, Woorim/0000-0002-1199-6822				Cabana MD, 2004, J FAM PRACTICE, V53, P974; Catty J, 2013, INT J SOC PSYCHIATR, V59, P5, DOI 10.1177/0020764011421440; Chang SM, 2012, SOC PSYCH PSYCH EPID, V47, P683, DOI 10.1007/s00127-011-0382-8; Desai RA, 2005, AM J PSYCHIAT, V162, P311, DOI 10.1176/appi.ajp.162.2.311; Feng L, 2009, INT PSYCHOGERIATR, V21, P568, DOI 10.1017/S1041610209008965; Gulliford Martin, 2006, J Health Serv Res Policy, V11, P248, DOI 10.1258/135581906778476490; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; Hoertel N, 2014, EUR PSYCHIAT, V29, P358, DOI 10.1016/j.eurpsy.2013.12.001; Jee SH, 2006, MED CARE RES REV, V63, P158, DOI 10.1177/1077558705285294; King EA, 2001, BRIT J PSYCHIAT, V178, P531, DOI 10.1192/bjp.178.6.531; Korea National Statistical Office (KNSO), 2011, 2010 DEATH CAUS DEAT; Mainous AG, 1998, AM J PUBLIC HEALTH, V88, P1539, DOI 10.2105/AJPH.88.10.1539; Melartin T, 2006, J AFFECT DISORDERS, V91, pS62; Menec Verena H, 2006, J Health Serv Res Policy, V11, P196, DOI 10.1258/135581906778476562; Nemeroff CB, 2007, J PSYCHIATR RES, V41, P189, DOI 10.1016/j.jpsychires.2006.05.008; Park SC, 2015, KAOHSIUNG J MED SCI, V31, P47, DOI 10.1016/j.kjms.2014.11.001; Prina AM, 2015, J PSYCHOSOM RES, V78, P25, DOI 10.1016/j.jpsychores.2014.11.002; Reilly S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036468; Reininghaus U, 2015, SCHIZOPHRENIA BULL, V41, P664, DOI 10.1093/schbul/sbu138; ROGERS J, 1980, AM J PUBLIC HEALTH, V70, P122, DOI 10.2105/AJPH.70.2.122; Shin C, 2017, J KOREAN MED SCI, V32, P1861, DOI 10.3346/jkms.2017.32.11.1861; Szymanski BR, 2013, J GEN INTERN MED, V28, P346, DOI 10.1007/s11606-012-2218-y; Uijen AA, 2014, EUR J GEN PRACT, V20, P161, DOI 10.3109/13814788.2013.828201; van Walraven C, 2010, J EVAL CLIN PRACT, V16, P947, DOI 10.1111/j.1365-2753.2009.01235.x; Wolinsky FD, 2010, J GERONTOL A-BIOL, V65, P421, DOI 10.1093/gerona/glp188; Wong SY, 2009, J AFFECT DISORDERS, V113, P272, DOI 10.1016/j.jad.2008.06.008; Y C, 2017, STUDY QUALITY CARE P	28	4	4	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2018	13	11							e0207740	10.1371/journal.pone.0207740	http://dx.doi.org/10.1371/journal.pone.0207740			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HA9FQ	30452465	gold, Green Published, Green Submitted			2023-01-03	WOS:000450603800037
J	Liebrecht, LK; Newton, J; Martin, EJ; Wickramaratne, N; Jayaraman, S; Han, JF; Aboutanos, M; Brophy, DF; Mangino, MJ				Liebrecht, Loren K.; Newton, Jason; Martin, Erika J.; Wickramaratne, Nina; Jayaraman, Sudha; Han, Jinfeng; Aboutanos, Michel; Brophy, Donald F.; Mangino, Martin J.			Thromboelastographic analysis of novel polyethylene glycol based low volume resuscitation solutions	PLOS ONE			English	Article							UNCONTROLLED HEMORRHAGIC-SHOCK; PEG-20K; SALINE; RATS	Background Low volume resuscitation (LVR) in shock prevents deleterious effects of crystalloid loading in pre-hospital settings. Polyethylene glycol 20,000 (PEG-20k) based LVR solutions are 20-fold more effective at maintaining perfusion and survival in shock compared to conventional crystalloids. The aim of this study was to determine coagulation and platelet function of whole blood treated with 10% PEG-20k. Methods Citrated blood from volunteers (n = 25) or early admission severely injured trauma patients (n = 9) were diluted 10% with various LVR solutions in a matched design with a paired volume control (saline), and studied using thromboelastography (TEG). Findings In healthy volunteers and patients, 10% PEG-20k significantly increased clot amplification time (k), decreased propagation (angle), maximal clot size and strength (MA), and the overall coagulation index (Cl), but not clot initiation (R) or fibrinolysis (Ly30), relative to paired saline dilutional controls. Clinically, K, angle, and MA were just outside of the normal limits in volunteers but not in patients. No statistical differences existed between PEG-20k and Hextend (HES) in either patient population. In a dose response series using volunteer blood, all effects of 10% PEG-20k on TEG were reversed and normalized by lower concentrations (7.5% and 5%). Furthermore, 7.5% PEG-20k produced similar resuscitation effects as 10% PEG in rodent hemorrhagic shock models (n = 5). Conclusions In conclusion, PEG-20k based LVR solutions produced a dose-dependent minor hypocoagulative state, possibly associated with changes in clot propagation and platelet function, which can be reversed by dose reduction in concentration while providing superior LVR, microvascular rescue, and lactate clearance compared to saline or starch.	[Liebrecht, Loren K.; Wickramaratne, Nina; Jayaraman, Sudha; Han, Jinfeng; Aboutanos, Michel; Mangino, Martin J.] Virginia Commonwealth Univ, Dept Surg, Div Acute Care Surg, Sch Med, Richmond, VA 23284 USA; [Newton, Jason] Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Sch Med, Richmond, VA USA; [Martin, Erika J.; Brophy, Donald F.] Virginia Commonwealth Univ, Sch Pharm, Dept Pharmacotherapy & Outcomes Sci, Richmond, VA USA; [Mangino, Martin J.] Virginia Commonwealth Univ, Dept Physiol & Biophys, Sch Med, Richmond, VA 23284 USA; [Mangino, Martin J.] Virginia Commonwealth Univ, Dept Emergency Med, Sch Med, Richmond, VA 23284 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Mangino, MJ (corresponding author), Virginia Commonwealth Univ, Dept Surg, Div Acute Care Surg, Sch Med, Richmond, VA 23284 USA.; Mangino, MJ (corresponding author), Virginia Commonwealth Univ, Dept Physiol & Biophys, Sch Med, Richmond, VA 23284 USA.; Mangino, MJ (corresponding author), Virginia Commonwealth Univ, Dept Emergency Med, Sch Med, Richmond, VA 23284 USA.	mjmangino@vcu.edu	Jayaraman, Sudha/AAH-3059-2019; Newton, Jason/AAN-8428-2020; Brophy, Donald F./AAJ-3805-2021	Jayaraman, Sudha/0000-0003-1094-5836; Brophy, Donald F./0000-0003-3447-8523; Newton, Jason/0000-0003-2952-2008; Mangino, Martin/0000-0003-2440-1952	Department of Defense [W81XWH-12-1-0599, W81XWH-16-2-0040, W81XWH-17-1-0602]	Department of Defense(United States Department of Defense)	This work was supported by Department of Defense, W81XWH-16-2-0040, Polyethylene glycol polymers in low volume resuscitation, PI, Martin Mangino; Department of Defense, W81XWH-17-1-0602, Treatment of Spinal Cord Ischemia with Cell Impermeant-Based Resuscitation, PI, Martin Mangino; Department of Defense, W81XWH-12-1-0599, Cell impermeants in low volume resuscitation, PI, Martin Mangino. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arora TK, 2012, J TRAUMA ACUTE CARE, V72, P397, DOI 10.1097/TA.0b013e3181d039fd; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Duchesne JC, 2010, J TRAUMA, V69, P976, DOI 10.1097/TA.0b013e3181f2abc9; Hauet T, 2008, KIDNEY INT, V74, P998, DOI 10.1038/ki.2008.336; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1111/j.1476-5381.2010.00872.x, 10.1113/expphysiol.2010.053793, 10.1113/jphysiol.2010.192278]; Mangino MJ, 2017, HEMORRHAGIC SHOCK RE; Parrish D, 2016, ANN SURG, V263, P565, DOI 10.1097/SLA.0000000000001049; Parrish D, 2015, J TRAUMA ACUTE CARE, V79, P22, DOI 10.1097/TA.0000000000000682; Plant V, 2017, J PHARMACOL EXP THER, V361, P334, DOI 10.1124/jpet.116.239822; Plant V, 2016, J TRAUMA ACUTE CARE, V81, P1056, DOI 10.1097/TA.0000000000001155; Riha GM, 2013, J TRAUMA ACUTE CARE, V75, P129, DOI 10.1097/TA.0b013e3182984a9b; Riha GM, 2011, J TRAUMA, V71, P1755, DOI 10.1097/TA.0b013e3182367b1c; Stein Deborah M, 2012, Adv Surg, V46, P237; Torres LN, 2013, J TRAUMA ACUTE CARE, V75, P759, DOI 10.1097/TA.0b013e3182a92514; VANLAMBALGEN AA, 1990, INT J MICROCIRC, V9, P303	15	4	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2018	13	11							e0207147	10.1371/journal.pone.0207147	http://dx.doi.org/10.1371/journal.pone.0207147			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA4SR	30439979	Green Submitted, Green Published, gold			2023-01-03	WOS:000450254000038
J	Nascimento, ALB; Medeiros, PM; Albuquerque, UP				Borba Nascimento, Andre Luiz; Medeiros, Patricia Muniz; Albuquerque, Ulysses Paulino			Factors in hybridization of local medical systems: Simultaneous use of medicinal plants and modern medicine in Northeast Brazil	PLOS ONE			English	Article							INDIGENOUS COMMUNITIES; RURAL-COMMUNITY; KNOWLEDGE	The presence of mainstream medicine in local medical systems inserts a set of external treatments and concepts that generate adjustments in the local conceptions of health and disease. What points in the system are most receptive to change? Who are the residents most likely to adopt these external treatments to deal with diseases? To answer these questions, this work used a study model consisting of the simultaneous use of medicinal plants and modern medicine, testing whether diseases that require greater treatment efforts are the main targets of adherence to modern medicine and if socioeconomic characteristics of residents can cause intracultural variation in relation to simultaneous use. To obtain socioeconomic data on the knowledge of medicinal plants and simultaneous use of these resources with modern medicine, semi-structured interviews were conducted in a rural community that has easy access to modern medicine. Participatory workshops were held to access the local perceptions about the frequency of occurrence and severity of illnesses. A multilevel logistic regression model was applied for data analysis. We found that chronic, severe and frequently occurring diseases in the community tended to show greater simultaneous use locally. Among the socioeconomic factors, we determined that high educational levels positively influenced the combined use of plants and modern medicine. The need to ensure the cure of frequent, severe and chronic diseases is a factor that leads residents to seek a greater number of possible treatments, stimulating the combined use of plants and modern medicine. Residents with higher educational levels were more likely to use a combination of treatments than those with lower educational levels, demonstrating that more participation in formal education may facilitate the combined use of medicinal plants and modern medicine.	[Borba Nascimento, Andre Luiz; Albuquerque, Ulysses Paulino] Univ Fed Pernambuco, Lab Ecol & Evolucao Sistemas Socioecol LEA, Ctr Biociencias, Recife, PE, Brazil; [Borba Nascimento, Andre Luiz] Univ Fed Rural Pernambuco, Programa Posgrad Bot, Recife, PE, Brazil; [Medeiros, Patricia Muniz] Univ Fed Alagoas, Grp Etnobiol & Ecol Humana, Ctr Ciencias Agr, Rio Largo, Alagoas, Brazil	Universidade Federal de Pernambuco; Universidade Federal Rural de Pernambuco (UFRPE); Universidade Federal de Alagoas	Albuquerque, UP (corresponding author), Univ Fed Pernambuco, Lab Ecol & Evolucao Sistemas Socioecol LEA, Ctr Biociencias, Recife, PE, Brazil.	upa677@hotmail.com	Albuquerque, Ulysses P/I-5037-2012; de Medeiros, Patricia Muniz/H-7198-2012	Albuquerque, Ulysses P/0000-0002-8131-8429; de Medeiros, Patricia Muniz/0000-0002-3835-5232; Nascimento, Andre/0000-0002-6536-0926	National Council for Scientific and Technological Development (CNPq); FACEPE (Foundation for Support to Science and Technology of the State of Pernambuco) [APQ-0562-2.01/17]; CAPES [001]	National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FACEPE (Foundation for Support to Science and Technology of the State of Pernambuco)(Fundacao de Amparo a Ciencia e Tecnologia do Estado de Pernambuco (FACEPE)); CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	We are especially grateful to the National Council for Scientific and Technological Development (CNPq) for financial support in the form of scholarships for scientific productivity given to PMM and UPA. Also to the Nacional Institute in Science and Technology in Ethnobiology, Bioprospecting and Nature Conservation, certified by CNPq, with financial support from FACEPE (Foundation for Support to Science and Technology of the State of Pernambuco -www.facepe.br), grant number APQ-0562-2.01/17 to UPA. AN received funding from CAPES (001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Windi A, 2004, COMPLEMENT THER MED, V12, P99, DOI 10.1016/j.ctim.2004.09.007; Albuquerque UP, 2016, PRESS; ALBUQUERQUE UP, 2016, INTRODUCTION TO ETHN, P73104; Albuquerque UP., 2014, METHODS TECHNIQUES E, V1, DOI [10.1007/978-1-4614-8636-7, DOI 10.1007/978-1-4614-8636-7]; Aswani S, 2018, EVID BASED COMPLEMEN, V3, DOI 10.1371/journal.pone.0195440; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Brazilian Health Ministry, 2000, PORTAL DA SAUDE ACE, V34, P316; Calvet-Mir L, 2008, J ETHNOBIOL ETHNOMED, V4, DOI 10.1186/1746-4269-4-18; CORE T, 2014, VIENNA, P73104; Albuquerque UP, 2007, J ETHNOPHARMACOL, V113, P156, DOI 10.1016/j.jep.2007.05.025; DEALBUQUERQUE UP, 2006, J ETHNOBIOL ETHNOMED, V2; Elliott M., 2005, ENV PRACT, V5, P214; Elliott M., 2005, ETHNOBIOL CONSERV, V5, P214; FABREGA H, 1997, PRESS, P73104; Fabrega H, 1997, SPRINGER; Ferreira WS, 2011, J ETHNOPHARMACOL, V138, P238, DOI 10.1016/j.jep.2011.09.018; Finch WH, 2014, CH CRC STAT SOC BEHA, P1; GARRO LC, 1986, AM ANTHROPOL, V88, P351, DOI 10.1525/aa.1986.88.2.02a00040; Garro LC, 2012, PLOS ONE, V88, P351; Giovannini P, 2011, SOC SCI MED, V72, P928, DOI 10.1016/j.socscimed.2011.01.007; Ladio AH, 2014, ETHNOBIOL CONSERV, V3, DOI 10.15451/ec2014-11-3.6-1-9; Henrich J, 2001, EVOL HUM BEHAV, V22, P165, DOI 10.1016/S1090-5138(00)00071-4; Henrich J, 2009, EVOL HUM BEHAV, V30, P244, DOI 10.1016/j.evolhumbehav.2009.03.005; HOLO P, SPRINGER, P73104; Kuznetsova A, 2017, J STAT SOFTW, V82, P1, DOI 10.18637/jss.v082.i13; Ladio A. H., 2014, SOC SCI MED, V3, P1; LUSPACING D, 2018, SOCIAL SCIENCE, P73104; Mathez-Stiefel SL, 2012, J ETHNOBIOL ETHNOMED, V8, DOI 10.1186/1746-4269-8-26; Medlin LG, 2014, AUST HEALTH REV, V38, P447, DOI 10.1071/AH13136; Morgan TJH, 2012, P ROY SOC B-BIOL SCI, V279, P653, DOI 10.1098/rspb.2011.1172; Nascimento ALB, 2016, J ETHNOPHARMACOL, V194, P348, DOI 10.1016/j.jep.2016.08.017; Nguyen PH, 2009, HEALTH POLICY, V90, P8, DOI 10.1016/j.healthpol.2008.08.006; Press I, 1980, PRESS, V148, P45; Reyes-Garcia V, 2010, INT J EDUC DEV, V30, P305, DOI 10.1016/j.ijedudev.2009.11.007; Ross N, 2012, MED ANTHROPOL Q, V26, P159, DOI 10.1111/j.1548-1387.2012.01199.x; Gazzaneo LRS, 2005, J ETHNOBIOL ETHNOMED, V1, DOI 10.1186/1746-4269-1-9; Santoro FR, 2015, REV, V10, DOI 10.1371/journal.pone.0119826; SANTORO FR, 2015, PLOS ONE, V20, P10; Silva FD, 2011, REV BRAS FARMACOGN, V21, P382, DOI 10.1590/S0102-695X2011005000054; Sokolowska M, 1973, HEALTH MEDICINE SOCI, P331; Sternberg RJ, 2001, INTELLIGENCE, V29, P401, DOI 10.1016/S0160-2896(01)00065-4; Strasser R, 2003, FAM PRACT, V20, P457, DOI 10.1093/fampra/cmg422; Vandebroek I, 2004, B WORLD HEALTH ORGAN, V82, P243; Voeks RA, 2004, ECON BOT, V58, pS294, DOI 10.1663/0013-0001(2004)58[S294:FTFAMP]2.0.CO;2; Voeks RA, 2007, SINGAPORE J TROP GEO, V28, P7, DOI 10.1111/j.1467-9493.2006.00273.x; Waldstein A, 2006, J ROY ANTHROPOL INST, pS95; WHO W, 2017, ORGANIZATION, V2017, P12; WHO | World Health Organization, 2017, BIODIVERSIDADE DA CA; Wickham H., 2009, ELEGANT GRAPHICS FOR; Wickham H., 2009, SPRINGER	50	11	11	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2018	13	11							e0206190	10.1371/journal.pone.0206190	http://dx.doi.org/10.1371/journal.pone.0206190			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HA3GQ	30427870	Green Published, Green Submitted, gold			2023-01-03	WOS:000450138500036
J	Mazzawi, T; Lied, GA; Sangnes, DA; El-Salhy, M; Hov, JR; Gilja, OH; Hatlebakk, JG; Hausken, T				Mazzawi, Tarek; Lied, Gulen Arslan; Sangnes, Dag Andre; El-Salhy, Magdy; Hov, Johannes R.; Gilja, Odd Helge; Hatlebakk, Jan Gunnar; Hausken, Trygve			The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation	PLOS ONE			English	Article							QUALITY-OF-LIFE; INTESTINAL MICROBIOTA; ULCERATIVE-COLITIS; DIETARY GUIDANCE; HOSPITAL ANXIETY; DOUBLE-BLIND; DYSBIOSIS; SYMPTOMS; PATHOGENESIS; PREVALENCE	Background Gut microbiota alterations are important in irritable bowel syndrome (IBS). The aim was to investigate the effect of fecal microbiota transplantation (FMT) on gut microbiota and the symptoms in patients with IBS. Material and methods The study included 13 IBS patients according to Rome III criteria and 13 healthy donors. Freshly donated feces were administered to the descending part of the duodenum via a gastroscope. Feces were collected from donors and patients before FMT, and from the patients at 1, 3 and 12 weeks and donors and patients at 20/28 weeks after FMT. Microbiota analysis was performed using GA-map Dysbiosis test (Genetic Analysis AS, Oslo, Norway). The patients completed the following questionnaires before and at the aforementioned weeks after FMT: IBS Symptom Questionnaire (IBS-SQ), IBS-Symptom Severity Scoring system (IBS-SSS), Short Form of Nepean Dyspepsia Index (SF-NDI), Bristol stool form scale, the Eysenck Personality Questionnaire-Neuroticism and Hospital Anxiety and Depression. Results Donors and IBS patients had significantly different bacterial strain signals before FMT (Ruminococcus gnavus, Actinobacteria and Bifidobacteria) that became non-significant after 3 weeks following FMT. The changes in gut microbiota were similar between donors and patients at 20/28 weeks after FMT. Thus, patients' microbiota profiles became more-or-less similar to donors. The scores of all the questionnaires were significantly improved at all time points following FMT. No reported adverse effects. Conclusions FMT was associated with a change in gut microbiota and improvement in IBS symptoms and quality of life lasting for up to 28 weeks.	[Mazzawi, Tarek; Lied, Gulen Arslan; Sangnes, Dag Andre; Gilja, Odd Helge; Hatlebakk, Jan Gunnar; Hausken, Trygve] Haukeland Hosp, Sect Gastroenterol, Dept Med, Bergen, Norway; [Mazzawi, Tarek; Lied, Gulen Arslan; El-Salhy, Magdy; Gilja, Odd Helge; Hatlebakk, Jan Gunnar; Hausken, Trygve] Haukeland Hosp, Dept Med, Sect Gastroenterol, Norwegian Competence Ctr Funct Gastrointestinal D, Bergen, Norway; [Mazzawi, Tarek; Lied, Gulen Arslan; El-Salhy, Magdy; Gilja, Odd Helge; Hatlebakk, Jan Gunnar; Hausken, Trygve] Univ Bergen, Dept Clin Med, Ctr Nutr, Bergen, Norway; [El-Salhy, Magdy] Stord Hosp, Dept Med, Sect Gastroenterol, Helse Fonna, Stord, Norway; [Hov, Johannes R.] Oslo Univ Hosp, Norwegian PSC Res Ctr, Sect Gastroenterol, Oslo, Norway; [Hov, Johannes R.] Oslo Univ Hosp, Div Surg Inflammatory Dis & Transplantat, Res Inst Internal Med, Oslo, Norway; [Hov, Johannes R.] Univ Oslo, Oslo, Norway	University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; University of Bergen; University of Oslo; University of Oslo; University of Oslo	Mazzawi, T (corresponding author), Haukeland Hosp, Sect Gastroenterol, Dept Med, Bergen, Norway.; Mazzawi, T (corresponding author), Haukeland Hosp, Dept Med, Sect Gastroenterol, Norwegian Competence Ctr Funct Gastrointestinal D, Bergen, Norway.; Mazzawi, T (corresponding author), Univ Bergen, Dept Clin Med, Ctr Nutr, Bergen, Norway.	tarek.mazzawi@gmail.com	Mazzawi, Tarek/D-4776-2016	Mazzawi, Tarek/0000-0001-7983-3707	Western Norway Regional Health Authority [911802]; Norwegian Research Council [240787/F20]	Western Norway Regional Health Authority; Norwegian Research Council(Research Council of NorwayEuropean Commission)	The study was supported by Western Norway Regional Health Authority (grant no. 911802), www.helse-vest.no.Johannes R. Hov was funded by the Norwegian Research Council (240787/F20), www.forskningsradet.no.T	Aroniadis OC, 2013, CURR OPIN GASTROEN, V29, P79, DOI 10.1097/MOG.0b013e32835a4b3e; Arslan G, 2004, DIGEST DIS SCI, V49, P680, DOI 10.1023/B:DDAS.0000026318.81635.3b; Association WM, 2009, JB WISSENSCHAFT ETHI, V14, P233; BENNET JD, 1989, LANCET, V1, P164; Bennet SMP, 2015, GUT LIVER, V9, P318, DOI 10.5009/gnl14344; Borody TJ, 2003, J CLIN GASTROENTEROL, V37, P42, DOI 10.1097/00004836-200307000-00012; Botega NJ, 1995, REV SAUDE PUBL, V29, P355, DOI 10.1590/S0034-89101995000500004; Brandt LJ, 2013, AM J GASTROENTEROL, V108, P177, DOI 10.1038/ajg.2012.450; Brandt LJ, 2012, AM J GASTROENTEROL, V107, P1079, DOI 10.1038/ajg.2012.60; Cammarota G, 2014, J CLIN GASTROENTEROL, V48, P693, DOI 10.1097/MCG.0000000000000046; Casen C, 2015, ALIMENT PHARM THER, V42, P71, DOI 10.1111/apt.13236; Chang C, 2016, BEST PRACT RES CL GA, V30, P3, DOI 10.1016/j.bpg.2016.02.001; Duboc H, 2012, NEUROGASTROENT MOTIL, V24, P513, DOI 10.1111/j.1365-2982.2012.01893.x; EISEMAN B, 1958, SURGERY, V44, P854; El-Salhy M, 2014, WORLD J GASTROENTERO, V20, P384, DOI 10.3748/wjg.v20.i2.384; Eysenck H.J., 1953, STRUCTURE HUMAN PERS; Finegold SM, 2002, CLIN INFECT DIS, V35, pS6, DOI 10.1086/341914; Francis CY, 1997, ALIMENT PHARM THERAP, V11, P395, DOI 10.1046/j.1365-2036.1997.142318000.x; Ghoshal UC, 2014, WORLD J GASTROENTERO, V20, P2482, DOI 10.3748/wjg.v20.i10.2482; Gough E, 2011, CLIN INFECT DIS, V53, P994, DOI 10.1093/cid/cir632; Grover M, 2014, NEUROGASTROENT MOTIL, V26, P156, DOI 10.1111/nmo.12304; Gupta S, 2016, CHINA REP, V52, P306, DOI 10.1177/0009445516661885; Hanevik K, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-27; Holvoet T, 2017, GUT, V66, P980, DOI 10.1136/gutjnl-2016-312513; Hong SN, 2014, WORLD J GASTROENTERO, V20, P2470, DOI 10.3748/wjg.v20.i10.2470; Hungin APS, 2003, ALIMENT PHARM THER, V17, P643, DOI 10.1046/j.1365-2036.2003.01456.x; Hustoft TN, 2017, NEUROGASTROENT MOTIL, V29, DOI 10.1111/nmo.12969; Ishihara S, 2013, DIGESTION, V87, P204, DOI 10.1159/000350054; Jalanka-Tuovinen J, 2014, GUT, V63, P1737, DOI 10.1136/gutjnl-2013-305994; Jeffery IB, 2012, GUT, V61, P997, DOI 10.1136/gutjnl-2011-301501; Kane SV, 2003, AM J GASTROENTEROL, V98, P1309, DOI 10.1016/S0002-9270(03)00232-6; Karlsson FH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2266; Kassinen A, 2007, GASTROENTEROLOGY, V133, P24, DOI 10.1053/j.gastro.2007.04.005; Lewis SJ, 1997, SCAND J GASTROENTERO, V32, P920, DOI 10.3109/00365529709011203; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; MATHIAS JR, 1994, DIGEST DIS SCI, V39, P1155, DOI 10.1007/BF02093778; Mazzawi T, 2017, INT J MOL MED, V40, P943, DOI 10.3892/ijmm.2017.3096; Mazzawi T, 2013, MOL MED REP, V8, P845, DOI 10.3892/mmr.2013.1565; Menees SB, 2012, AM J GASTROENTEROL, V107, P28, DOI 10.1038/ajg.2011.355; Monsbakken KW, 2006, EUR J CLIN NUTR, V60, P667, DOI 10.1038/sj.ejcn.1602367; Nanayakkara WS, 2016, CLIN EXP GASTROENTER, V9, P131, DOI 10.2147/CEG.S86798; Niec AM, 1998, AM J GASTROENTEROL, V93, P2184, DOI 10.1111/j.1572-0241.1998.00531.x; Pinn DM, 2014, AM J GASTROENTEROL, V109, P1831, DOI [10.1038/ajg.2014.295, 10.1038/ajg.2014.395]; Ringel Y, 2013, AM J PHYSIOL-GASTR L, V305, pG529, DOI 10.1152/ajpgi.00207.2012; Saito YA, 2011, GASTROENTEROL CLIN N, V40, P45, DOI 10.1016/j.gtc.2010.12.011; SCHWAN A, 1983, LANCET, V2, P845; Simren M, 2001, DIGESTION, V63, P108, DOI 10.1159/000051878; Sisson G, 2014, ALIMENT PHARM THER, V40, P51, DOI 10.1111/apt.12787; Spiller R, 2009, GASTROENTEROLOGY, V136, P1979, DOI 10.1053/j.gastro.2009.02.074; Staley C, 2017, GUT MICROBES, V8, P276, DOI 10.1080/19490976.2017.1299310; Tana C, 2010, NEUROGASTROENT MOTIL, V22, P512, DOI 10.1111/j.1365-2982.2009.01427.x; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zoller V, 2015, DEUT MED WOCHENSCHR, V140, P1232, DOI 10.1055/s-0041-103798	55	43	45	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2018	13	11							e0194904	10.1371/journal.pone.0194904	http://dx.doi.org/10.1371/journal.pone.0194904			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA3GQ	30427836	gold, Green Submitted, Green Published			2023-01-03	WOS:000450138500001
J	Meda, IB; Dumont, A; Kouanda, S; Ridde, V				Meda, Ivlabehire Bertrand; Dumont, Alexandre; Kouanda, Seni; Ridde, Valery			Impact of fee subsidy policy on perinatal health in a low-resource setting: A quasi-experimental study	PLOS ONE			English	Article							POISSON REGRESSION APPROACH; INTERRUPTED TIME-SERIES; FACILITY-BASED DELIVERY; MATERNAL HEALTH; USER FEES; SERVICE UTILIZATION; NEONATAL HEALTH; RELATIVE RISKS; CHILD SURVIVAL; CARE	Background A national subsidy policy was introduced in 2007 in Burkina Faso to improve financial accessibility to facility-based delivery. In this article, we estimated the effects of reducing user fees on institutional delivery and neonatal mortality, immediately and three years after the introduction of the policy. Methods The study was based on a quasi-experimental design. We used data obtained from the 2010 Demographic and Health Survey, including survival information for 32,102 live-born infants born to 12,474 women. We used a multilevel Poisson regression model with robust variances to control for secular trends in outcomes between the period before the introduction of the policy (1 January, 2007) and the period after. In sensitivity analyses, we used two different models according to the different definitions of the period "before" and the period "after". Results Immediately following its introduction, the subsidy policy was associated with increases in institutional deliveries by 4% (RR = 1.04, 95% CI: 0.98-1.10) in urban areas and by 12% (RR = 1.12, 95% CI: 1.04-1.20) in rural areas. The results showed similar patterns in sensitivity analyses. This effect was particularly marked among rural clusters with low institutional delivery rates at baseline (RR = 1.44, 95% CI: 1.33-1.55). It was persistent for 42 months after the introduction of the policy but these increases were not statistically significant. At 42 months, the delivery rates had increased by 26% in rural areas (RR = 1.26; 95% CI: 0.86-1.86) and 13% (RR = 1.13; 95% CI: 0.88-1.46) in urban areas. There was no evidence of a significant decrease in neonatal mortality rates. Conclusion The delivery subsidy implemented in Burkina Faso is associated with short-term increases in health facility deliveries. This policy has been particularly beneficial for rural households.	[Meda, Ivlabehire Bertrand; Kouanda, Seni] Inst Rech Sci Sante IRSS CNRST, Dept Biomed & Sante Publ, Ouagadougou, Burkina Faso; [Meda, Ivlabehire Bertrand] ESPUM, Montreal, PQ, Canada; [Meda, Ivlabehire Bertrand; Ridde, Valery] IRSPUM, Montreal, PQ, Canada; [Meda, Ivlabehire Bertrand; Kouanda, Seni] IASP, Ouagadougou, Burkina Faso; [Dumont, Alexandre; Ridde, Valery] Univ Paris Sorbonne Cites, ERL INSERM SAGESUD, CEPED, IRD,Univ Paris Descartes,IRD French Inst Res Sust, Paris, France	Universite de Montreal; Universite de Montreal; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut de Recherche pour le Developpement (IRD)	Meda, IB (corresponding author), Inst Rech Sci Sante IRSS CNRST, Dept Biomed & Sante Publ, Ouagadougou, Burkina Faso.; Meda, IB (corresponding author), ESPUM, Montreal, PQ, Canada.; Meda, IB (corresponding author), IRSPUM, Montreal, PQ, Canada.; Meda, IB (corresponding author), IASP, Ouagadougou, Burkina Faso.	medabert@yahoo.fr	Ridde, Valery/AAD-2736-2019; ridde, valery/AAV-1016-2020	Ridde, Valery/0000-0001-9299-8266; Meda, Ivlabehire Bertrand/0000-0002-9717-3770	Canadian Institutes of Health Research (CIHR) [ROH-115213]; World Health Organization (WHO) [SPHQ10-RTG-14]; Quebec Health Research Fund (FRQS); University of Montreal Public Health Research Institute (IRSPUM); University of Montreal Hospital Research Centre (CRCHUM); International Development Research Centre (IDRC) [107473-99906075-058]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); World Health Organization (WHO)(World Health Organization); Quebec Health Research Fund (FRQS); University of Montreal Public Health Research Institute (IRSPUM); University of Montreal Hospital Research Centre (CRCHUM); International Development Research Centre (IDRC)	This work was supported by the Canadian Institutes of Health Research (CIHR), which funded the program [ROH-115213] to VR. This research project is part of the project "Community research studies and interventions for health equity in Burkina Faso". IBM also benefited from scholarships provided by the World Health Organization (WHO) [SPHQ10-RTG-14], the Quebec Health Research Fund (FRQS), the University of Montreal Public Health Research Institute (IRSPUM), the University of Montreal Hospital Research Centre (CRCHUM) and the International Development Research Centre (IDRC) [107473-99906075-058]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahern J, 2009, AM J EPIDEMIOL, V169, P1140, DOI 10.1093/aje/kwp015; Belaid L, 2015, HEALTH POLICY PLANN, V30, P309, DOI 10.1093/heapol/czu012; Bernal JL, 2017, INT J EPIDEMIOL, V46, P348, DOI 10.1093/ije/dyw098; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Cummings P, 2009, STATA J, V9, P175, DOI 10.1177/1536867X0900900201; De Allegri M, 2012, J PUBLIC HEALTH POL, V33, P439, DOI 10.1057/jphp.2012.27; Dzakpasu S, 2014, HEALTH POLICY PLANN, V29, P137, DOI 10.1093/heapol/czs142; Dzakpasu S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049430; French B, 2008, STAT MED, V27, P5005, DOI 10.1002/sim.3340; Gabrysch S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-34; Ganaba R, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0875-2; Greenland S, 2004, AM J EPIDEMIOL, V160, P301, DOI 10.1093/aje/kwh221; Hatt LE, 2013, J HEALTH POPUL NUTR, V31, P67; Nguyen HT, 2018, HEALTH POLICY PLANN, V33, P948, DOI 10.1093/heapol/czy077; Institut National de la Statistique et de la Demographie (INSD) ICF International, 2012, THE BURKINA FASO DEM; Kouanda S, 2016, INT J GYNECOL OBSTET, V135, pS39, DOI 10.1016/j.ijgo.2016.08.009; Lagarde M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009094; Lagarde M, 2012, HEALTH POLICY PLANN, V27, P76, DOI 10.1093/heapol/czr004; Lamichhane P, 2017, HEALTH POLICY PLANN, V32, P1427, DOI 10.1093/heapol/czx124; Langlois EV, 2016, HEALTH POLICY PLANN, V31, P462, DOI 10.1093/heapol/czv088; Lawn JE, 2010, SEMIN PERINATOL, V34, P371, DOI 10.1053/j.semperi.2010.09.011; Leone T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009692; McKinnon B, 2015, SOC SCI MED, V135, P117, DOI 10.1016/j.socscimed.2015.05.003; McKinnon B, 2015, HEALTH POLICY PLANN, V30, P432, DOI 10.1093/heapol/czu027; Meda IB, 2013, SANTE MATERNELLE ACC, P163; Mosley WH, 2003, B WORLD HEALTH ORGAN, V81, P140; Philibert A, 2017, HEALTH POLICY PLANN, V32, P405, DOI 10.1093/heapol/czw142; Rabe-Hesketh S., 2012, MULTILEVEL LONGITUDI, VI; Rabe-Hesketh S, 2012, MULTILEVEL LONGITUDI, VII; Ravit M, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000558; Richard F, 2010, AM J PUBLIC HEALTH, V100, P1845, DOI 10.2105/AJPH.2009.179689; Ridde V, 2011, HLTH POLICY PLAN S2, V26, pii30, DOI DOI 10.1093/HEAP0L/CZR060; Ridde V, 2013, EVAL PROGRAM PLANN, V36, P145, DOI 10.1016/j.evalprogplan.2012.09.005; Ronsmans C, 2010, LANCET, V375, P2024, DOI 10.1016/S0140-6736(10)60704-0; Rothman JK, 2008, MODERN EPIDEMIOLOGY, V3rd; Rutstein S., 2004, DHS WEALTH INDEX; Serumaga B, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d108; Stanton ME, 2013, J HEALTH POPUL NUTR, V31, P1; TALJAARD M, 2014, IMPLEMENT SCI, V0009; UNICEF, 2015, MON SIT CHILDR WOM D; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Witter S, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0412-y; Yelland LN, 2011, AM J EPIDEMIOL, V174, P984, DOI 10.1093/aje/kwr183; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	44	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2018	13	11							e0206978	10.1371/journal.pone.0206978	http://dx.doi.org/10.1371/journal.pone.0206978			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GZ5ZX	30408129	Green Submitted, Green Published, gold			2023-01-03	WOS:000449512300061
J	Cristescu, R; Mogg, R; Ayers, M; Albright, A; Murphy, E; Yearley, J; Sher, X; Liu, XQ; Lu, HC; Nebozhyn, M; Zhang, C; Lunceford, J; Joe, A; Cheng, J; Webber, AL; Ibrahim, N; Plimack, ER; Ott, PA; Seiwert, T; Ribas, A; McClanahan, TK; Tomassini, JE; Loboda, A; Kaufman, D				Cristescu, Razvan; Mogg, Robin; Ayers, Mark; Albright, Andrew; Murphy, Erin; Yearley, Jennifer; Sher, Xinwei; Liu, Xiao Qiao; Lu, Hongchao; Nebozhyn, Michael; Zhang, Chunsheng; Lunceford, Jared; Joe, Andrew; Cheng, Jonathan; Webber, Andrea L.; Ibrahim, Nageatte; Plimack, Elizabeth R.; Ott, Patrick A.; Seiwert, Tanguy; Ribas, Antoni; McClanahan, Terrill K.; Tomassini, Joanne E.; Loboda, Andrey; Kaufman, David			Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy	SCIENCE			English	Article							CELL LUNG-CANCER; MISMATCH-REPAIR DEFICIENCY; PROGRAMMED DEATH LIGAND-1; SEQUENCING DATA; MUTATIONAL PROCESSES; METASTATIC MELANOMA; SOMATIC MUTATIONS; CLINICAL-RESPONSE; CTLA-4 BLOCKADE; COPY NUMBER	Programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) checkpoint blockade immunotherapy elicits durable antitumor effects in multiple cancers, yet not all patients respond. We report the evaluation of >300 patient samples across 22 tumor types from four KEYNOTE clinical trials. Tumor mutational burden (TMB) and a Tcell-inflamed gene expression profile (GEP) exhibited joint predictive utility in identifying responders and nonresponders to the PD-1 antibody pembrolizumab. TMB and GEP were independently predictive of response and demonstrated low correlation, suggesting that they capture distinct features of neoantigenicity and Tcell activation. Analysis of The Cancer Genome Atlas database showed TMB and GEP to have a low correlation, and analysis by joint stratification revealed biomarker-defined patterns of targetable-resistance biology. These biomarkers may have utility in clinical trial design by guiding rational selection of anti-PD-1 monotherapy and combination immunotherapy regimens.	[Cristescu, Razvan; Mogg, Robin; Ayers, Mark; Albright, Andrew; Murphy, Erin; Yearley, Jennifer; Sher, Xinwei; Liu, Xiao Qiao; Lu, Hongchao; Nebozhyn, Michael; Zhang, Chunsheng; Lunceford, Jared; Joe, Andrew; Cheng, Jonathan; Webber, Andrea L.; Ibrahim, Nageatte; McClanahan, Terrill K.; Tomassini, Joanne E.; Loboda, Andrey; Kaufman, David] Merck & Co Inc, Kenilworth, NJ 07033 USA; [Plimack, Elizabeth R.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Ott, Patrick A.] Dana Farber Canc Inst, Boston, MA 02215 USA; [Seiwert, Tanguy] Univ Chicago, Chicago, IL 60637 USA; [Ribas, Antoni] Univ Calif Los Angeles, Los Angeles, CA 90095 USA; [Mogg, Robin; Kaufman, David] Bill & Melinda Gates Med Res Inst, Cambridge, MA 02139 USA	Merck & Company; Fox Chase Cancer Center; Harvard University; Dana-Farber Cancer Institute; University of Chicago; University of California System; University of California Los Angeles	Cristescu, R (corresponding author), Merck & Co Inc, Kenilworth, NJ 07033 USA.	razvan_cristescu@merck.com		Sher, Xinwei/0000-0003-3977-3695; Cristescu, Razvan/0000-0002-9978-0339	Merck, Kenilworth, NJ; NATIONAL CANCER INSTITUTE [R35CA197633] Funding Source: NIH RePORTER	Merck, Kenilworth, NJ(Merck & Company); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Merck, Kenilworth, NJ.	Alexandrov LB, 2014, CURR OPIN GENET DEV, V24, P52, DOI 10.1016/j.gde.2013.11.014; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Chow L. Q., 2014, ANN ONCOL         S4, V25, P14; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Coppola D, 2011, AM J PATHOL, V179, P37, DOI 10.1016/j.ajpath.2011.03.007; Dai HY, 2005, CANCER RES, V65, P4059, DOI 10.1158/0008-5472.CAN-04-3953; Daud AI, 2016, J CLIN ONCOL, V34, P4102, DOI 10.1200/JCO.2016.67.2477; Dolled-Filhart M, 2016, ARCH PATHOL LAB MED, V140, P1243, DOI 10.5858/arpa.2015-0542-OA; Dolled-Filhart M, 2016, ARCH PATHOL LAB MED, V140, P1259, DOI 10.5858/arpa.2015-0544-OA; Favero F, 2015, ANN ONCOL, V26, P64, DOI 10.1093/annonc/mdu479; Forbes SA, 2010, NUCLEIC ACIDS RES, V38, pD652, DOI 10.1093/nar/gkp995; Galon J, 2013, IMMUNITY, V39, P11, DOI 10.1016/j.immuni.2013.07.008; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Haddad RI, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.6009; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Huang AC, 2017, NATURE, V545, P60, DOI 10.1038/nature22079; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Johnson DB, 2016, CANCER IMMUNOL RES, V4, P959, DOI 10.1158/2326-6066.CIR-16-0143; Johnson DB, 2016, EXPERT OPIN EMERG DR, V21, P195, DOI 10.1080/14728214.2016.1184644; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Kowanetz M, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw363.25; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lee SJ, 2006, FEBS LETT, V580, P755, DOI 10.1016/j.febslet.2005.12.093; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lu CW, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1247135; Luksza M, 2017, NATURE, V551, P517, DOI 10.1038/nature24473; Lund O, 2004, IMMUNOGENETICS, V55, P797, DOI 10.1007/s00251-004-0647-4; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Neagu MR, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0371-3; Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403; Panda A, 2017, JCO PRECIS ONCOL, DOI [10.1200/PO.17.00146, DOI 10.1200/PO.17.00146]; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/NMETH.2883, 10.1038/nmeth.2883]; Salipante SJ, 2014, CLIN CHEM, V60, P1192, DOI 10.1373/clinchem.2014.223677; Segal NH, 2008, CANCER RES, V68, P889, DOI 10.1158/0008-5472.CAN-07-3095; Seiwert T. Y., 2018, P AM ASS CANC RES AN; Seiwert TY, 2016, LANCET ONCOL, V17, P956, DOI 10.1016/S1470-2045(16)30066-3; Sherry ST, 1999, GENOME RES, V9, P677; Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Szolek A, 2014, BIOINFORMATICS, V30, P3310, DOI 10.1093/bioinformatics/btu548; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; The Cancer Genome Atlas, TCGA DAT PORT; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Vaishampayan U, 2014, CURR OPIN ONCOL, V26, P265, DOI 10.1097/CCO.0000000000000066; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612	59	1029	1064	15	197	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 12	2018	362	6411			SI		197	+	eaar3593	10.1126/science.aar3593	http://dx.doi.org/10.1126/science.aar3593			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW9RX	30309915	Green Submitted, Green Accepted, Green Published			2023-01-03	WOS:000447337200046
J	Chowkwanyun, M; Bayer, R; Galea, S				Chowkwanyun, Merlin; Bayer, Ronald; Galea, Sandro			"Precision" Public Health - Between Novelty and Hype	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Chowkwanyun, Merlin; Bayer, Ronald] Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, Ctr Hist & Eth Publ Hlth, New York, NY 10027 USA; [Galea, Sandro] Boston Univ, Sch Publ Hlth, Boston, MA USA	Columbia University; Boston University	Chowkwanyun, M (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, Ctr Hist & Eth Publ Hlth, New York, NY 10027 USA.		Galea, Sandro/GLR-6066-2022					Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Committee on a Framework for Developing a New Taxonomy of Disease, 2011, PREC MED BUILD KNOWL; Dowell SF, 2016, NATURE, V540, P189, DOI 10.1038/540189a; Khoury MJ, 2018, GENET MED, V20, P574, DOI 10.1038/gim.2017.211; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32	5	66	66	3	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 11	2018	379	15					1398	1400		10.1056/NEJMp1806634	http://dx.doi.org/10.1056/NEJMp1806634			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GW4VQ	30184442				2023-01-03	WOS:000446923400003
J	Grinfeld, J; Nangalia, J; Baxter, EJ; Wedge, DC; Angelopoulos, N; Cantrill, R; Godfrey, AL; Papaemmanuil, E; Gundem, G; MacLean, C; Cook, J; O'Neil, L; O'Meara, S; Teague, JW; Butler, AP; Massie, CE; Williams, N; Nice, FL; Andersen, CL; Hasselbalch, HC; Guglielmelli, P; McMullin, MF; Vannucchi, AM; Harrison, CN; Gerstung, M; Green, AR; Campbell, PJ				Grinfeld, J.; Nangalia, J.; Baxter, E. J.; Wedge, D. C.; Angelopoulos, N.; Cantrill, R.; Godfrey, A. L.; Papaemmanuil, E.; Gundem, G.; MacLean, C.; Cook, J.; O'Neil, L.; O'Meara, S.; Teague, J. W.; Butler, A. P.; Massie, C. E.; Williams, N.; Nice, F. L.; Andersen, C. L.; Hasselbalch, H. C.; Guglielmelli, P.; McMullin, M. F.; Vannucchi, A. M.; Harrison, C. N.; Gerstung, M.; Green, A. R.; Campbell, P. J.			Classification and Personalized Prognosis in Myeloproliferative Neoplasms	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNATIONAL WORKING GROUP; ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ESSENTIAL THROMBOCYTHEMIA; PRIMARY MYELOFIBROSIS; POLYCYTHEMIA-VERA; PREDICT SURVIVAL; JAK2 MUTATIONS; CLONAL HEMATOPOIESIS; DIAGNOSTIC-CRITERIA	BACKGROUND Myeloproliferative neoplasms, such as polycythemia vera, essential thrombocythemia, and myelofibrosis, are chronic hematologic cancers with varied progression rates. The genomic characterization of patients with myeloproliferative neoplasms offers the potential for personalized diagnosis, risk stratification, and treatment. METHODS We sequenced coding exons from 69 myeloid cancer genes in patients with myeloproliferative neoplasms, comprehensively annotating driver mutations and copy-number changes. We developed a genomic classification for myeloproliferative neoplasms and multistage prognostic models for predicting outcomes in individual patients. Classification and prognostic models were validated in an external cohort. RESULTS A total of 2035 patients were included in the analysis. A total of 33 genes had driver mutations in at least 5 patients, with mutations in JAK2, CALR, or MPL being the sole abnormality in 45% of the patients. The numbers of driver mutations increased with age and advanced disease. Driver mutations, germline polymorphisms, and demographic variables independently predicted whether patients received a diagnosis of essential thrombocythemia as compared with polycythemia vera or a diagnosis of chronic-phase disease as compared with myelofibrosis. We defined eight genomic subgroups that showed distinct clinical phenotypes, including blood counts, risk of leukemic transformation, and event-free survival. Integrating 63 clinical and genomic variables, we created prognostic models capable of generating personally tailored predictions of clinical outcomes in patients with chronic-phase myeloproliferative neoplasms and myelofibrosis. The predicted and observed outcomes correlated well in internal cross-validation of a training cohort and in an independent external cohort. Even within individual categories of existing prognostic schemas, our models substantially improved predictive accuracy. CONCLUSIONS Comprehensive genomic characterization identified distinct genetic subgroups and provided a classification of myeloproliferative neoplasms on the basis of causal biologic mechanisms. Integration of genomic data with clinical variables enabled the personalized predictions of patients' outcomes and may support the treatment of patients with myeloproliferative neoplasms. (Funded by the Wellcome Trust and others.)	[Grinfeld, J.; Massie, C. E.; Nice, F. L.; Green, A. R.; Campbell, P. J.] Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England; [Grinfeld, J.; Massie, C. E.; Nice, F. L.; Green, A. R.; Campbell, P. J.] Cambridge Inst Med Res, Hills Rd, Cambridge CB2 0XY, England; [Grinfeld, J.; Baxter, E. J.; MacLean, C.; Cook, J.; Massie, C. E.; Nice, F. L.; Green, A. R.] Univ Cambridge, Dept Haematol, Cambridge, England; [Grinfeld, J.; Baxter, E. J.; Godfrey, A. L.; MacLean, C.; Cook, J.; Green, A. R.] Cambridge Univ Hosp NHS Fdn Trust, Dept Haematol, Cambridge, England; [Nangalia, J.; Wedge, D. C.; Angelopoulos, N.; Papaemmanuil, E.; Gundem, G.; O'Neil, L.; O'Meara, S.; Teague, J. W.; Butler, A. P.; Williams, N.; Campbell, P. J.] Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Hinxton, England; [Cantrill, R.; Gerstung, M.] European Bioinformat Inst, European Mol Biol Lab, Hinxton, England; [Wedge, D. C.] Univ Oxford, Big Data Inst, Oxford, England; [McMullin, M. F.] Queens Univ Belfast, Dept Haematol, Belfast, Antrim, North Ireland; [Harrison, C. N.] Guys & St ThomasNHS Fdn Trust, Dept Haematol, London, England; [Papaemmanuil, E.; Gundem, G.] Mem Sloan Kettering Canc Ctr, Ctr Mol Oncol, 1275 York Ave, New York, NY 10021 USA; [Papaemmanuil, E.; Gundem, G.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; [Andersen, C. L.; Hasselbalch, H. C.] Zealand Univ Hosp, Dept Hematol, Copenhagen, Denmark; [Andersen, C. L.; Hasselbalch, H. C.] Univ Copenhagen, Copenhagen, Denmark; [Guglielmelli, P.; Vannucchi, A. M.] Univ Florence, Azienda Osped Univ Careggi, Ctr Res & Innovat Myeloproliferat Neoplasms, Dept Expt & Clin Med, Florence, Italy	University of Cambridge; University of Cambridge; University of Cambridge; Wellcome Trust Sanger Institute; European Molecular Biology Laboratory (EMBL); University of Oxford; Queens University Belfast; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Copenhagen; University of Florence	Green, AR (corresponding author), Cambridge Inst Med Res, Hills Rd, Cambridge CB2 0XY, England.; Campbell, PJ (corresponding author), Wellcome Trust Sanger, Hinxton CB10 1SA, Cambs, England.	arg1000@cam.ac.uk; pc8@sanger.ac.uk	McMullin, Mary F/AAF-6472-2020; Vannucchi, Alessandro M./K-7499-2016; Guglielmelli, Paola/K-7509-2016; Wedge, David/AAC-4977-2021; McMullin, Mary Frances/AAG-6078-2021	Vannucchi, Alessandro M./0000-0001-5755-0730; Guglielmelli, Paola/0000-0003-1809-284X; McMullin, Mary Frances/0000-0002-0773-0204; Williams, Nicholas/0000-0003-3989-9167; Lykkegaard Andersen, Christen Bertel/0000-0001-7753-6768; Gerstung, Moritz/0000-0001-6709-963X; Wedge, David/0000-0002-7572-3196; Green, Anthony/0000-0002-9795-0218; Angelopoulos, Nicos/0000-0002-7507-9177	Wellcome Trust	Wellcome Trust(Wellcome TrustEuropean Commission)	Funded by the Wellcome Trust and others.	Al Assaf C, 2015, HAEMATOLOGICA, V100, P893, DOI 10.3324/haematol.2014.118299; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Barbui T, 2014, LEUKEMIA, V28, P1191, DOI 10.1038/leu.2013.380; Bercovich D, 2008, LANCET, V372, P1484, DOI 10.1016/S0140-6736(08)61341-0; Cabagnols X, 2016, BLOOD, V127, P333, DOI 10.1182/blood-2015-07-661983; Cervantes F, 2009, BLOOD, V113, P2895, DOI 10.1182/blood-2008-07-170449; Chen C, 2014, CANCER CELL, V25, P652, DOI 10.1016/j.ccr.2014.03.016; DAMESHEK W, 1951, BLOOD, V6, P372, DOI 10.1182/blood.V6.4.372.372; Feenstra JDM, 2016, BLOOD, V127, P325, DOI 10.1182/blood-2015-07-661835; Genovese G, 2014, NEW ENGL J MED, V371, P2477, DOI 10.1056/NEJMoa1409405; Gerstung M, 2017, NAT GENET, V49, P332, DOI 10.1038/ng.3756; Harrison CN, 2014, BRIT J HAEMATOL, V167, P421, DOI 10.1111/bjh.12986; Hultcrantz M, 2012, J CLIN ONCOL, V30, P2995, DOI 10.1200/JCO.2012.42.1925; Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617; Jones AV, 2009, NAT GENET, V41, P446, DOI 10.1038/ng.334; Kearney L, 2009, BLOOD, V113, P646, DOI 10.1182/blood-2008-08-170928; Lundberg P, 2014, BLOOD, V123, P2220, DOI 10.1182/blood-2013-11-537167; Malcovati L, 2014, BLOOD, V124, P1513, DOI 10.1182/blood-2014-03-560227; Marty C, 2014, BLOOD, V123, P1372, DOI 10.1182/blood-2013-05-504555; McMullin MF, 2007, BRIT J HAEMATOL, V138, P821, DOI 10.1111/j.1365-2141.2007.06741.x; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Nangalia J, 2015, HAEMATOLOGICA, V100, pE438, DOI 10.3324/haematol.2015.129510; Ortmann CA, 2015, NEW ENGL J MED, V372, P601, DOI 10.1056/NEJMoa1412098; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Papaemmanuil E, 2013, BLOOD, V122, P3616, DOI 10.1182/blood-2013-08-518886; Passamonti F, 2017, LEUKEMIA, V31, P2726, DOI 10.1038/leu.2017.169; Passamonti F, 2012, BLOOD, V120, P1197, DOI 10.1182/blood-2012-01-403279; Passamonti F, 2010, BLOOD, V115, P1703, DOI 10.1182/blood-2009-09-245837; Reilly JT, 2014, BRIT J HAEMATOL, V167, P418, DOI 10.1111/bjh.12985; Ruark E, 2013, NATURE, V493, P406, DOI 10.1038/nature11725; Stengel A, 2017, LEUKEMIA, V31, P705, DOI 10.1038/leu.2016.263; Tapper W, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7691; Taylor J, 2017, BLOOD, V130, P410, DOI 10.1182/blood-2017-02-734541; Tefferi A, 2017, MAYO CLIN PROC, V92, P1283, DOI 10.1016/j.mayocp.2017.06.002; Tefferi A, 2016, BLOOD ADV, V1, P21, DOI 10.1182/bloodadvances.2016000216; van der Harst P, 2012, NATURE, V492, P369, DOI 10.1038/nature11677; Vannucchi AM, 2013, LEUKEMIA, V27, P1861, DOI 10.1038/leu.2013.119; Wilkins BS, 2008, BLOOD, V111, P60, DOI 10.1182/blood-2007-05-091850; Wu QY, 2013, LEUKEMIA LYMPHOMA, V54, P2693, DOI 10.3109/10428194.2013.781171; Zhang LW, 2014, NAT GENET, V46, P726, DOI 10.1038/ng.2995	40	297	308	5	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 11	2018	379	15					1416	1430		10.1056/NEJMoa1716614	http://dx.doi.org/10.1056/NEJMoa1716614			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW4VQ	30304655	Green Accepted, Green Submitted, Bronze, Green Published			2023-01-03	WOS:000446923400006
J	Berns, JS; Glickman, A; McCoy, MS				Berns, Jeffrey S.; Glickman, Aaron; McCoy, Matthew S.			Dialysis-Facility Joint-Venture Ownership - Hidden Conflicts of Interest	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE		[Berns, Jeffrey S.; Glickman, Aaron; McCoy, Matthew S.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Berns, Jeffrey S.] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Berns, JS (corresponding author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.; Berns, JS (corresponding author), Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA.							Berns JS, 2018, AM J KIDNEY DIS, V71, P133, DOI 10.1053/j.ajkd.2017.04.024; Jha V, 2017, LANCET, V389, P1851, DOI 10.1016/S0140-6736(16)32408-4; Ozar DT, 2013, CLIN J AM SOC NEPHRO, V8, P840, DOI 10.2215/CJN.08490812; Parker JC, 2011, SEMIN DIALYSIS, V24, P5, DOI 10.1111/j.1525-139X.2010.00806.x; Trybou J, 2014, HEALTH POLICY, V118, P316, DOI 10.1016/j.healthpol.2014.09.012	5	5	5	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 4	2018	379	14					1295	1297		10.1056/NEJMp1805097	http://dx.doi.org/10.1056/NEJMp1805097			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GV6QX	30281994				2023-01-03	WOS:000446240100002
J	Lee, MJ; Park, JH; Moon, YR; Jo, SY; Yoon, D; Park, RW; Jeong, JC; Park, I; Shin, GT; Kim, H				Lee, Min-Jeong; Park, Joo-Han; Moon, Yeo Rae; Jo, Soo-Yeon; Yoon, Dukyong; Park, Rae Woong; Jeong, Jong Cheol; Park, Inwhee; Shin, Gyu-Tae; Kim, Heungsoo			Can we predict when to start renal replacement therapy in patients with chronic kidney disease using 6 months of clinical data?	PLOS ONE			English	Article							NATIONAL-HEALTH; VISUAL-FIELD; RISK SCORES; MODELS; COHORT; KOREA	Purpose We aimed to develop a model of chronic kidney disease (CKD) progression for predicting the probability and time to progression from various CKD stages to renal replacement therapy (RRT), using 6 months of clinical data variables routinely measured at healthcare centers. Methods Data were derived from the electronic medical records of Ajou University Hospital, Suwon, South Korea from October 1997 to September 2012. We included patients who were diagnosed with CKD (estimated glomerular filtration rate [eGFR] < 60 mL.min(-1) -1 .73 m(-2) for >= 3 months) and followed up for at least 6 months. The study population was randomly divided into training and test sets. Results We identified 4,509 patients who met reasonable diagnostic criteria. Patients were randomly divided into 2 groups, and after excluding patients with missing data, the training and test sets included 1,625 and 1,618 patients, respectively. The integral mean was the most powerful explanatory (R-2 = 0.404) variable among the 8 modified values. Ten variables (age, sex, diabetes mellitus[DM], polycystic kidney disease[PKD], serum albumin, serum hemoglobin, serum phosphorus, serum potassium, eGFR (calculated by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]), and urinary protein) were included in the final risk prediction model for CKD stage 3 (R-2 = 0.330). Ten variables (age, sex, DM, GN, PKD, serum hemoglobin, serum blood urea nitrogen[BUN], serum calcium, eGFR(calculated by Modification of Diet in Renal Disease[MDRD]), and urinary protein) were included in the final risk prediction model for CKD stage 4 (R-2 = 0.386). Four variables (serum hemoglobin, serum BUN, eGFR(calculated by MDRD) and urinary protein) were included in the final risk prediction model for CKD stage 5 (R-2 = 0.321). Conclusion We created a prediction model according to CKD stages by using integral means. Based on the results of the Brier score (BS) and Harrel's C statistics, we consider that our model has significant explanatory power to predict the probability and interval time to the initiation of RRT.	[Lee, Min-Jeong; Jeong, Jong Cheol; Park, Inwhee; Shin, Gyu-Tae; Kim, Heungsoo] Ajou Univ, Dept Nephrol, Sch Med, Suwon, South Korea; [Lee, Min-Jeong] Ajou Univ, Dept Emergency Med, Sch Med, Suwon, South Korea; [Park, Joo-Han] Ajou Univ, Dept Internal Med, Sch Med, Suwon, South Korea; [Moon, Yeo Rae] Ajou Univ, Dept Biostat, Sch Med, Suwon, South Korea; [Jo, Soo-Yeon; Yoon, Dukyong; Park, Rae Woong] Ajou Univ, Dept Med Informat, Sch Med, Suwon, South Korea	Ajou University; Ajou University; Ajou University; Ajou University; Ajou University	Kim, H (corresponding author), Ajou Univ, Dept Nephrol, Sch Med, Suwon, South Korea.	nephrohs@ajou.ac.kr		Lee, Min-Jeong/0000-0002-2611-7333				BOEGLIN RJ, 1992, AM J OPHTHALMOL, V113, P396, DOI 10.1016/S0002-9394(14)76161-6; Eriksen BO, 2006, KIDNEY INT, V69, P375, DOI 10.1038/sj.ki.5000058; Evans M, 2005, AM J KIDNEY DIS, V46, P863, DOI 10.1053/j.ajkd.2005.07.040; Fink JC, 2009, AM J KIDNEY DIS, V53, P681, DOI 10.1053/j.ajkd.2008.12.016; Garway-Heath DF, 2000, OPHTHALMOLOGY, V107, P1809, DOI 10.1016/S0161-6420(00)00284-0; Gerds TA, 2006, BIOMETRICAL J, V48, P1029, DOI 10.1002/bimj.200610301; Hailpern SM, 2007, J AM SOC NEPHROL, V18, P2205, DOI 10.1681/ASN.2006101165; Haroun MK, 2003, J AM SOC NEPHROL, V14, P2934, DOI 10.1097/01.ASN.0000095249.99803.85; Iseki K, 1996, KIDNEY INT, V49, P800, DOI 10.1038/ki.1996.111; Ishani A, 2006, J AM SOC NEPHROL, V17, P1444, DOI 10.1681/ASN.2005091012; James MT, 2009, AM J KIDNEY DIS, V54, P24, DOI 10.1053/j.ajkd.2009.04.005; Jin DC, 2016, KIDNEY RES CLIN PRAC, V35, P204, DOI 10.1016/j.krcp.2016.09.006; Keane WF, 2006, CLIN J AM SOC NEPHRO, V1, P761, DOI 10.2215/CJN.01381005; Levey AS, 2007, KIDNEY INT, V72, P247, DOI 10.1038/sj.ki.5002343; Levey AS, 2011, KIDNEY INT, V80, P17, DOI 10.1038/ki.2010.483; Malik R, 2012, CLIN EXP OPHTHALMOL, V40, P369, DOI 10.1111/j.1442-9071.2012.02770.x; Park JI, 2016, J KOREAN MED SCI, V31, P915, DOI 10.3346/jkms.2016.31.6.915; Soveri I, 2012, TRANSPLANTATION, V94, P57, DOI 10.1097/TP.0b013e3182516cdc; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Taal MW, 2008, KIDNEY INT, V73, P1216, DOI 10.1038/ki.2008.36; Wilhelm-Leen ER, 2009, AM J MED, V122, P664, DOI 10.1016/j.amjmed.2009.01.026	21	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2018	13	10							e0204586	10.1371/journal.pone.0204586	http://dx.doi.org/10.1371/journal.pone.0204586			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV8IQ	30286208	Green Published, gold, Green Submitted			2023-01-03	WOS:000446383500026
J	Machado, ML; Arantes, LP; Gubert, P; Zamberlan, DC; da Silva, TC; da Silveira, TL; Boligon, A; Soares, FAA				Machado, Marina Lopes; Arantes, Leticia Priscilla; Gubert, Priscila; Zamberlan, Daniele Coradini; da Silva, Thayanara Cruz; da Silveira, Tassia Limana; Boligon, Aline; Antunes Soares, Felix Alexandre			Ilex paraguariensis modulates fat metabolism in Caenorhabditis elegans through purinergic system (ADOR-1) and nuclear hormone receptor (NHR-49) pathways	PLOS ONE			English	Article							ANTIOXIDANT ACTIVITY; GREEN TEA; LIFE-SPAN; CATECHIN-POLYPHENOLS; ENERGY-EXPENDITURE; PHENOLIC-COMPOUNDS; AQUEOUS EXTRACT; LIPID DROPLETS; CAFFEINE; THERMOGENESIS	Ilex paraguariensis is a well-known plant that is widely consumed in South America, primarily as a drink called mate. Mate is described to have stimulant and medicinal properties. Considering the potential anti-lipid effects of I. paraguariensis infusion, we used an extract of this plant as a possible modulator of fat storage to control lipid metabolism in worms. Herein, the I. paraguariensis-dependent modulation of fat metabolism in Caenorhabditis elegans was investigated. C. elegans were treated with I. paraguariensis aqueous extract (1 mg/ml) from L1 larvae stage until adulthood, to simulate the primary form of consumption. Expression of adipocyte triglyceride lipase 1 (ATGL-1) and heat shock protein 16.2, lipid accumulation through C1-BODIPY-C12 (BODIPY) lipid staining, behavioral parameters, body length, total body energy expenditure and overall survival were analyzed. Total body energy expenditure was determined by the oxygen consumption rate in N2, nuclear hormone receptor knockout, nhr-49(nr2041), and adenosine receptor knockout, ador-1(ox489) strains. Ilex paraguariensis extract increased ATG L-1 expression 20.06% and decreased intestinal BODIPY fat staining 63.36%, compared with the respective control group, without affecting bacterial growth and energetic balance, while nhr-49 (nr2041) and ador-1(ox489) strains blocked the worm fat loss. In addition, I. paraguariensis increased the oxygen consumption in N2 worms, but not in mutant strains, increased N2 worm survival following juglone exposure, and did not alter hsp-16.2 expression. We demonstrate for the first time that I. paraguariensis can decrease fat storage and increase body energy expenditure in worms. These effects depend on the purinergic system (ADOR-1) and NHR-49 pathways. Ilex paraguariensis upregulated the expression of ATG L-1 to modulate fat metabolism. Furthermore, our data corroborates with other	[Machado, Marina Lopes; Arantes, Leticia Priscilla; Zamberlan, Daniele Coradini; da Silva, Thayanara Cruz; da Silveira, Tassia Limana; Antunes Soares, Felix Alexandre] Univ Fed Santa Maria, Dept Bioquim & Biol Mol, Programa Posgrad Ciencias Biol Bioquim Toxicol, Santa Maria, RS, Brazil; [Gubert, Priscila] Univ Fed Oeste Bahia, Ctr Ciencias Biol & Saude, Campus Reitor Edgard Santos, Barreiras, BA, Brazil; [Boligon, Aline] Univ Fed Santa Maria, Dept Farm Ind, Lab Pesquisa Fitoquim, Santa Maria, RS, Brazil	Universidade Federal de Santa Maria (UFSM); Universidade Federal do Oeste da Bahia; Universidade Federal de Santa Maria (UFSM)	Soares, FAA (corresponding author), Univ Fed Santa Maria, Dept Bioquim & Biol Mol, Programa Posgrad Ciencias Biol Bioquim Toxicol, Santa Maria, RS, Brazil.	felix@ufsm.br	Soares, Félix AA/K-7611-2012; Gubert, Priscila/ABC-1059-2020; Machado, Marina/AAI-6743-2020; Arantes, Leticia/AEC-9028-2022; Soares, Félix/AAE-6251-2020	Soares, Félix AA/0000-0002-6453-7902; Gubert, Priscila/0000-0002-3598-8050; Machado, Marina/0000-0001-7425-3316; Soares, Félix/0000-0002-6453-7902; Arantes, Leticia/0000-0001-7091-0067; Limana Da Silveira, Tassia/0000-0002-3947-1550	"Programa de Apoio a Nucleos Emergentes" (PRONEM) [16/25510000248-7]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES-PROEX) [23038.005848/2018-31, 0737/2018]	"Programa de Apoio a Nucleos Emergentes" (PRONEM); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES-PROEX)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	The financial support for this study was provided by "Programa de Apoio a Nucleos Emergentes" (PRONEM) [grant number 16/25510000248-7] to FAAS and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES-PROEX) [Process: 23038.005848/2018-31, grant number 0737/2018]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas SR, 2014, FOOD CHEM, V147, P10, DOI 10.1016/j.foodchem.2013.09.113; Abdollahi M, 2003, MIDDLE E PHARM, V11, P6; Arantes LP, 2014, IND CROP PROD, V62, P265, DOI 10.1016/j.indcrop.2014.08.038; Arcari DP, 2011, MOL CELL ENDOCRINOL, V335, P110, DOI 10.1016/j.mce.2011.01.003; Arcari DP, 2009, OBESITY, V17, P2127, DOI 10.1038/oby.2009.158; Argyropoulos G, 2002, J APPL PHYSIOL, V92, P2187, DOI 10.1152/japplphysiol.00994.2001; ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759; Bastos D.H.M., 2007, MED AROMATIC PLANT S, V1, P37; Belza A, 2009, EUR J CLIN NUTR, V63, P57, DOI 10.1038/sj.ejcn.1602901; BLUM J, 1983, ARCH BIOCHEM BIOPHYS, V222, P35, DOI 10.1016/0003-9861(83)90499-X; Boligon AA, 2013, ACTA PHYSIOL PLANT, V35, P2229, DOI 10.1007/s11738-013-1259-0; Bonomo LDF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089933; BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, pE671, DOI 10.1152/ajpendo.1995.269.4.E671; Bracesco N, 2011, J ETHNOPHARMACOL, V136, P378, DOI 10.1016/j.jep.2010.06.032; BRENNER S, 1974, GENETICS, V77, P71; Bridi JC, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00220; Brooks KK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007545; Brunton L, 2014, GOODMAN GILMANS MANU, V5th; Chamoli M, 2014, AGING CELL, V13, P641, DOI 10.1111/acel.12218; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Debas HT, 2006, COMPLEMENTARY ALTERN; Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101; DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44; Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040; Elle IC, 2010, FEBS LETT, V584, P2183, DOI 10.1016/j.febslet.2010.03.046; Filip R, 2000, NUTR RES, V20, P1437, DOI 10.1016/S0271-5317(00)80024-X; Filip R, 2001, FITOTERAPIA, V72, P774, DOI 10.1016/S0367-326X(01)00331-8; Filip R, 1998, PHYTOTHER RES, V12, P129, DOI 10.1002/(SICI)1099-1573(199803)12:2&lt;129::AID-PTR191&gt;3.0.CO;2-1; Frayn Keith N, 2009, METABOLIC REGULATION; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI21625, 10.1172/JCI20042162S]; Gilbert B, 2003, CURR MED CHEM, V10, P13, DOI 10.2174/0929867033368583; Goh GYS, 2018, AGING CELL, V17, DOI 10.1111/acel.12743; GONZALEZ A, 1993, J ETHNOPHARMACOL, V39, P217, DOI 10.1016/0378-8741(93)90040-C; Gorjanovic S, 2012, J AGR FOOD CHEM, V60, P9573, DOI 10.1021/jf302375t; Haldi J, 1941, J NUTR, V21, P307, DOI 10.1093/jn/21.3.307; Harpaz Eynav, 2017, Journal of Basic and Clinical Physiology and Pharmacology, V28, P1, DOI 10.1515/jbcpp-2016-0090; Hasani-Ranjbar S, 2009, WORLD J GASTROENTERO, V15, P3073, DOI 10.3748/wjg.15.3073; Higgins HL, 1915, J PHARMACOL EXP THER, V7, P1; Huang C, 2004, P NATL ACAD SCI USA, V101, P8084, DOI 10.1073/pnas.0400848101; Jacobson Kenneth A, 2009, Handb Exp Pharmacol, P1, DOI 10.1007/978-3-540-89615-9_1; Jones KT, 2009, DIS MODEL MECH, V2, P224, DOI 10.1242/dmm.001933; Kahkonen MP, 1999, J AGR FOOD CHEM, V47, P3954, DOI 10.1021/jf990146l; Kang JG, 2012, DIABETES METAB J, V36, P13, DOI 10.4093/dmj.2012.36.1.13; Kubagawa HM, 2006, NAT CELL BIOL, V8, P1143, DOI 10.1038/ncb1476; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Migliori ML, 2011, PHYSIOL BEHAV, V103, P315, DOI 10.1016/j.physbeh.2011.01.026; Lima ME, 2014, INT J ENV RES PUB HE, V11, P10091, DOI 10.3390/ijerph111010091; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lodish H., 2000, OXIDATION GLUCOSE FA, V4th; Mak HY, 2006, NAT GENET, V38, P363, DOI 10.1038/ng1739; Martin S, 2006, NAT REV MOL CELL BIO, V7, P373, DOI 10.1038/nrm1912; MILLER DS, 1974, P NUTR SOC, V33, pA28; Mosimann ALP, 2006, BIOFACTORS, V26, P59, DOI 10.1002/biof.5520260106; Mullaney BC, 2009, BBA-MOL CELL BIOL L, V1791, P474, DOI 10.1016/j.bbalip.2008.12.013; Narbonne P, 2009, NATURE, V457, P210, DOI 10.1038/nature07536; NEHLIG A, 1992, BRAIN RES REV, V17, P139, DOI 10.1016/0165-0173(92)90012-B; O'Rourke EJ, 2009, CELL METAB, V10, P430, DOI 10.1016/j.cmet.2009.10.002; Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732; Pi-Sunyer FX, 2004, NUTR REV, V62, pS120, DOI 10.1111/j.1753-4887.2004.tb00081.x; Ranjan M, 2013, FREE RADICAL BIO MED, V63, P381, DOI 10.1016/j.freeradbiomed.2013.05.025; Rates SMK, 2001, TOXICON, V39, P603, DOI 10.1016/S0041-0101(00)00154-9; Riedel A, 2012, FOOD FUNCT, V3, P955, DOI 10.1039/c2fo30053b; Salgueiro WG, 2017, FREE RADICAL BIO MED, V110, P133, DOI 10.1016/j.freeradbiomed.2017.05.020; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; Schinella GR, 2000, BIOCHEM BIOPH RES CO, V269, P357, DOI 10.1006/bbrc.2000.2293; Schweiger M, 2006, J BIOL CHEM, V281, P40236, DOI 10.1074/jbc.M608048200; Shen PY, 2017, J MED FOOD, V20, P887, DOI 10.1089/jmf.2016.0179; Sun QC, 2016, J MED FOOD, V19, P427, DOI 10.1089/jmf.2015.0133; Tsalik EL, 2003, J NEUROBIOL, V56, P178, DOI 10.1002/neu.10245; Van Gilst MR, 2005, PLOS BIOL, V3, P301, DOI 10.1371/journal.pbio.0030053; WAGNER H, 1993, J ETHNOPHARMACOL, V38, P105, DOI 10.1016/0378-8741(93)90004-O; Walther TC, 2012, ANNU REV BIOCHEM, V81, P687, DOI 10.1146/annurev-biochem-061009-102430; Watts JL, 2003, GENETICS, V163, P581; Waypa GB, 2016, MOL ASPECTS MED, V47-48, P76, DOI 10.1016/j.mam.2016.01.002; Williamson EM, 2001, PHYTOMEDICINE, V8, P401, DOI 10.1078/0944-7113-00060; WORMBASE, 2017, ADOR 1 GENE; Yilmaz LS, 2014, TRENDS GENET, V30, P496, DOI 10.1016/j.tig.2014.07.010; Zamberlan DC, 2014, NEUROSCIENCE, V278, P40, DOI 10.1016/j.neuroscience.2014.07.068	78	8	8	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2018	13	9							e0204023	10.1371/journal.pone.0204023	http://dx.doi.org/10.1371/journal.pone.0204023			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GU9BO	30252861	Green Submitted, Green Published, gold			2023-01-03	WOS:000445639700022
J	Larribau, R; Deham, H; Niquille, M; Sarasin, FP				Larribau, Robert; Deham, Helene; Niquille, Marc; Sarasin, Francois Pierre			Improvement of out-of-hospital cardiac arrest survival rate after implementation of the 2010 resuscitation guidelines	PLOS ONE			English	Article							AMERICAN-HEART-ASSOCIATION; INTERNATIONAL LIAISON COMMITTEE; LONG-TERM SURVIVAL; EUROPEAN-RESUSCITATION; CARDIOPULMONARY-RESUSCITATION; COUNCIL GUIDELINES; LIFE-SUPPORT; SECTION 4; OUTCOMES; REGISTRY	Objective The implementation of cardiopulmonary resuscitation guidelines, updated every five years, appears to improve patient survival rates after Out-Of-Hospital Cardiac Arrest (OHCA). The aim of this study is: 1) to measure the level of improvement in the prognosis of OHCA patient survival rates for the years 2009 and 2010 and the following two years 2011 and 2012; and 2) correlate the improvement in prognosis with the updated 2010 Advanced Cardiovascular Life Support (ACLS) Guidelines. Method We performed a retrospective observational study based on Geneva's OHCA register that includes data from January 1, 2009 to December 31, 2012. We compared the evolution of prognostic factors that influenced survival at hospital discharge between the periods before and after the implementation of the 2010 guidelines. We then compared the survival rates between each period. Finally, we adjusted the effects on survival in the second period to prognostic factors not linked with the care provided by Emergency Medical Services (EMS) teams, using a multivariable logistic regression model. Changes in advanced resuscitation treatment provided by EMS personnel were also examined. Results 795 OHCA were resuscitated between 1st January, 2009 and 31st December, 2012. The prognosis of patient survival at the time of hospital discharge rose from 10.33% in 2009-2010 to 17.01% in 2011-2012 (p = 0.007). After making adjustments for the effect of improved survival rates on the second period with factors not related to care provided by EMS teams, the odds ratio (OR) remains comparable (OR = 1.87, 95% CI [1.08-3.22]). Measured changes in treatment provided by EMS personnel were minor. Conclusions Survival rate for OHCA patients improved significantly in 2011-2012. This study suggests that it was probably the improvement in the quality of care provided during CPR and post-cardiac arrest care that have contributed to the increase in survival rates at the time of hospital discharge.	[Larribau, Robert; Deham, Helene; Niquille, Marc; Sarasin, Francois Pierre] Geneva Univ Hosp, Dept Community Med Primary Care & Emergency Med, Div Emergency Med, Geneva, Switzerland	University of Geneva	Larribau, R (corresponding author), Geneva Univ Hosp, Dept Community Med Primary Care & Emergency Med, Div Emergency Med, Geneva, Switzerland.	robert.larribau@hcuge.ch	Larribau, Robert/AAT-7988-2021	Larribau, Robert/0000-0002-5200-4199; NIQUILLE, Marc/0000-0002-2671-6889				Ageron FX, 2016, RESUSCITATION, V98, pE2, DOI 10.1016/j.resuscitation.2015.10.014; Becker L, 2008, RESUSCITATION, V79, P22, DOI 10.1016/j.resuscitation.2008.06.019; Bonnes JL, 2016, ANN EMERG MED, V67, P349, DOI 10.1016/j.annemergmed.2015.09.023; Chan PS, 2014, CIRCULATION, V130, P1876, DOI 10.1161/CIRCULATIONAHA.114.009711; Cummins RO, 2000, CIRCULATION, V102, DOI [10.1161/01.CIR.102.suppl_1.I-371, DOI 10.1161/01.CIR.102.SUPPL_1.I-371]; Daya MR, 2015, RESUSCITATION, V91, P108, DOI 10.1016/j.resuscitation.2015.02.003; Deakin CD, 2010, RESUSCITATION, V81, P1305, DOI 10.1016/j.resuscitation.2010.08.017; Deasy C, 2011, RESUSCITATION, V82, P984, DOI 10.1016/j.resuscitation.2011.04.005; Gunther A, 2015, Z EVIDENZ FORTBILD Q, V109, P714, DOI 10.1016/j.zefq.2015.06.003; Handley AJ, 2005, RESUSCITATION, V67, pS7, DOI 10.1016/j.resuscitation.2005.10.007; Hawkes C, 2017, RESUSCITATION, V110, P133, DOI 10.1016/j.resuscitation.2016.10.030; Hazinski MF, 2010, CIRCULATION, V122, P8250, DOI 10.1161/CIRCULATIONAHA.110.970897; Hazinski MF, 2005, CIRCULATION, V112, pIV206, DOI 10.1161/CIRCULATIONAHA.105.170809; Kajino K, 2016, PREHOSP EMERG CARE, V20, P477, DOI 10.3109/10903127.2015.1115931; Kaneko H, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004959; Kloeck W, 1997, RESUSCITATION, V34, P109, DOI 10.1016/S0300-9572(97)01100-3; Kudenchuk PJ, 2012, CIRCULATION, V125, P1787, DOI 10.1161/CIRCULATIONAHA.111.064873; Margey R, 2011, EUROPACE, V13, P1157, DOI 10.1093/europace/eur092; McNally Bryan, 2011, Morbidity and Mortality Weekly Report, V60, P1; Montgomery W H, 1992, Ann Acad Med Singap, V21, P92; Morrison LJ, 2010, CIRCULATION, V122, P8345, DOI 10.1161/CIRCULATIONAHA.110.971051; Nehme Z, 2015, CIRC-CARDIOVASC QUAL, V8, P56, DOI 10.1161/CIRCOUTCOMES.114.001185; Nolan J, 2010, RESUSCITATION, V81, P1, DOI 10.1016/j.resuscitation.2009.11.016; Nolan JP, 2005, RESUSCITATION, V67, pS39, DOI 10.1016/j.resuscitation.2005.10.009; OCSTAT, 2015, FEUILL INF; Olasveengen TM, 2009, RESUSCITATION, V80, P407, DOI 10.1016/j.resuscitation.2008.12.005; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Perkins GD, 2015, CIRCULATION, V132, P1286, DOI 10.1161/CIR.0000000000000144; Perkins GD, 2015, LANCET, V385, P947, DOI 10.1016/S0140-6736(14)61886-9; Perkins GD, 2012, HEART, V98, P529, DOI 10.1136/heartjnl-2011-300802; Ro YS, 2013, RESUSCITATION, V84, P547, DOI 10.1016/j.resuscitation.2012.12.020; Robinson S, 2010, RESUSCITATION, V81, P1648, DOI 10.1016/j.resuscitation.2010.07.009; Salam AM, 2013, RESUSCITATION, V84, pE97, DOI 10.1016/j.resuscitation.2013.04.008; Savastano S, 2014, J CARDIOVASC MED, V15, P609, DOI 10.2459/JCM.0000000000000040; Travers AH, 2010, CIRCULATION, V122, pS676, DOI 10.1161/CIRCULATIONAHA.110.970913; Wong MKY, 2014, CIRCULATION, V130, P1883, DOI 10.1161/CIRCULATIONAHA.114.010633; Yamaguchi Y, 2017, PREHOSP EMERG CARE, V21, P616, DOI 10.1080/10903127.2017.1308604	37	23	24	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2018	13	9							e0204169	10.1371/journal.pone.0204169	http://dx.doi.org/10.1371/journal.pone.0204169			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV3MI	30248116	Green Published, gold, Green Submitted			2023-01-03	WOS:000445998100025
J	Scheerens, C; Chambaere, K; Pardon, K; Derom, E; Van Belle, S; Joos, G; Pype, P; Deliens, L				Scheerens, Charlotte; Chambaere, Kenneth; Pardon, Koen; Derom, Eric; Van Belle, Simon; Joos, Guy; Pype, Peter; Deliens, Luc			Development of a complex intervention for early integration of palliative home care into standard care for end-stage COPD patients: A Phase 0-I study	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; GENERAL-PRACTITIONERS; LUNG-CANCER; OF-LIFE; SUPPORT; HEALTH; COSTS; BREATHLESSNESS; INITIATION	Background Research suggests that palliative home care should be integrated early into standard care for end-stage COPD patients. Patients also express the wish to be cared for and to die at home. However, a practice model for early integration of palliative home care (PHC) into standard care for end-stage COPD has not been fully developed. Aim To develop an intervention for early integration of PHC into standard care for end-stage COPD patients. Methods We conducted a Phase 0-I study according to the Medical Research Council Framework for the development of complex interventions. Phase 0 aimed to identify the inclusion criteria and key components of the intervention by way of an explorative literature search of interventions, expert consultations, and seven focus groups with general practitioners and community nurses on perceived barriers to and facilitators of early integrated PHC for COPD. In Phase 1, the intervention, its inclusion criteria and its components were developed and further refined by an expert panel and two expert opinions. Results Phase 0 resulted in identification of inclusion criteria and components from existing interventions, and barriers to and facilitators of early integration of PHC for end-stage COPD. Based on these findings, a nurse-led intervention was developed in Phase I consisting of training for PHC nurses in symptom recognition and physical therapy exercises for end-stage COPD, regular visits by PHC nurses at the patients' homes, two information leaflets on selfmanagement, a semi-structured protocol and follow-up plan to record the outcomes of the home visits, and integration of care by enabling collaboration and communication between home and hospital-based professional caregivers. Conclusion This Phase 0-I trial succeeded in developing a complex intervention for early integration of PHC for end-stage COPD. The use of three methods in Phase 0 gave reliable data on which to base inclusion criteria and components of the intervention. The preliminary effectiveness, feasibility and acceptability of the intervention will be subsequently tested in a Phase II study.	[Scheerens, Charlotte; Chambaere, Kenneth; Pardon, Koen; Van Belle, Simon; Pype, Peter; Deliens, Luc] Univ Ghent, End Of Life Care Res Grp, Ghent, Belgium; [Scheerens, Charlotte; Chambaere, Kenneth; Pardon, Koen; Van Belle, Simon; Pype, Peter; Deliens, Luc] Vrije Univ Brussel, Ghent, Belgium; [Scheerens, Charlotte; Chambaere, Kenneth; Derom, Eric; Joos, Guy; Deliens, Luc] Univ Ghent, Dept Internal Med, Ghent, Belgium; [Derom, Eric; Joos, Guy] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium; [Van Belle, Simon] Ghent Univ Hosp, Dept Med Oncol, Ghent, Belgium; [Pype, Peter] Univ Ghent, Dept Family Med & Primary Hlth Care, Ghent, Belgium	Ghent University; Vrije Universiteit Brussel; Ghent University; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Ghent University	Scheerens, C (corresponding author), Univ Ghent, End Of Life Care Res Grp, Ghent, Belgium.; Scheerens, C (corresponding author), Vrije Univ Brussel, Ghent, Belgium.; Scheerens, C (corresponding author), Univ Ghent, Dept Internal Med, Ghent, Belgium.	charlotte.scheerens@ugent.be	Chambaere, Kenneth/ACV-2311-2022	Joos, Guy/0000-0002-3149-9444; Pardon, Koen/0000-0002-0571-709X	IWT - Agentschap voor Innovatie door Wetenschap en Technologie & SBO - Strategisch Basis Onderzoek	IWT - Agentschap voor Innovatie door Wetenschap en Technologie & SBO - Strategisch Basis Onderzoek	Funded by IWT - Agentschap voor Innovatie door Wetenschap en Technologie & SBO - Strategisch Basis Onderzoek: 140009 (received: LD).	[Anonymous], 1999, CHEST, V116, P521; Bakitas MA, 2015, J CLIN ONCOL, V33, P1438, DOI 10.1200/JCO.2014.58.6362; Bereza BG, 2015, INT J CHRONIC OBSTR, V10, P739, DOI 10.2147/COPD.S82179; Booth S, 2011, J PALLIAT CARE, V27, P28, DOI 10.1177/082585971102700106; Bove DG, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008031; Buckingham S, 2015, NPJ PRIM CARE RESP M, V25, DOI 10.1038/npjpcrm.2015.20; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Cassel JB, 2016, J AM GERIATR SOC, V64, P2288, DOI 10.1111/jgs.14354; COCKCROFT A, 1987, BRIT MED J, V294, P225, DOI 10.1136/bmj.294.6566.225; Cohen J, 2017, NPJ PRIM CARE RESP M, V27, DOI 10.1038/s41533-017-0017-y; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Damps-Konstanska I, 2016, APPL NURS RES, V31, P60, DOI 10.1016/j.apnr.2015.12.003; De Vleminck A, 2016, BMC PALLIAT CARE, V15, DOI 10.1186/s12904-016-0091-x; Duenk RG, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-54; Enguidanos SM, 2005, J SOC WORK END-LIFE, V1, P37, DOI 10.1300/J457v01n03_04; Farquhar MC, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1304-6; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gex G, 2007, REV MED SUISSE, V3, P2648; Gex G, 2007, REV MED SUISSE, V3, P2652; goldcopd, 2022, GLOBAL STRATEGY DIAG; Gomes B, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-7; Gomes B, 2014, JAMA-J AM MED ASSOC, V311, P1060, DOI 10.1001/jama.2014.553; Gore JM, 2000, THORAX, V55, P1000, DOI 10.1136/thorax.55.12.1000; Halliwell J, 2004, BRIT J GEN PRACT, V54, P904; Higginson IJ, 2014, LANCET RESP MED, V2, P979, DOI 10.1016/S2213-2600(14)70226-7; Ho TW, 2016, SCI REP-UK, V6, DOI 10.1038/srep23797; Horton R, 2013, J PALLIAT MED, V16, P67, DOI 10.1089/jpm.2012.0285; Houben CHM, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004465; Leiva-Fernandez J, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1269-5; Maddocks M, 2017, LANCET, V390, P988, DOI 10.1016/S0140-6736(17)32127-X; Mannino DM, 2002, CHEST, V121, p121S, DOI 10.1378/chest.121.5_suppl.121S; MCSWEENY AJ, 1982, ARCH INTERN MED, V142, P473, DOI 10.1001/archinte.142.3.473; Medical Research Council, 2000, MED RES COUNC MRC FR; Randomized A, 2012, ORIGINAL RES COMPRE, V156; Guell MR, 2008, ARCH BRONCONEUMOL, V44, P512, DOI 10.1016/S1579-2129(08)60096-8; Scheerens C, COMP USE TIMING PALL; Scheerens C, 2018, NPJ PRIM CARE RESP M, V28, DOI 10.1038/s41533-018-0091-9; Scheerens C, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02405-2017; Singer AE, 2016, J PALLIAT MED, V19, P995, DOI 10.1089/jpm.2015.0367; Temel JS, 2017, J CLIN ONCOL, V35, P834, DOI 10.1200/JCO.2016.70.5046; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Teno J, 1997, J AM GERIATR SOC, V45, P500, DOI 10.1111/j.1532-5415.1997.tb05178.x; The Montreal Chest Institute of the McGill University Health Centre, LIV WELL COPD; Thoonsen B, 2015, BMC FAM PRACT, V16, DOI 10.1186/s12875-015-0342-6; Vanbutsele G, 2018, LANCET ONCOL; Weber C, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-47; Zimmermann C, 2014, LANCET, V383, P1721, DOI 10.1016/S0140-6736(13)62416-2	47	10	10	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2018	13	9							e0203326	10.1371/journal.pone.0203326	http://dx.doi.org/10.1371/journal.pone.0203326			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GU3GJ	30231042	gold, Green Submitted, Green Published			2023-01-03	WOS:000445164300039
J	Fu, X; Sluka, JP; Clendenon, SG; Dunn, KW; Wang, ZM; Klaunig, JE; Glazier, JA				Fu, Xiao; Sluka, James P.; Clendenon, Sherry G.; Dunn, Kenneth W.; Wang, Zemin; Klaunig, James E.; Glazier, James A.			Modeling of xenobiotic transport and metabolism in virtual hepatic lobule models	PLOS ONE			English	Article							BLOOD-FLOW; LIVER SINUSOIDS; IN-VIVO; MICROVESSELS; ZONATION; OXYGEN; RESISTANCE; VISCOSITY; TISSUES	Computational models of normal liver function and xenobiotic induced liver damage are increasingly being used to interpret in vitro and in vivo data and as an approach to the de novo prediction of the liver's response to xenobiotics. The microdosimetry (dose at the level of individual cells) of xenobiotics vary spatially within the liver because of both compound-independent and compound-dependent factors. In this paper, we build model liver lobules to investigate the interplay between vascular structure, blood flow and cellular transport that lead to regional variations in microdosimetry. We then compared simulation results obtained using this complex spatial model with a simpler linear pipe model of a sinusoid and a very simple single box model. We found that variations in diffusive transport, transporter-mediated transport and metabolism, coupled with complex liver sinusoid architecture and blood flow distribution, led to three essential patterns of xenobiotic exposure within the virtual liver lobule: (1) lobular-wise uniform, (2) radially varying and (3) both radially and azimuthally varying. We propose to use these essential patterns of exposure as a reference for selection of model representations when a computational study involves modeling detailed hepatic responses to xenobiotics.	[Fu, Xiao; Sluka, James P.; Clendenon, Sherry G.; Glazier, James A.] Indiana Univ, Biocomplex Inst, Bloomington, IN 47405 USA; [Fu, Xiao] Indiana Univ, Dept Phys, Bloomington, IN 47405 USA; [Sluka, James P.; Clendenon, Sherry G.; Glazier, James A.] Indiana Univ, Dept Intelligent Syst Engn, Bloomington, IN 47405 USA; [Dunn, Kenneth W.] Indiana Univ, Sch Med, Indianapolis, IN USA; [Wang, Zemin; Klaunig, James E.] Indiana Univ, Sch Publ Hlth, Bloomington, IN USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University Bloomington	Sluka, JP (corresponding author), Indiana Univ, Biocomplex Inst, Bloomington, IN 47405 USA.; Sluka, JP (corresponding author), Indiana Univ, Dept Intelligent Syst Engn, Bloomington, IN 47405 USA.	jsluka@indiana.edu	Clendenon, Sherry G/F-7651-2010; Clendenon, Sherry/AAG-6655-2019; Sluka, James P/AAL-9294-2021	Clendenon, Sherry G/0000-0002-3353-0919; Clendenon, Sherry/0000-0002-3353-0919; Sluka, James P/0000-0002-5901-1404; Klaunig, James/0000-0002-4736-2223; Fu, Xiao/0000-0002-8611-891X; Glazier, James Alexander/0000-0003-3634-190X	National Institutes of Health, National Institute of General Medical Sciences [GM111243, GM076692]; U.S. Environmental Protection Agency [R835001]; National Science Foundation [NSF 1720625]; Falk Medical Research Trust Catalyst Program [Falk 44-38-12]; National Institutes of Health O'Brien Center for Advanced Renal Microscopic Analysis [NIH-NIDDK P30DK079312]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM122424, U01GM111243] Funding Source: NIH RePORTER	National Institutes of Health, National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); U.S. Environmental Protection Agency(United States Environmental Protection Agency); National Science Foundation(National Science Foundation (NSF)); Falk Medical Research Trust Catalyst Program; National Institutes of Health O'Brien Center for Advanced Renal Microscopic Analysis(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	XF, JPS, SGC, KWD, ZW, JEK and JAG were supported by the National Institutes of Health, National Institute of General Medical Sciences (GM111243). XF, JPS, SGC and JAG were also supported by the U.S. Environmental Protection Agency (R835001), National Science Foundation (NSF 1720625), Falk Medical Research Trust Catalyst Program (https://hria.org/tmf/falkcap/) (Falk 44-38-12), and National Institutes of Health, National Institute of General Medical Sciences (GM076692). KWD was also supported by the National Institutes of Health O'Brien Center for Advanced Renal Microscopic Analysis (NIH-NIDDK P30DK079312).	Belmonte JM, 2016, MOL BIOL CELL, V27, P3673, DOI 10.1091/mbc.E16-01-0059; Ben-Shachar R, 2012, THEOR BIOL MED MODEL, V9, DOI 10.1186/1742-4682-9-55; Bhattacharya S, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00462; Birchmeier W, 2016, NAT CELL BIOL, V18, P463, DOI 10.1038/ncb3349; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; Bonfiglio A, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4002563; Chalhoub E, 2007, ANN BIOMED ENG, V35, P474, DOI 10.1007/s10439-006-9217-2; Chen M, 2013, CLIN PHARMACOL THER, V93, P409, DOI 10.1038/clpt.2013.16; Colnot S, 2011, MOL PATHOL LIB, V5, P7, DOI 10.1007/978-1-4419-7107-4_2; DAVIES B, 1993, PHARMACEUT RES, V10, P1093, DOI 10.1023/A:1018943613122; Debbaut C, 2014, COMPUT METHOD BIOMEC, V17, P1295, DOI 10.1080/10255842.2012.744399; Drasdo D, 2014, ARCH TOXICOL, V88, P2071, DOI 10.1007/s00204-014-1384-6; Fu X, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004932; Gebhardt R, 2014, WORLD J GASTROENTERO, V20, P8491, DOI 10.3748/wjg.v20.i26.8491; Ghallab A, 2016, J HEPATOL, V64, P860, DOI 10.1016/j.jhep.2015.11.018; Hammad S, 2014, ARCH TOXICOL, V88, P1161, DOI 10.1007/s00204-014-1243-5; Hoehme S, 2010, P NATL ACAD SCI USA, V107, P10371, DOI 10.1073/pnas.0909374107; Hunt CA, 2006, J PHARMACOKINET PHAR, V33, P737, DOI 10.1007/s10928-006-9031-3; Jungermann K, 2000, HEPATOLOGY, V31, P255, DOI 10.1002/hep.510310201; KOMATSU H, 1990, MICROVASC RES, V40, P1, DOI 10.1016/0026-2862(90)90002-9; KOO A, 1975, Q J EXP PHYSIOL CMS, V60, P261, DOI 10.1113/expphysiol.1975.sp002320; KOO A, 1979, J PHYSIOL-LONDON, V295, P191, DOI 10.1113/jphysiol.1979.sp012961; Lee-Montiel FT, 2017, EXP BIOL MED, V242, P1617, DOI 10.1177/1535370217703978; Leeson T., 1970, HISTOLOGY; MaassMoreno R, 1997, AM J PHYSIOL-HEART C, V272, pH2826, DOI 10.1152/ajpheart.1997.272.6.H2826; MACPHEE PJ, 1988, MICROVASC RES, V36, P140, DOI 10.1016/0026-2862(88)90014-3; MACPHEE PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG692, DOI 10.1152/ajpgi.1995.269.5.G692; Nishii K, 2016, J MECH BEHAV BIOMED, V57, P201, DOI 10.1016/j.jmbbm.2015.11.033; Ochoa JGD, 2013, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00204; Ohno H, 2008, ARTIF LIFE, V14, P3, DOI 10.1162/artl.2008.14.1.3; Planas-Paz L, 2016, NAT CELL BIOL, V18, P467, DOI 10.1038/ncb3337; Poplawski NJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010641; Pries AR, 2005, AM J PHYSIOL-HEART C, V289, pH2657, DOI 10.1152/ajpheart.00297.2005; PRIES AR, 1994, CIRC RES, V75, P904, DOI 10.1161/01.RES.75.5.904; Rani HP, 2006, J BIOMECH, V39, P551, DOI 10.1016/j.jbiomech.2004.11.029; Reddyhoff D, 2015, J THEOR BIOL, V386, P132, DOI 10.1016/j.jtbi.2015.08.021; Remien CH, 2012, HEPATOLOGY, V56, P727, DOI 10.1002/hep.25656; Rezania V, 2016, THEOR BIOL MED MODEL, V13, DOI 10.1186/s12976-016-0034-5; Ricken T, 2015, BIOMECH MODEL MECHAN, V14, P515, DOI 10.1007/s10237-014-0619-z; ROTEM A, 1992, BIOTECHNOL BIOENG, V40, P1286, DOI 10.1002/bit.260401020; Schleicher J, 2017, J R SOC INTERFACE, V14, DOI 10.1098/rsif.2017.0443; Schliess F, 2014, HEPATOLOGY, V60, P2040, DOI 10.1002/hep.27136; Schwingshackl L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140846; Secomb TW, 2013, CR PHYS, V14, P470, DOI 10.1016/j.crhy.2013.04.002; Shah I, 2010, J TOXICOL ENV HEAL B, V13, P314, DOI 10.1080/10937404.2010.483948; SHIBAYAMA Y, 1985, HEPATOLOGY, V5, P643, DOI 10.1002/hep.1840050421; Sluka JP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162428; Swat MH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127972; Swat MH, 2012, METHOD CELL BIOL, V110, P325, DOI 10.1016/B978-0-12-388403-9.00013-8; Wagner BA, 2011, FREE RADICAL BIO MED, V51, P700, DOI 10.1016/j.freeradbiomed.2011.05.024; Wambaugh J, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000756; Yan L, 2008, PHARM RES, V25, P1023, DOI 10.1007/s11095-007-9494-y	52	16	16	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2018	13	9							e0198060	10.1371/journal.pone.0198060	http://dx.doi.org/10.1371/journal.pone.0198060			34	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT5KH	30212461	Green Published, Green Submitted, gold			2023-01-03	WOS:000444545800001
J	Klaus, J; Schutter, DJLG				Klaus, Jana; Schutter, Dennis J. L. G.			Putting focus on transcranial direct current stimulation in language production studies	PLOS ONE			English	Article							NONINVASIVE BRAIN-STIMULATION; WORD PRODUCTION; TDCS; FACILITATION; FLUENCY; INTERFERENCE; METAANALYSIS; PERFORMANCE; ACTIVATION; MODEL	Previous language production studies targeting the inferior frontal and superior temporal gyrus using anodal tDCS have provided mixed results. Part of this heterogeneity may be explained by limited target region focality of conventionally used electrode montages. We examined the focality of conventionally and alternative electrode montages. Electrical field distributions of anodal tDCS targeting IFG and pSTG were simulated in conventional setups (anodal electrode over left IFG/pSTG, reference electrode over right supraorbital region) and an alternative electrode montage in four different brains. Conventional montages showed maximum field strengths outside of the target regions. Results from alternative electrode montages showed that focality of tDCS could be improved by adjustments in electrode placement. Heterogeneity of findings of language production studies deploying conventional montages may in part be explained by diffuse electrical field distributions. Alternative montages may improve focality and provide more unequivocal results.	[Klaus, Jana; Schutter, Dennis J. L. G.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands	Radboud University Nijmegen	Klaus, J (corresponding author), Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands.	j.klaus@donders.ru.nl	Klaus, Jana/F-4802-2016	Klaus, Jana/0000-0003-4398-8672	German Research Foundation [KL 2933/2]	German Research Foundation(German Research Foundation (DFG))	This work was supported by a grant from the German Research Foundation (http://www.dfg.de) awarded to JK (KL 2933/2). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bikson M, 2010, CLIN NEUROPHYSIOL, V121, P1976, DOI 10.1016/j.clinph.2010.05.020; Cattaneo Z, 2011, NEUROSCIENCE, V183, P64, DOI 10.1016/j.neuroscience.2011.03.058; Cerruti C, 2009, J COGNITIVE NEUROSCI, V21, P1980, DOI 10.1162/jocn.2008.21143; Ehlis AC, 2016, NEUROIMAGE, V140, P134, DOI 10.1016/j.neuroimage.2015.12.047; Elsner B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009760.pub3; Fertonani A, 2010, BEHAV BRAIN RES, V208, P311, DOI 10.1016/j.bbr.2009.10.030; Fiori V, 2014, NEUROSCIENCE, V256, P195, DOI 10.1016/j.neuroscience.2013.10.048; Galletta EE, 2015, BRAIN STIMUL, V8, P1108, DOI 10.1016/j.brs.2015.06.018; Henseler I, 2014, J COGNITIVE NEUROSCI, V26, P1403, DOI 10.1162/jocn_a_00572; Holland R, 2011, CURR BIOL, V21, P1403, DOI 10.1016/j.cub.2011.07.021; Horvath JC, 2015, BRAIN STIMUL, V8, P535, DOI 10.1016/j.brs.2015.01.400; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Klaus J, 2018, BRAIN COGNITION, V123, P10, DOI 10.1016/j.bandc.2018.02.007; Laakso I, 2016, NEUROIMAGE, V137, P140, DOI 10.1016/j.neuroimage.2016.05.032; Meinzer M, 2012, J NEUROSCI, V32, P1859, DOI 10.1523/JNEUROSCI.4812-11.2012; Oldrati V, 2017, CEREBELLUM, P1, DOI DOI 10.1007/S12311-015-0758-5; Opitz A, 2015, NEUROIMAGE, V109, P140, DOI 10.1016/j.neuroimage.2015.01.033; Parazzini M, 2015, COMPUT INTEL NEUROSC, V2015, DOI 10.1155/2015/963293; Pisoni A, 2012, NEUROSCIENCE, V223, P56, DOI 10.1016/j.neuroscience.2012.07.046; Pisoni A, 2017, NEUROSCIENCE, V352, P106, DOI 10.1016/j.neuroscience.2017.03.043; Pisoni A, 2018, CEREB CORTEX, V28, P1132, DOI 10.1093/cercor/bhx021; Price AR, 2015, BRAIN STIMUL, V8, P1093, DOI 10.1016/j.brs.2015.06.013; Rahman A, 2015, PROG BRAIN RES, V222, P25, DOI 10.1016/bs.pbr.2015.09.003; Rampersad SM, 2014, IEEE T NEUR SYS REH, V22, P441, DOI 10.1109/TNSRE.2014.2308997; Sandars M, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/8428256; Sebastian R, 2016, NEUROREHABILITATION, V39, P141, DOI 10.3233/NRE-161346; Sparing R, 2008, NEUROPSYCHOLOGIA, V46, P261, DOI 10.1016/j.neuropsychologia.2007.07.009; Turi Z, 2017, SCI REP-UK, V7, DOI 10.1038/srep41028; Vannorsdall TD, 2016, COGN BEHAV NEUROL, V29, P11, DOI 10.1097/WNN.0000000000000086; Vannorsdall Tracy D, 2012, Front Psychiatry, V3, P73, DOI 10.3389/fpsyt.2012.00073; Wagner T, 2007, NEUROIMAGE, V35, P1113, DOI 10.1016/j.neuroimage.2007.01.027; Westwood SJ, 2017, NEUROPSYCHOLOGIA, V104, P234, DOI 10.1016/j.neuropsychologia.2017.07.031; Westwood SJ, 2017, CORTEX, V86, P64, DOI 10.1016/j.cortex.2016.10.016; Windhoff M, 2013, HUM BRAIN MAPP, V34, P923, DOI 10.1002/hbm.21479	34	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2018	13	8							e0202730	10.1371/journal.pone.0202730	http://dx.doi.org/10.1371/journal.pone.0202730			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR6TZ	30138361	Green Published, gold, Green Submitted			2023-01-03	WOS:000442800100112
J	Segal, L; Nguyen, H; Gent, D; Hampton, C; Boffa, J				Segal, Leonie; Nguyen, Ha; Gent, Debra; Hampton, Catherine; Boffa, John			Child protection outcomes of the Australian Nurse Family Partnership Program for Aboriginal infants and their mothers in Central Australia	PLOS ONE			English	Article							HOME-VISITING PROGRAMS	Background The Nurse Family Partnership Program developed in the USA, designed to improve mother and infant/child outcomes, has reported lower rates of child protection system involvement. The study tested the hypothesis that an adapted Nurse Family Partnership Program implemented in an Aboriginal community in Central Australia (the FPP) would improve Child Protection outcomes. Methods This was a retrospective and prospective cohort study drawing on linked administrative data, including birth registry, primary health care client information system, FPP program data, and child protection data. Participants were children of women eligible for the FPP program (an exposed and a control group of women, eligible but not referred) live-born between 1/3/2009 (program commencement) and 31/12/2015. Child protection data covered all reports, investigations, substantiations and out-of-home care placements from the time of the child's birth to 31/12/2016. Generalised linear modelling was used to estimate the relative risk (RR) of involvement with child protection and type of involvement (report, investigation, substantiation, out-of-home-care placement) among FPP and control children. Results FPP mothers (n = 291) were on average younger, were more likely to be first-time mothers and experiencing housing instability than control mothers (n = 563). Among younger mothers <= 20 years, FPP children had statistically significantly lower rates of involvement with child protection (ARR(report) = 0.49, 95% CI: 0.29 to 0.82; ARR(investigation )= 0.34, 95% CI: 0.19 to 0.64; ARR(substantiation )= 0.45, 95% CI: 0.21 to 0.96) and experience fewer days in care (ARR = 0.10, 95% CI: 0.02 to 0.48). Among children of first-time mothers, FPP children also had statistically significantly lower rates of involvement with child protection (ARR(report )= 0.50, 95% CI: 0.30 to 0.83; ARR(investigation) = 0.36, 95% CI: 0.19 to 0.67; ARR(substantiation) 0.38, 95% CI: 0.18 to 0.80) and fewer days in care (ARR = 0.06, 95% CI: 0.01 to 0.27). Conclusion Study results suggest a modified Nurse Family Partnership delivered by an Indigenous community-controlled organisation may have reduced child protection system involvement in a highly vulnerable First Nations population, especially in younger or first-time mothers. Testing these results with an RCT design is desirable.	[Segal, Leonie; Nguyen, Ha] Univ South Australia, Sch Hlth Sci, Hlth Econ & Social Policy Grp, Adelaide, SA, Australia; [Gent, Debra; Hampton, Catherine; Boffa, John] Cent Australian Aboriginal Congress Aboriginal Co, Alice Springs, NT, Australia; [Nguyen, Ha] Univ Sydney, John Walsh Ctr Rehabil Res, Sydney, NSW, Australia; [Nguyen, Ha] George Inst Global Hlth, Sydney, NSW, Australia	University of South Australia; University of Sydney; George Institute for Global Health; University of Sydney	Segal, L (corresponding author), Univ South Australia, Sch Hlth Sci, Hlth Econ & Social Policy Grp, Adelaide, SA, Australia.	leonie.segal@unisa.edu.au	Nguyen, Ha/O-1586-2019; Segal, Leonie/B-2357-2009	Nguyen, Ha/0000-0001-8327-5488; Segal, Leonie/0000-0002-6391-6791	Australian National Health and Medical Research Council (NHMRC) [631947]; Central Australian Aboriginal Congress Aboriginal Corporation (CAAC)	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Central Australian Aboriginal Congress Aboriginal Corporation (CAAC)	Funds were contributed to the study from The Australian National Health and Medical Research Council (NHMRC) Program grant (No. 631947) [https://www.nhmrc.gov.au/] and a grant from Central Australian Aboriginal Congress Aboriginal Corporation (CAAC) [https://www.caac.org.au/]. JB, DG and CH are employed by Central Australian Aboriginal Congress Aboriginal Corporation. There was no commercial or sponsored funding. The NHMRC had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. A Project Steering Committee was established for the project that included persons from CAAC. Three persons from CAAC are identified as authors (JB, DG, CH). As such, CAAC contributed to the study design and analysis. However, all final decisions about the analysis plan, manuscript content and finalization and decision to publish were made by the senior author LS, an independent academic.	ABS, 2013, CENS POP HOUS SOC IN; Australian Institute of Health and Welfare, 2017, CHILD WELF SER, V66; Department of Social Services, 2009, NAT FRAM PROT AUSTR; Department of Social Services, 2015, FOOTPR TIM LONG STUD; Drake B, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14090971; Gomby DS, 2007, CHILD ABUSE NEGLECT, V31, P793, DOI 10.1016/j.chiabu.2007.07.001; Nguyen H, 2018, PREV SCI, V19, P966, DOI 10.1007/s11121-018-0930-5; Kitzman HJ, 2007, ENCY EARLY CHILDHOOD; Mejdoubi J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120182; Olds David L, 2008, J Scand Stud Criminol Crime Prev, V9, P2, DOI 10.1080/14043850802450096; OLDS DL, 1986, PEDIATRICS, V78, P65; Peacock S, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-17; Segal L, 2012, MILBANK Q, V90, P47, DOI 10.1111/j.1468-0009.2011.00655.x; Steering Committee for the Review of Government Service Provision, 2017, REP GOV SERV 2016; Sweet MA, 2004, CHILD DEV, V75, P1435, DOI 10.1111/j.1467-8624.2004.00750.x; Tilbury C, 2012, INTENSIVE FAMILY BAS	16	9	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2018	13	12							e0208764	10.1371/journal.pone.0208764	http://dx.doi.org/10.1371/journal.pone.0208764			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HD6IO	30532276	gold, Green Published, Green Submitted			2023-01-03	WOS:000452640900043
J	Horn, L; Mansfield, AS; Szczesna, A; Havel, L; Krzakowski, M; Hochmair, MJ; Huemer, F; Losonczy, G; Johnson, ML; Nishio, M; Reck, M; Mok, T; Lam, S; Shames, DS; Liu, J; Ding, B; Lopez-Chavez, A; Kabbinavar, F; Lin, W; Sandler, A; Liu, SV				Horn, L.; Mansfield, A. S.; Szczesna, A.; Havel, L.; Krzakowski, M.; Hochmair, M. J.; Huemer, F.; Losonczy, G.; Johnson, M. L.; Nishio, M.; Reck, M.; Mok, T.; Lam, S.; Shames, D. S.; Liu, J.; Ding, B.; Lopez-Chavez, A.; Kabbinavar, F.; Lin, W.; Sandler, A.; Liu, S. V.		IMpower133 Study Grp	First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OPEN-LABEL; MULTICENTER; ASSOCIATION; IPILIMUMAB; EXPRESSION; DOCETAXEL; SURVIVAL; SAFETY; TRIAL	BACKGROUND Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy. METHODS We conducted this double-blind, placebo-controlled, phase 3 trial to evaluate atezolizumab plus carboplatin and etoposide in patients with extensive-stage small-cell lung cancer who had not previously received treatment. Patients were randomly assigned in a 1:1 ratio to receive carboplatin and etoposide with either atezolizumab or placebo for four 21-day cycles (induction phase), followed by a maintenance phase during which they received either atezolizumab or placebo (according to the previous random assignment) until they had unacceptable toxic effects, disease progression according to Response Evaluation Criteria in Solid Tumors, version 1.1, or no additional clinical benefit. The two primary end points were investigator-assessed progression-free survival and overall survival in the intention-to-treat population. RESULTS A total of 201 patients were randomly assigned to the atezolizumab group, and 202 patients to the placebo group. At a median follow-up of 13.9 months, the median overall survival was 12.3 months in the atezolizumab group and 10.3 months in the placebo group (hazard ratio for death, 0.70; 95% confidence interval [CI], 0.54 to 0.91; P = 0.007). The median progression-free survival was 5.2 months and 4.3 months, respectively (hazard ratio for disease progression or death, 0.77; 95% CI, 0.62 to 0.96; P = 0.02). The safety profile of atezolizumab plus carboplatin and etoposide was consistent with the previously reported safety profile of the individual agents, with no new findings observed. CONCLUSIONS The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer resulted in significantly longer overall survival and progression-free survival than chemotherapy alone.	[Horn, L.] Vanderbilt Univ, Med Ctr, 2220 Pierce Ave,777 PRB, Nashville, TN 37232 USA; [Johnson, M. L.] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA; [Mansfield, A. S.] Mayo Clin, Rochester, MN USA; [Szczesna, A.] Mazowieckie Ctr Leczenia Chorob Pluc & Gruzlicy, Otwock, Poland; [Krzakowski, M.] Inst Marii Sklodowskiej Curie Warszawie, Ctr Onkol, Warsaw, Poland; [Havel, L.] Pneumologicka Klin 1 LF UK, Thomayerova Nemocnice, Prague, Czech Republic; [Hochmair, M. J.] Otto Wagner Spital, Dept Resp & Crit Care Med, Ludwig Boltzmann Inst COPD & Resp Epidemiol, Sozialmed Zentrum Baumgartner Hohe, Vienna, Austria; [Huemer, F.] Otto Wagner Spital, Dept Resp & Crit Care Med 2, Ludwig Boltzmann Inst COPD & Resp Epidemiol, Sozialmed Zentrum Baumgartner Hohe, Vienna, Austria; [Losonczy, G.] Semmelweis Egyet AOK, Pulmonologiai Klin, Budapest, Hungary; [Nishio, M.] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan; [Reck, M.] German Ctr Lung Res, LungenClin Grosshansdorf, Airway Res Ctr North, Grosshansdorf, Germany; [Mok, T.] Chinese Univ Hong Kong, State Key Lab South China, Hong Kong, Hong Kong, Peoples R China; [Liu, J.] Hoffmann La Roche, Shanghai, Peoples R China; [Lam, S.; Shames, D. S.; Ding, B.; Lopez-Chavez, A.; Kabbinavar, F.; Lin, W.; Sandler, A.] Genentech Inc, San Francisco, CA USA; [Liu, S. V.] Georgetown Univ, Washington, DC USA	Vanderbilt University; Sarah Cannon Research Institute; Tennessee Oncology; Mayo Clinic; Maria Sklodowska-Curie National Research Institute of Oncology; Thomayer Hospital; Ludwig Boltzmann Institute; Ludwig Boltzmann Institute; Semmelweis University; Japanese Foundation for Cancer Research; Grosshansdorf Hospital; Chinese University of Hong Kong; Roche Holding; Genentech; Georgetown University	Horn, L (corresponding author), Vanderbilt Univ, Med Ctr, 2220 Pierce Ave,777 PRB, Nashville, TN 37232 USA.	leora.horn@vumc.org	Mok, Tony Shu Kam/B-2310-2019; Liu, Stephen/E-5688-2019; Reck, Martin/ABF-5721-2020; de Azevedo, Sergio Jobim/P-5115-2015; Mansfield, Aaron/AAQ-8298-2021; Cortot, Alexis B/F-7006-2019; Liedke, Pedro/L-5063-2019; Berciano-Berciano, Miguel-Ángel/AAV-2120-2021; Pereira, Rodrigo Perez/U-6223-2019; Buti, Sebastiano/S-1314-2017	Mok, Tony Shu Kam/0000-0002-8251-0551; Liu, Stephen/0000-0002-4852-3914; Reck, Martin/0000-0002-5348-4462; Mansfield, Aaron/0000-0002-9483-6903; Cortot, Alexis B/0000-0003-0098-2238; Liedke, Pedro/0000-0002-8298-4765; Berciano-Berciano, Miguel-Ángel/0000-0002-5437-5196; Kowalczyk, Anna/0000-0002-0363-6261; Tomasini, Pascale/0000-0002-6474-5912; Kowalski, Dariusz/0000-0002-9452-3229; Bryl, Maciej/0000-0001-6873-5861; Buti, Sebastiano/0000-0003-0876-0226; Stroyakovskiy, Daniil/0000-0003-1973-1092	F. Hoffmann-La Roche/Genentech, a member of the Roche Group; Genentech	F. Hoffmann-La Roche/Genentech, a member of the Roche Group; Genentech(Roche HoldingGenentech)	Supported by F. Hoffmann-La Roche/Genentech, a member of the Roche Group.; We thank Daniel Waterkamp of Genentech for his contribution to the trial design; and Rachel Johnson, Ph.D., and Daniel Clyde, Ph.D., of Health Interactions for third-party writing assistance (funded by Genentech).	Antonia SJ, 2016, LANCET ONCOL, V17, P883, DOI 10.1016/S1470-2045(16)30098-5; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; Cortinovis D, 2017, ANN ONCOL, V28; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; Diaz LA, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3071; Dmitrienko A, 2018, NEW ENGL J MED, V378, P2115, DOI 10.1056/NEJMra1709701; Farago AF, 2018, TRANSL LUNG CANCER R, V7, P69, DOI 10.21037/tlcr.2018.01.16; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Gadgeel SM, 2018, J THORAC ONCOL, V13, P1393, DOI 10.1016/j.jtho.2018.05.002; Gandara DR, 2018, NAT MED, V24, P1441, DOI 10.1038/s41591-018-0134-3; Hellmann MD, 2018, CANCER CELL, V33, P853, DOI 10.1016/j.ccell.2018.04.001; Hellmann MD, 2018, CANCER CELL, V33, P843, DOI 10.1016/j.ccell.2018.03.018; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Ishii H, 2015, J THORAC ONCOL, V10, P426, DOI 10.1097/JTO.0000000000000414; Micke P, 2002, LUNG CANCER, V37, P271, DOI 10.1016/S0169-5002(02)00072-7; Ott PA, 2017, J CLIN ONCOL, V35, P3823, DOI 10.1200/JCO.2017.72.5069; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Reck M, 2016, J CLIN ONCOL, V34, P3740, DOI 10.1200/JCO.2016.67.6601; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rizvi H, 2018, J CLIN ONCOL, V36, P633, DOI 10.1200/JCO.2017.75.3384; Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405; Schultheis AM, 2015, EUR J CANCER, V51, P421, DOI 10.1016/j.ejca.2014.12.006; Sequist LV, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw389.3; Socinski MA, 2009, J CLIN ONCOL, V27, P4787, DOI 10.1200/JCO.2009.23.1548; Stahel R, 2011, ANN ONCOL, V22, P1973, DOI 10.1093/annonc/mdr313; Ye YN, 2013, STAT MED, V32, P1112, DOI 10.1002/sim.5700	26	1405	1461	14	114	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 6	2018	379	23					2220	2229		10.1056/NEJMoa1809064	http://dx.doi.org/10.1056/NEJMoa1809064			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD1HA	30280641	Bronze			2023-01-03	WOS:000452259200007
J	Minagawa, A; Yoshikawa, T; Yasukawa, M; Hotta, A; Kunitomo, M; Iriguchi, S; Takiguchi, M; Kassai, Y; Imai, E; Yasui, Y; Kawai, Y; Zhang, R; Uemura, Y; Miyoshi, H; Nakanishi, M; Watanabe, A; Hayashi, A; Kawana, K; Fujii, T; Nakatsura, T; Kaneko, S				Minagawa, Atsutaka; Yoshikawa, Toshiaki; Yasukawa, Masaki; Hotta, Akitsu; Kunitomo, Mihoko; Iriguchi, Shoichi; Takiguchi, Maiko; Kassai, Yoshiaki; Imai, Eri; Yasui, Yutaka; Kawai, Yohei; Zhang, Rong; Uemura, Yasushi; Miyoshi, Hiroyuki; Nakanishi, Mahito; Watanabe, Akira; Hayashi, Akira; Kawana, Kei; Fujii, Tomoyuki; Nakatsura, Tetsuya; Kaneko, Shin			Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy	CELL STEM CELL			English	Article							PIGMENT EPITHELIAL-CELLS; PLURIPOTENT STEM-CELLS; GLUCOCORTICOIDS; REGENERATION; LYMPHOCYTES; EXPRESSION; GENERATION; GLYPICAN-3; LEUKEMIA; GENES	Limited T cell availability and proliferative exhaustion present major barriers to successful T cell-based immunotherapies and may potentially be overcome through the use of "rejuvenated" induced pluripotent stem cells derived from antigen-specific T cells (T-iPSCs). However, strict antigen specificity is essential for safe and efficient T cell immunotherapy. Here, we report that CD8 alpha 8 T cells from human T-iPSCs lose their antigen specificity through additional rearrangement of the T cell receptor (TCR) alpha chain gene during the CD4/CD8 double positive stage of in vitro differentiation. CRISPR knockout of a recombinase gene in the T-iPSCs prevented this additional TCR rearrangement. Moreover, when CD8 alpha 8 T cells were differentiated from monocyte-derived iPSCs that were transduced with an antigen-specific TCR, they showed monoclonal expression of the transduced TCR. TCR-stabilized, regenerated CD8 alpha 8 T cells effectively inhibit tumor growth in xenograft cancer models. These approaches could contribute to safe and effective regenerative T cell immunotherapies.	[Minagawa, Atsutaka; Iriguchi, Shoichi; Imai, Eri; Yasui, Yutaka; Kawai, Yohei; Kaneko, Shin] Kyoto Univ, Ctr iPS Cell Res & Applicat CiRA, Dept Cell Growth & Differentiat, Shin Kaneko Lab, Kyoto, Japan; [Minagawa, Atsutaka; Kawana, Kei; Fujii, Tomoyuki] Univ Tokyo, Grad Sch Med, Dept Obstet & Gynecol, Tokyo, Japan; [Minagawa, Atsutaka; Kunitomo, Mihoko; Iriguchi, Shoichi; Takiguchi, Maiko; Kassai, Yoshiaki; Hayashi, Akira; Kaneko, Shin] Takeda CiRA Joint Program T CiRA, Fujisawa, Kanagawa, Japan; [Yoshikawa, Toshiaki; Zhang, Rong; Uemura, Yasushi; Nakatsura, Tetsuya] Natl Canc Ctr, Div Canc Immunotherapy, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan; [Yasukawa, Masaki] Ehime Univ, Grad Sch Med, Dept Hematol Clin Immunol & Infect Dis, Toon, Japan; [Hotta, Akitsu; Watanabe, Akira] Kyoto Univ, Dept Life Sci Frontiers, CiRA, Kyoto, Japan; [Kunitomo, Mihoko; Takiguchi, Maiko; Kassai, Yoshiaki; Hayashi, Akira] Takeda Pharmaceut Co, Regenerat Med Unit, Fujisawa, Kanagawa, Japan; [Miyoshi, Hiroyuki] Keio Univ, Dept Physiol, Sch Med, Tokyo, Japan; [Nakanishi, Mahito] Natl Inst Adv Ind Sci & Technol, Biotechnol Res Inst Drug Discovery, Tsukuba, Ibaraki, Japan; [Kawana, Kei] Nihon Univ, Dept Obstet & Gynecol, Sch Med, Tokyo, Japan; [Kaneko, Shin] Kyoto Univ, CiRA, Facil iPS Cell Therapy, Kyoto, Japan	Kyoto University; University of Tokyo; National Cancer Center - Japan; Ehime University; Kyoto University; Takeda Pharmaceutical Company Ltd; Keio University; National Institute of Advanced Industrial Science & Technology (AIST); Nihon University; Kyoto University	Kaneko, S (corresponding author), Kyoto Univ, Ctr iPS Cell Res & Applicat CiRA, Dept Cell Growth & Differentiat, Shin Kaneko Lab, Kyoto, Japan.; Kaneko, S (corresponding author), Takeda CiRA Joint Program T CiRA, Fujisawa, Kanagawa, Japan.; Kaneko, S (corresponding author), Kyoto Univ, CiRA, Facil iPS Cell Therapy, Kyoto, Japan.	kaneko.shin@cira.kyoto-u.ac.jp		Hotta, Akitsu/0000-0002-2619-7441	Ministry of Education, Culture, Sports, Science and Technology Japan [23591413, 15H04655, 15J05263, 26293357]; Japan Agency for Medical Research and Development (Project for Development of Innovative Research on Cancer Therapeutics, Practical Research for Innovative Cancer Control, and Core Center for iPS Cell Research); National Cancer Center Research Fund; Takeda-CiRA collaboration program; Thyas Co., Ltd.	Ministry of Education, Culture, Sports, Science and Technology Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Agency for Medical Research and Development (Project for Development of Innovative Research on Cancer Therapeutics, Practical Research for Innovative Cancer Control, and Core Center for iPS Cell Research)(Japan Agency for Medical Research and Development (AMED)); National Cancer Center Research Fund; Takeda-CiRA collaboration program; Thyas Co., Ltd.	We thank Prof. Shinya Yamanaka (Kyoto University) for providing the HLA homozygous iPSC line and giving critical advice for our research work. We thank Prof. Hiromitsu Nakauchi (The University of Tokyo) and Prof. Naoko Takasu (Kyoto University) for providing the iPSC lines; Dr. Seigo Izumo (T-CiRA) for giving critical advice; Prof. Michio Tomura (Osaka Otani University) for live imaging technique; Drs. Tatsuki Ueda, Yuta Mishima, Wang Bo, and Hisashi Yano (Kyoto University); Hiroshi Fujiwara and Toshimoto Ochi (Ehime University); Keiko Koga, Takayuki Sato, Masashi Yamada, and Sujatha Mohan (T-CiRA); Messrs. Shuichi Kitayama, Kohei Ohara, and Akito Tanaka (Kyoto University); Tokuyuki Shinohara, Kazuhide Nakayama, Suguru Arima, and Yuji Baba (TCiRA); Mses. Ayako Kumagai, Sanae Kamibayashi, and Hitomi Takakubo (Kyoto University); Mariko Sekiguchi, Maki Numazaki, Yuka Maruyama, Yuki Watanabe, and Ai Kikuchi (T-CiRA) for technical assistance. We thank Dr. Peter Karagiannis (Kyoto University) for editing the manuscript. The entire study was conducted in accordance with the Declaration of Helsinki and permitted by the institutional ethical board of Kyoto University. This work was supported in part by the Ministry of Education, Culture, Sports, Science and Technology Japan (23591413, 15H04655, 15J05263, and 26293357), Japan Agency for Medical Research and Development (Project for Development of Innovative Research on Cancer Therapeutics, Practical Research for Innovative Cancer Control, and Core Center for iPS Cell Research), the Takeda-CiRA collaboration program, collaborative research grant of Thyas Co., Ltd., and National Cancer Center Research Fund.	Bendle GM, 2010, NAT MED, V16, P565, DOI 10.1038/nm.2128; BLUTHMANN H, 1988, NATURE, V334, P156, DOI 10.1038/334156a0; Cheever MA, 2009, CLIN CANCER RES, V15, P5323, DOI 10.1158/1078-0432.CCR-09-0737; de Rham C, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/518135; Eyquem J, 2017, NATURE, V543, P113, DOI 10.1038/nature21405; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; Fraietta JA, 2018, NATURE, V558, P307, DOI 10.1038/s41586-018-0178-z; Hashizume O, 2015, SCI REP-UK, V5, DOI 10.1038/srep10434; Ito R, 2009, TRANSPLANTATION, V87, P1654, DOI 10.1097/TP.0b013e3181a5cb07; Karagiannis P, 2016, SEMIN IMMUNOL, V28, P35, DOI 10.1016/j.smim.2015.10.007; Kitayama S, 2016, STEM CELL REP, V6, P213, DOI 10.1016/j.stemcr.2016.01.005; Li HL, 2016, METHODS, V101, P27, DOI 10.1016/j.ymeth.2015.10.015; Maeda T, 2016, CANCER RES, V76, P6839, DOI 10.1158/0008-5472.CAN-16-1149; Michie AM, 2001, P NATL ACAD SCI USA, V98, P609, DOI 10.1073/pnas.021288598; Mittelstadt PR, 2012, J CLIN INVEST, V122, P2384, DOI 10.1172/JCI63067; Najima Y, 2016, BLOOD, V127, P722, DOI 10.1182/blood-2014-10-604777; Nakatsura T, 2004, CLIN CANCER RES, V10, P6612, DOI 10.1158/1078-0432.CCR-04-0348; Nishimura T, 2013, CELL STEM CELL, V12, P114, DOI 10.1016/j.stem.2012.11.002; Ochi T, 2011, BLOOD, V118, P1495, DOI 10.1182/blood-2011-02-337089; Ohminami H, 2000, BLOOD, V95, P286; Okamoto S, 2009, CANCER RES, V69, P9003, DOI 10.1158/0008-5472.CAN-09-1450; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; Provasi E, 2012, NAT MED, V18, P807, DOI 10.1038/nm.2700; Restifo NP, 2012, NAT REV IMMUNOL, V12, P269, DOI 10.1038/nri3191; Saito H, 2016, CANCER RES, V76, P3473, DOI 10.1158/0008-5472.CAN-15-1742; Sugita S, 2016, STEM CELL REP, V7, P619, DOI 10.1016/j.stemcr.2016.08.011; Sugita S, 2016, STEM CELL REP, V7, P635, DOI 10.1016/j.stemcr.2016.08.010; Themeli M, 2015, CELL STEM CELL, V16, P357, DOI 10.1016/j.stem.2015.03.011; Themeli M, 2013, NAT BIOTECHNOL, V31, P928, DOI 10.1038/nbt.2678; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; Vacchio MS, 1999, J IMMUNOL, V163, P1327; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Vizcardo R, 2013, CELL STEM CELL, V12, P31, DOI 10.1016/j.stem.2012.12.006; Yoshikawa T, 2011, CANCER SCI, V102, P918, DOI 10.1111/j.1349-7006.2011.01896.x	34	66	69	4	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	DEC 6	2018	23	6					850	+		10.1016/j.stem.2018.10.005	http://dx.doi.org/10.1016/j.stem.2018.10.005			13	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	HD5EH	30449714	Bronze			2023-01-03	WOS:000452550400012
J	de Morais, DV; Costa, MAPD; Barbara, MFS; Silva, FD; Moreira, MM; Delerue-Mato, C; Dias, LAG; Estevinho, MLM; de Carvalho, CAL				de Morais, Daniel Vieira; Pereira de Carvalho Costa, Maria Angelica; Santa Barbara, Marivalda Figueredo; Silva, Fabiane de Lima; Moreira, Manuela M.; Delerue-Mato, Cristina; Guimaraes Dias, Luis Avelino; Miranda Estevinho, Maria Leticia; Lopes de Carvalho, Carlos Alfredo			Antioxidant, photoprotective and inhibitory activity of tyrosinase in extracts of Dalbergia ecastaphyllum	PLOS ONE			English	Article							FLAVONOID CONTENTS; CAROTENOIDS; PLANTS; CONSTITUENTS; PHENOLICS; PROPOLIS; HEALTH; ACID	Dalbergia ecastaphyllum is a native Brazil plant with importance for beekeeping, and widely used in folk medicine. For the first time, the extracts of this plant were assessed for the presence of hydrophilic and lipophilic antioxidants, as well as inhibition of tyrosinase, free radicals scavenging and sunscreen protection. The antioxidant activity was evaluated by free radical scavenging (DPPH) and beta-carotene bleaching assay. The tyrosinase inhibitory activity was evaluated and calculated the EC50. The photoprotective activity was measured using different concentrations of D. ecastaphyllum extracts. The Sun Protection Factor (SPF) of the samples was higher than 6, and the sample from Ilheus showed the most pronounced photoprotective effect. Sample from Canavieiras presented the highest antioxidant activity by free radical scavenging DPPH and beta-carotene bleaching method, with 92.41% and 48.34%, respectively. All samples inhibited the tyrosinase, especially the sample from Prado that was most effective (124.62 mu g.mL(-1)). Significant negative correlation was found between flavonoid contents and inhibition of tyrosinase. The overall results provide relevant information about the Dalbergia ecastaphyllum species, indicating as potential material to cosmetic and pharmaceutical industry.	[de Morais, Daniel Vieira; Pereira de Carvalho Costa, Maria Angelica; Santa Barbara, Marivalda Figueredo; Silva, Fabiane de Lima; Lopes de Carvalho, Carlos Alfredo] Fed Univ Reconcavo Bahia UFRB, Ctr Agr Environm & Biol Sci, Cruz Das Almas, BA, Brazil; [Moreira, Manuela M.; Delerue-Mato, Cristina] Super Inst Engn Porto, REQUIMTE LAQV, Porto, Portugal; [Guimaraes Dias, Luis Avelino; Miranda Estevinho, Maria Leticia] Polytech Inst Braganca, Mt Res Ctr, Campus Santa Apolonia, Braganca, Portugal; [de Morais, Daniel Vieira] Univ Sao Paulo, Dept Agri Food Ind Food & Nutr, Luiz de Queiroz Coll Agr, Sao Paulo, Brazil	Polytechnic Institute of Porto; Instituto Politecnico de Braganca; Universidade de Sao Paulo	de Morais, DV (corresponding author), Fed Univ Reconcavo Bahia UFRB, Ctr Agr Environm & Biol Sci, Cruz Das Almas, BA, Brazil.; de Morais, DV (corresponding author), Univ Sao Paulo, Dept Agri Food Ind Food & Nutr, Luiz de Queiroz Coll Agr, Sao Paulo, Brazil.	engagromorais@gmail.com	Carvalho, Carlos A L/N-3321-2016; COSTA, ANGELICA C/I-8247-2018; Morais, Daniel V./P-9638-2019; Estevinho, Leticia M./L-2656-2017; Dias, Luis/I-5756-2012	Carvalho, Carlos A L/0000-0002-3306-3003; Morais, Daniel V./0000-0002-2737-7428; Estevinho, Leticia M./0000-0002-9249-1948; Moreira, Manuela M./0000-0003-1500-9211; Dias, Luis/0000-0002-1210-4259	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [156870/2014-2, 305228/2013-7]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior CAPES [88881.062167/20140-1]; Fundacao de Amparo a Pesquisa do Estado da Bahia [PET0008/2016]	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao de Amparo a Pesquisa do Estado da Bahia	This work was supported by Grant number: 156870/2014-2 to D.V. de Morais and 305228/2013-7 to C.A.L. de Carvalho - Conselho Nacional de Desenvolvimento Cientifico e Tecnologico; Grant number: 88881.062167/20140-1 to M.L.M. Estevinho - Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior CAPES; and Grant number: PET0008/2016 to L.A. G. Dias - Fundacao de Amparo a Pesquisa do Estado da Bahia.	Agati G, 2012, PLANT SCI, V196, P67, DOI 10.1016/j.plantsci.2012.07.014; Ahn MR, 2004, J AGR FOOD CHEM, V52, P7286, DOI 10.1021/jf048726s; Alencar SM, 2007, J ETHNOPHARMACOL, V113, P278, DOI 10.1016/j.jep.2007.06.005; Atoui AK, 2005, FOOD CHEM, V89, P27, DOI 10.1016/j.foodchem.2004.01.075; Aumeeruddy-Elalfi Z, 2016, S AFR J BOT, V103, P89, DOI 10.1016/j.sajb.2015.09.010; AYRES M., 2007, BIOESTAT; Ben Mohamed H, 2016, LWT-FOOD SCI TECHNOL, V74, P557, DOI 10.1016/j.lwt.2016.08.023; Bobin M.F., 1995, COSMET TOILETRIES, V7, P44; Bubols GB, 2013, MINI-REV MED CHEM, V13, P318; Chang TS, 2009, INT J MOL SCI, V10, P2440, DOI 10.3390/ijms10062440; Chen CY, 2010, J TAIWAN INST CHEM E, V41, P129, DOI 10.1016/j.jtice.2009.08.005; Cockell CS, 2000, ECOL ENG, V16, P293, DOI 10.1016/S0925-8574(99)00057-9; Costa SCC, 2015, REV BRAS FARMACOGN, V25, P413, DOI 10.1016/j.bjp.2015.07.013; Cotinguiba GGJ, 2013, UNOPAR CIENT CIENC B, V15, P231; de Oliveira RG, 2013, J YOUNG PHARM, V5, P102, DOI 10.1016/j.jyp.2013.08.005; Dimakou C, 2012, LWT-FOOD SCI TECHNOL, V46, P393, DOI 10.1016/j.lwt.2011.12.013; Dzoyem JP, 2015, J ETHNOPHARMACOL, V160, P194, DOI 10.1016/j.jep.2014.11.034; Faggio C, 2017, EUR J PHARMACOL, V807, P91, DOI 10.1016/j.ejphar.2017.04.009; Barbosa KBF, 2010, REV NUTR, V23, P629, DOI 10.1590/S1415-52732010000400013; Fiedor J, 2014, NUTRIENTS, V6, P466, DOI 10.3390/nu6020466; Gupta VK, 2016, S AFR J BOT, V103, P49, DOI 10.1016/j.sajb.2015.08.007; Han RM, 2012, MOLECULES, V17, P2140, DOI 10.3390/molecules17022140; Hasegawa T, 2010, INT J MOL SCI, V11, P1082, DOI 10.3390/ijms11031082; Heleno SA, 2015, FOOD CHEM, V173, P501, DOI 10.1016/j.foodchem.2014.10.057; Jia Z, 1999, FOOD CHEM, V64, P555, DOI 10.1016/S0308-8146(98)00102-2; Ko HH, 2014, J ETHNOPHARMACOL, V151, P386, DOI 10.1016/j.jep.2013.10.054; Liang CP, 2014, MOLECULES, V19, P4681, DOI 10.3390/molecules19044681; Lima CR, 2014, MOLECULES, V19, P9591, DOI 10.3390/molecules19079591; Lin YP, 2007, PHYTOCHEMISTRY, V68, P1189, DOI 10.1016/j.phytochem.2007.02.001; Magalhaes LM, 2008, ANAL CHIM ACTA, V613, P1, DOI 10.1016/j.aca.2008.02.047; Mansur J.S., 1986, AN BRAS DERMATOL, V61, P121, DOI 10.1590/S1516-93322004000300014; NAGATA M, 1992, J JPN SOC FOOD SCI, V39, P925; Neagu E, 2015, J TAIWAN INST CHEM E, V52, P1, DOI 10.1016/j.jtice.2015.01.026; Nerya O, 2003, J AGR FOOD CHEM, V51, P1201, DOI 10.1021/jf020935u; Orhan IE, 2012, FOOD CHEM, V130, P882, DOI 10.1016/j.foodchem.2011.07.119; Passeron T, 2005, CLIN DERMATOL, V23, P56, DOI 10.1016/j.clindermatol.2004.09.013; Pham-Huy Lien Ai, 2008, Int J Biomed Sci, V4, P89; R Core Team, 2021, R LANG ENV STAT COMP; Rubilar M, 2007, J AGR FOOD CHEM, V55, P10101, DOI 10.1021/jf0721996; Sarkar Rashmi, 2013, J Cutan Aesthet Surg, V6, P4, DOI 10.4103/0974-2077.110089; Shahidi F, 2015, J FUNCT FOODS, V18, P820, DOI 10.1016/j.jff.2015.06.018; Shin H, 2015, J MULTIVARIATE ANAL, V134, P1, DOI 10.1016/j.jmva.2014.10.001; Sousa CMDM, 2007, QUIM NOVA, V30, P351, DOI 10.1590/S0100-40422007000200021; Subedi L, 2014, J TRADIT CHIN MED, V34, P584, DOI 10.1016/S0254-6272(15)30067-4; Violante IMP, 2009, REV BRAS FARMACOGN, V19, P452, DOI 10.1590/S0102-695X2009000300020; Wolfe K, 2003, J AGR FOOD CHEM, V51, P609, DOI 10.1021/jf020782a	46	15	15	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2018	13	11							e0207510	10.1371/journal.pone.0207510	http://dx.doi.org/10.1371/journal.pone.0207510			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC6AO	30500832	gold, Green Published, Green Submitted			2023-01-03	WOS:000451883700011
J	Carson, MA; Nelson, J; Cancela, ML; Laize, V; Gavaia, PJ; Rae, M; Heesch, S; Verzin, E; Gilmore, BF; Clarke, SA				Carson, Matthew A.; Nelson, John; Cancela, M. Leonor; Laize, Vincent; Gavaia, Paulo J.; Rae, Margaret; Heesch, Svenja; Verzin, Eugene; Gilmore, Brendan F.; Clarke, Susan A.			Screening for osteogenic activity in extracts from Irish marine organisms: The potential of Ceramium pallidum	PLOS ONE			English	Article							IN-VIVO; BONE; DIFFERENTIATION; WOMEN; OSTEOPOROSIS; MOLECULES; FUCOIDAN; PROTEIN; CELLS	Extracts and compounds derived from marine organisms have reportedly shown some osteogenic potential. As such, these bioactives may aid in the treatment of musculoskeletal conditions such as osteoporosis; helping to address inefficacies with current treatment options. In this study, 72 fractions were tested for their in vitro osteogenic activity using a human foetal osteoblast (hFOB) cell line and bone marrow derived mesenchymal stem cells (MSCs), focusing on their cytotoxic, proliferative and differentiation effects. Extracts dissolved in dimethyl sulfoxide and ethanol showed no significant osteogenic potential. However, two extracts derived from powder residues (left over from original organic extractions) caused a significant promotion of MSC differentiation. Bioactivity from powder residues derived from the epiphytic red algae Ceramium pallidum is described in detail to highlight its treatment potential. In vitro, C. pallidum was shown to promote MSC differentiation and extracellular matrix mineralisation. In vivo, this extract caused a significant increase in opercular bone growth of zebrafish larvae and a significant increase in bone density of regenerated adult caudal fins. Our findings therefore show the importance of continued screening efforts, particularly of novel extract sources, and the presence of bioactive compounds in C. pallidum extract.	[Carson, Matthew A.; Clarke, Susan A.] Queens Univ Belfast, Sch Nursing & Midwifery, Belfast, Antrim, North Ireland; [Nelson, John] Queens Univ Belfast, Sch Biol Sci, Belfast, Antrim, North Ireland; [Cancela, M. Leonor; Laize, Vincent; Gavaia, Paulo J.] Univ Algarve, Ctr Marine Sci CCMAR, Faro, Portugal; [Cancela, M. Leonor] Univ Algarve, Dept Biomed Sci & Med, Faro, Portugal; [Cancela, M. Leonor] Univ Algarve, ABC, Faro, Portugal; [Rae, Margaret] Marine Inst & Seaweed Res Grp, Oranmore, Co Galway, Ireland; [Heesch, Svenja] Natl Univ Ireland Galway, Ryan Inst, Irish Seaweed Res Grp, Univ Rd, Galway, Ireland; [Verzin, Eugene] Royal Victoria Hosp, Orthopaed Dept, Belfast, Antrim, North Ireland; [Gilmore, Brendan F.] Queens Univ Belfast, Sch Pharm, Belfast, Antrim, North Ireland	Queens University Belfast; Queens University Belfast; Universidade do Algarve; Universidade do Algarve; Universidade do Algarve; Ollscoil na Gaillimhe-University of Galway; Queens University Belfast	Clarke, SA (corresponding author), Queens Univ Belfast, Sch Nursing & Midwifery, Belfast, Antrim, North Ireland.	s.a.clarke@qub.ac.uk	Gavaia, Paulo/A-6470-2011; Laizé, Vincent/B-4463-2008; Cancela, M. Leonor/F-4665-2012	Gavaia, Paulo/0000-0002-9582-1957; Laizé, Vincent/0000-0001-9565-9198; Cancela, M. Leonor/0000-0003-3114-6662; Heesch, Svenja/0000-0002-4531-0921; Carson, Matthew/0000-0003-2733-939X; Clarke, Susan A./0000-0002-7720-5405	Marine Institute under the Marine Research Sub-Programme of the Irish National Development Plan 2007-2013; Santander (Bank, UK); Engineering and Physical Sciences Research Council (EPSRC) [EP/M027473/1]	Marine Institute under the Marine Research Sub-Programme of the Irish National Development Plan 2007-2013; Santander (Bank, UK); Engineering and Physical Sciences Research Council (EPSRC)(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	Financial support for the Beaufort Marine Biodiscovery Project was received under the Irish Sea Change Strategy and the Strategy for Science Technology and Innovation (2006-2013), with the support of the Marine Institute, funded under the Marine Research Sub-Programme of the Irish National Development Plan 2007-2013. Santander (Bank, UK) contributed scholarship funding to support lab exchange work. This work was also supported by the Engineering and Physical Sciences Research Council (EPSRC) grant EP/M027473/1 'Building the Queen's University Belfast AMR Network.' The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708; Alves H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026678; [Anonymous], 2013, INT J FOOD SCI NUTR, V2, P9, DOI [10.19070/2326-3350-130003, DOI 10.19070/2326-3350-130003]; Atlan G, 1999, BIOMATERIALS, V20, P1017, DOI 10.1016/S0142-9612(98)90212-5; Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064; Bensimon-Brito A, 2016, BMC DEV BIOL, V16, DOI 10.1186/s12861-016-0102-4; Bilezikian JP, 2009, AM J MED, V122, P14, DOI 10.1016/j.amjmed.2008.12.003; Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724; Boominathan VP, 2012, ZEBRAFISH, V9, P207, DOI 10.1089/zeb.2012.0741; Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395; Cardeira J, 2016, SCI REP-UK, V6, DOI 10.1038/srep39191; Carson MA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26024-0; Cho YS, 2009, FOOD CHEM, V116, P990, DOI 10.1016/j.foodchem.2009.03.051; Cian RE, 2015, MAR DRUGS, V13, P5358, DOI 10.3390/md13085358; Czekanska EM, 2014, J BIOMED MATER RES A, V102, P2636, DOI 10.1002/jbm.a.34937; Du Xiaoyi, 2006, Journal of Pharmacological and Toxicological Methods, V54, P164, DOI 10.1016/j.vascn.2006.03.002; Ensrud KE, 2004, J BONE MINER RES, V19, P1259, DOI 10.1359/JBMR.040326; Fleming A, 2005, J BIOMOL SCREEN, V10, P823, DOI 10.1177/1087057105279952; Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035; Han CYE, 2009, BIOORG MED CHEM LETT, V19, P1442, DOI 10.1016/j.bmcl.2009.01.025; Harnedy PA, 2013, LWT-FOOD SCI TECHNOL, V51, P375, DOI 10.1016/j.lwt.2012.09.023; HARRIS SA, 1995, J BONE MINER RES, V10, P178; Hwang PA, 2016, CYTOTECHNOLOGY, V68, P1349, DOI 10.1007/s10616-015-9894-5; Jha R.K., 2004, MAR DRUGS, V2, P123, DOI DOI 10.3390/MD203123; Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198-006-0172-4; Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198-007-0543-5; KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200; Karadeniz F, 2014, MAR DRUGS, V12, P5132, DOI 10.3390/md12105132; Kim BS, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.95; Laize V., 2014, DRUG DISCOV TODAY DI, V13, P29, DOI [DOI 10.1016/J.DDMOD.2014.08.001, 10.1016/j.ddmod.2014.08.001]; Maggs CA, 2002, PHYCOLOGIA, V41, P409, DOI 10.2216/i0031-8884-41-4-409.1; Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027; Maurya R, 2009, BIOORG MED CHEM LETT, V19, P610, DOI 10.1016/j.bmcl.2008.12.064; Miron RJ, 2012, J DENT RES, V91, P736, DOI 10.1177/0022034511435260; O'Gorman DM, 2012, PHYTOTHER RES, V26, P375, DOI 10.1002/ptr.3561; Park MH, 2016, NUTR RES PRACT, V10, P148, DOI 10.4162/nrp.2016.10.2.148; Rae M, 2013, PHYTOCHEM REV, V12, P555, DOI 10.1007/s11101-012-9227-7; Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763; Ryu B, 2015, J FUNCT FOODS, V19, P505, DOI 10.1016/j.jff.2015.09.022; Shen L, 2008, FOOD CHEM, V107, P929, DOI 10.1016/j.foodchem.2007.08.047; Subramaniam M, 2002, J CELL BIOCHEM, V87, P9, DOI 10.1002/jcb.10259; Surget G, 2017, J APPL PHYCOL, V29, P575, DOI 10.1007/s10811-016-0968-3; Tarasco M, 2017, COMP BIOCHEM PHYS C, V197, P45, DOI 10.1016/j.cbpc.2017.04.006; Waybright TJ, 2009, J BIOMOL SCREEN, V14, P708, DOI 10.1177/1087057109335670; Westbroek P, 1998, NATURE, V392, P861, DOI 10.1038/31798; Wijesekara I, 2011, CARBOHYD POLYM, V84, P14, DOI 10.1016/j.carbpol.2010.10.062; Zhang F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124805	47	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2018	13	11							e0207303	10.1371/journal.pone.0207303	http://dx.doi.org/10.1371/journal.pone.0207303			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC4EO	30485314	Green Published, Green Submitted, gold			2023-01-03	WOS:000451755800060
J	Valadao, ALC; Pezzuto, P; Silva, VAO; Goncalves, BS; Rossi, AD; da Cunha, RD; Siani, AC; Tostes, JBD; Trovo, M; Damasco, P; Goncalves, G; Reis, RM; Aguiar, RS; Bento, CAD; Tanuri, A				Chaves Valadao, Ana Luiza; Pezzuto, Paula; Oliveira Silva, Viviane A.; Goncalves, Barbara Simonson; Rossi, Atila Duque; da Cunha, Rodrigo Delvecchio; Siani, Antonio Carlos; de Freitas Tostes, Joao Batista; Trovo, Marcelo; Damasco, Paulo; Goncalves, Gabriel; Reis, Rui Manuel; Aguiar, Renato Santana; de Melo Bento, Cleonice Alves; Tanuri, Amilcar			Reactivation of latent HIV-1 in vitro using an ethanolic extract from Euphorbia umbellata (Euphorbiaceae) latex	PLOS ONE			English	Article							PROTEIN-KINASE-C; PHORBOL ESTERS; T-CELLS; INFECTION; GRANTII; TIRUCALLI; THERAPY; PHASE	Euphorbia umbellata (E. umbellata) belongs to Euphorbiaceae family, popularly known as Janauba, and its latex contains a combination of phorbol esters with biological activities described to different cellular protein kinase C (PKC) isoforms. Here, we identified deoxiphorbol esters present in E. umbellata latex alcoholic extract that are able to increase HIV transcription and reactivate virus from latency models. This activity is probably mediated by NF-kB activation followed by nuclear translocation and binding to the HIV LTR promoter. In addition, E. umbellata latex extract induced the production of pro inflammatory cytokines in vitro in human PBMC cultures. This latex extract also activates latent virus in human PBMCs isolated from HIV positive patients as well as latent SIV in non-human primate primary CD4(+) T lymphocytes. Together, these results indicate that the phorbol esters present in E. umbellata latex are promising candidate compounds for future clinical trials for shock and kill therapies to promote HIV cure and eradication.	[Chaves Valadao, Ana Luiza; Pezzuto, Paula; Rossi, Atila Duque; da Cunha, Rodrigo Delvecchio; Goncalves, Gabriel; Aguiar, Renato Santana; Tanuri, Amilcar] Univ Fed Rio de Janeiro, Dept Genet, Lab Virol Mol, Rio De Janeiro, Brazil; [Oliveira Silva, Viviane A.] Hosp Canc Barretos, Ctr Pesquisa Oncol Mol, Barretos, Brazil; [Goncalves, Barbara Simonson; Damasco, Paulo; de Melo Bento, Cleonice Alves] Univ Fed Estado Rio de Janeiro, Dept Microbiol & Parasitol, Rio De Janeiro, Brazil; [Siani, Antonio Carlos; de Freitas Tostes, Joao Batista] Fundacao Oswaldo Cruz, Inst Tecnol Farmacos, Dept Prod Nat, Rio De Janeiro, Brazil; [Trovo, Marcelo] Univ Fed Rio de Janeiro, Inst Biol, Dept Bot, Rio De Janeiro, Brazil; [Reis, Rui Manuel] Univ Minho, Sch Med, Life & Hlth Sci Res Inst ICVS, Braga, Portugal; [Reis, Rui Manuel] 3Bs PT Govt Associate Lab, ICVS, Braga, Portugal; [Chaves Valadao, Ana Luiza] Inst Human Genet, Dept Mol Basis Humans Dis, Mol Basis Inflammat Lab, Montpellier, France	Universidade Federal do Rio de Janeiro; Hospital de Cancer de Barretos; Universidade Federal do Estado do Rio de Janeiro; Fundacao Oswaldo Cruz; Universidade Federal do Rio de Janeiro; Universidade do Minho; Universite de Montpellier	Tanuri, A (corresponding author), Univ Fed Rio de Janeiro, Dept Genet, Lab Virol Mol, Rio De Janeiro, Brazil.	atanuri1@gmail.com	Tostes, João B.F./P-2514-2017; Reis, Rui Manuel/B-1744-2018; Siani, Antonio C/L-3868-2014; Tanuri, Amilcar/AAM-8601-2021; Tostes, João/ABH-1936-2020; /AAD-2097-2020; Silva, Viviane A O/O-1772-2015; Aguiar, Renato S/G-3542-2015; Reis, Rui Manuel/AAD-6470-2020; Rossi, Atila Duque/AAV-6079-2020; Trovó, Marcelo/A-1763-2014	Tostes, João B.F./0000-0002-6085-365X; Reis, Rui Manuel/0000-0002-9639-7940; Tostes, João/0000-0002-6085-365X; Aguiar, Renato S/0000-0001-5180-3717; Reis, Rui Manuel/0000-0002-9639-7940; Rossi, Atila Duque/0000-0001-6235-8807; Trovó, Marcelo/0000-0002-0478-2332; Siani, Antonio Carlos/0000-0001-8108-2500; Silva, Viviane A O/0000-0001-5919-5242; Valadao, Ana Luiza/0000-0002-3839-3079	CNPq; CAPES; FAPERJ [E26/2015064289]; FAPERJ	CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); FAPERJ(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); FAPERJ(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ))	Postdoc fellowships and PhD stipends were supported by CNPq and CAPES during this work. Research and experimental expenses were funded by the grant E26/2015064289 from FAPERJ.; We thank Dr. Thomas Friedrich from Virology Services Unit at the Wisconsin National Primate Research Center, Wisconsin, USA for QVOA assay using SIVmac239 in NHP CD4<SUP>+</SUP> Lymphocytes. We are also grateful to Mr. Wilson Camargo Barros Filho and Mr. Luis Antonio Nogueira for providing E. umbellata's latex used in this work. This work was sponsored by CNPq, CAPES and FAPERJ.	Bachu M, 2012, J BIOL CHEM, V287, P44714, DOI 10.1074/jbc.M112.397158; BAGAVATHI R, 1988, Planta Medica, V54, P506, DOI 10.1055/s-2006-962531; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Blackhall FH, 2001, BRIT J CANCER, V84, P465, DOI 10.1054/bjoc.2000.1624; Campos A, 2016, INT J TOXICOL, V35, P666, DOI 10.1177/1091581816659660; Coffin J, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a012526; Costa LLG, 2012, REV BRAS FARMACOGN, V22, P1070, DOI 10.1590/S0102-695X2012005000050; Cunha LC, 2009, BRAZILIAN J PHARMACO, V19, P403; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7; Deeks SG, 2012, NATURE, V487, P439, DOI 10.1038/487439a; Dutra Rafael C, 2016, Pharmacol Res, V112, P4, DOI 10.1016/j.phrs.2016.01.021; El-Mekkawy S, 1998, PHYTOCHEMISTRY, V49, P1651, DOI 10.1016/S0031-9422(98)00254-4; Fatope MO, 1996, J MED CHEM, V39, P1005, DOI 10.1021/jm950509i; Franco-Salla GB, 2016, BMC COMPLEM ALTERN M, V16, P1, DOI [10.1186/s12906-015-0973-0, DOI 10.1186/S12906-015-0973-0]; Gallo RC, 1984, SCIENCE, V224, P3769; Hartmann D. B., 2011, Arquivos de Ciencias Veterinarias e Zoologia da UNIPAR, V14, P5; Hassan EM, 2012, REC NAT PROD, V6, P255; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; Jiang G, 2017, AIDS RES HUM RETROV, P1; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Jose DP, 2014, VIROLOGY, V462, P328, DOI 10.1016/j.virol.2014.05.033; Kared H, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003422; Kashiwada Y, 1998, J NAT PROD, V61, P1090, DOI 10.1021/np9800710; Kim HJ, 2011, AM J TRANSL RES, V3, P166; KINGHORN AD, 1980, J PHARM SCI-US, V69, P1446, DOI 10.1002/jps.2600691228; Laird GM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003398; Levy J A, 2011, Adv Dent Res, V23, P13, DOI 10.1177/0022034511398874; Lin MW, 2012, FOOD CHEM TOXICOL, V50, P4333, DOI 10.1016/j.fct.2012.05.029; Loya S, 1999, BIOCHEM J, V344, P85, DOI 10.1042/0264-6021:3440085; Martiny-Baron G, 1999, J BIOL CHEM, V274, P15320, DOI [10.1074/jbc.274.22.15320, DOI 10.1074/JBC.274.22.15320]; McManamy Mary E. Manson, 2014, Antiviral Chemistry & Chemotherapy, V23, P145, DOI 10.3851/IMP2551; Mehla R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011160; Mochly-Rosen D, 1998, FASEB J, V12, P35; Naghavi MH, 1999, AIDS RES HUM RETROV, V15, P1293, DOI 10.1089/088922299310197; Ohtake N, 2004, J CHROMATOGR B, V812, P135, DOI 10.1016/j.jchromb.2004.06.051; OLIVIER GWJ, 1992, J CHEM SOC PERK T 1, P1831, DOI 10.1039/p19920001831; Paiardini M, 2013, IMMUNOL REV, V254, P78, DOI 10.1111/imr.12079; Porichis F, 2011, CURR OPIN HIV AIDS, V6, P174, DOI 10.1097/COH.0b013e3283454058; Prakash E., 2013, UNIVERS J PLANT SCI, V1, P113, DOI [10.13189/ujps.2013.010401, DOI 10.13189/UJPS.2013.010401]; Savarino A, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-52; Shirakawa K, 2013, TRENDS MICROBIOL, V21, P277, DOI 10.1016/j.tim.2013.02.005; Siliciano RF, 2018, HIV LATENCY, P1, DOI [10.1101/cshperspect.a007096, DOI 10.1101/CSHPERSPECT.A007096]; Spitaler M, 2004, NAT IMMUNOL, V5, P785, DOI 10.1038/ni1097; Steinberg SF, 2008, PHYSIOL REV, V88, P1341, DOI 10.1152/physrev.00034.2007; Tanaka M, 2001, BIOORG MED CHEM LETT, V11, P719, DOI 10.1016/S0960-894X(01)00045-2; Trushin SA, 2005, J VIROL, V79, P9821, DOI 10.1128/JVI.79.15.9821-9830.2005; UNAIDS, 2017, GLOB HIV AIDS DAT, P1; UZABAKILIHO B, 1987, PHYTOCHEMISTRY, V26, P3041, DOI 10.1016/S0031-9422(00)84589-6; Valentine LE, 2009, J VIROL, V83, P11514, DOI 10.1128/JVI.01298-09; Wang L, 2013, MOL MED REP, V8, P1279, DOI 10.3892/mmr.2013.1650; Wei DG, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004071; Williams SA, 2004, J BIOL CHEM, V279, P42008, DOI 10.1074/jbc.M402124200; Ylisastigui L, 2004, AIDS, V18, P1101, DOI 10.1097/00002030-200405210-00003	54	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2018	13	11							e0207664	10.1371/journal.pone.0207664	http://dx.doi.org/10.1371/journal.pone.0207664			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB9UV	30481211	Green Published, Green Submitted, gold			2023-01-03	WOS:000451440000018
J	Siddique, AB; Perkins, J; Mazumder, T; Haider, MR; Banik, G; Tahsina, T; Islam, MJ; El Arifeen, S; Rahman, AE				Siddique, Abu Bakker; Perkins, Janet; Mazumder, Tapas; Haider, Mohammad Rifat; Banik, Goutom; Tahsina, Tazeen; Islam, Md Jahurul; El Arifeen, Shams; Rahman, Ahmed Ehsanur			Antenatal care in rural Bangladesh: Gaps in adequate coverage and content	PLOS ONE			English	Article							PRIVATE-SECTOR; INEQUITIES; COUNTRIES; TRENDS	Introduction Antenatal care (ANC) has long been considered a critical component of the continuum of care during pregnancy, with the potential to contribute to the survival and thriving of women and newborns. Although ANC utilization has increased in over the past decades, adequate coverage and content of ANC contacts have fallen under increased scrutiny. The objectives of this article are to describe the coverage and content of ANC contacts in the context of rural Bangladesh. Methods A community-based, cross-sectional household survey was conducted in two sub-districts of Netrokona district, Bangladesh in 2016. A total of 737 women with a recent birth outcome were interviewed. Respondents reported on the ANC contacts and the content of these contacts. Descriptive statistics were used to report coverage and content of ANC contacts stratified by covariates. Chi-square tests were performed to explore whether the estimates are different among different categories and significant differences were reported at p<0.05. Results Around 25% of women attended at least four ANC contacts, with only 11% initiating ANC in the first trimester of pregnancy. Blood pressure was measured in almost all of the ANC contacts (92%), and abdominal examination performed in 80% and weight measured in 85% of ANC contacts. Urine tests were conducted in less than half of the ANC contacts, whereas blood screening tests and ultrasound were conducted in 45% contacts. Health care providers counselled women on danger signs in only 66% of the ANC contacts. Overall, the content of facility-based ANC contacts were better than home-based ANC contacts across all components. Conclusions Adequate coverage of ANC remains poor in Netrokona, Bangladesh and important gaps remain in the content of ANC contacts when women attend these services.	[Siddique, Abu Bakker; Mazumder, Tapas; Banik, Goutom; Tahsina, Tazeen; El Arifeen, Shams; Rahman, Ahmed Ehsanur] Int Ctr Diarrhoea Dis Res, Bangladesh Icddr B, Maternal & Child Hlth Div, Dhaka, Bangladesh; [Perkins, Janet] Enfants Monde, Hlth Dept, Geneva, Switzerland; [Haider, Mohammad Rifat] Univ South Carolina, Norman J Arnold Sch Publ Hlth, Dept Hlth Promot Educ & Behav, Columbia, SC USA; [Islam, Md Jahurul] Minist Hlth & Family Welf MOH&FW, Directorate Gen Hlth Serv, Natl Newborn Hlth Program, Dhaka, Bangladesh; [Islam, Md Jahurul] Minist Hlth & Family Welf MOH&FW, Directorate Gen Hlth Serv, Integrated Management Childhood Illness, Dhaka, Bangladesh	International Centre for Diarrhoeal Disease Research (ICDDR); University of South Carolina System; University of South Carolina Columbia	Rahman, AE (corresponding author), Int Ctr Diarrhoea Dis Res, Bangladesh Icddr B, Maternal & Child Hlth Div, Dhaka, Bangladesh.	ehsanur@icddrb.org	Perkins, Janet/GVS-1117-2022; Rahman, Ahmed Ehsanur/ABC-5318-2021; Haider, Mohammad Rifat/N-9987-2016	Haider, Mohammad Rifat/0000-0002-0690-8242; Arifeen, Shams/0000-0002-5372-5932	PARI Development Trust, a local NGO in Bangladesh	PARI Development Trust, a local NGO in Bangladesh	The study was funded by the PARI Development Trust, a local NGO in Bangladesh. The funding agency did not have any role in the design of the study, data collection, analysis and interpretation of data, and writing the manuscript.	ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; [Anonymous], 2016, DROP; [Anonymous], 2011, NATL I POPULATION RE; [Anonymous], 2015, GLOBAL STRATEGY WOME; Anwar I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120309; Bailey PE, 2015, BMC PREGNANCY CHILDB, V15, DOI [10.1186/s12884-016-1035-4, 10.1186/s12884-015-0725-7]; Bangladesh Go, 2016, MATERNAL HLTH STRATE; Benova L, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000779; Bhattacharyya S, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1077-8; Campbell OMR, 2016, TROP MED INT HEALTH, V21, P486, DOI 10.1111/tmi.12681; Chattopadhyay A, 2012, J BIOSOC SCI, V44, P129, DOI 10.1017/S0021932011000502; Chaves SD, 2015, REV PANAM SALUD PUBL, V37, P203; EBCOG Sci Comm, 2015, FACTS VIEWS VIS OBGY, V7, P5; Ganle JK, 2015, BMC INT HEALTH HUM R, V15, DOI 10.1186/s12914-015-0048-9; Graham W, 2016, LANCET, V388, P2164, DOI 10.1016/S0140-6736(16)31533-1; Handler A, 2012, MATERN CHILD HLTH J, V16, P393, DOI 10.1007/s10995-011-0763-3; Heredia-Pi I, 2016, B WORLD HEALTH ORGAN, V94, P452, DOI 10.2471/BLT.15.168302; Hodgins S, 2014, GLOB HEALTH-SCI PRAC; Kanyangarara M, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.021101; Kuhnt J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017122; Kyei NNA, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-151; Mannava P, 2015, GLOBALIZATION HEALTH, V11, DOI 10.1186/s12992-015-0117-9; Marchant T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126840; MEASURE Evaluation ICF International, 2006, GUIE DHS STAT DEM HL; Moller AB, 2017, LANCET GLOB HEALTH, V5, pE977, DOI 10.1016/S2214-109X(17)30325-X; Mushi D, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-14; National Institute of Population Research and Training, 2012, BANGL MAT MORT HLTH; National Institute of Population Research and Training, 2014, BANGL DEM HLTH SURV; National Institute of Population Research and Training (NIPORT), 2011, MEAS EV UNC CH U ICD; National Institute of Population Research and Training (NIPORT) MaA and ICF International, 2016, BANGL DEM HLTH SURV; NIPORT, 2014, BANGL HLTH FAC SURV; NIPORT icddrb Evaluation M, 2017, BANGLADESH MATERNAL; NIPORT Mitra and Associates and ICF International, 2013, BANGL DEM HLTH SURV; Organization WH, 2010, COUNSELLING MATERNAL; Owolabi OO, 2017, LANCET CHILD ADOLESC, V1, P203, DOI 10.1016/S2352-4642(17)30025-1; Paudel YR, 2015, INT J REPROD MED, V2015; Pembe AB, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-35; Rahman AE, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1882-2; Rahman A, 2017, J HEALTH POPUL NUTR, V36, DOI 10.1186/s41043-016-0078-5; Rosen HE, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0728-4; Saad-Haddad G, 2016, J GLOB HEALTH, V6, DOI [10.7189/Jogh.06.010404, 10.7189/jogh.06.010404]; Sarker BK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146161; Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Souza JP, 2014, BJOG-INT J OBSTET GY, V121, P1, DOI 10.1111/1471-0528.12735; Story WT, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-28; Story WT, 2016, INT PERSPECT SEX R H, V42, P211, DOI 10.1363/42e2616; The White Ribbon Alliance, 2011, RESPECTFUL MATERNITY; UNICEF, 2018, MULT IND CLUST SURV; UNICEF, 2016, GLOB DAT; United Nations, 2015, SUST DEV GOALS 2015; Victora CG, 2010, HEALTH POLICY PLANN, V25, P253, DOI 10.1093/heapol/czp065; Villar J, 2002, WHO ANTENATAL CARE R; Vyas S, 2006, HEALTH POLICY PLANN, V21, P459, DOI 10.1093/heapol/czl029; White Deborah E, 2006, Health Care Women Int, V27, P777, DOI 10.1080/07399330600880335; WHO, 2016, WHO REC ANT CAR POST; WOLD S, 1987, CHEMOMETR INTELL LAB, V2, P37, DOI 10.1016/0169-7439(87)80084-9; World Health Organization, 2015, 9241508485 EPMM WORL; Yeoh PL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135301; Zolotor AJ, 2014, AM FAMILY PHYS, V89	60	21	21	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2018	13	11							e0205149	10.1371/journal.pone.0205149	http://dx.doi.org/10.1371/journal.pone.0205149			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HA9FQ	30452444	Green Submitted, Green Published, gold			2023-01-03	WOS:000450603800001
J	Brown, VA; Hedayati, M; Zanger, A; Mayn, S; Ray, L; Dillman-Hasso, N; Strand, JF				Brown, Violet A.; Hedayati, Maryam; Zanger, Annie; Mayn, Sasha; Ray, Lucia; Dillman-Hasso, Naseem; Strand, Julia F.			What accounts for individual differences in susceptibility to the McGurk effect?	PLOS ONE			English	Article							VISUAL SPEECH-PERCEPTION; WORKING-MEMORY; AUDIOVISUAL INTEGRATION; SENTENCE RECOGNITION; SELECTIVE ADAPTATION; CHILDRENS SPEECH; PHONETIC DETAIL; MECHANICAL TURK; HEARING-LIPS; INFORMATION	The McGurk effect is a classic audiovisual speech illusion in which discrepant auditory and visual syllables can lead to a fused percept (e.g., an auditory /ba/ paired with a visual /ga/ often leads to the perception of MO. The McGurk effect is robust and easily replicated in pooled group data, but there is tremendous variability in the extent to which individual participants are susceptible to it. In some studies, the rate at which individuals report fusion responses ranges from 0% to 100%. Despite its widespread use in the audiovisual speech perception literature, the roots of the wide variability in McGurk susceptibility are largely unknown. This study evaluated whether several perceptual and cognitive traits are related to McGurk susceptibility through correlational analyses and mixed effects modeling. We found that an individual's susceptibility to the McGurk effect was related to their ability to extract place of articulation information from the visual signal (i.e., a more fine-grained analysis of lipreading ability), but not to scores on tasks measuring attentional control, processing speed, working memory capacity, or auditory perceptual gradiency. These results provide support for the claim that a small amount of the variability in susceptibility to the McGurk effect is attributable to lipreading skill. In contrast, cognitive and perceptual abilities that are commonly used predictors in individual differences studies do not appear to underlie susceptibility to the McGurk effect.	[Brown, Violet A.; Hedayati, Maryam; Zanger, Annie; Mayn, Sasha; Ray, Lucia; Dillman-Hasso, Naseem; Strand, Julia F.] Carleton Coll, Dept Psychol, Northfield, MN 55057 USA	Carleton College	Brown, VA; Strand, JF (corresponding author), Carleton Coll, Dept Psychol, Northfield, MN 55057 USA.	violet.brown@wustl.edu; jstrand@carleton.edu	; Strand, Julia/J-5432-2014	Mayn, Alexandra/0000-0003-1472-3157; Strand, Julia/0000-0001-5950-0139; Ray, Lucia/0000-0001-9692-0909; Brown, Violet/0000-0001-5310-6499; Dillman-Hasso, Naseem/0000-0002-8284-4383	Carleton College	Carleton College	We are grateful to Eun Jong Kong and Jan Edwards for providing stimuli for the Visual Analogue Scale task, to Hunter Brown for feedback on an early draft of the paper, and to Aaron Swoboda for helpful suggestions on figure design. Carleton College supported this work. Correspondence should be addressed to Violet Brown(violet.brown@wustl.edu) or Julia Strand (jstrand@carleton.edu).	Aloufy S, 1996, BRAIN LANG, V53, P51, DOI 10.1006/brln.1996.0036; Alsius A, 2005, CURR BIOL, V15, P839, DOI 10.1016/j.cub.2005.03.046; Alsius A, 2007, EXP BRAIN RES, V183, P399, DOI 10.1007/s00221-007-1110-1; Alsius A, 2018, MULTISENS RES, V31, P111, DOI 10.1163/22134808-00002565; Alsius A, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00727; Auer ET, 2007, J SPEECH LANG HEAR R, V50, P1157, DOI 10.1044/1092-4388(2007/080); Barr DJ, 2013, J MEM LANG, V68, P255, DOI 10.1016/j.jml.2012.11.001; Mallick D, 2015, PSYCHON B REV, V22, P1299, DOI 10.3758/s13423-015-0817-4; Bates D., 2014, PACKAGE LME4, P12, DOI DOI 10.18637/JSS.V067.I01; Beauchamp MS, 2018, MULTISENS RES, V31, P1, DOI 10.1163/22134808-00002598; Beauchamp MS, 2010, J NEUROSCI, V30, P2414, DOI 10.1523/JNEUROSCI.4865-09.2010; Bebko JM, 2014, AUTISM RES, V7, P50, DOI 10.1002/aur.1343; Benoit MM, 2010, HUM BRAIN MAPP, V39; Besser J, 2012, J SPEECH LANG HEAR R, V55, P194, DOI 10.1044/1092-4388(2011/11-0008); Bleckley MK, 2003, PSYCHON B REV, V10, P884, DOI 10.3758/BF03196548; Brancazio L, 2005, PERCEPT PSYCHOPHYS, V67, P759, DOI 10.3758/BF03193531; Brancazio L, 2004, J EXP PSYCHOL HUMAN, V30, P445, DOI 10.1037/0096-1523.30.3.445; Buchan JN, 2012, SEEING PERCEIVING, V25, P87, DOI 10.1163/187847611X620937; Buhrmester M, 2011, PERSPECT PSYCHOL SCI, V6, P3, DOI 10.1177/1745691610393980; Calvert GA, 2000, CURR BIOL, V10, P649, DOI 10.1016/S0960-9822(00)00513-3; Chambers CD, 2013, CORTEX, V49, P609, DOI 10.1016/j.cortex.2012.12.016; Cienkowski KM, 2002, EAR HEARING, V23, P439, DOI 10.1097/00003446-200210000-00006; Conway ARA, 2001, PSYCHON B REV, V8, P331, DOI 10.3758/BF03196169; Crump MJC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057410; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; de Gelder B, 2003, SCHIZOPHR RES, V59, P211, DOI 10.1016/S0920-9964(01)00344-9; ERBER NP, 1969, J SPEECH HEAR RES, V12, P423, DOI 10.1044/jshr.1202.423; Erickson LC, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00534; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Fanelli D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010271; Feld JE, 2009, J SPEECH LANG HEAR R, V52, P1555, DOI 10.1044/1092-4388(2009/08-0137); Fernald A, 2006, DEV PSYCHOL, V42, P98, DOI 10.1037/0012-1649.42.1.98; Fullgrabe C, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01268; Gentilucci M, 2005, EXP BRAIN RES, V167, P66, DOI 10.1007/s00221-005-0008-z; Grant KW, 1996, J ACOUST SOC AM, V100, P2415, DOI 10.1121/1.417950; Grant KW, 1998, J ACOUST SOC AM, V104, P2438, DOI 10.1121/1.423751; Grant KW, 1998, J ACOUST SOC AM, V103, P2677, DOI 10.1121/1.422788; GREEN KP, 1991, J EXP PSYCHOL HUMAN, V17, P278, DOI 10.1037/0096-1523.17.1.278; GREEN KP, 1991, PERCEPT PSYCHOPHYS, V50, P524, DOI 10.3758/BF03207536; Hawkins S, 1998, AVSP 98 INT C AUD VI; Hedge C, 2018, BEHAV RES METHODS, V50, P1166, DOI 10.3758/s13428-017-0935-1; Hutchison KA, 2007, J EXP PSYCHOL LEARN, V33, P645, DOI 10.1037/0278-7393.33.4.645; Irwin JR, 2006, PERCEPT PSYCHOPHYS, V68, P582, DOI 10.3758/BF03208760; JACKSON PL, 1988, VOLTA REV, V90, P99; Julien HM, 2012, J SPEECH LANG HEAR R, V55, P1836, DOI 10.1044/1092-4388(2012/11-0131); KAIL R, 1994, DEV PSYCHOL, V30, P949, DOI 10.1037/0012-1649.30.6.949; Kapnoula EC, 2017, J EXP PSYCHOL HUMAN, V43, P1594, DOI 10.1037/xhp0000410; Keane BP, 2010, RES AUTISM SPECT DIS, V4, P276, DOI 10.1016/j.rasd.2009.09.015; Kong EJ, 2011, INDIVIDUAL DIFFERENC; Kong EJ, 2016, J PHONETICS, V59, P40, DOI 10.1016/j.wocn.2016.08.006; Kuznetsova A, 2017, J STAT SOFTW, V82, P1, DOI 10.18637/jss.v082.i13; Lange ND, 2012, FRONT PSYCHOL, V3, DOI [10.3389/fpsyg.2012.00552, 10.3389/fpsyg.2012.00215]; LIBERMAN AM, 1957, J EXP PSYCHOL, V54, P358, DOI 10.1037/h0044417; Luce PA, 1999, J EXP PSYCHOL HUMAN, V25, P174, DOI 10.1037/0096-1523.25.1.174; Ma WJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004638; MacDonald J, 2000, PERCEPTION, V29, P1155, DOI 10.1068/p3020; Magnotti JF, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202908; Magnotti JF, 2018, MULTISENS RES, V31, P19, DOI 10.1163/22134808-00002586; Magnotti JF, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005229; Magnotti JF, 2015, EXP BRAIN RES, V233, P2581, DOI 10.1007/s00221-015-4324-7; MASSARO DW, 1993, AM J PSYCHOL, V106, P25, DOI 10.2307/1422864; MASSARO DW, 1983, J EXP PSYCHOL HUMAN, V9, P753, DOI 10.1037/0096-1523.9.5.753; Massaro DW, 1987, SPEECH PERCEPTION EA; MCGURK H, 1976, NATURE, V264, P746, DOI 10.1038/264746a0; MEYER DE, 1971, J EXP PSYCHOL, V90, P227, DOI 10.1037/h0031564; Mongillo EA, 2008, J AUTISM DEV DISORD, V38, P1349, DOI 10.1007/s10803-007-0521-y; Fernandez LM, 2017, HUM BRAIN MAPP, V38, P5691, DOI 10.1002/hbm.23758; MULLENNIX JW, 1989, J ACOUST SOC AM, V85, P365, DOI 10.1121/1.397688; Munhall KG, 1996, PERCEPT PSYCHOPHYS, V58, P351, DOI 10.3758/BF03206811; Munson B, 2009, J ACOUST SOC AM, V125, P2529; Munson B, 2017, CLIN LINGUIST PHONET, V31, P56, DOI 10.1080/02699206.2016.1233292; Munson B, 2016, SPEECH LANG HEARING, V19, P36, DOI 10.1080/2050571X.2015.1116154; Munson B, 2012, AM J SPEECH-LANG PAT, V21, P124, DOI 10.1044/1058-0360(2011/11-0009); Nahorna O, 2015, J ACOUST SOC AM, V137, P362, DOI 10.1121/1.4904536; Nahorna O, 2012, J ACOUST SOC AM, V132, P1061, DOI 10.1121/1.4728187; Nath AR, 2012, NEUROIMAGE, V59, P781, DOI 10.1016/j.neuroimage.2011.07.024; Nieuwenhuis S, 2006, MEM COGNITION, V34, P1260, DOI 10.3758/BF03193270; Ostrand R, 2016, COGNITION, V151, P96, DOI 10.1016/j.cognition.2016.02.019; ROBERTS M, 1981, PERCEPT PSYCHOPHYS, V30, P309, DOI 10.3758/BF03206144; Rosenblum LD, 1996, J EXP PSYCHOL HUMAN, V22, P318, DOI 10.1037/0096-1523.22.2.318; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; SALDANA HM, 1994, J ACOUST SOC AM, V95, P3658, DOI 10.1121/1.409935; Schellinger SK, 2017, CLIN LINGUIST PHONET, V31, P80, DOI 10.1080/02699206.2016.1205665; Schmidt JR, 2011, ACTA PSYCHOL, V138, P176, DOI 10.1016/j.actpsy.2011.06.002; SEKIYAMA K, 1993, J PHONETICS, V21, P427, DOI 10.1016/S0095-4470(19)30229-3; SEKIYAMA K, 1991, J ACOUST SOC AM, V90, P1797, DOI 10.1121/1.401660; Setti A, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00575; Simcox T, 2014, BEHAV RES METHODS, V46, P95, DOI 10.3758/s13428-013-0345-y; SIMON JR, 1969, J EXP PSYCHOL, V81, P174, DOI 10.1037/h0027448; Slote J, 2016, BEHAV RES METHODS, V48, P553, DOI 10.3758/s13428-015-0599-7; Sommers MS, 2005, EAR HEARING, V26, P263, DOI 10.1097/00003446-200506000-00003; Soto-Faraco S, 2009, J EXP PSYCHOL HUMAN, V35, P580, DOI 10.1037/a0013483; Strand J, 2014, J SPEECH LANG HEAR R, V57, P2322, DOI 10.1044/2014_JSLHR-H-14-0059; Strand JF, 2018, J SPEECH LANG HEAR R, V61, P1463, DOI 10.1044/2018_JSLHR-H-17-0257; Stroop JR., 1935, J EXP PSYCHOL PSYCNE; SUMBY WH, 1954, J ACOUST SOC AM, V26, P212, DOI 10.1121/1.1907309; Thomas SM, 2002, PERCEPT PSYCHOPHYS, V64, P932, DOI 10.3758/BF03196797; Thornton A, 2000, J CLIN EPIDEMIOL, V53, P207, DOI 10.1016/S0895-4356(99)00161-4; Tiippana K, 2004, EUR J COGN PSYCHOL, V16, P457, DOI 10.1080/09541440340000268; Tiippana K, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00725; TURNER ML, 1989, J MEM LANG, V28, P127, DOI 10.1016/0749-596X(89)90040-5; Tye-Murray N, 2007, J AM ACAD AUDIOL, V18, P883, DOI 10.3766/jaaa.18.10.7; Tye-Murray N, 2016, PSYCHOL AGING, V31, P380, DOI 10.1037/pag0000094; TYLER RS, 1982, J ACOUST SOC AM, V72, P740, DOI 10.1121/1.388254; Unsworth N, 2005, BEHAV RES METHODS, V37, P498, DOI 10.3758/BF03192720; Van Engen KJ, 2017, ATTEN PERCEPT PSYCHO, V79, P396, DOI 10.3758/s13414-016-1238-9; Van Engen KJ, 2014, J SPEECH LANG HEAR R, V57, P1908, DOI 10.1044/JSLHR-H-13-0076; Van Hedger SC, 2015, COGNITION, V140, P95, DOI 10.1016/j.cognition.2015.03.012; Woods KJP, 2017, ATTEN PERCEPT PSYCHO, V79, P2064, DOI 10.3758/s13414-017-1361-2	109	17	17	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2018	13	11							e0207160	10.1371/journal.pone.0207160	http://dx.doi.org/10.1371/journal.pone.0207160			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HA0PF	30418995	gold, Green Submitted, Green Published			2023-01-03	WOS:000449909200052
J	Horumpende, PG; Said, SH; Mazuguni, FS; Antony, ML; Kumburu, HH; Sonda, TB; Mwanziva, CE; Mshana, SE; Mmbaga, BT; Kajeguka, DC; Chilongola, JO				Horumpende, Pius G.; Said, Sophia H.; Mazuguni, Festo S.; Antony, Magreth L.; Kumburu, Happiness H.; Sonda, Tolbert B.; Mwanziva, Charles E.; Mshana, Stephen E.; Mmbaga, Blandina T.; Kajeguka, Debora C.; Chilongola, Jaffu O.			Prevalence, determinants and knowledge of antibacterial self-medication: A cross sectional study in North-eastern Tanzania	PLOS ONE			English	Article							ANTIBIOTIC-RESISTANCE; ANTIMICROBIAL RESISTANCE; UNIVERSITY-STUDENTS; PRESCRIPTION; CHILDREN; AVAILABILITY; POPULATION; PHARMACIES; MANAGEMENT; CRISIS	Self-medication is very common especially in developing countries and is documented to be associated with many health risks including antibiotic resistance. This study investigated the prevalence, determinants and knowledge of self-medication among residents of Siha District in Tanzania. A cross-sectional study was conducted among 300 residents in a rural District of Kilimanjaro region, North-eastern Tanzania from 1st to 28th April 2017. A semi-structured questionnaire was used to collect information regarding drugs used, knowledge, history and reasons for antibiotic self-medication. Log-binomial regression analysis was done using STATA 13 to examine factors associated with self-medication. A slightly majority of the respondents (58%) admitted to self-medication. Antibiotics most commonly utilized were amoxycillin (43%) and an antiprotozoal drug metronidazole (10%). The most common symptoms that led to self-medication were cough (51.17%), headache/ fever/ malaria (25.57%) and diarrhoea (21.59%). The most common reasons for self-medication were emergency illness (24.00%), health facility charges (20.33%), proximity of pharmacy to home (17.00%) and no reason (16.66%). Almost all reported that self-medication is not better than seeking medical consultation, 98% can result into harmful effects and 96% can result to drug resistance. The level of self-medication in this study is comparable with findings from other studies in developing countries. Pharmacies were commonly used as the first point of medical care. There is therefore a need for educative antibiotic legislative intervention to mitigate the adverse effects of antibiotic self-medication in Siha district in Tanzania.	[Horumpende, Pius G.; Said, Sophia H.; Kumburu, Happiness H.; Sonda, Tolbert B.; Kajeguka, Debora C.; Chilongola, Jaffu O.] Kilimanjaro Christian Med Univ Coll, Dept Microbiol Immunol & Mol Biol, Moshi, Kilimanjaro, Tanzania; [Horumpende, Pius G.; Kumburu, Happiness H.; Sonda, Tolbert B.; Mmbaga, Blandina T.; Chilongola, Jaffu O.] Kilimanjaro Clin Res Inst, Dept Microbiol Immunol & Mol Biol, Moshi, Kilimanjaro, Tanzania; [Horumpende, Pius G.; Mwanziva, Charles E.] Lugalo Gen Mil Hosp, Dept Prevent Med & Res, Dar Es Salaam, Tanzania; [Mazuguni, Festo S.] Ifakara Hlth Inst, Dept Publ Hlth & Res, Dar Es Salaam, Tanzania; [Antony, Magreth L.] Qual Assurance & Training Ctr, Dept Parasitol & Entomol, Natl Hlth Lab, Dar Es Salaam, Tanzania; [Mshana, Stephen E.] Catholic Univ Hlth & Allied Sci, Dept Microbiol & Immunol, Mwanza, Tanzania; [Mmbaga, Blandina T.] Kilimanjaro Christian Med Ctr, Dept Paediat & Child Hlth, Moshi, Kilimanjaro, Tanzania	Ifakara Health Institute; Kilimanjaro Christian Medical Centre	Horumpende, PG (corresponding author), Kilimanjaro Christian Med Univ Coll, Dept Microbiol Immunol & Mol Biol, Moshi, Kilimanjaro, Tanzania.; Horumpende, PG (corresponding author), Kilimanjaro Clin Res Inst, Dept Microbiol Immunol & Mol Biol, Moshi, Kilimanjaro, Tanzania.; Horumpende, PG (corresponding author), Lugalo Gen Mil Hosp, Dept Prevent Med & Res, Dar Es Salaam, Tanzania.	p.horumpende@kcri.ac.tz	Mmbaga, Blandina Theophil/AAR-8707-2021; Chilongola, Jaffu/K-9552-2017; Mshana, Stephen/AAE-1900-2022; Horumpende, Pius/AAS-2712-2020; Kajeguka, Debora Charles/AAM-1007-2021	Mmbaga, Blandina Theophil/0000-0002-5550-1916; Chilongola, Jaffu/0000-0003-2997-6747; Horumpende, Pius/0000-0003-1241-6997; Kajeguka, Debora Charles/0000-0003-4341-5938; Mazuguni, Festo/0000-0002-0984-7529				Abasaeed A, 2009, J INFECT DEV COUNTR, V3, P491, DOI 10.3855/jidc.466; Al Rasheed A, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3916874; Bansal D, 2014, INDIAN J PHARM SCI, V76, P211; Baquero F, 2008, CURR OPIN BIOTECH, V19, P260, DOI 10.1016/j.copbio.2008.05.006; Bell BG, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-13; Casburn-Jones AC, 2004, GUT, V53, P296, DOI 10.1136/gut.2003.022103; Centre for Pharmaceutical Management, 2008, ACCREDITED DRUG DISP; Chalker JC, 2015, ANTIMICROB RESIST IN, V4, DOI 10.1186/s13756-015-0075-2; Chipwaza B, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-252; Chung A, 2007, BMJ-BRIT MED J, V335, P429, DOI 10.1136/bmj.39274.647465.BE; Coles CL, 2013, CLIN INFECT DIS, V56, P1519, DOI 10.1093/cid/cit137; Colom K, 2003, FEMS MICROBIOL LETT, V223, P147, DOI 10.1016/S0378-1097(03)00306-9; da Silva MGC, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-339; de Loyola AI, 2002, REV SAUDE PUBL, V36, P55, DOI 10.1590/S0034-89102002000100009; Del Mar C, 2007, BMJ-BRIT MED J, V335, P407, DOI 10.1136/bmj.39307.642963.80; Donkor ES, 2012, INT J ENV RES PUB HE, V9, P3519, DOI 10.3390/ijerph9103519; Donnan PT, 2004, BRIT MED J, V328, P1297, DOI 10.1136/bmj.328.7451.1297; Duong DV, 1997, TROP MED INT HEALTH, V2, P1133, DOI 10.1046/j.1365-3156.1997.d01-213.x; Esimone CO, 2007, PHARM WORLD SCI, V29, P655, DOI 10.1007/s11096-007-9124-0; Geissler PW, 2000, SOC SCI MED, V50, P1771, DOI 10.1016/S0277-9536(99)00428-1; Goodman C, 2007, HEALTH POLICY PLANN, V22, P393, DOI 10.1093/heapol/czm033; Justin-Temu M, 2010, East Afr J Public Health, V7, P282; Kuehn BM, 2013, JAMA-J AM MED ASSOC, V310, P2385, DOI 10.1001/jama.2013.283828; Kuehn BM, 2013, JAMA-J AM MED ASSOC, V310, P2135, DOI 10.1001/jama.2013.281452; Levson G, 2013, PEOPLES KNOWLEDGE AT; Liana JH, ACCREDITED DRUG DISP, DOI [10.1186/s40545-015-0044-4, DOI 10.1186/S40545-015-0044-4]; Lipsitch M, 2002, EMERG INFECT DIS, V8, P347, DOI 10.3201/eid0804.010312; Llor C, 2014, THER ADV DRUG SAF, V5, P229, DOI 10.1177/2042098614554919; LONDON N, 1994, J ANTIMICROB CHEMOTH, V34, P239, DOI 10.1093/jac/34.2.239; Lucet JC, 2011, J ANTIMICROB CHEMOTH, V66, P936, DOI 10.1093/jac/dkq541; Lyimo B, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0870-9; Mainous AG, 2009, ANN FAM MED, V7, P431, DOI 10.1370/afm.999; Marwa KJ, 2015, AIDS RES TREAT, V2015, DOI 10.1155/2015/103874; McNulty CAM, 2007, J ANTIMICROB CHEMOTH, V60, pI63, DOI 10.1093/jac/dkm161; Michael CA, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00145; Ministry of Planning E and E, 2012, TANZANIA POPULATION; MSHANA SE, 2013, ANN CLIN MICROB ANTI, V12, P15660; Mukonzo JK, 2013, J MULTIDISCIP HEALTH, V6, P303, DOI 10.2147/JMDH.S49075; Mwanyika G. O., 2017, African Journal of Microbiology Research, V11, P45, DOI 10.5897/ajmr2016.8282; Nesme J, 2014, CURR BIOL, V24, P1096, DOI 10.1016/j.cub.2014.03.036; Ngigi CK, 2016, IMP J INTERDISCIP RE, V2, P2454; Nunez M., 2016, PERU MED U, V18, P205; Ocan M, FACTORS PREDICTING H; Ogunfowokan AA, 2010, J SCH NURS, V26, P131, DOI 10.1177/1059840509349723; Omolase CO, 2007, ANN IBADAN POSTGRADU, V5, P64, DOI [DOI 10.4314/AIPM.V5I2.64032, 10.4314/aipm.v5i2.64032]; Osemene KP, 2012, TROP J PHARM RES, V11, P683, DOI 10.4314/tjpr.v11i4.21; Pan H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041314; Pawlowski SW, 2009, GASTROENTEROLOGY, V136, P1874, DOI 10.1053/j.gastro.2009.02.072; Rather IA, 2017, SAUDI J BIOL SCI, V24, P808, DOI 10.1016/j.sjbs.2017.01.004; Raz R, 2005, ISRAEL MED ASSOC J, V7, P722; Rutta Edmund, 2015, J Pharm Policy Pract, V8, P23, DOI 10.1186/s40545-015-0044-4; Sapkota AR, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-610; Saradamma RD, 2000, SOC SCI MED, V50, P891, DOI 10.1016/S0277-9536(99)00380-9; Sarahroodi S, 2010, INT J PHARMACOL, V6, P48; Shah SJ, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-74; Singh AS, 2014, INT J EC COMMER MANA, V2; Spellberg B, 2014, CLIN INFECT DIS, V59, pS71, DOI 10.1093/cid/ciu392; Valimba Richard, 2014, J Pharm Policy Pract, V7, P11, DOI 10.1186/2052-3211-7-11; Van Boeckel TP, 2015, P NATL ACAD SCI USA, V112, P5649, DOI 10.1073/pnas.1503141112; Vandebroek I, 2004, B WORLD HEALTH ORGAN, V82, P243; Ventola C Lee, 2015, P T, V40, P277; Williams-Nguyen J, 2016, J ENVIRON QUAL, V45, P394, DOI 10.2134/jeq2015.07.0336; Wright GD, 2010, CURR OPIN MICROBIOL, V13, P589, DOI 10.1016/j.mib.2010.08.005; Zafar Syed Nabeel, 2008, J Pak Med Assoc, V58, P214; Zhu YG, 2013, P NATL ACAD SCI USA, V110, P3435, DOI 10.1073/pnas.1222743110	65	31	31	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2018	13	10							e0206623	10.1371/journal.pone.0206623	http://dx.doi.org/10.1371/journal.pone.0206623			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GY7VH	30379961	Green Submitted, Green Published, gold			2023-01-03	WOS:000448823700138
J	Kim, K; Son, YK; Lee, SM; Kim, SE; An, WS				Kim, Kitae; Son, Young Ki; Lee, Su Mi; Kim, Seong Eun; An, Won Suk			Early technical complications and long-term survival of urgent peritoneal dialysis according to break-in periods	PLOS ONE			English	Article							START; HEMODIALYSIS; INITIATION; OPTION; CAPD	Background Guidelines recommend a break-in period of 2 weeks before starting peritoneal dialysis (PD), but PD within 14 days is also an acceptable and safe alternative to hemodialysis (HD) in patients with an urgent need. However, the effect of the break-in period within 48 hours or later had not been evaluated for early technical complications, long-term maintenance, and survival in patients starting urgent PD. Methods Of 360 patients with a surgically inserted PD catheter, we evaluated 190 patients who needed urgent PD and 29 patients who received conventional PD at a single center between January 2007 and December 2014 in this retrospective observational study. Enrolled patients were divided according to break-in period of <48 hours (P1) or 2-13 days (P2) before starting urgent PD. The primary endpoint was incidence of early technical complications and secondary endpoints included long-term PD maintenance, and patient survival. Results PD was started in 103 patients (54.2%) within 48 hours and in 87 patients (45.8%) within 2 to 13 days. The incidence of early technical complication was significantly higher in P1 group (28.2%) than in P2 group (10.3%) (P = 0.002). The need for a repositioning procedure was significantly greater in P1 group (14.6%) than in P2 group (3.4%) (P = 0.009). However, we observed no significant differences between the two groups with respect to the prevalence of catheter dysfunction requiring change to HD within 6 months or incidence of peritonitis or exit-site infection. There was no significant difference in PD maintenance and patient survival according to the break-in period between P1 and P2 as well as against the control group. Conclusion Urgent PD was associated with a low incidence of early technical complications if start was avoided within 48 hours after catheter insertion, and long-term PD maintenance was independent of the break-in period.	[Kim, Kitae; Son, Young Ki; Lee, Su Mi; Kim, Seong Eun; An, Won Suk] Dong A Univ, Dept Internal Med, Busan, South Korea	Dong A University	An, WS (corresponding author), Dong A Univ, Dept Internal Med, Busan, South Korea.	anws@dau.ac.kr			Dong-A University	Dong-A University	This study was supported by research funds from Dong-A University.	Arramreddy R, 2014, AM J KIDNEY DIS, V63, P390, DOI 10.1053/j.ajkd.2013.09.018; Bae IE, 2012, J KOREAN SURG SOC, V83, P381, DOI 10.4174/jkss.2012.83.6.381; Banli O, 2005, PERITON DIALYSIS INT, V25, P556; Cullis B, 2014, PERITON DIALYSIS INT, V34, P494, DOI 10.3747/pdi.2013.00222; Dombros N., 2005, NEPHROL DIAL TRANSPL, V20, pix8, DOI DOI 10.1093/NDT/GFI1117; Figueiredo A, 2010, PERITON DIALYSIS INT, V30, P424, DOI 10.3747/pdi.2010.00087; Garcia Falcon T, 1994, Adv Perit Dial, V10, P206; Ghaffari A, 2012, AM J KIDNEY DIS, V59, P400, DOI 10.1053/j.ajkd.2011.08.034; Heaf JG, 2002, NEPHROL DIAL TRANSPL, V17, P112, DOI 10.1093/ndt/17.1.112; Jo YI, 2007, PERITON DIALYSIS INT, V27, P179; Khoshhali M, 2017, KIDNEY RES CLIN PRAC, V36, P182, DOI 10.23876/j.krcp.2017.36.2.182; Leblanc M, 2001, SEMIN DIAL; Liem YS, 2007, KIDNEY INT, V71, P153, DOI 10.1038/sj.ki.5002014; Liu YR, 2014, PERITON DIALYSIS INT, V34, P49, DOI 10.3747/pdi.2012.00293; Peppelenbosch A, 2008, CLIN KIDNEY J, V1, pIV23, DOI 10.1093/ndtplus/sfn120; Perl J, 2011, J AM SOC NEPHROL, V22, P1113, DOI 10.1681/ASN.2010111155; Povlsen JV, 2006, NEPHROL DIAL TRANSPL, V21, DOI 10.1093/ndt/gfl192; Sharma AP, 2008, NEPHROLOGY, V13, P672, DOI 10.1111/j.1440-1797.2008.01000.x; Skipper K, 1999, JSLS, V3, P63; TZAMALOUKAS AH, 1990, ADV PERIT D, V6, P64; Yang YF, 2011, PERITON DIALYSIS INT, V31, P551, DOI 10.3747/pdi.2009.00171	21	14	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2018	13	10							e0206426	10.1371/journal.pone.0206426	http://dx.doi.org/10.1371/journal.pone.0206426			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY3KA	30365566	Green Published, gold, Green Submitted			2023-01-03	WOS:000448448700052
J	McCaw, ZR; Wei, LJ; Kim, DH				McCaw, Zachary R.; Wei, Lee-Jen; Kim, Dae Hyun			Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[McCaw, Zachary R.; Wei, Lee-Jen] Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Kim, Dae Hyun] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Wei, LJ (corresponding author), Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA.	wei@-hsph.-harvard.-edu	McCaw, Zachary/GQH-8336-2022; Wei, Lee-Jen/CAI-0175-2022	McCaw, Zachary/0000-0002-2006-9828; 				Cheng D, 2017, JAMA ONCOL, V3, P1430, DOI 10.1001/jamaoncol.2017.0737; Hasegawa T, 2016, NEW ENGL J MED, V375, P1097, DOI 10.1056/NEJMc1608323; Merchant FM, 2018, JAMA; Uno H, 2015, ANN INTERN MED, V163, P127, DOI 10.7326/M14-1741	4	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 25	2018	379	17					1681	1681						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY1GI	30358968				2023-01-03	WOS:000448273500018
J	Schink, A; Neumann, J; Leifke, AL; Ziegler, K; Frohlich-Nowoisky, J; Cremer, C; Thines, E; Weber, B; Poschl, U; Schuppan, D; Lucas, K				Schink, Anne; Neumann, Jan; Leifke, Anna Lena; Ziegler, Kira; Froehlich-Nowoisky, Janine; Cremer, Christoph; Thines, Eckhard; Weber, Bettina; Poeschl, Ulrich; Schuppan, Detlef; Lucas, Kurt			Screening of herbal extracts for TLR2-and TLR4-dependent anti-inflammatory effects	PLOS ONE			English	Article							TOLL-LIKE RECEPTOR; WILLOW BARK EXTRACT; ALCHEMILLA-VULGARIS; IMMUNOMODULATORY PROPERTIES; CHRONIC INFLAMMATION; CINNAMON EXTRACT; CINNAMALDEHYDE; INHIBITION; SUPPRESSION; ACTIVATION	Herbal extracts represent an ample source of natural compounds, with potential to be used in improving human health. There is a growing interest in using natural extracts as possible new treatment strategies for inflammatory diseases. We therefore aimed at identifying herbal extracts that affect inflammatory signaling pathways through toll-like receptors (TLRs), TLR2 and TLR4. Ninety-nine ethanolic extracts were screened in THP-1 monocytes and HeLa-TLR4 transfected reporter cells for their effects on stimulated TLR2 and TLR4 signaling pathways. The 28 identified anti-inflammatory extracts were tested in comparative assays of stimulated HEK-TLR2 and HEK-TLR4 transfected reporter cells to differentiate between direct TLR4 antagonistic effects and interference with downstream signaling cascades. Furthermore, the ten most effective anti-inflammatory extracts were tested on their ability to inhibit nuclear factor-kappa B (NF-kappa B) translocation in HeLa-TLR4 transfected reporter cell lines and for their ability to repolarize M1-type macrophages. Ethanolic extracts which showed the highest anti-inflammatory potential, up to a complete inhibition of pro-inflammatory cytokine production were Castanea sativa leaves, Cinchona pubescens bark, Cinnamomum verum bark, Salix alba bark, Rheum palmatum root, Alchemilla vulgaris plant, Humulus lupulus cones, Vaccinium myrtillus berries, Curcuma longa root and Arctostaphylos uva-ursi leaves. Moreover, all tested extracts mitigated not only TLR4, but also TLR2 signaling pathways. Seven of them additionally inhibited translocation of NF-kappa B into the nucleus. Two of the extracts showed impact on repolarization of pro-inflammatory M1-type to anti-inflammatory M2-type macrophages. Several promising anti-inflammatory herbal extracts were identified in this study, including extracts with previously unknown influence on key TLR signaling pathways and macrophage repolarization, serving as a basis for novel lead compound identification.	[Schink, Anne; Neumann, Jan; Leifke, Anna Lena; Ziegler, Kira; Froehlich-Nowoisky, Janine; Cremer, Christoph; Weber, Bettina; Poeschl, Ulrich; Lucas, Kurt] Max Planck Inst Chem, Multiphase Chem Dept, Mainz, Germany; [Neumann, Jan; Cremer, Christoph] Inst Mol Biol, Mainz, Germany; [Thines, Eckhard] Inst Biotechnol & Wirkstoff Forsch gGmbH, Kaiserslautern, Germany; [Thines, Eckhard] Johannes Gutenberg Univ Mainz, Inst Mol Physiol, Mainz, Germany; [Schuppan, Detlef] Johannes Gutenberg Univ Mainz, Inst Translat Immunol, Med Ctr, Mainz, Germany; [Schuppan, Detlef] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA USA	Max Planck Society; Institute of Molecular Biology (IMB); Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Lucas, K (corresponding author), Max Planck Inst Chem, Multiphase Chem Dept, Mainz, Germany.	k.lucas@mpic.de	Weber, Bettina/G-8316-2016; Froehlich, Janine/D-6227-2015; Pöschl, Ulrich/A-6263-2010	Weber, Bettina/0000-0002-5453-3967; Froehlich, Janine/0000-0002-1278-0054; Pöschl, Ulrich/0000-0003-1412-3557	Max Planck Graduate Center; Johannes Gutenberg University Mainz (MPGC); German Research Foundation (DFG) [402386039]; IMB Microscopy and Histology Core Facility	Max Planck Graduate Center(Max Planck Society); Johannes Gutenberg University Mainz (MPGC); German Research Foundation (DFG)(German Research Foundation (DFG)); IMB Microscopy and Histology Core Facility	AS, JN, KZ received funding from Max Planck Graduate Center with the Johannes Gutenberg University Mainz (MPGC) (http://www.mpgc-mainz.de/). IMB Microscopy and Histology Core Facility received funding from German Research Foundation (DFG) (http://www.dfg.de/en/) for Opera Phenix High Content Spinning Disk Microscope (Project 402386039). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors thank Fangxia Shen for providing samples from mung beans. The authors acknowledge the financial support by the Max Planck Graduate Center with the Johannes Gutenberg University Mainz (MPGC). They also acknowledge the stimulating exchange and discussions with the members of the Mainz Program for Chemical Allergology (MPCA), and numerous colleagues in the scientific communities in life sciences, pharmaceutics and medicine. Support by the IMB Microscopy and Histology Core Facility is gratefully acknowledged, as well as the German Research Foundation (DFG) for funding the Opera Phenix High Content Spinning Disk Microscope (Project 402386039).	Albini A, 2005, FASEB J, V19, P527, DOI 10.1096/fj.05-5128fje; Angel-Morales G, 2012, FOOD FUNCT, V3, P1286, DOI 10.1039/c2fo30023k; Bonaterra GA, 2010, PHYTOMEDICINE, V17, P1106, DOI 10.1016/j.phymed.2010.03.022; Buenz EJ, 2018, ANNU REV PHARMACOL, V58, P509, DOI 10.1146/annurev-pharmtox-010617-052703; Chahal DS, 2013, PHYTOTHER RES, V27, P1423, DOI 10.1002/ptr.4886; Chao LK, 2008, FOOD CHEM TOXICOL, V46, P220, DOI 10.1016/j.fct.2007.07.016; Chen M, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201700281; de Arriba SG, 2013, INT J TOXICOL, V32, P442, DOI 10.1177/1091581813507721; De Vasconcelos MCBM, 2010, J SCI FOOD AGR, V90, P1578, DOI 10.1002/jsfa.4016; Desborough MJR, 2017, BRIT J HAEMATOL, V177, P674, DOI 10.1111/bjh.14520; Elliott R, 2005, BBA-MOL BASIS DIS, V1740, P147, DOI 10.1016/j.bbadis.2004.12.009; Filippova EI, 2017, B EXP BIOL MED+, V163, P374, DOI 10.1007/s10517-017-3807-x; Fraternale A., 2015, J CLIN CELL IMMUNOL, V6, P319, DOI [10.4172/2155-9899.1000319, DOI 10.4172/2155-9899.1000319]; Gerhauser C, 2005, EUR J CANCER, V41, P1941, DOI 10.1016/j.ejca.2005.04.012; Ghosh S, 2016, GENE, V584, P97, DOI 10.1016/j.gene.2016.03.008; Gunawardena D., 2014, POLYPHENOLS HUMAN HL, P409; Gunawardena D, 2015, FOOD FUNCT, V6, P910, DOI [10.1039/C4FO00680A, 10.1039/c4fo00680a]; Hagenlocher Y, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201601085; Hagenlocher Y, 2016, J NUTR BIOCHEM, V30, P85, DOI 10.1016/j.jnutbio.2015.11.015; Hagenlocher Y, 2015, EUR J NUTR, V54, P1297, DOI 10.1007/s00394-014-0810-0; Ho SC, 2013, FOOD CHEM, V138, P2275, DOI 10.1016/j.foodchem.2012.12.020; Holmdahl R, 2014, EUR J IMMUNOL, V44, P1593, DOI 10.1002/eji.201444486; Jiao LJ, 2018, BIOL PROCED ONLINE, V20, DOI 10.1186/s12575-017-0066-1; Jovanovic JA, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00793; Jung SA, 2012, PPAR RES, V2012, DOI 10.1155/2012/541204; Kalia S, 2007, DERMATOL THER, V20, P160, DOI 10.1111/j.1529-8019.2007.00131.x; Kanuri G, 2009, J NUTR, V139, P482, DOI 10.3945/jn.108.100495; Karabin M, 2015, BIOTECHNOL ADV, V33, P1063, DOI 10.1016/j.biotechadv.2015.02.009; Karlsen A, 2010, EUR J NUTR, V49, P345, DOI 10.1007/s00394-010-0092-0; Kiselova Y, 2006, PHYTOTHER RES, V20, P961, DOI 10.1002/ptr.1985; Kolehmainen M, 2012, MOL NUTR FOOD RES, V56, P1501, DOI 10.1002/mnfr.201200195; Kramer CD, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00255; Kuznik A, 2011, J IMMUNOL, V186, P4794, DOI 10.4049/jimmunol.1000702; Landete JM, 2011, FOOD RES INT, V44, P1150, DOI 10.1016/j.foodres.2011.04.027; Lee HJ, 2012, INFLAMM RES, V61, P817, DOI 10.1007/s00011-012-0474-2; Lee IS, 2011, NEUROCHEM INT, V58, P153, DOI 10.1016/j.neuint.2010.11.008; Li B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00055; Liu X, 2013, TRENDS PHARMACOL SCI, V34, P620, DOI 10.1016/j.tips.2013.09.004; Liu YF, 2008, PHYTOTHER RES, V22, P935, DOI 10.1002/ptr.2429; Lu CC, 2016, INNATE IMMUN-LONDON, V22, P522, DOI 10.1177/1753425916661402; Lucas K, 2013, MOL NEUROBIOL, V48, P190, DOI 10.1007/s12035-013-8425-7; Luo H, 2014, INT J FOOD SCI NUTR, V65, P594, DOI 10.3109/09637486.2014.886184; Martel J, 2017, TRENDS PHARMACOL SCI, V38, P967, DOI 10.1016/j.tips.2017.07.006; Martel J, 2017, NAT REV ENDOCRINOL, V13, P149, DOI 10.1038/nrendo.2016.142; McAlees JW, 2015, MUCOSAL IMMUNOL, V8, P863, DOI 10.1038/mi.2014.117; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Meng GQ, 2010, BRIT J PHARMACOL, V161, P1628, DOI 10.1111/j.1476-5381.2010.00993.x; Nahrstedt A, 2007, WIEN MED WOCHENSCHR, V157, P348, DOI 10.1007/s10354-007-0437-3; Pan Y, 2018, PHARMACOL RES, V130, P438, DOI 10.1016/j.phrs.2018.02.020; Park SJ, 2009, BIOSCI BIOTECH BIOCH, V73, P1474, DOI 10.1271/bbb.80738; Peri F, 2014, J MED CHEM, V57, P3612, DOI 10.1021/jm401006s; Pinto D, 2017, FOOD FUNCT, V8, P201, DOI [10.1039/c6fo01469k, 10.1039/C6FO01469K]; Quave CL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136486; Schuppan D, 2013, J CLIN INVEST, V123, P1887, DOI 10.1172/JCI66028; Shakibaei M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/509383; Shara M, 2015, PHYTOTHER RES, V29, P1112, DOI 10.1002/ptr.5377; Shrimali D, 2013, CANCER LETT, V341, P139, DOI 10.1016/j.canlet.2013.08.023; Shrivastava R, 2007, PHYTOTHER RES, V21, P369, DOI 10.1002/ptr.2060; Stickel F, 2007, DIGEST LIVER DIS, V39, P293, DOI 10.1016/j.dld.2006.11.004; Takeuchi O, 2001, INT IMMUNOPHARMACOL, V1, P625, DOI 10.1016/S1567-5769(01)00010-8; Takir S, 2015, PHARMACOGN MAG, V11, P163, DOI 10.4103/0973-1296.149733; Tian JF, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/8214541; Tidswell M, 2010, CRIT CARE MED, V38, P72, DOI 10.1097/CCM.0b013e3181b07b78; Vlachojannis J, 2011, PHYTOTHER RES, V25, P1102, DOI 10.1002/ptr.3386; Walsh D, 2013, CYTOKINE GROWTH F R, V24, P91, DOI 10.1016/j.cytogfr.2012.09.003; Wink Michael, 2015, Medicines (Basel), V2, P251, DOI 10.3390/medicines2030251; Wink M, 2008, CURR DRUG METAB, V9, P996, DOI 10.2174/138920008786927794; Yamada M, 2005, J MED CHEM, V48, P7457, DOI 10.1021/jm050623t; Yao P, 2015, PANCREAS, V44, P799, DOI 10.1097/MPA.0000000000000339; Yarnell E, 2002, WORLD J UROL, V20, P285, DOI 10.1007/s00345-002-0293-0; Youn HS, 2008, BIOCHEM PHARMACOL, V75, P494, DOI 10.1016/j.bcp.2007.08.033; Youn HS, 2006, BIOCHEM PHARMACOL, V72, P850, DOI 10.1016/j.bcp.2006.06.021; Youn HS, 2006, BIOCHEM PHARMACOL, V72, P62, DOI 10.1016/j.bcp.2006.03.022; Yu S, 2016, CELL STRESS CHAPERON, V21, P697, DOI 10.1007/s12192-016-0695-3; Zhao YK, 2018, PHARMACOL RES, V130, P292, DOI 10.1016/j.phrs.2017.12.027; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59	76	34	34	4	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2018	13	10							e0203907	10.1371/journal.pone.0203907	http://dx.doi.org/10.1371/journal.pone.0203907			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW7TO	30307962	Green Published, Green Submitted, gold			2023-01-03	WOS:000447173500011
J	Ahs, JW; Dhejne, C; Magnusson, C; Dal, H; Lundin, A; Arver, S; Dalman, C; Kosidou, K				Ahs, Jill W.; Dhejne, Cecilia; Magnusson, Cecilia; Dal, Henrik; Lundin, Andreas; Arver, Stefan; Dalman, Christina; Kosidou, Kyriaki			Proportion of adults in the general population of Stockholm County who want gender-affirming medical treatment	PLOS ONE			English	Article							IDENTITY/GENDER DYSPHORIA QUESTIONNAIRE; HEALTH; ADOLESCENTS; PREVALENCE; CARE	The number of patients presenting for care at gender clinics is increasing, yet the proportion of adults in the general population who want gender-affirming medical treatment remains essentially unknown. We measured the wish for cross-sex hormones or gender-affirming surgery, as well as other aspects of gender incongruence, among the general adult population of Stockholm County, Sweden. A population-representative sample of 50,157 Stockholm County residents ages 22 and older comprise the Stockholm Public Health Cohort. They were enrolled in 2002, 2006, and 2010 and followed-up in roughly 4-year intervals, with questions on health, lifestyle and social characteristics. In 2014, participants received the item "I would like hormones or surgery to be more like someone of a different sex." Two additional items concerned other aspects of gender incongruence: "I feel like someone of a different sex, and I would like to live as or be treated as someone of a different sex." Each item had four answer options ("Not at all correct," "Somewhat or occasionally correct," "Quite correct," and "Absolutely correct"). For each item, any of the three affirmative answer choices were considered as some level of agreement. Calibration weights were used to estimate population-representative rates with 95% confidence intervals. The desire for cross-sex hormones or surgery was reported by 0.5% (95% CI, 0.4%-0.7%) of participants. Feeling like someone of a different sex was reported by 2.3% (95% CI, 2.1%-2.6%). Wanting to live as or be treated as a person of another sex was reported by 2.8% (95% CI, 2.4%-3.1%). These findings greatly exceed estimates of the number of patients receiving gender-affirming medical care. Clinicians must be prepared to recognize and care for patients experiencing discomfort due to gender incongruence and those who would like gender-affirming medical treatment.	[Ahs, Jill W.; Magnusson, Cecilia; Dal, Henrik; Lundin, Andreas; Dalman, Christina; Kosidou, Kyriaki] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden; [Dhejne, Cecilia; Arver, Stefan] Karolinska Univ Hosp, ANOVA, Ctr Expertise Androl Sexual Med &Transgender Med, Stockholm, Sweden; [Dhejne, Cecilia; Arver, Stefan] Karolinska Inst, Dept Med, Stockholm, Sweden; [Dhejne, Cecilia; Arver, Stefan] Karolinska Univ Hosp, Stockholm, Sweden; [Magnusson, Cecilia; Dal, Henrik; Dalman, Christina; Kosidou, Kyriaki] Stockholm Cty Council, Ctr Epidemiol & Community Med, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Stockholm County Council	Ahs, JW (corresponding author), Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden.	jill.w.ahs@gmail.com	Dhejne, Cecilia/AAH-5737-2019	Kosidou, Kyriaki/0000-0002-1165-9455; Dalman, Christina/0000-0002-3579-2357; Magnusson, Cecilia/0000-0002-8567-6725; Dhejne, Cecilia/0000-0003-1743-9012	Stockholm County Council; Swedish Research Council [2012-2264, 523-2010-1052]; Stockholm County Council [2007008]; Swedish Council for Working Life and Social Research [2007-2064]; Swedish Regional agreement on medical training and clinical research	Stockholm County Council(Stockholm County Council); Swedish Research Council(Swedish Research CouncilEuropean Commission); Stockholm County Council(Stockholm County Council); Swedish Council for Working Life and Social Research(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte)); Swedish Regional agreement on medical training and clinical research	This work was supported by the Stockholm County Council and the Swedish Research Council (Grant # 2012-2264). The data linkages and staff costs have also been supported by grants from the Stockholm County Council (Grant # 2007008), Swedish Council for Working Life and Social Research (Grant # 2007-2064), Swedish Research Council (Grant # 523-2010-1052), and Swedish Regional agreement on medical training and clinical research. The study sponsors had no role in the design and conduct of the study; the analysis or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.	Aitken M, 2015, J SEX MED, V12, P756, DOI 10.1111/jsm.12817; Algars M, 2010, SEX ROLES, V63, P118, DOI 10.1007/s11199-010-9758-6; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU; [Anonymous], 2016, STAT YB STOCKHOLM 20; Arcelus J, 2015, EUR PSYCHIAT, V30, P807, DOI 10.1016/j.eurpsy.2015.04.005; Atkinson SR, 2015, AUST FAM PHYSICIAN, V44, P792, DOI 10.1016/jc.2009-0345; Bockting WO, 2008, SEXOLOGIES, V17, P211, DOI 10.1016/j.sexol.2008.08.001; Byne W, 2012, ARCH SEX BEHAV, V41, P759, DOI 10.1007/s10508-012-9975-x; Collin L, 2016, J SEX MED, V13, P613, DOI 10.1016/j.jsxm.2016.02.001; Commission of the European Communities European Commission. Eurobarometer, 2012, 393 COMM EUR COMM, pv; de Vries A. L. C., 2015, TRANSGENDER HEALTHCA, P10; Deogracias JJ, 2007, J SEX RES, V44, P370, DOI 10.1080/00224490701586730; Socias ME, 2014, INT J EQUITY HEALTH, V13, DOI 10.1186/s12939-014-0081-7; Flores A., 2016, MANY ADULTS IDENTIFY, DOI 10.2105/AJPH.2016.303578; Gooren LJ, 2014, CURR OPIN ENDOCRINOL, V21, P233, DOI 10.1097/MED.0000000000000064; Hannan P, 2014, J GEN INTERN MED, V29, pS506; Kuyper L, 2014, ARCH SEX BEHAV, V43, P377, DOI 10.1007/s10508-013-0140-y; Lai MC, 2010, ARCH SEX BEHAV, V39, P1415, DOI 10.1007/s10508-009-9570-y; Laitila T, 2012, RES DEV METHODOLOGY; Lundstrom Sixten., 1999, J OFF STAT, V15, P305, DOI DOI 10.1002/SIM.1903.; Pfaefflin F, 2003, 18 BIENN S HBIGDA GH; Raffoul M, 2016, J AM BOARD FAM MED, V29, P496, DOI 10.3122/jabfm.2016.04.150317; Satistics Sweden (SCB), 2014, LONG INT DAT HLTH IN; Schneider C, 2016, ARCH SEX BEHAV, V45, P551, DOI 10.1007/s10508-016-0702-x; Statistics Sweden (SCB), 2014, TEKN RAPPT HALS STOC; Svensson AC, 2013, INT J EPIDEMIOL, V42, P1263, DOI 10.1093/ije/dys126; Unger CA, 2015, J WOMENS HEALTH, V24, P114, DOI 10.1089/jwh.2014.4918; Van Caenegem E, 2015, ARCH SEX BEHAV, V44, P1281, DOI 10.1007/s10508-014-0452-6; Vance SR, 2015, J ADOLESCENT HEALTH, V56, P251, DOI 10.1016/j.jadohealth.2014.11.002; Winter S, 2016, LANCET, V388, P390, DOI 10.1016/S0140-6736(16)00683-8; World Health Organization, 1992, INT CLASS DIS ICD 10	31	27	28	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2018	13	10							e0204606	10.1371/journal.pone.0204606	http://dx.doi.org/10.1371/journal.pone.0204606			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GW0HY	30289896	Green Submitted, Green Published, gold			2023-01-03	WOS:000446545500021
J	Koehler, F; Koehler, K; Deckwart, O; Prescher, S; Wegscheider, K; Kirwan, BA; Winkler, S; Vettorazzi, E; Bruch, L; Oeff, M; Zugck, C; Doerr, G; Naegele, H; Stork, S; Butter, C; Sechtem, U; Angermann, C; Gola, G; Prondzinsky, R; Edelmann, F; Spethmann, S; Schellong, SM; Schulze, PC; Bauersachs, J; Wellge, B; Schoebel, C; Tajsic, M; Dreger, H; Anker, SD; Stangl, K				Koehler, Friedrich; Koehler, Kerstin; Deckwart, Oliver; Prescher, Sandra; Wegscheider, Karl; Kirwan, Bridget-Anne; Winkler, Sebastian; Vettorazzi, Eik; Bruch, Leonhard; Oeff, Michael; Zugck, Christian; Doerr, Gesine; Naegele, Herbert; Stoerk, Stefan; Butter, Christian; Sechtem, Udo; Angermann, Christiane; Gola, Guntram; Prondzinsky, Roland; Edelmann, Frank; Spethmann, Sebastian; Schellong, Sebastian M.; Schulze, P. Christian; Bauersachs, Johann; Wellge, Brunhilde; Schoebel, Christoph; Tajsic, Milos; Dreger, Henryk; Anker, Stefan D.; Stangl, Karl			Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial	LANCET			English	Article							ALERTS; CARE	Background Remote patient management in patients with heart failure might help to detect early signs and symptoms of cardiac decompensation, thus enabling a prompt initiation of the appropriate treatment and care before a full manifestation of a heart failure decompensation. We aimed to investigate the efficacy of our remote patient management intervention on mortality and morbidity in a well defined heart failure population. Methods The Telemedical Interventional Management in Heart Failure II (TIM-HF2) trial was a prospective, randomised, controlled, parallel-group, unmasked (with randomisation concealment), multicentre trial with pragmatic elements introduced for data collection. The trial was done in Germany, and patients were recruited from hospitals and cardiology practices. Eligible patients had heart failure, were in New York Heart Association class II or III, had been admitted to hospital for heart failure within 12 months before randomisation, and had a left ventricular ejection fraction (LVEF) of 45% or lower (or if higher than 45%, oral diuretics were being prescribed). Patients with major depression were excluded. Patients were randomly assigned (1:1) using a secure web-based system to either remote patient management plus usual care or to usual care only and were followed up for a maximum of 393 days. The primary outcome was percentage of days lost due to unplanned cardiovascular hospital admissions or all-cause death, analysed in the full analysis set. Key secondary outcomes were all-cause and cardiovascular mortality. This study is registered with ClinicalTrials.gov, number NCT01878630, and has now been completed. Findings Between Aug 13,2013, and May 12,2017,1571 patients were randomly assigned to remote patient management (n=796) or usual care (n=775). Of these 1571 patients, 765 in the remote patient management group and 773 in the usual care group started their assigned care, and were included in the full analysis set. The percentage of days lost due to unplanned cardiovascular hospital admissions and all-cause death was 4.88% (95% CI 4.55-5.23) in the remote patient management group and 6.64% (6.19-7.13) in the usual care group (ratio 0.80, 95% CI 0.65-1.00; p=0.0460). Patients assigned to remote patient management lost a mean of 17.8 days (95% CI 16.6-19.1) per year compared with 24.2 days (22.6-26.0) per year for patients assigned to usual care. The all-cause death rate was 7.86 (95% CI 6.14-10.10) per 100 person-years of follow-up in the remote patient management group compared with 11.34 (9.21-13.95) per 100 person-years of follow-up in the usual care group (hazard ratio [HR] 0.70, 95% CI 0-50-0.96; p=0.0280). Cardiovascular mortality was not significantly different between the two groups (HR 0-671,95% CI 0.45-1.01; p=0.0560). Interpretation The TIM-HF2 trial suggests that a structured remote patient management intervention, when used in a well defined heart failure population, could reduce the percentage of days lost due to unplanned cardiovascular hospital admissions and all-cause mortality.	[Koehler, Friedrich; Koehler, Kerstin; Deckwart, Oliver; Prescher, Sandra; Wellge, Brunhilde] Charite Univ Med Berlin, Ctr Cardiovasc Telemed, Campus Mitte, Berlin, Germany; [Schoebel, Christoph; Tajsic, Milos; Dreger, Henryk; Stangl, Karl] Charite Univ Med Berlin, Dept Cardiol & Angiol, Campus Mitte, Berlin, Germany; [Edelmann, Frank] Charite Univ Med Berlin, Dept Cardiol, Campus Virchow Klinikum, Berlin, Germany; [Anker, Stefan D.] Charite Univ Med Berlin, Div Cardiol & Metab, Dept Cardiol, Campus Virchow Klinikum, Berlin, Germany; [Wegscheider, Karl; Vettorazzi, Eik] Med Ctr Hamburg Eppendorf UKE, Inst Med Biometry & Epidemiol, Hamburg, Germany; [Kirwan, Bridget-Anne] London Sch Hyg & Trop Med, Fac Epidemiol & Publ Hlth, London, England; [Winkler, Sebastian; Bruch, Leonhard] Unfallkrankenhaus Berlin, Clin Internal Med & Cardiol, Berlin, Germany; [Oeff, Michael] Municipal Hosp, Telemed Ctr, Dept Cardiol, Brandenburg Havel, Germany; [Oeff, Michael] Brandenburg Med Sch, Brandenburg Havel, Germany; [Zugck, Christian] Cardiol Practice Im Steiner Thor, Straubing, Germany; [Doerr, Gesine] St Josefs Krankenhaus Potsdam, Clin Internal Med, Potsdam, Germany; [Naegele, Herbert] Albertinen Cardiovasc Ctr, Dept Heart Insufficiency & Device Therapy, Hamburg, Germany; [Stoerk, Stefan; Angermann, Christiane] Univ & Univ Hosp Wurzburg, Comprehens Heart Failure Ctr CHFC Wurzburg, Wurzburg, Germany; [Butter, Christian] Immanuel Hosp Bernau, Dept Cardiol, Brandenburg Heart Ctr, Bernau, Germany; [Butter, Christian] Med Sch Brandenburg Theodor Fontane, Bernau, Germany; [Sechtem, Udo] Robert Bosch Krankenhaus, Dept Cardiol, Stuttgart, Germany; [Gola, Guntram] Cardiol Practice, Berlin, Germany; [Prondzinsky, Roland] Carl von Basedow Klinikum Merseburg, Dept Internal Med 1, Merseburg, Germany; [Edelmann, Frank] BIH, Berlin, Germany; [Spethmann, Sebastian] Fed Armed Forces Hosp Berlin, Dept Internal Med, Div Cardiol, Berlin, Germany; [Schellong, Sebastian M.] Municipal Hosp Dresden, Med Dept 2, Dresden, Germany; [Schulze, P. Christian] Friedrich Schiller Univ Jena, Div Cardiol Angiol Pneumol & Intens Med Care, Dept Internal Med 1, Univ Hosp Jena, Jena, Germany; [Bauersachs, Johann] Hannover Med Sch, Dept Cardiol & Angiol, Hannover, Germany; [Anker, Stefan D.] Berlin Brandenburg Ctr Regenerat Therapies BCRT, Berlin, Germany; [Edelmann, Frank; Anker, Stefan D.; Stangl, Karl] German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany; [Anker, Stefan D.] Univ Med Ctr Gottingen, Dept Cardiol & Pneumol, Gottingen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of London; London School of Hygiene & Tropical Medicine; University of Wurzburg; Bosch; Robert Bosch Krankenhaus; Berlin Institute of Health; Technische Universitat Dresden; Municipal Hospital Dresden; Friedrich Schiller University of Jena; Hannover Medical School; German Centre for Cardiovascular Research; University of Gottingen	Koehler, F (corresponding author), Charite Univ Med Berlin, Ctr Cardiovasc Telemed, Dept Cardiol & Angiol, Campus Mitte, D-10117 Berlin, Germany.	friedrich.koehler@charite.de	Deckwart, Oliver/Y-4218-2019; Dreger, Henryk/A-9733-2009; Stork, Stefan/AAR-4182-2020; Vettorazzi, Eik/B-8130-2019; Schulze, Christian/AGJ-7744-2022	Deckwart, Oliver/0000-0002-8333-0931; Dreger, Henryk/0000-0003-1909-4329; Stork, Stefan/0000-0002-1771-7249; Vettorazzi, Eik/0000-0002-3737-6402; Schulze, Christian/0000-0001-9442-7141; Winkler, Sebastian/0000-0002-0926-311X; Prescher, Sandra/0000-0002-1962-701X; Kohler, Kerstin/0000-0001-9503-2432; Spethmann, Sebastian/0000-0003-0987-8007; Edelmann, Frank/0000-0003-4401-5936; Koehler, Friedrich/0000-0003-0441-4123	German Federal Ministry of Education and Research	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	German Federal Ministry of Education and Research.	Abraham WT, 2011, LANCET, V377, P658, DOI 10.1016/S0140-6736(11)60101-3; Anker SD, 2011, LANCET, V378, P731, DOI 10.1016/S0140-6736(11)61229-4; Bohm M, 2016, EUR HEART J, V37, P3154, DOI 10.1093/eurheartj/ehw099; Chaudhry SI, 2010, NEW ENGL J MED, V363, P2301, DOI 10.1056/NEJMoa1010029; Chioncel O, 2017, EUR J HEART FAIL, V19, P1574, DOI 10.1002/ejhf.813; Cleland JGF, 2005, J AM COLL CARDIOL, V45, P1654, DOI 10.1016/j.jacc.2005.01.050; Cowie MR, 2016, EUR HEART J, V37, P63, DOI 10.1093/eurheartj/ehv416; Cowie MR, 2014, ESC HEART FAIL, V1, P110, DOI 10.1002/ehf2.12021; Dierckx R, 2017, EUR J HEART FAIL, V19, P304, DOI 10.1002/ejhf.759; Garthwaite PH, 1996, BIOMETRICS, V52, P1387, DOI 10.2307/2532852; Hindricks G, 2014, LANCET, V384, P583, DOI 10.1016/S0140-6736(14)61176-4; Inglis SC, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007228.pub3; Koehler F, EUR J HEART FAIL; Koehler F, 2012, INT J CARDIOL, V161, P143, DOI 10.1016/j.ijcard.2011.09.007; Koehler F, 2011, CIRCULATION, V123, P1873, DOI 10.1161/CIRCULATIONAHA.111.018473; Morgan JM, 2017, EUR HEART J, V38, P2352, DOI 10.1093/eurheartj/ehx227; Ong MK, 2016, JAMA INTERN MED, V176, P310, DOI 10.1001/jamainternmed.2015.7712; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; van Riet EES, 2016, EUR J HEART FAIL, V18, P242, DOI 10.1002/ejhf.483; van Veldhuisen DJ, 2011, CIRCULATION, V124, P1719, DOI 10.1161/CIRCULATIONAHA.111.043042	21	269	274	3	38	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 22	2018	392	10152					1047	1057		10.1016/S0140-6736(18)31880-4	http://dx.doi.org/10.1016/S0140-6736(18)31880-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU2KP	30153985				2023-01-03	WOS:000445098800027
J	Naito, T; Yoshikawa, K; Namiguchi, K; Mizoue, S; Shiraishi, A; Ichikawa, Y; Fujiwara, M; Miki, T; Araki, R; Umeda, Y; Morizane, Y; Shiraga, F				Naito, Tomoko; Yoshikawa, Keiji; Namiguchi, Koji; Mizoue, Shiro; Shiraishi, Atsushi; Ichikawa, Yuko; Fujiwara, Miyuki; Miki, Takako; Araki, Ryoichi; Umeda, Yuzo; Morizane, Yuki; Shiraga, Fumio			Comparison of success rates in eye drop instillation between sitting position and supine position	PLOS ONE			English	Article							GLAUCOMA; MUSCLE; AGE	Purpose To compare the success rates of eye drop instillation in the sitting position and supine position among Japanese patients with ocular diseases (cataract, glaucoma, or retinal and vitreous diseases). Methods Patients who were hospitalized in Okayama University Hospital for eye surgery were studied. Instillation procedures of each patient in both the sitting and supine positions were recorded using a video camera at the time of instillation. We defined "success" when one drop fell accurately onto the ocular surface at the first attempt. Instillation of two or more drops, drops delivered to a site other than the eye surface, and touching the eyelashes, eyelids, or conjunctiva with the tip of the eye drop bottle were regarded as "failure". We excluded patients with vision below counting finger. Results One-hundred and two patients (54 males and 58 females, aged 70.2 +/- 12.3 years) with ocular disease who were hospitalized for surgery (cataract: 61.8%, glaucoma: 15.7%, retinal and vitreous diseases: 22.5%) were included in this prospective observational study. The mean duration of eye drop use was 3.1 +/- 5.2 years. The success rate of eye drop instillation was significantly higher in the supine position than in the sitting position (64.7% vs. 50%, P = 0.0039). The mean age was significantly higher in the failure group than in the success group (74.0 +/- 11.5 vs. 67.7 +/- 12.4 years, P = 0.0085) for the sitting position, but not significantly different for the supine position (72.3 +/- 12.9 vs. 70.1 +/- 12.0 years, P = 0.3849). No significant differences in mean duration of drop use, mean corrected VA, and mean spherical equivalent refraction were observed between success and failure groups, for both sitting and supine positions. Conclusions In the present study, the success rate of eye drop instillation was significantly higher when applied in the supine position than in the sitting position.	[Naito, Tomoko; Ichikawa, Yuko; Fujiwara, Miyuki; Miki, Takako; Araki, Ryoichi; Morizane, Yuki; Shiraga, Fumio] Okayama Univ, Med Sch Hosp, Dept Ophthalmol, Okayama, Japan; [Yoshikawa, Keiji] Yoshikawa Eye Clin, Tokyo, Japan; [Namiguchi, Koji; Mizoue, Shiro; Shiraishi, Atsushi] Ehime Univ, Grad Sch Med, Dept Ophthalmol, Matsuyama, Ehime, Japan; [Umeda, Yuzo] Okayama Univ, Med Sch Hosp, Dept Gastroenterol Surg, Okayama, Japan	Okayama University; Ehime University; Okayama University	Naito, T (corresponding author), Okayama Univ, Med Sch Hosp, Dept Ophthalmol, Okayama, Japan.	tomokoum@gmail.com						Aptel F, 2009, BRIT J OPHTHALMOL, V93, P700, DOI 10.1136/bjo.2008.139840; BROWN MM, 1984, CAN J OPHTHALMOL, V19, P2; Dietlein TS, 2008, ACTA OPHTHALMOL, V86, P856, DOI 10.1111/j.1755-3768.2007.01155.x; Doherty TJ, 2003, J APPL PHYSIOL, V95, P1717, DOI 10.1152/japplphysiol.00347.2003; Frontera WR, 2000, J APPL PHYSIOL, V88, P1321; Gupta R, 2012, J GLAUCOMA, V21, P189, DOI 10.1097/IJG.0b013e31820bd2e1; Hennessy AL, 2011, AM J OPHTHALMOL, V152, P982, DOI 10.1016/j.ajo.2011.05.015; Jang HJ, 2015, J PHYS THER SCI, V27, P1161, DOI 10.1589/jpts.27.1161; KASS MA, 1982, ANN OPHTHALMOL, V14, P889; Kholdebarin R, 2008, CAN J OPHTHALMOL, V43, P454, DOI [10.1139/i08-076, 10.3129/i08-076]; Lazcano-Gomez Gabriel, 2015, J Curr Glaucoma Pract, V9, P47, DOI 10.5005/jp-journals-10008-1183; Levine ME, 2013, J GERONTOL A-BIOL, V68, P667, DOI 10.1093/gerona/gls233; MARSTON MV, 1970, NURS RES, V19, P312; Naito T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185874; Orimo Hajime, 2006, Nihon Ronen Igakkai Zasshi, V43, P27; Ouchi Y, 2017, GERIATR GERONTOL INT, V17, P1045, DOI 10.1111/ggi.13118; Rogers M A, 1993, Exerc Sport Sci Rev, V21, P65; Sabate E, 2003, ADHERENCE LONG TERM; Sabate E., 2001, ADHERENCE LONG TERM; Stone JL, 2009, ARCH OPHTHALMOL-CHIC, V127, P732, DOI 10.1001/archophthalmol.2009.96; Suzuki T, 2006, JPN J HLTH WELFARE, V53, P1; Visser M, 2005, J GERONTOL A-BIOL, V60, P324, DOI 10.1093/gerona/60.3.324; WHO, 2010, DEF OLD ELD PERS; WINFIELD AJ, 1990, BRIT J OPHTHALMOL, V74, P477, DOI 10.1136/bjo.74.8.477	24	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2018	13	9							e0204363	10.1371/journal.pone.0204363	http://dx.doi.org/10.1371/journal.pone.0204363			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GU8XH	30235323	gold, Green Submitted, Green Published			2023-01-03	WOS:000445626400121
J	Ngom, NF; Faye, MA; Ndiaye, K; Thiam, A; Ndour, CT; Etard, JF; Sow, PS; Seydi, M; Delaporte, E; Cournil, A				Ngom, Ndeye Fatou; Faye, Mame Awa; Ndiaye, Kine; Thiam, Aminata; Ndour, Cheikh Tidiane; Etard, Jean-Francois; Sow, Papa Salif; Seydi, Moussa; Delaporte, Eric; Cournil, Amandine			ART initiation in an outpatient treatment center in Dakar, Senegal: A retrospective cohort analysis (1998-2015)	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; ANTIRETROVIRAL THERAPY; HIV; CARE; METAANALYSIS; PREVALENCE	Objective To examine how patient characteristics combined with ART eligibility expansions affect the initiation of antiretroviral therapy (ART) among eligible patients attending a referral center in Senegal from 1998 to 2015. Methods This is a retrospective observational study carried out at the outpatient treatment Centre (Centre de Traitement Ambulatoire) in Dakar, Senegal, based on computerized medical records, gathered from 1998 to 2015, of ART-naive patients over 15 years of age. ART eligibility was defined as (CD4 count below 200) or as (WHO stage 4) or as (WHO stage 3 with (CD4 count below 350 or with unavailable CD4 count)) in 1998-2010; as (CD4 count below 350) or as (WHO stage 3 or 4) in 2011-2013; as (CD4 count below 500) or as (WHO stage 3 or 4) in 2014-2015. Four periods were defined according to ART eligibility expansions and Senegal's HIV care history: 1998-2003 (P 1), 2004-2010 (P 2), 2011-2013 (P3), and 2014-2015 (P4). Patients were expected to participate financially in their treatment during the first period (P1). Results A total of 3651 patient records were included. The median patient age was 40 years (IQR: 32-48). Women represented 56% of the population. The median CD4 count was 183 cells/mm(3). Overall, 53% of patients had CD4 < 200 cells/mm(3) at entry. This proportion reached 45% in 2014-2015. 2535 patients (69%) were eligible for therapy, including 1503 (41%) who started ART. The proportion of treated patients among those who were eligible at entry or later increased steadily from 25%, 47%, 75% to 82% in the four periods, respectively. The median time to treatment decreased from 5.6 months (IQR: 3-11) in P1 to 0.8 months (IQR: 0-2) in P4. Eligible patients with more advanced disease (CD4<200 cells/mm(3) and/or clinical stage 3 or 4) were more likely to be ART initiated than those with CD4 >= 200 cells/mm(3) and/or clinical stage 1 or 2 at each stage of ART eligibility expansion. Conclusion ART eligibility expansions were marked by a sharp increase in the proportion of eligible patients initiating treatment. These results show that in terms of management, the target of "Test and Treat" can be easily reached but that HIV testing will remain a key element to improve treatment success, as illustrated by the high proportion of people with advanced stage of infection at the time of ART initiation.	[Ngom, Ndeye Fatou; Ndiaye, Kine; Thiam, Aminata] Fann Hosp Univ, Ambulatory Treatment Ctr, Dakar, Senegal; [Ngom, Ndeye Fatou] Univ Alioune Diop of Bambey, Diourbel, Senegal; [Ngom, Ndeye Fatou; Faye, Mame Awa; Ndour, Cheikh Tidiane; Sow, Papa Salif; Seydi, Moussa] Fann Hosp Univ, Dept Infect Dis, Dakar, Senegal; [Ngom, Ndeye Fatou; Etard, Jean-Francois; Delaporte, Eric; Cournil, Amandine] Univ Montpellier, Inst Rech Dev, UMI 233, Transvihmi,U1175,Inserm, Montpellier, France	Institut de Recherche pour le Developpement (IRD); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Ngom, NF (corresponding author), Fann Hosp Univ, Ambulatory Treatment Ctr, Dakar, Senegal.; Ngom, NF (corresponding author), Univ Alioune Diop of Bambey, Diourbel, Senegal.; Ngom, NF (corresponding author), Fann Hosp Univ, Dept Infect Dis, Dakar, Senegal.; Ngom, NF (corresponding author), Univ Montpellier, Inst Rech Dev, UMI 233, Transvihmi,U1175,Inserm, Montpellier, France.	Ndeyetouti98@gmail.com	Etard, Jean François/A-9630-2008; Etard, Jean-Francois/V-4865-2019	Etard, Jean François/0000-0002-4873-0788; Etard, Jean-Francois/0000-0002-4873-0788; NGOM, Ndeye Fatou/0000-0001-5178-6603	French GIP ESTHER; CNLS (Conseil National de Lutte contre le Sida) in Senegal	French GIP ESTHER; CNLS (Conseil National de Lutte contre le Sida) in Senegal	We thank the French GIP ESTHER and the CNLS (Conseil National de Lutte contre le Sida) in Senegal for their technical and financial support in implementing the ESOPE computerized medical files system. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abebe N, 2014, PAN AFR MED J, V17, DOI 10.11604/pamj.2014.17.88.3262; Agence Nationale de la Statistique et de la De mographie, 2012, ENQ DEM SANT IND MUL, P520; Alvarez-Uria G., 2013, Interdisciplinary Perspectives on Infectious Diseases, V2013, P384805, DOI 10.1155/2013/384805; Anderegg N, 2018, CLIN INFECT DIS, V66, P893, DOI 10.1093/cid/cix915; Desclaux A, 2003, AIDS, V17, pS95, DOI 10.1097/00002030-200317003-00013; Geng EH, 2013, JAIDS-J ACQ IMM DEF, V63, pE64, DOI 10.1097/QAI.0b013e31828af5a6; Geng EH, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-46; Gesesew HA, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2971-6; Govindasamy D, 2012, AIDS, V26, P2059, DOI 10.1097/QAD.0b013e3283578b9b; Hall HI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077763; Hammer S, 2002, INFECT DIS CLIN PRAC, V11, P154; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2014, 90 90 90 AMB TREATM, V40; Lahuerta M, 2014, CLIN INFECT DIS, V58, P432, DOI 10.1093/cid/cit724; Lepretre A, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.19888; Mugglin C, 2012, TROP MED INT HEALTH, V17, P1509, DOI 10.1111/j.1365-3156.2012.03089.x; Myer L, 2012, TROP MED INT HEALTH, V17, P972, DOI 10.1111/j.1365-3156.2012.03033.x; Odhiambo JO, 2014, JAIDS-J ACQ IMM DEF, V66, pS116, DOI 10.1097/QAI.0000000000000122; ONUSIDA, 2006, RAPPORT ONUSIDA 2006; Plazy M, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1207-2; Republique du Senegal Conseil National de lutte contre le Sida, 2014, REP DU SEN, P73; Rosen S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001056; Siedner MJ, 2015, CLIN INFECT DIS, V60, P1120, DOI 10.1093/cid/ciu1137; Siedner MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039894; Tymejczyk O, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002534; Unaids, 2016, GLOB REP CIT REP UNA; UNAIDS, 2014, GAP REP 2014 UNEP SY; Wade AS, 2010, AIDS CARE, V22, P409, DOI 10.1080/09540120903253973; WHO, 2010, ANT THER HIV INF AD, V4911, P117; World Health Organisation (WHO), 2006, ANT THER HIV INF AD, P1, DOI DOI 10.1016/0004-6981(88)90109-6; World Health Organization, 2016, CONSOLIDATED GUIDELI, V2nd ed; World Health Organization (WHO), 2015, GUID START ANT THER, P78	31	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2018	13	9							e0202984	10.1371/journal.pone.0202984	http://dx.doi.org/10.1371/journal.pone.0202984			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GU3GJ	30231075	gold, Green Submitted, Green Published			2023-01-03	WOS:000445164300028
J	Bohnert, ASB; Guy, GP; Losby, JL				Bohnert, Amy S. B.; Guy, Gery P., Jr.; Losby, Jan L.			Opioid Prescribing in the United States Before and After the Centers for Disease Control and Prevention's 2016 Opioid Guideline	ANNALS OF INTERNAL MEDICINE			English	Article							INTERRUPTED TIME-SERIES; CLINICAL GUIDELINES; MEDICAL-PRACTICE; OVERDOSE DEATHS; CHRONIC PAIN; IMPACT; DRUG; PATTERNS; PHYSICIANS; EPIDEMIC	Background: In response to adverse outcomes from prescription opioids, the Centers for Disease Control and Prevention (CDC) released the Guideline for Prescribing Opioids for Chronic Pain in March 2016. Objective: To test the hypothesis that the CDC guideline release corresponded to declines in specific opioid prescribing practices. Design: Interrupted time series analysis of monthly prescribing measures from the IQVIA transactional data warehouse and Real-World Data Longitudinal Prescriptions population-level estimates based on retail pharmacy data. Population size was determined by U.S. Census monthly estimates. Setting: United States, 2012 to 2017. Patients: Persons prescribed opioid analgesics. Measurements: Outcomes included opioid dosage, days supplied, overlapping benzodiazepine prescriptions, and the overall rate of prescribing. Results: The rate of high-dosage prescriptions (>= 90 morphine equivalent milligrams per day) was 683 per 100 000 persons in January 2012 and declined by 3.56 (95% CI, -3.79 to -3.32) per month before March 2016 and by 8.00 (CI, -8.69 to -7.31) afterward. Likewise, the percentage of patients with overlapping opioid and benzodiazepine prescriptions was 21.04% in January 2012 and declined by 0.02% (CI, -0.04% to -0.01%) per month before the CDC guideline release and by 0.08% (CI, -0.08% to -0.07%) per month afterward. The overall opioid prescribing rate was 6577 per 100 000 persons in January 2012 and declined by 23.48 (CI, -26.18 to -20.78) each month before the guideline release and by 56.74 (CI, -65.96 to -47.53) per month afterward. Limitation: No control population; inability to determine the appropriateness of opioid prescribing. Conclusion: Several opioid prescribing practices were decreasing before the CDC guideline, but the time of its release was associated with a greater decline. Guidelines may be effective in changing prescribing practices.	[Bohnert, Amy S. B.] Univ Michigan, North Campus Res Complex,2800 Plymouth Rd,Bldg 16, Ann Arbor, MI 48109 USA; [Bohnert, Amy S. B.] Vet Affairs Ctr Clin Management Res, Ann Arbor, MI 48109 USA; [Guy, Gery P., Jr.; Losby, Jan L.] Ctr Dis Control & Prevent, 4770 Buford Highway NE,MS F-62, Atlanta, GA 30041 USA	University of Michigan System; University of Michigan; Centers for Disease Control & Prevention - USA	Guy, GP (corresponding author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, 4770 Buford Highway NE,MS F-62, Atlanta, GA 30041 USA.	gguy@cdc.gov			CDC	CDC(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This study was supported by the CDC via employment of Drs. Guy and Losby, an intergovernmental personnel agreement with Dr. Bohnert, and costs associated with data acquisition.	[Anonymous], 2010, VA DOD CLIN PRACT GU; AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; Bernal JL, 2017, INT J EPIDEMIOL, V46, P348, DOI 10.1093/ije/dyw098; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Brands B, 2004, DRUG ALCOHOL DEPEN, V73, P199, DOI 10.1016/j.drugalcdep.2003.10.012; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Cai R., 2010, Morbidity and Mortality Weekly Report, V59, P705; Centers for Disease Control and Prevention, OV PREV; Centers for Disease Control and Prevention, GUID RES; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Corcoran P, 2015, INT J EPIDEMIOL, V44, P969, DOI 10.1093/ije/dyv058; Cram P, 2003, ARCH INTERN MED, V163, P1601, DOI 10.1001/archinte.163.13.1601; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Evans DGR, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0442-6; French DD, 2005, PHARMACOEPIDEM DR S, V14, P17, DOI 10.1002/pds.967; Gellad WF, 2017, JAMA INTERN MED, V177, P611, DOI 10.1001/jamainternmed.2017.0147; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Guy GP, 2017, MMWR-MORBID MORTAL W, V66, P697, DOI 10.15585/mmwr.mm6626a4; Haegerich TM, 2014, DRUG ALCOHOL DEPEN, V145, P34, DOI 10.1016/j.drugalcdep.2014.10.001; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Han B, 2015, JAMA-J AM MED ASSOC, V314, P1468, DOI 10.1001/jama.2015.11859; Hedegaard H., 2017, DRUG OVERDOSE DEATHS; Lin LWA, 2017, PAIN, V158, P833, DOI 10.1097/j.pain.0000000000000837; Linden A, 2017, STATA J, V17, P73, DOI 10.1177/1536867X1701700105; Linden A, 2015, STATA J, V15, P480, DOI 10.1177/1536867X1501500208; Miller M, 2014, JAMA INTERN MED, V174, P899, DOI 10.1001/jamainternmed.2014.1053; National Center for Injury Prevention and Control, 2018, DAT RES OR MMES; Nuckols TK, 2014, ANN INTERN MED, V160, P38, DOI 10.7326/0003-4819-160-1-201401070-00732; Park TW, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2698; Paulozzi LJ, 2011, J CLIN PSYCHIAT, V72, P589, DOI 10.4088/JCP.10com06560; Radcliff S, 2015, J AM GERIATR SOC, V63, P2227, DOI 10.1111/jgs.13702; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Soumerai SB, 2017, J GEN INTERN MED, V32, P204, DOI 10.1007/s11606-016-3841-9; U. S. Census Bureau Population Division, 2017, MONTH POP EST US; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x	37	216	215	2	30	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 18	2018	169	6					367	+		10.7326/M18-1243	http://dx.doi.org/10.7326/M18-1243			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT7CZ	30167651	Green Accepted			2023-01-03	WOS:000444679800013
J	Lee, CH; Hung, SP; Hong, JH; Chang, JTC; Tsang, NM; Chan, KM; Tseng, JH; Huang, SC; Lin, SM; Lien, JM; Liu, NJ; Lin, CC; Chen, WT; Chen, WY; Chen, PJ; Huang, BS				Lee, Ching-Hsin; Hung, Sheng-Ping; Hong, Ji-Hong; Chang, Joseph Tung-Chieh; Tsang, Ngan-Ming; Chan, Kun-Ming; Tseng, Jeng-Hwei; Huang, Shih-Chiang; Lin, Shi-Ming; Lien, Jau-Min; Liu, Nai-Jen; Lin, Chen-Chun; Chen, Wei-Ting; Chen, Wan-Yu; Chen, Po-Jui; Huang, Bing-Shen			How small is TOO small? New liver constraint is needed- Proton therapy of hepatocellular carcinoma patients with small normal liver	PLOS ONE			English	Article							BODY RADIATION-THERAPY; NORMAL ORGAN WEIGHTS; II-THE-BRAIN; TRANSARTERIAL CHEMOEMBOLIZATION; SURFACE-AREA; BEAM THERAPY; RISK-FACTORS; VOLUME; RADIOTHERAPY; REGENERATION	Purpose This study evaluated the outcomes of hepatocellular carcinoma (HCC) patients with small normal liver volume (NLV) treated with proton beam therapy (PBT) and introduced estimated standard liver volume (eSLV) as a new constraint. Materials and methods HCC patients with NLV < 800 cm(3) and no distant metastasis who received treatment in our proton center were included. The doses of PBT were mainly 72.6 Gray equivalents (GyE) in 22 fractions and 66 GyE in 10 fractions according to tumor locations. The Urata equation was used to calculate eSLV. Results Twenty-two patients were treated between November 2015 and December 2016. The 1-year progression-free and overall survival rates were 40.4% and 81.8%, respectively. The 1-year in-field failure-free rate was 95.5%. NLV ranged from 483.9 to 795.8 cm(3) (median = 673.8 cm(3)), eSLV ranged from 889.3 to 1290.0 cm(3) (median = 1104.5 cm(3)), and the resulting NLV/eSLV ratio ranged from 44.3 to 81.2% (median = 57.7%). Non-irradiated liver volume (NILV) ranged from 232.9 to 531.6 cm(3) (median = 391.2 cm(3)). The NILV/eSLV ratio ranged from 21.2 to 48.0% (median = 33.3%). NLV in the patients who received <30 GyE (rV30) ranged from 319.1 to 633.3 cm(3) (median = 488.2 cm(3)), and their rV30/eSLV ratio ranged from 30.7 to 58.0%. None of our patients developed liver failure. One patient with initial abnormal liver enzyme levels developed non-classic radiation-induced liver disease (RILD). Conclusion From the viewpoint of minimal liver toxicity occurring in our patients with NLV < 800 cm(3), conventional liver constraints involving the use of absolute volume could not accurately predict the risk of RILD. It is reasonable to start using individualized constraints with eSLV for HCC patients undergoing PBT. According to the study results, an NILV/eSLV ratio of >20% and an rV30/eSLV ratio of >30% are acceptable.	[Lee, Ching-Hsin; Hung, Sheng-Ping; Hong, Ji-Hong; Chang, Joseph Tung-Chieh; Tsang, Ngan-Ming; Chen, Po-Jui; Huang, Bing-Shen] Linkou Chang Gung Mem Hosp & Univ, Dept Radiat Oncol, Proton & Radiat Therapy Ctr, Taoyuan, Taiwan; [Chan, Kun-Ming] Linkou Chang Gung Mem Hosp & Univ, Dept Gen Surg, Taoyuan, Taiwan; [Tseng, Jeng-Hwei] Linkou Chang Gung Mem Hosp & Univ, Dept Radiol, Taoyuan, Taiwan; [Huang, Shih-Chiang] Linkou Chang Gung Mem Hosp & Univ, Dept Anat Pathol, Taoyuan, Taiwan; [Lin, Shi-Ming; Lien, Jau-Min; Liu, Nai-Jen; Lin, Chen-Chun; Chen, Wei-Ting] Linkou Chang Gung Mem Hosp & Univ, Div Gastroenterol & Hepatol, Dept Internal Med, Taoyuan, Taiwan; [Chen, Wan-Yu] Natl Taiwan Univ Hosp, Div Radiat Oncol, Dept Oncol, Taipei, Taiwan; [Chen, Wan-Yu] Natl Taiwan Univ, Canc Res Ctr, Coll Med, Taipei, Taiwan; [Chen, Wan-Yu] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan; [Huang, Bing-Shen] Chang Gung Univ, Grad Inst Clin Med Sci, Taoyuan, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; Chang Gung University	Huang, BS (corresponding author), Linkou Chang Gung Mem Hosp & Univ, Dept Radiat Oncol, Proton & Radiat Therapy Ctr, Taoyuan, Taiwan.; Huang, BS (corresponding author), Chang Gung Univ, Grad Inst Clin Med Sci, Taoyuan, Taiwan.	beanson@cgmh.org.tw		Huang, Shih-Chiang/0000-0002-5092-4434	Chang Gung Memorial Hospital [CIRPG3D0143, CMRPG3H0471, CIRPD1D0071, CIRPD1D0072, CIRPD1D0073]; Chang Gung University [CIRPG3D0143, CMRPG3H0471, CIRPD1D0071, CIRPD1D0072, CIRPD1D0073]	Chang Gung Memorial Hospital(Chang Gung Memorial Hospital); Chang Gung University	This study is supported by the grant CIRPG3D0143, CMRPG3H0471, CIRPD1D0071, CIRPD1D0072, and CIRPD1D0073 from Chang Gung Memorial Hospital and Chang Gung University. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study is supported by the grant CIRPG3D0143, CMRPG3H0471, CIRPD1D0071, CIRP D1D0072, and CIRPD1D0073 from Chang Gung Memorial Hospital and Chang Gung University. This manuscript was edited by Wallace Academic Editing.	[Anonymous], 2014, MIN HLTH WELF ANN RE, P38; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Bush DA, 2016, INT J RADIAT ONCOL, V95, P477, DOI 10.1016/j.ijrobp.2016.02.027; Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65; Cheng JCH, 2001, INT J CANCER, V96, P243, DOI 10.1002/ijc.1022; DELAND FH, 1968, RADIOLOGY, V91, P1195, DOI 10.1148/91.6.1195; Du Bois D, 1989, Nutrition, V5, P303; FENG MUS, 2016, J CLIN ONCOL S, V34; Haga J, 2008, LIVER TRANSPLANT, V14, P1718, DOI 10.1002/lt.21622; Kaneko K, 2005, WORLD J GASTROENTERO, V11, DOI 10.3748/wjg.v11.i37.5888; Kanemoto A, 2013, ACTA ONCOL, V52, P538, DOI 10.3109/0284186X.2012.718094; Kawashima M, 2005, J CLIN ONCOL, V23, P1839, DOI 10.1200/JCO.2005.00.620; Kim J, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.85; Kim TH, INT J RAD ONCOLOGY B; Lee NH, 1998, BRIT J SURG, V85, P1654; Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132; Liang P, 2016, ONCOTARGETS THER, V9, P7169, DOI 10.2147/OTT.S112290; Liang SX, 2006, INT J RADIAT ONCOL, V65, P426, DOI 10.1016/j.ijrobp.2005.12.031; Liang SX, 2011, RADIOTHER ONCOL, V98, P265, DOI 10.1016/j.radonc.2010.10.014; Liu PH, 2014, ANN SURG ONCOL, V21, P1825, DOI 10.1245/s10434-014-3510-3; Livraghi T, 2000, RADIOLOGY, V214, P761, DOI 10.1148/radiology.214.3.r00mr02761; Lo CM, 1999, TRANSPLANTATION, V68, P1112, DOI 10.1097/00007890-199910270-00009; Maithel SK, 2011, J AM COLL SURGEONS, V212, P638, DOI 10.1016/j.jamcollsurg.2011.01.004; Asencio JM, 2014, J HEPATO-BIL-PAN SCI, V21, P399, DOI 10.1002/jhbp.97; Mizumoto M, 2012, INT J RADIAT ONCOL, V82, pE529, DOI 10.1016/j.ijrobp.2011.05.056; Molina DK, 2015, AM J FOREN MED PATH, V36, P182, DOI 10.1097/PAF.0000000000000175; Molina DK, 2012, AM J FOREN MED PATH, V33, P368, DOI 10.1097/PAF.0b013e31823d29ad; Network NCC, 2018, NCCN CLIN PRACT GUID; Pan CC, 2010, INT J RADIAT ONCOL, V76, pS94, DOI 10.1016/j.ijrobp.2009.06.092; Schefter TE, 2005, INT J RADIAT ONCOL, V62, P1371, DOI 10.1016/j.ijrobp.2005.01.002; Schindl MJ, 2005, GUT, V54, P289, DOI 10.1136/gut.2004.046524; Son SH, 2010, INT J RAD ONCOLOGY B, V78; Sugahara S, 2010, INT J RADIAT ONCOL, V76, P460, DOI 10.1016/j.ijrobp.2009.02.030; Takamatsu S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167155; Tanaka K, 1998, CANCER, V82, P78, DOI 10.1002/(SICI)1097-0142(19980101)82:1<78::AID-CNCR9>3.0.CO;2-G; Toramatsu C, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-48; Um Eun Hae, 2015, Korean J Hepatobiliary Pancreat Surg, V19, P133, DOI 10.14701/kjhbps.2015.19.4.133; URATA K, 1995, HEPATOLOGY, V21, P1317, DOI 10.1016/0270-9139(95)90053-5; Vauthey JN, 2002, LIVER TRANSPLANT, V8, P233, DOI 10.1053/jlts.2002.31654; Yuan D, 2008, TRANSPL P, V40, P3536, DOI 10.1016/j.transproceed.2008.07.135; Zakareya T, 2017, J LIVER DIS TRANSPLA, V6; Zappa M, 2009, RADIOLOGY, V252, P426, DOI [10.1148/radiol.2523080922, 10.1148/radiol.2522080922]	42	8	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2018	13	9							e0203854	10.1371/journal.pone.0203854	http://dx.doi.org/10.1371/journal.pone.0203854			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT2UM	30204800	Green Published, Green Submitted, gold			2023-01-03	WOS:000444355500052
J	Rooney-Varga, JN; Sterman, JD; Fracassi, E; Franck, T; Kapmeier, F; Kurker, V; Johnston, E; Jones, AP; Rath, K				Rooney-Varga, J. N.; Sterman, J. D.; Fracassi, E.; Franck, T.; Kapmeier, F.; Kurker, V; Johnston, E.; Jones, A. P.; Rath, K.			Combining role-play with interactive simulation to motivate informed climate action: Evidence from the World Climate simulation	PLOS ONE			English	Article							RISK PERCEPTION; COMMUNICATION; POLICY; PARIS; CHALLENGES; SUPPORT	Climate change communication efforts grounded in the information deficit model have largely failed to close the gap between scientific and public understanding of the risks posed by climate change. In response, simulations have been proposed to enable people to learn for themselves about this complex and politically charged topic. Here we assess the impact of a widely-used simulation, World Climate, which combines a socially and emotionally engaging role-play with interactive exploration of climate change science through the CROADS climate simulation model. Participants take on the roles of delegates to the UN climate negotiations and are challenged to create an agreement that meets international climate goals. Their decisions are entered into C-ROADS, which provides immediate feedback about expected global climate impacts, enabling them to learn about climate change while experiencing the social dynamics of negotiations. We assess the impact of World Climate by analyzing pre- and post-survey results from >2,000 participants in 39 sessions in eight nations. We find statistically significant gains in three areas: (i) knowledge of climate change causes, dynamics and impacts; (ii) affective engagement including greater feelings of urgency and hope; and (iii) a desire to learn and do more about climate change. Contrary to the deficit model, gains in urgency were associated with gains in participants' desire to learn more and intent to act, while gains in climate knowledge were not. Gains were just as strong among American participants who oppose government regulation of free markets-a political ideology that has been linked to climate change denial in the US-suggesting the simulation's potential to reach across political divides. The results indicate that World Climate offers a climate change communication tool that enables people to learn and feel for themselves, which together have the potential to motivate action informed by science.	[Rooney-Varga, J. N.; Kurker, V] Univ Massachusetts Lowell, UMass Lowell Climate Change Initiat, Lowell, MA 01854 USA; [Rooney-Varga, J. N.; Kurker, V] Univ Massachusetts Lowell, Dept Environm Earth & Atmospher Sci, Lowell, MA 01854 USA; [Sterman, J. D.] MIT, Syst Dynam Grp, Sloan Sch Management, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Fracassi, E.] Escuela Ingn & Gest, Inst Tecnol Buenos Aires, Buenos Aires, DF, Argentina; [Franck, T.; Johnston, E.; Jones, A. P.] Climate Interact, Washington, DC USA; [Kapmeier, F.] ESB Business Sch, Reutlingen, Germany; [Rath, K.] SageFox Consulting Grp, Amherst, MA USA	University of Massachusetts System; University of Massachusetts Lowell; University of Massachusetts System; University of Massachusetts Lowell; Massachusetts Institute of Technology (MIT)	Rooney-Varga, JN (corresponding author), Univ Massachusetts Lowell, UMass Lowell Climate Change Initiat, Lowell, MA 01854 USA.; Rooney-Varga, JN (corresponding author), Univ Massachusetts Lowell, Dept Environm Earth & Atmospher Sci, Lowell, MA 01854 USA.	Juliette_RooneyVarga@uml.edu		Kapmeier, Florian/0000-0002-7567-4873	National Science Foundation [DUE-124558, ICER-1701062]; SageFox Consulting Group	National Science Foundation(National Science Foundation (NSF)); SageFox Consulting Group	Author KR is employed by SageFox Consulting Group, which provided support in the form of KR's salary, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of author KR are articulated in the 'author contributions' section. This work was supported by the National Science Foundation under grants DUE-124558 and ICER-1701062.	Anderson S, 2017, J ENERGY NAT RESO LA, V35, P221, DOI 10.1080/02646811.2017.1321263; Barros V.R., 2014, CLIM CHANG 2014 IMP, P688, DOI DOI 10.1017/CBO9781107415324; Bartholomew D, 2011, WILEY SER PROBAB ST, P1, DOI 10.1002/9781119970583; CATTELL RB, 1966, MULTIVAR BEHAV RES, V1, P245, DOI 10.1207/s15327906mbr0102_10; Chung KC, 2017, INT SYST DYN C CAMBR; Clemencon R, 2016, J ENVIRON DEV, V25, P3, DOI 10.1177/1070496516631362; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Comrey A. L, 1992, 1 COURSE FACTOR ANAL, DOI DOI 10.4324/9781315827506; Cronin MA, 2009, ORGAN BEHAV HUM DEC, V108, P116, DOI 10.1016/j.obhdp.2008.03.003; Doherty KL, 2016, NAT CLIM CHANGE, V6, P879, DOI 10.1038/NCLIMATE3025; Dunlap RE, 2016, ENVIRONMENT, V58, P4, DOI 10.1080/00139157.2016.1208995; Feinberg M, 2011, PSYCHOL SCI, V22, P34, DOI 10.1177/0956797610391911; Figueres C, 2017, NATURE, V546, P593, DOI 10.1038/546593a; Fischhoff B, 2007, ENVIRON SCI TECHNOL, V41, P7204, DOI 10.1021/es0726411; Gold AU, 2012, J GEOSCI ED, V60, P295, DOI [10.5408/12-324.11234011, DOI 10.5408/12-324.11234011, DOI 10.5408/12-324.1]; GOODMAN E, 2001, PEDIATRICS, V108; Goodman E, 2015, PEDIATRICS, V136, pE633, DOI 10.1542/peds.2015-1300; Halford GS, 2005, PSYCHOL SCI, V16, P70, DOI 10.1111/j.0956-7976.2005.00782.x; Harvey D, 1997, INTERGOVERNMENTAL PA; Hays RT, 1992, MIL PSYCHOL, V4, P63, DOI DOI 10.1207/S15327876MP0402_1; Heath Y, 2006, ENVIRON BEHAV, V38, P48, DOI 10.1177/0013916505277998; Hoffman M. L., 2001, EMPATHY MORAL DEV IM; Homer J, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/pcd11.140130; Hornsey MJ, 2016, GLOBAL ENVIRON CHANG, V39, P26, DOI 10.1016/j.gloenvcha.2016.04.003; Iyer A, 2007, PERS SOC PSYCHOL B, V33, P572, DOI 10.1177/0146167206297402; Kahan D, 2012, NATURE, V488, P255, DOI 10.1038/488255a; Kahan DM, 2012, NAT CLIM CHANGE, V2, P732, DOI 10.1038/NCLIMATE1547; KAISER HF, 1974, PSYCHOMETRIKA, V39, P31, DOI 10.1007/BF02291575; KAISER HF, 1960, EDUC PSYCHOL MEAS, V20, P141, DOI 10.1177/001316446002000116; Kintisch E, 2015, SCIENCE, V350, P1018, DOI 10.1126/science.350.6264.1018; Kluge A, 2009, THEOR ISS ERGON SCI, V10, P489, DOI 10.1080/14639220902982192; Lattanzio R.K., 2014, INT CLIMATE CHANGE F; Ledley T.S., 2017, OXFORD RES ENCY ENV, V1, DOI [10.1093/acrefore/9780199389414.013.56, DOI 10.1093/ACREFORE/9780199389414.013.56]; Lee TM, 2015, NAT CLIM CHANGE, V5, P1014, DOI 10.1038/NCLIMATE2728; Leiserowitz A, 2011, AM TEENSKNOWLEDGE CL, P2; Leiserowitz A, 2006, CLIMATIC CHANGE, V77, P45, DOI 10.1007/s10584-006-9059-9; Lewandowsky S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075637; Marx SM, 2007, GLOBAL ENVIRON CHANG, V17, P47, DOI 10.1016/j.gloenvcha.2006.10.004; Minestere de l'education nationale, 2015, ORG SIM NEG CHANG CL; Moser SC, 2010, WIRES CLIM CHANGE, V1, P31, DOI 10.1002/wcc.11; Osgood E. C., 1957, MEASUREMENT MEANING; Pearce W, 2015, WIRES CLIM CHANGE, V6, P613, DOI 10.1002/wcc.366; Pidgeon N, 2011, NAT CLIM CHANGE, V1, P35, DOI [10.1038/NCLIMATE1080, 10.1038/nclimate1080]; Robinson S, 2002, SIMUL MODEL PRACT TH, V10, P513, DOI 10.1016/S1569-190X(02)00117-X; Sanderson BM, 2017, NAT CLIM CHANGE, V7, P92; Shi J, 2016, NAT CLIM CHANGE, V6, P759, DOI [10.1038/NCLIMATE2997, 10.1038/nclimate2997]; Smith N, 2014, RISK ANAL, V34, P937, DOI 10.1111/risa.12140; Stage EK, 2013, SCIENCE, V340, P276, DOI 10.1126/science.1234011; Sterman J, 2012, SUSTAINABILITY SCI E; Sterman J, 2015, SIMULAT GAMING, V46, P348, DOI 10.1177/1046878113514935; Sterman J, 2012, SYST DYNAM REV, V28, P295, DOI 10.1002/sdr.1474; Sterman JD, 2008, SCIENCE, V322, P532, DOI 10.1126/science.1162574; Sterman JD, 2013, ENVIRON MODELL SOFTW, V44, P122, DOI 10.1016/j.envsoft.2012.06.004; Sterman JD, 2011, CLIMATIC CHANGE, V108, P811, DOI 10.1007/s10584-011-0189-3; Stokes B., 2015, GLOBAL CLIMATE CHANG; Sweeney LB, 2000, SYST DYNAM REV, V16, P249, DOI 10.1002/sdr.198; Tollefson J, 2017, NATURE, V546, P198, DOI 10.1038/nature.2017.22096; United Nations Secretary-General, 2021, ASS REP 6 WORK GROUP; van der Linden S, 2014, EUR J SOC PSYCHOL, V44, P430, DOI 10.1002/ejsp.2008; Weber EU, 2017, NAT HUM BEHAV, V1, DOI 10.1038/s41562-016-0013; Weber EU, 2011, AM PSYCHOL, V66, P315, DOI 10.1037/a0023253; Weber EU, 2010, PERSPECT PSYCHOL SCI, V5, P410, DOI 10.1177/1745691610375556	62	27	27	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2018	13	8							e0202877	10.1371/journal.pone.0202877	http://dx.doi.org/10.1371/journal.pone.0202877			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GS2NZ	30161185	Green Published, gold			2023-01-03	WOS:000443388900048
J	Spilsbury, K; Rosenwax, L; Brameld, K; Kelly, B; Arendts, G				Spilsbury, Katrina; Rosenwax, Lorna; Brameld, Kate; Kelly, Brian; Arendts, Glenn			Morbidity burden and community-based palliative care are associated with rates of hospital use by people with schizophrenia in the last year of life: A population-based matched cohort study	PLOS ONE			English	Article							COST-EFFECTIVENESS; END; COMORBIDITIES; EXPECTANCY; MORTALITY; SERVICES; BARRIERS; MANITOBA; ILLNESS	Objective People with schizophrenia face an increased risk of premature death from chronic diseases and injury. This study describes the trajectory of acute care health service use in the last year of life for people with schizophrenia and how this varied with receipt of community-based specialist palliative care and morbidity burden. Method A population-based retrospective matched cohort study of people who died from 01/01/2009 to 31/12/2013 with and without schizophrenia in Western Australia. Hospital inpatient, emergency department, death and community-based care data collections were linked at the person level. Rates of emergency department presentations and hospital admissions over the last year of life were estimated. Results Of the 63508 decedents, 1196 (1.9%) had a lifetime history of schizophrenia. After adjusting for confounders and averaging over the last year of life there was no difference in the overall rate of ED presentation between decedents with schizophrenia and the matched cohort (HR 1.09; 95% CI 0.99-1.19). However, amongst the subset of decedents with cancer, choking or intentional self-harm recorded on their death certificate, those with schizophrenia presented to ED more often. Males with schizophrenia had the highest rates of emergency department use in the last year of life. Rates of hospital admission for decedents with schizophrenia were on average half (HR 0.53, 95% CI 0.44-0.65) that of the matched cohort although this varied by cause of death. Of all decedents with cancer, 27.5% of people with schizophrenia accessed community-based specialist palliative care compared to 40.4% of the matched cohort (p<0.001). Rates of hospital admissions for decedents with schizophrenia increased 50% (95% CI: 10%-110%) when enrolled in specialist palliative care. Conclusion In the last year of life, people with schizophrenia were less likely to be admitted to hospital and access community-based speciality palliative care, but more likely to attend emergency departments if male. Community-based specialist palliative care was associated with increased rates of hospital admissions.	[Spilsbury, Katrina; Brameld, Kate] Curtin Univ, Ctr Populat Hlth Res, Perth, WA, Australia; [Spilsbury, Katrina] Univ Notre Dame Australia, Inst Hlth Res, Perth, WA, Australia; [Rosenwax, Lorna] Curtin Univ, Sch Occupat Therapy & Social Work, Perth, WA, Australia; [Kelly, Brian] Univ Newcastle, Ctr Brain & Mental Hlth Res, Newcastle, NSW, Australia; [Kelly, Brian] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia; [Arendts, Glenn] Univ Western Australia, Ctr Clin Res Emergency Med, Harry Perkins Inst Med Res, Perth, WA, Australia; [Arendts, Glenn] Fiona Stanley Hosp, Dept Emergency Med, Perth, WA, Australia	Curtin University; University of Notre Dame Australia; Curtin University; University of Newcastle; University of Newcastle; Harry Perkins Institute of Medical Research; University of Western Australia	Rosenwax, L (corresponding author), Curtin Univ, Sch Occupat Therapy & Social Work, Perth, WA, Australia.	L.Rosenwax@curtin.edu.au	Kelly, Brian/G-7755-2013; Spilsbury, Katrina/B-5646-2016	Kelly, Brian/0000-0003-4460-1134; Spilsbury, Katrina/0000-0002-7434-2957; Arendts, Glenn/0000-0001-7830-7756	National Health and Medical Research Council of Australia [1084890]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the National Health and Medical Research Council of Australia through a project grant #1084890 (https://www.nhmrc.gov.au/grants-funding) awarded to LR. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Australian Bureau of Statistics, 2013, CAUS DEATH AUSTR 201; Blackwell M, 2009, STATA J, V9, P524, DOI 10.1177/1536867X0900900402; Butler H, 2018, INT J MENT HEALTH NU, V27, P737, DOI 10.1111/inm.12360; Chapman M, 2018, BMJ SUPPORT PALLIAT, V8, P102, DOI 10.1136/bmjspcare-2015-001071; Chochinov HM, 2012, SCHIZOPHR RES, V141, P241, DOI 10.1016/j.schres.2012.07.028; Crump C, 2013, AM J PSYCHIAT, V170, P324, DOI 10.1176/appi.ajp.2012.12050599; Dickerson F, 2013, PSYCHIAT SERV, V64, P44, DOI [10.1176/appi.ps.201200143, 10.1176/appi.ps.001432012]; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Every-Palmer S, 2017, CNS DRUGS, V31, P699, DOI 10.1007/s40263-017-0448-6; Ferroni E, 2016, J PALLIAT MED, V19, P1260, DOI 10.1089/jpm.2016.0158; Ganzini L, 2010, PSYCHIAT SERV, V61, P725, DOI 10.1176/ps.2010.61.7.725; Glover JST, 2003, WORKING PAPER SERIES, V9; Hetlevik O, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0719-1; Holman CDJ, 1999, AUST NZ J PUBL HEAL, V23, P453, DOI 10.1111/j.1467-842X.1999.tb01297.x; Holt RIG, 2010, J PSYCHOPHARMACOL, V24, P867, DOI 10.1177/0269881109102788; Hudson TJ, 2004, J CLIN PSYCHIAT, V65, P211; Irwin KE, 2014, CANCER-AM CANCER SOC, V120, P323, DOI 10.1002/cncr.28431; Kandratavicius L, 2014, EPILEPSY BEHAV, V38, P143, DOI 10.1016/j.yebeh.2014.01.005; Kulkarni DP, 2017, DYSPHAGIA, V32, P467, DOI 10.1007/s00455-017-9802-6; Lambert TJ, 2003, MED J AUSTRALIA, V178, pS67; Lan CC, 2011, GEN HOSP PSYCHIAT, V33, DOI 10.1016/j.genhosppsych.2011.02.006; Laursen TM, 2011, SCHIZOPHR RES, V131, P101, DOI 10.1016/j.schres.2011.06.008; Lavin K, 2017, J PAIN SYMPTOM MANAG, V54, P176, DOI 10.1016/j.jpainsymman.2017.04.003; Leng CH, 2016, SCHIZOPHR RES, V171, P97, DOI 10.1016/j.schres.2016.01.033; Martens PJ, 2013, J CLIN PSYCHIAT, V74, pE551, DOI 10.4088/JCP.12m08234; Miccinesi G, 2003, CANCER CAUSE CONTROL, V14, P971, DOI 10.1023/B:CACO.0000007964.16319.98; Muir-Cochrane E, 2006, J PSYCHIATR MENT HLT, V13, P447, DOI 10.1111/j.1365-2850.2006.01002.x; National Centre for Classification in Health, 2000, INT CLASS DIS AUSTR; National Coding Centre, 1995, INT CLASS DIS AUSTR; Olfson M, 2015, JAMA PSYCHIAT, V72, P1172, DOI 10.1001/jamapsychiatry.2015.1737; Pink B., 2008, INFORM PAPER INTRO S; Pink B (Australian Bureau of Statistics), 2008, INFORM PAPER CAUSE D; Pouliot K, 2017, AM J HOSP PALLIAT ME, V34, P166, DOI 10.1177/1049909115617139; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rosenwax LK, 2005, PALLIATIVE MED, V19, P556, DOI 10.1191/0269216305pm1067oa; Royston P, 2002, STAT MED, V21, P2175, DOI 10.1002/sim.1203; Sahlen KG, 2016, PALLIATIVE MED, V30, P296, DOI 10.1177/0269216315618544; Smith S, 2014, PALLIATIVE MED, V28, P130, DOI 10.1177/0269216313493466; Spilsbury K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185275; Spilsbury K, 2017, ANN EMERG MED, V69, P416, DOI 10.1016/j.annemergmed.2016.11.036; Sutradhar R, 2017, PALLIATIVE MED, V31, P448, DOI 10.1177/0269216316663508; Tiihonen J, 2009, LANCET, V374, P620, DOI 10.1016/S0140-6736(09)60742-X; Xiong GL, 2008, PSYCHIAT SERV, V59, P929, DOI 10.1176/ps.2008.59.8.929	43	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2018	13	11							e0208220	10.1371/journal.pone.0208220	http://dx.doi.org/10.1371/journal.pone.0208220			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HC4HL	30496266	Green Published, Green Submitted, gold			2023-01-03	WOS:000451763800111
J	Bae, SJ; Choi, JW; Park, BJ; Lee, J; Jo, EK; Lee, YH; Kim, SB; Yuk, JM				Bae, Su-Jin; Choi, Jae-Won; Park, Byung-Joon; Lee, Jina; Jo, Eun-Kyeong; Lee, Young-Ha; Kim, Sung-Bae; Yuk, Jae-Min			Protective effects of a traditional herbal extract from Stellaria dichotoma var. lanceolata against Mycobacterium abscessus infections	PLOS ONE			English	Article							TUMOR-NECROSIS-FACTOR; INNATE IMMUNE-RESPONSES; OXYGEN SPECIES ROS; NF-KAPPA-B; BUPLEURUM-FALCATUM; REACTIVE OXYGEN; INFLAMMATORY RESPONSES; PECTIC POLYSACCHARIDE; GENUS BUPLEURUM; FACTOR-ALPHA	Stellaria dichotoma var. lanceolata (SdLv), a member of the Caryophyllaceae, is a traditional herbal medicine that has been used to treat fever, night sweats, and malaria in East Asia. Inflammation plays an essential role in both host defense and pathogenesis during infection by diverse intracellular pathogens. Herein, we showed that an herbal extract from SdLv effectively attenuated inflammatory responses from infection of Mycobacterium abscessus (Mab), but not Toxoplasma gondii (T. gondii). In primary murine macrophages, Mab infection resulted in the rapid activation of nuclear factor (NF)-kappa B and mitogen-activated protein kinase (MAPK), as well as in the generation of proinflammatory cytokines, such as tumor necrosis factor a and interleukin-6, which were all significantly inhibited by pretreatment with SdLv. However, herbal extracts from Bupleurum chinense DC. (Buch) or Bupleurum falcatum L. (Bufa) did not affect M. abs-induced activation of proinflammatory responses. Importantly, we demonstrated that generation of intracellular reactive oxygen species, which are important signaling intermediaries in the activation of NF-kappa B and the MAPK signaling pathway, was rapidly increased in Mab-infected macrophages, and this was effectively suppressed by pretreatment with SdLv, but not Buch and Bufa. We further found that the treatment of Buch and Bufa, but not SdLv, led to the activation of NF-kappa B and the MAPK signaling pathway and the generation of intracellular reactive oxygen species. Moreover, oral administration of SdLvsignificantly reduced lethality in Mab-infected mice. Collectively, these results suggest the possible use of SdLv as an effective treatment for Mab infection.	[Bae, Su-Jin; Choi, Jae-Won; Park, Byung-Joon; Lee, Jina; Lee, Young-Ha; Yuk, Jae-Min] Chungnam Natl Univ, Coll Med, Dept Infect Biol, Daejeon, South Korea; [Bae, Su-Jin; Choi, Jae-Won; Park, Byung-Joon; Lee, Jina; Jo, Eun-Kyeong; Lee, Young-Ha; Yuk, Jae-Min] Chungnam Natl Univ, Coll Med, Dept Med Sci, Daejeon, South Korea; [Jo, Eun-Kyeong] Chungnam Natl Univ, Coll Med, Dept Microbiol, Daejeon, South Korea; [Kim, Sung-Bae] Korea Inst Oriental Med, Herbal Med Res Div, Daejeon, South Korea	Chungnam National University; Chungnam National University; Chungnam National University; Korea Institute of Oriental Medicine (KIOM)	Yuk, JM (corresponding author), Chungnam Natl Univ, Coll Med, Dept Infect Biol, Daejeon, South Korea.; Yuk, JM (corresponding author), Chungnam Natl Univ, Coll Med, Dept Med Sci, Daejeon, South Korea.; Kim, SB (corresponding author), Korea Inst Oriental Med, Herbal Med Res Div, Daejeon, South Korea.	suaa10@kiom.re.kr; yjaemin0@cnu.ac.kr		Eun-Kyeong, Jo/0000-0001-7191-0587	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [NRF-2016R1D1A1B03933345, NRF-2017R1A5A2015385]; Chungnam National University; Korea Institute of Oriental Medicine (KIOM) [K16402]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning; Chungnam National University; Korea Institute of Oriental Medicine (KIOM)	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2016R1D1A1B03933345 and NRF-2017R1A5A2015385) and research fund of Chungnam National University. This research was supported by grants for Evaluation of effectiveness of alternative herbal medicine (K16402) from Korea Institute of Oriental Medicine (KIOM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, KOR PHARM, P64; Arthur JSC, 2013, NAT REV IMMUNOL, V13, P679, DOI 10.1038/nri3495; Ashour ML, 2011, J PHARM PHARMACOL, V63, P305, DOI 10.1111/j.2042-7158.2010.01170.x; Bekker LG, 2000, INFECT IMMUN, V68, P6954, DOI 10.1128/IAI.68.12.6954-6961.2000; Benwill JL, 2014, CURR OPIN INFECT DIS, V27, P506, DOI 10.1097/QCO.0000000000000104; Bragonzi A, 2018, J CYST FIBROS, V17, pS40, DOI 10.1016/j.jcf.2017.10.004; Brown-Elliott BA, 2002, CLIN MICROBIOL REV, V15, P716, DOI 10.1128/CMR.15.4.716-746.2002; Calixto JB, 2000, BRAZ J MED BIOL RES, V33, P179, DOI 10.1590/S0100-879X2000000200004; Chen YF, 2010, J NAT PROD, V73, P1993, DOI 10.1021/np1003627; DEPASQUALE A, 1984, J ETHNOPHARMACOL, V11, P1, DOI 10.1016/0378-8741(84)90092-8; Di HY, 2013, INT J BIOL MACROMOL, V58, P179, DOI 10.1016/j.ijbiomac.2013.03.043; Dian Zhong Yao Da Ci, 2006, ENCY CHINESE MAT MED, P3029; Dubremetz JF, 1998, TRENDS MICROBIOL, V6, P27, DOI 10.1016/S0966-842X(97)01165-7; Dupont CD, 2012, SEMIN IMMUNOPATHOL, V34, P793, DOI 10.1007/s00281-012-0339-3; Elmore SA, 2010, TRENDS PARASITOL, V26, P190, DOI 10.1016/j.pt.2010.01.009; Finlay BB, 2006, CELL, V124, P767, DOI 10.1016/j.cell.2006.01.034; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; Harris KA, 2014, J MED MICROBIOL, V63, P1241, DOI 10.1099/jmm.0.077164-0; Ikegami F, 2006, HUM EXP TOXICOL, V25, P481, DOI 10.1191/0960327106het654oa; Jo EK, 2007, CELL MICROBIOL, V9, P1087, DOI 10.1111/j.1462-5822.2007.00914.x; Kim JH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06610-4; Kim JS, 2016, STEM CELLS, V34, P1957, DOI 10.1002/stem.2353; Kim L, 2006, J IMMUNOL, V177, P2584, DOI 10.4049/jimmunol.177.4.2584; Kim TS, 2014, J CLIN IMMUNOL, V34, P212, DOI 10.1007/s10875-013-9978-y; Kim YS, 2017, MICROBES INFECT, V19, P5, DOI 10.1016/j.micinf.2016.09.001; Kleinnijenhuis J, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/405310; Lee B, 2012, J MICROBIOL BIOTECHN, V22, P422, DOI 10.4014/jmb.1110.10077; Lim BO, 2008, J MED FOOD, V11, P723, DOI 10.1089/jmf.2007.0135; Lin MY, 2016, J ETHNOPHARMACOL, V193, P566, DOI 10.1016/j.jep.2016.09.052; Martiniano SL, 2017, PEDIATR PULM, V52, pS29, DOI 10.1002/ppul.23825; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; Medjahed H, 2010, TRENDS MICROBIOL, V18, P117, DOI 10.1016/j.tim.2009.12.007; Mordue DG, 2001, J IMMUNOL, V167, P4574, DOI 10.4049/jimmunol.167.8.4574; Morikawa T, 2004, CHEM PHARM BULL, V52, P1194, DOI 10.1248/cpb.52.1194; MORTON DB, 1985, VET REC, V116, P431, DOI 10.1136/vr.116.16.431; Nagai H, 2007, J BIOCHEM MOL BIOL, V40, P1; Napetschnig J, 2013, ANNU REV BIOPHYS, V42, P443, DOI 10.1146/annurev-biophys-083012-130338; Quan JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141550; Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008; Ribet D, 2015, MICROBES INFECT, V17, P173, DOI 10.1016/j.micinf.2015.01.004; Rottman M, 2007, INFECT IMMUN, V75, P5898, DOI 10.1128/IAI.00014-07; Russell EG, 2015, INT REV CEL MOL BIO, V319, P221, DOI 10.1016/bs.ircmb.2015.07.004; Ryan KA, 2004, INFECT IMMUN, V72, P2123, DOI 10.1128/IAI.72.4.2123-2130.2004; Sampaio EP, 2008, AM J RESP CELL MOL, V39, P431, DOI 10.1165/rcmb.2007-0413OC; Serbina NV, 2008, ANNU REV IMMUNOL, V26, P421, DOI 10.1146/annurev.immunol.26.021607.090326; Shin DM, 2008, CELL MICROBIOL, V10, P1608, DOI 10.1111/j.1462-5822.2008.01151.x; Sun BH, 2004, J NAT PROD, V67, P1464, DOI 10.1021/np040080a; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tang DL, 2012, IMMUNOL REV, V249, P158, DOI 10.1111/j.1600-065X.2012.01146.x; Teng J, 1985, Zhong Yao Tong Bao, V10, P15; YAMADA H, 1989, CARBOHYD RES, V189, P209, DOI 10.1016/0008-6215(89)84098-4; YAMADA H, 1991, CARBOHYD RES, V219, P173, DOI 10.1016/0008-6215(91)89050-P; Yang CS, 2008, CELL MICROBIOL, V10, P741, DOI 10.1111/j.1462-5822.2007.01081.x; Yang FD, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7597596; Yarovinsky F, 2014, NAT REV IMMUNOL, V14, P109, DOI 10.1038/nri3598; Yin F, 2008, NAT PROD COMMUN, V3, P155; Yuk JM, 2015, IMMUNITY, V43, P80, DOI 10.1016/j.immuni.2015.07.003; Yuk Jae-Min, 2011, Journal of Bacteriology and Virology, V41, P225; Yuk JM, 2009, IMMUNOL CELL BIOL, V87, P100, DOI 10.1038/icb.2008.74; Zhang TT, 2007, BIOCHEM SYST ECOL, V35, P801, DOI 10.1016/j.bse.2007.03.023; Zhao Bao-Lin, 2013, Zhonghua Yi Shi Za Zhi, V43, P200	61	1	1	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2018	13	11							e0207696	10.1371/journal.pone.0207696	http://dx.doi.org/10.1371/journal.pone.0207696			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA9FQ	30452471	Green Submitted, Green Published, gold			2023-01-03	WOS:000450603800033
J	Kearney, A; Rosala-Hallas, A; Bacon, N; Daykin, A; Shaw, ARG; Lane, AJ; Blazeby, JM; Clarke, M; Williamson, PR; Gamble, C				Kearney, Anna; Rosala-Hallas, Anna; Bacon, Naomi; Daykin, Anne; Shaw, Alison R. G.; Lane, Athene J.; Blazeby, Jane M.; Clarke, Mike; Williamson, Paula R.; Gamble, Cerrol			Reducing attrition within clinical trials: The communication of retention and withdrawal within patient information leaflets	PLOS ONE			English	Article							INFORMED-CONSENT; MISSING DATA; RECRUITMENT; CANCER; PARTICIPATION; RANDOMIZATION; INTERVENTIONS; PREVENTION; STRATEGIES; ATTITUDES	Background The recruitment and retention of patients are significant methodological challenges for trials. Whilst research has focussed on recruitment, the failure to retain recruited patients and collect outcome data can lead to additional problems and potentially biased results. Research to identify effective retention strategies has focussed on influencing patient behaviour through incentives, reminders and alleviating patient burden, but has not sought to improve patient understanding of the importance of retention. Our aim is to assess how withdrawal, retention and the value of outcome data collection is described within the Patient Information Leaflets (PIL) used during consent. Methods Fifty adult or parent PIL from a cohort of trials starting between 2009-2012 and funded by the NIHR Health Technology Assessment programme were obtained from protocols, websites or by contacting trialists. A checklist of PIL content based on Health Research Authority (HRA) and ICH GCP Guidelines was supplemented with retention specific questions. Corresponding protocols were also evaluated to cross reference trial specific procedures with information communicated to patients. Results PIL frequently reiterated the patient's right to withdraw at any time (n = 49, 98%), without having to give a reason and without penalty (n = 45, 90%). However, few informed patients they may be asked to give a withdrawal reason where willing (n = 6, 12%). Statements about the value of retention were infrequent (n = 8, 16%). Consent documents failed to include key content that might mitigate withdrawals, such as the need for treatment equipoise (n = 3, 6%). Nearly half the trials in the cohort (n = 23, 46%) wanted to continue to collect outcome data if patients withdraw. However, in 70% of PIL using prospective consent, withdrawal was described in generic terms leaving patients unaware of the difference between stopping treatment and all trial involvement. Nineteen (38%) trials offered withdrawing patients the option to delete existing data. Conclusions Withdrawal and retention is poorly described within PIL and addressing this might positively impact levels of patient attrition, reducing missing data. Consent information is unbalanced, focussing on patient's rights to withdraw without accompanying information that promotes robust consent and sustained participation. With many citing altruistic reasons for participation it is essential that PIL include more information on retention and clarify withdrawal terminology so patients are aware of how they can make a valuable contribution to clinical studies. There is a need to determine how retention can be described to patients to avoid concerns of coercion. Future research is needed to explore whether the absence of information about retention at the time of consent is impacting attrition.	[Kearney, Anna; Williamson, Paula R.; Gamble, Cerrol] Univ Liverpool, Clin Trial Res Ctr, North West Hub Trials Methodol Res, Biostat, Liverpool, Merseyside, England; [Rosala-Hallas, Anna; Bacon, Naomi] Univ Liverpool, Clin Trial Res Ctr, Biostat, Liverpool, Merseyside, England; [Daykin, Anne; Shaw, Alison R. G.; Lane, Athene J.; Blazeby, Jane M.] Univ Bristol, ConDuCT Hub Trials Methodol Res 2, Bristol, Avon, England; [Clarke, Mike] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland	University of Liverpool; University of Liverpool; University of Bristol; Queens University Belfast	Kearney, A (corresponding author), Univ Liverpool, Clin Trial Res Ctr, North West Hub Trials Methodol Res, Biostat, Liverpool, Merseyside, England.	a.kearney@liv.ac.uk	kearney, anna/AGU-8774-2022; Kearney, Anna/ABD-5316-2020; Gamble, Carrol/AAE-9895-2019; Williamson, Paula R/B-6425-2016	Gamble, Carrol/0000-0002-3021-1955; Williamson, Paula R/0000-0001-9802-6636; Kearney, Anna/0000-0003-1404-3370; Blazeby, Jane/0000-0002-3354-3330; Heawood (nee Shaw), Alison/0000-0002-5907-4608	Medical Research Council [MR/K024310/1]; MRC [G0901530, MR/K024310/1, MR/K025643/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by Medical Research Council Methodology Research Programme (Grant MR/K024310/1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Administration USDoHaHSFaD, 2008, GUID SPONS CLIN INV; Agency EM, 2010, GUID MISS DAT CONF C; Akl EA, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2809; Authority HR, 2017, HRA GUID APPL PROP A; Bell ML, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-118; Bidad N, 2014, RES ETHICS, V10, P47; Bower P, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-399; Brueton VC, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-003821; Busby-Grant J, 2009, J MED ETHICS, V35, P768, DOI 10.1136/jme.2008.028035; Cameron P, 2013, CURR ONCOL, V20, pE193, DOI 10.3747/co.20.1323; Cuzick J, 2015, ANN ONCOL, V26, P2363, DOI 10.1093/annonc/mdv392; Eakin EG, 2007, HEALTH EDUC RES, V22, P361, DOI [10.1093/her/cyl095, 10.1093/het/cyl095]; Eborall HC, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-7; Falagas ME, 2009, AM J SURG, V198, P420, DOI 10.1016/j.amjsurg.2009.02.010; Fallowfield LJ, 1998, EUR J CANCER, V34, P1554, DOI 10.1016/S0959-8049(98)00193-2; Flory J, 2004, JAMA-J AM MED ASSOC, V292, P1593, DOI 10.1001/jama.292.13.1593; Fortun P, 2008, QJM-INT J MED, V101, P625, DOI 10.1093/qjmed/hcn067; Furimsky I, 2008, CONTEMP CLIN TRIALS, V29, P862, DOI 10.1016/j.cct.2008.07.005; Griffin JM, 2006, CONTEMP CLIN TRIALS, V27, P441, DOI 10.1016/j.cct.2006.04.006; Henney S, 2014, J LARYNGOL OTOL, V128, P249, DOI 10.1017/S0022215114000449; Hussain JA, 2017, J CLIN EPIDEMIOL, V88, P81, DOI 10.1016/j.jclinepi.2017.05.009; ICH, 2016, ICH GUID GOOD CLIN P; Jenkins V, 2010, BRIT J CANCER, V103, P1801, DOI 10.1038/sj.bjc.6606004; KEARNEY A, 2017, TRIALS, V18; Kirkby HM, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000509; Knapp P, 2009, J MED ETHICS, V35, P573, DOI 10.1136/jme.2008.026708; KNAPP P, 2011, BMC MED, V9; Lamberti MJ, 2012, DRUG INF J, V46, P573, DOI 10.1177/0092861512453040; Loftin WA, 2005, DIABETES EDUCATOR, V31, P251, DOI 10.1177/0145721705275517; Lorell BH, 2015, CLIN TRIALS, V12, P692, DOI 10.1177/1740774515594362; Loue S, 2008, J IMMIGR MINOR HEALT, V10, P145, DOI 10.1007/s10903-007-9063-9; Man MS, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0820-0; Mandava A, 2012, J MED ETHICS, V38, P356, DOI 10.1136/medethics-2011-100178; Matsui K, 2005, J MED ETHICS, V31, P385, DOI 10.1136/jme.2004.009530; Moorcraft SY, 2016, TRIALS, V17, DOI 10.1186/s13063-015-1105-3; O'Neill RT, 2012, CLIN PHARMACOL THER, V91, P550, DOI 10.1038/clpt.2011.340; Reinert C, 2014, EUR J CANCER, V50, P150, DOI 10.1016/j.ejca.2013.09.006; Robinson EJ, 2005, HEALTH TECHNOL ASSES, V9, pIII; Robinson KA, 2007, J CLIN EPIDEMIOL, V60, P757, DOI 10.1016/j.jclinepi.2006.11.023; Shilling V, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15150; Smith CT, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-32; Toerien M, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-52; Treweek S, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002360; Walters SJ, 2017, BMJ OPEN, V7; Wittes J, 2009, J BIOPHARM STAT, V19, P957, DOI 10.1080/10543400903239825; World Medical Association Declaration of Helsinki, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI [10.1001/jama.2013.281053, DOI 10.1001/JAMA.2013.281053]	46	15	15	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2018	13	10							e0204886	10.1371/journal.pone.0204886	http://dx.doi.org/10.1371/journal.pone.0204886			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GY7VH	30379822	gold, Green Published, Green Submitted			2023-01-03	WOS:000448823700022
J	Haighton, C; Kidd, J; O'Donnell, A; Wilson, G; McCabe, K; Ling, J				Haighton, Catherine; Kidd, Jess; O'Donnell, Amy; Wilson, Graeme; McCabe, Karen; Ling, Jonathan			'I take my tablets with the whiskey': A qualitative study of alcohol and medication use in mid to later life	PLOS ONE			English	Article							DRUG-INTERACTIONS; CONCOMITANT USE; OLDER; DRINKING; PREVALENCE; HEALTH; INTERVENTION; NURSES; SAMPLE; RISK	Background Concurrent alcohol and medication use can result in significant problems especially in mid to later life. Alcohol is often used instead of medication for a number of health-related conditions. This novel qualitative study explored concurrent alcohol and medication use, as well as the use of alcohol for medicinal purposes, in a sample of individuals in mid to later life. Methods Twenty-four interviews (12 men/12 women, ages 51-90 years) and three focus groups (n = 27, 6 men/21 women, ages 50-95 years) from three branches of Age UK and two services for alcohol problems in North East England. Results Older people in this study often combined alcohol and medication, frequently without discussing this with their family doctor. However, being prescribed medication could act as a motivating factor to stop or reduce alcohol consumption. Participants also used alcohol to self-medicate, to numb pain, aid sleep or cope with stress and anxiety. Some participants used alcohol to deal with depression although alcohol was also reported as a cause of depression. Women in this study reported using alcohol to cope with mental health problems while men were more likely to describe reducing their alcohol consumption as a consequence of being prescribed medication. Conclusions As older people often combine alcohol and medication, health professionals such as family doctors, community nurses, and pharmacists should consider older patients' alcohol consumption prior to prescribing or dispensing medication and should monitor subsequent drinking. In particular, older people should be informed of the dangers of concurrent alcohol and medication use.	[Haighton, Catherine] Northumbria Univ, Dept Social Work Educ & Community Wellbeing, Newcastle Upon Tyne, Tyne & Wear, England; [Haighton, Catherine; Kidd, Jess; O'Donnell, Amy; Wilson, Graeme] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne, Tyne & Wear, England; [Wilson, Graeme] Univ Edinburgh, Reid Sch Mus, Edinburgh, Midlothian, Scotland; [McCabe, Karen; Ling, Jonathan] Univ Sunderland, Sch Nursing & Hlth Sci, Sunderland, Durham, England	Northumbria University; Newcastle University - UK; University of Edinburgh; University of Sunderland	Haighton, C (corresponding author), Northumbria Univ, Dept Social Work Educ & Community Wellbeing, Newcastle Upon Tyne, Tyne & Wear, England.; Haighton, C (corresponding author), Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne, Tyne & Wear, England.	Katie.haighton@northumbria.ac.uk	Wilson, Graeme/AAQ-2499-2020; Ling, Jonathan/AAY-4098-2020; Haighton, Catherine/H-1528-2015	Wilson, Graeme/0000-0003-2587-257X; Ling, Jonathan/0000-0003-2932-4474; Haighton, Catherine/0000-0002-8061-0428; O'Donnell, Amy/0000-0003-4071-9434	United Kingdom Charity Age UK South Tyneside; British Heart Foundation; Cancer Research UK; Economic and Social Research Council; Medical Research Council; National Institute for Health Research	United Kingdom Charity Age UK South Tyneside; British Heart Foundation(British Heart Foundation); Cancer Research UK(Cancer Research UK); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research(National Institute for Health Research (NIHR))	This research was supported by a grant from the United Kingdom Charity Age UK South Tyneside (http://www.ageuk.org.uk/southtyneside/). The organisation assisted in the identification and recruitment of study participants as described above. Apart from this, the funders had no role in study design, analysis, decision to publish, or preparation of the manuscript. CH was and JL is a partially funded staff member of Fuse, the Centre for Translational Research in Public Health, a UKCRC Public Health Research Centre of Excellence. Funding for Fuse from the British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, the National Institute for Health Research, is gratefully acknowledged.	ADAMS WL, 1995, J AM GERIATR SOC, V43, P1021, DOI 10.1111/j.1532-5415.1995.tb05567.x; Aira M, 2005, INT J GERIATR PSYCH, V20, P680, DOI 10.1002/gps.1340; Aira M, 2008, FAM PRACT, V25, P445, DOI 10.1093/fampra/cmn065; [Anonymous], 1995, IMPERATIVE HLTH PUBL; Atkinson RM, 2002, AM J GERIAT PSYCHIAT, V10, P649, DOI 10.1176/appi.ajgp.10.6.649; Barrett L. L., 2005, PRESCRIPTION DRUG US; Brennan PL, 2011, PAIN MED, V12, P1049, DOI 10.1111/j.1526-4637.2011.01156.x; Brennan PL, 2005, ADDICTION, V100, P777, DOI 10.1111/j.1360-0443.2005.01074.x; Breslow RA, 2015, ALCOHOL CLIN EXP RES, V39, P371, DOI 10.1111/acer.12633; Bryman A., 2008, SOCIAL RES METHODS, V3rd; Carney MA, 2000, J CONSULT CLIN PSYCH, V68, P788, DOI 10.1037/0022-006X.68.5.788; Clarke A.E., 2018, SITUATIONAL ANAL GRO, V2nd; Cousins G, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-57; CRAWFORD R, 1980, INT J HEALTH SERV, V10, P365, DOI 10.2190/3H2H-3XJN-3KAY-G9NY; Dare J, 2014, HEALTH SOC CARE COMM, V22, P524, DOI 10.1111/hsc.12110; DAVIDSON KM, 1995, BRIT J PSYCHIAT, V166, P199, DOI 10.1192/bjp.166.2.199; Francis JJ, 2010, PSYCHOL HEALTH, V25, P1229, DOI 10.1080/08870440903194015; Haighton C., 2017, ALCOHOL AGING CLIN P; Haighton C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148601; Hallgren MA, 2010, EUR J PUBLIC HEALTH, V20, P616, DOI 10.1093/eurpub/ckq111; Holley-Moore G, 2016, DRINK WISE AGE WELL; Hunter B, 2011, AUST NZ J PSYCHIAT, V45, P343, DOI 10.3109/00048674.2010.549997; Ilomaki J, 2013, DRUG ALCOHOL REV, V32, P218, DOI 10.1111/j.1465-3362.2012.00496.x; Ilomaki J, 2013, ANN PHARMACOTHER, V47, P257, DOI 10.1345/aph.1R449; Ilomaki J, 2011, ANN PHARMACOTHER, V45, P1240, DOI 10.1345/aph.1Q375; Ilomaki J, 2008, ALCOHOL, V42, P261, DOI 10.1016/j.alcohol.2008.02.002; Immonen S, 2013, SCAND J PRIM HEALTH, V31, P73, DOI 10.3109/02813432.2013.788272; Kaner EFS, 2001, BRIT J GEN PRACT, V51, P822; Kuhn T., 1962, STRUCTURE SCI RESOLU; Lock CA, 2004, FAM PRACT, V21, P270, DOI 10.1093/fampra/cmh310; Lock CA, 2002, J ADV NURS, V39, P333, DOI 10.1046/j.1365-2648.2002.02294.x; Moore Alison A, 2007, Am J Geriatr Pharmacother, V5, P64, DOI 10.1016/j.amjopharm.2007.03.006; Moos RH, 2010, AGING MENT HEALTH, V14, P33, DOI 10.1080/13607860902918264; Office for National Statistics, 2012, GEN LIF SURV 2010; Onder G, 2002, PHARMACOEPIDEM DR S, V11, P385, DOI 10.1002/pds.721; Pond R, 2010, J HEALTH PSYCHOL, V15, P734, DOI 10.1177/1359105310368068; Pringle KE, 2005, J AM GERIATR SOC, V53, P1930, DOI 10.1111/j.1532-5415.2005.00474.x; Pringle KE, 2006, J AGING HEALTH, V18, P837, DOI 10.1177/0898264306293583; QSR International Pty Ltd, 2012, QUALITATIVE ANAL USI; Reid MC, 1998, J GEN INTERN MED, V13, P729, DOI 10.1046/j.1525-1497.1998.00223.x; Riley JL, 2009, J PAIN, V10, P944, DOI 10.1016/j.jpain.2009.03.005; Robinson OC, 2014, QUAL RES PSYCHOL, V11, P25, DOI 10.1080/14780887.2013.801543; Sacco P, 2015, AGING MENT HEALTH, V19, P279, DOI 10.1080/13607863.2014.933307; Sacco P, 2013, DRUG ALCOHOL DEPEN, V131, P157, DOI 10.1016/j.drugalcdep.2012.10.008; Sproule BA, 1999, INT J GERIATR PSYCH, V14, P851, DOI 10.1002/(SICI)1099-1166(199910)14:10<851::AID-GPS33>3.3.CO;2-C; Stahl ST, 2014, J BEHAV MED, V37, P736, DOI 10.1007/s10865-013-9524-7; Strauss A., 1997, GROUNDED THEORY PRAC; Veenstra M., 2012, Norsk Epidemiologi, V22, P135; Wilson GB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071792	49	10	10	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2018	13	10							e0205956	10.1371/journal.pone.0205956	http://dx.doi.org/10.1371/journal.pone.0205956			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GX4KR	30335835	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000447701300077
J	Wu, WT; Chu, CY; Hsu, PC; Lee, WH; Su, HM; Yen, HW; Voon, WC; Lai, WT; Sheu, SH; Lin, TH				Wu, Wei-Tsung; Chu, Chun-Yuan; Hsu, Po-Chao; Lee, Wen-Hsien; Su, Ho-Ming; Yen, Hsueh-Wei; Voon, Wen-Chol; Lai, Wen-Ter; Sheu, Sheng-Hsiung; Lin, Tsung-Hsien			Impact of the duration of the evidence-based medicine use in acute heart failure: A nationwide cohort study	PLOS ONE			English	Article							EJECTION FRACTION; MORTALITY; TRIAL; SPIRONOLACTONE; MORBIDITY; SURVIVAL; DIGOXIN	Background Several randomized control trials have established that drugs can decrease the heart failure (HF) rehospitalization in patients with HF. However, limited studies have investigated the duration of medicine use to decrease the rehospitalization period in the real world. Hence, this study aims to investigate whether the evidence-based medicine decreases the HF rehospitalization in different treatment intervals in the clinical practice. Method We examined patients admitted with acute HF from the National Health Insurance Research Database in Taiwan. In addition, the major adverse cardiovascular events (MACE) were the composite endpoints of the in-hospital mortality and rehospitalization after 1 year. Furthermore, we analyzed the medicine use to decrease 14 days and 1, 6, and 12 months' HF rehospitalization. Results Overall, we examined 11,012 patients. The use of the renin-angiotensin system (RAS) blockers [hazard ratio (HR), 0.58; P< 0.01], beta-blocker (HR, 0.67; P < 0.01), spironolactone (HR, 0.63; P < 0.01), and digitalis (HR, 0.67; P < 0.01) associated with the lower in-hospital mortality rate. The Cox regression analysis revealed that RAS blocker (HR, 0.86; P< 0.01) and 8-blocker (HR, 0.71; P< 0.01) were independent predictors for MACE. Although RAS blockers declined rehospitalization to 6 months, beta-blocker decreased the rehospitalization rate after 1 month use and the benefit persisted till 12 months. Furthermore, digitalis only lowered rehospitalization to 14 days. Conclusion This study suggests that the use of evidence-based medicine is associated with lower MACE for patients with HF, and these drugs could play vital roles in different periods to decrease the rehospitalization in the clinical setting.	[Wu, Wei-Tsung; Chu, Chun-Yuan; Hsu, Po-Chao; Lee, Wen-Hsien; Su, Ho-Ming; Yen, Hsueh-Wei; Voon, Wen-Chol; Lai, Wen-Ter; Sheu, Sheng-Hsiung; Lin, Tsung-Hsien] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Cardiol, Kaohsiung, Taiwan; [Chu, Chun-Yuan; Hsu, Po-Chao; Lee, Wen-Hsien; Su, Ho-Ming; Yen, Hsueh-Wei; Voon, Wen-Chol; Lai, Wen-Ter; Sheu, Sheng-Hsiung; Lin, Tsung-Hsien] Kaohsiung Med Univ, Fac Med, Dept Internal Med, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University	Lin, TH (corresponding author), Kaohsiung Med Univ Hosp, Dept Internal Med, Div Cardiol, Kaohsiung, Taiwan.; Lin, TH (corresponding author), Kaohsiung Med Univ, Fac Med, Dept Internal Med, Kaohsiung, Taiwan.	lth@kmu.edu.tw	蘇, 河名/AAE-9843-2019	Wu, Wei Tsung/0000-0003-3702-1406; Lin, Tsung-Hsien/0000-0002-7226-8730; Su, Ho-Ming/0000-0003-0247-3250; Chu, Chun-Yuan/0000-0001-5550-102X; Hsu, Po-Chao/0000-0001-6217-3036				Ahmed A, 2007, J GERONTOL A-BIOL, V62, P323, DOI 10.1093/gerona/62.3.323; Bourge RC, 2013, AM J MED, V126, P701, DOI 10.1016/j.amjmed.2013.02.001; Chamberlain AM, 2015, AM J MED, V128, P38, DOI 10.1016/j.amjmed.2014.08.024; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Eichhorn EJ, 2001, CURR CONTR TRIALS C, V2, P20, DOI 10.1186/CVM-2-1-020; Hjalmarson A, 2000, BASIC RES CARDIOL, V95, P98; Lechat P, 1999, LANCET, V353, P9; Perry G, 1997, NEW ENGL J MED, V336, P525; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Pitt B, 2014, NEW ENGL J MED, V370, P1383, DOI 10.1056/NEJMoa1313731; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Yusuf S, 2003, LANCET, V362, P777, DOI 10.1016/S0140-6736(03)14285-7; Zannad F, 2011, NEW ENGL J MED, V364, P11, DOI 10.1056/NEJMoa1009492	13	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2018	13	10							e0205440	10.1371/journal.pone.0205440	http://dx.doi.org/10.1371/journal.pone.0205440			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW7TO	30308032	Green Published, gold, Green Submitted			2023-01-03	WOS:000447173500077
J	Hampton, T				Hampton, Tracy			Gut MicrobesMay Account for the Anti- Seizure Effects of the Ketogenic Diet	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	9	9	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2018	320	13					1307	1308		10.1001/jama.2017.12865	http://dx.doi.org/10.1001/jama.2017.12865			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV5LJ	30285157				2023-01-03	WOS:000446143400003
J	Wong, DPW; Ng, MY; Leung, JY; Boh, BK; Lim, EC; Tan, SH; Lim, S; Seah, WH; Hu, CZW; Ho, BC; Ng, DHP; Hagen, T				Wong, Daphne Pei Wen; Ng, Mei Ying; Leung, Jia Yu; Boh, Boon Kim; Lim, Ee Chien; Tan, Shi Hua; Lim, Shuying; Seah, Wen Hui; Hu, Christine Zhiwen; Ho, Boon Chuan; Ng, Daphne Hui Ping; Hagen, Thilo			Regulation of the NRF2 transcription factor by andrographolide and organic extracts from plant endophytes	PLOS ONE			English	Article							ANTIOXIDANT RESPONSE ELEMENT; COVALENT MODIFICATION; STRESS-RESPONSE; OXYGENASE 1; KEAP1; ACTIVATION; PROTEIN; CELLS; UBIQUITINATION; INFLAMMATION	The transcription factor NF-E2 Related Factor-2 (NRF2) is an important drug target. Activation of NRF2 has chemopreventive effects in cancer and exerts beneficial effects in a number of diseases, including neurodegenerative diseases, inflammatory diseases, hepatosteatosis, obesity and insulin resistance. Hence, there have been great efforts to discover and characterize novel NRF2 activators. One reported NRF2 activator is the labdane diterpenoid andrographolide. In this study, we identified the mechanism through which andrographolide activates NRF2. We showed that andrographolide inhibits the function of KEAP1, a protein that together with CUL3 and RBX1 forms an E3 ubiquitin ligase that polyu-biquitinates NRF2. Andrographolide partially inhibits the interaction of KEAP1 with CUL3 in a manner dependent on Cys151 in KEAP1. This suggests that andrographolide forms Michael acceptor dependent adducts with Cys151 in KEAP1 in vivo, leading to inhibition of NRF2 ubiquitination and consequently accumulation of the transcription factor. Interestingly, we also showed that at higher concentrations andrographolide increases NRF2 protein expression in a Cys151 independent, but likely KEAP1 dependent manner, possibly through modification of other Cys residues in KEAP1. In this study we also screened secondary metabolites produced by endophytes isolated from non-flowering plants for NRF2-inducing properties. One of the extracts, ORX 41, increased both NRF2 protein expression and transcriptional activity markedly. These results suggest that endophytes isolated from non-flowering or other plants may be a good source of novel NRF2 inducing compounds.	[Wong, Daphne Pei Wen; Ng, Mei Ying; Leung, Jia Yu; Boh, Boon Kim; Lim, Ee Chien; Tan, Shi Hua; Lim, Shuying; Seah, Wen Hui; Hu, Christine Zhiwen; Hagen, Thilo] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore, Singapore; [Tan, Shi Hua] Natl Heart Ctr Singapore, Singapore, Singapore; [Ho, Boon Chuan] Natl Pk Board, Singapore Bot Gardens, Herbarium, Singapore, Singapore; [Ng, Daphne Hui Ping] Nanyang Technol Univ, Sch Civil & Environm Engn, Singapore, Singapore	National University of Singapore; National Heart Centre Singapore; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Hagen, T (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore, Singapore.; Ng, DHP (corresponding author), Nanyang Technol Univ, Sch Civil & Environm Engn, Singapore, Singapore.	daphneng@ntu.edu.sg; daphneng@ntu.edu.sg; bchth@nus.edu.sg	Ho, Boon-Chuan/ABC-5638-2021	Ho, Boon-Chuan/0000-0003-0530-775X				Baird L, 2013, P NATL ACAD SCI USA, V110, P15259, DOI 10.1073/pnas.1305687110; Baird L, 2013, BIOCHEM BIOPH RES CO, V433, P58, DOI 10.1016/j.bbrc.2013.02.065; Bascom-Slack CA, 2012, SCIENCE, V338, P485, DOI 10.1126/science.1215227; Chapla VM, 2014, MOLECULES, V19, P6597, DOI 10.3390/molecules19056597; Chew EH, 2007, J BIOL CHEM, V282, P17032, DOI 10.1074/jbc.M701153200; Cleasby A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098896; COOPERDRIVER G, 1977, SCIENCE, V198, P1260, DOI 10.1126/science.198.4323.1260; Dhakshinamoorthy S, 2004, J BIOL CHEM, V279, P20096, DOI 10.1074/jbc.M312492200; Eggler AL, 2009, BIOCHEM J, V422, P171, DOI 10.1042/BJ20090471; Ichikawa T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008391; Kansanen E, 2011, J BIOL CHEM, V286, P14019, DOI 10.1074/jbc.M110.190710; Li XC, 2014, TURK J BIOCHEM, V39, P30, DOI 10.5505/tjb.2014.65882; Lim JCW, 2012, CLIN EXP PHARMACOL P, V39, P300, DOI 10.1111/j.1440-1681.2011.05633.x; Norhajar Eswani, 2010, Journal of Agricultural Science (Toronto), V2, P189; Rachakonda G, 2008, CHEM RES TOXICOL, V21, P705, DOI 10.1021/tx700302s; Revathi R., 2013, PTERID RES, V2, P1; Stefanson AL, 2014, NUTRIENTS, V6, P3777, DOI 10.3390/nu6093777; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Tan WSD, 2017, BIOCHEM PHARMACOL, V139, P71, DOI 10.1016/j.bcp.2017.03.024; Trivedi P.C., 2009, MED PLANTS UTILISATI; Wang XJ, 2008, TOXICOL APPL PHARM, V230, P383, DOI 10.1016/j.taap.2008.03.003; WHO, WHO MON SEL MED PLAN, P12; Wong DPW, 2010, EUR J PHARMACOL, V643, P188, DOI 10.1016/j.ejphar.2010.06.040; Wong SY, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0723-3; Xia YF, 2004, J IMMUNOL, V173, P4207, DOI 10.4049/jimmunol.173.6.4207; Yang CH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081638; Yen TL, 2016, TRANSL RES, V170, P57, DOI 10.1016/j.trsl.2015.12.002; Yuan YL, 2012, FITOTERAPIA, V83, P1506, DOI 10.1016/j.fitote.2012.08.018; Zakaria ZA, 2011, AFR J BIOTECHNOL, V10, P273; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhao J, 2011, MINI-REV MED CHEM, V11, P159, DOI 10.2174/138955711794519492	32	14	15	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2018	13	10							e0204853	10.1371/journal.pone.0204853	http://dx.doi.org/10.1371/journal.pone.0204853			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV5EV	30273379	Green Published, gold			2023-01-03	WOS:000446124700042
J	Ware, D; Palella, FJ; Chew, KW; Friedman, MR; D'Souza, G; Ho, K; Plankey, M				Ware, Deanna; Palella, Frank J., Jr.; Chew, Kara W.; Friedman, M. Reuel; D'Souza, Gypsyamber; Ho, Ken; Plankey, Michael			Prevalence and trends of polypharmacy among HIV-positive and -negative men in the Multicenter AIDS Cohort Study from 2004 to 2016	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; DRUG-INTERACTIONS; MEDICATION USE; UNITED-STATES; OLDER-ADULTS; POPULATION; BURDEN; HEALTH; RISK; PARTICIPANTS	Rates of aging-related comorbidities, which require targeted medications to treat, have been shown to be increased among persons living with HIV compared with uninfected counterparts. Polypharmacy is generally defined as the concurrent use of 5 or more medications. We investigated polypharmacy prevalence for non-HIV medications over a 12-year period among HIV-positive and -negative participants in the Multicenter AIDS Cohort Study. Information regarding non-HIV medication use, HIV status, age, race/ethnicity, enrollment period, and medication insurance was obtained on 3,160 participants from semiannual visits between 2004 and 2016. Polypharmacy was defined as taking 5 or more non-HIV medications since the last health care visit. Generalized estimating equation models with repeated measures were produced overall and by HIV status to examine polypharmacy. The unadjusted prevalence of polypharmacy across all study visits was 18.6% and was higher among HIV-positive participants (24.4%) compared with HIV-negative participants (11.6%) (P< .0001). Among the 50 years and older age group, HIV-positive and HIV-negative participants had increases in polypharmacy over the observation period, from 38.4% to 46.8% (P = .0081) and from 16.7% to 46.0% (P < .0001), respectively. Among participants younger than 50, polypharmacy among HIV-positive participants remained stable (18.9% in 2004 to 17.3% in 2016; P= .5374) but increased among HIV-negative men (5.6% to 20.4%; P < .0001). After adjusting for age, race/ethnicity, and medication insurance, HIV-positive participants had a higher prevalence of polypharmacy than HIV-negative participants (25.3% vs 18.7%; P < .0001). Older age, white race, and having medication insurance coverage were also associated with greater polypharmacy. A convergence of polypharmacy prevalence was observed between HIV-positive and -negative participants at the end of observation. HIV-positive status was associated with an increased likelihood of polypharmacy, after adjusting for age, race/ethnicity, enrollment period, medication insurance, and study visit. Over time, polypharmacy prevalence increased among all participants, with converging rates between HIV-positive and -negative participants by the end of the observation period.	[Ware, Deanna; Plankey, Michael] Georgetown Univ, Med Ctr, Dept Infect Dis, Washington, DC 20007 USA; [Palella, Frank J., Jr.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Chew, Kara W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Friedman, M. Reuel] Univ Pittsburgh, Grad Sch Publ Hlth, Infect Dis & Microbiol, Pittsburgh, PA USA; [D'Souza, Gypsyamber] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Ho, Ken] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA	Georgetown University; Northwestern University; Feinberg School of Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ware, D (corresponding author), Georgetown Univ, Med Ctr, Dept Infect Dis, Washington, DC 20007 USA.	dpf38@georgetown.edu			Baltimore : Johns Hopkins University Bloomberg School of Public Health [U01-AI35042]; Chicago : Feinberg School of Medicine, Northwestern University [U01-AI35039]; Chicago : Cook County Bureau of Health Services [U01-AI35039]; Los Angeles : University of California, UCLA Schools of Public Health and Medicine [U01-AI35040]; Pittsburgh : University of Pittsburgh, Graduate School of Public Health [U01-AI35041]; Data Coordinating Center : Johns Hopkins University Bloomberg School of Public Health [UM1-AI35043]; Institute of Allergy and Infectious Diseases; National Cancer Institute (NCI); National Institute of Allergy and Infectious Diseases (NIAID); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH); National Heart, Lung, and Blood Institute (NHLBI); National Institute on Deafness and Communication Disorders (NIDCD); National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1-TR001079]; NIH Roadmap for Medical Research; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001079, KL2TR001882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH058107] Funding Source: NIH RePORTER	Baltimore : Johns Hopkins University Bloomberg School of Public Health; Chicago : Feinberg School of Medicine, Northwestern University; Chicago : Cook County Bureau of Health Services; Los Angeles : University of California, UCLA Schools of Public Health and Medicine; Pittsburgh : University of Pittsburgh, Graduate School of Public Health; Data Coordinating Center : Johns Hopkins University Bloomberg School of Public Health; Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute on Drug Abuse (NIDA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Deafness and Communication Disorders (NIDCD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Data in this manuscript were collected by the Multicenter AIDS Cohort Study (MACS) with centers at Baltimore (U01-AI35042): The Johns Hopkins University Bloomberg School of Public Health to MP; Chicago (U01-AI35039): Feinberg School of Medicine, Northwestern University, and Cook County Bureau of Health Services to FP; Los Angeles (U01-AI35040): University of California, UCLA Schools of Public Health and Medicine to KC; Pittsburgh (U01-AI35041): University of Pittsburgh, Graduate School of Public Health: KH, MF; Data Coordinating Center (UM1-AI35043): The Johns Hopkins University Bloomberg School of Public Health to GD. Institute of Allergy and Infectious Diseases: Robin E. Huebner; National Cancer Institute: Geraldina Dominguez. The MACS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID;https://www.niaid.nih.gov/), with additional co-funding from the National Cancer Institute (NCI;https://www.cancer.gov/), the National Institute on Drug Abuse (NIDA;https://www.drugabuse.gov/), and the National Institute of Mental Health (NIMH; https://www.nimh.nih.gov/index.shtml). Targeted supplemental funding for specific projects was also provided by the National Heart, Lung, and Blood Institute (NHLBI;https://www.nhlbi.nih.gov), and the National Institute on Deafness and Communication Disorders (NIDCD;https://www. nidcd.nih.gov). MACS data collection is also supported by UL1-TR001079 (JHU ICTR) from the National Center for Advancing Translational Sciences (NCATS;https://ncats.nih.gov/) a component of the National Institutes of Health (NIH; https://nih.gov/), and NIH Roadmap for Medical Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Althoff KN, 2014, J GERONTOL A-BIOL, V69, P189, DOI 10.1093/gerona/glt148; Detels R., 1992, J EPIDEMIOL, V2, P11, DOI [https://doi.org/10.2188/jea.2.2sup_11, DOI 10.2188/JEA.2.2SUP_11]; DUDLEY J, 1995, AM J EPIDEMIOL, V142, P323, DOI 10.1093/oxfordjournals.aje.a117638; Edelman EJ, 2013, DRUG AGING, V30, P613, DOI 10.1007/s40266-013-0093-9; Feeney Eoin R, 2011, Open Cardiovasc Med J, V5, P49, DOI 10.2174/1874192401105010049; Gimeno-Gracia M, 2016, CLIN INTERV AGING, V11, P1149, DOI 10.2147/CIA.S108072; Greene M, 2014, J AM GERIATR SOC, V62, P447, DOI 10.1111/jgs.12695; Gu QP, 2012, CIRCULATION, V126, P2105, DOI 10.1161/CIRCULATIONAHA.112.096156; Guaraldi G, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0789-0; Hasse B, 2011, CLIN INFECT DIS, V53, P1130, DOI 10.1093/cid/cir626; Holtzman C, 2013, J GEN INTERN MED, V28, P1302, DOI 10.1007/s11606-013-2449-6; Hovstadius B, 2012, CLIN GERIATR MED, V28, P159, DOI 10.1016/j.cger.2012.01.001; Justice AC, 2018, AIDS, V32, P739, DOI [10.1097/QAD.0000000000001756, 10.1097/qad.0000000000001756]; Justice Amy C, 2010, Curr HIV/AIDS Rep, V7, P69, DOI 10.1007/s11904-010-0041-9; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; Kleeberger CA, 2001, J ACQ IMMUN DEF SYND, V26, P82, DOI 10.1097/00126334-200101010-00012; Krentz HB, 2012, ANTIVIR THER, V17, P833, DOI 10.3851/IMP2076; Mann DM, 2009, ARCH INTERN MED, V169, P1718, DOI 10.1001/archinternmed.2009.296; Metkus TS, 2015, HIV MED, V16, P635, DOI 10.1111/hiv.12262; Petoumenos K, 2011, SEX HEALTH, V8, P465, DOI 10.1071/SH11020; Post WS, 2014, ANN INTERN MED, V160, P458, DOI 10.7326/M13-1754; Rodriguez-Penney AT, 2013, AIDS PATIENT CARE ST, V27, P5, DOI 10.1089/apc.2012.0329; Siefried KJ, 2018, AIDS, V32, P35, DOI [10.1097/QAD.0000000000001685, 10.1097/qad.0000000000001685]; So-Armah K, 2014, CURR OPIN HIV AIDS, V9, P346, DOI 10.1097/COH.0000000000000065	25	36	37	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2018	13	9							e0203890	10.1371/journal.pone.0203890	http://dx.doi.org/10.1371/journal.pone.0203890			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT2UM	30204807	Green Published, Green Submitted, gold			2023-01-03	WOS:000444355500054
J	Wen, ZJ; Chen, JY; Bian, LZ; Xie, AL; Peng, MQ; Li, M; Wei, L				Wen, Zunjia; Chen, Junyu; Bian, Lanzheng; Xie, Ailing; Peng, Mingqi; Li, Mei; Wei, Li			The nasal oxygen practice in intensive care units in China: A multi-centered survey	PLOS ONE			English	Article							MECHANICAL VENTILATION; THERAPY; ANESTHESIA; EMERGENCY; OPINION	Background Nurses frequently administer nasal oxygen therapy for patients in intensive care units (ICUs). However, little is known about the current status, nurses' management and perception on the nasal oxygen therapy in China. Therefore, we aimed to investigate the nasal oxygen practice of ICUs in China to provide insights into future direction. Methods A cross-sectional survey on 10 hospitals was conducted. A self-designed questionnaire was administered to ICU nurses. Descriptive statistics, univariate, and multiple stepwise regression analyses were performed to analyze the respondents' questionnaires. Results A total of 580 respondents with a response rate of 96.67% were included in this study. The average correct answer rate was 58.28%. The current status of nasal oxygen administration in ICUs in Chinese hospitals lagged behind the recommendations of related guidelines. Nurses in China were eager to learn about the updated knowledge on oxygen therapy. The gender, age, clinical experience, degree, job title, and classification of working hospitals were not related to the oxygen therapy-related knowledge scores (all P>0.05). Conclusion Many deficiencies are observed regarding the nasal oxygen practice in ICUs of Chinese hospitals. Increased efforts by authorities and medical staff are required to narrow the gap between the current status of oxygen practice and the recommendations from related guidelines.	[Wen, Zunjia; Chen, Junyu; Wei, Li] Nanjing Med Univ, SICU, Childrens Hosp, Nanjing, Jiangsu, Peoples R China; [Wen, Zunjia; Chen, Junyu; Bian, Lanzheng; Xie, Ailing; Peng, Mingqi; Li, Mei] Nanjing Med Univ, Nursing Dept, Childrens Hosp, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University	Wei, L (corresponding author), Nanjing Med Univ, SICU, Childrens Hosp, Nanjing, Jiangsu, Peoples R China.	13815889954@163.com						Asfar P, 2015, INTENS CARE MED, V41, P1118, DOI 10.1007/s00134-015-3670-z; Camporota L, 2015, MINERVA ANESTESIOL, V81, P1170; [楚姝 Chu Shu], 2016, [中国护理管理, Chinese Nursing Management], V16, P88; Eastwood GM, 2011, ANAESTH INTENS CARE, V39, P122, DOI 10.1177/0310057X1103900120; Eastwood GM, 2014, AUST CRIT CARE, V27, P120, DOI 10.1016/j.aucc.2013.11.004; Fang Yu-xia, 2013, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, V31, P753; Franchini ML, 2016, CHEST, V150, P407, DOI 10.1016/j.chest.2016.03.035; Galiatsatos P, 2017, NEW ENGL J MED, V376, P286, DOI 10.1056/NEJMc1615074; Gao, 2016, CHINESE J CRITICAL C, V2, P63; Girardis M, 2016, JAMA-J AM MED ASSOC, V316, P1583, DOI 10.1001/jama.2016.11993; Hafner S, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0084-6; Hickey Steven, 2007, Br J Nurs, V16, P1132; Kallstrom Thomas J, 2002, Respir Care, V47, P717; Kill C, 2013, ANASTH INTENSIV NOTF, V48, P84, DOI 10.1055/s-0032-1333087; La Fauci V, 2017, J Prev Med Hyg, V58, pE161; Liu Yangyun, 2010, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V24, P890; Mao C, 1999, CRIT CARE MED, V27, P2806, DOI 10.1097/00003246-199912000-00033; Martin Daniel, 2017, J Intensive Care Soc, V18, P279, DOI 10.1177/1751143717712162; Meyhoff CS, 2012, CURR OPIN ANESTHESIO, V25, P363, DOI 10.1097/ACO.0b013e328352b402; Niu YM, 2012, HUM EXP TOXICOL, V31, P126, DOI 10.1177/0960327111412806; O'Driscoll BR, 2017, BMJ OPEN RESPIR RES, V4, DOI 10.1136/bmjresp-2016-000170; Pannu SR, 2016, AM J RESP CRIT CARE, V193, P4, DOI 10.1164/rccm.201509-1810ED; Raman S, 2016, CRIT CARE RES PRACT, V2016, DOI 10.1155/2016/6312970; Renda T, 2018, BRIT J ANAESTH, V120, P18, DOI 10.1016/j.bja.2017.11.010; Ricard JD, 2009, INTENS CARE MED, V35, P963, DOI 10.1007/s00134-009-1457-9; Rush B, 2016, CHEST, V6, P23, DOI DOI 10.1016/J.CHEST.2016.06.023; Sun X, 2016, CHINESE J EVIDENCE B, V4, P1097; Templeton L, 1997, BRIT J GEN PRACT, V47, P91; Wen ZJ, 2017, J ADV NURS, V73, P2522, DOI 10.1111/jan.13323; Xiao A, 2011, CHINESE J MODERN NUR, V17, P3461; You L, 2017, INTERNAL MED NURSING; 张静, 2017, [中华医学杂志, National Medical Journal of China], V97, P1540; 남애리나, 2013, [Journal of Korean Academy of Nursing Administration, 간호행정학회지], V19, P87, DOI 10.11111/jkana.2013.19.1.87	33	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2018	13	8							e0203332	10.1371/journal.pone.0203332	http://dx.doi.org/10.1371/journal.pone.0203332			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS2NZ	30161225	gold, Green Published, Green Submitted			2023-01-03	WOS:000443388900112
J	Kamei, Y; Kamei, D; Tsuchiya, K; Mineshima, M; Nitta, K				Kamei, Yuiko; Kamei, Daigo; Tsuchiya, Ken; Mineshima, Michio; Nitta, Kosaku			Association between 4-year all-cause mortality and carnitine profile in maintenance hemodialysis patients	PLOS ONE			English	Article							FATTY-ACID OXIDATION; MITOCHONDRIAL BETA-OXIDATION; DIALYSIS THERAPY GUIDELINES; NUCLEAR HORMONE-RECEPTORS; CHRONIC KIDNEY-DISEASE; JAPANESE SOCIETY; SEPTIC SHOCK; RAT-LIVER; SEPSIS; METABOLISM	Background Patients on dialysis are in a chronic carnitine-deficient state. This condition may be associated with abnormalities of the fatty acid and organic acid metabolisms. Carnitine is required for beta-oxidation of the long-chain fatty acids; therefore, carnitine deficiency decreases the efficiency of ATP synthesis and may incur death. However, the details of this association remain unknown. We examined the relationship between beta-oxidation efficiency represented by the carnitine profile and 4-year all-cause mortality in hemodialysis patients. Methods The carnitine profiles of 122 hemodialysis patients were determined by liquid chromatography- tandem mass spectrometry (LC-MS/MS). The associations between the 4-year allcause mortality and carnitine profile as well as the clinical backgrounds of the patients were investigated. A survival analysis was conducted by the Kaplan +/- Meier survival method and multivariable Cox proportional hazard analysis. The bootstrap method was performed to confirm the stability and robustness of our model. Results Of the 122 subjects analyzed, 111 were selected and 24 died during the observation period. Stepwise multivariable Cox regression demonstrated that diabetes state [Hazard ratio (95% confidence interval), 4.981 (2.107 +/- 11.77)], age [HR (95% CI), 1.052 (1.014 +/- 1.091)], and the acetylcarnitine/(palmitoylcarnitine+ octadecenoylcarnitine) [C2/(C16+ C18: 1)] ratio [HR (95% CI), 0.937 (0.904 +/- 0.971)] were independent significant factors of 4-year all-cause mortality. The bootstrap method confirmed the significance of these three factors. Conclusion The 4-year all-cause mortality negatively correlated with the C2/(C16+C18: 1) ratio. Improvement of the impaired beta-oxidation state after L-carnitine administration may ameliorate prognosis.	[Kamei, Yuiko; Kamei, Daigo; Nitta, Kosaku] Tokyo Womens Med Univ, Dept Med, Kidney Ctr, Shinjuku Ku, Tokyo, Japan; [Kamei, Daigo; Mineshima, Michio] Tokyo Womens Med Univ, Kidney Ctr, Dept Blood Purificat, Tokyo, Japan; [Kamei, Daigo; Tsuchiya, Ken] Tokyo Womens Med Univ, Dept Clin Engn, Tokyo, Japan	Tokyo Women's Medical University; Tokyo Women's Medical University; Tokyo Women's Medical University	Kamei, D (corresponding author), Tokyo Womens Med Univ, Dept Med, Kidney Ctr, Shinjuku Ku, Tokyo, Japan.; Kamei, D (corresponding author), Tokyo Womens Med Univ, Kidney Ctr, Dept Blood Purificat, Tokyo, Japan.; Kamei, D (corresponding author), Tokyo Womens Med Univ, Dept Clin Engn, Tokyo, Japan.	Kamei-wak@umin.net	Kamei, Daigo/W-4853-2019					Afshinnia F, 2018, J AM SOC NEPHROL, V29, P295, DOI 10.1681/ASN.2017030350; Anthony Weil P., HARPERS ILLUSTRATED; Arts RJW, 2017, J LEUKOCYTE BIOL, V101, P151, DOI 10.1189/jlb.4MR0216-066R; Brealey David, 2003, Curr Infect Dis Rep, V5, P365, DOI 10.1007/s11908-003-0015-9; Chopra M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021285; CLSI, 2010, NBS04 CLSI; Eaton S, 1996, BIOCHEM J, V320, P345, DOI 10.1042/bj3200345; Evans A, 2003, AM J KIDNEY DIS, V41, pS13, DOI 10.1016/S0272-6386(03)00113-6; Feingold KR, 2008, J LIPID RES, V49, P2179, DOI 10.1194/jlr.M800233-JLR200; Feingold KR, 2009, J LIPID RES, V50, P2055, DOI 10.1194/jlr.M800655-JLR200; Flanagan JL, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-30; Fornasini G, 2007, BRIT J CLIN PHARMACO, V64, P335, DOI 10.1111/j.1365-2125.2007.02926.x; Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744-9987.12058; Hayashino Y, 2007, DIABETOLOGIA, V50, P1170, DOI 10.1007/s00125-007-0650-z; Higuchi T, 2016, AM J KIDNEY DIS, V67, P260, DOI 10.1053/j.ajkd.2015.09.010; Hirakata H, 2012, THER APHER DIAL, V16, P387, DOI 10.1111/j.1744-9987.2012.01088.x; HRYB DJ, 1979, BIOCHEM BIOPH RES CO, V87, P1200, DOI 10.1016/S0006-291X(79)80034-0; Hunter WG, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003190; Kalim S, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000542; Kamei D, 2018, NEPHROLOGY, V23, P737, DOI 10.1111/nep.13079; Kamei D, 2017, THER APHER DIAL, V21, P43, DOI 10.1111/1744-9987.12479; Langley RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005893; Liu TF, 2012, J BIOL CHEM, V287, P25758, DOI 10.1074/jbc.M112.362343; Matsumoto Y, 2000, AM J NEPHROL, V20, P201, DOI 10.1159/000013584; Murphy WJA, 2012, NEPHROL DIAL TRANSPL, V27, P304, DOI 10.1093/ndt/gfr334; Nakao T, 2015, THER APHER DIAL, V19, P40, DOI 10.1111/1744-9987.12299; NANNI G, 1985, JPEN-PARENTER ENTER, V9, P483, DOI 10.1177/0148607185009004483; Puskarich MA, 2015, ANN AM THORAC SOC, V12, P46, DOI 10.1513/AnnalsATS.201409-415OC; Reuter SE, 2009, NEPHROL DIAL TRANSPL, V24, P990, DOI 10.1093/ndt/gfn588; Ruiz M, 2017, AM J PHYSIOL-HEART C, V313, pH768, DOI 10.1152/ajpheart.00820.2016; Sakurabayashi T, 1999, AM J NEPHROL, V19, P480, DOI 10.1159/000013502; Sakurabayashi T, 2008, CIRC J, V72, P926, DOI 10.1253/circj.72.926; Schreiber Brian, 2005, Nutr Clin Pract, V20, P218, DOI 10.1177/0115426505020002218; SCHULZ H, 1994, J NUTR, V124, P165, DOI 10.1093/jn/124.2.165; Singer M, 2008, CLIN CHEST MED, V29, P655, DOI 10.1016/j.ccm.2008.06.003; TAKEYAMA N, 1990, AM J PHYSIOL, V259, pE498, DOI 10.1152/ajpendo.1990.259.4.E498; TAKEYAMA N, 1989, AM J PHYSIOL, V256, pE31, DOI 10.1152/ajpendo.1989.256.1.E31; Tappy L, 2007, CRIT CARE MED, V35, pS531, DOI 10.1097/01.CCM.0000278062.28122.A4; Tsubakihara Y, 2010, THER APHER DIAL, V14, P240, DOI 10.1111/j.1744-9987.2010.00836.x; Ueland T, 2013, INT J CARDIOL, V167, P1892, DOI 10.1016/j.ijcard.2012.04.150; Vary TC, 1999, MOL CELL BIOCHEM, V198, P113, DOI 10.1023/A:1006993910781; Vaz FM, 2002, BIOCHEM J, V361, P417, DOI 10.1042/0264-6021:3610417; Wahl P, 2016, AM J PHYSIOL-RENAL, V310, pF433, DOI 10.1152/ajprenal.00375.2015; Wasserstein RL, 2016, AM STAT, V70, P129, DOI 10.1080/00031305.2016.1154108; Watanabe Y, 2015, THER APHER DIAL, V19, P67, DOI 10.1111/1744-9987.12294; WINTER BK, 1995, BRIT J CANCER, V72, P1173, DOI 10.1038/bjc.1995.482; Wolfe RR, 1998, AM J CLIN NUTR, V67, p519S, DOI 10.1093/ajcn/67.3.519S; Wolfe RR, 2000, WORLD J SURG, V24, P639, DOI 10.1007/s002689910105; Yamamoto H., 2015, RENAL REPLACE THERAP, V3, P36, DOI [10.1186/s41100-017-0114-y, DOI 10.1186/S41100-017-0114-Y]; YAMAMOTO T, 1993, SURG TODAY, V23, P137, DOI 10.1007/BF00311231; Yoshihisa A, 2017, ESC HEART FAIL, V4, P360, DOI 10.1002/ehf2.12176	51	9	9	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2018	13	8							e0201591	10.1371/journal.pone.0201591	http://dx.doi.org/10.1371/journal.pone.0201591			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR3NR	30133480	Green Published, gold, Green Submitted			2023-01-03	WOS:000442500400026
J	Yuan, X				Yuan, Xun			China's vaccine production scare	LANCET			English	Editorial Material																			0	14	15	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 4	2018	392	10145					371	371		10.1016/S0140-6736(18)31725-2	http://dx.doi.org/10.1016/S0140-6736(18)31725-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GP1SM	30152367				2023-01-03	WOS:000440597100005
J	Schlom, J; Gulley, JL				Schlom, Jeffrey; Gulley, James L.			Vaccines as an Integral Component of Cancer Immunotherapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PHASE-I TRIAL		[Schlom, Jeffrey] NCI, Lab Tumor Immunol & Biol, Ctr Canc Res, NIH, 10 Ctr Dr,Room 8B09, Bethesda, MD 20852 USA; [Gulley, James L.] NCI, Genitourinary Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Gulley, James L.] NCI, Med Oncol Serv, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schlom, J (corresponding author), NCI, Lab Tumor Immunol & Biol, Ctr Canc Res, NIH, 10 Ctr Dr,Room 8B09, Bethesda, MD 20852 USA.	js141c@nih.gov	Gulley, James L/Y-7576-2019	Gulley, James L/0000-0002-6569-2912	NCI; EMD Serono; NantBioScience; NATIONAL CANCER INSTITUTE [ZIABC010425] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EMD Serono; NantBioScience; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Drs Schlom and Gulley reported that the research conducted at the Center for Cancer Research, National Cancer Institute (NCI), was supported in part by the NCI's collaborative research and development agreements with EMD Serono and NantBioScience. In addition, the NCI has financial relationships via collaborative research and development agreements with 6 other entities relevant to the research conducted at the Laboratory of Tumor Immunology and Biology. No other disclosures were reported.	Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; Boyerinas B, 2015, CANCER IMMUNOL RES, V3, P1148, DOI 10.1158/2326-6066.CIR-15-0059; Heery CR, 2015, CANCER IMMUNOL RES, V3, P1248, DOI 10.1158/2326-6066.CIR-15-0119; Iwai Y, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0329-9; Marconcini Riccardo, 2018, Oncotarget, V9, P12452, DOI 10.18632/oncotarget.23746; Pathangey LB, 2017, ONCOTARGET, V8, P10785, DOI 10.18632/oncotarget.13911; Rajabi H, 2017, BBA-REV CANCER, V1868, P117, DOI 10.1016/j.bbcan.2017.03.003; Small EJ, 2006, J CLIN ONCOL, V24, P3089, DOI 10.1200/JCO.2005.04.5252; Strauss J, 2018, CLIN CANCER RES, V24, P1287, DOI 10.1158/1078-0432.CCR-17-2653; Wong CH, 2019, BIOSTATISTICS, V20, P273, DOI 10.1093/biostatistics/kxx069	10	18	19	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	2018	320	21					2195	2196		10.1001/jama.2018.9511	http://dx.doi.org/10.1001/jama.2018.9511			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD4MB	30419097	Green Accepted			2023-01-03	WOS:000452500600004
J	Liang, Q; Monetti, C; Shutova, MV; Neely, EJ; Hacibekiroglu, S; Yang, HJ; Kim, C; Zhang, PZ; Li, CJ; Nagy, K; Mileikovsky, M; Gyongy, I; Sung, HK; Nagy, A				Liang, Qin; Monetti, Claudio; Shutova, Maria V.; Neely, Eric J.; Hacibekiroglu, Sabiha; Yang, Huijuan; Kim, Christopher; Zhang, Puzheng; Li, Chengjin; Nagy, Kristina; Mileikovsky, Maria; Gyongy, Istvan; Sung, Hoon-Ki; Nagy, Andras			Linking a cell-division gene and a suicide gene to define and improve cell therapy safety	NATURE			English	Article							EMBRYONIC STEM-CELLS; MUTATION-RATE; ES CELLS; MUTANT; CDK1; SUPPRESSION; EXPRESSION; FREQUENCY; LINES	Human pluripotent cell lines hold enormous promise for the development of cell-based therapies. Safety, however, is a crucial prerequisite condition for clinical applications. Numerous groups have attempted to eliminate potentially harmful cells through the use of suicide genes(1), but none has quantitatively defined the safety level of transplant therapies. Here, using genome-engineering strategies, we demonstrate the protection of a suicide system from inactivation in dividing cells. We created a transcriptional link between the suicide gene herpes simplex virus thymidine kinase (HSV-TK) and a cell-division gene (CDK1); this combination is designated the safe-cell system. Furthermore, we used a mathematical model to quantify the safety level of the cell therapy as a function of the number of cells that is needed for the therapy and the type of genome editing that is performed. Even with the highly conservative estimates described here, we anticipate that our solution will rapidly accelerate the entry of cell-based medicine into the clinic.	[Liang, Qin; Monetti, Claudio; Shutova, Maria V.; Neely, Eric J.; Hacibekiroglu, Sabiha; Yang, Huijuan; Kim, Christopher; Zhang, Puzheng; Li, Chengjin; Nagy, Kristina; Mileikovsky, Maria; Sung, Hoon-Ki; Nagy, Andras] Sinai Hlth Syst, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Liang, Qin; Neely, Eric J.; Hacibekiroglu, Sabiha; Kim, Christopher; Nagy, Andras] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Yang, Huijuan; Nagy, Kristina] Univ Toronto, Dept Physiol, Toronto, ON, Canada; [Gyongy, Istvan] Univ Edinburgh, Sch Math, Edinburgh, Midlothian, Scotland; [Gyongy, Istvan] Univ Edinburgh, Maxwell Inst, Edinburgh, Midlothian, Scotland; [Sung, Hoon-Ki] Hosp Sick Children Res Inst, Toronto, ON, Canada; [Nagy, Andras] Monash Univ, Australian Regenerat Med Inst, Melbourne, Vic, Australia; [Nagy, Andras] Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Edinburgh; Heriot Watt University; University of Edinburgh; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Australian Regenerative Medicine Institute; Monash University; University of Toronto	Nagy, A (corresponding author), Sinai Hlth Syst, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.; Nagy, A (corresponding author), Univ Toronto, Inst Med Sci, Toronto, ON, Canada.; Nagy, A (corresponding author), Monash Univ, Australian Regenerat Med Inst, Melbourne, Vic, Australia.; Nagy, A (corresponding author), Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON, Canada.	nagy@lunenfeld.ca	Nagy, Andras/G-6465-2013; Sung, Hoon-Ki/A-1922-2016	Nagy, Andras/0000-0003-4311-0413; Sung, Hoon-Ki/0000-0001-6677-9385	CIHR Foundation; Foundation Fighting Blindness; Canadian Research Chair; Medicine by Design (University of Toronto)	CIHR Foundation(Canadian Institutes of Health Research (CIHR)); Foundation Fighting Blindness(European Commission); Canadian Research Chair(Canada Research Chairs); Medicine by Design (University of Toronto)	We thank the TCP Transgenic Core and M. Gertsenstein for mouse line derivation; A. Bang for flow cytometry; the TCP Pathology Core and K. Harpal for histology analysis; M. Kownacka for providing MEFs; M. S. Shoichet for HAMC; N. Mitrousis for qPCR primers; S. Nurk for advice on Monte Carlo simulation; I. P. Michael, P. D. Tonge, B. V. Varga, C. He and R. El-Rass for experimental advice and J. S. Harding and K. C. Davidson for their proofreading of the manuscript, to J. S. Harding for the artwork in Fig. 4. This work was supported by CIHR Foundation Grant, Foundation Fighting Blindness, Canadian Research Chair and Medicine by Design (University of Toronto) funding to A.N.	Adewumi O, 2007, NAT BIOTECHNOL, V25, P803, DOI 10.1038/nbt1318; Barry J, 2015, CURR STEM CELL REP, V1, P110, DOI 10.1007/s40778-015-0011-7; Behringer R., 2013, MANIPULATING MOUSE E; Berger C, 2006, BLOOD, V107, P2294, DOI 10.1182/blood-2005-08-3503; Bianconi E, 2013, ANN HUM BIOL, V40, P463, DOI 10.3109/03014460.2013.807878; Biancotti JC, 2012, STEM CELL RES, V9, P218, DOI 10.1016/j.scr.2012.07.002; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; Cervantes RB, 2002, P NATL ACAD SCI USA, V99, P3586, DOI 10.1073/pnas.062527199; Chong JJH, 2014, NATURE, V510, P273, DOI 10.1038/nature13233; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Damjanov I, 2016, INT J DEV BIOL, V60, P337, DOI 10.1387/ijdb.160274id; Diril MK, 2012, P NATL ACAD SCI USA, V109, P3826, DOI 10.1073/pnas.1115201109; Dobie K, 1997, TRENDS GENET, V13, P127, DOI 10.1016/S0168-9525(97)01097-4; Fillat C., 2003, Current Gene Therapy, V3, P13, DOI 10.2174/1566523033347426; Gertsenstein M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011260; GREEN MHL, 1995, MUTAT RES-ENVIR MUTA, V334, P323, DOI 10.1016/0165-1161(95)90070-5; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420; Koike H, 2002, EMBO REP, V3, P433, DOI 10.1093/embo-reports/kvf097; Kotini AG, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2015.57; Larson JS, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-36; Li WQ, 2013, ORGANOGENESIS, V9, P34, DOI 10.4161/org.24317; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Luria SE, 1943, GENETICS, V28, P491; Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368; MEREAU A, 1993, J CELL BIOL, V122, P713, DOI 10.1083/jcb.122.3.713; Mesnil M, 2000, CANCER RES, V60, P3989; MONNAT RJ, 1989, CANCER RES, V49, P81; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Park J, 2010, AM J PATHOL, V177, P3133, DOI 10.2353/ajpath.2010.100595; Preuss E, 2010, HUM GENE THER, V21, P929, DOI 10.1089/hum.2009.042; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Satyanarayana A, 2008, DEVELOPMENT, V135, P3389, DOI 10.1242/dev.024919; Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3; Sun XN, 2013, CELL STEM CELL, V13, P230, DOI 10.1016/j.stem.2013.06.014; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tomicic MT, 2002, ONCOGENE, V21, P2141, DOI 10.1038/sj.onc.1205280; Wu SM, 2011, NAT CELL BIOL, V13, P497, DOI 10.1038/ncb0511-497; Yagyu S, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.3; Yusa K, 2004, NATURE, V429, P896, DOI 10.1038/nature02646	40	67	70	3	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 29	2018	563	7733					701	+		10.1038/s41586-018-0733-7	http://dx.doi.org/10.1038/s41586-018-0733-7			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC1YT	30429614				2023-01-03	WOS:000451599900057
J	Grenyer, BFS; Lewis, KL; Fanaian, M; Kotze, B				Grenyer, Brin F. S.; Lewis, Kate L.; Fanaian, Mahnaz; Kotze, Beth			Treatment of personality disorder using a whole of service stepped care approach: A cluster randomized controlled trial	PLOS ONE			English	Article							PSYCHIATRIC OUTPATIENTS; PREVALENCE	Background and objectives People with personality disorders are prevalent in emergency and inpatient mental health services. We examined whether implementing a stepped care model of psychological therapy reduces demand on hospital units by people with personality disorder, in a cluster randomized controlled trial. Method A total of 642 inpatients (average age 36.8, 50.5% female) with a primary ICD-10 personality disorder were recruited during 18 months baseline, then monitored during an 18 month active trial phase. In the active trial phase two equivalent sites were randomised to either treatment as usual (TAU), or a whole of service intervention that diverted people away from hospital and into stepped care psychological therapy clinics. The study design was cost neutral, with no additional staff or resources deployed between sites. A linear mixed models analysis evaluated outcomes. Results As predicted, demand on hospital services reduced significantly in the intervention compared to TAU site. The intervention site evidenced shorter bed days, from an average of 13.46 days at baseline to 4.28 days per admission, and patients were 1.3 times less likely to re-present to the emergency department compared to TAU. Direct cost savings for implementing the approach was estimated at USD$2,720 per patient per year. Limitations included not directly comparing individual symptom changes. Conclusions Using a whole of service stepped care model of treatment for personality disorder significantly reduced demand on hospital services.	[Grenyer, Brin F. S.; Lewis, Kate L.; Fanaian, Mahnaz] Univ Wollongong, Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia; [Grenyer, Brin F. S.; Lewis, Kate L.] Univ Wollongong, Sch Psychol, Wollongong, NSW, Australia; [Fanaian, Mahnaz] Univ Wollongong, Sch Nursing, Wollongong, NSW, Australia; [Kotze, Beth] NSW Minist Hlth, Sydney, NSW, Australia	University of Wollongong; University of Wollongong; University of Wollongong	Grenyer, BFS (corresponding author), Univ Wollongong, Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia.; Grenyer, BFS (corresponding author), Univ Wollongong, Sch Psychol, Wollongong, NSW, Australia.	grenyer@uow.edu.au	Grenyer, Brin FS/AAB-6452-2020	Grenyer, Brin FS/0000-0003-1501-4336; Fanaian, Mahnaz/0000-0003-2613-8465	New South Wales Ministry of Health	New South Wales Ministry of Health	This study is part of a larger project funded by New South Wales Ministry of Health (to Professor Brin F.S. Grenyer). The funding body provided the authors with the data, however had no role in the design, data analysis, or preparation of the manuscript. The funding body gave approval for the manuscript to be published.	Australian Institute of Health and Welfare, 2014, AUSTR REF DIAGN REL; Bailey RC, 2014, J PERS DISORD, V28, P796, DOI 10.1521/pedi_2014_28_136; Beckwith H, 2014, PERSONAL MENT HEALTH, V8, P91, DOI 10.1002/pmh.1252; Bender DS, 2001, AM J PSYCHIAT, V158, P295, DOI 10.1176/appi.ajp.158.2.295; Bland J Martin, 2004, BMC Med Res Methodol, V4, P21, DOI 10.1186/1471-2288-4-21; Borschmann R, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009353.pub2; Bourke ME, 2017, J PSYCHIATR PRACT, V23, P246, DOI 10.1097/PRA.0000000000000247; Bower P, 2005, BRIT J PSYCHIAT, V186, P11, DOI 10.1192/bjp.186.1.11; Cailhol L, 2013, J PERS DISORD, V27, P252, DOI 10.1521/pedi.2013.27.2.252; Campbell MK, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5661; Commonwealth of Australia, 1993, NAT MENT HLTH PLAN; Cristea IA, 2017, JAMA PSYCHIAT, V74, P319, DOI 10.1001/jamapsychiatry.2016.4287; Day NJS, 2018, PERSONAL MENT HEALTH, V12, P309, DOI 10.1002/pmh.1429; Fanaian M, 2013, INT J MENT HEALTH NU, V22, P465, DOI 10.1111/inm.12009; Grenyer BFS., 2014, ACPARIAN, V9, P8; Grenyer BFS, 2018, AUST NZ J PSYCHIAT, V52, P202, DOI 10.1177/0004867417741984; Grenyer BFS, 2013, MED J AUSTRALIA, V198, P464, DOI 10.5694/mja13.10470; Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310; Holmes Alex, 2006, Australas Psychiatry, V14, P272, DOI 10.1111/j.1440-1665.2006.02284.x; Kealy D, 2010, J PSYCHIATR PRACT, V16, P145, DOI 10.1097/01.pra.0000375710.39713.4d; Korzekwa MI, 2008, COMPR PSYCHIAT, V49, P380, DOI 10.1016/j.comppsych.2008.01.007; Laporte L, 2018, PERSONAL MENT HEALTH, V12, P252, DOI 10.1002/pmh.1421; Leichsenring F, 2011, LANCET, V377, P74, DOI 10.1016/S0140-6736(10)61422-5; Leontieva L, 2013, J PERS DISORD, V27, P222, DOI 10.1521/pedi.2013.27.2.222; Meuldijk D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171592; Milner AJ, 2015, BRIT J PSYCHIAT, V206, P184, DOI 10.1192/bjp.bp.114.147819; *NAT I MENT HLTH E, 2003, PERS DIS NO LONG DIA; National Centre for Classification in Health, 2010, AUSTR CLASS HLTH INT; National Health and Medical Research Council, 2012, CLIN PRACT GUID MAN; National Institute for Health and Care Excellence, 2009, BORDERLINE PERSONALI; New South Wales Department of Health, 2001, YOUR GUID MH OAT CLI; Paris J, 2013, PSYCHIAT SERV, V64, P1035, DOI 10.1176/appi.ps.201200451; Project Air Strategy for Personality Disorders, 2015, TREATM GUID PERS DIS, DOI [10.1037/per0000091, DOI 10.1037/PER0000091]; Project Air Strategy for Personality Disorders, 2015, PROJ AIR STRAT PERS; Reserve Bank of Australia, 2018, EXCH RAT DAIL 2010 2; Shaikh U, 2017, FRONT PSYCHIATRY, V8, DOI 10.3389/fpsyt.2017.00136; Tyrer P, 2010, WORLD PSYCHIATRY, V9, P56; Wilhelm K, 2007, AUSTRALAS PSYCHIATRY, V15, P35, DOI 10.1080/10398560601083068; World Health Organization, 2004, ICD 10 INT STAT CLAS; Zimmerman M, 2005, AM J PSYCHIAT, V162, P1911, DOI 10.1176/appi.ajp.162.10.1911	40	28	29	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2018	13	11							e0206472	10.1371/journal.pone.0206472	http://dx.doi.org/10.1371/journal.pone.0206472			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GZ4NU	30399184	Green Published, gold, Green Submitted			2023-01-03	WOS:000449374000013
J	Wagner, FB; Mignardot, JB; Le Goff-Mignardot, CG; Demesmaeker, R; Komi, S; Capogrosso, M; Rowald, A; Seanez, I; Caban, M; Pirondini, E; Vat, M; McCracken, LA; Heimgartner, R; Fodor, I; Watrin, A; Seguin, P; Paoles, E; Van Den Keybus, K; Eberle, G; Schurch, B; Pralong, E; Becce, F; Prior, J; Buse, N; Buschman, R; Neufeld, E; Kuster, N; Carda, S; von Zitzewitz, J; Delattre, V; Denison, T; Lambert, H; Minassian, K; Bloch, J; Courtine, G				Wagner, Fabien B.; Mignardot, Jean-Baptiste; Le Goff-Mignardot, Camille G.; Demesmaeker, Robin; Komi, Salif; Capogrosso, Marco; Rowald, Andreas; Seanez, Ismael; Caban, Miroslav; Pirondini, Elvira; Vat, Molywan; McCracken, Laura A.; Heimgartner, Roman; Fodor, Isabelle; Watrin, Anne; Seguin, Perrine; Paoles, Edoardo; Van Den Keybus, Katrien; Eberle, Gregoire; Schurch, Brigitte; Pralong, Etienne; Becce, Fabio; Prior, John; Buse, Nicholas; Buschman, Rik; Neufeld, Esra; Kuster, Niels; Carda, Stefano; von Zitzewitz, Joachim; Delattre, Vincent; Denison, Tim; Lambert, Hendrik; Minassian, Karen; Bloch, Jocelyne; Courtine, Gregoire			Targeted neurotechnology restores walking in humans with spinal cord injury	NATURE			English	Article							EPIDURAL ELECTRICAL-STIMULATION; RANDOMIZED CLINICAL-TRIAL; ACTIVITY-BASED THERAPY; CIRCUIT REORGANIZATION; MOTOR FUNCTION; RECOVERY; LOCOMOTION; NEUROMODULATION; PLASTICITY; EXCITABILITY	Spinal cord injury leads to severe locomotor deficits or even complete leg paralysis. Here we introduce targeted spinal cord stimulation neurotechnologies that enabled voluntary control of walking in individuals who had sustained a spinal cord injury more than four years ago and presented with permanent motor deficits or complete paralysis despite extensive rehabilitation. Using an implanted pulse generator with real-time triggering capabilities, we delivered trains of spatially selective stimulation to the lumbosacral spinal cord with timing that coincided with the intended movement. Within one week, this spatiotemporal stimulation had re-established adaptive control of paralysed muscles during overground walking. Locomotor performance improved during rehabilitation. After a few months, participants regained voluntary control over previously paralysed muscles without stimulation and could walk or cycle in ecological settings during spatiotemporal stimulation. These results establish a technological framework for improving neurological recovery and supporting the activities of daily living after spinal cord injury.	[Wagner, Fabien B.; Mignardot, Jean-Baptiste; Le Goff-Mignardot, Camille G.; Demesmaeker, Robin; Komi, Salif; Rowald, Andreas; Seanez, Ismael; Pirondini, Elvira; McCracken, Laura A.; Heimgartner, Roman; Seguin, Perrine; Minassian, Karen; Courtine, Gregoire] Swiss Fed Inst Technol EPFL, Sch Life Sci, Ctr Neuroprosthet & Brain Mind Inst, Lausanne, Switzerland; [Wagner, Fabien B.; Mignardot, Jean-Baptiste; Le Goff-Mignardot, Camille G.; Demesmaeker, Robin; Komi, Salif; Rowald, Andreas; Seanez, Ismael; Pirondini, Elvira; McCracken, Laura A.; Heimgartner, Roman; Fodor, Isabelle; Seguin, Perrine; Van Den Keybus, Katrien; Eberle, Gregoire; Schurch, Brigitte; Carda, Stefano; Minassian, Karen; Bloch, Jocelyne; Courtine, Gregoire] Lausanne Univ Hosp CHUV, Dept Clin Neurosci, Lausanne, Switzerland; [Capogrosso, Marco] Univ Fribourg, Dept Neurosci & Movement Sci, Platform Translat Neurosci, Fribourg, Switzerland; [Caban, Miroslav; Watrin, Anne; Paoles, Edoardo; von Zitzewitz, Joachim; Delattre, Vincent; Lambert, Hendrik] GTXmedical, Lausanne, Switzerland; [Caban, Miroslav] Swiss Fed Inst Technol EPFL, Inst Bioengn, Lausanne, Switzerland; [Pirondini, Elvira] Univ Geneva, Dept Radiol & Med Informat, Geneva, Switzerland; [Vat, Molywan; Pralong, Etienne; Bloch, Jocelyne; Courtine, Gregoire] Lausanne Univ Hosp CHUV, Dept Neurosurg, Lausanne, Switzerland; [Becce, Fabio] Lausanne Univ Hosp CHUV, Dept Diagnost & Intervent Radiol, Lausanne, Switzerland; [Prior, John] Lausanne Univ Hosp CHUV, Dept Nucl Med & Mol Imaging, Lausanne, Switzerland; [Buse, Nicholas; Buschman, Rik; Denison, Tim] Medtronic, Minneapolis, MN USA; [Neufeld, Esra; Kuster, Niels] Fdn Res Informat Technol Soc ITIS, Zurich, Switzerland; [Kuster, Niels] Swiss Fed Inst Technol ETHZ, Dept Informat Technol & Elect Engn, Zurich, Switzerland; [Denison, Tim] Univ Oxford, Dept Engn Sci, Oxford, England; [Bloch, Jocelyne; Courtine, Gregoire] Univ Lausanne UNIL, Fac Biol & Med, Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Fribourg; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Medtronic; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Oxford; University of Lausanne	Courtine, G (corresponding author), Swiss Fed Inst Technol EPFL, Sch Life Sci, Ctr Neuroprosthet & Brain Mind Inst, Lausanne, Switzerland.; Courtine, G (corresponding author), Lausanne Univ Hosp CHUV, Dept Clin Neurosci, Lausanne, Switzerland.; Courtine, G (corresponding author), Lausanne Univ Hosp CHUV, Dept Neurosurg, Lausanne, Switzerland.; Courtine, G (corresponding author), Univ Lausanne UNIL, Fac Biol & Med, Lausanne, Switzerland.	gregoire.courtine@epfl.ch	Wagner, Fabien/ABC-4084-2020; Seanez-Gonzalez, Ismael/N-1746-2014; Seáñez, Ismael/AAS-7910-2021; Becce, Fabio/I-6781-2019; PRIOR, John O/I-5364-2017; Bloch, Jocelyne/A-9668-2017	Wagner, Fabien/0000-0002-9582-6109; Seanez-Gonzalez, Ismael/0000-0003-0068-7124; Seáñez, Ismael/0000-0003-0068-7124; Becce, Fabio/0000-0001-8444-8504; PRIOR, John O/0000-0003-1429-1374; Bloch, Jocelyne/0000-0002-6405-1590; Carda, Stefano/0000-0001-7849-1290; Demesmaeker, Robin/0000-0003-0856-0929; Denison, Timothy/0000-0002-5404-4004; Komi, Salif/0000-0002-2655-6213; Rowald, Andreas/0000-0001-5493-195X; Kuster, Niels/0000-0002-5827-3728; courtine, gregoire/0000-0002-5744-4142; Minassian, Karen/0000-0003-4197-6141; McCracken, Laura/0000-0003-1663-2558	International Foundation for Research in Paraplegia (IRP); Wings for Life; Wyss Center for Neuroengineering; European Union's Horizon 2020 [785907]; Eurostars [E10889]; GTXmedical; National Center of Competence in Research (NCCR) Robotics of the Swiss National Foundation; Commission of Technology and Innovation Innosuisse (CTI) [25761.1]; Voirol Foundation; Firmenich Foundation; Pictet Group Charitable Foundation; Panacee Foundation; riders4riders; SOFMER; Whitaker International Scholars Program; H2020-MSCA-COFUND-2015 EPFL Fellows program [665667]	International Foundation for Research in Paraplegia (IRP); Wings for Life; Wyss Center for Neuroengineering; European Union's Horizon 2020; Eurostars; GTXmedical; National Center of Competence in Research (NCCR) Robotics of the Swiss National Foundation; Commission of Technology and Innovation Innosuisse (CTI); Voirol Foundation; Firmenich Foundation; Pictet Group Charitable Foundation; Panacee Foundation; riders4riders; SOFMER; Whitaker International Scholars Program; H2020-MSCA-COFUND-2015 EPFL Fellows program	See Supplementary Notes. Support: International Foundation for Research in Paraplegia (IRP), Wings for Life, Wyss Center for Neuroengineering, European Union's Horizon 2020 No. 785907 (Human Brain Project SGA2), Eurostars No. E10889, GTXmedical, National Center of Competence in Research (NCCR) Robotics of the Swiss National Foundation, the Commission of Technology and Innovation Innosuisse (CTI) No. 25761.1, Voirol Foundation, Firmenich Foundation, Pictet Group Charitable Foundation, Panacee Foundation, riders4riders, SOFMER (to P.S.), the Whitaker International Scholars Program (to I.S.) and the H2020-MSCA-COFUND-2015 EPFL Fellows program (No. 665667 to F.B.W.).	Angeli CA, 2018, NEW ENGL J MED, V379, P1244, DOI 10.1056/NEJMoa1803588; Angeli CA, 2014, BRAIN, V137, P1394, DOI 10.1093/brain/awu038; ASANUMA H, 1989, JPN J PHYSIOL, V39, P1, DOI 10.2170/jjphysiol.39.1; Asboth L, 2018, NAT NEUROSCI, V21, P576, DOI 10.1038/s41593-018-0093-5; BAROLAT G, 1986, APPL NEUROPHYSIOL, V49, P307; Behrman AL, 2017, J NEUROL PHYS THER, V41, pS39, DOI 10.1097/NPT.0000000000000184; Borton D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005968; Capogrosso M, 2018, NAT PROTOC, V13, P2031, DOI 10.1038/s41596-018-0030-9; Capogrosso M, 2016, NATURE, V539, P284, DOI 10.1038/nature20118; Capogrosso M, 2013, J NEUROSCI, V33, P19326, DOI 10.1523/JNEUROSCI.1688-13.2013; Cappellini G, 2010, J NEUROPHYSIOL, V104, P3064, DOI 10.1152/jn.00318.2010; Carhart MR, 2004, IEEE T NEUR SYS REH, V12, P32, DOI 10.1109/TNSRE.2003.822763; Cote MP, 2017, J NEUROTRAUM, V34, P1841, DOI 10.1089/neu.2016.4577; Danner SM, 2015, BRAIN, V138, P577, DOI 10.1093/brain/awu372; Dietz V, 2010, NAT REV NEUROL, V6, P167, DOI 10.1038/nrneurol.2009.227; Dominici N, 2012, NAT MED, V18, P1142, DOI 10.1038/nm.2845; Edgerton VR, 2008, BRAIN RES REV, V57, P241, DOI 10.1016/j.brainresrev.2007.09.002; Field-Fote Edelle C, 2005, J Neurol Phys Ther, V29, P127; Field-Fote EC, 2011, PHYS THER, V91, P48, DOI 10.2522/ptj.20090359; Formento E, 2018, NAT NEUROSCI, V21, P1728, DOI 10.1038/s41593-018-0262-6; Gerasimenko Y, 2008, EXP NEUROL, V209, P417, DOI 10.1016/j.expneurol.2007.07.015; Gill ML, 2018, NAT MED, V24, P1677, DOI 10.1038/s41591-018-0175-7; Gourab K, 2010, CLIN NEUROPHYSIOL, V121, P2017, DOI 10.1016/j.clinph.2010.05.012; Grahn PJ, 2017, MAYO CLIN PROC, V92, P544, DOI 10.1016/j.mayocp.2017.02.014; Herrity AN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26602-2; Holtmaat A, 2009, NAT REV NEUROSCI, V10, P647, DOI 10.1038/nrn2699; Jones ML, 2014, ARCH PHYS MED REHAB, V95, P2239, DOI 10.1016/j.apmr.2014.07.400; Mignardot JB, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3621; Minassian K, 2004, SPINAL CORD, V42, P401, DOI 10.1038/sj.sc.3101615; Minassian K, 2016, NEUROTHERAPEUTICS, V13, P284, DOI 10.1007/s13311-016-0421-y; Moraud EM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18293-y; Moraud EM, 2016, NEURON, V89, P814, DOI 10.1016/j.neuron.2016.01.009; Nishimura Y, 2013, NEURON, V80, P1301, DOI 10.1016/j.neuron.2013.08.028; Perez MA, 2003, J NEUROSCI, V23, P2014; Rattay F, 2000, SPINAL CORD, V38, P473, DOI 10.1038/sj.sc.3101039; SCHIEPPATI M, 1987, PROG NEUROBIOL, V28, P345, DOI 10.1016/0301-0082(87)90007-4; Schindler-Ivens S, 2000, EXP BRAIN RES, V133, P233, DOI 10.1007/s002210000377; SHARRARD W J, 1964, Ann R Coll Surg Engl, V35, P106; Takeoka A, 2014, CELL, V159, P1626, DOI 10.1016/j.cell.2014.11.019; Urbin MA, 2017, J NEUROPHYSIOL, V118, P2171, DOI 10.1152/jn.00111.2017; van den Brand R, 2012, SCIENCE, V336, P1182, DOI 10.1126/science.1217416; van Middendorp JJ, 2011, LANCET, V377, P1004, DOI 10.1016/S0140-6736(10)62276-3; Wenger N, 2016, NAT MED, V22, P138, DOI 10.1038/nm.4025; Wenger N, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008325; West CR, 2018, JAMA NEUROL, V75, P630, DOI 10.1001/jamaneurol.2017.5055; Yakovenko S, 2002, J NEUROPHYSIOL, V87, P1542, DOI 10.1152/jn.00479.2001	46	401	427	30	282	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 1	2018	563	7729					65	+		10.1038/s41586-018-0649-2	http://dx.doi.org/10.1038/s41586-018-0649-2			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY8RS	30382197				2023-01-03	WOS:000448900900046
J	Sibbritt, D; Peng, WB; Lauche, R; Ferguson, C; Frawley, J; Adams, J				Sibbritt, David; Peng, Wenbo; Lauche, Romy; Ferguson, Caleb; Frawley, Jane; Adams, Jon			Efficacy of acupuncture for lifestyle risk factors for stroke: A systematic review	PLOS ONE			English	Review							ASIAN YOUNG-ADULTS; AURICULAR ACUPRESSURE; SMOKING-CESSATION; WEIGHT-REDUCTION; BLOOD-PRESSURE; ACUPOINT STIMULATION; OBESE WOMEN; ALCOHOL-WITHDRAWAL; RANDOMIZED-TRIAL; DOUBLE-BLIND	Background Modifications to lifestyle risk factors for stroke may help prevent stroke events. This systematic review aimed to identify and summarise the evidence of acupuncture interventions for those people with lifestyle risk factors for stroke, including alcohol-dependence, smoking-dependence, hypertension, and obesity. Methods MEDLINE, CINAHL/EBSCO, SCOPUS, and Cochrane Database were searched from January 1996 to December 2016. Only randomised controlled trials (RCTs) with empirical research findings were included. PRISMA guidelines were followed and risk of bias was assessed via the Cochrane Collaboration risk of bias assessment tool. The systematic review reported in this paper has been registered on the PROSPERO (#CRD42017060490). Results A total of 59 RCTs (5,650 participants) examining the use of acupuncture in treating lifestyle risk factors for stroke met the inclusion criteria. The seven RCTs focusing on alcohol-dependence showed substantial heterogeneity regarding intervention details. No evidence from meta-analysis has been found regarding post-intervention or long-term effect on blood pressure control for acupuncture compared to sham intervention. Relative to sham acupuncture, individuals receiving auricular acupressure for smoking-dependence reported lower numbers of consumed cigarettes per day (two RCTs, mean difference (MD) = -2.75 cigarettes/day; 95% confidence interval (CI) = -5.33, -0.17; p = 0.04). Compared to sham acupuncture those receiving acupuncture for obesity reported lower waist circumference (five RCTs, MD = -2.79 cm; 95% CI: -4.13, -1.46; p<0.001). Overall, only few trials were considered of low risk of bias for smoking-dependence and obesity, and as such none of the significant effects in favour of acupuncture interventions were robust against potential selection, performance, and detection bias. Conclusions This review found no convincing evidence for effects of acupuncture interventions for improving lifestyle risk factors for stroke.	[Sibbritt, David; Peng, Wenbo; Lauche, Romy; Frawley, Jane; Adams, Jon] Univ Technol Sydney, Fac Hlth, ARCCIM, Sydney, NSW, Australia; [Ferguson, Caleb] Western Sydney Univ, Nursing Res Ctr, Sydney, NSW, Australia; [Ferguson, Caleb] Blacktown Hosp, Western Sydney Local Hlth Dist, Blacktown Clin & Res Sch, Sydney, NSW, Australia	University of Technology Sydney; Western Sydney University; Blacktown & Mount Druitt Hospital	Sibbritt, D (corresponding author), Univ Technol Sydney, Fac Hlth, ARCCIM, Sydney, NSW, Australia.	David.Sibbritt@uts.edu.au	Sibbritt, David W/F-8070-2017; Ferguson, Caleb/G-4972-2015; Lauche, Romy/AAQ-7175-2021; Frawley, Jane/G-4476-2016; Peng, Wenbo/J-6322-2016	Sibbritt, David W/0000-0003-3561-9447; Ferguson, Caleb/0000-0002-2417-2216; Lauche, Romy/0000-0002-4171-7935; Frawley, Jane/0000-0001-6037-0140; Peng, Wenbo/0000-0001-9747-2466	Nancy and Vic Allen Stroke Prevention Fund	Nancy and Vic Allen Stroke Prevention Fund	This work was supported by the Nancy and Vic Allen Stroke Prevention Fund. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdi H, 2012, SCI WORLD J, DOI 10.1100/2012/603539; Au DWH, 2015, ACUPUNCT MED, V33, P353, DOI 10.1136/acupmed-2014-010720; Baccetti S, 2015, ACUPUNCT RELAT THER, V3, P48, DOI 10.1016/j.arthe.2016.05.002; Belivani M, 2013, ACUPUNCT MED, V31, P88, DOI 10.1136/acupmed-2012-010247; Bier ID, 2002, AM J PUBLIC HEALTH, V92, P1642, DOI 10.2105/AJPH.92.10.1642; Bullock ML, 2002, J SUBST ABUSE TREAT, V22, P71, DOI 10.1016/S0740-5472(01)00217-3; Cai YM, 2000, AM J CHINESE MED, V28, P443, DOI 10.1142/S0192415X00000520; Cerniauskaite M, 2012, AM J PHYS MED REHAB, V91, pS39, DOI 10.1097/PHM.0b013e31823d4df7; Chae Y, 2010, NEUROL RES, V32, pS27, DOI 10.1179/016164109X12537002793805; Chen HY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/808971; Chmielnicki B., 2016, EVIDENCE BASED ACUPU; Cho SH, 2009, ALCOHOL CLIN EXP RES, V33, P1305, DOI 10.1111/j.1530-0277.2009.00959.x; Darbandi M, 2014, J DIABETES METAB DIS, V13, DOI 10.1186/s40200-014-0092-3; Darbandi M, 2012, ACUPUNCT MED, V30, P208, DOI 10.1136/acupmed-2011-010121; Elder C, 2007, J ALTERN COMPLEM MED, V13, P67, DOI 10.1089/acm.2006.6237; Feigin VL, 2016, NAT REV NEUROL, V12, P501, DOI 10.1038/nrneurol.2016.107; Flachskampf FA, 2007, CIRCULATION, V115, P3121, DOI 10.1161/CIRCULATIONAHA.106.661140; Fritz DJ, 2013, J AM BOARD FAM MED, V26, P61, DOI 10.3122/jabfm.2013.01.120157; Gee ME, 2012, AM J CARDIOL, V109, P570, DOI 10.1016/j.amjcard.2011.09.051; Georgiou AJ, 1998, J SUBST ABUSE, V10, P265, DOI 10.1016/S0899-3289(99)00005-X; GORELICK PB, 1994, STROKE, V25, P220, DOI 10.1161/01.STR.25.1.220; Guo YF, 2014, ACUPUNCT MED, V32, P313, DOI 10.1136/acupmed-2014-010530; He D, 1997, PREV MED, V26, P208, DOI 10.1006/pmed.1996.0125; He D, 2001, PREV MED, V33, P364, DOI 10.1006/pmed.2001.0901; He JF, 2015, J ACUPUNCT MERIDIAN, V8, P61, DOI 10.1016/j.jams.2014.08.001; He W, 2012, MED ACUPUNCT, V24, P227, DOI 10.1089/acu.2012.0881; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hsieh CH, 2012, AM J CHINESE MED, V40, P713, DOI 10.1142/S0192415X1250053X; Hsieh CH, 2011, AM J CHINESE MED, V39, P433, DOI 10.1142/S0192415X11008932; Hsieh CH, 2010, AM J CHINESE MED, V38, P675, DOI 10.1142/S0192415X10008147; Hsieh CH, 2007, MED ACUPUNCT, V19, P181, DOI 10.1089/acu.2007.0542; Hsu CH, 2005, J WOMENS HEALTH, V14, P434, DOI 10.1089/jwh.2005.14.434; Hsu CH, 2009, J WOMENS HEALTH, V18, P813, DOI 10.1089/jwh.2008.1005; Jiao C, 2015, INT J CLIN EXP MED, V8, P11317; Karst M, 2002, ADDICT BIOL, V7, P415, DOI 10.1080/1355621021000006017; Kim D, 2014, J ALTERN COMPLEM MED, V20, P258, DOI 10.1089/acm.2012.0283; Kim HM, 2012, J ALTERN COMPLEM MED, V18, P918, DOI 10.1089/acm.2011.0508; Kunz S, 2007, ALCOHOL CLIN EXP RES, V31, P436, DOI 10.1111/j.1530-0277.2006.00333.x; Lambert C, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen074; Langevin HM, 2015, J ALTERN COMPLEM MED, V21, P113, DOI 10.1089/acm.2014.0186; Lee H, 2009, AM J HYPERTENS, V22, P122, DOI 10.1038/ajh.2008.311; Lee JS, 2015, CHIN J INTEGR MED, V21, P307, DOI 10.1007/s11655-014-1851-1; Lewith G., 1995, COMPLEMENT THER MED, V3, P142; Li P, 2015, MED ACUPUNCT, V27, P253, DOI 10.1089/acu.2015.1106; Lien CY, 2012, EUR J INTEGR MED, V4, pE45, DOI 10.1016/j.eujim.2011.12.002; Lin GH, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/1549658; Liu Y, 2015, COMPLEMENT THER MED, V23, P658, DOI 10.1016/j.ctim.2015.06.014; Luo J, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0676-6; Macklin EA, 2006, HYPERTENSION, V48, P838, DOI 10.1161/01.HYP.0000241090.28070.4c; Mazzoni R, 1999, Eat Weight Disord, V4, P198; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; National Center for Complementary and Integrative Health, 2016, AC IN DEPTH; National Center for Complementary and Integrative Health, 2015, AC RES AR HIGH LOW P; Nourshahi M, 2009, INT J OBESITY, V33, P583, DOI 10.1038/ijo.2009.41; Rampes H., 1997, COMPLEMENT THER MED, V5, P19; Rerksuppaphol Lakkana, 2012, J Med Assoc Thai, V95 Suppl 12, pS32; Rerksuppaphol L, 2011, INT J COLLAB RES INT, V3, P811; Richards D, 1998, AUST FAM PHYSICIAN, V27, P73; Sapir-Weise R, 1999, ALCOHOL ALCOHOLISM, V34, P629, DOI 10.1093/alcalc/34.4.629; Schukro RP, 2014, COMPLEMENT THER MED, V22, P21, DOI 10.1016/j.ctim.2013.10.002; Sriloy M, 2015, ACUPUNCT RELAT THER, V3, P15, DOI 10.1016/j.arthe.2015.08.001; Stroke Foundation, 2017, STROK RISK FACT; Tong J, 2010, ZHONGGUO LINCHUANG K, V27, P579; Trumpler F, 2003, ALCOHOL ALCOHOLISM, V38, P369, DOI 10.1093/alcalc/agg091; Waite NR, 1998, BRIT J GEN PRACT, V48, P1487; White Adrian R, 2007, BMC Complement Altern Med, V7, P8, DOI 10.1186/1472-6882-7-8; White AR, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000009.pub4; White AR, 1998, ARCH INTERN MED, V158, P2251, DOI 10.1001/archinte.158.20.2251; Wing YK, 2010, MED ACUPUNCT, V22, P265, DOI 10.1089/acu.2010.0763; World Health Organization, 2002, AC REV AN REP CONTR; Wu J, 2014, J TRADIT CHIN MED, V34, P274, DOI 10.1016/S0254-6272(14)60090-X; Wu Ta-Peng, 2007, J Chin Med Assoc, V70, P331, DOI 10.1016/S1726-4901(08)70014-5; Yeh CH, 2008, J ALTERN COMPLEM MED, V14, P309, DOI 10.1089/acm.2007.0678; Yeh ML, 2015, WESTERN J NURS RES, V37, P1517, DOI 10.1177/0193945914548707; Yeh ML, 2009, AM J CHINESE MED, V37, P829, DOI 10.1142/S0192415X09007314; Yeo S, 2014, ACUPUNCT MED, V32, P132, DOI 10.1136/acupmed-2013-010435; Yin C, 2007, NEUROL RES, V29, pS98, DOI 10.1179/016164107X172220; Zhan HR, 2016, CHIN J INTEGR MED, V22, P696, DOI 10.1007/s11655-016-2502-5; Zhang AL, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/637073; Zhang CS, 2014, J ALTERN COMPLEM MED, V20, P147, DOI 10.1089/acm.2013.0238; Zhang J, 2009, J CHIROPR MED, V8, P9, DOI 10.1016/j.jcm.2008.07.003; Zhang J, 2008, J CHIROPR MED, V7, P59, DOI 10.1016/j.jcme.2008.02.004	82	2	2	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2018	13	10							e0206288	10.1371/journal.pone.0206288	http://dx.doi.org/10.1371/journal.pone.0206288			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GY3KA	30365567	Green Published, gold			2023-01-03	WOS:000448448700038
J	Dobler, CC; Harb, N; Maguire, CA; Armour, CL; Coleman, C; Murad, MH				Dobler, Claudia C.; Harb, Nathan; Maguire, Catherine A.; Armour, Carol L.; Coleman, Courtney; Murad, M. Hassan			Treatment burden should be included in clinical practice guidelines	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							COMPLEX PATIENTS; MEASUREMENT FRAMEWORK		[Dobler, Claudia C.; Murad, M. Hassan] Mayo Clin, Evidence Based Practice Ctr, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, Rochester, MN 55902 USA; [Dobler, Claudia C.; Maguire, Catherine A.; Armour, Carol L.] Univ Sydney, Woolcock Inst Med Res, Sydney, NSW, Australia; [Dobler, Claudia C.; Harb, Nathan] Univ New South Wales, South Western Sydney Clin Sch, Sydney, NSW, Australia; [Armour, Carol L.] Cent Sydney Area Hlth Serv, Sydney, NSW, Australia; [Coleman, Courtney] European Lung Fdn, Sheffield, S Yorkshire, England	Mayo Clinic; University of Sydney; Woolcock Institute of Medical Research; University of New South Wales Sydney	Dobler, CC (corresponding author), Mayo Clin, Evidence Based Practice Ctr, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, Rochester, MN 55902 USA.; Dobler, CC (corresponding author), Univ Sydney, Woolcock Inst Med Res, Sydney, NSW, Australia.; Dobler, CC (corresponding author), Univ New South Wales, South Western Sydney Clin Sch, Sydney, NSW, Australia.	dobler.claudia@mayo.edu	Murad, M. Hassan/AAW-4367-2020	Dobler, Claudia/0000-0002-5460-0189; Murad, Mohammad Hassan/0000-0001-5502-5975	National Health and Medical Research Council [APP1123733]	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	We have read and understood BMJ policy on declaration of interests and have no relevant interests to declare. CCD is supported by a fellowship of the National Health and Medical Research Council (APP1123733). The fellowship sponsor had no role in manuscript design, data interpretation, or writing of the manuscript.	Alonso-Coello P, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2016; Barber N, 2004, QUAL SAF HEALTH CARE, V13, P172, DOI 10.1136/qshc.2003.005926; Eton DT, 2017, QUAL LIFE RES, V26, P489, DOI 10.1007/s11136-016-1397-0; Eton DT, 2015, PATIENT-RELAT OUTCOM, V6, P117, DOI 10.2147/PROM.S78955; Eton DT, 2012, PATIENT-RELAT OUTCOM, V3, P39, DOI 10.2147/PROM.S34681; Harb N, 2017, INT J CHRONIC OBSTR, V12, P1641, DOI 10.2147/COPD.S130353; Holmqvist Malin, 2018, Home Healthc Now, V36, P238, DOI 10.1097/NHH.0000000000000671; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Muth C, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0223-1; National Institute for Health and Care Excellence, 2015, CHRON KIDN DIS AD AS; National Institute for Health and Care Excellence, 2015, TYP 2 DIAB AD MAN; Ravaud P, 2016, BMJ OPEN, V6, DOI [DOI 10.1136/BMJOPEN-2015-010119, 10.1136/bmjopen-2015-010119]; Ridgeway JL, 2014, PATIENT PREFER ADHER, V8, P339, DOI 10.2147/PPA.S58014; Shippee ND, 2012, J CLIN EPIDEMIOL, V65, P1041, DOI 10.1016/j.jclinepi.2012.05.005; Spencer-Bonilla G, 2017, J GEN INTERN MED, V32, P1141, DOI 10.1007/s11606-017-4117-8; Unruh Kenton T, 2008, Conf Proc Ethnogr Prax Ind Conf, V2008, P40; Tran VT, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-109; Tran VT, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-68; Wedzicha JA, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.00791-2016; Wenger N, 2017, ANN INTERN MED, V166, P579, DOI 10.7326/M16-2238	20	61	61	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 12	2018	363								k4065	10.1136/bmj.k4065	http://dx.doi.org/10.1136/bmj.k4065			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GX4EG	30314981				2023-01-03	WOS:000447679500002
J	Caulley, L				Caulley, Lisa			A Seat at the Table	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Caulley, Lisa] Guys & St Thomas Hosp, Ear Nose & Throat Dept, London, England; [Caulley, Lisa] Erasmus Univ, Dept Epidemiol, Med Ctr, Rotterdam, Rotterdam, Netherlands; [Caulley, Lisa] Ottawa Hosp Res Inst, Ottawa, ON, Canada	Erasmus University Rotterdam; Erasmus MC; University of Ottawa; Ottawa Hospital Research Institute	Caulley, L (corresponding author), Guys & St Thomas Hosp, Ear Nose & Throat Dept, London, England.; Caulley, L (corresponding author), Erasmus Univ, Dept Epidemiol, Med Ctr, Rotterdam, Rotterdam, Netherlands.; Caulley, L (corresponding author), Ottawa Hosp Res Inst, Ottawa, ON, Canada.			Caulley, Lisa/0000-0002-9661-4634				Bernal W, 2015, LANCET, V386, P1576, DOI 10.1016/S0140-6736(15)00309-8; Boyd K, 2012, HEPATOLOGY, V55, P1650, DOI 10.1002/hep.25621	2	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 11	2018	379	15					1400	1401		10.1056/NEJMp1808347	http://dx.doi.org/10.1056/NEJMp1808347			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GW4VQ	30304651				2023-01-03	WOS:000446923400004
J	Nishikawa, G; Prasad, V				Nishikawa, Go; Prasad, Vinay			Diagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Nishikawa, Go] Oregon Hlth & Sci Univ, Portland, OR USA; [Prasad, Vinay] Oregon Hlth & Sci Univ, Med, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Prasad, V (corresponding author), Oregon Hlth & Sci Univ, Med, Portland, OR 97239 USA.	prasad@ohsu.edu		Prasad, Vinayak/0000-0002-6110-8221	Laura and John Arnold Foundation	Laura and John Arnold Foundation	We have read and understood BMJ policy on declaration of interests and declare that VP is funded by the Laura and John Arnold Foundation and receives royalties for his book Ending Medical Reversal. VP has received honorariums for lectures to universities, non-profit medical centres, non-profit groups, and professional societies. VP is a writer for Medscape.	Bill-Axelson A, 2014, NEW ENGL J MED, V370, P932, DOI 10.1056/NEJMoa1311593; Bonnet F, 2017, LANCET, V389, P1097, DOI 10.1016/S0140-6736(17)30712-2; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Crow RS, 2005, AM J EPIDEMIOL, V161, P377, DOI 10.1093/aje/kwi048; D'Amico AV, 2017, J CLIN ONCOL, V35, P1638, DOI 10.1200/JCO.2016.70.9527; Donovan JL, 2016, NEW ENGL J MED, V375, P1425, DOI 10.1056/NEJMoa1606221; Friedberg MW, 2017, JAMA INTERN MED, V177, P1058, DOI 10.1001/jamainternmed.2017.2142; Hamdy FC, 2016, NEW ENGL J MED, V375, P1415, DOI 10.1056/NEJMoa1606220; Kontos MC, 2004, J AM COLL CARDIOL, V43, P958, DOI 10.1016/j.jacc.2003.10.036; Kontos MC, 2003, AM HEART J, V146, P446, DOI 10.1016/S0002-8703(03)00245-X; Mauguen A, 2013, LANCET ONCOL, V14, P619, DOI 10.1016/S1470-2045(13)70158-X; McDougall JA, 2016, ONCOLOGIST, V21, P320, DOI 10.1634/theoncologist.2015-0327; Mills NL, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1533; Powers JH, 2017, VALUE HEALTH, V20, P2, DOI 10.1016/j.jval.2016.11.005; Ravaud A, 2016, NEW ENGL J MED, V375, P2246, DOI 10.1056/NEJMoa1611406; Redberg RF, 2017, NEW ENGL J MED, V377, P786, DOI 10.1056/NEJMc1708587; Sabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI [10.1056/NEJMoa1615664, 10.4997/JRCPE.2017.212]; Thygesen K, 2012, EUR HEART J, V33, P2551, DOI 10.1093/eurheartj/ehs184; Thygesen K, 2012, J AM COLL CARDIOL, V60, P1581, DOI 10.1016/j.jacc.2012.08.001; Vermeer SE, 2007, LANCET NEUROL, V6, P611, DOI 10.1016/S1474-4422(07)70170-9; Vernooij MW, 2007, NEW ENGL J MED, V357, P1821, DOI 10.1056/NEJMoa070972; Zhong WZ, 2018, LANCET ONCOL, V19, P139, DOI 10.1016/S1470-2045(17)30729-5	22	6	6	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 19	2018	362								k3783	10.1136/bmj.k3783	http://dx.doi.org/10.1136/bmj.k3783			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU8YC	30232089				2023-01-03	WOS:000445628900003
J	El-Say, KM; Hosny, KM				El-Say, Khalid Mohamed; Hosny, Khaled Mohamed			Optimization of carvedilol solid lipid nanoparticles: An approach to control the release and enhance the oral bioavailability on rabbits	PLOS ONE			English	Article							IN-VITRO; SILDENAFIL CITRATE; TOPICAL DELIVERY; DRUG-DELIVERY; FORMULATION; SLN; CARRIERS; TABLETS; SURFACE; DESIGN	Solid lipid nanoparticles (SLNs) are prospective carriers for oral delivery of poorly soluble drugs with low bioavailability. Therefore, the study aimed at developing carvedilol (CVD) in SLNs to control its release and enhance its bioavailability in the management of hypertension, and cardiac diseases. Box-Behnken design (BBD) was applied to optimize the variables affecting the quality of CVD-SLNs which prepared by homogenization-ultrasonication technique. The concentrations of Percirol (X-1), Gelucire (X-2), and stearylamine (X-3) were chosen as the crucial independent variables. The dependent variables were estimated and analyzed by Statgraphics software to achieve the optimum characteristics of the developed SLNs. The optimized SLNs was evaluated in vitro and in vivo for pharmacokinetic parameters on male New Zealand white rabbits. The results of this study revealed that the CVD-SLNs have a colloidal size of 31.3 nm with zeta potential of 24.25 mV indicating good stability and 91.43% entrapment efficiency. The in vitro release of CVD from the SLNs was best fitted to Hixon-Crowell model that describes the release from the particles with uniform size. The in vivo pharmacokinetics results indicated the prolongation in the mean residence time of CVD to 23 h when delivered in SLNs and its oral bioavailability enhanced by more than 2-folds.	[El-Say, Khalid Mohamed; Hosny, Khaled Mohamed] King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut, Jeddah, Saudi Arabia; [Hosny, Khaled Mohamed] Beni Suef Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Bani Suwayf, Egypt	King Abdulaziz University; Egyptian Knowledge Bank (EKB); Beni Suef University	El-Say, KM (corresponding author), King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut, Jeddah, Saudi Arabia.	kelsay1@kau.edu.sa	El-Say, Khalid/I-7339-2012; Hosny, Khaled M/H-9793-2012; Hosny, Khaled/GWC-2586-2022	El-Say, Khalid/0000-0002-5539-3193; 	King Abdulaziz University, Jeddah [D-169-166-1437]; DSR	King Abdulaziz University, Jeddah; DSR	This work was supported by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, under grant No. D-169-166-1437. The authors, therefore, gratefully acknowledge the DSR technical and financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, under grant No. (D-169-166-1437). The authors, therefore, gratefully acknowledge the DSR technical and financial support.	Ahmed TA, 2016, DRUG DES DEV THER, V10, P405, DOI 10.2147/DDDT.S98078; Al-Subaie MM, 2015, INT J NANOMED, V10, P3973, DOI 10.2147/IJN.S83962; Aljimaee YHM, 2015, DRUG DES DEV THER, V9, P1379, DOI 10.2147/DDDT.S80294; Becker K, 2015, PHARM RES-DORDR, V32, P1519, DOI 10.1007/s11095-015-1661-y; Cavalli R, 2002, INT J PHARM, V238, P241, DOI 10.1016/S0378-5173(02)00080-7; Chakraborty S., 2009, Current Drug Delivery, V6, P291; El-Housiny S, 2018, DRUG DELIV, V25, P78, DOI 10.1080/10717544.2017.1413444; El-Say KM, 2016, J LIPOSOME RES, V26, P57, DOI 10.3109/08982104.2015.1029495; El-Say KM, 2015, PHARM DEV TECHNOL, V20, P738, DOI 10.3109/10837450.2014.920353; Elshafeey AH, 2009, AAPS PHARMSCITECH, V10, P361, DOI 10.1208/s12249-009-9213-6; Harbi I, 2016, AAPS PHARMSCITECH, V17, P1404, DOI 10.1208/s12249-016-0481-7; Harde H, 2011, EXPERT OPIN DRUG DEL, V8, P1407, DOI 10.1517/17425247.2011.604311; Hixson AW, 1931, IND ENG CHEM, V23, P1160, DOI 10.1021/ie50262a025; Hosny KM, 2018, J DRUG DELIV SCI TEC, V45, P168, DOI 10.1016/j.jddst.2018.03.010; Hosny KM, 2014, EXPERT OPIN DRUG DEL, V11, P1015, DOI 10.1517/17425247.2014.912212; Jeon HS, 2013, INT J PHARMACEUT, V452, P311, DOI 10.1016/j.ijpharm.2013.05.023; Kassem MA, 2017, J PHARM SCI-US, V106, P111, DOI 10.1016/j.xphs.2016.07.007; Khalil RM, 2014, BRIT J PHARM RES, V4, P490, DOI 10.9734/BJPR/2014/7055; Kim S-H., 2010, AM J ANAL CHEM, V01, P135, DOI [10.4236/AJAC.2010.13017, DOI 10.4236/AJAC.2010.13017]; KORSMEYER RW, 1983, INT J PHARM, V15, P25, DOI 10.1016/0378-5173(83)90064-9; Lingayat V.J., 2017, J NANOSCI NANOTECHNO, V4, P67, DOI [10.12691/nnr-4-2-5, DOI 10.12691/NNR-4-2-5]; Mukherjee S, 2009, INDIAN J PHARM SCI, V71, P349, DOI 10.4103/0250-474X.57282; Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4; Naseri N, 2015, ADV PHARM BULL, V5, P305, DOI 10.15171/apb.2015.043; Nimbalkar UA, 2011, INT J PHARM SCI RES, V2, P2974, DOI 10.13040/IJPSR.0975-8232.2(11).2974-82; Padhye SG, 2013, INDIAN J PHARM SCI, V75, P591; Pandita D, 2009, PHARMAZIE, V64, P301, DOI 10.1691/ph.2009.8338; PEPPAS NA, 1985, PHARM ACTA HELV, V60, P110; Ponchel G, 1997, EUR J PHARM BIOPHARM, V44, P25, DOI 10.1016/S0939-6411(97)00098-2; Potluri RHK, 2011, ARCH PHARM RES, V34, P51, DOI 10.1007/s12272-011-0106-3; Runge S., 1996, European Journal of Pharmaceutical Sciences, V4, pS132, DOI 10.1016/S0928-0987(97)86381-6; Sarangi M.K., 2016, J CRIT REV, V3, P5, DOI DOI 10.5958/0975-4377.2016.00030.6; Shidhaye S. S., 2008, Current Drug Delivery, V5, P324, DOI 10.2174/156720108785915087; Stancampiano A.H.S., 2008, OPEN DRUG DELIV, V2, P26; Tanwar Yuveraj Singh, 2007, Acta Pharmaceutica (Zagreb), V57, P151, DOI 10.2478/v10007-007-0012-x; Ubaidulla U, 2007, AAPS PHARMSCITECH, V8, DOI 10.1208/pt0801002; Uner M, 2007, INT J NANOMED, V2, P289; Venishetty VK, 2012, COLLOID SURFACE B, V95, P1, DOI 10.1016/j.colsurfb.2012.01.001; Verma S, 2016, J CHEM RES, V8, P102, DOI DOI 10.20959/WJPPS20164-6495; Wissing SA, 2004, ADV DRUG DELIVER REV, V56, P1257, DOI 10.1016/j.addr.2003.12.002; Xie SY, 2011, INT J NANOMED, V6, P547, DOI 10.2147/IJN.S17083; Zirak MB., 2015, INT J CURR MICROBIOL, V4, P924, DOI 10.20964/2016.10.30	42	34	34	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2018	13	8							e0203405	10.1371/journal.pone.0203405	http://dx.doi.org/10.1371/journal.pone.0203405			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS2NZ	30161251	Green Published, Green Submitted, gold			2023-01-03	WOS:000443388900121
J	Grabosch, S; Bulatovic, M; Zeng, FTZ; Ma, TZ; Zhang, LX; Ross, M; Brozickl, J; Fang, YS; Tseng, G; Kim, E; Gambotto, A; Elishaev, E; Edwards, RP; Vlad, AM				Grabosch, Shannon; Bulatovic, Mirna; Zeng, Feitianzhi; Ma, Tianzhou; Zhang, Lixin; Ross, Malcolm; Brozickl, Joan; Fang, YuSi; Tseng, George; Kim, Eun; Gambotto, Andrea; Elishaev, Esther; Edwards, Robert P.; Vlad, Anda M.			Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles	ONCOGENE			English	Article							LONG-TERM SAFETY; CELLS; CHEMOTHERAPY; SURVIVAL; EXPRESSION; APOPTOSIS; ANTIBODY; THERAPY; TUMORS; PD-L1	The backbone of ovarian cancer treatment is platinum-based chemotherapy and aggressive surgical debulking. New therapeutic approaches using immunotherapy via immune checkpoint blockade, which have demonstrated clinical efficacy in other tumor types, have been less promising in ovarian cancer. To increase their clinical efficacy, checkpoint inhibitors are now being tested in clinical trials in combination with chemotherapy. Here, we evaluated the impact of cisplatin on tumor immunogenicity and its in vivo roles when used alone or in combination with anti-PD-L1, in two novel murine ovarian cancer cell models. The 2F8 and its platinum-resistant derivative 2F8cis model, display distinct inflammatory profiles and chemotherapy sensitivities, and mirror the primary and recurrent human disease, respectively. Acute and chronic exposure to cisplatin enhances tumor immunogenicity by increasing calreticulin, MHC class I, antigen presentation and T-cell infiltration. Cisplatin also upregulates PD-L1 expression in vitro and in vivo, demonstrating a dual, paradoxical immune modulatory effect and supporting the rationale for combination with immune checkpoint blockade. One of the pathways activated by cisplatin treatment is the cGAS/STING pathway. Chronic cisplatin treatment led to upregulation of cGAS and STING proteins in 2F8cis compared to parental 2F8 cells, while acute exposure to cisplatin further increases cGAS and STING levels in both 2F8 and 2F8cis cells. Overexpression of cGAS/STING modifies tumor immunogenicity by upregulating PD-L1, MHC I and calreticulin in tumor cells. Anti-PD-L1 alone in a platinum-sensitive model or with cisplatin in a platinum-resistant model increases survival. These studies have high translational potential in ovarian cancer.	[Grabosch, Shannon; Bulatovic, Mirna; Zeng, Feitianzhi; Zhang, Lixin; Ross, Malcolm; Brozickl, Joan; Edwards, Robert P.; Vlad, Anda M.] Magee Womens Res Inst, Pittsburgh, PA 15213 USA; [Grabosch, Shannon; Bulatovic, Mirna; Zeng, Feitianzhi; Zhang, Lixin; Ross, Malcolm; Edwards, Robert P.; Vlad, Anda M.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA; [Grabosch, Shannon; Ross, Malcolm; Edwards, Robert P.] Univ Pittsburgh, Magee Womens Hosp, Med Ctr, Pittsburgh, PA 15213 USA; [Zeng, Feitianzhi] Cent South Univ, Xiangya Sch Med, Changsha, Hunan, Peoples R China; [Ma, Tianzhou; Fang, YuSi; Tseng, George] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Kim, Eun; Gambotto, Andrea] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA; [Elishaev, Esther] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Ma, Tianzhou] Univ Maryland, Dept Epidemiol & Biostat, Sch Publ Hlth, Pittsburgh, MD 20742 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Central South University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Vlad, AM (corresponding author), Magee Womens Res Inst, Pittsburgh, PA 15213 USA.; Vlad, AM (corresponding author), Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA.	vladam@upmc.edu	Ma, Tianzhou/AAC-8221-2021; Bulatovic, Mirna/L-6826-2015	Ma, Tianzhou/0000-0003-3605-0811; Bulatovic, Mirna/0000-0002-5472-6144	NIH/NCI [R01 CA163462]; Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE [R01CA163462] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was partly supported by the NIH/NCI R01 CA163462, Pennsylvania Department of Health and a philanthropic donation from Mr. Matthew Fletcher Deitch.	Bakhoum SF, 2018, NATURE, V553, P467, DOI 10.1038/nature25432; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Bilbao R, 2003, GENE THER, V10, P1821, DOI 10.1038/sj.gt.3302084; Budiu RA, 2013, ONCOGENE, V32, P3664, DOI 10.1038/onc.2012.397; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cortez MA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv303; Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025; Demaria O, 2015, P NATL ACAD SCI USA, V112, P15408, DOI 10.1073/pnas.1512832112; Di Blasio S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1192739; Dieu-Nosjean MC, 2014, TRENDS IMMUNOL, V35, P571, DOI 10.1016/j.it.2014.09.006; Ding L, 2015, BBA-MOL BASIS DIS, V1852, P2494, DOI 10.1016/j.bbadis.2015.08.011; Feili-Hariri M, 2003, HUM GENE THER, V14, P13, DOI 10.1089/10430340360464679; Feng MY, 2015, P NATL ACAD SCI USA, V112, P2145, DOI 10.1073/pnas.1424907112; Gaillard Stephanie L, 2016, Gynecol Oncol Res Pract, V3, P11; Gao WT, 2004, BIOTECHNOL PROGR, V20, P443, DOI 10.1021/bp0300467; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Grabosch S, 2017, GYNECOL ONCOL, V146, P137, DOI 10.1016/j.ygyno.2017.04.008; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; Hamanishi J, 2016, INT IMMUNOL, V28, P339, DOI 10.1093/intimm/dxw020; Hamanishi J, 2015, J CLIN ONCOL, V33, P4015, DOI 10.1200/JCO.2015.62.3397; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HAVRILESKY LJ, 1995, OBSTET GYNECOL, V85, P1007, DOI 10.1016/0029-7844(95)00058-Y; Hughes PE, 2016, TRENDS IMMUNOL, V37, P462, DOI 10.1016/j.it.2016.04.010; Jiang Run-De, 2003, Ai Zheng, V22, P337; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lemos H, 2016, CANCER RES, V76, P2076, DOI 10.1158/0008-5472.CAN-15-1456; Markman M, 2000, Oncologist, V5, P26, DOI 10.1634/theoncologist.5-1-26; McDermott DF, 2015, J CLIN ONCOL, V33, P2013, DOI 10.1200/JCO.2014.58.1041; Merritt RE, 2003, J THORAC CARDIOV SUR, V126, P1609, DOI 10.1016/S0022-5223(03)00707-4; Mesnage SJL, 2017, ANN ONCOL, V28, P651, DOI 10.1093/annonc/mdw625; Mony JT, 2015, CANCER IMMUNOL IMMUN, V64, P1095, DOI 10.1007/s00262-015-1712-6; Nejad EB, 2016, CANCER RES, V76, P6017, DOI 10.1158/0008-5472.CAN-16-0881; Oliveros J.C, 2007, VENNY INTERACTIVE TO; Parker BS, 2016, NAT REV CANCER, V16, P131, DOI 10.1038/nrc.2016.14; Pujade-Lourraine E, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.TPS5600; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tang CHA, 2016, CANCER RES, V76, P2137, DOI 10.1158/0008-5472.CAN-15-1885; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Varga A, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.5513; Webb JR, 2016, GYNECOL ONCOL, V141, P293, DOI 10.1016/j.ygyno.2016.03.008; Yang H, 2017, P NATL ACAD SCI USA, V114, pE4612, DOI 10.1073/pnas.1705499114	48	108	116	1	40	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2380	2393		10.1038/s41388-018-0581-9	http://dx.doi.org/10.1038/s41388-018-0581-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30518877	Green Accepted			2023-01-03	WOS:000462588000011
J	Chen, TL; Chen, JS; Zhu, YB; Li, Y; Wang, Y; Chen, HJ; Wang, JH; Li, X; Liu, Y; Li, BS; Sun, XL; Ke, YQ				Chen, Taoliang; Chen, Jiansheng; Zhu, Yubo; Li, Yan; Wang, Yun; Chen, Huajian; Wang, Jihui; Li, Xiao; Liu, Yang; Li, Baisheng; Sun, Xinlin; Ke, Yiquan			CsD163, a novel therapeutic target, regulates the proliferation and stemness of glioma cells via casein kinase 2	ONCOGENE			English	Article							MACROPHAGE SCAVENGER RECEPTOR; PROTEIN-KINASE; HUMAN GLIOBLASTOMA; CANCER; CD163; EXPRESSION; BRAIN; CK2; ANTIGEN; CD133	Glioma is a devastating cancer with a dismal prognosis and there is an urgent need to discover novel glioma-specific antigens for glioma therapy. Previous studies have identified CD163-positive tumour cells in certain solid tumours, but CD163 expression in glioma remains unknown. In this study, via an analysis of public datasets, we demonstrated that CD163 overexpression in glioma specimens correlated with an unfavourable patient prognosis. CD163 expression was increased in glioma cells, especially primary glioma cells. The loss of CD163 expression inhibited both cell cycle progression and the proliferation of glioblastoma multiforme (GBM) cell lines and primary glioma cells. CD163 interacted directly with casein kinase 2 (CK2) and CD163 silencing reduced AKT/GSK3 beta/beta-catenin/cyclin D1 pathway activity via CK2. Moreover, CD163 was upregulated in CD133-positive glioma stem cells (GSCs), and CD163 downregulation decreased the expression of GSC markers, including CD133, ALDH1A1, NANOG and OCT4. The knockdown of CD163 impaired GSC stemness by inhibiting the CK2/AKT/GSK3 beta/beta-catenin pathway. Finally, a CD163 antibody successfully induced complement-dependent cytotoxicity against glioma cells. Our findings indicate that CD163 contributes to gliomagenesis via CK2 and provides preclinical evidence that CD163 and the CD163 pathway might serve as a therapeutic target for glioma.	[Chen, Taoliang; Chen, Jiansheng; Zhu, Yubo; Li, Yan; Wang, Yun; Chen, Huajian; Wang, Jihui; Li, Xiao; Liu, Yang; Li, Baisheng; Sun, Xinlin; Ke, Yiquan] Southern Med Univ, Dept Neurosurg,Zhujiang Hosp,Minist China, Natl Key Clin Specialty,Engn Technol Res Ctr Educ, Guangdong Prov Key Lab Brain Funct Repair & Regen, Guangzhou 510282, Guangdong, Peoples R China; [Wang, Yun] Xinjiang Med Univ, Hosp 1, Dept Neurosurg, Urumqi 830054, Peoples R China; [Li, Baisheng] Huizhou Cent Peoples Hosp, Dept Neurosurg, Huizhou 516001, Peoples R China	Southern Medical University - China; Xinjiang Medical University	Sun, XL; Ke, YQ (corresponding author), Southern Med Univ, Dept Neurosurg,Zhujiang Hosp,Minist China, Natl Key Clin Specialty,Engn Technol Res Ctr Educ, Guangdong Prov Key Lab Brain Funct Repair & Regen, Guangzhou 510282, Guangdong, Peoples R China.	zjsunxinlin@163.com; kyquan@smu.edu.cn			Natural Science Foundation of China [81772651, 81772652]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the Natural Science Foundation of China (nos. 81772651 and 81772652).	Beatty GL, 2015, CLIN CANCER RES, V21, P687, DOI 10.1158/1078-0432.CCR-14-1860; BIGNER SH, 1985, NEUROL CLIN, V3, P769, DOI 10.1016/S0733-8619(18)31008-9; Binnemars-Postma K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050979; Boussiotis VA, 2018, ONCOGENE, V37, P1121, DOI 10.1038/s41388-017-0024-z; Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497; Calvert JG, 2007, J VIROL, V81, P7371, DOI 10.1128/JVI.00513-07; Chang AL, 2016, CANCER RES, V76, P5671, DOI 10.1158/0008-5472.CAN-16-0144; Cole MF, 2008, GENE DEV, V22, P746, DOI 10.1101/gad.1642408; Condello S, 2015, ONCOGENE, V34, P2297, DOI 10.1038/onc.2014.178; Di Maira G, 2005, CELL DEATH DIFFER, V12, P668, DOI 10.1038/sj.cdd.4401604; Dixit D, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.10; Fabriek BO, 2009, BLOOD, V113, P887, DOI 10.1182/blood-2008-07-167064; He CJ, 2018, THERANOSTICS, V8, P237, DOI 10.7150/thno.21945; Ikushima H, 2011, J BIOL CHEM, V286, P41434, DOI 10.1074/jbc.M111.300863; Jensen TO, 2010, J CLIN ONCOL, V28; Kaminska B, 2009, INT J ONCOL, V35, P1091, DOI 10.3892/ijo_00000424; Kemper K, 2010, CANCER RES, V70, P719, DOI 10.1158/0008-5472.CAN-09-1820; Kim WK, 2006, AM J PATHOL, V168, P822, DOI 10.2353/ajpath.2006.050215; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; Lai SS, 2016, J HEPATOL, V64, P352, DOI 10.1016/j.jhep.2015.09.025; LAW SKA, 1993, EUR J IMMUNOL, V23, P2320, DOI 10.1002/eji.1830230940; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lin KY, 2010, ANN SURG ONCOL, V17, P1695, DOI 10.1245/s10434-010-0911-9; Lisi L, 2017, NEUROSCI LETT, V645, P106, DOI 10.1016/j.neulet.2017.02.076; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Lu X, 2011, ADV EXP MED BIOL, V714, P129, DOI 10.1007/978-94-007-0782-5_6; Ma CY, 2018, MED MOL MORPHOL, V51, P13, DOI 10.1007/s00795-017-0165-8; Natsume A, 2008, DRUG DES DEV THER, V3, P7; Nitta RT, 2015, ONCOGENE, V34, P3688, DOI 10.1038/onc.2014.299; Noubissi FK, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091587; Olsen BB, 2010, ONCOGENE, V29, P6016, DOI 10.1038/onc.2010.337; Ostrom QT, 2017, NEURO-ONCOLOGY, V19, pV1, DOI 10.1093/neuonc/nox158; Ostuni R, 2015, TRENDS IMMUNOL, V36, P229, DOI 10.1016/j.it.2015.02.004; Pallares J, 2009, AM J PATHOL, V174, P287, DOI 10.2353/ajpath.2009.080552; Ponce DP, 2011, J CELL PHYSIOL, V226, P1953, DOI 10.1002/jcp.22527; Prinz M, 2011, NAT NEUROSCI, V14, P1227, DOI 10.1038/nn.2923; Prosniak M, 2013, CLIN CANCER RES, V19, P3776, DOI 10.1158/1078-0432.CCR-12-1940; Qi L, 2016, ONCOTARGET, V7, P71673, DOI 10.18632/oncotarget.12317; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Rasper M, 2010, NEURO-ONCOLOGY, V12, P1024, DOI 10.1093/neuonc/noq070; Reardon DA, 2016, CANCER IMMUNOL RES, V4, P124, DOI 10.1158/2326-6066.CIR-15-0151; Reardona DA, 2017, NEURO-ONCOLOGY, V19, P21, DOI 10.1093/neuonc/nox036.071; Ritter M, 2001, EUR J IMMUNOL, V31, P999, DOI 10.1002/1521-4141(200104)31:4<999::AID-IMMU999>3.0.CO;2-R; Sanchez-Torres C, 2003, ARCH VIROL, V148, P2307, DOI 10.1007/s00705-003-0188-4; Shabo I, 2008, INT J CANCER, V123, P780, DOI 10.1002/ijc.23527; Shabo I, 2011, ADV EXP MED BIOL, V714, P141, DOI 10.1007/978-94-007-0782-5_7; Shabo I, 2009, INT J CANCER, V125, P1826, DOI 10.1002/ijc.24506; Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15080; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Tang YY, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0222-5; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Xi G, 2016, ONCOGENE, V35, P241, DOI 10.1038/onc.2015.78; Ye XZ, 2012, J IMMUNOL, V189, P444, DOI 10.4049/jimmunol.1103248; Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhang ZR, 2012, BRAIN RES, V1461, P102, DOI 10.1016/j.brainres.2012.04.038	57	27	28	3	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1183	1199		10.1038/s41388-018-0515-6	http://dx.doi.org/10.1038/s41388-018-0515-6			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30258108				2023-01-03	WOS:000459249800003
J	Kent, DM; Steyerberg, E; van Klaveren, D				Kent, David M.; Steyerberg, Ewout; van Klaveren, David			Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PERCUTANEOUS CORONARY INTERVENTION; INDIVIDUAL PATIENTS DEVELOPMENT; DUAL ANTIPLATELET THERAPY; TIMI RISK SCORE; CLINICAL-TRIALS; SUBGROUP ANALYSES; MYOCARDIAL-INFARCTION; RANDOMIZED-TRIALS; PLASMINOGEN-ACTIVATOR; USERS GUIDES	The use of evidence from clinical trials to support decisions for individual patients is a form of "reference class forecasting": implicit predictions for an individual are made on the basis of outcomes in a reference class of "similar" patients treated with alternative therapies. Evidence based medicine has generally emphasized the broad reference class of patients qualifying for a trial. Yet patients in a trial (and in clinical practice) differ from one another in many ways that can affect the outcome of interest and the potential for benefit. The central goal of personalized medicine, in its various forms, is to narrow the reference class to yield more patient specific effect estimates to support more individualized clinical decision making. This article will review fundamental conceptual problems with the prediction of outcome risk and heterogeneity of treatment effect (HTE), as well as the limitations of conventional (one-variable-at-a-time) subgroup analysis. It will also discuss several regression based approaches to "predictive" heterogeneity of treatment effect analysis, including analyses based on "risk modeling" (such as stratifying trial populations by their risk of the primary outcome or their risk of serious treatment-related harms) and analysis based on "effect modeling" (which incorporates modifiers of relative effect). It will illustrate these approaches with clinical examples and discuss their respective strengths and vulnerabilities.	[Kent, David M.; van Klaveren, David] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Predict Analyt & Comparat Effectiveness Ctr, Boston, MA 02111 USA; [Steyerberg, Ewout; van Klaveren, David] Leiden Univ, Med Ctr, Dept Biomed Data Sci, Einthovenweg 20, NL-2333 ZC Leiden, Netherlands	Tufts Medical Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Kent, DM (corresponding author), Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Predict Analyt & Comparat Effectiveness Ctr, Boston, MA 02111 USA.	dkent1@tuftsmedicalcenter.org	van Klaveren, David/ABF-3020-2021	van Klaveren, David/0000-0002-2096-606X	Patient-Centered Outcomes Research Institute (PCORI) grant (the Predictive Analytics Resource Center (PARC)) [SA.Tufts.PARC.OSCO.2018.01.25]; National Institutes of Health [U01NS086294]; Patient-Centered Outcomes Research Institute (PCORI) grant [ME-1606-35555]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS086294] Funding Source: NIH RePORTER	Patient-Centered Outcomes Research Institute (PCORI) grant (the Predictive Analytics Resource Center (PARC))(Patient-Centered Outcomes Research Institute - PCORI); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Patient-Centered Outcomes Research Institute (PCORI) grant(Patient-Centered Outcomes Research Institute - PCORI); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was partially supported through two Patient-Centered Outcomes Research Institute (PCORI) grants (the Predictive Analytics Resource Center (PARC) (SA.Tufts.PARC.OSCO.2018.01.25) and Methods Award (ME-1606-35555)), as well as by the National Institutes of Health (U01NS086294).	Abadie A, 2013, W19742 NBER; Abraham E, 2005, NEW ENGL J MED, V353, P1332, DOI 10.1056/NEJMoa050935; Agoritsas T, 2017, JAMA-J AM MED ASSOC, V317, P748, DOI 10.1001/jama.2016.20029; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Andersen HR, 2003, NEW ENGL J MED, V349, P733, DOI 10.1056/NEJMoa025142; [Anonymous], 1988, LANCET, V2, P349; Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; Athey S, 2016, P NATL ACAD SCI USA, V113, P7353, DOI 10.1073/pnas.1510489113; Baker SG, 2010, J NATL CANCER I, V102, P1756, DOI 10.1093/jnci/djq427; Basu S, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002410; Brookes S T, 2001, Health Technol Assess, V5, P1; Brookes ST, 2004, J CLIN EPIDEMIOL, V57, P229, DOI 10.1016/j.jclinepi.2003.08.009; Burke JF, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5651; Burke JF, 2014, CIRC-CARDIOVASC QUAL, V7, P163, DOI 10.1161/CIRCOUTCOMES.113.000497; BYAR DP, 1985, STAT MED, V4, P255, DOI 10.1002/sim.4780040304; Cai TX, 2011, BIOSTATISTICS, V12, P270, DOI 10.1093/biostatistics/kxq060; Califf RM, 1997, AM HEART J, V133, P630, DOI 10.1016/S0002-8703(97)70164-9; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Claggett B, 2015, BIOSTATISTICS, V16, P60, DOI 10.1093/biostatistics/kxu037; Clarke RT, 2007, HYDROL EARTH SYST SC, V11, P408, DOI 10.5194/hess-11-408-2007; Collins GS, 2015, ANN INTERN MED, V162, P55, DOI [10.7326/M14-0697, 10.1161/CIRCULATIONAHA.114.014508, 10.1038/bjc.2014.639, 10.1136/bmj.g7594, 10.1016/j.eururo.2014.11.025, 10.1016/j.jclinepi.2014.11.010, 10.7326/M14-0698, 10.1002/bjs.9736, 10.1186/s12916-014-0241-z]; Costa F, 2017, LANCET, V389, P1025, DOI 10.1016/S0140-6736(17)30397-5; Dahabreh IJ, 2016, INT J EPIDEMIOL, V45, P2184, DOI 10.1093/ije/dyw125; Dahabreh IJ, 2014, JAMA-J AM MED ASSOC, V312, P129, DOI 10.1001/jama.2014.4364; Davidoff F, 2017, ANN INTERN MED, V166, P141, DOI 10.7326/M16-1721; Davidoff F, 2009, JAMA-J AM MED ASSOC, V302, P2580, DOI 10.1001/jama.2009.1845; Decker C, 2016, AM HEART J, V178, P190, DOI 10.1016/j.ahj.2016.03.027; Dijkman B, 2009, CAN J SURG, V52, P515; Dorresteijn JAN, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1548; Dorresteijn JAN, 2013, CIRCULATION, V127, P2485, DOI 10.1161/CIRCULATIONAHA.112.000712; Dorresteijn JAN, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5888; Ebrahim S, 1999, J HUM HYPERTENS, V13, P721, DOI 10.1038/sj.jhh.1000919; Farooq V, 2013, LANCET, V381, P639, DOI 10.1016/S0140-6736(13)60108-7; Franklin JM, 2017, CLIN PHARMACOL THER, V102, P924, DOI 10.1002/cpt.857; FURBERG CD, 1983, CIRCULATION, V67, P98; Furukawa TA, 2002, INT J EPIDEMIOL, V31, P72, DOI 10.1093/ije/31.1.72; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; Goff DC, 2014, CIRCULATION, V129, pS49, DOI 10.1161/01.cir.0000437741.48606.98; Goodman SN, 1999, ANN INTERN MED, V130, P604, DOI 10.7326/0003-4819-130-7-199904060-00022; Goodman SN, 2017, JAMA-J AM MED ASSOC, V317, P705, DOI 10.1001/jama.2016.19970; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; HALPERIN M, 1977, BIOMETRIKA, V64, P271; Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7; Harrell FE, STAT THINKING VIEWPO; Hayward RA, 2005, HEALTH AFFAIR, V24, P1571, DOI 10.1377/hlthaff.24.6.1571; Hayward Rodney A, 2006, BMC Med Res Methodol, V6, P18, DOI 10.1186/1471-2288-6-18; Hernandez AV, 2006, AM HEART J, V151, P257, DOI 10.1016/j.ahj.2005.04.020; HILL AB, 1966, ANN RHEUM DIS, V25, P107, DOI 10.1136/ard.25.2.107; Hingorani AD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e5793; Hochman JS, 2006, NEW ENGL J MED, V355, P2395, DOI 10.1056/NEJMoa066139; HOERL AE, 1970, TECHNOMETRICS, V12, P55, DOI 10.1080/00401706.1970.10488634; HOLLAND PW, 1986, J AM STAT ASSOC, V81, P945, DOI 10.2307/2289064; Huang Y, 2012, BIOMETRICS, V68, P687, DOI 10.1111/j.1541-0420.2011.01722.x; Ioannidis JPA, 2008, EPIDEMIOLOGY, V19, P640, DOI 10.1097/EDE.0b013e31818131e7; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Janes H, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv157; Julien M, 2008, CLIN TRIALS, V5, P107, DOI 10.1177/1740774508089511; KAHNEMAN D, 1993, MANAGE SCI, V39, P17, DOI 10.1287/mnsc.39.1.17; Kahneman D., 2011, THINKING FAST SLOW; Kent DM, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-30; Kent DM, 2007, JAMA-J AM MED ASSOC, V298, P1209, DOI 10.1001/jama.298.10.1209; Kent DM, 2006, STROKE, V37, P2957, DOI 10.1161/01.STR.0000249054.96644.c6; Kent DM, 2016, INT J EPIDEMIOL, V45, P2075, DOI 10.1093/ije/dyw118; Kent DM, 2013, NEUROLOGY, V81, P619, DOI 10.1212/WNL.0b013e3182a08d59; Kent DM, 2012, JAMA-J AM MED ASSOC, V307, P1585, DOI 10.1001/jama.2012.469; Kent DM, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-185; Kent DM, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-85; Kent DM, 2002, J GEN INTERN MED, V17, P887, DOI 10.1046/j.1525-1497.2002.11232.x; Kent DM, 2003, STROKE, V34, P464, DOI 10.1161/01.STR.0000051506.43212.8B; Kent DM, 2002, AM J MED, V113, P104, DOI 10.1016/S0002-9343(02)01160-9; Kernan WN, 2017, JAMA NEUROL, V74, P1319, DOI 10.1001/jamaneurol.2017.2136; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kohane IS, 2009, GENOME MED, V1, DOI 10.1186/gm4; Kovalchik SA, 2013, NEW ENGL J MED, V369, P245, DOI 10.1056/NEJMoa1301851; Kraemer HC, 2006, JAMA-J AM MED ASSOC, V296, P1286, DOI 10.1001/jama.296.10.1286; Kravitz RL, 2004, MILBANK Q, V82, P661, DOI 10.1111/j.0887-378X.2004.00327.x; Krumholz HM, 2014, HEALTH AFFAIR, V33, P1163, DOI 10.1377/hlthaff.2014.0053; Krumholz HM, 2013, ANN INTERN MED, V158, P910, DOI 10.7326/0003-4819-158-12-201306180-00009; Kumar V, 2018, ANN INTERN MED, V168, P161, DOI 10.7326/M17-1401; Lagakos SW, 2006, NEW ENGL J MED, V354, P1667, DOI 10.1056/NEJMp068070; LECESSIE S, 1992, APPL STAT-J ROY ST C, V41, P191; Li F, 2018, J AM STAT ASSOC, V113, P390, DOI 10.1080/01621459.2016.1260466; Lipkovich I, 2017, STAT MED, V36, P136, DOI 10.1002/sim.7064; Luedtke AR, 2016, ANN STAT, V44, P713, DOI 10.1214/15-AOS1384; Marcucci M, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003143; Meehl P. E., 1954, CLIN VERSUS STAT PRE, DOI [10.1037/11281-000, DOI 10.1037/11281-000]; Mehta SR, 2009, NEW ENGL J MED, V360, P2165, DOI 10.1056/NEJMoa0807986; Mehta SR, 2005, JAMA-J AM MED ASSOC, V293, P2908, DOI 10.1001/jama.293.23.2908; Morrow DA, 2002, EUR HEART J, V23, P223, DOI 10.1053/euhj.2001.2738; Mozaffarian D, 2007, CIRCULATION, V116, P392, DOI 10.1161/CIRCULATIONAHA.106.687103; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; Parker AB, 2000, AM HEART J, V139, P952, DOI 10.1067/mhj.2000.106610; Patient-Centered Outcomes Research Institute (PCORI) Methodology Committee, PCORI METH REP; Pocock SJ, 2002, STAT MED, V21, P2917, DOI 10.1002/sim.1296; Pocock SJ, 2008, NEW ENGL J MED, V358, P2076, DOI 10.1056/NEJMc0800616; Powers S, 2018, STAT MED, V37, P1767, DOI 10.1002/sim.7623; Raman G, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-017641; Reichenbach H., 1949, THEORY PROBABILITY; Rothman KJ, 2008, CONCEPTS INTERACTION; Rothwell PM, 2005, LANCET, V365, P176, DOI 10.1016/S0140-6736(05)17709-5; Rothwell PM, 2005, LANCET, V365, P256; Rothwell PM, 1999, LANCET, V353, P2105, DOI 10.1016/S0140-6736(98)11415-0; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; Saita Y, 2015, THER ADV CHRONIC DIS, V6, P185, DOI 10.1177/2040622315584114; Salisbury AC, 2015, CIRC-CARDIOVASC QUAL, V8, P332, DOI 10.1161/CIRCOUTCOMES.115.002038; Selker HP, 2002, ANN INTERN MED, V137, P87, DOI 10.7326/0003-4819-137-2-200207160-00006; Selker HP, 1997, ANN INTERN MED, V127, P538, DOI 10.7326/0003-4819-127-7-199710010-00006; Serruys PW, 2009, NEW ENGL J MED, V360, P961, DOI 10.1056/NEJMoa0804626; Shepherd J, 1996, LANCET, V348, P1339; Simon N, 2011, J STAT SOFTW, V39, P1; SIMON R, 1982, BRIT J CLIN PHARMACO, V14, P473, DOI 10.1111/j.1365-2125.1982.tb02015.x; Sinclair JC, 2011, J CLIN EPIDEMIOL, V64, P893, DOI 10.1016/j.jclinepi.2010.12.006; STALLONES RA, 1987, PREV MED, V16, P183, DOI 10.1016/0091-7435(87)90082-X; Stern RH, 2012, J CLIN HYPERTENS, V14, P261, DOI 10.1111/j.1751-7176.2012.00592.x; Steyerberg EW, 2009, CLIN PREDICTION MODE, DOI 10.1007/978-0-387-77244-8; Study to Prospectively Evaluate Reamed Intramedullary Nails in Tibial Fractures (SPRINT) Investigators, 2011, J Bone Joint Surg Am, V93, pe8, DOI 10.2106/JBJS.I.01555; Sun X, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1553; Sun X, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c117; Sun X, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-101; Sussman JB, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h454; Tanniou J, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0122-6; Tannock IF, 1996, J NATL CANCER I, V88, P206, DOI 10.1093/jnci/88.3-4.206; Thune JJ, 2005, CIRCULATION, V112, P2017, DOI 10.1161/CIRCULATIONAHA.105.558676; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Treweek S, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-37; van der Laan MJ, 2015, J CAUSAL INFERENCE, V3, P61, DOI 10.1515/jci-2013-0022; van Klaveren D, 2018, J CLIN EPIDEMIOL, V94, P59, DOI 10.1016/j.jclinepi.2017.10.021; van Klaveren D, 2015, J CLIN EPIDEMIOL, V68, P1366, DOI 10.1016/j.jclinepi.2015.02.012; Varadhan R, 2013, DEV PROTOCOL OBSERVA; Varadhan R., 2012, REV GUIDANCE DOCUMEN; Varadhan R, 2013, J CLIN EPIDEMIOL, V66, P818, DOI 10.1016/j.jclinepi.2013.02.009; VENEMA E, 2017, BMJ-BRIT MED J, V357, DOI DOI 10.1136/BMJ.J1710; Venn J., 1876, LOGIC CHANCE, V2nd ed.; Vickers AJ, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-14; Vickers AJ, 2006, MED DECIS MAKING, V26, P565, DOI 10.1177/0272989X06295361; Vickers AJ, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i6; Vickers AJ, 2015, ANN INTERN MED, V162, P866, DOI 10.7326/M14-2767; Viscoli CM, 2019, STROKE, V50, P95, DOI 10.1161/STROKEAHA.118.022745; Wallace PJ, 2014, HEALTH AFFAIR, V33, P1187, DOI 10.1377/hlthaff.2014.0038; Wallach JD, 2017, JAMA INTERN MED, V177, P554, DOI 10.1001/jamainternmed.2016.9125; Wallach JD, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5826; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; Wilson PWF, 2007, ARCH INTERN MED, V167, P1068, DOI 10.1001/archinte.167.10.1068; Yeh RW, 2016, JAMA-J AM MED ASSOC, V315, P1735, DOI 10.1001/jama.2016.3775; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; Zhao LH, 2013, J AM STAT ASSOC, V108, P527, DOI 10.1080/01621459.2013.770705	152	141	141	6	52	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 10	2018	363								k4245	10.1136/bmj.k4245	http://dx.doi.org/10.1136/bmj.k4245			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HE8IS	30530757	Green Published, Green Submitted			2023-01-03	WOS:000453690500001
J	Ray, AS; Joardar, N; Mukherjee, S; Rahaman, CH; Babu, SPS				Ray, Anindya Sundar; Joardar, Nikhilesh; Mukherjee, Suprabhat; Rahaman, Chowdhury Habibur; Babu, Santi P. Sinha			Polyphenol enriched ethanolic extract of Cajanus scarabaeoides (L.) Thouars exerts potential antifilarial activity by inducing oxidative stress and programmed cell death	PLOS ONE			English	Article							PARASITE SETARIA-CERVI; AZADIRACHTA-INDICA; INDUCED APOPTOSIS; ACID; NANOPARTICLES	Development of antifilarial drug from the natural sources is considered as one of the most efficacious, safe, and affordable approaches. In this study, we report the antifilarial activity of a leguminous plant Cajanus scarabaeoides (L.) Thouars. The polyphenol-rich ethanolic extract obtained from the stem part of the plant C. scarabaeoides (EECs) was found to be efficient in killing the filarial nematode Setaria centi in all the three developmental stages viz. oocytes, microfilariae (Mf) and adults with LD50 values of 2.5, 10 and 35 mu g/ml, respectively. While studying the molecular mechanism of action, we found that induction of oxidative stress plays the key role in inducing the mortality in S. cervi. The redox imbalance finally results in activation of the nematode CED pathway that executes the death of the parasite. Intriguingly, EECs was found to be selectively active against the worm and absolutely nontoxic to the mammalian cells and tissues. Taken together, our experimental data demonstrate that C. scarabaeoides can be chosen as an affordable natural therapeutic for treating filarial infection in the future with high efficacy and less toxicity.	[Ray, Anindya Sundar; Rahaman, Chowdhury Habibur] Visva Bharati Univ, Dept Bot, Ethnopharmacol Lab, Santini Ketan, W Bengal, India; [Joardar, Nikhilesh; Mukherjee, Suprabhat; Babu, Santi P. Sinha] Visva Bharati Univ, Dept Zool, Parasitol Lab, Santini Ketan, W Bengal, India	Visva Bharati University; Visva Bharati University	Rahaman, CH (corresponding author), Visva Bharati Univ, Dept Bot, Ethnopharmacol Lab, Santini Ketan, W Bengal, India.; Babu, SPS (corresponding author), Visva Bharati Univ, Dept Zool, Parasitol Lab, Santini Ketan, W Bengal, India.	habibur_cr@yahoo.co.in; spsinhababu@gmail.com	Joardar, Nikhilesh/AHE-8804-2022; Mukherjee, Suprabhat/AAD-7187-2020; Rahaman, Chowdhury Habibur/AAT-8871-2020	Rahaman, Chowdhury Habibur/0000-0003-0503-1271; JOARDAR, NIKHILESH/0000-0002-6460-0377; Sinha Babu, Santi P./0000-0002-7441-6426	Department of Science and Technology, Govt. of India [SR/SO/AS-006/2014]; UGC-DRS-SAP Phase II, Govt. of India	Department of Science and Technology, Govt. of India(Department of Science & Technology (India)); UGC-DRS-SAP Phase II, Govt. of India	The work was funded by Department of Science and Technology (SR/SO/AS-006/2014), Govt. of India and UGC-DRS-SAP Phase II, Govt. of India.	Bourguinat C, 2006, PARASITOLOGY, V132, P255, DOI 10.1017/S0031182005008899; Chowdhury P, 2018, ADV COMPOS HYBRID MA, V1, P577, DOI 10.1007/s42114-018-0040-7; Gucchait A, 2018, EUR J MED CHEM, V143, P598, DOI 10.1016/j.ejmech.2017.11.047; Joardar N, 2018, INT J BIOL MACROMOL, V107, P2375, DOI 10.1016/j.ijbiomac.2017.10.114; KAUSHAL NA, 1987, IMMUNOL INVEST, V16, P139, DOI 10.3109/08820138709030571; Khare C.P., 2007, INDIAN MED PLANTS AN; Mondal Shovan, 2017, Current Bioactive Compounds, V13, P347, DOI 10.2174/1573407212666161028160745; Mukherjee N, 2019, J HELMINTHOL, V93, P519, DOI 10.1017/S0022149X18000615; Mukherjee N, 2016, MINI-REV MED CHEM, V16, P1415, DOI 10.2174/1389557516666151120121036; Mukherjee N, 2016, FREE RADICAL BIO MED, V93, P130, DOI 10.1016/j.freeradbiomed.2016.01.027; Mukherjee N, 2014, RES VET SCI, V97, P309, DOI 10.1016/j.rvsc.2014.04.017; Mukherjee N, 2014, EXP PARASITOL, V136, P41, DOI 10.1016/j.exppara.2013.11.006; Mukherjee S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30610-7; Mukherjee S, 2016, CURR DRUG METAB, V17, P937, DOI 10.2174/1389200217666161004143152; Mukherjee S, 2015, INDIAN J EXP BIOL, V53, P574; Mukherjee S, 2014, J FOOD SCI TECH MYS, V51, P3301, DOI 10.1007/s13197-012-0848-z; Nayak A, 2012, PARASITOL RES, V111, P1173, DOI 10.1007/s00436-012-2948-0; Ottesen EA, 1997, B WORLD HEALTH ORGAN, V75, P491; Pakrashi S. C., 2004, MED AROMATIC PLANTS; Pal D.C., 1998, TRIBAL MED; Quattrocchi U, 2012, CRC WORLD DICT MED P; Ray AS., 2018, RES J PHARMACOGN PHY, V10, P120, DOI [10.5958/0975-4385.2018.00018.3, DOI 10.5958/0975]; Roy B, 2014, RSC ADV, V4, P34487, DOI 10.1039/c4ra03732d; Saha SK, 2016, CARBOHYD POLYM, V137, P390, DOI 10.1016/j.carbpol.2015.11.007; Saini P, 2015, PHARM BIOL, V53, P813, DOI 10.3109/13880209.2014.943244; Saini P, 2014, PARASITOL INT, V63, P717, DOI 10.1016/j.parint.2014.06.008; Saini P, 2012, PARASITOL INT, V61, P520, DOI 10.1016/j.parint.2012.04.002; Sardar AH, 2013, J PROTEOMICS, V81, P185, DOI 10.1016/j.jprot.2013.01.011; Senathilake KS, 2017, EXP PARASITOL, V177, P13, DOI 10.1016/j.exppara.2017.03.007; Shenoy RK, 2008, KOREAN J PARASITOL, V46, P119, DOI 10.3347/kjp.2008.46.3.119; Uniting to Combat Neglected Tropical Diseases, LOND DECL; Verpoorte R, 2000, J PHARM PHARMACOL, V52, P253, DOI 10.1211/0022357001773931	32	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 6	2018	13	12							e0208201	10.1371/journal.pone.0208201	http://dx.doi.org/10.1371/journal.pone.0208201			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD1YF	30521546	Green Published, Green Submitted, gold			2023-01-03	WOS:000452307600031
J	Cooper, DJ; Nichol, AD; Bailey, M; Bernard, S; Cameron, PA; Pili-Floury, S; Forbes, A; Gantner, D; Higgins, AM; Huet, O; Kasza, J; Murray, L; Newby, L; Presneill, JJ; Rashford, S; Rosenfeld, JV; Stephenson, M; Vallance, S; Varma, D; Webb, SAR; Trapani, T; McArthur, C				Cooper, D. James; Nichol, Alistair D.; Bailey, Michael; Bernard, Stephen; Cameron, Peter A.; Pili-Floury, Sebastien; Forbes, Andrew; Gantner, Dashiell; Higgins, Alisa M.; Huet, Olivier; Kasza, Jessica; Murray, Lynne; Newby, Lynette; Presneill, Jeffrey J.; Rashford, Stephen; Rosenfeld, Jeffrey V.; Stephenson, Michael; Vallance, Shirley; Varma, Dinesh; Webb, Steven A. R.; Trapani, Tony; McArthur, Colin		POLAR Trial Investigators ANZICS	Effect of Early Sustained Prophylactic Hypothermia on Neurologic Outcomes Among Patients With Severe Traumatic Brain Injury The POLAR Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THERAPEUTIC HYPOTHERMIA; MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; MANAGEMENT; PATHOPHYSIOLOGY; RESUSCITATION; GUIDELINES; SALINE	IMPORTANCE After severe traumatic brain injury, induction of prophylactic hypothermia has been suggested to be neuroprotective and improve long-term neurologic outcomes. OBJECTIVE To determine the effectiveness of early prophylactic hypothermia compared with normothermic management of patients after severe traumatic brain injury. DESIGN, SETTING, AND PARTICIPANTS The Prophylactic Hypothermia Trial to Lessen Traumatic Brain Injury-Randomized Clinical Trial (POLAR-RCT) was a multicenter randomized trial in 6 countries that recruited 511 patients both out-of-hospital and in emergency departments after severe traumatic brain injury. The first patient was enrolled on December 5. 2010, and the last on November 10.2017. The final date of follow-up was May 15, 2018. INTERVENTIONS There were 266 patients randomized to the prophylactic hypothermia group and 245 to normothermic management. Prophylactic hypothermia targeted the early induction of hypothermia (33 degrees C-35 degrees C) for at least 72 hours and up to 7 days if intracranial pressures were elevated, followed by gradual rewarming. Normothermia targeted 37 degrees C, using surface-cooling wraps when required. Temperature was managed in both groups for 7 days. All other care was at the discretion of the treating physician. MAIN OUTCOMES AND MEASURES The primary outcome was favorable neurologic outcomes or independent living (Glasgow Outcome Scale-Extended score, 5-8 [scale range, 1-8]) obtained by blinded assessors 6 months after injury. RESULTS Among 511 patients who were randomized. 500 provided ongoing consent (mean age, 34.5 years [SD. 13.4); 402 men [80.2%]) and 466 completed the primary outcome evaluation. Hypothermia was initiated rapidly after injury (median, 1.8 hours [IQR, 1.0-2.7 hours]) and rewarming occurred slowly (median, 22.5 hours [IQR, 16-27 hours)). Favorable outcomes (Glasgow Outcome Scale-Extended score, 5-8) at 6 months occurred in 117 patients (48.8%) in the hypothermia group and 111(49.1%) in the normothermia group (risk difference, 0.4% [95% CI, -9.4% to 8.7%]; relative risk with hypothermia, 0.99 [95% CI, 0.82-1.19]; P = .94). In the hypothermia and normothermia groups, the rates of pneumonia were 55.0% vs 51.3%, respectively, and rates of increased intracranial bleeding were 18.1% vs 15.4%, respectively. CONCLUSIONS AND RELEVANCE Among patients with severe traumatic brain injury, early prophylactic hypothermia compared with normothermia did not improve neurologic outcomes at 6 months. These findings do not support the use of early prophylactic hypothermia for patients with severe traumatic brain injury.	[Cooper, D. James; Nichol, Alistair D.; Bailey, Michael; Gantner, Dashiell; Higgins, Alisa M.; Huet, Olivier; Murray, Lynne; Newby, Lynette; Presneill, Jeffrey J.; Stephenson, Michael; Vallance, Shirley; Webb, Steven A. R.; Trapani, Tony; McArthur, Colin] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Cooper, D. James; Nichol, Alistair D.; Bernard, Stephen; Gantner, Dashiell; Vallance, Shirley; Trapani, Tony] Alfred Hosp, Dept Intens Care, Melbourne, Vic, Australia; [Nichol, Alistair D.] St Vincents Univ Hosp, Univ Coll Dublin, Clin Res Ctr, Irish Crit Care Clin Trials Network, Dublin, Ireland; [Nichol, Alistair D.] St Vincents Univ Hosp, Dept Anaesthesia & Intens Care Med, Dublin, Ireland; [Nichol, Alistair D.] Univ Coll Dublin, Sch Med & Med Sci, Dublin, Ireland; [Bernard, Stephen; Stephenson, Michael] Ambulance Victoria, Melbourne, Vic, Australia; [Cameron, Peter A.; Forbes, Andrew; Kasza, Jessica] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Cameron, Peter A.; Gantner, Dashiell] Monash Univ, Ctr Excellence Traumat Brain Injury Res, Melbourne, Vic, Australia; [Cameron, Peter A.] Hamad Med Corp, Emergency Med, Dhueta, Qatar; [Cameron, Peter A.] Alfred Hosp, Emergency & Trauma Ctr, Melbourne, Vic, Australia; [Pili-Floury, Sebastien] CHU Besancon, Serv Reanimat Chirurg, Pole Anesthesie & Reanimat, Besancon, France; [Huet, Olivier] CHRU Brest, Hop La Cavale Blanche, Dept Anaesthesia & Intens Care Med, Brest, France; [Huet, Olivier] Univ Bretagne Occidenta, UFR Med & Sci Sante, Brest, France; [Newby, Lynette; McArthur, Colin] Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand; [Presneill, Jeffrey J.] Royal Melbourne Hosp, Intens Care Unit, Melbourne, Vic, Australia; [Presneill, Jeffrey J.] Univ Melbourne, Dept Med, Melbourne, Vic, Australia; [Rashford, Stephen] Queensland Ambulance Serv, Brisbane, Qld, Australia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Neurosurg, Melbourne, Vic, Australia; [Rashford, Stephen; Varma, Dinesh] Monash Univ, Dept Surg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Surg, Bethesda, MD 20814 USA; [Varma, Dinesh] Alfred Hosp, Radiol, Melbourne, Vic, Australia; [Webb, Steven A. R.] Royal Perth Hosp, Intens Care Unit, Perth, WA, Australia	Monash University; Florey Institute of Neuroscience & Mental Health; University College Dublin; Saint Vincent's University Hospital; University College Dublin; Saint Vincent's University Hospital; University College Dublin; Monash University; Monash University; Hamad Medical Corporation; Florey Institute of Neuroscience & Mental Health; Universite de Franche-Comte; CHU Besancon; CHU Brest; Universite de Bretagne Occidentale; Universite de Bretagne Occidentale; Auckland City Hospital; Royal Melbourne Hospital; University of Melbourne; Florey Institute of Neuroscience & Mental Health; Monash University; Uniformed Services University of the Health Sciences - USA; Florey Institute of Neuroscience & Mental Health; Royal Perth Hospital; University of Western Australia	Cooper, DJ (corresponding author), Monash Univ, ANZIC Res Ctr, 553 St Kilda Rd,Level 3, Melbourne, Vic 3004, Australia.	jamie.cooper@monash.edu	/AAB-3060-2019; Haenggi, Matthias/O-2642-2019; Higgins, Alisa/AAM-8088-2020; Haenggi, Matthias/A-8073-2008; Cooper, D. James/G-7961-2013; Presneill, Jeffrey/B-4894-2012	Haenggi, Matthias/0000-0001-5845-031X; Higgins, Alisa/0000-0001-8295-7559; Haenggi, Matthias/0000-0001-5845-031X; Cooper, D. James/0000-0002-5872-9051; Myburgh, John/0000-0003-4088-7016; Nichol, Alistair/0000-0002-4689-1238; Abdurraheim, Nuri/0000-0001-9498-4853; Presneill, Jeffrey/0000-0001-7177-7667; Alsolamy, Sami/0000-0002-0127-0307; Forbes, Andrew/0000-0003-4269-914X	National Health and Medical Research Council of Australia [545901, 1121037]; Victorian Neurotrauma Initiative (VNI) [VNI D162]; Teaching Hospital of Besancon, France; Health Research Board of Ireland Clinical Trial Network Program	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Victorian Neurotrauma Initiative (VNI); Teaching Hospital of Besancon, France; Health Research Board of Ireland Clinical Trial Network Program	This trial was supported by grants from the National Health and Medical Research Council of Australia (545901 and 1121037); the Victorian Neurotrauma Initiative (VNI for the Transport Accident Commission, Victoria, Australia) (VNI D162); the Teaching Hospital of Besancon, France; and Health Research Board of Ireland Clinical Trial Network Program.	Access Economics Pty Limited for the Victorian Neurotrauma Initiative, 2009, EC COST SPIN CORD IN; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Bramlett HM, 2012, THER HYPOTHERMIA TEM, V2, P14, DOI 10.1089/ther.2012.0002; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Dengler B, 2015, J CRIT CARE, V30, P823, DOI 10.1016/j.jcrc.2015.03.027; Geurts M, 2014, CRIT CARE MED, V42, P231, DOI 10.1097/CCM.0b013e3182a276e8; Liu YH, 2015, EXP THER MED, V9, P464, DOI 10.3892/etm.2014.2130; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maekawa T, 2015, J NEUROTRAUM, V32, P422, DOI 10.1089/neu.2013.3197; Marion DW, 2014, CRIT CARE, V18, DOI 10.1186/cc13955; McGinn MJ, 2016, NEUROSURG CLIN N AM, V27, P397, DOI 10.1016/j.nec.2016.06.002; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Nichol A, 2015, CRIT CARE RESUSC, V17, P92; Nichol AD, 2011, LANCET NEUROL, V10, P405, DOI 10.1016/S1474-4422(11)70085-0; Olah E, 2018, J NEUROTRAUM, V35, P2407, DOI 10.1089/neu.2018.5649; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Presneill J, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2610-y; Sahuquillo J, 2007, CURR PHARM DESIGN, V13, P2310; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smrcka M, 2005, ACT NEUR S, V95, P273; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tang CH, 2017, J CRIT CARE, V39, P267, DOI 10.1016/j.jcrc.2016.12.012; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zhao QJ, 2011, J CRIT CARE, V26, P311, DOI 10.1016/j.jcrc.2010.08.014; Zhao WY, 2017, BRAIN RES, V1669, P141, DOI 10.1016/j.brainres.2017.06.006; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	33	128	137	2	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	2018	320	21					2211	2220		10.1001/jama.2018.17075	http://dx.doi.org/10.1001/jama.2018.17075			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD4MB	30357266	Green Published, Bronze			2023-01-03	WOS:000452500600012
J	Formento, E; Minassian, K; Wagner, F; Mignardot, JB; Le Goff-Mignardot, CG; Rowald, A; Bloch, J; Micera, S; Capogrosso, M; Courtine, G				Formento, Emanuele; Minassian, Karen; Wagner, Fabien; Mignardot, Jean Baptiste; Le Goff-Mignardot, Camille G.; Rowald, Andreas; Bloch, Jocelyne; Micera, Silvestro; Capogrosso, Marco; Courtine, Gregoire			Electrical spinal cord stimulation must preserve proprioception to enable locomotion in humans with spinal cord injury	NATURE NEUROSCIENCE			English	Article							HIGH-FREQUENCY STIMULATION; CIRCUIT REORGANIZATION; EPIDURAL STIMULATION; FUNCTIONAL WALKING; MOTOR CONTROL; LUMBAR CORD; MODULATION; INPUT; CAT; MOTONEURONS	Epidural electrical stimulation (EES) of the spinal cord restores locomotion in animal models of spinal cord injury but is less effective in humans. Here we hypothesized that this interspecies discrepancy is due to interference between EES and proprioceptive information in humans. Computational simulations and preclinical and clinical experiments reveal that EES blocks a significant amount of proprioceptive input in humans, but not in rats. This transient deafferentation prevents modulation of reciprocal inhibitory networks involved in locomotion and reduces or abolishes the conscious perception of leg position. Consequently, continuous EES can only facilitate locomotion within a narrow range of stimulation parameters and is unable to provide meaningful locomotor improvements in humans without rehabilitation. Simulations showed that burst stimulation and spatiotemporal stimulation profiles mitigate the cancellation of proprioceptive information, enabling robust control over motor neuron activity. This demonstrates the importance of stimulation protocols that preserve proprioceptive information to facilitate walking with EES.	[Formento, Emanuele; Micera, Silvestro] Swiss Fed Inst Technol EPFL, Inst Bioengn, Bertarelli Fdn Chair Translat NeuroEngn, Lausanne, Switzerland; [Formento, Emanuele; Minassian, Karen; Wagner, Fabien; Mignardot, Jean Baptiste; Le Goff-Mignardot, Camille G.; Rowald, Andreas; Courtine, Gregoire] Swiss Fed Inst Technol EPFL, Sch Life Sci, Ctr Neuroprosthet, Lausanne, Switzerland; [Formento, Emanuele; Minassian, Karen; Wagner, Fabien; Mignardot, Jean Baptiste; Le Goff-Mignardot, Camille G.; Rowald, Andreas; Courtine, Gregoire] Swiss Fed Inst Technol EPFL, Sch Life Sci, Brain Mind Inst, Lausanne, Switzerland; [Rowald, Andreas; Capogrosso, Marco] Univ Fribourg, Dept Med, Fac Sci, Fribourg, Switzerland; [Bloch, Jocelyne; Courtine, Gregoire] Univ Hosp Lausanne CHUV, Dept Neurosurg, Lausanne, Switzerland; [Micera, Silvestro] Scuola Super Sant Anna, Inst Biorobot, Neural Engn Area, Pisa, Italy	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Fribourg; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Scuola Superiore Sant'Anna	Courtine, G (corresponding author), Swiss Fed Inst Technol EPFL, Sch Life Sci, Ctr Neuroprosthet, Lausanne, Switzerland.; Courtine, G (corresponding author), Swiss Fed Inst Technol EPFL, Sch Life Sci, Brain Mind Inst, Lausanne, Switzerland.; Courtine, G (corresponding author), Univ Hosp Lausanne CHUV, Dept Neurosurg, Lausanne, Switzerland.	gregoire.courtine@epfl.ch	Formento, Emanuele/AAX-9095-2020; Wagner, Fabien/ABC-4084-2020; Micera, Silvestro/AAD-6630-2021; Bloch, Jocelyne/A-9668-2017	Formento, Emanuele/0000-0002-7870-2710; Wagner, Fabien/0000-0002-9582-6109; Mignardot, Jean-Baptiste/0000-0003-0614-0453; Capogrosso, Marco/0000-0002-0975-316X; Minassian, Karen/0000-0003-4197-6141; courtine, gregoire/0000-0002-5744-4142; Bloch, Jocelyne/0000-0002-6405-1590; Rowald, Andreas/0000-0001-5493-195X	HBP Neurorobotics Platform from the European Union's Horizon 2020 Framework Programme for Research and Innovation [720270]; European Union [720270, 785907]; RESTORE: Eurostars [E10889]; Wings for Life; GTXmedical; European Research Council [HOW2WALKAGAIN 682999]; National Center of Competence in Research (NCCR) Robotics of the Swiss National Science Foundation; Commission of Technology and Innovation (CTI) Innosuisse (CTI) OptiStim [25761.1]; International Foundation for Research in Paraplegia (IRP); Michel-Adrien Voirol Foundation; Firmenich Foundation; Pictet Group Charitable Foundation; Panacee Foundation; Marie-Curie EPFL fellowship program; Wyss Center for Neuroengineering	HBP Neurorobotics Platform from the European Union's Horizon 2020 Framework Programme for Research and Innovation; European Union(European Commission); RESTORE: Eurostars; Wings for Life; GTXmedical; European Research Council(European Research Council (ERC)European Commission); National Center of Competence in Research (NCCR) Robotics of the Swiss National Science Foundation; Commission of Technology and Innovation (CTI) Innosuisse (CTI) OptiStim; International Foundation for Research in Paraplegia (IRP); Michel-Adrien Voirol Foundation; Firmenich Foundation; Pictet Group Charitable Foundation; Panacee Foundation; Marie-Curie EPFL fellowship program; Wyss Center for Neuroengineering	We thank K. Bartholdi, A. Bichat, and L. Baud for their help with the rat experiments, and we thank all the individuals involved in the STIMO clinical study. This research was supported by the HBP Neurorobotics Platform, funded from the European Union's Horizon 2020 Framework Programme for Research and Innovation under the Specific Grant Agreement No. 720270 (Human Brain Project SGA1). Financial support was provided by the European Union's Horizon 2020 Framework Programme for Research and Innovation under Specific Grant Agreements No. 720270 (Human Brain Project SGA1) and No. 785907 (Human Brain Project SGA2); RESTORE: Eurostars E10889, Wings for Life, GTXmedical, Consolidator Grant from the European Research Council (ERC-2015-CoG HOW2WALKAGAIN 682999), Wyss Center for Neuroengineering, National Center of Competence in Research (NCCR) Robotics of the Swiss National Science Foundation, the Commission of Technology and Innovation (CTI) Innosuisse (CTI) OptiStim 25761.1, International Foundation for Research in Paraplegia (IRP), the Michel-Adrien Voirol Foundation, the Firmenich Foundation, the Pictet Group Charitable Foundation, the Panacee Foundation, and the Marie-Curie EPFL fellowship program.	Albert F, 2006, EXP BRAIN RES, V172, P163, DOI 10.1007/s00221-005-0325-2; Angeli CA, 2018, NEW ENGL J MED, V379, P1244, DOI 10.1056/NEJMoa1803588; Angeli CA, 2014, BRAIN, V137, P1394, DOI 10.1093/brain/awu038; Asboth L, 2018, NAT NEUROSCI, V21, P576, DOI 10.1038/s41593-018-0093-5; Bawa P, 2008, MUSCLE NERVE, V38, P1604, DOI 10.1002/mus.21184; Buonocore M, 2008, SPINE, V33, pE90, DOI 10.1097/BRS.0b013e3181642a97; BURKE RE, 1968, J PHYSIOL-LONDON, V196, P605, DOI 10.1113/jphysiol.1968.sp008526; CALANCIE B, 1993, ELECTROEN CLIN NEURO, V89, P177, DOI 10.1016/0168-5597(93)90131-8; CAPADAY C, 1986, J NEUROSCI, V6, P1308; Capogrosso M, 2016, NATURE, V539, P284, DOI 10.1038/nature20118; Capogrosso M, 2013, J NEUROSCI, V33, P19326, DOI 10.1523/JNEUROSCI.1688-13.2013; Carhart MR, 2004, IEEE T NEUR SYS REH, V12, P32, DOI 10.1109/TNSRE.2003.822763; Cole J., 1995, PRIDE DAILY MARATHON; COLLINS WF, 1984, J NEUROPHYSIOL, V52, P980, DOI 10.1152/jn.1984.52.5.980; CONWAY BA, 1987, EXP BRAIN RES, V68, P643; Courtine GG, 2007, J PHYSIOL-LONDON, V582, P1125, DOI 10.1113/jphysiol.2007.128447; Courtine G, 2009, NAT NEUROSCI, V12, P1333, DOI 10.1038/nn.2401; Delp SL, 2007, IEEE T BIO-MED ENG, V54, P1940, DOI 10.1109/TBME.2007.901024; DELP SL, 1990, IEEE T BIO-MED ENG, V37, P757, DOI 10.1109/10.102791; Dietz V, 2000, GAIT POSTURE, V11, P102, DOI 10.1016/S0966-6362(99)00052-1; Dietz V, 2002, NAT REV NEUROSCI, V3, P781, DOI 10.1038/nrn939; Dimitrijevic MR, 1998, ANN NY ACAD SCI, V860, P360, DOI 10.1111/j.1749-6632.1998.tb09062.x; Dy CJ, 2010, J NEUROPHYSIOL, V103, P2808, DOI 10.1152/jn.00316.2009; Edgerton VR, 2004, ANNU REV NEUROSCI, V27, P145, DOI 10.1146/annurev.neuro.27.070203.144308; Gerasimenko YP, 2006, J NEUROSCI METH, V157, P253, DOI 10.1016/j.jneumeth.2006.05.004; Gill ML, 2018, NAT MED, V24, P1677, DOI 10.1038/s41591-018-0175-7; Han J, 2016, J SPORT HEALTH SCI, V5, P80, DOI 10.1016/j.jshs.2014.10.004; Harkema S, 2011, LANCET, V377, P1938, DOI 10.1016/S0140-6736(11)60547-3; HARRISON PJ, 1981, J PHYSIOL-LONDON, V312, P455, DOI 10.1113/jphysiol.1981.sp013638; Herman R, 2002, SPINAL CORD, V40, P65, DOI 10.1038/sj.sc.3101263; Hines ML, 1997, NEURAL COMPUT, V9, P1179, DOI 10.1162/neco.1997.9.6.1179; HNIK P, 1973, PFLUG ARCH EUR J PHY, V341, P155, DOI 10.1007/BF00587322; Hultborn H, 2007, ACTA PHYSIOL, V189, P111, DOI 10.1111/j.1748-1716.2006.01651.x; HUNTER JP, 1994, J PHYSIOL-LONDON, V474, P407, DOI 10.1113/jphysiol.1994.sp020032; ISHIKAWA K, 1966, EXP NEUROL, V15, P140, DOI 10.1016/0014-4886(66)90039-2; Johnson WL, 2008, J BIOMECH, V41, P610, DOI 10.1016/j.jbiomech.2007.10.004; Johnson WL, 2011, IEEE T BIO-MED ENG, V58, P3328, DOI 10.1109/TBME.2011.2106784; Kiehn O, 2016, NAT REV NEUROSCI, V17, P224, DOI 10.1038/nrn.2016.9; KOERBER HR, 1991, J NEUROPHYSIOL, V65, P1313, DOI 10.1152/jn.1991.65.6.1313; McIntyre CC, 2002, J NEUROPHYSIOL, V88, P1592, DOI 10.1152/jn.2002.88.4.1592; MENDELL LM, 1971, J NEUROPHYSIOL, V34, P171, DOI 10.1152/jn.1971.34.1.171; Mignardot JB, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3621; Minassian K, 2007, HUM MOVEMENT SCI, V26, P275, DOI 10.1016/j.humov.2007.01.005; Minassian K, 2004, SPINAL CORD, V42, P401, DOI 10.1038/sj.sc.3101615; Moraud EM, 2016, NEURON, V89, P814, DOI 10.1016/j.neuron.2016.01.009; MUNSON JB, 1980, J NEUROPHYSIOL, V44, P713, DOI 10.1152/jn.1980.44.4.713; Musienko P, 2012, J NEUROPHYSIOL, V107, P2072, DOI 10.1152/jn.00730.2011; Park SW, 2008, NEUROREHAB NEURAL RE, V22, P486, DOI 10.1177/1545968308316906; Prochazka A, 1999, PROG BRAIN RES, V123, P133, DOI 10.1016/S0079-6123(08)62850-2; Prochazka A., 1996, COMPR PHYSL, V76, P125; Prochazka A, 2007, INTEGR COMP BIOL, V47, P474, DOI 10.1093/icb/icm065; Proske U, 2012, PHYSIOL REV, V92, P1651, DOI 10.1152/physrev.00048.2011; Rattay F, 2000, SPINAL CORD, V38, P473, DOI 10.1038/sj.sc.3101039; Restuccia D, 2000, J NEUROL NEUROSUR PS, V69, P91, DOI 10.1136/jnnp.69.1.91; Roll JP, 2004, EXP BRAIN RES, V157, P359, DOI 10.1007/s00221-004-1853-x; Rossignol S, 2006, PHYSIOL REV, V86, P89, DOI 10.1152/physrev.00028.2005; Saal HP, 2015, NEUROPSYCHOLOGIA, V79, P344, DOI 10.1016/j.neuropsychologia.2015.06.010; SANES JN, 1985, HUM NEUROBIOL, V4, P101; Schindler-Ivens S, 2000, EXP BRAIN RES, V133, P233, DOI 10.1007/s002210000377; SEGEV I, 1990, J NEUROPHYSIOL, V64, P648, DOI 10.1152/jn.1990.64.2.648; SU CF, 1992, SPINE, V17, P504, DOI 10.1097/00007632-199205000-00006; Takeoka A, 2014, CELL, V159, P1626, DOI 10.1016/j.cell.2014.11.019; Tuthill JC, 2018, CURR BIOL, V28, pR194, DOI 10.1016/j.cub.2018.01.064; VALLBO AB, 1990, J PHYSIOL-LONDON, V421, P553, DOI 10.1113/jphysiol.1990.sp017961; Vallery H., 2013, IEEE INT C REH ROB, V2013; van den Brand R, 2012, SCIENCE, V336, P1182, DOI 10.1126/science.1217416; Wagner F., 2018, NATURE, DOI [10.1038/s41593-018-0262-6, DOI 10.1038/S41593-018-0262-6]; Wenger N, 2016, NAT MED, V22, P138, DOI 10.1038/nm.4025; Wenger N, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008325; Wojtusch J, 2015, IEEE-RAS INT C HUMAN, P74, DOI 10.1109/HUMANOIDS.2015.7363534	70	145	151	5	78	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	DEC	2018	21	12					1728	+		10.1038/s41593-018-0262-6	http://dx.doi.org/10.1038/s41593-018-0262-6			18	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HB8GE	30382196	Green Submitted, Green Accepted			2023-01-03	WOS:000451324700011
J	Pavo, N; Yarragudi, R; Puttinger, H; Arfsten, H; Strunk, G; Bojic, A; Hulsmann, M; Vychytil, A				Pavo, Noemi; Yarragudi, Rajashri; Puttinger, Heidi; Arfsten, Henrike; Strunk, Guido; Bojic, Andja; Huelsmann, Martin; Vychytil, Andreas			Parameters associated with therapeutic response using peritoneal dialysis for therapy refractory heart failure and congestive right ventricular dysfunction	PLOS ONE			English	Article							GLOMERULAR-FILTRATION-RATE; EUROPEAN ASSOCIATION; DIURETIC RESPONSE; AMERICAN SOCIETY; ULTRAFILTRATION; ECHOCARDIOGRAPHY; GUIDELINES; MANAGEMENT; PRESSURE; ADULTS	Background In patients with refractory heart failure (HF) peritoneal dialysis (PD) is associated with improved functional status and decrease in hospitalization. However, previous studies did not focus on right ventricular dysfunction as an important pathophysiologic component of cardiorenal syndrome. Methods In a prospective cohort study PD was started in 40 patients with refractory right HF (with/ without left HF). Refractoriness to conservative therapy was defined as persistent right heart congestion/ascites with intensified diuretic treatment and/or >= 2 hospitalizations within 6 months because of cardiac decompensation despite optimal medical treatment, and/or acute renal failure during intensified conservative treatment of cardiac decompensations. Results Patient survival was 55.0% at 1 year, 35.0% at 2 years and 27.5% at 3 years. The number of hospitalization days declined after initiation of PD for both cardiac [13 (IQR 1-53) days before vs. 1 (IQR 0-12) days after start of PD, p<0.001] and unplanned reasons [12 (IQR 3-44) days before vs. 1 (IQR 0-33) days after start of PD, p = 0.007]. Using a combined endpoint including survival time of >= 1 year and either improvement in quality of life or decline in hospitalizations we found that patients with extended ascites, higher systolic pulmonary artery pressure, more marked impairment of right ventricular function and tricuspid valve insufficiency, higher residual renal function as well as those who could perform PD without assistance have benefited most from this therapy. Conclusions Patients with more pronounced backward failure, less marked residual renal functional impairment and those not depending on assistance for therapy are likely to profit most from PD.	[Pavo, Noemi; Arfsten, Henrike; Bojic, Andja; Huelsmann, Martin] Med Univ Vienna, Dept Internal Med 2, Clin Div Cardiol, Vienna, Austria; [Yarragudi, Rajashri; Puttinger, Heidi; Vychytil, Andreas] Med Univ Vienna, Dept Internal Med 3, Clin Div Nephrol & Dialysis, Vienna, Austria; [Strunk, Guido] Complex Res, Vienna, Austria; [Strunk, Guido] FH Campus Vienna, Vienna, Austria; [Strunk, Guido] Tech Univ Dortmund, Dortmund, Germany	Medical University of Vienna; Medical University of Vienna; Dortmund University of Technology	Vychytil, A (corresponding author), Med Univ Vienna, Dept Internal Med 3, Clin Div Nephrol & Dialysis, Vienna, Austria.	andreas.vychytil@meduniwien.ac.at	Strunk, Guido/ABD-5425-2021	Strunk, Guido/0000-0002-0607-5105	Baxter Healthcare	Baxter Healthcare	This study was supported by an unrestricted grant from Baxter Healthcare. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adlbrecht C, 2016, EUR J CLIN INVEST, V46, P34, DOI 10.1111/eci.12562; Bart BA, 2012, NEW ENGL J MED, V367, P2296, DOI 10.1056/NEJMoa1210357; Bertoli SV, 2014, PERITON DIALYSIS INT, V34, P64, DOI 10.3747/pdi.2012.00290; Brause M, 1999, KIDNEY INT, V56, pS95, DOI 10.1046/j.1523-1755.56.s.72.4.x; Costanzo MR, 2007, J AM COLL CARDIOL, V49, P675, DOI 10.1016/j.jacc.2006.07.073; Courivaud C, 2014, PERITON DIALYSIS INT, V34, P100, DOI 10.3747/pdi.2012.00149; Crespo-Leiro MG, 2018, EUR J HEART FAIL, V20, P1505, DOI 10.1002/ejhf.1236; Delanaye P, 2016, CLIN KIDNEY J, V9, P700, DOI 10.1093/ckj/sfw071; Dickstein K, 2008, EUR HEART J, V29, P2388, DOI 10.1093/eurheartj/ehn309; Dini FL, 2012, EUR J HEART FAIL, V14, P287, DOI 10.1093/eurjhf/hfr176; Doty JM, 1999, J TRAUMA, V47, P1000, DOI 10.1097/00005373-199912000-00002; Elhalel-Dranitzki M, 1998, NEPHROL DIAL TRANSPL, V13, P3041, DOI 10.1093/ndt/13.12.3041; Frohlich H, 2015, CLIN KIDNEY J, V8, P219, DOI 10.1093/ckj/sfv007; Gaspari F, 2013, KIDNEY INT, V84, P164, DOI 10.1038/ki.2013.47; Goliasch G, 2018, EUR HEART J, V39, P39, DOI 10.1093/eurheartj/ehx402; Gotloib L, 2005, NEPHROL DIAL TRAN S7, V20, pvii32, DOI DOI 10.1093/NDT/GFH1105; Grootendorst DC, 2011, NEPHROL DIAL TRANSPL, V26, P1932, DOI 10.1093/ndt/gfq667; Koch M, 2012, EUR J HEART FAIL, V14, P530, DOI 10.1093/eurjhf/hfs035; Kwok CS, 2017, INT J CARDIOL, V228, P122, DOI 10.1016/j.ijcard.2016.11.136; Lang RM, 2015, EUR HEART J-CARD IMG, V16, P233, DOI 10.1093/ehjci/jev014; Lu RH, 2015, CARDIORENAL MED, V5, P145, DOI 10.1159/000380915; Luis-Lima S, 2015, TRANSPLANTATION, V99, P2625, DOI 10.1097/TP.0000000000000786; Mehrotra R, 2006, KIDNEY INT, V70, pS67, DOI 10.1038/sj.ki.5001918; Mullens W, 2008, J CARD FAIL, V14, P508, DOI 10.1016/j.cardfail.2008.02.010; Mullens W, 2009, J AM COLL CARDIOL, V53, P589, DOI 10.1016/j.jacc.2008.05.068; Packer M, 2016, CIRCULATION, V134, P629, DOI 10.1161/CIRCULATIONAHA.116.024498; Ponce D, 2017, PERITON DIALYSIS INT, V37, P578, DOI 10.3747/pdi.2016.00217; Rector TS, 2012, CIRC-HEART FAIL, V5, P217, DOI 10.1161/CIRCHEARTFAILURE.111.964221; Rector TS, 1987, HEART FAIL, V3, P198, DOI DOI 10.1177/1474515111435605; Rossing P, 2006, DIABETES CARE, V29, P1024, DOI 10.2337/dc05-2201; Rudski LG, 2010, J AM SOC ECHOCARDIOG, V23, P685, DOI 10.1016/j.echo.2010.05.010; Ruggenenti P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032533; Ryckelynck JP, 1998, NEPHROL DIAL TRANSPL, V13, P56, DOI 10.1093/ndt/13.suppl_4.56; Valente MAE, 2014, EUR HEART J, V35, P1284, DOI 10.1093/eurheartj/ehu065; Voors AA, 2014, EUR J HEART FAIL, V16, P1230, DOI 10.1002/ejhf.170; Zaman T, 2013, J RENAL NUTR, V23, P233, DOI 10.1053/j.jrn.2013.01.028	36	12	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 19	2018	13	11							e0206830	10.1371/journal.pone.0206830	http://dx.doi.org/10.1371/journal.pone.0206830			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA9FQ	30452453	Green Published, gold, Green Submitted			2023-01-03	WOS:000450603800005
J	Campos, NA; da Cunha, MSB; Arruda, SF				Campos, Natalia A.; da Cunha, Marcela S. B.; Arruda, Sandra F.			Tucum-do-cerrado (Bactris setosa Mart.) modulates oxidative stress, inflammation, and apoptosis-related proteins in rats treated with azoxymethane	PLOS ONE			English	Article							ABERRANT CRYPT FOCI; NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; INDUCED COLON-CANCER; METABOLIC-ACTIVATION; CELL-PROLIFERATION; PHENOLIC-COMPOUNDS; TNF-ALPHA; EXPRESSION; RESVERATROL	Oxidative and inflammatory responses play an important role in the development and prevention of cancer, with both responses being modulated by phytochemical compounds. This study investigated the chemopreventive effect of tucum-do-cerrado fruit in rats treated with azoxymethane. Wistar rats were treated for 12 weeks with: a control diet (CT); a control diet + AOM (CT/DR); a control diet + 15% tucum-do-cerrado (TU); or a control diet + 15% tucum-do-cerrado + AOM (TU/DR). The association of tucum-do-cerrado and AOM (TU/DR) increased glutathione-S-transferase activity, decreased MDA levels, increased levels of COX2, TNF alpha and BAX, and decreased Bcl2/Bax ratio, compared to the CT/DR group. Carbonyl levels, IL-1 beta and IL-6 mRNA levels, and aberrant crypt foci showed no difference between the treatments. In conclusion, tucum-do-cerrado reduced lipid oxidative damage, induced a pro-inflammatory effect, and promoted a pro-apoptotic "environment" in rats treated with AOM; however no changes in aberrant crypts were observed.	[Campos, Natalia A.; da Cunha, Marcela S. B.; Arruda, Sandra F.] Univ Brasilia, Campus Univ Darcy Ribeiro, Fac Hlth Sci, Postgrad Program Human Nutr, Brasilia, DF, Brazil; [da Cunha, Marcela S. B.] Univ Fed Oeste Bahia, Campus Reitor Edgard Santos, Biol & Hlth Sci Ctr, Barreiras, BA, Brazil; [Arruda, Sandra F.] Univ Brasilia, Campus Univ Darcy Ribeiro, Fac Hlth Sci, Dept Nutr, Brasilia, DF, Brazil	Universidade de Brasilia; Universidade Federal do Oeste da Bahia; Universidade de Brasilia	Campos, NA (corresponding author), Univ Brasilia, Campus Univ Darcy Ribeiro, Fac Hlth Sci, Postgrad Program Human Nutr, Brasilia, DF, Brazil.	nataboudib@gmail.com	da Cunha, Marcela S B/F-6523-2014; Arruda, Sandra Fernandes/AAC-6778-2019	da Cunha, Marcela S B/0000-0002-1388-033X; Fernandes Arruda, Sandra/0000-0003-0774-8276	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Fundacao de Apoio a Pesquisa do Distrito Federal (FAP-DF)	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fundacao de Apoio a Pesquisa do Distrito Federal (FAP-DF)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF))	The Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) provided a pH.D scholarship and the Fundacao de Apoio a Pesquisa do Distrito Federal (FAP-DF) provided financial aid. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) for the scholarship and the Fundacao de Apoio a Pesquisa do Distrito Federal (FAP-DF) for financial aid.	Arruda LF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061058; BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1; Boateng J, 2007, FOOD CHEM TOXICOL, V45, P725, DOI 10.1016/j.fct.2006.10.019; Candan N, 2008, NEUROTOXICOLOGY, V29, P708, DOI 10.1016/j.neuro.2008.04.012; Chen JZ, 2009, CANCER BIOL THER, V8, P1313, DOI 10.4161/cbt.8.14.8983; Choi YJ, 2017, GUT LIVER, V11, P243, DOI 10.5009/gnl16068; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Siqueira EMD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072826; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Delage B, 2005, INT J CANCER, V116, P839, DOI 10.1002/ijc.21108; Di Liddo R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0248-1; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Falchetti R, 2001, LIFE SCI, V70, P81, DOI 10.1016/S0024-3205(01)01367-4; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fustinoni-Reis AM, 2016, NUTRIENTS, V8, DOI 10.3390/nu8020038; Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200; Gendron ME, 2012, DOSE-RESPONSE, V10, P108, DOI 10.2203/dose-response.11-014.Thorin; Ghirardi M, 1999, EUR SURG RES, V31, P272, DOI 10.1159/000008703; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gualdoni GA, 2014, BBA-GEN SUBJECTS, V1840, P95, DOI 10.1016/j.bbagen.2013.09.009; Habig W H, 1981, Methods Enzymol, V77, P218; Halliwell B, 2007, BIOCHEM J, V401, P1, DOI 10.1042/BJ20061131; Halliwell B, 2013, BRIT J CLIN PHARMACO, V75, P637, DOI 10.1111/j.1365-2125.2012.04272.x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; Joanisse DR, 1996, AM J PHYSIOL-REG I, V271, pR545, DOI 10.1152/ajpregu.1996.271.3.R545; Kauntz H, 2012, INT J ONCOL, V41, P849, DOI 10.3892/ijo.2012.1526; Kawamori T, 1998, CANCER RES, V58, P409; Kim J, 2013, FOOD FUNCT, V4, P681, DOI 10.1039/c3fo30287c; Li YB, 2006, PHARMACOL RES, V53, P6, DOI 10.1016/j.phrs.2005.08.002; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Megaraj V, 2014, CHEM RES TOXICOL, V27, P656, DOI 10.1021/tx4004769; Mohseni M, 2012, MUTAT RES-FUND MOL M, V738, P19, DOI 10.1016/j.mrfmmm.2012.08.006; Moskaug JO, 2005, AM J CLIN NUTR, V81, p277S, DOI 10.1093/ajcn/81.1.277S; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; OBERLEY LW, 1988, FREE RADICAL BIO MED, V5, P113, DOI 10.1016/0891-5849(88)90036-6; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Palomer X, 2013, INT J CARDIOL, V167, P2507, DOI 10.1016/j.ijcard.2012.06.006; Paur I, 2008, FOOD CHEM TOXICOL, V46, P1288, DOI 10.1016/j.fct.2007.09.103; Peinnequin Andre, 2004, BMC Immunology, V5, P1, DOI 10.1186/1471-2172-5-3; Pool-Zobel B, 2005, MUTAT RES-FUND MOL M, V591, P74, DOI 10.1016/j.mrfmmm.2005.04.020; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Richert S, 2002, ARCH BIOCHEM BIOPHYS, V397, P430, DOI 10.1006/abbi.2001.2683; Rijken PJ, 1999, CARCINOGENESIS, V20, P2267, DOI 10.1093/carcin/20.12.2267; Romier B, 2008, BRIT J NUTR, V100, P542, DOI 10.1017/S0007114508966666; Rosa FR, 2016, NUTRIENTS, V8, DOI 10.3390/nu8030110; Shureiqi I, 2011, CANCER PREV RES, V4, P296, DOI 10.1158/1940-6207.CAPR-11-0060; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Sohn OS, 2001, CANCER RES, V61, P8435; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Umesalma S, 2010, BASIC CLIN PHARMACOL, V107, P650, DOI 10.1111/j.1742-7843.2010.00565.x; Vaskivuo TE, 2002, CANCER-AM CANCER SOC, V95, P1463, DOI 10.1002/cncr.10876; Verma M, 2015, ADV EXP MED BIOL, V867, P59, DOI 10.1007/978-94-017-7215-0_5; Waly MI, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-60; Wang J, 2002, J AGR FOOD CHEM, V50, P4183, DOI 10.1021/jf011613d; Wang LK, 2014, INT J MOL SCI, V15, P16226, DOI 10.3390/ijms150916226; Wang Q, 2008, ENDOCRINOLOGY, V149, P3920, DOI 10.1210/en.2007-1626; Warren CA, 2009, J NUTR, V139, P101, DOI 10.3945/jn.108.096271; Williams D, 2007, FOOD CHEM TOXICOL, V45, P153, DOI 10.1016/j.fct.2006.08.014; Yi WG, 2005, J AGR FOOD CHEM, V53, P7320, DOI 10.1021/jf051333o	65	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2018	13	11							e0206670	10.1371/journal.pone.0206670	http://dx.doi.org/10.1371/journal.pone.0206670			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA3GQ	30427888	Green Published, Green Submitted, gold			2023-01-03	WOS:000450138500065
J	Lee, BY; Clemens, DL; Silva, A; Dillon, BJ; Maslesa-Galic, S; Nava, S; Ho, CM; Horwitz, MA				Lee, Bai-Yu; Clemens, Daniel L.; Silva, Aleidy; Dillon, Barbara Jane; Maslesa-Galic, Sasa; Nava, Susana; Ho, Chih-Ming; Horwitz, Marcus A.			Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility	PLOS ONE			English	Article							C3HEB/FEJ MOUSE MODEL; MYCOBACTERIUM-TUBERCULOSIS; RESISTANT TUBERCULOSIS; CELL-WALL; PYRAZINAMIDE; SQ109; PHARMACOKINETICS; PHARMACODYNAMICS; CLOFAZIMINE; MMPL3	As current treatment of tuberculosis is burdensomely long, provoking non-adherence and drug resistance, effective short-course treatments are needed. Using the output-driven parabolic response surface (PRS) platform, we have identified drug regimens that treat tuberculosis more rapidly in mice than the current Standard Regimen used in humans. We show that PRS Regimen III, comprising clofazimine, SQ109, bedaquiline and pyrazinamide, rapidly sterilizes the lung both in conventionally studied BALB/c mice and in C3HeB/FeJ mice, highly susceptible mice that develop massive necrotic granulomatous lung lesions akin to those in humans, achieving relapse-free cure in only 4 weeks (p<0.0001 versus Standard Regimen). In contrast, the Standard Regimen required 16 weeks to attain lung culture negative status and 20 weeks to achieve relapse-free cure. Thus, PRS Regimen III dramatically cuts by similar to 80% the time to relapse-free cure in mouse tuberculosis models. PRS Regimen III, with three nonstandard drugs, can potentially treat both drug-sensitive and most drug-resistant tuberculosis.	[Lee, Bai-Yu; Clemens, Daniel L.; Dillon, Barbara Jane; Maslesa-Galic, Sasa; Nava, Susana; Horwitz, Marcus A.] Univ Calif Los Angeles, Dept Med, Div Infect Dis, Los Angeles, CA 90024 USA; [Silva, Aleidy; Ho, Chih-Ming] Univ Calif Los Angeles, Dept Mech & Aerosp Engn, Los Angeles, CA USA; [Ho, Chih-Ming] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Horwitz, MA (corresponding author), Univ Calif Los Angeles, Dept Med, Div Infect Dis, Los Angeles, CA 90024 USA.	MHorwitz@mednet.ucla.edu			Shanghai Jiao Tong University; Bill and Melinda Gates Foundation [OPP1070754]	Shanghai Jiao Tong University; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	This work was supported by a subgrant from Shanghai Jiao Tong University, a grantee (Global Health Grant No. OPP1070754) of the Bill and Melinda Gates Foundation (CH and MAH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; Diacon AH, 2012, ANTIMICROB AGENTS CH, V56, P3271, DOI 10.1128/AAC.06126-11; Diacon AH, 2014, EXPERT REV ANTI-INFE, V12, P223, DOI 10.1586/14787210.2014.870884; Falzon D, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02308-2016; Goude R, 2009, ANTIMICROB AGENTS CH, V53, P4138, DOI 10.1128/AAC.00162-09; Irwin SM, 2016, ACS INFECT DIS, V2, P251, DOI 10.1021/acsinfecdis.5b00127; Irwin SM, 2014, ANTIMICROB AGENTS CH, V58, P4026, DOI 10.1128/AAC.02565-14; Jia J, 2005, BRIT J PHARMACOL, V144, P80, DOI 10.1038/sj.bjp.0705984; Jindani A, 2003, AM J RESP CRIT CARE, V167, P1348, DOI 10.1164/rccm.200210-1125OC; JONMALUNG J, 2010, BMC MICROBIOL, V10; Kramnik I, 2008, CURR TOP MICROBIOL, V321, P123; Kramnik I, 2016, SEMIN IMMUNOPATHOL, V38, P221, DOI 10.1007/s00281-015-0538-9; Kurbatova EV, 2013, CLIN INFECT DIS, V57, P1081, DOI 10.1093/cid/cit452; Lanoix JP, 2016, ANTIMICROB AGENTS CH, V60, P1091, DOI 10.1128/AAC.02637-15; Lanoix JP, 2015, DIS MODEL MECH, V8, P603, DOI 10.1242/dmm.019513; Lee BY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14183; LEVY L, 1974, AM J TROP MED HYG, V23, P1097, DOI 10.4269/ajtmh.1974.23.1097; Li K, 2014, J MED CHEM, V57, P3126, DOI 10.1021/jm500131s; Li SY, 2015, ANTIMICROB AGENTS CH, V59, P4026, DOI 10.1128/AAC.00105-15; Li W, 2014, ANTIMICROB AGENTS CH, V58, P6413, DOI 10.1128/AAC.03229-14; MIKUSOVA K, 1995, ANTIMICROB AGENTS CH, V39, P2484, DOI 10.1128/AAC.39.11.2484; Nikonenko BV, 2007, ANTIMICROB AGENTS CH, V51, P1563, DOI 10.1128/AAC.01326-06; Rouan MC, 2012, ANTIMICROB AGENTS CH, V56, P1444, DOI 10.1128/AAC.00720-11; Sacksteder KA, 2012, FUTURE MICROBIOL, V7, P823, DOI [10.2217/FMB.12.56, 10.2217/fmb.12.56]; Silva A, 2016, P NATL ACAD SCI USA, V113, pE2172, DOI 10.1073/pnas.1600812113; Simons SO, 2012, J CLIN MICROBIOL, V50, P428, DOI 10.1128/JCM.05435-11; Stoffels K, 2012, ANTIMICROB AGENTS CH, V56, P5186, DOI 10.1128/AAC.05385-11; Swanson RV, 2015, ANTIMICROB AGENTS CH, V59, P3042, DOI 10.1128/AAC.00260-15; Tahlan K, 2012, ANTIMICROB AGENTS CH, V56, P1797, DOI 10.1128/AAC.05708-11; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493, DOI 10.1128/AAC.33.9.1493; Tyagi S, 2015, P NATL ACAD SCI USA, V112, P869, DOI 10.1073/pnas.1416951112; World Health Organization, 2016, GLOBAL TUBERCULOSIS; Xia Q, 2015, ANTIMICROB AGENTS CH, V59, P1695, DOI 10.1128/AAC.04541-14; Xu ZJ, 2017, P NATL ACAD SCI USA, V114, P7993, DOI 10.1073/pnas.1700062114; Zarrinpar A, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aac5954	35	13	15	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2018	13	11							e0207469	10.1371/journal.pone.0207469	http://dx.doi.org/10.1371/journal.pone.0207469			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA3GQ	30427938	Green Submitted, Green Published, gold			2023-01-03	WOS:000450138500105
J	Siemieniuk, RAC; Chu, DK; Kim, LHY; Guell-Rous, MR; Alhazzani, W; Soccal, PM; Karanicolas, PJ; Farhoumand, PD; Siemieniuk, JLK; Satia, I; Irusen, EM; Refaat, MM; Mikita, JS; Smith, M; Cohen, DN; Vandvik, PO; Agoritsas, T; Lytvyn, L; Guyatt, GH				Siemieniuk, Reed A. C.; Chu, Derek K.; Kim, Lisa Ha-Yeon; Guell-Rous, Maria-Rosa; Alhazzani, Waleed; Soccal, Paola M.; Karanicolas, Paul J.; Farhoumand, Pauline D.; Siemieniuk, Jillian L. K.; Satia, Imran; Irusen, Elvis M.; Refaat, Marwan M.; Mikita, J. Stephen; Smith, Maureen; Cohen, Dian N.; Vandvik, Per O.; Agoritsas, Thomas; Lytvyn, Lyubov; Guyatt, Gordon H.			Oxygen therapy for acutely ill medical patients: a clinical practice guideline	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; TASK-FORCE; MANAGEMENT; STROKE; ADULTS; GRADE; PROFESSIONALS; ELEVATION; EMERGENCY; CONSENSUS		[Siemieniuk, Reed A. C.; Alhazzani, Waleed; Agoritsas, Thomas; Lytvyn, Lyubov; Guyatt, Gordon H.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON L8S 4K1, Canada; [Chu, Derek K.; Kim, Lisa Ha-Yeon; Alhazzani, Waleed; Satia, Imran; Guyatt, Gordon H.] McMaster Univ, Dept Med, Hamilton, ON L8S 4K1, Canada; [Guell-Rous, Maria-Rosa] Hosp Santa Creu & Sant Pau, Dept Pneumol, Barcelona 08041, Catalonia, Spain; [Soccal, Paola M.] Geneva Univ Hosp, Div Pulm Med, CH-1211 Geneva, Switzerland; [Soccal, Paola M.] Univ Geneva, Fac Med, CH-1206 Geneva, Switzerland; [Karanicolas, Paul J.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Surg, Toronto, ON M4N 3M5, Canada; [Farhoumand, Pauline D.; Agoritsas, Thomas] Univ Hosp Geneva, Div Gen Internal Med, CH-1205 Geneva, Switzerland; [Siemieniuk, Jillian L. K.] Alberta Hlth Serv, Calgary, AB T1Y 6J4, Canada; [Irusen, Elvis M.] Stellenbosch Univ, Div Pulmonol, ZA-7505 Cape Town, South Africa; [Irusen, Elvis M.] Stellenbosch Univ, Div Med Intens Care, ZA-7505 Cape Town, South Africa; [Refaat, Marwan M.] Amer Univ Beirut, Fac Med, Dept Internal Med, Beirut 11072020, Lebanon; [Refaat, Marwan M.] Amer Univ Beirut, Fac Med, Dept Biochem & Mol Genet, Beirut 11072020, Lebanon; [Refaat, Marwan M.] Amer Univ Beirut, Med Ctr, Beirut 11072020, Lebanon; [Vandvik, Per O.] Univ Oslo, Fac Med, Inst Hlth & Soc, Oslo, Norway; [Agoritsas, Thomas] Univ Hosp Geneva, Div Clin Epidemiol, CH-1205 Geneva, Switzerland	McMaster University; McMaster University; Hospital of Santa Creu i Sant Pau; University of Geneva; University of Geneva; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Geneva; Alberta Health Services (AHS); University of Calgary; Stellenbosch University; Stellenbosch University; American University of Beirut; American University of Beirut; American University of Beirut; University of Oslo; University of Geneva	Siemieniuk, RAC (corresponding author), McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON L8S 4K1, Canada.	reed.siemieniuk@medportal.ca	Refaat, Marwan/AAI-2179-2021; Irusen, Elvis/AAU-4571-2020; Agoritsas, Thomas/F-4321-2014; Farhoumand, Pauline Darbellay/I-7869-2016; T, E/HII-8943-2022; Satia, Imran/ABA-2872-2020	Agoritsas, Thomas/0000-0002-6182-9969; Satia, Imran/0000-0003-4206-6000; Chu, Derek/0000-0001-8269-4496; Darbellay Farhoumand, Pauline/0000-0003-4108-4266				Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; [Anonymous], 1920, BMJ-BRIT MED J, Vi, P150; Aside LM, 2018, JAMA-J AM MED ASSOC, V319, P2190, DOI 10.1001/jama.2018.5725; Austin MA, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5462; Beasley R, 2015, RESPIROLOGY, V20, P1182, DOI 10.1111/resp.12620; Blodgett AN., 1890, BOSTON MED SURG J, V123, P481, DOI [10.1056/NEJM189011201232101, DOI 10.1056/NEJM189011201232101]; Burls A, 2010, EMERG MED J, V27, P283, DOI 10.1136/emj.2009.077370; Chu DK, 2018, LANCET, V391, P1693, DOI 10.1016/S0140-6736(18)30479-3; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hafner S, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0084-6; Hale KE, 2008, EMERG MED J, V25, P773, DOI 10.1136/emj.2008.059287; Hofmann R, 2017, NEW ENGL J MED, V377, P1240, DOI 10.1056/NEJMoa1706222; Ibanez B, 2018, KARDIOL POL, V76, P229, DOI 10.5603/KP.2018.0041; Kallstrom Thomas J, 2002, Respir Care, V47, P717; Kobayashi A, 2018, EUR J NEUROL, V25, P425, DOI 10.1111/ene.13539; O'Driscoll BR, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2016-209729; O'Gara PT, 2013, J AM COLL CARDIOL, V61, pE78, DOI [10.1016/j.jacc.2012.11.019, 10.1161/CIR.0b013e3182742cf6]; Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158; Roffe C, 2017, JAMA-J AM MED ASSOC, V318, P1125, DOI 10.1001/jama.2017.11463; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; SIEMIENIUK RA, 2016, BMJ-BRIT MED J, V354, DOI DOI 10.1136/BMJ.I5191; Wetterslev J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008884.pub2	23	121	132	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 24	2018	363								k4169	10.1136/bmj.k4169	http://dx.doi.org/10.1136/bmj.k4169			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY8PQ	30355567				2023-01-03	WOS:000448895300004
J	Zhen, LM; Li, X; Gao, X; Wei, HD; Lei, XM				Zhen, Luming; Li, Xiao; Gao, Xue; Wei, Haidong; Lei, Xiaoming			Dose determination of sufentanil for intravenous patient-controlled analgesia with background infusion in abdominal surgeries: A random study	PLOS ONE			English	Article							TARGET-CONTROLLED INFUSION; EPIDURAL ANALGESIA; PAIN MANAGEMENT; NATIONAL-SURVEY; PHARMACOKINETICS; LEVOBUPIVACAINE; EFFICACY; OPIOIDS; SAFETY	Objectives Sufentanil has been widely used in epidural PCA, while its use in intravenous PCA has rarely been reported. Based on its use in target controlled infusion, we reckoned that the effect-site concentration of sufentanil would be steady if background infusion is given in intravenous PCA. This prospective, single center, randomized study with a three arm parallel group design aims to find out the appropriate dose of sufentanil when used in intravenous PCA with background infusion in abdominal surgeries. Methods Patients diagnosed with gastrointestinal cancer and consented to the study were recruited. The analgesia pump with one of three different doses of sufentanil (1.5, 2.0 or 2.5 mu g/kg) was attached to the patient through peripheral venous line right after surgery. The primary endpoint was pain scale VAS up to 48 hours postoperatively. Results In our study 90 patients were analyzed. In group B (SF 2.0) and C (SF2.5), patients had better pain relief than in group A (SF 1.5). There was no difference between group B and C in pain intensity at rest. While in group C more patients got pain relived at activity than in group B. All three groups had low and similar incidence of adverse effects of sufentanil. Conclusion The dose 2.5 pg/kg of sufentanil with background infusion is preferred because of better pain alleviation at activity without increase of adverse effects up to 48 hours after surgery.	[Zhen, Luming; Li, Xiao; Gao, Xue; Wei, Haidong; Lei, Xiaoming] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Anesthesiol, Xian, Shaanxi, Peoples R China	Xi'an Jiaotong University	Wei, HD; Lei, XM (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Anesthesiol, Xian, Shaanxi, Peoples R China.	weihdxj@xjtu.edu.cn; leixiaoming007@163.com	Wei, Haidong/GZG-6935-2022					Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Bastin R, 2005, ACTA ANAESTH BELG, V56, P31; Boselli E, 2004, ANESTHESIOLOGY, V100, P968, DOI 10.1097/00000542-200404000-00030; Brown C, 2013, PAIN MANAG NURS, V14, P184, DOI 10.1016/j.pmn.2010.12.002; Coller J, 2009, EUR J CLIN PHARMACOL, V65, P121, DOI 10.1007/s00228-008-0570-y; Ethuin F, 2003, INTENS CARE MED, V29, P1916, DOI 10.1007/s00134-003-1920-y; Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002; Gan TJ, 2014, CURR MED RES OPIN, V30, P149, DOI 10.1185/03007995.2013.860019; GEPTS E, 1995, ANESTHESIOLOGY, V83, P1194, DOI 10.1097/00000542-199512000-00010; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Jeleazcov C, 2016, ANESTHESIOLOGY, V124, P56, DOI 10.1097/ALN.0000000000000937; Li W, 2016, PLOS ONE, V11; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; Mendola C, 2009, BRIT J ANAESTH, V102, P418, DOI 10.1093/bja/aep004; Oberhofer D, 2005, WORLD J SURG, V29, P446, DOI 10.1007/s00268-004-7612-0; Olivier P, 1999, J CARDIOTHOR VASC AN, V13, P3, DOI 10.1016/S1053-0770(99)90164-7; PARKER RK, 1991, JAMA-J AM MED ASSOC, V266, P1947, DOI 10.1001/jama.266.14.1947; SCHUG SA, 1993, PAIN, V55, P387, DOI 10.1016/0304-3959(93)90016-I; Sitsen E, 2012, ACTA ANAESTH BELG, V63, P169; Smet I, 2008, BRIT J ANAESTH, V100, P99, DOI 10.1093/bja/aem309; Wu CL, 2005, ANESTHESIOLOGY, V103, P1079, DOI 10.1097/00000542-200511000-00023; Zhang CH, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0003-2; Zhao Y, 2009, CHINESE MED J-PEKING, V122, P1979, DOI 10.3760/cmaj.issn.0366-6999.2009.17.004; Zhao Y, 2009, CHINESE MED J-PEKING, V122, P291, DOI 10.3760/cma.j.issn.0366-6999.2009.03.010	24	5	5	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2018	13	10							e0205959	10.1371/journal.pone.0205959	http://dx.doi.org/10.1371/journal.pone.0205959			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX3PM	30332482	gold, Green Published, Green Submitted			2023-01-03	WOS:000447638200078
J	Arnolda, G; Chien, TD; Hayen, A; Hoi, NTX; Maningas, K; Joe, P; Cavallin, F; Trevisanuto, D; Moccia, L				Arnolda, Gaston; Chien, Tran Dinh; Hayen, Andrew; Hoi, Nguyen Thi Xuan; Maningas, Katherine; Joe, Priscilla; Cavallin, Francesco; Trevisanuto, Daniele; Moccia, Luciano			A comparison of the effectiveness of three LED phototherapy machines, single- and double-sided, for treating neonatal jaundice in a low resource setting	PLOS ONE			English	Article							NEWBORN-INFANT 35; TERM NEWBORNS; HYPERBILIRUBINEMIA; MANAGEMENT; TRIAL	Introduction Neonatal jaundice is one of the most common reasons for hospital admission in low resource settings. Treatment is frequently inadequate as conventional phototherapy requires frequent bulb changes. LED phototherapy has comparable efficacy to conventional phototherapy, and the bulbs last over 40,000 hours. This observational study compares the effectiveness of three LED machines, two single-sided and one double-sided in routine use in Vietnam. Methods We included all infants weighting >= 1500g and with jaundice diagnosed visually or by Total Serum Bilirubin (TSB) measurement at The Da Nang Hospital for Women and Children (Da Nang, Vietnam). The primary endpoint was the average hourly change in TSB over the first six hours of treatment. The secondary endpoints were duration of treatment; average hourly change in TSB over treatment, and length of stay in the neonatal unit. Multivariable analysis and bootstrap methods was performed to compare outcomes, adjusting for potential confounders. Results All outcomes were comparable in the two single-sided machines. The double-sided machine showed 54% increase in the hourly speed of TSB reduction (1.3 mu mol/L/hr, 95% CI 0.3-2.3), with a 45% increase in the speed of TSB reduction over the duration of treatment (0.9 mu mol/ L/hr, 95% CI 0.6-1.3). In addition, the double-sided machine was associated with 21% reduction in the duration of treatment (14 hours, 95% CI 5-22) and 16% reduction of length of stay (14 hours, 95% CI 3-25). Conclusion The results confirm and quantify the benefits of increasing surface-area exposure during phototherapy. Adjusted for multiple potential confounders, use of double-sided phototherapy can substantially increase the speed of TSB reduction, and substantially decrease the duration of treatment and length of stay in the NCU.	[Arnolda, Gaston] Univ New South Wales, Fac Med, Sch Publ Hlth & Community Med, Sydney, NSW, Australia; [Chien, Tran Dinh; Hoi, Nguyen Thi Xuan; Maningas, Katherine] Thrive Networks, Oakland, CA USA; [Hayen, Andrew] Univ Technol Sydney, Fac Hlth, Sch Publ Hlth, Sydney, NSW, Australia; [Joe, Priscilla] Childrens Hosp & Res Ctr, Div Neonatol, Oakland, CA USA; [Trevisanuto, Daniele; Moccia, Luciano] Amici Neonatol Trentina, Trento, Italy; [Trevisanuto, Daniele] Univ Padua, Med Sch, Dept Woman & Child Hlth, Padua, Italy; [Moccia, Luciano] Day One Hlth, Redding, CA USA	University of New South Wales Sydney; University of Technology Sydney; University of Padua	Trevisanuto, D (corresponding author), Amici Neonatol Trentina, Trento, Italy.; Trevisanuto, D (corresponding author), Univ Padua, Med Sch, Dept Woman & Child Hlth, Padua, Italy.	daniele.trevisanuto@unipd.it	Arnolda, Gaston R/D-8528-2017	Arnolda, Gaston R/0000-0003-4948-7633; Hayen, Andrew/0000-0003-4046-8030	Regione Trentino Alto Adige, Italy; Breath of Life Program; Thrive Networks; Amici della Neonatologia Trentina, Trento, Italy; Da Nang Women and Children's Hospital	Regione Trentino Alto Adige, Italy; Breath of Life Program; Thrive Networks; Amici della Neonatologia Trentina, Trento, Italy; Da Nang Women and Children's Hospital	The funding for the pilot project described in this study was provided by Eric Hemel and Barbara Morgen, donors to Thrive Networks, a no-profit international non-governmental organization (https://thrivenetworks.org/) headquartered in Oakland, California, USA, as well as a development grant from the Regione Trentino Alto Adige, Italy. The study was implemented by the Breath of Life Program, Thrive Networks, in full partnership with Amici della Neonatologia Trentina, Trento, Italy, which supported the involvement of some of the authors as consultants [GA, LM] and volunteers [KM]. THT was financially supported by the Da Nang Women and Children's Hospital, in her roles as director of the neonatal unit. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abd Hamid IJ, 2013, J PAEDIATR CHILD H, V49, P375, DOI 10.1111/jpc.12192; Arnolda G, 2015, BMC PEDIATR, V15, P1; Bhutani VK, 2011, PEDIATRICS, V128, pE1046, DOI 10.1542/peds.2011-1494; Bhutani Vinod K., 2005, Indian Journal of Pediatrics, V72, P53, DOI 10.1007/BF02760581; Boonyarittipong Payon, 2008, Journal of the Medical Association of Thailand, V91, P50; Cline BK, 2013, J TROP PEDIATRICS, V59, P321, DOI 10.1093/tropej/fmt027; Efron B., 1994, INTRO BOOTSTRAP, V57; Greco C, 2016, NEONATOLOGY, V110, P172, DOI 10.1159/000445708; HOLTROP PC, 1992, PEDIATRICS, V90, P674; KANG JH, 1995, AM J PERINAT, V12, P178, DOI 10.1055/s-2007-994446; Kumar P, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007969.pub2; Maisels MJ, 2008, NEW ENGL J MED, V358, P920, DOI 10.1056/NEJMct0708376; Maisels MJ, 2009, EARLY HUM DEV, V85, P727, DOI 10.1016/j.earlhumdev.2009.09.003; Maisels MJ, 2004, PEDIATRICS, V114, P297; National Collaborating Centre for Women's and Children's Health (UK), 2010, NEON JAUND; Nuntnarumit Pracha, 2002, Journal of the Medical Association of Thailand, V85, pS1159; Olusanya BO, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0358-z; Owa JA, 2011, INDIAN J PEDIATR, V78, P996, DOI 10.1007/s12098-011-0382-4; Sarici SU, 2000, J TROP PEDIATRICS, V46, P36, DOI 10.1093/tropej/46.1.36; Silva I, 2009, J PEDIAT-BRAZIL, V85, P455, DOI [10.2223/JPED.1927, 10.1590/S0021-75572009000500015]; Slusher TM, 2015, NEW ENGL J MED, V373, P1115, DOI 10.1056/NEJMoa1501074; Slusher TM, 2014, PEDIATRICS, V133, pE1568, DOI 10.1542/peds.2013-3500; Slusher TM, 2011, SEMIN PERINATOL, V35, P185, DOI 10.1053/j.semperi.2011.02.014; TAN KL, 1975, PEDIATRICS, V56, P550; Thaithumyanon Pimolrat, 2002, Journal of the Medical Association of Thailand, V85, P1176; Xiong T, 2011, EUR J PEDIATR, V170, P1247, DOI 10.1007/s00431-011-1454-1; Zabetta CDC, 2013, NEONATOLOGY, V103, P177, DOI 10.1159/000345425	27	7	8	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2018	13	10							e0205432	10.1371/journal.pone.0205432	http://dx.doi.org/10.1371/journal.pone.0205432			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW7TO	30308024	Green Published, gold, Green Submitted			2023-01-03	WOS:000447173500075
J	Park, MH; Lee, JY; Park, KH; Jung, IK; Kim, KT; Lee, YS; Ryu, HH; Jeong, Y; Kang, M; Schwaninger, M; Gulbins, E; Reichel, M; Kornhuber, J; Yamaguchi, T; Kim, HJ; Kim, SH; Schuchman, EH; Jin, HK; Bae, JS				Park, Min Hee; Lee, Ju Youn; Park, Kang Ho; Jung, In Kyung; Kim, Kyoung-Tae; Lee, Yong-Seok; Ryu, Hyun-Hee; Jeong, Yong; Kang, Minseok; Schwaninger, Markus; Gulbins, Erich; Reichel, Martin; Kornhuber, Johannes; Yamaguchi, Tomoyuki; Kim, Hee Jin; Kim, Seung Hyun; Schuchman, Edward H.; Jin, Hee Kyung; Bae, Jae-Sung			Vascular and Neurogenic Rejuvenation in Aging Mice by Modulation of ASM	NEURON			English	Article							BLOOD-BRAIN-BARRIER; ACID SPHINGOMYELINASE/CERAMIDE PATHWAY; CAVEOLAE-MEDIATED TRANSCYTOSIS; ALZHEIMERS-DISEASE; PERMEABILITY; CELLS; CYTOSKELETON; DYSFUNCTION; DISRUPTION; MECHANISMS	Although many reports have revealed dysfunction of endothelial cells in aging, resulting in blood-brain barrier (BBB) breakdown, the underlying mechanism or mechanisms remain to be explored. Here, we find that acid sphingomyelinase (ASM) is a critical factor for regulating brain endothelial barrier integrity. ASM is increased in brain endothelium and/or plasma of aged humans and aged mice, leading to BBB disruption by increasing caveolae-mediated transcytosis. Genetic inhibition and endothelial-specific knockdown of ASM in mice ameliorated BBB breakdown and neurocognitive impairment during aging. Using primary mouse brain endothelial cells, we found that ASM regulated the caveolae-cytoskeleton interaction through protein phosphatase 1-mediated ezrin/radixin/moesin (ERM) dephosphorylation and apoptosis. Moreover, mice with conditional ASM overexpression in brain endothelium accelerated significant BBB impairment and neurodegenerative change. Overall, these results reveal a novel role for ASM in the control of neurovascular function in aging, suggesting that ASM may represent a new therapeutic target for anti-aging.	[Park, Min Hee; Lee, Ju Youn; Park, Kang Ho; Jung, In Kyung; Jin, Hee Kyung; Bae, Jae-Sung] Kyungpook Natl Univ, Stem Cell Neuroplast Res Grp, Daegu, South Korea; [Park, Min Hee; Lee, Ju Youn; Park, Kang Ho; Jung, In Kyung; Bae, Jae-Sung] Kyungpook Natl Univ, Dept Physiol, Cell & Matrix Res Inst, Sch Med, Daegu, South Korea; [Park, Min Hee; Lee, Ju Youn; Park, Kang Ho; Jung, In Kyung; Bae, Jae-Sung] Kyungpook Natl Univ, Dept Biomed Sci, Plus KNU Biomed Convergence Program BK21, Daegu, South Korea; [Kim, Kyoung-Tae] Kyungpook Natl Univ Hosp, Dept Neurosurg, Daegu, South Korea; [Lee, Yong-Seok; Ryu, Hyun-Hee] Seoul Natl Univ, Coll Med, Dept Physiol, Seoul, South Korea; [Ryu, Hyun-Hee] Chung Ang Univ, Dept Life Sci, Seoul, South Korea; [Jeong, Yong; Kang, Minseok] Korea Advance Inst Sci & Technol, Dept Bio & Brain Engn, Daejeon, South Korea; [Schwaninger, Markus] Univ Lubeck, Inst Expt & Clin Pharmacol & Toxicol, Lubeck, Germany; [Gulbins, Erich] Univ Duisburg Essen, Dept Mol Biol, Essen, Germany; [Reichel, Martin; Kornhuber, Johannes] Friedrich Alexander Univ Erlangen Nuremberg, Dept Psychiat & Psychotherapy, Erlangen, Germany; [Yamaguchi, Tomoyuki] Univ Tokyo, Inst Med Sci, Div Stem Cell Therapy, Ctr Stem Cell Biol & Regenerat Med,Minato Ku, Tokyo, Japan; [Kim, Hee Jin; Kim, Seung Hyun] Hanyang Univ, Dept Neurol, Coll Med, Seoul, South Korea; [Schuchman, Edward H.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Jin, Hee Kyung] Kyungpook Natl Univ, Dept Lab Anim Med, Coll Vet Med, Daegu, South Korea	Kyungpook National University; Kyungpook National University; Kyungpook National University; Kyungpook National University; Kyungpook National University Hospital; Seoul National University (SNU); Chung Ang University; University of Lubeck; University of Duisburg Essen; University of Erlangen Nuremberg; University of Tokyo; Hanyang University; Icahn School of Medicine at Mount Sinai; Kyungpook National University	Jin, HK; Bae, JS (corresponding author), Kyungpook Natl Univ, Stem Cell Neuroplast Res Grp, Daegu, South Korea.; Bae, JS (corresponding author), Kyungpook Natl Univ, Dept Physiol, Cell & Matrix Res Inst, Sch Med, Daegu, South Korea.; Bae, JS (corresponding author), Kyungpook Natl Univ, Dept Biomed Sci, Plus KNU Biomed Convergence Program BK21, Daegu, South Korea.; Jin, HK (corresponding author), Kyungpook Natl Univ, Dept Lab Anim Med, Coll Vet Med, Daegu, South Korea.	hkjin@knu.ac.kr; jsbae@knu.ac.kr	Kim, Seung Hyun/T-5133-2017; Jeong, Yong/C-1677-2011; Kornhuber, Johannes/B-9613-2014; Bae, Jong-Sup/AAU-9724-2020; Bae, Jae-sung/AAM-8663-2021	Kim, Seung Hyun/0000-0001-9644-9598; Jeong, Yong/0000-0002-5907-3787; Kornhuber, Johannes/0000-0002-8096-3987; Reichel, Martin/0000-0001-7886-2784	National Research Foundation (NRF) grants - Korea government (MSIT) [2017R1A2A1A17069686, 2017R1A4A1015652]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI16C2131]	National Research Foundation (NRF) grants - Korea government (MSIT); Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	This work was supported by National Research Foundation (NRF) grants funded by the Korea government (MSIT) (2017R1A2A1A17069686 and 2017R1A4A1015652). This research was also supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI16C2131).	Adada M, 2014, BBA-MOL CELL BIOL L, V1841, P727, DOI 10.1016/j.bbalip.2013.07.002; Andreone BJ, 2017, NEURON, V94, P581, DOI 10.1016/j.neuron.2017.03.043; Arenz C, 2010, CELL PHYSIOL BIOCHEM, V26, P1, DOI 10.1159/000315100; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Begley DJ, 2004, CURR PHARM DESIGN, V10, P1295, DOI 10.2174/1381612043384844; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Ben-Zvi A, 2014, NATURE, V509, P507, DOI 10.1038/nature13324; Bien-Ly N, 2015, NEURON, V88, P289, DOI 10.1016/j.neuron.2015.09.036; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Brown WR, 2010, J ALZHEIMERS DIS, V21, P725, DOI 10.3233/JAD-2010-100219; Campbell M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1852; Chakravarthy H, 2016, STEM CELLS, V34, P972, DOI 10.1002/stem.2259; Coelho-Santos V, 2016, CELL MOL LIFE SCI, V73, P4701, DOI 10.1007/s00018-016-2301-3; Corrotte M, 2013, ELIFE, V2, DOI 10.7554/eLife.00926; Cowan PJ, 2003, XENOTRANSPLANTATION, V10, P223, DOI 10.1034/j.1399-3089.2003.01140.x; Farkas E, 2001, PROG NEUROBIOL, V64, P575, DOI 10.1016/S0301-0082(00)00068-X; Farrall AJ, 2009, NEUROBIOL AGING, V30, P337, DOI 10.1016/j.neurobiolaging.2007.07.015; Fernandez-Lopez D, 2012, J NEUROSCI, V32, P9588, DOI 10.1523/JNEUROSCI.5977-11.2012; Frye M, 2015, J EXP MED, V212, P2267, DOI 10.1084/jem.20150718; Garcia-Ponce A, 2015, THROMB HAEMOSTASIS, V113, P20, DOI 10.1160/TH14-04-0298; Gorelik A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12196; Gulbins E, 2013, NAT MED, V19, P934, DOI 10.1038/nm.3214; He XX, 1999, BBA-PROTEIN STRUCT M, V1432, P251, DOI 10.1016/S0167-4838(99)00069-2; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Katsimpardi L, 2014, SCIENCE, V344, P630, DOI 10.1126/science.1251141; Knowland D, 2014, NEURON, V82, P603, DOI 10.1016/j.neuron.2014.03.003; Kornhuber J, 2015, BIOL CHEM, V396, P707, DOI 10.1515/hsz-2015-0109; Lazear HM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4304; Lee JK, 2014, J EXP MED, V211, P1551, DOI 10.1084/jem.20132451; Li HH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081903; Li YQ, 2003, CANCER RES, V63, P5950; Lutz SE, 2017, CELL REP, V21, P2104, DOI 10.1016/j.celrep.2017.10.094; Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; Miner JJ, 2015, NAT MED, V21, P1464, DOI 10.1038/nm.3974; Montagne A, 2015, NEURON, V85, P296, DOI 10.1016/j.neuron.2014.12.032; Muramatsu R, 2012, NAT MED, V18, P1658, DOI 10.1038/nm.2943; Ohanian J, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12015; Oomen CA, 2009, FRONT AGING NEUROSCI, V1, DOI 10.3389/neuro.24.004.2009; Ridder DA, 2015, J EXP MED, V212, P1529, DOI 10.1084/jem.20150165; Rosenberg GA, 2012, J CEREBR BLOOD F MET, V32, P1139, DOI 10.1038/jcbfm.2011.197; Sacket SJ, 2009, ACTA PHARMACOL SIN, V30, P1454, DOI 10.1038/aps.2009.136; Samapati R, 2012, AM J RESP CRIT CARE, V185, P160, DOI 10.1164/rccm.201104-0717OC; Smith LK, 2015, NAT MED, V21, P932, DOI 10.1038/nm.3898; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Velasco B, 2001, GENE THER, V8, P897, DOI 10.1038/sj.gt.3301468; Winkler EA, 2015, NAT NEUROSCI, V18, P521, DOI 10.1038/nn.3966; Yao Z, 2009, BIOFACTORS, V35, P407, DOI 10.1002/biof.52; Zeidan YH, 2010, CURR MOL MED, V10, P454, DOI 10.2174/156652410791608225; Zeidan YH, 2008, J CELL BIOL, V181, P335, DOI 10.1083/jcb.200705060; Zhao YL, 2014, REV NEUROSCIENCE, V25, P247, DOI 10.1515/revneuro-2013-0039; Zhao Z, 2015, CELL, V163, P1064, DOI 10.1016/j.cell.2015.10.067; Zhao Z, 2015, NAT NEUROSCI, V18, P978, DOI 10.1038/nn.4025; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	54	24	24	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	OCT 10	2018	100	1					167	+		10.1016/j.neuron.2018.09.010	http://dx.doi.org/10.1016/j.neuron.2018.09.010			25	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GW4DV	30269989	Bronze			2023-01-03	WOS:000446862000018
J	Estrellas, KM; Chung, L; Cheug, LA; Sadtler, K; Majumdar, S; Mula, J; Wolf, MT; Elisseeff, JH; Wagner, KR				Estrellas, Kenneth M.; Chung, Liam; Cheug, Lindsay A.; Sadtler, Kaitlyn; Majumdar, Shoumyo; Mula, Jyothi; Wolf, Matthew T.; Elisseeff, Jennifer H.; Wagner, Kathryn R.			Biological scaffold-mediated delivery of myostatin inhibitor promotes a regenerative immune response in an animal model of Duchenne muscular dystrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						muscle; muscle regeneration; muscular dystrophy; immunology; cytokine; biomaterials; myostatin; mdx; myostatin; extracellular matrix; bioengineering; hydrogel; dystrophin; drug delivery; stem cells	SKELETAL-MUSCLE MASS; HYALURONIC-ACID; CELLS; FIBROSIS; MYOBLASTS; MICE; HYPERTROPHY; ENGRAFTMENT; STRATEGIES; HYDROGELS	Recent studies have reported that the immune system significantly mediates skeletal muscle repair and regeneration. Additionally, biological scaffolds have been shown to play a role in polarizing the immune microenvironment toward pro-myogenic outcomes. Moreover, myostatin inhibitors are known to promote muscle regeneration and ameliorate fibrosis in animal models of Duchenne muscular dystrophy (DMD), a human disease characterized by chronic muscle degeneration. Biological scaffolds and myostatin inhibition can potentially influence immune-mediated regeneration in the dystrophic environment, but have not been evaluated together. Toward this end, here we created an injectable biological scaffold composed of hyaluronic acid and processed skeletal muscle extracellular matrix. This material formed a cytocompatible hydrogel at physiological temperatures in vitro. When injected subfascially above the tibialis anterior muscles of both WT and dystrophic mdx-5(Cv) mice, a murine model of DMD, the hydrogel spreads across the entire muscle before completely degrading at 3 weeks in vivo. We found that the hydrogel is associated with CD206(+) pro-regenerative macrophage polarization and elevated anti-inflammatory cytokine expression in both WT and dystrophic mice. Co-injection of both hydrogel and myostatin inhibitor significantly increased FoxP3(+) regulatory T cell modulation and Foxp3 gene expression in the scaffold immune microenvironment. Finally, delivery of myostatin inhibitor with the hydrogel increased its bioactivity in vivo, and transplantation of immortalized human myoblasts with the hydrogel promoted their survival in vivo. This study identifies a key role for biological scaffolds and myostatin inhibitors in modulating a pro-regenerative immune microenvironment in dystrophic muscle.	[Estrellas, Kenneth M.; Wagner, Kathryn R.] Kennedy Krieger, Hugo W Moser Res Inst, Baltimore, MD 21205 USA; [Estrellas, Kenneth M.; Chung, Liam; Wolf, Matthew T.; Elisseeff, Jennifer H.] Johns Hopkins Univ, Sch Med, Translat Tissue Engn Ctr, 400 N Broadway Rm 5031, Baltimore, MD 21231 USA; [Chung, Liam; Wolf, Matthew T.; Elisseeff, Jennifer H.] Johns Hopkins Univ, Sch Med, Bloomberg Kimmel Inst Canc Immunotherapy, 400 N Broadway Rm 5031, Baltimore, MD 21231 USA; [Cheug, Lindsay A.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Sadtler, Kaitlyn] MIT, Dept Chem Engn, David H Koch Inst Integrat Canc Res, Cambridge, MA 02142 USA; [Sadtler, Kaitlyn] Boston Childrens Hosp, Dept Anesthesiol, Boston, MA 02115 USA; [Majumdar, Shoumyo] Otomagnetics LLC, Rockville, MD 20852 USA; [Mula, Jyothi] NCI Frederick, NIH, Frederick, MD 21702 USA; [Wagner, Kathryn R.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA; [Wagner, Kathryn R.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Northwestern University; Feinberg School of Medicine; Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; Johns Hopkins University; Johns Hopkins University	Elisseeff, JH (corresponding author), Johns Hopkins Univ, Sch Med, Translat Tissue Engn Ctr, 400 N Broadway Rm 5031, Baltimore, MD 21231 USA.; Wagner, KR (corresponding author), Kennedy Krieger Inst, Ctr Genet Muscle Disorders, 707 N Broadway Rm 406, Baltimore, MD 21205 USA.	jhe@jhu.edu; wagnerk@kennedykrieger.org	Elisseeff, Jennifer/A-3324-2010	Elisseeff, Jennifer/0000-0002-5066-1996; Estrellas, Kenneth/0000-0003-0413-6258; Wolf, Matthew/0000-0002-0328-2475	Maryland Stem Cell Research Foundation; Team Saij	Maryland Stem Cell Research Foundation; Team Saij	This work was supported by the Maryland Stem Cell Research Foundation and Team Saij. The authors declare that they have no conflicts of interest with the contents of this article.	Acharyya S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012479; Beastrom N, 2011, AM J PATHOL, V179, P2464, DOI 10.1016/j.ajpath.2011.07.009; Bhattacharya I, 2018, CLIN PHARM DRUG DEV, V7, P484, DOI 10.1002/cpdd.386; Bhattacharya I, 2018, J CLIN PHARMACOL, V58, P314, DOI 10.1002/jcph.1015; Borselli C, 2011, BIOMATERIALS, V32, P8905, DOI 10.1016/j.biomaterials.2011.08.019; Bursac N, 2015, ANNU REV BIOMED ENG, V17, P217, DOI 10.1146/annurev-bioeng-071114-040640; Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054; Calve S, 2012, AM J PHYSIOL-CELL PH, V303, pC577, DOI 10.1152/ajpcell.00057.2012; Campbell C, 2017, MUSCLE NERVE, V55, P458, DOI 10.1002/mus.25268; Cezar CA, 2015, ADV DRUG DELIVER REV, V84, P188, DOI 10.1016/j.addr.2014.09.008; Chang CY, 2012, BIOMATERIALS, V33, P8026, DOI 10.1016/j.biomaterials.2012.07.058; Dankbar B, 2015, NAT MED, V21, P1085, DOI 10.1038/nm.3917; Dziki JL, 2016, TISSUE ENG PT A, V22, P1129, DOI 10.1089/ten.tea.2016.0340; Fuoco C, 2015, EMBO MOL MED, V7, P411, DOI 10.15252/emmm.201404062; Gaetani R, 2016, CELL TRANSPLANT, V25, P1653, DOI 10.3727/096368915X689794; Gerard C, 2012, CELL TRANSPLANT, V21, P127, DOI 10.3727/096368911X576018; Griggs RC, 2016, NEUROLOGY, V87, P2123, DOI 10.1212/WNL.0000000000003217; Hardy D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147198; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Holzbaur ELF, 2006, NEUROBIOL DIS, V23, P697, DOI 10.1016/j.nbd.2006.05.009; Kabra H, 2015, ACS BIOMATER SCI ENG, V1, P7, DOI 10.1021/ab500021a; Larkindale J, 2014, MUSCLE NERVE, V49, P431, DOI 10.1002/mus.23942; Lee SJ, 1999, CURR OPIN GENET DEV, V9, P604, DOI 10.1016/S0959-437X(99)00004-0; Li ZB, 2012, J CELL SCI, V125, P3957, DOI 10.1242/jcs.090365; Li ZB, 2008, J BIOL CHEM, V283, P19371, DOI 10.1074/jbc.M802585200; Londhe P, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004633; Londhe P, 2011, MOL CELL BIOL, V31, P2854, DOI 10.1128/MCB.05397-11; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Mendell JR, 2013, ANN NEUROL, V74, P637, DOI 10.1002/ana.23982; Mendell JR, 2012, ANN NEUROL, V71, P304, DOI 10.1002/ana.23528; Misra S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00201; Moyer AL, 2011, CURR OPIN RHEUMATOL, V23, P568, DOI 10.1097/BOR.0b013e32834bac92; Muir LA, 2016, STEM CELLS DEV, V25, P1559, DOI 10.1089/scd.2016.0136; Palacios D, 2010, CELL STEM CELL, V7, P455, DOI 10.1016/j.stem.2010.08.013; Rosenberg AS, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7322; Sadtler K, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.40; Sadtler K, 2016, SCIENCE, V352, P366, DOI 10.1126/science.aad9272; Sahenk Z, 2011, CURR RHEUMATOL REP, V13, P199, DOI 10.1007/s11926-011-0178-6; Schiaffino S, 2015, SKELET MUSCLE, V5, DOI 10.1186/s13395-015-0046-6; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; Serrano AL, 2017, SEMIN CELL DEV BIOL, V64, P181, DOI 10.1016/j.semcdb.2016.09.013; Sicari BM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008085; St Andre Michael, 2017, Skelet Muscle, V7, P25, DOI 10.1186/s13395-017-0141-y; Sun Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021073; Thies RS, 2001, GROWTH FACTORS, V18, P251; Tidball JG, 2017, NAT REV IMMUNOL, V17, P165, DOI 10.1038/nri.2016.150; Villalta SA, 2015, RARE DIS, V3, DOI 10.1080/21675511.2015.1010966; Villalta SA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009925; Villalta SA, 2011, J IMMUNOL, V187, P5419, DOI 10.4049/jimmunol.1101267; Wagner KR, 2008, ANN NEUROL, V63, P561, DOI 10.1002/ana.21338; Wang RT, 2014, PLOS CURR, V6, P1, DOI [DOI 10.1371/CURRENTS.MD.E1E8F2BE7C94, DOI 10.1371/CURRENTS.MD.E1E8F2BE7C949F9FFE81EC6FCA1CCE6A]; Wolf MT, 2015, ADV DRUG DELIVER REV, V84, P208, DOI 10.1016/j.addr.2014.08.011; Zhu CH, 2007, AGING CELL, V6, P515, DOI 10.1111/j.1474-9726.2007.00306.x; Zuidema JM, 2014, J BIOMED MATER RES B, V102, P1063, DOI 10.1002/jbm.b.33088	54	13	13	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	2018	293	40					15594	15605		10.1074/jbc.RA118.004417	http://dx.doi.org/10.1074/jbc.RA118.004417			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW0JH	30139748	Green Published, hybrid			2023-01-03	WOS:000446549200023
J	Wienholz, A; Nuhbalaoglu, D; Mani, N; Herrmann, A; Onea, E; Steinbach, M				Wienholz, Anne; Nuhbalaoglu, Derya; Mani, Nivedita; Herrmann, Annika; Onea, Edgar; Steinbach, Markus			Pointing to the right side? An ERP study on anaphora resolution in German Sign Language	PLOS ONE			English	Article							SYNTACTIC POSITIVE SHIFT; DEAF NATIVE SIGNERS; BRAIN POTENTIALS; SPOKEN SENTENCES; COMPREHENSION; WORDS; PERCEPTION; RESPONSES; N400; SPECIFICITY	Sign languages use the horizontal plane to refer to discourse referents introduced at referential locations. However, the question remains whether the assignment of discourse referents follows a particular default pattern as recently proposed such that two new discourse referents are respectively assigned to the right (ipsilateral) and left (contralateral) side of (right handed) signers. The present event-related potential study on German Sign Language investigates the hypothesis that signers assign distinct and contrastive referential locations to discourse referents even in the absence of overt localization. By using a semantic mismatch-design, we constructed sentence sets where the second sentence was either consistent or inconsistent with the used pronoun. Semantic mismatch conditions evoked an N400, whereas a contralateral INDEX sign engendered a Phonological Mismatch Negativity. The current study provides supporting evidence that signers are sensitive to the mismatch and make use of a default pattern to assign distinct and contrastive referential locations to discourse referents.	[Wienholz, Anne; Nuhbalaoglu, Derya; Herrmann, Annika; Steinbach, Markus] Univ Goettingen, Dept German Philol, Gottingen, Lower Saxony, Germany; [Wienholz, Anne; Mani, Nivedita] Univ Goettingen, Georg Elias Muller Inst Psychol, Psychol Language Res Grp, Gottingen, Lower Saxony, Germany; [Wienholz, Anne; Nuhbalaoglu, Derya; Mani, Nivedita; Herrmann, Annika; Steinbach, Markus] German Primate Ctr, Leibniz Sci Campus Primate Cognit, Gottingen, Lower Saxony, Germany; [Onea, Edgar] Univ Goettingen, Jr Res Grp Theoret Linguist, Courant Res Ctr Text Struct, Gottingen, Lower Saxony, Germany; [Wienholz, Anne] Boston Univ, Wheelock Coll Educ & Human Dev, Boston, MA 02215 USA; [Herrmann, Annika] Univ Hamburg, Inst German Sign Language & Commun Deaf, Hamburg, Germany; [Onea, Edgar] Karl Franzens Univ Graz, Dept German Studies, Graz, Styria, Austria	University of Gottingen; University of Gottingen; Deutsches Primatenzentrum (DPZ); University of Gottingen; Boston University; University of Hamburg; University of Graz	Wienholz, A (corresponding author), Univ Goettingen, Dept German Philol, Gottingen, Lower Saxony, Germany.; Wienholz, A (corresponding author), Univ Goettingen, Georg Elias Muller Inst Psychol, Psychol Language Res Grp, Gottingen, Lower Saxony, Germany.; Wienholz, A (corresponding author), German Primate Ctr, Leibniz Sci Campus Primate Cognit, Gottingen, Lower Saxony, Germany.; Wienholz, A (corresponding author), Boston Univ, Wheelock Coll Educ & Human Dev, Boston, MA 02215 USA.	anne.wienholz@psych.uni-goettingen.de	Wienholz, Anne/AAV-3959-2020; Nuhbalaoglu, Derya/AAH-2416-2019; Onea, Edgar/T-4412-2017	Wienholz, Anne/0000-0002-0762-2983; Onea, Edgar/0000-0002-8217-4463	Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [SPP 1727, 254142454 /GRK 2070]; Leibniz ScienceCampus Primate Cognition	Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)(German Research Foundation (DFG)); Leibniz ScienceCampus Primate Cognition	This work was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation; Priority Program (SPP 1727) Xprag.de: New Pragmatic Theories based on experimental evidence, research project 'Discourse Referens in Space - Anaphora Resolution in German Sign Language'), the Leibniz ScienceCampus Primate Cognition, and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Project number 254142454 /GRK 2070.	ANDREASSI JL, 1975, PSYCHOPHYSIOLOGY, V12, P541, DOI 10.1111/j.1469-8986.1975.tb00043.x; ARDAL S, 1990, BRAIN LANG, V39, P187, DOI 10.1016/0093-934X(90)90011-5; Ariel M., 1990, ACCESSING NOUN PHRAS; Ariel M., 2001, TEXT REPRESENT LINGU, V8, P29, DOI DOI 10.1075/HCP.8.04ARI; Barbera G., 2012, MEANING SPACE SIGN L; Brentari D., 1998, PROSODIC MODEL SIGN; Capek CM, 2009, P NATL ACAD SCI USA, V106, P8784, DOI 10.1073/pnas.0809609106; CONNOLLY JF, 1992, BRAIN LANG, V43, P1, DOI 10.1016/0093-934X(92)90018-A; CONNOLLY JF, 1990, BRAIN LANG, V39, P302, DOI 10.1016/0093-934X(90)90016-A; CONNOLLY JF, 1994, J COGNITIVE NEUROSCI, V6, P256, DOI 10.1162/jocn.1994.6.3.256; D'Arcy RCN, 2000, CLIN NEUROPHYSIOL, V111, P40, DOI 10.1016/S1388-2457(99)00210-2; Ebbinghaus H., 2001, HANDS ARE HEAD MOUTH, P133; Eichmann H, 2014, SIGN LANG STUD, V14, P175, DOI 10.1353/sls.2014.0001; EMMOREY K, 1991, LANG COGNITIVE PROC, V6, P207, DOI 10.1080/01690969108406943; Emmorey K, 1997, LANG COGNITIVE PROC, V12, P103, DOI 10.1080/016909697386925; Emmorey K, 1995, LANG COGNITIVE PROC, V10, P631, DOI 10.1080/01690969508407116; Emmorey K, 2004, J PSYCHOLINGUIST RES, V33, P321, DOI 10.1023/B:JOPR.0000035104.83502.0b; EMMOREY K, 1990, PERCEPT MOTOR SKILL, V71, P1227, DOI 10.2466/PMS.71.7.1227-1252; Emmorey K., 2002, LANGUAGE COGNITION B; Emmorey K., 2007, OXFORD HDB PSYCHOLIN, P703, DOI [10.1093/oxfordhb/9780198568971.013.0043, DOI 10.1093/OXFORDHB/9780198568971.013.0043]; Engberg-Pedersen E., 1993, SPACE DANISH SIGN LA; Friederici AD, 1999, J PSYCHOLINGUIST RES, V28, P467, DOI 10.1023/A:1023264209610; Geraci C., 2013, LING SEM CNRS I JEA; Geraci Carlo, 2014, N E LINGUISTIC SOC N, V1, P123; GREENHOUSE SW, 1959, PSYCHOMETRIKA, V24, P95, DOI 10.1007/BF02289823; Gutierrez E, 2012, BRAIN RES, V1468, P63, DOI 10.1016/j.brainres.2012.04.029; Hanel-Faulhaber B, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-62; HAGOORT P, 1993, LANG COGNITIVE PROC, V8, P439, DOI 10.1080/01690969308407585; Herrmann A, 2007, ZITAT UND BEDEUTUNG, P153; HOLCOMB PJ, 1992, DEV NEUROPSYCHOL, V8, P203, DOI 10.1080/87565649209540525; Hosemann J., 2015, THESIS; Hosemann J, 2018, LANG COGN NEUROSCI, V33, P1107, DOI 10.1080/23273798.2018.1465986; Hosemann J, 2013, NEUROPSYCHOLOGIA, V51, P2224, DOI 10.1016/j.neuropsychologia.2013.07.013; Kaan E, 2000, LANG COGNITIVE PROC, V15, P159, DOI 10.1080/016909600386084; Klima E.S., 1979, SIGNS LANGUAGE; Kubus O, 2015, APPL PSYCHOLINGUIST, V36, P831, DOI 10.1017/S0142716413000520; Kutas M, 1987, Electroencephalogr Clin Neurophysiol Suppl, V39, P325; Kutas M, 2000, TRENDS COGN SCI, V4, P463, DOI 10.1016/S1364-6613(00)01560-6; Kutas M, 2011, ANNU REV PSYCHOL, V62, P621, DOI 10.1146/annurev.psych.093008.131123; Langer Gabriele, 2012, 5 WORKSH REPR PROC S, P101; Lau EF, 2008, NAT REV NEUROSCI, V9, P920, DOI 10.1038/nrn2532; LIDDELL SK, 1990, SIGN LANGUAGE RESEARCH, P176; Lillo-Martin D., 2012, SIGN LANGUAGE INT HD, P365; Lillo-Martin D, THEORETICAL ISSUES S, V1; LILLOMARTIN D, 1986, NAT LANG LINGUIST TH, V4, P415, DOI 10.1007/BF00134469; Lopez-Calderon J, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00213; Mathur G, 2012, SIGN LANGUAGE INT HD; McLaughlin J, 2004, NAT NEUROSCI, V7, P703, DOI 10.1038/nn1264; Meier R., 2012, SIGN LANGUAGE INT HD, P574, DOI DOI 10.1515/9783110261325.574; Meier Richard P., 2002, MODALITY STRUCTURE, P1, DOI DOI 10.1017/CBO9780511486777.001; Meir Irit, 2008, LANGUAGE SPACE STORY; Midgley KJ, 2009, J NEUROLINGUIST, V22, P281, DOI 10.1016/j.jneuroling.2008.08.001; Munte TF, 1998, NEUROPSYCHOLOGIA, V36, P217, DOI 10.1016/S0028-3932(97)00119-X; Munte TF, 1997, J COGNITIVE NEUROSCI, V9, P318, DOI 10.1162/jocn.1997.9.3.318; Murmann C., 2012, THESIS; Newman RL, 2003, PSYCHOPHYSIOLOGY, V40, P640, DOI 10.1111/1469-8986.00065; NICOL J, 1989, J PSYCHOLINGUIST RES, V18, P5, DOI 10.1007/BF01069043; PADDEN CA, 1990, SIGN LANGUAGE RESEARCH, P118; Pfau R., 2006, LINGUIST TYPOL, V10, P135, DOI [10.1515/LINGTY.2006.006, DOI 10.1515/LINGTY.2006.006]; Pfau R, 2003, SIGN LANG LINGUIST, V6, P3, DOI DOI 10.1075/SLL.6.1.03PFA; Poizner H., 1987, LANGUAGE, DOI [10.2307/414579, DOI 10.2307/414579]; Rathmann Christian, 2003, TEXAS LINGUISTICS FO, V53, P181; RUGG MD, 1985, ELECTROEN CLIN NEURO, V62, P81, DOI 10.1016/0168-5597(85)90019-X; Sandler W, 2006, SIGN LANGUAGE AND LINGUISTIC UNIVERSALS, P1, DOI 10.2277/ 0521483956; Schlenker P., 2013, LANG COGN INT ACT 10; Steinbach M, 2016, J SEMANT, V33, P409, DOI 10.1093/jos/ffv002; Sutton-Spence R., 1999, LINGUISTICS BRIT SIG; Thierry G, 2007, P NATL ACAD SCI USA, V104, P12530, DOI 10.1073/pnas.0609927104; de Meerendonk N, 2009, LANG LINGUIST COMPAS, V3, DOI 10.1111/j.1749-818x.2009.00163.x; van de Meerendonk N, 2011, NEUROIMAGE, V54, P2350, DOI 10.1016/j.neuroimage.2010.10.022; van der Kooij E, 2006, J PRAGMATICS, V38, P1598, DOI 10.1016/j.pragma.2005.07.006; van Herten M, 2006, J COGNITIVE NEUROSCI, V18, P1181, DOI 10.1162/jocn.2006.18.7.1181; Vissers CTWM, 2006, BRAIN RES, V1106, P150, DOI 10.1016/j.brainres.2006.05.012; WINSTON Elizabeth, 1996, P 1996 C INT TRAIN C, P1; Wittenburg P, 2006, P LREC GEN IT	75	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2018	13	9							e0204223	10.1371/journal.pone.0204223	http://dx.doi.org/10.1371/journal.pone.0204223			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GU8XH	30235306	Green Published, Green Submitted, gold			2023-01-03	WOS:000445626400088
J	Fernandez, RJ; Liria, IC; Vazquez, RR; Fernandez, SC; Iglesias, MEL; Vallejo, RBD				Jimenez Fernandez, Raquel; Corral Liria, Inmaculada; Rodriguez Vazquez, Rocio; Cabrera Fernandez, Susana; Losa Iglesias, Marta Elena; de Bengoa Vallejo, Ricardo Becerro			Exploring the knowledge, explanatory models of illness, and patterns of healthcare-seeking behaviour of Fang culture-bound syndromes in Equatorial Guinea	PLOS ONE			English	Article							TRADITIONAL HEALERS; CHALLENGES; SYNCHRONICITY; PERCEPTION; WITCHCRAFT; DISORDERS; ATTITUDES; SYMPTOMS; CHILDREN; NIGERIA	In 1994, the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) included "culture-bound syndromes" in its classification of psychiatric disorders and associated them with disease processes that manifest in behavioural or thought disorders that develop within a given cultural context. This study examines the definitions, explanatory models, signs and symptoms, and healthcare-seeking behaviours common to Fang culture-bound syndromes (i.e., kong, eluma, witchcraft, mibili, mikug, and nsamadalu). The Fang ethnic group is the majority ethnic group in Equatorial Guinea. From September 2012 to January 2013, 45 key Fang informants were selected, including community leaders, tribal elders, healthcare workers, traditional healers, and non-Catholic pastors in 39 of 724 Fang tribal villages in 6 of 13 districts in the mainland region of Equatorial Guinea. An ethnographic approach with an emic-etic perspective was employed. Data were collected using semi-structured interviews, participant observation and a questionnaire that included DHS6 key indicators. Interviews were designed based on the Cultural Formulation form in the DSM-5 and explored the definition of Fang cultural syndromes, symptoms, cultural perceptions of cause, and current helpseeking. Participants defined "Fang culture-bound syndromes" as those diseases that cannot be cured, treated, or diagnosed by science. Such syndromes present with the same signs and symptoms as diseases identified by Western medicine. However, they arise because of the actions of enemies, because of the actions of spirits or ancestors, as punishments for disregarding the law of God, because of the violation of sexual or dietary taboos, or because of the violation of a Fang rite of passage, the dzas, which is celebrated at birth. Six Fang culture-bound syndromes were included in the study: 1) Eluma, a disease that is targeted at the victim out of envy and starts out with sharp, intense, focussed pain and aggressiveness; 2) Witchcraft, characterized by isolation from the outside, socially maladaptive behaviour, and the use of hallucinogenic substances; 3) Kong, which is common among the wealthy class and manifests as a disconnection from the environment and a lack of vital energy; 4) Mibili, a possession by evil spirits that manifests through visual and auditory hallucinations; 5) Mikug, which appears after a person has had contact with human bones in a ritual; and 6) Nsamadalu, which emerges after a traumatic process caused by violating traditions through having sexual relations with one's sister or brother. The therapeutic resources of choice for addressing Fang culture-bound syndromes were traditional Fang medicine and the religious practices of the Bethany and Pentecostal churches, among others. Among African ethnic groups, symbolism, the weight of tradition, and the principle of chance in health and disease are underlying factors in the presentation of certain diseases, which in ethno-psychiatry are now referred to as culture-bound syndromes. In this study, traditional healers, elders, healthcare professionals, religious figures, and leaders of the Fang community in Equatorial Guinea referred to six such cultural syndromes: eluma, witchcraft, kong, mibili, mikug, and nsamadalu. In the absence of a multidisciplinary approach to mental illness in the country, the Fang ethnic group seeks healthcare for culture-bound syndromes from traditional healing and religious rites in the Evangelical faiths.	[Jimenez Fernandez, Raquel; Corral Liria, Inmaculada; Rodriguez Vazquez, Rocio; Cabrera Fernandez, Susana; Losa Iglesias, Marta Elena] Univ Rey Juan Carlos, Fac Ciencias Salud, Avda Atenas, Madrid, Spain; [de Bengoa Vallejo, Ricardo Becerro] Univ Complutense Madrid, Escuela Univ Enfermeria Fisioterapia & Podol, Fac Med, Ave Complutense, Madrid, Spain	Universidad Rey Juan Carlos; Complutense University of Madrid	Iglesias, MEL (corresponding author), Univ Rey Juan Carlos, Fac Ciencias Salud, Avda Atenas, Madrid, Spain.	marta.losa@urjc.es	Iglesias, Marta E Losa/B-8830-2009; de Bengoa Vallejo, Ricardo Becerro/P-4153-2019; Becerro de Bengoa Vallejo, Ricardo/B-8857-2009	Iglesias, Marta E Losa/0000-0001-7588-2069; Becerro de Bengoa Vallejo, Ricardo/0000-0003-1568-7602				Abdullahi, 2011, AFR J TRADIT COMPLEM, V8, P115, DOI 10.4314/ajtcam.v8i5S.5; Abubakar A, 2011, RURAL REMOTE HEALTH, V11; African Development Bank Group, 2014, AFR STAT YB 2014; Aguirre Beltran G., 1973, MED MAGIA PROCESO AC; Akinlua JT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154287; Alegria M, 2004, INT J METH PSYCH RES, V13, P270, DOI 10.1002/mpr.181; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, DOI DOI 10.1176/APPI.BOOKS.9780890425596.X00DIAGNOSTICCLASSIFICATION; [Anonymous], 1981, TRADICIONES PUEBLO F; [Anonymous], 2014, OFICINA EC COMERCIAL; [Anonymous], 2004, BRUJERIA FANG GUINEA; Arias D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162305; Arrey AE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119653; Asamoah-Gyadu JK, 2015, INT BULL MISSION RES, V39, P23; Astuti R, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00136; Atim P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159549; Atmanspacher H, 2014, J ANAL PSYCHOL, V59, P429, DOI 10.1111/1468-5922.12086; Atobrah D, 2012, Ghana Med J, V46, P46; Bennett S, 2014, TROP MED INT HEALTH, V19, P872, DOI 10.1111/tmi.12319; Berenzon-Gorn S, 2006, SALUD PUBLICA MEXICO, V48, P45, DOI 10.1590/s0036-36342006000100008; Bonhomme J, 2012, HAU-J ETHNOGR THEORY, V2, P205, DOI 10.14318/hau2.2.012; Burgos B., CULTURAS AFRICANAS D; Campbell MM, 2017, BMC PSYCHIAT, V17; Casado Aijon I, 2008, 11 C ANTR RET TEOR N, P41; Castillo Franco Armando, 2006, Index Enferm, V15, P18, DOI 10.4321/s1132-12962006000300004; Colman W, 2011, J ANAL PSYCHOL, V56, P471, DOI 10.1111/j.1468-5922.2011.01924.x; Creswell J.W., 2005, ED RES PLANNING COND; Culqui Dante R., 2008, Rev. perú. med. exp. salud publica, V25, P59; Custodio E, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-225; De Sreeja, 2013, Indian J Psychol Med, V35, P268, DOI 10.4103/0253-7176.119484; DÍAZ MUJICA ALEJANDRO, 2004, Cienc. enferm., V10, P9, DOI 10.4067/S0717-95532004000100002; Essen B, 2011, J PSYCHOSOM OBST GYN, V32, P10, DOI 10.3109/0167482X.2010.547966; Foster D, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-240; Fottrell E, 2012, J EPIDEMIOL COMMUN H, V66, P704, DOI 10.1136/jech.2010.124305; Gallagher M.R., 2012, Enferm. glob., V11, P1, DOI 10.4321/s1695-61412012000300001; Gonzalez Conesa F., 1950, GUINEA CONTINENTAL E; Gonzalez Echegaray C., 1999, ETNO HIST CULTURAS B; Gracey M, 2009, LANCET, V374, P65, DOI 10.1016/S0140-6736(09)60914-4; GRIMSHAW AD, 1991, CONTEMP SOCIOL, V20, P843, DOI 10.2307/2076144; Guarnaccia PJ, 1999, AM J PSYCHIAT, V156, P1322; Hammersley M, 1994, ETNOGRAFIA METODOS I; HARRIS M, 1976, ANNU REV ANTHROPOL, V5, P329, DOI 10.1146/annurev.an.05.100176.001553; Hodes RM, 1997, WESTERN J MED, V166, P29; ICF International, 2011, DEM HLTH SURV METH Q; Igbinomwanhia NG, 2013, AFR J PSYCHIATRY, V16, P196, DOI [http://dx.doi.org/10.4314/ajpsy.v16i3.26, 10.4314/ajpsy.v16i3.26]; Jacob KS, 2013, INDIAN J PSYCHIAT, V55, P12, DOI 10.4103/0019-5545.105500; Jones CHD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151606; Kohrt BA, 2014, INT J EPIDEMIOL, V43, P365, DOI 10.1093/ije/dyt227; Laplantine F., 1999, ANTROPOLOGIA ENFERMA, P57; Leavey G, 2007, SOC SCI MED, V65, P548, DOI 10.1016/j.socscimed.2007.03.050; Lee Jieun, 2014, Asia Taepyongyang Sangdam Yongu, V4, P49; Leseth AB, 2015, BJPSYCH BULL, V39, P187, DOI 10.1192/pb.bp.114.047936; LETT J, 1990, FRONT ANTHR, P127; Liddell C, 2008, PSYCHOSOM MED, V70, P496, DOI 10.1097/PSY.0b013e31816fdf0e; LOGAN MH, 1987, AM ANTHROPOL, V89, P465, DOI 10.1525/aa.1987.89.2.02a00350; Lopez-Ibor Alino JJ, 2002, DSM 4 TR MANUAL DIAG; Fernandez DL, 2013, REV ESP ANTROPOL AM, V43, P285; Main R, 2014, J ANAL PSYCHOL, V59, P174, DOI 10.1111/1468-5922.12067; Mallart i Guimera L, 2007, SOY HIJO EVUZOK; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; Mavhu W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032475; Meel BL, 2009, AFR HEALTH SCI, V9, P61; Mianji Fahimeh, 2015, Iran J Psychiatry, V10, P225; Naseef K. A., 2013, International Journal of Developing Societies, V2, P29; Novoa JM, 1984, GUINEA ECUATORIAL HI; Nyabwari BG, 2014, IMPACT MAGIC WITCHCR; Nze Abuy RM, 1984, BREVES DATOS HISTORI; O'Neill S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160464; Okeke TA, 2006, J BIOSOC SCI, V38, P491, DOI 10.1017/S002193200502660X; Olive J. L., 2014, FORUM QUAL SOC RES, V15; Panyella A., 1963, PROCESO TRANSFORMACI; Panyella A, 1958, INDIVIDUO SOC FANG M; Peeters Grietens K, 2012, PLOS ONE, V7; Peltzer K, 2008, AFR J TRADIT COMPLEM, V5, P370; Peretti L, 2010, SCR ETHNOL, V32, P17; Pfeiffer J, 2007, AM ANTHROPOL, V109, P688, DOI 10.1525/AA.2007.109.4.688; PHILLIPS MR, 1988, J PSYCHOHIST, V15, P383; Pilkington H, 2004, J EPIDEMIOL COMMUN H, V58, P826, DOI 10.1136/jech.2003.016089; Price R., 1986, J LAT AM STUD, V18, P241; Reuter KE, 2014, PAN AFR MED J, V19, DOI 10.11604/pamj.2014.19.369.5552; Roura M, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-427; Ruano AL, 2014, HEALTH EXPECT, V17, P93, DOI 10.1111/j.1369-7625.2011.00731.x; Sabuni LP, 2007, QUAL HEALTH RES, V17, P1280, DOI 10.1177/1049732307307864; Shringarpure KS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150849; Sifunda S, 2007, HEALTH EDUC RES, V22, P805, DOI 10.1093/her/cyl105; Sorsdahl KR, 2010, AFR J PSYCHIATRY, V13, P284; Sumathipala A, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-54; Teuton J, 2007, SOC SCI MED, V65, P1260, DOI 10.1016/j.socscimed.2007.03.055; THOMPSON EE, 1965, B MED LIBR ASSOC, V53, P80; Towns AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105972; Tylor E.B, 1871, PRIMITIVE CULTURE RE, V2; UN_ UNICEF and World Health Organization (WHO), 2013, JOINT MON PROGR EQ G; van Duijl M, 2014, INT J MENT HEALTH SY, V8, DOI 10.1186/1752-4458-8-24; van Duijl M, 2010, CULT MED PSYCHIAT, V34, P380, DOI 10.1007/s11013-010-9171-1; YAP PM, 1967, AUST NZ J PSYCHIAT, V1, P172, DOI 10.3109/00048676709159191	94	2	2	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2018	13	9							e0201339	10.1371/journal.pone.0201339	http://dx.doi.org/10.1371/journal.pone.0201339			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GT0BU	30192763	Green Published, gold			2023-01-03	WOS:000444093600010
J	Chevalier, A; Ntala, E; Fung, C; Priebe, S; Bird, VJ				Chevalier, Agnes; Ntala, Eleni; Fung, Catherine; Priebe, Stefan; Bird, Victoria J.			Exploring the initial experience of hospitalisation to an acute psychiatric ward	PLOS ONE			English	Article							PATIENT SATISFACTION; INPATIENT CARE; PATIENTS VIEWS; HEALTH-CARE; SCHIZOPHRENIA; PREDICTOR; COUNTRIES; ADMISSION; SERVICES	Background Patient-reported satisfaction with inpatient psychiatric services, within the first few days of admission, is related to positive future outcomes. Despite its predictive value, little is known about this initial experience and what underlies these appraisals. The aim of this study was to qualitatively explore the initial experience of being admitted to an inpatient psychiatric ward. Methods Semi-structured interviews were conducted with 61 recently admitted patients across five psychiatric hospitals in London, England. Participants were purposively sampled to ensure a mix of experiences including people with high and low satisfaction scores as measured by the Client Assessment of Treatment. Thematic analysis was used to identify, analyse and report patterns within the data, with content analysis applied to determine whether certain themes were more common to either negative or positive appraisals. Results Four broad themes were evident 1) 'Best place for me right now?' 2) 'Different from out in society' 3) 'Moving from uncertainty to being informed' and 4) 'Relating & Alienating'. Individuals with very positive appraisals spoke most frequently of helpful relationships with both staff and other patients, and feeling cared for. They also spoke of having had previous admissions and the assessment process on entering the ward suggesting that these may be valuable experiences. Conversely, the group with very negative appraisals spoke of relationships that were alienating or where there was a perceived abuse of power. They described restrictions to their freedom, compared hospital to prison and generally had the view that hospital makes you worse. Conclusions The experience of hospital within the first few days of admission determines whether an individual has a positive or negative experience of their inpatient care. Reducing the impact of uncertainty and promoting good relationships may help services to improve the initial experience of hospital admission and ultimately improve future outcomes for patients.	[Chevalier, Agnes; Ntala, Eleni; Fung, Catherine; Priebe, Stefan; Bird, Victoria J.] Queen Mary Univ London, Blizard Inst, Unit Social & Community Psychiat, London, England; [Chevalier, Agnes; Fung, Catherine; Priebe, Stefan; Bird, Victoria J.] East London NHS Fdn Trust, London, England; [Chevalier, Agnes; Ntala, Eleni; Fung, Catherine; Priebe, Stefan; Bird, Victoria J.] East London NHS Fdn, Unit Social & Community Psychiat, Newham Ctr Mental Hlth, London, England	University of London; Queen Mary University London	Bird, VJ (corresponding author), Queen Mary Univ London, Blizard Inst, Unit Social & Community Psychiat, London, England.; Bird, VJ (corresponding author), East London NHS Fdn Trust, London, England.; Bird, VJ (corresponding author), East London NHS Fdn, Unit Social & Community Psychiat, Newham Ctr Mental Hlth, London, England.	v.j.bird@qmul.ac.uk	Bird, Victoria/N-1165-2013	Bird, Victoria/0000-0002-2053-7679; Chevalier, Agnes/0000-0002-0895-8059	European Commission [602645]	European Commission(European CommissionEuropean Commission Joint Research Centre)	This study was funded by the European Commission 7th Framework Programme, Grant agreement number is 602645 to S.P., https://ec.europa.eu/commission/index_en. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Awad A, 1995, INT CLIN PSYCHOPHARM; Barker DA, 1996, BRIT J PSYCHIAT, V168, P641, DOI 10.1192/bjp.168.5.641; Bird VJ, 2018, BRIT J PSYCHIAT, V212, P81, DOI 10.1192/bjp.2017.20; Bleich SN, 2009, B WORLD HEALTH ORGAN, V87, P271, DOI 10.2471/BLT.07.050401; Braun V., 2013, SUCCESSFUL QUALITATI; BROKER M, 1995, PSYCHIAT RES, V58, P77, DOI 10.1016/0165-1781(95)02718-C; Burt J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014718; Giacco D, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008996; Gilburt H, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-92; Henderson C, 1999, ACTA PSYCHIAT SCAND, V99, P188, DOI 10.1111/j.1600-0447.1999.tb00975.x; Hughes R, 2009, J MENT HEALTH, V18, P152, DOI 10.1080/09638230802053326; Johansson IM, 2009, NORD J PSYCHIAT, V63, P501, DOI 10.3109/08039480903118208; Jones J, 2010, J PSYCHIATR MENT HLT, V17, P124, DOI 10.1111/j.1365-2850.2009.01482.x; Kallert TW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028191; Katsakou C, 2011, PSYCHIAT RES, V187, P275, DOI 10.1016/j.psychres.2011.01.001; Katsakou C, 2010, PSYCHIAT SERV, V61, P286, DOI 10.1176/ps.2010.61.3.286; Krupchanka D, 2017, SOC PSYCH PSYCH EPID, V52, P989, DOI 10.1007/s00127-017-1366-0; Kuosmanen L, 2006, J ADV NURS, V55, P655, DOI 10.1111/J.1365-2648.2006.03957.x; McGuinness D, 2013, J PSYCHIATR MENT HLT, V20, P726, DOI 10.1111/jpm.12007; NHS Digital, 2017, ANN REPORT; NICE, SERVICE USER EXPERIE; PRIEBE S, 1995, SCHIZOPHRENIA BULL, V21, P87, DOI 10.1093/schbul/21.1.87; PRIEBE S, 1994, COMPR PSYCHIAT, V35, P234, DOI 10.1016/0010-440X(94)90196-1; Priebe S, 2010, BRIT J PSYCHIAT, V196, P179, DOI 10.1192/bjp.bp.109.068916; Priebe S, 2009, BRIT J PSYCHIAT, V194, P49, DOI 10.1192/bjp.bp.108.052266; Savill M, 2012, PSYCHIAT RES, V199, P79, DOI 10.1016/j.psychres.2012.04.011; Stenhouse RC, 2013, J CLIN NURS, V22, P3109, DOI 10.1111/jocn.12111; Valenti E, 2013, J MED ETHICS; VANPUTTEN T, 1978, ARCH GEN PSYCHIAT, V35, P477; Walsh Jim, 2009, Issues Ment Health Nurs, V30, P31, DOI 10.1080/01612840802500733; WILLIAMS B, 1995, BRIT J PSYCHIAT, V166, P559, DOI 10.1192/bjp.166.5.559; Wood Lisa, 2016, J PSYCHIAT INTENSIVE, V12, P35, DOI DOI 10.20299/JPI.2016.001; Woodward S, 2017, J PSYCHIATR RES, V92, P81, DOI 10.1016/j.jpsychires.2017.03.020; Wykes T, 2018, PSYCHOL MED, V48, P488, DOI 10.1017/S003329171700188X	34	17	18	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2018	13	9							e0203457	10.1371/journal.pone.0203457	http://dx.doi.org/10.1371/journal.pone.0203457			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GT1IK	30180196	gold, Green Published, Green Submitted			2023-01-03	WOS:000444222400045
J	Rehman, IU; Munib, S; Ramadas, A; Khan, TM				Rehman, Inayat Ur; Munib, Syed; Ramadas, Amutha; Khan, Tahir Mehmood			Prevalence of chronic kidney disease-associated pruritus, and association with sleep quality among hemodialysis patients in Pakistan	PLOS ONE			English	Article							OF-LIFE; UREMIC PRURITUS; DIALYSIS OUTCOMES; PRACTICE PATTERNS; IMPACT; HYPERTENSION; DURATION; ITCH	Background The prevalence of chronic kidney disease-associated pruritus (CKD-aP) varies from 22% to 84% among patients receiving hemodialysis. It occurs more frequently at night, and often affects patient's sleep quality. CKD-aP is often unreported by patients, and many do not receive effective treatment. There is, however, a paucity of available data on the prevalence and impact of CKD-aP on patients receiving hemodialysis in Pakistan. Methods A multicenter cross-sectional study was undertaken from July 2016 to April 2017 at a tertiary care hospitals in Pakistan. Results 354 patients undergoing hemodialysis were studied. 35.6% had CKD for 1-2 years, and 42.4% were receiving hemodialysis for 1-2 years. The prevalence of pruritus was 74%. The median [interquartile range] score for pruritus was 10.0 (out of possible 25) [8.0-12.0]; while the median [interquartile range] Pittsburgh Sleep Quality Index (PSQI) score was 8.0 (out of possible 21) [7.0-10.0]'. Pruritus was significantly correlated with the sleep score (r = 0.423, p< 0.001). The results of the multivariate linear regression revealed a positive association between pruritus and age of patients (beta = 0.031; 95% CI = 0.002-0.061; p = 0.038) and duration of CKD (beta = -0.013; 95% CI = -0.023-0.003; p = 0.014). Similarly there was a positive association between sleep score and duration of CKD (beta = 0.010; 95% CI = 0.002-0.019; p = 0.012) and pruritus (beta = 0.143; 95% CI = 0.056-0.230; p = 0.001). Conclusions Chronic kidney disease-associated pruritus is very common in patients receiving hemodialysis in Pakistan. Pruritus is significantly associated with poor sleep quality.	[Rehman, Inayat Ur; Khan, Tahir Mehmood] Monash Univ, Sch Pharm, Jalan Lagoon Selatan, Selangor Darul Ehsan, Malaysia; [Rehman, Inayat Ur] Abdul Wali Khan Univ, Dept Pharm, Mardan, Pakistan; [Munib, Syed] Inst Kidney Dis, Dept Nephrol, Peshawar, Pakistan; [Ramadas, Amutha] Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, Jalan Lagoon Selatan, Selangor Darul Ehsan, Malaysia; [Khan, Tahir Mehmood] UVAS, IPS, Lahore, Pakistan	Monash University; Monash University Sunway; Abdul Wali Khan University; Monash University; Monash University Sunway	Rehman, IU; Khan, TM (corresponding author), Monash Univ, Sch Pharm, Jalan Lagoon Selatan, Selangor Darul Ehsan, Malaysia.; Rehman, IU (corresponding author), Abdul Wali Khan Univ, Dept Pharm, Mardan, Pakistan.; Khan, TM (corresponding author), UVAS, IPS, Lahore, Pakistan.	inayat.rehman@monash.edu; tahir.mehmood@monash.edu	Ramadas, Amutha/G-7532-2014; Munib, Syed/AAW-7080-2021; Khan, Tahir/ABA-6714-2021; Khan, Yusra Habib/AFK-9024-2022; Rehman, Inayat Ur/GVT-4724-2022	Khan, Yusra Habib/0000-0002-9479-6147; Rehman, Inayat Ur/0000-0002-8657-9791; Ramadas, Amutha/0000-0002-8238-9659				Adejumo O, 2016, ETHIOP J HEALTH SCI, V26, P549, DOI 10.4314/ejhs.v26i6.7; Akca NK, 2013, ALTERN THER HEALTH M, V19, P12; Baglioni C, 2011, J AFFECT DISORDERS, V135, P10, DOI 10.1016/j.jad.2011.01.011; Boivin MJ, 2018, AIDS, V32, P189, DOI 10.1097/QAD.0000000000001683; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cengic B, 2012, INT UROL NEPHROL, V44, P557, DOI 10.1007/s11255-010-9881-x; Chauhan R, 2015, Indian J Nephrol, V25, P329, DOI 10.4103/0971-4065.151762; Daniel W.W., 1999, BIOSTATISTICS FDN AN; Einollahi B, 2015, NEPHROUROL MON, V7, P1; Elder SJ, 2008, NEPHROL DIAL TRANSPL, V23, P998, DOI 10.1093/ndt/gfm630; Elman S, 2010, BRIT J DERMATOL, V162, P587, DOI 10.1111/j.1365-2133.2009.09586.x; Erturk IE, 2012, ANN DERMATOL, V24, P406, DOI 10.5021/ad.2012.24.4.406; Guo XF, 2015, J SLEEP RES, V24, P351, DOI 10.1111/jsr.12274; HIROSHIGE K, 1995, AM J KIDNEY DIS, V25, P413, DOI 10.1016/0272-6386(95)90102-7; Hu XM, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010633; Ibrahim MK, 2016, J CLIN DIAGN RES, V10, pWC1, DOI 10.7860/JCDR/2016/16273.7488; Karadag E, 2014, JPN J NURS SCI, V11, P180, DOI 10.1111/jjns.12019; Kavurmaci M, 2015, HEMODIAL INT, V19, P531, DOI 10.1111/hdi.12301; Khan Sla TI, 2010, PAKISTAN J MED HLTH, V4, P116; Khan TM, 2016, SCI REPORTS, V6; Kim KH, 2010, J PAIN SYMPTOM MANAG, V40, P117, DOI 10.1016/j.jpainsymman.2009.11.325; Kimata N, 2014, HEMODIAL INT, V18, P657, DOI 10.1111/hdi.12158; Ko MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071404; Luqman N., 2012, J PAK ASS DERMATOL, V22, P219; Mathur VS, 2010, CLIN J AM SOC NEPHRO, V5, P1410, DOI 10.2215/CJN.00100110; Meisinger C, 2005, DIABETOLOGIA, V48, P235, DOI 10.1007/s00125-004-1634-x; Melo NCV, 2009, HEMODIAL INT, V13, P38, DOI 10.1111/j.1542-4758.2009.00346.x; Mirza R, 2012, J LIAQUAT UNIV MED H, V11, P24; Mistik S, 2006, J EUR ACAD DERMATOL, V20, P672, DOI 10.1111/j.1468-3083.2006.01570.x; Narita I, 2006, KIDNEY INT, V69, P1626, DOI 10.1038/sj.ki.5000251; Narita I, 2008, J NEPHROL, V21, P161; Noh SH, 2018, ANN DERMATOL, V30, P473, DOI 10.5021/ad.2018.30.4.473; Novak M, 2004, J PSYCHOSOM RES, V56, P527, DOI 10.1016/j.jpsychores.2004.02.007; Ozen N, 2018, KIDNEY RES CLIN PRAC, V37, P138, DOI 10.23876/j.krcp.2018.37.2.138; Pisoni RL, 2006, NEPHROL DIAL TRANSPL, V21, P3495, DOI 10.1093/ndt/gfl461; Ramakrishnan K, 2014, INT J NEPHROL RENOV, V7, P1, DOI 10.2147/IJNRD.S52985; Rehman IU, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0717-0; Sheikh M., 2016, J PAK ASS DERMATOL, V24, P150; Shirazian S, 2017, INT J NEPHROL RENOV, V10, P11, DOI 10.2147/IJNRD.S108045; Takahashi N, 2016, RENAL REPLACEMENT TH, V2, P1; Tattersall J, 2018, NEPHROL DIAL TRANSPL, V33, P742, DOI 10.1093/ndt/gfy042; Tessari G, 2009, J NEPHROL, V22, P241; Van Cauter E, 2011, DIABETIC MED, V28, P1455, DOI 10.1111/j.1464-5491.2011.03459.x; Vozoris NT, 2013, J HYPERTENS, V31, P663, DOI 10.1097/HJH.0b013e32835ed5d0; Weiss M, 2015, ACTA DERM-VENEREOL, V95, P816, DOI 10.2340/00015555-2087; Yamamoto R, 2012, AM J KIDNEY DIS, V59, P343, DOI 10.1053/j.ajkd.2011.08.032; Yosipovitch G, 2001, ACTA DERM-VENEREOL, V81, P108; Zucker I, 2003, J AM ACAD DERMATOL, V49, P842, DOI 10.1016/S0190-9622(03)02478-2	48	12	12	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2018	13	11							e0207758	10.1371/journal.pone.0207758	http://dx.doi.org/10.1371/journal.pone.0207758			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HC4HL	30496235	gold, Green Submitted, Green Published			2023-01-03	WOS:000451763800046
J	Viguria, N; Martinez-Baz, I; Moreno-Galarraga, L; Sierrasesumaga, L; Salcedo, B; Castilla, J				Viguria, Natividad; Martinez-Baz, Ivan; Moreno-Galarraga, Laura; Sierrasesumaga, Luis; Salcedo, Blanca; Castilla, Jesus			Respiratory syncytial virus hospitalization in children in northern Spain	PLOS ONE			English	Article							TRACT INFECTION; RISK-FACTORS; BRONCHIOLITIS; EPIDEMIOLOGY; MORTALITY; ILLNESS; INFANTS; BURDEN; TRENDS; AGE	Objectives Understanding respiratory syncytial virus (RSV) morbidity may help to plan health care and future vaccine recommendations. We aim to describe the characteristics and temporal distribution of children diagnosed with RSV admitted in a Spanish hospital. Methods Descriptive study for which the hospital discharges of children <5 years of age with RSV infection were analyzed. The information was extracted from the hospital discharge data- base of a reference pediatric hospital in northern Spain for the 2010-2011 to 2014-2015 RSV seasons. Results Six hundred and forty-seven hospitalizations of children with RSV infection were analyzed, 94% of which occurred between the second week of November and the last week of March. Most children (72%) were under one year of age and 95% were previously healthy infants. Infants born from October to December had the highest risk of hospitalization in the first year of life. The median length of hospital stay of children with and without comorbidities was six and three days, respectively. 6.5% of the hospitalized cases were admitted to the pediatric intensive care unit; this percentage was higher among children <2 months (adjusted odds ratio 4.15; 95% confidence interval: 1.37-12.61) or with comorbidities (adjusted odds ratio 4.15; 95% confidence interval: 1.53-11.28). The case lethality was 0.3%. Conclusions The risk of hospitalizations for RSV is high during the first year of life and increases among infants born in the fall. Being under two months of age and presenting comorbidities are the main risk factors associated to pediatric intensive care unit admission.	[Viguria, Natividad; Moreno-Galarraga, Laura] Complejo Hosp Navarra, Dept Pediat, Pamplona, Spain; [Viguria, Natividad; Martinez-Baz, Ivan; Moreno-Galarraga, Laura; Castilla, Jesus] IdiSNA, Inst Invest Sanitaria Navarra, Pamplona, Spain; [Martinez-Baz, Ivan; Castilla, Jesus] Inst Salud Publ Navarra, Pamplona, Spain; [Martinez-Baz, Ivan; Castilla, Jesus] GIBER Epidemiol & Salud Publ, Pamplona, Spain; [Sierrasesumaga, Luis] Clin Univ Navarra, Pamplona, Spain; [Salcedo, Blanca] Complejo Hosp Navarra, Serv Gest Informac & Evaluac, Pamplona, Spain	Servicio Navarro de Salud - Osasunbidea; Public Health Institute of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; University of Navarra; Servicio Navarro de Salud - Osasunbidea	Viguria, N (corresponding author), Complejo Hosp Navarra, Dept Pediat, Pamplona, Spain.; Viguria, N (corresponding author), IdiSNA, Inst Invest Sanitaria Navarra, Pamplona, Spain.	nviguris@cfnavarra.es	Moreno Galarraga, Laura/B-2460-2017; Martínez-Baz, Iván/H-4954-2017; Castilla, Jesus/B-9048-2008	Moreno Galarraga, Laura/0000-0003-0293-0749; Martínez-Baz, Iván/0000-0002-3405-2277; Castilla, Jesus/0000-0002-6396-7265; Viguria, Natividad/0000-0003-0920-5072	Spanish Carlos III Institute of Health; European Regional Development Fund [INT17/00066]; Caixa Foundation	Spanish Carlos III Institute of Health; European Regional Development Fund(European Commission); Caixa Foundation(La Caixa Foundation)	This study has been partially funded by the Spanish Carlos III Institute of Health, the collaboration of the European Regional Development Fund (INT17/00066), and the Caixa Foundation. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Birkhaug IM, 2013, PEDIATR INFECT DIS J, V32, pE235, DOI 10.1097/INF.0b013e31828ab9ff; Byington CL, 2015, PEDIATRICS, V135, pE24, DOI 10.1542/peds.2014-2151; Cilla G, 2006, EPIDEMIOL INFECT, V134, P506, DOI 10.1017/S0950268805005571; Darniot M, 2018, J CLIN VIROL, V104, P77, DOI 10.1016/j.jcv.2018.05.002; Doucette A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152208; Esposito S, 2017, EXPERT REV VACCINES, V16, P175, DOI 10.1080/14760584.2017.1237875; Falagas ME, 2007, RESP MED, V101, P1845, DOI 10.1016/j.rmed.2007.04.011; Figueras Aloy J, 2015, An Pediatr (Barc), V82, DOI 10.1016/j.anpedi.2014.10.004; Gil-Prieto R, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000831; Griffiths C, 2017, CLIN MICROBIOL REV, V30, P277, DOI 10.1128/CMR.00010-16; Gupta P, 2016, PEDIATR CRIT CARE ME, V17, pE343, DOI 10.1097/PCC.0000000000000850; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; Jepsen MT, 2018, EURO SURVEILL, V23; Justicia-Grande AJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157665; Light M, 2008, PEDIATR INFECT DIS J, V27, P512, DOI 10.1097/INF.0b013e318168daf1; Lloyd PC, 2014, PEDIATR INFECT DIS J, V33, pE135, DOI 10.1097/INF.0000000000000250; Garcia-Garcia ML, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173504; Midgley CM, 2017, J INFECT DIS, V216, P345, DOI 10.1093/infdis/jix275; Moreno-Perez D, 2014, INFLUENZA OTHER RESP, V8, P209, DOI 10.1111/irv.12224; Noveroske DB, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2004-2; Paes BA, 2013, PEDIATR INFECT DIS J, V32, pE360, DOI 10.1097/INF.0b013e31829479d3; Ramos-Fernandez JM, 2016, AN PEDIAT; Reeves RM, 2016, EPIDEMIOL INFECT, V144, P2049, DOI 10.1017/S0950268816000352; Ricart S, 2014, PEDIATR INFECT DIS J, V33, P988, DOI 10.1097/INF.0000000000000365; Rossi GA, 2007, EUR J PEDIATR, V166, P1267, DOI 10.1007/s00431-007-0418-y; Sanchez-Luna M, 2016, CURR MED RES OPIN, V32, P693, DOI 10.1185/03007995.2015.1136606; Sandweiss DR, 2013, JAMA PEDIATR, V167, P422, DOI 10.1001/jamapediatrics.2013.1435; Saso A, 2016, LANCET INFECT DIS, V16, pE153, DOI 10.1016/S1473-3099(16)00119-5; Shi T, 2017, LANCET; Sirimi N, 2016, J MED VIROL, V88, P931, DOI 10.1002/jmv.24430; Sommer Constanze, 2011, Open Microbiol J, V5, P144, DOI 10.2174/1874285801105010144; Stein RT, 2017, PEDIATR PULM, V52, P556, DOI 10.1002/ppul.23570; Tam J, 2018, CLIN INFECT DIS; Tang JW, 2017, LANCET INFECT DIS, V17, pE320, DOI 10.1016/S1473-3099(17)30238-4; Wang EEL, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.3.e9	35	16	16	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2018	13	11							e0206474	10.1371/journal.pone.0206474	http://dx.doi.org/10.1371/journal.pone.0206474			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA4SR	30439987	Green Published, Green Submitted, gold			2023-01-03	WOS:000450254000017
J	Iacobucci, G				Iacobucci, Gareth			NHS outpatient model is no longer fit for purpose, says RCP	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Royal College of Physicians, 2018, OUTP FUT	1	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	2018	363								k4759	10.1136/bmj.k4759	http://dx.doi.org/10.1136/bmj.k4759			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA2DR	30409816				2023-01-03	WOS:000450043500002
J	Chou, L; Ranger, TA; Peiris, W; Cicuttini, FM; Urquhart, DM; Sullivan, K; Seneviwickrama, M; Briggs, AM; Wluka, AE				Chou, Louisa; Ranger, Tom A.; Peiris, Waruna; Cicuttini, Flavia M.; Urquhart, Donna M.; Sullivan, Kaye; Seneviwickrama, Maheeka; Briggs, Andrew M.; Wluka, Anita E.			Patients' perceived needs for medical services for non-specific low back pain: A systematic scoping review	PLOS ONE			English	Review							PRIMARY-CARE; CLINICAL GUIDELINES; GENERAL-PRACTICE; MUSCULOSKELETAL HEALTH; PATIENTS EXPERIENCES; SELF-MANAGEMENT; PATIENTS VIEWS; PEOPLE; PREVALENCE; BELIEFS	Background An improved understanding of patients' perceived needs for medical services for low back pain (LBP) will enable healthcare providers to better align service provision with patient expectations, thus improving patient and health care system outcomes. Thus, we aimed to identify the existing literature regarding patients' perceived needs for medical services for LBP. Methods A systematic scoping review was performed of publications identified from MEDLINE, EMBASE, CINAHL and PsycINFO (1990-2016). Descriptive data regarding each study, its design and methodology were extracted and risk of bias assessed. Aggregates of patients' perceived needs for medical services for LBP were categorised. Results 50 studies (35 qualitative, 14 quantitative and 1 mixed-methods study) from 1829 were relevant. Four areas of perceived need emerged: (1) Patients with LBP sought healthcare from medical practitioners to obtain a diagnosis, receive management options, sickness certification and legitimation for their LBP. However, there was dissatisfaction with the cursory and superficial approach of care. (2) Patients had concerns about pharmacotherapy, with few studies reporting on patients' preferences for medications. (3) Of the few studies which examined the patients' perceived need of invasive therapies, these found that patients avoided injections and surgeries (4) Patients desired spinal imaging for diagnostic purposes and legitimation of symptoms. Conclusions Across many different patient populations with data obtained from a variety of study designs, common themes emerged which highlighted areas of patient dissatisfaction with the medical management of LBP, in particular, the superficial approach to care perceived by patients and concerns regarding pharmacotherapy. Patients perceive unmet needs from medical services, including the need to obtain a diagnosis, the desire for pain control and the preference for spinal imaging. These issues need to be considered in developing approaches for the management of LBP in order to improve patient outcomes.	[Chou, Louisa; Ranger, Tom A.; Peiris, Waruna; Cicuttini, Flavia M.; Urquhart, Donna M.; Seneviwickrama, Maheeka; Wluka, Anita E.] Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia; [Sullivan, Kaye] Monash Univ, Monash Univ Lib, Melbourne, Vic, Australia; [Briggs, Andrew M.] Curtin Univ, Sch Physiotherapy & Exercise Sci, Perth, WA, Australia; [Briggs, Andrew M.] MOVE Muscle Bone & Joint Hlth, Elsternwick, Vic, Australia	Monash University; Monash University; Curtin University	Wluka, AE (corresponding author), Monash Univ, Sch Publ Hlth & Prevent Med, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia.	anita.wluka@monash.edu	Seneviwickrama, Maheeka/AAT-4215-2020; Wluka, Anita E/H-5349-2011; Cicuttini, Flavia/H-4978-2014	Wluka, Anita E/0000-0001-8024-9049; Ranger, Tom/0000-0003-3091-2337; Cicuttini, Flavia/0000-0002-8200-1618; Seneviwickrama, Maheeka/0000-0002-4182-284X	Australian Postgraduate Award; Arthritis Foundation Scholarship; Australian Government Research Training Program Scholarship; NHMRC Career Development Fellowships [1011975, 1063574]	Australian Postgraduate Award(Australian Government); Arthritis Foundation Scholarship; Australian Government Research Training Program Scholarship(Australian GovernmentDepartment of Industry, Innovation and Science); NHMRC Career Development Fellowships(National Health and Medical Research Council (NHMRC) of Australia)	This work was performed in partnership with Move: muscle, bone & joint health and was supported by a partnership grant awarded by the organisation. L.C is the recipient of an Australian Postgraduate Award and Arthritis Foundation Scholarship. T.R is the recipient of an Australian Government Research Training Program Scholarship. D.M.U and A.E.W are recipients of NHMRC Career Development Fellowships (Clinical Level 1 #1011975 and Clinical Level 2 #1063574). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allegretti A, 2010, FAM PRACT, V27, P676, DOI 10.1093/fampra/cmq063; Amonkar SJ., 2011, INT MUSCULOSKELET ME, V33, P3, DOI [10.1179/175361511X12972993698186, DOI 10.1179/175361511X12972993698186]; [Anonymous], SPINE J; Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [10.1080/1364557032000119616, https://doi.org/10.1080/1364557032000119616, DOI 10.1080/1364557032000119616]; Armstrong R, 2011, J PUBLIC HEALTH-UK, V33, P147, DOI 10.1093/pubmed/fdr015; Asadi-Lari Mohsen, 2004, Health Qual Life Outcomes, V2, P32, DOI 10.1186/1477-7525-2-32; Balague F, 2012, LANCET, V379, P482, DOI 10.1016/S0140-6736(11)60610-7; Banbury Paula, 2008, Br J Nurs, V17, P1215; Birnbaum HG, 2011, PAIN MED, V12, P657, DOI 10.1111/j.1526-4637.2011.01075.x; Bishop FL, 2015, SPINE, V40, P1842, DOI 10.1097/BRS.0000000000001215; BORKAN J, 1995, SOC SCI MED, V40, P977, DOI 10.1016/0277-9536(94)00156-N; Briggs AM, 2013, EUR J PAIN, V17, P766, DOI 10.1002/j.1532-2149.2012.00246.x; BRIGGS AM, 2012, BMC HEALTH SERV RES, V12; Briggs AM, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1173-9; Briggs AM, 2014, AUST HEALTH REV, V38, P401, DOI 10.1071/AH14032; Buchbinder M, 2015, PATIENT EDUC COUNS, V98, P137, DOI 10.1016/j.pec.2014.10.021; Bunzli S, 2013, CLIN J PAIN, V29, P907, DOI 10.1097/AJP.0b013e31827a6dd8; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Campbell C, 2007, J HEALTH PSYCHOL, V12, P641, DOI 10.1177/1359105307078171; Carey TS, 1999, MED CARE, V37, P157, DOI 10.1097/00005650-199902000-00006; CAREY TS, 1995, NEW ENGL J MED, V333, P913, DOI 10.1056/NEJM199510053331406; Carey TS, 1996, SPINE, V21, P339, DOI 10.1097/00007632-199602010-00018; Chaparro LE, 2013, COCHRANE DATABASE SY; Chenot JF, 2008, EUR J PAIN, V12, P275, DOI 10.1016/j.ejpain.2007.06.004; Cheriyan T, 2015, SPINE J, V15, P2564, DOI 10.1016/j.spinee.2015.09.033; Chew CA, 1997, FAM PRACT, V14, P461, DOI 10.1093/fampra/14.6.461; Chou R, 2011, ANN INTERN MED, V154, P181, DOI 10.7326/0003-4819-154-3-201102010-00008; Chou R, 2009, SPINE, V34, P1078, DOI 10.1097/BRS.0b013e3181a103b1; Cook FM, 2000, PHYSIOTHERAPY, V86, P61; COOLE C, 2010, BMC MUSCULOSKEL DIS, V11; Coole C, 2010, J OCCUP REHABIL, V20, P472, DOI 10.1007/s10926-010-9237-5; Coudeyre E, 2007, CLIN J PAIN, V23, P720, DOI 10.1097/AJP.0b013e31814da407; Crowe M, 2010, J ADV NURS, V66, P1478, DOI 10.1111/j.1365-2648.2010.05316.x; Dagenais S, 2010, SPINE J, V10, P514, DOI 10.1016/j.spinee.2010.03.032; Darlow B, 2015, SPINE, V40, P842, DOI 10.1097/BRS.0000000000000901; Darlow B, 2013, ANN FAM MED, V11, P527, DOI 10.1370/afm.1518; Dennis S, 2018, J PHYSIOTHER, V64, P178, DOI 10.1016/j.jphys.2018.05.006; Deyo RA, 2001, NEW ENGL J MED, V344, P363, DOI 10.1056/NEJM200102013440508; DEYO RA, 2015, BMJ BRIT MED J, V350; Dieleman JL, 2016, JAMA-J AM MED ASSOC, V316, P2627, DOI 10.1001/jama.2016.16885; Dima A, 2013, BRIT J GEN PRACT, V63, pE490, DOI 10.3399/bjgp13X669211; Enthoven WTM, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012087; Fersum KV, 2013, EUR J PAIN, V17, P916, DOI 10.1002/j.1532-2149.2012.00252.x; Foster NE, 2018, LANCET, V391, P2368, DOI 10.1016/S0140-6736(18)30489-6; Franz EW, 2015, J NEUROSURG-SPINE, V22, P496, DOI 10.3171/2014.10.SPINE14537; French SD, 2010, COCHRANE DATABASE SY; Gonzaalez-Urzelai V, 2003, EUR SPINE J, V12, P589, DOI 10.1007/s00586-003-0567-2; Grimshaw JM, 2004, MED J AUSTRALIA, V180, pS50; Grol R, 2001, MED CARE, V39, pII46; Hero JO, 2016, ANN FAM MED, V14, P575, DOI 10.1370/afm.1994; Heyduck K, 2014, J CLIN PSYCHOL MED S, V21, P267, DOI 10.1007/s10880-014-9405-4; Hoffmann TC, 2013, BMC FAM PRACT, V14, DOI 10.1186/1471-2296-14-7; Holt N, 2015, BRIT J GEN PRACT, V65, pE692, DOI 10.3399/bjgp15X686953; Hopayian K, 2014, SPINE J, V14, P1769, DOI 10.1016/j.spinee.2014.02.029; Hoy D, 2014, ANN RHEUM DIS, V73, P968, DOI 10.1136/annrheumdis-2013-204428; Jenkins HJ, 2016, EUR J PAIN, V20, P573, DOI 10.1002/ejp.764; Kawi J, 2014, PAIN MANAG NURS, V15, P258, DOI 10.1016/j.pmn.2012.09.003; Kirby ER, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083559; Klojgaard ME, 2014, VALUE HEALTH, V17, P390, DOI 10.1016/j.jval.2014.01.005; Koes BW, 2010, EUR SPINE J, V19, P2075, DOI 10.1007/s00586-010-1502-y; Koes BW, 2001, SPINE, V26, P2504, DOI 10.1097/00007632-200111150-00022; LACROIX A, 1995, PATIENT EDUC COUNS, V26, P301, DOI 10.1016/0738-3991(95)00762-O; Laerum E, 2006, J REHABIL MED, V38, P255, DOI 10.1080/16501970600613461; Layzell M, 2001, Br J Nurs, V10, P800; Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69; Lewis J, 2018, BR J SPORTS MED; Liddle SD, 2007, MANUAL THER, V12, P310, DOI 10.1016/j.math.2006.12.009; Loeser JD, 2013, CLIN J PAIN, V29, P311, DOI 10.1097/AJP.0b013e3182516e64; Lyons KJ, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-225; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; Martin BI, 2009, SPINE, V34, P2077, DOI 10.1097/BRS.0b013e3181b1fad1; May S, 2007, PHYSIOTHER RES INT, V12, P126, DOI 10.1002/pri.367; McIntosh Aileen, 2003, Health Expect, V6, P19, DOI 10.1046/j.1369-6513.2003.00197.x; McPhillips-Tangum CA, 1998, J GEN INTERN MED, V13, P289, DOI 10.1046/j.1525-1497.1998.00093.x; Montori VM, 2013, JAMA-J AM MED ASSOC, V310, P2503, DOI 10.1001/jama.2013.281422; National Institute for Health and Clinical Excellence (NICE), 2016, LOW BACK PAIN SCIATI; Ong BN, 2011, SPINE, V36, P1251, DOI 10.1097/BRS.0b013e318204f7a2; Papandony MC, 2017, OSTEOARTHRITIS CARTI; Pillastrini P, 2012, JOINT BONE SPINE, V79, P176, DOI 10.1016/j.jbspin.2011.03.019; Ramanathan SA, 2017, SPINE, V42, pE802, DOI 10.1097/BRS.0000000000001972; Rhodes LA, 1999, SOC SCI MED, V48, P1189, DOI 10.1016/S0277-9536(98)00418-3; Roelofs PDDM, 2008, COCHRANE DATABASE SY; Rogers WA, 1999, J MED ETHICS, V25, P388, DOI 10.1136/jme.25.5.388; Rudd RA, 2016, MMWR MORB MORTAL WKL; Sanders T, 2015, HEALTH SOCIOL REV, V24, P1, DOI 10.1080/14461242.2014.999399; Sanders T, 2013, RHEUMATOLOGY, V52, P99; Sanderson Kristen B, 2012, J Pain Res, V5, P15, DOI 10.2147/JPR.S28636; Savigny P, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1805; Scheermesser M, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-5; Schers H, 2000, BRIT J GEN PRACT, V50, P640; Schers H, 2001, Spine (Phila Pa 1976), V26, pE348, DOI 10.1097/00007632-200108010-00013; Scott NA, 2010, PAIN RES MANAG, V15, P392, DOI 10.1155/2010/252695; Sharma R, 2003, AM J PUBLIC HEALTH, V93, P2111, DOI 10.2105/AJPH.93.12.2111; Skelton AM, 1996, BRIT J GEN PRACT, V46, P153; Slade SC, 2009, CLIN REHABIL, V23, P270, DOI 10.1177/0269215508100468; Slade SC, 2009, PAIN MED, V10, P143, DOI 10.1111/j.1526-4637.2008.00540.x; Slater H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038037; Snelgrove S, 2013, PSYCHOL HEALTH, V28, P121, DOI 10.1080/08870446.2011.630734; Speerin R, BEST PRACTICE RES CL, V28, P479; Staal JB, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001824.pub3; Steffens D, 2014, EUR J PAIN, V18, P755, DOI 10.1002/j.1532-2149.2013.00427.x; Stisen DB, 2016, DISABIL REHABIL, V38, P307, DOI 10.3109/09638288.2015.1037465; Synnott A, 2015, J PHYSIOTHER, V61, P68, DOI 10.1016/j.jphys.2015.02.016; Toye Francine, 2012, Prim Health Care Res Dev, V13, P72, DOI 10.1017/S1463423611000387; Toye F, 2010, DISABIL REHABIL, V32, P1722, DOI 10.3109/09638281003657857; van Tulder MW, 2003, COCHRANE DATABASE SY; Verbeek J, 2004, SPINE, V29, P2309, DOI 10.1097/01.brs.0000142007.38256.7f; Walker B F, 2003, Asia Pac J Public Health, V15, P79, DOI 10.1177/101053950301500202; Walker BF, 2004, J MANIP PHYSIOL THER, V27, P238, DOI 10.1016/j.jmpt.2004.02.002; Wallace AS, 2009, SPINE J, V9, P721, DOI 10.1016/j.spinee.2009.04.022; Walsh D, 2005, J ADV NURS, V50, P204, DOI 10.1111/j.1365-2648.2005.03380.x; Westmoreland JL, 2007, COMPLEMENT THER MED, V15, P121, DOI 10.1016/j.ctim.2005.11.006; Williams CM, 2010, ARCH INTERN MED, V170, P271, DOI 10.1001/archinternmed.2009.507; Wilson IB, 2001, ARCH INTERN MED, V161, P256, DOI 10.1001/archinte.161.2.256; Wluka A, 2016, UNDERSTANDING NEEDS; Yi D, 2011, EUROPEAN J PAIN, V15, P531; Zgierska A, 2012, JAMA-J AM MED ASSOC, V307, P1377, DOI 10.1001/jama.2012.419	118	26	26	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2018	13	11							e0204885	10.1371/journal.pone.0204885	http://dx.doi.org/10.1371/journal.pone.0204885			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GZ5ZX	30408039	Green Published, gold			2023-01-03	WOS:000449512300008
J	Dimopoulos, MA; Dytfeld, D; Grosicki, S; Moreau, P; Takezako, N; Hori, M; Leleu, X; LeBlanc, R; Suzuki, K; Raab, MS; Richardson, PG; McKiver, MP; Jou, YM; Shelat, SG; Robbins, M; Rafferty, B; San-Miguel, J				Dimopoulos, Meletios A.; Dytfeld, Dominik; Grosicki, Sebastian; Moreau, Philippe; Takezako, Naoki; Hori, Mitsuo; Leleu, Xavier; LeBlanc, Richard; Suzuki, Kenshi; Raab, Marc S.; Richardson, Paul G.; McKiver, Mihaela Popa; Jou, Ying-Ming; Shelat, Suresh G.; Robbins, Michael; Rafferty, Brian; San-Miguel, Jesus			Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DOSE DEXAMETHASONE; LENALIDOMIDE; CYTOTOXICITY; COMBINATION; PROGRESSION; MECHANISMS; SURVIVAL; THERAPY; PHASE-2; TARGET	Background The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor. Methods Patients with multiple myeloma that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor were randomly assigned to receive elotuzumab plus pomalidomide and dexamethasone (elotuzumab group) or pomalidomide and dexamethasone alone (control group). The primary end point was investigator-assessed progression-free survival. Results A total of 117 patients were randomly assigned to the elotuzumab group (60 patients) or the control group (57 patients). After a minimum follow-up period of 9.1 months, the median progression-free survival was 10.3 months in the elotuzumab group and 4.7 months in the control group. The hazard ratio for disease progression or death in the elotuzumab group as compared with the control group was 0.54 (95% confidence interval [CI], 0.34 to 0.86; P=0.008). The overall response rate was 53% in the elotuzumab group as compared with 26% in the control group (odds ratio, 3.25; 95% CI, 1.49 to 7.11). The most common grade 3 or 4 adverse events were neutropenia (13% in the elotuzumab group vs. 27% in the control group), anemia (10% vs. 20%), and hyperglycemia (8% vs. 7%). A total of 65% of the patients in each group had infections. Infusion reactions occurred in 3 patients (5%) in the elotuzumab group. Conclusions Among patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor had failed, the risk of progression or death was significantly lower among those who received elotuzumab plus pomalidomide and dexamethasone than among those who received pomalidomide plus dexamethasone alone.	[Dimopoulos, Meletios A.] Univ Athens, Athens, Greece; [Dytfeld, Dominik] Poznan Univ Med Sci, Poznan, Poland; [Grosicki, Sebastian] Silesian Med Univ, Katowice, Poland; [Moreau, Philippe] Univ Hosp, Nantes, France; [Leleu, Xavier] Ctr Hosp Univ Poitiers La Mil, Poitiers, France; [Takezako, Naoki] Natl Hosp Org Disaster Med Ctr, Tokyo, Japan; [Suzuki, Kenshi] Japanese Red Cross Med Ctr, Tokyo, Japan; [Hori, Mitsuo] Ibaraki Cent Hosp, Kasama, Ibaraki, Japan; [LeBlanc, Richard] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada; [Raab, Marc S.] Heidelberg Univ Hosp, Heidelberg, Germany; [Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA; [McKiver, Mihaela Popa; Jou, Ying-Ming; Shelat, Suresh G.; Robbins, Michael; Rafferty, Brian] Bristol Myers Squibb, Princeton, NJ USA; [San-Miguel, Jesus] Clin Univ Navarra, Ctr Invest Med Aplicada, Inst Invest Sanitaria Navarra IDISNA, Ctr Invest Biomed Red Canc CIBERONC, Pamplona, Spain	National & Kapodistrian University of Athens; Poznan University of Medical Sciences; Medical University Silesia; Nantes Universite; CHU de Nantes; CHU Poitiers; Universite de Poitiers; Japanese Red Cross Medical Center; University of Tokyo; Universite de Montreal; Ruprecht Karls University Heidelberg; Harvard University; Dana-Farber Cancer Institute; Bristol-Myers Squibb; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; University of Navarra	Dimopoulos, MA (corresponding author), Univ Athens, Alexandra Hosp, 80 Vasilissis Sofias Ave, Athens 11528, Greece.	mdimop@med.uoa.gr	Grosicki, Sebastian/AAG-2917-2019; Dimopoulos, Meletios Athanasios/AAD-4130-2019; San-Miguel, Jesús F./V-8977-2018	San-Miguel, Jesús F./0000-0002-9183-4857; moreau, philippe/0000-0003-1780-8746; Grosicki, Sebastian/0000-0003-2644-1050; Dytfeld, Dominik/0000-0003-0855-6591	Bristol-Myers Squibb; AbbVie Biotherapeutics	Bristol-Myers Squibb(Bristol-Myers Squibb); AbbVie Biotherapeutics(AbbVie)	Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-3 ClinicalTrials.gov number, NCT02654132.	[Anonymous], 2017, EMPLICITI ELOTUZUMAB; [Anonymous], 2018, POMALYST POMALIDOMID; [Anonymous], 2018, DARATUMUMAB DARZALEX; Balasa B, 2015, CANCER IMMUNOL IMMUN, V64, P61, DOI 10.1007/s00262-014-1610-3; Baz RC, 2016, BLOOD, V127, P2561, DOI 10.1182/blood-2015-11-682518; Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; Busch L, 2018, LEUKEMIA; Chari A, 2017, BLOOD, V130, P974, DOI 10.1182/blood-2017-05-785246; Chng WJ, 2014, LEUKEMIA, V28, P269, DOI 10.1038/leu.2013.247; Collins SM, 2013, CANCER IMMUNOL IMMUN, V62, P1841, DOI 10.1007/s00262-013-1493-8; Cornell RF, 2016, BONE MARROW TRANSPL, V51, P479, DOI 10.1038/bmt.2015.307; Dimopoulos MA, 2017, BRIT J HAEMATOL, V178, P896, DOI 10.1111/bjh.14787; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; European Medicines Agency, 2017, ELOT SUMM PROD CHAR; European Medicines Agency, 2013, POM SUMM PROD CHAR; Hayashi T, 2005, BRIT J HAEMATOL, V128, P192, DOI 10.1111/j.1365-2141.2004.05286.x; Hsi ED, 2008, CLIN CANCER RES, V14, P2775, DOI 10.1158/1078-0432.CCR-07-4246; Jagannath S, 2017, CL LYMPH MYELOM LEUK, V17, pE127, DOI 10.1016/j.clml.2017.03.230; Kumar SK, 2012, LEUKEMIA, V26, P149, DOI 10.1038/leu.2011.196; Kurdi AT, 2018, MOL CANCER THER, V17, P1454, DOI 10.1158/1535-7163.MCT-17-0998; Lonial S, 2015, NEW ENGL J MED, V373, P621, DOI 10.1056/NEJMoa1505654; Lopez-Girona A, 2012, LEUKEMIA, V26, P2326, DOI 10.1038/leu.2012.119; Ocio EM, 2015, LEUKEMIA, V29, P705, DOI 10.1038/leu.2014.238; Pazina T, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1339853; Rajkumar SV, 2011, BLOOD, V117, P4691, DOI 10.1182/blood-2010-10-299487; Richardson PG, 2014, BLOOD, V123, P1826, DOI 10.1182/blood-2013-11-538835; Miguel JS, 2013, LANCET ONCOL, V14, P1055, DOI 10.1016/S1470-2045(13)70380-2; Tai YT, 2008, BLOOD, V112, P1329, DOI 10.1182/blood-2007-08-107292; Weisel K, 2018, HEMASPHERE S1, V2, P590	29	294	305	3	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 8	2018	379	19					1811	1822		10.1056/NEJMoa1805762	http://dx.doi.org/10.1056/NEJMoa1805762			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ5UT	30403938	Bronze			2023-01-03	WOS:000449495700007
J	Ferner, RE; McGettigan, P				Ferner, Robin E.; McGettigan, Patricia			Adverse drug reactions	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SAFETY; RISK; PHARMACOVIGILANCE; EXPERIENCES; THERAPY; CANCER		[Ferner, Robin E.] City Hosp, West Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England; [McGettigan, Patricia] Queen Mary Univ London, William Harvey Res Inst, London EC1M 6BQ, England	University of Birmingham; University of London; Queen Mary University London	Ferner, RE (corresponding author), City Hosp, West Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England.	r.e.ferner@bham.ac.uk		Ferner, Robin/0000-0003-3769-1346				Abrahamsen B, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i3365; Adams A., INTRO YELLOW CARD HO; Agbabiaka TB, 2008, DRUG SAFETY, V31, P21, DOI 10.2165/00002018-200831010-00003; Alfirevic A, 2012, CLIN PHARMACOL THER, V92, P376, DOI 10.1038/clpt.2012.107; Anton R, 2017, CLIN PHARMACOL THER, V102, P283, DOI 10.1002/cpt.604; Aronson JK, 2005, DRUG SAFETY, V28, P851, DOI 10.2165/00002018-200528100-00003; Aronson JK, 2003, BRIT MED J, V327, P1222, DOI 10.1136/bmj.327.7425.1222; Avery AJ, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15200; Bankowski Z, 1999, REPORTING ADVERSE DR; Bouvy JC, 2015, DRUG SAFETY, V38, P437, DOI 10.1007/s40264-015-0281-0; Butt TF, 2012, DRUG SAFETY, V35, P1159, DOI 10.2165/11631950-000000000-00000; Centers for Disease Control and Prevention, IS IT REALL PEN ALL; Chan SW, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2224; Choi Ji Hui, 2017, Obstet Gynecol Sci, V60, P314, DOI 10.5468/ogs.2017.60.3.314; COULTER DM, 1987, BRIT MED J, V294, P1521, DOI 10.1136/bmj.294.6586.1521; CPRD, WELC CLIN PRACT RES; Crandall JP, 2017, BMJ OPEN DIAB RES CA, V5, DOI 10.1136/bmjdrc-2017-000438; Danlos FX, 2018, EUR J CANCER, V91, P21, DOI 10.1016/j.ejca.2017.12.008; eMC, 2017, AL AC 70MG TABL; European Medicines Agency, COND MARK AUTH; European Medicines Agency, 2017, SGLT2 INGH INF POT R; European Medicines Agency and Heads of Medicines Agencies, 2017, GUID GOOD PHARM PRAC; Eurosurveillance editorial team, 2010, EUR MED AG UPD REV P, V15, DOI [10.2807/ese.15.38.19670-en, DOI 10.2807/ESE.15.38.19670-EN]; Ferner RE, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c6456; Flexman AM, 2007, LANCET, V369, P1972, DOI 10.1016/S0140-6736(07)60918-0; Grobner T, 2007, KIDNEY INT, V72, P260, DOI 10.1038/sj.ki.5002338; Hanley MJ, 2010, CLIN PHARMACOKINET, V49, P71, DOI 10.2165/11318100-000000000-00000; Hassel JC, 2017, CANCER TREAT REV, V57, P36, DOI 10.1016/j.ctrv.2017.05.003; Hauben M, 2007, DRUG SAFETY, V30, P645, DOI 10.2165/00002018-200730080-00001; Hauben M, 2009, DRUG SAFETY, V32, P99, DOI 10.2165/00002018-200932020-00003; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Hodkinson A, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003436; Katory M, 2005, DIS COLON RECTUM, V48, P1442, DOI 10.1007/s10350-005-0027-7; Laties A, 2006, J SEX MED, V3, P12, DOI 10.1111/j.1743-6109.2005.00194.x; Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936; McDowell SE, 2006, BMJ-BRIT MED J, V332, P1177, DOI 10.1136/bmj.38803.528113.55; Medicines and Healthcare products Regulatory Agency, 2007, PUBL ASS REP; Medicines and Healthcare products Regulatory Agency, CLOZ REM POT FAT RIS; Medicines and Healthcare products Regulatory Agency, 2015, BISPH VER RAR REP OS; Medsafe. Post-finasteride syndrome, 2016, PRESCRIBER UPDATE, V37, P8; MHRA UK public assessment report, 2013, AW CREAM CONT SOD LA; Mostaghim SR, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3837; Mouton JP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172830; Muller H, 2012, AM J MED, V125, pE3, DOI 10.1016/j.amjmed.2012.01.031; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Nohynek H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033536; Onakpoya IJ, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0553-2; Paus S, 2003, MOVEMENT DISORD, V18, P659, DOI 10.1002/mds.10417; Pierce CE, 2017, DRUG SAFETY, V40, P317, DOI 10.1007/s40264-016-0491-0; Pirmohamed M, 1998, BRIT MED J, V316, P1295, DOI 10.1136/bmj.316.7140.1295; Pituskin E, 2017, J CLIN ONCOL, V35, P870, DOI 10.1200/JCO.2016.68.7830; Ramsay HM, 2003, ARCH DIS CHILD, V88, P1056, DOI 10.1136/adc.88.12.1056; Rochon PA, 1997, BMJ-BRIT MED J, V315, P1096, DOI 10.1136/bmj.315.7115.1096; Root AA, 2016, BRIT J CLIN PHARMACO, V82, P512, DOI 10.1111/bcp.12983; Rosenstock J, 2015, DIABETES CARE, V38, P1638, DOI 10.2337/dc15-1380; Schaapveld M, 2015, NEW ENGL J MED, V373, P2499, DOI 10.1056/NEJMoa1505949; Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650; Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125; Snodgrass Amanda J, 2010, Pharmacotherapy, V30, P112, DOI 10.1592/phco.30.1.112; Sorup FKH, 2015, PHARM MED, V29, P211, DOI [10.1007/s40290-015-0102-x, DOI 10.1007/s40290-015-0102-x]; SWERDLOW AJ, 1992, BRIT MED J, V304, P1137, DOI 10.1136/bmj.304.6835.1137; University of Birmingham, HLTH IMPR NETW THIN; US Food and Drug Administration, PAT FAST TRACK; US Food and Drug Administration, 2018, TITL 21 FOOD DRUGS; US Food and Drug Administration, NEWS EV FDA UNV PLAN; van Hunsel F, 2012, DRUG SAFETY, V35, P45, DOI 10.2165/11594320-000000000-00000; Vukadinovic D, 2018, CLIN PHARM THER; Wei L, 2017, BRIT J CLIN PHARMACO, V83, P1298, DOI 10.1111/bcp.13205; Zorzela L, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.f7668	69	16	16	3	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 6	2018	363								k4051	10.1136/bmj.k4051	http://dx.doi.org/10.1136/bmj.k4051			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA2CX	30401691				2023-01-03	WOS:000450040400001
J	Peitz, M; Behringer, M; Granacher, U				Peitz, Matti; Behringer, Michael; Granacher, Urs			A systematic review on the effects of resistance and plyometric training on physical fitness in youth-What do comparative studies tell us?	PLOS ONE			English	Review							STRETCH-SHORTENING CYCLE; WHOLE-BODY VIBRATION; OF-DIRECTION SPEED; ENDURANCE PERFORMANCE; MOTOR-PERFORMANCE; MUSCULAR FITNESS; ATHLETIC PERFORMANCE; SURFACE INSTABILITY; JUMPING PERFORMANCE; THROWING VELOCITY	Introduction To date, several meta-analyses clearly demonstrated that resistance and plyometric training are effective to improve physical fitness in children and adolescents. However, a methodological limitation of meta-analyses is that they synthesize results from different studies and hence ignore important differences across studies (i.e., mixing apples and oranges). Therefore, we aimed at examining comparative intervention studies that assessed the effects of age, sex, maturation, and resistance or plyometric training descriptors (e.g., training intensity, volume etc.) on measures of physical fitness while holding other variables constant. Methods To identify relevant studies, we systematically searched multiple electronic databases (e.g., PubMed) from inception to March 2018. We included resistance and plyometric training studies in healthy young athletes and non-athletes aged 6 to 18 years that investigated the effects of moderator variables (e.g., age, maturity, sex, etc.) on components of physical fitness (i.e., muscle strength and power). Results Our systematic literature search revealed a total of 75 eligible resistance and plyometric training studies, including 5,138 participants. Mean duration of resistance and plyometric training programs amounted to 8.9 +/- 3.6 weeks and 7.1 +/- 1.4 weeks, respectively. Our findings showed that maturation affects plyometric and resistance training outcomes differently, with the former eliciting greater adaptations pre-peak height velocity (PHV) and the latter around-and post-PHV. Sex has no major impact on resistance training related outcomes (e.g., maximal strength, 10 repetition maximum). In terms of plyometric training, around-PHV boys appear to respond with larger performance improvements (e.g., jump height, jump distance) compared with girls. Different types of resistance training (e.g., body weight, free weights) are effective in improving measures of muscle strength (e.g., maximum voluntary contraction) in untrained children and adolescents. Effects of plyometric training in untrained youth primarily follow the principle of training specificity. Despite the fact that only 6 out of 75 comparative studies investigated resistance or plyometric training in trained individuals, positive effects were reported in all 6 studies (e.g., maximum strength and vertical jump height, respectively). Conclusions The present review article identified research gaps (e.g., training descriptors, modern alternative training modalities) that should be addressed in future comparative studies.	[Peitz, Matti] German Sport Univ Cologne, German Res Ctr Elite Sport Momentum, Cologne, Germany; [Behringer, Michael] Goethe Univ Frankfurt, Inst Sports Sci, Frankfurt, Germany; [Granacher, Urs] Univ Potsdam, Fac Human Sci, Div Training & Movement Sci, Potsdam, Germany	German Sport University Cologne; Goethe University Frankfurt; University of Potsdam	Granacher, U (corresponding author), Univ Potsdam, Fac Human Sci, Div Training & Movement Sci, Potsdam, Germany.	urs.granacher@uni-potsdam.de	Granacher, Urs/GXM-3858-2022; Granacher, Urs/T-9900-2017; Granacher, Urs/N-1963-2019	Granacher, Urs/0000-0002-7095-813X; Granacher, Urs/0000-0002-7095-813X; Granacher, Urs/0000-0002-7095-813X				Altman DG., 2008, ASSESSING RISK BIAS; [Anonymous], 1983, Phys Sportsmed, V11, P157, DOI 10.1080/00913847.1983.11708490; [Anonymous], 2016, J TRAINOL, DOI DOI 10.17338/trainology.5.1_6; Asadi A, 2017, J STRENGTH COND RES, V31, P2609, DOI 10.1519/JSC.0000000000001994; Bass SL, 2000, SPORTS MED, V30, P73, DOI 10.2165/00007256-200030020-00001; Bazett-Jones DM, 2008, J STRENGTH COND RES, V22, P25, DOI 10.1519/JSC.0b013e31815f99a4; Bedoya AA, 2015, J STRENGTH COND RES, V29, P2351, DOI 10.1519/JSC.0000000000000877; Behm DG, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00423; Behm DG, 2006, J SPORT SCI MED, V5, P33; Behringer M, 2013, PEDIATR EXERC SCI, V25, P370, DOI 10.1123/pes.25.3.370; Behringer M, 2011, PEDIATR EXERC SCI, V23, P186, DOI 10.1123/pes.23.2.186; Behringer M, 2010, PEDIATRICS, V126, pE1199, DOI 10.1542/peds.2010-0445; Benson AC, 2008, INT J OBESITY, V32, P1016, DOI 10.1038/ijo.2008.5; BLIMKIE CJR, 1992, CAN J SPORT SCI, V17, P264; Bolger R, 2015, J STRENGTH COND RES, V29, P1146, DOI 10.1519/JSC.0000000000000720; Bottaro M, 2011, PEDIATR EXERC SCI, V23, P311, DOI 10.1123/pes.23.3.311; Brughelli M, 2008, SPORTS MED, V38, P1045, DOI 10.2165/00007256-200838120-00007; Bulgakova NZ, 1987, THEORY PRACTICE PHYS, P31; Busch D., 2015, SPORTS ORTHOP TRAUMA, V31, P299, DOI [DOI 10.1016/J.ORTHTR.2015.07.007, 10.1016/j.orthtr.2015.07.007]; Chaabene H, 2017, INT J SPORT PHYSIOL, V9, P1, DOI [DOI 10.1123/IJSPP.2016-0372, 10.1123/ijspp.2016-0372]; Channell BT, 2008, J STRENGTH COND RES, V22, P1522, DOI 10.1519/JSC.0b013e318181a3d0; Chaouachi A, 2014, J STRENGTH COND RES, V28, P1483, DOI 10.1519/JSC.0000000000000305; Chaouachi A, 2014, J STRENGTH COND RES, V28, P401, DOI 10.1519/JSC.0b013e3182987059; Coutts AJ, 2004, J STRENGTH COND RES, V18, P316, DOI 10.1519/00124278-200405000-00021; Crowther RG, 2007, J STRENGTH COND RES, V21, P460; DAVIES BN, 1991, J SPORT MED PHYS FIT, V31, P532; Davies G, 2015, INT J SPORTS PHYS TH, V10, P760; de Hoyo M, 2016, J STRENGTH COND RES, V30, P368, DOI 10.1519/JSC.0000000000001094; Deley G, 2011, J STRENGTH COND RES, V25, P520, DOI 10.1519/JSC.0b013e3181bac451; DeRenne C, 1996, J STRENGTH CONDITION, V10; Deschenes MR, 2002, AM J PHYS MED REHAB, V81, pS3, DOI 10.1097/01.PHM.0000029722.06777.E9; Desmangles JC, 2006, J PEDIATR ENDOCR MET, V19, P213; Escamilla RF, 2012, J STRENGTH COND RES, V26, P1767, DOI 10.1519/JSC.0b013e3182578301; Faigenbaum AD, 2005, PEDIATR EXERC SCI, V17, P237, DOI 10.1123/pes.17.3.237; Faigenbaum AD, 2002, RES Q EXERCISE SPORT, V73, P416, DOI 10.1080/02701367.2002.10609041; Faigenbaum AD, 2001, J STRENGTH COND RES, V15, P459; Faigenbaum AD, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.1.e5; Faigenbaum AD, 2007, J SPORT SCI MED, V6, P519; Faigenbaum AD, 2009, J STRENGTH COND RES, V23, pS60, DOI 10.1519/JSC.0b013e31819df407; Faigenbaum AD, 2008, PEDIATR EXERC SCI, V20, P457, DOI 10.1123/pes.20.4.457; Filipovic A, 2012, J STRENGTH COND RES, V26, P2600, DOI 10.1519/JSC.0b013e31823f2cd1; Filipovic A, 2011, J STRENGTH COND RES, V25, P3218, DOI 10.1519/JSC.0b013e318212e3ce; Flanagan SP, 2002, RES Q EXERCISE SPORT, V73, P340, DOI 10.1080/02701367.2002.10609029; Ford P, 2011, J SPORT SCI, V29, P389, DOI 10.1080/02640414.2010.536849; Foschini D, 2010, OBESITY, V18, P766, DOI 10.1038/oby.2009.247; Gabbett TJ, 2008, J STRENGTH COND RES, V22, P910, DOI 10.1519/JSC.0b013e31816a5fa5; Gomez-Bruton A, 2017, WORLD J PEDIATR, V13, P112, DOI 10.1007/s12519-016-0076-0; Gonzalez-Badillo JJ, 2006, J STRENGTH COND RES, V20, P73; Gonzalez-Badillo JJ, 2005, J STRENGTH COND RES, V19, P689; Granacher U, 2015, INT J SPORTS MED, V36, P386, DOI 10.1055/s-0034-1395519; Granacher U, 2009, DEUT Z SPORTMED, V60, P41; Granacher U, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00164; Granados A, 2015, J CLIN RES PEDIATR E, V7, P235, DOI 10.4274/jcrpe.2007; Harries SK, 2016, J SCI MED SPORT, V19, P163, DOI 10.1016/j.jsams.2015.01.007; Harries SK, 2015, J STRENGTH COND RES, V29, P1113, DOI 10.1519/JSC.0000000000000712; Harries SK, 2012, J SCI MED SPORT, V15, P532, DOI 10.1016/j.jsams.2012.02.005; Hassan SE, 1991, LEISTUNGSSPORT, P17; Heitkamp HC, 2015, J SPORT MED PHYS FIT, V55, P446; HORTOBAGYI T, 1985, INT J SPORTS MED, V6, P317, DOI 10.1055/s-2008-1025862; Johnson BA, 2011, J STRENGTH COND RES, V25, P2623, DOI 10.1519/JSC.0b013e318204caa0; Klusemann MJ, 2012, J STRENGTH COND RES, V26, P2677, DOI 10.1519/JSC.0b013e318241b021; Kokkonen J, 2007, MED SCI SPORT EXER, V39, P1825, DOI 10.1249/mss.0b013e3181238a2b; Kraemer WJ, 1998, J ORTHOP SPORT PHYS, V28, P110, DOI 10.2519/jospt.1998.28.2.110; Legerlotz K, 2016, PEDIATR EXERC SCI, V28, P501, DOI 10.1123/pes.2016-0023; Lephart SM, 2005, BRIT J SPORT MED, V39, P932, DOI 10.1136/bjsm.2005.019083; Lesinski M, 2018, INT J SPORTS MED, V39, P50, DOI 10.1055/s-0043-117610; Lesinski M, 2016, BRIT J SPORT MED, V50, P781, DOI 10.1136/bjsports-2015-095497; Letzelter M, 1984, DTSCH Z SPORTMEDIZIN, P62; Lillegard W A, 1997, Pediatr Rehabil, V1, P147; Lloyd RS, 2011, J SPORT MED PHYS FIT, V51, P595; Lloyd RS, 2016, J STRENGTH COND RES, V30, P1239, DOI 10.1519/JSC.0000000000001216; Lloyd RS, 2014, BRIT J SPORT MED, V48, P498, DOI 10.1136/bjsports-2013-092952; Lloyd RS, 2012, J STRENGTH COND RES, V26, P2812, DOI 10.1519/JSC.0b013e318242d2ec; Lloyd RS, 2012, STRENGTH COND J, V34, P61, DOI 10.1519/SSC.0b013e31825760ea; Loturco I, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.01034; Mahieu NN, 2006, J ATHL TRAINING, V41, P286; Malina RM, 2004, GROWTH MATURATION PH, V2nd; Marginson V, 2005, J APPL PHYSIOL, V99, P1174, DOI 10.1152/japplphysiol.01193.2004; Marques MC, 2012, PERCEPT MOTOR SKILL, V115, P895, DOI 10.2466/25.23.PMS.115.6.895-902; Marta CC, 2014, AM J HUM BIOL, V26, P469, DOI 10.1002/ajhb.22549; Matavulj D, 2001, J SPORT MED PHYS FIT, V41, P159; Matute-Llorente A, 2014, J ADOLESCENT HEALTH, V54, P385, DOI 10.1016/j.jadohealth.2013.11.001; McCormick BT, 2016, INT J SPORT PHYSIOL, V11, P102, DOI 10.1123/ijspp.2015-0058; McKay D, 2012, BRIT J SPORT MED, V46, P727, DOI 10.1136/bjsports-2012-091417; Medeiros Radamés Maciel Vitor, 2014, Rev. paul. pediatr., V32, P229, DOI 10.1590/0103-0582201432313; Meinhardt U, 2013, PEDIATRICS, V132, P1105, DOI 10.1542/peds.2013-1343; Meylan CMP, 2014, SCAND J MED SCI SPOR, V24, pE156, DOI 10.1111/sms.12128; Mirwald RL, 2002, MED SCI SPORT EXER, V34, P689, DOI 10.1097/00005768-200204000-00020; Moraes E, 2013, J STRENGTH COND RES, V27, P3310, DOI 10.1519/JSC.0b013e31828de8c3; Moran J, 2018, SPORTS MED, V48, P1661, DOI 10.1007/s40279-018-0914-4; Moran J, 2018, J STRENGTH COND RES, V32, P139, DOI 10.1519/JSC.0000000000001780; Moran J, 2017, PEDIATR EXERC SCI, V29, P194, DOI 10.1123/pes.2016-0151; Moran JJ, 2017, J STRENGTH COND RES, V31, P552, DOI 10.1519/JSC.0000000000001444; Muehlbauer T, 2012, PERCEPT MOTOR SKILL, V115, P953, DOI 10.2466/06.10.30.PMS.115.6.953-968; Myer GD, 2013, CURR SPORT MED REP, V12, P304, DOI 10.1097/01.CSMR.0000434106.12813.69; Negra Y, 2017, INT J SPORTS MED, V38, P370, DOI 10.1055/s-0042-122337; Nielsen B, 1980, TRAINING FUNCTIONAL, P69; O'Brien TD, 2010, EXP PHYSIOL, V95, P202, DOI 10.1113/expphysiol.2009.048967; Olsen OE, 2005, BRIT MED J, V330, P449, DOI 10.1136/bmj.38330.632801.8F; Park SY, 2015, J EXERC REHABIL, V11, P289, DOI 10.12965/jer.150254; PFEIFFER RD, 1986, PHYSICIAN SPORTSMED, V14, P134, DOI 10.1080/00913847.1986.11709173; Piazza Marina, 2014, Italian Journal of Anatomy and Embryology, V119, P10; Prieske O, 2013, EUR J APPL PHYSIOL, V113, P2943, DOI 10.1007/s00421-013-2724-6; Radnor JM, 2017, J STRENGTH COND RES, V31, P787, DOI 10.1519/JSC.0000000000001527; Ramirez-Campillo R, 2018, SPORTS MED, V48, P1059, DOI 10.1007/s40279-018-0870-z; Ramirez-Campillo R, 2015, J STRENGTH COND RES, V29, P1884, DOI 10.1519/JSC.0000000000000836; Ramirez-Campillo R, 2015, J STRENGTH COND RES, V29, P1784, DOI 10.1519/JSC.0000000000000827; Ramirez-Campillo R, 2015, J STRENGTH COND RES, V29, P1317, DOI 10.1519/JSC.0000000000000762; Ramirez-Campillo R, 2015, J STRENGTH COND RES, V29, P972, DOI 10.1519/JSC.0000000000000283; Ramirez-Campillo R, 2014, J SPORT SCI MED, V13, P287; Ramirez-Campillo R, 2013, J STRENGTH COND RES, V27, P2714, DOI 10.1519/JSC.0b013e318280c9e9; Rarick GL, 1958, AM ASS HLTH PHYS ED, V29, P333, DOI [10.1080/10671188.1958.10762026, DOI 10.1080/10671188.1958.10762026]; Reuter K., 2003, GENTLE STRENGTH TRAI; Rhea MR, 2004, RES Q EXERCISE SPORT, V75, P413, DOI 10.1080/02701367.2004.10609174; Rhea MR, 2004, J STRENGTH COND RES, V18, P918, DOI 10.1519/00124278-200411000-00040; Riviere M, 2017, J STRENGTH COND RES, V31, P947, DOI 10.1519/JSC.0000000000001574; Roig M, 2009, BRIT J SPORT MED, V43, P556, DOI 10.1136/bjsm.2008.051417; Rosas F, 2016, INT J SPORTS MED, V37, P1060, DOI 10.1055/s-0042-111046; Rubini EC, 2007, SPORTS MED, V37, P213, DOI 10.2165/00007256-200737030-00003; Ryan J R, 1976, Am J Sports Med, V4, P26, DOI 10.1177/036354657600400105; de Villarreal ESS, 2008, J STRENGTH COND RES, V22, P715, DOI 10.1519/JSC.0b013e318163eade; Sarwar R, 1996, J PHYSIOL-LONDON, V493, P267, DOI 10.1113/jphysiol.1996.sp021381; Schoenfeld BJ, 2016, SPORTS MED, V46, P1689, DOI 10.1007/s40279-016-0543-8; Schranz N, 2013, SPORTS MED, V43, P893, DOI 10.1007/s40279-013-0062-9; Scott BR, 2016, J SCI MED SPORT, V19, P360, DOI 10.1016/j.jsams.2015.04.014; SHIELDS C L JR, 1985, Physician and Sportsmedicine, V13, P49, DOI 10.1080/00913847.1985.11708745; Siegel J.A., 1989, PEDIATR EXERC SCI, V1, P145, DOI [10.1123/pes.1.2.145, DOI 10.1123/PES.1.2.145]; Sipaviciene S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/243572; Skurvydas A, 2010, PEDIATR EXERC SCI, V22, P547, DOI 10.1123/pes.22.4.547; Smart DJ, 2013, J STRENGTH COND RES, V27, P708, DOI 10.1519/JSC.0b013e31825d99b0; Smith JJ, 2014, SPORTS MED, V44, P1209, DOI 10.1007/s40279-014-0196-4; SMITH MJ, 1981, AM J SPORT MED, V9, P275, DOI 10.1177/036354658100900420; Soria-Gila MA, 2015, J STRENGTH COND RES, V29, P3260, DOI 10.1519/JSC.0000000000000971; STEBEN RE, 1981, J SPORT MED PHYS FIT, V21, P28; Steele J, 2017, APPL PHYSIOL NUTR ME, V42, P193, DOI 10.1139/apnm-2016-0418; Steinmann W., 1990, SPORTUNTERRICHT, V39, P326; Szymanski DJ, 2007, J STRENGTH COND RES, V21, P894; Tan B, 1999, J STRENGTH COND RES, V13, P289, DOI 10.1519/00124278-199908000-00019; TANNER JM, 1962, GROWTH ADOLESCENCE, P326; Thomas K, 2009, J STRENGTH COND RES, V23, P332, DOI 10.1519/JSC.0b013e318183a01a; Tibana RA, 2012, J STRENGTH COND RES, V26, P1027, DOI 10.1519/JSC.0b013e31822dfefb; Toigo M, 2006, EUR J APPL PHYSIOL, V97, P643, DOI 10.1007/s00421-006-0238-1; Tous-Fajardo J, 2016, INT J SPORT PHYSIOL, V11, P66, DOI 10.1123/ijspp.2015-0010; Ullrich B, 2016, J STRENGTH COND RES, V30, P2083, DOI 10.1519/JSC.0000000000001305; Uppal A, 1991, TELESNA VYCHOVA SPOR, V1, P18; van den Tillaar R, 2013, J STRENGTH COND RES, V27, P1196, DOI 10.1519/JSC.0b013e318267a494; Vom Heede A., 2007, HALTUNG BEWEGUNG, V27, P11; Vrijens J, 1978, MED SPORT, V11, P152, DOI 10.1159/000401890; Wisloff U, 2004, BRIT J SPORT MED, V38, P285, DOI 10.1136/bjsm.2002.002071; World Health Organization, 2010, GLOB REC PHYS ACT HL; Yuktasir B, 1998, NEW STUD ATHLETICS, V13, P41	151	35	35	10	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2018	13	10							e0205525	10.1371/journal.pone.0205525	http://dx.doi.org/10.1371/journal.pone.0205525			44	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GW4VA	30304033	Green Submitted, Green Published, gold			2023-01-03	WOS:000446921100103
J	Takeda, S; Shimoda, H; Takarada, T; Imokawa, G				Takeda, Shogo; Shimoda, Hiroshi; Takarada, Toru; Imokawa, Genji			Strawberry seed extract and its major component, tiliroside, promote ceramide synthesis in the stratum corneum of human epidermal equivalents	PLOS ONE			English	Article							PERMEABILITY BARRIER HOMEOSTASIS; N-ACYL LINKAGE; ATOPIC-DERMATITIS; KERATINOCYTE DIFFERENTIATION; SPHINGOMYELIN DEACYLASE; ABNORMAL EXPRESSION; LIPID-METABOLISM; TRANS-TILIROSIDE; ETIOLOGIC FACTOR; DRY SKIN	The activation of peroxisomeproliferator-activated receptor (PPAR) a can stimulate the expression of ceramide-related enzymes, and a major component of strawberry seed extract (SSE) tiliroside enhances the expression of PPAR alpha. We determined whether SSE and tiliroside may stimulate ceramide synthesis in the stratum corneum (SC) of the human epidermal equivalents (HEEs) culture model. Treatment with SSE at 1.0 and 3.0 mu g/mL elicited a significant increase in the total ceramide content in the SC, which was accompanied by a significant increase in almost all ceramide species except for ceramide [EOS] and [AP]. Treatment with tiliroside at 0.3 mu g/mL slightly accentuated the total ceramide content in the SC together with a significant increase in the ceramide [NS, NDS] content. Messenger RNA analysis demonstrated that SSE at 1 or 3 mu g/mL significantly stimulated the gene expression of serine palmitoyltransferase (SPT) 2, ceramide synthase (CerS) 3, glucosylceramide synthase (GCS), and beta-glucocerebrosidase (GBA) but not of SPT1, sphingomyelin synthase (SMS) 1/2 and acid sphingomyelinase (ASM). In contrast, tiliroside elicited significant increases in the gene expression levels of GCS and GBA only at 0.3 and/or 0.1 mu g/mL. Western blotting analysis revealed that both SSE and tiliroside enhanced the protein expression levels of GCS and GBA but not of SPT2 at 1 or 3 and 0.1 or 0.3 mu g/mL, respectively. These findings suggested that both SSE and tiliroside have a distinct potential to stimulate the level of ceramide [NS, NDS] in the SC by enhancing the expression of GCS and GBA. The higher stimulatory effect with SSE than tiliroside on SC ceramide synthesis correlates with the significant increase observed with SSE but not tiliroside in the gene expression levels of SPT2 and CerS3. Therefore, it is anticipated that SSE is effective in improving skin barrier function and moisture retention in several ceramide-deficit skin conditions, including surfactant-induced roughened skin, xerosis, and atopic dermatitis.	[Takeda, Shogo; Shimoda, Hiroshi; Takarada, Toru] Oryza Oil & Fat Chem Co Ltd, Res & Dev Div, Ichinomiya, Aichi, Japan; [Imokawa, Genji] Chubu Univ, Res Inst Biol Funct, Kasugai, Aichi, Japan; [Imokawa, Genji] Utsunomiya Univ, Ctr Biosci Res & Educ, Utsunomiya, Tochigi, Japan	Chubu University; Utsunomiya University	Imokawa, G (corresponding author), Chubu Univ, Res Inst Biol Funct, Kasugai, Aichi, Japan.; Imokawa, G (corresponding author), Utsunomiya Univ, Ctr Biosci Res & Educ, Utsunomiya, Tochigi, Japan.	imokawag@dream.ocn.ne.jp		TAKARADA, TORU/0000-0001-9993-4433	Oryza Oil and Fat Chemical Co., Ltd.	Oryza Oil and Fat Chemical Co., Ltd.	This work was supported by Oryza Oil and Fat Chemical Co., Ltd. The funder provided support in the form of salaries for authors [ST, HS, TT] and research materials, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akimoto Kayoko, 1993, Journal of Dermatology (Tokyo), V20, P1; Baranowski M, 2007, J PHYSIOL PHARMACOL, V58, P57; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Funasaka Y., 2004, SKI, V31, P62; Goto T, 2012, MOL NUTR FOOD RES, V56, P435, DOI 10.1002/mnfr.201100458; GREEN H, 1978, CELL, V15, P801, DOI 10.1016/0092-8674(78)90265-9; Hamanaka S, 2002, J INVEST DERMATOL, V119, P416, DOI 10.1046/j.1523-1747.2002.01836.x; Hanada K, 2003, BBA-MOL CELL BIOL L, V1632, P16, DOI 10.1016/S1388-1981(03)00059-3; Hara J, 2000, J INVEST DERMATOL, V115, P406, DOI 10.1046/j.1523-1747.2000.00072.x; Hata M, 2002, NISHINIHON J DERMATO, V64, P413; Higuchi K, 2000, BIOCHEM J, V350, P747, DOI 10.1042/0264-6021:3500747; IMOKAWA G, 1991, J INVEST DERMATOL, V96, P523, DOI 10.1111/1523-1747.ep12470233; IMOKAWA G, 1989, J SOC COSMET CHEM, V40, P273; Imokawa G., 2014, J CLIN EXPT DERMATOL, V05; Imokawa G, 2009, J DERMATOL SCI, V55, P1, DOI 10.1016/j.jdermsci.2009.04.006; Ishibashi M, 2003, LAB INVEST, V83, P397, DOI 10.1097/01.LAB.0000059931.66821.92; Jenkins RW, 2009, CELL SIGNAL, V21, P836, DOI 10.1016/j.cellsig.2009.01.026; Jin X, 2016, EXP THER MED, V12, P499, DOI 10.3892/etm.2016.3305; Jurgonski A, 2015, FOOD NUTR RES, V59, DOI 10.3402/fnr.v59.26104; Komuves LG, 2000, J INVEST DERMATOL, V115, P353, DOI 10.1046/j.1523-1747.2000.00073.x; Levy M, 2010, IUBMB LIFE, V62, P347, DOI 10.1002/iub.319; Man MQ, 2006, J INVEST DERMATOL, V126, P386, DOI 10.1038/sj.jid.5700046; Mao-Qiang M, 2004, J INVEST DERMATOL, V123, P305, DOI 10.1111/j.0022-202X.2004.23235.x; Masukawa Y, 2008, J LIPID RES, V49, P1466, DOI 10.1194/jlr.M800014-JLR200; Masukawa Y, 2009, J LIPID RES, V50, P1708, DOI 10.1194/jlr.D800055-JLR200; Matsuda H, 2002, BIOORGAN MED CHEM, V10, P707, DOI 10.1016/S0968-0896(01)00321-2; Matsuki H., 2006, NISHINIHON J DERMATO, V68, P413; Matsuki H., 2004, EXOG DERMATOL, V3, P293, DOI [10.1159/000091910, DOI 10.1159/000091910]; Mizutani H., 2001, NISHINIHON J DERMATO, V63, P457, DOI [10.2336/nishinihonhifu.63.457, DOI 10.2336/NISHINIHONHIFU.63.457]; Murata Y, 1996, J INVEST DERMATOL, V106, P1242, DOI 10.1111/1523-1747.ep12348937; Nakamura T., 2000, SKIN RES, V42, P264; Ninomiya K, 2007, BIOORG MED CHEM LETT, V17, P3059, DOI 10.1016/j.bmcl.2007.03.051; Okamoto R, 2003, J LIPID RES, V44, P93, DOI 10.1194/jlr.M200225-JLR200; Pieszka M, 2013, ENVIRON TOXICOL PHAR, V36, P1055, DOI 10.1016/j.etap.2013.09.007; Qiao W, 2011, J ETHNOPHARMACOL, V135, P515, DOI 10.1016/j.jep.2011.03.062; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Rivier M, 2000, J INVEST DERMATOL, V114, P681, DOI 10.1046/j.1523-1747.2000.00939.x; Sala A, 2003, EUR J PHARMACOL, V461, P53, DOI 10.1016/S0014-2999(02)02953-9; Sawada E, 2012, J DERMATOL SCI, V68, P25, DOI 10.1016/j.jdermsci.2012.07.004; Schmuth M, 2004, J INVEST DERMATOL, V122, P971, DOI 10.1111/j.0022-202X.2004.22412.x; Schmuth M, 2008, J INVEST DERMATOL, V128, P2211, DOI [10.1038/jid, DOI 10.1038/JID]; Schmuth M, 2014, BBA-MOL CELL BIOL L, V1841, P463, DOI 10.1016/j.bbalip.2013.11.012; Shimoda H, 2012, J MED FOOD, V15, P1064, DOI 10.1089/jmf.2011.2137; Staumont-Salle D, 2008, J ALLERGY CLIN IMMUN, V121, P962, DOI 10.1016/j.jaci.2007.12.1165; Sugiura A, 2014, ARCH DERMATOL RES, V306, P427, DOI 10.1007/s00403-013-1430-x; Tafesse FG, 2006, J BIOL CHEM, V281, P29421, DOI 10.1074/jbc.R600021200; Takagi Y, 1999, J LIPID RES, V40, P861; Takagi Y, 2004, J INVEST DERMATOL, V123, P1102, DOI 10.1111/j.0022-202X.2004.23491.x; Takashima I., 2002, NISHIHIHON J DERM, V64, P612, DOI [10.2336/nishinihonhifu.64.612, DOI 10.2336/NISHINIHONHIFU.64.612]; Uchida Y, 2000, J LIPID RES, V41, P2071; Velagapudi R, 2014, BBA-GEN SUBJECTS, V1840, P3311, DOI 10.1016/j.bbagen.2014.08.008; Yamanaka M, 2001, SKIN, V43, P341; Yoshida N, 2012, ARCH DERMATOL RES, V304, P563, DOI 10.1007/s00403-012-1232-6	53	11	11	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2018	13	10							e0205061	10.1371/journal.pone.0205061	http://dx.doi.org/10.1371/journal.pone.0205061			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW4OW	30300355	gold, Green Published, Green Submitted			2023-01-03	WOS:000446897200033
J	Goyal, V; Grimwood, K; Byrnes, CA; Morris, PS; Masters, IB; Ware, RS; McCallum, GB; Binks, MJ; Marchant, JM; van Asperen, P; O'Grady, KAF; Champion, A; Buntain, HM; Petsky, H; Torzillo, PJ; Chang, AB				Goyal, Vikas; Grimwood, Keith; Byrnes, Catherine A.; Morris, Peter S.; Masters, I. Brent; Ware, Robert S.; McCallum, Gabrielle B.; Binks, Michael J.; Marchant, Julie M.; van Asperen, Peter; O'Grady, Kerry-Ann F.; Champion, Anita; Buntain, Helen M.; Petsky, Helen; Torzillo, Paul J.; Chang, Anne B.			Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial	LANCET			English	Article							CYSTIC-FIBROSIS BRONCHIECTASIS; SUPPURATIVE LUNG-DISEASE; LONG-TERM AZITHROMYCIN; CHRONIC WET COUGH; NASOPHARYNGEAL CARRIAGE; INDIGENOUS CHILDREN; NEW-ZEALAND; ANTIBIOTICS; AIRWAY; NONINFERIORITY	Background Although amoxicillin-clavulanate is the recommended first-line empirical oral antibiotic treatment for non-severe exacerbations in children with bronchiectasis, azithromycin is also often prescribed for its convenient once-daily dosing. No randomised controlled trials involving acute exacerbations in children with bronchiectasis have been published to our knowledge. We hypothesised that azithromycin is non-inferior to amoxicillin-davulanate for resolving exacerbations in children with bronchiectasis. Methods We did this parallel-group, double-dummy, double-blind, non-inferiority randomised controlled trial in three Australian and one New Zealand hospital between April, 2012, and August, 2016. We enrolled children aged 1-19 years with radiographically proven bronchiectasis unrelated to cystic fibrosis. At the start of an exacerbation, children were randomly assigned to oral suspensions of either amoxicillin-clavulanate (22.5 mg/kg, twice daily) and placebo or azithromycin (5 mg/kg per day) and placebo for 21 days. We used permuted block randomisation (stratified by age, site, and cause) with concealed allocation. The primary outcome was resolution of exacerbation (defined as a return to baseline) by 21 days in the per-protocol population, with a non-inferiority margin of -20%. We assessed several secondary outcomes including duration of exacerbation, time to next exacerbation, laboratory, respiratory, and quality-of-life measurements, and microbiology. This trial was registered with the Australian/New Zealand Registry (ACTRN12612000010897). Findings We screened 604 children and enrolled 236.179 children had an exacerbation and were assigned to treatment: 97 to amoxicillin-clavulanate, 82 to azithromycin). By day 21, 61 (84%) of 73 exacerbations had resolved in the azithromycin group versus 73 (84%) of 87 in the amoxicillin-clavulanate group. The risk difference showed noninferiority (-0.3%, 95% CI -11.8 to 11.1). Exacerbations were significantly shorter in the amoxicillin-clavulanate group than in the azithromycin group (median 10 days [IQR 6-15] vs 14 days [8-16]; p=0.014). Adverse events were attributed to the trial medication in 17 (21%) of 82 children in the azithromycin group versus 23 (24%) of 97 in the amoxicillin-clavulanate group (relative risk 0.9, 95% CI 0.5 to 1.5). Interpretation By 21 days of treatment, azithromycin is non-inferior to amoxicillin-clavulanate for resolving exacerbations in children with non-severe bronchiectasis. In some patients, such as those with penicillin hypersensitivity or those likely to have poor adherence, azithromycin provides another option for treating exacerbations, but must be balanced with risk of treatment failure (within a 20% margin), longer exacerbation duration, and the risk of inducing macrolide resistance. Copyright (C) 2018 Elsevier Ltd. All rights reserved.	[Goyal, Vikas; Masters, I. Brent; Marchant, Julie M.; Buntain, Helen M.; Chang, Anne B.] Lady Cilento Childrens Hosp, Dept Resp & Sleep Med, Brisbane, Qld, Australia; [Champion, Anita] Lady Cilento Childrens Hosp, Dept Pharm, Brisbane, Qld, Australia; [Goyal, Vikas; Masters, I. Brent; Marchant, Julie M.] Univ Queensland, Sch Med, Brisbane, Qld, Australia; [Goyal, Vikas; Marchant, Julie M.; O'Grady, Kerry-Ann F.; Chang, Anne B.] Queensland Univ Technol, Ctr Childrens Hlth Res, Brisbane, Qld, Australia; [Grimwood, Keith] Griffith Univ, Sch Med, Gold Coast, Qld, Australia; [Grimwood, Keith; Ware, Robert S.; Petsky, Helen] Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast, Qld, Australia; [Petsky, Helen] Griffith Univ, Sch Nursing & Midwifery, Gold Coast, Qld, Australia; [Grimwood, Keith] Gold Coast Hlth, Dept Infect Dis, Gold Coast, Qld, Australia; [Grimwood, Keith] Gold Coast Hlth, Dept Paediat, Gold Coast, Qld, Australia; [Byrnes, Catherine A.] Univ Auckland, Dept Paediat, Auckland, New Zealand; [Byrnes, Catherine A.] Starship Childrens Hosp, Resp Dept, Auckland, New Zealand; [Morris, Peter S.; McCallum, Gabrielle B.; Binks, Michael J.; Chang, Anne B.] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT, Australia; [Morris, Peter S.] Royal Darwin Hosp, Dept Paediat, Darwin, NT, Australia; [van Asperen, Peter] Childrens Hosp Westmcad, Dept Resp Med, Sydney, NSW, Australia; [Torzillo, Paul J.] Univ Sydney, Cent Clin Sch, Sydney, NSW, Australia; [Torzillo, Paul J.] Royal Prince Alfred Hosp, Dept Resp Med, Sydney, NSW, Australia	University of Queensland; Queensland University of Technology (QUT); Griffith University; Griffith University; Menzies Health Institute Queensland; Griffith University; University of Auckland; Starship Children's Hospital; Charles Darwin University; Menzies School of Health Research; University of Sydney; University of Sydney	Goyal, V (corresponding author), Lady Client Childrens Hosp, Dept Resp & Sleep Med, South Brisbane, Qld 4101, Australia.	drvikasgoyal@gmail.com	Goyal, Vikas/AAK-2769-2020; McCallum, Gabrielle/AAO-8158-2020; O'Grady, Kerry-Ann F/F-2529-2010; Chang, Anne/F-2066-2013; Ware, Robert/B-2024-2014; Petsky, Helen/None	Goyal, Vikas/0000-0001-7533-2315; McCallum, Gabrielle/0000-0002-0210-1468; O'Grady, Kerry-Ann F/0000-0002-8159-2620; Chang, Anne/0000-0002-1331-3706; Marchant, Julie/0000-0002-8614-1829; Ware, Robert/0000-0002-6129-6736; Grimwood, Keith/0000-0003-3174-9834; Petsky, Helen/0000-0002-5315-9002	Australian National Health and Medical Research Council	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	Australian National Health and Medical Research Council.	Chalmers JD, 2012, AM J RESP CRIT CARE, V186, P657, DOI 10.1164/rccm.201203-0487OC; Chang AB, 1998, EUR RESPIR J, V11, P462, DOI 10.1183/09031936.98.11020462; Chang AB, 2015, MED J AUSTRALIA, V202, P21, DOI 10.5694/mja14.00287; Chang AB, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-53; de Vries JJV, 2018, PEDIATR PULM, V53, P467, DOI 10.1002/ppul.23952; Fonseca W, 2003, ANTIMICROB AGENTS CH, V47, P997, DOI 10.1128/AAC.47.3.997-1001.2003; Gotzsche PC, 2006, JAMA-J AM MED ASSOC, V295, P1172, DOI 10.1001/jama.295.10.1172; Goyal V, 2016, PEDIATR PULM, V51, P450, DOI 10.1002/ppul.23380; Goyal V, 2014, ARCH DIS CHILD, V99, P522, DOI 10.1136/archdischild-2013-304793; Grimwood K, 2014, EXPERT REV ANTI-INFE, V12, P1277, DOI 10.1586/14787210.2014.952282; Hare KM, 2015, EUR J CLIN MICROBIOL, V34, P2275, DOI 10.1007/s10096-015-2480-0; Hare KM, 2012, INT J ANTIMICROB AG, V40, P365, DOI 10.1016/j.ijantimicag.2012.05.018; Hoberman A, 2005, PEDIATR INFECT DIS J, V24, P525, DOI 10.1097/01.inf.0000164794.50281.1a; IP M, 1993, RESP MED, V87, P449, DOI 10.1016/0954-6111(93)90072-8; Kapur N, 2012, CHEST, V141, P1018, DOI 10.1378/chest.11-0679; Kapur N, 2012, PEDIATR PULM, V47, P68, DOI 10.1002/ppul.21518; Kapur N, 2010, CHEST, V138, P158, DOI 10.1378/chest.09-2932; King PT, 2012, REV RECENT CLIN TRIA, V7, P24, DOI 10.2174/157488712799363280; Laopaiboon M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001954.pub4; Marchant J, 2012, THORAX, V67, P689, DOI 10.1136/thoraxjnl-2011-201506; McCallum GB, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00027; McMullan BJ, 2016, JAMA PEDIATR, V170, P979, DOI 10.1001/jamapediatrics.2016.1477; Munro KA, 2011, PEDIATR PULM, V46, P131, DOI 10.1002/ppul.21331; Newcombe PA, 2011, CHEST, V139, P576, DOI 10.1378/chest.10-1476; Piaggio G, 2012, JAMA-J AM MED ASSOC, V308, P2594, DOI 10.1001/jama.2012.87802; Polverino E, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00629-2017; Redondo M, 2016, BREATHE, V12, P223, DOI 10.1183/20734735.007516; Serisier DJ, 2013, LANCET RESP MED, V1, P262, DOI 10.1016/S2213-2600(13)70038-9; Valery PC, 2013, LANCET RESP MED, V1, P610, DOI 10.1016/S2213-2600(13)70185-1; Woodhead M, 2011, CLIN MICROBIOL INFEC, V17, pE1, DOI 10.1111/j.1469-0691.2011.03672.x	30	34	35	1	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 6	2018	392	10154					1197	1206		10.1016/S0140-6736(18)31723-9	http://dx.doi.org/10.1016/S0140-6736(18)31723-9			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV9SO	30241722	Bronze, Green Published			2023-01-03	WOS:000446500900025
J	Lee, JK; Liu, ZQ; Sa, JK; Shin, S; Wang, JG; Bordyuh, M; Cho, H; Elliott, O; Chu, T; Choi, SW; Rosenbloom, DIS; Lee, IH; Shin, YJ; Kang, HJ; Kim, D; Kim, SY; Sim, MH; Kim, J; Lee, T; Seo, YJ; Shin, H; Lee, M; Kim, SH; Kwon, YJ; Oh, JW; Song, M; Kim, M; Kong, DS; Choi, JW; Seol, HJ; Lee, JI; Kim, ST; Park, JO; Kim, KM; Song, SY; Lee, JW; Kim, HC; Lee, JE; Choi, MG; Seo, SW; Shim, YM; Zo, JI; Jeong, BC; Yoon, Y; Ryu, GH; Kim, NKD; Bae, JS; Park, WY; Lee, J; Verhaak, RGW; Iavarone, A; Lee, J; Rabadan, R; Nam, DH				Lee, Jin-Ku; Liu, Zhaoqi; Sa, Jason K.; Shin, Sang; Wang, Jiguang; Bordyuh, Mykola; Cho, Heejin; Elliott, Oliver; Chu, Timothy; Choi, Seung Won; Rosenbloom, Daniel I. S.; Lee, In-Hee; Shin, Yong Jae; Kang, Hyun Ju; Kim, Donggeon; Kim, Sun Young; Sim, Moon-Hee; Kim, Jusun; Lee, Taehyang; Seo, Yun Jee; Shin, Hyemi; Lee, Mijeong; Kim, Sung Heon; Kwon, Yong-Jun; Oh, Jeong-Woo; Song, Minsuk; Kim, Misuk; Kong, Doo-Sik; Choi, Jung Won; Seol, Ho Jun; Lee, Jung-Il; Kim, Seung Tae; Park, Joon Oh; Kim, Kyoung-Mee; Song, Sang-Yong; Lee, Jeong-Won; Kim, Hee-Cheol; Lee, Jeong Eon; Choi, Min Gew; Seo, Sung Wook; Shim, Young Mog; Zo, Jae Ill; Jeong, Byong Chang; Yoon, Yeup; Ryu, Gyu Ha; Kim, Nayoung K. D.; Bae, Joon Seol; Park, Woong-Yang; Lee, Jeongwu; Verhaak, Roel G. W.; Iavarone, Antonio; Lee, Jeeyun; Rabadan, Raul; Nam, Do-Hyun			Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy	NATURE GENETICS			English	Article							GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; ERBB FAMILY BLOCKER; KRAS-MUTANT LUNG; DRUG-SENSITIVITY; TYROSINE KINASES; GASTRIC-CANCER; BREAST-CANCER; DUAL PHOSPHOINOSITIDE-3-KINASE; MOLECULAR CHARACTERIZATION	Outcomes of anticancer therapy vary dramatically among patients due to diverse genetic and molecular backgrounds, highlighting extensive intertumoral heterogeneity. The fundamental tenet of precision oncology defines molecular characterization of tumors to guide optimal patient-tailored therapy. Towards this goal, we have established a compilation of pharmacological landscapes of 462 patient-derived tumor cells (PDCs) across 14 cancer types, together with genomic and transcriptomic profiling in 385 of these tumors. Compared with the traditional long-term cultured cancer cell line models, PDCs recapitulate the molecular properties and biology of the diseases more precisely. Here, we provide insights into dynamic pharmacogenomic associations, including molecular determinants that elicit therapeutic resistance to EGFR inhibitors, and the potential repurposing of ibrutinib (currently used in hematological malignancies) for EGFR-specific therapy in gliomas. Lastly, we present a potential implementation of PDC-derived drug sensitivities for the prediction of clinical response to targeted therapeutics using retrospective clinical studies.	[Lee, Jin-Ku; Sa, Jason K.; Shin, Sang; Cho, Heejin; Choi, Seung Won; Lee, In-Hee; Shin, Yong Jae; Kang, Hyun Ju; Kim, Donggeon; Seo, Yun Jee; Shin, Hyemi; Lee, Mijeong; Kim, Sung Heon; Kwon, Yong-Jun; Oh, Jeong-Woo; Song, Minsuk; Kim, Misuk; Nam, Do-Hyun] Samsung Med Ctr, Inst Refractory Canc Res, Seoul, South Korea; [Lee, Jin-Ku; Shin, Yong Jae; Kim, Sung Heon; Kong, Doo-Sik; Choi, Jung Won; Seol, Ho Jun; Lee, Jung-Il; Nam, Do-Hyun] Sungkyunkwan Univ, Samsung Med Ctr, Dept Neurosurg, Sch Med, Seoul, South Korea; [Lee, Jin-Ku; Sa, Jason K.; Cho, Heejin; Lee, In-Hee; Shin, Yong Jae; Kang, Hyun Ju; Kim, Donggeon; Seo, Yun Jee; Kim, Misuk; Yoon, Yeup; Ryu, Gyu Ha; Kim, Nayoung K. D.; Bae, Joon Seol; Park, Woong-Yang] Samsung Med Ctr, Res Inst Future Med, Seoul, South Korea; [Liu, Zhaoqi; Bordyuh, Mykola; Elliott, Oliver; Chu, Timothy; Rosenbloom, Daniel I. S.; Rabadan, Raul] Columbia Univ, Dept Syst Biol, New York, NY 10027 USA; [Liu, Zhaoqi; Bordyuh, Mykola; Elliott, Oliver; Chu, Timothy; Rosenbloom, Daniel I. S.; Rabadan, Raul] Columbia Univ, Dept Biomed Informat, New York, NY 10027 USA; [Shin, Sang; Choi, Seung Won; Shin, Hyemi; Lee, Mijeong; Oh, Jeong-Woo; Park, Joon Oh; Yoon, Yeup; Park, Woong-Yang; Lee, Jeeyun; Nam, Do-Hyun] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul, South Korea; [Wang, Jiguang] Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China; [Wang, Jiguang] Hong Kong Univ Sci & Technol, Dept Chem & Biol Engn, Hong Kong, Hong Kong, Peoples R China; [Wang, Jiguang] Hong Kong Univ Sci & Technol, Ctr Syst Biol & Human Hlth, Hong Kong, Hong Kong, Peoples R China; [Kim, Sun Young; Sim, Moon-Hee; Kim, Jusun; Lee, Taehyang; Kim, Seung Tae; Park, Joon Oh; Lee, Jeeyun] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea; [Kim, Kyoung-Mee; Song, Sang-Yong] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pathol & Translat Genom, Sch Med, Seoul, South Korea; [Lee, Jeong-Won] Sungkyunkwan Univ, Samsung Med Ctr, Dept Obstet & Gynecol, Sch Med, Seoul, South Korea; [Kim, Hee-Cheol; Lee, Jeong Eon; Choi, Min Gew] Sungkyunkwan Univ, Samsung Med Ctr, Dept Surg, Sch Med, Seoul, South Korea; [Seo, Sung Wook] Sungkyunkwan Univ, Samsung Med Ctr, Dept Orthoped Surg, Sch Med, Seoul, South Korea; [Shim, Young Mog; Zo, Jae Ill] Sungkyunkwan Univ, Samsung Med Ctr, Dept Thorac & Cardiovasc Surg, Sch Med, Seoul, South Korea; [Jeong, Byong Chang] Sungkyunkwan Univ, Samsung Med Ctr, Dept Urol, Sch Med, Seoul, South Korea; [Kim, Nayoung K. D.; Bae, Joon Seol; Park, Woong-Yang] Samsung Med Ctr, Samsung Genome Inst, Seoul, South Korea; [Lee, Jeongwu] Cleveland Clin, Lerner Res Inst, Dept Stem Cell Biol & Regenerat Med, Cleveland, OH 44106 USA; [Verhaak, Roel G. W.] Jackson Lab Genom Med, Farmington, CT USA; [Iavarone, Antonio] Columbia Univ, Inst Canc Genet, New York, NY USA; [Iavarone, Antonio] Columbia Univ, Dept Neurol, New York, NY USA; [Iavarone, Antonio] Columbia Univ, Dept Pathol, New York, NY USA	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Columbia University; Columbia University; Sungkyunkwan University (SKKU); Samsung Medical Center; Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Cleveland Clinic Foundation; Jackson Laboratory; Columbia University; Columbia University; Columbia University	Nam, DH (corresponding author), Samsung Med Ctr, Inst Refractory Canc Res, Seoul, South Korea.; Nam, DH (corresponding author), Sungkyunkwan Univ, Samsung Med Ctr, Dept Neurosurg, Sch Med, Seoul, South Korea.; Rabadan, R (corresponding author), Columbia Univ, Dept Syst Biol, New York, NY 10027 USA.; Rabadan, R (corresponding author), Columbia Univ, Dept Biomed Informat, New York, NY 10027 USA.; Lee, J; Nam, DH (corresponding author), Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul, South Korea.; Lee, J (corresponding author), Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea.	jyunlee@skku.edu; rr2579@cumc.columbia.edu; nsnam@skku.edu	Lee, Jee Yun/C-9646-2011; lee, jw/O-6237-2014; kim, st/O-5928-2014; Verhaak, Roel/ABE-7058-2020; Rabadan, Raul/AAZ-7367-2020; Wang, Jiguang/B-2717-2012; Kim, Sun Young/O-4847-2018	Sa, Jason Kyungha/0000-0002-3251-5004; Park, Woong-Yang/0000-0003-4234-0380; Choi, Seung Won/0000-0003-1203-6126; Lee, In-Hee/0000-0002-8857-1355; Wang, Jiguang/0000-0002-6923-4097; Lee, Jin-Ku/0000-0003-0263-3234; Kim, Sun Young/0000-0002-1180-0367; Rabadan, Raul/0000-0001-7946-9255	Korea Health Technology Research and Development project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea [HI14C3418]; NIH [R01 CA185486, R01 CA179044, U54 CA193313, U54 209997]; NSF/SU2C/V Foundation Ideas Lab Multidisciplinary Team [PHY-1545805]; Hong Kong RGC grants [N_HKUST601/17, C6002-17G]; NATIONAL CANCER INSTITUTE [U54CA193313, R01CA185486, R01CA179044] Funding Source: NIH RePORTER	Korea Health Technology Research and Development project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF/SU2C/V Foundation Ideas Lab Multidisciplinary Team; Hong Kong RGC grants(Hong Kong Research Grants Council); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by a grant of the Korea Health Technology Research and Development project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (HI14C3418). This work has been funded by NIH grants (R01 CA185486, R01 CA179044, U54 CA193313 and U54 209997) and NSF/SU2C/V Foundation Ideas Lab Multidisciplinary Team (PHY-1545805) and Hong Kong RGC grants (N_HKUST601/17 and C6002-17G). The biospecimens for this study were provided by the Samsung Medical Center BioBank.	Abate F, 2014, BMC SYST BIOL, V8, DOI 10.1186/s12918-014-0097-z; Alshami J, 2015, ONCOTARGET, V6, P34030, DOI 10.18632/oncotarget.5297; Altman RB, 2015, CANCER DISCOV, V5, P237, DOI 10.1158/2159-8290.CD-15-0093; Bang YJ, 2010, LANCET, V376, P1302; Baras A, 2009, ONCOGENE, V28, P2919, DOI 10.1038/onc.2009.150; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Basu A, 2013, CELL, V154, P1151, DOI 10.1016/j.cell.2013.08.003; Belmont PJ, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005516; Bernard S, 2015, BLOOD, V126, P1695, DOI 10.1182/blood-2015-05-647834; Bhattacharya B, 2012, CANCER BIOL THER, V13, P34, DOI 10.4161/cbt.13.1.18437; Blumenschein GR, 2015, ANN ONCOL, V26, P894, DOI 10.1093/annonc/mdv072; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625; Byrd JC, 2013, NEW ENGL J MED, V369, P1278, DOI 10.1056/NEJMc1309710; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Cai Y, 2015, ONCOTARGET, V6, P18997, DOI 10.18632/oncotarget.3620; Camara PG, 2016, CELL SYST, V3, P83, DOI 10.1016/j.cels.2016.05.008; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Cen L, 2012, NEURO-ONCOLOGY, V14, P870, DOI 10.1093/neuonc/nos114; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Choi MC, 2012, MOL CELL, V47, P122, DOI 10.1016/j.molcel.2012.04.025; Cloughesy TF, 2014, ANNU REV PATHOL-MECH, V9, P1, DOI 10.1146/annurev-pathol-011110-130324; Cui JJ, 2012, CURR PHARM DESIGN, V18, P2464, DOI 10.2174/13816128112092464; Dempke WCM, 2010, ANTICANCER RES, V30, P4673; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Dhomen Nathalie S., 2012, Critical Reviews in Oncogenesis, V17, P31; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dong XY, 2016, NEOPLASIA, V18, P162, DOI 10.1016/j.neo.2016.02.001; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Ellis LM, 2009, CLIN CANCER RES, V15, P7471, DOI 10.1158/1078-0432.CCR-09-1070; Fallahi-Sichani M, 2013, NAT CHEM BIOL, V9, P708, DOI [10.1038/NCHEMBIO.1337, 10.1038/nchembio.1337]; Fan QW, 2007, CANCER RES, V67, P7960, DOI 10.1158/0008-5472.CAN-07-2154; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Ferguson BD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067668; Fernandez-Cuesta L, 2015, CLIN CANCER RES, V21, P1989, DOI 10.1158/1078-0432.CCR-14-0854; Filbin MG, 2013, NAT MED, V19, P1518, DOI 10.1038/nm.3328; Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Gao W, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju204; Garassino MC, 2011, ANN ONCOL, V22, P235, DOI 10.1093/annonc/mdq680; Garnett MJ, 2014, CURR OPIN GENET DEV, V24, P114, DOI 10.1016/j.gde.2013.12.002; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Geeleher P, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r47; Geng H, 2011, J BIOL CHEM, V286, P38095, DOI 10.1074/jbc.M111.257055; Geng L, 2006, CANCER RES, V66, P11298, DOI 10.1158/0008-5472.CAN-06-0049; Grasso CS, 2015, NAT MED, V21, P555, DOI 10.1038/nm.3855; Griffith M, 2013, NAT METHODS, V10, P1209, DOI [10.1038/nmeth.2689, 10.1038/NMETH.2689]; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Hajian-Tilaki K, 2013, CASP J INTERN MED, V4, P627; Hamburg MA, 2010, NEW ENGL J MED, V363, P301, DOI 10.1056/NEJMp1006304; Hatzivassiliou G, 2013, NATURE, V501, P232, DOI 10.1038/nature12441; Hecht JR, 2016, J CLIN ONCOL, V34, P443, DOI 10.1200/JCO.2015.62.6598; Heinemann V, 2009, CANCER TREAT REV, V35, P262, DOI 10.1016/j.ctrv.2008.11.005; Holbeck SL, 2010, MOL CANCER THER, V9, P1451, DOI 10.1158/1535-7163.MCT-10-0106; Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107; Hopper-Borge EA, 2009, EXPERT OPIN THER TAR, V13, P339, DOI [10.1517/14712590902735795 , 10.1517/14712590902735795]; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huang MH, 2013, MOL ONCOL, V7, P112, DOI 10.1016/j.molonc.2012.09.002; Huang SG, 2012, ASSAY DRUG DEV TECHN, V10, P88, DOI 10.1089/adt.2011.0388; Hui Zou TH, 2005, J R STAT SOC B, V67, P20; Hutchinson Lisa, 2011, Nat Rev Clin Oncol, V8, P193, DOI 10.1038/nrclinonc.2011.29; Infante JR, 2012, LANCET ONCOL, V13, P773, DOI 10.1016/S1470-2045(12)70270-X; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Ivanescu Ana-Maria, 2014, Maedica (Bucur), V9, P217; Iyer MK, 2011, BIOINFORMATICS, V27, P2903, DOI 10.1093/bioinformatics/btr467; Jain P, 2013, BLOOD, V121, P4867, DOI 10.1182/blood-2013-03-490128; Jang IS, 2014, BIOCOMPUT-PAC SYM, P63; Jing JP, 2012, MOL CANCER THER, V11, P720, DOI 10.1158/1535-7163.MCT-11-0505; Joo KM, 2013, CELL REP, V3, P260, DOI 10.1016/j.celrep.2012.12.013; Joo KM, 2012, CANCER RES, V72, P3828, DOI 10.1158/0008-5472.CAN-11-3760; Kaley TJ, 2015, NEURO-ONCOLOGY, V17, P116, DOI 10.1093/neuonc/nou148; Kanabur P, 2016, ONCOTARGET, V7, P86406, DOI 10.18632/oncotarget.13415; Kawata H, 2003, BIOCHEM J, V373, P747, DOI 10.1042/BJ20030171; Kim ST, 2018, ANN ONCOL, V29, P1037, DOI 10.1093/annonc/mdy034; Kondor R. I., 2002, P 19 INT C MACH LEAR, V8; Ku B. M., NEW DRUGS, V33, P12; Kumar SR, 2006, AM J PATHOL, V169, P279, DOI 10.2353/ajpath.2006.050889; Lasocki A, 2016, J CLIN NEUROSCI, V31, P92, DOI 10.1016/j.jocn.2016.02.022; Lee EQ, 2015, NEURO-ONCOLOGY, V17, P862, DOI 10.1093/neuonc/nou350; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lee JY, 2015, ONCOTARGET, V6, P25619, DOI 10.18632/oncotarget.4627; Lee JK, 2017, NAT GENET, V49, P594, DOI 10.1038/ng.3806; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Lim SH, 2017, ONCOTARGET, V8, P3237, DOI 10.18632/oncotarget.13700; Liu Q, 2015, ACTA NEUROPATHOL, V130, P587, DOI 10.1007/s00401-015-1470-8; Loeb LA, 2011, NAT REV CANCER, V11, P450, DOI 10.1038/nrc3063; Louvet C, 2001, CANCER, V91, P2033, DOI 10.1002/1097-0142(20010601)91:11<2033::AID-CNCR1229>3.0.CO;2-J; Ma DJ, 2015, NEURO-ONCOLOGY, V17, P1261, DOI 10.1093/neuonc/nou328; Magi A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r120; Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Munarini N, 2002, J CELL SCI, V115, P25; Nagaraj AB, 2015, ONCOTARGET, V6, P23720, DOI 10.18632/oncotarget.4690; Nakada Mitsutoshi, 2011, Cancers (Basel), V3, P3242, DOI 10.3390/cancers3033242; Nathanson DA, 2014, SCIENCE, V343, P72, DOI 10.1126/science.1241328; Nicolau M, 2011, P NATL ACAD SCI USA, V108, P7265, DOI 10.1073/pnas.1102826108; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Ohka F, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/878425; Park YH, 2015, ONCOTARGET, V6, P32027, DOI 10.18632/oncotarget.5184; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Plass C, 2013, NAT REV GENET, V14, P765, DOI 10.1038/nrg3554; Puputti M, 2006, MOL CANCER RES, V4, P927, DOI 10.1158/1541-7786.MCR-06-0085; Raub TJ, 2015, DRUG METAB DISPOS, V43, P1360, DOI 10.1124/dmd.114.062745; Reardon DA, 2015, NEURO-ONCOLOGY, V17, P430, DOI 10.1093/neuonc/nou160; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Ritch PS, 2005, GLIA, V51, P217, DOI 10.1002/glia.20197; Rizvi A. H., NAT BIOTECH; Rubio-Perez C, 2015, CANCER CELL, V27, P382, DOI 10.1016/j.ccell.2015.02.007; Schroder LBW, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00259; Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047; Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Song HN, 2016, ONCOTARGET, V7, P19610, DOI 10.18632/oncotarget.7526; Soreide K, 2009, J CLIN PATHOL, V62, P1, DOI 10.1136/jcp.2008.061010; Spaans JN, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00190; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Suzuki H, 2015, NAT GENET, V47, P458, DOI 10.1038/ng.3273; Szerlip NJ, 2012, P NATL ACAD SCI USA, V109, P3041, DOI 10.1073/pnas.1114033109; Tapia O, 2014, VIRCHOWS ARCH, V465, P25, DOI 10.1007/s00428-014-1588-4; Taylor P, 2012, MOL CANCER THER, V11, P1713, DOI 10.1158/1535-7163.MCT-11-0990; Taylor TE, 2012, CURR CANCER DRUG TAR, V12, P197; Thiessen B, 2010, CANCER CHEMOTH PHARM, V65, P353, DOI 10.1007/s00280-009-1041-6; Torres-Garcia W, 2014, BIOINFORMATICS, V30, P2224, DOI 10.1093/bioinformatics/btu169; Tricker EM, 2015, CANCER DISCOV, V5, P960, DOI 10.1158/2159-8290.CD-15-0063; Trifonov V, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-S2-S2; Tsimberidou AM, 2015, LANCET ONCOL, V16, pE579, DOI 10.1016/S1470-2045(15)00397-6; Uhm JH, 2011, INT J RADIAT ONCOL, V80, P347, DOI 10.1016/j.ijrobp.2010.01.070; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Walkinshaw DR, 2013, J BIOL CHEM, V288, P9345, DOI 10.1074/jbc.M113.456996; Wang J., 2016, CURR BIOINFORM, V11, P8; Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220; Wang ZK, 2014, EPIGENOMICS-UK, V6, P139, DOI 10.2217/epi.13.73; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wen PY, 2012, NEURO-ONCOLOGY, V14, P819, DOI 10.1093/neuonc/nos117; Wilson TR, 2011, CANCER CELL, V20, P158, DOI 10.1016/j.ccr.2011.07.011; Wu H, 2015, ONCOTARGET, V6, P31313, DOI 10.18632/oncotarget.5182; Xie Y, 2015, EBIOMEDICINE, V2, P1351, DOI 10.1016/j.ebiom.2015.08.026; Yang NY, 2006, J BIOL CHEM, V281, P32574, DOI 10.1074/jbc.M604338200; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Yeh JJ, 2009, MOL CANCER THER, V8, P834, DOI 10.1158/1535-7163.MCT-08-0972; Yeung J, 2010, CANCER CELL, V18, P606, DOI 10.1016/j.ccr.2010.10.032; Yi YW, 2013, J CELL MOL MED, V17, P648, DOI 10.1111/jcmm.12046; Yiin JJ, 2010, MOL CANCER THER, V9, P929, DOI 10.1158/1535-7163.MCT-09-0953; Ying JE, 2015, ONCOTARGETS THER, V8, P2427, DOI 10.2147/OTT.S88592; Yoo KH, 2016, TRANSL ONCOL, V9, P173, DOI 10.1016/j.tranon.2016.01.007; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	155	95	98	2	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2018	50	10					1399	+		10.1038/s41588-018-0209-6	http://dx.doi.org/10.1038/s41588-018-0209-6			16	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	GV4DF	30262818	Green Accepted			2023-01-03	WOS:000446047000012
J	Saxena, M; Srivastava, A; Dwivedi, P; Bhattacharyya, S				Saxena, Malvika; Srivastava, Aradhana; Dwivedi, Pravesh; Bhattacharyya, Sanghita			Is quality of care during childbirth consistent from admission to discharge? A qualitative study of delivery care in Uttar Pradesh, India	PLOS ONE			English	Article							HEALTH FACILITIES; NEWBORN HEALTH; IMPROVEMENT; BIRTHS	Background Improving quality of maternal healthcare services is key to reducing maternal mortality across developing nations, including India. Expanding access to institutionalized care alone has failed to address critical quality barriers to safe, effective, patient-centred, timely and equitable care. Multi-dimensional quality improvement focusing on Person Centred Care (PCC) has an important role in expanding utilization of maternal health services and reducing maternal mortality. Methods Nine public health facilities were selected in two rural districts of Uttar Pradesh(UP), India, to understand women's experiences of childbirth and identify quality gaps in the process of maternity care. 23 direct, non-participant observations of uncomplicated vaginal deliveries were conducted using checklists with special reference to PCC, capturing quality of care provision at five stages D admission; pre-delivery; delivery; post-delivery and discharge. Data was thematically analysed using the framework approach. Case studies, good practices and gaps were noted at each stage of delivery care. Results Admission to maternity wards was generally prompt. All deliveries were conducted by skilled providers and at least one staff was available at all times. Study findings were discussed under two broad themes of care 'structure' and 'process'. While infrastructure, supplies and human resource were available across most facilities, gaps were observed in the process of care, particularly during delivery and post-delivery stages. Key areas of concern included compromised patient safety like poor hand hygiene, usage of unsterilized instruments; inadequate clinical care like lack of routine monitoring of labour progression, inadequate postpartum care; partially compromised privacy in the labour room and postnatal ward; and few incidents of abuse and demand for informal payments. Conclusions The study findings reflect gaps in the quality of maternity care across public health facilities in the study area and support the argument for strengthening PCC as an important effort towards quality improvement across the continuum of delivery care.	[Saxena, Malvika; Srivastava, Aradhana; Dwivedi, Pravesh; Bhattacharyya, Sanghita] Publ Hlth Fdn India, Res Dept, Gurugram, Haryana, India	Public Health Foundation of India	Bhattacharyya, S (corresponding author), Publ Hlth Fdn India, Res Dept, Gurugram, Haryana, India.	sanghita@phfi.org		Bhattacharyya, Sanghita/0000-0003-4447-6484	 [OPP1127467]		This work was supported by Grant number - OPP1127467, URL - https://www.gatesfoundation.org/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abuya T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123606; [Anonymous], 2016, IND FACT SHEET NAT F; [Anonymous], 2006, QUAL CAR PROC MAK ST; Asefa A, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0024-9; Balde MD, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-016-0262-5; Bhattacharyya S, 2013, GLOBAL HEALTH ACTION, V6, DOI 10.3402/gha.v6i0.22635; Bhattacharyya S, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1077-8; Bohren MA, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-016-0265-2; Chaturvedi S, 2015, GLOBAL HEALTH ACTION, V8, DOI 10.3402/gha.v8.27427; de Silva D., HELPING MEASURE PERS; Dey A, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0409-z; Directorate of Census Operations Uttar Pradesh Lucknow, 2011, DISTR CENS HDB KAP N, V10; Directorate of Census Operations Uttar Pradesh Lucknow, 2011, DISTR CENS HDB UN 10, V10; Donabedian A., 1980, EXPLORATIONS QUALITY; Duysburgh E, 2013, TROP MED INT HEALTH, V18, P534, DOI 10.1111/tmi.12076; Epstein RM, 2010, HEALTH AFFAIR, V29, P1489, DOI 10.1377/hlthaff.2009.0888; Every Woman Every Child (EWEC), 2015, GLOBAL STRATEGY WOME; Flicker L, 1999, BMJ-BRIT MED J, V318, P880, DOI DOI 10.1136/BMJ.318.7187.880A; Graham WJ, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001368; Hulton L, 2000, FRAMEWORK EVALUATION; Hurst TE, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0727-5; Idris Suleman Hadejia, 2013, Niger Med J, V54, P27, DOI 10.4103/0300-1652.108890; Institute of Medicine (US) Committee on Quality of Health Care in America, 2001, CROSSING QUALITY CHA; International Institute for Population Sciences (IIPS) and Macro International, NAT FAM HLTH SURV NF, P20072; Issac A, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0221-1; Ith P, 2013, WOMEN BIRTH, V26, P71, DOI 10.1016/j.wombi.2012.05.002; Iyengar K, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-270; Kumar S, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1139-x; Kumbani LC, 2012, REPROD HEALTH, V9, DOI 10.1186/1742-4755-9-30; Makuka Gerald J, 2017, Int J MCH AIDS, V6, P60, DOI 10.21106/ijma.191; Maternal and Newborn Health, 2013, MAT NEWB HLTH TOOLK; Miller S, 2003, INT J GYNECOL OBSTET, V82, P89, DOI 10.1016/S0020-7292(03)00148-6; Ministry of Health and Family Welfare, 2009, REPR CHILD HLTH PROG; Ministry of Health and Family Welfare, 2012, IND PUBL HLTH STAND; Ministry of Health and Family Welfare Government of India, 2013, OPERATIONAL GUIDELIN; MIRKOVIC KR, 2017, BMC PREGNANCY CHILDB, V17; Mirzabagi E, 2013, MIDWIFERY, V29, P902, DOI 10.1016/j.midw.2012.11.004; Modugu HR, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1048; Nair M, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004749; Ng M, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.24939; Office of the Registrar General India, 2013, SRS STAT REP 2013; Prick BW, 2013, ACTA OBSTET GYN SCAN, V92, P1277, DOI 10.1111/aogs.12238; Raven J, 2011, INT J GYNECOL OBSTET, V114, P4, DOI 10.1016/j.ijgo.2011.02.007; Registrar General & Census Commissioner, 2013, ANN HLTH SURV 2012 1; Registrar General of India, 2013, MAT MORT RAT B 2011; Rosen HE, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0728-4; Sabde Y, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0896-x; Sando D, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1019-4; Sarin E, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1318-4; Sharma G, 2017, B WORLD HEALTH ORGAN, V95, P419, DOI [10.2471/BLT.16.179291, 10.2471/blt.16.179291]; Sheferaw ED, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0323-4; Sidney K, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0362-4; Slater Lynne, 2006, Contemp Nurse, V23, P135; Spector JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035151; Srivastava A, 2017, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-017-4575-2; Stanton CK, 2014, INT J GYNECOL OBSTET, V127, P25, DOI 10.1016/j.ijgo.2014.04.014; Sudhinaraset M, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1124-4; Tuncalp O, 2015, BJOG-INT J OBSTET GY, V122, P1045, DOI 10.1111/1471-0528.13451; UN, 2015, MILL DEV GOALS REP 2, DOI DOI 10.18356/6CD11401-EN; van den Broek NR, 2009, BJOG-INT J OBSTET GY, V116, P18, DOI 10.1111/j.1471-0528.2009.02333.x; Vidler M, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0138-8; WHO, 2016, STANDARDS IMPROVING; World Health Organization, 2015, TRENDS MAT MORT 1990; World Health Organization, 2007, PEOPL CTR HLTH CAR H	64	11	11	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 27	2018	13	9							e0204607	10.1371/journal.pone.0204607	http://dx.doi.org/10.1371/journal.pone.0204607			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV2HB	30261044	gold, Green Published, Green Submitted			2023-01-03	WOS:000445907400074
J	Bisconti, AV; Devoto, M; Venturelli, M; Bryner, R; Olfert, IM; Chantler, PD; Esposito, F				Bisconti, Angela Valentina; Devoto, Michela; Venturelli, Massimo; Bryner, Randall; Olfert, I. Mark; Chantler, Paul D.; Esposito, F.			Respiratory muscle training positively affects vasomotor response in young healthy women	PLOS ONE			English	Article							HEART-RATE-VARIABILITY; FLOW-MEDIATED DILATION; INCREASES CYCLING ENDURANCE; BRACHIAL-ARTERY; BLOOD-PRESSURE; ENDOTHELIAL DYSFUNCTION; CARDIOVASCULAR-DISEASE; SYMPATHOVAGAL BALANCE; ULTRASOUND ASSESSMENT; SHEAR-STRESS	Vasomotor response is related to the capacity of the vessel to maintain vascular tone within a narrow range. Two main control mechanisms are involved: the autonomic control of the sympathetic neural drive (global control) and the endothelial smooth cells capacity to respond to mechanical stress by releasing vasoactive factors (peripheral control). The aim of this study was to evaluate the effects of respiratory muscle training (RMT) on vasomotor response, assessed by flow-mediated dilation (FMD) and heart rate variability, in young healthy females. The hypothesis was that RMT could enhance the balance between sympathetic and parasympathetic neural drive and reduce vessel shear stress. Thus, twenty-four women were randomly assigned to either RMT or SHAM group. Maximal inspiratory mouth pressure and maximum voluntary ventilation were utilized to assess the effectiveness of the RMT program, which consisted of three sessions of isocapnic hyperventilation/week for eight weeks, (twenty-four training sessions). Heart rate variability assessed autonomic balance, a global factor regulating the vasomotor response. Endothelial function was determined by measuring brachial artery vasodilation normalized by shear rate (%FMD/SR). After RMT, but not SHAM, maximal inspiratory mouth pressure and maximum voluntary ventilation increased significantly (+31% and +16%, respectively). Changes in heart rate variability were negligible in both groups. Only RMT exhibited a significant increase in % FMD/SR (+45%; p < 0.05). These data suggest a positive effect of RMT on vasomotor response that may be due to a reduction in arterial shear stress, and not through modulation of sympatho-vagal balance.	[Bisconti, Angela Valentina; Devoto, Michela; Venturelli, Massimo; Esposito, F.] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy; [Venturelli, Massimo] Univ Verona, Dept Neurosci Biomed & Movement Sci, Verona, Italy; [Bryner, Randall; Olfert, I. Mark; Chantler, Paul D.] West Virginia Univ, Sch Med, Div Exercise Physiol, Morgantown, WV USA; [Esposito, F.] IRCCS, Galeazzi Orthoped Inst, Milan, Italy	University of Milan; University of Verona; West Virginia University; IRCCS Istituto Ortopedico Galeazzi	Bisconti, AV (corresponding author), Univ Milan, Dept Biomed Sci Hlth, Milan, Italy.	angela.bisconti@unimi.it	BISCONTI, ANGELA VALENTINA/AAM-3509-2021; Esposito, Fabio/E-9340-2011; Venturelli, Massimo/AAQ-4613-2020	BISCONTI, ANGELA VALENTINA/0000-0003-0156-2593; Esposito, Fabio/0000-0002-4420-2611; Venturelli, Massimo/0000-0002-2469-8787				Atkinson G, 2013, J HYPERTENS, V31, P287, DOI 10.1097/HJH.0b013e32835b8164; Badrov MB, 2016, EUR J APPL PHYSIOL, V116, P1289, DOI 10.1007/s00421-016-3366-2; Bellenger CR, 2016, SPORTS MED, V46, P1461, DOI 10.1007/s40279-016-0484-2; Birk GK, 2012, J APPL PHYSIOL, V112, P1653, DOI 10.1152/japplphysiol.01489.2011; Camm AJ, 1996, CIRCULATION, V93, P1043; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; Chen X, 2015, EXP THER MED, V10, P2311, DOI 10.3892/etm.2015.2784; Chiappa GR, 2008, J AM COLL CARDIOL, V51, P1663, DOI 10.1016/j.jacc.2007.12.045; Corretti MC, 2002, J AM COLL CARDIOL, V39, P257, DOI 10.1016/S0735-1097(01)01746-6; Dall'Ago P, 2006, J AM COLL CARDIOL, V47, P757, DOI 10.1016/j.jacc.2005.09.052; Donoghue D, 2009, J REHABIL MED, V41, P343, DOI 10.2340/16501977-0337; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; Esposito F, 2010, RESP PHYSIOL NEUROBI, V173, P115, DOI 10.1016/j.resp.2010.07.008; Esposito F, 2010, EUR J APPL PHYSIOL, V110, P219, DOI 10.1007/s00421-010-1487-6; Esposito F, 2010, RESP PHYSIOL NEUROBI, V170, P268, DOI 10.1016/j.resp.2010.02.004; Faghy MA, 2016, EUR J SPORT SCI, V16, P585, DOI 10.1080/17461391.2015.1071878; Feairheller DL, 2014, J CLIN HYPERTENS, V16, P504, DOI 10.1111/jch.12328; Ferreira JB, 2013, INT J CARDIOL, V166, P61, DOI 10.1016/j.ijcard.2011.09.069; Green DJ, 2008, J APPL PHYSIOL, V105, P766, DOI 10.1152/japplphysiol.01028.2007; Green DJ, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a029819; Green DJ, 2009, EXERC SPORT SCI REV, V37, P196, DOI 10.1097/JES.0b013e3181b7b6e3; Harris RA, 2010, HYPERTENSION, V55, P1075, DOI 10.1161/HYPERTENSIONAHA.110.150821; He F, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00486; Hepburn H, 2005, EUR J APPL PHYSIOL, V94, P681, DOI 10.1007/s00421-005-1355-y; Joyner MJ, 2009, J PHYSIOL-LONDON, V587, P5551, DOI 10.1113/jphysiol.2009.179432; Maiorana A, 2000, AM J PHYSIOL-HEART C, V279, pH1999, DOI 10.1152/ajpheart.2000.279.4.H1999; Markov G, 2001, EUR J APPL PHYSIOL, V85, P233, DOI 10.1007/s004210100450; Milicevic G, 2005, COLLEGIUM ANTROPOL, V29, P295; Mosca L, 2011, CIRCULATION, V124, P2145, DOI 10.1161/CIRCULATIONAHA.110.968792; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Naylor LH, 2005, J APPL PHYSIOL, V98, P2311, DOI 10.1152/japplphysiol.01047.2004; Naylor LH, 2011, AM J PHYSIOL-HEART C, V300, pH664, DOI 10.1152/ajpheart.00985.2010; Niebauer J, 1996, J AM COLL CARDIOL, V28, P1652, DOI 10.1016/S0735-1097(96)00393-2; Okamoto T, 2011, EUR J APPL PHYSIOL, V111, P743, DOI 10.1007/s00421-010-1702-5; Puricel S, 2016, INT J CARDIOL, V202, P525, DOI 10.1016/j.ijcard.2015.09.085; Pyke KE, 2005, J PHYSIOL-LONDON, V568, P357, DOI 10.1113/jphysiol.2005.089755; Sandoo A, 2010, OPEN CARDIOVASC MED, V4, P302, DOI 10.2174/1874192401004010302; Schafer A, 2013, INT J CARDIOL, V166, P15, DOI 10.1016/j.ijcard.2012.03.119; Spengler CM, 1999, EUR J APPL PHYSIOL O, V79, P299, DOI 10.1007/s004210050511; Stein PK, 1997, AM J CARDIOL, V80, P302, DOI 10.1016/S0002-9149(97)00350-0; Stuessi C, 2001, EUR J APPL PHYSIOL, V84, P582, DOI 10.1007/s004210100408; Szocs K, 2004, GEN PHYSIOL BIOPHYS, V23, P265; Tarvainen MP, 2014, COMPUT METH PROG BIO, V113, P210, DOI 10.1016/j.cmpb.2013.07.024; Thijssen DHJ, 2011, ACTA PHYSIOL, V201, P427, DOI 10.1111/j.1748-1716.2010.02213.x; Thijssen DHJ, 2014, J APPL PHYSIOL, V116, P1300, DOI 10.1152/japplphysiol.00110.2014; Thijssen DHJ, 2011, AM J PHYSIOL-HEART C, V300, pH2, DOI 10.1152/ajpheart.00471.2010; Thompson PD, 2003, CIRCULATION, V107, P3109, DOI 10.1161/01.CIR.0000075572.40158.77; Tinken TM, 2010, HYPERTENSION, V55, P312, DOI 10.1161/HYPERTENSIONAHA.109.146282; Uehata A, 1997, Vasc Med, V2, P87; Umetani K, 1998, J AM COLL CARDIOL, V31, P593, DOI 10.1016/S0735-1097(97)00554-8; Verges S, 2009, RESP PHYSIOL NEUROBI, V169, P282, DOI 10.1016/j.resp.2009.09.005; Voss A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118308; Widlansky ME, 2003, J AM COLL CARDIOL, V42, P1149, DOI 10.1016/S0735-1097(03)00994-X; Wilson C, 2016, J PHYSIOL-LONDON, V594, P7267, DOI 10.1113/JP272927; Wray DW, 2013, HYPERTENSION, V62, P345, DOI 10.1161/HYPERTENSIONAHA.113.01578; Ylitalo A, 1999, AM J CARDIOL, V83, P885, DOI 10.1016/S0002-9149(98)01067-4; Zuo L, 2015, ACTA PHYSIOL, V213, P700, DOI 10.1111/apha.12410	57	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2018	13	9							e0203347	10.1371/journal.pone.0203347	http://dx.doi.org/10.1371/journal.pone.0203347			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GU9BO	30252845	Green Published, Green Submitted, gold			2023-01-03	WOS:000445639700006
J	Bates, MJ; Mphwatiwa, T; Ardrey, J; Desmond, N; Niessen, LW; Squire, SB				Bates, M. Jane; Mphwatiwa, Treza; Ardrey, Jane; Desmond, Nicola; Niessen, Louis W.; Squire, S. Bertel			Household concepts of wellbeing and the contribution of palliative care in the context of advanced cancer: A Photovoice study from Blantyre, Malawi	PLOS ONE			English	Article							QUALITY-OF-LIFE; AFRICAN ORGANIZATION; HEALTH; CHALLENGES; DEPRESSION; ANXIETY	Introduction Cancer and other life-limiting non-communicable diseases are on the increase in Africa affecting younger populations frequently diagnosed at an advanced stage of disease. The United Nations Sustainable Development Goal 3 aims for 'healthy life and wellbeing for all at all ages', though there is a limited understanding of wellbeing particularly from patients' and families' perspectives in these populations. Palliative care is an approach which aims to improve the quality of life for patients and families affected by life-limiting disease, though access to palliative care has been described as an issue which is 'largely ignored' on the global health agenda. The aim of this Photovoice study was to explore patient and family perspectives of wellbeing and the contribution of palliative care following a diagnosis of advanced cancer in Blantyre, Malawi. Methods Between November 2016 and February 2017, 13 co-researchers (6 patients receiving palliative care for advanced cancer and 7 un-paid family caregivers) gathered photographs to depict aspects of their daily lives. Participatory analysis was conducted and an advocacy event (including photographic exhibits) held. Results Wellbeing was described as seeing improvements in the patients' function facilitating inclusion in activities of daily living (including income generation) that had not previously been possible due to their illness. Family caregivers, neighbours and community members play a key role as 'courage givers' supported by health workers and religious groups, though discrimination in the form of social exclusion was also reported to be significant with patients expressing that they may be considered 'prematurely dead' in their community. Palliative care improves wellbeing by providing pain and symptom management enabling patients and / or family caregivers to return to household and income generating tasks. Through close interaction with households and ongoing counselling palliative care services assist to reduce fear and discrimination. Conclusions To achieve Sustainable Development Goal 3 for patients and families affected by life limiting illnesses in low resource settings, further understanding of the frequency and impact of discrimination is required as well as improved access to palliative care.	[Bates, M. Jane; Ardrey, Jane; Desmond, Nicola; Niessen, Louis W.; Squire, S. Bertel] Univ Liverpool Liverpool Sch Trop Med, Dept Clin Sci, Liverpool, Merseyside, England; [Bates, M. Jane] Coll Med, Dept Family Med, Blantyre, Malawi; [Mphwatiwa, Treza] Coll Med, African Network Care Children Affected HIV & AIDS, Lilongwe, Malawi; [Ardrey, Jane; Desmond, Nicola] Malawi Liverpool Wellcome Trust, Blantyre, Malawi	Liverpool School of Tropical Medicine; University of Malawi; University of Malawi; University of Malawi	Bates, MJ (corresponding author), Univ Liverpool Liverpool Sch Trop Med, Dept Clin Sci, Liverpool, Merseyside, England.; Bates, MJ (corresponding author), Coll Med, Dept Family Med, Blantyre, Malawi.	Jane.Bates@lstmed.ac.uk	Desmond, Nicola/ABA-6504-2020; Niessen, Louis/F-6254-2015; Harding, Richard/G-9729-2012; Desmond, Nicola/GYQ-8574-2022	Desmond, Nicola/0000-0002-2874-8569; Niessen, Louis/0000-0002-8639-5191; Squire, Stephen/0000-0001-7173-9038; Bates, Maya Jane/0000-0002-4459-837X; Ardrey, Jane/0000-0003-4558-5113	METHOD project by the Department for International Development; True Colours Trust in the UK; National Institute of Health Research using Official Development Assistance (ODA) [16/136/35]	METHOD project by the Department for International Development; True Colours Trust in the UK; National Institute of Health Research using Official Development Assistance (ODA)	This research was funded through the METHOD project by the Department for International Development and The True Colours Trust in the UK. The Palliative Care Support Trust and EMMS International are implementation partners on the METHOD project. The authors thank the NIHR Global Health Research Unit on Lung Health and TB in Africa at LSTM - "IMPALA" for helping to make this work possible. IMPALA (grant number 16/136/35) was commissioned by the National Institute of Health Research using Official Development Assistance (ODA) funding. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. Funding bodies were not involved in data collection, interpretation or reporting of the study.	Ardrey J, 2016, PUBLIC LIB SCI; Bates MJ, 2015, MALAWI MED J, V27, P93, DOI 10.4314/mmj.v27i3.4; Bates MJ, 2018, BMJ SUPPORT PALLIAT; Cardoso G, 2016, PSYCHOL HEALTH MED, V21, P562, DOI 10.1080/13548506.2015.1125006; Catalani C, 2010, HEALTH EDUC BEHAV, V37, P424, DOI 10.1177/1090198109342084; Chambers R., 1997, WHOSE REALITY COUNTS; Defilippi K, 2013, INT J PALLIAT NURS, V19, P577, DOI 10.12968/ijpn.2013.19.12.577; Downing J, 2012, BMC PALLIAT CARE, V11, DOI 10.1186/1472-684X-11-1; Duren-Winfield VT, 2006, INT J SELF HELP SELF, V5; Duthey B, 2014, J PAIN SYMPTOM MANAG, V47, P283, DOI 10.1016/j.jpainsymman.2013.03.015; Fraser BA, 2017, J GLOBAL ONCOLOGY; Gopal S, 2016, NEW ENGL J MED, V374, P1604, DOI 10.1056/NEJMp1601982; Grant L, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.010419; Greco G, 2015, SOC SCI MED, V130, P69, DOI 10.1016/j.socscimed.2015.01.042; Higginson IJ, 2010, CANCER J, V16, P423, DOI 10.1097/PPO.0b013e3181f684e5; Hoffman M, 2012, MALAWI MED J, V24, P74; Kendig Claire E, 2013, World J Oncol, V4, P142; Knaul FM, LANCET; Markham K, 2017, EUROPEAN J PALLIATIV, V24, P134; Masamba L, 2015, MALAWI MED J, V27, P77, DOI 10.4314/mmj.v27i3.1; McCaffrey N, 2016, J PAIN SYMPTOM MANAG, V52, P318, DOI 10.1016/j.jpainsymman.2016.02.012; McNaught A, 2013, INT J WELLBEING, V3; Mitchell Alex J, 2013, Lancet Oncol, V14, P721, DOI 10.1016/S1470-2045(13)70244-4; Morhason-Bello IO, 2013, LANCET ONCOL, V14, pE142, DOI 10.1016/S1470-2045(12)70482-5; Msyamboza KP, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3530-y; Mwangi-Powell FN, 2013, CURR OPIN SUPPORT PA, V7, P223, DOI 10.1097/SPC.0b013e328360f835; Ngunjiri FW, 2016, ADV DEV HUM RESOUR, V18, P223, DOI 10.1177/1523422316641416; Ntizimira CR, 2014, ECANCERMEDICALSCIENC, V8, DOI 10.3332/ecancer.2014.493; Ogunbiyi JO, 2016, INFECT AGENTS CANCER, V11, DOI 10.1186/s13027-016-0110-9; Parkin DM, 2014, CANCER EPIDEM BIOMAR, V23, P953, DOI 10.1158/1055-9965.EPI-14-0281; Powell RA, 2014, J PAIN SYMPTOM MANAG, V47, P315, DOI 10.1016/j.jpainsymman.2013.03.022; Selman L, 2011, J CLIN EPIDEMIOLOGY; Selman LE, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-21; Stjernsward J, 2007, J PAIN SYMPTOM MANAG, V33, P486, DOI 10.1016/j.jpainsymman.2007.02.016; Sutton-Brown CA, 2014, PHOTOGR CULT, V7, P169, DOI 10.2752/175145214X13999922103165; Tapsfield JB, 2011, BMC PALLIAT CARE, V10, DOI 10.1186/1472-684X-10-12; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Vodermaier A, 2017, J PAIN SYMPTOM MANAG; Waage J, 2015, LANCET GLOB HEALTH, V3, pE251, DOI 10.1016/S2214-109X(15)70112-9; Wang C, 1997, HEALTH EDUC BEHAV, V24, P369, DOI 10.1177/109019819702400309; Wang CC, 1998, HEALTH PROMOT INT, V13, P75, DOI 10.1093/heapro/13.1.75; White S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155043; who, WHO DEF PALL CAR; WHO, COMM HLTH APPR PALL; World Health Organization,, NONC DIS THEIR RISK	46	7	7	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2018	13	8							e0202490	10.1371/journal.pone.0202490	http://dx.doi.org/10.1371/journal.pone.0202490			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GR3NR	30133511	Green Accepted, gold, Green Published			2023-01-03	WOS:000442500400074
J	Wei, JY; Guo, FF; Zhang, MY; Xian, MH; Wang, TT; Gao, JH; Wu, HW; Song, L; Zhang, Y; Li, DF; Yang, HJ; Huang, LQ				Wei, Junying; Guo, Feifei; Zhang, Minyu; Xian, Minghua; Wang, Tingting; Gao, Jinhuan; Wu, Hongwei; Song, Lei; Zhang, Yi; Li, Defeng; Yang, Hongjun; Huang, Luqi			Signature-oriented investigation of the efficacy of multicomponent drugs against heart failure	FASEB JOURNAL			English	Article						personalized medicine; biomarker; traditional Chinese medicine	PLURIPOTENT STEM-CELL; ACID-BINDING PROTEIN; MYOCARDIAL DYSFUNCTION; PRECISION MEDICINE; ADJUVANT TREATMENT; SHENMAI INJECTION; QILI QIANGXIN; DOUBLE-BLIND; QUANTIFICATION; CARDIOMYOCYTES	Increasing attention has been paid to the application of precision medicine in heart failure (HF), and biomarker-based personalized medical care has shown great progress in HF management. Additionally, multicomponent drugs represented by traditional Chinese medicine (TCM) are demonstrating safety and efficacy in the management of HF. However, the potential mechanism is unclear, and the ambiguous clinical locations of TCM remain a hindrance to its extensive application. To meet this requirement, a precise investigation on the efficacy of multicomponent drugs against HF using the signature biomarkers-oriented approach was developed and applied to a conventional drug for cardiac disease, YiXinShu (YXS). On the basis of in vitro and in vivo efficacy evaluation of YXS against HF, and with the aid of proteomics and network pharmacology approaches, specific signatures regulated by YXS against HF were identified. YXS may show distinctive treatment features for those HF patients showing the elevation of fatty acid-binding protein 3 and cytoskeleton-associated protein 5, as well as other classic HF biomarkers. This study provides the first precise investigation of the efficacy of multicomponent drugs against HF and offers a practicable and low-cost approach for personalized management of HF.Wei, J., Guo, F., Zhang, M., Xian, M., Wang, T., Gao, J., Wu, H., Song, L., Zhang, Y., Li, D., Yang, H., Huang, L. Signature-oriented investigation of the efficacy of multicomponent drugs against heart failure.	[Wei, Junying; Guo, Feifei; Xian, Minghua; Wang, Tingting; Gao, Jinhuan; Wu, Hongwei; Zhang, Yi; Li, Defeng; Yang, Hongjun] China Acad Chinese Med Sci, Natl Resource Ctr Chinese Materia Med, Inst Chinese Materia Med, Beijing, Peoples R China; [Huang, Luqi] China Acad Chinese Med Sci, Natl Resource Ctr Chinese Materia Med, State Key Lab Breeding Base Daodi Herbs, Dongzhimen Nanxiao Rd 16, Beijing, Peoples R China; [Zhang, Minyu] Capital Med Univ, Sch Tradit Chinese Med, Beijing Key Lab TCM Collateral Dis Theory Res, Beijing, Peoples R China; [Song, Lei] Beijing Inst Radiat Med, Beijing Proteome Res Ctr, State Key Lab Prote, Beijing, Peoples R China	China Academy of Chinese Medical Sciences; China Academy of Chinese Medical Sciences; Capital Medical University; Academy of Military Medical Sciences - China	Huang, LQ (corresponding author), China Acad Chinese Med Sci, Natl Resource Ctr Chinese Materia Med, State Key Lab Breeding Base Daodi Herbs, Dongzhimen Nanxiao Rd 16, Beijing, Peoples R China.; Wei, JY; Yang, HJ (corresponding author), Inst Chinese Materia Med, Dongzhimen Nanxiao Rd 16, Beijing 100700, Peoples R China.	13683350075@163.com; hongjun0420@vip.sina.com; huangluqi01@126.com	wang, tingting/AAK-2640-2020		National Science and Technology Major Project [2014ZX09201021-009]; National Program on Key Basic Research Project [2015CB554406]; National Natural Science Foundation of China [81330086, 81603422, 81703951, IPX0001125000/PXD008489]	National Science and Technology Major Project; National Program on Key Basic Research Project(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The authors acknowledge financial support from the National Science and Technology Major Project (2014ZX09201021-009 to H.Y.), the National Program on Key Basic Research Project (2015CB554406 to H.Y.), and the National Natural Science Foundation of China (81330086 to H.Y., 81603422, and 81703951 to F.G.). All data related to this study have been made publicly available on iProX (http://www.iprox.org/) with ID IPX0001125000/PXD008489. The authors declare no conflicts of interests.	Abukar Y, 2016, AM J PHYSIOL-REG I, V310, pR94, DOI 10.1152/ajpregu.00205.2015; Arimoto T, 2005, J CARD FAIL, V11, P56, DOI 10.1016/j.cardfail.2004.03.005; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bateman A, 2015, NUCLEIC ACIDS RES, V43, pD204, DOI 10.1093/nar/gku989; Bayes-Genis A, 2018, EUR HEART J, V39, P2793, DOI 10.1093/eurheartj/ehx027; Cai J, 2015, STEM CELL REP, V5, P963, DOI 10.1016/j.stemcr.2015.10.020; Csermely P, 2013, PHARMACOL THERAPEUT, V138, P333, DOI 10.1016/j.pharmthera.2013.01.016; de Boer RA, 2009, EUR J HEART FAIL, V11, P811, DOI 10.1093/eurjhf/hfp097; Ding C, 2013, MOL CELL PROTEOMICS, V12, P2370, DOI 10.1074/mcp.O112.025023; Ertl G, 2014, EUR HEART J, V35, P470, DOI 10.1093/eurheartj/eht555; Fridman MD, 2017, CLIN SCI, V131, P439, DOI 10.1042/CS20160414; Fu F, 2015, SCI REP-UK, V5, DOI 10.1038/srep17927; Gan XT, 2014, CIRC-HEART FAIL, V7, P491, DOI 10.1161/CIRCHEARTFAILURE.113.000978; Genth-Zotz S, 2004, INT J CARDIOL, V96, P397, DOI 10.1016/j.ijcard.2003.08.008; Ginghina C, 2011, J Med Life, V4, P280; Gunaseeli I, 2010, CURR MED CHEM, V17, P759, DOI 10.2174/092986710790514480; Hao PP, 2015, NAT REV CARDIOL, V12, P115, DOI 10.1038/nrcardio.2014.177; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Hu ZY, 2014, THERANOSTICS, V4, P215, DOI 10.7150/thno.7868; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jenei ZM, 2013, CELL STRESS CHAPERON, V18, P809, DOI 10.1007/s12192-013-0425-z; Kostin S, 2000, Heart Fail Rev, V5, P271; Lainscak M, 2010, EUR J HEART FAIL, V12, P193, DOI 10.1093/eurjhf/hfp185; Layne K, 2017, BRIT J CLIN PHARMACO, V83, P20, DOI 10.1111/bcp.13013; Li C, 2016, SCI REP-UK, V6, DOI 10.1038/srep36949; Li XL, 2013, J AM COLL CARDIOL, V62, P1065, DOI 10.1016/j.jacc.2013.05.035; Liang P, 2013, CIRCULATION, V127, P1677, DOI 10.1161/CIRCULATIONAHA.113.001883; Liu ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep21146; Mallick P, 2010, NAT BIOTECHNOL, V28, P695, DOI 10.1038/nbt.1658; McMurray JJV, 2005, LANCET, V365, P1877, DOI 10.1016/S0140-6736(05)66621-4; Medhekar SK, 2016, INT J STEM CELLS, V9, P21, DOI 10.15283/ijsc.2016.9.1.21; Niizeki T, 2007, J CARD FAIL, V13, P120, DOI 10.1016/j.cardfail.2006.10.014; Qi JY, 2017, SCI REP-UK, V7, DOI 10.1038/srep42843; Ruiz-Castaneda G., 2015, J RECEPT SIG TRANSD, V2015, P1; Schuetz P, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14079; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Shi LW, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0939-2; Shimizu Y, 2016, CIRC-HEART FAIL, V9, DOI 10.1161/CIRCHEARTFAILURE.115.002368; Sun J, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1174-1; Tang WHW, 2013, J AM COLL CARDIOL, V62, P1073, DOI 10.1016/j.jacc.2013.05.028; Thygesen K, 2007, J AM COLL CARDIOL, V50, P2173, DOI 10.1016/j.jacc.2007.09.011; Wang NY, 2002, CIRC J, V66, P763, DOI 10.1253/circj.66.763; Wang XY, 2016, DRUG DES DEV THER, V10, P3725, DOI 10.2147/DDDT.S112333; Wei HM, 2015, J ETHNOPHARMACOL, V169, P347, DOI 10.1016/j.jep.2015.04.016; Wei JY, 2016, SCI REP-UK, V6, DOI 10.1038/srep29823; Wei JY, 2014, J PROTEOME RES, V13, P5724, DOI 10.1021/pr5007119; Wilmut I, 2007, CELL STEM CELL, V1, P593, DOI 10.1016/j.stem.2007.11.013; Xian SX, 2016, J ETHNOPHARMACOL, V186, P136, DOI 10.1016/j.jep.2016.03.066; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; Zhang FB, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/802784; Zhang MY, 2017, MOL BIOSYST, V13, P1469, DOI 10.1039/c6mb00813e; Zhao YC, 2016, SCI REP-UK, V6, DOI 10.1038/srep23025; Zhou Q, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005052.pub5	53	11	14	0	28	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2019	33	2					2187	2198		10.1096/fj.201800673RR	http://dx.doi.org/10.1096/fj.201800673RR			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HJ6KJ	30230922				2023-01-03	WOS:000457296600053
J	Macdougall, IC; White, C; Anker, SD; Bhandari, S; Farrington, K; Kalra, PA; McMurray, JJV; Murray, H; Tomson, CRV; Wheeler, DC; Winearls, CG; Ford, I				Macdougall, Iain C.; White, Claire; Anker, Stefan D.; Bhandari, Sunil; Farrington, Kenneth; Kalra, Philip A.; McMurray, John J. V.; Murray, Heather; Tomson, Charles R. V.; Wheeler, David C.; Winearls, Christopher G.; Ford, Ian		PIVOTAL Investigators Comm	Intravenous Iron in Patients Undergoing Maintenance Hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC KIDNEY-DISEASE; INFECTION; SAFETY; SUPPLEMENTATION; HEMOGLOBIN; MORTALITY; DIALYSIS; OUTCOMES; ALPHA; TIME	BACKGROUND Intravenous iron is a standard treatment for patients undergoing hemodialysis, but comparative data regarding clinically effective regimens are limited. METHODS In a multicenter, open-label trial with blinded end-point evaluation, we randomly assigned adults undergoing maintenance hemodialysis to receive either high-dose iron sucrose, administered intravenously in a proactive fashion (400 mg monthly, unless the ferritin concentration was >700 mu g per liter or the transferrin saturation was >= 40%), or low-dose iron sucrose, administered intravenously in a reactive fashion (0 to 400 mg monthly, with a ferritin concentration of <200 mu g per liter or a transferrin saturation of <20% being a trigger for iron administration). The primary end point was the composite of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or death, assessed in a time-to-first-event analysis. These end points were also analyzed as recurrent events. Other secondary end points included death, infection rate, and dose of an erythropoiesis-stimulating agent. Noninferiority of the high-dose group to the low-dose group would be established if the upper boundary of the 95% confidence interval for the hazard ratio for the primary end point did not cross 1.25. RESULTS A total of 2141 patients underwent randomization (1093 patients to the high-dose group and 1048 to the low-dose group). The median follow-up was 2.1 years. Patients in the high-dose group received a median monthly iron dose of 264 mg (interquartile range [25th to 75th percentile], 200 to 336), as compared with 145 mg (interquartile range, 100 to 190) in the low-dose group. The median monthly dose of an erythropoiesis-stimulating agent was 29,757 IU in the high-dose group and 38,805 IU in the low-dose group (median difference, -7539 IU; 95% confidence interval [CI], -9485 to -5582). A total of 320 patients (29.3%) in the high-dose group had a primary end-point event, as compared with 338 (32.3%) in the low-dose group (hazard ratio, 0.85; 95% CI, 0.73 to 1.00; P<0.001 for noninferiority; P=0.04 for superiority). In an analysis that used a recurrent-events approach, there were 429 events in the high-dose group and 507 in the low-dose group (rate ratio, 0.77; 95% CI, 0.66 to 0.92). The infection rate was the same in the two groups. CONCLUSIONS Among patients undergoing hemodialysis, a high-dose intravenous iron regimen administered proactively was superior to a low-dose regimen administered reactively and resulted in lower doses of erythropoiesis-stimulating agent being administered.	[Macdougall, Iain C.; White, Claire] Kings Coll Hosp London, Dept Renal Med, London, England; [Wheeler, David C.] UCL, London, England; [Bhandari, Sunil] East Yorkshire Hosp NHS Trust, Kingston Upon Hull, N Humberside, England; [Bhandari, Sunil] Hull York Med Sch, Kingston Upon Hull, N Humberside, England; [Farrington, Kenneth] Lister Hosp, Stevenage, Herts, England; [Farrington, Kenneth] Univ Hertfordshire, Hatfield, Herts, England; [Kalra, Philip A.] Salford Royal NHS Fdn Trust, Dept Renal Med, Salford, Lancs, England; [McMurray, John J. V.] Univ Glasgow, British Heart Fdn Cardiovasc Res Ctr, Glasgow, Lanark, Scotland; [Murray, Heather; Ford, Ian] Univ Glasgow, Robertson Ctr Biostat, Level 11,Boyd Orr Bldg, Glasgow G12 8QQ, Lanark, Scotland; [Tomson, Charles R. V.] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Winearls, Christopher G.] Oxford Univ Hosp NHS Fdn Trust, Oxford Kidney Unit, Churchill Hosp, Oxford, England; [Anker, Stefan D.] Charite Univ Med Berlin, German Ctr Cardiovasc Res Partner Site Berlin, Berlin Brandenburg Ctr Regenerat Therapies, Div Cardiol & Metab,Dept Cardiol, Berlin, Germany	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; University College London; University of Hull; University of York - UK; Lister Hospital; University of Hertfordshire; Salford Royal NHS Foundation Trust; University of Glasgow; University of Glasgow; Newcastle Freeman Hospital; Newcastle University - UK; Oxford University Hospitals NHS Foundation Trust; University of Oxford; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Ford, I (corresponding author), Univ Glasgow, Robertson Ctr Biostat, Level 11,Boyd Orr Bldg, Glasgow G12 8QQ, Lanark, Scotland.	ian.ford@glasgow.ac.uk	Hall, Matthew/AAB-8228-2019; mcmurray, John/B-2467-2013; Ford, Ian/ABE-6145-2020; Murray, Heather/GQY-8016-2022; Mark, Patrick/N-5536-2014	Hall, Matthew/0000-0002-3900-1735; mcmurray, John/0000-0002-6317-3975; Mark, Patrick/0000-0003-3387-2123; Tomson, Charles/0000-0002-0224-8726; Power, Albert/0000-0003-2283-5431; Khwaja, Arif/0000-0002-4690-3649; Barratt, Jonathan/0000-0002-9063-7229; Bell, Samira/0000-0001-9100-1575; Maxwell, Alexander P./0000-0002-6110-7253	Kidney Research UK; Vifor Fresenius Medical Care Renal Pharma	Kidney Research UK(Kidney Research UK (KRUK)); Vifor Fresenius Medical Care Renal Pharma	Supported by Kidney Research UK, which was supported by an unrestricted grant from Vifor Fresenius Medical Care Renal Pharma.	Anemia Work Group, 2012, KIDNEY INT, V2, P279, DOI [DOI 10.1038/kisup.2012.37, DOI 10.1093/NDT/GFT033.13]; Anker SD, 2018, EUR J HEART FAIL, V20, P125, DOI 10.1002/ejhf.823; [Anonymous], 2018, US DOPPS DIALYSIS OU; Bailie GR, 2015, KIDNEY INT, V87, P162, DOI 10.1038/ki.2014.275; Bailie GR, 2013, NEPHROL DIAL TRANSPL, V28, P2570, DOI 10.1093/ndt/gft062; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Brookhart MA, 2013, J AM SOC NEPHROL, V24, P1151, DOI 10.1681/ASN.2012121164; Cassat JE, 2013, CELL HOST MICROBE, V13, P510, DOI 10.1016/j.chom.2013.04.010; Coyne DW, 2012, KIDNEY INT, V82, P235, DOI 10.1038/ki.2012.76; Cross JH, 2015, SCI REP-UK, V5, DOI 10.1038/srep16670; Cunha GJL, 2018, EUR J INTERN MED, V52, P1, DOI 10.1016/j.ejim.2018.04.013; Dalal J, 2017, INDIAN HEART J, V69, P736, DOI 10.1016/j.ihj.2017.10.009; Del Vecchio L, 2016, CLIN KIDNEY J, V9, P260, DOI 10.1093/ckj/sfv142; Drakesmith H, 2012, SCIENCE, V338, P768, DOI 10.1126/science.1224577; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; Ganguli A, 2009, RENAL FAILURE, V31, P106, DOI 10.1080/08860220802599106; Ghosh D, 2000, BIOMETRICS, V56, P554, DOI 10.1111/j.0006-341X.2000.00554.x; Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502; Hougen I, 2018, CLIN J AM SOC NEPHRO, V13, P457, DOI 10.2215/CJN.05390517; Kalantar-Zadeh K, 2005, J AM SOC NEPHROL, V16, P3070, DOI 10.1681/ASN.2005040423; Kshirsagar AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078930; Lin DY, 2000, J ROY STAT SOC B, V62, P711, DOI 10.1111/1467-9868.00259; Macdougall IC, 2018, AM J NEPHROL, V48, P260, DOI 10.1159/000493551; Macdougall IC, 2016, KIDNEY INT, V89, P28, DOI 10.1016/j.kint.2015.10.002; Miskulin DC, 2014, CLIN J AM SOC NEPHRO, V9, P1930, DOI 10.2215/CJN.03370414; Nairz M, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00110; Neven E, 2011, NEPHROL DIAL TRANSPL, V26, P1137, DOI 10.1093/ndt/gfq858; NICE, 2015, MOT NEUR DIS BRIEF P; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Qian C, 2016, CAN J CARDIOL, V32, P151, DOI 10.1016/j.cjca.2015.06.009; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Stefanova D, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00253-18; Wish JB, 2018, AM J NEPHROL, V47, P72, DOI 10.1159/000486968	33	211	218	1	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 31	2019	380	5					447	458		10.1056/NEJMoa1810742	http://dx.doi.org/10.1056/NEJMoa1810742			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ4HS	30365356	Green Published, Bronze, Green Accepted			2023-01-03	WOS:000457135700008
J	Dusetzina, SB; Mello, MM				Dusetzina, Stacie B.; Mello, Michelle M.			Disclosing Prescription-Drug Prices in Advertisements - Legal and Public Health Issues	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Dusetzina, Stacie B.] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA; [Mello, Michelle M.] Stanford Univ, Sch Med, Stanford Law Sch, Stanford, CA 94305 USA; [Mello, Michelle M.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA	Vanderbilt University; Stanford University; Stanford University	Dusetzina, SB (corresponding author), Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA.			Mello, Michelle/0000-0003-2877-4270				Centers for Medicare and Medicaid Services, 2018, FED REGISTER, V83, P52789; Kirzinger Ashley, 2018, KAISER FAMILY FDN BL; Mintzes B, 2012, ANNU REV PUBL HEALTH, V33, P259, DOI 10.1146/annurev-publhealth-031811-124540	3	4	4	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 13	2018	379	24					2290	2293		10.1056/NEJMp1814065	http://dx.doi.org/10.1056/NEJMp1814065			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HD9HM	30428275				2023-01-03	WOS:000452872600003
J	Adu, MD; Malabu, UH; Malau-Aduli, AEO; Malau-Aduli, BS				Adu, Mary D.; Malabu, Usman H.; Malau-Aduli, Aduli E. O.; Malau-Aduli, Bunmi S.			Users' preferences and design recommendations to promote engagements with mobile apps for diabetes self-management: Multi-national perspectives	PLOS ONE			English	Article							HEALTH; INTERVENTION; PERCEPTIONS; TYPE-1	Background Mobile phone applications (apps) offer motivation and support for self-management of diabetes mellitus (DM), but their use is limited by high attrition due to insufficient consideration of end-users perspectives and usability requirements. This study aimed to examine app usage and feature preferences among people with DM, and explore their recommendations for future inclusions to foster engagement with diabetes apps. Methods The study was conducted internationally on adults with type 1 or type 2 DM using online questionnaire (quantitative) to investigate usage and preferences for app features that support diabetes self-management and semi structured telephone interview (qualitative) to explore suggestions on fostering engagement and specific educational information for inclusion into diabetes apps. Survey and interview data were analysed using descriptive/inferential statistics and inductive thematic analysis respectively. Results A total of 217 respondents with type 1 DM (38.25%) or type 2 DM (61.8%), from 4 continents (Australia, Europe, Asia and America) participated in the survey. About half of the respondents (48%) use apps, mainly with features for tracking blood glucose (56.6%), blood pressure (51.9%) and food calories (48.1%). Preferred features in future apps include nutrient values of foods (56.7%), blood glucose (54.8%), physical exercise tracker (47%), health data analytics (42.9%) and education on diabetes self-management (40.6%). Irrespective of the type of DM, participants proposed future apps that are user friendly, support healthy eating, provide actionable reminders and consolidate data across peripheral health devices. Participants with type 1 DM recommended customised features with news update on developments in the field of diabetes. Nominated specific educational topics included tips on problem solving, use of insulin pump therapy, signs of diabetes complication and transitioning from paediatric into adult care. Conclusions The study has highlighted patients' perspectives on essential components for inclusion in diabetes apps to promote engagement and foster better health outcomes.	[Adu, Mary D.; Malabu, Usman H.; Malau-Aduli, Bunmi S.] James Cook Univ, Coll Med & Dent, Townsville, Qld, Australia; [Malau-Aduli, Aduli E. O.] James Cook Univ, Coll Publ Hlth Med & Vet Sci, Townsville, Qld, Australia	James Cook University; James Cook University	Adu, MD (corresponding author), James Cook Univ, Coll Med & Dent, Townsville, Qld, Australia.	mary.adu@my.jcu.edu.au	Malau-Aduli, Aduli Enoch Othniel/C-2419-2014; Malau-Aduli, Bunmi/J-9388-2014	Malau-Aduli, Aduli Enoch Othniel/0000-0002-3660-7862; Adu, Damilola Mary/0000-0003-0046-9215; Malau-Aduli, Bunmi/0000-0001-6054-8498	Australian Government International Training Program Scholarship	Australian Government International Training Program Scholarship(Australian Government)	The first author (MDA) of this study is supported by the Australian Government International Training Program Scholarship. The funding body had no role in the study design, data collection and analysis, decision to publish or preparation of manuscript.	Adu MD, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/10115; Ancker JS, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4209; Arnhold M, 2014, J MED INTERNET RES, V16, P34, DOI 10.2196/jmir.2968; Arsand E, 2008, INFORM HEALTH SOC CA, V33, P158, DOI 10.1080/17538150802457562; Bender MS, 2014, JMIR MHEALTH UHEALTH, V2, DOI 10.2196/mhealth.3710; Bickmore T, 2010, APPL ARTIF INTELL, V24, P648, DOI 10.1080/08839514.2010.492259; Boyle L, 2017, JMIR MHEALTH UHEALTH, V5; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Chiauzzi E, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0319-2; Cho J, 2014, J MED INTERNET RES, V16, P206, DOI 10.2196/jmir.3283; Chomutare T, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1874; Conway N, 2016, HEALTH INFORM J, V22, P1111, DOI 10.1177/1460458215616265; Crane D, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00039; Creswell JW, 2003, HDB MIXED METHODS SO, P223; Demidowich AP, 2012, J TELEMED TELECARE, V18, P235, DOI 10.1258/jtt.2012.111002; Dennison L, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2583; DiMatteo MR, 2004, HEALTH PSYCHOL, V23, P207, DOI 10.1037/0278-6133.23.2.207; Dobson Rosie, 2017, JMIR Diabetes, V2, pe4, DOI 10.2196/diabetes.7221; Flesch R, 1948, J APPL PSYCHOL, V32, P221, DOI 10.1037/h0057532; Franz MJ, 2010, J AM DIET ASSOC, V110, P1852, DOI 10.1016/j.jada.2010.09.014; Gagnon MP, 2016, J AM MED INFORM ASSN, V23, P212, DOI 10.1093/jamia/ocv052; Garabedian LF, 2015, CURR DIABETES REP, V15, DOI 10.1007/s11892-015-0680-8; Giroux D, 2014, TELEMED E-HEALTH, V20, P923, DOI 10.1089/tmj.2013.0222; Glasgow RE, 2007, DIABETES CARE, V30, P33, DOI 10.2337/dc06-1390; Goyal S, 2013, QJM-INT J MED, V106, P1067, DOI 10.1093/qjmed/hct203; Guertler D, J MED INTERNET RES; Heisler M, 2007, DIABETES SPECTR, V20, P214, DOI [10.2337/diaspect.20.4.214, DOI 10.2337/DIASPECT.20.4.214]; Hill-Briggs F, 2003, ANN BEHAV MED, V25, P182, DOI 10.1207/S15324796ABM2503_04; Hill-Briggs F, 2001, DIABETES CARE, V24, P959, DOI 10.2337/diacare.24.5.959; Holmen H, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7045; Holmen H, 2014, JMIR MHEALTH UHEALTH, V2, DOI 10.2196/mhealth.3882; Holtz B, 2012, TELEMED E-HEALTH, V18, P175, DOI 10.1089/tmj.2011.0119; Istepanian RS, 2009, J TELEMED TELECARE; Izahar S, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00318; Juarascio AS, 2015, INT J MED INFORM, V84, P808, DOI 10.1016/j.ijmedinf.2015.06.004; Kayyali R, 2017, PHARMACY-BASEL, V5, DOI 10.3390/pharmacy5020033; Kessels RPC, 2003, J ROY SOC MED, V96, P219, DOI 10.1258/jrsm.96.5.219; Kim YJ, 2015, DIABETES METAB J, V39, P207, DOI 10.4093/dmj.2015.39.3.207; Klein MCA, 2017, SENSORS-BASEL, V17, DOI 10.3390/s17061436; Kontos E., 2014, J MED INTERNET RES, V16; Lalmas M., 2014, SYNTHESIS LECT INFOR, V6, P1, DOI [DOI 10.2200/S00605ED1V01Y201410ICR038, https://doi.org/10.2200/S00605ED1V01Y201410ICR038]; Liang X, 2011, DIABETIC MED, V28, P455, DOI 10.1111/j.1464-5491.2010.03180.x; Lithgow Kirstie, 2017, JMIR Diabetes, V2, pe2, DOI 10.2196/diabetes.6643; Lustria MLA, 2011, HEALTH INFORM J, V17, P224, DOI 10.1177/1460458211414843; Mallenius S., 2007, 6 ANN GLOBAL MOBILIT, V31, P12; McCurdie Tara, 2012, Biomed Instrum Technol, VSuppl, P49, DOI 10.2345/0899-8205-46.s2.49; Mulcahy K, 2003, DIABETES EDUCATOR, V29, P768, DOI 10.1177/014572170302900509; O'Brien HL, 2008, J AM SOC INF SCI TEC, V59, P938, DOI 10.1002/asi.20801; Payne KFB, 2012, BMC MED INFORM DECIS, V12, DOI 10.1186/1472-6947-12-121; Plain Language Action and Information Network [PLAIN], WHAT IS PLAIN LANG; Qenam B, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.8536; Quinn CC, 2011, DIABETES CARE; Rao Anoop, 2010, J Diabetes Sci Technol, V4, P949; Scheibe M, 2015, MED 2 0, V4; Shibuta T, 2017, BMJ OPEN DIAB RES CA, V5, DOI 10.1136/bmjdrc-2016-000322; Shrivastava SR, 2013, J DIABETES METAB DIS, V12, DOI 10.1186/2251-6581-12-14; Smith A, 2018, AM FAM PHYSICIAN, V98, P154; Stableford S, 2007, J PUBLIC HEALTH POL, V28, P71, DOI 10.1057/palgrave.jphp.3200102; Taki S, 2017, JMIR MHEALTH UHEALTH, V5; Tatara N, 2013, JMIR MHEALTH UHEALTH, V1, DOI 10.2196/mhealth.2432; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Torous J, 2018, EVID-BASED MENT HEAL, V21, P116, DOI 10.1136/eb-2018-102891; Tran J., 2012, CLIN DIABETES, V30, P173, DOI 10.2337/diaclin.30.4.173; Wallace S, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001099; Winters-Miner LA, TECHNOLOGY HLTH COMM; Woldaregay AZ, 2018, STUD HEALTH TECHNOL, V249, P151, DOI 10.3233/978-1-61499-868-6-151; Ye Qing, 2018, J Diabetes Sci Technol, V12, P808, DOI 10.1177/1932296818754907	67	28	28	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2018	13	12							e0208942	10.1371/journal.pone.0208942	http://dx.doi.org/10.1371/journal.pone.0208942			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HD6JR	30532235	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000452644700058
J	Ray, WA; Chung, CP; Murray, KT; Smalley, WE; Daugherty, JR; Dupont, WD; Stein, CM				Ray, Wayne A.; Chung, Cecilia P.; Murray, Katherine T.; Smalley, Walter E.; Daugherty, James R.; Dupont, William D.; Stein, C. Michael			Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE RISK SCORES; ATRIAL-FIBRILLATION; DABIGATRAN; WARFARIN; RIVAROXABAN; PREVENTION; SAFETY; STROKE	IMPORTANCE Anticoagulant choice and proton pump inhibitor (PPI) cotherapy could affect the risk of upper gastrointestinal tract bleeding, a frequent and potentially serious complication of oral anticoagulant treatment. OBJECTIVES To compare the incidence of hospitalization for upper gastrointestinal tract bleeding in patients using individual anticoagulants with and without PPI cotherapy, and to determine variation according to underlying gastrointestinal bleeding risk. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study in Medicare beneficiaries between January 1, 2011, and September 30, 2015. EXPOSURES Apixaban, dabigatran, rivaroxaban, or warfarin with or without PPI cotherapy. MAIN OUTCOMES AND MEASURES Hospitalizations for upper gastrointestinal tract bleeding: adjusted incidence and risk difference (RD) per 10 000 person-years of anticoagulant treatment, incidence rate ratios (IRRs). RESULTS Therewere 1 643 123 patients with 1 713 183 new episodes of oral anticoagulant treatment included in the cohort (mean [SD] age, 76.4 [2.4] years, 651 427 person-years of follow-up [56.1%] were for women, and the indication was atrial fibrillation for 870330 person-years [74.9%]). During 754 389 treatment person-years without PPI cotherapy, the adjusted incidence of hospitalization for upper gastrointestinal tract bleeding (n = 7119) was 115 per 10000 person-years (95% CI, 112-118). The incidence for rivaroxaban (n = 1278) was 144 per 10000 person-years (95% CI, 136-152), which was significantly greater than the incidence of hospitalizations for apixaban (n = 279; 73 per 10000 person-years; IRR, 1.97 [95% CI, 1.73-2.25]; RD, 70.9 [95% CI, 59.1-82.7]), dabigatran (n = 629; 120 per 10000 person-years; IRR, 1.19 [95% CI, 1.08-1.32]; RD, 23.4 [95% CI, 10.6-36.2]), and warfar in (n = 4933; 113 per 10000 person-years; IRR, 1.27 [95% CI, 1.19-1.35]; RD, 30.4 [95% CI, 20.3-40.6]). The incidence for apixaban was significantly lower than that for dabigatran (IRR, 0.61 [95% CI, 0.52-0.70]; RD, -47.5 [95% CI,-60.6 to -34.3]) and warfar in (IRR, 0.64 [95% CI, 0.57-0.73]; RD, -40.5 [95% CI, -50.0 to -31.0]). When anticoagulant treatment with PPI cotherapy (264 447 person-years; 76 per 10000 person-years) was compared with treatment without PPI cotherapy, risk of upper gastrointestinal tract bleeding hospitalizations (n = 2245) was lower overall (IRR, 0.66 [95% CI, 0.62-0.69]) and for apixaban (IRR, 0.66 [95% CI, 0.52-0.85]; RD, -24 [95% CI, -38 to -11]), dabigatran (IRR, 0.49 [95% CI, 0.41-0.59]; RD, -61.1 [95% CI, -74.8 to -47.4]), rivaroxaban (IRR, 0.75 [95% CI, 0.68-0.84]; RD, -35.5 [95% CI, -48.6 to -22.4]), and warfar in (IRR, 0.65 [95% CI, 0.62-0.69]; RD, -39.3 [95% CI, -44.5 to -34.2]). CONCLUSIONS AND RELEVANCE Among patients initiating oral anticoagulant treatment, incidence of hospitalization for upper gastrointestinal tract bleeding was the highest in patients prescribed rivaroxaban, and the lowest for patients prescribed apixaban. For each anticoagulant, the incidence of hospitalization for upper gastrointestinal tract bleeding was lower among patients who were receiving PPI cotherapy. These findings may inform assessment of risks and benefits when choosing anticoagulant agents.	[Ray, Wayne A.; Smalley, Walter E.; Daugherty, James R.] Vanderbilt Univ, Dept Hlth Policy, Sch Med, 1501 21st Ave S,Ste 2600, Nashville, TN 37212 USA; [Chung, Cecilia P.; Stein, C. Michael] Vanderbilt Univ, Sch Med, Dept Med, Div Rheumatol, Nashville, TN 37212 USA; [Chung, Cecilia P.; Stein, C. Michael] Vanderbilt Univ, Sch Med, Dept Pharmacol, Div Rheumatol, Nashville, TN 37212 USA; [Chung, Cecilia P.; Murray, Katherine T.; Stein, C. Michael] Vanderbilt Univ, Sch Med, Dept Med, Div Clin Pharmacol, Nashville, TN 37212 USA; [Chung, Cecilia P.; Murray, Katherine T.; Stein, C. Michael] Vanderbilt Univ, Sch Med, Dept Pharmacol, Div Clin Pharmacol, Nashville, TN 37212 USA; [Chung, Cecilia P.; Smalley, Walter E.] Vet Adm Tennessee Valley Hlth Care Syst, Nashville, TN USA; [Murray, Katherine T.] Vanderbilt Univ, Sch Med, Div Cardiol, Dept Med, Nashville, TN 37212 USA; [Murray, Katherine T.] Vanderbilt Univ, Sch Med, Div Cardiol, Dept Pharmacol, Nashville, TN 37212 USA; [Smalley, Walter E.] Vanderbilt Univ, Sch Med, Div Gastroenterol, Dept Med, Nashville, TN 37212 USA; [Smalley, Walter E.] Vanderbilt Univ, Sch Med, Div Gastroenterol, Dept Pharmacol, Nashville, TN 37212 USA; [Dupont, William D.] Vanderbilt Univ, Sch Med, Div Biostat, Dept Med, Nashville, TN 37212 USA; [Dupont, William D.] Vanderbilt Univ, Sch Med, Div Biostat, Dept Pharmacol, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Ray, WA (corresponding author), Vanderbilt Univ, Dept Hlth Policy, Sch Med, 1501 21st Ave S,Ste 2600, Nashville, TN 37212 USA.	wayne.ray@vanderbilt.edu	Chung, Cecilia P/ABE-2177-2021	Chung, Cecilia P/0000-0001-5908-9423	National Heart, Lung, and Blood Institute [HL114518]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [K23AR064768]; Rheumatology Research Foundation Career Development K Supplement; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL114518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR064768] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Rheumatology Research Foundation Career Development K Supplement; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This study was supported in part by a grant from the National Heart, Lung, and Blood Institute (HL114518). Dr Chung was funded by grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23AR064768) and the Rheumatology Research Foundation Career Development K Supplement.	Abraham NS, 2017, GASTROENTEROLOGY, V152, P1014, DOI 10.1053/j.gastro.2016.12.018; Arbogast PG, 2008, EPIDEMIOLOGY, V19, P30, DOI 10.1097/EDE.0b013e31815be000; Arbogast PG, 2011, AM J EPIDEMIOL, V174, P613, DOI 10.1093/aje/kwr143; Arbogast PG, 2009, STAT METHODS MED RES, V18, P67, DOI 10.1177/0962280208092347; Bolek T, 2019, AM J THER, V26, pE308, DOI 10.1097/MJT.0000000000000599; Bosch J, 2017, CAN J CARDIOL, V33, P1027, DOI 10.1016/j.cjca.2017.06.001; BRUNNER G, 1989, SCAND J GASTROENTERO, V24, P101, DOI 10.3109/00365528909091254; Chan EW, 2015, GASTROENTEROLOGY, V149, P586, DOI 10.1053/j.gastro.2015.05.002; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Cunningham A, 2011, PHARMACOEPIDEM DR S, V20, P560, DOI 10.1002/pds.2109; Glynn RJ, 2012, PHARMACOEPIDEM DR S, V21, P138, DOI 10.1002/pds.3231; Gong IY, 2013, CAN J CARDIOL, V29, pS24, DOI 10.1016/j.cjca.2013.04.002; Graham DJ, 2016, JAMA INTERN MED, V176, P1662, DOI 10.1001/jamainternmed.2016.5954; Li XS, EFFECTIVENESS SAFETY, V117, P1072, DOI [10.1160/TH17-01-0068, DOI 10.1160/TH17-01-0068]; Liesenfeld KH, 2011, J THROMB HAEMOST, V9, P2168, DOI 10.1111/j.1538-7836.2011.04498.x; Mazurek M, 2017, GASTROENTEROLOGY, V152, P932, DOI 10.1053/j.gastro.2017.02.027; Proietti M, 2018, STROKE, V49, P98, DOI 10.1161/STROKEAHA.117.018395; Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231; Ray WA, 2003, NEW ENGL J MED, V349, P1592, DOI 10.1056/NEJMp038145; Ray WA, 2016, GASTROENTEROLOGY, V151, P1105, DOI 10.1053/j.gastro.2016.08.054; Reilly PA, 2014, J AM COLL CARDIOL, V63, P321, DOI 10.1016/j.jacc.2013.07.104; Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0; Singh Saurabh, 2013, BMJ Case Rep, V2013, DOI 10.1136/bcr-2013-009139; Tadrous M, 2013, PHARMACOEPIDEM DR S, V22, P122, DOI 10.1002/pds.3377; Uddin MJ, 2016, INT J CLIN PHARM-NET, V38, P714, DOI 10.1007/s11096-016-0299-0; Vinogradova Y, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k2505; Zhang NX, 2016, INT J CARDIOL, V212, P358, DOI 10.1016/j.ijcard.2016.03.178	27	103	111	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	2018	320	21					2221	2230		10.1001/jama.2018.17242	http://dx.doi.org/10.1001/jama.2018.17242			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD4MB	30512099	Green Accepted, Bronze			2023-01-03	WOS:000452500600013
J	Schmid, P; Adams, S; Rugo, HS; Schneeweiss, A; Barrios, CH; Iwata, H; Dieras, V; Hegg, R; Im, SA; Wright, GS; Henschel, V; Molinero, L; Chui, SY; Funke, R; Husain, A; Winer, EP; Loi, S; Emens, LA				Schmid, P.; Adams, S.; Rugo, H. S.; Schneeweiss, A.; Barrios, C. H.; Iwata, H.; Dieras, V.; Hegg, R.; Im, S. -A.; Wright, G. Shaw; Henschel, V.; Molinero, L.; Chui, S. Y.; Funke, R.; Husain, A.; Winer, E. P.; Loi, S.; Emens, L. A.		IMpassion 130 Trial Investigators	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; ANTI-PD-L1 ANTIBODY; PREDICTIVE-VALUE; CHEMOTHERAPY; EXPRESSION; SURVIVAL	BACKGROUND Unresectable locally advanced or metastatic triple-negative (hormone-receptor-negative and human epidermal growth factor receptor 2 [HER2]-negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)paclitaxel may enhance the anticancer activity of atezolizumab. METHODS In this phase 3 trial, we randomly assigned (in a 1: 1 ratio) patients with untreated metastatic triple-negative breast cancer to receive atezolizumab plus nab-paclitaxel or placebo plus nab-paclitaxel; patients continued the intervention until disease progression or an unacceptable level of toxic effects occurred. Stratification factors were the receipt or nonreceipt of neoadjuvant or adjuvant taxane therapy, the presence or absence of liver metastases at baseline, and programmed death ligand 1 (PD-L1) expression at baseline (positive vs. negative). The two primary end points were progression-free survival (in the intention-to-treat population and PD-L1-positive subgroup) and overall survival (tested in the intention-to-treat population; if the finding was significant, then it would be tested in the PD-L1-positive subgroup). RESULTS Each group included 451 patients (median follow-up, 12.9 months). In the intention-to-treat analysis, the median progression-free survival was 7.2 months with atezolizumab plus nab-paclitaxel, as compared with 5.5 months with placebo plus nab-paclitaxel (hazard ratio for progression or death, 0.80; 95% confidence interval [CI], 0.69 to 0.92; P = 0.002); among patients with PD-L1-positive tumors, the median progression-free survival was 7.5 months and 5.0 months, respectively (hazard ratio, 0.62; 95% CI, 0.49 to 0.78; P<0.001). In the intention-to-treat analysis, the median overall survival was 21.3 months with atezolizumab plus nab-paclitaxel and 17.6 months with placebo plus nab-paclitaxel (hazard ratio for death, 0.84; 95% CI, 0.69 to 1.02; P = 0.08); among patients with PD-L1-positive tumors, the median overall survival was 25.0 months and 15.5 months, respectively (hazard ratio, 0.62; 95% CI, 0.45 to 0.86). No new adverse effects were identified. Adverse events that led to the discontinuation of any agent occurred in 15.9% of the patients who received atezolizumab plus nab-paclitaxel and in 8.2% of those who received placebo plus nab-paclitaxel. CONCLUSIONS Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and the PD-L1-positive subgroup. Adverse events were consistent with the known safety profiles of each agent.	[Schmid, P.] Queen Mary Univ London, Barts Canc Inst, Charterhouse Sq, London EC1M 6BQ, England; [Emens, L. A.] Univ Pittsburgh, Med Ctr, Canc Ctr, 5117 Ctr Ave,Rm G 27b, Pittsburgh, PA 15213 USA; [Adams, S.] NYU, Sch Med, Perlmutter Canc Ctr, New York, NY 10003 USA; [Rugo, H. S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Molinero, L.; Chui, S. Y.; Funke, R.] Genentech Inc, San Francisco, CA USA; [Schneeweiss, A.] Univ Hosp Heidelberg, Heidelberg, Germany; [Barrios, C. H.] Pontifical Cathol Univ Rio Grande Sul, Hosp Sao Lucas, Ctr Pesquisa Oncol, Porto Alegre, RS, Brazil; [Hegg, R.] Univ Sao Paulo, Sao Paulo, Brazil; [Iwata, H.] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan; [Dieras, V.] Inst Curie, Dept Med Oncol, Paris, France; [Im, S. -A.] Seoul Natl Univ Hosp, Seoul Natl Univ Coll Med, Canc Res Inst, Seoul, South Korea; [Wright, G. Shaw] Florida Canc Specialists & Res Inst, New Port Richey, FL USA; [Henschel, V.; Husain, A.] Roche, Basel, Switzerland; [Winer, E. P.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Loi, S.] Univ Melbourne, Peter Maccallum Canc Ctr, Melbourne, Vic, Australia; [Emens, L. A.] Bloomberg Kimmel Inst Canc Immunotherapy Johns Ho, Baltimore, MD USA	University of London; Queen Mary University London; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; New York University; University of California System; University of California San Francisco; Roche Holding; Genentech; Ruprecht Karls University Heidelberg; Pontificia Universidade Catolica Do Rio Grande Do Sul; Universidade de Sao Paulo; Aichi Cancer Center; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Seoul National University (SNU); Seoul National University Hospital; Florida Cancer Specialists; Roche Holding; Harvard University; Dana-Farber Cancer Institute; Peter Maccallum Cancer Center; University of Melbourne	Schmid, P (corresponding author), Queen Mary Univ London, Barts Canc Inst, Charterhouse Sq, London EC1M 6BQ, England.; Emens, LA (corresponding author), Univ Pittsburgh, Med Ctr, Canc Ctr, 5117 Ctr Ave,Rm G 27b, Pittsburgh, PA 15213 USA.	p.schmid@qmul.ac.uk; emensla@upmc.edu	Schmid, Peter/AAE-2788-2019; Schneeweiss, Andreas/HHS-4098-2022; Barrios, Carlos/HJG-7197-2022; Liedke, Pedro/L-5063-2019	Barrios, Carlos/0000-0001-6021-667X; Liedke, Pedro/0000-0002-8298-4765; Hegg, Roberto/0000-0002-6453-8155; Adams, Sylvia/0000-0003-4737-1952	F. Hoffmann-La Roche/Genentech, a member of the Roche Group	F. Hoffmann-La Roche/Genentech, a member of the Roche Group	Supported by F. Hoffmann-La Roche/Genentech, a member of the Roche Group.	Adams S, JAMA ONCOL; ADAMS S, 2018, CANCER RES S, V78; Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; [Anonymous], 2018, TECENTRIQ ATEZOLIZUM; Bonotto M, 2014, ONCOLOGIST, V19, P608, DOI 10.1634/theoncologist.2014-0002; Brahmer JR, 2018, J CLIN ONCOL, V36, P1714, DOI 10.1200/JCO.2017.77.6385; Cardoso F, 2018, ANN ONCOL, V29, P1634, DOI 10.1093/annonc/mdy192; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; den Brok WD, 2017, BREAST CANCER RES TR, V161, P549, DOI 10.1007/s10549-016-4080-9; Dirix LY, 2018, BREAST CANCER RES TR, V167, P671, DOI 10.1007/s10549-017-4537-5; Emens LA, 2018, JAMA ONCOL; Emens LA, 2015, CANCER IMMUNOL RES, V3, P436, DOI 10.1158/2326-6066.CIR-15-0064; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gobbini E, 2018, EUR J CANCER, V96, P17, DOI 10.1016/j.ejca.2018.03.015; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Jotte RM, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.18_suppl.LBA9000; Liu SV, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.9092; LOI S, 2017, ANN ONCOL S, V28; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Miles DW, 2013, ANN ONCOL, V24, P2773, DOI 10.1093/annonc/mdt276; Mittendorf EA, 2014, CANCER IMMUNOL RES, V2, P361, DOI 10.1158/2326-6066.CIR-13-0127; Molinero L, 2018, CANC RES S, V78; Sabatier R, 2015, ONCOTARGET, V6, P5449, DOI 10.18632/oncotarget.3216; Senkus E, 2015, ANN ONCOL, V26, pV8, DOI 10.1093/annonc/mdv298; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Soliman HH, 2017, ONCOTARGETS THER, V10, P101, DOI 10.2147/OTT.S122974; Vennapusa B, 2018, APPL IMMUNOHISTOCHEM; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yardley DA, 2018, ANN ONCOL, V29, P1763, DOI 10.1093/annonc/mdy201	30	2100	2167	38	291	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 29	2018	379	22					2108	2121		10.1056/NEJMoa1809615	http://dx.doi.org/10.1056/NEJMoa1809615			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB9HQ	30345906	Bronze			2023-01-03	WOS:000451402500006
J	Yanala, UR; Johanning, JM; Pipinos, II; High, RR; Larsen, G; Velander, WH; Carlson, MA				Yanala, Ujwal R.; Johanning, Jason M.; Pipinos, Iraklis I.; High, Robin R.; Larsen, Gustavo; Velander, William H.; Carlson, Mark A.			Fluid administration rate for uncontrolled intraabdominal hemorrhage in swine	PLOS ONE			English	Article							HYPOTENSIVE RESUSCITATION; LACTATED RINGERS; TRAUMA PATIENTS; ANIMAL-MODEL; BLOOD-LOSS; COAGULOPATHIC SWINE; HYPERTONIC SALINE; IMPROVES SURVIVAL; CLOSED-ABDOMEN; SHOCK	Background We hypothesized that slow crystalloid resuscitation would result in less blood loss and a smaller hemoglobin decrease compared to a rapid resuscitation during uncontrolled hemorrhage. Methods Anesthetized, splenectomized domestic swine underwent hepatic lobar hemitransection. Lactated Ringers was given at 150 or 20 mL/min IV (rapid vs. slow, respectively, N = 12 per group; limit of 100 mL/kg). Primary endpoints were blood loss and serum hemoglobin; secondary endpoints included survival, vital signs, coagulation parameters, and blood gases. Results The slow group had a less blood loss (1.6 vs. 2.7 L, respectively) and a higher final hemoglobin concentration (6.0 vs. 3.4 g/dL). Conclusions Using a fixed volume of crystalloid resuscitation in this porcine model of uncontrolled intraabdominal hemorrhage, a slow IV infusion rate produced less blood loss and a smaller hemoglobin decrease compared to rapid infusion.	[Yanala, Ujwal R.; Johanning, Jason M.; Pipinos, Iraklis I.; Carlson, Mark A.] Univ Nebraska, Med Ctr, Dept Surg, Omaha, NE 68588 USA; [Yanala, Ujwal R.; Johanning, Jason M.; Pipinos, Iraklis I.; Carlson, Mark A.] VA Nebraska Western Iowa Hlth Care Syst, Dept Surg, Omaha, NE 68105 USA; [High, Robin R.] Univ Nebraska, Med Ctr, Dept Biostat, Omaha, NE USA; [Larsen, Gustavo; Velander, William H.] Univ Nebraska, Coll Engn, Dept Chem & Biomol Engn, Lincoln, NE USA; [Carlson, Mark A.] Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68588 USA	University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Medical Center	Carlson, MA (corresponding author), Univ Nebraska, Med Ctr, Dept Surg, Omaha, NE 68588 USA.; Carlson, MA (corresponding author), VA Nebraska Western Iowa Hlth Care Syst, Dept Surg, Omaha, NE 68105 USA.; Carlson, MA (corresponding author), Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68588 USA.	macarlso@unmc.edu	yanala, ujwal/AGE-1225-2022	Pipinos, Iraklis/0000-0001-6873-6346; Carlson, Mark/0000-0002-8113-9199; Yanala, Ujwal/0000-0002-1344-9208	United States Army [W81XWH-11-1-0836]	United States Army(United States Department of DefenseUnited States Army)	This work was supported by a grant from the United States Army (W81XWH-11-1-0836).	Aksu U, 2012, RESUSCITATION, V83, P767, DOI 10.1016/j.resuscitation.2011.11.022; American Veterinary Medical Association, 2013, AVMA GUIDELINES EUTH; [Anonymous], 2011, GUIDE CARE USE LAB A; Bebarta VS, 2013, J TRAUMA ACUTE CARE, V75, P920, DOI 10.1097/TA.0b013e3182a539b8; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BICKELL WH, 1992, ANN EMERG MED, V21, P1077, DOI 10.1016/S0196-0644(05)80648-1; Blackbourne LH, 2010, J TRAUMA, V69, pS1, DOI 10.1097/TA.0b013e3181e4206f; Boysen SR, 2016, SHOCK, V46, P439, DOI 10.1097/SHK.0000000000000608; Butler FK, 2013, J SPEC OPER MED, V14, P13; Cannon JW, 2018, NEW ENGL J MED, V378, P370, DOI 10.1056/NEJMra1705649; Cannon WB, 1918, J AMER MED ASSOC, V70, P618; Carlson MA, 2014, J SURG RES, V187, P334, DOI 10.1016/j.jss.2013.09.039; Cho SD, 2009, SHOCK, V31, P87, DOI 10.1097/SHK.0b013e3181777ffb; Committee on Tactical Combat Casualty Care, 2018, ICCC GUID MED PERS 1; Delgado AV, 2008, J TRAUMA, V64, P75, DOI 10.1097/TA.0b013e31815b843c; Duggan M, 2013, J TRAUMA ACUTE CARE, V74, P1462, DOI 10.1097/TA.0b013e31828da937; Duggan MJ, 2014, J SURG RES, V187, P536, DOI 10.1016/j.jss.2013.12.005; Duggan MJ, 2013, J SURG RES, V182, P101, DOI 10.1016/j.jss.2012.07.048; Eastridge BJ, 2011, J TRAUMA, V71, pS4, DOI 10.1097/TA.0b013e318221147b; Grottke O, 2011, J SURG RES, V171, P234, DOI 10.1016/j.jss.2010.02.002; Hildebrand F, 2013, SHOCK, V40, P247, DOI 10.1097/SHK.0b013e3182a3cd74; Holcomb JB, 1999, J TRAUMA, V46, P49, DOI 10.1097/00005373-199901000-00009; Kellum JA, 2006, CHEST, V130, P962, DOI 10.1378/chest.130.4.962; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kiraly LN, 2006, J TRAUMA, V61, P57, DOI 10.1097/01.ta.0000220373.29743.69; KOWALENKO T, 1992, J TRAUMA, V33, P349, DOI 10.1097/00005373-199209000-00003; Langan NR, 2014, JAMA SURG, V149, P904, DOI 10.1001/jamasurg.2014.940; Moore HB, 2018, LANCET, V392, P283, DOI 10.1016/S0140-6736(18)31553-8; Morrison CA, 2011, J TRAUMA, V70, P652, DOI 10.1097/TA.0b013e31820e77ea; Neter John, 1990, APPL LINEAR STAT MOD; Pusateri AE, 2003, J TRAUMA, V55, P518, DOI 10.1097/01.TA.0000075336.92129.27; Riha GM, 2011, J TRAUMA, V71, P1755, DOI 10.1097/TA.0b013e3182367b1c; Schreiber MA, 2002, J TRAUMA, V53, P252, DOI 10.1097/00005373-200208000-00011; Schreiber MA, 2015, J TRAUMA ACUTE CARE, V78, P687, DOI 10.1097/TA.0000000000000600; Sena MJ, 2013, J SURG RES, V183, P704, DOI 10.1016/j.jss.2013.02.039; Shrestha B, 2015, J TRAUMA ACUTE CARE, V78, P336, DOI 10.1097/TA.0000000000000514; Sillesen M, 2014, J TRAUMA ACUTE CARE, V76, P998, DOI 10.1097/TA.0000000000000193; Soller B, 2015, SHOCK, V44, P90, DOI 10.1097/SHK.0000000000000307; Sondeen JL, 2003, J TRAUMA, V54, pS110, DOI 10.1097/01.TA.0000047220.81795.3D; Sperry JL, 2018, NEW ENGL J MED, V379, P315, DOI 10.1056/NEJMoa1802345; Swindle MM, 2016, SWINE LAB SURG ANEST; Via D, 2001, J TRAUMA, V50, P1076, DOI 10.1097/00005373-200106000-00016; Woolley T, 2018, J TRAUMA ACUTE CARE, V84, pS3, DOI 10.1097/TA.0000000000001856; Yanala UR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108293	44	2	2	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2018	13	11							e0207708	10.1371/journal.pone.0207708	http://dx.doi.org/10.1371/journal.pone.0207708			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC4HL	30496239	Green Published, gold			2023-01-03	WOS:000451763800044
J	Neiva, DM; Araujo, S; Gominho, J; Carneiro, AD; Pereira, H				Neiva, Duarte M.; Araujo, Solange; Gominho, Jorge; Carneiro, Angelica de Cassia; Pereira, Helena			An integrated characterization of Picea abies industrial bark regarding chemical composition, thermal properties and polar extracts activity	PLOS ONE			English	Article							NORWAY SPRUCE; EUCALYPTUS-GLOBULUS; PINUS-SYLVESTRIS; BIOREFINERY; AUTOHYDROLYSIS; ANTIOXIDANTS; VALORIZATION; FEEDSTOCK; INNER	The present work determines the chemical and thermal characteristics as well as the phytochemical and antioxidant potential of the polar extractives of the Picea abies bark from an industrial mill, their wood and bark components and also different bark fractions obtained by mechanical fractionation (fine B-1, Phi<0.180 mm, medium B-3, 0.450<Phi<0.850 mm and coarse B-6, 2<Phi<10 mm). The aim is to increase the knowledge on the Picea abies bark to better determine possible uses other than burning for energy production and to test an initial size reduction process to achieve fractions with different characteristics. Compared to wood, bark presented similar lignin (27%), higher mineral (3.9% vs 0.4%) and extractives (20.3% vs 3.8%) and lower polysaccharides (48% vs 71%) contents. Regarding bark fractions the fines showed higher ash (6.3%), extractives (25%) and lignin (29%) than the coarse fraction (3.9%, 19% and 25% respectively). Polysaccharide contents increased with particle size of the bark fractions (38% vs 52% for B-1 and B-6) but showed the same relative composition. The phytochemical profile of ethanol and water extracts presented higher contents for bark than wood of total phenols (2x higher), flavonoids (3x higher) and tannins (4-10x higher) with an increasing tendency with particle size. Bark antioxidant activity was higher than that of wood for ferric-reducing antioxidant power (FRAP, 10 vs 6 mmolFe(2+)/g(Ext) for the ethanol extract) and free radical scavenging activity (DPPH, 6 vs 18 mg/L IC50 for the ethanol extract) methods. The different bark fractions antioxidant activity was very similar. Bark thermal properties showed a much lower volatiles to fixed carbon ratio (V/FC) than wood (3.1 vs 5.2) although the same higher heating value (20.3 MJ/kg). The fractions were quite similar. Bark presented chemical features that point to their possible upgrade, whether by taking advantage of the high extractives with bioactive compounds or the production potential for hemicellulose-derived oligomers with possible use in nutraceutical and pharmaceutical industries.	[Neiva, Duarte M.; Araujo, Solange; Gominho, Jorge; Pereira, Helena] Univ Lisbon, Ctr Estudos Florestais, Inst Super Agron, Lisbon, Portugal; [Carneiro, Angelica de Cassia] Univ Fed Vicosa, Vicosa, MG, Brazil	Universidade de Lisboa; Universidade Federal de Vicosa	Neiva, DM (corresponding author), Univ Lisbon, Ctr Estudos Florestais, Inst Super Agron, Lisbon, Portugal.	duarteneiva@isa.ulisboa.pt	Gominho, Jorge/B-4816-2009; Pereira, Helena/V-5236-2019; Neiva, Duarte Miranda/E-3135-2016	Gominho, Jorge/0000-0003-3419-6075; Pereira, Helena/0000-0002-5393-4443; Neiva, Duarte Miranda/0000-0002-5913-5976	Fundacao para a Ciencia e a Tecnologia (FCT) [UID/AGR/00239/2013]; FCT [PD/BD/52697/2014, SFRH/BPD/118743/2016]	Fundacao para a Ciencia e a Tecnologia (FCT)(Portuguese Foundation for Science and TechnologyEuropean Commission); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	The Forest Research Center (CEF) is a research unit funded by Fundacao para a Ciencia e a Tecnologia (FCT) under UID/AGR/00239/2013. The first author acknowledges a PhD scholarship (PD/BD/52697/2014) under the SUSFOR doctoral program, and the second author a Post Doc scholarship (SFRH/BPD/118743/2016) that are both financed by FCT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alfredsen G, 2008, EUR J FOREST RES, V127, P387, DOI 10.1007/s10342-008-0222-x; Bridgeman TG, 2007, FUEL, V86, P60, DOI 10.1016/j.fuel.2006.06.022; Co M, 2012, PHYTOCHEM ANALYSIS, V23, P1, DOI 10.1002/pca.1316; Corder S. E., 1976, PROPERTIES USES BARK; Feng SH, 2013, RENEW SUST ENERG REV, V26, P560, DOI 10.1016/j.rser.2013.06.024; Ferreira JPA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197135; Ferreira JPA, 2015, IND CROP PROD, V74, P998, DOI 10.1016/j.indcrop.2015.05.065; Francezon N, 2017, IND CROP PROD, V108, P348, DOI 10.1016/j.indcrop.2017.06.052; Garrote G, 2002, J FOOD ENG, V52, P211, DOI 10.1016/S0260-8774(01)00108-X; Harkin JM, 1971, BARK ITS POSSIBLE US; Kemppainen K, 2014, IND CROP PROD, V52, P158, DOI 10.1016/j.indcrop.2013.10.009; Krogell J, 2012, NORD PULP PAP RES J, V27, P6, DOI 10.3183/npprj-2012-27-01-p006-017; Lacoste C, 2015, IND CROP PROD, V73, P144, DOI 10.1016/j.indcrop.2015.03.089; Latva-Maenpaa H, 2013, TREES-STRUCT FUNCT, V27, P131, DOI 10.1007/s00468-012-0780-x; Le Normand M, 2014, CELLULOSE, V21, P4583, DOI 10.1007/s10570-014-0423-z; Le Normand M, 2014, CARBOHYD POLYM, V111, P979, DOI 10.1016/j.carbpol.2014.04.092; Le Normand M, 2014, CARBOHYD POLYM, V101, P699, DOI 10.1016/j.carbpol.2013.09.067; Le Normand M, 2012, NORD PULP PAP RES J, V27, P18, DOI 10.3183/npprj-2012-27-01-p018-023; Leite C, 2017, FRONT MATER, V3, DOI 10.3389/fmats.2016.00063; MANNILA E, 1992, PHYTOCHEMISTRY, V31, P3288, DOI 10.1016/0031-9422(92)83500-X; Matthews S, 1997, PHYTOCHEMISTRY, V45, P405, DOI 10.1016/S0031-9422(96)00873-4; Miranda I, 2017, MADERAS-CIENC TECNOL, V19, P185, DOI 10.4067/S0718-221X2017005000016; Miranda I, 2012, BIORESOURCES, V7, P4350; Miranda I, 2013, IND CROP PROD, V41, P299, DOI 10.1016/j.indcrop.2012.04.024; Miranda I, 2012, IND CROP PROD, V36, P395, DOI 10.1016/j.indcrop.2011.10.035; Moniz P, 2017, RICE RICE STRAW PROD, P55; Neiva DM, 2018, IND CROP PROD, V123, P262, DOI 10.1016/j.indcrop.2018.06.070; Neiva DM, 2016, J WOOD CHEM TECHNOL, V36, P383, DOI 10.1080/02773813.2016.1184280; Neiva DM, 2014, BIORESOURCES, V9, P2907; NORIN T, 1972, ACTA CHEM SCAND, V26, P2289, DOI 10.3891/acta.chem.scand.26-2289; Pan SB, 2013, BIOENERG RES, V6, P24, DOI 10.1007/s12155-012-9223-1; PELTONEN S, 1981, PAP PUU-PAP TIM, V63, P593; Pietarinen SP, 2006, J WOOD SCI, V52, P436, DOI 10.1007/s10086-005-0780-1; Pizzi A, 2006, J ADHES SCI TECHNOL, V20, P829, DOI 10.1163/156856106777638635; Ragauskas AJ, 2006, SCIENCE, V311, P484, DOI 10.1126/science.1114736; Rhen C, 2004, SCAND J FOREST RES, V19, P72, DOI 10.1080/02827580310019185; Sanchez-Moreno C, 1998, J SCI FOOD AGR, V76, P270, DOI 10.1002/(SICI)1097-0010(199802)76:2<270::AID-JSFA945>3.3.CO;2-0; Scherer R, 2009, FOOD CHEM, V112, P654, DOI 10.1016/j.foodchem.2008.06.026; Sen A, 2016, IND CROP PROD, V92, P42, DOI 10.1016/j.indcrop.2016.07.044; Tamaki Y, 2010, IND CROP PROD, V31, P534, DOI 10.1016/j.indcrop.2010.02.004; Vazquez MJ, 2005, BIORESOURCE TECHNOL, V96, P889, DOI 10.1016/j.biortech.2004.08.013; Voipio R, 1992, FOLIA FORESTALIA, V789; Xavier D, 2012, CELL CHEM TECHNOL, V46, P541; Yemele MCN, 2013, IND CROP PROD, V42, P50, DOI 10.1016/j.indcrop.2012.05.012; Zhang Lu, 2009, CHARACTERIZATION LIG, P1	45	28	28	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2018	13	11							e0208270	10.1371/journal.pone.0208270	http://dx.doi.org/10.1371/journal.pone.0208270			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB9UV	30481221	gold, Green Published, Green Submitted			2023-01-03	WOS:000451440000046
J	Pontefract, SK; Coleman, JJ; Vallance, HK; Hirsch, CA; Shah, S; Marriott, JF; Redwood, S				Pontefract, Sarah K.; Coleman, Jamie J.; Vallance, Hannah K.; Hirsch, Christine A.; Shah, Sonal; Marriott, John F.; Redwood, Sabi			The impact of computerised physician order entry and clinical decision support on pharmacist-physician communication in the hospital setting: A qualitative study	PLOS ONE			English	Article							ELECTRONIC PRESCRIBING SYSTEM; ERRORS; IMPLEMENTATION; TECHNOLOGIES; INPATIENTS; CONTEXT; SAFETY; RATES; WORK	Background The implementation of Computerised Physician Order Entry (CPOE) and Clinical Decision Support (CDS) has been found to have some unintended consequences. The aim of this study is to explore pharmacists and physicians perceptions of their interprofessional communication in the context of the technology and whether electronic messaging and CDS has an impact on this. Method This qualitative study was conducted in two acute hospitals: the University Hospitals Birmingham NHS Foundation Trust (UHBFT) and Guy's and St Thomas' NHS Foundation Trust (GSTH). UHBFT use an established locally developed CPOE system that can facilitate pharmacist-physician communication with the ability to assign a message directly to an electronic prescription. In contrast, GSTH use a more recently implemented commercial system where such communication is not possible. Focus groups were conducted with pharmacists and physicians of varying grades at both hospitals. Focus group data were transcribed and analysed thematically using deductive and inductive approaches, facilitated by NVivo 10. Results Three prominent themes emerged during the study: increased communication load; impaired decision-making; and improved workflow. CPOE and CDS were found to increase the communication load for the pharmacist owing to a reduced ability to amend electronic prescriptions, new types of prescribing errors, and the provision of technical advice relating to the use of the system. Decision-making was found to be affected, owing to the difficulties faced by pharmacists and physicians when trying to determine the context of prescribing decisions and knowledge of the patient. The capability to communicate electronically facilitated a non-interruptive workflow, which was found to be beneficial for staff time, coordination of work and for limiting distractions. Conclusion The increased communication load for the pharmacist, and consequent workload for the physician, has the potential to impact on the quality and coordination of care in the hospital setting. The ability to communicate electronically has some benefits, but functions need to be designed to facilitate collaborative working, and for this to be optimised through interprofessional training.	[Pontefract, Sarah K.; Vallance, Hannah K.; Hirsch, Christine A.; Shah, Sonal; Marriott, John F.] Univ Birmingham, Coll Med & Dent Sci, Sch Pharm, Birmingham, W Midlands, England; [Pontefract, Sarah K.; Coleman, Jamie J.; Vallance, Hannah K.] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England; [Coleman, Jamie J.] Univ Birmingham, Coll Med & Dent Sci, Sch Med, Birmingham, W Midlands, England; [Redwood, Sabi] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Bristol	Pontefract, SK (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Sch Pharm, Birmingham, W Midlands, England.; Pontefract, SK (corresponding author), Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England.	s.k.pontefract@bham.ac.uk		Sabi, Redwood/0000-0002-2159-1482; Coleman, Jamie/0000-0002-7512-5153; Pontefract, Sarah Katie/0000-0002-0344-4075	National Institute for Health Research (NIHR) [DRF-2013-06-003]	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR))	This report is independent research arising from a Doctoral Research Fellowship [DRF-2013-06-003] supported by the National Institute for Health Research (NIHR). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackermann EW, 1996, MED J AUSTRALIA, V164, P315; Atkins J, 2002, LEARNING HLTH SOCIAL, V1, P172; Bardram JE, 2010, COMPUT SUPP COOP W J, V19, P105, DOI 10.1007/s10606-010-9110-2; Baysari MT, 2012, J AM MED INFORM ASSN, V19, P1003, DOI 10.1136/amiajnl-2011-000730; Bradley EH, 2007, HEALTH SERV RES, V42, P1758, DOI 10.1111/j.1475-6773.2006.00684.x; Brown CL, 2017, J AM MED INFORM ASSN, V24, P432, DOI 10.1093/jamia/ocw119; Castro GM, 2016, JT COMM J QUAL PATIE, V42, P70, DOI 10.1016/S1553-7250(16)42008-8; Coiera E, 1998, BRIT MED J, V316, P673, DOI 10.1136/bmj.316.7132.673; Cook KE, 2012, HEALTH PROMOT INT, V27, P90, DOI 10.1093/heapro/dar027; Cresswell KM, 2013, J AM MED INFORM ASSN, V20, pE9, DOI 10.1136/amiajnl-2013-001684; Curran H.J, 2018, THESIS WALDEN U; Dornan T, 2009, AN IN DEPTH INVESTIG; Edwards A, 2009, INT J MED INFORM, V78, P629, DOI 10.1016/j.ijmedinf.2009.04.006; Ferner RE, 2018, DRUG SAFETY, V41, P103, DOI 10.1007/s40264-017-0588-0; General Pharmaceutical Society, 2017, STAND PHARM PROF LON; Green J, 2009, QUALITATIVE METHODS; Harrison MI, 2007, J AM MED INFORM ASSN, V14, P542, DOI 10.1197/jamia.M2384; Heath C., 2002, Computer Supported Cooperative Work: The Journal of Collaborative Computing, V11, P317, DOI 10.1023/A:1021247413718; Ighani F, 2010, J MED SYST, V34, P677, DOI 10.1007/s10916-009-9281-x; Kahneman D., 2011, THINKING FAST SLOW; Kaushal R, 2003, ARCH INTERN MED, V163, P1409, DOI 10.1001/archinte.163.12.1409; Liu W, 2014, NURS INQ, V21, P246, DOI 10.1111/nin.12043; Liu YF, 2010, RES SOC ADMIN PHARM, V6, P324, DOI 10.1016/j.sapharm.2009.11.002; Malhotra S, 2016, J AM MED INFORM ASSN, V23, P891, DOI 10.1093/jamia/ocv192; Mark G, 2008, P SIGCHI C HUM FACT; McDonough R, 2001, J AM PHARM ASS, V41, P682, DOI DOI 10.1016/S1086-5802(16)31315-8; McMullen CK, 2015, AM J HEALTH-SYST PH, V72, P133, DOI 10.2146/ajhp140106; Morgan DL, 1998, PLANNING FOCUS GROUP; Mozaffar H, 2017, BMJ QUALITY SAFETY; National Institute for Health and Care Excellence, 2015, MEDICINES OPTIMISATI; NHS England, 2016, CLINICAL DIGITAL MAT; Niazkhani Z, 2008, STUD HEALTH TECHNOL, V136, P321; Nuckols TK, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-56; Office of the Chief Pharmaceutical Officer MD, 2016, REPORT; Parker J, 2000, J AM MED INFORM ASSN, V7, P453, DOI 10.1136/jamia.2000.0070453; Pontefract SK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160075; Popovici I, 2015, INT J QUAL HEALTH C, V27, P183, DOI 10.1093/intqhc/mzv016; Radley DC, 2013, J AM MED INFORM ASSN, V20, P470, DOI 10.1136/amiajnl-2012-001241; Reason J., 1990, HUMAN ERROR; Reddy MC, 2005, J BIOMED INFORM, V38, P229, DOI 10.1016/j.jbi.2004.11.010; Redwood S, 2011, BMC MED INFORM DECIS, V11, DOI 10.1186/1472-6947-11-29; Ross S, 2013, BMJ QUAL SAF, V22, P97, DOI 10.1136/bmjqs-2012-001175; Ryan C, 2013, BRIT J CLIN PHARMACO, V76, P980, DOI 10.1111/bcp.12154; Schmidt K, 2004, COMPUT SUPP COOP W J, V11, P285, DOI [DOI 10.1023/A:1021272909573, 10.1023/A:1021272909573]; Singh H, 2009, ARCH INTERN MED, V169, P982, DOI 10.1001/archinternmed.2009.102; The Joint Commission, 2014, SENTINEL EVENT ALERT; Thomas SK, 2012, EUR J HOSP PHARM-S P, V19, P349, DOI 10.1136/ejhpharm-2012-000110; Tully MP, 2009, DRUG SAFETY, V32, P819, DOI 10.2165/11316560-000000000-00000; Varpio L, 2015, INT J MED INFORM, V84, P1019, DOI 10.1016/j.ijmedinf.2015.09.004; Varpio L, 2015, MED EDUC, V49, P476, DOI 10.1111/medu.12665; Westbrook JI, 2013, J AM MED INFORM ASSN, V20, P1159, DOI 10.1136/amiajnl-2013-001745; Westbrook JI, 2010, QUAL SAF HEALTH CARE, V19, P284, DOI 10.1136/qshc.2009.039255	52	7	8	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2018	13	11							e0207450	10.1371/journal.pone.0207450	http://dx.doi.org/10.1371/journal.pone.0207450			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HA6WB	30444894	Green Published, Green Submitted, gold			2023-01-03	WOS:000450420900036
J	Abaraogu, UO; Ezenwankwo, EF; Dall, PM; Seenan, CA				Abaraogu, Ukachukwu Okoroafor; Ezenwankwo, Elochukwu Fortune; Dall, Philippa Margaret; Seenan, Chris Andrew			Living a burdensome and demanding life: A qualitative systematic review of the patients experiences of peripheral arterial disease	PLOS ONE			English	Review							INTERMITTENT CLAUDICATION; OF-LIFE; PHYSICAL-ACTIVITY; PRACTICE GUIDELINES; VASCULAR-SURGERY; MANAGEMENT; KNOWLEDGE; WALKING; PAIN; BARRIERS	Background Peripheral arterial disease (PAD) has a significant negative impact on the quality of life of individuals. Understanding the experiences of people living with PAD will be useful in developing comprehensive patient-centred secondary prevention therapies for this population. Aim The aim of this study is to identify first-hand accounts of patients' experiences of living with PAD. Methods Six databases (CINALH, PsycINFO, MEDLINE, AMED, EMBASE, Social citation index/Science citation index via Web of Science (WOS)) and reference lists of identified studies were searched until September 2017 (updated February 2018). Qualitative studies reporting patients' account of living with PAD were eligible for inclusion. A framework thematic synthesis was implemented. Results Fourteen studies with 360 participants were included. Pain and walking limitation were recurrent among the varied symptom descriptions. Patients' ignorance and trivialisation of symptoms contributed to delays in diagnosis. Inadequate engagement in disease under-standing and treatment decisions meant patients had poor attitudes towards walking treatments and unrealistic expectations about surgery. Depending on symptom progression, patients battle with walking impairment, powerlessness, and loss of independence which were a source of burden to them. Lack of disease understanding is central through patients' journey with PAD and, although they subsequently began adaptation to long term living with PAD, many worried about their future. Conclusions Disease understanding is vital across the illness trajectory in patients with PAD. Although certain experiences are common throughout patient journey, some might be unique to a particular stage (e.g. unrealistic expectation about surgery, or rationale of walking in spite of pain in a supervised exercise program). Given that PAD is an overarching construct ranging from the mildest form of intermittent claudication to severe critical limb ischemia with ulceration and gangrene, consideration of important patient constructs specific to each stage of the disease may enhance treatment success. Systematic review registration CRD42017070417.	[Abaraogu, Ukachukwu Okoroafor; Ezenwankwo, Elochukwu Fortune] Univ Nigeria, Dept Med Rehabil, Enugu, Nigeria; [Abaraogu, Ukachukwu Okoroafor; Dall, Philippa Margaret; Seenan, Chris Andrew] Glasgow Caledonian Univ, Sch Hlth & Life Sci, Glasgow, Lanark, Scotland	University of Nigeria; Glasgow Caledonian University	Abaraogu, UO (corresponding author), Univ Nigeria, Dept Med Rehabil, Enugu, Nigeria.; Abaraogu, UO (corresponding author), Glasgow Caledonian Univ, Sch Hlth & Life Sci, Glasgow, Lanark, Scotland.	ukachukwu.abaraogu@unn.edu.ng	Ezenwankwo, Elochukwu Fortune/AAZ-5135-2020; Seenan, Chris/G-9215-2019; Abaraogu, Ukachukwu O/N-8174-2015; Abaraogu, Ukachukwu/N-2082-2019	Ezenwankwo, Elochukwu Fortune/0000-0001-8483-9302; Seenan, Chris/0000-0003-4379-7913; Abaraogu, Ukachukwu/0000-0002-1967-1459; Dall, Philippa/0000-0002-1958-1517	University of Nigeria through the TETFUND	University of Nigeria through the TETFUND	UO received funding for his PhD from the University of Nigeria through the TETFUND, of which this forms part. However University of Nigeria or TETFUND do not role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abaraogu UO, 2017, EUR J VASC ENDOVASC, V54, P58, DOI 10.1016/j.ejvs.2017.04.003; Abaraogu U, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201095; Arigo D, 2014, HEALTH PSYCHOL REV, V8, P154, DOI 10.1080/17437199.2011.634572; Barbosa JP, 2015, INT J BEHAV MED, V22, P70, DOI 10.1007/s12529-014-9408-4; Bin Ayeed S, 2017, VASCULAR, V25, P86, DOI 10.1177/1708538116649801; Carroll C, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-29; Carthy ER, 2013, ANN MED SURG, V2, P26, DOI 10.1016/S2049-0801(13)70024-4; Cavalcante BR, 2015, ARCH PHYS MED REHAB, V96, P248, DOI 10.1016/j.apmr.2014.09.009; Conte MS, 2015, J VASC SURG, V61, p2S, DOI 10.1016/j.jvs.2014.12.009; Cooke A, 2012, QUAL HEALTH RES, V22, P1435, DOI 10.1177/1049732312452938; Cooke JP, 2015, CIRC RES, V116, P1505, DOI 10.1161/CIRCRESAHA.115.306403; Criqui M H, 1996, Vasc Med, V1, P65; Critical Appraisal Skills Programme (CASP), 2014, CASP QUAL CHECKL; Cunningham MA, 2014, J CARDIOPULM REHABIL, V34, P195, DOI 10.1097/HCR.0000000000000046; Davies MJ, 2008, BMJ-BRIT MED J, V336, P491, DOI 10.1136/bmj.39474.922025.BE; Dorenkamp S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146828; Dumville JC, 2004, BRIT J GEN PRACT, V54, P826; Egberg L, 2012, J VASC NURS, V30, P5, DOI 10.1016/j.jvn.2011.11.001; El Morr C, 2017, VASCULAR, V25, P479, DOI 10.1177/1708538116689355; Farah BQ, 2013, CLINICS, V68, P537, DOI 10.6061/clinics/2013(04)16; Galea MN, 2008, J AGING PHYS ACTIV, V16, P69, DOI 10.1123/japa.16.1.69; Galea MN, 2007, J CARDIOPULM REHABIL, V27, P107; Gardner AW, 2016, INT J VASC MED, V2016, DOI 10.1155/2016/2191350; Gerhard-Herman MD, 2017, CIRCULATION, V135, pE726, DOI 10.1161/CIR.0000000000000471; Gibson JME, 1998, J ADV NURS, V27, P737, DOI 10.1046/j.1365-2648.1998.00599.x; Gorely T, 2015, J VASC NURS, V33, P4, DOI 10.1016/j.jvn.2014.12.001; Hallin A, 2002, EUR J VASC ENDOVASC, V24, P255, DOI 10.1053/ejvs.2002.1647; Harwood AE, 2017, J VASC NURS, V35, P131, DOI 10.1016/j.jvn.2017.03.001; Hiatt WR, 1997, ATHEROSCLEROSIS, V131, pS35, DOI 10.1016/S0021-9150(97)06124-8; Hirsch AT, 2007, CIRCULATION, V116, P2086, DOI 10.1161/CIRCULATIONAHA.107.725101; Hirsch AT, 2006, CIRCULATION, V113, P1474, DOI 10.1161/CIRCULATIONAHA.106.173994; Holmes MNG, 2017, J HEALTH PSYCHOL, V22, P255, DOI 10.1177/1359105315600238; Johnstone Carolyn C, 2003, Prof Nurse, V18, P446; Johnstone Carolyn Catherine, 2004, Nurs Times, V100, P36; Kruidenier LM, 2009, EUR J VASC ENDOVASC, V38, P449, DOI 10.1016/j.ejvs.2009.04.020; Layden J, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e4947; Lin YS, 2016, INT J CARDIOL, V203, P204, DOI 10.1016/j.ijcard.2015.10.091; Lokin JLC, 2015, J VASC NURS, V33, P112, DOI 10.1016/j.jvn.2015.02.002; Maksimovic M, 2014, ANGIOLOGY, V65, P501, DOI 10.1177/0003319713488640; McDermott MM, 2010, VASC MED, V15, P83, DOI 10.1177/1358863X09353653; McDermott MM, 2001, JAMA-J AM MED ASSOC, V286, P1599; Moher D, 2016, REV ESP NUTR HUM DIE, V20, P148, DOI 10.14306/renhyd.20.2.223; Nordanstig J, 2014, J VASC SURG, V59, P700, DOI 10.1016/j.jvs.2013.08.099; O'Donnell M E, 2011, Ulster Med J, V80, P33; Rejeski WJ, 2008, J CARDIOPULM REHABIL, V28, P65, DOI 10.1097/01.HCR.0000311512.61967.6e; Schorr EN, 2015, GERIATR NURS, V36, P293, DOI 10.1016/j.gerinurse.2015.03.004; Sharath SE, 2017, VASC MED, V22, P378, DOI 10.1177/1358863X17709944; Treat-Jacobson D, 2002, J NURS SCHOLARSHIP, V34, P55, DOI 10.1111/j.1547-5069.2002.00055.x; Walker CM, 2015, CLIN INTERV AGING, V10, P1147, DOI 10.2147/CIA.S79355; Wann-Hansson C, 2005, INT J NURS STUD, V42, P851, DOI 10.1016/j.ijnurstu.2004.11.009; Wann-Hansson C, 2008, INT J NURS STUD, V45, P552, DOI 10.1016/j.ijnurstu.2006.11.006; Wann-Hansson C, 2016, BMC NURS, V15, DOI 10.1186/s12912-016-0151-9; Watson Kristin, 2006, Am J Geriatr Pharmacother, V4, P365, DOI 10.1016/j.amjopharm.2006.12.006; Willigendael EM, 2004, EUR J VASC ENDOVASC, V27, P622, DOI 10.1016/j.ejvs.2004.02.019; World Health Organization, 2015, WHOCDSCSRISR992EN, P107	55	23	22	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2018	13	11							e0207456	10.1371/journal.pone.0207456	http://dx.doi.org/10.1371/journal.pone.0207456			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HA4SR	30440040	Green Published, gold, Green Submitted			2023-01-03	WOS:000450254000082
J	Wolter, T; Kleinmann, B				Wolter, Tilman; Kleinmann, Barbara			Placebo acceptability in chronic pain patients: More dependent on application mode and resulting condition than on individual factors	PLOS ONE			English	Article							OPEN-LABEL PLACEBO; DOSE REDUCTION; DECEPTION; DEPRESSION; RESPONSES; EFFICACY; ANXIETY; DASS	Introduction Placebo effects can be very effective in certain pain conditions, but their use is still highly controversial. Several studies show that patients would accept a placebo treatment under certain circumstances, particularly when they are informed prior to the treatment or when there are no effective treatment alternatives. This study examines the question, which factors influence the degree of acceptability of a hypothetical placebo application. Methods Patients filled in a questionnaire dealing with placebo applications. Moreover general data, diagnosis, duration of pain, pain ratings and anxiety/depression/stress scores, sleep disorders and opioid intake were collected from the patients' charts. 129 patients (44 men / 85 women, mean age 51.5 years, 18.0-80.9 years) entered the study. All patients had chronic pain syndromes and were treated in an universitary academic interdisciplinary pain center. Mean duration of pain was 14.7 years. Results The study did not show significant differences in placebo acceptability among patients with different pain diagnoses or accompanying psychological diagnoses or disorders. Hidden placebo application was considered much more unacceptable for the patients than the enhanced placebo or the open placebo application. An improved condition was associated with less feeling of deception, more trust and less negative mood than an unchanged or worsened condition. Conclusion Acceptance of placebo as pain therapy is much more dependent on the way of application (hidden or open) or on the resulting condition (improved, unchanged or worsened) than on factors inherent in the individual patients.	[Wolter, Tilman; Kleinmann, Barbara] Univ Hosp Freiburg, Interdisciplinary Pain Ctr, Freiburg, Germany	University of Freiburg	Wolter, T (corresponding author), Univ Hosp Freiburg, Interdisciplinary Pain Ctr, Freiburg, Germany.	tilman.wolter@uniklinik-freiburg.de						Association A. M., 2016, AMA COD MED ETH; Avins AL, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-44; Beck AT, 1997, BEHAV RES THER, V35, P1039, DOI 10.1016/S0005-7967(97)00073-9; Bingel U, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001244; Blease C, 2016, BIOETHICS, V30, P407, DOI 10.1111/bioe.12245; Carvalho C, 2016, PAIN, V157, P2766, DOI 10.1097/j.pain.0000000000000700; Colloca L, 2006, PAIN, V124, P126, DOI 10.1016/j.pain.2006.04.005; Colloca L, 2010, PAIN, V151, P430, DOI 10.1016/j.pain.2010.08.007; Doering BK, 2012, TRENDS PHARMACOL SCI, V33, P165, DOI 10.1016/j.tips.2011.12.001; Enck P, 2013, NAT REV DRUG DISCOV, V12, P191, DOI 10.1038/nrd3923; Chaparro LE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004959.pub4; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; Fassler M, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-15; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Hrobjartsson A, 2003, EVAL HEALTH PROF, V26, P153, DOI 10.1177/0163278703026002002; Kam-Hansen S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3006175; Kaptchuk TJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015591; Kelley JM, 2012, PSYCHOTHER PSYCHOSOM, V81, P312, DOI 10.1159/000337053; Kisaalita N, 2014, PAIN, V155, P2638, DOI 10.1016/j.pain.2014.09.029; Kisaalita NR, 2012, J PAIN, V13, P891, DOI 10.1016/j.jpain.2012.06.003; Kisaalita NR, 2011, J PAIN, V12, P920, DOI 10.1016/j.jpain.2011.02.353; LEVINE JD, 1981, PAIN, V10, P379, DOI 10.1016/0304-3959(81)90099-3; Locher C, 2017, PAIN; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; Miller FG, 2005, PLOS MED, V2, P853, DOI 10.1371/journal.pmed.0020262; Miller FG, 2009, AM J BIOETHICS, V9, P39, DOI 10.1080/15265160903316263; Moseley JB, 2002, NEW ENGL J MED, V347, P81, DOI 10.1056/NEJMoa013259; Muller M, 2016, EUR J PAIN, V20, P1530, DOI 10.1002/ejp.877; Nagel B, 2002, SCHMERZ, V16, P263, DOI 10.1007/s00482-002-0162-1; Nilges P, 2015, SCHMERZ, V29, P649, DOI 10.1007/s00482-015-0019-z; Nilges P, 2010, SCHMERZ, V24, P209, DOI 10.1007/s00482-010-0908-0; Sandler AD, 2008, CHILD CARE HLTH DEV, V34, P104, DOI 10.1111/j.1365-2214.2007.00797.x; Sandler AD, 2010, J DEV BEHAV PEDIATR, V31, P369, DOI 10.1097/DBP.0b013e3181e121ed; Sinke C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118363; Sullivan M, 2005, J PAIN, V6, P215, DOI 10.1016/j.jpain.2005.01.347; Vase L, 2009, PAIN, V145, P36, DOI 10.1016/j.pain.2009.04.008	36	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2018	13	11							e0206968	10.1371/journal.pone.0206968	http://dx.doi.org/10.1371/journal.pone.0206968			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GZ4NU	30399194	Green Published, gold, Green Submitted			2023-01-03	WOS:000449374000036
J	Adusei, KA; Owusu-Ofori, A				Adusei, Kwame Agyemang; Owusu-Ofori, Alex			Prevalence of Plasmodium parasitaemia in blood donors and a survey of the knowledge, attitude and practices of transfusion malaria among health workers in a hospital in Kumasi, Ghana	PLOS ONE			English	Article							TRANSMITTED MALARIA; FALCIPARUM MALARIA; TRANSMISSION; DIAGNOSIS	Malaria is one of the transfusion transmissible infections in malaria endemic countries such as Ghana. Healthy blood donors may harbour Plasmodium parasites without showing signs of malaria. Blood from such donors constitutes a risk to transfusion recipients and the recipients of this blood may go on to develop transfusion transmitted malaria (TTM). In many malaria endemic countries, blood donors are not screened for Plasmodium parasites. We investigated the prevalence of Plasmodium in blood donors in a hospital in Ghana as well as evaluate health workers knowledge, attitude and practices towards TTM. The study was carried out at the Kwadaso Seventh Day Adventist Hospital in Kumasi, Ghana from September 2016 to May 2017. Blood samples from 100 blood donors and 100 non-donors were examined for Plasmodium using microscopy and a rapid diagnostic test (RDT). In addition the blood groups of participants were determined. To obtain information concerning knowledge, attitude and practices of transfusion transmitted malaria, questionnaires were administered to 100 health workers including doctors, nurses and laboratory technicians. The prevalence rate of Plasmodium parasitaemia in blood donors by RDT and microscopy was 8% and 3% respectively, compared to non-donors who had a prevalence of 5% and 2% by RDT and microscopy respectively. Out of 100 health workers surveyed, 26% (26/100) had never heard of transfusion transmitted malaria. In an emergency situation, 41% health workers were willing to transfuse malaria positive blood but only 2%, 4% and 8% were willing to transfuse blood that was positive for HIV, Hepatitis B and Syphilis respectively. Regular training workshops may help improve the knowledge of health workers as a quarter of workers had not heard about transfusion transmitted malaria and 6.8% did not know that malaria was transmissible by transfusion.	[Adusei, Kwame Agyemang] Kwame Nkrumah Univ Sci & Technol, Med Lab Technol, Kumasi, Ghana; [Owusu-Ofori, Alex] Kwame Nkrumah Univ Sci & Technol, Dept Clin Microbiol, Kumasi, Ghana	Kwame Nkrumah University Science & Technology; Kwame Nkrumah University Science & Technology	Adusei, KA (corresponding author), Kwame Nkrumah Univ Sci & Technol, Med Lab Technol, Kumasi, Ghana.	kwameagadusie@gmail.com	Owusu-Ofori, Alex/AAU-9071-2020	adusei, kwame/0000-0002-8909-5178; Owusu-Ofori, Alex Kwame/0000-0002-2172-8645				Alli J. A., 2010, Research Journal of Medical Sciences, V4, P255, DOI 10.3923/rjmsci.2010.255.275; Appiah-Darkwah I., 2011, International Journal of Tropical Medicine, V6, P61; Ayensu F, 2016, DOMA INT J RES DUR, V1, P75; BRUCECHW.LJ, 1974, B WORLD HEALTH ORGAN, V50, P337; Chattopadhyay R, 2011, TRANSFUSION, V51, P630, DOI 10.1111/j.1537-2995.2010.02872.x; Cserti CM, 2007, BLOOD, V110, P2250, DOI 10.1182/blood-2007-03-077602; Diop S, 2009, TRANSFUS CLIN BIOL, V16, P454, DOI 10.1016/j.tracli.2009.02.004; Directorate Generale of Health Services (BANBACT), 2013, MOH TECHN ASS WHO SU; District Health Information System, 2016, MAL CONTR SURV B; GARFIELD MD, 1978, JAMA-J AM MED ASSOC, V240, P2285, DOI 10.1001/jama.240.21.2285; Kakkilaya BS, 2003, LAB MED, V34, P602, DOI 10.1309/J4ANKCCJ147JB2FR; Kim S, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0633-3; Kitchen AD, 2006, VOX SANG, V90, P77, DOI 10.1111/j.1423-0410.2006.00733.x; Mouatcho JC, 2013, J MED MICROBIOL, V62, P1491, DOI 10.1099/jmm.0.052506-0; Nag Ipsita, 2012, Asian J Transfus Sci, V6, P54, DOI 10.4103/0973-6247.95059; Owusu-Ofori A, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1289-3; Owusu-Ofori AK, 2010, CLIN INFECT DIS, V51, P1192, DOI 10.1086/656806; Pathirana SL, 2005, ANN TROP MED PARASIT, V99, P119, DOI 10.1179/136485905X19946; Periyavan Sundar, 2010, Asian J Transfus Sci, V4, P41, DOI 10.4103/0973-6247.59391; Ross R., 1911, PREVENTION MALARIA; Seed CR, 2005, TRANSFUS MED REV, V19, P229, DOI 10.1016/j.tmrv.2005.02.004; Strom GEA, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-417; Tagny CT, 2010, TRANSFUSION MED, V20, P1, DOI 10.1111/j.1365-3148.2009.00958.x; Tela I, 2015, R A J APPL RES, V1, P255, DOI [DOI 10.18535/RAJAR/V18531I18537.18504, 10.18535/rajar/v18531i18537.18504]; Thongdee P, 2014, KOREAN J PARASITOL, V52, P377, DOI [10.3347/kjp.2014.52.4.377, 10.3347/kjp.2014.52.4.377.]; Ukaga CN, 2011, NIGERIAN J PARASITOL, V32, P175; Vareil MO, 2011, EMERG INFECT DIS, V17, P248, DOI 10.3201/eid1702.100595; Warhurst D, 1996, J CLIN PATHOL, P49; WHO, PREQ DIAGN PROGR PUB; WHO, 2009, GLOB MAL PROGR PREGN; WHO, 2009, BLOOD TRANSF SAF TES; Wongsrichanalai C, 2007, AM J TROP MED HYG, V77, P119, DOI 10.4269/ajtmh.2007.77.119; World Health Organization, 2016, MAL PAR COUNT MAL MI; World Health Organization (WHO), 2015, WORLD MALARIA REPORT	34	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2018	13	11							e0206303	10.1371/journal.pone.0206303	http://dx.doi.org/10.1371/journal.pone.0206303			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ3MT	30395615	gold, Green Published, Green Submitted			2023-01-03	WOS:000449291400019
J	Gao, K				Gao, Kate			Analyzing the drug overdose epidemic in the United States	NATURE MEDICINE			English	Editorial Material														Gao, Peng (Kate)/0000-0002-6557-8511					0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2018	24	11					1637	1637		10.1038/s41591-018-0261-x	http://dx.doi.org/10.1038/s41591-018-0261-x			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	GZ4VS	30401865	Bronze			2023-01-03	WOS:000449404200008
J	Gill, ML; Grahn, P; Calvert, JS; Linde, MB; Lavrov, IA; Strommen, JA; Beck, LA; Sayenko, DG; Van Straaten, MG; Drubach, DI; Veith, DD; Thoreson, AR; Lopez, C; Gerasimenko, YP; Edgerton, VR; Lee, KH; Zhao, KD				Gill, Megan L.; Grahn, Peteri; Calvert, Jonathan S.; Linde, Margaux B.; Lavrov, Igor A.; Strommen, Jeffrey A.; Beck, Lisa A.; Sayenko, Dimitry G.; Van Straaten, Meegan G.; Drubach, Dina, I; Veith, Daniel D.; Thoreson, Andrew R.; Lopez, Cesar; Gerasimenko, Yury P.; Edgerton, V. Reggie; Lee, Kendall H.; Zhao, Kristin D.			Neuromodulation of lumbosacral spinal networks enables independent stepping after complete paraplegia	NATURE MEDICINE			English	Article							CORD-INJURY; EPIDURAL STIMULATION; ELECTRICAL-STIMULATION; VOLITIONAL CONTROL; HUMANS; WALKING; RATS; MOVEMENTS; RECOVERY; POTENTIALS	Spinal sensorimotor networks that are functionally disconnected from the brain because of spinal cord injury (SCI) can be facilitated via epidural electrical stimulation (EES) to restore robust, coordinated motor activity in humans with paralysis(1-3). Previously, we reported a clinical case of complete sensorimotor paralysis of the lower extremities in which EES restored the ability to stand and the ability to control step-like activity while side-lying or suspended vertically in a body-weight support system (BWS)(4). Since then, dynamic task-specific training in the presence of EES, termed multimodal rehabilitation (MMR), was performed for 43 weeks and resulted in bilateral stepping on a treadmill, independent from trainer assistance or BWS. Additionally, MMR enabled independent stepping over ground while using a front-wheeled walker with trainer assistance at the hips to maintain balance. Furthermore, MMR engaged sensorimotor networks to achieve dynamic performance of standing and stepping. To our knowledge, this is the first report of independent stepping enabled by task-specific training in the presence of EES by a human with complete loss of lower extremity sensorimotor function due to SCI.	[Gill, Megan L.; Linde, Margaux B.; Strommen, Jeffrey A.; Beck, Lisa A.; Van Straaten, Meegan G.; Veith, Daniel D.; Thoreson, Andrew R.; Lopez, Cesar; Lee, Kendall H.; Zhao, Kristin D.] Mayo Clin, Rehabil Med Res Ctr, Dept Phys Med & Rehabil, Rochester, MN 55905 USA; [Grahn, Peteri; Lavrov, Igor A.; Drubach, Dina, I; Lee, Kendall H.; Zhao, Kristin D.] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA; [Calvert, Jonathan S.] Mayo Clin, Grad Sch Biomed Sci, Rochester, MN USA; [Lavrov, Igor A.] Mayo Clin, Dept Biomed Engn, Rochester, MN USA; [Lavrov, Igor A.] Kazan Fed Univ, Inst Fundamental Med & Biol, Kazan, Russia; [Sayenko, Dimitry G.; Gerasimenko, Yury P.; Edgerton, V. Reggie] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA USA; [Sayenko, Dimitry G.] Houston Methodist Res Inst, Ctr Neuroregenerat, Dept Neurosurg, Houston, TX USA; [Gerasimenko, Yury P.] Russian Acad Sci, Pavlov Inst Physiol, St Petersburg, Russia; [Lee, Kendall H.; Zhao, Kristin D.] Mayo Clin, Dept Physiol & Biomed Engn, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Kazan Federal University; University of California System; University of California Los Angeles; The Methodist Hospital System; The Methodist Hospital - Houston; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Pavlov Institute of Physiology Russian Academy of Sciences; Mayo Clinic	Lee, KH; Zhao, KD (corresponding author), Mayo Clin, Rehabil Med Res Ctr, Dept Phys Med & Rehabil, Rochester, MN 55905 USA.; Lee, KH; Zhao, KD (corresponding author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.; Lee, KH; Zhao, KD (corresponding author), Mayo Clin, Dept Physiol & Biomed Engn, Rochester, MN 55905 USA.	lee.kendall@mayo.edu; zhao.kristin@mayo.edu	Lavrov, Igor/E-4334-2016; Calvert, Jonathan/AAW-3147-2021; Sayenko, Dimitry/AAP-4936-2020; Gerasimenko, Yury/A-3655-2017	Lavrov, Igor/0000-0002-3885-4509; Calvert, Jonathan/0000-0001-7197-9082; Sayenko, Dimitry/0000-0002-4154-6873; 	Grainger Foundation; Jack Jablonski Bel13ve in Miracles Foundation; Mayo Clinic Rehabilitation Medicine Research Center; Craig H. Neilsen Foundation; Regenerative Medicine Minnesota; Mayo Clinic Center for Regenerative Medicine; Mayo Clinic Graduate School of Biomedical Sciences; Dana and Albert R. Broccoli Charitable Foundation; Christopher and Dana Reeve Foundation; Walkabout Foundation; Mayo Clinic Transform the Practice	Grainger Foundation; Jack Jablonski Bel13ve in Miracles Foundation; Mayo Clinic Rehabilitation Medicine Research Center; Craig H. Neilsen Foundation; Regenerative Medicine Minnesota; Mayo Clinic Center for Regenerative Medicine; Mayo Clinic Graduate School of Biomedical Sciences; Dana and Albert R. Broccoli Charitable Foundation; Christopher and Dana Reeve Foundation; Walkabout Foundation; Mayo Clinic Transform the Practice	We thank the participant for his time, effort, and continuous feedback throughout the study. We also thank C. Blaha, J. Chen, B. Cloud, T. Gardner, D. Hare, Y. Li, A. Mendez, C. Mitrovich, A. Schmeling, T. Scrabeck, M. Shaft, C. Stoppel, B. Wessel, and L. Zoecklein as well as the surgical team for their support during EES system implantation. K.H.L. received funding from The Grainger Foundation. K.H.L. and K.D.Z. received funding from the Jack Jablonski Bel13ve in Miracles Foundation, Mayo Clinic Rehabilitation Medicine Research Center, Mayo Clinic Transform the Practice, and Craig H. Neilsen Foundation. P.J.G. was supported by Regenerative Medicine Minnesota and the Mayo Clinic Center for Regenerative Medicine. J.S.C. was supported by the Mayo Clinic Graduate School of Biomedical Sciences. V.R.E. received funding from the Dana and Albert R. Broccoli Charitable Foundation, the Christopher and Dana Reeve Foundation, and the Walkabout Foundation.	Angeli CA, 2014, BRAIN, V137, P1394, DOI 10.1093/brain/awu038; [Anonymous], 2016, AM J NEUROPROT NEURO, DOI [DOI 10.1166/AJNN.2016.1120, 10.1166/ajnn.2016.1120]; Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; Capogrosso M, 2016, NATURE, V539, P284, DOI 10.1038/nature20118; Carhart MR, 2004, IEEE T NEUR SYS REH, V12, P32, DOI 10.1109/TNSRE.2003.822763; Courtine G, 2015, NEURON, V86, P29, DOI 10.1016/j.neuron.2015.02.039; Danner SM, 2015, BRAIN, V138, P577, DOI 10.1093/brain/awu372; Dimitrijevic M R, 1988, Adv Neurol, V47, P138; Dimitrijevic MR, 1998, ANN NY ACAD SCI, V860, P360, DOI 10.1111/j.1749-6632.1998.tb09062.x; DIMITRIJEVIC MR, 1983, ELECTROEN CLIN NEURO, V56, pS68; Dobkin B, 2006, NEUROLOGY, V66, P484, DOI 10.1212/01.wnl.0000202600.72018.39; Field-Fote EC, 2011, PHYS THER, V91, P48, DOI 10.2522/ptj.20090359; Forrest GF, 2008, J SPINAL CORD MED, V31, P509, DOI 10.1080/10790268.2008.11753646; Gad P, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00333; Gerasimenko YP, 2007, J NEUROPHYSIOL, V98, P2525, DOI 10.1152/jn.00836.2007; Gerasimenko YP, 2015, J NEUROTRAUM, V32, P1968, DOI 10.1089/neu.2015.4008; Grahn PJ, 2017, MAYO CLIN PROC, V92, P544, DOI 10.1016/j.mayocp.2017.02.014; Harkema S. J., 2011, LOCOMOTOR TRAINING P, P54; Harkema S, 2011, LANCET, V377, P1938, DOI 10.1016/S0140-6736(11)60547-3; Harkema SJ, 2012, ARCH PHYS MED REHAB, V93, P1508, DOI 10.1016/j.apmr.2011.01.024; Huang H, 2006, IEEE T NEUR SYS REH, V14, P14, DOI 10.1109/TNSRE.2005.862694; Ichiyama RM, 2005, NEUROSCI LETT, V383, P339, DOI 10.1016/j.neulet.2005.04.049; Kakulas B A, 1984, Cent Nerv Syst Trauma, V1, P117; Lavrov I, 2008, J NEUROSCI, V28, P6022, DOI 10.1523/JNEUROSCI.0080-08.2008; Lavrov I, 2008, J NEUROSCI, V28, P7774, DOI 10.1523/JNEUROSCI.1069-08.2008; Lu DC, 2016, NEUROREHAB NEURAL RE, V30, P951, DOI 10.1177/1545968316644344; Minassian K, 2004, SPINAL CORD, V42, P401, DOI 10.1038/sj.sc.3101615; Minassian K, 2016, CNS NEUROSCI THER, V22, P262, DOI 10.1111/cns.12530; Moritz CT, 2018, NEUROTHERAPEUTICS, V15, P628, DOI 10.1007/s13311-018-0637-0; Rattay F, 2000, SPINAL CORD, V38, P473, DOI 10.1038/sj.sc.3101039; Rejc E, 2017, J NEUROTRAUM, V34, P1787, DOI 10.1089/neu.2016.4516; Rejc E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133998; Sayenko DG, 2015, NEUROSCI LETT, V609, P229, DOI 10.1016/j.neulet.2015.10.005; Sayenko DG, 2015, J APPL PHYSIOL, V118, P1364, DOI 10.1152/japplphysiol.01128.2014; Sayenko DG, 2014, J NEUROPHYSIOL, V111, P1088, DOI 10.1152/jn.00489.2013; Shah PK, 2017, NEUROSCIENTIST, V23, P664, DOI 10.1177/1073858417699554; Shah PK, 2012, EUR J NEUROSCI, V36, P2054, DOI 10.1111/j.1460-9568.2012.08106.x; SHERWOOD AM, 1992, J NEUROL SCI, V110, P90, DOI 10.1016/0022-510X(92)90014-C; Taccola G, 2018, PROG NEUROBIOL, V160, P64, DOI 10.1016/j.pneurobio.2017.10.004; van den Brand R, 2012, SCIENCE, V336, P1182, DOI 10.1126/science.1217416; Wenger N, 2016, NAT MED, V22, P138, DOI 10.1038/nm.4025; Wenger N, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008325	42	231	245	3	55	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2018	24	11					1677	+		10.1038/s41591-018-0175-7	http://dx.doi.org/10.1038/s41591-018-0175-7			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	GZ4VS	30250140				2023-01-03	WOS:000449404200018
J	Pedersen, PB; Hrobjartsson, A; Nielsen, DL; Henriksen, DP; Brabrand, M; Lassen, AT				Pedersen, Peter Bank; Hrobjartsson, Asbjorn; Nielsen, Daniel Lykke; Henriksen, Daniel Pilsgaard; Brabrand, Mikkel; Lassen, Annmarie Touborg			Prevalence and prognosis of acutely ill patients with organ failure at arrival to hospital: A systematic review	PLOS ONE			English	Review							INFLAMMATORY RESPONSE SYNDROME; EMERGENCY-DEPARTMENT PATIENTS; INTENSIVE-CARE UNITS; SEVERE SEPSIS; DYSFUNCTION; MORTALITY; SOFA; SCORE	Introduction Patients in an emergency department are diverse. Some are more seriously ill than others and some even arrive in multi-organ failure. Knowledge of the prevalence of organ failure and its prognosis in unselected patients is important from a diagnostic, hospital planning, and from a quality evaluation point of view, but is not reported systematically. Objectives To analyse the prevalence and prognosis of new onset organ failure in unselected acute patients at arrival to hospital. Methods A systematic review of studies of prevalence and prognosis of acutely ill patients with organ failure at arrival to hospital. We searched PubMed, Cochrane Library, Embase and Cinahl, and read references in included studies. Two authors decided independently on study eligibility and extracted data. Results were summarised qualitatively. Results Four studies were included with a total of 678,960 patients. The number of different organ failures reported in the studies ranged from one to six, and the settings were emergency departments and wards. The definitions of organ failure varied between studies. The prevalence of organ failure was 7%, 14%, 14%, and 23%, and in-hospital mortality was 5%, 11% and 15% respectively. The relative risk of in-hospital mortality for patients with organ failure compared to patients without organ failure varied from 2.58 to 8.65. Numbers of organ failures per 1,000 visits varied from 71 to 256. Conclusion The results of this review indicate that clinicians have good reasons to be alert when a patient arrives to the emergency department; as a state of organ failure seems both frequent and highly severe. However, most studies identified were performed in patients after a diagnosis was established, and only very few studies were performed in unselected patients. Systematic review registration number PROSPERO: CRD42017060871.	[Pedersen, Peter Bank; Nielsen, Daniel Lykke; Henriksen, Daniel Pilsgaard; Brabrand, Mikkel; Lassen, Annmarie Touborg] Odense Univ Hosp, Dept Emergency Med, Odense, Denmark; [Pedersen, Peter Bank; Lassen, Annmarie Touborg] Univ Southern Denmark, Inst Clin Res, Odense, Denmark; [Hrobjartsson, Asbjorn] Univ Southern Denmark, Ctr Evidence Based Med, Odense, Denmark; [Hrobjartsson, Asbjorn] Odense Univ Hosp, Odense, Denmark; [Henriksen, Daniel Pilsgaard] Odense Univ Hosp, Dept Resp Med, Odense, Denmark; [Brabrand, Mikkel] Hosp South West Jutland, Dept Emergency Med, Esbjerg, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; University of Southern Denmark; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital	Pedersen, PB (corresponding author), Odense Univ Hosp, Dept Emergency Med, Odense, Denmark.; Pedersen, PB (corresponding author), Univ Southern Denmark, Inst Clin Res, Odense, Denmark.	Peter.Bank.Pedersen@rsyd.dk	Lassen, Annmarie/AAA-5816-2019; Brabrand, Mikkel/F-7276-2011	Henriksen, Daniel Pilsgaard/0000-0003-1303-6195; Brabrand, Mikkel/0000-0002-3340-8251; Lassen, Annmarie/0000-0003-4942-6152; Bank Pedersen, Peter/0000-0002-2831-674X	University of Southern Denmark; Region of Southern Denmark; private philanthropic fund TrygFonden	University of Southern Denmark; Region of Southern Denmark; private philanthropic fund TrygFonden	No external funding has been received for this review. PBP was supported by the University of Southern Denmark and the Region of Southern Denmark and DLN was supported by the Foundation of December 17, 1981, but they were not involved in any aspect of this systematic review, and had no influence on the study results or publication, and no role in study design, data collection or analysis. ATL received an unrestricted grant from the private philanthropic fund TrygFonden given to the University of Southern Denmark.	Angus DC, 2013, NEW ENGL J MED, V369, P840, DOI [10.1056/NEJMra1208623, 10.1056/NEJMc1312359]; Benns M, 2013, J TRAUMA ACUTE CARE, V75, P426, DOI 10.1097/TA.0b013e31829cfa19; Bingold TM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134329; Challiner R, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-84; Chen YX, 2014, CRIT CARE, V18, DOI 10.1186/cc13832; Churpek MM, 2015, AM J RESP CRIT CARE, V192, P958, DOI 10.1164/rccm.201502-0275OC; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Guirgis FW, 2016, J TRAUMA ACUTE CARE, V81, P525, DOI 10.1097/TA.0000000000001135; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Hayden JA, 2006, ANN INTERN MED, V144, P427, DOI 10.7326/0003-4819-144-6-200603210-00010; Henriksen DP, 2015, CRIT CARE MED, V43, P13, DOI 10.1097/CCM.0000000000000611; Jessen MK, 2015, EUROPEAN J EMERGENCY; Kakebeeke D, 2013, INT J EMERG MED, V6, DOI 10.1186/1865-1380-6-4; Levy MM, 2012, LANCET INFECT DIS, V12, P919, DOI 10.1016/S1473-3099(12)70239-6; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Linder A, 2015, CRIT CARE MED, V43, P2378, DOI 10.1097/CCM.0000000000001265; Lindvig KP, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/1757-7241-22-39; Lone NI, 2012, AM J RESP CRIT CARE, V186, P640, DOI 10.1164/rccm.201201-0059OC; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Macdonald SPJ, 2014, ACAD EMERG MED, V21, P1257, DOI 10.1111/acem.12515; Moher D, 2015, STATEMENT SYST REV, V4, DOI [10.1186/2046-4053-4-1, DOI 10.1186/2046-4053-4-1, 10.1186/s13643-015-0163-7, DOI 10.14306/RENHYD.20.2.223]; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Pedersen PB, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0622-4; Quinten VM, 2011, EUROPEAN J EMERGENCY; Ranzani OT, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0986-6; Rohde JM, 2013, J HOSP MED, V8, P243, DOI 10.1002/jhm.2012; Ryan R., 2016, HETEROGENEITY SUBGRO, V1, P1; Ryan R, 2016, GRADE QUALITY EVIDEN; Sakr Y, 2012, CRIT CARE, V16, DOI 10.1186/cc11868; Shapiro N, 2006, ANN EMERG MED, V48, P583, DOI 10.1016/j.annemergmed.2006.07.007; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wells G.A., 2014, APPL ENG AGRIC, V18, P727; Williams JM, 2017, CHEST, V151, P586, DOI 10.1016/j.chest.2016.10.057	35	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 1	2018	13	11							e0206610	10.1371/journal.pone.0206610	http://dx.doi.org/10.1371/journal.pone.0206610			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ0DG	30383864	Green Published, gold, Green Submitted			2023-01-03	WOS:000449027600073
J	Sudirman, S; Hsu, YH; He, JL; Kong, ZL				Sudirman, Sabri; Hsu, Yuan-Hua; He, Jia-Ling; Kong, Zwe-Ling			Dietary polysaccharide-rich extract from Eucheuma cottonii modulates the inflammatory response and suppresses colonic injury on dextran sulfate sodium-induced colitis in mice	PLOS ONE			English	Article							NECROSIS-FACTOR-ALPHA; KAPPAPHYCUS-ALVAREZII; COLORIMETRIC DETERMINATION; MARINE-ALGAE; FIBER; SEAWEEDS; DISEASE; TUMOR; HOST; 3,6-ANHYDROGALACTOSE	Inflammatory bowel disease (IBD) is a known medical burden in most developed countries and a significant cause of morbidity. The IBD label includes Crohn's disease (CD) and ulcerative colitis (UC). Pharmacological and surgical intervention are the two main management approaches for IBD. Some drugs have been developed for IBD therapy, but accessibility is limited due to high costs. Furthermore, these agents have demonstrated inactivity over long-term treatment courses. Therefore, an urgent need is present for new treatment options that are safe, able to sustain clinical remission, and improve mucosal gut healing. Seaweed has received much attention in the pharmacological field owing to its various biomedical properties, including the prolongation of blood clotting time, as well as antitumor, anti-inflammation, and antioxidant effects. This study therefore aimed to examine the effects of a dietary polysaccharide-rich extract obtained from Eucheuma cottonii (EC) on a model of colitis. Colitis was induced in male BALB/c mice by the administration of 2.5% (w/v) dextran sulfate sodium (DSS) for 7 days. DSS-induced mice were treated with either one of three different doses of EC extracts (0.35, 0.70, and 1.75 g/kg body weight) or curcumin as a positive control (0.10 g/kg). Mice were sacrificed post-treatment and blood samples were collected. The disease activity index (DAI) and inflammatory cytokine levels (tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, IL-6, IL-10) were measured. After treatment for 7 days, EC extract administration protected against weight loss and decreased the colon weight per length ratio. EC extract administration also decreased pro-inflammatory cytokine expression, increased IL-10 levels, and reduced colonic damage. Therefore, a dietary polysaccharide-rich extract from E. cottonii reduced DSS-induced bowel inflammation, thereby becoming a promising candidate for the treatment of colitis.	[Sudirman, Sabri; Hsu, Yuan-Hua; He, Jia-Ling; Kong, Zwe-Ling] Natl Taiwan Ocean Univ, Dept Food Sci, Keelung, Taiwan	National Taiwan Ocean University	Kong, ZL (corresponding author), Natl Taiwan Ocean Univ, Dept Food Sci, Keelung, Taiwan.	kongzl@mail.ntou.edu.tw	Kong, Zwe-Ling/E-8763-2013; Kong, Zwe-Ling/AAB-5328-2019; Sudirman, Sabri/O-2980-2018; Kong, Zwe-Ling/AAB-5261-2019	Kong, Zwe-Ling/0000-0002-4877-6524; Kong, Zwe-Ling/0000-0002-4877-6524; Sudirman, Sabri/0000-0003-2821-3772; He, Jia-Ling/0000-0002-1194-2533				Abdelali A, 2016, TOXICOL APPL PHARM, V311, P61, DOI 10.1016/j.taap.2016.09.023; Abu Bakar N, 2015, J FUNCT FOODS, V19, P710, DOI 10.1016/j.jff.2015.10.011; Arafa HMM, 2009, FOOD CHEM TOXICOL, V47, P1311, DOI 10.1016/j.fct.2009.03.003; Bakar Nurul'Ain Abu, 2017, J Microsc Ultrastruct, V5, P70, DOI 10.1016/j.jmau.2016.08.001; Barbalho SM, 2018, J MED FOOD, V21, P633, DOI 10.1089/jmf.2017.0120; Bitencourt MAO, 2015, REV BRAS FARMACOGN, V25, P677, DOI 10.1016/j.bjp.2015.10.001; da Matta CBB, 2011, MAR DRUGS, V9, P307, DOI 10.3390/md9030307; Brito TV, 2016, CARBOHYD POLYM, V151, P957, DOI 10.1016/j.carbpol.2016.06.047; Brumatti LV, 2014, MOLECULES, V19, P21127, DOI 10.3390/molecules191221127; Campo VL, 2009, CARBOHYD POLYM, V77, P167, DOI 10.1016/j.carbpol.2009.01.020; Chang VS, 2017, BIOMED PHARMACOTHER, V87, P296, DOI 10.1016/j.biopha.2016.12.092; Chassaing Benoit, 2014, Curr Protoc Immunol, V104, DOI 10.1002/0471142735.im1525s104; Cho EJ, 2011, J ETHNOPHARMACOL, V136, P428, DOI 10.1016/j.jep.2010.04.047; Cosnes J, 2011, GASTROENTEROLOGY, V140, P1785, DOI 10.1053/j.gastro.2011.01.055; D'Orazio N, 2012, MAR DRUGS, V10, P812, DOI 10.3390/md10040812; de Souza ET, 2009, MAR DRUGS, V7, P689, DOI 10.3390/md7040689; Dhingra D, 2012, J FOOD SCI TECH MYS, V49, P255, DOI 10.1007/s13197-011-0365-5; Fard SG, 2011, J ANIM VET ADV, V10, P601, DOI 10.3923/javaa.2011.601.605; Fayaz M, 2005, J AGR FOOD CHEM, V53, P792, DOI 10.1021/jf0493627; Galvez J, 2005, MOL NUTR FOOD RES, V49, P601, DOI 10.1002/mnfr.200500013; Ghani NAA, 2019, ARAB J CHEM, V12, P370, DOI 10.1016/j.arabjc.2018.06.008; Gomez-Ordonez E, 2010, FOOD RES INT, V43, P2289, DOI 10.1016/j.foodres.2010.08.005; Gommeaux J, 2007, MOL CELL BIOL, V27, P2215, DOI 10.1128/MCB.01454-06; Hamamoto N, 1999, CLIN EXP IMMUNOL, V117, P462; Hendrickson BA, 2002, CLIN MICROBIOL REV, V15, P79, DOI 10.1128/CMR.15.1.79-94.2002; Hwang Eun-Sun, 2014, Prev Nutr Food Sci, V19, P40, DOI 10.3746/pnf.2014.19.1.040; Ilott NE, 2016, ISME J, V10, P2389, DOI 10.1038/ismej.2016.40; Jeon YD, 2016, MOLECULES, V21, DOI 10.3390/molecules21040523; Jimenez-Escrig A, 2000, NUTR RES, V20, P585, DOI 10.1016/S0271-5317(00)00149-4; Kai Y, 2005, GASTROENTEROLOGY, V128, P922, DOI 10.1053/j.gastro.2005.01.013; Kaplan GG, 2015, NAT REV GASTRO HEPAT, V12, P720, DOI 10.1038/nrgastro.2015.150; KIM DB, 2013, EVID-BASED COMPL ALT, DOI DOI 10.1155/2013/671281; Kim SJ, 2010, MOLECULES, V15, P7208, DOI 10.3390/molecules15107208; Kitajima S, 2000, EXP ANIM TOKYO, V49, P9, DOI 10.1538/expanim.49.9; Koh A, 2016, CELL, V165, P1332, DOI 10.1016/j.cell.2016.05.041; Kumar KS, 2008, FOOD CHEM, V107, P289, DOI 10.1016/j.foodchem.2007.08.016; Lean QY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128453; Lee J, 2017, ANN PHARM PHARM, V2, P1056; Li MC, 2004, WORLD J GASTROENTERO, V10, P620, DOI 10.3748/wjg.v10.i5.620; Liang WA, 2014, CARBOHYD POLYM, V101, P776, DOI 10.1016/j.carbpol.2013.10.010; Lim C.L., 2015, J MED BIOENG, V4, P461, DOI [10.12720/jomb.4.6.461-465, DOI 10.12720/JOMB.4.6.461-465]; Makki K, 2018, CELL HOST MICROBE, V23, P705, DOI 10.1016/j.chom.2018.05.012; Matanjun P, 2008, J APPL PHYCOL, V20, P367, DOI 10.1007/s10811-007-9264-6; MATSUHIRO B, 1983, CARBOHYD RES, V118, P276, DOI 10.1016/0008-6215(83)88056-2; Molodecky NA, 2012, GASTROENTEROLOGY, V142, P46, DOI 10.1053/j.gastro.2011.10.001; Myers KJ, 2003, J PHARMACOL EXP THER, V304, P411, DOI 10.1124/jpet.102.040329; Namvar F, 2014, INDIAN J CLIN BIOCHE, V29, P13, DOI 10.1007/s12291-013-0313-4; Namvar F, 2012, FOOD CHEM, V130, P376, DOI 10.1016/j.foodchem.2011.07.054; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Park Yo Han, 2015, J Cancer Prev, V20, P260, DOI 10.15430/JCP.2015.20.4.260; Pugliese D, 2017, EXPERT REV CLIN IMMU, V13, P223, DOI 10.1080/1744666X.2017.1243468; Raman M, 2015, J FUNCT FOODS, V15, P354, DOI 10.1016/j.jff.2015.03.037; Randhawa PK, 2014, KOREAN J PHYSIOL PHA, V18, P279, DOI 10.4196/kjpp.2014.18.4.279; Rodriguez-Cabezas ME, 2002, J NUTR, V132, P3263, DOI 10.1093/jn/132.11.3263; Rooks MG, 2014, ISME J, V8, P1403, DOI 10.1038/ismej.2014.3; Shamsabadi FT, 2013, NUTR CANCER, V65, P255, DOI 10.1080/01635581.2013.756528; Soriano A, 2000, LAB INVEST, V80, P1541, DOI 10.1038/labinvest.3780164; Su LP, 2013, GASTROENTEROLOGY, V145, P407, DOI 10.1053/j.gastro.2013.04.011; Torres FAE, 2014, REV BRAS FARMACOGN, V24, P265, DOI 10.1016/j.bjp.2014.07.001; Triantafillidis JK, 2011, DRUG DES DEV THER, V5, P185, DOI 10.2147/DDDT.S11290; Ung VYL, 2010, DIGEST DIS SCI, V55, P1272, DOI 10.1007/s10620-009-0843-z; VANDELOOSDRECHT AA, 1994, J IMMUNOL METHODS, V174, P311, DOI 10.1016/0022-1759(94)90034-5; Wanyonyi S, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111261; Yang Joon-Yeop, 2013, J Cancer Prev, V18, P186; YAPHE W, 1960, ANAL CHEM, V32, P1327, DOI 10.1021/ac60166a030	65	25	25	6	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2018	13	10							e0205252	10.1371/journal.pone.0205252	http://dx.doi.org/10.1371/journal.pone.0205252			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW0HY	30289911	Green Published, gold, Green Submitted			2023-01-03	WOS:000446545500059
J	Heinonen, M; Milliat, F; Benadjaoud, MA; Francois, A; Buard, V; Tarlet, G; d'Alche-Buc, F; Guipaud, O				Heinonen, Markus; Milliat, Fabien; Benadjaoud, Mohamed Amine; Francois, Agnes; Buard, Valerie; Tarlet, Georges; d'Alche-Buc, Florence; Guipaud, Olivier			Temporal clustering analysis of endothelial cell gene expression following exposure to a conventional radiotherapy dose fraction using Gaussian process clustering	PLOS ONE			English	Article							IONIZING-RADIATION; NORMAL TISSUE; TIME-SERIES; COEFFICIENT	The vascular endothelium is considered as a key cell compartment for the response to ionizing radiation of normal tissues and tumors, and as a promising target to improve the differential effect of radiotherapy in the future. Following radiation exposure, the global endothelial cell response covers a wide range of gene, miRNA, protein and metabolite expression modifications. Changes occur at the transcriptional, translational and post-translational levels and impact cell phenotype as well as the microenvironment by the production and secretion of soluble factors such as reactive oxygen species, chemokines, cytokines and growth factors. These radiation-induced dynamic modifications of molecular networks may control the endothelial cell phenotype and govern recruitment of immune cells, stressing the importance of clearly understanding the mechanisms which underlie these temporal processes. A wide variety of time series data is commonly used in bioinformatics studies, including gene expression, protein concentrations and metabolomics data. The use of clustering of these data is still an unclear problem. Here, we introduce kernels between Gaussian processes modeling time series, and subsequently introduce a spectral clustering algorithm. We apply the methods to the study of human primary endothelial cells (HUVECs) exposed to a radiotherapy dose fraction (2 Gy). Time windows of differential expressions of 301 genes involved in key cellular processes such as angiogenesis, inflammation, apoptosis, immune response and protein kinase were determined from 12 hours to 3 weeks post-irradiation. Then, 43 temporal clusters corresponding to profiles of similar expressions, including 49 genes out of 301 initially measured, were generated according to the proposed method. Forty-seven transcription factors (TFs) responsible for the expression of clusters of genes were predicted from sequence regulatory elements using the MotifMap system. Their temporal profiles of occurrences were established and clustered. Dynamic network interactions and molecular pathways of TFs and differential genes were finally explored, revealing key node genes and putative important cellular processes involved in tissue infiltration by immune cells following exposure to a radiotherapy dose fraction.	[Heinonen, Markus] Aalto Univ, Dept Informat & Comp Sci, Aalto, Finland; [Milliat, Fabien; Francois, Agnes; Buard, Valerie; Tarlet, Georges; Guipaud, Olivier] Inst Radiol Protect & Nucl Safety IRSN, PSE SANTE, SERAMED, LRMed, Fontenay Aux Roses, France; [Benadjaoud, Mohamed Amine] Inst Radiol Protect & Nucl Safety IRSN, PSE SANTE, SERAMED, Fontenay Aux Roses, France; [d'Alche-Buc, Florence] Univ Paris Saclay, LTCI, Telecom ParisTech, Paris, France	Aalto University; IMT - Institut Mines-Telecom; Institut Polytechnique de Paris; UDICE-French Research Universities; Universite Paris Saclay	Guipaud, O (corresponding author), Inst Radiol Protect & Nucl Safety IRSN, PSE SANTE, SERAMED, LRMed, Fontenay Aux Roses, France.	olivier.guipaud@irsn.fr		Milliat, Fabien/0000-0001-8249-9498; TARLET, Georges/0000-0002-4756-5127	Electricite de France (Groupe Gestion Projet Radioprotection); Institut de Radioprotection et de Surete Nucleaire (programme ROSIRIS)	Electricite de France (Groupe Gestion Projet Radioprotection); Institut de Radioprotection et de Surete Nucleaire (programme ROSIRIS)	This work has been supported by Electricite de France (Groupe Gestion Projet Radioprotection) and Institut de Radioprotection et de Surete Nucleaire (programme ROSIRIS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aijo T, 2009, BIOINFORMATICS, V25, P2937, DOI 10.1093/bioinformatics/btp511; Angelini C, 2007, STAT APPL GENET MOL, V6; Bach FR, 2004, ADV NEUR IN, V16, P305; Bar-Joseph Z, 2004, BIOINFORMATICS, V20, P2493, DOI 10.1093/bioinformatics/bth283; Borghini A, 2013, ATHEROSCLEROSIS, V230, P40, DOI 10.1016/j.atherosclerosis.2013.06.010; Caldas J, 2009, BIOINFORMATICS, V25, pI145, DOI 10.1093/bioinformatics/btp215; Chawla S, 2013, P 2013 SIAM INT C DA; Cheng JD, 2002, BIOCHEM BIOPH RES CO, V297, P1128, DOI 10.1016/S0006-291X(02)02301-X; Chung AS, 2010, NAT REV CANCER, V10, P505, DOI 10.1038/nrc2868; Conesa A, 2006, BIOINFORMATICS, V22, P1096, DOI 10.1093/bioinformatics/btl056; Cooke EJ, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-399; Corre I, 2013, INT J MOL SCI, V14, P22678, DOI 10.3390/ijms141122678; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Daily K, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-495; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; DeVita VT, 2011, ROSENBERGS CANC PRIN; Dudoit S, 2002, STAT SINICA, V12, P111; Duong T, 2011, KS KERNEL SMOOTHING; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Gao P, 2008, BIOINFORMATICS, V24, pI70, DOI 10.1093/bioinformatics/btn278; Guipaud O, 2018, BRIT J RADIOL, V91, DOI 10.1259/bjr.20170762; Heinonen M, 2015, BIOINFORMATICS, V31, P728, DOI 10.1093/bioinformatics/btu699; Hensman J, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-252; Holsclaw T, 2013, TECHNOMETRICS, V55, P57, DOI 10.1080/00401706.2012.723918; INMAN HF, 1989, COMMUN STAT THEORY, V18, P3851, DOI 10.1080/03610928908830127; Jaakkola T, 1999, Proc Int Conf Intell Syst Mol Biol, P149; Jebara T, 2004, J MACH LEARN RES, V5, P819; Jebara T, 2003, LECT NOTES ARTIF INT, V2777, P57, DOI 10.1007/978-3-540-45167-9_6; Kalaitzis AA, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-180; Karhunen K, 1947, ANN ACAD SCI FENNI A, V37, P1; Kim J, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-310; Kirk PDW, 2009, BIOINFORMATICS, V25, P1300, DOI 10.1093/bioinformatics/btp139; Laube M, 2016, ANTIOXIDANTS-BASEL, V5, DOI 10.3390/antiox5020014; Lawrence N. D., 2007, ADV NEURAL INFORM PR, P785; LEE YJ, 1995, J BIOL CHEM, V270, P28790, DOI 10.1074/jbc.270.48.28790; Liauw SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005148; Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64; Moding EJ, 2013, NAT REV DRUG DISCOV, V12, P526, DOI 10.1038/nrd4003; Moreno PJ, 2004, ADV NEUR IN, V16, P1385; Nikitin A, 2003, BIOINFORMATICS, V19, P2155, DOI 10.1093/bioinformatics/btg290; Potters L, 2010, INT J RADIAT ONCOL, V76, P326, DOI 10.1016/j.ijrobp.2009.09.042; Ramsay J.O., 2005, FUNCTIONAL DATA ANAL, VSecond; Rannou E, 2015, SCI REP-UK, V5, DOI 10.1038/srep15738; Rasmussen CE, 2003, BAYESIAN STATISTICS 7, P651; Rasmussen CE, 2005, ADAPT COMPUT MACH LE, P1; Riihimaki J., 2010, J MACH LEARN RES, V9, P645; Schliep A, 2005, IEEE ACM T COMPUT BI, V2, P179, DOI 10.1109/TCBB.2005.31; Schmid F, 2006, COMPUT STAT DATA AN, V50, P1583, DOI 10.1016/j.csda.2005.01.014; Simone CB, 2013, CHEST, V143, P1784, DOI 10.1378/chest.12-2580; Snyder AR, 2004, CANCER METAST REV, V23, P259, DOI 10.1023/B:CANC.0000031765.17886.fa; Solak E., 2002, P ADV NEUR INF PROC, P1033; Stegle O, 2010, J COMPUT BIOL, V17, P355, DOI 10.1089/cmb.2009.0175; Stone HB, 2003, LANCET ONCOL, V4, P529, DOI 10.1016/S1470-2045(03)01191-4; Storey JD, 2005, P NATL ACAD SCI USA, V102, P12837, DOI 10.1073/pnas.0504609102; Tamm I, 1998, CANCER RES, V58, P5315; Valerie K, 2007, MOL CANCER THER, V6, P789, DOI 10.1158/1535-7163.MCT-06-0596; von Luxburg U, 2007, STAT COMPUT, V17, P395, DOI 10.1007/s11222-007-9033-z; Weitzman M.S., 1970, MEASURES OVERLAP INC; Xie XH, 2009, BIOINFORMATICS, V25, P167, DOI 10.1093/bioinformatics/btn605; Yang C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016229; Yao F., 2015, PACE PACKAGE FUNCTIO; Yuan M, 2006, COMPUT STAT DATA AN, V51, P1754, DOI 10.1016/j.csda.2005.11.017	62	4	4	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2018	13	10							e0204960	10.1371/journal.pone.0204960	http://dx.doi.org/10.1371/journal.pone.0204960			31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV7VQ	30281653	Green Published, gold, Green Submitted			2023-01-03	WOS:000446342400072
J	Malling, ASB; Morberg, BM; Wermuth, L; Gredal, O; Bech, P; Jensen, BR				Malling, Anne Sofie Bogh; Morberg, Bo Mohr; Wermuth, Lene; Gredal, Ole; Bech, Per; Jensen, Bente Rona			Effect of transcranial pulsed electromagnetic fields (T-PEMF) on functional rate of force development and movement speed in persons with Parkinson's disease: A randomized clinical trial	PLOS ONE			English	Article							CHAIR-RISE PERFORMANCE; MAGNETIC STIMULATION; MUSCLE ACTIVATION; OLDER-ADULTS; FREQUENCY; NEUROGENESIS; EXPOSURE	Background Parkinson's disease is caused by dopaminergic neurodegeneration resulting in motor impairments as slow movement speed and impaired balance and coordination. Pulsed electromagnetic fields are suggested to have neuroprotective effects, and could alleviate symptoms. Objective To study 1) effects of 8-week daily transcranial pulsed electromagnetic field treatment on functional rate of force development and movement speed during two motor tasks with different levels of complexity, 2) if treatment effects depend on motor performance at baseline. Methods Ninety-seven persons with Parkinson's disease were randomized to active transcranial pulsed electromagnetic field (squared bipolar 3 ms pulses, 50 Hz) or placebo treatment with homebased treatment 30 min/day for 8 weeks. Functional rate of force development and completion time of a sit-to-stand and a dynamic postural balance task were assessed pre and post intervention. Participants were sub-grouped in high- and low-performers according to their baseline motor performance level. Repeated measure ANOVAs were used. Results Active treatment tended to improve rate of force development during chair rise more than placebo (P = 0.064). High-performers receiving active treatment improved rate of force development during chair rise more than high-performers receiving placebo treatment (P = 0.049, active/placebo: 11.9 +/- 1.1 to 12.5 +/- 1.9 BW/s approximate to 5% /12.4 +/- 1.3 to 12.2 +/- 1.3 BW/s, no change). No other between-treatment-group or between-treatment-subgroup differences were found. Data on rate of force development of the dynamic balance task and completion times of both motor tasks improved but did not allow for between-treatment differentiation. Conclusion Treatment with transcranial pulsed electromagnetic fields was superior to placebo regarding functional rate of force development during chair rise among high-performers. Active treatment tended to increase functional rate of force development while placebo did not. Our results suggest that mildly affected persons with Parkinson's disease have a larger potential for neural rehabilitation than more severely affected persons and indicate that early treatment initiation may be beneficial.	[Malling, Anne Sofie Bogh; Morberg, Bo Mohr; Wermuth, Lene; Jensen, Bente Rona] Univ Southern Denmark, Odense Univ Hosp, Dept Neurol, Odense, Denmark; [Malling, Anne Sofie Bogh; Morberg, Bo Mohr; Wermuth, Lene] Univ Southern Denmark, Dept Clin Res, Odense, Denmark; [Gredal, Ole] Danish Rehabil Ctr Neuromuscular Dis, Taastrup, Denmark; [Bech, Per] Univ Copenhagen, Psychiat Ctr North Zealand, Psychiat Res Unit, Hillerod, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; University of Copenhagen	Malling, ASB; Jensen, BR (corresponding author), Univ Southern Denmark, Odense Univ Hosp, Dept Neurol, Odense, Denmark.; Malling, ASB (corresponding author), Univ Southern Denmark, Dept Clin Res, Odense, Denmark.	amalling@health.sdu.dk; bente.r.jensen@rsyd.dk	Wermuth, Lene/O-9464-2014	Wermuth, Lene/0000-0001-6930-8562; Malling, Anne Sofie Bogh/0000-0002-9267-9334; Bech, Per/0000-0002-4948-6115	Den A. P. Mollerske Stottefond, Copenhagen, Denmark [10415]; Grosserer L. F. Foghts Fond, Charlottenlund, Denmark [20825]	Den A. P. Mollerske Stottefond, Copenhagen, Denmark; Grosserer L. F. Foghts Fond, Charlottenlund, Denmark	This work was supported by Den A. P. Mollerske Stottefond, Copenhagen, Denmark (grant# 10415, https://www.apmollerfonde.dk/ ansoegning/stoettefonden, received by Lene Wermuth) and Grosserer L. F. Foghts Fond, Charlottenlund, Denmark (grant# 20825, http://foghtsfond.dk, received by Ole Gredal). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arias-Carrion O, 2004, J NEUROSCI RES, V78, P16, DOI 10.1002/jnr.20235; Berthelsen MP, 2014, NEUROMUSCULAR DISORD, V24, P492, DOI 10.1016/j.nmd.2014.03.001; Bragin DE, 2015, J NEUROSURG, V122, P1239, DOI 10.3171/2014.8.JNS132083; Brucke T, 1997, J NEURAL TRANSM-SUPP, P9; Capone F, 2009, J NEURAL TRANSM, V116, P257, DOI 10.1007/s00702-009-0184-2; Cuccurazzu B, 2010, EXP NEUROL, V226, P173, DOI 10.1016/j.expneurol.2010.08.022; Di Lazzaro V, 2013, BRAIN STIMUL, V6, P469, DOI 10.1016/j.brs.2013.01.004; Dietz V, 1995, ELECTROMYOGR MOTOR C, V97, P408, DOI 10.1016/0924-980X(95)00109-X; Dimitrova D, 2004, J NEUROPHYSIOL, V91, P489, DOI 10.1152/jn.00094.2003; Fahn S.R.L.E., 1987, RECENT DEV PARKINSON; Fereshtehnejad SM, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0738-x; Fitzgerald PB, 2006, CLIN NEUROPHYSIOL, V117, P2584, DOI 10.1016/j.clinph.2006.06.712; Folland JP, 2014, SCAND J MED SCI SPOR, V24, P894, DOI 10.1111/sms.12131; Hammond KG, 2017, CLIN BIOMECH, V45, P14, DOI 10.1016/j.clinbiomech.2017.04.003; Hei WH, 2016, INT J NEUROSCI, V126, P739, DOI 10.3109/00207454.2015.1054032; Kalia LV, 2015, LANCET, V386, P896, DOI 10.1016/S0140-6736(14)61393-3; Khedr EM, 2003, EUR J NEUROL, V10, P567, DOI 10.1046/j.1468-1331.2003.00649.x; Khedr EM, 2006, MOVEMENT DISORD, V21, P2201, DOI 10.1002/mds.21089; Lidstone Sarah Christine, 2014, Handb Exp Pharmacol, V225, P139, DOI 10.1007/978-3-662-44519-8_8; Longo FM, 1999, J NEUROSCI RES, V55, P230, DOI 10.1002/(SICI)1097-4547(19990115)55:2<230::AID-JNR10>3.0.CO;2-3; Martiny K, 2010, BIOL PSYCHIAT, V68, P163, DOI 10.1016/j.biopsych.2010.02.017; Morberg BM, 2018, EUROPEAN J NEUROLOGY; Morberg BM, 2017, MOVEMENT DISORD, V32, P625, DOI 10.1002/mds.26927; Paasuke M, 2004, J AGING PHYS ACTIV, V12, P511; Rahbek U. L., 2005, ORAL BIOSCI MED, V2, P1; Rose MH, 2013, MOTOR CONTROL, V17, P203, DOI 10.1123/mcj.17.2.203; ROSE MH, 2013, REHABILITATION PARKI; Samuel D, 2013, ARCH GERONTOL GERIAT, V57, P192, DOI 10.1016/j.archger.2013.03.003; Spedden ME, 2017, DEV NEUROPSYCHOL, V42, P495, DOI 10.1080/87565641.2017.1399129; Stevens-Lapsley J, 2012, NEUROREHAB NEURAL RE, V26, P533, DOI 10.1177/1545968311425925; Strafella AP, 2006, NEUROIMAGE, V31, P1666, DOI 10.1016/j.neuroimage.2006.02.005; Tepper OM, 2004, FASEB J, V18, P1231, DOI 10.1096/fj.03-0847fje; Thompson BJ, 2014, AGE, V36, P839, DOI 10.1007/s11357-013-9605-0; Tomlinson CL, 2010, MOVEMENT DISORD, V25, P2649, DOI 10.1002/mds.23429; Tran MTD, 2017, ACTA NEUROPSYCHIATR, V29, P267, DOI 10.1017/neu.2016.51; Urnukhsaikhan E, 2016, LIFE SCI, V151, P130, DOI 10.1016/j.lfs.2016.02.066; WEINER DK, 1993, J AM GERIATR SOC, V41, P6, DOI 10.1111/j.1532-5415.1993.tb05939.x; Zhang Y, 2006, J BIOL PHYS, V32, P1, DOI 10.1007/s10867-006-6901-2	38	7	7	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2018	13	9							e0204478	10.1371/journal.pone.0204478	http://dx.doi.org/10.1371/journal.pone.0204478			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GU9BO	30252895	Green Published, Green Submitted, gold			2023-01-03	WOS:000445639700054
J	Said, A; Vlachaki, E; Abukar, J; Tsitsikas, DA				Said, Ammaarah; Vlachaki, Efthymia; Abukar, Jibril; Tsitsikas, Dimitris A.			A man with fever and haemoglobinuria after blood transfusion	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SICKLE-CELL-DISEASE; HYPERHEMOLYSIS SYNDROME		[Said, Ammaarah; Abukar, Jibril; Tsitsikas, Dimitris A.] Homerton Univ Hosp NHS Fdn Trust, Haemoglobinopathy Serv, London, England; [Vlachaki, Efthymia] Hippokrateion Hosp, Dept Internal Med 2, Adults Thalassemia Unit, Thessaloniki, Greece		Said, A (corresponding author), Homerton Univ Hosp NHS Fdn Trust, Haemoglobinopathy Serv, London, England.	ammaarah.said@nhs.net	Tsitsikas, Dimitris A./AGL-2303-2022; TSITSIKAS, DIMITRIS/GNW-3079-2022	Tsitsikas, Dimitris A./0000-0003-3468-049X; 				Knowles S, SERIOUS HAZARDS TRAN; Marti-Carvajal AJ, 2010, COCHRANE DB SYST REV, V6; Petz LD, 1997, TRANSFUSION, V37, P382, DOI 10.1046/j.1537-2995.1997.37497265338.x; Royal Children's Hospital Melbourne, ADV EFF TRANSF; Win N, 2008, TRANSFUSION, V48, P1231, DOI 10.1111/j.1537-2995.2008.01693.x; Win N, 2009, EXPERT REV HEMATOL, V2, P111, DOI 10.1586/EHM.09.2	6	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 6	2018	362								k3138	10.1136/bmj.k3138	http://dx.doi.org/10.1136/bmj.k3138			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT4WS	30190313				2023-01-03	WOS:000444507200001
J	Glass, RI; Stoll, BJ				Glass, Roger I.; Stoll, Barbara J.			Oral Rehydration Therapy for Diarrheal Diseases A 50-Year Perspective	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SYSTEMATIC ANALYSIS; MORTALITY		[Glass, Roger I.] NIH, Fogarty Int Ctr, 31 Ctr Dr,Mailstop 2220, Bethesda, MD 20892 USA; [Stoll, Barbara J.] UTHealth, McGovern Sch Med, Houston, TX USA	National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC); University of Texas System; University of Texas Health Science Center Houston	Glass, RI (corresponding author), NIH, Fogarty Int Ctr, 31 Ctr Dr,Mailstop 2220, Bethesda, MD 20892 USA.	roger.glass@nih.gov						Duggan C, 1992, MMWR Recomm Rep, V41, P1; Liu L, 2016, LANCET, V388, P3027, DOI 10.1016/S0140-6736(16)31593-8; NALIN DR, 1968, LANCET, V2, P370; RUXIN JN, 1994, MED HIST, V38, P363, DOI 10.1017/S0025727300036905; SNYDER JD, 1982, B WORLD HEALTH ORGAN, V60, P605; Troeger C, 2017, LANCET INFECT DIS, V17, P909, DOI 10.1016/S1473-3099(17)30276-1; UNICEF, 2016, ENDING CHILD DEATHS	7	7	7	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	2018	320	9					865	866		10.1001/jama.2018.10963	http://dx.doi.org/10.1001/jama.2018.10963			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GS4OQ	30128535				2023-01-03	WOS:000443627300005
J	Onyango, MA; Vian, T; Hirsch, I; Salvi, DD; Laing, R; Rockers, PC; Ashigbie, PG; Wirtz, VJ				Onyango, Monica Adhiambo; Vian, Taryn; Hirsch, Isabel; Salvi, Devashri D.; Laing, Richard; Rockers, Peter C.; Ashigbie, Paul G.; Wirtz, Veronika J.			Perceptions of Kenyan adults on access to medicines for non-communicable diseases: A qualitative study	PLOS ONE			English	Article							MIDDLE-INCOME COUNTRIES; SOCIAL-RESPONSIBILITY; AVAILABILITY; CARE	In Kenya, noncommunicable diseases (NCDs) account for 27% of all deaths. Adult Kenyans have an 18% chance of dying prematurely from cancers, diabetes, cardiovascular diseases or chronic respiratory diseases. A Novartis Access Initiative is making medicines available to treat cardiovascular diseases, diabetes, chronic respiratory diseases, and breast cancer in 30 countries, including Kenya. Little is known about patients' perceptions of access to medicines for NCDs in Kenya. The study objective was to understand patients' perceptions of access to medicines; as well as barriers and facilitators at the household, community, and healthcare system level. A baseline qualitative study was conducted in eight of 47 counties as part of an evaluation of the Novartis Access Initiative in Kenya. The 84 patients interviewed through a household survey had been diagnosed and treated for an NCD. Although medicines at government facilities were free or cheaper than those sold in private pharmacies, the availability of medicines presented a constant challenge. Patients often resorted to private pharmacies, where NCD medicines cost more than at public facilities. Participants with an NCD took their health seriously and strove to get the medicines, even under difficult circumstances. Buying NCD medicines put a strain on the household budget, especially for the lower-income participants. Some actions to overcome affordability barriers included: borrowing money, selling assets, seeking help from relatives, taking on extra work, buying partial dosages, leaving without the medicines, or resorting to non-medical alternatives. In conclusion, access to NCD medicines is a major challenge for most adults in Kenya. As a result, they engage in complex interactions between public, private facilities and pharmacies to overcome the barriers. The government should ensure well-stocked public sector pharmacies and subsidize prices of medicines for lower-income patients. Integration of industry-led access to medicine programs may help governments to obtain low cost supplies.	[Onyango, Monica Adhiambo; Vian, Taryn; Hirsch, Isabel; Salvi, Devashri D.; Laing, Richard; Rockers, Peter C.; Ashigbie, Paul G.; Wirtz, Veronika J.] Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA 02118 USA; [Laing, Richard] Univ Western Cape, Fac Community Hlth Sci, Sch Publ Hlth, Cape Town, South Africa	Boston University; University of the Western Cape	Onyango, MA (corresponding author), Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA 02118 USA.	monyango@bu.edu	Vian, Taryn/H-4609-2019; Wirtz, Veornika/AAG-9712-2019; Salvi, Devashri/CAJ-3216-2022	Wirtz, Veronika J./0000-0002-0863-8768; Onyango, Monica Adhiambo/0000-0003-4998-1682; Salvi, Devashri/0000-0002-7924-1418	Sandoz International GmbH [55205062]; Novartis Access Project [55205062]	Sandoz International GmbH(Novartis); Novartis Access Project	This work received support from Sandoz International GmbH (55205062) and Novartis Access Project, Grant 55205062. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, GLOBAL EC BURDEN NON; Beaglehole R, 2011, LANCET, V378, P449, DOI 10.1016/S0140-6736(11)60879-9; Blackburn DF, 2013, PATIENT PREFER ADHER, V7, P183, DOI 10.2147/PPA.S30613; Cameron A, 2011, B WORLD HEALTH ORGAN, V89, P412, DOI 10.2471/BLT.10.084327; Droppert H, 2015, GLOBALIZATION HEALTH, V11, DOI 10.1186/s12992-015-0100-5; Hogerzeil HV, 2013, NEW ENGL J MED, V369, P896, DOI 10.1056/NEJMp1303723; Hogerzeil HV, 2013, LANCET, V381, P680, DOI 10.1016/S0140-6736(12)62128-X; Ministry of Health Government of Kenya, 2014, 2013 KEN HOUS HLTH E; Mwai D., 2016, PUBLIC HLTH RES, V6, P83, DOI [10.5923/j.phr.20160603.02, DOI 10.5923/J.PHR.20160603.02]; Novozymes, 2016, NOV ENZ BIOD HDB, P1; Robertson J, 2015, GLOBALIZATION HEALTH, V11, DOI 10.1186/s12992-015-0105-0; Rockers PC, 2017, HEALTH AFFAIR, V36, P706, DOI 10.1377/hlthaff.2016.1213; Rockers PC, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013386; Siddharthan T, 2015, HEALTH AFFAIR, V34, P1506, DOI 10.1377/hlthaff.2015.0382; Subramanian S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190113; Vedanthan R, 2015, GLOB HEART, V10, P313, DOI 10.1016/j.gheart.2015.09.003; Vialle-Valentin CE, 2015, HEALTH POLICY PLANN, V30, P1044, DOI 10.1093/heapol/czu107; Vian T, 2018, J HEALTH PSYCHOL, V23, P1895, DOI 10.1177/1359105316672922; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; World Health Organization, 2015, WHO GLOBAL ACTION PL; World Health Organization, 2014, NONC DIS COUNTR PROF	22	10	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2018	13	8							e0201917	10.1371/journal.pone.0201917	http://dx.doi.org/10.1371/journal.pone.0201917			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR5ZQ	30142218	Green Submitted, Green Published, gold			2023-01-03	WOS:000442722500006
J	Andre, P; Denis, C; Soulas, C; Bourbon-Caillet, C; Lopez, J; Arnoux, T; Blery, M; Bonnafous, C; Gauthier, L; Morel, A; Rossi, B; Remark, R; Breso, V; Bonnet, E; Habif, G; Guia, S; Lalanne, AI; Hoffmann, C; Lantz, O; Fayette, J; Boyer-Chammard, A; Zerbib, R; Dodion, P; Ghadially, H; Jure-Kunkel, M; Morel, Y; Herbst, R; Narni-Mancinelli, E; Cohen, RB; Vivier, E				Andre, Pascale; Denis, Caroline; Soulas, Caroline; Bourbon-Caillet, Clarisse; Lopez, Julie; Arnoux, Thomas; Blery, Mathieu; Bonnafous, Cecile; Gauthier, Laurent; Morel, Ariane; Rossi, Benjamin; Remark, Romain; Breso, Violette; Bonnet, Elodie; Habif, Guillaume; Guia, Sophie; Lalanne, Ana Ines; Hoffmann, Caroline; Lantz, Olivier; Fayette, Jerome; Boyer-Chammard, Agnes; Zerbib, Robert; Dodion, Pierre; Ghadially, Hormas; Jure-Kunkel, Maria; Morel, Yannis; Herbst, Ronald; Narni-Mancinelli, Emilie; Cohen, Roger B.; Vivier, Eric			Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells	CELL			English	Article							DIFFERENTIAL REGULATION; ACTIVATING RECEPTORS; HLA-E; CANCER; EXPRESSION; LYMPHOCYTES; CD94/NKG2A; CETUXIMAB; EFFICACY; IMMUNOTHERAPY	Checkpoint inhibitors have revolutionized cancer treatment. However, only a minority of patients respond to these immunotherapies. Here, we report that blocking the inhibitory NKG2A receptor enhances tumor immunity by promoting both natural killer (NK) and CD8(+) T cell effector functions in mice and humans. Monalizumab, a humanized anti-NKG2A antibody, enhanced NK cell activity against various tumor cells and rescued CD8(+) T cell function in combination with PD-x axis blockade. Monalizumab also stimulated NK cell activity against antibody-coated target cells. Interim results of a phase II trial of monalizumab plus cetuximab in previously treated squamous cell carcinoma of the head and neck showed a 31% objective response rate. Most common adverse events were fatigue (17%), pyrexia (13%), and headache (10%). NKG2A targeting with monalizumab is thus a novel checkpoint inhibitory mechanism promoting anti-tumor immunity by enhancing the activity of both T and NK cells, which may complement first-generation immunotherapies against cancer.	[Andre, Pascale; Denis, Caroline; Soulas, Caroline; Bourbon-Caillet, Clarisse; Lopez, Julie; Arnoux, Thomas; Blery, Mathieu; Bonnafous, Cecile; Gauthier, Laurent; Morel, Ariane; Rossi, Benjamin; Remark, Romain; Breso, Violette; Bonnet, Elodie; Habif, Guillaume; Boyer-Chammard, Agnes; Zerbib, Robert; Dodion, Pierre; Morel, Yannis; Vivier, Eric] Innate Pharma, 117 Ave Luminy, F-13009 Marseille, France; [Guia, Sophie; Narni-Mancinelli, Emilie; Vivier, Eric] Aix Marseille Univ, INSERM, CNRS, Ctr Immunol Marseille Luminy, F-13009 Marseille, France; [Lalanne, Ana Ines; Hoffmann, Caroline; Lantz, Olivier] Inst Curie, INSERM, U932, Immunite & Canc, F-75248 Paris 5, France; [Hoffmann, Caroline] Inst Curie, Serv ORL & Chirurg Cervicofaciale, F-75248 Paris 5, France; [Fayette, Jerome] Ctr Leon Berard, F-69008 Lyon, France; [Ghadially, Hormas] MedImmune Ltd, Aaron Klug Bldg,Granta Pk, Cambridge CB21 6GH, England; [Jure-Kunkel, Maria; Herbst, Ronald] MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878 USA; [Cohen, Roger B.] Abramson Canc Ctr, 3400 Civic Ctr Blvd, West Pavilion, Philadelphia, PA USA; [Vivier, Eric] Hop La Timone, AP HP, Serv Immunol, Marseille Immunopole, F-13005 Marseille, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Centre Leon Berard; AstraZeneca; Medimmune; AstraZeneca; Medimmune; University of Pennsylvania; Pennsylvania Medicine; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Andre, P; Vivier, E (corresponding author), Innate Pharma, 117 Ave Luminy, F-13009 Marseille, France.; Vivier, E (corresponding author), Aix Marseille Univ, INSERM, CNRS, Ctr Immunol Marseille Luminy, F-13009 Marseille, France.; Vivier, E (corresponding author), Hop La Timone, AP HP, Serv Immunol, Marseille Immunopole, F-13005 Marseille, France.	pascale.andre@innate-pharma.fr; vivier@ciml.univ-mrs.fr	Narni-Mancinelli, Emilie/X-1888-2018; Hoffmann, Caroline/AAH-6489-2021; Vivier, Eric/F-8939-2010	Narni-Mancinelli, Emilie/0000-0002-7001-1026; Hoffmann, Caroline/0000-0002-4430-3439; Vivier, Eric/0000-0001-7022-8287; Lantz, olivier/0000-0003-3161-7719; BLERY, Mathieu/0000-0003-4738-6038	European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (TILC) [694502]; Agence Nationale de la Recherche; Equipe Labellisee "La Ligue"; Ligue Nationale contre le Cancer; MSDAvenir; Innate Pharma; INSERM; CNRS; Aix-Marseille University; Marseille Immunopole	European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (TILC)(European Research Council (ERC)); Agence Nationale de la Recherche(French National Research Agency (ANR)); Equipe Labellisee "La Ligue"; Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); MSDAvenir; Innate Pharma; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); CNRS(Centre National de la Recherche Scientifique (CNRS)); Aix-Marseille University; Marseille Immunopole	We thank Mohammed Dar (Mediumme) for critically reviewing the manuscript; Francois Romagne (MI-mAbs), Fabien Chanuc, Nicolas Fuseri, and Flavien Caraguel (Innate Pharma) for help and advice during these studies. The E.V. lab was supported by funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (TILC, grant agreement no. 694502), the Agence Nationale de la Recherche, Equipe Labellisee "La Ligue," Ligue Nationale contre le Cancer, MSDAvenir, Innate Pharma, and institutional grants to the CIML (INSERM, CNRS, and Aix-Marseille University) and Marseille Immunopole.	Andre P, 1999, EUR J IMMUNOL, V29, P1076, DOI 10.1002/(SICI)1521-4141(199904)29:04<1076::AID-IMMU1076>3.0.CO;2-Z; Baumeister SH, 2016, ANNU REV IMMUNOL, V34, P539, DOI 10.1146/annurev-immunol-032414-112049; Benson DM, 2012, BLOOD, V120, P4324, DOI 10.1182/blood-2012-06-438028; Bertone S, 1999, EUR J IMMUNOL, V29, P23, DOI 10.1002/(SICI)1521-4141(199901)29:01<23::AID-IMMU23>3.0.CO;2-Y; Brady J, 2004, J IMMUNOL, V172, P2048, DOI 10.4049/jimmunol.172.4.2048; Braud VM, 2003, TRENDS IMMUNOL, V24, P162, DOI 10.1016/S1471-4906(03)00064-4; Callahan MK, 2016, IMMUNITY, V44, P1069, DOI 10.1016/j.immuni.2016.04.023; Cartron G, 2017, BLOOD, V130, P581, DOI 10.1182/blood-2017-03-771832; Cerwenka A, 2018, SCIENCE, V359, P1460, DOI 10.1126/science.aat2184; Charych D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179431; Charych DH, 2016, CLIN CANCER RES, V22, P680, DOI 10.1158/1078-0432.CCR-15-1631; Chiossone L, 2018, NAT REV IMMUNOL, V18, P671, DOI 10.1038/s41577-018-0061-z; Corrales L, 2016, J CLIN INVEST, V126, P2404, DOI 10.1172/JCI86892; Daeron M, 2008, IMMUNOL REV, V224, P11, DOI 10.1111/j.1600-065X.2008.00666.x; Du B., 2016, J CANC METASTASIS TR, V2, P463, DOI DOI 10.20517/2394-4722.2016.62; Ferris RL, 2018, CANCER TREAT REV, V63, P48, DOI 10.1016/j.ctrv.2017.11.008; Garrido F, 2017, CANCER IMMUNOL IMMUN, V66, P259, DOI 10.1007/s00262-016-1947-x; Hashimoto M, 2018, ANNU REV MED, V69, P301, DOI 10.1146/annurev-med-012017-043208; Horowitz A, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aag1672; Le Drean E, 1998, EUR J IMMUNOL, V28, P264, DOI 10.1002/(SICI)1521-4141(199801)28:01<264::AID-IMMU264>3.0.CO;2-O; Lopez-Botet M, 2000, SEMIN IMMUNOL, V12, P109, DOI 10.1006/smim.2000.0213; Mahapatra S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181134; Mamessier E, 2011, J CLIN INVEST, V121, P3609, DOI 10.1172/JCI45816; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; Manser AR, 2016, CANCER IMMUNOL IMMUN, V65, P417, DOI 10.1007/s00262-015-1750-0; Levy EM, 2009, INNATE IMMUN-LONDON, V15, P91, DOI 10.1177/1753425908101404; McMahon CW, 2002, J IMMUNOL, V169, P1444, DOI 10.4049/jimmunol.169.3.1444; Mingari MC, 1998, P NATL ACAD SCI USA, V95, P1172, DOI 10.1073/pnas.95.3.1172; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Mori S, 1998, INT J ONCOL, V12, P1165; Muntasell A, 2017, CURR OPIN IMMUNOL, V45, P73, DOI 10.1016/j.coi.2017.01.003; Okazaki T, 2007, INT IMMUNOL, V19, P813, DOI 10.1093/intimm/dxm057; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; Orr MT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015184; Paulson KG, 2018, J AM ACAD DERMATOL, V78, P457, DOI 10.1016/j.jaad.2017.10.028; Platonova S, 2011, CANCER RES, V71, P5412, DOI 10.1158/0008-5472.CAN-10-4179; Ramsuran V, 2018, SCIENCE, V359, P86, DOI 10.1126/science.aam8825; Rapaport AS, 2015, IMMUNITY, V43, P1112, DOI 10.1016/j.immuni.2015.11.005; Rautela J, 2018, IMMUNOL CELL BIOL, V96, P477, DOI 10.1111/imcb.12045; Sagiv-Barfi I, 2015, P NATL ACAD SCI USA, V112, pE966, DOI 10.1073/pnas.1500712112; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; SEGAL NH, 2018, J CLIN ONCOL S15, V36; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Sheu BC, 2005, CANCER RES, V65, P2921, DOI 10.1158/0008-5472.CAN-04-2108; Sivori S, 1996, EUR J IMMUNOL, V26, P2487, DOI 10.1002/eji.1830261032; Sockolosky JT, 2018, SCIENCE, V359, P1037, DOI 10.1126/science.aar3246; van Montfoort N, 2018, CELL, V175, P1744, DOI 10.1016/j.cell.2018.10.028; Vance RE, 1999, J EXP MED, V190, P1801, DOI 10.1084/jem.190.12.1801; Vermorken JB, 2008, CANCER-AM CANCER SOC, V112, P2710, DOI 10.1002/cncr.23442; Vermorken JB, 2007, J CLIN ONCOL, V25, P2171, DOI 10.1200/JCO.2006.06.7447; Viant C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6108; Vivier E, 2012, NAT REV IMMUNOL, V12, P239, DOI 10.1038/nri3174; Yazdi MT, 2016, ONCOTARGET, V7, P3467	55	536	560	21	134	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 13	2018	175	7					1731	+		10.1016/j.cell.2018.10.014	http://dx.doi.org/10.1016/j.cell.2018.10.014			26	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HE3GZ	30503213	Green Published, hybrid			2023-01-03	WOS:000453242200006
J	Antonia, SJ; Villegas, A; Daniel, D; Vicente, D; Murakami, S; Hui, R; Kurata, T; Chiappori, A; Lee, KH; de Wit, M; Cho, BC; Bourhaba, M; Quantin, X; Tokito, T; Mekhail, T; Planchard, D; Kim, YC; Karapetis, CS; Hiret, S; Ostoros, G; Kubota, K; Gray, JE; Paz-Ares, L; Carpeno, JD; Faivre-Finn, C; Reck, M; Vansteenkiste, J; Spigel, DR; Wadsworth, C; Melillo, G; Taboada, M; Dennis, PA; Ozguroglu, M				Antonia, S. J.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Kurata, T.; Chiappori, A.; Lee, K. H.; de Wit, M.; Cho, B. C.; Bourhaba, M.; Quantin, X.; Tokito, T.; Mekhail, T.; Planchard, D.; Kim, Y. -C.; Karapetis, C. S.; Hiret, S.; Ostoros, G.; Kubota, K.; Gray, J. E.; Paz-Ares, L.; Carpeno, J. de Castro; Faivre-Finn, C.; Reck, M.; Vansteenkiste, J.; Spigel, D. R.; Wadsworth, C.; Melillo, G.; Taboada, M.; Dennis, P. A.; Ozguroglu, M.		PACIFIC Investigators	Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL LUNG-CANCER; PHASE-III; CONCURRENT CHEMORADIOTHERAPY; CONSOLIDATION CHEMOTHERAPY; RADIATION; DOCETAXEL; CHEMORADIATION; RADIOTHERAPY; EXPRESSION; CISPLATIN	BACKGROUND An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients with stage III, unresectable non-small-cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy. Here we report the results for the second primary end point of overall survival. METHODS We randomly assigned patients, in a 2: 1 ratio, to receive durvalumab intravenously, at a dose of 10 mg per kilogram of body weight, or matching placebo every 2 weeks for up to 12 months. Randomization occurred 1 to 42 days after the patients had received chemoradiotherapy and was stratified according to age, sex, and smoking history. The primary end points were progression-free survival (as assessed by blinded independent central review) and overall survival. Secondary end points included the time to death or distant metastasis, the time to second progression, and safety. RESULTS Of the 713 patients who underwent randomization, 709 received the assigned intervention (473 patients received durvalumab and 236 received placebo). As of March 22, 2018, the median follow-up was 25.2 months. The 24-month overall survival rate was 66.3% (95% confidence interval [CI], 61.7 to 70.4) in the durvalumab group, as compared with 55.6% (95% CI, 48.9 to 61.8) in the placebo group (two-sided P = 0.005). Durvalumab significantly prolonged overall survival, as compared with placebo (stratified hazard ratio for death, 0.68; 99.73% CI, 0.47 to 0.997; P = 0.0025). Updated analyses regarding progression-free survival were similar to those previously reported, with a median duration of 17.2 months in the durvalumab group and 5.6 months in the placebo group (stratified hazard ratio for disease progression or death, 0.51; 95% CI, 0.41 to 0.63). The median time to death or distant metastasis was 28.3 months in the durvalumab group and 16.2 months in the placebo group (stratified hazard ratio, 0.53; 95% CI, 0.41 to 0.68). A total of 30.5% of the patients in the durvalumab group and 26.1% of those in the placebo group had grade 3 or 4 adverse events of any cause; 15.4% and 9.8% of the patients, respectively, discontinued the trial regimen because of adverse events. CONCLUSIONS Durvalumab therapy resulted in significantly longer overall survival than placebo. No new safety signals were identified.	[Antonia, S. J.; Chiappori, A.; Gray, J. E.] H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr,MRC 3-E, Tampa, FL 33612 USA; [Villegas, A.] Canc Specialists North Florida, Jacksonville, FL USA; [Villegas, A.] Florida Canc Specialists, Fleming Isl, FL USA; [Mekhail, T.] Florida Hosp, Canc Inst, Orlando, FL USA; [Daniel, D.] Tennessee Oncol, Chattanooga, TN USA; [Daniel, D.; Spigel, D. R.] Sarah Cannon Res Inst, Nashville, TN USA; [Vicente, D.] Hosp Univ Virgen Macarena, Seville, Spain; [Paz-Ares, L.] Univ Complutense, CiberOnc, Hosp Univ 12 Octubre, Madrid, Spain; [Paz-Ares, L.] Spanish Natl Canc Res Ctr, Madrid, Spain; [Carpeno, J. de Castro] Hosp Univ La Paz, Madrid, Spain; [Murakami, S.] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan; [Kurata, T.] Kansai Med Univ Hosp, Hirakata, Osaka, Japan; [Tokito, T.] Kurume Univ Hosp, Kurume, Fukuoka, Japan; [Kubota, K.] Nippon Med Coll Hosp, Tokyo, Japan; [Hui, R.] Westmead Hosp, Sydney, NSW, Australia; [Hui, R.] Univ Sydney, Sydney, NSW, Australia; [Karapetis, C. S.] Flinders Univ S Australia, Adelaide, SA, Australia; [Karapetis, C. S.] Flinders Med Ctr, Adelaide, SA, Australia; [Lee, K. H.] Chungbuk Natl Univ, Coll Med, Chungbuk Natl Univ Hosp, Cheongju, South Korea; [Cho, B. C.] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea; [Kim, Y. -C.] Chonnam Natl Univ, Hwasun Hosp, Med Sch, Gwangju, South Korea; [de Wit, M.] Vivantes Klinikum Neukoelln, Berlin, Germany; [Reck, M.] German Ctr Lung Res, Airway Res Ctr North, Grosshansdorf, Germany; [Bourhaba, M.] Ctr Hosp Univ Liege, Liege, Belgium; [Vansteenkiste, J.] Katholieke Univ Leuven, Univ Hosp, Leuven, Belgium; [Quantin, X.] CHU Montpellier, Montpellier, France; [Quantin, X.] Inst Canc Montpellier Val Aurelle, Montpellier, France; [Planchard, D.] Inst Gustave Roussy, Villejuif, France; [Hiret, S.] Inst Cancerol Ouest Site Rene Gauducheau, St Herblain, France; [Ostoros, G.] Natl Koranyi Inst Pulmonol, Budapest, Hungary; [Faivre-Finn, C.] Univ Manchester, Manchester, Lancs, England; [Faivre-Finn, C.] Christie NHS Fdn Trust, Manchester, Lancs, England; [Wadsworth, C.; Taboada, M.] AstraZeneca, Alderley Pk, Cambridge, England; [Ozguroglu, M.] Istanbul Univ, Cerrahpasa, Turkey; [Ozguroglu, M.] Cerrahpasa Med Sch, Istanbul, Turkey	H Lee Moffitt Cancer Center & Research Institute; Florida Cancer Specialists; Adventist Health Services; AdventHealth; Tennessee Oncology; Sarah Cannon Research Institute; Hospital Universitario Virgen Macarena; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Complutense University of Madrid; Hospital Universitario 12 de Octubre; Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitario La Paz; Kanagawa Prefectural Cancer Center; Kansai Medical University; Kurume University; Nippon Medical School; University of Sydney; University of Sydney; Flinders University South Australia; Flinders Medical Centre; Chungbuk National University; Chungbuk National University Hospital; Yonsei University; Yonsei University Health System; Chonnam National University; VIivantes Klinikum Neukolln; University of Liege; KU Leuven; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; UNICANCER; Gustave Roussy; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); University of Manchester; Christie NHS Foundation Trust; AstraZeneca; Istanbul University; Istanbul University - Cerrahpasa; Istanbul University; Istanbul University - Cerrahpasa	Antonia, SJ (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr,MRC 3-E, Tampa, FL 33612 USA.	scott.antonia@moffitt.org	MUSTAFA, ÖZGÜROĞLU/A-8234-2016; Paz-Ares, Luis/AAH-2750-2019; van den Heuvel, Michel M/D-9491-2017; Reck, Martin/ABF-5721-2020; Hui, Rina/L-6114-2019; Cortot, Alexis B/F-7006-2019	MUSTAFA, ÖZGÜROĞLU/0000-0002-8417-8628; van den Heuvel, Michel M/0000-0002-6372-2153; Reck, Martin/0000-0002-5348-4462; Cortot, Alexis B/0000-0003-0098-2238; Lee, Ki Hyeong/0000-0002-7830-5950; Gomez, Jorge/0000-0001-6859-363X; Cho, Byoung Chul/0000-0002-5562-270X; O'Byrne, Kenneth/0000-0002-6754-5633; Karapetis, Christos/0000-0003-1741-996X; De Castro, Javier/0000-0002-3622-6306; Blasco Cordellat, Ana/0000-0001-5889-0382; Haigentz, Missak/0000-0002-3610-2266; Faivre-Finn, Corinne/0000-0001-5617-9781; SOTO PARRA, HECTOR/0000-0001-7966-4472	AstraZeneca; NATIONAL CANCER INSTITUTE [P30CA076292] Funding Source: NIH RePORTER	AstraZeneca(AstraZeneca); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by AstraZeneca.	Ahn JS, 2015, J CLIN ONCOL, V33, P2660, DOI 10.1200/JCO.2014.60.0130; Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937; AstraZeneca, 2018, IMF DURV US PRESCR I; Bradley JD, 2017, INT J RADIAT ONCOL, V99, pS105, DOI 10.1016/j.ijrobp.2017.06.250; Chakraborty M, 2004, CANCER RES, V64, P4328, DOI 10.1158/0008-5472.CAN-04-0073; Deng LF, 2014, J CLIN INVEST, V124, P687, DOI 10.1172/JCI67313; Dovedi SJ, 2014, CANCER RES, V74, P5458, DOI 10.1158/0008-5472.CAN-14-1258; Goldstraw P, 2010, STAGING MANUAL THORA; Hanna N, 2008, J CLIN ONCOL, V26, P5755, DOI 10.1200/JCO.2008.17.7840; Ibrahim R, 2015, SEMIN ONCOL, V42, P474, DOI 10.1053/j.seminoncol.2015.02.007; Kelly K, 2008, J CLIN ONCOL, V26, P2450, DOI 10.1200/JCO.2007.14.4824; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lugade AA, 2005, J IMMUNOL, V174, P7516, DOI 10.4049/jimmunol.174.12.7516; Mauguen A, 2013, LANCET ONCOL, V14, P619, DOI 10.1016/S1470-2045(13)70158-X; Moya-Horno I, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758834017745012; O'Kane GM, 2017, ONCOLOGIST, V22, P70, DOI 10.1634/theoncologist.2016-0164; Reits EA, 2006, J EXP MED, V203, P1259, DOI 10.1084/jem.20052494; Skrzypski M, 2018, CANCER TREAT REV, V66, P114, DOI 10.1016/j.ctrv.2018.04.001; Stewart R, 2015, CANCER IMMUNOL RES, V3, P1052, DOI 10.1158/2326-6066.CIR-14-0191; Tsujino K, 2013, J THORAC ONCOL, V8, P1181, DOI 10.1097/JTO.0b013e3182988348; Yoon SM, 2017, WORLD J CLIN ONCOL, V8, P1, DOI 10.5306/wjco.v8.i1.1; Zhang P, 2008, MOL IMMUNOL, V45, P1470, DOI 10.1016/j.molimm.2007.08.013	22	1461	1500	5	117	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 13	2018	379	24					2342	2350		10.1056/NEJMoa1809697	http://dx.doi.org/10.1056/NEJMoa1809697			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD9HM	30280658	Green Published, Bronze			2023-01-03	WOS:000452872600009
J	Azoulay, E; Lemiale, V; Mokart, D; Nseir, S; Argaud, L; Pene, F; Kontar, L; Bruneel, F; Klouche, K; Barbier, F; Reignier, J; Berrahil-Meksen, L; Louis, G; Constantin, JM; Mayaux, J; Wallet, F; Kouatchet, A; Peigne, V; Theodose, I; Perez, P; Girault, C; Jaber, S; Oziel, J; Nyunga, M; Terzi, N; Bouadma, L; Lebert, C; Lautrette, A; Bige, N; Raphalen, JH; Papazian, L; Darmon, M; Chevret, S; Demoule, A				Azoulay, Elie; Lemiale, Virginie; Mokart, Djamel; Nseir, Saad; Argaud, Laurent; Pene, Frederic; Kontar, Loay; Bruneel, Fabrice; Klouche, Kada; Barbier, Francois; Reignier, Jean; Berrahil-Meksen, Lilia; Louis, Guillaume; Constantin, Jean-Michel; Mayaux, Julien; Wallet, Florent; Kouatchet, Achille; Peigne, Vincent; Theodose, Igor; Perez, Pierre; Girault, Christophe; Jaber, Samir; Oziel, Johanna; Nyunga, Martine; Terzi, Nicolas; Bouadma, Lila; Lebert, Christine; Lautrette, Alexandre; Bige, Naike; Raphalen, Jean-Herle; Papazian, Laurent; Darmon, Michael; Chevret, Sylvie; Demoule, Alexandre			Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients With Acute Respiratory Failure The HIGH Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE-UNIT; NONINVASIVE VENTILATION; CANNULA OXYGEN; HYPOXEMIC PATIENTS; THERAPY; INTUBATION; PREOXYGENATION; HEMATOLOGY; DISTRESS; SURGERY	IMPORTANCE High-flow nasal oxygen therapy is increasingly used for acute hypoxemic respiratory failure (AHRF). OBJECTIVE To determine whether high-flow oxygen therapy decreases mortality among immunocompromised patients with AHRF compared with standard oxygen therapy. DESIGN, SETTING, AND PARTICIPANTS The HIGH randomized clinical trial enrolled 776 adult immunocompromised patients with AHRF (PaO2 < 60mmHg or SpO(2) < 90% on room air, or tachypnea > 30/min or labored breathing or respiratory distress, and need for oxygen < 6 L/min) at 32 intensive care units (ICUs) in France between May 19, 2016, and December 31, 2017. INTERVENTIONS Patients were randomized 1: 1 to continuous high-flow oxygen therapy (n = 388) or to standard oxygen therapy (n = 388). MAIN OUTCOMES AND MEASURES The primary outcomewas day-28 mortality. Secondary outcomes included intubation and mechanical ventilation by day 28, PaO2: FIO2 ratio over the 3 days after intubation, respiratory rate, ICU and hospital lengths of stay, ICU-acquired infections, and patient comfort and dyspnea. RESULTS Of 778 randomized patients (median age, 64 [IQR, 54-71] years; 259 [33.3%] women), 776 (99.7%) completed the trial. At randomization, median respiratory rate was 33/min (IQR, 28-39) vs 32 (IQR, 27-38) and PaO2: FIO2 was 136 (IQR, 96-187) vs 128 (IQR, 92-164) in the intervention and control groups, respectively. Median SOFA score was 6 (IQR, 4-8) in both groups. Mortality on day 28 was not significantly different between groups (35.6% vs 36.1%; difference, -0.5%[95% CI, -7.3% to + 6.3%]; hazard ratio, 0.98 [95% CI, 0.77 to 1.24]; P =.94). Intubation rate was not significantly different between groups (38.7% vs 43.8%; difference, -5.1% [95% CI, -12.3% to + 2.0%]). Compared with controls, patients randomized to high-flow oxygen therapy had a higher PaO2: FIO2 (150 vs 119; difference, 19.5 [95% CI, 4.4 to 34.6]) and lower respiratory rate after 6 hours (25/min vs 26/min; difference, -1.8/min [95% CI, -3.2 to -0.2]). No significant difference was observed in ICU length of stay (8 vs 6 days; difference, 0.6 [95% CI, -1.0 to + 2.2]), ICU-acquired infections (10.0% vs 10.6%; difference, -0.6%[95% CI, -4.6 to + 4.1]), hospital length of stay (24 vs 27 days; difference, -2 days [95% CI, -7.3 to + 3.3]), or patient comfort and dyspnea scores. CONCLUSIONS AND RELEVANCE Among critically ill immunocompromised patients with acute respiratory failure, high-flow oxygen therapy did not significantly decrease day-28 mortality compared with standard oxygen therapy.	[Azoulay, Elie; Lemiale, Virginie; Theodose, Igor; Chevret, Sylvie] Hop St Louis, AP HP, Med Intens Care Unit, 1 Ave Claude Vellefaux, F-75010 Paris, France; [Azoulay, Elie; Lemiale, Virginie; Theodose, Igor; Chevret, Sylvie] Hop St Louis, AP HP, Dept Biostat, Paris, France; [Mokart, Djamel] Paoli Calmettes Inst, Intens Care Unit, Marseille, France; [Nseir, Saad] CHU Lille, Crit Care Ctr, Lille, France; [Argaud, Laurent] Hop Edouard Herriot, Med Intens Care Unit, Hosp Civils Lyon, Lyon, France; [Pene, Frederic] Univ Paris 05, Hop Cochin, AP HP, Med Intens Care Unit, Paris, France; [Kontar, Loay] Amiens Univ Hosp, Med Intens Care Unit, INSERM, U1088, Amiens, France; [Bruneel, Fabrice] Andre Mignot Hosp, Med Intens Care Unit, Versailles, France; [Klouche, Kada] CHU Montpellier, Med Intens Care Unit, Montpellier, France; [Barbier, Francois] CHR Orleans, La Source Hosp, Med Intens Care Unit, Orleans, France; [Reignier, Jean] CHU Nantes, Med Intens Care Unit, Hotel Dieu, Nantes, France; [Berrahil-Meksen, Lilia] Inst Gustave Roussy, Intens Care Unit, Villejuif, France; [Louis, Guillaume] CHR Metz Thionville, Intens Care Unit, Metz, France; [Constantin, Jean-Michel] CHU Clermont Ferrand, Dept Perioperat Med, Clermont Ferrand, France; [Mayaux, Julien; Demoule, Alexandre] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Med Intens Care Unit & Resp Div, Paris, France; [Wallet, Florent] Lyon Sud Med Ctr, Intens Care Unit, Lyon, France; [Kouatchet, Achille] CHRU, Med Intens Care Unit, Angers, France; [Peigne, Vincent] Ctr Hosp Metropole Savoie, Intens Care Unit, Chambery, France; [Perez, Pierre] Hop Brabois, Med Intens Care Unit, Vandoeuvre Les Nancy, France; [Girault, Christophe] Hop Charles Nicolle, Med Intens Care Unit, Rouen, France; [Jaber, Samir] Montpellier Univ Hosp, PhyMedExp, INSERM U 1046, CNRS 34295, Montpellier, France; [Oziel, Johanna] Avicenne Univ Hosp, Med Intens Care Unit, Bobigny, France; [Nyunga, Martine] Roubaix Hosp, Intens Care Unit, Roubaix, France; [Terzi, Nicolas] CHU Grenoble Alpes, Med Intens Care Unit, Grenoble, France; [Bouadma, Lila] CHU Bichat, Med Intens Care Unit, Paris, France; [Lebert, Christine] Ctr Hosp, Intens Care Unit, Dept Les Oudairies, La Roche Sur Yon, France; [Lautrette, Alexandre] Gabriel Montpied Univ Hosp, Med Intens Care Unit, Clermont Ferrand, France; [Bige, Naike] CHU St Antoine, Med Intens Care Unit, Paris, France; [Raphalen, Jean-Herle] Hop Necker Enfants Malad, Dept Anesthesia & Crit Care, Paris, France; [Papazian, Laurent] Aix Marseille Univ, Fac Med, Hop Nord, AP HP,Reanimat Detresses Resp & Infect, Marseille, France; [Darmon, Michael] Hop Cochin, Resp Intens Care Unit, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Institut Paoli-Calmette (IPC); Universite de Lille - ISITE; CHU Lille; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Centre Hospitalier de Versailles; Universite de Montpellier; CHU de Montpellier; Centre Hospitalier Regional d'Orleans; Nantes Universite; CHU de Nantes; UNICANCER; Gustave Roussy; CHR Metz-Thionville; CHU Clermont Ferrand; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU de Nancy; CHU de Rouen; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; CHU Grenoble Alpes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; CHD Vendee; CHU Clermont Ferrand; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Azoulay, E (corresponding author), Hop St Louis, AP HP, Med Intens Care Unit, 1 Ave Claude Vellefaux, F-75010 Paris, France.; Azoulay, E (corresponding author), Hop St Louis, AP HP, Dept Biostat, Paris, France.	elie.azoulay@aphp.fr	Demoule, Alexandre/ABG-4915-2021; TERZI, Nicolas/AAD-4348-2019; Carmen, Team3/Y-7384-2019; Louis, Guillaume/AAF-4340-2021	Demoule, Alexandre/0000-0002-0432-7217; TERZI, Nicolas/0000-0003-4036-6245; Carmen, Team3/0000-0002-3614-0924; Louis, Guillaume/0000-0002-4208-8122; wallet, florent/0000-0003-3174-6246; Lab, Carmen/0000-0002-5935-3236	French Ministry of Health [P150912 HIGH]	French Ministry of Health	All financial support for this study was provided by the French Ministry of Health (P150912 HIGH). Supplies for high-flow oxygen therapy were provided by Fisher & Paykel France.	Azoulay E, 2004, MEDICINE, V83, P360, DOI 10.1097/01.md.0000145370.63676.fb; Azoulay E, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2492-z; Azoulay E, 2017, INTENS CARE MED, V43, P1808, DOI 10.1007/s00134-017-4947-1; Azoulay E, 2015, BLOOD REV, V29, P359, DOI 10.1016/j.blre.2015.04.002; Azoulay E, 2013, J CLIN ONCOL, V31, P2810, DOI 10.1200/JCO.2012.47.2365; Azoulay E, 2010, AM J RESP CRIT CARE, V182, P1038, DOI 10.1164/rccm.201001-0018OC; Bellani G, 2017, AM J RESP CRIT CARE, V195, P67, DOI 10.1164/rccm.201606-1306OC; Brainard J, 2017, J CRIT CARE, V40, P225, DOI 10.1016/j.jcrc.2017.04.023; Canet E, 2011, CRIT CARE, V15, DOI 10.1186/cc10091; Chu DK, 2018, LANCET, V391, P1693, DOI 10.1016/S0140-6736(18)30479-3; Corley A, 2015, INTENS CARE MED, V41, P887, DOI 10.1007/s00134-015-3765-6; Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST; Frat JP, 2016, LANCET RESP MED, V4, P646, DOI 10.1016/S2213-2600(16)30093-5; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; Futier E, 2016, INTENS CARE MED, V42, P1888, DOI 10.1007/s00134-016-4594-y; Girardis M, 2016, JAMA-J AM MED ASSOC, V316, P1583, DOI 10.1001/jama.2016.11993; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Harpaz R, 2016, JAMA-J AM MED ASSOC, V316, P2547, DOI 10.1001/jama.2016.16477; Hernandez G, 2016, JAMA-J AM MED ASSOC, V315, P1354, DOI 10.1001/jama.2016.2711; Hilbert G, 2001, NEW ENGL J MED, V344, P481, DOI 10.1056/NEJM200102153440703; Israni AK, 2018, AM J TRANSPLANT, V18, P434, DOI 10.1111/ajt.14563; Jaber S, 2016, INTENS CARE MED, V42, P1877, DOI 10.1007/s00134-016-4588-9; Jones PG, 2016, RESP CARE, V61, P291, DOI 10.4187/respcare.04252; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lemiale Virginie, 2017, Crit Care Med, V45, pe274, DOI 10.1097/CCM.0000000000002085; Lemiale V, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1097-0; Lemiale V, 2015, JAMA-J AM MED ASSOC, V314, P1711, DOI 10.1001/jama.2015.12402; Ruan PK, 2008, STAT MED, V27, P5709, DOI 10.1002/sim.3402; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Simon M, 2016, RESP CARE, V61, P1160, DOI 10.4187/respcare.04413; STEPHAN F, 2015, JAMA-J AM MED ASSOC, V313, P2331, DOI [DOI 10.1001/JAMA.2015.5213, 10.1001/jama.2015.5213]; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Vourc'h M, 2015, INTENS CARE MED, V41, P1538, DOI 10.1007/s00134-015-3796-z; Weyand CM, 2014, NEW ENGL J MED, V371, P1653, DOI [10.1056/NEJMcp1214825, 10.1056/NEJMc1409206]	34	140	146	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	2018	320	20					2099	2107		10.1001/jama.2018.14282	http://dx.doi.org/10.1001/jama.2018.14282			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB9ET	30357270	Green Published, Bronze			2023-01-03	WOS:000451395000017
J	Dyer, C				Dyer, Clare			Petition against "cruel" and "ridiculous" guidance on access to medicinal cannabis attracts 400 000 signatures	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		British Paediatric Neurology Association, 2018, GUID US CANN BAS PRO; HAWKES N, 2018, BMJ-BRIT MED J, V362, P76556, DOI DOI 10.1136/BMJ.K2957; Hurley R, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4654; TORJESEN I, 2018, BMJ-BRIT MED J, V362, P25288, DOI DOI 10.1136/BMJ.K3290	4	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 15	2018	363								k4833	10.1136/bmj.k4833	http://dx.doi.org/10.1136/bmj.k4833			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB0SF	30442640				2023-01-03	WOS:000450727100009
J	Chapman, M; Peake, SL; Bellomo, R; Davies, A; Deane, A; Horowitz, M; Hurford, S; Lange, K; Little, L; Mackle, D; O'Connor, S; Presneill, J; Ridley, E; Williams, P; Young, P				Chapman, Marianne; Peake, Sandra L.; Bellomo, Rinaldo; Davies, Andrew; Deane, Adam; Horowitz, Michael; Hurford, Sally; Lange, Kylie; Little, Lorraine; Mackle, Diane; O'Connor, Stephanie; Presneill, Jeffrey; Ridley, Emma; Williams, Patricia; Young, Paul		TARGET Investigators ANZICS	Energy-Dense versus Routine Enteral Nutrition in the Critically Ill	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTENSIVE-CARE UNITS; ACUTE LUNG INJURY; PARENTERAL-NUTRITION; CALORIE DELIVERY; MULTICENTER; PREVALENCE; GUIDELINES; PROVISION; OUTCOMES; BLIND	Background The effect of delivering nutrition at different calorie levels during critical illness is uncertain, and patients typically receive less than the recommended amount. Methods We conducted a multicenter, double-blind, randomized trial, involving adults undergoing mechanical ventilation in 46 Australian and New Zealand intensive care units (ICUs), to evaluate energy-dense (1.5 kcal per milliliter) as compared with routine (1.0 kcal per milliliter) enteral nutrition at a dose of 1 ml per kilogram of ideal body weight per hour, commencing at or within 12 hours of the initiation of nutrition support and continuing for up to 28 days while the patient was in the ICU. The primary outcome was all-cause mortality within 90 days. Results There were 3957 patients included in the modified intention-to-treat analysis (1971 in the 1.5-kcal group and 1986 in the 1.0-kcal group). The volume of enteral nutrition delivered during the trial was similar in the two groups; however, patients in the 1.5-kcal group received a mean (SD) of 1863478 kcal per day as compared with 1262 +/- 313 kcal per day in the 1.0-kcal group (mean difference, 601 kcal per day; 95% confidence interval [CI], 576 to 626). By day 90, a total of 523 of 1948 patients (26.8%) in the 1.5-kcal group and 505 of 1966 patients (25.7%) in the 1.0-kcal group had died (relative risk, 1.05; 95% CI, 0.94 to 1.16; P=0.41). The results were similar in seven predefined subgroups. Higher calorie delivery did not affect survival time, receipt of organ support, number of days alive and out of the ICU and hospital or free of organ support, or the incidence of infective complications or adverse events. Conclusions In patients undergoing mechanical ventilation, the rate of survival at 90 days associated with the use of an energy-dense formulation for enteral delivery of nutrition was not higher than that with routine enteral nutrition.	[Chapman, Marianne; Peake, Sandra L.; Bellomo, Rinaldo; Davies, Andrew; Little, Lorraine; O'Connor, Stephanie; Presneill, Jeffrey; Ridley, Emma; Williams, Patricia] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Bellomo, Rinaldo] Austin Hosp, Melbourne, Vic, Australia; [Davies, Andrew] Frankston Hosp, Melbourne, Vic, Australia; [Deane, Adam; Presneill, Jeffrey] Royal Melbourne Hosp, Melbourne, Vic, Australia; [Deane, Adam; Presneill, Jeffrey] Univ Melbourne, Melbourne, Vic, Australia; [Ridley, Emma] Alfred Hosp, Melbourne, Vic, Australia; [Chapman, Marianne; Peake, Sandra L.; Deane, Adam; Horowitz, Michael; Lange, Kylie; O'Connor, Stephanie; Williams, Patricia] Univ Adelaide, Adelaide, SA, Australia; [Peake, Sandra L.; Williams, Patricia] Queen Elizabeth Hosp, Adelaide, SA, Australia; [Chapman, Marianne; Horowitz, Michael; O'Connor, Stephanie] Royal Adelaide Hosp, Adelaide, SA, Australia; [Chapman, Marianne; Horowitz, Michael; Lange, Kylie] Natl Hlth & Med Res Council Ctr Res Excellence Tr, Adelaide, SA, Australia; [Hurford, Sally; Mackle, Diane; Young, Paul] Med Res Inst New Zealand, Wellington, New Zealand; [Young, Paul] Wellington Hosp, Wellington, New Zealand	Monash University; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Frankston Hospital; Royal Melbourne Hospital; University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Adelaide; Royal Adelaide Hospital; Medical Research Institute Of New Zealand	Peake, SL (corresponding author), Queen Elizabeth Hosp, Dept Intens Care Med, 28 Woodville Rd, Woodville, SA 5011, Australia.	sandra.peake@sa.gov.au	Ridley, Emma J./H-2864-2019; Deane, Adam/AAF-7370-2020; Williams, Patricia/AAH-6571-2019; Horowitz, Michael/AAY-3397-2021; Presneill, Jeffrey/B-4894-2012	Ridley, Emma J./0000-0002-7922-5717; Deane, Adam/0000-0002-7620-5577; Horowitz, Michael/0000-0002-0942-0306; Young, Paul/0000-0002-3428-3083; Green, Cameron/0000-0001-8949-3590; Barlow-Armstrong, Jewel/0000-0001-7350-0397; Presneill, Jeffrey/0000-0001-7177-7667	National Health and Medical Research Institute of Australia; Health Research Council of New Zealand	National Health and Medical Research Institute of Australia(National Health and Medical Research Council (NHMRC) of Australia); Health Research Council of New Zealand(Health Research Council of New Zealand)	Funded by National Health and Medical Research Institute of Australia and the Health Research Council of New Zealand; TARGET ClinicalTrials.gov number, NCT02306746.	Al-Dorzi HM, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1539-3; Alberda Cathy, 2009, Intensive Care Med, V35, P1728, DOI 10.1007/s00134-009-1567-4; Arabi YM, 2015, NEW ENGL J MED, V372, P2398, DOI 10.1056/NEJMoa1502826; Braunschweig CA, 2015, JPEN-PARENTER ENTER, V39, P13, DOI 10.1177/0148607114528541; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Cade JF, 2016, CRIT CARE RESUSC, V18, P224; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Chapman MJ, 2011, GUT, V60, P1336, DOI 10.1136/gut.2010.227934; De Beaux I, 2001, ANAESTH INTENS CARE, V29, P619, DOI 10.1177/0310057X0102900611; Doig GS, 2015, LANCET RESP MED, V3, P943, DOI 10.1016/S2213-2600(15)00418-X; Fergusson D, 2002, BMJ-BRIT MED J, V325, P652, DOI 10.1136/bmj.325.7365.652; Hart Graeme K, 2008, Crit Care Resusc, V10, P83; Heidegger CP, 2013, LANCET, V381, P385, DOI 10.1016/S0140-6736(12)61351-8; Heyland DK, 2015, CLIN NUTR, V34, P659, DOI 10.1016/j.clnu.2014.07.008; Kar P, 2016, JPEN-PARENTER ENTER, V40, P1050, DOI 10.1177/0148607115588333; Kreymann KG, 2006, CLIN NUTR, V25, P210, DOI 10.1016/j.clnu.2006.01.021; McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI [10.1177/0148607115621863, 10.1097/CCM.0000000000001525]; Parikh HG, 2016, CRIT CARE RESUSC, V18, P17; Passier RHA, 2013, INTENS CARE MED, V39, P1221, DOI 10.1007/s00134-013-2934-8; Paul E, 2013, J CRIT CARE, V28, P935, DOI 10.1016/j.jcrc.2013.07.058; Peake S, 2018, CRIT CARE RESUSC, V20, P15; Peake SL, 2014, AM J CLIN NUTR, V100, P616, DOI 10.3945/ajcn.114.086322; Peake SL, 2012, CRIT CARE RESUSC, V14, P148; Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137; Ridley EJ, 2017, CLIN NUTR; Ridley EJ, 2018, JPEN-PARENTER ENTER, V42, P1349, DOI 10.1002/jpen.1163; Rubinson L, 2004, CRIT CARE MED, V32, P350, DOI 10.1097/01.CCM.0000089641.06306.68; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Singer P, 2011, INTENS CARE MED, V37, P601, DOI 10.1007/s00134-011-2146-z; Villet S, 2005, CLIN NUTR, V24, P502, DOI 10.1016/j.clnu.2005.03.006; Wei XJ, 2015, CRIT CARE MED, V43, P1569, DOI 10.1097/CCM.0000000000001000; WELCH IM, 1988, GASTROENTEROLOGY, V94, P401, DOI 10.1016/0016-5085(88)90428-3; Williams P, 2018, CRIT CARE RESUSC, V20, P6; World Health Organization, 2000, WHO TECHN REP SER, V894	34	152	155	4	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 8	2018	379	19					1823	1834		10.1056/NEJMoa1811687	http://dx.doi.org/10.1056/NEJMoa1811687			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ5UT	30346225	Bronze			2023-01-03	WOS:000449495700008
J	Vieten, C; Wahbeh, H; Cahn, BR; MacLean, K; Estrada, M; Mills, P; Murphy, M; Shapiro, S; Radin, D; Josipovic, Z; Presti, DE; Sapiro, M; Bays, JC; Russell, P; Vago, D; Travis, F; Walsh, R; Delorme, A				Vieten, Cassandra; Wahbeh, Helene; Cahn, B. Rael; MacLean, Katherine; Estrada, Mica; Mills, Paul; Murphy, Michael; Shapiro, Shauna; Radin, Dean; Josipovic, Zoran; Presti, David E.; Sapiro, Michael; Bays, Jan Chozen; Russell, Peter; Vago, David; Travis, Fred; Walsh, Roger; Delorme, Arnaud			Future directions in meditation research: Recommendations for expanding the field of contemplative science	PLOS ONE			English	Article							MYSTICAL EXPERIENCE QUESTIONNAIRE; ORIENTED RECOVERY ENHANCEMENT; MINDFULNESS MEDITATION; TRANSCENDENTAL-MEDITATION; CHRONIC PAIN; PSYCHOLOGICAL STRESS; BRAIN; METAANALYSIS; AWARENESS; MECHANISMS	The science of meditation has grown tremendously in the last two decades. Most studies have focused on evaluating the clinical effectiveness of mindfulness-based interventions, neural and other physiological correlates of meditation, and individual cognitive and emotional aspects of meditation. Far less research has been conducted on more challenging domains to measure, such as group and relational, transpersonal and mystical, and difficult aspects of meditation; anomalous or extraordinary phenomena related to meditation; and post-conventional stages of development associated with meditation. However, these components of meditation may be crucial to people's psychological and spiritual development, could represent important mediators and/or mechanisms by which meditation confers benefits, and could themselves be important outcomes of meditation practices. In addition, since large numbers of novices are being introduced to meditation, it is helpful to investigate experiences they may encounter that are not well understood. Over the last four years, a task force of meditation researchers and teachers met regularly to develop recommendations for expanding the current meditation research field to include these important yet often neglected topics. These meetings led to a cross-sectional online survey to investigate the prevalence of a wide range of experiences in 1120 meditators. Results show that the majority of respondents report having had many of these anomalous and extraordinary experiences. While some of the topics are potentially controversial, they can be subjected to rigorous scientific investigation. These arenas represent largely uncharted scientific terrain and provide excellent opportunities for both new and experienced researchers. We provide suggestions for future directions, with accompanying online materials to encourage such research.	[Vieten, Cassandra; Wahbeh, Helene; Radin, Dean; Sapiro, Michael; Russell, Peter; Delorme, Arnaud] Inst Noet Sci, Res Dept, Petaluma, CA 94952 USA; [Wahbeh, Helene] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; [Cahn, B. Rael] Univ Southern Calif, Dept Psychiat, Los Angeles, CA USA; [MacLean, Katherine] Ctr Optimal Living, New York, NY USA; [Estrada, Mica] Univ Calif San Francisco, Sch Nursing, Inst Hlth & Aging, San Francisco, CA 94143 USA; [Mills, Paul; Delorme, Arnaud] Univ Calif San Diego, Dept Family Med & Publ Hlth, San Diego, CA 92103 USA; [Murphy, Michael] Esalen Inst, Ctr Theory & Res, Big Sur, CA USA; [Shapiro, Shauna] Santa Clara Univ, Dept Counseling Psychol, Santa Clara, CA 95053 USA; [Josipovic, Zoran] NYU, Dept Psychol, 6 Washington Pl, New York, NY 10003 USA; [Josipovic, Zoran] Nondual Inst, New York, NY USA; [Presti, David E.] Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA; [Bays, Jan Chozen] Randall Childrens Hosp, Portland, OR USA; [Vago, David] Vanderbilt Univ, Med Ctr, Osher Ctr Integrat Med, Nashville, TN USA; [Travis, Fred] Maharishi Univ Management, Ctr Brain Consciousness & Cognit, Fairfield, IA USA; [Walsh, Roger] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA	Oregon Health & Science University; University of Southern California; University of California System; University of California San Francisco; University of California System; University of California San Diego; Santa Clara University; New York University; University of California System; University of California Berkeley; Vanderbilt University; University of California System; University of California Irvine	Vieten, C (corresponding author), Inst Noet Sci, Res Dept, Petaluma, CA 94952 USA.	cvieten@noetic.org	Vago, David R/P-5264-2014; Vago, David/I-4341-2019	Vago, David R/0000-0002-6269-9027; Vago, David/0000-0002-6269-9027; Josipovic, Zoran/0000-0003-0262-4370; Vieten, Cassandra/0000-0003-3081-5174; Delorme, Arnaud/0000-0002-0799-3557	Mental Insight Foundation; Social Relations of Knowledge Institute	Mental Insight Foundation; Social Relations of Knowledge Institute	We appreciate the support of the Mental Insight Foundation (https://projects.propublica.org/nonprofits/organizations/943256579) and the Social Relations of Knowledge Institute (http://www.nonprofitfacts.com/CA/Social-Relations-Of-Knowledge-Institute.html) for their financial support of this project. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Aldwin C. M., 2015, APA HDB PSYCHOL APA, V1, P331, DOI 10.1037/14458-014; Augustinova M, 2012, J EXP SOC PSYCHOL, V48, P1213, DOI 10.1016/j.jesp.2012.04.014; Aurobindo S, 1963, FUTURE EVOLUTION MAN; Bair P, 2010, LIVING HEART LIVING; Barnes Patricia M., 2008, NATL HLTH STAT REPOR, V12, P1, DOI DOI 10.1037/E623942009-001; Barrett FS, 2015, J PSYCHOPHARMACOL, V29, P1182, DOI 10.1177/0269881115609019; BENSON H, 1982, NATURE, V295, P234, DOI 10.1038/295234a0; Berkovich-Ohana A, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00912; Berman AE, 2015, CONSCIOUS COGN, V31, P1, DOI 10.1016/j.concog.2014.10.002; Black D. S., 2016, ANN NY ACAD SCI, V1373, P13, DOI [10.1111/nyas.12998, DOI 10.1111/nyas.12998, DOI 10.1111/NYAS.12998]; Boccia M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/419808; BOND CF, 1983, PSYCHOL BULL, V94, P265, DOI 10.1037/0033-2909.94.2.265; Bormann JE, 2012, INT J BEHAV MED, V19, P496, DOI 10.1007/s12529-011-9186-1; Bornemann B, 2015, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01504; Bowen S, 2014, JAMA PSYCHIAT, V71, P547, DOI 10.1001/jamapsychiatry.2013.4546; Braboszcz C, 2011, NEUROIMAGE, V54, P3040, DOI 10.1016/j.neuroimage.2010.10.008; Braud W., 2010, PATANJALI YOGA SUTRA, P241; Brewer JA, 2013, PSYCHOL ADDICT BEHAV, V27, P366, DOI 10.1037/a0028490; Cahn BR, 2013, SOC COGN AFFECT NEUR, V8, P100, DOI 10.1093/scan/nss060; Carter OL, 2005, CURR BIOL, V15, pR412, DOI 10.1016/j.cub.2005.05.043; CASTILLO RJ, 1990, PSYCHIATRY, V53, P158; Chebat JC, 2003, J BUS RES, V56, P529, DOI 10.1016/S0148-2963(01)00247-8; Chiesa A, 2011, CLIN PSYCHOL REV, V31, P449, DOI 10.1016/j.cpr.2010.11.003; Cialdini RB, 2004, ANNU REV PSYCHOL, V55, P591, DOI 10.1146/annurev.psych.55.090902.142015; Cloninger CR, 1994, TCI MANUAL UBERSETZU; Cloninger CR., 2004, FEELING GOOD SCI WEL; Condon P, 2013, PSYCHOL SCI, V24, P2125, DOI 10.1177/0956797613485603; Cook-Greuter S, 1999, POSTAUTONOMOUS EGO D; Cooney JW, 2003, TRENDS COGN SCI, V7, P161, DOI 10.1016/S1364-6613(03)00058-5; Csikszentmihalyi M, 2014, APPL FLOW HUMAN DEV, P99; Curiati JA, 2005, J ALTERN COMPLEM MED, V11, P465, DOI 10.1089/acm.2005.11.465; Dahl CJ, 2015, TRENDS COGN SCI, V19, P515, DOI 10.1016/j.tics.2015.07.001; Daubenmier J, 2013, PSYCHOPHYSIOLOGY, V50, P777, DOI 10.1111/psyp.12057; Demick J, 2012, HDB ADULT DEV; Deng W, 2016, PSYCHONEUROENDOCRINO, V64, P150, DOI 10.1016/j.psyneuen.2015.11.017; Dura-Vila G, 2009, MENT HEALTH RELIG CU, V12, P543, DOI 10.1080/13674670902858800; Farb N, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00763; Felver JC, 2016, MINDFULNESS, V7, P34, DOI 10.1007/s12671-015-0389-4; Feuerstein G, 2002, YOGA TRADITION ITS H; FISCHER R, 1971, SCIENCE, V174, P897, DOI 10.1126/science.174.4012.897; Fox KCR, 2016, NEUROSCI BIOBEHAV R, V65, P208, DOI 10.1016/j.neubiorev.2016.03.021; Fox KCR, 2014, NEUROSCI BIOBEHAV R, V43, P48, DOI 10.1016/j.neubiorev.2014.03.016; FRENCH AP, 1975, J NERV MENT DIS, V161, P55, DOI 10.1097/00005053-197507000-00007; Fresco DM, 2007, BEHAV THER, V38, P234, DOI 10.1016/j.beth.2006.08.003; Gard T, 2014, ANN NY ACAD SCI, V1307, P89, DOI 10.1111/nyas.12348; Garland EL, 2014, J CONSULT CLIN PSYCH, V82, P448, DOI 10.1037/a0035798; Garland EL, 2013, PSYCHOTHER PSYCHOSOM, V82, P311, DOI 10.1159/000348868; Gittelsohn J, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110015; Goleman D, 1971, J TRANSPERS PSYCHOL, V3, P1; Goleman D, 1988, THE MEDITATION MIND; Gotink RA, 2016, BRAIN COGNITION, V108, P32, DOI 10.1016/j.bandc.2016.07.001; Goyal M, 2014, JAMA INTERN MED, V174, P357, DOI 10.1001/jamainternmed.2013.13018; Grant BF, 2004, ARCH GEN PSYCHIAT, V61, P807, DOI 10.1001/archpsyc.61.8.807; Grof S, 2012, J TRANSPERSONAL PSYC, V44, P137, DOI DOI 10.1002/9781118591277.CH5; Guerin B, 2010, SOCIAL FACILITATION; Gutchess A, 2014, SCIENCE, V346, P579, DOI 10.1126/science.1254604; Guzman G, 2008, ECON BOT, V62, P404, DOI 10.1007/s12231-008-9033-8; Hackett C, 2014, YB INT RELIG DEMOGRA, P131; Hasenkamp W, 2012, NEUROIMAGE, V59, P750, DOI 10.1016/j.neuroimage.2011.07.008; Heeter C., 1992, PRESENCE, V2, P262, DOI DOI 10.1162/PRES.1992.1.2.262; Holzel BK, 2011, PSYCHIAT RES-NEUROIM, V191, P36, DOI 10.1016/j.pscychresns.2010.08.006; Hood R.W., 2005, HDB PSYCHOL RELIG SP, P348; Hood R. W., 2018, PSYCHOL RELIG EMPIRI; Hutcherson CA, 2008, EMOTION, V8, P720, DOI 10.1037/a0013237; Jain Shamini, 2015, Glob Adv Health Med, V4, P58, DOI 10.7453/gahmj.2015.034.suppl; James W, 1985, VARIETIES RELIG EXPE; Jaseja H, 2010, EPILEPSY BEHAV, V17, P124, DOI 10.1016/j.yebeh.2009.10.022; Josipovic Z, 2016, ANN NY ACAD SCI, V1373, P65, DOI 10.1111/nyas.13078; Josipovic Z, 2014, ANN NY ACAD SCI, V1307, P9, DOI 10.1111/nyas.12261; Josipovic Z, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00538; Josipovic Z, 2012, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00183; Jung C, 1943, PSYCHOL E MEDITATION; Jung C. G., 1963, MEMORIES DREAMS REFL; Kabat-Zinn J., 1986, CLIN J PAIN, V2, P159, DOI DOI 10.1097/00002508-198602030-00004; KABATZINN J, 1982, GEN HOSP PSYCHIAT, V4, P33, DOI 10.1016/0163-8343(82)90026-3; Katterman SN, 2014, EAT BEHAV, V15, P197, DOI 10.1016/j.eatbeh.2014.01.005; Kegan R., 1995, OUR HEADS MENTAL DEM; Kelly EdwardF., 2015, PHYS RECONCILIATION, P315; Kelly EF, 2007, IRREDUCIBLE MIND PSY; Kemeny ME, 2012, EMOTION, V12, P338, DOI 10.1037/a0026118; Kerr CE, 2011, BRAIN RES BULL, V85, P96, DOI 10.1016/j.brainresbull.2011.03.026; Kessler RC, 2012, INT J METH PSYCH RES, V21, P169, DOI 10.1002/mpr.1359; Khalsa SS, 2008, PSYCHOPHYSIOLOGY, V45, P671, DOI 10.1111/j.1469-8986.2008.00666.x; Khoury B, 2013, CLIN PSYCHOL REV, V33, P763, DOI 10.1016/j.cpr.2013.05.005; Killen M., 2005, HDB MORAL DEV; Kohlberg L, 2010, MORAL PSYCHOL HIST C, P40; Kozhevnikov M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058244; Kuijpers HJH, 2007, PSYCHOPATHOLOGY, V40, P461, DOI 10.1159/000108125; Kuyken W, 2016, JAMA PSYCHIAT, V73, P565, DOI 10.1001/jamapsychiatry.2016.0076; Lansky EP, 2006, EPILEPSY BEHAV, V9, P394, DOI 10.1016/j.yebeh.2006.04.019; Last N, 2017, J ALZHEIMERS DIS, V56, P275, DOI 10.3233/JAD-160899; Lazar SW, 2005, NEUROREPORT, V16, P1893, DOI 10.1097/01.wnr.0000186598.66243.19; Lebuda I, 2016, PERS INDIV DIFFER, V93, P22, DOI 10.1016/j.paid.2015.09.040; Levin J, 2005, EXPLORE-NY, V1, P89, DOI 10.1016/j.explore.2004.12.002; Lim D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118221; Lindahl JR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176239; Lindahl JR, 2014, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00973; Lutz A, 2015, AM PSYCHOL, V70, P632, DOI 10.1037/a0039585; MacLean KA, 2012, J SCI STUD RELIG, V51, P721, DOI 10.1111/j.1468-5906.2012.01685.x; MacLean KA, 2010, PSYCHOL SCI, V21, P829, DOI 10.1177/0956797610371339; Mantzios M, 2014, APPL PSYCHOL-HLTH WE, V6, P173, DOI 10.1111/aphw.12023; MARKUS HR, 1991, PSYCHOL REV, V98, P224, DOI 10.1037/0033-295X.98.2.224; Maslow A.H., 1970, RELIG VALUES PEAK EX; Maslow A.H., 1968, PSYCHOL BEING, V(2nd); Melloni M, 2013, BEHAV BRAIN FUNCT, V9, DOI 10.1186/1744-9081-9-47; Metzner R, 1998, J PSYCHOACTIVE DRUGS, V30, P333; Miller WR, 2004, J CLIN PSYCHOL, V60, P453, DOI 10.1002/jclp.20000; Murphy Michael, 1992, FUTURE BODY EXPLORAT; Norbu CN, 2013, RELIGIONS, V4, P412, DOI 10.3390/rel4030412; O'Connor M, 2002, COUNS VALUES, V46, P137, DOI DOI 10.1002/j.2161-007X.2002.tb00284.x; Otis L. S., 1984, MEDITATION CLASSIC C, P201; Pew Research Center, 2012, GLOBAL RELIG LANDSCA; Radin D.I., 2007, J SCI EXPLORATION, V21, P295; Radin Dean, 2015, Glob Adv Health Med, V4, P67, DOI 10.7453/gahmj.2015.012.suppl; Radin D, 2015, EXPLORE-NY, V11, P82, DOI 10.1016/j.explore.2014.12.011; Radin D, 2012, PHYS ESSAYS, V25, P157, DOI 10.4006/0836-1398-25.2.157; Radin Dean.., 2013, SUPERNORMAL SCI YOGA; Radin DI, 2011, EXPLORE-NY, V7, P286, DOI 10.1016/j.explore.2011.06.004; Rangdrol T, 1994, FLIGHT GARUDA; Ricard Matthieu, 2012, WOLF SING SESS INT S; Rocha T, 2014, ATLANTIC, V25; Roney-Dougal S. M., 2008, J SCI EXPLOR, V22, P161; Roney-Dougal SM, 2013, J SOC PSYCHICAL RES, V77, P72; Roney-Dougal SM, 2011, J SCI EXPLORATION, V25; Rosenberg EL, 2015, EMOTION, V15, P775, DOI 10.1037/emo0000080; Saatcioglu F, 2013, ASIAN J PSYCHIATR, V6, P74, DOI 10.1016/j.ajp.2012.10.002; Sanada K, 2016, FRONT PHYSIOL, V7, DOI 10.3359/fphys.2016.00/171; Sauer S., 2010, ASSESSING MINDFULNES, P25; Saunders SM, 2010, PROF PSYCHOL-RES PR, V41, P355, DOI 10.1037/a0020953; Schlitz M, 2008, LIVING DEEPLY ART SC; Schultes R.E., 1995, ETHNOBOTANY EVOLUTIO; Scotton BW, 2008, TXB TRANSPERSONAL PS; Segal Z.V., 2004, MINDFULNESS BASED CO; Shankar SSR, 2014, PATANJALI YOGA SUTRA; Shapiro DH, 1992, INT J PSYCHOSOMATICS; Shapiro SL, 2015, EDUC PSYCHOL REV, V27, P1, DOI 10.1007/s10648-014-9265-3; Shapiro SL, 2006, J CLIN PSYCHOL, V62, P373, DOI 10.1002/jclp.20237; Shapiro SL, 2017, MINDFULNESS SELF CAR; Sherrill HN, 2017, PSYCHIAT RES; Soldat AS, 1997, SOC COGNITION, V15, P55, DOI 10.1521/soco.1997.15.1.55; Stace W. T., 1960, MYSTICISM PHILOS; Sze JA, 2010, EMOTION, V10, P803, DOI 10.1037/a0020146; Tang YY, 2015, NAT REV NEUROSCI, V16, P213, DOI 10.1038/nrn3916; Tart C. T., 1972, ALTERED STATES CONSC; Teasdale JD, 2002, J CONSULT CLIN PSYCH, V70, P275, DOI 10.1037//0022-006X.70.2.275; Teixeira M Elizabeth, 2008, Holist Nurs Pract, V22, P225, DOI 10.1097/01.HNP.0000326006.65310.a7; Tiller WA, 2007, J ALTERN COMPLEM MED, V13, P133, DOI 10.1089/acm.2006.6143; Tomasino B, 2014, BRAIN COGNITION, V90, P32, DOI 10.1016/j.bandc.2014.03.013; Tran Ulrich S, 2014, PLoS One, V9, pe110192, DOI 10.1371/journal.pone.0110192; Travis F, 2002, BIOL PSYCHOL, V61, P293, DOI 10.1016/S0301-0511(02)00048-0; Travis F, 1999, CONSCIOUS COGN, V8, P302, DOI 10.1006/ccog.1999.0403; Travis F, 2000, INT J NEUROSCI, V100, P77, DOI 10.3109/00207450008999678; Travis F, 2014, ANN NY ACAD SCI, V1307, P1, DOI 10.1111/nyas.12316; Vago DR, 2016, ANN NY ACAD SCI, V1373, P96, DOI 10.1111/nyas.13171; Vago DR, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00296; Vaillant G. E., 2008, AGING WELL SURPRISIN; Vaillant GE, 2015, POSITIVE PSYCHOL PRA, P595; Vedanta S., 2015, VEDANTA PHILOS 8 LEC; Vieten C, 2008, MEANING LIFE 21 CENT, P265; Vieten C, 2006, ZYGON, V41, P915; Vimalaramsi U., 1997, ANAPANASATI SUTTA PR; Wachholtz AB, 2005, J BEHAV MED, V28, P369, DOI 10.1007/s10865-005-9008-5; Walsh R, 2006, AM PSYCHOL, V61, P227, DOI 10.1037/0003-066X.61.3.227; Walsh R., 2014, WORLDS GREAT WISDOM; Walsh R, 1979, AM J PSYCHIAT; Walsh RE., 1993, PATHS EGO TRANSPERSO; Walsh R, 2015, REV GEN PSYCHOL, V19, P278, DOI 10.1037/gpr0000045; Walton Kenneth G, 2004, Cardiol Rev, V12, P262, DOI 10.1097/01.crd.0000113021.96119.78; Watts AW., 1957, SUPREME IDENTITY ESS; Wilber Ken., 2000, INTEGRAL PSYCHOL CON; WILBER Ken, 1993, SPECTRUM CONSCIOUSNE; Wu SD, 2008, BIOMED RES-TOKYO, V29, P245, DOI 10.2220/biomedres.29.245; YAMANE D, 1994, SOCIOL RELIG, V55, P1, DOI 10.2307/3712173; Young S, 2011, S YOUNG; Zeidan F, 2012, NEUROSCI LETT, V520, P165, DOI 10.1016/j.neulet.2012.03.082; Zeidan F, 2016, ANN NY ACAD SCI, V1373, P114, DOI 10.1111/nyas.13153; Zeidan F, 2010, J PAIN, V11, P199, DOI 10.1016/j.jpain.2009.07.015; Zeng X, 2015, FRONT PSYCHOL, P6	178	49	49	5	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2018	13	11							e0205740	10.1371/journal.pone.0205740	http://dx.doi.org/10.1371/journal.pone.0205740			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GZ4PQ	30403693	gold, Green Submitted, Green Published			2023-01-03	WOS:000449379500021
J	Norman, JE; Heazell, AEP; Rodriguez, A; Weir, CJ; Stock, SJE; Calderwood, CJ; Burley, SC; Froen, JF; Geary, M; Breathnach, F; Hunter, A; McAuliffe, FM; Higgins, MF; Murdoch, E; Ross-Davie, M; Scott, J; Whyte, S				Norman, Jane E.; Heazell, Alexander E. P.; Rodriguez, Aryelly; Weir, Christopher J.; Stock, Sarah J. E.; Calderwood, Catherine J.; Burley, Sarah Cunningham; Froen, J. Frederik; Geary, Michael; Breathnach, Fionnuala; Hunter, Alyson; McAuliffe, Fionnuala M.; Higgins, Mary F.; Murdoch, Edile; Ross-Davie, Mary; Scott, Janet; Whyte, Sonia		AFFIRM Investigators	Awareness of fetal movements and care package to reduce fetal mortality (AFFIRM): a stepped wedge, cluster-randomised trial	LANCET			English	Article							STILLBIRTH RISK; STANDARDS; WEIGHT	Background 2.6 million pregnancies were estimated to have ended in stillbirth in 2015. The aim of the AFFIRM study was to test the hypothesis that introduction of a reduced fetal movement (RFM), care package for pregnant women and clinicians that increased women's awareness of the need for prompt reporting of RFM and that standardised management, including timely delivery, would alter the incidence of stillbirth. Methods This stepped wedge, cluster-randomised trial was done in the UK and Ireland. Participating maternity hospitals were grouped and randomised, using a computer-generated allocation scheme, to one of nine intervention implementation dates (at 3 month intervals). This date was concealed from clusters and the trial team until 3 months before the implementation date. Each participating hospital had three observation periods: a control period from Jan 1, 2014, until randomised date of intervention initiation; a washout period from the implementation date and for 2 months; and the intervention period from the end of the washout period until Dec 31, 2016. Treatment allocation was not concealed from participating women and caregivers. Data were derived from observational maternity data. The primary outcome was incidence of stillbirth. The primary analysis was done according to the intention-to-treat principle, with births analysed according to whether they took place during the control or intervention periods, irrespective of whether the intervention had been implemented as planned. This study is registered with ClinicalTrials. gov, number NCT01777022. Findings 37 hospitals were enrolled in the study. Four hospitals declined participation, and 33 hospitals were randomly assigned to an intervention implementation date. Between Jan 1, 2014, and Dec, 31, 2016, data were collected from 409 175 pregnancies (157 692 deliveries during the control period, 23 623 deliveries in the washout period, and 227 860 deliveries in the intervention period). The incidence of stillbirth was 4.40 per 1000 births during the control period and 4.06 per 1000 births in the intervention period (adjusted odds ratio [ aOR] 0.90, 95% CI 0.75-1.07; p= 0.23). Interpretation The RFM care package did not reduce the risk of stillbirths. The benefits of a policy that promotes awareness of RFM remains unproven. Copyright (c) 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.	[Norman, Jane E.; Stock, Sarah J. E.; Whyte, Sonia] Univ Edinburgh, Queens Med Res Inst, MRC Ctr Reprod Hlth, Tommys Ctr Maternal & Fetal Hlth, Edinburgh, Midlothian, Scotland; [Heazell, Alexander E. P.] Univ Manchester, Fac Biol Med & Hlth, Sch Med Sci, Tommys Maternal & Fetal Hlth Res Ctr, Manchester, Lancs, England; [Heazell, Alexander E. P.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, St Marys Hosp, Manchester, Lancs, England; [Rodriguez, Aryelly; Weir, Christopher J.; Burley, Sarah Cunningham] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Calderwood, Catherine J.] Scottish Govt, Edinburgh, Midlothian, Scotland; [Froen, J. Frederik] Norwegian Inst Publ Hlth, Div Hlth Serv, Global Hlth Cluster, Oslo, Norway; [Geary, Michael; Breathnach, Fionnuala] Rotunda Hosp, Dublin, Ireland; [Hunter, Alyson] Royal Matern Hosp, Ctr Fetal Med, Belfast, Antrim, North Ireland; [McAuliffe, Fionnuala M.; Higgins, Mary F.] Univ Coll Dublin, Natl Matern Hosp, Sch Med, UCD Perinatal Res Ctr, Dublin, Ireland; [Murdoch, Edile] Royal Infirm Edinburgh NHS Lothian, Dept Neonatol, Edinburgh, Midlothian, Scotland; [Ross-Davie, Mary] Royal Coll Midwives, Edinburgh, Midlothian, Scotland; [Scott, Janet] Victoria Charity Ctr, Sands, London, England	University of Edinburgh; University of Manchester; University of Manchester; University of Edinburgh; Norwegian Institute of Public Health (NIPH); National Maternity Hospital, Dublin; University College Dublin	Norman, JE (corresponding author), People & Culture Univ Edinburgh, MRC Ctr Reprod Hlth, Queens Med Res Inst, Tommys Ctr Maternal & Fetal Hlth, Edinburgh EH16 4TJ, Midlothian, Scotland.	jane.norman@ed.ac.uk	Whyte, Sonia/ABB-3075-2021; Whyte, Sonia/ABC-9345-2021	Whyte, Sonia/0000-0003-0878-4244; Norman, Jane/0000-0001-6031-6953; Higgins, Mary/0000-0002-6469-5169; Cunningham-Burley, Sarah/0000-0002-0009-7653; Weir, Christopher/0000-0002-6494-4903	Chief Scientist Office, Scottish Government [CZH/4/882]; Tommy's Centre for Maternal and Fetal Health; Sands	Chief Scientist Office, Scottish Government; Tommy's Centre for Maternal and Fetal Health; Sands	Chief Scientist Office, Scottish Government (CZH/4/882), Tommy's Centre for Maternal and Fetal Health, Sands.	Anderson NH, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2015.10.931; Benchimol EI, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001885; de Bernis L, 2016, LANCET, V387, P703, DOI 10.1016/S0140-6736(15)00954-X; Draper E, 2017, LEICESTER INFANT MOR; Dutton PJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039784; Efkarpidis Savvas, 2004, MedGenMed, V6, P53; Flenady V, 2011, LANCET, V377, P1703, DOI 10.1016/S0140-6736(11)60064-0; Flenady V, 2011, LANCET, V377, P1331, DOI 10.1016/S0140-6736(10)62233-7; Francis A, 2018, AM J OBSTET GYNECOL, V218, pS692, DOI 10.1016/j.ajog.2017.12.013; GRANT A, 1989, LANCET, V2, P345; Heazell AEP, 2008, J OBSTET GYNAECOL, V28, P147, DOI 10.1080/01443610801912618; Heazell AEP, 2015, ULTRASOUND OBST GYN, V46, P641, DOI 10.1002/uog.15738; Heazell AEP, 2008, ACTA OBSTET GYN SCAN, V87, P331, DOI 10.1080/00016340801902034; Heazell AEP, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1555-6; Heazell AEP, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014813; Mangesi L, 2015, COCHRANE DB SYST REV, V15; Radestad I, 2016, SEX REPROD HEALTHC, V10, P56, DOI 10.1016/j.srhc.2016.10.004; Stacey T, 2011, BIRTH-ISS PERINAT C, V38, P311, DOI 10.1111/j.1523-536X.2011.00490.x; Tveit JVH, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-32; Villar J, 2014, LANCET, V384, P857, DOI 10.1016/S0140-6736(14)60932-6; Warland J, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0602-4; Warrander LK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034851; Winje BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039259	23	84	84	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 3	2018	392	10158					1629	1638		10.1016/S0140-6736(18)31543-5	http://dx.doi.org/10.1016/S0140-6736(18)31543-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GZ0JO	30269876	hybrid, Green Published			2023-01-03	WOS:000449048900028
J	Freeman, L; Middeldorp, J; van den Akker, E; Oudijk, M; Bax, C; van Huizen, M; Radder, C; Fong, B; Bloemenkamp, K; Dahan, A; Struys, M; Mol, BW; van Lith, J; van den Akker-van Marle, E				Freeman, Liv; Middeldorp, Johanna; van den Akker, Eline; Oudijk, Martijn; Bax, Caroline; van Huizen, Marloes; Radder, Celine; Fong, Bianca; Bloemenkamp, Kitty; Dahan, Albert; Struys, Michel; Mol, Ben Willem; van Lith, Jan; van den Akker-van Marle, Elske			An economic analysis of patient controlled remifentanil and epidural analgesia as pain relief in labour (RAVEL trial); a randomised controlled trial	PLOS ONE			English	Article							INTRAVENOUS REMIFENTANIL; IMPUTATION	Objective To compare the costs of a strategy of patient controlled remifentanil versus epidural analgesia for pain relief in labour. Design We performed a multicentre randomised controlled trial in 15 hospitals in the Netherlands, the RAVEL trial. Costs were analysed from a health care perspective alongside the RAVEL trial. Population Pregnant women of intermediate to high risk beyond 32 weeks gestation who planned vaginal delivery. Methods Women were randomised before the onset of labour, to receive either patient controlled remifentanil or epidural analgesia when pain relief was requested during labour. Main outcome measures Primary outcome for effectiveness was satisfaction with pain relief, expressed as the area under the curve (AUC). A higher AUC represents higher satisfaction with pain relief. Here, we present an economic analysis from a health care perspective including costs from the start of labour to ten days postpartum. Health-care utilization was documented in the Case Report Forms and by administering an additional questionnaire. Results The costs in the patient controlled remifentanil group (n = 687) and in the epidural group (n = 671) were (sic)2900 versus (sic)3185 respectively (mean difference of -(sic)282 (95% CI -(sic)611 to (sic)47)). The (non-significant) higher costs in the epidural analgesia group could be mainly attributed to higher costs of neonatal admission. Conclusion From an economic perspective, there is no preferential pain treatment in labouring intermediate to high risk women. Since patient controlled remifentanil is not equivalent to epidural analgesia with respect to AUC for satisfaction with pain relief we recommend epidural analgesia as the method of choice. However, if appropriately counselled on effect and side effects there is, from an economic perspective, no reason to deny women patient controlled remifentanil.	[Freeman, Liv; Middeldorp, Johanna; van Lith, Jan] Leiden Univ, Obstet, Med Ctr, Leiden, Netherlands; [van den Akker, Eline] Onze Lieve Vrouw Hosp, Gynaecol & Obstet, Amsterdam, Netherlands; [Oudijk, Martijn] Amsterdam UMC, Locat Meibergdreef, Gyneacol & Obstet, Amsterdam, Netherlands; [Bax, Caroline] Amsterdam UMC, Locat Meibergdreef, Gyneacol & Obstet, Locat Boelelaan, Amsterdam, Netherlands; [van Huizen, Marloes] HagaZiekenhuis, Gyneacol & Obstet, The Hague, Netherlands; [Radder, Celine] St Lucas Andreas Ziekenhuis, Gyneacol & Obstet, Amsterdam, Netherlands; [Fong, Bianca] Zaans Med Ctr, Gyneacol & Obstet, Amsterdam, Netherlands; [Bloemenkamp, Kitty] UMC Utrecht, Wilhelmina Children Hosp, Birth Ctr, Utrecht, Netherlands; [Dahan, Albert] Leiden Univ, Med Ctr, Anaesthesiol, Leiden, Netherlands; [Struys, Michel] Univ Med Ctr Groningen, Anaesthesiol, Groningen, Netherlands; [Mol, Ben Willem] Univ Adelaide, Sch Paediat & Reprod Hlth, Robinson Inst, Adelaide, SA, Australia; [van den Akker-van Marle, Elske] Leiden Univ, Med Ctr, Dept Med Decis Making, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Onze Lieve Vrouwe Gasthuis Hospital; University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Haga Hospital; Sint Lucas Andreas Hospital; Utrecht University; Utrecht University Medical Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Groningen; Robinson Research Institute; University of Adelaide; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Freeman, L (corresponding author), Leiden Univ, Obstet, Med Ctr, Leiden, Netherlands.	l.freeman@ikazia.nl	Dahan, Albert/B-8845-2008; Oudijk, Martijn A/C-1520-2019	Dahan, Albert/0000-0003-3161-3945; Oudijk, Martijn A/0000-0001-8672-4365; Struys, Michel/0000-0003-0421-536X; van den Akker-van Marle, M. Elske/0000-0002-5269-509X	ZonMW (Dutch Organization for Health Care Research and Development), Hague, Netherlands [80-82310-97-11039]	ZonMW (Dutch Organization for Health Care Research and Development), Hague, Netherlands	Financial support for this trial was provided by ZonMW (Dutch Organization for Health Care Research and Development), the Hague, the Netherlands, project number 80-82310-97-11039. www.zonmw.nl. The grant applicant was JM, the funding was transfered to the Leiden University Medical Center. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, PHARM COMP 2011; Donders ART, 2006, J CLIN EPIDEMIOL, V59, P1087, DOI 10.1016/j.jclinepi.2006.01.014; Douma MR, 2011, INT J OBSTET ANESTH, V20, P118, DOI 10.1016/j.ijoa.2010.11.009; Freeman LM, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h846; Freeman LM, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-63; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; Hakkaart-van Roijen L, 2010, HANDLEIDING KOSTENON; Hodnett ED, 2013, COCHRANE DB SYST REV, P1, DOI [10.1002/14651858.CD003766.pub4, 10.1002/14651858.CD003766.pub5, 10.1002/14651858.CD003766.pub6]; Hughes D, 2016, PHARMACOECONOMICS, V34, P447, DOI 10.1007/s40273-015-0371-y; Kan RE, 1998, ANESTHESIOLOGY, V88, P1467, DOI 10.1097/00000542-199806000-00008; Macario A, 2000, ANESTHESIOLOGY, V92, P841, DOI 10.1097/00000542-200003000-00028; Michelsen LG, 1996, J CLIN ANESTH, V8, P679, DOI 10.1016/S0952-8180(96)00179-1; NVOG (Dutch Society of Obstetrics and Gynaecology), 2008, GUID PIJNST TIJD BEV; Statistics Netherlands, STATL CONS PRIC IND; van der Heijden GJMG, 2006, J CLIN EPIDEMIOL, V59, P1102, DOI 10.1016/j.jclinepi.2006.01.015; Vijgen SMC, 2011, ACTA OBSTET GYN SCAN, V90, P772, DOI 10.1111/j.1600-0412.2011.01138.x; Volmanen P, 2008, ACTA ANAESTH SCAND, V52, P249, DOI 10.1111/j.1399-6576.2007.01509.x	17	3	4	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2018	13	10							e0205220	10.1371/journal.pone.0205220	http://dx.doi.org/10.1371/journal.pone.0205220			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW7TO	30307986	Green Published, gold			2023-01-03	WOS:000447173500049
J	van de Berg, S; Jansen-Aaldring, N; de Vries, G; van den Hof, S				van de Berg, Sarah; Jansen-Aaldring, Niesje; de Vries, Gerard; van den Hof, Susan			Patient support for tuberculosis patients in low-incidence countries: A systematic review	PLOS ONE			English	Review							MULTIDRUG-RESISTANT TUBERCULOSIS; DIRECTLY OBSERVED THERAPY; NEW-YORK-CITY; PULMONARY TUBERCULOSIS; PROMOTE ADHERENCE; RISK-FACTORS; HEALTH; CARE; TB; STRATEGIES	Background Patient support during tuberculosis treatment is expected to be more often available and more customized in low tuberculosis incidence, high-resource settings than in lower-resource settings. The aim of this systematic review is to provide an overview of tuberculosis patient support interventions implemented in low-incidence countries and an evaluation of their effects on treatment-related outcomes as well as their acceptability by patients and providers. Methods PubMed, Social Science Citation Index and Cumulative Index to Nursing and Allied Health and Literature were searched for the period 01.2006-05.2016 on publications describing tuberculosis patient support interventions in low-incidence countries (<20 patients per 100,000 population). Results Through our search strategy, 1875 unique publications were identified. Forty publications were included: 17 evaluated patient support quantitatively, 9 qualitatively and 14 only described the patient support. Nineteen publications assessed treatment supervision options only, 21 assessed (combinations of) treatment supervision, socio-economic, psycho-emotional, health-educational and other support. Of eight studies quantitatively evaluating the effects of support with a control group, four showed positive effects: two out of three that used combinations of patient support and two out of five that compared treatment supervision options. Heterogeneity of interventions precluded pooling of results. Qualitative and descriptive studies showed that patients appreciated individualized support including treatment supervision, psycho-emotional and socio-economic support; and digital health interventions. Conclusion Our review shows that a variety of patient support interventions is implemented in low-incidence countries. Although only a few interventions were evaluated quantitatively, we identified potential best practices. The scarcity of evidence on effectiveness, however, indicates the need for further research to evaluate potential best practices.	[van de Berg, Sarah; Jansen-Aaldring, Niesje; de Vries, Gerard; van den Hof, Susan] KNCV TB Fdn, The Hague, Netherlands; [de Vries, Gerard] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands; [van den Hof, Susan] Acad Med Ctr, Dept Global Hlth, Amsterdam, Netherlands; [van den Hof, Susan] Amsterdam Inst Global Hlth & Dev, Amsterdam, Netherlands	KNCV Tuberculosis Foundation; Netherlands National Institute for Public Health & the Environment; University of Amsterdam; Academic Medical Center Amsterdam	van de Berg, S (corresponding author), KNCV TB Fdn, The Hague, Netherlands.	Sarah.vandeberg@kncvtbc.org	van de Berg, Sarah/AGZ-0990-2022	de Vries, Gerard/0000-0003-1278-4503	KNCV Tuberculosis Foundation	KNCV Tuberculosis Foundation	This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. KNCV Tuberculosis Foundation supported the work through internal dedicated funding.	Anger HA, 2010, J ANTIMICROB CHEMOTH, V65, P775, DOI 10.1093/jac/dkq017; [Anonymous], 2003, ADHERENCE LONG TERM; [Anonymous], 2013, J ROY SOC MED, V106, P130, DOI [10.1177/0141076812472620, DOI 10.1177/0141076812472620]; Babalik A, 2013, BALK MED J, V30, P204, DOI 10.5152/balkanmedj.2013.005; Banerjee R, 2008, CLIN INFECT DIS, V47, P450, DOI 10.1086/590009; Bender A, 2011, INT J NURS STUD, V48, P1409, DOI 10.1016/j.ijnurstu.2011.04.012; Bock NN, 2001, INT J TUBERC LUNG D, V5, P96; Cayla JA, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-121; Charokopos N, 2013, RURAL REMOTE HEALTH, V13, P1; Chaudhry LA, 2015, PAN AFR MED J, V20, DOI 10.11604/pamj.2015.20.115.5865; Chuck C, 2016, INT J TUBERC LUNG D, V20, P588, DOI 10.5588/ijtld.15.0738; Clark PM, 2007, AM J HEALTH-SYST PH, V64, P497, DOI 10.2146/ajhp050543; Craig GA, 2008, J ADV NURS, V61, P413, DOI 10.1111/j.1365-2648.2007.04498.x; Craig GM, 2015, INT J INFECT DIS, V32, P105, DOI 10.1016/j.ijid.2015.01.007; Cremers AL, 2017, LANCET INFECT DIS, V17, P128, DOI [10.1016/S1473-3099(17)30008-7, DOI 10.1016/S1473-3099(17)30008-7]; D'Ambrosio L, 2014, EUR RESPIR J, V43, P1410, DOI 10.1183/09031936.00198813; Dara M, 2012, EUR RESPIR J, V40, P1081, DOI 10.1183/09031936.00053012; Davidson H, 2000, INT J TUBERC LUNG D, V4, P860; ECDC EC for DP and C, TUB EUR PASS CONTR A; Ehman M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110645; Escudero E, 2006, INT J TUBERC LUNG D, V10, P409; Falzon D, 2016, EUR RESPIR J, V48, P29, DOI 10.1183/13993003.00424-2016; Ferrer G, 2010, AM J TROP MED HYG, V83, P1056, DOI 10.4269/ajtmh.2010.10-0145; Franke MF, 2008, CLIN INFECT DIS, V46, P1844, DOI 10.1086/588292; Garcia-Garcia JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016272; Garfein RS, 2015, INT J TUBERC LUNG D, V19, P1057, DOI 10.5588/ijtld.14.0923; Gebhard A., 2014, LESSONS LEARNED BEST; Gerrish K, 2013, J ADV NURS, V69, P2285, DOI 10.1111/jan.12112; Guglielmi S, 2006, INT J TUBERC LUNG D, V10, P1236; Hayashi Y, 2011, CLIN INFECT DIS, V52, P1232, DOI 10.1093/cid/cir063; Heuvelings CC, 2017, LANCET INFECT DIS, V17, P144, DOI [10.1016/S1473-3099(17)30016-6, DOI 10.1016/S1473-3099(17)30016-6]; Heymann SJ, 1998, AM J PUBLIC HEALTH, V88, P442, DOI 10.2105/AJPH.88.3.442; Horsburgh CR, 2015, NEW ENGL J MED, V373, P2149, DOI 10.1056/NEJMra1413919; Horter S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108591; Jansen-Aaldring N, 2018, J ADV NURS, P1, DOI [10.1111/jan.13186, DOI 10.1111/JAN.13186]; Jit M, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5376; Kaona FAD, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-68; Karumbi J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003343.pub4; Katsuda N, 2015, NAGOYA J MED SCI, V77, P19; Kawatsu L, 2013, INT J TUBERC LUNG D, V17, P940, DOI 10.5588/ijtld.12.0503; Khan K, 2011, EMERG INFECT DIS, V17, P357, DOI 10.3201/eid1703.100833; Khan PY, 2017, INT J TUBERC LUNG D, V21, P1147, DOI 10.5588/ijtld.17.0162; Kik SV, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-283; King L, 2010, INT J TUBERC LUNG D, V14, P1613; Krueger K, 2010, INT J TUBERC LUNG D, V14, P779; Kurt AO, 2012, CENT EUR J PUBL HEAL, V20, P144, DOI 10.21101/cejph.a3713; Liu Q, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006594.pub3; LoBue PA, 1999, CHEST, V115, P218, DOI 10.1378/chest.115.1.218; Lonnroth K, 2015, EUR RESPIR J, V45, P928, DOI 10.1183/09031936.00214014; Luzzati R, 2011, Monaldi Arch Chest Dis, V75, P141; Macq J, 2007, TROP MED INT HEALTH, V12, P873, DOI 10.1111/j.1365-3156.2007.01858.x; Mejuto B, 2010, CHARACTERIZATION EVA, P21; Mejuto B, 2010, RISK MANAG HEALTHC P, V3, P21, DOI 10.2147/RMHP.S8921; Mtui Leah, 2014, J Infect Prev, V15, P24, DOI 10.1177/1757177413500511; Munro SA, 2007, PLOS MED, V4, P1230, DOI 10.1371/journal.pmed.0040238; Ngwatu BK, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01596-2017; Pevzner ES, 2010, AM J PUBLIC HEALTH, V100, P2481, DOI 10.2105/AJPH.2009.162388; Pritchett EN, 2009, INT J TUBERC LUNG D, V13, P323; Pursnani S, 2014, CHEST, V145, P95, DOI 10.1378/chest.13-0324; Ricks PM, 2015, INT J TUBERC LUNG D, V19, P326, DOI 10.5588/ijtld.14.0471; RIVM, 2016, TUB KERNC 2016; Rubado DJ, 2008, INT J TUBERC LUNG D, V12, P301; Sagbakken M, 2012, SCAND J CARING SCI, V26, P313, DOI 10.1111/j.1471-6712.2011.00935.x; Searle A, 2007, INT J TUBERC LUNG D, V11, P72; Shimamura T, 2013, PUBLIC HEALTH NURS, V30, P370, DOI 10.1111/phn.12010; Stewart M, 2001, BRIT MED J, V322, P444, DOI 10.1136/bmj.322.7284.444; Story A, 2007, THORAX, V62, P667, DOI 10.1136/thx.2006.065409; Suwankeeree W, 2014, INT J EVID-BASED HEA, V12, P3, DOI 10.1097/01.XEB.0000444614.17658.46; The World Health Organization, 2010, TREATM TUB GUID, V160, DOI [10.1164/rccm.201012-1949oc, DOI 10.1164/RCCM.201012-1949OC]; Timmermans L, 2014, TEGEN TUBERC, V110, P8; van Altena R, 2015, INT J TUBERC LUNG D, V19, P406, DOI 10.5588/ijtld.14.0838; van Hoorn R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154095; Verver S, 2005, AM J RESP CRIT CARE, V171, P1430, DOI 10.1164/rccm.200409-1200OC; Volmink J, 1997, BMJ-BRIT MED J, V315, P1403, DOI 10.1136/bmj.315.7120.1403; Wade VA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050155; WHO, 2015, GLOB TUB CONTR WHO R, V1, DOI [10.1017/CBO9781107415324.004, DOI 10.1017/CBO9781107415324.004]; WHO, 2017, TREATMENT TUBERCULOS; Zignol M, 2006, J INFECT DIS, V194, P479, DOI 10.1086/505877; Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7	79	5	7	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2018	13	10							e0205433	10.1371/journal.pone.0205433	http://dx.doi.org/10.1371/journal.pone.0205433			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GW4VA	30304052	Green Published, gold, Green Submitted			2023-01-03	WOS:000446921100092
J	Hosomi, K; Fujimoto, M; Ushio, K; Mao, LL; Kato, J; Takada, M				Hosomi, Kouichi; Fujimoto, Mai; Ushio, Kazutaka; Mao, Lili; Kato, Juran; Takada, Mitsutaka			An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; SEQUENCE SYMMETRY ANALYSIS; SPONTANEOUS REPORTING DATABASE; NF-KAPPA-B; CONNECTIVITY MAP; SIGNAL-DETECTION; GENE-EXPRESSION; CLAIMS DATABASE; ADVERSE EVENTS; STATIN USE	Different computational approaches are employed to efficiently identify novel repositioning possibilities utilizing different sources of information and algorithms. It is critical to propose high-valued candidate-repositioning possibilities before conducting lengthy in vivo validation studies that consume significant resources. Here we report a novel multi-methodological approach to identify opportunities for drug repositioning. We performed analyses of real-world data (RWD) acquired from the United States Food and Drug Administration's Adverse Event Reporting System (FAERS) and the claims database maintained by the Japan Medical Data Center (JMDC). These analyses were followed by cross-validation through bioinformatics analyses of gene expression data. Inverse associations revealed using disproportionality analysis (DPA) and sequence symmetry analysis (SSA) were used to detect potential drug-repositioning signals. To evaluate the validity of the approach, we conducted a feasibility study to identify marketed drugs with the potential for treating inflammatory bowel disease (IBD). Primary analyses of the FAERS and JMDC claims databases identified psycholeptics such as haloperidol, diazepam, and hydroxyzine as candidates that may improve the treatment of IBD. To further investigate the mechanistic relevance between hit compounds and disease pathology, we conducted bioinformatics analyses of the associations of the gene expression profiles of these compounds with disease. We identified common biological features among genes differentially expressed with or without compound treatment as well as disease-perturbation data available from open sources, which strengthened the mechanistic rationale of our initial findings. We further identified pathways such as cytokine signaling that are influenced by these drugs. These pathways are relevant to pathologies and can serve as alternative targets of therapy. Integrative analysis of RWD such as those available from adverse-event databases, claims databases, and transcriptome analyses represent an effective approach that adds value to efficiently identifying potential novel therapeutic opportunities.	[Hosomi, Kouichi; Fujimoto, Mai; Takada, Mitsutaka] Kindai Univ, Sch Pharm, Div Clin Drug Informat, Higashiosaka, Osaka, Japan; [Ushio, Kazutaka; Mao, Lili; Kato, Juran] Takeda Pharmaceut Co Ltd, Innovat & Entrepreneurship Res, 2 Chome, Fujisawa, Kanagawa, Japan; [Ushio, Kazutaka] Chugai Pharmaceut Co Ltd, Med Liaison Dept, Med Affairs Div, Shinagawa Ku, Kitashinagawa 5 Chome, Tokyo, Japan; [Mao, Lili; Kato, Juran] GEXVal Inc, 2 Chome, Fujisawa, Kanagawa, Japan	Takeda Pharmaceutical Company Ltd; Chugai Pharmaceutical Co., Ltd.	Takada, M (corresponding author), Kindai Univ, Sch Pharm, Div Clin Drug Informat, Higashiosaka, Osaka, Japan.	takada@phar.kindai.ac.jp		Hosomi, Kouichi/0000-0002-2091-2766; Ushio, Kazutaka/0000-0002-1263-1948	Takeda Pharmaceutical Company Limited; Chugai Pharmaceutical Company Limited	Takeda Pharmaceutical Company Limited(Takeda Pharmaceutical Company Ltd); Chugai Pharmaceutical Company Limited	This work was supported by Takeda Pharmaceutical Company Limited in the form of salaries to KU, LM, JK. Additional support came from Chugai Pharmaceutical Company Limited in the form of salaries to KU. The funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almenoff JS, 2007, CLIN PHARMACOL THER, V82, P157, DOI 10.1038/sj.clpt.6100258; Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468; Bate A, 1998, EUR J CLIN PHARMACOL, V54, P315, DOI 10.1007/s002280050466; Bohm R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157753; De Plaen IG, 2006, IMMUNOLOGY, V118, P153, DOI 10.1111/j.1365-2567.2006.02344.x; Dudley JT, 2011, BRIEF BIOINFORM, V12, P303, DOI 10.1093/bib/bbr013; Fujimoto M, 2015, INT J MED SCI, V12, P223, DOI 10.7150/ijms.10656; Hallas J, 1997, EPIDEMIOLOGY, V8, P666, DOI 10.1097/00001648-199710000-00009; Hallas J, 1996, EPIDEMIOLOGY, V7, P478, DOI 10.1097/00001648-199609000-00004; Hodos RA, 2016, WIRES SYST BIOL MED, V8, P186, DOI 10.1002/wsbm.1337; Hurle MR, 2013, CLIN PHARMACOL THER, V93, P335, DOI 10.1038/clpt.2013.1; Jorgensen WL, 2004, SCIENCE, V303, P1813, DOI 10.1126/science.1096361; Kimura S, 2010, J EPIDEMIOL, V20, P413, DOI 10.2188/jea.JE20090066; Kupershmidt I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013066; Lamb J, 2007, NAT REV CANCER, V7, P54, DOI 10.1038/nrc2044; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; LECHIN F, 1982, J CLIN GASTROENTEROL, V4, P445, DOI 10.1097/00004836-198210000-00010; Li J, 2016, BRIEF BIOINFORM, V17, P2, DOI 10.1093/bib/bbv020; Lipinski C, 2004, NATURE, V432, P855, DOI 10.1038/nature03193; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Lussier YA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001512; Mizoguchi A, 2012, PROG MOL BIOL TRANSL, V105, P263, DOI 10.1016/B978-0-12-394596-9.00009-3; Montero-Melendez T, 2014, DRUG DISCOV TODAY, V19, P820, DOI 10.1016/j.drudis.2013.11.022; MORRIS JA, 1988, BRIT MED J, V296, P1313, DOI 10.1136/bmj.296.6632.1313; Musa A, 2018, BRIEF BIOINFORM, V19, P506, DOI 10.1093/bib/bbw112; Nagashima T, 2016, SCI REP-UK, V6, DOI 10.1038/srep26375; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Nosengo N, 2016, NATURE, V534, P314, DOI 10.1038/534314a; Qu XYA, 2012, DRUG DISCOV TODAY, V17, P1289, DOI 10.1016/j.drudis.2012.07.017; Sakaeda T, 2013, INT J MED SCI, V10, P796, DOI 10.7150/ijms.6048; Santiago JA, 2016, SCI REP-UK, V6, DOI 10.1038/srep34579; Scannell JW, 2012, NAT REV DRUG DISCOV, V11, P191, DOI 10.1038/nrd3681; Shah SB, 2007, REV GASTROENTEROL DI, V7, pS3; Shameer K, 2015, CURR TOP MED CHEM, V15, P5, DOI 10.2174/1568026615666150112103510; Sirota M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001318; Straus DS, 2000, P NATL ACAD SCI US; Takada M, 2016, INT J MED SCI, V13, P825, DOI 10.7150/ijms.16185; Takada M, 2016, INT J MED SCI, V13, P48, DOI 10.7150/ijms.13834; Takada M, 2014, DRUG SAFETY, V37, P421, DOI 10.1007/s40264-014-0163-x; Tsiropoulos I, 2009, PHARMACOEPIDEM DR S, V18, P483, DOI 10.1002/pds.1736; van Puijenbroek EP, 2002, PHARMACOEPIDEM DR S, V11, P3, DOI 10.1002/pds.668; Wahab IA, 2013, ADV PHARMACOEPIDEMIO, P02; Wahab IA, 2016, DRUG SAFETY, V39, P347, DOI 10.1007/s40264-015-0391-8; Wahab IA, 2013, PHARMACOEPIDEM DR S, V22, P496, DOI 10.1002/pds.3417; Wang KJ, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.4541; Wullaert A, 2011, CELL RES, V21, P146, DOI 10.1038/cr.2010.175; Yang L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028025; Yella JK, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11020057; Zhao S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006548; Zhao ZJ, 2012, INT IMMUNOPHARMACOL, V12, P169, DOI 10.1016/j.intimp.2011.11.007	50	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2018	13	10							e0204648	10.1371/journal.pone.0204648	http://dx.doi.org/10.1371/journal.pone.0204648			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW4OW	30300381	Green Submitted, gold, Green Published			2023-01-03	WOS:000446897200013
J	Szymanski, L; Cios, A; Lewicki, S; Szymanski, P; Stankiewicz, W				Szymanski, Lukasz; Cios, Aleksandra; Lewicki, Slawomir; Szymanski, Pawel; Stankiewicz, Wanda			Fas/FasL pathway and cytokines in keratinocytes in atopic dermatitis - Manipulation by the electromagnetic field	PLOS ONE			English	Article							MAPK SIGNALING PATHWAYS; FAS LIGAND; STEM-CELLS; IN-VITRO; EXPOSURE; LEVEL; SKIN; ACTIVATION; RADIATION; APOPTOSIS	Background Atopic dermatitis (AD) is one of the most frequent skin diseases. Changes of the keratinocytes functionality play a major role in the development of AD. For example, activation of the Fas (CD95)/FasL (CD178) pathway in AD does not lead to extensive apoptosis in skin. Binding of the Fas receptor to its protein ligand-FasL, which are present on the (AD)-modified keratinocytes, should result in the sequential induction of cell death, but there is no evidence of extensive apoptosis of these cells. This suggests that non-apoptotic mechanism of Fas/FasL pathway is commonly encountered, although not examined in the case of AD, phenomenon. An electromagnetic field, which was used to influence cultured cells in this study, can modulate proliferation, apoptosis, differentiation, and metabolism in various cells. Objective Here, we evaluate the possibility to manipulate the immune activation of AD keratinocytes and their response to the electromagnetic field, which was not tested before. Methods Keratinocytes isolated from the skin of healthy subjects (n = 20) and patients with atopic dermatitis (n = 20) as well as HaCaT and PCS-200-010 cell were exposed to the 900 MHz electromagnetic field for 60 minutes. Cytometric analysis of viability, Fas/FasL, p-ERK, p-p38 and p-JNK expression and Luminex analysis of cytokine concentration were performed in two-time points: 4 and 24 hours after the exposition. Results This research has shown upregulated Fas, FasL, p-ERK, p-p38, and p-JNK expression along with increased cytokine secretion (IL-1 beta, IL-4, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-31 and TNF alpha) by keratinocytes derived from the skin of patients with the AD when compared with healthy control. Exposure of keratinocyte cultures obtained from AD patients to EMF resulted in a decrease of 1 beta, IL-4, IL-10, IL-12, I L-13, IL-17, IL-31 and TNF alpha levels. Keratinocytes derived from the skin of AD patients are characterized by elevated Fas and FasL expression when compared to healthy control. Conclusion Apoptotic and nonapoptotic activation of the Fas/FasL-dependent signaling pathway may play a significant role in the pathogenesis of AD, by adjusting the local cytokine and chemokine environment at the site of inflammation. Moreover, the electromagnetic field exhibits strong immunomodulatory effects on AD-modified keratinocytes.	[Szymanski, Lukasz; Cios, Aleksandra; Szymanski, Pawel; Stankiewicz, Wanda] Mil Inst Hyg & Epidemiol, Dept Microwave Safety, Warsaw, Poland; [Lewicki, Slawomir] Mil Inst Hyg & Epidemiol, Dept Regenerat Med & Cell Biol, Warsaw, Poland	Military Institute of Hygiene & Epidemiology (MIHE); Military Institute of Hygiene & Epidemiology (MIHE)	Szymanski, L (corresponding author), Mil Inst Hyg & Epidemiol, Dept Microwave Safety, Warsaw, Poland.	lukas91.sz@gmail.com	Szymanski, Lukasz/HDM-8142-2022	Szymanski, Lukasz/0000-0003-0148-541X; Lewicki, Slawomir/0000-0002-0539-0680	Polish Ministry of Science and Higher Education	Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland)	This study was funded by Polish Ministry of Science and Higher Education grant for Young Scientist.	Aasen T, 2010, NAT PROTOC, V5, P371, DOI 10.1038/nprot.2009.241; Bien K, 2017, INFLAMM RES, P1; Boehm I, 2006, CURR MOL MED, V6, P375, DOI 10.2174/156652406777435390; Bort A, 2017, MOL PAIN, V13, P1, DOI 10.1177/1744806916688220; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; D'Angelo C, 2015, SAUDI J BIOL SCI, V22, P75, DOI 10.1016/j.sjbs.2014.07.006; Dabrowski MP, 2003, ELECTROMAGN BIOL MED, V22, P1, DOI 10.1081/JBC-120020347; Farley SM, 2006, J INVEST DERMATOL, V126, P2438, DOI 10.1038/sj.jid.5700477; Gazel A, 2006, J BIOL CHEM, V281, P20530, DOI 10.1074/jbc.M602712200; Huang CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113424; Keller M, 2008, CELL, V132, P818, DOI 10.1016/j.cell.2007.12.040; Kennedy NJ, 2010, HDB CELL SIGNALING, P1315, DOI [10.1016/B978-0-12-374145-5.00164-9, DOI 10.1016/B978-0-12-374145-5.00164-9]; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Kjellerup RB, 2008, EXP DERMATOL, V17, P498, DOI 10.1111/j.1600-0625.2007.00672.x; Lee SH, 1998, BRIT J DERMATOL, V139, P186; Leshem YA, 2015, BRIT J DERMATOL, V172, P1353, DOI 10.1111/bjd.13662; Lesniak M, 2018, TISSUE ENG REGEN MED, V15, P211, DOI 10.1007/s13770-017-0103-9; Lu B, 2002, AM J PHYSIOL-CELL PH, V283, pC831, DOI 10.1152/ajpcell.00045.2002; Maier E, 2014, J IMMUNOL, V193, P645, DOI 10.4049/jimmunol.1301836; Mutou Y, 2010, J HEALTH SCI, V56, P675, DOI 10.1248/jhs.56.675; Mycielska ME, 2004, J CELL SCI, V117, P1631, DOI 10.1242/jcs.01125; Nylund R, 2004, PROTEOMICS, V4, P1359, DOI 10.1002/pmic.200300773; Patruno A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139644; Rosado MM, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00085; Sobiech Jaromir, 2015, Przeglad Elektrotechniczny, V91, P218, DOI 10.15199/48.2015.12.56; Stankiewicz W, 2006, ELECTROMAGN BIOL MED, V25, P45, DOI 10.1080/15368370600572961; Sun YJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40605; Tan Q, 2017, MOL MED REP, V16, P8863, DOI 10.3892/mmr.2017.7689; Wajant H, 2003, CYTOKINE GROWTH F R, V14, P53, DOI 10.1016/S1359-6101(02)00072-2; Wolf-Goldberg T, 2013, BBA-MOL CELL RES, V1833, P1396, DOI 10.1016/j.bbamcr.2013.02.011; Wu D, 2013, CELL BIOCHEM BIOPHYS, V67, P1115, DOI 10.1007/s12013-013-9615-7; Zhang HL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026805; Zhi WJ, 2017, MILITARY MED RES, V4, DOI 10.1186/s40779-017-0139-0; Zmyslony M, 2004, BIOELECTROMAGNETICS, V25, P324, DOI 10.1002/bem.10191	34	14	14	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2018	13	10							e0205103	10.1371/journal.pone.0205103	http://dx.doi.org/10.1371/journal.pone.0205103			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV8IQ	30286163	Green Published, gold, Green Submitted			2023-01-03	WOS:000446383500085
J	Pamenter, ME; Lau, GY; Richards, JG				Pamenter, Matthew E.; Lau, Gigi Y.; Richards, Jeffrey G.			Effects of cold on murine brain mitochondrial function	PLOS ONE			English	Article							HYPOTHERMIA; HYPOXIA; ANOXIA; INJURY; SUPPRESSION; TOLERANCE; RESISTANT; RESPONSES; MICE	Therapeutic hypothermia is a strategy that reduces metabolic rate and brain damage during clinically-relevant hypoxic events. Mitochondrial respiration is compromised by hypoxia, with deleterious consequences for the mammalian brain; however, little is known about the effects of reduced temperature on mitochondrial metabolism. Therefore, we examined how mitochondrial function is impacted by temperature using high resolution respirometry to assess electron transport system (ETS) function in saponin-permeabilized mouse brain at 28 and 37 degrees C. Respirometric analysis revealed that, at the colder temperature, ETS respiratory flux was similar to 40-75% lower relative to the physiological temperature in all respiratory states and for all fuel substrates tested. In whole brain tissue, the enzyme maximum respiratory rates for complexes I-V were similarly reduced by between 37-88%. Complexes II and V were particularly temperature-sensitive; a temperature-mediated decrease in complex II activity may support a switch to complex I mediated ATP-production, which is considerably more oxygen-efficient. Finally, the mitochondrial H+-gradient was more tightly coupled, indicating that mitochondrial respiration is more efficient at the colder temperature. Taken together, our results suggest that improvements in mitochondrial function with colder temperatures may contribute to energy conservation and enhance cellular viability in hypoxic brain.	[Pamenter, Matthew E.] Univ Ottawa, Dept Biol, Ottawa, ON, Canada; [Pamenter, Matthew E.] Ottawa Brain & Mind Res Inst, Ottawa, ON, Canada; [Lau, Gigi Y.; Richards, Jeffrey G.] Univ British Columbia, Dept Zool, Vancouver, BC, Canada	University of Ottawa; University of British Columbia	Pamenter, ME (corresponding author), Univ Ottawa, Dept Biol, Ottawa, ON, Canada.; Pamenter, ME (corresponding author), Ottawa Brain & Mind Res Inst, Ottawa, ON, Canada.	mpamenter@uottawa.ca	Pamenter, Matt/R-9216-2019	Pamenter, Matt/0000-0003-4035-9555	NSERC Discovery grant; NSERC CGS; Parker B Francis PDF	NSERC Discovery grant(Natural Sciences and Engineering Research Council of Canada (NSERC)); NSERC CGS(Natural Sciences and Engineering Research Council of Canada (NSERC)); Parker B Francis PDF	This work was supported by a NSERC Discovery grant to JGR, a Parker B Francis PDF to MEP, and an NSERC CGS to GYL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali SS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036801; Barksdale KA, 2010, FASEB J, V24, P3590, DOI 10.1096/fj.09-152108; BARNES BM, 1989, SCIENCE, V244, P1593, DOI 10.1126/science.2740905; Bickler PE, 2007, ANNU REV PHYSIOL, V69, P145, DOI 10.1146/annurev.physiol.69.031905.162529; Bogdanov NN, 1999, B EXP BIOL MED+, V128, P1100, DOI 10.1007/BF02433410; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buck LT, 2006, RESP PHYSIOL NEUROBI, V154, P226, DOI 10.1016/j.resp.2006.03.004; Chouchani ET, 2014, NATURE, V515, P431, DOI 10.1038/nature13909; Chretien D, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2003992; Cramer NP, 2015, PHYSIOL BEHAV, V143, P158, DOI 10.1016/j.physbeh.2015.01.036; Galli GLJ, 2013, J EXP BIOL, V216, P3283, DOI 10.1242/jeb.087155; Ghosh S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15002-7; Hinkle PC, 2005, BBA-BIOENERGETICS, V1706, P1, DOI 10.1016/j.bbabio.2004.09.004; HOCHACHKA PW, 1994, J CEREBR BLOOD F MET, V14, P671, DOI 10.1038/jcbfm.1994.84; Hogg DW, 2015, J PHYSIOL-LONDON, V593, P2311, DOI 10.1113/JP270474; Ilacqua AN, 2017, BIOL LETTERS, V13, DOI 10.1098/rsbl.2017.0545; Koo E, 2017, PEDIATR RES, V82, P518, DOI 10.1038/pr.2017.75; Kuter N, 2018, NEONATOLOGY, V113, P360, DOI 10.1159/000487221; Larson J, 2014, J EXP BIOL, V217, P1024, DOI 10.1242/jeb.085381; Liu BJ, 2017, BRAIN RES, V1672, P18, DOI 10.1016/j.brainres.2017.07.008; Marcinkeviciute  A, 2000, BIOCHEM J, V349, P519, DOI 10.1042/0264-6021:3490519; McFarlane SV, 2017, AM J PHYSIOL-REG I, V312, pR434, DOI 10.1152/ajpregu.00316.2016; Muleme HM, 2006, PHYSIOL BIOCHEM ZOOL, V79, P474, DOI 10.1086/501053; Nakayama S, 2017, NEUROCRIT CARE; Pamenter ME, 2018, J EXP BIOL, V221, DOI 10.1242/jeb.171397; Pamenter ME, 2016, BIOL LETTERS, V12, DOI 10.1098/rsbl.2015.0797; Pamenter ME, 2014, CAN J ZOOL, V92, P569, DOI 10.1139/cjz-2013-0247; Pamenter ME, 2012, BRAIN RES, V1452, P165, DOI 10.1016/j.brainres.2012.03.004; Pamenter ME, 2007, FASEB J, V21, pA594; Pamenter ME, 2007, J COMP PHYSIOL B, V177, P473, DOI 10.1007/s00360-007-0145-8; Pamenter ME, 2012, J CEREBR BLOOD F MET, V32, P2033, DOI 10.1038/jcbfm.2012.103; Peterson BL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031568; ROTTENBERG H, 1984, J MEMBRANE BIOL, V81, P127, DOI 10.1007/BF01868977; St-Pierre J, 2000, P NATL ACAD SCI USA, V97, P8670, DOI 10.1073/pnas.140093597; Tong G, 2017, NEUROSCIENCE, V358, P201, DOI 10.1016/j.neuroscience.2017.06.055; West JB, 2006, INTEGR COMP BIOL, V46, P25, DOI 10.1093/icb/icj005	36	11	11	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 6	2018	13	12							e0208453	10.1371/journal.pone.0208453	http://dx.doi.org/10.1371/journal.pone.0208453			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD1YF	30521596	gold, Green Published, Green Submitted			2023-01-03	WOS:000452307600071
J	Braslow, JT; Messac, L				Braslow, Joel T.; Messac, Luke			Medicalization and Demedicalization - A Gravely Disabled Homeless Man with Psychiatric Illness	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Braslow, Joel T.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA; [Messac, Luke] Brown Univ, Providence, RI 02912 USA	University of California System; University of California Los Angeles; Brown University	Braslow, JT (corresponding author), Univ Calif Los Angeles, Los Angeles, CA 90095 USA.		Braslow, Joel/AAG-9564-2021	Braslow, Joel/0000-0002-6830-2991	NIMH NIH HHS [K23 MH001856] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Conrad P., 2007, MED SOC; FOX RC, 1977, DAEDALUS, V106, P9; Porter R., 2002, MADNESS BRIEF HIST; Rose N, 2007, LANCET, V369, P700, DOI 10.1016/S0140-6736(07)60319-5; ROSENBAUM M, 1995, J PSYCHOACTIVE DRUGS, V27, P145, DOI 10.1080/02791072.1995.10471683	5	10	10	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 15	2018	379	20					1885	1888		10.1056/NEJMp1811623	http://dx.doi.org/10.1056/NEJMp1811623			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HA2FL	30428298	Green Published			2023-01-03	WOS:000450049800001
J	Kuwajima, K; Sumitani, M; Kurano, M; Kano, K; Nishikawa, M; Uranbileg, B; Tsuchida, R; Ogata, T; Aoki, J; Yatomi, Y; Yamada, Y				Kuwajima, Ken; Sumitani, Masahiko; Kurano, Makoto; Kano, Kuniyuki; Nishikawa, Masako; Uranbileg, Baasanjav; Tsuchida, Rikuhei; Ogata, Toru; Aoki, Junken; Yatomi, Yutaka; Yamada, Yoshitsugu			Lysophosphatidic acid is associated with neuropathic pain intensity in humans: An exploratory study	PLOS ONE			English	Article							GLIAL INTERACTIONS; SYSTEM; VALIDATION; CHEMOKINES; PATHWAYS; SUBUNIT; SAMPLES; PLASMA	The underlying mechanisms of neuropathic pain remain to be elucidated. Basic animal research has suggested that lysophosphatidic acids, which are bioactive lipids produced by autotaxin from lysophosphatidylcholine, may play key roles in the initiation and maintenance of neuropathic pain. Here, we investigated the clinical relevance of lysophosphatidic acids signaling on neuropathic pain in humans. Eighteen patients who had been diagnosed with neuropathic pain with varied etiologies participated in the study. Cerebrospinal fluid samples were obtained by lumbar puncture and the concentrations of 12 species of lysophosphatidic acids and lysophosphatidylcholine, autotaxin, and the phosphorylated neurofilament heavy subunit were measured. Pain symptoms were assessed using an 11-point numeric rating scale and the Neuropathic Pain Symptom Inventory regarding intensity and descriptive dimensions of neuropathic pain. The total lysophosphatidic acids were significantly associated with both pain intensity and symptoms. 18:1 and 20:4 lysophosphatidic acids in particular demonstrated the most correlations with dimensions of pain symptoms. Autotaxin and the phosphorylated neurofilament heavy subunit showed no association with pain symptoms. In conclusions, lysophosphatidic acids were significantly associated with pain symptoms in neuropathic pain patients. These results suggest that lysophosphatidic acids signaling might be a potential therapeutic target for neuropathic pain.	[Kuwajima, Ken; Tsuchida, Rikuhei; Yamada, Yoshitsugu] Univ Tokyo Hosp, Dept Anesthesiol, Bunkyo Ku, Tokyo, Japan; [Kuwajima, Ken; Tsuchida, Rikuhei; Yamada, Yoshitsugu] Univ Tokyo Hosp, Pain Relief Ctr, Bunkyo Ku, Tokyo, Japan; [Sumitani, Masahiko] Univ Tokyo Hosp, Dept Pain & Palliat Med, Bunkyo Ku, Tokyo, Japan; [Kurano, Makoto; Nishikawa, Masako; Uranbileg, Baasanjav; Yatomi, Yutaka] Univ Tokyo Hosp, Dept Clin Lab Med, Bunkyo Ku, Tokyo, Japan; [Kano, Kuniyuki; Aoki, Junken] Tohoku Univ, Grad Sch Pharmaceut Sci, Dept Mol & Cellular Biochem, Sendai, Miyagi, Japan; [Ogata, Toru] Natl Rehabil Ctr Persons Disabil, Res Inst, Dept Rehabil Movement Funct, Tokorozawa, Saitama, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; Tohoku University	Sumitani, M (corresponding author), Univ Tokyo Hosp, Dept Pain & Palliat Med, Bunkyo Ku, Tokyo, Japan.	SUMITANIM-ANE@h.u-tokyo.ac.jp	Ogata, Toru/ADC-3560-2022	Ogata, Toru/0000-0001-9011-8640; Tsuchida, Rikuhei/0000-0003-2274-7917; Sumitani, Masahiko/0000-0002-3662-8217; Kano, Kuniyuki/0000-0002-4539-5750; Yatomi, Yutaka/0000-0003-1719-4297	Core Research for Evolutional Science and Technology (CREST) from Japan Science and Technology Agency (JST)/Japan Agency for Medical Research and Development (AMED) [17gm0710001h0105]; Japan Agency for Medical Research and Development (AMED) [17gm0010004s0101]; Japan Society for the Promotion of Science (JSPS) [15H05906]	Core Research for Evolutional Science and Technology (CREST) from Japan Science and Technology Agency (JST)/Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by Core Research for Evolutional Science and Technology (CREST) from Japan Science and Technology Agency (JST)/Japan Agency for Medical Research and Development (AMED) Grant number: 17gm0710001h0105 Recipient: Junken Aoki Leading Advanced Projects for medical innovation (LEAP) from the Japan Agency for Medical Research and Development (AMED) Grant number: 17gm0010004s0101 Recipient: Junken Aoki Grant-in-Aid for Scientific Research on Innovative Areas from Japan Society for the Promotion of Science (JSPS) (Grant number: 15H05906 Recipient: Yutaka Yatomi). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; Bennett MI, 2007, PAIN, V127, P199, DOI 10.1016/j.pain.2006.10.034; Boadas-Vaello P, 2016, SPINAL CORD, V54, P330, DOI 10.1038/sc.2015.225; Bouhassira D, 2004, PAIN, V108, P248, DOI 10.1016/j.pain.2003.12.024; Bouhassira D, 2008, PAIN, V136, P380, DOI 10.1016/j.pain.2007.08.013; Forstenpointner J, 2018, PAIN, V159, P569, DOI 10.1097/j.pain.0000000000001088; Fujita R, 2007, NEUROCHEM INT, V50, P351, DOI 10.1016/j.neuint.2006.09.003; Gao YJ, 2010, PHARMACOL THERAPEUT, V126, P56, DOI 10.1016/j.pharmthera.2010.01.002; Hayakawa K, 2012, SPINAL CORD, V50, P493, DOI 10.1038/sc.2011.184; Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060; Inoue M, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-6; Kurano M, 2015, ARTERIOSCL THROM VAS, V35, P463, DOI 10.1161/ATVBAHA.114.304748; Ma L, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-29; Matsubayashi Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143350; Nagai J, 2011, J NEUROCHEM, V118, P256, DOI 10.1111/j.1471-4159.2011.07297.x; Nagai J, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-78; Nakamura K, 2008, CLIN CHIM ACTA, V388, P51, DOI 10.1016/j.cca.2007.10.005; Ohya J, 2015, SPINE J, V15, P1587, DOI 10.1016/j.spinee.2015.03.013; Okudaira M, 2014, J LIPID RES, V55, P2178, DOI 10.1194/jlr.D048439; Rivera A, 2016, CURR DRUG TARGETS, V17, P1829, DOI 10.2174/1389450117666160711154529; Sattikar A, 2017, BRIT J PHARMACOL, V174, P227, DOI 10.1111/bph.13671; Sumitani M, 2008, RHEUMATOLOGY, V47, P1038, DOI 10.1093/rheumatology/ken170; Tanaka M, 2004, FEBS LETT, V571, P197, DOI 10.1016/j.febslet.2004.06.083; Treede RD, 2008, NEUROLOGY, V70, P1630, DOI 10.1212/01.wnl.0000282763.29778.59; Tsuda M, 2012, CURR OPIN PHARMACOL, V12, P74, DOI 10.1016/j.coph.2011.10.014; Ueda H, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-11; Ueda H, 2017, PAIN, V158, pS55, DOI 10.1097/j.pain.0000000000000813; Ueda H, 2013, BBA-MOL CELL BIOL L, V1831, P61, DOI 10.1016/j.bbalip.2012.08.014; Wilkie DJ, 2001, J PAIN SYMPTOM MANAG, V22, P899, DOI 10.1016/S0885-3924(01)00351-7; Zhang ZJ, 2017, CELL MOL LIFE SCI, V74, P3275, DOI 10.1007/s00018-017-2513-1	30	25	25	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2018	13	11							e0207310	10.1371/journal.pone.0207310	http://dx.doi.org/10.1371/journal.pone.0207310			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ5ZX	30408112	gold, Green Published, Green Submitted			2023-01-03	WOS:000449512300096
J	Kasaie, P; Radford, M; Kapoor, S; Jung, Y; Novoa, BH; Dowdy, D; Shah, M				Kasaie, Parastu; Radford, Matthew; Kapoor, Sunaina; Jung, Younghee; Novoa, Beatriz Hernandez; Dowdy, David; Shah, Maunank			Economic and epidemiologic impact of guidelines for early ART initiation irrespective of CD4 count in Spain	PLOS ONE			English	Article							PLAN RECOMMENDED GUIDELINES; COST-EFFECTIVENESS ANALYSIS; ADJUSTED LIFE-YEARS; ANTIRETROVIRAL THERAPY; HIV-1 TRANSMISSION; NATURAL-HISTORY; VIRAL LOAD; INFECTION; CARE; PREVALENCE	Introduction Emerging data suggest that early antiretroviral therapy (ART) could reduce serious AIDS and non-AIDS events and deaths but could also increase costs. In January 2016, the Spanish guidelines were updated to recommend ART at any CD4 count. However, the epidemiologic and economic impacts of early ART initiation in Spain remain unclear. Methods The Johns Hopkins HIV Economic-Epidemiologic Mathematical Model (JHEEM) was utilized to estimate costs, transmissions, and outcomes in Spain over 20 years. We compared implementation of guidelines for early ART initiation to a counterfactual scenario deferring ART until CD4-counts fall below 350 cells/mm(3). We additionally studied the impact of early ART initiation in combination with improvements to HIV screening, care linkage and engagement. Results Early ART initiation (irrespective of CD4-count) is expected to avert 20,100 [95% Uncertainty Range (UR) 11,100-83,000] new HIV cases over the next two decades compared to delayed ART (28% reduction), at an incremental health system cost of (sic)1.05 billion [(sic)0.66 - (sic)1.63] billion, and an incremental cost-effectiveness ratio (ICER) of (sic)29,700 [(sic)13,700 - (sic)41,200] per QALY gained. Projected ICERs declined further over longer time horizon; e.g., an ICER of (sic)12,691 over 30 years. Furthermore, the impact of early ART initiation was potentiated by improved HIV screening among high-risk individuals, averting an estimated 41,600 [23,200-172,200] HIV infections (a 58% decline) compared to delayed ART. Conclusions Recommendations for ART initiation irrespective of CD4-counts are cost-effective and could avert > 30% of new cases in Spain. Improving HIV diagnosis can amplify this impact.	[Kasaie, Parastu; Jung, Younghee; Dowdy, David] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Radford, Matthew; Novoa, Beatriz Hernandez] ViiV Healthcare Inc, Brentford, Middx, England; [Kapoor, Sunaina; Shah, Maunank] Johns Hopkins Sch Med, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine	Kasaie, P (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.	pkasaie@jhu.edu	Kasaie, Parastu/AAD-1960-2021		Johns Hopkins University Center for AIDS Research [P30AI094189]; ViiV Healthcare Inc.; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI094189] Funding Source: NIH RePORTER	Johns Hopkins University Center for AIDS Research; ViiV Healthcare Inc.; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	PK was supported by Johns Hopkins University Center for AIDS Research (P30AI094189); PK and MS were supported by a research grant from ViiV Healthcare Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. MR and BH are employees of ViiV Healthcare Inc. The funders had an indirect role through the participation of two co-authors, who contributed by providing guidance on locally relevant data sources and interpretation for HIV epidemiology and costs, and assisted with the review of the manuscript and final approval. MR and BH specific roles are articulated in the 'author contributions' section.	Alkema L, 2008, SEX TRANSM INFECT, V84, pI11, DOI 10.1136/sti.2008.029991; Alkema L, 2007, ANN APPL STAT, V1, P229, DOI 10.1214/07-AOAS111; [Anonymous], 2016, GLOB AIDS UPD 2016; [Anonymous], 2017, IGUALDAD MDSSSE PLAN; [Anonymous], 2017, PANEL EXPERTOS GESID; Gullon JA, 2016, ARCH BRONCONEUMOL, V52, P583, DOI 10.1016/j.arbres.2016.05.002; Berenguer J, 2016, ENFERM INFEC MICR CL, V34, P361, DOI 10.1016/j.eimc.2015.07.012; Brown T, 2010, SEX TRANSM INFECT, V86, pI3, DOI 10.1136/sti.2010.044784; Campbell CNJ, 2015, AIDS CARE, V27, P1449, DOI 10.1080/09540121.2015.1109584; CASCADE Collaboration, 2000, LANCET, V355, P1158, DOI 10.1016/S0140-6736(00)02069-9; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Control ECfDPa, 2017, STAT HIV RESP EUR UN; Corral J, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0725-3; Currie S, 2009, INT J STD AIDS, V20, P265, DOI 10.1258/ijsa.2008.008268; Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198; Del Amo J, 2016, GES C; Donnell D, 2010, LANCET, V375, P2092, DOI 10.1016/S0140-6736(10)60705-2; European AIDS Clinical Society, 2017, EUR GUID TREATM HIV; European Centre for Disease Prevention and Control, 2016, HIV AIDS SURV EUR 20; Gourlay A, 2017, CLIN INFECT DIS, V64, P1644, DOI 10.1093/cid/cix212; Hollingsworth TD, 2008, J INFECT DIS, V198, P687, DOI 10.1086/590501; Honiden S, 2006, QUAL LIFE RES, V15, P69, DOI 10.1007/s11136-005-8485-x; Hyle EP, 2013, JAMA INTERN MED, V173, P1746, DOI 10.1001/jamainternmed.2013.9329; IMF, 2017, WORLD EC FIN SURV RE; Katz DA, 2014, SEX TRANSM DIS, V41, P2, DOI 10.1097/OLQ.0000000000000046; Lingappa JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012598; Long EF, 2010, ANN INTERN MED, V153, P778, DOI 10.7326/0003-4819-153-12-201012210-00004; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Lyles RH, 2000, J INFECT DIS, V181, P872, DOI 10.1086/315339; Mabileau G, 2017, EFFECTIVENESS COST E; Rodriguez JM, 2011, VALUE HEALTH, V14, P458, DOI 10.1016/j.jval.2010.10.039; Marseille E, 2015, B WORLD HEALTH ORGAN, V93, P118, DOI 10.2471/BLT.14.138206; Martin-Fernandez J, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-287; Mocroft A, 2012, ANTIVIR THER, V17, P1291, DOI 10.3851/IMP2407; Moreno S, 2017, ENFERM INFEC MICR CL, V35, P377, DOI [10.1016/j.eimc.2016.11.016, 10.1016/j.eimce.2016.11.002]; Moreno S, 2012, SEX TRANSM INFECT, V88, P522, DOI 10.1136/sextrans-2012-050481; Murphy EL, 2001, ANN INTERN MED, V135, P17, DOI 10.7326/0003-4819-135-1-200107030-00005; Nakagawa F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125018; National Center for Epidemiology, 2011, AR HIV SURV RISK BEH; National Center for Epidemiology/General Subdirectorate for Health Promotion and Epidemiology National Plan on AIDS, 2016, MORT HIV AIDS SPAIN; National Center for Epidemiology/General Subdirectorate for Health Promotion and Epidemiology National Plan on AIDS, 2016, EP SURV HIV AIDS SPA; Oliva J, 2014, ENFERM INFEC MICR CL, V32, P170, DOI 10.1016/j.eimc.2013.09.007; Pares-Badell O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105471; Reekie J, 2011, AIDS, V25, P2259, DOI 10.1097/QAD.0b013e32834cdb4b; Regueiro A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009148; Rivero A, 2018, ENFERM INFEC MICR CL, V36, P268, DOI 10.1016/j.eimc.2017.04.002; Rivero A, 2017, ENFERM INFEC MICR CL, V35, P88, DOI 10.1016/j.eimc.2016.06.013; Roser M., 2017, HIV AIDS; Rushby JF, 2001, HEALTH POLICY PLANN, V16, P326, DOI 10.1093/heapol/16.3.326; Sabater E, 2016, APPL HEALTH ECON HEA, V14, P465, DOI 10.1007/s40258-016-0243-4; Sacristán J.A., 2002, Gac Sanit, V16, P334; Schackman BR, 2002, MED DECIS MAKING, V22, P27, DOI 10.1177/02729890222062892; Services CfMM, 2017, CLIN LAB FEE SCHED 2; Shah M, 2016, LANCET HIV, V3, pE140, DOI 10.1016/S2352-3018(16)00007-2; Shah M, 2016, CLIN INFECT DIS, V62, P220, DOI 10.1093/cid/civ801; Sobrino-Vegas P, 2011, ENFERM INFEC MICR CL, V29, P645, DOI 10.1016/j.eimc.2011.06.002; Trapero-Bertran M, 2014, HEALTH ECON REV, V4, DOI 10.1186/s13561-014-0015-5; Treskova M, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003961; UNAIDS, 2014, 90 90 90 AMB TREATM; UNAIDS, 2016, AIDSINFO 2016; Vergis EN, 2000, INFECT DIS CLIN N AM, V14, P809, DOI 10.1016/S0891-5520(05)70135-5; Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411; Wolbers M, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000239; Yazdanpanah Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084173; Yazdanpanah Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013132	65	8	9	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2018	13	11							e0206755	10.1371/journal.pone.0206755	http://dx.doi.org/10.1371/journal.pone.0206755			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ3MT	30395635	Green Submitted, gold, Green Published			2023-01-03	WOS:000449291400049
J	Dhahbi, W; Sellami, M; Chaouachi, A; Padulo, J; Milic, M; Mekki, I; Chamari, K				Dhahbi, Wissem; Sellami, Maha; Chaouachi, Anis; Padulo, Johnny; Milic, Mirjana; Mekki, Imed; Chamari, Karim			Seasonal weather conditions affect training program efficiency and physical performance among special forces trainees: A long-term follow-up study	PLOS ONE			English	Article							SPRINT EXERCISE PERFORMANCE; BODY-COMPOSITION; MILITARY; HEAT; FITNESS; TEMPERATURE; RESPONSES; HUMANS	The purpose of the present investigation was to follow-up the effect of specific commandos' training-cycles (SCTCs) on upper-body strength resistance and running endurance performance, as well as determine whether variation in seasonal parameters has any effect on physical performance. Fourteen SCTCs were held over eight years, involving 466 participants. Participants were assigned to four subgroups according to their distribution over the seasons: summer (n = 124), autumn (n = 145), winter (n = 52) and spring (n = 145). Before and after each SCTC, four tests (maximal pull-up, push-up and sit-up repetitions in 70-seconds for muscle strength resistance) and a 5-km cross-country run (endurance) were performed. Seasonal data were continuously recorded during all SCTCs. Body mass decreased significantly (p<0.05) in all groups following SCTCs. These training-cycles induced a significant increase (p<0.05) in the 70-seconds push-ups, pull-ups and sit-ups and a decrease (p<0.01) in the 5-km cross-country running time among all trainees. The main effect of the season was present in all tests (p<0.01). With regard to the percentage of changes, the results from the 70-seconds push-up, pull-up and sit-up tests were significantly higher in winter and spring (p<0.01) compared with the two other seasons, while 5-km cross-country performance improvements were significantly higher (p<0.01) in spring and summer, compared to the two other seasons. In summary, 14-week of SCTCs improved upper-body strength resistance and running endurance performance in the commandos. Improvements in strength resistance performance were greater during cool weather (winter and spring), while improvements in running endurance performance were higher during hotter (spring and summer) seasons.	[Dhahbi, Wissem; Chaouachi, Anis; Padulo, Johnny] Natl Ctr Med & Sci Sports CNMSS, Tunisian Res Lab Sport Performance Optimisat, Tunis, Tunisia; [Dhahbi, Wissem] Qatar Police Coll, Training Dept, Doha, Qatar; [Dhahbi, Wissem; Mekki, Imed] Tunisian Natl Guard Commandos Sch, Oued Zarga, Tunisia; [Dhahbi, Wissem; Sellami, Maha] Univ Qatar, Coll Arts & Sci Qu CAS, SSP, Doha, Qatar; [Padulo, Johnny] Univ eCampus, Novedrate, Italy; [Padulo, Johnny; Milic, Mirjana] Univ Split, Fac Kinesiol, Split, Croatia; [Chamari, Karim] Qatar Orthopaed & Sports Med Hosp, Athlete Hlth & Performance Res Ctr, ASPETAR, Doha, Qatar	Centre National de la Medecine Sciences des Sports; Qatar University; Universita Ecampus; University of Split; Aspetar Orthopaedic & Sports Medicine Hospital	Padulo, J (corresponding author), Natl Ctr Med & Sci Sports CNMSS, Tunisian Res Lab Sport Performance Optimisat, Tunis, Tunisia.; Padulo, J (corresponding author), Univ eCampus, Novedrate, Italy.; Padulo, J (corresponding author), Univ Split, Fac Kinesiol, Split, Croatia.	sportcinetic@gmail.com	Padulo, Johnny/AAK-2207-2020; milić, mirjana/C-1605-2012; CHAMARI, Karim/AAJ-7938-2021; Dhahbi, Wissem/A-1445-2019	Padulo, Johnny/0000-0002-4254-3105; milić, mirjana/0000-0002-6914-8666; CHAMARI, Karim/0000-0001-9178-7678; Dhahbi, Wissem/0000-0001-6221-546X; Sellami, Maha/0000-0003-1832-409X				Aharony S, 2008, SPINE J, V8, P578, DOI 10.1016/j.spinee.2007.01.001; Belcher CP, 2012, INT J EXERCISE SCI, V5, P7; Bottinelli R, 1996, J PHYSIOL-LONDON, V495, P573, DOI 10.1113/jphysiol.1996.sp021617; Carlson Mark J, 2012, J Strength Cond Res, V26 Suppl 2, pS2, DOI 10.1519/JSC.0b013e31825d7ff9; Cheung SS, 2004, J SPORT SCI, V22, P605, DOI 10.1080/02640410310001655813; Cheuvront SN, 2001, SPORTS MED, V31, P743, DOI 10.2165/00007256-200131100-00004; Crandall CG, 2008, J PHYSIOL-LONDON, V586, P293, DOI 10.1113/jphysiol.2007.143057; Delvecchio L, 2016, J EXERC REHABIL, V12, P442, DOI 10.12965/jer.1632672.336; Dhahbi W, 2015, INT J SPORT PHYSIOL, V10, P509, DOI 10.1123/ijspp.2014-0334; Duffield R, 2007, EUR J APPL PHYSIOL, V100, P727, DOI 10.1007/s00421-007-0468-x; Fairbrother B, 1995, NUTR IMMUNOLOGICAL A; Hargreaves M, 2008, J SCI MED SPORT, V11, P66, DOI 10.1016/j.jsams.2007.07.002; Hayes M, 2014, INT J SPORT PHYSIOL, V9, P387, DOI [10.1123/ijspp.2012-0247, 10.1123/IJSPP.2012-0247]; Heinrich KM, 2012, MIL MED, V177, P1125, DOI 10.7205/MILMED-D-12-00143; Holcomb John, 2007, US Army Med Dep J, P24; Johnson JM, 2010, SCAND J MED SCI SPOR, V20, P29, DOI 10.1111/j.1600-0838.2010.01206.x; Klika B, 2013, ACSMS HEALTH FIT J, V17, P8, DOI 10.1249/FIT.0b013e31828cb1e8; Kraemer William J, 2012, J Strength Cond Res, V26 Suppl 2, pS107, DOI 10.1519/JSC.0b013e31825d8263; Kyrolainen H, 2017, J SCI MED SPORT; Lacerda ACR, 2007, EUR J APPL PHYSIOL, V99, P87, DOI 10.1007/s00421-006-0329-z; Lieberman HR, 2005, BIOL PSYCHIAT, V57, P422, DOI 10.1016/j.biopsych.2004.11.014; Locke M, 2014, CELL STRESS CHAPERON, V19, P519, DOI 10.1007/s12192-013-0478-z; Malavolti M, 2008, J STRENGTH COND RES, V22, P503, DOI 10.1519/JSC.0b013e318163441f; Martin RC, 2016, J STRENGTH COND RES, V30, P26, DOI 10.1519/JSC.0000000000001026; Montain SJ, 2003, APPETITE, V40, P255, DOI 10.1016/S0195-6663(03)00011-4; Nindl BC, 2007, MED SCI SPORT EXER, V39, P1380, DOI 10.1249/mss.0b013e318067e2f7; No M, 2016, INTEGR MED RES, V5, P216, DOI 10.1016/j.imr.2016.06.002; Pemrick MD, 1999, PHYS FITNESS 75 RANG; Prusaczyk WK, 1995, PHYS DEMANDS US NAVY; Ronnestad BR, 2014, SCAND J MED SCI SPOR, V24, P603, DOI 10.1111/sms.12104; Santtila M, 2015, J STRENGTH COND RES, V29, pS154, DOI 10.1519/JSC.0000000000001035; Shippee R., 1994, NUTR IMMUNOLOGICAL A; Smith CJ, 2016, AUTON NEUROSCI-BASIC, V196, P25, DOI 10.1016/j.autneu.2016.01.002; Sporis G, 2012, J STRENGTH COND RES, V26, P2872, DOI 10.1519/JSC.0b013e318242966c; Tharion WJ, 2005, APPETITE, V44, P47, DOI 10.1016/j.appet.2003.11.010; Vickers Jr RR, 1999, EFFECTS BASIC FITNES, V38	36	4	5	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2018	13	10							e0206088	10.1371/journal.pone.0206088	http://dx.doi.org/10.1371/journal.pone.0206088			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX4KR	30335826	Green Published, Green Submitted, gold			2023-01-03	WOS:000447701300095
J	Gholipour, K; Tabrizi, JS; Jafarabadi, MA; Iezadi, S; Mardi, A				Gholipour, Kamal; Tabrizi, Jafar Sadegh; Jafarabadi, Mohammad Asghari; Iezadi, Shabnam; Mardi, Ahmad			Effects of customer self-audit on the quality of maternity care in Tabriz: A cluster-randomized controlled trial	PLOS ONE			English	Article							GROUP PRENATAL-CARE; GROUP ANTENATAL CARE; SERVICE QUALITY; HEALTH-CARE; PATIENT SATISFACTION; CENTERING PREGNANCY; TECHNICAL QUALITY; PERCEPTIONS; IMPACT; AUSTRALIA	Objective To study the effects of customer self-audit on the service quality (SQ) and customer quality (CQ) of maternity care. Design A community-based cluster-randomized controlled trial. Setting Twenty-one health centres and health posts in Tabriz, Iran. Participants Of 21 health centres/health posts, 10 were randomly assigned to the intervention group and 11 randomly assigned to the control group. Participants were 185 pregnant women selected from health centre/post registration lists (intervention group: n = 92; control group: n = 93). Interventions The intervention was a customer self-audit based on the CenteringPregnancy((R)) model of prenatal group care. The intervention group attended group support sessions focused on participants' opinions, questions, and self-management concerns. They also received sessions on experiential learning, coping, problem-solving, and goal-setting by a family health expert, a midwife, and a doctor. Control group participants continued to receive individual care. Primary outcome measures SQ and CQ were assessed using questionnaires. Patients rated the importance and performance of non-health quality dimensions. SQ was calculated as: SQ = 10 - (Importance x Performance). Results Total mean SQ scores were 7.63 (0.91) and 8.91 (0.76) for the control and intervention groups, respectively, a statistically significant difference (p<0.001). Compared with the control group, the intervention group scored higher on the SQ aspects confidentiality, communication, autonomy, availability of support group, dignity, safety, prevention, and accessibility. Total mean CQ scores for the control and intervention groups were 82.63(7.21) and 87.47 (6.75), respectively, a statistically significant difference (p<0.001). After intervention, 82.6% of intervention group participants and 50.5% of control group participants reached the highest stage of self-management, showing an ability to take care of themselves under stress and financial constraints. Conclusions The group prenatal care customer self-audit improved the SQ and CQ of maternity care by increased involvement of participants and giving them active roles in the care process.	[Gholipour, Kamal] Tabriz Univ Med Sci, Iranian Ctr Excellence Hlth Management, Sch Management & Med Informat, Tabriz, Iran; [Gholipour, Kamal; Tabrizi, Jafar Sadegh] Tabriz Univ Med Sci, Hlth Serv Management Res Ctr, Hlth Management & Safety Promot Res Inst, Tabriz, Iran; [Jafarabadi, Mohammad Asghari] Tabriz Univ Med Sci, Hlth Management & Safety Promot Res Inst, Rd Traff Injury Res Ctr, Tabriz, Iran; [Jafarabadi, Mohammad Asghari] Tabriz Univ Med Sci, Fac Hlth, Dept Stat & Epidemiol, Tabriz, Iran; [Iezadi, Shabnam] Tabriz Univ Med Sci, Social Determinants Hlth Res Ctr, Hlth Management & Safety Promot Res Inst, Tabriz, Iran; [Mardi, Ahmad] Tabriz Univ Med Sci, East Azerbaijan Prov Hlth Ctr, Tabriz, Iran	Tabriz University of Medical Science; Tabriz University of Medical Science; Tabriz University of Medical Science; Tabriz University of Medical Science; Tabriz University of Medical Science; Tabriz University of Medical Science	Iezadi, S (corresponding author), Tabriz Univ Med Sci, Social Determinants Hlth Res Ctr, Hlth Management & Safety Promot Res Inst, Tabriz, Iran.	sh_iezadi@yahoo.com	Gholipour, Kamal/L-1269-2017; tabrizi, jafarsadegh/L-5036-2017; Iezadi, Shabnam/R-5434-2018	Gholipour, Kamal/0000-0002-6595-4150; tabrizi, jafarsadegh/0000-0002-1458-8672; Iezadi, Shabnam/0000-0002-9644-5105	Tabriz Health Services Management Research Centre, Health Deputy of Tabriz University of Medical Sciences; National Public health Management Centre (NPMC)	Tabriz Health Services Management Research Centre, Health Deputy of Tabriz University of Medical Sciences; National Public health Management Centre (NPMC)	This study was supported by Tabriz Health Services Management Research Centre, Health Deputy of Tabriz University of Medical Sciences and National Public health Management Centre (NPMC). The code of ethics is TBZMED. REC. 5/4/12323 plan.	Afsharnia F, 2011, IMPROVING TECHNICAL; ALEXANDER GR, 1995, FUTURE CHILD, V5, P103, DOI 10.2307/1602510; Andersson E, 2013, SEX REPROD HEALTHC, V4, P113, DOI 10.1016/j.srhc.2013.08.002; Barber SL, 2009, HEALTH POLICY PLANN, V24, P18, DOI 10.1093/heapol/czn039; Berman P, 2000, B WORLD HEALTH ORGAN, V78, P791; Berwick DM, 2003, MED CARE, V41, pI30; Carter EB, 2016, OBSTET GYNECOL, V128, P551, DOI 10.1097/AOG.0000000000001560; Cunningham SD, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1327-3; Dai L., 2014, PLOS ONE, V9, DOI DOI 10.1371/JOURNAL.PONE.0113377; DeCesare JZ, 2015, ARCH GYNECOL OBSTET, V291, P499, DOI 10.1007/s00404-014-3467-2; Doaee S, 2013, J PAK MED ASSOC, V63, P50; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Feijen-de Jong EI, 2015, WOMEN BIRTH, V28, P87, DOI 10.1016/j.wombi.2015.01.005; Garretto D, 2014, AM J OBSTET GYNECOL, V210, P14, DOI 10.1016/j.ajog.2013.10.002; Gennaro S, 2016, MCN-AM J MATERN-CHIL, V41, P147, DOI 10.1097/NMC.0000000000000227; Gholipour K, 2016, E MEDITERR HEALTH J, V22, P309; Goldberg H, 2009, J PERINAT EDUC, V18, P32, DOI 10.1624/105812409X396219; Hale N, 2014, AM J OBSTET GYNECOL, V210, pE1; Health F, 1999, MAT CAR SERV ISL REP; Heberlein EC, 2016, J MIDWIFERY WOM HEAL, V61, P224, DOI 10.1111/jmwh.12379; Herrman JW, 2012, MCN-AM J MATERN-CHIL, V37, P19, DOI 10.1097/NMC.0b013e3182385204; Hibbard JH, 2003, MED CARE, V41, pi61; Ickovics JR, 2007, OBSTET GYNECOL, V110, P330, DOI 10.1097/01.AOG.0000275284.24298.23; Jafari F, 2010, IRAN J PUBLIC HEALTH, V39, P52; John J., 2015, P 1989 AC MARK SCI A, P518; Joshi C, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-94; Kennedy HP, 2009, J MIDWIFERY WOM HEAL, V54, P176, DOI 10.1016/j.jmwh.2008.11.004; Kitapci O, 2014, PROCD SOC BEHV, V148, P161, DOI 10.1016/j.sbspro.2014.07.030; Klima C, 2009, J MIDWIFERY WOM HEAL, V54, P27, DOI 10.1016/j.jmwh.2008.05.008; Klima CS, 2003, J MIDWIFERY WOM HEAL, V48, P220, DOI 10.1016/S1526-9523(03)00062-X; Koch E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036613; Kumaraswamy S, 2012, INT J BUSINESS SOCIA, V3, P141; Lathrop B, 2013, NURS WOMENS HLTH, V17, P120; Lin HC, 2004, INT J QUAL HEALTH C, V16, P437, DOI 10.1093/intqhc/mzh072; Maizes V, 2009, EXPLORE NY; Martins Maria de Fatima da Silva Vieira, 2014, Rev Bras Enferm, V67, P1008, DOI 10.1590/0034-7167.2014670621; Massey Z, 2006, JOGNN-J OBST GYN NEO, V35, P286, DOI 10.1111/J.1552-6909.2006.00040.x; Mehdizadeh A, 2003, RAZI J MED SCI, V10, P455; Moghani Lankarani Maryam, 2014, J Family Reprod Health, V8, P97; Mpinganjira M, 2011, AFR J BUS MANAGE, V5, P3690; Neupane S, 2014, EUR J PEDIATR, V173, P99, DOI 10.1007/s00431-013-2136-y; Novick G, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.03.026; Oyelese Y, 2005, AM FAM PHYSICIAN, V71, P1264; Papanikolaou V, 2014, HEALTH EXPECT, V17, P197, DOI 10.1111/j.1369-7625.2011.00747.x; Patil CL, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1493-3; Picklesimer A, 2015, CLIN OBSTET GYNECOL, V58, P380, DOI 10.1097/GRF.0000000000000095; Picklesimer A, 2012, AM J OBSTET GYNECOL, V206, pS55, DOI 10.1016/j.ajog.2011.10.109; Tabrizi JS, 2008, DIABETIC MED, V25, P612, DOI 10.1111/j.1464-5491.2008.02420.x; Tabrizi JS, 2013, HOSPITAL, V12, P9; Tabrizi JS, 2012, J CLIN RES GOV, V1, P11; Teate A, 2011, MIDWIFERY, V27, P138, DOI 10.1016/j.midw.2009.03.001; Tuncalp O, 2015, BJOG-INT J OBSTET GY, V122, P1045, DOI 10.1111/1471-0528.13451; van der Eijk I, 2001, AM J GASTROENTEROL, V96, P3329, DOI 10.1016/S0002-9270(01)03896-5; Wedin K, 2010, MIDWIFERY, V26, P389, DOI 10.1016/j.midw.2008.10.010; WHO (World Health Organization), SEX REPR HLTH; WHO-WORLD HEALTH ORGANIZATION, 2009, INF YOUNG CHILD FEED; Wilson A, 2013, HEALTH PROMOT PERSPE, V3, P23, DOI 10.5681/hpp.2013.003	58	4	4	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2018	13	10							e0203255	10.1371/journal.pone.0203255	http://dx.doi.org/10.1371/journal.pone.0203255			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GW7TO	30307957	gold, Green Published, Green Submitted			2023-01-03	WOS:000447173500006
J	Nakamura, N; Mihara, T; Hijikata, T; Goto, T; Ka, K				Nakamura, Nobuhito; Mihara, Takahiro; Hijikata, Toshiyuki; Goto, Takahisa; Ka, Koui			Unilateral electrical stimulation of the heart 7 acupuncture point to prevent emergence agitation in children: A prospective, double-blinded, randomized clinical trial	PLOS ONE			English	Article							PREOPERATIVE ANXIETY SCALE; SEVOFLURANE ANESTHESIA; POSTOPERATIVE NAUSEA; GENERAL-ANESTHESIA; P6 ACUPUNCTURE; DELIRIUM; ACUPRESSURE; PROPOFOL; METAANALYSIS; MYRINGOTOMY	Background Emergence agitation (EA) is a frequent phenomenon in children recovering from general anaesthesia and increases the risk of self-injury. Previously, our group reported that stimulating the heart 7 (HT7) acupuncture point bilaterally using two neuromuscular transmission monitoring devices (NTMs) decreased the incidence of EA. However, bilateral stimulation is a barrier to clinical use because two NTMs are needed for one patient. Objective The objective of this study was to examine the efficacy of unilateral electrical stimulation of HT7 using an NTM to prevent EA in children. Design Prospective, double-blinded, randomized clinical trial. Setting Kanagawa Children's Medical Centre, Yokohama, Japan. Patients One hundred children (ages 18-96 months) with ASA-PS I or II, who were scheduled to undergo inguinal hernia repair or orchiopexy under sevoflurane anaesthesia. Intervention Patients were randomly assigned to one of the following two groups: (1) HT7 group: unilateral (right side) stimulation of the HT7 acupuncture point using a single-twitch electrical stimulus (1 Hz, 50 mA) throughout the surgery, and (2) control group: electrodes alone were attached to the HT7 point on the right side; an electrical stimulus was not applied. Main outcome measures The primary outcome was the incidence of EA evaluated using the pediatric anaesthesia emergence delirium (PAED) scale. The secondary outcomes were the incidence of EA evaluated using Aono's scale, the severity of EA, PACU stay duration, and postoperative pain. Results There was no statistical difference between the incidence of EA in the HT7 and the control group (28.0% and 24.0%, respectively; P > 0.99). The risk ratio was 1.17 (95% confidence interval: 0.60-2.27). Conclusions We observed that there was no effect of unilateral single-twitch electrical stimulation to the HT7 on the incidence of EA, contrary to the findings with bilateral HT7 stimulation.	[Nakamura, Nobuhito; Mihara, Takahiro; Hijikata, Toshiyuki; Ka, Koui] Kanagawa Childrens Med Ctr, Dept Anesthesiol, Yokohama, Kanagawa, Japan; [Mihara, Takahiro; Goto, Takahisa] Yokohama City Univ, Dept Anesthesiol & Crit Care Med, Grad Sch Med, Yokohama, Kanagawa, Japan; [Hijikata, Toshiyuki] Itabashi Chuo Med Ctr, Dept Anesthesiol, Tokyo, Japan	Yokohama City University	Mihara, T (corresponding author), Kanagawa Childrens Med Ctr, Dept Anesthesiol, Yokohama, Kanagawa, Japan.; Mihara, T (corresponding author), Yokohama City Univ, Dept Anesthesiol & Crit Care Med, Grad Sch Med, Yokohama, Kanagawa, Japan.	miharaxxxtotoro@yahoo.co.jp	Mihara, Takahiro/AAH-8487-2020	Mihara, Takahiro/0000-0003-0613-511X				Acar HV, 2012, PEDIATR ANESTH, V22, P1105, DOI 10.1111/j.1460-9592.2012.03876.x; ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Au DWH, 2015, ACUPUNCT MED, V33, P353, DOI 10.1136/acupmed-2014-010720; Bajwa SA, 2010, PEDIATR ANESTH, V20, P704, DOI 10.1111/j.1460-9592.2010.03328.x; Carpenter RD, 1997, PAEDIATR ANAESTH, V7, P25, DOI 10.1046/j.1460-9592.1997.d01-36.x; Dahmani S, 2010, BRIT J ANAESTH, V104, P216, DOI 10.1093/bja/aep376; Fan CF, 1997, ANESTH ANALG, V84, P821, DOI 10.1097/00000539-199704000-00023; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Harmon D, 1999, BRIT J ANAESTH, V82, P387, DOI 10.1093/bja/82.3.387; Hijikata T, 2016, EUR J ANAESTH, V33, P535, DOI 10.1097/EJA.0000000000000379; Jenkins BN, 2014, ANESTH ANALG, V119, P643, DOI 10.1213/ANE.0000000000000350; Kain ZN, 1997, ANESTH ANALG, V85, P783, DOI 10.1097/00000539-199710000-00012; Kain ZN, 2004, ANESTH ANALG, V99, P1648, DOI 10.1213/01.ANE.0000136471.36680.97; Kim MS, 2013, BRIT J ANAESTH, V110, P274, DOI 10.1093/bja/aes382; Kim YH, 2011, ANESTH ANALG, V112, P819, DOI 10.1213/ANE.0b013e31820f819e; LEWIS IH, 1991, BRIT J ANAESTH, V67, P73, DOI 10.1093/bja/67.1.73; Lin YC, 2009, PEDIATR ANESTH, V19, P1096, DOI 10.1111/j.1460-9592.2009.03129.x; Malarbi S, 2011, PEDIATR ANESTH, V21, P942, DOI 10.1111/j.1460-9592.2011.03646.x; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Somaini M, 2016, BRIT J ANAESTH, V116, P377, DOI 10.1093/bja/aev552; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; YENTIS SM, 1991, BRIT J ANAESTH, V67, P779, DOI 10.1093/bja/67.6.779	24	2	2	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2018	13	10							e0204533	10.1371/journal.pone.0204533	http://dx.doi.org/10.1371/journal.pone.0204533			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW4VA	30304047	gold, Green Submitted, Green Published			2023-01-03	WOS:000446921100050
J	Yue, Q; Yin, FT; Zhang, Q; Yuan, C; Ye, MY; Wang, XL; Li, JJ; Gan, YH				Yue, Qi; Yin, Fei-Ting; Zhang, Qian; Yuan, Chao; Ye, Mei-Yan; Wang, Xiao-Ling; Li, Ji-Jun; Gan, Ye-Hua			Carious status and supragingival plaque microbiota in hemodialysis patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; ORAL-HEALTH; STREPTOCOCCUS-MUTANS; DENTAL-CARIES; PERIODONTAL-DISEASE; MORTALITY; SUCROSE; PREVALENCE; XEROSTOMIA; CHILDREN	Objective The aim of this study was to evaluate the carious status and the microbial profiles of supragingival plaque in patients with chronic kidney disease undergoing hemodialysis. Methods This study included 30 patients with chronic kidney disease undergoing hemodialysis as well as 30 control subjects. Dental examination was performed and the decayed-missing-filled-teeth was recorded. Supragingival plaque was taken and analyzed using 16S rRNA gene amplicon by Illumina MiSeq sequencing to detect microbial composition and community diversity and structure. Results The level of decayed-missing-filled-teeth was higher in the hemodialysis group than that in the control group. Microbial analysis showed a decrease in a diversity and a increase in relative abundance and prevalence of many acidogenic and aciduric caries related species in the supragingival plaque samples of the hemodialysis patients, including Streptococcus mutans, Lactobacillus salivarius, Lactobacillus fermentum, Lactobacillus vaginalis, Scardovia wiggsiae F0424, and Actinomyces naeslundii. Conclusion Our results suggested that the hemodialysis patients were more susceptible to caries. More attentions for caries prevention and treatment should be paid to improve their life quality, and even to reduce their cardiovascular events and survival.	[Yue, Qi; Zhang, Qian; Wang, Xiao-Ling; Gan, Ye-Hua] Peking Univ, Sch & Hosp Stomatol, Cent Lab, Beijing, Peoples R China; [Yue, Qi; Zhang, Qian; Yuan, Chao; Ye, Mei-Yan; Wang, Xiao-Ling; Gan, Ye-Hua] Natl Engn Lab Digital & Mat Technol Stomatol, Beijing, Peoples R China; [Yue, Qi; Zhang, Qian; Yuan, Chao; Ye, Mei-Yan; Wang, Xiao-Ling; Gan, Ye-Hua] Beijing Key Lab Digital Stomatol, Beijing, Peoples R China; [Yin, Fei-Ting; Ye, Mei-Yan; Li, Ji-Jun] PLA, Gen Hosp, Affiliated Hosp 1, Dept Nephrol, Beijing, Peoples R China; [Yuan, Chao] Peking Univ, Sch & Hosp Stomatol, Dept Prevent Dent, Beijing, Peoples R China; [Ye, Mei-Yan] Peking Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Beijing, Peoples R China	Peking University; Peking University; Peking University	Wang, XL; Gan, YH (corresponding author), Peking Univ, Sch & Hosp Stomatol, Cent Lab, Beijing, Peoples R China.; Wang, XL; Gan, YH (corresponding author), Natl Engn Lab Digital & Mat Technol Stomatol, Beijing, Peoples R China.; Wang, XL; Gan, YH (corresponding author), Beijing Key Lab Digital Stomatol, Beijing, Peoples R China.; Li, JJ (corresponding author), PLA, Gen Hosp, Affiliated Hosp 1, Dept Nephrol, Beijing, Peoples R China.	kqwxl@bjmu.edu.cn; lijj9536@sina.com; kqyehuagan@bjmu.edu.cn			National Natural Science Foundation of China [81472764]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (grant number: 81472764 to YHG); (http://www.nsfc.gov.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aas JA, 2008, J CLIN MICROBIOL, V46, P1407, DOI 10.1128/JCM.01410-07; Akar H, 2011, CLIN J AM SOC NEPHRO, V6, P218, DOI 10.2215/CJN.05470610; Al Nowaiser A, 2003, PEDIATR NEPHROL, V18, P39, DOI 10.1007/s00467-002-0999-7; Anuradha Beela Ram, 2015, J Indian Soc Periodontol, V19, P297, DOI 10.4103/0972-124X.154178; Badger JH, 2011, METAGENOMICS OF THE HUMAN BODY, P1, DOI 10.1007/978-1-4419-7089-3_1; Bossola M, 2012, NAT REV NEPHROL, V8, P176, DOI 10.1038/nrneph.2011.218; Bots CP, 2007, BRIT DENT J, V202, DOI 10.1038/sj.bdj.47; Bots CP, 2005, NEPHROL DIAL TRANSPL, V20, P578, DOI 10.1093/ndt/gfh675; Carlen A, 2010, CARIES RES, V44, P341, DOI 10.1159/000315273; Cunningham LL, 2014, OR SURG OR MED OR PA, V117, P435, DOI 10.1016/j.oooo.2013.11.502; de Souza CM, 2014, J PERIODONTOL, V85, pE169, DOI 10.1902/jop.2013.130427; Durso SC, 2014, CARIES RES, V48, P214, DOI 10.1159/000354410; Eberhard J, 2017, CLIN ORAL INVEST, V21, P447, DOI 10.1007/s00784-016-1811-6; Gosmanov AR, 2016, NEPHROL DIAL TRANSPL, V31, P8, DOI 10.1093/ndt/gfv258; Hayashi T, 2015, NEPHROLOGY, V20, P1, DOI 10.1111/nep.12642; Kim J, 2006, ODONTOLOGY, V94, P10, DOI 10.1007/s10266-006-0060-6; Kshirsagar AV, 2009, KIDNEY INT, V75, P746, DOI 10.1038/ki.2008.660; Leme AFP, 2006, J DENT RES, V85, P878, DOI 10.1177/154405910608501002; Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013; Li Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137030; Manley KJ, 2014, J REN CARE, V40, P172, DOI 10.1111/jorc.12062; Marsh P D, 1994, Adv Dent Res, V8, P263; Marsh Philip D, 2006, BMC Oral Health, V6 Suppl 1, pS14, DOI 10.1186/1472-6831-6-S1-S14; Montebugnoli L, 2004, J CLIN PERIODONTOL, V31, P25, DOI 10.1111/j.0303-6979.2004.00432.x; Nakano K, 2009, ORAL MICROBIOL IMMUN, V24, P64, DOI 10.1111/j.1399-302X.2008.00479.x; Nakano K, 2006, J CLIN MICROBIOL, V44, P3313, DOI 10.1128/JCM.00377-06; Naugle K, 1998, Ann Periodontol, V3, P197, DOI 10.1902/annals.1998.3.1.197; Novak MJ, 2008, J PERIODONTOL, V79, P1870, DOI 10.1902/jop.2008.070554 ; Olsen I, 2015, ACTA ODONTOL SCAND, V73, P563, DOI 10.3109/00016357.2015.1007480; Organization WH, 2013, ORAL HLTH SURVEYS BA; Palmer SC, 2015, AM J KIDNEY DIS, V66, P666, DOI 10.1053/j.ajkd.2015.04.051; PEARCE E I F, 1991, Proceedings of the Finnish Dental Society, V87, P527; Marques PLP, 2015, ARTIF ORGANS, V39, P181, DOI 10.1111/aor.12334; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Ruospo M, 2014, NEPHROL DIAL TRANSPL, V29, P364, DOI 10.1093/ndt/gft401; Sanz M, 2017, J CLIN PERIODONTOL, V44, pS5, DOI 10.1111/jcpe.12682; Saraithong P, 2015, CLIN ORAL INVEST, V19, P1955, DOI 10.1007/s00784-015-1437-0; Sobrado Marinho Jorge Serafin, 2007, Med Oral Patol Oral Cir Bucal, V12, pE305; Takeuchi Y, 2007, NEPHROLOGY, V12, P182, DOI 10.1111/j.1440-1797.2007.00767.x; Andrade MRTC, 2014, PEDIATR NEPHROL, V29, P771, DOI 10.1007/s00467-013-2437-4; Tian J, 2015, BIOCHEM BIOPH RES CO, V468, P294, DOI 10.1016/j.bbrc.2015.10.110; Tomas I, 2008, ARCH ORAL BIOL, V53, P528, DOI 10.1016/j.archoralbio.2008.01.006; Tonelli M, 2006, J AM SOC NEPHROL, V17, P2034, DOI 10.1681/ASN.2005101085; Tsamtsouris A, 1980, J Pedod, V5, P51; Wang XL, 2015, CHIN J DENT RES, V18, P185, DOI 10.3290/j.cjdr.a34783; Xie T, 2014, HEMODIAL INT, V18, P668, DOI 10.1111/hdi.12149; Xu X, 2015, ENVIRON MICROBIOL, V17, P699, DOI 10.1111/1462-2920.12502; Yang F, 2012, ISME J, V6, P1, DOI 10.1038/ismej.2011.71; Yu Y, 2017, ORAL DIS, V23, P353, DOI 10.1111/odi.12618	49	2	4	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2018	13	10							e0204674	10.1371/journal.pone.0204674	http://dx.doi.org/10.1371/journal.pone.0204674			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW4OW	30300382	gold, Green Published, Green Submitted			2023-01-03	WOS:000446897200015
J	Stewart, C; Subbarayan, S; Paton, P; Gemmell, E; Abraha, I; Myint, PK; O'Mahony, D; Cruz-Jentoft, AJ; Cherubini, A; Soiza, RL				Stewart, Carrie; Subbarayan, Selvarani; Paton, Pamela; Gemmell, Elliot; Abraha, Iosief; Myint, Phyo Kyaw; O'Mahony, Denis; Cruz-Jentoft, Alfonso J.; Cherubini, Antonio; Soiza, Roy L.			Non-pharmacological interventions for the improvement of post-stroke activities of daily living and disability amongst older stroke survivors: A systematic review	PLOS ONE			English	Review							RANDOMIZED CONTROLLED-TRIAL; OCCUPATIONAL-THERAPY INTERVENTION; MOTOR RELEARNING PROGRAM; INDUCED MOVEMENT THERAPY; SELF-CARE INTERVENTION; QUALITY-OF-LIFE; SUBACUTE STROKE; ISCHEMIC-STROKE; ACUPUNCTURE TREATMENT; UNILATERAL NEGLECT	Globally, stroke remains a leading cause of death and disability, with older adults disproportionately affected. Numerous non-pharmacological stroke rehabilitation approaches are in use to address impairments, but their efficacy in older persons is largely unknown. This systematic review examined the evidence for such interventions as part of the Optimal Evidence- Based Non-Drug Therapies in Older Persons (ONTOP) project conducted under an European Union funded project called the Software Engine for the Assessment and Optimisation of Drug and Non-Drug Therapies in Older Persons (SENATOR) [http://www. senatorproject. eu]. A Delphi panel of European geriatric experts agreed activities of daily living and disability to be of critical importance as stroke rehabilitation outcomes. A comprehensive search strategy was developed and five databases (Pubmed, CINAHL, Embase, PsycInfo and Cochrane Database of Systematic Reviews) searched for eligible systematic reviews. Primary studies meeting our criteria (non-pharmacologic interventions, involving stroke survivors aged >= 65 years, assessing activities of daily living and/or disability as outcome) were then identified from these reviews. Eligible papers were double reviewed, and due to heterogeneity, narrative analysis performed. Cochrane risk of bias and GRADE assessment tools were used to assess bias and quality of evidence, allowing us to make recommendations regarding specific non-pharmacologic rehabilitation in older stroke survivors. In total, 72 primary articles were reviewed spanning 14 types of non-pharmacological intervention. Non-pharmacological interventions based on physiotherapy and occupational therapy techniques improved activities of daily living amongst older stroke survivors. However, no evidence was found to support use of any non-pharmacological approach to benefit older stroke survivors' disability. Evidence was limited by poor study quality and the small number of studies targeting older stroke survivors. We recommend future studies explore such interventions exclusively in older adult populations and improve methodological and outcome reporting.	[Stewart, Carrie; Subbarayan, Selvarani; Paton, Pamela; Gemmell, Elliot; Myint, Phyo Kyaw; Soiza, Roy L.] Aberdeen Royal Infirm, Dept Old Age Med, Aberdeen, Scotland; [Subbarayan, Selvarani; Myint, Phyo Kyaw; Soiza, Roy L.] Univ Aberdeen, Sch Med & Dent, Aberdeen, Scotland; [Abraha, Iosief; Cherubini, Antonio] IRCCS INRCA, Geriatria, Accettaz Geriatr, Ancona, Italy; [Abraha, Iosief; Cherubini, Antonio] IRCCS INRCA, Ctr Ric Invecchiamento, Ancona, Italy; [O'Mahony, Denis] Univ Coll Cork, Dept Geriatr Med, Cork, Ireland; [Cruz-Jentoft, Alfonso J.] Hosp Univ Ramon y Cajal, Fdn Invest Biomed, Madrid, Spain	University of Aberdeen; University of Aberdeen; IRCCS INRCA; IRCCS INRCA; University College Cork; Hospital Universitario Ramon y Cajal	Stewart, C (corresponding author), Aberdeen Royal Infirm, Dept Old Age Med, Aberdeen, Scotland.	carrie.stewart.06@aberdeen.ac.uk	Cherubini, Antonio/AAL-4632-2020; , roysoiza/Q-3525-2019; Cruz-Jentoft, Alfonso J/G-2675-2015; myint, phyo/G-5730-2013; Abraha, Iosief/K-4327-2018	, roysoiza/0000-0002-1397-4272; Cruz-Jentoft, Alfonso J/0000-0001-7628-4861; stewart, carrie/0000-0002-2325-3380; myint, phyo/0000-0003-3852-6158; Abraha, Iosief/0000-0002-5440-775X; O'Mahony, Denis/0000-0003-2236-5222	European Union [305930]	European Union(European Commission)	This work was supported by the European Union Seventh Framework program (FP7/2007-2013) under grant agreement no. 305930 (www.senator-project.eu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraha I, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007488; Askim T, 2010, STROKE, V41, P1697, DOI 10.1161/STROKEAHA.110.584284; Bagley P, 2005, CLIN REHABIL, V19, P354, DOI 10.1191/0269215505cr874oa; Barrett JA, 2001, CLIN REHABIL, V15, P32, DOI 10.1191/026921501672264719; Boutron I, 2007, PLOS MED, V4, P370, DOI 10.1371/journal.pmed.0040061; Bowen A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003586.pub2; Bradley L, 1998, CLIN REHABIL, V12, P11, DOI 10.1191/026921598677671932; Bradt J, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006787.pub2; Braun SM, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2010.07.009; Chiu CWY, 2004, OTJR-OCCUP PART HEAL, V24, P113, DOI 10.1177/153944920402400305; Clark MS, 2003, CLIN REHABIL, V17, P703, DOI 10.1191/0269215503cr681oa; Corr S, 1995, CLIN REHABIL, V9, P291; de Seze M, 2001, ARCH PHYS MED REHAB, V82, P793, DOI 10.1053/apmr.2001.0820793; DICKSTEIN R, 1986, PHYS THER, V66, P1233, DOI 10.1093/ptj/66.8.1233; Donkervoort M, 2001, NEUROPSYCHOL REHABIL, V11, P549, DOI 10.1080/09602010143000093; Duncan P, 1998, STROKE, V29, P2055, DOI 10.1161/01.STR.29.10.2055; Duncan P, 2003, STROKE, V34, P2173, DOI 10.1161/01.STR.0000083699.95351.F2; Ertel KA, 2007, CLIN REHABIL, V21, P511, DOI 10.1177/0269215507078312; Forster A, 1996, BRIT MED J, V312, P1642, DOI 10.1136/bmj.312.7047.1642; Franceschini M, 2009, STROKE, V40, P3079, DOI 10.1161/STROKEAHA.109.555540; Galvin R, 2011, STROKE, V42, P681, DOI 10.1161/STROKEAHA.110.594689; Gelber DA, 1995, J NEUROL REHABIL, V9, P191; Gilbertson L, 2000, BRIT MED J, V320, P603, DOI 10.1136/bmj.320.7235.603; Glass TA, 2004, PSYCHOSOM MED, V66, P889, DOI 10.1097/01.psy.0000146326.01642.ca; Gosman-Hedstrom G, 1998, STROKE, V29, P2100, DOI 10.1161/01.STR.29.10.2100; Green J, 2002, LANCET, V359, P199, DOI 10.1016/S0140-6736(02)07443-3; Guidetti S, 2011, DISABIL REHABIL, V33, P494, DOI 10.3109/09638288.2010.498553; Guidetti S, 2010, SCAND J OCCUP THER, V17, P276, DOI 10.3109/11038120903281169; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Hopwood V, 2008, J NEUROL, V255, P858, DOI 10.1007/s00415-008-0790-1; Hsieh RL, 2007, J REHABIL MED, V39, P205, DOI 10.2340/16501977-0032; Johansson BB, 2001, STROKE, V32, P707, DOI 10.1161/01.STR.32.3.707; JOHANSSON K, 1993, NEUROLOGY, V43, P2189, DOI 10.1212/WNL.43.11.2189; Johnston M, 2007, DISABIL REHABIL, V29, P1117, DOI 10.1080/03323310600950411; JONGBLOED L, 1989, AM J OCCUP THER, V43, P391, DOI 10.5014/ajot.43.6.391; Kalra L, 2004, BMJ-BRIT MED J, V328, P1099, DOI 10.1136/bmj.328.7448.1099; Kalra L, 1997, STROKE, V28, P1386, DOI 10.1161/01.STR.28.7.1386; Keeney S, 2001, INT J NURS STUD, V38, P195, DOI 10.1016/S0020-7489(00)00044-4; Kim SM, 2016, J PHYS THER SCI, V28, P169, DOI [10.1589/jpts.28.169, 10.1589/jpts.28.1669]; Kwakkel G, 2002, J NEUROL NEUROSUR PS, V72, P473; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; Landi F, 2006, GERONTOLOGY, V52, P85, DOI 10.1159/000090953; Langhammer B, 2003, CLIN REHABIL, V17, P731, DOI 10.1191/0269215503cr670oa; Langhammer B, 2000, CLIN REHABIL, V14, P361, DOI 10.1191/0269215500cr338oa; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Laver KE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008349.pub2, 10.1002/14651858.CD008349.pub3, 10.1002/14651858.CD008349.pub4]; Lee G, 2013, J PHYS THER SCI, V25, P595, DOI 10.1589/jpts.25.595; Lieberman D, 2005, J REHABIL RES DEV, V42, P47, DOI 10.1682/JRRD.2004.01.0001; Lincoln NB, 1999, STROKE, V30, P573, DOI 10.1161/01.STR.30.3.573; Lincoln NB, 2003, STROKE, V34, P111, DOI 10.1161/01.STR.0000044167.44670.55; Liu CH, 2016, ACUPUNCT MED, V34, P349, DOI 10.1136/acupmed-2015-010825; Liu KPY, 2016, EUR J NEUROL, V23, P1351, DOI 10.1111/ene.13037; Logan PA, 2004, BMJ-BRIT MED J, V329, P1372, DOI 10.1136/bmj.38264.679560.8F; Logan PA, 1997, CLIN REHABIL, V11, P107, DOI 10.1177/026921559701100203; Lozano-Montoya I, 2016, J AM MED DIR ASSOC, V17, DOI 10.1016/j.jamda.2015.12.091; Macdonell R A, 1994, J Stroke Cerebrovasc Dis, V4, P155, DOI 10.1016/S1052-3057(10)80178-8; Mao Min, 2008, J Tradit Chin Med, V28, P90; Masiero S, 2007, ARCH PHYS MED REHAB, V88, P142, DOI 10.1016/j.apmr.2006.10.032; Mizuno K, 2011, NEUROREHAB NEURAL RE, V25, P711, DOI 10.1177/1545968311407516; Montori VM, 2005, BMJ-BRIT MED J, V330, P68, DOI 10.1136/bmj.38336.804167.47; Morris JH, 2008, ARCH PHYS MED REHAB, V89, P1237, DOI 10.1016/j.apmr.2007.11.039; National Institute for Health and Care Excellence (NICE), 2013, STROK STROKE REHABIL; Ng MFW, 2008, STROKE, V39, P154, DOI 10.1161/STROKEAHA.107.495705; Nir Z, 2004, AM J PHYS MED REHAB, V83, P522, DOI 10.1097/01.PHM.0000130026.12790.20; Owolabi MO, 2015, CARDIOVASC J AFR, V26, pS27, DOI 10.5830/CVJA-2015-038; Park J, 2005, ARCH INTERN MED, V165, P2026, DOI 10.1001/archinte.165.17.2026; Parker CJ, 2001, CLIN REHABIL, V15, P42, DOI 10.1191/026921501666968247; Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202; Pei J, 2001, J Tradit Chin Med, V21, P270; Pohjasvaara T, 1997, STROKE, V28, P729, DOI 10.1161/01.STR.28.4.729; Popay J., 2006, PROD ESRC METHODS PR, DOI [10.13140/2.1.1018.4643, DOI 10.13140/2.1.1018.4643]; Rabadi MH, 2008, CLIN REHABIL, V22, P1071, DOI 10.1177/0269215508095358; Raglio A, 2017, NEUROL SCI, V38, P893, DOI 10.1007/s10072-017-2827-7; Rimland JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161579; Rodgers H, 1999, STROKE, V30, P2585, DOI 10.1161/01.STR.30.12.2585; Royal College of Physicians Intercollegiate Stroke Working Party (RCP), 2016, NATIONAL CLINICAL GU; Rydwik E, 2006, CLIN REHABIL, V20, P645, DOI 10.1191/0269215506cre986oa; Sackley C, 2006, STROKE, V37, P2336, DOI 10.1161/01.STR.0000237124.20596.92; Sarkamo T, 2008, BRAIN, V131, P866, DOI 10.1093/brain/awn013; Schneider S, 2007, J NEUROL, V254, P1339, DOI 10.1007/s00415-006-0523-2; Schuler MS, 2005, J AM GERIATR SOC, V53, P549, DOI 10.1111/j.1532-5415.2005.53178_6.x; Scottish Intercollegiate Guidelines Network (SIGN), 2010, GUIDELINE NUMBER 118; SIVENIUS J, 1985, STROKE, V16, P928, DOI 10.1161/01.STR.16.6.928; Smith J, 2004, CLIN REHABIL, V18, P726, DOI 10.1191/0269215504cr790oa; Soiza RL, 2017, THER ADV DRUG SAF, V8, P81, DOI 10.1177/2042098616675851; Sonde L, 1998, SCAND J REHABIL MED, V30, P95; Sonde L, 2000, CLIN REHABIL, V14, P14, DOI 10.1191/026921500673534278; Stroke Association, 2017, STATE OF THE NATION; Studenski S, 2005, STROKE, V36, P1764, DOI 10.1161/01.STR.0000174192.87887.70; SUNDERLAND A, 1992, J NEUROL NEUROSUR PS, V55, P530, DOI 10.1136/jnnp.55.7.530; Sze FKH, 2002, STROKE, V33, P186, DOI 10.1161/hs0102.101815; Tangiisuran B., 2009, ADVERSE DRUG REACTIO; Teasell Robert W, 2003, Top Stroke Rehabil, V10, P29; Tsang MHM, 2009, DISABIL REHABIL, V31, P630, DOI 10.1080/09638280802240621; Vafadar AK, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/729768; van Vliet PM, 2005, J NEUROL NEUROSUR PS, V76, P503, DOI 10.1136/jnnp.2004.040436; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; WADE DT, 1992, BRIT MED J, V304, P609, DOI 10.1136/bmj.304.6827.609; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5; WALKER MF, 1996, CLIN REHABIL, V10, P23, DOI DOI 10.1177/026921559601000105; Watkins CL, 2007, STROKE, V38, P1004, DOI 10.1161/01.STR.0000258114.28006.d7; Watts G, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3445; Wellwood I, 2004, CLIN REHABIL, V18, P529, DOI 10.1191/0269215504cr768oa; Wiart L, 1997, ARCH PHYS MED REHAB, V78, P424, DOI 10.1016/S0003-9993(97)90236-7; Wu CY, 2007, ARCH PHYS MED REHAB, V88, P273, DOI 10.1016/j.apmr.2006.11.021; Zhu Y, 2013, PHYS THER, V93, P1447, DOI 10.2522/ptj.20110138	107	7	7	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2018	13	10							e0204774	10.1371/journal.pone.0204774	http://dx.doi.org/10.1371/journal.pone.0204774			52	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GV8IQ	30286144	gold, Green Submitted, Green Published			2023-01-03	WOS:000446383500042
J	Wetmore, JB; Li, SY; Yan, H; Xu, HR; Peng, Y; Sinsakul, MV; Liu, JN; Gilbertson, DT				Wetmore, James B.; Li, Suying; Yan, Heng; Xu, Hairong; Peng, Yi; Sinsakul, Marvin, V; Liu, Jiannong; Gilbertson, David T.			Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis	PLOS ONE			English	Article							DOPPS PRACTICE MONITOR; 3RD NATIONAL-HEALTH; HEMODIALYSIS-PATIENTS; EPOETIN-ALPHA; DARBEPOETIN ALPHA; HEMATOCRIT VALUES; CARE UPDATE; MORTALITY; HEMOGLOBIN; ASSOCIATION	Whether and how anemia treatment with erythropoiesis stimulating agents (ESAs) before hemodialysis initiation may be associated with lower mortality after dialysis initiation is unknown. We compared all-cause and cardiovascular mortality in two groups of patients who experienced distinct anemia treatment patterns with ESAs before and after hemodialysis initiation. This retrospective cohort analysis included patients initiating hemodialysis April 1, 2012-June 30, 2013, identified from United States Renal Data System end-stage renal disease (ESRD) and pre-ESRD files. Patients treated with ESAs before and after hemodialysis initiation who maintained Hb >= 9.0 g/dL throughout (comparator group, n = 3662) were compared with patients with Hb < 9.0 g/dL before hemodialysis initiation (with or without ESAs) whose levels increased with ESAs after hemodialysis initiation (referent group, n = 4461). Cox proportional hazards models were used to calculate the hazard ratio of all-cause and cardiovascular mortality after hemodialysis initiation. Of 20,454 patients, 4855 (23.7%) had Hb < 9.0 g/dL upon hemodialysis initiation; of these 4855, 26.6% received ESAs before initiation. Comparator group Hb levels increased from 8.2 +/- 0.8 mg/dL upon initiation to 10.9 +/- 1.2 with ESAs afterward. Comparator patients were more likely than referent patients to be younger (76.3 +/- 6.7 versus 77.2 +/- 6.9 years), male (51.5% versus 49.8%), and black (24.6% versus 18.6%). Risk of all-cause mortality was lower for the comparator group versus the referent group at 3 (HR 0.83, 95% CI 0.68-1.00, P = 0.052), 6 (0.86, 0.74-1.00, P = 0.047), and 12 (0.88, 0.78-0.99, P = 0.036) months. The pattern was similar for cardiovascular mortality. Hb >= 9.0 with ESAs before and after hemodialysis initiation was generally associated with lower post-initiation all-cause and cardiovascular mortality compared with predialysis Hb < 9.0 g/dL in patients whose Hb levels subsequently improved with ESAs after hemodialysis initiation.	[Wetmore, James B.; Li, Suying; Yan, Heng; Peng, Yi; Liu, Jiannong; Gilbertson, David T.] Minneapolis Med Res Fdn Inc, Chron Dis Res Grp, Minneapolis, MN 55404 USA; [Wetmore, James B.] Univ Minnesota, Hennepin Cty Med Ctr, Div Nephrol, Minneapolis, MN 55415 USA; [Xu, Hairong; Sinsakul, Marvin, V] AstraZeneca, Gaithersburg, MD USA	Minneapolis Medical Research Foundation; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities; AstraZeneca	Wetmore, JB (corresponding author), Minneapolis Med Res Fdn Inc, Chron Dis Res Grp, Minneapolis, MN 55404 USA.; Wetmore, JB (corresponding author), Univ Minnesota, Hennepin Cty Med Ctr, Div Nephrol, Minneapolis, MN 55415 USA.	James.Wetmore@hcmed.org		Wetmore, James/0000-0003-1380-8597	AstraZeneca, Inc., Wilmington, Delaware	AstraZeneca, Inc., Wilmington, Delaware	This work was supported by a research contract from AstraZeneca, Inc., Wilmington, Delaware. The funder provided salary support for the academic investigators (JBW, SL, HY, YP, JL, and DTG) to conduct the analysis. HX and MVS, employees of AstraZeneca, provided insights into study design and the preparation of the manuscript, and so are included as coauthors as per ICMJE guidelines, but did not influence the decision to publish, which was solely the domain of the academic authors.	Astor BC, 2002, ARCH INTERN MED, V162, P1401, DOI 10.1001/archinte.162.12.1401; Berns Jeffrey S, 2007, Semin Dial, V20, P277, DOI 10.1111/j.1525-139X.2007.00290.x; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Bradbury BD, 2008, AM J KIDNEY DIS, V51, P62, DOI 10.1053/j.ajkd.2007.09.015; Bradbury BD, 2009, CLIN J AM SOC NEPHRO, V4, P630, DOI 10.2215/CJN.03580708; Collins AJ, 2001, J AM SOC NEPHROL, V12, P2465, DOI 10.1681/ASN.V12112465; Daza JC, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011122.pub2; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; ESCHBACH JW, 1989, NEW ENGL J MED, V321, P158, DOI 10.1056/NEJM198907203210305; Foley RN, 2014, KIDNEY INT, V86, P392, DOI 10.1038/ki.2014.15; Foley RN, 2009, PEDIATR NEPHROL, V24, P2279, DOI 10.1007/s00467-009-1123-z; Freburger JK, 2012, AM J MED, V125, P906, DOI 10.1016/j.amjmed.2012.03.011; Fuller DS, 2013, AM J KIDNEY DIS, V62, P1213, DOI 10.1053/j.ajkd.2013.09.006; Hahn D, 2014, COCHRANE DB SYST REV, V5; Hsu CY, 2002, J AM SOC NEPHROL, V13, P504, DOI 10.1681/ASN.V132504; Icardi A, 2013, NEPHROL DIAL TRANSPL, V28, P1672, DOI 10.1093/ndt/gft021; Kausz AT, 2005, AM J KIDNEY DIS, V45, P136, DOI 10.1053/j.ajkd.2004.08.042; Levin A, 2007, NEPHROL DIAL TRANSPL, V22, P309, DOI 10.1093/ndt/gfl824; Locatelli F, 2004, NEPHROL DIAL TRANSPL, V19, P121, DOI 10.1093/ndt/gfg458; Ma JZ, 1999, J AM SOC NEPHROL, V10, P610; Miskulin DC, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-264; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Singh AK, 2008, SEMIN DIALYSIS, V21, P1, DOI 10.1111/j.1525-139X.2007.00329.x; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Teehan G, 2011, ANEMIA, V2011, DOI 10.1155/2011/623673; Weiner DE, 2013, AM J KIDNEY DIS, V62, P1217, DOI 10.1053/j.ajkd.2013.10.006; Wilhelm-Leen ER, 2015, AM J KIDNEY DIS, V66, P69, DOI 10.1053/j.ajkd.2014.12.012; Winkelmayer WC, 2010, SEMIN DIALYSIS, V23, P486, DOI 10.1111/j.1525-139X.2010.00768.x; Xue JL, 2002, AM J KIDNEY DIS, V40, P1153, DOI 10.1053/ajkd.2002.36861	29	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2018	13	9							e0203767	10.1371/journal.pone.0203767	http://dx.doi.org/10.1371/journal.pone.0203767			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV3NB	30256836	Green Published, Green Submitted, gold			2023-01-03	WOS:000446000200026
J	Xing, ZH; Tang, L; Zhu, ZW; Hu, XQ				Xing, Zhenhua; Tang, Liang; Zhu, Zhaowei; Hu, Xinqun			Effects of thrombolysis on outcomes of patients with deep venous thrombosis: An updated meta-analysis	PLOS ONE			English	Article							CATHETER-DIRECTED THROMBOLYSIS; VEIN THROMBOSIS; POSTTHROMBOTIC SYNDROME; RISK	Background Small randomized controlled studies and meta-analyses have shown that thrombolysis, especially catheter-directed thrombolysis, can reduce the incidence of post-thrombotic syndrome (PTS). However, the recent ATTRACT trial did not demonstrate the same effects. Given this confusing situation, we performed an updated meta-analysis of randomized controlled trials (RCTs) to evaluate the effects of thrombolysis, especially catheter-directed thrombolysis, on the outcomes of deep venous thrombosis (DVT). Methods We searched PubMed, Embase, and the Cochrane Library for relevant studies comparing thrombolysis in combination with anticoagulation and with anticoagulation alone. The primary endpoint was PTS during the longest follow-up period. The safety endpoint was the incidence of major bleeding events. We also evaluated the outcomes of catheter-directed thrombolysis as a subgroup analysis. Results Six RCTs, including 1418 patients with DVT, were included in our meta-analysis. Thrombolysis in combination with anticoagulation did not reduce PTS (RR: 0.90, [0.80-1.01], P = 0.19) and increased major bleeding (RR: 2.07, [1.12-3.81], P = 0.02). However, trial sequential analysis (TSA) showed that more patients are needed to support the conclusion that thrombolysis in combination with anticoagulation increased major bleeding. Catheter-directed thrombolysis did not reduce the incidence of PTS (RR: 0.88, [0.68-1.13], P = 0.31) and did increase the incidence of major bleeding events (RR: 1.89, [1.00-3.59], P = 0.05). Conclusion Thrombolysis, including catheter-directed thrombolysis, did not reduce the incidence of PTS and increased the incidence of major bleeding. However, the results were not supported by TSA and sensitivity analysis, so more relevant studies are needed.	[Xing, Zhenhua; Tang, Liang; Zhu, Zhaowei; Hu, Xinqun] Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Med, Changsha, Hunan, Peoples R China	Central South University	Hu, XQ (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Med, Changsha, Hunan, Peoples R China.	huxinqun@csu.edu.cn						Baglin T, 2003, LANCET, V362, P523, DOI 10.1016/S0140-6736(03)14111-6; Baldwin MJ, 2013, J THROMB HAEMOST, V11, P795, DOI 10.1111/jth.12180; Broholm R, 2010, INT ANGIOL, V29, P292; Chatterjee S, 2014, JAMA-J AM MED ASSOC, V311, P2414, DOI 10.1001/jama.2014.5990; COMMON HH, 1976, ANGIOLOGY, V27, P645, DOI 10.1177/000331977602701105; Elsharawy M, 2002, EUR J VASC ENDOVASC, V24, P209, DOI 10.1053/ejvs.2002.1665; Enden T, 2012, LANCET, V379, P31, DOI 10.1016/S0140-6736(11)61753-4; Fowkes FJI, 2003, EUR J VASC ENDOVASC, V25, P1, DOI 10.1053/ejvs.2002.1778; Ioannidis JPA, 2005, JAMA-J AM MED ASSOC, V294, P218, DOI 10.1001/jama.294.2.218; Kahn SR, 2008, ANN INTERN MED, V149, P698, DOI 10.7326/0003-4819-149-10-200811180-00004; Kohi MP, 2016, CARDIOVASC DIAGN THE, V6, P599, DOI 10.21037/cdt.2016.11.20; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Schweizer J, 2000, J AM COLL CARDIOL, V36, P1336, DOI 10.1016/S0735-1097(00)00863-9; Subbiah R, 2016, LANCET HAEMATOL, V3, pE293, DOI 10.1016/S2352-3026(16)30017-5; Trikalinos TA, 2004, J CLIN EPIDEMIOL, V57, P1124, DOI 10.1016/j.jclinepi.2004.02.018; Ugurlu B, 2002, J CARDIOVASC SURG, V43, P881; Vedantham S, 2017, NEW ENGL J MED, V377, P2240, DOI 10.1056/NEJMoa1615066; Watson L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002783.pub3; Wetterslev J, 2008, J CLIN EPIDEMIOL, V61, P64, DOI 10.1016/j.jclinepi.2007.03.013; Wetterslev J, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-86; Winter MP, 2017, J THROMB HAEMOST, V15, P1531, DOI 10.1111/jth.13741	21	2	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2018	13	9							e0204594	10.1371/journal.pone.0204594	http://dx.doi.org/10.1371/journal.pone.0204594			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GU9BO	30252917	gold, Green Published, Green Submitted			2023-01-03	WOS:000445639700064
J	Sanches, IC; Buzin, M; Conti, FF; Dias, DD; dos Santos, CP; Sirvente, R; Salemi, VMC; Llesuy, S; Irigoyen, MC; De Angelis, K				Sanches, Iris Callado; Buzin, Morgana; Conti, Filipe Fernandes; Dias, Danielle da Silva; dos Santos, Camila Paixao; Sirvente, Raquel; Cury Salemi, Vera Maria; Llesuy, Susana; Irigoyen, Maria-Claudia; De Angelis, Katia			Combined aerobic and resistance exercise training attenuates cardiac dysfunctions in a model of diabetes and menopause	PLOS ONE			English	Article							OXIDATIVE STRESS; CARDIOVASCULAR-DISEASE; ENDOTHELIAL DYSFUNCTION; BAROREFLEX SENSITIVITY; AUTONOMIC DYSFUNCTION; RISK; 17-BETA-ESTRADIOL; CARDIOMYOPATHY; HYPERGLYCEMIA; GLUTATHIONE	The study aimed at evaluating the effects of combined aerobic and resistance exercise training on cardiac morphometry and function, oxidative stress and inflammatory parameters in diabetic ovariectomized rats. For this, female Wistar rats (10 weeks-old) were divided into 4 groups (n = 8): euglycemic (E), diabetic (streptozotocin, 50 mg/kg, iv) (D), diabetic ovariectomized (DO) and trained diabetic ovariectomized (TDO). The combined exercise training was performed on a treadmill and in a ladder adapted to rats (8 weeks, at 40 +/- 60% of maximal capacity). The left ventricle (LV) morphometry and function were evaluated by echocardiography. Oxidative stress and inflammatory markers were measured on ventricles tissue. The sedentary diabetic animals (D and DO) showed impaired systolic and diastolic functions, as well as increased cardiac overload, evaluated by myocardial performance index (MPI-D: 0.32 +/- 0.05; DO: 0.39 +/- 0.13 vs. E: 0.25 +/- 0.07), in relation to E group. Systolic and MPI dysfunctions were exacerbated in DO when compared to D group. The DO group presented higher protein oxidation and TNF-alpha/IL-10 ratio than D groups. Glutathione redox ratio (GSH/GSSG) and IL-10 were decreased in both D and DO groups when compared to E group. Exercise training improved exercise capacity, systolic and diastolic functions and MPI (0.18 +/- 0.11). The TDO group showed reduced protein oxidation and TNF-alpha/IL-10 ratio and increased GSH/GSSG and IL-10 in relation to the DO group. These results showed that combined exercise training was able to attenuate the cardiac dysfunctions, probably by reducing inflammation and oxidative stress in an experimental model of diabetes and menopause.	[Sanches, Iris Callado] Sao Judas Tadeu Univ USJT, Human Movement Lab, Sao Paulo, Brazil; [Buzin, Morgana; Conti, Filipe Fernandes; Dias, Danielle da Silva; dos Santos, Camila Paixao; Llesuy, Susana; De Angelis, Katia] Univ Nove Julho UNINOVE, Lab Translat Physiol, Sao Paulo, Brazil; [Sirvente, Raquel; Cury Salemi, Vera Maria; Irigoyen, Maria-Claudia] Univ Sao Paulo, Heart Inst InCor, Sch Med, Hypertens Unit, Sao Paulo, Brazil; [Llesuy, Susana] Univ Buenos Aires, Fac Farm & Bioquim, Buenos Aires, DF, Argentina; [De Angelis, Katia] Fed Univ Sao Paulo UNIFESP, Dept Physiol, Sao Paulo, Brazil	Universidade Sao Judas Tadeu; Universidade Nove de Julho; Universidade de Sao Paulo; University of Buenos Aires; Universidade Federal de Sao Paulo (UNIFESP)	De Angelis, K (corresponding author), Univ Nove Julho UNINOVE, Lab Translat Physiol, Sao Paulo, Brazil.; De Angelis, K (corresponding author), Fed Univ Sao Paulo UNIFESP, Dept Physiol, Sao Paulo, Brazil.	prof.kangelis@yahoo.com.br	da Silva Dias, Danielle/AAN-7618-2020; Sanches, Iris Callado/D-5079-2013; Salemi, Vera/AAY-5024-2020; DE ANGELIS, KATIA/I-6098-2016	da Silva Dias, Danielle/0000-0003-4152-0849; Sanches, Iris Callado/0000-0001-6195-4340; DE ANGELIS, KATIA/0000-0002-3640-9049	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES-PROSUP, CAPES-PVE, CAPES DFAIT) [8881.062178/2014-01]; Sao Paulo Research Foundation (FAPESP) [2012/20141-5]; CNPq [563961/2010-4, 479766/2011-8]; CNPq-BPQ fellowships	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES-PROSUP, CAPES-PVE, CAPES DFAIT); Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CNPq-BPQ fellowships	This study was supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES-PROSUP, CAPES-PVE: 8881.062178/2014-01; CAPES DFAIT), Sao Paulo Research Foundation (FAPESP: 2012/20141-5); and CNPq (563961/2010-4, 479766/2011-8). K.D.A. and M.C.I. are the recipients of CNPq-BPQ fellowships.	Acar E, 2011, ANATOL J CARDIOL, V11, P732, DOI 10.5152/akd.2011.196; AEBI H, 1984, METHOD ENZYMOL, V105, P121; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Battiprolu Pavan K, 2010, Drug Discov Today Dis Mech, V7, pe135; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; CAGNACCI A, 1992, J CLIN ENDOCR METAB, V74, P1396, DOI 10.1210/jc.74.6.1396; Cai L, 2001, Cardiovasc Toxicol, V1, P181, DOI 10.1385/CT:1:3:181; Call JA, 2015, CIRC-HEART FAIL, V8, P188, DOI 10.1161/CIRCHEARTFAILURE.114.001540; DallAgo P, 1997, BRAZ J MED BIOL RES, V30, P119, DOI 10.1590/S0100-879X1997000100018; De Angelis K, 2002, BRAZ J MED BIOL RES, V35, P1091, DOI 10.1590/S0100-879X2002000900010; De Angelis K, 2009, AUTON NEUROSCI-BASIC, V145, P3, DOI 10.1016/j.autneu.2008.10.013; Dhingra R, 2007, AM J MED, V120, P1054, DOI 10.1016/j.amjmed.2007.08.037; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Flues K, 2010, MATURITAS, V65, P267, DOI 10.1016/j.maturitas.2009.11.007; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Goff DC, 2007, AM J CARDIOL, V99, p4I, DOI 10.1016/j.amjcard.2007.03.002; Guha M, 2000, J BIOL CHEM, V275, P17728, DOI 10.1074/jbc.275.23.17728; Hernandez I, 2000, AM J PHYSIOL-REG I, V279, pR1599, DOI 10.1152/ajpregu.2000.279.5.R1599; Hsueh WA, 2003, AM J CARDIOL, V92, p10J, DOI 10.1016/S0002-9149(03)00611-8; Irigoyen MC, 2005, HYPERTENSION, V46, P998, DOI 10.1161/01.HYP.0000176238.90688.6b; Jorge L, 2012, EXP DIABETES RES, DOI 10.1155/2012/108680; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; Kaseta JR, 1999, J CLIN ENDOCR METAB, V84, P1835, DOI 10.1210/jc.84.6.1835; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kim JS, 2014, BIOL SPORT, V31, P73, DOI 10.5604/20831862.1093775; Latour MG, 2001, J APPL PHYSIOL, V90, P235, DOI 10.1152/jappl.2001.90.1.235; Leuzzi C, 2012, G ITAL CARDIOL, V13, P401, DOI 10.1714/1073.11757; LITWIN SE, 1990, J CLIN INVEST, V86, P481, DOI 10.1172/JCI114734; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAEDA CY, 1995, HYPERTENSION, V26, P1100, DOI 10.1161/01.HYP.26.6.1100; MAEDA CY, 1995, BRAZ J MED BIOL RES, V28, P497; Maritim AC, 2003, J BIOCHEM MOL TOXIC, V17, P24, DOI 10.1002/jbt.10058; MATUTE ML, 1973, ENDOCRINOLOGY, V92, P762, DOI 10.1210/endo-92-3-762; Mosca L, 2007, J AM COLL CARDIOL, V49, P1230, DOI 10.1016/j.jacc.2007.02.020; Pinkney JH, 1997, DIABETES, V46, pS9, DOI 10.2337/diab.46.2.S9; Quinteiro H, 2015, MENOPAUSE, V22, P534, DOI [10.1097/GME.0000000000000344, 10.1097/gme.0000000000000344]; Renna NF, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/513251; REZNICK AZ, 1994, METHOD ENZYMOL, V233, P357; Rossi R, 2002, PATHOPHYSIOL HAEMO T, V32, P325, DOI 10.1159/000073591; Rouyer O, 2007, EXP PHYSIOL, V92, P1047, DOI 10.1113/expphysiol.2007.038851; RUBLER S, 1972, AM J CARDIOL, V30, P595, DOI 10.1016/0002-9149(72)90595-4; Samsioe G, 1998, MATURITAS, V30, P11, DOI 10.1016/S0378-5122(98)00054-1; Sanches IC, 2014, INT J SPORTS MED, V35, P323, DOI 10.1055/s-0033-1351254; Sans S, 1997, EUR HEART J, V18, P1231; SATO Y, 1979, BIOCHEM MED METAB B, V21, P104, DOI 10.1016/0006-2944(79)90061-9; Schaan BD, 2004, BRAZ J MED BIOL RES, V37, P1895, DOI 10.1590/S0100-879X2004001200016; Shiguemoto GE, 2012, SCAND J MED SCI SPOR, V22, P607, DOI 10.1111/j.1600-0838.2010.01284.x; Souza SBC, 2007, HYPERTENSION, V50, P786, DOI 10.1161/HYPERTENSIONAHA.107.095000; Sowers MR, 1995, EPIDEMIOL REV, V17, P287, DOI 10.1093/oxfordjournals.epirev.a036194; Strasser B, 2010, SPORTS MED, V40, P397, DOI 10.2165/11531380-000000000-00000; VANNINEN E, 1992, AM J CARDIOL, V70, P371, DOI 10.1016/0002-9149(92)90622-6; Wichi R, 2007, CARDIOVASC DIABETOL, V6, DOI 10.1186/1475-2840-6-14	53	6	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2018	13	9							e0202731	10.1371/journal.pone.0202731	http://dx.doi.org/10.1371/journal.pone.0202731			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT0BU	30192778	Green Submitted, Green Published, gold			2023-01-03	WOS:000444093600031
J	Moriyama, Y; Tamiya, N; Kawamura, A; Mayers, TD; Noguchi, H; Takahashi, H				Moriyama, Yoko; Tamiya, Nanako; Kawamura, Akira; Mayers, Thomas D.; Noguchi, Haruko; Takahashi, Hideto			Effect of short-stay service use on stay-at-home duration for elderly with certified care needs: Analysis of long-term care insurance claims data in Japan	PLOS ONE			English	Article							RESPITE CARE; CAREGIVERS; BURDEN; SYSTEM; HEALTH	Objective Home independence is an important issue for the elderly in many countries and cultures. The aim of this study was to examine the effect of short-stay service use on stay-at-home duration for elderly people by level of care need under the Japanese long-term care insurance system. Methods We analyzed anonymous, Ministry of Health, Labour and Welfare of Japan Long-Term Care Insurance claims data from Ibaraki Prefecture. All participants were certified as eligible for long-term care insurance and had moved into a facility under long-term care insurance after certification between April 2006 and March 2012. Data was analyzed for 2,454 participants aged 65 years or older who entered residential care at least 1 month after initial use of care services. The participants were divided into 2 groups (low- and high-care need), depending on their required level of care. Cox proportional hazard modeling was used to calculate the adjusted hazard ratio (HR) of residential care admission after initial use of care services. Results Use of short-stay services was positively correlated to delay of residential care admission compared to non-use in the low-care need group (HR; 0.834, 95% confidence interval (CI); 0.740 +/- 0.939). In the high-care need group, however, use of short-stay services was somewhat correlated with earlier admission (HR; 1.254, 95% CI; 1.084 +/- 1.451). Conclusions The results of this study show that appropriate timing short-stay service use is necessary for the elderly to stay at home longer.	[Moriyama, Yoko] Natl Inst Publ Hlth, Dept Hlth & Welf Serv, Saitama, Japan; [Moriyama, Yoko; Tamiya, Nanako; Mayers, Thomas D.] Univ Tsukuba, Dept Hlth Serv Res, Fac Med, Ibaraki, Japan; [Tamiya, Nanako] Univ Tsukuba, Hlth Serv Res & Dev Ctr, Ibaraki, Japan; [Kawamura, Akira; Noguchi, Haruko] Waseda Univ, Sch Polit Sci & Econ, Tokyo, Japan; [Mayers, Thomas D.] Univ Tsukuba, Med English Commun Ctr, Fac Med, Ibaraki, Japan; [Takahashi, Hideto] Natl Inst Publ Hlth, Saitama, Japan	National Institute of Public Health - Japan; University of Tsukuba; University of Tsukuba; Waseda University; University of Tsukuba; National Institute of Public Health - Japan	Moriyama, Y (corresponding author), Natl Inst Publ Hlth, Dept Hlth & Welf Serv, Saitama, Japan.; Moriyama, Y (corresponding author), Univ Tsukuba, Dept Hlth Serv Res, Fac Med, Ibaraki, Japan.	moriyama.y.aa@niph.go.jp	Kawamura, Akira/AAX-3214-2021; Noguchi, Haruko/ABF-3059-2020	Noguchi, Haruko/0000-0002-4437-8238	Japan Society for the Promotion of Science, JSPS KAKENHI [JP16K21643]; Japan Agency for Medical Research and Development, AMED [JP18dk0110026]; Ministry of Health, Labour and Welfare [H27-seisaku-senryaku-012]	Japan Society for the Promotion of Science, JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Agency for Medical Research and Development, AMED(Japan Agency for Medical Research and Development (AMED)); Ministry of Health, Labour and Welfare(Ministry of Health, Labour and Welfare, Japan)	This work was supported by 1. Japan Society for the Promotion of Science, JSPS KAKENHI Grant Number JP16K21643; 2. Japan Agency for Medical Research and Development, AMED under Grant Number JP18dk0110026; 3. Ministry of Health, Labour and Welfare (H27-seisaku-senryaku-012). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, DAI 5 KI TSUKUBA SHI; Arai Y, 2004, INT J GERIATR PSYCH, V19, P1205, DOI 10.1002/gps.1153; Cabinet Office in Japan, 2012, KOR KENK KANS CHOUS; Campbell JC, 2000, HEALTH AFFAIR, V19, P26, DOI 10.1377/hlthaff.19.3.26; Goto M., 2003, J HLTH WELF STAT, V50, P17; Ikegami N, 2003, INT J GERIATR PSYCH, V18, P217, DOI 10.1002/gps.818; Ishizuki T, 2010, J SOCIAL WELFARE, V51, P57; Kato Gohei, 2009, BMC Geriatr, V9, P58, DOI 10.1186/1471-2318-9-58; Kim Jung-Nim, 2012, J Rural Med, V7, P6, DOI 10.2185/jrm.7.6; Kono A., 2009, RONEN SHAKAI KAGAKU, V30, P498; Kuchimura A., 2013, KOUREISHA SHOTO STEI; Kuchimura A., 2007, RYUKOKU U J GRADUATE, V15, P35; Kuzuya M, 2011, AM J GERIAT PSYCHIAT, V19, P382, DOI 10.1097/JGP.0b013e3181e9b98d; Matsuda Tomoyuki, 2013, Nihon Koshu Eisei Zasshi, V60, P586; Ministry of Health Labour and Welfare, 2010, KOK SEIK KIS CHOUS G; Neville CC, 2007, INT J MENT HEALTH NU, V16, P81, DOI 10.1111/j.1447-0349.2007.00450.x; Neville CC, 2008, COLLEGIAN, V15, P159, DOI 10.1016/j.colegn.2008.06.003; Ohwa M, 2012, J GERONTOL SOC WORK, V55, P659, DOI 10.1080/01634372.2012.670869; Salminen M, 2017, AGING CLIN EXP RES, V29, P507, DOI 10.1007/s40520-016-0530-9; Schofield HL, 1999, AUST NZ J PUBL HEAL, V23, P585, DOI 10.1111/j.1467-842X.1999.tb01541.x; SCHULZ R, 1990, J GERONTOL, V45, pP181, DOI 10.1093/geronj/45.5.P181; Tamiya N, 2001, ARCH GERONTOL GERIAT, V33, P109, DOI 10.1016/S0167-4943(01)00100-5; Tamiya N, 2011, LANCET, V378, P1183, DOI 10.1016/S0140-6736(11)61176-8; Tatematsu M., 2014, J JAPAN SOC HOME EC, V65, P632; Tatematsu M, 2002, J HOME EC JAPAN, V53, P369; The project of Ministry of Health Labour and Welfare, 2011, INC NONPR ORG SUPP N; Tomita N, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-345; Tsutsui T, 2007, J AM GERIATR SOC, V55, P1458, DOI 10.1111/j.1532-5415.2007.01281.x; Umegaki H, 2014, ARCH GERONTOL GERIAT, V58, P130, DOI 10.1016/j.archger.2013.08.010; van Exel J, 2008, HEALTH POLICY, V88, P73, DOI 10.1016/j.healthpol.2008.03.001; van Exel J, 2006, HEALTH POLICY, V78, P194, DOI 10.1016/j.healthpol.2005.11.002; Vecchio N, 2015, ASS COGNITIVE IMPAIR, DOI [10.1111/HSC.12212, DOI 10.1111/HSC.12212]; Yokozeki M, 2006, JAPANESE J SOCIAL WE, V47, P59; ZARIT SH, 1986, GERONTOLOGIST, V26, P260, DOI 10.1093/geront/26.3.260	34	10	11	3	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2018	13	8							e0203112	10.1371/journal.pone.0203112	http://dx.doi.org/10.1371/journal.pone.0203112			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GR9JD	30157253	Green Published, gold, Green Submitted			2023-01-03	WOS:000443071400090
J	Voelker, R				Voelker, Rebecca			States Move to Substitute Opioids With Medical Marijuana to Quell Epidemic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	14	14	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 18	2018	320	23					2408	2410		10.1001/jama.2018.17329	http://dx.doi.org/10.1001/jama.2018.17329			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE7FX	30484825				2023-01-03	WOS:000453596700001
J	Simao, M; Wirtz, VJ; Al-Ansary, LA; Hill, S; Grove, J; Gray, AL; Nannei, C; Hedman, L; Das, P; Hogerzeil, H				Simao, Mariangela; Wirtz, Veronika J.; Al-Ansary, Lubna A.; Hill, Suzanne; Grove, John; Gray, Andrew L.; Nannei, Claudia; Hedman, Lisa; Das, Pamela; Hogerzeil, Hans			A global accountability mechanism for access to essential medicines	LANCET			English	Editorial Material									[Simao, Mariangela; Hill, Suzanne; Nannei, Claudia; Hedman, Lisa] WHO, Access Med Vaccines & Pharmaceut, Geneva, Switzerland; [Al-Ansary, Lubna A.; Grove, John] WHO, Hlth Metr & Measurement, Geneva, Switzerland; [Wirtz, Veronika J.] Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA 02118 USA; [Gray, Andrew L.] Univ KwaZulu Natal, Sch Hlth Sci, Durban, South Africa; [Das, Pamela] Lancet, London, England; [Hogerzeil, Hans] Univ Groningen, Dept Hlth Sci Global Hlth, Groningen, Netherlands	World Health Organization; World Health Organization; Boston University; University of Kwazulu Natal; University of Groningen	Wirtz, VJ (corresponding author), Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA 02118 USA.	vwirtz@bu.edu	Wirtz, Veornika/AAG-9712-2019; Gray, Andrew/F-2104-2013	Wirtz, Veronika J./0000-0002-0863-8768; Gray, Andrew/0000-0001-7815-8180; Al-Ansary, Lubna/0000-0001-7127-914X	World Health Organization [001] Funding Source: Medline	World Health Organization(World Health Organization)		AusAID, 2012, MILL DEV GOALS; Das J, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1716; Health Action International, 2018, MED PRIC AV AFF PRIC; Health Organization W, HDB HLTH IN MON SPEC; Horton R, 2013, LANCET, V382, P1082, DOI 10.1016/S0140-6736(13)61971-6; Hosseinpoor AR, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0229-9; Lu Y, 2011, WHOEMPMIE201126; MDG Gap Task Force, 2015, REP 2015 MILL DEV GO; Transparency International, 2013, TRANSP INT CALL UN M; UN Secretary-General, 2015, EV WOM EV CHILD; UNAIDS, 2018, MILES GO CLOSING GAP; Wirtz VJ, 2017, LANCET, V389, P403, DOI 10.1016/S0140-6736(16)31599-9; World Health Organization, 2018, WORLD HLTH STAT MON	13	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 8	2018	392	10163					2418	2420						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HD5RO	30527401				2023-01-03	WOS:000452587800006
J	Son, HY; Chae, BR; Choi, JY; Shin, DJ; Goo, YT; Lee, ES; Kang, TH; Kim, CH; Yoon, HY; Choi, YW				Son, Ho Yong; Chae, Bo Ram; Choi, Ji Yeh; Shin, Dong Jun; Goo, Yoon Tae; Lee, Eun Seok; Kang, Tae Hoon; Kim, Chang Hyun; Yoon, Ho Yub; Choi, Young Wook			Optimization of self-microemulsifying drug delivery system for phospholipid complex of telmisartan using D-optimal mixture design	PLOS ONE			English	Article							AMORPHOUS SOLID DISPERSIONS; BOX-BEHNKEN DESIGN; ORAL BIOAVAILABILITY; IN-VITRO; DISSOLUTION; PH; FORMULATION; RELEASE; SMEDDS; NANOPARTICLES	To improve the dissolution behavior of telmisartan (TMS), a poorly water-soluble angioten-sin II receptor blocker, TMS-phospholipid complex (TPC) was prepared by solvent evaporation method and characterized by differential scanning calorimetry and powder X-ray diffractometry. The crystalline structure of TMS was transited into an amorphous state by TPC formation. The equilibrium solubility of TPC (1.3-6.1 mg/mL) in various vehicles was about 100 times higher than that of TMS (0.009-0.058 mg/mL). TPC-loaded self-microemulsifying drug delivery system (SMEDDS) formulation was optimized using the D-optimal mixture design with the composition of 14% Capryol 90 (oil; X-1), 59.9% tween 80 (surfactant; X-2), and 26.1% tetraglycol (cosurfactant; X-3) as independent variables, which resulted in a droplet size of 22.17 nm (Y-1), TMS solubilization of 4.06 mg/mL (Y-2), and 99.4% drug release in 15 min (Y-3) as response factors. The desirability function value was 0.854, indicating the reliability and accuracy of optimization; in addition, good agreement was found between the model prediction and experimental values of Y-1, Y-2, and Y-3. Dissolution of raw TMS was poor and pH-dependent, where it had extremely low dissolution (< 1% for 2 h) in water, pH 4, and pH 6.8 media; however, it showed fast and high dissolution (< 90% in 5 min) in pH 1.2 medium. In contrast, the dissolution of the optimized TPC-loaded SMEDDS was pH-independent and reached over 90% within 5 min in all the media tested. Thus, we suggested that phospholipid complex formation and SMEDDS formulation using the experimental design method might be a promising approach to enhance the dissolution of poorly soluble drugs.	[Son, Ho Yong; Chae, Bo Ram; Shin, Dong Jun; Goo, Yoon Tae; Lee, Eun Seok; Kang, Tae Hoon; Kim, Chang Hyun; Yoon, Ho Yub; Choi, Young Wook] Chung Ang Univ, Coll Pharm, Seoul, South Korea; [Choi, Ji Yeh] Natl Univ Singapore, Dept Psychol, Singapore, Singapore	Chung Ang University; National University of Singapore	Choi, YW (corresponding author), Chung Ang Univ, Coll Pharm, Seoul, South Korea.	ywchoi@cau.ac.kr		Choi, Young Wook/0000-0003-2431-3995; Chae, Boram/0000-0002-3141-245X	Advanced Technology Center program - Ministry of Trade, Industry & Energy (MI, Korea) [10051950]; National Research Foundation of Korea (NRF) - Korea government (MSIP) [2016R1A2B4011449]	Advanced Technology Center program - Ministry of Trade, Industry & Energy (MI, Korea); National Research Foundation of Korea (NRF) - Korea government (MSIP)	This work was supported by the Advanced Technology Center program (10051950 to Y.W.C.) funded by the Ministry of Trade, Industry & Energy (MI, Korea). This research was also supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2016R1A2B4011449 to Y.W.C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad J, 2011, J DISPER SCI TECHNOL, V32, P958, DOI 10.1080/01932691.2010.488511; Bhumika P, 2012, J PHARM BIOALLIED SC, V4, pS64, DOI 10.4103/0975-7406.94142; Bruning T, 2000, CRIT REV TOXICOL, V30, P253, DOI 10.1080/10408440091159202; Chae JS, 2018, AAPS PHARMSCITECH, V19, P2990, DOI 10.1208/s12249-018-1124-y; Cho HJ, 2013, J PHARM PHARMACOL, V65, P1440, DOI 10.1111/jphp.12115; Cui F, 2006, J CONTROL RELEASE, V114, P242, DOI 10.1016/j.jconrel.2006.05.013; Dukeck R, 2013, EUR J PHARM SCI, V49, P723, DOI 10.1016/j.ejps.2013.05.003; Gu B, 2015, INT J PHARMACEUT, V495, P393, DOI 10.1016/j.ijpharm.2015.08.089; Holm R, 2006, DRUG DEV IND PHARM, V32, P1025, DOI 10.1080/03639040600559024; Jaiswal P, 2014, INT J PHARM INVESTIG, V4, P195, DOI 10.4103/2230-973X.143123; Kang BK, 2004, INT J PHARMACEUT, V274, P65, DOI 10.1016/j.ijpharm.2003.12.028; Khoo SM, 1998, INT J PHARM, V167, P155, DOI 10.1016/S0378-5173(98)00054-4; Konno H, 2008, EUR J PHARM BIOPHARM, V70, P493, DOI 10.1016/j.ejpb.2008.05.023; Kothawade SN., 2010, INT J PHARM TECH RES, V2, P341; Liu Y, 2009, INT J PHARMACEUT, V365, P136, DOI 10.1016/j.ijpharm.2008.08.009; Liu YH, 2010, J PHARM PHARM SCI, V13, P589, DOI 10.18433/J3530J; Maiti K, 2007, INT J PHARMACEUT, V330, P155, DOI 10.1016/j.ijpharm.2006.09.025; Marasini N, 2013, INT J PHARMACEUT, V441, P424, DOI 10.1016/j.ijpharm.2012.11.012; Marasini N, 2012, J PHARM SCI-US, V101, P4584, DOI 10.1002/jps.23333; Mura P, 2005, J PHARMACEUT BIOMED, V37, P65, DOI 10.1016/j.jpba.2004.09.047; O'Neil M.J., 2013, MERCK INDEX ENCY CHE, P1691; Oh DH, 2011, INT J PHARMACEUT, V420, P412, DOI 10.1016/j.ijpharm.2011.09.007; Padia N, 2015, B PHARM RES, V5, P59; Ruan JH, 2010, INT J PHARMACEUT, V386, P282, DOI 10.1016/j.ijpharm.2009.11.026; Tran T, 2018, ASIAN J PHARM SCI, V13, P536, DOI 10.1016/j.ajps.2017.09.006; Tran PHL, 2008, J CONTROL RELEASE, V129, P59, DOI 10.1016/j.jconrel.2008.04.001; Vasconcelos T, 2007, DRUG DISCOV TODAY, V12, P1068, DOI 10.1016/j.drudis.2007.09.005; VENEMA FR, 1988, J COLLOID INTERF SCI, V125, P484, DOI 10.1016/0021-9797(88)90013-6; Wienen W, 2000, CARDIOVASC DRUG REV, V18, P127; Xiao YY, 2006, INT J PHARMACEUT, V307, P77, DOI 10.1016/j.ijpharm.2005.10.001; Yamashita Shinji, 2017, Journal of Pharmaceutical Investigation, V47, P163, DOI 10.1007/s40005-017-0310-3; Yang L, 2014, INT J PHARMACEUT, V471, P258, DOI 10.1016/j.ijpharm.2014.05.009; Yeom DW, 2017, INT J NANOMED, V12, P3533, DOI 10.2147/IJN.S136599; Yeom DW, 2015, INT J NANOMED, V10, P3865, DOI 10.2147/IJN.S83520; Yusuf S, 2008, NEW ENGL J MED, V359, P1225, DOI 10.1056/NEJMoa0804593; Zhang JJ, 2011, INT J NANOMED, V6, P3405, DOI 10.2147/IJN.S25824; Zhang YZ, 2010, J CONTROL RELEASE, V145, P257, DOI 10.1016/j.jconrel.2010.04.029	37	10	10	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2018	13	12							e0208339	10.1371/journal.pone.0208339	http://dx.doi.org/10.1371/journal.pone.0208339			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD0QO	30517187	Green Published, Green Submitted, gold			2023-01-03	WOS:000452212400089
J	Tabiri, S; Russell, KW; Gyamfi, FE; Jalali, A; Price, RR; Katz, MG				Tabiri, Stephen; Russell, Katie W.; Gyamfi, Frank E.; Jalali, Ali; Price, Raymond R.; Katz, Micah G.			Local anesthesia underutilized for inguinal hernia repair in northern Ghana	PLOS ONE			English	Article							GENERAL-ANESTHESIA; COST-EFFECTIVENESS; MORTALITY; SURGERY; BLOCK	Introduction Inguinal hernia repair is a common procedure and a priority for public health efforts in Ghana. It is essential that inguinal hernia repair be performed in a safe, efficient manner to justify its widespread use. Local anesthesia has many favorable properties and has been shown to be superior, compared to regional or general anesthesia, in terms of pain control, safety profile, cost-effectiveness, resources required, and time to discharge. Local anesthesia is recommended for open repair of reducible hernias, provided clinician experience, by multiple international guidelines. Regional anesthesia is associated with myocardial infarction and other complications, and its use is discouraged by multiple guidelines, especially in older patients. This study aims to assess the current state of anesthesia for inguinal hernia repair in the northern and transitional zone of Ghana. In addition we will assess the perceptions of different types of anesthesia along with understanding of evidence-based guidelines among clinicians participating in inguinal hernia repair. Methods We performed a retrospective review of all inguinal hernia repairs for male patients, 18 and older, in over 90% of hospitals in northern Ghana. All 41 hospitals were visited and caselogs and patient charts were manually reviewed to extract data. Multivariate logistic regression was used to determine predictors of local anesthesia use. We designed a survey instrument to assess the perceptions of physicians and anesthetists regarding different types of anesthesia for inguinal hernia repair. The survey was designed by a Ghanaian surgeon, reviewed by all co-authors, and tested prior to implementation using a sample (n = 8) of clinicians having similar practices to those of the survey population. Of 70 clinicians, 66 responded, yielding a response rate of 94%. Results 8080 patients underwent hernia repair of which 37% were performed under local anesthesia, while the majority, 60%, were performed under regional anesthesia. Negative predictors of local anesthesia were emergent repair (OR = 0.258, p < 0.001), surgery performed at a teaching hospital (OR = 0.105, p < 0.001), and bilateral hernia repair (OR = 0.374, p < 0.001). 1,839 (22.8%) of IH repairs were done on patients age 65 or older and RA was most frequently used among the elderly population (57.8%), while local anesthesia was used 39.5% of the time. Sixty-six clinicians participated in the survey with the majority reporting that local anesthesia requires fewer staff, less equipment, has a shorter recovery, is more cost-effective, and might be safer for patients. However 66% were unfamiliar with or incorrectly perceived international guidelines. Conclusion To our knowledge, this study is the largest assessment of anesthesia use for inguinal hernia repair in an LMIC. Although the selection of anesthetic technique should be guided by a patient's general health, the anatomy of the hernia, and clinician judgment, local anesthesia appears to be underutilized in northern Ghana. Survey responses demonstrate high rates of unfamiliarity or incorrectly perceived evidence-based guidelines. Future research should assess how education on the benefits and technique of local anesthesia administration may further increase rates for inguinal hernia repair, especially for older patients.	[Tabiri, Stephen] Univ Dev Studies, Sch Med & Hlth Sci, Tamale, Northern Region, Ghana; [Tabiri, Stephen] Univ Dev Studies, Tamale Teaching Hosp, Tamale, Northern Region, Ghana; [Russell, Katie W.; Price, Raymond R.; Katz, Micah G.] Univ Utah, Dept Surg, Ctr Global Surg, Salt Lake City, UT 84112 USA; [Gyamfi, Frank E.] Holy Family Hosp, Berekum, Brong Ahafo Reg, Ghana; [Jalali, Ali] Univ Utah, Hlth Econ Core, Populat Hlth Res Fdn, Dept Econ, Salt Lake City, UT USA	University for Development Studies; University for Development Studies; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Tabiri, S (corresponding author), Univ Dev Studies, Sch Med & Hlth Sci, Tamale, Northern Region, Ghana.; Tabiri, S (corresponding author), Univ Dev Studies, Tamale Teaching Hosp, Tamale, Northern Region, Ghana.; Katz, MG (corresponding author), Univ Utah, Dept Surg, Ctr Global Surg, Salt Lake City, UT 84112 USA.	stabiri@uds.edu.gh; micah.katz@hsc.utah.edu	Price, Raymond/AAJ-4203-2020; Katz, Micah/L-3841-2019	Price, Raymond/0000-0002-9496-0488; Katz, Micah/0000-0001-8315-0909; Gyamfi, Frank Enoch/0000-0002-8893-5956				Aasbo V, 2002, ACTA ANAESTH SCAND, V46, P647; Abantanga FA, 2012, PMJG, V1, P3; AMID PK, 1994, ANN SURG, V220, P735, DOI 10.1097/00000658-199412000-00004; Amid PK, 1996, EUR J SURG, V162, P447; [Anonymous], SURG CAR SYST STRENG; [Anonymous], 2003, SURG CAR DISTR HOSP; Bay-Nielsen M, 2008, ACTA ANAESTH SCAND, V52, P169, DOI 10.1111/j.1399-6576.2007.01514.x; Bhattacharya P, 2010, ACTA ANAESTH SCAND, V54, P246, DOI 10.1111/j.1399-6576.2009.02128.x; Bourgouin S, 2017, HERNIA, V21, P749, DOI 10.1007/s10029-017-1631-x; British Hernia Society, 2013, GROIN HERN GUID; Callesen T, 2001, ANESTH ANALG, V93, P1373, DOI 10.1097/00000539-200112000-00004; Compagna R, 2012, BMC SURG, V12, DOI 10.1186/1471-2482-12-S1-S12; Dabic Dejan, 2012, Acta Chir Iugosl, V59, P87; Ribeiro Flavio Antonio de Sá, 2010, Rev. Col. Bras. Cir., V37, P397; FINLEY RK, 1991, AM SURGEON, V57, P486; GLASSOW F, 1976, ANN ROY COLL SURG, V58, P133; Gonullu N N, 2002, Hernia, V6, P29; Hansen D, 2000, TROP DOCT, V30, P146, DOI 10.1177/004947550003000311; HEYWOOD AJ, 1989, ANN ROY COLL SURG, V71, P354; Joshi GP, 2012, BRIT J SURG, V99, P168, DOI 10.1002/bjs.7660; Kark AE, 1998, J AM COLL SURGEONS, V186, P447, DOI 10.1016/S1072-7515(98)00057-X; Kehlet H, 2005, ACTA ANAESTH SCAND, V49, P143, DOI 10.1111/j.1399-6576.2004.00600.x; Kendell J, 2000, ANAESTHESIA, V55, P1106, DOI 10.1046/j.1365-2044.2000.01547.x; Kingsnorth A N, 2004, Hernia, V8, P283; Kingsnorth AN, 2003, ANN ROY COLL SURG, V85, P18, DOI 10.1308/003588403321001363; Kulacoglu H, 2011, J KOREAN SURG SOC, V81, P408, DOI 10.4174/jkss.2011.81.6.408; Maman AFOB, 2005, TROP DOCT, V35, P220, DOI 10.1258/004947505774938666; Mark AE, 1998, J AM COLL SURGEONS, V198, P447; McKenzie AG, 1996, S AFR MED J, V86, P338; McQueen K., 2015, Disease control priorities, third edition: Volume 1. Essential surgery, P263; MERHAV H, 1993, INT SURG, V78, P257; Milone M, 2013, HERNIA, V17, P749, DOI 10.1007/s10029-012-1022-2; Mock C, 2010, WORLD J SURG, V34, P381, DOI 10.1007/s00268-009-0263-4; Nilsson H, 2007, ANN SURG, V245, P656, DOI 10.1097/01.sla.0000251364.32698.4b; Nordin P, 2007, BRIT J SURG, V94, P500, DOI 10.1002/bjs.5543; Nordin P, 2004, Hernia, V8, P220; Nordin P, 2003, LANCET, V362, P853, DOI 10.1016/S0140-6736(03)14339-5; Ozgun H, 2002, EUR J SURG, V168, P455, DOI 10.1080/110241502321116442; Rosenberg J, 2011, DANISH MED B, V58, P4243; Sanjay P, 2013, HERNIA, V17, P745, DOI 10.1007/s10029-012-1011-5; Shillcutt SD, 2010, ARCH SURG-CHICAGO, V145, P954, DOI 10.1001/archsurg.2010.208; Simons MP, 2018, HERNIA, V22, P1, DOI 10.1007/s10029-017-1668-x; Simons MP, 2009, HERNIA, V13, P343, DOI 10.1007/s10029-009-0529-7; Song DJ, 2000, ANESTH ANALG, V91, P876, DOI 10.1097/00000539-200010000-00020; Sultana A, 1999, J Indian Med Assoc, V97, P169; Tansley G, 2017, WORLD J SURG, V41, P639, DOI 10.1007/s00268-016-3765-x; Wilhelm TJ, 2006, TROP DOCT, V36, P147, DOI 10.1258/004947506777978046; Yenli Edwin M T, 2017, Ghana Med J, V51, P78	48	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2018	13	11							e0206465	10.1371/journal.pone.0206465	http://dx.doi.org/10.1371/journal.pone.0206465			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB4VL	30462684	Green Submitted, Green Published, gold			2023-01-03	WOS:000451054800018
J	Das, P; Nof, E; Amirav, I; Kassinos, SC; Sznitman, J				Das, Prashant; Nof, Eliram; Amirav, Israel; Kassinos, Stavros C.; Sznitman, Josue			Targeting inhaled aerosol delivery to upper airways in children: Insight from computational fluid dynamics (CFD)	PLOS ONE			English	Article							PARTICLE DEPOSITION; INHALATION-THERAPY; AIR-FLOW; RESPIRATORY-TRACT; INSPIRATORY FLOW; LARYNGEAL JET; HUMAN LUNG; ASTHMA; MODELS; TRANSPORT	Despite the prevalence of inhalation therapy in the treatment of pediatric respiratory disorders, most prominently asthma, the fraction of inhaled drugs reaching the lungs for maximal efficacy remains adversely low. By and large drug delivery devices and their inhalation guidelines are typically derived from adult studies with child dosages adapted according to body weight. While it has long been recognized that physiological (e.g. airway sizes, breathing maneuvers) and physical transport (e.g. aerosol dynamics) characteristics are critical in governing deposition outcomes, such knowledge has yet to be extensively adapted to younger populations. Motivated by such shortcomings, the present work leverages in a first step in silico computational fluid dynamics (CFD) to explore opportunities for augmenting aerosol deposition in children based on respiratory physiological and physical transport determinants. Using an idealized, anatomically-faithful upper airway geometry, airflow and aerosol motion are simulated as a function of age, spanning a five year old to an adult. Breathing conditions mimic realistic age-specific inhalation maneuvers representative of Dry Powder Inhalers (DPI) and nebulizer inhalation. Our findings point to the existence of a single dimensionless curve governing deposition in the conductive airways via the dimensionless Stokes number (Stk). Most significantly, we uncover the existence of a distinct deposition peak irrespective of age. For the DPI simulations, this peak (similar to 80%) occurs at Stk 0.06 whereas for nebulizer simulations, the corresponding peak (similar to 45%) occurs in the range of Stk between 0.03-0.04. Such dimensionless findings hence translate to an optimal window of micron-sized aerosols that evolves with age and varies with inhalation device. The existence of such deposition optima advocates revisiting design guidelines for optimizing deposition outcomes in pediatric inhalation therapy.	[Das, Prashant; Nof, Eliram; Sznitman, Josue] Technion Israel Inst Technol, Dept Biomed Engn, Haifa, Israel; [Amirav, Israel] Univ Alberta, Fac Med & Dent, Dept Pediat, Edmonton, AB, Canada; [Kassinos, Stavros C.] Univ Cyprus, Dept Mech & Mfg Engn, Computat Sci Lab UCY CompSci, Kallipoleos Ave 75, CY-1678 Nicosia, Cyprus	Technion Israel Institute of Technology; University of Alberta; University of Cyprus	Sznitman, J (corresponding author), Technion Israel Inst Technol, Dept Biomed Engn, Haifa, Israel.	sznitman@bm.technion.ac.il	Amirav, Israel/I-9286-2019; Kassinos, Stavros C./B-6404-2016	Amirav, Israel/0000-0002-6917-5285; Kassinos, Stavros C./0000-0002-3501-3851; Sznitman, Josue/0000-0001-8217-3842; Das, Prashant/0000-0002-7071-1161; Nof, Eliram/0000-0001-6452-1401	European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program [677772]; European Cooperation in Science and Technology (COST) [MP1404]	European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program(European Research Council (ERC)); European Cooperation in Science and Technology (COST)(European Cooperation in Science and Technology (COST))	This work was supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement No. 677772). The authors acknowledge COST Action MP1404 SimInhale 'Simulation and pharmaceutical technologies for advanced patient-tailored inhaled medicines', supported by the European Cooperation in Science and Technology (COST).	Akinbami LJ, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2354; Albuquerque-Silva I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095456; Amirav I, 2005, PEDIATR PULM, V39, P447, DOI 10.1002/ppul.20180; Amirav I., 2004, ITAL J PEDIATR, V30, P147; Amirav I, 2012, PAEDIATR RESPIR REV, V13, P73, DOI 10.1016/j.prrv.2011.05.006; Amirav Israel, 2008, Expert Rev Respir Med, V2, P597, DOI 10.1586/17476348.2.5.597; Ari A, 2013, EXPERT REV RESP MED, V7, P665, DOI 10.1586/17476348.2013.847369; Asgharian B, 2006, INHAL TOXICOL, V18, P795, DOI 10.1080/08958370600748687; Asgharian B, 2004, J AEROSOL MED, V17, P213, DOI 10.1089/0894268042176337; Asher I, 2014, INT J TUBERC LUNG D, V18, P1269, DOI 10.5588/ijtld.14.0170; Batchelor HK, 2015, BRIT J CLIN PHARMACO, V79, P405, DOI 10.1111/bcp.12268; Bauer K, 2015, J BIOMECH ENG-T ASME, V137, DOI 10.1115/1.4030621; Bender BG, 2015, JAMA PEDIATR, V169, P317, DOI 10.1001/jamapediatrics.2014.3280; Bickmann D, 2016, J AEROSOL MED PULM D, V29, P76, DOI 10.1089/jamp.2014.1166; Borojeni AAT, 2015, J AEROSOL SCI, V85, P10, DOI 10.1016/j.jaerosci.2015.03.002; Brand P L, 2000, Minerva Pediatr, V52, P137; Brand PLP, 2005, CURR MED RES OPIN, V21, pS27, DOI 10.1185/030079905X61767; Byron P.R., 2014, RESP DRUG DELIV, P295; Byron PR, 2010, J AEROSOL MED PULM D, V23, pS59, DOI 10.1089/jamp.2010.0846; Cheng YS, 2003, AEROSOL SCI TECH, V37, P659, DOI 10.1080/02786820300906; Cheng YS, 1999, AEROSOL SCI TECH, V31, P286, DOI 10.1080/027868299304165; Dalby R, 2003, ADV DRUG DELIVER REV, V55, P779, DOI 10.1016/S0169-409X(03)00077-2; De Benedictis Fernando Maria, 2003, Paediatr Drugs, V5, P629, DOI 10.2165/00148581-200305090-00005; DeHaan WH, 2001, J AEROSOL MED, V14, P361, DOI 10.1089/089426801316970321; Delvadia RR, 2012, J AEROSOL MED PULM D, V25, P32, DOI 10.1089/jamp.2011.0905; Deng QH, 2018, SCI TOTAL ENVIRON, V612, P339, DOI 10.1016/j.scitotenv.2017.08.240; Devadason SG, 2006, J AEROSOL MED, V19, P61, DOI 10.1089/jam.2006.19.61; DiBlasi RM, 2015, RESP CARE, V60, P894, DOI 10.4187/respcare.04137; Dolovich M, 1999, PEDIATR PULM, P79; DUNNILL M. S., 1962, THORAX, V17, P329, DOI 10.1136/thx.17.4.329; Fink JB, 2012, CLIN THER, V34, pS36, DOI 10.1016/j.clinthera.2012.10.004; Finlay W.H, 2001, MECH INHALED PHARM A; Fleming S, 2011, LANCET, V377, P1011, DOI 10.1016/S0140-6736(10)62226-X; Forno E, 2017, AM J RESP CRIT CARE, V195, P314, DOI 10.1164/rccm.201605-1039OC; Golshahi L, 2012, AEROSOL SCI TECH, V46, pI, DOI 10.1080/02786826.2012.667170; GRISCOM NT, 1986, AM J ROENTGENOL, V146, P233, DOI 10.2214/ajr.146.2.233; HEYDER J, 1986, J AEROSOL SCI, V17, P811, DOI 10.1016/0021-8502(86)90035-2; Heyder Joachim, 2004, Proc Am Thorac Soc, V1, P315, DOI 10.1513/pats.200409-046TA; Hinds W.C, 1999, AEROSOL TECHNOLOGY P; Hofemeier P, 2015, J APPL PHYSIOL, V118, P1375, DOI 10.1152/japplphysiol.01117.2014; HOFMANN W, 1982, RESP PHYSIOL, V49, P115, DOI 10.1016/0034-5687(82)90106-2; Hofmann W., 1989, J AEROSOL MED, V2, P49, DOI DOI 10.1089/JAM.1989.2.49; HORSFIEL.K, 1971, J APPL PHYSIOL, V31, P207, DOI 10.1152/jappl.1971.31.2.207; Hossny E, 2016, WORLD ALLERGY ORGAN, V9, DOI 10.1186/s40413-016-0117-0; Inthavong K, 2019, CLIN BIOMECH, V66, P97, DOI 10.1016/j.clinbiomech.2017.10.006; Katan JT, 2016, J AEROSOL MED PULM D, V29, P288, DOI 10.1089/jamp.2015.1271; Kleinstreuer C, 2008, ANNU REV BIOMED ENG, V10, P195, DOI 10.1146/annurev.bioeng.10.061807.160544; Kleinstreuer C, 2010, ANNU REV FLUID MECH, V42, P301, DOI 10.1146/annurev-fluid-121108-145453; Koullapis P, 2018, EUR J PHARM SCI, V113, P77, DOI 10.1016/j.ejps.2017.09.003; Koullapis PG, 2018, J AEROSOL SCI, V117, P164, DOI 10.1016/j.jaerosci.2017.12.001; Koullapis PG, 2016, J BIOMECH, V49, P2201, DOI 10.1016/j.jbiomech.2015.11.029; Kwok PCL, 2014, ADV DRUG DELIVER REV, V73, P83, DOI 10.1016/j.addr.2013.11.007; Lambert AR, 2011, AEROSOL SCI TECH, V45, P11, DOI 10.1080/02786826.2010.517578; Laube BL, 2011, EUR RESPIR J, V37, P1308, DOI 10.1183/09031936.00166410; Lexmond AJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099304; Lin CL, 2007, RESP PHYSIOL NEUROBI, V157, P295, DOI 10.1016/j.resp.2007.02.006; Longest PW, 2007, MED ENG PHYS, V29, P350, DOI 10.1016/j.medengphy.2006.05.012; Longest PW, 2006, J AEROSOL SCI, V37, P1234, DOI 10.1016/j.jaerosci.2006.01.011; Longest PW, 2012, PHARM RES-DORDR, V29, P1670, DOI 10.1007/s11095-012-0691-y; Longest PW, 2012, ADV DRUG DELIVER REV, V64, P296, DOI 10.1016/j.addr.2011.05.009; Lugogo NL, 2008, CLIN ASTHMA; Lundback B, 2016, EXPERT REV RESP MED, V10, P39, DOI 10.1586/17476348.2016.1114417; Luo HY, 2009, J BIOMECH, V42, P1869, DOI 10.1016/j.jbiomech.2009.05.004; Makela MJ, 2013, RESP MED, V107, P1481, DOI 10.1016/j.rmed.2013.04.005; MARTONEN TB, 1993, AEROSOL SCI TECH, V19, P133, DOI 10.1080/02786829308959627; Milenkovic J, 2014, INT J PHARMACEUT, V461, P129, DOI 10.1016/j.ijpharm.2013.11.047; Oakes JM, 2018, ANN BIOMED ENG, V46, P498, DOI 10.1007/s10439-017-1971-9; Oldham MJ, 2000, AEROSOL SCI TECH, V32, P61, DOI 10.1080/027868200303939; Ostrovski Y, 2019, FLOW TURBUL COMBUST, V102, P73, DOI 10.1007/s10494-018-9927-1; Schueepp KG, 2009, RESP MED, V103, P1738, DOI 10.1016/j.rmed.2009.04.029; Schuepp KG, 2004, J AEROSOL MED, V17, P153, DOI 10.1089/0894268041457228; Soni B, 2013, COMPUT FLUIDS, V88, P804, DOI 10.1016/j.compfluid.2013.06.015; Stahlhofen W., 1989, J AEROSOL MED, V2, P285, DOI [DOI 10.1089/JAM.1989.2.285, 10.1089/jam.1989.2.285]; Stylianou FS, 2016, INT J HEAT FLUID FL, V61, P677, DOI 10.1016/j.ijheatfluidflow.2016.07.013; Suissa S, 2001, J ALLERGY CLIN IMMUN, V107, P937, DOI 10.1067/mai.2001.115653; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; SWIFT DL, 1991, RADIAT PROT DOSIM, V38, P29; Sznitman J, 2013, J BIOMECH, V46, P284, DOI 10.1016/j.jbiomech.2012.10.028; Teague WG, 2014, J ASTHMA, V51, P677, DOI 10.3109/02770903.2014.914535; Tu J, 2013, BIOL MED PHYS BIOMED; Walenga RL, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4024630; Weers J, 2017, PHARM RES-DORDR, V34, P507, DOI 10.1007/s11095-016-2050-x; Weibel E. R., 1963, MORPHOMETRY HUMAN LU; Wildhaber JH, 1999, J PEDIATR-US, V135, P28, DOI 10.1016/S0022-3476(99)70323-9; Wildhaber JH, 2002, J PAEDIATR CHILD H, V38, P115, DOI 10.1046/j.1440-1754.2002.00794.x; Xi JX, 2008, J APPL PHYSIOL, V104, P1761, DOI 10.1152/japplphysiol.01233.2007; Xi JX, 2007, ANN BIOMED ENG, V35, P560, DOI 10.1007/s10439-006-9245-y; XU GB, 1986, AEROSOL SCI TECH, V5, P349, DOI 10.1080/02786828608959099; Yin YB, 2010, J BIOMECH, V43, P2159, DOI 10.1016/j.jbiomech.2010.03.048; Zhang Z, 2009, J AEROSOL SCI, V40, P16, DOI 10.1016/j.jaerosci.2008.08.003	90	28	29	2	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2018	13	11							e0207711	10.1371/journal.pone.0207711	http://dx.doi.org/10.1371/journal.pone.0207711			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB1IJ	30458054	Green Submitted, Green Published, gold			2023-01-03	WOS:000450775300038
J	Szabo, ER; Brand, M; Hans, S; Hideghety, K; Karsch, L; Lessmann, E; Pawelke, J; Schurer, M; Beyreuther, E				Szabo, Emilia Rita; Brand, Michael; Hans, Stefan; Hideghety, Katalin; Karsch, Leonhard; Lessmann, Elisabeth; Pawelke, Joerg; Schuerer, Michael; Beyreuther, Elke			Radiobiological effects and proton RBE determined by wildtype zebrafish embryos	PLOS ONE			English	Article							RELATIVE BIOLOGICAL EFFECTIVENESS; RADIATION; BEAM; VERIFICATION; IRRADIATION; DAMAGE; MODEL	The increasing use of proton radiotherapy during the last decade and the rising number of long-term survivors has given rise to a vital discussion on potential effects on normal tissue. So far, deviations from clinically applied generic RBE (relative biological effectiveness) of 1.1 were only obtained by in vitro studies, whereas indications from in vivo trials and clinical studies are rare. In the present work, wildtype zebrafish embryos (Danio rerio) were used to characterize the effects of plateau and mid-SOBP (spread-out Bragg peak) proton radiation relative to that induced by clinical MV photon beam reference. Based on embryonic survival data, RBE values of 1.13 +/- 0.08 and of 1.20 +/- 0.04 were determined four days after irradiations with 20 Gy plateau and SOBP protons relative to 6 MV photon beams. These RBE values were confirmed by relating the rates of embryos with morphological abnormalities for the respective radiation qualities and doses. Besides survival, the rate of spine bending, as one type of developmental abnormality, and of pericardial edema, as an example for acute radiation effects, were assessed. The results revealed that independent on radiation quality both rates increased with time approaching almost 100% at the 4th day post irradiation with doses higher than 15 Gy. To sum up, the applicability of the zebrafish embryo as a robust and simple alternative model for in vivo characterization of radiobiological effects in normal tissue was validated and the obtained RBE values are comparable to previous finding in animal trials.	[Szabo, Emilia Rita; Hideghety, Katalin] ELI HU Nonprofit Ltd, Attosecond Light Pulse Source, Szeged, Hungary; [Brand, Michael; Hans, Stefan] Tech Univ Dresden, CMCB, DFG Ctr Regenerat Therapies Dresden CRTD, Dresden, Germany; [Karsch, Leonhard; Pawelke, Joerg; Beyreuther, Elke] Helmholtz Zentrum Dresden Rossendorf, Dresden, Germany; [Karsch, Leonhard; Lessmann, Elisabeth; Pawelke, Joerg; Schuerer, Michael; Beyreuther, Elke] Tech Univ Dresden, Helmholtz Zentrum Dresden Rossendorf, Fac Med, OncoRay Natl Ctr Radiat Res Oncol, Dresden, Germany; [Karsch, Leonhard; Lessmann, Elisabeth; Pawelke, Joerg; Schuerer, Michael; Beyreuther, Elke] Tech Univ Dresden, Helmholtz Zentrum Dresden Rossendorf, Univ Hosp Carl Gustav Carus, Dresden, Germany; [Schuerer, Michael] Partner Site Dresden, Natl Ctr Tumor Dis NCT, Dresden, Germany	ELI-HU Research & Development Non-Profit; Technische Universitat Dresden; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Technische Universitat Dresden; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Technische Universitat Dresden; Carl Gustav Carus University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Beyreuther, E (corresponding author), Helmholtz Zentrum Dresden Rossendorf, Dresden, Germany.; Beyreuther, E (corresponding author), Tech Univ Dresden, Helmholtz Zentrum Dresden Rossendorf, Fac Med, OncoRay Natl Ctr Radiat Res Oncol, Dresden, Germany.; Beyreuther, E (corresponding author), Tech Univ Dresden, Helmholtz Zentrum Dresden Rossendorf, Univ Hosp Carl Gustav Carus, Dresden, Germany.	E.Boyreuther@hzdr.de	Brand, Michael/A-5509-2010	Brand, Michael/0000-0001-5711-6512; Beyreuther, Elke/0000-0002-0582-1444	European Union [654148, GINOP-2.3.6-15-2015-00001]; European Regional Development Fund; European Union (ERC Advanced Grant Zf-BrainReg)	European Union(European Commission); European Regional Development Fund(European Commission); European Union (ERC Advanced Grant Zf-BrainReg)	The ELI-ALPS project (GINOP-2.3.6-15-2015-00001) is supported by the European Union and co-financed by the European Regional Development Fund. Moreover, the project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no 654148 Laserlab-Europe. Michael Brand and Stefan Hans are supported by the European Union (ERC Advanced Grant Zf-BrainReg).	Barriuso J, 2015, CLIN CANCER RES, V21, P969, DOI 10.1158/1078-0432.CCR-14-2921; Berger M. J., 2005, ESTAR PSTAR ASTAR CO; Beyreuther E, 2018, INT J PART THER, V5, P172, DOI 10.14338/IJPT-18-00008.1; Brand M, 2002, KEEPING RAISING ZEBR, P7; Brannen KC, 2010, BIRTH DEFECTS RES B, V89, P66, DOI 10.1002/bdrb.20223; Chaudhary P, 2014, INT J RADIAT ONCOL, V90, P27, DOI 10.1016/j.ijrobp.2014.05.010; Freeman JL, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00268; Gould, 1977, ONTOGENY PHYLOGENY; Gueulette J, 1997, RADIOTHER ONCOL, V42, P303, DOI 10.1016/S0167-8140(97)01919-1; Helmbrecht S, 2016, J INSTRUM, V11, DOI 10.1088/1748-0221/11/11/T11001; Hu M, 2016, RADIAT ENVIRON BIOPH, V55, P441, DOI 10.1007/s00411-016-0663-4; ICRU, 2007, J ICRU, V7; Ilicic K, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-018-0954-9; Jang GH, 2008, ARCH PHARM RES, V31, P779, DOI 10.1007/s12272-001-1226-1; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kumar MKP, 2017, ECOTOX ENVIRON SAFE, V142, P95, DOI 10.1016/j.ecoenv.2017.03.054; Li XM, 2018, CHEMOSPHERE, V200, P302, DOI 10.1016/j.chemosphere.2018.02.141; Luhr A, 2018, RADIOTHER ONCOL, V128, P56, DOI 10.1016/j.radonc.2018.05.018; McAleer MF, 2005, INT J RADIAT ONCOL, V61, P10, DOI 10.1016/j.ijrobp.2004.09.046; Muller J, 2017, ACTA ONCOL, V56, P1399, DOI 10.1080/0284186X.2017.1352102; Paganetti H, 2014, PHYS MED BIOL, V59, pR419, DOI 10.1088/0031-9155/59/22/R419; Peeler CR, 2016, RADIOTHER ONCOL, V121, P395, DOI 10.1016/j.radonc.2016.11.001; Pei DS, 2013, MUTAT RES-FUND MOL M, V743, P151, DOI 10.1016/j.mrfmmm.2012.10.003; Richter C, 2016, RADIOTHER ONCOL, V118, P232, DOI 10.1016/j.radonc.2016.01.004; Saager M, 2017, RADIOTHER ONCOL, V123, pS273, DOI 10.1016/S0167-8140(17)30957-X; Saager M, 2018, RADIOTHER ONCOL, V128, P115, DOI 10.1016/j.radonc.2018.03.002; Sayed AEH, 2016, J PHOTOCH PHOTOBIO B, V164, P132, DOI 10.1016/j.jphotobiol.2016.09.023; Schaue D, 2012, RADIAT RES, V178, P505, DOI 10.1667/RR3031.1; Sorensen BS, 2017, ACTA ONCOL, V56, P1387, DOI 10.1080/0284186X.2017.1351621; Stern HM, 2003, NAT REV CANCER, V3, P533, DOI 10.1038/nrc1126; Szabo ER, 2016, ZEBRAFISH, V13, P481, DOI 10.1089/zeb.2016.1269; Szabo ER, 2018, INT J RADIAT BIOL, V17, P1; URANO M, 1984, INT J RADIAT ONCOL, V10, P509, DOI 10.1016/0360-3016(84)90031-2; Uzawa A, 2007, J RADIAT RES, V48, pA75, DOI 10.1269/jrr.48.A75; Zeil K, 2009, NUCL INSTRUM METH B, V267, P2403, DOI 10.1016/j.nimb.2009.04.015	35	13	14	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2018	13	11							e0206879	10.1371/journal.pone.0206879	http://dx.doi.org/10.1371/journal.pone.0206879			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ5ZX	30408095	Green Published, gold, Green Submitted			2023-01-03	WOS:000449512300049
J	Akizawa, T; Shimazaki, R; Fukagawa, M				Akizawa, Tadao; Shimazaki, Ryutaro; Fukagawa, Masafumi		Evocalcet Study Grp	Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; CINACALCET HYDROCHLORIDE; PHARMACOKINETICS; DIALYSIS; HCL; FIBROBLAST-GROWTH-FACTOR-23; PROGRESSION; MANAGEMENT; GUIDELINE	Background Evocalcet has been developed as a new calcimimetic agent for hemodialysis (HD) patients with secondary hyperparathyroidism (HDSHPT), eliciting fewer gastrointestinal symptoms and drug interactions. We evaluated the efficacy, safety, and optimal starting dose of evocalcet in HDSHPT. Methods In this 3-week, Phase 2b, randomized, double-blind, placebo-controlled, multicenter, parallel-group, dose-finding study, Japanese HDSHPT with intact parathyroid hormone (iPTH) >= 240 pg/mL and serum calcium level corrected for albumin >= 8.4 mg/dL were randomized to evocalcet 0.5, 1, 2 mg/day administered orally or placebo under double-blind conditions, and cinacalcet 25 mg/day (open-label conditions). Results In total, 152 HDSHPT were randomized. The mean +/- standard deviation (median, interquartile range) of percent changes in iPTH from baseline to end of treatment were -8.40 +/- 25.43% (-12.16, 39.60), -10.56 +/- 22.86% (-14.24, 27.85), and -20.16 +/- 34.23% (-23.83, 39.05) in the evocalcet 0.5, 1, and 2 mg/day groups and 5.44 +/- 25.85% (3.52, 35.39) and -25.86 +/- 27.76% (-29.79, 34.15) in the placebo and cinacalcet groups, respectively. The dose-response profile for each evocalcet group vs placebo showed statistically significant differences for all contrast patterns. Whole PTH, corrected calcium, ionized calcium, phosphorus, and intact fibroblast growth factor 23 decreased after treatment initiation in the evocalcet and cinacalcet groups. Adverse events were observed in 30%-50% of patients (all groups). Incidence of adverse events was similar among all groups except for decreased calcium, which occurred more frequently in the evocalcet 2 mg and cinacalcet groups. Conclusions The dose response and safety of all administered doses of evocalcet were confirmed, as well as the efficacy of evocalcet >= 1 mg in a strictly Japanese sample of HDSHPT. Therefore, evocalcet 1 mg was considered appropriate as an initial dose for HDSHPT.	[Akizawa, Tadao] Showa Univ, Sch Med, Div Nephrol, Dept Med,Minato Ku, Namics 301, Tokyo, Japan; [Shimazaki, Ryutaro] Kyowa Hakko Kirin Co Ltd, R&D Div, Tokyo, Japan; [Fukagawa, Masafumi] Tokai Univ, Dept Internal Med, Div Nephrol Endocrinol & Metab, Sch Med, Kanagawa, Japan	Showa University; Kyowa Kirin Ltd; Tokai University	Akizawa, T (corresponding author), Showa Univ, Sch Med, Div Nephrol, Dept Med,Minato Ku, Namics 301, Tokyo, Japan.	akizawa@med.showa-u.ac.jp			Kyowa Hakko Kirin Co., Ltd (KHK)	Kyowa Hakko Kirin Co., Ltd (KHK)	This study was sponsored by Kyowa Hakko Kirin Co., Ltd (KHK). KHK had the role in study design, data collection and analysis, decision to publish, and preparation of the manuscript.; All authors are members of the Evocalcet Study Group, which also includes the investigators in the participating institutions as follows: Noritomo Itami (Higashimuroran Satellite Clinic), Toshinobu Sato (Japan Community Health Care Organization Sendai Hospital), Itaru Ebihara (Mito Saiseikai General Hospital), Jun Niwayama (Sumiyoshi Clinic Hospital), Takayuki Toda (Tsuchiura Kyodo General Hospital), Yoshitaka Maeda (JA Toride Medical Center), Tadashi Iitsuka (Ibaraki Seinan Medical Center Hospital), Haruyuki Ogura (Kurosawa Hospital), Kazue Ueki (Toho hospital), Johji Ohshima (Kubojima Clinic), Yoshihiro Miyauchi (Asahi General Hospital), Hiroyuki Tamura (Toshima Chuou Hospital), Kenichi Oguchi (Ikegami General Hospital), Eriko Kinugasa (Showa University Northern Yokohama Hospital), Shigeru Miyazaki (Shinrakuen Hospital), Ryoichi Miyazaki (Fujita Memorial Hospital), Yutaka Kanno (Kanno Dialysis & Vascular Access Clinic), Hiroaki Shimosaka (Tajimi Clinic), Hisanori Azekura (Sanaru Sun-Clinic), Masanobu Horie (Daiyukaidaiichi Hospital), Yoshinari Tsuruta (Meiyo Clinic Hemodialysis Center), Hirotake Kasuga (Kaikoukai Central Clinic), Hajime Inoue (Ama Kyoritsu Clinic), Hiroshi Ogawa (Sinseikai Dai-Ichi Hospital), Morihiro Kondo (Rakuwakai Otowa Memorial Hospital), Yoshihiro Tsujimoto (Inoue Hospital), Shigeichi Shoji (Shirasagi Hospital), Mitsuru Yoshimoto (Ohno Memorial Hospital), Akira Fujimori (Konan Hospital), Masaki Fukushima (Shigei Medical Research Hospital), Misaki Moriishi (Nakajima Tsuchiya Clinic), Zenzou Fujii (St. Hill Hospital), Jun Minakuchi (Kawashima Hospital), Seiichi Obayashi (Kinashi Obayashi Hospital), Yuzuru Sato (Sato Cardiologic Clinic), Kenji Yuasa (Kochi Takasu Hospital), Hiroshi Kimura (Fukuoka Renal Clinic), Satoshi Funakoshi (Nagasaki Kidney Center), Manei Oku (Seijinkai Ikeda Hospital), and Masayuki Okazaki (Jyoban Hospital). Dr Akizawa is the lead author of the Evocalcet Study Group. The authors thank Keyra Martinez Dunn, MD, of Edanz Medical Writing for providing medical writing support, which was funded by Kyowa Hakko Kirin Co., Ltd.	Akiba T, 2008, THER APHER DIAL, V12, P117, DOI 10.1111/j.1744-9987.2008.00556.x; Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633; Cunningham J, 2011, CLIN J AM SOC NEPHRO, V6, P913, DOI 10.2215/CJN.06040710; Fliser D, 2007, J AM SOC NEPHROL, V18, P2600, DOI 10.1681/ASN.2006080936; Fukagawa M, 2008, NEPHROL DIAL TRANSPL, V23, P328, DOI 10.1093/ndt/gfm534; Fukagawa M, 2017, NEPHROL DIAL TRANSPL, V32, P1723, DOI 10.1093/ndt/gfw408; Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744-9987.12058; Fukuma S, 2013, KIDNEY INT SUPPL, V3, P436, DOI 10.1038/kisup.2013.91; Gutierrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130; Harris RZ, 2007, CLIN PHARMACOKINET, V46, P495, DOI 10.2165/00003088-200746060-00003; Harris RZ, 2007, EUR J CLIN PHARMACOL, V63, P159, DOI 10.1007/s00228-006-0129-8; Isakova T, 2011, JAMA-J AM MED ASSOC, V305, P2432, DOI 10.1001/jama.2011.826; Kawata T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195316; Koizumi M, 2012, NEPHROL DIAL TRANSPL, V27, P784, DOI 10.1093/ndt/gfr384; Komaba H, 2008, THER APHER DIAL, V12, pS44, DOI 10.1111/j.1744-9987.2008.00631.x; Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512; Moe SM, 2015, CIRCULATION, V132, P27, DOI 10.1161/CIRCULATIONAHA.114.013876; Nakashima D, 2007, J CLIN PHARMACOL, V47, P1311, DOI 10.1177/0091270007304103; Palmer SC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001436; Quarles LD, 2003, J AM SOC NEPHROL, V14, P575, DOI 10.1097/01.ASN.0000050224.03126.AD; Tominaga Y, 2005, THER APHER DIAL, V9, P44, DOI 10.1111/j.1774-9987.2005.00213.x; Westfhall PH, 1993, RESAMPLING BASED MUL	22	8	9	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2018	13	10							e0204896	10.1371/journal.pone.0204896	http://dx.doi.org/10.1371/journal.pone.0204896			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY7VH	30379826	Green Submitted, gold, Green Published			2023-01-03	WOS:000448823700024
J	Cantrell, CL; Abbas; Jones, AMP				Cantrell, Charles L.; Abbas; Jones, A. Maxwell P.			Isolation and identification of mosquito biting deterrents from the North American mosquito repelling folk remedy plant, Matricaria discoidea DC.	PLOS ONE			English	Article							VITRO BIOASSAY SYSTEM; NATURAL-PRODUCTS; FATTY-ACIDS; REPELLENTS; DISCOVERY; DIPTERA	Matricaria discoidea DC. (Asteraceae) has documented use as an insect repellent by Blackfoot Indians and other indigenous groups of North America. This investigation was conducted to evaluate this practice and systematically identify chemical constituents responsible for any insect repelling effect by utilizing a mosquito (Aedes aegypti (Linnaeus)) biting deterrent bioactivity-directed purification approach. Hydrodistilled oil from dried aerial parts of M. discoidea was the most bioactive crude extract generated and was as. Fractionation of this extract, followed by re-evaluation for mosquito biting deterrence using the K & D (Klun and Debboun) bioassay, produced many active fractions that were subsequently evaluated by spectroscopic techniques and the most active compounds were determined to be alpha-terpineol, spathulenol, and neryl isovalerate. A & K (Ali and Khan) large cage in vitro evaluation of pure compounds isolated from M. discoidea indicated alpha-terpineol to be the most active compound providing complete protection at 25 mu g/cm(2). This is the first report on the mosquito repellency of neryl isovalerate and scientific evidence reported here validates the traditional use of M. discoidea as a biting-insect deterrent.	[Cantrell, Charles L.] ARS, Nat Prod Utilizat Res Unit, USDA, University, MS 38635 USA; [Abbas] Univ Mississippi, Natl Ctr Nat Prod Res, University, MS 38677 USA; [Jones, A. Maxwell P.] Univ Guelph, Gosling Res Inst Plant Preservat, Dept Plant Agr, Guelph, ON, Canada	United States Department of Agriculture (USDA); University of Mississippi; University of Guelph	Cantrell, CL (corresponding author), ARS, Nat Prod Utilizat Res Unit, USDA, University, MS 38635 USA.	charles.cantrell@ars.usda.gov			Deployed War-Fighter Protection (DWFP) research program grant - U.S. Department of Defense through the Armed Forces Pest Management Board [6060-32000-002-04-I]; Deployed War-Fighter Protection (DWFP) research program grant - U.S. Department of Defense through USDA/ARS [58-6066-6-043]	Deployed War-Fighter Protection (DWFP) research program grant - U.S. Department of Defense through the Armed Forces Pest Management Board; Deployed War-Fighter Protection (DWFP) research program grant - U.S. Department of Defense through USDA/ARS	This study was supported in part by a Deployed War-Fighter Protection (DWFP) research program grant funded by the U.S. Department of Defense through the Armed Forces Pest Management Board (project No. 6060-32000-002-04-I) and through USDA/ARS grant No. 58-6066-6-043.	Adams R.P., 2007, IDENTIFICATION ESSEN, V4th; Ali A, 2017, J MED ENTOMOL, V54, P1328, DOI 10.1093/jme/tjx100; Ali A, 2012, J MED ENTOMOL, V49, P1370, DOI 10.1603/ME12026; Bohbot JD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012138; Buono-Core GE, 2011, J CHIL CHEM SOC, V56, P549, DOI 10.4067/S0717-97072011000100006; Cantrell CL, 2016, J AGR FOOD CHEM, V64, P8352, DOI 10.1021/acs.jafc.6b01668; Cantrell CL, 2012, J NAT PROD, V75, P1231, DOI 10.1021/np300024u; Cantrell CL, 2011, J MED ENTOMOL, V48, P836, DOI 10.1603/ME10244; Cantrell CL, 2005, J AGR FOOD CHEM, V53, P5948, DOI 10.1021/jf0509308; DEPASCUAL J, 1983, PHYTOCHEMISTRY, V22, P1757, DOI 10.1016/S0031-9422(00)80265-4; FONTANA A, 1993, J CHEM ECOL, V19, P339, DOI 10.1007/BF00993700; HART J, 1992, MONTANA NATIVE PLANT; HWANG YS, 1985, J CHEM ECOL, V11, P1297, DOI 10.1007/BF01024117; Jones AMP, 2012, J AGR FOOD CHEM, V60, P3867, DOI 10.1021/jf300101w; Klun JA, 2005, J AM MOSQUITO CONTR, V21, P64, DOI 10.2987/8756-971X(2005)21[64:ANIVBS]2.0.CO;2; Linda K., 2000, EDIBLE MED PLANTS RO; Lopes D, 2013, J ESSENT OIL BEAR PL, V8, P178; Moerman DE, 1998, NATIVE AM ETHNOBOTAN, P337; SAS Institute, 2007, SAS ONL DOC VERS 9 2; Shiwakoti S, 2016, IND CROP PROD, V94, P251, DOI 10.1016/j.indcrop.2016.08.036; Tabanca N, 2016, CURR ORG CHEM, V20, P2690, DOI 10.2174/1385272820666160421151503; WEYERSTAHL P, 1992, LIEBIGS ANN CHEM, P1325	22	2	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2018	13	10							e0206594	10.1371/journal.pone.0206594	http://dx.doi.org/10.1371/journal.pone.0206594			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY7VH	30379955	Green Published, Green Submitted, gold			2023-01-03	WOS:000448823700135
J	Sage, EE; Jailani, N; Taib, AZM; Noor, NM; Said, MIM; Abu Bakar, M; Mackeen, MM				Sage, Edison Eukun; Jailani, Nashriq; Taib, Azney Zuhaily Md.; Noor, Normah Mohd; Said, Md. Ikram Mohd; Abu Bakar, Muntaz; Mackeen, Mukram Mohamed			From the Front or Back Door? Quantitative analysis of direct and indirect extractions of alpha-mangostin from mangosteen (Garcinia mangostana)	PLOS ONE			English	Article							PRENYLATED XANTHONES; PROSTATE-CANCER; PERICARP; FRUIT; CARBON; CONSTITUENTS; INHIBITION; SOLVENTS; CELLS; PARTS	The pulp and pericarp of mangosteen (Garcinia mangostana) fruit are popular food, beverage and health products whereby 60% of the fruit consist of the pericarp. The major metabolite in the previously neglected or less economically significant part of the fruit, the pericarp, is the prenylated xanthone alpha-mangostin. This highly bioactive secondary metabolite is typically isolated using solvent extraction methods that involve large volumes of halogenated solvents either via direct or indirect extraction. In this study, we compared the quantities of alpha-mangostin extracted using three different extraction methods based on the environmentally friendly solvents methanol and ethyl acetate. The three solvent extractions methods used were direct extractions from methanol (DM) and ethyl acetate (DEA) as well as indirect extraction of ethyl acetate obtained via solvent partitioning from an initial methanol extract (IEA). Our results showed that direct extraction afforded similar and higher quantities of alpha-mangostin than indirect extraction (DM: 318 mg; DEA: 305 mg; IEA: 209 mg per 5 g total dried pericarp). Therefore, we suggest that the commonly used method of indirect solvent extraction using halogenated solvents for the isolation of alpha-mangostin is replaced by single solvent direct extraction using the environmentally friendly solvents methanol or ethyl acetate.	[Sage, Edison Eukun; Said, Md. Ikram Mohd; Abu Bakar, Muntaz; Mackeen, Mukram Mohamed] Univ Kebangsaan Malaysia, Fac Sci & Technol, Ctr Adv Mat & Renewable Resources, Chem Programme, Bangi, Malaysia; [Jailani, Nashriq; Noor, Normah Mohd; Mackeen, Mukram Mohamed] Univ Kebangsaan Malaysia, Inst Syst Biol, Bangi, UKM Bangi, Malaysia; [Taib, Azney Zuhaily Md.] Malaysia Genome Inst, Jalan Bangi, Selangor, Malaysia	Universiti Kebangsaan Malaysia; Universiti Kebangsaan Malaysia	Mackeen, MM (corresponding author), Univ Kebangsaan Malaysia, Fac Sci & Technol, Ctr Adv Mat & Renewable Resources, Chem Programme, Bangi, Malaysia.; Mackeen, MM (corresponding author), Univ Kebangsaan Malaysia, Inst Syst Biol, Bangi, UKM Bangi, Malaysia.	mukram.mackeen@ukm.edu.my	Noor, Normah Mohd/X-1754-2019; Mackeen, Mukram Mohamed/AAN-6344-2020	Mackeen, Mukram Mohamed/0000-0001-7344-2932	Ministry of Higher Education [FRGS/1/2014/ST01/UKM/01/1]	Ministry of Higher Education(Science and Technology Development Fund (STDF)Ministry of Higher Education & Scientific Research (MHESR))	This work was supported by the Ministry of Higher Education under Grant FRGS/1/2014/ST01/UKM/01/1. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	Abdallah HM, 2017, J NAT MED-TOKYO, V71, P216, DOI 10.1007/s11418-016-1051-8; Abdalrahim F. A. A., 2012, J MED PLANTS RES, V6, P4526; Ahmad M, 2013, CHEM CENT J, V7, DOI 10.1186/1752-153X-7-85; Alberti A, 2018, J PHARMACEUT BIOMED, V147, P13, DOI 10.1016/j.jpba.2017.08.051; Arunrattiyakorn P, 2014, J MOL CATAL B-ENZYM, V102, P174, DOI 10.1016/j.molcatb.2014.02.010; Arunrattiyakorn P, 2011, PHYTOCHEMISTRY, V72, P730, DOI 10.1016/j.phytochem.2011.02.007; Ashraf MA, 2017, SOILS OF MALAYSIA; Bundeesomchok K, 2016, LWT-FOOD SCI TECHNOL, V65, P297, DOI 10.1016/j.lwt.2015.08.036; Burkill I. H, 2015, DICT EC PRODUCTS MAL; Capello C, 2007, GREEN CHEM, V9, P927, DOI 10.1039/b617536h; Chaijaroenkul W, 2015, ACTA PARASITOL, V60, P105, DOI 10.1515/ap-2015-0013; Chen LG, 2008, FOOD CHEM TOXICOL, V46, P688, DOI 10.1016/j.fct.2007.09.096; Chen YD, 2011, J TAIWAN INST CHEM E, V42, P837, DOI 10.1016/j.jtice.2011.01.007; Chhouk K, 2016, J SUPERCRIT FLUID, V110, P167, DOI 10.1016/j.supflu.2015.11.016; Ee GCL, 2006, NAT PROD RES, V20, P1067, DOI 10.1080/14786410500463114; Fairchild D, 1915, J HERED, V6, P339, DOI 10.1093/oxfordjournals.jhered.a109140; Fei X, 2014, BIOORG MED CHEM LETT, V24, P2062, DOI 10.1016/j.bmcl.2014.03.047; Gross Paul M, 2009, SUPERFRUITS TOP 20 F; Guideline I.H.T., 2005, INT C HARM; Gutierrez-Orozco F, 2013, NUTRIENTS, V5, P3163, DOI 10.3390/nu5083163; He L, 2014, PHYTOCHEM LETT, V9, P175, DOI 10.1016/j.phytol.2014.06.009; Ho C-T, 2005, ASIAN FUNCTIONAL FOO; Ismail M, 2017, AIP C P, DOI [10.1063/1.4976594, DOI 10.1063/1.4976594]; Jantan I, 2011, J NAT MED-TOKYO, V65, P400, DOI 10.1007/s11418-010-0492-8; Johnson JJ, 2012, CARCINOGENESIS, V33, P413, DOI 10.1093/carcin/bgr291; Jung HA, 2006, J AGR FOOD CHEM, V54, P2077, DOI 10.1021/jf052649z; Kondo M, 2009, J AGR FOOD CHEM, V57, P8788, DOI 10.1021/jf901012f; Kunnumakkara AB, 2017, BRIT J PHARMACOL, V174, P1325, DOI 10.1111/bph.13621; Li GB, 2014, BIOCHEM BIOPH RES CO, V453, P75, DOI 10.1016/j.bbrc.2014.09.054; Li GB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081572; Li GB, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00080; Li L, 2011, MOL NUTR FOOD RES, V55, pS67, DOI 10.1002/mnfr.201000511; Lin SM, 2017, J MED CHEM, V60, P10135, DOI 10.1021/acs.jmedchem.7b01348; Loo AEK, 2007, J AGR FOOD CHEM, V55, P9805, DOI 10.1021/jf071500f; MAHABUSARAKAM W, 1986, J SCI SOC THAILAND, V12, P239; Matsumoto K, 2004, BIOORGAN MED CHEM, V12, P5799, DOI 10.1016/j.bmc.2004.08.034; Mohamed GA, 2017, J ETHNOPHARMACOL, V198, P302, DOI 10.1016/j.jep.2017.01.030; Mohamed GA, 2014, FITOTERAPIA, V98, P215, DOI 10.1016/j.fitote.2014.08.014; Narasimhan S, 2017, MOLECULES, V22, DOI 10.3390/molecules22020275; Normah MN, 1997, SEED SCI RES, V7, P179, DOI 10.1017/S0960258500003512; Perry LM, 1980, MED PLANTS E SE ASIA; Pothitirat W, 2009, FUNCTIONAL PLANT SCI, V3, P16; Pothitirat W, 2010, MED PRIN PRACT, V19, P281, DOI 10.1159/000312714; Ramaiya A, 2012, CURR DRUG TARGETS, V13, P1698, DOI 10.2174/138945012804545524; Ryu HW, 2011, PHYTOCHEMISTRY, V72, P2148, DOI 10.1016/j.phytochem.2011.08.007; Sakagami Y, 2005, PHYTOMEDICINE, V12, P203, DOI 10.1016/j.phymed.2003.09.012; Samsir SA, 2016, DATA BRIEF, V8, P1, DOI 10.1016/j.dib.2016.04.062; Seesom W, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-182; Sosef M.S.M., 1998, PLANT RESOURCES S E; Suksamrarn S, 2003, CHEM PHARM BULL, V51, P857, DOI 10.1248/cpb.51.857; Tan GYT, 2017, FOOD BIOPROD PROCESS, V102, P233, DOI 10.1016/j.fbp.2016.12.016; Tarasuk M, 2017, VIRUS RES, V240, P180, DOI 10.1016/j.virusres.2017.08.011; Le TT, 2014, APPL MICROBIOL BIOT, V98, P8527, DOI 10.1007/s00253-014-5947-5; Win H, 2017, ANAL TROPICAL FRUITS; Yodhnu S, 2009, J CHROMATOGR SCI, V47, P185, DOI 10.1093/chromsci/47.3.185; Zarena AS, 2015, J FOOD SCI TECH MYS, V52, P6547, DOI 10.1007/s13197-014-1705-z; Zhang YC, 2015, SEP PURIF TECHNOL, V144, P215, DOI 10.1016/j.seppur.2015.02.038; Zhao Y, 2010, NAT PROD RES, V24, P1664, DOI 10.1080/14786419.2010.499539; Zhou XJ, 2015, NAT PROD RES, V29, P19, DOI 10.1080/14786419.2014.927873	59	3	3	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2018	13	10							e0205753	10.1371/journal.pone.0205753	http://dx.doi.org/10.1371/journal.pone.0205753			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX0RD	30321238	Green Published, gold, Green Submitted			2023-01-03	WOS:000447417900049
J	Shaikh, M; Miraldo, M; Renner, AT				Shaikh, Mujaheed; Miraldo, Marisa; Renner, Anna-Theresa			Waiting time at health facilities and social class: Evidence from the Indian caste system	PLOS ONE			English	Article							PATIENT-CENTERED COMMUNICATION; SOCIOECONOMIC-STATUS; PHYSICIAN GENDER; SERVICES; CARE; RESPONSIVENESS; ETHNICITY; INEQUALITIES; DISPARITIES; EXCLUSION	Waiting time for non-emergency medical care in developing countries is rarely of immediate concern to policy makers that prioritize provision of basic health services. However, waiting time as a measure of health system responsiveness is important because longer waiting times worsen health outcomes and affect utilization of services. Studies that assess socioeconomic inequalities in waiting time provide evidence from developed countries such as England and the United States; evidence from developing countries is lacking. In this paper, we assess the relationship between social class i.e. caste of an individual and waiting time at health facilities-a client orientation dimension of responsiveness. We use household level data from two rounds of the Indian Human Development Survey with a sample size of 27,251 households in each wave (2005 and 2012) and find that lower social class is associated with higher waiting time. This relationship is significant for individuals that visited a male provider but not so for those that visited a female provider. Further, caste is positively related to higher waiting time only if visiting a private facility; for individuals visiting a government facility the relationship between waiting time and caste is not significant. In general, caste related inequality in waiting time has worsened over time. The results are robust to different specifications and the inclusion of several confounders.	[Shaikh, Mujaheed; Renner, Anna-Theresa] Vienna Univ Econ & Business, Hlth Econ & Policy, Vienna, Austria; [Miraldo, Marisa] Imperial Coll London, Imperial Coll Business Sch, Dept Management, London, England; [Miraldo, Marisa] Imperial Coll London, Imperial Coll Business Sch, Ctr Hlth Econ & Policy Innovat, London, England	Vienna University of Economics & Business; Imperial College London; Imperial College London	Shaikh, M (corresponding author), Vienna Univ Econ & Business, Hlth Econ & Policy, Vienna, Austria.	mujaheed.shaikh@wu.ac.at	Miraldo, Marisa/ABF-2584-2020	Miraldo, Marisa/0000-0002-5772-7740; Shaikh, Mujaheed/0000-0002-4231-6631; Renner, Anna-Theresa/0000-0003-4591-3412				Adamson J, 2003, SOC SCI MED, V57, P895, DOI 10.1016/S0277-9536(02)00458-6; Balarajan Y, 2011, LANCET, V377, P505, DOI 10.1016/S0140-6736(10)61894-6; Betancourt JR, 2003, PUBLIC HEALTH REP, V118, P293, DOI 10.1093/phr/118.4.293; Borooah VK, 2005, REV DEV ECON, V9, P399, DOI 10.1111/j.1467-9361.2005.00284.x; Borooah VK, 2005, J DEV STUD, V41, P1369, DOI 10.1080/00220380500186960; Burstrom B, 2002, HEALTH POLICY, V62, P117, DOI 10.1016/S0168-8510(02)00016-7; Cooper LA, 2003, ANN INTERN MED, V139, P907, DOI 10.7326/0003-4819-139-11-200312020-00009; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; Coulter A, 2005, EUR J PUBLIC HEALTH, V15, P355, DOI 10.1093/eurpub/cki004; Desai Sonalde, 2012, Econ Polit Wkly, V46, P40; Desai Sonalde, 2005, **DATA OBJECT**, DOI [10.3886/ ICPSR22626.v12, 10.3886/ICPSR22626.v12]; Desai Sonalde, 2018, **DATA OBJECT**, DOI [10.3886/ICPSR36151. V6, 10.3886/ICPSR36151.v6]; Deshpande A, 2000, AM ECON REV, V90, P322, DOI 10.1257/aer.90.2.322; Dunlop S, 2000, SOC SCI MED, V51, P123, DOI 10.1016/S0277-9536(99)00424-4; Habicht J, 2005, SOC SCI MED, V60, P777, DOI 10.1016/j.socscimed.2004.06.026; Johnson E.M., 2014, ENCY HLTH EC, V3, P77; Jones AM, 2011, J HEALTH ECON, V30, P616, DOI 10.1016/j.jhealeco.2011.05.003; Kaplan GA, 1996, BMJ-BRIT MED J, V312, P9; Kiwanuka SN, 2008, T ROY SOC TROP MED H, V102, P1067, DOI 10.1016/j.trstmh.2008.04.023; Koopmanschap MA, 2005, SOC SCI MED, V60, P2501, DOI 10.1016/j.socscimed.2004.11.022; Laudicella M, 2012, SOC SCI MED, V74, P1331, DOI 10.1016/j.socscimed.2011.12.049; Malhotra C, 2013, HEALTH POLICY PLANN, V28, P197, DOI 10.1093/heapol/czs051; Morris S, 2003, 27 U YORK CTR HLTH E; Moscelli G, 2016, SOC SCI MED, V161, P151, DOI 10.1016/j.socscimed.2016.05.043; Nayar KR, 2007, INDIAN J MED RES, V126, P355; Peltzer K, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-117; Rama Baru, 2010, Economic and Political Weekly, V45, P49; Robone S, 2011, HEALTH SERV RES, V46, P2079, DOI 10.1111/j.1475-6773.2011.01291.x; Roter DL, 2004, ANNU REV PUBL HEALTH, V25, P497, DOI 10.1146/annurev.publhealth.25.101802.123134; Sabin JA, 2009, J HEALTH CARE POOR U, V20, P896, DOI 10.1353/hpu.0.0185; Santana P, 2002, SOC SCI MED, V55, P33, DOI 10.1016/S0277-9536(01)00218-0; Siciliani L, 2014, ISR J HEALTH POLICY, V3, DOI 10.1186/2045-4015-3-38; Sitzia J, 1997, SOC SCI MED, V45, P1829, DOI 10.1016/S0277-9536(97)00128-7; Smaje C, 1997, SOC SCI MED, V45, P485, DOI 10.1016/S0277-9536(96)00380-2; Stith AY, 2003, UNEQUAL TREATMENT CO; STREET RL, 1991, SOC SCI MED, V32, P541, DOI 10.1016/0277-9536(91)90288-N; Subramanian SV, 2006, AM J PUBLIC HEALTH, V96, P818, DOI 10.2105/AJPH.2004.060103; Subramanian SV., 2008, BROWN J WORLD AFF, V14, P127; TEMKINGREENER H, 1988, SOC SCI MED, V26, P989, DOI 10.1016/0277-9536(88)90216-X; Thind A, 2004, J TROP PEDIATRICS, V50, P137, DOI 10.1093/tropej/50.3.137; van Doorslaer E, 2004, HEALTH ECON, V13, P629, DOI 10.1002/hec.919; WEISMAN CS, 1985, SOC SCI MED, V20, P1119, DOI 10.1016/0277-9536(85)90189-3; Willems S, 2005, PATIENT EDUC COUNS, V56, P139, DOI 10.1016/j.pec.2004.02.011; World Health Organization (WHO), HLTH IMP ASS	44	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2018	13	10							e0205641	10.1371/journal.pone.0205641	http://dx.doi.org/10.1371/journal.pone.0205641			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GX0RD	30321215	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000447417900042
J	Koppelmans, V; Scott, JM; Downs, ME; Cassady, KE; Yuan, P; Pasternak, O; Wood, SJ; De Dios, YE; Gadd, NE; Kofman, I; Riascos, R; Reuter-Lorenz, PA; Bloomberg, JJ; Mulavara, AP; Ploutz-Snyder, LL; Seidler, RD				Koppelmans, Vincent; Scott, Jessica M.; Downs, Meghan E.; Cassady, Kaitlin E.; Yuan, Peng; Pasternak, Ofer; Wood, Scott J.; De Dios, Yiri E.; Gadd, Nichole E.; Kofman, Igor; Riascos, Roy; Reuter-Lorenz, Patricia A.; Bloomberg, Jacob J.; Mulavara, Ajitkumar P.; Ploutz-Snyder, Lori L.; Seidler, Rachael D.			Exercise effects on bed rest-induced brain changes	PLOS ONE			English	Article							LONG-DURATION SPACEFLIGHT; AEROBIC EXERCISE; HUMAN CEREBELLUM; MANUAL MOTOR; PLASTICITY; MRI; WEIGHTLESSNESS; RESISTANCE; FMRI	Purpose Spaceflight negatively affects sensorimotor behavior; exercise mitigates some of these effects. Head down tilt bed rest (HDBR) induces body unloading and fluid shifts, and is often used to investigate spaceflight effects. Here, we examined whether exercise mitigates effects of 70 days HDBR on the brain and if fitness and brain changes with HDBR are related. Methods HDBR subjects were randomized to no-exercise (n = 5) or traditional aerobic and resistance exercise (n = 5). Additionally, a flywheel exercise group was included (n = 8). Exercise protocols for exercise groups were similar in intensity, therefore these groups were pooled in statistical analyses. Pre and post-HDBR MRI (structure and structural/functional connectivity) and physical fitness measures (lower body strength, muscle cross sectional area, VO2 max, body composition) were collected. Voxel-wise permutation analyses were used to test group differences in brain changes, and their associations with fitness changes. Results Comparisons of exercisers to controls revealed that exercise led to smaller fitness deterioration with HDBR but did not affect brain volume or connectivity. Group comparisons showed that exercise modulated post-HDBR recovery of brain connectivity in somatosensory regions. Posthoc analysis showed that this was related to functional connectivity decrease with HDBR in non-exercisers but not in exercisers. Correlational analyses between fitness and brain changes showed that fitness decreases were associated with functional connectivity and volumetric increases (all r >.74), potentially reflecting compensation. Modest brain changes or even decreases in connectivity and volume were observed in subjects who maintained or showed small fitness gains. These results did not survive Bonferroni correction, but can be considered meaningful because of the large effect sizes. Conclusion Exercise performed during HDBR mitigates declines in fitness and strength. Associations between fitness and brain connectivity and volume changes, although unadjusted for multiple comparisons in this small sample, suggest that supine exercise reduces compensatory HDBR-induced brain changes.	[Koppelmans, Vincent; Yuan, Peng; Ploutz-Snyder, Lori L.; Seidler, Rachael D.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48109 USA; [Koppelmans, Vincent] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Scott, Jessica M.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Scott, Jessica M.; Ploutz-Snyder, Lori L.] NASA, Univ Space Res Assoc, Johnson Space Ctr, Houston, TX USA; [Downs, Meghan E.; De Dios, Yiri E.; Gadd, Nichole E.; Kofman, Igor; Mulavara, Ajitkumar P.] KBRwyle, Houston, TX USA; [Cassady, Kaitlin E.; Reuter-Lorenz, Patricia A.; Seidler, Rachael D.] Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA; [Pasternak, Ofer] Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat & Radiol, Boston, MA USA; [Wood, Scott J.; Bloomberg, Jacob J.] NASA, Johnson Space Ctr, Houston, TX USA; [Riascos, Roy] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA; [Reuter-Lorenz, Patricia A.] Univ Michigan, Neurosci Program, Ann Arbor, MI 48109 USA; [Seidler, Rachael D.] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA	University of Michigan System; University of Michigan; Utah System of Higher Education; University of Utah; Memorial Sloan Kettering Cancer Center; National Aeronautics & Space Administration (NASA); Universities Space Research Association (USRA); University of Michigan System; University of Michigan; Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Aeronautics & Space Administration (NASA); University of Texas System; University of Texas Health Science Center Houston; University of Michigan System; University of Michigan; State University System of Florida; University of Florida	Seidler, RD (corresponding author), Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48109 USA.; Seidler, RD (corresponding author), Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA.; Seidler, RD (corresponding author), Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA.	rachaelseidler@ufl.edu	Riascos, Roy/AAE-3822-2019; Koppelmans, Vincent/V-2604-2019	Riascos, Roy/0000-0002-3081-0413; Koppelmans, Vincent/0000-0003-2036-7603; Seidler, Rachael/0000-0003-2452-9024; Scott, Jessica/0000-0002-4845-5800	The National Space Biomedical Research Institute [NCC 9-58, MA02701, PF04101]; National Aeronautics and Space Administration [NNX11AR02G]; National Institutes of Health, National Center for Advancing Translational Sciences; NASA Flight Analogs Project [1UL1RR029876-01]; The National Center for Advancing Translational Sciences [UL1TR000071]; National Institutes of Health (NIH) [P41 EB015902]; KBRwyle; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000071] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029876] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB015902] Funding Source: NIH RePORTER	The National Space Biomedical Research Institute; National Aeronautics and Space Administration(National Aeronautics & Space Administration (NASA)); National Institutes of Health, National Center for Advancing Translational Sciences; NASA Flight Analogs Project; The National Center for Advancing Translational Sciences; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); KBRwyle; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This work is supported by grants from the following institutions: 1) The National Space Biomedical Research Institute (http://nsbri.org/funding/): a. NASA cooperative agreement NCC 9-58 awarded to RDS. b. MA02701 awarded to RDS. c. PF04101 awarded to VK. 2) The National Aeronautics and Space Administration (https://www.nasa.gov/about/research/index.html): a. NASA; NNX11AR02G awarded to RDS. b. NASA Flight Analogs Project. 3) National Institutes of Health (https://www.nih.gov), National Center for Advancing Translational Sciences (https://ncats.nih.gov), NASA Flight Analogs Project (1UL1RR029876-01) awarded to AR Brasier. 4) The National Center for Advancing Translational Sciences (UL1TR000071). 5) The National Institutes of Health (NIH P41 EB015902). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. MED, YED, NEG, IK, and APM are employed by KBRwyle. KBRwyle only provided support in the form of salaries for these authors but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Alperin N, 2017, NEUROLOGY, V89, P2187, DOI 10.1212/WNL.0000000000004475; Archer T, 2012, NEUROTOX RES, V21, P418, DOI 10.1007/s12640-011-9297-0; Bherer L., 2013, J AGING RES, V2013, DOI [10.1155/2013/657508., 10.1155/2013/657508]; Bloomberg JJ, 2003, IEEE ENG MED BIOL, V22, P58, DOI 10.1109/MEMB.2003.1195697; Buehring B, 2011, J APPL PHYSIOL, V111, P87, DOI 10.1152/japplphysiol.01294.2010; Carpenter R. D., 2010, J COSMOLOGY, V12, P3778; Cassady K, 2016, NEUROIMAGE, V141, P18, DOI 10.1016/j.neuroimage.2016.07.029; Cohen HS, 2012, J VESTIBUL RES-EQUIL, V22, P191, DOI 10.3233/VES-2012-0456; Cromwell RL, 2018, MED SCI SPORT EXER, V50, P1909, DOI 10.1249/MSS.0000000000001617; Demertzi A, 2016, BRAIN STRUCT FUNCT, V221, P2873, DOI 10.1007/s00429-015-1054-3; Diedrichsen J, 2006, NEUROIMAGE, V33, P127, DOI 10.1016/j.neuroimage.2006.05.056; Eickhoff SB, 2006, HUM BRAIN MAPP, V27, P611, DOI 10.1002/hbm.20205; Eulenburg PZ, 2012, NEUROIMAGE, V60, P162, DOI 10.1016/j.neuroimage.2011.12.032; Goldstein JM, 2007, BIOL PSYCHIAT, V61, P935, DOI 10.1016/j.biopsych.2006.06.027; Gomez-Pinilla F, 2013, COMPR PHYSIOL, V3, P403, DOI 10.1002/cphy.c110063; Hargens AR, 2016, J APPL PHYSIOL, V120, P891, DOI 10.1152/japplphysiol.00935.2015; Hayes SM, 2014, CURR GERIATR REP, V3, P282, DOI 10.1007/s13670-014-0101-x; Hillman CH, 2011, PREV MED, V52, pS21, DOI 10.1016/j.ypmed.2011.01.024; Kassem MS, 2013, MOL NEUROBIOL, V47, P645, DOI 10.1007/s12035-012-8365-7; Kilgour AHM, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-85; Koppelmans V, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03311-w; Koppelmans V, 2017, BRAIN STRUCT FUNCT, V222, P1929, DOI 10.1007/s00429-016-1317-7; Koppelmans V, 2016, NPJ MICROGRAVITY, V2, DOI 10.1038/s41526-016-0001-9; Koppelmans V, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00121; Koppelmans V, 2015, HUM BRAIN MAPP, V36, P2352, DOI 10.1002/hbm.22775; Koppelmans V, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-205; Langer N, 2012, NEUROLOGY, V78, P182, DOI 10.1212/WNL.0b013e31823fcd9c; Lautenschlager NT, 2012, BBA-MOL BASIS DIS, V1822, P474, DOI 10.1016/j.bbadis.2011.07.010; Li K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135835; Lustig C, 2009, NEUROPSYCHOL REV, V19, P504, DOI 10.1007/s11065-009-9119-9; Mulavara AP, 2018, MED SCI SPORT EXER, V50, P1961, DOI 10.1249/MSS.0000000000001615; Mulavara AP, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00117; Mulavara AP, 2010, EXP BRAIN RES, V202, P649, DOI 10.1007/s00221-010-2171-0; Mulder E, 2014, J MUSCULOSKEL NEURON, V14, P359; Murach KA, 2018, MED SCI SPORT EXER, V50, P1950, DOI 10.1249/MSS.0000000000001620; PARKER DE, 1985, AVIAT SPACE ENVIR MD, V56, P601; Pasternak O, 2009, MAGN RESON MED, V62, P717, DOI 10.1002/mrm.22055; Ploutz-Snyder LL, 2018, MED SCI SPORT EXER, V50, P1920, DOI 10.1249/MSS.0000000000001618; Ploutz-Snyder LL, 2014, MED SCI SPORT EXER, V46, P358, DOI 10.1249/MSS.0b013e3182a62f85; Rao LL, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00187; Roberts DR, 2017, NEW ENGL J MED, V377, P1746, DOI 10.1056/NEJMoa1705129; Roberts DR, 2010, AVIAT SPACE ENVIR MD, V81, P30, DOI 10.3357/ASEM.2532.2009; Scott JM, 2011, MED SCI SPORT EXER, V43, P823, DOI 10.1249/01.MSS.0000402294.26570.46; Seghier ML, 2013, NEUROSCIENTIST, V19, P43, DOI 10.1177/1073858412440596; Singh MAF, 2014, J AM MED DIR ASSOC, V15, P873, DOI 10.1016/j.jamda.2014.09.010; Stoodley CJ, 2009, NEUROIMAGE, V44, P489, DOI 10.1016/j.neuroimage.2008.08.039; Taibbi G, 2014, AVIAT SPACE ENVIR MD, V85, P983, DOI 10.3357/ASEM.4055.2014; Thomas AG, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00086; Xu HJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084729; YOUNG LR, 1984, SCIENCE, V225, P205, DOI 10.1126/science.6610215; Yuan P, 2018, J NEUROPHYSIOL, V119, P2145, DOI 10.1152/jn.00693.2017; Yuan P, 2018, HUM BRAIN MAPP, V39, P2753, DOI 10.1002/hbm.24037; Yuan P, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00071	53	6	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2018	13	10							e0205515	10.1371/journal.pone.0205515	http://dx.doi.org/10.1371/journal.pone.0205515			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW7TO	30308004	Green Published, Green Submitted, gold			2023-01-03	WOS:000447173500093
J	Ataguba, JEO				Ataguba, John Ele-Ojo			A reassessment of global antenatal care coverage for improving maternal health using sub-Saharan Africa as a case study	PLOS ONE			English	Article							PRENATAL-CARE; BIRTH-WEIGHT; QUALITY; OUTCOMES; CONTEXT; DEMAND	Background Antenatal period is an opportunity for reaching pregnant women with vital interventions. In fact, antenatal care (ANC) coverage was an indicator for assessing progress towards the Millennium Development Goals. This paper applies a novel index of service coverage using ANC, which accounts for every ANC visit. An index of service coverage gap is also proposed. These indices are additively decomposable by population groups and they are sensitive to the receipt of more ANC visits below a defined threshold. These indices have also been generalised to account for the quality of services. Methods Data from recent rounds of the Demographic and Health Survey (DHS) are used to reassess ANC service coverage in 35 sub-Saharan African countries. An index of ANC coverage was estimated. These countries were ranked, and their ranks are compared with those based on attaining at least four ANC visits (ANC4+). Findings The index of ANC coverage reflected the level of service coverage in countries. Further, disparities exist in country ranking as some countries, e.g. Cameroon, Benin Republic and Nigeria are ranked better using the ANC4+ indicator but poorly using the proposed index. Also, Rwanda and Malawi are ranked better using the proposed index. Conclusion The proposed ANC index allows for the assessment of progressive realisation, rooted in the move towards universal health coverage. In fact, the index reflects progress that countries make in increasing service coverage. This is because every ANC visit counts. Beyond ANC coverage, the proposed index is applicable to assessing service coverage generally including quality education.	[Ataguba, John Ele-Ojo] Univ Cape Town, Hlth Econ Unit, Sch Publ Hlth & Family Med, Hlth Sci Fac, Cape Town, South Africa	University of Cape Town	Ataguba, JEO (corresponding author), Univ Cape Town, Hlth Econ Unit, Sch Publ Hlth & Family Med, Hlth Sci Fac, Cape Town, South Africa.	John.Ataguba@uct.ac.za		Ataguba, John Ele-Ojo/0000-0002-7746-3826	National Research Foundation [103687]	National Research Foundation	The work is supported by the National Research Foundation (Fund number: 103687). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, MDG REP ASS PROGR AF; Arunda M, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1328796; BACKE B, 1993, BRIT J OBSTET GYNAEC, V100, P727, DOI 10.1111/j.1471-0528.1993.tb14263.x; Beeckman K, 2013, EUR J PUBLIC HEALTH, V23, P366, DOI 10.1093/eurpub/cks123; Boller C, 2003, B WORLD HEALTH ORGAN, V81, P116; Bryce J, 2008, LANCET, V371, P1247, DOI 10.1016/S0140-6736(08)60559-0; Carroli G, 2001, LANCET, V357, P1565, DOI 10.1016/S0140-6736(00)04723-1; Diamond-Smith N, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0208-y; Evans WN, 2005, J ECONOMETRICS, V125, P207, DOI 10.1016/j.jeconom.2004.04.007; Every Woman Every Child (EWEC), 2015, GLOBAL STRATEGY WOME; Habibov NN, 2011, ECON HUM BIOL, V9, P56, DOI 10.1016/j.ehb.2010.08.003; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; Hodgins S, 2014, GLOB HEALTH-SCI PRAC, V2, P173, DOI 10.9745/GHSP-D-13-00176; Hosseinpoor AR, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001727; Izugbara CO, 2018, HEALTH POLICY PLANN, V33, P1, DOI 10.1093/heapol/czx131; Koroma MM, 2017, HEALTH RES POLICY SY, V15, DOI 10.1186/s12961-017-0218-4; Kyei NNA, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-151; Linard M, 2018, BJOG-INT J OBSTET GY, V125, P587, DOI 10.1111/1471-0528.14794; Ng M, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001730; ROSENZWEIG MR, 1983, J POLIT ECON, V91, P723, DOI 10.1086/261179; Say L, 2007, B WORLD HEALTH ORGAN, V85, P812, DOI 10.2471/BLT.06.035659; Uganda Bureau of Statistics (UBOS) and ICF, 2018, UG DEM HLTH SURV 201; United Nations Development Programme, 2015, SUST DEV GOALS; Wehby GL, 2009, ECON HUM BIOL, V7, P84, DOI 10.1016/j.ehb.2008.10.001; WHO, 2022, WHO RECOMMENDATIONS; WHO, 2014, WORLD HLTH STAT 2014; *WHO, COUNTD 2015 DEC REP; WHO, 2014, EV NEWB ACT PLAN END; World Health Organization, 2015, WORLD HLTH STAT 2015	29	25	25	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2018	13	10							e0204822	10.1371/journal.pone.0204822	http://dx.doi.org/10.1371/journal.pone.0204822			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW0HY	30289886	gold, Green Submitted, Green Published			2023-01-03	WOS:000446545500024
J	Rubab, M; Chellia, R; Saravanakumar, K; Mandava, S; Khan, I; Tango, CN; Hussain, MS; Daliri, EBM; Kim, SH; Ramakrishnan, SR; Wang, MH; Lee, J; Kwon, JH; Chandrashekar, S; Oh, DH				Rubab, Momna; Chellia, Ramachandran; Saravanakumar, Kandasamy; Mandava, Suresh; Khan, Imran; Tango, Charles Nkufi; Hussain, Mohammad Shakhawat; Daliri, Eric Banan-Mwine; Kim, Se-Hun; Ramakrishnan, Sudha Rani; Wang, Myeong-Hyeon; Lee, Jongkook; Kwon, Joong-Ho; Chandrashekar, Sangeeta; Oh, Deog-Hwan			Preservative effect of Chinese cabbage (Brassica rapa subsp pekinensis) extract on their molecular docking, antioxidant and antimicrobial properties	PLOS ONE			English	Article							CHEMICAL-COMPOSITION; ANTIBACTERIAL ACTIVITY; CRYSTAL-STRUCTURE; VAR. CAPITATA; SOUTH-KOREA; IN-VIVO; BIOSYNTHESIS; AGENTS; PLANTS; LPXC	This study aimed at investigating the antimicrobial activity of different solvent extracts of Chinese cabbage Brassica rapa subsp. pekinensis (BRARP) and their antioxidant and cytotoxicity properties. Of the different solvents extracts, the chloroform extracts (CE) were significantly inhibited the bacterial pathogens at minimum inhibitory concentration (MIC) of 16.5 mg.mL(-1). Biochemical analysis revealed that total phenol (62.6 +/- 0.05 mg GAE.g(-1)) and flavonoids (27.6 +/- 0.04 mg QE.g(-1)) were higher in the extracts of BRARP, which resulted in enhanced antioxidant activity in CE. A total of eight dominant compounds were detected in the potent antimicrobial extract from BRARP based on GC-MS analysis. The molecular interactions study revealed that, among the screened compounds the 1,2-benzenedicarboxylic acid and 2,3-dicyanopropionamide interacted with the active site of pathogenicity and survival related protein with lipopolysaccharide (LpxC) with higer binding energy. This work concluded that the 1, 2-Benzenedicarboxylic acid and 2, 3-Dicyanopropionamide from BRARP was reported to be good non-cytotoxic and antioxidant antimicrobials against bacterial pathogens.	[Rubab, Momna; Chellia, Ramachandran; Khan, Imran; Tango, Charles Nkufi; Hussain, Mohammad Shakhawat; Daliri, Eric Banan-Mwine; Kim, Se-Hun; Oh, Deog-Hwan] Kangwon Natl Univ, Coll Agr & Life Sci, Dept Food Sci & Biotechnol, Chunchon, South Korea; [Saravanakumar, Kandasamy; Wang, Myeong-Hyeon] Kangwon Natl Univ, Coll Biomed Sci, Dept Med Biotechnol, Chunchon, South Korea; [Mandava, Suresh; Lee, Jongkook] Kangwon Natl Univ, Coll Pharm, Chunchon, South Korea; [Ramakrishnan, Sudha Rani; Kwon, Joong-Ho] Kyungpook Natl Univ, Sch Food Sci & Biotechnol, Daegu, South Korea; [Chandrashekar, Sangeeta] Sri Venkateshwara Dent Coll, Madras, Tamil Nadu, India	Kangwon National University; Kangwon National University; Kangwon National University; Kyungpook National University	Oh, DH (corresponding author), Kangwon Natl Univ, Coll Agr & Life Sci, Dept Food Sci & Biotechnol, Chunchon, South Korea.	deoghwa@kangwon.ac.kr	Saravanakumar, Kandasamy/P-6745-2018; Ramakrishnan, Sudha Rani/V-6342-2017; Khan, Imran/S-3149-2018	Saravanakumar, Kandasamy/0000-0002-4465-4378; Ramakrishnan, Sudha Rani/0000-0002-4460-416X; Lee, Jongkook/0000-0003-0739-7963; Kwon, Joong-Ho/0000-0002-3875-1438; Khan, Imran/0000-0001-9802-0429; Myeong-Hyeon, Wang/0000-0003-1760-1622	Brain Korea (BK) 21 Plus Project [22A20153713433]; National Research Foundation of Korea, Ministry of Science [2018007551]; National Research Foundation of Korea (NRF) [2017H1D3A1A01052610]; Brain Korea (BK) 21 Plus Project - Korean Government, Republic of Korea [22A20153713433]; National Research Foundation of Korea (NRF) - Ministry of Science, ICT [2017H1D3A1A01052610]; Young Researchers Program [2018007551]	Brain Korea (BK) 21 Plus Project; National Research Foundation of Korea, Ministry of Science; National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Brain Korea (BK) 21 Plus Project - Korean Government, Republic of Korea; National Research Foundation of Korea (NRF) - Ministry of Science, ICT; Young Researchers Program	Funded by Brain Korea (BK) 21 Plus Project 22A20153713433 to Ms Momna Rubab. Korea Research Fellowship Program, National Research Foundation of Korea, Ministry of Science, Young Researchers Program for 2018007551 to Dr Ramachandran Chelliah. Korea Research Fellowship Program through the National Research Foundation of Korea (NRF) 2017H1D3A1A01052610 to Dr Kandasamy Saravanakumar.; We thank Mr. Park-Yong IK (Kangwon National University, Central laboratory) for technical support for GC-MS and CLSM analysis. This work was supported by a grant from the Brain Korea (BK) 21 Plus Project (Grant No. 22A20153713433) Funded by the Korean Government, Republic of Korea. The part of this work was supported by Korea Research Fellowship Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT (2017H1D3A1A01052610) and Young Researchers Program for (2018007551) (http://www.nrf.re.kr/eng/main).	Alam MN, 2013, SAUDI PHARM J, V21, P143, DOI 10.1016/j.jsps.2012.05.002; [Anonymous], 1994, HERBALGRAM; Arabshahi-D S, 2007, FOOD CHEM, V100, P1100, DOI 10.1016/j.foodchem.2005.11.014; Armesto J, 2019, INT J FOOD SCI NUTR, V70, P136, DOI 10.1080/09637486.2018.1482530; Arora S., 2018, J PHARMACOGNOSY PHYT, V7, P1445; Ashraf S, 2018, ENVIRON TOXICOL PHAR, V58, P54, DOI 10.1016/j.etap.2017.12.017; Balouiri M, 2016, J PHARM ANAL, V6, P71, DOI 10.1016/j.jpha.2015.11.005; Borges A, 2015, J FOOD SCI TECH MYS, V52, P4737, DOI 10.1007/s13197-014-1533-1; Brown MF, 2012, J MED CHEM, V55, P914, DOI 10.1021/jm2014748; Chalannavar RK, 2014, J ESSENT OIL BEAR PL, V17, P1293, DOI 10.1080/0972060X.2014.892840; Cho JI, 2014, FOOD SCI BIOTECHNOL, V23, P209, DOI 10.1007/s10068-014-0028-1; CLSI, 2012, PERF STAND ANT DISK; DICKERMAN JM, 1952, FOOD RES, V17, P438; Ding C, 2017, STUD NAT PROD CHEM, V54, P141, DOI 10.1016/B978-0-444-63929-5.00005-X; El-Hefny M, 2017, BIORESOURCES, V12, P1835, DOI 10.15376/biores.12.1.1835-1849; Elshouny WAF, 2017, J MICROB BIOTEC FOOD, V6, P1203, DOI 10.15414/jmbfs.2017.6.5.1203-1208; Gersnoviez A., 2018, 2018 13 TECHN APPL E, P1, DOI [10.1007/s00425-017-2798-1, DOI 10.1007/S00425-017-2798-1]; Gogo L. A., 2010, Journal of Applied Sciences Research, P1807; Gronow S, 2001, J ENDOTOXIN RES, V7, P3, DOI 10.1179/096805101101532468; Gyawali R, 2014, FOOD CONTROL, V46, P412, DOI 10.1016/j.foodcont.2014.05.047; Hanschen FS, 2018, FOOD CHEM, V263, P240, DOI 10.1016/j.foodchem.2018.04.069; HarborneJB, 1984, PHYTOCHEMICAL METHOD, P1, DOI [DOI 10.1007/978-94-009-5570-7_1, 10.1007/978-94-009-5570-7_1]; Hariharan B, 2013, MICROBIAL BIOCH TECH, V6; Hong Eunyoung, 2013, Prev Nutr Food Sci, V18, P218, DOI 10.3746/pnf.2013.18.3.218; Hu Shu-Hui, 2004, Kaohsiung Journal of Medical Sciences, V20, P591, DOI 10.1016/S1607-551X(09)70264-5; Igwe K.K., 2016, INT J SCI TECH RES E, V1, P9; Igwe KK, 2016, INT J ADV RES SCI EN, V3, P1765; Jackman JE, 2000, J BIOL CHEM, V275, P11002, DOI 10.1074/jbc.275.15.11002; Jaiswal AK, 2012, J FOOD BIOCHEM, V36, P344, DOI 10.1111/j.1745-4514.2011.00545.x; Jang Dai-Ja, 2015, Journal of Ethnic Foods, V2, P126; Kalinin DV, 2017, EXPERT OPIN THER PAT, V27, P1227, DOI 10.1080/13543776.2017.1360282; Kim GH, 2015, J FOOD SCI, V80, pM2257, DOI 10.1111/1750-3841.12996; Koncic MZ, 2010, FOOD CHEM TOXICOL, V48, P1537, DOI 10.1016/j.fct.2010.03.021; LIU J Y, 1986, Annals of the Phytopathological Society of Japan, V52, P669, DOI 10.3186/jjphytopath.52.669; Males E, 2004, JPC-J PLANAR CHROMAT, V17, P280, DOI 10.1556/JPC.17.2004.4.7; Mataragas M, 2015, MEAT SCI, V103, P39, DOI 10.1016/j.meatsci.2015.01.002; Matuschek E, 2014, CLIN MICROBIOL INFEC, V20, pO255, DOI 10.1111/1469-0691.12373; Mochalkin I, 2008, PROTEIN SCI, V17, P450, DOI 10.1110/ps.073324108; Mollica A, 2018, BIOMED PHARMACOTHER, V107, P129, DOI 10.1016/j.biopha.2018.07.169; Mudzengi CP, 2017, PHARM BIOL, V55, P1054, DOI 10.1080/13880209.2017.1287744; Nabavi SM, 2015, FOOD CHEM, V173, P339, DOI 10.1016/j.foodchem.2014.10.042; Oliveira DA, 2013, J BIOTECHNOL, V164, P423, DOI 10.1016/j.jbiotec.2012.09.014; Ortega-Ramirez Luis Alberto, 2014, J Food Sci, V79, pR129, DOI 10.1111/1750-3841.12341; Parashar S., 2014, J PHARMACOGN PHYTOCH, V3, P160; Pederson CS, 1944, NEW YORK STATE AGR E, V237; Perez IA, 2015, ADV METEOROL, V2015, DOI 10.1155/2015/284213; Pirbalouti AG, 2014, J MED FOOD, V17, P1151, DOI 10.1089/jmf.2013.0057; Prasanna G, 2014, MED CHEM RES, V23, P2651, DOI 10.1007/s00044-013-0858-z; Puupponen-Pimia R, 2001, J APPL MICROBIOL, V90, P494, DOI 10.1046/j.1365-2672.2001.01271.x; Rokayya S, 2013, ASIAN PAC J CANCER P, V14, P6657, DOI 10.7314/APJCP.2013.14.11.6657; Shen XJ, 2017, IND CROP PROD, V96, P110, DOI 10.1016/j.indcrop.2016.11.053; Shen ZH, 2017, CURR ORG CHEM, V21, P1626, DOI 10.2174/1385272821666170410145554; Shenoy N, 2017, LAB INVEST, V97, P494, DOI 10.1038/labinvest.2017.18; Sherman J. M., 1936, J BACTERIOL, V31; Shin J, 2016, FOODBORNE PATHOG DIS, V13, P535, DOI 10.1089/fpd.2016.2147; Soengas P., 2018, J AGR FOOD CHEM; Soengas P, 2018, ACS OMEGA, V3, P5237, DOI 10.1021/acsomega.8b00242; Thangam R, 2013, PHYTOTHER RES, V27, P1664, DOI 10.1002/ptr.4908; Thielmann J, 2017, INT J FOOD MICROBIOL, V251, P48, DOI 10.1016/j.ijfoodmicro.2017.03.019; Thiruvengadam M, 2015, SCI HORTIC-AMSTERDAM, V193, P136, DOI 10.1016/j.scienta.2015.07.007; Tomaras AP, 2014, MBIO, V5, DOI 10.1128/mBio.01551-14; Varghese P., 2015, J STUDENT RES, V4, P87; Vijayan A., 2017, J NATURAL PRODUCTS R, V3, P125; Whittington DA, 2003, P NATL ACAD SCI USA, V100, P8146, DOI 10.1073/pnas.1432990100; Wu Q, 2013, ARCH PHARM RES, V36, P423, DOI 10.1007/s12272-013-0068-8; Yee LW, 2007, MALAYSIAN J NUTR, V13, P71; YILDIZ F, 1981, J FOOD SCI, V46, P962, DOI 10.1111/j.1365-2621.1981.tb15397.x; [周璐 Zhou Lu], 2017, [机械传动, Journal of Mechanical Transmission], V41, P1	68	16	16	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2018	13	10							e0203306	10.1371/journal.pone.0203306	http://dx.doi.org/10.1371/journal.pone.0203306			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV7VQ	30281596	Green Published, Green Submitted, gold			2023-01-03	WOS:000446342400018
J	Fan, X; Li, N; Wang, XS; Zhang, JY; Xu, MY; Liu, XT; Wang, BN				Fan, Xin; Li, Ning; Wang, Xiaoshuang; Zhang, Jingyu; Xu, Meiyi; Liu, Xueting; Wang, Beinan			Protective immune mechanisms of Yifei Tongluo, a Chinese herb formulation, in the treatment of mycobacterial infection	PLOS ONE			English	Article							HOST-DIRECTED THERAPIES; INFLAMMATORY RESPONSE; T-CELLS; TUBERCULOSIS; BCG; LUNG; OPPORTUNITIES; MACROPHAGES; ACTIVATION; CHALLENGES	Yifei Tongluo (YFTL) is a traditional Chinese medicine (TCM) formulation which has been shown clinical efficacy in treatment of patients with multidrug-resistant tuberculosis in China. However, the underlying mechanisms of the effects of YFTL are lacking. This study investigated the effects of YFTL on immune regulation with a mouse lung infection model with Bacille Calmette-Guerin (BCG). We found that compared with untreated mice, the lung mycobacterial load in YFTL-treated mice was significantly reduced, accompanied by alleviated pulmonary inflammation with reduction of pro-inflammatory cytokines and increase of prostaglandin E2 (PGE2). Flow cytometry analyses showed that Th1 cells were significantly higher in the lungs of YFTL-treated mice at early infection time. The results suggest that YFTL-treatment down-regulates pulmonary inflammation, which facilitates a rapid infiltration of Thl cells into the lungs. Moreover, the Th1 cells in the lungs were resolved faster at later time concomitant with increased the regulatory T cells (Tregs). The reduction of mycobacterial burden associated with improved tissue pathology, faster Th1 cell trafficking, and accelerated resolution of Th1 cells in the lungs of YFTL-treated mice indicates that YFTL improves mycobacterial clearance by maintaining lung homeostasis and dynamically regulating T cells in the lung parenchyma, and suggests that YFTL can be used as host-directed therapies that target immune responses to mycobacterial infection.	[Fan, Xin; Li, Ning; Wang, Xiaoshuang; Zhang, Jingyu; Xu, Meiyi; Liu, Xueting; Wang, Beinan] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China; [Xu, Meiyi; Wang, Beinan] Univ Chinese Acad Sci, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Microbiology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Wang, BN (corresponding author), Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China.; Wang, BN (corresponding author), Univ Chinese Acad Sci, Beijing, Peoples R China.	wangbn@im.ac.cn		Wang, Beinan/0000-0002-9260-7197	National Major Science and Technology Project [2013ZX10005004-005]; National Natural Science Foundation of China [31370928, 31400760]	National Major Science and Technology Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by funding from the National Major Science and Technology Project Grant (2013ZX10005004-005), the National Natural Science Foundation of China Grant (31370928) and Grant (31400760) for Young Scholars. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by funding from the National Major Science and Technology Project Grant (2013ZX10005004-005), the National Natural Science Foundation of China Grant (31370928) and Grant (31400760) for Young Scholars.	Altaf M, 2010, TUBERCULOSIS, V90, P333, DOI 10.1016/j.tube.2010.09.002; Anderson KG, 2014, NAT PROTOC, V9, P209, DOI 10.1038/nprot.2014.005; Ansari AW, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00312; Brighenti S, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.TBTB2-0006-2016; Cao YG, 2009, FUND CLIN PHARMACOL, V23, P457, DOI 10.1111/j.1472-8206.2009.00696.x; Chavez-Galan L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00999; Chen K, 2013, ANNU REV IMMUNOL, V31, P605, DOI 10.1146/annurev-immunol-032712-100019; Chen MJ, 2008, J EXP MED, V205, P2791, DOI 10.1084/jem.20080767; Desvignes L, 2009, IMMUNITY, V31, P974, DOI 10.1016/j.immuni.2009.10.007; Dick T, 1998, FEMS MICROBIOL LETT, V163, P159, DOI 10.1111/j.1574-6968.1998.tb13040.x; Divangahi M, 2013, ADV EXP MED BIOL, V783, P103, DOI 10.1007/978-1-4614-6111-1_6; Dovedi SJ, 2005, J UROLOGY, V174, P332, DOI 10.1097/01.ju.0000161589.85869.ae; Erb KJ, 1999, EUR CYTOKINE NETW, V10, P147; Etna MP, 2014, SEMIN IMMUNOL, V26, P543, DOI 10.1016/j.smim.2014.09.011; Fan X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107638; Feng WJ, 2012, J NEW CHIN MED, V44, P22; Feng WJ, 2014, J HUNAN U CHIN MED, V34, P46; Friedland JS, 2014, NEW ENGL J MED, V371, P1354, DOI 10.1056/NEJMcibr1408663; Gopal R, 2012, EUR J IMMUNOL, V42, P364, DOI 10.1002/eji.201141569; Haoues M, 2012, Arch Inst Pasteur Tunis, V89, P3; Jaron B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002833; Jeevan A, 2007, CLIN EXP IMMUNOL, V149, P387, DOI 10.1111/j.1365-2249.2007.03425.x; Kalinski P, 2012, J IMMUNOL, V188, P21, DOI 10.4049/jimmunol.1101029; Larson RP, 2013, ADV EXP MED BIOL, V783, P165, DOI 10.1007/978-1-4614-6111-1_9; Lyadova IV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010469; Machelart A, 2017, DRUG DISCOV TODAY, V22, P1250, DOI 10.1016/j.drudis.2017.05.005; Mayer-Barber KD, 2014, NATURE, V511, P99, DOI 10.1038/nature13489; Mayer-Barber KD, 2015, COLD SPRING HARB PER, V5, P12; Moliva Juan I, 2017, Front Immunol, V8, P407, DOI 10.3389/fimmu.2017.00407; Orme IM, 2015, NAT IMMUNOL, V16, P57, DOI 10.1038/ni.3048; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Sachan M, 2016, CURR PHARM DESIGN, V22, P2599, DOI 10.2174/1381612822666160128150636; Sakai S, 2014, J IMMUNOL, V192, P2965, DOI 10.4049/jimmunol.1400019; Sasindran SJ, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00002; Shehzad A, 2013, BRAZ J INFECT DIS, V17, P74, DOI 10.1016/j.bjid.2012.10.009; Tobin DM, 2012, CELL, V148, P434, DOI 10.1016/j.cell.2011.12.023; Tobin DM, 2015, COLD SPRING HARB PER, V5; Tomioka H, 2017, AM J CHINESE MED, V45, P1597, DOI 10.1142/S0192415X17500860; Tripathi RP, 2012, CURR MED CHEM, V19, P488; Wang XS, 2017, J INFECT DIS, V215, P644, DOI 10.1093/infdis/jiw598; Wang YJ, 2016, J ETHNOPHARMACOL, V194, P72, DOI 10.1016/j.jep.2016.08.046; Winslow GM, 2008, IMMUNOL REV, V225, P284, DOI 10.1111/j.1600-065X.2008.00693.x; World Health Organization, GLOBAL TUBERCULOSIS; YOSHIDA A, 1995, J IMMUNOL, V155, P2057	44	7	9	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2018	13	9							e0203678	10.1371/journal.pone.0203678	http://dx.doi.org/10.1371/journal.pone.0203678			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT2UM	30204794	Green Published, Green Submitted, gold			2023-01-03	WOS:000444355500037
J	Sullivan, LB				Sullivan, Lucas B.			Metabolic Frugality Marks Cancer Cells for Immune Targeting	CELL			English	Editorial Material								Altered cell metabolism is ubiquitous in cancer cells; however, it remains challenging to exploit these alterations for cancer therapy. A new study reveals that metabolic alterations to the urea cycle promote tumor growth but unexpectedly also trigger mutations that mark cancer cells for recognition by immunotherapy.	[Sullivan, Lucas B.] Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Sullivan, LB (corresponding author), Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA.	lucas@fredhutch.org		Sullivan, Lucas/0000-0002-6745-8222				Chowell D, 2015, P NATL ACAD SCI USA, V112, pE1754, DOI 10.1073/pnas.1500973112; Delage B, 2010, INT J CANCER, V126, P2762, DOI 10.1002/ijc.25202; Garcia-Bermudez J, 2018, NAT CELL BIOL, V20, P775, DOI 10.1038/s41556-018-0118-z; Kim J, 2017, NATURE, V546, P168, DOI 10.1038/nature22359; Lee JS, 2018, CELL, V174, P1559, DOI 10.1016/j.cell.2018.07.019; Rabinovich S, 2015, NATURE, V527, P379, DOI 10.1038/nature15529; Schvartzman JM, 2018, J CELL BIOL, V217, P2247, DOI 10.1083/jcb.201803061; Sullivan LB, 2018, NAT CELL BIOL, V20, P782, DOI 10.1038/s41556-018-0125-0; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039	9	5	5	1	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	2018	174	6					1344	1346		10.1016/j.cell.2018.08.023	http://dx.doi.org/10.1016/j.cell.2018.08.023			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GS6WP	30193108	Bronze			2023-01-03	WOS:000443841000006
J	Schad, F; Thronicke, A; Steele, ML; Merkle, A; Matthes, B; Grah, C; Matthes, H				Schad, Friedemann; Thronicke, Anja; Steele, Megan L.; Merkle, Antje; Matthes, Burkhard; Grah, Christian; Matthes, Harald			Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis	PLOS ONE			English	Article							STANDARDIZED MISTLETOE EXTRACT; QUALITY-OF-LIFE; COMPLEMENTARY TREATMENT; GENDER-DIFFERENCES; SUPPORTIVE CARE; IN-VITRO; THERAPY; SAFETY; HISTOLOGY; EPIDEMIOLOGY	Background Stage IV non-small cell lung cancer (NSCLC) is associated with a five-year survival rate of around 1%. Treatment with Viscum album L. (VA) extracts has been shown to reduce chemotherapy (CTx)-related adverse events, decrease CTx dose reductions and improve quality of life in a number of cancers. Recent data suggest a beneficial effect of add-on treatment with Viscum album L. (VA, European mistletoe) on survival in cancer patients. The objective of this study was to evaluate the effect of VA in addition to chemotherapy on survival in stage IV NSCLC patients. Methods The observational study was conducted using data from the Network Oncology clinical registry which is an accredited conjoint clinical registry of German oncological hospitals, practitioners and out-patient centers.Patients were included if they had stage IV NSCLC at diagnosis, lived at least for four weeks post-diagnosis and received chemotherapeutic treatment. Patients with EGFR mutations as well as patients receiving tyrosine kinase inhibitors or immune checkpoint inhibitors were not included. Overall survival and impact on hazard in patients with chemotherapy (CTx) to patients receiving CTx plus VA were compared. To identify factors associated with survival and to address potential sources of bias a multivariate analyses using Cox proportional hazard model was performed. Results The median age of the population was 64.1 years with 55.7% male patients. The highest proportion of patients had adenocarcinoma (72.2%) and most of the patients were current or past smokers (70.9%). Of 158 stage IV NSCLC patients, 108 received CTx only and 50 additional VA. Median survival was 17.0 months in the CTx plus VA group (95%CI : 11.040.0) and was 8.0 months (95%CI: 7.0-11.0) in the CTx only group (chi(2) = 7.2, p = .007). Overall survival was significantly prolonged in the VA group (HR 0.44, 95%CI: 0.26-0.74, p = .002). One-year and three-year overall survival rates were greater with CTx plus VA compared to CTX alone (1y: 60.2% vs. 35.5%; 3y: 25.7% vs. 14.2%). Conclusion Our findings suggest that concomitant VA is positively associated with survival in stage IV NSCLC patients treated with standard CTx. These findings complement pre-existing knowldedge of add-on VA's clinical impact, however, results should be interpreted with caution in light of the study's observational character.	[Schad, Friedemann; Thronicke, Anja; Merkle, Antje; Matthes, Burkhard; Grah, Christian; Matthes, Harald] Hosp Havelhohe, Res Inst Havelhohe, Berlin, Germany; [Schad, Friedemann; Merkle, Antje; Matthes, Burkhard] Hosp Havelhohe, Interdisciplinary Oncol & Palliat Care, Berlin, Germany; [Steele, Megan L.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia; [Grah, Christian] Hosp Havelhohe, Lung Canc Ctr, Berlin, Germany; [Grah, Christian] Hosp Havelhohe, Dept Pneumol, Berlin, Germany; [Matthes, Harald] Charite Univ Med Berlin, Med Clin Gastroenterol Infectiol & Rheumatol CBF, Berlin, Germany; [Matthes, Harald] Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ CCM, Berlin, Germany	Queensland University of Technology (QUT); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schad, F (corresponding author), Hosp Havelhohe, Res Inst Havelhohe, Berlin, Germany.; Schad, F (corresponding author), Hosp Havelhohe, Interdisciplinary Oncol & Palliat Care, Berlin, Germany.	fschad@havelhoehe.de	Thronicke, Anja/AAZ-3508-2020; Thronicke, Anja/AAR-2482-2021; Matthes, Harald/AAR-2256-2021; Steele, Megan/D-8647-2013	Matthes, Harald/0000-0002-4053-4379; Steele, Megan/0000-0001-5728-8365; Thronicke, Anja/0000-0002-6421-8290	Iscador AG Arlesheim, Switzerland; ABNOBA GmbH Pforzheim, Germany; Helixor GmbH Rosenfeld, Germany	Iscador AG Arlesheim, Switzerland; ABNOBA GmbH Pforzheim, Germany; Helixor GmbH Rosenfeld, Germany	The Network Oncology was funded by unrestricted research grants from Iscador AG Arlesheim, Switzerland; ABNOBA GmbH Pforzheim, Germany; and Helixor GmbH Rosenfeld, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. By contract, researchers were independent from the funder.	Administration USFD, 2016, PEMBR KEYTRUDA CHECK; Administration USFD, 2015, FDA EXP APPR US OPD; Axtner J, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2594-5; Bar-Sela G, 2013, EUR J CANCER, V49, P1058, DOI 10.1016/j.ejca.2012.11.007; Bennouna J, 2011, LUNG CANCER, V74, P30, DOI 10.1016/j.lungcan.2011.02.004; Berg PA, 1996, GRUNDLAGEN MISTELTHE; Bock Paul R., 2014, Inflammation & Allergy Drug Targets, V13, P105; Bock PR, 2004, ARZNEIMITTELFORSCH, V54, P456; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Bussing A, 2009, EUR J MED RES, V14, P223; Bussing A, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI [10.1155/2012/219402, 10.1155/2012/165410]; Cetin Karynsa, 2011, Clin Epidemiol, V3, P139, DOI 10.2147/CLEP.S17191; Champiat S, 2016, ANN ONCOL, V27, P559, DOI 10.1093/annonc/mdv623; Chen G, 2013, ANN ONCOL, V24, P1615, DOI 10.1093/annonc/mdt012; David EA, 2017, J THORAC ONCOL, V12, P1636, DOI 10.1016/j.jtho.2017.08.008; Delebinski CI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133892; Eisenbraun J, 2011, PHYTOMEDICINE, V18, P151, DOI 10.1016/j.phymed.2010.06.013; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Emmons KM, 1999, CHEST, V116, p490S, DOI 10.1378/chest.116.suppl_3.490S; Fonnebo V, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-7; Garattini S, 2016, EUR J INTERN MED, V32, P13, DOI 10.1016/j.ejim.2016.03.020; Gardin NE, 2009, PHYTOTHER RES, V23, P407, DOI 10.1002/ptr.2643; Girard N, 2017, CLIN LUNG CANCER, V18, pE89, DOI 10.1016/j.cllc.2016.10.004; Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397; Greenlee Heather, 2014, Journal of the National Cancer Institute Monographs, P346, DOI 10.1093/jncimonographs/lgu041; Grossarth-Maticek R, 2001, ALTERN THER HEALTH M, V7, P57; Hajto T, 1998, NAT IMMUN, V16, P34, DOI 10.1159/000069428; Heinzerling L, 2006, J CLIN IMMUNOL, V26, P347, DOI 10.1007/s10875-006-9023-5; Horneber MA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003297.pub2; Hostanska K, 1995, NAT IMMUN, V14, P295; Jackman DM, 2017, J ONCOL PRACT, V13, pE346, DOI 10.1200/JOP.2017.021741; Khozin S, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx187; Kienle GS, 2007, EUR J MED RES, V12, P103; Kienle GS, 2003, EUR J MED RES, V8, P109; Kienle GS, 2003, MISTEL ONKOLOGIE FAK; Kienle GS, 2017, UBERSICHT MERKURSTAB, V70, p176 ; Kienle GS, 2017, MERKURSTAB, V3, P176; Kienle GS, 2010, INTEGR CANCER THER, V9, P142, DOI 10.1177/1534735410369673; Kim S, 2017, PHYTOMEDICINE, V36, P183, DOI 10.1016/j.phymed.2017.09.017; Kobold S, 2015, DTSCH ARZTEBL INT, V112, P809, DOI 10.3238/arztebl.2015.0809; Lange-Lindberg Anna-Maria, 2006, GMS Health Technol Assess, V2, pDoc18; Lee SJ, 2007, J CLIN IMMUNOL, V27, P477, DOI 10.1007/s10875-007-9098-7; Lynch TJ, 2014, J THORAC ONCOL, V9, P1332, DOI 10.1097/JTO.0000000000000257; Matthes H, 2010, CURR MOL MED, V10, P430, DOI 10.2174/156652410791317057; Mistletoe Bussing A., THE GENUS VISCUM2000; Mol M, 2016, J THORAC ONCOL, V11, pS138; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; Morgensztern D, 2009, J THORAC ONCOL, V4, P1524, DOI 10.1097/JTO.0b013e3181ba3634; Mulsow K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153825; Naidoo J, 2015, ANN ONCOL, V26, P2375, DOI 10.1093/annonc/mdv383; Nishijima TF, 2017, ONCOLOGIST, V22, P470, DOI 10.1634/theoncologist.2016-0419; Ostermann T, 2012, EXPLORE-NY, V8, P277, DOI 10.1016/j.explore.2012.06.005; Ostermann T, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-451; Putora PM, 2015, CLIN EXP METASTAS, V32, P143, DOI 10.1007/s10585-015-9699-0; R Core Team, 2021, R LANG ENV STAT COMP; Raez LE, 2013, CANCER CHEMOTH PHARM, V72, P1103, DOI 10.1007/s00280-013-2301-z; Rasco DW, 2010, J THORAC ONCOL, V5, P1529, DOI 10.1097/JTO.0b013e3181e9a00f; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Ribas A, 2013, NEW ENGL J MED, V368, P1365, DOI 10.1056/NEJMc1302338; Rizvi NA, 2016, J CLIN ONCOL, V34, P2969, DOI 10.1200/JCO.2016.66.9861; Sakurai H, 2010, J THORAC ONCOL, V5, P1594, DOI 10.1097/JTO.0b013e3181f1923b; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Schad F, 2018, INTEGR CANCER THER, V17, P41, DOI 10.1177/1534735416681641; Schad F, 2014, INTEGR CANCER THER, V13, P332, DOI 10.1177/1534735413513637; Schad F, 2013, FORSCH KOMPLEMENTMED, V20, P353, DOI 10.1159/000356204; SCHOENFELD DA, 1983, BIOMETRICS, V39, P499, DOI 10.2307/2531021; Schuette W, 2016, PNEUMOLOGIE, V70, P579, DOI 10.1055/s-0042-109760; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Singh BN, 2016, RSC ADV, V6, P23837, DOI 10.1039/c5ra27381a; Sobin LH, 2009, TNM CLASSIFICATION M, V7th, DOI DOI 10.1002/9780471420194.TNMC26.PUB2; Spahn G, 2013, INTEGRATIVE APPROACH; Steele M, 2014, EVID-BASED COMPL ALT, V2014, DOI DOI 10.1155/2014/724258; Steele ML, 2015, INTEGR CANCER THER, V14, P140, DOI 10.1177/1534735414563977; Steele ML, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/236310; Thies A, 2005, TOXICOLOGY, V207, P105, DOI 10.1016/j.tox.2004.09.009; Trani L, 2010, LUNG CANCER, V70, P200, DOI 10.1016/j.lungcan.2010.02.003; Troger W, 2013, EUR J CANCER, V49, P3788, DOI 10.1016/j.ejca.2013.06.043; Visbal AL, 2004, ANN THORAC SURG, V78, P209, DOI 10.1016/j.athoracsur.2003.11.021; Warren GW, 2013, J THORAC ONCOL, V8, P543, DOI 10.1097/JTO.0b013e318288dc96; Weber JS, 2017, J CLIN ONCOL, V35, P785, DOI 10.1200/JCO.2015.66.1389; Weissenstein U, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1246-2; World Health Organization, 2017, GLOB HLTH OBS; Yan H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135829; Yang JY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005599; Yoshida Y, 2016, THORAC CARDIOV SURG, V64, P507, DOI 10.1055/s-0035-1558995	85	24	24	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2018	13	8							e0203058	10.1371/journal.pone.0203058	http://dx.doi.org/10.1371/journal.pone.0203058			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR6UK	30148853	Green Submitted, gold, Green Published			2023-01-03	WOS:000442804200044
J	Navathe, AS; Emanuel, EJ; Liao, JM				Navathe, Amol S.; Emanuel, Ezekiel J.; Liao, Joshua M.			Pitfalls and Potential in Medicare's Move Toward Outpatient Care Episodes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Navathe, Amol S.; Emanuel, Ezekiel J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Navathe, Amol S.] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA; [Liao, Joshua M.] Univ Washington, Sch Med, Seattle, WA USA; [Liao, Joshua M.] UW Med Value & Syst Sci Lab, Seattle, WA USA; [Liao, Joshua M.] Univ Washington, 1959 NE Pacific St, Seattle, WA 98115 USA; [Navathe, Amol S.] Univ Penn, 423 Guardian Dr,Blockley 1108, Philadelphia, PA 19104 USA; [Emanuel, Ezekiel J.] Univ Penn, 423 Guardian Dr,Blockley 14th Floor, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Pennsylvania; University of Pennsylvania	Liao, JM (corresponding author), Univ Washington, 1959 NE Pacific St, Seattle, WA 98115 USA.	joshliao@uw.edu		Navathe, Amol/0000-0001-7182-4988				Centers for Medicare and Medicaid Services, 2018, ONC CAR MOD; Centers for Medicare & Medicaid Services, 2018, BPCI ADV; Centers for Medicare & Medicaid Services, 2017, MER BAS INC PAYM SYS; Dummit LA, 2016, JAMA-J AM MED ASSOC, V316, P1267, DOI 10.1001/jama.2016.12717; Maddox KEJ, 2018, NEW ENGL J MED, V379, P260, DOI [10.1056/NEJMsa1801369, 10.1056/NEJMsa1801569]; Navathe AS., HLTH AFFAIRS BLOG, DOI [10.1377/hblog20180828.844613/full/, DOI 10.1377/HBLOG20180828.844613/FULL]; Struijs JN, 2016, BUNDLED HLTH CARE PA; U. S. Department of Health and Human Services, 2018, PTAC PREL REV TEAMS	8	2	2	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 4	2018	169	11					802	+		10.7326/M18-2563	http://dx.doi.org/10.7326/M18-2563			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC4WR	30458472				2023-01-03	WOS:000451806000011
J	Grauzdyte, D; Pukalskas, A; Viranaicken, W; El Kalamouni, C; Venskutonis, PR				Grauzdyte, Dovile; Pukalskas, Audrius; Viranaicken, Wildriss; El Kalamouni, Chaker; Venskutonis, Petras Rimantas			Protective effects of Phyllanthus phillyreifolius extracts against hydrogen peroxide induced oxidative stress in HEK293 cells	PLOS ONE			English	Article							ANTIOXIDANT PROPERTIES; GERANIIN; CHEMISTRY; TANNINS; PLASMA; PLANTS; HEPG2; ABTS	Phyllanthus phillyreifolius, a plant species indigenous to Reunion Island, is used in folk medicine for treating diarrhea and as a diuretic. In the present study acetone and hydroethanol extracts of P. phillyreifolius were evaluated for their cytotoxicity and antioxidant effects using in vitro (TPC, ABTS, DPPH, FRAP, ORAC) and in cellulo (MIT, DCFH-DA, RT-qPCR) assays. Major compounds were evaluated using UPLC-QTOF-MS. MTT cell viability assay showed low cytotoxicity of extracts towards human embryonic kidney 293 (HEK293) cell line. Both extracts were rich in polyphenols (mainly ellagitannins) and showed high antioxidant potential and intracellular ROS decreasing effect. Preconditioning of HEK293 cells with extracts influenced gene expression of antioxidant enzymes, however ROS level decreasing effect was more related to their capacity to scavenge free radicals and with their reducing power. Strong antioxidant activity of extracts as well as the presence of geraniin supports the use of P. phillyreifolius in traditional medicine.	[Grauzdyte, Dovile; Pukalskas, Audrius; Venskutonis, Petras Rimantas] Kaunas Univ Technol, Dept Food Sci & Technol, Kaunas, Lithuania; [Viranaicken, Wildriss; El Kalamouni, Chaker] Univ la Reunion, PIMIT, Plateforme Technol CYROI, IRD UMR249,INSERM,U1187,CNRS,UMR9192,UM 134, St Clotilde, France	Kaunas University of Technology; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut National de la Sante et de la Recherche Medicale (Inserm); University of La Reunion	Venskutonis, PR (corresponding author), Kaunas Univ Technol, Dept Food Sci & Technol, Kaunas, Lithuania.; El Kalamouni, C (corresponding author), Univ la Reunion, PIMIT, Plateforme Technol CYROI, IRD UMR249,INSERM,U1187,CNRS,UMR9192,UM 134, St Clotilde, France.	chaker.el-kalamouni@univ-reunion.fr; rimas.venskutonis@ktu.lt	Venskutonis, Petras Rimantas/A-1498-2008	Venskutonis, Petras Rimantas/0000-0002-6063-8132; El Kalamouni, Chaker/0000-0003-4673-6614	Campus France [841528E]	Campus France	This study was supported by the grant from Campus France, dossier no841528E to DG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agbor GA, 2014, PHARM BIOL, V52, P1128, DOI 10.3109/13880209.2013.879189; Alia M, 2006, TOXICOL APPL PHARM, V212, P110, DOI 10.1016/j.taap.2005.07.014; Bagalkotkar G, 2006, J PHARM PHARMACOL, V58, P1559, DOI 10.1211/jpp.58.12.0001; Baret P, 2013, INT J BIOCHEM CELL B, V45, P167, DOI 10.1016/j.biocel.2012.10.007; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25; Chen PX, 2017, J FUNCT FOODS, V38, P675, DOI 10.1016/j.jff.2016.12.027; Cheng HS, 2017, PHYTOCHEM REV, V16, P159, DOI 10.1007/s11101-016-9464-2; Eldeen IMS, 2011, S AFR J BOT, V77, P75, DOI 10.1016/j.sajb.2010.05.009; FOO LY, 1992, PHYTOCHEMISTRY, V31, P711, DOI 10.1016/0031-9422(92)90071-W; Frumence E, 2016, VIROLOGY, V493, P217, DOI 10.1016/j.virol.2016.03.006; Girard-Lalancette K, 2009, FOOD CHEM, V115, P720, DOI 10.1016/j.foodchem.2008.12.002; Hossen MJ, 2015, J ETHNOPHARMACOL, V168, P217, DOI 10.1016/j.jep.2015.03.043; Huang DJ, 2005, J AGR FOOD CHEM, V53, P1841, DOI 10.1021/jf030723c; Kellett ME, 2018, FOOD CHEM, V244, P359, DOI 10.1016/j.foodchem.2017.10.035; Klaunig JE, 2011, TOXICOL APPL PHARM, V254, P86, DOI 10.1016/j.taap.2009.11.028; Kumar J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118255; Kumar J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098696; Luger P, 1998, ACTA CRYSTALLOGR B, V54, P687, DOI 10.1107/S0108768198000081; Masella R, 2005, J NUTR BIOCHEM, V16, P577, DOI 10.1016/j.jnutbio.2005.05.013; Nabavi SF, 2015, NUTRIENTS, V7, P7708, DOI 10.3390/nu7095361; Okuda T, 2011, MOLECULES, V16, P2191, DOI 10.3390/molecules16032191; Olejnik A, 2016, FOOD CHEM, V190, P1069, DOI 10.1016/j.foodchem.2015.06.080; Patel JR, 2011, J ETHNOPHARMACOL, V138, P286, DOI 10.1016/j.jep.2011.09.040; Perera A, 2015, TRENDS FOOD SCI TECH, V44, P243, DOI 10.1016/j.tifs.2015.04.010; Poullain C, 2004, J ETHNOPHARMACOL, V95, P19, DOI 10.1016/j.jep.2004.05.023; Prior RL, 2003, J AGR FOOD CHEM, V51, P3273, DOI 10.1021/jf0262256; Qader SW, 2011, MOLECULES, V16, P3433, DOI 10.3390/molecules16043433; Quideau, 2009, CHEM BIOL ELLAGITANN; Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3; Schaich KM, 2015, J FUNCT FOODS, V14, P111, DOI 10.1016/j.jff.2015.01.043; Septembre-Malaterre A, 2016, FOOD CHEM, V212, P225, DOI 10.1016/j.foodchem.2016.05.147; Singleton VL, 1999, METHOD ENZYMOL, V299, P152; Sowndhararajan K, 2015, SAUDI J BIOL SCI, V22, P685, DOI 10.1016/j.sjbs.2015.03.010; Sprenger RD, 2013, J CHROMATOGR A, V1291, P97, DOI 10.1016/j.chroma.2013.03.030; Tuominen A, 2013, PHYTOCHEMISTRY, V95, P394, DOI 10.1016/j.phytochem.2013.05.013; vanSteensel F. J. A, 2015, J INFLAMM, P1; Wang P, 2015, BBA-GEN SUBJECTS, V1850, P1751, DOI 10.1016/j.bbagen.2015.04.010; Wang X, 2010, J ETHNOPHARMACOL, V127, P424, DOI 10.1016/j.jep.2009.10.022	39	19	19	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2018	13	11							e0207672	10.1371/journal.pone.0207672	http://dx.doi.org/10.1371/journal.pone.0207672			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA6WB	30444889	Green Published, gold, Green Submitted			2023-01-03	WOS:000450420900051
J	Eggmann, S; Verra, ML; Luder, G; Takala, J; Jakob, SM				Eggmann, Sabrina; Verra, Martin L.; Luder, Gere; Takala, Jukka; Jakob, Stephan M.			Effects of early, combined endurance and resistance training in mechanically ventilated, critically ill patients: A randomised controlled trial	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; HANDGRIP STRENGTH; ACQUIRED WEAKNESS; CRITICAL ILLNESS; MUSCLE STRENGTH; WALK TEST; REHABILITATION; SURVIVORS; EXERCISE; MOBILIZATION	Introduction Neuromuscular weakness resulting in severe functional impairment is common in critical care survivors. This study aimed to evaluate effects of an early progressive rehabilitation intervention in mechanically ventilated adults at risk. Methods This was a parallel, two-arm, assessor-blinded, randomised controlled trial with 6-months follow-up that was conducted in a mixed ICU of an academic centre in Switzerland. Previously independent, mechanically ventilated, critically ill adults with expected critical care stay >= 72 hours (n = 115) were randomised to a control group receiving standard physiotherapy including early mobilisation or to an experimental group with early endurance and resistance training combined with mobilisation. Primary endpoints were functional capacity (6-Minute Walk Distance) and functional independence (Functional Independence Measure) at hospital discharge. Secondary endpoints including muscle strength were assessed at critical care discharge. Safety was monitored closely by standard monitoring and predefined adverse events. Results Physiotherapy started within 48 hours of critical care admission while 97% of participants were still ventilated and 68% on inotropes. Compared to the control group (n = 57), the experimental group (n = 58) received significantly more physiotherapy (sessions: 407 vs 377, p<0.001; time/session: 25min vs 18min, p<0.001) and had less days with sedation (p<0.001). Adverse events were rare (0.6%) and without consequences. There were no significant between-group differences in 6-Minute Walk Distance (experimental 123m (IQR 25-280) vs control 100m (IQR 0-300); p = 0.542) or functional independence (98 (IQR 66119) vs 98 (IQR 18-115); p = 0.308). Likewise, no differences were found for the secondary outcomes, except a trend towards improved mental health in the experimental group after 6 months (84 (IQR 68-88) vs 70 (IQR 64-76); p = 0.023). Conclusions Early endurance and resistance training in mechanically ventilated, intensive care patients does not improve functional capacity or independence at hospital discharge compared to early standard physiotherapy but may improve mental health 6-months after critical care discharge.	[Eggmann, Sabrina; Verra, Martin L.; Luder, Gere] Bern Univ Hosp, Inselspital, Dept Physiotherapy, Bern, Switzerland; [Takala, Jukka; Jakob, Stephan M.] Univ Bern, Bern Univ Hosp, Inselspital, Dept Intens Care Med, Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Eggmann, S (corresponding author), Bern Univ Hosp, Inselspital, Dept Physiotherapy, Bern, Switzerland.	sabrina.eggmann@insel.ch	Eggmann, Sabrina/J-2951-2019; Luder, Gere/A-3508-2012; Verra, Martin/R-5285-2016	Eggmann, Sabrina/0000-0002-7379-7343; Luder, Gere/0000-0003-4742-4225; Verra, Martin/0000-0002-3933-8020	Departments of Physiotherapy and Intensive Care Medicine at the Inselspital, Bern University Hospital, Bern, Switzerland	Departments of Physiotherapy and Intensive Care Medicine at the Inselspital, Bern University Hospital, Bern, Switzerland	This study was self-funded and supported by the Departments of Physiotherapy and Intensive Care Medicine at the Inselspital, Bern University Hospital, Bern, Switzerland. None of the authors received funding for this work.	Ali NA, 2008, AM J RESP CRIT CARE, V178, P261, DOI 10.1164/rccm.200712-1829OC; Baldwin CE, 2013, J CRIT CARE, V28, P77, DOI 10.1016/j.jcrc.2012.03.001; Bellet RN, 2012, PHYSIOTHERAPY, V98, P277, DOI 10.1016/j.physio.2011.11.003; Bernhardt J, 2016, NEUROLOGY, V86, P2138, DOI 10.1212/WNL.0000000000002459; Bernhardt J, 2015, LANCET, V386, P46, DOI 10.1016/S0140-6736(15)60690-0; Bienvenu OJ, 2018, INTENS CARE MED, V44, P38, DOI 10.1007/s00134-017-5009-4; Burtin C, 2009, CRIT CARE MED, V37, P2499, DOI 10.1097/CCM.0b013e3181a38937; Chan KS, 2015, CHEST, V147, P1316, DOI 10.1378/chest.14-1808; Clavet H, 2008, CAN MED ASSOC J, V178, P691, DOI 10.1503/cmaj.071056; Collings N, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/1471-2253-15-1; Cournan M, 2011, REHABIL NURS, V36, P111, DOI 10.1002/j.2048-7940.2011.tb00075.x; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; De Jonghe B, 2007, CRIT CARE MED, V35, P2007, DOI 10.1097/01.ccm.0000281450.01881.d8; Denehy L, 2013, CRIT CARE, V17, DOI 10.1186/cc12835; Doig GS, 2005, J CRIT CARE, V20, P187, DOI 10.1016/j.jcrc.2005.04.005; Eggmann S., 2015, PHYSIOTHERAPY, V101, pe344, DOI [10.1016/j.physio.2015.03.553, DOI 10.1016/J.PHYSIO.2015.03.553]; Eggmann S, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1533-8; Fan E, 2014, CRIT CARE MED, V42, P849, DOI 10.1097/CCM.0000000000000040; Ferrante LE, 2015, JAMA INTERN MED, V175, P523, DOI 10.1001/jamainternmed.2014.7889; Fossat G, 2018, JAMA-J AM MED ASSOC, V320, P368, DOI 10.1001/jama.2018.9592; Friedrich O, 2015, PHYSIOL REV, V95, P1025, DOI 10.1152/physrev.00028.2014; Fritz CO, 2012, J EXP PSYCHOL GEN, V141, P2, DOI 10.1037/a0024338; Griffith DM, 2018, CRIT CARE MED, V46, P1376, DOI 10.1097/CCM.0000000000003234; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hermans G, 2014, AM J RESP CRIT CARE, V190, P410, DOI 10.1164/rccm.201312-2257OC; Hermans G, 2012, MUSCLE NERVE, V45, P18, DOI 10.1002/mus.22219; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Heyland DK, 2000, CRIT CARE MED, V28, P3599, DOI 10.1097/00003246-200011000-00006; Hickmann CE, 2018, CRIT CARE MED, V46, P1436, DOI 10.1097/CCM.0000000000003263; Hodgson CL, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0658-y; Jakob SM, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1730-1; Kayambu G, 2015, INTENS CARE MED, V41, P865, DOI 10.1007/s00134-015-3763-8; Kho ME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167561; McCarthy B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub3; Mehrholz J, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008828; Morris PE, 2016, JAMA-J AM MED ASSOC, V315, P2694, DOI 10.1001/jama.2016.7201; Moss M, 2016, AM J RESP CRIT CARE, V193, P1101, DOI 10.1164/rccm.201505-1039OC; Norrenberg M, 2000, INTENS CARE MED, V26, P988, DOI 10.1007/s001340051292; Pfoh ER, 2016, INTENS CARE MED, V42, P1557, DOI 10.1007/s00134-016-4530-1; Pires-Neto RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074182; Ploutz-Snyder LL, 2014, MED SCI SPORT EXER, V46, P358, DOI 10.1249/MSS.0b013e3182a62f85; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Puthucheary ZA, 2013, JAMA-J AM MED ASSOC, V310, P1591, DOI 10.1001/jama.2013.278481; Redelmeier DA, 1997, AM J RESP CRIT CARE, V155, P1278, DOI 10.1164/ajrccm.155.4.9105067; Schaller SJ, 2016, LANCET, V388, P1377, DOI 10.1016/S0140-6736(16)31637-3; Schefold JC, 2017, CRIT CARE MED, V45, P2061, DOI 10.1097/CCM.0000000000002765; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Stevens Robert D, 2009, Crit Care Med, V37, pS299, DOI 10.1097/CCM.0b013e3181b6ef67; Takala J, 2008, INTENS CARE MED, V34, P1401, DOI 10.1007/s00134-008-1084-x; Tanner RE, 2015, J PHYSIOL-LONDON, V593, P4259, DOI 10.1113/JP270699; van der Schaaf M, 2009, J REHABIL MED, V41, P1041, DOI 10.2340/16501977-0443; Wright SE, 2018, THORAX, V73, P213, DOI 10.1136/thoraxjnl-2016-209858	53	36	37	4	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2018	13	11							e0207428	10.1371/journal.pone.0207428	http://dx.doi.org/10.1371/journal.pone.0207428			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA3GQ	30427933	Green Published, gold, Green Submitted			2023-01-03	WOS:000450138500100
J	Marfil-Garza, BA; Belaunzaran-Zamudio, PF; Gulias-Herrero, A; Zuniga, AC; Caro-Vega, Y; Kershenobich-Stalnikowitz, D; Sifuentes-Osornio, J				Marfil-Garza, Braulio A.; Belaunzaran-Zamudio, Pablo F.; Gulias-Herrero, Alfonso; Camiro Zuniga, Antonio; Caro-Vega, Yanink; Kershenobich-Stalnikowitz, David; Sifuentes-Osornio, Jose			Risk factors associated with prolonged hospital length-of-stay: 18-year retrospective study of hospitalizations in a tertiary healthcare center in Mexico	PLOS ONE			English	Article							MORTALITY; SURGERY; COMPLICATIONS	Background Hospital length-of-Stay has been traditionally used as a surrogate to evaluate healthcare efficiency, as well as hospital resource utilization. Prolonged Length-of-stay (PLOS) is associated with increased mortality and other poor outcomes. Additionally, these patients represent a significant economic problem on public health systems and their families. We sought to describe and compare characteristics of patients with Normal hospital Length-of-Stay (NLOS) and PLOS to identify sociodemographic and disease-specific factors associated with PLOS in a tertiary care institution that attends adults with complicated diseases from all over Mexico. Materials and methods We conducted a retrospective analysis of hospital discharges from January 2000-December 2017 using institutional databases of medical records. We compared NLOS and PLOS using descriptive and inferential statistics. PLOS were defined as those above the 95th percentile of length of hospitalization. Results We analyzed 85,904 hospitalizations (1,069,875 bed-days), of which 4,427 (5.1%) were PLOS (247,428 bed-days, 23.1% of total bed-days). Hematological neoplasms were the most common discharge diagnosis and surgery of the small bowel was the most common type of surgery. Younger age, male gender, a lower physician-to-patient ratio, emergency and weekend admissions, surgery, the number of comorbidities, residence outside Mexico City and lower socioeconomic status were associated with PLOS. Bone marrow transplant (OR 18.39 [95% CI 12.50-27.05, p<0.001), complex infectious diseases such as systemic mycoses and parasitoses (OR 4.65 [95% CI 3.40-6.63, p<0.001), and complex abdominal diseases such as intestinal fistula (OR 2.57 [95% CI 1.98-3.32) had the greatest risk for PLOS. Risk of mortality in patients with PLOS increased more than threefold (3.7% vs 13.3%, p<0.001). Conclusions We report some key sociodemographic and disease-specific differences in patients with PLOS. These could serve to develop a specific model of directed hospital healthcare for patients identified as in risk of PLOS.	[Marfil-Garza, Braulio A.; Gulias-Herrero, Alfonso; Kershenobich-Stalnikowitz, David; Sifuentes-Osornio, Jose] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico; [Belaunzaran-Zamudio, Pablo F.; Camiro Zuniga, Antonio; Caro-Vega, Yanink; Sifuentes-Osornio, Jose] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Mexico City, DF, Mexico	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico	Sifuentes-Osornio, J (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.; Sifuentes-Osornio, J (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infectol, Mexico City, DF, Mexico.	jose.sifuenteso@incmnsz.mx	camiro, antonio/AGW-3423-2022; Marfil-Garza, Braulio A/AAQ-4959-2020; Belaunzaran-Zamudio, Pablo/T-4218-2019; Belaunzarán-Zamudio, Pablo Francisco/T-4085-2019	camiro, antonio/0000-0003-0957-9509; Marfil-Garza, Braulio A/0000-0002-7224-2127; Belaunzaran-Zamudio, Pablo/0000-0003-4775-4734; Sifuentes-Osornio, Jose/0000-0001-9584-1360				Baek H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195901; Bentes ME, 1993, EVALUATION EXPERIENC, P173; Butterworth J, 2000, ANESTHESIOLOGY, V92, P414, DOI 10.1097/00000542-200002000-00023; Chaudhury H, 2005, ENVIRON BEHAV, V37, P760, DOI 10.1177/0013916504272658; Collins TC, 1999, ANN SURG, V230, P251, DOI 10.1097/00000658-199908000-00016; Cyganska M, 2016, PROC ECON FINANC, V39, P251, DOI 10.1016/S2212-5671(16)30320-3; Donze JD, 2016, JAMA INTERN MED, V176, P496, DOI 10.1001/jamainternmed.2015.8462; Fischer C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112282; Freitas A, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-265; Gutierrez J.P., 2012, ENCUESTA NACL SALUD; Jarman B, 1999, BMJ-BRIT MED J, V318, P1515, DOI 10.1136/bmj.318.7197.1515; Kastor A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196106; Kelly M, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-77; Krell RW, 2014, JAMA SURG, V149, P815, DOI 10.1001/jamasurg.2014.629; Kripalani S, 2014, ANNU REV MED, V65, P471, DOI 10.1146/annurev-med-022613-090415; Kuwabara Kazuaki, 2008, Environmental Health and Preventive Medicine, V13, P130, DOI 10.1007/s12199-007-0022-9; Marshall Adele, 2005, Health Care Manag Sci, V8, P213, DOI 10.1007/s10729-005-2012-z; McIntyre D, 2006, SOC SCI MED, V62, P858, DOI 10.1016/j.socscimed.2005.07.001; Ono T, 2010, PSYCHOGERIATRICS, V10, P153, DOI 10.1111/j.1479-8301.2010.00328.x; Pirson Magali, 2006, Eur J Health Econ, V7, P55, DOI 10.1007/s10198-005-0331-0; Puentes-Rosas E, 2011, SALUD PUBLICA MEXICO, V53, pS480; Ruiz M, 2015, BMJ QUAL SAF, V24, P492, DOI 10.1136/bmjqs-2014-003467; Stausberg J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143365; WHO, GLOB HLTH EXP DAT; Williams TA, 2010, BRIT J ANAESTH, V104, P459, DOI 10.1093/bja/aeq025	25	24	24	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2018	13	11							e0207203	10.1371/journal.pone.0207203	http://dx.doi.org/10.1371/journal.pone.0207203			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ5ZX	30408118	gold, Green Submitted, Green Published			2023-01-03	WOS:000449512300090
J	Mathew, J; Danion, FR				Mathew, James; Danion, Frederic R.			Ups and downs in catch-up saccades following single-pulse TMS-methodological considerations	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; PURSUIT EYE-MOVEMENTS; PRIMARY MOTOR CORTEX; SMOOTH-PURSUIT; COIL ORIENTATION; HEAD MOVEMENTS; CONTROL-SYSTEM; CEREBELLUM; TRACKING; COORDINATION	Transcranial magnetic stimulation (TMS) can interfere with smooth pursuit or with saccades initiated from a fixed position toward a fixed target, but little is known about the effect of TMS on catch-up saccade made to assist smooth pursuit. Here we explored the effect of TMS on catch-up saccades by means of a situation in which the moving target was driven by an external agent, or moved by the participants' hand, a condition known to decrease the occurrence of catch-up saccade. Two sites of stimulation were tested, the vertex and M1 hand area. Compared to conditions with no TMS, we found a consistent modulation of saccadic activity after TMS such that it decreased at 40-100ms, strongly resumed at 100-160ms, and then decreased at 200-300ms. Despite this modulatory effect, the accuracy of catch-up saccade was maintained, and the mean saccadic activity over the 0-300ms period remained unchanged. Those findings are discussed in the context of studies showing that single-pulse TMS can induce widespread effects on neural oscillations as well as perturbations in the latency of saccades during reaction time protocols. At a more general level, despite challenges and interpretational limitations making uncertain the origin of this modulatory effect, our study provides direct evidence that TMS over presumably non-oculomotor regions interferes with the initiation of catch-up saccades, and thus offers methodological considerations for future studies that wish to investigate the underlying neural circuitry of catch-up saccades using TMS.	[Mathew, James; Danion, Frederic R.] Aix Marseille Univ, Inst Neurosci Timone, CNRS, UMR 7289, Marseille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Danion, FR (corresponding author), Aix Marseille Univ, Inst Neurosci Timone, CNRS, UMR 7289, Marseille, France.	frederic.danion@univ-amu.fr	Danion, Frederic/ABS-1799-2022	mathew, james/0000-0002-5315-5212	European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie [642961]	European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie	This work was part of Innovative Training Network 'Perception and Action in Complex Environment' (http://itn-pace.eu/) that has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 642961. This paper reflects only the authors' view and that the Research Executive Agency (REA) of the European Commission is not responsible for any use that may be made of the information it contains. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANGEL RW, 1972, J EXP PSYCHOL, V96, P92, DOI 10.1037/h0033457; Ariff G, 2002, J NEUROSCI, V22, P7721; BRASILNETO JP, 1992, J CLIN NEUROPHYSIOL, V9, P132, DOI 10.1097/00004691-199201000-00014; Buttner-Ennever JA, 2004, HUMAN NERVOUS SYSTEM, P479; Carlsen AN, 2004, J MOTOR BEHAV, V36, P253, DOI 10.3200/JMBR.36.3.253-264; Castellote JM, 2007, EXP BRAIN RES, V177, P129, DOI 10.1007/s00221-006-0659-4; Chen J, 2016, J NEUROPHYSIOL, V116, P18, DOI 10.1152/jn.00184.2016; Colnaghi S, 2010, FUNCT NEUROL, V25, P165; de Brouwer S, 2002, J NEUROPHYSIOL, V87, P1646, DOI 10.1152/jn.00432.2001; de Xivry JJO, 2007, J PHYSIOL-LONDON, V584, P11, DOI 10.1113/jphysiol.2007.139881; de Xivry JJO, 2006, J NEUROPHYSIOL, V95, P418, DOI 10.1152/jn.00596.2005; Fuggetta G, 2005, NEUROIMAGE, V27, P896, DOI 10.1016/j.neuroimage.2005.05.013; Gagnon D, 2006, J NEUROSCI, V26, P458, DOI 10.1523/JNEUROSCI.2789-05.2006; Goffart L, 2017, PROG BRAIN RES, V236, P243, DOI 10.1016/bs.pbr.2017.07.009; Haarmeier T, 2010, CEREB CORTEX, V20, P2234, DOI 10.1093/cercor/bhp285; Haith AM, 2016, J NEUROSCI, V36, P3007, DOI 10.1523/JNEUROSCI.3245-15.2016; Krauzlis RJ, 2004, J NEUROPHYSIOL, V91, P591, DOI 10.1152/jn.00801.2003; Krauzlis RJ, 2000, J NEUROPHYSIOL, V84, P876, DOI 10.1152/jn.2000.84.2.876; Landelle C, 2016, J NEUROPHYSIOL, V116, P1859, DOI 10.1152/jn.00007.2016; MATHER J, 1975, EXP BRAIN RES, V24, P103; Mathew J, 2017, J NEUROSCI, V37, P9730, DOI 10.1523/JNEUROSCI.0564-17.2017; MILLS KR, 1992, ELECTROEN CLIN NEURO, V85, P17, DOI 10.1016/0168-5597(92)90096-T; Nagel M, 2003, J NEUROL SCI, V213, P35, DOI 10.1016/S0022-510X(03)00145-X; Nagel M, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-89; Nuding U, 2009, CEREB CORTEX, V19, P1144, DOI 10.1093/cercor/bhn162; Nyffeler T, 2004, EUR J NEUROSCI, V20, P2240, DOI 10.1111/j.1460-9568.2004.03667.x; Ohtsuka K, 1998, BRAIN, V121, P429, DOI 10.1093/brain/121.3.429; Paus T, 2001, J NEUROPHYSIOL, V86, P1983, DOI 10.1152/jn.2001.86.4.1983; PRIORI A, 1993, BRAIN, V116, P355, DOI 10.1093/brain/116.2.355; Ro T, 1997, J COGNITIVE NEUROSCI, V9, P433, DOI 10.1162/jocn.1997.9.4.433; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Scarchilli K, 1999, NEUROSCI LETT, V265, P139, DOI 10.1016/S0304-3940(99)00224-4; STEINBACH MJ, 1968, SCIENCE, V161, P187, DOI 10.1126/science.161.3837.187; Takagi M, 1998, J NEUROPHYSIOL, V80, P1911, DOI 10.1152/jn.1998.80.4.1911; Takagi M, 2000, J NEUROPHYSIOL, V83, P2047, DOI 10.1152/jn.2000.83.4.2047; Thickbroom GW, 1996, J NEUROL SCI, V144, P114, DOI 10.1016/S0022-510X(96)00194-3; Valero-Cabre A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038674; Valls-Sole J, 1999, J PHYSIOL-LONDON, V516, P931, DOI 10.1111/j.1469-7793.1999.0931u.x; Van Der Werf YD, 2006, EXP BRAIN RES, V175, P246, DOI 10.1007/s00221-006-0548-x; Van der Werf YD, 2006, EXP BRAIN RES, V175, P231, DOI 10.1007/s00221-006-0551-2; Vercher JL, 2003, PROG BRAIN RES, V142, P203; Vernet M, 2014, FRONT INTEGR NEUROSC, V8, DOI 10.3389/fnint.2014.00066; Xu-Wilson M, 2011, J NEUROSCI, V31, P11537, DOI 10.1523/JNEUROSCI.1584-11.2011; Zangemeister WH, 2001, ACTA OTO-LARYNGOL, P140	44	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2018	13	10							e0205208	10.1371/journal.pone.0205208	http://dx.doi.org/10.1371/journal.pone.0205208			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW7TO	30307976	Green Submitted, gold, Green Published			2023-01-03	WOS:000447173500047
J	Papademetriou, I; Vedula, E; Charest, J; Porter, T				Papademetriou, Iason; Vedula, Else; Charest, Joseph; Porter, Tyrone			Effect of flow on targeting and penetration of angiopep-decorated nanoparticles in a microfluidic model blood-brain barrier	PLOS ONE			English	Article							IN-VITRO MODEL; MICROVASCULAR ENDOTHELIAL-CELLS; ORGANS-ON-CHIPS; SHEAR-STRESS; DRUG-DELIVERY; HYDRAULIC CONDUCTIVITY; ADHESION MOLECULE-1; CARBON NANOTUBES; PERMEABILITY; TRANSPORT	The blood-brain barrier (BBB) limits transport of nanoparticles from the circulation to the brain parenchyma. Angiopep-2, a peptide which functions as a brain transport vector, can be coupled to nanoparticles in order to facilitate binding and internalization by brain endothelial cells (ECs), and subsequent BBB penetration. This multi-step process may be affected by blood flow over brain ECs, as flow influences endothelial cell phenotype as well as interactions of nanoparticles with ECs. In the present study a microfluidic BBB model was constructed to evaluate binding and internalization by brain ECs, as well as BBB penetration of Angiopep-2 coupled liposomes (Ang2-Liposomes) in static and flow conditions. Ang2 conjugation to liposomes markedly improved binding relative to unconjugated liposomes. Ang2-Liposomes bound and were internalized efficiently by brain endothelial cells after static incubation or with 1 dyne/cm(2) of fluid shear stress (FSS), while binding was reduced at a FSS of 6 dyne/cm(2). Penetration of the model microfluidic BBB by Ang2-Liposomes was higher at a FSS of 1 dyne/cm(2) and 6 dyne/cm(2) than with static incubation. Analysis of barrier function and control experiments for receptor-mediated penetration provided insight into the magnitude of transcellular versus paracellular transport at each tested FSS. Overall, the results demonstrate that flow impacted the binding and BBB penetration of Ang2-functionalized nanoparticles. This highlights the relevance of the local flow environment for in vitro modeling of the performance of nanoparticles functionalized with BBB penetrating ligands.	[Papademetriou, Iason; Porter, Tyrone] Boston Univ, Dept Mech Engn, Boston, MA 02215 USA; [Papademetriou, Iason; Vedula, Else; Charest, Joseph] Draper Lab, Human Organ Syst, Cambridge, MA USA; [Porter, Tyrone] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA	Boston University; Boston University	Porter, T (corresponding author), Boston Univ, Dept Mech Engn, Boston, MA 02215 USA.; Porter, T (corresponding author), Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.	tmp@bu.edu	Porter, Tyrone/GSD-7665-2022		National Institutes of Health [R01EB016102, R21 NS105837]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding for this study was provided by the National Institutes of Health grants R01EB016102 and R21 NS105837 (TP), www.nih.gov. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott NJ, 2013, J INHERIT METAB DIS, V36, P437, DOI 10.1007/s10545-013-9608-0; Achyuta AKH, 2013, LAB CHIP, V13, P542, DOI 10.1039/c2lc41033h; Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev-bioeng-071811-150124, 10.1146/annurev.bioeng-071811-150124]; Apawu AK, 2018, NANOMED-NANOTECHNOL, V14, P1999, DOI 10.1016/j.nano.2018.04.003; Bhatia SN, 2014, NAT BIOTECHNOL, V32, P760, DOI 10.1038/nbt.2989; Bhowmick T, 2012, J CONTROL RELEASE, V157, P485, DOI 10.1016/j.jconrel.2011.09.067; Blanchette M, 2015, MECH DEVELOP, V138, P8, DOI 10.1016/j.mod.2015.07.007; Booth R, 2014, ANN BIOMED ENG, V42, P2379, DOI 10.1007/s10439-014-1086-5; Booth R, 2012, LAB CHIP, V12, P1784, DOI 10.1039/c2lc40094d; Brown JA, 2015, BIOMICROFLUIDICS, V9, DOI 10.1063/1.4934713; Calderon AJ, 2009, BIORHEOLOGY, V46, P323, DOI 10.3233/BIR-2009-0544; Charoenphol P, 2012, J BIOMECH, V45, P2822, DOI 10.1016/j.jbiomech.2012.08.035; Charoenphol P, 2010, BIOMATERIALS, V31, P1392, DOI 10.1016/j.biomaterials.2009.11.007; Cho A, 1997, CIRC RES, V81, P328, DOI 10.1161/01.RES.81.3.328; Cho HS, 2015, SCI REP-UK, V5, DOI 10.1038/srep15222; Colgan OC, 2007, AM J PHYSIOL-HEART C, V292, pH3190, DOI 10.1152/ajpheart.01177.2006; Cooley M, 2018, NANOSCALE, V10, P15350, DOI 10.1039/c8nr04042g; Cucullo L, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-18; Cucullo L, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-40; DAVIES PF, 1984, J CLIN INVEST, V73, P1121, DOI 10.1172/JCI111298; Deli MA, 2011, SOLUBILITY, DELIVERY AND ADME PROBLEMS OF DRUGS AND DRUG CANDIDATES, P144; Demaio L, 2001, AM J PHYSIOL-HEART C, V281, pH105, DOI 10.1152/ajpheart.2001.281.1.H105; Demeule M, 2008, J PHARMACOL EXP THER, V324, P1064, DOI 10.1124/jpet.107.131318; Demeule M, 2008, J NEUROCHEM, V106, P1534, DOI 10.1111/j.1471-4159.2008.05492.x; Deosarkar SP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142725; DeStefano JG, 2017, FLUIDS BARRIERS CNS, V14, DOI 10.1186/s12987-017-0068-z; Dimmeler S, 1996, FEBS LETT, V399, P71, DOI 10.1016/S0014-5793(96)01289-6; Doshi N, 2010, J CONTROL RELEASE, V146, P196, DOI 10.1016/j.jconrel.2010.04.007; Engelhardt B, 2017, NAT IMMUNOL, V18, P123, DOI 10.1038/ni.3666; Eniola AO, 2003, BIOPHYS J, V85, P2720, DOI 10.1016/S0006-3495(03)74695-5; Esch EW, 2015, NAT REV DRUG DISCOV, V14, P248, DOI 10.1038/nrd4539; Farokhzad OC, 2005, ANAL CHEM, V77, P5453, DOI 10.1021/ac050312q; Fish MB, 2017, BIOMATERIALS, V124, P169, DOI 10.1016/j.biomaterials.2017.02.002; Frohlich EM, 2013, LAB CHIP, V13, P2311, DOI 10.1039/c3lc50199j; Frohlich EM, 2012, INTEGR BIOL-UK, V4, P75, DOI 10.1039/c1ib00096a; Fromen CA, 2016, BIOENG TRANSL MED, V1, P103, DOI 10.1002/btm2.10008; Gao HL, 2011, BIOMATERIALS, V32, P8669, DOI 10.1016/j.biomaterials.2011.07.069; Gao JQ, 2013, BIOMATERIALS, V34, P5628, DOI 10.1016/j.biomaterials.2013.03.097; Gao XH, 2013, PHARM RES-DORDR, V30, P2538, DOI 10.1007/s11095-013-1004-9; Gooch KJ, 1997, J CELL PHYSIOL, V171, P252, DOI 10.1002/(SICI)1097-4652(199706)171:3<252::AID-JCP3>3.3.CO;2-3; Hajal C, 2018, BIOMICROFLUIDICS, V12, DOI 10.1063/1.5027118; Han JY, 2015, J CONTROL RELEASE, V210, P39, DOI 10.1016/j.jconrel.2015.05.006; Han JY, 2012, ACS NANO, V6, P8824, DOI 10.1021/nn302687n; Helms HC, 2016, J CEREBR BLOOD F MET, V36, P862, DOI 10.1177/0271678X16630991; Ishibazawa A, 2013, EXP EYE RES, V116, P308, DOI 10.1016/j.exer.2013.10.001; Jamieson JJ, 2017, J BIOL ENG, V11, DOI 10.1186/s13036-017-0076-1; JO H, 1991, AM J PHYSIOL, V260, pH1992, DOI 10.1152/ajpheart.1991.260.6.H1992; Johnsen KB, 2018, THERANOSTICS, V8, P3416, DOI 10.7150/thno.25228; Kafa H, 2016, J CONTROL RELEASE, V225, P217, DOI 10.1016/j.jconrel.2016.01.031; Kang H, 2014, ATHEROSCLEROSIS, V233, P682, DOI 10.1016/j.atherosclerosis.2014.01.056; Ke WL, 2009, BIOMATERIALS, V30, P6976, DOI 10.1016/j.biomaterials.2009.08.049; Khor SY, 2018, SMALL, V14, DOI 10.1002/smll.201801702; Kim JA, 2015, BIOMICROFLUIDICS, V9, DOI 10.1063/1.4917508; Kim JS, 2018, J CONTROL RELEASE, V269, P245, DOI 10.1016/j.jconrel.2017.11.026; Kolhar P, 2013, P NATL ACAD SCI USA, V110, P10753, DOI 10.1073/pnas.1308345110; Liu J, 2011, BIOPHYS J, V101, P319, DOI 10.1016/j.bpj.2011.05.063; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MORIGI M, 1995, BLOOD, V85, P1696, DOI 10.1182/blood.V85.7.1696.bloodjournal8571696; Murase T, 1998, CIRC RES, V83, P328, DOI 10.1161/01.RES.83.3.328; Muro S, 2006, J PHARMACOL EXP THER, V317, P1161, DOI 10.1124/jpet.105.098970; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Niwa K, 2004, ANN BIOMED ENG, V32, P537, DOI 10.1023/B:ABME.0000019173.79939.54; Noria S, 1999, CIRC RES, V85, P504, DOI 10.1161/01.RES.85.6.504; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Pang ZY, 2005, ANN BIOMED ENG, V33, P1536, DOI 10.1007/s10439-005-7786-0; Papademetriou IT, 2015, THER DELIV, V6, P989, DOI [10.4155/tde.15.48, 10.4155/TDE.15.48]; Papademetriou J, 2013, J INHERIT METAB DIS, V36, P467, DOI 10.1007/s10545-012-9534-6; Pardridge WM, 2012, J CEREBR BLOOD F MET, V32, P1959, DOI 10.1038/jcbfm.2012.126; Park J, 2015, LAB CHIP, V15, P141, DOI 10.1039/c4lc00962b; Partyka PP, 2017, BIOMATERIALS, V115, P30, DOI 10.1016/j.biomaterials.2016.11.012; Paulis LEM, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-25; Pradhan S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21075-9; Preston Jane E, 2014, Adv Pharmacol, V71, P147, DOI 10.1016/bs.apha.2014.06.001; Rappaport J, 2016, DRUG DELIVERY ACROSS PHYSIOLOGICAL BARRIERS, P313; Ren JF, 2012, BIOMATERIALS, V33, P3324, DOI 10.1016/j.biomaterials.2012.01.025; Rizzo V, 2003, AM J PHYSIOL-HEART C, V285, pH1720, DOI 10.1152/ajpheart.00344.2002; Rizzo V, 1998, J BIOL CHEM, V273, P34724, DOI 10.1074/jbc.273.52.34724; Ruan SB, 2014, BIOCONJUGATE CHEM, V25, P2252, DOI 10.1021/bc500474p; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Sellgren KL, 2015, BIOMICROFLUIDICS, V9, DOI 10.1063/1.4935594; Shao K, 2012, BIOMATERIALS, V33, P6898, DOI 10.1016/j.biomaterials.2012.06.050; Siddharthan V, 2007, BRAIN RES, V1147, P39, DOI 10.1016/j.brainres.2007.02.029; SILL HW, 1995, AM J PHYSIOL-HEART C, V268, pH535, DOI 10.1152/ajpheart.1995.268.2.H535; SPRAGUE EA, 1987, CIRCULATION, V76, P648, DOI 10.1161/01.CIR.76.3.648; STEWART PA, 1981, DEV BIOL, V84, P183, DOI 10.1016/0012-1606(81)90382-1; Sun RJ, 2002, EUR BIOPHYS J BIOPHY, V30, P605, DOI 10.1007/s00249-001-0195-x; Swaminathan TN, 2011, IUBMB LIFE, V63, P640, DOI 10.1002/iub.475; Tarbell JM, 2010, CARDIOVASC RES, V87, P320, DOI 10.1093/cvr/cvq146; Terrell-Hall TB, 2017, FLUIDS BARRIERS CNS, V14, DOI 10.1186/s12987-017-0050-9; Tian XH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11990; Walter FR, 2016, SENSOR ACTUAT B-CHEM, V222, P1209, DOI 10.1016/j.snb.2015.07.110; Wang JD, 2016, MOL PHARMACEUT, V13, P895, DOI 10.1021/acs.molpharmaceut.5b00805; Wang YI, 2017, BIOTECHNOL BIOENG, V114, P184, DOI 10.1002/bit.26045; Xin HL, 2012, BIOMATERIALS, V33, P1673, DOI 10.1016/j.biomaterials.2011.11.018; Xu H, 2016, SCI REP-UK, V6, DOI 10.1038/srep36670; Yang H, 2013, INT J NANOMED, V8, DOI 10.2147/IJN.S44997; Zhao Z, 2015, CELL, V163, P1064, DOI 10.1016/j.cell.2015.10.067	97	40	40	5	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2018	13	10							e0205158	10.1371/journal.pone.0205158	http://dx.doi.org/10.1371/journal.pone.0205158			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW4OW	30300391	Green Published, gold, Green Submitted			2023-01-03	WOS:000446897200042
J	Fujita, N; Yamasaki, N; Eto, K; Asaeda, M; Kuwahara, W; Imagita, H				Fujita, Naoto; Yamasaki, Natsuki; Eto, Kanako; Asaeda, Makoto; Kuwahara, Wataru; Imagita, Hidetaka			Oxygen therapy may worsen the survival rate in rats with monocrotaline-induced pulmonary arterial hypertension	PLOS ONE			English	Article							CARDIAC CACHEXIA; SKELETAL-MUSCLE; COPD PATIENTS; DISEASE; HEMODYNAMICS; INHALATION	Although oxygen therapy rapidly improves arterial oxygen saturation in idiopathic pulmonary arterial hypertension, the effects of chronic administration of oxygen are unknown. The purpose of the present study was to investigate the effects of chronic oxygen therapy on the histological changes and survival rate in rats with idiopathic pulmonary arterial hypertension. Idiopathic pulmonary arterial hypertension was induced by monocrotaline injection. The rats were then randomly assigned to receive or not receive oxygen therapy (O-2 group and non-O-2 group, respectively). The rats in the O-2 group were exposed to a high (90%) oxygen environment from day 17 following injection of monocrotaline, when hypoxemia was first observed. The pulmonary arteriole walls were significantly thicker in monocrotaline-injected rats than in saline-injected rats as vehicle on day 19 and were significantly thicker in the rats that received oxygen therapy than in the rats that did not. Right ventricular inflammations were significantly higher in monocrotaline-injected rats than in saline-injected rats on day 19 and were significantly higher in the rats that received oxygen therapy than in the rats that did not. By day 20 after injection of monocrotaline, the survival rate was significantly lower in the rats that received oxygen therapy than in those that did not. Superoxide dismutase activity in the lungs was higher in monocrotaline-injected rats than in saline-injected rats on day 19 after monocrotaline injection and was also higher in the saline-injected rats that received oxygen therapy than in the saline-injected rats that did not. No interaction was detected between monocrotaline injection and oxygen therapy. These results suggest that chronic oxygen therapy worsens the histological changes and survival rate in idiopathic pulmonary arterial hypertension. The fact that degradation of the histological changes and survival rate was accompanied by increase in superoxide dismutase activity suggests that antioxidant capacity may contribute to the degradation.	[Fujita, Naoto; Yamasaki, Natsuki; Eto, Kanako; Kuwahara, Wataru] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Musculoskeletal Funct Res & Regenerat, Minami Ku, Hiroshima, Japan; [Asaeda, Makoto] Hiroshima Univ Hosp, Sports Med Ctr, Minami Ku, Hiroshima, Japan; [Imagita, Hidetaka] Kio Univ, Grad Sch Hlth Sci, Koryo, Nara, Japan	Hiroshima University; Hiroshima University	Fujita, N (corresponding author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Musculoskeletal Funct Res & Regenerat, Minami Ku, Hiroshima, Japan.	fujitan@hiroshima-u.ac.jp	Asaeda, Makoto/AAU-4445-2020	Fujita, Naoto/0000-0001-9416-3502; Asaeda, Makoto/0000-0001-9323-8146				[Anonymous], 1980, Ann Intern Med, V93, P391; Anwar A, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0396-6; Barst RJ, 2009, J AM COLL CARDIOL, V54, pS78, DOI 10.1016/j.jacc.2009.04.017; Chaouat A, 2008, EUR RESPIR J, V32, P1371, DOI 10.1183/09031936.00015608; Chaouat A, 2005, AM J RESP CRIT CARE, V172, P189, DOI 10.1164/rccm.200401-006OC; Criner GJ, 2013, RESP CARE, V58, P48, DOI 10.4187/respcare.01918; Dias-Freitas F, 2016, RESP MED, V119, P23, DOI 10.1016/j.rmed.2016.08.010; FLENLEY DC, 1981, LANCET, V1, P681; Fujimoto K, 2002, CHEST, V122, P457, DOI 10.1378/chest.122.2.457; Fujita N, 2015, BIOMED RES-TOKYO, V36, P383, DOI 10.2220/biomedres.36.383; Galie N, 2009, EUR RESPIR J, V34, P1219, DOI 10.1183/09031936.00139009; Galie N, 2016, EUR HEART J, V37, P67, DOI 10.1093/eurheartj/ehv317; Handoko ML, 2009, CIRCULATION, V120, P42, DOI 10.1161/CIRCULATIONAHA.108.829713; HEATH D, 1958, CIRCULATION, V18, P533, DOI 10.1161/01.CIR.18.4.533; Itoh T, 2004, AM J RESP CRIT CARE, V170, P1204, DOI 10.1164/rccm.200404-455OC; Itoh T, 2004, AM J RESP CRIT CARE, V169, P34, DOI 10.1164/rccm.200303-346OC; Jindal SK, 2012, EXPERT REV RESP MED, V6, P639, DOI [10.1586/ERS.12.69, 10.1586/ers.12.69]; Katsuyama M, 2012, J CLIN BIOCHEM NUTR, V50, P9, DOI 10.3164/jcbn.11-06SR; McLaughlin VV, 2009, CIRCULATION, V119, P2250, DOI 10.1161/CIRCULATIONAHA.109.192230; Molinari F, 2016, INT J CARDIOL, V219, P105, DOI 10.1016/j.ijcard.2016.05.071; Montani D, 2014, PHARMACOL THERAPEUT, V141, P172, DOI 10.1016/j.pharmthera.2013.10.002; NAGASAKA Y, 1978, CHEST, V74, P299, DOI 10.1378/chest.74.3.299; Nagaya N, 2003, AM J PHYSIOL-HEART C, V285, pH2125, DOI 10.1152/ajpheart.00548.2002; OSWALDMAMMOSSER M, 1995, CHEST, V107, P1193, DOI 10.1378/chest.107.5.1193; Roberts DH, 2001, CHEST, V120, P1547, DOI 10.1378/chest.120.5.1547; Sandoval J, 2001, AM J RESP CRIT CARE, V164, P1682, DOI 10.1164/ajrccm.164.9.2106076; Steffen BT, 2008, J APPL PHYSIOL, V105, P1950, DOI 10.1152/japplphysiol.90884.2008; TIMMS RM, 1985, ANN INTERN MED, V102, P29, DOI 10.7326/0003-4819-102-1-29; Weir-McCall JR, 2015, RESP MED, V109, P1381, DOI 10.1016/j.rmed.2015.06.005; WEITZENBLUM E, 1985, AM REV RESPIR DIS, V131, P493, DOI 10.1164/arrd.1985.131.4.493; Yoshida M, 1997, AM J RESP CRIT CARE, V155, P526, DOI 10.1164/ajrccm.155.2.9032189; Zielinski J, 1998, CHEST, V113, P65, DOI 10.1378/chest.113.1.65	32	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2018	13	9							e0204254	10.1371/journal.pone.0204254	http://dx.doi.org/10.1371/journal.pone.0204254			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GU8XH	30235299	Green Published, gold, Green Submitted			2023-01-03	WOS:000445626400098
J	Abelairas-Gomez, C; Rey, E; Gonzalez-Salvado, V; Mecias-Calvo, M; Rodriguez-Ruiz, E; Rodriguez-Nunez, A				Abelairas-Gomez, Cristian; Rey, Ezequiel; Gonzalez-Salvado, Violeta; Mecias-Calvo, Marcos; Rodriguez-Ruiz, Emilio; Rodriguez-Nunez, Antonio			Acute muscle fatigue and CPR quality assisted by visual feedback devices: A randomized-crossover simulation trial	PLOS ONE			English	Article							PROFESSIONAL SOCCER PLAYERS; COMPRESSION-ONLY CPR; CARDIOPULMONARY-RESUSCITATION; CHEST COMPRESSIONS; TENSIOMYOGRAPHY; GUIDELINES	Objective To analyse the acute muscular fatigue (AMF) in triceps brachii and rectus abdominis during compression-only and standard cardiopulmonary resuscitation (CPR) performed by certified basic life support providers. Methods Twenty-six subjects were initially recruited and randomly allocated to two study groups according to the muscles analysed; eighteen finally met the inclusion criteria (nine in each group). Both groups carried out two CPR tests (compression-only and standard CPR) of 10 min divided into five 2-min intermittent periods. The ventilation method was freely chosen by each participant (mouth-to-mouth, pocket-mask or bag-valve-mask). CPR feedback was provided all the time. AMF was measured by tensiomyography at baseline and after each 2-min period of the CPR test, in triceps brachii or rectus abdominis according to the study group. Results Rectus abdominis' contraction time increased significantly during the fifth CPR period (p = 0.020). Triceps brachii's radial muscle belly displacement (p = 0.047) and contraction velocity (p = 0.018) were lower during compression-only CPR than during standard CPR. Participants who had trained previously with feedback devices achieved better CPR quality results in both protocols. Half of participants chose bag-valve-mask to perform ventilations but attained lower significant ventilation quality than the other subjects. Conclusions Compression-only CPR induces higher AMF than standard CPR. Significantly higher fatigue levels were found during the fifth CPR test period, regardless of the method. Adequate rescuer's strength seems to be a requisite to take advantage of CPR quality feedback devices. Training should put more emphasis on the quality of ventilation during CPR.	[Abelairas-Gomez, Cristian; Rodriguez-Nunez, Antonio] Univ Santiago de Compostela, CLINURSID Res Grp, Santiago De Compostela, Spain; [Abelairas-Gomez, Cristian; Gonzalez-Salvado, Violeta; Rodriguez-Nunez, Antonio] Inst Hlth Res Santiago DIS, Santiago De Compostela, Spain; [Abelairas-Gomez, Cristian] Univ Santiago de Compostela, Fac Educ Sci, Santiago De Compostela, Spain; [Rey, Ezequiel] Univ Vigo, Fac Educ & Sport Sci, Pontevedra, Spain; [Rey, Ezequiel] Univ Vigo, REMOSS Res Grp, Pontevedra, Spain; [Gonzalez-Salvado, Violeta] Univ Clin Hosp Santiago, Cardiol Dept, CiberCV, Santiago De Compostela, Spain; [Mecias-Calvo, Marcos] European Atlantic Univ, Fac Hlth Sci, Santander, Spain; [Mecias-Calvo, Marcos] Univ Clin Hosp Santiago, Crit Care & Intens Care Med Dept, SERGAS, Santiago De Compostela, Spain; [Rodriguez-Ruiz, Emilio; Rodriguez-Nunez, Antonio] Univ Clin Hosp Santiago, Paediat Emergency & Crit Care Div, SERGAS, Santiago De Compostela, Spain; [Rodriguez-Nunez, Antonio] Univ Santiago de Compostela, Univ Sch Nursing, Santiago De Compostela, Spain; [Rodriguez-Nunez, Antonio] Carlos III Hlth Inst, Mother Child Hlth & Dev Network Red SAMID, Madrid, Spain	Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; Universidade de Vigo; Universidade de Vigo; CIBER - Centro de Investigacion Biomedica en Red; CIBERCV; Complexo Hospitalario Universitario de Santiago de Compostela; Universidade de Santiago de Compostela	Rey, E (corresponding author), Univ Vigo, Fac Educ & Sport Sci, Pontevedra, Spain.; Rey, E (corresponding author), Univ Vigo, REMOSS Res Grp, Pontevedra, Spain.	zequirey@uvigo.es	Rey, Ezequiel/K-8723-2013; Abelairas-Gomez, Cristian/K-3338-2017	Rey, Ezequiel/0000-0003-4770-2694; Abelairas-Gomez, Cristian/0000-0002-1056-7778; Rodriguez-Ruiz, Emilio/0000-0003-1447-877X; Rodriguez-Nunez, Antonio/0000-0003-3414-2771	Sociedad para el Desarrollo de Cantabria (SODERCAN) [RH16-XX-023]	Sociedad para el Desarrollo de Cantabria (SODERCAN)	This study was supported by grants from the Sociedad para el Desarrollo de Cantabria (SODERCAN) (Ref. RH16-XX-023).	Abelairas-Gomez C, 2017, KARDIOL POL, V75, P21, DOI 10.5603/KP.a2016.0165; Adelborg K, 2011, RESUSCITATION, V82, P618, DOI 10.1016/j.resuscitation.2011.01.009; [Anonymous], 2018, ANESTH PROG, DOI [10.2344/anpr-65-01-06, DOI 10.2344/ANPR-65-01-06]; Dahmane R, 2001, MED BIOL ENG COMPUT, V39, P51, DOI 10.1007/BF02345266; Hasegawa T, 2014, J PHYSIOL ANTHROPOL, V33, DOI 10.1186/1880-6805-33-16; Hong DY, 2012, RESUSCITATION, V83, P353, DOI 10.1016/j.resuscitation.2011.11.006; Hunter AM, 2012, J ELECTROMYOGR KINES, V22, P334, DOI 10.1016/j.jelekin.2012.01.009; Krizaj D, 2008, J ELECTROMYOGR KINES, V18, P645, DOI 10.1016/j.jelekin.2007.01.008; Liu S, 2016, CAN J EMERG MED, V18, P461, DOI 10.1017/cem.2016.373; Lopez-Gonzalez A, 2014, RESUCITATION, V85, pS40; Macgregor LJ, 2018, SPORTS MED, V48, P1607, DOI 10.1007/s40279-018-0912-6; Garcia-Manso JM, 2011, J SPORT SCI, V29, P619, DOI 10.1080/02640414.2010.548822; Nehme Z, 2016, PREHOSP EMERG CARE, V20, P783, DOI 10.3109/10903127.2016.1164776; Perkins GD., 2004, ABC RESUSCITATION, V5th ed., P97; Rey E, 2016, INT J SPORTS MED, V37, P878, DOI 10.1055/s-0042-109268; Rey E, 2012, J ELECTROMYOGR KINES, V22, P866, DOI 10.1016/j.jelekin.2012.06.003; Shin J, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/s13049-014-0059-x; Simola RAD, 2015, J STRENGTH COND RES, V29, P1339, DOI 10.1519/JSC.0000000000000768; Trowbridge C, 2009, BMC NURS, V8, DOI 10.1186/1472-6955-8-6; Tsou JY, 2014, AM J EMERG MED, V32, P216, DOI 10.1016/j.ajem.2013.10.044; WHO, 2015, GLOB REC PHYS ACT HL; Wiewelhove T, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00406; Wiewelhove T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139801; Yang ZF, 2014, AM J EMERG MED, V32, P50, DOI 10.1016/j.ajem.2013.09.043; Yasuda Y, 2013, PREHOSP EMERG CARE, V17, P162, DOI 10.3109/10903127.2012.749964	26	12	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2018	13	9							e0203576	10.1371/journal.pone.0203576	http://dx.doi.org/10.1371/journal.pone.0203576			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GU3GJ	30231037	Green Published, Green Submitted, gold			2023-01-03	WOS:000445164300046
J	Stevens, ER; Li, LF; Nucifora, KA; Zhou, QL; McNairy, ML; Gachuhi, A; Lamb, MR; Nuwagaba-Biribonwoha, H; Sahabo, R; Okello, V; El-Sadr, WM; Braithwaite, RS				Stevens, Elizabeth R.; Li, Lingfeng; Nucifora, Kimberly A.; Zhou, Qinlian; McNairy, Margaret L.; Gachuhi, Averie; Lamb, Matthew R.; Nuwagaba-Biribonwoha, Harriet; Sahabo, Ruben; Okello, Velephi; El-Sadr, Wafaa M.; Braithwaite, R. Scott			Cost-effectiveness of a combination strategy to enhance the HIV care continuum in Swaziland: Link4Health	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; FOLLOW-UP; SEXUAL-BEHAVIOR; NORTHERN TANZANIA; PREVENTION; INFECTION; OUTCOMES; WORKERS; HEALTH; RISK	Introduction Link4Health, a cluster-RCT, demonstrated the effectiveness of a combination strategy targeting barriers at various HIV continuum steps on linkage to and retention in care; showing effectiveness in achieving linkage to HIV care within 1 month plus retention in care at 12 months after HIV testing for people living with HIV (RR 1.48, 95% CI 1.19-1.96, p = 0.002). In addition to standard of care, Link4Health included: 1) Point-of-care CD4+ count testing; 2) Accelerated ART initiation; 3) Mobile phone appointment reminders; 4) Care and prevention package including commodities and informational materials; and 5) Non-cash financial incentive. Our objective was to evaluate the cost-effectiveness of a scale-up of the Link4Health strategy in Swaziland. Methods and findings We incorporated the effects and costs of the Link4Health strategy into a computer simulation of the HIV epidemic in Swaziland, comparing a scenario where the strategy was scaled up to a scenario with no implementation. The simulation combined a deterministic compartmental model of HIV transmission with a stochastic microsimulation of HIV progression calibrated to Swaziland epidemiological data. It incorporated downstream health costs potentially saved and infections potentially prevented by improved linkage and treatment adherence. We assessed the incremental cost-effectiveness ratio of Link4Health compared to standard care from a health sector perspective reported in US$2015, a time horizon of 20 years, and a discount rate of 3% in accordance with WHO guidelines.[1] Our results suggest that scale-up of the Link4Health strategy would reduce new HIV infections over 20 years by 11,059 infections, a 7% reduction from the projected 169,019 cases and prevent 5,313 deaths, an 11% reduction from the projected 49,582 deaths. Link4Health resulted in an incremental cost per infection prevented of $13,310 and an incremental cost per QALY gained of $3,560/QALY from the health sector perspective. Conclusions Using a threshold of <3 x per capita GDP, the Link4Health strategy is likely to be a cost-effective strategy for responding to the HIV epidemic in Swaziland.	[Stevens, Elizabeth R.; Li, Lingfeng; Nucifora, Kimberly A.; Zhou, Qinlian; Braithwaite, R. Scott] NYU, Sch Med, Dept Populat Hlth, New York, NY 10016 USA; [McNairy, Margaret L.; Gachuhi, Averie; Lamb, Matthew R.; Nuwagaba-Biribonwoha, Harriet; El-Sadr, Wafaa M.] Columbia Univ, ICAP, New York, NY USA; [Nuwagaba-Biribonwoha, Harriet] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA; [Sahabo, Ruben; Okello, Velephi] Columbia Univ, ICAP, Mbabane, Eswatini	New York University; Columbia University; Columbia University	Stevens, ER (corresponding author), NYU, Sch Med, Dept Populat Hlth, New York, NY 10016 USA.	Elizabeth.stevens@nyumc.org		Stevens, Elizabeth R./0000-0001-6063-1523; Braithwaite, Ronald Scott/0000-0001-7067-3655	NIH [R01AI100059]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This manuscript was funded by NIH Award Number: R01AI100059. The funder had no role in the in the writing of the manuscript or the decision to submit it for publication.	Adam Taghreed, 2003, Cost Eff Resour Alloc, V1, P3, DOI 10.1186/1478-7547-1-3; Amanyire G, 2016, LANCET HIV, V3, pE539, DOI 10.1016/S2352-3018(16)30090-X; Ao TTH, 2006, SEX TRANSM DIS, V33, P163, DOI 10.1097/01.olq.0000187204.57006.b3; Attia S, 2009, AIDS, V23, P1397, DOI 10.1097/QAD.0b013e32832b7dca; Auld AF, 2015, JAIDS-J ACQ IMM DEF, V69, pE1, DOI 10.1097/QAI.0000000000000547; Auld AF, 2014, MMWR-MORBID MORTAL W, V63, P1097; Bassett IV, 2015, CURR OPIN HIV AIDS, V10, P451, DOI 10.1097/COH.0000000000000196; Bicego GT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077101; Bisson GP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001725; Boily MC, 2009, LANCET INFECT DIS, V9, P118, DOI 10.1016/S1473-3099(09)70021-0; Braithwaite RS, 2008, VALUE HEALTH, V11, P975, DOI 10.1111/j.1524-4733.2007.00315.x; Braithwaite RS, 2014, ALCOHOL CLIN EXP RES, V38, P1059, DOI 10.1111/acer.12332; Braithwaite RS, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-38; Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790; Centers for Disease Control, 2017, FACTSH; Central Bank of eSwatini, 2018, MONTHL STAT REL; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Cohen Stacy M., 2011, Morbidity and Mortality Weekly Report, V60, P1618; Dalal RP, 2008, JAIDS-J ACQ IMM DEF, V47, P101, DOI 10.1097/QAI.0b013e31815b833a; Eaton JW, 2014, LANCET GLOB HEALTH, V2, pE23, DOI 10.1016/S2214-109X(13)70172-4; Elul B, 2017, COMBINATION INTERVEN; Elul B, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002433; Elul B, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0549-5; Fairall LR, 2008, ARCH INTERN MED, V168, P86, DOI 10.1001/archinternmed.2007.10; Fox MP, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20888; Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243; Govindasamy D, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19032; Grimsrud A, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.19984; Harripersaud K, 2017, MAJOR INFECT DIS, V6; Heffernan A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158303; Hyle EP, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001725; Jobanputra Kiran, 2014, J Acquir Immune Defic Syndr, V67, P45, DOI 10.1097/QAI.0000000000000224; Jobanputra K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116144; Justman J, 2017, LANCET HIV, V4, pE83, DOI 10.1016/S2352-3018(16)30190-4; Kapiga SH, 2006, AIDS CARE, V18, P379, DOI 10.1080/09540120500465012; Kingdom of Swaziland Ministry of Health, 2015, MON EV UN STRAT INF; Koenig SP, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002357; Krebs DW, 2008, AIDS CARE, V20, P311, DOI 10.1080/09540120701594776; Lawn SD, 2006, CLIN INFECT DIS, V42, P431, DOI 10.1086/499527; Louwagie GM, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-244; Mafirakureva N, 2016, AIDS CARE, V28, P904, DOI 10.1080/09540121.2016.1173639; Marks G, 2005, JAIDS-J ACQ IMM DEF, V39, P446, DOI 10.1097/01.qai.0000151079.33935.79; Maskew M, 2007, SAMJ S AFR MED J, V97, P853; Mbizvo MT, 1996, AIDS, V10, P895, DOI 10.1097/00002030-199607000-00013; McGrath N, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-601; McNairy ML, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0291-4; McNairy ML, 2012, AIDS, V26, P1735, DOI 10.1097/QAD.0b013e328355d67b; MCNAIRY ML, 2017, PLOS MED, V14, DOI DOI 10.1371/JOURNAL.PMED.1002420; Mishra V, 2009, DHS WORKING PAPERS, V62; Naslund JA, 2014, AIDS RES TREAT, V2014, DOI 10.1155/2014/137545; Organization WH, 2018, SWAZ INT HIV MAN GUI; Patel AR, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006078; Quigley M, 1997, AIDS, V11, P237, DOI 10.1097/00002030-199702000-00015; Sanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195; Siegfried N, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003362.pub2; UNAIDS, 2014, SWAZ GLOB AIDS RESP; UNAIDS, 2020, UNAIDS 2020 GLOB REP; UNAIDS, 2017, AIDSINFO; Vandepitte J, 2006, SEX TRANSM INFECT, V82, pIII18, DOI 10.1136/sti.2006.020081; Volle J, 2009, BASELINE SURVEY MULT; Walker DG, 2010, VACCINE, V28, P2356, DOI 10.1016/j.vaccine.2009.06.035; Warusawitharana M., 2014, SOCIAL DISCOUNT RATE; Weller S, 2002, Cochrane Database Syst Rev, pCD003255; WHO, 2012, GLOB INC PREV SEL CU; WHO, 2003, MAKING CHOICES HLTH; World Health Organization, 2015, GUID START ANT THER; World Health Organization, 2017, HIV AIDS GLOB PRIC R; Yu JKL, 2007, B WORLD HEALTH ORGAN, V85, P550, DOI 10.2471/BLT.06.037739	68	2	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2018	13	9							e0204245	10.1371/journal.pone.0204245	http://dx.doi.org/10.1371/journal.pone.0204245			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GT8SG	30222768	gold, Green Published, Green Submitted			2023-01-03	WOS:000444809400033
J	Kim, SA; Smith, S; Beauchamp, C; Song, Y; Chiang, M; Giuseppetti, A; Frukhtbeyn, S; Shaffer, I; Wilhide, J; Routkevitch, D; Ondov, JM; Kim, JJ				Kim, Shin Ae; Smith, Samuel; Beauchamp, Carlos; Song, Yang; Chiang, Martin; Giuseppetti, Anthony; Frukhtbeyn, Stanislav; Shaffer, Ian; Wilhide, Joshua; Routkevitch, Denis; Ondov, John M.; Kim, Jeffrey J.			Cariogenic potential of sweet flavors in electronic-cigarette liquids	PLOS ONE			English	Article							HIGH-SCHOOL-STUDENTS; NICOTINE DELIVERY-SYSTEMS; TOBACCO PRODUCT USE; STREPTOCOCCUS-MUTANS; DENTAL-CARIES; UNITED-STATES; BIOFILM FORMATION; SURFACE; MIDDLE; PROTEINS	Background Most electronic-cigarette liquids contain propylene glycol, glycerin, nicotine and a wide variety of flavors of which many are sweet. Sweet flavors are classified as saccharides, esters, acids or aldehydes. This study investigates changes in cariogenic potential when tooth surfaces are exposed to e-cigarette aerosols generated from well-characterized reference eliquids with sweet flavors. Methods Reference e-liquids were prepared by combining 20/80 propylene glycol/glycerin (by volume fraction), 10 mg/mL nicotine, and flavors. Aerosols were generated by a Universal Electronic- Cigarette Testing Device (49.2 W, 0.2 Omega). Streptococcus mutans (UA159) were exposed to aerosols on tooth enamel and the biological and physiochemical parameters were measured. Results E-cigarette aerosols produced four-fold increase in microbial adhesion to enamel. Exposure to flavored aerosols led to two-fold increase in biofilm formation and up to a 27% decrease in enamel hardness compared to unflavored controls. Esters (ethyl butyrate, hexyl acetate, and triacetin) in e-liquids were associated with consistent bacteria-initiated enamel demineralization, whereas sugar alcohol (ethyl maltol) inhibited S. mutans growth and adhesion. The viscosity of the e-liquid allowed S. mutans to adhere to pits and fissures. Aerosols contained five metals (mean +/- standard deviation): calcium (0.409 +/- 0.002) mg/L, copper (0.011 +/- 0.001) mg/L, iron (0.0051 +/- 0.0003) mg/L, magnesium (0.017 +/- 0.002) mg/L, and silicon (0.166 +/- 0.005) mg/L. Conclusions This study systematically evaluated e-cigarette aerosols and found that the aerosols have similar physio-chemical properties as high-sucrose, gelatinous candies and acidic drinks. Our data suggest that the combination of the viscosity of e-liquids and some classes of chemicals in sweet flavors may increase the risk of cariogenic potential. Clinical investigation is warranted to confirm the data shown here.	[Kim, Shin Ae; Giuseppetti, Anthony; Frukhtbeyn, Stanislav; Kim, Jeffrey J.] Amer Dent Assoc Fdn, Volpe Res Ctr, Gaithersburg, MD 20899 USA; [Smith, Samuel] Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA; [Beauchamp, Carlos; Song, Yang; Chiang, Martin] NIST, US Dept Commerce, Gaithersburg, MD 20899 USA; [Shaffer, Ian; Wilhide, Joshua] Univ Maryland Baltimore Cty, Mol Characterizat & Anal Complex, Baltimore, MD 21228 USA; [Routkevitch, Denis] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD USA; [Ondov, John M.] Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA; [Song, Yang] Univ Calif Los Angeles, Dept Mat Sci & Engn, Los Angeles, CA 90024 USA	University of Colorado System; University of Colorado Boulder; National Institute of Standards & Technology (NIST) - USA; University System of Maryland; University of Maryland Baltimore County; Johns Hopkins University; University System of Maryland; University of Maryland College Park; University of California System; University of California Los Angeles	Kim, JJ (corresponding author), Amer Dent Assoc Fdn, Volpe Res Ctr, Gaithersburg, MD 20899 USA.	jeffrey.kim@nist.gov		Routkevitch, Denis/0000-0002-7144-6347; Kim, Shinae/0000-0002-6729-8097	ADA Foundation [CR97200019]	ADA Foundation	This work was supported by the ADA Foundation, CR97200019 (JJK).	Allison DG, 2003, BIOFOULING, V19, P139, DOI 10.1038/nrmicro2415; Ambrose BK, 2015, JAMA-J AM MED ASSOC, V314, P1871, DOI 10.1001/jama.2015.13802; Anderson CA, 2009, OBES REV, V10, P41, DOI 10.1111/j.1467-789X.2008.00564.x; ARANHA H, 1982, INFECT IMMUN, V35, P456, DOI 10.1128/IAI.35.2.456-460.1982; Banas JA, 2003, CRIT REV ORAL BIOL M, V14, P89, DOI 10.1177/154411130301400203; Behar RZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117222; Berg Joel H, 2006, BMC Oral Health, V6 Suppl 1, pS6, DOI 10.1186/1472-6831-6-S1-S6; Berlutti F, 2004, BIOMETALS, V17, P271; Bourbia M, 2013, J DENT RES, V92, P989, DOI 10.1177/0022034513504436; Bowen WH, 2011, CARIES RES, V45, P69, DOI 10.1159/000324598; Cameron JM, 2014, TOB CONTROL, V23, P77, DOI 10.1136/tobaccocontrol-2012-050604; Cheah NP, 2014, TOB CONTROL, V23, P119, DOI 10.1136/tobaccocontrol-2012-050483; Cobb NK, 2010, AM J PUBLIC HEALTH, V100, P2340, DOI 10.2105/AJPH.2010.199281; CRAIG R. G., 1959, JOUR DENTAL RES, V38, P624, DOI 10.1177/00220345590380032701; Diaz-Garrido Natalia, 2016, Eur J Dent, V10, P345, DOI 10.4103/1305-7456.184163; Ervin R Bethene, 2012, NCHS Data Brief, P1; Etter JF, 2016, DRUG ALCOHOL DEPEN, V160, P218, DOI 10.1016/j.drugalcdep.2016.01.003; Etter JF, 2013, ADDICTION, V108, P1671, DOI 10.1111/add.12235; Featherstone J D B, 2004, J Dent Res, V83 Spec No C, pC39; Featherstone JDB, 2000, J AM DENT ASSOC, V131, P887, DOI 10.14219/jada.archive.2000.0307; Food and Drug Administration HHS, 2016, Fed Regist, V81, P28973; FROSTELL G, 1967, J NUTR, V93, P65, DOI 10.1093/jn/93.1.65; Gaetke LM, 2003, TOXICOLOGY, V189, P147, DOI 10.1016/S0300-483X(03)00159-8; Garcia SS, 2016, MOL ORAL MICROBIOL, V31, P515, DOI 10.1111/omi.12150; Goniewicz ML, 2013, NICOTINE TOB RES, V15, P158, DOI 10.1093/ntr/nts103; Goniewicz ML, 2014, TOB CONTROL, V23, P133, DOI 10.1136/tobaccocontrol-2012-050859; GUGGENHEIM B, 1970, INT DENT J, V20, P657; Hadwiger ME, 2010, J CHROMATOGR A, V1217, P7547, DOI 10.1016/j.chroma.2010.10.018; HAMADA S, 1980, MICROBIOL REV, V44, P331, DOI 10.1128/MMBR.44.2.331-384.1980; Hayacibara MF, 2004, CARBOHYD RES, V339, P2127, DOI 10.1016/j.carres.2004.05.031; Huilgol P, 2019, J PUBLIC HEALTH-UK, V41, P354, DOI 10.1093/pubmed/fdy082; Hutzler C, 2014, ARCH TOXICOL, V88, P1295, DOI 10.1007/s00204-014-1294-7; Jamal A, 2017, MMWR-MORBID MORTAL W, V66, P597, DOI 10.15585/mmwr.mm6623a1; KEYES PH, 1954, J DENT RES, V33, P830, DOI 10.1177/00220345540330061101; Kilian M, 2016, BRIT DENT J, V221, P657, DOI 10.1038/sj.bdj.2016.865; Kim JJ, 2017, TOB INDUC DIS, V15, DOI 10.1186/s12971-017-0119-x; Kim JN, 2015, APPL ENVIRON MICROB, V81, P5015, DOI 10.1128/AEM.01160-15; Kowitt SD, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14040338; Krusemann EJZ, 2019, NICOTINE TOB RES, V21, P1310, DOI 10.1093/ntr/nty101; Leitao TJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191284; Lemos JA, 2008, MICROBIOL-SGM, V154, P3247, DOI 10.1099/mic.0.2008/023770-0; Leung V, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01176; Li QD, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3326-0; Lindblom EN, 2015, FOOD DRUG LAW J, V70, P55; Lippert F, 2014, ARCH ORAL BIOL, V59, P704, DOI 10.1016/j.archoralbio.2014.04.005; Liu SQ, 1998, INT DAIRY J, V8, P651, DOI 10.1016/S0958-6946(98)00100-9; LOESCHE WJ, 1986, MICROBIOL REV, V50, P353, DOI 10.1128/MMBR.50.4.353-380.1986; Matsumoto-Nakano M, 2018, JPN DENT SCI REV, V54, P22, DOI 10.1016/j.jdsr.2017.08.002; Moynihan P, 2004, PUBLIC HEALTH NUTR, V7, P201, DOI 10.1079/PHN2003589; O'Toole GA, 2011, JOVE-J VIS EXP, DOI 10.3791/2437; ORSTAVIK D, 1974, INFECT IMMUN, V9, P794; Passalacqua KD, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.VMBF-0027-2015; Pearson JL, 2012, AM J PUBLIC HEALTH, V102, P1758, DOI 10.2105/AJPH.2011.300526; Peres MA, 2016, J DENT RES, V95, P388, DOI 10.1177/0022034515625907; Perez DL, 2017, BIOFOULING, V33, P222, DOI 10.1080/08927014.2017.1286476; Pietroiusti A, 2016, TOXICOL APPL PHARM, V299, P90, DOI 10.1016/j.taap.2015.12.017; Pitts NB, 2017, NAT REV DIS PRIMERS, V3, P1, DOI 10.1038/nrdp.2017.30; Rosbrook K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185334; Rosenfeld CS, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00396; Rosinger Asher, 2017, NCHS Data Brief, P1; RUGGGUNN AJ, 1984, ARCH ORAL BIOL, V29, P983, DOI 10.1016/0003-9969(84)90145-6; Sasaki K, 2012, INT OR HLTH SCI 2011, Vxx; SCHILLING KM, 1992, INFECT IMMUN, V60, P284, DOI 10.1128/IAI.60.1.284-295.1992; Schneider S, 2016, NICOTINE TOB RES, V18, P647, DOI 10.1093/ntr/ntv193; Schved F, 1996, LETT APPL MICROBIOL, V22, P189, DOI 10.1111/j.1472-765X.1996.tb01139.x; Sheiham A, 2015, J DENT RES, V94, P1341, DOI 10.1177/0022034515590377; Singh T, 2016, MMWR-MORBID MORTAL W, V65, P1425, DOI 10.15585/mmwr.mm655051a2; Singh T, 2016, MMWR-MORBID MORTAL W, V65, P361, DOI 10.15585/mmwr.mm6514a1; Small DM, 2005, EXP BRAIN RES, V166, P345, DOI 10.1007/s00221-005-2376-9; Smith EG, 2012, J DENT RES, V91, P133, DOI 10.1177/0022034511415415; Soneji S, 2017, JAMA PEDIATR, V171, P788, DOI 10.1001/jamapediatrics.2017.1488; Soneji SS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193328; Soussy S, 2016, TOB CONTROL, V25, pii88, DOI 10.1136/tobaccocontrol-2016-053220; Spear F, 2008, J AM DENT ASSOC, V139, P1399, DOI 10.14219/jada.archive.2008.0052; Spindle TR, 2015, NICOTINE TOB RES, V17, P142, DOI 10.1093/ntr/ntu186; Sutherland IW, 1990, BIOTECHNOLOGY MICROB, Vviii; TATEVOSSIAN A, 1990, J DENT RES, V69, P1309, DOI 10.1177/00220345900690061801; Tierney PA, 2016, TOB CONTROL, V25, pE10, DOI 10.1136/tobaccocontrol-2014-052175; Trehy ML, 2011, J LIQ CHROMATOGR R T, V34, P1442, DOI 10.1080/10826076.2011.572213; Tuson HH, 2013, SOFT MATTER, V9, P4368, DOI 10.1039/c3sm27705d; Villanti AC, 2017, AM J PREV MED, V53, P139, DOI 10.1016/j.amepre.2017.01.026; WILSON RF, 1990, CARIES RES, V24, P203, DOI 10.1159/000261266; Zero D T, 1999, Dent Clin North Am, V43, P635; Zhou JY, 2017, APPL ENVIRON MICROB, V83, DOI 10.1128/AEM.02412-16; Zhu SH, 2014, TOB CONTROL, V23, P3, DOI 10.1136/tobaccocontrol-2014-051670	85	34	35	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2018	13	9							e0203717	10.1371/journal.pone.0203717	http://dx.doi.org/10.1371/journal.pone.0203717			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GT0BU	30192874	Green Published, gold, Green Submitted			2023-01-03	WOS:000444093600137
J	Morschhauser, F; Fowler, NH; Feugier, P; Bouabdallah, R; Tilly, H; Palomba, ML; Fruchart, C; Libby, EN; Casasnovas, RO; Flinn, IW; Haioun, C; Maisonneuve, H; Ysebaert, L; Bartlett, NL; Bouabdallah, K; Brice, P; Ribrag, V; Daguindau, N; Le Gouill, S; Pica, GM; Garcia-Sancho, AM; Lopez-Guillermo, A; Larouche, JF; Ando, K; da Silva, MG; Andre, M; Zachee, P; Sehn, LH; Tobinai, K; Cartron, G; Liu, D; Wang, J; Xerri, L; Salles, GA				Morschhauser, F.; Fowler, N. H.; Feugier, P.; Bouabdallah, R.; Tilly, H.; Palomba, M. L.; Fruchart, C.; Libby, E. N.; Casasnovas, R-O.; Flinn, I. W.; Haioun, C.; Maisonneuve, H.; Ysebaert, L.; Bartlett, N. L.; Bouabdallah, K.; Brice, P.; Ribrag, V.; Daguindau, N.; Le Gouill, S.; Pica, G. M.; Martin Garcia-Sancho, A.; Lopez-Guillermo, A.; Larouche, J-F.; Ando, K.; Gomes da Silva, M.; Andre, M.; Zachee, P.; Sehn, L. H.; Tobinai, K.; Cartron, G.; Liu, D.; Wang, J.; Xerri, L.; Salles, G. A.		RELEVANCE Trial Investigators	Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MANTLE CELL LYMPHOMA; 1ST-LINE TREATMENT; OPEN-LABEL; INDOLENT; IKAROS; IMMUNOCHEMOTHERAPY; POMALIDOMIDE; DEGRADATION; PHASE-3; AIOLOS	BACKGROUND Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will have a relapse. Combination immunotherapy with lenalidomide and rituximab is an immunomodulatory regimen that has shown promising activity in patients with indolent B-cell non-Hodgkin's lymphoma. METHODS We conducted this multicenter, international, phase 3 superiority trial to evaluate rituximab plus lenalidomide, as compared with rituximab plus chemotherapy, in patients with previously untreated follicular lymphoma. Patients were randomly assigned to receive one of the two regimens, followed by maintenance monotherapy with rituximab. Treatment with rituximab plus lenalidomide consisted of 18 cycles of the two drugs, followed by rituximab maintenance therapy every 8 weeks for 12 cycles (six additional doses). Treatment with rituximab plus chemotherapy consisted of the investigator's choice of one of three rituximab-based regimens, followed by maintenance monotherapy with rituximab every 8 weeks for 12 cycles. The primary end points were complete response (confirmed or unconfirmed) at 120 weeks and progression-free survival. RESULTS A total of 1030 patients were randomly assigned to receive rituximab plus lenalidomide (513 patients) or rituximab plus chemotherapy (517 patients). The rate of confirmed or unconfirmed complete response at 120 weeks was similar in the two groups: 48% (95% confidence interval [CI], 44 to 53) in the rituximab-lenalidomide group and 53% (95% CI, 49 to 57) in the rituximab-chemotherapy group (P = 0.13). The interim 3-year rate of progression-free survival was 77% (95% CI, 72 to 80) and 78% (95% CI, 74 to 82), respectively. A higher percentage of patients in the rituximabchemotherapy group had grade 3 or 4 neutropenia (32% vs. 50%) and febrile neutropenia of any grade (2% vs. 7%), and a higher percentage of patients in the rituximab-lenalidomide group had grade 3 or 4 cutaneous reactions (7% vs. 1%). CONCLUSIONS Among patients with previously untreated follicular lymphoma, efficacy results were similar with rituximab plus lenalidomide and rituximab plus chemotherapy (with both regimens followed by rituximab maintenance therapy). The safety profile differed in the two groups.	[Morschhauser, F.] Univ Lille, CHU, Grp Rech Formes Injectables & Technol Associees, Lille, France; [Feugier, P.] CHU Reg Nancy, Serv Hematol, Vandoeuvre Les Nancy, France; [Bouabdallah, R.] Inst Paoli Calmettes, Marseille, France; [Xerri, L.] Aix Marseille Univ, Ctr Rech Cancerol Marseille, CNRS, Dept Pathol,Inst Paoli Calmettes,INSERM, Marseille, France; [Tilly, H.] Univ Rouen, Ctr Henri Becquerel, U1245, Rouen, France; [Tilly, H.] Univ Rouen, Dept Hematol, Rouen, France; [Fruchart, C.] Inst Hematol Basse Normandie, Caen, France; [Casasnovas, R-O.] CHU Bocage, Serv Hematol Clin, Dijon, France; [Haioun, C.] Hop Henri Mondor, Unite Hemopathies Lymphoides, Creteil, France; [Maisonneuve, H.] Ctr Hosp Dept Vendee, Serv Oncohematol, La Roche Sur Yon, France; [Ysebaert, L.] Inst Univ Canc Toulouse Oncopole, Serv Hematol, Toulouse, France; [Bouabdallah, K.] CHU Bordeaux, Serv Hematol, Bordeaux, France; [Brice, P.] Hop St Louis, Serv Oncohematol, Paris, France; [Ribrag, V.] Gustave Roussy Canc, Villejuif, France; [Daguindau, N.] Ctr Hosp Annecy Genevois Serv, Annecy, France; [Le Gouill, S.] Univ Nantes, Ctr Rech Cancerol & Immunol, CNRS, Hotel Dieu,Serv Hematol Clin,INSERM, Nantes, France; [Pica, G. M.] Ctr Hosp Metropole Savoie, Serv Hematol, Chambery, France; [Cartron, G.] Univ Montpellier, CHU Montpellier, Dept Hematol, Montpellier, France; [Salles, G. A.] Univ Lyon, Ctr Hosp Lyon Sud, Hosp Civils Lyon, Pierre Benite, France; [Fowler, N. H.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA; [Palomba, M. L.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA; [Libby, E. N.] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA; [Flinn, I. W.] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA; [Bartlett, N. L.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA; [Martin Garcia-Sancho, A.] Hosp Univ Salamanca, Dept Hematol, Salamanca, Spain; [Martin Garcia-Sancho, A.] Ctr Invest Biomed Red Canc, Inst Invest Biomed Salamanca, Salamanca, Spain; [Lopez-Guillermo, A.] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain; [Larouche, J-F.] CHU Quebec, Hop Enfant Jesus, Quebec City, PQ, Canada; [Sehn, L. H.] Univ British Columbia, British Columbia Canc Ctr Lymphoid Canc, Vancouver, BC, Canada; [Ando, K.] Tokai Univ Hosp, Dept Hematol & Oncol, Isehara, Kanagawa, Japan; [Gomes da Silva, M.] Inst Portugues Oncol Francisco Gentil, Dept Hematol, Lisbon, Portugal; [Andre, M.] Univ Catholique Louvain Namur, CHU, Dept Hematol, Yvoir, Belgium; [Zachee, P.] Ziekenhuis Netwerk Antwerpen Stuivenberg, Dept Hematol, Antwerp, Belgium; [Tobinai, K.] Natl Canc Ctr, Dept Hematol, Tokyo, Japan; [Liu, D.; Wang, J.] Celgene, Summit, NJ USA	Universite de Lille - ISITE; CHU Lille; Universite de Lille; UNICANCER; Institut Paoli-Calmette (IPC); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Centre Henri Becquerel; Universite de Rouen Normandie; Universite de Rouen Normandie; CHU Dijon Bourgogne; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CHD Vendee; CHU Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre Hospitalier Annecy Genevois; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Universite de Montpellier; CHU de Montpellier; CHU Lyon; University of Texas System; UTMD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; University of Washington; University of Washington Seattle; Sarah Cannon Research Institute; Tennessee Oncology; Siteman Cancer Center; Washington University (WUSTL); University of Salamanca; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Barcelona; Hospital Clinic de Barcelona; Laval University; University of British Columbia; Tokai University; Portuguese Institute of Oncology; ZNA Stuivenberg; National Cancer Center - Japan; Bristol-Myers Squibb; Celgene Corporation	Morschhauser, F (corresponding author), Univ Lille, CHU Lille, EA 7365, GRITA Grp Rech Formes Injectables & Technol Assoc, F-59000 Lille, France.	franck.morschhauser@chru-lille.fr	Ysebaert, Loic/H-1554-2016; AndrÃ©, Marc/AAP-2355-2020; Remy, GRESSIN/G-7303-2014; Lopez-Guillermo, Armando/Z-5684-2019; Martín, Alejandro/B-8611-2018; Salles, Gilles/Z-2336-2019; , Van Eygen Koen/AAF-7668-2020; DECONINCK, ERIC/AAF-3647-2021; Soubeyran, Pierre-Louis/F-4523-2012	Ysebaert, Loic/0000-0001-8478-5623; Remy, GRESSIN/0000-0002-9188-3501; Martín, Alejandro/0000-0001-6330-1028; Salles, Gilles/0000-0002-9541-8666; , Van Eygen Koen/0000-0001-8285-906X; DECONINCK, ERIC/0000-0002-6006-8088; GYAN, Emmanuel/0000-0002-7651-9189; Haioun, Corinne/0000-0003-0095-5379; Bartlett, Nancy/0000-0001-8470-394X; Delmer, Alain/0000-0002-1430-2574; le gouill, steven/0000-0001-9840-2128; DEAU FISCHER, Benedicte/0000-0002-7468-5466; Novelli, Silvana/0000-0001-8750-0195; Gomes da Silva, Maria/0000-0002-6993-2450; Soubeyran, Pierre-Louis/0000-0003-3244-7299	Celgene	Celgene(Bristol-Myers SquibbCelgene Corporation)	Funded by Celgene; RELEVANCE ClinicalTrials.gov numbers, NCT01476787 and NCT01650701, and EudraCT number,2011-002792-42.	Bjorklund CC, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.66; Brice P, 1997, J CLIN ONCOL, V15, P1110, DOI 10.1200/JCO.1997.15.3.1110; Casulo C, 2015, BLOOD, V125, P40, DOI 10.1182/blood-2014-04-516815; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Chiu HL, 2017, BLOOD, V130; Crawford J, 2010, ANN ONCOL, V21, pv248, DOI 10.1093/annonc/mdq195; Dumortier A, 2003, BLOOD, V101, P2219, DOI 10.1182/blood-2002-05-1336; Flinn IW, 2014, BLOOD, V123, P2944, DOI 10.1182/blood-2013-11-531327; Fowler N., 2015, HEMATOL ONCOL, V33, P200; Fowler NH, 2014, LANCET ONCOL, V15, P1311, DOI 10.1016/S1470-2045(14)70455-3; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; Gandhi AK, 2014, BRIT J HAEMATOL, V164, P811, DOI 10.1111/bjh.12708; Hernandez-Ilizaliturri FJ, 2005, CLIN CANCER RES, V11, P5984, DOI 10.1158/1078-0432.CCR-05-0577; HUBBARD SM, 1982, BLOOD, V59, P258; Kimby E, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.1099.1099; Kridel R, 2012, J CLIN INVEST, V122, P3424, DOI 10.1172/JCI63186; Lagrue K, 2015, BLOOD, V126, P50, DOI 10.1182/blood-2015-01-625004; Link BK, 2013, J CLIN ONCOL, V31, P3272, DOI 10.1200/JCO.2012.48.3990; Lopez-Girona A, 2012, LEUKEMIA, V26, P2326, DOI 10.1038/leu.2012.119; Marcus R, 2017, NEW ENGL J MED, V377, P1331, DOI 10.1056/NEJMoa1614598; Martin P, 2017, ANN ONCOL, V28, P2806, DOI 10.1093/annonc/mdx496; Ramsay AG, 2009, BLOOD, V114, P4713, DOI 10.1182/blood-2009-04-217687; Reddy N, 2008, BRIT J HAEMATOL, V140, P36, DOI 10.1111/j.1365-2141.2007.06841.x; Rummel MJ, 2013, LANCET, V381, P1203, DOI 10.1016/S0140-6736(12)61763-2; SALLES GA, 2017, BLOOD S1, V130; Salles G, 2011, LANCET, V377, P42, DOI 10.1016/S0140-6736(10)62175-7; Salles Gilles A, 2007, Hematology Am Soc Hematol Educ Program, P216; Schulz H, 2007, JNCI-J NATL CANCER I, V99, P706, DOI 10.1093/jnci/djk152; Shi Q, 2017, J CLIN ONCOL, V35, P552, DOI 10.1200/JCO.2016.70.8651; Smith TJ, 2015, J CLIN ONCOL, V33, P3199, DOI 10.1200/JCO.2015.62.3488; Zhang L, 2009, AM J HEMATOL, V84, P553, DOI 10.1002/ajh.21468	31	184	189	1	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 6	2018	379	10					934	947		10.1056/NEJMoa1805104	http://dx.doi.org/10.1056/NEJMoa1805104			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GS5XM	30184451	Bronze			2023-01-03	WOS:000443748200008
J	Fleckenstein, J; Kruger, P; Ittner, KP				Fleckenstein, Johannes; Krueger, Peter; Ittner, Karl-Peter			Effects of single-point acupuncture (HT7) in the prevention of test anxiety: Results of a RCT	PLOS ONE			English	Article							TRIER SOCIAL STRESS; RANDOMIZED CONTROLLED-TRIAL; HEALTHY-SUBJECTS; WITHDRAWAL; RESPONSES; SYSTEM; WOMEN; RATS	Background The number of students using neuro enhancement to improve their performance and to prevent test anxiety is increasing. The acupuncture point Heart 7 (HT7) has been described as being prominent in reducing states of anxiety. Methods We conducted a randomized placebo-controlled, two-armed pilot trial to investigate the efficacy of a single-point acupuncture treatment at bilateral HT7 compared to sham laser acupuncture on test anxiety. Test anxiety was induced applying the standardised protocol of the Trier Social Stress Test. Outcome measures included saliva samples analysed for cortisol and amylase, anxiety questionnaires and heart rate variability. Results Twenty-five male subjects (age 28 +/- 5 years) were allocated to either verum acupuncture (n = 12) or sham laser acupuncture (n = 13). Cortisol peaked 20 min after the stress test (2-fold, 18.11 +/- 2 nmo1/1) and amylase 10 min after (2-fold, 259 +/- 49 U/ml) with no difference between groups. There were no differences between groups regarding either anxiety questionnaires or physiological parameters. Compared to reference data (3-fold increase in cortisol), increase in stress hormones and heart rate seemed somewhat reduced. Conclusions Acupuncture may be a possible approach for the treatment of anxiety. Due to the lack of a no control treatment group, we cannot determine the magnitude of possible specific needle effects at HT7 to promote specific effects in the neuroendocrine system. Finally this study only examines the efficacy of a single time treatment.	[Fleckenstein, Johannes] Univ Bern, Inst Complementary Med, Dept TCM Acupuncture, Personalhaus 4 Inselspital, Bern, Switzerland; [Fleckenstein, Johannes; Krueger, Peter; Ittner, Karl-Peter] Univ Hosp Regensburg, Franz Josef Str Allee 11, Regensburg, Germany; [Fleckenstein, Johannes] Goethe Univ Frankfurt, Inst Sports Sci, Dept Sports Med, Frankfurt, Germany	University of Bern; University of Regensburg; Goethe University Frankfurt	Fleckenstein, J (corresponding author), Univ Bern, Inst Complementary Med, Dept TCM Acupuncture, Personalhaus 4 Inselspital, Bern, Switzerland.; Fleckenstein, J (corresponding author), Univ Hosp Regensburg, Franz Josef Str Allee 11, Regensburg, Germany.; Fleckenstein, J (corresponding author), Goethe Univ Frankfurt, Inst Sports Sci, Dept Sports Med, Frankfurt, Germany.	johannes.fleckenstein@ikom.unibe.ch	Fleckenstein, Johannes/AAL-1315-2021	Fleckenstein, Johannes/0000-0003-3442-0380				Akimoto T, 2003, MED SCI SPORT EXER, V35, P1296, DOI 10.1249/01.MSS.0000078934.07213.25; de Lorent L, 2016, J ACUPUNCT MERIDIAN, V9, P191, DOI 10.1016/j.jams.2016.03.008; Diekelmann S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003512; Gaab J, 2005, PSYCHONEUROENDOCRINO, V30, P599, DOI 10.1016/j.psyneuen.2005.02.001; Greely H, 2008, NATURE, V456, P702, DOI 10.1038/456702a; Gruner F, 2010, THESIS; Haker E, 2000, J AUTONOM NERV SYST, V79, P52, DOI 10.1016/S0165-1838(99)00090-9; Henze GI, 2017, PSYCHONEUROENDOCRINO, V75, P52, DOI 10.1016/j.psyneuen.2016.10.002; Hinz A, 2012, PSYCHOTHER PSYCH MED, V62, P52, DOI 10.1055/s-0031-1297960; Irnich D, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq009; Isoyama D, 2012, ACUPUNCT MED, V30, P85, DOI 10.1136/acupmed-2011-010064; Isserstedt W, 2010, EC SOCIAL CONDITIONS; Kamody RC, 2018, BODY IMAGE, V25, P168, DOI 10.1016/j.bodyim.2018.04.003; Kim DH, 2018, NEUROSCI LETT, V664, P38, DOI 10.1016/j.neulet.2017.11.008; Kim SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081018; KIRSCHBAUM C, 1993, NEUROPSYCHOBIOLOGY, V28, P76, DOI 10.1159/000119004; Klausenitz C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168338; Kwong EYL, 2010, J VOICE, V24, P719, DOI 10.1016/j.jvoice.2009.05.005; MacPherson H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093739; MacPherson Hugh, 2002, Acupunct Med, V20, P22; Mandl H., 2006, HDB LERNSTRATEGIEN; Middendorff E., 2012, HOCHSCHUL INF SYST E, P11; Nedeljkovic M, 2012, PSYCHONEUROENDOCRINO, V37, P1171, DOI 10.1016/j.psyneuen.2011.12.007; Park HJ, 2011, CELL MOL NEUROBIOL, V31, P1123, DOI 10.1007/s10571-011-9718-x; Reschke-Hernandez AE, 2017, J NEUROSCI RES, V95, P106, DOI 10.1002/jnr.23851; Rizi MS, 2017, COMPLEMENT THER CLIN, V29, P136, DOI 10.1016/j.ctcp.2017.09.002; Schneider A, 2007, COMPLEMENT THER MED, V15, P255, DOI 10.1016/j.ctim.2006.12.002; Schweden TLK, 2016, J ANXIETY DISORD, V43, P99, DOI 10.1016/j.janxdis.2016.09.005; Shu Shi, 2011, Zhong Xi Yi Jie He Xue Bao, V9, P605; So EWS, 2010, REPROD BIOMED ONLINE, V20, P814, DOI 10.1016/j.rbmo.2010.02.024; Spielberger C.D., 1989, REDW CITY MIND GARD, Vsecond; Goyata SLT, 2016, REV BRAS ENFERM, V69, P564, DOI 10.1590/0034-7167.2016690325i; Villas-Boas JD, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/219579; VINCENT C, 1995, J ROY SOC MED, V88, P199; Wichmann S, 2017, PSYCHONEUROENDOCRINO, V77, P9, DOI 10.1016/j.psyneuen.2016.11.030; Zhao RJ, 2006, NEUROSCI LETT, V395, P28, DOI 10.1016/j.neulet.2005.10.043; Zhao ZL, 2015, NEUROSCI LETT, V597, P143, DOI 10.1016/j.neulet.2015.04.045	38	7	8	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2018	13	8							e0202659	10.1371/journal.pone.0202659	http://dx.doi.org/10.1371/journal.pone.0202659			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS2NZ	30161153	Green Published, Green Submitted, gold			2023-01-03	WOS:000443388900036
J	Sarker, S; Lim, UT				Sarker, Souvic; Lim, Un Taek			Extract of Nicotiana tabacum as a potential control agent of Grapholita molesta (Lepidoptera: Tortricidae)	PLOS ONE			English	Article							SPODOPTERA-FRUGIPERDA LEPIDOPTERA; ORIENTAL FRUIT MOTH; PLANT-EXTRACTS; ESSENTIAL OILS; INSECTICIDAL ACTIVITY; BIOLOGICAL-ACTIVITY; GRAPHOLITA-MOLESTA; AQUEOUS EXTRACTS; NOCTUIDAE; GROWTH	Oriental fruit moth, Grapholita molesta (Busck) (Lepidoptera: Tortricidae), is an important pest of stone and pome fruits. Growers usually depend on chemical insecticides to control this pest, but demand for more environmentally-friendly means of controlling pests is increasing. At least 91 plant extracts have been reported to be effective against other lepidopterans, but their acute toxicity against G. molesta has rarely been studied. Among these 91 materials, we assessed the residual toxicity of 32 extracts against first instar larvae (< 5 h old) of G. molesta in the laboratory. Nicotiana tabacum L., used at the concentration of 2 mg/ml, showed the highest corrected mortality (92.0%) with a lethal time (LT50) value of 12.9 h. The extract was followed in its efficacy by Allium sativum L. (88.0%), Zanthoxylum piperitum (L.) De Candolle (70.0%), and Sapindus mukorossi Gaertner (65.0%), when mortality was assessed at 20 h after exposure. Against adult fruit moths (< 5 d old), N. tabacum also showed the highest corrected mortality among tested extracts, being 85 and 100% in adult females and males, respectively, at 168 h after exposure. However, there was no synergistic effect of the combined application of any of the top four extracts in either laboratory or greenhouse assays. Oviposition by G. molesta on peach twigs was reduced 85-90% when N. tabacum was applied at 4 ml/ twig compared to control (methanol), demonstrating that N. tabacum may have potential for use as a botanical insecticide against G. molesta.	[Sarker, Souvic; Lim, Un Taek] Andong Natl Univ, Dept Plant Med, Andong, South Korea; [Lim, Un Taek] Andong Natl Univ, Inst Agr Sci & Technol, Andong, South Korea	Andong National University; Andong National University	Lim, UT (corresponding author), Andong Natl Univ, Dept Plant Med, Andong, South Korea.; Lim, UT (corresponding author), Andong Natl Univ, Inst Agr Sci & Technol, Andong, South Korea.	utlim@andong.ac.kr		Lim, Un Taek/0000-0002-6704-0627; Sarker, Souvic/0000-0001-6346-9656	Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry, and Fisheries (IPET) through the Advanced Production Technology Development Program; Ministry of Agriculture, Food, and Rural Affairs (MAFRA) [315007-03-2-HD050]	Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry, and Fisheries (IPET) through the Advanced Production Technology Development Program; Ministry of Agriculture, Food, and Rural Affairs (MAFRA)	This work was supported by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry, and Fisheries (IPET) through the Advanced Production Technology Development Program, funded by Ministry of Agriculture, Food, and Rural Affairs (MAFRA) (315007-03-2-HD050) to UTL.	Abbott WS, 1925, J ECON ENTOMOL, V18, P265, DOI 10.1093/jee/18.2.265a; Alim MA, 2017, FLA ENTOMOL, V100, P350, DOI 10.1653/024.100.0234; Alves DS, 2011, NEOTROP ENTOMOL, V40, P123, DOI 10.1590/S1519-566X2011000100019; Amoabeng BW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078651; Arivoli S., 2013, J ENTOMOL ZOOL STUD, V1, P87, DOI DOI 10.1186/1756-3305-6-337; Barboza J, 2010, REV BIOL TROP, V58, P1; Baskaran V, 1995, TRADITIONAL PEST CON, P91; Basukriadi A, 2014, J INSECT SCI, V14, DOI 10.1093/jisesa/ieu106; Ben Jannet H, 2001, IND CROP PROD, V14, P213, DOI 10.1016/S0926-6690(01)00086-3; Beninger CW, 2004, J CHEM ECOL, V30, P589, DOI 10.1023/B:JOEC.0000018631.67394.e5; BINDER RG, 1984, J ECON ENTOMOL, V77, P1585, DOI 10.1093/jee/77.6.1585; Bogorni PC, 2005, NEOTROP ENTOMOL, V34, P311, DOI 10.1590/S1519-566X2005000200020; Bouzouina M, 2012, BULG J AGRIC SCI, V18, P334; Brunherotto R, 2010, NEOTROP ENTOMOL, V39, P784, DOI 10.1590/S1519-566X2010000500018; Bullangpoti V, 2012, PEST MANAG SCI, V68, P1255, DOI 10.1002/ps.3291; Carrero J., 1996, LUCHAINTEGRADA PLAGA; Cloyd R., 2004, AM NURSERYMAN, V200, P41; Cox PD, 2004, J STORED PROD RES, V40, P1, DOI 10.1016/S0022-474X(02)00078-4; Dadang, 2001, Applied Entomology and Zoology, V36, P143, DOI 10.1303/aez.2001.143; de Brito EF, 2015, PESQUI AGROPECU BRAS, V50, P196, DOI 10.1590/S0100-204X2015000300002; Derbalah Aly S, 2012, ScientificWorldJournal, V2012, P639854, DOI 10.1100/2012/639854; Du J, 2015, ENVIRON ENTOMOL, V44, P1522, DOI 10.1093/ee/nvv124; Eddaya T, 2013, IND CROP PROD, V50, P325, DOI 10.1016/j.indcrop.2013.07.045; Eldefrawi M. E., 1990, SAFER INSECTICIDES D, P155; Er MK, 2009, J PEST SCI, V82, P95, DOI 10.1007/s10340-008-0223-z; Farias-Rivera LA, 2003, FLA ENTOMOL, V86, P239, DOI 10.1653/0015-4040(2003)086[0239:EOLEOT]2.0.CO;2; Figueroa-Brito R, 2011, INTERCIENCIA, V36, P752; Fouad HA, 2014, J STORED PROD RES, V57, P6, DOI 10.1016/j.jspr.2014.01.001; Freitas AF, 2014, NEOTROP ENTOMOL, V43, P446, DOI 10.1007/s13744-014-0225-x; Gallo MBC, 2006, PEST MANAG SCI, V62, P1072, DOI 10.1002/ps.1278; Ghanim NM, 2014, EGYPT J BIOL PEST CO, V24, P45; Han KyeungSik, 2001, Journal of Asia-Pacific Entomology, V4, P31, DOI 10.1016/S1226-8615(08)60099-0; Haouas D, 2010, CROP PROT, V29, P992, DOI 10.1016/j.cropro.2010.05.002; Hasheminia SM, 2011, PESTIC BIOCHEM PHYS, V99, P244, DOI 10.1016/j.pestbp.2010.12.009; Hernandez- Lambrano Ricardo, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, P695; HUANG XP, 1993, ENTOMOL EXP APPL, V68, P59, DOI 10.1007/BF02380582; Isman MB, 2000, CROP PROT, V19, P603, DOI 10.1016/S0261-2194(00)00079-X; Javed Iqbal, 2010, Pakistan Journal of Zoology, V42, P597; Jeong SE, 2001, J EXP BIOL, V204, P3935; Juarez ZN, 2014, NAT PROD COMMUN, V9, P895; Kanga LHB, 2003, PEST MANAG SCI, V59, P921, DOI 10.1002/ps.702; Karakoc OC, 2013, TURK ENTOMOL DERG-TU, V37, P73; Karakoc OC, 2012, TURK ENTOMOL DERG-TU, V36, P423; Kawuki RS, 2005, CROP PROT, V24, P473, DOI 10.1016/j.cropro.2004.09.017; Kraiss H, 2008, PEST MANAG SCI, V64, P660, DOI 10.1002/ps.1541; Kubo I, 2006, ADV PHYTOMED, V3, P61; Elisa GPL, 2010, AFR J BIOTECHNOL, V9, P3659; Magrini FE, 2015, IND CROP PROD, V65, P150, DOI 10.1016/j.indcrop.2014.11.032; Meriga B, 2012, ASIAN PAC J TROP MED, V5, P391, DOI 10.1016/S1995-7645(12)60065-0; Meshram P. B., 2000, Indian Forester, V126, P961; Najar-Rodriguez A, 2013, PHYSIOL ENTOMOL, V38, P63, DOI 10.1111/phen.12003; Natale D, 2003, B ENTOMOL RES, V93, P335, DOI 10.1079/BER2003250; Noosidum A, 2014, J VECTOR ECOL, V39, P298, DOI 10.1111/jvec.12104; Salinas-Sanchez DO, 2012, FLA ENTOMOL, V95, P428, DOI 10.1653/024.095.0225; Panneerselvam A., 2013, INT J PHARM SCI REV, V18, P150; Pessoa Alciani da Silva, 2014, Arq. Inst. Biol., V81, P329, DOI 10.1590/1808-1657000962012; Trindade RCP, 2011, REV COLOMB ENTOMOL, V37, P223; Pree DJ, 1998, CAN ENTOMOL, V130, P245, DOI 10.4039/Ent130245-3; Ramos-Lopez MA, 2010, AFR J BIOTECHNOL, V9, P1359; Ramzi S, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00328; Reegan Appadurai Daniel, 2015, Osong Public Health Res Perspect, V6, P64, DOI 10.1016/j.phrp.2014.08.009; Regnault-Roger C, 2004, BIOPESTICIDAS ORIGEN; RICE RE, 1972, J ECON ENTOMOL, V65, P1212, DOI 10.1093/jee/65.4.1212; Rizwan-ul-Haq M, 2010, PAK J BOT, V42, P3971; Rothschild G.H.L., 1991, TORTRICID PESTS THEI, V72, P389; SAS Institute, 2012, SAS US GUID STAT, V4th; Shalaby FF, 2013, TOXICOL ENVIRON CHEM, V95, P778, DOI 10.1080/02772248.2013.817724; Shonouda ML, 2000, J ENVIRON SCI HEAL B, V35, P347, DOI 10.1080/03601230009373275; Silva G, 2013, CHIL J AGR RES, V73, P135, DOI 10.4067/S0718-58392013000200008; Silva LB, 2009, BRAZ ARCH BIOL TECHN, V52, P653, DOI 10.1590/S1516-89132009000300018; Singh R, 2007, ENTOMOL GEN, V30, P51; So SS, 2012, ENTOMOL RES, V42, P158, DOI 10.1111/j.1748-5967.2012.00449.x; Soliman MMM, 2012, EGYPT J BIOL PEST CO, V22, P19; Soto F, 2011, REV BIOL TROP, V59, P487; SUN YP, 1960, J ECON ENTOMOL, V53, P887, DOI 10.1093/jee/53.5.887; Tambwekar KR, 2003, J PHARMACEUT BIOMED, V32, P441, DOI 10.1016/S0731-7085(03)00236-X; Tavares WD, 2013, J FOOD PROTECT, V76, P1892, DOI 10.4315/0362-028X.JFP-13-123; Tavares WD, 2009, IND CROP PROD, V30, P384, DOI 10.1016/j.indcrop.2009.07.007; Tilahun B, 2013, INT J TROP INSECT SC, V33, P256, DOI 10.1017/S1742758413000258; Trandafirescu M, 2013, ACTA HORTIC, V981, P533; Vandenborre G, 2010, J EXP BOT, V61, P1003, DOI 10.1093/jxb/erp365; Vijayalakshmi K, 1996, PLANT PEST CONTROL G, P1; Yang Chang Yeol, 2001, Korean Journal of Applied Entomology, V40, P117; Zaitoun ST, 2007, J FOOD AGRIC ENVIRON, V5, P289; Zar J.H., 2010, BIOSTAT ANAL; [张志祥 Zhang Zhixiang], 2008, [植物保护, Plant Protection], V34, P34; Zhong GH, 2001, J APPL ENTOMOL, V125, P563, DOI 10.1046/j.1439-0418.2001.00590.x; Zibaee I., 2015, Arthropods, V4, P107	88	11	14	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2018	13	8							e0198302	10.1371/journal.pone.0198302	http://dx.doi.org/10.1371/journal.pone.0198302			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR6TZ	30138428	Green Submitted, Green Published, gold			2023-01-03	WOS:000442800100003
J	Wang, T; Rodina, A; Dunphy, MP; Corben, A; Modi, S; Guzman, ML; Gewirth, DT; Chiosis, G				Wang, Tai; Rodina, Anna; Dunphy, Mark P.; Corben, Adriana; Modi, Shanu; Guzman, Monica L.; Gewirth, Daniel T.; Chiosis, Gabriela			Chaperome heterogeneity and its implications for cancer study and treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review						cancer biology; chaperone; chemical biology; stress response; biomarker; cancer therapy; heat shock protein 90 (Hsp90); 70 kilodalton heat shock protein (Hsp70); chaperome; chemical probes; epichaperome; protein networks	SHOCK-PROTEIN 90; ENDOPLASMIC-RETICULUM HSP90; PLANT-SPECIFIC THIOREDOXIN; TARGET RESIDENCE TIME; CONFORMATIONAL DYNAMICS; POSTTRANSLATIONAL MODIFICATIONS; INTERACTION NETWORK; ALLOSTERIC SITE; DRUG DISCOVERY; INHIBITORS	The chaperome is the collection of proteins in the cell that carry out molecular chaperoning functions. Changes in the interaction strength between chaperome proteins lead to an assembly that is functionally and structurally distinct from each constituent member. In this review, we discuss the epichaperome, the cellular network that forms when the chaperome components of distinct chaperome machineries come together as stable, functionally integrated, multimeric complexes. In tumors, maintenance of the epichaperome network is vital for tumor survival, rendering them vulnerable to therapeutic interventions that target critical epichaperome network components. We discuss how the epichaperome empowers an approach for precision medicine cancer trials where a new target, biomarker, and relevant drug candidates can be correlated and integrated. We introduce chemical biology methods to investigate the heterogeneity of the chaperome in a given cellular context. Lastly, we discuss how ligand-protein binding kinetics are more appropriate than equilibrium binding parameters to characterize and unravel chaperome targeting in cancer and to gauge the selectivity of ligands for specific tumor-associated chaperome pools.	[Wang, Tai; Rodina, Anna; Chiosis, Gabriela] Mem Sloan Kettering Canc Ctr, Chem Biol Program, New York, NY 10065 USA; [Dunphy, Mark P.] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10065 USA; [Modi, Shanu; Chiosis, Gabriela] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Corben, Adriana] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA; [Guzman, Monica L.] Weill Cornell Med Coll, Dept Med, Hematol & Med Oncol, New York, NY 10065 USA; [Gewirth, Daniel T.] Hauptman Woodward Med Res Inst, Buffalo, NY 14203 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Icahn School of Medicine at Mount Sinai; Cornell University; Hauptman Woodward Medical Research Institute	Chiosis, G (corresponding author), Mem Sloan Kettering Canc Ctr, Chem Biol Program, New York, NY 10065 USA.; Chiosis, G (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA.	chiosisg@mskcc.org		Wang, Tai/0000-0001-9984-9634	Lymphoma Research Foundation; National Institutes of Health [R01 CA172546, R56 AG061869, R01 CA155226, P01 CA186866, P30 CA08748, P50 CA192937, R01 CA102031]; Irma T. Hirschl/Monique Weill-Caulier Trust; Commonwealth Foundation for Cancer Research; Experimental Therapeutics Center of the Memorial Sloan Kettering Cancer Center; Unravel Pediatric Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA102031, P01CA186866, P30CA008748, R01CA172546, P50CA192937] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002384] Funding Source: NIH RePORTER	Lymphoma Research Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Irma T. Hirschl/Monique Weill-Caulier Trust; Commonwealth Foundation for Cancer Research; Experimental Therapeutics Center of the Memorial Sloan Kettering Cancer Center; Unravel Pediatric Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Supported by the Lymphoma Research Foundation.; Supported by National Institutes of Health Grants R01 CA172546 and R01 CA102031 and the Irma T. Hirschl/Monique Weill-Caulier Trust and Unravel Pediatric Cancer Foundation.; Supported by National Institutes of Health Grant P01 CA186866. 4 Supported by the National Institutes of Health Grants R01 CA172546, R56 AG061869, R01 CA155226, P01 CA186866, P30 CA08748, and P50 CA192937 and the Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research and the Experimental Therapeutics Center of the Memorial Sloan Kettering Cancer Center.	Albert R, 2005, J CELL SCI, V118, P4947, DOI 10.1242/jcs.02714; Amaral M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02258-w; Angelidis CE, 1999, EUR J BIOCHEM, V259, P505, DOI 10.1046/j.1432-1327.1999.00078.x; Bhagwat N, 2014, BLOOD, V123, P2075, DOI 10.1182/blood-2014-01-547760; Bhat R, 2014, J MED CHEM, V57, P8718, DOI 10.1021/jm500823a; Bracher A, 2015, FRONT MOL BIOSCI, V2, DOI 10.3389/fmolb.2015.00010; Brehme M, 2016, DIS MODEL MECH, V9, P823, DOI 10.1242/dmm.024703; Brehme M, 2014, CELL REP, V9, P1135, DOI 10.1016/j.celrep.2014.09.042; Brough PA, 2005, BIOORG MED CHEM LETT, V15, P5197, DOI 10.1016/j.bmcl.2005.08.091; Brough PA, 2008, J MED CHEM, V51, P196, DOI 10.1021/jm701018h; Brough PA, 2009, J MED CHEM, V52, P4794, DOI 10.1021/jm900357y; Bruce NJ, 2018, CURR OPIN STRUC BIOL, V49, P1, DOI 10.1016/j.sbi.2017.10.001; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Bussenius J, 2012, BIOORG MED CHEM LETT, V22, P5396, DOI 10.1016/j.bmcl.2012.07.052; Butler LM, 2015, MOL CANCER RES, V13, P1445, DOI 10.1158/1541-7786.MCR-15-0234; Calderwood SK, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/217513; Casale E, 2014, BIOORGAN MED CHEM, V22, P4135, DOI 10.1016/j.bmc.2014.05.056; Cha JY, 2013, PLANT PHYSIOL BIOCH, V70, P368, DOI 10.1016/j.plaphy.2013.05.039; Chadli A, 1999, J BIOL CHEM, V274, P4133, DOI 10.1074/jbc.274.7.4133; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; Chatterjee S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091978; Chiosis G, 2001, CHEM BIOL, V8, P289, DOI 10.1016/S1074-5521(01)00015-1; Corben AD, 2014, JOVE-J VIS EXP, DOI 10.3791/52157; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; Cusack KP, 2015, BIOORG MED CHEM LETT, V25, P2019, DOI 10.1016/j.bmcl.2015.02.027; DAHMER MK, 1984, ANNU REV PHYSIOL, V46, P67; Darby JF, 2011, NATURE, V478, P334, DOI 10.1038/478334b; Davies NGM, 2012, BIOORGAN MED CHEM, V20, P6770, DOI 10.1016/j.bmc.2012.08.050; de Witte WEA, 2016, TRENDS PHARMACOL SCI, V37, P831, DOI 10.1016/j.tips.2016.06.008; Dey B, 1996, MOL BIOL CELL, V7, P91, DOI 10.1091/mbc.7.1.91; Dollins DE, 2005, J BIOL CHEM, V280, P30438, DOI 10.1074/jbc.M503761200; Echeverria PC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026044; Echtenkamp FJ, 2012, BBA-MOL CELL RES, V1823, P668, DOI 10.1016/j.bbamcr.2011.08.011; Ernst JT, 2014, J MED CHEM, V57, P3382, DOI 10.1021/jm500042s; Esfahani AH, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1005890; Ferraro M, 2019, J MED CHEM, V62, P60, DOI 10.1021/acs.jmedchem.8b00825; Finka A, 2013, CELL STRESS CHAPERON, V18, P591, DOI 10.1007/s12192-013-0413-3; Finka A, 2011, CELL STRESS CHAPERON, V16, P15, DOI 10.1007/s12192-010-0216-8; Folmer RHA, 2018, DRUG DISCOV TODAY, V23, P12, DOI 10.1016/j.drudis.2017.07.016; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; Gewirth DT, 2016, CURR TOP MED CHEM, V16, P2779, DOI 10.2174/1568026616666160413141154; Goeckeler JL, 2002, MOL BIOL CELL, V13, P2760, DOI 10.1091/mbc.02-04-0051; Goldstein RL, 2015, J CLIN INVEST, V125, P4559, DOI 10.1172/JCI80714; Hatayama T, 1998, BIOCHEM BIOPH RES CO, V248, P395, DOI 10.1006/bbrc.1998.8979; He HZ, 2006, J MED CHEM, V49, P381, DOI 10.1021/jm0508078; Hiller S, 2018, J MAGN RESON, V289, P142, DOI 10.1016/j.jmr.2017.12.008; Horwich AL, 2013, J BIOL CHEM, V288, P23622, DOI 10.1074/jbc.X113.497321; Hothersall JD, 2016, DRUG DISCOV TODAY, V21, P90, DOI 10.1016/j.drudis.2015.07.015; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; Huth JR, 2007, CHEM BIOL DRUG DES, V70, P1, DOI 10.1111/j.1747-0285.2007.00535.x; Immormino RM, 2006, J MED CHEM, V49, P4953, DOI 10.1021/jm060297x; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Joshi S, 2018, NAT REV CANCER, V18, P562, DOI 10.1038/s41568-018-0020-9; Kakihara Y, 2012, BBA-MOL CELL RES, V1823, P101, DOI 10.1016/j.bbamcr.2011.08.016; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kampinga HH, 2010, NAT REV MOL CELL BIO, V11, P579, DOI 10.1038/nrm2941; Kanamaru C, 2014, J TOXICOL SCI, V39, P59, DOI 10.2131/jts.39.59; Kang YL, 2014, J MED CHEM, V57, P1188, DOI 10.1021/jm401551n; Khandelwal A, 2016, MED RES REV, V36, P92, DOI 10.1002/med.21351; Kim YE, 2013, ANNU REV BIOCHEM, V82, P323, DOI 10.1146/annurev-biochem-060208-092442; Kishinevsky S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06486-6; Kitson RRA, 2013, NAT CHEM, V5, P307, DOI [10.1038/NCHEM.1596, 10.1038/nchem.1596]; Koldewey P, 2017, J BIOL CHEM, V292, P12010, DOI 10.1074/jbc.R117.796862; Kourtis N, 2018, NAT MED, V24, P1157, DOI 10.1038/s41591-018-0105-8; Krukenberg KA, 2011, Q REV BIOPHYS, V44, P229, DOI 10.1017/S0033583510000314; Kucine N, 2015, BLOOD, V126, P2479, DOI 10.1182/blood-2015-03-635821; Kumar S, 2016, CANCER LETT, V374, P156, DOI 10.1016/j.canlet.2016.01.056; Kuznetsov G, 1996, P NATL ACAD SCI USA, V93, P8584, DOI 10.1073/pnas.93.16.8584; Lackie RE, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00254; Lee JR, 2009, P NATL ACAD SCI USA, V106, P5978, DOI 10.1073/pnas.0811231106; Lee SS, 2015, INT J MOL SCI, V16, P27302, DOI 10.3390/ijms161126019; Lepvrier E, 2015, ANAL CHEM, V87, P7043, DOI 10.1021/acs.analchem.5b00051; Li J, 2012, BBA-MOL CELL RES, V1823, P624, DOI 10.1016/j.bbamcr.2011.09.003; Li XK, 2016, CURR TOP MED CHEM, V16, P2729, DOI 10.2174/1568026616666160413140911; Li Z, 2013, NAT STRUCT MOL BIOL, V20, P929, DOI 10.1038/nsmb.2608; Lindberg I, 2015, J NEUROSCI, V35, P13853, DOI 10.1523/JNEUROSCI.2600-15.2015; Liu XD, 1999, J BIOL CHEM, V274, P26654, DOI 10.1074/jbc.274.38.26654; McBride CM, 2014, J MED CHEM, V57, P9124, DOI 10.1021/jm501107q; Miller SBM, 2015, J MOL BIOL, V427, P1564, DOI 10.1016/j.jmb.2015.02.006; Miyata Y, 2013, CURR PHARM DESIGN, V19, P347, DOI 10.2174/138161213804143725; Mollapour M, 2012, BBA-MOL CELL RES, V1823, P648, DOI 10.1016/j.bbamcr.2011.07.018; Moulick K, 2011, NAT CHEM BIOL, V7, P818, DOI 10.1038/nchembio.670; Murray CW, 2010, J MED CHEM, V53, P5942, DOI 10.1021/jm100059d; Nayar U, 2013, BLOOD, V122, P2837, DOI 10.1182/blood-2013-01-479972; Nemoto T, 1998, BIOCHEM J, V330, P989, DOI 10.1042/bj3300989; Nemoto TK, 2001, BIOCHEM J, V354, P663, DOI 10.1042/0264-6021:3540663; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Ojala PM, 2013, BLOOD, V122, P2767, DOI 10.1182/blood-2013-08-522425; Padhan N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01516-7; Palotai R, 2008, IUBMB LIFE, V60, P10, DOI 10.1002/iub.8; Patel HJ, 2015, J MED CHEM, V58, P3922, DOI 10.1021/acs.jmedchem.5b00197; Patel HJ, 2011, EXPERT OPIN DRUG DIS, V6, P559, DOI 10.1517/17460441.2011.563296; Patel PD, 2013, NAT CHEM BIOL, V9, P677, DOI [10.1038/NCHEMBIO.1335, 10.1038/nchembio.1335]; Pickrell AM, 2015, NEURON, V85, P257, DOI 10.1016/j.neuron.2014.12.007; Proisy N, 2006, CHEM BIOL, V13, P1203, DOI 10.1016/j.chembiol.2006.09.015; Radons J., 2016, BR J MED MED RES, V14, P1, DOI [10.9734/BJMMR/2016/24631, DOI 10.9734/BJMMR/2016/24631]; Rizzolo K, 2019, J BIOL CHEM, V294, P2142, DOI 10.1074/jbc.TM118.002805; Rodina A, 2016, NATURE, V538, P397, DOI 10.1038/nature19807; Rodina A, 2014, ACS CHEM BIOL, V9, P1698, DOI 10.1021/cb500256u; Rodina A, 2013, CHEM BIOL, V20, P1469, DOI 10.1016/j.chembiol.2013.10.008; Roughley SD, 2011, J MED CHEM, V54, P3989, DOI 10.1021/jm200350g; Sarah Kishinevsky AC, 2013, J ALZHEMERS DIS S10, ps10, DOI DOI 10.4172/2161-0460.S10-007; Schopf FH, 2017, NAT REV MOL CELL BIO, V18, P345, DOI 10.1038/nrm.2017.20; Shaner L, 2007, CELL STRESS CHAPERON, V12, P1, DOI 10.1379/CSC-245R.1; Shrestha L, 2016, CURR TOP MED CHEM, V16, P2753, DOI 10.2174/1568026616666160413141911; Shrestha L, 2016, CELL CHEM BIOL, V23, P158, DOI 10.1016/j.chembiol.2015.12.006; Sontag EM, 2017, ANNU REV BIOCHEM, V86, P97, DOI 10.1146/annurev-biochem-060815-014616; Speranza G, 2018, INVEST NEW DRUG, V36, P230, DOI 10.1007/s10637-017-0495-3; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Suda A, 2012, BIOORG MED CHEM LETT, V22, P1136, DOI 10.1016/j.bmcl.2011.11.100; Taipale M, 2014, CELL, V158, P434, DOI 10.1016/j.cell.2014.05.039; Taipale M, 2012, CELL, V150, P987, DOI 10.1016/j.cell.2012.06.047; Taipale M, 2010, NAT REV MOL CELL BIO, V11, P515, DOI 10.1038/nrm2918; Taldone T, 2016, J LABELLED COMPD RAD, V59, P129, DOI 10.1002/jlcr.3369; Taldone T, 2014, TRENDS PHARMACOL SCI, V35, P48, DOI 10.1016/j.tips.2014.09.001; Taldone T, 2014, J MED CHEM, V57, P1208, DOI 10.1021/jm401552y; Taldone T, 2013, J MED CHEM, V56, P6803, DOI 10.1021/jm400619b; Taldone T, 2013, BEILSTEIN J ORG CHEM, V9, P544, DOI 10.3762/bjoc.9.60; Taldone T, 2013, HETEROCYCLES, V87, P91, DOI 10.3987/COM-12-12613; Taldone T, 2011, BIOORG MED CHEM LETT, V21, P5347, DOI 10.1016/j.bmcl.2011.07.026; Taldone T, 2011, BIOORGAN MED CHEM, V19, P2603, DOI 10.1016/j.bmc.2011.03.013; Tautermann CS, 2016, CURR OPIN PHARMACOL, V30, P22, DOI 10.1016/j.coph.2016.07.004; Thompson AD, 2012, CELL STRESS CHAPERON, V17, P313, DOI 10.1007/s12192-011-0307-1; Tonge PJ, 2018, ACS CHEM NEUROSCI, V9, P29, DOI 10.1021/acschemneuro.7b00185; Vallee F, 2011, J MED CHEM, V54, P7206, DOI 10.1021/jm200784m; Vilenchik M, 2004, CHEM BIOL, V11, P787, DOI 10.1016/j.chembiol.2004.04.008; Wallace EWJ, 2015, CELL, V162, P1286, DOI 10.1016/j.cell.2015.08.041; Wang T, 2014, J MED CHEM, V57, P2524, DOI 10.1021/jm401801t; Wang XD, 2006, CELL, V127, P803, DOI 10.1016/j.cell.2006.09.043; Weidenauer L, 2017, EXPERT REV PROTEOMIC, V14, P1105, DOI 10.1080/14789450.2017.1389649; Woodford MR, 2016, ADV CANCER RES, V129, P31, DOI 10.1016/bs.acr.2015.09.002; Wright L, 2004, CHEM BIOL, V11, P775, DOI 10.1016/j.chembiol.2004.03.033; Wu ZX, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.016675; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641; Zhao RM, 2007, ADV EXP MED BIOL, V594, P27; Zhou D, 2013, TOXICOL APPL PHARM, V273, P401, DOI 10.1016/j.taap.2013.09.018; Zong HL, 2015, CELL REP, V13, P2159, DOI 10.1016/j.celrep.2015.10.073; Zuehlke AD, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0527	139	27	28	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2019	294	6					2162	2179		10.1074/jbc.REV118.002811	http://dx.doi.org/10.1074/jbc.REV118.002811			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HM8EO	30409908	hybrid, Green Published			2023-01-03	WOS:000459711400034
J	Klose, K; Gossen, M; Stamm, C				Klose, Kristin; Gossen, Manfred; Stamm, Christof			Turning fibroblasts into cardiomyocytes: technological review of cardiac transdifferentiation strategies	FASEB JOURNAL			English	Review						cardiac regeneration; heart disease; induced cardiomyocyte; in vivo reprogramming	PLURIPOTENT STEM-CELLS; HUMAN DERMAL FIBROBLASTS; BONE-MARROW-CELLS; MOUSE FIBROBLASTS; ENDOTHELIAL-CELLS; PROGENITOR CELLS; GENE-TRANSFER; TRANSCRIPTION FACTORS; DIRECT CONVERSION; IN-VITRO	To date, no viable therapeutic options exist for the effective and sustained reversal of cardiac failure, other than heart transplantation and mechanical circulatory assist devices. Therefore, divergent strategies aiming at the de novo formation of contractile tissue, as a prerequisite for the restoration of cardiac pump function, are currently being pursued. Clinical trials involving the transplantation of somatic progenitor cells failed. The search for alternative cell-based strategies to combat the consequences of ischemic injury has sparked widespread interest in the genetic and pharmacologic reprogramming of fibroblasts into cardiomyocytes, harnessing the abundant in vivo pool of cardiac fibroblasts. Here, we provide a comprehensive overview of in vitro and in vivo cardiac reprogramming studies identified in an extensive literature search. We systematically review and evaluate feasibility, efficiency, and reproducibility of the different technologies currently being explored. Finally, we discuss potential safety issues deduced from preclinical studies and identify obstacles that must be overcome before clinical translation.Klose, K., Gossen, M., Stamm, C. Turning fibroblasts into cardiomyocytes: technological review of cardiac transdifferentiation strategies.	[Klose, Kristin; Gossen, Manfred; Stamm, Christof] Berlin Brandenburg Ctr Regenerat Therapies BCRT, Berlin, Germany; [Klose, Kristin; Stamm, Christof] Berlin Brandenburg Sch Regenerat Therapies BSRT, Berlin, Germany; [Klose, Kristin; Stamm, Christof] Charite Univ Med Berlin, Berlin, Germany; [Gossen, Manfred] Helmholtz Zentrum Geesthacht HZG, Inst Biomat Sci, Teltow, Germany; [Stamm, Christof] German Ctr Cardiovasc Res DZHK, Partner Site Berlin, Berlin, Germany; [Stamm, Christof] Deutsch Herzzentrum Berlin DHZB, Dept Cardiothorac & Vasc Surg, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Helmholtz-Zentrum Geesthacht - Zentrum fur Material- und Kustenforschung; German Centre for Cardiovascular Research; German Heart Center Berlin	Stamm, C (corresponding author), Deutsch Herzzentrum Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany.	stamm@dhzb.de	Gossen, Manfred/K-9602-2013	Gossen, Manfred/0000-0002-1761-4063	Federal Ministry of Education and Research [FKZ 13GW0098, FKZ 13GW0099]; DFG through the Berlin-Brandenburg School for Regenerative Therapies GSC 203	Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); DFG through the Berlin-Brandenburg School for Regenerative Therapies GSC 203	This work was supported by the Federal Ministry of Education and Research (Grants FKZ 13GW0098 and FKZ 13GW0099). Moreover, contributions were made possible by DFG funding through the Berlin-Brandenburg School for Regenerative Therapies GSC 203. The authors declare no conflicts of interest.	Abad M, 2017, STEM CELL REP, V8, P548, DOI 10.1016/j.stemcr.2017.01.025; Addis RC, 2013, J MOL CELL CARDIOL, V60, P97, DOI 10.1016/j.yjmcc.2013.04.004; Bai F, 2015, SCI REP-UK, V5, DOI 10.1038/srep15014; Bakker ML, 2012, CARDIOVASC RES, V94, P439, DOI 10.1093/cvr/cvs120; Banerjee I, 2007, AM J PHYSIOL-HEART C, V293, pH1883, DOI 10.1152/ajpheart.00514.2007; Bar-Nur O, 2015, NAT BIOTECHNOL, V33, P761, DOI 10.1038/nbt.3247; Bektik E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183000; Belian E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125384; Ben-David U, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5825; Bian Q, 2016, TRENDS BIOTECHNOL, V34, P993, DOI 10.1016/j.tibtech.2016.05.010; Birket MJ, 2015, NAT BIOTECHNOL, V33, P970, DOI 10.1038/nbt.3271; Black JB, 2016, CELL STEM CELL, V19, P406, DOI 10.1016/j.stem.2016.07.001; Byun JH, 2000, J GENE MED, V2, P2; Cahan P, 2014, CELL, V158, P903, DOI 10.1016/j.cell.2014.07.020; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; Cao N, 2016, SCIENCE, V352, P1216, DOI 10.1126/science.aaf1502; Chandler RJ, 2017, HUM GENE THER, V28, P314, DOI 10.1089/hum.2017.009; Chandler RJ, 2016, MOL THER, V24, P198, DOI 10.1038/mt.2016.17; Chang YQ, 2016, CELL PHYSIOL BIOCHEM, V39, P157, DOI 10.1159/000445613; Chen JX, 2012, CIRC RES, V111, P50, DOI 10.1161/CIRCRESAHA.112.270264; Cho HJ, 2010, BLOOD, V116, P386, DOI 10.1182/blood-2010-02-269589; Christoforou N, 2008, J CLIN INVEST, V118, P894, DOI 10.1172/JCI33942; Christoforou N, 2017, SCI REP-UK, V7, DOI 10.1038/srep40285; Christoforou N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063577; Condorelli G, 2001, P NATL ACAD SCI USA, V98, P10733, DOI 10.1073/pnas.191217898; Dal-Pra S, 2017, CIRC RES, V120, P1403, DOI 10.1161/CIRCRESAHA.116.308741; David R, 2008, NAT CELL BIOL, V10, P338, DOI 10.1038/ncb1696; David R, 2009, CARDIOVASC RES, V84, P263, DOI 10.1093/cvr/cvp211; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Efe JA, 2011, NAT CELL BIOL, V13, P215, DOI 10.1038/ncb2164; EGHBALI M, 1991, P NATL ACAD SCI USA, V88, P795, DOI 10.1073/pnas.88.3.795; Fernandez-Perez A, 2017, JOVE-J VIS EXP, DOI 10.3791/55456; Fisher SA, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007888.pub3; Fisher SA, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006536.pub4; Fu JD, 2013, STEM CELL REP, V1, P235, DOI 10.1016/j.stemcr.2013.07.005; Fu YB, 2015, CELL RES, V25, P1013, DOI 10.1038/cr.2015.99; Furtado MB, 2014, CIRC RES, V114, P1422, DOI 10.1161/CIRCRESAHA.114.302530; Genovese JA, 2008, BIOCHEM BIOPH RES CO, V370, P450, DOI 10.1016/j.bbrc.2008.03.115; Ghazizadeh Z, 2017, MOL BIOTECHNOL, V59, P207, DOI 10.1007/s12033-017-0007-x; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gossen M, 2002, ANNU REV GENET, V36, P153, DOI 10.1146/annurev.genet.36.041002.120114; Greenberg B, 2016, LANCET, V387, P1178, DOI 10.1016/S0140-6736(16)00082-9; Guo YJ, 2017, ANIM SCI J, V88, P745, DOI 10.1111/asj.12700; GURDON JB, 1962, J EMBRYOL EXP MORPH, V10, P622; Hartung S, 2013, STEM CELLS DEV, V22, P1112, DOI 10.1089/scd.2012.0351; Hirai H, 2014, CARDIOVASC RES, V102, P188, DOI 10.1093/cvr/cvu023; Hirai H, 2013, CARDIOVASC RES, V100, P105, DOI 10.1093/cvr/cvt167; Hirai H, 2011, STEM CELLS, V29, P1349, DOI 10.1002/stem.684; Hu YF, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008681; Huang CW, 2018, CELL RES, V28, P686, DOI 10.1038/s41422-018-0036-4; Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002; Ifkovits JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089678; Inagawa K, 2012, CIRC RES, V111, P1147, DOI 10.1161/CIRCRESAHA.112.271148; Islas JF, 2012, P NATL ACAD SCI USA, V109, P13016, DOI 10.1073/pnas.1120299109; Jayawardena T, 2014, METHODS MOL BIOL, V1150, P263, DOI 10.1007/978-1-4939-0512-6_18; Jayawardena TM, 2015, CIRC RES, V116, P418, DOI 10.1161/CIRCRESAHA.116.304510; Jayawardena TM, 2012, CIRC RES, V110, P1465, DOI 10.1161/CIRCRESAHA.112.269035; Kamaraj US, 2016, CELL CYCLE, V15, P3343, DOI 10.1080/15384101.2016.1238119; Kapoor N, 2013, NAT BIOTECHNOL, V31, P54, DOI 10.1038/nbt.2465; Kim H, 2017, J BIOMAT SCI-POLYM E, V28, P1070, DOI 10.1080/09205063.2017.1287537; Kim TK, 2011, P NATL ACAD SCI USA, V108, P11918, DOI 10.1073/pnas.1101223108; Kofron CM, 2017, J PHYSIOL-LONDON, V595, P3891, DOI 10.1113/JP273100; Kong P, 2013, AM J PHYSIOL-HEART C, V305, pH1363, DOI 10.1152/ajpheart.00395.2013; Kong YP, 2013, SCI REP-UK, V3, DOI 10.1038/srep03474; Lalit PA, 2017, NAT PROTOC, V12, P1029, DOI 10.1038/nprot.2017.021; Lalit PA, 2016, CELL STEM CELL, V18, P354, DOI 10.1016/j.stem.2015.12.001; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; Lee K, 2015, INT J NANOMED, V10, P1841, DOI 10.2147/IJN.S75124; Lee S, 2017, CIRC RES, V120, P848, DOI 10.1161/CIRCRESAHA.116.309833; Li XH, 2015, STEM CELL TRANSL MED, V4, P1415, DOI 10.5966/sctm.2015-0136; Li YZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep38815; Li YX, 2010, TRENDS CARDIOVAS MED, V20, P228, DOI 10.1016/j.tcm.2011.11.006; Liu L, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.36; Liu ZQ, 2017, NATURE, V551, P100, DOI 10.1038/nature24454; Liu ZQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02460-2; Liu ZQ, 2016, STEM CELL RES, V16, P507, DOI 10.1016/j.scr.2016.02.037; Loew R, 2010, BMC BIOTECHNOL, V10, DOI 10.1186/1472-6750-10-81; Lucke C, 2010, EUR RADIOL, V20, P2074, DOI 10.1007/s00330-010-1791-x; Ma H, 2017, METHODS MOL BIOL, V1521, P69, DOI 10.1007/978-1-4939-6588-5_5; Ma H, 2015, CARDIOVASC RES, V108, P217, DOI 10.1093/cvr/cvv223; Maioli M, 2013, CELL TRANSPLANT, V22, P1227, DOI 10.3727/096368912X657297; Margariti A, 2012, P NATL ACAD SCI USA, V109, P13793, DOI 10.1073/pnas.1205526109; Mathison M, 2017, J THORAC CARDIOV SUR, V154, P1601, DOI 10.1016/j.jtcvs.2017.06.035; Mathison M, 2017, J THORAC CARDIOV SUR, V153, P329, DOI 10.1016/j.jtcvs.2016.09.041; Mathison M, 2014, J THORAC CARDIOV SUR, V148, P1656, DOI 10.1016/j.jtcvs.2014.03.033; Mathison M, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.005652; Maza I, 2015, NAT BIOTECHNOL, V33, P769, DOI 10.1038/nbt.3270; Menasche P, 2015, EUR HEART J, V36, P2011, DOI 10.1093/eurheartj/ehv189; MILLER RA, 1976, CELL, V9, P45, DOI 10.1016/0092-8674(76)90051-9; Miyamoto K, 2018, CELL STEM CELL, V22, P91, DOI 10.1016/j.stem.2017.11.010; Moerkamp AT, 2017, STEM CELLS DEV, V26, P1552, DOI 10.1089/scd.2017.0048; Mohamed TMA, 2017, CIRCULATION, V135, P978, DOI 10.1161/CIRCULATIONAHA.116.024692; Morez C, 2015, BIOMATERIALS, V70, P94, DOI 10.1016/j.biomaterials.2015.07.063; Muraoka N, 2014, EMBO J, V33, P1565, DOI 10.15252/embj.201387605; Murry CE, 1996, J CLIN INVEST, V98, P2209, DOI 10.1172/JCI119030; Nahrendorf M, 2010, CIRCULATION, V121, P2437, DOI 10.1161/CIRCULATIONAHA.109.916346; Nam YJ, 2014, DEVELOPMENT, V141, P4267, DOI 10.1242/dev.114025; Nam YJ, 2013, P NATL ACAD SCI USA, V110, P5588, DOI 10.1073/pnas.1301019110; Nasseri BA, 2007, CELL TRANSPLANT, V16, P941, DOI 10.3727/096368907783338235; Nasseri BA, 2014, EUR HEART J, V35, P1263, DOI 10.1093/eurheartj/ehu007; Nishimura K, 2011, J BIOL CHEM, V286, P4760, DOI 10.1074/jbc.M110.183780; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; O'Neill BT, 2005, J CLIN INVEST, V115, P2059, DOI 10.1172/JCI25900; Palazzolo G, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/4969430; Park G, 2015, BIOMATERIALS, V54, P201, DOI 10.1016/j.biomaterials.2015.02.029; Pillai ICL, 2017, CELL STEM CELL, V20, P218, DOI 10.1016/j.stem.2016.10.005; Pinto AR, 2016, CIRC RES, V118, P400, DOI 10.1161/CIRCRESAHA.115.307778; Piras BA, 2016, GENE THER, V23, P469, DOI 10.1038/gt.2016.20; Pratico ED, 2015, STEM CELLS DEV, V24, P2622, DOI 10.1089/scd.2015.0073; Protze S, 2012, J MOL CELL CARDIOL, V53, P323, DOI 10.1016/j.yjmcc.2012.04.010; Qian L, 2013, NAT PROTOC, V8, P1204, DOI 10.1038/nprot.2013.067; Qian L, 2012, NATURE, V485, P593, DOI 10.1038/nature11044; Raper SE, 2002, HUM GENE THER, V13, P163, DOI 10.1089/10430340152712719; Rastegar-Pouyani S, 2017, J CELL PHYSIOL, V232, P2053, DOI 10.1002/jcp.25580; Rentschler S, 2012, CIRCULATION, V126, P1058, DOI 10.1161/CIRCULATIONAHA.112.103390; Sauls K, 2018, CELL REP, V22, P1913, DOI 10.1016/j.celrep.2018.01.047; Sayed N, 2015, CIRCULATION, V131, P300, DOI 10.1161/CIRCULATIONAHA.113.007394; Schaffer DV, 2008, ANNU REV BIOMED ENG, V10, P169, DOI 10.1146/annurev.bioeng.10.061807.160514; Sia JR, 2016, BIOMATERIALS, V103, P1, DOI 10.1016/j.biomaterials.2016.06.034; Singh VP, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003922; Smith AW, 2013, BIOMATERIALS, V34, P6559, DOI 10.1016/j.biomaterials.2013.05.050; Solaro R, 2010, MATERIALS, V3, P1928, DOI 10.3390/ma3031928; Song KH, 2012, NATURE, V485, P599, DOI 10.1038/nature11139; Srivastava D, 2012, CIRC RES, V111, P5, DOI 10.1161/CIRCRESAHA.112.271452; Stamm C, 2004, THORAC CARDIOV SURG, V52, P152, DOI 10.1055/s-2004-817981; Stamm C, 2003, LANCET, V361, P45, DOI 10.1016/S0140-6736(03)12110-1; Stamm C, 2007, J THORAC CARDIOV SUR, V133, P717, DOI 10.1016/j.jtcvs.2006.08.077; Steinhoff G, 2017, EBIOMEDICINE, V22, P208, DOI 10.1016/j.ebiom.2017.07.022; Sun Y, 2000, CARDIOVASC RES, V46, P250, DOI 10.1016/S0008-6363(00)00032-8; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takeuchi JK, 2009, NATURE, V459, P708, DOI 10.1038/nature08039; Talaei-Khozani T, 2014, IRAN J MED SCI, V39, P203; Talkhabi M, 2017, J CELL COMMUN SIGNAL, V11, P193, DOI 10.1007/s12079-017-0387-5; Talkhabi M, 2015, BIOCHEM BIOPH RES CO, V463, P699, DOI 10.1016/j.bbrc.2015.05.127; Tallquist MD, 2017, NAT REV CARDIOL, V14, P484, DOI 10.1038/nrcardio.2017.57; Tang CC, 2010, CHINESE MED J-PEKING, V123, P2586, DOI 10.3760/cma.j.issn.0366-6999.2010.18.018; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; Tomaru Y, 2014, NUCLEIC ACIDS RES, V42, P8905, DOI 10.1093/nar/gku567; Treutlein B, 2016, NATURE, V534, P391, DOI 10.1038/nature18323; Ubil E, 2014, NATURE, V514, P585, DOI 10.1038/nature13839; Umei TC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081805; van Tuyn J, 2007, FASEB J, V21, P3369, DOI 10.1096/fj.07-8211com; Vaseghi HR, 2016, GENESIS, V54, P398, DOI 10.1002/dvg.22947; Wada R, 2013, P NATL ACAD SCI USA, V110, P12667, DOI 10.1073/pnas.1304053110; Wang HX, 2014, CELL REP, V6, P951, DOI 10.1016/j.celrep.2014.01.038; Wang L., 2015, JOVE-J VIS EXP, V105, P53426; Wang L, 2015, CIRC RES, V116, P237, DOI 10.1161/CIRCRESAHA.116.305547; Wang XW, 2016, SCI REP-UK, V6, DOI 10.1038/srep23017; Wang YY, 2016, CELL REPROGRAM, V18, P1, DOI 10.1089/cell.2015.0051; Wang YS, 2012, CELL BIOCHEM FUNCT, V30, P24, DOI 10.1002/cbf.1813; Wong WT, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731416628329; Xu JY, 2016, STEM CELLS, V34, P2693, DOI 10.1002/stem.2438; Yamakawa H, 2015, STEM CELL REP, V5, P1128, DOI 10.1016/j.stemcr.2015.10.019; Yoo J, 2017, J BIOMED NANOTECHNOL, V13, P269, DOI 10.1166/jbn.2017.2347; Zaglia T, 2009, J MOL CELL CARDIOL, V46, P653, DOI 10.1016/j.yjmcc.2008.12.010; Zhang H, 2013, CELL STEM CELL, V13, P30, DOI 10.1016/j.stem.2013.05.012; Zhang RL, 2013, NATURE, V498, P497, DOI 10.1038/nature12322; Zhang Y, 2016, CELL STEM CELL, V18, P368, DOI 10.1016/j.stem.2016.02.001; Zhao YB, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9243; Zhou HY, 2015, P NATL ACAD SCI USA, V112, P11864, DOI 10.1073/pnas.1516237112; Zhou L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048028; Zhou Q, 2008, CELL STEM CELL, V3, P382, DOI 10.1016/j.stem.2008.09.015; Zhou Y, 2016, CELL STEM CELL, V18, P382, DOI 10.1016/j.stem.2016.02.003	164	8	9	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2019	33	1					49	70		10.1096/fj.201800712R	http://dx.doi.org/10.1096/fj.201800712R			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HJ7TZ	30188756	Bronze			2023-01-03	WOS:000457401500005
J	Lan, YX; Mohr, C; Hu, XM; Kuhn, G				Lan, Yuxuan; Mohr, Christine; Hu, Xiaomeng; Kuhn, Gustav			Fake science: The impact of pseudo-psychological demonstrations on people's beliefs in psychological principles	PLOS ONE			English	Article							MAGICAL THINKING; MISINFORMATION; COEXISTENCE; SUGGESTION; CHILDREN	Magicians use deception to create effects that allow us to experience the impossible. More recently, magicians have started to contextualize these tricks in psychological demonstrations. We investigated whether witnessing a magic demonstration alters people's beliefs in these pseudo-psychological principles. In the classroom, a magician claimed to use psychological skills to read a volunteer's thoughts. After this demonstration, participants reported higher beliefs that an individual can 1) read a person's mind by evaluating micro expressions, psychological profiles and muscle activities, and 2) effectively prime a person's behaviour through subtle suggestions. Whether he was presented as a magician or psychologist did not influence people's beliefs about how the demonstration was achieved, nor did it influence their beliefs in pseudo-psychological principles. Our results demonstrate that pseudo-psychological demonstrations can have a significant impact on perpetuating false beliefs in scientific principles and raise important questions about the wider impact of scientific misinformation.	[Lan, Yuxuan; Hu, Xiaomeng] Tsinghua Univ, Sch Social Sci, Dept Psychol, Beijing, Peoples R China; [Mohr, Christine] Lausanne Univ, Dept Psychol, Lausanne, Switzerland; [Kuhn, Gustav] Goldsmiths Univ London, Dept Psychol, London, England	Tsinghua University; University of Lausanne; University of London; Goldsmiths University London	Kuhn, G (corresponding author), Goldsmiths Univ London, Dept Psychol, London, England.	g.kuhn@gold.ac.uk		Kuhn, Gustav/0000-0003-2888-914X; Mohr, Christine/0000-0002-3720-7115	Swiss National Science Foundation - SNF [100014_162370]	Swiss National Science Foundation - SNF(Swiss National Science Foundation (SNSF))	Funding was provided by Swiss National Science Foundation - SNF (100014_162370) to CM. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BENASSI VA, 1980, J SCI STUD RELIG, V19, P337, DOI 10.2307/1386128; Braddock K, 2016, COMMUN MONOGR, V83, P446, DOI 10.1080/03637751.2015.1128555; Busselle R, 2008, COMMUN THEOR, V18, P255, DOI 10.1111/j.1468-2885.2008.00322.x; Chan MPS, 2017, PSYCHOL SCI, V28, P1531, DOI 10.1177/0956797617714579; Christopher Milbourne, 2006, ILLUSTRATED HIST MAG; CRAWFORD HJ, 1992, J ABNORM PSYCHOL, V101, P663, DOI 10.1037/0021-843X.101.4.663; GILBERT DT, 1991, AM PSYCHOL, V46, P107, DOI 10.1037/0003-066X.46.2.107; Kuhn G., EXPERIENCING IMPOSSI; Lamont P., 2018, SECRET HIST MAGIC TR; Lamont Peter, 2013, EXTRAORDINARY BELIEF; Leddington J, 2016, J AESTHET ART CRITIC, V74, P253, DOI 10.1111/jaac.12290; Legare CH, 2008, COGNITIVE SCI, V32, P607, DOI 10.1080/03640210802066766; Legare CH, 2012, CHILD DEV, V83, P779, DOI 10.1111/j.1467-8624.2012.01743.x; Lesaffre L, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02129; Lewandowsky S, 2017, J APPL RES MEM COGN, V6, P353, DOI 10.1016/j.jarmac.2017.07.008; Lewandowsky S, 2012, PSYCHOL SCI PUBL INT, V13, P106, DOI 10.1177/1529100612451018; LOFTUS EF, 1995, PSYCHIAT ANN, V25, P720, DOI 10.3928/0048-5713-19951201-07; LOFTUS EF, 1974, J VERB LEARN VERB BE, V13, P585, DOI 10.1016/S0022-5371(74)80011-3; Marks D.F., 2000, PSYCHOL PSYCHIC; Mohr C, 2017, SCI MAG ASS C LOND; Mohr C, 2015, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01542; Nash M.R., 2012, OXFORD HDB HYPNOSIS, DOI DOI 10.3389/fpsyg.2013.00387; Parris BA, 2009, NEUROIMAGE, V45, P1033, DOI 10.1016/j.neuroimage.2008.12.036; Rensink RA, 2015, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01508; Subbotsky E, 2004, BRIT J DEV PSYCHOL, V22, P123, DOI 10.1348/026151004772901140; Subbotsky E, 2007, BRIT J PSYCHOL, V98, P547, DOI 10.1348/000712606X166069; Thomas C, 2017, Q J EXPT PSYCHOL; Thomas C, 2016, COGNITION, V154, P169, DOI 10.1016/j.cognition.2016.06.002; Wicht C, 2018, EXPLAIN PARANORMAL E; Wiseman R, 2003, BRIT J PSYCHOL, V94, P285, DOI 10.1348/000712603767876235; Woolley JD, 1997, CHILD DEV, V68, P991, DOI 10.2307/1132282	31	4	4	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2018	13	11							e0207629	10.1371/journal.pone.0207629	http://dx.doi.org/10.1371/journal.pone.0207629			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HB9UV	30481220	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000451440000016
J	Ramella, S; Fiore, M; Greco, C; Cordelli, E; Sicilia, R; Merone, M; Molfese, E; Miele, M; Cornacchione, P; Ippolito, E; Lannello, G; D'Angelillo, RM; Soda, P				Ramella, Sara; Fiore, Michele; Greco, Carlo; Cordelli, Ermanno; Sicilia, Rosa; Merone, Mario; Molfese, Elisabetta; Miele, Marianna; Cornacchione, Patrizia; Ippolito, Edy; Lannello, Giulio; D'Angelillo, Rolando Maria; Soda, Paolo			A radiomic approach for adaptive radiotherapy in non-small cell lung cancer patients	PLOS ONE			English	Article							TUMOR VOLUME CHANGES; MEGAVOLTAGE CT; FEATURES	The primary goal of precision medicine is to minimize side effects and optimize efficacy of treatments. Recent advances in medical imaging technology allow the use of more advanced image analysis methods beyond simple measurements of tumor size or radio tracer uptake metrics. The extraction of quantitative features from medical images to characterize tumor pathology or heterogeneity is an interesting process to investigate, in order to provide information that may be useful to guide the therapies and predict survival. This paper discusses the rationale supporting the concept of radiomics and the feasibility of its application to Non-Small Cell Lung Cancer in the field of radiation oncology research. We studied 91 stage III patients treated with concurrent chemoradiation and adaptive approach in case of tumor reduction during treatment. We considered 12 statistics features and 230 textural features extracted from the CT images. In our study, we used an ensemble learning method to classify patients' data into either the adaptive or non-adaptive group during chemoradiation on the basis of the starting CT simulation. Our data supports the hypothesis that a specific signature can be identified (AUC 0.82). In our experience, a radiomic signature mixing semantic and image-based features has shown promising results for personalized adaptive radiotherapy in non-small cell lung cancer.	[Ramella, Sara; Fiore, Michele; Greco, Carlo; Molfese, Elisabetta; Miele, Marianna; Cornacchione, Patrizia; Ippolito, Edy; D'Angelillo, Rolando Maria] Campus Biomed Univ, Radiotherapy Unit, Rome, Italy; [Cordelli, Ermanno; Sicilia, Rosa; Merone, Mario; Lannello, Giulio; Soda, Paolo] Campus Biomed Univ, Integrated Res Ctr, Comp Sci & Bioinformat Lab, Rome, Italy	University Campus Bio-Medico - Rome Italy; University Campus Bio-Medico - Rome Italy	Greco, C (corresponding author), Campus Biomed Univ, Radiotherapy Unit, Rome, Italy.	c.greco@unicampus.it	Merone, Mario/AAA-8945-2019; RAMELLA, SARA/AAC-6523-2022; Sicilia, Rosa/AAC-6012-2022; Michele, Fiore/AAC-6070-2022; Cornacchione, Patrizia/AAA-3420-2022; Soda, Paolo/K-8126-2016	Merone, Mario/0000-0002-9406-2397; RAMELLA, SARA/0000-0002-5782-7717; Sicilia, Rosa/0000-0002-2513-0827; Cornacchione, Patrizia/0000-0002-5573-6352; Fiore, Michele/0000-0003-1889-4578; ippolito, edy/0000-0003-1775-2009; Iannello, Giulio/0000-0003-3864-5800; Soda, Paolo/0000-0003-2621-072X				Aerts HJWL, 2016, JAMA ONCOL, V2, P1636, DOI 10.1001/jamaoncol.2016.2631; Alan Agresti, 2003, CATEGORICAL DATA ANA, V482; Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937; Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625; Cho Paik Myunghee, 2013, STAT METHODS RATES P; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Coroller TP, 2016, RADIOTHER ONCOL, V119, P480, DOI 10.1016/j.radonc.2016.04.004; Coroller TP, 2015, RADIOTHER ONCOL, V114, P345, DOI 10.1016/j.radonc.2015.02.015; Duda R.O., 2000, PATTERN CLASSIFICATI, V2nd; Fox J, 2009, INT J RADIAT ONCOL, V74, P341, DOI 10.1016/j.ijrobp.2008.07.063; Grossmann P, 2017, ELIFE, V6, DOI 10.7554/eLife.23421; HANLEY JA, 1982, RADIOLOGY, V29, P143, DOI DOI 10.1148/RADI0L0GY.143.1.7063747; Hua JP, 2005, BIOINFORMATICS, V21, P1509, DOI 10.1093/bioinformatics/bti171; Huynh E, 2016, RADIOTHER ONCOL, V120, P258, DOI 10.1016/j.radonc.2016.05.024; Knap MM, 2010, ACTA ONCOL, V49, P1077, DOI 10.3109/0284186X.2010.498434; Kohavi R., 1995, IJCAI, V14, P2; Kupelian PA, 2005, INT J RADIAT ONCOL, V63, P1024, DOI 10.1016/j.ijrobp.2005.04.046; Lambin P, 2012, EUR J CANCER, V48, P441, DOI 10.1016/j.ejca.2011.11.036; Li Q, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0892-y; Lim G, 2011, J THORAC ONCOL, V6, P531, DOI 10.1097/JTO.0b013e31820b8a52; Mackinnon A, 2000, COMPUT BIOL MED, V30, P127, DOI 10.1016/S0010-4825(00)00006-8; Manrai AK, 2014, JAMA INTERN MED, V174, P991, DOI 10.1001/jamainternmed.2014.1059; Ramella S, 2017, J THORAC ONCOL, V12, P1122, DOI 10.1016/j.jtho.2017.03.025; Saad M, 2017, COMPUT BIOL MED, V91, P222, DOI 10.1016/j.compbiomed.2017.10.029; Saeys Y, 2007, BIOINFORMATICS, V23, P2507, DOI 10.1093/bioinformatics/btm344; Siker ML, 2006, INT J RADIAT ONCOL, V66, P135, DOI 10.1016/j.ijrobp.2006.03.064; van Timmeren JE, 2017, RADIOTHER ONCOL, V123, P363, DOI 10.1016/j.radonc.2017.04.016; Velazquez ER, 2017, CANCER RES, V77, P3922, DOI 10.1158/0008-5472.CAN-17-0122; Wang H, 2015, CLIN LUNG CANCER, V16, pE141, DOI 10.1016/j.cllc.2015.05.007; Woodford C, 2007, INT J RADIAT ONCOL, V69, P1316, DOI 10.1016/j.ijrobp.2007.07.2369; Zhao GY, 2007, IEEE T PATTERN ANAL, V29, P915, DOI 10.1109/TPAMI.2007.1110	31	30	30	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2018	13	11							e0207455	10.1371/journal.pone.0207455	http://dx.doi.org/10.1371/journal.pone.0207455			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HB4VL	30462705	Green Published, gold, Green Submitted			2023-01-03	WOS:000451054800059
J	Ravi, R; Zulkrnin, NSH; Rozhan, NN; Yusoff, NRN; Rasat, MSM; Ahmad, MI; Ishak, IH; Amin, MFM				Ravi, Rajiv; Zulkrnin, Nor Shaida Husna; Rozhan, Nurul Nadiah; Yusoff, Nik Raihan Nik; Rasat, Mohd Sukhairi Mat; Ahmad, Muhammad Iqbal; Ishak, Intan H.; Amin, Mohamad Faiz Mohd			Chemical composition and larvicidal activities of Azolla pinnata extracts against Aedes (Diptera:Culicidae)	PLOS ONE			English	Article							COMMERCIAL BOTANICAL INSECTICIDES; OREOCHROMIS-NILOTICUS; VOLATILE COMPONENTS; AZADIRACHTA-INDICA; PLANT-EXTRACTS; CONSTITUENTS; MOSQUITO; ACID; PHYTOCHEMISTRY; OVIPOSITION	Background The resistance problem of dengue vectors to different classes of insecticides that are used for public health has raised concerns about vector control programmes. Hence, the discovery of alternative compounds that would enhance existing tools is important for overcoming the resistance problem of using insecticides in vectors and ensuring a chemical-free environment. The larvicidal effects of Azolla pinnata extracts by using two different extraction methods with methanol solvent against Aedes in early 4th instar larvae was conducted. Methods The fresh Azolla pinnata plant from Kuala Krai, Kelantan, Malaysia was used for crude extraction using Soxhlet and maceration methods. Then, the chemical composition of extracts and its structure were identified using GCMS-QP2010 Ultra (Shimadzu). Next, following the WHO procedures for larval bioassays, the extracts were used to evaluate the early 4th instar larvae of Aedes mosquito vectors. Results The larvicidal activity of Azolla pinnata plant extracts evidently affected the early 4th instar larvae of Aedes aegypti mosquito vectors. The Soxhlet extraction method had the highest larvicidal effect against Ae. aegypti early 4th instar larvae, with LC50 and LC95 values of 1093 and 1343 mg/L, respectively. Meanwhile, the maceration extraction compounds were recorded with the LC50 and LC95 values of 1280 and 1520 mg/L, respectively. The larvae bioassay test for Ae. albopictus showed closely similar values in its Soxhlet extraction, with LC50 and LC95 values of 1035 and 1524 mg/L, compared with the maceration extraction LC50 and LC95 values of 1037 and 1579 mg/L, respectively. The non-target organism test on guppy fish, Poecilia reticulata, showed no mortalities and posed no toxic effects. The chemical composition of the Azolla pinnata plant extract has been found and characterized as having 18 active compounds for the Soxhlet method and 15 active compounds for the maceration method. Conclusions Our findings showed that the crude extract of A. pinnata bioactive molecules are effective and have the potential to be developed as biolarvicides for Aedes mosquito vector control. This study recommends future research on the use of active ingredients isolated from A. pinnata extracts and their evaluation against larvicidal activity of Aedes in small-scale field trials for environmentally safe botanical insecticide invention.	[Ravi, Rajiv; Zulkrnin, Nor Shaida Husna; Rozhan, Nurul Nadiah; Yusoff, Nik Raihan Nik; Amin, Mohamad Faiz Mohd] Univ Malaysia Kelantan, Fac Earth Sci, Jeli Campus, Jeli, Kelantan, Malaysia; [Rasat, Mohd Sukhairi Mat; Ahmad, Muhammad Iqbal] Univ Malaysia Kelantan, Fac Bioengn & Technol, Jeli Campus, Jeli, Kelantan, Malaysia; [Ishak, Intan H.] Univ Sains Malaysia, Sch Biol Sci, Minden, Penang, Malaysia; [Ishak, Intan H.] Univ Sains Malaysia, Sch Biol Sci, Vector Control Res Unit, Minden, Penang, Malaysia	Universiti Malaysia Kelantan; Universiti Malaysia Kelantan; Universiti Sains Malaysia; Universiti Sains Malaysia	Amin, MFM (corresponding author), Univ Malaysia Kelantan, Fac Earth Sci, Jeli Campus, Jeli, Kelantan, Malaysia.; Ishak, IH (corresponding author), Univ Sains Malaysia, Sch Biol Sci, Minden, Penang, Malaysia.; Ishak, IH (corresponding author), Univ Sains Malaysia, Sch Biol Sci, Vector Control Res Unit, Minden, Penang, Malaysia.	intanishak@usm.my; mohamadfaiz@umk.edu.my	Yusoff, Nik Raihan Nik/Q-4215-2019; Ishak, Intan H./C-8723-2016; , Ravi/X-7522-2019; Amin, Mohamad Faiz Mohd/AAL-6357-2020; Ahmad, Dr. Muhammad Iqbal/AAX-3791-2021	Yusoff, Nik Raihan Nik/0000-0002-6879-3006; Ishak, Intan H./0000-0002-8916-0451; Amin, Mohamad Faiz Mohd/0000-0002-4283-1975; Ravi, Rajiv/0000-0003-4386-3810	Ministry of Higher Education, Malaysia [R/FRGS/A08.00/00425A/002/2017/000440]	Ministry of Higher Education, Malaysia(Ministry of Education, Malaysia)	This work was funded by the Ministry of Higher Education, Malaysia in support of this study through the Fundamental Research Grant Scheme (R/FRGS/A08.00/00425A/002/2017/000440).	Abou Y, 2007, AQUAC RES, V38, P595, DOI 10.1111/j.1365-2109.2007.01700.x; Adebowale KO, 2006, AFR J BIOTECHNOL, V5, P901; AhbiRami R, 2014, J INSECT SCI, V14, DOI 10.1093/jisesa/ieu042; Akhtar Y., 2008, Phytochemistry Reviews, V7, P77, DOI 10.1007/s11101-006-9048-7; Akpuaka A, 2013, NAT SCI, V11, P141; [Anonymous], 2017, UPD DENG SIT W PAC R; Aparna V, 2012, CHEM BIOL DRUG DES, V80, P434, DOI 10.1111/j.1747-0285.2012.01418.x; Atanasova D, 2018, MAYFEB J AGR SCI, V1, P10; Barakat D. A., 2011, Australian Journal of Basic and Applied Sciences, V5, P693; Baranitharan M, 2017, PROCESS SAF ENVIRON, V106, P23, DOI 10.1016/j.psep.2016.12.003; Bashir Ahmad, 2012, Journal of Medicinal Plants Research, V6, P4653; Bekele D, 2016, J FERTIL PESTIC, V7, P2; Bekele J, 2001, PHYTOCHEMISTRY, V57, P385, DOI 10.1016/S0031-9422(01)00067-X; Bindhu K. B., 2013, International Research Journal of Biological Sciences, V2, P88; Caceres LA, 2015, J ANAL APPL PYROL, V112, P333, DOI 10.1016/j.jaap.2015.01.003; Chen Y, 2018, ARCH BIOL SCI, V70, P349, DOI 10.2298/ABS170729052C; Cruz-Estrada A, 2013, ELECTRON J BIOTECHN, V16, DOI 10.2225/vol16-issue1-fulltext-6; Cuadrado V, 2010, INT J SYST EVOL MICR, V60, P2606, DOI 10.1099/ijs.0.018341-0; Cui SF, 2009, J CHROMATOGR B, V877, P1901, DOI 10.1016/j.jchromb.2009.05.022; Ekanayake T.H., 2007, P PERADENIYA U RES S, V12, P98; El-Sayed A.-F.M., 1992, Aquaculture and Fisheries Management, V23, P167, DOI 10.1111/j.1365-2109.1992.tb00607.x; Falodun A, 2009, TROPICAL J PHARM RES, V8; FENG R, 1995, EXPERIENTIA, V51, P831, DOI 10.1007/BF01922438; Fernando GKAW, 2018, BMC ECOL, V18, DOI 10.1186/s12898-018-0180-1; Gherraf N, 2017, ARAB J CHEM, V10, pS2476, DOI 10.1016/j.arabjc.2013.09.013; Ghosh A, 2012, INDIAN J MED RES, V135, P581; Ishak IH, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0797-2; Isman MB, 1996, RECENT ADV PHYTOCHEM, V30, P155; Jiang C. H., 2012, J MED PLANTS RES, V6, P3464; Kannathasan K, 2008, PARASITOL RES, V103, P999, DOI 10.1007/s00436-008-1078-1; Karabay-Yavasoglu NU, 2007, PHYTOTHER RES, V21, P153, DOI 10.1002/ptr.2045; Katsvanga C. A. T., 2004, Tropical and Subtropical Agroecosystems, V4, P101; KENAGA E E, 1969, Bulletin of the Entomological Society of America, V15, P85; Kisa A, 2018, REC NAT PROD, V12, P201, DOI 10.25135/rnp.23.17.07.126; Kumar A, 2011, NAT PROD RES, V25, P1680, DOI 10.1080/14786419.2010.511620; Kumar P. P., 2010, African Journal of Biochemistry Research, V4, P191; Kusumawathie PHD, 2006, J MED ENTOMOL, V43, P79, DOI 10.1603/0022-2585(2006)043[0079:LPOFSF]2.0.CO;2; Larvicides M., 2005, GUIDELINES LAB FIELD; Lu XM, 2018, APPL MICROBIOL BIOT, V102, P475, DOI 10.1007/s00253-017-8596-7; Lucie A.T., 2013, J LIFE SCI, V7, P1030; Truong MX, 2017, J ESSENT OIL BEAR PL, V20, P1157, DOI [10.1080/0972060X.2016.1259590, 10.1080/0972060x.2016.1259590]; McKerr C, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003639; Medhi SM, 2010, ASIAN PAC J TROP MED, V3, P841, DOI 10.1016/S1995-7645(10)60203-9; Michielin EMZ, 2009, BIORESOURCE TECHNOL, V100, P6615, DOI 10.1016/j.biortech.2009.07.061; Mohammad Shaheen Khan, 2016, Journal of Applied Pharmaceutical Science, V6, P157; Navarro-Silva MA, 2009, REV BRAS ENTOMOL, V53, P1, DOI 10.1590/S0085-56262009000100002; Nazni W, 2009, SUSCEPTIBILITY STATU; Ogunlesi M, 2009, AFRICAN J BIOTECHNOL, V8; Ojekale AB, 2013, IOSR J PHARM, V3; Olaoluwa OO, 2016, WORLD J PHARM PHARM, V5, P224; Paitan Y, 2004, ANAL BIOCHEM, V335, P175, DOI 10.1016/j.ab.2004.08.032; Pasdaran A., 2013, Pharmaceutical Sciences, V19, P1; Pavela R, 2016, PLANT PROTECT SCI, V52, P229, DOI 10.17221/31/2016-PPS; Peng ZK, 2004, J ALLERGY CLIN IMMUN, V114, P1189, DOI 10.1016/j.jaci.2004.08.014; Pereira Boscolli Barbosa, 2014, Cad. saúde colet., V22, P241, DOI 10.1590/1414-462X201400030004; Qian H, 2018, J CHROMATOGR A, V1559, P86, DOI 10.1016/j.chroma.2018.04.031; Ranson H., 2010, TROPIKA NET, V1, P0; Riaz M. A., 2018, Bangladesh Journal of Scientific and Industrial Research, V53, P169, DOI 10.3329/bjsir.v53i3.38262; SAWAGUCHI T, 1995, MACROMOL CHEM PHYSIC, V196, P4139, DOI 10.1002/macp.1995.021961221; Shadrach AU, 2018, AM J MICROBIOLOGY BI, V5, P12; Siddiqui BS, 2009, NAT PROD RES, V23, P271, DOI 10.1080/14786410802006082; Sivakumar R, 2011, ASIAN PAC J TROP MED, V4, P706, DOI 10.1016/S1995-7645(11)60178-8; Smaoui S, 2012, WORLD J MICROB BIOT, V28, P793, DOI 10.1007/s11274-011-0872-6; Ullah Z, 2018, CULEX QUIN QUEFASCIA; Villanes A, 2018, AM J TROP MED HYG, V98, P181, DOI 10.4269/ajtmh.17-0253; Ware GW, 2004, PESTICIDE BOOK, V6; Yayli N, 2006, TURK J CHEM, V30, P71; Zellagui Amar, 2012, Org Med Chem Lett, V2, P2, DOI 10.1186/2191-2858-2-2; Zulkrnin H, 2018, J PARASITOLOGY RES, V2018	69	14	17	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2018	13	11							e0206982	10.1371/journal.pone.0206982	http://dx.doi.org/10.1371/journal.pone.0206982			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ4NU	30399167	gold, Green Published, Green Submitted			2023-01-03	WOS:000449374000038
J	Stiles, L; Zheng, YW; Smith, PF				Stiles, Lucy; Zheng, Yiwen; Smith, Paul F.			The effects of electrical stimulation of the peripheral vestibular system on neurochemical release in the rat striatum	PLOS ONE			English	Article							D-SERINE; PARAFASCICULAR NUCLEUS; ACETYLCHOLINE-RELEASE; HIPPOCAMPAL-FORMATION; BRAIN MICRODIALYSIS; DOPAMINE RELEASE; BASAL GANGLIA; ACTIVATION; GLUTAMATE; CONNECTIONS	For over a century, it has been speculated that the vestibular system transmits information about self-motion to the striatum. There have been inconsistent reports of such a connection, and interest in the subject has been increased by the experimental use of galvanic vestibular stimulation in the treatment of Parkinson's Disease patients. Nonetheless, there are few data available on the effects of vestibular stimulation on neurochemical changes in the striatum. We used in vivo microdialysis to analyse changes in the extracellular levels of amino acids and monoamines in the rat striatum, following electrical vestibular stimulation. Stimulation caused a significant decrease in serine and threonine, compared to the no-stimulation controls (P <= 0.005 and P <= 0.01, respectively). The ratio of DOPAC:dopamine, decreased on the ipsilateral side following stimulation (P <= 0.005). There was a significant treatment x side x intensity interaction for taurine levels (P <= 0.002), due to a decrease on the contralateral side in stimulated animals, which varied as a function of current. These results show that peripheral vestibular stimulation causes some neurochemical changes in the striatum and support the view that activaton of the vestibular system exerts effects on the function of the striatum.	[Stiles, Lucy; Zheng, Yiwen; Smith, Paul F.] Univ Otago, Sch Biomed Sci, Dept Pharmacol & Toxicol, Dunedin, New Zealand; [Stiles, Lucy; Zheng, Yiwen; Smith, Paul F.] Univ Otago, Brain Hlth Res Ctr, Dunedin, New Zealand; [Stiles, Lucy; Zheng, Yiwen; Smith, Paul F.] Univ Otago, Brain Res New Zealand Ctr Res Excellence, Dunedin, New Zealand; [Stiles, Lucy; Zheng, Yiwen; Smith, Paul F.] Univ Auckland, Brain Res New Zealand Ctr Res Excellence, Auckland, New Zealand; [Stiles, Lucy; Zheng, Yiwen; Smith, Paul F.] Univ Auckland, Eisdell Moore Ctr Hearing & Balance Res, Auckland, New Zealand	University of Otago; University of Otago; University of Otago; University of Auckland; University of Auckland	Smith, PF (corresponding author), Univ Otago, Sch Biomed Sci, Dept Pharmacol & Toxicol, Dunedin, New Zealand.; Smith, PF (corresponding author), Univ Otago, Brain Hlth Res Ctr, Dunedin, New Zealand.; Smith, PF (corresponding author), Univ Otago, Brain Res New Zealand Ctr Res Excellence, Dunedin, New Zealand.; Smith, PF (corresponding author), Univ Auckland, Brain Res New Zealand Ctr Res Excellence, Auckland, New Zealand.; Smith, PF (corresponding author), Univ Auckland, Eisdell Moore Ctr Hearing & Balance Res, Auckland, New Zealand.	paul.smith@otago.ac.nz			University of Otago Research Committee [9076]; Maurice and Phyllis Paykel Trust [1954]; University of Otago PhD Scholarship; Jean Cathie Estate Senior Research Fellowship	University of Otago Research Committee; Maurice and Phyllis Paykel Trust; University of Otago PhD Scholarship; Jean Cathie Estate Senior Research Fellowship	This research was supported by grants from the University of Otago Research Committee (9076 to PFS*) and the Maurice and Phyllis Paykel Trust (1954 to PFS*). LS was supported by a University of Otago PhD Scholarship and YZ by a Jean Cathie Estate Senior Research Fellowship administered by the Auckland Medical Research Foundation.	Aitken P, 2017, BRAIN STRUCT FUNCT, V222, P3319, DOI 10.1007/s00429-017-1407-1; Aitken P, 2016, HIPPOCAMPUS, V26, P1509, DOI 10.1002/hipo.22651; Avila-Luna A, 2015, NEUROCHEM RES, V40, P1431, DOI 10.1007/s11064-015-1611-4; Babu GN, 2018, CLIN CHIM ACTA, V480, P214, DOI 10.1016/j.cca.2018.02.022; Beckstead R. M., 1993, NEUROANATOMY, P449; Blandini F, 1996, MOL NEUROBIOL, V12, P73, DOI 10.1007/BF02740748; Borland LM, 2005, J NEUROSCI METH, V146, P149, DOI 10.1016/j.jneumeth.2005.02.002; BOTTINI G, 1994, EXP BRAIN RES, V99, P164; Charpier S, 1997, P NATL ACAD SCI USA, V94, P7036, DOI 10.1073/pnas.94.13.7036; CLARKE DJ, 1983, BRAIN RES, V289, P342, DOI 10.1016/0006-8993(83)90039-2; Dawson R, 1999, BRAIN RES BULL, V48, P319, DOI 10.1016/S0361-9230(99)00003-9; Dehorter N, 2014, BASAL GANGLIA, V3, P197, DOI 10.1016/j.baga.2013.10.001; Della-Justina HM, 2015, EXP BRAIN RES, V233, P237, DOI 10.1007/s00221-014-4107-6; El Arfani A, 2015, NEUROCHEM INT, V88, P88, DOI 10.1016/j.neuint.2015.07.005; FALLON JH, 1978, J COMP NEUROL, V180, P545, DOI 10.1002/cne.901800310; FREUND TF, 1985, J NEUROSCI, V5, P603; GEYER MA, 1976, BRAIN RES, V106, P241, DOI 10.1016/0006-8993(76)91023-4; Giardino L, 1996, BRAIN RES, V736, P111, DOI 10.1016/S0006-8993(96)00692-0; Henneberger C, 2010, NATURE, V463, P232, DOI 10.1038/nature08673; HORII A, 1994, J NEUROPHYSIOL, V72, P605, DOI 10.1152/jn.1994.72.2.605; KELLEY AE, 1982, NEUROSCIENCE, V7, P2321, DOI 10.1016/0306-4522(82)90198-1; Khlebnikova NN, 2017, B EXP BIOL MED+, V163, P190, DOI 10.1007/s10517-017-3763-5; Kilb W, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00328; Kim DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069055; Kim N, 2017, EXP BRAIN RES, V235, P1617, DOI 10.1007/s00221-016-4864-5; Lai H, 2000, BRAIN RES, V872, P208, DOI 10.1016/S0006-8993(00)02457-4; LIEDGREN SRC, 1976, ACTA OTO-LARYNGOL, V81, P73, DOI 10.3109/00016487609107480; MATSUNAMI K, 1975, BRAIN RES, V91, P140, DOI 10.1016/0006-8993(75)90473-4; McCulloch C.E., 2008, GEN LINEAR MIXED MOD; Molchanova S, 2004, AMINO ACIDS, V27, P261, DOI 10.1007/s00726-004-0139-8; MOORE RY, 1978, ANNU REV NEUROSCI, V1, P129, DOI 10.1146/annurev.ne.01.030178.001021; Mothet JP, 2000, P NATL ACAD SCI USA, V97, P4926, DOI 10.1073/pnas.97.9.4926; Muskens LJJ, 1913, BRAIN, V36, P352; Muskens LJJ, 1922, BRAIN, V45, P454, DOI 10.1093/brain/45.3-4.454; Pan WD, 2008, J NEUROL, V255, P1657, DOI 10.1007/s00415-008-0950-3; Paxinos G., 2007, RAT BRAIN STEREOTAXI; Pisani A, 2005, MOVEMENT DISORD, V20, P395, DOI 10.1002/mds.20394; Rancz EA, 2015, J NEUROSCI, V35, P5926, DOI 10.1523/JNEUROSCI.1869-14.2015; Saddoris MP, 2015, J NEUROSCI, V35, P11572, DOI 10.1523/JNEUROSCI.2344-15.2015; Samoudi G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029308; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; SEGUNDO JP, 1956, J NEUROPHYSIOL, V19, P325, DOI 10.1152/jn.1956.19.4.325; Sergeeva OA, 2001, NEUROSCIENCE, V104, P1043, DOI 10.1016/S0306-4522(01)00130-0; SPIEGEL EA, 1965, ARCH NEUROL-CHICAGO, V12, P258, DOI 10.1001/archneur.1965.00460270034005; Stevens ER, 2003, P NATL ACAD SCI USA, V100, P6789, DOI 10.1073/pnas.1237052100; Stiles L, 2018, PHYSIOL REP, V6, DOI 10.14814/phy2.13791; Stiles L, 2015, BRAIN RES, V1597, P180, DOI 10.1016/j.brainres.2014.11.063; Tepper JM, 2004, CURR OPIN NEUROBIOL, V14, P685, DOI 10.1016/j.conb.2004.10.003; Timmerman W, 1997, SYNAPSE, V27, P242, DOI 10.1002/(SICI)1098-2396(199711)27:3<242::AID-SYN9>3.0.CO;2-D; VERSTEEG DHG, 1976, BRAIN RES, V113, P563, DOI 10.1016/0006-8993(76)90057-3; Vitte E, 1996, EXP BRAIN RES, V112, P523; Walker RH, 2009, SYNAPSE, V63, P136, DOI 10.1002/syn.20592; Ward RP, 1996, J COMP NEUROL, V370, P405, DOI 10.1002/(SICI)1096-9861(19960701)370:3<405::AID-CNE10>3.0.CO;2-R; WEINER DM, 1990, P NATL ACAD SCI USA, V87, P7050, DOI 10.1073/pnas.87.18.7050; WESTERINK BHC, 1988, J NEUROCHEM, V51, P683, DOI 10.1111/j.1471-4159.1988.tb01798.x; Wolosker H, 1999, P NATL ACAD SCI USA, V96, P13409, DOI 10.1073/pnas.96.23.13409; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Yamamoto Y, 2005, ANN NEUROL, V58, P175, DOI 10.1002/ana.20574; Zheng YW, 2014, HIPPOCAMPUS, V24, P541, DOI 10.1002/hipo.22247	59	7	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2018	13	10							e0205869	10.1371/journal.pone.0205869	http://dx.doi.org/10.1371/journal.pone.0205869			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY5SG	30372453	Green Published, Green Submitted, gold			2023-01-03	WOS:000448641200017
J	Manohar, P; Tamhankar, AJ; Lundborg, CS; Ramesh, N				Manohar, Prasanth; Tamhankar, Ashok J.; Lundborg, Cecilia Stalsby; Ramesh, Nachimuthu			Isolation, characterization and in vivo efficacy of Escherichia phage myPSH1131	PLOS ONE			English	Article							THERAPY; COLI; BACTERIOPHAGE; INFECTION; COCKTAILS; DIARRHEA; STRAINS	Phage therapy is the use of lytic bacteriophages to cure infections caused by bacteria. The aim of this study is to isolate and to characterize the bacteriophages against Escherichia coli isolated from clinical samples. For isolation of bacteriophages, water samples were collected from the Ganges River, and phage enrichment method was followed for phage isolation. Microbiological, genomic and lyophilization experiments were carried out to characterize the bacteriophage. Galleria mellonella was used to study the potential of phages against E. coli infection. Escherichia phage myPSH1131 belonging to Podoviridae family and found to have broad host range infectivity (n = 31) to infect Enterohemorrhagic E. coli (n = 9), Enteropathogenic E. coli (n = 6), Enterotoxigenic E. coli (n = 3), Enteroaggregative E. coli (n = 3), Uropathogenic E. coli (n = 9) and one unknown E. coll. The genome size is 76,163 base pairs (97 coding regions) and their genes show high similarity to SU10 phage. Lyophilization studies showed that the use of 1M sucrose, 2% gelatin and the combination of both 0.5M sucrose plus 1% gelatin could restore phage viability up to 20 months at 4 degrees C. For in vivo studies, it was observed that a single phage dose can reduce the E. coli infection but to achieve 100% survival rate the infected larvae should be treated with three phage doses (20 mu L, 10(3) PFU/mL) at 6 hours interval. The characterized Escherichia phage myPSH1131 was found to have broad host range activity against E. coli pathogens and in vivo studies showed that multiple doses are required for effective treatment.	[Manohar, Prasanth; Ramesh, Nachimuthu] VIT, Sch Biosci & Technol, Antibiot Resistance & Phage Therapy Lab, Vellore, Tamil Nadu, India; [Tamhankar, Ashok J.; Lundborg, Cecilia Stalsby] Karolinska Inst, Dept Publ Hlth Sci, Global Hlth Hlth Syst & Policy HSP Med Focusing A, Stockholm, Sweden; [Tamhankar, Ashok J.] Indian Initiat Management Antibiot Resistance, Bombay, Maharashtra, India	Vellore Institute of Technology; Karolinska Institutet	Ramesh, N (corresponding author), VIT, Sch Biosci & Technol, Antibiot Resistance & Phage Therapy Lab, Vellore, Tamil Nadu, India.	drpnramesh@gmail.com	Nachimuthu, Ramesh/S-8552-2016; Nachimuthu/N-8689-2019; Manohar, Prasanth/S-8486-2016	Nachimuthu, Ramesh/0000-0002-8350-1809; Nachimuthu/0000-0002-8350-1809; Manohar, Prasanth/0000-0002-5546-1117; Stalsby Lundborg, Cecilia/0000-0001-6525-1861	Vellore Institute of Technology; Swedish Research Council [2012-02889, 2017-01327]	Vellore Institute of Technology; Swedish Research Council(Swedish Research CouncilEuropean Commission)	This work was supported by the Vellore Institute of Technology in the form of a VIT Seed Grant. This work was partly supported by Swedish Research Council with grants to CSL (Grant No. 2012-02889 and 2017-01327). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agus A, 2016, SCI REP-UK, V6, DOI 10.1038/srep19032; Bisi-Johnson MA, 2011, GUT PATHOG, V3, DOI 10.1186/1757-4749-3-9; Bourdin G, 2014, APPL ENVIRON MICROB, V80, P1469, DOI 10.1128/AEM.03357-13; Bourdin G, 2014, MICROB BIOTECHNOL, V7, P165, DOI 10.1111/1751-7915.12113; Bruttin A, 2005, ANTIMICROB AGENTS CH, V49, P2874, DOI 10.1128/AAC.49.7.2874-2878.2005; Chan BK, 2013, FUTURE MICROBIOL, V8, P769, DOI [10.2217/fmb.13.47, 10.2217/FMB.13.47]; Dalmasso M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156773; Endersen L, 2014, ANNU REV FOOD SCI T, V5, P327, DOI 10.1146/annurev-food-030713-092415; Gill JJ, 2010, CURR PHARM BIOTECHNO, V11, P2, DOI 10.2174/138920110790725311; Hua YH, 2014, ARCH VIROL, V159, P3249, DOI 10.1007/s00705-014-2189-x; Jurczak-Kurek A, 2016, SCI REP-UK, V6, DOI 10.1038/srep34338; Maal KB, 2015, JUNDISHAPUR J MICROB, V8, DOI 10.5812/jjm.14945; Malik DJ, 2017, ADV COLLOID INTERFAC, V249, P100, DOI 10.1016/j.cis.2017.05.014; Merabishvili M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104853; Merabishvili M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068797; Merril CR, 1996, P NATL ACAD SCI USA, V93, P3188, DOI 10.1073/pnas.93.8.3188; Mirzaei MK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118557; Mirzaei MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116294; Nale JY, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01383; Nobrega FL, 2015, TRENDS MICROBIOL, V23, P185, DOI 10.1016/j.tim.2015.01.006; Olszak T, 2015, APPL MICROBIOL BIOT, V99, P6021, DOI 10.1007/s00253-015-6492-6; Pirnay JP, 2015, PHARM RES-DORDR, V32, P2173, DOI 10.1007/s11095-014-1617-7; Puapermpoonsiri U, 2010, INT J PHARMACEUT, V389, P168, DOI 10.1016/j.ijpharm.2010.01.034; Reardon S, 2014, NATURE, V510, P15, DOI 10.1038/510015a; Sabri MB, 2014, IRAQI J MED SCI, V12; Sarker SA, 2016, ANN NY ACAD SCI, V1372, P42, DOI 10.1111/nyas.13087; Seed KD, 2009, ANTIMICROB AGENTS CH, V53, P2205, DOI 10.1128/AAC.01166-08; Sharma S, 2017, FOLIA MICROBIOL, V62, P17, DOI 10.1007/s12223-016-0471-x; Tsai CJY, 2016, VIRULENCE, V7, P214, DOI 10.1080/21505594.2015.1135289; Vahedi A, 2018, FEMS MICROBIOL LETT, V365, DOI 10.1093/femsle/fny136	30	36	37	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2018	13	10							e0206278	10.1371/journal.pone.0206278	http://dx.doi.org/10.1371/journal.pone.0206278			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY3FL	30356310	Green Published, gold, Green Submitted			2023-01-03	WOS:000448434000088
J	Ma, ZY; Wang, P; Gao, ZH; Wang, RB; Khalighi, K				Ma, Zhiyuan; Wang, Ping; Gao, Zehui; Wang, Ruobing; Khalighi, Koroush			Ensemble of machine learning algorithms using the stacked generalization approach to estimate the warfarin dose	PLOS ONE			English	Article							VKORC1; PHARMACOGENETICS; PREDICT; CYP2C9; POLYMORPHISM; RESISTANCE; GENOTYPES	Warfarin dosing remains challenging due to narrow therapeutic index and highly individual variability. Incorrect warfarin dosing is associated with devastating adverse events. Remarkable efforts have been made to develop the machine learning based warfarin dosing algorithms incorporating clinical factors and genetic variants such as polymorphisms in CYP2C9 and VKORC1. The most widely validated pharmacogenetic algorithm is the IWPC algorithm based on multivariate linear regression (MLR). However, with only a single algorithm, the prediction performance may reach an upper limit even with optimal parameters. Here, we present novel algorithms using stacked generalization frameworks to estimate the warfarin dose, within which different types of machine learning algorithms function together through a meta-machine learning model to maximize the prediction accuracy. Compared to the IWPC-derived MLR algorithm, Stack 1 and 2 based on stacked generalization frameworks performed significantly better overall. Subgroup analysis revealed that the mean of the percentage of patients whose predicted dose of warfarin within 20% of the actual stable therapeutic dose (mean percentage within 20%) for Stack 1 was improved by 12.7% (from 42.47% to 47.86%) in Asians and by 13.5% (from 22.08% to 25.05%) in the low-dose group compared to that for MLR, respectively. These data suggest that our algorithms would especially benefit patients requiring low warfarin maintenance dose, as subtle changes in warfarin dose could lead to adverse clinical events (thrombosis or bleeding) in patients with low dose. Our study offers novel pharmacogenetic algorithms for clinical trials and practice.	[Ma, Zhiyuan; Wang, Ping; Khalighi, Koroush] Easton Cardiovasc Associates, Easton, PA 18042 USA; [Ma, Zhiyuan] Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA; [Gao, Zehui] San Diego State Univ, Dept Math & Stat, La Mesa, CA USA; [Wang, Ruobing] Duke Univ, Dept Chem, Durham, NC 27706 USA; [Wang, Ruobing] Duke Univ, Social Sci Res Inst, Durham, NC 27708 USA; [Wang, Ruobing] Sci Ctr Opera Solut LLC, San Diego, CA 92101 USA; [Khalighi, Koroush] Easton Hosp, Dept Med, Div Cardiol, Easton, PA 18042 USA; [Khalighi, Koroush] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA	Duke University; California State University System; San Diego State University; Duke University; Duke University; Drexel University	Ma, ZY; Khalighi, K (corresponding author), Easton Cardiovasc Associates, Easton, PA 18042 USA.; Ma, ZY (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA.; Wang, RB (corresponding author), Duke Univ, Dept Chem, Durham, NC 27706 USA.; Wang, RB (corresponding author), Duke Univ, Social Sci Res Inst, Durham, NC 27708 USA.; Wang, RB (corresponding author), Sci Ctr Opera Solut LLC, San Diego, CA 92101 USA.; Khalighi, K (corresponding author), Easton Hosp, Dept Med, Div Cardiol, Easton, PA 18042 USA.; Khalighi, K (corresponding author), Drexel Univ, Coll Med, Philadelphia, PA 19104 USA.	zhiyuan.ma@duke.edu; ruobing.wang@duke.edu; koroushkhalighi@gmail.com	Ma, ZhiYuan/GWN-1061-2022; Ma, Zhiyuan/I-6678-2015	Ma, Zhiyuan/0000-0002-0381-7804	Science Center of Opera Solutions LLC	Science Center of Opera Solutions LLC	The funder Science Center of Opera Solutions LLC provided support in the form of salaries for the author [R.W.], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Anderson JL, 2012, CIRCULATION, V125, P1997, DOI 10.1161/CIRCULATIONAHA.111.070920; Breiman L, 1996, MACH LEARN, V24, P49; D'Andrea G, 2005, BLOOD, V105, P645, DOI 10.1182/blood-2004-06-2111; Gage BF, 2008, CLIN PHARMACOL THER, V84, P326, DOI 10.1038/clpt.2008.10; Gage BF, 2017, JAMA-J AM MED ASSOC, V318, P1115, DOI 10.1001/jama.2017.11469; Grossi E, 2014, PHARMACOGENOMICS, V15, P29, DOI 10.2217/pgs.13.212; Hu YH, 2012, ARTIF INTELL MED, V56, P27, DOI 10.1016/j.artmed.2012.04.001; Joffe HV, 2004, THROMB HAEMOSTASIS, V91, P1123, DOI 10.1160/TH04-02-0083; Johnson JA, 2012, CIRCULATION, V125, P1964, DOI 10.1161/CIRCULATIONAHA.112.100628; Ke G., 2017, ADV NEURAL INFORM PR, P3146, DOI 10.5555/3294996.3295074; Kimmel SE, 2013, NEW ENGL J MED, V369, P2283, DOI 10.1056/NEJMoa1310669; Klein TE, 2009, NEW ENGL J MED, V360, P753, DOI 10.1056/NEJMoa0809329; Lenzini P, 2010, CLIN PHARMACOL THER, V87, P572, DOI 10.1038/clpt.2010.13; Limdi NA, 2010, BLOOD, V115, P3827, DOI 10.1182/blood-2009-12-255992; Liu K, 2013, METHOD INFORM MED, V52, P308, DOI 10.3414/ME12-01-0029; Liu R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135784; Ma Z, 2018, CLIN MODEL PRE UNPUB; Martin B, 2010, LECT NOTES ARTIF INT, V6304, P151, DOI 10.1007/978-3-642-15431-7_16; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Rieder MJ, 2005, NEW ENGL J MED, V352, P2285, DOI 10.1056/NEJMoa044503; Rost S, 2004, NATURE, V427, P537, DOI 10.1038/nature02214; Schalekamp T, 2006, CLIN PHARMACOL THER, V80, P13, DOI 10.1016/j.clpt.2006.04.006; Scott SA, 2008, AM J HUM GENET, V82, P495, DOI 10.1016/j.ajhg.2007.10.002; Shaw K, 2015, THER DRUG MONIT, V37, P428, DOI 10.1097/FTD.0000000000000192; Tao YY, 2019, IEEE J BIOMED HEALTH, V23, P395, DOI 10.1109/JBHI.2018.2812165; Ting KM, 1997, INT JOINT CONF ARTIF, P866; Wang RB, 2018, J PHYS CHEM C, V122, P8868, DOI 10.1021/acs.jpcc.8b03405; Wang SQ, 2006, J THEOR BIOL, V242, P941, DOI 10.1016/j.jtbi.2006.05.006; WOLPERT DH, 1992, NEURAL NETWORKS, V5, P241, DOI 10.1016/S0893-6080(05)80023-1	29	45	46	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2018	13	10							e0205872	10.1371/journal.pone.0205872	http://dx.doi.org/10.1371/journal.pone.0205872			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX5DH	30339708	gold, Green Published, Green Submitted			2023-01-03	WOS:000447761400022
J	Fujiwara, N; Wagatsuma, M; Oba, N; Yoshihara, D; Tokuda, E; Sakiyama, H; Eguchi, H; Ichihashi, M; Furukawa, Y; Inoue, T; Suzuki, K				Fujiwara, Noriko; Wagatsuma, Michiru; Oba, Naoto; Yoshihara, Daisaku; Tokuda, Eiichi; Sakiyama, Haruhiko; Eguchi, Hironobu; Ichihashi, Motoko; Furukawa, Yoshiaki; Inoue, Tadashi; Suzuki, Keiichiro			Cu/Zn-superoxide dismutase forms fibrillar hydrogels in a pH-dependent manner via a water-rich extended intermediate state	PLOS ONE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; QUARTZ-CRYSTAL MICROBALANCE; MOTOR-NEURON DEGENERATION; BETA-LACTOGLOBULIN GELS; TRANSGENIC MICE; WILD-TYPE; HYDROPHOBIC INTERACTIONS; AQUEOUS-SOLUTION; PROTEINS; AGGREGATION	Under certain conditions, amyloid-like fibrils can develop into three-dimensional networks and form hydrogels by a self-assembly process. When Cu/Zn superoxide dismutase (SOD1), an anti-oxidative enzyme, undergoes misfolding, fibrillar aggregates are formed, which are a hallmark of a certain form of familial amyotrophic lateral sclerosis (ALS). However, the issue of whether SOD1 fibrils can be assembled into hydrogels remains to be tested. Here, we show that the SOD1 polypeptides undergo hydrogelation accompanied by the formation of thioflavin T-positive fibrils at pH 3.0 and 4.0, but not at pH 5.0 where precipitates are formed. The results of viscoelastic analyses indicate that the properties of SOD1 hydrogels (2%) were similar to and slightly more fragile than a 0.25% agarose gel. In addition, monitoring by a quartz crystal microbalance with admittance analysis showed that the denaturing of immobilized SOD1 on a sensor under the hydrogelation conditions at pH 3.0 and 4.0 resulted in an increase in the effective acoustic thickness from similar to 3.3 nm (a folded rigid form) to similar to 50 and similar to 100 nm (an extended water-rich state), respectively. In contrast, when SOD1 was denatured under the same conditions at pH 5.0, a compact water-poor state with an effective acoustic thickness of similar to 10 nm was formed. The addition of physiological concentrations of NaCl to the pH 4.0 sample induced a further extension of the SOD1 with larger amounts of water molecules (with an effective acoustic thickness of similar to 200 nm) but suppressed hydrogel formation. These results suggest that different denatured intermediate states of the protein before self-assembly play a major role in determining the characteristics of the resulting aggregates and that a conformational change to a suitable level of extended water-rich intermediate state before and/or during intermolecular assembling is required for fibrillation and hydrogelation in the case of globular proteins.	[Fujiwara, Noriko; Yoshihara, Daisaku; Sakiyama, Haruhiko; Eguchi, Hironobu; Suzuki, Keiichiro] Hyogo Coll Med, Dept Biochem, Nishinomiya, Hyogo, Japan; [Wagatsuma, Michiru; Ichihashi, Motoko] ULVAC, Res & Dev, Chigasaki, Kanagawa, Japan; [Oba, Naoto; Inoue, Tadashi] Osaka Univ, Grad Sch Sci, Dept Macromol Sci, Toyonaka, Osaka, Japan; [Tokuda, Eiichi; Furukawa, Yoshiaki] Keio Univ, Dept Chem, Yokohama, Kanagawa, Japan	Hyogo College of Medicine; Osaka University; Keio University	Fujiwara, N (corresponding author), Hyogo Coll Med, Dept Biochem, Nishinomiya, Hyogo, Japan.	noriko-f@hyo-med.ac.jp	Tokuda, Eiichi/GXF-7231-2022; Furukawa, Yoshiaki/F-2871-2014; Yoshihara, Daisaku/L-6664-2019; INOUE, Tadashi/B-5581-2014	Furukawa, Yoshiaki/0000-0002-1918-372X; Tokuda, Eiichi/0000-0002-7690-3025; INOUE, Tadashi/0000-0002-9934-1299	Hyogo College of Medicine; JSPS [16K13060]	Hyogo College of Medicine; JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by Grant-in-Aid for Researchers, Hyogo College of Medicine, 2015 and JSPS KAKENHI (Grant Number 16K13060).	Abelein A, 2016, J AM CHEM SOC, V138, P6893, DOI 10.1021/jacs.6b04511; Aggeli A, 1997, NATURE, V386, P259, DOI 10.1038/386259a0; [Anonymous], 2009, MOR SOL STICK PROBL, P79; Arnesano F, 2004, J BIOL CHEM, V279, P47998, DOI 10.1074/jbc.M406021200; Baler K, 2014, BIOMACROMOLECULES, V15, P3625, DOI 10.1021/bm500883h; Bhak G, 2010, BIOMATERIALS, V31, P5986, DOI 10.1016/j.biomaterials.2010.03.080; Bowerman CJ, 2010, J AM CHEM SOC, V132, P9526, DOI 10.1021/ja1025535; Chan PK, 2013, P NATL ACAD SCI USA, V110, P10934, DOI 10.1073/pnas.1309613110; DiDonato M, 2003, J MOL BIOL, V332, P601, DOI 10.1016/S0022-2836(03)00889-1; Foegeding EA, 2006, FOOD BIOPHYS, V1, P41, DOI 10.1007/s11483-005-9003-y; Fujiwara N, 2005, J BIOL CHEM, V280, P5061, DOI 10.1074/jbc.M406106200; Fujiwara N, 2007, J BIOL CHEM, V282, P35933, DOI 10.1074/jbc.M702941200; Furukawa Y, 2005, J BIOL CHEM, V280, P17266, DOI 10.1074/jbc.M500482200; Furukawa Y, 2008, J BIOL CHEM, V283, P24167, DOI 10.1074/jbc.M802083200; Furusawa H, 2009, ANAL CHEM, V81, P2268, DOI 10.1021/ac802412t; Gosal WS, 2004, BIOMACROMOLECULES, V5, P2408, DOI 10.1021/bm049659d; Gosal WS, 2004, BIOMACROMOLECULES, V5, P2420, DOI 10.1021/bm049660c; Goto Yuji, 2018, Biophys Rev, V10, P493, DOI 10.1007/s12551-017-0370-7; Groot CCM, 2016, J PHYS CHEM LETT, V7, P1800, DOI 10.1021/acs.jpclett.6b00708; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hook F, 2002, COLLOID SURFACE B, V24, P155, DOI 10.1016/S0927-7765(01)00236-3; Hook F, 2001, ANAL CHEM, V73, P5796, DOI 10.1021/ac0106501; Hovgaard MB, 2007, BIOPHYS J, V93, P2162, DOI 10.1529/biophysj.107.109686; Ihara K, 2012, BIOSCIENCE REP, V32, P539, DOI 10.1042/BSR20120029; Itoh A, 2011, MEAS SCI TECHNOL, V22, DOI 10.1088/0957-0233/22/1/015402; Jean L, 2016, SCI REP-UK, V6, DOI 10.1038/srep32124; Kato M, 2012, CELL, V149, P753, DOI 10.1016/j.cell.2012.04.017; Kato S, 1999, HISTOL HISTOPATHOL, V14, P973, DOI 10.14670/HH-14.973; Krebs MRH, 2004, P NATL ACAD SCI USA, V101, P14420, DOI 10.1073/pnas.0405933101; Levy Y, 2006, ANNU REV BIOPH BIOM, V35, P389, DOI 10.1146/annurev.biophys.35.040405.102134; Manno M, 2010, LANGMUIR, V26, P1424, DOI 10.1021/la903340v; Miller AF, 2005, MACROMOL SY, V222, P109, DOI 10.1002/masy.200550412; MIURA N, 1994, BIOPOLYMERS, V34, P357, DOI 10.1002/bip.360340307; Murakami T, 2015, NEURON, V88, P678, DOI 10.1016/j.neuron.2015.10.030; Raman B, 2005, BIOCHEMISTRY-US, V44, P1288, DOI 10.1021/bi048029t; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; ROSSMURPHY SB, 1992, POLYMER, V33, P2622, DOI 10.1016/0032-3861(92)91146-S; Sakiyama H, 2016, FREE RADICAL RES, V50, P666, DOI 10.3109/10715762.2016.1164856; Sathaye S, 2014, BIOMACROMOLECULES, V15, P3891, DOI 10.1021/bm500874t; SAUERBREY G, 1959, Z PHYS, V155, P206, DOI 10.1007/BF01337937; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; Takeuchi S, 2010, J NEUROPATH EXP NEUR, V69, P1044, DOI 10.1097/NEN.0b013e3181f4a90a; Thirumalai D, 2012, ACCOUNTS CHEM RES, V45, P83, DOI 10.1021/ar2000869; Trabbic-Carlson K, 2003, BIOMACROMOLECULES, V4, P572, DOI 10.1021/bm025671z; Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155; Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647; Walters RH, 2012, J MOL BIOL, V421, P329, DOI 10.1016/j.jmb.2012.03.017; Wang J, 2002, NEUROBIOL DIS, V10, P128, DOI 10.1006/nbdi.2002.0498; Woodard D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094789; Yan H, 2006, BIOMACROMOLECULES, V7, P2776, DOI 10.1021/bm0605560; Yoshihara D, 2016, FREE RADICAL RES, V50, P1245, DOI 10.1080/10715762.2016.1234048	51	4	3	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2018	13	10							e0205090	10.1371/journal.pone.0205090	http://dx.doi.org/10.1371/journal.pone.0205090			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW0HY	30289953	Green Published, Green Submitted, gold			2023-01-03	WOS:000446545500047
J	Bartlow, CM; Mann, KA; Damron, TA; Oest, ME				Bartlow, Christopher M.; Mann, Kenneth A.; Damron, Timothy A.; Oest, Megan E.			Limited field radiation therapy results in decreased bone fracture toughness in a murine model	PLOS ONE			English	Article							HUMAN CORTICAL BONE; GLYCATION END-PRODUCTS; COLLAGEN CROSS-LINKS; SOFT-TISSUE SARCOMA; AGE-RELATED-CHANGES; X-RAY-IRRADIATION; BIOMECHANICAL PROPERTIES; NONENZYMATIC GLYCATION; IONIZING-RADIATION; GAMMA-IRRADIATION	Fragility fractures are a well-known complication following oncologic radiotherapy, and it is suspected that radiation-induced embrittlement of bone within the treatment field may contribute to fracture risk. To explore this phenomenon, a mouse model (BALB/cJ) of fractionated, limited field, bilateral hindlimb irradiation (4x5 Gy) was used. The effects of radiation on femoral (cortical) bone fracture toughness, morphology, and biochemistry-including advanced glycation end products (AGEs)-were quantified and compared to Sham group samples prior to irradiation and at 0, 4, 8, and 12 weeks post-irradiation. Additionally, alterations to bone fracture toughness mediated directly by radiation (independent of cellular mechanisms) were determined using devitalized mouse cadaver femurs. Finally, the contribution of AGEs to reduced fracture toughness was examined by artificially ribosylating mouse femurs ex vivo. These data demonstrate that in vivo irradiation results in an immediate (-42% at 0 weeks, p < 0.001) and sustained (-28% at 12 weeks, p < 0.001) decrease in fracture toughness with small changes in morphology (-5% in cortical area at 12 weeks), and minimal changes in bone composition (tissue mineral density, mineral:matrix ratio, and AGE content). Irradiation of devitalized femurs also reduced fracture toughness (-29%, p < 0.001), but to a lesser extent than was seen in vivo. While artificial ribosylation decreased fracture toughness with time, the extent of glycation needed to induce this effect exceeded the AGE accumulation that occurred in vivo. Overall, hindlimb irradiation induced a substantial and sustained decrease in bone fracture toughness. Approximately half of this decrease in fracture toughness is due to direct radiation damage, independent of cellular remodeling. Collagen glycation in vivo was not substantially altered, suggesting other matrix changes may contribute to post-radiotherapy bone embrittlement.	[Bartlow, Christopher M.; Mann, Kenneth A.; Damron, Timothy A.; Oest, Megan E.] SUNY Upstate Med Univ, Dept Orthoped Surg, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Oest, ME (corresponding author), SUNY Upstate Med Univ, Dept Orthoped Surg, Syracuse, NY 13210 USA.	oestm@upstate.edu	Damron, Timothy A./AAE-5816-2020		National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [R01AR065419, R01AR070142]; David G. Murray Endowment; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR070142, R01AR065419] Funding Source: NIH RePORTER	National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); David G. Murray Endowment; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under awards R01AR065419 (TAD) & R01AR070142 (MEO), and by the David G. Murray Endowment (TAD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding agency URLS: https://www.niams.nih.gov David G. Murray endowment has no url The funders had no role in study design, data, collection and analysis, decision to publish, or preparation of the manuscript.	Acevedo C, 2018, NAT BIOMED ENG, V2, P62, DOI 10.1038/s41551-017-0183-9; Akkus O, 2001, J ORTHOP RES, V19, P927, DOI 10.1016/S0736-0266(01)00004-3; Azzam EI, 2012, CANCER LETT, V327, P48, DOI 10.1016/j.canlet.2011.12.012; Bandstra ER, 2008, RADIAT RES, V169, P607, DOI 10.1667/RR1310.1; Barth HD, 2011, BIOMATERIALS, V32, P8892, DOI 10.1016/j.biomaterials.2011.08.013; Barth HD, 2010, BONE, V46, P1475, DOI 10.1016/j.bone.2010.02.025; Baxter NN, 2005, JAMA-J AM MED ASSOC, V294, P2587, DOI 10.1001/jama.294.20.2587; Bierhaus A, 1998, CARDIOVASC RES, V37, P586, DOI 10.1016/S0008-6363(97)00233-2; Burr DB, 2002, BONE, V31, P8, DOI 10.1016/S8756-3282(02)00815-3; Burton B, 2014, BONE, V61, P71, DOI 10.1016/j.bone.2014.01.006; Carriero A, 2014, J MECH BEHAV BIOMED, V39, P38, DOI 10.1016/j.jmbbm.2014.06.017; Chandra A, 2015, J BIOL CHEM, V290, P157, DOI 10.1074/jbc.M114.608158; Chandra A, 2013, BONE, V55, P449, DOI 10.1016/j.bone.2013.02.023; Chen HHW, 2002, RADIOTHER ONCOL, V62, P239, DOI 10.1016/S0167-8140(02)00002-6; Currey JD, 1997, J ORTHOP RES, V15, P111, DOI 10.1002/jor.1100150116; DARLEYUSMAR VM, 1992, FREE RADICAL RES COM, V17, P9, DOI 10.3109/10715769209061085; Dhakal S, 2011, INT J RADIAT ONCOL, V80, P1158, DOI 10.1016/j.ijrobp.2010.04.012; Dickie CI, 2009, INT J RADIAT ONCOL, V75, P1119, DOI 10.1016/j.ijrobp.2008.12.006; Doube M, 2010, BONE, V47, P1076, DOI 10.1016/j.bone.2010.08.023; FIDELER BM, 1995, AM J SPORT MED, V23, P643, DOI 10.1177/036354659502300521; Garnero P, 2006, BONE, V38, P300, DOI 10.1016/j.bone.2005.09.014; GIBBONS MJ, 1991, J ORTHOPAED RES, V9, P209, DOI 10.1002/jor.1100090209; Gong B, 2013, BONE, V57, P252, DOI 10.1016/j.bone.2013.08.014; Gortzak Y, 2010, CANCER-AM CANCER SOC, V116, P1553, DOI 10.1002/cncr.24949; Green DE, 2014, BONE, V63, P87, DOI 10.1016/j.bone.2014.02.018; Green DE, 2012, J BONE MINER RES, V27, P749, DOI 10.1002/jbmr.1505; Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11-10-1121; Hamer AJ, 1999, J BONE JOINT SURG BR, V81B, P342, DOI 10.1302/0301-620X.81B2.9083; Hamer AJ, 1996, J BONE JOINT SURG BR, V78B, P363, DOI 10.1302/0301-620X.78B3.0780363; Hernandez CJ, 2006, BONE, V39, P1173, DOI 10.1016/j.bone.2006.06.001; Hernandez CJ, 2005, BONE, V37, P825, DOI 10.1016/j.bone.2005.07.019; Inoue Yasuhiro, 2003, Int J Clin Oncol, V8, P336, DOI 10.1007/s10147-003-0340-x; Katsamenis OL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055641; Kondo H, 2010, J APPL PHYSIOL, V108, P152, DOI 10.1152/japplphysiol.00294.2009; Kondo H, 2009, RADIAT RES, V171, P283, DOI 10.1667/RR1463.1; Konski A, 1996, INT J RADIAT ONCOL, V35, P361, DOI 10.1016/0360-3016(95)02139-6; Kwon JW, 2008, AM J ROENTGENOL, V191, P987, DOI 10.2214/AJR.07.3634; McCormack J, 2012, BONE, V50, P1275, DOI 10.1016/j.bone.2012.02.018; Morales A, 1998, INT J RADIAT ONCOL, V42, P191, DOI 10.1016/S0360-3016(98)00185-0; Nalla RK, 2005, J BIOMECH, V38, P1517, DOI 10.1016/j.jbiomech.2004.07.010; NEUMAN RE, 1950, J BIOL CHEM, V184, P299; Nyaruba MM, 1998, ACTA RADIOL, V39, P43; Nystrom T, 2005, EMBO J, V24, P1311, DOI 10.1038/sj.emboj.7600599; Oest ME, 2018, J BONE MINER RES, V33, P99, DOI 10.1002/jbmr.3289; Oest ME, 2016, CALCIFIED TISSUE INT, V98, P619, DOI 10.1007/s00223-016-0111-0; Oest ME, 2016, BONE, V86, P91, DOI 10.1016/j.bone.2016.03.003; Oest ME, 2015, J ORTHOP RES, V33, P334, DOI 10.1002/jor.22761; Oest ME, 2014, RADIAT RES, V181, P439, DOI 10.1667/RR13451.1; Oh D, 2008, INT J RADIAT ONCOL, V70, P1183, DOI 10.1016/j.ijrobp.2007.08.005; Ott C, 2014, REDOX BIOL, V2, P411, DOI 10.1016/j.redox.2013.12.016; Park SH, 2011, RADIAT ONCOL J, V29, P269, DOI 10.3857/roj.2011.29.4.269; Paschalis EP, 2004, J BONE MINER RES, V19, P2000, DOI 10.1359/JBMR.040820; Paulino AC, 2004, INT J RADIAT ONCOL, V60, P265, DOI 10.1016/j.ijrobp.2004.02.001; Poundarik AA, 2015, J MECH BEHAV BIOMED, V50, P82, DOI 10.1016/j.jmbbm.2015.05.025; Poundarik AA, 2015, J MECH BEHAV BIOMED, V52, P120, DOI 10.1016/j.jmbbm.2015.08.012; Reddy GK, 1996, CLIN BIOCHEM, V29, P225, DOI 10.1016/0009-9120(96)00003-6; Reisz JA, 2014, ANTIOXID REDOX SIGN, V21, P260, DOI 10.1089/ars.2013.5489; Ritchie RO, 2008, BONE, V43, P798, DOI 10.1016/j.bone.2008.04.027; Saito M, 2011, CALCIFIED TISSUE INT, V88, P314, DOI 10.1007/s00223-011-9472-6; Salehpour A, 1995, J ORTHOP RES, V13, P898, DOI 10.1002/jor.1100130614; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; SINGH A, 1983, PROG BIOPHYS MOL BIO, V39, P69, DOI 10.1016/0079-6107(83)90014-7; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; Sroga GE, 2012, CURR OSTEOPOROS REP, V10, P141, DOI 10.1007/s11914-012-0103-6; Sternheim A, 2013, BONE JOINT J, V95B, P1144, DOI [10.1302/0301-620X.9588.31832, 10.1302/0301-620X.95B8.31832]; Tang SY, 2007, BONE, V40, P1144, DOI 10.1016/j.bone.2006.12.056; Tang SY, 2011, J BIOMECH, V44, P330, DOI 10.1016/j.jbiomech.2010.10.016; Vashishth D, 2001, BONE, V28, P195, DOI 10.1016/S8756-3282(00)00434-8; Viguet-Carrin S, 2006, OSTEOPOROSIS INT, V17, P319, DOI 10.1007/s00198-005-2035-9; Wang X, 2002, BONE, V31, P1, DOI 10.1016/S8756-3282(01)00697-4; Wernle JD, 2010, J BIOMECH, V43, P2738, DOI 10.1016/j.jbiomech.2010.06.017; Willey JS, 2008, RADIAT RES, V170, P388, DOI 10.1667/RR1388.1; Willey JS, 2010, BONE, V46, P101, DOI 10.1016/j.bone.2009.09.002; Wright LE, 2015, J BONE MINER RES, V30, P1268, DOI 10.1002/jbmr.2458; Yumoto K, 2010, RADIAT RES, V173, P494, DOI 10.1667/RR1754.1; Zimmermann EA, 2011, P NATL ACAD SCI USA, V108, P14416, DOI 10.1073/pnas.1107966108; Zioupos P, 2001, J BIOMATER APPL, V15, P187, DOI 10.1106/5JUJ-TFJ3-JVVA-3RJ0; Zou Q, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018-015-0339-9	78	14	14	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2018	13	10							e0204928	10.1371/journal.pone.0204928	http://dx.doi.org/10.1371/journal.pone.0204928			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV7VQ	30281657	gold, Green Submitted, Green Published			2023-01-03	WOS:000446342400068
J	Khalatbari-Soltani, S; Marques-Vidal, P				Khalatbari-Soltani, Saman; Marques-Vidal, Pedro			Adherence to hospital nutritional status monitoring and reporting guidelines	PLOS ONE			English	Article							CONSENSUS STATEMENT; CHARLSON INDEX; MALNUTRITION; CARE; NURSES; UNDERNUTRITION; DOCUMENTATION; DOCTORS; HEALTH; IDENTIFICATION	Aims of the study Despite the widespread existence of guidelines regarding undernutrition monitoring and reporting, there is scarce information whether they are followed. We aimed to evaluate the adherence to guidelines regarding undernutrition monitoring and reporting as well as their determinants in a university hospital. Methods Retrospective analysis of discharged patients with data on Nutritional Risk Screening score (NRS-2002) from the department of internal medicine of the Lausanne University Hospital for years 2013-14. Adherence to the hospital monitoring guidelines, i.e.: 1) discharged patients with NRS-2002 score >= 3 should have prealbumin levels measured, and 2) discharged patients with prealbumin levels<0.20 g/l should be rechecked 7 days afterwards, was assessed. Reporting of nutritionally 'at-risk' status in the discharge letter was also assessed. Multivariable logistic regression was used to examine potential determinants of adherence to guidelines. Results Of the 2,539 discharged patients with NRS-2002 data, 1,605 (63.0%) were nutritionally 'atrisk'. Complete adherence to the monitoring guideline was observed in 238 (14.8%) of 'atrisk' patients. After multivariable analysis, adherence to the first step of monitoring guideline was associated with older age (>= 80 years) [OR (95% CI): 2.03 (1.29-3.18)], high comorbidity index [1.36 (1.05-1.77)], and nutritional management [5.57 (4.38-7.07)]. Nutritional management was also associated with adherence to the second step of monitoring [3.98 (2.33-6.78)]. Adherence to the reporting guideline was observed in 343 (21.4%) of 'at-risk' patients. Multivariable analysis showed that adherence to the reporting guideline was associated with NRS-2002 score>4 [1.97 (1.47-2.64)], nutritional management [3.80 (2.85-5.07)], and adherence to the monitoring guideline [3.33 (2.35-4.71)]. Conclusions Our results show a poor adherence to guidelines regarding undernutrition monitoring and reporting, possibly due to lack of training, staff, and time.	[Khalatbari-Soltani, Saman] Inst Social & Prevent Med IUMSP, Lausanne, Switzerland; [Khalatbari-Soltani, Saman; Marques-Vidal, Pedro] Lausanne Univ Hosp CHUV, Dept Med, Internal Med, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Khalatbari-Soltani, S (corresponding author), Inst Social & Prevent Med IUMSP, Lausanne, Switzerland.; Khalatbari-Soltani, S (corresponding author), Lausanne Univ Hosp CHUV, Dept Med, Internal Med, Lausanne, Switzerland.	Saman.KhalatbariSoltani@unil.ch	Marques-Vidal, Pedro/C-9449-2009; Khalatbari Soltani, Saman/M-7161-2014	Marques-Vidal, Pedro/0000-0002-4548-8500; Khalatbari Soltani, Saman/0000-0001-8437-1906	Swiss Government Excellence PhD Scholarship [2014.0739]	Swiss Government Excellence PhD Scholarship	SK-S is a recipient of a Swiss Government Excellence PhD Scholarship [2014.0739]. This funding source had no contribution to the study design, analysis and interpretation, the writing of the report, or the decision to submit the article for publication.	Ahmed T, 2010, CLIN INTERV AGING, V5, P207; Attar A, 2012, NUTR CANCER, V64, P535, DOI 10.1080/01635581.2012.670743; Badia T, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0033-0; Barker LA, 2011, INT J ENV RES PUB HE, V8, P514, DOI 10.3390/ijerph8020514; Bavelaar JW, 2008, CLIN NUTR, V27, P431, DOI 10.1016/j.clnu.2008.01.016; Beck AM, 2002, CLIN NUTR, V21, P351, DOI 10.1054/clnu.2002.0555; Beck AM, 2001, CLIN NUTR, V20, P455, DOI 10.1054/clnu.2001.0494; Becker P, 2015, NUTR CLIN PRACT, V30, P147, DOI 10.1177/0884533614557642; Cederholm T, 2015, CLIN NUTR, V34, P335, DOI 10.1016/j.clnu.2015.03.001; Cereda E, 2010, EUR J CLIN NUTR, V64, P894, DOI 10.1038/ejcn.2010.85; Costa Sandra Patricia da, 2010, Rev. Gaúcha Enferm., V31, P62, DOI 10.1590/S1983-14472010000100009; Elia M, 2005, CLIN NUTR, V24, P867, DOI 10.1016/j.clnu.2005.03.004; Geurden B, 2014, INT J NURS KNOWL, V25, P43, DOI 10.1111/2047-3095.12011; Goldstein LB, 2004, STROKE, V35, P1941, DOI 10.1161/01.STR.0000135225.80898.1c; Guenter P, 2015, JT COMM J QUAL PATIE, V41, P469, DOI 10.1016/S1553-7250(15)41061-X; Imoberdorf R, 2010, CLIN NUTR, V29, P38, DOI 10.1016/j.clnu.2009.06.005; Khalatbari-Soltani S, 2016, CLIN NUTR, V35, P1340, DOI 10.1016/j.clnu.2016.02.012; Kondrup J, 2003, CLIN NUTR, V22, P415, DOI 10.1016/S0261-5614(03)00098-0; Kondrup J, 2003, CLIN NUTR, V22, P321, DOI 10.1016/S0261-5614(02)00214-5; Kyle UG, 2006, CLIN NUTR, V25, P409, DOI 10.1016/j.clnu.2005.11.001; Lindorff-Larsen K, 2007, CLIN NUTR, V26, P371, DOI 10.1016/j.clnu.2007.01.006; Meijers JMM, 2009, NUTRITION, V25, P512, DOI 10.1016/j.nut.2008.11.004; Mowe M, 2008, CLIN NUTR, V27, P196, DOI 10.1016/j.clnu.2007.10.014; Mowe M, 2006, CLIN NUTR, V25, P524, DOI 10.1016/j.clnu.2005.11.011; Mueller C, 2011, JPEN-PARENTER ENTER, V35, P16, DOI 10.1177/0148607110389335; Organisation for Economic Cooperation and Development; World Health Organization, 2011, OECD REV HLTH SYST, DOI [10.1787/9789264120914-en, DOI 10.1787/9789264120914-EN]; Persenius MW, 2008, J CLIN NURS, V17, P2125, DOI 10.1111/j.1365-2702.2007.02202.x; Porben SS, 2006, CLIN NUTR, V25, P1015, DOI 10.1016/j.clnu.2006.04.001; Rasmussen HH, 1999, CLIN NUTR, V18, P153, DOI 10.1016/S0261-5614(99)80005-3; Sauer AC, 2016, NURSINGPLUS OPEN, V2, P21, DOI [10.1016/j.npls.2016.05.001, DOI 10.1016/J.NPLS.2016.05.001]; Schindler K, 2010, CLIN NUTR, V29, P552, DOI 10.1016/j.clnu.2010.04.001; Soeters P, 2017, CLIN NUTR, V36, P896, DOI 10.1016/j.clnu.2016.09.032; Sukkar SG, 2012, MEDITERR J NUTR META, V5, P75, DOI 10.1007/s12349-012-0105-z; Sundararajan V, 2007, MED CARE, V45, P1210, DOI 10.1097/MLR.0b013e3181484347; Tappenden KA, 2013, JPEN-PARENTER ENTER, V37, P482, DOI 10.1177/0148607113484066; Vonzun N, 2014, THER UMSCH, V71, P185, DOI 10.1024/0040-5930/a000501	37	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2018	13	9							e0204000	10.1371/journal.pone.0204000	http://dx.doi.org/10.1371/journal.pone.0204000			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GU5MM	30240436	Green Submitted, gold, Green Published			2023-01-03	WOS:000445329700019
J	Eklund, A; Jensen, I; Lohela-Karlsson, M; Hagberg, J; Leboeuf-Yde, C; Kongsted, A; Bodin, L; Axen, I				Eklund, Andreas; Jensen, Irene; Lohela-Karlsson, Malin; Hagberg, Jan; Leboeuf-Yde, Charlotte; Kongsted, Alice; Bodin, Lennart; Axen, Iben			The Nordic Maintenance Care program: Effectiveness of chiropractic maintenance care versus symptom-guided treatment for recurrent and persistent low back pain-A pragmatic randomized controlled trial	PLOS ONE			English	Article							SPINAL MANIPULATIVE THERAPY; SWEDISH VERSION; SUBPOPULATION PROGRAM; DANISH CHIROPRACTORS; HEALTH-PROMOTION; CLINICAL-COURSE; MPI-S; RELIABILITY; INTERVIEW; VALIDITY	Background For individuals with recurrent or persistent non-specific low back pain (LBP), exercise and exercise combined with education have been shown to be effective in preventing new episodes or in reducing the impact of the condition. Chiropractors have traditionally used Maintenance Care (MC), as secondary and tertiary prevention strategies. The aim of this trial was to investigate the effectiveness of MC on pain trajectories for patients with recurrent or persistent LBP. Method This pragmatic, investigator-blinded, two arm randomized controlled trial included consecutive patients (18-65 years old) with non-specific LBP, who had an early favorable response to chiropractic care. After an initial course of treatment, eligible subjects were randomized to either MC or control (symptom-guided treatment). The primary outcome was total number of days with bothersome LBP during 52 weeks collected weekly with text-messages (SMS) and estimated by a GEE model. Results Three hundred and twenty-eight subjects were randomly allocated to one of the two treatment groups. MC resulted in a reduction in the total number of days per week with bothersome LBP compared with symptom-guided treatment. During the 12 month study period, the MC group (n = 163, 3 dropouts) reported 12.8 (95% CI = 10.1, 15.5; p = <0.001) fewer days in total with bothersome LBP compared to the control group (n = 158, 4 dropouts) and received 1.7 (95% CI = 1.8, 2.1; p = <0.001) more treatments. Numbers presented are means. No serious adverse events were recorded. Conclusion MC was more effective than symptom-guided treatment in reducing the total number of days over 52 weeks with bothersome non-specific LBP but it resulted in a higher number of treatments. For selected patients with recurrent or persistent non-specific LBP who respond well to an initial course of chiropractic care, MC should be considered an option for tertiary prevention.	[Eklund, Andreas; Jensen, Irene; Lohela-Karlsson, Malin; Hagberg, Jan; Bodin, Lennart; Axen, Iben] Karolinska Institutet, Inst Environm Med, Unit Intervent & Implementat Res Worker Hlth, Stockholm, Sweden; [Leboeuf-Yde, Charlotte; Axen, Iben] Univ Southern Denmark, Inst Reg Hlth Res, Odense, Denmark; [Kongsted, Alice] Nord Inst Chiropract & Clin Biomech, Odense, Denmark; [Kongsted, Alice] Univ Southern Denmark, Dept Sports Sci & Clin Biomech, Odense, Denmark	Karolinska Institutet; University of Southern Denmark; University of Southern Denmark	Eklund, A (corresponding author), Karolinska Institutet, Inst Environm Med, Unit Intervent & Implementat Res Worker Hlth, Stockholm, Sweden.	andreas.eklund@ki.se	Kongsted, Alice/H-2811-2019; Axén, Iben/AAC-8638-2020; Jensen, Irene B/B-6012-2012	Kongsted, Alice/0000-0001-5537-6038; Axén, Iben/0000-0001-5251-5995; Jensen, Irene B/0000-0003-1745-866X; Eklund, Andreas/0000-0002-2162-7537; Lohela Karlsson, Malin/0000-0002-9376-846X	Institute for Chiropractic and Neuro-musculoskeletal Research; European Chiropractors' Union [A13.02]; Danish Chiropractic Research Foundation [11/148]	Institute for Chiropractic and Neuro-musculoskeletal Research; European Chiropractors' Union; Danish Chiropractic Research Foundation	This study was funded by the Institute for Chiropractic and Neuro-musculoskeletal Research (awarded to AE), the European Chiropractors' Union (project ID A13.02, awarded to AE) and the Danish Chiropractic Research Foundation (grant number 11/148, awarded to IA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahlberg I., 2014, 20144 IHE; Axen I, 2005, J MANIP PHYSIOL THER, V28, P381, DOI 10.1016/j.jmpt.2005.06.008; Axen I, 2002, J MANIP PHYSIOL THER, V25, P450, DOI 10.1067/mmt.2002.126473; Axen I, 2013, BEST PRACT RES CL RH, V27, P601, DOI 10.1016/j.berh.2013.10.004; Axen I, 2013, CHIROPR MAN THER, V21, DOI 10.1186/2045-709X-21-10; Axen I, 2012, J CLIN EPIDEMIOL, V65, P454, DOI 10.1016/j.jclinepi.2011.07.012; Axen I, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-99; Axen Iben, 2009, Chiropr Osteopat, V17, P1, DOI 10.1186/1746-1340-17-1; Axen Iben, 2008, Chiropr Osteopat, V16, P6, DOI 10.1186/1746-1340-16-6; Bergstrom C, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-81; Bergstrom G, 1998, PAIN, V75, P101, DOI 10.1016/S0304-3959(97)00210-8; Bergstrom KG, 1999, EUR J PAIN-LONDON, V3, P261, DOI 10.1016/S1090-3801(99)90053-8; Breen A, 1976, ANN SWISS CHIROPRACT, V6, P207; Bringsli M, 2012, CHIROPR MAN THER, V20, DOI 10.1186/2045-709X-20-25; Bronfort G, 2008, SPINE J, V8, P213, DOI 10.1016/j.spinee.2007.10.023; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Cherkin DC, 1998, NEW ENGL J MED, V339, P1021, DOI 10.1056/NEJM199810083391502; Coronado RA, 2012, J ELECTROMYOGR KINES, V22, P752, DOI 10.1016/j.jelekin.2011.12.013; da Silva TM, 2017, J ORTHOP SPORT PHYS, P1; Daltroy LH, 1996, SPINE, P21; Descarreaux M, 2004, J MANIP PHYSIOL THER, V27, P509, DOI 10.1016/j.jmpt.2004.08.003; Deyo RA, 1998, SPINE, V23, P2003, DOI 10.1097/00007632-199809150-00018; Dunn KM, 2005, SPINE, V30, P1887, DOI 10.1097/01.brs.0000173900.46863.02; Eklund A, 2016, CHIROPR MAN THER, V24, DOI 10.1186/s12998-016-0085-z; Eklund A, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-0933-y; Eklund A, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0753-5; Eklund A, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-102; Field Jonathan R, 2010, Chiropr Osteopat, V18, P21, DOI 10.1186/1746-1340-18-21; Fritz JM, 2011, SPINE, V36, P1772, DOI 10.1097/BRS.0b013e318216337d; Haavik H, 2012, J ELECTROMYOGR KINES, V22, P768, DOI 10.1016/j.jelekin.2012.02.012; Hansen Signe F, 2010, Chiropr Osteopat, V18, P25, DOI 10.1186/1746-1340-18-25; Hoy D, 2010, BEST PRACT RES CL RH, V24, P769, DOI 10.1016/j.berh.2010.10.002; Hoy D, 2014, ANN RHEUM DIS, V73, P968, DOI 10.1136/annrheumdis-2013-204428; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; Johansen Bendt, 2010, Chiropr Osteopat, V18, P10, DOI 10.1186/1746-1340-18-10; Johansson E, 1998, SCAND J REHABIL MED, V30, P139; Kongsted Alice, 2010, Chiropr Osteopat, V18, P2, DOI 10.1186/1746-1340-18-2; Koppenhaver SL, 2012, J ELECTROMYOGR KINES, V22, P724, DOI 10.1016/j.jelekin.2012.03.004; Kristjansdottir OB, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-51; Leboeuf-Yde C, 2004, J MANIP PHYSIOL THER, V27, P493, DOI 10.1016/j.jmpt.2004.08.001; Leboeuf-Yde C, 1997, J Manipulative Physiol Ther, V20, P507; Leboeuf-Yde Charlotte, 2008, Chiropr Osteopat, V16, P3, DOI 10.1186/1746-1340-16-3; Lidgren L, 2003, B WORLD HEALTH ORGAN, V81, P629; Malmqvist Stefan, 2009, Chiropr Osteopat, V17, P7, DOI 10.1186/1746-1340-17-7; Martel J, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-41; Mitchell M, 1980, ACA J CHIROPR, V17, P53; Moller Lars Top, 2009, Chiropr Osteopat, V17, P5, DOI 10.1186/1746-1340-17-5; Myburgh C, 2013, CHIROPR MAN THER, V21, DOI 10.1186/2045-709X-21-27; PATRICK DL, 1995, SPINE, V20, P1899, DOI 10.1097/00007632-199509000-00011; Pickar JG, 2012, J ELECTROMYOGR KINES, V22, P785, DOI 10.1016/j.jelekin.2012.01.015; Rasmussen CDN, 2015, PAIN, V156, P1786, DOI 10.1097/j.pain.0000000000000234; REILLY MC, 1993, PHARMACOECONOMICS, V4, P353, DOI 10.2165/00019053-199304050-00006; Rubinstein SM, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008112.pub2; Rubinstein SM, 2011, SPINE, V36, DOI [10.1016/j.spinee.2007.10.023, DOI 10.1016/J.SPINEE.2007.10.023]; Rupert RL, 2000, J MANIP PHYSIOL THER, V23, P10, DOI 10.1016/S0161-4754(00)90108-8; Rupert RL, 2000, J MANIP PHYSIOL THER, V23, P1, DOI 10.1016/S0161-4754(00)90107-6; Sandnes Kjerstin F, 2010, Chiropr Osteopat, V18, P5, DOI 10.1186/1746-1340-18-5; Senna MK, 2011, SPINE, V36, P1427, DOI 10.1097/BRS.0b013e3181f5dfe0; Senstad O, 1997, SPINE, V22, P435, DOI 10.1097/00007632-199702150-00017; Sorensen LP, 2006, J MANIP PHYSIOL THER, V29, P419, DOI 10.1016/j.jmpt.2006.06.001; Steffens D, 2016, JAMA INTERN MED, V176, P199, DOI 10.1001/jamainternmed.2015.7431; SULLIVAN M, 1995, SOC SCI MED, V41, P1349, DOI 10.1016/0277-9536(95)00125-Q; Voss M, 2008, OCCUP ENVIRON MED, V65, P61, DOI 10.1136/oem.2006.031427; Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x	64	27	27	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2018	13	9							e0203029	10.1371/journal.pone.0203029	http://dx.doi.org/10.1371/journal.pone.0203029			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT7EB	30208070	Green Published, Green Submitted, gold			2023-01-03	WOS:000444683000051
J	Temprana, CF; Arguelles, MH; Gutierrez, NM; Barril, PA; Esteban, LE; Silvestre, D; Mandile, MG; Glikmann, G; Castello, AA				Facundo Temprana, C.; Arguelles, Marcelo H.; Gutierrez, Nicolas M.; Barril, Patricia A.; Esteban, Laura E.; Silvestre, Dalila; Mandile, Marcelo G.; Glikmann, Graciela; Castello, Alejandro A.			Rotavirus VP6 protein mucosally delivered by cell wall-derived particles from Lactococcus lactis induces protection against infection in a murine model	PLOS ONE			English	Article							HELICOBACTER-PYLORI INFECTION; GROUP-A ROTAVIRUS; INTRANASAL IMMUNIZATION; ORAL IMMUNIZATION; PRECLINICAL EVALUATION; ANTIBODY-RESPONSES; IMMUNE-RESPONSES; BUENOS-AIRES; ETEC VACCINE; LIVE VECTOR	Rotaviruses are the primary cause of acute gastroenteritis in children worldwide. Although the implementation of live attenuated vaccines has reduced the number of rotavirus-associated deaths, variance in their effectiveness has been reported in different countries. This fact, among other concerns, leads to continuous efforts for the development of new generation of vaccines against rotavirus. In this work, we describe the obtention of cell wall-derived particles from a recombinant Lactococcus lactis expressing a cell wall-anchored version of the rotavirus VP6 protein. After confirming by SDS-PAGE, Western blot, flow cytometry and electronic immunomicroscopy that these particles were carrying the VP6 protein, their immunogenic potential was evaluated in adult BALB/c mice. For that, mucosal immunizations (oral or intranasal), with or without the dmLT [(double mutant Escherichia coli heat labile toxin LT(R192G/L211A)] adjuvant were performed. The results showed that these cell wall-derived particles were able to generate anti-rotavirus IgG and IgA antibodies only when administered intranasally, whether the adjuvant was present or not. However, the presence of dmLT was necessary to confer protection against rotavirus infection, which was evidenced by a 79.5 percent viral shedding reduction. In summary, this work describes the production of cell wall-derived particles which were able to induce a protective immune response after intranasal immunization. Further studies are needed to characterize the immune response elicited by these particles as well as to determine their potential as an alternative to the use of live L. lactis for mucosal antigen delivery.	[Facundo Temprana, C.; Arguelles, Marcelo H.; Gutierrez, Nicolas M.; Esteban, Laura E.; Silvestre, Dalila; Mandile, Marcelo G.; Glikmann, Graciela; Castello, Alejandro A.] Univ Nacl Quilmes, Dept Ciencia & Tecnol, LIV, Bernal, Buenos Aires, Argentina; [Facundo Temprana, C.; Silvestre, Dalila; Mandile, Marcelo G.] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina; [Barril, Patricia A.] Consejo Nacl Invest Cient & Tecn, Ctr Invest & Asistencia Tecn Ind CIATI AC, Lab Microbiol Alimentos, Centenario, Neuquen, Argentina; [Castello, Alejandro A.] Univ Nacl Arturo Jauretche, Inst Ciencias Salud, Florencio Varela, Buenos Aires, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Temprana, CF; Castello, AA (corresponding author), Univ Nacl Quilmes, Dept Ciencia & Tecnol, LIV, Bernal, Buenos Aires, Argentina.; Temprana, CF (corresponding author), Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina.; Castello, AA (corresponding author), Univ Nacl Arturo Jauretche, Inst Ciencias Salud, Florencio Varela, Buenos Aires, Argentina.	ctemprana@unq.edu.ar; acastello@unq.edu.ar			Agencia Nacional de Promocion Cientifica y Tecnologica (ANCyPT), Argentina [PICT-2012-300]; Universidad Nacional de Quilmes [PUNQ1407/15]; Universidad Nacional Arturo Jauretche [290/12, 404/15]; CONICET	Agencia Nacional de Promocion Cientifica y Tecnologica (ANCyPT), Argentina(ANPCyT); Universidad Nacional de Quilmes; Universidad Nacional Arturo Jauretche; CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET))	This study was supported by PICT-2012-300 to C.F.T from Agencia Nacional de Promocion Cientifica y Tecnologica (ANCyPT), Argentina; and grant from the Universidad Nacional de Quilmes for the research program "Basic and Applied Molecular Microbiology" (PUNQ1407/15) and the research grants issued by Universidad Nacional Arturo Jauretche, Res.(R) 290/12 and 404/15. Doctoral and Postdoctoral Fellowship from CONICET for D. Silvestre and M.G. Mandile, respectively, are also acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arguelles MH, 2000, J CLIN MICROBIOL, V38, P252; Audouy SAL, 2006, VACCINE, V24, P5434, DOI 10.1016/j.vaccine.2006.03.054; Bermudez-Humaran LG, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-S1-S4; Bermudez-Humaran LG, 2009, HUM VACCINES, V5, P264, DOI 10.4161/hv.5.4.7553; Bosma T, 2006, APPL ENVIRON MICROB, V72, P880, DOI 10.1128/AEM.72.1.880-889.2006; Bouvet JP, 1999, INFECT IMMUN, V67, P2687, DOI 10.1128/IAI.67.6.2687-2691.1999; Bucardo F, 2015, INFECT GENET EVOL, V34, P106, DOI 10.1016/j.meegid.2015.06.013; Bucardo F, 2012, INFECT GENET EVOL, V12, P1282, DOI 10.1016/j.meegid.2012.03.007; Burnett E, 2017, J INFECT DIS, V215, P1666, DOI 10.1093/infdis/jix186; Burns JW, 1996, SCIENCE, V272, P104, DOI 10.1126/science.272.5258.104; Choi AH, 2002, VACCINE, V20, P3310, DOI 10.1016/S0264-410X(02)00315-8; Choi AH, 2002, VACCINE, V20, P1733, DOI 10.1016/S0264-410X(02)00043-9; Choi AHC, 1999, J VIROL, V73, P7574, DOI 10.1128/JVI.73.9.7574-7581.1999; de Haan A, 2012, VACCINE, V30, P4884, DOI 10.1016/j.vaccine.2012.04.032; Dieye Y, 2001, J BACTERIOL, V183, P4157, DOI 10.1128/JB.183.14.4157-4166.2001; Donato CM, 2012, J INFECT DIS, V206, P377, DOI 10.1093/infdis/jis361; El-Kamary SS, 2013, CLIN VACCINE IMMUNOL, V20, P1764, DOI 10.1128/CVI.00464-13; Enouf V, 2001, APPL ENVIRON MICROB, V67, P1423, DOI 10.1128/AEM.67.4.1423-1428.2001; Esteban LE, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/298598; Estes MK, 2007, FIELDS VIROLOGY, P1917; Feng NG, 2002, J CLIN INVEST, V109, P1203, DOI 10.1172/JCI200214397; Franco MA, 1999, J INFECT DIS, V179, pS466, DOI 10.1086/314805; Franco MA, 1997, VIROLOGY, V238, P169, DOI 10.1006/viro.1997.8843; FRANCO MA, 1995, J VIROL, V69, P7800, DOI 10.1128/JVI.69.12.7800-7806.1995; Fredj MB, 2013, INFECT GENET EVOL, V18, P132, DOI 10.1016/j.meegid.2013.05.008; Gil MT, 2001, FEMS MICROBIOL LETT, V203, P269, DOI 10.1016/S0378-1097(01)00367-6; Gray J., 2000, METHODS MOL MED, V34, P198; Hemming M, 2013, INFECT GENET EVOL, V19, P51, DOI 10.1016/j.meegid.2013.06.026; Hemming M, 2012, PEDIATR INFECT DIS J, V31, P992, DOI 10.1097/INF.0b013e31825d611e; Holmgren J, 2013, VACCINE, V31, P2457, DOI 10.1016/j.vaccine.2013.03.027; Jalilvand S, 2015, VACCINE, V33, P3281, DOI 10.1016/j.vaccine.2015.05.026; Jiang V, 2010, HUM VACCINES, V6, P532, DOI 10.4161/hv.6.7.11278; Kaminski RW, 2014, CLIN VACCINE IMMUNOL, V21, P366, DOI 10.1128/CVI.00683-13; Keijzer C, 2014, VACCINE, V32, P2904, DOI 10.1016/j.vaccine.2014.02.019; Lappalainen S, 2015, ARCH VIROL, V160, P2075, DOI 10.1007/s00705-015-2461-8; Larena M, 2015, J IMMUNOL, V194, P3829, DOI 10.4049/jimmunol.1401633; Li XY, 2014, PATHOG DIS, V72, P78, DOI 10.1111/2049-632X.12173; Li Yi-jing, 2010, J Biomed Biotechnol, V2010, P708460, DOI 10.1155/2010/708460; Lundgren A, 2014, VACCINE, V32, P7077, DOI 10.1016/j.vaccine.2014.10.069; Mandile MG, 2014, J CLIN VIROL, V60, P282, DOI 10.1016/j.jcv.2014.04.022; Marelli B, 2011, J VIROL METHODS, V175, P28, DOI 10.1016/j.jviromet.2011.04.011; Martinez-Becerra FJ, 2012, INFECT IMMUN, V80, P1222, DOI 10.1128/IAI.06174-11; McNeal MM, 2006, VIROLOGY, V346, P338, DOI 10.1016/j.virol.2005.11.016; McNeal MM, 2002, J VIROL, V76, P560, DOI 10.1128/JVI.76.2.560-568.2002; Mercenier A, 2000, Curr Issues Mol Biol, V2, P17; Mierau I, 2005, APPL MICROBIOL BIOT, V68, P705, DOI 10.1007/s00253-005-0107-6; Morello E, 2008, J MOL MICROB BIOTECH, V14, P48, DOI 10.1159/000106082; Nandre R, 2016, FEMS MICROBIOL LETT, V363, DOI 10.1093/femsle/fnw246; Nganou-Makamdop K, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-50; Norton EB, 2015, VACCINE, V33, P1909, DOI 10.1016/j.vaccine.2015.02.069; Norton EB, 2011, CLIN VACCINE IMMUNOL, V18, P546, DOI 10.1128/CVI.00538-10; Nouaille Sebastien, 2003, Genet Mol Res, V2, P102; Ottsjo LS, 2017, IMMUNOLOGY, V150, P172, DOI 10.1111/imm.12676; Parker EPK, 2018, FUTURE MICROBIOL, V13, P97, DOI 10.2217/fmb-2017-0128; Patel MM, 2009, EXPERT REV VACCINES, V8, P1555, DOI 10.1586/ERV.09.106; Patel NC, 2010, NEW ENGL J MED, V362, P314, DOI 10.1056/NEJMoa0904485; Perez CA, 2005, J APPL MICROBIOL, V99, P1158, DOI 10.1111/j.1365-2672.2005.02709.x; Piard JC, 1997, J BACTERIOL, V179, P3068, DOI 10.1128/jb.179.9.3068-3072.1997; Pontes DS, 2011, PROTEIN EXPRES PURIF, V79, P165, DOI 10.1016/j.pep.2011.06.005; Ramirez K, 2010, MUCOSAL IMMUNOL, V3, P159, DOI 10.1038/mi.2009.131; Rigter A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071072; Rodriguez-Diaz J, 2011, BIOTECHNOL LETT, V33, P1169, DOI 10.1007/s10529-011-0551-6; Rose TL, 2013, EMERG INFECT DIS, V19, P1843, DOI 10.3201/eid1911.121407; Saluja V, 2010, VACCINE, V28, P7963, DOI 10.1016/j.vaccine.2010.09.066; Sambrook Joseph, 1989, MOL CLONING LAB MANU; Song AAL, 2017, MICROB CELL FACT, V16, DOI 10.1186/s12934-017-0669-x; Steen A, 2003, J BIOL CHEM, V278, P23874, DOI 10.1074/jbc.M211055200; Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013; Van Braeckel-Budimir N, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00282; van Roosmalen ML, 2006, METHODS, V38, P144, DOI 10.1016/j.ymeth.2005.09.015; VanCott JL, 2001, EUR J IMMUNOL, V31, P3380, DOI 10.1002/1521-4141(200111)31:11<3380::AID-IMMU3380>3.0.CO;2-0; Almeida TNV, 2017, ACTA TROP, V173, P153, DOI 10.1016/j.actatropica.2017.06.009; Ward RL, 2010, J INFECT DIS, V202, pS101, DOI 10.1086/653556; Wells JM, 2008, NAT REV MICROBIOL, V6, P349, DOI 10.1038/nrmicro1840; White JA, 2017, J IMMUNOL METHODS, V451, P83, DOI 10.1016/j.jim.2017.09.003; World health Organization, 2013, WKLY EPIDEMIOL REC, V88, P49; YEN C, 2014, HUM VACC IMMUNOTHER, V10, P1436, DOI DOI 10.4161/hv.28857; Zeller M, 2017, PEERJ, V5, DOI 10.7717/peerj.2733; Zeller M, 2015, GENOME BIOL EVOL, V7, P2473, DOI 10.1093/gbe/evv157	79	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2018	13	9							e0203700	10.1371/journal.pone.0203700	http://dx.doi.org/10.1371/journal.pone.0203700			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT0BU	30192869	Green Published, gold, Green Submitted			2023-01-03	WOS:000444093600134
J	George, DM; Huntley, RJ; Cusack, K; Duignan, DB; Hoemann, M; Loud, J; Mario, R; Melim, T; Mullen, K; Somal, G; Wang, L; Edmunds, JJ				George, Dawn M.; Huntley, Raymond J.; Cusack, Kevin; Duignan, David B.; Hoemann, Michael; Loud, Jacqueline; Mario, Regina; Melim, Terry; Mullen, Kelly; Somal, Gagandeep; Wang, Lu; Edmunds, Jeremy J.			Prodrugs for colon-restricted delivery: Design, synthesis, and in vivo evaluation of colony stimulating factor 1 receptor (CSF1R) inhibitors	PLOS ONE			English	Article							MULTIPLE-DOSE PHARMACOKINETICS; APPENDED ALPHA-CYCLODEXTRIN; TISSUE IMPLICATIONS; BETA-CYCLODEXTRIN; CSF-1R INHIBITOR; P-GLYCOPROTEIN; RECTAL TISSUE; MACROPHAGES; EXPRESSION; CANCER	The ability to restrict low molecular weight compounds to the gastrointestinal (GI) tract may enable an enhanced therapeutic index for molecular targets known to be associated with systemic toxicity. Using a triazolopyrazine CSF1R inhibitor scaffold, a broad range of prodrugs were synthesized and evaluated for enhanced delivery to the colon in mice. Subsequently, the preferred cyclodextrin prodrug moiety was appended to a number of CSF1R inhibitory active parent molecules, enabling GI-restricted delivery. Evaluation of a cyclodextrin prodrug in a dextran sodium sulfate (DSS)-induced mouse colitis model resulted in enhanced GI tissue levels of active parent. At a dose where no significant depletion of systemic monocytes were detected, the degree of pharmacodynamic effect-measured as reduction in macrophages in the colon +/- was inferior to that observed with a systemically available positive control. This suggests that a suitable therapeutic index cannot be achieved with CSF1R inhibition by using GI-restricted delivery in mice. However, these efforts provide a comprehensive frame-work in which to pursue additional gut-restricted delivery strategies for future GI targets.	[George, Dawn M.] AbbVie Biores Ctr, Immunol Discovery, Worcester, MA 01605 USA; [Huntley, Raymond J.; Cusack, Kevin; Hoemann, Michael; Mullen, Kelly; Somal, Gagandeep; Wang, Lu; Edmunds, Jeremy J.] AbbVie Biores Ctr, Dept Chem, Immunol Discovery, Worcester, MA USA; [Duignan, David B.] AbbVie Biores Ctr, Dept Drug Metab Pharmacokinet & Bioanal, Worcester, MA USA; [Loud, Jacqueline; Mario, Regina; Melim, Terry] AbbVie Biores Ctr, Dept Pharmacol, Immunol Discovery, Worcester, MA USA	AbbVie; AbbVie; AbbVie; AbbVie	George, DM (corresponding author), AbbVie Biores Ctr, Immunol Discovery, Worcester, MA 01605 USA.	dawn.george@abbvie.com		Hoemann, Michael/0000-0001-9259-7702	AbbVie	AbbVie(AbbVie)	This work was supported by AbbVie. All authors are employees of AbbVie. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.	[Anonymous], 2015, OMICSOFT R ARRAYSUIT; Bendell JC, 2013, MOL CANC THERAPEUTIC, V12; Brown KC, 2012, JAIDS-J ACQ IMM DEF, V61, P138, DOI 10.1097/QAI.0b013e31825cb645; Brown KC, 2011, J INFECT DIS, V203, P1484, DOI 10.1093/infdis/jir059; Cannarile MA, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0257-y; Chen ZF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022913; Clas SD, 2014, DRUG DISCOV TODAY, V19, P79, DOI 10.1016/j.drudis.2013.08.014; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Dhaneshwar SS, 2011, CURR TOP MED CHEM, V11, P2318; Huynh D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056951; Erblich B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026317; Fujiwara Nagatoshi, 2005, Current Drug Targets - Inflammation and Allergy, V4, P281, DOI 10.2174/1568010054022024; Genovese MC, 2015, J RHEUMATOL, V42, P1752, DOI 10.3899/jrheum.141580; George DM, 2017, MED CHEM REV, V52, P165; Greener BN, 2013, JAIDS-J ACQ IMM DEF, V64, P39, DOI 10.1097/QAI.0b013e31829ed7a4; Hirayama F, 2000, J PHARM SCI, V89, P1486, DOI 10.1002/1520-6017(200011)89:11<1486::AID-JPS11>3.0.CO;2-D; Kagan L, 2010, DRUG METAB DISPOS, V38, P1560, DOI 10.1124/dmd.110.033019; Kamada N, 2008, J CLIN INVEST, V118, P2269, DOI [10.1172/JC134610, 10.1172/JCI34610]; Kawane K, 2006, NATURE, V443, P998, DOI 10.1038/nature05245; KIMURA T, 1994, BIOL PHARM BULL, V17, P327; Kubota Y, 2009, J EXP MED, V206, P1089, DOI 10.1084/jem.20081605; Laharie D, 2008, GASTROEN CLIN BIOL, V32, P134, DOI 10.1016/j.gcb.2007.11.002; Landis MS, 2013, THER DELIV, V4, P225, DOI [10.4155/tde.12.150, 10.4155/TDE.12.150]; Lebakken CS, 2009, J BIOMOL SCREEN, V14, P924, DOI 10.1177/1087057109339207; MacLean C, 2008, DRUG METAB DISPOS, V36, P1249, DOI 10.1124/dmd.108.020859; Manthey CL, 2009, MOL CANCER THER, V8, P3151, DOI 10.1158/1535-7163.MCT-09-0255; McConnell EL, 2008, J PHARM PHARMACOL, V60, P63, DOI 10.1211/jpp.60.1.0008; MCLEOD AD, 1993, INT J PHARM, V92, P105, DOI 10.1016/0378-5173(93)90269-L; Moore B, 2014, GASTROENTEROLOGY, V146, pS900; Moss DM, 2014, J ANTIMICROB CHEMOTH, V69, P3275, DOI 10.1093/jac/dku312; Mulvihill MJ, Patent No. [WO2011243645, 2011243645]; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Patel S, 2009, CURR TOP MED CHEM, V9, P599, DOI 10.2174/156802609789007327; Patterson KB, 2013, AIDS, V27, P1413, DOI 10.1097/QAD.0b013e32835f2b49; Patterson KB, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003174; Pridans C, 2013, SCI REP-UK, V3, DOI 10.1038/srep03013; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Radi ZA, 2011, AM J PATHOL, V179, P240, DOI 10.1016/j.ajpath.2011.03.029; Ramsay RG, 2004, J INTERF CYTOK RES, V24, P416, DOI 10.1089/1079990041535638; Ries CH, 2015, CURR OPIN PHARMACOL, V23, P45, DOI 10.1016/j.coph.2015.05.008; Rugtveit J, 1997, GASTROENTEROLOGY, V112, P1493, DOI 10.1016/S0016-5085(97)70030-1; Sadis S, 2009, ARTHRITIS RHEUM S10, V60, P408, DOI DOI 10.1002/ART.25491; Schubert C, 2007, J BIOL CHEM, V282, P4094, DOI 10.1074/jbc.M608183200; Smith AM, 2009, J EXP MED, V206, P1883, DOI 10.1084/jem.20091233; Thiesen S, 2014, J LEUKOCYTE BIOL, V95, P531, DOI 10.1189/jlb.0113021; Thorn M, 2005, BRIT J CLIN PHARMACO, V60, P54, DOI 10.1111/j.1365-2125.2005.02389.x; Tian Y, 2006, AM J PHYSIOL-CELL PH, V290, pC1083, DOI 10.1152/ajpcell.00381.2005; Wang T, 2011, INT J TOXICOL, V30, P300, DOI 10.1177/1091581811401920; Yano H, 2002, J CONTROL RELEASE, V79, P103, DOI 10.1016/S0168-3659(01)00532-6; Yano H, 2001, J PHARM SCI-US, V90, P493, DOI 10.1002/1520-6017(200104)90:4<493::AID-JPS1007>3.3.CO;2-N; Zhang Xia, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1401s83; Zhou L, 2015, ARTHRITIS RHEUMATOL, P67; Zwicker S, 2015, CLIN SCI, V129, P281, DOI 10.1042/CS20150176	54	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2018	13	9							e0203567	10.1371/journal.pone.0203567	http://dx.doi.org/10.1371/journal.pone.0203567			40	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT0BU	30192846	Green Submitted, gold, Green Published			2023-01-03	WOS:000444093600105
J	Sanchez-Fernandez, MDM; del Paso, GAR; Gil-Cunquero, JM; Fernandez-Serrano, MJ				del Mar Sanchez-Fernandez, Maria; Reyes del Paso, Gustavo A.; Manuel Gil-Cunquero, Jose; Jose Fernandez-Serrano, Maria			Executive function in end-stage renal disease: Acute effects of hemodialysis and associations with clinical factors	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; QUALITY-OF-LIFE; COGNITIVE FUNCTION; PSYCHOMOTOR FUNCTIONS; DIALYSIS PATIENTS; DIALYZED PATIENTS; TRANSPLANTATION; IMPAIRMENT; HYPONATREMIA; COMPONENTS	Objective There is evidence of cognitive impairment in patients with end-stage renal disease in hemodialysis (ESRD-HD). However, few studies have exhaustively analyzed executive functions (EFs) in this population, especially considering the influence of a wide range of clinical variables. This study analyzes performance in different EF components in ESRD-HD patients compared to a group of healthy controls (HCs), in addition to the acute effects of HD and the associations of cognitive performance with clinical variables. Method EFs were evaluated pre- and post-HD in 43 ESRD-HD patients and 42 HCs, using a battery of tests designed to assess EF domains. Age, schooling, mood and blood pressure were statistically controlled. Associations between performance and clinical factors were computed by correlations and hierarchical multiple regression analyses. Results The performance of the ESRD-HD patients was significantly lower than that of HCs in all the EF domains except for planning. Group differences were marginally significant for reasoning. HD produced no acute changes in global performance, with improvements see only in inhibition and working memory. EF scores were positively associated with total number of months previously transplanted, body mass index (BMI), dry weight, and levels of hemoglobin, albumin, ferritin, calcium, phosphorus, sodium, urea, and creatinine. Conclusions Global EF functioning was lower in ESRD-HD patients than in HCs. No major acute HD-related EF changes were detected. These findings underline the importance of an adequate nutritional status for maintaining executive functioning in ESRD-HD patients.	[del Mar Sanchez-Fernandez, Maria; Reyes del Paso, Gustavo A.; Jose Fernandez-Serrano, Maria] Univ Jaen, Dept Psychol, Jaen, Spain; [Manuel Gil-Cunquero, Jose] Jaen Hosp Complex, Dept Nephrol, Jaen, Spain	Universidad de Jaen; Complejo Hospitalario de Jaen	Sanchez-Fernandez, MDM (corresponding author), Univ Jaen, Dept Psychol, Jaen, Spain.	mmsanche@ujaen.es	Serrano, M Josefa Fernández/V-3124-2019; Reyes del Paso, Gustavo A./G-4179-2011; Fernandez-Serrano, Maria Jose/AGA-6711-2022	Serrano, M Josefa Fernández/0000-0002-6158-237X; Reyes del Paso, Gustavo A./0000-0002-2188-8673; 	Council of Equality, Health, and Social Policy, Junta de Andalucia [PI-0674-2012]	Council of Equality, Health, and Social Policy, Junta de Andalucia	This research was supported by grant PI-0674-2012 from the Council of Equality, Health, and Social Policy, Junta de Andalucia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albabtain M, 2016, MED SCI MONITOR, V22, P4978, DOI 10.12659/MSM.898538; Anwar W, 2015, NEFROLOGIA, V35, P567, DOI [10.1016/j.nefro.2015.07.004, 10.1016/j.nefroe.2015.09.005]; Bechara A, 2001, NEUROPSYCHOLOGIA, V39, P376, DOI 10.1016/S0028-3932(00)00136-6; Benton A, 1978, PSYCHOL ASSESSMENT R; Caro I., 1992, BOL PSICOL, V36, P43; Cortese S, 2014, POSTGRAD MED, V126, P155, DOI 10.3810/pgm.2014.07.2793; Costa AS, 2014, AM J KIDNEY DIS, V64, P434, DOI 10.1053/j.ajkd.2014.02.012; Darcet F, 2016, PHARMACEUTICALS-BASE, V9, DOI 10.3390/ph9010009; Filiopoulos Vasilis, 2009, Inflammation & Allergy Drug Targets, V8, P369; Gelb S, 2008, NEPHROL DIAL TRANSPL, V23, P1032, DOI 10.1093/ndt/gfm659; Giang LM, 2011, AM J NEPHROL, V33, P33, DOI 10.1159/000322611; Gilbert SJ, 2008, CURR BIOL, V18, pR110, DOI 10.1016/j.cub.2007.12.014; Grant DA., 1993, WISCONSIN CARD SORTI; Griva K, 2003, HEALTH PSYCHOL, V22, P570, DOI 10.1037/0278-6133.22.6.570; Griva K, 2006, NEPHROL DIAL TRANSPL, V21, P3275, DOI 10.1093/ndt/gfl385; Gupta A, 2016, AM J NEPHROL, V43, P50, DOI 10.1159/000444334; Harciarek M, 2012, J INT NEUROPSYCH SOC, V18, P162, DOI 10.1017/S1355617711001445; Harciarek M, 2009, J INT NEUROPSYCH SOC, V15, P684, DOI 10.1017/S1355617709990221; Hoffmann A, 2017, BRAIN COGNITION, V118, P108, DOI 10.1016/j.bandc.2017.08.003; Huarte-Loza E., 2006, DIAL TRASPL, V27, P138; Fernandez-Serrano MJ, 2010, J PSYCHOPHARMACOL, V24, P1317, DOI 10.1177/0269881109349841; Koushik NS, 2010, NEUROPSYCHOL REV, V20, P33, DOI 10.1007/s11065-009-9110-5; Lee SY, 2004, J PSYCHOSOM RES, V57, P5, DOI 10.1016/S0022-3999(03)00528-2; Lezak MD, 2004, NEUROPSYCHOLOGICAL A; Murray AM, 2006, NEUROLOGY, V67, P216, DOI 10.1212/01.wnl.0000225182.15532.40; Montilla CMP, 2016, NEFROLOGIA, V36, P275, DOI 10.1016/j.nefro.2015.12.002; Pereira Arema A, 2007, Hemodial Int, V11, P309, DOI 10.1111/j.1542-4758.2007.00185.x; Pi HC, 2016, KIDNEY BLOOD PRESS R, V41, P986, DOI 10.1159/000452603; Post JB, 2012, AM J NEPHROL, V35, P120, DOI 10.1159/000334871; Radic J, 2010, NETH J MED, V68, P153; Radic J, 2011, THER APHER DIAL, V15, P532, DOI 10.1111/j.1744-9987.2011.00995.x; Radic J, 2011, AM J NEPHROL, V34, P399, DOI 10.1159/000330849; Ruff R.M., 1996, RUFF FIGURAL FLUENCY; Schneider SM, 2015, SEMIN NEPHROL, V35, P304, DOI 10.1016/j.semnephrol.2015.06.002; Schneider SM, 2015, NEPHROL DIAL TRANSPL, V30, P1551, DOI 10.1093/ndt/gfv213; SEDO M, 2005, TEST CINCO DIGITOS 5; Shavit L, 2014, CLIN NEPHROL, V82, P313, DOI 10.5414/CN108335; Tamura MK, 2013, AM J KIDNEY DIS, V61, P228, DOI 10.1053/j.ajkd.2012.09.009; Thornton WL, 2007, J INT NEUROPSYCH SOC, V13, P344, DOI 10.1017/S1355617707070361; Verdejo-Garcia A, 2007, PSYCHOPHARMACOLOGY, V190, P517, DOI 10.1007/s00213-006-0632-8; Wechsler D, 1997, ESCALA INTELIGENCIA; Wilson BA, 1996, BEHARIORAL ASSESSMEN	42	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2018	13	9							e0203424	10.1371/journal.pone.0203424	http://dx.doi.org/10.1371/journal.pone.0203424			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GT1IK	30180208	Green Published, gold, Green Submitted			2023-01-03	WOS:000444222400041
J	Sheridan, C				Sheridan, Cormac			Roche splashes $2.4 billion on Foundation Medicine's cancer platform	NATURE BIOTECHNOLOGY			English	News Item																			0	2	2	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2018	36	9					779	780		10.1038/nbt0918-779	http://dx.doi.org/10.1038/nbt0918-779			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	GS8TJ	30188548				2023-01-03	WOS:000443986000005
J	Choukem, SP; Efie, DT; Djiogue, S; Kaze, FF; Mboue-Djieka, Y; Boudjeko, T; Dongo, E; Gautier, JF; Kengne, AP				Choukem, Simeon-Pierre; Efie, Derrick Tembi; Djiogue, Sefirin; Kaze, Francois F.; Mboue-Djieka, Yannick; Boudjeko, Thad; Dongo, Etienne; Gautier, Jean-Francois; Kengne, Andre-Pascal			Effects of hydroquinone-containing creams on capillary glycemia before and after serial hand washings in Africans	PLOS ONE			English	Article							BLOOD-GLUCOSE	Background Hydroquinone-containing creams cause false increases in capillary glycemia. However, the magnitude of this false increase, and the means to reverse it have not been investigated. Objective To evaluate the technical and clinical impact of hydroquinone-containing creams on capillary glycemia and investigate the efficacy of hand washing and other common practices, in reversing cream effects. Methods We included 91 participants in a quasi-experimental study in Buea, Cameroon. After determining the hydroquinone content of a cream, Caro Light, we used two glucometers with different enzymatic systems (Accu-Chek Active and OneTouch Ultra 2) to measure fasting glycemia after: initial hand washing (reference), application of 1 ml of hydroquinone-containing cream, finger swabbing with wet gauze, sanitizer application and a series of three hand washings following cream application. Reference glycemia was compared to those obtained after various interventions. Statistical significance was assessed by paired sample t-test, clinical significance by total error allowable (TEa), and clinical impact by Parke's error grid analysis. Results The mean differences in capillary glycemia (Intervention-reference) measured by Accu-Chek Active in mg/dl were 28, 27, 38, 16, 4, and -2 after cream application, finger swabbing, sanitizer application, one, two, and three hand washings respectively. Corresponding values for OneTouch Ultra2 were 41, 44, 64, 22, 5 and -5. These differences, except after two and three hand washings were both statistically (p < 0.0001) and clinically significant (TEa). After cream application, Accu-Check had 9.9% of values in Parke's Zones C-E, while OneTouch had 18.7%. Conclusion Hydroquinone-containing creams cause significant false increase in capillary glycemia irrespective of the enzymatic system of the glucometer used, and can lead to potentially wrong clinical decisions. A minimum of two hand washings is required prior to capillary glucose measurement.	[Choukem, Simeon-Pierre; Efie, Derrick Tembi] Univ Buea, Fac Hlth Sci, Dept Internal Med & Paediat, Buea, Cameroon; [Choukem, Simeon-Pierre; Efie, Derrick Tembi; Mboue-Djieka, Yannick] Hlth & Human Dev 2HD Res Network, Douala, Cameroon; [Choukem, Simeon-Pierre] Douala Gen Hosp, Dept Internal Med, Douala, Cameroon; [Djiogue, Sefirin] Univ Yaounde I, Fac Sci, Dept Anim Biol & Physiol, Yaounde, Cameroon; [Kaze, Francois F.] Univ Yaounde I, Fac Med & Biomed Sci, Dept Internal Med & Subspecialties, Yaounde, Cameroon; [Boudjeko, Thad] Univ Yaounde I, Fac Sci, Dept Biochem, Yaounde, Cameroon; [Dongo, Etienne] Univ Yaounde I, Fac Sci, Dept Organ Chem, Yaounde, Cameroon; [Gautier, Jean-Francois] Univ Paris Diderot, Paris 7, Lariboisiere Hosp, AP HP,Dept Diabet Endocrinol & Nutr, Paris, France; [Kengne, Andre-Pascal] South African Med Res Council, Cape Town, South Africa; [Kengne, Andre-Pascal] Univ Cape Town, Cape Town, South Africa	University of Yaounde I; University of Yaounde I; University of Yaounde I; University of Yaounde I; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; South African Medical Research Council; University of Cape Town	Choukem, SP (corresponding author), Univ Buea, Fac Hlth Sci, Dept Internal Med & Paediat, Buea, Cameroon.; Choukem, SP (corresponding author), Hlth & Human Dev 2HD Res Network, Douala, Cameroon.; Choukem, SP (corresponding author), Douala Gen Hosp, Dept Internal Med, Douala, Cameroon.	schoukem@gmail.com	Kengne, Andre Pascal/ABB-3696-2020	DJIOGUE, Sefirin/0000-0002-3525-7047; Tembi Efie, Derrick/0000-0003-3609-809X; Choukem, Simeon Pierre/0000-0003-1399-5513; Kengne, Andre Pascal/0000-0002-5183-131X	Tseu Medical Institute, Harris Manchester College, University of Oxford, UK	Tseu Medical Institute, Harris Manchester College, University of Oxford, UK	The Health and Human Development (2HD) Research Network is supported by a Cruddas Link Fellowship (SPC), Tseu Medical Institute, Harris Manchester College, University of Oxford, UK. The authors are grateful to all participants, and to the collaborators of the Department of Organic Chemistry, Faculty of Sciences, University of Yaounde I.	Bihan H, 2011, ANN INTERN MED, V155, P649, DOI 10.7326/0003-4819-155-9-201111010-00023; Bouche CH, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3879; García Pedro López, 2007, Rev. Bras. Cienc. Farm., V43, P397, DOI 10.1590/S1516-93322007000300008; Ginsberg Barry H, 2009, J Diabetes Sci Technol, V3, P903; Harr KE, 2013, VET CLIN PATH, V42, P424, DOI 10.1111/vcp.12101; Hortensius J, 2012, DIABETES EDUCATOR, V38, P101, DOI 10.1177/0145721711427787; Hortensius J, 2011, DIABETES CARE, V34, P556, DOI 10.2337/dc10-1694; ISO, ISO STAND BLOOD GLUC; Mahoney John J, 2011, J Diabetes Sci Technol, V5, P1444; Olumide YM, 2008, INT J DERMATOL, V47, P344, DOI 10.1111/j.1365-4632.2008.02719.x; Parkes JL, 2000, DIABETES CARE, V23, P1143, DOI 10.2337/diacare.23.8.1143; Rajaratnam H, 2012, SRI LANKA J DIABETES, V1, P22; Rosindale S, 2004, J DIABETES NURS, V8, P272; Sobngwi E, 2013, DIABETES METAB, V39, pA2; Westgard, DES BIOL VAR DAT SPE	15	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2018	13	8							e0202271	10.1371/journal.pone.0202271	http://dx.doi.org/10.1371/journal.pone.0202271			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR8TH	30153255	Green Published, Green Submitted, gold			2023-01-03	WOS:000443001700010
J	Pawar, GN; Parayath, NN; Nocera, AL; Bleier, BS; Amiji, MM				Pawar, Grishma N.; Parayath, Neha N.; Nocera, Angela L.; Bleier, Benjamin S.; Amiji, Mansoor M.			Direct CNS delivery of proteins using thermosensitive liposome-in-gel carrier by heterotopic mucosal engrafting	PLOS ONE			English	Article							INTRANASAL DELIVERY; MECHANISMS; JUNCTIONS; MODELS; TIGHT; DRUGS	Delivering therapeutics across the blood-brain barrier (BBB) for treating central nervous system (CNS) diseases is one of the biggest challenges today as the BBB limits the uptake of molecules greater than 500 Da into the CNS. Here we describe a novel trans-nasal mucosal drug delivery as an alternative to the intranasal drug delivery to overcome its limitations and deliver high molecular weight (HMW) therapeutics efficiently to the brain. This approach is based on human endoscopic skull base surgical techniques in which a surgical defect is repaired by engrafting semipermeable nasal mucosa over a skull base defect. Based on endoscopic skull based surgeries, our groups has developed a trans-nasal mucosal rodent model where we have evaluated the permeability of ovalbumin (45 kDa) as a model protein through the implanted mucosal graft for delivering HMW therapeutics to the brain. A thermo sensitive liposome-in-gel (LiG) system was developed for creating a drug depot allowing for a sustained release from the site of delivery to the brain through the implanted nasal graft. We would like to report this as an exploratory pilot study where we are using this novel surgical model to show that the implanted nasal mucosal graft and the LiG delivery system result in an efficient and a sustained brain delivery of HMW proteins. Hence, this study demonstrates that the trans-nasal mucosal engrafting technique could overcome the limitations for intranasal drug delivery and enable the uptake of HMW protein therapeutics into the CNS for the treatment of a wide range of neurodegenerative diseases.	[Pawar, Grishma N.; Parayath, Neha N.; Nocera, Angela L.; Amiji, Mansoor M.] Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA; [Bleier, Benjamin S.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Boston, MA USA	Northeastern University; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Amiji, MM (corresponding author), Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA.	m.amiji@northeastern.edu	Amiji, Mansoor M/AAK-1531-2020; Bleier, Benjamin S/H-6726-2019	Amiji, Mansoor M/0000-0001-6170-881X; Bleier, Benjamin S/0000-0003-0783-8861; Pawar, Grishma/0000-0001-5223-152X; Parayath, Neha/0000-0003-0860-1663				Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037; Antunes MB, 2007, BIOTECHNIQUES, V43, P195, DOI 10.2144/000112531; Bleier BS, 2016, NEUROSURGERY, V78, P448, DOI 10.1227/NEU.0000000000001016; Bleier BS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061694; Bleier BS, 2011, INT FORUM ALLERGY RH, V1, P361, DOI 10.1002/alr.20041; Bleier Benjamin S, 2009, Otolaryngol Clin North Am, V42, P901, DOI 10.1016/j.otc.2009.07.002; Chaaban MR, 2013, ADV OTO-RHINO-LARYNG, V74, P148, DOI 10.1159/000342291; Chaize B, 2004, ARTIF CELL BLOOD SUB, V32, P67, DOI 10.1081/BIO-120028669; Cuomo F, 2014, LANGMUIR, V30, P7993, DOI 10.1021/la501978u; Dhuria SV, 2010, J PHARM SCI-US, V99, P1654, DOI 10.1002/jps.21924; Djupesland PG, 2014, THER DELIV, V5, P709, DOI [10.4155/tde.14.41, 10.4155/TDE.14.41]; Enna SJ, 2009, J PHARMACOL EXP THER, V329, P404, DOI 10.1124/jpet.108.143420; Escobar-Chavez JJ, 2006, J PHARM PHARM SCI, V9, P339; Gitler AD, 2017, DIS MODEL MECH, V10, P499, DOI 10.1242/dmm.030205; Gudis D, 2012, AM J RHINOL ALLERGY, V26, P1, DOI 10.2500/ajra.2012.26.3716; Harvey RJ, 2012, LARYNGOSCOPE, V122, P452, DOI 10.1002/lary.22475; Illum L, 2004, J PHARM PHARMACOL, V56, P3, DOI 10.1211/0022357022539; Jucker M, 2010, NAT MED, V16, P1210, DOI 10.1038/nm.2224; Kohman RE, 2014, JOVE-J VIS EXP, DOI 10.3791/51452; Krishan M, 2014, DRUG DELIV, V21, P8, DOI 10.3109/10717544.2013.840017; Kumar NN, 2016, SCI REP-UK, V6, DOI 10.1038/srep31732; Lu CT, 2014, INT J NANOMED, V9, P2241, DOI 10.2147/IJN.S61288; Marcel M, 2015, WORLD J OTORHINOLARY, V1, P11, DOI [10.1016/j.wjorl.2015.09.001, DOI 10.1016/J.WJORL.2015.09.001]; Meredith ME, 2015, AAPS J, V17, P780, DOI 10.1208/s12248-015-9719-7; Noble Wendy, 2010, Front Psychiatry, V1, P7, DOI 10.3389/fpsyt.2010.00007; Oliveira SLB, 2013, CYTOM PART A, V83A, P76, DOI 10.1002/cyto.a.22161; Ooi EH, 2008, AM J RHINOL, V22, P13, DOI 10.2500/ajr.2008.22.3127; Pardridge William M, 2005, NeuroRx, V2, P1, DOI 10.1602/neurorx.2.1.1; Pathan Shadab A, 2009, Recent Pat Drug Deliv Formul, V3, P71; Poewe W, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.13, 10.1111/ene.14108]; Quintana DS, 2016, MOL PSYCHIATR, V21, P29, DOI 10.1038/mp.2015.166; Sandeep Nema DMK, 1994, PDA J PHARM SCI TECH, V48; Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323; Steinke A, 2008, HISTOCHEM CELL BIOL, V130, P339, DOI 10.1007/s00418-008-0441-8; van Woensel Matthias, 2013, Cancers (Basel), V5, P1020, DOI 10.3390/cancers5031020; Zuris JA, 2015, NAT BIOTECHNOL, V33, P73, DOI 10.1038/nbt.3081	36	13	13	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2018	13	12							e0208122	10.1371/journal.pone.0208122	http://dx.doi.org/10.1371/journal.pone.0208122			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD0QO	30517163	Green Submitted, Green Published, gold			2023-01-03	WOS:000452212400080
J	Wittekamp, BH; Plantinga, NL; Cooper, B; Lopez-Contreras, J; Coll, P; Mancebo, J; Wise, MP; Morgan, MPG; Depuydt, P; Boelens, J; Dugernier, T; Verbelen, V; Jorens, PG; Verbrugghe, W; Malhotra-Kumar, S; Damas, P; Meex, C; Leleu, K; van den Abeele, AM; de Matos, AFGP; Mendez, SF; Gomez, AV; Tomic, V; Sifrer, F; Villarreal, E; Ramos, JR; Aragao, I; Santos, C; Sperning, RHM; Coppadoro, P; Nardi, G; Brun-Buisson, C; Bonten, MJM				Wittekamp, Bastiaan H.; Plantinga, Nienke L.; Cooper, Ben S.; Lopez-Contreras, Joaquin; Coll, Pere; Mancebo, Jordi; Wise, Matt P.; Morgan, Matt P. G.; Depuydt, Pieter; Boelens, Jerina; Dugernier, Thierry; Verbelen, Valerie; Jorens, Philippe G.; Verbrugghe, Walter; Malhotra-Kumar, Surbhi; Damas, Pierre; Meex, Cecile; Leleu, Kris; van den Abeele, Anne-Marie; Gomes Pimenta de Matos, Ana Filipa; Fernandez Mendez, Sara; Vergara Gomez, Andrea; Tomic, Viktorija; Sifrer, Franc; Villarreal, Esther; Ruiz Ramos, Jesus; Aragao, Irene; Santos, Claudia; Sperning, Roberta H. M.; Coppadoro, Patrizia; Nardi, Giuseppe; Brun-Buisson, Christian; Bonten, Marc J. M.			Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE UNITS; SELECTIVE DECONTAMINATION; DIGESTIVE-TRACT; INTESTINAL-TRACT; OROPHARYNX; MORTALITY; BACTERIA; ICUS	IMPORTANCE The effects of chlorhexidine (CHX) mouthwash, selective oropharyngeal decontamination (SOD), and selective digestive tract decontamination (SDD) on patient outcomes in ICUs with moderate to high levels of antibiotic resistance are unknown. OBJECTIVE To determine associations between CHX 2%, SOD, and SDD and the occurrence of ICU-acquired bloodstream infections with multidrug-resistant gram-negative bacteria (MDRGNB) and 28-day mortality in ICUs with moderate to high levels of antibiotic resistance. DESIGN, SETTING, ANDPARTICIPANTS RandomizedtrialconductedfromDecember1,2013, toMay 31, 2017, in 13 European ICUs where at least 5% of bloodstream infections are caused by extendedspectrum beta-lactamase-producingEnterobacteriaceae. Patientswithanticipatedmechanicalventilation of more than 24 hourswere eligible. The final date of follow-upwas September 20, 2017. INTERVENTIONS Standard carewas daily CHX 2% bodywashings and a hand hygiene improvement program. Following a baseline period from 6 to 14 months, each ICUwas assigned in random order to 3 separate 6-month intervention periods with either CHX 2% mouthwash, SOD (mouthpaste with colistin, tobramycin, and nystatin), or SDD (the same mouthpaste and gastrointestinal suspension with the same antibiotics), all applied 4 times daily. MAIN OUTCOMES AND MEASURES The occurrence of ICU-acquired bloodstream infection with MDRGNB (primary outcome) and 28-day mortality (secondary outcome) during each intervention period compared with the baseline period. RESULTS A total of 8665 patients (median age, 64.1 years; 5561 men [64.2%]) were included in the study (2251, 2108, 2224, and 2082 in the baseline, CHX, SOD, and SDD periods, respectively). ICU-acquired bloodstream infection with MDRGNB occurred among 144 patients (154 episodes) in 2.1%, 1.8%, 1.5%, and 1.2% of included patients during the baseline, CHX, SOD, and SDD periods, respectively. Absolute risk reductions were 0.3%(95% CI, -0.6% to 1.1%), 0.6%(95% CI, -0.2% to 1.4%), and 0.8%(95% CI, 0.1% to 1.6%) for CHX, SOD, and SDD, respectively, compared with baseline. Adjusted hazard ratios were 1.13 (95% CI, 0.68-1.88), 0.89 (95% CI, 0.55-1.45), and 0.70 (95% CI, 0.43-1.14) during the CHX, SOD, and SDD periods, respectively, vs baseline. Crude mortality risks on day 28 were 31.9%, 32.9%, 32.4%, and 34.1% during the baseline, CHX, SOD, and SDD periods, respectively. Adjusted odds ratios for 28-day mortality were 1.07 (95% CI, 0.86-1.32), 1.05 (95% CI, 0.85-1.29), and 1.03 (95% CI, 0.80-1.32) for CHX, SOD, and SDD, respectively, vs baseline. CONCLUSIONS AND RELEVANCE Among patients receiving mechanical ventilation in ICUs with moderate to high antibiotic resistance prevalence, use of CHX mouthwash, SOD, or SDD was not associated with reductions in ICU-acquired bloodstream infections caused by MDRGNB compared with standard care.	[Wittekamp, Bastiaan H.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Huispostnummer Str 6-131,POB 85500, NL-3508 GA Utrecht, Netherlands; [Wittekamp, Bastiaan H.] Univ Med Ctr Utrecht, Intens Care Ctr, Utrecht, Netherlands; [Plantinga, Nienke L.; Bonten, Marc J. M.] Univ Med Ctr Utrecht, Med Microbiol & Julius Ctr Hlth Sci & Primary Car, Utrecht, Netherlands; [Cooper, Ben S.] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England; [Lopez-Contreras, Joaquin] Univ Autonoma Barcelona, Infect Diseases Internal Med, Hosp St Pau, Barcelona, Spain; [Coll, Pere] Univ Autonoma Barcelona, Hosp St Pau, Dept Microbiol, Barcelona, Spain; [Mancebo, Jordi] Univ Autonoma Barcelona, Hosp St Pau, Dept Intens Care, Barcelona, Spain; [Wise, Matt P.; Morgan, Matt P. G.] Univ Hosp Wales, Adult Crit Care, Cardiff, S Glam, Wales; [Depuydt, Pieter] Ghent Univ Hosp, Intens Care, Ghent, Belgium; [Boelens, Jerina] Ghent Univ Hosp, Dept Lab Med, Ghent, Belgium; [Dugernier, Thierry] Clin St Pierre, Dept Intens Care Med, Ottignies, Belgium; [Verbelen, Valerie] Clin St Pierre, Microbiol Dept, Ottignies, Belgium; [Jorens, Philippe G.; Verbrugghe, Walter] Univ Antwerp, Antwerp Univ Hosp, Intens Care Med, Antwerp, Belgium; [Malhotra-Kumar, Surbhi] Univ Antwerp, Lab Med Microbiol, Vaccine & Infect Dis Inst, Antwerp, Belgium; [Damas, Pierre] CHU Liege, Dept Intens Care Med, Liege, Belgium; [Meex, Cecile] CHU Liege, Clin Microbiol, Liege, Belgium; [Leleu, Kris] AZ Sint Jan Bruges, Anesthesiol & Crit Care, Brugge, Belgium; [van den Abeele, Anne-Marie] St Lucas Hosp Ghent, Microbiol Lab, Ghent, Belgium; [Gomes Pimenta de Matos, Ana Filipa] Ctr Hosp Tras os Montes os Montes & Alto Douro, Serv Med Intens, Vila Real, Portugal; [Fernandez Mendez, Sara] Hosp Clin Barcelona, Med Intens Care Unit, Barcelona, Spain; [Vergara Gomez, Andrea] Hosp Clin Barcelona, Microbiol Dept, Barcelona, Spain; [Tomic, Viktorija] Univ Clin Resp & Allerg Dis, Lab Resp Microbiol, Golnik, Slovenia; [Sifrer, Franc] Univ Clin Resp & Allerg Dis, Intens Care Unit, Golnik, Slovenia; [Villarreal, Esther; Ruiz Ramos, Jesus] Hosp Univ La Fe, Intens Care Unit, Valencia, Spain; [Aragao, Irene] CHP, Intens Care UCIP, Hosp Santo Antonio, Porto, Portugal; [Santos, Claudia] CHP, Microbiol Lab, Hosp Santo Antonio, Porto, Portugal; [Sperning, Roberta H. M.] Azienda Osped San Camillo Forlanini, Dept Microbiol, Rome, Italy; [Coppadoro, Patrizia] Azienda Osped San Camillo Forlanini, Intens Care Unit, Rome, Italy; [Nardi, Giuseppe] Osped Infermi RIMINI AUSL Romagna, Dept Anesthesia & Intens Care, Rimini, Italy; [Brun-Buisson, Christian] CHU Henri Mondor, Med Intens Care & Infect Control Unit, Paris, France; [Brun-Buisson, Christian] Univ Paris Est Creteil, Paris, France	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Oxford; Autonomous University of Barcelona; Autonomous University of Barcelona; Autonomous University of Barcelona; Cardiff University; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; University of Antwerp; University of Antwerp; University of Liege; University of Liege; Ghent University; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; Hospital Universitari i Politecnic La Fe; Azienda Ospedaliera San Camillo-Forlanini; Azienda Ospedaliera San Camillo-Forlanini; AUSL della Romagna; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Wittekamp, BH (corresponding author), Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Huispostnummer Str 6-131,POB 85500, NL-3508 GA Utrecht, Netherlands.	b.h.j.wittekamp@umcutrecht.nl	Ramos, Jesús Ruiz/V-1919-2019; Cooper, Ben/HGC-7082-2022; RUIZ, JESUS/AAM-9339-2021	RUIZ, JESUS/0000-0002-0008-641X; VERGARA, ANDREA/0000-0002-5046-4490; Leleu, Kris/0000-0002-8184-4648; dos Santos, Claudia/0000-0002-6446-8791; Lopez-Contreras, Joaquin/0000-0002-3166-4016; Cooper, Ben/0000-0002-9445-7217; Aragao, Irene/0000-0001-5750-2739	European Commission under the Seventh Framework Programme (FP7-HEALTH-2011-single-stage) [282512]	European Commission under the Seventh Framework Programme (FP7-HEALTH-2011-single-stage)	This study was funded by the European Commission under the Seventh Framework Programme (FP7-HEALTH-2011-single-stage, grant agreement number 282512).	CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Daneman N, 2013, LANCET INFECT DIS, V13, P328, DOI 10.1016/S1473-3099(12)70322-5; de Jonge E, 2003, LANCET, V362, P1011, DOI 10.1016/S0140-6736(03)14409-1; de Smet AMGA, 2009, NEW ENGL J MED, V360, P20, DOI 10.1056/NEJMoa0800394; Derde LPG, 2014, LANCET INFECT DIS, V14, P31, DOI 10.1016/S1473-3099(13)70295-0; Duncan EM, 2014, J CRIT CARE, V29, P634, DOI 10.1016/j.jcrc.2014.03.013; Hua F, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008367.pub3; Klompas M, 2014, JAMA INTERN MED, V174, P751, DOI 10.1001/jamainternmed.2014.359; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Labeau SO, 2011, LANCET INFECT DIS, V11, P845, DOI 10.1016/S1473-3099(11)70127-X; Le Gall JR, 2005, CRIT CARE, V9, pR645, DOI 10.1186/cc3821; Magiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469-0691.2011.03570.x; McCaffrey DF, 2013, STAT MED, V32, P3388, DOI 10.1002/sim.5753; Oostdijk EAN, 2017, JAMA-J AM MED ASSOC, V317, P1583, DOI 10.1001/jama.2017.1282; Oostdijk EAN, 2014, JAMA-J AM MED ASSOC, V312, P1429, DOI 10.1001/jama.2014.7247; Organization WH, 2009, WHO GUID HAND HYG HL; Plantinga NL, 2018, CLIN MICROBIOL INFEC, V24, P505, DOI 10.1016/j.cmi.2017.08.019; Plantinga NL, 2016, INTENS CARE MED, V42, P620, DOI 10.1007/s00134-016-4217-7; Price R, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2197; Scott RD, 2009, DIRECT MED COSTS HEA; Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754	21	85	85	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	2018	320	20					2087	2098		10.1001/jama.2018.13765	http://dx.doi.org/10.1001/jama.2018.13765			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB9ET	30347072	Green Published, Bronze			2023-01-03	WOS:000451395000016
J	Amaria, RN; Reddy, SM; Tawbi, HA; Davies, MA; Ross, MI; Glitza, IC; Cormier, JN; Lewis, C; Hwu, WJ; Hanna, E; Diab, A; Wong, MK; Royal, R; Gross, N; Weber, R; Lai, SY; Ehlers, R; Blando, J; Milton, DR; Woodman, S; Kageyama, R; Wells, DK; Hwu, P; Patel, SP; Lucci, A; Hessel, A; Lee, JE; Gershenwald, J; Simpson, L; Burton, EM; Posada, L; Haydu, L; Wang, LH; Zhang, SJ; Lazar, A; Hudgens, CW; Gopalakrishnan, V; Reuben, A; Andrews, MC; Spencer, CN; Prieto, V; Sharma, P; Allison, J; Tetzlaff, MT; Wargo, JA				Amaria, Rodabe N.; Reddy, Sangeetha M.; Tawbi, Hussein A.; Davies, Michael A.; Ross, Merrick, I; Glitza, Isabella C.; Cormier, Janice N.; Lewis, Carol; Hwu, Wen-Jen; Hanna, Ehab; Diab, Adi; Wong, Michael K.; Royal, Richard; Gross, Neil; Weber, Randal; Lai, Stephen Y.; Ehlers, Richard; Blando, Jorge; Milton, Denai R.; Woodman, Scott; Kageyama, Robin; Wells, Daniel K.; Hwu, Patrick; Patel, Sapna P.; Lucci, Anthony; Hessel, Amy; Lee, Jeffrey E.; Gershenwald, Jeffrey; Simpson, Lauren; Burton, Elizabeth M.; Posada, Liberty; Haydu, Lauren; Wang, Linghua; Zhang, Shaojun; Lazar, Alexanderj; Hudgens, Courtney W.; Gopalakrishnan, Vancheswaran; Reuben, Alexandre; Andrews, Miles C.; Spencer, Christine N.; Prieto, Victor; Sharma, Padmanee; Allison, James; Tetzlaff, Michael T.; Wargo, Jennifer A.			Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma	NATURE MEDICINE			English	Article							STAGE-III; ADJUVANT DABRAFENIB; COMBINED NIVOLUMAB; IPILIMUMAB; TRAMETINIB; SURVIVAL	Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is associated with enhanced survival and antigen-specific T cell responses compared with adjuvant treatment(1); however, optimal regimens have not been defined. Here we report results from a randomized phase 2 study of neoadjuvant nivolumab versus combined ipilimumab with nivolumab in 23 patients with high-risk resectable melanoma (NCT02519322). RECIST overall response rates (ORR), pathologic complete response rates (pCR), treatment-related adverse events (trAEs) and immune correlates of response were assessed. Treatment with combined ipilimumab and nivolumab yielded high response rates (RECIST ORR 73%, pCR 45%) but substantial toxicity (73% grade 3 trAEs), whereas treatment with nivolumab monotherapy yielded modest responses (ORR 25%, pCR 25%) and low toxicity (8% grade 3 trAEs). Immune correlates of response were identified, demonstrating higher lymphoid infiltrates in responders to both therapies and a more clonal and diverse T cell infiltrate in responders to nivolumab monotherapy. These results describe the feasibility of neoadjuvant immune checkpoint blockade in melanoma and emphasize the need for additional studies to optimize treatment regimens and to validate putative biomarkers.	[Amaria, Rodabe N.; Tawbi, Hussein A.; Davies, Michael A.; Glitza, Isabella C.; Hwu, Wen-Jen; Diab, Adi; Wong, Michael K.; Woodman, Scott; Hwu, Patrick; Patel, Sapna P.; Simpson, Lauren; Posada, Liberty] MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX USA; [Reddy, Sangeetha M.] MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX USA; [Ross, Merrick, I; Cormier, Janice N.; Royal, Richard; Ehlers, Richard; Lucci, Anthony; Lee, Jeffrey E.; Gershenwald, Jeffrey; Burton, Elizabeth M.; Haydu, Lauren; Gopalakrishnan, Vancheswaran; Reuben, Alexandre; Andrews, Miles C.; Wargo, Jennifer A.] MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Lewis, Carol; Hanna, Ehab; Gross, Neil; Weber, Randal; Lai, Stephen Y.; Hessel, Amy] MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX USA; [Blando, Jorge; Sharma, Padmanee; Allison, James] MD Anderson Canc Ctr, Dept Immunol, Houston, TX USA; [Milton, Denai R.] MD Anderson Canc Ctr, Dept Biostat, Houston, TX USA; [Kageyama, Robin; Wells, Daniel K.] Parker Inst Canc Immunotherapy, San Francisco, CA USA; [Wang, Linghua; Zhang, Shaojun; Spencer, Christine N.; Wargo, Jennifer A.] MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Lazar, Alexanderj; Hudgens, Courtney W.; Prieto, Victor; Tetzlaff, Michael T.] MD Anderson Canc Ctr, Dept Pathol, Houston, TX USA; [Sharma, Padmanee] MD Anderson Canc Ctr, Dept Genitourinary Canc, Houston, TX USA; [Tetzlaff, Michael T.] MD Anderson Canc Ctr, Dept Translat & Mol Pathol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Wargo, JA (corresponding author), MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.; Wargo, JA (corresponding author), MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.	jwargo@mdanderson.org	Gershenwald, Jeff/AAX-4367-2020; Reddy, Sangeetha/GNZ-8658-2022; Gopalakrishnan, Vancheswaran/S-9550-2019; Burton, Elizabeth/AAB-9393-2021; Davies, Michael/GWV-2527-2022; Hanna, Ehab Y/B-1593-2017; Wells, Daniel K./AAH-4015-2020	Gershenwald, Jeff/0000-0003-4519-5369; Gopalakrishnan, Vancheswaran/0000-0002-8704-035X; Burton, Elizabeth/0000-0002-3424-4922; Hanna, Ehab Y/0000-0003-3241-2440; Lai, Stephen/0000-0001-8301-7286; Lucci, Anthony/0000-0003-4039-174X; Hudgens, Courtney/0000-0001-8312-7485; Zhang, Shaojun/0000-0001-5760-5797; Andrews, Miles/0000-0003-1231-8641; Reddy, Sangeetha/0000-0002-8401-1481; Lazar, Alexander/0000-0002-6395-4499; Wang, Linghua/0000-0001-9380-0266	Bristol-Myers Squibb; US Department of Defense Grant [CA150619]; NATIONAL CANCER INSTITUTE [T32CA009666] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000371] Funding Source: NIH RePORTER	Bristol-Myers Squibb(Bristol-Myers Squibb); US Department of Defense Grant(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank the patients and their families for participating in this clinical trial. The clinical aspects of this study were funded by Bristol-Myers Squibb. The correlative research was supported by the philanthropic contributions to The University of Texas MD Anderson Cancer Center Melanoma Moon Shot Program, The Parker Institute for Cancer Immunotherapy and US Department of Defense Grant CA150619.	Amaria RN, 2018, LANCET ONCOL, V19, P181, DOI 10.1016/S1470-2045(18)30015-9; [Anonymous], 2009, NAT CANC I COMM TERM; Cha E, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008211; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Edge S.B., 2010, AJCC CANC STAGING MA, V649; Eggermont AMM, 2016, NEW ENGL J MED, V375, P1845, DOI 10.1056/NEJMoa1611299; Eggermont AMM, 2018, NEW ENGL J MED, V378, P1789, DOI 10.1056/NEJMoa1802357; Eggermont AMM, 2017, NEW ENGL J MED, V376, P399, DOI 10.1056/NEJMc1615564; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Gershenwald JE, 2017, CA-CANCER J CLIN, V67, P472, DOI 10.3322/caac.21409; Huang AC, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-CT181; Inoue H, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1204507; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu J, 2016, CANCER DISCOV, V6, P1382, DOI 10.1158/2159-8290.CD-16-0577; Long GV, 2017, NEW ENGL J MED, V377, P1813, DOI 10.1056/NEJMoa1708539; Provenzano E, 2015, MODERN PATHOL, V28, P1185, DOI 10.1038/modpathol.2015.74; Rimmer A, 2014, NAT GENET, V46, P912, DOI 10.1038/ng.3036; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Weber J, 2017, NEW ENGL J MED, V377, P1824, DOI 10.1056/NEJMoa1709030; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394	28	401	405	5	44	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2018	24	11					1649	+		10.1038/s41591-018-0197-1	http://dx.doi.org/10.1038/s41591-018-0197-1			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	GZ4VS	30297909	Green Accepted			2023-01-03	WOS:000449404200014
J	Saiphoklang, N; Auttajaroon, J				Saiphoklang, Narongkorn; Auttajaroon, Jeerayuth			Incidence and outcome of weaning from mechanical ventilation in medical wards at Thammasat University Hospital	PLOS ONE			English	Article							EXTUBATION FAILURE; PARAMETERS; TRIAL	Background Weaning from mechanical ventilation is classified as simple, difficult, or prolonged according to weaning process. Theoretically, simple weaning group usually has better clinical outcomes than non-simple group; however, the results of previous studies were still inconsistent. Objectives The purpose of the study was to determine the incidence, predictors, and outcomes of ventilator weaning and causes of weaning failure. Methods A prospective observational study was performed between June and December 2013 in all patients (n = 164) who required mechanical ventilation with endotracheal intubation in medical wards at Thammasat University Hospital, Thailand. Duration of weaning, causes of weaning failure, extubation, reintubation, tracheostomy, number of ventilator-free days within 28 days, length of hospital stay, and hospital mortality were measured. Results 103 patients were eligible for final analysis. Mean +/- SD age was 65.1 +/- 17.5 years and 55.3% were males. The incidences of simple, difficult and prolonged weaning were 46.6%, 36.9% and 16.5%, respectively. The mortality rates for simple, difficult, and prolonged weaning were 0%, 10.5% and 23.5% (p = 0.006), respectively. The 3 causes of weaning failure in non-simple weaning were bronchospasm, pneumonia, and malnutrition. Conclusions Non-simple weaning increased mortality. Bronchospasm, pneumonia, and malnutrition were key risk factors for weaning failure. Strategies are needed to minimize their effects.	[Saiphoklang, Narongkorn; Auttajaroon, Jeerayuth] Thammasat Univ, Div Pulm & Crit Care Med, Dept Med, Fac Med, Pathum Thani, Thailand	Thammasat University	Saiphoklang, N (corresponding author), Thammasat Univ, Div Pulm & Crit Care Med, Dept Med, Fac Med, Pathum Thani, Thailand.	m_narongkorn@hotmail.com	Saiphoklang, Narongkorn/AGA-9282-2022; Saiphoklang, Narongkorn/GPG-4003-2022	Saiphoklang, Narongkorn/0000-0003-2462-9471	Division of Pulmonary and Critical Care Medicine, Thammasat University	Division of Pulmonary and Critical Care Medicine, Thammasat University	The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study was fully supported by Division of Pulmonary and Critical Care Medicine, Thammasat University. The division supported financial, human resources and statistical analysis. The authors received no income from the division for this study.	Beduneau G, 2017, AM J RESP CRIT CARE, V195, P772, DOI 10.1164/rccm.201602-0320OC; Beuret P, 2009, INTENS CARE MED, V35, P1090, DOI 10.1007/s00134-009-1404-9; Boles JM, 2007, EUR RESPIR J, V29, P1033, DOI 10.1183/09031936.00010206; Dalar L, 2013, ANAESTH INTENS CARE, V41, P108, DOI 10.1177/0310057X1304100118; Ely EW, 2001, CHEST, V120, p454S, DOI 10.1378/chest.120.6_suppl.454S; Esteban A, 1999, AM J RESP CRIT CARE, V159, P512, DOI 10.1164/ajrccm.159.2.9803106; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Funk GC, 2010, EUR RESPIR J, V35, P88, DOI 10.1183/09031936.00056909; Huang CT, 2013, RESP CARE, V58, P1307, DOI 10.4187/respcare.01773; MacIntyre N, 2017, AM J RESP CRIT CARE, V195, P710, DOI 10.1164/rccm.201610-1988ED; Thille AW, 2011, CRIT CARE MED, V39, P2612, DOI 10.1097/CCM.0b013e3182282a5a; TOBIN MJ, 1994, NEW ENGL J MED, V330, P1056, DOI 10.1056/NEJM199404143301507; Tonnelier A, 2011, RESP CARE, V56, P583, DOI 10.4187/respcare.00842; Vallverdu I, 1998, AM J RESP CRIT CARE, V158, P1855, DOI 10.1164/ajrccm.158.6.9712135	15	9	9	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2018	13	10							e0205106	10.1371/journal.pone.0205106	http://dx.doi.org/10.1371/journal.pone.0205106			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV8IQ	30286153	Green Published, gold, Green Submitted			2023-01-03	WOS:000446383500086
J	Faraci, C; Jin, J; Woods, DC				Faraci, Christine; Jin, Joyce; Woods, Dori C.			Calorie restriction does not influence oocyte quality in oocytes from POLG mitochondrial mutator mice	PLOS ONE			English	Article							OXIDATIVE STRESS; DIETARY RESTRICTION; DNA POLYMERASE; LIFE-SPAN; AGED RAT; MUTATIONS; EXERCISE; BRAIN	It has recently been demonstrated that moderate adult onset caloric restriction (e.g. calorie restriction; CR) has a positive impact on female fertility in aged mice, due in large to preventing the age-associated decline in the quality of oocytes available for fertilization. The impact of CR on oocyte quality has been attributed, at least in part, to mitochondrial functions. In mitochondrial DNA (mtDNA) mutator mice (polg(D257A)(/)(D257A)) which harbor a mutation in the proofreading mtDNA polymerase-gamma (POLG), mitochondrial mutations rapidly accumulate, resulting in a premature aging phenotype and female infertility. As CR has been shown to extend both lifespan and 'healthspan' as well as improve oocyte quality in aged mice, we investigated whether adult onset CR could improve oocyte quality in the POLG mouse. Female Polg(D)(257A/D257A) mice exhibited infertility based on an inability to produce litters through natural mating. Analysis of oocytes from 8-9-month-old Polg(D)(257A/D257A) mice on CR following hormone stimulation revealed no improvement in the number of oocytes ovulated. Furthermore, CR did not result in a greater percentage of metaphase II oocytes, with the majority of the oocytes prematurely arrested at the germinal vesicle stage. Finally, CR did not improve the abnormal mitochondrial distribution or pronounced defects in meiotic spindle assembly and chromosomal distribution observed in the ad libitum fed Polg(D)(257A/D257A). Taken together, these data suggest that although CR benefits oocyte quality and fertility outcomes in naturally aged female mice, it does not sufficiently improve oocyte quality in Polg(D)(257A/D257A).	[Faraci, Christine; Jin, Joyce; Woods, Dori C.] Northeastern Univ, Dept Biol, Lab Aging & Infertil Res, Boston, MA 02115 USA	Northeastern University	Woods, DC (corresponding author), Northeastern Univ, Dept Biol, Lab Aging & Infertil Res, Boston, MA 02115 USA.	d.woods@northeastern.edu			National Science Foundation [1750996]	National Science Foundation(National Science Foundation (NSF))	This material is based upon work supported by the National Science Foundation under grant number 1750996 to D.C.W. The funding agency had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; Boudoures AL, 2016, REPRODUCTION, V151, P261, DOI 10.1530/REP-15-0419; Cassano P, 2004, ANN NY ACAD SCI, V1019, P269, DOI 10.1196/annals.1297.045; Faraci C, 2018, REPRODUCTION, V156, P185, DOI 10.1530/REP-18-0061; Hansen AB, 2006, DNA REPAIR, V5, P71, DOI 10.1016/j.dnarep.2005.07.009; Hauser DN, 2015, ENEURO, V2, DOI 10.1523/ENEURO.0075-14.2015; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Lezza AMS, 2008, NEUROCHEM RES, V33, P2609, DOI 10.1007/s11064-008-9866-7; Logan A, 2014, AGING CELL, V13, P765, DOI 10.1111/acel.12212; Macao B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8303; NELSON JF, 1985, BIOL REPROD, V32, P515, DOI 10.1095/biolreprod32.3.515; Ni T, 2015, SCI REP-UK, V5, DOI 10.1038/srep12049; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Safdar A, 2016, CURR OPIN GENET DEV, V38, P127, DOI 10.1016/j.gde.2016.06.011; Safdar A, 2016, SKELET MUSCLE, V6, DOI 10.1186/s13395-016-0075-9; Safdar A, 2011, P NATL ACAD SCI USA, V108, P4135, DOI 10.1073/pnas.1019581108; Safdar A, 2011, J BIOL CHEM, V286, P10605, DOI 10.1074/jbc.M110.211466; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Selesniemi K, 2011, P NATL ACAD SCI USA, V108, P12319, DOI 10.1073/pnas.1018793108; Sharov AA, 2008, BMC BIOL, V6, DOI 10.1186/1741-7007-6-24; Someya S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171159; Szklarczyk R, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0439; Tamura H, 2008, J PINEAL RES, V44, P280, DOI [10.1111/j.1600-079X.2007.00524.x, 10.1111/j.1600-079X.2007.00524.X]; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492; Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95; Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; Woods DC, 2018, GENES-BASEL, V9, DOI 10.3390/genes9050265	29	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2018	13	9							e0204373	10.1371/journal.pone.0204373	http://dx.doi.org/10.1371/journal.pone.0204373			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GU5MM	30240410	Green Submitted, Green Published, gold			2023-01-03	WOS:000445329700043
J	Pohl, P; Carlsson, G; Kall, LB; Nilsson, M; Blomstrand, C				Pohl, Petra; Carlsson, Gunnel; Kall, Lina Bunketorp; Nilsson, Michael; Blomstrand, Christian			A qualitative exploration of post-acute stroke participants' experiences of a multimodal intervention incorporating horseback riding	PLOS ONE			English	Article							REHABILITATION; CHALLENGES; GAIT; HIPPOTHERAPY; EXERCISE; BALANCE; FOCUS	Background Multimodal rehabilitation interventions delivered in late phase of stroke recovery involve physical (motor and sensory), social, and cognitively challenging activities. Horseback riding can be incorporated within such interventions, leading to meaningful long-term improvements when applied to individuals with moderate levels of disability. There is a lack of research illuminating stroke survivors' experiences and perceptions of horseback riding in the context of multimodal interventions. Aim To explore stroke survivors' experiences of participation in a multimodal group-based intervention that included horseback riding. Methods An explorative interview study was conducted with individual face-to-face interviews performed on a single occasion, utilising a semi-structured interview guide. Eighteen participants were purposively selected from a larger trial (mean age 62, 12 men, 6 women) within four weeks after treatment completion. The interview duration was between 17 and 50 minutes. The data was analysed using a qualitative content analysis method. Findings Four broad themes were identified from the analysis. These themes were: transformative experiences; human-horse interaction; togetherness and belonging; and the all-in-one solution. Interacting with the horse and peers had a profound emotional impact on the participants. The participants also reported having learned new skills, increased self-efficacy and self-esteem, and improvements in balance and gait, all of which could be transferred to everyday life. The horse itself played a central role, but other components, such as the other group members, the instructors, and the challenging tasks on the horseback, were also important. Conclusion A multimodal rehabilitation intervention that includes horseback riding may provide stroke survivors in a late phase of recovery with rich pleasurable experiences that may have life-changing and profound impacts on their emotional and physical state.	[Pohl, Petra; Carlsson, Gunnel; Nilsson, Michael; Blomstrand, Christian] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, Gothenburg, Sweden; [Pohl, Petra] Linkoping Univ, Dept Act & Hlth, Linkoping, Sweden; [Pohl, Petra] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden; [Kall, Lina Bunketorp] Sahlgrenska Univ Hosp Molndal, Ctr Adv Reconstruct Extrem, Molndal, Sweden; [Kall, Lina Bunketorp] Univ Gothenburg, Dept Hlth & Rehabil, Inst Neurosci & Physiol, Sahlgrenska Acad, Gothenburg, Sweden; [Nilsson, Michael] Univ Newcastle, Hunter Med Res Inst, Newcastle, NSW, Australia; [Blomstrand, Christian] Univ Gothenburg, Sahlgrenska Acad, Stroke Ctr West, Gothenburg, Sweden	University of Gothenburg; Linkoping University; Linkoping University; Sahlgrenska University Hospital; University of Gothenburg; Hunter Medical Research Institute; University of Newcastle; University of Gothenburg	Pohl, P (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, Gothenburg, Sweden.; Pohl, P (corresponding author), Linkoping Univ, Dept Act & Hlth, Linkoping, Sweden.; Pohl, P (corresponding author), Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden.	petra.pohl@liu.se	NILSSON, MICHAEL/ABE-7821-2020; Bunketorp-Käll, Lina/AAI-1237-2020; ARSLAN, Okan/AAA-3232-2020	NILSSON, MICHAEL/0000-0002-8826-1621; Pohl, Petra/0000-0002-3447-6547; Bunketorp Kall, lina/0000-0002-4571-0335	Swedish Stroke Association's foundations; Hjalmar Svensson Research Foundation; Peter Eriksson Memorial Foundation for Brain Research; Mary von Sydow, nee Wijk, Foundation; John and Brit Wennerstrom Foundation for Neurological Research; Rune and Ulla Amlov Foundation for Neurological, Rheumatological, and Audiological Research	Swedish Stroke Association's foundations; Hjalmar Svensson Research Foundation; Peter Eriksson Memorial Foundation for Brain Research; Mary von Sydow, nee Wijk, Foundation; John and Brit Wennerstrom Foundation for Neurological Research; Rune and Ulla Amlov Foundation for Neurological, Rheumatological, and Audiological Research	This work received support from the Swedish Stroke Association's foundations, http://www.strokeforbundet.se (PP); the Hjalmar Svensson Research Foundation (LBK); the Peter Eriksson Memorial Foundation for Brain Research (PP); the Mary von Sydow, nee Wijk, Foundation (PP); the John and Brit Wennerstrom Foundation for Neurological Research (PP); and the Rune and Ulla Amlov Foundation for Neurological, Rheumatological, and Audiological Research (PP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alwis DS, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00156; Bandura A., 1986, SOCIAL FDNS THOUGHTS; Bandura A., 1997, SELF EFFICACY EXERCI; Beinotti F, 2013, TOP STROKE REHABIL, V20, P226, DOI 10.1310/tsr2003-226; Beinotti F, 2010, ARQ NEURO-PSIQUIAT, V68, P908, DOI 10.1590/S0004-282X2010000600015; Bizub AL, 2003, PSYCHIATR REHABIL J, V26, P377, DOI 10.2975/26.2003.377.384; Blumer H, 1968, ANN M SOC ED SCHOL L; Bunketorp-Kall L, 2017, STROKE, V48, P1916, DOI 10.1161/STROKEAHA.116.016433; Carlsson C, 2015, CHILD ADOLESC SOC WO, V32, P329, DOI 10.1007/s10560-015-0376-6; Carr JH, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/515938; Cassidy JM, 2017, TRANSL STROKE RES, V8, P33, DOI 10.1007/s12975-016-0467-5; Clayton HM, 2011, AM J OCCUP THER, V65, P211, DOI 10.5014/ajot.2011.000851; Corbett D, 2015, PROG BRAIN RES, V218, P413, DOI 10.1016/bs.pbr.2014.12.002; De Wit L, 2017, DISABIL REHABIL, V39, P1435, DOI 10.1080/09638288.2016.1200676; Elo S, 2008, J ADV NURS, V62, P107, DOI 10.1111/j.1365-2648.2007.04569.x; Gabriels RL, 2015, J AM ACAD CHILD PSY, V54, P541, DOI 10.1016/j.jaac.2015.04.007; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Graneheim UH, 2017, NURS EDUC TODAY, V56, P29, DOI 10.1016/j.nedt.2017.06.002; Green J., 2014, QUALITATIVE METHODS, V3rd; Greenhalgh T, 1997, BMJ-BRIT MED J, V315, P740, DOI 10.1136/bmj.315.7110.740; Hakanson M, 2009, J BODYW MOV THER, V13, P43, DOI 10.1016/j.jbmt.2007.06.002; Hammer Ann, 2005, Physiotherapy Theory and Practice, V21, P51, DOI 10.1080/09593980590911525; Hole E, 2014, SCI WORLD J, DOI 10.1155/2014/349151; Homnick DN, 2013, J ALTERN COMPLEM MED, V19, P622, DOI 10.1089/acm.2012.0642; Jackson K, 2019, DISABIL REHABIL, V41, P2731, DOI 10.1080/09638288.2018.1473508; Johansson BB, 2011, ACTA NEUROL SCAND, V123, P147, DOI 10.1111/j.1600-0404.2010.01417.x; Johansson BB, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00060; Johnson RA, 2018, MILITARY MED RES, V5, DOI 10.1186/s40779-018-0149-6; Kall LB, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-141; Kim YN, 2015, J PHYS THER SCI, V27, P607, DOI 10.1589/jpts.27.607; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Lincoln YS., 1985, NATURALISTIC INQUIRY, DOI 10.1016/0147-1767(85)90062-8; Livingston-Thomas J, 2016, NEUROTHERAPEUTICS, V13, P395, DOI 10.1007/s13311-016-0423-9; Lundquist Wanneberg P, 2014, QUALITATIVE STUDY IN, DOI [10.1080/1034912X.2014.878543, DOI 10.1080/1034912X.2014.878543]; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; Masini A, 2010, J PSYCHOSOC NURS MEN, V48, P30, DOI 10.3928/02793695-20100831-08; McKevitt C, 2004, STROKE, V35, P1499, DOI 10.1161/01.STR.0000127532.64840.36; Mead G.H., 1962, MIND SELF SOC STANDP; Munoz-Lasa Susana, 2011, G Ital Med Lav Ergon, V33, P462; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Ohman A, 2005, J REHABIL MED, V37, P273, DOI 10.1080/16501970510040056; Peoples H, 2011, SCAND J OCCUP THER, V18, P163, DOI 10.3109/11038128.2010.509887; Rigby BR, 2016, J ALTERN COMPLEM MED, V22, P9, DOI 10.1089/acm.2015.0171; Simmons-Mackie N, 2008, LANGUAGE INTERVENTIO; Snider Laurie, 2007, Phys Occup Ther Pediatr, V27, P5; Sung YH, 2013, NEUROREHABILITATION, V33, P407, DOI 10.3233/NRE-130971; Teasell R, 2012, TOP STROKE REHABIL, V19, P457, DOI 10.1310/tsr1906-457; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Uvnas-Moberg K, 2005, INT J BEHAV MED, V12, P59, DOI 10.1207/s15327558ijbm1202_3; VanderKaay S, 2018, DISABIL REHABIL, V40, P705, DOI 10.1080/09638288.2016.1261414	50	10	11	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2018	13	9							e0203933	10.1371/journal.pone.0203933	http://dx.doi.org/10.1371/journal.pone.0203933			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GU8XH	30235246	Green Published, gold, Green Submitted			2023-01-03	WOS:000445626400041
J	Cordovilla-Guardia, S; Garcia-Jimenez, C; Fernandez-Mondejar, E; Calderon-Garcia, JF; Lopez-Espuela, F; Franco-Antonio, C; Rico-Martin, S; Lardelli-Claret, P				Cordovilla-Guardia, Sergio; Garcia-Jimenez, Celia; Fernandez-Mondejar, Enrique; Calderon-Garcia, Julian Fernando; Lopez-Espuela, Fidel; Franco-Antonio, Cristina; Rico-Martin, Sergio; Lardelli-Claret, Pablo			Association between the detection of alcohol, illicit drugs and/or psychotropic medications/opioids in patients admitted due to trauma and trauma recidivism: A cohort study	PLOS ONE			English	Article							SUBSTANCE USE; PREVALENCE; INJURIES; POPULATION; PREDICTOR; SEVERITY; HISTORY; COCAINE; ABUSE; RISK	Objective To quantify the association between the presence and type of drug detected and trauma recidivism in a cohort of patients admitted due to trauma. Method A cohort study was conducted based on data from a project where the presence of alcohol and other drugs (cannabis, cocaine, amphetamines, methamphetamines, tricyclic antidepressants, barbiturates, opiates and benzodiazepines) was analysed in 1,187 patients aged 16 to 70 years admitted due to trauma. The patients were followed for a period of between 10 to 52 months until June 2016. For this study, the recurrence of injuries from a sample of 929 patients from this cohort was analysed according to their consumption profile. Survival curves were estimated and adjusted Hazard Rate Ratios (aHRR) and adjusted incidence rate ratios (aIRR) were calculated. Results The incidence rate of TR was 10.94 cases per 100 patient-years in the group of patients negative for substances and 27.99 per 100 patient-years in positive patients. The survival curves show very significant differences in cumulative recurrence-free survival between the groups (Log Rank: p<0.001). Both the aHRR and the aIRR estimates show an increased risk of re-injury due to alcohol consumption (aIRR: 2.33 (1.72-3.15), p<0.001), cannabis use (aIRR: 1.87 (1.09-3.20), p = 0.022) and polydrug use (aIRR: 2.34 (1.80-3.04), p<0.001). Conclusions The presence of alcohol and/or illicit drugs in these patients doubles the risk of trauma recidivism.	[Cordovilla-Guardia, Sergio; Calderon-Garcia, Julian Fernando; Lopez-Espuela, Fidel; Franco-Antonio, Cristina; Rico-Martin, Sergio] Univ Extremadura, Nursing & Occupat Therapy Coll, Nursing Dept, Caceres, Spain; [Garcia-Jimenez, Celia; Lardelli-Claret, Pablo] Univ Granada, Sch Med, Dept Prevent Med & Publ Hlth, Granada, Spain; [Fernandez-Mondejar, Enrique] Hosp Univ Virgen Nieves, Unidad Cuidados Intens, Granada, Spain; [Fernandez-Mondejar, Enrique; Lardelli-Claret, Pablo] Inst Invest Biosanitaria IBS, Granada, Spain; [Lardelli-Claret, Pablo] CIBER Epidemiol & Publ Hlth, Madrid, Spain	Universidad de Extremadura; University of Granada; Hospital Universitario Virgen de las Nieves; Instituto de Investigacion Biosanitaria IBS Granada; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP	Cordovilla-Guardia, S (corresponding author), Univ Extremadura, Nursing & Occupat Therapy Coll, Nursing Dept, Caceres, Spain.	cordovilla@unex.es	Martín, Sergio Rico/ABE-4372-2020; Sergio, Cordovilla-Guardia/I-7268-2019; Espuela, Fidel Lopez/R-1843-2017; Antonio, Cristina Franco/AAL-1752-2020	Martín, Sergio Rico/0000-0003-4932-1940; Sergio, Cordovilla-Guardia/0000-0001-7651-5017; Espuela, Fidel Lopez/0000-0002-7509-1192; Antonio, Cristina Franco/0000-0001-8427-2836	Direccion General de Trafico, Spain [0100DGT22389]	Direccion General de Trafico, Spain	This work was supported by the Direccion General de Trafico, Spain [grant number: 0100DGT22389] (http://www.dgt.es/). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2005, ABBR INJ SCAL 2005 U; Asbridge M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e536; Babor Thomas F, 2007, Subst Abus, V28, P7, DOI 10.1300/J465v28n03_03; Borges G, 2006, ADDICTION, V101, P993, DOI 10.1111/j.1360-0443.2006.01462.x; Cannon R, 2014, J TRAUMA ACUTE CARE, V76, P172, DOI 10.1097/TA.0b013e3182ab10de; Caufeild J, 2004, J TRAUMA, V57, P872, DOI 10.1097/01.TA.0000135350.06670.60; Cherpitel CJ, 2013, AM J ADDICTION, V22, P87, DOI 10.1111/j.1521-0391.2013.00316.x; Cordovilla-Guardia S, 2014, EUR J TRAUMA EMERG S, V40, P693, DOI 10.1007/s00068-014-0384-9; Cordovilla-Guardia S, 2019, GAC SANIT, V33, P4, DOI 10.1016/j.gaceta.2017.06.006; Cordovilla-Guardia S, 2017, NURS RES, V66, P399, DOI 10.1097/NNR.0000000000000231; Cordovilla-Guardia S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182441; Demetriades D, 2004, J AM COLL SURGEONS, V199, P687, DOI 10.1016/j.jamcollsurg.2004.07.017; Draus JM, 2008, J PEDIATR SURG, V43, P208, DOI 10.1016/j.jpedsurg.2007.09.046; Fabbri A, 2005, ANN EMERG MED, V46, P161, DOI 10.1016/j.annemergmed.2005.04.002; Farley M, 2004, J SUBST ABUSE TREAT, V27, P161, DOI 10.1016/j.jsat.2004.06.006; Jackson JS, 2012, WHO GLOBAL BURDEN DI; Kaufmann CR, 1998, J TRAUMA, V45, P325, DOI 10.1097/00005373-199808000-00019; Keough V, 2001, J Emerg Nurs, V27, P340, DOI 10.1067/men.2001.116214; Longo MC, 2000, ACCIDENT ANAL PREV, V32, P613, DOI 10.1016/S0001-4575(99)00111-6; McCoy AM, 2013, J TRAUMA ACUTE CARE, V75, P116, DOI 10.1097/TA.0b013e31829231b7; Moore EE, 2005, J TRAUMA, V59, pS53, DOI 10.1097/01.ta.0000174868.13616.67; Nunn J, 2016, INJURY, V47, P551, DOI 10.1016/j.injury.2016.01.008; Ramchand R, 2009, J TRAUMA, V66, P1461, DOI 10.1097/TA.0b013e318184821d; REINER DS, 1990, AM SURGEON, V56, P556; Socie E, 2012, J STUD ALCOHOL DRUGS, V73, P260, DOI 10.15288/jsad.2012.73.260; Soderstrom CA, 2001, J TRAUMA, V51, P557, DOI 10.1097/00005373-200109000-00024; Toschlog EA, 2007, ARCH SURG-CHICAGO, V142, P77, DOI 10.1001/archsurg.142.1.77; Vaaramo K, 2014, EUR J NEUROL, V21, P293, DOI 10.1111/ene.12302; Vitale S, 2006, DRUG ALCOHOL DEPEN, V82, P1, DOI 10.1016/j.drugalcdep.2005.08.017	29	8	8	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2018	13	9							e0203963	10.1371/journal.pone.0203963	http://dx.doi.org/10.1371/journal.pone.0203963			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GT7EB	30208111	gold, Green Published, Green Submitted			2023-01-03	WOS:000444683000087
J	Gupta, A; Cifu, AS; Khanna, S				Gupta, Arjun; Cifu, Adam S.; Khanna, Sahil			Diagnosis and Treatment of Clostridium difficile Infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ADULTS		[Gupta, Arjun] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; [Cifu, Adam S.] Univ Chicago, Dept Internal Med, Chicago, IL 60637 USA; [Khanna, Sahil] Mayo Clin, Div Gastroenterol & Hepatol, 200 First St SW, Rochester, MN 55905 USA	Johns Hopkins University; Johns Hopkins Medicine; University of Chicago; Mayo Clinic	Khanna, S (corresponding author), Mayo Clin, Div Gastroenterol & Hepatol, 200 First St SW, Rochester, MN 55905 USA.	khanna.sahil@mayo.edu			Premier Inc; Merck and Co; Facile Therapeutics; Pro Biotech LLC; Rebiotix Inc.	Premier Inc; Merck and Co(Merck & Company); Facile Therapeutics; Pro Biotech LLC; Rebiotix Inc.	The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Khanna reports receipt of personal fees from Premier Inc, Merck and Co, Facile Therapeutics, and Pro Biotech LLC and a grant from Rebiotix Inc. No other disclosures were reported.	Abramowicz M, 2017, JAMA-J AM MED ASSOC, V318, P659, DOI 10.1001/jama.2017.10092; Bagdasarian N, 2015, JAMA-J AM MED ASSOC, V313, P398, DOI 10.1001/jama.2014.17103; Comely OA, 2012, CLIN INFECT DIS, V55, pS154, DOI 10.1093/cid/cis462; Gupta A, 2016, JAMA-J AM MED ASSOC, V316, P2422, DOI 10.1001/jama.2016.17173; Kao D, 2017, JAMA-J AM MED ASSOC, V318, P1985, DOI 10.1001/jama.2017.17077; Louie TJ, 2011, NEW ENGL J MED, V364, P422, DOI 10.1056/NEJMoa0910812; Ma GK, 2017, ANN INTERN MED, V167, P152, DOI [10.7326/M16-2733, 10.7326/m16-2733]; McDonald LC, 2018, CLIN INFECT DIS, V66, pE1, DOI [10.1093/cid/cix1085, 10.1093/cid/ciy149]	8	23	25	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	2018	320	10					1031	1032		10.1001/jama.2018.12194	http://dx.doi.org/10.1001/jama.2018.12194			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT2QE	30178042				2023-01-03	WOS:000444341400018
J	Saraiva, MMS; Moreira, ALB; Freitas Neto, OC; Silva, NMV; Givisiez, PEN; Gebreyes, WA; Oliveira, CJB				Saraiva, Mauro M. S.; Moreira Filho, Alexandre L. B.; Freitas Neto, Oliveiro C.; Silva, Nubia M., V; Givisiez, Patricia E. N.; Gebreyes, Wondwossen A.; Oliveira, Celso J. B.			Off-label use of ceftiofur in one-day chicks triggers a short-term increase of ESBL- producing E. coli in the gut	PLOS ONE			English	Article							SPECTRUM-BETA-LACTAMASE; ESCHERICHIA-COLI; ANTIMICROBIAL RESISTANCE; FARM-ANIMALS; FOOD ANIMALS; GENES; MEAT; SALMONELLA; ENTEROBACTERIACEAE; DISSEMINATION	This trial was designed to evaluate the off-label use of ceftiofur with Marek's vaccine in one-day-old broiler chicks, a prophylactic treatment that has been done in some commercial hatcheries, on the emergence of extended-spectrum beta-lactamase producing Escherichia coli (ESBL-E. coli). A total of 168 chicks (Cobb500 (R)) were used in a completely randomized design. Birds were assigned to two treatments (Marek's vaccine plus saline vs Marek's vaccine plus ceftiofur) and six repetitions, with 14 animals each. Cloacal swabs were collected from 1 to 14 days post-hatch. The majority (86%; p<0.0001) of the ESBL-producing isolates harboring bla(CTX-M) and bla(SHV) genes originated from animals receiving the antimicrobial. None of the isolates were positive for plasmid-mediated AmpC betalactamase genes (bla(ACC), bla(CMY-2), bla(DHA), bla(FOX), bla(MOX) and bla(MIR)). These findings indicate that the off-label use of ceftiofur with Marek's vaccine is associated with the short-term increase in ESBL-producing Escherichia coli in the gut of chicks.	[Saraiva, Mauro M. S.; Moreira Filho, Alexandre L. B.; Silva, Nubia M., V; Givisiez, Patricia E. N.; Oliveira, Celso J. B.] Fed Univ Paraiba CCA UFPB, Ctr Agr Sci, Dept Anim Sci, Areia, Paraiba, Brazil; [Moreira Filho, Alexandre L. B.; Oliveira, Celso J. B.] Natl Inst Res Antimicrobial Resistance INPRA, Porto Alegre, RS, Brazil; [Freitas Neto, Oliveiro C.] Fed Univ Paraiba CCA UFPB, Ctr Agr Sci, Dept Vet Sci, Areia, Paraiba, Brazil; [Gebreyes, Wondwossen A.] Ohio State Univ, Coll Vet Med, Dept Prevent Vet Med, Columbus, OH 43210 USA; [Gebreyes, Wondwossen A.; Oliveira, Celso J. B.] Ohio State Univ, GOHi, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Oliveira, CJB (corresponding author), Fed Univ Paraiba CCA UFPB, Ctr Agr Sci, Dept Anim Sci, Areia, Paraiba, Brazil.; Oliveira, CJB (corresponding author), Natl Inst Res Antimicrobial Resistance INPRA, Porto Alegre, RS, Brazil.; Oliveira, CJB (corresponding author), Ohio State Univ, GOHi, Columbus, OH 43210 USA.	celso.bruno.oliveira@gmail.com	GIVISIEZ, PATRICIA/V-2140-2019; de Oliveira, Celso José Bruno/V-2167-2019; Saraiva, Mauro M S/T-1745-2018; de, Freitas Neto O. C./E-8713-2012; Saraiva, Mauro/AAR-3642-2020	GIVISIEZ, PATRICIA/0000-0002-2480-1780; de Oliveira, Celso José Bruno/0000-0002-7761-0697; Saraiva, Mauro M S/0000-0003-1875-4495; de, Freitas Neto O. C./0000-0002-1437-069X; Saraiva, Mauro/0000-0003-1875-4495; Silva, Nubia Michelle Vieira/0000-0002-9800-9585	Coordination for the Improvement of Higher Education Personnel (CAPE); Brazilian National Council for Scientific and Technological Development (CNPq); Institute of International Education / Global Innovation Initiative [S-ECAGD-13-CA 149 DT]; Department of Animal Science of The University of Illinois at Urbana-Champaign under CAPES [BEX 1910/14-0, BEX 1853/14-7]	Coordination for the Improvement of Higher Education Personnel (CAPE); Brazilian National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Institute of International Education / Global Innovation Initiative; Department of Animal Science of The University of Illinois at Urbana-Champaign under CAPES	This study was supported by the Coordination for the Improvement of Higher Education Personnel (CAPES; https://www.capes.gov.br/) that provided scholarships to graduate students (MMSS) and post-docs (ALBMF, NMVS). This study was also granted by The Brazilian National Council for Scientific and Technological Development (CNPq: http://cnpq.br/in-english-summary) (CJBO) and The Institute of International Education / Global Innovation Initiative / S-ECAGD-13-CA 149 DT (IIE: https://www.iie.org/) (WAG). The project has been conceptualized, written and submitted during CJBO and PENG time as visiting scholars at the Department of Animal Science of The University of Illinois at Urbana-Champaign under senior fellowship grants from CAPES (BEX 1910/14-0 and BEX 1853/14-7, respectively).; This study was supported by the Coordination for the Improvement of Higher Education Personnel (CAPES; https://www.capes.gov.br/) that provided scholarships to graduate students (MMSS) and post-docs (ALBMF, NMVS). This study was also granted by The Brazilian National Council for Scientific and Technological Development (CNPq: http://cnpq.br/in-english-summary) (CJBO) and The Institute of International Education / Global Innovation Initiative / S-ECAGD-13-CA 149 DT (IIE: https://www.iie.org/) (WAG). The project has been conceptualized, written and submitted during CJBO and PENG time as visiting scholars at the Department of Animal Science of The University of Illinois at Urbana-Champaign under senior fellowship grants from CAPES (BEX 1910/14-0 and BEX 1853/14-7, respectively. Fertile eggs were provided by Guaraves Alimentos Ltda, Guarabira-PB. We are in debt with Prof. Walter Esfrain Pereira (CCA/UFPB) for the valuable support in the statistical analyses, Prof. Eloiza H. Campana (CCS/UFPB) for providing the primers and the positive controls for the PCR assays, and also for critically reviewing the manuscript, and Priscylla C. Vasconcelos (PDIZ/CCA/UFPB) for performing the MICs of ceftiofur of the E. coli isolates.	[Anonymous], R LANG ENV STAT COMP; Baron S, 2014, ANTIMICROB AGENTS CH, V58, P5428, DOI 10.1128/AAC.03106-14; Beyer A, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0578-3; Borjesson S, 2016, EMERG INFECT DIS, V22, P634, DOI 10.3201/eid2204.151142; Casella T, 2015, INT J FOOD MICROBIOL, V197, P88, DOI 10.1016/j.ijfoodmicro.2014.12.001; CLSI, 2021, PERFORMANCE STANDARD, V5th; Collignon PC, 2016, CLIN INFECT DIS, V63, P1087, DOI 10.1093/cid/ciw475; Dropa M, 2015, J INFECT DEV COUNTR, V9, P890, DOI 10.3855/jidc.6241; Dutil L, 2010, EMERG INFECT DIS, V16, P48, DOI 10.3201/eid1601.090729; Fang LX, 2015, INT J ANTIMICROB AG, V46, P209, DOI 10.1016/j.ijantimicag.2015.04.003; Founou LL, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00188; Fritsch E.F., 1989, MOL CLONING LAB MANU; Gibbons JF, 2016, ZOONOSES PUBLIC HLTH, V63, P241, DOI 10.1111/zph.12225; Heider LC, 2009, FOODBORNE PATHOG DIS, V6, P1235, DOI 10.1089/fpd.2009.0294; Hiki M, 2017, J VET DIAGN INVEST, V29, P716, DOI 10.1177/1040638717713794; Horton RA, 2011, APPL ENVIRON MICROB, V77, P3715, DOI 10.1128/AEM.02831-10; HUNTER PR, 1990, J CLIN MICROBIOL, V28, P1903, DOI 10.1128/JCM.28.9.1903-1905.1990; Jacoby GA, 2009, CLIN MICROBIOL REV, V22, P161, DOI 10.1128/CMR.00036-08; Kojima A, 2005, ANTIMICROB AGENTS CH, V49, P3533, DOI 10.1128/AAC.49.8.3533-3537.2005; KRUSE H, 1994, APPL ENVIRON MICROB, V60, P4015, DOI 10.1128/AEM.60.11.4015-4021.1994; Liu H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9494; Martin LC, 2012, APPL ENVIRON MICROB, V78, P1285, DOI 10.1128/AEM.06498-11; Overdevest I, 2011, EMERG INFECT DIS, V17, P1216, DOI 10.3201/eid1707.110209; Perez-Perez FJ, 2002, J CLIN MICROBIOL, V40, P2153, DOI 10.1128/JCM.40.6.2153-2162.2002; Queenan AM, 2004, J CLIN MICROBIOL, V42, P269, DOI 10.1128/JCM.42.1.269-275.2004; Randall LP, 2017, INT J FOOD MICROBIOL, V241, P283, DOI 10.1016/j.ijfoodmicro.2016.10.036; Touzain F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0188768; Warjri I, 2015, VET WORLD, V8, P599, DOI 10.14202/vetworld.2015.599-604; Webster P, 2009, CAN MED ASSOC J, V181, P21, DOI 10.1503/cmaj.091009; Ye YW, 2011, FOODBORNE PATHOG DIS, V8, P935, DOI 10.1089/fpd.2010.0799; Zhao SH, 2001, ANTIMICROB AGENTS CH, V45, P3647, DOI 10.1128/AAC.45.12.3647-3650.2001	31	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2018	13	9							e0203158	10.1371/journal.pone.0203158	http://dx.doi.org/10.1371/journal.pone.0203158			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT2UM	30204766	gold, Green Published, Green Submitted			2023-01-03	WOS:000444355500019
J	Sato, Y; Toida, T; Nakagawa, H; Iwakiri, T; Nishizono, R; Kikuchi, M; Fujimoto, S				Sato, Yuji; Toida, Tatsunori; Nakagawa, Hideto; Iwakiri, Takashi; Nishizono, Ryuzoh; Kikuchi, Masao; Fujimoto, Shouichi			Diminishing dry weight is strongly associated with all-cause mortality among long-term maintenance prevalent dialysis patients	PLOS ONE			English	Article							SURVIVAL	Objectives To investigate the relationship between dry weight (DW) change and survival in long-term maintenance prevalent dialysis patients. Methods We conducted a prospective data collection study with retrospective analysis of the registered data. Patients were followed up for 5 years (1-year observation of DW changes and subsequent 4-year follow-up). The outcome was all-cause mortality. The predictors were 1-year DW change rates. The hazard ratios (HRs) for all-cause mortality were calculated using multivariable Cox regression analysis, fully adjusted for age, sex, basal kidney disease, dialysis vintage, current smoking, past cardiovascular events, serum albumin, DW at enrollment, serum creatinine, mean predialysis systolic blood pressure, and cardiothoracic ratio or 1-year cardiothoracic ratio change rate. Propensity score (PS) analysis was also conducted using the same covariates of Cox regression analysis. Results In total, 899 dialysis patients (mean dialysis vintage: 101.2 months) were followed up, and 180 deaths were recorded, of which 90 were of cardiovascular origin. Each 2% decrement of DW showed adjusted HR, and the 95% confidence interval was 1.24 [1.16-1.33]. According to the 1-year DW change rate, participants were divided into five groups (group A, >=+3%; group B, +1 to +2.9%; group C, -0.9 to +0.9%; group D, -2.9 to -1.0%; and group E, <=-3%). For survival curves based on grouping, group B had the best and group E had the worst survival rate (p<0.01, log-rank test). Therefore, we set group B as a reference; adjusted risks for death of groups D and E were 2.16 [1.23-3.79] and 2.66 [1.54-4.58], respectively. However, this relation was blunted in patients of heavier DW. The PS-matched cohort showed a poorer prognosis in patients with diminishing DW divided by DW change rate at -0.635% (mean value of DW change rate). Conclusion In the long-term maintenance hemodialysis cohort, 1-year DW decrement, especially <=-3.0%, was significantly associated with all-cause mortality, and cardiovascular diseaserelated death was prominent in these patients.	[Sato, Yuji; Nakagawa, Hideto; Iwakiri, Takashi] Univ Miyazaki Hosp, Dialysis Div, Miyazaki, Japan; [Toida, Tatsunori; Fujimoto, Shouichi] Univ Miyazaki, Fac Med, Dept Hemovasc Med & Artificial Organs, Miyazaki, Japan; [Nishizono, Ryuzoh; Kikuchi, Masao] Univ Miyazaki, Fac Med, Dept Internal Med, Div Circulatory & Body Fluid Regulat, Miyazaki, Japan	University of Miyazaki; University of Miyazaki; University of Miyazaki	Sato, Y (corresponding author), Univ Miyazaki Hosp, Dialysis Div, Miyazaki, Japan.	ysato@med.miyazaki-u.ac.jp						Badve SV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114897; Bonanni A, 2011, INT J ENV RES PUB HE, V8, P1631, DOI 10.3390/ijerph8051631; Cabezas-Rodriguez I, 2013, CLIN J AM SOC NEPHRO, V8, P1725, DOI 10.2215/CJN.10951012; Herzog CA, 1998, NEW ENGL J MED, V339, P799, DOI 10.1056/NEJM199809173391203; Johansen KL, 2004, AM J CLIN NUTR, V80, P324, DOI 10.1093/ajcn/80.2.324; Kalantar-Zadeh K, 2005, AM J KIDNEY DIS, V46, P489, DOI 10.1053/j.ajkd.2005.05.020; London GM, 2000, J AM SOC NEPHROL, V11, P778, DOI 10.1681/ASN.V114778; Nanri A, 2010, INT J OBESITY, V34, P348, DOI 10.1038/ijo.2009.234; Saito I, 2009, J EPIDEMIOL COMMUN H, V63, P447, DOI 10.1136/jech.2008.082065; Sato Y, 2017, THER APHER DIAL, V21, P287, DOI 10.1111/1744-9987.12512; Sato Y, 2016, CLIN J AM SOC NEPHRO, V11, P840, DOI 10.2215/CJN.09830915; Tanaka Y, 2015, BLOOD PURIFICAT, V40, P332, DOI 10.1159/000441582; Thygesen K, 2012, J AM COLL CARDIOL, V60, P1581, DOI 10.1016/j.jacc.2012.08.001; Wong JS, 1999, KIDNEY INT, V55, P2515, DOI 10.1046/j.1523-1755.1999.00464.x; Yotsueda R, 2017, AM J KIDNEY DIS, V70, P84, DOI 10.1053/j.ajkd.2016.11.026	15	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2018	13	8							e0203060	10.1371/journal.pone.0203060	http://dx.doi.org/10.1371/journal.pone.0203060			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR6UK	30148875	Green Submitted, Green Published, gold			2023-01-03	WOS:000442804200045
J	Paparini, S; Nutland, W; Rhodes, T; Nguyen, V; Anderson, J				Paparini, Sara; Nutland, Will; Rhodes, Tim; Vinh-Kim Nguyen; Anderson, Jane			DIY HIV prevention: Formative qualitative research with men who have sex with men who source PrEP outside of clinical trials	PLOS ONE			English	Article							PREEXPOSURE PROPHYLAXIS PREP; GAY MEN; INFECTION; LONDON; SCIENCE; MSM	Pre-exposure prophylaxis (PrEP) with antiretroviral medication is an effective, evidence-based option for HIV prevention. In England, issues of cost-effectiveness and of responsibility for commissioning prevention services have so far led National Health Service (NHS) England to decide not to commission PrEP. Given the significant lag between the awareness of PrEP efficacy and the opportunity to obtain PrEP through traditional health care routes, many gay and other men who have sex with men (MSM) have turned to DIY PrEP', purchasing generic formulations of PrEP for themselves on the internet or via other alternative routes. However, there is very little research on DIY PrEP practices and no qualitative study with DIY PrEP users in the UK. A formative qualitative study was conducted in 2017 to inform the development of an intervention (PrEP Club) to support DIY PrEP users and improve the safety and experience of this prevention strategy. Focus groups were held with 20 MSM who are based in London and are obtaining PrEP through means other than clinical trials, to explore their accounts of sourcing and using PrEP and the experiential meanings of these. In this article, we report findings from this first, formative study and present the different practices involved in finding out about PrEP, buying it and ascertaining legitimacy of sellers and products. We reflect on the uncertainties participants described related to actually using PrEP, including deciding on drug dosing and monitoring their health. Finally, we present the results of the discussions participants had about the kind of support they had received, the help they would have liked, and their views on proposed interventions to support DIY PrEP users, such as PrEP Club.	[Paparini, Sara; Vinh-Kim Nguyen] Grad Inst Int & Dev Studies, Dept Anthropol & Sociol Dev, Geneva, Switzerland; [Nutland, Will; Rhodes, Tim] London Sch Hyg & Trop Med, Fac Publ Hlth Policy, Dept Social & Environm Hlth Res, London, England; [Anderson, Jane] Homerton Univ Hosp NHS Fdn Trust, London, England	University of London; London School of Hygiene & Tropical Medicine	Paparini, S (corresponding author), Grad Inst Int & Dev Studies, Dept Anthropol & Sociol Dev, Geneva, Switzerland.	sara.paparini@graduateinstitute.ch	Anderson, Jane/A-1632-2012; Rhodes, Tim/DNJ-9679-2022	Anderson, Jane/0000-0001-5294-8707; Rhodes, Tim/0000-0003-2400-9838; Paparini, Sara/0000-0002-1909-2481	European Research Council ERC [CoG 617930]; Independent Social Research Foundation (ISRF); Flexible Grant for Small Groups Award; Small Group as part of the same ISRF Award	European Research Council ERC(European Research Council (ERC)); Independent Social Research Foundation (ISRF); Flexible Grant for Small Groups Award; Small Group as part of the same ISRF Award	SP and VKN are funded by the European Research Council ERC CoG 617930 (https://erc.europa.eu/). Direct research costs related to this study were funded by the Independent Social Research Foundation (ISRF) with a Flexible Grant for Small Groups Award (http://www.isrf.org/). The Award was granted to SP in September 2016, in collaboration with TR, VKN and JA. WN has received consultancy funding from the Small Group as part of the same ISRF Award.	Aghaizu A, 2013, SEX TRANSM INFECT, V89, P207, DOI 10.1136/sextrans-2012-050648; Aloysius I, 2017, J VIRUS ERAD, V3, P218; [Anonymous], 2017, ELIMINATION HIV TRAN; Brisson J, 2018, GLOB PUBLIC HEALTH, V13, P1382, DOI 10.1080/17441692.2017.1373139; Brisson J, 2017, CULT HEALTH SEX, V19, P1066, DOI 10.1080/13691058.2017.1291994; British HIV Association and British Association for Sexual Health and HIV, 2017, CONS VERS BHIVA BASH; Brown AE, 2017, EURO SURVEILLANCE, V22; Caceres CF, 2015, J INT AIDS SOC, V18, P5, DOI [10.7448/IAS.18.4.19949, 10.7448/IAS.18.4.20527]; Caceres CF, 2016, J INT AIDS SOC, V19; Cain M, 2017, GUARDIAN; Castro DR, 2017, HIV MED, V18, P308, DOI 10.1111/hiv.12419; Collins SP, 2017, INT J SEX HEALTH, V29, P55, DOI 10.1080/19317611.2016.1206051; Dean T, 2015, SEXUALITIES, V18, P224, DOI 10.1177/1363460715569137; Frankis J, 2014, HIV MED, V15, P16; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Green J, 2014, QUALITATIVE METHODS; Greenhough B, 2017, HLTH GEOGRAPHIES CRI; Hill A, 2017, J VIRUS ERAD, V3, P200; Keogh P, 2015, AIDS CARE, V27, P796, DOI 10.1080/09540121.2014.989484; Koester K, 2017, CULT HEALTH SEX, V19, P1301, DOI 10.1080/13691058.2017.1310927; Mavedzenge SN, 2013, CLIN INFECT DIS, V57, P126, DOI 10.1093/cid/cit156; Mazanderani F, 2018, BIOSOCIETIES, V13, P232, DOI 10.1057/s41292-017-0066-z; McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2; Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273; Molina JM, 2017, LANCET HIV, V4, pE402, DOI 10.1016/S2352-3018(17)30089-9; Nguyen VK, 2017, INCIDENCE SEXUALLY T; Nwokolo N, 2017, LANCET HIV, V4, pE482, DOI 10.1016/S2352-3018(17)30181-9; Pai NP, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001414; Quet M, 2017, THEOR CULT SOC; Sigma Research, 2011, SIGM PAN INS BLAST 6; Slawson N, 2016, GUARDIAN; Spieldenner A, 2016, J HOMOSEXUAL, V63, P1685, DOI 10.1080/00918369.2016.1158012; Strudwick P, 2017, BUZZFEED; THNG C, 2012, HIV MED S1, V13, P84; Wang X, 2018, HIV MED, V19, P1, DOI 10.1111/hiv.12528; Young I, 2016, SOCIOL HEALTH ILL, V38, P411, DOI 10.1111/1467-9566.12372; Young I, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005717; Young I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064038; Zablotska IB, 2013, JAIDS-J ACQ IMM DEF, V62, P334, DOI 10.1097/QAI.0b013e31827e854a	39	13	13	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2018	13	8							e0202830	10.1371/journal.pone.0202830	http://dx.doi.org/10.1371/journal.pone.0202830			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GR6TZ	30138482	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000442800100135
J	Grum, T; Brhane, E				Grum, Teklit; Brhane, Ermyas			Magnitude and factors associated with late antenatal care booking on first visit among pregnant women in public health centers in central zone of Tigray Region, Ethiopia: A cross sectional study	PLOS ONE			English	Article								Background Antenatal care (ANC) is a care given for pregnant women and is a good opportunity to deliver maternal health interventions. Even though pregnant women should start their first antenatal care within 12 weeks of gestational age, many pregnant women start their first ANC late. So, the aim of this study is to determine magnitude of late ANC booking at first visit and factors associated with it. Methods Institutional based cross sectional study design was conducted in central zone of Tigray Region, Ethiopia from November 1/2017 to January 30/2018 among total of 632 pregnant women. Stratified multi stage cluster sampling method was used to select health centers and systematic random sampling technique was used during the selection of study units. Data were collected using interview administer questionnaire by face to face. The collected data were entered into EPI info-7. Later on, it was exported to STATA-14 for further analysis. Proportion was used to estimate the magnitude of late ANC booking. Bivariable and multi-variable analysis were done to see factors associated with the magnitude of late ANC booking. Results The magnitude of late ANC booking at first visit were 85.67% (95%, CI: 82.89, 88.45). Factors that were independently associated with the late ANC booking at first visit in multivariable analysis were; having home delivery in previous delivery (AOR = 2.2, 95%, CI: 1.1, 4.49), women who had no previous ANC follow up (AOR = 3.43, 95%, CI: 1.32, 8.92) and women with poor knowledge about the advantage and service availability of ANC (AOR = 3.9, 95%, CI: 1.83, 8.29). Conclusion In summary, most of pregnant women were not started their first ANC at the recommended time. Home delivery and history of ANC in previous pregnancy as well as women with poor knowledge about ANC were associated with late ANC booking at first visit. Health workers should work on avoiding home delivery and increasing the knowledge of pregnant women on ANC may help on reducing late ANC booking at first visit.	[Grum, Teklit] Aksum Univ, Coll Hlth Sci, Dept Reprod Hlth, Aksum, Ethiopia; [Brhane, Ermyas] Aksum Univ, Coll Hlth Sci, Dept Human Nutr, Aksum, Ethiopia		Grum, T (corresponding author), Aksum Univ, Coll Hlth Sci, Dept Reprod Hlth, Aksum, Ethiopia.	teklitvip@gmail.com		Grum, Teklit/0000-0003-4541-471X	Health sciences College, Aksum University	Health sciences College, Aksum University	This study was funded by Health sciences College, Aksum University. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adekanle DA, 2008, ONLINE J HLTH ALLIED, V7, P1; [Anonymous], 2012, ETHIOPIA DEMOGRAPHIC; Aung TZ., 2017, INT J COMMUNITY MED, V3, P900; Central Statistical Agency, 2007, POP HOUS CENS REP AD; Central Statistical Agency [Ethiopia] ICF, 2016, ETH DEM HLTH SURV 20; Ejeta E, 2017, PAN AFRICAN MED J; Federal democratic republic of Ethiopia Ministry of Health, 2015, HLTH SECT TRANSF PLA; Geta M. B., 2017, EARLY INITIATION ANT; Gudayu TW, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-287; Kisuule I, 2013, KAMPALA UGANDA BMC P, V13, P121, DOI DOI 10.1371/J0URNAL.P0NE.0101893; Lerebo W, 2015, CLIN MOTHER CHILD HL, V12; Lilungulu AG., 2016, TANZANIA J PEDIAT NE, V4, P8; Maano NE, 2017, INT J MED MUSHROOMS, V5, P37, DOI [10.14419/ijm.v5i1.7152, DOI 10.14419/IJM.V5I1.7152]; Okhiai O., 2015, INT J PUBLIC HEAL RE, V3, P331; Tekelab T., 2014, SCI TECHNOL ARTS RES, V3, P108, DOI [10.4314/star.v3i1.17, DOI 10.4314/STAR.V3I1.17]; Tesfaye G, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0412-4; WHO, 2016, WHO REC ANT CAR POST	17	14	14	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2018	13	12							e0207922	10.1371/journal.pone.0207922	http://dx.doi.org/10.1371/journal.pone.0207922			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD0QO	30517182	Green Published, Green Submitted, gold			2023-01-03	WOS:000452212400073
J	Al-Rousan, T; Sparks, JA; Pettinger, M; Chlebowski, R; Manson, JE; Kauntiz, AM; Wallace, R				Al-Rousan, Tala; Sparks, Jeffrey A.; Pettinger, Mary; Chlebowski, Rowan; Manson, JoAnn E.; Kauntiz, Andrew M.; Wallace, Robert			Menopausal hormone therapy and the incidence of carpal tunnel syndrome in postmenopausal women: Findings from the Women's Health Initiative	PLOS ONE			English	Article							REPLACEMENT THERAPY; RISK-FACTORS; ESTROGEN; PREVALENCE; TENOSYNOVIUM; ARTHRALGIA; EXPRESSION; RECEPTORS; OUTCOMES	Importance Carpal tunnel syndrome (CTS) is a common and debilitating condition that commonly affects postmenopausal women. Objective To determine the effect of menopausal hormone therapy (HT) in healthy postmenopausal women on CTS risk. Design We conducted a secondary analysis of the Women's Health Initiative's (WHI) HT trials linked to Medicare claims data. Separate intention-to-treat analyses were performed for the two trials; the conjugated equine estrogens alone (CEE alone) and the trial of CEE plus medroxyprogesterone acetate (MPA) trial. (ClinicalTrials. gov, NCT number): NCT00000611. Setting Two randomized, double-blind, placebo-controlled trials conducted at 40 US clinical centers. Participants The sample size included in the analysis was 16,053 community-dwelling women aged. 65 years at study entry or those who later aged into Medicare eligibility, and who were enrolled in Medicare (including Part A and/or Part B coverage). Intervention Women with hysterectomy were randomized to 0.625 mg/d of conjugated equine estrogens (CEE) or placebo (n = 8376). Women without hysterectomy were randomized to estrogen plus progestin (E+P), given as CEE plus 2.5 mg/d of medroxyprogesterone acetate (n = 14203). Main outcome(s) The primary outcome was incident CTS and the secondary outcome was therapeutic CTS procedure occurring during the intervention phases of the trials. Results A total of 16,053 women were randomized in both trials. During mean follow up of 4.5 +/- 2.8 years in the CEE trial (n = 6,833), there were 203 incident CTS cases in the intervention and 262 incident CTS cases in the placebo group (HR, 0.78; 95% CI, 0.65-0.94; P = 0.009). The CEE+MPA trial (n = 9,220) followed participants for a mean of 3.7 +/- 2.3 years. There were 173 incident CTS cases in the intervention compared to 203 cases in the placebo group (HR, 0.80, 95% CI, 0.65-0.97; P = 0.027). Conclusions These findings suggest a protective effect of menopausal HT on the incidence of CTS among postmenopausal women. A potential therapeutic role for other forms of estrogen therapy in the management of CTS warrants future research.	[Al-Rousan, Tala] Harvard Univ, Dept Global Hlth, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Sparks, Jeffrey A.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA; [Sparks, Jeffrey A.] Harvard Med Sch, Boston, MA USA; [Pettinger, Mary] Fred Hutchinson Canc Res Ctr, Publ Hlth Sci Div, 1124 Columbia St, Seattle, WA 98104 USA; [Chlebowski, Rowan] City Hope Natl Med Ctr, Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA; [Manson, JoAnn E.] Harvard Med Sch, Div Prevent Med, Brigham & Womens Hosp, Boston, MA USA; [Kauntiz, Andrew M.] Univ Florida, Coll Med, Dept Obstet & Gynecol, Jacksonville, FL USA; [Wallace, Robert] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Fred Hutchinson Cancer Center; City of Hope; Harvard University; Brigham & Women's Hospital; Harvard Medical School; State University System of Florida; University of Florida; University of Iowa	Al-Rousan, T (corresponding author), Harvard Univ, Dept Global Hlth, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA.	talrousan@ucsd.edu	Sparks, Jeffrey/Z-1574-2018	Sparks, Jeffrey/0000-0002-5556-4618	National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services [HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, HHSN268201600004C]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR069688] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C.	Ali ES, 2017, MENOPAUSE, V24, P1081, DOI 10.1097/GME.0000000000000855; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Atroshi I, 1999, JAMA-J AM MED ASSOC, V282, P153, DOI 10.1001/jama.282.2.153; BJORKQVIST SE, 1977, ACTA OBSTET GYN SCAN, V56, P127; Bliss JM, 2012, J CLIN ONCOL, V30, P709, DOI 10.1200/JCO.2010.33.7899; Chatterjee A, 2011, ANN PLAS SURG, V66, P245, DOI 10.1097/SAP.0b013e3181db7784; CONFINOCOHEN R, 1991, BRIT MED J, V303, P1514, DOI 10.1136/bmj.303.6816.1514; Dale AM, 2013, SCAND J WORK ENV HEA, V39, P495, DOI 10.5271/sjweh.3351; Din OS, 2010, BREAST CANCER RES TR, V120, P525, DOI 10.1007/s10549-010-0757-7; Ferry S, 2000, AM J EPIDEMIOL, V151, P566, DOI 10.1093/oxfordjournals.aje.a010244; Foley M, 2007, AM J IND MED, V50, P155, DOI 10.1002/ajim.20430; Gambacciani M, 2001, MATURITAS, V39, P125, DOI 10.1016/S0378-5122(01)00194-3; Geoghegan JM, 2004, J HAND SURG-BRIT EUR, V29B, P315, DOI 10.1016/j.jhsb.2004.02.009; Georgiadou P, 2009, ADV CLIN CHEM, V47, P59, DOI 10.1016/S0065-2423(09)47003-3; Graham B, 2006, J HAND SURG-AM, V31A, P919, DOI 10.1016/j.jhsa.2006.03.005; HALL GM, 1992, BRIT MED J, V304, P382, DOI 10.1136/bmj.304.6823.382; Hamano T, 2005, CLIN CALCIUM S1, V15; Hamano Takayuki, 2005, Clin Calcium, V15 Suppl 1, P161; Hirata H, 2004, J PATHOL, V204, P605, DOI 10.1002/path.1673; Jansson C, 2003, MATURITAS, V45, P129, DOI 10.1016/S0378-5122(03)00127-0; Jerosch-Herold C, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-35; Kalbfleisch J.D., 2011, STAT ANAL FAILURE TI, DOI DOI 10.1016/0197-2456(81)90009-X; Kaplan Y, 2008, J NEUROL SCI, V270, P77, DOI 10.1016/j.jns.2008.02.003; Kim JK, 2010, J ORTHOP RES, V28, P1469, DOI 10.1002/jor.21160; Lewis CE, 2017, JAMA-J AM MED ASSOC, V318, P2187, DOI 10.1001/jama.2017.16974; Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040; Mondelli M, 2002, NEUROLOGY, V58, P289, DOI 10.1212/WNL.58.2.289; Morales L, 2008, J CLIN ONCOL, V26, P3147, DOI 10.1200/JCO.2007.15.4005; Niver GE, 2012, ORTHOP CLIN N AM, V43, P521, DOI 10.1016/j.ocl.2012.07.021; Oktayoglu P, 2015, J CLIN DIAGN RES, V9, pOC14, DOI 10.7860/JCDR/2015/13149.6101; PASCUAL E, 1991, BRIT J RHEUMATOL, V30, P60; Riley G, 2004, RHEUMATOLOGY, V43, P131, DOI 10.1093/rheumatology/keg448; Robins JM, 2000, BIOMETRICS, V56, P779, DOI 10.1111/j.0006-341X.2000.00779.x; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sestak I, 2009, J CLIN ONCOL, V27, P4961, DOI 10.1200/JCO.2009.22.0236; Sperka P, 2008, OCCUP MED-OXFORD, V58, P490, DOI 10.1093/occmed/kqn099; Stefanick ML, 2003, ANN EPIDEMIOL, V13, pS78, DOI 10.1016/S1047-2797(03)00045-0; STEVENS JC, 1988, NEUROLOGY, V38, P134, DOI 10.1212/WNL.38.1.134; Stocks SJ, 2015, OCCUP ENVIRON MED, V72, P294, DOI 10.1136/oemed-2014-102534; Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001; Sumino H, 2000, ATHEROSCLEROSIS, V148, P189, DOI 10.1016/S0021-9150(99)00262-2; Thomsen NOB, 2014, BMC ENDOCR DISORD, V14, DOI 10.1186/1472-6823-14-85; Toesca A, 2008, CELL BIOL INT, V32, P75, DOI 10.1016/j.cellbi.2007.08.014; Vegeto E, 2002, MOL PSYCHIATR, V7, P236, DOI 10.1038/sj.mp.4001007	45	10	10	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2018	13	12							e0207509	10.1371/journal.pone.0207509	http://dx.doi.org/10.1371/journal.pone.0207509			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD0NQ	30513095	Green Published, gold, Green Submitted			2023-01-03	WOS:000452204800011
J	Wolchok, J				Wolchok, Jedd			Putting the Immunologic Brakes on Cancer	CELL			English	Editorial Material							CTLA-4; MEMBER; B7-H1; SUPERFAMILY	The 2018 Nobel Prize in Medicine and Physiology has been awarded to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation. These insights have given rise to a class of medicines that have now entered routine use in the treatment of advanced cancers and have provided a foundation for additional exploration and discovery of pathways critical to modulating the immune response to cancer.	[Wolchok, Jedd] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA; [Wolchok, Jedd] Weill Cornell Med Coll, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Wolchok, J (corresponding author), Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.; Wolchok, J (corresponding author), Weill Cornell Med Coll, New York, NY 10065 USA.	wolchokj@mskcc.org			Bristol Myers Squibb; Genentech; Medimmune	Bristol Myers Squibb(Bristol-Myers Squibb); Genentech(Roche HoldingGenentech); Medimmune(AstraZenecaMedimmune)	Institutional Research Funding: Bristol Myers Squibb, Genentech; Medimmune. Founder and Shareholder: Potenza Therapeutics; Tizona Pharmaceuticals; Trieza. Scientific Advisory Board member and Shareholder: Beigene. Consultant for: Adaptive Biotech; Advaxis; Amgen; Apricity; Array BioPharma; Ascentage Pharma; Astellas; Bayer; Bristol Myers Squibb; Celgene; Chugai; Elucida; Eli Lilly; F Star; Genentech; Imvaq; Janssen; Kleo Pharma; MedImmune; Merck; Neon Therapuetics; Ono; Polaris Pharma; Polynoma; Psioxus; Puretech; Recepta; Sellas Life Sciences; Serametrix; Surface Oncology; Syndax. Equity in: Adaptive Biotechnologies; Elucida; Imvaq.	BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; Dong HD, 1999, NAT MED, V5, P1365; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Linsley PS, 1996, CURR BIOL, V6, P398, DOI 10.1016/S0960-9822(02)00506-7; Strome SE, 2003, CANCER RES, V63, P6501; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985	12	45	45	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 29	2018	175	6					1452	1454		10.1016/j.cell.2018.11.006	http://dx.doi.org/10.1016/j.cell.2018.11.006			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HC4KG	30500529	Bronze			2023-01-03	WOS:000451771700003
J	Wu, Q; Fu, M; Zheng, KX; Bo, H; Yang, H; Zhong, X; Liang, GL; Xu, YJ; Hao, BB; Hu, Z; Zhang, ZW; Jin, XD; Kang, Y				Wu, Qin; Fu, Min; Zheng, Kexin; Bo, Hong; Yang, Hao; Zhong, Xi; Liang, Guanlin; Xu, Yujun; Hao, Bibo; Hu, Zhi; Zhang, Zhongwei; Jin, Xiaodong; Kang, Yan			Elevated triglycerides level in hospital stay as a risk factor of mortality in patients with severe acute pancreatitis	PLOS ONE			English	Article							HYPERTRIGLYCERIDEMIA; ASSOCIATION; MANAGEMENT; GUIDELINE; SERUM	Hypertriglyceridaemia is one of the most common causes of severe acute pancreatitis (SAP). However, the association between elevated triglycerides (TG) level in hospital stay and outcome in SAP patients with normal TG level at admission has not been clearly demonstrated. This retrospective study assessed the serum TG levels of patients with SAP admitted to the intensive care unit (ICU) in 2017. Variables with a statistically significant association with the incidence of in-hospital TG elevation, as determined by univariate analysis, were analysed using a logistic regression model to predictors. Of the 99 patients included in the study, TG levels were within the normal range in 59 (59.59%) patients at admission. Among patients with normal TG level when admitted to ICU, 28 (47.46%) experienced at least one episode of TG level elevation during their ICU stay. Elevated TG level in hospitalization is associated with an increased length of ICU stay, as well as increased mortality. In addition to other factors, propofol usage was independently associated with the occurrence of in-hospital-TG elevation. To conclude, we retrospectively investigated the incidence, outcome, and risk factors for in-hospital TG elevation events in SAP patients admitted to the ICU. We found a high incidence of both preexisting and in-hospital-acquired TG elevation in SAP patients admitted to the ICU. The TG elevation that occurred during the ICU stay was associated with worse outcomes and long-term hospitalization of the ICU. Propofol usage was independently associated with the TG elevation occurrence in the ICU.	[Wu, Qin; Fu, Min; Zheng, Kexin; Bo, Hong; Yang, Hao; Zhong, Xi; Liang, Guanlin; Xu, Yujun; Hu, Zhi; Zhang, Zhongwei; Jin, Xiaodong; Kang, Yan] Sichuan Univ, West China Hosp, Dept Crit Care Med, Chengdu, Sichuan, Peoples R China; [Hao, Bibo] IBM Res, Beijing, Peoples R China	Sichuan University	Kang, Y (corresponding author), Sichuan Univ, West China Hosp, Dept Crit Care Med, Chengdu, Sichuan, Peoples R China.	kangyan@scu.edu.cn	Hao, Bibo/X-8485-2019; Hao, Bibo/I-2476-2013; Wu, Qin/AAF-5707-2022; Wu, Qin/AFJ-8752-2022	Hao, Bibo/0000-0003-1138-8365; Hao, Bibo/0000-0003-1138-8365; Wu, Qin/0000-0002-7470-8429; Wu, Qin/0000-0002-7470-8429	National Natural Science Foundation of China [81801892]; Wu Jieping Medical Foundation's special funding fund for clinical research [320.6750.17570]; Sichuan University Postdoctoral Research Fund [2018SCU12036]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Wu Jieping Medical Foundation's special funding fund for clinical research; Sichuan University Postdoctoral Research Fund	The work was supported by grants from National Natural Science Foundation of China (81801892), Wu Jieping Medical Foundation's special funding fund for clinical research (No.320.6750.17570) and Sichuan University Postdoctoral Research Fund (No.2018SCU12036). The funder (IBM Research) provided support in the form of salary for author (BH), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banks PA, 2013, GUT, V62, P102, DOI 10.1136/gutjnl-2012-302779; Berglund L, 2012, J CLIN ENDOCR METAB, V97, P2969, DOI 10.1210/jc.2011-3213; Brahm A, 2013, NUTRIENTS, V5, P981, DOI 10.3390/nu5030981; Brereton MF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13496; Carr RA, 2016, PANCREATOLOGY, V16, P469, DOI 10.1016/j.pan.2016.02.011; Carroll JK, 2007, AM FAM PHYSICIAN, V75, P1513; Deng LH, 2008, WORLD J GASTROENTERO, V14, P4558, DOI 10.3748/wjg.14.4558; Devaud JC, 2012, INTENS CARE MED, V38, P1990, DOI 10.1007/s00134-012-2688-8; Jacobson TA, 2015, J CLIN LIPIDOL, V9, P129, DOI 10.1016/j.jacl.2015.02.003; Kiss L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32337-x; Lankisch PG, 2015, LANCET, V386, P85, DOI 10.1016/S0140-6736(14)60649-8; Lu GT, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6089430; Mao EQ, 2003, WORLD J GASTROENTERO, V9, P2622; Papachristou GI, 2017, ANN GASTROENTEROL, V30, P106, DOI 10.20524/aog.2016.0109; Rawla P, 2018, CLIN J GASTROENTEROL, V11, P441, DOI 10.1007/s12328-018-0881-1; Roberts SE, 2017, PANCREATOLOGY, V17, P155, DOI 10.1016/j.pan.2017.01.005; Santos MA, 2017, J GEN INTERN MED, V32, P1267, DOI 10.1007/s11606-017-4086-y; Shen X, 2016, J CRIT CARE, V36, P140, DOI 10.1016/j.jcrc.2016.06.035; Silverman MG, 2016, JAMA-J AM MED ASSOC, V316, P1289, DOI 10.1001/jama.2016.13985; Siriwardena AK, 2017, BRIT J SURG, V104, P1591, DOI 10.1002/bjs.10585; Swaroop VS, 2004, JAMA-J AM MED ASSOC, V291, P2865, DOI 10.1001/jama.291.23.2865; Tenner S, 2013, AM J GASTROENTEROL, V108, P1400, DOI 10.1038/ajg.2013.218; Wang Q, 2017, J CLIN GASTROENTEROL, V51, P586, DOI 10.1097/MCG.0000000000000846; Wu CY, 2017, PANCREATOLOGY, V17, P561, DOI 10.1016/j.pan.2017.06.006; Zerem E, 2014, WORLD J GASTROENTERO, V20, P13879, DOI 10.3748/wjg.v20.i38.13879	25	4	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2018	13	11							e0207875	10.1371/journal.pone.0207875	http://dx.doi.org/10.1371/journal.pone.0207875			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC4HL	30496237	Green Published, Green Submitted, gold			2023-01-03	WOS:000451763800059
J	Perez, T; Moriarty, F; Wallace, E; McDowell, R; Redmond, P; Fahey, T				Perez, Teresa; Moriarty, Frank; Wallace, Emma; McDowell, Ronald; Redmond, Patrick; Fahey, Tom			Prevalence of potentially inappropriate prescribing in older people in primary care and its association with hospital admission: longitudinal study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADVERSE DRUG EVENTS; SCREENING TOOL; STOPP/START CRITERIA; ELDERLY-PEOPLE; STOPP CRITERIA; MEDICATION; ADULTS; PRESCRIPTIONS; PHARMACISTS; IMPACT	OBJECTIVE To determine whether hospital admission is associated with potentially inappropriate prescribing among older primary care patients (aged >= 65 years) and whether such prescribing was more likely after hospital admission than before. DESIGN Longitudinal study of retrospectively extracted data from general practice records. SETTING 44 general practices in Ireland in 2012-15. PARTICIPANTS Adults aged 65 years or over attending participating practices. EXPOSURE Admission to hospital (any hospital admission versus none, and post-admission versus pre-admission). MAIN OUTCOME MEASURES Prevalence of potentially inappropriate prescribing assessed using 45 criteria from the Screening Tool for Older Persons' Prescription (STOPP) version 2, analysed both as rate of distinct potentially inappropriate prescribing criteria met (stratified Cox regression) and binary presence of potentially inappropriate prescribing (logistic regression) and adjusted for patients' characteristics. A sensitivity analysis used matching with propensity scores based on patients' characteristics and diagnoses. RESULTS Overall 38 229 patients were included, and during 2012 the mean age was 76.8 (SD 8.2) years and 43% (13 212) were male. Each year, 10.4- 15.0% (3015/29 077 in 2015 to 4537/30 231 in 2014) of patients had at least one hospital admission. The overall prevalence of potentially inappropriate prescribing ranged from 45.3% (13 940/30 789) of patients in 2012 to 51.0% (14 823/29 077) in 2015. Independently of age, sex, number of prescription items, comorbidity, and health cover, hospital admission was associated with a higher rate of distinct potentially inappropriate prescribing criteria met; the adjusted hazard ratio for hospital admission was 1.24 (95% confidence interval 1.20 to 1.28). Among participants who were admitted to hospital, the likelihood of potentially inappropriate prescribing after admission was higher than before admission, independent of patients' characteristics; the adjusted odds ratio for after hospital admission was 1.72 (1.63 to 1.84). Analysis of propensity score matched pairs showed a slight reduction in the hazard ratio for hospital admission to 1.22 (1.18 to 1.25). CONCLUSION Hospital admission was independently associated with potentially inappropriate prescribing. It is important to determine how hospital admission may affect appropriateness of prescribing for older people and how potential adverse consequences of admission can be minimised.	[Perez, Teresa] Univ Complutense Madrid, Dept Stat & Data Sci, Madrid, Spain; [Perez, Teresa; Moriarty, Frank; Wallace, Emma; McDowell, Ronald; Redmond, Patrick; Fahey, Tom] Royal Coll Surgeons Ireland, HRB Ctr Primary Care Res, Dublin, Ireland; [McDowell, Ronald] Queens Univ Belfast, Ctr Publ Hlth, Canc Epidemiol & Hlth Serv Res Grp, Belfast, Antrim, North Ireland; [Redmond, Patrick] Univ Cambridge, Sch Clin Med, Dept Publ Hlth & Primary Care, Cambridge, England	Complutense University of Madrid; Health Research Board - Ireland; Royal College of Surgeons - Ireland; Queens University Belfast; University of Cambridge	Moriarty, F (corresponding author), Royal Coll Surgeons Ireland, HRB Ctr Primary Care Res, Dublin, Ireland.	frankmoriarty@rcsi.ie	Moriarty, Frank/L-3180-2014; Perez, Teresa/G-6333-2017; Fahey, Tom/C-9367-2012; redmond, patrick/M-5419-2016	Moriarty, Frank/0000-0001-9838-3625; Perez, Teresa/0000-0003-0439-8952; Fahey, Tom/0000-0002-5896-5783; wallace, emma/0000-0002-9315-2956; redmond, patrick/0000-0002-3929-2018	Health Research Board in Ireland [HRC/2014/1]; Spanish Ministry of Economy, Industry, and Competitiveness [MTM2016-75351-R]	Health Research Board in Ireland; Spanish Ministry of Economy, Industry, and Competitiveness(Spanish Government)	The study was funded by the Health Research Board in Ireland through grant No HRC/2014/1 (TF) and the Spanish Ministry of Economy, Industry, and Competitiveness through grant MTM2016-75351-R (TP). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.	Almanasreh E, 2016, BRIT J CLIN PHARMACO, V82, P645, DOI 10.1111/bcp.13017; Anderson K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006544; Blanco-Reina E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167586; Bowden T, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-017-0523-4; Brown JD, 2016, J AM GERIATR SOC, V64, P22, DOI 10.1111/jgs.13884; Cahir C, 2010, BRIT J CLIN PHARMACO, V69, P543, DOI 10.1111/j.1365-2125.2010.03628.x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Clyne B, 2016, J AM GERIATR SOC, V64, P1210, DOI 10.1111/jgs.14133; Coleman EA, 2003, J AM GERIATR SOC, V51, P549, DOI 10.1046/j.1532-5415.2003.51185.x; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Dreischulte T, 2016, NEW ENGL J MED, V374, P1053, DOI 10.1056/NEJMsa1508955; FAHEY T, 1993, IRISH MED J, V86, P122; Farrell B, 2017, CAN FAM PHYSICIAN, V63, P354; Fick D, 2001, J MANAGE CARE PHARM, V7, P407, DOI [10.18553/jmcp.2001.7.5.407, DOI 10.18553/JMCP.2001.7.5.407]; Galvin S, 2015, BMC FAM PRACT, V16, DOI 10.1186/s12875-015-0280-3; Goodwin N, 2011, IMPROVING QUALITY OF; Grimes Tamasine, 2010, Int J Pharm Pract, V18, P346, DOI 10.1111/j.2042-7174.2010.00064.x; Gutierrez-Valencia M, 2017, GERIATR GERONTOL INT, V17, P2354, DOI 10.1111/ggi.13073; Hadfield JD, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i02; Hamilton H, 2011, ARCH INTERN MED, V171, P1013, DOI 10.1001/archinternmed.2011.215; Hedna K, 2015, EUR J CLIN PHARMACOL, V71, P1525, DOI 10.1007/s00228-015-1950-8; Hill-Taylor B, 2013, J CLIN PHARM THER, V38, P360, DOI 10.1111/jcpt.12059; Ho DE, 2007, POLIT ANAL, V15, P199, DOI 10.1093/pan/mpl013; Huntley AL, 2012, ANN FAM MED, V10, P134, DOI 10.1370/afm.1363; Pardo-Cabello AJ, 2018, ARCH GERONTOL GERIAT, V74, P150, DOI 10.1016/j.archger.2017.10.009; Kimura T, 2017, J CLIN PHARM THER, V42, P209, DOI 10.1111/jcpt.12496; Kongkaew C, 2008, ANN PHARMACOTHER, V42, P1017, DOI 10.1345/aph.1L037; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Laroche ML, 2006, DRUG AGING, V23, P49, DOI 10.2165/00002512-200623010-00005; Lau MHM, 2017, GERIATRICS-BASEL, V2, DOI 10.3390/geriatrics2040033; Le Berre M, 2017, J AM GERIATR SOC, V65, P1597, DOI 10.1111/jgs.14828; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Lumley T., 2020, PACKAGE SURVIVAL; Mallet L, 2007, LANCET, V370, P185, DOI 10.1016/S0140-6736(07)61092-7; Mangoni AA, 2004, BRIT J CLIN PHARMACO, V57, P6, DOI 10.1046/j.1365-2125.2003.02007.x; Maurice Andrew P, 2014, BMJ Qual Improv Rep, V3, DOI 10.1136/bmjquality.u200548.w2201; McMahon CG, 2014, AGE AGEING, V43, P44, DOI 10.1093/ageing/aft114; Moore C, 2003, J GEN INTERN MED, V18, P646, DOI 10.1046/j.1525-1497.2003.20722.x; Moriarty F, 2016, BRIT J CLIN PHARMACO, V82, P849, DOI 10.1111/bcp.12995; Moriarty F, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008656; National Patient Experience Survey, 2018, FINDINGS OF THE 2017; O'Connor MN, 2016, J AM GERIATR SOC, V64, P1558, DOI 10.1111/jgs.14312; O'Kelly M, 2016, STRUCTURE OF GENERAL; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; Pellegrin KL, 2017, J AM GERIATR SOC, V65, P212, DOI 10.1111/jgs.14518; Petty DR, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-76; Pottie K, 2018, CAN FAM PHYSICIAN, V64, P339; PRENTICE RL, 1981, BIOMETRIKA, V68, P373, DOI 10.1093/biomet/68.2.373; Qato DM, 2016, JAMA INTERN MED, V176, P473, DOI 10.1001/jamainternmed.2015.8581; R Core Team, 2013, R A LANGUAGE AND ENV; Redmond P, 2013, FAM PRACT, V30, P483, DOI 10.1093/fampra/cmt051; Reeve E, 2013, DRUG AGING, V30, P793, DOI 10.1007/s40266-013-0106-8; Del Rio ER, 2018, ATEN PRIM, V50, P467, DOI 10.1016/j.aprim.2017.03.018; Sinnott SJ, 2017, EUR J CLIN PHARMACOL, V73, P1449, DOI 10.1007/s00228-017-2310-7; Spinewine A, 2007, LANCET, V370, P173, DOI 10.1016/S0140-6736(07)61091-5; Stocks SJ, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5501; Sweeney J, 2017, FORUM J IRISH COLL G, V34, P52; Tache SV, 2011, ANN PHARMACOTHER, V45, P977, DOI 10.1345/aph.1P627; Van Craen K, 2010, J AM GERIATR SOC, V58, P83, DOI 10.1111/j.1532-5415.2009.02621.x; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]; Wallace E, 2017, J GERONTOL A-BIOL, V72, P271, DOI 10.1093/gerona/glw140; Walsh KA, 2016, AGE AGEING, V45, P201, DOI 10.1093/ageing/afv190; Wauters M, 2016, BRIT J CLIN PHARMACO, V82, P1382, DOI 10.1111/bcp.13055; Witherington EMA, 2008, QUAL SAF HEALTH CARE, V17, P71, DOI 10.1136/qshc.2006.020842; Wu KL, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0087588, 10.1371/journal.pone.0103480, 10.1371/journal.pone.0110033, 10.1371/journal.pone.0103535, 10.1371/journal.pone.0099366, 10.1371/journal.pone.0091910, 10.1371/journal.pone.0103267, 10.1371/journal.pone.0113637, 10.1371/journal.pone.0096514, 10.1371/journal.pone.0095422, 10.1371/journal.pone.0095536, 10.1371/journal.pone.0105072, 10.1371/journal.pone.0107196, 10.1371/journal.pone.0087348, 10.1371/journal.pone.0093049]	65	75	75	2	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 14	2018	363								k4524	10.1136/bmj.k4524	http://dx.doi.org/10.1136/bmj.k4524			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HB0RW	30429122	Green Published, hybrid			2023-01-03	WOS:000450726100006
J	Blank, CU; Rozeman, EA; Fanchi, LF; Sikorska, K; van de Wiel, B; Kvistborg, P; Krijgsman, O; van den Braber, M; Philips, D; Broeks, A; van Thienen, JV; Mallo, HA; Adriaansz, S; ter Meulens, S; Pronk, LM; Grijpink-Ongering, LG; Bruining, A; Gittelman, RM; Warren, S; van Tinteren, H; Peeper, DS; Haanen, JBAG; van Akkooi, ACJ; Schumacher, TN				Blank, Christian U.; Rozeman, Elisa A.; Fanchi, Lorenzo F.; Sikorska, Karolina; van de Wiel, Bart; Kvistborg, Pia; Krijgsman, Oscar; van den Braber, Marlous; Philips, Daisy; Broeks, Annegien; van Thienen, Johannes, V; Mallo, Henk A.; Adriaansz, Sandra; ter Meulens, Sylvia; Pronk, Loes M.; Grijpink-Ongering, Lindsay G.; Bruining, Annemarie; Gittelman, Rachel M.; Warren, Sarah; van Tinteren, Harm; Peeper, Daniel S.; Haanen, John B. A. G.; van Akkooi, Alexander C. J.; Schumacher, Ton N.			Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma	NATURE MEDICINE			English	Article							PD-1 BLOCKADE; BREAST-CANCER; IMMUNOTHERAPY; RESISTANCE; RESPONSES; SURVIVAL; THERAPY; DISEASE; CLONES; PHASE	Adjuvant ipilimumab (anti-CTLA-4) and nivolumab (antiPD-1) both improve relapse-free survival of stage III melanoma patients(1,2). In stage IV disease, the combination of ipilimumab + nivolumab is superior to ipilimumab alone and also appears to be more effective than nivolumab monotherapy(3). Preclinical work suggests that neoadjuvant application of checkpoint inhibitors may be superior to adjuvant therapy(4). To address this question and to test feasibility, 20 patients with palpable stage III melanoma were 1:1 randomized to receive ipilimumab 3 mg kg(-1) and nivolumab 1 mg kg(-1), as either four courses after surgery (adjuvant arm) or two courses before surgery and two courses postsurgery (neoadjuvant arm). Neoadjuvant therapy was feasible, with all patients undergoing surgery at the preplanned time point. However in both arms, 9/10 patients experienced one or more grade 3/4 adverse events. Pathological responses were achieved in 7/9 (78%) patients treated in the neoadjuvant arm. None of these patients have relapsed so far (median follow-up, 25.6months). We found that neoadjuvant ipilimumab + nivolumab expand more tumor-resident T cell clones than adjuvant application. While neoadjuvant therapy appears promising, with the current regimen it induced high toxicity rates; therefore, it needs further investigation to preserve efficacy but reduce toxicity.	[Blank, Christian U.; Rozeman, Elisa A.; van Thienen, Johannes, V; Mallo, Henk A.; Adriaansz, Sandra; Haanen, John B. A. G.] Netherlands Canc Inst, Med Oncol Dept, Amsterdam, Netherlands; [Blank, Christian U.; Rozeman, Elisa A.; Fanchi, Lorenzo F.; Kvistborg, Pia; Krijgsman, Oscar; van den Braber, Marlous; Philips, Daisy; Peeper, Daniel S.; Haanen, John B. A. G.; Schumacher, Ton N.] Netherlands Canc Inst, Div Mol Oncol & Immunol, Amsterdam, Netherlands; [Sikorska, Karolina; Pronk, Loes M.; Grijpink-Ongering, Lindsay G.; van Tinteren, Harm] Netherlands Canc Inst, Dept Biometr, Amsterdam, Netherlands; [van de Wiel, Bart; Broeks, Annegien] Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands; [ter Meulens, Sylvia; van Akkooi, Alexander C. J.] Netherlands Canc Inst, Surg Oncol Dept, Amsterdam, Netherlands; [Bruining, Annemarie] Netherlands Canc Inst, Dept Radiol, Amsterdam, Netherlands; [Gittelman, Rachel M.] Adapt Biotechnol, Seattle, WA USA; [Warren, Sarah] NanoString Technol Inc, Seattle, WA USA	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Blank, CU (corresponding author), Netherlands Canc Inst, Med Oncol Dept, Amsterdam, Netherlands.; Blank, CU; Schumacher, TN (corresponding author), Netherlands Canc Inst, Div Mol Oncol & Immunol, Amsterdam, Netherlands.	c.blank@nki.nl; t.schumacher@nki.nl	Schumacher, Ton/Y-2432-2019; Peeper, Daniel/AAA-2430-2020; Haanen, John/AAD-8578-2022; Haanen, John/AAD-8534-2022	Schumacher, Ton/0000-0003-0517-8804; Haanen, John/0000-0001-5884-7704; Gittelman, Rachel/0000-0003-3202-6582; van Tinteren, Harm/0000-0002-4626-8702; van Akkooi, Alexander Christopher Jonathan/0000-0002-3262-6935				Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Balch CM, 2001, J CLIN ONCOL, V19, P3622, DOI 10.1200/JCO.2001.19.16.3622; Blank C, 2004, CANCER RES, V64, P1140, DOI 10.1158/0008-5472.CAN-03-3259; Blank CU, 2016, SCIENCE, V352, P658, DOI 10.1126/science.aaf2834; Burmeister BH, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70138-9; Carlson CS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3680; Eggermont A. M., 2014, J CLIN ONCOL, V32; Eggermont AMM, 2016, NEW ENGL J MED, V375, P1845, DOI 10.1056/NEJMoa1611299; Eggermont AMM, 2015, LANCET ONCOL, V16, P522, DOI 10.1016/S1470-2045(15)70122-1; Eroglu Z., 2017, ANN M SOC MEL RES SM; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Kvistborg P, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008918; Larkin J, 2017, ONCOLOGIST, V22, P709, DOI 10.1634/theoncologist.2016-0487; Liu J, 2016, CANCER DISCOV, V6, P1382, DOI 10.1158/2159-8290.CD-16-0577; Long GV, 2017, NEW ENGL J MED, V377, P1813, DOI 10.1056/NEJMoa1708539; Long GV, 2017, LANCET ONCOL, V18, P1202, DOI 10.1016/S1470-2045(17)30428-X; LUI VK, 1975, BRIT J CANCER, V32, P323, DOI 10.1038/bjc.1975.230; Meerveld-Eggink A, 2017, ANN ONCOL, V28, P862, DOI 10.1093/annonc/mdw692; Memarnejadian A, 2017, J IMMUNOL, V199, P3348, DOI 10.4049/jimmunol.1700643; Reddy S. M., 2017, 32 SITC ANN M NAT HA; Robins H, 2012, J IMMUNOL METHODS, V375, P14, DOI 10.1016/j.jim.2011.09.001; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Steenbruggen TG, 2017, DRUGS, V77, P1313, DOI 10.1007/s40265-017-0774-5; Straver ME, 2010, BRIT J SURG, V97, P1226, DOI 10.1002/bjs.7073; Toebes M, 2006, NAT MED, V12, P246, DOI 10.1038/nm1360; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; van Rooij N, 2013, J CLIN ONCOL, V31, pE439, DOI 10.1200/JCO.2012.47.7521; Weber J, 2017, NEW ENGL J MED, V377, P1824, DOI 10.1056/NEJMoa1709030; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958	32	370	377	3	39	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2018	24	11					1655	+		10.1038/s41591-018-0198-0	http://dx.doi.org/10.1038/s41591-018-0198-0			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	GZ4VS	30297911				2023-01-03	WOS:000449404200015
J	Horwitz, MEM; Molina, RL; Snowden, JM				Horwitz, Mara E. Murray; Molina, Rose L.; Snowden, Jonathan M.			Postpartum Care in the United States - New Policies for a New Paradigm	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Horwitz, Mara E. Murray] Harvard Med Sch, Dept Populat Med, Boston, MA 02115 USA; [Horwitz, Mara E. Murray] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA; [Molina, Rose L.] Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, Boston, MA 02215 USA; [Snowden, Jonathan M.] Portland State Univ, Oregon Hlth & Sci Univ, Sch Publ Hlth, Portland, OR 97207 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Beth Israel Deaconess Medical Center; Oregon Health & Science University; Portland State University	Horwitz, MEM (corresponding author), Harvard Med Sch, Dept Populat Med, Boston, MA 02115 USA.; Horwitz, MEM (corresponding author), Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA.			Molina, Rose/0000-0001-7977-7960; Murray Horwitz, Mara/0000-0001-6142-0285				Burtle A, 2016, HEALTHCARE-BASEL, V4, DOI 10.3390/healthcare4020030; Henderson V, 2016, MATERN CHILD HLTH J, V20, pS132, DOI 10.1007/s10995-016-2044-7; Stuebe A, 2018, OBSTET GYNECOL, V131, pE140, DOI 10.1097/AOG.0000000000002633; Stumbras K, 2016, MATERN CHILD HLTH J, V20, pS103, DOI 10.1007/s10995-016-2053-6; WHO, 2012, WHO RECOMMENDATIONS	5	20	20	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 1	2018	379	18					1691	1693		10.1056/NEJMp1806516	http://dx.doi.org/10.1056/NEJMp1806516			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GY8OL	30380385				2023-01-03	WOS:000448891600002
J	Schuster-Amft, C; Eng, K; Suica, Z; Thaler, I; Signer, S; Lehmann, I; Schmid, L; McCaskey, MA; Hawkins, M; Verra, ML; Kiper, D				Schuster-Amft, Corina; Eng, Kynan; Suica, Zorica; Thaler, Irene; Signer, Sandra; Lehmann, Isabelle; Schmid, Ludwig; McCaskey, Michael A.; Hawkins, Miura; Verra, Martin L.; Kiper, Daniel			Effect of a four-week virtual reality-based training versus conventional therapy on upper limb motor function after stroke: A multicenter parallel group randomized trial	PLOS ONE			English	Article							UPPER EXTREMITY; REHABILITATION; RECOVERY; RELIABILITY; SENSITIVITY; SURVIVORS; VALIDITY; SYSTEM; ARM	Background Virtual reality-based training has found increasing use in neurorehabilitation to improve upper limb training and facilitate motor recovery. Objective The aim of this study was to directly compare virtual reality-based training with conventional therapy. Methods In a multi-center, parallel-group randomized controlled trial, patients at least 6 months after stroke onset were allocated either to an experimental group (virtual reality-based training) or a control group receiving conventional therapy (16x45 minutes within 4 weeks). The virtual reality-based training system replicated patients' upper limb movements in real-time to manipulate virtual objects. Blinded assessors tested patients twice before, once during, and twice after the intervention up to 2-month follow-up for dexterity (primary outcome: Box and Block Test), bimanual upper limb function (Chedoke-McMaster Arm and Hand Activity Inventory), and subjective perceived changes (Stroke Impact Scale). Results 54 eligible patients (70 screened) participated (15 females, mean age 61.3 years, range 2081 years, time since stroke 3.0 +/- SD 3 years). 22 patients were allocated to the experimental group and 32 to the control group (3 drop-outs). Patients in the experimental and control group improved: Box and Block Test mean 21.5 +/- SD 16 baseline to mean 24.1 +/- SD 17 follow-up; Chedoke-McMaster Arm and Hand Activity Inventory mean 66.0 +/- SD 21 baseline to mean 70.2 +/- SD 19 follow-up. An intention-to-treat analysis found no between-group differences. Conclusions Patients in the experimental and control group showed similar effects, with most improvements occurring in the first two weeks and persisting until the end of the two-month followup period. The study population had moderate to severely impaired motor function at entry (Box and Block Test mean 21.5 +/- SD 16). Patients, who were less impaired (Box and Block Test range 18 to 72) showed higher improvements in favor of the experimental group. This result could suggest that virtual reality-based training might be more applicable for such patients than for more severely impaired patients.	[Schuster-Amft, Corina; Suica, Zorica; Schmid, Ludwig; McCaskey, Michael A.] Reha Rheinfelden, Res Dept, Rheinfelden, Switzerland; [Schuster-Amft, Corina] Bern Univ Appl Sci, Inst Rehabil & Performance Technol, Burgdorf, Switzerland; [Eng, Kynan; Hawkins, Miura; Kiper, Daniel] Univ Zurich, Inst Neuroinformat, Zurich, Switzerland; [Eng, Kynan; Hawkins, Miura; Kiper, Daniel] Swiss Fed Inst Technol, Zurich, Switzerland; [Thaler, Irene; Lehmann, Isabelle; Verra, Martin L.] Bern Univ Hosp, Dept Physiotherapy, Insel Grp, Bern, Switzerland; [Signer, Sandra] Buergerspital Solothurn, Physiotherapy Dept, Solothurn, Switzerland; [Schmid, Ludwig] Zurcher RehaZentrum Lengg, Physiotherapy Dept, Zurich, Switzerland; [McCaskey, Michael A.] Swiss Fed Inst Technol, Inst Human Movement Sci, Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Bern; University Hospital of Bern; Swiss Federal Institutes of Technology Domain; ETH Zurich	McCaskey, MA (corresponding author), Reha Rheinfelden, Res Dept, Rheinfelden, Switzerland.; McCaskey, MA (corresponding author), Swiss Fed Inst Technol, Inst Human Movement Sci, Zurich, Switzerland.	michael.mccaskey@hest.ethz.ch	Schuster, Corina/B-6939-2008; Verra, Martin/R-5285-2016	Suica, Zorica/0000-0002-1703-8713; Verra, Martin/0000-0002-3933-8020; Schuster-Amft, Corina/0000-0003-1120-4423; Eng, Kynan/0000-0002-1434-8767	Swiss Commission for Technology and Innovation [14454.1 PFLS-LS]; REHA STIM MEDTEC AG	Swiss Commission for Technology and Innovation; REHA STIM MEDTEC AG	The Swiss Commission for Technology and Innovation (project: 14454.1 PFLS-LS) and YouRehab AG (now renamed REHA STIM MEDTEC AG) funded the study. However, they had no influence on the study implementation, data collection, data analyses and interpretation, or manuscript writing.	Aminov A, 2018, J NEUROENG REHABIL, V15, DOI 10.1186/s12984-018-0370-2; Armijo-Olivo S, 2009, PHYS THER REV, V14, P36, DOI 10.1179/174328809X405928; Armstrong RA, 2014, OPHTHAL PHYSL OPT, V34, P502, DOI 10.1111/opo.12131; Barreca S, 2003, NEUROREHAB NEURAL RE, V17, P220, DOI 10.1177/0888439003259415; Barreca S, 2006, PHYSIOTHER CAN, V58, P148, DOI DOI 10.3138/PTC.58.2.148; Barreca SR, 2005, ARCH PHYS MED REHAB, V86, P1616, DOI 10.1016/j.apmr.2005.03.017; Barreca Susan, 2004, Top Stroke Rehabil, V11, P31; Brunner I, 2017, NEUROLOGY, V89, P2413, DOI 10.1212/WNL.0000000000004744; Chen HM, 2009, NEUROREHAB NEURAL RE, V23, P435, DOI 10.1177/1545968308331146; Ribeiro NMD, 2015, TOP STROKE REHABIL, V22, P299, DOI 10.1179/1074935714Z.0000000017; Dimbwadyo-Terrer I, 2016, DISABIL REHABIL-ASSI, V11, P462, DOI 10.3109/17483107.2015.1027293; Duncan P W, 2001, Top Stroke Rehabil, V8, P19; Duncan PW, 1999, STROKE, V30, P2131, DOI 10.1161/01.STR.30.10.2131; Eng K, 2007, MED BIOL ENG COMPUT, V45, P901, DOI 10.1007/s11517-007-0239-1; Faul F, 2007, GPOWER 3 0 8; FEIGENSON JS, 1977, STROKE, V8, P651, DOI 10.1161/01.STR.8.6.651; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gowland C, 1995, CHEDOKE MCMASTER STR; GOWLAND CA, 1990, STROKE, V21, P19; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Jansa J, 2004, NEUROREHAB NEURAL RE, V18, P37, DOI 10.1177/0888439003262287; Kalron A, 2016, J NEUROENG REHABIL, V13, DOI 10.1186/s12984-016-0124-y; Kwakkel G, 2004, RESTOR NEUROL NEUROS, V22, P281; Laver KE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008349.pub2, 10.1002/14651858.CD008349.pub3, 10.1002/14651858.CD008349.pub4]; Lehmann I, 2017, PHYSIOTHERAPY; Leonhart R, 2004, Rehabilitation (Stuttg), V43, P241; Lin KC, 2010, NEUROREHAB NEURAL RE, V24, P486, DOI 10.1177/1545968309356295; Luke C, 2004, CLIN REHABIL, V18, P888, DOI 10.1191/0269215504cr793oa; MATHIOWETZ V, 1985, AM J OCCUP THER, V39, P386, DOI 10.5014/ajot.39.6.386; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Plummer P, 2003, PHYS THER, V83, P732, DOI 10.1093/ptj/83.8.732; Pollock A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010820.pub2; Powney M, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-237; Rand D, 2014, NEUROREHAB NEURAL RE, V28, P733, DOI 10.1177/1545968314521008; Saposnik G, 2016, LANCET NEUROL, V15, P1019, DOI 10.1016/S1474-4422(16)30121-1; Saposnik G, 2010, STROKE, V41, P1477, DOI 10.1161/STROKEAHA.110.584979; Schmidt RA, 1988, MOTOR CONTROL AND LE; Schuster C, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-106; Schuster-Amft C, 2015, DISABIL REHABIL-ASSI, V10, P385, DOI 10.3109/17483107.2014.908963; Schuster-Amft C, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-350; Siekierka EM, 2007, NEURODEGENER DIS, V4, P57, DOI 10.1159/000100360; Stewart JC, 2014, EXP BRAIN RES, V232, P2407, DOI 10.1007/s00221-014-3938-5; Thielbar KO, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-171; Verheyden G, 2008, NEUROREHAB NEURAL RE, V22, P173, DOI 10.1177/1545968307305456; Wick K, 2011, IMPROVING DEXTERITY; Winstein C, 2014, J NEUROL PHYS THER, V38, P190, DOI 10.1097/NPT.0000000000000046	46	24	29	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2018	13	10							e0204455	10.1371/journal.pone.0204455	http://dx.doi.org/10.1371/journal.pone.0204455			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY3FL	30356229	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000448434000010
J	Suwarto, S; Diahtantri, RA; Hidayat, MJ; Widjaya, B				Suwarto, Suhendro; Diahtantri, Riyanti Astrid; Hidayat, Mohammad Jauharsyah; Widjaya, Bing			Nonalcoholic fatty liver disease is associated with increased hemoconcentration, thrombocytopenia, and longer hospital stay in dengue-infected patients with plasma leakage	PLOS ONE			English	Article							HEMORRHAGIC-FEVER; METABOLIC SYNDROME; VIRUS-REPLICATION; CHILDREN; PATHOGENESIS; INVOLVEMENT; SEVERITY; SIZE; SEROTYPE; FAILURE	A prominent histopathological feature of fatal dengue cases is hepatic steatosis. However, the association between hepatic steatosis and dengue severity is unknown. We conducted a study to determine the associations of nonalcoholic fatty liver disease (NAFLD) with laboratory markers of dengue severity and length of hospital stay (LOS). A retrospective study was conducted at a private hospital in Jakarta, Indonesia, from December 2011 to December 2016. Bivariate analysis was performed to analyze the associations of laboratory markers of dengue severity and LOS with the presence or absence of NAFLD in no-plasma-leakage (no leakage) and plasma-leakage (leakage) groups. There were 267 dengue-infected patients included in this study. Of these patients, 115 (43.1%) were classified as belonging to the no leakage group, and 152 (56.9%) were classified as belonging to the leakage group. Of the 115 patients belonging to the no leakage group, 53 (46.1%) did not have NAFLD, and 62 (53.9%) had NAFLD. Of the 152 patients belonging to the leakage group, 85 (55.9%) did not have NAFLD, and 67 (44.1%) had NAFLD. Leakage group patients with NAFLD experienced significantly higher hemoconcentration severity (p = 0.04), lower platelet count (p = 0.004) and higher LOS (p = 0.042) than did leakage group patients without NAFLD. The presence of NAFLD in dengue-infected patients with plasma leakage was associated with more severe hemoconcentration, thrombocytopenia and prolonged hospital stay.	[Suwarto, Suhendro] Pondok Indah Hosp, Jakarta, Indonesia; [Suwarto, Suhendro] Univ Indonesia, Div Trop & Infect Dis, Dept Internal Med, Fac Med,Cipto Mangunkusumo Natl Hosp RSCM, Jakarta, Indonesia; [Diahtantri, Riyanti Astrid] Univ Indonesia, Fac Med, Jakarta, Indonesia; [Hidayat, Mohammad Jauharsyah] Pondok Indah Hosp, Dept Radiol, Jakarta, Indonesia; [Widjaya, Bing] Pondok Indah Hosp, Dept Clin Pathol, Jakarta, Indonesia	University of Indonesia; University of Indonesia	Suwarto, S (corresponding author), Pondok Indah Hosp, Jakarta, Indonesia.; Suwarto, S (corresponding author), Univ Indonesia, Div Trop & Infect Dis, Dept Internal Med, Fac Med,Cipto Mangunkusumo Natl Hosp RSCM, Jakarta, Indonesia.	suhendro@ui.ac.id		, Suhendro/0000-0001-6394-0591				Amarapurkar DN, 2007, J GASTROEN HEPATOL, V22, P788, DOI 10.1111/j.1440-1746.2007.05042.x; Aye KS, 2014, HUM PATHOL, V45, P1221, DOI 10.1016/j.humpath.2014.01.022; Balasubramanian S, 2006, INDIAN PEDIATR, V43, P334; Bruewer M, 2003, J IMMUNOL, V171, P6164, DOI 10.4049/jimmunol.171.11.6164; Buzzetti E, 2016, METABOLISM, V65, P1038, DOI 10.1016/j.metabol.2015.12.012; Chalasani N, 2012, HEPATOLOGY, V55, P2005, DOI 10.1002/hep.25762; Chen ZW, 2008, J ZHEJIANG UNIV-SC B, V9, P616, DOI 10.1631/jzus.B0720016; Dhanoa A, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1731-8; Dinh TT, 2010, AM J TROP MED HYG, V83, P774, DOI 10.4269/ajtmh.2010.10-0090; Duyen HTL, 2011, J INFECT DIS, V203, P1292, DOI 10.1093/infdis/jir014; Fernando S, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1656-2; Gan VC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060946; Ghamar-Chehreh Mohammad Ebrahim, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P702, DOI 10.1016/S2221-1691(12)60213-5; Gowda S, 2009, PAN AFR MED J, V3, P1; Heaton NS, 2010, CELL HOST MICROBE, V8, P422, DOI 10.1016/j.chom.2010.10.006; Hertzog MA, 2008, RES NURS HEALTH, V31, P180, DOI 10.1002/nur.20247; Huerre MR, 2001, VIRCHOWS ARCH, V438, P107; Hunsperger EA, 2016, J INFECT DIS, V214, P836, DOI 10.1093/infdis/jiw103; Jagadishkumar K, 2012, IRAN J PEDIATR, V22, P231; Kalayanarooj Siripen, 2005, Southeast Asian Journal of Tropical Medicine and Public Health, V36, P378; Karyanti MR, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-412; Kim WR, 2008, HEPATOLOGY, V47, P1363, DOI 10.1002/hep.22109; Kitade H, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040387; Laoprasopwattana K, 2016, J TROP PEDIATRICS, V62, P200, DOI 10.1093/tropej/fmv099; Li L, 2016, OBES REV, V17, P510, DOI 10.1111/obr.12407; Lin YW, 2002, J VIROL, V76, P12242, DOI 10.1128/JVI.76.23.12242-12249.2002; Michels M, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002277; Huy NT, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002412; Obika M, 2012, EXP DIABETES RES, DOI 10.1155/2012/145754; Ojha A, 2017, SCI REP-UK, V7, DOI 10.1038/srep41697; Paes MV, 2009, LAB INVEST, V89, P1140, DOI 10.1038/labinvest.2009.83; Paschos P, 2009, HIPPOKRATIA, V13, P9; Pichainarong Natchaporn, 2006, Southeast Asian Journal of Tropical Medicine and Public Health, V37, P283; Povoa TF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083386; Ramachandran A, 2010, J OBES, V2010, DOI 10.1155/2010/868573; Samsa MM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000632; Seneviratne SL, 2006, T ROY SOC TROP MED H, V100, P608, DOI 10.1016/j.trstmh.2005.10.007; Sourianarayanane Achuthan, 2013, J Crohns Colitis, V7, pe279, DOI 10.1016/j.crohns.2012.10.015; Srikiatkhachorn A, 2009, THROMB HAEMOSTASIS, V102, P1042, DOI 10.1160/TH09-03-0208; Suwarto S, 2017, J INFECT DIS; Suwarto S, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1671-3; Tan VPK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200698; Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215; Vervaeke P, 2015, REV MED VIROL, V25, P50, DOI 10.1002/rmv.1818; Wang CC, 2007, AM J TROP MED HYG, V77, P151, DOI 10.4269/ajtmh.2007.77.151; Wang L, 2016, ONCOTARGET, V7, P73229, DOI 10.18632/oncotarget.12302; Wills BA, 2004, J INFECT DIS, V190, P810, DOI 10.1086/422754; World Health Organization, 2009, DENG GUID DIAGN TREA, P147, DOI DOI 10.7705/BIOMEDICA.V37I4.3370; Yacoub S., 2016, F1000RES, V5; Yoon HJ, 2014, WORLD J HEPATOL, V6, P800, DOI 10.4254/wjh.v6.i11.800	50	2	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2018	13	10							e0205965	10.1371/journal.pone.0205965	http://dx.doi.org/10.1371/journal.pone.0205965			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX3PM	30332476	Green Submitted, Green Published, gold			2023-01-03	WOS:000447638200079
J	Neumann, MS; Plant, A; Margolis, AD; Borkowf, CB; Malotte, CK; Rietmeijer, CA; Flores, SA; O'Donnell, L; Robilotto, S; Myint-U, A; Montoya, JA; Javanbakht, M; Klausner, JD				Neumann, Mary Spink; Plant, Aaron; Margolis, Andrew D.; Borkowf, Craig B.; Malotte, C. Kevin; Rietmeijer, Cornelis A.; Flores, Stephen A.; O'Donnell, Lydia; Robilotto, Susan; Myint-U, Athi; Montoya, Jorge A.; Javanbakht, Marjan; Klausner, Jeffrey D.			Effects of a brief video intervention on treatment initiation and adherence among patients attending human immunodeficiency virus treatment clinics	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; WAITING ROOMS; INFECTION; PREVENTION; TRIAL; COST; SAFE	Background Persons with human immunodeficiency virus (HIV) who get and keep a suppressed viral load are unlikely to transmit HIV. Simple, practical interventions to help achieve HIV viral suppression that are easy and inexpensive to administer in clinical settings are needed. We evaluated whether a brief video containing HIV-related health messages targeted to all patients in the waiting room improved treatment initiation, medication adherence, and retention in care. Methods and findings In a quasi-experimental trial all patients (N = 2,023) attending two HIV clinics from June 2016 to March 2017 were exposed to a theory-based, 29-minute video depicting persons overcoming barriers to starting treatment, taking medication as prescribed, and keeping medical appointments. New prescriptions at index visit, HIV viral load test results, and dates of return visits were collected through review of medical records for all patients during the 10 months that the video was shown. Those data were compared with the same variables collected for all patients (N = 1,979) visiting the clinics during the prior 10 months (August 2015 to May 2016). Among patients exposed to the video, there was an overall 10.4 percentage point increase in patients prescribed treatment (60.3% to 70.7%, p<0.01). Additionally, there was an overall 6.0 percentage point improvement in viral suppression (56.7% to 62.7%, p<0.01), however mixed results between sites was observed. There was not a significant change in rates of return visits (77.5% to 78.8%). A study limitation is that, due to the lack of randomization, the findings may be subject to bias and secular trends. Conclusions Showing a brief treatment-focused video in HIV clinic waiting rooms can be effective at improving treatment initiation and may help patients achieve viral suppression. This feasible, low resource-reliant video intervention may be appropriate for adoption by other clinics treating persons with HIV.	[Neumann, Mary Spink; Margolis, Andrew D.; Borkowf, Craig B.; Flores, Stephen A.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD &TB Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA; [Plant, Aaron; Montoya, Jorge A.] Sentient Res, West Covina, CA USA; [Malotte, C. Kevin] Calif State Univ Long Beach, Long Beach, CA 90840 USA; [Rietmeijer, Cornelis A.] Univ Colorado, Colorado Sch Publ Hlth, Denver, CO 80202 USA; [O'Donnell, Lydia; Myint-U, Athi] Educ Dev Ctr, Waltham, MA USA; [Robilotto, Susan] Hlth Resources & Serv Adm, HIV AIDS Bur, Rockville, MD USA; [Javanbakht, Marjan; Klausner, Jeffrey D.] Univ Calif Los Angeles, Los Angeles, CA USA	Centers for Disease Control & Prevention - USA; California State University System; California State University Long Beach; Colorado School of Public Health; University of Colorado System; University of Colorado Denver; United States Health Resources & Service Administration (HRSA); University of California System; University of California Los Angeles	Margolis, AD (corresponding author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD &TB Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.	avm8@cdc.gov	Javanbakht, Marjan/Q-2183-2019	Javanbakht, Marjan/0000-0003-0088-3803	Health and Human Services Secretary's Minority AIDS Initiative; Centers for Disease Control and Prevention [200-2013-57577]; Secretary's Minority AIDS Initiative; Centers for Disease Control and Prevention	Health and Human Services Secretary's Minority AIDS Initiative; Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Secretary's Minority AIDS Initiative; Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	The data collected and used for this study were funded by the Health and Human Services Secretary's Minority AIDS Initiative and by the Centers for Disease Control and Prevention through contract number 200-2013-57577 awarded to Sentient Research. The Secretary's Minority AIDS Initiative provided direct funding. The Centers for Disease Control and Prevention provided direct funding and support in the form of salaries for authors MSN, ADM, CBB and SAF, but did not have any additional role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contribution' section. The four authors who are employees of the Centers for Disease Control and Prevention had roles in study design, data collection and analyses, decision to publish, and preparation of the manuscript. Two authors are employees of the commercial company, Sentient Research (AP and JAM), and had roles in study design, data collection, and preparation of the manuscript. The specific roles of these authors are articulated in the 'author contribution' section.	[Anonymous], COMP EV BAS INT BEST; [Anonymous], 2011, HIGH IMP HIV PREV CD; Besera GT, 2016, HEALTH PROMOT PRACT, V17, P731, DOI 10.1177/1524839916631537; Carey MP, 2015, AIDS BEHAV, V19, P1228, DOI 10.1007/s10461-014-0960-3; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Gift TL, 2016, SEX TRANSM DIS, V43, P61, DOI 10.1097/OLQ.0000000000000388; Gunthard HF, 2016, JAMA-J AM MED ASSOC, V316, P191, DOI 10.1001/jama.2016.8900; Harshbarger C, 2006, AIDS EDUC PREV, V18, P184, DOI 10.1521/aeap.2006.18.supp.184; Harshbarger CL, 2012, AM J PREV MED, V42, P468, DOI 10.1016/j.amepre.2012.01.029; Health Resources & Services Administration, RYAN WHIT HIV AIDS P; ITTC-Recommended Procedures and Guidelines, 2017, GUID US RANS TOOLS M; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Myint-U A, 2010, HEALTH PROMOT PRACT, V11, P408, DOI 10.1177/1524839908318830; Neumann MS, 2011, SEX TRANSM DIS, V38, P133, DOI 10.1097/OLQ.0b013e3181f0c051; Neumann MS, 2017, AM PUBL HLTH ASS GLO; O'Donnell CR, 1998, SEX TRANSM DIS, V25, P161, DOI 10.1097/00007435-199803000-00010; Office of National AIDS Policy WHDPC, 2015, NAT HIV AIDS STRAT U; Sweat M, 2001, AIDS, V15, P781, DOI 10.1097/00002030-200104130-00014; Warner L, 2008, PLOS MED, V5, P919, DOI 10.1371/journal.pmed.0050135; World Health Organization, 2014, CONS GUID HIV PREV D	20	14	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2018	13	10							e0204599	10.1371/journal.pone.0204599	http://dx.doi.org/10.1371/journal.pone.0204599			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW0HY	30289884	Green Published, Green Submitted, gold			2023-01-03	WOS:000446545500020
J	Sanmamed, MF; Chen, LP				Sanmamed, Miguel F.; Chen, Lieping			A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization	CELL			English	Review							CELL LUNG-CANCER; MODIFIED T-CELLS; METASTATIC MELANOMA; ANTI-PD-L1 ANTIBODY; INTERLEUKIN-2 THERAPY; COMBINED NIVOLUMAB; DENDRITIC CELLS; DOUBLE-BLIND; B7-H1 PD-L1; IPILIMUMAB	Harnessing an antitumor immune response has been a fundamental strategy in cancer immunotherapy. For over a century, efforts have primarily focused on amplifying immune activation mechanisms that are employed by humans to eliminate invaders such as viruses and bacteria. This "immune enhancement'' strategy often results in rare objective responses and frequent immune-related adverse events (irAEs). However, in the last decade, cancer immunotherapies targeting the B7-H1/PD-1 pathway (anti-PD therapy), have achieved higher objective response rates in patients with much fewer irAEs. This more beneficial tumor response-to-toxicity profile stems from distinct mechanisms of action that restore tumor-induced immune deficiency selectively in the tumor microenvironment, here termed "(i)mmune normalization,'' which has led to its FDA approval in more than 10 cancer indications and facilitated its combination with different therapies. In this article, we wish to highlight the principles of immune normalization and learn from it, with the ultimate goal to guide better designs for future cancer immunotherapies.	[Sanmamed, Miguel F.; Chen, Lieping] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; [Sanmamed, Miguel F.; Chen, Lieping] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA	Yale University; Yale University	Chen, LP (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA.; Chen, LP (corresponding author), Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA.	lieping.chen@yale.edu	F Sanmamed, Miguel/I-5572-2017	F Sanmamed, Miguel/0000-0002-7295-6074	US NIH [P50 CA196530, P30 CA16359]; Yale University endowed chair from the United Technologies Corporation; Miguel Servet contract from Instituto de Salud Carlos III, Fondo de Investigacion Sanitaria (Spain); NATIONAL CANCER INSTITUTE [P50CA196530, P30CA016359] Funding Source: NIH RePORTER	US NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Yale University endowed chair from the United Technologies Corporation; Miguel Servet contract from Instituto de Salud Carlos III, Fondo de Investigacion Sanitaria (Spain); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Beth Cadugan for editing the manuscript. This work is partially supported by US NIH grants P50 CA196530 and P30 CA16359 and a Yale University endowed chair from the United Technologies Corporation. M.F.S. is supported by a Miguel Servet contract from Instituto de Salud Carlos III, Fondo de Investigacion Sanitaria (Spain).	Agarwala SS, 2002, J CLIN ONCOL, V20, P125, DOI 10.1200/JCO.20.1.125; Ahmed N, 2015, J CLIN ONCOL, V33, P1688, DOI 10.1200/JCO.2014.58.0225; Aznar MA, 2017, J IMMUNOL, V198, P31, DOI 10.4049/jimmunol.1601145; Ascierto PA, 2017, LANCET ONCOL, V18, P611, DOI 10.1016/S1470-2045(17)30231-0; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Azuma T, 2008, BLOOD, V111, P3635, DOI 10.1182/blood-2007-11-123141; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Benson DM, 2010, BLOOD, V116, P2286, DOI 10.1182/blood-2010-02-271874; Bilusic M, 2017, CLIN CANCER RES, V23, P6764, DOI 10.1158/1078-0432.CCR-17-0019; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Brudno JN, 2016, BLOOD, V127, P3321, DOI 10.1182/blood-2016-04-703751; Bulliard Y, 2013, J EXP MED, V210, P1685, DOI 10.1084/jem.20130573; Burel JG, 2016, TRENDS IMMUNOL, V37, P53, DOI 10.1016/j.it.2015.11.006; Callahan MK, 2016, IMMUNITY, V44, P1069, DOI 10.1016/j.immuni.2016.04.023; Charych D.H., 2016, NAT REV IMMUNOL; Chen LP, 2015, J CLIN INVEST, V125, P3384, DOI 10.1172/JCI80011; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Chen L, 2018, P NATL ACAD SCI USA, V115, P3126, DOI 10.1073/pnas.1722043115; Chin YT, 2018, ENDOCR-RELAT CANCER, V25, P533, DOI 10.1530/ERC-17-0376; Corrales L, 2016, J CLIN INVEST, V126, P2404, DOI 10.1172/JCI86892; Das R, 2015, J IMMUNOL, V194, P950, DOI 10.4049/jimmunol.1401686; Desjardins A, 2018, NEW ENGL J MED, V379, P150, DOI 10.1056/NEJMoa1716435; Diaz L, 2017, ANN ONCOL, V28; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Du XX, 2018, CELL RES, V28, P416, DOI 10.1038/s41422-018-0011-0; Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gardiner D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063818; Gay CL, 2017, J INFECT DIS, V215, P1725, DOI 10.1093/infdis/jix191; Gros A, 2014, J CLIN INVEST, V124, P2246, DOI [10.1172/JC173639, 10.1172/JCI73639]; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hodi FS, 2016, LANCET ONCOL, V17, P1558, DOI 10.1016/S1470-2045(16)30366-7; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Huang BY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134715; Hughes PE, 2016, TRENDS IMMUNOL, V37, P462, DOI 10.1016/j.it.2016.04.010; Jenkins RW, 2018, CANCER DISCOV, V8, P196, DOI 10.1158/2159-8290.CD-17-0833; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Klein C, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1277306; Lang FF, 2018, J CLIN ONCOL, V36, P1419, DOI 10.1200/JCO.2017.75.8219; Larkin J, 2018, J CLIN ONCOL, V36, P383, DOI 10.1200/JCO.2016.71.8023; Lawler SE, 2017, JAMA ONCOL, V3, P841, DOI 10.1001/jamaoncol.2016.2064; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lee SJ, 2006, FEBS LETT, V580, P755, DOI 10.1016/j.febslet.2005.12.093; Li K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020404; Lynch TJ, 2012, J CLIN ONCOL, V30, P2046, DOI 10.1200/JCO.2011.38.4032; Martinez-Usatorre A, 2018, J IMMUNOL, V201, P792, DOI 10.4049/jimmunol.1701644; Melero I, 2015, NAT REV CANCER, V15, P457, DOI 10.1038/nrc3973; Melero I, 2014, NAT REV CLIN ONCOL, V11, P509, DOI 10.1038/nrclinonc.2014.111; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24; Naidoo J, 2015, ANN ONCOL, V26, P2375, DOI 10.1093/annonc/mdv383; Namuduri M, 2016, EXPERT REV HEMATOL, V9, P511, DOI 10.1080/17474086.2016.1183479; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Overwijk WW, 2000, CRIT REV IMMUNOL, V20, P433; PARKINSON DR, 1990, J CLIN ONCOL, V8, P1650, DOI 10.1200/JCO.1990.8.10.1650; Petroff MG, 2002, PLACENTA, V23, pS95, DOI 10.1053/plac.2002.0813; Phan GQ, 2001, EXPERT OPIN BIOL TH, V1, P511, DOI 10.1517/14712598.1.3.511; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Ribas A, 2015, LANCET ONCOL, V16, P908, DOI 10.1016/S1470-2045(15)00083-2; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Robert C, 2014, LANCET, V384, P1109, DOI 10.1016/S0140-6736(14)60958-2; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Rosenberg SA, 2005, J IMMUNOL, V175, P6169, DOI 10.4049/jimmunol.175.9.6169; ROSENBERG SA, 1985, J EXP MED, V161, P1169, DOI 10.1084/jem.161.5.1169; ROSENBERG SA, 1994, JAMA-J AM MED ASSOC, V271, P907, DOI 10.1001/jama.271.12.907; Rosenberg SA, 2014, J IMMUNOL, V192, P5451, DOI 10.4049/jimmunol.1490019; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Sanmamed MF, 2014, CANCER J, V20, P256, DOI 10.1097/PPO.0000000000000061; Schafer K, 2017, CHEM-EUR J, V23, P370, DOI 10.1002/chem.201603807; Schwartzentruber DJ, 2011, NEW ENGL J MED, V364, P2119, DOI 10.1056/NEJMoa1012863; Scott AM, 2012, NAT REV CANCER, V12, P278, DOI 10.1038/nrc3236; Selby MJ, 2013, CANCER IMMUNOL RES, V1, P32, DOI 10.1158/2326-6066.CIR-13-0013; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; Smyth MJ, 2016, NAT REV CLIN ONCOL, V13, P143, DOI 10.1038/nrclinonc.2015.209; Sznol M, 2013, CLIN CANCER RES, V19, P5542, DOI 10.1158/1078-0432.CCR-13-2234; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Tang J, 2018, ANN ONCOL, V29, P84, DOI 10.1093/annonc/mdx755; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; Tarhini AA, 2007, J CLIN ONCOL, V25, P3802, DOI 10.1200/JCO.2006.10.2822; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237; Vargas FA, 2018, CANCER CELL, V33, P649, DOI 10.1016/j.ccell.2018.02.010; Vari F, 2018, BLOOD, V131, P1809, DOI 10.1182/blood-2017-07-796342; Vinay DS, 2015, SEMIN CANCER BIOL, V35, pS185, DOI 10.1016/j.semcancer.2015.03.004; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Weiner GJ, 2015, NAT REV CANCER, V15, P361, DOI 10.1038/nrc3930; Weiner LM, 2010, NAT REV IMMUNOL, V10, P317, DOI 10.1038/nri2744; Yao S, 2009, BLOOD, V113, P5811, DOI 10.1182/blood-2009-02-203141; Zhang Y, 2016, JAMA ONCOL, V2, P1403, DOI 10.1001/jamaoncol.2016.2450; Zitvogel L, 2016, NAT REV CANCER, V16, P759, DOI 10.1038/nrc.2016.91; Zou WP, 2008, NAT REV IMMUNOL, V8, P467, DOI 10.1038/nri2326; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	104	618	671	34	358	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	2018	175	2					313	326		10.1016/j.cell.2018.09.035	http://dx.doi.org/10.1016/j.cell.2018.09.035			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GV7PQ	30290139	Green Accepted, Bronze			2023-01-03	WOS:000446321300007
J	Kassa, A; Human, SP; Gemeda, H				Kassa, Andargachew; Human, Sarie Petronella; Gemeda, Hirut			Knowledge of preconception care among healthcare providers working in public health institutions in Hawassa, Ethiopia	PLOS ONE			English	Article							RECOMMENDATIONS; DETERMINANTS; WOMEN	Background Preconception care (PCC) is an evidence-based health promotion intervention to prevent adverse pregnancy outcomes. Nevertheless, it is one of the missing elements within the continuum of maternal and child healthcare. Despite the WHO's recommendation, most of the developing countries have not yet started implementing preconception care. Objective To determine the knowledge level of healthcare providers about PCC and to identify predictors of effective knowledge of preconception care. Method This is a cross-sectional study conducted among 634 healthcare providers (HCP) working in public health institutions of Hawassa. A pilot-tested and validated self-administered survey tool was used to collect data from individual healthcare providers who were selected randomly using a multistage sampling technique. The data entry and analysis were conducted using SPSS version 20 software. Frequency, proportions, means and standard deviations were used to describe the data. Bivariate and multivariate logistic regression models were implemented to determine the predictors of HCP's PCC knowledge. Results Only a few (31%) of the healthcare providers demonstrated a good level of knowledge on preconception care. The odds of having good PCC knowledge was high among HCPs working in hospitals (AOR = 1.8, 95% C.I. 1.3-2.6), HCPs using their smart phone to access clinical resources (AOR = 1.4, 95% C.I. 1.1-2.0), among those HCPs ever have read PCC guideline prepared by organization outside of Ethiopia (AOR = 1.9, 95% C.I. 1.4-2.7), among those who claimed practicing PCC (AOR = 3.4, 95% C.I. 2.0-5.9), and among those who earn salary of >= 146.0 $(AOR = 1.5, 95% C.I. 1.1-2.1). Conclusion There is an unacceptably low level of knowledge about PCC among most of the healthcare providers in public health facilities in Ethiopia. The predictors identified in this study can be used to enhance the knowledge of healthcare providers about preconception care.	[Kassa, Andargachew; Gemeda, Hirut] Hawassa Univ, Coll Med & Hlth Sci, Sch Nursing & Midwifery, Hawassa, Ethiopia; [Human, Sarie Petronella] Univ South Africa, Coll Human Sci, Dept Hlth Sci, UNISA, Pretoria, South Africa	Hawassa University; University of South Africa	Kassa, A (corresponding author), Hawassa Univ, Coll Med & Hlth Sci, Sch Nursing & Midwifery, Hawassa, Ethiopia.	akandkassa@gmail.com		Biratu, Andargachew Kassa/0000-0003-4696-2582				ACP-ACOG, 2007, GUID PER CAR; Ajayi GO, 2013, CLIN EXP OBSTET GYN, V40, P359; Al-Darzi W, 2014, E MEDITERR HEALTH J, V20, P561, DOI 10.26719/2014.20.9.561; Asemahagn MA, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-431; Ayalew Y, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0279-4; Bradley EH, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000987; Braspenningx S, 2013, FACTS VIEWS VIS OBGY, V5, P13; BSRC, 2009, PREC HLTH PHYS PRACT; Ebrahimipour Bayram, 2013, J RES HLTH, V3; Fleuren M, 2004, INT J QUAL HEALTH C, V16, P107, DOI 10.1093/intqhc/mzh030; Fleuren MAH, 2014, INT J QUAL HEALTH C, V26, P501, DOI 10.1093/intqhc/mzu060; ICF CSACEa, 2016, ETH DEM HLTH SURV 20; Kassa A, 2017, ADDRESSING HIGH ADVE; Kitamura Kazuya, 2005, BMC Fam Pract, V6, P31, DOI 10.1186/1471-2296-6-31; McCluskey A., 2003, AUST OCCUP THER J, V50, P3, DOI [10.1046/j.1440-1630.2003.00303.x, DOI 10.1046/J.1440-1630.2003.00303.X]; MOH, 2015, GUIDL MAT CAR S AFR; Moos MK, 2008, AM J OBSTET GYNECOL, V199, pS280, DOI 10.1016/j.ajog.2008.08.060; Mosale F. A., 2012, EL MINIA MED B, V23, P14; National AIDS and STI Control Programme, 2014, GUIDELINES USE ANTIR; Sanders Lorraine B, 2009, Policy Polit Nurs Pract, V10, P129, DOI 10.1177/1527154409338494; Sardasht FG, 2013, J MIDWIFERY REPROD H, V1, P10; World Health Organisation, 2013, M DEV GLOB CONS PREC; World Health Organization, 2013, PREC HLTH MAX GAINS; Zambia Ministry of Health, 2019, REP ZAMB MINISTRY HL, P2009	24	9	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2018	13	10							e0204415	10.1371/journal.pone.0204415	http://dx.doi.org/10.1371/journal.pone.0204415			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GV5EV	30273381	Green Published, gold, Green Submitted			2023-01-03	WOS:000446124700021
J	Wichmann, AB; Adang, EMM; Vissers, KCP; Szczerbinska, K; Kylanen, M; Payne, S; Gambassi, G; Onwuteaka-Philipsen, BD; Smets, T; Van den Block, L; Deliens, L; Vernooij-Dassen, MJFJ; Engels, Y				Wichmann, Anne B.; Adang, Eddy M. M.; Vissers, Kris C. P.; Szczerbinska, Katarzyna; Kylanen, Marika; Payne, Sheila; Gambassi, Giovanni; Onwuteaka-Philipsen, Bregje D.; Smets, Tinne; Van den Block, Lieve; Deliens, Luc; Vernooij-Dassen, Myrra J. F. J.; Engels, Yvonne		PACE Consortium	Technical-efficiency analysis of end-of-life care in long-term care facilities within Europe: A cross-sectional study of deceased residents in 6 EU countries (PACE)	PLOS ONE			English	Article							DATA ENVELOPMENT ANALYSIS; QUALITY	Background An ageing population in the EU leads to a higher need of long-term institutional care at the end of life. At the same time, healthcare costs rise while resources remain limited. Consequently, an urgency to extend our knowledge on factors affecting efficiency of long-term care facilities (LTCFs) arises. This study aims to investigate and explain variation in technical efficiency of end-of-life care within and between LTCFs of six EU countries: Belgium (Flanders), England, Finland, Italy, the Netherlands and Poland. In this study, technical efficiency reflects the LTCFs' ability to obtain maximal quality of life (QoL) and quality of dying (QoD) for residents from a given set of resource inputs (personnel and capacity). Methods Cross-sectional data were collected by means of questionnaires on deceased residents identified by LTCFs over a three-month period. An output-oriented data-envelopment analysis (DEA) was performed, producing efficiency scores, incorporating personnel and capacity as input and QoL and QoD as output. Scenario analysis was conducted. Regression analysis was performed on explanatory (country, LTCF type, ownership, availability of palliative care and opioids) and case mix (disease severity) variables. Results 133 LTCFs of only one type (onsite nurses and offsite GPs) were considered in order to reduce heterogeneity. Variation in LTCF efficiency was found across as well as within countries. This variation was not explained by country, ownership, availability of palliative care or opioids. However, in the 'hands-on care at the bedside' scenario, i.e. only taking into account nursing and care assistants as input, Poland (p = 0.00) and Finland (p = 0.04) seemed to be most efficient. Conclusions Efficiency of LTCFs differed extensively across as well as within countries, indicating room for considerable efficiency improvement. Our findings should be interpreted cautiously, as comprehensive comparative EU-wide research is challenging as it is influenced by many factors.	[Wichmann, Anne B.; Vernooij-Dassen, Myrra J. F. J.] Radboud Univ Nijmegen, Radboud Inst Hlth Sci, IQ Healthcare, Med Ctr, Nijmegen, Netherlands; [Adang, Eddy M. M.] Radboud Univ Nijmegen, Dept Hlth Evidence, Med Ctr, Nijmegen, Netherlands; [Vissers, Kris C. P.; Engels, Yvonne] Radboud Univ Nijmegen, Dept Anesthesiol Pain & Palliat Med, Med Ctr, Nijmegen, Netherlands; [Szczerbinska, Katarzyna] Jagiellonian Univ, Med Coll, Unit Res Aging Soc, Epidemiol & Prevent Med Chair, Krakow, Poland; [Kylanen, Marika] Natl Inst Hlth & Welf, Helsinki, Finland; [Payne, Sheila] Univ Lancaster, Div Hlth Res, Lancaster, England; [Gambassi, Giovanni] Univ Cattolica Sacro Cuore, Fac Med & Surg, Rome, Italy; [Onwuteaka-Philipsen, Bregje D.] Vrije Univ Amsterdam Med Ctr, Dept Publ & Occupat Hlth, Amsterdam Publ Hlth Res Inst, Amsterdam, Netherlands; [Onwuteaka-Philipsen, Bregje D.] Vrije Univ Brussel, End Life Care Res Grp, Brussels, Belgium; [Smets, Tinne; Van den Block, Lieve; Deliens, Luc] Univ Ghent, Brussels, Belgium	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Jagiellonian University; Collegium Medicum Jagiellonian University; Finland National Institute for Health & Welfare; Lancaster University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Brussel; Ghent University	Wichmann, AB (corresponding author), Radboud Univ Nijmegen, Radboud Inst Hlth Sci, IQ Healthcare, Med Ctr, Nijmegen, Netherlands.	Anne.Wichmann@radboudumc.nl	Szczerbinska, Katarzyna/AGG-8995-2022; Adang, E.M.M./L-4169-2015; Engels, Yvonne/I-1814-2015; Wichmann, Anne/F-3166-2016; Vissers, Kris/H-8110-2014; Szczerbinska, Katarzyna/AAG-9333-2020; Van den Block, Lieve/D-1247-2011	Szczerbinska, Katarzyna/0000-0002-0004-3858; Engels, Yvonne/0000-0002-7669-1018; Wichmann, Anne/0000-0003-0085-9782; Vissers, Kris/0000-0002-2919-6356; Szczerbinska, Katarzyna/0000-0002-0004-3858; Onwuteaka-Philipsen, Bregje/0000-0002-9440-1248; Smets, Tinne/0000-0003-1439-316X; Van den Block, Lieve/0000-0002-7770-348X	EU 7th Framework Programme [6031111]	EU 7th Framework Programme	This study was supported by the EU 7th Framework Programme (https://ec.europa.eu/research/fp7), grant agreement 6031111. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adang EMM, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0434-2; [Anonymous], 2016, VALUING HLTH RELATED; Bjorkgren M A, 2001, Health Care Manag Sci, V4, P193; Coelli TJ, 2005, MEDICINE; Dowd B, 2014, HEALTH ECON, V23, P1465, DOI 10.1002/hec.3000; EuroQol, 2017, EQ 5D 5L VAL; EuroStat, 2017, HEALTHC EXP STAT; EUROSTAT, 2017, POPULATION STRUCTURE; EuroStat, 2017, LOOK LIV ELD EU TOD; Feng Zhanlian, 2005, J Am Med Dir Assoc, V6, P27, DOI 10.1016/j.jamda.2004.12.008; Froggatt K, 2010, PALLIATIVE CARE LONG; Garavaglia G, 2011, HEALTH CARE MANAG SC, V14, P22, DOI 10.1007/s10729-010-9139-2; Harrington C, 2012, J NURS SCHOLARSHIP, V44, P88, DOI 10.1111/j.1547-5069.2011.01430.x; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Lee RH, 2009, HEALTH SERV RES, V44, P15, DOI 10.1111/j.1475-6773.2008.00895.x; Munn JC, 2007, J AM GERIATR SOC, V55, P1371, DOI 10.1111/j.1532-5415.2007.01293.x; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Norman R, 2009, VALUE HEALTH, V12, P1194, DOI 10.1111/j.1524-4733.2009.00581.x; Organisation for Economic Co-operation and Development, 2017, PUBL SPEND HLTH LONG; Reitlinger E, 2013, EUR J PALLIAT CARE, V20, P251; Rodrigues R., 2012, FACTS FIGURES HLTH A; Shimshak DG, 2009, OMEGA-INT J MANAGE S, V37, P672, DOI 10.1016/j.omega.2008.05.004; Simar L, 1998, MANAGE SCI, V44, P49, DOI 10.1287/mnsc.44.1.49; Van den Block L, 2016, J AM MED DIR ASSOC, V17, DOI 10.1016/j.jamda.2016.03.008; Wichmann AB, 2017, PALLIATIVE MED; World Health Organization, 2000, WORLD HLTH REP 2000	26	2	2	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2018	13	9							e0204120	10.1371/journal.pone.0204120	http://dx.doi.org/10.1371/journal.pone.0204120			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GU9BO	30252888	Green Published, Green Submitted, gold			2023-01-03	WOS:000445639700031
J	Niu, QY; Hong, Y; Lee, CH; Men, CC; Zhao, HP; Zuo, L				Niu, Qingyu; Hong, Yang; Lee, Cho-Hao; Men, Chuncui; Zhao, Huiping; Zuo, Li			Abdominal aortic calcification can predict all-cause mortality and CV events in dialysis patients: A systematic review and meta-analysis	PLOS ONE			English	Review							CHRONIC KIDNEY-DISEASE; CORONARY-ARTERY CALCIFICATION; PRACTICE GUIDELINE UPDATE; CARDIOVASCULAR EVENTS; MAINTENANCE HEMODIALYSIS; MEDIA CALCIFICATION; PROGNOSTIC VALUE; RENAL-DISEASE; PREVENTION; DIAGNOSIS	Background Abdominal aortic calcification (AAC) has a pretty high incidence in dialysis patients and may be associated with their prognosis. AAC can be assessed by abdominal CT or X-ray. We determined to investigate whether the occurrence of AAC is associated with all-cause mortality and cardiovascular (CV) events in dialysis patients through this meta-analysis and systematic review. Methods A comprehensive literature search was conducted using the PubMed, Cochrane library, Embase, Medline databases to collect cohort studies investigating whether AAC is associated with all-cause mortality and CV events of patients, and we also searched gray articles and conferences abstracts. Meta-analysis was performed by STATA software. Pooled results were expressed as hazard ratio (HR) with corresponding 95% confidence intervals (CI). Fixed-effect models were used to pool the HR of each trial. Results 10 studies (2,724 dialysis patients) were identified. The presence of AAC was associated with increased risk for all-cause mortality among dialysis patients (HR, 2.84; 95% CI, 2.03-3.98; I-2 = 9.8%; P = 0.354). Meanwhile, there was an association between AAC and increased risk for all CV events (fatal and non-fatal) in patients (HR, 2.04; 95% CI, 1.51-2.76, I-2 = 44.6%; P = 0.125). 3 studies presented their endpoint as CV mortality, and the pooled HR was 2.46 (95% CI 1.38-4.40; I-2 = 0.0%; P = 0.952). There were also 2 studies that reported their primary endpoint as all-cause mortality and CV events, and the pooled HR was 5.72 (95% CI 3.24-10.10; I-2 = 0.0%; P = 0.453). Conclusions Among patients treated with dialysis, AAC is associated with adverse outcomes, including all-cause mortality and CV events (fatal and non-fatal). The abdominal X-ray or CT scan can be used as a useful added method to evaluate the patient's calcification. This may provide reasonable data for estimating the risk of adverse events in dialysis patients, which is helpful in guiding clinical treatment and improving the prognosis of dialysis patients.	[Niu, Qingyu; Men, Chuncui; Zhao, Huiping; Zuo, Li] Peking Univ, Dept Nephrol, Peoples Hosp, Beijing, Peoples R China; [Hong, Yang] Peking Univ, Urol & Lithotripsy Ctr, Peoples Hosp, Beijing, Peoples R China; [Lee, Cho-Hao] Triserv Gen Hosp, Div Hematol & Oncol Med, Dept Internal Med, Natl Def Med Ctr, Taipei, Taiwan	Peking University; Peking University; National Defense Medical Center; Tri-Service General Hospital	Zhao, HP (corresponding author), Peking Univ, Dept Nephrol, Peoples Hosp, Beijing, Peoples R China.	huipingzhao2009@163.com	Lee, Cho-Hao/AAT-1548-2021	Lee, Cho-Hao/0000-0002-6061-5168				Amann K, 2008, CLIN J AM SOC NEPHRO, V3, P1599, DOI 10.2215/CJN.02120508; Anaya P, 2016, CLIN NEPHROL, V86, P291, DOI 10.5414/CN108940; [Anonymous], 1994, HDB RES SYNTHESIS; Bae E, 2017, HEMODIAL INT, V21, P367, DOI 10.1111/hdi.12493; Budoff MJ, 2006, CIRCULATION, V114, P1761, DOI 10.1161/CIRCULATIONAHA.106.178458; Chen HC, 2019, NEPHROLOGY, V24, P336, DOI 10.1111/nep.13231; Golestani R, 2010, ANN MED, V42, P539, DOI 10.3109/07853890.2010.515604; Greenland P, 2004, JAMA-J AM MED ASSOC, V291, P210, DOI 10.1001/jama.291.2.210; Hong DQ, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-120; IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25; Isakova T, 2017, AM J KIDNEY DIS, V70, P737, DOI 10.1053/j.ajkd.2017.07.019; Jegatheesan D, 2018, SEMIN NEPHROL, V38, P277, DOI 10.1016/j.semnephrol.2018.02.007; Kauppila LI, 1997, ATHEROSCLEROSIS, V132, P245, DOI 10.1016/S0021-9150(97)00106-8; Ketteler M, 2018, ANN INTERN MED, V168, P422, DOI 10.7326/M17-2640; Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188; Kwon HY, 2014, KIDNEY RES CLIN PRAC, V33, P95, DOI 10.1016/j.krcp.2014.04.003; London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414; Makela S, 2018, PERITON DIALYSIS INT, V38, P366, DOI 10.3747/pdi.2017.00043; Martino F, 2013, THER APHER DIAL, V17, P448, DOI 10.1111/j.1744-9987.2012.01084.x; NasrAllah MM, 2016, INT J CARDIOL, V220, P884, DOI 10.1016/j.ijcard.2016.06.064; Nitta K, 2001, AM J NEPHROL, V21, P465, DOI 10.1159/000046650; Ohya M, 2011, CLIN EXP NEPHROL, V15, P877, DOI 10.1007/s10157-011-0517-y; Okuno S, 2007, AM J KIDNEY DIS, V49, P417, DOI 10.1053/j.ajkd.2006.12.017; Rodondi N, 2007, J INTERN MED, V261, P238, DOI 10.1111/j.1365-2796.2007.01769.x; Rroji M, 2017, NEPHROL DIAL TRANSPL, V32, P659; Saha HHT, 2007, PERITON DIALYSIS INT, V27, pS210; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Verbeke F, 2011, CLIN J AM SOC NEPHRO, V6, P153, DOI 10.2215/CJN.05120610; Wang Z, 2017, NEPHROL DIAL TRANSPL, V32, piii656; Wu CF, 2018, J FORMOS MED ASSOC, V117, P87, DOI 10.1016/j.jfma.2017.11.009; Yoon HE, 2013, INT J MED SCI, V10, P617, DOI 10.7150/ijms.5773; Yoon HE, 2012, J KOREAN MED SCI, V27, P870, DOI 10.3346/jkms.2012.27.8.870; Zhang A, 2016, SCI REP-UK, V6, DOI 10.1038/srep35375	34	18	20	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2018	13	9							e0204526	10.1371/journal.pone.0204526	http://dx.doi.org/10.1371/journal.pone.0204526			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GU5MM	30240443	Green Published, gold			2023-01-03	WOS:000445329700058
J	Raberahona, M; Razafinambinintsoa, T; Andriananja, V; Ravololomanana, N; Tongavelona, J; Rakotomalala, R; Andriamamonjisoa, J; Andrianasolo, RL; Rakotoarivele, RA; Randria, MJD				Raberahona, Mihaja; Razafinambinintsoa, Tiana; Andriananja, Volatiana; Ravololomanana, Njaratiana; Tongavelona, Juliana; Rakotomalala, Rado; Andriamamonjisoa, Johary; Andrianasolo, Radonirina Lazasoa; Rakotoarivele, Rivonirina Andry; Randria, Mamy Jean de Dieu			Hospitalization of HIV positive patients in a referral tertiary care hospital in Antananarivo Madagascar, 2010-2016: Trends, causes and outcome	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; COHORT; RATES; METAANALYSIS; MORTALITY; WORLDWIDE; MARKERS; COST; ERA	Background During the last few years, significant efforts have been made to improve access to antiretroviral therapy which led to dramatic reduction in AIDS-related events and mortality in HIV positive patients at the global level. However, current data in Africa suggested modest impact of widespread antiretroviral therapy scale-up especially regarding HIV-related hospitalization. In this study, we aimed to describe causes of hospitalization and factors associated with AIDS-defining events and inpatient mortality. Materials and methods A retrospective study was performed on medical records of HIV positive patients admitted for at least 24 hours in the Infectious Diseases Unit of the University Hospital Joseph Raseta Befelatanana Antananarivo. Cause of hospitalization was considered as the main diagnosis related to the symptoms at admission. Diagnostic criteria were based on criteria described in WHO guidelines. AIDS-defining events were defined as diseases corresponding to WHO stage 4 or category C of CDC classification. Results From 2010 to 2016, 236 hospital admissions were included. AIDS-defining events were the most frequent cause of hospitalization (61.9%) with an increasing trend during the study period. Tuberculosis (28.4%), pneumocystis pneumonia (11.4%), cerebral toxoplasmosis (7.2%) and cryptococcosis (5.5%) were the most frequent AIDS-defining events. Tuberculosis was also the most frequent cause of overall hospitalization. In multivariate analysis, recent HIV diagnosis (aOR = 2.0, 95% CI: 1.0-3.9), CD4<200 cells/mu l (aOR = 4.0, 95% CI: 1.9-8.1), persistent fever (aOR = 4.4, 95%Cl: 2.1-9.0), duration of symptoms >= 6 weeks (aOR = 2.6, 95%Cl: 1.2-5.4) were associated with AIDS-defining events. Overall inpatient mortality was 19.5%. Age >= 55 years (aOR = 4.9, 95%Cl: 1.5-16.6), neurological signs (aOR = 3.2, 95%Cl: 1.5-6.9) and AIDS-defining events (aOR = 2.9, 95%Cl: 1.2-7.2) were associated with inpatient mortality. Conclusions AIDS-defining events were the most frequent cause of hospitalization during the study period. Factors associated with AIDS-defining events mostly reflected delay in HIV diagnosis. Factors associated with mortality were advanced age, neurological signs and AIDS-defining events.	[Raberahona, Mihaja; Andriananja, Volatiana; Randria, Mamy Jean de Dieu] Univ Hosp Antananar, Univ Hosp Joseph Raseta Befelatanana, Infect Dis Unit, Antananarivo, Madagascar; [Razafinambinintsoa, Tiana; Ravololomanana, Njaratiana; Tongavelona, Juliana; Rakotomalala, Rado; Andriamamonjisoa, Johary; Andrianasolo, Radonirina Lazasoa; Randria, Mamy Jean de Dieu] Univ Antananar, Fac Med, Antananarivo, Madagascar; [Tongavelona, Juliana; Rakotoarivele, Rivonirina Andry] Univ Hosp Tambohobe, Infect Dis Unit, Fianarantsoa, Madagascar; [Rakotoarivele, Rivonirina Andry] Univ Fianarantsoa, Fianarantsoa, Madagascar		Raberahona, M (corresponding author), Univ Hosp Antananar, Univ Hosp Joseph Raseta Befelatanana, Infect Dis Unit, Antananarivo, Madagascar.	raberahona@gamil.com		Rakotoarivelo, Rivonirina Andry/0000-0003-3438-8624				Agbor AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115211; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Assen A, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3263-y; Buchacz K, 2008, AIDS, V22, P1345, DOI 10.1097/QAD.0b013e328304b38b; Buve A, 1997, TROP MED INT HEALTH, V2, P136, DOI 10.1046/j.1365-3156.1997.d01-235.x; Chi BH, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001111; Coelho LE, 2017, BRAZ J INFECT DIS, V21, P190, DOI 10.1016/j.bjid.2016.10.007; Druyts EF, 2009, HIV MED, V10, P88, DOI 10.1111/j.1468-1293.2008.00656.x; Falster K, 2010, AIDS, V24, P1329, DOI 10.1097/QAD.0b013e328339e245; Fielden SJ, 2008, AIDS CARE, V20, P297, DOI 10.1080/09540120701561296; Ford N, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20714; Ford N, 2015, LANCET HIV, V2, pE438, DOI 10.1016/S2352-3018(15)00137-X; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2020, SEIZ MOM TACKL ENTR; Kigozi IM, 2009, JAIDS-J ACQ IMM DEF, V52, P280, DOI 10.1097/QAI.0b013e3181ab6eab; Krentz HB, 2004, HIV MED, V5, P93, DOI 10.1111/j.1468-1293.2004.00193.x; Lewden C, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.18797; Luo B, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003802; Mahlab-Guri K, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000006812, 10.1097/md.0000000000006812]; Meintjes G, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002269; Mocroft A, 2004, HIV MED, V5, P437, DOI 10.1111/j.1468-1293.2004.00250.x; Paul S, 2002, AIDS RES HUM RETROV, V18, P501, DOI 10.1089/088922202317406646; Sanders GD, 2005, NEW ENGL J MED, V352, P570, DOI 10.1056/NEJMsa042657; UNAIDS, AMB TREATM TARG HELP; UNAIDS, 2018, COUNTR FACTSH MAD; van der Kop ML, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1500-8; WHO (World Health Organization), 2017, TREAT ALL POL AD IMP; World Health Organisation, 2007, WHO CAS DEF HIV SURV; World Health Organization, 2015, GUID START ANT THER; World Health Organization, 2016, CONS GUID US ANT DRU; World Health Organization, 2016, TUB PROF MAD	30	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2018	13	8							e0203437	10.1371/journal.pone.0203437	http://dx.doi.org/10.1371/journal.pone.0203437			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS2NZ	30161228	gold, Green Published, Green Submitted			2023-01-03	WOS:000443388900126
J	Akombi, BJ; Ghimire, PR; Agho, KE; Renzaho, AM				Akombi, Blessing Jaka; Ghimire, Pramesh Raj; Agho, Kingsley Emwinyore; Renzaho, Andre Masumbuko			Stillbirth in the African Great Lakes region: A pooled analysis of Demographic and Health Surveys	PLOS ONE			English	Article							DEVELOPING-COUNTRIES; MATERNAL SMOKING; PREGNANCY; DETERMINANTS; SURVIVAL; INDIA; COST; RISK; CARE	Background The aim of this study was to estimate the rate and predisposing factors associated with stillbirth in the African Great Lakes region (Burundi, Congo Democratic Republic, Kenya, Rwanda, Tanzania and Uganda). Methods and findings Cross-sectional data from the most recent Demographic and Health Surveys (DHS) of countries in the African Great Lakes region were used in this study. DHS from Congo Democratic Republic was not included in the analyses because data was not collected for stillbirth in the country survey. A pooled sample of 57046 pregnancies of 7+ months' duration and 1002 stillbirths were included in the final analysis. The analyses were restricted to stillbirths reported in the 5 years preceding the surveys. Stillbirth was defined as foetal death in the third trimester (>= 28 weeks' gestation). Multilevel logistic regression analyses that adjusted for cluster and survey weights were used to determine the factors associated with stillbirth in the Africa Great Lakes region. Health service variables and maternal medical condition variables were not included in the analysis because DHS do not collect data on these variables for pregnancies that did not result in a live birth. Burundi had the highest stillbirth rate per 1000 births [23% (95% CI: 20, 25)] within the region. Factors associated with stillbirth across the region were: no schooling [1.85 (95% Cl: 1.44, 2.38)] and primary education [1.64 (1.32, 2.05)], advanced maternal age [2.39 (95% CI: 1.59, 3.59)], smoking [1.99 (95% CI: 1.19, 3.32)] and drinking water from unimproved sources [1.18 (95% CI: 1.01, 1.37)]. Conclusion To achieve Every Newborn Action Plan (ENAP) stillbirth target of 12 per 1000 births or less by 2030, policy interventions to prevent stillbirth should focus on promoting community-based socio-educational programmes which encourages a healthy lifestyle especially among uneducated women in the advanced age spectrum.	[Akombi, Blessing Jaka; Ghimire, Pramesh Raj; Agho, Kingsley Emwinyore] Western Sydney Univ, Sch Sci & Hlth, Penrith, NSW, Australia; [Renzaho, Andre Masumbuko] Western Sydney Univ, Sch Social Sci & Psychol, Penrith, NSW, Australia	Western Sydney University; Western Sydney University	Akombi, BJ (corresponding author), Western Sydney Univ, Sch Sci & Hlth, Penrith, NSW, Australia.	B.Akombi@westernsydney.edu.au	Agho, Kingsley/AAW-5622-2021; Agho, Kingsley/AAE-9971-2020; Akombi-Inyang, Blessing/AAT-6507-2020; Renzaho, Andre M.N./AAH-7679-2021	Agho, Kingsley/0000-0003-4111-3207; Akombi-Inyang, Blessing/0000-0002-6410-4154; Ghimire, Pramesh/0000-0002-7902-7294; RENZAHO, ANDRE/0000-0002-6844-0833; Ghimire, Pramesh Raj/0000-0003-2816-0463				Abir T, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1410048; Afulani PA, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0925-9; Badimsuguru AB, 2016, PAN AFR MED J, V25, DOI 10.11604/pamj.supp.2016.25.1.6168; Bernis L, 2016, LANCET, V387, P703, DOI [10.1016/S0140-6736(15)00954-X, DOI 10.1016/S0140-6736(15)00954-X]; Bhutta ZA, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002364; Bhutta ZA, 2014, LANCET, V384, P347, DOI 10.1016/S0140-6736(14)60792-3; Bhutto ZA, 2011, LANCET, V377, P1523, DOI 10.1016/S0140-6736(10)62269-6; Bjornholt SM, 2016, ACTA OBSTET GYN SCAN, V95, P1305, DOI 10.1111/aogs.13011; BRADLEY S. E. K., 2015, DHS METHODOLOGICAL R, V17; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Chahande M. S., 2002, INDIAN J COMMUNITY M, V27, P106; Chakraborty N, 2003, HLTH PROMOTION INT, V18; Christou A, 2017, TROP MED INT HEALTH, V22, P294, DOI 10.1111/tmi.12828; Di Mario S, 2007, SEX TRANSM DIS, V34, pS11, DOI 10.1097/01.olq.0000258130.07476.e3; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; Froen JF, 2016, LANCET, V387, P574, DOI 10.1016/S0140-6736(15)00818-1; Ghimire PR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181332; Ghosh Banerjee S, TRACKING ACCESS NONS; Giri A, 2012, NEPAL MED COLL J NMC, V15, P87; Goldenberg RL, 2007, ACTA OBSTET GYN SCAN, V86, P1303, DOI 10.1080/00016340701644876; Grossman D.S., 2017, W VIRGINIA U COLL BU, P17; Hogberg L, 2007, BJOG-INT J OBSTET GY, V114, P699, DOI 10.1111/j.1471-0528.2007.01340.x; Kenny LC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056583; Kenya National Bureau of Statistics Ministry of Health National AIDS Control Council Kenya Medical Research Institute, 2015, KEN DEM HLTH SURV 20; Khalil A, 2013, ULTRASOUND OBST GYN, V42, P634, DOI 10.1002/uog.12494; Lawn JE, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-S1-S2; Lean SC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186287; Marufu TC, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1552-5; Ministry of Health Community Development Gender Elderly and Children (MoHCDGEC) Ministry of Health (MoH) National Bureau of Statistics (NBS) Office of the Chief Government Statistician (OCGS) and ICF, 2016, TANZ DEM HLTH SURV M; Ministry to the Presidency in charge of Good Governance and Planning [Burundi] (MPBGP) Ministry of Health Public Health and the Fight against AIDS [Burundi] (MSPLS) Institute of Statistics and Economic Studies of Burundi (ISTEEBU) and ICF, 2017, 3 DEM HLTH SURV; Mosley WH, 1984, POPUL DEV REV, V10, P25, DOI 10.2307/2807954; Mukhopadhyay P, 2010, J HEALTH POPUL NUTR, V28, P494; National Institute of Statistics of Rwanda (NISR) [Rwanda]; Ministry of Health (MOH) [Rwanda]; and ICF International, 2015, RWAND DEM HLTH SURV; Olusanya BO, 2009, ACTA OBSTET GYN SCAN, V88, P1243, DOI 10.3109/00016340903287474; Onadeko M O, 1996, Afr J Med Med Sci, V25, P81; Pattinson R, 2011, LANCET, V377, P1610, DOI 10.1016/S0140-6736(10)62306-9; Philips M, 2004, BRIT J GEN PRACT, V54, P634; Rabe-Hesketh S, 2006, J R STAT SOC A STAT, V169, P805, DOI 10.1111/j.1467-985X.2006.00426.x; Shaikh BT, 2005, J PUBLIC HEALTH-UK, V27, P49, DOI 10.1093/pubmed/fdh207; Sharma A K, 2001, Indian Pediatr, V38, P1405; Stringer EM, 2011, OBSTET GYNECOL, V117, P1151, DOI 10.1097/AOG.0b013e3182167627; Tshibumbu DD, 2016, AFR J PRIM HEALTH CA, V8, DOI 10.4102/phcfm.v8i1.1054; UBOS Icf, 2018, UGANDA DEMOGRAPHIC H; United Nations, 2016, GREAT LAK REG STRAT; USAID, GLOBAL HLTH; Varner MW, 2014, OBSTET GYNECOL, V123, P113, DOI 10.1097/AOG.0000000000000052; WHO/UNICEF, 2014, PROGR DRINK WAT SAN; World Health Organization, 2015, MAT NEWB CHILD AD HL; World Health Organization UNICEF, 2003, ANT CAR DEV COUNTR P	49	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2018	13	8							e0202603	10.1371/journal.pone.0202603	http://dx.doi.org/10.1371/journal.pone.0202603			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR9JD	30157230	Green Submitted, gold, Green Published			2023-01-03	WOS:000443071400065
J	Boehnke, KF				Boehnke, Kevin F.			Pain Management: Assembling a Tool Kit, Building a Life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							FIBROMYALGIA; PATIENT		[Boehnke, Kevin F.] Univ Michigan, Dept Anesthesiol, Sch Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Boehnke, KF (corresponding author), 24 Frank Lloyd Wright Dr, Ann Arbor, MI 48106 USA.	kboehnke@med.umich.edu	Boehnke, Kevin/AAM-9429-2020	Boehnke, Kevin/0000-0003-3696-3979				Bernardy K, 2018, EUR J PAIN, V22, P242, DOI 10.1002/ejp.1121; Boehnke KF, 2017, SCIENCE, V357, P726, DOI 10.1126/science.357.6352.726; Buchbinder R, 2018, LANCET, V391, P2384, DOI 10.1016/S0140-6736(18)30488-4; Chen JH, 2016, JAMA-J AM MED ASSOC, V315, P1701, DOI 10.1001/jama.2016.0221; Choy E, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-102; Hilton L, 2017, ANN BEHAV MED, V51, P199, DOI 10.1007/s12160-016-9844-2; Kligler B, 2018, J GEN INTERN MED, V33, pS16, DOI 10.1007/s11606-018-4323-z; Sullivan MJL, 1995, PSYCHOL ASSESSMENT, V7, P524, DOI 10.1037/1040-3590.7.4.524	8	7	7	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 4	2018	320	21					2201	2202		10.1001/jama.2018.17722	http://dx.doi.org/10.1001/jama.2018.17722			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD4MB	30512103				2023-01-03	WOS:000452500600007
J	Thapa, K; Mohan, D; Williams, E; Rai, C; Bista, S; Mishra, S; Hamal, PK				Thapa, Kusum; Mohan, Diwakar; Williams, Emma; Rai, Chandra; Bista, Sangita; Mishra, Sangeeta; Hamal, Pawan Kumar			Feasibility assessment of an ergonomic baby wrap for kangaroo mother care: A mixed methods study from Nepal	PLOS ONE			English	Article								Background Kangaroo mother care, an evidence based practice and a national policy for management of low birth weight newborns in Nepal, is not widely practiced. This implementation research study aimed to explore the consumer preference and acceptability of the traditional and a new ergonomic wrap on the continuation of kangaroo mother care in the facility and community following discharge. Methods A mixed method feasibility study was done from May to October 2015. Ninety-six families of stable low birth weight newborns weighing 1800 to 2499 grams were counseled and taught to practice kangaroo mother care using both wraps. They were randomized into two groups of 48 with one group trying out the traditional wrap for the first six hours and the new wrap for the next six, and vice versa. Mothers were allowed to choose between the wraps for continuation of kangaroo mother care at the facility and post discharge. They were followed up telephonically weekly over 28 days postpartum to ascertain practice of kangaroo mother care. In-depth interviews with mothers (n = 12) and focus group discussions with health workers (n = 16) further evaluated the intervention. Descriptive statistics are presented for the quantitative part of the study. Results Mothers in the two groups chose the new wrap with no significant difference (81.3% vs 89.6%, p = 0.24). Of the 96 randomized mothers, 85% chose the new wrap. During the hospital stay, six mothers dropped out and remaining 90 mothers who were discharged with the intention of continuing Kangaroo Mother Care, 78 and 12 mothers did so with the new and traditional wrap respectively. New wrap users (429.1 hours, 95% confidence interval [CI]: 351.7-470.3) performed skin-to-skin contact for an extra 77.4 hours overall than wrap (351.7 hours, 95%CI: 259.3-444) users from first day to 28 day postpartum. Health workers and mothers reported positive experience with the new wrap as it was easy to wear without assistance, secure and flexible to move around in kangaroo mother care position. Conclusions Involvement of mothers and families with provision of ergonomic wraps showed improvement in kangaroo mother care practice during hospital stay and at home.	[Thapa, Kusum; Williams, Emma] Jhpiego, Maternal & Child Survival Program, Washington, DC 20036 USA; [Mohan, Diwakar] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Rai, Chandra; Bista, Sangita] Jhpiego Nepal, Oasis Bldg, Kathmandu, Nepal; [Mishra, Sangeeta] Koshi Zonal Hosp, Biratnagar, Nepal; [Hamal, Pawan Kumar] Natl Acad Med Sci, Natl Trauma Ctr, Kathmandu, Nepal	Jhpiego; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Jhpiego	Thapa, K (corresponding author), Jhpiego, Maternal & Child Survival Program, Washington, DC 20036 USA.	Kusum.Thapa@jhpiego.org	mishra, sangeeta/AAA-8943-2022; Mohan, Diwakar/S-2439-2019	Mohan, Diwakar/0000-0002-7532-366X; Williams, Emma/0000-0003-0547-0194; Hamal, Pawan Kumar/0000-0003-4887-3487				Blomqvist YT, 2013, SCAND J CARING SCI, V27, P345, DOI 10.1111/j.1471-6712.2012.01040.x; Boundy EO, 2015, PEDIATRICS, V137, P2015; Chan GJ, 2016, B WORLD HEALTH ORGAN, V94, P130, DOI 10.2471/BLT.15.157818; Charpak N, 2005, ACTA PAEDIATR, V94, P514, DOI 10.1080/08035250510027381; Community-Based Care for Low Birth Weight Newborns, 2008, ROL COMM SKIN TO SKI; CONDEAGUDELO A, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002771; Creswell J.W., 2009, RES DESIGNQUALITATIV, DOI DOI 10.2307/1523157; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Engmann C, 2013, LANCET, V382, pE26, DOI 10.1016/S0140-6736(13)62293-X; Gathwala G, 2010, TROP DOCT, V40, P199, DOI 10.1258/td.2010.090513; Laerdal, CAN MOTH FRIENDL APP; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Ministry of Health and Population (MOHP) [Nepali] New ERA ICF International Inc., 2012, NEP DEM HLTH SURV 20; Ministry of Health Government of Nepal, 2016, NEP EV NEWB ACT PLAN; Moreira Jacqueline de Oliveira, 2009, Psicol. Estud., V14, P475; Nguah SB, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-99; Pervin J, 2015, ACTA PAEDIATR, V104, P458, DOI 10.1111/apa.12929; Peters DH, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6753; Raajashri R, 2018, J MATERN-FETAL NEO M, V31, P666, DOI 10.1080/14767058.2017.1293035; Seidman G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125643; Sharma SR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123962; Singh U, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1252-5; Smith ER, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-016-0769-5; United Nations Inter agency Group for Child Mortality Estimation (UN IGME), 2015, LEV TRENDS CHILD MOR; World Health Organization, SDG 3 ENS HLTH LIV P	25	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2018	13	11							e0207206	10.1371/journal.pone.0207206	http://dx.doi.org/10.1371/journal.pone.0207206			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA4SR	30439998	Green Submitted, Green Published, gold			2023-01-03	WOS:000450254000047
J	Bruhn, WE; Fracica, EA; Makary, MA				Bruhn, William E.; Fracica, Elizabeth A.; Makary, Martin A.			Group Purchasing Organizations, Health Care Costs, and Drug Shortages	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Bruhn, William E.; Makary, Martin A.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; [Fracica, Elizabeth A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Makary, Martin A.] Johns Hopkins Univ, Dept Hlth Policy & Management, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Makary, MA (corresponding author), Johns Hopkins Univ, 600 Wolfe St,Blalock 665, Baltimore, MD 21287 USA.	mmakary1@jhmi.edu	Bruhn, William/AAG-3127-2019	Fracica, Elizabeth/0000-0003-0218-9954				Burns LR, 2014, HOSPITAL SUPP CHAIN; Committee on Oversight and Government Reform, 2012, FDAS CONTRI DRUG S; Healthcare Supply Chain Association, A PRIMER GROUP PURC; Hiltzik M, 2005, LOS ANGELES TIMES; Kohn LT, 2010, GROUP PURCHASING ORG; Litan RE, 2010, HARVARD BUSINESS REV; Litan Robert E, 2011, J Contemp Health Law Policy, V28, P23; Schneller ES, 2009, VALUE GROUP PURC; US Government Accountability Office, 2016, DRUG SHORTAGES CERT	9	14	14	2	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2018	320	18					1859	1860		10.1001/jama.2018.13604	http://dx.doi.org/10.1001/jama.2018.13604			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA1BH	30347037				2023-01-03	WOS:000449945900008
J	Li, T; Du, X; Shewade, HD; Soe, KT; Zhang, H				Li, Tao; Du, Xin; Shewade, Hemant Deepak; Soe, Kyaw Thu; Zhang, Hui			What happens to migrant tuberculosis patients who are transferred out using a web-based system in China?	PLOS ONE			English	Article							PULMONARY TUBERCULOSIS; METAANALYSIS	Background In China, internal migrants constitute one-fifth of tuberculosis (TB) patients registered for treatment in web-based TB information management system (TBIMS). Though China added a specific module in the web-based TBIMS in 2009, web-based transfer-out is not specifically recommended in the national guidelines. Objective In this country wide study among all registered migrant TB patients (2014-2015) that were transferred out using web-based TBIMS in China, to determine the i) timing of transfer-out in relation to period of treatment; ii) delay and attrition during transfer interval (between transfer-out and transfer-in); and iii) extent and risk factors for 'not evaluated' as the treatment outcome. Methods This was a cohort study involving review of web-based TBIMS data. Modified Poisson regression was used to build a predictive model for risk factors of 'not evaluated' as the treatment outcome. Results Among 7 284 patients, 5 900 (81.0%) were transferred out during the first two months after initiation of treatment or before treatment initiation and 7 088 (97.3%) patients had arrived at transfer-in unit. The median transfer interval was three (interquartile range: 0-14) days. Sixteen percent (1 176/7 284) patients had 'not evaluated' as their treatment outcome. 'Not evaluated' contributed to 66% of the unfavourable outcomes. Patients transferred from referral hospitals, migrated from out of prefecture, transferred out of prefecture, with sputum smear negative pulmonary TB, with TB pleurisy and with long delay between symptom onset and treatment initiation had significantly higher risk of 'not evaluated' as the outcome. Conclusion Web-based transfer helped as the delay and attrition during the transfer interval was quite short and treatment outcomes of more than four-fifths of transferred out migrant TB patients were available with transfer-out BMU. Once strategies to address the independent predictors of 'not evaluated' treatment outcome are devised, China may consider mandatory use of web-based TBIMS for transferring out migrant TB patients.	[Li, Tao; Du, Xin; Zhang, Hui] China CDC, Natl Ctr TB Control & Prevent, Beijing, Peoples R China; [Shewade, Hemant Deepak] Int Union TB & Lung Dis Union, South East Asia Off, New Delhi, India; [Shewade, Hemant Deepak] Int Union TB & Lung Dis Union, Paris, France; [Soe, Kyaw Thu] Minist Hlth & Sports, Dept Med Res, Pyin Oo Lwin Branch, Pyin Oo Lwin, Myanmar	Chinese Center for Disease Control & Prevention	Zhang, H (corresponding author), China CDC, Natl Ctr TB Control & Prevent, Beijing, Peoples R China.	zhanghui@chinatb.org		SOE, KYAW THU/0000-0003-0969-8815	Department for International Development (DFID), UK; La Fondation Veuve Emile Metz-Tesch (Luxembourg)	Department for International Development (DFID), UK; La Fondation Veuve Emile Metz-Tesch (Luxembourg)	The author(s) received no specific funding for this work. The training programme and open access publications costs were funded by the Department for International Development (DFID), UK and La Fondation Veuve Emile Metz-Tesch (Luxembourg). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Tomas BA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082440; [Anonymous], 2016, CHINA STAT YB 2015; Arshad S, 2010, EUR RESPIR J, V35, P1336, DOI 10.1183/09031936.00054709; Belayneh Tadesse, 2016, Tuberc Res Treat, V2016, P1294876, DOI 10.1155/2016/1294876; Bozorgmehr K, 2017, EUROSURVEILLANCE, V22, P8, DOI 10.2807/1560-7917.ES.2017.22.12.30491; Chan IHY, 2017, LANCET INFECT DIS, V17, P770, DOI 10.1016/S1473-3099(17)30194-9; Chinese Center for Diseases Control and Prevention, 2015, GLOB FUND TUB PROGR; Dara M, 2017, INT J TUBERC LUNG D, V21, P727, DOI 10.5588/ijtld.16.0940; Ge L, 2007, CHINESE J PUBLIC HEA, V23, P701; Huang F, 2014, J AM MED INFORM ASSN, V21, P938, DOI 10.1136/amiajnl-2013-002001; Jiang S, 2014, CHIN J ANTITUBERC, V36, P798; Jie L, 2011, PREV MED TRIB, V17, P438; Kiwuwa MS, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-122; Li X, 2009, CHIN J ANTITUBERC, V31, P561; Lin ShuFang, 2011, China Tropical Medicine, V11, P1334; Liu X, 2010, CHIN J ANTITUBER, V32, P775; Ministry of Health, 2009, GUID IMPL NAT TUB CO; Scotto Gaetano, 2017, Infez Med, V25, P199; Sreeramareddy CT, 2014, INT J TUBERC LUNG D, V18, P255, DOI 10.5588/ijtld.13.0585; Sun YX, 2016, CHINESE MED J-PEKING, V129, P1856, DOI 10.4103/0366-6999.186650; Takarinda KC, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-981; United Nations Office for Project Services, 2015, PAR SHIFT 2016 2020; White PJ, 2017, LANCET INFECT DIS, V17, P1124, DOI 10.1016/S1473-3099(17)30567-4; WHO, 2012, WHOHTMTB201122; World Health Organization, 2006, STOP TB STRAT BUILD; World Health Organization, 2014, DEF REP FRAM TUB 201; World Health Organization, 2017, WHOHTMTB201723; World Health Organization, 2015, IMPLEMENTING END TB; World Health Organization, 2017, GUIDELINES TREATMENT; World Health Organization Executive Board, 2007, HLTH MIGR MIGR FLOWS; World Health Organization Regional Office for the Western Pacific, 2016, TUB CONTR MIGR POP G; World Health Organization (WHO), 2015, HLTH 2015 MDGS MILL, DOI 10.1007/BF01918387; Zhou Y., 2012, CHIN J DIS CONTR, V16, P874	33	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2018	13	11							e0206580	10.1371/journal.pone.0206580	http://dx.doi.org/10.1371/journal.pone.0206580			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ5ZX	30408131	Green Published, gold, Green Submitted			2023-01-03	WOS:000449512300025
J	Kuhn, P; Kalariya, HM; Poulev, A; Ribnicky, DM; Jaja-Chimedza, A; Roopchand, DE; Raskin, I				Kuhn, Peter; Kalariya, Hetalben M.; Poulev, Alexander; Ribnicky, David M.; Jaja-Chimedza, Asha; Roopchand, Diana E.; Raskin, Ilya			Grape polyphenols reduce gut-localized reactive oxygen species associated with the development of metabolic syndrome in mice	PLOS ONE			English	Article							AKKERMANSIA-MUCINIPHILA; OXIDATIVE STRESS; GASTROINTESTINAL-TRACT; INSULIN SENSITIVITY; PROANTHOCYANIDINS; OBESITY; KINASE; BIOAVAILABILITY; HYPERGLYCEMIA; INFLAMMATION	High-fat diet (HFD)-induced leaky gut syndrome combined with low-grade inflammation increase reactive oxygen species (ROS) in the intestine and may contribute to dysbiosis and metabolic syndrome (MetS). Poorly bioavailable and only partially metabolizable dietary polyphenols, such as proanthocyanidins (PACs), may exert their beneficial effects on metabolic health by scavenging intestinal ROS. To test this hypothesis, we developed and validated a novel, noninvasive, in situ method for visualizing intestinal ROS using orally administered ROS-sensitive indocyanine green (ICG) dye. C57BLJ6J mice fed HFD for 10 weeks accumulated high levels of intestinal ROS compared to mice fed low-fat diet (LFD). Oral administration of poorly bioavailable grape polyphenol extract (GPE) and beta-carotene decreased HFD-induced ROS in the gut to levels comparable to LFD-fed mice, while administration of more bioavailable dietary antioxidants (alpha-lipoic acid, vitamin C, vitamin E) did not. Forty percent of administered GPE antioxidant activity was measured in feces collected over 24 h, confirming poor bioavailability and persistence in the gut. The bloom of beneficial anaerobic gut bacteria, such as Akkermansia muciniphila, associated with improved metabolic status in rodents and humans may be directly linked to protective antioxidant activity of some dietary components. These findings suggest a possible mechanistic explanation for the beneficial effects of poorly bioavailable polyphenols on metabolic health.	[Kuhn, Peter; Kalariya, Hetalben M.; Poulev, Alexander; Ribnicky, David M.; Jaja-Chimedza, Asha; Raskin, Ilya] Rutgers State Univ, Dept Plant Biol, Foran Hall, New Brunswick, NJ 08901 USA; [Roopchand, Diana E.] Rutgers State Univ, Dept Food Sci, Inst Food Nutr & Hlth, Ctr Digest Hlth, New Brunswick, NJ USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Raskin, I (corresponding author), Rutgers State Univ, Dept Plant Biol, Foran Hall, New Brunswick, NJ 08901 USA.	raskin@rutgers.edu		Poulev, Alexander/0000-0003-0939-0642; Raskin, Ilya/0000-0002-3025-8112	National Center for Complementary and Alternative Medicine [R01-AT-008618-01, 1 T32 AT004094]; Office of Dietary Supplements (ODS); NCCIH / ODS [P50-AT-002776-01, K01-AT008829]; National Center for Complementary & Integrative Health [P50AT002776, R01AT008618, K01AT008829] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Office of Dietary Supplements (ODS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCCIH / ODS; National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by R01-AT-008618-01 and 1 T32 AT004094 from the National Center for Complementary and Alternative Medicine to IR and by the Office of Dietary Supplements (ODS); DMR is funded by P50-AT-002776-01 from NCCIH / ODS; DER is funded by K01-AT008829 from NCCIH / ODS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abia R, 2001, J SCI FOOD AGR, V81, P1156, DOI 10.1002/jsfa.924; Anhe FF, 2015, GUT, V64, P872, DOI 10.1136/gutjnl-2014-307142; Bertoia ML, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i17; Burton LJ, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-97; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Choy YY, 2013, J AGR FOOD CHEM, V61, P121, DOI 10.1021/jf301939e; Czank C, 2013, AM J CLIN NUTR, V97, P995, DOI 10.3945/ajcn.112.049247; Daglia M, 2012, CURR OPIN BIOTECH, V23, P174, DOI 10.1016/j.copbio.2011.08.007; Dao MC, 2016, GUT, V65, P426, DOI 10.1136/gutjnl-2014-308778; DAWSON AM, 1965, NATURE, V206, P943, DOI 10.1038/206943b0; de Kort S, 2011, OBES REV, V12, P449, DOI 10.1111/j.1467-789X.2010.00845.x; Espey MG, 2013, FREE RADICAL BIO MED, V55, P130, DOI 10.1016/j.freeradbiomed.2012.10.554; Everard A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/pnas.1219451110; Felgines C, 2010, BRIT J NUTR, V103, P1738, DOI 10.1017/S0007114510000061; Fernandez-Sanchez A, 2011, INT J MOL SCI, V12, P3117, DOI 10.3390/ijms12053117; Forslund K, 2015, NATURE, V528, P262, DOI 10.1038/nature15766; Geurts L, 2014, BENEF MICROBES, V5, P3, DOI 10.3920/BM2012.0065; Gonzalez-Sarrias A, 2017, TRENDS FOOD SCI TECH, V69, P281, DOI 10.1016/j.tifs.2017.07.010; Guariguata L, 2014, DIABETES, V63, pA391; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HAUSER CJ, 1988, J LAB CLIN MED, V112, P68; He GL, 1999, P NATL ACAD SCI USA, V96, P4586, DOI 10.1073/pnas.96.8.4586; Imlay JA, 2013, NAT REV MICROBIOL, V11, P443, DOI 10.1038/nrmicro3032; KESHAVARZIAN A, 1992, GASTROENTEROLOGY, V103, P177, DOI 10.1016/0016-5085(92)91111-G; Kundu K, 2009, ABSTR PAP AM CHEM S, V238, P1; Liang ZC, 2012, J AGR FOOD CHEM, V60, P1291, DOI 10.1021/jf2046637; Liou AP, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005687; Magalotti S, 2013, MOL IMAGING BIOL, V15, P423, DOI 10.1007/s11307-013-0614-2; Masumoto S, 2016, SCI REP-UK, V6, DOI 10.1038/srep31208; Mu QH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00598; Ottman N, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01157; Plovier H, 2017, NAT MED, V23, P107, DOI 10.1038/nm.4236; Prior RL, 2010, J SCI FOOD AGR, V90, P1473, DOI 10.1002/jsfa.3966; Prunty MC, 2015, INVEST OPHTH VIS SCI, V56, P5862, DOI 10.1167/iovs.15-16810; Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3; Roopchand DE, 2015, DIABETES, V64, P2847, DOI 10.2337/db14-1916; Roopchand DE, 2013, PHARMACOL RES, V68, P59, DOI 10.1016/j.phrs.2012.11.008; Roopchand DE, 2012, J AGR FOOD CHEM, V60, P8860, DOI 10.1021/jf300232h; Sadlowski CM, 2017, MOL SYST DES ENG, V2, P191, DOI 10.1039/c7me00014f; Saura-Calixto F, 2007, FOOD CHEM, V101, P492, DOI 10.1016/j.foodchem.2006.02.006; Scalbert A, 2000, J NUTR, V130, p2073S, DOI 10.1093/jn/130.8.2073S; Selma MV, 2009, J AGR FOOD CHEM, V57, P6485, DOI 10.1021/jf902107d; Selvam S, 2011, BIOMATERIALS, V32, P7785, DOI 10.1016/j.biomaterials.2011.07.020; Shin NR, 2014, GUT, V63, P727, DOI 10.1136/gutjnl-2012-303839; Singleton V. L., 1965, AM J ENOL VITICULT, V16; Stull AJ, 2010, J NUTR, V140, P1764, DOI 10.3945/jn.110.125336; Swanson PA, 2011, P NATL ACAD SCI USA, V108, P8803, DOI 10.1073/pnas.1010042108; Takikawa M, 2010, J NUTR, V140, P527, DOI 10.3945/jn.109.118216; Teixeira TFS, 2012, NUTR RES, V32, P637, DOI 10.1016/j.nutres.2012.07.003; Tresserra-Rimbau A, 2016, J NUTR, V146, P767, DOI 10.3945/jn.115.223610; Wang X, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4490; Wentworth CC, 2011, J BIOL CHEM, V286, P38448, DOI 10.1074/jbc.M111.268938; Xu YP, 2011, J AGR FOOD CHEM, V59, P10586, DOI 10.1021/jf202438d; Zhang L, 2018, J NUTR BIOCH	54	30	32	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2018	13	10							e0198716	10.1371/journal.pone.0198716	http://dx.doi.org/10.1371/journal.pone.0198716			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW7TO	30308002	gold, Green Published, Green Submitted			2023-01-03	WOS:000447173500001
J	Lin, PY; Chang, YJ; Chen, YC; Lin, CH; Erkekoglu, P; Chao, MW; Tseng, CY				Lin, Pei-Ying; Chang, Yu-Jung; Chen, Yu-Chen; Lin, Chin-Hung; Erkekoglu, Pinar; Chao, Ming-Wei; Tseng, Chia-Yi			Anti-cancer effects of 3,5-dimethylaminophenol in A549 lung cancer cells	PLOS ONE			English	Article							OXIDATIVE DNA-DAMAGE; CELLULAR-RESPONSE; RISK-FACTORS; STRESS; APOPTOSIS; SMOKING; P53; EPIDEMIOLOGY; GENOTOXICITY; METASTASIS	Exposure to 3,5-dimethylaminophenol (3,5-DMAP), the metabolite of the 3-5-dimethylaniline, was shown to cause high levels of oxidative stress in different cells. The aim of the present work was to observe whether this metabolite can lead to cytotoxicity, oxidative stress, DNA damage and cell cycle changes in non-small cell lung cancer A549 cells. 3,5-DMAP caused a dose-dependent increase in cytotoxicity, generation of superoxide (O-2(-center dot)), inductions in the enzyme activities orchestrating cellular antioxidant balance, increases in lipid peroxidation as well as DNA damage. However, 3,5-DMAP showed significantly lower cytotoxicity towards human lung fibroblast (HLF) cells. 3,5-DMAP also led to molecular events, like inducing apoptotic markers (ie. p53, Bad, Box and cytochrome c); decreasing anti-apoptotic proteins (Bcl-2) and alterations in cell cycle. Our findings indicate that the cytotoxicity caused by this particular alkylaniline metabolite led to initiation of caspase 3-mediated apoptosis. Furthermore, 3,5-DMAP attenuated carcinogenic properties like migration capacity of A549 cells and eventually inhibited growth of A549 cells in an in vivo mouse model. Tumor sections showed that 3,5-DMAP down-regulated c-Myc expression but up-regulated p53 and cytochrome c, all of which might result in tumor growth arrest. Co-treatment with N-acetylcysteine provided reductions in cytotoxicity and positively modulated genetic events induced by 3,5-DMAP in A549 cells. In conclusion, our findings demonstrate 3,5-DMAP may be a potential anti-cancer drug in cancer, due to its self redox cycling properties.	[Lin, Pei-Ying; Chang, Yu-Jung; Lin, Chin-Hung; Chao, Ming-Wei] Chung Yuan Christian Univ, Coll Sci, Dept Biosci Technol, Taoyuan, Taiwan; [Chen, Yu-Chen] Taoyuan Gen Hosp, Dept Radiol, Taoyuan, Taiwan; [Erkekoglu, Pinar] Hacettepe Univ, Fac Pharm, Dept Toxicol, Ankara, Turkey; [Chao, Ming-Wei; Tseng, Chia-Yi] Chung Yuan Christian Univ, Ctr Nanotechnol, Taoyuan, Taiwan; [Tseng, Chia-Yi] Chung Yuan Christian Univ, Coll Engn, Dept Biomed Engn, Taoyuan, Taiwan	Chung Yuan Christian University; Hacettepe University; Chung Yuan Christian University; Chung Yuan Christian University	Tseng, CY (corresponding author), Chung Yuan Christian Univ, Ctr Nanotechnol, Taoyuan, Taiwan.; Tseng, CY (corresponding author), Chung Yuan Christian Univ, Coll Engn, Dept Biomed Engn, Taoyuan, Taiwan.	cytseng@cycu.edu.tw		Chao, Ming-Wei/0000-0002-1574-6425	Ministry of Science and Technology [NSC-102-2320-B-033-001-MY3, NSC-101-2320-B-033-004, MOST-106-2314-B-033-001]; Taoyuan General Hospital in Taiwan [PTH10531]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Taoyuan General Hospital in Taiwan	This work was supported by grants from Ministry of Science and Technology (NSC-102-2320-B-033-001-MY3, NSC-101-2320-B-033-004 and MOST-106-2314-B-033-001) and Taoyuan General Hospital (PTH10531) in Taiwan.	Alberg AJ, 2003, CHEST, V123, p21S, DOI 10.1378/chest.123.1_suppl.21S; Aslani BA, 2016, LIFE SCI, V146, P163, DOI 10.1016/j.lfs.2016.01.014; Chao MW, 2015, J APPL TOXICOL, V35, P466, DOI 10.1002/jat.3046; Chao MW, 2014, TOXICOL SCI, V141, P300, DOI 10.1093/toxsci/kfu127; Chao MW, 2012, TOXICOL SCI, V130, P48, DOI 10.1093/toxsci/kfs229; Chen JH, 2008, TOXICOL SCI, V106, P364, DOI 10.1093/toxsci/kfn195; Cheng XH, 2014, ONCOTARGETS THER, V7, P1689, DOI 10.2147/OTT.S66502; Chou KJ, 2015, EUR ARCH PSY CLIN N, V265, P249, DOI 10.1007/s00406-014-0515-7; Collins LG, 2007, AM FAM PHYSICIAN, V75, P56; DeMarini DM, 2004, MUTAT RES-REV MUTAT, V567, P447, DOI 10.1016/j.mrrev.2004.02.001; Erkekoglu P, 2014, FOOD CHEM TOXICOL, V72, P98, DOI 10.1016/j.fct.2014.06.031; Evans P, 2001, BRIT J NUTR, V85, pS67, DOI 10.1079/BJN2000296; Fidler IJ, 2002, DIFFERENTIATION, V70, P498, DOI 10.1046/j.1432-0436.2002.700904.x; Gan JP, 2004, JNCI-J NATL CANCER I, V96, P1425, DOI 10.1093/jnci/djh274; Gao YT, 1996, LUNG CANCER-J IASLC, V14, pS39, DOI 10.1016/S0169-5002(96)90209-3; Gros L, 2002, ONCOGENE, V21, P8905, DOI 10.1038/sj.onc.1206005; Gustavsson P, 2002, AM J EPIDEMIOL, V155, P1016, DOI 10.1093/aje/155.11.1016; Hamilton W, 2005, THORAX, V60, P1059, DOI 10.1136/thx.2005.045880; Hauptmann M, 2002, AM J IND MED, V41, P89, DOI 10.1002/ajim.10020; Hengstler JG, 2008, ARCH TOXICOL, V82, P271, DOI 10.1007/s00204-008-0305-y; Iyengar P, 2002, SURG ONCOL, V11, P167, DOI 10.1016/S0960-7404(02)00047-6; Kang SW, 2015, INT J CLIN EXP MED, V8, P14647; KASTAN MB, 1991, CANCER RES, V51, P6304; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Langer CJ, 2010, J CLIN ONCOL, V28, P5311, DOI 10.1200/JCO.2010.28.8126; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Mates JM, 2008, ARCH TOXICOL, V82, P273, DOI 10.1007/s00204-008-0304-z; Mates JM, 2012, ARCH TOXICOL, V86, P1649, DOI 10.1007/s00204-012-0906-3; Melis JPM, 2013, ANTIOXID REDOX SIGN, V18, P2409, DOI 10.1089/ars.2012.5036; Minna J, 2008, LIB J, V133; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; Murata M, 2004, CHEM RES TOXICOL, V17, P1750, DOI 10.1021/tx0497550; Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Oral D, 2016, J ENVIRON PATHOL TOX, V35, P43, DOI 10.1615/JEnvironPatholToxicolOncol.2016014200; Pfister DG, 2004, J CLIN ONCOL, V22, P330, DOI 10.1200/JCO.2004.09.053; Program, 2009, CHEM INF PROF ALK; RICHARD MJ, 1992, CLIN CHEM, V38, P704; Risom L, 2005, MUTAT RES-FUND MOL M, V592, P119, DOI 10.1016/j.mrfmmm.2005.06.012; Sanchez-Perez Y, 2009, CANCER LETT, V278, P192, DOI 10.1016/j.canlet.2009.01.010; Skipper PL, 2010, CARCINOGENESIS, V31, P50, DOI 10.1093/carcin/bgp267; Spaans JN, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00190; Spiro SG, 2005, AM J RESP CRIT CARE, V172, P523, DOI 10.1164/rccm.200504-531OE; Svilar D, 2011, ANTIOXID REDOX SIGN, V14, P2491, DOI 10.1089/ars.2010.3466; Valavanidis A, 2008, J ENVIRON SCI HEAL C, V26, P339, DOI 10.1080/10590500802494538; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang TJ, 1996, LUNG CANCER-J IASLC, V14, pS93, DOI 10.1016/S0169-5002(96)90214-7; Ye WJ, 2012, CHEM RES TOXICOL, V25, P2627, DOI 10.1021/tx3004517; Zarogoulidis K, 2013, J THORAC DIS, V5, pS389, DOI 10.3978/j.issn.2072-1439.2013.07.10	50	3	3	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2018	13	10							e0205249	10.1371/journal.pone.0205249	http://dx.doi.org/10.1371/journal.pone.0205249			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW7TO	30307971	gold, Green Submitted, Green Published			2023-01-03	WOS:000447173500051
J	Dey, A; Hay, K; Afroz, B; Chandurkar, D; Singh, K; Dehingia, N; Raj, A; Silverman, JG				Dey, Arnab; Hay, Katherine; Afroz, Bilal; Chandurkar, Dharmendra; Singh, Kultar; Dehingia, Nabamallika; Raj, Anita; Silverman, Jay G.			Understanding intersections of social determinants of maternal healthcare utilization in Uttar Pradesh, India	PLOS ONE			English	Article							INEQUALITIES	Objective To explore intersections of social determinants of maternal healthcare utilization using the Classification and Regression Trees (CART) algorithm which is a machine-learning method used to construct prediction models. Methods Institutional review board approval for this study was granted from Public Health Service- Ethical Review Board (PHS-ERB) and from the Health Ministry Screening Committee (HMSC) facilitated by Indian Council for Medical Research (ICMR). IRB review and approval for the current analyses was obtained from University of California, San Diego. Cross-sectional data were collected from women with children aged 0-11 months (n = 5,565) from rural households in 25 districts of Uttar Pradesh, India. Participants were surveyed on maternal healthcare utilization including registration of pregnancy (model-1), receipt of antenatal care (ANC) during pregnancy (model-2), and delivery at health facilities (model -3). Social determinants of health including wealth, social group, literacy, religion, and early age at marriage were captured during the survey. The Classification and Regression Tree (CART) algorithm was used to explore intersections of social determinants of healthcare utilization. Results CART analyses highlight the intersections, particularly of wealth and literacy, in maternal healthcare utilization in Uttar Pradesh. Model-1 documents that women who are poorer, illiterate and Muslim are less likely to have their pregnancies registered (71.4% vs. 86.0% in the overall sample). Model-2 documents that poorer, illiterate women had the lowest ANC coverage (37.7% vs 45% in the overall sample). Model-3, developed for deliveries at health facilities, highlighted that illiterate and poor women have the lowest representation among facility deliveries (59.6% vs. 69% in the overall sample). Conclusion This paper explores the interactions between determinants of maternal healthcare utilization indicators. The findings in this paper highlights that the interaction of wealth and literacy can play a very strong role in accentuating or diminishing healthcare utilization among women. The study also reveals that religion and women's age at marriage also interact with wealth and literacy to create substantial disparities in utilization. The study provides insights into the effect of intersections of determinants, and highlights the importance of using a more nuanced understanding of the impact of co-occurring forms of marginalization to effectively tackle inequities in healthcare utilization.	[Dey, Arnab; Afroz, Bilal; Chandurkar, Dharmendra; Singh, Kultar; Dehingia, Nabamallika] Sambodhi Res & Commun Pvt Ltd, Noida, India; [Hay, Katherine] Bill & Melinda Gates Fdn, Seattle, WA USA; [Raj, Anita; Silverman, Jay G.] Univ Calif San Diego, Sch Med, Div Global Publ Hlth, Ctr Gender Equ & Hlth, La Jolla, CA 92093 USA	Bill & Melinda Gates Foundation; University of California System; University of California San Diego	Dey, A (corresponding author), Sambodhi Res & Commun Pvt Ltd, Noida, India.	arnab@sambodhi.co.in	Dehingia, Nabamallika/AAY-5588-2021; Dehingia, Nabamallika/AAF-1639-2021; Hay, Katherine/ABB-7795-2021	Dehingia, Nabamallika/0000-0003-1787-9050; Dey, Arnab K./0000-0003-4585-3130	Bill and Melinda Gates Foundation [OPP1083531]; Sambodhi Research and Communications Pvt. Ltd.	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Sambodhi Research and Communications Pvt. Ltd.	This study was funded by the Bill and Melinda Gates Foundation (https://www.gatesfoundation.org/) Grant No. OPP1083531. Sambodhi Research and Communications Pvt. Ltd. provided support in the form of salaries for authors AD, BA, DC, KS and ND but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Ahmed S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011190; Breiman L., 1984, CLASSIFICATION REGRE, DOI [10.2307/2530946, DOI 10.1201/9781315139470]; CALDWELL JC, 1993, SOC SCI MED, V36, P125, DOI 10.1016/0277-9536(93)90204-H; Census of India, 2011, MMR B 2011 2013; Census of India, PRIM CENS ABSTR 2011; Census of India, UTT PRAD REL CENS 20; International Institute of Population Sciences, 2014, NAT FAM HLTH SURV IN; Iyer A, 2008, Glob Public Health, V3 Suppl 1, P13, DOI 10.1080/17441690801892174; Joe W, 2015, MATERNAL MORTALITY I; Joe W, 2015, HEALTH POLICY PLANN, V30, P407, DOI 10.1093/heapol/czu023; Kapilashrami A, 2015, SOC THEOR HEALTH, V13, P288, DOI 10.1057/sth.2015.16; Lemon SC, 2003, ANN BEHAV MED, V26, P172, DOI 10.1207/S15324796ABM2603_02; Montgomery AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083331; Open Working Group, OP WORK GROUP PROP S; Ostlin P, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001115; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Sanneving L, 2013, GLOBAL HEALTH ACTION, V6, P1, DOI 10.3402/gha.v6i0.19145; Sciences IIfP, 2007, IND NAT FAM HLTH SUR; Sen G, 2009, J HUM DEV CAPABIL, V10, P397, DOI 10.1080/19452820903048894; Seth A, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0538-6; Singh PK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031666; Sridharan S, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1287493; SUBBARAO K, 1995, ECON DEV CULT CHANGE, V44, P105, DOI 10.1086/452202; Tan P.-N., 2006, INTRO DATA MINING, P145; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7; Weber L, 2003, ADV GEND RES, V7, P181; World Health Organization, 2015, TRENDS MAT MORT 1990	27	16	16	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2018	13	10							e0204810	10.1371/journal.pone.0204810	http://dx.doi.org/10.1371/journal.pone.0204810			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GV8IQ	30286134	Green Published, Green Submitted, gold			2023-01-03	WOS:000446383500046
J	Angeli, CA; Boakye, M; Morton, RA; Vogt, J; Benton, K; Chen, YS; Ferreira, CK; Harkema, SJ				Angeli, Claudia A.; Boakye, Maxwell; Morton, Rebekah A.; Vogt, Justin; Benton, Kristin; Chen, Yangshen; Ferreira, Christie K.; Harkema, Susan J.			Recovery of Over-Ground Walking after Chronic Motor Complete Spinal Cord Injury	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPIDURAL STIMULATION; LOCOMOTION; PATHWAYS; CAT; PARAPLEGIA; DOPA	Persons with motor complete spinal cord injury, signifying no voluntary movement or sphincter function below the level of injury but including retention of some sensation, do not recover independent walking. We tested intense locomotor treadmill training with weight support and simultaneous spinal cord epidural stimulation in four patients 2.5 to 3.3 years after traumatic spinal injury and after failure to improve with locomotor training alone. Two patients, one with damage to the mid-cervical region and one with damage to the high-thoracic region, achieved over-ground walking (not on a treadmill) after 278 sessions of epidural stimulation and gait training over a period of 85 weeks and 81 sessions over a period of 15 weeks, respectively, and all four achieved independent standing and trunk stability. One patient had a hip fracture during training.	[Angeli, Claudia A.; Morton, Rebekah A.; Vogt, Justin; Benton, Kristin; Harkema, Susan J.] Univ Louisville, Frazier Rehabil Inst, Louisville, KY 40202 USA; [Angeli, Claudia A.; Boakye, Maxwell; Chen, Yangshen; Ferreira, Christie K.; Harkema, Susan J.] Univ Louisville, Kentucky Spinal Cord Injury Res Ctr, 220 Abraham Flexner Way,Suite 1509, Louisville, KY 40202 USA; [Boakye, Maxwell; Morton, Rebekah A.; Vogt, Justin; Benton, Kristin; Chen, Yangshen; Ferreira, Christie K.; Harkema, Susan J.] Univ Louisville, Dept Neurosurg, Sch Med, Louisville, KY 40202 USA	University of Louisville; University of Louisville; University of Louisville	Harkema, SJ (corresponding author), Univ Louisville, Kentucky Spinal Cord Injury Res Ctr, 220 Abraham Flexner Way,Suite 1509, Louisville, KY 40202 USA.	susanharkema@kentuckyonehealth.org		Angeli, Claudia/0000-0003-4127-7121	Leona M. and Harry B. Helmsley Charitable Trust	Leona M. and Harry B. Helmsley Charitable Trust	Funded by the Leona M. and Harry B. Helmsley Charitable Trust and others;ClinicalTrials.gov number, NCT02339233.)	Angeli CA, 2014, BRAIN, V137, P1394, DOI 10.1093/brain/awu038; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; BERGMANS J, 1973, BRAIN RES, V62, P155, DOI 10.1016/0006-8993(73)90625-2; BUDAKOVA N N, 1972, Neuroscience and Behavioral Physiology, V5, P355, DOI 10.1007/BF01183110; CALANCIE B, 1994, BRAIN, V117, P1143, DOI 10.1093/brain/117.5.1143; Courtine G, 2009, NAT NEUROSCI, V12, P1333, DOI 10.1038/nn.2401; Danner SM, 2015, BRAIN, V138, P577, DOI 10.1093/brain/awu372; Dimitrijevic M R, 1988, Adv Neurol, V47, P138; Ditunno PL, 2008, SPINAL CORD, V46, P500, DOI 10.1038/sj.sc.3102172; Dominici N, 2011, SCIENCE, V334, P997, DOI 10.1126/science.1210617; EDGERTON VR, 1992, J NEUROTRAUM, V9, pS119; Gibson C., 2009, ONE DEGREE SEPARATIO; Grahn PJ, 2017, MAYO CLIN PROC, V92, P544, DOI 10.1016/j.mayocp.2017.02.014; Grillner S., 1981, HDB PHYSL NERVOUS SY, VII, P1179; Harkema S, 2011, LANCET, V377, P1938, DOI 10.1016/S0140-6736(11)60547-3; JANKOWSKA E, 1973, BRAIN RES, V53, P227, DOI 10.1016/0006-8993(73)90786-5; JANKOWSKA E, 1967, ACTA PHYSIOL SCAND, V70, P369, DOI 10.1111/j.1748-1716.1967.tb03636.x; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Lavrov I, 2015, BRAIN RES, V1600, P84, DOI 10.1016/j.brainres.2014.11.003; Nadeau S, 2010, NEUROREHAB NEURAL RE, V24, P377, DOI 10.1177/1545968309349945; Rejc E, 2017, J NEUROTRAUM, V34, P1787, DOI 10.1089/neu.2016.4516; Rejc E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133998; Rossignol S, 1996, ACTA NEUROBIOL EXP, V56, P449; SHIK ML, 1976, PHYSIOL REV, V56, P465, DOI 10.1152/physrev.1976.56.3.465; van den Brand R, 2012, SCIENCE, V336, P1182, DOI 10.1126/science.1217416	25	259	267	9	81	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 27	2018	379	13					1244	1250		10.1056/NEJMoa1803588	http://dx.doi.org/10.1056/NEJMoa1803588			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV1KS	30247091	Bronze			2023-01-03	WOS:000445835100009
J	Fujiwara, M; Ando, I; Satoh, K; Shishido, Y; Totsune, K; Sato, H; Imai, Y				Fujiwara, Masako; Ando, Itiro; Satoh, Keisuke; Shishido, You; Totsune, Kazuhito; Sato, Hiroshi; Imai, Yutaka			Biochemical evidence of cell starvation in diabetic hemodialysis patients	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; AMINO-ACID; INSULIN; QUANTIFICATION; METABOLISM; DIAGNOSIS; MELLITUS; MUSCLE	Recently, the ratio of patients with diabetes mellitus (DM) among hemodialysis (HD) patients has increased to become the largest sub-population. Their prognoses are significantly worse than those of patients without diabetes (non-DM). In the present study, 10 DM patients who did not take meals and 10 non-DM patients who took meals during HD sessions were investigated. The time courses of the change in plasma levels of metabolites during HD were determined. DM patients exhibited decreased plasma levels of lactate, pyruvate and alanine and dramatically increased levels of ketone bodies. At the end of HD, the plasma levels of lactate, pyruvate, alanine and ketone body were 0.46 +/- 0.07, 0.026 +/- 0.01, 0.12 +/- 0.04 and 0.26 +/- 0.04 mM (mean +/- standard error), respectively. The profile was 'hypolactatemia and hyperketonemia', indicating non-homeostasis. Glycolysis and tricarboxylic acid cycle were suppressed, and the oxidation of fatty acid was accelerated, indicating starvation, even though high amounts of glucose (150 mg/dl) in dialysate were supplied continuously to the bloodstream. In contrast, the plasma levels of lactate, pyruvate, and alanine in the non-DM patients were increased, with the levels of ketone body remaining low during HD to maintain homeostasis, indicating accelerated glycolysis. Furthermore, their plasma levels of insulin increased from 8.1 +/- 1.4 to 19.8 +/- 3.4 mu U/ml, which indicated endogenous secretion stimulated by glucose in dialysate and meal intake. In contrast, in the DM patients, the levels decreased from 19.2 +/- 3.4 to 5.5 +/- 1.1 mu U/ml. This value was the lower limit of the normal range. The depletion of the insulin through extracorporeal circulation may inhibit the transportation of glucose from the blood into the muscles, with the consequence of cell starvation. Such cell starvation along with lipolysis every two days may accelerate proteolysis and affect the prognosis of DM patients.	[Fujiwara, Masako; Ando, Itiro; Totsune, Kazuhito; Imai, Yutaka] Tohoku Univ, Grad Sch Pharmaceut Sci, Dept Planning Drug Dev & Clin Evaluat, Sendai, Miyagi, Japan; [Satoh, Keisuke] Koujikai Nagamachi Clin, Sendai, Miyagi, Japan; [Shishido, You] Midorinosato Clin, Iwanuma, Miyagi, Japan; [Sato, Hiroshi] Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Clin Pharmacol & Therapeut, Sendai, Miyagi, Japan; [Imai, Yutaka] Tohoku Inst Management Blood Pressure, Sendai, Miyagi, Japan	Tohoku University; Tohoku University	Fujiwara, M (corresponding author), Tohoku Univ, Grad Sch Pharmaceut Sci, Dept Planning Drug Dev & Clin Evaluat, Sendai, Miyagi, Japan.	fmasako@m.tohoku.ac.jp		Fujiwara, Masako/0000-0001-9468-1617	Ministry of Education, Culture, Sports, Science and Technology of Japan [15K15326]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Grants-in-Aids from the Ministry of Education, Culture, Sports, Science and Technology of Japan, 15K15326, H.S. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. * Foundation from the Japanese Association of Dialysis Physicians 2015-9 and 2017-12. M.F. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Two of our authors [KS, YS], are employed by a commercial company: "Koujikai Nagamachi Clinic and Midorinosato Clinic", respectively. These funders provided support in the form of salaries for authors [KS, YS], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe M, 2015, NAT REV NEPHROL, V11, P302, DOI 10.1038/nrneph.2015.38; Abe M, 2011, ARTIF ORGANS, V35, P398, DOI 10.1111/j.1525-1594.2010.01112.x; Ando I, 2013, MAGN RESON MED SCI, V12, P129, DOI 10.2463/mrms.2012-0076; Ando I, 2010, J TOXICOL SCI, V35, P253, DOI 10.2131/jts.35.253; BATES MW, 1968, BIOCHEM J, V110, P655, DOI 10.1042/bj1100655; Berg JM, 2012, BIOCHEMISTRY-US, P534; Bonanni A, 2011, INT J ENV RES PUB HE, V8, P1631, DOI 10.3390/ijerph8051631; Caglar K, 2002, KIDNEY INT, V62, P1408, DOI 10.1111/j.1523-1755.2002.kid556.x; Cahill GF, 2006, ANNU REV NUTR, V26, P1, DOI 10.1146/annurev.nutr.26.061505.111258; Couser WG, 2011, KIDNEY INT, V80, P1258, DOI 10.1038/ki.2011.368; DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; FELIG P, 1977, ARCH INTERN MED, V137, P507, DOI 10.1001/archinte.137.4.507; Fujiwara M, 2015, J PHARMACEUT BIOMED, V111, P159, DOI 10.1016/j.jpba.2015.03.035; Geiyo F, 1986, KIDNEY INT, V30, P385; IKIZLER TA, 1994, KIDNEY INT, V46, P830, DOI 10.1038/ki.1994.339; Ikizler TA, 2002, AM J PHYSIOL-ENDOC M, V282, pE107, DOI 10.1152/ajpendo.2002.282.1.E107; Iwase H, 2001, FORENSIC SCI INT, V115, P123, DOI 10.1016/S0379-0738(00)00298-X; Kallen AJ, 2010, EXPERT REV ANTI-INFE, V8, P643, DOI [10.1586/eri.10.47, 10.1586/ERI.10.47]; Kobayashi S, 2017, ANN VASC DIS, V10, P1, DOI 10.3400/avd.ra.17-00006; Koppel JD, 1973, T AM SOC ARTIF ORG, V13, P309; Kraut JA, 2005, AM J KIDNEY DIS, V45, P978, DOI 10.1053/j.ajkd.2005.03.003; LAIDLAW SA, 1994, AM J KIDNEY DIS, V23, P504, DOI 10.1016/S0272-6386(12)80371-4; Lim VS, 2003, J AM SOC NEPHROL, V14, P2297, DOI 10.1097/01.ASN.0000085590.83005.A0; Mak R. H. K., 1994, DIABETES REV, V2, P19; Masakane I, 2015, THER APHER DIAL, V19, P540, DOI 10.1111/1744-9987.12378; MCGARRY JD, 1972, METABOLISM, V21, P471, DOI 10.1016/0026-0495(72)90059-5; Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957; Schrauwen P, 2008, DIABETOLOGIA, V51, P1694, DOI 10.1007/s00125-008-1069-x; Wang XNH, 2014, NAT REV NEPHROL, V10, P504, DOI 10.1038/nrneph.2014.112	29	6	6	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 27	2018	13	9							e0204406	10.1371/journal.pone.0204406	http://dx.doi.org/10.1371/journal.pone.0204406			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV2HB	30261059	gold, Green Published, Green Submitted			2023-01-03	WOS:000445907400045
J	Seo, MK; Cairns, J				Seo, Mikyung Kelly; Cairns, John			Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer	PLOS ONE			English	Review							HEALTH-CARE-SYSTEM; BEVACIZUMAB PLUS MFOLFOX6; 1ST-LINE TREATMENT; CETUXIMAB PLUS; MONOCLONAL-ANTIBODIES; ECONOMIC-ANALYSIS; SUPPORTIVE CARE; LAST-LINE; KRAS; IRINOTECAN	Background Recent advances in targeted therapies have raised expectations that the clinical application of biomarkers would improve patient's health outcomes and potentially save costs. However, the cost-effectiveness of biomarkers remains unclear irrespective of the cost-effectiveness of corresponding therapies. It is thus important to determine whether biomarkers for targeted therapies provide good value for money. This study systematically reviews economic evaluations of biomarkers for targeted therapies in metastatic colorectal cancer (mCRC) and assesses the cost-effectiveness of predictive biomarkers in mCRC. Methods A literature search was performed using Medline, Embase, EconLit, NHSEED. Papers published from 2000 until June 2018 were searched. All economic evaluations assessing biomarker-guided therapies with companion diagnostics in mCRC were searched. To make studies more comparable, cost-effectiveness results were synthesized as per biomarker tests and corresponding therapies. Methodological quality was assessed using the Quality of Health Economic Studies (QHES) instrument. Results Forty-six studies were included in this review. Of these, 17 studies evaluated the intrinsic value of cancer biomarkers, whereas the remaining studies focused on assessing the cost-effectiveness of corresponding drugs. Most studies indicated favourable cost-effectiveness of biomarkers for targeted therapies in mCRC. Some studies reported that biomarkers were cost-effective, while their corresponding therapies were not cost-effective. A considerable number of economic evaluations were conducted in pre-defined genetic populations and thus, often failed to fully capture the biomarker's clinical and economic values. The average QHES score was 73.6. Conclusion Cancer biomarkers for targeted therapies in mCRC were mostly found to be cost-effective; otherwise, they at least improved the cost-effectiveness of targeted therapies by saving some costs. However, this did not necessarily make their corresponding therapies cost-effective. While companion biomarkers reduced therapy costs, the savings were not sufficient to make the corresponding agents cost-effective. Evaluation of biomarkers was often restricted to the cost of tests and did not consider their clinical values or biomarker prevalence.	[Seo, Mikyung Kelly; Cairns, John] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, Dept Hlth Serv Res & Policy, London, England; [Seo, Mikyung Kelly; Cairns, John] Univ Bergen, Ctr Canc Biomarkers, Fac Med, Bergen, Norway	University of London; London School of Hygiene & Tropical Medicine; University of Bergen	Seo, MK (corresponding author), London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, Dept Hlth Serv Res & Policy, London, England.; Seo, MK (corresponding author), Univ Bergen, Ctr Canc Biomarkers, Fac Med, Bergen, Norway.	kelly.seo@lshtm.ac.uk	Cairns, John/AAD-1168-2020	Cairns, John/0000-0001-6442-0440	Centre for Cancer Biomarkers (CCBIO), Centre of Excellence at the Faculty of Medicine and Dentistry, University of Bergen	Centre for Cancer Biomarkers (CCBIO), Centre of Excellence at the Faculty of Medicine and Dentistry, University of Bergen	MKS received a PhD studentship from Centre for Cancer Biomarkers (CCBIO), Centre of Excellence at the Faculty of Medicine and Dentistry, University of Bergen.	Annemans L, 2007, ACTA CLIN BELG, V62, P419, DOI 10.1179/acb.2007.061; Asseburg C, 2011, CLIN THER, V33, P482, DOI 10.1016/j.clinthera.2011.04.010; BAaS R., 2017, CANC BIOMARKERS ETHI, P25; Behl AS, 2012, JNCI-J NATL CANCER I, V104, P1785, DOI 10.1093/jnci/djs433; Berry K, 2012, J CLIN ONCOL, V30; Blank PR, 2011, CLIN CANCER RES, V17, P6338, DOI 10.1158/1078-0432.CCR-10-2267; Butzke B, 2016, ACTA ONCOL, V55, P318, DOI 10.3109/0284186X.2015.1053983; Carlson JJ, 2010, VALUE HEALTH, V13, pA36, DOI 10.1016/S1098-3015(10)72156-2; Carvalho AC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175409; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chaugule S, 2012, VALUE HEALTH, V15, pA219, DOI 10.1016/j.jval.2012.03.1181; Chiou CF, 2003, MED CARE, V41, P32, DOI 10.1097/00005650-200301000-00007; Ciombor KK, 2018, ONCOLOGIST, V23, P25, DOI 10.1634/theoncologist.2017-0203; Davari M, 2015, INT J PREVENTIVE MED, V6, DOI 10.4103/2008-7802.161068; Deschoolmeester V, 2010, ONCOLOGIST, V15, P699, DOI 10.1634/theoncologist.2010-0025; dos Santos RF, 2015, VALUE HEALTH, V18, pA821, DOI 10.1016/j.jval.2015.09.260; Drummond MF, 2015, METHODS EC EVALUATIO, V4th; Edwards MS, 2012, COLORECTAL DIS, V14, pe31, DOI 10.1111/j.1463-1318.2011.02765.x; Ewara EM, 2014, CURR ONCOL, V21, pE541, DOI 10.3747/co.21.1837; Excellence NIfC, 2013, GUID METH TECHN APPR; Faulkner E, 2012, VALUE HEALTH, V15, P1162, DOI 10.1016/j.jval.2012.05.006; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Frank M, 2013, PHARMACOECONOMICS, V31, P215, DOI 10.1007/s40273-012-0017-2; Gold HT, 2009, CANCER-AM CANCER SOC, V115, P3858, DOI 10.1002/cncr.24428; Graham CN, 2016, CLIN THER, V38, P1376, DOI 10.1016/j.clinthera.2016.03.023; Graham CN, 2014, EUR J CANCER, V50, P2791, DOI 10.1016/j.ejca.2014.08.016; Guglielmo A, 2018, COST EFFECT RESOUR A, V16, DOI 10.1186/s12962-018-0085-z; Harty GT, 2015, VALUE HEALTH, V18, pA456, DOI 10.1016/j.jval.2015.09.1165; Hnoosh A, 2015, VALUE HEALTH, V18, pA454, DOI 10.1016/j.jval.2015.09.1157; Hnoosh A, 2015, VALUE HEALTH, V18, P92, DOI [10.1093/jnci/djp232, DOI 10.1093/JNCI/DJP232]; Holch J, 2016, VISC MED, V32, P178, DOI 10.1159/000446052; Hoyle M, 2013, VALUE HEALTH, V16, P288, DOI 10.1016/j.jval.2012.11.001; Husereau Don, 2013, Cost Eff Resour Alloc, V11, P6, DOI 10.1186/1478-7547-11-6; Huxley N, 2017, HEALTH TECHNOL ASSES, V21, P1, DOI 10.3310/hta21380; Junqueira M, 2015, VALUE HEALTH, V18, pA205, DOI 10.1016/j.jval.2015.03.1190; Junqueira M, 2015, VALUE HEALTH, V18, pA204, DOI 10.1016/j.jval.2015.03.1183; KOURLABA G, 2014, VALUE HEALTH, V17, pA633; Krol M, 2015, VALUE HEALTH, V18, pA464, DOI 10.1016/j.jval.2015.09.1209; Lange A, 2014, EUR J CANCER, V50, P40, DOI 10.1016/j.ejca.2013.08.008; Lawrence Donna, 2013, J Med Econ, V16, P1387, DOI 10.3111/13696998.2013.852097; Linardou H, 2008, LANCET ONCOL, V9, P962, DOI 10.1016/S1470-2045(08)70206-7; Medical Advisory Secretariat, 2010, Ont Health Technol Assess Ser, V10, P1; Michor F, 2005, SEMIN CANCER BIOL, V15, P484, DOI 10.1016/j.semcancer.2005.06.005; Mittmann N, 2009, J NATL CANCER I, V101, P1182, DOI 10.1093/jnci/djp232; Moreno B., 2012, J CLIN ONCOLOGY C S1, V30; National Institute for Health and Care Excellence, 2017, CET PAN PREV UNTR ME; National Institute for Health and Care Excellence, 2018, MAN ADV MET COL CANC; Niedersuess-Beke D, 2015, ANN ONCOL, V26, piv68; Norum J, 2006, J CHEMOTHERAPY, V18, P532, DOI 10.1179/joc.2006.18.5.532; Obradovic M, 2008, PHARMACOGENOMICS, V9, P539, DOI 10.2217/14622416.9.5.539; Ofman Joshua J, 2003, J Manag Care Pharm, V9, P53; Ortendahl JD, 2014, VALUE HEALTH, V17, pA86, DOI 10.1016/j.jval.2014.03.500; Palomaki GE, 2009, GENET MED, V11, P21, DOI 10.1097/GIM.0b013e31818efd77; Pichereau S, 2010, J PHARM PHARM SCI, V13, P615; Riesco-Martinez MC, 2016, J ONCOL PRACT, V12, P574, DOI 10.1200/JOP.2015.008730; Rivera F, 2017, J MED ECON, V20, P574, DOI 10.1080/13696998.2017.1285780; Saito S, 2017, J Cancer Policy, V12, P61, DOI 10.1016/j.jcpo.2017.03.008; Samyshkin Y, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.e16571; Seyfried Thomas N., 2013, Critical Reviews in Oncogenesis, V18, P43; Sforza V, 2016, WORLD J GASTROENTERO, V22, P6345, DOI 10.3748/wjg.v22.i28.6345; Shankaran VO J. D., 2015, AM J CLIN ONCOLOGY C, P22; Shemilt I, 2008, INCORPORATING ECONOM, P449; Shiroiwa T, 2010, MOL DIAGN THER, V14, P375, DOI 10.2165/11587610-000000000-00000; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Souza PV, 2017, VALUE HEALTH, V20, pA875; Starling N, 2007, BRIT J CANCER, V96, P206, DOI 10.1038/sj.bjc.6603561; Stewart B., 2014, WORLD CANC REPORT 20; US Food and Drug Administration, 2018, LIST CLEAR APPR COMP; Vargas-Valencia J, 2015, VALUE HEALTH, V18, P287; Vijayaraghavan A, 2012, INT J CANCER, V131, P438, DOI 10.1002/ijc.26400; Vogelstein B., 2002, GENETIC BASIS HUMAN; Wen F, 2015, CANCER BIOL THER, V16, P1577, DOI 10.1080/15384047.2015.1095398; World Bank, 2016, GDP PER CAP CURR US; Wu B, 2017, ONCOTARGET, V8, P71164, DOI 10.18632/oncotarget.17029; Xu Y, 2016, J CLIN ONCOLOGY C S1, V34; Zhou J, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003762; Zlobec I, 2008, J CLIN PATHOLOGY	77	13	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2018	13	9							e0204496	10.1371/journal.pone.0204496	http://dx.doi.org/10.1371/journal.pone.0204496			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV3NB	30256829	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000446000200049
J	Yan, JK; Zhang, T; Dai, LN; Gu, BL; Zhu, J; Yan, WH; Cai, W; Wang, Y				Yan, Jun-Kai; Zhang, Tian; Dai, Li-Na; Gu, Bei-Lin; Zhu, Jie; Yan, Wei-Hui; Cai, Wei; Wang, Ying			CELF1/p53 axis: a sustained antiproliferative signal leading to villus atrophy under total parenteral nutrition	FASEB JOURNAL			English	Article						IEC proliferation; RNA binding protein	CUG-BINDING PROTEIN-1; EPITHELIAL-CELL PROLIFERATION; MESSENGER-RNA; MOUSE MODEL; DOWN-REGULATION; CACO-2 CELLS; CANCER-CELLS; E-CADHERIN; APOPTOSIS; TRANSLATION	Intestinal villus atrophy is a major complication of total parenteral nutrition (TPN). Our previous study revealed that TPN-induced villus atrophy is accompanied by elevated expression of CUGBP, Elav-like family member 1 (CELF1); however, its mechanism of action has not been fully understood. Herein, we report a pivotal role of CELF1/p53 axis, which induces a sustained antiproliferative signal, leading to suppressed proliferation of intestinal epithelial cells (IECs). By using a rat model of TPN, we found synchronous upregulation of CELF1 and p53 in jejunum mucosa, accompanied by a 51% decrease in crypt cell proliferation rate. By using HCT-116 cells as an IEC model in vitro, we found that the expression of CELF1 altered dynamically in parallel to proliferation rate, suggesting a self-adaptive expression pattern in IECs in vitro. Furthermore, ectopic overexpression of CELF1 elicited a significant antiproliferative effect in HCT-116, Caco-2, and IEC-6 cells, whereas knockdown of CELF1 elicited a significant proproliferative effect. Moreover, cell-cycle assay revealed that ectopic overexpression of CELF1 induced sustained G2 arrest and G1 arrest in HCT-116 and IEC-6 cells, respectively, which could be abolished by p53 silencing. Mechanistically, polysomal profiling and nascent protein analysis revealed that regulation of p53 by CELF1 was mediated through accelerating its protein translation in polysomes. Taken together, our findings revealed a sustained suppression of IEC proliferation evoked by CELF1/p53 axis, which may be a potential therapeutic target for the treatment of TPN-induced villus atrophy.Yan, J.-K., Zhang, T., Dai, L.-N., Gu, B.-L., Zhu, J., Yan, W.-H., Cai, W., Wang, Y. CELF1/p53 axis: a sustained antiproliferative signal leading to villus atrophy under total parenteral nutrition.	[Yan, Jun-Kai; Zhang, Tian; Dai, Li-Na; Gu, Bei-Lin; Zhu, Jie; Yan, Wei-Hui; Cai, Wei; Wang, Ying] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Shanghai, Peoples R China; [Yan, Jun-Kai; Gu, Bei-Lin; Cai, Wei; Wang, Ying] Shanghai Inst Pediat Res, Shanghai Key Lab Pediat Gastroenterol & Nutr, Shanghai, Peoples R China	Shanghai Jiao Tong University	Cai, W; Wang, Y (corresponding author), Shanghai Jiao Tong Univ, Shanghai Inst Pediat Res, Shanghai Key Lab Pediat Gastroenterol & Nutr, Xin Hua Hosp,Sch Med, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.	caiw204@sjtu.edu.cn; wangying02@xinhuamed.com.cn			Shanghai Municipal Commission of Health and Family Planning [20184Y0337]; Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition [17DZ2272000]; National Natural Science Foundation of China [81630039, 81700787]	Shanghai Municipal Commission of Health and Family Planning; Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by Shanghai Municipal Commission of Health and Family Planning (20184Y0337); Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition (17DZ2272000); and National Natural Science Foundation of China [81630039 (to W.C.) and 81700787 (to Y.K.Y.)]. The authors declare no conflicts of interest.	Belcheva A, 2017, BIOESSAYS, V39, DOI 10.1002/bies.201600200; Braga M, 2009, CLIN NUTR, V28, P378, DOI 10.1016/j.clnu.2009.04.002; Breaux M, 2015, MOL CELL BIOL, V35, P3005, DOI 10.1128/MCB.00421-15; BROOK, 1992, CELL, V69, P385; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang ET, 2012, BIOCHEM J, V446, P113, DOI 10.1042/BJ20120112; Cui YH, 2012, MOL BIOL CELL, V23, P151, DOI 10.1091/mbc.E11-05-0456; Dupont A, 2014, GUT MICROBES, V5, P761, DOI 10.4161/19490976.2014.972238; El Kasmi KC, 2012, HEPATOLOGY, V55, P1518, DOI 10.1002/hep.25500; Feng YJ, 2012, AM J PHYSIOL-GASTR L, V302, pG236, DOI 10.1152/ajpgi.00142.2011; Feng YJ, 2010, AM J PHYSIOL-GASTR L, V298, pG833, DOI 10.1152/ajpgi.00030.2010; Feng YJ, 2009, J PHYSIOL-LONDON, V587, P641, DOI 10.1113/jphysiol.2008.162719; Freeman JJ, 2015, FASEB J, V29, P2943, DOI 10.1096/fj.14-269480; Grossmann J, 1998, AM J PATHOL, V153, P53, DOI 10.1016/S0002-9440(10)65545-9; Hansraj NZ, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12858; He C, 2017, GASTROENTEROLOGY, V152, P1434, DOI 10.1053/j.gastro.2017.01.049; Iakova P, 2004, EMBO J, V23, P406, DOI 10.1038/sj.emboj.7600052; Jain AK, 2012, AM J PHYSIOL-GASTR L, V302, pG218, DOI 10.1152/ajpgi.00280.2011; Jones K, 2012, AGEING RES REV, V11, P442, DOI 10.1016/j.arr.2012.02.007; Kim HH, 2008, MOL CELL, V29, P151, DOI 10.1016/j.molcel.2008.01.005; Koukos G, 2013, GASTROENTEROLOGY, V145, P842, DOI 10.1053/j.gastro.2013.07.001; Kress C, 2007, MOL CELL BIOL, V27, P1146, DOI 10.1128/MCB.01009-06; Lee J, 2015, SCI REP-UK, V5, DOI 10.1038/srep18174; Liu JB, 2011, ARCH ANIM NUTR, V65, P376, DOI 10.1080/1745039X.2011.594352; Liu L, 2015, MOL BIOL CELL, V26, P1797, DOI 10.1091/mbc.E14-11-1500; Liu L, 2014, MOL BIOL CELL, V25, P3308, DOI 10.1091/mbc.E14-03-0853; Natarajan G, 2008, AM J PHYSIOL-GASTR L, V294, pG1235, DOI 10.1152/ajpgi.00037.2008; Nightingale J, 2006, GUT S4, V55, piv1, DOI [10.1136/gut.2006.091108, DOI 10.1136/GUT.2006.091108]; Oste M, 2010, BRIT J NUTR, V104, P989, DOI 10.1017/S0007114510001613; Qi LW, 2015, AM J CHINESE MED, V43, P743, DOI 10.1142/S0192415X15500469; Ray RM, 2001, AM J PHYSIOL-GASTR L, V281, pG37, DOI 10.1152/ajpgi.2001.281.1.G37; Ray RM, 1999, AM J PHYSIOL-CELL PH, V276, pC684, DOI 10.1152/ajpcell.1999.276.3.C684; Rowland KJ, 2008, MOL CELL ENDOCRINOL, V288, P63, DOI 10.1016/j.mce.2008.02.014; Sato T, 2013, SCIENCE, V340, P1190, DOI 10.1126/science.1234852; Shalimar, 2013, ARCH PATHOL LAB MED, V137, P1262, DOI 10.5858/arpa.2012-0354-OA; Sofola OA, 2007, NEURON, V55, P565, DOI 10.1016/j.neuron.2007.07.021; Talwar S, 2013, RNA BIOL, V10, P277, DOI 10.4161/rna.23315; Timchenko LT, 2006, J BIOL CHEM, V281, P32806, DOI 10.1074/jbc.M605701200; Timmons Jennifer, 2012, J Gastrointest Dig Syst, V2; Tolhurst Gwen, 2012, Handb Exp Pharmacol, P309, DOI 10.1007/978-3-642-24716-3_14; Vincent A, 2015, STEM CELL RES, V14, P105, DOI 10.1016/j.scr.2014.12.002; Vlasova IA, 2008, RNA BIOL, V5, P201, DOI 10.4161/rna.7056; Wang JY, 2007, AMINO ACIDS, V33, P241, DOI 10.1007/s00726-007-0518-z; Wang J. Y., 2017, WILEY INTERDISCIP RE, V8; Wang XF, 2016, THORAC CANCER, V7, P32, DOI 10.1111/1759-7714.12268; Wu W, 2015, SCI REP-UK, V5, DOI 10.1038/srep10501; Xiao L, 2014, CURR OPIN PHARMACOL, V19, P46, DOI 10.1016/j.coph.2014.07.006; Xiao L, 2011, MOL BIOL CELL, V22, P3055, DOI 10.1091/mbc.E11-01-0069; Xiao WD, 2014, FASEB J, V28, P2073, DOI 10.1096/fj.13-238311; Yan JK, 2018, J CELL MOL MED, V22, P1562, DOI 10.1111/jcmm.13430; Yan JK, 2017, CELL PHYSIOL BIOCHEM, V41, P711, DOI 10.1159/000458430; Yan JK, 2016, CELL PHYSIOL BIOCHEM, V39, P1581, DOI 10.1159/000447860; Yu TX, 2016, AM J PHYSIOL-CELL PH, V310, pC54, DOI 10.1152/ajpcell.00112.2015; Zhou Y, 2014, CELL BIOL INT, V38, P1408, DOI 10.1002/cbin.10356; Zhu J., 2016, JPEN J PARENTER ENTE, V42, P436	55	4	4	4	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2019	33	3					3378	3391		10.1096/fj.201801695R	http://dx.doi.org/10.1096/fj.201801695R			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HM9HS	30514107	Bronze			2023-01-03	WOS:000459794800025
J	Bonanno, AM; Graham, TL; Wilson, LN; Madtson, BM; Ross, JD				Bonanno, Alicia M.; Graham, Todd L.; Wilson, Lauren N.; Madtson, Brianne M.; Ross, James D.			Efficacy of the perfluorocarbon dodecafluoropentane as an adjunct to pre-hospital resuscitation	PLOS ONE			English	Article							ACTIVATION-RELATED PSEUDOALLERGY; COMPLEMENT; LIPOSOMES; TRAUMA; PLASMA; VOLUME; MODEL	Background Hemorrhage is the most common cause of preventable death in the pre-hospital phase in trauma, with a critical capability gap optimizing pre-hospital resuscitation in austere environments. One promising avenue is the concept of a multi-functional resuscitation fluid (MRF) that contains a blood product backbone with agents that promote clotting and enhance oxygen delivery. Oxygen therapeutics, such as hemoglobin based oxygen carriers(HBOCs) and perfluorocarbons(PFCs), may be a critical MRF component. Our purpose was to assess the efficacy of resuscitation with a PFC, dodecafluoropentane(DDFPe), compared to fresh whole blood(FWB). Methods and findings Forty-five swine(78 +/- 5kg) underwent splenectomy and controlled hemorrhage via femoral arterial catheter until shock physiology(lactate = 7.0) was achieved prior to randomization into the following groups: 1) Control-no intervention, 2) Hextend-500mL, 3) FFP-500mL, 4) FFP+DDFPe-500mL, 5) FWB-500mL. Animals were observed for an additional 180 minutes following randomization. Results Baseline physiologic values did not statistically differ. At T = 60min, FWB had significantly decreased lactate(p = 0.001) and DDFPe was not statistically different from control. There was no statistical significance in tissue oxygenation(StO2) between groups at T = 60min. Survival was highest in the FWB and Hextend groups(30% at 180min). Kaplan-Meier analysis showed decreased survival of DDFPe+FFP in comparison to FWB(p<0.05) and was not significantly different from control or FFP. Four animals who received DDFPe died within 10 minutes of administration. This study was limited by a group receiving DDFPe alone, however this would not be feasible in this lethal swine model as DDFPe given its small volume. Conclusion DDFPe administration with FFP does not improve survival or enhance tissue oxygenation. However, given similar survival rates of Hextend and FWB, there is evidence that an ideal MRF should contain an element of volume expansion to enhance oxygen delivery.	[Bonanno, Alicia M.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA; [Graham, Todd L.; Wilson, Lauren N.; Madtson, Brianne M.; Ross, James D.] Oregon Hlth & Sci Univ, Div Trauma & Acute Care Surg, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Ross, JD (corresponding author), Oregon Hlth & Sci Univ, Div Trauma & Acute Care Surg, Portland, OR 97201 USA.	rosja@ohsu.edu		Graham, Todd/0000-0002-2255-6603	Military Health and Research Foundation [SC-15-03 PO 0019]	Military Health and Research Foundation	This work was supported by Military Health and Research Foundation, Grant #SC-15-03 PO 0019, JDR, http://www.militaryhealthresearch.org/.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arthur C, 2015, STROKE, V46; Arthur MC, 2017, MOL NEUROBIOL, V54, P4764, DOI 10.1007/s12035-016-0019-8; Cho SD, 2009, SHOCK, V31, P87, DOI 10.1097/SHK.0b013e3181777ffb; Correas JM, 2001, ULTRASOUND MED BIOL, V27, P565, DOI 10.1016/S0301-5629(00)00363-X; Culp WC, 2015, MOL NEUROBIOL, V52, P979, DOI 10.1007/s12035-015-9243-x; Culp WC, 2012, J VASC INTERV RADIOL, V23, P116, DOI 10.1016/j.jvir.2011.10.001; Fabian TC, 2011, J TRAUMA, V70, pS42, DOI 10.1097/TA.0b013e31821a5a3f; Fergusson DA, 2008, JAMA-J AM MED ASSOC, V299, P2324, DOI 10.1001/jama.299.19.jed80027; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Johnson JLH, 2009, ARTIF CELL BLOOD SUB, V37, P156, DOI 10.1080/10731190903043192; Lee TH, 2013, J TRAUMA ACUTE CARE, V75, P369, DOI 10.1097/TA.0b013e31829bb67c; Lewis CJ, 2006, BLOOD SUBSTITUTES, V77, P325; Sailliol A, 2013, TRANSFUSION S1, V53; Schreiber MA, 2005, CURR OPIN CRIT CARE, V11, P590, DOI 10.1097/01.ccx.0000186374.49320.ab; Sheppard FR, 2017, J TRAUMA ACUTE CARE, V1; Spinella PC, 2008, WORLD J SURG, V32, P2, DOI 10.1007/s00268-007-9201-5; Strom J, 2014, CARDIOVASC DRUG THER, V28, P541, DOI 10.1007/s10557-014-6557-2; Szebeni J, 2005, TOXICOLOGY, V216, P106, DOI 10.1016/j.tox.2005.07.023; Szebeni J, 2001, CRIT REV THER DRUG, V18, P567; Szebeni J, 2012, ADV DRUG DELIVER REV, V64, P1706, DOI 10.1016/j.addr.2012.07.005; Szebeni J, 2011, ADV DRUG DELIVER REV, V63, P1020, DOI 10.1016/j.addr.2011.06.017	22	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2018	13	11							e0207197	10.1371/journal.pone.0207197	http://dx.doi.org/10.1371/journal.pone.0207197			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC4HL	30496190	Green Published, gold, Green Submitted			2023-01-03	WOS:000451763800026
J	Hussain, A; Zaheer, S; Shafique, K				Hussain, Azmina; Zaheer, Sidra; Shafique, Kashif			School-based behavioral intervention to reduce the habit of smokeless tobacco and betel quid use in high-risk youth in Karachi: A randomized controlled trial	PLOS ONE			English	Article							ORAL-CANCER; METAANALYSIS; BIOLOGY; HEALTH	There have been recent surges in the use of smokeless tobacco (SLT) and betel quid (BQ) chew among adolescents in South East Asian countries, with an increase, on average, of 7% to 15% between 2004 and 2013, necessitating interventional investigations to modify this behavior. The current intervention was aimed towards changing adolescents' perceptions regarding the harmful effects of SLT and BQ use and encouraging them to quit. This randomized control trial involved 2140 adolescents from 26 private and public-sector schools in Karachi, Pakistan. After randomization, 1185 individuals were placed in the intervention group and administered a behavior changing intervention (BCI), while 955 individuals constituted the control group. A generalized estimating equation was employed to measure differences in repeated measures for both groups. The beta coefficients were reported after adjusting the covariates with the 95% confidence interval, and the p-value was considered significant at <0.050. Cohen's d was employed to report the effect size of the intervention. The BCI resulted in a 0.176-unit (95% CI 0.078-0.274, p-value <0.001) increase in knowledge scores regarding the health hazards of SLT and BQ, a 0.141-unit (95% CI 0.090-0.192, p-value <0.001) increase in use perception scores, and a 0.067-unit (95% CI 0.006-0.129, p-value 0.031) increase in quit perception scores in the intervention group compared with those in the control group. A knowledge related module (p-value 0.024) and quit preparation module (p-value 0.005) were found to be helpful by adolescents in either changing their perceptions regarding SLT and/or BQ chew use or in quitting. The role of BCI is promising in improving adolescents' knowledge and changing their perceptions in a positive manner regarding their harmful SLT and BQ use. Convincing results may be achieved if interventions are tailored, with an emphasis on the identification of the products that are used by adolescents in addition to highlighting their ill effects and how students may manage to quit them. If included in the schools' curricula, this BCI method may help in developing schools that are free of SLT and BQ use.	[Hussain, Azmina] Dow Univ Hlth Sci, Dr Ishrat Ul Ibad Khan Inst Oral Hlth Sci, Karachi, Pakistan; [Zaheer, Sidra; Shafique, Kashif] Dow Univ Hlth Sci, Sch Publ Hlth, Karachi, Pakistan; [Shafique, Kashif] Univ Glasgow, Inst Hlth & Wellbeing, Publ Hlth, Glasgow, Lanark, Scotland	Dow University of Health Sciences; Dow University of Health Sciences; University of Glasgow	Hussain, A (corresponding author), Dow Univ Hlth Sci, Dr Ishrat Ul Ibad Khan Inst Oral Hlth Sci, Karachi, Pakistan.	azmina.hussain@duhs.edu.pk		Shafique, Kashif/0000-0001-7151-5122; , AZMINA/0000-0001-5244-5333				Ali TS, 2013, INT J BEHAV MED, V20, P131, DOI 10.1007/s12529-011-9201-6; Anwar Shahid, 2005, Prim Dent Care, V12, P5, DOI 10.1308/1355761052894176; Arrazola Rene A, 2017, MMWR Morb Mortal Wkly Rep, V66, P533, DOI 10.15585/mmwr.mm6620a3; Bennett S, 1991, SIMPLIFIED GEN METHO; Biglan A, 2000, TOB CONTROL, V9, P24, DOI 10.1136/tc.9.1.24; Boucher BJ, 2002, ADDICT BIOL, V7, P103, DOI 10.1080/13556210120091464; Cai YD, 2015, CURR BIOINFORM, V10, P3, DOI 10.2174/157489361001150309120940; Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Danaher Brian G, 2015, Internet Interv, V2, P143, DOI 10.1016/j.invent.2015.02.005; Ebbert J, 2011, COCHRANE DATABASE SY, V2; Ebbert JO, 2007, COCHRANE DATABASE SY, V4; Ebbert JO, 2015, INTERVENTIONS SMOKEL; Gansky SA, 2005, J ATHL TRAINING, V40, P76; Gupta PC, 2003, RESPIROLOGY, V8, P419, DOI 10.1046/j.1440-1843.2003.00507.x; Gupta R, 2018, RISK CORONARY HEART; Hussain A, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4916-1; Macy JT, 2016, NICOTINE TOB RES, V18, P186, DOI 10.1093/ntr/ntv070; Mbongwe B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175640; Michie S, 2011, ADDICT BEHAV, V36, P315, DOI 10.1016/j.addbeh.2010.11.016; Moher D, 2001, CONSORT STATEMENT RE; Nair U, 2004, MUTAGENESIS, V19, P251, DOI 10.1093/mutage/geh036; NICE, SMOKL TOB CESS S AS; Organization WH, 2018, CATCH APPR SMOK TOB; Siddiqi K, 2015, NICOTINE TOB RES; Siddiqi K, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3177-8; Siddiqi K, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0424-2; Siddiqi K, 2013, LANCET GLOB HEALTH, V1, pE71, DOI 10.1016/S2214-109X(13)70021-4; Sinha DN, 2016, INT J CANCER, V138, P1368, DOI 10.1002/ijc.29884; Sundquist E, ROLE TUMOR MICROENVI; Thomas RE, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006976; Thomas SJ, 2007, INT J CANCER, V120, P1318, DOI 10.1002/ijc.22304; Walsh MM, 2010, NICOTINE TOB RES, V12, P543, DOI 10.1093/ntr/ntq022; Walsh MM, 1999, AM J PUBLIC HEALTH, V89, P228, DOI 10.2105/AJPH.89.2.228; Walsh MM, 2003, ADDICT BEHAV, V28, P1095, DOI 10.1016/S0306-4603(02)00228-9; Warnakulasuriya S, 2002, ADDICT BIOL, V7, P75, DOI 10.1080/13556210020091428; Warren CW, 2006, LANCET, V367, P749, DOI 10.1016/S0140-6736(06)68192-0; WHO, 2010, GLOBAL YOUTH TOBACCO; Winstock A, 2002, ADDICT BIOL, V7, P133, DOI 10.1080/13556210120091509; Wray JM, 2017, NICOTINE TOBACCO RES; Zhu CD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080482	41	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2018	13	11							e0206919	10.1371/journal.pone.0206919	http://dx.doi.org/10.1371/journal.pone.0206919			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GZ3MD	30388182	Green Published, Green Accepted, gold			2023-01-03	WOS:000449289800070
J	Cai, BY; Zhong, T; Chen, PZ; Fu, J; Jin, YB; Liu, YL; Huang, R; Tan, LJ				Cai, Baoyi; Zhong, Tian; Chen, Peizhou; Fu, Jia; Jin, Yuanbao; Liu, Yinglei; Huang, Ran; Tan, Lianjiang			Preparation, characterization and in vitro release study of drug-loaded sodium carboxy-methylcellulose/chitosan composite sponge	PLOS ONE			English	Article							CHITOSAN; CELLULOSE; ALGINATE; SUBSTITUTION; SCAFFOLDS; HYDROGELS	A sodium carboxy-methylcellulose (CMC)/chitosan (CS) composite sponge as drug carrier was prepared, and its structure and functions were investigated. Samples with different CMC/chitosan ratios and under different pH conditions were synthesized via a freeze-drying method. The microstructure of the dried sponges was analyzed by Scanning Electron Microscope (SEM). Molecule interactions between polymers were confirmed by Fourier transform infrared (FTIR) spectra and Thermal gravimetric analyze (TGA). The swelling degree, weight loss, in vitro drug release behavior and antibacterial property of the sponges were determined as well. The results showed that the CMC/chitosan ratio and the pH value significantly affected the appearance of the blending solution and the microstructure of the final product, and also affected the sponge's degradation behavior, drug-loading capacity and the antibacterial activity. Gentamicin (GEN) as a hydrophilic model drug was remarkably superior to the other two hydrophobic drugs, ibuprofen (IBU) and roxithromycin (ROX), with respect to in vitro releasing. Moreover, higher CMC content and lower pH value of the sponge were confirmed to lead a larger loading for GEN. The bacteriostatic experiment showed a strong antimicrobial ability of GEN-loaded sponges on inhibiting Escherichia coli.	[Cai, Baoyi; Zhong, Tian; Chen, Peizhou; Jin, Yuanbao; Liu, Yinglei] Jilin Univ, Zhuhai Coll, Sch Pharm & Food Sci, Zhuhai, Guangdong, Peoples R China; [Zhong, Tian; Huang, Ran; Tan, Lianjiang] Zhejiang Univ Taizhou, Res Inst, Dept Mat Technol & Engn, Taizhou, Zhejiang, Peoples R China; [Fu, Jia] Jilin Univ, Zhuhai Coll, Sch Hlth, Zhuhai, Guangdong, Peoples R China; [Huang, Ran] Shanghai Jiao Tong Univ, State Key Lab Microbial Metab, Shanghai, Peoples R China; [Huang, Ran] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai, Peoples R China	Jilin University; Taizhou University; Jilin University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhong, T (corresponding author), Jilin Univ, Zhuhai Coll, Sch Pharm & Food Sci, Zhuhai, Guangdong, Peoples R China.; Zhong, T; Huang, R (corresponding author), Zhejiang Univ Taizhou, Res Inst, Dept Mat Technol & Engn, Taizhou, Zhejiang, Peoples R China.; Huang, R (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Microbial Metab, Shanghai, Peoples R China.; Huang, R (corresponding author), Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai, Peoples R China.	zhongtiancc@foxmail.com; ranhuang84@outlook.com	Huang, Ran/AAL-8076-2020	Huang, Ran/0000-0001-7778-0920; Zhong, Tian/0000-0002-8319-9144	National Natural Science Foundation of China [11505110]; China Postdoctoral Science Foundation [2016M591666]; Shanghai Pujiang Talent Grant [16PJ1431900]; Innovation Project by the Education Bureau of Guangdong Province [2016KTSCX175]; Taizhou Municipal Science and Technology Program [1701GY15, 2017CLS01]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Shanghai Pujiang Talent Grant; Innovation Project by the Education Bureau of Guangdong Province; Taizhou Municipal Science and Technology Program	This work was supported by: National Natural Science Foundation of China (Grant No. 11505110) to RH (URL: http://www.nsfc.gov.cn/); China Postdoctoral Science Foundation (Grant No. 2016M591666) to RH (URL: http://jj.chinapostdoctor.org.cn/); Shanghai Pujiang Talent Grant (Grant No. 16PJ1431900) to RH (URL: N/A); Innovation Project by the Education Bureau of Guangdong Province (Grant No. 2016KTSCX175) to TZ (URL: N/A); Taizhou Municipal Science and Technology Program (Grant No. 1701GY15 to RH and 2017CLS01 to LT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Admane P, 2017, INT J PHARMACEUT, V520, P284, DOI 10.1016/j.ijpharm.2017.01.071; Archana D, 2013, CARBOHYD POLYM, V95, P530, DOI 10.1016/j.carbpol.2013.03.034; Archana D, 2013, INT J BIOL MACROMOL, V57, P193, DOI 10.1016/j.ijbiomac.2013.03.002; Archana D., 2013, CHITOSAN PECTIN ALGI; Cai Z, 2009, J APPL POLYM SCI, V114, P288, DOI 10.1002/app.30456; Cai ZJ, 2008, SMART MATER STRUCT, V17, DOI 10.1088/0964-1726/17/3/035028; Chang CY, 2010, CARBOHYD POLYM, V82, P122, DOI 10.1016/j.carbpol.2010.04.033; Chen SC, 2004, J CONTROL RELEASE, V96, P285, DOI 10.1016/j.jconrel.2004.02.002; Choi YS, 1999, BIOMATERIALS, V20, P409, DOI 10.1016/S0142-9612(98)00180-X; Cui WX, 2001, CELL TRANSPLANT, V10, P499; Deng CM, 2007, CARBOHYD POLYM, V69, P583, DOI 10.1016/j.carbpol.2007.01.014; Dubey V, 2005, J MEMBRANE SCI, V251, P131, DOI 10.1016/j.memsci.2004.11.009; Ferro M, 2017, CARBOHYD POLYM, V169, P16, DOI 10.1016/j.carbpol.2017.03.097; Hu SH, 2007, J CONTROL RELEASE, V121, P181, DOI 10.1016/j.jconrel.2007.06.002; Jayakumar R, 2010, CARBOHYD POLYM, V82, P227, DOI 10.1016/j.carbpol.2010.04.074; Klemm D, 2005, ANGEW CHEM INT EDIT, V44, P3358, DOI 10.1002/anie.200460587; Kuhn KD, 2008, J PHARMACEUT BIOMED, V48, P612, DOI 10.1016/j.jpba.2008.05.041; Lai HL, 2003, INT J PHARMACEUT, V251, P175, DOI 10.1016/S0378-5173(02)00590-2; Lee YM, 2000, J PERIODONTOL, V71, P410, DOI 10.1902/jop.2000.71.3.410; Lv FB, 2014, CELLULOSE, V21, P4405, DOI 10.1007/s10570-014-0440-y; Mi FL, 2002, CARBOHYD POLYM, V48, P61, DOI 10.1016/S0144-8617(01)00212-0; Miculescu F, 2017, ACS SUSTAIN CHEM ENG, V5, P8491, DOI 10.1021/acssuschemeng.7b02314; Muhulet A, 2018, MATER TODAY ENERGY, V9, P154, DOI 10.1016/j.mtener.2018.05.002; Nair LS, 2007, PROG POLYM SCI, V32, P762, DOI 10.1016/j.progpolymsci.2007.05.017; Novotna K, 2013, CELLULOSE, V20, P2263, DOI 10.1007/s10570-013-0006-4; Park YJ, 2000, BIOMATERIALS, V21, P153; Risbud MV, 2000, J CONTROL RELEASE, V68, P23, DOI 10.1016/S0168-3659(00)00208-X; SHALABY WSW, 1991, J CONTROL RELEASE, V16, P355, DOI 10.1016/0168-3659(91)90013-4; Thakur S, 2017, VACUUM, V146, P342, DOI 10.1016/j.vacuum.2017.08.011; Thakur VK, 2016, CARBOHYD POLYM, V146, P148, DOI 10.1016/j.carbpol.2016.03.030; Twu YK, 2003, CARBOHYD POLYM, V54, P425, DOI 10.1016/j.carbpol.2003.03.001; Wu YB, 2004, CARBOHYD POLYM, V57, P435, DOI 10.1016/j.carbpol.2004.05.013; Xiong XP, 2010, J MEMBRANE SCI, V363, P96, DOI 10.1016/j.memsci.2010.07.031	33	22	22	3	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 22	2018	13	10							e0206275	10.1371/journal.pone.0206275	http://dx.doi.org/10.1371/journal.pone.0206275			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX7HS	30346976	gold, Green Submitted, Green Published			2023-01-03	WOS:000447938400043
J	Gross, J; Williams, B; Fade, P; Brett, SJ				Gross, Jamie; Williams, Barry; Fade, Premila; Brett, Stephen J.			Intensive care: balancing risk and benefit to facilitate informed decisions	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							QUALITY-OF-LIFE; CRITICAL ILLNESS; FRAILTY; ICU; DISABILITY; MORTALITY; RECOVERY; OUTCOMES; IMPACT; OLDER		[Gross, Jamie; Fade, Premila] London North West Univ Healthcare NHS Trust, Watford Rd, Harrow HA1 3UJ, Middx, England; [Brett, Stephen J.] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Ctr Perioperat Med & Crit Care Res, Du Cane Rd, London W12 0HS, England	Imperial College London	Gross, J (corresponding author), London North West Univ Healthcare NHS Trust, Watford Rd, Harrow HA1 3UJ, Middx, England.	j.gross@nhs.net						Azoulay E, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1887-7; Bagshaw SM, 2014, CAN MED ASSOC J, V186, pE95, DOI 10.1503/cmaj.130639; Bernacki R, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009032; Carey I, 2015, BMJ SUPPORT PALLIAT, V5, P12, DOI 10.1136/bmjspcare-2013-000634; Chamberlain AM, 2016, J AM GERIATR SOC, V64, P285, DOI 10.1111/jgs.13944; Clegg A, 2013, LANCET, V381, P752, DOI 10.1016/S0140-6736(12)62167-9; Cooper C, 2016, AGE AGEING, V45, P148, DOI [10.1093/ageing/afu148, 10.1093/ageing/afv154]; Cuthbertson BH, 2010, CRIT CARE, V14, DOI 10.1186/cc8848; Davidson JE, 2012, CRIT CARE MED, V40, P618, DOI 10.1097/CCM.0b013e318236ebf9; Department of Health, 2008, END LIF CAR STRAT PR; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; Flaatten H, 2017, INTENS CARE MED, V43, P1820, DOI 10.1007/s00134-017-4940-8; Fried TR, 2007, J GEN INTERN MED, V22, P495, DOI 10.1007/s11606-007-0104-9; Griffith DM, 2018, CRIT CARE MED, V46, P594, DOI 10.1097/CCM.0000000000002952; Griffiths J, 2013, CRIT CARE, V17, DOI 10.1186/cc12745; Guidelines for the Provision of Intensive Care Services (GPICS), 2015, JOINT GUID INT CAR S; Herridge Margaret S, 2009, Crit Care Med, V37, pS457, DOI 10.1097/CCM.0b013e3181b6f35c; Heyland DK, 2015, INTENS CARE MED, V41, P1911, DOI 10.1007/s00134-015-4028-2; Institute for Public Policy Research, END LIF CAR ENGL; Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553; Khandelwal N, 2015, CRIT CARE MED, V43, P1102, DOI 10.1097/CCM.0000000000000852; Le Guen J, 2016, AGE AGEING, V45, P303, DOI 10.1093/ageing/afv191; Lone NI, 2016, AM J RESP CRIT CARE, V194, P198, DOI 10.1164/rccm.201511-2234OC; Muscedere J, 2017, INTENS CARE MED, V43, P1105, DOI 10.1007/s00134-017-4867-0; NHS England, 2010, STAT WORK AR CRIT CA; Oeyen SG, 2010, CRIT CARE MED, V38, P2386, DOI 10.1097/CCM.0b013e3181f3dec5; Reade MC, 2014, NEW ENGL J MED, V370, P444, DOI 10.1056/NEJMra1208705; Reay H, 2014, J INTENSIVE CARE SOC, V15, P288, DOI DOI 10.1177/175114371401500405; Scottish Government, REAL MED; Sukantarat KT, 2003, UPD INT CAR, V39, P51; van Oostrom SH, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0595-0; Wade DM, 2015, BRIT J HEALTH PSYCH, V20, P613, DOI 10.1111/bjhp.12109	32	12	12	2	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 19	2018	363								k4135	10.1136/bmj.k4135	http://dx.doi.org/10.1136/bmj.k4135			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY1FS	30341067	Green Published			2023-01-03	WOS:000448271300001
J	Gluck, E; Nguyen, HB; Yalamanchili, K; McCusker, M; Madala, J; Corvino, FA; Zhu, XL; Balk, R				Gluck, Eric; Nguyen, H. Bryant; Yalamanchili, Kishore; McCusker, Margaret; Madala, Jaya; Corvino, Frank A.; Zhu, Xuelian; Balk, Robert			Real-world use of procalcitonin and other biomarkers among sepsis hospitalizations in the United States: A retrospective, observational study	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; C-REACTIVE PROTEIN; SEPTIC SHOCK; LOW LIKELIHOOD; MORTALITY; HOSPITALS; BACTEREMIA; PREDICTION; PNEUMONIA; INFECTION	Background Sepsis management guidelines endorse use of biomarkers to support clinical assessment and treatment decisions in septic patients. The impact of biomarkers on improving patient outcomes remains uncertain. Methods Retrospective observational study of adult sepsis discharges between January 1, 2012, and December 31, 2015, from Premier Healthcare Database hospitals. Sepsis was defined by an All Patients Refined Diagnosis-Related Group code of 720 (septicemia and disseminated infections). Use of four biomarker strategies was evaluated based on hospital records: (i) >1 procalcitonin (PCT), (ii) 1 PCT, (iii) no PCT but >= 1 C-reactive protein (CRP) and/or lactate and (iv) no sepsis biomarkers. Associations between biomarker use and clinical and cost outcomes were examined. The primary outcome was impact of biomarker strategy on hospital costs per day. Results Among 933,591 adult sepsis discharges during the study period, 731,392 (78%) had biomarker tests ordered. In multivariable analyses, discharges with >1 PCT had higher hospital costs per day ($1,904; 95% confidence interval [CI] $1,896-$1,911) compared with discharges with no sepsis biomarkers ($1,606; 95% CI $1,658-$1,664). Discharges with >1 PCT also had greater illness severity and antimicrobial exposure compared with other biomarker-use groups. The adjusted odds of dying during hospital stay compared with being discharged were significantly lower for sepsis discharges with >1 PCT (0.64; 95% CI 0.61-0.67) and 1 PCT (0.88; 95% CI 0.85-0.91) compared with no sepsis biomarker use. The proportion of discharges with >= 1 PCT increased almost six-fold during the study; use of other biomarkers remained constant. Conclusions Between 2012 and 2015, PCT use among sepsis discharges increased six-fold while lactate and CRP use remained unchanged. PCT use was associated with decreased odds of in hospital mortality but increased hospital costs per day. Serial biomarker monitoring may be associated with improved patient outcomes in the most critically ill septic patients.	[Gluck, Eric] Swedish Covenant Med Grp, Chicago, IL USA; [Nguyen, H. Bryant] Loma Linda Univ, Div Pulm Crit Care Hyperbar & Sleep Med, Loma Linda, CA 92350 USA; [Yalamanchili, Kishore] Texas Tech Univ, Hlth Sci Ctr, Amarillo, TX USA; [McCusker, Margaret; Madala, Jaya] Roche Diagnost, Diagnost Informat Solut, Pleasanton, CA USA; [Corvino, Frank A.; Zhu, Xuelian] Genesis Res LLC, Hoboken, NJ USA; [Balk, Robert] Rush Univ, Med Ctr, Chicago, IL 60612 USA	Loma Linda University; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; Roche Holding; Rush University	Balk, R (corresponding author), Rush Univ, Med Ctr, Chicago, IL 60612 USA.	rbalk@rush.edu		Balk, Robert/0000-0001-5757-2649	Roche Diagnostics	Roche Diagnostics	Roche Diagnostics provided financial support for data acquisition and analysis. Support for medical writing assistance was provided by Roche Diagnostics International Ltd. Roche Diagnostics provided salary support for MM and JM, who are employees of Roche Diagnostics. Roche Diagnostics provided financial support for data acquisition through purchase of a license for the Premier Healthcare Database. In addition, Roche Diagnostics provided support for data analysis through a contract with Genesis Research (XZ and FAC are employees of Genesis Research). Other than providing financial support for the aforementioned items, the funder did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Genesis Research LLC provided support in the form of salaries for authors XZ and FAC, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.; The authors would like to thank Jingzi Sherman for her contributions to the study. Support for third-party writing assistance for this manuscript, under the guidance and approval of the authors, was provided by Lucy Carrier of Gardiner-Caldwell Communications, Macclesfield, UK, and was funded by Roche Diagnostics.	Adamik B, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001085; Andriolo BNG, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010959.pub2; [Anonymous], 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19440; Averill RF, 2003, ALL PATIENT REFINED; Balk RA, 2017, CHEST, V151, P23, DOI 10.1016/j.chest.2016.06.046; Baram Daniel, 2008, Clin Med Circ Respirat Pulm Med, V2, P19; Bishop BM, 2014, ANN PHARMACOTHER, V48, P577, DOI 10.1177/1060028014520957; Burnham JP, 2015, CRIT CARE MED, V43, P1580, DOI 10.1097/CCM.0000000000001013; Chu DC, 2017, CLIN INFECT DIS, V64, P1509, DOI 10.1093/cid/cix179; *CTR MED MED SERV, 2015, SEPS BUNDL PROJ SEP; de Jong E, 2016, LANCET INFECT DIS, V16, P819, DOI 10.1016/S1473-3099(16)00053-0; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Dunne WM, 2015, J CLIN MICROBIOL, V53, P2404, DOI 10.1128/JCM.03681-14; Elze MC, 2017, J AM COLL CARDIOL, V69, P345, DOI 10.1016/j.jacc.2016.10.060; Fisher BT, 2014, CLIN INFECT DIS, V58, P74, DOI 10.1093/cid/cit679; Han JH, 2015, ANTIMICROB AGENTS CH, V59, P6494, DOI 10.1128/AAC.00958-15; Hohn A, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-158; HUANG MY, 2016, BIOMED RES INT, V2016, pNIL_0001, DOI DOI 10.1155/2016/1758501; Kelly BJ, 2016, DIAGN MICR INFEC DIS, V85, P109, DOI 10.1016/j.diagmicrobio.2016.01.003; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kojic Dubravka, 2015, World J Exp Med, V5, P50, DOI 10.5493/wjem.v5.i2.50; Liu D, 2016, RESPIROLOGY, V21, P280, DOI 10.1111/resp.12704; Liu Y, 2013, P 59 WORLD STAT C AU; Magrini L, 2014, CLIN CHEM LAB MED, V52, P1465, DOI 10.1515/cclm-2014-0210; Malehi AS, 2015, HEALTH ECON REV, V5, DOI 10.1186/s13561-015-0045-7; Maseda E, 2015, J CRIT CARE, V30, P537, DOI 10.1016/j.jcrc.2014.12.014; Okere AN, 2015, ANN PHARMACOTHER, V49, P1273, DOI 10.1177/1060028015603072; Oliveira CF, 2013, CRIT CARE MED, V41, P2336, DOI 10.1097/CCM.0b013e31828e969f; Pierrakos C, 2010, CRIT CARE, V14, DOI 10.1186/cc8872; Pirson M, 2008, J HOSP INFECT, V68, P9, DOI 10.1016/j.jhin.2007.10.006; Reed HL, 2014, AM J MED QUAL, V29, P315, DOI 10.1177/1062860613496452; Reinhart K, 2012, CLIN MICROBIOL REV, V25, P609, DOI 10.1128/CMR.00016-12; Rhee C, 2017, JAMA-J AM MED ASSOC, V318, P1241, DOI 10.1001/jama.2017.13836; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Romano PS, 2000, HEALTH SERV RES, V34, P1469; Ryu JA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138150; Scerbo MH, 2016, SURG INFECT, V17, P294, DOI 10.1089/sur.2015.099; Schuetz P, 2017, CRIT CARE MED, V45, P781, DOI [10.1097/CCM.0000000000002321, 10.1097/ccm.0000000000002321]; Schuetz P, 2013, CRIT CARE, V17, DOI 10.1186/cc12787; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Suarez-de-la-Rica A, 2015, SURG INFECT, V16, P346, DOI 10.1089/sur.2014.178; US Department of Labor Bureau of Labor Statistics, DAT TABL CALC SUBJ; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Zhang ZH, 2014, CRIT CARE MED, V42, P2118, DOI 10.1097/CCM.0000000000000405	44	15	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 17	2018	13	10							e0205924	10.1371/journal.pone.0205924	http://dx.doi.org/10.1371/journal.pone.0205924			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX3PM	30332466	Green Published, gold, Green Submitted			2023-01-03	WOS:000447638200077
J	Vetreno, RP; Crews, FT				Vetreno, Ryan P.; Crews, Fulton T.			Adolescent binge ethanol-induced loss of basal forebrain cholinergic neurons and neuroimmune activation are prevented by exercise and indomethacin	PLOS ONE			English	Article							NERVE GROWTH-FACTOR; NF-KAPPA-B; POSTNATAL-DEVELOPMENT; GENE-EXPRESSION; CHRONIC NEUROINFLAMMATION; HIPPOCAMPAL-FORMATION; RAT HIPPOCAMPUS; NUCLEUS BASALIS; DIAGONAL BAND; ADULT	Basal forebrain cholinergic neurons mature in adolescence coinciding with development of adult cognitive function. Preclinical studies using the rodent model of adolescent intermittent ethanol (AIE; 5.0 g/kg, i.g., 2-days on/2-days off from postnatal day [P] 25 to P55) reveal persistent increases of brain neuroimmune genes that are associated with cognitive dysfunction. Adolescent intermittent ethanol exposure also reduces basal forebrain expression of choline acetyltransferase (ChAT), an enzyme critical for acetylcholine synthesis in cholinergic neurons similar to findings in the post-mortem human alcoholic basal forebrain. We report here that AIE decreases basal forebrain ChAT+IR neurons in both adult female and male Wistar rats following early or late adolescent ethanol exposure. In addition, we find reductions in ChAT+IR somal size as well as the expression of the high-affinity nerve growth factor (NGF) receptor tropomyosin receptor kinase A (TrkA) and the low-affinity NGF receptor p75(NTR), both of which are expressed on cholinergic neurons. The decrease in cholinergic neuron marker expression was accompanied by increased phosphorylation of NF-kappa B p65 (pNF-kappa B p65) consistent with increased neuroimmune signaling. Voluntary wheel running from P24 to P80 prevented AIE-induced cholinergic neuron shrinkage and loss of cholinergic neuron markers (i.e., ChAT, TrkA, and p75(NTR)) as well as the increase of pNF-kappa B p65 in the adult basal forebrain. Administration of the anti-inflammatory drug indomethacin (4.0 mg/kg, i.p prior to each ethanol exposure) during AIE also prevented the loss of basal forebrain cholinergic markers and the concomitant increase of pNF-kappa B p65. In contrast, treatment with the proinflammatory immune activator lipopolysaccharide (1.0 mg/kg, i.p. on P70) caused a loss of cholinergic neuron markers that was paralleled by increased pNF-kappa B p65 in the basal forebrain. These novel findings are consistent with AIE causing lasting activation of the neuroimmune system that contributes to the persistent loss of basal forebrain cholinergic neurons in adulthood.	[Vetreno, Ryan P.; Crews, Fulton T.] Univ North Carolina Chapel Hill, Sch Med, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Vetreno, RP (corresponding author), Univ North Carolina Chapel Hill, Sch Med, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA.	rvetreno@email.unc.edu	Crews, Fulton/T-1181-2019	Crews, Fulton/0000-0003-2393-4976; Vetreno, Ryan/0000-0003-0449-395X	National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism [AA019767, AA011605, AA007573, AA021040]; Neurobiology of Adolescent Drinking in Adulthood (NADIA) [AA020023, AA020024, AA020022]; Bowles Center for Alcohol Studies; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [U54AA019767, U01AA020023, U24AA020024, P60AA011605] Funding Source: NIH RePORTER	National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Neurobiology of Adolescent Drinking in Adulthood (NADIA); Bowles Center for Alcohol Studies; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This work was supported in part by the National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism (AA019767, AA011605, AA007573, and AA021040), the Neurobiology of Adolescent Drinking in Adulthood (NADIA [AA020023, AA020024, and AA020022]), and the Bowles Center for Alcohol Studies. The NIH, NIAAA, NADIA, and Bowles Center for Alcohol Studies had no further role in the study design, data collection, analysis, and interpretation of data, writing of the report, or decision to submit the article for publication.	Alfonso-Loeches S, 2011, CRIT REV CL LAB SCI, V48, P19, DOI 10.3109/10408363.2011.580567; Ang ET, 2004, NEUROSCIENCE, V129, P337, DOI 10.1016/j.neuroscience.2004.06.087; Ang ET, 2003, NEUROSCIENCE, V118, P335, DOI 10.1016/S0306-4522(02)00989-2; ARENDT T, 1995, NEUROSCIENCE, V65, P633, DOI 10.1016/0306-4522(94)00526-B; ARMSTRONG DM, 1987, J COMP NEUROL, V264, P421, DOI 10.1002/cne.902640309; Ballinger EC, 2016, NEURON, V91, P1199, DOI 10.1016/j.neuron.2016.09.006; Banuelos C, 2013, NEUROBIOL AGING, V34, P845, DOI 10.1016/j.neurobiolaging.2012.06.013; Baxter MG, 1999, CURR OPIN NEUROBIOL, V9, P178, DOI 10.1016/S0959-4388(99)80024-5; Blake MG, 2018, CURR TOP BEHAV NEURO, V37, P253, DOI 10.1007/7854_2016_467; Boissiere F, 1997, NEUROREPORT, V8, P2849, DOI 10.1097/00001756-199709080-00009; Boutros N, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyu003; Broadwater M, 2013, BEHAV BRAIN RES, V256, P10, DOI 10.1016/j.bbr.2013.08.013; Chomczynski P, 2006, NAT PROTOC, V1, P581, DOI 10.1038/nprot.2006.83; Coleman LG, 2011, ALCOHOL CLIN EXP RES, V35, P671, DOI 10.1111/j.1530-0277.2010.01385.x; Crews FT, 2004, ALCOHOL CLIN EXP RES, V28, P350, DOI 10.1097/01.ALC.0000113416.65546.01; Crews FT, 2004, ALCOHOL, V33, P63, DOI 10.1016/j.alcohol.2004.04.005; Crews F, 2007, PHARMACOL BIOCHEM BE, V86, P189, DOI 10.1016/j.pbb.2006.12.001; Crews F, 2006, ALCOHOL CLIN EXP RES, V30, P1938, DOI 10.1111/j.1530-0277.2006.00239.x; Crews FT, 2017, PSYCHOPHARMACOLOGY, V234, P1483, DOI 10.1007/s00213-017-4560-6; Crews FT, 2016, PHARMACOL REV, V68, P1074, DOI 10.1124/pr.115.012138; Crews FT, 2016, PSYCHOPHARMACOLOGY, V233, P1543, DOI 10.1007/s00213-015-3906-1; DINOPOULOS A, 1992, DEV BRAIN RES, V65, P65, DOI 10.1016/0165-3806(92)90009-L; Ehlers CL, 2011, NEUROSCIENCE, V199, P333, DOI 10.1016/j.neuroscience.2011.10.011; Fernandez GM, 2017, NEUROSCIENCE, V361, P129, DOI 10.1016/j.neuroscience.2017.08.013; Gibbs RB, 1998, EXP NEUROL, V151, P289, DOI 10.1006/exnr.1998.6789; GOULD E, 1989, DEV BRAIN RES, V46, P297, DOI 10.1016/0165-3806(89)90293-9; GOULD E, 1991, BRAIN RES BULL, V27, P767, DOI 10.1016/0361-9230(91)90209-3; Guan ZW, 2006, BRAIN BEHAV IMMUN, V20, P64, DOI 10.1016/j.bbi.2005.04.005; Guo KH, 2014, INT J DEV NEUROSCI, V35, P72, DOI 10.1016/j.ijdevneu.2014.03.004; Hall JM, 2016, EXP NEUROL, V278, P62, DOI 10.1016/j.expneurol.2016.01.018; HIGGINS GA, 1989, EXP NEUROL, V106, P222, DOI 10.1016/0014-4886(89)90155-6; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Isaev NK, 2017, BIOCHEMISTRY-MOSCOW+, V82, P291, DOI 10.1134/S0006297917030075; Johnston LD, 2013, MONITORING THE FUTUR; KORSCHING S, 1986, NEUROSCI LETT, V66, P175, DOI 10.1016/0304-3940(86)90186-2; Lazo OM, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-5; Leasure JL, 2009, HIPPOCAMPUS, V19, P907, DOI 10.1002/hipo.20563; LEHERICY S, 1993, J COMP NEUROL, V330, P15, DOI 10.1002/cne.903300103; LINKE R, 1993, J COMP NEUROL, V332, P69, DOI 10.1002/cne.903320106; MATTHEWS DA, 1974, DEV BIOL, V36, P130, DOI 10.1016/0012-1606(74)90196-1; MCMILLIAN M, 1995, BIOCHEM BIOPH RES CO, V215, P572, DOI 10.1006/bbrc.1995.2503; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; Miller R, 2002, BRAIN RES, V950, P137, DOI 10.1016/S0006-8993(02)03014-7; Montesinos J, 2016, BRAIN BEHAV IMMUN, V53, P159, DOI 10.1016/j.bbi.2015.12.006; Mufson EJ, 1996, NEUROREPORT, V8, P25, DOI 10.1097/00001756-199612200-00006; NADLER JV, 1974, DEV BIOL, V36, P142, DOI 10.1016/0012-1606(74)90197-3; Nagahara AH, 2009, EXP NEUROL, V215, P153, DOI 10.1016/j.expneurol.2008.10.004; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pascual M, 2007, EUR J NEUROSCI, V25, P541, DOI 10.1111/j.1460-9568.2006.05298.x; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Peterson DA, 1999, J COMP NEUROL, V404, P1, DOI 10.1002/(SICI)1096-9861(19990201)404:1<1::AID-CNE1>3.0.CO;2-#; Richwine AF, 2008, PSYCHONEUROENDOCRINO, V33, P1369, DOI 10.1016/j.psyneuen.2008.08.003; SOBREVIELA T, 1994, J COMP NEUROL, V350, P587, DOI 10.1002/cne.903500407; Spear LP, 2009, BEHAV NEUROSCIENCE A; Stranahan AM, 2006, NAT NEUROSCI, V9, P526, DOI 10.1038/nn1668; Sung S, 2004, AM J PATHOL, V165, P2197, DOI 10.1016/S0002-9440(10)63269-5; Swartzwelder HS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140042; ToliverKinsky T, 1997, J NEUROSCI RES, V48, P580, DOI 10.1002/(SICI)1097-4547(19970615)48:6<580::AID-JNR11>3.0.CO;2-Z; Unal CT, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00021; Vetreno RP, 2012, NEUROSCIENCE, V226, P475, DOI 10.1016/j.neuroscience.2012.08.046; Vetreno RP, FRONTIERS NEUROSCIEN; Vetreno RP, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00200; Vetreno RP, 2017, BRAIN BEHAV IMMUN, V60, P333, DOI 10.1016/j.bbi.2016.09.018; Vetreno RP, 2016, ADDICT BIOL, V21, P939, DOI 10.1111/adb.12232; Vetreno RP, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00035; Vetreno RP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113421; Vetreno RP, 2013, NEUROBIOL DIS, V59, P52, DOI 10.1016/j.nbd.2013.07.002; Wenk GL, 2003, NEUROSCIENCE, V121, P719, DOI 10.1016/S0306-4522(03)00545-1; White AM, 2006, ALCOHOL CLIN EXP RES, V30, P1006, DOI 10.1111/j.1530-0277.2006.00122.x; Willard LB, 2000, EXP BRAIN RES, V134, P58, DOI 10.1007/s002210000446; Willard LB, 1999, NEUROSCIENCE, V88, P193; Wu CK, 2005, EXP NEUROL, V195, P484, DOI 10.1016/j.expneurol.2005.06.020; ZAHALKA EA, 1993, BRAIN RES, V601, P221, DOI 10.1016/0006-8993(93)91714-4	73	38	38	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 8	2018	13	10							e0204500	10.1371/journal.pone.0204500	http://dx.doi.org/10.1371/journal.pone.0204500			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW1KF	30296276	Green Submitted, gold, Green Published			2023-01-03	WOS:000446632700012
J	Schifano, F; Chiappini, S				Schifano, Fabrizio; Chiappini, Stefania			Is there such a thing as a 'lope' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports	PLOS ONE			English	Article							P-GLYCOPROTEIN; CARDIAC DYSRHYTHMIAS; ABUSE; MISUSE; DRUG; CARDIOMYOPATHY; INHIBITION; MEDICATION; TRENDS	Background Among over-the-counter (OTC) drugs, loperamide has recently emerged for its potential of misuse and cardiotoxicity issues. Hence, we aimed here at assessing the loperamiderelated cases being reported to the EMA's EudraVigilance (EV) database. Methods All spontaneous EV reports relating to loperamide misuse/abuse/dependence/withdrawal and cardiotoxicity issues were here retrieved, performing a descriptive analysis. Findings During the years 2005-2017, EV collected a number of 1,983 (out of a total of 7,895; 25.11%) loperamide-related misuse/abuse/dependence/withdrawal adverse drug reaction (ADR) reports, with a progressively increasing trend since 2014. Most cases were classified as drug use disorder (37.4%) or intentional overdose (25.4%). Loperamide was used on its own in 41.9% of cases; remaining, polydrug, cases included antidepressants; benzodiazepines; and other OTCs. Some 1,085 (1,085/7,895 = 13.7%) cardiovascular ADRs were reported, being conduction abnormalities and EKG alterations the most frequently identified. Conclusions EV data may support the levels of concern relating to loperamide potential of abuse and associated cardiotoxicity issues.	[Schifano, Fabrizio; Chiappini, Stefania] Univ Hertfordshire, Sch Life & Med Sci, Psychopharmacol Drug Misuse & Novel Psychoact Sub, Hatfield, Herts, England; [Chiappini, Stefania] Casa Cura Villa Rosa, Viterbo, VT, Italy	University of Hertfordshire	Chiappini, S (corresponding author), Univ Hertfordshire, Sch Life & Med Sci, Psychopharmacol Drug Misuse & Novel Psychoact Sub, Hatfield, Herts, England.; Chiappini, S (corresponding author), Casa Cura Villa Rosa, Viterbo, VT, Italy.	stefaniachiappini9@gmail.com	CHIAPPINI, STEFANIA/ABC-3831-2020	CHIAPPINI, STEFANIA/0000-0002-6810-1540; Schifano, Fabrizio/0000-0002-4178-5401				Akel T, 2018, ANN NONINVAS ELECTRO, V23, DOI 10.1111/anec.12505; Amin ML, 2013, DRUG TARGET INSIGHT, V7, P27, DOI 10.4137/DTI.S12519; [Anonymous], 2012, GREY PAGES MERITS HI; [Anonymous], 2016, NY TIMES; Baker DE, 2007, REV GASTROENTEROL DI, V7, pS11; Bhatti Z, 2017, CLIN TOXICOL, V55, P659, DOI 10.1080/15563650.2017.1304555; Bishop-Freeman SC, 2016, J ANAL TOXICOL, V40, P677, DOI 10.1093/jat/bkw069; Bluelight.org, LOP; Borron SW, 2017, J EMERG MED, V53, P73, DOI 10.1016/j.jemermed.2017.03.018; CHURCH J, 1994, MOL PHARMACOL, V45, P747; Cooper RJ, 2013, J SUBST USE, V18, P82, DOI 10.3109/14659891.2011.615002; Council of Europe, 2014, AG MED PROD MED DEV; Daniulaityte R, 2013, DRUG ALCOHOL DEPEN, V130, P241, DOI 10.1016/j.drugalcdep.2012.11.003; Drugs-forum, LOP; Eggleston W, 2016, MMWR-MORBID MORTAL W, V65, P1276, DOI 10.15585/mmwr.mm6545a7; Eggleston W, 2017, ANN EMERG MED, V69, P83, DOI 10.1016/j.annemergmed.2016.03.047; Eggleston W, 2015, CLIN TOXICOL, V53, P495, DOI 10.3109/15563650.2015.1026971; Eichenberg C, 2017, GESUNDHEITSWESEN, V79, P80, DOI 10.1055/s-0035-1549970; Enakpene EO, 2015, AM J MED, V128, P1083, DOI 10.1016/j.amjmed.2015.05.019; Erowid, 2016, LOP; Erowid, 2010, WOULDNT SAY THIS IS; Erowid, 2007, ABS AW LOP; Erowid, 2014, MY NEW FAV OTC HIGH; Erowid, 2012, REC WITHDR; EudraVigilance, EUR DAT SUSP ADV DRU; European Medicines Agency (EMA), 2015, BUYING MED ONL; Finch M., 2015, USE LOPERAMIDE OPIAT; Finkelstein Y, 2017, PEDIATR EMERG CARE, V33, P451, DOI 10.1097/PEC.0000000000000571; Food and Drug Administration, 2018, PUBL DASHB; Food and Drug Administration (FDA), 2016, IM LAB; Fox N, 2005, SOC SCI MED, V61, P1474, DOI 10.1016/j.socscimed.2005.03.011; Heads of Medicines Agencies (HMA) European Medicines Agency (EMA), 2017, GUID GOOD PHARM PRAC; JAFFE JH, 1980, CLIN PHARMACOL THER, V28, P812, DOI 10.1038/clpt.1980.239; Kang JS, 2016, N-S ARCH PHARMACOL, V389, P1133, DOI 10.1007/s00210-016-1286-7; Karami S., 2017, CLIN TOXICOL, V20, P1; Kozak PM, 2017, J ELECTROCARDIOL, V50, P355, DOI 10.1016/j.jelectrocard.2017.01.011; Lasoff DR, 2017, PHARMACOTHERAPY, V37, P249, DOI 10.1002/phar.1885; Le V.T., 2016, J AM COLL HEALTH, V16, P1; Leo RJ, 2017, J ADDICT MED, V11, P402, DOI 10.1097/ADM.0000000000000325; Levine DA, 2007, CURR OPIN PEDIATR, V19, P270, DOI 10.1097/MOP.0b013e32814b09cf; MacDonald R., 2015, BMJ CASE REP; Manchikanti Laxmaiah, 2006, Pain Physician, V9, P287; Marraffa JM, 2014, CLIN TOXICOL, V52, P952, DOI 10.3109/15563650.2014.969371; MedDRA, 2017, INTR GUID VERS 20 1; MedDRA, 2017, INTR GUID STAND MEDD; Medicines and Healthcare products Regulatory Agency (MHRA), 2018, YELL CARD SCHEM LOP; Miller H, 2017, J AM PHARM ASSOC, V57, pS45, DOI 10.1016/j.japh.2016.12.079; Mukarram O, 2016, CASE REP MED, V2016, DOI 10.1155/2016/4061980; National Association of Boards of Pharmacy (NABP), 2012, INT DRUG OUTL ID PRO; Nguyen L, 2016, PHARMACOL THERAPEUT, V159, P1, DOI 10.1016/j.pharmthera.2016.01.016; Nielsen S, 2017, CURR TOP BEHAV NEURO, V34, P59, DOI 10.1007/7854_2015_422; Nozaki-Taguchi N, 1999, ANESTHESIOLOGY, V90, P225, DOI 10.1097/00000542-199901000-00029; Rasla Somwail, 2017, R I Med J (2013), V100, P33; Reeves RR, 2015, SOUTH MED J, V108, P151, DOI 10.14423/SMJ.0000000000000256; Riaz IB, 2017, AM J THER; Rose B.J., 2016, PHARM TODAY, P34; Schifano F, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00239; Stanciu CN, 2017, J PSYCHOACTIVE DRUGS, V49, P18, DOI 10.1080/02791072.2016.1260188; Swank KA, 2017, J AM PHARM ASSOC, V57, pS63, DOI 10.1016/j.japh.2016.11.011; U.S. Food and Drug Administration, 2020, FDA WARNS SER PROBL; Upadhyay A, 2016, CASE REP CARDIOL, V2016, DOI 10.1155/2016/5040176; Vakkalanka JP, 2017, ANN EMERG MED, V69, P73, DOI 10.1016/j.annemergmed.2016.08.444; Vaughn P, 2016, J CARDIOVASC ELECTR, V27, P1230, DOI 10.1111/jce.13052; Wightman RS, 2016, CLIN TOXICOL, V54, P454, DOI 10.3109/15563650.2016.1159310; Wright J, 2016, J PUBLIC HEALTH-UK, V38, P793, DOI 10.1093/pubmed/fdv169; Wu PE, 2017, ANN EMERG MED, V70, P245, DOI 10.1016/j.annemergmed.2017.04.008; Zaprutko T, 2016, HEALTH POLICY, V120, P875, DOI 10.1016/j.healthpol.2016.06.008; Zhang Y, 2013, BIOMED PHARMACOTHER, V67, P757, DOI 10.1016/j.biopha.2013.04.012; Zhou SF, 2004, DRUG METAB REV, V36, P57, DOI 10.1081/DMR-120028427	69	23	23	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2018	13	10							e0204443	10.1371/journal.pone.0204443	http://dx.doi.org/10.1371/journal.pone.0204443			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV8IQ	30286103	gold, Green Published, Green Submitted			2023-01-03	WOS:000446383500021
J	Gao, CC; Su, XY; Shi, FF; Chen, Y; Gu, XY				Gao Chanchan; Su Xiangyu; Shi Fangfang; Chen Yan; Gu Xiaoyi			The efficacy and safety of targeted therapy plus fulvestrant in postmenopausal women with hormone-receptor positive advanced breast cancer: A meta-analysis of randomized-control trials	PLOS ONE			English	Article							PREVIOUS ENDOCRINE THERAPY; GROWTH-FACTOR RECEPTOR; PHASE-III TRIAL; DOUBLE-BLIND; PIK3CA MUTATIONS; PLACEBO; ANASTROZOLE; COMBINATION; MULTICENTER; PALBOCICLIB	Objective To evaluate the efficacy and safety of targeted therapy plus fulvestrant for postmenopausal patients with hormone receptor-positive advanced breast cancer. Methods Pubmed, Embase and Web of Science databases were systematically searched on February 26, 2018. Eligible studies were screened according to selection criteria, and two reviewers independently extracted outcome data which included progression-free survival, overall survival, objective response rate, clinical benefit rate and toxicities. RevMan 5.3 and STATA 11.0 software were used to conduct meta-analysis. Results Thirteen articles including twelve randomized-control trials fulfilled selection criteria. There was no evidence regarding the existence of publication bias and high-risk bias of quality in the selected studies. In previously endocrine therapy-treated postmenopausal patients with hormone-receptor positive advanced breast cancer, the PFS (HR = 0.77, 95% CI: 0.66-0.91) and ORR (RR = 1.78, 95% CI: 1.35-2.34) of combination therapy group were significantly higher than that from fulvestrant monotherapy group. Besides, a statistically significant difference in PFS was found across the two arms in postmenopausal women with PIK3CA-mutant ctDNA tumor (HR = 0.52, 95% CI: 0.39-0.69). Moreover, the risk of adverse events (RR = 1.09, 95% CI: 1.05-1.13), CTCAE >= 3 (RR = 1.97, 95% CI: 1.49-2.60) and discontinuation due to adverse events (RR = 4.91, 95% CI: 3.37-7.15) were also significantly different between two treatment groups. Sensitivity analysis showed PLOMA-3 trial was an important factor of heterogeneity. Discussion Even though the combination of targeted therapy plus fulvestrant improved PFS and increased ORR in advanced breast cancer patients, the toxicities of combination therapy were also higher than fulvestrant monotherapy. Further studies related to inhibitors targeting the specific signaling pathway or receptors are urgently needed, and more efforts concerning precision medicine of targeted therapy plus endocrine therapy should be taken to improve the clinical benefits.	[Gao Chanchan; Su Xiangyu; Shi Fangfang; Chen Yan; Gu Xiaoyi] Southeast Univ, Dept Oncol, Zhongda Hosp, Nanjing, Jiangsu, Peoples R China	Southeast University - China	Gu, XY (corresponding author), Southeast Univ, Dept Oncol, Zhongda Hosp, Nanjing, Jiangsu, Peoples R China.	xy_gu@sohu.com						Adelson K, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2016.37; Baselga J, 2017, LANCET ONCOL, V18, P904, DOI 10.1016/S1470-2045(17)30376-5; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Bergh J, 2012, J CLIN ONCOL, V30, P1919, DOI 10.1200/JCO.2011.38.1095; Bundred N, 2005, CANCER INVEST, V23, P173, DOI 10.1081/CNV-50480; Burstein HJ, 2014, J CLIN ONCOL, V32, P3959, DOI 10.1200/JCO.2014.56.7941; Cardoso F, 2017, ANN ONCOL, V28, P16, DOI 10.1093/annonc/mdw544; Cepa M, 2015, ACTA REUMATOL PORT, V40, P323; Chopra N, 2017, LANCET ONCOL, V18, P842, DOI 10.1016/S1470-2045(17)30430-8; Clemons MJ, 2014, BREAST CANCER RES TR, V146, P153, DOI 10.1007/s10549-014-3015-6; Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; De Marchi T, 2016, DRUG DISCOV TODAY, V21, P1181, DOI 10.1016/j.drudis.2016.05.012; Di Leo A, 2018, LANCET ONCOL, V19, P87, DOI 10.1016/S1470-2045(17)30688-5; Di Leo A, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt337; Di Leo A, 2010, J CLIN ONCOL, V28, P4594, DOI 10.1200/JCO.2010.28.8415; Early Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2; Elwy Fatma, 2017, Asian Pac J Cancer Prev, V18, P57; Fan WM, 2015, FUTURE MED CHEM, V7, P1511, DOI 10.4155/fmc.15.93; Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/s0140-6736(16)31891-8, 10.1016/S0140-6736(16)31891-8]; Hyams DM, 2013, INVEST NEW DRUG, V31, P1345, DOI 10.1007/s10637-013-9991-2; Johnston SRD, 2013, LANCET ONCOL, V14, P989, DOI 10.1016/S1470-2045(13)70322-X; Krop IE, 2016, LANCET ONCOL, V17, P811, DOI 10.1016/S1470-2045(16)00106-6; Lee CI, 2017, COCHRANE DB SYST REV, V2017, P1; Lin WZ, 2017, BREAST CANCER-TOKYO, V24, P345, DOI 10.1007/s12282-017-0770-3; Loibl S, 2017, ONCOLOGIST, V22, P1028, DOI 10.1634/theoncologist.2017-0072; Mayer IA, 2017, J CLIN ONCOL, V35, DOI [10.1007/s12282-017-0770-3, DOI 10.1007/S12282-017-0770-3]; Mehta RS, 2012, NEW ENGL J MED, V367, P435, DOI 10.1056/NEJMoa1201622; Moynahan ME, 2017, BRIT J CANCER, V116, P726, DOI 10.1038/bjc.2017.25; Murphy CG, 2016, ENDOCR-RELAT CANCER, V23, pR337, DOI 10.1530/ERC-16-0121; Musolino A, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0807-8; Nathan MR, 2017, ONCOL THER, V5, P17, DOI 10.1007/s40487-017-0046-2; National Comprehensive Cancer Network (NCCN), 2018, NCCN CLIN PRACT GUID; Osborne CK, 2002, J CLIN ONCOL, V20, P3386, DOI 10.1200/JCO.2002.10.058; Partridge AH, 2014, J CLIN ONCOL, V32, P3307, DOI 10.1200/JCO.2014.56.7479; Polk A, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000093; Tan PS, 2013, BREAST CANCER RES TR, V138, P961, DOI 10.1007/s10549-013-2495-0; Robertson JFR, 2013, LANCET ONCOL, V14, P228, DOI 10.1016/S1470-2045(13)70026-3; Sledge GW, 2017, J CLIN ONCOL, V35, P2875, DOI 10.1200/JCO.2017.73.7585; Tabesh GA, 2017, CANCER INVEST, V35, P36, DOI 10.1080/07357907.2016.1247455; Thill M, 2017, BREAST CARE, V12, P184, DOI 10.1159/000477576; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270; Wang JY, 2018, BREAST CANCER RES TR, V171, P535, DOI 10.1007/s10549-018-4867-y; Zaman K, 2015, EUR J CANCER, V51, P1212, DOI 10.1016/j.ejca.2015.03.016	46	1	1	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 20	2018	13	9							e0204202	10.1371/journal.pone.0204202	http://dx.doi.org/10.1371/journal.pone.0204202			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GU8XH	30235292	Green Published, gold, Green Submitted			2023-01-03	WOS:000445626400084
J	Mittel, M; Wang, CHE; Goben, AH; Boyd, AD				Mittel, Manish; Wang, Chih-Hsiung E.; Goben, Abigail H.; Boyd, Andrew D.			Proprietary management and higher readmission rates: A correlation	PLOS ONE			English	Article							HEART-FAILURE; FOR-PROFIT; CARE; HOSPITALIZATION	Introduction Reducing preventable readmissions among Medicare beneficiaries is an effective way to not only reduce the exorbitantly rising cost in healthcare but also as a measure to improve the quality of patient care. Many of the previous efforts in reducing readmission rate of patients have not been very successful because of ill-defined quality measures, improper data collection methods and lack of effective strategies based on data driven solutions. Methods In this study, we analyzed the readmission data of patients for six major diseases including acute myocardial infarction (AMI), heart failure (HF), coronary artery bypass graft (CABG), pneumonia (PN), chronic obstructive pulmonary disease (COPD), and total hip arthroplasty and/or total knee arthroplasty (THA/TKA) from the Center for Medicare and Medicaid Readmissions Reduction Program (HRRP) program for the period 2012-2015 in context with the ownership structure of the hospitals. Results Our analysis demonstrates that the readmission rates of patients were statistically higher in proprietary (for profit) hospitals compared to the government and non-profit hospitals which was independent of their geographical distribution across all six major diseases. Conclusion This finding we believe has strong implications for policy makers to mitigate any potential risks in the quality of patient care arising from unintended revenue pressure in healthcare institutions.	[Mittel, Manish] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL USA; [Mittel, Manish; Wang, Chih-Hsiung E.; Boyd, Andrew D.] Univ Illinois, Dept Biomed & Hlth Informat Sci, Coll Appl Hlth Sci, Chicago, IL 60607 USA; [Goben, Abigail H.] Univ Illinois, Univ Lib, Lib Hlth Sci, Chicago, IL 60607 USA; [Boyd, Andrew D.] Univ Illinois, Coll Med, Dept Med Educ, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Boyd, AD (corresponding author), Univ Illinois, Dept Biomed & Hlth Informat Sci, Coll Appl Hlth Sci, Chicago, IL 60607 USA.; Boyd, AD (corresponding author), Univ Illinois, Coll Med, Dept Med Educ, Chicago, IL 60607 USA.	boyda@uic.edu		Goben, Abigail/0000-0002-6520-3648; Boyd, Andrew/0000-0002-3459-9379	AHRQ [R18 HS024679-01];  [NCATS UL1TR002003-01]; AHRQ [5R18HS024679-03] Funding Source: Federal RePORTER; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS024679] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002003] Funding Source: NIH RePORTER	AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); ; AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	The research is not affiliated with any funded grants. I am actively receiving funding from the following grant for other work NCATS UL1TR002003-01, AHRQ, R18 HS024679-01. They have no role is design of conduct of the study.	Akintoye E, 2017, AM J CARDIOL, V120, P831, DOI 10.1016/j.amjcard.2017.06.009; Center for Healthcare Quality and Payment Reform, RED HOSP READM; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Comondore VR, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2732; Daras LC, 2017, NON TRADITIONAL REF, P31406; Devereaux PJ, 2002, JAMA-J AM MED ASSOC, V288, P2449, DOI 10.1001/jama.288.19.2449; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Fonarow GC, 2017, J AM COLL CARDIOL, V70, P1931, DOI 10.1016/j.jacc.2017.08.046; Herrera CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093456; Hillmer MP, 2005, MED CARE RES REV, V62, P139, DOI 10.1177/1077558704273769; Horwitz LI, 2017, MED CARE, V55, P528, DOI 10.1097/MLR.0000000000000713; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Kripalani S, 2014, ANNU REV MED, V65, P471, DOI 10.1146/annurev-med-022613-090415; Leleu H, 2017, HLTH SERVICES MANAGE; Miller H. D, 2017, NON TRADITIONAL REF; Mor V, 2010, HEALTH AFFAIR, V29, P57, DOI 10.1377/hlthaff.2009.0629; Rosenau PV, 2003, SOC SCI QUART, V84, P219, DOI 10.1111/1540-6237.8402001	17	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2018	13	9							e0204272	10.1371/journal.pone.0204272	http://dx.doi.org/10.1371/journal.pone.0204272			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GU0DL	30226863	Green Submitted, Green Published, gold			2023-01-03	WOS:000444918300054
J	Ball, IM; Sibbald, R; Truog, RD				Ball, Ian M.; Sibbald, Robert; Truog, Robert D.			Voluntary Euthanasia - Implications for Organ Donation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Ball, Ian M.] Western Univ, Dept Med, London, ON, Canada; [Ball, Ian M.] Western Univ, Dept Epidemiol & Biostat, London, ON, Canada; [Sibbald, Robert] London Hlth Sci Ctr, Eth Program, London, ON, Canada; [Truog, Robert D.] Harvard Med Sch, Ctr Bioeth, Boston, MA USA	Western University (University of Western Ontario); Western University (University of Western Ontario); London Health Sciences Centre; Harvard University; Harvard Medical School	Ball, IM (corresponding author), Western Univ, Dept Med, London, ON, Canada.; Ball, IM (corresponding author), Western Univ, Dept Epidemiol & Biostat, London, ON, Canada.		Ball, Ian/GRR-4073-2022	Ball, Ian/0000-0002-8503-2153				Bollen J, 2016, AM J TRANSPLANT, V16, P1967, DOI 10.1111/ajt.13746; Bollen J, 2016, J MED ETHICS, V42, P486, DOI 10.1136/medethics-2015-102898; Hawryluck LA, 2000, J PALLIATIVE CARE, V16, pS24, DOI 10.1177/082585970001601S06; Robertson JA, 1999, HASTINGS CENT REP, V29, P6, DOI 10.2307/3527865	4	14	14	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 6	2018	379	10					909	911		10.1056/NEJMp1804276	http://dx.doi.org/10.1056/NEJMp1804276			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GS5XM	30184447				2023-01-03	WOS:000443748200005
J	Lee, YJ; Lee, IH; Kim, YJ; Chung, YS; Lee, JY; Nam, EJ; Kim, S; Kim, SW; Kim, YT				Lee, Yong Jae; Lee, In Ha; Kim, Yun-Ji; Chung, Young Shin; Lee, Jung-Yun; Nam, Eun Ji; Kim, Sunghoon; Kim, Sang Wun; Kim, Young Tae			Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy	PLOS ONE			English	Article							PREDICT OPTIMAL CYTOREDUCTION; INTERVAL DEBULKING SURGERY; RESIDUAL DISEASE; FALLOPIAN-TUBE; SURVIVAL; REGRESSION; REDUCTION; TRIAL	Various kinetic parameters of serum CA-125 have been reported to have better correlation with outcomes for patients treated with neoadjuvant chemotherapy (NAC). This study aimed to compare the available kinetic parameters of serum CA-125 in an external cohort of advanced-stage ovarian cancer. Using the cancer registry databases from the Yonsei Cancer Hospital, we retrospectively reviewed 210 patients with advanced-stage ovarian cancer, treated with NAC followed by interval debulking surgery. We compared area under the receiver-operating characteristics curves (AUCs), false negative rate, and negative predictive value (NPV) using 10 different models for optimal cytoreduction and platinum resistance. In addition, we compared incremental AUC for progression-free survival (PFS) and overall survival (OS). No gross residual tumor was observed in 37.0% and residual tumors <1 cm in 82.2% of patients. No model using CA-125 kinetic parameters had an AUC higher than >0.6 for predicting optimal cytoreduction. After adjusting for age, BMI, disease stage, and histologic subtypes, all models had an AUC >0.70 for predicting platinum resistance. However, no model had a high enough NPV (highest value = 82.0%) to avoid chemotherapy futility. For survival outcomes, no model had an incremental AUC >0.70 for predicting either PFS or OS. None of the proposed serum CA-125 kinetic parameters showed high accuracy in predicting optimal cytoreduction, platinum resistance, or survival in patients receiving NAC. For advanced-stage ovarian cancer treated with NAC, there is a need to discover reliable biomarkers to better stratify patient response groups for optimal treatment decision making.	[Lee, Yong Jae; Lee, In Ha; Kim, Yun-Ji; Chung, Young Shin; Lee, Jung-Yun; Nam, Eun Ji; Kim, Sunghoon; Kim, Sang Wun; Kim, Young Tae] Yonsei Univ, Inst Womens Med Life Sci, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea	Yonsei University; Yonsei University Health System	Lee, JY (corresponding author), Yonsei Univ, Inst Womens Med Life Sci, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea.	jungyunlee@yuhs.ac	Lee, Yong Jae/GLR-4153-2022	Kim, Young Tae/0000-0002-7347-1052; Kim, Sang Wun/0000-0002-8342-8701; Lee, Yong Jae/0000-0003-0297-3116; kim, sunghoon/0000-0002-1570-3230; Lee, Inha/0000-0003-4869-6281; Nam, Eun Ji/0000-0003-0189-3560; Lee, Jung-Yun/0000-0001-7948-1350; Kim, Sunghoon/0000-0002-1645-7473	National Research Foundation (NRF) - Ministry of Science, ICT & Future Planning [2017M3A9E8029714]	National Research Foundation (NRF) - Ministry of Science, ICT & Future Planning	This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science, ICT & Future Planning (2017M3A9E8029714).; This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science, ICT & Future Planning (2017M3A9E8029714).	Bohm S, 2015, J CLIN ONCOL, V33, P2457, DOI 10.1200/JCO.2014.60.5212; Chan YM, 2003, GYNECOL ONCOL, V88, P9, DOI 10.1006/gyno.2002.6849; Fagotti A, 2016, EUR J CANCER, V59, P22, DOI 10.1016/j.ejca.2016.01.017; Furukawa N, 2013, J GYNECOL ONCOL, V24, P141, DOI 10.3802/jgo.2013.24.2.141; Hou JY, 2007, GYNECOL ONCOL, V105, P211, DOI 10.1016/j.ygyno.2006.11.025; Jung KW, 2017, CANCER RES TREAT, V49, P292, DOI 10.4143/crt.2017.118; Kehoe S, 2015, LANCET, V386, P249, DOI 10.1016/S0140-6736(14)62223-6; Le T, 2008, J OBSTET GYNAECOL CA, V30, P665, DOI 10.1016/S1701-2163(16)32914-0; Ledermann JA, 2013, ANN ONCOL, V24, P24, DOI 10.1093/annonc/mdt333; Lee JY, 2017, J GYNECOL ONCOL, V28, DOI 10.3802/jgo.2017.28.e73; Lee JY, 2014, J GYNECOL ONCOL, V25, P174, DOI 10.3802/jgo.2014.25.3.174; Luo YL, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004797; Mahdi H, 2015, INT J GYNECOL CANCER, V25, P823, DOI 10.1097/IGC.0000000000000434; Morimoto A, 2016, JPN J CLIN ONCOL, V46, P517, DOI 10.1093/jjco/hyw029; Onda T, 2008, JPN J CLIN ONCOL, V38, P74, DOI 10.1093/jjco/hym145; Pelissier A, 2016, ANTICANCER RES, V36, P1865; Pelissier A, 2014, GYNECOL ONCOL, V135, P542, DOI 10.1016/j.ygyno.2014.09.005; Rodriguez N, 2012, GYNECOL ONCOL, V125, P362, DOI 10.1016/j.ygyno.2012.02.006; Saha A, 2012, INT J GYNECOL CANCER, V22, P566, DOI 10.1097/IGC.0b013e318247727f; Tate S, 2005, GYNECOL ONCOL, V96, P143, DOI 10.1016/j.ygyno.2004.09.020; Vasudev NS, 2011, ARCH GYNECOL OBSTET, V284, P221, DOI 10.1007/s00404-010-1655-2; Vergote I, 2010, NEW ENGL J MED, V363, P943, DOI 10.1056/NEJMoa0908806; Zeng J, 2016, J CANCER, V7, P2327, DOI 10.7150/jca.16761	23	4	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2018	13	9							e0203366	10.1371/journal.pone.0203366	http://dx.doi.org/10.1371/journal.pone.0203366			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT1KN	30188915	Green Published, gold, Green Submitted			2023-01-03	WOS:000444228700028
J	Deng, JY; Jhandey, A; Zhu, X; Yang, ZB; Yik, KFP; Zuo, Z; Lam, TN				Deng, Jianyuan; Jhandey, Anika; Zhu, Xiao; Yang, Zhibo; Yik, Kin Fu Patrick; Zuo, Zhong; Lam, Tai Ning			In silico drug absorption tract: An agent-based biomimetic model for human oral drug absorption	PLOS ONE			English	Article							TRANSPORT; METABOLISM; PHARMACOKINETICS; BIOAVAILABILITY; BIOEQUIVALENCE; DISPOSITION; SIMULATION; MIDAZOLAM; DEVICE	Background An agent-based modeling approach has been suggested as an alternative to traditional, equation-based modeling methods for describing oral drug absorption. It enables researchers to gain a better understanding of the pharmacokinetic (PK) mechanisms of a drug. This project demonstrates that a biomimetic agent-based model can adequately describe the absorption and disposition kinetics both of midazolam and clonazepam. Methods An agent-based biomimetic model, in silico drug absorption tract (ISDAT), was built to mimic oral drug absorption in humans. The model consisted of distinct spaces, membranes, and metabolic enzymes, and it was altogether representative of human physiology relating to oral drug absorption. Simulated experiments were run with the model, and the results were compared to the referent data from clinical equivalence trials. Acceptable similarity was verified by pre-specified criteria, which included 1) qualitative visual matching between the clinical and simulated concentration-time profiles, 2) quantitative similarity indices, namely, weighted root mean squared error (RMSE), and weighted mean absolute percentage error (MAPE) and 3) descriptive similarity which requires less than 25% difference between key PK parameters calculated by the clinical and the simulated concentration-time profiles. The model and its parameters were iteratively refined until all similarity criteria were met. Furthermore, simulated PK experiments were conducted to predict bioavailability (F). For better visualization, a graphical user interface for the model was developed and a video is available in Supporting Information. Results Simulation results satisfied all three levels of similarity criteria for both drugs. The weighted RMSE was 0.51 and 0.92, and the weighted MAPE was 5.99% and 8.43% for midazolam and clonazepam, respectively. Calculated PK parameter values, including area under the curve (AUC), peak plasma drug concentration (C-max), time to reach C-max (T-max), terminal elimination rate constant (Kel), terminal elimination half life (T-1/2), apparent oral clearance (CL/F), and apparent volume of distribution (V/F), were reasonable compared to the referent values. The predicted absolute oral bioavailability (F) was 44% for midazolam (literature reported value, 31-72%) and 93% (literature reported value, >= 90%) for clonazepam. Conclusion The ISDAT met all the pre-specified similarity criteria for both midazolam and clonazepam, and demonstrated its ability to describe absorption kinetics of both drugs. Therefore, the validated ISDAT can be a promising platform for further research into the use of similar in silico models for drug absorption kinetics.	[Deng, Jianyuan; Jhandey, Anika; Zhu, Xiao; Yik, Kin Fu Patrick; Zuo, Zhong; Lam, Tai Ning] Chinese Univ Hong Kong, Sch Pharm, Fac Med, Hong Kong, Hong Kong, Peoples R China; [Jhandey, Anika] Univ Nottingham, Sch Pharm, Nottingham, England; [Yang, Zhibo] SUNY Stony Brook, Dept Comp Sci, Stony Brook, NY 11794 USA; [Lam, Tai Ning] Chinese Univ Hong Kong, Sch Pharm, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; University of Nottingham; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Chinese University of Hong Kong	Lam, TN (corresponding author), Chinese Univ Hong Kong, Sch Pharm, Fac Med, Hong Kong, Hong Kong, Peoples R China.; Lam, TN (corresponding author), Chinese Univ Hong Kong, Sch Pharm, Shatin, Hong Kong, Peoples R China.	teddylam@cuhk.edu.hk	Deng, Jianyuan/ABE-5454-2021; Zuo, Zhong/B-6884-2008; Lam, Teddy/C-6180-2016; Deng, Jianyuan/ABE-5456-2021	Deng, Jianyuan/0000-0003-0647-1287; Zhu, Xiao/0000-0003-3295-619X; Lam, Tai Ning/0000-0002-7259-4050; Zuo, Zhong/0000-0002-6976-6157	Hong Kong University Grants Committee Research Grants Council Early Career Scheme [CUHK489813]	Hong Kong University Grants Committee Research Grants Council Early Career Scheme	This project is partially supported by research grants from the Hong Kong University Grants Committee Research Grants Council Early Career Scheme (https://www.ugc.edu.hk/eng/rgc/funding_opport/early_career.html), Grant number CUHK489813 (TNL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	An G, 2007, J CRIT CARE, V22, P169, DOI 10.1016/j.jcrc.2006.12.011; An G, 2009, WIRES SYST BIOL MED, V1, P159, DOI 10.1002/wsbm.45; An G, 2008, THEOR BIOL MED MODEL, V5, DOI 10.1186/1742-4682-5-11; Cavedal LE, 2007, J MASS SPECTROM, V42, P81, DOI 10.1002/jms.1141; Chen ML, 2001, CLIN PHARMACOKINET, V40, P701, DOI 10.2165/00003088-200140100-00001; Cosgrove J, 2015, CPT-PHARMACOMET SYST, V4, P615, DOI 10.1002/psp4.12018; Crevoisier C, 2003, EUR NEUROL, V49, P173, DOI 10.1159/000069089; El-Kattan A, 2012, TOPICS ON DRUG METABOLISM, P1; Engelberg JA, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002030; Garmire LX, 2007, PHARM RES-DORDR, V24, P2171, DOI 10.1007/s11095-007-9391-4; HEIZMANN P, 1983, BRIT J CLIN PHARMACO, V16, pS43, DOI 10.1111/j.1365-2125.1983.tb02270.x; Hunt CA, 2013, WIRES SYST BIOL MED, V5, P461, DOI 10.1002/wsbm.1222; Hunt CA, 2011, THEOR BIOL MED MODEL, V8, DOI 10.1186/1742-4682-8-35; Hunt CA, 2009, PHARM RES-DORDR, V26, P2369, DOI 10.1007/s11095-009-9958-3; Jaki T, 2011, PHARM STAT, V10, P284, DOI 10.1002/pst.449; Kadono K, 2010, DRUG METAB DISPOS, V38, P1230, DOI 10.1124/dmd.109.029322; Kim SHJ, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-122; Lalonde RL, 2007, CLIN PHARMACOL THER, V82, P21, DOI 10.1038/sj.clpt.6100235; Lam TN, 2010, J PHARMACOL EXP THER, V332, P398, DOI 10.1124/jpet.109.160739; Lam TN, 2008, IEEE ENG MED BIO, P5462, DOI 10.1109/IEMBS.2008.4650450; Lam TN, 2009, DRUG METAB DISPOS, V37, P237, DOI 10.1124/dmd.108.023820; Landersdorfer CB, 2008, CLIN PHARMACOKINET, V47, P417, DOI 10.2165/00003088-200847070-00001; Liu Y, 2006, PHARM RES-DORDR, V23, P493, DOI 10.1007/s11095-006-9505-4; Liu Y, 2005, BIOSYSTEMS, V82, P154, DOI 10.1016/j.biosystems.2005.06.008; Luke S, 2005, SIMUL-T SOC MOD SIM, V81, P517, DOI 10.1177/0037549705058073; Marino S, 2010, J THEOR BIOL, V265, P586, DOI 10.1016/j.jtbi.2010.05.012; Park S, 2010, J PHARMACOL EXP THER, V334, P124, DOI 10.1124/jpet.110.168526; Sakuda S, 2006, XENOBIOTICA, V36, P331, DOI 10.1080/00498250600571749; Seal JB, 2011, THEOR BIOL MED MODEL, V8, DOI 10.1186/1742-4682-8-33; Sheiner LB, 2000, ANNU REV PHARMACOL, V40, P67, DOI 10.1146/annurev.pharmtox.40.1.67; Spector P, 2008, USE R, P1; Tang J, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000681; Wang ZH, 2015, J PHARMACOKINET PHAR, V42, P179, DOI 10.1007/s10928-015-9403-7; Wang ZH, 2012, MATH MED BIOL, V29, P95, DOI 10.1093/imammb/dqq023; Wening K, 2011, INT J PHARMACEUT, V404, P1, DOI 10.1016/j.ijpharm.2010.11.001; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Yan L, 2008, PHARM RES, V25, P1023, DOI 10.1007/s11095-007-9494-y; Zhou HH, 2003, J CLIN PHARMACOL, V43, P211, DOI 10.1177/0091270002250613; Zhu X, 2016, AAPS J, V18, P1475, DOI 10.1208/s12248-016-9955-5	39	1	1	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2018	13	8							e0203361	10.1371/journal.pone.0203361	http://dx.doi.org/10.1371/journal.pone.0203361			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS2JK	30169515	Green Published, Green Submitted, gold			2023-01-03	WOS:000443374400037
J	Linde, K; Atmann, O; Meissner, K; Schneider, A; Meister, R; Kriston, L; Werner, C				Linde, Klaus; Atmann, Oxana; Meissner, Karin; Schneider, Antonius; Meister, Ramona; Kriston, Levente; Werner, Christoph			How often do general practitioners use placebos and non-specific interventions? Systematic review and meta-analysis of surveys	PLOS ONE			English	Review							PRIMARY-CARE PHYSICIANS; CLINICAL-PRACTICE; QUESTIONNAIRE SURVEY; FAMILY PHYSICIANS; IMPURE PLACEBO; PERSPECTIVES; ATTITUDES; GERMANY; BELIEVE; GPS	Background In a systematic review and meta-analysis we summarize the available evidence on how frequently general practitioners/family physicians (GPs) use pure placebos (e.g., placebo pills) and non-specific therapies (sometimes referred to as impure placebos; e.g., antibiotics for common cold). Methods We searched Medline, PubMed and SCOPUS up to July 2018 to identify cross-sectional quantitative surveys among GPs. Outcomes of primary interest were the percentages of GPs having used any placebo, pure placebos or non-specific therapies at least once in their career, at least once in the last year, at least monthly or at least weekly. Outcomes were described as proportions and pooled with random-effects meta-analysis. Results Of 674 publications, 16 studies from 13 countries with a total of 2.981 participating GPs (range 27 to 783) met the inclusion criteria. The percentage of GPs having used any form of placebo at least once in their career ranged from 29% to 97%, in the last year at least once from 46% to 95%, at least monthly from 15% to 89%, and at least weekly from 1% to 75%. The use of non-specific therapies by far outnumbered the use of pure placebo. For example, the proportion of GPs using pure placebos at least monthly varied between 2% and 15% compared to 53% and 89% for non-specific therapies; use at least weekly varied between 1% and 3% for pure placebos and between 16% and 75% for non-specific therapies. Besides eliciting placebos effects, many other reasons related to patient expectations, demands and medical problems were reported as reasons for applying placebo interventions. Conclusion High prevalence estimates of placebo use among GPs are mainly driven by the frequent use of non-specific therapies; pure placebos are used rarely. The interpretation of our quantitative findings is complicated by the diversity of definitions and survey methods.	[Linde, Klaus; Atmann, Oxana; Schneider, Antonius; Werner, Christoph] Tech Univ Munich, TUM Sch Med, Inst Gen Practice, Munich, Germany; [Meissner, Karin] Univ Appl Sci Coburg, Div Hlth Promot, Coburg, Germany; [Meissner, Karin] Ludwig Maximilians Univ Munchen, Fac Med, Inst Med Psychol, Munich, Germany; [Meister, Ramona; Kriston, Levente] Univ Med Ctr Hamburg Eppendorf, Dept Med Psychol, Hamburg, Germany	Technical University of Munich; Hochschule Coburg; University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf	Linde, K (corresponding author), Tech Univ Munich, TUM Sch Med, Inst Gen Practice, Munich, Germany.	klaus.linde@mri.tum.de	MEISSNER, Karin/AAS-2483-2021; Kriston, Levente/D-1713-2013	Kriston, Levente/0000-0003-0748-264X; Linde, Klaus/0000-0002-2902-970X				Babel P, 2013, MED PRIN PRACT, V22, P484, DOI 10.1159/000351563; Babel P, 2012, EVAL HEALTH PROF, V35, P447, DOI 10.1177/0163278711420285; Bishop FL, 2014, FAM PRACT, V31, P357, DOI 10.1093/fampra/cmu016; Bostick NA, 2008, J CLIN ETHIC, V19, P58; Braga-Simoes J, 2017, EUR J GEN PRACT, V23, P98, DOI 10.1080/13814788.2017.1291625; Charlesworth James E G, 2017, J Evid Based Med, V10, P97, DOI 10.1111/jebm.12251; Colloca L, 2011, PHILOS T R SOC B, V366, P1922, DOI 10.1098/rstb.2010.0399; COMAROFF J, 1976, SOCIOL REV, V24, P79, DOI 10.1111/j.1467-954X.1976.tb00574.x; Fassler M, 2011, BRIT J GEN PRACT, V61, P101, DOI 10.3399/bjgp11X556209; Fassler M, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-15; Fassler M, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-144; Fent R, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-11; Ferentzi E, 2010, CLIN EXPT MED J, V5, P21, DOI DOI 10.1556/CEMED.4.2010.2.5; Ferentzi E, 2011, CLIN EXP MED J, V5, P73, DOI DOI 10.1556/CEMED.5.2011.2.2; Guimet P., 2011, USAGE PLACEBOS MED G; Harris C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140876; Harris Gardiner, 2008, NY TIMES; Henriksen K, 2004, SOC SCI MED, V59, P47, DOI 10.1016/j.socscimed.2003.10.004; Holt S, 2009, NZ MED J, V122, P1298; Howick J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058247; Hrobjartsson A, 2003, EVAL HEALTH PROF, V26, P153, DOI 10.1177/0163278703026002002; Hrobjartsson A, 2008, J CLIN ETHIC, V19, P66; Kaptchuk TJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015591; Kermen R, 2010, FAM MED, V42, P636; Khan SAF, 2015, INDOAMERICAN J PHARM, V5; Koch K, 2011, DTSCH ARZTEBL INT, V108, P255, DOI 10.3238/arztebl.2011.0255; Kumar A, 2015, RES J PHARM BIOL CHE, V6, P1036; Linde K, 2015, Z ALLGMED, V91, P254; Lindea K, 2015, FAM PRACT, V32, P62, DOI 10.1093/fampra/cmu071; Linde K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092938; Linde K, 2013, FORSCH KOMPLEMENTMED, V20, P361, DOI 10.1159/000356230; Linde K, 2011, PHILOS T R SOC B, V366, P1905, DOI 10.1098/rstb.2010.0383; Louhiala P, 2015, THEOR MED BIOETH, V36, P279, DOI 10.1007/s11017-015-9336-6; Meissner K, 2012, FAM PRACT, V29, P79, DOI 10.1093/fampra/cmr045; Miller FG, 2009, AM J BIOETHICS, V9, P39, DOI 10.1080/15265160903316263; Nitzan U, 2004, BMJ-BRIT MED J, V329, P944, DOI 10.1136/bmj.38236.646678.55; Raz A, 2011, CAN J PSYCHIAT, V56, P198, DOI 10.1177/070674371105600403; Rotenstein LS, 2016, JAMA-J AM MED ASSOC, V316, P2214, DOI 10.1001/jama.2016.17324; Schoen C, 2009, HEALTH AFFAIR, V28, pW1171, DOI 10.1377/hlthaff.28.6.w1171; SCHWARTZ RK, 1989, SOC SCI MED, V28, P577, DOI 10.1016/0277-9536(89)90252-9; Shah Kartik N, 2009, Indian J Med Sci, V63, P472, DOI 10.4103/0019-5359.57640; Shermon R, 2008, J GEN INTERN MED, V23, P7, DOI 10.1007/s11606-007-0332-z; Tilburt JC, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1938; Tonkin-Crine S, 2011, J ANTIMICROB CHEMOTH, V66, P2215, DOI 10.1093/jac/dkr279; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Weiss MC, 1997, PHARM J, V259, P339; Wells GA, NEWCASTLE OTTAWA SCA	47	27	27	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2018	13	8							e0202211	10.1371/journal.pone.0202211	http://dx.doi.org/10.1371/journal.pone.0202211			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GR5ZQ	30142199	Green Published, Green Submitted, gold			2023-01-03	WOS:000442722500008
J	Brinkman-Stoppelenburg, A; Witkamp, FE; van Zuylen, L; van der Rijt, CCD; van der Heide, A				Brinkman-Stoppelenburg, Arianne; Witkamp, Frederika E.; van Zuylen, Lia; van der Rijt, Carin C. D.; van der Heide, Agnes			Palliative care team consultation and quality of death and dying in a university hospital: A secondary analysis of a prospective study	PLOS ONE			English	Article							OF-LIFE CARE; RANDOMIZED CONTROLLED-TRIAL; BEREAVED RELATIVES; CANCER-PATIENTS; FAMILY-MEMBERS; END; OUTCOMES; INTERVENTION; HEALTH; IMPACT	Purpose Involvement of palliative care experts improves the quality of life and satisfaction with care of patients who are in the last stage of life. However, little is known about the relation between palliative care expert involvement and quality of dying (QOD) in the hospital. We studied the association between palliative care team (PCT) consultation and QOD in the hospital as experienced by relatives. Methods We conducted a secondary analysis of data from a prospective study among relatives of patients who died from cancer in a university hospital and compared characteristics and QOD of patients for whom the PCT was or was not consulted. Results 175 out of 343 (51%) relatives responded to the questionnaire. In multivariable linear regression PCT was associated with a 1.0 point better QOD (95% CI 0.07-1.96). In most of the subdomains of QOD, we found a non-significant trend towards a more favorable outcome for patients for whom the PCT was consulted. Patients for whom the PCT was consulted had more often discussed their preferences for medical treatment, had more often been aware of their imminent death and had more often been at peace with their imminent death. Further, patients for whom the PCT was consulted and their relatives had more often been able to say goodbye. Relatives had also more often been present at the moment of death when a PCT had been consulted. Conclusion For patients dying in the hospital, palliative care consultation is associated with a favorable QOD.	[Brinkman-Stoppelenburg, Arianne; Witkamp, Frederika E.; van der Heide, Agnes] Erasmus MC, Univ Med Ctr Rotterdam, Dept Publ Hlth, Rotterdam, Netherlands; [Witkamp, Frederika E.] Rotterdam Univ Appl Sci, Fac Nursing, Rotterdam, Netherlands; [Witkamp, Frederika E.] Rotterdam Univ Appl Sci, Ctr Expertise Care Innovat, Rotterdam, Netherlands; [van Zuylen, Lia; van der Rijt, Carin C. D.] Erasmus MC, Canc Inst, Dept Med Oncol, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Brinkman-Stoppelenburg, A (corresponding author), Erasmus MC, Univ Med Ctr Rotterdam, Dept Publ Hlth, Rotterdam, Netherlands.	a.brinkman-stoppelenburg@erasmusmc.nl	Solari, Alessandra/AAO-1741-2021; Van der Rijt, Carin C.D./CAF-8390-2022	Solari, Alessandra/0000-0001-9930-7579; Van der Rijt, Carin C.D./0000-0001-5996-1242; Stoppelenburg, Arianne/0000-0001-6377-1599; van Zuylen, Lia/0000-0002-7142-7605	Erasmus MC Medical Research Committee [2007-7208]; Tom and Josephine Rijckes Legacy Foundation	Erasmus MC Medical Research Committee; Tom and Josephine Rijckes Legacy Foundation	This study was financially supported by grants from the Erasmus MC Medical Research Committee (grant number 2007-7208 to FEW) and the Tom and Josephine Rijckes Legacy Foundation to FEW; neither had any involvement in the study or publication. The study was conducted independent from the funders. All authors have full access to all the data (including statistical reports and tables) in the study and take responsibility for the integrity of the data and the accuracy of the analysis.	Addington-Hall JM, 2009, PALLIATIVE MED, V23, P190, DOI 10.1177/0269216309102525; Ahmed N, 2004, PALLIATIVE MED, V18, P525, DOI 10.1191/0269216304pm921oa; Bakitas M, 2009, JAMA-J AM MED ASSOC, V302, P741, DOI 10.1001/jama.2009.1198; Blinderman CD, 2015, NEW ENGL J MED, V373, P2549, DOI 10.1056/NEJMra1411746; Brinkman-Stoppelenburg A, 2015, SUPPORT CARE CANCER, V23, P2899, DOI 10.1007/s00520-015-2655-3; Cantin B, 2009, J PALLIAT CARE, V25, P92, DOI 10.1177/082585970902500203; Casarett D, 2008, J AM GERIATR SOC, V56, P593, DOI 10.1111/j.1532-5415.2007.01610.x; Chou WC, 2013, SUPPORT CARE CANCER, V21, P1973, DOI 10.1007/s00520-013-1733-7; Costantini M, 2014, LANCET, V383, P226, DOI 10.1016/S0140-6736(13)61725-0; Curtis JR, 2011, AM J RESP CRIT CARE, V183, P348, DOI 10.1164/rccm.201006-1004OC; Curtis JR, 2002, J PAIN SYMPTOM MANAG, V24, P17, DOI 10.1016/S0885-3924(02)00419-0; Gade G, 2008, J PALLIAT MED, V11, P180, DOI 10.1089/jpm.2007.0055; Glavan BJ, 2008, CRIT CARE MED, V36, P1138, DOI 10.1097/CCM.0b013e318168f301; Hales S, 2008, ARCH INTERN MED, V168, P912, DOI 10.1001/archinte.168.9.912; Hales S, 2014, J PAIN SYMPTOM MANAG, V48, P839, DOI 10.1016/j.jpainsymman.2013.12.240; Higginson IJ, 2005, CLIN GERIATR MED, V21, P45, DOI 10.1016/j.cger.2004.08.003; Hui D, 2014, CANCER-AM CANCER SOC, V120, P1743, DOI 10.1002/cncr.28628; Jongen Joost L M, 2011, BMJ Support Palliat Care, V1, P322, DOI 10.1136/bmjspcare-2011-000087; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Nevadunsky NS, 2014, GYNECOL ONCOL, V132, P3, DOI 10.1016/j.ygyno.2013.10.025; Penrod JD, 2006, J PALLIAT MED, V9, P855, DOI 10.1089/jpm.2006.9.855; Perrin KO, 2015, CRIT CARE NURSE, V35, P44, DOI 10.4037/ccn2015357; Sasahara T, 2014, J PAIN SYMPTOM MANAG, V47, P579, DOI 10.1016/j.jpainsymman.2013.04.009; Sasahara T, 2010, PALLIAT SUPPORT CARE, V8, P49, DOI 10.1017/S1478951509990708; Seale C, 1997, SOC SCI MED, V45, P477, DOI 10.1016/S0277-9536(96)00379-6; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Van Scoy LJ, 2016, DEATH STUD, V40, P486, DOI 10.1080/07481187.2016.1181121; Wentlandt K, 2012, J CLIN ONCOL, V30, P4380, DOI 10.1200/JCO.2012.44.0248; Witkamp FE., 2015, INT J PALLIATIVE CAR, V2015, P1, DOI [10.1155/2015/623890, DOI 10.1155/2015/623890]; Witkamp FE, 2015, J PAIN SYMPTOM MANAG, V49, P203, DOI 10.1016/j.jpainsymman.2014.06.013; Witkamp FE, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-115; Zimmermann C, 2014, LANCET, V383, P1721, DOI 10.1016/S0140-6736(13)62416-2	33	21	21	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2018	13	8							e0201191	10.1371/journal.pone.0201191	http://dx.doi.org/10.1371/journal.pone.0201191			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GR6TZ	30138316	Green Published, Green Submitted, gold			2023-01-03	WOS:000442800100013
J	Jha, AK				Jha, Ashish K.			End-of-Life Care, Not End-of-Life Spending	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									[Jha, Ashish K.] Harvard TH Chan Sch Publ Hlth, Global Hlth & Hlth Policy, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Jha, AK (corresponding author), Harvard TH Chan Sch Publ Hlth, Global Hlth & Hlth Policy, Boston, MA 02115 USA.	ajha@hsph.harvard.edu							0	4	4	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	2018	320	7					631	632		10.1001/jama.2018.11177	http://dx.doi.org/10.1001/jama.2018.11177			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR1XH	30140864	Bronze			2023-01-03	WOS:000442348100002
J	Nalin, DR; Cash, RA				Nalin, David R.; Cash, Richard A.			50 years of oral rehydration therapy: the solution is still simple	LANCET			English	Editorial Material							NASOGASTRIC MAINTENANCE THERAPY; CHOLERA; ELECTROLYTE; DISEASE		[Nalin, David R.] Albany Med Coll, Ctr Immunol & Microbial Dis, W Chester, PA USA; [Cash, Richard A.] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02446 USA	Albany Medical College; Harvard University; Harvard T.H. Chan School of Public Health	Cash, RA (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02446 USA.	racash@hsph.harvard.edu						[Anonymous], 1978, LANCET, V2, P300; CASH RA, 1970, LANCET, V2, P549; CASH RA, 1970, AM J TROP MED HYG, V19, P653, DOI 10.4269/ajtmh.1970.19.653; Chowdhury A.M.R., 1996, SIMPLE SOLUTION TEAC; Lamontagne F, 2018, LANCET, V391, P700, DOI 10.1016/S0140-6736(17)31795-6; Luquero FJ, 2016, EMERG INFECT DIS, V22, P410, DOI 10.3201/eid2203.141970; MAHALANABIS D, 1973, JOHNS HOPKINS MED J, V132, P197; Mata LJ, 1978, CHILDREN SANTA MARIA; Mehta RL, 2015, LANCET, V385, P2616, DOI 10.1016/S0140-6736(15)60126-X; NALIN DR, 1971, J PEDIATR-US, V78, P355, DOI 10.1016/S0022-3476(71)80028-8; NALIN DR, 1970, T ROY SOC TROP MED H, V64, P769, DOI 10.1016/0035-9203(70)90020-9; NALIN DR, 1968, LANCET, V2, P370; Patino AM, 2018, NEW ENGL J MED, V378, P1475, DOI 10.1056/NEJMp1801772; PIERCE NF, 1969, ANN INTERN MED, V70, P1173, DOI 10.7326/0003-4819-70-6-1173; Pinker Steven, 2018, ENLIGHTENMENT NOW CA; RUXIN JN, 1994, MED HIST, V38, P363, DOI 10.1017/S0025727300036905; SNYDER JD, 1982, B WORLD HEALTH ORGAN, V60, P605; United Nations Children Fund, 2008, UNICEF DAT MON SIT C; 2017, LANCET, V390, P626	19	21	22	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 18	2018	392	10147					536	538		10.1016/S0140-6736(18)31488-0	http://dx.doi.org/10.1016/S0140-6736(18)31488-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GQ8MN	30152375				2023-01-03	WOS:000442009500006
J	Guo, H; Zeng, DF; Zhang, H; Bell, T; Yao, J; Liu, Y; Huang, SJ; Li, CJ; Lorence, E; Zhou, SH; Gong, TJ; Jiang, CY; Ahmed, M; Yao, YX; Nomie, KJ; Zhang, L; Wang, M				Guo, Hui; Zeng, Dongfeng; Zhang, Hui; Bell, Taylor; Yao, Jun; Liu, Yang; Huang, Shengjian; Li, Carrie J.; Lorence, Elizabeth; Zhou, Shouhao; Gong, Tiejun; Jiang, Changying; Ahmed, Makhdum; Yao, Yixin; Nomie, Krystle J.; Zhang, Liang; Wang, Michael			( Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma )	ONCOGENE			English	Article							IBRUTINIB RESISTANCE; FOLLICULAR LYMPHOMA; DNA-DAMAGE; OPEN-LABEL; PHASE-I; IDELALISIB; CUDC-907; HDAC; APOPTOSIS; PATHWAY	The dysregulation of PI3K signaling has been implicated as an underlying mechanism associated with resistance to Bruton's tyrosine kinase inhibition by ibrutinib in both chronic lymphocytic leukemia and mantle cell lymphoma (MCL). Ibrutinib resistance has become a major unmet clinical need, and the development of therapeutics to overcome ibrutinib resistance will greatly improve the poor outcomes of ibrutinib-exposed MCL patients. CUDC-907 inhibits both PI3K and HDAC functionality to exert synergistic or additive effects. Therefore, the activity of CUDC-907 was examined in MCL cell lines and patient primary cells, including ibrutinib-resistant MCL cells. The efficacy of CUDC-907 was further examined in an ibrutinib-resistant MCL patient-derived xenograft (PDX) mouse model. The molecular mechanisms by which CUDC-907 dually inhibits PI3K and histone deacetylation were assessed using reverse protein array, immunoblotting, and chromatin immunoprecipitation (ChIP) coupled with sequencing. We showed evidence that CUDC-907 treatment increased histone acetylation in MCL cells. We found that CUDC-907 caused decreased proliferation and increased apoptosis in MCL in vitro and in vivo MCL models. In addition, CUDC-907 was effective in inducing lethality in ibrutinib-resistant MCL cells. Lastly, CUDC-907 treatment increased histone acetylation in MCL cells. Overall, these studies suggest that CUDC-907 may be a promising therapeutic option for relapsed or resistant MCL.	[Guo, Hui; Zeng, Dongfeng; Zhang, Hui; Bell, Taylor; Liu, Yang; Huang, Shengjian; Li, Carrie J.; Lorence, Elizabeth; Jiang, Changying; Ahmed, Makhdum; Yao, Yixin; Nomie, Krystle J.; Zhang, Liang; Wang, Michael] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA; [Zeng, Dongfeng] Third Mil Med Univ, Xinqiao Hosp, Dept Hematol, Chongqing 430000, Peoples R China; [Yao, Jun] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Zhou, Shouhao] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Gong, Tiejun] First Hosp Harbin, Inst Hematol & Oncol, Harbin 150010, Heilongjiang, Peoples R China; [Wang, Michael] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Army Medical University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Wang, M (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA.; Wang, M (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA.	miwang@mdanderson.org	Jiang, Changying/AAL-3711-2020	Guo, Hui/0000-0003-3901-6336; Jiang, Changying/0000-0003-3778-4438; Yao, Yixin/0000-0002-8439-6043; dongfeng, zeng/0000-0002-0460-7593	NIH [P30 CA016672, R21 CA202104]; Gary Rogers Foundation; Kinder Foundation; Pharmacyclics, an AbbVie Company; NCI [CA016672]; NATIONAL CANCER INSTITUTE [R21CA202104, P30CA016672] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Gary Rogers Foundation; Kinder Foundation; Pharmacyclics, an AbbVie Company; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the NIH-funded Cancer Center Support Grant (CCSG) P30 CA016672 and the R21 CA202104 (Michael Wang, PI). This study was also partially supported by the generous philanthropic support to the MD Anderson B Cell Lymphoma Moon Shot Project and philanthropy funds from The Gary Rogers Foundation and the Kinder Foundation. Pharmacyclics, an AbbVie Company, also provided funds for this laboratory work. The reagent CUDC-907 was provided by Curis, Inc. The laboratory research was not supported by Curis, Inc. Ibrutinib was provided by Pharmacyclics, an AbbVie Company. Cell line authentication was performed by the MD Anderson Cancer Center Characterized Cell Line Core Facility, funded by grant NCI # CA016672.	Ahn IE, 2017, BLOOD, V129, P1469, DOI 10.1182/blood-2016-06-719294; Ali D, 2017, STEM CELLS DEV, V26, P353, DOI 10.1089/scd.2016.0183; Bolden JE, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.9; Cheah CY, 2016, J CLIN ONCOL, V34, P1256, DOI 10.1200/JCO.2015.63.5904; Cheah CY, 2015, BLOOD, V125, P3357, DOI 10.1182/blood-2015-03-633156; Cheng S, 2015, LEUKEMIA, V29, P895, DOI 10.1038/leu.2014.263; Chiron D, 2014, CANCER DISCOV, V4, P1022, DOI 10.1158/2159-8290.CD-14-0098; Dreyling M, 2016, LANCET, V387, P770, DOI 10.1016/S0140-6736(15)00667-4; Dudakovic A, 2013, J BIOL CHEM, V288, P28783, DOI 10.1074/jbc.M113.489732; Ghosh K, 2018, J DERMATOL SCI, V89, P226, DOI 10.1016/j.jdermsci.2017.12.006; Giles F, 2006, CLIN CANCER RES, V12, P4628, DOI 10.1158/1078-0432.CCR-06-0511; Gopal AK, 2017, BLOOD, V129, P3037, DOI 10.1182/blood-2016-12-757740; Gopal AK, 2014, NEW ENGL J MED, V370, P1008, DOI 10.1056/NEJMoa1314583; Goy A, 2016, HEMATOL ONCOL CLIN N, V30, P1345, DOI 10.1016/j.hoc.2016.07.014; Graf SA, 2016, EXPERT OPIN PHARMACO, V17, P265, DOI 10.1517/14656566.2016.1135130; Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100; Lee EJ, 2011, BIOCHEM BIOPH RES CO, V414, P384, DOI 10.1016/j.bbrc.2011.09.083; Lee JH, 2010, P NATL ACAD SCI USA, V107, P14639, DOI 10.1073/pnas.1008522107; Lemoine M, 2010, DISCOV MED, V10, P462; Lim HJ, 2016, ANTICANCER RES, V36, P5765, DOI 10.21873/anticanres.11160; Martin P, 2016, LANCET, V388, P535, DOI 10.1016/S0140-6736(16)30451-2; Martin P, 2016, LANCET, V387, P728, DOI 10.1016/S0140-6736(15)01040-5; Medina DJ, 2012, HAEMATOL-HEMATOL J, V97, P1255, DOI 10.3324/haematol.2011.040659; Oki Y, 2017, HAEMATOLOGICA, V102, P1923, DOI 10.3324/haematol.2017.172882; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Qian DZ, 2006, CLIN CANCER RES, V12, P634, DOI 10.1158/1078-0432.CCR-05-1132; Rahal R, 2014, NAT MED, V20, P87, DOI 10.1038/nm.3435; Rahmani M, 2009, BLOOD, V114, P4507, DOI 10.1182/blood-2008-09-177881; Salles G, 2017, HAEMATOLOGICA, V102, pE156, DOI 10.3324/haematol.2016.151738; Scuto A, 2008, BLOOD, V111, P5093, DOI 10.1182/blood-2007-10-117762; Sun KM, 2017, MOL CANCER THER, V16, P285, DOI 10.1158/1535-7163.MCT-16-0390; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang CH, 2014, FEBS LETT, V588, P4654, DOI 10.1016/j.febslet.2014.10.037; Woyach JA, 2017, J CLIN ONCOL, V35, P1437, DOI 10.1200/JCO.2016.70.2282; Yoshioka T, 2013, GYNECOL ONCOL, V129, P425, DOI 10.1016/j.ygyno.2013.02.008; Younes A, 2016, LANCET ONCOL, V17, P622, DOI 10.1016/S1470-2045(15)00584-7; Zhang L, 2017, CLIN CANCER RES, V23, P4212, DOI 10.1158/1078-0432.CCR-16-2703; Zhang XC, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-168; Zhao XH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14920	39	11	11	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1802	1814		10.1038/s41388-018-0550-3	http://dx.doi.org/10.1038/s41388-018-0550-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30361685				2023-01-03	WOS:000461164400002
J	Martinez, KA; Rood, M; Jhangiani, N; Boissy, A; Rothberg, MB				Martinez, Kathryn A.; Rood, Mark; Jhangiani, Nikhyl; Boissy, Adrienne; Rothberg, Michael B.			Antibiotic Prescribing for Respiratory Tract Infections and Encounter Length: An Observational Study of Telemedicine	ANNALS OF INTERNAL MEDICINE			English	Letter									[Martinez, Kathryn A.; Rood, Mark; Jhangiani, Nikhyl; Boissy, Adrienne; Rothberg, Michael B.] Cleveland Clin, Cleveland, OH 44106 USA	Cleveland Clinic Foundation	Martinez, KA (corresponding author), Cleveland Clin, Cleveland, OH 44106 USA.	martink12@ccf.org						Fleming-Dutra KE, 2016, JAMA-J AM MED ASSOC, V315, P1864, DOI 10.1001/jama.2016.4151; Imanpour Sara, 2017, JRSM Open, V8, p2054270417717668, DOI 10.1177/2054270417717668; Linder JA, 2003, CLIN THER, V25, P2419, DOI 10.1016/S0149-2918(03)80284-9; Martinez KA, 2018, JAMA INT MED; Welschen I, 2004, FAM PRACT, V21, P234, DOI 10.1093/fampra/cmh303	5	16	16	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 19	2019	170	4					275	+		10.7326/M18-2042	http://dx.doi.org/10.7326/M18-2042			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL7AH	30285078				2023-01-03	WOS:000458888200022
J	Iversen, K; Ihlemann, N; Gill, SU; Madsen, T; Elming, H; Jensen, KT; Bruun, NE; Hofsten, DE; Fursted, K; Christensen, JJ; Schultz, M; Klein, CF; Fosboll, EL; Rosenvinge, F; Schonheyder, HC; Kober, L; Torp-Pedersen, C; Helweg-Larsen, J; Tonder, N; Moser, C; Bundgaard, H				Iversen, Kasper; Ihlemann, Nikolaj; Gill, Sabine U.; Madsen, Trine; Elming, Hanne; Jensen, Kaare T.; Bruun, Niels E.; Hofsten, Dan E.; Fursted, Kurt; Christensen, Jens J.; Schultz, Martin; Klein, Christine F.; Fosboll, Emil L.; Rosenvinge, Flemming; Schonheyder, Henrik C.; Kober, Lars; Torp-Pedersen, Christian; Helweg-Larsen, Jannik; Tonder, Niels; Moser, Claus; Bundgaard, Henning			Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IN-HOSPITAL MORTALITY; INFECTIVE ENDOCARDITIS; ANTIMICROBIAL THERAPY; RISK-FACTORS; DRUG-USERS; FUNCTIONAL DECLINE; MANAGEMENT; DIAGNOSIS; CRITERIA	BACKGROUND Patients with infective endocarditis on the left side of the heart are typically treated with intravenous antibiotic agents for up to 6 weeks. Whether a shift from intravenous to oral antibiotics once the patient is in stable condition would result in efficacy and safety similar to those with continued intravenous treatment is unknown. METHODS In a randomized, noninferiority, multicenter trial, we assigned 400 adults in stable condition who had endocarditis on the left side of the heart caused by streptococcus, Enterococcus faecalis, Staphylococcus aureus, or coagulase-negative staphylococci and who were being treated with intravenous antibiotics to continue intravenous treatment (199 patients) or to switch to oral antibiotic treatment (201 patients). In all patients, antibiotic treatment was administered intravenously for at least 10 days. If feasible, patients in the orally treated group were discharged to outpatient treatment. The primary outcome was a composite of all-cause mortality, unplanned cardiac surgery, embolic events, or relapse of bacteremia with the primary pathogen, from the time of randomization until 6 months after antibiotic treatment was completed. RESULTS After randomization, antibiotic treatment was completed after a median of 19 days (interquartile range, 14 to 25) in the intravenously treated group and 17 days (interquartile range, 14 to 25) in the orally treated group (P=0.48). The primary composite outcome occurred in 24 patients (12.1%) in the intravenously treated group and in 18 (9.0%) in the orally treated group (between-group difference, 3.1 percentage points; 95% confidence interval, -3.4 to 9.6; P=0.40), which met noninferiority criteria. CONCLUSIONS In patients with endocarditis on the left side of the heart who were in stable condition, changing to oral antibiotic treatment was noninferior to continued intravenous anti-biotic treatment.	[Iversen, Kasper; Schultz, Martin; Klein, Christine F.] Herlev Gentofte Univ Hosp, Dept Cardiol, Herlev, Denmark; [Ihlemann, Nikolaj; Hofsten, Dan E.; Fosboll, Emil L.; Kober, Lars; Bundgaard, Henning] Copenhagen Univ Hosp, Rigshosp, Heart Ctr, Dept Cardiol, Copenhagen, Denmark; [Helweg-Larsen, Jannik] Rigshosp, Dept Infect Dis, Copenhagen, Denmark; [Moser, Claus] Rigshosp, Dept Clin Microbiol, Copenhagen, Denmark; [Tonder, Niels] Hillerod Hosp, Dept Cardiol, Hillerod, Denmark; [Christensen, Jens J.] Univ Copenhagen, Slagelse Hosp, Dept Clin Microbiol, Copenhagen, Denmark; [Christensen, Jens J.] Univ Copenhagen, Inst Clin Med, Copenhagen, Denmark; [Gill, Sabine U.] Odense Univ Hosp, Dept Cardiol, Odense, Denmark; [Rosenvinge, Flemming] Odense Univ Hosp, Dept Clin Microbiol, Odense, Denmark; [Madsen, Trine] Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark; [Torp-Pedersen, Christian] Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark; [Torp-Pedersen, Christian] Aalborg Univ Hosp, Dept Epidemiol & Biostat, Aalborg, Denmark; [Schonheyder, Henrik C.] Aalborg Univ, Aalborg Univ Hosp, Dept Clin Microbiol, Aalborg, Denmark; [Torp-Pedersen, Christian] Aalborg Univ, Dept Hlth Sci & Technol, Aalborg, Denmark; [Elming, Hanne] Zealand Univ Hosp, Dept Cardiol, Roskilde, Denmark; [Jensen, Kaare T.] Aarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark; [Bruun, Niels E.] Univ Hosp Copenhagen, Dept Cardiol, Gentofte, Denmark; [Fursted, Kurt] Statens Serum Inst, Dept Bacteria Parasites & Fungi, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University; Aalborg University Hospital; Aalborg University; Aarhus University; University of Copenhagen; Statens Serum Institut	Bundgaard, H (corresponding author), Copenhagen Univ Hosp, Rigshosp, Heart Ctr, Dept Cardiol B 2141, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	henning.bundgaard@regionh.dk	Bundgaard, Henning/AAA-4381-2020; Iversen, Kasper/GSD-6427-2022; Christensen, Jens Jørgen/L-4078-2019; Moser, Claus Ernst/N-5951-2017; Moser, Claus Ernst/GPK-5546-2022	Bundgaard, Henning/0000-0002-0563-7049; Moser, Claus Ernst/0000-0002-7664-8570; Moser, Claus Ernst/0000-0002-7664-8570; Fosbol, Emil/0000-0002-2048-4167; Kober, Lars/0000-0002-6635-1466; Falk Klein, Christine/0000-0001-9401-6502; Iversen, Kasper/0000-0003-0504-8487; Helweg-Larsen, Jannik/0000-0001-7192-0144	Danish Heart Foundation; Capital Regions Research Council; Hartmann's Foundation; Svend Aage Andersens Foundation; Novo Nordisk Foundation (Borregaard Clinical Scientist Fellowship in translational research) [NNF17OC0025074]	Danish Heart Foundation; Capital Regions Research Council; Hartmann's Foundation; Svend Aage Andersens Foundation; Novo Nordisk Foundation (Borregaard Clinical Scientist Fellowship in translational research)	Supported by unrestricted grants from the Danish Heart Foundation, the Capital Regions Research Council, the Hartmann's Foundation, Svend Aage Andersens Foundation, and the Novo Nordisk Foundation (Borregaard Clinical Scientist Fellowship in translational research; grant no. NNF17OC0025074).	Al-Omari A, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-140; Andrews MM, 2001, CLIN INFECT DIS, V33, P203, DOI 10.1086/321814; [Anonymous], 2017, R LANG ENV STAT COMP; [Anonymous], PRODLIM PRODUCT LIMI; Baddour LM, 2015, CIRCULATION, V132, P1435, DOI 10.1161/CIR.0000000000000296; Berg SK, 2010, EUR J CARDIOVASC NUR, V9, P126, DOI 10.1016/j.ejcnurse.2009.11.007; BLOOMFIELD AL, 1950, CIRCULATION, V2, P801, DOI 10.1161/01.CIR.2.6.801; De Saint-Hubert M, 2009, ACTA CLIN BELG, V64, P187, DOI 10.1179/acb.2009.034; Delahaye F, 2007, SCAND J INFECT DIS, V39, P849, DOI 10.1080/00365540701393088; Dickerman SA, 2007, AM HEART J, V154, P1086, DOI 10.1016/j.ahj.2007.07.023; DWORKIN RJ, 1989, LANCET, V2, P1071; Habib G, 2015, EUR HEART J, V36, P3075, DOI [10.5603/KP.2015.0227, 10.1093/eurheartj/ehv319]; Heldman AW, 1996, AM J MED, V101, P68, DOI 10.1016/S0002-9343(96)00070-8; Isaia G, 2009, AGING CLIN EXP RES, V21, P453, DOI 10.1007/BF03327448; Iversen K, 2013, AM HEART J, V165, P116, DOI 10.1016/j.ahj.2012.11.006; Kehlet H, 2008, LANCET, V371, P791, DOI 10.1016/S0140-6736(08)60357-8; Khoo CK, 2007, ANN SURG, V245, P867, DOI 10.1097/01.sla.0000259219.08209.36; Lacroix A, 2014, MED MALADIES INFECT, V44, P327, DOI 10.1016/j.medmal.2014.05.001; Li JS, 2000, CLIN INFECT DIS, V30, P633, DOI 10.1086/313753; Martin-Davila P, 2005, AM HEART J, V150, P1099, DOI 10.1016/j.ahj.2005.02.009; Mistiaen WP, 2018, SCAND CARDIOVASC J, V52, P58, DOI 10.1080/14017431.2018.1433318; Murdoch DR, 2009, ARCH INTERN MED, V169, P463, DOI 10.1001/archinternmed.2008.603; Mzabi A, 2016, CLIN MICROBIOL INFEC, V22, P607, DOI 10.1016/j.cmi.2016.04.003; Sy RW, 2010, EUR HEART J, V31, P1890, DOI 10.1093/eurheartj/ehq110; THOMAS D J, 1949, Med J Aust, V1, P377; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Wind J, 2006, BRIT J SURG, V93, P800, DOI 10.1002/bjs.5384; [No title captured]	28	287	292	3	50	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 31	2019	380	5					415	424		10.1056/NEJMoa1808312	http://dx.doi.org/10.1056/NEJMoa1808312			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HJ4HS	30152252	Green Published, Bronze			2023-01-03	WOS:000457135700005
J	Wharam, JF; Lu, CY; Zhang, F; Callahan, M; Xu, X; Wallace, J; Soumerai, S; Ross-Degnan, D; Newhouse, JP				Wharam, J. Frank; Lu, Christine Y.; Zhang, Fang; Callahan, Matthew; Xu, Xin; Wallace, Jamie; Soumerai, Stephen; Ross-Degnan, Dennis; Newhouse, Joseph P.			High-Deductible Insurance and Delay in Care for the Macrovascular Complications of Diabetes	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; EMERGENCY-DEPARTMENT; NATURAL EXPERIMENT; HEALTH PLAN; RISK-FACTOR; MORTALITY; QUALITY; STROKE; IMPACT	Background: Little is known about the long-term effects of high-deductible insurance on care for chronic medical conditions. Objective: To determine whether a transition from low-deductible to high-deductible insurance is associated with delayed medical care for macrovascular complications of diabetes. Design: Observational longitudinal comparison of matched groups. Setting: A large national health insurer during 2003 to 2012. Participants: The intervention group comprised 33 957 persons with diabetes who were continuously enrolled in low-deductible (<=$500) insurance plans during a baseline year followed by up to 4 years in high-deductible (>=$1000) plans. The control group included 294 942 persons with diabetes who were enrolled in low-deductible plans contemporaneously with matched intervention group members. Intervention: Employer-mandated transition to a high-deductible plan. Measurements: The number of months it took for persons in each study group to seek care for their first major macrovascular symptom, have their first major diagnostic test for macrovascular disease, and have their first major procedure-based treatment was determined. Between-group differences in time to reach a midpoint event rate were then calculated. Results: No baseline differences were found between groups. During follow-up, the delay for the high-deductible group was 1.5 months (95% CI, 0.8 to 2.3 months) for seeking care for the first major symptom, 1.9 months (CI, 1.4 to 2.3 months) for the first diagnostic test, and 3.1 months (CI, 0.5 to 5.8 months) for the first procedure-based treatment. Limitation: Health outcomes were not examined. Conclusion: Among persons with diabetes, mandated enrollment in a high-deductible insurance plan was associated with delays in seeking care for the first major symptoms of macrovascular disease, the first diagnostic test, and the first procedure-based treatment.	[Wharam, J. Frank; Lu, Christine Y.; Zhang, Fang; Callahan, Matthew; Xu, Xin; Wallace, Jamie; Soumerai, Stephen; Ross-Degnan, Dennis; Newhouse, Joseph P.] Harvard Med Sch, Boston, MA USA; [Wharam, J. Frank; Lu, Christine Y.; Zhang, Fang; Callahan, Matthew; Xu, Xin; Wallace, Jamie; Soumerai, Stephen; Ross-Degnan, Dennis] Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Newhouse, Joseph P.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Newhouse, Joseph P.] Harvard Kennedy Sch, Cambridge, MA USA; [Newhouse, Joseph P.] Natl Bur Econ Res, Cambridge, MA 02138 USA; [Wharam, J. Frank; Lu, Christine Y.; Zhang, Fang; Callahan, Matthew; Xu, Xin; Wallace, Jamie; Soumerai, Stephen; Ross-Degnan, Dennis] Harvard Med Sch, Dept Populat Med, 401 Pk Dr,Suite 401, Boston, MA 02215 USA; [Wharam, J. Frank; Lu, Christine Y.; Zhang, Fang; Callahan, Matthew; Xu, Xin; Wallace, Jamie; Soumerai, Stephen; Ross-Degnan, Dennis] Harvard Pilgrim Hlth Care Inst, 401 Pk Dr,Suite 401, Boston, MA 02215 USA; [Newhouse, Joseph P.] Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; National Bureau of Economic Research; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School	Wharam, JF (corresponding author), Harvard Med Sch, Dept Populat Med, 401 Pk Dr,Suite 401, Boston, MA 02215 USA.; Wharam, JF (corresponding author), Harvard Pilgrim Hlth Care Inst, 401 Pk Dr,Suite 401, Boston, MA 02215 USA.	jwharam@post.harvard.edu	Zhang, Fang/HHN-2153-2022; Newhouse, Joseph/AGJ-5632-2022; Newhouse, Joseph/AAD-9763-2019	Wharam, James/0000-0003-2053-0757	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01-DK100304]; NIDDK Health Delivery Systems Center for Diabetes Translational Research [1P30-DK092924]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK100304, P30DK092924] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK Health Delivery Systems Center for Diabetes Translational Research; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	By grants R01-DK100304 (principal investigator: Dr. Wharam) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and 1P30-DK092924 from the NIDDK Health Delivery Systems Center for Diabetes Translational Research.	Abbott RD, 2003, J CLIN EPIDEMIOL, V56, P479, DOI 10.1016/S0895-4356(02)00611-X; Anand DV, 2006, EUR HEART J, V27, P713, DOI 10.1093/eurheartj/ehi808; Anderson JL, 2007, J AM COLL CARDIOL, V50, P652, DOI 10.1016/j.jacc.2007.02.028; Antman EM, 2008, J AM COLL CARDIOL, V51, P2028, DOI 10.1016/j.jacc.2007.10.001; Antman Elliott M, 2004, J Am Coll Cardiol, V44, P671, DOI 10.1016/j.jacc.2004.07.002; Ayanian JZ, 2000, JAMA-J AM MED ASSOC, V284, P2061, DOI 10.1001/jama.284.16.2061; Beckles GLA, 1998, DIABETES CARE, V21, P1432, DOI 10.2337/diacare.21.9.1432; Bray GA, 2013, DIABETES CARE, V36, P11, DOI 10.2337/dc12-1631; Brot-Goldberg ZC, 2017, Q J ECON, V132, P1261, DOI 10.1093/qje/qjx013; Charles M, 2011, DIABETES CARE, V34, P2244, DOI 10.2337/dc11-0903; Chernew ME, 2008, HEALTH AFFAIR, V27, P103, DOI 10.1377/hlthaff.27.1.103; da Graca B, 2013, CIRC-CARDIOVASC QUAL, V6, P124, DOI 10.1161/CIRCOUTCOMES.112.968826; Deshpande AD, 2008, PHYS THER, V88, P1254, DOI 10.2522/ptj.20080020; Duru OK, 2015, J GEN INTERN MED, V30, P1645, DOI 10.1007/s11606-015-3284-8; Ethnic Technologies, 2018, FREQ ASK QUEST; Fang J, 2004, AM J PUBLIC HEALTH, V94, P778, DOI 10.2105/AJPH.94.5.778; Fox CS, 2004, DIABETES CARE, V27, P704, DOI 10.2337/diacare.27.3.704; Gibbons LW, 2000, AM J CARDIOL, V86, P53, DOI 10.1016/S0002-9149(00)00827-4; Hammoud T, 2000, J AM COLL CARDIOL, V36, P355, DOI 10.1016/S0735-1097(00)00732-4; HOLM S, 1979, SCAND J STAT, V6, P65; Hu FB, 2001, ARCH INTERN MED, V161, P1717, DOI 10.1001/archinte.161.14.1717; Iacus SM, 2017, CEM COARSENED EXACT; Iacus SM, 2012, POLIT ANAL, V20, P1, DOI 10.1093/pan/mpr013; Iacus SM, 2011, J AM STAT ASSOC, V106, P345, DOI 10.1198/jasa.2011.tm09599; ject, 2003, EUR HEART J, V24, P987, DOI [DOI 10.1016/S0195-668X(02)00618-8, 10.1016/s0195-668x(03)00114-3, DOI 10.1016/S0195-668X(03)00114-3]; Kalbfleisch J.D., 2002, WILEY SERIES PROBABI; Krieger N, 2003, AM J PUBLIC HEALTH, V93, P1655, DOI 10.2105/AJPH.93.10.1655; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Laakso M, 1999, PRIMARY CARE, V26, P829, DOI 10.1016/S0095-4543(05)70133-0; Lee JL, 2013, HEALTH AFFAIR, V32, P1251, DOI 10.1377/hlthaff.2012.0902; Lievre MM, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-23; Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261; MOSS SE, 1991, AM J PUBLIC HEALTH, V81, P1158, DOI 10.2105/AJPH.81.9.1158; Newhouse JP, 1993, FREE ALL LESSONS RAN; Newhouse JP, 1996, FREE ALL LESSONS RAN; Ohira T, 2006, STROKE, V37, P2493, DOI 10.1161/01.STR.0000239694.19359.88; Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75; Powell-Griner E, 1999, AM J PUBLIC HEALTH, V89, P882, DOI 10.2105/AJPH.89.6.882; Reid RJ, 2002, HEALTH SERV RES, V37, P1345, DOI 10.1111/1475-6773.01029; Sarwar N, 2010, LANCET, V375, P2215, DOI 10.1016/S0140-6736(10)60484-9; Schreyogg J, 2011, HEALTH ECON, V20, P85, DOI 10.1002/hec.1568; Selby JV, 1996, NEW ENGL J MED, V334, P635, DOI 10.1056/NEJM199603073341006; Selvin E, 2006, DIABETES CARE, V29, P2415, DOI 10.2337/dc06-1058; Shadish W., 2001, EXPT QUASIEXPERIMENT; The Johns Hopkins University, 2018, J HOPK ACG SYST; Towfighi A, 2012, CEREBROVASC DIS, V33, P411, DOI 10.1159/000334192; United States Bureau of the Census, 1994, GEOGR AR REF MAN; United States Census Bureau, 2018, CENS 2000 GAT; VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607; Wharam JF, 2007, JAMA-J AM MED ASSOC, V297, P1093, DOI 10.1001/jama.297.10.1093; Wharam JF, 2018, DIABETES CARE, V41, P940, DOI 10.2337/dc17-1183; Wharam JF, 2018, J CLIN ONCOL, V36, P1121, DOI 10.1200/JCO.2017.75.2501; Wharam JF, 2017, JAMA INTERN MED, V177, P358, DOI 10.1001/jamainternmed.2016.8411; Wharam JF, 2016, MED CARE, V54, P466, DOI 10.1097/MLR.0000000000000521; Whitmore H, 2018, KAISER FAMILY FDN EM; Yang D, 2012, SAS GLOBAL FORUM	56	31	31	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 18	2018	169	12					845	+		10.7326/M17-3365	http://dx.doi.org/10.7326/M17-3365			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HF2JB	30458499	Green Accepted			2023-01-03	WOS:000454061700016
J	[Anonymous]				[Anonymous]			The Effect of High-Deductible Insurance Plans on Diabetes Care	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 18	2018	169	12					I18	I18		10.7326/P18-0018	http://dx.doi.org/10.7326/P18-0018			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HF2JB	30458498				2023-01-03	WOS:000454061700003
J	Wang, LG; Yu, Y; Tao, T; Zhang, JY; Gao, WB				Wang, Ligang; Yu, Yan; Tao, Ting; Zhang, Jingyi; Gao, Wenbin			The self-care dilemma of type 2 diabetic patients: The mechanism of self-regulation resource depletion	PLOS ONE			English	Article							STRENGTH MODEL; COGNITIVE CONTROL; EGO DEPLETION; FAILURE; BEHAVIORS; MEMORY; LIFE	Self-care is important for type 2 diabetes mellitus (T2DM) patients' disease prognosis, but there is a common phenomenon of self-regulation failure in T2DMs. In order to figure this problem out, the current study explored the interaction between self-regulation resource depletion and diabetes self-care based on the limited resource model of self-regulation. 104 patients were surveyed using the Self-Regulatory Fatigue Scale (SRF-S) and the Diabetes Self-care Scale (DSCS) in study 1. Study 2 recruited 30 T2DM patients and 30 healthy controls, and used a sequential-task paradigm to test the effect of self-regulation resource depletion on them. Participants in study 3 were 60 T2DM patients under different levels of self-regulation resource depletion manipulation, and their self-regulation performance was recorded and compared. Study 1 indicated that the correlation between self-regulation resource depletion and exercise and diet was significant and negative, suggesting that patients with greater self-regulation resource depletion performed poorly in exercise and diet. In Study 2, T2DM patients exhibited a poorer performance on the Spatial Incompatibility Task than the participants in the control group, suggesting that their self-regulation resource was insufficient. Study 3 indicated that there was no difference in Spatial Incompatibility Task performance, reaction time or error number among patients who were requested to complete a dietary record for one week and patients who were only requested to record eating times. This research demonstrated that low levels of diabetes self-care execution was associated with patients' deficiency in self-regulatory resource, and self-care as a series of goal-directed behaviors consumed patients' self-regulatory resources before these behaviors became a habit.	[Wang, Ligang; Yu, Yan; Tao, Ting; Zhang, Jingyi; Gao, Wenbin] Inst Psychol, CAS Key Lab Mental Hlth, Beijing, Peoples R China; [Wang, Ligang; Yu, Yan; Tao, Ting; Zhang, Jingyi; Gao, Wenbin] Univ Chinese Acad Sci, Beijing, Peoples R China	Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Gao, WB (corresponding author), Inst Psychol, CAS Key Lab Mental Hlth, Beijing, Peoples R China.; Gao, WB (corresponding author), Univ Chinese Acad Sci, Beijing, Peoples R China.	gaowb@psych.ac.cn		Gao, Wenbin/0000-0002-6526-5013	National Natural Science Foundation of China [31400885]; Foundation for Cooperation between Hebei Province and University [130000115]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation for Cooperation between Hebei Province and University	This work was supported by the National Natural Science Foundation of China (No. 31400885; URL: http://www.nsfc.gov.cn/publish/portal1/).The work was also supported by the Foundation for Cooperation between Hebei Province and University (No. 130000115; URL: http://www.hebjh.gov.cn/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ausili D, 2016, INT J NURS STUD, V63, P18, DOI 10.1016/j.ijnurstu.2016.08.006; Bagozzi RP, 2004, BASIC APPL SOC PSYCH, V26, P199, DOI 10.1207/s15324834basp2602&3_7; Baumeister RF, 2007, CURR DIR PSYCHOL SCI, V16, P351, DOI 10.1111/j.1467-8721.2007.00534.x; Biessels GJ, 2014, DIABETES, V63, P2244, DOI 10.2337/db14-0348; Burkard C, 2014, NEUROPSYCHOL REHABIL, V24, P266, DOI 10.1080/09602011.2014.887023; Dahm T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026351; Dang JH, 2013, CONSCIOUS COGN, V22, P816, DOI 10.1016/j.concog.2013.05.005; Davidson MC, 2006, NEUROPSYCHOLOGIA, V44, P2037, DOI 10.1016/j.neuropsychologia.2006.02.006; de Bresser J, 2010, DIABETES CARE, V33, P1309, DOI 10.2337/dc09-1923; Denson TF, 2010, J EXP SOC PSYCHOL, V46, P1023, DOI 10.1016/j.jesp.2010.05.023; DERIDDER DTD, 2012, TAKING STOCK OF SELF, V16, P76, DOI DOI 10.1177/1088868311418749; Detweiler-Bedell JB, 2008, CLIN PSYCHOL REV, V28, P1426, DOI 10.1016/j.cpr.2008.09.002; Ginis KAM, 2010, PSYCHOL HEALTH, V25, P1147, DOI 10.1080/08870440903111696; Hagger MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076888; Hagger MS, 2010, PSYCHOL BULL, V136, P495, DOI 10.1037/a0019486; Hagger MS, 2009, HEALTH PSYCHOL REV, V3, P208, DOI 10.1080/17437190903414387; Heatherton TF, 1998, PSYCHOL INQ, V9, P212, DOI 10.1207/s15327965pli0903_4; Hofmann W, 2012, PSYCHOL SCI, V23, P582, DOI 10.1177/0956797612437426; Hofmann W, 2009, J EXP SOC PSYCHOL, V45, P431, DOI 10.1016/j.jesp.2008.09.013; Hurley A C, 1992, Diabetes Educ, V18, P146, DOI 10.1177/014572179201800208; Jostmann NB, 2007, J EXP PSYCHOL GEN, V136, P593, DOI 10.1037/0096-3445.136.4.593; Kargar Jahromi Marzieh, 2014, Glob J Health Sci, V7, P10, DOI 10.5539/gjhs.v7n1p10; Liu Y, 2011, JILIN MED J, V32, P5738; McCrimmon RJ, 2012, LANCET, V379, P2291, DOI 10.1016/S0140-6736(12)60360-2; Monette MCE, 2014, CAN J DIABETES, V38, P401, DOI 10.1016/j.jcjd.2014.01.014; Muraven M, 2000, PSYCHOL BULL, V126, P247, DOI 10.1037/0033-2909.126.2.247; Muraven M, 1999, J SOC PSYCHOL, V139, P446, DOI 10.1080/00224549909598404; Nes LS, 2010, PAIN, V151, P37, DOI 10.1016/j.pain.2010.05.009; Pan J, 2006, J NURSING SCI, V21, P7; Pare G, 2010, J MED INTERNET RES, V12, DOI 10.2196/jmir.1357; Saleh F, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-431; Shah AK, 2012, SCIENCE, V338, P682, DOI 10.1126/science.1222426; Shmueli D, 2009, HEALTH PSYCHOL, V28, P300, DOI 10.1037/a0013826; SN L, 2013, J PAIN RES; van den Berg E, 2010, DIABETOLOGIA, V53, P58, DOI 10.1007/s00125-009-1571-9; Vohs KD, 2000, PSYCHOL SCI, V11, P249, DOI 10.1111/1467-9280.00250; Wagner DD, 2013, PSYCHOL SCI, V24, P2262, DOI 10.1177/0956797613492985; Walker RJ, 2014, ETHNIC DIS, V24, P349; Wang LG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142220; [王利刚 Wang LiGang], 2015, [中国心理卫生杂志, Chinese Mental Health Journal], V29, P290; Wang Q., 2009, J NURS SCI, V24, P14; Williams IC, 2014, DIABETES EDUCATOR, V40, P231, DOI 10.1177/0145721713520570; Wills TA, 2007, J ADOLESCENT HEALTH, V41, P551, DOI 10.1016/j.jadohealth.2007.06.013; Yu Pingping, 2013, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V38, P425, DOI 10.3969/j.issn.1672-7347.2013.04.015; Yuan C, 2014, EFFECT DIABETES SELF, V2014, DOI [10.1155/2014/789761, DOI 10.1155/2014/789761]	45	4	4	3	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 6	2018	13	12							e0208690	10.1371/journal.pone.0208690	http://dx.doi.org/10.1371/journal.pone.0208690			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HD1YF	30521626	Green Published, gold, Green Submitted			2023-01-03	WOS:000452307600103
J	Day, M				Day, Michael			Three Belgian doctors are investigated over euthanasia of woman with Asperger's	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Thienpont L, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007454	1	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	2018	363								k5106	10.1136/bmj.k5106	http://dx.doi.org/10.1136/bmj.k5106			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC9MI	30504182				2023-01-03	WOS:000452130000011
J	Dat, VQ; Huong, VTL; Turner, HC; Thwaites, L; van Doorn, HR; Nadjm, B				Vu Quoc Dat; Vu Thi Lan Huong; Turner, Hugo C.; Thwaites, Louise; van Doorn, H. Rogier; Nadjm, Behzad			Excess direct hospital cost of treating adult patients with ventilator associated respiratory infection (VARI) in Vietnam	PLOS ONE			English	Article							CARE-ASSOCIATED INFECTIONS; HEALTH; PNEUMONIA; METAANALYSIS; PATTERNS; BURDEN; IMPACT	Introduction Ventilator associated respiratory infections (VARIs) are the most common hospital acquired infections in critical care worldwide. This work aims to estimate the total annual direct hospital cost of treating VARI throughout Vietnam. Methods A costing model was constructed to evaluate the excess cost of diagnostics and treatment of VARI in Vietnam. Model inputs included costs for extra lengths of stay, diagnostics, VARI incidence, utilisation of ventilators and antibiotic therapy. Results With the current VARI incidence rate of 21.7 episodes per 1000 ventilation-days, we estimated 34,428 VARI episodes in the 577 critical care units in Vietnam per year. The extra cost per VARI episode was $1,174.90 and the total annual excess cost was US$40.4 million. A 1% absolute reduction in VARI incidence density would save US$1.86 million annually. For each episode of VARI, the share of excess cost components was 45.1% for critical care unit stay and ventilation, 3.7% for diagnostics and 51.1% for extra antimicrobial treatment. Conclusions At the current annual government health expenditure of US$117 per capita, VARI represents a substantial cost to the health service in Vietnam. Enhanced infection prevention and control and antimicrobial stewardship programmes should be implemented to reduce this.	[Vu Quoc Dat] Hanoi Med Univ, Dept Infect Dis, Hanoi, Vietnam; [Vu Quoc Dat; Vu Thi Lan Huong; Turner, Hugo C.; Thwaites, Louise; van Doorn, H. Rogier; Nadjm, Behzad] Univ Oxford, Wellcome Trust Asia Programme, Clin Res Unit, Hanoi, Vietnam; [Turner, Hugo C.; Thwaites, Louise; van Doorn, H. Rogier; Nadjm, Behzad] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Clin Med, Oxford, England	Hanoi Medical University; University of Oxford; University of Oxford	Dat, VQ (corresponding author), Hanoi Med Univ, Dept Infect Dis, Hanoi, Vietnam.; Dat, VQ (corresponding author), Univ Oxford, Wellcome Trust Asia Programme, Clin Res Unit, Hanoi, Vietnam.	datvq@hmu.edu.vn	van Doorn, H. Rogier/H-3080-2019; Dat, Vu Quoc/L-8899-2017	van Doorn, H. Rogier/0000-0002-9807-1821; Dat, Vu Quoc/0000-0002-5904-5970	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allegranzi B, 2011, LANCET, V377, P228, DOI 10.1016/S0140-6736(10)61458-4; Alvarez-Lerma F, 2006, CRIT CARE, V10, DOI 10.1186/cc4919; [Anonymous], 2015, JOINT CIRCULAR UNIFY; [Anonymous], 2017, DECISION CEILLING PR; [Anonymous], 2016, COMMON INDEX CODES A; Arefian H, 2016, AM J INFECT CONTROL, V44, P160, DOI 10.1016/j.ajic.2015.09.005; Dieleman J, 2017, LANCET, V389, P1981, DOI 10.1016/S0140-6736(17)30874-7; Drug Administration of Vietnam, 2018, SUMM BID WINN RES NA; Duong MC, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2290-3; General Statistics Office, 2017, STAT YB VIETN 2016; Gilbert DN, 2017, SANFORD GUIDE ANTIMI; Graves N, 2010, CLIN INFECT DIS, V50, P1017, DOI 10.1086/651110; Ha DT, 2015, INT J EMERG MED, V8, DOI 10.1186/s12245-015-0066-3; Ha N, 2012, AM J INFECT CONTROL, V40, pe146, DOI [10.1016/j.ajic.2012.04.259, DOI 10.1016/J.AJIC.2012.04.259]; Kalil AC, 2016, CLIN INFECT DIS, V63, pE61, DOI 10.1093/cid/ciw353; Kollef MH, 2012, INFECT CONT HOSP EP, V33, P250, DOI 10.1086/664049; Kollef MH, 2006, CHEST, V129, P1210, DOI 10.1378/chest.129.5.1210; Thu LTA, 2015, AM J INFECT CONTROL, V43, pE93, DOI 10.1016/j.ajic.2015.08.006; Ling ML, 2015, CLIN INFECT DIS, V60, P1690, DOI 10.1093/cid/civ095; Magill SS, 2014, NEW ENGL J MED, V370, P1198, DOI 10.1056/NEJMoa1306801; Mathai AS, 2015, J INFECT PUBLIC HEAL, V8, P127, DOI 10.1016/j.jiph.2014.07.005; Melsen WG, 2013, LANCET INFECT DIS, V13, P665, DOI 10.1016/S1473-3099(13)70081-1; Pekerti A, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14101118; Le P, 2014, TROP MED INT HEALTH, V19, P1321, DOI 10.1111/tmi.12370; Safdar N, 2005, CRIT CARE MED, V33, P2184, DOI 10.1097/01.CCM.0000181731.53912.D9; Stone PW, 2005, AM J INFECT CONTROL, V33, P501, DOI 10.1016/j.ajic.2005.04.246; Tarricone R, 2006, HEALTH POLICY, V77, P51, DOI 10.1016/j.healthpol.2005.07.016; The World Bank, GNI PER CAP ATL METH; Torres A, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00582-2017; Vietnam Medical Services Administration, 2015, SURV REP CAP CLIN MA; Vincent JL, 2003, LANCET, V361, P2068, DOI 10.1016/S0140-6736(03)13644-6; Phu VD, 2017, J INTENSIVE CARE, V5, DOI 10.1186/s40560-017-0266-4; Phu VD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147544; Dat VQ, 2017, J CRIT CARE, V42, P109, DOI 10.1016/j.jcrc.2017.07.020; World Bank, 2018, OFF EXCH RAT LCU PER; World Health Organization, 2018, GLOBAL HLTH EXPENDIT; World Health Organization, MED PRIC MAK PEOPL S; Wyncoll D, 2012, CRIT CARE, V16, DOI 10.1186/cc11346; Zarb P, 2012, EURO SURVEILLANCE B, V17; Zimlichman E, 2013, JAMA INTERN MED, V173, P2039, DOI 10.1001/jamainternmed.2013.9763	40	2	2	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2018	13	10							e0206760	10.1371/journal.pone.0206760	http://dx.doi.org/10.1371/journal.pone.0206760			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY7VH	30379956	Green Submitted, Green Published, gold			2023-01-03	WOS:000448823700147
J	Wu, XJ; Li, Z; Cao, J; Jiao, J; Wang, YL; Liu, G; Liu, Y; Li, FF; Song, BY; Jin, JF; Liu, YL; Wen, XX; Cheng, SZ; Wan, X				Wu, Xinjuan; Li, Zhen; Cao, Jing; Jiao, Jing; Wang, Yingli; Liu, Ge; Liu, Ying; Li, Fangfang; Song, Baoyun; Jin, Jingfen; Liu, Yilan; Wen, Xianxiu; Cheng, Shouzhen; Wan, Xia			The association between major complications of immobility during hospitalization and quality of life among bedridden patients: A 3 month prospective multi-center study	PLOS ONE			English	Article							URINARY-TRACT-INFECTIONS; PRESSURE ULCERS; THROMBOSIS; PNEUMONIA; IMPACT; PREDICTORS; PREVENTION; COST; RISK	Purpose To describe the association between major complications of immobility (pressure ulcer, pneumonia, deep vein thrombosis and urinary tract infection) during hospitalization and the patients' health-related quality of life after discharge. Methods The data were obtained from a multi-center study conducted in 2015. Complications of immobility during hospitalization was measured by case report form and quality of life after discharge was measured using the EQ-5D scale by telephone interview. Multilevel mixed-effects models were used to explore the association of complications and responses in the EQ-5D dimensions after controlling for important covariates. Results Among the 20,515 bedridden patients, 2,601(12.72%) patients experienced at least one of the major complications of immobility during hospitalization, including pressure ulcer (527, 2.57%), deep vein thrombosis (343, 1.67%), pneumonia (1647, 8.16%), and urinary tract infection (265, 1.29%). Patients with any of the four complications during hospitalization reported more problems in all EQ-5D dimensions except for pain/discomfort, and had lower mean EQ-VAS scores than those without any complications. The four complications all showed significant associations with the proportion of reported problems in certain dimensions after adjustment for confounding variables. Conclusions Major complications of immobility were significantly associated with reduced health related quality of life. Prevention of complications is critical to reduce the burden of decreased quality of life for bedridden patients.	[Wu, Xinjuan; Li, Zhen; Cao, Jing; Jiao, Jing; Liu, Ge; Liu, Ying; Li, Fangfang] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Nursing, Beijing, Peoples R China; [Wu, Xinjuan; Li, Zhen; Cao, Jing; Jiao, Jing; Wang, Yingli; Liu, Ge; Liu, Ying; Li, Fangfang] Peking Union Med Coll, Beijing, Peoples R China; [Wang, Yingli] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Operat Ctr, Beijing, Peoples R China; [Song, Baoyun] Henan Prov Peoples Hosp, Dept Nursing, Zhengzhou, Henan, Peoples R China; [Jin, Jingfen] Zhejiang Univ, Dept Nursing, Sch Med, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China; [Liu, Yilan] Huazhong Univ Sci & Technol, Union Hosp, Dept Nursing, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [Wen, Xianxiu] Sichuan Prov Peoples Hosp, Dept Nursing, Chengdu, Sichuan, Peoples R China; [Cheng, Shouzhen] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Nursing, Guangzhou, Guangdong, Peoples R China; [Wan, Xia] Chinese Acad Med Sci, Inst Basic Med Sci, Beijing, Peoples R China; [Wan, Xia] Peking Union Med Coll, Sch Basic Med, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Zhengzhou University; Zhejiang University; Huazhong University of Science & Technology; Sichuan Provincial People's Hospital; Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Wu, XJ (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Nursing, Beijing, Peoples R China.; Wu, XJ (corresponding author), Peking Union Med Coll, Beijing, Peoples R China.	wuxinjuan@sina.com		, Zhen/0000-0002-4052-199X	National Health and Family Planning Commission (Beijing, China) [201502017]	National Health and Family Planning Commission (Beijing, China)	The present study was supported by the National Health and Family Planning Commission (Beijing, China) [grant numbers 201502017]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bermingham SL, 2012, BJU INT, V110, pE830, DOI 10.1111/j.1464-410X.2012.11337.x; Black Joyce, 2007, Adv Skin Wound Care, V20, P269, DOI 10.1097/01.ASW.0000269314.23015.e9; Brogan E, 2014, DYSPHAGIA, V29, P340, DOI 10.1007/s00455-013-9514-5; Bulum B, 2014, ACTA PAEDIATR, V103, pE454, DOI 10.1111/apa.12732; Cao B, 2018, CLIN RESPIR J, V12, P1320, DOI 10.1111/crj.12674; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cheng Gregory, 2011, Thrombosis, V2011, P629383, DOI 10.1155/2011/629383; Chou CL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127731; Ciani O, 2013, CLIN DRUG INVEST, V33, P255, DOI 10.1007/s40261-013-0069-x; Coleman S, 2013, INT J NURS STUD, V50, P974, DOI 10.1016/j.ijnurstu.2012.11.019; Costa N, 2016, VALUE HEALTH, V19, pA113, DOI 10.1016/j.jval.2016.03.445; Dellinger EP, 2016, SURG INFECT, V17, P422, DOI 10.1089/sur.2016.048; Dick AW, 2015, AM J INFECT CONTROL, V43, P4, DOI 10.1016/j.ajic.2014.07.014; Eriksson I, 2011, INT PSYCHOGERIATR, V23, P496, DOI 10.1017/S1041610210001456; Ghanima W, 2018, THROMB RES, V164, P170, DOI 10.1016/j.thromres.2017.07.025; Gorecki C, 2009, J AM GERIATR SOC, V57, P1175, DOI 10.1111/j.1532-5415.2009.02307.x; Guo FY, 2015, J NEUROSCI RURAL PRA, V6, P471, DOI 10.4103/0976-3147.169801; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; Hogg K, 2013, J THROMB HAEMOST, V11, P82; Honselmann KC, 2015, J CRIT CARE, V30, P721, DOI 10.1016/j.jcrc.2015.03.009; Kahn SR, 2011, THROMB RES, V127, pS89, DOI 10.1016/S0049-3848(11)70024-X; Kivits J, 2013, REV EPIDEMIOL SANTE, V61, pS189, DOI 10.1016/j.respe.2013.06.001; Kwong E, 2005, APPL NURS RES, V18, P122, DOI 10.1016/j.apnr.2005.01.001; Lourenco L, 2014, J WOUND CARE, V23, P331, DOI 10.12968/jowc.2014.23.6.331; Mangen MJJ, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2302-3; Palfreyman SJ, 2013, QUAL LIFE RES, V22; Peyrani P, 2017, J RESP INFECT, V1, DOI [10.18297/jri/vol1/iss4/10, DOI 10.18297/JRI/VOL1/ISS4/10]; Raskob GE, 2014, SEMIN THROMB HEMOST, V40, P724, DOI 10.1055/s-0034-1390325; Reeve B, 2013, QUAL LIFE RES, V22, P1889, DOI 10.1007/s11136-012-0344-y; Saldias F, 2013, REV MED CHILE, V141, P831, DOI 10.4067/S0034-98872013000700002; Schaeffer AJ, 2016, NEW ENGL J MED, V374, P562, DOI 10.1056/NEJMcp1503950; de Souza DMST, 2015, J WOUND OSTOMY CONT, V42, P352, DOI 10.1097/WON.0000000000000142; Souza DMST, 2013, J WOUND OSTOMY CONT, V40, pS76; Spilsbury K, 2007, J ADV NURS, V57, P494, DOI 10.1111/j.1365-2648.2006.04140.x; Sun S, 2011, QUAL LIFE RES, V20, P309, DOI 10.1007/s11136-010-9762-x; Theisen S, 2012, J CLIN NURS, V21, P380, DOI 10.1111/j.1365-2702.2011.03915.x; Tichopad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071375; Utne KK, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2949-z; Wang H, 2005, QUAL LIFE RES, V14, P119, DOI 10.1007/s11136-004-0612-6; Wang HM, 2012, QUAL LIFE RES, V21, P155, DOI 10.1007/s11136-011-9915-6; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wu CM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164334	42	37	41	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2018	13	10							e0205729	10.1371/journal.pone.0205729	http://dx.doi.org/10.1371/journal.pone.0205729			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GX0UN	30312330	Green Submitted, gold, Green Published			2023-01-03	WOS:000447427300052
J	Muftuoglu, M; Olson, A; Marin, D; Ahmed, S; Mulanovich, V; Tummala, S; Chi, TL; Ferrajoli, A; Kaur, I; Li, L; Champlin, R; Shpall, E; Rezvani, K				Muftuoglu, Muharrem; Olson, Amanda; Marin, David; Ahmed, Sairah; Mulanovich, Victor; Tummala, Sudhakar; Chi, T. Linda; Ferrajoli, Alessandra; Kaur, Indreshpal; Li, Li; Champlin, Richard; Shpall, Elizabeth; Rezvani, Katayoun			Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							JC VIRUS; CROSS-REACTIVITY; TRANSPLANTATION; ASSOCIATION; INFECTIONS; DISEASE	JC virus, the cause of progressive multifocal leukoencephalopathy (PML), and the BK virus are genetically similar and share sequence homology in immunogenic proteins. We treated three immunosuppressed patients with PML with ex vivo-expanded, partially HLA-matched, third-party-produced, cryopreserved BK virus-specific T cells. The immunosuppression in these patients was due to the conditioning regimen for cord-blood transplantation in one patient, a myeloproliferative neoplasm treated with ruxolitinib in another, and acquired immunodeficiency syndrome in the third. After T-cell infusion in two of the patients, alleviation of the clinical signs and imaging features of PML was seen and JC virus in the cerebrospinal fluid (CSF) cleared. The other patient had a reduction in JC viral load and stabilization of symptoms that persisted until her death 8 months after the first infusion. Two of the patients had immune reconstitution syndrome. Donor-derived T cells were detected in the CSF after infusion.	[Muftuoglu, Muharrem; Olson, Amanda; Marin, David; Ahmed, Sairah; Kaur, Indreshpal; Li, Li; Champlin, Richard; Shpall, Elizabeth; Rezvani, Katayoun] MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, 1515 Holcombe Blvd,Box 448, Houston, TX 77030 USA; [Mulanovich, Victor] MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77030 USA; [Tummala, Sudhakar] MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; [Chi, T. Linda] MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA; [Ferrajoli, Alessandra] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Rezvani, K (corresponding author), MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, 1515 Holcombe Blvd,Box 448, Houston, TX 77030 USA.	krezvani@mdanderson.org		ahmed, sairah/0000-0001-7302-8299; Muftuoglu, Muharrem/0000-0001-8100-8554	M.D. Anderson Cancer Center Moon Shots Program; National Institutes of Health; NATIONAL CANCER INSTITUTE [R01CA061508, P30CA016672] Funding Source: NIH RePORTER	M.D. Anderson Cancer Center Moon Shots Program; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by the M.D. Anderson Cancer Center Moon Shots Program and the National Institutes of Health; ClinicalTrials.gov number, NCT02479698.	Alstadhaug KB, 2014, JAMA NEUROL, V71, P1030, DOI 10.1001/jamaneurol.2014.825; Balduzzi A, 2011, BONE MARROW TRANSPL, V46, P987, DOI 10.1038/bmt.2010.221; Barbanti-Brodano G, 2006, ADV EXP MED BIOL, V577, P319; Berger JR, 2013, NEUROLOGY, V80, P1430, DOI 10.1212/WNL.0b013e31828c2fa1; Cantalupo P, 2005, J VIROL, V79, P13094, DOI 10.1128/JVI.79.20.13094-13104.2005; Ferenczy MW, 2012, CLIN MICROBIOL REV, V25, P471, DOI 10.1128/CMR.05031-11; Kharfan-Dabaja MA, 2007, BONE MARROW TRANSPL, V39, P101, DOI 10.1038/sj.bmt.1705548; Koralnik IJ, 2002, J IMMUNOL, V168, P499, DOI 10.4049/jimmunol.168.1.499; Krymskaya L, 2005, J VIROL, V79, P11170, DOI 10.1128/JVI.79.17.11170-11178.2005; Kunschner L, 2005, NEUROLOGY, V65, P1510, DOI 10.1212/01.wnl.0000183064.10227.b5; Leen AM, 2013, BLOOD, V121, P5113, DOI 10.1182/blood-2013-02-486324; Li J, 2006, J GEN VIROL, V87, P2951, DOI 10.1099/vir.0.82094-0; Molloy ES, 2009, ARTHRITIS RHEUM-US, V60, P3761, DOI 10.1002/art.24966; PADGETT BL, 1971, LANCET, V1, P1257; Pavlovic D, 2015, THER ADV NEUROL DISO, V8, P255, DOI 10.1177/1756285615602832; RHEIN GMZ, 1965, SCIENCE, V148, P1477, DOI 10.1126/science.148.3676.1477; Schwab N, 2017, NEUROLOGY, V88, P1197, DOI 10.1212/WNL.0000000000003739; Sospedra M, 2014, CLIN INFECT DIS, V59, P1588, DOI 10.1093/cid/ciu682; Tan CS, 2010, LANCET NEUROL, V9, P425, DOI 10.1016/S1474-4422(10)70040-5; Tzannou I, 2017, J CLIN ONCOL, V35, P3547, DOI [10.1200/jco.2017.73.0655, 10.1200/JCO.2017.73.0655]; Verma S, 2007, J INFECT DIS, V196, P709, DOI 10.1086/520514	21	83	85	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 11	2018	379	15					1443	1451		10.1056/NEJMoa1801540	http://dx.doi.org/10.1056/NEJMoa1801540			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW4VQ	30304652	Green Accepted, Bronze			2023-01-03	WOS:000446923400008
J	Lin, YP; Lee, YL; Hung, CY; Chang, CF; Chen, Y				Lin, Yen-Ping; Lee, Ying-Lin; Hung, Chien-Ya; Chang, Chuan-Fa; Chen, Yi			Detection of adulterated drugs in traditional Chinese medicine and dietary supplements using hydrogen as a carrier gas	PLOS ONE			English	Article							CHROMATOGRAPHY-MASS SPECTROMETRY; HERBAL MEDICINES; LIQUID-CHROMATOGRAPHY; GC-MS; PATENT MEDICINES; SYNTHETIC DRUGS; WEIGHT-LOSS; SIBUTRAMINE; IDENTIFICATION; CONFIRMATION	Helium, a minor component of natural gas and radioactive minerals, is most commonly used as a carrier in gas chromatography-mass spectrometry (GC-MS). Its scarcity leads to limited availability and higher costs. In this experiment, hydrogen from a safe source of a hydrogen generator was tested as a substitutive carrier gas for the detection of adulterant in traditional Chinese medicine (TCM) and food supplements by GC-MS analysis. We found that the limits of detection (LODs) of using hydrogen were from 10 to 1000 mu g/g. The levels of LODs tested among 170 drugs remain the same whether hydrogen or helium was used as a carrier gas with the exception of 7 drugs-benzbromarone, estradiol benzoate, bezafibrate, mefenamic acid, oxymetholone, piperidenafil and cetilistat. The real sample analysis results using hydrogen were as satisfactory as those using helium. In addition, the retention time was shortened after the chromatographic performance was optimized. In summary, it is worth considering hydrogen as a carrier gas due to its affordable costs, energy efficiency, carbon reduction and chromatographic advantages to detect adulterated drugs in TCM and dietary supplement using GC-MS.	[Lin, Yen-Ping; Lee, Ying-Lin; Hung, Chien-Ya; Chen, Yi] Tainan City Govt, Publ Hlth Bur, Tainan, Taiwan; [Chang, Chuan-Fa] Natl Cheng Kung Univ, Coll Med, Dept Med Lab Sci & Biotechnol, Tainan, Taiwan	National Cheng Kung University	Lin, YP; Lee, YL (corresponding author), Tainan City Govt, Publ Hlth Bur, Tainan, Taiwan.; Chang, CF (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Med Lab Sci & Biotechnol, Tainan, Taiwan.	lab17@tncghb.gov.tw; lab01@tncghb.gov.tw; affa@mail.ncku.edu.tw	Chang, Chuan-Fa/F-8660-2011	Chang, Chuan-Fa/0000-0003-2404-1248	Tainan City Government	Tainan City Government	This work was supported by the Tainan City Government. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, METHOD TEST ADULTERA; Ariburnu E, 2012, J PHARMACEUT BIOMED, V64-65, P77, DOI 10.1016/j.jpba.2012.02.004; Au AM, 2000, B ENVIRON CONTAM TOX, V65, P112, DOI 10.1007/s001280000102; Avivanalytical, HEL SHORT HYDR CARR; Bartram RJ, 2010, LC GC N AM, V28, P890; Bodeker G, 2002, AM J PUBLIC HEALTH, V92, P1582, DOI 10.2105/AJPH.92.10.1582; Champagne AB, 2011, VIB SPECTROSC, V55, P216, DOI 10.1016/j.vibspec.2010.11.009; Cheng HL, 2001, RAPID COMMUN MASS SP, V15, P1473, DOI 10.1002/rcm.396; Connor E, USING HYDROGEN CARRI; Ernst E, 2002, J INTERN MED, V252, P107, DOI 10.1046/j.1365-2796.2002.00999.x; Gregori A, 2013, SCI JUSTICE, V53, P286, DOI 10.1016/j.scijus.2012.10.002; Haneef J, 2013, DRUG TEST ANAL, V5, P607, DOI 10.1002/dta.1482; Impens S, 2001, RAPID COMMUN MASS SP, V15, P2409, DOI 10.1002/rcm.515; Khazan M, 2014, IRAN RED CRESCENT ME, V16, DOI 10.5812/ircmj.15344; Kim SH, 2009, BIOMED CHROMATOGR, V23, P1259, DOI 10.1002/bmc.1248; Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951; Ko RJ, 1998, NEW ENGL J MED, V339, P847, DOI 10.1056/NEJM199809173391214; Lin MC, 2001, J FOOD DRUG ANAL, V9, P139; Liu ZZ, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0002-5; Marcus DM, 2002, NEW ENGL J MED, V347, P2073, DOI 10.1056/NEJMsb022858; Mokhtar SU, 2016, J PHARMACEUT BIOMED, V121, P188, DOI 10.1016/j.jpba.2016.01.034; Munoz-Guerra JA, 2011, J CHROMATOGR A, V1218, P7365, DOI 10.1016/j.chroma.2011.08.009; Nnaji CN, 2015, SCI JUSTICE, V55, P162, DOI 10.1016/j.scijus.2015.01.003; OLIVER BM, 1984, GEOCHIM COSMOCHIM AC, V48, P1759, DOI 10.1016/0016-7037(84)90030-9; Phattanawasin P, 2012, FORENSIC SCI INT, V219, P96, DOI 10.1016/j.forsciint.2011.12.004; Popescu AM, 2015, UNIV POLITEH BUCHAR, V77, P221; Shi F, 2014, J CHROMATOGR A, V1344, P91, DOI 10.1016/j.chroma.2013.12.030; Shimadzu, EV HYDR CARR GAS GAS; Song FH, 2014, J PHARMACEUT BIOMED, V88, P136, DOI 10.1016/j.jpba.2013.08.031; Stypulkowska K, 2011, J PHARMACEUT BIOMED, V56, P969, DOI 10.1016/j.jpba.2011.08.028; Tagami T, 2013, FOOD HYG SAFE SCI, V54, P232, DOI 10.3358/shokueishi.54.232; Tseng MC, 2000, J FOOD DRUG ANAL, V8, P315; Vaysse J, 2010, FOOD ADDIT CONTAM A, V27, P903, DOI 10.1080/19440041003705821; Watanabe A, 2016, ANAL CHEM, V88, P5462, DOI 10.1021/acs.analchem.6b00892; Zhao JC, 2006, CHIN J CHROMATOGR, V24, P660; Zhu QX, 2014, ANAL BIOANAL CHEM, V406, P1877, DOI 10.1007/s00216-013-7605-7	36	14	14	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2018	13	10							e0205371	10.1371/journal.pone.0205371	http://dx.doi.org/10.1371/journal.pone.0205371			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW4VA	30304050	Green Published, Green Submitted, gold			2023-01-03	WOS:000446921100085
J	Koval, R; Willett, J; Briggs, J				Koval, Robin; Willett, Jeffrey; Briggs, Jodie			Potential Benefits and Risks of High-Nicotine e-Cigarettes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Koval, Robin] Truth Initiat, Washington, DC 20001 USA; [Willett, Jeffrey; Briggs, Jodie] Truth Initiat, Schroeder Inst, 900 G St NW, Washington, DC 20001 USA		Briggs, J (corresponding author), Truth Initiat, Schroeder Inst, 900 G St NW, Washington, DC 20001 USA.	jbriggs@truthinitiative.org						Ambrose BK, 2015, JAMA-J AM MED ASSOC, V314, P1871, DOI 10.1001/jama.2015.13802; Centers for Disease Control and Prevention, 2014, SMOK CESS REP SURG G; Cohen G, 2018, SOC RES NIC TOB ANN; Duell AK, 2018, CHEM RES TOXICOL, V31, P431, DOI 10.1021/acs.chemrestox.8b00097; JUUL Laboratories Inc, OUR RESP; McDevitt M., HLTH GROUPS SUE FDA; National Academies of Sciences Engineering and Medicine, 2018, PUBL HLTH CONS E CIG; Schulenberg JE., 2018, MONITORING FUTURE NA, DOI [10.3998/2027.42/146531, DOI 10.3998/2027.42/146531]; Wells Fargo Securities Equity Research, 2018, NIELS TOB ALL CHANN; Willett JG, 2019, TOB CONTROL, V28, P115, DOI 10.1136/tobaccocontrol-2018-054273	10	7	7	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	2018	320	14					1429	1430		10.1001/jama.2018.12328	http://dx.doi.org/10.1001/jama.2018.12328			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW3IX	30326513				2023-01-03	WOS:000446792500007
J	Riang'a, RM; Nangulu, AK; Broerse, JEW				Riang'a, Roselyter Monchari; Nangulu, Anne Kisaka; Broerse, Jacqueline E. W.			"I should have started earlier, but I was not feeling ill!" Perceptions of Kalenjin women on antenatal care and its implications on initial access and differentials in patterns of antenatal care utilization in rural Uasin Gishu County Kenya	PLOS ONE			English	Article							DETERMINANTS; BOOKING	Aim The aim of this study was to explore how Kalenjin women in rural Uasing Gishu County in Kenya perceive antenatal care and how their perceptions impede or motivate earlier access and continuous use of antenatal care services. Methods A study was conducted among 188 pregnant and post-natal mothers seeking care in 23 rural public health facilities. Gestational age at the initial antenatal care booking was established from their medical cards. Further researcher-administered questionnaire with closed and open-ended questions was used. Key informant interviews with traditional birth attendants (n = 6) and maternal and child health nursing officers (n = 6) were also conducted for triangulation. Descriptive statistics were applied using SPSS programme. The interviews of women who gave consent to be audio recorded (n = 52) were transcribed and thematically analysed using MAXQDA program, based on Andersen and Newman's (1973) behavioural model of health services utilization. Results The mean gestational age at booking initial biomedical care was 23.36 weeks. Only 18 patients (10%) booked before 13 weeks and 45% made four or more visits. The main reasons given for early booking were: illness in index pregnancy (42%) checking the foetus position and monitoring foetus progress (7%). The main reasons given for late booking were: no reason (31%), was not feeling sick (16%), fear or shame due to unexpected pregnancy (13%). Almost half of the respondents (44%) used both biomedical and traditional antenatal care services. Main reasons for visiting traditional care were to: check foetus position and reposition it (63%), collect medicinal herbs (31%), relief discomforts through massage (18%). Conclusion Early antenatal care booking is meant for women with unpleasant physical signs and symptoms. Later ANC is meant to check foetus position and reposition it to cephalic presentation and monitor its progress and this is only possible if the foetus is large.	[Riang'a, Roselyter Monchari] Moi Univ, Sch Arts & Social Sci, Dept Sociol & Psychol, Eldoret, Kenya; [Riang'a, Roselyter Monchari; Broerse, Jacqueline E. W.] Vrije Univ Amsterdam, Fac Sci, Athena Inst, Amsterdam, Netherlands; [Nangulu, Anne Kisaka] Commiss Univ Educ, Nairobi, Kenya; [Nangulu, Anne Kisaka] Moi Univ, Sch Arts & Social Sci, Dept Hist, Eldoret, Kenya	Moi University; Vrije Universiteit Amsterdam; Moi University	Riang'a, RM (corresponding author), Moi Univ, Sch Arts & Social Sci, Dept Sociol & Psychol, Eldoret, Kenya.; Riang'a, RM (corresponding author), Vrije Univ Amsterdam, Fac Sci, Athena Inst, Amsterdam, Netherlands.	monchari2002@yahoo.com	Riang'a, Roselyter/AAW-7541-2021		A Sustainable Approach to Livelihood Improvement (ASALI) project	A Sustainable Approach to Livelihood Improvement (ASALI) project	The authors acknowledge the financial support by A Sustainable Approach to Livelihood Improvement (ASALI) project (https://acwfs.vu.nl/en/research/themes/inequality-in-food-security/projects/sustainable-livelihood/index.aspx). ASALI is a joint collaboration project of Moi University Kenya, South Eastern Kenya University (SEKU) and Vrije Universiteit Amsterdam (VU) that is being implemented in Kenya. The project is coordinated by: Prof. Ann Nangulu - Moi University, Prof. Mary Mburu - South Eastern Kenya University, Dr. Denyse Snelder - Vrije Universiteit Amsterdam. The funding was granted to RMR. This financial support proved fundamental to the design of the study, the collection and analysis of data, and the writing of this manuscript. Only one coordinator (Prof. Anne Nangulu) of ASALI project who participated in this study. Prof. Anne Nangulu contributed to design, analysis, supervision, methodology, prove-reading,review, and decision to publish.	Abu-Saad K, 2010, EPIDEMIOL REV, V32, P5, DOI 10.1093/epirev/mxq001; Adekanle DA, 2008, ONLINE J HLTH ALLIED, V7, P1; Amna A., 2015, ISRA MED J, V7, P38; ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; Banda I, 2012, MED J ZAMBIA, V39, P29; Blomberg M, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005840; Bourbonnais B., 2013, IMPLEMENTING FREE MA; Braun V., 2013, SUCCESSFUL QUALITATI; Brown CA, 2008, BMC PREGNANCY CHILDB, V8, P1, DOI [10.1186/1471-2393-8-1, DOI 10.1186/1471-2393-8-1]; Central Statistical Agency and ICF International, 2012, ETH DEM HLTH SURV, P452; Cheptum J., 2014, Developing Country Studies, V4, P48; Chorongo D, 2016, PAN AFR MED J, V25, DOI 10.11604/pamj.supp.2016.25.2.10520; County Government of Uasin Gishu Department of Health Services, 2013, COUNT HLTH STRAT INV; Ebeigbe P N, 2010, Ghana Med J, V44, P47; Essendi H, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0078-8; Fisher C, 2015, ASSESSING ENHANCING, DOI [10.1207/S1532480XADS0701, DOI 10.1207/S1532480XADS0701]; Floridia M, 2014, HIV CLIN TRIALS, V15, P104, DOI 10.1310/hct1503-104; Government of Uasin Gishu County, 2013, UAS GISH COUNT INT D; Grinnel RM, 2007, SOCIAL WORK RES EVAL; Gross J, 2015, AFR J MIDWIFERY WOME, V9; Gross K, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-16; Helman CG, 2007, CUTURE HLTH ILLINESS; Izugbara CO, 2009, PUBLIC HEALTH REP, V124, P585, DOI 10.1177/003335490912400416; Jebet CJ, 2013, FACTORS CONTRIBUTING; Jebet J, 2015, POOR PREGNANCY OUTCO, P4, DOI [10.12968/ajmw.2012.6.4.183, DOI 10.12968/AJMW.2012.6.4.183]; Kaingu CK, 2011, J ETHNOPHARMACOL, V137, P495, DOI 10.1016/j.jep.2011.05.044; Kanogo Tabitha, 2005, AFRICAN WOMANHOOD CO; Kenya M, 2013, MATERNAL INFANT YOUN; Kenya National Bureau of Statistics, 2014, KEN DEM HLTH SURV 20; Kenya National Bureau of Statistics (KNBS) ICF Macro, 2010, KEN DEM HLTH SURV 20; Kisuule I, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-121; Kitui J, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-40; Lincetto O, ANTENATAL CARE, P51; Magadi M, 2000, SOC BIOL, V47, P164; Magadi MA, 2000, SOC SCI MED, V51, P551, DOI 10.1016/S0277-9536(99)00495-5; Mothupi MC, 2014, BMC COMPLEM ALTERN M, P1, DOI [10.1186/1472-6882-14-1, DOI 10.1186/1472-6882-14-1]; Ngom P, 2000, INTRA HOUSEHOLD DECI; Ochako R, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-1; Okunlola M A, 2006, J Obstet Gynaecol, V26, P195, DOI 10.1080/01443610500508220; Olungah CO, 2006, THESIS; Onoh RC, 2012, ANN MED HEALTH SCI R, V2, P169, DOI 10.4103/2141-9248.105666; Pell C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053747; Riang'a RM, 2017, J HEALTH POPUL NUTR, V36, DOI 10.1186/s41043-017-0130-0; Riang'a RM, 2017, J ETHNOBIOL ETHNOMED, V13, DOI 10.1186/s13002-017-0157-8; Rono AK., 2015, THESIS, DOI [10.1007/s13398-014-0173-7.2, DOI 10.1007/S13398-014-0173-7.2]; Ruiz-Canela M, 2013, BMC MED ETHICS, V14, DOI 10.1186/1472-6939-14-2; Severinski NS, 2009, INT J GYNECOL OBSTET, V107, P63, DOI 10.1016/j.ijgo.2009.05.011; Shah AT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170415; van Eijk Anna M, 2006, Reprod Health, V3, P2, DOI 10.1186/1742-4755-3-2; Verschuren P., 2010, DESIGNING RES PROJEC, V2; Villar J, 2001, LANCET, V357, P1551, DOI 10.1016/S0140-6736(00)04722-X	51	3	3	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2018	13	10							e0202895	10.1371/journal.pone.0202895	http://dx.doi.org/10.1371/journal.pone.0202895			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV7VQ	30281594	gold, Green Published, Green Submitted			2023-01-03	WOS:000446342400015
J	Lewicky, JD; Martel, AL; Fraleigh, NL; Boraman, A; Nguyen, TMD; Schiller, PW; Shiao, TC; Roy, R; Le, HT				Lewicky, Jordan D.; Martel, Alexandrine L.; Fraleigh, Nya L.; Boraman, Amanda; Nguyen, Thi M. -D.; Schiller, Peter W.; Shiao, Tze Chieh; Roy, Rene; Le, Hoang-Thanh			Strengthening peptide-based drug activity with novel glyconanoparticle	PLOS ONE			English	Article							KAPPA-OPIOID RECEPTOR; IN-VITRO; MANNOSYLATED LIPOSOMES; STABILITY; NANOPARTICLES; DELIVERY; ANTAGONISTS; ANALOGS; DESIGN; SYSTEM	The therapeutic application of peptide-based drugs is significantly limited by the rapid proteolytic degradation that occurs when in blood. Encapsulation of these peptide structures within a delivery system, such as liposomes, can greatly improve both stability and target delivery. As part of our work focused on novel ambiphilic mannosylated neoglycolipids as targeted drug delivery systems, we have developed a C14-alkyl-mannopyranoside that forms self-assembled monodisperse liposomes. Herein, these glycoliposomes are investigated as a potential method to improve the plasma stability of peptide-based drugs. Reversed phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry (MS) methods were developed to assess the in vitro plasma stability of two structurally diverse peptides, including the kappa opioid receptor selective antagonist dynantin, and the NOD2 innate immune receptor ligand muramyl dipeptide (MDP). The RP-HPLC methods developed were able to resolve the peptides from background plasma contaminants and provided suitable response levels and linearity over an appropriate concentration range. Both compounds were found to be significantly degraded in rat plasma. Increasing degrees of both entrapment and stabilization were noted when dynantin was combined with the C14(-) alkyl-mannopyranoside in increasing peptide:glycoside ratios. The combination of MDP with the glycolipid also led to peptide entrapment, which greatly improved the plasma stability of the peptide. Overall, the results clearly indicate that the stability of peptide-based structures, which are subject to degradation in plasma, can be greatly improved via entrapment within C14-alkyl-mannopyranoside-bearing glycoliposomes.	[Lewicky, Jordan D.; Martel, Alexandrine L.; Fraleigh, Nya L.; Boraman, Amanda; Le, Hoang-Thanh] Hlth Sci North Res Inst, Sudbury, ON, Canada; [Nguyen, Thi M. -D.; Schiller, Peter W.] Clin Res Inst Montreal, Lab Chem Biol & Peptide Res, Montreal, PQ, Canada; [Schiller, Peter W.] Univ Montreal, Dept Pharmacol & Physiol, Montreal, PQ, Canada; [Shiao, Tze Chieh; Roy, Rene] Glycovax Pharma Inc, Montreal, PQ, Canada; [Le, Hoang-Thanh] Northern Ontario Sch Med, Med Sci Div, Sudbury, ON, Canada; [Le, Hoang-Thanh] Laurentian Univ, Dept Chem & Biochem, Sudbury, ON, Canada; [Le, Hoang-Thanh] Laurentian Univ, Dept Biol, Sudbury, ON, Canada	Health Sciences North; Northern Ontario School of Medicine; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Northern Ontario School of Medicine; Laurentian University; Laurentian University	Le, HT (corresponding author), Hlth Sci North Res Inst, Sudbury, ON, Canada.; Le, HT (corresponding author), Northern Ontario Sch Med, Med Sci Div, Sudbury, ON, Canada.; Le, HT (corresponding author), Laurentian Univ, Dept Chem & Biochem, Sudbury, ON, Canada.; Le, HT (corresponding author), Laurentian Univ, Dept Biol, Sudbury, ON, Canada.	hle@hsnri.ca			Canadian Institutes of Health Research [PJT-148531]; Northern Cancer Foundation	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Northern Cancer Foundation	This work was supported by the Canadian Institutes of Health Research (Project Grant PJT-148531 to HTL) and the Northern Cancer Foundation (2017-2019 to HTL). The funders provided support in the form of salaries for authors [JDL, AM, NF, AB] but did not have any role in study design, data collection and interpretation, or the decision to submit the work for publication. The specific roles of these authors are articulated in the 'author contributions' section.	Ahmad N, 2016, EXPERT OPIN DRUG DEL, V13, P621, DOI 10.1517/17425247.2016.1160889; Albrechtsen NJW, 2015, ENDOCR CONNECT, V4, DOI 10.1530/EC-14-0126; Asthana GS, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/526391; Bottger R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178943; Boge L, 2018, J COLLOID INTERF SCI, V522, P126, DOI 10.1016/j.jcis.2018.03.062; Bruchas MR, 2007, J BIOL CHEM, V282, P29803, DOI 10.1074/jbc.M705540200; Brugos B, 2004, PHARMAZIE, V59, P339; Bruno BJ, 2013, THER DELIV, V4, P1443, DOI [10.4155/TDE.13.104, 10.4155/tde.13.104]; Butelman ER, 2012, TRENDS NEUROSCI, V35, P587, DOI 10.1016/j.tins.2012.05.005; Carrillo-Conde B, 2011, MOL PHARMACEUT, V8, P1877, DOI 10.1021/mp200213r; Carroll FI, 2013, J MED CHEM, V56, P2178, DOI 10.1021/jm301783x; Costa A, 2018, EUR J PHARM SCI, V114, P103, DOI 10.1016/j.ejps.2017.12.006; De Prins A, 2018, EUR J MED CHEM, V144, P887, DOI 10.1016/j.ejmech.2017.12.035; Diao L, 2013, CLIN PHARMACOKINET, V52, P855, DOI 10.1007/s40262-013-0079-0; Dissanayake S, 2017, J CONTROL RELEASE, V250, P62, DOI 10.1016/j.jconrel.2017.02.006; Domhan C, 2018, INT J ANTIMICROB AG, V52, P52, DOI 10.1016/j.ijantimicag.2018.03.023; Domi E, 2018, NEUROPSYCHOPHARMACOL, V43, P1805, DOI 10.1038/s41386-018-0015-y; Dong WB, 2018, EUR J MED CHEM, V150, P546, DOI 10.1016/j.ejmech.2018.03.025; Eley J., 2001, AAPS PHARMSCITECH, V2, P81, DOI DOI 10.1208/PT020319; Erak M, 2018, BIOORGAN MED CHEM, V26, P2759, DOI 10.1016/j.bmc.2018.01.012; Fredholt K, 2000, J CONTROL RELEASE, V63, P261, DOI 10.1016/S0168-3659(99)00196-0; Goyard D, 2016, J MATER CHEM B, V4, P4227, DOI 10.1039/c6tb00344c; Habibi N, 2016, NANO TODAY, V11, P41, DOI 10.1016/j.nantod.2016.02.004; Hamman JH, 2005, BIODRUGS, V19, P165, DOI 10.2165/00063030-200519030-00003; HARRISON J, 1985, INFECT IMMUN, V50, P320, DOI 10.1128/IAI.50.1.320-321.1985; Hayward AR, 2013, PLANT PHYSIOL BIOCH, V64, P84, DOI 10.1016/j.plaphy.2012.12.018; Helal MA, 2017, EUR J MED CHEM, V141, P632, DOI 10.1016/j.ejmech.2017.10.012; Karhu L, 2018, PEPTIDES, V102, P54, DOI 10.1016/j.peptides.2018.02.004; Lai CH, 2016, NANO LETT, V16, P807, DOI 10.1021/acs.nanolett.5b04984; Lalanne L, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00170; Lu YX, 2001, J MED CHEM, V44, P3048, DOI 10.1021/jm0101186; Mangal V, 2016, ANAL BIOANAL CHEM, V408, P1891, DOI 10.1007/s00216-015-9295-9; Mentlein R, 1997, BRAIN RES PROTOC, V1, P237, DOI 10.1016/S1385-299X(96)00035-9; Merhi G, 1996, J MED CHEM, V39, P4483, DOI 10.1021/jm960147u; MEYER JP, 1995, PEPTIDES, V16, P1215, DOI 10.1016/0196-9781(95)02005-H; Muller S, 1996, PHARMAZIE, V51, P581; Niu ZG, 2018, J CONTROL RELEASE, V276, P125, DOI 10.1016/j.jconrel.2018.03.004; Noto PB, 2008, PROTEIN SCI, V17, P1249, DOI 10.1110/ps.034330.108; Ogawa Chikako, 2011, Curr Bioact Compd, V7, P180; PARANT M, 1979, INT J IMMUNOPHARMACO, V1, P35, DOI 10.1016/0192-0561(79)90028-6; Perez-Ortiz M, 2017, COLLOID SURFACE B, V158, P25, DOI 10.1016/j.colsurfb.2017.06.015; POWELL MF, 1993, PHARMACEUT RES, V10, P1268, DOI 10.1023/A:1018953309913; Rader AFB, 2018, BIOORGAN MED CHEM, V26, P2766, DOI 10.1016/j.bmc.2017.08.031; RIVEAU G, 1980, J EXP MED, V152, P869, DOI 10.1084/jem.152.4.869; Ryu J, 2010, BIOTECHNOL BIOENG, V105, P221, DOI 10.1002/bit.22544; SCHWARTZMAN SM, 1980, PREP BIOCHEM, V10, P255, DOI 10.1080/10826068009412828; Stimac A, 2016, INT J PHARMACEUT, V511, P44, DOI 10.1016/j.ijpharm.2016.06.123; Tu ZG, 2007, BIOCHEM BIOPH RES CO, V361, P712, DOI 10.1016/j.bbrc.2007.06.178; Uhlig T., 2014, EUPA OPEN PROTEOMICS, V4, P58, DOI [10.1016/j.euprot.2014.05.003, DOI 10.1016/J.EUPROT.2014.05.003]; Vieira ACC, 2018, ARTIF CELL NANOMED B, V46, pS653, DOI 10.1080/21691401.2018.1434186; Vieira ACC, 2016, INT J NANOMED, V11, P2601, DOI 10.2147/IJN.S104908; Wijagkanalan W, 2008, J CONTROL RELEASE, V125, P121, DOI 10.1016/j.jconrel.2007.10.011; Witoonsaridsilp W, 2012, AAPS PHARMSCITECH, V13, P699, DOI 10.1208/s12249-012-9788-1; Ye Z, 2016, CHEM-EUR J, V22, P15216, DOI 10.1002/chem.201603294; Yi JZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134427; Yi JZ, 2011, METHODS MOL BIOL, V728, P161, DOI 10.1007/978-1-61779-068-3_10; Ying M, 2016, J CONTROL RELEASE, V243, P86, DOI 10.1016/j.jconrel.2016.09.035; Zhang MF, 2018, ACTA PHARM SIN B, V8, P106, DOI 10.1016/j.apsb.2017.11.004; Zhou L, 2015, NEUROPHARMACOLOGY, V99, P131, DOI 10.1016/j.neuropharm.2015.07.001; Zhou XR, 2017, INT J PHARMACEUT, V528, P723, DOI 10.1016/j.ijpharm.2017.06.051	60	7	7	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 27	2018	13	9							e0204472	10.1371/journal.pone.0204472	http://dx.doi.org/10.1371/journal.pone.0204472			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV2HB	30260999	Green Published, gold, Green Submitted			2023-01-03	WOS:000445907400056
J	Sollgruber, A; Bornemann-Cimenti, H; Szilagyi, IS; Sandner-Kiesling, A				Sollgruber, Anja; Bornemann-Cimenti, Helmar; Szilagyi, Istvan-Szilard; Sandner-Kiesling, Andreas			Spirituality in pain medicine: A randomized experiment of pain perception, heart rate and religious spiritual well-being by using a single session meditation methodology	PLOS ONE			English	Article							MINDFULNESS MEDITATION; STRESS REDUCTION; HEALTH; LIFE; IMPACT; COMPLEMENTARY	The aim of this study is to investigate different effects on pain perception among randomly assigned volunteers practicing meditation compared to a relaxation condition. The study examines whether participants of the experimental conditions (meditation versus relaxation) differ in the change of pain perception and heart rate measurement and in religious and spiritual well-being after an intervention. Method: 147 volunteers (long-term practitioners and novices) were randomly assigned to the experimental conditions with a headphone guided 20-minute single session intervention. The change in their pre- and post-intervention pain perception was measured using Quantitative Sensory Testing and Cold Pressor Testing (CPTest), their stress-level was compared by monitoring heart rate, and their religious and spiritual well-being by using the Multidimensional Inventory for Religious/Spiritual Well-Being (MI-RSB48). Additionally, dimensions of the Brief Symptom Inventory (BSI) measured the psychological resilience of the participants; pain and stress experience, and the state of relaxation and spirituality experience were assessed. Five persons were excluded due to failure in measuring the heart rate and 29 participants had to be excluded because of high values on the BSI. Results: The meditation group showed an increase in their pain tolerance on the CPTest and a decrease in their pain intensity for heat after the experimental condition, in contrast to the relaxation group. Futhermore, the meditation group showed a higher level of religious spiritual well-being (MI-RSB48 Total score) as well as in the sub-dimensions General Religiosity, Forgiveness, and Connectedness after the experimental condition, compared to the relaxation group. Our data is consistent with the hypothesis that meditation increases pain tolerance and reduces pain intensity, however, further work is required to determine whether meditation contains similar implications for pain patients.	[Sollgruber, Anja] Univ Med, Dept Anaesthesiol Pain & Intens Care Med, Graz, Austria; [Bornemann-Cimenti, Helmar; Szilagyi, Istvan-Szilard; Sandner-Kiesling, Andreas] Univ Med, Dept Special Anaesthesiol Pain & Intens Care Med, Graz, Austria		Sollgruber, A (corresponding author), Univ Med, Dept Anaesthesiol Pain & Intens Care Med, Graz, Austria.	anja.sollgruber@stud.medunigraz.at	Bornemann-Cimenti, Helmar/C-1252-2009	Bornemann-Cimenti, Helmar/0000-0002-1201-3752	Doctoral School of General and Clinical Pathophysiology	Doctoral School of General and Clinical Pathophysiology	Special thanks to the Doctoral School of General and Clinical Pathophysiology for the financial assistance for publication fees. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALEXANDER CN, 1991, J SOC BEHAV PERS, V6, P189; American Psychological Association, 2009, APA CONC DICT PSYCH; Ang DC, 2006, RHEUMATOL INT, V26, P567, DOI 10.1007/s00296-005-0025-z; Astin JA, 1997, PSYCHOTHER PSYCHOSOM, V66, P97, DOI 10.1159/000289116; Backonja MM, 2009, CLIN J PAIN, V25, P641, DOI 10.1097/AJP.0b013e3181a68c7e; Baer RA, 2003, CLIN PSYCHOL-SCI PR, V10, P125, DOI 10.1093/clipsy/bpg015; Bair MJ, 2003, ARCH INTERN MED, V163, P2433, DOI 10.1001/archinte.163.20.2433; Barnett JE, 2006, RES PRACTICE, V43, P576; Bawa FLM, 2015, BRIT J GEN PRACT, V65, pE387, DOI 10.3399/bjgp15X685297; Bond K, 2009, PSYCHOL RELIG SPIRIT, V1, P129, DOI 10.1037/a0015736; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Brugnoli MP, 2009, CLIN HYPNOSIS SPIRIT; Bussing A, 2009, PAIN MED, V10, P327, DOI 10.1111/j.1526-4637.2009.00572.x; Bush EG, 1999, APPL PSYCHOPHYS BIOF, V24, P249, DOI 10.1023/A:1022234913899; Carmody J, 2008, J BEHAV MED, V31, P23, DOI 10.1007/s10865-007-9130-7; Cohen MM, 2005, J ALTERN COMPLEM MED, V11, P995, DOI 10.1089/acm.2005.11.995; Creswell JD, 2014, CURR DIR PSYCHOL SCI, V23, P401, DOI 10.1177/0963721414547415; Davidson RJ, 2015, AM PSYCHOL, V70, P581, DOI 10.1037/a0039512; Derogatis L., 1992, BRIEF SYMPTOM INVENT; Dezutter J, 2010, J SCI STUD RELIG, V49, P507, DOI 10.1111/j.1468-5906.2010.01525.x; Dezutter J, 2010, PAIN MED, V11, P765, DOI 10.1111/j.1526-4637.2010.00827.x; Frankowski G, 2000, P SOC PHOTO-OPT INS, V3958, P90, DOI 10.1117/12.380051; FRUHSTORFER H, 1976, J NEUROL NEUROSUR PS, V39, P1071, DOI 10.1136/jnnp.39.11.1071; Gamelin FX, 2006, MED SCI SPORT EXER, V38, P887, DOI 10.1249/01.mss.0000218135.79476.9c; Grom B, 2007, RELIGIONSPSYCHOLOGIE, P182; Grossman P, 2004, J PSYCHOSOM RES, V57, P35, DOI 10.1016/S0022-3999(03)00573-7; Henschke N, 2015, MAYO CLIN PROC, V90, P139, DOI 10.1016/j.mayocp.2014.09.010; Hilton L, 2017, ANN BEHAV MED, V51, P199, DOI 10.1007/s12160-016-9844-2; Holmes DA, 1985, AM PSYCHOL, V39, P1; Holmes DA, 1987, PSYCHOL MEDITATION, P81; Huguelet P., 2009, RELIG SPIRITUALITY P, P65; Hussain D., 2010, INT J PSYCHOL PSYCHO, V10, P439; Infante JR, 1998, PHYSIOL BEHAV, V64, P311, DOI 10.1016/S0031-9384(98)00071-7; John PJ, 2007, HEADACHE, V47, P654, DOI 10.1111/j.1526-4610.2007.00789.x; Jonckheer-Sheehy VSM, 2012, J VET BEHAV, V7, P205, DOI 10.1016/j.jveb.2011.10.006; Keefe FJ, 2001, J PAIN, V2, P101, DOI 10.1054/jpai.2001.19296; Koenig HG, 2004, SOUTH MED J, V97, P1194, DOI 10.1097/01.SMJ.0000146489.21837.CE; Koenig HG, 2012, HDB RELIG HLTH; Linton SJ, 2005, EUR J PAIN, V9, P355, DOI 10.1016/j.ejpain.2004.08.002; Linton SJ, 2011, PHYS THER, V91, P700, DOI 10.2522/ptj.20100330; Lutz A, 2008, TRENDS COGN SCI, V12, P163, DOI 10.1016/j.tics.2008.01.005; Maier C, 2017, SCHMERZMEDIZIN INTER, P4; Manhas M., 2011, JK SCI, V13, P145; McCracken LM, 2009, J PSYCHOPATHOL BEHAV, V31, P75, DOI 10.1007/s10862-008-9099-8; Melzack R, 2001, J Dent Educ, V65, P1378; Merskey H, 1994, CLASSIFICATION CHRON, P209, DOI DOI 10.1002/ANA.20394; Michenbaum D, 1974, SELF CONTROL POWER P; Miller C, 2006, PAIN MANAG NURS, V7, P148, DOI 10.1016/j.pmn.2006.09.004; Moreira-Almeida A, 2008, CURR PAIN HEADACHE R, V12, P327, DOI 10.1007/s11916-008-0055-9; Nilges P, 2013, PRAKTISCHE SCHMERZME, P79; Pargament K.I., 2013, INT J PSYCHOL RELIG, V1, P3, DOI [DOI 10.1207/S15327582IJPR0901_2, 10.1207/s15327582ijpr0901_2, DOI 10.1037/E568022011-002]; Paul G, 1974, J ABNORM PSYCHOL, V74, P425; PECKERMAN A, 1994, PSYCHOPHYSIOLOGY, V31, P282, DOI 10.1111/j.1469-8986.1994.tb02217.x; Pruitt IT, 2010, VOICES EXPERIENCED M, DOI [10.1007/s10591-009-9112-8, DOI 10.1007/S10591-009-9112-8]; Rashiq S, 2009, PAIN RES MANAG, V14, P454, DOI 10.1155/2009/919628; Reiner K, 2013, PAIN MED, V14, P230, DOI 10.1111/pme.12006; Rippentrop AE, 2005, REHABIL PSYCHOL, V50, P278, DOI 10.1037/0090-5550.50.3.278; Rippentrop AE, 2005, PAIN, V116, P311, DOI 10.1016/j.pain.2005.05.008; Rolke R, 2002, STANDARDISIERTE TEST; Rosenberg EI, 2008, PAIN MED, V9, P1065, DOI 10.1111/j.1526-4637.2008.00477.x; SHAPIRO DH, 1985, AM PSYCHOL, V40, P719; Shapiro DH, 1974, AM J PSYCHIAT, V139, P267; Siddall PJ, 2015, PAIN MED, V16, P51, DOI 10.1111/pme.12511; Thomas JW, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00074; Thorn BE, 2004, COGNITIVE THERAPY CH; Traue H, 2013, PRAKTISCHE SCHMERZME, P117; Turk D. C., 2002, PSYCHOL APPROACHES P, P3; TURNER JA, 1986, PAIN, V24, P355, DOI 10.1016/0304-3959(86)90121-1; Unruh AM, 2007, CAN J NURS RES, V39, P66; Unterrainer HF, 2010, DIAGNOSTICA, V56, P82, DOI 10.1026/0012-1924/a000001; Wachholtz AB, 2005, J BEHAV MED, V28, P369, DOI 10.1007/s10865-005-9008-5; Wachholtz AB, 2006, THESIS; Wachholtz AB, 2008, J BEHAV MED, V31, P351, DOI 10.1007/s10865-008-9159-2; Wachholtz AB, 2007, J BEHAV MED, V30, P311, DOI 10.1007/s10865-007-9114-7; Wachholtz AB, 2017, BEHAV MED, V43, P1, DOI 10.1080/08964289.2015.1024601; Wachholtz AB, 2009, CURR PAIN HEADACHE R, V13, P127, DOI 10.1007/s11916-009-0022-0; Walsh R, 2006, AM PSYCHOL, V61, P227, DOI 10.1037/0003-066X.61.3.227; Wenneberg SR, 1997, INT J NEUROSCI, V89, P15, DOI 10.3109/00207459708988461; Wiech K, 2008, PAIN, V139, P467, DOI 10.1016/j.pain.2008.07.030; Williams ACD, 2016, PAIN, V157, P2420, DOI 10.1097/j.pain.0000000000000613; Wong S. Y. S., 2009, Hong Kong Medical Journal, V15, P13; Zeidan F., 2009, J PAIN, V10, P1016, DOI DOI 10.1016/J.JPAIN.2009.07.015; Zeidan F, 2015, J NEUROSCI, V35, P15307, DOI 10.1523/JNEUROSCI.2542-15.2015; Znoj H. J., 2004, RELIG MESSVERFAHREN, P277	84	10	11	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2018	13	9							e0203336	10.1371/journal.pone.0203336	http://dx.doi.org/10.1371/journal.pone.0203336			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GT0BU	30192807	Green Published, gold, Green Submitted			2023-01-03	WOS:000444093600061
J	Shi, LW; Lai, YQ; Chen, SY; Fu, LR; Lin, Q				Shi, Liwan; Lai, Youqun; Chen, Shanyu; Fu, Lirong; Lin, Qin			Dosimetric superiority of IMRT with jaw tracking technique for whole esophagus and T-shaped field radiotherapy in advanced esophageal cancer	PLOS ONE			English	Article							3D CONFORMAL RADIOTHERAPY; RADIATION PNEUMONITIS; RANDOMIZED-TRIAL; CHEMORADIOTHERAPY; VMAT; VALIDATION; LUNG	Purpose For whole esophagus and T-shaped field radiotherapy using intensity modulated radiotherapy (IMRT) technique in advanced esophageal cancer, lower absorbed doses to lung and heart remains a challenge. The aim of this study was to investigate the dosimetric superiority in IMRT plans with jaw tracking technique for whole esophagus radiotherapy. Methods and materials Thirty-two patients with esophageal cancer were subjected to IMRT treatment plans using Eclipse treatment planning system. For every patient, four different plans were generated with six gantry angles: six large fields IMRT plans with fixed jaw (6F-IMRT), six large fields IMRT plans with jaw tracking technique (6F-IMRT-T), twelve small fields IMRT plans with fixed jaw (12F-IMRT), and twelve small fields IMRT plans with jaw tracking technique (12F-IMRT-T). Dosimetric evaluation was assessed for all plans. Results For every technique, there were no differences in planning target volume (PTV) coverage and conformity. 6F-IMRT-T plans could significantly reduce lung irradiation with 7.9% (P<0.001) reduction in V5(lung) and 2.5% (P<0.001) reduction in V20(lung) respectively compared to 6F-IMRT plans. 12F-IMRT-T plans resulted in superior plans compared to 12-IMRT plans with a reduction of 2.9% (P<0.001) in V5(lung) and 0.9% (P<0.001) in V20(lung), respectively. For heart irradiation, 6F-IMRT-T and 12F-IMRT-T plans were slightly superior to 6F-IMRT and 12-IMRT plans respectively with a reduction of 1.1 Gy and 0.5 Gy in the respective mean doses. Conclusions By the use of jaw tracking technique, the IMRT plans resulted in further lung and heart sparing compared to fixed jaw plans for radiotherapy in esophageal cancer.	[Shi, Liwan; Lai, Youqun; Chen, Shanyu; Fu, Lirong; Lin, Qin] Xiamen Univ, Affiliated Hosp 1, Xiamen Canc Hosp, Dept Radiat Oncol, Xiamen, Peoples R China	Xiamen University	Lai, YQ; Lin, Q (corresponding author), Xiamen Univ, Affiliated Hosp 1, Xiamen Canc Hosp, Dept Radiat Oncol, Xiamen, Peoples R China.	laiyq520@qq.com; linqin05@163.com						Cadman P, 2005, J APPL CLIN MED PHYS, V6, P74, DOI 10.1120/jacmp.2024.25341; Cooper JS, 1999, JAMA-J AM MED ASSOC, V281, P1623, DOI 10.1001/jama.281.17.1623; Feng ZS, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0329-4; Fenkell L, 2008, RADIOTHER ONCOL, V89, P287, DOI 10.1016/j.radonc.2008.08.008; Fogliata A, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0530-5; Harder EM, 2016, PRACT RADIAT ONCOL, V6, pE353, DOI 10.1016/j.prro.2016.01.015; Joy S, 2012, J APPL CLIN MED PHYS, V13, P136, DOI 10.1120/jacmp.v13i2.3707; Kim JI, 2014, J APPL CLIN MED PHYS, V15, P160, DOI 10.1120/jacmp.v15i2.4625; Kumar S, 2007, RADIOTHER ONCOL, V83, P139, DOI 10.1016/j.radonc.2007.03.013; Kuo YC, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-76; Marks LB, 2010, INT J RADIAT ONCOL, V76, pS70, DOI 10.1016/j.ijrobp.2009.06.091; Mayo CS, 2008, INT J RADIAT ONCOL, V71, P1408, DOI 10.1016/j.ijrobp.2007.12.008; Mohan R, 2008, J MED PHYS, V33, P114, DOI 10.4103/0971-6203.42757; Munch S, 2016, STRAHLENTHER ONKOL, V192, P722, DOI 10.1007/s00066-016-1020-x; Nicolini G, 2012, INT J RADIAT ONCOL, V84, P553, DOI 10.1016/j.ijrobp.2011.12.041; Ortholan C, 2010, CANCER RADIOTHER, V14, P312, DOI 10.1016/j.canrad.2010.02.009; Smyth EC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.48; Sung K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196664; Vuong TNT, 2010, DIS ESOPHAGUS, V23, P324, DOI 10.1111/j.1442-2050.2009.01016.x; Wu H, 2016, J APPL CLIN MED PHYS, V17, P133, DOI 10.1120/jacmp.v17i5.6252; Yao B, 2016, NIGER J CLIN PRACT, V19, P25, DOI 10.4103/1119-3077.173709; Zhang Q, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20140362	22	4	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 5	2018	13	9							e0202628	10.1371/journal.pone.0202628	http://dx.doi.org/10.1371/journal.pone.0202628			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS6HC	30183753	gold, Green Published, Green Submitted			2023-01-03	WOS:000443789900032
J	Amnie, AG				Amnie, Asrat Genet			An impact evaluation of two rounds of mass drug administration on the prevalence of active trachoma: A clustered cross sectional survey	PLOS ONE			English	Article							NIGERIA	Introduction We investigated the impact of two round of mass drug administration on trachoma prevalence in Plateau and Nasarawa States of Nigeria. The mass drug administration was conducted as a component of the SAFE Strategy, a combination of interventions recommended for the global elimination of blinding trachoma. Methods The study consisted of a two-stage cross-sectional clustered sample survey in which 3990 people from 793 households were screened for clinical signs of trachoma. Results Of the total 3990 people examined, 1530 were children, of which 808 (53%) were boys and 704 (47%) were girls. The impact of intervention as measured by the changes in overall prevalence of follicular trachoma were as follows: At baseline the overall prevalence of follicular trachoma among children 1 +/- 9 years of age was 6.4%, 95% CI [5.8, 7.0]; the overall prevalence of trachomatous trichiasis in the total population was 0.20%, 95% CI [0.16, 0.25]. At follow up, the overall prevalence of follicular trachoma among children 1 +/- 9 years of age was 3.4%, 95% CI [1.9, 4.9]; the overall prevalence of trachomatous trichiasis in the total population was 0.20%, 95% CI [0.00, 0.05]. The highest statistically significant reduction (96%) in follicular trachoma prevalence was observed in Doma Local Government Area of Nasarawa State from baseline prevalence of 13.6%, 95% CI [9.7, 17.5] to follow-up prevalence of 0.5%, 95% CI [0.0, 1.5] and the lowest reduction (58%) in follicular trachoma prevalence was observed in Langtang North Local Government Area of Plateau State from baseline prevalence of 15.8%, 95% CI [9.3, 22.3] to 6.6%, 95% CI [1.6, 11.6], (p< 0.05). Conclusion A significant reduction in the overall prevalence of follicular trachoma was achieved after two rounds of mass drug administration. In the absence of significant activities pertaining to facial cleanliness and environmental sanitation components of the SAFE strategy in the intervention areas, the observed deep reductions in prevalence could mainly be attributed to mass drug administration. Therefore, two rounds of mass azithromycin administration may be as effective as guideline-recommended three or more rounds in reducing active trachoma prevalence but findings should be replicated in more robustly designed studies.	[Amnie, Asrat Genet] CUNY, Eugenio Maria de Hostos Community Coll, Dept Educ, Hlth Educ Unit, New York, NY 10021 USA	City University of New York (CUNY) System	Amnie, AG (corresponding author), CUNY, Eugenio Maria de Hostos Community Coll, Dept Educ, Hlth Educ Unit, New York, NY 10021 USA.	aamnie@hostos.cuny.edu						[Anonymous], 2013, SAS COMP PROGR VERS; [Anonymous], 2013, MICROSOFT EXCEL; Chidambaram JD, 2006, JAMA-J AM MED ASSOC, V295, P1142, DOI 10.1001/jama.295.10.1142; Emerson PM, 2006, B WORLD HEALTH ORGAN, V84, P613, DOI 10.2471/BLT.05.28696; Hopkins DR, 2008, ANN NY ACAD SCI, V1136, P45, DOI 10.1196/annals.1425.015; Hotez PJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001600; Hotez PJ, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000412; Hu VH, 2010, TROP MED INT HEALTH, V15, P673, DOI 10.1111/j.1365-3156.2010.02521.x; King JD, 2010, BRIT J OPHTHALMOL, V94, P14, DOI 10.1136/bjo.2009.165282; King JD, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002732; Kyari F, 2009, INVEST OPHTH VIS SCI, V50, P2033, DOI 10.1167/iovs.08-3133; Mariotti SP, 2008, BRIT J OPHTHALMOLOGY; Mathew AA, 2009, DRUGS, V69, P953, DOI 10.2165/00003495-200969080-00002; Means AR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005085; Ngondi J, 2008, T ROY SOC TROP MED H, V102, P432, DOI 10.1016/j.trstmh.2008.02.014; Oswald .WE, 2017, B WORLD HEALTH ORGAN, V95, P250, DOI [10.2471/BLT.16.177758, 10.2471/blt.16.177758]; Rabiu M, 2012, COCHRANE LIB, DOI [10.1002/14651858.CD010274, DOI 10.1002/14651858.CD010274]; Rabiu MM, 2011, MIDDLE EAST AFR J OP, V18, P115, DOI 10.4103/0974-9233.80699; Roba AA, 2011, J EPIDEMIOL COMMUN H, V65, P626, DOI 10.1136/jech.2009.094763; Stocks ME, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001605; The Carter Center, 2010, SUMM P 11 ANN TRACH; The World Health Organization, 2006, TRACH CONTR GUID PRO, P34; WHO, 2016, GUID TREATM CHLAM TR; World Health Organization, 2008, HUM RES HLTH COUNTR; World Health Organization, 2008, PREV BLINDN VIS IMP	25	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2018	13	8							e0201911	10.1371/journal.pone.0201911	http://dx.doi.org/10.1371/journal.pone.0201911			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR9JD	30157193	Green Published, gold			2023-01-03	WOS:000443071400019
J	Zhao, X; Ren, YM; Hu, Y; Cui, NQ; Wang, XM; Cui, YF				Zhao, Xin; Ren, Yiming; Hu, Yong; Cui, Naqiang; Wang, Ximo; Cui, Yunfeng			Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials	PLOS ONE			English	Article							RESECTABLE ESOPHAGEAL; CARCINOMA; SURGERY; SURVIVAL; THERAPY; PROGNOSIS; RADIOCHEMOTHERAPY; ADENOCARCINOMA; MULTICENTER; STRATEGIES	Background The benefit of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy for treating cancer of the esophagus or the gastroesophageal junction remains controversial. In the present study, we conducted a comprehensive meta-analysis to examine the efficacy of these two management strategies. Methods The MEDLINE (PubMed), SinoMed, Embase, and Cochrane Library databases were searched for eligible studies. We searched for the most relevant studies published until the end of September 2017. Data were extracted independently and were analyzed using RevMan statistical software version 5.3 (Cochrane Collaboration, http://tech.cochrane.org/revman/download). Weighted mean differences, risk ratios (RRs), and 95% confidence intervals (Cls) were calculated. Cochrane Collaboration's risk of bias tool was used to assess the risk of bias. In this comprehensive meta-analysis, we examined the efficiency of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy for the treatment of cancer of the esophagus or the gastroesophageal junction as reported in qualified clinical trials. Results Six qualified articles that included a total of 866 patients were identified. The meta-analysis showed that for 3-year and 5-year survival rates in primary outcomes, the results favored neoadjuvant chemoradiotherapy strategies compared with neoadjuvant chemotherapy (RR = 0.78, 95% CI = 0.62-0.98, P = 0.03; RR = 0.69, 95% CI = 0.50-0.96, P = 0.03, respectively). In terms of secondary outcomes, neoadjuvant chemoradiotherapy significantly increased the rate of R0 resection and pathological complete response as well (RR = 0.87, 95% CI = 0.81-0.92, P < 0.0001; RR = 0.16, 95% CI = 0.09-0.28, P < 00001, respectively). However, there were no significant differences in postoperative mortality between the two groups (RR = 1.85, 95% CI = 0.93-3.65, P = 0.08). For the results of postoperative complications, revealed that there was a statistically significant difference between the two groups in the incidence of postoperative complications such as pulmonary, anastomotic leak and cardiovascular complications. The subgroup analysis of patients with esophageal adenocarcinoma or squamous cell carcinoma showed that both esophageal adenocarcinoma and squamous cell carcinoma patients achieved a high rate of R0 resection (RR = 0.85, 95% CI = 0.77-0.93, P = 0.0006; RR = 0.88, 95% CI = 0.81-0.96, P = 0.005, respectively) and pathological complete response benefit of neoadjuvant chemoradiotherapy (RR = 0.23, 95% CI = 0.09-0.57, P = 0.001; RR = 0.18, 95% CI = 0.03-0.96, P = 0.05, respectively). Conclusion Our findings suggested that compared with neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy should be recommended with a significant long-term survival benefit in patients with cancer of the esophagus or the gastroesophageal junction. In view of the clinical heterogeneity, whether these conclusions are broadly applicable should be further determined.	[Zhao, Xin; Hu, Yong] Tianjin Med Univ, Tianjin, Peoples R China; [Zhao, Xin; Hu, Yong; Cui, Naqiang; Wang, Ximo; Cui, Yunfeng] Tianjin Med Univ, Tianjin Nankai Hosp, Nankai Clin Sch, Dept Surg, Tianjin, Peoples R China; [Ren, Yiming] Tianjin Union Med Ctr, Dept Bone & Joint, Tianjin, Peoples R China	Tianjin Medical University; Tianjin Medical University	Cui, YF (corresponding author), Tianjin Med Univ, Tianjin Nankai Hosp, Nankai Clin Sch, Dept Surg, Tianjin, Peoples R China.	nkyycyf@163.com		Cui, Yunfeng/0000-0001-6415-0321	Foundation of Tianjin Clinical Medical Research Center of Acute Abdomen with integrated Chinese and Western medicine [15ZXLCSY00030]; Key project of Tianjin science and technology support plan [14ZCZDSY00021]	Foundation of Tianjin Clinical Medical Research Center of Acute Abdomen with integrated Chinese and Western medicine; Key project of Tianjin science and technology support plan	This study was funded by Foundation of Tianjin Clinical Medical Research Center of Acute Abdomen with integrated Chinese and Western medicine, 15ZXLCSY00030, Key project of Tianjin science and technology support plan 14ZCZDSY00021.	Altorki N, 2017, ANN CARDIOTHORAC SUR, V6, P167, DOI 10.21037/acs.2017.03.16; Ando N, 2003, J CLIN ONCOL, V21, P4592, DOI 10.1200/JCO.2003.12.095; Ando N, 2012, ANN SURG ONCOL, V19, P68, DOI 10.1245/s10434-011-2049-9; Briasoulis E, 2006, EXPERT REV ANTICANC, V6, P931, DOI 10.1586/14737140.6.6.931; Burmeister BH, 2011, EUR J CANCER, V47, P354, DOI 10.1016/j.ejca.2010.09.009; Cao XF, 2009, DIS ESOPHAGUS, V22, P477, DOI 10.1111/j.1442-2050.2008.00910.x; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Deng HY, 2017, EUR J CARDIO-THORAC, V51, P421, DOI 10.1093/ejcts/ezw315; Fan MY, 2016, THORAC CANCER, V7, P173, DOI 10.1111/1759-7714.12299; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fu T, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1341-7; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hozo S.P., 2005, BMC MED RES METHODOL, V5, P13, DOI [10.1186/1471-2288-5-13, DOI 10.1186/1471-2288-5-13]; Huang YW, 2017, INT J SURG, V38, P41, DOI 10.1016/j.ijsu.2016.12.035; Hyngstrom JR, 2010, J SURG ONCOL, V101, P299, DOI 10.1002/jso.21479; Ioannidis JPA, 2008, J EVAL CLIN PRACT, V14, P951, DOI 10.1111/j.1365-2753.2008.00986.x; Khushalani NI, 2008, MAYO CLIN PROC, V83, P712; Klevebro F, 2016, ANN ONCOL, V27, P660, DOI 10.1093/annonc/mdw010; Klevebro F, 2015, EJSO-EUR J SURG ONC, V41, P920, DOI 10.1016/j.ejso.2015.03.226; Kumagai K, 2014, BRIT J SURG, V101, P321, DOI 10.1002/bjs.9418; Liu BX, 2017, ONCOTARGET, V8, P20410, DOI 10.18632/oncotarget.14669; Mariette C, 2003, ANN THORAC SURG, V75, P1720, DOI 10.1016/S0003-4975(03)00172-3; Martel MK, 1998, INT J RADIAT ONCOL, V40, P155, DOI 10.1016/S0360-3016(97)00584-1; Moher D, 2015, SYST REV-LONDON, V4, DOI [10.1186/2046-4053-4-1, 10.1186/s13643-015-0087-2]; NYGAARD K, 1992, WORLD J SURG, V16, P1104, DOI 10.1007/BF02067069; Ohashi S, 2015, GASTROENTEROLOGY, V149, P1700, DOI 10.1053/j.gastro.2015.08.054; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Rice TW, 2010, ANN SURG ONCOL, V17, P1721, DOI 10.1245/s10434-010-1024-1; Sathornviriyapong S, 2016, ANN SURG ONCOL, V23, P3632, DOI 10.1245/s10434-016-5298-9; Schneider PM, 2005, ANN SURG, V242, P684, DOI 10.1097/01.sla.0000186170.38348.7b; Shapiro J, 2015, LANCET ONCOL, V16, P1090, DOI 10.1016/S1470-2045(15)00040-6; Sjoquist KM, 2011, LANCET ONCOL, V12, P681, DOI 10.1016/S1470-2045(11)70142-5; Stahl M, 2017, EUR J CANCER, V81, P183, DOI 10.1016/j.ejca.2017.04.027; Stein HJ, 2004, WORLD J SURG, V28, P520, DOI 10.1007/s00268-004-7417-1; Swisher SG, 2010, ANN THORAC SURG, V90, P892, DOI 10.1016/j.athoracsur.2010.04.061; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; Wang DB, 2012, DIGEST DIS SCI, V57, P3226, DOI 10.1007/s10620-012-2263-8; Ychou M, 2011, J CLIN ONCOL, V29, P1715, DOI 10.1200/JCO.2010.33.0597	38	37	37	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2018	13	8							e0202185	10.1371/journal.pone.0202185	http://dx.doi.org/10.1371/journal.pone.0202185			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR6TZ	30138325	Green Submitted, Green Published, gold			2023-01-03	WOS:000442800100045
J	Yan, BJ; Su, XL; Xu, BY; Qiao, X; Wang, LH				Yan, Bingjuan; Su, Xiaole; Xu, Boyang; Qiao, Xi; Wang, Lihua			Effect of diet protein restriction on progression of chronic kidney disease: A systematic review and meta-analysis	PLOS ONE			English	Review							GLOMERULAR-FILTRATION-RATE; TERM-FOLLOW-UP; RENAL-FAILURE; DIABETIC-NEPHROPATHY; MORTALITY; ALBUMINURIA; ASSOCIATION; PREVALENCE; PHOSPHORUS; MANAGEMENT	Background Dietary protein restriction has long been thought to play an important role in the progression of chronic kidney disease (CKD); however, the effect of dietary protein on the rate of decline in kidney function remains controversial. Objective We undertook a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the influence of protein restriction on chronic kidney disease. Method Ovid MEDLINE (from 1946 to March 5, 2016), EMBASE (from 1966 to March 5, 2016), and the Cochrane Library (Inception to March 5, 2016) were searched to identify RCTs comparing different levels of protein intake for at least 24 weeks in adult patients with CKD. The outcomes included kidney failure events, the rate of change in estimated glomerular filtration rate (eGFR) per year, all cause death events, and changes in proteinuria, serum phosphorus concentration, serum albumin, and body mass index (BMI). Results Nineteen trials with 2492 subjects were analyzed. A low protein diet reduced the risk of kidney failure (odds ratio (OR) = 0.59, 95% CI: 0.41 to 0.85) and end-stage renal disease (ESRD) (OR = 0.64, 95% CI: 0.43 to 0.96), but did not produce a clear beneficial effect for all cause death events (OR = 1.17, 95% CI: 0.67 to 2.06). The change in the mean difference (MD) for the rate of decline in the eGFR was significant (MD: -1.85, P = 0.001), and for proteinuria (MD: -0.44, P = 0.02). A low protein diet also reduced the serum phosphorus concentration (MD: -0.37, 95% CI: -0.5 to -0.24) and BMI (MD: -0.61, 95% CI: -1.05 to -0.17). However the change in albumin presented no significant difference between two groups (MD: 0.23, 95% CI: -0.51 to 0.97). Conclusions Based on the findings of our meta-analysis, protein-restricted diet may reduce the rate of decline in renal function and the risk of kidney failure for CKD populations, but did not produce a clear beneficial effect for all cause death events. Besides However, the optimal level of protein intake in different participants is left unanswered, and the nutritional status should be regarded with caution.	[Yan, Bingjuan; Su, Xiaole; Xu, Boyang; Qiao, Xi; Wang, Lihua] Shanxi Med Univ, Div Renal, Hosp 2, Taiyuan, Shanxi, Peoples R China	Shanxi Medical University	Wang, LH (corresponding author), Shanxi Med Univ, Div Renal, Hosp 2, Taiyuan, Shanxi, Peoples R China.	lihuawang236@126.com			Science and Technology Project of Shanxi Province [20140313013-5]; Natural Science Foundation of Shanxi Province [201701D221173]; Shanxi Province Health and Family Planning Commission, Science and Technology [201601054]	Science and Technology Project of Shanxi Province; Natural Science Foundation of Shanxi Province(Natural Science Foundation of Shanxi Province); Shanxi Province Health and Family Planning Commission, Science and Technology	Support was provided by the Science and Technology Project of Shanxi Province (Grant No. 20140313013-5), Natural Science Foundation of Shanxi Province (Grant No. 201701D221173), [http://www.sxinfo.gov.cn/]; Shanxi Province Health and Family Planning Commission, Science and Technology (Grant No. 201601054), [http://www.sxwsjs.gov.cn/].The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Astor BC, 2011, KIDNEY INT, V79, P1331, DOI 10.1038/ki.2010.550; Barsotti G., 1983, Kidney International, V24, pS278; Chen Wei, 2008, Journal of Chinese Integrative Medicine, V6, P473, DOI 10.3736/jcim20080508; Coresh J, 2007, JAMA-J AM MED ASSOC, V298, P2038, DOI 10.1001/jama.298.17.2038; Coresh J, 2014, JAMA-J AM MED ASSOC, V311, P2518, DOI 10.1001/jama.2014.6634; Da JJ, 2015, AM J KIDNEY DIS, V66, P258, DOI 10.1053/j.ajkd.2015.01.009; DAMICO G, 1994, NEPHROL DIAL TRANSPL, V9, P1590; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Di Iorio BR, 2003, KIDNEY INT, V64, P1822, DOI 10.1046/j.1523-1755.2003.00282.x; Dumler F, 2011, J RENAL NUTR, V21, P76, DOI 10.1053/j.jrn.2010.10.005; Fouque D, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001892.pub3; Fouque D, 2007, NAT CLIN PRACT NEPHR, V3, P383, DOI 10.1038/ncpneph0524; Garneata L, 2016, J AM SOC NEPHROL, V27, P2164, DOI 10.1681/ASN.2015040369; HARVILLE DA, 1977, J AM STAT ASSOC, V72, P320, DOI 10.2307/2286796; Hemmelgarn BR, 2010, JAMA-J AM MED ASSOC, V303, P423, DOI 10.1001/jama.2010.39; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; IHLE BU, 1989, NEW ENGL J MED, V321, P1773, DOI 10.1056/NEJM198912283212601; Ikizler TA, 2014, J RENAL NUTR, V24, P58, DOI 10.1053/j.jrn.2013.10.006; Imai E, 2009, CLIN EXP NEPHROL, V13, P621, DOI 10.1007/s10157-009-0199-x; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jiang N, 2009, NEPHROL DIAL TRANSPL, V24, P2551, DOI 10.1093/ndt/gfp085; Johnson DW, 2006, NEPHROLOGY, V11, P58, DOI 10.1111/j.1440-1797.2006.00550.x; Kalantar-Zadeh K, 2013, J CACHEXIA SARCOPENI, V4, P89, DOI 10.1007/s13539-013-0111-0; Kasiske BL, 1998, AM J KIDNEY DIS, V31, P954, DOI 10.1053/ajkd.1998.v31.pm9631839; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; Knapp G, 2003, STAT MED, V22, P2693, DOI 10.1002/sim.1482; Kopple JD, 1997, KIDNEY INT, V52, P778, DOI 10.1038/ki.1997.395; Kovesdy CP, 2013, AM J CLIN NUTR, V97, P1163, DOI 10.3945/ajcn.112.036418; Koya D, 2009, DIABETOLOGIA, V52, P2037, DOI 10.1007/s00125-009-1467-8; Levey AS, 2006, AM J KIDNEY DIS, V48, P879, DOI 10.1053/j.ajkd.2006.08.023; Levey AS, 1999, J AM SOC NEPHROL, V10, P2426; LOCATELLI F, 1991, LANCET, V337, P1299, DOI 10.1016/0140-6736(91)92977-A; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; MASCHIO G, 1982, KIDNEY INT, V22, P371, DOI 10.1038/ki.1982.184; Matsushita K, 2010, LANCET, V375, P2073, DOI 10.1016/S0140-6736(10)60674-5; Meloni C, 2004, J RENAL NUTR, V14, P208, DOI 10.1053/j.jm.2004.07.011; Menon V, 2009, AM J KIDNEY DIS, V53, P208, DOI 10.1053/j.ajkd.2008.08.009; Mircescu G, 2007, J RENAL NUTR, V17, P179, DOI 10.1053/j.jrn.2006.12.012; Mitch WE, 2004, J AM SOC NEPHROL, V15, P234, DOI 10.1097/01.ASN.0000106014.20274.C7; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; MORRIS CN, 1983, J AM STAT ASSOC, V78, P47, DOI 10.2307/2287098; Nezu U, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002934; Obi Y, 2015, CURR OPIN CLIN NUTR, V18, P254, DOI 10.1097/MCO.0000000000000171; Pan Y, 2008, AM J CLIN NUTR, V88, P660, DOI 10.1093/ajcn/88.3.660; Pedrini MT, 1996, ANN INTERN MED, V124, P627, DOI 10.7326/0003-4819-124-7-199604010-00002; Prakash S, 2004, J RENAL NUTR, V14, P89, DOI 10.1053/j.jrn.2004.01.008; Qiu Hong-yu, 2012, Sichuan Da Xue Xue Bao Yi Xue Ban, V43, P425; RAAL FJ, 1994, AM J CLIN NUTR, V60, P579, DOI 10.1093/ajcn/60.4.579; Rughooputh MS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145505; Schwarz S, 2006, CLIN J AM SOC NEPHRO, V1, P825, DOI 10.2215/CJN.02101205; Shah BV, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0360-1; WILLIAMS PS, 1991, Q J MED, V81, P837; ZELLER K, 1991, NEW ENGL J MED, V324, P78, DOI 10.1056/NEJM199101103240202; Zhang J, 2016, J NUTR HEALTH AGING, V20, P420, DOI 10.1007/s12603-015-0612-y; Zhang LX, 2012, LANCET, V379, P815, DOI 10.1016/S0140-6736(12)60033-6	55	40	42	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2018	13	11							e0206134	10.1371/journal.pone.0206134	http://dx.doi.org/10.1371/journal.pone.0206134			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GZ4PQ	30403710	gold, Green Published, Green Submitted			2023-01-03	WOS:000449379500054
J	Martin, SA; Chiodo, LM; Bosse, JD; Wilson, A				Martin, Stephen A.; Chiodo, Lisa M.; Bosse, Jordon D.; Wilson, Amanda			The Next Stage of Buprenorphine Care for Opioid Use Disorder	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RANDOMIZED CLINICAL-TRIAL; UNOBSERVED HOME INDUCTION; MAINTENANCE THERAPY; PSYCHOSOCIAL INTERVENTIONS; PRESCRIBING BUPRENORPHINE; SUBSTITUTION TREATMENT; OVERDOSE DEATHS; UNITED-STATES; DEPENDENCE; BENZODIAZEPINE	Buprenorphine has been used internationally for the treatment of opioid use disorder (OUD) since the 1990s and has been available in the United States for more than a decade. Initial practice recommendations were intentionally conservative, were based on expert opinion, and were influenced by methadone regulations. Since 2003, the American crisis of OUD has dramatically worsened, and much related empirical research has been undertaken. The findings in several important areas conflict with initial clinical practice that is still prevalent. This article reviews research findings in the following 7 areas: location of buprenorphine induction, combining buprenorphine with a benzodiazepine, relapse during buprenorphine treatment, requirements for counseling, uses of drug testing, use of other substances during buprenorphine treatment, and duration of buprenorphine treatment. For each area, evidence for needed updates and modifications in practice is provided. These modifications will facilitate more successful, evidence-based treatment and care for patients with OUD.	[Martin, Stephen A.] Univ Massachusetts, Sch Med, Barre, MA USA; [Martin, Stephen A.] Barre Family Hlth Ctr, Barre, MA USA; [Martin, Stephen A.; Chiodo, Lisa M.; Bosse, Jordon D.; Wilson, Amanda] CleanSlate Res & Educ Fdn, Florence, MA USA; [Chiodo, Lisa M.; Bosse, Jordon D.] Univ Massachusetts, Coll Nursing, 228 Skinner Hall,651 North Pleasant St, Amherst, MA 01003 USA; [Martin, Stephen A.] UMassMemorial Hlth Care, Barre Family Hlth Ctr, 151 Worcester Rd, Barre, MA 01005 USA; [Wilson, Amanda] 46 Sovereign Way, Florence, MA 01062 USA	University of Massachusetts System; University of Massachusetts System; University of Massachusetts Amherst	Martin, SA (corresponding author), UMassMemorial Hlth Care, Barre Family Hlth Ctr, 151 Worcester Rd, Barre, MA 01005 USA.	stmartin@gmail.com	Martin, Stephen A/L-9381-2013; Bosse, Jordon D/AAH-2028-2021	Martin, Stephen A/0000-0002-0356-5440; Bosse, Jordon/0000-0003-3547-9077	CleanSlate Research and Education Foundation	CleanSlate Research and Education Foundation	By the CleanSlate Research and Education Foundation.	Abrahamsson T, 2017, DRUG ALCOHOL DEPEN, V174, P58, DOI 10.1016/j.drugalcdep.2017.01.013; Alderks C.E., 2017, TRENDS USE METHADONE; Alford DP, 2007, J GEN INTERN MED, V22, P171, DOI 10.1007/s11606-006-0023-1; American Society of Addiction Medicine, 2017, ASAM APPR US DRUG TE; American Society of Addiction Medicine, 2015, NAT PRACT GUID US ME; Andrilla CHA, 2017, ANN FAM MED, V15, P359, DOI 10.1370/afm.2099; Bakker A, 2017, J PSYCHOPHARMACOL, V31, P62, DOI 10.1177/0269881116675508; Bebinger M., 2015, WBUR COMMONHEAL 1113; Bentzley BS, 2015, J SUBST ABUSE TREAT, V56, P48, DOI 10.1016/j.jsat.2015.04.002; Bentzley BS, 2015, J SUBST ABUSE TREAT, V52, P48, DOI 10.1016/j.jsat.2014.12.011; Bhatraju EP, 2017, ADDICT SCI CLIN PRAC, V12, DOI 10.1186/s13722-017-0072-2; Burns RM, 2016, SUBST ABUS, V37, P63, DOI 10.1080/08897077.2015.1080208; Center for Substance Abuse Treatment, 2004, CLIN GUID US BUPR TR; Cornish R, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5475; Cunningham CO, 2013, AM J ADDICTION, V22, P352, DOI 10.1111/j.1521-0391.2013.12032.x; Cunningham CO, 2011, J SUBST ABUSE TREAT, V40, P349, DOI 10.1016/j.jsat.2010.12.002; D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474; Ding KY, 2016, 2016 NORW I PUBL HLT; Dugosh K, 2016, J ADDICT MED, V10, P93, DOI 10.1097/ADM.0000000000000193; Dupouy J, 2017, ANN FAM MED, V15, P355, DOI 10.1370/afm.2098; Fiellin DA, 2014, JAMA INTERN MED, V174, P1947, DOI 10.1001/jamainternmed.2014.5302; Friedmann PD, 2012, ADDICT SCI CLIN PRAC, V7, DOI 10.1186/1940-0640-7-10; Gabrielson R, 2016, NY TIMES, pMM34; Glass I., 2011, THIS AM LIFE    0325; Gryczynski J, 2014, J SUBST ABUSE TREAT, V46, P356, DOI 10.1016/j.jsat.2013.10.004; Gunderson EW, 2011, J ADDICT MED, V5, P304, DOI 10.1097/ADM.0b013e31821ee8fe; Hartzler B, 2010, J SUBST ABUSE TREAT, V39, P114, DOI 10.1016/j.jsat.2010.05.008; Heikman PK, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1415-y; Heit HA, 2014, PATIENT CENTERED URI; Howland RH, 2015, J PSYCHOSOC NURS MEN, V53, P11, DOI 10.3928/02793695-20151117-01; Hser YI, 2015, HARVARD REV PSYCHIAT, V23, P76, DOI 10.1097/HRP.0000000000000052; Hutchinson E, 2014, ANN FAM MED, V12, P128, DOI 10.1370/afm.1595; Jones CM, 2014, MMWR-MORBID MORTAL W, V63, P881; Jones CM, 2018, OPIOID EPIDEMIC HHS; Kakko J, 2003, LANCET, V361, P662, DOI 10.1016/S0140-6736(03)12600-1; Kelly JF, 2015, AM J MED, V128, P8, DOI 10.1016/j.amjmed.2014.07.043; Knopf A., 2017, ALCOHOLISM DRUG ABUS, V29, P3; Larochelle MR, 2018, ANN INTERN MED, V169, P137, DOI 10.7326/M17-3107; Lee JD, 2014, J ADDICT MED, V8, P299, DOI 10.1097/ADM.0000000000000059; Lofwall MR, 2014, J ADDICT MED, V8, P315, DOI 10.1097/ADM.0000000000000045; Massachusetts Department of Public Health Bureau of Sub-stance Abuse Services, 2013, PRACT GUID RESP REL; McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689; Mund B, 2018, J LAW MED ETHICS, V46, P279, DOI 10.1177/1073110518782935; National Institute on Drug Abuse, 2012, PRINC EFF TREATM PRI; National Institute on Drug Abuse, 2013, SEEK DRUG AB TREATM; Nielsen S, 2007, ADDICTION, V102, P616, DOI 10.1111/j.1360-0443.2006.01731.x; Paone D, 2015, DRUG ALCOHOL DEPEN, V155, P298, DOI 10.1016/j.drugalcdep.2015.08.007; Park TW, 2017, J ADDICT MED, V11, P87, DOI 10.1097/ADM.0000000000000292; Park TW, 2014, PSYCHIAT SERV, V65, P4, DOI 10.1176/appi.ps.201300419; Posternak MA, 2001, AM J ADDICTION, V10, P48; Reckitt Benckiser Healthcare, 2017, SUBOXONE CIII BUPR H; Rees VW, 2015, SUMMARY OPIOID OVERD; Reynaud M, 1998, AM J PSYCHIAT, V155, P448; Reynaud M, 1998, ADDICTION, V93, P1385, DOI 10.1046/j.1360-0443.1998.93913859.x; Ruan XL, 2017, DRUG RES, V67, P189, DOI 10.1055/s-0042-119946; Sabate E, 2003, ADHERENCE LONG TERM; Salsitz E., 2017, FREQUENTLY ASKED QUE; Sansone Randy A, 2015, Innov Clin Neurosci, V12, P32; Schuman-Olivier Z, 2013, DRUG ALCOHOL DEPEN, V132, P580, DOI 10.1016/j.drugalcdep.2013.04.006; Schwartz RP, 2016, J ADDICT MED, V10, P283, DOI 10.1097/ADM.0000000000000236; Schwartz RP, 2013, AM J PUBLIC HEALTH, V103, P917, DOI 10.2105/AJPH.2012.301049; Sohler NL, 2010, J SUBST ABUSE TREAT, V38, P153, DOI 10.1016/j.jsat.2009.08.001; Starrels JL, 2012, J GEN INTERN MED, V27, P1521, DOI 10.1007/s11606-012-2165-7; Substance Abuse and Mental Health Services Administration, 2018, TIP 63 MED OP US DIS; Substance Abuse and Mental Health Services Administration, 2014, RES 2013 NAT SURV DR; The BDN Editorial Board, 2016, BANGOR DAILY NE 0421; The Pew Charitable Trusts, 2017, CAS MED ASS TREATM M; Tofighi B, 2016, J ADDICT MED, V10, P309, DOI 10.1097/ADM.0000000000000198; TVERSKY A, 1983, PSYCHOL REV, V90, P293, DOI 10.1037/0033-295X.90.4.293; U. S. Food and Drug Administration, 2017, FDA DRUG SAF COMM FD; United States Food and Drug Administration, 2016, FDA DRUG SAF COMM FD; Visconti AJ, 2015, J URBAN HEALTH, V92, P758, DOI 10.1007/s11524-015-9967-y; Volkow ND, 2014, NEW ENGL J MED, V370, P2063, DOI 10.1056/NEJMp1402780; Wakeman SE, 2017, J ADDICT MED, V11, P1, DOI 10.1097/ADM.0000000000000275; Warner Margaret, 2016, Natl Vital Stat Rep, V65, P1; World Health Organization, 2009, GUID PSYCH ASS PHARM; Zhu YM, 2018, DRUG ALCOHOL DEPEN, V187, P221, DOI 10.1016/j.drugalcdep.2018.02.019	77	79	79	2	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 6	2018	169	9					628	+		10.7326/M18-1652	http://dx.doi.org/10.7326/M18-1652			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ4UP	30357262				2023-01-03	WOS:000449399700006
J	Huebinger, RM; Smith, AD; Zhang, Y; Monson, NL; Ireland, SJ; Barber, RC; Kubasiak, JC; Minshall, CT; Minei, JP; Wolf, SE; Allen, MS				Huebinger, Ryan M.; Smith, Ashley D.; Zhang, Yan; Monson, Nancy L.; Ireland, Sara J.; Barber, Robert C.; Kubasiak, John C.; Minshall, Christian T.; Minei, Joseph P.; Wolf, Steven E.; Allen, Michael S.			Variations of the lung microbiome and immune response in mechanically ventilated surgical patients	PLOS ONE			English	Article							PULMONARY INFECTION SCORE; BRONCHOALVEOLAR LAVAGE; PNEUMONIA SURVEILLANCE; ENDOTRACHEAL ASPIRATE; TRAUMA PATIENTS; DIAGNOSIS; CARE; GUIDELINES; MANAGEMENT; DYSBIOSIS	Mechanically ventilated surgical patients have a variety of bacterial flora that are often undetectable by traditional culture methods. The source of infection in many of these patients remains unclear. To address this clinical problem, the microbiome profile and host inflammatory response in bronchoalveolar lavage samples from the surgical intensive care unit were examined relative to clinical pathology diagnoses. The hypothesis was tested that clinical diagnosis of respiratory tract flora were similar to culture positive lavage samples in both microbiome and inflammatory profile. Bronchoalveolar lavage samples were collected in the surgical intensive care unit as standard of care for intubated individuals with a clinical pulmonary infection score of >6 or who were expected to be intubated for >48 hours. Cytokine analysis was conducted with the Bioplex Pro Human Th17 cytokine panel. The microbiome of the samples was sequenced for the 16S rRNA region using the Ion Torrent. Microbiome diversity analysis showed the culture-positive samples had the lowest levels of diversity and culture negative with the highest based upon the Shannon-Wiener index (culture positive: 0.77 +/- 0.36, respiratory tract flora: 2.06 +/- 0.73, culture negative: 3.97 +/- 0.65). Culture-negative samples were not dominated by a single bacterial genera. Lavages classified as respiratory tract flora were more similar to the culture-positive in the microbiome profile. A comparison of cytokine expression between groups showed increased levels of cytokines (IFN-g, IL-17F, IL-1 B, IL-31, TNF-a) in culture-positive and respiratory tract flora groups. Culture-positive samples exhibited a more robust immune response and reduced diversity of bacterial genera. Lower cytokine levels in culture-negative samples, despite a greater number of bacterial species, suggest a resident nonpathogenic bacterial community may be indicative of a normal pulmonary environment. Respiratory tract flora samples were most similar to the culture-positive samples and may warrant classification as culture-positive when considering clinical treatment.	[Huebinger, Ryan M.; Kubasiak, John C.; Minshall, Christian T.; Minei, Joseph P.; Wolf, Steven E.] Univ Texas Southwestern Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [Smith, Ashley D.; Zhang, Yan; Allen, Michael S.] Univ North Texas, Hlth Sci Ctr, Dept Microbiol Immunol & Genet, Ft Worth, TX 76107 USA; [Monson, Nancy L.; Ireland, Sara J.] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Monson, Nancy L.] Univ Texas Southwestern Med Ctr Dallas, Dept Immunol, Dallas, TX 75390 USA; [Barber, Robert C.] Univ North Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of North Texas System; University of North Texas Denton; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of North Texas System; University of North Texas Denton	Huebinger, RM (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA.; Allen, MS (corresponding author), Univ North Texas, Hlth Sci Ctr, Dept Microbiol Immunol & Genet, Ft Worth, TX 76107 USA.	Ryan.Huebinger@UTSouthwestern.edu; Michael.Allen@unthsc.edu	Smith, Ashley/GZB-0298-2022; Zhang, Yan/L-1738-2015	Zhang, Yan/0000-0001-5784-4659; Allen, Michael/0000-0003-2293-8078; Wolf, Steven/0000-0003-2972-3440				Baselski V, 2013, J CLIN MICROBIOL, V51, P740, DOI 10.1128/JCM.03383-12; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; de Brito RDCM, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0324-z; Croce MA, 2006, J TRAUMA, V60, P523, DOI 10.1097/01.ta.0000204033.78125.1b; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Einarsson GG, 2016, THORAX, V71, P795, DOI 10.1136/thoraxjnl-2015-207235; Erb-Downward JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016384; Fujitani S, 2009, RESP CARE, V54, P1453; Grgurich PE, 2013, CURR OPIN INFECT DIS, V26, P140, DOI 10.1097/QCO.0b013e32835ebbd0; Grover V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109686; Hellyer TP, 2015, THORAX, V70, P41, DOI 10.1136/thoraxjnl-2014-205766; Hoggard M, 2017, INT FORUM ALLERGY RH, V7, P230, DOI 10.1002/alr.21871; Kalil AC, 2016, CLIN INFECT DIS, V63, pE61, DOI 10.1093/cid/ciw353; Kitsios GD, 2017, J CRIT CARE, V38, P84, DOI 10.1016/j.jcrc.2016.09.029; LaPar DJ, 2012, J AM COLL SURGEONS, V214, P478, DOI 10.1016/j.jamcollsurg.2011.12.015; Leonard KL, 2016, SURG INFECT, V17, P363, DOI 10.1089/sur.2014.076; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; May AK, 2015, CHEST, V147, P1494, DOI 10.1378/chest.14-1687; Michetti CP, 2012, J TRAUMA ACUTE CARE, V72, P1165, DOI 10.1097/TA.0b013e31824d10fa; Millo JL, 2004, INTENS CARE MED, V30, P68, DOI 10.1007/s00134-003-2060-0; Minei JP, 2006, J TRAUMA, V60, P1106, DOI 10.1097/01.ta.0000220424.34835.f1; Morris AC, 2017, THORAX, V72, P1046, DOI 10.1136/thoraxjnl-2016-209065; Morris AC, 2010, THORAX, V65, P201, DOI 10.1136/thx.2009.122291; Nair GB, 2015, INTENS CARE MED, V41, P34, DOI 10.1007/s00134-014-3564-5; O'Horo JC, 2016, AM J INFECT CONTROL, V44, P661, DOI 10.1016/j.ajic.2015.12.032; Piriyapatsom A, 2016, RESP CARE, V61, P269, DOI 10.4187/respcare.04280; Piters WAAD, 2016, ISME J, V10, P97, DOI 10.1038/ismej.2015.99; SAUAIA A, 1993, J TRAUMA, V35, P512, DOI 10.1097/00005373-199310000-00003; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Scholte JBJ, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0087-y; Scholte JBJ, 2014, J CLIN MICROBIOL, V52, P3597, DOI 10.1128/JCM.01494-14; Schurink CAM, 2004, INTENS CARE MED, V30, P217, DOI 10.1007/s00134-003-2018-2; Smith AD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166313; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Wang Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007401; Wu CL, 2002, CHEST, V122, P662, DOI 10.1378/chest.122.2.662; Yeh A, 2016, SHOCK, V46, P649, DOI 10.1097/SHK.0000000000000691; Zakharkina T, 2017, THORAX, V72, P803, DOI 10.1136/thoraxjnl-2016-209158; Zhang QL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152724; Zosa BM, 2017, SURG INFECT, V18, P558, DOI 10.1089/sur.2016.152	40	2	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2018	13	10							e0205788	10.1371/journal.pone.0205788	http://dx.doi.org/10.1371/journal.pone.0205788			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY3FL	30356313	Green Published, gold, Green Submitted			2023-01-03	WOS:000448434000060
J	Lamarca, A; Galdy, S; Barriuso, J; Moghadam, S; Beckett, E; Rogan, J; Backen, A; Billington, C; McNamara, MG; Hubner, RA; Cramer, A; Valle, JW				Lamarca, Angela; Galdy, Salvatore; Barriuso, Jorge; Moghadam, Sharzad; Beckett, Elizabeth; Rogan, Jane; Backen, Alison; Billington, Catherine; McNamara, Mairead G.; Hubner, Richard A.; Cramer, Angela; Valle, Juan W.			The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers	PLOS ONE			English	Article							EPIDERMAL-GROWTH-FACTOR; POOR-PROGNOSIS; ERBB RECEPTORS; OVEREXPRESSION; THERAPY; COEXPRESSION; EXPRESSION; FAMILY; EGFR; IMMUNOHISTOCHEMISTRY	Introduction Expression of human epidermal growth factor receptor (HER) 2 and HER3 have been investigated in small BTC studies using variable scoring systems. Methods HER2 and HER3 overexpression/amplification were explored following internationally agreed guidelines using immunohistochemistry (IHC) and fluorescent in-situ hybridisation (FISH), respectively. Logistic regression and survival analysis (Kaplan Meier, Log rank test and Cox Regression) were used for statistical analysis. Results Sixty-seven eligible patients with Stage I/II (31.3%) or III/IV (68.7%) disease at diagnosis were included. Membrane HER2 overexpression/amplification was identified in 1 patient (1%). HER3 overexpression was predominantly cytoplasmic; the rate of overexpression/amplification of HER3 in membrane and cytoplasm was 16% [ampullary cancer (AMP) (1/13; 8%), gallbladder cancer (GBC) (1/10; 10%), intra-hepatic cholangiocarcinoma (ICC) (6/26; 23%), extra-hepatic cholangiocarcinoma (ECC) (3/18; 17%)] and 24% [AMP (1/13; 8%), GBC (1/10; 10%), ICC (10/26; 38%), ECC (4/18; 22%)], respectively. Conclusions A significant subset of patients with BTC expressed HER3. Inhibition of HER3 warrants further investigation. A better understanding of the downstream effects of HER3 in BTC requires further mechanistic investigations to identify new biomarkers and improve patient selection for future clinical trials.	[Lamarca, Angela; Galdy, Salvatore; Barriuso, Jorge; Backen, Alison; McNamara, Mairead G.; Hubner, Richard A.; Valle, Juan W.] Christie NHS Fdn Trust Manchester, Dept Med Oncol, Manchester, Lancs, England; [Galdy, Salvatore] European Inst Oncol, Unit Gastrointestinal Med Oncol & Neuroendocrine, Milan, Italy; [Barriuso, Jorge; McNamara, Mairead G.; Valle, Juan W.] Univ Manchester, Div Canc Sci, Sch Med Sci, Fac Biol Med & Hlth, Manchester, Lancs, England; [Moghadam, Sharzad; Rogan, Jane] Univ Manchester, Manchester Canc Res Ctr Biobank, Manchester, Lancs, England; [Beckett, Elizabeth; Billington, Catherine; Cramer, Angela] Christie NHS Fdn Trust, Christie Pathol Partnership, Manchester, Lancs, England	IRCCS European Institute of Oncology (IEO); University of Manchester; University of Manchester; Christie NHS Foundation Trust	Lamarca, A; Valle, JW (corresponding author), Christie NHS Fdn Trust Manchester, Dept Med Oncol, Manchester, Lancs, England.; Valle, JW (corresponding author), Univ Manchester, Div Canc Sci, Sch Med Sci, Fac Biol Med & Hlth, Manchester, Lancs, England.	angela.lamarca@christie.nhs.uk; juan.valle@manchester.ac.uk	; Mcnamara, Mairead/J-1621-2015	Lamarca, Angela/0000-0001-9696-6122; Mcnamara, Mairead/0000-0002-2272-3678; Barriuso, Jorge/0000-0002-5641-9105	European Society for Medical Oncology (ESMO) Translational Fellowship Programme; Spanish Society of Medical Oncology (SEOM) Fellowship Programme; American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award; 'Clinical Unit Visit' ESMO Fellowship	European Society for Medical Oncology (ESMO) Translational Fellowship Programme; Spanish Society of Medical Oncology (SEOM) Fellowship Programme; American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award; 'Clinical Unit Visit' ESMO Fellowship	Angela Lamarca was part-funded by the European Society for Medical Oncology (ESMO) Translational Fellowship Programme, by the Spanish Society of Medical Oncology (SEOM) Fellowship Programme and by the American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award. Salvatore Galdy was part-funded by 'Clinical Unit Visit' ESMO Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aceto N, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3329; Aloysius MM, 2009, HISTOPATHOLOGY, V55, P236, DOI 10.1111/j.1365-2559.2009.03351.x; Anagnostou VK, 2010, CANCER EPIDEM BIOMAR, V19, P982, DOI 10.1158/1055-9965.EPI-10-0097; Bae SY, 2013, BREAST CANCER RES TR, V139, P741, DOI 10.1007/s10549-013-2570-6; Bang YJ, 2010, LANCET, V376, P1302; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; COLLIER JD, 1992, J HEPATOL, V14, P377, DOI 10.1016/0168-8278(92)90186-S; Debska-Szmich S, 2015, POSTEP HIG MED DOSW, V69, P586, DOI 10.5604/17322693.1151339; DeOliveira ML, 2007, ANN SURG, V245, P755, DOI 10.1097/01.sla.0000251366.62632.d3; El-Khoueiry AB, 2014, BRIT J CANCER, V110, P882, DOI 10.1038/bjc.2013.801; Elebro J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153533; Galdy S, 2017, CANCER METAST REV, V36, P141, DOI 10.1007/s10555-016-9645-x; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Goyal L., CANC DISCOV; Hofmann M, 2008, HISTOPATHOLOGY, V52, P797, DOI 10.1111/j.1365-2559.2008.03028.x; Hsieh AC, 2007, BRIT J CANCER, V97, P453, DOI 10.1038/sj.bjc.6603910; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Hyman DM, 2018, NATURE, V554, P189, DOI 10.1038/nature25475; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jaiswal BS, 2013, CANCER CELL, V23, P603, DOI 10.1016/j.ccr.2013.04.012; Javle MM, 2016, J CLIN ONCOL S4S, V34; Jusakul A, 2017, CANCER DISCOV, V7, P1116, DOI 10.1158/2159-8290.CD-17-0368; Kawamoto T, 2015, J GASTROENTEROL, V50, P467, DOI 10.1007/s00535-014-0984-5; Kol A, 2014, PHARMACOL THERAPEUT, V143, P1, DOI 10.1016/j.pharmthera.2014.01.005; Krahn G, 2001, EUR J CANCER, V37, P251, DOI 10.1016/S0959-8049(00)00364-6; Lamarca A., ANN ONCOL; Lamarca A., 2014, ANN ONCOL         S4, V25, DOI [10.1093/annonc/mdu334.133, DOI 10.1093/ANNONC/MDU334.133]; Lamarca A, 2018, ILCA ANN M SEPT; Lee HJ, 2012, VIRCHOWS ARCH, V461, P521, DOI 10.1007/s00428-012-1321-0; Mazzaferro V, 2016, PATIENTS ADV METASTA; Mitri Zahi, 2012, Chemother Res Pract, V2012, P743193, DOI 10.1155/2012/743193; Mota JM, 2017, ONCOTARGET, V8, P89284, DOI 10.18632/oncotarget.18467; Ocana A, 2013, JNCI-J NATL CANCER I, V105, P266, DOI 10.1093/jnci/djs501; Peck J, 2012, ONCOLOGY-BASEL, V82, P175, DOI 10.1159/000336488; Pellat A., HEPATOLOGY, V10; Ramanathan RK, 2009, CANCER CHEMOTH PHARM, V64, P777, DOI 10.1007/s00280-009-0927-7; Saha S. K., CANC DISCOV; Shankaran H, 2006, BIOPHYS J, V90, P3993, DOI 10.1529/biophysj.105.080580; Sirica AE, 2008, WORLD J GASTROENTERO, V14, P7033, DOI 10.3748/wjg.14.7033; Spears M, 2012, BREAST CANCER RES TR, V132, P463, DOI 10.1007/s10549-011-1606-z; Tanner KG, 1999, J BIOL CHEM, V274, P35985, DOI 10.1074/jbc.274.50.35985; te Velde EA, 2009, EJSO-EUR J SURG ONC, V35, P1098, DOI 10.1016/j.ejso.2009.02.013; Thomas G, 2014, ONCOTARGET, V5, P7138, DOI 10.18632/oncotarget.2231; Vaidya P, 1996, J PATHOL, V178, P140, DOI 10.1002/(SICI)1096-9896(199602)178:2<140::AID-PATH450>3.0.CO;2-U; Valle JW, 2016, ANN ONCOL, V27, pv28, DOI 10.1093/annonc/mdw324; Valle JW, 2009, BRIT J CANCER, V101, P621, DOI 10.1038/sj.bjc.6605211; Valle J. W., CANC DISCOV; Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721; Vollmann-Zwerenz A, 2010, CYTOM PART A, V77A, P387, DOI 10.1002/cyto.a.20868; Wang L, 2013, PROSTATE CANCER P D, V16, P301, DOI 10.1038/pcan.2013.25; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yan M, 2015, CANCER METAST REV, V34, P157, DOI 10.1007/s10555-015-9552-6; Yang JJ, 2014, EXPERT OPIN THER TAR, V18, P1011; Yang XQ, 2014, ONCOL REP, V32, P700, DOI 10.3892/or.2014.3261; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yoshida H, 2016, VIRCHOWS ARCH, V468, P431, DOI 10.1007/s00428-015-1898-1; Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278; Zhang NY, 2016, ACTA BIOCH BIOPH SIN, V48, P39, DOI 10.1093/abbs/gmv103; Zhao S, 2016, ONCOTARGETS THER, V9, P6695, DOI 10.2147/OTT.S110926	60	13	14	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2018	13	10							e0206007	10.1371/journal.pone.0206007	http://dx.doi.org/10.1371/journal.pone.0206007			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX4KR	30335866	gold, Green Submitted, Green Published			2023-01-03	WOS:000447701300086
J	Goncalves, GMR; da Silva, EN				Reis Goncalves, Gabriela Maria; da Silva, Everton Nunes			Cost of chronic kidney disease attributable to diabetes from the perspective of the Brazilian Unified Health System	PLOS ONE			English	Article							STAGE RENAL-DISEASE; UNITED-STATES; NATIONAL-HEALTH; MORTALITY; IMPACT; CARE; ASSOCIATION; PROGRESSION; POPULATION; DIALYSIS	Introduction Diabetes is the most common cause of chronic kidney disease, with a high economic impact on health systems. Objective To estimate the cost of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) attributable to diabetes, stratified by sex, race/skin color, and age, from the perspective of the Brazilian public health system between 2010 and 2016. Methods Population attributable risk (PAR) was calculated from the Brazilian prevalence of diabetes and the relative risk (or odds ratio) of persons with diabetes developing CKD and ESKD as compared to non-diabetic subjects. The variables of interest were sex, race/skin color, and age. A top-down approach was used to measure the direct costs of the disease reimbursed by the Brazilian Ministry of Health, using data from outpatient and inpatient records. Results The cost of CKD and ESKD attributable to diabetes in the period 2010-2016 was US$1.2 billion (US$180 million per year) and trending upward. Female sex, age 65-75, and black race/skin color contributed substantially to the costs of CKD and ESKD (US$475 million, US $63 million, and US$25 million respectively). The clinical procedures accounting for the greatest share of disease-attributable costs are hemodialysis and peritoneal dialysis. Conclusion Diabetes accounted for 22% of the costs of CKD and ESKD. Female sex, age 65-75 years, and black race/skin color were the variables which contributed most to disease-related expenditure. The economic burden of CKD may increase gradually in the coming years, with serious implications for the financial sustainability of the Brazilian public health system.	[Reis Goncalves, Gabriela Maria; da Silva, Everton Nunes] Univ Brasilia, Brasilia, DF, Brazil; [da Silva, Everton Nunes] CNPq, Natl Inst Sci & Technol Hlth Technol Assessment I, Porto Alegre, RS, Brazil	Universidade de Brasilia	Goncalves, GMR (corresponding author), Univ Brasilia, Brasilia, DF, Brazil.	gabimaria.nut@gmail.com		Reis Goncalves, Gabriela Maria/0000-0003-0544-3831; Silva, Everton/0000-0001-8747-4185				Atkins Robert C., 2010, Arch. Cardiol. Méx., V80, P44; Barreto SM, 2016, J EPIDEMIOL COMMUN H, V70, P380, DOI 10.1136/jech-2015-205834; Barros MBDA, 2017, REV SAUDE PUBL, V51; Benzaquem DC, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0112217, 10.1371/journal.pone.0121160]; Brasil Ipea I de PEA, 2011, RETR DES GEN RAC, P39; Carrero JJ, 2011, NEPHROL DIAL TRANSPL, V26, P270, DOI 10.1093/ndt/gfq386; Carrero JJ, 2018, NAT REV NEPHROL, V14, P151, DOI 10.1038/nrneph.2017.181; Cherchiglia ML, 2010, CAD SAUDE PUBLICA, V26, P1627, DOI 10.1590/S0102-311X2010000800016; Collins AJ, 2015, KIDNEY INT SUPPL, V5, P2, DOI 10.1038/kisup.2015.2; Collins AJ, 2009, AM J KIDNEY DIS, V53, pS1, DOI 10.1053/j.ajkd.2008.10.005; Couser WG, 2011, KIDNEY INT, V80, P1258, DOI 10.1038/ki.2011.368; da BRASILM S, 2011, PLANO ACOES ESTRATEG; Danaei G, 2014, LANCET DIABETES ENDO, V2, P634, DOI 10.1016/S2213-8587(14)70102-0; De Cosmo S, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004007; de Moura L, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-111; de Oliveira ML, 2014, REV NUTR, V27, DOI 10.1590/1415-52732014000500007; Ene-Iordache B, 2016, LANCET GLOB HEALTH, V4, pE307, DOI 10.1016/S2214-109X(16)00071-1; Goes F, 2011, MULHERES NEGRAS BRAN, P571; Gregg EW, 2014, NEW ENGL J MED, V370, P1514, DOI 10.1056/NEJMoa1310799; Hemmelgarn BR, 2006, KIDNEY INT, V69, P2155, DOI 10.1038/sj.ki.5000270; Hemmelgarn BR, 2012, JAMA-J AM MED ASSOC, V307, P2507, DOI 10.1001/jama.2012.6455; Hill NR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158765; Hippisley-Cox J, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-49; Instituto Brasileiro de Geografia e Estatistica-IBGE, 2014, PESQ NAC SAUD; *INT ORG MIGR, 2017, WORLD MIGR REP 2018, P1, DOI DOI 10.1093/ESR/JCN046; Jha V, 2016, KIDNEY INT, V90, P1164, DOI 10.1016/j.kint.2016.09.009; Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X; Levin Adeera, 2017, Lancet, V390, P1888, DOI 10.1016/S0140-6736(17)30788-2; Lewis EF, 2015, AM HEART J, V170, P322, DOI 10.1016/j.ahj.2015.05.008; Lipworth L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048407; Lorenzo V, 2010, NEPHROL DIAL TRANSPL, V25, P2283, DOI 10.1093/ndt/gfp761; Marinho Ana Wanda Guerra Barreto, 2017, Cad. saúde colet., V25, P379, DOI 10.1590/1414-462x201700030134; Martins D, 2006, AM J KIDNEY DIS, V47, P965, DOI 10.1053/j.ajkd.2006.02.179; Morton RL, 2016, NEPHROL DIAL TRANSPL, V31, P46, DOI 10.1093/ndt/gfu394; Moura L, 2013, REV BRAS EPIDEMIO S2, V18, P181; Muka T, 2015, EUR J EPIDEMIOL, V30, P251, DOI 10.1007/s10654-014-9984-2; Narres M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147329; Ng BL, 2011, INTERN MED J, V41, P761, DOI 10.1111/j.1445-5994.2011.02590.x; Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8; Pinheiro Rejane Sobrino, 2002, Ciênc. saúde coletiva, V7, P687; Schmidt MI, 2011, LANCET, V377, P1949, DOI 10.1016/S0140-6736(11)60135-9; Scialla JJ, 2012, KIDNEY INT, V82, P106, DOI 10.1038/ki.2012.82; Sesso Ricardo Cintra, 2017, Braz. J. Nephrol., V39, P261, DOI 10.5935/0101-2800.20170049; Seuring T, 2015, PHARMACOECONOMICS, V33, P811, DOI 10.1007/s40273-015-0268-9; Shen YJ, 2017, ENDOCRINE, V55, P75, DOI 10.1007/s12020-016-1014-6; Silva Junior Geraldo Bezerra da, 2017, Braz. J. Nephrol., V39, P65, DOI 10.5935/0101-2800.20170011; Tsai WC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003013; van den Beukel TO, 2013, CLIN J AM SOC NEPHRO, V8, P1540, DOI 10.2215/CJN.10761012; Webster AC, 2017, LANCET, V389, P1238, DOI 10.1016/S0140-6736(16)32064-5; Wen CP, 2008, LANCET, V371, P2173, DOI 10.1016/S0140-6736(08)60952-6; Xavier DB, 2017, OBES SURG, V27, P641, DOI 10.1007/s11695-016-2327-5; Xue JL, 2007, J AM SOC NEPHROL, V18, P1299, DOI 10.1681/ASN.2006050524; Yu MK, 2015, NEPHROLOGY, V20, P451, DOI 10.1111/nep.12468; Zhou B, 2016, LANCET, V387, P1513, DOI 10.1016/S0140-6736(16)00618-8	54	10	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2018	13	10							e0203992	10.1371/journal.pone.0203992	http://dx.doi.org/10.1371/journal.pone.0203992			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV5EV	30273345	Green Published, gold, Green Submitted			2023-01-03	WOS:000446124700011
J	LeBlanc, ES; Patnode, CD; Webber, EM; Redmond, N; Rushkin, M; O'Connor, EA				LeBlanc, Erin S.; Patnode, Carrie D.; Webber, Elizabeth M.; Redmond, Nadia; Rushkin, Megan; O'Connor, Elizabeth A.			Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults Updated Evidence Report and Systematic Review for the US Preventive Services Task Force	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							BODY-MASS INDEX; LIFE-STYLE-INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; LONG-TERM WEIGHT; QUALITY-OF-LIFE; CARDIOVASCULAR-DISEASE RISK; ALL-CAUSE MORTALITY; PRIMARY-CARE INTERVENTION; PLACEBO-CONTROLLED TRIAL; DIABETES PREVENTION	IMPORTANCE Overweight and obesity have been associated with adverse health effects. OBJECTIVE To systematically review evidence on benefits and harms of behavioral and pharmacotherapy weight loss and weight loss maintenance interventions in adults to inform the US Preventive Services Task Force. DATA SOURCES MEDLINE, PubMed Publisher-Supplied Records, PsycINFO, and the Cochrane Central Register of Controlled Trials for studies published through June 6, 2017; ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform for ongoing trials through August 2017; and ongoing surveillance in targeted publications through March 23, 2018. Studies from previous reviews were reevaluated for inclusion. STUDY SELECTION Randomized clinical trials (RCTs) focusing on weight loss or weight loss maintenance in adults. DATA EXTRACTION AND SYNTHESIS Data were abstracted by one reviewer and confirmed by another. Random-effects meta-analyses were conducted for weight loss outcomes in behavior-based interventions. MAIN OUTCOMES AND MEASURES Health outcomes, weight loss or weight loss maintenance, reduction in obesity-related conditions, and adverse events. RESULTS A total of 122 RCTs (N = 62 533) and 2 observational studies (N = 209 993) were identified. Compared with controls, participants in behavior-based interventions had greater mean weight loss at 12 to 18 months (-2.39 kg [95% CI, -2.86 to -1.93]; 67 studies [n = 22065]) and less weight regain (-1.59 kg [95% CI, -2.38 to -0.79]; 8 studies [n = 1408]). Studies of medication-based weight loss and maintenance interventions also reported greater weight loss or less weight regain in intervention compared with placebo groups at 12 to 18 months (range, -0.6 to -5.8 kg; nometa-analysis). Participants with prediabetes in weight loss interventions had a lower risk of developing diabetes compared with controls (relative risk, 0.67 [95% CI, 0.51 to 0.89]). There was no evidence of other benefits, but most health outcomes such as mortality, cardiovascular disease, and cancer were infrequently reported. Small improvements in quality of life in some medication trials were noted but were of unclear clinical significance. There was no evidence of harm such as cardiovascular disease from behavior-based interventions; higher rates of adverse events were associated with higher dropout rates in medication groups than in placebo groups. CONCLUSIONS AND RELEVANCE Behavior-based weight loss interventions with or without weight loss medications were associated with more weight loss and a lower risk of developing diabetes than control conditions. Weight loss medications, but not behavior-based interventions, were associated with higher rates of harms. Long-term weight and health outcomes data, as well as data on important subgroups, were limited.	[LeBlanc, Erin S.; Patnode, Carrie D.; Webber, Elizabeth M.; Redmond, Nadia; Rushkin, Megan; O'Connor, Elizabeth A.] Kaiser Permanente, Ctr Hlth Res, Res Affiliates Evidence Based Practice Ctr, Portland, OR USA	Kaiser Permanente	LeBlanc, ES (corresponding author), Kaiser Permanente Northwest, Ctr Hlth Res, Res Affiliates Evidence Based Practice Ctr, 3800 N Interstate Ave, Portland, OR 97227 USA.	Erin.S.LeBlanc@kpchr.org			Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services [HHSA290201200015I, 6]	Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services	This research was funded under contract HHSA290201200015I, Task Order 6, from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services, under a contract to support the USPSTF.	Abell JE, 2008, AM J PUBLIC HEALTH, V98, P63, DOI 10.2105/AJPH.2006.093781; Abell JE, 2007, PUBLIC HEALTH REP, V122, P507, DOI 10.1177/003335490712200412; Acharya NV, 2006, INT J OBESITY, V30, P1645, DOI 10.1038/sj.ijo.0803323; Ackermann RT, 2015, AM J PUBLIC HEALTH, V105, P2328, DOI 10.2105/AJPH.2015.302641; Ackermann RT, 2009, OBESITY, V17, P2176, DOI 10.1038/oby.2009.114; Ackermann RT, 2008, AM J PREV MED, V35, P357, DOI 10.1016/j.amepre.2008.06.035; Adams KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMoa055643; Afshin A, 2017, NEW ENGL J MED, V377, P13, DOI 10.1056/NEJMoa1614362; Ahern AL, 2017, LANCET, V389, P2214, DOI 10.1016/S0140-6736(17)30647-5; Allison DB, 2012, OBESITY, V20, P330, DOI 10.1038/oby.2011.330; Anderson AS, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1823; Apovian CM, 2013, OBESITY, V21, P935, DOI 10.1002/oby.20309; Appel LJ, 2011, NEW ENGL J MED, V365, P1959, DOI 10.1056/NEJMoa1108660; Aronne LJ, 2013, OBESITY, V21, P2163, DOI 10.1002/oby.20584; Astrup A, 2012, INT J OBESITY, V36, P843, DOI 10.1038/ijo.2011.158; Aveyard P, 2016, LANCET, V388, P2492, DOI 10.1016/S0140-6736(16)31893-1; Bakris G, 2002, J HYPERTENS, V20, P2257, DOI 10.1097/00004872-200211000-00026; Barba C, 2004, LANCET, V363, P157, DOI 10.1016/S0140-6736(03)15268-3; Beeken RJ, 2017, INT J OBESITY, V41, P246, DOI 10.1038/ijo.2016.206; Befort CA, 2016, OBESITY, V24, P2070, DOI 10.1002/oby.21625; Bennett GG, 2012, ARCH INTERN MED, V172, P565, DOI 10.1001/archinternmed.2012.1; Bhaskaran K, 2014, LANCET, V384, P755, DOI 10.1016/S0140-6736(14)60892-8; Bhopal RS, 2014, LANCET DIABETES ENDO, V2, P218, DOI 10.1016/S2213-8587(13)70204-3; Bogers RP, 2007, ARCH INTERN MED, V167, P1720, DOI 10.1001/archinte.167.16.1720; Broom I, 2002, INT J CLIN PRACT, V56, P494; Broom I, 2002, BR J CARDIOL, V9, P460; Burke V, 2005, J HYPERTENS, V23, P1241, DOI 10.1097/01.hjh.0000170388.61579.4f; Cadmus-Bertram L, 2016, J BEHAV MED, V39, P551, DOI 10.1007/s10865-016-9735-9; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Chang SH, 2014, JAMA SURG, V149, P275, DOI 10.1001/jamasurg.2013.3654; Chen Y, 2006, SPINAL CORD, V44, P82, DOI 10.1038/sj.sc.3101818; Chirinos DA, 2016, J BEHAV MED, V39, P483, DOI 10.1007/s10865-016-9721-2; Christian JG, 2011, J AM DIET ASSOC, V111, P75, DOI 10.1016/j.jada.2010.10.006; Cohen M D, 1991, Fam Med, V23, P25; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; Courcoulas AP, 2014, JAMA SURG, V149, P707, DOI 10.1001/jamasurg.2014.467; Cussler EC, 2008, OBESITY, V16, P1052, DOI 10.1038/oby.2008.19; Danaei G, 2016, EPIDEMIOLOGY, V27, P302, DOI 10.1097/EDE.0000000000000428; Danaei G, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000058; Davidson MH, 1999, JAMA-J AM MED ASSOC, V281, P235, DOI 10.1001/jama.281.3.235; Dawes AJ, 2016, JAMA-J AM MED ASSOC, V315, P150, DOI 10.1001/jama.2015.18118; de Gonzalez AB, 2010, NEW ENGL J MED, V363, P2211, DOI 10.1056/NEJMoa1000367; de Vos BC, 2014, EUR J NUTR, V53, P95, DOI 10.1007/s00394-013-0505-y; Demark-Wahnefried W, 2015, BREAST CANCER RES TR, V154, P329, DOI 10.1007/s10549-015-3627-5; Demark-Wahnefried W, 2014, CANCER-AM CANCER SOC, V120, P2522, DOI 10.1002/cncr.28761; Derosa G, 2003, CLIN THER, V25, P1107, DOI 10.1016/S0149-2918(03)80070-X; DerSarkissian M, 2017, CURR MED RES OPIN, V33, P1105, DOI 10.1080/03007995.2017.1307173; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Di Angelantonio E, 2016, LANCET, V388, P776, DOI 10.1016/S0140-6736(16)30175-1; Dulloo AG, 2015, OBES REV, V16, P1, DOI 10.1111/obr.12250; Eaton CB, 2016, ANN FAM MED, V14, P311, DOI 10.1370/afm.1952; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Farr OM, 2016, DIABETES, V65, P2943, DOI 10.2337/db16-0635; Feller S, 2015, OBESITY, V23, P1112, DOI 10.1002/oby.21054; Fidler MC, 2011, J CLIN ENDOCR METAB, V96, P3067, DOI 10.1210/jc.2011-1256; Finer N, 2000, INT J OBESITY, V24, P306, DOI 10.1038/sj.ijo.0801128; Fischer HH, 2016, DIABETES CARE, V39, P1364, DOI 10.2337/dc15-2137; Fitzgibbon ML, 2010, OBESITY, V18, P2317, DOI 10.1038/oby.2010.47; Flegal KM, 2017, J CLIN EPIDEMIOL, V88, P21, DOI 10.1016/j.jclinepi.2017.04.007; Flegal KM, 2013, JAMA-J AM MED ASSOC, V309, P71, DOI 10.1001/jama.2012.113905; Flegal KM, 2004, AM J PUBLIC HEALTH, V94, P1486, DOI 10.2105/AJPH.94.9.1486; Florez H, 2012, J GEN INTERN MED, V27, P1594, DOI 10.1007/s11606-012-2122-5; French SA, 1999, AM J EPIDEMIOL, V149, P504, DOI 10.1093/oxfordjournals.aje.a009844; Gadde KM, 2011, LANCET, V377, P1341, DOI 10.1016/S0140-6736(11)60205-5; Godino JG, 2016, LANCET DIABETES ENDO, V4, P747, DOI 10.1016/S2213-8587(16)30105-X; Greaves C, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-014-0159-z; Greenway FL, 2010, LANCET, V376, P595, DOI 10.1016/S0140-6736(10)60888-4; Gregg EW, 2003, ANN INTERN MED, V138, P383, DOI 10.7326/0003-4819-138-5-200303040-00007; Guh DP, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-88; Haapala I, 2009, PUBLIC HEALTH NUTR, V12, P2382, DOI 10.1017/S1368980009005230; Hauptman J, 2000, ARCH FAM MED, V9, P160, DOI 10.1001/archfami.9.2.160; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hill JO, 1999, AM J CLIN NUTR, V69, P1108; Hong JL, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5039; Hunt K, 2014, LANCET, V383, P1211, DOI 10.1016/S0140-6736(13)62420-4; Huseinovic E, 2016, AM J CLIN NUTR, V104, P362, DOI 10.3945/ajcn.116.135673; Huxley R, 2007, DIABETES CARE, V30, P3116, DOI 10.2337/dc07-1455; Jackson CL, 2014, OBESITY, V22, P842, DOI 10.1002/oby.20471; Jakicic JM, 2011, OBESITY, V19, P100, DOI 10.1038/oby.2010.122; Jansson Stefan Po, 2013, BMC Res Notes, V6, P213, DOI 10.1186/1756-0500-6-213; Jebb SA, 2011, LANCET, V378, P1485, DOI 10.1016/S0140-6736(11)61344-5; JEFFERY RW, 1993, J CONSULT CLIN PSYCH, V61, P1038, DOI 10.1037/0022-006X.61.6.1038; Jenkins DJA, 2017, J AM COLL CARDIOL, V69, P1103, DOI 10.1016/j.jacc.2016.10.089; Jolly K, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6500; Jones DW, 1999, AM J HYPERTENS, V12, P1175, DOI 10.1016/S0895-7061(99)00123-5; Rodriguez-Cristobal JJ, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-017-0644-y; Kamvissi-Lorenz V, 2017, CURR ATHEROSCLER REP, V19, DOI 10.1007/s11883-017-0642-5; Kanke Satoshi, 2015, Asia Pac Fam Med, V14, P5, DOI 10.1186/s12930-015-0022-7; Katula JA, 2011, DIABETES CARE, V34, P1451, DOI 10.2337/dc10-2115; Kim SH, 2013, DIABETES CARE, V36, P3276, DOI 10.2337/dc13-0354; King WC, 2016, JAMA-J AM MED ASSOC, V315, P1362, DOI 10.1001/jama.2016.3010; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kraschnewski JL, 2013, MED CARE, V51, P186, DOI 10.1097/MLR.0b013e3182726c33; Krempf M, 2003, INT J OBESITY, V27, P591, DOI 10.1038/sj.ijo.0802281; Kruseman M, 2017, OBESITY FACTS, V10, P373, DOI 10.1159/000478096; Kuller LH, 2012, OBESITY, V20, P636, DOI 10.1038/oby.2011.80; Kulzer B, 2009, DIABETES CARE, V32, P1143, DOI 10.2337/dc08-2141; Kumanyika SK, 2012, OBESITY, V20, P1249, DOI 10.1038/oby.2011.329; Kyrgiou M, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j477; le Roux CW, 2017, LANCET, V389, P1399, DOI 10.1016/S0140-6736(17)30069-7; LeBlanc E, 2011, US PREVENTIVE SERVIC; Lenz M, 2009, DTSCH ARZTEBL INT, V106, P641, DOI 10.3238/arztebl.2009.0641; Lindgarde F, 2000, J INTERN MED, V248, P245, DOI 10.1046/j.1365-2796.2000.00720.x; Lindstrom J, 2013, DIABETOLOGIA, V56, P284, DOI 10.1007/s00125-012-2752-5; Little P, 2016, LANCET DIABETES ENDO, V4, P821, DOI 10.1016/S2213-8587(16)30099-7; Logue E, 2005, OBES RES, V13, P917, DOI 10.1038/oby.2005.106; Low S, 2009, ANN ACAD MED SINGAP, V38, P66; Luley C, 2014, J AM COLL NUTR, V33, P363, DOI 10.1080/07315724.2013.875437; Ma J, 2009, ARCH INTERN MED, V169, P313, DOI 10.1001/archinternmed.2008.582; Ma J, 2013, OBESITY, V21, P1734, DOI 10.1002/oby.20285; Ma J, 2013, JAMA INTERN MED, V173, P113, DOI 10.1001/2013.jamainternmed.987; Mackie GM, 2017, OBES RES CLIN PRACT, V11, P131, DOI 10.1016/j.orcp.2016.10.284; Marrero DG, 2016, AM J PUBLIC HEALTH, V106, P949, DOI 10.2105/AJPH.2015.303035; Martin CK, 2011, J CLIN ENDOCR METAB, V96, P837, DOI 10.1210/jc.2010-1848; Martin PD, 2008, OBESITY, V16, P2462, DOI 10.1038/oby.2008.399; Maskarinec G, 2009, ETHNIC DIS, V19, P49; McCarroll ML, 2014, GYNECOL ONCOL, V132, P397, DOI 10.1016/j.ygyno.2013.12.023; Mensink M, 2003, DIABETES RES CLIN PR, V61, P49, DOI 10.1016/S0168-8227(03)00067-6; Mhurchu CN, 2004, INT J EPIDEMIOL, V33, P751, DOI 10.1093/ije/dyh163; Mitsui T, 2008, TOHOKU J EXP MED, V215, P355, DOI 10.1620/tjem.215.355; Moore H, 2003, BRIT MED J, V327, P1085, DOI 10.1136/bmj.327.7423.1085; Morgan PJ, 2011, OBESITY, V19, P142, DOI 10.1038/oby.2010.119; Moyer VA, 2012, ANN INTERN MED, V157, P373, DOI 10.7326/0003-4819-157-5-201209040-00475; Muls E, 2001, INT J OBESITY, V25, P1713, DOI 10.1038/sj.ijo.0801814; Nakade M, 2012, ASIA PAC J CLIN NUTR, V21, P22; Nanchahal K, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000793; Narayan KMV, 1998, DIABETIC MED, V15, P66; National Center for Health Statistics. Health United States, 2017, HLTH US REP 2016 CHA; Nicklas JM, 2014, OBSTET GYNECOL, V124, P563, DOI 10.1097/AOG.0000000000000420; Nilsen V, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-893; O'Brien MJ, 2017, AM J PREV MED, V52, P788, DOI 10.1016/j.amepre.2017.01.008; Ockene IS, 2012, AM J PUBLIC HEALTH, V102, P336, DOI 10.2105/AJPH.2011.300357; Pacanowski C. R., 2015, Journal of Obesity, V2015, P763680; Padwal RS, 2011, CAN MED ASSOC J, V183, pE1059, DOI 10.1503/cmaj.110387; Parikh P, 2010, AM J PUBLIC HEALTH, V100, pS232, DOI 10.2105/AJPH.2009.170910; Parker ED, 2003, INT J OBESITY, V27, P1447, DOI 10.1038/sj.ijo.0802437; Patrick K, 2011, ANN BEHAV MED, V42, P391, DOI 10.1007/s12160-011-9296-7; Peeters A, 2003, ANN INTERN MED, V138, P24, DOI 10.7326/0003-4819-138-1-200301070-00008; Pekkarinen T., 2015, Journal of Obesity, V2015, P651460; Penn L, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-342; PERRI MG, 1988, J CONSULT CLIN PSYCH, V56, P529, DOI 10.1037/0022-006X.56.4.529; Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676; Phelan S, 2017, JAMA-J AM MED ASSOC, V317, P2381, DOI 10.1001/jama.2017.7119; Pi-Sunyer X, 2015, NEW ENGL J MED, V373, P11, DOI 10.1056/NEJMoa1411892; Puhkala J, 2015, SCAND J WORK ENV HEA, V41, P54, DOI 10.5271/sjweh.3463; Puhl RM, 2017, ANN BEHAV MED, V51, P754, DOI 10.1007/s12160-017-9898-9; Ratner R, 2005, DIABETES CARE, V28, P888, DOI 10.2337/diacare.28.4.888; Razak F, 2005, INT J OBESITY, V29, P656, DOI 10.1038/sj.ijo.0802937; Razak F, 2007, CIRCULATION, V115, P2111, DOI 10.1161/CIRCULATIONAHA.106.635011; Richelsen B, 2007, DIABETES CARE, V30, P27, DOI 10.2337/dc06-0210; Rock CL, 2007, OBESITY, V15, P939, DOI 10.1038/oby.2007.614; Rock CL, 2015, J CLIN ONCOL, V33, P3169, DOI 10.1200/JCO.2015.61.1095; Rosas LG, 2015, J ACAD NUTR DIET, V115, P537, DOI 10.1016/j.jand.2014.10.020; Ross R, 2012, ARCH INTERN MED, V172, P414, DOI 10.1001/archinternmed.2011.1972; Rossner S, 2000, OBES RES, V8, P49, DOI 10.1038/oby.2000.8; Rubin RR, 2013, QUAL LIFE RES, V22, P2389, DOI 10.1007/s11136-013-0363-3; Sanchez-Castillo CP, 2003, OBES RES, V11, P442, DOI 10.1038/oby.2003.60; Sarkhosh K, 2013, OBES SURG, V23, P414, DOI 10.1007/s11695-012-0862-2; Sarwer DB, 2013, INT J OBESITY, V37, pS25, DOI 10.1038/ijo.2013.93; Sarwer DB, 2010, SURG OBES RELAT DIS, V6, P608, DOI 10.1016/j.soard.2010.07.015; Shapiro JR, 2012, PREV MED, V55, P412, DOI 10.1016/j.ypmed.2012.08.011; Sharma AM, 2017, OBESITY, V25, P660, DOI 10.1002/oby.21801; Shea MK, 2011, AM J CLIN NUTR, V94, P839, DOI 10.3945/ajcn.110.006379; Sherwood NE, 2013, PREV MED, V56, P171, DOI 10.1016/j.ypmed.2012.12.014; Silva MN, 2010, J BEHAV MED, V33, P110, DOI 10.1007/s10865-009-9239-y; Simkin-Silverman LR, 2005, PREV MED, V40, P71, DOI 10.1016/j.ypmed.2004.05.012; Simpson SA, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19500; Sjostrom L, 1998, LANCET, V352, P167, DOI 10.1016/S0140-6736(97)11509-4; Smith AW, 2011, AM J PREV MED, V41, P33, DOI 10.1016/j.amepre.2011.03.017; Smith SR, 2011, OBESITY, V19, P1796, DOI 10.1038/oby.2011.143; Smith SR, 2010, NEW ENGL J MED, V363, P245, DOI 10.1056/NEJMoa0909809; Smith TJ, 2012, J ACAD NUTR DIET, V112, P533, DOI 10.1016/j.jada.2011.10.006; Sorensen TIA, 2005, PLOS MED, V2, P510, DOI 10.1371/journal.pmed.0020171; Stafford RS, 2000, ARCH FAM MED, V9, P631, DOI 10.1001/archfami.9.7.631; Steeves JA, 2015, OBES RES CLIN PRACT, V9, P243, DOI 10.1016/j.orcp.2014.08.002; Stevens J, 2002, AM J CLIN NUTR, V75, P986, DOI 10.1093/ajcn/75.6.986; Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007; STEVENS VJ, 1993, ARCH INTERN MED, V153, P849, DOI 10.1001/archinte.153.7.849; Stommel M, 2010, OBESITY, V18, P1821, DOI 10.1038/oby.2009.472; Svetkey LP, 2008, JAMA-J AM MED ASSOC, V299, P1139, DOI 10.1001/jama.299.10.1139; Svetkey LP, 2015, OBESITY, V23, P2133, DOI 10.1002/oby.21226; Swencionis C, 2013, HEALTH PSYCHOL, V32, P439, DOI 10.1037/a0029186; Swinburn BA, 2005, DIABETES OBES METAB, V7, P254, DOI 10.1111/j.1463-1326.2004.00467.x; Thomas JG, 2017, OBESITY, V25, P1014, DOI 10.1002/oby.21846; Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155; Tsai AG, 2010, OBESITY, V18, P1614, DOI 10.1038/oby.2009.457; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; US Preventive Services Task Force, 2015, US PREV SERV TASK FO; Uusitupa M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005656; Van Gaal LF, 1998, EUR J CLIN PHARMACOL, V54, P125, DOI 10.1007/s002280050433; van Wier MF, 2011, J OCCUP ENVIRON MED, V53, P680, DOI 10.1097/JOM.0b013e31821f2bbb; Vieira PN, 2013, J BEHAV MED, V36, P601, DOI 10.1007/s10865-012-9454-9; Voils CI, 2017, ANN INTERN MED, V166, P463, DOI [10.7326/M16-2160, 10.7326/m16-2160]; von Gruenigen V, 2012, GYNECOL ONCOL, V125, P699, DOI 10.1016/j.ygyno.2012.03.042; Wadden TA, 2013, INT J OBESITY, V37, P1443, DOI 10.1038/ijo.2013.120; Wadden TA, 2011, NEW ENGL J MED, V365, P1969, DOI 10.1056/NEJMoa1109220; Wadden TA, 2011, OBESITY, V19, P110, DOI 10.1038/oby.2010.147; Wannamethee SG, 2005, J EPIDEMIOL COMMUN H, V59, P134, DOI 10.1136/jech.2003.015651; Weiss EC, 2007, AM J PREV MED, V33, P34, DOI 10.1016/j.amepre.2007.02.040; Wen CP, 2009, PUBLIC HEALTH NUTR, V12, P497, DOI 10.1017/S1368980008002802; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4; Wijnhoven HAH, 2014, J GERONTOL A-BIOL, V69, P1236, DOI 10.1093/gerona/glu005; Williamson DF, 1999, AM J EPIDEMIOL, V149, P491, DOI 10.1093/oxfordjournals.aje.a009843; WILLIAMSON DF, 1995, AM J EPIDEMIOL, V141, P1128, DOI 10.1093/oxfordjournals.aje.a117386; Wing RR, 2006, NEW ENGL J MED, V355, P1563, DOI 10.1056/NEJMoa061883; Wing RR, 2005, AM J CLIN NUTR, V82, p222S, DOI 10.1093/ajcn/82.1.222S; Wing RR, 1998, DIABETES CARE, V21, P350, DOI 10.2337/diacare.21.3.350; Wylie-Rosett J, 2001, J AM DIET ASSOC, V101, P1155, DOI 10.1016/S0002-8223(01)00284-X; Yaari S, 1998, AM J EPIDEMIOL, V148, P546, DOI 10.1093/oxfordjournals.aje.a009680; Yeh MC, 2016, DIABETIC MED, V33, P547, DOI 10.1111/dme.12848; Young MD, 2017, OBESITY, V25, P56, DOI 10.1002/oby.21696; Yu E, 2017, ANN INTERN MED, V166, P613, DOI 10.7326/M16-1390	214	184	189	9	34	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	2018	320	11					1172	1191		10.1001/jama.2018.7777	http://dx.doi.org/10.1001/jama.2018.7777			20	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GT9QL	30326501	Bronze			2023-01-03	WOS:000444878600017
J	Pohl, P; Carlsson, G; Kall, LB; Nilsson, M; Blomstrand, C				Pohl, Petra; Carlsson, Gunnel; Kall, Lina Bunketorp; Nilsson, Michael; Blomstrand, Christian			Experiences from a multimodal rhythm and music-based rehabilitation program in late phase of stroke recovery - A qualitative study	PLOS ONE			English	Article							ENRICHED ENVIRONMENT; NEURAL PLASTICITY; OLDER-ADULTS; CHALLENGES; BRAIN; PARTICIPATION; SETTINGS; THERAPY; FOCUS	Background Rehabilitative stroke interventions based on principles of multimodal stimulation have the potential to profoundly affect neuroplastic processes beyond the sub-acute phase. In order to identify important core mechanisms, there is a need to explore how interventions that combine physical, social, sensory, and cognitively challenging activities are perceived and experienced by the participants. This qualitative study, based on an interpretive interactionist perspective, explored the experiences of stroke survivors who participated in a group-based multimodal rehabilitation program based on rhythm and music. Methods and findings Within four weeks after completion of the multimodal rehabilitation program, face-to-face semi-structured interviews were conducted on a single occasion with 15 purposively selected individuals (mean age 65, 8 men, 7 women). The interview duration was between 13 and 44 minutes. Qualitative content analysis with an inductive approach was used to analyze data. Three categories were identified, each containing several sub-categories: To be intellectually challenged (energy-consuming activity and coordinating multiple input and output), Perceived therapeutic benefits (motor skills, cognitive skills, emotional and psychological responses), and Pros and cons with social integration (fellowship, competing with others, and instructor characteristics). From these categories, an overall theme was derived: The multifaceted layers of multimodal stimulation. Enjoying music, being part of a group with peers, a skilled instructor, and being able to manage the challenging movements, were related to positive experiences. In contrast, negative experiences were associated with not being able to perform the exercises, and with group members who dominated the conversational space. Conclusion This study shows that access to a multimodal rehabilitation program with rhythm and music as operating ingredients may contribute to positive experiences for many individuals in a late phase after stroke in terms of motor, cognitive, as well as emotional enhancements. Important components were the music, the social interaction, the challenging exercises, and the skilled instructor.	[Pohl, Petra; Carlsson, Gunnel; Nilsson, Michael; Blomstrand, Christian] Univ Gothenburg, Sahlgrenska Acad, Dept Clin Neurosci, Inst Neurosci & Physiol, Gothenburg, Sweden; [Pohl, Petra] Linkoping Univ, Dept Act & Hlth, Linkoping, Sweden; [Pohl, Petra] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden; [Kall, Lina Bunketorp] Sahlgrenska Univ Hosp Molndal, Ctr Adv Reconstruct Extrem, Molndal, Sweden; [Kall, Lina Bunketorp] Univ Gothenburg, Dept Hlth & Rehabil, Inst Neurosci & Physiol, Sahlgrenska Acad, Gothenburg, Sweden; [Nilsson, Michael] Univ Newcastle, Hunter Med Res Inst, Newcastle, NSW, Australia; [Blomstrand, Christian] Univ Gothenburg, Sahlgrenska Acad, Stroke Ctr West, Gothenburg, Sweden	University of Gothenburg; Linkoping University; Linkoping University; Sahlgrenska University Hospital; University of Gothenburg; Hunter Medical Research Institute; University of Newcastle; University of Gothenburg	Pohl, P (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Dept Clin Neurosci, Inst Neurosci & Physiol, Gothenburg, Sweden.; Pohl, P (corresponding author), Linkoping Univ, Dept Act & Hlth, Linkoping, Sweden.; Pohl, P (corresponding author), Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden.	petra.pohl@liu.se; lina.bunketorp-kall@neuro.gu.se	NILSSON, MICHAEL/ABE-7821-2020; Bunketorp-Käll, Lina/AAI-1237-2020	NILSSON, MICHAEL/0000-0002-8826-1621; Bunketorp Kall, lina/0000-0002-4571-0335; Pohl, Petra/0000-0002-3447-6547	Rune and Ulla Amlov Foundation; Peter Eriksson Memorial Foundation; John and Brit Wennerstroms Foundation for Neurological Research; Hjalmar Svensson foundation; Anna Ahrenbergs Foundation	Rune and Ulla Amlov Foundation; Peter Eriksson Memorial Foundation; John and Brit Wennerstroms Foundation for Neurological Research; Hjalmar Svensson foundation; Anna Ahrenbergs Foundation	This work was supported by the Rune and Ulla Amlov Foundation (PP); Peter Eriksson Memorial Foundation (PP); John and Brit Wennerstroms Foundation for Neurological Research (PP); Hjalmar Svensson foundation; and the Anna Ahrenbergs Foundation.	Alwis DS, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00156; Anderson C, 2009, J PERS SOC PSYCHOL, V96, P491, DOI 10.1037/a0014201; Beesley K, 2011, DISABIL REHABIL, V33, P2346, DOI 10.3109/09638288.2011.571333; Blumer H, 1986, SYMBOLIC INTERACTION, Vx; Boos M, 2015, BEHAV PROCESS, V120, P64, DOI 10.1016/j.beproc.2015.07.011; Bunketorp-Kall L, 2017, STROKE, DOI [10.1161/STORKEAHA.116.016433, DOI 10.1161/STORKEAHA.116.016433]; Cassidy JM, 2017, TRANSL STROKE RES, V8, P33, DOI 10.1007/s12975-016-0467-5; Corbett D, 2015, PROG BRAIN RES, V218, P413, DOI 10.1016/bs.pbr.2014.12.002; Craig DG, 2008, OCCUP THER HEALTH CA, V22, P73, DOI 10.1080/J003v22n01_06; Cramer SC, 2008, ANN NEUROL, V63, P549, DOI 10.1002/ana.21412; DiCicco-Bloom B, 2006, MED EDUC, V40, P314, DOI 10.1111/j.1365-2929.2006.02418.x; Enderby P, 2016, DISABIL REHABIL, P1, DOI DOI 10.3109/09638288.2016.1160448; Estabrooks PA, 2004, J AGING PHYS ACTIV, V12, P232, DOI 10.1123/japa.12.3.232; Ferro JM, 2009, CEREBROVASC DIS, V27, P197, DOI 10.1159/000200460; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Graneheim UH, 2017, NURS EDUC TODAY, V56, P29, DOI 10.1016/j.nedt.2017.06.002; Green J, 2014, QUALITATIVE METHODS, Vxvii; Harden SM, 2015, EVAL HEALTH PROF, V38, P3, DOI 10.1177/0163278713488117; Johansson BB, 2011, ACTA NEUROL SCAND, V123, P147, DOI 10.1111/j.1600-0404.2010.01417.x; Johansson BB, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00060; Kall LB, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-141; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Koelsch S, 2010, TRENDS COGN SCI, V14, P131, DOI 10.1016/j.tics.2010.01.002; Kogan AC, 2016, J AM GERIATR SOC, V64, pE8, DOI 10.1111/jgs.13876; Kwakkel G, 2003, STROKE, V34, P2181, DOI 10.1161/01.STR.0000087172.16305.CD; Law T, 2012, J VOICE, V26, pE41, DOI 10.1016/j.jvoice.2010.12.003; Lewin Simon, 2009, BMJ, V339, pb3496, DOI 10.1136/bmj.b3496; Lincoln Y.S., 1985, NATURALISTIC INQUIRY; Livingston-Thomas J, 2016, NEUROTHERAPEUTICS, V13, P395, DOI 10.1007/s13311-016-0423-9; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; Mead GH, 1962, MIND SELF SOC STANDP; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Pekna M, 2012, STROKE, V43, P2819, DOI 10.1161/STROKEAHA.112.654228; Rathore SS, 2002, STROKE, V33, P2718, DOI 10.1161/01.STR.0000035286.87503.31; Richards CL, 2015, PROG BRAIN RES, V218, P253, DOI 10.1016/bs.pbr.2015.01.003; Rosbergen ICM, 2017, CLIN REHABIL, V31, P1516, DOI 10.1177/0269215517705181; Simmons-Mackie R., 2008, LANGUAGE INTERVENTIO, P290; SKILBECK CE, 1983, J NEUROL NEUROSUR PS, V46, P5, DOI 10.1136/jnnp.46.1.5; Tarrant M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009652; Thornberg K, 2014, DISABIL REHABIL, V36, P1869, DOI 10.3109/09638288.2013.876107; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; VanderKaay S, 2018, DISABIL REHABIL, V40, P705, DOI 10.1080/09638288.2016.1261414; Venna VR, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2013.128; White JH, 2015, DISABIL REHABIL, V37, P593, DOI 10.3109/09638288.2014.935876	44	10	12	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2018	13	9							e0204215	10.1371/journal.pone.0204215	http://dx.doi.org/10.1371/journal.pone.0204215			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GU0DL	30226862	Green Submitted, Green Published, gold			2023-01-03	WOS:000444918300052
J	Gomes, T; Khuu, W; Martins, D; Tadrous, M; Mamdani, MM; Paterson, JM; Juurlink, DN				Gomes, Tara; Khuu, Wayne; Martins, Diana; Tadrous, Mina; Mamdani, Muhammad M.; Paterson, J. Michael; Juurlink, David N.			Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OVERDOSE-RELATED DEATHS; FENTANYL OVERDOSES; BRITISH-COLUMBIA; HEROIN; MORTALITY; PAIN; ANALGESICS; GUIDELINE; EPIDEMIC; PATTERNS	OBJECTIVE To describe the contributions of prescribed and non-prescribed opioids to opioid related deaths. DESIGN Population based cohort study. SETTING Ontario, Canada, from 1 January 2013 to 31 December 2016. PARTICIPANTS All Ontarians who died of an opioid related cause. EXPOSURE Active opioid prescriptions, defined as those with a duration overlapping the date of death, and recent opioid prescriptions, defined as those dispensed in the 30 and 180 days preceding death. Postmortem toxicology results from the Drug and Drug/Alcohol Related Death database were used to characterise deaths on the basis of presence of prescribed and non-prescribed (that is, diverted or illicit) opioids, overall and stratified by year and age. RESULTS 2833 opioid related deaths occurred. An active opioid prescription on the date of death was relatively common but declined slightly throughout the study period (38.2% (241/631) in 2013 and 32.5% (278/855) in 2016; P for trend=0.03). Older people and women were relatively more likely to have an active opioid prescription at time of death. In 2016, 46% (169/364) of people aged 45-64 had an active opioid prescription compared with only 12% (8/69) among those aged 24 or younger (P for trend<0.001). Similarly, 46% (124/272) of women had an active opioid prescription at time of death compared with 26.4% (154/583) of men (P<0.001). Among people with active opioid prescriptions at time of death, 37.8% (375/993) also had evidence of a non-prescribed opioid on postmortem toxicology. By 2016, the non-prescribed opioid most commonly identified after death was fentanyl (41%; 47 of 115 cases). Among people without an active opioid prescription at time of death, fentanyl was detected in 20% (78/390) of deaths in 2013, increasing to 47.5% (274/577) by 2016 (P<0.001). CONCLUSIONS Prescribed, diverted, and illicit opioids all play an important role in opioid related deaths. Although more than half of all opioid related deaths still involved prescription drugs (either dispensed or diverted) in 2016, the increased rate of deaths involving fentanyl between 2015 and 2016 is concerning and suggests the need for a multifactorial approach to this problem that considers both the prescribed and illicit opioid environments.	[Gomes, Tara; Martins, Diana; Tadrous, Mina] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Khuu, Wayne; Paterson, J. Michael] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Mamdani, Muhammad M.] St Michaels Hosp, Li Ka Shing Ctr Healthcare Analyt Res & Training, Toronto, ON, Canada; [Juurlink, David N.] Sunnybrook Res Inst, Toronto, ON, Canada	University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Gomes, T (corresponding author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.	GomesT@smh.ca	; Tadrous, Mina/E-9136-2018	Gomes, Tara/0000-0002-1468-1965; Tadrous, Mina/0000-0003-1911-6129	Ontario Ministry of Health and Long-Term Care (MOHLTC) [06673]; Canadian Institutes for Health Research [153070]; Institute for Clinical Evaluative Sciences (ICES); Ontario MOHLTC	Ontario Ministry of Health and Long-Term Care (MOHLTC)(Ministry of Health and Long-Term Care, Ontario); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Institute for Clinical Evaluative Sciences (ICES)(University of Toronto); Ontario MOHLTC(Ministry of Health and Long-Term Care, Ontario)	This study was supported by a grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC; grant # 06673) and the Canadian Institutes for Health Research (grant # 153070). It was also supported by the Institute for Clinical Evaluative Sciences (ICES), a non-profit research institute sponsored by the Ontario MOHLTC. The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.	Alberta Health, 2017, OP SUBST MIS ALB REP; Baldwin N, 2018, DRUG ALCOHOL DEPEN, V185, P322, DOI 10.1016/j.drugalcdep.2017.12.032; Barry CL, 2018, PSYCHIAT SERV, V69, P100, DOI 10.1176/appi.ps.201700235; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; British Columbia Coroners Service, 2018, FENT DET ILL DRUG OV; Busse JW, 2017, CAN MED ASSOC J, V189, pE659, DOI 10.1503/cmaj.170363; Cheng T, 2017, CAN J PUBLIC HEALTH, V108, pE325, DOI [10.17269/CJPH.108.6075, 10.17269/cjph.108.6075]; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Dhalla IA, 2009, CAN MED ASSOC J, V181, P891, DOI 10.1503/cmaj.090784; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Fischer B, 2018, PREV MED, V107, P109, DOI 10.1016/j.ypmed.2017.11.001; Gladstone EJ, 2015, MED CARE, V53, P954, DOI 10.1097/MLR.0000000000000431; Gomes T, 2017, ONTARIO DRUG POLICY, DOI [10.31027/ODPRN.2017.04, DOI 10.31027/ODPRN.2017.04]; Gomes T, 2018, J ADDICT MED, V12, P418, DOI 10.1097/ADM.0000000000000412; Gomes Tara, 2017, CMAJ Open, V5, pE800, DOI 10.9778/cmajo.20170104; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Government of Canada, 2017, ACT OP 2016 2017; Juurlink DN, 2012, J MED TOXICOL, V8, P393, DOI 10.1007/s13181-012-0269-4; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Ontario College of Pharmacists, 2016, PATCH FOR PATCH FENT; Ontario Ministry of Health and Long-Term Care, 2015, ONT NARC STRAT CHANG; Park TW, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2698; Public Health Ontario, 2018, OP REL MORB MORT ONT; RUBIN R, 2017, JAMA-J AM MED ASSOC, V318, P2174, DOI DOI 10.1001/JAMA.2017.18602; Slavova S, 2017, INT J DRUG POLICY, V46, P120, DOI 10.1016/j.drugpo.2017.05.051; Special Advisory Committee on the Epidemic of Opioid Overdoses, 2017, NAT REP APP OP REL D; U. S. Centers for Disease Control and Prevention, 2017, OP OV	28	89	89	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 29	2018	362								k3207	10.1136/bmj.k3207	http://dx.doi.org/10.1136/bmj.k3207			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU9VE	30158106	Green Published, hybrid			2023-01-03	WOS:000445701700001
J	Monteiro, BP; de Lorimier, LP; Moreau, M; Beauchamp, G; Blair, J; Lussier, B; Pelletier, JP; Troncy, E				Monteiro, Beatriz P.; de Lorimier, Louis-Philippe; Moreau, Maxim; Beauchamp, Guy; Blair, Jeffrey; Lussier, Bertrand; Pelletier, Jean-Pierre; Troncy, Eric			Pain characterization and response to palliative care in dogs with naturally-occurring appendicular osteosarcoma: An open label clinical trial	PLOS ONE			English	Article								This study aimed to characterize bone cancer pain (quantitative sensory testing (QST), stance asymmetry index, actimetry, scores of pain and quality of life (QoL)) in dogs with appendicular osteosarcoma (OSA), and to evaluate a stepwise palliative analgesic treatment. The pain profile of thirteen client-owned dogs with OSA was compared with seven healthy dogs. Dogs with OSA were then enrolled in a prospective, open-label, clinical trial. Outcome measures included: primary and secondary mechanical thresholds (MT), conditioned pain modulation (CPM), stance asymmetry index, actimetry (most and least active periods), visual analog scales and QoL. After baseline assessments, stepwise treatment comprised orally administered cimicoxib (2 mg/kg q 24h), amitriptyline (1-1.5 mg/kg q 24h) and gabapentin (10 mg/kg q 8h); re-evaluations were performed after 14 (D14), 21 (D21) and 28 (D28) days, respectively. Statistics used mixed linear models (alpha = 5%; one-sided). Centralized nociceptive sensitivity (primary and secondary MT, and dynamic allodynia) was recorded in OSA dogs. Healthy dogs had responsive CPM, but CPM was deficient in OSA dogs. Construct validity was observed for the QST protocol. Asymmetry index was significantly present in OSA dogs. The CPM improved significantly at D14. When compared with baseline (log mean +/- SD: 4.1 +/- 0.04), most active actimetry significantly improved at D14 (4.3 +/- 0.04), D21 and D28 (4.2 +/- 0.04 for both). When compared with baseline, least active actimetry significantly decreased after treatment at all time-points indicating improvement in night-time restlessness. No other significant treatment effect was observed. Except for tactile threshold and actimetry, all outcomes worsened when gabapentin was added to cimicoxib-amitriptyline. Dogs with bone cancer are affected by widespread somatosensory sensitivity characterized by peripheral and central sensitization and have a deficient inhibitory system. This severe pain is mostly refractory to palliative analgesic treatment, and the latter was only detected by specific and sensitive outcomes.	[Monteiro, Beatriz P.; Moreau, Maxim; Beauchamp, Guy; Lussier, Bertrand; Troncy, Eric] Univ Montreal, Fac Vet Med, Dept Biomed Sci, GREPAQ, St Hyacinthe, PQ, Canada; [de Lorimier, Louis-Philippe] Ctr Vet Rive Sud, Brossard, PQ, Canada; [Moreau, Maxim; Lussier, Bertrand; Pelletier, Jean-Pierre; Troncy, Eric] Univ Montreal, Hosp Res Ctr CRCHUM, Osteoarthrit Res Unit, Montreal, PQ, Canada; [Blair, Jeffrey] Vetoquinol SA, Global Grp Vetoquinol, Magny Vernois, France	Universite de Montreal; Universite de Montreal	Troncy, E (corresponding author), Univ Montreal, Fac Vet Med, Dept Biomed Sci, GREPAQ, St Hyacinthe, PQ, Canada.; Troncy, E (corresponding author), Univ Montreal, Hosp Res Ctr CRCHUM, Osteoarthrit Res Unit, Montreal, PQ, Canada.	eric.troncy@umontreal.ca	Monteiro, Beatriz/W-7596-2019; Pelletier, Jean-Pierre/AAG-2896-2019; Troncy, Eric/J-6650-2013	Monteiro, Beatriz/0000-0002-5722-5687; Troncy, Eric/0000-0003-0209-5261	Vetoquinol SA, Global -Le Groupe Vetoquinol; Natural Sciences and Engineering Research Council of Canada [RDCPJ 491953-2016, 441651-2013]; Canada Foundation for Innovation [9483, 24601]; Vanier Canada Graduate Scholarship	Vetoquinol SA, Global -Le Groupe Vetoquinol; Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Vanier Canada Graduate Scholarship	This study was sponsored in part by Vetoquinol SA, Global -Le Groupe Vetoquinol (ETr, LPdL and JPP). This work was also supported (ETr) by a Discovery grant (#441651-2013, supporting salaries) and Collaborative Research and Development grants (#RDCPJ #RDCPJ 491953-2016 supporting operations and salaries in partnership with ArthroLab Inc.) from the Natural Sciences and Engineering Research Council of Canada, as well as by an ongoing New Opportunities Fund grant (#9483) and a Leader Opportunity Fund grant (#24601), supporting pain/function equipment, from the Canada Foundation for Innovation. BPM is a recipient of a Vanier Canada Graduate Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The Vetoquinol SA funder (JBl) provided support in the form of research materials and organization, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of all authors are articulated in the 'author contributions' section.		0	12	12	2	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 6	2018	13	12							e0207200	10.1371/journal.pone.0207200	http://dx.doi.org/10.1371/journal.pone.0207200			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD1YF	30521538	Green Submitted, Green Published, gold			2023-01-03	WOS:000452307600008
J	Sporri, D; Ditroilo, M; Rodriguez, ECP; Johnston, RJ; Sheehan, WB; Watsford, ML				Sporri, Daniel; Ditroilo, Massimiliano; Rodriguez, Elizabeth C. Pickering; Johnston, Richard J.; Sheehan, William B.; Watsford, Mark L.			The effect of water-based plyometric training on vertical stiffness and athletic performance	PLOS ONE			English	Article							GROUND REACTION FORCE; SPRINT PERFORMANCE; STRETCH PROTOCOLS; ELASTIC ENERGY; LEG STIFFNESS; RUGBY UNION; JUMP; STRENGTH; POWER; RELIABILITY	Since higher vertical stiffness is related to superior athletic performance, training has traditionally been aimed at augmenting this variable to enhance neuromuscular output. However, research has linked elevated stiffness with increased injury risk, therefore, this study examined the effect of a novel training intervention on vertical stiffness and athletic performance. Vertical stiffness, jump performance and athletic performance were assessed in two randomly allocated groups, prior to, and following, an eight-week period. One group was exposed to a training intervention involving aqua-based plyometrics (n = 11) over the 8 weeks while the other acted as a control group (n = 9). The training intervention involved hopping, jumping and bounding in water at a depth of 1.2m whilst control participants performed their normal training. There were no significant changes in vertical stiffness in either group. Countermovement jump height and peak power significantly increased within the aqua plyometric group (p < 0.05). Athletic performance markers improved in the aqua plyometric group as measured using an agility and a 5-bound test exhibiting superior values at the post-test (p < 0.05). The results suggest that an aqua plyometric training program can enhance athletic performance without elevating stiffness. The increase in athletic performance is likely due to a reduction in ground reaction forces created by the buoyancy of the water, causing a shorter amortization phase and a more rapid application of concentric force. The findings from this study can inform exercise professionals and medical staff regarding the ability to enhance neuromuscular performance without elevating vertical stiffness. This has implications for improving athletic performance while concurrently minimising injury risk.	[Sporri, Daniel; Rodriguez, Elizabeth C. Pickering; Johnston, Richard J.; Sheehan, William B.; Watsford, Mark L.] Univ Technol Sydney, Fac Hlth, Human Performance Res Ctr, Sydney, NSW, Australia; [Ditroilo, Massimiliano] Univ Coll Dublin, Sch Publ Hlth Physiotherapy & Sports Sci, Dublin, Ireland	University of Technology Sydney; University College Dublin	Sheehan, WB (corresponding author), Univ Technol Sydney, Fac Hlth, Human Performance Res Ctr, Sydney, NSW, Australia.	william.b.sheehan@student.uts.edu.au	Ditroilo, Massimiliano/X-5394-2019	Ditroilo, Massimiliano/0000-0003-1021-0362; Sheehan, William/0000-0001-6976-367X				Alberton CL, 2013, INT J SPORTS MED, V34, P881, DOI 10.1055/s-0032-1331757; Alberton CL, 2015, J SPORT SCI, V33, P795, DOI 10.1080/02640414.2014.964748; Arampatzis A, 1999, J BIOMECH, V32, P1349, DOI 10.1016/S0021-9290(99)00133-5; Baker D, 2001, STRENGTH COND J, V23, P47, DOI 10.1519/00126548-200102000-00011; BOSCO C, 1982, ACTA PHYSIOL SCAND, V114, P557, DOI 10.1111/j.1748-1716.1982.tb07024.x; Bret C, 2002, J SPORT MED PHYS FIT, V42, P274; Burgess KE, 2007, J STRENGTH COND RES, V21, P986, DOI 10.1519/00124278-200708000-00055; Butler RJ, 2003, CLIN BIOMECH, V18, P511, DOI 10.1016/S0268-0033(03)00071-8; Cohen J., 1988, STATISTICAL POWER AN, DOI DOI 10.1234/12345678; Donoghue OA, 2011, SPORTS HEALTH, V3, P303, DOI 10.1177/1941738111403872; FARLEY CT, 1991, J APPL PHYSIOL, V71, P2127, DOI 10.1152/jappl.1991.71.6.2127; Fernandez-Pena E, 2009, J STRENGTH COND RES, V23, P1764, DOI 10.1519/JSC.0b013e3181b3e094; Flanagan EP, 2008, J STRENGTH COND RES, V22, P1677, DOI 10.1519/JSC.0b013e318182034b; Fletcher IM, 2007, J STRENGTH COND RES, V21, P784; Fletcher IM, 2004, J STRENGTH COND RES, V18, P885; Horita T, 1999, EUR J APPL PHYSIOL O, V79, P160, DOI 10.1007/s004210050490; KOMI PV, 1978, MED SCI SPORT EXER, V10, P261; Kubo K, 2006, EUR J APPL PHYSIOL, V96, P305, DOI 10.1007/s00421-005-0087-3; Kubo K, 2002, J PHYSIOL-LONDON, V538, P219, DOI 10.1113/jphysiol.2001.012703; Lockie RG, 2012, J STRENGTH COND RES, V26, P1539, DOI 10.1519/JSC.0b013e318234e8a0; Markovic G, 2004, J STRENGTH COND RES, V18, P551, DOI 10.1519/00124278-200408000-00028; Martel GF, 2005, MED SCI SPORT EXER, V37, P1814, DOI 10.1249/01.mss.0000184289.87574.60; Miller MG, 2002, J SPORT REHABIL, V11, P268, DOI 10.1123/jsr.11.4.268; Nelson AG, 2005, J SPORT SCI, V23, P449, DOI 10.1080/02640410410001730205; POUSSON M, 1990, J BIOMECH, V23, P343, DOI 10.1016/0021-9290(90)90062-8; Pruyn EC, 2012, J SPORT SCI, V30, P71, DOI 10.1080/02640414.2011.624540; Robinson LE, 2004, J STRENGTH COND RES, V18, P84; Ryan ED, 2009, J SPORT SCI, V27, P957, DOI 10.1080/02640410902998254; Spinks CD, 2007, J STRENGTH COND RES, V21, P77, DOI 10.1519/00124278-200702000-00015; Spurrs RW, 2003, EUR J APPL PHYSIOL, V89, P1, DOI 10.1007/s00421-002-0741-y; Turner AN, 2010, STRENGTH COND J, V32, P87, DOI 10.1519/SSC.0b013e3181e928f9; Watsford ML, 2010, AM J SPORT MED, V38, P2058, DOI 10.1177/0363546510370197; WILSON GJ, 1994, J APPL PHYSIOL, V76, P2714, DOI 10.1152/jappl.1994.76.6.2714; WILSON GJ, 1992, MED SCI SPORT EXER, V24, P116	34	4	4	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 6	2018	13	12							e0208439	10.1371/journal.pone.0208439	http://dx.doi.org/10.1371/journal.pone.0208439			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD1YF	30521576	Green Published, gold, Green Submitted			2023-01-03	WOS:000452307600069
J	Khanam, SS; Choi, E; Son, JW; Lee, JW; Youn, YJ; Yoon, J; Lee, SH; Kim, JY; Ahn, SG; Min, MS; Kang, SM; Baek, SH; Jeon, ES; Kim, JJ; Cho, MC; Chae, SC; Oh, BH; Choi, DJ; Yoo, BS				Khanam, Sayma Sabrina; Choi, Eunhee; Son, Jung-Woo; Lee, Jun-Won; Youn, Young Jin; Yoon, Junghan; Lee, Seung-Hwan; Kim, Jang-Young; Ahn, Sung Gyun; Min, Min-Soo; Kang, Seok-Min; Baek, Sang Hong; Jeon, Eun-Seok; Kim, Jae-Joong; Cho, Myeong-Chan; Chae, Shung Chull; Oh, Byung-Hee; Choi, Dong-Ju; Yoo, Byung-Su			Validation of the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) heart failure risk score and the effect of adding natriuretic peptide for predicting mortality after discharge in hospitalized patients with heart failure	PLOS ONE			English	Article							VENTRICULAR EJECTION FRACTION; AMBULATORY PATIENTS; PROGNOSTIC VALUE; NT-PROBNP; SURVIVAL; EPIDEMIOLOGY; ADMISSION; ASSOCIATION; BIOMARKERS; MORBIDITY	Background In clinical practice, a risk prediction model is an effective solitary program to predict prognosis in particular patient groups. B-type natriuretic peptide (BNP) and N-terminal pro-b-type natriuretic peptide (NT-proBNP) are widely recognized outcome-predicting factors for patients with heart failure (HF). This study derived external validation of a risk score to predict 1-year mortality after discharge in hospitalized patients with HF using the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) program data. We also assessed the effect of adding BNP or NT-proBNP to this risk score model in a Korean HF registry population. Method and results We included 5625 patients from the Korean acute heart failure registry (KorAHF) and excluded those who died in hospital. The MAGGIC constructed a risk score to predict mortality in patients with HF by using 13 routinely available patient characteristics (age, gender, diabetes, chronic obstructive pulmonary disorder (COPD), HF diagnosed within the last 18 months, current smoker, NYHA class, use of beta blocker, ACEI or ARB, body mass index, systolic blood pressure, creatinine, and EF). We added BNP or NT-proBNP, which are the most important biomarkers, to the MAGGIC risk scoring system in patients with HF. The outcome measure was 1-year mortality. In multivariable analysis, BNP or NT-proBNP independently predicted death. The risk score was significantly varied between alive and dead groups (30.61 +/- 6.32 vs. 24.80 +/- 6.81, p < 0.001). After the conjoint use of BNP or NT-proBNP and MAGGIC risk score in patients with HF, a significant difference in risk score was noted (31.23 +/- 6.46 vs. 25.25 +/- 6.96, p < 0.001). The discrimination abilities of the risk score model with and without biomarker showed minimal improvement (C index of 0.734 for MAGGIC risk score and 0.736 for MAGGIC risk score plus BNP or NT-proBNP, p = 0.0502) and the calibration was found good. However, we achieved a significant improvement in net reclassification and integrated discrimination for mortality (NRI of 33.4%, p < 0.0001 and IDI of 0.002, p < 0.0001). Conclusion In the KorAHF, the MAGGIC project HF risk score performed well in a large nationwide contemporary external validation cohort. Furthermore, the addition of BNP or NT-proBNPto the MAGGIC risk score was beneficial in predicting more death in hospitalized patients with HF.	[Khanam, Sayma Sabrina; Son, Jung-Woo; Lee, Jun-Won; Youn, Young Jin; Yoon, Junghan; Lee, Seung-Hwan; Kim, Jang-Young; Ahn, Sung Gyun; Min, Min-Soo; Yoo, Byung-Su] Yonsei Univ, Wonju Coll Med, Dept Cardiol, Wonju, South Korea; [Choi, Eunhee] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Smith Ctr Outcomes Res Cardiol, Boston, MA USA; [Kang, Seok-Min] Yonsei Univ, Coll Med, Seoul, South Korea; [Baek, Sang Hong] Catholic Univ Korea, Seoul, South Korea; [Jeon, Eun-Seok] Sungkyunkwan Univ, Coll Med, Seoul, South Korea; [Kim, Jae-Joong] Univ Ulsan, Coll Med, Seoul, South Korea; [Cho, Myeong-Chan] Chungbuk Natl Univ, Coll Med, Cheongju, South Korea; [Chae, Shung Chull] Kyungpook Natl Univ, Coll Med, Daegu, South Korea; [Oh, Byung-Hee] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; [Choi, Dong-Ju] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea	Yonsei University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Yonsei University; Yonsei University Health System; Catholic University of Korea; Sungkyunkwan University (SKKU); University of Ulsan; Chungbuk National University; Kyungpook National University; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU)	Yoo, BS (corresponding author), Yonsei Univ, Wonju Coll Med, Dept Cardiol, Wonju, South Korea.	yubs@yonsei.ac.kr	Ahn, Sung Gyun/AAG-5976-2020	Ahn, Sung Gyun/0000-0002-1528-2739; Youn, Young Jin/0000-0001-7066-7474; Kang, Seok-Min/0000-0001-9856-9227; Lee, Jun-Won/0000-0001-6206-1704; Choi, Eunhee/0000-0002-3449-0672	Research of Korea Centers for Disease Control and Prevention [2010-E63003-00, 2011-E63002-00, 2012-E63005-00, 2013-E63003-00, 2013-E63003-01, 2013-E63003-02, 2016-ER6303-00]	Research of Korea Centers for Disease Control and Prevention	This work was supported by Research of Korea Centers for Disease Control and Prevention [2010-E63003-00, 2011-E63002-00, 2012-E63005-00, 2013-E63003-00, 2013-E63003-01, 2013-E63003-02, and 2016-ER6303-00]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."	Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660; Abraham WT, 2008, J AM COLL CARDIOL, V52, P347, DOI 10.1016/j.jacc.2008.04.028; Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.3.CO;2-X; Berry C, 2012, EUR HEART J, V33, P1750, DOI 10.1093/eurheartj/ehr254; Bosseau C, 2015, HEART, V101, P1855, DOI 10.1136/heartjnl-2015-308515; Braunwald E, 2008, NEW ENGL J MED, V358, P2148, DOI 10.1056/NEJMra0800239; Chen J, 2011, JAMA-J AM MED ASSOC, V306, P1669, DOI 10.1001/jama.2011.1474; Choi H, 2013, CARDIOVASC J AFR, V24, P165, DOI 10.5830/CVJA-2013-024; Denardo SJ, 2016, CIRC-HEART FAIL, V9, DOI 10.1161/CIRCHEARTFAILURE.115.002529; Fonarow GC, 2005, JAMA-J AM MED ASSOC, V293, P572, DOI 10.1001/jama.293.5.572; Gluba A, 2012, J HYPERTENS, V30, P1681, DOI 10.1097/HJH.0b013e3283569a9c; HUANG YP, 2016, SCI REP UK, V6; Kajimoto K, 2013, INT J CARDIOL, V168, P554, DOI 10.1016/j.ijcard.2013.01.187; Kang SH, 2015, HEART, V101, P1881, DOI 10.1136/heartjnl-2015-307782; Ketchum Eric S, 2011, Congest Heart Fail, V17, P205, DOI 10.1111/j.1751-7133.2011.00241.x; Lam CSP, 2015, ESC HEART FAIL, V2, P46, DOI 10.1002/ehf2.12036; Lee JH, 2016, KOREAN CIRC J, V46, P658, DOI 10.4070/kcj.2016.46.5.658; Lee SE, 2017, KOREAN CIRC J, V47, P341, DOI 10.4070/kcj.2016.0419; Lee SE, 2014, EUR J HEART FAIL, V16, P700, DOI 10.1002/ejhf.91; Levy WC, 2006, CIRCULATION, V113, P1424, DOI 10.1161/CIRCULATIONAHA.105.584102; Logeart D, 2004, J AM COLL CARDIOL, V43, P635, DOI 10.1016/j.jacc.2003.09.044; Martinez-Selles M, 2012, EUR J HEART FAIL, V14, P473, DOI 10.1093/eurjhf/hfs026; McMurray JJ, 2000, HEART, V83, P596, DOI 10.1136/heart.83.5.596; Mosterd A, 2007, HEART, V93, P1137, DOI 10.1136/hrt.2003.025270; Nieminen MS, 2006, EUR HEART J, V27, P2725, DOI 10.1093/eurheartj/ehl193; Noveanu M, 2011, CRIT CARE, V15, DOI 10.1186/cc9398; O'Connor CM, 2012, CIRC-HEART FAIL, V5, P63, DOI 10.1161/CIRCHEARTFAILURE.111.963462; Okamoto Hiroshi, 2003, Nihon Rinsho, V61, P709; Passantino A, 2015, WORLD J CARDIOL, V7, P902, DOI 10.4330/wjc.v7.i12.902; Peterson PN, 2010, CIRC-CARDIOVASC QUAL, V3, P25, DOI 10.1161/CIRCOUTCOMES.109.854877; Pocock SJ, 2006, EUR HEART J, V27, P65, DOI 10.1093/eurheartj/ehi555; Pocock SJ, 2013, EUR HEART J, V34, P1404, DOI 10.1093/eurheartj/ehs337; Rusinaru D, 2012, EUR J HEART FAIL, V14, P1139, DOI 10.1093/eurjhf/hfs099; Santaguida PL, 2014, HEART FAIL REV, V19, P453, DOI 10.1007/s10741-014-9442-y; Santas E, 2017, INT J CARDIOLOGY; Sartipy U, 2014, EUR J HEART FAIL, V16, P173, DOI 10.1111/ejhf.32; Schocken DD, 2008, CIRCULATION, V117, P2544, DOI 10.1161/CIRCULATIONAHA.107.188965; Somaratne JB, 2009, EUR J HEART FAIL, V11, P855, DOI 10.1093/eurjhf/hfp103; Spinar J, 2011, CRIT CARE, V15, DOI 10.1186/cc10584; Stewart S, 2001, EUR J HEART FAIL, V3, P315, DOI 10.1016/S1388-9842(00)00141-0; Vazquez R, 2009, EUR HEART J, V30, P1088, DOI 10.1093/eurheartj/ehp032; Wei Bing-qi, 2009, Zhonghua Xinxueguanbing Zazhi, V37, P481, DOI 10.3760/cma.j.issn.0253-3758.2009.06.001; Yoo BS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086596; 안민수, 2007, Korean Circulation Journal, V37, P393	44	27	29	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2018	13	11							e0206380	10.1371/journal.pone.0206380	http://dx.doi.org/10.1371/journal.pone.0206380			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HC4EO	30485284	gold, Green Published, Green Submitted			2023-01-03	WOS:000451755800019
J	Tomioka, K; Kurumatani, N; Saeki, K				Tomioka, Kimiko; Kurumatani, Norio; Saeki, Keigo			The differential effects of type and frequency of social participation on IADL declines of older people	PLOS ONE			English	Article							INSTRUMENTAL ACTIVITIES; FUNCTIONAL DISABILITY; ASSOCIATION; MORTALITY; HEALTH; LIFE; PERFORMANCE; NETWORKS; GENDER; ADULTS	Background Although social participation (SP) is valid in active aging, it is vague which types and the frequency of SP are effective in maintaining instrumental activities of daily living (IADL). We conducted a community-based prospective cohort study and investigated the association of the types and frequency for SP with IADL decline in community-dwelling older adults. Methods The target population were all individuals aged >= 65 living in a commuter town in Nara, Japan. A total of 6,013 participants with independent IADL at baseline were analyzed. IADL was assessed using the Tokyo Metropolitan Institute of Gerontology Index of Competence. Six SP types were assessed: volunteer groups, sports groups, hobby clubs, senior citizens' clubs, neighborhood community associations, and cultural clubs. The frequency of SP was categorized into frequent (i.e., weekly or more), moderate (i.e., monthly or yearly), and non-participation. Using multiple logistic regression models, the odds ratio (OR) and a 95% confidence interval (CI) for IADL decline were calculated. Covariates included age, marital status, education, subjective economic status, work status, body mass index, chronic medical conditions (i.e., hypertension, diabetes mellitus, heart disease, and cerebrovascular disease), lifestyle factors (i.e., alcohol, smoking, and exercise), self-rated health, depression, and cognitive functioning. To examine gender differences, stratified analyses by gender were performed. Results During the 33-month follow-up, 16.4% of men and 8.7% of women exhibited IADL decline. After adjustment for all covariates, compared to those who never participated, women with moderate participation had significantly lower odds of IADL decline in volunteer groups (OR = 0.53, 95% CI = 0.31-0.88), hobby clubs (OR = 0.55, 95% CI = 0.38-0.79), neighborhood community associations (OR = 0.58, 95% CI = 0.42-0.81), and cultural clubs (OR = 0.51, 95% CI = 0.31-0.82), and women with frequent participation had lower odds of IADL decline in hobby clubs (OR = 0.63, 95% CI = 0.43-0.93). In contrast, among men, the significant association between SP and less risk of IADL decline was limited to moderate participation in neighborhood community associations (OR = 0.79, 95% CI = 0.63-0.99), and there were no differences between frequent participation and non-participation in all types of SP. Regarding volunteer groups, compared to women with frequent participation, women with moderate participation had a significantly lower risk of IADL decline (OR = 0.37, 95% CI = 0.18-0.77). The results of additional stratified analyses by self-rated health, depression, and cognitive functioning showed that the associations of the type and frequency of SP with IADL decline varied according to physical and mental functioning. Conclusions Several types of SP have a favorable effect on IADL through moderate participation rather than frequent participation, and women with moderate participation in volunteer groups have a more beneficial effect on IADL than women with frequent participation. When advising community-dwelling older adults on SP for IADL maintenance, health professionals may need to take into account plateau effects, gender differences, and physical and mental functioning.	[Tomioka, Kimiko; Kurumatani, Norio; Saeki, Keigo] Nara Med Univ, Nara Prefectural Hlth Res Ctr, Kashihara, Nara, Japan	Nara Medical University	Tomioka, K (corresponding author), Nara Med Univ, Nara Prefectural Hlth Res Ctr, Kashihara, Nara, Japan.	tkimiko@naramed-u.ac.jp	SAEKI, KEIGO/GWU-5723-2022		Center Administrative Expense from Nara Medical University; JSPS KAKENHI [JP17K09209]	Center Administrative Expense from Nara Medical University; JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Center Administrative Expense from Nara Medical University and JSPS KAKENHI Grant Number JP17K09209. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amagasa S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175392; Ang S., 2016, J GERONTOL B-PSYCHOL, DOI [10.1093/geronb/gbw078, DOI 10.1093/GER0NB/GBW078]; [Anonymous], 2003, GERIATR GERONTOL INT; Ashida T, 2016, PREV MED, V89, P121, DOI 10.1016/j.ypmed.2016.05.006; Baek J, 2016, J GERIATR CARDIOL, V13, P580, DOI 10.11909/j.issn.1671-5411.2016.07.005; Cohen S, 2004, AM PSYCHOL, V59, P676, DOI 10.1037/0003-066X.59.8.676; EAGLY AH, 1991, PERS SOC PSYCHOL B, V17, P306, DOI 10.1177/0146167291173011; Fiori KL, 2012, J AGING HEALTH, V24, P407, DOI 10.1177/0898264311425087; Fujiwara Yoshinori, 2003, Nihon Koshu Eisei Zasshi, V50, P360; Fujiwara Y, 2016, GERIATR GERONTOL INT, V16, P126, DOI 10.1111/ggi.12441; Hansen LR, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4871-x; Hoyl MT, 1999, J AM GERIATR SOC, V47, P873, DOI 10.1111/j.1532-5415.1999.tb03848.x; Iwasaki M, 2002, INT J EPIDEMIOL, V31, P1208, DOI 10.1093/ije/31.6.1208; Iwase T, 2012, J EPIDEMIOL COMMUN H, V66, P557, DOI 10.1136/jech.2010.115592; James BD, 2011, J GERONTOL A-BIOL, V66, P467, DOI 10.1093/gerona/gly231; Kanamori S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099638; Kanamori S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051061; Kawachi I, 2001, J URBAN HEALTH, V78, P458, DOI 10.1093/jurban/78.3.458; Kawachi I, 2006, INT J EPIDEMIOL, V35, P989, DOI 10.1093/ije/dyl117; Kishimoto Y, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1189; Kondo N, 2012, J EPIDEMIOL, V22, P543, DOI 10.2188/jea.JE20120025; KOYANO W, 1991, ARCH GERONTOL GERIAT, V13, P103, DOI 10.1016/0167-4943(91)90053-S; Koyano W., 1987, JPN J PUBLIC HLTH, V34, P109; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lee S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180017; Lennartsson C, 2001, J GERONTOL B-PSYCHOL, V56, pS335, DOI 10.1093/geronb/56.6.S335; Levasseur M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1824-0; Meltzer H, 2012, DISABIL HEALTH J, V5, P102, DOI 10.1016/j.dhjo.2012.02.001; Minami U, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144069; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; Morrow-Howell N, 2010, J GERONTOL B-PSYCHOL, V65, P461, DOI 10.1093/geronb/gbq024; Murayama H, 2015, SOC SCI MED, V124, P171, DOI 10.1016/j.socscimed.2014.11.042; Musick MA, 1999, J GERONTOL B-PSYCHOL, V54, pS173, DOI 10.1093/geronb/54B.3.S173; OECD, 2016, OECD EMPL OUTL 2016; OECD, 2015, HLTH CAR ACT HLTH GL, P112, DOI 10.1787/health_glance-2015-en; Peres K, 2008, J AM GERIATR SOC, V56, P37, DOI 10.1111/j.1532-5415.2007.01499.x; Raghunathan T.E., 2001, SURV METHODOL, V27, P85; Roh HW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132838; Rowe JW, 2015, J GERONTOL B-PSYCHOL, V70, P593, DOI 10.1093/geronb/gbv025; Shinkai S., 2003, GERIATR GERONTOL INT, V3, pS31, DOI [DOI 10.1111/J.1444-0594.2003.00094.X, 10.1111/j.1444-0594.2003.00094.x]; SPECTOR PE, 1987, J APPL PSYCHOL, V72, P438, DOI 10.1037/0021-9010.72.3.438; Sugihara Y, 2008, J GERONTOL B-PSYCHOL, V63, pP227, DOI 10.1093/geronb/63.4.P227; Takeuchi K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061741; Tomioka K, 2019, J EPIDEMIOL, V29, P407, DOI 10.2188/jea.JE20180113; Tomioka K, 2017, GERIATR GERONTOL INT, V17, P2537, DOI 10.1111/ggi.13074; Tomioka K, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0502-8; Tomioka K, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0491-7; Tomioka K, 2017, AGE AGEING, V46, P265, DOI 10.1093/ageing/afw164; Tomioka K, 2018, J GERONTOL B-PSYCHOL, V73, P799, DOI 10.1093/geronb/gbw059; Tomioka K, 2017, J AM GERIATR SOC, V65, P107, DOI 10.1111/jgs.14447; Tomioka K, 2016, J EPIDEMIOL, V26, P553, DOI 10.2188/jea.JE20150253; Tomioka K, 2016, J EPIDEMIOL, V26, P361, DOI 10.2188/jea.JE20150153; Umberson D, 2010, J HEALTH SOC BEHAV, V51, pS54, DOI 10.1177/0022146510383501; Yamauchi K, 1999, JPN J GERIATR PSYCHI, V10, P943	54	29	30	2	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2018	13	11							e0207426	10.1371/journal.pone.0207426	http://dx.doi.org/10.1371/journal.pone.0207426			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HB4VL	30462711	Green Published, Green Submitted, gold			2023-01-03	WOS:000451054800054
J	Xia, Y; Chen, YL; Zeng, Z; Zhou, Q; Wang, YY; Xie, RS; Xie, XL; Li, H				Xia Yun; Chen Yaolong; Zeng Zhao; Zhou Qi; Wang Yangyang; Xie Runshen; Xie Xiuli; Li Hui			Using the RIGHT statement to evaluate the reporting quality of clinical practice guidelines in traditional Chinese medicine	PLOS ONE			English	Article								Objective To evaluate the reporting quality of clinical practice guidelines (CPGs) in traditional Chinese medicine (TCM). Methods A systematic search was undertaken to extract CPGs for TCM. The RIGHT (Reporting Items for practice Guidelines in Healthcare) statement was used to calculate scores for the reporting quality in terms of domains and items, followed by a subgroup analysis of the results and determination of the correlation between the RIGHT and AGREE II (Appraisal of Guidelines for Research and Evaluation II) scores. Results Overall, 539 TCM CPGs were included. (1) The mean scores (Med, IQR) for each RIGHT domain were as follows: basic information (4, 1), background (3, 2), evidence (0, 0), recommendations (2, 2), review and quality assurance (0, 0), funding and declaration and management of interests (0, 0.5), and other information (0, 0). (2) The items with a low reporting rate (<10%) included 2, 5, 8b, 9a, 10a, 10b, 11a, 11b, 14a, 14b, 14c, 16, 17, 19b, 20, 21, and 22, and those with a high reporting rate (> 90%) included la, 1b, 1c, 7b, 13a, and 13b. (3) In recent years, the reporting quality of TCM CPGs has improved, and there was a significant difference among the organizations (P = 0.000), where that of the updated versions was greater than that of the historical versions (P = 0.047). (4) The RIGHT and AGREE II scores were positively correlated (P = 0.014). Conclusions At present, although the reporting quality of TCM CPGs is improving, the overall quality remains suboptimal. Guideline developers should strictly follow the evidence-based process of developing guidelines and should follow the RIGHT statement to produce a standardized report when writing guidelines.	[Xia Yun; Zeng Zhao] Guangzhou Chinese Med Univ, Guangzhou, Guangdong, Peoples R China; [Xia Yun; Wang Yangyang; Xie Runshen; Xie Xiuli; Li Hui] Guangdong Prov Hosp Chinese Med, Guangzhou, Guangdong, Peoples R China; [Chen Yaolong; Zhou Qi] Lanzhou Univ, Lanzhou, Gansu, Peoples R China	Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Lanzhou University	Li, H (corresponding author), Guangdong Prov Hosp Chinese Med, Guangzhou, Guangdong, Peoples R China.	lihuitcm@126.com		Chen, Yaolong/0000-0002-9841-5233; Zhou, Qi/0000-0001-7884-7074	Science and Technology Planning Project of Guangdong Province, China [2017A030303071]; Specific Research Fund for TCM Science and Technology of Guangdong Province Hospital of Chinese Medicine [YN2015MS22]	Science and Technology Planning Project of Guangdong Province, China; Specific Research Fund for TCM Science and Technology of Guangdong Province Hospital of Chinese Medicine	The study was supported by the Science and Technology Planning Project of Guangdong Province, China (2017A030303071) and The Specific Research Fund for TCM Science and Technology of Guangdong Province Hospital of Chinese Medicine (YN2015MS22). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], ANN ONCOL; Chen Ke-Ji, 2009, Zhong Xi Yi Jie He Xue Bao, V7, P301, DOI 10.3736/jcim20090401; Chen YL, 2017, JAMA-J AM MED ASSOC, V318, P866, DOI 10.1001/jama.2017.9672; Chen YL, 2017, ANN INTERN MED, V166, P128, DOI 10.7326/M16-1565; Chen YL, 2015, DEV REPORTING STANDA; Cheng CW, 2017, ANN INTERN MED, V167, P112, DOI [10.7326/M16-2977, 10.7326/IsTranslatedFrom_M17-2977_2, 10.7326/IsTranslatedFrom_M17-2977_1]; Clinical Practice Guidelines We Can Trust, 2011, PORT J NEPHROL HYPER; Djulbegovic B, 2017, LANCET, V390, P415, DOI 10.1016/S0140-6736(16)31592-6; Shaneyfelt TM, 1999, JAMA-J AM MED ASSOC, V281, P1900, DOI 10.1001/jama.281.20.1900; Smith M, 2014, WHO TRADITIONAL MED; Sun GR, 2012, CHINA PRESS TRADITIO; Wang X, 2015, CHIN J OBSTET EMERG, V4, P193; [卫茂玲 Wei Maoling], 2013, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V13, P927; Wu Taixiang, 2017, J Evid Based Med, V10, P155, DOI 10.1111/jebm.12268; Yao L, 2017, INT J CLIN PRACT, V71, DOI 10.1111/ijcp.12931	15	9	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2018	13	11							e0207580	10.1371/journal.pone.0207580	http://dx.doi.org/10.1371/journal.pone.0207580			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA6WB	30444924	Green Published, Green Submitted, gold			2023-01-03	WOS:000450420900043
J	Sondell, A; Rosendahl, E; Sommar, JN; Littbrand, H; Lundin-Olsson, L; Lindelof, N				Sondell, Anna; Rosendahl, Erik; Sommar, Johan Nilsson; Littbrand, Hakan; Lundin-Olsson, Lillemor; Lindelof, Nina			Motivation to participate in high-intensity functional exercise compared with a social activity in older people with dementia in nursing homes	PLOS ONE			English	Article							MILD COGNITIVE IMPAIRMENT; SELF-DETERMINATION THEORY; PHYSICAL-ACTIVITY; PERFORMANCE-MEASURES; GAIT ANALYSIS; ALZHEIMERS; ADULTS; RESIDENTS; BALANCE; INTERVENTION	Background Motivation to participate in exercise among people with dementia has not been well studied. The symptoms of dementia, including apathy, may lead to low motivation to participate in exercise. The aim of this study was to evaluate the motivation of older people with dementia to participate in a high-intensity exercise program compared with motivation of those participating in a social group activity. Methods The Umea Dementia and Exercise Study (UMDEX) was a cluster-randomized controlled intervention trial including 186 people (mean age; 85, 75% female) with dementia in nursing homes. Participants were randomized to participate in the High-Intensity Functional Exercise (HIFE) Program (n = 93) or a seated social group activity (n = 93). The activities were conducted in groups of 3-8 participants for 45 minutes, five times per two-week period, for 4 months (40 sessions in total). Participants' motivation to go to and during activity sessions were assessed by the activity leaders and nursing homes staff using a five-point Likert scale. Data were analyzed using cumulative link mixed models. Results Motivation was high or very high during 61.0% of attended sessions in the exercise group and 62.6% in the social activity group. No overall significant difference between groups was observed, but motivation increased over time in the exercise group and decreased in the social activity group (p < 0.05). Motivation during the sessions was significantly higher than motivation to go to the sessions, especially in the exercise group [OR 2.39 (95% CI 2.382.40) and 1.50 (95% CI 1.32-1.70), respectively]. Conclusions Among older people with dementia in nursing homes, motivation to participate in a high-intensity functional exercise program seems to be high, comparable to motivation to participate in a social activity, and increase over time. Since motivation during activity sessions was higher than motivation to go to sessions the promotion of strategies to encourage people with dementia to join exercise groups is of great importance.	[Sondell, Anna; Rosendahl, Erik; Littbrand, Hakan; Lundin-Olsson, Lillemor; Lindelof, Nina] Umea Univ, Dept Community Med & Rehabil, Physiotherapy, Umea, Sweden; [Sondell, Anna; Rosendahl, Erik; Littbrand, Hakan; Lindelof, Nina] Umea Univ, Dept Community Med & Rehabil, Geriatr Med, Umea, Sweden; [Sommar, Johan Nilsson] Umea Univ, Dept Publ Hlth & Clin Med, Occupat & Environm Med, Umea, Sweden	Umea University; Umea University; Umea University	Sondell, A (corresponding author), Umea Univ, Dept Community Med & Rehabil, Physiotherapy, Umea, Sweden.; Sondell, A (corresponding author), Umea Univ, Dept Community Med & Rehabil, Geriatr Med, Umea, Sweden.	anna.sondell@umu.se		Lindelof, Nina/0000-0002-4449-049X	Swedish Research Council [K2009-69P-21298-01-4, K2009-69X-21299-01-1, K2009-69P-21298-04-4, K2014-99X-22610-01-6]; Forte - Swedish Research Council for Health, Working Life and Welfare; Vardal Foundation; Swedish Dementia Association; Promobilia Foundation; Swedish Society of Medicine; Swedish Alzheimer Foundation; County Council of Vasterbotten; Umea University Foundation for Medical Research; Ragnhild and Einar Lundstrom's Memorial Foundation; Erik and Anne-Marie Detlof's Foundation	Swedish Research Council(Swedish Research CouncilEuropean Commission); Forte - Swedish Research Council for Health, Working Life and Welfare; Vardal Foundation; Swedish Dementia Association; Promobilia Foundation; Swedish Society of Medicine; Swedish Alzheimer Foundation; County Council of Vasterbotten; Umea University Foundation for Medical Research; Ragnhild and Einar Lundstrom's Memorial Foundation; Erik and Anne-Marie Detlof's Foundation	This work was supported by the Swedish Research Council (grant numbers K2009-69P-21298-01-4, K2009-69X-21299-01-1, K2009-69P-21298-04-4, K2014-99X-22610-01-6) www.vr.se; Forte - Swedish Research Council for Health, Working Life and Welfare (formerly FAS - Swedish Council for Working Life and Social Research) www.forte.se; the Vardal Foundation; the Swedish Dementia Association www.demensforbundet.se; the Promobilia Foundation https://www.promobilia.se/; the Swedish Society of Medicine www.slf.se; the Swedish Alzheimer Foundation; the County Council of Vasterbotten www.vll.se, the Umea University Foundation for Medical Research www.umu.se; the Ragnhild and Einar Lundstrom's Memorial Foundation; and the Erik and Anne-Marie Detlof's Foundation.	Allali G, 2016, EUR J NEUROL, V23, P527, DOI 10.1111/ene.12882; Allan LM, 2005, J AM GERIATR SOC, V53, P1681, DOI 10.1111/j.1532-5415.2005.53552.x; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], R LANG ENV STAT COMP; [Anonymous], 2014, HIFE PROGRAM HIGH IN; [Anonymous], 2018, HIGH INTENSITY FUNCT; Bandura A, 1997, EFFICACY EXERCISE CO; Barreto PD, 2015, J SPORT SCI, V33, P116, DOI 10.1080/02640414.2014.928828; Brassington GS, 2002, AM J PREV MED, V23, P80, DOI 10.1016/S0749-3797(02)00477-4; Burton E, 2015, CLIN INTERV AGING, V10, P421, DOI 10.2147/CIA.S71691; Cedervall Y, 2015, AGING MENT HEALTH, V19, P679, DOI 10.1080/13607863.2014.962004; Chodzko-Zajko WJ, 2009, MED SCI SPORT EXER, V41, P1510, DOI 10.1249/MSS.0b013e3181a0c95c; Chong TWH, 2014, ASIA-PAC PSYCHIAT, V6, P179, DOI 10.1111/appy.12015; Coaten R, 2013, DEMENTIA-LONDON, V12, P677, DOI 10.1177/1471301213507033; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Deci EL, 2008, CAN PSYCHOL, V49, P182, DOI 10.1037/a0012801; den Ouden M, 2015, J AM MED DIR ASSOC, V16, P963, DOI 10.1016/j.jamda.2015.05.016; Fjellman-Wiklundl A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166686; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forbes D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006489.pub4; Galik EM, 2009, INT J NURS PRACT, V15, P48, DOI 10.1111/j.1440-172X.2008.01721.x; Gallagher D, 2011, INT J GERIATR PSYCH, V26, P166, DOI 10.1002/gps.2509; Guigoz Y, 1994, FACTS RES GERONTOL, V2, P15, DOI DOI 10.1016/S0899-9007(98)00171-3; Guzman-Garcia A, 2013, INT J GERIATR PSYCH, V28, P914, DOI 10.1002/gps.3913; Howe TE, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004963.pub3; Huang WNW, 2010, J AM GERIATR SOC, V58, P844, DOI 10.1111/j.1532-5415.2010.02820.x; KATZ S, 1983, J AM GERIATR SOC, V31, P721, DOI 10.1111/j.1532-5415.1983.tb03391.x; Kovach CR, 2010, AM J ALZHEIMERS DIS, V25, P317, DOI 10.1177/1533317510363471; Lesinski M, 2015, SPORTS MED, V45, P557, DOI 10.1007/s40279-014-0284-5; Lindelof N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188225; Littbrand H, 2006, PHYS THER, V86, P489, DOI 10.1093/ptj/86.4.489; Littbrand H, 2011, AM J PHYS MED REHAB, V90, P495, DOI 10.1097/PHM.0b013e318214de26; Liu C, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004434.pub4; McDowel I., 2006, MEASURING HLTH GUIDE, V3rd ed.; Morgan D, 2007, CAN J AGING, V26, P19, DOI 10.3138/1457-2411-V402-62L1; Morley JE, 2016, J AM MED DIR ASS; Muir SW, 2008, PHYS THER, V88, P449, DOI 10.2522/ptj.20070251; Olsen CF, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1041-7; Penninx BWJH, 2000, J GERONTOL A-BIOL, V55, pM691, DOI 10.1093/gerona/55.11.M691; Pettersson AF, 2002, DEMENT GERIATR COGN, V13, P213, DOI 10.1159/000057699; Phillips EM, 2004, ARCH PHYS MED REHAB, V85, pS52, DOI 10.1016/j.apmr.2004.03.012; Phillips EM, 2004, ARCH PHYS MED REHAB, V7, pS8; Pitkala K, 2013, EXP GERONTOL, V48, P85, DOI 10.1016/j.exger.2012.08.008; Prick AE, 2016, DEMENTIA LONDON; Rao AK, 2014, AM J OCCUP THER, V68, P50, DOI 10.5014/ajot.2014.009035; Ratamess NA, 2009, MED SCI SPORT EXER, V41, P687, DOI 10.1249/MSS.0b013e3181915670; Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68; Schunk D.H., 2012, OXFORD HDB HUMAN MOT, P13, DOI [DOI 10.1093/OXFORDHB/9780195399820.013.0002, DOI 10.1093/OXFORDHB/9780195399820.001.0001]; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; Sondell A, 2019, J GERIATR PHYS THER, V42, pE16, DOI 10.1519/JPT.0000000000000199; Strom BS, 2017, DEMENT GER COGN D EX, V7, P122, DOI 10.1159/000468147; Stubbs B, 2014, ARCH GERONTOL GERIAT, V59, P195, DOI 10.1016/j.archger.2014.06.006; Studenski S, 2003, J AM GERIATR SOC, V51, P314, DOI 10.1046/j.1532-5415.2003.51104.x; Tak SH, 2015, EDUC GERONTOL, V41, P182, DOI 10.1080/03601277.2014.937217; Teixeira PJ, 2012, INT J BEHAV NUTR PHY, V9, DOI 10.1186/1479-5868-9-78; Telenius EW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126102; Teng E, 2007, DEMENT GERIATR COGN, V24, P253, DOI 10.1159/000107100; Toots A, 2016, J AM GERIATR SOC, V64, P55, DOI 10.1111/jgs.13880; van Alphen HJM, 2016, ARCH GERONTOL GERIAT, V66, P109, DOI 10.1016/j.archger.2016.05.008; van Iersel MB, 2004, Z GERONTOL GERIATR, V37, P27, DOI 10.1007/s00391-004-0176-7; Wade D T, 1988, Int Disabil Stud, V10, P64; Whitney J, 2011, J WHITN TEH WORLD C; Williams AK, 2005, TOP GERIATR REHABIL, V21, P123	63	16	16	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2018	13	11							e0206899	10.1371/journal.pone.0206899	http://dx.doi.org/10.1371/journal.pone.0206899			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HA3GQ	30427894	Green Published, Green Submitted, gold			2023-01-03	WOS:000450138500071
J	Bennett, MV; McLaurin, K; Ambrose, C; Lee, HC				Bennett, Mihoko, V; McLaurin, Kimmie; Ambrose, Christopher; Lee, Henry C.			Population-based trends and underlying risk factors for infant respiratory syncytial virus and bronchiolitis hospitalizations	PLOS ONE			English	Article							PROPHYLAXIS; PALIVIZUMAB; MORTALITY; CHILDREN	Objective Respiratory syncytial virus (RSV) is a common pathogen during infancy, with the potential to cause serious disease and mortality in high-risk groups. The objective of this study was to characterize trends of RSV and bronchiolitis hospitalizations in the first year in a population-based cohort and assess differences in trends according to risk status. Methods Using an observational retrospective cohort design, we examined a California populationbased dataset of vital statistics linked to hospital discharge data for up to 1 year after birth from 1997-2011. Infants were categorized by medical condition and then by gestational age. Medical conditions of interest included chronic lung disease, certain congenital heart diseases, or others known to affect risk for developing severe bronchiolitis. The primary outcome was hospitalization due to RSV; secondary outcome was hospitalization for unspecified bronchiolitis (UB) not coded as RSV. Annual person-year rates were calculated for infants <12 months of age during January to December of each year. Results Of 7,298,401 infants born during the study period, 121,230 (1.7%) had a medical condition associated with risk; these infants experienced 6853 RSV and 6568 UB hospitalizations in the first year. In infants without medical conditions, 96,694 RSV and 69,886 UB hospitalizations occurred. All-cause infant hospitalizations declined over time from 12.2 to 9.3 per 100 person-years. RSV hospitalization rates for infants with medical conditions decreased from 7.6 to 3.4 per 100 person-years, with the largest relative decline in infants with chronic lung disease (12.0 to 5.0 per 100 person-years). For infants without medical conditions, RSV hospitalizations declined from 1.4 to 0.8 per 100 person-years, with greater decreases among preterm infants with earlier gestational age. UB hospitalization rates remained relatively stable across the study years, from 6.2 to 5.4 and 1.0 to 0.8 per 100 person-years for infants with and without medical conditions. Conclusions Various interventions may have contributed to observed decreases in RSV hospitalizations from 1998-2011, which were greater in high-risk populations recommended for RSV immunoprophylaxis and not observed with UB. Further efforts to promote evidence-based practice and optimal targeting of appropriate interventions will ensure continued improvement in care for vulnerable infants.	[Bennett, Mihoko, V; Lee, Henry C.] Stanford Sch Med, Div Neonatal & Dev Med, Stanford, CA 94305 USA; [Bennett, Mihoko, V; Lee, Henry C.] Calif Perinatal Qual Care Collaborat, Stanford, CA 94305 USA; [McLaurin, Kimmie; Ambrose, Christopher] AstraZeneca, Gaithersburg, MD USA	Stanford University; AstraZeneca	Lee, HC (corresponding author), Stanford Sch Med, Div Neonatal & Dev Med, Stanford, CA 94305 USA.; Lee, HC (corresponding author), Calif Perinatal Qual Care Collaborat, Stanford, CA 94305 USA.	hclee@stanford.edu	Lee, Henry/GVS-2114-2022	Lee, Henry/0000-0001-8383-1720; Ambrose, Christopher/0000-0003-4175-7336	AstraZeneca (Gaithersburg, MD); AstraZeneca	AstraZeneca (Gaithersburg, MD)(AstraZeneca); AstraZeneca(AstraZeneca)	This study was supported by AstraZeneca (Gaithersburg, MD). HL received funding from AstraZeneca for research effort and travel expenses to present findings at a national conference. MB received research funding from AstraZeneca. AstraZeneca provided support in the form of salaries for authors KM and CA, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. Editorial support was provided by The Lockwood Group, which was in accordance with Good Publication Practice (GPP3) and funded by AstraZeneca.	Brady MT, 2014, PEDIATRICS, V134, pE620, DOI [10.1542/peds.2014-1666, 10.1542/peds.2014-1665]; Centers for Disease Control and Prevention, BREASTF RAT NAT IMM; Checchia PA, 2011, PEDIATR CRIT CARE ME, V12, P580, DOI 10.1097/PCC.0b013e3182070990; Chu PY, 2017, CARDIOL YOUNG, V27, P16, DOI 10.1017/S1047951116000470; Doucette A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152208; Farber HJ, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0627; Friedman D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172512; Hampp C, 2010, J PEDIATR-US, V156, P953, DOI 10.1016/j.jpeds.2009.12.016; Hasegawa K, 2013, PEDIATRICS, V132, P28, DOI 10.1542/peds.2012-3877; Herrchen B, 1997, COMPUT BIOMED RES, V30, P290, DOI 10.1006/cbmr.1997.1448; McDowell Margaret A, 2008, NCHS Data Brief, P1; Mejias A., 2005, NEOREVIEWS, V6, pe26, DOI [10.1542/neo.6-1-e26, DOI 10.1542/NEO.6-1-E26]; Michels KA, 2017, AM J CLIN NUTR, V106, P1456, DOI 10.3945/ajcn.116.144279; Pavilack M, 2018, INFECT DIS THER, V7, P121, DOI 10.1007/s40121-017-0178-6; Sangare L, 2006, J PEDIATR-US, V149, P373, DOI 10.1016/j.jpeds.2006.04.063; Tarrant M, 2010, EPIDEMIOLOGY, V21, P847, DOI 10.1097/EDE.0b013e3181f55803; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179	17	14	16	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2018	13	10							e0205399	10.1371/journal.pone.0205399	http://dx.doi.org/10.1371/journal.pone.0205399			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY7VH	30379957	Green Published, Green Submitted, gold			2023-01-03	WOS:000448823700045
J	Keers, RN; Placido, M; Bennett, K; Clayton, K; Brown, P; Ashcroft, DM				Keers, Richard N.; Placido, Madalena; Bennett, Karen; Clayton, Kristen; Brown, Petra; Ashcroft, Darren M.			What causes medication administration errors in a mental health hospital? A qualitative study with nursing staff	PLOS ONE			English	Article							ADVERSE DRUG EVENTS; CARE; NURSES; INTERVENTIONS; POLYPHARMACY; FREQUENCY	Objective Medication administration errors (MAEs) are a common risk to patient safety in mental health hospitals, but an absence of in-depth studies to understand the underlying causes of these errors limits the development of effective remedial interventions. This study aimed to investigate the causes of MAEs affecting inpatients in a mental health National Health Service (NHS) hospital in the North West of England. Methods Registered and student mental health nurses working in inpatient psychiatric units were identified using a combination of direct advertisement and incident reports and invited to participate in semi-structured interviews utilising the critical incident technique. Interviews were designed to capture the participants' experiences of inpatient MAEs. All interviews were transcribed verbatim and subject to framework analysis to illuminate the underlying active failures, error/violation-provoking conditions and latent failures according to Reason's model of accident causation. Results A total of 20 participants described 26 MAEs (including 5 near misses) during the interviews. The majority of MAEs were skill-based slips and lapses (n = 16) or mistakes (n = 5), and were caused by a variety of interconnecting error/violation-provoking conditions relating to the patient, medicines used, medicines administration task, health care team, individual nurse and working environment. Some of these local conditions had origins in wider organisational latent failures. Recurrent and influential themes included inadequate staffing levels, unbalanced staff skill mix, interruptions/distractions, concerns with how the medicines administration task was approached and problems with communication. Conclusions To our knowledge this is the first published in-depth qualitative study to investigate the underlying causes of specific MAEs in a mental health hospital. Our findings revealed that MAEs may arise due to multiple interacting error and violation provoking conditions and latent 'system' failures, which emphasises the complexity of this everyday task facing practitioners in clinical practice. Future research should focus on developing and testing interventions which address key local and wider organisational 'systems' failures to reduce error.	[Keers, Richard N.; Placido, Madalena; Ashcroft, Darren M.] Univ Manchester, MAHSC, Sch Hlth Sci, Div Pharm & Optometry,Ctr Pharmacoepidemiol & Dru, Manchester, Lancs, England; [Keers, Richard N.; Ashcroft, Darren M.] Univ Manchester, MAHSC, NIHR Greater Manchester Patient Safety Translat R, Manchester, Lancs, England; [Keers, Richard N.; Bennett, Karen; Clayton, Kristen; Brown, Petra] North Manchester Gen Hosp, Pk House Hosp, Greater Manchester Mental Hlth NHS Fdn Trust, Med Management Team, Manchester, Lancs, England; [Bennett, Karen] Univ Bolton, Sch Hlth & Human Sci, Bolton, England	University of Manchester; University of Manchester; University of Bolton	Keers, RN (corresponding author), Univ Manchester, MAHSC, Sch Hlth Sci, Div Pharm & Optometry,Ctr Pharmacoepidemiol & Dru, Manchester, Lancs, England.; Keers, RN (corresponding author), Univ Manchester, MAHSC, NIHR Greater Manchester Patient Safety Translat R, Manchester, Lancs, England.; Keers, RN (corresponding author), North Manchester Gen Hosp, Pk House Hosp, Greater Manchester Mental Hlth NHS Fdn Trust, Med Management Team, Manchester, Lancs, England.	richard.keers@manchester.ac.uk	Keers, Richard/D-9136-2012; Ashcroft, Darren/G-3244-2015	Keers, Richard/0000-0001-7854-8154; Ashcroft, Darren/0000-0002-2958-915X; Placido, Madalena/0000-0002-0981-951X	University of Manchester; NHS trust	University of Manchester; NHS trust	This work was supported internally by The University of Manchester and participating NHS trust, no specific grant or funding stream was used. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abduldaeem HMK., 2016, IJPP, V24, P4; Alshehri GH, 2017, DRUG SAFETY, V40, P871, DOI 10.1007/s40264-017-0557-7; [Anonymous], 2016, 5 YEAR FORW VIEW MEN; Baldwin DS, 2007, ADV PSYCHIAT TREAT, V13, P414, DOI DOI 10.1192/APT.BP.107.004184; Barnes TRE, 2011, CNS DRUGS, V25, P383, DOI 10.2165/11587810-000000000-00000; Berdot S, 2016, INT J NURS STUD, V53, P342, DOI 10.1016/j.ijnurstu.2015.08.012; Browne G, 2013, INT J NURS PRACT, V19, P539, DOI 10.1111/ijn.12090; Cottney A, 2015, INT J MENT HEALTH NU, V24, P65, DOI 10.1111/inm.12096; De Hert M, 2011, WORLD PSYCHIATRY, V10, P52, DOI 10.1002/j.2051-5545.2011.tb00014.x; Dickens Geoff, 2008, Nurs Stand, V22, P35; Dickinson Tommy, 2008, Br J Nurs, V17, P82; Donisi V, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-1114-0; Dougherty L, 2012, J ADV NURS, V68, P1302, DOI 10.1111/j.1365-2648.2011.05838.x; Duxbury JA, 2010, INT J MENT HEALTH NU, V19, P53, DOI 10.1111/j.1447-0349.2009.00638.x; Emily H., 2014, OECD HLTH POLICY STU; Fanneran T, 2015, J PSYCHIATR MENT HLT, V22, P764, DOI 10.1111/jpm.12263; FLANAGAN JC, 1954, PSYCHOL BULL, V51, P327, DOI 10.1037/h0061470; Ford R, 1998, BRIT MED J, V317, P1279, DOI 10.1136/bmj.317.7168.1279; Fornaro M, 2016, NEUROPSYCH DIS TREAT, V12, P719, DOI 10.2147/NDT.S100846; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Grimm P., 2010, WILEY INT ENCY MARKE, DOI [10.1002/9781444316568.wiem02057/abstract, DOI 10.1002/9781444316568.WIEM02057/ABSTRACT]; Harris N, 2009, MED MANAGEMENT MENTA; Haw C, 2011, J PSYCHIATR MENT HLT, V18, P308, DOI 10.1111/j.1365-2850.2010.01664.x; Haw C, 2007, INT J QUAL HEALTH C, V19, P210, DOI 10.1093/intqhc/mzm019; Haw C, 2015, J ADV NURS, V71, P281, DOI 10.1111/jan.12495; Haw CM, 2005, PSYCHIAT SERV, V56, P1610, DOI 10.1176/appi.ps.56.12.1610; Ito H, 2003, INT J QUAL HEALTH C, V15, P207, DOI 10.1093/intqhc/mzg038; Janssen EM, 2015, GEN HOSP PSYCHIAT, V37, P199, DOI 10.1016/j.genhosppsych.2015.03.004; Jheeta S, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2462-2; Keers RN, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-005948; Keers RN, 2014, DRUG SAFETY, V37, P317, DOI 10.1007/s40264-014-0152-0; Keers RN, 2013, DRUG SAFETY, V36, P1045, DOI 10.1007/s40264-013-0090-2; Kemppainen JK, 2000, J ADV NURS, V32, P1264, DOI 10.1046/j.1365-2648.2000.01597.x; Lane R, 2006, APPL ERGON, V37, P669, DOI 10.1016/j.apergo.2005.08.001; Lewis PJ, 2014, BRIT J CLIN PHARMACO, V78, P310, DOI 10.1111/bcp.12332; Maidment ID, 2005, PSYCHIATR BULL, V29, P298, DOI 10.1192/pb.29.8.298; McGinty EE, 2015, SCHIZOPHR RES, V165, P227, DOI 10.1016/j.schres.2015.04.010; McLeod M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128958; Mezulis AH, 2004, PSYCHOL BULL, V130, P711, DOI 10.1037/0033-2909.130.5.711; Mojtabai R, 2010, ARCH GEN PSYCHIAT, V67, P26, DOI 10.1001/archgenpsychiatry.2009.175; National Collaborating Centre for Mental Health, 2012, SERV US EXP AD MENT; National Institute for Health and Care Excellence, 2014, SAF STAFF NURS AD IN; Ozkan S, 2011, J NURS CARE QUAL, V26, P136, DOI 10.1097/NCQ.0b013e3182031006; Parameswaran SG, 2015, ADM POLICY MENT HLTH, V42, P288, DOI 10.1007/s10488-014-0569-x; Peusschers E, 2015, AUSTRALAS PSYCHIATRY, V23, P142, DOI 10.1177/1039856214568215; Pincus HA, 2016, HEALTH AFFAIR, V35, P1000, DOI 10.1377/hlthaff.2016.0027; Raban MZ, 2014, BMJ QUAL SAF, V23, P414, DOI 10.1136/bmjqs-2013-002118; Reason J., 1990, HUMAN ERROR; Reason J., 1997, MANAGING RISKS ORG A; Ritchie J, 1994, ANAL QUALITATIVE DAT, P172; Royal College of Nursing, 2010, GUID SAF NURS STAFF; Rutter L, 2015, SAFE STAFFING NURSIN; Rylander M, 2016, QUAL MANAG HEALTH CA, V25, P22, DOI 10.1097/QMH.0000000000000077; Sawamura K, 2005, PSYCHIAT CLIN NEUROS, V59, P379, DOI 10.1111/j.1440-1819.2005.01389.x; Simon M, 2014, EFFECTIVENESS MANAGE; Smetzer J, 2007, MEDICATION ERRORS, P513, DOI 10.21019/9781582120928.ch19; Taylor D, 2015, MAUDSLEY PRESCRIBING; THORNICROFT G, 2013, BMJ-BRIT MED J, V346, DOI DOI 10.1136/BMJ.F2969; Tully MP, 2009, DRUG SAFETY, V32, P819, DOI 10.2165/11316560-000000000-00000; Vigo D, 2016, LANCET PSYCHIAT, V3, P171, DOI 10.1016/S2215-0366(15)00505-2; World Health Organization, 2017, IMPR ACC APPR US MED	61	16	18	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2018	13	10							e0206233	10.1371/journal.pone.0206233	http://dx.doi.org/10.1371/journal.pone.0206233			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GY3KA	30365509	Green Published, Green Submitted, gold			2023-01-03	WOS:000448448700033
J	Stam, H; van der Wouden, JC; Hugtenburg, JG; Twisk, JWR; van der Horst, HE; Maarsingh, OR				Stam, Hanneke; van der Wouden, Johannes C.; Hugtenburg, Jacqueline G.; Twisk, Jos W. R.; van der Horst, Henriette E.; Maarsingh, Otto R.			Effectiveness of a multifactorial intervention for dizziness in older people in primary care: A cluster randomised controlled trial	PLOS ONE			English	Article							RISK-INCREASING DRUGS; DEPRESSIVE SYMPTOMS; CLINICAL-PRACTICE; ADULTS; FALLS; DISABILITY; FRAIL; VERTIGO; HEALTH; PARTICIPATION	Objectives Dizziness is common in older people. Physicians are often unable to identify a specific cause for dizziness in older people, even after an extensive diagnostic work-up. A prognosis-oriented approach, i.e. treating modifiable risk factors for an unfavourable course of dizziness, may reduce dizziness-related impairment in older people in primary care. Design Cluster randomized controlled trial. Setting 45 primary care practices in The Netherlands. Participants 168 participants aged >= 65y who consulted their general practitioner for dizziness and experienced significant dizziness-related impairment (Dizziness Handicap Inventory (DHI) >= 30). Participants were part of to the intervention group (n = 83) or control group (n = 85), depending on whether they were enlisted in an intervention practice or in a control practice. Interventions The multifactorial intervention consisted of: medication adjustment in case of >= 3 prescribed fall-risk-increasing drugs (FRIDs) and/or stepped mental health care in case of anxiety disorder and/or depression and/or exercise therapy in case of impaired functional mobility. The intervention was compared to usual care. Outcome measures The primary outcome was dizziness-related impairment. Secondary outcomes were quality of life (QoL), dizziness frequency, fall frequency, anxiety and depression, use of FRIDs. Results Intention-to-treat analysis showed no significant intervention effect on dizziness-related impairment (DHI score difference -0.69 [95% CI -5.66; 4.28]; p = 0.79). The intervention proved effective in reducing the number of FRIDs (FRID difference -0.48 [95% CI -0.89;-0.06]; p = 0.02). No significant intervention effects were found on other secondary outcomes. The uptake of and adherence to the interventions was significantly lower in patients eligible for >= 2 interventions compared to patients eligible for one intervention (p<0.001). Conclusions The multifactorial intervention for dizziness in older patients showed no significant intervention effect on most outcomes and adherence to the multifactorial intervention was low. Although multifactorial treatment for older dizzy people seems promising in theory, we question its feasibility in daily practice. Future research could focus on a sequential treatment for dizziness, e.g. measuring effectiveness of various evidence-based therapies in a stepwise approach.	[Stam, Hanneke; van der Wouden, Johannes C.; van der Horst, Henriette E.; Maarsingh, Otto R.] Vrije Univ, Amsterdam Publ Hlth Res Inst, Amsterdam UMC, Dept Gen Practice & Elderly Care Med, Amsterdam, Netherlands; [Hugtenburg, Jacqueline G.] Vrije Univ, Amsterdam UMC, Dept Clin Pharmacol & Pharm, Amsterdam, Netherlands; [Twisk, Jos W. R.] Vrije Univ, Amsterdam UMC, Dept Clin Epidemiol & Biostat, Amsterdam, Netherlands	University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam	Stam, H (corresponding author), Vrije Univ, Amsterdam Publ Hlth Res Inst, Amsterdam UMC, Dept Gen Practice & Elderly Care Med, Amsterdam, Netherlands.	stam.h@vumc.nl	Maarsingh, Otto/AAD-1553-2022; van der Wouden, Johannes C/O-5109-2019	van der Wouden, Johannes C/0000-0001-6639-6050; Maarsingh, Otto/0000-0002-3747-9217	Netherlands Organisation for Health Research and Development [839110001]	Netherlands Organisation for Health Research and Development(Netherlands Organization for Health Research and Development)	This research project was funded by the Netherlands Organisation for Health Research and Development (project number 839110001). The funding body did not have any role in trial design, collection, analysis, or interpretation of data, nor in writing the manuscript.	Aggarwal NT, 2000, J GERONTOL A-BIOL, V55, pM288, DOI 10.1093/gerona/55.5.M288; Bhattacharyya N, 2017, OTOLARYNG HEAD NECK, V156, pS1, DOI 10.1177/0194599816689667; Campbell MK, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5661; Cigolle CT, 2007, ANN INTERN MED, V147, P156, DOI 10.7326/0003-4819-147-3-200708070-00004; Cooper JA, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009235; Croft P, 2015, BMC MED, V13, DOI 10.1186/s12916-014-0265-4; de Moraes SA, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-4; Deandrea S, 2010, EPIDEMIOLOGY, V21, P658, DOI 10.1097/EDE.0b013e3181e89905; Dros J, 2012, J AM GERIATR SOC, V60, P2263, DOI 10.1111/jgs.12031; Dros J, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-44; Fairhall N, 2014, AGE AGEING, V43, P616, DOI 10.1093/ageing/aft204; Ferrucci L, 2004, J AM GERIATR SOC, V52, P625, DOI 10.1111/j.1532-5415.2004.52174.x; Gassmann KG, 2009, J NUTR HEALTH AGING, V13, P278, DOI 10.1007/s12603-009-0073-2; Gomez F, 2011, J NUTR HEALTH AGING, V15, P490, DOI 10.1007/s12603-011-0050-4; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Johansson T, 2016, BRIT J CLIN PHARMACO, V82, P532, DOI 10.1111/bcp.12959; Kammerlind ASC, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0335-x; Kammerlind ASC, 2001, CLIN REHABIL, V15, P463, DOI 10.1191/026921501680425180; Kao AC, 2001, J AM GERIATR SOC, V49, P72, DOI 10.1046/j.1532-5415.2001.49012.x; Lasisi AO, 2010, J LARYNGOL OTOL, V124, P957, DOI 10.1017/S0022215110000538; Maarsingh OR, 2014, FRONT MED, V1, DOI 10.3389/fmed.2014.00050; Maarsingh OR, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-2; McDonnell MN, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005397.pub4; Moller UO, 2013, ARCH GERONTOL GERIAT, V56, P160, DOI 10.1016/j.archger.2012.08.013; Moller UO, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-97; Mueller M, 2014, QUAL LIFE RES, V23, P2301, DOI 10.1007/s11136-014-0684-x; Nyman SR, 2012, AGE AGEING, V41, P16, DOI 10.1093/ageing/afr103; Page AT, 2016, BRIT J CLIN PHARMACO, V82, P583, DOI 10.1111/bcp.12975; Phelan E, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-63; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Provencher V, 2014, ARCH GERONTOL GERIAT, V59, P18, DOI 10.1016/j.archger.2014.03.006; Sherrington C., 2016, BR J SPORTS MED; Sloane PD, 2001, ANN INTERN MED, V134, P823, DOI 10.7326/0003-4819-134-9_Part_2-200105011-00005; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Stam H, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0474-3; Stam H, 2016, SCAND J PRIM HEALTH, V34, P165, DOI 10.3109/02813432.2016.1160634; Stam H, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0848-1; Tamber AL, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-101; The National Institute for Health and Care Excellence, 2017, CLIN KNOWL SUMM VERT; Tinetti ME, 2000, ANN INTERN MED, V132, P337, DOI 10.7326/0003-4819-132-5-200003070-00002; Tinetti ME, 2000, J AM GERIATR SOC, V48, P417, DOI 10.1111/j.1532-5415.2000.tb04700.x; Twisk JW, 2013, APPL LONGITUDINAL DA; van Beljouw IMJ, 2015, AM J GERIAT PSYCHIAT, V23, P807, DOI 10.1016/j.jagp.2014.09.012; Van der Velde N, 2007, BRIT J CLIN PHARMACO, V63, P232, DOI 10.1111/j.1365-2125.2006.02736.x; van der Weele GM, 2012, AGE AGEING, V41, P482, DOI 10.1093/ageing/afs027; van Vugt VA, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3727; Verheij AAA, 2002, HUISARTS WET, V45, P601; Versteegh MM, 2016, VALUE HEALTH, V19, P343, DOI 10.1016/j.jval.2016.01.003; Whitney SL, 2004, OTOL NEUROTOL, V25, P139, DOI 10.1097/00129492-200403000-00010	51	8	8	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2018	13	10							e0204876	10.1371/journal.pone.0204876	http://dx.doi.org/10.1371/journal.pone.0204876			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GW4OW	30300371	gold, Green Submitted, Green Published			2023-01-03	WOS:000446897200023
J	Yamamoto, T; Kadoya, N; Morishita, Y; Sato, Y; Matsushita, H; Umezawa, R; Ishikawa, Y; Takahashi, N; Katagiri, Y; Takeda, K; Jingu, K				Yamamoto, Takaya; Kadoya, Noriyuki; Morishita, Yohei; Sato, Yoshinao; Matsushita, Haruo; Umezawa, Rei; Ishikawa, Yojiro; Takahashi, Noriyoshi; Katagiri, Yu; Takeda, Ken; Jingu, Keiichi			Assessment and agreement of the CT appearance pattern and its severity grading of radiation-induced lung injury after stereotactic body radiotherapy for lung cancer	PLOS ONE			English	Article							RISK-FACTORS; THERAPY; PNEUMONITIS; TUMORS; TOXICITY; METAANALYSIS; PATIENT; SBRT	Purpose Radiographic severity of radiation-induced lung injury (RILI) has not been well-studied. The goal of this study was to assess the CT appearance pattern and severity of RILI without consideration of the clinical presentation. Material and methods A total of 49 patients, 41 with primary lung cancer and 8 with metastatic lung cancer, were treated by 4-fraction stereotactic body radiotherapy (SBRT). RILI after SBRT was separately assessed by two observers. The early and late CT appearance patterns and CT-based severity grading were explored. Results The median follow-up period was 39.0 months. In the early CT findings of observers 1 and 2, there was diffuse consolidation in 15 and 8, diffuse ground glass opacity (GGO) in 0 and 0, patchy consolidation and GGO in 17 and 20, patchy GGO in 3 and 3, and no changes in 10 and 14, respectively (kappa = 0.61). In late CT findings of observer 1 and 2, there were modified conventional pattern in 28 and 24, mass-like pattern in 8 and 11, scar-like pattern in 12 and 12, and no changes in 1 and 2, respectively (kappa = 0.63). In the results of the CT-based grading by observers 1 and 2, there were grade 0 in 1 and 2, grade 1 in 10 and 14, grade 2 in 31 and 29, grade 3 in 7 and 4, and none of grade 4 or more, respectively (kappa = 0.66). According to multivariate analyses (MVA), the significant predicting factors of grade 2 or more CT-based RILI were age (p = 0.01), oxygen dependence (p = 0.03) and interstitial shadow (p = 0.03). Conclusions The agreement of the CT appearance and CT-based grading between two observers was good. These indicators may be able to provide us with more objective information and a better understanding of RILI.	[Yamamoto, Takaya; Kadoya, Noriyuki; Matsushita, Haruo; Umezawa, Rei; Ishikawa, Yojiro; Takahashi, Noriyoshi; Katagiri, Yu; Takeda, Ken; Jingu, Keiichi] Tohoku Univ, Grad Sch Med, Dept Radiat Oncol, Sendai, Miyagi, Japan; [Morishita, Yohei; Sato, Yoshinao] Tohoku Univ, Grad Sch Med, Dept Diagnost Radiol, Sendai, Miyagi, Japan	Tohoku University; Tohoku University	Yamamoto, T (corresponding author), Tohoku Univ, Grad Sch Med, Dept Radiat Oncol, Sendai, Miyagi, Japan.	t.yamamoto@rad.med.tohoku.ac.jp	Takahashi, Noriyoshi/GPP-0779-2022; Takeda, Ken/L-1914-2019; Yamamoto, Takaya/AAO-6488-2020	Yamamoto, Takaya/0000-0003-3562-1037				Aoki T, 2004, RADIOLOGY, V230, P101, DOI 10.1148/radiol.2301021226; Avanzo M, 2015, PHYS MEDICA, V31, P1, DOI 10.1016/j.ejmp.2014.10.006; Avanzo M, 2017, PHYS MEDICA, V42, P150, DOI 10.1016/j.ejmp.2017.09.127; Barriger RB, 2012, INT J RADIAT ONCOL, V82, P457, DOI 10.1016/j.ijrobp.2010.08.056; Bernchou U, 2017, RADIOTHER ONCOL, V123, P93, DOI 10.1016/j.radonc.2017.02.001; Cha JH, 2009, AM J ROENTGENOL, V193, pW95, DOI [10.2214/AJR.08.1833, 10.2214/AJR.08.2298]; Dahele M, 2015, ACTA ONCOL, V54, P1237, DOI 10.3109/0284186X.2014.1003961; Dahele M, 2011, J THORAC ONCOL, V6, P1221, DOI 10.1097/JTO.0b013e318219aac5; Deng GD, 2017, ONCOL LETT, V14, P501, DOI 10.3892/ol.2017.6268; Graves PR, 2010, SEMIN RADIAT ONCOL, V20, P201, DOI 10.1016/j.semradonc.2010.01.010; Guckenberger M, 2007, RADIOTHER ONCOL, V85, P435, DOI 10.1016/j.radonc.2007.10.044; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kimura T, 2012, BRIT J RADIOL, V85, P135, DOI 10.1259/bjr/32629867; Kundel HL, 2003, RADIOLOGY, V228, P303, DOI 10.1148/radiol.2282011860; Linda A, 2011, EUR J RADIOL, V79, P147, DOI 10.1016/j.ejrad.2009.10.029; Matsuo Y, 2012, INT J RADIAT ONCOL, V83, pE545, DOI 10.1016/j.ijrobp.2012.01.018; Nagata Y, 2009, INT J RADIAT ONCOL, V75, P343, DOI 10.1016/j.ijrobp.2009.02.087; Okubo M, 2017, BRIT J RADIOL, V90, DOI 10.1259/bjr.20160508; Palma DA, 2013, INT J RADIAT ONCOL, V85, P444, DOI 10.1016/j.ijrobp.2012.04.043; Pan H, 2011, CANCER-AM CANCER SOC, V117, P4566, DOI 10.1002/cncr.26067; Takeda A, 2008, RADIAT MED, V26, P504, DOI 10.1007/s11604-008-0261-8; Timmerman R, 2010, JAMA-J AM MED ASSOC, V303, P1070, DOI 10.1001/jama.2010.261; Trovo M, 2010, LUNG CANCER, V69, P77, DOI 10.1016/j.lungcan.2009.09.006; Vogelius IR, 2012, ACTA ONCOL, V51, P975, DOI 10.3109/0284186X.2012.718093; Wang JB, 2013, INT J RADIAT ONCOL, V85, P798, DOI 10.1016/j.ijrobp.2012.06.040; Yamaguchi S, 2013, LUNG CANCER, V82, P260, DOI 10.1016/j.lungcan.2013.08.024; Zhao J, 2016, INT J RADIAT ONCOL, V95, P1357, DOI 10.1016/j.ijrobp.2016.03.024	27	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2018	13	10							e0204734	10.1371/journal.pone.0204734	http://dx.doi.org/10.1371/journal.pone.0204734			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV8IQ	30286105	Green Published, gold, Green Submitted			2023-01-03	WOS:000446383500037
J	Yuda, M				Yuda, Michio			The medical assistance system and inpatient health care provision: Empirical evidence from short-term hospitalizations in Japan	PLOS ONE			English	Article							SUPPLIER-INDUCED DEMAND; INSURANCE EXPERIMENT; RED HERRINGS; COST; EXPENDITURES; POPULATION; MORTALITY; TIMES; VARIABLES; PAYMENTS	This paper uses two nationally representative sets of medical claims data from medical assistance and universal public health insurance systems to examine how medical assistance system assignment affects short-term inpatient health care provision. In Japan, the medical assistance system, which is part of a public assistance system, provides medical care services for its beneficiaries without imposing any financial burdens, such as copayments or advance premium payments. These circumstances can lead to inpatient costs, as physicians may provide more treatments because there is a financial incentive. Because the assignment of public assistance in Japan is not random but is subject to means testing by the local government, I employ the instrumental variable model to control the potential correlation. I find that medical expenditure is significantly higher for medical assistance patients than for universal public health insurance patients, with an arc elasticity of approximately 0.20. This elasticity is slightly greater than that found for inpatient care in the randomized RAND Health Insurance Experiment and recent empirical studies on low-income populations. In addition, the elasticities for patients who receive medication, treatment and surgery are greater.	[Yuda, Michio] Tohoku Univ, Grad Sch Econ & Management, Sendai, Miyagi, Japan	Tohoku University	Yuda, M (corresponding author), Tohoku Univ, Grad Sch Econ & Management, Sendai, Miyagi, Japan.	myuda@tohoku.ac.jp			Japan Society for the Promotion of Science [26780180]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This study is financially supported by the Grand-in-Aid for Young Scientists (B) (#26780180) from the Japan Society for the Promotion of Science. http://www.jsps.go.jp/english/e-grants/grants01.html.	Aron-Dine A, 2013, J ECON PERSPECT, V27, P197, DOI 10.1257/jep.27.1.197; Baker LC, 2000, J HUM RESOUR, V35, P480, DOI 10.2307/146389; Card D, 2009, Q J ECON, V124, P597, DOI 10.1162/qjec.2009.124.2.597; Chandra A, 2014, J HEALTH ECON, V33, P57, DOI 10.1016/j.jhealeco.2013.10.008; Choi MK, 2011, J HEALTH ECON, V30, P1020, DOI 10.1016/j.jhealeco.2011.08.002; CURRIE J, 1995, AM ECON REV, V85, P106; Currie J, 2009, J ECON LIT, V47, P87, DOI 10.1257/jel.47.1.87; Felder S, 2000, J HEALTH ECON, V19, P679, DOI 10.1016/S0167-6296(00)00039-4; Felder S, 2010, J HEALTH ECON, V29, P205, DOI 10.1016/j.jhealeco.2009.11.014; Finkelstein A, 2007, Q J ECON, V122, P1, DOI 10.1162/qjec.122.1.1; Finkelstein A, 2012, Q J ECON, V127, P1057, DOI 10.1093/qje/qjs020; Fukushima K, 2016, J HEALTH ECON, V45, P115, DOI 10.1016/j.jhealeco.2015.10.005; Gerdtham UG, 2006, ECON HUM BIOL, V4, P298, DOI 10.1016/j.ehb.2006.04.001; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; Granados JAT, 2008, DEMOGRAPHY, V45, P323, DOI 10.1353/dem.0.0008; Gross T, 2011, J PUBLIC ECON, V95, P767, DOI 10.1016/j.jpubeco.2011.01.012; Haaland VF, 2015, J HEALTH ECON, V39, P248, DOI 10.1016/j.jhealeco.2014.08.005; Hashimoto H, 2010, INT J ENV RES PUB HE, V7, P3022, DOI 10.3390/ijerph7083022; Hayashi M., 2012, NEW RISK SOCIAL SECU, P273; Hayashi M, 2011, INT J HEALTH CARE FI, V11, P287, DOI 10.1007/s10754-011-9098-2; HECKMAN JJ, 1978, ECONOMETRICA, V46, P931, DOI 10.2307/1909757; Iizuka T, 2007, RAND J ECON, V38, P844, DOI 10.1111/j.0741-6261.2007.00115.x; Iizuka T, 2012, AM ECON REV, V102, P2826, DOI 10.1257/aer.102.6.2826; Kan M, 2010, JPN WORLD ECON, V22, P1, DOI 10.1016/j.japwor.2009.06.005; Kawaguchi H., 2012, SEIJO EC REV, V196, P59; Keeler EB, 1988, RAND PUBLICATION SER; Kondo A, 2013, J PUBLIC ECON, V99, P1, DOI 10.1016/j.jpubeco.2012.12.004; Kumagai N., 2002, J HLTH CARE SOC, V12, P39, DOI [10.4091/iken1991.12.3_39, DOI 10.4091/IKEN1991.12.3_39]; Lubitz J, 1984, Health Care Financ Rev, V5, P117; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; MANNING WG, 1987, AM ECON REV, V77, P251; National Institute of Population and Social Security Studies, 2014, SOC SEC JAP; NEWEY WK, 1990, J APPL ECONOM, V5, P99, DOI 10.1002/jae.3950050202; Newhouse JP, 1993, FREE ALL LESSONS RAN; Nishikawa M., 2010, AOYAMA J EC, V62, P195; Ruhm CJ, 2000, Q J ECON, V115, P617, DOI 10.1162/003355300554872; Ruhm CJ, 2005, J HEALTH ECON, V24, P341, DOI 10.1016/j.jhealeco.2004.09.007; Ruhm CJ, 2003, J HEALTH ECON, V22, P637, DOI 10.1016/S0167-6296(03)00041-9; Sato E, 2009, HEALTH ECON, V18, P843, DOI 10.1002/hec.1410; SCITOVSKY AA, 1984, MILBANK Q, V62, P591, DOI 10.2307/3349838; Shigeoka H, 2014, AM ECON REV, V104, P2152, DOI 10.1257/aer.104.7.2152; Shigeoka H, 2014, J HEALTH ECON, V35, P162, DOI 10.1016/j.jhealeco.2014.03.003; Suzuki W., 2007, J INCOME DISTRIB, V16, P88, DOI [10.25071/1874-6322.7232, DOI 10.25071/1874-6322.7232]; Takaku R, 2016, SOC SCI MED, V151, P46, DOI 10.1016/j.socscimed.2015.12.038; The Fiscal System Council, 2013, POL FISC YEAR 2013 B; The Government Revitalization Unit, 2011, SOC SEC REV PUBL ASS; Travis KM, 1999, ECON INQ, V37, P86, DOI 10.1111/j.1465-7295.1999.tb01418.x; Werblow A, 2007, HEALTH ECON, V16, P1109, DOI 10.1002/hec.1213; Wooldridge JM, 2010, ECONOMETRIC ANALYSIS OF CROSS SECTION AND PANEL DATA, 2ND EDITION, P1; Yuda M, 2013, 9 WORLD C INT HLTH E; Yuda M, 2013, HITOTSUB J ECON, V54, P79, DOI 10.15057/25780; Zweifel P, 1999, HEALTH ECON, V8, P485, DOI 10.1002/(SICI)1099-1050(199909)8:6<485::AID-HEC461>3.0.CO;2-4	53	4	4	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2018	13	10							e0204798	10.1371/journal.pone.0204798	http://dx.doi.org/10.1371/journal.pone.0204798			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GV8IQ	30286118	gold, Green Published, Green Submitted			2023-01-03	WOS:000446383500044
J	Heser, K; Pohontsch, NJ; Scherer, M; Loffler, A; Luck, T; Riedel-Heller, SG; Maier, W; Parker, D; Haenisch, B; Jessen, F				Heser, Kathrin; Pohontsch, Nadine Janis; Scherer, Martin; Loeffler, Antje; Luck, Tobias; Riedel-Heller, Steffi G.; Maier, Wolfgang; Parker, Debora; Haenisch, Britta; Jessen, Frank			Perspective of elderly patients on chronic use of potentially inappropriate medication - Results of the qualitative CIM-TRIAD study	PLOS ONE			English	Article							DECISION-MAKING; PRISCUS LIST; OLDER-ADULTS; DEMENTIA; MEDICINES; VIEWS	Although potentially inappropriate medication (PIM) is associated with risk of harm due to adverse effects, it is frequently prescribed for elderly patients. The aim of this qualitative multi-center study was to gain insight into contextual factors that might lead to chronic PIM use. We conducted semi-structured interviews with elderly patients with or without chronic PIM use (patient interviews: n = 52). Patients were between 86 and 96 years old. The participants were recruited from the AgeCoDe study. Interviews were audiotaped and transcribed verbatim. The transcripts of the interviews were analysed using qualitative content analysis. Deductive and inductive categories were determined. We found contextual factors related to the patient and related to patient-general practitioner (GP) communication that might lead to chronic PIM use (i.e., positive features of PIM, maintaining characteristics of medication intake, barriers to deprescribe PIM, external actors supporting PIM intake, system-related factors). Besides certain health-related behaviours (e.g., own obligation to report to GP) and medication-related attitudes and knowledge (e.g., awareness of side effects and interaction of medicines), patient-GP-interactions that were characterised by mutual agreements on drugs (e.g., concerning dosage or discontinuation of a drug) might be advantageous to reduce the probability of chronic PIM use. The results might assist in the development of guidelines and educational programs aiming to reduce PIM use in the elderly.	[Heser, Kathrin; Maier, Wolfgang] Univ Bonn, Dept Neurodegenerat Dis & Geriatr Psychiat, Bonn, Germany; [Pohontsch, Nadine Janis; Scherer, Martin] Univ Med Ctr Hamburg Eppendorf, Dept Gen Practice Primary Care, Hamburg, Germany; [Loeffler, Antje; Riedel-Heller, Steffi G.] Univ Leipzig, Inst Social Med Occupat Hlth & Publ Hlth ISAP, Leipzig, Germany; [Loeffler, Antje] Brandenburg Univ Technol BTU Cottbus Senftenberg, Inst Hlth Sci, Senftenberg, Germany; [Luck, Tobias] Univ Appl Sci Nordhausen, Dept Econ & Social Sci, Nordhausen, Germany; [Luck, Tobias] Univ Appl Sci Nordhausen, Inst Social Med Rehabil Sci & Healthcare Res ISRV, Nordhausen, Germany; [Parker, Debora; Haenisch, Britta; Jessen, Frank] German Ctr Neurodegenerat Dis DZNE, Bonn, Germany; [Haenisch, Britta] Fed Inst Drugs & Med Devices BfArM, Bonn, Germany; [Haenisch, Britta] Univ Bonn, Ctr Translat Med, Bonn, Germany; [Jessen, Frank] Univ Cologne, Dept Psychiat & Psychotherapy, Cologne, Germany	University of Bonn; University of Hamburg; University Medical Center Hamburg-Eppendorf; Leipzig University; Brandenburg University of Technology Cottbus; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Bonn; University of Cologne	Heser, K (corresponding author), Univ Bonn, Dept Neurodegenerat Dis & Geriatr Psychiat, Bonn, Germany.	Kathrin.Heser@ukbonn.de; frank.jessen@uk-koeln.de	Riedel-Heller, Steffi/ABG-1537-2021; Pohontsch, Nadine/AAK-6573-2020; Jessen, Frank/AAK-6170-2020	Luck, Tobias/0000-0001-7551-4397	German Federal Ministry of Education and Research [01GY1311A, 01GY1311B, 01GY1311C, KND 01GI0102, 01GI0420, 01GI0422, 01GI0423, 01GI0429, 01GI0431, 01GI0433, 01GI0434, 01GI0710, 01GI0711, 01GI0712, 01GI0713, 01GI0714, 01GI0715, 01GI0716, 01GY1322A, 01GY1322B, 01GY1322C, 01GY1322D, 01GY1322E, 01GY1322F, 01GY1322G]	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	This work is part of the CIM-TRIAD study that was funded by the German Federal Ministry of Education and Research (https://www.bmbf.de/; grants: 01GY1311A, 01GY1311B, 01GY1311C) and is published in affiliation with the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe; funded by the German Federal Ministry of Education and Research; grants KND 01GI0102, 01GI0420, 01GI0422, 01GI0423, 01GI0429, 01GI0431, 01GI0433, 01GI0434; grants KNDD 01GI0710, 01GI0711, 01GI0712, 01GI0713, 01GI0714, 01GI0715, 01GI0716; and grants AgeQualiDe 01GY1322A, 01GY1322B, 01GY1322C, 01GY1322D, 01GY1322E, 01GY1322F, 01GY1322G). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amann U, 2012, DTSCH ARZTEBL INT, V109, P69, DOI 10.3238/arztebl.2012.0069; Britten N, 2000, BMJ-BRIT MED J, V320, P484, DOI 10.1136/bmj.320.7233.484; Chang CB, 2011, BRIT J CLIN PHARMACO, V72, P482, DOI 10.1111/j.1365-2125.2011.04010.x; Cook JM, 2007, J GEN INTERN MED, V22, P1094, DOI 10.1007/s11606-007-0205-5; Cook JM, 2007, J GEN INTERN MED, V22, P303, DOI 10.1007/s11606-006-0021-3; Dowell J, 1997, FAM PRACT, V14, P369, DOI 10.1093/fampra/14.5.369; Fried TR, 2008, J AM GERIATR SOC, V56, P1839, DOI 10.1111/j.1532-5415.2008.01923.x; Guthrie B, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3514; Holt S, 2010, DTSCH ARZTEBL INT, V107, P543, DOI 10.3238/arztebl.2010.0543; Jessen F, 2010, EUR ARCH PSY CLIN N, V260, pS111, DOI 10.1007/s00406-010-0156-4; Lau DT, 2005, ARCH INTERN MED, V165, P68, DOI 10.1001/archinte.165.1.68; Leydon GM, 2007, FAM PRACT, V24, P570, DOI 10.1093/fampra/cmm069; Luck T, 2014, ACTA PSYCHIAT SCAND, V129, P63, DOI 10.1111/acps.12129; Mah Leevin, 2002, BMC Fam Pract, V3, P9, DOI 10.1186/1471-2296-3-9; Mayring P, 2010, QUALITATIVE INHALTSA, DOI DOI 10.1007/978-3-531-92052-8_42; Modig S, 2012, BMC GERIATR, V12, DOI 10.1186/1471-2318-12-46; Moen J, 2009, PATIENT EDUC COUNS, V74, P135, DOI 10.1016/j.pec.2008.08.019; Pohontsch NJ, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-017-0595-3; Puening SE, 2017, J EMERG MED, V52, P66, DOI 10.1016/j.jemermed.2016.05.035; Spinewine A, 2005, BMJ-BRIT MED J, V331, P935, DOI 10.1136/bmj.38551.410012.06; Stevenson FA, 2000, SOC SCI MED, V50, P829, DOI 10.1016/S0277-9536(99)00376-7; Thorpe JM, 2012, AM J GERIATR PHARMAC, V10, P230, DOI 10.1016/j.amjopharm.2012.05.001; Verbeek-Heida PM, 2006, CHRONIC ILLN, V2, P133, DOI 10.1179/174592006X111003; Voigt K, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0482-3	24	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2018	13	9							e0202068	10.1371/journal.pone.0202068	http://dx.doi.org/10.1371/journal.pone.0202068			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GU3GJ	30231027	gold, Green Submitted, Green Published			2023-01-03	WOS:000445164300014
J	Mohr, E; Snyman, L; Mbakaz, Z; Caldwell, J; DeAzevedo, V; Kock, Y; Duran, LT; Venables, E				Mohr, Erika; Snyman, Leigh; Mbakaz, Zodwa; Caldwell, Judy; DeAzevedo, Virginia; Kock, Yulene; Duran, Laura Trivino; Venables, Emilie			"Life continues": Patient, health care and community care workers perspectives on self-administered treatment for rifampicin-resistant tuberculosis in Khayelitsha, South Africa	PLOS ONE			English	Article							EASTERN CAPE; HIV; ADHERENCE; SUPPORT; INTERVENTIONS; EXPERIENCES; PROVINCE; QUALITY; MODEL	Background Self-administered treatment (SAT), a differentiated model of care for rifampicin-resistant tuberculosis (RR-TB), might address adherence challenges faced by patients and health care systems. This study explored patient, health-care worker (HCW) and community care worker (CCW) perspectives on a SAT pilot programme in South Africa, in which patients were given medication to take at home with the optional support of a CCW. Methods We conducted a mixed-methods study from July 2016-June 2017. The quantitative component included semi-structured questionnaires with patients, HCWs and CCWs; the qualitative component involved in-depth interviews with patients enrolled in the pilot programme. Interviews were conducted in isiXhosa, translated, transcribed and manually coded. Results Overall, 27 patients, 12 HCWs and 44 CCWs were enrolled in the quantitative component; nine patients were also interviewed. Of the 27 patients who completed semi-structured questionnaires, 22 were HIV-infected and 17 received a monthly supply of RR TB treatment. Most HCWs and CCWs (10 and 32, respectively) understood the pilot programme; approximately half (n = 14) of the patients could not correctly describe the pilot programme. Overall, 11 and 41 HCWs and CCWs reported that the pilot programme promoted treatment adherence. Additionally, 11 HCWs reported that the pilot programme relieved pressure on the clinic. Key qualitative findings highlighted the importance of a support person and how the flexibility of SAT enabled integration of treatment into their daily routines and reduced time spent in clinics. The pilot programme was also perceived to allow patients more autonomy and made it easier for them to manage side-effects. Conclusion The SAT pilot programme was acceptable from the perspective of patients, HCWs and CCWs and should be considered as a differentiated model of care for RR-TB, particularly in settings with high burdens of HIV, in order to ease management of treatment for patients and health-care providers.	[Mohr, Erika; Snyman, Leigh; Mbakaz, Zodwa; Duran, Laura Trivino] MSF, Khayelitsha, South Africa; [Caldwell, Judy; DeAzevedo, Virginia] City Cape Town Hlth Dept, Cape Town, South Africa; [Kock, Yulene] Prov Govt Western Cape Dept Hlth, Cape Town, South Africa; [Venables, Emilie] MSF, Southern Africa Med Unit, Cape Town, South Africa; [Venables, Emilie] UCT, Div Social & Behav Sci, Sch Publ Hlth & Family Med, Cape Town, South Africa	Doctors Without Borders; Doctors Without Borders; University of Cape Town	Mohr, E (corresponding author), MSF, Khayelitsha, South Africa.	msfocb-khayelitsha-drtb-epi@brussels.msf.org		Mohr, Erika/0000-0001-5269-6503				Attride-Stirling J., 2001, QUAL RES, V1, P385; Benbaba S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144936; Cape Town City Health, 2013, CIT CAP TOWN 2011 CE; Chaulk CP, 2016, INT J TUBERC LUNG D, V20, P1141, DOI 10.5588/ijtld.16.0503; Cox H, 2014, INT J TUBERC LUNG D, V18, P441, DOI 10.5588/ijtld.13.0742; Crowley T, 2015, AFR J PRIM HEALTH CA, V7, DOI [10.4102/phcfm.v7i1.807, 10.4102/PHCFM.V7I1.807]; Decroo T, 2011, JAIDS-J ACQ IMM DEF, V56, pE39, DOI 10.1097/QAI.0b013e3182055138; Grimsrud A, 2016, JAIDS-J ACQ IMM DEF, V71, pE16, DOI 10.1097/QAI.0000000000000863; Heunis C, 2013, AJAR-AFR J AIDS RES, V12, P113, DOI 10.2989/16085906.2013.855641; Horter S, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-81; HSE National Drug Treatment Centre, 2016, CERV SMEAR GUID; Inzaule SC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167492; Isaakidis P, 2013, TROP MED INT HEALTH, V18, P1128, DOI 10.1111/tmi.12146; Isaakidis P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040781; Kader R, 2014, AIDS BEHAV, V18, P525, DOI 10.1007/s10461-013-0587-9; Kaplan R, 2016, INT J TUBERC LUNG D, V20, P1185, DOI 10.5588/ijtld.15.0855; Kendall EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083480; Kibaara C, 2016, AIDS RES TREAT, V2016, DOI 10.1155/2016/9124541; Medecins Sans Frontieres, 2016, SELF ADM TREATM DRUG; Medecins Sans Frontieres, 2011, SCAL UP DIAGN TREATM; Mohr E, 2015, SAMJ S AFR MED J, V105, P631, DOI [10.7196/SAMJNEW.7803, 10.7196/SAMJnew.7803, 10.7196/samj.10093]; Mohr E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178054; Mohr E, 2015, T ROY SOC TROP MED H, V109, P425, DOI 10.1093/trstmh/trv037; Morton D, 2015, J PSYCHOL AFR, V25, P104, DOI 10.1080/14330237.2015.1021509; Moyo S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118919; National Department of Health, 2013, REP S AFRICA MAN DRU; Pellecchia U, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21374; Peltzer K, 2011, J PSYCHOL AFR, V21, P53, DOI 10.1080/14330237.2011.10820429; Plano Clark V. L., 2010, DESIGNING CONDUCTING, V2nd; Ramma L, 2015, INT J TUBERC LUNG D, V19, P1513, DOI 10.5588/ijtld.15.0341; Reuter A, 2017, INT J TUBERC LUNG D, V21, P1114, DOI 10.5588/ijtld.17.0468; Sanchez-Padilla E, 2014, INT J TUBERC LUNG D, V18, P160, DOI 10.5588/ijtld.13.0369; Scott V, 2012, SAMJ S AFR MED J, V102, P837, DOI [10.7196/SAMJ.5469, 10.7196/samj.5469]; Shean K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063057; Shringarpure KS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150849; Snyman L, 2018, INT J TUBERC LUNG D, V22, P1023, DOI 10.5588/ijtld.17.0826; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Tupasi T, 2017, INT J TUBERC LUNG D, V21, P23, DOI 10.5588/ijtld.16.0433; Wilkinson L, 2016, TROP MED INT HEALTH, V21, P743, DOI 10.1111/tmi.12699; World Health Organization, 2014, COMPANION HDB WHO GU; Yin J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150511	41	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2018	13	9							e0203888	10.1371/journal.pone.0203888	http://dx.doi.org/10.1371/journal.pone.0203888			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GT7EG	30216368	Green Submitted, Green Published, gold			2023-01-03	WOS:000444683700039
J	Sparby, T; Ott, U				Sparby, Terje; Ott, Ulrich			A qualitative study of motivations for meditation in anthroposophic practitioners	PLOS ONE			English	Article							MINDFULNESS	Research on meditation is advancing, but few studies about the motivations of meditators exist. Additionally, many forms and traditions of meditation have yet to be investigated. This study addresses both of these issues by presenting an overview of different forms of motivations found in contemporary Anthroposophic meditation practice. 30 Anthroposophic meditators were interviewed about their meditation experiences. The interviews were examined using thematic analysis. 14 data-driven themes were extracted and organized within a framework consisting of three superordinate theory-driven forms of motivation: External, internal and service. A developmental trajectory running from external and internal to service motivations is indicated. This approach improves upon a scheme developed by Shapiro by including additional types of motivations and being able to differentiate between forms of motivations that are fundamentally different: Self-related (heteronomous and autonomous) motivations and other-related motivations.	[Sparby, Terje; Ott, Ulrich] Univ Giessen, Bender Inst Neuroimaging, Giessen, Hessen, Germany; [Sparby, Terje] Witten Herdecke Univ, Dept Psychol & Psychotherapy, Witten, Germany	Justus Liebig University Giessen	Sparby, T (corresponding author), Univ Giessen, Bender Inst Neuroimaging, Giessen, Hessen, Germany.; Sparby, T (corresponding author), Witten Herdecke Univ, Dept Psychol & Psychotherapy, Witten, Germany.	terje.sparby@gmail.com	Ott, Ulrich/AAC-1262-2021	Ott, Ulrich/0000-0002-2140-6056	Mind and Life Institute; Rudolf Steinerstiftelsen; Vidarstiftelsen; Anthroposophische Gesellschaft in Deutschland	Mind and Life Institute; Rudolf Steinerstiftelsen; Vidarstiftelsen; Anthroposophische Gesellschaft in Deutschland	This study was funded by the following and received by TS: Mind and Life Institute (2014 Varela Awards), Rudolf Steinerstiftelsen, Vidarstiftelsen and Anthroposophische Gesellschaft in Deutschland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baan B., 2008, EINE EINFUHRUNG; Bakhshani Nour Mohammad, 2015, Glob J Health Sci, V8, P142, DOI 10.5539/gjhs.v8n4p142; Barlow D, 2007, ACAD MANAGEMENT EXEC, DOI [10.5465/AME.2003.10954667, DOI 10.5465/AME.2003.10954667]; Bodhi B., 2000, NOBLE EIGHTFOLD PATH; Carmody J, 2009, J CLIN PSYCHOL, V65, P613, DOI 10.1002/jclp.20579; Deci E. L., 1985, INTRINSIC MOTIVATION; Deci EL, 2000, PSYCHOL INQ, V11, P227, DOI 10.1207/S15327965PLI1104_01; DeCuir-Gunby JT, 2011, FIELD METHOD, V23, P136, DOI 10.1177/1525822X10388468; Dehmelt A-K, 2013, DREI, V5; Dekkers H, 2010, ANTHROPOSOPHISCH MED; Eberth J, 2012, MINDFULNESS, V3, P174, DOI 10.1007/s12671-012-0101-x; Einleitung Clement C., 2015, SCHRIFTEN ERKENNTNIS, pXIX; Eliade M., 1959, SACRED PROFANE NATUR; Eliade M., 2012, RITES SYMBOLS INITIA; Elo S, 2008, J ADV NURS, V62, P107, DOI 10.1111/j.1365-2648.2007.04569.x; Faugier J, 1997, J ADV NURS, V26, P790, DOI 10.1046/j.1365-2648.1997.00371.x; Guest G., 2012, APPL THEMATIC ANAL, V3, P20, DOI DOI 10.4135/9781483384436; Hegel GWF, 1970, ENZYKLOPA PHILOS WIS; Heusser P, 2014, SEINE BEDEUTUNG WISS; Heusser P., 2016, HIST SEXUALITY; Hlewind G., 2003, LEITFADEN MEDITATION; Horowitz Maryanne C., 1998, SEEDS VIRTUE KNOWLED; Kant I., 1968, KRITIK PRAKTISCHEN V; Kruger Alexander Thiersch P., 2014, MITTEILUNGEN ANTHROP, V8-9, P9; Kuyken W, 2015, LANCET, V386, P63, DOI 10.1016/S0140-6736(14)62222-4; Leiberg S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017798; Lindahl JR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176239; Lindahl JR, 2014, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00973; Netzt B., 2012, THESIS; Orth U, 2008, J PERS SOC PSYCHOL, V95, P695, DOI 10.1037/0022-3514.95.3.695; OTIS LS, 1974, PSYCHOL TODAY, V7, P45; Pepping CA, 2016, WHY DO PEOPLE PRACTI, DOI [10.1007/s12671-016-0490-3, DOI 10.1007/S12671-016-0490-3]; Powers J., 2007, INTRO TIBETAN BUDDHI; Saldaua, 2016, CODING MANUAL QUALIT; Schickler J., 2005, ASHGATE NEW CRITICAL; Schiller PE, ANTHROPOSOPHISCHE SC; Schmidt D, 2010, LEBENSKRAFTE BILDEKR; Schmidt S, 2011, 4 EUR EC C INTMED BE; Schmidt Stefan., 2014, MEDITATION NEUROSCIE; Schneider JW, 2010, MEDITATION ASIATISCH; SHAPIRO DH, 1992, J TRANSPERSONAL PSY, V24, P23; Sijmons J., 2008, PHANOMENOLOGIE IDEAL; SOSKIS DA, 1989, INT J CLIN EXP HYP, V37, P285, DOI 10.1080/00207148908414483; Sparby T, 2017, STUD SPIRITUAL, V27, P195, DOI 10.2143/SIS.27.0.3254103; Sparby T, 2018, RELIGIONS, V9, DOI 10.3390/rel9080245; Sparby Terje, 2016, EPOCHE J HIST PHILOS, V21, P173, DOI [DOI 10.5840/EPOCHE201682970, 10.5840/]; Stace Walter T., 1961, MYSTICISM PHILOS; Staudenmeier Peter., 2014, OCCULTISM NAZISM ANT; Steiner R., 1996, INHALTEN ESOTERISCHE; Steiner R., 1975, THEOSOPHY INTRO SUPE; Steiner R., 1998, ED FOR SPECIAL NEEDS; Steiner R., 1997, RITUALTEXTE FEIERN F; Steiner R, 2011, OUTLINE OCCULT SCI; Steiner R., 1992, WIE ERLANGT MAN ERKE; Steiner R., 1995, THEOSOPHIE; Steiner R., 1999, GEHEIMNIS TRINITAT; Steiner R., 1995, HEILPA DAGOGISCHER K; Steiner R., 1994, MODERN PATH INITIATI; Steiner R., 1991, MYSTERY TRINITY MISS; Steiner Rudolf, 1989, GEHEIMWISSENSCHAFT U, VGA 13; Tart Charles., 2009, END MAT EVIDENCE PAR; Traub Hartmut, 2011, PHILOSOPHIE ANTHROPO; Tulku Rinpoche D., 2002, PRACTICE TIBETAN MED; Ustinova J., 2013, B I CLASS STUD, V56, P105; Van Gennep Arnold, 1960, RITES PASSAGE, P65, DOI [10.1007/s13398-014-0173-7.2, DOI 10.1007/S13398-014-0173-7.2]; Wagemann Johannes, 2011, ROSE RES STEINER ED, V2, P50; Weger U, 2015, NEW IDEAS PSYCHOL, V39, P23, DOI 10.1016/j.newideapsych.2015.07.002; Wehr G., 1983, ANTHROPOSOPHISCHE ER; Wood David W., 2015, CORRESPONDENCES, V3, P111; Yates J, 2015, A COMPLETE MEDITATIO; Zajonc A., 2009, MEDITATION CONTEMPLA; Zander H., 2007, ANTHROPOSOPHIE DTSCH	72	7	7	3	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2018	13	9							e0203184	10.1371/journal.pone.0203184	http://dx.doi.org/10.1371/journal.pone.0203184			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GT5KH	30212522	Green Published, Green Submitted, gold			2023-01-03	WOS:000444545800024
J	Chong, WT; Tang, CP; Cheah, YK; Lajis, AFB; Dian, NLHM; Kanagaratnam, S; Lai, OM				Chong, Wai-Ting; Tang, Chin-Ping; Cheah, Yoke-Kqueen; Lajis, Ahmad Firdaus B.; Dian, Noor Lida Habi Mat; Kanagaratnam, Sivaruby; Lai, Oi-Ming			Optimization of process parameters in preparation of tocotrienol-rich red palm oil-based nanoemulsion stabilized by Tween80-Span 80 using response surface methodology	PLOS ONE			English	Article							HIGH-PRESSURE HOMOGENIZATION; FOOD-GRADE MICROEMULSIONS; NANO-EMULSION FORMATION; IN-WATER NANOEMULSIONS; ALPHA-TOCOPHEROL; PHASE-BEHAVIOR; SPONTANEOUS EMULSIFICATION; ULTRASONIC EMULSIFICATION; PROPYLENE-GLYCOL; REQUIRED HLB	Red palm oil (RPO) is a natural source of Vitamin E (70-80% tocotrienol). It is a potent natural antioxidant that can be used in skin-care products. Its antioxidant property protects skin from inflammation and aging. In our work, a tocotrienol-rich RPO-based nanoemulsion formulation was optimized using response surface methodology (RSM) and formulated using high pressure homogenizer. Effect of the concentration of three independent variables [surfactant (5-15 wt%), co-solvent (10-30 wt%) and homogenization pressure (500-700 bar)] toward two response variables (droplet size, polydispersity index) was studied using central composite design (CCD) coupled to RSM. RSM analysis showed that the experimental data could be fitted into a second-order polynomial model and the coefficients of multiple determination (R-2) is 0.9115. The optimized formulation of RPO-based nanoemulsion consisted of 6.09 wt% mixed surfactant [Tween 80/Span 80 (63: 37, wt)], 20 wt% glycerol as a co-solvent via homogenization pressure (500 bar). The optimized tocotrienol-rich RPO-based nanoemulsion response values for droplet size and polydispersity index were 119.49nm and 0.286, respectively. The actual values of the formulated nanoemulsion were in good agreement with the predicted values obtained from RSM, thus the optimized compositions have the potential to be used as a nanoemulsion for cosmetic formulations.	[Chong, Wai-Ting; Lajis, Ahmad Firdaus B.; Lai, Oi-Ming] Univ Putra Malaysia, Inst Biosci, Serdang, Selangor, Malaysia; [Tang, Chin-Ping] Univ Putra Malaysia, Fac Food Sci & Technol, Dept Food Technol, Serdang, Selangor, Malaysia; [Cheah, Yoke-Kqueen] Univ Putra Malaysia, Dept Biomed Sci, Fac Med & Hlth Sci, Serdang, Selangor, Malaysia; [Dian, Noor Lida Habi Mat; Kanagaratnam, Sivaruby] Malaysian Palm Oil Board, Prot & Food Technol Unit, Kajang, Selangor, Malaysia; [Lai, Oi-Ming] Univ Putra Malaysia, Fac Biotechnol & Biomol Sci, Dept Bioproc Technol, Serdang, Selangor, Malaysia	Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Putra Malaysia; Malaysian Palm Oil Board; Universiti Putra Malaysia	Lai, OM (corresponding author), Univ Putra Malaysia, Inst Biosci, Serdang, Selangor, Malaysia.; Lai, OM (corresponding author), Univ Putra Malaysia, Fac Biotechnol & Biomol Sci, Dept Bioproc Technol, Serdang, Selangor, Malaysia.	omlai@upm.edu.my	Lajis, Ahmad Firdaus B./AAD-3717-2020; Tan, Chin-Ping/A-8130-2008; Lajis, Ahmad Firdaus B./T-7088-2018	Lajis, Ahmad Firdaus B./0000-0003-2766-8986; Tan, Chin-Ping/0000-0003-4177-4072; Lajis, Ahmad Firdaus B./0000-0003-2766-8986	Universiti Putra Malaysia, Malaysia (Putra Grant-Putra Graduate Initiative) [9622900]	Universiti Putra Malaysia, Malaysia (Putra Grant-Putra Graduate Initiative)	This project was financially supported by Universiti Putra Malaysia, Malaysia (Putra Grant-Putra Graduate Initiative, Grant No.: 9622900). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acosta E, 2009, CURR OPIN COLLOID IN, V14, P3, DOI 10.1016/j.cocis.2008.01.002; Ali A, 2016, INT J PHARMACEUT, V500, P291, DOI 10.1016/j.ijpharm.2016.01.035; Anarjan N, 2010, FOOD CHEM, V123, P477, DOI 10.1016/j.foodchem.2010.05.036; Aramaki K, 1999, LANGMUIR, V15, P6226, DOI 10.1021/la9900573; Ayeleso A. O., 2012, African Journal of Biotechnology, V11, P8275; Benichou A, 2001, J DISPER SCI TECHNOL, V22, P269, DOI 10.1081/DIS-100105214; Bergstrom M, 2000, LANGMUIR, V16, P7173, DOI 10.1021/la000397k; Bezerra MA, 2008, TALANTA, V76, P965, DOI 10.1016/j.talanta.2008.05.019; Bouchemal K, 2004, INT J PHARM, V280, P241, DOI 10.1016/j.ijpharm.2004.05.016; Cavalli R, 1996, J DISPER SCI TECHNOL, V17, P717, DOI 10.1080/01932699608943535; Chaturvedi PA, 2000, PLANT FOOD HUM NUTR, V55, P147, DOI 10.1023/A:1008197931085; Che HL, 2015, INT J ANAL CHEM, V2015, DOI 10.1155/2015/357609; Cheong JN, 2008, J FOOD ENG, V89, P204, DOI 10.1016/j.jfoodeng.2008.04.018; Choo YM, 1993, PORIM INF SER, V11; Choo YM, 1995, PALM OIL DEV, V22, P1; Chu BS, 2007, J AM OIL CHEM SOC, V84, P1053, DOI 10.1007/s11746-007-1132-7; Edem DO, 2009, EUR J SCI RES, P32; Eqbal Dauqan, 2011, American Journal of Applied Sciences, V8, P407; Fan YR, 2010, COLLOID SURFACE A, V366, P120, DOI 10.1016/j.colsurfa.2010.05.034; Fanun M, 2007, J DISPER SCI TECHNOL, V28, P1244, DOI 10.1080/01932690701528159; Floury J, 2003, J FOOD ENG, V58, P227, DOI 10.1016/S0260-8774(02)00372-2; Floury J., 2000, Innovative Food Science & Emerging Technologies, V1, P127, DOI 10.1016/S1466-8564(00)00012-6; Fu ZS, 2010, FUEL, V89, P2838, DOI 10.1016/j.fuel.2010.05.031; Garti N, 2001, J AGR FOOD CHEM, V49, P2552, DOI 10.1021/jf001390b; Genot C, 2013, WOODHEAD PUBL FOOD S, V252, P150, DOI 10.1533/9780857098863.2.150; GENSLER HL, 1991, NUTR CANCER, V15, P97, DOI 10.1080/01635589109514117; Gharibzahedi SMT, 2013, FOOD BIOPROCESS TECH, V6, P456, DOI 10.1007/s11947-011-0763-8; Gutierrez JM, 2008, CURR OPIN COLLOID IN, V13, P245, DOI 10.1016/j.cocis.2008.01.005; Hatanaka J, 2010, INT J PHARMACEUT, V396, P188, DOI 10.1016/j.ijpharm.2010.06.017; He J, 2016, INT J PSYCHOL, V51, P445, DOI 10.1002/ijop.12263; Hecht LL, 2011, LANGMUIR, V27, P2279, DOI 10.1021/la104480s; Hsieh CW, 2012, J OLEO SCI, V61, P483, DOI 10.5650/jos.61.483; Izquierdo P, 2005, J COLLOID INTERF SCI, V285, P388, DOI 10.1016/j.jcis.2004.10.047; Izquierdo P, 2004, LANGMUIR, V20, P6594, DOI 10.1021/la049566h; Jiang Q, 2014, FREE RADICAL BIO MED, V72, P76, DOI 10.1016/j.freeradbiomed.2014.03.035; Keck CM, 2006, EUR J PHARM BIOPHARM, V62, P3, DOI 10.1016/j.ejpb.2005.05.009; Kommuru TR, 2001, INT J PHARM, V212, P233, DOI 10.1016/S0378-5173(00)00614-1; Kosmadaki MG, 2004, MICRON, V35, P155, DOI 10.1016/j.micron.2003.11.002; Lee Junsoo, 2000, Journal of Food Composition and Analysis, V13, P45, DOI 10.1006/jfca.1999.0845; Li PH, 2012, ULTRASON SONOCHEM, V19, P192, DOI 10.1016/j.ultsonch.2011.05.017; Li QH, 2005, FOOD CHEM, V92, P701, DOI 10.1016/j.foodchem.2004.08.042; Lietz G, 2001, AM J CLIN NUTR, V74, P501; Liyana-Pathirana C, 2005, FOOD CHEM, V93, P47, DOI 10.1016/j.foodchem.2004.08.050; Maindarkar SN, 2013, CHEM ENG SCI, V89, P102, DOI 10.1016/j.ces.2012.12.001; Mao LK, 2009, FOOD TECHNOL BIOTECH, V47, P336; Mba OI, 2015, FOOD BIOSCI, V10, P26, DOI 10.1016/j.fbio.2015.01.003; McClements D. J., 2015, Food emulsions: principles, practices, and techniques; McClements DJ, 2018, ADV COLLOID INTERFAC, V251, P55, DOI 10.1016/j.cis.2017.12.001; McClements DJ, 2011, CRIT REV FOOD SCI, V51, P285, DOI 10.1080/10408398.2011.559558; McClements DJ, 2011, SOFT MATTER, V7, P2297, DOI 10.1039/c0sm00549e; Meganathan P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111682; Mohan S, 1997, J COLLOID INTERF SCI, V192, P1, DOI 10.1006/jcis.1997.5012; Morales D, 2003, LANGMUIR, V19, P7196, DOI 10.1021/la0300737; Nagendran B., 2000, Food and Nutrition Bulletin, V21, P189; Niemann B, 2010, J COLLOID INTERF SCI, V342, P361, DOI 10.1016/j.jcis.2009.10.066; Oguntibeju OO, 2009, BRIT J BIOMED SCI, V66, P216, DOI 10.1080/09674845.2009.11730279; Orafidiya LO, 2002, INT J PHARMACEUT, V237, P241, DOI 10.1016/S0378-5173(02)00051-0; Peh HY, 2016, PHARMACOL THERAPEUT, V162, P152, DOI 10.1016/j.pharmthera.2015.12.003; Petrovic LB, 2010, J COLLOID INTERF SCI, V342, P333, DOI 10.1016/j.jcis.2009.10.077; Pey CM, 2006, COLLOID SURFACE A, V288, P144, DOI 10.1016/j.colsurfa.2006.02.026; Pinheiro-Santana HMF, 1998, SOC BRAS CIENC E; Poletto FS, 2009, J NANOSCI NANOTECHNO, V9, P4933, DOI 10.1166/jnn.2009.1270; PORRETTA S, 1995, FOOD CHEM, V52, P35, DOI 10.1016/0308-8146(94)P4178-I; Preetz C, 2010, EUR J PHARM SCI, V39, P141, DOI 10.1016/j.ejps.2009.11.009; Qian C, 2011, FOOD HYDROCOLLOID, V25, P1000, DOI 10.1016/j.foodhyd.2010.09.017; Rao J, 2012, FOOD HYDROCOLLOID, V29, P326, DOI 10.1016/j.foodhyd.2012.04.008; Rebolleda S, 2015, FOOD CHEM, V167, P16, DOI 10.1016/j.foodchem.2014.06.097; Saberi AH, 2013, FOOD RES INT, V54, P812, DOI 10.1016/j.foodres.2013.08.028; Scamehorn JF, 1986, ANAL CHEM, V58, p1250A, DOI [10.1021/BK-1986-0311, DOI 10.1021/BK-1986-0311]; Schmidts T, 2010, COLLOID SURFACE A, V372, P48, DOI 10.1016/j.colsurfa.2010.09.025; SERBINOVA E, 1991, FREE RADICAL BIO MED, V10, P263, DOI 10.1016/0891-5849(91)90033-Y; Shi AM, 2011, CARBOHYD POLYM, V83, P1604, DOI 10.1016/j.carbpol.2010.10.011; Shibata A, 2010, J AGR FOOD CHEM, V58, P7013, DOI 10.1021/jf100691g; Solans C, 2005, CURR OPIN COLLOID IN, V10, P102, DOI 10.1016/j.cocis.2005.06.004; Sole I, 2006, COLLOID SURFACE A, V288, P138, DOI 10.1016/j.colsurfa.2006.02.013; Sun MH, 2011, DRUG DEV IND PHARM, V37, P986, DOI 10.3109/03639045.2011.553618; SUNDRAM K, 1992, BRIT J NUTR, V68, P677, DOI 10.1079/BJN19920125; Sundram K, 2003, ASIA PAC J CLIN NUTR, V12, P355; Tadros T, 2004, ADV COLLOID INTERFAC, V108, P303, DOI 10.1016/j.cis.2003.10.023; Tan SF, 2016, ULTRASON SONOCHEM, V29, P299, DOI 10.1016/j.ultsonch.2015.09.015; Uskokovic V, 2005, SURF REV LETT, V12, P239, DOI 10.1142/S0218625X05007001; Wang LJ, 2009, J COLLOID INTERF SCI, V330, P443, DOI 10.1016/j.jcis.2008.10.077; Wooster TJ, 2008, LANGMUIR, V24, P12758, DOI 10.1021/la801685v; Yaghmur A, 2002, COLLOID SURFACE A, V209, P71, DOI 10.1016/S0927-7757(02)00168-1; Yamada Y, 2008, J NUTR SCI VITAMINOL, V54, P117, DOI 10.3177/jnsv.54.117; Yuan Y, 2008, FOOD RES INT, V41, P61, DOI 10.1016/j.foodres.2007.09.006	86	32	33	5	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2018	13	8							e0202771	10.1371/journal.pone.0202771	http://dx.doi.org/10.1371/journal.pone.0202771			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR5ZQ	30142164	Green Submitted, Green Published, gold			2023-01-03	WOS:000442722500030
J	Aboumatar, H; Naqibuddin, M; Chung, SN; Chaudhry, H; Kim, SW; Saunders, J; Bone, L; Gurses, AP; Knowlton, A; Pronovost, P; Putcha, N; Rand, C; Roter, D; Sylvester, C; Thompson, C; Wolff, JL; Hibbard, J; Wise, RA				Aboumatar, Hanan; Naqibuddin, Mohammad; Chung, Suna; Chaudhry, Hina; Kim, Samuel W.; Saunders, Jamia; Bone, Lee; Gurses, Ayse P.; Knowlton, Amy; Pronovost, Peter; Putcha, Nirupama; Rand, Cynthia; Roter, Debra; Sylvester, Carol; Thompson, Carol; Wolff, Jennifer L.; Hibbard, Judith; Wise, Robert A.			RETRACTED: Effect of a Program Combining Transitional Care and Long-term Self-management Support on Outcomes of Hospitalized Patients With Chronic Obstructive Pulmonary Disease A Randomized Clinical Trial (Retracted article. See vol. 322, pg. 1417, 2019)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper; Retracted Publication	Annual Meeting of the American-Public-Health-Association	NOV 10-14, 2018	San Diego, CA	Amer Public Hlth Assoc			UNITED-STATES; HEALTH-STATUS; COPD; INTERVENTIONS; REHOSPITALIZATION; EXACERBATIONS	IMPORTANCE Patients hospitalized for chronic obstructive pulmonary disease (COPD) exacerbations have high rehospitalization rates and reduced quality of life. OBJECTIVE To evaluate a hospital-initiated program that combined transition and long-term self-management support for patients hospitalized due to COPD and their family caregivers. DESIGN, SETTING, AND PARTICIPANTS This single-site randomized clinical trial was conducted in Baltimore, Maryland, with 240 participants. Participants were patients hospitalized due to COPD, randomized to intervention or usual care, and followed up for 6 months after hospital discharge. Enrollment occurred from March 2015 to May 2016; follow-up ended in December 2016. INTERVENTIONS The intervention (n = 120) was a comprehensive 3-month program to help patients and their family caregivers with long-term self-management of COPD. It was delivered by COPD nurses (nurses with special training on supporting patients with COPD using standardized tools). Usual care (n = 120) included transition support for 30 days after discharge to ensure adherence to discharge plan and connection to outpatient care. MAIN OUTCOMES AND MEASURES The primary outcome was number of COPD-related acute care events (hospitalizations and emergency department visits) per participant at 6 months. The co-primary outcome was change in participants' health-related quality of life measured by the St George's Respiratory Questionnaire (SGRQ) at 6 months after discharge (score, 0 [best] to 100 [worst]; 4-point difference is clinically meaningful). RESULTS Among 240 patients who were randomized (mean [SD] age, 64.9 [9.8] years; females, 61.7%), 203 (85%) completed the study. The mean (SD) baseline SGRQ score was 63.1 (19.9) in the intervention group and 62.6 (19.3) in the usual care group. The mean number of COPD-related acute care events per participant at 6 months was 0.72 (95% CI, 0.45-0.97) in the intervention group vs 1.40 (95% CI, 1.01-1.79) in the usual care group (difference, 0.68 [95% CI, 0.22 to 1.15]; P =.004). The mean change in participants' SGRQ total score at 6 months was -1.53 in the intervention and +5.44 in the usual care group (adjusted difference, -6.69 [95% CI, -12.97 to -0.40]; P =.04). During the study period, there were 15 deaths (intervention: 7; usual care: 8) and 337 hospitalizations (intervention: 135; usual care: 202). CONCLUSIONS AND RELEVANCE In a single-site randomized clinical trial of patients hospitalized due to COPD, a 3-month program that combined transition and long-term self-management support resulted in significantly fewer COPD-related hospitalizations and emergency department visits and better health-related quality of life at 6 months after discharge. Further research is needed to evaluate this intervention in other settings.	[Aboumatar, Hanan; Naqibuddin, Mohammad; Chung, Suna; Chaudhry, Hina; Kim, Samuel W.; Saunders, Jamia; Gurses, Ayse P.; Pronovost, Peter] Johns Hopkins Sch Med, Armstrong Inst Patient Safety & Qual, 750 E Pratt St,15th Floor, Baltimore, MD 21202 USA; [Aboumatar, Hanan] Johns Hopkins Sch Med, Div Gen Internal Med, Dept Med, Baltimore, MD USA; [Aboumatar, Hanan; Bone, Lee; Knowlton, Amy; Roter, Debra] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA; [Aboumatar, Hanan; Bone, Lee; Roter, Debra] Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA; [Aboumatar, Hanan; Pronovost, Peter; Wolff, Jennifer L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [Gurses, Ayse P.; Pronovost, Peter] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA; [Gurses, Ayse P.] Johns Hopkins Sch Med, Div Hlth Sci Informat, Baltimore, MD USA; [Gurses, Ayse P.] Johns Hopkins Univ, Malone Ctr Engn Healthcare, Whiting Sch Engn, Baltimore, MD USA; [Putcha, Nirupama; Rand, Cynthia; Wise, Robert A.] Johns Hopkins Sch Med, Pulm & Crit Care Med, Baltimore, MD USA; [Sylvester, Carol] Johns Hopkins Bayview Med Ctr, Baltimore, MD USA; [Thompson, Carol] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Biostat Ctr, Baltimore, MD USA; [Hibbard, Judith] Univ Oregon, Hlth Policy Res Grp, Eugene, OR 97403 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Oregon	Aboumatar, H (corresponding author), Johns Hopkins Sch Med, Armstrong Inst Patient Safety & Qual, 750 E Pratt St,15th Floor, Baltimore, MD 21202 USA.	habouma1@jhmi.edu		Wise, Robert/0000-0002-8353-2349	Patient-Centered Outcomes Research Institute (PCORI) [IHS 1304-7118]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL123594] Funding Source: NIH RePORTER	Patient-Centered Outcomes Research Institute (PCORI)(Patient-Centered Outcomes Research Institute - PCORI); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Funding was provided by the Patient-Centered Outcomes Research Institute (PCORI) (Award IHS 1304-7118).	Aboumatar H, 2017, CONTEMP CLIN TRIALS, V62, P159, DOI 10.1016/j.cct.2017.08.018; Aboumatar H, 2015, BRING ENG RES RUBR L; Bahadori Katayoon, 2007, Int J Chron Obstruct Pulmon Dis, V2, P241; Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585; Calverley Peter M A, 2005, COPD, V2, P143; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P421; Chapman KR, 2013, COPD, V10, P243, DOI 10.3109/15412555.2012.733463; Fan VS, 2012, ANN INTERN MED, V156, P673, DOI 10.7326/0003-4819-156-10-201205150-00003; Ford ES, 2013, CHEST, V144, P284, DOI 10.1378/chest.13-0809; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883; Jones PW, 2014, AM J RESP CRIT CARE, V189, P250, DOI 10.1164/rccm.201310-1863PP; JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6; Jones PW, 2002, EUR RESPIR J, V19, P398, DOI 10.1183/09031936.02.00063702; Kumbhare SD, 2016, CHRON OBSTR PULM DIS, V3, P539, DOI 10.15326/jcopdf.3.2.2015.0155; McGhan R, 2007, CHEST, V132, P1748, DOI 10.1378/chest.06-3018; Naylor MD, 2011, HEALTH AFFAIR, V30, P746, DOI 10.1377/hlthaff.2011.0041; Newham JJ, 2017, INT J CHRONIC OBSTR, V12, P1705, DOI 10.2147/COPD.S133317; Ospina MB, 2017, THORAX, V72, P31, DOI 10.1136/thoraxjnl-2016-208820; Pedersen Preben Ulrich, 2017, JBI Database System Rev Implement Rep, V15, P2060, DOI 10.11124/JBISRIR-2016-003045; Prieto-Centurion Valentin, 2014, Ann Am Thorac Soc, V11, P417, DOI 10.1513/AnnalsATS.201308-254OC; Rice KL, 2010, AM J RESP CRIT CARE, V182, P890, DOI 10.1164/rccm.200910-1579OC; Shah T, 2016, CHEST, V150, P916, DOI 10.1016/j.chest.2016.05.002; Spencer S, 2004, EUR RESPIR J, V23, P698, DOI 10.1183/09031936.04.00121404; Zwerink M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002990.pub3	25	34	36	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 11	2018	320	22					2335	2343		10.1001/jama.2018.17933	http://dx.doi.org/10.1001/jama.2018.17933			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	HD9GV	30419103	Bronze, Green Published			2023-01-03	WOS:000452870700017
J	Montastruc, F; Loo, SY; Renoux, C				Montastruc, Francois; Loo, Simone Y.; Renoux, Christel			Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Montastruc, Francois] Ctr Hosp Univ, Serv Pharmacol Med & Clin, Toulouse, France; [Loo, Simone Y.; Renoux, Christel] McGill Univ, Ctr Clin Epidemiol, Montreal, PQ, Canada	CHU de Toulouse; McGill University	Renoux, C (corresponding author), Jewish Gen Hosp, Ctr Clin Epidemiol, Lady Davis Inst, 3755 Cote Ste Catherine,Ste H-461, Montreal, PQ H3T 1E2, Canada.	christel.renoux@mcgill.ca	Montastruc, François/ABE-9903-2020	Montastruc, François/0000-0001-7056-8126	La Fondation Pierre Deniker; Toulouse University Hospital (CHU Toulouse)	La Fondation Pierre Deniker; Toulouse University Hospital (CHU Toulouse)	Dr Montastruc is the recipient of postdoctoral fellowships from La Fondation Pierre Deniker and Toulouse University Hospital (CHU Toulouse).	Gomes T, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002396; Goodman CW, 2017, NEW ENGL J MED, V377, P411, DOI 10.1056/NEJMp1704633; Herrett E, 2015, INT J EPIDEMIOL, V44, P827, DOI 10.1093/ije/dyv098; IACOBUCCI G, 2017, BMJ-BRIT MED J, V358, P1454, DOI DOI 10.1136/BMJ.J4441; Johansen ME, 2018, JAMA INTERN MED, V178, P292, DOI 10.1001/jamainternmed.2017.7856; Wallach JD, 2018, JAMA-J AM MED ASSOC, V319, P776, DOI 10.1001/jama.2017.21897	6	59	59	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	2018	320	20					2149	2151		10.1001/jama.2018.12358	http://dx.doi.org/10.1001/jama.2018.12358			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB9ET	30480717	Bronze, Green Published			2023-01-03	WOS:000451395000026
J	Martin, P; Tamblyn, R; Benedetti, A; Ahmed, S; Tannenbaum, C				Martin, Philippe; Tamblyn, Robyn; Benedetti, Andrea; Ahmed, Sara; Tannenbaum, Cara			Effect of a Pharmacist-Led Educational Intervention on Inappropriate Medication Prescriptions in Older Adults The D-PRESCRIBE Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BEERS CRITERIA; SAMPLE-SIZE; PHYSICIAN; SCALES	IMPORTANCE High rates of inappropriate prescribing persist among older adults in many outpatient settings, increasing the risk of adverse drug events and drug-related hospitalizations. OBJECTIVE To compare the effectiveness of a consumer-targeted, pharmacist-led educational intervention vs usual care on discontinuation of inappropriate medication among community-dwelling older adults. DESIGN, SETTING, AND PARTICIPANTS A cluster randomized trial (D-PRESCRIBE [Developing Pharmacist-Led Research to Educate and Sensitize Community Residents to the Inappropriate Prescriptions Burden in the Elderly]) that recruited community pharmacies in Quebec, Canada, from February 2014 to September 2017, with follow-up until February 2018, and randomly allocated them to intervention or control groups. Patients included were adults aged 65 years and older who were prescribed 1 of 4 Beers Criteria medications (sedative-hypnotics, first-generation antihistamines, glyburide, or nonsteroidal anti-inflammatory drugs), recruited from 69 community pharmacies. Patients were screened and enrolled before randomization. INTERVENTIONS Pharmacists in the intervention group were encouraged to send patients an educational deprescribing brochure in parallel to sending their physicians an evidence-based pharmaceutical opinion to recommend deprescribing. The pharmacists in the control group provided usual care. Randomization occurred at the pharmacy level, with 34 pharmacies randomized to the intervention group (248 patients) and 35 to the control group (241patients). Patients, physicians, pharmacists, and evaluators were blinded to outcome assessment. MAIN OUTCOMES AND MEASURES Discontinuation of prescriptions for inappropriate medication at 6 months, ascertained by pharmacy medication renewal profiles. RESULTS Among 489 patients (mean age, 75 years; 66% women), 437 (89%) completed the trial (219 [88%] in the intervention group vs 218 [91%) in the control group). At 6 months, 106 of 248 patients (43%) in the intervention group no longer filled prescriptions for inappropriate medication compared with 29 of 241(12%) in the control group (risk difference, 31% [95% CI, 23% to 38%]). In the intervention vs control group, discontinuation of inappropriate medication occurred among 63 of 146 sedative-hypnotic drug users (43.2%) vs 14 of 155 (9.0%), respectively (risk difference, 34% [95% CI, 25% to 43%]); 19 of 62 glyburide users (30.6%) vs 8 of 58 (13.8%), respectively (risk difference, 17% [95% CI, 2% to 31%]); and 19 of 33 nonsteroidal anti-inflammatory drug users (57.6%) vs 5 of 23 (21.7%), respectively (risk difference, 35% [95% CI, 10% to 55%]) (p for interaction = .09). Analysis of the antihistamine drug class was not possible because of the small sample size (n = 12). No adverse events requiring hospitalization were reported, although 29 of 77 patients (38%) who attempted to taper sedative-hypnotics reported withdrawal symptoms. CONCLUSIONS AND RELEVANCE Among older adults in Quebec, a pharmacist-led educational intervention compared with usual care resulted in greater discontinuation of prescriptions for inappropriate medication after 6 months. The generalizability of these findings to other settings requires further research.	[Martin, Philippe; Tannenbaum, Cara] Univ Montreal, Fac Pharm, Montreal, PQ, Canada; [Tamblyn, Robyn; Benedetti, Andrea] McGill Univ, Dept Med, Montreal, PQ, Canada; [Benedetti, Andrea] McGill Univ, Dept Epidemiol, Montreal, PQ, Canada; [Benedetti, Andrea] McGill Univ, Dept Biostat & Occupat Hlth, Montreal, PQ, Canada; [Benedetti, Andrea] McGill Univ, Resp Epidemiol & Clin Res Unit, Hlth Ctr, Montreal, PQ, Canada; [Ahmed, Sara] McGill Univ, Fac Med, Sch Phys & Occupat Therapy, Montreal, PQ, Canada; [Tannenbaum, Cara] Univ Montreal, Fac Med, Montreal, PQ, Canada	Universite de Montreal; McGill University; McGill University; McGill University; McGill University; McGill University; Universite de Montreal	Tannenbaum, C (corresponding author), Inst Univ Geriatrie Montreal, Ctr Rech, 4545 Queen Mary Rd, Montreal, PQ H3W 1W5, Canada.	cara.tannenbaum@umontreal.ca			Canadian Institutes of Health Research Grant [CIHR 201303MOP-299872-KTR]	Canadian Institutes of Health Research Grant(Canadian Institutes of Health Research (CIHR))	This study was funded by Canadian Institutes of Health Research Grant CIHR 201303MOP-299872-KTR.	Allard J, 2001, CAN MED ASSOC J, V164, P1291; American Pharmacists Association, 2019, BILL PRIM PHARM GUID; Anderson K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006544; Avery AJ, 2012, LANCET, V379, P1310, DOI 10.1016/S0140-6736(11)61817-5; Daniel SB, 2011, NEW ENGL J MED, V365, P2002, DOI 10.1056/NEJMsa1103053; Canadian Foundation for Pharmacy, 2017, CHANG FAC PHARM FEES; Canadian Institute for Health Information, 2018, DRUG USE SEN CAN 201; Canadian Pharmacist Association, 2016, REV PHARM SERV CAN H; Cheng AYY, 2013, CAN J DIABETES, V37, pS1, DOI 10.1016/j.jcjd.2013.01.009; COCKRELL JR, 1988, PSYCHOPHARMACOL BULL, V24, P689; Curran HV, 2003, PSYCHOL MED, V33, P1223, DOI 10.1017/S0033291703008213; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; Eldridge SM, 2006, INT J EPIDEMIOL, V35, P1292, DOI 10.1093/ije/dyl129; Hanlon JT, 1996, AM J MED, V100, P428, DOI 10.1016/S0002-9343(97)89519-8; Kaur S, 2009, DRUG AGING, V26, P1013, DOI 10.2165/11318890-000000000-00000; Krska J, 2001, AGE AGEING, V30, P205, DOI 10.1093/ageing/30.3.205; Martin P, 2018, CAN PHARM J, V151, P133, DOI 10.1177/1715163518755813; Martin P, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-015959; Martin P, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0791-1; Martin P, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-80; McAlister FA, 2000, JAMA-J AM MED ASSOC, V283, P2829, DOI 10.1001/jama.283.21.2829; Monane M, 1998, JAMA-J AM MED ASSOC, V280, P1249, DOI 10.1001/jama.280.14.1249; Patel R, 2018, CONSULT PHARM, V33, P48, DOI 10.4140/TCP.n.2018.48; Radcliff S, 2015, J AM GERIATR SOC, V63, P2227, DOI 10.1111/jgs.13702; Rat C, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-301; Saliba D, 2001, J AM GERIATR SOC, V49, P1691, DOI 10.1046/j.1532-5415.2001.49281.x; Schnipper JL, 2012, LANCET, V379, P1278, DOI 10.1016/S0140-6736(12)60078-6; Scott IA, 2015, JAMA INTERN MED, V175, P827, DOI 10.1001/jamainternmed.2015.0324; Spinewine A, 2012, DRUG AGING, V29, P495, DOI 10.2165/11631720-000000000-00000; Sussman JB, 2015, JAMA INTERN MED, V175, P1942, DOI 10.1001/jamainternmed.2015.5110; Tamblyn R, 2012, J AM MED INFORM ASSN, V19, P635, DOI 10.1136/amiajnl-2011-000609; Tannenbaum C, 2014, JAMA INTERN MED, V174, P890, DOI 10.1001/jamainternmed.2014.949; Tannenbaum C, 2013, CAN MED ASSOC J, V185, P1228, DOI 10.1503/cmaj.121990; Ukoumunne OC, 2008, STAT MED, V27, P5143, DOI 10.1002/sim.3359; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Zhang YZ, 2018, PHARMACY, V6, DOI 10.3390/pharmacy6020031	36	157	161	2	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2018	320	18					1889	1898		10.1001/jama.2018.16131	http://dx.doi.org/10.1001/jama.2018.16131			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HA1BH	30422193	Bronze, Green Published			2023-01-03	WOS:000449945900016
J	Sade-Feldman, M; Yizhak, K; Bjorgaard, SL; Ray, JP; de Boer, CG; Jenkins, RW; Lieb, DJ; Chen, JH; Frederick, DT; Barzily-Rokni, M; Freeman, SS; Reuben, A; Hoover, PJ; Villani, AC; Ivanova, E; Portell, A; Lizotte, PH; Aref, AR; Eliane, JP; Hammond, MR; Vitzthum, H; Blackmon, SM; Li, B; Gopalakrishnan, V; Reddy, SM; Cooper, ZA; Paweletz, CP; Barbie, DA; Stemmer-Rachamimov, A; Flaherty, KT; Wargo, JA; Boland, GM; Sullivan, RJ; Getz, G; Hacohen, N				Sade-Feldman, Moshe; Yizhak, Keren; Bjorgaard, Stacey L.; Ray, John P.; de Boer, Carl G.; Jenkins, Russell W.; Lieb, David J.; Chen, Jonathan H.; Frederick, Dennie T.; Barzily-Rokni, Michal; Freeman, Samuel S.; Reuben, Alexandre; Hoover, Paul J.; Villani, Alexandra-Chloe; Ivanova, Elena; Portell, Andrew; Lizotte, Patrick H.; Aref, Amir R.; Eliane, Jean-Pierre; Hammond, Marc R.; Vitzthum, Hans; Blackmon, Shauna M.; Li, Bo; Gopalakrishnan, Vancheswaran; Reddy, Sangeetha M.; Cooper, Zachary A.; Paweletz, Cloud P.; Barbie, David A.; Stemmer-Rachamimov, Anat; Flaherty, Keith T.; Wargo, Jennifer A.; Boland, Genevieve M.; Sullivan, Ryan J.; Getz, Gad; Hacohen, Nir			Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma	CELL			English	Article							PD-1 BLOCKADE; ANTITUMOR-ACTIVITY; CLINICAL-RESPONSE; CTLA-4 BLOCKADE; READ ALIGNMENT; TUMOR-CELLS; EXPRESSION; ANTI-PD-1; PROMOTES; LYMPHOCYTES	Treatment of cancer has been revolutionized by immune checkpoint blockade therapies. Despite the high rate of response in advanced melanoma, the majority of patients succumb to disease. To identify factors associated with success or failure of checkpoint therapy, we profiled transcriptomes of 16,291 individual immune cells from 48 tumor samples of melanoma patients treated with checkpoint inhibitors. Two distinct states of CD8(+) T cells were defined by clustering and associated with patient tumor regression or progression. A single transcription factor, TCF7, was visualized within CD8(+) T cells in fixed tumor samples and predicted positive clinical outcome in an independent cohort of checkpoint-treated patients. We delineated the epigenetic landscape and clonality of these T cell states and demonstrated enhanced antitumor immunity by targeting novel combinations of factors in exhausted cells. Our study of immune cell transcriptomes from tumors demonstrates a strategy for identifying predictors, mechanisms, and targets for enhancing checkpoint immunotherapy.	[Sade-Feldman, Moshe; Bjorgaard, Stacey L.; Jenkins, Russell W.; Frederick, Dennie T.; Barzily-Rokni, Michal; Villani, Alexandra-Chloe; Hammond, Marc R.; Vitzthum, Hans; Blackmon, Shauna M.; Flaherty, Keith T.; Boland, Genevieve M.; Sullivan, Ryan J.; Getz, Gad; Hacohen, Nir] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA; [Sade-Feldman, Moshe; Yizhak, Keren; Bjorgaard, Stacey L.; Ray, John P.; de Boer, Carl G.; Lieb, David J.; Chen, Jonathan H.; Freeman, Samuel S.; Hoover, Paul J.; Villani, Alexandra-Chloe; Li, Bo; Getz, Gad; Hacohen, Nir] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Sade-Feldman, Moshe; Jenkins, Russell W.; Villani, Alexandra-Chloe; Ivanova, Elena; Portell, Andrew; Lizotte, Patrick H.; Aref, Amir R.; Paweletz, Cloud P.; Barbie, David A.; Flaherty, Keith T.; Sullivan, Ryan J.; Hacohen, Nir] HMS, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA; [Jenkins, Russell W.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Chen, Jonathan H.; Eliane, Jean-Pierre; Stemmer-Rachamimov, Anat; Getz, Gad] HMS, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA; [Freeman, Samuel S.] HMS, Dept Biomed Informat, Boston, MA USA; [Reuben, Alexandre; Gopalakrishnan, Vancheswaran; Reddy, Sangeetha M.; Cooper, Zachary A.; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Hoover, Paul J.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA; [Ivanova, Elena; Portell, Andrew; Lizotte, Patrick H.; Aref, Amir R.; Paweletz, Cloud P.] Dana Farber Canc Inst, Belfer Ctr Appl Canc Sci, Boston, MA 02115 USA; [Li, Bo] Harvard Med Sch, Dept Virol, Boston, MA USA; [Cooper, Zachary A.; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Boland, Genevieve M.] HMS, Massachusetts Gen Hosp, Dept Surg, Boston, MA USA; [Getz, Gad] Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School	Getz, G; Hacohen, N (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA.; Getz, G; Hacohen, N (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Hacohen, N (corresponding author), HMS, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA.; Getz, G (corresponding author), HMS, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA.; Getz, G (corresponding author), Harvard Med Sch, Dept Pathol, Boston, MA 02115 USA.	gadgetz@broadinstitute.org; nhacohen@mgh.harvard.edu	Gopalakrishnan, Vancheswaran/S-9550-2019; Boland, Genevieve/AAP-2767-2021; Reddy, Sangeetha/GNZ-8658-2022; Ray, John/F-3187-2015	Gopalakrishnan, Vancheswaran/0000-0002-8704-035X; Ray, John/0000-0001-7294-4260; de Boer, Carl/0000-0001-8935-5921; Ivanova, Elena/0000-0002-5069-4974; Cooper, Zachary/0000-0003-1059-0940; Portell, Andrew/0000-0002-0757-909X; Reddy, Sangeetha/0000-0002-8401-1481; Freeman, Samuel/0000-0001-8285-0057	NIH Shared Instrumentation program [1S10OD012027-01A1, 1S10OD016372-01, 1S10RR020936-01, 1S10RR023440-01A1]; Broad Next-10; Cancer Research Institute (Clinic and Laboratory Integration Program); Adelson Medical Research Foundation; Sanofi; Arthur; Sandra; Sarah Irving; MGH; NIH/NHGRI [5U54HG003067]; NIH/NCI [R01CA208756, U54CA224068]; Institute for Medical Research Israel-Canada; Tosteson & Fund for Medical Discovery fellowships; Broad-ISF fellowship; NIH [F32AI129249, 1T32CA207021-01]; John R. Svenson Fellowship; NCI [R01 CA190394-01, U01 CA214381]; Expect Miracles Foundation; Weizmann award for Women in Science; NATIONAL CANCER INSTITUTE [U54CA224068, T32CA207021, R01CA208756, U01CA214381, R01CA190394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI129249] Funding Source: NIH RePORTER	NIH Shared Instrumentation program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Broad Next-10; Cancer Research Institute (Clinic and Laboratory Integration Program); Adelson Medical Research Foundation; Sanofi; Arthur; Sandra; Sarah Irving; MGH; NIH/NHGRI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Institute for Medical Research Israel-Canada; Tosteson & Fund for Medical Discovery fellowships; Broad-ISF fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); John R. Svenson Fellowship; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Expect Miracles Foundation; Weizmann award for Women in Science; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank the Genomics Platform of the Broad Institute of Harvard and MIT for the whole-exome sequencing performed in this study. All cytometric findings reported here were performed in the MGH Department of Pathology Flow and Image Cytometry Research Core, which obtained support from the NIH Shared Instrumentation program with grants 1S10OD012027-01A1, 1S10OD016372-01, 1S10RR020936-01, and 1S10RR023440-01A1. Additional thanks to Natasha Mathur of the Belfer Center for applied Cancer Sciences for assistance with immunofluorescence staining. The research was supported by grants from Broad Next-10 (N.H.), Cancer Research Institute (Clinic and Laboratory Integration Program, N.H.), Adelson Medical Research Foundation (N.H), Sanofi (N.H.), the David P. Ryan, MD, Chair funded by a gift from Arthur, Sandra, and Sarah Irving (N.H.), the Paul C. Zamecnick, MD, Chair in Oncology at MGH (G.G.), NIH/NHGRI (5U54HG003067, PIs: Stacey Gabriel and Eric S. Lander), NIH/NCI (R01CA208756, PI: N.H.; U54CA224068, PIs: Ryan Corcoran and K.T.F.). We also thank the following grants for their support: Institute for Medical Research Israel-Canada (M.S.-F.), Tosteson & Fund for Medical Discovery fellowships (M.S.-F.), the Broad-ISF fellowship (K.Y.) Weizmann award for Women in Science (K.Y.), NIH award number F32AI129249 (J.P.R.), 1T32CA207021-01 (J.H.C.), Robert A. and Renee E. Belfer (R.W.J.), John R. Svenson Fellowship (R.W.J.), NCI-R01 CA190394-01 (D.A.B.), NCI-U01 CA214381 (D.A.B., R.W.J.), and the Expect Miracles Foundation (C.P.P.).	Allard B, 2013, CLIN CANCER RES, V19, P5626, DOI 10.1158/1078-0432.CCR-13-0545; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Bastid J, 2015, CANCER IMMUNOL RES, V3, P254, DOI 10.1158/2326-6066.CIR-14-0018; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Callahan MK, 2016, IMMUNITY, V44, P1069, DOI 10.1016/j.immuni.2016.04.023; Canale FP, 2018, CANCER RES, V78, P115, DOI 10.1158/0008-5472.CAN-16-2684; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cibulskis K, 2011, BIOINFORMATICS, V27, P2601, DOI 10.1093/bioinformatics/btr446; Corces MR, 2016, NAT GENET, V48, P1193, DOI 10.1038/ng.3646; Costello M, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks1443; Daud AI, 2016, J CLIN INVEST, V126, P3447, DOI 10.1172/JCI87324; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Ellrott K, 2018, CELL SYST, V6, P271, DOI 10.1016/j.cels.2018.03.002; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gao JJ, 2016, CELL, V167, P397, DOI 10.1016/j.cell.2016.08.069; Gattinoni L, 2009, NAT MED, V15, P808, DOI 10.1038/nm.1982; Granek JA, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-10-r87; Gupta PK, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005177; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Huang AC, 2017, NATURE, V545, P60, DOI 10.1038/nature22079; Hurton LV, 2016, P NATL ACAD SCI USA, V113, pE7788, DOI 10.1073/pnas.1610544113; Im SJ, 2016, NATURE, V537, P417, DOI 10.1038/nature19330; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; Mami-Chouaib F, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0399-6; Marraco SAF, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00310; McGranahan N, 2017, CELL, V170, P825, DOI 10.1016/j.cell.2017.08.012; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Paley MA, 2012, SCIENCE, V338, P1220, DOI 10.1126/science.1229620; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Philip M, 2017, NATURE, V545, P452, DOI 10.1038/nature22367; Prat A, 2017, CANCER RES, V77, P3540, DOI 10.1158/0008-5472.CAN-16-3556; Qiu XJ, 2017, NAT METHODS, V14, P979, DOI [10.1038/NMETH.4402, 10.1038/nmeth.4402]; Ramos AH, 2015, HUM MUTAT, V36, pE2423, DOI 10.1002/humu.22771; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sade-Feldman M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01062-w; Sen DR, 2016, SCIENCE, V354, P1165, DOI 10.1126/science.aae0491; Sharma P, 2007, P NATL ACAD SCI USA, V104, P3967, DOI 10.1073/pnas.0611618104; Shum T, 2017, CANCER DISCOV, V7, P1238, DOI 10.1158/2159-8290.CD-17-0538; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Speiser DE, 2016, NAT REV IMMUNOL, V16, P500, DOI 10.1038/nri.2016.80; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; Sun XF, 2010, GASTROENTEROLOGY, V139, P1030, DOI 10.1053/j.gastro.2010.05.007; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Utzschneider DT, 2016, IMMUNITY, V45, P415, DOI 10.1016/j.immuni.2016.07.021; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Waugh KA, 2016, J IMMUNOL, V197, P1477, DOI 10.4049/jimmunol.1600589; Weirauch MT, 2014, CELL, V158, P1431, DOI 10.1016/j.cell.2014.08.009; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Young A, 2014, CANCER DISCOV, V4, P879, DOI 10.1158/2159-8290.CD-14-0341; Zhou XY, 2010, IMMUNITY, V33, P229, DOI 10.1016/j.immuni.2010.08.002	65	738	751	18	108	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 1	2018	175	4					998	+		10.1016/j.cell.2018.10.038	http://dx.doi.org/10.1016/j.cell.2018.10.038			36	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GZ1BO	30388456	Green Accepted, Bronze			2023-01-03	WOS:000449100600014
J	Barbar, SD; Clere-Jehl, R; Bourredjem, A; Hernu, R; Montini, F; Bruyere, R; Lebert, C; Bohe, J; Badie, J; Eraldi, JP; Rigaud, JP; Levy, B; Siami, S; Louis, G; Bouadma, L; Constantin, JM; Mercier, E; Klouche, K; du Cheyron, D; Piton, G; Annane, D; Jaber, S; van der Linden, T; Blasco, G; Mira, JP; Schwebel, C; Chimot, L; Guiot, P; Nay, MA; Meziani, F; Helms, J; Roger, C; Louart, B; Trusson, R; Dargent, A; Binquet, C; Quenot, JP				Barbar, S. D.; Clere-Jehl, R.; Bourredjem, A.; Hernu, R.; Montini, F.; Bruyere, R.; Lebert, C.; Bohe, J.; Badie, J.; Eraldi, J-P; Rigaud, J-P; Levy, B.; Siami, S.; Louis, G.; Bouadma, L.; Constantin, J-M; Mercier, E.; Klouche, K.; du Cheyron, D.; Piton, G.; Annane, D.; Jaber, S.; van der Linden, T.; Blasco, G.; Mira, J-P; Schwebel, C.; Chimot, L.; Guiot, P.; Nay, M-A; Meziani, F.; Helms, J.; Roger, C.; Louart, B.; Trusson, R.; Dargent, A.; Binquet, C.; Quenot, J-P		IDEAL-ICU Trial Investigators; CRICS TRIGG ERSEP Network	Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNATIONAL CONSENSUS CONFERENCE; CRITICALLY-ILL PATIENTS; ORGAN FAILURE; INITIATION; HEMOFILTRATION	BACKGROUND Acute kidney injury is the most frequent complication in patients with septic shock and is an independent risk factor for death. Although renal-replacement therapy is the standard of care for severe acute kidney injury, the ideal time for initiation remains controversial. METHODS In a multicenter, randomized, controlled trial, we assigned patients with early-stage septic shock who had severe acute kidney injury at the failure stage of the risk, injury, failure, loss, and end-stage kidney disease (RIFLE) classification system but without life-threatening complications related to acute kidney injury to receive renal-replacement therapy either within 12 hours after documentation of failure-stage acute kidney injury (early strategy) or after a delay of 48 hours if renal recovery had not occurred (delayed strategy). The failure stage of the RIFLE classification system is characterized by a serum creatinine level 3 times the baseline level (or >= 4 mg per deciliter with a rapid increase of >= 0.5 mg per deciliter), urine output less than 0.3 ml per kilogram of body weight per hour for 24 hours or longer, or anuria for at least 12 hours. The primary outcome was death at 90 days. RESULTS The trial was stopped early for futility after the second planned interim analysis. A total of 488 patients underwent randomization; there were no significant betweengroup differences in the characteristics at baseline. Among the 477 patients for whom follow-up data at 90 days were available, 58% of the patients in the early-strategy group (138 of 239 patients) and 54% in the delayed-strategy group (128 of 238 patients) had died (P = 0.38). In the delayed-strategy group, 38% (93 patients) did not receive renal-replacement therapy. Criteria for emergency renal-replacement therapy were met in 17% of the patients in the delayed-strategy group (41 patients). CONCLUSIONS Among patients with septic shock who had severe acute kidney injury, there was no significant difference in overall mortality at 90 days between patients who were assigned to an early strategy for the initiation of renal-replacement therapy and those who were assigned to a delayed strategy. (Funded by the French Ministry of Health; IDEAL-ICU ClinicalTrials.gov number, NCT01682590.)	[Barbar, S. D.; Louart, B.; Trusson, R.] CHU Nimes, Reanimat Med, Nimes, France; [Jaber, S.] Univ Montpellier, St Eloi CHU Montpellier, Montpellier, France; [Jaber, S.] INSERM, Unite 1046, Montpellier, France; [Klouche, K.] CHU Lapeyronie, Serv Reanimat Med, Montpellier, France; [Clere-Jehl, R.; Meziani, F.; Helms, J.] Univ Strasbourg, Fac Med, Hop Univ Strasbourg, Serv Reanimat,Nouvel Hop Civil, Strasbourg, France; [Bourredjem, A.; Dargent, A.; Quenot, J-P] Hop Univ Francois Mitterrand, Serv Med Intens Reanimat, Dijon, France; [Bourredjem, A.; Dargent, A.; Quenot, J-P] INSERM, Lipness Team, Res Ctr Lipids Nutr Canc, Unite Mixte Rech 1231, Dijon, France; [Bourredjem, A.; Dargent, A.; Quenot, J-P] Lab Excellence LipSTIC, Dijon, France; [Bourredjem, A.; Binquet, C.; Quenot, J-P] CHU Dijon Bourgogne, Ctr Invest Clin Epidemiol Clin, Dijon, France; [Bourredjem, A.; Binquet, C.; Quenot, J-P] Univ Bourgogne, INSERM, Ctr Invest Clin 1432, Dijon, France; [Hernu, R.] Hosp Civils Lyon, Hop Edouard Herriot, Reanimat Med, Lyon, France; [Montini, F.] Ctr Hosp Avignon, Reanimat Polyvalente, Avignon, France; [Bruyere, R.] Ctr Hosp Bourg En Bresse, Reanimat Polyvalente, Bourg En Bresse, France; [Lebert, C.] Ctr Hosp La Roche Sur Yon, Serv Med Intens Reanimat, La Roche Sur Yon, France; [Bohe, J.] Ctr Hosp Lyon Sud, Intens Care Unit, Hosp Civils Lyon, Pierre Benite, France; [Badie, J.] Hop Nord Franche Comte, Reanimat Polyvalente, Belfort, France; [Eraldi, J-P; Rigaud, J-P] Ctr Hosp Dieppe, Med Intens Reanimat, Dieppe, France; [Levy, B.] CHU Nancy Brabois, Serv Reanimat Med, Nancy, France; [Siami, S.] Ctr Hosp Etampes, Serv Anesthesie Reanimat, Etampes, France; [Louis, G.] Hop Bon Secours, Ctr Hosp Reg Metz, Reanimat Polyvalente, Metz, France; [Bouadma, L.] Univ Paris Diderot, Team Decis Sci Infect Dis Prevent Control & Care, Infect Antimicrobiens Modelisat Evolut, Sorbonne Paris Cite,Unite 1137, Paris, France; [Bouadma, L.] Bichat Claude Bernard Hosp, AP HP, Med & Infect Dis ICU, Paris, France; [Mira, J-P] Hop Cochin, Serv Reanimat Med, Paris, France; [Constantin, J-M] CHU Clermont Ferrand, Pole Med Perioperatoire, GReD, Clermont Ferrand, France; [Constantin, J-M] CHU Clermont Ferrand, INSERM, Unite 1103, Clermont Ferrand, France; [Mercier, E.] CHU Reg Tours, Serv Reanimat Med, Tours, France; [du Cheyron, D.] CHU Caen, Serv Reanimat Med, Caen, France; [Piton, G.] CHU Besancon, Serv Reanimat Med, Besancon, France; [Blasco, G.] CHU Besancon, Serv Reanimat Chirurg, Besancon, France; [Annane, D.] Hop Raymond Poincare, Serv Med Intens & Reanimat, Garches, France; [Annane, D.] Univ Versailles St Quentin En Yvelines, INSERM, Unite 1173, Lab Infect & Inflammat, Montigny Le Bretonneux, France; [van der Linden, T.] Univ Catholique Lille, Grp Hop, Inst Catholique Lille, Serv Med Intens Reanimat, Lille, France; [Schwebel, C.] CHU Grenoble, Serv Reanimat Med, Grenoble, France; [Chimot, L.] Ctr Hosp Perigueux, Serv Reanimat, Perigueux, France; [Guiot, P.] Ctr Hosp Gen Mulhouse, Serv Reanimat Polyvalente, Mulhouse, France; [Nay, M-A] Ctr Hosp Reg Orleans, Med Intens Reanimat, Orleans, France; [Nay, M-A] CHU Nimes, Reanimat Chirurg, Nimes, France	Universite de Montpellier; CHU de Nimes; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Dijon Bourgogne; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; CHU Lyon; CHD Vendee; CHU Lyon; CHU de Nancy; CHR Metz-Thionville; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Clermont Ferrand; CHU Clermont Ferrand; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Caen NORMANDIE; Universite de Caen Normandie; Universite de Franche-Comte; CHU Besancon; Universite de Franche-Comte; CHU Besancon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Universite Catholique de Lille; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Centre Hospitalier Regional d'Orleans; Universite de Montpellier; CHU de Nimes	Quenot, JP (corresponding author), Hop Univ Francois Mitterrand, Serv Med Intens Reanimat, Dijon, France.; Quenot, JP (corresponding author), INSERM, Lipness Team, Res Ctr Lipids Nutr Canc, Unite Mixte Rech 1231, Dijon, France.; Quenot, JP (corresponding author), Lab Excellence LipSTIC, Dijon, France.; Quenot, JP (corresponding author), CHU Dijon Bourgogne, Ctr Invest Clin Epidemiol Clin, Dijon, France.; Quenot, JP (corresponding author), Univ Bourgogne, INSERM, Ctr Invest Clin 1432, Dijon, France.		Carmen, Team3/Y-7384-2019; Louis, Guillaume/AAF-4340-2021; Dargent, Auguste/ABB-5690-2021; Nay, Mai-Anh/AAX-8128-2021; Binquet, Christine/E-8953-2018; Chiche, Jean-Daniel/P-5220-2017	Carmen, Team3/0000-0002-3614-0924; Louis, Guillaume/0000-0002-4208-8122; Dargent, Auguste/0000-0003-1784-1212; Binquet, Christine/0000-0002-9417-5754; Lab, Carmen/0000-0002-5935-3236; wallet, florent/0000-0003-3174-6246; QUENOT, Jean-Pierre/0000-0003-2351-682X; Helms, Julie/0000-0003-0895-6800; Barbar, Saber Davide/0000-0002-5089-8088; LEPAPE, Alain/0000-0001-5950-7533; MOURVILLIER, BRUNO/0000-0001-5227-1468; Chiche, Jean-Daniel/0000-0002-6433-6254; TERZI, Nicolas/0000-0003-4036-6245	French Ministry of Health; IDEAL-ICU	French Ministry of Health; IDEAL-ICU	Funded by the French Ministry of Health; IDEAL-ICU ClinicalTrials.gov number, NCT01682590.	Bagshaw SM, 2008, CRIT CARE, V12, DOI [10.1186/cc6268, 10.1186/cc6863]; Barbar SD, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-270; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413; Bellomo R, 2017, INTENS CARE MED, V43, P816, DOI 10.1007/s00134-017-4755-7; Brochard L, 2010, AM J RESP CRIT CARE, V181, P1128, DOI 10.1164/rccm.200711-1664ST; Dellepiane S, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1219-3; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Gaudry S, 2018, AM J RESP CRIT CARE, V198, P58, DOI 10.1164/rccm.201706-1255OC; Gaudry S, 2016, NEW ENGL J MED, V375, P122, DOI 10.1056/NEJMoa1603017; Hoste E, 2015, INTENS CARE MED, V41, P1411, DOI 10.1007/s00134-015-3934-7; Mehta RL, 2015, LANCET, V385, P2616, DOI 10.1016/S0140-6736(15)60126-X; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; Payen D, 2009, CRIT CARE MED, V37, P803, DOI 10.1097/CCM.0b013e3181962316; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Piccinni P, 2006, INTENS CARE MED, V32, P80, DOI 10.1007/s00134-005-2815-x; Quenot JP, 2013, CRIT CARE, V17, DOI 10.1186/cc12598; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wald R, 2015, KIDNEY INT, V88, P897, DOI 10.1038/ki.2015.184; Wald R, 2014, CRIT CARE MED, V42, P1933, DOI 10.1097/CCM.0000000000000432; Zarbock A, 2016, JAMA-J AM MED ASSOC, V315, P2190, DOI 10.1001/jama.2016.5828	22	290	316	5	59	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 11	2018	379	15					1431	1442		10.1056/NEJMoa1803213	http://dx.doi.org/10.1056/NEJMoa1803213			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GW4VQ	30304656	Green Submitted, Bronze			2023-01-03	WOS:000446923400007
J	Sager, ZS				Sager, Zachary S.			Nurturing Medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Sager, Zachary S.] VA Boston Healthcare Syst, New England Geriatr Res Educ & Clin Ctr, Div Geriatr & Palliat Care, Boston, MA USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Sager, ZS (corresponding author), Boston VA Healthcare Syst, 150 S Huntington Ave, Boston, MA 02130 USA.	zachary.sager2@va.gov							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2018	320	13					1325	1325		10.1001/jama.2018.13766	http://dx.doi.org/10.1001/jama.2018.13766			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV5LJ	30285182				2023-01-03	WOS:000446143400012
J	Sasaki, N; Sato, S; Yamaguchi, S; Shimodaira, M; Kawakami, N				Sasaki, Natsuki; Sato, Sayaka; Yamaguchi, Sosei; Shimodaira, Michiyo; Kawakami, Norito			Development of a scale to assess motivation for competitive employment among persons with severe mental illness	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; NEGATIVE SYNDROME SCALE; SUPPORTED EMPLOYMENT; INDIVIDUAL PLACEMENT; INTRINSIC MOTIVATION; PEOPLE; SCHIZOPHRENIA; DISORDERS; EXPERIENCES; PREDICTORS	Background The employment rate among people with severe mental illness has recently increased, though it is still low. The motivation to work appears to be an important role as an intermediate outcome measure in vocational rehabilitation programs. In addition, measuring the work motivation for people with severe mental illness appears to be essential to identify candidates who are likely to benefit and monitor candidates' motivation in a supported employment program. This study aimed to develop a new measure for assessing both intrinsic and extrinsic motivation to work among people with severe mental illness, as there are currently no well-established instruments of this kind. Methods A focus group interview and review of previous qualitative research were used to identify possible items for inclusion in the new scale. A provisional scale was constructed and further refined for content and format based on feedback from a researcher and also three peer workers with severe mental illness. The resulting provisional 38-item version of the scale was completed by 136 respondents with severe mental illness, and we performed exploratory factor analysis to identify latent constructs within the new measure. The finalized scale was analyzed for test-retest reliability, internal consistency, and convergent validity. Result An exploratory factor analysis yielded a four-factor scale with 23 items. The finalized 23 items had high internal consistency (Cronbach's alpha = 0.91) and relatively high test-retest reliability (ICC = 0.83). The four subscales had fair internal consistency (Cronbach's alpha >= 0.69) and good test-retest reliability (ICC >= 0.61). Convergent validity was weakly supported by the significant positive correlations with the overall question on motivation to work (r >= 0.19, p < 0.01). Besides these correlations, only the "Pressure from others" subscale was negatively and significantly correlated with the negative symptoms evaluated using the Positive and Negative Syndrome Scale (r = -0.18, p = 0.04). Conclusions This study used factor analysis to develop a new multidimensional scale assessing motivation for competitive employment among persons with severe mental illness. The scale showed acceptable levels of reliability and factor-based and convergent validity. The new measure can be used for measuring the motivation for competitive employment among people with severe mental illness, and it would be useful to identify candidates who are likely to benefit from a certain supported employment program, and to monitor interim progress of the state of participants' motivation in a program.	[Sasaki, Natsuki; Sato, Sayaka; Yamaguchi, Sosei] Natl Ctr Neurol & Psychiat, Natl Inst Mental Hlth, Dept Community Mental Hlth & Law, Kodaira, Tokyo, Japan; [Shimodaira, Michiyo; Kawakami, Norito] Univ Tokyo, Grad Sch Med, Dept Mental Hlth, Tokyo, Japan	National Center for Neurology & Psychiatry - Japan; University of Tokyo	Sasaki, N (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Mental Hlth, Dept Community Mental Hlth & Law, Kodaira, Tokyo, Japan.	natsuki.sasaki2018@gmail.com	Yamaguchi, Sosei/T-9439-2019	Yamaguchi, Sosei/0000-0002-0579-4431; Sasaki, Natsuki/0000-0001-8813-1432	Ministry of Health, Labour and Welfare in Japan - Policy research for improving the quality of community life of people with mental disorders [H28-001, H26-002]; Japan Society for the Promotion of Science KAKENHI [25871175]	Ministry of Health, Labour and Welfare in Japan - Policy research for improving the quality of community life of people with mental disorders; Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by 1. Ministry of Health, Labour and Welfare in Japan - Policy research for improving the quality of community life of people with mental disorders [no. H28-001] (S.S received the funding); - A study on facilitating employment for people with mental illness [no. H26-002] (S.Y received the funding), URL: https://mhlw-grants.niph.go.jp/; 2. Japan Society for the Promotion of Science KAKENHI Grant-in-Aid for Young Scientists [B]: Development of assessment tools and collecting of fundamental data which would be helpful for vocational services to support people with severe mental illness in community settings [no. 25871175] (S.S received the funding), URL: https://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-25871175/.	[Anonymous], 2016, ZENK ZAIT SHOUG SHA; [Anonymous], 2017, SYOG NO SYUG JYOK TO; [Anonymous], 2013, LAB FORC SURV JAP; [Anonymous], 2016, COMPREHENSIVE SUPPOR; Areberg C, 2013, SCAND J OCCUP THER, V20, P420, DOI 10.3109/11038128.2013.765911; Asahi M, 2009, THOUGHTS USERS STAFF; Auerbach ES, 2005, PSYCHIATR REHABIL J, V28, P267, DOI 10.2975/28.2005.267.273; Bedell JR, 1998, PSYCHIATR REHABIL J, V21, P279, DOI 10.1037/h0095301; Bejerholm U, 2017, J AFFECT DISORDERS, V207, P212, DOI 10.1016/j.jad.2016.08.028; Bond GR, 2012, WORLD PSYCHIATRY, V11, P32, DOI 10.1016/j.wpsyc.2012.01.005; Braveman B, 2005, WORKER ROLE INTERVIE; Burns JK, 2008, SOC PSYCH PSYCH EPID, V43, P331, DOI 10.1007/s00127-008-0308-2; Choi J, 2010, SCHIZOPHRENIA BULL, V36, P966, DOI 10.1093/schbul/sbp030; Choi KH, 2013, J NERV MENT DIS, V201, P173, DOI 10.1097/NMD.0b013e3182848bd4; Corson TR, 2017, IMPACT PERCEIVED MEN; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Crowther R, 2001, Cochrane Database Syst Rev, pCD003080, DOI 10.1002/14651858.CD003080; Davidson M, 2016, SCHIZOPHRENIA BULL, V42, P443, DOI 10.1093/schbul/sbv023; Drake RE, 2008, PSYCHIATR REHABIL J, V31, P367, DOI 10.2975/31.4.2008.367.376; Dunn EC, 2008, PSYCHIATR REHABIL J, V32, P59, DOI 10.2975/32.1.2008.59.62; Dunn EC, 2010, AM J ORTHOPSYCHIAT, V80, P185, DOI 10.1111/j.1939-0025.2010.01022.x; Fukuhara S., 2004, MANUAL SF 8 JAPANESE; HEINRICHS DW, 1984, SCHIZOPHRENIA BULL, V10, P388, DOI 10.1093/schbul/10.3.388; Howard LM, 2010, BRIT J PSYCHIAT, V196, P404, DOI 10.1192/bjp.bp.108.061465; Igarashi Y, 1998, PSYCHIAT CLIN NEUROS, V52, P467, DOI 10.1046/j.1440-1819.1998.00425.x; Japanese Ministry of Health LaW, 2013, SURV EMPL STAT PERS; Kageyama M, 2016, ARCH PSYCHIAT NURS, V30, P614, DOI 10.1016/j.apnu.2016.02.003; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kinoshita Y, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008297.pub2; Knaeps J, 2015, J MENT HEALTH, V24, P196, DOI 10.3109/09638237.2015.1036972; McQuilken M., 2003, J VOCAT REHABIL, V18, P59; Metcalfe JD, 2018, SCHIZOPHRENIA BULL, V44, P22, DOI 10.1093/schbul/sbx132; Metcalfe JD, 2017, ADM POLICY MENT HLTH, V44, P345, DOI 10.1007/s10488-016-0774-x; Nakatogawa S, 2009, JAPAN ACAD PSYCHIAT, V18, P70; Oshima I, 2014, PSYCHIATR REHABIL J, V37, P137, DOI 10.1037/prj0000085; Reddy LF, 2016, SCHIZOPHR RES, V176, P462, DOI 10.1016/j.schres.2016.08.006; Salkever DS, 2007, PSYCHIAT SERV, V58, P315, DOI 10.1176/appi.ps.58.3.315; Saperstein AM, 2011, J NERV MENT DIS, V199, P672, DOI 10.1097/NMD.0b013e318229d0eb; Scupin R., 1997, HUM ORGAN, V56, P2; Suzuki Y, 2008, WORK, V30, P185; Tremblay MA, 2009, CAN J BEHAV SCI, V41, P213, DOI 10.1037/a0015167; Waghorn G, 2007, BIPOLAR DISORD, V9, P166, DOI 10.1111/j.1399-5618.2007.00417.x; Ware JE, 2001, GLAXOSMITHKLINE SC S; Yamaguchi S, 2017, PSYCHOL MED, V47, P53, DOI 10.1017/S0033291716002063	44	3	3	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2018	13	10							e0204809	10.1371/journal.pone.0204809	http://dx.doi.org/10.1371/journal.pone.0204809			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GV3QJ	30278081	Green Submitted, Green Published, gold			2023-01-03	WOS:000446010200022
J	Vollbehr, NK; Bartels-Velthuis, AA; Nauta, MH; Castelein, S; Steenhuis, LA; Hoenders, HJR; Ostafin, BD				Vollbehr, Nina K.; Bartels-Velthuis, Agna A.; Nauta, Maaike H.; Castelein, Stynke; Steenhuis, Laura A.; Hoenders, H. J. Rogier; Ostafin, Brian D.			Hatha yoga for acute, chronic and/or treatment-resistant mood and anxiety disorders: A systematic review and meta-analysis	PLOS ONE			English	Review							COGNITIVE-BEHAVIORAL THERAPY; REPETITIVE NEGATIVE THINKING; RANDOMIZED CONTROLLED-TRIAL; REDUCE PRENATAL DEPRESSION; MAJOR DEPRESSION; DSM-IV; INDIVIDUAL PSYCHOTHERAPY; COMPLEMENTARY THERAPY; MINDFULNESS; WOMEN	Background The aim of this study was to systematically investigate the effectiveness of hatha yoga in treating acute, chronic and/or treatment-resistant mood and anxiety disorders. Methods Medline, Cochrane Library, Current Controlled Trials, Clinical Trials. gov, NHR Centre for Reviews and Dissemination, PsycINFO and CINAHL were searched through June 2018. Randomized controlled trials with patients with mood and anxiety disorders were included. Main outcomes were continuous measures of severity of mood and anxiety symptoms. Cohen's d was calculated as a measure of effect size. Meta-analyses using a random effects model was applied to estimate direct comparisons between yoga and control conditions for depression and anxiety outcomes. Publication bias was visually inspected using funnel plots. Results Eighteen studies were found, fourteen in acute patients and four in chronic patients. Most studies were of low quality. For depression outcomes, hatha yoga did not show a significant effect when compared to treatment as usual, an overall effect size of Cohen's d -0.64 (95% CI = -1.41, 0.13) or to all active control groups, Cohen's d -0.13 (95% CI = -0.49, 0.22). A sub-analysis showed that yoga had a significant effect on the reduction of depression compared to psychoeducation control groups, Cohen's d -0.52 (95% CI = -0.96, -0.08) but not to other active control groups, Cohen's d 0.28 (95% CI = -0.07, 0.63) For studies using a follow-up of six months or more, hatha yoga had no effect on the reduction of depression compared to active control groups, Cohen's d -0.14 (95% CI = -0.60, 0.33). Regarding anxiety, hatha yoga had no significant effect when compared to active control groups, Cohen's d -0.09 (95% CI = -0.47, 0.30). The I-2 and Q-statistic revealed heterogeneity amongst comparisons. Qualitative analyses suggest some promise of hatha yoga for chronic populations. Conclusions The ability to draw firm conclusions is limited by the notable heterogeneity and low quality of most of the included studies. With this caveat in mind, the results of the current meta-analysis suggest that hatha yoga does not have effects on acute, chronic and/or treatment-resistant mood and anxiety disorders compared to treatment as usual or active control groups. However, when compared to psychoeducation, hatha yoga showed more reductions in depression. It is clear that more high-quality studies are needed to advance the field.	[Vollbehr, Nina K.; Bartels-Velthuis, Agna A.; Hoenders, H. J. Rogier] Lentis Psychiat Inst, Ctr Integrat Psychiat, Groningen, Netherlands; [Vollbehr, Nina K.; Nauta, Maaike H.; Castelein, Stynke; Steenhuis, Laura A.; Ostafin, Brian D.] Univ Groningen, Fac Behav & Social Sci, Dept Clin Psychol & Expt Psychopathol, Groningen, Netherlands; [Bartels-Velthuis, Agna A.] Univ Groningen, Univ Med Ctr Groningen, Univ Ctr Psychiat, Rob Giel Res Ctr, Groningen, Netherlands; [Castelein, Stynke] Lentis Psychiat Inst, Lentis Res, Groningen, Netherlands	University of Groningen; University of Groningen	Vollbehr, NK (corresponding author), Lentis Psychiat Inst, Ctr Integrat Psychiat, Groningen, Netherlands.; Vollbehr, NK (corresponding author), Univ Groningen, Fac Behav & Social Sci, Dept Clin Psychol & Expt Psychopathol, Groningen, Netherlands.	n.vollbehr@lentis.nl		Castelein, Stynke/0000-0002-8419-568X; Hoenders, Rogier/0000-0001-5069-0239				Abrantes Ana M, 2012, Ment Health Phys Act, V5, P155; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU; American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, VThird; American Psychiatric Association, 1952, DIAGN STAT MAN MENT; American Psychiatric Association, 1968, DIAGN STAT MAN MENT, V2; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Angermeyer MC, 2005, SOC PSYCH PSYCH EPID, V40, P855, DOI 10.1007/s00127-005-0958-x; Arch JJ, 2006, BEHAV RES THER, V44, P1849, DOI 10.1016/j.brat.2005.12.007; Balasubramaniam Meera, 2012, Front Psychiatry, V3, P117, DOI 10.3389/fpsyt.2012.00117; Barnes PM, 2008, NATL HLTH STAT REPOR, P1; Baxter AJ, 2014, PSYCHOL MED, V44, P2363, DOI 10.1017/S0033291713003243; Beck A.T., 1996, MANUAL BDI 2, DOI [10.1037/t00742-000, DOI 10.1037/T00742-000]; BECKER BJ, 1988, BRIT J MATH STAT PSY, V41, P257, DOI 10.1111/j.2044-8317.1988.tb00901.x; Berlim MT, 2007, EUR NEUROPSYCHOPHARM, V17, P696, DOI 10.1016/j.euroneuro.2007.03.009; Borenstein M, 2009, INTRO META ANAL, DOI [10.1007/978-3-319-14908-0_2, DOI 10.1002/9780470743386]; Boyd RC, 2005, ARCH WOMEN MENT HLTH, V8, P141, DOI 10.1007/s00737-005-0096-6; Broota A, 1990, J PERS CLIN STUD, V6, P83; Brown TA, 1998, J ABNORM PSYCHOL, V107, P179, DOI 10.1037/0021-843X.107.2.179; Butler LD, 2008, J CLIN PSYCHOL, V64, P806, DOI 10.1002/jclp.20496; Bystritsky A, 2006, MOL PSYCHIATR, V11, P805, DOI 10.1038/sj.mp.4001852; Campbell-Sills L, 2006, EMOTION, V6, P587, DOI 10.1037/1528-3542.6.4.587; Carson JW, 2007, J PAIN SYMPTOM MANAG, V33, P331, DOI 10.1016/j.jpainsymman.2006.08.009; Carson JW, 2010, PAIN, V151, P530, DOI 10.1016/j.pain.2010.08.020; Carson JW, 2009, SUPPORT CARE CANCER, V17, P1301, DOI 10.1007/s00520-009-0587-5; CLARK LA, 1991, J ABNORM PSYCHOL, V100, P316, DOI 10.1037/0021-843X.100.3.316; COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666; Cooper AA, 2015, CLIN PSYCHOL REV, V40, P57, DOI 10.1016/j.cpr.2015.05.001; Cooper HM, 1994, HDB RES SYNTHESIS; Cramer H, 2018, DEPRESS ANXIETY, V35, P830, DOI 10.1002/da.22762; Cramer H, 2017, J AFFECT DISORDERS, V213, P70, DOI 10.1016/j.jad.2017.02.006; Cramer H, 2013, DEPRESS ANXIETY, V30, P1068, DOI 10.1002/da.22166; Crocq MA, 2015, DIALOGUES CLIN NEURO, V17, P319; Cuijpers P, 2016, PSYCHOL MED, V46, P3451, DOI 10.1017/S0033291716002348; Cuijpers P, 2013, CAN J PSYCHIAT, V58, P376, DOI 10.1177/070674371305800702; Cuijpers P, 2010, CLIN PSYCHOL REV, V30, P51, DOI 10.1016/j.cpr.2009.09.003; Cusin C, 2010, CURR CLIN PSYCHIAT, P7, DOI 10.1007/978-1-59745-387-5_2; da Silva TL, 2009, ASIAN J PSYCHIATR, V2, P6, DOI 10.1016/j.ajp.2008.12.002; de Graaf R, 2012, SOC PSYCH PSYCH EPID, V47, P203, DOI 10.1007/s00127-010-0334-8; Dhananjai S, 2013, Int J Yoga, V6, P66, DOI 10.4103/0973-6131.105949; Drost J, 2014, BEHAV RES THER, V63, P177, DOI 10.1016/j.brat.2014.06.004; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ehring T, 2008, INT J COGN THER, V1, P192, DOI 10.1680/ijct.2008.1.3.192; Evans S, 1996, J AFFECT DISORDERS, V38, P73, DOI 10.1016/0165-0327(95)00045-3; Falsafi N, 2016, J AM PSYCHIAT NURSES, V22, P483, DOI 10.1177/1078390316663307; Fava M, 1996, PSYCHIAT CLIN N AM, V19, P179, DOI 10.1016/S0193-953X(05)70283-5; Field T, 2013, J BODYW MOV THER, V17, P397, DOI 10.1016/j.jbmt.2013.03.010; Field T, 2012, J BODYW MOV THER, V16, P204, DOI 10.1016/j.jbmt.2011.08.002; Gersh E, 2017, J ANXIETY DISORD, V52, P25, DOI 10.1016/j.janxdis.2017.10.001; Gilmer WS, 2005, ACTA PSYCHIAT SCAND, V112, P425, DOI 10.1111/j.1600-0447.2005.00633.x; Goldberg DP, 2009, PSYCHOL MED, V39, P2043, DOI 10.1017/S0033291709990298; Gupta K, 2013, INT J RES AYURVEDA P, V4, P858, DOI [10.7897/2277-4343.04616, DOI 10.7897/2277-4343.04616]; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hawley LL, 2014, COGNITIVE THER RES, V38, P1, DOI 10.1007/s10608-013-9586-4; Helgadottir B, 2017, PREV MED, V105, P37, DOI 10.1016/j.ypmed.2017.08.008; Helgadottir B, 2016, PREV MED, V91, P123, DOI 10.1016/j.ypmed.2016.08.011; Hellerstein DJ, 2002, J AFFECT DISORDERS, V71, P85, DOI 10.1016/S0165-0327(01)00371-8; Herring MP, 2012, PSYCHOTHER PSYCHOSOM, V81, P21, DOI 10.1159/000327898; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hofmann SG, 2008, J CLIN PSYCHIAT, V69, P621, DOI 10.4088/jcp.v69n0415; Hofmann SG, 2010, J CONSULT CLIN PSYCH, V78, P169, DOI 10.1037/a0018555; Hofmann SG, 2009, INT J COGN THER, V2, P160, DOI 10.1521/ijct.2009.2.2.160; JACOBS KW, 1993, PSYCHOL REP, V73, P431, DOI 10.2466/pr0.1993.73.2.431; Kessler R.C., 2002, NEUROPSYCHOPHARMACOL, V67, P981; Kessler RC, 2001, AM J PSYCHIAT, V158, P289, DOI 10.1176/appi.ajp.158.2.289; Kessler RC, 2013, ANNU REV PUBL HEALTH, V34, P119, DOI 10.1146/annurev-publhealth-031912-114409; Kessler RC, 2012, INT J METH PSYCH RES, V21, P169, DOI 10.1002/mpr.1359; Kinser PA, 2014, ARCH PSYCHIAT NURS, V28, P377, DOI 10.1016/j.apnu.2014.08.014; Kinser PA, 2013, ARCH PSYCHIAT NURS, V27, P137, DOI 10.1016/j.apnu.2013.01.003; Kirkwood G, 2005, BRIT J SPORT MED, V39, P884, DOI 10.1136/bjsm.2005.018069; Lepine JP, 2002, J CLIN PSYCHIAT, V63, P4; Lowe B, 2004, MED CARE, V42, P1194, DOI 10.1097/00005650-200412000-00006; Mehta P, 2010, J EVID-BASED INTEGR, V15, P156, DOI 10.1177/1533210110387405; Mitchell J., 2012, PSYCHOLOGY, V3, P782, DOI DOI 10.4236/PSYCH.2012.329118; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Moher David, 2009, Open Med, V3, pe123; Parthasarathy S, 2014, W INDIAN MED J, V63, P78, DOI 10.7727/wimj.2012.054; Penninx BWJH, 2011, J AFFECT DISORDERS, V133, P76, DOI 10.1016/j.jad.2011.03.027; Pilkington K, 2005, J AFFECT DISORDERS, V89, P13, DOI 10.1016/j.jad.2005.08.013; Prathikanti S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173869; Ruhe HG, 2012, J AFFECT DISORDERS, V137, P35, DOI 10.1016/j.jad.2011.02.020; Sahasi G., 1989, J PERSONALITY CLIN S, V5, P51; Salmon P, 2009, COGN BEHAV PRACT, V16, P59, DOI 10.1016/j.cbpra.2008.07.002; SANTOR DA, 1995, PSYCHOL ASSESSMENT, V7, P131, DOI 10.1037/1040-3590.7.2.131; Sarubin N, 2014, J PSYCHIATR RES, V53, P76, DOI 10.1016/j.jpsychires.2014.02.022; Schuver KJ, 2016, COMPLEMENT THER MED, V26, P85, DOI 10.1016/j.ctim.2016.03.003; Sharma M, 2013, J EVID-BASED INTEGR, V18, P15, DOI 10.1177/2156587212460046; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Shohani M, 2018, INT J PREVENTIVE MED, V9, DOI 10.4103/ijpvm.IJPVM_242_16; Spijker J., 2012, MULTIDISCIPLINARY GU; Spinhoven P, 2015, J ANXIETY DISORD, V33, P45, DOI 10.1016/j.janxdis.2015.05.001; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Strauss C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096110; Tarrier N, 2004, BEHAV RES THER, V42, P1377, DOI 10.1016/j.brat.2004.06.020; Taylor S, 2012, J ANXIETY DISORD, V26, P583, DOI 10.1016/j.janxdis.2012.02.010; Tolahunase MR, 2018, RESTOR NEUROL NEUROS, V36, P423, DOI 10.3233/RNN-170810; Tsang HWH, 2008, BRIT J CLIN PSYCHOL, V47, P303, DOI 10.1348/014466508X279260; Uebelacker LA, 2017, PSYCHOL MED, V47, P2130, DOI 10.1017/S0033291717000575; Uebelacker LA, 2016, ARCH WOMEN MENT HLTH, V19, P543, DOI 10.1007/s00737-015-0571-7; Vahia N. S., 1973, INDIAN J PSYCHIAT, V15, P32; Viechtbauer W., 2010, METAFOR METAANALYSIS; Vollestad J, 2012, BRIT J CLIN PSYCHOL, V51, P239, DOI 10.1111/j.2044-8260.2011.02024.x; W.H. Organization, 1993, WHO APPL ICD 10 DEAT, V2; WATSON D, 1988, J ABNORM PSYCHOL, V97, P346, DOI 10.1037/0021-843X.97.3.346; Williams J.B.W., 2002, STRUCTURED CLIN INTE; Wittchen HU, 2002, DEPRESS ANXIETY, V16, P162, DOI 10.1002/da.10065; Wykes T, 2008, SCHIZOPHRENIA BULL, V34, P523, DOI 10.1093/schbul/sbm114	106	24	24	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2018	13	10							e0204925	10.1371/journal.pone.0204925	http://dx.doi.org/10.1371/journal.pone.0204925			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GV5EV	30273409	Green Published, Green Submitted, gold			2023-01-03	WOS:000446124700050
J	Vinding, RK; Stokholm, J; Sevelsted, A; Sejersen, T; Chawes, BL; Bonnelykke, K; Thorsen, J; Howe, LD; Krakauer, M; Bisgaard, H				Vinding, Rebecca Kofod; Stokholm, Jakob; Sevelsted, Astrid; Sejersen, Tobias; Chawes, Bo L.; Bonnelykke, Klaus; Thorsen, Jonathan; Howe, Laura D.; Krakauer, Martin; Bisgaard, Hans			Effect of fish oil supplementation in pregnancy on bone, lean, and fat mass at six years: randomised clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DHA SUPPLEMENTATION; AND/OR LACTATION; MATERNAL FISH; ACID INTAKE; FOLLOW-UP; BIRTH; GROWTH; INFANT; HEALTH; ADIPOSITY	OBJECTIVE To examine the effect of supplementation with n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) in pregnancy on anthropometry and body composition in offspring. DESIGN Double blinded, randomised controlled trial. SETTING Copenhagen Prospective Studies on Asthma in Childhood(2010) cohort. PARTICIPANTS 736 pregnant women and their offspring. INTERVENTION n-3 LCPUFA (fish oil) or control (olive oil) daily from pregnancy week 24 until one week after birth. MAIN OUTCOME MEASURES Height/length, weight, head, and waist measurements and body composition from dual energy x ray absorptiometry (all pre-specified secondary endpoints of the n-3 LCPUFA trial; the primary outcome for the trial was persistent wheeze/asthma). RESULTS The mean body mass index (BMI) z score was increased between age 0 and 6 years in the fish oil supplementation group compared with the control group (0.14 (95% confidence interval 0.04 to 0.23); P=0.006). At 6 years, supplementation was associated with a higher BMI z score (0.19 (0.06 to 0.32); P=0.004), a higher weight/height (3.48 (0.38 to 6.57) g/cm; P=0.03), and a larger waist circumference (0.6 (0.0 to 1.2) cm; P=0.04) but not a higher proportion of obese children, using International Obesity Task Force grades. The dual energy x ray absorptiometry scan at age 6 years showed a higher total mass (395.4 (86.6 to 704.3) g; P=0.01) in the supplementation versus the control group, explained by a higher lean mass (280.7 (98.9 to 462.4) g; P=0.002), a higher bone mineral content (10.3 (2.3 to 18.1) g; P=0.01), and a non-significantly higher fat mass (116.3 (-92.9 to 325.5) g; P=0.28), but no differences were seen in total body fat or lean mass percentage. CONCLUSION Fish oil supplementation from the 24th week of pregnancy led to a higher BMI in the offspring from 0 to 6 years of age but not an increased risk of obesity at age 6. The body composition at age 6 years in children given fish oil supplementation was characterised by a proportional increase in lean, bone, and fat mass suggesting a general growth stimulating effect of n-3 LCPUFA.	[Vinding, Rebecca Kofod; Stokholm, Jakob; Sevelsted, Astrid; Sejersen, Tobias; Chawes, Bo L.; Bonnelykke, Klaus; Thorsen, Jonathan; Bisgaard, Hans] Univ Copenhagen, Herlev & Gentofte Hosp, Copenhagen Prospect Studies Asthma Childhood, COPSAC, Copenhagen, Denmark; [Vinding, Rebecca Kofod; Sejersen, Tobias] Naestved Hosp, Dept Pediat, Naestved, Denmark; [Howe, Laura D.] Univ Bristol, Sch Social & Community Med, MRC Integrat Epidemiol Unit, Bristol, Avon, England; [Krakauer, Martin] Univ Copenhagen Hosp, Herlev & Gentofte Hosp, Dept Clin Physiol & Nucl Med, Copenhagen, Denmark	University of Copenhagen; Naestved Hospital; University of Bristol; University of Copenhagen	Bisgaard, H (corresponding author), Univ Copenhagen, Herlev & Gentofte Hosp, Copenhagen Prospect Studies Asthma Childhood, COPSAC, Copenhagen, Denmark.	bisgaard@copsac.com	Krakauer, Martin/M-4657-2019; Thorsen, Jonathan/AAQ-9269-2021; Bisgaard, Hans/N-4761-2016	Krakauer, Martin/0000-0002-2191-1861; Thorsen, Jonathan/0000-0003-0200-0461; Bonnelykke, Klaus/0000-0003-2003-1018; Howe, Laura/0000-0003-3357-2796; Bisgaard, Hans/0000-0003-4131-7592; Stokholm, Jakob/0000-0003-4989-9769	Lundbeck Foundation [R16-A1694]; Ministry of Health [903516]; Danish Council for Strategic Research [0603-00280B]; Capital Region Research Foundation; UK Medical Research Council career development award [MR/M020894/1]; UK Medical Research Council; University of Bristol [MC_UU_12013/5]; MRC [MR/M020894/1] Funding Source: UKRI	Lundbeck Foundation(Lundbeckfonden); Ministry of Health; Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF)); Capital Region Research Foundation; UK Medical Research Council career development award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University of Bristol; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	All funding received by COPSAC is listed on www.copsac.com. The Lundbeck Foundation (grant no R16-A1694), the Ministry of Health (grant no 903516), the Danish Council for Strategic Research (grant no 0603-00280B), and the Capital Region Research Foundation have provided core support to the COPSAC research centre. LDH is funded by a UK Medical Research Council career development award (MR/M020894/1) and works in a unit funded by the UK Medical Research Council and the University of Bristol (MC_UU_12013/5). The funding agencies did not have any role in the design and conduct of the trial; the collection, management, and interpretation of the data; or the preparation, review, or approval of the manuscript. No pharmaceutical company was involved in the trial.	Ailhaud G, 2006, PROG LIPID RES, V45, P203, DOI 10.1016/j.plipres.2006.01.003; Bergmann RL, 2012, J PERINAT MED, V40, P677, DOI 10.1515/jpm-2012-0080; Bisgaard H, 2013, CLIN EXP ALLERGY, V43, P1384, DOI 10.1111/cea.12213; Bisgaard H, 2016, NEW ENGL J MED, V375, P2530, DOI 10.1056/NEJMoa1503734; Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0; BONJOUR JP, 1994, OSTEOPOROSIS INT, V4, P7; Carlson SE, 2013, AM J CLIN NUTR, V97, P808, DOI 10.3945/ajcn.112.050021; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Delgado-Noguera MF, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007901.pub3; Gordon CM, 2014, J CLIN DENSITOM, V17, P219, DOI 10.1016/j.jocd.2014.01.007; Helland IB, 2008, PEDIATRICS, V122, pE472, DOI 10.1542/peds.2007-2762; Imhoff-Kunsch B, 2012, PAEDIATR PERINAT EP, V26, P91, DOI 10.1111/j.1365-3016.2012.01292.x; Kim HK, 2006, J NUTR, V136, P2965, DOI 10.1093/jn/136.12.2965; Lauritzen L, 2005, PEDIATR RES, V58, P235, DOI 10.1203/01.PDR.0000169978.92437.58; Lauritzen L, 2016, BRIT J NUTR, V116, P2082, DOI 10.1017/S0007114516004293; Lauritzen L, 2001, PROG LIPID RES, V40, P1, DOI 10.1016/S0163-7827(00)00017-5; Lemaitre RN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002193; Makrides M, 2010, JAMA-J AM MED ASSOC, V304, P1675, DOI 10.1001/jama.2010.1507; Marsal K, 1996, ACTA PAEDIATR, V85, P843, DOI 10.1111/j.1651-2227.1996.tb14164.x; Much D, 2013, PEDIATR RES, V74, P230, DOI 10.1038/pr.2013.82; Muhlhausler BS, 2011, PROSTAG LEUKOTR ESS, V85, P83, DOI 10.1016/j.plefa.2011.04.027; Muhlhausler BS, 2016, AM J CLIN NUTR, V103, P1489, DOI 10.3945/ajcn.115.126714; OLSEN SF, 1992, LANCET, V339, P1003, DOI 10.1016/0140-6736(92)90533-9; OLSEN SF, 1993, J EPIDEMIOL COMMUN H, V47, P436, DOI 10.1136/jech.47.6.436; Ong KK, 2006, HORM RES, V65, P65, DOI 10.1159/000091508; Rytter D, 2011, AM J CLIN NUTR, V94, P701, DOI 10.3945/ajcn.111.014969; Steer Colin D, 2012, Hum Mol Genet, V21, P1504, DOI 10.1093/hmg/ddr588; Stratakis N, 2014, EUR J CLIN NUTR, V68, P1277, DOI 10.1038/ejcn.2014.158; Tinggaard J, 2014, ACTA PAEDIATR, V103, P214, DOI 10.1111/apa.12468; Voortman T, 2015, PROG LIPID RES, V59, P67, DOI 10.1016/j.plipres.2015.05.001; WHO, 2009, WHO CHILD GROWTH STA	31	21	22	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 4	2018	362								k3312	10.1136/bmj.k3312	http://dx.doi.org/10.1136/bmj.k3312			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT4VO	30181143	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000444503800002
J	Hsu, CK; Lee, CC; Chen, YT; Ting, MK; Sun, CY; Chen, CY; Hsu, HJ; Chen, YC; Wu, IW				Hsu, Cheng-Kai; Lee, Chin-Chan; Chen, Yih-Ting; Ting, Ming-Kuo; Sun, Chiao-Yin; Chen, Chun-Yu; Hsu, Heng-Jung; Chen, Yung-Chang; Wu, I-Wen			Multidisciplinary predialysis education reduces incidence of peritonitis and subsequent death in peritoneal dialysis patients: 5-year cohort study	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; MANAGEMENT; MORTALITY; IMPACT; RISK; CARE; FREQUENCIES; MODALITY; PROGRAM	Background Technique failure secondary to peritonitis is a grave impediment to remain in peritoneal dialysis (PD) therapy leading to high mortality. Multidisciplinary predialysis education (MPE) has shown improvement in outcomes of chronic kidney disease (CKD) patients. However, the legacy effects of MPE in PD patients remain unclear. Methods All patients who started PD at single hospital in 2007-16 were enrolled. The incidences of peritonitis and peritonitis-related mortality were compared between MPE recipients and non-recipients. The content of the MPE was standardized in accordance with the NKF/DOQI guidelines. Kaplan-Meier analysis and Cox proportional hazards model were applied to identify the prognostic factors associated with peritonitis-free survival. Results Of 398 PD patients, 169 patients had received MPE before starting PD. The patients of MPE group had a lower peritonitis rate [median (IQR) 0 (0.29) versus 0.11 (0.69) episodes/ person-year, P< 0.001] and a lower percentage of peritonitis-related deaths (3.6% versus 8.7%, P= 0.04) compared with the non-MPE group. The median time to the first episode of peritonitis in the non-MPE and MPE groups was 33.9 months and 46.7 months, respectively (Cox-Mantel log rank test, P= 0.003). Cox regression analysis revealed that MPE assignment (HR: 0.594; 95% CI: 0.434-0.813, P< 0.001) were significant independent predictors for peritonitis-free survival. Conclusions An efficient standardized MPE program may prolong the time to the first episode of peritonitis and reduce peritonitis rate, independent of age, gender, diabetes, hypertension, educational status and PD modality. Subsequently, decreased peritonitis-related death.	[Hsu, Cheng-Kai; Lee, Chin-Chan; Chen, Yih-Ting; Sun, Chiao-Yin; Chen, Chun-Yu; Hsu, Heng-Jung; Chen, Yung-Chang; Wu, I-Wen] Chang Gung Mem Hosp, Dept Nephrol, Keelung, Taiwan; [Ting, Ming-Kuo] Chang Gung Mem Hosp, Div Endocrinol & Metab, Keelung, Taiwan; [Chen, Yung-Chang; Wu, I-Wen] Chang Gung Univ, Coll Med, Taoyuan, Taiwan	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University	Wu, IW (corresponding author), Chang Gung Mem Hosp, Dept Nephrol, Keelung, Taiwan.; Wu, IW (corresponding author), Chang Gung Univ, Coll Med, Taoyuan, Taiwan.	fliawu@yahoo.com		Hsu, Cheng-Kai/0000-0002-6812-526X; WU, I-WEN/0000-0001-8535-3582	Chang Gung Memorial Hospital Research Projects [CMRPG260323, CMRPG2A0423, CMRPG2C0093, CMRPG2E0232]	Chang Gung Memorial Hospital Research Projects	This study was sponsored by the Chang Gung Memorial Hospital Research Projects (CMRPG260323, CMRPG2A0423, CMRPG2C0093 and CMRPG2E0232) to I-WW. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2017, AM J KIDNEY DIS, V69, pA4, DOI [DOI 10.1053/j.ajkd.2017.01.036, 10.1053/j.ajkd.2017.01.036, DOI 10.1053/J.AJKD.2017.01.036]; Cankaya E, 2013, TRANSPL P, V45, P887, DOI 10.1016/j.transproceed.2013.02.075; Chao CT, 2015, PERITON DIALYSIS INT, V35, P333, DOI 10.3747/pdi.2013.00108; Chen SH, 2011, NEPHROL DIAL TRANSPL, V26, P3560, DOI 10.1093/ndt/gfr047; Chen YR, 2014, NEPHROLOGY, V19, P699, DOI 10.1111/nep.12316; Chen YR, 2013, NEPHROL DIAL TRANSPL, V28, P671, DOI 10.1093/ndt/gfs469; Cho EJ, 2012, NEPHROLOGY, V17, P472, DOI 10.1111/j.1440-1797.2012.01598.x; Devins GM, 2003, AM J KIDNEY DIS, V42, P693, DOI 10.1016/S0272-6386(03)00835-7; Devoe DJ, 2016, AM J KIDNEY DIS, V68, P422, DOI 10.1053/j.ajkd.2016.02.053; Elios Russo G, 2013, G ITAL NEFROL, V30; Fan XG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107485; Fontan MP, 2005, PERITON DIALYSIS INT, V25, P274; Hsieh YP, 2014, PERITON DIALYSIS INT, V34, P627, DOI 10.3747/pdi.2013.00024; Inaguma Daijo, 2006, Clin Exp Nephrol, V10, P274, DOI 10.1007/s10157-006-0439-2; Inker LA, 2014, AM J KIDNEY DIS, V63, P713, DOI 10.1053/j.ajkd.2014.01.416; Johnson DW, 2009, NEPHROL DIAL TRANSPL, V24, P1598, DOI 10.1093/ndt/gfn684; Kofteridis DP, 2010, INT J INFECT DIS, V14, pE489, DOI 10.1016/j.ijid.2009.07.016; Lameire N, 2000, PERITON DIALYSIS INT, V20, pS134; Li PKT, 2016, PERITON DIALYSIS INT, V36, P481, DOI 10.3747/pdi.2016.00078; Manns BJ, 2005, KIDNEY INT, V68, P1777, DOI 10.1111/j.1523-1755.2005.00594.x; Martin LC, 2011, CLIN J AM SOC NEPHRO, V6, P1944, DOI 10.2215/CJN.11431210; Nessim SJ, 2009, CLIN J AM SOC NEPHRO, V4, P1195, DOI 10.2215/CJN.00910209; Nishina M, 2014, CLIN EXP NEPHROL, V18, P649, DOI 10.1007/s10157-013-0872-y; Okayama Mika, 2012, Adv Perit Dial, V28, P50; Ravani P, 2003, J NEPHROL, V16, P870; Ribitsch W, 2013, PERITON DIALYSIS INT, V33, P367, DOI 10.3747/pdi.2011.00255; Tian YS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005569; Wang Z, 2015, KIDNEY BLOOD PRESS R, V40, P298, DOI 10.1159/000368505; Wu IW, 2009, NEPHROL DIAL TRANSPL, V24, P3426, DOI 10.1093/ndt/gfp259; Xu R, 2013, PERITON DIALYSIS INT, V33, P436, DOI 10.3747/pdi.2012.00163; Yu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112820	31	14	14	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2018	13	8							e0202781	10.1371/journal.pone.0202781	http://dx.doi.org/10.1371/journal.pone.0202781			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR6TZ	30138478	gold, Green Published, Green Submitted			2023-01-03	WOS:000442800100126
J	Gokal, K; Munir, F; Ahmed, S; Kancherla, K; Wallis, D				Gokal, Kajal; Munir, Fehmidah; Ahmed, Samreen; Kancherla, Kiran; Wallis, Deborah			Does walking protect against decline in cognitive functioning among breast cancer patients undergoing chemotherapy? Results from a small randomised controlled trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; ADJUVANT CHEMOTHERAPY; PHYSICAL-ACTIVITY; EXERCISE INTERVENTION; WORKING-MEMORY; SURVIVORS; WOMEN; IMPAIRMENT; THERAPY; PERFORMANCE	Background Cancer related cognitive impairments have been subjectively reported and objectively detected in breast cancer patients treated with chemotherapy and are known to have a profound negative impact on productivity, psychosocial well-being and overall quality of life. Moderate levels of walking are known to be of benefit to the psychosocial well-being of those affected by breast cancer and for managing cognitive impairment in healthy adults, children, and the elderly. The purpose of this study is to investigate the effects of a home-based, self-managed, moderate intensity walking intervention on subjective and objective cognitive functioning in breast cancer patients undergoing chemotherapy. Methods A home-based, self-managed intervention that consisted of moderate levels of walking was compared to usual care among breast cancer patients treated with chemotherapy in a ran-domised controlled trial. Outcome measures included changes in subjective (CFQ) and objectively detected cognitive functioning (Stroop, SART and two subscales from the WAIS-Digit Span and Block Design). Fifty participants were randomised to either the intervention group (n = 25), who completed 12 weeks of moderate intensity walking, or to the control group (n = 25) mid-way through chemotherapy. Results Compared with the control group, the self-managed walking intervention had positive effects on perceived cognitive function but not on sustained attention, executive function, memory or visual spatial skills when assessed objectively using neuropsychological measures. Conclusion This home-based, self-managed intervention is beneficial for protecting against perceived cognitive decline in breast cancer patients treated with chemotherapy. There is a need for further research to objectively assess cognitive decline within this population with larger sample sizes of patients.	[Gokal, Kajal; Munir, Fehmidah; Wallis, Deborah] Loughborough Univ Technol, Sch Sport Exercise & Hlth Sci, Loughborough, Leics, England; [Gokal, Kajal; Munir, Fehmidah; Wallis, Deborah] Loughborough Univ Technol, Natl Ctr Sport & Exercise Med, Loughborough, Leics, England; [Ahmed, Samreen; Kancherla, Kiran] Univ Hosp Leicester, Leicester Royal Infirm, Leicester, Leics, England; [Gokal, Kajal] Coventry Univ, Fac Hlth & Life Sci, Ctr Advances Behav Sci, Coventry, W Midlands, England; [Wallis, Deborah] Birmingham City Univ, Sch Social Sci, Dept Psychol, Birmingham, W Midlands, England	Loughborough University; Loughborough University; University Hospitals of Leicester NHS Trust; University of Leicester; Coventry University; Birmingham City University	Munir, F (corresponding author), Loughborough Univ Technol, Sch Sport Exercise & Hlth Sci, Loughborough, Leics, England.; Munir, F (corresponding author), Loughborough Univ Technol, Natl Ctr Sport & Exercise Med, Loughborough, Leics, England.	f.munir@lboro.ac.uk		Wallis, Deborah/0000-0002-2216-1775; Munir, Fehmidah/0000-0002-5585-0243	Loughborough University; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre	Loughborough University; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre	The study was funded by Loughborough University as a part of a PhD project to KG. Dr Fehmidah Munir acknowledges support from the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, which is a partnership between University Hospitals of Leicester NHS Trust, Loughborough University and the University of Leicester. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research Leicester BRC or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The study was funded by Loughborough University as a part of a PhD project to KG. Dr Fehmidah Munir acknowledges support from the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, which is a partnership between University Hospitals of Leicester NHS Trust, Loughborough University and the University of Leicester. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research Leicester BRC or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahles TA, 2012, J CLIN ONCOL, V30, P3675, DOI 10.1200/JCO.2012.43.0116; Ahles TA, 2010, J CLIN ONCOL, V28, P4434, DOI 10.1200/JCO.2009.27.0827; AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Alloway TP, 2006, CHILD DEV, V77, P1698, DOI 10.1111/j.1467-8624.2006.00968.x; Altman DG, 1999, BRIT MED J, V319, P703, DOI 10.1136/bmj.319.7211.703; [Anonymous], 1965, ACCEPTANCE COMMITMEN; Baumann FT, 2011, BREAST CARE, V6, P142, DOI 10.1159/000327505; Bender CM, 2006, PSYCHO-ONCOLOGY, V15, P422, DOI 10.1002/pon.964; Benedict RHB, 2010, HOPKINS VERBAL LEARN, DOI [10.1076/clin.12.1.43.1726#.VIw8VHtrZ-w, DOI 10.1076/CLIN.12.1.43.1726#.VIW8VHTRZ-W]; Biddle S. J. H., 2014, BRIT J SPORT MED, V45, P886; Biegler KA, 2009, ACTA ONCOL, V48, P18, DOI 10.1080/02841860802415535; Biglia N, 2012, EUR J CANCER CARE, V21, P485, DOI 10.1111/j.1365-2354.2011.01320.x; Borg G., 1998, CHAMPAIGN; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Callaghan P, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-465; Campbell KL, 2017, PSYCHOONCOLOGY; Castellon SA, 2004, J CLIN EXP NEUROPSYC, V26, P955, DOI 10.1080/13803390490510905; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Collins B, 2009, PSYCHO-ONCOLOGY, V18, P811, DOI 10.1002/pon.1453; Corder K, 2007, CURR OPIN CLIN NUTR, V10, P597, DOI 10.1097/MCO.0b013e328285d883; Crowley S., 2011, EFFECT STRUCTURED EX; Culos-Reed SN, 2006, PSYCHO-ONCOLOGY, V15, P891, DOI 10.1002/pon.1021; Daley AJ, 2007, EUR J ONCOL NURS, V11, P392, DOI 10.1016/j.ejon.2007.03.001; Derry HM, 2015, PSYCHO-ONCOLOGY, V24, P958, DOI 10.1002/pon.3707; Dimeo F, 2003, SUPPORT CARE CANCER, V11, P623, DOI 10.1007/s00520-003-0512-2; Ehlers DK, 2017, BREAST CANCER RES TR, V165, P699, DOI 10.1007/s10549-017-4363-9; Fan HGM, 2005, J CLIN ONCOL, V23, P8025, DOI 10.1200/JCO.2005.01.6550; Ferguson RJ, 2012, PSYCHO-ONCOLOGY, V21, P176, DOI 10.1002/pon.1878; Friedenreich CM, 2010, J CLIN ONCOL, V28, P1458, DOI 10.1200/JCO.2009.24.9557; Galantino ML, 2012, EXPLORE-NY, V8, P127, DOI 10.1016/j.explore.2011.12.001; Gokal K, 2016, SUPPORT CARE CANCER, V24, P1139, DOI 10.1007/s00520-015-2884-5; Gokal K, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1751-0; Gupta Sandeep K, 2011, Perspect Clin Res, V2, P109, DOI 10.4103/2229-3485.83221; Hartman SJ, 2018, CANCER-AM CANCER SOC, V124, P192, DOI 10.1002/cncr.30987; Hermelink K, 2007, CANCER, V109, P1905, DOI 10.1002/cncr.22610; Hillman CH, 2009, NEUROSCIENCE, V159, P1044, DOI 10.1016/j.neuroscience.2009.01.057; Janelsins MC, 2014, INT REV PSYCHIATR, V26, P102, DOI 10.3109/09540261.2013.864260; Jansen CE, 2007, ONCOL NURS FORUM, V34, P997, DOI 10.1188/07.ONF.997-1005; Jansen CE, 2008, PSYCHO-ONCOLOGY, V17, P1189, DOI 10.1002/pon.1342; Jenkins V, 2006, BRIT J CANCER, V94, P828, DOI 10.1038/sj.bjc.6603029; Jim HSL, 2012, J CLIN ONCOL, V30, P3578, DOI 10.1200/JCO.2011.39.5640; Jung MS, 2017, BRAIN IMAGING BEHAV, V11, P86, DOI 10.1007/s11682-016-9507-8; Kesler S, 2013, CLIN BREAST CANCER, V13, P299, DOI 10.1016/j.clbc.2013.02.004; Kim LS, 2008, NEUROSCI LETT, V447, P1, DOI 10.1016/j.neulet.2008.09.077; Knobf MT, 2014, CANCER NURS, V37, pE43, DOI 10.1097/NCC.0b013e318288d40e; Mackenzie MJ, 2016, J WOMENS HEALTH, V25, P99, DOI 10.1089/jwh.2015.5246; Matthews CE, 2007, SUPPORT CARE CANCER, V15, P203, DOI 10.1007/s00520-006-0122-x; McDougall GJ, 2011, ARCH PSYCHIAT NURS, V25, P24, DOI 10.1016/j.apnu.2010.05.004; Mehlsen M, 2009, PSYCHO-ONCOL, V18, P248, DOI 10.1002/pon.1398; Myers Jamie S, 2012, Oncol Nurs Forum, V39, pE31, DOI 10.1188/12.ONF.E31-E40; Norton S, 2014, LANCET NEUROL, V13, P788, DOI 10.1016/S1474-4422(14)70136-X; Oh B, 2012, SUPPORT CARE CANCER, V20, P1235, DOI 10.1007/s00520-011-1209-6; Ottati A, 2013, J CANCER SURVIV, V7, P262, DOI 10.1007/s11764-013-0275-9; Persinger R, 2004, MED SCI SPORT EXER, V36, P1632, DOI 10.1249/01.MSS.0000074690.03001.98; Pinto BM, 2013, PSYCHOONCOLOGY; Poppelreuter M, 2009, J PSYCHOSOC ONCOL, V27, P274, DOI 10.1080/07347330902776044; Pullens MJJ, 2010, PSYCHO-ONCOLOGY, V19, P1127, DOI 10.1002/pon.1673; Quesnel C, 2009, BREAST CANCER RES TR, V116, P113, DOI 10.1007/s10549-008-0114-2; Reid-Arndt Stephanie A, 2012, Complement Ther Clin Pract, V18, P26, DOI 10.1016/j.ctcp.2011.02.005; Reid-Arndt SA, 2010, PSYCHO-ONCOLOGY, V19, P535, DOI 10.1002/pon.1581; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rogers LQ, 2009, PSYCHO-ONCOLOGY, V18, P412, DOI 10.1002/pon.1497; Schilder CMT, 2012, PSYCHO-ONCOLOGY, V21, P479, DOI 10.1002/pon.1928; Schilder CM, 2009, ACTA ONCOL, V48, P76, DOI 10.1080/02841860802314738; Schmitz KH, 2010, MED SCI SPORT EXER, V42, P1409, DOI 10.1249/MSS.0b013e3181e0c112; Schuurs A, 2013, PSYCHO-ONCOLOGY, V22, P1043, DOI 10.1002/pon.3102; SHACHAM S, 1983, J PERS ASSESS, V47, P305, DOI 10.1207/s15327752jpa4703_14; Shilling V, 2005, BREAST, V14, P142, DOI 10.1016/j.breast.2004.10.004; Shilling V, 2006, BREAST CANCER RES TR, V95, P125, DOI 10.1007/s10549-005-9055-1; Shilling V, 2007, EUR J ONCOL NURS, V11, P6, DOI 10.1016/j.ejon.2006.02.005; Vallance JKH, 2007, J CLIN ONCOL, V25, P2352, DOI 10.1200/JCO.2006.07.9988; van Dam FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/jnci/90.3.210; van Waart H, 2016, PSYCHO-ONCOLOGY, V25, P964, DOI 10.1002/pon.3936; Vardy J, 2007, CRIT REV ONCOL HEMAT, V63, P183, DOI 10.1016/j.critrevonc.2007.06.001; Von Ah D, 2012, BREAST CANCER RES TR, V135, P799, DOI 10.1007/s10549-012-2210-6; Wallis DJ, 2004, APPETITE, V43, P39, DOI 10.1016/j.appet.2004.02.001; Wefel JS, 2015, CA-CANCER J CLIN, V65, P123, DOI 10.3322/caac.21258; Wefel JS, 2011, LANCET ONCOL, V12, P703, DOI 10.1016/S1470-2045(10)70294-1; Wefel JS, 2004, CANCER-AM CANCER SOC, V100, P2292, DOI 10.1002/cncr.20272; Weis J, 2009, PSYCHO-ONCOLOGY, V18, P775, DOI 10.1002/pon.1472; Yellen SB, 1997, J PAIN SYMPTOM MANAG, V13, P63, DOI 10.1016/S0885-3924(96)00274-6; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	82	21	23	3	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2018	13	11							e0206874	10.1371/journal.pone.0206874	http://dx.doi.org/10.1371/journal.pone.0206874			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HC4EO	30485297	Green Published, Green Accepted, gold			2023-01-03	WOS:000451755800031
J	Chang, S; Lee, TH				Chang, Stacey; Lee, Thomas H.			Beyond Evidence-Based Medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Chang, Stacey] Dell Med Sch, Design Inst Hlth, Austin, TX 78712 USA; [Lee, Thomas H.] Press Ganey, Boston, MA USA; [Lee, Thomas H.] Harvard Med Sch, Boston, MA USA	Harvard University; Harvard Medical School	Chang, S (corresponding author), Dell Med Sch, Design Inst Hlth, Austin, TX 78712 USA.							GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; Kelley JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094207; Lee TH, 2007, NEW ENGL J MED, V357, P1175, DOI 10.1056/NEJMp078102; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; Zolnierek KBH, 2009, MED CARE, V47, P826, DOI 10.1097/MLR.0b013e31819a5acc	5	23	23	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 22	2018	379	21					1983	1985		10.1056/NEJMp1806984	http://dx.doi.org/10.1056/NEJMp1806984			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HB1VX	30462934				2023-01-03	WOS:000450816900002
J	Lin, ZP; Zhu, YL; Lo, YC; Moscarelli, J; Xiong, A; Korayem, Y; Huang, PH; Giri, S; LoRusso, P; Ratner, ES				Lin, Z. Ping; Zhu, Yong-Lian; Lo, Ying-Chun; Moscarelli, Jake; Xiong, Amy; Korayem, Yasmin; Huang, Pamela H.; Giri, Smith; LoRusso, Patricia; Ratner, Elena S.			Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer	PLOS ONE			English	Article							3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE 3-AP; RIBONUCLEOTIDE REDUCTASE-ACTIVITY; HOMOLOGOUS RECOMBINATION REPAIR; PEGYLATED LIPOSOMAL DOXORUBICIN; ENDOTHELIAL GROWTH-FACTOR; OPEN-LABEL; PHASE-I; MUTATIONS; CISPLATIN; CELLS	PARP inhibitors target BRCA mutations and defective homologous recombination repair (HRR) for the treatment of epithelial ovarian cancer (EOC). However, the treatment of HRR-proficient EOC with PARP inhibitors remains challenging. The objective of this study was to determine whether the combination of triapine (ribonucleotide reductase inhibitor), cediranib (vascular endothelial growth factor receptor tyrosine kinase inhibitor), and the PARP inhibitor olaparib synergized against BRCA wild-type and HRR-proficient EOC in xenograft mouse models. In addition, the mechanisms by which cediranib augmented the efficacy of triapine and olaparib were investigated. BRCA-wild type and PARP inhibitor-resistant EOC cell lines were implanted subcutaneously (s.c.) into nude mice or injected intraperitoneally (i.p.) into SCID-Beige mice. Mice were then treated i.p. with olaparib, cediranib, triapine, various double and triple combinations. The volume of s.c tumor in nude mice and the abdominal circumference of SCID-Beige mice were measured to evaluate the effectiveness of the treatment to delay tumor growth and prolong the survival time of mice. In both xenograft mouse models, the combination of triapine, olaparib and cediranib resulted in marked suppression of BRCA-wild type EOC growth and significant prolongation of the survival time of mice, with efficacy greater than any double combinations and single drugs. Furthermore, we identified that cediranib abrogated pro-survival and anti-apoptotic AKT signaling, thereby enhancing the efficacy of triapine and olaparib against BRCA-wild type EOC cells. Taken together, our results demonstrate a proof-of-principle approach and the combination regiment holds promise in treating BRCA-wild type and PARP inhibitor-resistant EOC.	[Lin, Z. Ping; Zhu, Yong-Lian; Moscarelli, Jake; Xiong, Amy; Korayem, Yasmin; Ratner, Elena S.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA; [Lo, Ying-Chun; Huang, Pamela H.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Giri, Smith; LoRusso, Patricia] Yale Univ, Sch Med, Yale Canc Ctr, Sect Med Oncol, New Haven, CT USA	Yale University; Yale University; Yale University	Lin, ZP; Ratner, ES (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA.	z.ping.lin@yale.edu; elena.ratner@yale.edu		Lin, Z Ping/0000-0003-2783-725X; Xiong, Amy/0000-0002-6846-814X	"Discovery to Cure" program at Yale University	"Discovery to Cure" program at Yale University	This work was supported by the "Discovery to Cure" program at Yale University (to ESR). ESR and ZPL are Discovery to Cure Fellows. ESR has board membership and consultancy with Tesaro and Genentech. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Barker CA, 2006, CLIN CANCER RES, V12, P2912, DOI 10.1158/1078-0432.CCR-05-2860; Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x; BOOCOCK CA, 1995, JNCI-J NATL CANCER I, V87, P506, DOI 10.1093/jnci/87.7.506; Bookman MA, 1996, J CLIN ONCOL, V14, P1895, DOI 10.1200/JCO.1996.14.6.1895; Burkhalter MD, 2009, DNA REPAIR, V8, P1258, DOI 10.1016/j.dnarep.2009.07.009; Chen HY, 2004, ADV APPL MATH, V33, P136, DOI 10.1016/j.aam.2003.08.001; Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246; CORY JG, 1995, ADV ENZYME REGUL, V35, P55, DOI 10.1016/0065-2571(94)00005-N; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; du Bois A, 2003, JNCI-J NATL CANCER I, V95, P1320, DOI 10.1093/jnci/djg036; Finch RA, 1999, ADV ENZYME REGUL, V39, P3, DOI 10.1016/S0065-2571(98)00017-X; Finch RA, 2000, BIOCHEM PHARMACOL, V59, P983, DOI 10.1016/S0006-2952(99)00419-0; Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589; FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Gordon AN, 2001, J CLIN ONCOL, V19, P3312, DOI 10.1200/JCO.2001.19.14.3312; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Howlader N, 2016, SEER CANCER STATISTI; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Ivy SP, 2016, EXPERT OPIN INV DRUG, V25, P597, DOI 10.1517/13543784.2016.1156857; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Jenner ZB, 2016, FUTURE ONCOL, V12, P1439, DOI 10.2217/fon-2016-0002; Kaye SB, 2012, J CLIN ONCOL, V30, P372, DOI 10.1200/JCO.2011.36.9215; Kunos CA, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00184; Kunos CA, 2013, GYNECOL ONCOL, V130, P75, DOI 10.1016/j.ygyno.2013.04.019; Kunos CA, 2012, FUTURE ONCOL, V8, P145, DOI [10.2217/fon.11.147, 10.2217/FON.11.147]; Kunos CA, 2010, CLIN CANCER RES, V16, P1298, DOI 10.1158/1078-0432.CCR-09-2469; LANGDON SP, 1988, CANCER RES, V48, P6166; Lee TH, 2007, PLOS MED, V4, P1101, DOI 10.1371/journal.pmed.0040186; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Lin ZP, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00303; Lin ZP, 2014, MOL CANCER RES, V12, P381, DOI 10.1158/1541-7786.MCR-13-0480; Lin ZP, 2011, MOL PHARMACOL, V80, P1000, DOI 10.1124/mol.111.074708; Lin ZP, 2004, J BIOL CHEM, V279, P27030, DOI 10.1074/jbc.M402056200; Liu JF, 2014, LANCET ONCOL, V15, P1207, DOI 10.1016/S1470-2045(14)70391-2; LIU MC, 1992, J MED CHEM, V35, P3672, DOI 10.1021/jm00098a012; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Memmott RM, 2009, CELL SIGNAL, V21, P656, DOI 10.1016/j.cellsig.2009.01.004; Monk BJ, 2016, ANN ONCOL, V27, P33, DOI 10.1093/annonc/mdw093; Norquist B, 2011, J CLIN ONCOL, V29, P3008, DOI 10.1200/JCO.2010.34.2980; Paster EV, 2009, COMPARATIVE MED, V59, P234; Piccart MJ, 2000, JNCI-J NATL CANCER I, V92, P699, DOI 10.1093/jnci/92.9.699; Ratner ES, 2016, BRIT J CANCER, V114, P777, DOI 10.1038/bjc.2016.54; Ratner ES, 2012, CURR OPIN ONCOL, V24, P564, DOI 10.1097/CCO.0b013e3283564230; Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105; Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633; Sakai W, 2009, CANCER RES, V69, P6381, DOI 10.1158/0008-5472.CAN-09-1178; Sgagias MK, 2004, CELL CYCLE, V3, P1451, DOI 10.4161/cc.3.11.1211; Shou J, 2018, MOL CELL, V71, P498, DOI 10.1016/j.molcel.2018.06.021; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Stordal B, 2013, MOL ONCOL, V7, P567, DOI 10.1016/j.molonc.2012.12.007; Swisher EM, 2008, CANCER RES, V68, P2581, DOI 10.1158/0008-5472.CAN-08-0088; Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/S1470-2045(16)30559-9, 10.1016/s1470-2045(16)30559-9]; Swisher EM, 1997, GYNECOL ONCOL, V66, P480, DOI 10.1006/gyno.1997.4787; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Ullman-Cullere MH, 1999, LAB ANIM SCI, V49, P319; Vencken PMLH, 2011, ANN ONCOL, V22, P1346, DOI 10.1093/annonc/mdq628; Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008-5472.CAN-04-4409; Weigand Melanie, 2005, Angiogenesis, V8, P197, DOI 10.1007/s10456-005-9010-0; Whicker ME, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2598-1; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468; Xu NH, 2012, J ONCOL, V2012, DOI 10.1155/2012/951724; Yang D, 2011, JAMA-J AM MED ASSOC, V306, P1557, DOI 10.1001/jama.2011.1456; Zhang WS, 2012, TRANSL ONCOL, V5, P422, DOI 10.1593/tlo.12241	66	13	15	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2018	13	11							e0207399	10.1371/journal.pone.0207399	http://dx.doi.org/10.1371/journal.pone.0207399			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA6WB	30444904	Green Published, Green Submitted, gold			2023-01-03	WOS:000450420900032
J	Kim, KH; Chung, JB; Suh, TS; Kang, SW; Kang, SH; Eom, KY; Song, C; Kim, IA; Kim, JS				Kim, Kyeong-Hyeon; Chung, Jin-Beom; Suh, Tae Suk; Kang, Sang-Won; Kang, Seong-Hee; Eom, Keun-Yong; Song, Changhoon; Kim, In-Ah; Kim, Jae-Sung			Dosimetric and radiobiological comparison in different dose calculation grid sizes between Acuros XB and anisotropic analytical algorithm for prostate VMAT	PLOS ONE			English	Article							VOLUMETRIC MODULATED ARC; ENDORECTAL BALLOON; RADIATION-THERAPY; SMALL FIELDS; RADIOTHERAPY; IMRT; IMPACT; PLANS; VALIDATION; RESOLUTION	To investigate feasible treatment planning parameters, we aimed to evaluate the dosimetric and radiobiological impact of the dose calculation algorithm and grid size in the volumetric modulated arc therapy (VMAT) plan for prostate cancer. Twenty patients were selected, and the treatment plans were initially generated with anisotropic analytical algorithm (AAA) and recalculated with Acuros XB (AXB) algorithm. Various dose grids were used for AXB (1, 2, and 3 mm) and AAA (1, 3, and 5 mm) plan. Dosimetric parameters such as homogeneity index (HI) and conformity index (CI), and radiobiological parameters such as tumor control probability (TCP) and normal tissue complication probability (NTCP) were calculated. Significant differences were observed in the planning target volume (PTV) coverage between both algorithms, and the V-95(%), HI, and CI of AAA were significantly affected by grid (p < 0.01). On 1 mm grid, the mean rectal dose difference between both algorithms was 2.87% of the prescription dose (p < 0.01), which was the highest among the critical organs. The TCP and NTCP of the AAA were higher than those of AXB (p < 0.01). Compared to AXB with 1 mm grid, the 2 mm grid showed comparable dose calculation accuracy with short calculation time. This study found that the PTV and rectum show significant differences according to dose calculation algorithm and grid. Considering the dose calculation performance for heterogeneous area, we recommend AXB with 2 mm grid for improving treatment efficiency of prostate VMAT.	[Kim, Kyeong-Hyeon; Suh, Tae Suk; Kang, Sang-Won] Catholic Univ Korea, Coll Med, Res Inst Biomed Engn, Dept Biomed & Hlth Sci, Seoul, South Korea; [Chung, Jin-Beom; Kang, Seong-Hee; Eom, Keun-Yong; Song, Changhoon; Kim, In-Ah; Kim, Jae-Sung] Seoul Natl Univ, Bundang Hosp, Dept Radiat Oncol, Seongnam, South Korea	Catholic University of Korea; Seoul National University (SNU)	Suh, TS (corresponding author), Catholic Univ Korea, Coll Med, Res Inst Biomed Engn, Dept Biomed & Hlth Sci, Seoul, South Korea.; Chung, JB (corresponding author), Seoul Natl Univ, Bundang Hosp, Dept Radiat Oncol, Seongnam, South Korea.	jbchung1213@gmail.com; suhsanta@catholic.ac.kr		Kim, Jae-Sung/0000-0001-5348-9178; Kang, Sang-Won/0000-0002-6376-7757	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea [HI15C0638]; National Research Foundation of Korea - Korean Government [NRF-2017M2A2A7A01021264]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea; National Research Foundation of Korea - Korean Government(National Research Foundation of KoreaKorean Government)	This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (Grant Number: HI15C0638) and the National Research Foundation of Korea Grant funded by the Korean Government (NRF-2017M2A2A7A01021264). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1976, J INT COMMISSION RAD, Vos13, DOI 10.1093/jicru/os13.1.report24; Both S, 2011, INT J RADIAT ONCOL, V81, P1302, DOI 10.1016/j.ijrobp.2010.08.052; Bush K, 2011, MED PHYS, V38, P2208, DOI 10.1118/1.3567146; Chung HT, 2006, PHYS MED BIOL, V51, P4841, DOI 10.1088/0031-9155/51/19/008; Deasy JO, 2003, MED PHYS, V30, P979, DOI 10.1118/1.1568978; Dempsey JF, 2005, MED PHYS, V32, P380, DOI 10.1118/1.1843354; Failla GA, 2010, ACUROS XB ADV DOSE C, V20, P18; Fogliata A, 2012, INT J RADIAT ONCOL, V83, P1587, DOI 10.1016/j.ijrobp.2011.10.078; Gay HA, 2007, PHYS MEDICA, V23, P115, DOI 10.1016/j.ejmp.2007.07.001; Hasenbalg F, 2007, PHYS MED BIOL, V52, P3679, DOI 10.1088/0031-9155/52/13/002; Huang BT, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0357-0; Jiang XQ, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-140; Kan MWK, 2013, MED PHYS, V40, DOI 10.1118/1.4792308; Kan MWK, 2013, INT J RADIAT ONCOL, V85, pE73, DOI 10.1016/j.ijrobp.2012.08.031; Kan MWK, 2012, MED PHYS, V39, P4705, DOI 10.1118/1.4736819; Kang SW, 2017, INT J RADIAT RES, V15, P157, DOI 10.18869/acadpub.ijrr.15.2.157; Kang SW, 2017, J KOREAN PHYS SOC, V70, P424, DOI 10.3938/jkps.70.424; Kang SW, 2015, J KOREAN PHYS SOC, V67, P2138, DOI 10.3938/jkps.67.2138; Kim JS, 2013, J KOREAN PHYS SOC, V63, P1637, DOI 10.3938/jkps.63.1637; Koo T, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0346-3; Kroon PS, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-149; NIEMIERKO A, 1993, INT J RADIAT ONCOL, V25, P135, DOI 10.1016/0360-3016(93)90156-P; Ostheimer C, 2016, RADIAT ONCOL J, V34, P313, DOI 10.3857/roj.2016.01935; Otto K, 2008, MED PHYS, V35, P310, DOI 10.1118/1.2818738; Papanikolaou N., 2004, AAPM TASK GROUP, V65, P1; Park JM, 2017, AUSTRALAS PHYS ENG S, V40, P209, DOI 10.1007/s13246-016-0517-z; Quan EZM, 2012, INT J RADIAT ONCOL, V83, P1169, DOI 10.1016/j.ijrobp.2011.09.015; Rana S, 2013, J MED PHYS, V38, P9, DOI 10.4103/0971-6203.106600; Rong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126222; Sievinen J, 2005, AAA PHOTON DOSE CALC, V118, P2894; Smeenk RJ, 2012, INT J RADIAT ONCOL, V83, P661, DOI 10.1016/j.ijrobp.2011.07.028; Srivastava SP, 2017, PRACT RADIAT ONCOL, V7, P209, DOI 10.1016/j.prro.2016.10.001; Streller T, 2017, RADIOTHER ONCOL, V123, P454, DOI 10.1016/j.radonc.2017.04.014; Tillikainen L, 2008, PHYS MED BIOL, V53, P3821, DOI 10.1088/0031-9155/53/14/008; van Lin ENJT, 2005, INT J RADIAT ONCOL, V61, P278, DOI 10.1016/j.ijrobp.2004.09.042; Vanneste BGL, 2018, STRAHLENTHER ONKOL, V194, P31, DOI 10.1007/s00066-017-1222-x; Vassiliev ON, 2010, PHYS MED BIOL, V55, P581, DOI 10.1088/0031-9155/55/3/002; WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269; Zhang WZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121385	39	8	9	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 12	2018	13	11							e0207232	10.1371/journal.pone.0207232	http://dx.doi.org/10.1371/journal.pone.0207232			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA0PF	30419058	gold, Green Submitted, Green Published			2023-01-03	WOS:000449909200061
J	Carico, R; Zhao, XH; Thorpe, CT; Thorpe, JM; Sileanu, FE; Cashy, JP; Hale, JA; Mor, MK; Radomski, TR; Hausmann, LRM; Donohue, JM; Suda, KJ; Stroupe, K; Hanlon, JT; Good, CB; Fine, MJ; Gellad, WF				Carico, Ron; Zhao, Xinhua; Thorpe, Carolyn T.; Thorpe, Joshua M.; Sileanu, Florentina E.; Cashy, John P.; Hale, Jennifer A.; Mor, Maria K.; Radomski, Thomas R.; Hausmann, Leslie R. M.; Donohue, Julie M.; Suda, Katie J.; Stroupe, Kevin; Hanlon, Joseph T.; Good, Chester B.; Fine, Michael J.; Gellad, Walid F.			Receipt of Overlapping Opioid and Benzodiazepine Prescriptions Among Veterans Dually Enrolled in Medicare Part D and the Department of Veterans Affairs A Cross-sectional Study	ANNALS OF INTERNAL MEDICINE			English	Article							DRUG OVERDOSE; UNITED-STATES; MORTALITY; DEATHS; COHORT; ANALGESICS; BENEFITS; IMPACT	Background: Overlapping use of opioids and benzodiazepines is associated with increased risk for overdose. Veterans receiving medications concurrently from the U.S. Department of Veterans Affairs (VA) and Medicare may be at higher risk for such overlap. Objective: To assess the association between dual use of VA and Medicare drug benefits and receipt of overlapping opioid and benzodiazepine prescriptions. Design: Cross-sectional. Setting: VA and Medicare. Participants: All veterans enrolled in VA and Medicare Part D who filled at least 2 opioid prescriptions in 2013 (n = 368 891). Measurements: Outcomes were the proportion of patients with a Pharmacy Quality Alliance (PQA) measure of opioid-benzodiazepine overlap (= 2 filled prescriptions for benzodiazepines with = 30 days of overlap with opioids) and the proportion of patients with high-dose opioid-benzodiazepine overlap (= 30 days of overlap with a daily opioid dose >120 morphine milligram equivalents). Augmented inverse probability weighting regression was used to compare these measures by prescription drug source: VA only, Medicare only, or VA and Medicare (dual use). Results: Of 368 891 eligible veterans, 18.3% received prescriptions from the VA only, 30.3% from Medicare only, and 51.4% from both VA and Medicare. The proportion with PQA opioid-benzodiazepine overlap was larger for the dual-use group than the VA-only group (23.1% vs. 17.3%; adjusted risk ratio [aRR], 1.27 [95% CI, 1.24 to 1.30]) and Medicare-only group (23.1% vs. 16.5%; aRR, 1.12 [CI, 1.10 to 1.14]). The proportion with high-dose overlap was also larger for the dual-use group than the VA-only group (4.7% vs. 2.3%; aRR, 2.23 [CI, 2.10 to 2.36]) and Medicare-only group (4.7% vs. 2.9%; aRR, 1.06 [CI, 1.02 to 1.11]). Limitation: Data are from 2013 and cannot capture medications purchased without insurance; unmeasured confounding may remain in this cross-sectional study. Conclusion: Among a national cohort of veterans dually enrolled in VA and Medicare, receiving prescriptions from both sources was associated with greater risk for receiving potentially unsafe overlapping prescriptions for opioids and benzodiazepines.	[Carico, Ron; Zhao, Xinhua; Thorpe, Carolyn T.; Thorpe, Joshua M.; Sileanu, Florentina E.; Cashy, John P.; Hale, Jennifer A.; Mor, Maria K.; Radomski, Thomas R.; Hausmann, Leslie R. M.; Donohue, Julie M.; Fine, Michael J.; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Univ Dr 151C, Pittsburgh, PA 15240 USA; [Thorpe, Carolyn T.; Thorpe, Joshua M.] Univ N Carolina, Sch Pharm, Chapel Hill, NC 27515 USA; [Mor, Maria K.; Donohue, Julie M.; Suda, Katie J.; Hanlon, Joseph T.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA; [Radomski, Thomas R.; Hausmann, Leslie R. M.; Fine, Michael J.; Gellad, Walid F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Suda, Katie J.; Stroupe, Kevin] Edward Hines Jr VA Hosp, Chicago, IL USA; [Suda, Katie J.] Univ Illinois, Coll Pharm, Chicago, IL USA; [Hanlon, Joseph T.; Good, Chester B.] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA; [Good, Chester B.] UPMC Hlth Plan, Pittsburgh, PA USA; [Carico, Ron; Zhao, Xinhua; Thorpe, Carolyn T.; Thorpe, Joshua M.; Sileanu, Florentina E.; Hale, Jennifer A.; Mor, Maria K.; Radomski, Thomas R.; Hausmann, Leslie R. M.; Fine, Michael J.; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr 151C,Bldg 30, Pittsburgh, PA 15240 USA; [Cashy, John P.] Corporal Michael J Crescenz VA Med Ctr, 4100 Chester Ave, Philadelphia, PA 19104 USA; [Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 7130 De Soto St, Pittsburgh, PA 15261 USA; [Suda, Katie J.; Stroupe, Kevin] Hines VA Hosp, Ctr Innovat Complex Chron Healthcare, 5000 5th Ave, Hines, IL 60141 USA; [Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Div Geriatr Med, 3471 Fifth Ave,Kaufmann Med Bldg,Suite 500, Pittsburgh, PA 15213 USA; [Good, Chester B.] UPMC Hlth Plan, Ctr Value Based Pharm Initiat, 600 Grant St, Pittsburgh, PA 15219 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; University of North Carolina; University of North Carolina Chapel Hill; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gellad, WF (corresponding author), VA Pittsburgh Healthcare Syst, Univ Dr 151C, Pittsburgh, PA 15240 USA.	walid.gellad@va.gov		Radomski, Thomas/0000-0002-7279-188X; Carico, Ronald/0000-0003-3794-1835; Hausmann, Leslie/0000-0002-3909-6009	U.S. Department of Veterans Affairs; Veterans Affairs [I01HX001765] Funding Source: NIH RePORTER	U.S. Department of Veterans Affairs(US Department of Veterans Affairs); Veterans Affairs(US Department of Veterans Affairs)	U.S. Department of Veterans Affairs.	Abrahamsson T, 2017, DRUG ALCOHOL DEPEN, V174, P58, DOI 10.1016/j.drugalcdep.2017.01.013; Becker WC, 2017, MED CARE, V55, pS33, DOI 10.1097/MLR.0000000000000722; Calcaterra S, 2013, DRUG ALCOHOL DEPEN, V131, P263, DOI 10.1016/j.drugalcdep.2012.11.018; Centers for Disease Control and Prevention, AN PRESCR DAT MORPH; Centers for Medicare & Medicaid Services, 2018, CONC US OP BENZ COB; Dasgupta N, 2016, PAIN MED, V17, P85, DOI 10.1111/pme.12907; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI [10.1001/jama.2016.1464, 10.15585/mmwr.rr7103a1]; Eicheldinger C, 2008, HEALTH CARE FINANC R, V29, P27; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Frandsen BR, 2015, AM J MANAG CARE, V21, P355; Gellad WF, 2018, AM J PUBLIC HEALTH, V108, P248, DOI [10.2105/ajph.2017.304174, 10.2105/AJPH.2017.304174]; Gellad WF, 2017, JAMA INTERN MED, V177, P611, DOI 10.1001/jamainternmed.2017.0147; Gellad WF, 2015, JAMA INTERN MED, V175, P26, DOI 10.1001/jamainternmed.2014.5405; Hall SA, 2006, J URBAN HEALTH, V83, P162, DOI 10.1007/s11524-005-9016-3; Hanlon JT, 2017, J AM GERIATR SOC, V65, P1183, DOI 10.1111/jgs.14759; Jann Michael, 2014, J Pharm Pract, V27, P5, DOI 10.1177/0897190013515001; Jia HG, 2007, STROKE, V38, P355, DOI 10.1161/01.STR.0000254457.38901.fb; Liang YY, 2016, PAIN MED, V17, P2268, DOI 10.1093/pm/pnw071; Malte CA, 2018, MED CARE, V56, P171, DOI 10.1097/MLR.0000000000000861; Mamdani M, 2005, BMJ-BRIT MED J, V330, P960, DOI 10.1136/bmj.330.7497.960; National Alliance for Model State Drug Laws, 2017, MAND US STAT PRESCR; National Committee for Quality Assurance, 2018, HEDIS 2018; Park TW, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2698; Pharmacy Quality Alliance, 2017, PQA PERF MEAS; Radomski TR, 2017, J GEN INTERN MED, V32, P967, DOI 10.1007/s11606-017-4064-4; Radomski TR, 2016, J GEN INTERN MED, V31, P524, DOI 10.1007/s11606-016-3631-4; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Suda KJ, 2017, J AM PHARM ASSOC, V57, P333, DOI 10.1016/j.japh.2017.02.018; Sun EC, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j760; Thorpe JM, 2017, ANN INTERN MED, V166, P157, DOI 10.7326/M16-0551; Turner BJ, 2015, J GEN INTERN MED, V30, P1081, DOI 10.1007/s11606-015-3199-4; U.S. Department of Veterans Affairs, 2011, 2011 SURV VET ENR HL; U. S. Department of Veterans Affairs; U. S. Department of Defense; Opioid Therapy for Chronic Pain Work Group, 2017, VA DOD CLIN PRACT GU; U. S. Food and Drug Administration, 2016, FDA REQ STRONG WARN; Wang CY, 2001, BIOMETRICS, V57, P414, DOI 10.1111/j.0006-341X.2001.00414.x; Weisberg DF, 2015, JAIDS-J ACQ IMM DEF, V69, P223, DOI 10.1097/QAI.0000000000000591; Wolinsky FD, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-70; Wolinsky FD, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-131; Zamparutti G, 2011, BRIT J CLIN PHARMACO, V72, P330, DOI 10.1111/j.1365-2125.2011.03908.x	40	17	17	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 6	2018	169	9					593	+		10.7326/M18-0852	http://dx.doi.org/10.7326/M18-0852			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ4UP	30304353	Green Accepted			2023-01-03	WOS:000449399700002
J	Marmora, L; Casas, CP; Grubb, I; McClure, C				Marmora, Lelio; Casas, Carmen Perez; Grubb, Ian; McClure, Craig			Long-acting technologies for infectious diseases in LMICs	LANCET			English	Editorial Material									[Marmora, Lelio; Casas, Carmen Perez] Unitaid, CH-1218 Geneva, Switzerland; [Grubb, Ian; McClure, Craig] Hlth Hounds Inc, Toronto, ON, Canada		Casas, CP (corresponding author), Unitaid, CH-1218 Geneva, Switzerland.	perezcasasc@unitaid.who.int						Bakshi RP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02603-z; Barnwal P, 2017, THER ADV PSYCHOPHARM, V7, P119, DOI 10.1177/2045125316681984; Bellinger AM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag2374; Clinton Health Access Initiative, 2016, ARV MARK REP STAT AN; Kaplan G, 2013, PATIENT PREFER ADHER, V7, P1171, DOI 10.2147/PPA.S53795; Mansur AH, 2017, RESP MED, V124, P36, DOI 10.1016/j.rmed.2017.01.008; Markowitz M, 2017, LANCET HIV, V4, pE331, DOI 10.1016/S2352-3018(17)30068-1; Swindells S, 2018, INT J TUBERC LUNG D, V22, P125, DOI 10.5588/ijtld.17.0486; Tsui AO, 2017, POPUL DEV REV, V43, P166, DOI 10.1111/padr.12051; Wu XL, 2018, ADV EXP MED BIOL, V1075, P53, DOI 10.1007/978-981-13-0484-2_3	10	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 3	2018	392	10158					1610	1611		10.1016/S0140-6736(18)32544-3	http://dx.doi.org/10.1016/S0140-6736(18)32544-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GZ0JO	30497794				2023-01-03	WOS:000449048900010
J	Caulley, L; Caplan, B; Ross, E				Caulley, Lisa; Caplan, Benjamin; Ross, Edgar			Medical Marijuana for Chronic Pain	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NEUROPATHIC PAIN; CANNABINOIDS; METAANALYSIS; SYSTEM; MODEL		[Caulley, Lisa] Guys Hosp, Ear Nose & Throat Dept, London, England; [Caplan, Benjamin] CED Fdn, Boston, MA USA; [Caplan, Benjamin] CED Clin, Boston, MA USA; [Caplan, Benjamin] Solo Sci, Boston, MA USA; [Ross, Edgar] Brigham & Womens Hosp, Dept Anesthesia Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA; [Ross, Edgar] Harvard Med Sch, Boston, MA USA	Guy's & St Thomas' NHS Foundation Trust; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Caulley, L (corresponding author), Guys Hosp, Ear Nose & Throat Dept, London, England.			Caulley, Lisa/0000-0002-9661-4634				Ahrens J, 2009, PHARMACOLOGY, V83, P217, DOI 10.1159/000201556; Bossong MG, 2013, EUR NEUROPSYCHOPHARM, V23, P1687, DOI 10.1016/j.euroneuro.2013.06.009; Boychuk DG, 2015, J ORAL FACIAL PAIN H, V29, P7, DOI 10.11607/ofph.1274; Casey SL, 2017, PAIN, V158, P2452, DOI 10.1097/j.pain.0000000000001051; Donvito G, 2018, NEUROPSYCHOPHARMACOL, V43, P52, DOI 10.1038/npp.2017.204; Gilliam WP, 2018, J PAIN, V19, P678, DOI 10.1016/j.jpain.2018.02.010; Jensen B, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0524-x; Joy JE, 1999, MARIJUANA MED ASSESS, P137; Marconi A, 2016, SCHIZOPHRENIA BULL, V42, P1262, DOI 10.1093/schbul/sbw003; Mondello E, 2018, J PAIN RES, V11, P1761, DOI 10.2147/JPR.S166617; Tetrault JM, 2007, ARCH INTERN MED, V167, P221, DOI 10.1001/archinte.167.3.221; Volkow ND, 2014, NEW ENGL J MED, V370, P2219, DOI 10.1056/NEJMra1402309; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358; Wilkerson JL, 2016, J PHARMACOL EXP THER, V357, P145, DOI 10.1124/jpet.115.229971; Wilkie G, 2016, JAMA ONCOL	15	9	9	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 18	2018	379	16					1575	1577		10.1056/NEJMclde1808149	http://dx.doi.org/10.1056/NEJMclde1808149			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GX4EI	30332574				2023-01-03	WOS:000447679900015
J	Jalal, H; Buchanich, JM; Roberts, MS; Balmert, LC; Zhang, K; Burke, DS				Jalal, Hawre; Buchanich, Jeanine M.; Roberts, Mark S.; Balmert, Lauren C.; Zhang, Kun; Burke, Donald S.			Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016	SCIENCE			English	Article							HEROIN-RELATED OVERDOSE; POISONING DEATHS; OPIOID ABUSE; TRENDS; INCREASES; RATES; US; MORTALITY; OXYCONTIN; COCAINE	Better understanding of the dynamics of the current U.S. overdose epidemic may aid in the development of more effective prevention and control strategies. We analyzed records of 599,255 deaths from 1979 through 2016 from the National Vital Statistics System in which accidental drug poisoning was identified as the main cause of death. By examining all available data on accidental poisoning deaths back to 1979 and showing that the overall 38-year curve is exponential, we provide evidence that the current wave of opioid overdose deaths (due to prescription opioids, heroin, and fentanyl) may just be the latest manifestation of a more fundamental longer-term process. The 38+ year smooth exponential curve of total U.S. annual accidental drug poisoning deaths is a composite of multiple distinctive subepidemics of different drugs (primarily prescription opioids, heroin, methadone, synthetic opioids, cocaine, and methamphetamine), each with its own specific demographic and geographic characteristics.	[Jalal, Hawre; Roberts, Mark S.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA; [Buchanich, Jeanine M.; Balmert, Lauren C.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Burke, Donald S.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA; [Balmert, Lauren C.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med Biostat, Chicago, IL 60611 USA; [Zhang, Kun] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Atlanta, GA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwestern University; Feinberg School of Medicine; Centers for Disease Control & Prevention - USA	Burke, DS (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.	donburke@pitt.edu		Jalal, Hawre/0000-0002-8224-6834; /0000-0002-5704-8094	CDC [IPA 16IPA1605230]; NIH/NCATS [1KL2TR0001856]; Robert Wood Johnson Foundation [72858]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001856] Funding Source: NIH RePORTER	CDC(Centre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NIH/NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This study was supported in part by CDC grant IPA 16IPA1605230 and NIH/NCATS grant 1KL2TR0001856 (H.J.) and by Robert Wood Johnson Foundation grant 72858 (J.M.B. and D.S.B.).	[Anonymous], 2011, EPIDEMIC RESPONDING; [Anonymous], 2018, GREAT ATT GIV COMB S; [Anonymous], 2017, HHS ACTING SECRETARY; [Anonymous], 2006, PUBLIC HEALTH ADVISO; [Anonymous], [No title captured]; Balmert LC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151655; Becker WC, 2008, DRUG ALCOHOL DEPEN, V94, P38, DOI 10.1016/j.drugalcdep.2007.09.018; Buchanich JM, 2018, PUBLIC HEALTH REP, V133, P423, DOI 10.1177/0033354918774330; Buchanich JM, 2016, PREV MED, V89, P317, DOI 10.1016/j.ypmed.2016.04.007; Burke DS, 2016, SCIENCE, V354, P529, DOI 10.1126/science.aal2943; Calcaterra S, 2013, DRUG ALCOHOL DEPEN, V131, P263, DOI 10.1016/j.drugalcdep.2012.11.018; Case A, 2017, BROOKINGS PAP ECO AC, P397; Center for Behavioral Health Statistics and Quality, 2017, 2016 NAT SURV DRUG U; Cicero TJ, 2015, JAMA PSYCHIAT, V72, P424, DOI 10.1001/jamapsychiatry.2014.3043; Cicero TJ, 2012, NEW ENGL J MED, V367, P187, DOI 10.1056/NEJMc1204141; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Compton WM, 2013, AM J PSYCHIAT, V170, P660, DOI 10.1176/appi.ajp.2012.12060737; Dowell D, 2016, HEALTH AFFAIR, V35, P1876, DOI 10.1377/hlthaff.2016.0448; Faul M, 2017, MMWR-MORBID MORTAL W, V66, P320, DOI 10.15585/mmwr.mm6612a2; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Guy GP, 2018, AM J PREV MED, V54, pE33, DOI 10.1016/j.amepre.2017.09.003; Guy GP, 2017, MMWR-MORBID MORTAL W, V66, P697, DOI 10.15585/mmwr.mm6626a4; Hedegaard H., 2017, DRUG OVERDOSE DEATHS; Jones CM, 2016, JAMA INTERN MED, V176, P399, DOI 10.1001/jamainternmed.2015.7799; Jones CM, 2017, AM J PUBLIC HEALTH, V107, P430, DOI 10.2105/AJPH.2016.303627; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Mars SG, 2015, SOC SCI MED, V140, P44, DOI 10.1016/j.socscimed.2015.06.032; Miroff N., 2017, WASHINGTON POST, pA01; Office of National Drug Control Policy, 2016, NAT DRUG CONTR STRAT; Paulozzi L., 2007, Morbidity and Mortality Weekly Report, V56, P93; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Police Executive Research Forum, 2017, UNPR OP EP; Ruhm CJ, 2017, AM J PREV MED, V53, P745, DOI 10.1016/j.amepre.2017.06.009; Seth P, 2018, MMWR-MORBID MORTAL W, V67, P349, DOI 10.15585/mmwr.mm6712a1; Stein EM, 2017, AM J PUBLIC HEALTH, V107, P1541, DOI [10.2105/AJPH.2017.303941, 10.2105/ajph.2017.303941]; Stewart K, 2017, J URBAN HEALTH, V94, P572, DOI 10.1007/s11524-017-0177-7; Tedesco D, 2017, HEALTH AFFAIR, V36, P1748, DOI 10.1377/hlthaff.2017.0260; Unick G, 2014, ADDICTION, V109, P1889, DOI 10.1111/add.12664; Vivolo-Kantor AM, 2018, MMWR-MORBID MORTAL W, V67, P279, DOI 10.15585/mmwr.mm6709e1; Warner M, 2013, ACAD FORENSIC PATHOL, V3, P231, DOI [DOI 10.23907/2013.029, 10.23907/2013.029]; Warner Margaret, 2009, NCHS Data Brief, P1	42	285	286	6	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 21	2018	361	6408			SI		1218	+	eaau1184	10.1126/science.aau1184	http://dx.doi.org/10.1126/science.aau1184			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GU3CQ	30237320	Green Accepted			2023-01-03	WOS:000445152500032
J	Kurskaya, O; Ryabichenko, T; Leonova, N; Shi, WF; Bi, HT; Sharshov, K; Kazachkova, E; Sobolev, I; Prokopyeva, E; Kartseva, T; Alekseev, A; Shestopalov, A				Kurskaya, Olga; Ryabichenko, Tatyana; Leonova, Natalya; Shi, Weifeng; Bi, Hongtao; Sharshov, Kirill; Kazachkova, Eugenia; Sobolev, Ivan; Prokopyeva, Elena; Kartseva, Tatiana; Alekseev, Alexander; Shestopalov, Alexander			Viral etiology of acute respiratory infections in hospitalized children in Novosibirsk City, Russia (2013-2017)	PLOS ONE			English	Article							INFLUENZA-LIKE ILLNESS; VIRUS-INFECTIONS; ADULTS; EPIDEMIOLOGY; SURVEILLANCE; SHENZHEN	Background Acute respiratory infections (ARIs) cause a considerable morbidity and mortality worldwide especially in children. However, there are few studies of the etiological structure of ARIs in Russia. In this work, we analyzed the etiology of ARIs in children (0-15 years old) admitted to Novosibirsk Children's Municipal Clinical Hospital in 2013-2017. Methods We tested nasal and throat swabs of 1560 children with upper or lower respiratory infection for main respiratory viruses (influenza viruses A and B, parainfluenza virus types 1-4, respiratory syncytial virus, metapneumovirus, four human coronaviruses, rhinovirus, adenovirus and bocavirus) using a RT-PCR Kit. Results We detected 1128 (72.3%) samples were positive for at least one virus. The most frequently detected pathogens were respiratory syncytial virus (358/1560, 23.0%), influenza virus (344/1560, 22.1%), and rhinovirus (235/1560, 15.1%). Viral co-infections were found in 163 out of the 1128 (14.5%) positive samples. We detected significant decrease of the respiratory syncytial virus-infection incidence in children with increasing age, while the reverse relationship was observed for influenza viruses. Conclusions We evaluated the distribution of respiratory viruses in children with ARIs and showed the prevalence of respiratory syncytial virus and influenza virus in the etiological structure of infections. This study is important for the improvement and optimization of diagnostic tactics, control and prevention of the respiratory viral infections.	[Kurskaya, Olga; Sharshov, Kirill; Kazachkova, Eugenia; Sobolev, Ivan; Prokopyeva, Elena; Alekseev, Alexander; Shestopalov, Alexander] Fed Res Ctr Fundamental & Translat Med, Dept Expt Modeling & Pathogenesis Infect Dis, Novosibirsk, Russia; [Ryabichenko, Tatyana; Kartseva, Tatiana] Novosibirsk State Med Univ, Dept Propaedeut Childhood Dis, Novosibirsk, Russia; [Leonova, Natalya] Novosibirsk Childrens Municipal Clin Hosp 6, Dept Childrens Dis, Novosibirsk, Russia; [Shi, Weifeng] Taishan Med Coll, Key Lab Etiol & Epidemiol Emerging Infect Dis Uni, Tai An, Shandong, Peoples R China; [Bi, Hongtao] Chinese Acad Sci, Northwest Inst Plateau Biol, Qinghai Key Lab Tibetan Med Pharmacol & Safety Ev, Xining, Qinghai, Peoples R China	Novosibirsk State Medical University; Shandong First Medical University & Shandong Academy of Medical Sciences; Chinese Academy of Sciences	Kurskaya, O (corresponding author), Fed Res Ctr Fundamental & Translat Med, Dept Expt Modeling & Pathogenesis Infect Dis, Novosibirsk, Russia.	kurskaya_og@mail.ru	Alekseev, Alexander/C-4998-2011; Shestopalov, Alexander/AAO-5569-2020; Sobolev, Ivan/AAD-4881-2020; Bi, Hongtao/AAJ-3106-2020; Sharshov, Kirill/C-7693-2011	Alekseev, Alexander/0000-0003-0015-9305; Sobolev, Ivan/0000-0002-4561-6517; Kartseva, Tatiana/0000-0001-7007-1996; Kazackova, Evgenia/0000-0003-3794-1018; Sharshov, Kirill/0000-0002-3946-9872; Prokopyeva, Elena/0000-0002-5349-8362	Russian Scientific Foundation [17-44-07001]; Russian Science Foundation [17-44-07001] Funding Source: Russian Science Foundation	Russian Scientific Foundation(Russian Science Foundation (RSF)); Russian Science Foundation(Russian Science Foundation (RSF))	The study was supported by a grant of Russian Scientific Foundation (project # 17-44-07001). KSh research activities have been supported by this grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102; Anh HLD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018176; Asner SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099392; Brittain-Long R, 2008, J CLIN VIROL, V41, P53, DOI 10.1016/j.jcv.2007.10.029; Cai XY, 2014, J MED VIROL, V86, P1249, DOI 10.1002/jmv.23931; Cebey-Lopez M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136526; Coleman CM, 2014, J VIROL, V88, P5209, DOI 10.1128/JVI.03488-13; De Marco MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100859; Delangue J, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-35; Dong W, 2016, ARCH VIROL, V161, P1907, DOI 10.1007/s00705-016-2866-z; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Eccles R, 2005, LANCET INFECT DIS, V5, P718, DOI 10.1016/S1473-3099(05)70270-X; Falchi A, 2011, J MED VIROL, V83, P1451, DOI 10.1002/jmv.22113; Feuillet F, 2012, J CLIN VIROL, V53, P97, DOI 10.1016/j.jcv.2011.10.002; Gurgel RQ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003090; Harper SA, 2009, CLIN INFECT DIS, V48, P1003, DOI 10.1086/598513; Hasman H, 2009, J MED MICROBIOL, V58, P408, DOI 10.1099/jmm.0.006098-0; He Y, 2014, INFLUENZA OTHER RESP, V8, P443, DOI 10.1111/irv.12257; Homaira N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147982; Hombrouck A, 2012, EUR J CLIN MICROBIOL, V31, P999, DOI 10.1007/s10096-011-1398-4; Huang GH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064254; Huo X, 2012, J MED VIROL, V84, P1980, DOI 10.1002/jmv.23401; Ilyicheva T, 2013, INFECT GENET EVOL, V20, P177, DOI 10.1016/j.meegid.2013.08.025; Ju XF, 2014, ARCH VIROL, V159, P2003, DOI 10.1007/s00705-014-2035-1; Khor CS, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-32; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Lee DH, 2017, EMERG INFECT DIS, V23, P358, DOI 10.3201/eid2302.161252; Li HX, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-143; Low D, 2008, CLIN MICROBIOL INFEC, V14, P298, DOI 10.1111/j.1469-0691.2007.01910.x; Lu YQ, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/210490; [Львов Н.И. Lvov N.I.], 2014, [Журнал инфектологии, Zhurnal infektologii], V6, P62; Peng JS, 2012, J MED VIROL, V84, P672, DOI 10.1002/jmv.22247; Pierangeli A, 2007, J MED VIROL, V79, P463, DOI 10.1002/jmv.20832; Pyrc K, 2007, J VIROL, V81, P3051, DOI 10.1128/JVI.01466-06; Richter J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147041; Schlaudecker EP, 2012, PEDIATR INFECT DIS J, V31, P1113, DOI 10.1097/INF.0b013e31826052eb; Sentilhes AC, 2013, INFLUENZA OTHER RESP, V7, P1070, DOI 10.1111/irv.12135; Sharshov K, 2010, ARCH VIROL, V155, P1145, DOI 10.1007/s00705-010-0676-2; Tecu Cristina, 2013, Roum Arch Microbiol Immunol, V72, P242; Tsukagoshi H, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00278; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; Wang HP, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0493-7; Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0; Zhang GC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044568	44	19	22	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2018	13	9							e0200117	10.1371/journal.pone.0200117	http://dx.doi.org/10.1371/journal.pone.0200117			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GU0DL	30226876	Green Submitted, Green Published, gold			2023-01-03	WOS:000444918300003
J	Hansen, RN; Pham, AT; Boing, EA; Lovelace, B; Wan, GJ; Urman, RD				Hansen, Ryan N.; Pham, An T.; Boing, Elaine A.; Lovelace, Belinda; Wan, George J.; Urman, Richard D.			Reduced length of stay and hospitalization costs among inpatient hysterectomy patients with postoperative pain management including IV versus oral acetaminophen	PLOS ONE			English	Article							INTRAVENOUS PARACETAMOL ACETAMINOPHEN; TOTAL ABDOMINAL HYSTERECTOMY; MULTIMODAL ANALGESIA; CARDIAC-SURGERY; OPIOIDS; MORPHINE; ABSORPTION; GUIDELINE; PLASMA; HEALTH	Objective To compare the outcomes of hysterectomy patients who received standard pain management including IV acetaminophen (IV APAP) versus oral APAP. Methods We performed a retrospective analysis of the Premier Database (January 2012 to September 2015) comparing hysterectomy patients who received postoperative pain management including IV APAP to those who received oral APAP starting on the day of surgery and continuing up to the third post-operative day, with no exclusions based on additional pain management. We compared the groups on length of stay (LOS), hospitalization costs, and average daily morphine equivalent dose (MED). The quarterly rate of IV APAP use for all hospitalizations by hospital was used as an instrumental variable in two-stage least squares regressions also adjusting for patient demographics, clinical risk factors, and hospital characteristics. Results We identified 22,828 hysterectomy patients including 14,811 (65%) who had received IV APAP. Study subjects averaged 50 and 52 years of age, respectively in the IV APAP and oral APAP cohorts and were predominantly non-Hispanic Caucasians (>= 60% in both cohorts). Instrumental variable models found IV APAP associated with 0.8 days shorter hospitalization (95% CI: -0.92 to -0.68, p < 0.0001) and $2,449 lower hospitalization costs (95% CI: -$2,902 to -$1,996, p < 0.0001). Average daily MED trended lower without statistical significance (-1.41 mg, 95% CI:-3.43 mg to 0.61 mg, p = 0.17). Conclusions Compared to oral APAP, managing post-hysterectomy pain with IV APAP is associated with shorter LOS and lower total hospitalization costs.	[Hansen, Ryan N.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA; [Pham, An T.; Boing, Elaine A.; Lovelace, Belinda; Wan, George J.] Mallinckrodt Pharmaceut, Hlth Econ & Outcomes Res Dept, Hampton, NJ USA; [Pham, An T.] Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA; [Urman, Richard D.] Harvard Med Sch, Boston, MA USA; [Urman, Richard D.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA	University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Hansen, RN (corresponding author), Univ Washington, Sch Pharm, Seattle, WA 98195 USA.	rhansen@uw.edu	Urman, Richard/ABG-4830-2020; Urman, Richard/AAH-7758-2019	Urman, Richard/0000-0002-0516-5977	Mallinckrodt Pharmaceuticals	Mallinckrodt Pharmaceuticals	This study was funded by Mallinckrodt Pharmaceuticals to RNH. The study funder was involved in study design, data acquisition, and review/approval of the final manuscript.	[Anonymous], 2017, STANDARD YESTERDAY T; Apfel C, 2015, AM J HEALTH-SYST PH, V72, P1961, DOI 10.2146/ajhp140179; Arici S, 2009, AGRI, V21, P54; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Azari L, 2013, OBSTET GYNECOL SURV, V68, P215, DOI 10.1097/OGX.0b013e31827f5119; Berger MM, 2000, CRIT CARE MED, V28, P2217, DOI 10.1097/00003246-200007000-00006; Berwick DM, 2008, HEALTH AFFAIR, V27, P759, DOI 10.1377/hlthaff.27.3.759; Blanton E, 2016, AM J OBSTET GYNECOL; Buvanendran A, 2009, CURR OPIN ANESTHESIO, V22, P588, DOI 10.1097/ACO.0b013e328330373a; Centers for Disease Control and Prevention, 2017, DAT STAT; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Devarakonda K, 2016, MORPHINE IMPACTS ABS; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; ELFANT AB, 1995, AM J SURG, V169, P430, DOI 10.1016/S0002-9610(99)80192-5; Elia N, 2005, ANESTHESIOLOGY, V103, P1296, DOI 10.1097/00000542-200512000-00025; Gan TJ, 2004, BRIT J ANAESTH, V92, P681, DOI 10.1093/bja/aeh123; Gold LS, 2016, CLIN J PAIN, V32, P747, DOI 10.1097/AJP.0000000000000322; GOLDHILL DR, 1995, ANAESTHESIA, V50, P122, DOI 10.1111/j.1365-2044.1995.tb15093.x; Guha A, 2002, EUR J ANAESTH, V19, P652, DOI 10.1017/S0265021502001072; Hansen RN, 2016, J WOMENS HEALTH, V25; Hansen RN, 2018, CURR MED RES OPIN, V4, P1; Hansen RN, 2016, ADV THER, V33, P1635, DOI 10.1007/s12325-016-0368-8; Hanson R., 2017, CURR MED RES OPIN, P1; Jibril Farah, 2015, Can J Hosp Pharm, V68, P238; Kennedy JM, 2003, J PHARM PHARMACOL, V55, P1345, DOI 10.1211/0022357021846; Macario A, 2011, PAIN PRACT, V11, P290, DOI 10.1111/j.1533-2500.2010.00426.x; Maiese BA, 2017, ADV THER, V34, P421, DOI 10.1007/s12325-016-0449-8; Pettersson PH, 2005, J CARDIOTHOR VASC AN, V19, P306, DOI 10.1053/j.jvca.2005.03.006; Pham A HR, 2016, NATL FORUM QUALITY I; Plunkett A, 2016, PRELIMINARY EXAMINA; Raffa RB, 2018, CLIN DRUG INVEST, V38, P259, DOI 10.1007/s40261-017-0610-4; Santoso JT, 2014, EUR J OBSTET GYN R B, V183, P48, DOI 10.1016/j.ejogrb.2014.10.007; Shaffer EE, 2017, ADV THER, V33, P2211, DOI 10.1007/s12325-016-0438-y; Singla NK, 2012, PAIN PRACT, V12, P523, DOI 10.1111/j.1533-2500.2012.00556.x; Smith HS, 2011, PAIN MED, V12, P961, DOI 10.1111/j.1526-4637.2011.01141.x; Steiner E, 2017, EUR J NUCL MED MOL I, V44, P509, DOI 10.1007/s00259-016-3451-0; van der Westhuizen J, 2011, ANAESTH INTENS CARE, V39, P242, DOI 10.1177/0310057X1103900214; Yeh YC, 2012, PHARMACOTHERAPY, V32, P559, DOI 10.1002/j.1875-9114.2011.01085.x; Zhao SZ, 2004, J PAIN SYMPTOM MANAG, V28, P35, DOI 10.1016/j.jpainsymman.2003.11.001	39	15	15	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2018	13	9							e0203746	10.1371/journal.pone.0203746	http://dx.doi.org/10.1371/journal.pone.0203746			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GT5KH	30212524	gold, Green Published, Green Submitted			2023-01-03	WOS:000444545800063
J	Ma, MX; Proffitt, R; Skubic, M				Ma, Mengxuan; Proffitt, Rachel; Skubic, Marjorie			Validation of a Kinect V2 based rehabilitation game	PLOS ONE			English	Article							VIRTUAL-REALITY; IN-HOME; RELIABILITY; MOVEMENT; EFFICACY; VALIDITY; MOTION; RANGE; WII	Interactive technologies are beneficial to stroke recovery as rehabilitation interventions; however, they lack evidence for use as assessment tools. Mystic Isle is a multi-planar full-body rehabilitation game developed using the Microsoft Kinect (R) V2. It aims to help stroke patients improve their motor function and daily activity performance and to assess the motions of the players. It is important that the assessment results generated from Mystic Isle are accurate. The Kinect V2 has been validated for tracking lower limbs and calculating gait-specific parameters. However, few studies have validated the accuracy of the Kinect (R) V2 skeleton model in upper-body movements. In this paper, we evaluated the spatial accuracy and measurement validity of a Kinect-based game Mystic Isle in comparison to a gold-standard optical motion capture system, the Vicon system. Thirty participants completed six trials in sitting and standing. Game data from the Kinect sensor and the Vicon system were recorded simultaneously, then filtered and sample rate synchronized. The spatial accuracy was evaluated using Pearson's r correlation coefficient, signal to noise ratio (SNR) and 3D distance difference. Each arm-joint signal had an average correlation coefficient above 0.9 and a SNR above 5. The hip joints data had less stability and a large variation in SNR. Also, the mean 3D distance difference of joints were less than 10 centimeters. For measurement validity, the accuracy was evaluated using mean and standard error of the difference, percentage error, Pearson's r correlation coefficient and intra-class correlation (ICC). Average errors of maximum hand extent of reach were less than 5% and the average errors of mean and maximum velocities were about 10% and less than 5%, respectively. We have demonstrated that Mystic Isle provides accurate measurement and assessment of movement relative to the Vicon system.	[Ma, Mengxuan; Skubic, Marjorie] Univ Missouri, Dept Elect Engn & Comp Sci, Columbia, MO 65211 USA; [Proffitt, Rachel] Univ Missouri, Dept Occupat Therapy, Columbia, MO USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Ma, MX (corresponding author), Univ Missouri, Dept Elect Engn & Comp Sci, Columbia, MO 65211 USA.	mmrnc@mail.missouri.edu	Proffitt, Rachel M/B-6179-2016	Proffitt, Rachel M/0000-0002-7357-6495	Telemedicine and Advanced Technology Research Center (TATRC) at the US Army Medical Research and Materiel Command (USAMRMC) [W911NF-04-D-0005]; NIH National Center for Advancing Translational Sciences (NCATS), components of the National Institutes of Health (NIH) [UL1 TR000448]; NIH Roadmap for Medical Research; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR002346, UL1TR002345] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024994] Funding Source: NIH RePORTER	Telemedicine and Advanced Technology Research Center (TATRC) at the US Army Medical Research and Materiel Command (USAMRMC)(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); NIH National Center for Advancing Translational Sciences (NCATS), components of the National Institutes of Health (NIH); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This study was supported by the Telemedicine and Advanced Technology Research Center (TATRC) at the US Army Medical Research and Materiel Command (USAMRMC) (W911NF-04-D-0005) (PI: Lange) and by Grant Number UL1 TR000448 from the NIH National Center for Advancing Translational Sciences (NCATS), components of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdulsatar F, 2013, J PEDIATR REHAB MED, V6, P193, DOI 10.3233/PRM-130260; Acar G, 2016, J PHYS THER SCI, V28, P774, DOI 10.1589/jpts.28.774; Alexandrova Ivelina V, 2012, Stud Health Technol Inform, V173, P16; Anderson Kelly R, 2015, Arch Phys Med Rehabil, V96, P973, DOI 10.1016/j.apmr.2014.09.008; Baheux Kenji, 2005, Technol Health Care, V13, P245; BOONE DC, 1978, PHYS THER, V58, P1355, DOI 10.1093/ptj/58.11.1355; Brennan DM, 2009, STUD HEALTH TECHNOL, V145, P231, DOI 10.3233/978-1-60750-018-6-231; Broeren J, 2002, CYBERPSYCHOL BEHAV, V5, P207, DOI 10.1089/109493102760147196; Chanpimol Shane, 2017, Arch Physiother, V7, DOI 10.1186/s40945-017-0033-9; Chien-Yen Chang, 2012, 2012 6th International Conference on Pervasive Computing Technologies for Healthcare, P159, DOI 10.4108/icst.pervasivehealth.2012.248714; Chow Y. W., 2017, J WIRELESS MOBILE NE, V8, P18; Geerse DJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139913; Guess TM, 2017, J APPL BIOMECH, V33, P176, DOI 10.1123/jab.2016-0107; Hartmann M, 2014, GAIT POSTURE, V39, pS109, DOI [10.1016/j.gaitpost.2014.04.150, DOI 10.1016/J.GAITPOST.2014.04.150]; HORGER MM, 1990, AM J OCCUP THER, V44, P342, DOI 10.5014/ajot.44.4.342; Hotrabhavananda B, 2016, IEEE ENG MED BIO, P2274, DOI 10.1109/EMBC.2016.7591183; Kurillo G, 2013, TECHNOL HEALTH CARE, V21, P641, DOI 10.3233/THC-130764; Lange B, 2012, DISABIL REHABIL, V34, P1863, DOI 10.3109/09638288.2012.670029; LifeModeler, MARK PLAC PROT LIFEM; Ma MX, 2017, 2017 IEEE/ACM SECOND INTERNATIONAL CONFERENCE ON CONNECTED HEALTH - APPLICATIONS, SYSTEMS AND ENGINEERING TECHNOLOGIES (CHASE), P255, DOI 10.1109/CHASE.2017.90; Mentiplay BF, 2015, J BIOMECH, V48, P2166, DOI 10.1016/j.jbiomech.2015.05.021; Microsoft, REFL HLTH; Mitchell K, 2014, PHYSIOTHER THEOR PR, V30, P521, DOI 10.3109/09593985.2014.900593; Motiian S, 2015, BIOMED ENG ONLINE, V14, DOI 10.1186/s12938-015-0102-9; Mousavi Hondori Hossein, 2014, J Med Eng, V2014, P846514, DOI 10.1155/2014/846514; Muller B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175813; Nixon ME, 2011, 2013 INT C VIRT REH, P222; Otte K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166532; Pathirana PN, 2016, IEEE T IND ELECTRON, V63, P1822, DOI 10.1109/TIE.2015.2497662; Pourmand A, 2017, GAMES HEALTH J, V6, P263, DOI 10.1089/g4h.2017.0046; Proffitt R, 2015, INT J TELEREHABILITA, V7, P23, DOI 10.5195/ijt.2015.6177; Proffitt R, 2015, PHYS THER, V95, P441, DOI 10.2522/ptj.20130571; Springer S, 2016, SENSORS-BASEL, V16, DOI 10.3390/s16020194; Stone E, 2011, J AMB INTEL SMART EN, V3, P349, DOI 10.3233/AIS-2011-0124; Sugarman H., 2011, VIRTUAL REHABILITATI, P1; Therapy P., MAKING PHYS THERAPY; van de Pol RJ, 2010, J PHYSIOTHER, V56, P7, DOI 10.1016/S1836-9553(10)70049-7; Vicon Motion Systems, FULL BOD MOD PLUG GA; Wilson JD, 2017, J SHOULDER ELB SURG, V26, pE382, DOI 10.1016/j.jse.2017.06.004	39	36	35	2	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2018	13	8							e0202338	10.1371/journal.pone.0202338	http://dx.doi.org/10.1371/journal.pone.0202338			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR5ZQ	30142631	Green Published, Green Submitted, gold			2023-01-03	WOS:000442722500011
J	Ajong, AB; Njotang, PN; Kenfack, B; Essi, MJ; Yakum, MN; Lballa, FBS; Mbu, ER				Ajong, Atem Bethel; Njotang, Philip Nana; Kenfack, Bruno; Essi, Marie Jose; Yakum, Martin Ndinakie; Lballa, Francklin Brice Soung; Mbu, Enow Robinson			Contraceptive method mix and preference: A focus on long acting reversible contraception in Urban Cameroon	PLOS ONE			English	Article								Introduction Meeting targets of the Sustainable Development Goals in the domain of maternal health and the Family Planning 2020 commitments for Cameroon requires an increased use of modern contraception. Long acting reversible contraceptives (LARCs) are methods which have been proven highly efficient with contraceptive failure rates of less than 1%. The objective of this survey was to determine the contraceptive method mix in the Biyem-Assi Health District and identify factors associated to the use of LARCs. Methodology A cross-sectional community-based study was conducted from March 2015 to April 2015 targeting current female contraceptive users of childbearing age in the Biyem-Assi Health District. A multistep cluster sampling was used and data collected by trained surveyors using a pretested and validated questionnaire. Data were analysed using the statistical software Epi-Info version 3.5.4. Logistic regressions were used to identify associations between the use of LARCs and selected covariates and the strength of association measured with the odds ratio. Results A total of 437 eligible women were included in the survey. Their mean age was 26.7 +/- 5.8 years and 45.8% were in a union. The contraceptive method mix decreased in this order; male condoms (76.0%), female condoms (7.6%), oral contraceptive pills (5.0%), implants (4.6%), and intrauterine devices (3.4%) giving us a LARC rate of 8%. Only 54.0% and 46.9% of the participants reported to be knowledgeable of the implant and intrauterine device respectively. Their contraceptive choices were determined principally by perceived efficiency and accessibility. The major factor significantly associated to LARC use was the number of living children above 2 (AOR = 3.90[1.53-9.94], p-value = 0.004). Though not statistically significant, associations were found between LARC use and other factors like marital status, level of education, religion and future fertility desire. Conclusion The rate of use of LARCs is still very low among these women. The number of living children is significantly associated with the use of LARCs. The local family planning policy makers should intensify sensitization on the benefits and side effects of modern contraception and LARCs in order to create more awareness and improve contraceptive uptake.	[Ajong, Atem Bethel; Njotang, Philip Nana; Mbu, Enow Robinson] Univ Yaounde I, Fac Med & Biomed Sci, Dept Obstet & Gynaecol, Yaounde, Cameroon; [Njotang, Philip Nana] Yaounde Cent Hosp, Obstet & Gynaecol Unit, Yaounde, Cameroon; [Kenfack, Bruno; Lballa, Francklin Brice Soung] Univ Dschang, Fac Sci, Dept Biomed Sci, Dschang, Cameroon; [Essi, Marie Jose] Univ Yaounde I, Fac Med & Biomed Sci, Dept Publ Hlth, Yaounde, Cameroon; [Yakum, Martin Ndinakie] Meilleur Acces Soins Sante, Yaounde, Cameroon; [Lballa, Francklin Brice Soung] Global Fund, MC CCAM, Bamenda, Cameroon; [Mbu, Enow Robinson] Minist Publ Hlth, Directorate Family Hlth, Yaounde, Cameroon	University of Yaounde I; University of Yaounde I	Ajong, AB (corresponding author), Univ Yaounde I, Fac Med & Biomed Sci, Dept Obstet & Gynaecol, Yaounde, Cameroon.	christrah@yahoo.fr	Yakum, Martin/R-5738-2019	Yakum, Martin/0000-0003-3149-2020; Ajong, Atem Bethel/0000-0002-5513-2110; SOUNG IBALLA, Francklin Brice/0000-0001-7182-6254				Ajong AB, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0283-9; Akam E, 2005, DOCUMENTS DANALYSE; Bulto GA, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-46; Dockalova B, 2016, SUSTAINABLE DEV GOAL, P1; Earsido A, 2015, J PREG CHILD HLTH, V2, P1; Gebeyehu WA, TRENDS DETERMINANTS; Getinet S., 2014, GREENER J EPIDEMIOL, V2, P23, DOI [10.15580/GJEPH.2014.1.070514294, DOI 10.15580/GJEPH.2014.1.070514294]; Gudaynhe SW, 2014, GLOB J MED RES E, V14, P8; Institut National de la Statistique(INS) et ICF, 2011, ENQ DEM SANT IND MUL, P99; National Institute of Statistics/UNDP, 2008, COUNTR REP PROGR ACH; Sahilemichael A., 2015, W ETHIOPIA J WOMENS, V4, P1; Seiber EE, 2007, INT FAM PLAN PERSPEC, V33, P117, DOI 10.1363/3311707; Tebeje B, 2017, J WOMENS HLTH CARE, V6, DOI [10.4172/2167-0420.1000351, DOI 10.4172/2167-0420.1000351]; Teferra AS., 2015, SCI J PUBLIC HLTH, V3, P143, DOI DOI 10.11648/J.SJPH; Warriner IK., 2006, PREVENTING UNSAFE AB	15	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2018	13	8							e0202967	10.1371/journal.pone.0202967	http://dx.doi.org/10.1371/journal.pone.0202967			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR6TZ	30138474	gold, Green Published, Green Submitted			2023-01-03	WOS:000442800100147
J	Jiang, H; Huai, Y; Cheng, H; Uyeki, TM; Chen, MY; Guan, XH; Liu, SL; Peng, YX; Yang, H; Luo, J; Zheng, JD; Huang, JG; Peng, ZB; Xiang, NJ; Zhang, YZ; Klena, JD; Hu, DJ; Rainey, JJ; Huo, XX; Xiao, L; Xing, XS; Zhan, FX; Yu, HJ; Varma, JK				Jiang, Hui; Huai, Yang; Cheng, Hui; Uyeki, Timothy M.; Chen, Maoyi; Guan, Xuhua; Liu, Shali; Peng, Youxing; Yang, Hui; Luo, Jun; Zheng, Jiandong; Huang, Jigui; Peng, Zhibin; Xiang, Nijuan; Zhang, Yuzhi; Klena, John D.; Hu, Dale J.; Rainey, Jeanette J.; Huo, Xixiang; Xiao, Lin; Xing, Xuesen; Zhan, Faxian; Yu, Hongjie; Varma, Jay K.			Invasive Streptococcus pneumoniae infection among hospitalized patients in Jingzhou city, China, 2010-2012	PLOS ONE			English	Article							PNEUMOCOCCAL CONJUGATE VACCINE; INFLUENZAE TYPE-B; BACTERIAL-MENINGITIS; BLOOD CULTURE; CHILDREN; DISEASE; SURVEILLANCE; BURDEN; ADULTS	Background Streptococcus pneumoniae (Sp) is a leading cause of bacterial pneumonia, meningitis, and sepsis and a major source of morbidity and mortality worldwide. Invasive pneumococcal disease (IPD) is defined as isolation of Sp from a normally sterile site, including blood or cerebrospinal fluid. The aim of this study is to describe outcomes as well as clinical and epidemiological characteristics of hospitalized IPD case patients in central China. Methods We conducted surveillance for IPD among children and adults from April 5, 2010 to September 30, 2012, in four major hospitals in Jingzhou City, Hubei Province. We collected demographic, clinical, and outcome data for all enrolled hospitalized patients with severe acute respiratory infection (SARI) or meningitis, and collected blood, urine, and cerebrospinal fluid (CSF) for laboratory testing for Sp infections. Collected data were entered into Epidata software and imported into SPSS for analysis. Results We enrolled 22,375 patients, including 22,202 (99%) with SARI and 173 (1%) with meningitis. One hundred and eighteen (118, 3%) with either SARI or meningitis were Sp positive, 32 (0.8%) from blood/CSF culture, and 87 (5%) from urine antigen testing. Of those 118 patients, 57% were aged >= 65 years and nearly 100% received antibiotics during hospitalization. None were previously vaccinated with 7-valent pneumococcal conjugate vaccine (PCV 7), 23-valent pneumococcal polysaccharide vaccine, or seasonal influenza vaccine. The main serotypes identified were 14, 12, 3, 1, 19F, 4, 5, 9V, 15 and 18C, corresponding to serotype coverage rates of 42%, 63%, and 77% for PCV7, PCV10, and PCV13, respectively. Conclusions Further work is needed to expand access to pneumococcal vaccination in China, both among children and potentially among the elderly, and inappropriate use of antibiotics is a widespread and serious problem in China.	[Jiang, Hui; Zheng, Jiandong; Peng, Zhibin; Xiang, Nijuan; Yu, Hongjie] Chinese Ctr Dis Control & Prevent, Div Infect Dis, Key Lab Surveillance & Early Warning Infect Dis, Beijing, Peoples R China; [Huai, Yang; Zhang, Yuzhi; Klena, John D.; Hu, Dale J.; Rainey, Jeanette J.; Varma, Jay K.] Ctr Dis Control & Prevent, Ctr Global Hlth, China US Collaborat Program Emerging & Reemerging, Beijing, Peoples R China; [Cheng, Hui; Guan, Xuhua; Huo, Xixiang; Xing, Xuesen; Zhan, Faxian] Hubei Prov Ctr Dis Control & Prevent, Wuhan, Hubei, Peoples R China; [Uyeki, Timothy M.] Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA USA; [Chen, Maoyi; Huang, Jigui; Xiao, Lin] Jingzhou Ctr Dis Control & Prevent, Jingzhou, Peoples R China; [Liu, Shali] Jingzhou Cent Hosp, Jingzhou, Peoples R China; [Peng, Youxing] Jingzhou First Peoples Hosp, Jingzhou, Peoples R China; [Yang, Hui] Jingzhou Second Peoples Hosp, Jingzhou, Peoples R China; [Luo, Jun] Jingzhou Maternal & Childrens Hosp, Jingzhou, Peoples R China; [Rainey, Jeanette J.; Varma, Jay K.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global Hlth Protect, Global Dis Detect Branch, Atlanta, GA USA; [Yu, Hongjie] Fudan Univ, Sch Publ Hlth, Key Lab Publ Hlth Safety, Minist Educ, Shanghai, Peoples R China	Chinese Center for Disease Control & Prevention; Chinese Center for Disease Control & Prevention; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Fudan University	Yu, HJ (corresponding author), Chinese Ctr Dis Control & Prevent, Div Infect Dis, Key Lab Surveillance & Early Warning Infect Dis, Beijing, Peoples R China.; Yu, HJ (corresponding author), Fudan Univ, Sch Publ Hlth, Key Lab Publ Hlth Safety, Minist Educ, Shanghai, Peoples R China.	cfetpyhj@vip.sina.com	Yu, Hongjie/GZK-5351-2022	Hu, Dale/0000-0002-0519-1032	U.S. Centers for Disease Control and Prevention [5U2GGH000018]; National Science Fund for Distinguished Young Scholars [81525023]; US National Institutes of Health [U19 AI51915]; China CDC's Key Laboratory of Surveillance and Early-warning on Infectious Disease; Jingzhou Health Bureau	U.S. Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Science Fund for Distinguished Young Scholars(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China CDC's Key Laboratory of Surveillance and Early-warning on Infectious Disease; Jingzhou Health Bureau	This study was funded by grants from U.S. Centers for Disease Control and Prevention (5U2GGH000018), the National Science Fund for Distinguished Young Scholars (81525023), the US National Institutes of Health (Comprehensive International Program for Research on AIDS grant U19 AI51915), China CDC's Key Laboratory of Surveillance and Early-warning on Infectious Disease. The funding bodies had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript.; We thank the participating hospitals and Jingzhou Health Bureau for assistance in coordinating data collection and supporting this study. We thank Xiaojia Nie and Fang Ma from China-US Collaborative Program on Emerging and Re-Emerging Infection Disease, Center for Global Health, Centers for Disease Control and Prevention, Beijing, China; Jingping Ma, Aimin Li, and Jun Qin from Jingzhou Central Hospital, Xiaoxia Huang, Shaohua Zhou, and Hongzhu Lu from Jingzhou First People's Hospital, Zhangliang Hu and Daoyong Yuan from Jingzhou Second People's Hospital, and Hanbin Wu and Kewu Wang from Jingzhou Maternal and Children's Hospital for assistance in coordinating data collection and supporting this study. We thank Hui Wang from Peking University People's Hospital, Beijing, China for assistance in blood/CSF culture. The views expressed are those of the authors and do not necessarily represent the policy of the China CDC or the U.S. Centers for Disease Control and Prevention.	[Anonymous], 2012, Wkly Epidemiol Rec, V87, P129; [Anonymous], 2008, Wkly Epidemiol Rec, V83, P373; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; Batuwanthudawe R, 2009, CLIN INFECT DIS, V48, pS136, DOI 10.1086/596492; Bijlsma MW, 2016, LANCET INFECT DIS, V16, P339, DOI 10.1016/S1473-3099(15)00430-2; Brouwer MC, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004405.pub5; Currie J, 2014, J DEV ECON, V110, P39, DOI 10.1016/j.jdeveco.2014.05.006; Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6; FISCHER GW, 1984, JAMA-J AM MED ASSOC, V252, P1742, DOI 10.1001/jama.252.13.1742; [付盼 Fu Pan], 2010, [中国循证儿科杂志, Chinese JOurnal of Evidence Based Pediatrics], V5, P371; Grace CJ, 2001, CLIN INFECT DIS, V32, P1651, DOI 10.1086/320527; Houck PM, 2004, ARCH INTERN MED, V164, P637, DOI 10.1001/archinte.164.6.637; Isaacman DJ, 2010, INT J INFECT DIS, V14, pE197, DOI 10.1016/j.ijid.2009.05.010; Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060; Kobayashi M, 2015, MMWR-MORBID MORTAL W, V64, P944, DOI 10.15585/mmwr.mm6434a4; Levine OS, 2000, EMERG INFECT DIS, V6, P165, DOI 10.3201/eid0602.000209; Li F, 2014, CHIN J CLIN RATIONAL, V7, P176; Mylotte JM, 2000, EUR J CLIN MICROBIOL, V19, P157, DOI 10.1007/s100960050453; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; Ortqvist A, 2005, SEMIN RESP CRIT CARE, V26, P563, DOI 10.1055/s-2005-925523; Pan F, 2015, LAB MED, V30, P599; Saha SK, 2005, PEDIATR INFECT DIS J, V24, P1093, DOI 10.1097/01.inf.0000190030.75892.78; Sun H.L., 2008, CHIN J INFECT CHEMOT, V8, P24; van de Beek D, 2004, LANCET INFECT DIS, V4, P139, DOI 10.1016/S1473-3099(04)00937-5; Wang YJ, 2002, PEDIATR INFECT DIS J, V21, P271, DOI 10.1097/00006454-200204000-00002; Wei G, 2003, CHIN PHARM, V14, P220; XIE Y, 2015, PLOS ONE, V10, DOI DOI 10.1371/JOURNAL.PONE.0144366; Yu HJ, 2014, INFLUENZA OTHER RESP, V8, P53, DOI 10.1111/irv.12205; Yu HJ, 2012, HEALTH AFFAIR, V31, P2545, DOI 10.1377/hlthaff.2011.1272; Zhang QL, 2011, PEDIATR INFECT DIS J, V30, P7, DOI 10.1097/INF.0b013e3181ec6245; Zheng Y, LANDSCAPE VACCINES C	32	4	6	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2018	13	8							e0201312	10.1371/journal.pone.0201312	http://dx.doi.org/10.1371/journal.pone.0201312			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR0JS	30125283	Green Submitted, Green Published, gold			2023-01-03	WOS:000442202100006
J	Urtishak, KA; Wang, LS; Culjkovic-Kraljacic, B; Davenport, JW; Porazzi, P; Vincent, TL; Teachey, DT; Tasian, SK; Moore, JS; Seif, AE; Jin, SH; Barrett, JS; Robinson, BW; Chen, IML; Harvey, RC; Carroll, MP; Carroll, AJ; Heerema, NA; Devidas, M; Dreyer, ZE; Hilden, JM; Hunger, SP; Willman, CL; Borden, KLB; Felix, CA				Urtishak, Karen A.; Wang, Li-San; Culjkovic-Kraljacic, Biljana; Davenport, James W.; Porazzi, Patrizia; Vincent, Tiffaney L.; Teachey, David T.; Tasian, Sarah K.; Moore, Jonni S.; Seif, Alix E.; Jin, Shenghao; Barrett, Jeffrey S.; Robinson, Blaine W.; Chen, I-Ming L.; Harvey, Richard C.; Carroll, Martin P.; Carroll, Andrew J.; Heerema, Nyla A.; Devidas, Meenakshi; Dreyer, ZoAnn E.; Hilden, Joanne M.; Hunger, Stephen P.; Willman, Cheryl L.; Borden, Katherine L. B.; Felix, Carolyn A.			Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; INITIATION-FACTOR EIF4E; GENE-EXPRESSION; PROGNOSTIC-FACTORS; IMPROVED SURVIVAL; DRUG-RESISTANCE; ANTIVIRAL DRUG; RNA REGULON; CELL-CYCLE; FACTOR 4E	The poor outcomes in infant acute lymphoblastic leukemia (ALL) necessitate new treatments. Here we discover that EIF4E protein is elevated in most cases of infant ALL and test EIF4E targeting by the repurposed antiviral agent ribavirin, which has anticancer properties through EIF4E inhibition, as a potential treatment. We find that ribavirin treatment of actively dividing infant ALL cells on bone marrow stromal cells (BMSCs) at clinically achievable concentrations causes robust proliferation inhibition in proportion with EIF4E expression. Further, we find that ribavirin treatment of KMT2A-rearranged (KMT2A-R) infant ALL cells and the KMT2A-AFF1 cell line RS4:11 inhibits EIF4E, leading to decreases in oncogenic EIF4E-regulated cell growth and survival proteins. In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5. Ribavirin-treated RS4:11 cells exhibit impaired EIF4E-dependent nuclear to cytoplasmic export and/or translation of the corresponding mRNAs, as well as reduced phosphorylation of the p-AKT1, p-EIF4EBP1, p-RPS6 and p-EIF4E signaling proteins. This leads to an S-phase cell cycle arrest in RS4:11 cells corresponding to the decreased proliferation. Ribavirin causes nuclear EIF4E to re-localize to the cytoplasm in KMT2A-AFF1 infant ALL and RS4:11 cells, providing further evidence for EIF4E inhibition. Ribavirin slows increases in peripheral blasts in KMT2A-R infant ALL xenograft-bearing mice. Ribavirin cooperates with chemotherapy, particularly L-asparaginase, in reducing live KMT2A-AFF1 infant ALL cells in BMSC co-cultures. This work establishes that EIF4E is broadly elevated across infant ALL and that clinically relevant ribavirin exposures have preclinical activity and effectively inhibit EIF4E in KMT2A-R cases, suggesting promise in EIF4E targeting using ribavirin as a means of treatment.	[Urtishak, Karen A.; Davenport, James W.; Porazzi, Patrizia; Vincent, Tiffaney L.; Teachey, David T.; Tasian, Sarah K.; Seif, Alix E.; Robinson, Blaine W.; Hunger, Stephen P.; Felix, Carolyn A.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Wang, Li-San; Moore, Jonni S.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA; [Culjkovic-Kraljacic, Biljana; Borden, Katherine L. B.] Univ Montreal, IRIC, Dept Pathol & Cell Biol, Montreal, PQ, Canada; [Teachey, David T.; Tasian, Sarah K.; Seif, Alix E.; Barrett, Jeffrey S.; Hunger, Stephen P.; Felix, Carolyn A.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Jin, Shenghao; Carroll, Martin P.] Univ Penn, Div Hematol & Oncol, Perelman Sch Med, Philadelphia, PA USA; [Barrett, Jeffrey S.] Childrens Hosp Philadelphia, Div Clin Pharmacol & Therapeut, Philadelphia, PA 19104 USA; [Chen, I-Ming L.; Harvey, Richard C.; Willman, Cheryl L.] Univ New Mexico Hlth Serv, Dept Pathol, Albuquerque, NM USA; [Chen, I-Ming L.; Harvey, Richard C.; Willman, Cheryl L.] Univ New Mexico Hlth Serv, UNM Canc Ctr, Albuquerque, NM USA; [Carroll, Andrew J.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA; [Heerema, Nyla A.] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Devidas, Meenakshi] Dept Biostat, Childrens Oncol Grp, Gainesville, FL USA; [Dreyer, ZoAnn E.] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; [Hilden, Joanne M.] Childrens Hosp Colorado, Aurora, CO USA; [Hilden, Joanne M.] Univ Colorado, Sch Med, Aurora, CO USA; [Urtishak, Karen A.] NewAgeSys Inc, Princeton Jct, NJ USA; [Porazzi, Patrizia] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Barrett, Jeffrey S.] Bill & Melinda Gates Med Res Inst, Cambridge, MA USA; [Robinson, Blaine W.] Leukemia & Lymphoma Soc, Therapy Accelerat Program, Rye Brook, NY USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Universite de Montreal; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of New Mexico; University of New Mexico; University of Alabama System; University of Alabama Birmingham; University System of Ohio; Ohio State University; Children's Oncology Group (COG); Baylor College of Medicine; Texas Children's Cancer Center; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Jefferson University	Felix, CA (corresponding author), Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA.; Felix, CA (corresponding author), Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA.	felix@email.chop.edu	Porazzi, Patrizia/AAA-3151-2020; Devidas, Meenakshi/H-1170-2019; Seif, Alix/B-9918-2013	Devidas, Meenakshi/0000-0002-1099-3478; Teachey, David/0000-0001-7373-8987; Porazzi, Patrizia/0000-0002-1372-7482; Tasian, Sarah/0000-0003-1327-1662; Seif, Alix/0000-0002-1799-2582	Leukemia & Lymphoma Society [SCOR 7372-07]; ASH Bridge Funding Program; CHOP Bridge Funding Program; Eagles Fly for Leukemia; CHOP Hematologic Malignancies Research Fund; SU2C St. Baldrick's Pediatric Dream Team Translational Research [SU2C-AACR-DT1113]; Cookies for Kids' Cancer Foundation; Rally Foundation [K08CA184418]; Hyundai Hope on Wheels Scholar Award [ACS MRSG-12-215-01-LIB]; Canada Research Chair [R01CA098571, R01CA080728]; COG Statistical Center [U10CA98413]; COG Specimen Banking [U24CA114766];  [R01CA198089]; NATIONAL CANCER INSTITUTE [U10CA098413, R01CA080728, R01CA098571, K08CA184418, U10CA180886, R01CA198089, P30CA016520, U10CA180899] Funding Source: NIH RePORTER	Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); ASH Bridge Funding Program; CHOP Bridge Funding Program; Eagles Fly for Leukemia; CHOP Hematologic Malignancies Research Fund; SU2C St. Baldrick's Pediatric Dream Team Translational Research; Cookies for Kids' Cancer Foundation; Rally Foundation; Hyundai Hope on Wheels Scholar Award; Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs); COG Statistical Center; COG Specimen Banking; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	CAF, LSW, J.S.B., CLW, MD, and SPH supported by Leukemia & Lymphoma Society SCOR 7372-07. CAF supported by ASH Bridge Funding Program, CHOP Bridge Funding Program, Eagles Fly for Leukemia, and CHOP Hematologic Malignancies Research Fund. C.A.F. and S.K.T. supported by SU2C St. Baldrick's Pediatric Dream Team Translational Research Grant SU2C-AACR-DT1113 (SU2C is a program of Entertainment Industry Foundation administered by AACR). CAF and DTT supported by Cookies for Kids' Cancer Foundation. SKT supported by K08CA184418 and Rally Foundation for Childhood Cancer Research and was ALSF Scholar in Developmental Therapeutics. AES supported by ACS MRSG-12-215-01-LIB and Hyundai Hope on Wheels Scholar Award. MPC supported by R01CA198089. KLBB funded by R01CA098571 and R01CA080728 and holds a Canada Research Chair. Other support provided by U10CA98413 (COG Statistical Center), U24CA114766 (COG Specimen Banking).	Aebi C, 1997, J PEDIATR-US, V130, P612, DOI 10.1016/S0022-3476(97)70246-4; Asano K, 2001, COLD SPRING HARB SYM, V66, P403, DOI 10.1101/sqb.2001.66.403; ASSELIN BL, 1993, J CLIN ONCOL, V11, P1780, DOI 10.1200/JCO.1993.11.9.1780; Assouline S, 2015, HAEMATOLOGICA, V100, pE7, DOI 10.3324/haematol.2014.111245; Assouline S, 2009, BLOOD, V114, P257, DOI 10.1182/blood-2009-02-205153; Barrett D, 2012, PEDIATR DRUGS, V14, P299, DOI 10.2165/11594740-000000000-00000; Barrington-Trimis JL, 2017, INT J CANCER, V140, P1000, DOI 10.1002/ijc.30487; Biondi A, 2006, HAEMATOLOGICA, V91, P534; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Borden KLB, 2016, TRANSLATION, V4, DOI 10.1080/21690731.2016.1220899; Borden KLB, 2010, LEUKEMIA LYMPHOMA, V51, P1805, DOI 10.3109/10428194.2010.496506; Bunpo P, 2010, J NUTR, V140, P2020, DOI 10.3945/jn.110.129197; Bunpo P, 2009, J BIOL CHEM, V284, P32742, DOI 10.1074/jbc.M109.047910; Chapuis N, 2010, LEUKEMIA, V24, P1686, DOI 10.1038/leu.2010.170; Cheok MH, 2006, NAT REV CANCER, V6, P117, DOI 10.1038/nrc1800; Culjkovic B, 2008, J CELL BIOL, V181, P51, DOI 10.1083/jcb.200707018; Culjkovic B, 2006, J CELL BIOL, V175, P415, DOI 10.1083/jcb.200607020; Culjkovic B, 2007, CELL CYCLE, V6, P65, DOI 10.4161/cc.6.1.3688; Culjkovic B, 2009, J ONCOL, V2009, DOI 10.1155/2009/981679; Culjkovic-Kraljacic B, 2016, BLOOD, V127, P858, DOI 10.1182/blood-2015-05-645069; Dai DH, 2017, BIOCHEM BIOPH RES CO, V482, P1259, DOI 10.1016/j.bbrc.2016.12.025; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dordelmann M, 1999, BLOOD, V94, P1209, DOI 10.1182/blood.V94.4.1209.416k05_1209_1217; Dreyer ZE, 2015, PEDIATR BLOOD CANCER, V62, P419, DOI 10.1002/pbc.25322; Dunn LA, 2018, HEAD NECK-J SCI SPEC, V40, P233, DOI 10.1002/hed.24938; Ekins S, 2011, DRUG DISCOV TODAY, V16, P298, DOI 10.1016/j.drudis.2011.02.016; Endres CJ, 2009, J PHARMACOL EXP THER, V331, P287, DOI 10.1124/jpet.109.153130; Faber J, 2009, BLOOD, V113, P2375, DOI 10.1182/blood-2007-09-113597; FERSTER A, 1994, BRIT J HAEMATOL, V86, P284, DOI 10.1111/j.1365-2141.1994.tb04727.x; Frost BM, 2002, MED PEDIATR ONCOL, V38, P329, DOI 10.1002/mpo.10052; Glue P, 1999, SEMIN LIVER DIS, V19, P17; Groninger E, 2004, CRIT REV ONCOL HEMAT, V52, P173, DOI 10.1016/j.critrevonc.2004.08.007; HALL CB, 1983, NEW ENGL J MED, V308, P1443, DOI 10.1056/NEJM198306163082403; Hijiya N, 2009, CANCER-AM CANCER SOC, V115, P23, DOI 10.1002/cncr.23988; Hilden JM, 2006, BLOOD, V108, P441, DOI 10.1182/blood-2005-07-3011; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Holleman A, 2004, NEW ENGL J MED, V351, P533, DOI 10.1056/NEJMoa033513; Hunger SP, 2012, J CLIN ONCOL, V30, P1663, DOI 10.1200/JCO.2011.37.8018; Imamura T, 2002, BRIT J HAEMATOL, V119, P119, DOI 10.1046/j.1365-2141.2002.03803.x; Isakovic AM, 2017, EXP CELL RES, V350, P32, DOI 10.1016/j.yexcr.2016.11.001; Jarvis SM, 1998, BRIT J PHARMACOL, V123, P1587, DOI 10.1038/sj.bjp.0701775; Jedema I, 2004, EXP HEMATOL, V32, P188, DOI 10.1016/j.exphem.2003.11.005; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Kang HN, 2012, BLOOD, V119, P1872, DOI 10.1182/blood-2011-10-382861; Kentsis A, 2005, RNA, V11, P1762, DOI 10.1261/rna.2238705; Kentsis A, 2004, P NATL ACAD SCI USA, V101, P18105, DOI 10.1073/pnas.0406927102; KHARE GP, 1973, ANTIMICROB AGENTS CH, V3, P517, DOI 10.1128/AAC.3.4.517; Koren G, 2003, CAN MED ASSOC J, V168, P1289; Kosaka T, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.6_suppl.329; Kosaka T, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e14010; Kraljacic BC, 2011, LEUKEMIA, V25, P1197, DOI 10.1038/leu.2011.57; Krilov LR, 2002, PEDIATR INFECT DIS J, V21, P479, DOI 10.1097/00006454-200205000-00037; KRISHAN A, 1976, CANCER RES, V36, P143; Landon AL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6413; LASKIN OL, 1987, CLIN PHARMACOL THER, V41, P546, DOI 10.1038/clpt.1987.70; Lin CJ, 2009, CANCER RES, V69, P7491, DOI 10.1158/0008-5472.CAN-09-0813; LOWIS SP, 1993, CANCER RES, V53, P4881; Mamane Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000242; Manara MC, 2013, CURR PHARM DESIGN, V19, P5344, DOI 10.2174/1381612811319300004; Matsuo Y, 1998, LEUKEMIA RES, V22, P567, DOI 10.1016/S0145-2126(98)00050-2; MCLEOD HL, 1992, BRIT J CANCER, V66, pS23; MCLEOD HL, 1993, CANCER SURV, V17, P253; Mihara K, 2003, BRIT J HAEMATOL, V120, P846, DOI 10.1046/j.1365-2141.2003.04217.x; Moore AS, 2011, J PAEDIATR CHILD H, V47, P875, DOI 10.1111/j.1440-1754.2011.02103.x; Munson ME, 2010, CYTOM PART A, V77A, P909, DOI 10.1002/cyto.a.20935; Ogino A, 2014, ONCOL LETT, V8, P2469, DOI 10.3892/ol.2014.2569; Pessetto ZY, 2013, MOL CANCER THER, V12, P1299, DOI 10.1158/1535-7163.MCT-12-0968; Pettersson F, 2015, CANCER RES, V75, P1102, DOI 10.1158/0008-5472.CAN-14-1996; Pettersson F, 2011, CLIN CANCER RES, V17, P2874, DOI 10.1158/1078-0432.CCR-10-2334; Pieters R, 2007, LANCET, V370, P240, DOI 10.1016/S0140-6736(07)61126-X; Pozarowski Piotr, 2004, Curr Protoc Cell Biol, VChapter 18, DOI [10.1002/0471142956.cy0719s25, 10.1002/0471143030.cb1808s21]; Ramakers-van Woerden NL, 2004, LEUKEMIA, V18, P521, DOI 10.1038/sj.leu.2403253; Reaman GH, 1999, J CLIN ONCOL, V17, P445, DOI 10.1200/JCO.1999.17.2.445; Riner A, 2009, POSTGRAD MED, V121, P139, DOI 10.3810/pgm.2009.05.2014; Rixe O, 2007, CLIN CANCER RES, V13, P7280, DOI 10.1158/1078-0432.CCR-07-2141; Robinson BW, 2008, BRIT J HAEMATOL, V141, P827, DOI 10.1111/j.1365-2141.2008.07100.x; Roederer M, 2011, CYTOM PART A, V79A, P95, DOI 10.1002/cyto.a.21010; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schotte D, 2011, HAEMATOL-HEMATOL J, V96, P703, DOI 10.3324/haematol.2010.026138; Scully RE, 2007, CARDIOVASC TOXICOL, V7, P122, DOI 10.1007/s12012-007-0006-4; Shi FF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136746; Sidwell RW, 2005, ANTIVIR RES, V68, P10, DOI 10.1016/j.antiviral.2005.06.003; Smee Donald F., 2004, Antiviral Chemistry & Chemotherapy, V15, P261; Stam RW, 2010, BLOOD, V115, P2835, DOI 10.1182/blood-2009-07-233049; Tan J, 2018, J BIOCHEM MOL TOXIC, V32, DOI 10.1002/jbt.22007; Tan K, 2008, BIOCHEM BIOPH RES CO, V375, P341, DOI 10.1016/j.bbrc.2008.07.163; Teachey DT, 2006, BLOOD, V107, P1149, DOI 10.1182/blood-2005-05-1935; Teng LC, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-63; Topisirovic I, 2005, MOL CELL BIOL, V25, P1100, DOI 10.1128/MCB.25.3.1100-1112.2005; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Topisirovic I, 2009, MOL CELL BIOL, V29, P1152, DOI 10.1128/MCB.01532-08; Trentin L, 2009, EUR J HAEMATOL, V83, P406, DOI 10.1111/j.1600-0609.2009.01305.x; Urtishak KA, 2013, BLOOD, V121, P2689, DOI 10.1182/blood-2012-04-425033; Vallee S, 2000, EUR J PHARMACOL, V404, P49, DOI 10.1016/S0014-2999(00)00596-3; van Leeuwen IMM, 2012, CELL CYCLE, V11, P1851, DOI 10.4161/cc.20254; Volpin F, 2017, ONCOGENE, V36, P3037, DOI 10.1038/onc.2016.457; Volpon L, 2016, P NATL ACAD SCI USA, V113, P5263, DOI 10.1073/pnas.1524291113; Volpon L, 2013, BIOCHEM BIOPH RES CO, V434, P614, DOI 10.1016/j.bbrc.2013.03.125; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; WILLIS RC, 1978, P NATL ACAD SCI USA, V75, P3042, DOI 10.1073/pnas.75.7.3042; Xi CL, 2018, BIOCHEM BIOPH RES CO, V503, P2286, DOI 10.1016/j.bbrc.2018.06.150; Xu K, 2011, BRIEF BIOINFORM, V12, P341, DOI 10.1093/bib/bbr006; Yang CHT, 2017, J CLIN TRANSL HEPATO, V5, P59, DOI 10.14218/JCTH.2016.00053; Yang L, 2008, J CLIN ONCOL, V26, P1932, DOI 10.1200/JCO.2007.13.8404; Zahreddine HA, 2014, NATURE, V511, P90, DOI 10.1038/nature13283	108	21	21	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2241	2262		10.1038/s41388-018-0567-7	http://dx.doi.org/10.1038/s41388-018-0567-7			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30478448	Green Accepted			2023-01-03	WOS:000462588000002
J	Khan, MI; Shin, JH; Shin, TS; Kim, MY; Cho, NJ; Kim, JD				Khan, Muhammad Imran; Shin, Jin Hyuk; Shin, Tai Sun; Kim, Min Yong; Cho, Nam Jun; Kim, Jong Deog			Anthocyanins from Cornus kousa ethanolic extract attenuate obesity in association with anti-angiogenic activities in 3T3-L1 cells by down-regulating adipogeneses and lipogenesis	PLOS ONE			English	Article							BREAST-CANCER; INSULIN-RESISTANCE; GENE-EXPRESSION; PPAR-GAMMA; ADIPOCYTES; HEALTH; PROTEIN; LIVER; RISK	Cornus kousa the Korean dogwood has been traditionally used in East Asia as therapeutic traditional medicine however biological activities of Cornus kousa have not been investigated previously. The aim of the present study was to evaluate anti-obesity activities coupled with anti-angiogenic activities of anthocyanins rich fraction of ethanolic leaf extract of Cornus kousa (ELECk) in HUVECs and 3T3- L1 cells. Dried plants leaves were extracted with 70% ethanol and anthocyanin fraction (AnT Fr) was obtained by eluting the ethanolic extract through non-polar macroporous resin and further purification by HPLC. Antiangiogenic activities were determined by antiproliferative effect of AnT Fr on HUVECs. In the presence of various concentrations of AnT Fr, 3T3-L1 preadipocytes were induced to differentiate. Lipid accumulation in differentiated adipocytes were quantified by Oil-Red O staining. AnT Fr significantly suppressed angiogenesis by inhibiting proliferation and tube formation of HUVECs via downregulating VEGRF 2, PI3K, beta-catenin, NF-kB, and Akt1 in a dose dependent manner. AnT Fr inhibited lipid accumulation by down-regulating adipogenesis and lipogenesis promoting signaling proteins, PPAR gamma, CCAAT, C/EBP alpha, aP2, FAS, and LPL, however enhanced AMPK activation to p-AMPK in 3T3 cells quantified and expressed by western blotting. AnT Fr inhibit lipid accumulation by regulating adipogenesis and lipogenesis related genes and signaling proteins. The anti-obesity activities exerted by Cornus kousa are associated with antiangiogenic activities of anthocyanins rich fraction of Cornus kousa. Hence the presence of bioactive anthocyanins, Cornus kosa, is a good candidate for nutraceutical and pharmaceutical formulation for treating or controlling obesity.	[Khan, Muhammad Imran; Shin, Jin Hyuk; Cho, Nam Jun; Kim, Jong Deog] Chonnam Natl Univ, Dept Biotechnol, Yeosu, Chonnam, South Korea; [Shin, Tai Sun] Chonnam Natl Univ, Dept Food Sci & Nutr, Gwangju, South Korea; [Kim, Min Yong] Chonnam Natl Univ, Dept Refrigerat Engn, Yeosu, Chonnam, South Korea; [Shin, Tai Sun; Kim, Min Yong; Kim, Jong Deog] Chonnam Natl Univ, Res Ctr Antiobes & Hlth Care, Yeosu, Chonnam, South Korea	Chonnam National University; Chonnam National University; Chonnam National University; Chonnam National University	Kim, JD (corresponding author), Chonnam Natl Univ, Dept Biotechnol, Yeosu, Chonnam, South Korea.; Kim, JD (corresponding author), Chonnam Natl Univ, Res Ctr Antiobes & Hlth Care, Yeosu, Chonnam, South Korea.	pasteur@jnu.ac.kr			Chonnam National University	Chonnam National University	The research work was funded by Chonnam National University.	Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8; Blando J, 2011, CANCER PREV RES, V4, P2002, DOI 10.1158/1940-6207.CAPR-11-0182; Bronckaers A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071104; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Cao YH, 2010, NAT REV DRUG DISCOV, V9, P107, DOI 10.1038/nrd3055; DeFuria J, 2009, J NUTR, V139, P1510, DOI 10.3945/jn.109.105155; Ding LC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057477; Dirat B, 2011, CANCER RES, V71, P2455, DOI 10.1158/0008-5472.CAN-10-3323; Ejaz A, 2009, J NUTR, V139, P919, DOI 10.3945/jn.108.100966; Elena A, 2017, OXID MED CELL LONGEV, V11; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Gungor NK, 2014, J CLIN RES PEDIATR E, V6, P129, DOI [10.4274/jcrpe.1471, 10.4274/Jcrpe.1471]; Harris HR, 2011, JNCI-J NATL CANCER I, V103, P273, DOI 10.1093/jnci/djq500; Iizukaa Y, 2016, TOXICOL REP, V3, P4, DOI 10.1016/j.toxrep.2015.11.003; Jana S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182137; Jansson PA, 2007, J INTERN MED, V262, P173, DOI 10.1111/j.1365-2796.2007.01830.x; Kim KH, 2011, ANNU REV FOOD SCI T, V2, P237, DOI 10.1146/annurev-food-022510-133656; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Lee DR, 2015, ASIAN PAC J TROP MED, V8, P879, DOI 10.1016/j.apjtm.2015.10.011; Liu RH, 2003, AM J CLIN NUTR, V78, p517S, DOI 10.1093/ajcn/78.3.517S; Mau JL, 2001, J AGR FOOD CHEM, V49, P183, DOI 10.1021/jf000263c; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; Mohamed G. A., 2014, Bulletin of the Faculty of Pharmacy, Cairo University, V52, P269, DOI 10.1016/j.bfopcu.2014.05.001; Peng CH, 2011, J AGR FOOD CHEM, V59, P2663, DOI 10.1021/jf1043508; Picon-Ruiz M, 2016, CANCER RES, V76, P491, DOI 10.1158/0008-5472.CAN-15-0927; Qin Y, 2009, AM J CLIN NUTR, V90, P485, DOI 10.3945/ajcn.2009.27814; Rayalam S, 2008, J NUTR BIOCHEM, V19, P717, DOI 10.1016/j.jnutbio.2007.12.007; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Seeram NP, 2002, J AGR FOOD CHEM, V50, P2519, DOI 10.1021/jf0115903; Shimocka II, 2006, BMC COMPLEM ALTERN M, V6, P9, DOI [10.1186/1472-6882-6-9, DOI 10.1186/1472-6882-6-9]; Tsuda T, 2008, J AGR FOOD CHEM, V56, P642, DOI 10.1021/jf073113b; Tyler C., 2007, CURR OPIN CELL BIOL, V19, P612, DOI [10.1016/j.ceb.2007.09.014, DOI 10.1016/J.CEB.2007.09.014]; Umegaki K, 2014, TOXICOL REP, V1, P787, DOI 10.1016/j.toxrep.2014.09.013; Vareed SK, 2006, LIFE SCI, V78, P777, DOI 10.1016/j.lfs.2005.05.094; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Viollet B, 2007, DIABETES METAB, V33, P395, DOI 10.1016/j.diabet.2007.10.004; White AJ, 2015, CANCER-AM CANCER SOC, V121, P3700, DOI 10.1002/cncr.29552	38	15	15	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 6	2018	13	12							e0208556	10.1371/journal.pone.0208556	http://dx.doi.org/10.1371/journal.pone.0208556			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HD1YF	30521605	Green Submitted, gold, Green Published			2023-01-03	WOS:000452307600091
J	Belz, M; Rehling, N; Schmidt, U; Wiltfang, J; Kis, B; Wolff-Menzler, C				Belz, Michael; Rehling, Nico; Schmidt, Ulrike; Wiltfang, Jens; Kis, Bernhard; Wolff-Menzler, Claus			Bacterial infections among patients with psychiatric disorders: Relation with hospital stay, age, and psychiatric diagnoses	PLOS ONE			English	Article							CARE-ASSOCIATED INFECTIONS; LENGTH-OF-STAY; SCHIZOPHRENIA; IMPACT; COSTS	The prevalence of infections is supposed to be higher in older patients and to extend the length of hospital stays. This study aimed, first, to test this supposition within a large psychiatric population which we divided into four clusters of psychiatric ICD-10 diagnoses: F00-F03 (dementias), F10 (substance disorders), F20-29 (schizophrenia, schizophreniform and other non-mood psychotic disorders), F32-F33 (major depressive disorders). Second, despite the increasing evidence for the role of infections in psychiatric disorders, it is, to the best of our knowledge, largely unknown whether the rates of infections with pathogens of the four most frequent germ families differ between psychiatric diseases. Thus, in a retrospective study, the results of clinical routine examinations (pap smear, analysis of midstream urine, stool) dependent on symptoms in 8545 patients of a German psychiatric clinic were analyzed in a 12-year dataset. Results show that a longer hospital stay was associated with an increased number of microbiological tests, but led to no significant difference between positive vs. negative findings. Consistent with previous studies, patients with infections were older than patients without infections. For the F10 diagnosis cluster we found a significantly reduced (F10: Staphylococcaceae) and for the F20-29 cluster a heightened risk of infections (Staphylococcaceae, Corynebacteriaceae). Furthermore, patients belonging to the F00-F03 cluster exhibited elevated rates of infections with all four germ families. The latter can be ascribed to patients' age as we found higher age to be associated with these infections, independently of the presence of dementia. Our results suggest that different psychiatric diagnoses are associated with a heightened or lowered risk of bacterial infections and, furthermore, that clinical routine infection-screenings for elderly psychiatric patients seems to be reasonable.	[Belz, Michael; Rehling, Nico; Schmidt, Ulrike; Wiltfang, Jens; Kis, Bernhard; Wolff-Menzler, Claus] Univ Med Ctr Gottingen UMG, Dept Psychiat & Psychotherapy, Gottingen, Lower Saxony, Germany; [Wiltfang, Jens] German Ctr Neurodegenerat Dis DZNE, Gottingen, Lower Saxony, Germany; [Wiltfang, Jens] Univ Aveiro, Med Sci Dept, Inst Biomed iBiMED, Aveiro, Portugal	Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Universidade de Aveiro	Belz, M (corresponding author), Univ Med Ctr Gottingen UMG, Dept Psychiat & Psychotherapy, Gottingen, Lower Saxony, Germany.	mbelz1@gwdg.de	Cruz e Silva, Odete/AAH-5595-2020	Wiltfang, Jens/0000-0003-1492-5330				*ALZH EUR, PREVALENCE OF DEMENT; Alzheimer Europe, 2013, RESEARCH; Arefian H, 2016, AM J INFECT CONTROL, V44, P160, DOI 10.1016/j.ajic.2015.09.005; Castle SC, 2000, CLIN INFECT DIS, V31, P578, DOI 10.1086/313947; Cevizci S, 2015, WORLD J BIOL PSYCHIA, V16, P230, DOI 10.3109/15622975.2015.1012224; Cohen J., 1988, STATISTICALPOWER ANA, V2; Fellerhoff B, 2011, SCHIZOPHR RES, V129, P191, DOI 10.1016/j.schres.2011.04.015; Geffers C, 2002, GESUNDHEITSBERICHTER; Ingrosso L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094728; Krause D, 2010, WORLD J BIOL PSYCHIA, V11, P739, DOI 10.3109/15622971003653246; Li H, 2017, ASIA-PAC J PUBLIC HE, V29, P440, DOI 10.1177/1010539517717366; Maheshwari P, 2015, J ALZHEIMERS DIS, V43, P957, DOI 10.3233/JAD-140621; Mutlu EA, 2012, AM J PHYSIOL-GASTR L, V302, pG966, DOI 10.1152/ajpgi.00380.2011; Nguyen TT, 2018, J PSYCHIATR RES, V99, P50, DOI 10.1016/j.jpsychires.2018.01.013; Parte AC, 2014, NUCLEIC ACIDS RES, V42, pD613, DOI 10.1093/nar/gkt1111; ROUX ADE, 2006, CHEST, V129, P1219; Shima K, 2010, MED MICROBIOL IMMUN, V199, P283, DOI 10.1007/s00430-010-0162-1; Statistisches Bundesamt, 2017, DIE 10 HAUFIGSTEN PS; Szabo G, 2015, ALCOHOL RES-CURR REV, V37, P159; van Beurden YH, 2017, J HOSP INFECT, V95, P421, DOI 10.1016/j.jhin.2016.12.019; Vrijens F, 2012, EPIDEMIOL INFECT, V140, P126, DOI 10.1017/S0950268811000100; WANG X, 2014, SCI REP UK, V4; Yolken RH, 2008, MOL PSYCHIATR, V13, P470, DOI 10.1038/mp.2008.5; Zimlichman E, 2013, JAMA INTERN MED, V173, P2039, DOI 10.1001/jamainternmed.2013.9763	24	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2018	13	12							e0208458	10.1371/journal.pone.0208458	http://dx.doi.org/10.1371/journal.pone.0208458			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HD0NQ	30513128	Green Submitted, gold, Green Published			2023-01-03	WOS:000452204800032
J	Dean, CR; Shemar, M; Ostrowski, GAU; Painter, RC				Dean, Caitlin R.; Shemar, Manjeet; Ostrowski, Gillian A. U.; Painter, Rebecca C.			CLINICAL UPDATES Management of severe pregnancy sickness and hyperemesis gravidarum	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							1ST TRIMESTER; RISK-FACTORS; NAUSEA; OUTCOMES; WOMEN; ASSOCIATION; ONDANSETRON; TERMINATION; WEIGHT; SAFETY		[Dean, Caitlin R.; Shemar, Manjeet; Ostrowski, Gillian A. U.] Dunmore Farm, Pregnancy Sickness Support, Par, Cornwall, England; [Painter, Rebecca C.] Univ Amsterdam, Amsterdam UMC, Obstet & Gynaecol, Amsterdam, Netherlands; Birmingham Womens & Childrens Hosp, Birmingham, W Midlands, England; Bridge Lane Grp Practice, London, England; NHS England, London, England	University of Amsterdam; Birmingham Women's Hospital	Dean, CR (corresponding author), Dunmore Farm, Pregnancy Sickness Support, Par, Cornwall, England.	caitlinrdean@gmail.com	/W-5933-2019; Painter, Rebecca/O-8973-2019	Painter, Rebecca/0000-0001-9336-6033				Al-Ozairi E, 2009, OBSTET MED, V2, P34, DOI 10.1258/om.2008.080046; American College of Obstetricians and Gynecologists, 2018, OBSTET GYNECOL, V131, pe15, DOI DOI 10.1097/AOG.0000000000002456; Anaforoglu I, 2012, NEUROENDOCRINOL LETT, V33, P285; Armstrong LE, 2016, CURR OPIN CLIN NUTR, V19, P434, DOI 10.1097/MCO.0000000000000320; Attarbashi S., 2016, GUIDELINE GYN, V27, P1; Ayyavoo A, 2014, AM J OBSTET GYNECOL, V210, P521, DOI 10.1016/j.ajog.2013.11.035; Birkeland E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119962; Boelig RC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010607.pub2; Bolin M, 2013, BJOG-INT J OBSTET GY, V120, P541, DOI 10.1111/1471-0528.12132; Brecht-Doscher A, 2010, P NAT C PREGN SICKN; Chambers P, 2010, ANTIEMETIC GUIDELINE; Chiossi G, 2006, OBSTET GYNECOL SURV, V61, P255, DOI 10.1097/01.ogx.0000206336.08794.65; Christodoulou-Smith J, 2011, J MATERN-FETAL NEO M, V24, P1307, DOI 10.3109/14767058.2011.582904; Coetzee RL, 2011, J DEV ORIG HLTH DIS, V2, P81, DOI 10.1017/S2040174410000735; Colodro-Conde L, 2016, BEHAV GENET, V46, P481, DOI 10.1007/s10519-016-9781-7; Danielsson B, 2014, REPROD TOXICOL, V50, P134, DOI 10.1016/j.reprotox.2014.10.017; Dean C, 2015, I COULD NOT SURVIVE; Dean C, 2018, BR J MIDWIFERY, V26, P109, DOI [10.12968/bjom.2018.26.2.109, DOI 10.12968/BJOM.2018.26.2.109]; Dean C., 2014, BR J MIDWIFERY, V22, P847, DOI DOI 10.12968/BJOM.2014.22.12.847; Dean C, 2017, MIDIRS MIDWIFERY DIG, V27, P177; Dean C., 2014, ESSENTIALLY MIDIRS, V5, P32; Dean Caitlin, 2017, JBI Database System Rev Implement Rep, V15, P2659, DOI 10.11124/JBISRIR-2016-003271; Debby A, 2008, J REPROD MED, V53, P347; Ebrahimi N, 2009, J OBSTET GYNAECOL CA, V31, P803, DOI 10.1016/S1701-2163(16)34298-0; Einarson TR, 2013, J POPUL THER CLIN PH, V20, pE171; European Medicines Agency, 2013, EMA5794912013, P1; Faramarzi M, 2015, HUM REPROD, V30, P2764, DOI 10.1093/humrep/dev248; Fejzo MS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03258-0; Fejzo MS, 2011, J MIDWIFERY WOM HEAL, V56, P132, DOI 10.1111/j.1542-2011.2010.00019.x; Fiaschi L, 2016, HUM REPROD, V31, P1675, DOI 10.1093/humrep/dew128; Gadsby R, 2011, NAUSEA VOMITING PREG; Gill SK, 2009, CAN J GASTROENTEROL, V23, P270, DOI 10.1155/2009/678514; Grooten I, 2016, COMMUNICATION; Grooten IJ, 2015, BJOG-INT J OBSTET GY, V122, P1664, DOI 10.1111/1471-0528.13042; Grooten IJ, 2017, AM J CLIN NUTR, V106, P812, DOI 10.3945/ajcn.117.158931; Grooten IJ, 2015, NUTR METAB INSIGHTS, V8, P33, DOI 10.4137/NMI.S29523; Grooten IJ, 2015, NUTR METAB INSIGHTS, V8, P23, DOI 10.4137/NMI.S29532; Gyesi- Appiah A, GYNAECOLOGY MANAGEME; Hinkle SN, 2016, JAMA INTERN MED, V176, P1621, DOI 10.1001/jamainternmed.2016.5641; Huusom LD, 2011, BJOG-INT J OBSTET GY, V118, P1, DOI 10.1111/j.1471-0528.2010.02782.x; Joint Formulary Committee, 2017, BRIT NAT FORM MARCH, P1458; Jordan K, 2005, EUR J CANCER, V41, P199, DOI 10.1016/j.ejca.2004.09.026; Kemp MW, 2016, HUM REPROD UPDATE, V22, P240, DOI 10.1093/humupd/dmv047; Kim DR, 2009, ARCH WOMEN MENT HLTH, V12, P61, DOI 10.1007/s00737-009-0064-7; King R, 2015, PRIMARY CARE MANAGEM; Knight M, 2020, SAVING LIVES IMPROVI; Koren G, 2004, J Obstet Gynaecol, V24, P530; Koren G, 2014, REPROD TOXICOL, V47, P77, DOI 10.1016/j.reprotox.2014.05.012; Koren G, 2013, AM J OBSTET GYNECOL, V208, pS20, DOI 10.1016/j.ajog.2012.10.205; Kramer J, 2013, MCN-AM J MATERN-CHIL, V38, P21, DOI 10.1097/NMC.0b013e3182748489; Lacroix R, 2000, AM J OBSTET GYNECOL, V182, P931, DOI 10.1016/S0002-9378(00)70349-8; Lerner L, 2016, J CACHEXIA SARCOPENI, V7, P467, DOI 10.1002/jcsm.12077; MacGibbon K. W., 2015, WOMENS HLTH GYNECOL, V1, P1; Maltepe C, 2013, P BIOPYSCHOSOCIAL UN; Martin RP, 1999, J ABNORM CHILD PSYCH, V27, P323, DOI 10.1023/A:1022662726587; Matok I, 2009, NEW ENGL J MED, V360, P2528, DOI 10.1056/NEJMoa0807154; Mazzotta P, 1999, CLIN PHARMACOL THER, V65, P199, DOI 10.1016/S0009-9236(99)80327-0; McCarthy FP, 2014, OBSTET GYNECOL, V124, P743, DOI 10.1097/AOG.0000000000000449; McParlin C, 2016, JAMA-J AM MED ASSOC, V316, P1392, DOI 10.1001/jama.2016.14337; Mitchell-Jones N, 2017, BJOG-INT J OBSTET GY, V124, P20, DOI 10.1111/1471-0528.14180; Mitchell-Jones N, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017566; Mullin PM, 2012, J MATERN-FETAL NEO M, V25, P632, DOI 10.3109/14767058.2011.598588; Niemeijer MN, 2012, AM J OBSTET GYNECOL, V211, P150; Niemeijer MN, 2012, AM J OBSTET GYNECOL, V211, pe1; O'Hara ME, 2013, P BIOPS UND HYP GRAV; Parker SE, 2014, PAEDIATR PERINAT EP, V28, P527, DOI 10.1111/ppe.12151; Pasternak B, 2013, NEW ENGL J MED, V368, P814, DOI 10.1056/NEJMoa1211035; Petry CJ, 2017, BIORXIV, DOI [10.1101/221267, DOI 10.1101/221267]; Piwko C, J POPUL THER CLIN PH; Poursharif B, 2007, CONTRACEPTION, V76, P451, DOI 10.1016/j.contraception.2007.08.009; Pregnancy Sickness Support, 2018, DITCH THE KET; Rochelson B, 2003, J REPROD MED, V48, P422; Royal College of Obstetricians and Gynaecologists, 2016, MAN NAUS VOM PREGN H; Seto A, 1997, AM J PERINAT, V14, P119, DOI 10.1055/s-2007-994110; Swallow BL, 2010, P 1 NAT C NVP HYP GR; Swallow BL, 2010, PSYCHOLOGIST, V23, P206; Tan PC, 2013, OBSTET GYNECOL, V121, P291, DOI 10.1097/AOG.0b013e31827c5e99; The Acute and Chronic Special interest Group, 2015, REG GUID MAN HYP GRA; Toriello HV, 2013, AM J MED GENET A, V161A, P417, DOI 10.1002/ajmg.a.35765; Trovik J, 2016, ISR J HEALTH POLICY, V5, DOI 10.1186/s13584-016-0099-y; VANSTUIJVENBERG ME, 1995, AM J OBSTET GYNECOL, V172, P1585, DOI 10.1016/0002-9378(95)90501-4; Veenendaal MVE, 2011, BJOG-INT J OBSTET GY, V118, P1302, DOI 10.1111/j.1471-0528.2011.03023.x; Vikanes A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2050	83	13	13	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	2018	363								k5000	10.1136/bmj.k5000	http://dx.doi.org/10.1136/bmj.k5000			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HC9MI	30504245				2023-01-03	WOS:000452130000005
J	Wise, J				Wise, Jacqui			Baby care: RCOG finds average of seven factors behind each stillbirth, neonatal death, and brain injury	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Royal College of Obstetricians and Gynaecologists, 2018, EACH BAB COUNTS	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2018	363								k4792	10.1136/bmj.k4792	http://dx.doi.org/10.1136/bmj.k4792			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB0RO	30420410				2023-01-03	WOS:000450725200007
J	Advani, R; Flinn, I; Popplewell, L; Forero, A; Bartlett, NL; Ghosh, N; Kline, J; Roschewski, M; LaCasce, A; Collins, GP; Tran, T; Lynn, J; Chen, JY; Volkmer, JP; Agoram, B; Huang, J; Majeti, R; Weissman, IL; Takimoto, CH; Chao, MP; Smith, SM				Advani, Ranjana; Flinn, Ian; Popplewell, Leslie; Forero, Andres; Bartlett, Nancy L.; Ghosh, Nilanjan; Kline, Justin; Roschewski, Mark; LaCasce, Ann; Collins, Graham P.; Thu Tran; Lynn, Judith; Chen, James Y.; Volkmer, Jens-Peter; Agoram, Balaji; Huang, Jie; Majeti, Ravindra; Weissman, Irving L.; Takimoto, Chris H.; Chao, Mark P.; Smith, Sonali M.			CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							B-CELL LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; FOLLICULAR LYMPHOMA; STEM-CELLS; OPEN-LABEL; PHAGOCYTOSIS; OBINUTUZUMAB; MULTICENTER; TARGET; CANCER	BACKGROUND The Hu5F9-G4 (hereafter, 5F9) antibody is a macrophage immune checkpoint inhibitor blocking CD47 that induces tumor-cell phagocytosis. 5F9 synergizes with rituximab to eliminate B-cell non-Hodgkin's lymphoma cells by enhancing macrophage-mediated antibody-dependent cellular phagocytosis. This combination was evaluated clinically. METHODS We conducted a phase 1b study involving patients with relapsed or refractory non-Hodgkin's lymphoma. Patients may have had diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma. 5F9 (at a priming dose of 1 mg per kilogram of body weight, administered intravenously, with weekly maintenance doses of 10 to 30 mg per kilogram) was given with rituximab to determine safety and efficacy and to suggest a phase 2 dose. RESULTS A total of 22 patients (15 with DLBCL and 7 with follicular lymphoma) were enrolled. Patients had received a median of 4 (range, 2 to 10) previous therapies, and 95% of the patients had disease that was refractory to rituximab. Adverse events were predominantly of grade 1 or 2. The most common adverse events were anemia and infusion-related reactions. Anemia (an expected on-target effect) was mitigated by the strategy of 5F9 prime and maintenance dosing. Dose-limiting side effects were rare. A selected phase 2 dose of 30 mg of 5F9 per kilogram led to an approximate 100% CD47-receptor occupancy on circulating white and red cells. A total of 50% of the patients had an objective (i.e., complete or partial) response, with 36% having a complete response. The rates of objective response and complete response were 40% and 33%, respectively, among patients with DLBCL and 71% and 43%, respectively, among those with follicular lymphoma. At a median follow-up of 6.2 months among patients with DLBCL and 8.1 months among those with follicular lymphoma, 91% of the responses were ongoing. CONCLUSIONS The macrophage checkpoint inhibitor 5F9 combined with rituximab showed promising activity in patients with aggressive and indolent lymphoma. No clinically significant safety events were observed in this initial study. (Funded by Forty Seven and the Leukemia and Lymphoma Society; ClinicalTrials. gov number, NCT02953509.)	[Advani, Ranjana; Thu Tran; Majeti, Ravindra; Weissman, Irving L.] Stanford Univ, Stanford, CA 94305 USA; [Popplewell, Leslie] City Hope Natl Med Ctr, Duarte, CA USA; [Lynn, Judith; Chen, James Y.; Volkmer, Jens-Peter; Agoram, Balaji; Huang, Jie; Majeti, Ravindra; Weissman, Irving L.; Takimoto, Chris H.; Chao, Mark P.] Forty Seven, Menlo Pk, CA USA; [Flinn, Ian] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA; [Forero, Andres] Univ Alabama Birmingham, Birmingham, AL USA; [Bartlett, Nancy L.] Washington Univ, St Louis, MO 63130 USA; [Ghosh, Nilanjan] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA; [Kline, Justin; Smith, Sonali M.] Univ Chicago, Chicago, IL 60637 USA; [Roschewski, Mark] NCI, Rockville, MD USA; [LaCasce, Ann] Dana Farber Canc Inst, Boston, MA 02115 USA; [Collins, Graham P.] Univ Oxford, Oxford, England	Stanford University; City of Hope; Sarah Cannon Research Institute; Tennessee Oncology; University of Alabama System; University of Alabama Birmingham; Washington University (WUSTL); University of Chicago; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Dana-Farber Cancer Institute; University of Oxford	Advani, R (corresponding author), Stanford Univ, Stanford, CA 94305 USA.	radvani@stanford.edu	Smith, Sonali/AAD-9328-2020	Majeti, Ravindra/0000-0002-5814-0984; Advani, Ranjana/0000-0002-3219-2292; Bartlett, Nancy/0000-0001-8470-394X; Collins, Graham/0000-0002-8803-4234	Leukemia and Lymphoma Society; Forty Seven; NATIONAL CANCER INSTITUTE [ZIABC011916] Funding Source: NIH RePORTER	Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Forty Seven; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Forty Seven and the Leukemia and Lymphoma Society.	Casulo C, 2015, J CLIN ONCOL, V33, P2516, DOI 10.1200/JCO.2014.59.7534; Chao MP, 2011, BLOOD, V118, P4890, DOI 10.1182/blood-2011-02-338020; Chao MP, 2011, CANCER RES, V71, P1374, DOI 10.1158/0008-5472.CAN-10-2238; Chao MP, 2010, CELL, V142, P699, DOI 10.1016/j.cell.2010.07.044; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Crump M, 2017, BLOOD, V130, P1800, DOI 10.1182/blood-2017-03-769620; Czuczman MS, 2017, CLIN CANCER RES, V23, P4127, DOI 10.1158/1078-0432.CCR-16-2818; Department of Health and Human Services, 2010, COMM TERM CRIT ADV E; Gholamin S, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf2968; Gopal AK, 2014, NEW ENGL J MED, V370, P1008, DOI 10.1056/NEJMoa1314583; Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046; Keating GM, 2010, DRUGS, V70, P1445, DOI 10.2165/11201110-000000000-00000; Le Tourneau C, 2009, JNCI-J NATL CANCER I, V101, P708, DOI 10.1093/jnci/djp079; Liu J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137345; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Marcus R, 2017, NEW ENGL J MED, V377, P1331, DOI 10.1056/NEJMoa1614598; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Palanca-Wessels MCA, 2015, LANCET ONCOL, V16, P704, DOI 10.1016/S1470-2045(15)70128-2; Sehn LH, 2016, LANCET ONCOL, V17, P1081, DOI 10.1016/S1470-2045(16)30097-3; Solal-Celigny P, 2018, BRIT J HAEMATOL, V180, P217, DOI 10.1111/bjh.15023; Taylor RP, 2010, SEMIN HEMATOL, V47, P124, DOI 10.1053/j.seminhematol.2010.01.006; Tseng D, 2013, P NATL ACAD SCI USA, V110, P11103, DOI 10.1073/pnas.1305569110; Willingham SB, 2012, P NATL ACAD SCI USA, V109, P6662, DOI 10.1073/pnas.1121623109; Younes A, 2017, NAT REV CLIN ONCOL, V14, P335, DOI 10.1038/nrclinonc.2016.205	26	518	543	19	79	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 1	2018	379	18					1711	1721		10.1056/NEJMoa1807315	http://dx.doi.org/10.1056/NEJMoa1807315			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GY8OL	30380386	Bronze, Green Accepted			2023-01-03	WOS:000448891600006
J	Robert, C				Robert, Caroline			Is earlier better for melanoma checkpoint blockade?	NATURE MEDICINE			English	Article							ADJUVANT DABRAFENIB; STAGE-III; TRAMETINIB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; CANCER; TRIAL	A neoadjuvant approach relying on the administration of combined anti-CTLA-4-anti-PD-1 treatment before lymph node surgery is evaluated in two phase 1 trials. Encouraging clinical, pathological and immunological responses to neoadjuvant therapy were observed, suggesting that this concept warrants further exploration; however, any future approach must address the unacceptably high toxicity of the regimens evaluated in these trials.	[Robert, Caroline] Paris Sud Univ, Le Kremlin Bicetre, France; [Robert, Caroline] Oncol Dept, Villejuf, France; [Robert, Caroline] INSERM, U981, Villejuf, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Robert, C (corresponding author), Paris Sud Univ, Le Kremlin Bicetre, France.	caroline.robert@gustaveroussy.fr	Robert, Caroline/G-6157-2018	Robert, Caroline/0000-0002-9493-0238				Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; Amaria RN, 2018, LANCET ONCOL, V19, P181, DOI 10.1016/S1470-2045(18)30015-9; Blank CU, 2018, NAT MED, V24, P1655, DOI 10.1038/s41591-018-0198-0; Chen Y, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010634; Eggermont AMM, 2018, NEW ENGL J MED, V378, P1789, DOI 10.1056/NEJMoa1802357; Gershenwald JE, 2017, CA-CANCER J CLIN, V67, P472, DOI 10.3322/caac.21409; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Liu J, 2016, CANCER DISCOV, V6, P1382, DOI 10.1158/2159-8290.CD-16-0577; Long GV, 2017, NEW ENGL J MED, V377, P1813, DOI 10.1056/NEJMoa1708539; MacLean Matthew, 2018, Oncotarget, V9, P24470, DOI 10.18632/oncotarget.25327; Morton DL, 2014, NEW ENGL J MED, V370, P599, DOI 10.1056/NEJMoa1310460; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2018, J CLIN ONCOL, V36, P1668, DOI 10.1200/JCO.2017.75.6270; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Tetzlaff MT, 2018, ANN ONCOL, V29, P1861, DOI 10.1093/annonc/mdy226; Weber J, 2017, NEW ENGL J MED, V377, P1824, DOI 10.1056/NEJMoa1709030; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624	20	20	21	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2018	24	11					1645	1648		10.1038/s41591-018-0250-0	http://dx.doi.org/10.1038/s41591-018-0250-0			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	GZ4VS	30401867				2023-01-03	WOS:000449404200013
J	Honorio, ICG; Coppede, JS; Delprete, PG; Costa, FHS; Telles, MPC; Braga, RS; Diniz, JAF; Correa, VSC; Franca, SC; Pereira, AMS; Bertoni, BW				Honorio, Isabela Cristina G.; Coppede, Juliana S.; Delprete, Piero G.; Costa, Frederico Henrique S.; Telles, Mariana P. C.; Braga, Ramilla S.; Diniz-Filho, Jose Alexandre F.; Correa, Valeria S. C.; Franca, Suzelei C.; Pereira, Ana Maria S.; Bertoni, Bianca Waleria			Genetic structure and chemical diversity in natural populations of Uncaria guianensis (Aubl.) JFGmel. (Rubiaceae)	PLOS ONE			English	Article							TOMENTOSA; INDIVIDUALS; ALKALOIDS; SOFTWARE; NUMBER	Uncaria guianensis is native to the Amazon and is used traditionally as an anti-inflammatory. Natural populations of the species have declined markedly in recent times because of strong anthropic pressure brought about by deforestation and indiscriminate collection. The aim of the present study was to assess the genetic and chemical diversity among eight natural populations of U. guianensis located in the Brazilian states of Acre, Amapa and Amazonas. A set of four primer combinations was employed in sequence-related amplified polymorphism (SRAP) amplifications of leaf DNA, and the fragments were analyzed in an LI-COR model 4300 DNA Analyzer. Genetic variability within the populations (81%) was substantially greater than that detected between them (19%). The highest percentage of polymorphic loci (90.21%) and the largest genetic variability were observed in the population located in Mazagao, Amapa. Genetic differentiation between populations was high (F-st = 0.188) and the studied populations formed three distinct genetic groups (K = 3). The population located in Assis Brasil, Acre, presented the highest average content of the mitraphylline (0.60 mg/g dry weight,). However, mitraphylline and isomitraphylline not detected in most individuals in the studied populations, and it is questionable whether they should be considered as chemical markers of the species. The genetic data confirm the urgent need for conservation programs for U. guianensis, and for further studies aimed at ascertaining the genetic basis and heritability of alkaloid accumulation.	[Honorio, Isabela Cristina G.] Univ Estadual Paulista Julio de Mesquite Filho, Botucatu, SP, Brazil; [Coppede, Juliana S.; Franca, Suzelei C.; Pereira, Ana Maria S.; Bertoni, Bianca Waleria] Univ Ribeirao Preto, Ribeirao Preto, SP, Brazil; [Delprete, Piero G.] Herbier Guyane, Inst Rech Dev, Cayenne, French Guiana; [Costa, Frederico Henrique S.] Univ Fed Acre, Rio Branco, AC, Brazil; [Telles, Mariana P. C.] Pontificia Univ Catolica Goias, Escola Ciencias Agr & Biol, Goiania, Go, Brazil; [Telles, Mariana P. C.; Braga, Ramilla S.] Univ Fed Goias, Lab Genet & Biodiversidade, Goiania, Go, Brazil; [Diniz-Filho, Jose Alexandre F.] Univ Fed Goias, ICB, Dept Ecol, Goiania, Go, Brazil; [Correa, Valeria S. C.] Reserve EcoCerrado Brasil, Araxa, MG, Brazil	Universidade Estadual Paulista; Universidade de Ribeirao Preto; Institut de Recherche pour le Developpement (IRD); Universidade Federal do Acre (UFAC); Pontificia Universidade Catolica de Goias; Universidade Federal de Goias; Universidade Federal de Goias	Pereira, AMS (corresponding author), Univ Ribeirao Preto, Ribeirao Preto, SP, Brazil.	apereira@unaerp.br	Diniz-Filho, José Alexandre Felizola/D-9405-2013; Delprete, Piero/U-4699-2019; Honório, Isabela Cristina ICGH Gomes/M-1391-2016; Braga, Ramilla/AAS-1010-2021; Franca, Suzelei C/E-4069-2013; Soares Pereira, Ana Maria/P-5646-2014	Diniz-Filho, José Alexandre Felizola/0000-0002-0967-9684; Honório, Isabela Cristina ICGH Gomes/0000-0002-5029-2238; Soares Pereira, Ana Maria/0000-0002-3478-4718	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [408296/2013-5]	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	The research was funded by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; Grant no. 408296/2013-5). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Zevallos-Pollito PA, 2010, ECOL APL, V9, P19, DOI 10.21704/rea.v9i1-2.391; Auguie B., 2017, GRIDEXTRA MISCELLANE; Rossi AAB, 2009, GENETICA, V136, P57, DOI 10.1007/s10709-008-9309-z; Bertol G, 2012, PHYTOCHEM ANALYSIS, V23, P143, DOI 10.1002/pca.1335; Penaloza EMC, 2015, QUIM NOVA, V38, P378, DOI 10.5935/0100-4042.20150007; Doyle J. L. ., 1987, FOCUS, V19, P11, DOI DOI 10.2307/2419362; Evanno G, 2005, MOL ECOL, V14, P2611, DOI 10.1111/j.1365-294X.2005.02553.x; Falkiewicz B, 2001, AM J CASE REP, V2, P305; Honorio ICG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177103; Honorio ICG, 2016, CIENC RURAL, V46, P1401, DOI 10.1590/0103-8478cr20150138; Hamrick J. L., 1992, New Forests, V6, P95, DOI 10.1007/BF00120641; Laus G, 1997, PHYTOCHEMISTRY, V45, P855, DOI 10.1016/S0031-9422(97)00061-7; Li G, 2001, THEOR APPL GENET, V103, P455, DOI 10.1007/s001220100570; LOVELESS MD, 1984, ANNU REV ECOL SYST, V15, P65, DOI 10.1146/annurev.es.15.110184.000433; Luna-Palencia GR, 2013, BIOTECHNOL LETT, V35, P791, DOI 10.1007/s10529-012-1128-8; NEI M, 1978, GENETICS, V89, P583; Nybom H, 2004, MOL ECOL, V13, P1143, DOI 10.1111/j.1365-294X.2004.02141.x; Peakall R, 2012, BIOINFORMATICS, V28, P2537, DOI 10.1093/bioinformatics/bts460; Pritchard JK, 2000, GENETICS, V155, P945; SILVA S.R., 2001, PLANTAS MED BRASIL A; Vilches LEO, 1997, GATO GENERO UNCARIA; Zhang Q, 2015, J ETHNOPHARMACOL, V173, P48, DOI 10.1016/j.jep.2015.06.011; Zheng YQ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177508	23	4	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2018	13	10							e0205667	10.1371/journal.pone.0205667	http://dx.doi.org/10.1371/journal.pone.0205667			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GY3KA	30365495	Green Published, Green Submitted, gold			2023-01-03	WOS:000448448700012
J	Lan, YS; Huang, ZY; Jiang, YJ; Zhou, XH; Zhang, JY; Zhang, DY; Wang, B; Hou, GQ				Lan, Yongsheng; Huang, Zhaoyuan; Jiang, Yanjie; Zhou, Xuehua; Zhang, Jingyu; Zhang, Dianyu; Wang, Bo; Hou, Guangqing			Strength exercise weakens aerobic exercise-induced cognitive improvements in rats	PLOS ONE			English	Article							ADULT HIPPOCAMPAL NEUROGENESIS; CELL-PROLIFERATION; PERFORMANCE; METABOLISM; QUALITY	Aerobic exercise improves cognitive function and adult hippocampal neurogenesis. However, the effects of aerobic exercise combined with strength exercise on cognitive function and adult hippocampal neurogenesis are still unknown. In this study, we established exercise paradigms in rats to mimic aerobic exercise combined with low- and high-intensity strength exercise. We found that aerobic exercise improved spatial learning and memory as well as adult hippocampal neurogenesis, whereas strength exercise suppressed aerobic exercise-induced cognitive improvements and adult hippocampal neurogenesis in an intensity-dependent manner. Furthermore, the levels of beta-hydroxybutyrate (beta-HB) and its downstream effector brain-derived neurotrophic factor (BDNF) were increased in the aerobic exercise group, and strength exercise impaired the aerobic exercise-induced increases in beta-HB and BDNF mRNA levels. Taken together, these results demonstrated that strength exercise weakened aerobic exercise-induced cognitive improvements and adult hippocampal neurogenesis in rats.	[Lan, Yongsheng; Huang, Zhaoyuan; Jiang, Yanjie; Zhou, Xuehua; Zhang, Jingyu; Zhang, Dianyu; Hou, Guangqing] Changchun Normal Univ, Coll Phys Educ, Changchun, Jilin, Peoples R China; [Wang, Bo] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Orthopaed, Wuhan, Hubei, Peoples R China	Changchun Normal University; Huazhong University of Science & Technology	Hou, GQ (corresponding author), Changchun Normal Univ, Coll Phys Educ, Changchun, Jilin, Peoples R China.	48516085@qq.com	Zhang, Jing/GWZ-7332-2022		Nature Science Foundation of Changchun Normal University [20202814]; "Thirteen Five" science and technology research project of Jilin Province Education Department [2016-395]	Nature Science Foundation of Changchun Normal University; "Thirteen Five" science and technology research project of Jilin Province Education Department	This work was supported by: (1) 20202814 Nature Science Foundation of Changchun Normal University, the role of the funder was in data collection and analysis; (2) 2016-395 "Thirteen Five" science and technology research project of Jilin Province Education Department, the role of the funder was in preparation of the manuscript.	BOYD AE, 1974, METABOLISM, V23, P531, DOI 10.1016/0026-0495(74)90081-X; Brisswalter J, 2002, SPORTS MED, V32, P555, DOI 10.2165/00007256-200232090-00002; Cahill GF, 2006, ANNU REV NUTR, V26, P1, DOI 10.1146/annurev.nutr.26.061505.111258; Carolina N, 2009, PSYCHOSOM MED, V72, P239; Chapman SB, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00075; Choi SH, 2018, SCIENCE, V361, P991, DOI 10.1126/science.aan8821; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Cox PJ, 2016, CELL METAB, V24, P256, DOI 10.1016/j.cmet.2016.07.010; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gano LB, 2014, J LIPID RES, V55, P2211, DOI 10.1194/jlr.R048975; Gasior M, 2006, BEHAV PHARMACOL, V17, P431, DOI 10.1097/00008877-200609000-00009; Gobeske KT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007506; ISSEKUTZ B, 1962, P SOC EXP BIOL MED, V110, P237; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Lee H, 2018, BEHAV BRAIN RES, V345, P59, DOI 10.1016/j.bbr.2018.01.017; Liu CL, 2009, J BIOL CHEM, V284, P2811, DOI 10.1074/jbc.M806409200; Marosi K, 2016, J NEUROCHEM, V139, P769, DOI 10.1111/jnc.13868; Marston KJ, 2017, J SCI MED SPORT; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Mosti MP, 2014, J STRENGTH COND RES, V28, P2935, DOI 10.1519/JSC.0000000000000493; Mustroph ML, 2012, NEUROSCIENCE, V219, P62, DOI 10.1016/j.neuroscience.2012.06.007; Nilsen TS, 2015, ACTA ONCOL, V54, P1805, DOI 10.3109/0284186X.2015.1037008; Nokia MS, 2016, J PHYSIOL-LONDON, V594, P1855, DOI 10.1113/JP271552; Gomes FGN, 2014, PSYCHONEUROENDOCRINO, V50, P106, DOI 10.1016/j.psyneuen.2014.08.009; OWEN OE, 1967, J CLIN INVEST, V46, P1589, DOI 10.1172/JCI105650; PERSSON B, 1970, SCAND J CLIN LAB INV, V25, P9, DOI 10.3109/00365517009046184; Pinnock SB, 2010, EUROPEAN J NEUROSCIE, V27, P2493; Pinto RS, 2014, AGE, V36, P365, DOI 10.1007/s11357-013-9567-2; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Sleiman SF, 2016, ELIFE, V5, DOI 10.7554/eLife.15092; Snyder JS, 2011, NATURE, V476, P458, DOI 10.1038/nature10287; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Vilela TC, 2016, MOL NEUROBIOL, V1, DOI [10.1007/s12035-014-8981-5, DOI 10.1007/S12035-014-8981-5]; Waterhouse EG, 2012, J NEUROSCI, V32, P14318, DOI 10.1523/JNEUROSCI.0709-12.2012	35	14	14	4	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2018	13	10							e0205562	10.1371/journal.pone.0205562	http://dx.doi.org/10.1371/journal.pone.0205562			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW4VA	30304037	gold, Green Submitted, Green Published			2023-01-03	WOS:000446921100001
J	Kaur, M; Gupta, M; Purayil, VP; Rana, M; Chakrapani, V				Kaur, Manmeet; Gupta, Madhu; Purayil, Vijin Pandara; Rana, Monica; Chakrapani, Venkatesan			Contribution of social factors to maternal deaths in urban India: Use of care pathway and delay models	PLOS ONE			English	Article							MORTALITY; INTERVENTIONS; CHANDIGARH; CHILD	This paper uses care pathway and delay models to better understand the possible social reasons for maternal deaths in a city with good public and private health infrastructure. The findings can inform programmes to reduce maternal mortality. During 2007-15, 136 maternal deaths were reported in Chandigarh, India. Using World Health Organisation's verbal autopsy questionnaire, interviews were conducted with primary caregivers of 68 (50%) of the 136 deceased women, as majority of the families had returned to their native places. We used process-tracing techniques to construct the care pathways and identify delays, and explored open-ended responses using thematic analysis. The mean age of the deceased women was 27 years, 51% resided in slums, 32% were primigravida, 25% had their deliveries assisted by traditional birth attendants, and 23% had Caesarean section. Eight percent died at home, and 54% died in tertiary level facilities. Post-partum haemorrhage (26.5%), and complications of puerperium (25%) and labour/delivery (14.7%) were the reported medical causes. Male child preference and norms for home delivery were identified as the distal socio-cultural causes. Individual and family level factors included: shame on multiple pregnancies; fear of discrimination from providers; past successful deliveries at home leading to overconfidence and not seeking institutional care; and lack of awareness about family planning, antenatal care, and danger signs of pregnancy. Healthcare system factors were: non-availability of senior doctors at the time of consultation in the emergency that delayed initiation of immediate treatment, and lack of availability of life-saving equipment due to patient load. Empirical evidence was found on social causes of maternal deaths, which could have been prevented by appropriate actions at individual, family, societal, institutional and policy levels. This study identified potential preventable causes of primarily social origin, which could help in taking actionable steps at several levels to further reduce maternal deaths in India.	[Gupta, Madhu] Postgrad Inst Med Educ & Res PGIMER, Dept Community Med, Chandigarh, India; Postgrad Inst Med Educ & Res PGIMER, Sch Publ Hlth, Chandigarh, India	Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh	Gupta, M (corresponding author), Postgrad Inst Med Educ & Res PGIMER, Dept Community Med, Chandigarh, India.	madhugupta21@gmail.com	; Chakrapani, Venkatesan/P-8056-2014	Gupta, Madhu/0000-0003-3877-9956; Chakrapani, Venkatesan/0000-0001-9998-9135	Health and Family Welfare, Chandigarh Administration [MH-IV-2008/27/3/18]	Health and Family Welfare, Chandigarh Administration	This work was supported by Health and Family Welfare, Chandigarh Administration - no. MH-IV-2008/27/3/18 to MG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The project was sanctioned to Prof Madhu Gupta (MG).	[Anonymous], 2010, SCI IIOP DISTR LEV H; Barnes-Josiah D, 1998, SOC SCI MED, V46, P981, DOI 10.1016/S0277-9536(97)10018-1; Beach Derek, 2013, PROCESS TRACING METH; Bhutta ZA, 2008, LANCET, V372, P972, DOI 10.1016/S0140-6736(08)61407-5; Calvello EJ, 2015, B WORLD HEALTH ORGAN, V93, P417, DOI 10.2471/BLT.14.146571; Dhaliwal T., 2015, HINDUSTAN TIMES; Diamond-Smith NG, 2016, FOOD NUTR BULL, V37, P132, DOI 10.1177/0379572116637721; Goldenberg RL, 2012, LANCET, V379, P1178, DOI 10.1016/S0140-6736(12)60474-7; Guest G, 2011, APPL THEMATIC ANAL, DOI [10.4135/9781483384436, DOI 10.4135/9781483384436]; Gupta M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170175; Gupta M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150537; Gwatkin D R, 2007, Niger J Clin Pract, V10, P272; International Institute for Sciences, 2016, NAT FAM HLTH SURV 4, V4, P2015; Kaur M, 2015, INT J MIGR HEALTH SO, V11, P147, DOI 10.1108/IJMHSC-03-2014-0010; Mathur A, 2014, BJOG-INT J OBSTET GY, V121, P67, DOI 10.1111/1471-0528.13001; *MIN HLTH FAM WELF, 2013, ANN REPORT; Ministry of Health and Family Welfare, 2013, NAT URB HLTH MISS FR; Ministry of Health and Family Welfare (MoHFW), 2013, STRAT APPR REP MAT N; Montgomery AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083331; Office of the Registrar General & Census Commissioner I, 2017, CENS DAT; Rani, 2017, INT J REPROD CONTRAC, V6, P575; Sarker BK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146161; Schiffman J, 2010, SEMINARS PERINATOLOG; School of Public Health, 2016, IMPR MON IND REPR CH; Singh A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044931; Singh A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037037; THADDEUS S, 1994, SOC SCI MED, V38, P1091, DOI 10.1016/0277-9536(94)90226-7; Thorsen VC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052090; United Nations, 2017, SUST DEV GOAL 3, V3; Vanhaecht K, 2010, INT J CARE COORD, V14, P117, DOI 10.1258/jicp.2010.010019; WHO, 2014, SUC FACT WOM CHILDR; WHO, INT STAND VERB AUT Q; WHO, 2014, MAT MORT FACT SHEET, V4; World Health Organization, PARTN MAT NEWB CHILD; World Health Organization, ICD 10 VERS 2010 INT	35	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2018	13	10							e0203209	10.1371/journal.pone.0203209	http://dx.doi.org/10.1371/journal.pone.0203209			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GW4OW	30300352	gold, Green Submitted, Green Published			2023-01-03	WOS:000446897200005
J	Nagappa, M; Wong, DT; Cozowicz, C; Ramachandran, SK; Memtsoudis, SG; Chung, F				Nagappa, Mahesh; Wong, David T.; Cozowicz, Crispiana; Ramachandran, Satya Krishna; Memtsoudis, Stavros G.; Chung, Frances			Is obstructive sleep apnea associated with difficult airway? Evidence from a systematic review and meta-analysis of prospective and retrospective cohort studies	PLOS ONE			English	Review							IMPOSSIBLE MASK VENTILATION; STOP-BANG QUESTIONNAIRE; NATIONAL AUDIT PROJECT; TRACHEAL INTUBATION; RESPIRATORY COMPLICATIONS; ENDOTRACHEAL INTUBATION; MAJOR COMPLICATIONS; SCREENING TOOL; ROYAL-COLLEGE; RISK-FACTOR	Background Difficult airway management and obstructive sleep apnea may contribute to increased risk of perioperative morbidity and mortality. The objective of this systematic review and metaanalysis (SRMA) is to evaluate the evidence of a difficult airway being associated with obstructive sleep apnea (OSA) patients undergoing surgery. Methods The standard databases were searched from 1946 to April 2017 to identify the eligible articles. The studies which included adult surgical patients with either suspected or diagnosed obstructive sleep apnea must report at least one difficult airway event [either difficult intubation (DI), difficult mask ventilation (DMV), failed supraglottic airway insertion or difficult surgical airway] in sleep apnea and non-sleep apnea patients were included. Results Overall, DI was 3.46-fold higher in the sleep apnea vs non-sleep apnea patients (OSA vs. non-OSA: 13.5% vs 2.5%; OR 3.46; 95% CI: 2.32 +/- 5.16, p < 0.00001). DMV was 3.39-fold higher in the sleep apnea vs non-sleep apnea patients (OSA vs. non-OSA: 4.4% vs 1.1%; OR 3.39; 95% CI: 2.74 +/- 4.18, p < 0.00001). Combined DI and DMV was 4.12-fold higher in the OSA vs. non-OSA patients (OSA vs. non-OSA: 1.1% vs 0.3%; OR 4.12; 95% CI: 2.93 +/- 5.79, p < 0.00001). There was no significant difference in the supraglottic airway failure rates in the sleep apnea vs non-sleep apnea patients (OR: 1.34; 95% CI: 0.70 +/- 2.59; p = 0.38). Meta-regression to adjust for various subgroups and baseline confounding factors did not impact the final inference of our results. Conclusion This SRMA found that patients with obstructive sleep apnea had a three to four-fold higher risk of difficult intubation or mask ventilation or both, when compared to non-sleep apnea patients.	[Nagappa, Mahesh] Western Univ, Dept Anesthesia & Perioperat Med, Univ Hosp, Victoria Hosp, London, ON, Canada; [Nagappa, Mahesh] Western Univ, St Joseph Hosp, London Hlth Sci Ctr, London, ON, Canada; [Nagappa, Mahesh] Western Univ, St Joseph Hlth Care, London, ON, Canada; [Wong, David T.; Chung, Frances] Univ Toronto, Dept Anesthesia & Pain Med, Toronto Western Hosp, Univ Hlth Network, Toronto, ON, Canada; [Cozowicz, Crispiana; Memtsoudis, Stavros G.] Hosp Special Surg, Dept Anesthesiol Crit Care & Pain Management, 535 E 70th St, New York, NY 10021 USA; [Cozowicz, Crispiana; Memtsoudis, Stavros G.] Weill Cornell Med Coll, New York, NY USA; [Cozowicz, Crispiana] Paracelsus Med Univ, Dept Anesthesiol Perioperat Med & Intens Care Med, Salzburg, Austria; [Ramachandran, Satya Krishna] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Harvard Med Sch, Boston, MA 02215 USA	University of Victoria; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Cornell University; Paracelsus Private Medical University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Chung, F (corresponding author), Univ Toronto, Dept Anesthesia & Pain Med, Toronto Western Hosp, Univ Hlth Network, Toronto, ON, Canada.	frances.chung@uhn.ca	Ramachandran, Satya Krishna/P-6636-2016; Chung, Frances/F-5618-2015; Cozowicz, Crispiana/U-5874-2019; Nagappa, Mahesh/AAA-7389-2022	Ramachandran, Satya Krishna/0000-0002-7176-6375; Chung, Frances/0000-0001-9576-3606; Nagappa, Mahesh/0000-0001-8036-3319				Acar HV, 2014, EUR REV MED PHARMACO, V18, P1869; Amer Soc Anesthesiologists, 2013, ANESTHESIOLOGY, V118, P251, DOI 10.1097/ALN.0b013e31827773b2; BELLHOUSE CP, 1988, ANAESTH INTENS CARE, V16, P329, DOI 10.1177/0310057X8801600315; Brodsky JB, 2002, ANESTH ANALG, V94, P732, DOI 10.1097/00000539-200203000-00047; Cattano D, 2014, F1000RESEARCH, V3, P1, DOI DOI 10.12688/F1000RESEARCH.3-1.V2; Chou HC, 2001, ANESTHESIOLOGY, V94, P936, DOI 10.1097/00000542-200105000-00043; CHOU HC, 1993, BRIT J ANAESTH, V71, P335, DOI 10.1093/bja/71.3.335; Chung F, 2008, ANESTH ANALG, V107, P915, DOI 10.1213/ane.0b013e31817bd36f; Chung F, 2016, ANESTH ANALG, V123, P452, DOI 10.1213/ANE.0000000000001416; Cook TM, 2011, BRIT J ANAESTH, V106, P632, DOI 10.1093/bja/aer059; Cook TM, 2011, BRIT J ANAESTH, V106, P617, DOI 10.1093/bja/aer058; CORMACK RS, 1984, ANAESTHESIA, V39, P1105, DOI 10.1111/j.1365-2044.1984.tb08932.x; Corso RM, 2014, MINERVA ANESTESIOL, V80, P877; Crosby ET, 1998, CAN J ANAESTH, V45, P757, DOI 10.1007/BF03012147; DAVIES RJO, 1990, EUR RESPIR J, V3, P509; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fouladpour N, 2016, ANESTH ANALG, V122, P145, DOI 10.1213/ANE.0000000000000841; Gokay P, 2016, J CLIN NURS, V25, P1238, DOI 10.1111/jocn.13133; Gross JB, 2014, ANESTHESIOLOGY, V120, P268, DOI 10.1097/ALN.0000000000000053; Han R, 2004, ANESTHESIOLOGY, V101, P267, DOI 10.1097/00000542-200407000-00059; HAPONIK EF, 1983, AM REV RESPIR DIS, V127, P221; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hiremath AS, 1998, BRIT J ANAESTH, V80, P606, DOI 10.1093/bja/80.5.606; HOFFSTEIN V, 1993, SLEEP, V16, P118; Kheterpal S, 2006, ANESTHESIOLOGY, V105, P885, DOI 10.1097/00000542-200611000-00007; Kheterpal S, 2013, ANESTHESIOLOGY, V119, P1360, DOI 10.1097/ALN.0000435832.39353.20; Kheterpal S, 2009, ANESTHESIOLOGY, V110, P891, DOI 10.1097/ALN.0b013e31819b5b87; Kim JA, 2006, CAN J ANAESTH, V53, P393, DOI 10.1007/BF03022506; Leong SM, 2018, J CLIN ANESTH, V45, P63, DOI 10.1016/j.jclinane.2017.12.024; Liao P, 2009, CAN J ANAESTH, V56, P819, DOI 10.1007/s12630-009-9190-y; Lunn D, 2009, STAT MED, V28, P3049, DOI 10.1002/sim.3680; MALLAMPATI SR, 1985, CAN ANAESTH SOC J, V32, P429, DOI 10.1007/BF03011357; Nagappa M, 2017, ANESTH ANALG, V125, P1301, DOI 10.1213/ANE.0000000000002344; Opperer M, 2016, ANESTH ANALG, V122, P1321, DOI 10.1213/ANE.0000000000001178; Ramachandran SK, 2017, ANESTH ANALG, V125, P272, DOI 10.1213/ANE.0000000000002132; Ramachandran SK, 2012, ANESTHESIOLOGY, V116, P1217, DOI 10.1097/ALN.0b013e318255e6ab; Ravesloot MJL, 2012, EUR ARCH OTO-RHINO-L, V269, P1865, DOI 10.1007/s00405-012-1948-0; Sabers C, 2003, ANESTH ANALG, V96, P1328, DOI 10.1213/01.ANE.0000061585.09157.66; Senaratna CV, 2017, SLEEP MED REV, V34, P70, DOI 10.1016/j.smrv.2016.07.002; Shah Prerana N, 2012, J Anaesthesiol Clin Pharmacol, V28, P451, DOI 10.4103/0970-9185.101901; Shiga T, 2005, ANESTHESIOLOGY, V103, P429, DOI 10.1097/00000542-200508000-00027; Singh M, 2013, BRIT J ANAESTH, V110, P629, DOI 10.1093/bja/aes465; Siyam MA, 2002, ANESTH ANALG, V95, P1098, DOI 10.1097/00000539-200210000-00058; Solow B, 1996, EUR J ORTHODONT, V18, P571; STRELZOW VV, 1988, LARYNGOSCOPE, V98, P1149; Subramani Y, 2017, BRIT J ANAESTH, V119, P885, DOI 10.1093/bja/aex341; Toshniwal G, 2014, J CLIN ANESTH, V26, P360, DOI 10.1016/j.jclinane.2014.01.010; Wells G, 2014, NEWCASTLE OTTAWA SCA; WHITE A, 1975, BRIT J ANAESTH, V47, P468, DOI 10.1093/bja/47.4.468	49	25	28	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 4	2018	13	10							e0204904	10.1371/journal.pone.0204904	http://dx.doi.org/10.1371/journal.pone.0204904			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV8IQ	30286122	Green Submitted, gold, Green Published			2023-01-03	WOS:000446383500061
J	Boehm, RE; Arbo, BD; Leal, D; Hansen, AW; Pulcinelli, RR; Thiesen, FV; Balsan, AM; Onsten, TGH; Gomez, R				Boehm, Renata E.; Arbo, Bruno D.; Leal, Denise; Hansen, Alana W.; Pulcinelli, Rianne R.; Thiesen, Flavia, V; Balsan, Almeri M.; Onsten, Tor G. H.; Gomez, Rosane			Smoking fewer than 20 cigarettes per day and remaining abstinent for more than 12 hours reduces carboxyhemoglobin levels in packed red blood cells for transfusion	PLOS ONE			English	Article							TOBACCO-SMOKE; LEAD LEVELS; DONORS; INFLAMMATION; MEMBRANES; EXPOSURE; US	Background The prevalence of smokers among blood donors and the effect of smoking on the quality of donated blood have not been extensively explored. In the present study, we determined the prevalence of smoker donors in a large blood bank in Southern Brazil and evaluated the quality of packed red blood cells (RBCs) from these donors through recommended quality control tests and measurement of carboxyhemoglobin (COHb) levels. We then assessed the influence of smoking habits and abstinence before donation on these parameters. Material and methods An observational study was conducted to determine the prevalence of smoking donors, while a prospective cohort study compared conventional hematological and serological parameters and COHb levels at 0, 15, and 30 days after donation in RBCs donated by smokers (N = 31) and nonsmokers (N = 31) and their association with smoking habits and abstinence before donation. Results Of 14,428 blood donations received in 1 year, 5.9% were provided by smokers. Storage over time slightly altered some quality parameters, such as hematocrit, hemoglobin, hemolysis, and COHb levels, in RBC packs. COHb levels were higher in RBC packs from smokers (8%) than from non-smokers (2%), and increased as a function of the number of cigarettes smoked daily and time elapsed since the last cigarette smoked before donation. Lower levels were found in RBC packs from donors who smoked fewer than 20 cigarettes per day or remained abstinent for more than 12h before giving blood. Conclusion Although cigarette smoke had no significant effect on blood quality parameters such as hematocrit, hemoglobin, or hemolysis, it quadrupled COHb levels in packed RBCs. Abstinence from smoking for more than 12h or smoking fewer than 20 cigarettes daily helped decrease COHb levels.	[Boehm, Renata E.; Gomez, Rosane] UFCSPA, Postgrad Program Hlth Sci, Porto Alegre, RS, Brazil; [Boehm, Renata E.; Balsan, Almeri M.; Onsten, Tor G. H.] HCPA, Hemoterapy Ctr, Porto Alegre, RS, Brazil; [Boehm, Renata E.; Arbo, Bruno D.; Hansen, Alana W.; Pulcinelli, Rianne R.; Gomez, Rosane] Univ Fed Rio Grande do Sul, Postgrad Program Pharmacol & Therapeut, Porto Alegre, RS, Brazil; [Leal, Denise; Thiesen, Flavia, V] Pontificia Univ Catolica Rio Grande do Sul PUCRS, Sch Pharm, Porto Alegre, RS, Brazil	Universidade Federal de Ciencias da Saude de Porto Alegre; Universidade Federal do Rio Grande do Sul; Pontificia Universidade Catolica Do Rio Grande Do Sul	Gomez, R (corresponding author), UFCSPA, Postgrad Program Hlth Sci, Porto Alegre, RS, Brazil.; Gomez, R (corresponding author), Univ Fed Rio Grande do Sul, Postgrad Program Pharmacol & Therapeut, Porto Alegre, RS, Brazil.	rosane.gomez@ufrgs.br	Gomez, Rosane/H-5615-2013; Arbo, Bruno D/T-2263-2017; Gomez, Rosane/K-8603-2019; thiesen, flavia/A-3470-2017; Onsten, Tor/W-5474-2019	Gomez, Rosane/0000-0002-0868-8394; thiesen, flavia/0000-0003-4907-6789; Arbo, Bruno/0000-0001-7929-1688; Boehm, Renata/0000-0001-7334-286X	Fundo de Incentivo a Pesquisa e Eventos (FIPE)/HCPA; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq	Fundo de Incentivo a Pesquisa e Eventos (FIPE)/HCPA; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by a grant from the Fundo de Incentivo a Pesquisa e Eventos (FIPE)/HCPA and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq (RG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aberg AM, 2009, TRANSFUSION, V49, P347, DOI 10.1111/j.1537-2995.2008.01951.x; Abramson Joseph H, 2011, Epidemiol Perspect Innov, V8, P1, DOI 10.1186/1742-5573-8-1; ARONOW WS, 1984, CHEST, V85, P694, DOI 10.1378/chest.85.5.694; ARONOW WS, 1981, AM HEART J, V101, P154, DOI 10.1016/0002-8703(81)90658-X; Atsma F, 2011, TRANSFUSION, V51, P412, DOI 10.1111/j.1537-2995.2010.02867.x; Aubron C, 2014, J CRIT CARE, V29, DOI 10.1016/j.jcrc.2014.01.006; BEUTLER E, 1984, CLIN CHEM, V30, P871; Bolton-Maggs PHB, 2013, BRIT J HAEMATOL, V163, P303, DOI 10.1111/bjh.12547; Brand A, 2016, PRESSE MED, V45, pE313, DOI 10.1016/j.lpm.2016.06.024; BRASIL. Ministerio da Saude, 2016, RED REG TECN PROC HE, V25, P37; Brucker N, 2013, SCI TOTAL ENVIRON, V463, P884, DOI 10.1016/j.scitotenv.2013.06.098; Collard Keith James, 2014, World J Clin Pediatr, V3, P19, DOI 10.5409/wjcp.v3.i3.19; Cronenberger C, 2008, BRIT J CLIN PHARMACO, V65, P30, DOI 10.1111/j.1365-2125.2007.02974.x; Delage G, 2015, TRANSFUSION, V55, P2633, DOI 10.1111/trf.13199; EATOUGH DJ, 1989, ENVIRON SCI TECHNOL, V23, P679, DOI 10.1021/es00064a006; Ehlers M, 2009, J CARDIOTHOR VASC AN, V23, P336, DOI 10.1053/j.jvca.2008.12.006; El Kenz H, 2014, EUR J ANAESTH, V31, P345, DOI 10.1097/EJA.0000000000000015; Ernst E, 1995, J Cardiovasc Risk, V2, P435; FREEMAN R, 1990, ANAESTHESIA, V45, P581, DOI 10.1111/j.1365-2044.1990.tb14836.x; Fung MK, 2014, AM ASS BLOOD BANKS A; Gangopadhyay S, 2012, COPD, V9, P322, DOI 10.3109/15412555.2012.668581; Garraud O, 2016, PRESSE MED, V45, pE303, DOI 10.1016/j.lpm.2016.06.022; Geiss O., 2007, J EUR SCI TECH RES S; Goldstein M, 2008, J EMERG NURS, V34, P538, DOI 10.1016/j.jen.2007.11.014; Guimaraes LSP, 2012, REV HCPA, V32, P503; Hampson NB, 2008, AM J EMERG MED, V26, P191, DOI 10.1016/j.ajem.2007.04.028; Hughes J R, 1999, Nicotine Tob Res, V1 Suppl 2, pS149; HUGHES JR, 1999, NICOTINE TOB RES S2, V1, pS165; Koch CG, 2013, ANN THORAC SURG, V96, P1894, DOI 10.1016/j.athoracsur.2013.05.116; MADANY IM, 1992, SCI TOTAL ENVIRON, V116, P53, DOI 10.1016/0048-9697(92)90364-X; Mannino DM, 2005, NICOTINE TOB RES, V7, P557, DOI 10.1080/14622200500185264; Milnerowicz H, 2015, J TRACE ELEM MED BIO, V29, P1, DOI 10.1016/j.jtemb.2014.04.008; Pretorius E, 2014, TRANSFUSION, V54, P266, DOI 10.1111/trf.12338; Sakuma A, 2011, MANUAL CONTROLE QUAL; Spada Celso, 2006, Rev. Bras. Hematol. Hemoter., V28, P19, DOI 10.1590/S1516-84842006000100006; Strobel E, 2008, TRANSFUS MED HEMOTH, V35, P346, DOI 10.1159/000154811; Symvoulakis EK, 2010, XENOBIOTICA, V40, P613, DOI 10.3109/00498254.2010.500745; Talhout R, 2011, INT J ENV RES PUB HE, V8, P613, DOI 10.3390/ijerph8020613; UKBTS, 2013, GUID BLOOD TRANSF SE; Valieva OA, 2009, J PEDIATR-US, V155, P331, DOI 10.1016/j.jpeds.2009.02.026; WHO. World Health Organization, 2016, RAIS TAX TOB WHAT YO; World Health Organization, 2012, BLOOD DON SEL	42	18	18	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2018	13	9							e0204102	10.1371/journal.pone.0204102	http://dx.doi.org/10.1371/journal.pone.0204102			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GV3NB	30256832	Green Published, gold, Green Submitted			2023-01-03	WOS:000446000200035
J	Beek, YH; Shin, JY				Beek, Yeon-Hee; Shin, Ju-Young			Trends in polypharmacy over 12 years and changes in its social gradients in South Korea	PLOS ONE			English	Article							SOCIOECONOMIC-STATUS; UNITED-STATES; DRUG-INTERACTIONS; ELDERLY-PEOPLE; OLDER-ADULTS; HEALTH-CARE; POPULATION; IMPACT; ASSOCIATION; MORTALITY	Polypharmacy is associated with adverse drug reactions and represents an economic burden on the health insurance system. The objective of our study was to assess the trends in polypharmacy and its associated factors in South Korea. This cross-sectional study used a nationwide sampled database between 2002 and 2013, including outpatients of all ages who received at least 1 prescription in the same period. Polypharmacy was defined as the concomitant prescription of >= 6 distinct medications on a single prescription at least once without a given duration. The yearly prescribing trends were calculated and plotted. We conducted comparative analyses to identify the changes in social gradients of polypharmacy between the first 2 years, 2002-2003, and the final 2 years, 2012-2013. We repeated logistic regressions for pediatrics <20 years of age and adults >= 20 years of age to estimate the adjusted odds ratios (aOR) and 95% confidence intervals (CI). The distributions of polypharmacy in the respective periods were examined according to patient economic status (0 = most deprived and 10 = most affluent). The age-standardized prevalence of polypharmacy decreased from 65.8% in 2002 to 43.7% in 2013. Our study included 1,108,298 outpatients throughout 2002-2013. Pediatric patients aged 1-9 years had the highest number of medications among all age groups (mean: 5.1 +/- 1.1 in 2002-2003 vs. 4.1 +/- 1.1 in 2012-2013) in both periods. Changes in the association between deprivation and polypharmacy over 10 years were observed in adults (aOR = 0.68; 95% CI = 0.62-0.75 in 2002-2003 vs. 1.60; 95% CI = 1.54-1.66 in 2012-2013) and pediatrics (aOR = 0.60; 95% CI = 0.52-0.68 in 2002-2003 vs. 1.07; 95% CI = 1.01-1.14 in 2012-2013) compared with those in the most affluent patients. The high level of polypharmacy in pediatric patients is a public health concern that warrants policymaker attention.	[Beek, Yeon-Hee; Shin, Ju-Young] Sungkyunkwan Univ, Sch Pharm, Suwon, Gyeonggi Do, South Korea	Sungkyunkwan University (SKKU)	Shin, JY (corresponding author), Sungkyunkwan Univ, Sch Pharm, Suwon, Gyeonggi Do, South Korea.	shin.jy@skku.edu		Baek, Yeon-Hee/0000-0001-9597-6310; Shin, Ju-Young/0000-0003-1010-7525	Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [NHCR-HC17C0020]	Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	This research was supported by a grant of the Korean Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea, Grant number: NHCR-HC17C0020; URL: http://www.khidi.or.kr/eps. Our study used the National Health Insurance Service-National Sample Cohort (NHIS-NSC), a population-based cohort established by the NHIS in South Korea (Data number: NHIS-2018-2-024). NHIS forbids the transfer, rent, or sale of the database to any third party other than the researcher, who obtained the approval for the provided database (Official website of NHIS: https://nhiss.nhis.or.kr/bd/ab/bdaba022eng.do; Contact information of data access committee: +82-33-736-2430). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2009, DECR NUMB OUTP VIS C; Bae B, 2018, INT J HEALTH PLAN M, V33, P235, DOI 10.1002/hpm.2416; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Bushardt RL, 2008, CLIN INTERV AGING, V3, P383, DOI 10.2147/CIA.S2468; Caldwell P, 1996, SOC SCI MED, V43, P609, DOI 10.1016/0277-9536(96)00109-8; Centre THaSCI, 2001, PRESCR DISP COMM STA; Chan DC, 2009, PHARMACOEPIDEM DR S, V18, P327, DOI 10.1002/pds.1712; Charlesworth CJ, 2015, J GERONTOL A-BIOL, V70, P989, DOI 10.1093/gerona/glv013; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; De Cock RFW, 2011, EUR J CLIN PHARMACOL, V67, pS5, DOI 10.1007/s00228-009-0782-9; Franchi C, 2014, EUR J CLIN PHARMACOL, V70, P437, DOI 10.1007/s00228-013-1621-6; Fried TR, 2014, J AM GERIATR SOC, V62, P2261, DOI 10.1111/jgs.13153; Guthrie B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0322-7; Hajjar Emily R, 2007, Am J Geriatr Pharmacother, V5, P345, DOI 10.1016/j.amjopharm.2007.12.002; Hernandez J, 2003, NEW ENGL J MED, V349, P303; Herr M, 2015, PHARMACOEPIDEM DR S, V24, P637, DOI 10.1002/pds.3772; Hersh AL, 2011, PEDIATRICS, V128, P1053, DOI 10.1542/peds.2011-1337; HIRA, 2007, MAN EV PROJ APPR PRE; HIRA, 2014, PRESCR AN PROGR REP; Immonen S, 2013, SCAND J PRIM HEALTH, V31, P73, DOI 10.3109/02813432.2013.788272; Jones R. S., 2010, OECD EC DEP WORKING, V797; Jung KH, 2012, ELDERLY SURVEY KOREA; Jyrkka J, 2011, PHARMACOEPIDEM DR S, V20, P514, DOI 10.1002/pds.2116; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; Kim DS, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1059-x; Kim HA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098043; Kivimaki M, 2015, LANCET DIABETES ENDO, V3, P27, DOI 10.1016/S2213-8587(14)70178-0; Kojima T, 2012, GERIATR GERONTOL INT, V12, P425, DOI 10.1111/j.1447-0594.2011.00783.x; Kwon S, 2009, HEALTH POLICY PLANN, V24, P63, DOI 10.1093/heapol/czn037; Laflamme L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123390; Lai SW, 2012, GERIATR GERONTOL INT, V12, P491, DOI 10.1111/j.1447-0594.2011.00800.x; Lee J, 2017, INT J EPIDEMIOL, V46, DOI 10.1093/ije/dyv319; Mallet L, 2007, LANCET, V370, P185, DOI 10.1016/S0140-6736(07)61092-7; Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2; Mohammed S, 2016, CURR VASC PHARMACOL, V14, P388, DOI 10.2174/1570161113666151030105805; Nandi A, 2014, EPIDEMIOLOGY, V25, P170, DOI 10.1097/EDE.0000000000000038; Narayan Sujita W, 2015, Drugs Real World Outcomes, V2, P137; Niikawa H, 2017, GERIATR GERONTOL INT, V17, P1286, DOI 10.1111/ggi.12862; Nishtala PS, 2015, GERONTOLOGY, V61, P195, DOI 10.1159/000368191; Odubanjo E, 2004, BRIT J CLIN PHARMACO, V58, P496, DOI 10.1111/j.1365-2125.2004.02179.x; Onder G, 2013, J AM MED DIR ASSOC, V14, DOI 10.1016/j.jamda.2013.03.014; Park J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177435; Rawshani A, 2015, DIABETES CARE, V38, P1518, DOI 10.2337/dc15-0145; Richardson K, 2011, DRUG AGING, V28, P547, DOI 10.2165/11592000-000000000-00000; Rotermann M, 2014, HLTH REPORTS PRESCRI; Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085; Slabaugh SL, 2010, DRUG AGING, V27, P1019, DOI 10.2165/11584990-000000000-00000; Sohn HS, 2015, ARCH PHARM RES, V38, P1389, DOI 10.1007/s12272-014-0406-5; Song YJ, 2009, JPN MED ASS J, V52, P206; Statistics NCfH, 2017, HLTH US 2016 CHARTB; van den Bussche H, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-101; Veehof LJG, 2000, FAM PRACT, V17, P261, DOI 10.1093/fampra/17.3.261; Wauters M, 2016, ACTA CLIN BELG, V71, P158, DOI 10.1080/17843286.2016.1148298; Wise J, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7033; Yoon YK, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002100; Youngster I, 2017, J PEDIATR-US, V182, P239, DOI 10.1016/j.jpeds.2016.11.027; 주정미, 2009, [Health Policy and Mangemnet, 보건행정학회지], V19, P125	58	10	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2018	13	9							e0204018	10.1371/journal.pone.0204018	http://dx.doi.org/10.1371/journal.pone.0204018			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GU0DL	30226885	Green Published, gold, Green Submitted			2023-01-03	WOS:000444918300035
J	Pal, AR; Mercer, J; Jones, SA; Bruce, IA; Bigger, BW				Pal, Abhijit Ricky; Mercer, Jean; Jones, Simon A.; Bruce, Iain A.; Bigger, Brian W.			Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy	PLOS ONE			English	Article							HEMATOPOIETIC STEM-CELL; ALPHA-L-IDURONIDASE; HEPARAN-SULFATE; BACTERIAL SUPERINFECTION; PROTEOGLYCAN DEPOSITION; ENDOTHELIAL-CELLS; HURLER-SYNDROME; MANAGEMENT; LARONIDASE; COLLAGEN	Introduction Mucopolysaccharide diseases are a group of lysosomal storage disorders caused by deficiencies of hydrolase enzymes, leading to pathological glycosaminoglycan accumulation. A number of mucopolysaccharidosis (MPS) types are characterised by severe airway disease, the aetiology of which is poorly understood. There is ongoing evidence of significant clinical disease in the long-term despite disease modifying therapeutic strategies, including enzyme-replacement therapy (ERT). To provide a better understanding of this aspect of disease, we have characterised extracellular matrix (ECM) and inflammatory alterations in adenotonsillar tissue samples from 8 MPS patients. Methods Adenotonsillar samples from MPS I, IVA and VI ERT treated patients and from a single enzyme naive MPS IIIA individual were compared to non-affected control samples using quantitative immunohistochemistry, qPCR and biochemical analysis. Results Significantly increased lysosomal compartment size and total sulphated glycosaminoglycan (p = 0.0007, 0.02) were identified in patient samples despite ERT. Heparan sulphate glycosaminoglycan was significantly elevated in MPS I and IIIA (p = 0.002), confirming incomplete reversal of disease. Collagen IV and laminin alpha-5 (p = 0.002, 0.0004) staining demonstrated increased ECM deposition within the reticular and capillary network of MPS samples. No significant change in the expression of the pro-inflammatory cytokines IL-1 alpha, IL-6 or TNF-alpha was seen compared to control. Conclusion This study suggests a role for ECM remodelling contributing to the obstructive phenotype of airway disease in MPS. Current therapeutic strategies with ERT fail to normalise these pathological alterations within adenotonsillar samples. Our findings lend novel insight into the pathological cascade of events, with primarily structural rather than inflammatory changes contributing to the continuing phenotype seen in patients despite current therapeutic regimes.	[Pal, Abhijit Ricky; Bruce, Iain A.] Royal Manchester Childrens Hosp, Dept Paediat Otolaryngol, Manchester, Lancs, England; [Pal, Abhijit Ricky; Bigger, Brian W.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Div Cell Matrix Biol & Regenerat Med,Stem Cell &, Manchester, Lancs, England; [Mercer, Jean; Jones, Simon A.] St Marys Hosp, Manchester Ctr Genom Med, Willink Biochem Genet Unit, Manchester, Lancs, England; [Bruce, Iain A.] Univ Manchester, Fac Med & Human Sci, Resp & Allergy Ctr, Inst Inflammat & Repair, Manchester, Lancs, England	Royal Manchester Children's Hospital; University of Manchester; University of Manchester; University of Manchester	Bigger, BW (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Div Cell Matrix Biol & Regenerat Med,Stem Cell &, Manchester, Lancs, England.	brian.bigger@manchester.ac.uk	Bruce, Iain A/H-9508-2019	Bruce, Iain A/0000-0003-0831-4760; jones, simon/0000-0002-5117-0566	Shire Human Genetics Therapies [RO1844]	Shire Human Genetics Therapies	This research was supported by an unrestricted research grant from Shire Human Genetics Therapies (RO1844 to ARP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aldenhoven M, 2015, BLOOD, V125, P2164, DOI 10.1182/blood-2014-11-608075; Am P, 2015, ANN OTO RHINOL LARYN, V124, P198, DOI 10.1177/0003489414550154; Archer LD, 2014, J INHERIT METAB DIS, V37, P1, DOI 10.1007/s10545-013-9613-3; Ausseil J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002296; Beck-Schimmer B, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-61; Bengtsson E, 2002, J BIOL CHEM, V277, P15061, DOI 10.1074/jbc.M108285200; Berger KI, 2013, J INHERIT METAB DIS, V36, P201, DOI 10.1007/s10545-012-9555-1; Brandtzaeg P, 2003, INT J PEDIATR OTORHI, V67, pS69, DOI 10.1016/j.ijporl.2003.08.018; Clarke Lorne A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000550; Clarke LA, 2009, PEDIATRICS, V123, P229, DOI 10.1542/peds.2007-3847; Eliyahu E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022447; Findlay EG, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/140937; Fischer Andrew H, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4986; Dualibi APFF, 2016, BRAZ J OTORHINOLAR, V82, P522, DOI 10.1016/j.bjorl.2015.09.006; FUJITANI T, 1985, INT J PEDIATR OTORHI, V10, P205, DOI 10.1016/S0165-5876(85)80066-5; Giugliani R, 2010, GENET MOL BIOL, V33, P589, DOI 10.1590/S1415-47572010005000093; Gonuldas B, 2014, INT J PEDIATR OTORHI, V78, P944, DOI 10.1016/j.ijporl.2014.03.021; Goulding J, 2011, J INFECT DIS, V204, P1086, DOI 10.1093/infdis/jir467; Habibzay M, 2013, FUTURE MICROBIOL, V8, P247, DOI [10.2217/FMB.12.143, 10.2217/fmb.12.143]; Harmatz P, 2008, MOL GENET METAB, V94, P469, DOI 10.1016/j.ymgme.2008.04.001; Hendriksz CJ, 2015, MOL GENET METAB, V114, P178, DOI 10.1016/j.ymgme.2014.08.012; Hendriksz CJ, 2014, J INHERIT METAB DIS, V37, P979, DOI 10.1007/s10545-014-9715-6; Heppner JM, 2015, MOL GENET METAB, V114, P146, DOI 10.1016/j.ymgme.2014.09.012; Holley RJ, 2011, J BIOL CHEM, V286, P37515, DOI 10.1074/jbc.M111.287474; Huang J, 1999, AM J RESP CRIT CARE, V160, P725, DOI 10.1164/ajrccm.160.2.9809040; Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153; Jikko A, 1998, CELL BIOL INT, V22, P615, DOI 10.1006/cbir.1998.0304; Juneja SC, 2013, ARTHRITIS, DOI 10.1155/2013/154812; Keilmann A, 2015, INT J PEDIATR OTORHI, V79, P115, DOI 10.1016/j.ijporl.2014.11.014; Kirkpatrick K, 2012, PEDIATR ANESTH, V22, P745, DOI 10.1111/j.1460-9592.2012.03897.x; Langford-Smith A, 2012, MOL THER, V20, P1610, DOI 10.1038/mt.2012.82; Maatta M, 2004, J HISTOCHEM CYTOCHEM, V52, P1073, DOI 10.1369/jhc.4a6253.2004; Mehta A.B., 2012, LYSOSOMAL STORAGE DI; Muenzer J, 2011, GENET MED, V13, P95, DOI 10.1097/GIM.0b013e3181fea459; Muenzer J, 2009, PEDIATRICS, V123, P19, DOI 10.1542/peds.2008-0416; Muhlebach MS, 2013, PEDIATR PULM, V48, P601, DOI 10.1002/ppul.22629; Muhlebach MS, 2011, PAEDIATR RESPIR REV, V12, P133, DOI 10.1016/j.prrv.2010.10.005; Ohmi K, 2003, P NATL ACAD SCI USA, V100, P1902, DOI 10.1073/pnas.252784899; Pal Abhijit Ricky, 2015, J. inborn errors metab. screen., V3, pe150008, DOI 10.1177/2326409815616392; Pal AR, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0255-4; Pini L, 2007, EUR RESPIR J, V29, P71, DOI 10.1183/09031936.00047905; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; QUANTOCK AJ, 1993, CAN J OPHTHALMOL, V28, P266; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sergijenko A, 2013, MOL THER, V21, P1938, DOI 10.1038/mt.2013.141; Simmons MA, 2005, INT J PEDIATR OTORHI, V69, P589, DOI 10.1016/j.ijporl.2005.01.017; Simonaro CM, 2008, AM J PATHOL, V172, P112, DOI 10.2353/ajpath.2008.070564; Simonaro CM, 2010, P NATL ACAD SCI USA, V107, P222, DOI 10.1073/pnas.0912937107; Standards for Services for Children with Disorders of Sleep Physiology, 2009, WORK PART SLEEP PHYS, DOI DOI 10.1016/J.IJPORL.2014.11.014; Strazynski M, 2004, J BIOL CHEM, V279, P21266, DOI 10.1074/jbc.M309782200; Sunami-Kataoka Y, 2001, ARCH HISTOL CYTOL, V64, P535, DOI 10.1679/aohc.64.535; Taylor KR, 2006, FASEB J, V20, P9, DOI 10.1096/fj.05-4682rev; Vareille M, 2011, CLIN MICROBIOL REV, V24, P210, DOI 10.1128/CMR.00014-10; Wilkinson FL, 2013, MOL THER, V21, P868, DOI 10.1038/mt.2013.29; Wilkinson FL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035787; Wraith JE, 2007, PEDIATRICS, V120, pE37, DOI 10.1542/peds.2006-2156; Wraith JE, 2013, HAND CLINIC, V113, P1723, DOI 10.1016/B978-0-444-59565-2.00042-3; Wraith JE, 2005, EXPERT OPIN PHARMACO, V6, P489, DOI 10.1517/14656566.6.3.489; WRAITH JE, 1995, ARCH DIS CHILD, V72, P263, DOI 10.1136/adc.72.3.263; Young RD, 2011, INVEST OPHTH VIS SCI, V52, P6720, DOI 10.1167/iovs.11-7377	61	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2018	13	9							e0203216	10.1371/journal.pone.0203216	http://dx.doi.org/10.1371/journal.pone.0203216			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GU0DL	30226843	Green Published, gold, Green Submitted			2023-01-03	WOS:000444918300012
J	Zago, M; Capodaglio, P; Ferrario, C; Tarabini, M; Galli, M				Zago, Matteo; Capodaglio, Paolo; Ferrario, Cristina; Tarabini, Marco; Galli, Manuela			Whole-body vibration training in obese subjects: A systematic review	PLOS ONE			English	Review							L-CITRULLINE SUPPLEMENTATION; REDUCES ARTERIAL STIFFNESS; LIFE-STYLE MODIFICATION; HEART-RATE-VARIABILITY; SKIN BLOOD-FLOW; MUSCLE STRENGTH; POSTMENOPAUSAL WOMEN; WAVE REFLECTION; WEIGHT-LOSS; CENTRAL HEMODYNAMICS	Objective (i) to determine the outcomes of whole-body vibration training (WBVT) on obese individuals, and the intervention settings producing such effects; (ii) identify potential improper or harmful use of WBVT. Design Systematic review. Data sources Medline, Scopus, Web of Science, PEDro and Scielo until July 2018. Eligibility criteria Full papers evaluating the effect of WBVT on body composition, cardiovascular status and functional performance in obese adults. Papers with PEDro score<4 were excluded. Study appraisal and synthesis Risk of bias and quality of WBVT reporting were assessed with PEDro scale (randomized controlled trials) or TREND checklist (non-randomized studies) and a 14-items checklist, respectively. Weighted acceleration, daily exposure and Hedges' adjusted g were computed. Results We included 18 papers published 2010-2017. Typical interventions consisted in three sessions/week of exercises (squats, calf-raises) performed on platforms vibrating at 25-40 Hz (amplitude: 1-2 mm); according to ISO 2631-1:1997, daily exposure was ''unsafe'' in 7/18 studies. Interventions lasting >= 6 weeks improved cardiac autonomic function and reduced central/peripheral arterial stiffness in obese women; 10 weeks of WBVT produced significant weight/fat mass reduction, leg strength improvements as resistance training, and enhanced glucose regulation when added to hypocaloric diet. No paper evidenced losses of lean mass. Isolated cases of adverse effects were reported. Summary To date, WBVT is a promising adjuvant intervention therapy for obese women; long-term studies involving larger cohorts and male participants are required to demonstrate the associated safety and health benefits. The therapeutic use of WBVT in the management of obese patients is still not standardised and should be supported by an extensive knowledge on the causality between vibration parameters and outcomes.	[Zago, Matteo; Ferrario, Cristina; Galli, Manuela] Politecn Milan, Dipartimento Elettron Informaz & Bioingn, Milan, Italy; [Zago, Matteo] Fdn Ist Farmacol Filippo Serpero, Milan, Italy; [Capodaglio, Paolo] Osped San Giuseppe, IRCCS Ist Auxol Italiano, Orthoped Rehabil Unit, Res Lab Biomech & Rehabil, Oggebbio, Vco, Italy; [Ferrario, Cristina; Tarabini, Marco] Politecn Milan, Dipartimento Meccan, Milan, Italy	Polytechnic University of Milan; IRCCS Istituto Auxologico Italiano; Polytechnic University of Milan	Zago, M (corresponding author), Politecn Milan, Dipartimento Elettron Informaz & Bioingn, Milan, Italy.; Zago, M (corresponding author), Fdn Ist Farmacol Filippo Serpero, Milan, Italy.	matteo2.zago@polimi.it	Zago, Matteo/B-1481-2015; Stefanadis, Christodoulos/ABH-2232-2020; Galli, Manuela/AAH-8783-2019; Tarabini, Marco/D-3624-2011	Zago, Matteo/0000-0002-0649-3665; Stefanadis, Christodoulos/0000-0001-5974-6454; Tarabini, Marco/0000-0002-2640-1764; Galli, Manuela/0000-0003-2772-4837	"Filippo Serpero Foundation", Milan, Italy	"Filippo Serpero Foundation", Milan, Italy	This project was partially supported by an unconditioned Research Grant supplied from the "Filippo Serpero Foundation", Milan, Italy. There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMoa055643; Adsuar JC, 2013, REV INT MED CIENC AC, V13, P295; Alvarez-Alvarado S, 2017, HYPERTENS RES, V40, P487, DOI 10.1038/hr.2016.178; Andrade AM, 2010, PATIENT EDUC COUNS, V79, P320, DOI 10.1016/j.pec.2010.01.006; Ashor AW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110034; Baek J, 2013, CLIN AUTON RES, V23, P325, DOI 10.1007/s10286-013-0215-9; Beck DT, 2013, AM J HYPERTENS, V26, P1093, DOI 10.1093/ajh/hpt080; Bellia A, 2014, INT J SPORTS MED, V35, P511, DOI 10.1055/s-0033-1354358; Bogaerts ACG, 2009, AGE AGEING, V38, P448, DOI 10.1093/ageing/afp067; Bogers RP, 2007, ARCH INTERN MED, V167, P1720, DOI 10.1001/archinte.167.16.1720; Cardinale M, 2003, EXERC SPORT SCI REV, V31, P3, DOI 10.1097/00003677-200301000-00002; Cochrane DJ, 2011, INT J SPORTS MED, V32, P75, DOI 10.1055/s-0030-1268010; Croymans DM, 2014, J HUM HYPERTENS, V28, P157, DOI 10.1038/jhh.2013.81; Delecluse C, 2003, MED SCI SPORT EXER, V35, P1033, DOI 10.1249/01.MSS.0000069752.96438.B0; Des Jarlais DC, 2004, AM J PUBLIC HEALTH, V94, P361, DOI 10.2105/AJPH.94.3.361; Di Loreto C, 2004, J ENDOCRINOL INVEST, V27, P323, DOI 10.1007/BF03351056; Dillon EL, 2011, AM J PHYSIOL-REG I, V301, pR1408, DOI 10.1152/ajpregu.00211.2011; Dipla K, 2016, EXP PHYSIOL, V101, P717, DOI 10.1113/EP085556; Durlak JA, 2009, J PEDIATR PSYCHOL, V34, P917, DOI 10.1093/jpepsy/jsp004; Emerenziani GP, 2014, J SPORT SCI, V32, P1033, DOI 10.1080/02640414.2013.877150; Figueroa A, 2014, J HUM HYPERTENS, V28, P118, DOI 10.1038/jhh.2013.59; Figueroa A, 2015, EXP GERONTOL, V63, P35, DOI 10.1016/j.exger.2015.01.046; Figueroa A, 2014, MENOPAUSE, V21, P131, DOI 10.1097/GME.0b013e318294528c; Figueroa A, 2013, AM J HYPERTENS, V26, P416, DOI 10.1093/ajh/hps050; Figueroa A, 2012, HYPERTENS RES, V35, P667, DOI 10.1038/hr.2012.15; Fitzpatrick Roberta Bronson, 2008, Medical Reference Services Quarterly, V27, P189, DOI 10.1080/02763860802114397; Fjeldstad Cecilie, 2008, Dyn Med, V7, P4, DOI 10.1186/1476-5918-7-4; Gerage AM, 2013, INT J SPORTS MED, V34, P806, DOI 10.1055/s-0032-1331185; Giunta M, 2012, OBESITY FACTS, V5, P567, DOI 10.1159/000342066; Guerin E, 2012, J OBES, V2012, DOI 10.1155/2012/269320; Hales CM, 2018, JAMA-J AM MED ASSOC, V319, P1723, DOI 10.1001/jama.2018.3060; Himes CL, 2012, J AM GERIATR SOC, V60, P124, DOI 10.1111/j.1532-5415.2011.03767.x; Irving BA, 2008, MED SCI SPORT EXER, V40, P1863, DOI 10.1249/MSS.0b013e3181801d40; ISO 2631-1, 1997, MECH VIBRATION SHOCK; Ives SJ, 2013, AM J PHYSIOL-HEART C, V304, pH154, DOI 10.1152/ajpheart.00532.2012; Janssen I, 1999, INT J OBESITY, V23, P1035, DOI 10.1038/sj.ijo.0801038; Jurca R, 2004, AM HEART J, V147, DOI 10.1016/j.ahj.2003.10.024; Kelley CP, 2016, PRIMARY CARE, V43, P159, DOI 10.1016/j.pop.2015.10.004; Kelly RP, 2001, HYPERTENSION, V37, P1429, DOI 10.1161/01.HYP.37.6.1429; Koenig J, 2014, J NUTR HEALTH AGING, V18, P300, DOI 10.1007/s12603-014-0022-6; Kvorning T, 2006, EUR J APPL PHYSIOL, V96, P615, DOI 10.1007/s00421-006-0139-3; Lampert R, 2005, AM HEART J, V150, P153, DOI 10.1016/j.ahj.2004.08.008; Lohman EB, 2007, MED SCI MONITOR, V13, pCR71; Machado A, 2010, SCAND J MED SCI SPOR, V20, P200, DOI 10.1111/j.1600-0838.2009.00919.x; Maddalozzo GF, 2008, INT J OBESITY, V32, P1348, DOI 10.1038/ijo.2008.111; Maffiuletti NA, 2007, EUR J APPL PHYSIOL, V101, P51, DOI 10.1007/s00421-007-0471-2; Maloney-Hinds C, 2009, DIABETES TECHNOL THE, V11, P39, DOI 10.1089/dia.2008.0011; Matarese LE, 2014, NUTR CLIN PRACT, V29, P759, DOI 10.1177/0884533614550251; Mcgee DL, 2005, ANN EPIDEMIOL, V15, P87, DOI 10.1016/j.annepidem.2004.05.012; Mester J, 2006, J BIOMECH, V39, P1056, DOI 10.1016/j.jbiomech.2005.02.015; Milanese C, 2013, INT J MED SCI, V10, P307, DOI 10.7150/ijms.5161; Miyaki A, 2012, ARTERY RES, V6, P85, DOI 10.1016/j.artres.2012.01.006; Moher D, 2015, STATEMENT SYST REV, V4, DOI [10.1186/2046-4053-4-1, DOI 10.1186/2046-4053-4-1, 10.1186/s13643-015-0163-7, DOI 10.14306/RENHYD.20.2.223]; Muir J, 2013, J SCI MED SPORT, V16, P526, DOI 10.1016/j.jsams.2013.01.004; Nam Sang-Seok, 2016, J Exerc Nutrition Biochem, V20, P19, DOI 10.20463/jenb.2016.06.20.2.3; Ogoh S, 2005, J PHYSIOL-LONDON, V566, P599, DOI 10.1113/jphysiol.2005.084541; Pal GK, 2012, BMC CARDIOVASC DISOR, V12, DOI 10.1186/1471-2261-12-54; Palmer BF, 2015, MOL CELL ENDOCRINOL, V402, P113, DOI 10.1016/j.mce.2014.11.029; Piche ME, 2008, METABOLISM, V57, P1101, DOI 10.1016/j.metabol.2008.03.015; Premaor MO, 2011, J CLIN ENDOCR METAB, V96, P2414, DOI 10.1210/jc.2011-0076; Prisby RD, 2008, AGEING RES REV, V7, P319, DOI 10.1016/j.arr.2008.07.004; Rauch F, 2010, J MUSCULOSKEL NEURON, V10, P193; Rittweger J, 2010, EUR J APPL PHYSIOL, V108, P877, DOI 10.1007/s00421-009-1303-3; Roelants M, 2004, J AM GERIATR SOC, V52, P901, DOI 10.1111/j.1532-5415.2004.52256.x; Rossow LM, 2014, EXP GERONTOL, V53, P48, DOI 10.1016/j.exger.2014.02.010; Rubin C, 2002, BONE, V30, P445, DOI 10.1016/S8756-3282(01)00689-5; Rubin CT, 2007, P NATL ACAD SCI USA, V104, P17879, DOI 10.1073/pnas.0708467104; Russo C, 2012, HYPERTENSION, V60, P362, DOI 10.1161/HYPERTENSIONAHA.112.191148; RYAN AS, 1995, J APPL PHYSIOL, V79, P818, DOI 10.1152/jappl.1995.79.3.818; Sanudo B, 2013, EUR J APPL PHYSIOL, V113, P2245, DOI 10.1007/s00421-013-2654-3; Sanudo B, 2013, J REHABIL MED, V45, P678, DOI 10.2340/16501977-1174; SARTORIO A, 1988, J ENDOCRINOL INVEST, V11, P727, DOI 10.1007/BF03350930; Schwedhelm E, 2008, BRIT J CLIN PHARMACO, V65, P51, DOI 10.1111/j.1365-2125.2007.02990.x; Severino G, 2017, J AGING PHYS ACTIV, V25, P395, DOI 10.1123/japa.2016-0087; Shim CY, 2011, J AM COLL CARDIOL, V57, P1226, DOI 10.1016/j.jacc.2010.09.067; Signorile J, 2011, J ACT AGING, V10, P46; Snitker S, 2000, Obes Rev, V1, P5, DOI 10.1046/j.1467-789x.2000.00001.x; So R, 2014, OBES RES CLIN PRACT, V8, pE238, DOI 10.1016/j.orcp.2013.03.002; Song GE, 2011, KOREAN J FAM MED, V32, P399, DOI 10.4082/kjfm.2011.32.7.399; Strazzullo P, 2010, STROKE, V41, pE418, DOI 10.1161/STROKEAHA.109.576967; Tadic M, 2014, J AM SOC HYPERTENS, V8, P699, DOI 10.1016/j.jash.2014.07.032; Totosy de Zepetnek JO, 2009, J REHABIL RES DEV, V46, P529, DOI 10.1682/JRRD.2008.09.0136; TOWNEND JN, 1995, HYPERTENSION, V25, P1270, DOI 10.1161/01.HYP.25.6.1270; van der Linde H, 2004, J REHABIL RES DEV, V41, P555, DOI 10.1682/JRRD.2003.06.0102; Vissers D, 2009, PHYSICIAN SPORTSMED, V37, P88, DOI 10.3810/psm.2009.10.1733; Vissers D, 2010, OBESITY FACTS, V3, P93, DOI 10.1159/000301785; Vlachopoulos C, 2010, EUR HEART J, V31, P1865, DOI 10.1093/eurheartj/ehq024; Wadden TA, 2004, OBES RES, V12, p151S, DOI 10.1038/oby.2004.282; Wildman RP, 2003, HYPERTENSION, V42, P468, DOI 10.1161/01.HYP.0000090360.78539.CD; Willis LH, 2012, J APPL PHYSIOL, V113, P1831, DOI 10.1152/japplphysiol.01370.2011; Wilms B, 2012, INT J SPORTS MED, V33, P740, DOI 10.1055/s-0032-1306284; Wong A, 2016, J ALTERN COMPLEM MED, V22, P970, DOI 10.1089/acm.2016.0124; Wong A, 2016, APPL PHYSIOL NUTR ME, V41, P292, DOI 10.1139/apnm-2015-0465; Wu XF, 2012, J BIOMECH, V45, P1042, DOI 10.1016/j.jbiomech.2011.12.021; Yang F, 2017, J BIOMECH, V57, P87, DOI 10.1016/j.jbiomech.2017.03.024; Yang F, 2015, J BIOMECH, V48, P3206, DOI 10.1016/j.jbiomech.2015.06.029; Yumuk V, 2015, OBESITY FACTS, V8, P402, DOI 10.1159/000442721; Zaki ME, 2014, J OSTEOPOROS, V2014, DOI 10.1155/2014/702589	98	35	36	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 5	2018	13	9							e0202866	10.1371/journal.pone.0202866	http://dx.doi.org/10.1371/journal.pone.0202866			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GS6HC	30183742	gold, Green Published, Green Submitted			2023-01-03	WOS:000443789900039
J	Zhang, R; Li, SS; Li, C; Zhao, DD; Guo, LQ; Qu, PF; Liu, DM; Dang, SN; Yan, H				Zhang, Ruo; Li, Shanshan; Li, Chao; Zhao, Doudou; Guo, Leqian; Qu, Pengfei; Liu, Danmeng; Dang, Shaonong; Yan, Hong			Socioeconomic inequalities and determinants of maternal health services in Shaanxi Province, Western China	PLOS ONE			English	Article							CESAREAN-SECTION; CARE; INTERVENTIONS; COUNTRIES; TRENDS	Prenatal health care interventions are effective ways to improve maternal and neonatal health. There have been few large investigations conducted on the inequalities in maternal health services utilization in Shaanxi Province of west China since the health care reform in 2009. This study examined the inequalities and determinants of maternal health services utilization in Shaanxi Province. A household survey was conducted from August to November in 2013. By using a multistage sampling method, local women aged 15-49 who had given birth in the preceding three years were recruited. Information including social-demographic characteristics and maternal health services utilization was collected through a face-to-face interview. A concentration index approach was used to measure inequalities in maternal health services utilization. A logistic regression model was employed to investigate the determinants of maternal health services utilization. There were 8,488 women from urban areas and 18,724 women from rural areas enrolled in this study. The concentration index for all the indicators of maternal health services utilization showed significance in these two areas. In urban areas, the concentration index of having 5 or more prenatal visits, receiving the first prenatal visit within 12 weeks, delivering at secondary-or higher-level health facilities and delivering by C-section were 0.0356, 0.0166, 0.0177 and 0.0591, respectively, while in rural areas, the corresponding figures were 0.0385, 0.0183, 0.0334 and 0.0566, respectively. The determinants related to maternal health services utilization were women's age at delivery, educational level, employment status, parity, health problems during pregnancy and household income. Inequalities in maternal health services utilization still exist in Shaanxi Province. Providing maternal health services for younger, less educated, unemployed, high parity and poorer women, especially in rural areas, is expected to reduce the inequalities in maternal health services utilization.	[Zhang, Ruo; Li, Shanshan; Li, Chao; Zhao, Doudou; Guo, Leqian; Qu, Pengfei; Liu, Danmeng; Dang, Shaonong; Yan, Hong] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Xian, Shaanxi, Peoples R China; [Yan, Hong] Nutr & Food Safety Engn Res Ctr Shaanxi Prov, Xian, Shaanxi, Peoples R China	Xi'an Jiaotong University	Dang, SN; Yan, H (corresponding author), Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Xian, Shaanxi, Peoples R China.; Yan, H (corresponding author), Nutr & Food Safety Engn Res Ctr Shaanxi Prov, Xian, Shaanxi, Peoples R China.	tjdshn@mail.xjtu.edu.cn; xjtu_yh.paper@aliyun.com	Shaonong, Dang/J-7421-2019	Shaonong, Dang/0000-0002-6980-8169	National Natural Science Foundation of China [81230016]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	National Natural Science Foundation of China provided grant no. 81230016 and had no role in the design, analysis or writing of this article.	Amano A, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-105; Azami-Aghdash S, 2014, IRAN J PUBLIC HEALTH, V43, P545; Barros AJD, 2012, LANCET, V379, P1225, DOI 10.1016/S0140-6736(12)60113-5; CAI JL, 2017, INT J EQUITY HEALTH, V16, P46204, DOI DOI 10.1186/S12939-017-0624-9; Darling Rosa D, 2012, Policy Polit Nurs Pract, V13, P17, DOI 10.1177/1527154412442391; Doctor HV, 2011, HEALTH PLACE, V17, P480, DOI 10.1016/j.healthplace.2010.12.003; Fan XJ, 2017, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-017-4601-4; Feng Xing Lin, 2012, J Glob Health, V2, P010405, DOI 10.7189/jogh.02.010405; Feyissa TR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097194; Friberg IK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000295; Garg Pankaj, 2015, Asia Pac Fam Med, V14, P7, DOI 10.1186/s12930-015-0024-5; Harrison MS, 2017, ACTA OBSTET GYN SCAN, V96, P410, DOI 10.1111/aogs.13098; Joshi C, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-94; Kebede A, 2016, INT J WOMENS HEALTH, V8, P463, DOI 10.2147/IJWH.S109498; Kifle D, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-016-0270-5; Lassi ZS, 2015, EBIOMEDICINE, V2, P985, DOI 10.1016/j.ebiom.2015.05.023; Li C, 2015, PUBLIC HEALTH, V129, P1251, DOI 10.1016/j.puhe.2015.07.002; Liu XN, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-102; Liu Ying-hui, 2006, Zhonghua Liu Xing Bing Xue Za Zhi, V27, P1029; Long Q, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0686-x; Manzi A, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-290; Matsumura M, 2001, WOMENS STATUS HOUSEH; Meng Q, 2012, LANCET, V379, P805, DOI 10.1016/S0140-6736(12)60278-5; Muhwava LS, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0807-1; Murray KD, 2007, PAEDIATR PERINAT EP, V21, P274, DOI 10.1111/j.1365-3016.2007.00800.x; Mustafa MH, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1128-1; National Bureau of Statistics of the People's Republic of China, 2015, B 6 NAT CENS SHAANX; Pei LL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139452; Pulok MH, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0970-4; Rahman A, 2017, J HEALTH POPUL NUTR, V36, DOI 10.1186/s41043-016-0078-5; Rajabi Abdolhalim, 2015, Med J Islam Repub Iran, V29, P294; Sagna ML, 2012, HEALTH PLACE, V18, P415, DOI 10.1016/j.healthplace.2011.12.006; Shen Y, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-155; Sprague DA, 2016, EMERG THEMES EPIDEMI, V13, DOI 10.1186/s12982-016-0049-8; Wado YD, 2013, BMC INT HEALTH HUM R, V13, DOI 10.1186/1472-698X-13-36; Wagstaff A, 1989, OXFORD REV EC, V5, P89, DOI DOI 10.1093/oxrep/5.1.89; Wang C, 2013, CHEST, V143, P524, DOI 10.1378/chest.12-1839; Wang YP, 2016, LANCET, V387, P273, DOI 10.1016/S0140-6736(15)00554-1; WHO, 2018, MAT MORT; Xiao SB, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-695; Yang W, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-20; Yuan BB, 2013, GLOBAL HEALTH ACTION, V6, P1, DOI 10.3402/gha.v6i0.19542; Zhao Q, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1012; Zhou Y, 2012, J REPROD MED, V57, P441	44	16	16	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 5	2018	13	9							e0202129	10.1371/journal.pone.0202129	http://dx.doi.org/10.1371/journal.pone.0202129			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS6HC	30183720	Green Submitted, Green Published, gold			2023-01-03	WOS:000443789900016
J	Dzhonova, D; Olariu, R; Leckenby, J; Dhayani, A; Vemula, PK; Prost, JC; Banz, Y; Taddeo, A; Rieben, R				Dzhonova, Dzhuliya; Olariu, Radu; Leckenby, Jonathan; Dhayani, Ashish; Vemula, Praveen Kumar; Prost, Jean-Christophe; Banz, Yara; Taddeo, Adriano; Rieben, Robert			Local release of tacrolimus from hydrogel-based drug delivery system is controlled by inflammatory enzymes in vivo and can be monitored non-invasively using in vivo imaging	PLOS ONE			English	Article							REJECTION	Background Local drug delivery systems that adjust the release of immunosuppressive drug in response to the nature and intensity of inflammation represent a promising approach to reduce systemic immunosuppression and its side effects in allotransplantation. Here we aimed to demonstrate that release of tacrolimus from triglycerol monostearate hydrogel is inflammationdependent in vivo. We further report that by loading the hydrogel with a near-infrared dye, it is possible to monitor drug release non-invasively in an in vivo model of vascularized composite allotransplantation. Materials and methods Inflammation was induced by local challenge with lipopolysaccharides in naive rats 7 days after injection of tacrolimus-loaded hydrogel in the hind limb. Tacrolimus levels in blood and tissues were measured at selected time points. A near-infrared dye was encapsulated in the hydrogel together with tacrolimus in order to monitor hydrogel deposits and drug release in vitro and in vivo in a model of vascularized composite allotransplantation. Results Injection of lipopolysaccharides led to increased blood and skin tacrolimus levels (p = 0.0076, day 7 vs. day 12 in blood, and p = 0.0007 in treated limbs, 48 h after injection compared to controls). Moreover, lipopolysaccharides-injected animals had higher tacrolimus levels in treated limbs compared to contralateral limbs (p = 0.0003 for skin and p = 0.0053 for muscle). Imaging of hydrogel deposits and tacrolimus release was achieved by encapsu-lating near-infrared dye in the hydrogel for 160 days. The correlation of tacrolimus and near infrared dye release from hydrogel was R-2 = 0.6297 and R-2 = 0.5619 in blood and grafts of transplanted animals respectively and R-2 = 0.6066 in vitro. Conclusions Here we demonstrate the inflammation-responsiveness of a tacrolimus-loaded hydrogel in vivo. Moreover, we show that encapsulating a near-infrared dye in the hydrogel provides a reliable correlation of tacrolimus and dye release from the hydrogel, and an accessible noninvasive method for monitoring drug release from hydrogel deposits.	[Dzhonova, Dzhuliya; Taddeo, Adriano; Rieben, Robert] Univ Bern, Dept BioMed Res DBMR, Bern, Switzerland; [Dzhonova, Dzhuliya] Univ Bern, Grad Sch Cellular & Biomed Sci, Bern, Switzerland; [Olariu, Radu; Leckenby, Jonathan; Taddeo, Adriano] Bern Univ Hosp, Inselspital, Dept Plast & Hand Surg, Bern, Switzerland; [Dhayani, Ashish; Vemula, Praveen Kumar] Inst Stem Cell Biol & Regenerat Med, Bangalore, Karnataka, India; [Dhayani, Ashish] SASTRA Univ, Sch Chem & Biotechnol, Thanjavur, Tamil Nadu, India; [Prost, Jean-Christophe] Univ Hosp, Univ Inst Clin Chem, Ctr Lab Med, Bern, Switzerland; [Banz, Yara] Univ Bern, Inst Pathol, Bern, Switzerland	University of Bern; University of Bern; University of Bern; University Hospital of Bern; Department of Biotechnology (DBT) India; Institute for Stem Cell Biology & Regenerative Medicine - inStem; Shanmugha Arts, Science, Technology & Research Academy (SASTRA); University of Bern; University Hospital of Bern; University of Bern	Taddeo, A; Rieben, R (corresponding author), Univ Bern, Dept BioMed Res DBMR, Bern, Switzerland.; Taddeo, A (corresponding author), Bern Univ Hosp, Inselspital, Dept Plast & Hand Surg, Bern, Switzerland.	adriano.taddeo@dbmr.unibe.ch; robert.rieben@dbmr.unibe.ch	Taddeo, Adriano/AAW-3861-2021; Rieben, Robert/D-7044-2017	Taddeo, Adriano/0000-0003-3281-1548; Bovet, Cedric/0000-0002-1600-3818; Dzhonova, Dzhuliya/0000-0001-5196-5417; Prost, Jean-Christophe/0000-0002-8820-706X; Dhayani, Ashish/0000-0002-5488-8952; Rieben, Robert/0000-0003-4179-8891; Olariu, Radu/0000-0002-0204-4432	Indo-Swiss Joint Research Program of the Swiss National Science Foundation (SNF) [156773]; Department of Science and Technology, Govt. of India [INT/SWISS/SNSFP-51/2015]; University Grant Commission	Indo-Swiss Joint Research Program of the Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF)); Department of Science and Technology, Govt. of India(Department of Science & Technology (India)); University Grant Commission(University Grants Commission, India)	This work was supported by Indo-Swiss Joint Research Program of the Swiss National Science Foundation (SNF, grant 156773) and the Department of Science and Technology, Govt. of India (grant INT/SWISS/SNSFP-51/2015) to R.R. and P.V. respectively. A.D. thanks the University Grant Commission for the senior research fellowship.	Asai D, 2012, BIOMATERIALS, V33, P5451, DOI 10.1016/j.biomaterials.2012.03.083; Bloch S, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2070148; Capron A, 2012, TRANSPL INT, V25, P41, DOI 10.1111/j.1432-2277.2011.01365.x; Dzhonova DV, 2018, TRANSPLANTATION, P1; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Gajanayake T, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008778; Gharb BB, 2013, TRANSPLANTATION, V95, P1197, DOI 10.1097/TP.0b013e31828bca61; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Mieog JSD, 2011, ANN SURG ONCOL, V18, P2483, DOI 10.1245/s10434-011-1566-x; Olariu R, 2017, J SURG RES, V218, P49, DOI 10.1016/j.jss.2017.05.046; Petrou P, 2018, CULT HEALTH SEX, V20, P640, DOI 10.1080/13691058.2017.1368710; Petruzzo P, 2017, CURRENT TRANSPLANTAT, P1; Selvam S, 2011, BIOMATERIALS, V32, P7785, DOI 10.1016/j.biomaterials.2011.07.020; Solari MG, 2009, PLAST RECONSTR SURG, V123, p17S, DOI 10.1097/PRS.0b013e318191bcbd; Sotocinal SG, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-55; Taddeo A, 2018, CURRENT OPINION ORGA, V1; Unadkat JV, 2017, PLAST RECONSTR SURG, V139, p403E, DOI 10.1097/PRS.0000000000002951; Wang T, 2010, AM J TRANSPLANT, V10, P1524, DOI 10.1111/j.1600-6143.2010.03066.x	18	12	12	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2018	13	8							e0203409	10.1371/journal.pone.0203409	http://dx.doi.org/10.1371/journal.pone.0203409			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS2NZ	30161258	Green Published, gold, Green Submitted			2023-01-03	WOS:000443388900123
J	O'Sullivan, NP; Lelijveld, N; Rutishauser-Perera, A; Kerac, M; James, P				O'Sullivan, Natasha Phillipa; Lelijveld, Natasha; Rutishauser-Perera, Alexandra; Kerac, Marko; James, Philip			Follow-up between 6 and 24 months after discharge from treatment for severe acute malnutrition in children aged 6-59 months: A systematic review	PLOS ONE			English	Review							NUTRITION; MORTALITY; GROWTH; UNDERNUTRITION; INTERVENTIONS; KWASHIORKOR; MANAGEMENT; EFFICACY; TRIAL; DHAKA	Background Severe acute malnutrition (SAM) is a major global health problem affecting some 16.9 million children under five. Little is known about what happens to children 6-24 months post discharge as this window often falls through the gap between studies on SFPs and those focusing on longer-term effects. Methods A protocol was registered on PROSPERO (PROSPERO 2017:CRD42017065650). Embase, Global Health and MEDLINE In-Process and Non-Indexed Citations were systematically searched with terms related to SAM, nutritional intervention and follow-up between June and August 2017. Studies were selected if they included children who experienced an episode of SAM, received a therapeutic feeding intervention, were discharged as cured and presented any outcome from follow-up between 6-24 months later. Results 3,691 articles were retrieved from the search, 55 full-texts were screened and seven met the inclusion criteria. Loss-to-follow-up, mortality, relapse, morbidity and anthropometry were outcomes reported. Between 0.0% and 45.1% of cohorts were lost-to-follow-up. Of those discharged as nutritionally cured, mortality ranged from 0.06% to 10.4% at an average of 12 months post-discharge. Relapse was inconsistently defined, measured, and reported, ranging from 0% to 6.3%. Two studies reported improved weight-for-height z-scores, whilst three studies that reported height-for-age z-scores found either limited or no improvement. Conclusions Overall, there is a scarcity of studies that follow-up children 6-24 months post-discharge from SAM treatment. Limited data that exists suggest that children may exhibit sustained vulnerability even after achieving nutritional cure, including heightened mortality and morbidity risk and persistent stunting. Prospective cohort studies assessing a wider range of outcomes in children post-SAM treatment are a priority, as are intervention studies exploring how to improve post-SAM outcomes and identify high-risk children.	[O'Sullivan, Natasha Phillipa; Lelijveld, Natasha; Kerac, Marko] London Sch Hyg & Trop Med, Dept Populat Hlth, London, England; [O'Sullivan, Natasha Phillipa] Brighton & Sussex Med Sch, Falmer, E Sussex, England; [Lelijveld, Natasha; Rutishauser-Perera, Alexandra] Act Hunger, London, England; [Kerac, Marko] London Sch Hyg & Trop Med, Ctr Maternal Adolescent Reprod & Child Hlth MARCH, London, England; [James, Philip] London Sch Hyg & Trop Med, Med Res Council MRC Unit Gambia, London, England	University of London; London School of Hygiene & Tropical Medicine; University of Brighton; University of Sussex; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	O'Sullivan, NP (corresponding author), London Sch Hyg & Trop Med, Dept Populat Hlth, London, England.; O'Sullivan, NP (corresponding author), Brighton & Sussex Med Sch, Falmer, E Sussex, England.	bsms3556@uni.bsms.ac.uk	Kerac, Marko/GQR-1136-2022; James, Philip/AAG-4618-2020	Kerac, Marko/0000-0002-3745-7317; James, Philip/0000-0001-5448-8193; Lelijveld, Natasha/0000-0002-8452-0198; O'Sullivan, Natasha/0000-0002-4429-2901				Annan RA., 2014, CMAM FORUM TECHNICAL; Aprameya H. S., 2015, International Journal of Health and Allied Sciences, V4, P148; Ashraf H, 2012, J TROP PEDIATRICS, V58, P253, DOI 10.1093/tropej/fmr083; Bahwere P., 2012, Journal of Public Health and Epidemiology, V4, P215; Bahwere Paluku, 2017, BMC Res Notes, V10, P570, DOI 10.1186/s13104-017-2909-x; Bahwere P, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-106; Bailey J., 2016, Field Exchange - Emergency Nutrition Network ENN, P44; Banapurmath C R, 1999, Indian Pediatr, V36, P139; BARTEL PR, 1979, AM J CLIN NUTR, V32, P753, DOI 10.1093/ajcn/32.4.753; Bhandari N, 2016, BMJ GLOB HEALTH, V1, DOI 10.1136/bmjgh-2016-000144; Bhutta ZA, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.67; Bhutta ZA, 2013, LANCET, V382, P452, DOI 10.1016/S0140-6736(13)60996-4; Black RE, 2013, LANCET, V382, P427, DOI 10.1016/S0140-6736(13)60937-X; Brennhofer S, 2017, PUBLIC HEALTH NURS, V34, P401, DOI 10.1111/phn.12273; Briend A., 2016, BMC NUTR, V2, P63, DOI [10.1186/s40795-016-0101-7, DOI 10.1186/S40795-016-0101-7, 10.1186/s40795-016, DOI 10.1186/S40795-016]; Burza S, 2016, EUR J CLIN NUTR, V70, P437, DOI 10.1038/ejcn.2015.140; CARVALHO NM, 1992, REV SAUDE PUBL, V26, P223, DOI 10.1590/S0034-89101992000400003; Collins S, 2006, FOOD NUTR B, V27; Collins S., 2004, COMMUNITY BASED THER; Council of Research & Technical Advice on Acute Malnutrition (CORTASAM), 2017, RES AG AC MALN; Council of Research & Technical Advice on Acute Malnutrition (CORTASAM), 2017, STAT COUNC RES RECHN; Department of Maternal and Child Health and Community Health Ministry of Health PRC, 2009, CHILD GROWTH STAND I; Fergusson P, 2009, ARCH DIS CHILD, V94, P512, DOI 10.1136/adc.2008.142646; Grellety E., 2016, BMC NUTR, V2, P1173, DOI [10.1038/ng.3097, DOI 10.1038/NG.3097, DOI 10.1186/S40795-016-0049-7]; Grellety E, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0848-y; Guerrero Saul, 2013, IS COMMUNITY BASED T, V1; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HENNART P, 1987, J TROP PEDIATRICS, V33, P10, DOI 10.1093/tropej/33.1.10; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hure A, 2016, AM J EPIDEMIOL, V184, P870, DOI 10.1093/aje/kww131; Idohou-Dossou N, 2003, BRIT J NUTR, V90, P1123, DOI 10.1079/BJN2003990; Keenan JD, 2018, NEW ENGL J MED, V378, P1583, DOI [10.1056/NEJMoa1715474, 10.1056/nejmoa1715474]; Kerac M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096030; Kerac M, 2009, LANCET, V374, P136, DOI 10.1016/S0140-6736(09)60884-9; Khanum S, 1998, AM J CLIN NUTR, V67, P940, DOI 10.1093/ajcn/67.5.940; Khara T, 2014, TECHNICAL BRIEFING P; KHARE RD, 1976, INDIAN J MED RES, V64, P1119; Lelijveld N, 2016, LANCET GLOB HEALTH, V4, pE654, DOI 10.1016/S2214-109X(16)30133-4; Lutter CK, 2011, PEDIATRICS, V128, pE1418, DOI 10.1542/peds.2011-1392; Mann J, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6851; McDonald CM, 2013, AM J CLIN NUTR, V97, P896, DOI 10.3945/ajcn.112.047639; Meghji J, 2016, AM J RESP CRIT CARE, V194, P67, DOI 10.1164/rccm.201509-1807OC; National Institute for Health and Care Excellence, 2012, METH DEV NICE PUBL H; National Institute of Health and Care Excellence, 2017, FALT GROWTH REC MAN; National Statistical Office (NSO) [Malawi] and ICF, 2017, MALAWI DEMOGRAPHIC H; Olofin I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064636; Organization W.H, 1989, COMM BAS MAN SEV AC; Patel D, 2010, INDIAN PEDIATR, V47, P694, DOI 10.1007/s13312-010-0102-6; PECOUL B, 1992, ANN TROP PAEDIATR, V12, P47, DOI 10.1080/02724936.1992.11747546; Prentice AM, 2013, AM J CLIN NUTR, V97, P911, DOI 10.3945/ajcn.112.052332; Project Sphere, 2018, HUM CHART MIN STAND; Sadler K, 2008, J TROP PEDIATRICS, V54, P364, DOI 10.1093/tropej/fmn029; Seal A, 2007, BMJ-BRIT MED J, V334, P733, DOI 10.1136/bmj.39101.664109.AE; Singhal Atul, 2014, Nestle Nutr Inst Workshop Ser, V78, P123, DOI 10.1159/000354951; Somasse YE, 2016, MATERN CHILD NUTR, V12, P908, DOI 10.1111/mcn.12197; Tadesse E, 2018, MATERN CHILD NUTR, V14, DOI 10.1111/mcn.12519; United Nations Children's Fund World Health Organization World Bank Group, 2017, LEV TRENDS CHILD MAL; VANROOSMALENWIEBENGA MW, 1987, J TROP PEDIATRICS, V33, P24, DOI 10.1093/tropej/33.1.24; WHO, 2013, GUID UPD MAN SEV AC; WHO, 2006, GROWTH REF DAT 5 19; World Health Organization, 2013, CHILDH STUNT CONT CA	61	20	21	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2018	13	8							e0202053	10.1371/journal.pone.0202053	http://dx.doi.org/10.1371/journal.pone.0202053			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GS2NZ	30161151	Green Published, gold, Green Accepted			2023-01-03	WOS:000443388900019
J	Jin, S; Lee, MY				Jin, Solee; Lee, Mi-Young			The ameliorative effect of hemp seed hexane extracts on the Propionibacterium acnes-induced inflammation and lipogenesis in sebocytes	PLOS ONE			English	Article							NF-KAPPA-B; SIGNALING PATHWAYS; HUMAN KERATINOCYTES; PROTEIN EXPRESSION; MAMMALIAN TARGET; CELLS; AKT; MACROPHAGES; SUPPRESSION; ACTIVATION	In this study, we investigated the anti-microbial, anti-inflammatory, and anti-lipogenic effects of hemp (Cannabis sativa L.) seed hexane extracts, focusing on the Propionibacterium acnes-triggered inflammation and lipogenesis. Hemp seed hexane extracts (HSHE) showed anti-microbial activity against P. acnes. The expression of iNOS, COX-2, and the subsequent production of nitric oxide and prostaglandin increased after infection of P. acnes in HaCaT cells, however, upon treating with HSHE, their expressions were reduced. P. acnes induced expressions of IL-1 beta and IL-8 were also reduced. HSHE exerted anti-inflammatory effects by regulating NF-kappa B and MAPKs signaling and blunting the translocation of p-NF-kappa B to the nucleus in P. acnes-stimulated HaCaT cells. Moreover, P. acnes-induced phosphorylation of ERK and JNK, and their downstream targets c-Fos and c-Jun, was also inhibited by HSHE. In addition, the transactivation of AP-1 induced by P. acnes infection was also downregulated by HSHE. Notably, HSHE regulated inflammation and lipid biosynthesis via regulating AMPK and AKT/FoxO1 signaling in IGF-1-induced inflammation and lipogenesis of sebocytes. In addition, HSHE inhibited 5-lipoxygenase level and P. acnes-induced MMP-9 activity, and promoted collagen biosynthesis in vitro. Thus, HSHE could be utilized to treat acne vulgaris, through its anti-microbial, anti-inflammatory, anti-lipogenic, and collagen-promoting properties.	[Jin, Solee; Lee, Mi-Young] SoonChunHyang Univ, Coll Med Sci, Dept Med Sci, Asan, Chungnam, South Korea; [Lee, Mi-Young] SoonChunHyang Univ, Coll Med Sci, Dept Med Biotechnol, Asan, Chungnam, South Korea	Soonchunhyang University; Soonchunhyang University	Lee, MY (corresponding author), SoonChunHyang Univ, Coll Med Sci, Dept Med Sci, Asan, Chungnam, South Korea.; Lee, MY (corresponding author), SoonChunHyang Univ, Coll Med Sci, Dept Med Biotechnol, Asan, Chungnam, South Korea.	miyoung@sch.ac.kr			Soonchunhyang University	Soonchunhyang University	This work was supported by Soonchunhyang University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by Soonchunhyang University.	Al-Mariri A, 2013, IRAN J MED SCI, V38, P44; Amar MB, 2006, J ETHNOPHARMACOL, V105, P1, DOI 10.1016/j.jep.2006.02.001; Badowski M, 2017, CANCER CHEMOTH PHARM, V80, P441, DOI 10.1007/s00280-017-3387-5; Bai S, 2005, MATRIX BIOL, V24, P247, DOI 10.1016/j.matbio.2005.03.007; Byrum RS, 1999, J IMMUNOL, V163, P6810; Chang CS, 2010, INFLAMMATION, V33, P46, DOI 10.1007/s10753-009-9157-8; Croxford JL, 2008, J NEUROIMMUNOL, V193, P120, DOI 10.1016/j.jneuroim.2007.10.024; Deferne J.L, 1996, J INT HEMP ASS, V3, P4; Dhupal M, 2017, MOL CELL TOXICOL, V13, P115, DOI 10.1007/s13273-017-0012-y; Gao YL, 2012, TOXICOL IN VITRO, V26, P1, DOI 10.1016/j.tiv.2011.09.019; Ge YJ, 2012, J BIOL CHEM, V287, P43928, DOI 10.1074/jbc.R112.406942; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hirayama K, 2002, J COMP PATHOL, V127, P249, DOI 10.1053/jcpa.2002.0590; Jeon YM, 2015, LIFE SCI, V124, P56, DOI 10.1016/j.lfs.2014.12.029; Jeong JW, 2017, MOL CELL TOXICOL, V13, P405, DOI 10.1007/s13273-017-0045-2; Jeong M, 2014, J ETHNOPHARMACOL, V154, P745, DOI 10.1016/j.jep.2014.04.052; Jung JY, 2014, ACTA DERM-VENEREOL, V94, P521, DOI 10.2340/00015555-1802; Kim JH, 2016, MOL CELL TOXICOL, V12, P53, DOI 10.1007/s13273-016-0008-z; Kim M, 2015, ARCH BIOCHEM BIOPHYS, V583, P79, DOI 10.1016/j.abb.2015.07.007; Kim SY, 2015, INT J MOL MED, V35, P1042, DOI 10.3892/ijmm.2015.2098; Ko JW, 2017, MOL CELL TOXICOL, V13, P295, DOI 10.1007/s13273-017-0033-6; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; Lee H, 2016, MOL CELL TOXICOL, V12, P337, DOI 10.1007/s13273-016-0038-6; Lee H, 2016, MOL CELL TOXICOL, V12, P273, DOI 10.1007/s13273-016-0032-z; Lee NR, 2016, MOL CELL TOXICOL, V12, P371, DOI 10.1007/s13273-016-0041-y; Leizer C., 2000, Journal of Nutraceuticals, Functional & Medical Foods, V2, P35, DOI 10.1300/J133v02n04_04; Levy LL, 2012, AM J CLIN DERMATOL, V13, P331, DOI 10.2165/11631410-000000000-00000; Luo Q, 2017, MOL CELL BIOCHEM, V428, P129, DOI 10.1007/s11010-016-2923-7; McCusker MM, 2010, CLIN DERMATOL, V28, P440, DOI 10.1016/j.clindermatol.2010.03.020; Nissen L, 2010, FITOTERAPIA, V81, P413, DOI 10.1016/j.fitote.2009.11.010; Ottaviani M, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/858176; Ouchi N, 2004, J BIOL CHEM, V279, P1304, DOI 10.1074/jbc.M310389200; Park JY, 2014, EVID-BASED COMPL ALT, V2014, P11; Ryu AR, 2017, PHOTODIAGN PHOTODYN, V20, P71, DOI 10.1016/j.pdpdt.2017.08.002; Saklatvala J, 2004, CURR OPIN PHARMACOL, V4, P372, DOI 10.1016/j.coph.2004.03.009; Sato T, 2012, J DERMATOL, V39, P774, DOI 10.1111/j.1346-8138.2012.01525.x; Shan JH, 2009, INT IMMUNOPHARMACOL, V9, P1042, DOI 10.1016/j.intimp.2009.04.011; Shibata M, 2009, J INVEST DERMATOL, V129, P375, DOI 10.1038/jid.2008.237; Tsai HH, 2013, J DERMATOL SCI, V69, P122, DOI 10.1016/j.jdermsci.2012.10.009; Tzivion G, 2011, BBA-MOL CELL RES, V1813, P1938, DOI 10.1016/j.bbamcr.2011.06.002; Wang YY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170599; Won J, 2016, MOL CELL TOXICOL, V12, P37, DOI 10.1007/s13273-016-0006-1; Wu WJ, 2015, INT J MOL MED, V35, P1734, DOI 10.3892/ijmm.2015.2187; Yoon JY, 2013, J INVEST DERMATOL, V133, P429, DOI 10.1038/jid.2012.292; Zhang JH, 2016, DRUG DES DEV THER, V10, P1829, DOI 10.2147/DDDT.S104602; Zouboulis CC, 2010, EXP DERMATOL, V19, P148, DOI 10.1111/j.1600-0625.2009.00929.x; Zouboulis CC, 2009, DERM-ENDOCRINOL, V1, P188, DOI 10.4161/derm.1.3.8368; Zuardi AW, 2006, REV BRAS PSIQUIATR, V28, P153, DOI 10.1590/S1516-44462006000200015	48	19	21	2	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2018	13	8							e0202933	10.1371/journal.pone.0202933	http://dx.doi.org/10.1371/journal.pone.0202933			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR6UK	30148860	gold, Green Published, Green Submitted			2023-01-03	WOS:000442804200035
J	Lee, DH; Tsao, MS; Kambartel, KO; Isobe, H; Huang, MS; Barrios, CH; Khattak, A; de Marinis, F; Kothari, S; Arunachalam, A; Cao, XT; Burke, T; Valladares, A; de Castro, J				Lee, Dae Ho; Tsao, Ming-Sound; Kambartel, Karl-Otto; Isobe, Hiroshi; Huang, Ming-Shyan; Barrios, Carlos H.; Khattak, Adnan; de Marinis, Filippo; Kothari, Smita; Arunachalam, Ashwini; Cao, Xiting; Burke, Thomas; Valladares, Amparo; de Castro, Javier			Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PlvOTAL observational study	PLOS ONE			English	Article							GROWTH-FACTOR-RECEPTOR; 1ST-LINE TREATMENT; 2ND-LINE THERAPY; NSCLC PATIENTS; RESOURCE USE; MUTATIONS; EGFR; ASSOCIATION; MANAGEMENT; DIAGNOSIS	Background The goals of this multinational retrospective study were to describe treatment patterns and survival outcomes by receipt of molecular testing and molecular status of patients with advanced non-small cell lung cancer (NSCLC). Methods This chart review study, conducted in Italy, Spain, Germany, Australia, Japan, Korea, Taiwan, and Brazil, included 1440 patients with newly diagnosed advanced (stage IIIB/IV) NSCLC initiating systemic therapy from January 2011 through June 2013, with follow-up until July 2016. We evaluated treatment patterns and survival by histology, line of therapy, molecular testing, and test results for epidermal growth factor receptor (EGFR) mutation and/or anaplastic lymphoma kinase (ALK) rearrangement. Country-specific data were analyzed descriptively and presented as ranges (lowest to highest country). Overall survival (OS) was estimated using Kaplan-Meier method. Results Patients with >= 1 molecular test varied from 43% (Brazil) to 85% (Taiwan). Numerically greater proportions of patients who were female, Asian, or never/former-smokers, and those with nonsquamous histology or stage-IV NSCLC, received a test. Testing was common for nonsquamous NSCLC (54%, Brazil, to 91%, Taiwan), with positive EGFR and ALK tests from 17% (Brazil and Spain) to 67% (Taiwan) and from 0% (Brazil) to 60% (Taiwan), respectively. First-line treatment regimens for nonsquamous NSCLC with positive EGFR/ ALKtests included targeted therapy for 30% (Germany) to 89% (Japan); with negative/ inconclusive test results, platinum-based combinations for 88% (Japan) to 98% (Brazil); and if not tested, platinum-based combinations for 80% (Australia) to 95% (Japan), except in Taiwan, where 44% received single agents. Median OS from first-line therapy initiation was 10.0 (Japan) to 26.7 (Taiwan) months for those tested and 7.6 (Australia/Brazil) to 19.3 (Taiwan) months for those not tested. Conclusions We observed substantial variation among countries in testing percentages, treatment patterns, and survival outcomes. Efforts to optimize molecular testing rates should be implemented in the context of each country's health care scenario.	[Lee, Dae Ho] Asan Med Ctr, Seoul, South Korea; [Tsao, Ming-Sound] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Kambartel, Karl-Otto] Krankenhaus Bethanien, Moers, Germany; [Isobe, Hiroshi] KKR Sapporo Med Ctr, Sapporo, Hokkaido, Japan; [Huang, Ming-Shyan] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Coll Med, Kaohsiung, Taiwan; [Barrios, Carlos H.] Hosp Canc Mae Deus, Porto Alegre, RS, Brazil; [Khattak, Adnan] Fiona Stanley Hosp, Murdoch, WA, Australia; [de Marinis, Filippo] IRCCS, European Inst Oncol, Milan, Italy; [Kothari, Smita; Arunachalam, Ashwini; Cao, Xiting; Burke, Thomas] Merck & Co Inc, Ctr Observat & Real World Evidence CORE, Kenilworth, NJ USA; [Valladares, Amparo] Merck Sharp & Dohme Espana, Outcomes Res, Madrid, Spain; [de Castro, Javier] Hosp Univ La Paz IDIPAZ, Madrid, Spain; [Huang, Ming-Shyan] I Shou Univ, Sch Med, E DA Canc Hosp, Kaohsiung, Taiwan	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Kaohsiung Medical University; Kaohsiung Medical University Hospital; IRCCS European Institute of Oncology (IEO); Merck & Company; Hospital Universitario La Paz; E-Da Hospital; I Shou University	Arunachalam, A (corresponding author), Merck & Co Inc, Ctr Observat & Real World Evidence CORE, Kenilworth, NJ USA.	ashwini.arunachalam@merck.com	Tsao, Ming Sound/AFQ-7332-2022; de Marinis, Filippo/AAR-2826-2020; Barrios, Carlos/HJG-7197-2022; Tsao, Ming-Sound/M-3503-2017	Tsao, Ming Sound/0000-0002-9160-5405; Barrios, Carlos/0000-0001-6021-667X; De Castro, Javier/0000-0002-3622-6306	Merck & Co., Inc., Kenilworth, NJ, USA; Merck Sharp Dohme Corp.	Merck & Co., Inc., Kenilworth, NJ, USA; Merck Sharp Dohme Corp.(Merck & Company)	This work was supported by Merck & Co., Inc., Kenilworth, NJ, USA. The funder of the study participated in the study design and data analysis. Medical writing and editorial assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA. All authors, including those employed by the funder of the study, participated in the data interpretation, decision to publish, and preparation of the manuscript.	American Cancer Society, NON SMALL CELL LUNG; [Anonymous], 2017, NCCN GUID NON SMALL; Carrato A, 2014, CURR MED RES OPIN, V30, P447, DOI 10.1185/03007995.2013.860372; Cheema PK, 2017, CURR ONCOL, V24, P16, DOI 10.3747/co.24.3266; Cheng TYD, 2016, J THORAC ONCOL, V11, P1653, DOI 10.1016/j.jtho.2016.05.021; de Castro J, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12734; De Geer Anna, 2013, J Med Econ, V16, P134, DOI 10.3111/13696998.2012.703631; Gainor JF, 2013, CLIN CANCER RES, V19, P4273, DOI 10.1158/1078-0432.CCR-13-0318; Greenhalgh J, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010383.pub2; Gridelli C, 2014, J CANCER RES CLIN, V140, P1783, DOI 10.1007/s00432-014-1715-2; Hiley CT, 2016, LANCET, V388, P1002, DOI 10.1016/S0140-6736(16)31340-X; International Agency for Research on Cancer, CANC TOD; Isobe H, 2017, LUNG CANCER-TARGETS, V8, P191, DOI 10.2147/LCTT.S140491; Jain A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123587; Japan Lung Cancer Society, TREATM GUID LUNG CAN; Kerr KM, 2012, HISTOPATHOLOGY, V60, P531, DOI 10.1111/j.1365-2559.2011.03854.x; Kim Hyojin, 2014, Korean J Pathol, V48, P1, DOI 10.4132/KoreanJPathol.2014.48.1.1; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Lee DH, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2946-8; Leighl NB, 2014, J CLIN ONCOL, V32, P3673, DOI 10.1200/JCO.2014.57.3055; Lim C, 2015, ANN ONCOL, V26, P1415, DOI 10.1093/annonc/mdv208; Moro-Sibilot D, 2015, LUNG CANCER, V88, P215, DOI 10.1016/j.lungcan.2015.02.011; Moro-Sibilot D, 2010, CURR MED RES OPIN, V26, P2661, DOI 10.1185/03007995.2010.525489; Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326; Reck M, 2011, LUNG CANCER, V74, P1, DOI 10.1016/j.lungcan.2011.05.002; Sacher AG, 2016, JAMA ONCOL, V2, P313, DOI 10.1001/jamaoncol.2015.4482; Salto-Tellez M, 2011, J THORAC ONCOL, V6, P1663, DOI 10.1097/JTO.0b013e318227816a; Schnabel PA, 2012, LUNG CANCER, V78, P263, DOI 10.1016/j.lungcan.2012.09.001; Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993; Sherman RE, 2016, NEW ENGL J MED, V375, P2293, DOI 10.1056/NEJMsb1609216; Solomon B, 2017, LANCET, V389, P884, DOI 10.1016/S0140-6736(17)30124-1; Tanner NT, 2012, LUNG CANCER, V76, P131, DOI 10.1016/j.lungcan.2011.11.013; The World Health Organization, 2018, FACT SHEETS CANC; Thunnissen E, 2012, LUNG CANCER, V76, P1, DOI 10.1016/j.lungcan.2011.10.017; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Vergnenegre A, 2012, CURR MED RES OPIN, V28, P1253, DOI 10.1185/03007995.2012.703133; von Verschuer U, 2017, LUNG CANCER, V112, P216, DOI 10.1016/j.lungcan.2017.07.031; Walters S, 2013, THORAX, V68, P551, DOI 10.1136/thoraxjnl-2012-202297; Yatabe Y, 2015, J THORAC ONCOL, V10, P438, DOI 10.1097/JTO.0000000000000422	39	31	31	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2018	13	8							e0202865	10.1371/journal.pone.0202865	http://dx.doi.org/10.1371/journal.pone.0202865			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR6UK	30148862	Green Submitted, Green Published, gold			2023-01-03	WOS:000442804200029
J	Torjesen, I				Torjesen, Ingrid			Children's intensive care units are failing to monitor breathing adequately	BMJ-BRITISH MEDICAL JOURNAL			English	News Item							NATIONAL AUDIT PROJECT; AIRWAY MANAGEMENT; MAJOR COMPLICATIONS; ROYAL-COLLEGE; ANESTHETISTS; ANESTHESIA											Cook TM, 2016, BRIT J ANAESTH, V117, P182, DOI 10.1093/bja/aew177; Cook TM, 2011, BRIT J ANAESTH, V106, P632, DOI 10.1093/bja/aer059; Cook TM, 2011, BRIT J ANAESTH, V106, P617, DOI 10.1093/bja/aer058; Foy KE, 2018, ANAESTHESIA, V73, P1337, DOI 10.1111/anae.14359	4	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 16	2018	362								k3549	10.1136/bmj.k3549	http://dx.doi.org/10.1136/bmj.k3549			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GR3HS	30115625				2023-01-03	WOS:000442481200003
J	Halliday, BP; Wassall, R; Lota, AS; Khalique, Z; Gregson, J; Newsome, S; Jackson, R; Rahneva, T; Wage, R; Smith, G; Venneri, L; Tayal, U; Auger, D; Midwinter, W; Whiffin, N; Rajani, R; Dungu, JN; Pantazis, A; Cook, SA; Ware, JS; Baksi, AJ; Pennell, DJ; Rosen, SD; Cowie, MR; Cleland, JGF; Prasad, SK				Halliday, Brian P.; Wassall, Rebecca; Lota, Amrit S.; Khalique, Zohya; Gregson, John; Newsome, Simon; Jackson, Robert; Rahneva, Tsveta; Wage, Rick; Smith, Gillian; Venneri, Lucia; Tayal, Upasana; Auger, Dominique; Midwinter, William; Whiffin, Nicola; Rajani, Ronak; Dungu, Jason N.; Pantazis, Antonis; Cook, Stuart A.; Ware, James S.; Baksi, A. John; Pennell, Dudley J.; Rosen, Stuart D.; Cowie, Martin R.; Cleland, John G. F.; Prasad, Sanjay K.			Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial	LANCET			English	Article							EJECTION FRACTION; BETA-BLOCKADE; DOUBLE-BLIND; OUTCOMES; ASSOCIATION; PERIPARTUM; GUIDELINES; TERM	Background Patients with dilated cardiomyopathy whose symptoms and cardiac function have recovered often ask whether their medications can be stopped. The safety of withdrawing treatment in this situation is unknown. Methods We did an open-label, pilot, randomised trial to examine the effect of phased withdrawal of heart failure medications in patients with previous dilated cardiomyopathy who were now asymptomatic, whose left ventricular ejection fraction (LVEF) had improved from less than 40% to 50% or greater, whose left ventricular end-diastolic volume (LVEDV) had normalised, and who had an N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) concentration less than 250 ng/L. Patients were recruited from a network of hospitals in the UK, assessed at one centre (Royal Brompton and Harefield NHS Foundation Trust, London, UK), and randomly assigned (1: 1) to phased withdrawal or continuation of treatment. After 6 months, patients in the continued treatment group had treatment withdrawn by the same method. The primary endpoint was a relapse of dilated cardiomyopathy within 6 months, defined by a reduction in LVEF of more than 10% and to less than 50%, an increase in LVEDV by more than 10% and to higher than the normal range, a two-fold rise in NT-pro-BNP concentration and to more than 400 ng/L, or clinical evidence of heart failure, at which point treatments were re-established. The primary analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT02859311. Findings Between April 21, 2016, and Aug 22, 2017, 51 patients were enrolled. 25 were randomly assigned to the treatment withdrawal group and 26 to continue treatment. Over the first 6 months, 11 (44%) patients randomly assigned to treatment withdrawal met the primary endpoint of relapse compared with none of those assigned to continue treatment (Kaplan-Meier estimate of event rate 45.7% [95% CI 28.5-67.2]; p=0.0001). After 6 months, 25 (96%) of 26 patients assigned initially to continue treatment attempted its withdrawal. During the following 6 months, nine patients met the primary endpoint of relapse (Kaplan-Meier estimate of event rate 36.0% [95% CI 20.6-57.8]). No deaths were reported in either group and three serious adverse events were reported in the treatment withdrawal group: hospital admissions for non-cardiac chest pain, sepsis, and an elective procedure. Interpretation Many patients deemed to have recovered from dilated cardiomyopathy will relapse following treatment withdrawal. Until robust predictors of relapse are defined, treatment should continue indefinitely. Funding British Heart Foundation, Alexander Jansons Foundation, Royal Brompton Hospital and Imperial College London, Imperial College Biomedical Research Centre, Wellcome Trust, and Rosetrees Trust. Copyright (c) 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.	[Halliday, Brian P.; Wassall, Rebecca; Lota, Amrit S.; Khalique, Zohya; Jackson, Robert; Rahneva, Tsveta; Wage, Rick; Smith, Gillian; Venneri, Lucia; Tayal, Upasana; Auger, Dominique; Midwinter, William; Whiffin, Nicola; Pantazis, Antonis; Cook, Stuart A.; Ware, James S.; Baksi, A. John; Pennell, Dudley J.; Rosen, Stuart D.; Cowie, Martin R.; Cleland, John G. F.; Prasad, Sanjay K.] Royal Brompton Hosp, Cardiovasc Res Ctr, London, England; [Halliday, Brian P.; Wassall, Rebecca; Lota, Amrit S.; Khalique, Zohya; Jackson, Robert; Rahneva, Tsveta; Wage, Rick; Smith, Gillian; Venneri, Lucia; Tayal, Upasana; Auger, Dominique; Midwinter, William; Whiffin, Nicola; Pantazis, Antonis; Cook, Stuart A.; Ware, James S.; Baksi, A. John; Pennell, Dudley J.; Rosen, Stuart D.; Cowie, Martin R.; Cleland, John G. F.; Prasad, Sanjay K.] Royal Brompton Hosp, Cardiovasc Magnet Resonance Unit, London SW3 6NP, England; [Halliday, Brian P.; Lota, Amrit S.; Khalique, Zohya; Tayal, Upasana; Midwinter, William; Whiffin, Nicola; Cook, Stuart A.; Ware, James S.; Baksi, A. John; Pennell, Dudley J.; Rosen, Stuart D.; Cowie, Martin R.; Cleland, John G. F.; Prasad, Sanjay K.] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Whiffin, Nicola; Cook, Stuart A.; Ware, James S.] Imperial Coll London, MRC London Inst Med Sci, London, England; [Gregson, John; Newsome, Simon] London Sch Hyg & Trop Med, London, England; [Rajani, Ronak] Guys & St Thomas NHS Fdn Trust, London, England; [Rajani, Ronak] Kings Coll London, London, England; [Dungu, Jason N.] Basildon & Thurrock Hosp NHS Fdn Trust, Basildon, Essex, England; [Cook, Stuart A.] Natl Heart Ctr Singapore, Singapore, Singapore; [Rosen, Stuart D.] Ealing Gen Hosp, Dept Cardiol, London, England; [Cleland, John G. F.] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland	Royal Brompton Hospital; Royal Brompton Hospital; Imperial College London; Imperial College London; University of London; London School of Hygiene & Tropical Medicine; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; National Heart Centre Singapore; Imperial College London; University of Glasgow	Prasad, SK (corresponding author), Royal Brompton Hosp, Cardiovasc Magnet Resonance Unit, London SW3 6NP, England.	s.prasad@rbht.nhs.uk	Halliday, Brian/R-5634-2019; Cleland, John G./AAZ-4185-2020; Cowie, Martin R/AAQ-2818-2020; Ware, James S/G-5139-2012; W, Nicola/AAG-3227-2020; Rosen, Stuart/AAE-4649-2020; Auger, Dominique/AAG-3819-2020	Cleland, John G./0000-0002-1471-7016; Cowie, Martin R/0000-0001-7457-2552; Ware, James S/0000-0002-6110-5880; W, Nicola/0000-0003-1554-6594; Halliday, Brian/0000-0002-5876-1748; Pennell, Dudley/0000-0001-5523-1314; Dungu, Jason/0000-0002-6086-6813	Royal Brompton and Harefield NHS Trust; Alexander Jansons Foundation; Cardiovascular Research Centre; NIHR Biomedical Research Unit at Royal Brompton Hospital; NIHR Imperial College Biomedical Research Centre; Wellcome Trust [107469/Z/15/Z]; Rosetrees Trust; British Heart Foundation [FS/15/29/31492]; Medical Research Council [MC_UP_1102/20] Funding Source: researchfish; Rosetrees Trust [M189, M232-CD1] Funding Source: researchfish; MRC [MR/M003191/1, MC_UP_1102/20] Funding Source: UKRI	Royal Brompton and Harefield NHS Trust; Alexander Jansons Foundation; Cardiovascular Research Centre; NIHR Biomedical Research Unit at Royal Brompton Hospital; NIHR Imperial College Biomedical Research Centre; Wellcome Trust(Wellcome TrustEuropean Commission); Rosetrees Trust(Rosetrees Trust); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Rosetrees Trust(Rosetrees Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	TRED-HF was an investigator-led trial sponsored by the Royal Brompton and Harefield NHS Trust. The study was funded by a Clinical Research Training Fellowship from the British Heart Foundation (FS/15/29/31492) awarded to BPH and SKP, and received additional support from the Alexander Jansons Foundation, the Cardiovascular Research Centre and NIHR Biomedical Research Unit at Royal Brompton Hospital, the NIHR Imperial College Biomedical Research Centre, and grants from the Wellcome Trust (107469/Z/15/Z) awarded to JSW and from Rosetrees Trust awarded to SKP. We thank Theresa McDonagh for acting as trial data monitor. We wish to thank Cardiomyopathy UK and the Pumping Marvellous Foundation who provided important support throughout the study. We thank all our colleagues and the Guy's and St Thomas' NHS Foundation Trust, King's College Hospital NHS Foundation Trust, St George's NHS Foundation Trust, London Northwest NHS Healthcare Trust, Epsom and St Helier University Hospitals, and Basildon and Thurrock University Hospitals for their help in identifying potential participants. We thank Jonathan Myers and Carl J Lavie for their input with designing the CPET protocols and Roddy Walsh for helpful discussions about genetic sequencing. Finally, we thank all the participants who dedicated large amounts of time to the study, in the hope of improving care for patients.	Amos AM, 2006, AM HEART J, V152, P509, DOI 10.1016/j.ahj.2006.02.008; Basuray A, 2014, CIRCULATION, V129, P2380, DOI 10.1161/CIRCULATIONAHA.113.006855; Bellenger NG, 2002, J CARDIOVASC MAGN R, V2, P271; Bohm M, 2010, LANCET, V376, P886, DOI 10.1016/S0140-6736(10)61259-7; Cleland JGF, 2018, EUR HEART J, V39, P26, DOI 10.1093/eurheartj/ehx564; Felker GM, 2000, NEW ENGL J MED, V342, P1077, DOI 10.1056/NEJM200004133421502; Felkin LE, 2016, JAMA CARDIOL, V1, P234, DOI 10.1001/jamacardio.2016.0208; Florea VG, 2016, CIRC-HEART FAIL, V9, DOI 10.1161/CIRCHEARTFAILURE.116.003123; Maceira AM, 2006, J CARDIOVASC MAGN R, V8, P417, DOI 10.1080/10976640600572889; Mann DL, 2012, J AM COLL CARDIOL, V60, P2465, DOI 10.1016/j.jacc.2012.06.062; Merlo M, 2015, J AM HEART ASSOC, V4, DOI [10.1161/JAHA.114.001504, 10.1161/JAHA.114.000570]; Merlo M, 2011, J AM COLL CARDIOL, V57, P1468, DOI 10.1016/j.jacc.2010.11.030; Moon J, 2009, CAN J CARDIOL, V25, pE147, DOI 10.1016/S0828-282X(09)70497-0; Morimoto S, 1999, AM HEART J, V138, P456, DOI 10.1016/S0002-8703(99)70147-X; MYERS J, 1994, AM J CARDIOL, V73, P591, DOI 10.1016/0002-9149(94)90340-9; PFLUGFELDER PW, 1993, J AM COLL CARDIOL, V22, P1557, DOI 10.1016/0735-1097(93)90578-O; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Punnoose LR, 2011, J CARD FAIL, V17, P527, DOI 10.1016/j.cardfail.2011.03.005; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841; Roberts AM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010134; SWEDBERG K, 1980, BRIT HEART J, V44, P134; Tayal U, 2017, J AM COLL CARDIOL, V70, P2264, DOI 10.1016/j.jacc.2017.08.063; WAAGSTEIN F, 1989, CIRCULATION, V80, P551, DOI 10.1161/01.CIR.80.3.551; Walsh R, 2017, GENET MED, V19, P192, DOI 10.1038/gim.2016.90; Ware JS, 2018, J AM COLL CARDIOL, V71, P2293, DOI 10.1016/j.jacc.2018.03.462; Ware JS, 2016, NEW ENGL J MED, V374, P233, DOI 10.1056/NEJMoa1505517; Whiffin N, 2017, GENET MED, V19, P1151, DOI 10.1038/gim.2017.26	28	234	238	3	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 5	2019	393	10166					61	73		10.1016/S0140-6736(18)32484-X	http://dx.doi.org/10.1016/S0140-6736(18)32484-X			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HG4DR	30429050	Green Published, Green Submitted, Green Accepted, hybrid			2023-01-03	WOS:000454925000033
J	Vazquez, FL; Otero, P; Garcia-Casal, JA; Blanco, V; Torres, AJ; Arrojo, M				Vazquez, Fernando L.; Otero, Patricia; Antonio Garcia-Casal, J.; Blanco, Vanessa; Torres, Angela J.; Arrojo, Manuel			Efficacy of video game-based interventions for active aging. A systematic literature review and meta-analysis	PLOS ONE			English	Review							RANDOMIZED CONTROLLED-TRIAL; DWELLING OLDER-ADULTS; QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; EXERCISE REGIMEN; ENHANCES ASPECTS; COMPUTER GAMES; WII BIT; BALANCE; HEALTH	Background Due to the appeal and recent technological advances of video games, the games have gained interest as an intervention tool for active aging. The aim of this systematic literature review and meta-analysis was to determine the efficacy of video games for active aging and to examine the influence of potential moderator variables. Methods A systematic search was done using the following databases: Medline, PsycINFO, EMBASE, CINAHL and the Cochrane Central Register of Controlled Trials. In addition, previous reviews and meta-analyses were used to identify randomized controlled trials (RCT) of video game-based interventions for active aging published through February 28, 2018. An evaluation of the methodological quality of the articles and a meta-analysis and moderator analysis was conducted. Results A total of 22 articles depicting 21 RCT with 1125 participants were included. The results indicated that video game-based interventions produced positive effects on objectively measured physical health, negative affect and social health, with small effect sizes (d = 0.41, d = 0.26 and d = 0.40, respectively). The magnitude of this effect was moderated by the presence of subclinical conditions of participants, the type of game (exergames), the presence of physical activity, the type of prevention (indicated), non-blinded assignation, and older age of participants. The methodological quality of the studies was acceptable, the weakest area being external validity. Conclusion These finding indicate that video game-based interventions may assist adults in leading active aging processes and preventing secondary aging. Although more research is needed, video game-based interventions are a promising and accessible tool for active aging promotion.	[Vazquez, Fernando L.; Antonio Garcia-Casal, J.] Univ Santiago de Compostela, Dept Clin Psychol & Psychobiol, Santiago De Compostela, Spain; [Otero, Patricia] Univ A Coruna, Dept Psychol, La Coruna, Spain; [Blanco, Vanessa] Univ Santiago de Compostela, Dept Dev & Educ Psychol, Santiago De Compostela, Spain; [Torres, Angela J.] Univ Santiago de Compostela, Dept Psychiat Radiol Publ Hlth Nursing & Med, Santiago De Compostela, Spain; [Arrojo, Manuel] Complejo Hosp Univ Santiago Compostela, SERGAS, Inst Invest Sanitaria IDIS, Dept Psychiat, Santiago De Compostela, Spain	Universidade de Santiago de Compostela; Universidade da Coruna; Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela	Vazquez, FL (corresponding author), Univ Santiago de Compostela, Dept Clin Psychol & Psychobiol, Santiago De Compostela, Spain.	fernandolino.vazquez@usc.es	Arrojo, Manuel/AAA-2163-2019; Torres, Angela/D-3003-2019; Vazquez, Fernando L./W-4173-2018; Garcia-Casal, J. Antonio/B-1976-2012	Torres, Angela/0000-0002-0430-1076; Blanco Seoane, Vanessa/0000-0002-6277-0671; Arrojo-Romero, manuel/0000-0002-5609-7134; Vazquez, Fernando L./0000-0002-5868-4025; Garcia-Casal, J. Antonio/0000-0003-0533-4918	Center for Industrial Technological Development; European Regional Development Fund [EXP - 00091195/ITC-20161137]	Center for Industrial Technological Development; European Regional Development Fund(European Commission)	This study was funded by Center for Industrial Technological Development and the European Regional Development Fund (Grant: EXP - 00091195/ITC-20161137 to FLV). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2002, Aging Male, V5, P1; [Anonymous], METAANALISIS CIENCIA; ANSTEY K, 1993, PSYCHOL AGING, V8, P562, DOI 10.1037/0882-7974.8.4.562; Ballesteros S, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00354; Ballesteros S, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00082; Ballesteros S, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00045; Ballesteros S, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00277; Baranowski T, 2008, AM J PREV MED, V34, P74, DOI 10.1016/j.amepre.2007.09.027; Barnett JH, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-101; Basak C, 2008, PSYCHOL AGING, V23, P765, DOI 10.1037/a0013494; Belchior P, 2016, GAMES HEALTH J, V5, P151, DOI 10.1089/g4h.2015.0049; Bleakley CM, 2015, J APPL GERONTOL, V34, pNP166, DOI 10.1177/0733464812470747; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Bozoki A, 2013, ARCH GERONTOL GERIAT, V57, P1, DOI 10.1016/j.archger.2013.02.009; Buitenweg JIV, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00529; Cayley P, 2008, HEART LUNG CIRC, V17, pS70, DOI 10.1016/j.hlc.2008.08.015; Chao YY, 2015, J AGING HEALTH, V27, P379, DOI 10.1177/0898264314551171; Cohen J., 2013, STAT POWER ANAL BEHA; Cuijpers P, 2003, AM J PSYCHIAT, V160, P1385, DOI 10.1176/appi.ajp.160.8.1385; de Bruin ED, 2010, BEHAV BRAIN FUNCT, V6, DOI 10.1186/1744-9081-6-59; DeSmet A, 2014, PREV MED, V69, P95, DOI 10.1016/j.ypmed.2014.08.026; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Duncan S, 2007, COGNITION EMOTION, V21, P1184, DOI 10.1080/02699930701437931; DUSTMAN RE, 1984, NEUROBIOL AGING, V5, P35, DOI 10.1016/0197-4580(84)90083-6; DUSTMAN RE, 1992, J GERONTOL, V47, pP168, DOI 10.1093/geronj/47.3.P168; Eggenberger P, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00066; Eggenberger P, 2015, CLIN INTERV AGING, V10, P1711, DOI 10.2147/CIA.S91997; Eggenberger P, 2015, CLIN INTERV AGING, V10, P1335, DOI 10.2147/CIA.S87732; European-Social-Network, 2008, SERV OLD PEOPL EUR F; Eurostat. European- Comission, 2016, EUR PUBL DAT; Fjell AM, 2010, NEUROIMAGE, V50, P1376, DOI 10.1016/j.neuroimage.2010.01.061; Fleming T., 2014, REV PSICOPATOLOG AY, V19, P227, DOI [10.5944/rppc.vol.19.num.3.2014.13904, DOI 10.5944/RPPC.V0L.19.NUM.3.2014.13904, DOI 10.5944/RPPC.VOL.19.NUM.3.2014.13904]; Franco JR, 2012, TECHNOL HEALTH CARE, V20, P95, DOI 10.3233/THC-2011-0661; Fu AS, 2015, ARCH PHYS MED REHAB, V96, P2096, DOI 10.1016/j.apmr.2015.08.427; Garris R., 2002, Simulation & Gaming, V33, P441, DOI 10.1177/1046878102238607; Goldstein J, 1997, SOC BEHAV PERSONAL, V25, P345, DOI 10.2224/sbp.1997.25.4.345; Green CS, 2008, PSYCHOL AGING, V23, P692, DOI 10.1037/a0014345; Gronholm-Nyman P, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00069; Hall AK, 2012, GAMES HEALTH J, V1, P402, DOI 10.1089/g4h.2012.0046; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Hill NTM, 2017, AM J PSYCHIAT, V174, P329, DOI 10.1176/appi.ajp.2016.16030360; Holt-Lunstad J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000316; Hsu Jason K., 2011, Physiotherapy Theory and Practice, V27, P185, DOI 10.3109/09593985.2010.483267; Huber Machteld, 2011, BMJ, V343, pd4163, DOI 10.1136/bmj.d4163; Jorgensen MG, 2013, J GERONTOL A-BIOL, V68, P845, DOI 10.1093/gerona/gls222; Kahlbaugh PE, 2011, ACT ADAPT AGING, V35, P331, DOI 10.1080/01924788.2011.625218; Karahan AY, 2015, CENT EUR J PUBL HEAL, V23, pS14; Kim KW, 2015, J AM GERIATR SOC, V63, P603, DOI 10.1111/jgs.13304; Li JH, 2016, GAMES HEALTH J, V5, P175, DOI 10.1089/g4h.2015.0100; Lipsey M. W., 2001, PRACTICAL META ANAL; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Maillot P, 2012, PSYCHOL AGING, V27, P589, DOI 10.1037/a0026268; Marston HR, 2016, GAMES CULT, V11, P201, DOI 10.1177/1555412015605219; Mayas J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092269; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Morone G, 2016, AGING CLIN EXP RES, V28, P1187, DOI 10.1007/s40520-016-0578-6; Mrazek P., 1994, REDUCING RISKS MENTA; Murray E, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004274.pub4; Nikolic M, 2010, COLLEGIUM ANTROPOL, V34, P105; Nouchi R, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00302; Nouchi R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029676; Ownby RL, 2006, ARCH GEN PSYCHIAT, V63, P530, DOI 10.1001/archpsyc.63.5.530; Peretz C, 2011, NEUROEPIDEMIOLOGY, V36, P91, DOI 10.1159/000323950; Pichierri G, 2012, BMC GERIATR, V12, DOI 10.1186/1471-2318-12-74; Read JL, 2011, JAMA-J AM MED ASSOC, V305, P1704, DOI 10.1001/jama.2011.408; Rendon AA, 2012, AGE AGEING, V41, P549, DOI 10.1093/ageing/afs053; Bacha JMR, 2018, GAMES HEALTH J, V7, P24, DOI 10.1089/g4h.2017.0065; Sadeghi H, 2017, ARCH GERONTOL GERIAT, V69, P144, DOI 10.1016/j.archger.2016.11.009; Sato K, 2015, GAMES HEALTH J, V4, P161, DOI 10.1089/g4h.2014.0057; Schaie KW, 2010, HDB PSYCHOL AGING; Schattin A, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnag.2016.00278; Schoene D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145161; Shams TA, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0609-6; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; Sidorenko Alexandre, 2013, Curr Gerontol Geriatr Res, V2013, P261819, DOI 10.1155/2013/261819; Souders DJ, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00041; Stanmore E, 2017, NEUROSCI BIOBEHAV R, V78, P34, DOI 10.1016/j.neubiorev.2017.04.011; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Street TD, 2017, GAMES HEALTH J, V6, P136, DOI 10.1089/g4h.2016.0102; Szturm T, 2011, PHYS THER, V91, P1449, DOI 10.2522/ptj.20090205; Toril P, 2014, PSYCHOL AGING, V29, P706, DOI 10.1037/a0037507; Torres ACS, 2011, INT J DISABIL HUMAN, V10, P55, DOI [10.1515/ijdhd.2011.003, DOI 10.1515/IJDHD.2011.003]; Toulotte C, 2012, CLIN REHABIL, V26, P827, DOI 10.1177/0269215511434996; van den Berg M, 2016, J PHYSIOTHER, V62, P20, DOI 10.1016/j.jphys.2015.11.005; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; West GL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187779; Whitton JP, 2017, CURR BIOL, V27, P3237, DOI 10.1016/j.cub.2017.09.014; Whyatt C, 2015, GAMES HEALTH J, V4, P423, DOI 10.1089/g4h.2015.0006; Wolinsky FD, 2016, INT PSYCHOGERIATR, V28, P317, DOI 10.1017/S1041610215001428; Woods R, 2015, HDB CLIN PSYCHOL AGE	91	24	25	2	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2018	13	12							e0208192	10.1371/journal.pone.0208192	http://dx.doi.org/10.1371/journal.pone.0208192			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HD8CS	30533015	Green Submitted, Green Published, gold			2023-01-03	WOS:000452782500014
J	[Anonymous]				[Anonymous]			The Production of Drug Plants in the United States (Reprinted from The Medical Letter on Drugs and Therapeutics vol 71, pg 1916-1917, 1918)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint																		Stockberger W. W., 1917, PRODUCTION DRUG PLAN, P169	1	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 27	2018	320	20					2156	2156		10.1001/jama.2017.12677	http://dx.doi.org/10.1001/jama.2017.12677			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HB9ET	30480715				2023-01-03	WOS:000451395000035
J	Hilton, MC; Zhang, X; Boyle, BT; Alegre-Requena, JV; Paton, RS; McNally, A				Hilton, Michael C.; Zhang, Xuan; Boyle, Benjamin T.; Alegre-Requena, Juan V.; Paton, Robert S.; McNally, Andrew			Heterobiaryl synthesis by contractive C-C coupling via P(V) intermediates	SCIENCE			English	Article							CORRELATED MOLECULAR CALCULATIONS; LATE-STAGE FUNCTIONALIZATION; MEDICINAL CHEMISTS TOOLBOX; GAUSSIAN-BASIS SETS; ORBITAL METHODS; PYRIDINES; PHOSPHINES; CATALYST; SOLVENT; MODEL	Heterobiaryls composed of pyridine and diazine rings are key components of pharmaceuticals and are often central to pharmacological function. We present an alternative approach to metal-catalyzed cross-coupling to make heterobiaryls using contractive phosphorus C-C couplings, also termed phosphorus ligand coupling reactions. The process starts by regioselective phosphorus substitution of the C-H bonds para to nitrogen in two successive heterocycles; ligand coupling is then triggered via acidic alcohol solutions to form the heterobiaryl bond. Mechanistic studies imply that ligand coupling is an asynchronous process involving migration of one heterocycle to the ipso position of the other around a central pentacoordinate P(V) atom. The strategy can be applied to complex drug-like molecules containing multiple reactive sites and polar functional groups, and also enables convergent coupling of drug fragments and late-stage heteroarylation of pharmaceuticals.	[Hilton, Michael C.; Zhang, Xuan; Boyle, Benjamin T.; Alegre-Requena, Juan V.; Paton, Robert S.; McNally, Andrew] Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA; [Paton, Robert S.] Univ Oxford, Chem Res Lab, Oxford OX1 3TA, England	Colorado State University; University of Oxford	Paton, RS; McNally, A (corresponding author), Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA.; Paton, RS (corresponding author), Univ Oxford, Chem Res Lab, Oxford OX1 3TA, England.	robert.paton@chem.ox.ac.uk; andy.mcnally@colostate.edu	Alegre-Requena, Juan V./GRR-1595-2022; Alegre-Requena, Juan V./AAF-5329-2020; Paton, Robert/A-4564-2010; Alegre-Requena, Juan V./AFQ-0674-2022	Alegre-Requena, Juan V./0000-0002-0769-7168; Paton, Robert/0000-0002-0104-4166; Boyle, Benjamin/0000-0002-9360-2179; McNally, Andrew/0000-0002-8651-1631	Colorado State University; NIH [R01 GM124094-01]; NSF [ACI-1548562, ACI-1532235, ACI-1532236]; University of Colorado Boulder; Extreme Science and Engineering Discovery Environment (XSEDE) [TG-CHE180006, TG-CHE180056]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM124094] Funding Source: NIH RePORTER	Colorado State University; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); University of Colorado Boulder; Extreme Science and Engineering Discovery Environment (XSEDE); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by startup funds from Colorado State University and by NIH award R01 GM124094-01 (A.M., M.C.H., X.Z., and B.T.B.). We acknowledge the RMACC Summit supercomputer, supported by NSF grants ACI-1532235 and ACI-1532236, the University of Colorado Boulder, Colorado State University, and the Extreme Science and Engineering Discovery Environment (XSEDE) through allocations TG-CHE180006 and TG-CHE180056. XSEDE is supported by NSF grant ACI-1548562.	Abreo MA, 1996, J MED CHEM, V39, P817, DOI 10.1021/jm9506884; Afzal O, 2015, EUR J MED CHEM, V97, P871, DOI 10.1016/j.ejmech.2014.07.044; Alonso F, 2012, GREEN CHEM, V14, P2699, DOI 10.1039/c2gc35898k; ANDERS E, 1987, TETRAHEDRON LETT, V28, P2675, DOI 10.1016/S0040-4039(00)96178-1; Anderson RG, 2018, ANGEW CHEM INT EDIT, V57, P12514, DOI 10.1002/anie.201807322; [Anonymous], PYMOL MOL GRAPH SYST; [Anonymous], 2016, GAUSS 16 REV A 03; Becke AD, 1998, J CHEM PHYS, V109, P2092, DOI 10.1063/1.476722; Bergbreiter DE, 2011, J ORG CHEM, V76, P6912, DOI 10.1021/jo201097x; Bhunia A, 2014, ORG LETT, V16, P5132, DOI 10.1021/ol502490t; Billingsley KL, 2006, ANGEW CHEM INT EDIT, V45, P3484, DOI 10.1002/anie.200600493; Blakemore DC, 2018, NAT CHEM, V10, P383, DOI 10.1038/s41557-018-0021-z; Brow DG, 2016, J MED CHEM, V59, P4443, DOI 10.1021/acs.jmedchem.5b01409; Campeau LC, 2007, CHEM SOC REV, V36, P1058, DOI 10.1039/b616082d; Cances E, 1997, J CHEM PHYS, V107, P3032, DOI 10.1063/1.474659; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Cernak T, 2016, CHEM SOC REV, V45, P546, DOI 10.1039/c5cs00628g; Chai JD, 2008, PHYS CHEM CHEM PHYS, V10, P6615, DOI 10.1039/b810189b; CLARK T, 1983, J COMPUT CHEM, V4, P294, DOI 10.1002/jcc.540040303; Corey EJ, 2005, ORG LETT, V7, P5535, DOI 10.1021/ol052476z; COSMOtherm, COSMOTHERM VERS 18 0; Cox PA, 2017, J AM CHEM SOC, V139, P13156, DOI 10.1021/jacs.7b07444; Crawley M. L., 2012, APPL TRANSITION META, P25; Crawley M. L., 2012, APPL TRANSITION META, P25, DOI DOI 10.1002/9781118309872.CH2; Davidson ER, 1996, CHEM PHYS LETT, V260, P514, DOI 10.1016/0009-2614(96)00917-7; de Meijere A., 2004, METAL CATALYZED CROS, VSecond, DOI 10.1002/9783527619535; Do HQ, 2011, J AM CHEM SOC, V133, P13577, DOI 10.1021/ja2047717; Dolewski RD, 2018, J AM CHEM SOC, V140, P8020, DOI 10.1021/jacs.8b04530; DUNNING TH, 1989, J CHEM PHYS, V90, P1007, DOI 10.1063/1.456153; Eckert F, 2002, AICHE J, V48, P369, DOI 10.1002/aic.690480220; Erlanson DA, 2016, NAT REV DRUG DISCOV, V15, P605, DOI 10.1038/nrd.2016.109; Fier PS, 2017, J AM CHEM SOC, V139, P9499, DOI 10.1021/jacs.7b05414; Finet J.-P, 1998, TETR ORG CH, V18; FRANCL MM, 1982, J CHEM PHYS, V77, P3654, DOI 10.1063/1.444267; FUKUI K, 1981, ACCOUNTS CHEM RES, V14, P363, DOI 10.1021/ar00072a001; Funes-Ardoiz I., 2018, GOODVIBES VERSION 2, DOI [10.5281/zenodo.595246, DOI 10.5281/ZENODO.595246]; Goerigk L, 2011, PHYS CHEM CHEM PHYS, V13, P6670, DOI 10.1039/c0cp02984j; GraphPad Prism, GRAPHPAD PRISM VERS; Grimme S, 2012, CHEM-EUR J, V18, P9955, DOI 10.1002/chem.201200497; GRIMMETT MR, 1993, ADV HETEROCYCL CHEM, V58, P271, DOI 10.1016/S0065-2725(08)60288-3; Guram AS, 2007, J ORG CHEM, V72, P5104, DOI 10.1021/jo070341w; HARIHARA.PC, 1973, THEOR CHIM ACTA, V28, P213, DOI 10.1007/BF00533485; Hassan J, 2002, CHEM REV, V102, P1359, DOI 10.1021/cr000664r; HEHRE WJ, 1972, J CHEM PHYS, V56, P2257, DOI 10.1063/1.1677527; Hilton MC, 2016, J AM CHEM SOC, V138, P13806, DOI 10.1021/jacs.6b08662; Hirai T, 2007, ORG LETT, V9, P53, DOI 10.1021/ol062505l; HOFFMANN R, 1972, J AM CHEM SOC, V94, P3047, DOI 10.1021/ja00764a028; Joule J. A., 2013, HETEROCYCLIC CHEM; Kiehne U, 2007, SYNTHESIS-STUTTGART, P1061, DOI 10.1055/s-2007-965952; Kiehne U., 2007, SYNTHESIS, P1061; KLAMT A, 1995, J PHYS CHEM-US, V99, P2224, DOI 10.1021/j100007a062; Klamt A, 1998, J PHYS CHEM A, V102, P5074, DOI 10.1021/jp980017s; Koniarczyk JL, 2018, J AM CHEM SOC, V140, P1990, DOI 10.1021/jacs.7b11710; Kudo N, 2006, ANGEW CHEM INT EDIT, V45, P1282, DOI 10.1002/anie.200503479; Larsen MA, 2014, J AM CHEM SOC, V136, P4287, DOI 10.1021/ja412563e; Liakos DG, 2015, J CHEM THEORY COMPUT, V11, P1525, DOI 10.1021/ct501129s; Lu T, 2012, J COMPUT CHEM, V33, P580, DOI 10.1002/jcc.22885; MANN FG, 1948, J ORG CHEM, V13, P502, DOI 10.1021/jo01162a007; Marenich AV, 2009, J PHYS CHEM B, V113, P6378, DOI 10.1021/jp810292n; Markovic T, 2017, CHEM SCI, V8, P4437, DOI 10.1039/c7sc00675f; Martina SD, 2005, ANN PHARMACOTHER, V39, P854, DOI 10.1345/aph.1E543; Mennucci B, 1997, J PHYS CHEM B, V101, P10506, DOI 10.1021/jp971959k; Mennucci B, 1997, J CHEM PHYS, V106, P5151, DOI 10.1063/1.473558; Molitor S, 2014, J AM CHEM SOC, V136, P15517, DOI 10.1021/ja509381w; MUETTERTIES EL, 1963, INORG CHEM, V2, P613, DOI 10.1021/ic50007a047; Murray CW, 2009, NAT CHEM, V1, P187, DOI [10.1038/NCHEM.217, 10.1038/nchem.217]; NBO version 6.0, 2013, VERS 6 0; Neese F, 2012, WIRES COMPUT MOL SCI, V2, P73, DOI 10.1002/wcms.81; NEWKOME GR, 1978, J AM CHEM SOC, V100, P5567, DOI 10.1021/ja00485a053; Perrin D.D., 1988, PURIFICATION LAB CHE, V3rd; POPLE JA, 1987, J CHEM PHYS, V87, P5968, DOI 10.1063/1.453520; PURVIS GD, 1982, J CHEM PHYS, V76, P1910, DOI 10.1063/1.443164; Rassolov VA, 2001, J COMPUT CHEM, V22, P976, DOI 10.1002/jcc.1058; Reichl KD, 2014, CHEM COMMUN, V50, P9302, DOI 10.1039/c4cc03415e; Rezac J, 2013, J CHEM THEORY COMPUT, V9, P2151, DOI 10.1021/ct400057w; Riplinger C, 2016, J CHEM PHYS, V144, DOI 10.1063/1.4939030; Riplinger C, 2013, J CHEM PHYS, V139, DOI 10.1063/1.4821834; Riplinger C, 2013, J CHEM PHYS, V138, DOI 10.1063/1.4773581; Roecker AJ, 2014, CHEMMEDCHEM, V9, P311, DOI 10.1002/cmdc.201300447; Roughley SD, 2011, J MED CHEM, V54, P3451, DOI 10.1021/jm200187y; Savin A, 1997, ANGEW CHEM INT EDIT, V36, P1809, DOI 10.1002/anie.199718081; Scalmani G, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3359469; Silverman R. B., 2014, ORGANIC CHEM DRUG DE; Sure R, 2015, J CHEM THEORY COMPUT, V11, P3785, DOI 10.1021/acs.jctc.5b00296; Tomasi J, 1999, J MOL STRUC-THEOCHEM, V464, P211, DOI 10.1016/S0166-1280(98)00553-3; Truhlar DG, 1998, CHEM PHYS LETT, V294, P45, DOI 10.1016/S0009-2614(98)00866-5; UCHIDA Y, 1994, HETEROATOM CHEM, V5, P409, DOI 10.1002/hc.520050414; UCHIDA Y, 1989, TETRAHEDRON LETT, V30, P6365, DOI 10.1016/S0040-4039(01)93895-X; UCHIDA Y, 1989, TETRAHEDRON LETT, V30, P567, DOI 10.1016/S0040-4039(00)95256-0; Weigend F, 2006, PHYS CHEM CHEM PHYS, V8, P1057, DOI 10.1039/b515623h; Weigend F, 2005, PHYS CHEM CHEM PHYS, V7, P3297, DOI 10.1039/b508541a; WIBERG KB, 1968, TETRAHEDRON, V24, P1083, DOI 10.1016/0040-4020(68)88057-3; WOON DE, 1993, J CHEM PHYS, V98, P1358, DOI 10.1063/1.464303; Zhang X, 2017, ANGEW CHEM INT EDIT, V56, P9833, DOI 10.1002/anie.201704948; Zhao DB, 2011, CHEM-EUR J, V17, P5466, DOI 10.1002/chem.201003039	95	92	93	11	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 16	2018	362	6416			SI		799	+		10.1126/science.aas8961	http://dx.doi.org/10.1126/science.aas8961			446	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA7TZ	30442804	Green Accepted, Green Submitted			2023-01-03	WOS:000450488500046
J	Jacq, G; Melot, K; Bezou, M; Foucault, L; Courau-Courtois, J; Cavelot, S; Lang, A; Bedos, JP; Le-Boeuf, D; Boussard, JM; Legriel, S				Jacq, Gwenaelle; Melot, Karine; Bezou, Mathilde; Foucault, Laura; Courau-Courtois, Josette; Cavelot, Sebastien; Lang, Annie; Bedos, Jean-Pierre; Le-Boeuf, Dominique; Boussard, Jean-Marc; Legriel, Stephane			Music for pain relief during bed bathing of mechanically ventilated patients: A pilot study	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; INTERVENTION; THERAPY; ANALGESIA; THRESHOLD; ANXIETY; RECALL	Background Pain is a universal issue and is of particular concern in mechanically ventilated patients, as they require intensive nursing care and multiple invasive procedures, while being unable to communicate verbally. The aim of this study was to assess the effect of music on pain experienced by mechanically ventilated patients during morning bed bathing. Methods Of the 60 mechanically ventilated patients enrolled in this single-center pilot study between March 2013 and October 2015, the first 30 received no music and the next 30 the music intervention, during the morning bed bath. The Behavioral Pain Scale (BPS) score was determined during and at the end of the bath then 30, 60, and 120 minutes after the bath. BPS score changes over time were assessed and the proportions of bath times spent with a BPS score >= 5 and with the maximal BPS score were determined. Results At baseline, no patient had pain (defined as a BPS score <5) and the median BPS score was 3 [IQR, 3;3] in both groups (P= 0.43). After bed bath initiation, 88% of patients experienced pain. The maximum BPS value during the bath was lower in the music group (5 [5;6.7] vs. 7 [5;7]). Proportions of total bath time spent with BPS >= 5 and with the maximum BPS were significantly lower in the music group than in the control group (2.0 [0.3;4.0] vs. 10 [4.3;18.0]; P < .0001 and 1.5 [0;3.0] vs. 3.5 [2.0;6.0]; P = .005; respectively). Two hours after the end of the bath, the BPS values had returned to baseline in both groups. Conclusion In our population, music significantly decreased pain intensity and duration during the morning bed bath in mechanically ventilated patients. These results warrant further assessment in a large multicenter randomized controlled trial.	[Jacq, Gwenaelle; Melot, Karine; Bezou, Mathilde; Foucault, Laura; Courau-Courtois, Josette; Cavelot, Sebastien; Lang, Annie; Bedos, Jean-Pierre; Le-Boeuf, Dominique; Legriel, Stephane] Ctr Hosp Versailles, GHT Sud Yvelines, Dept Intens Care, Site Andre Mignot, Le Chesnay, France; [Boussard, Jean-Marc] Ctr Hosp Rambouillet, GHT Sud Yvelines, Direct Soins, Rambouillet, France	Centre Hospitalier de Versailles; UDICE-French Research Universities; Universite Paris Saclay	Jacq, G (corresponding author), Ctr Hosp Versailles, GHT Sud Yvelines, Dept Intens Care, Site Andre Mignot, Le Chesnay, France.	gjacq@ch-versailles.fr	Legriel, Stephane/J-1307-2017	Legriel, Stephane/0000-0003-4782-6734; JACQ, Gwenaelle/0000-0003-2927-9570	French public funding agency Delegation a la Recherche Clinique et a l'Innovation (DRCI), Versailles, France	French public funding agency Delegation a la Recherche Clinique et a l'Innovation (DRCI), Versailles, France	The study was supported by the French public funding agency Delegation a la Recherche Clinique et a l'Innovation (DRCI), Versailles, France. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The study was supported by the French public funding agency Delegation a la Recherche Clinique et a l'Innovation (DRCI), Versailles, France. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aceto P, 2015, MINERVA ANESTESIOL, V81, P1201; Aceto P, 2013, ANAESTHESIA, V68, P1141, DOI 10.1111/anae.12386; Aceto P, 2007, NEUROREPORT, V18, P823, DOI 10.1097/WNR.0b013e3280e129f5; Aktas YY, 2016, NURS CRIT CARE, V21, P44, DOI 10.1111/nicc.12159; Arroyo-Novoa Carmen Mabel, 2008, Intensive Crit Care Nurs, V24, P20, DOI 10.1016/j.iccn.2007.05.002; Boer KR, 2008, INTENS CARE MED, V34, P664, DOI 10.1007/s00134-007-0941-3; Bradt J, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006902.pub3; Bradt J, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006911.pub2, 10.1002/14651858.CD006911]; Chanques G, 2017, BRIT J ANAESTH, V119, P812, DOI 10.1093/bja/aex210; Chlan LL, 2013, JAMA-J AM MED ASSOC, V309, P2335, DOI 10.1001/jama.2013.5670; Downey Lindsey, 2008, Nurs Stand, V22, P35; Dunbar RIM, 2012, EVOL PSYCHOL-US, V10, P688, DOI 10.1177/147470491201000403; Fourrier F, 2010, REANIMATION, V19, P191; Fritz TH, 2018, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.02312; Gelinas C, 2016, INTENS CRIT CARE NUR, V34, P1, DOI 10.1016/j.iccn.2016.03.001; Gelinas Celine, 2007, Intensive Crit Care Nurs, V23, P298, DOI 10.1016/j.iccn.2007.03.002; Guetin S, 2012, CLIN J PAIN, V28, P329, DOI 10.1097/AJP.0b013e31822be973; Hartling L, 2013, JAMA PEDIATR, V167, P826, DOI 10.1001/jamapediatrics.2013.200; Jaber S, 2007, ANN FRANCAISES ANEST; Jenkins JS, 2001, J ROY SOC MED, V94, P170, DOI 10.1177/014107680109400404; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lukaszewicz AC, 2015, ANESTH ANALG, V120, P1297, DOI 10.1213/ANE.0000000000000609; Mondanaro John F, 2017, Am J Orthop (Belle Mead NJ), V46, pE13; Payen JF, 2008, ANN FR ANESTH, V27, P633, DOI 10.1016/j.annfar.2008.04.015; Payen JF, 2009, ANESTHESIOLOGY, V111, P1308, DOI 10.1097/ALN.0b013e3181c0d4f0; Payen JF, 2001, CRIT CARE MED, V29, P2258, DOI 10.1097/00003246-200112000-00004; PUNTILLO KA, 1990, HEART LUNG, V19, P526; Puntillo KA, 2004, CRIT CARE MED, V32, P421, DOI 10.1097/01.CCM.0000108875.35298.D2; Puntillo KA, 2014, AM J RESP CRIT CARE, V189, P39, DOI 10.1164/rccm.201306-1174OC; Sauder P, 2008, ANN FRANCAISES ANEST; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Trappe Hans-Joachim, 2012, Int J Crit Illn Inj Sci, V2, P27, DOI 10.4103/2229-5151.94893; van Rompaey B, 2009, CRIT CARE, V13, DOI 10.1186/cc7892; Whitehead-Pleaux AM, 2007, J MUSIC THER, V44, P217, DOI 10.1093/jmt/44.3.217; Wong HLC, 2001, HEART LUNG, V30, P376, DOI 10.1067/mhl.2001.118302; Yang CY, 2016, J CLIN NURS, V25, P777, DOI 10.1111/jocn.13098	36	5	5	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2018	13	11							e0207174	10.1371/journal.pone.0207174	http://dx.doi.org/10.1371/journal.pone.0207174			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA3GQ	30427906	gold, Green Submitted, Green Published			2023-01-03	WOS:000450138500075
J	Meiring, C; Dixit, A; Harris, S; MacCallum, NS; Brealey, DA; Watkinson, PJ; Jones, A; Ashworth, S; Beale, R; Brett, SJ; Singer, M; Ercole, A				Meiring, Christopher; Dixit, Abhishek; Harris, Steve; MacCallum, Niall S.; Brealey, David A.; Watkinson, Peter J.; Jones, Andrew; Ashworth, Simon; Beale, Richard; Brett, Stephen J.; Singer, Mervyn; Ercole, Ari			Optimal intensive care outcome prediction over time using machine learning	PLOS ONE			English	Article							ORGAN DYSFUNCTION SCORE; SEPTIC SHOCK; APACHE-III; HOSPITAL MORTALITY; LIMITED TRIALS; SAPS-II; UNIT; END; PATIENT; SEPSIS	Background Prognostication is an essential tool for risk adjustment and decision making in the intensive care unit (ICU). Research into prognostication in ICU has so far been limited to data from admission or the first 24 hours. Most ICU admissions last longer than this, decisions are made throughout an admission, and some admissions are explicitly intended as time-limited prognostic trials. Despite this, temporal changes in prognostic ability during ICU admission has received little attention to date. Current predictive models, in the form of prognostic clinical tools, are typically derived from linear models and do not explicitly handle incremental information from trends. Machine learning (ML) allows predictive models to be developed which use non-linear predictors and complex interactions between variables, thus allowing incorporation of trends in measured variables over time; this has made it possible to investigate prognosis throughout an admission. Methods and findings This study uses ML to assess the predictability of ICU mortality as a function of time. Logistic regression against physiological data alone outperformed APACHE-II and demonstrated several important interactions including between lactate & noradrenaline dose, between lactate & MAP, and between age & MAP consistent with the current sepsis definitions. ML models consistently outperformed logistic regression with Deep Learning giving the best results. Predictive power was maximal on the second day and was further improved by incorporating trend data. Using a limited range of physiological and demographic variables, the best machine learning model on the first day showed an area under the receiver-operator characteristic curve (AUC) of 0.883 (sigma = 0.008), compared to 0.846 (sigma = 0.010) for a logistic regression from the same predictors and 0.836 (sigma= 0.007) for a logistic regression based on the APACHE-II score. Adding information gathered on the second day of admission improved the maximum AUC to 0.895 (sigma= 0.008). Beyond the second day, predictive ability declined. Conclusion This has implications for decision making in intensive care and provides a justification for time-limited trials of ICU therapy; the assessment of prognosis over more than one day may be a valuable strategy as new information on the second day helps to differentiate outcomes. New ML models based on trend data beyond the first day could greatly improve upon current risk stratification tools.	[Meiring, Christopher; Dixit, Abhishek; Ercole, Ari] Univ Cambridge, Div Anaesthesia, Cambridge, England; [Harris, Steve; MacCallum, Niall S.; Brealey, David A.; Singer, Mervyn] UCL, Bloomsbury Inst Intens Care Med, London, England; [Watkinson, Peter J.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford, England; [Jones, Andrew; Beale, Richard] St Thomas Hosp, Guys & St Thomas NHS Fdn Trust, Dept Intens Care, Westminster Bridge Rd, London, England; [Ashworth, Simon; Brett, Stephen J.] Imperial Coll Healthcare NHS Trust, Ctr Perioperat Med & Crit Care Res, Praed St, London, England	University of Cambridge; University of London; University College London; University of Oxford; Guy's & St Thomas' NHS Foundation Trust; Imperial College London	Ercole, A (corresponding author), Univ Cambridge, Div Anaesthesia, Cambridge, England.	ae105@cam.ac.uk	Singer, Mervyn/Q-6142-2019; Brealey, David/AAL-1777-2021; Ercole, Ari/B-6288-2009	Singer, Mervyn/0000-0002-1042-6350; Ercole, Ari/0000-0001-8350-8093; Watkinson, Peter/0000-0003-1023-3927; Harris, Steve/0000-0002-4982-1374; Brealey, David/0000-0002-1982-3379; Meiring, Christopher/0000-0002-7758-0715	National Institute for Health Research Cambridge Biomedical Research Centre; Clinical Research Informatics Unit, University College London Hospitals Biomedical Research Centre	National Institute for Health Research Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); Clinical Research Informatics Unit, University College London Hospitals Biomedical Research Centre	This research was conducted using NIHR Health Informatics Collaborative (NIHR HIC) data resources. This research was supported by the National Institute for Health Research Cambridge Biomedical Research Centre and the Clinical Research Informatics Unit, University College London Hospitals Biomedical Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This research was conducted using NIHR Health Informatics Collaborative (NIHR HIC) data resources. This research was supported by the National Institute for Health Research Cambridge Biomedical Research Centre and the Clinical Research Informatics Unit, University College London Hospitals Biomedical Research Centre.	Allaire J, 2019, R PACKAGE VERSION, V1, P1; Allaire J.J., KERAS R INTERFACE KE; Beck DH, 2003, INTENS CARE MED, V29, P249, DOI 10.1007/s00134-002-1607-9; Calvert J, 2016, ANN MED SURG, V11, P52, DOI 10.1016/j.amsu.2016.09.002; Calvert J, 2016, ANN MED SURG, V8, P50, DOI 10.1016/j.amsu.2016.04.023; Calvert JS, 2016, COMPUT BIOL MED, V74, P69, DOI 10.1016/j.compbiomed.2016.05.003; Celi LA, 2012, J PERS MED, V2, P138, DOI 10.3390/jpm2040138; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; Deo RC, 2015, CIRCULATION, V132, P1920, DOI 10.1161/CIRCULATIONAHA.115.001593; Desautels T, 2017, BIOMED INFORM INSIGH, V9, DOI 10.1177/1178222617712994; Desautels T, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017199; Desautels T, 2016, JMIR MED INF, V4, P67, DOI 10.2196/medinform.5909; Fernandez-Delgado M, 2014, J MACH LEARN RES, V15, P3133; Harrisa S, 2018, INT J MED INFORM, V112, P82, DOI 10.1016/j.ijmedinf.2018.01.006; Jacobs S, 1999, CRIT CARE MED, V27, P741, DOI 10.1097/00003246-199904000-00027; Johnson AEW, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.35; Jones AE, 2009, CRIT CARE MED, V37, P1649, DOI 10.1097/CCM.0b013e31819def97; Keegan MT, 2012, CHEST, V142, P851, DOI 10.1378/chest.11-2164; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kourou K, 2015, COMPUT STRUCT BIOTEC, V13, P8, DOI 10.1016/j.csbj.2014.11.005; Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05; Kuzniewicz MW, 2008, CHEST, V133, P1319, DOI 10.1378/chest.07-3061; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Livingston BM, 2000, CRIT CARE MED, V28, P1820, DOI 10.1097/00003246-200006000-00023; Luce JM, 2002, AM J RESP CRIT CARE, V165, P750, DOI 10.1164/ajrccm.165.6.2109045; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Metnitz PGH, 2005, INTENS CARE MED, V31, P1336, DOI 10.1007/s00134-005-2762-6; MOONS KGM, 2009, BRIT MED J, V338; Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5; Quill TE, 2011, JAMA-J AM MED ASSOC, V306, P1483, DOI 10.1001/jama.2011.1413; Rajkomar A, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0029-1; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Schenker Y, 2013, J CRIT CARE, V28, P862, DOI 10.1016/j.jcrc.2013.04.015; Shankar-Hari M, 2016, JAMA-J AM MED ASSOC, V315, P775, DOI 10.1001/jama.2016.0289; Shi S, 2017, J OPEN SOURCE SOFTWA, V2, P513, DOI [10.21105/joss.00513, DOI 10.21105/JOSS.00513]; Shrime MG, 2016, JAMA ONCOL, V2, P76, DOI 10.1001/jamaoncol.2015.3336; SIRIO CA, 1992, CRIT CARE MED, V20, P1207, DOI 10.1097/00003246-199209000-00006; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; TERES D, 1987, CRIT CARE MED, V15, P208, DOI 10.1097/00003246-198703000-00005; Truog RD, 2008, CRIT CARE MED, V36, P953, DOI 10.1097/CCM.0B013E3181659096; van Buuren S, 2011, J STAT SOFTW, V45, P1; VINCENT JL, 2010, CRIT CARE, V14; Vink EE, 2018, INTENS CARE MED, V44, P1369, DOI 10.1007/s00134-018-5339-x; WONG DT, 1995, CRIT CARE MED, V23, P1177, DOI 10.1097/00003246-199507000-00005; Yeo IK, 2000, BIOMETRIKA, V87, P954, DOI 10.1093/biomet/87.4.954	46	37	38	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2018	13	11							e0206862	10.1371/journal.pone.0206862	http://dx.doi.org/10.1371/journal.pone.0206862			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HA3GQ	30427913	gold, Green Published, Green Submitted			2023-01-03	WOS:000450138500069
J	Evoy, KE; Hill, LG; Groff, L; Mazin, L; Carlson, CC; Reveles, KR				Evoy, Kirk E.; Hill, Lucas G.; Groff, Lindsey; Mazin, Lubna; Carlson, Christian C.; Reveles, Kelly R.			Naloxone Accessibility Without a Prescriber Encounter Under Standing Orders at Community Pharmacy Chains in Texas	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Evoy, Kirk E.; Hill, Lucas G.; Groff, Lindsey; Mazin, Lubna; Carlson, Christian C.; Reveles, Kelly R.] Univ Texas Austin, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Evoy, KE (corresponding author), Univ Texas Austin, Pharmacotherapy Educ & Res Ctr, Coll Pharm, 7703 Floyd Curl Dr,MC 6220, San Antonio, TX 78229 USA.	evoy@uthscsa.edu	Reveles, Kelly/AAI-1575-2021; Hill, Lucas G./U-6003-2019	Hill, Lucas G./0000-0001-5958-0159; Groff, Lindsey/0000-0002-7073-3600	University of Texas Health San Antonio Institute for Integration of Medicine and Science; Texas Health and Human Services; Kleberg Foundation	University of Texas Health San Antonio Institute for Integration of Medicine and Science; Texas Health and Human Services; Kleberg Foundation	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Evoy reported receipt of grant funding from the University of Texas Health San Antonio Institute for Integration of Medicine and Science, the Kleberg Foundation, and Texas Health and Human Services to conduct opioid overdose prevention and response training, including providing education on proper use of naloxone and distribution of naloxone within the community. All formulations of naloxone are discussed in these trainings. The trainings conducted are solely for the purposes of reducing opioid overdose harm in the community. Dr Hill reported previously receiving donations of branded formulations of naloxone from Kaleo Pharma and Adapt Pharma for community distribution in support of efforts to reduce opioid overdose harm in the community. He received a donation of Evzio Auto-Injectors from Kaleo Pharma immediately following Hurricane Harvey for distribution to people who use illicit opioids whose risk of overdose was increased by a destabilized supply chain. He also received a donation of Narcan nasal spray from Adapt Pharma to distribute on campus in support of overdose preparedness efforts at The University of Texas at Austin. No other disclosures were reported.	Dickerson, 2018, NEW YORK TIMES; Meyerson BE, 2018, DRUG ALCOHOL DEPEN, V188, P187, DOI 10.1016/j.drugalcdep.2018.03.032; Network for Public Health Law, LEGAL INT REDUCE OV	3	41	41	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 13	2018	320	18					1932	1937		10.1001/jama.2018.15892	http://dx.doi.org/10.1001/jama.2018.15892			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HA1BH	30422186	Green Published, Bronze			2023-01-03	WOS:000449945900021
J	Nishio, A; Horita, R; Marutani, T; Yamamoto, M				Nishio, Akihiro; Horita, Ryo; Marutani, Toshiyuki; Yamamoto, Mayumi			Factors that influence delaying initial psychiatric treatment in rural Cambodia: A pilot study	PLOS ONE			English	Article							UNTREATED PSYCHOSIS; 1ST-EPISODE PSYCHOSIS; DURATION; POPULATION; CARE	Background The WHO reported the gap between the need for treatment and its provision is huge in low- and middle-income countries. It is estimated there are lots of burden to obtain treatment in these countries. This survey intended to show the delay of their first visit to a psychiatric department and the factors that influence the delay. To elucidate the factors affecting medical accessibility for people with mental illness, we propose the concept of duration of untreated mental illness (DUM), which is the duration between the onset or first symptom of mental illness and the first visit to a psychiatric department or clinic. Methods Participants were 109 Cambodian adults (18 years old and up) who had a psychiatric consultation in one of the following hospitals. We analyzed the relationships between DUM and patients' background; age, gender, economic status, education level, occupation, hospital access, and diagnosis. Results The average DUM of all participants was 34.8 +/- 42.4 months, ranging from 0 to 240 There was no significant difference in DUM by difference in hospital, gender, age, hospital access, education level, occupation, or economic status. Only patient diagnosis was related to DUM. The DUM for patients with schizophrenia and epilepsy was long, while the DUM for patients with neurosis and substance use were short. Conclusion To compare DUM with that of other low- and middle-income countries, DUM of our survey is extremely long. However, those reports were from urban areas within the low- and middle-income countries. We considered our report to include a very important sample showing the condition of psychiatric services in rural areas of low-income countries.	[Nishio, Akihiro; Horita, Ryo; Marutani, Toshiyuki; Yamamoto, Mayumi] Gifu Univ, Hlth Adm Ctr, Gifu, Japan; [Nishio, Akihiro] Gifu Univ, Grad Sch Med, Dept Psychopathol, Div Neurosci, Gifu, Japan; [Marutani, Toshiyuki] Tokyo Inst Technol, Hlth Support Ctr, Yokohama, Kanagawa, Japan; [Yamamoto, Mayumi] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, Gifu, Japan	Gifu University; Gifu University; Tokyo Institute of Technology; Gifu University	Nishio, A (corresponding author), Gifu Univ, Hlth Adm Ctr, Gifu, Japan.; Nishio, A (corresponding author), Gifu Univ, Grad Sch Med, Dept Psychopathol, Div Neurosci, Gifu, Japan.	a_nishio@gifu-u.ac.jp			Gifu University	Gifu University	This survey was supported by Gifu University.	Al Fayez H, 2017, EARLY INTERV PSYCHIA, V11, P47, DOI 10.1111/eip.12214; Apiquian R, 2002, SCHIZOPHR RES, V53, P161, DOI 10.1016/S0920-9964(00)00087-6; Ayres AM, 2007, SCHIZOPHR RES, V90, P338, DOI 10.1016/j.schres.2006.09.026; Bora E, 2017, SCHIZOPHR RES; Burns JK, 2010, AFR J PSYCHIATRY, V13, P395; Dong H, 2016, DURATION UNTREATED P, V11, DOI [10.1371/journal.pone.0157083, DOI 10.1371/JOURNAL.PONE.0157083]; Hui CLM, 2015, EARLY INTERV PSYCHIA, V9, P118, DOI 10.1111/eip.12094; Naqvi HA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007409; Norman RMG, 2004, PSYCHOL MED, V34, P255, DOI 10.1017/S0033291703001119; Oosthuizen P, 2005, ACTA PSYCHIAT SCAND, V111, P214, DOI 10.1111/j.1600-0447.2004.00448.x; Padilla E, 2015, SCHIZOPHR RES, V161, P184, DOI 10.1016/j.schres.2014.10.039; Penttila M, 2013, SCHIZOPHR RES, V143, P3, DOI 10.1016/j.schres.2012.10.029; Sharifi V, 2009, EARLY INTERV PSYCHIA, V3, P131, DOI 10.1111/j.1751-7893.2009.00119.x; Tang JY, 2009, SCHIZOPHR RES, V109, P15, DOI [10.1016/j.schres.2009.01.008, DOI 10.1016/J.SCHRES.2009.01.008]; Tomita A, 2015, J NERV MENT DIS, V203, P222, DOI 10.1097/NMD.0000000000000268; WHO-AIMS, MENT HLTH SYST SEL L; World Bank, WORLD BANK DAT	17	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 1	2018	13	11							e0206882	10.1371/journal.pone.0206882	http://dx.doi.org/10.1371/journal.pone.0206882			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GZ0DG	30383851	Green Published, Green Submitted, gold			2023-01-03	WOS:000449027600103
J	Bae, EY; Kim, HJ; Lee, HJ; Jang, J; Lee, SM; Jung, Y; Yoon, N; Kim, TK; Kim, K; Yang, BM				Bae, Eun-Young; Kim, Hui Jeong; Lee, Hye-Jae; Jang, Junho; Lee, Seung Min; Jung, Yunkyung; Yoon, Nari; Kim, Tae Kyung; Kim, Kookhee; Yang, Bong-Min			Role of economic evidence in coverage decision-making in South Korea	PLOS ONE			English	Article							DRUG REIMBURSEMENT DECISIONS; 4 EUROPEAN COUNTRIES; COST-EFFECTIVENESS; AUSTRALIA; HEALTH; CANADA; NICE; RECOMMENDATIONS	Objectives The South Korean government required the submission of economic evidence when it implemented the Positive-List System in December 2006. This study investigates the key factors that influenced actual public insurance reimbursement decisions, including the role of economic evidence, after 10 years of decision practice under compulsory health technology assessment (HTA) for new drugs. Method Logistic regression analysis was used to estimate the impact of the variables involved, including cost-effectiveness ratio as a key variable, on reimbursement decisions. The latter were defined as "yes" or "no" at a submitted price and indication. Only cases (n = 91) that present a cost-effectiveness ratio, and that have been reviewed based on this ratio from January 2007 to December 2016, were included in the analysis. Results Cases with higher cost-effectiveness ratios were less likely to be accepted. In addition, drugs that were used to treat severe diseases and drugs with no substitute were more likely to be recommended. The probability of acceptance declined along with the level of uncertainty in the submitted evidence. The acceptance rate for severe-disease drugs has increased since 2013, when the government introduced several policies that lowered the existing barriers to positive reimbursement. However, such an increase was not statistically significant. Conclusions Cost-effectiveness is one of the most influential factors in drug-reimbursement decisions. However, inclusion of other explanatory variables, in addition to the cost-effectiveness ratio, predicted the results of decisions more accurately.	[Bae, Eun-Young] Gyeongsang Natl Univ, Sch Pharm, Jinju, South Korea; [Bae, Eun-Young] Gyeongsang Natl Univ, Inst Pharm, Jinju, South Korea; [Kim, Hui Jeong; Jang, Junho; Lee, Seung Min; Jung, Yunkyung; Yoon, Nari; Kim, Tae Kyung; Kim, Kookhee] Hlth Insurance Review & Assessment Serv, Pharmaceut Benefit Dept, Wonju, South Korea; [Lee, Hye-Jae] Natl Hlth Insurance Serv, Hlth Insurance Policy Res Inst, Wonju, South Korea; [Yang, Bong-Min] Seoul Natl Univ, Grad Sch Publ Hlth, Seoul, South Korea	Gyeongsang National University; Gyeongsang National University; National Health Insurance Service; Seoul National University (SNU)	Bae, EY (corresponding author), Gyeongsang Natl Univ, Sch Pharm, Jinju, South Korea.; Bae, EY (corresponding author), Gyeongsang Natl Univ, Inst Pharm, Jinju, South Korea.	eybae@gnu.ac.kr						Bae E-Y, 2013, STUDY PERFORMANCE PO; Bae EY, 2016, HEALTH POLICY, V120, P612, DOI 10.1016/j.healthpol.2016.03.013; Birkett DJ, 2001, HEALTH AFFAIR, V20, P104, DOI 10.1377/hlthaff.20.3.104; Chim L, 2010, PHARMACOECONOMICS, V28, P463, DOI 10.2165/11533000-000000000-00000; Clement FM, 2009, JAMA-J AM MED ASSOC, V302, P1437, DOI 10.1001/jama.2009.1409; Dakin H, 2014, HEALTH ECON, DOI [10.1002/hec.3086, DOI 10.1002/HEC.3086]; Dakin HA, 2006, HEALTH POLICY, V77, P352, DOI 10.1016/j.healthpol.2005.08.008; Devlin N, 2004, HEALTH ECON, V13, P437, DOI 10.1002/hec.864; Drummond M., 2004, AUST ECON REV, V37, P3, DOI [10.1111/j.1467-8462.2004.00304.x, DOI 10.1111/J.1467-8462.2004.00304.X]; Drummond M, 2013, J HEALTH POLIT POLIC, V38, P1081, DOI 10.1215/03616878-2373148; Franken M, 2015, HEALTH POLICY, V119, P195, DOI 10.1016/j.healthpol.2014.10.007; Franken M, 2013, PHARMACOECONOMICS, V31, P781, DOI 10.1007/s40273-013-0074-1; Harris AH, 2008, MED DECIS MAKING, V28, P713, DOI 10.1177/0272989X08315247; HIRA, 2017, PHARM BEN LIST; Mauskopf J, 2013, HEALTH POLICY, V110, P49, DOI 10.1016/j.healthpol.2013.01.017; McMahon M, 2006, HEALTH POLICY, V77, P339, DOI 10.1016/j.healthpol.2005.08.006; Nicod E, 2017, VALUE HEALTH, V20, P919, DOI 10.1016/j.jval.2017.03.005; Park SE, 2012, HEALTH POLICY, V104, P32, DOI 10.1016/j.healthpol.2011.09.006; Rutten F, 1996, HEALTH POLICY, V36, P215, DOI 10.1016/0168-8510(96)00814-7; Salas-Vega S, 2016, HEALTH POLICY, V120, P1104, DOI 10.1016/j.healthpol.2016.08.006; Simoens S, 2010, INT J ENV RES PUB HE, V7, P1835, DOI 10.3390/ijerph7041835; Whitty JA, 2015, HEALTH POLICY, V119, P127, DOI 10.1016/j.healthpol.2014.09.003; Yong JHE, 2013, PHARMACOECONOMICS, V31, P229, DOI 10.1007/s40273-012-0022-5	23	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2018	13	10							e0206121	10.1371/journal.pone.0206121	http://dx.doi.org/10.1371/journal.pone.0206121			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GY3FL	30356251	Green Published, gold, Green Submitted			2023-01-03	WOS:000448434000074
J	Ejeta, E; Beyene, G; Balay, G; Bonsa, Z; Abebe, G				Ejeta, Eyasu; Beyene, Getenet; Balay, Getu; Bonsa, Zegeye; Abebe, Gemeda			Factors associated with unsuccessful treatment outcome in tuberculosis patients among refugees and their surrounding communities in Gambella Regional State, Ethiopia	PLOS ONE			English	Article							SOUTHERN REGION; POPULATIONS; PREVALENCE; COUNTRIES; GENDER; INDIA; HIV; TB	Background Tuberculosis (TB) is a leading cause of public health challenges among immigrant refugees and their surrounding communities in developing countries. Evaluating the treatment outcome of TB patients is one of the key indicators to understand the performance of TB control program. Hence, this study aims to assess profile, treatment outcome and factors associated with unsuccessful outcome of TB patients treated under the TB control program among refugees and their surrounding communities (SCs) in Gambella Regional State, Ethiopia. Methodology Retrospective study was conducted in the health facilities of refugee and their SCs in Gambella Regional State from March 1 to May 30, 2017. Demographic and related data of all TB patients registered in TB Control Program between September, 2008 and October, 2017 in health facilities of refugee and the SCs was extracted using data extraction format. Eight years trend of TB, treatment outcome and factors associated with unsuccessful outcome among refugees and the SCs were computed using SPSS version 20.0 software. Result A total of 886 refugees and 3284 SCs TB patients, registered for anti TB treatment in the last eight years, were evaluated in the study. The trend of all forms of TB is progressively increasing among refugees contrary to the SCs in the course of the study period (X-2 trend = 207.7; P<0.0001). Smear positive pulmonary TB (PTB+) was found to be predominant (57.6%) TB form in refugees while smear negative pulmonary TB (PTB-) (44.8%) is in the SCs (X-2 = 185.834; P<0.0001). There was also significant difference in the treatment outcome (X-2 = 170.915; P<0.0001). Mean treatment success rate was 74.2% and 88.1% for refugees and the SCs, respectively (X-2 = 92.887; P<0.0001). The study also revealed that the risk of unsuccessful TB treatment outcome was significantly higher among refugee (AOR = 2.17; 95% CI: 1.69-2.77), retreated cases (AOR = 1.53; 95% CI: 1.07-2.17), patients aged between 35-44 years (AOR = 1.38; 95% CI: 1.0-1.91), and greater than 44 years old (AOR = 1.77; 95% CI: 1.28-2.44), and patients with extra pulmonary TB (EPTB) form (AOR = 1.34; 95% CI: 1.04-1.73) compared to their counterparts. Patient coming from rural area (AOR = 0.77; 95% CI: 0.62-0.97), who are female (AOR = 0.76; 95% CI: 0.63-0.91) and TB/HIV non-infected (AOR = 0.63; 95% CI: 0.51-0.77) were more likely to be successfully treated. Conclusion The study confirmed that there was low treatment success rate among refugees compared to the SCs. Being refugee, retreated case, patient's age. 35 years old, EPTB form, gender, rural patient address and HIV status were predictor factors for unsuccessful treatment outcome. Hence, the study urges the need for strengthened TB prevention program among refugees with due consideration of identified predictor factors to prevent the potential effect of hosting refugee to the SCs and the nations at large.	[Ejeta, Eyasu; Balay, Getu; Bonsa, Zegeye; Abebe, Gemeda] Jimma Univ, Mycobacteriol Res Ctr, Jimma, Ethiopia; [Ejeta, Eyasu; Beyene, Getenet; Abebe, Gemeda] Jimma Univ, Dept Med Lab Sci & Pathol, Fac Hlth Sci, Jimma, Ethiopia; [Ejeta, Eyasu] Wollega Univ, Dept Med Lab Sci, Coll Med & Hlth Sci, Nekemte, Ethiopia	Jimma University; Jimma University	Ejeta, E (corresponding author), Jimma Univ, Mycobacteriol Res Ctr, Jimma, Ethiopia.; Ejeta, E (corresponding author), Jimma Univ, Dept Med Lab Sci & Pathol, Fac Hlth Sci, Jimma, Ethiopia.; Ejeta, E (corresponding author), Wollega Univ, Dept Med Lab Sci, Coll Med & Hlth Sci, Nekemte, Ethiopia.	eyasu.ejeta@gmail.com	Abebe, Gemeda/AAB-8789-2019; Ejeta, Eyasu/A-9493-2019	Abebe, Gemeda/0000-0002-7172-9136; Ejeta, Eyasu/0000-0001-7999-9440	Jimma University Mega Research Project; Jimma University Research Grant	Jimma University Mega Research Project; Jimma University Research Grant	Funding for this work was secured from Jimma University Mega Research Project. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This research is part of a mega research project on Tuberculosis among refugees, and its impact in the surrounding communities in Ethiopia. It was funded by Jimma University Research Grant. The funding agents had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abebe Y, 2003, AIDS, V17, P1835, DOI 10.1097/00002030-200308150-00013; Administration for refuge and returnee affairs (ARRA), 2011, CLIM CHANG AD PROGR; Bao Q S, 2007, BMC PUBLIC HEALTH, V7, P344, DOI DOI 10.1186/; Belay M, 2015, GLOBAL HEALTH ACTION, V8, P1, DOI 10.3402/gha.v8.27949; Berhe G, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-537; Boccia D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020824; Bodiang CK, 2000, SCOT MED J, V45, P25, DOI 10.1177/00369330000450S112; Borgdorff MW, 2000, INT J TUBERC LUNG D, V4, P123; Dangisso MH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125135; Dogar OF, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-244; Eshetie S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194675; Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537; Federal Ministry of Health of Ethiopia, 2010, NAT TRAIN PACK PROV; Federal Ministry of Health of Ethiopia (FMoH), 2011, NAT TB LEPR CONTR PR; Gebrezgabiher G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150560; Gelaw M, 2001, East Afr Med J, V78, P382; Getahun B, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-127; Gosoniu GD, 2008, INT J TUBERC LUNG D, V12, P848; Hamusse SD, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25382; Kimbrough W, 2012, LANCET INFECT DIS, V12, P950, DOI 10.1016/S1473-3099(12)70225-6; Lillebaek T, 2002, EMERG INFECT DIS, V8, P679, DOI 10.3201/eid0807.010482; Melese Addisu, 2016, Tuberc Res Treat, V2016, P1354356, DOI 10.1155/2016/1354356; Minetti A, 2010, INT J TUBERC LUNG D, V14, P1589; Muniyandi M, 2006, J Commun Dis, V38, P204; Muniyandi M, 2008, EXPERT OPIN PHARMACO, V9, P1623, DOI 10.1517/14656566.9.10.1623 ; Munoz-Sellart M, 2010, INT J TUBERC LUNG D, V14, P973; PORTER J, 1995, T ROY SOC TROP MED H, V89, P241, DOI 10.1016/0035-9203(95)90522-7; RIEDER HL, 1994, EUR RESPIR J, V7, P1545, DOI 10.1183/09031936.94.07081545; Rutta E, 2001, INT J TUBERC LUNG D, V5, P628; SHEARS P, 1984, TUBERCLE, V65, P111, DOI 10.1016/0041-3879(84)90062-X; Sisay Solomon, 2014, BMC Res Notes, V7, P44, DOI 10.1186/1756-0500-7-44; SUKRAKANCHANATRIKHAM P, 1992, TUBERCLE LUNG DIS, V73, P384, DOI 10.1016/0962-8479(92)90045-L; Tadesse S., 2014, Health, V6, P306, DOI 10.4236/health.2014.65044; Tessema B, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-371; UNHCR, 2017, REF AS SEEK ETH; United Nations High Commissioner for Refugees (UNHCR), 2015, GLOB APP 2014 2015; van Hest R, 2013, EUR RESPIR J, V41, P635, DOI 10.1183/09031936.00030612; Wen YF, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3019-7; World Health Organization, 2021, B WORLD HEALTH ORGAN, DOI DOI 10.2471/BLT.21.286807; Yassin MA, 2004, SCAND J INFECT DIS, V36, P670, DOI 10.1080/00365540410020848	40	18	19	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2018	13	10							e0205468	10.1371/journal.pone.0205468	http://dx.doi.org/10.1371/journal.pone.0205468			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GX4KR	30335777	Green Published, Green Submitted, gold			2023-01-03	WOS:000447701300033
J	Steeg, S; Carr, M; Emsley, R; Hawton, K; Waters, K; Bickley, H; Ness, J; Geulayov, G; Kapur, N				Steeg, Sarah; Carr, Matthew; Emsley, Richard; Hawton, Keith; Waters, Keith; Bickley, Harriet; Ness, Jennifer; Geulayov, Galit; Kapur, Nav			Suicide and all-cause mortality following routine hospital management of self-harm: Propensity score analysis using multicentre cohort data	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; NATIONWIDE MULTICENTER; EMERGENCY-DEPARTMENTS; PSYCHOSOCIAL THERAPY; DEATH; ENGLAND; RISK; REPETITION; CENTERS; PEOPLE	Background Observational studies are suited to examining links between the routine hospital management of self-harm and future suicide and all-cause mortality due to their large scale. However, care must be taken when attempting to infer causal associations in non-experimental settings. Methods Data from the Multicentre Study of Self-Harm in England were used to examine associations between four types of hospital management (specialist psychosocial assessment, general hospital admission, psychiatric outpatient referral and psychiatric admission) following self-harm and risks of suicide and all-cause mortality in the subsequent 12 months. Missing data were handled by multiple imputation and propensity score (PS) methods were used to address observed differences between patients at baseline. Unadjusted, PS stratified and PS matched risk ratios (RRs) were calculated. Results The PSs balanced the majority of baseline differences between treatment groups. Unadjusted RRs showed that all four treatment types were associated with either increased risks or no change in risks of suicide and all-cause mortality within a year. None of the four types of hospital management were associated with lowered risks of suicide or all-cause mortality following propensity score stratification (psychosocial assessment and medical admission) and propensity score matching (psychiatric outpatient referral and psychiatric admission), though there was no longer an increased risk among people admitted to a psychiatric bed. Individuals who self-cut were at an increased risk of death from any cause following psychosocial assessment and medical admission. Medical admission appeared to be associated with reduced risk of suicide in individuals already receiving outpatient or GP treatment for a psychiatric disorder. Conclusions More intensive forms of hospital management following self-harm appeared to be appropriately allocated to individuals with highest risks of suicide and all-cause mortality. PS adjustment appeared to attenuate only some of the observed increased risks, suggesting that either differences between treatment groups remained, or that some treatments had little impact on reducing subsequent suicide or all-cause mortality risk. These findings are in contrast to some previous studies that have suggested psychosocial assessment by a mental health specialist reduces risk of repeat self-harm. Future observational self-harm studies should consider increasing the number of potential confounding variables collected.	[Steeg, Sarah; Carr, Matthew; Bickley, Harriet; Kapur, Nav] Univ Manchester, Ctr Mental Hlth & Safety, Sch Hlth Sci, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Emsley, Richard] Kings Coll London, Inst Psychiat, Biostat & Hlth Informat, London, England; [Hawton, Keith; Geulayov, Galit] Univ Oxford, Ctr Suicide Res, Dept Psychiat, Warneford Hosp, Oxford, England; [Waters, Keith; Ness, Jennifer] Derbyshire Healthcare NHS Fdn Trust, Ctr Self Harm & Suicide Prevent Res, Derby, England; [Kapur, Nav] Greater Manchester Mental Hlth NHS Fdn Trust, Manchester, Lancs, England	University of Manchester; University of London; King's College London; University of Oxford	Steeg, S (corresponding author), Univ Manchester, Ctr Mental Hlth & Safety, Sch Hlth Sci, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.	sarah.steeg@manchester.ac.uk	Emsley, Richard/N-1342-2016; Waters, Keith/AAH-5503-2019	Emsley, Richard/0000-0002-1218-675X; Waters, Keith/0000-0002-5031-0870; Steeg, Sarah/0000-0002-7935-1414; Bickley, Harriet/0000-0002-3756-7137; Ness, Jennifer/0000-0002-7445-4510; Kapur, Nav/0000-0002-3100-3234	National Institute for Health Research (NIHR) [DRF 2013-06-070]	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR))	This study was supported by funding from a National Institute for Health Research (NIHR) (https://www.nihr.ac.uk) Doctoral Research Fellowship (DRF 2013-06-070 to SS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2008, ENGLISH INDICES DEPR; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; BECK RW, 1974, PSYCHOL REP, V34, P445, DOI 10.2466/pr0.1974.34.2.445; Bergen H, 2012, LANCET, V380, P1568, DOI 10.1016/S0140-6736(12)61141-6; Bergen H, 2010, BRIT J PSYCHIAT, V197, P493, DOI 10.1192/bjp.bp.110.077651; Bergen H, 2010, J AFFECT DISORDERS, V127, P257, DOI 10.1016/j.jad.2010.05.001; Birkbak J, 2016, PSYCHOL MED, V46, P3419, DOI 10.1017/S0033291716001872; Carroll R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089944; Chan KY, 2016, BRITISH JOURNAL OF P; Cooper J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003444; Erlangsen A, 2015, LANCET PSYCHIAT, V2, P49, DOI 10.1016/S2215-0366(14)00083-2; Geulayov G, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010538; Griffin E, 2014, NATIONAL REGISTRY OF; Hawton K, 2007, SOC PSYCH PSYCH EPID, V42, P513, DOI 10.1007/s00127-007-0199-7; Hawton K, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012189; Hawton K, 2015, J AFFECT DISORDERS, V175, P147, DOI 10.1016/j.jad.2014.12.062; Hernan MA, 2004, J EPIDEMIOL COMMUN H, V58, P265, DOI 10.1136/jech.2002.006361; Hjorthoj CR, 2014, SOC PSYCH PSYCH EPID, V49, P1357, DOI 10.1007/s00127-014-0860-x; Hunt IM, 2009, PSYCHOL MED, V39, P443, DOI 10.1017/S0033291708003644; Hunter J, 2018, PSYCHIAT RES, V259, P333, DOI 10.1016/j.psychres.2017.09.029; Kanehara A, 2015, BJPSYCH OPEN, V1, P158, DOI 10.1192/bjpo.bp.115.002204; Kapur N, 2015, LANCET PSYCHIAT, V2, P809, DOI 10.1016/S2215-0366(15)00169-8; Kapur N, 2013, BRIT J PSYCHIAT, V202, P326, DOI 10.1192/bjp.bp.112.116111; Karasouli E, 2015, CRISIS, V36, P65, DOI 10.1027/0227-5910/a000285; Kawanishi C, 2014, LANCET PSYCHIAT, V1, P193, DOI 10.1016/S2215-0366(14)70259-7; Large MM, 2014, SOC PSYCH PSYCH EPID, V49, P1353, DOI 10.1007/s00127-014-0912-2; Larkin GL, 2010, CRISIS, V31, P1, DOI 10.1027/0227-5910/a000001; NICE, 2013, SELF HARM LONGER TER; NICE, 2011, CLINICAL GUIDELINE 1; Olfson M, 2017, AM J PSYCHIAT, V174, P765, DOI 10.1176/appi.ajp.2017.16111288; Ougrin D, 2013, ARCH DIS CHILD, V98, P772, DOI 10.1136/archdischild-2012-303200; Owens D, 2002, BRIT J PSYCHIAT, V181, P193, DOI 10.1192/bjp.181.3.193; Rajapakse T, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-331; Riblet NBV, 2017, BRIT J PSYCHIAT, V210, P396, DOI 10.1192/bjp.bp.116.187799; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; StataCorp, 2013, PANCREATOLOGY; StataCorp, STAT MULT IMP REF MA; Steeg S, 2018, Psychol Med, V48, P315, DOI 10.1017/S0033291717001702; Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313; Ting SA, 2012, GEN HOSP PSYCHIAT, V34, P557, DOI 10.1016/j.genhosppsych.2012.03.020; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; World Health Organization, 2014, PREVENTING SUICIDE A; World Health Organization, INT STAT CLASS DIS R	44	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 27	2018	13	9							e0204670	10.1371/journal.pone.0204670	http://dx.doi.org/10.1371/journal.pone.0204670			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GV2HB	30261030	Green Published, gold			2023-01-03	WOS:000445907400087
J	Watts, L				Watts, Lucy			Stepping up to adult services	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												lucyalexandriawatts@hotmail.co.uk							0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	2018	362								k3886	10.1136/bmj.k3886	http://dx.doi.org/10.1136/bmj.k3886			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GV6MJ	30257916	Bronze			2023-01-03	WOS:000446225200004
J	Costa, HTMD; Costa, TX; Martins, RR; Oliveira, AG				Matias de Lima Costa, Haline Tereza; Costa, Tatiana Xavier; Martins, Rand Randall; Oliveira, Antonio Gouveia			Use of off-label and unlicensed medicines in neonatal intensive care	PLOS ONE			English	Article							DRUG-USE; HOSPITALIZED CHILDREN; MEDICATION USE; UNIT; PATTERNS	Purpose To evaluate the use of off-label and unlicensed medicines in a neonatal intensive care unit (NICU) of a teaching maternity hospital specialized in high risk pregnancy. Methods A prospective cohort study was conducted between August 2015 and July 2016. All new-borns admitted to the NICU who had at least one medication prescribed and a hospital stay longer than 24 hours were included. The classification of off-label and unlicensed drugs for the neonatal population was done according to the information of Food and Drug Administration. Results A total of 17421 medication items were analyzed in 3935 prescriptions of 220 newborns. The proportion of newborns exposed to off-label drugs was 96.4%, and to unlicensed medicines was 66.8%. About one-half (49.3%) of the medication items were off-label and 24.6% were unlicensed. The main reason for off-label and unlicensed classification was, respectively, frequency of administration and the administration of adaptations of pharmaceutical forms. Conclusions Although there are actions to encourage the development of pharmacological studies with neonates, this study observed a high rate of prescription and exposure of newborns to off-label and unlicensed drugs in NICUs and pointed out areas of neonatal therapy that require scientific investment.	[Matias de Lima Costa, Haline Tereza] Univ Fed Rio Grande do Norte, Hlth Sci Ctr, Pharm Dept, Integrated Multiprofess Hlth Residency Program Ne, Natal, RN, Brazil; [Costa, Tatiana Xavier] Univ Fed Rio Grande do Norte, Hlth Sci Ctr, Sch Matern Januario Cicco, Natal, RN, Brazil; [Martins, Rand Randall; Oliveira, Antonio Gouveia] Univ Fed Rio Grande do Norte, Hlth Sci Ctr, Pharm Dept, Natal, RN, Brazil; [Matias de Lima Costa, Haline Tereza] Univ Fed Rio Grande do Norte, Fac Farm, Ctr Ciencias Saude, Natal, RN, Brazil	Universidade Federal do Rio Grande do Norte; Universidade Federal do Rio Grande do Norte; Universidade Federal do Rio Grande do Norte; Universidade Federal do Rio Grande do Norte	Costa, HTMD (corresponding author), Univ Fed Rio Grande do Norte, Hlth Sci Ctr, Pharm Dept, Integrated Multiprofess Hlth Residency Program Ne, Natal, RN, Brazil.; Costa, HTMD (corresponding author), Univ Fed Rio Grande do Norte, Fac Farm, Ctr Ciencias Saude, Natal, RN, Brazil.	halinetcosta@gmail.com	Costa, Maria Fernanda Furtado de Lima e/ABE-3779-2021; Martins, Rand Randall/X-8188-2019	Costa, Maria Fernanda Furtado de Lima e/0000-0002-3474-2980; Martins, Rand Randall/0000-0001-9668-0482; Xavier da Costa, Tatiana/0000-0003-4306-981X				Aamir M, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1211-y; Allegaert K, 2014, NEONATOLOGY, V105, P344, DOI 10.1159/000360648; Anand KJS, 2007, PEDIATRICS, V119, P605, DOI 10.1542/peds.2006-2723; Aranda JV, 2005, CLIN THER, V27, P877, DOI 10.1016/j.clinthera.2005.06.019; Balain M, 2013, PAEDIAT CHILD HLTH, V24, P17; Blanco-Reina E, 2015, MED INTENSIVA, V40, P1; Camacho-Gonzalez A, 2013, PEDIATR CLIN N AM, V60, P367, DOI 10.1016/j.pcl.2012.12.003; Clark RH, 2006, PEDIATRICS, V117, P1979, DOI 10.1542/peds.2005-1707; Conroy S, 1999, ARCH DIS CHILD-FETAL, V80, pF142, DOI 10.1136/fn.80.2.F142; Conroy S, 2011, ARCH DIS CHILD, V96, P305, DOI 10.1136/adc.2010.191940; Cuzzolin L., 2014, J PEDIAT NEONAT INDI, V3, P1; de Souza AS, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0551-8; Dell'Aera M, 2007, PHARM WORLD SCI, V29, P361, DOI 10.1007/s11096-006-9081-z; Dessi A, 2010, PHARM WORLD SCI, V32, P120, DOI 10.1007/s11096-009-9356-2; Di Paolo Ermindo R, 2006, Swiss Med Wkly, V136, P218; Du W, 2006, AM J PERINAT, V23, P279, DOI 10.1055/s-2006-946719; Flint RB, 2018, BRIT J CLIN PHARMACO, V84, P1313, DOI 10.1111/bcp.13563; Flor-De-Lima F, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/643246; Food and Drug Administration, FOOD DRUG ADM MOD AC; Giacoia GP, 2012, CLIN PERINATOL, V39, P11, DOI 10.1016/j.clp.2011.12.016; Hsieh EM, 2014, AM J PERINAT, V31, P811, DOI 10.1055/s-0033-1361933; Hsien L, 2008, PHARM WORLD SCI, V30, P497, DOI 10.1007/s11096-008-9193-8; Institute for Safe Medication Practices, ISMP LIST HIGH AL ME; Kieran EA, 2014, ACTA PAEDIATR, V103, pE139, DOI 10.1111/apa.12541; Krzyzaniak N, 2016, J CLIN PHARM THER, V41, P612, DOI 10.1111/jcpt.12440; Krzyzaniak N, 2017, INT J PHARM PRACT, V25, P107, DOI 10.1111/ijpp.12284; Laforgia N, 2014, PEDIATR INT, V56, P57, DOI 10.1111/ped.12190; Lass J, 2011, EUR J CLIN PHARMACOL, V67, P1263, DOI 10.1007/s00228-011-1072-x; Lee JL, 2013, INT J CLIN PHARM-NET, V35, P1025, DOI 10.1007/s11096-013-9846-0; Neubert A, 2010, EUR J CLIN PHARMACOL, V66, P87, DOI 10.1007/s00228-009-0722-8; O'Donnell CPF, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e52; Oguz SS, 2012, INT J CLIN PHARM-NET, V34, P136, DOI 10.1007/s11096-011-9604-0; Reuters T, 2016, THOMSON MICROMEDEX D; Santos DB, 2008, EUR J CLIN PHARMACOL, V64, P1111, DOI 10.1007/s00228-008-0543-1; Shah SS, 2007, ARCH PEDIAT ADOL MED, V161, P282, DOI 10.1001/archpedi.161.3.282; Stafford RS, 2008, NEW ENGL J MED, V358, P1427, DOI 10.1056/NEJMp0802107; Tayman Cuneyt, 2011, J Pediatr Pharmacol Ther, V16, P170, DOI 10.5863/1551-6776-16.3.170; Wiles JR, 2013, J PEDIATR-US, V162, P12, DOI 10.1016/j.jpeds.2012.08.034	38	25	28	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2018	13	9							e0204427	10.1371/journal.pone.0204427	http://dx.doi.org/10.1371/journal.pone.0204427			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GU9BO	30252920	Green Published, gold, Green Submitted			2023-01-03	WOS:000445639700051
J	Nash, D; Robertson, MM; Penrose, K; Chamberlin, S; Robbins, RS; Braunstein, SL; Myer, JE; Abraham, B; Kulkarni, S; Waldron, L; Levin, B; Irvine, MK				Nash, Denis; Robertson, McKaylee M.; Penrose, Kate; Chamberlin, Stephanie; Robbins, Rebekkah S.; Braunstein, Sarah L.; Myer, Julie E.; Abraham, Bisrat; Kulkarni, Sarah; Waldron, Levi; Levin, Bruce; Irvine, Mary K.			Short-term effectiveness of HIV care coordination among persons with recent HIV diagnosis or history of poor HIV outcomes	PLOS ONE			English	Article							VIRAL LOAD SUPPRESSION; NEW-YORK-CITY; CASE-MANAGEMENT; ANCILLARY SERVICES; INFECTED PERSONS; RANDOMIZED-TRIAL; HOUSING STATUS; UNITED-STATES; MEDICAL-CARE; RETENTION	The New York City HIV Care Coordination Program (CCP) combines multiple evidence-based strategies to support persons living with HIV (PLWH) at risk for, or with a recent history of, poor HIV outcomes. We assessed the comparative effectiveness of the CCP by merging programmatic data on CCP clients with population-based surveillance data on all New York City PLWH. A non-CCP comparison group of similar PLWH who met CCP eligibility criteria was identified using surveillance data. The CCP and non-CCP groups were matched on propensity for CCP enrollment within four baseline treatment status groups (newly diagnosed or previously diagnosed and either consistently unsuppressed, inconsistently suppressed or consistently suppressed). We compared CCP to non-CCP proportions with viral load suppression at 12-month follow-up. Among the 13,624 persons included, 15.3% were newly diagnosed; among the 84.7% previously diagnosed, 14.2% were consistently suppressed, 28.9% were inconsistently suppressed, and 41.6% were consistently unsuppressed in the year prior to baseline. At 12-month follow-up, 59.9% of CCP and 53.9% of non-CCP participants had viral load suppression (Relative Risk = 1.11, 95% CI:1.08-1.14). Among those newly diagnosed and those consistently unsuppressed at baseline, the relative risk of viral load suppression in the CCP versus non-CCP participants was 1.15 (95%CI:1.09-1.23) and 1.32 (95%CI:1.23-1.42), respectively. CCP exposure shows benefits over no CCP exposure for persons newly diagnosed or consistently unsuppressed, but not for persons suppressed in the year prior to baseline. We recommend more targeted case finding for CCP enrollment and increased attention to viral load suppression maintenance.	[Nash, Denis; Robertson, McKaylee M.; Kulkarni, Sarah; Waldron, Levi] CUNY, Inst Implementat Sci Populat Hlth, New York, NY 10021 USA; [Nash, Denis; Robertson, McKaylee M.; Kulkarni, Sarah; Waldron, Levi] CUNY, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10021 USA; [Penrose, Kate; Chamberlin, Stephanie; Robbins, Rebekkah S.; Braunstein, Sarah L.; Myer, Julie E.; Abraham, Bisrat; Irvine, Mary K.] New York City Dept Hlth & Mental Hyg, Bur HIV AIDS, New York, NY USA; [Myer, Julie E.] Columbia Univ Coll Phys & Surg, Div Infect Dis, Dept Med, 630 W 168th St, New York, NY 10032 USA; [Levin, Bruce] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA	City University of New York (CUNY) System; City University of New York (CUNY) System; New York City Department of Health & Mental Hygiene; Columbia University; Columbia University	Nash, D (corresponding author), CUNY, Inst Implementat Sci Populat Hlth, New York, NY 10021 USA.; Nash, D (corresponding author), CUNY, Grad Sch Publ Hlth & Hlth Policy, New York, NY 10021 USA.	denis.nash@sph.cuny.edu	Robertson, McKaylee/GLU-4343-2022; Nash, Denis/AFI-7485-2022; Waldron, Levi/H-2967-2019	Robertson, McKaylee/0000-0002-8426-6572; Waldron, Levi/0000-0003-2725-0694; Penrose, Katherine/0000-0002-7808-7439; Nash, Denis/0000-0002-3280-5386	National Institute of Mental Health of the National Institutes of Health [R01 MH101028]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI096299] Funding Source: NIH RePORTER	National Institute of Mental Health of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the National Institute of Mental Health of the National Institutes of Health [grant number R01 MH101028 to DN]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aidala AA, CHAIN 2012 3 REPORT; Aidala AA, 2016, AM J PUBLIC HEALTH, V106, pE1, DOI 10.2105/AJPH.2015.302905; Ashman JJ, 2002, AIDS CARE, V14, pS109, DOI [10.1080/09540120220149993, 10.1080/09540120220149993a]; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Bogart LM, 2012, AIDS EDUC PREV, V24, P1, DOI 10.1521/aeap.2012.24.1.1; Braunstein SL, 2016, JAIDS-J ACQ IMM DEF, V73, P222, DOI 10.1097/QAI.0000000000001052; Centers for Disease Control and Prevention, 2016, 4 CDCP; Charania MR, 2014, AIDS BEHAV, V18, P646, DOI 10.1007/s10461-013-0594-x; Cohen Stacy M., 2011, Morbidity and Mortality Weekly Report, V60, P1618; Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198; Finitsis DJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088166; Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243; Gardner LI, 2005, AIDS, V19, P423, DOI 10.1097/01.aids.0000161772.51900.eb; Gardner LI, 2014, CLIN INFECT DIS, V59, P725, DOI 10.1093/cid/ciu357; Hanna DB, 2016, AIDS RES HUM RETROV, V32, P955, DOI 10.1089/aid.2015.0345; Higa DH, 2012, CURR HIV-AIDS REP, V9, P313, DOI 10.1007/s11904-012-0136-6; HOOVER DR, 1991, STAT MED, V10, P1993, DOI 10.1002/sim.4780101212; Irvine MK, 2017, AIDS BEHAV, V21, P1572, DOI 10.1007/s10461-016-1460-4; Irvine MK, 2015, CLIN INFECT DIS, V60, P298, DOI 10.1093/cid/ciu783; Kushel MB, 2006, CLIN INFECT DIS, V43, P234, DOI 10.1086/505212; Lehrman SE, 2001, AIDS CARE, V13, P481, DOI 10.1080/09540120120058012; Lo W, 2002, AIDS CARE, V14, pS45, DOI 10.1080/0954012022014992049984; Milloy MJ, 2012, CURR HIV-AIDS REP, V9, P364, DOI 10.1007/s11904-012-0137-5; Nel A, 2011, AIDS CARE, V23, P1360, DOI 10.1080/09540121.2011.565025; New York City Department of Health and Mental Hygiene, HIV CAR COORD; New York City Department of Health and Mental Hygiene, 2015, HIV SURV ANN REP 201; New York State Department of Health, 2015, BLUEPR END EP; Parsons LS, PERFORMING 1 N CASE; Pati R, 2017, J PUBLIC HEALTH MAN, V23, P564, DOI 10.1097/PHH.0000000000000515; Perlman DC, 2017, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00296; Risher KA, 2017, AIDS BEHAV, P1; Robertson MM, 2018, AM J EPIDEMIOL, V187, P1980, DOI 10.1093/aje/kwy103; Sabharwal C, 2013, COUNC STA TERR EP CS; Sherer R, 2002, AIDS CARE, V14, pS31, DOI 10.1080/09540120220149975; Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313; Torian LV, 2014, AM J PUBLIC HEALTH, V104, pE24, DOI 10.2105/AJPH.2014.302080; Willis S, 2013, JAIDS-J ACQ IMM DEF, V64, pS33, DOI 10.1097/QAI.0b013e3182a99b67; Wohl DA, 2011, AIDS BEHAV, V15, P356, DOI 10.1007/s10461-010-9843-4; Xia Q, 2016, JAIDS-J ACQ IMM DEF, V72, P552, DOI 10.1097/QAI.0000000000001008	39	11	11	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2018	13	9							e0204017	10.1371/journal.pone.0204017	http://dx.doi.org/10.1371/journal.pone.0204017			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GV3MI	30248136	Green Submitted, Green Published, gold			2023-01-03	WOS:000445998100020
J	Spyropoulos, AC; Ageno, W; Albers, GW; Elliott, CG; Halperin, JL; Hiatt, WR; Maynard, GA; Steg, PG; Weitz, JI; Suh, E; Spiro, TE; Barnathan, ES; Raskob, GE; Jure, H; Alvarisqueta, A; Cartasegna, L; Hominal, M; Cursack, G; Alzogaray, M; Maillo, M; Parody, M; Caccavo, A; Dran, RD; Muntaner, JA; Casas, M; Schmidberg, J; Sarjanovich, R; Gabito, A; Garrido, M; Amuchastegui, M; Fernandez, A; Loureyro, J; Giumelli, C; Heazlewood, V; Karrasch, J; Colquhoun, D; White, H; Sabet, A; Bowler, S; Carroll, P; Khalafallah, A; Baker, R; Hedger, S; Simpson, FG; Jackson, D; Chong, B; Eichinger-Hasenauer, S; Siostrzonek, P; Gary, T; Hoppe, U; Dosta, N; Krivenchuk, V; Prystrom, A; Gorokhovsky, S; Yanushko, V; Skrahin, A; Kulik, A; Maslianski, B; Yakubtsevich, R; Timkin, I; Moguchaya, O; Tanaskovic, N; Miljkovic, S; Stojkovic, S; Kovacevic-Preradovic, T; Jovic, D; Basagic, E; Radjen, M; Mutapcic, M; Rizvanovic-Vojic, E; Galic, K; Terzic, I; Pojskic, B; Stevanovic, D; Cehajic, M; Trbojevic, S; Rech, R; Annichino-Bizzacchi, J; Stelmach, R; Blanco, D; Castro, I; Backes, LM; Saraiva, JF; Ramacciotti, E; de Barros e Silva, PGM; Reis, G; Vieira, EM; Leaes, P; Zimmermann, S; Van Bellen, B; Precoma, D; Silvestrini, TL; Hernandes, ME; Kyoleyan, M; Kalinova, T; Tiholov, R; Petrov, I; Mihov, A; Chompalova, B; Velikov, C; Pencheva, G; Atanasov, P; Raev, D; Kinova, E; Peltegov, V; Marchev, S; Mincheva, V; Siulemezova, S; Ayryanova, ID; Grigorov, M; Naydenova, I; Koteva, N; Dimov, B; Runev, N; Getov, D; Metev, H; Donchev, K; Taseva, M; Hadzhieva, A; Benov, H; Stoyanov, M; Tisheva-Gospodinova, S; Mihaylova, N; Abadzhiev, S; Atzev, B; Georgiev, R; Mollov, M; Stoikov, A; Mazhdrakov, G; Karastanev, K; Dube, F; Roth, S; Mansour, S; Carrier, M; Wu, C; Dolan, S; Pesant, Y; Pietrangelo, M; Dresser, G; Kahn, S; Kruisselbrink, R; Bonfanti, AC; Botero, R; Ossa, AQ; Poveda, CM; Cedano, J; Isaza, LG; Torres, CV; Mesa, JG; Alonso, RV; Espinosa, D; Rodriguez, JM; Sanchez, G; Mendoza, JLA; Florez, CCG; Millan, FC; Pesek, K; Horvat, D; Fuckar, K; Tudoric, N; Ruzic, A; Ostricki, B; Knezevic, A; Breitenfeld, T; Laganovic, M; Samodol, A; Sikic, J; Starcevic, B; Babic, Z; Samarzija, M; Milas, K; Votocek, S; Kvapil, M; Spinar, J; Kolman, P; Bindas, P; Simon, V; Adamek, T; Svobodova, J; Gergely, L; Lastuvka, J; Macel, I; Navratil, K; Gregor, P; Lacnak, B; Janousek, J; Kellnerova, I; Hulinsky, V; Matusek, Z; Prucek, L; Dunaj, M; Pirchala, M; Vencour, D; Pavolko, M; Gorican, K; Fiksa, J; Tuxen, C; Meyer, C; Ulrik, CS; Marandi, T; Uuetoa, T; Shaburishvili, T; Otarishvili, N; Khintibidze, I; Emukhvari, N; Kipiani, Z; Gochitashvili, D; Mamatsashvili, M; Megreladze, I; Paposhvili, K; Agladze, R; Eradze, Z; Chelidze, K; Lominadze, S; Chukhrukidze, A; Chumburidze, V; Metreveli, S; Danelia, V; Orjonikidze, S; Kobulia, B; Nikolaishvili, G; Gvenetadze, R; Melia, A; Tsinamdzgvrishvili, B; Sekhniashvili, M; Sikharulidze, I; Meuser, M; Licka, M; Beyer-Westendorf, J; Rauch-Kroehnert, U; Graf, K; Brachmann, J; Akin, I; Toumbis, M; Vassilikos, V; Konstantinides, S; Steiropoulos, P; Gogos, C; Andrikopoulos, G; Parthenakis, F; Karydi, P; Tsivgoulis, G; Mertzanos, G; Olympios, C; Karapanayiotides, T; Paraskevopoulou, E; Kifnidis, K; Hahalis, G; Skoutelis, A; Vadikolias, K; Nyirati, G; Nagy, L; Matoltsy, A; Komoly, S; Lippai, J; Kiss, K; Kalman, T; Pozsegovits, K; Csaba, K; Bereczki, D; Zolyomi, S; Boda, Z; Szakal, I; Pall, D; Futo, L; Forster, T; Lovasz, O; Papp, A; Kiraly, Z; Pozsonyi, Z; Hajko, E; Kristof, P; Lakatos, F; Zsolt, P; Kirschner, R; Lupkovics, G; Timar, G; Pinter, I; Kristof, T; Kis, E; Kovacs, A; Jakab, G; Palinkas, A; Muller, G; Turi, T; Horvath, C; Kondakor, I; Csanyi, A; Frankfurter, Z; Gurzo, M; Gafter-Gvili, A; Kuchuk, M; Azzam, Z; Elis, A; Halabi, M; Hussein, O; Blum, A; Tsoran-Rosenthal, I; Lishner, M; Hochberg-Klein, S; Caraco, Y; Atar, S; Elias, N; Gavish, D; Butnaru, A; Cosmi, F; Garbelotto, R; Pierfranceschi, MG; Simioni, L; Gronda, E; Pesci, A; D'Angelo, A; Fedele, F; Ghirarduzzi, A; Piovaccari, G; Lembo, G; Ria, L; Monaco, GL; Brunelli, C; Tosetto, A; Capucci, A; Zanatta, N; Pistolesi, M; Mazzi, V; Testa, S; Scherillo, M; Di Biase, M; Antonicelli, R; Lodigiani, C; Nassiacos, D; Krievins, D; Viksne, I; Lapkovska, Z; Rancane, G; Sime, I; Pontaga, N; Eglite, R; Puzule, S; Smolova, R; Butkiene, Z; Bagdonas, A; Raugaliene, R; Norkiene, S; Norviliene, R; Petrauskiene, B; Basijokiene, V; Stonkus, S; Griskeviciene, V; Miskiniene, A; Norvaisiene, R; Skripkauskiene, I; Jovkovska-Kaeva, B; Kochovska-Kamchevska, N; Antovski, A; Nechevska, L; Celeska, V; Ilievska-Poposka, B; Kostojchinoska, M; Donchovska, S; Kedev, S; Kuzmanovski, I; Bushletikj, O; Stojchev, S; Bakrachevski, N; Kuzmanovska, B; Angusheva, T; Esperon, GL; Lopez, HV; Pech, CM; Hernandez, MC; Carrillo, LV; Gans, S; Smulders, S; Swart, H; Middeldorp, S; Boersma, W; Goosens, M; Hovens, M; Semplonius, G; Sohne, M; Osores, JL; Perez, MDS; Rodriguez, A; Oliva, CR; Cotrina, R; Argandona, PB; Yanez, LT; Ayala, CC; Mirek-Bryniarska, E; Goch, A; Skucha, W; Skorski, M; Miekus, P; Szyszka, A; Piotrowski, G; Gniot, J; Czerski, T; Debich, P; Zaluska, R; Bebenek, W; Wozakowska-Kaplon, B; Sciborski, R; Ilkowski, J; Wojnowski, P; Uscinska, E; Gaciong, Z; Bonek, R; Sobkowicz, B; Berkowski, P; Bejgier, K; Polonski, L; Kosior, D; Lata, S; Kolodziej, P; Gessek, J; Kachel, T; Talalaj, M; Musial, J; Lewczuk, J; Krysiak, W; Kucharski, L; Wysokinski, A; Minc, P; Martinez, J; Gregorio, T; Almeida, F; Monteiro, P; Stanciulescu, G; Mercea, CD; Iosipescu, LC; Militaru, C; Ciobotaru, V; Crisu, D; Burca, M; Tudoran, M; Savu, A; Negrean, V; Cojocaru, C; Minescu, B; Popa, V; Blajan, D; Nastase-Melicovici, D; Fruntelata, A; Barbulescu, S; Lukinyh, L; Akhunova, S; Vishneva, E; Semenova, I; Nikolaev, K; Shaydyuk, O; Nilk, R; Shalnev, V; Apartsin, K; Goloshchekin, BM; Shpagina, L; Khlevchuk, T; Arkhipov, M; Malygin, A; Shvarts, Y; Khaisheva, L; Popov, D; Kobalava, Z; Lipchenko, A; Shapovalova, Y; Zrazhevsky, K; Greshnova, I; Maslova, N; Karabenenko, A; Shogenov, Z; Budankova, E; Barbarash, O; Uspenskiy, Y; Kosmacheva, E; Berns, S; Kostenko, V; Zateyshchikov, D; Vishnevsky, A; Boldueva, S; Podzolkov, V; Sergeeva, E; Grinshtein, Y; Khrustalev, O; Bugrova, O; Repin, A; Andreev, D; Petrovic, P; Matic, TB; Apostolovic, S; Lazic, Z; Stankovic, D; Stankovic, A; Mitov, V; Sofronic, D; Kopitovic, I; Zdravkovic, V; Joksimovic, Z; Lazovic, N; Petrovic-Stanojevic, N; Ilic, A; Vujadinovic, O; Pencic-Popovic, B; Andjelkovic, N; Sekularac, N; Hinic, S; Radjen, G; Zivkovic, A; Putnikovic, B; Vuckovic, B; Ivanov, I; Babic, R; Van Zyl, L; Hobson, B; Basson, M; Engelbrecht, J; Mitha, I; Siebert, H; Jacobson, B; Breedt, J; Prozesky, H; Ntsekhe, M; Bayat, J; Ellis, G; Tarr, G; Adler, D; Van Dyk, C; Ismail, SM; Spargo, CE; Abdool-Gaffar, M; Saaiman, J; Venter, K; Aroca, MLL; Portales, FF; Navas, JP; Botaro, AR; Siminiani, ASC; Reyes, RL; Company, JBI; Selfa, MP; Garrido, JV; Sobrino-Martinez, J; Delgado, GM; Llinas, ES; Coronado, JB; Bonet, LA; Gutierrez, MV; Lora, FS; Martinez, RS; Calderon, E; Blanch, JV; De la Hera Galarza, JM; Ruiz, AB; Garcia-Fuster, MJ; Vera, TR; Walter, LAS; Parra, JAT; Fernandez, JD; Ojeda, FB; Pellicer-Ciscar, C; Palomares, LJ; Granado, JQ; Bautista, AT; Bustillo, SR; Ros, JO; Tolosa-Vilella, C; Ortuno, FM; Sanchez, FG; Martin, RB; Cubero, JS; Martinez, VCM; Montejano, MG; Meseguer, ML; Comert, SS; Koksal, N; Tertemiz, K; Ernam, D; Dursun, AB; Yildiz, O; Rudenko, L; Abrahamovych, O; Goloborodko, A; Holovchenko, N; Kulyk, A; Yagensky, A; Batushkin, V; Zolotaikina, V; Kozyolkin, O; Faynyk, A; Maslovskyy, V; Petrovskyy, R; Koshlia, V; Chopey, I; Burmak, I; Malynovsky, Y; Voronkov, L; Karpenko, O; Dziublyk, O; Godlevska, O; Borovyk, V; Bezrodna, L; Serik, S; Ovsyannikova, N; Vynnychenko, L; Kopytsya, M; Rudkovskiy, V; Grishyna, O; Vyshnyvetskyy, I; Prystupa, L; Tseluyko, V; Perepeliuk, M; Koval, O; Sychov, O; Church, A; Goudie, A; Elliott, M; Ferguson, C; Welker, J; Kao, CK; Bhagwat, R; Serota, H; Rosenberg, D; Bozorgchami, H; Nambiar, R; Hazelrigg, M; Spilseth, S; Bhagwath, G; Syed, F; Morrow, L; Updegrove, J; Bercz, P; Kambo, V; Henderson, D; Wright, P; Dang, N; Nadar, V; Jaffrani, N; El-Shahawy, M; Grossman, CH; Pearle, J; Weinstein, D; Galanis, TP; Gazmuri, R; Kastelic, R; Martinez, R; Laman, D; Macchiavelli, A; Kmetzo, J; Thurm, C; Kayembe, T; Chandrashekhar, Y; Bassetti, D; Jaoude, P; Williams, H; Dewhurst, R; Naqvi, S; Burr, J; Rodriguez-Cintron, W; Jeanfreau, R; Kosinski, E; Ndukwu, IM; Sotolongo, C; Daboul, N; Wilmer, C; Simon, P; Tak, T; Rees, C; Gupta, N; Lerner, R; Tapson, V; Graffagnino, C; Reed, RM; Alford, CM; Mody, F; Wellmon, B; Hamroff, G; Rajan, R; Kaatz, S				Spyropoulos, Alex C.; Ageno, Walter; Albers, Gregory W.; Elliott, C. Gregory; Halperin, Jonathan L.; Hiatt, William R.; Maynard, Gregory A.; Steg, P. Gabriel; Weitz, Jeffrey I.; Suh, Eunyoung; Spiro, Theodore E.; Barnathan, Elliot S.; Raskob, Gary E.; Jure, Horacio; Alvarisqueta, Andres; Cartasegna, Luis; Hominal, Miguel; Cursack, Guillermo; Alzogaray, Maria; Maillo, Martin; Parody, Maria; Caccavo, Alberto; Dran, R. Dario; Muntaner, Juan Antonio; Casas, Marcelo; Schmidberg, Jorge; Sarjanovich, Rodolfo; Gabito, Andrea; Garrido, Marcelo; Amuchastegui, Marcos; Fernandez, Alberto; Loureyro, Juan; Giumelli, Carla; Heazlewood, Vernon; Karrasch, Jeff; Colquhoun, David; White, Hayden; Sabet, Arman; Bowler, Simon; Carroll, Patrick; Khalafallah, Alhossain; Baker, Ross; Hedger, Stephen; Simpson, Frederick Graham; Jackson, David; Chong Beng; Eichinger-Hasenauer, Sabine; Siostrzonek, Peter; Gary, Thomas; Hoppe, Uta; Dosta, Nikolay; Krivenchuk, Vitaly; Prystrom, Andrei; Gorokhovsky, Sergey; Yanushko, Viachaslav; Skrahin, Aliaksandr; Kulik, Anatoly; Maslianski, Boris; Yakubtsevich, Ruslan; Timkin, Ivan; Moguchaya, Olga; Tanaskovic, Natasa; Miljkovic, Sinisa; Stojkovic, Sanja; Kovacevic-Preradovic, Tamara; Jovic, Darko; Basagic, Edin; Radjen, Mirjana; Mutapcic, Meliha; Rizvanovic-Vojic, Etida; Galic, Kristina; Terzic, Ibrahim; Pojskic, Belma; Stevanovic, Dragan; Cehajic, Mili; Trbojevic, Stevan; Rech, Rafael; Annichino-Bizzacchi, Joyce; Stelmach, Rafael; Blanco, Daniela; Castro, Iran; Backes, Luciano Marcelo; Saraiva, Jose Francisco; Ramacciotti, Eduardo; de Barros e Silva, Pedro Gabriel Melo; Reis, Gilmar; Vieira, Moreira Eduardo; Leaes, Paulo; Zimmermann, Sergio; Van Bellen, Bonno; Precoma, Dalton; Silvestrini, Luiz Tiago; Hernandes, Mauro Esteves; Kyoleyan, Michael; Kalinova, Tanya; Tiholov, Rumen; Petrov, Iliyan; Mihov, Atanas; Chompalova, Boryana; Velikov, Chavdar; Pencheva, Galina; Atanasov, Peter; Raev, Dimitar; Kinova, Elena; Peltegov, Valentin; Marchev, Sotir; Mincheva, Valentina; Siulemezova, Silvia; Ayryanova, Ivaneta Dimitrova; Grigorov, Mladen; Naydenova, Iveta; Koteva, Nadya; Dimov, Bojidar; Runev, Nikolay; Getov, Dimitar; Metev, Hristo; Donchev, Krasimir; Taseva, Margarita; Hadzhieva, Antoaneta; Benov, Haralambi; Stoyanov, Miroslav; Tisheva-Gospodinova, Snezhanka; Mihaylova, Nadya; Abadzhiev, Stefan; Atzev, Borislav; Georgiev, Rosen; Mollov, Mihail; Stoikov, Anastas; Mazhdrakov, Georgi; Karastanev, Krassimir; Dube, Francois; Roth, Sherryn; Mansour, Samer; Carrier, Marc; Wu, Cynthia; Dolan, Sean; Pesant, Yves; Pietrangelo, Maria; Dresser, George; Kahn, Susan; Kruisselbrink, Rebecca; Cadena Bonfanti, Andres; Botero, Rodrigo; Quintero Ossa, Alvaro; Poveda, Claudia Marcela; Cedano, Jorge; Gomez Isaza, Luis; Villaquiran Torres, Claudio; Gomez Mesa, Juan; Vargas Alonso, Ruben; Espinosa, David; Maria Rodriguez, Jose; Sanchez, Gregorio; Accini Mendoza, Jose Luis; Gomez Florez, Carmen Cecilia; Cuervo Millan, Francisco; Pesek, Ksenija; Horvat, Davor; Fuckar, Krunoslav; Tudoric, Neven; Ruzic, Alen; Ostricki, Branko; Knezevic, Aleksandar; Breitenfeld, Tomislav; Laganovic, Mario; Samodol, Ante; Sikic, Jozica; Starcevic, Boris; Babic, Zdravko; Samarzija, Miroslav; Milas, Kresimir; Votocek, Stepan; Kvapil, Milan; Spinar, Jindrich; Kolman, Petr; Bindas, Pavol; Simon, Vladimir; Adamek, Tomas; Svobodova, Jaromira; Gergely, Ladislav; Lastuvka, Jiri; Macel, Igor; Navratil, Karel; Gregor, Pavel; Lacnak, Borek; Janousek, Jiri; Kellnerova, Ivana; Hulinsky, Vaclav; Matusek, Zdenek; Prucek, Lukas; Dunaj, Milan; Pirchala, Marian; Vencour, David; Pavolko, Martin; Gorican, Karel; Fiksa, Jan; Tuxen, Christian; Meyer, Christian; Ulrik, Suppli; Marandi, Toomas; Uuetoa, Tiina; Shaburishvili, Tamaz; Otarishvili, Nino; Khintibidze, Irakli; Emukhvari, Nodar; Kipiani, Zviad; Gochitashvili, David; Mamatsashvili, Merab; Megreladze, Irakli; Paposhvili, Kakhi; Agladze, Rusudan; Eradze, Zviad; Chelidze, Kakhaber; Lominadze, Sulkhan; Chukhrukidze, Archil; Chumburidze, Vakhtang; Metreveli, Shorena; Danelia, Vakhtang; Orjonikidze, Sergo; Kobulia, Bondo; Nikolaishvili, Giorgi; Gvenetadze, Rusudan; Melia, Anzor; Tsinamdzgvrishvili, Bezhan; Sekhniashvili, Marika; Sikharulidze, Ioseb; Meuser, Mario; Licka, Manuela; Beyer-Westendorf, Jan; Rauch-Kroehnert, Ursula; Graf, Kristof; Brachmann, Johannes; Akin, Ibrahim; Toumbis, Michalis; Vassilikos, Vassilios; Konstantinides, Stavros; Steiropoulos, Paschalis; Gogos, Charalambos; Andrikopoulos, Giorgos; Parthenakis, Fragkiskos; Karydi, Panagiota; Tsivgoulis, Georgios; Mertzanos, Georgios; Olympios, Christopher; Karapanayiotides, Theodoros; Paraskevopoulou, Efrosyni; Kifnidis, Konstantinos; Hahalis, George; Skoutelis, Athanasios; Vadikolias, Konstantinos; Nyirati, Gabor; Nagy, Laszlo; Matoltsy, Andras; Komoly, Samuel; Lippai, Jozsef; Kiss, Krisztian; Kalman, Toth; Pozsegovits, Krisztian; Csaba, Kiraly; Bereczki, Daniel; Zolyomi, Szilard; Boda, Zoltan; Szakal, Imre; Pall, Denes; Futo, Laszlo; Forster, Tamas; Lovasz, Orsolya; Papp, Aniko; Kiraly, Zsolt; Pozsonyi, Zoltan; Erik, Hajko; Kristof, Piroska; Lakatos, Ferenc; Zsolt, Ples; Kirschner, Robert; Lupkovics, Geza; Timar, Gyula; Pinter, Istvan; Kristof, Tunde; Kis, Erno; Kovacs, Aranka; Jakab, Gabor; Palinkas, Attila; Mueller, Gabor; Turi, Tibor; Horvath, Csaba; Kondakor, Istvan; Csanyi, Attila; Frankfurter, Zsuzsanna; Gurzo, Mihaly; Gafter-Gvili, Anat; Kuchuk, Michael; Azzam, Zaher; Elis, Avishay; Halabi, Majdi; Hussein, Osamah; Blum, Arnon; Tsoran-Rosenthal, Inna; Lishner, Michael; Hochberg-Klein, Sarit; Caraco, Yoseph; Atar, Shaul; Elias, Nizar; Gavish, Dov; Butnaru, Adi; Cosmi, Franco; Garbelotto, Raffaella; Pierfranceschi, Giorgi; Simioni, Livio; Gronda, Edoardo; Pesci, Alberto; D'Angelo, Armando; Fedele, Francesco; Ghirarduzzi, Angelo; Piovaccari, Giancarlo; Lembo, Giuseppe; Ria, Luigi; Monaco, Giuseppe; Brunelli, Claudio; Tosetto, Alberto; Capucci, Alessandro; Zanatta, Nello; Pistolesi, Massimo; Mazzi, Valeria; Testa, Sophie; Scherillo, Marino; Di Biase, Matteo; Antonicelli, Roberto; Lodigiani, Corrado; Nassiacos, Daniele; Krievins, Dainis; Viksne, Inese; Lapkovska, Zinaida; Rancane, Gita; Sime, Iveta; Pontaga, Natalija; Eglite, Ruta; Puzule, Sarmite; Smolova, Rita; Butkiene, Zita; Bagdonas, Alfredas; Raugaliene, Rasa; Norkiene, Sigute; Norviliene, Rita; Petrauskiene, Birute; Basijokiene, Vida; Stonkus, Sigitas; Griskeviciene, Violeta; Miskiniene, Ausra; Norvaisiene, Rima; Skripkauskiene, Irena; Jovkovska-Kaeva, Biserka; Kochovska-Kamchevska, Nade; Antovski, Antonio; Nechevska, Liljana; Celeska, Violeta; Ilievska-Poposka, Biljana; Kostojchinoska, Mira; Donchovska, Snezhana; Kedev, Sashko; Kuzmanovski, Igor; Bushletikj, Oliver; Stojchev, Sasho; Bakrachevski, Nikola; Kuzmanovska, Biljana; Angusheva, Tanja; Llamas Esperon, Guillermo; Valdez Lopez, Hector; Medina Pech, Carlos; Cortes Hernandez, Miguel; Virgen Carrillo, Luis; Gans, Stephanus; Smulders, Sietske; Swart, Henk; Middeldorp, Saskia; Boersma, Willem; Goosens, Martijn; Hovens, Marcel; Semplonius, Geesje; Sohne, M.; Osores, Lema; Salas Perez, Marcia; Rodriguez, Aldo; Rios Oliva, Carlos; Cotrina, Rosa; Berrospi Argandona, Percy; Toce Yanez, Luis; Chavez Ayala, Carlos; Mirek-Bryniarska, Ewa; Goch, Aleksander; Skucha, Wojciech; Skorski, Marcin; Miekus, Pawel; Szyszka, Andrzej; Piotrowski, Grzegorz; Gniot, Jacek; Czerski, Tomasz; Debich, Piotr; Zaluska, Roman; Bebenek, Waldemar; Wozakowska-Kaplon, Beata; Sciborski, Ryszard; Ilkowski, Jan; Wojnowski, Piotr; Uscinska, Ewa; Gaciong, Zbigniew; Bonek, Robert; Sobkowicz, Bozena; Berkowski, Piotr; Bejgier, Katarzyna; Polonski, Lech; Kosior, Dariusz; Lata, Stanislaw; Kolodziej, Piotr; Gessek, Jacek; Kachel, Tomasz; Talalaj, Marek; Musial, Jacek; Lewczuk, Jerzy; Krysiak, Waldemar; Kucharski, Lech; Wysokinski, Andrzej; Minc, Piotr; Martinez, Jorge; Gregorio, Tiago; Almeida, Filipa; Monteiro, Pedro; Stanciulescu, Gabriela; Mercea, Corina; Iosipescu, Laura; Militaru, Constantin; Ciobotaru, Valentina; Crisu, Daniela; Burca, Mitel; Tudoran, Mariana; Savu, Angelica; Negrean, Vasile; Cojocaru, Cristian; Minescu, Bogdan; Popa, Virgil; Blajan, Daniel; Nastase-Melicovici, Dorel; Fruntelata, Ana; Barbulescu, Sanziana; Lukinyh, Liya; Akhunova, Svetlana; Vishneva, Elena; Semenova, Irina; Nikolaev, Konstantin; Shaydyuk, Oxana; Nilk, Rostislav; Shalnev, Vladimir; Apartsin, Konstantin; Goloshchekin, Boris; Shpagina, Liubov; Khlevchuk, Tatiana; Arkhipov, Mikhail; Malygin, Alexander; Shvarts, Yury; Khaisheva, Larisa; Popov, Dmitry; Kobalava, Zhanna; Lipchenko, Alexander; Shapovalova, Yulia; Zrazhevsky, Konstantin; Greshnova, Irina; Maslova, Natalia; Karabenenko, Alexander; Shogenov, Zaur; Budankova, Ekaterina; Barbarash, Olga; Uspenskiy, Yury; Kosmacheva, Elena; Berns, Svetlana; Kostenko, Victor; Zateyshchikov, Dmitry; Vishnevsky, Alexandr; Boldueva, Svetlana; Podzolkov, Valeriy; Sergeeva, Elena; Grinshtein, Yury; Khrustalev, Oleg; Bugrova, Olga; Repin, Alexey; Andreev, Denis; Petrovic, Predrag; Matic, Tatjana; Apostolovic, Svetlana; Lazic, Zorica; Stankovic, Dusica; Stankovic, Aleksandar; Mitov, Vladimir; Sofronic, Dejan; Kopitovic, Ivan; Zdravkovic, Vladimir; Joksimovic, Zoran; Lazovic, Nada; Petrovic-Stanojevic, Natasa; Ilic, Aleksandra; Vujadinovic, Olivera; Pencic-Popovic, Biljana; Andjelkovic, Nebojsa; Sekularac, Nikola; Hinic, Sasa; Radjen, Goran; Zivkovic, Aleksandar; Putnikovic, Biljana; Vuckovic, Biljana; Ivanov, Igor; Babic, Rade; Van Zyl, Louis; Hobson, Biano; Basson, Matthys; Engelbrecht, Johannes; Mitha, Ismail; Siebert, Heidi; Jacobson, Barry; Breedt, Johannes; Prozesky, Hans; Ntsekhe, Mpiko; Bayat, Junaid; Ellis, Graham; Tarr, Gareth; Adler, David; Van Dyk, Christo; Ismail, S.; Spargo, Catherine; Abdool-Gaffar, Mohamed; Saaiman, Jan; Venter, Karl; Lorente Aroca, Maria; Fernandez Portales, Francisco; Pedrajas Navas, Jose; Rodriguez Botaro, Antonio; Cruz Siminiani, Antonio; Lopez Reyes, Raquel; Bisbe i Company, Josep; Piedecausa Selfa, Mar; Velasco Garrido, Jose; Sobrino-Martinez, Javier; Munoz Delgado, Gregorio; Sala Llinas, Ernest; Blanco Coronado, Jose; Almenar Bonet, Luis; Vida Gutierrez, Manuel; Sanchez Lora, Fernando; Sanchez Martinez, Rosario; Calderon, Enrique; Villalta Blanch, Jaume; De la Hera Galarza, Jesus; Bustamante Ruiz, Ana; Jose Garcia-Fuster, Maria; Ripoll Vera, Tomas; Alvarez-Sala Walter, Luis; Todoli Parra, Jose; Diaz Fernandez, Jose; Bosa Ojeda, Francisco; Pellicer-Ciscar, Concepcion; Jara Palomares, Luis; Quiles Granado, Juan; Trigo Bautista, Alberto; Ruiz Bustillo, Sonia; Ordi Ros, Josep; Tolosa-Vilella, Carles; Marin Ortuno, Francisco; Garcia Sanchez, Florentino; Barba Martin, Raquel; Segovia Cubero, Javier; Cuervas-Mons Martinez, Valentin; Galan Montejano, Miguel; Lopez Meseguer, Manuel; Sener Comert, Sevda; Koksal, Nurhan; Tertemiz, Kemal; Ernam, Dilek; Dursun, Adile; Yildiz, Oznur; Rudenko, Leonid; Abrahamovych, Orest; Goloborodko, Alla; Holovchenko, Nataliia; Kulyk, Anna; Yagensky, Andriy; Batushkin, Valerii; Zolotaikina, Viktoriia; Kozyolkin, Oleksandr; Faynyk, Andriy; Maslovskyy, Valentyn; Petrovskyy, Roman; Koshlia, Volodymyr; Chopey, Ivan; Burmak, Iurii; Malynovsky, Yaroslav; Voronkov, Leonid; Karpenko, Olexandr; Dziublyk, Oleksandr; Godlevska, Olga; Borovyk, Valentyna; Bezrodna, Larysa; Serik, Sergii; Ovsyannikova, Nataliya; Vynnychenko, Lyudmyla; Kopytsya, Mykola; Rudkovskiy, Volodymyr; Grishyna, Olena; Vyshnyvetskyy, Ivan; Prystupa, Lyudmyla; Tseluyko, Vira; Perepeliuk, Mykola; Koval, Olena; Sychov, Oleg; Church, Alistair; Goudie, Andrew; Elliott, Mark; Ferguson, Craig; Welker, James; Kao, Cheng-Kai; Bhagwat, Ravi; Serota, Harvey; Rosenberg, David; Bozorgchami, Hormozd; Nambiar, Rajesh; Hazelrigg, Monica; Spilseth, Sara; Bhagwath, Gayathri; Syed, Faizullah; Morrow, Lee; Updegrove, John; Bercz, Peter; Kambo, Varinder; Henderson, David; Wright, Patrick; Dang, Nguyen; Nadar, Venkatesh; Jaffrani, Naseem; El-Shahawy, Mohamed; Grossman, Colby; Pearle, James; Weinstein, Debra; Galanis, Taki; Gazmuri, Raul; Kastelic, Richard; Martinez, Rafael; Laman, David; Macchiavelli, Anthony; Kmetzo, James; Thurm, Craig; Kayembe, Tshiswaka; Chandrashekhar, Yellapragada; Bassetti, Dennis; Jaoude, Philippe; Williams, Hayes; Dewhurst, Robert; Naqvi, Syed; Burr, John; Rodriguez-Cintron, William; Jeanfreau, Robert; Kosinski, Edward; Ndukwu, Ikeadi; Sotolongo, Carlos; Daboul, Nizar; Wilmer, Charles; Simon, Peter; Tak, Tahir; Rees, Christopher; Gupta, Nishant; Lerner, Robert; Tapson, Victor; Graffagnino, Carmelo; Reed, Robert; Alford, Chad; Mody, Freny; Wellmon, Baxter; Hamroff, Glenn; Rajan, Raj; Kaatz, Scott		MARINER Investigators	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VENOUS THROMBOEMBOLISM; HIGH-RISK; VTE; PREVENTION; HEPARIN; TRIAL	BACKGROUND Patients who are hospitalized for medical illness remain at risk for venous thromboembolism after discharge, but the role of extended thromboprophylaxis in the treatment of such patients is a subject of controversy. METHODS In this randomized, double-blind trial, medically ill patients who were at increased risk for venous thromboembolism on the basis of a modified International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) score of 4 or higher (scores range from 0 to 10, with higher scores indicating a higher risk of venous thromboembolism) or a score of 2 or 3 plus a plasma n-dimer level of more than twice the upper limit of the normal range (defined according to local laboratory criteria) were assigned at hospital discharge to either once-daily rivaroxaban at a dose of 10 mg (with the dose adjusted for renal insufficiency) or placebo for 45 days. The primary efficacy outcome was a composite of symptomatic venous thromboembolism or death due to venous thromboembolism. The principal safety outcome was major bleeding. RESULTS Of the 12,024 patients who underwent randomization, 12,019 were included in the intention-to-treat analysis. The primary efficacy outcome occurred in 50 of 6007 patients (0.83%) who were given rivaroxaban and in 66 of 6012 patients (1.10%) who were given placebo (hazard ratio, 0.76; 95% confidence interval [CI], 0.52 to 1.09; P=0.14). The prespecified secondary outcome of symptomatic nonfatal venous thromboembolism occurred in 0.18% of patients in the rivaroxaban group and 0.42% of patients in the placebo group (hazard ratio, 0.44; 95% CI, 0.22 to 0.89). Major bleeding occurred in 17 of 5982 patients (0.28%) in the rivaroxaban group and in 9 of 5980 patients (0.15%) in the placebo group (hazard ratio, 1.88; 95% CI, 0.84 to 4.23). CONCLUSIONS Rivaroxaban, given to medical patients for 45 days after hospital discharge, was not associated with a significantly lower risk of symptomatic venous thromboembolism and death due to venous thromboembolism than placebo. The incidence of major bleeding was low.	[Spyropoulos, Alex C.] Hofstra Northwell, Donald & Barbara Zucker Sch Med, Feinstein Inst Med Res, New York, NY USA; [Spyropoulos, Alex C.] Northwell Hlth, Lenox Hill Hosp, Anticoagulat & Clin Thrombosis Serv, Dept Med, New York, NY USA; [Halperin, Jonathan L.] Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY 10029 USA; [Ageno, Walter] Univ Insubria, Dept Med & Surg, Varese, Italy; [Albers, Gregory W.] Stanford Univ, Med Ctr, Stanford Stroke Ctr, Stanford, CA 94305 USA; [Maynard, Gregory A.] Univ Calif Davis, Sacramento, CA 95817 USA; [Elliott, C. Gregory] Univ Utah, Dept Med, Intermt Med Ctr, Salt Lake City, UT 84112 USA; [Elliott, C. Gregory] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; [Hiatt, William R.] Univ Colorado, Sch Med, Div Cardiol, Aurora, CO USA; [Hiatt, William R.] CPC Clin Res, Aurora, CO USA; [Steg, P. Gabriel] Univ Paris Diderot, Dept Hosp Univ FIRE Fibrose Inflammat Remodelage, AP HP, Paris, France; [Steg, P. Gabriel] INSERM, Unite 1148, Paris, France; [Steg, P. Gabriel] Imperial Coll, Royal Brompton Hosp, London, England; [Weitz, Jeffrey I.] McMaster Univ, Hamilton, ON, Canada; [Weitz, Jeffrey I.] Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada; [Suh, Eunyoung; Barnathan, Elliot S.] Janssen Res & Dev, Raritan, NJ USA; [Spiro, Theodore E.] Bayer US, Thrombosis & Hematol Therapeut Area, Clin Dev, Pharmaceut, Whippany, NJ USA; [Raskob, Gary E.] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Oklahoma City, OK USA; [Jure, Horacio] Hosp San Roque, Clin Chutro SA, Cordoba, Argentina; [Alvarisqueta, Andres] Ctr Invest Med Mar Plata SRL, Mar Del Plata, Buenos Aires, Argentina; [Cartasegna, Luis] Hosp Italiano La Plata, La Plata, Buenos Aires, Argentina; [Hominal, Miguel] Sanat Med Diagnost, Inst Cardiovasc Rosario, Ctr Invest Clin Litoral SRL, Santa Fe, Argentina; [Cursack, Guillermo] Sanat Esperanza, Esperanza, Santa Fe, Argentina; [Alzogaray, Maria] Hosp Italiano La Plata, Inst Med Platense, La Plata, Buenos Aires, Argentina; [Maillo, Martin] Inst Buen Aire, Santa Fe, Argentina; [Parody, Maria] Hosp San Roque, Ctr Med Colon, Cordoba, Argentina; [Caccavo, Alberto] Clin Coronel Suarez SA, Coronel Suarez, Argentina; [Dran, R. Dario] Sanat Mariano Pelliza ROPHE SA, Munro, Argentina; [Muntaner, Juan Antonio] Ctr Modelo Cardil, San Miguel De Tucuman, Argentina; [Casas, Marcelo] Clin Adventista Belgrano, Ctr Med Respire, Buenos Aires, DF, Argentina; [Schmidberg, Jorge] Inst Med Aguero, Moron, Argentina; [Sarjanovich, Rodolfo] HOSP CORDOBA, Cordoba, Argentina; [Gabito, Andrea] Sanat Mujer, Cibic, Cent Invest Clin Argentina, Alvear Ctr Med, Rosario, Santa Fe, Argentina; [Garrido, Marcelo] Clin Privada Prov SA Merlo, Merlo, Argentina; [Amuchastegui, Marcos] Hosp Privado Ctr Med Cordoba, Cordoba, Argentina; [Fernandez, Alberto] Sanat Modelo Quilmes, Quilmes, Argentina; [Loureyro, Juan] Inst Caici, Rosario, Santa Fe, Argentina; [Giumelli, Carla] Inst Cardiol JF Cabral, Corrientes, Argentina; [Heazlewood, Vernon] Caboolture Private Hosp, Morayfield, Australia; [Karrasch, Jeff] Holy Spirit Northside, Chermside, Australia; [Colquhoun, David] Core Res Pty Ltd, Milton, Australia; [White, Hayden] Logan Hosp, Meadowbank, Australia; [Sabet, Arman] Gold Coast Univ Hosp, Southport, Qld, Australia; [Bowler, Simon] Mater Hlth Serv, South Brisbane, Australia; [Carroll, Patrick] Redcliffe Hosp, Monash Hlth Corp Off, Redcliffe, Australia; [Khalafallah, Alhossain] Launceston Gen Hosp, Launceston, Tas, Australia; [Baker, Ross] Royal Perth Hosp, Perth Blood Inst, Nedlands, WA, Australia; [Baker, Ross] Royal Perth Hosp, Perth Blood Inst, Perth, WA, Australia; [Hedger, Stephen] Flinders Med Ctr, Bedford Pk, SA, Australia; [Simpson, Frederick Graham] Cairns Base Hosp, Cairns, Australia; [Jackson, David] Lismore Base Hosp, Lismore, NSW, Australia; [Chong Beng] St George Hosp, Kogarah, NSW, Australia; [Chong Beng] St George Hosp, Sydney, NSW, Australia; [Eichinger-Hasenauer, Sabine] Med Univ Vienna, Univ Klin Innere Med 1, AKH Wien, Vienna, Austria; [Siostrzonek, Peter] Krankenhaus Barmherzigen Schwestern, Ordensklinikum Linz, Linz, Austria; [Gary, Thomas] LKH Univ Klinikum Graz, Graz, Austria; [Hoppe, Uta] Univ Klin Salzburg, Salzburg, Austria; [Dosta, Nikolay] Minsk Reg Clin Hosp, Minsk, BELARUS; [Krivenchuk, Vitaly] Republican Res Ctr Radiat Med & Human E, Republican Res Ctr, Gomel, BELARUS; [Prystrom, Andrei] City Clin Hosp 1, Minsk, BELARUS; [Gorokhovsky, Sergey] Gomel Reg Clin Cardiol Dispensary, Gomel, BELARUS; [Yanushko, Viachaslav] Republican Sci Clin Ctr Cardiol, Minsk, BELARUS; [Skrahin, Aliaksandr] Republic Res & Pract Ctr Pulmonol & TB, Minsk, BELARUS; [Kulik, Anatoly] Mogilev Reg Hosp, Mogilev, BELARUS; [Maslianski, Boris] Gomel Reg Hosp, Gomel Reg Clin Hosp, Gomel, BELARUS; [Yakubtsevich, Ruslan] Grodno Reg Clin Hosp, Grodno, BELARUS; [Timkin, Ivan] Vitebsk Reg Clin Hosp, Vitebsk, BELARUS; [Moguchaya, Olga] Brest Reg Hosp, Brest, BELARUS; [Tanaskovic, Natasa; Miljkovic, Sinisa; Stojkovic, Sanja; Kovacevic-Preradovic, Tamara; Jovic, Darko; Trbojevic, Stevan] Univ Clin Ctr Republ Srpska, Banja Luka, Bosnia & Herceg; [Basagic, Edin; Rizvanovic-Vojic, Etida] Cantonal Hosp Dr Irfan Ljubijankic, Bihac, Bosnia & Herceg; [Radjen, Mirjana] Univ Hosp Foca, Foca, Bosnia & Herceg; [Mutapcic, Meliha; Pojskic, Belma] Cantonal Hosp Zenica, Zenica, Bosnia & Herceg; [Galic, Kristina; Cehajic, Mili] Univ Clin Hosp Mostar, Mostar, Bosnia & Herceg; [Terzic, Ibrahim] BH Heart Ctr Tuzla, Tuzla, Bosnia & Herceg; [Stevanovic, Dragan] Gen Hosp Prim Dr Abdulah Nakas, Sarajevo, Bosnia & Herceg; [Rech, Rafael] Hosp Univ Mae De Deus Canoas, Canoas, Brazil; [Annichino-Bizzacchi, Joyce] Univ Estadual Campinas, Hemoctr, Campinas, SP, Brazil; [Stelmach, Rafael] Univ Sao Paulo, Hosp Clin, Fac Med, Heart Inst InCor, Sao Paulo, Brazil; [Blanco, Daniela] Pontificia Univ Cat, Hosp Sao Lucas PUCRS, Uniao Brasileira Educ &, Porto Alegre, RS, Brazil; [Castro, Iran] Fundacao Univ Cardiol, Inst Cardiol, Porto Alegre, RS, Brazil; [Backes, Luciano Marcelo] Hosp Sao Vicente Paulo, Bioserv SMO, Passo Fundo, RS, Brazil; [Saraiva, Jose Francisco] Univ Fed Pernambuco, Hosp & Maternidade Celso Pierro PUC Campinas, Campinas, SP, Brazil; [Ramacciotti, Eduardo] Hosp & Maternidade Dr Christovao da Gama, Santo Andre, Brazil; [de Barros e Silva, Pedro Gabriel Melo] Hosp TotalCor, Sao Paulo, Brazil; [Reis, Gilmar] Fundacao Hosp Sao Francisco Assis, Santa Casa Belo Horizonte, CARDRES Cardiol Assistencial & Pesquisa, CARDRES Cardiol Assistencial, Belo Horizonte, MG, Brazil; [Vieira, Moreira Eduardo] Hosp Coracao Brazil, Brasilia, DF, Brazil; [Leaes, Paulo] Hosp Sao Francisco, Santa Casa Porto Alegre, Porto Alegre, RS, Brazil; [Zimmermann, Sergio] Clin Procardio Ltda, Blumenau, Brazil; [Van Bellen, Bonno] Univ Sao Paulo, Fac Med, Hosp Clin, Hosp Beneficencia Portuguesa, Sao Paulo, Brazil; [Precoma, Dalton] Hosp Angelina Caron, Campina Grande Do Sul, Brazil; [Silvestrini, Luiz Tiago] IPEMI, Itajai, SC, Brazil; [Hernandes, Mauro Esteves] Santa Casa Votuporanga, Unidade Pesquisa Clin, Votuporanga, Brazil; [Kyoleyan, Michael] MHAT Sveta Sofia, Sofia, Bulgaria; [Kalinova, Tanya] Univ Specialized Hosp Act Treatment Card, Sofia, Bulgaria; [Tiholov, Rumen] NBAL SV IVAN RILSKI KOZLODUY, MHAT Sveti Ivan Rilski, Kozlodui, Bulgaria; [Petrov, Iliyan] MHAT Sv Nikolay Chudotvorets EOOD, Lom, Bulgaria; [Mihov, Atanas] MHAT St Ekaterina, Dimitrovgrad, Bulgaria; [Chompalova, Boryana] MHAT Plovdiv, MBAL Plovdiv, Plovdiv, Bulgaria; [Velikov, Chavdar] MHAT Sv Vrach, Sandanski, Bulgaria; [Pencheva, Galina] Fouth MHAT Sofia, Sofia, Bulgaria; [Atanasov, Peter] UMHATEM N I Pirogov, Sofia, Bulgaria; [Raev, Dimitar] Synexus Bulgaria DCC Ascendent, Synexus, MHAT Sveta Anna Sofia AD, Sofia, Bulgaria; [Kinova, Elena] UMBAL Tsaritsa Yoanna ISUL, Sofia, Bulgaria; [Peltegov, Valentin] MHAT Razlog, Razlog, Bulgaria; [Marchev, Sotir] SHAT Cardiol Pleven, Pleven, Bulgaria; [Mincheva, Valentina] NMTH Tsar Boris III, Diagnost Consultat Ctr Borola OOD, Sofia, Bulgaria; [Siulemezova, Silvia] MHAT Ivan Seliminski AD, Sliven, Bulgaria; [Ayryanova, Ivaneta Dimitrova] Univ Multiprofile Hosp Act Treatment Deva Maria, Burgas, Bulgaria; [Grigorov, Mladen] 2th MHAT Sofia, Sofia, Bulgaria; [Naydenova, Iveta] MHAT Sveta Petka AD, Vidin, Bulgaria; [Koteva, Nadya] SHAT Pneumophthisiatr Dis Sofia Dist, Sofia, Bulgaria; [Dimov, Bojidar] Fifth Multiprofile Hosp Act Treatment Sofia, V MH, V MBAL, UMHAT Hosp Sofia 5,MHAT Sofia EAD 5, Sofia, Bulgaria; [Runev, Nikolay] Umhat Alexandrovska, Sofia, Bulgaria; [Getov, Dimitar] Reg Hosp Pulm Dis Rousse 1, SHAT Pneumophthisiatry Dis Dr Dimitar Gramatikov, SHATPPD Ruse, MHAT Dr Tota Venkova AD Gabrovo, Ruse, Bulgaria; [Metev, Hristo] Specialized Hosp Act Treatment Pneumophtisiat, Ruse, Bulgaria; [Donchev, Krasimir] SMO Bulgaria LTD, MHAT Dr Tota Venkova AD Gabrovo, MHAT Dr Tota Venkova AD, Gabrovo, Bulgaria; [Taseva, Margarita; Benov, Haralambi] MDHAT Dr Stefan Cherkezov, Veliko Tarnovo, Bulgaria; [Hadzhieva, Antoaneta] MHAT Puls, Blagoevgrad, Bulgaria; [Stoyanov, Miroslav] SMO Bulgaria Ltd, MHAT Dr Tota Venkova AD, Gabrovo, Bulgaria; [Tisheva-Gospodinova, Snezhanka] Univ Multiprofile Hosp Act Treatment Dr Geo, Pleven, Bulgaria; [Mihaylova, Nadya] SMO Bulgaria, MHAT Stamen Iliev AD, Montana, Bulgaria; [Abadzhiev, Stefan] MHAT Prof Dr Paraskev Stoyanov, Lovech, Bulgaria; [Atzev, Borislav] MHAT Puls, Sofija, Bulgaria; [Georgiev, Rosen] 5th MHAT Sofia, Sofia, Bulgaria; [Mollov, Mihail] I St Multiprofile Hosp Act Treatment, Sofia, Bulgaria; [Stoikov, Anastas] MHAT VITA, Sofia, Bulgaria; [Mazhdrakov, Georgi] SHATC Sv Georgi, MLADOST St Ame 1, Pernik, Bulgaria; [Karastanev, Krassimir] Mhat Sveti Georgi, Plovdiv, Bulgaria; [Dube, Francois] Inst Univ Pneumol & Cardiol Quebec, Quebec City, PQ, Canada; [Roth, Sherryn] Scarborough Gen Hosp, Scarborough, ON, Canada; [Mansour, Samer] Hotel Dieu Montreal, Chum Hotel Dieu Hosp, Ctr Rech Ctr Hosp Univ, Montreal, PQ, Canada; [Carrier, Marc] Ottawa Hosp, Ottawa Hosp Res Inst, Ottawa, ON, Canada; [Wu, Cynthia] Univ Alberta Hosp, Edmonton, AB, Canada; [Dolan, Sean] St Johns Hosp, St John, NB, Canada; [Pesant, Yves] St Jerome Med Res Inc, Polyclin St Jerome, St Jerome, PQ, Canada; [Pietrangelo, Maria] Charles LeMoyne Hosp, Greenfield Pk, PQ, Canada; [Dresser, George] Pediat Asthma Clin, London, ON, Canada; [Kahn, Susan] Sir Mortimer B Davis Jewish Hosp, Jewish Gen Hosp, Montreal, PQ, Canada; [Kruisselbrink, Rebecca] McMaster Univ, St Josephs Healthcare Hamilton Cha, Hamilton, ON, Canada; [Cadena Bonfanti, Andres] Clin Costa, Barranquilla, Colombia; [Botero, Rodrigo] IPS Rodrigo Botero SAS, Clin Medellin, Medellin, Colombia; [Quintero Ossa, Alvaro] Clin Cardio VID, Ctr Cardiovasc Colombiano Clin Santa Maria, Medellin, Colombia; [Poveda, Claudia Marcela] Clin Shaio, Bogota, Colombia; [Cedano, Jorge] Ctr Med Imbanaco, INST INVEST, Cali, Colombia; [Gomez Isaza, Luis] Hosp San Vicente de Paul, Medellin, Colombia; [Villaquiran Torres, Claudio] Hosp Univ San Ignacio, Bogota, Colombia; [Gomez Mesa, Juan] Fdn Valle Lili, Clin Valle Lili, Unidad Invest Clin, Cali, Colombia; [Vargas Alonso, Ruben] Fdn Cardiovasc Colombia, Bucaramanga, Colombia; [Espinosa, David] Hosp Univ Clin San Rafael, Bogota, Colombia; [Maria Rodriguez, Jose] Hosp Gen Medellin Luz Castro de Gutierrez ESE, Medellin, Colombia; [Sanchez, Gregorio] Univ Quindio, Hosp Univ San Juan de Dios, Fdn Cardiomet Cequin, Armenia, Colombia; [Accini Mendoza, Jose Luis] Fdn Hosp Univ Norte, IPS Ctr Cient Asistencial Jose Luis Accini SAS, Barranquilla, Colombia; [Gomez Florez, Carmen Cecilia] Fdn Cardio Infantil, Invest Dept, Bogota, Colombia; [Cuervo Millan, Francisco] Clin Univ la Sabana, Jazmin Pinzon, Chia, Colombia; [Pesek, Ksenija] OB Zabok, Zabok, Croatia; [Horvat, Davor] Gen Hosp Karlovac, Karlovac, Croatia; [Fuckar, Krunoslav] Specijalna Bolnica Med Rehabil Krapinske To, Krapinske Toplice, Croatia; [Tudoric, Neven] Univ Hosp Dubrava, Zagreb, Croatia; [Ruzic, Alen] Klin Bolnicki, Ctr Rijeka, Rijeka, Croatia; [Ostricki, Branko] Zupanijska Bolnica Cakovec, Cakovec, Croatia; [Knezevic, Aleksandar] Opca Bolnica Zadar, Zadar, Croatia; [Breitenfeld, Tomislav] Klin Bolnicki, Ctr Sestre Milosrdnice, Zagreb, Croatia; [Laganovic, Mario] KBC Zagreb, Zagreb, Croatia; [Samodol, Ante] Opca Bolnica Sibenik, Shibenik, Croatia; [Sikic, Jozica] Klin Bolnica Sv Duh, Zagreb, Croatia; [Starcevic, Boris] Klin Bolnica Dubrava, Zagreb, Croatia; [Babic, Zdravko] CH Sestre Milosrdnice, Zagreb, Croatia; [Samarzija, Miroslav] Univ Hosp Ctr Zagreb, Zagreb, Croatia; [Milas, Kresimir] Opca Bolnica Pula, Pula, Croatia; [Votocek, Stepan] Nemocnice Slany, Slany, Czech Republic; [Kvapil, Milan] ResTrial Sro, Fak Nemocnice Motole, Prague 5, Czech Republic; [Spinar, Jindrich] Univ Hosp, Fak Nemocnice Brno, Vseobecna Fak Nemocnice Praze, Brno, Czech Republic; [Kolman, Petr] Nemocnice Kyjov Po, Plicni Ambulance Petr Kolman, Kyjov, Czech Republic; [Bindas, Pavol] Slezska Nemocnice Opave Po, Opava, Czech Republic; [Simon, Vladimir] Nemocnice Pardubickeho Kraje As, Orlickoustecka nemocnice, Usti Nad Orlici, Czech Republic; [Adamek, Tomas] Thomayerova Nemocnice, Prague 4, Czech Republic; [Svobodova, Jaromira] Nemocnice Cesky Krumlov As, Cesky Krumlov, Czech Republic; [Gergely, Ladislav] Nemocnice Pisek As, Pisek, Czech Republic; [Lastuvka, Jiri] Krajska Zdravotni As, Masarykova Nemocnice Usti N Labem, Usti Nad Labem, Czech Republic; [Macel, Igor] Nemocnice Nove Mesto Morave Po, Nefrol Ambulance, Nove Mesto Morav, Czech Republic; [Navratil, Karel] Vojenska Nemocnice Olomouc, Olomouc, Czech Republic; [Gregor, Pavel] Fak Nemocnice Kralovske Vinohrady, Prague 10, Czech Republic; [Lacnak, Borek] Vsetinska Nemocnice As, Sdruzene Zdravotnicke Zarizeni Krnov Op, Vsetin, Czech Republic; [Janousek, Jiri] Oblastni Nemocnice Trutnov As, Trutnov, Czech Republic; [Kellnerova, Ivana] Nemocnice Pardubickeho Kraje As, Pardubicka Nemocnice, Svitavska Nemocnice As, Svitavy, Czech Republic; [Hulinsky, Vaclav] Nemocnice Nymburk Sro, Nymburk, Czech Republic; [Matusek, Zdenek] Nemocnice Trinec Po, Trinec, Czech Republic; [Prucek, Lukas] Nemocnice Sternberk Oz, Hosp Sternberk, Stredomoravska Nemocnicni As, Sternberk, Czech Republic; [Dunaj, Milan] Litomyslska Nemocnice As, Litomysl, Czech Republic; [Pirchala, Marian] NsP Karvina RAJ, Karvina, Czech Republic; [Vencour, David] Mestska Nemocnice Mestec Kralove, Mestec Kralove, Czech Republic; [Pavolko, Martin] Nemocnice Pardubickeho Kraje As, Pardubicka Nemocnice, Pardubice, Czech Republic; [Gorican, Karel; Fiksa, Jan] Vseobecna Fak Nemocnice Praze, Prague 2, Czech Republic; [Tuxen, Christian] Bispebjerg Hosp, Copenhagen, Denmark; [Tuxen, Christian] Frederiksberg Univ Hosp, Copenhagen, Denmark; [Meyer, Christian] Roskilde Sygehus, Roskilde, Denmark; [Ulrik, Suppli] Hvidovre Univ Hosp, Hvidovre, Denmark; [Marandi, Toomas] North Estonia Med Ctr, Tallinn, Estonia; [Uuetoa, Tiina] East Tallinn Cent Hosp, Tallinn, Estonia; [Shaburishvili, Tamaz] Tbilisi Heart & Vasc Clin Ltd, Tbilisi, Georgia; [Otarishvili, Nino] LTD Clin Rustavi, Rustavi, Georgia; [Khintibidze, Irakli; Emukhvari, Nodar; Chelidze, Kakhaber] Aleksandre Aladashvili Clin LLC, Tbilisi, Georgia; [Khintibidze, Irakli] Israel Georgian Med Res Clin Helsicore, Tbilisi, Georgia; [Kipiani, Zviad] LTD NEW Hosp, Tbilisi, Georgia; New Hosp, Tbilisi, Georgia; [Gochitashvili, David] LTD MediClubGeorgia, Tbilisi, Georgia; [Gochitashvili, David] LTD MediClubGeorgia, Tbilisi, Georgia; [Mamatsashvili, Merab] LTD ADAPT, Tbilisi, Georgia; [Mamatsashvili, Merab] LTD Adapti Angiogardiol Clin, Tbilisi, Georgia; [Megreladze, Irakli] LTD Tbilisi Sea Hosp, Tbilisi, Georgia; [Paposhvili, Kakhi] Ltd Georgia Archangel St Michael Multiprofile Cli, Tbilisi, Georgia; [Agladze, Rusudan] LTD Ctr Vasc & Heart Desease, Tbilisi, Georgia; [Eradze, Zviad] LTD DIACOR, Tbilisi, Georgia; [Chelidze, Kakhaber] TSMU First Univ Clin, Tbilisi, Georgia; [Lominadze, Sulkhan] Cardiac Surg Clin Ghia GULI LTD, Tbilisi, Georgia; [Chukhrukidze, Archil] LTD Tbilisi Heart Ctr, Tbilisi, Georgia; [Chumburidze, Vakhtang] LTD Emergency Cardiol Ctr Acc G Chapidze, Tbilisi, Georgia; [Metreveli, Shorena] LTD Marnecore, Marneuli, Georgia; [Danelia, Vakhtang] LTD Med Rehabil Reg Clin Ctr Invalids & Elderly O, Marneuli, Georgia; [Orjonikidze, Sergo] Univ Clin, High Technol Med Ctr, Tbilisi, Georgia; [Kobulia, Bondo] Inst Clin Cardiol Ltd, Tbilisi, Georgia; [Nikolaishvili, Giorgi; Sikharulidze, Ioseb] LTD Hlth Ctr Medina, Batumi, Georgia; [Nikolaishvili, Giorgi] Unimed Adjara Ltd, Batumi Referral Hosp, Batumi, Georgia; [Gvenetadze, Rusudan] LTD Aversi Clin, Tbilisi, Georgia; [Melia, Anzor] LTD Cardiol Clin Guli, Tbilisi, Georgia; [Tsinamdzgvrishvili, Bezhan] Georgian Soc Hypertens Ltd, Tsinamdzgvrishvili Cardiol Ctr, German Georgian Cli, Tbilisi, Georgia; [Sekhniashvili, Marika] LTD Unimed Kakheti Kakheti Referral Hosp, Tbilisi, Georgia; [Sikharulidze, Ioseb] LTD Brothers, Batumi, Georgia; [Meuser, Mario] St Elisabeth Krankenhaus Julich, Julich, Germany; [Licka, Manuela] Univ Hosp Heidelberg, Clin Cardiol Angiol & Pneumonol, Dept Internal Med, Heidelberg, Germany; [Beyer-Westendorf, Jan] Dresden Univ, Clin Med Clin 3, Dresden, Germany; [Beyer-Westendorf, Jan] GWT TUD Dresden, Dresden, Germany; [Rauch-Kroehnert, Ursula; Graf, Kristof] Charite Univ Med Berlin, Campus Benjamin Franklin, Berlin, Germany; [Brachmann, Johannes] Med Klin 2, Kardiol Angiol & Pneumo, Coburg, Germany; [Akin, Ibrahim] Klinikum Mannheim GmbH Univ Klinikum Med, Mannheim, Germany; [Toumbis, Michalis] Gen Hosp Chest Dis Athens Sotiri, Athens, Greece; [Toumbis, Michalis] Natl & Kapodistrian Univ SOTIRA Chest Dis H, Athens, Greece; [Vassilikos, Vassilios] Gen Hosp Thessaloniki Ippokrateio, Thessaloniki, Greece; [Konstantinides, Stavros] Univ Gen Hosp Alexanrdoupolis, Alexanrdoupolis, Greece; [Steiropoulos, Paschalis] Univ Gen Hosp Evros, Alexandroupolis, Greece; [Steiropoulos, Paschalis] Univ Hosp Ioannina, Alexandroupolis, Greece; [Gogos, Charalambos] Hellen Soc Infect Dis, Patras, Greece; [Gogos, Charalambos] Patras Univ RION PATRAS, Patras, Greece; [Gogos, Charalambos] Univ Hosp Patras, Patras, Greece; [Nikolaishvili, Giorgi; Andrikopoulos, Giorgos] Errikos Dynan Hosp, Athens, Greece; [Parthenakis, Fragkiskos] Univ Gen Hosp Crete, Iraklion, Crete, Greece; [Karydi, Panagiota] Iaso Gen Hosp, Athens, Greece; [Tsivgoulis, Georgios] Attikon Gen Hosp Athens, Athens, Greece; [Mertzanos, Georgios] Gen Hosp Attica KAT, Kifissia Athens, Greece; [Olympios, Christopher] Gen Hosp Elefsina Thriassio, Magoula, Greece; [Karapanayiotides, Theodoros] Aristotle Univ Thessaloniki, Ahepa Hosp, Thessaloniki, Greece; [Paraskevopoulou, Efrosyni] Constantopoulio Gen Hosp Nea Ionia Agia Olga, Nea Ionia, Greece; [Paraskevopoulou, Efrosyni] Gen Hosp Athens Evangelismos, Nea Ionia, Greece; [Paraskevopoulou, Efrosyni] Univ Gen Hosp Crete, Nea Ionia, Greece; [Kifnidis, Konstantinos] Gen Hosp Voulas Asklipieion, Voula, Greece; [Hahalis, George] Univ Gen Hosp Patras, Rion, Greece; [Skoutelis, Athanasios] Gen Hosp Athens Evangelismos, Athens, Greece; [Vadikolias, Konstantinos] Democritus Univ Thrace, Alexandroupolis, Greece; [Nyirati, Gabor; Jakab, Gabor] Bajai Szent Rokus Korhaz, Baja, Hungary; [Nagy, Laszlo; Kovacs, Aranka] Csongrad Megyei Dr Bugyi Istvan Korhaz, Szentes, Hungary; [Nagy, Laszlo] Dr Bugyi Istvan Hosp Szentes, Szentes, Hungary; [Matoltsy, Andras] Kanizsai Dorottya Korhaz, Nagykanizsa, Hungary; [Komoly, Samuel] Pecsi Tudomanyegyet Klin Kp, Pecs, Hungary; [Komoly, Samuel] Pecsi Tudomanyegyet Klin Kozpont, Pecs, Hungary; [Lippai, Jozsef] Del Pesti Korhaz, Budapest, Hungary; [Lippai, Jozsef] Jahn Ferenc Del Pesti Korhaz, Budapest, Hungary; [Lippai, Jozsef] Jahn Ferenc Del Pesti Korhaz & Rendelointezet, Budapest, Hungary; [Lippai, Jozsef] Szent Erzsebet Korhaz, Budapest, Hungary; [Kiss, Krisztian] Meditoll Kft, Godollo, Hungary; [Kiss, Krisztian] Pest Megyei Flor Ferenc Korhaz, Godollo, Hungary; [Kalman, Toth] PTE KK Lsz, Belgyogyaszati Klin, Pecs, Hungary; [Pozsegovits, Krisztian] Dr Kenessey Albert Korhaz Rendelointeze, Balassagyarmat, Hungary; [Csaba, Kiraly; Horvath, Csaba] Bacs Kiskun Megyei Korhaz, Kecskemet, Hungary; [Bereczki, Daniel; Pozsonyi, Zoltan] Semmelweis Egyet, Budapest, Hungary; [Zolyomi, Szilard] Kalocsai Szent Kereszt Korhaz, Kalocsa, Hungary; [Boda, Zoltan; Pall, Denes] Debreceni Egyet, Debrecen, Hungary; [Boda, Zoltan] Debreceni Egyet, Klin Kozpont, Belgyogyaszati Intezet, Debrecen, Hungary; [Szakal, Imre] Selye Janos Korhaz & Rendelointezet, Komarom, Hungary; [Szakal, Imre] Selye Janos Hosp, Komarom, Hungary; [Pall, Denes] Coordinat Ctr Drug Dev, Debrecen, Hungary; [Pall, Denes] Debreceni Egyet, Klin Kozpont, Debrecen, Hungary; [Pall, Denes] Univ Debrecen, Debrecen, Hungary; [Futo, Laszlo; Mueller, Gabor] Markhot Ferenc Oktatokorhaz & Rendelointeze, Eger, Hungary; [Forster, Tamas] Clin Res Coordinat Ctr, Szeged, Hungary; [Forster, Tamas] Szegedi Tudomanyegyet, Szeged, Hungary; [Forster, Tamas] Szegedi Tudomanyegyet, Szent Gyorgyi Albert Orvos & Gy, Szeged, Hungary; [Lovasz, Orsolya] Fovarosi Onkormanyzat Uzsoki Utcai Korhaz Honved, Budapest, Hungary; [Papp, Aniko] Grof Tisza Istvan Korhaz, Berettyoujfalu, Hungary; [Kiraly, Zsolt] Veszprem Megyei Onkormanyzat Tudogyogyintezete, Farkasgyepu, Hungary; [Erik, Hajko] Toldy Ferenc Korhaz Rendelointezet, Cegled, Hungary; [Kristof, Piroska] Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz R, Neurol Osztaly, Szolnok, Hungary; [Lakatos, Ferenc] Oroshazi Korhaz, Oroshaza, Hungary; [Zsolt, Ples] Dent Med Co Bt, Satoraljaujhely, Hungary; [Kirschner, Robert] Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary; [Lupkovics, Geza] Zala Megyei Korhaz, Zalaegerszeg, Hungary; [Lupkovics, Geza] Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Hungary; [Timar, Gyula] Bajai Szent Rokus Korhaz, Neurol Osztaly, Baja, Hungary; [Pinter, Istvan] COROMED Kft, Siofok, Hungary; [Pinter, Istvan] COROMED SMO Kft, Siofok, Hungary; [Pinter, Istvan] Pecsi Tudomanyegyet Klin Kozpont, Siofok, Hungary; [Pinter, Istvan] Siofoki Korhaz & Rendelointezet, Siofok, Hungary; [Kristof, Tunde] BAZ Megyei Korhaz & Egyet Oktato Korhaz, Miskolc, Hungary; [Kristof, Tunde] Borsod Abauj Zemplen Megyei Korhaz & Egyet Oktato, Miskolc, Hungary; [Kristof, Tunde] Endomedix Kft, Miskolc, Hungary; [Kis, Erno; Kovacs, Aranka] MRC, Eth Comm Clin Pharm, Szekszard, Hungary; [Kis, Erno] Pulmocard Egeszsegugyi Bt, Szekszard, Hungary; [Kis, Erno] Tolna Megyei Onkormanyzat Balassa Janos Korhaz, Intezmenyi E, Szekszard, Hungary; [Kis, Erno] Tolna Megyei Onkormanyzat Balassa Janos Korhaz, Szekszard, Hungary; [Kovacs, Aranka] Dr Bugyi Istvan Korhaz Intezeti Kutatasetikai Biz, Szentes, Hungary; [Mueller, Gabor] Uzsoki Utcai Korhaz, Budapest, Hungary; [Palinkas, Attila] Csongrad Megyei Egeszsegugyi Ellato Kozpont Hodme, Hodmezovasarhely, Hungary; [Turi, Tibor] Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz, Szekesfehervar, Hungary; [Horvath, Csaba] Varosi Korhaz Keszthely, Keszthely, Hungary; [Kondakor, Istvan] Tolna Megyei Balassa Janos Korhaz, Szekszard, Hungary; [Csanyi, Attila] Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary; [Frankfurter, Zsuzsanna] D Kenessey A Hosp, Balassagyarmat, Hungary; [Frankfurter, Zsuzsanna] Dr Kenessey Albert Korhaz Rendelointezet, Balassagyarmat, Hungary; [Gurzo, Mihaly] Bacs Kiskun Megyei Onkormanyzat Korhaza Kutatas E, Kecskemet, Hungary; [Gurzo, Mihaly] Bacs Kiskun Megyei Korhaz, Kecskemet, Hungary; [Gurzo, Mihaly] MRC, Eth Comm Clin Pharm, Kecskemet, Hungary; [Gafter-Gvili, Anat] Beilinson Med Ctr, Petah Tiqwa, Israel; [Kuchuk, Michael] Hillel Yaffe Med Ctr, Hadera, Israel; [Azzam, Zaher] Rambam Hlth Care Campus, Haifa, Israel; [Elis, Avishay] Rabin Med Ctr, Petah Tiqwa, Israel; [Halabi, Majdi; Hussein, Osamah] Ziv Med Ctr, Safed, Israel; [Blum, Arnon] Baruch Padeh Poria Hosp, Lower Galilee, Israel; [Tsoran-Rosenthal, Inna] Rambam Med Ctr, Haifa, Israel; [Lishner, Michael] Meir Med Ctr, Kefar Sava, Israel; [Hochberg-Klein, Sarit] Hadassah Med Org, Modiin, Israel; [Hochberg-Klein, Sarit] Hadassah Hebrew Univ Hosp, Modiin, Israel; [Hochberg-Klein, Sarit] Hadassah Mt Scopus, Modiin, Israel; [Caraco, Yoseph] Hadassah Univ Hosp, Hadassah Clin Res Ce, Jerusalem, Israel; [Atar, Shaul] Galilee Med Ctr, Nahariyya, Israel; [Atar, Shaul] Western Galilee Hosp, Nahariyya, Israel; [Elias, Nizar] Bnai Zion Med Ctr, Haifa, Israel; [Gavish, Dov] E Wolfson Med Ctr, Holon, Israel; [Butnaru, Adi] Shaare Zedek Med Ctr, Jerusalem, Israel; [Cosmi, Franco] Santa Margherita Hosp, Cortona, Italy; Osped Circolo Varese, Varese, Italy; Fdn Macchi, Varese, Italy; [Garbelotto, Raffaella] Azienda ULSS7, Presidio Osped Vittorio Veneto, Vittorio Veneto, TV, Italy; [Pierfranceschi, Giorgi] AUSL Piacenza Osped Unico Val DArda, Fiorenzuola Darda, Piacenza, Italy; [Simioni, Livio] ULSS 2 Feltre, Feltre, Italy; [Gronda, Edoardo] IRCCS Multimed, Sesto San Giovanni, Italy; [Pesci, Alberto] AO San Gerardo di Monza, Monza, Italy; [D'Angelo, Armando] Osped San Raffaele, Milan, Italy; [D'Angelo, Armando] Osped San Raffaele, IRCCS, Milan, Italy; [Fedele, Francesco] Azienda Policlin Umberto I, Rome, Italy; [Fedele, Francesco] Univ Roma La Sapienza, Umberto Policlin Roma 1, Rome, Italy; [Ghirarduzzi, Angelo] Emilia Romagna Azienda Osped, Serv Sanit Reg, Reggio Emilia, Italy; [Piovaccari, Giancarlo] Azienda Unita Sanit Locale Romagna, Rimini, Italy; [Piovaccari, Giancarlo] Osped Infermi, Rimini, Italy; [Lembo, Giuseppe] IRCCS Neuromed Ist Neurol Mediterraneo, Pozzilli, IS, Italy; [Ria, Luigi] ASL LECCE, PO S CUORE DI GESU, Gallipoli, Italy; [Monaco, Giuseppe] Complesso Osped San Giovanni Addolorata, Rome, Italy; [Brunelli, Claudio] AOU S Martino, IRCCS, IST Ist Nazl Ric Can, Genoa, Italy; [Brunelli, Claudio] Univ Genoa, Clin Pneumol & Tisiol, Genoa, Italy; [Brunelli, Claudio] IRCCS AOU San Martino IST, Genoa, Italy; [Tosetto, Alberto] Osped San Bortolo, ULSS 6 Vicenza, Vicenza, Italy; [Capucci, Alessandro] AOU Osped Riuniti Umberto I GM Lancisi G Sales, Torrette Di Ancona, AN, Italy; [Zanatta, Nello] Azienda USSL7, PO Conegliano, Conegliano, Italy; [Pistolesi, Massimo] AOU Careggi, Florence, Italy; [Mazzi, Valeria] Azienda USL Nord Ovest Toscana, Livorno, Italy; [Testa, Sophie] AO Cremona, Ist Ospitalieri Cremona, Cremona, Italy; [Scherillo, Marino] Azienda Osped G Rummo, Benevento, Italy; [Di Biase, Matteo] AOU Osped Riuniti Foggia, Foggia, Italy; [Antonicelli, Roberto] INRCA IRCCS, Ancona, Italy; [Lodigiani, Corrado] IRCCS Ist Clin Humanitas, Rozzano, Italy; [Lodigiani, Corrado] Tedeschi Michele, Rozzano, Italy; [Nassiacos, Daniele] Osped Saronno, Saronno, Italy; [Krievins, Dainis] P Stradina Clin Univ Hosp, Riga, Latvia; [Viksne, Inese] Jekabpils Hosp, Jekabpils, Latvia; [Lapkovska, Zinaida] Kraslava Hosp, Kraslava, Latvia; [Rancane, Gita] Northern Kurzeme Reg Hosp, Ventspils, Latvia; [Sime, Iveta] Liepaja Reg Hosp, Liepaja, Latvia; [Pontaga, Natalija; Eglite, Ruta] Daugavpils Reg Hosp, Daugavpils, Latvia; [Puzule, Sarmite] Union Balvu & Gulbenes Hosp, Balvi & Gulbene Hosp union, Balvi, Latvia; [Smolova, Rita] SIA Jelgavas pilsetas slimnica, Jelgava, Latvia; [Butkiene, Zita] Vilnius Univ, Hosp Santariskiu Klinikos, Vilnius, Lithuania; [Bagdonas, Alfredas] Kaunas Clin Hosp, Kaunas, Lithuania; [Raugaliene, Rasa] Kaunas City Clin Hosp, Kaunas, Lithuania; [Norkiene, Sigute] Klaipeda Seamens Hosp, Klaipeda, Lithuania; [Norviliene, Rita] Klaipeda Dist Hosp, Respublikine, Klaipedos Iigonine, Klaipeda, Lithuania; [Petrauskiene, Birute] Vilnius Univ, Hosp Santariskiu Klinikos, Vilnius, Lithuania; [Basijokiene, Vida] SiaulSiauliai Republican Hosp, Reumatologijos klinika, Shiauliai, Lithuania; [Stonkus, Sigitas] Klaipeda Univ Hosp, MB A. Navicko konsultacine poliklinika, A. Navicko konsultacine poliklinika, Klaipeda, Lithuania; [Griskeviciene, Violeta] PI Utenos Iigonine, Utena, Lithuania; [Miskiniene, Ausra] Vilnius Univ, Antakalnio Hosp, Vilnius, Lithuania; [Norvaisiene, Rima] Respublikine Klaipedos Iigonine, Klaipeda, Lithuania; [Skripkauskiene, Irena] Respublikine Panevezio Iigonine, Panevezys, Lithuania; [Jovkovska-Kaeva, Biserka] PHI Univ Clin, Skopje, North Macedonia; [Kochovska-Kamchevska, Nade] PHI Gen City Hosp 8mi Septemvri, Skopje, North Macedonia; [Antovski, Antonio; Nechevska, Liljana] City Hosp 8 September, Skopje, North Macedonia; [Celeska, Violeta] Gen Hosp Ohrid, PHI Univ Clin, Ohrid, North Macedonia; [Ilievska-Poposka, Biljana] Inst Iung Dis & TB, PHI Inst Lung Diseaes TB, Skopje, North Macedonia; [Kostojchinoska, Mira] PHI Gen Hosp Struga, Struga, North Macedonia; [Donchovska, Snezhana] Clin Hosp Stip, Stip, North Macedonia; [Kedev, Sashko] Univ Clin Cardiol, Skopje, North Macedonia; [Kuzmanovski, Igor] Univ Clin Neurol, Skopje, North Macedonia; [Bushletikj, Oliver] Clin Hosp SISTINA Acibadem, Skopje, North Macedonia; [Stojchev, Sasho] Gen City Hosp 8 September, Skopje, North Macedonia; [Bakrachevski, Nikola] Inst Cardiovascular Dis Ohrid, Ohrid, North Macedonia; [Kuzmanovska, Biljana] KARIL Clin anestez, Reanimat & intes care, Skopje, North Macedonia; [Angusheva, Tanja] Special Hosp Surg Dis Filip Vtori, Skopje, North Macedonia; [Llamas Esperon, Guillermo] Hosp Cardiolog Aguascalientes, Aguascalientes, Mexico; [Valdez Lopez, Hector] CRI Ctr Regiomontano Investigac SC, Monterrey, Mexico; [Medina Pech, Carlos] Comite Etica Investigac Med Care & Res, Merida, Mexico; [Cortes Hernandez, Miguel] Consultorio Privado, Dr Miguel Cortes Hernandez, Cuernavaca, Morelos, Mexico; [Virgen Carrillo, Luis] Virgen Cardiovascular Res SC, Guadalajara, Mexico; [Gans, Stephanus] Ziekenhuis St Jansdal, Harderwijk, Netherlands; [Smulders, Sietske] Jeroen Bosch Ziekenhuis, sHertogenbosch, Netherlands; [Swart, Henk] Antonius Hosp Sneek, Antonius Hosp, D & A Res Genet, Sneek, Netherlands; [Middeldorp, Saskia] Acad Medisch Centrum Univ, Amsterdam, Netherlands; [Boersma, Willem] Noordwest Ziekenhuisgroep, Alkmaar, Netherlands; [Goosens, Martijn] Gelre Ziekenhuis Zutphen, Zutphen, Netherlands; [Hovens, Marcel] Rijnstate Arnhem, Rijnstate Ziekenhuis, Arnhem, Netherlands; [Semplonius, Geesje] Gelre Ziekenhuizen, Zutphen, Netherlands; [Sohne, M.] St Antonius Ziekenhuis St Antonius Hosp, Nieuwegein, Netherlands; [Osores, Lema] Cardiometabol Hosp Nacl Arzobispo Loayza, Ctr Investigac enfermedades, Lima, Peru; [Salas Perez, Marcia] Hosp Dos de Mayo, Lima, Peru; [Rodriguez, Aldo] EsSalud Hosp Nacl Alberto Sabogal Sologuren, Hosp IV Alberto Sabogal Sologuren EsSalud, Hosp Nacl Alberto Sabogal Sologuren ESSALUD, Callao, Peru; [Rios Oliva, Carlos] Hosp Nacl Arzobispo Loayza, Lima, Peru; [Cotrina, Rosa] Hosp Nacl Guillermo, Hosp Nacl Guillermo Almenara, Hosp Nacl Guillermo Almenara Irigoyen Orthoped, Lima, Peru; [Berrospi Argandona, Percy] Clin El Golf, Lima, Peru; [Toce Yanez, Luis] Clin Internac, Lima, Peru; [Medina Pech, Carlos; Chavez Ayala, Carlos] Hosp Nacl Daniel Alcides Carrion, Callao, Peru; [Mirek-Bryniarska, Ewa] Gabinet Lekarski dr Ewa Mirek, Szpital Specjalistyczny J Dietla Krakowie, Krakow, Poland; [Goch, Aleksander] 10 Wojskowy Szpital Klin Poliklin, Bydgoszcz, Poland; [Skucha, Wojciech] SPZOZ Proszowicach, Proszowice, Poland; [Skorski, Marcin] SP ZOZ Lecznej, SP ZOZ Leczna, Leczna, Poland; [Miekus, Pawel] NZOZ Sopockie Centrum Badan, Kardiologicznych Pro Cordis, Szpital Sw Wincentego Paulo Sp zoo, Sopot, Poland; [Szyszka, Andrzej] Uniwersytet Medyczny Karola Marcinkowskiego Pozna, NZOZ Ctr Medyczne HCP Lecznictwo Stacjonarne, Poznan, Poland; [Piotrowski, Grzegorz] Wojewodzki Szpital Specjalistyczny M Kopernika Lo, Lodz, Poland; [Gniot, Jacek] SPZOZ Szpital Specjalistyczny Pulawach, Pulawy, Poland; [Czerski, Tomasz] SPZOZ Szpital Powiatowy Wegrowie, Wegrow, Poland; [Debich, Piotr] Pabianickie Ctr Medyczne Sp zoo, Pabianice, Poland; [Zaluska, Roman] Mazowiecki Szpital Specjalistyczny dr J Psarskieg, SZPZOZ dr J Psarskiego, Szpital Specjalistyczny, Ostroleka, Poland; [Bebenek, Waldemar] Wojewodzki Szpital Zespolony L Rydygiera Toruniu, Osrodek Badan Klin CLINSANTE SC, Ewa Galczak Nowak Malgorzata Trzaska, Torun, Poland; [Wozakowska-Kaplon, Beata] Swietokrzyskie Ctr Kardiol, Kielce, Poland; [Sciborski, Ryszard] Zespol Opieki Zdrowotnej Szpital Olawie, Olawa, Poland; [Ilkowski, Jan] NZOZ NEURO KARD Ilkowski Partnerzy Sp Partnerska, SP ZOZ dr Kazimierza Hologi, Poznan, Poland; [Wojnowski, Piotr] Szpital Wojewodzki Bielsku Bialej, Bielsko Biala, Poland; [Uscinska, Ewa] Samodzielny Publ Zespol Zakladow Opieki Zdro, Ostrow Mazowiecka, Poland; [Gaciong, Zbigniew] Centralny Szpital Klin, NZOZ AURUM, Samodzielny Publiczny, Warsaw, Poland; [Bonek, Robert] 10 Wojskowy Szpital Klin Poliklin, SP ZOZ, Regionalny Szpital Specjalistyczny Dr Wl Biegansk, Bydgoszcz, SP, Poland; [Sobkowicz, Bozena] Uniwersytecki Szpital Klin Bialymstoku, Bialystok, Poland; [Berkowski, Piotr] Zespol Opieki Zdrowotnej Klodzku, Klodzko, Poland; [Bejgier, Katarzyna] Osrodek Badan Klini CLINSANTE SC Ewa Galczak Nowa, Bydgoszcz, Poland; [Polonski, Lech] 1 Klin Kardiol Slaskiej Akad Med, Silesian Ctr Heart Dis, Sosnowieckie Ctr Kardiol, Zabrze, Poland; [Kosior, Dariusz] Centralny Szpital Klin MSWiA Warszawie, Warsaw, Poland; [Lata, Stanislaw] Szpital Wojewodzki Sw Lukasza SP ZOZ, Tarnow, Poland; [Kolodziej, Piotr] Samodzielny Publ Zaklad Opieki, Zdrowotnej Siedlcach, Siedlce, Poland; [Gessek, Jacek] Prywatny Gabinet Lekarski Jacek Gessek, Specjalistyczny Szpital Miejski, Torun, Poland; [Kachel, Tomasz] Centrum Pulmonologii Torakochirurgii Bystrej, NZOZ ODDECH Sp Zoo, Specjalistyczny Gabinet Lekarski Tomasz Kachel, Bystra, Poland; [Talalaj, Marek] SP Szpital Klin prof dr Orlowskiego CMKP, Warsaw, SP, Poland; [Musial, Jacek] Szpital Uniwersytecki Krakowie, Krakow, Poland; [Lewczuk, Jerzy] Wojewodzki Szpital Specjalist, Osrodek Badawczo Rozwojowy, Wroclaw, Poland; [Krysiak, Waldemar] 109 Szpital Wojskowy Przychodnia SP ZOZ, Neocard, Szczecin, Poland; [Kucharski, Lech] Szpital Specjalistyczny S Zeromskiego, SPZOZ Krakowie, Krakow, Poland; [Wysokinski, Andrzej] Samodzielny Publ Szpital Klin 4 Lublinie, Lublin, Poland; [Minc, Piotr] Wojewodzki Szpital Specjalistyczny M Kopernika Lo, Szpital Miejski dr. K. Jonschera Lodzi 3, Przychodnia Lekarska MED POL Sc M Cieslak K Ciesl, Lodz, Poland; [Martinez, Jorge] H Pero Covilha Ctr Hospitalar Cova daBeira, Covilha, Portugal; [Gregorio, Tiago] CH Vila Nova Gaia Espinho, Vila Nova De Gaia, Portugal; [Almeida, Filipa] H Guimaraes N Senhora Oliveira Ctr Hospitalar Alt, Guimaraes, Portugal; [Monteiro, Pedro] Hospitais Univ Coimbra, Coimbra, Portugal; [Stanciulescu, Gabriela] Spitalul Judetean Urgenta Pitesti, Pitesti, Romania; [Mercea, Corina] Spitalul Judetean Urgenta Dr Constantin Opris Bai, Cabinet Med Cardiol Dr Mercea Corina, Baia Mare, Romania; [Iosipescu, Laura] Spitalul Judetean Urgenta Bacau, Bacau, Romania; [Militaru, Constantin] Emergency Hosp Craiova, Spitalul Clin Judetean Urgenta Craiova, Spitalul Clin Municipal Cluj Napoca, CARDIOMED</suborg2> <city id=0>Craiova</city> <c, ry id=0>Romania</country> <mainorg id=0>Emergency, Craiova, Romania; [Ciobotaru, Valentina] Medicalis, Timisoara, Romania; [Crisu, Daniela] Consultmed, Iasi, Romania; [Burca, Mitel] Spitalul Judetean Urgenta Sf Pantelimon, Focsani, Romania; [Tudoran, Mariana] Spitalul Clin Judetean Urgenta Timisoara, Timisoara, Romania; [Savu, Angelica] Angisan Grp, Bucharest, Romania; [Negrean, Vasile] Bendis Clin, Spitalul Clin CF Cluj Napoca, Cluj Napoca, Romania; [Cojocaru, Cristian] Netconsult, Ctr Oncol Euroclin, Iasi, Romania; [Minescu, Bogdan] Spitalul Judetean Urgenta Braila, Braila, Romania; [Popa, Virgil] Spitalul Clin Judetean Urgenta Oradea, Oradea, Romania; [Blajan, Daniel] Spitalul Judetean Urgenta Pitesti, Pitesti, Romania; [Nastase-Melicovici, Dorel] Inst Urg pt Boli Cardiovasculare si Transplant Tg, Spital clin judetean urgenta mure, Mediab, Rai Medicals, Targu Mures, Romania; [Fruntelata, Ana] Ctr Med Policlin Monza, Bucharest, Romania; [Barbulescu, Sanziana] Ambulator NEOMED, Ctr Med Diagnost si Tratament, Brasov, Romania; [Lukinyh, Liya] MUZ Vsevolzhsk Cent Reg Hosp, Vsevolzhsk, Russia; [Akhunova, Svetlana] Interreg Clinicodiagnost Ctr, Kazan, Russia; [Vishneva, Elena] City Hosp 14, Ekaterinburg, Russia; [Semenova, Irina] First City Clin Hosp, Arkhangelsk, Russia; [Nikolaev, Konstantin] State Budgetary Healthcare Inst Novosibirsk Regio, Sci Res Inst Therapy & prevent, City Clin Hosp 19, Novosibirsk, Russia; [Shaydyuk, Oxana] City Clin Hosp 15, Moscow, Russia; [Nilk, Rostislav] City Hosp 38, St Petersburg, Russia; [Shalnev, Vladimir] North Western State Med Univ, City Alexanrovskaya Hosp, Saint-Petersburg, Russia; [Apartsin, Konstantin] Hosp Irkutsk Sci Ctr Siberian, Fed State Healthcare Inst, Branch Russian Acad Sci, Irkutsk, Russia; [Goloshchekin, Boris] St Petersburg City Hosp 15, St Petersburg, Russia; [Shpagina, Liubov] MUZ City Clin Hosp 2, Novosibirsk, Russia; [Khlevchuk, Tatiana] GBUZ City Clin Hosp, City Clin Hosp 20, Moscow 20, Russia; [Arkhipov, Mikhail] Med Acad, Cent City Hosp 3, GOU VPO Ural State, Ekaterinburg, Russia; [Malygin, Alexander] Yaroslavl Clin Hosp 8, Yaroslavl, Russia; [Shvarts, Yury] Clin Hosp 3, Saratov, Russia; [Khaisheva, Larisa] Rostov state Med Univ, Rostov Na Donu, Russia; [Popov, Dmitry] Reg Clin Hosp 3, Chelyabinsk, Russia; [Kobalava, Zhanna] FGAOU VO Peoples Friendship Univ Russia, City clin Hosp 64, Moscow, Russia; [Lipchenko, Alexander] LLC Med Union New Hosp, Med Assoc New Hosp, Off Dr Alexander, Ekaterinburg, Russia; [Shapovalova, Yulia] NUZ Rd Clin Hosp st Cheliabinsk, Chelyabinsk, Russia; [Zrazhevsky, Konstantin] City Hosp 38, St Petersburg, Russia; [Greshnova, Irina] Ulyanovsk Reg Clin Hosp, SHI Cent Clin Med & Sanit Unit, Ulyanovsk, Russia; [Maslova, Natalia] State Med Univ, GOU VPO Smolensk State Med Acad Roszdrav, Smolensk, Russia; [Karabenenko, Alexander] GBUZ City Clin Hosp 12, Healthcare Dept, Moscow, Russia; [Shogenov, Zaur] City Clin Hosp 81, Moscow, Russia; [Budankova, Ekaterina] Tomsk Reg Clin Hosp, Tomsk, Russia; [Barbarash, Olga] GBOU VPO Kemerovo State Med Acad, Kemerovo Med Acad Reg Clin Hosp, FSBI Res Inst Complex Issues Cardiovascula, Inst Complex Issues Cardiovascular Dis, Kemerovo, Russia; [Uspenskiy, Yury] North Western State Med Univ, City Hosp St venerable Martyr Elizabeth, Skin venerol dispensary 10, St Petersburg, Russia; [Kosmacheva, Elena] Krasnodar Krai Clin Hosp 1, Ochapovsky Hosp, Krasnodar, Russia; [Berns, Svetlana] FSBI Res Inst Complex Issues, Dept Healthcare Moscow, Fed State Budgetary Inst Res Inst C, Inst Complex Issues Cardiovascular Dis, Moscow, Russia; [Kostenko, Victor] LCC Med Res Inst, Res Inst Emergency Care, State Budgatory Healthcare Inst City Polyclin 109, St Petersburg, Russia; [Zateyshchikov, Dmitry] City Clin Hosp 51, City Clin Hosp 17, Moscow, Russia; [Vishnevsky, Alexandr] Spb SBHI City Pokrovskaya Hosp, St Petersburg, Russia; [Boldueva, Svetlana] North Western State Med Univ, MEDEM Int Clin LLC, St Petersburg, Russia; [Podzolkov, Valeriy] M Sechenov First Moscow State Med Univ, Moscow, Russia; [Sergeeva, Elena] First Pavlov State Med Univ, St Petersburg, Russia; [Grinshtein, Yury] Krasnoyarsk State Med Univ, Krasnoyarsk, Russia; [Khrustalev, Oleg] Yaroslavl Reg Clin Hosp, Yaroslavl, Russia; [Bugrova, Olga] Orenburg State Med Univ, GBOU VPO Orenburg State Med Univ, GBUZ Orenburg Clin Reg Hosp, Orenburg, Russia; [Repin, Alexey] RAMS Inst Res Inst Cardiol Siberia, Tomsk, Russia; [Andreev, Denis] Univ Clin Hosp 1, Moscow, Russia; [Petrovic, Predrag] Gen Hosp Smederevo, Smederevo, Serbia; [Matic, Tatjana; Zdravkovic, Vladimir; Andjelkovic, Nebojsa] Clin Ctr Kragujevac, Kragujevac, Serbia; [Apostolovic, Svetlana] Clin Ctr Nis, Clin Cardiol, Clin Cardiovasc Deseases, Nish, Serbia; [Lazic, Zorica] Clin Ctr Kragujevac, Clin Pulmol, Kragujevac, Serbia; [Stankovic, Dusica] Gen Hosp Vranje, Iazar bogavac, Vranje, Serbia; [Stankovic, Aleksandar] Gen Hosp Leskovac, Leskovac, Serbia; [Mitov, Vladimir] Hlth Ctr Zajecar, Zajecar, Serbia; [Sofronic, Dejan] Gen Hosp Valjevo, Valjevo, Serbia; [Kopitovic, Ivan] Inst Pulm Dis Vojvodina, Sremska Kamenica, Serbia; [Joksimovic, Zoran] Gen Hosp Cuprija, Cuprija, Serbia; [Lazovic, Nada] Gen Hosp Cacak, Cacak, Serbia; [Petrovic-Stanojevic, Natasa] Zvezdara Univ Clin Ctr, Municipal Inst Lung Dis & TB, Internal Clin, Belgrade, Serbia; [Ilic, Aleksandra] Clin Ctr Serbia, Clin Pulmol, Belgrade, Serbia; [Vujadinovic, Olivera] Gen Hosp Sabac, Sabac, Serbia; [Pencic-Popovic, Biljana] Univ Clin Hosp Ctr Dr Dragisa Misovic Dedinje, Belgrade, Serbia; [Sekularac, Nikola] Zvezdara Univ Med Ctr, Belgrade, Serbia; [Hinic, Sasa] Clin Hosp Ctr Bezanijska Kosa, Belgrade, Serbia; [Radjen, Goran] Medigrp Bulevar Milutina Milankov 3, Belgrade, Serbia; [Zivkovic, Aleksandar] Hlth Ctr Subotica, Subotica, Serbia; [Putnikovic, Biljana] Clin Hosp Ctr Zemun, Belgrade, Serbia; [Vuckovic, Biljana] CCV, Clin Thrombosis Ad Hemostasis, Novi Sad, Serbia; [Ivanov, Igor] Inst Cardiovasc Dis Vojvodina, Sremska Kamenica, Serbia; [Babic, Rade] Inst Cardiovasc Dis Dedinje, Dedinje, Serbia; [Van Zyl, Louis] Clin Projects Res, Worcester, South Africa; [Hobson, Biano] Vergelegen Mediclin, Cape Town, South Africa; [Basson, Matthys] Karl Bremer Hosp, Tiervlei Trial Ctr, Bellville, South Africa; [Engelbrecht, Johannes] Dr JM Engelbrecht Trial Site, Vergelegen Medicity, Vergelegen Mediclin, Somerset West, South Africa; [Mitha, Ismail] WWCT Lakeview Hosp, Worthwhile Clin Trials, Benoni, South Africa; [Siebert, Heidi] Life Groenkloof Hosp, Pretoria, South Africa; [Jacobson, Barry] Charlotte Maxeke Johannesburg Hosp, Charlotte Maxeke Johannesburg Acad, Charlotte Maxeke Johannesburg Acad Hosp, Johannesburg, South Africa; [Breedt, Johannes] Jacaranda Hosp, Emmed Res, Pretoria, South Africa; [Prozesky, Hans] Univ Stellenbosch, TREAD Res CC, Tygerberg Hosp, Tygerberg, South Africa; [Ntsekhe, Mpiko] Groote Schuur Hosp, Cape Town, South Africa; [Bayat, Junaid] Practice Dr Junaid Bayat, Durban, South Africa; [Ellis, Graham] Synexus Ltd, Synexus Helderberg Clin Res Ctr, Somerset West, South Africa; [Tarr, Gareth] Winelands Med Res Ctr, Stellenbosch, South Africa; [Adler, David] Kopano Clin Trials, Johannesburg, South Africa; [Van Dyk, Christo] Boland Eth Res Grp, Worcester, South Africa; [Ismail, S.] Gatesville Med Ctr, Room 310, Gatesville Cape Town, South Africa; [Spargo, Catherine] Arthrit Clin Res Trials, Cape Town, South Africa; [Abdool-Gaffar, Mohamed] Kingsway Med Ctr, Durban, South Africa; [Saaiman, Jan] SA Endovasc Multidisciplinary Cardiovasc Practic, Dr JA Saaiman, Kuils River, South Africa; [Venter, Karl] Iatros Int, Bloemfontein, South Africa; [Lorente Aroca, Maria] HU Ribera, Alzira, Spain; [Fernandez Portales, Francisco] H San Pedro Alcantara, Caceres, Spain; [Pedrajas Navas, Jose] Hosp Clin San Carlos, Madrid, Spain; [Rodriguez Botaro, Antonio] H Inf Luisa, Seville, Spain; [Cruz Siminiani, Antonio] HU Santa Lucia, Serv Neumol, Cartagena, Spain; [Lopez Reyes, Raquel] HUP La Fe, Valencia, Spain; [Bisbe i Company, Josep] Hosp Olot & Comarcal Garrotxa, Olot, Spain; [Piedecausa Selfa, Mar] HGU Elche, Elche, Spain; [Velasco Garrido, Jose] HU Virgen de la Victoria, Malaga, Spain; [Sobrino-Martinez, Javier] Fdn Hosp Esperit St, Santa Coloma de Gramenet, Spain; [Munoz Delgado, Gregorio] H Tajo, Aranjuez, Spain; [Sala Llinas, Ernest] Hosp Son Espases, HU Son Espases, Palma de Mallorca, Spain; [Blanco Coronado, Jose] HV Mar, Almeria, Spain; [Almenar Bonet, Luis; Todoli Parra, Jose] HUP La Fe, Valencia, Spain; [Vida Gutierrez, Manuel] HV Mar, CH Torrecardenas, Almeria, Spain; [Sanchez Lora, Fernando] HU Virgen de la Victoria, Malaga, Spain; [Sanchez Martinez, Rosario] HGU Alicante, Alicante, Spain; [Calderon, Enrique] Hosp Univ Virgen del Rocio, Seville, Spain; [Calderon, Enrique] CIBERESP, Seville, Spain; [Villalta Blanch, Jaume] Hosp Clin Barcelona, Fdn Clin, HUP Hierro Majadahonda, Barcelona, Spain; [De la Hera Galarza, Jesus] HUC Asturias, Oviedo, Spain; [Bustamante Ruiz, Ana] Hosp Marques De Valdecilla, CEIC Reg Cantabria, H Sierrallana, Torrelavega, Spain; [Jose Garcia-Fuster, Maria] Hosp Clin Univ Valencia, Valencia, Spain; [Ripoll Vera, Tomas] H Son Llatzer, Palma de Mallorca, Spain; [Alvarez-Sala Walter, Luis; Diaz Fernandez, Jose] HGUG Maranon, Madrid, Spain; [Bosa Ojeda, Francisco] Fdn Rafael Clavijo, HU Canarias, San Cristobal la Laguna, Spain; [Pellicer-Ciscar, Concepcion] H Francesc Borja, Valencia, Spain; [Jara Palomares, Luis] HUV Rocio, Seville, Spain; [Quiles Granado, Juan] HU San Juan Alicante, San Juan, Spain; [Trigo Bautista, Alberto] CAAH Ntra SradeSonsoles, Avila, Spain; [Ruiz Bustillo, Sonia] Hosp del Mar, Barcelona, Spain; [Ordi Ros, Josep] Hosp Univ Vall dHebron, Barcelona, Spain; [Tolosa-Vilella, Carles] Univ Hosp, Parc Tauli, Barcelona, Spain; [Marin Ortuno, Francisco] Hosp Univ Virgen de la Arrixaca, Fdn FORMAC INVEST SANIT ENLA, El Palmar, Spain; [Garcia Sanchez, Florentino] HU Ppe Asturias, Madrid, Spain; [Barba Martin, Raquel] Hosp Rey Juan Carlos, Mostoles, Spain; [Segovia Cubero, Javier; Cuervas-Mons Martinez, Valentin] Hosp Univ Puerta Hierro Majadahonda, Majadahonda Madrid, Spain; [Galan Montejano, Miguel] HC Don Benito, Fundesalud, Don Benito, Spain; [Lopez Meseguer, Manuel] Hosp Univ Vall dHebron, Barcelona, Spain; [Sener Comert, Sevda] Kartal Lutfi Kirdar Educ & Res Hosp, Istanbul, Turkey; [Koksal, Nurhan] Ondokuz Mayis Univ, Med Fac, Samsun, Turkey; [Tertemiz, Kemal] Dokuz Eylul Univ, Med Fac, Izmir, Turkey; [Ernam, Dilek] Sureyyapasa Ctr Chest Dis, Istanbul, Turkey; [Dursun, Adile] Recep Tayyip Erdogan Univ, Med Fac, Rize, Turkey; [Yildiz, Oznur] Ankara Univ, ZEYNEP PINAR ONEN, Sch Med Pulm Dis, Ankara, Turkey; [Rudenko, Leonid] Kiev Municipal Emergency Hosp, Kiev, Ukraine; [Abrahamovych, Orest] Danylo Halytsky Lviv Natl Med Univ, Lvov, Ukraine; [Goloborodko, Alla] Odessa Reg Clin Hosp, Odessa, Ukraine; [Holovchenko, Nataliia] KZ Khersonska Miska Klin Iikarnia Imeni Afanasiia, Kherson, Ukraine; [Kulyk, Anna] Cherkaska Oblasna Iikarnia, Oblasna Iikarnia, M Cherkasy, Ukraine; [Yagensky, Andriy] Lutsk City Hosp, Lutsk, Ukraine; [Batushkin, Valerii] Kyiv City Clin Hosp 5, Kiev, Ukraine; [Zolotaikina, Viktoriia] Kharkivska Miska Klin Likarnia 27, Kharkov, Ukraine; [Kozyolkin, Oleksandr] MI City Clin Hosp 6, Zaporizhzhia, Ukraine; [Faynyk, Andriy] Lviv Reg Cardiol Ctr, Lvov, Ukraine; [Maslovskyy, Valentyn] Vinnitsa Reg Clin Hosp Vet, Vinnitsa, Ukraine; [Petrovskyy, Roman] Ivano Frankivskyy Oblasnyy Klin Kardiol, Ivano Frankivsk, Ukraine; [Koshlia, Volodymyr] SI Zaporizhzhya Med Acad Postgrad Educ, Zaporizhzhya Med Acad Postraduate Educ, Miska Klin Iikarnia 9, Zaporizhzhia, Ukraine; [Chopey, Ivan] Viddilkova Iikarnia Stantsii Uzhgorod, M Uzhgorod, Ukraine; [Burmak, Iurii] 4 City Clin Hosp, Ukranian Med Stomatol Acad, Poltava, Ukraine; [Malynovsky, Yaroslav] Reg Med Ctr CardioVasc Dis, Zaporizhzhya, Ukraine; [Voronkov, Leonid] Natl Sci Ctr MD Strazhesko Inst Car, Inst Cardiol AMS, Kiev, Ukraine; [Karpenko, Olexandr] City Clin Hosp 1, Kiev, Ukraine; [Dziublyk, Oleksandr] Nasl Inst Ftyziatrii Pulmonol Yanovskoho, Kiev, Ukraine; [Godlevska, Olga] City Clin Emergency Hosp, Khark Mis Klin Lik Shvydk Ta Nevidkladnoi Meddopo, Kharkiv City Clin Emergency Hosp, Komunalna Ustanova Okhorony Zdorovia Kharkivska M, Kharkov, Ukraine; [Borovyk, Valentyna] Chernihivska Miska Iikarnia 2, Chernihiv, Ukraine; [Bezrodna, Larysa] SI NSC Inst Cardiol, Kiev, Ukraine; [Serik, Sergii] LT Malaya Therapy Inst NAMS of Ukraine, Kharkov, Ukraine; [Ovsyannikova, Nataliya] DLPZ Tsentralna Klin Iikarnia Ukrzaliznytsi, Kharkov, Ukraine; [Vynnychenko, Lyudmyla] Sumy Reg Clin Oncol Ctr, Komunalna Ustanova Sumska Miska Klin Iikarnia 1, Sumska Miska Klin Iikarnia 1, Sumy, Ukraine; [Kopytsya, Mykola] Inst Therapy, Kharkov, Ukraine; [Rudkovskiy, Volodymyr] Kyivska Miska Klin Iikarnia 8, Kiev, Ukraine; [Grishyna, Olena] Mechnikov Inst, Miska Bagatoprofilna Iikarnia 18, Kharkov, Ukraine; [Vyshnyvetskyy, Ivan] Zhytomyr Cent City Hosp 1, Zhytomyr, Ukraine; [Prystupa, Lyudmyla] Komunalnyi Zaklad Sumskoi Oblasnoi Rady Sumska Ob, Sumska Oblasna Klin Iikarnia, Sumy, Ukraine; [Tseluyko, Vira] Kharkiv Med Acad Postgrad Educ, KZOZ Kharkivska Miska Klin Iikarnia 8, Kzoz Kh Mkl 8, Kharkov, Ukraine; [Perepeliuk, Mykola] Odesa Natl Med Univ, Odessa, Ukraine; [Koval, Olena] Kl Obied Shv Med Dop, Dnepropetrovsk, Ukraine; [Sychov, Oleg] Nasl Naukovyi Tsentr Inst Kardiol M Strazh, Kiev, Ukraine; [Church, Alistair] Queen Elizabeth Univ Hosp Glasgow, NHS Greater Gla, nSGUH, Glasgow, Lanark, Scotland; [Goudie, Andrew] Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; [Elliott, Mark] St James Univ Hosp, Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England; [Ferguson, Craig] Univ Manchester, GM LCRN Great Manchester Local Clin Res Network, Manchester Royal Infirm, Manchester, Lancs, England; [Welker, James] Anne Arundel Med Ctr, Anne Arundel Hlth Syst, Annapolis, MD USA; [Kao, Cheng-Kai] Univ Chicago, Chicago, IL 60637 USA; [Bhagwat, Ravi] Cardiol Associates Northwest Indiana PC, Cardiovasc Res Northwest Indiana, Munster, Germany; [Serota, Harvey] PC SLHV Christian Hosp, St Louis Heart & Vasc, Practice Dr Harvey Serota, St Louis Heart & Vasc Res Dept, St Louis, MO USA; [Rosenberg, David] North Shore Univ Hosp, Long Isl Jewish Med Ctr, Montefiore Med Ctr, Manhasset, NY USA; [Bozorgchami, Hormozd] Oregon Hlth & Sci Univ Hosp, Portland, OR USA; [Nambiar, Rajesh] Amarillo Heart Grp, Amarillo, TX USA; [Hazelrigg, Monica] McGuire VA Med Ctr, Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA; [Spilseth, Sara] Reg Hosp, HealthPartners Res & Educ, Bloomington, IN USA; [Bhagwath, Gayathri] Angeles Clin & Res Inst Los Angeles, Dallas, TX USA; [Syed, Faizullah] Shoals Primary Care LLC, SYED Res Res Consultants LLC Www Syedreserach Com, Res Consultants, Sheffield, S Yorkshire, England; [Morrow, Lee] Creighton Univ, Med Ctr, Alegent Creighton Clin Pulm, Omaha, NE USA; [Updegrove, John] Corsicana Med Res, Corsicana, TX USA; [Bercz, Peter] Pensacola Lung Grp PA, Pensacola, FL USA; [Kambo, Varinder] Lenox Hill Hosp, New York, NY 10021 USA; [Henderson, David] Cardiol Associates Res Co, Daytona Beach, FL USA; [Wright, Patrick] Moses Cone Hlth Syst, Piedmontresp Res Fdn, Greensboro, NC USA; [Dang, Nguyen] Cardiol Consultants Orange Cty Med Grp Inc, Anaheim, CA USA; [Nadar, Venkatesh] Capital Area Res LLC, Heritage Med Grp HMG Heritage Cardiol Associate, Camp Hill, PA USA; [Jaffrani, Naseem] Cambridge Med Trials, Alexandria Cardiol Clin, DM Clin Res, Alexandria, VA USA; [El-Shahawy, Mohamed] Acad Med Res Inst, Los Angeles, CA USA; [Grossman, Colby] Palmetto Clin Res, Summerville, SC USA; [Pearle, James] Calif Res Med Grp Inc, ClinEdge, Fullerton, CA USA; [Weinstein, Debra] Atlantic Clin Res LLC, Atlantic Clin Res Collaborat, ACRC Cardiol Atlantic Clin Res, ClinEdge Orthoped Res Inst,Vis Clin Res Zasa Clin, Boynton Beach, FL USA; [Galanis, Taki] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA; [Gazmuri, Raul] Captain James Lovell Fed Hlth Care Ctr, North Chicago VA Med Ctr, N Chicago, IL USA; [Kastelic, Richard] Richard M Kastel MD & Associates, Johnstown, PA USA; [Martinez, Rafael] Pulm & Sleep Tampa Bay, Brandon, FL USA; [Laman, David] Consolidated Clin Trials Inc, Piedmont Healthcare Piedmont Heart Inst, Pittsburgh Pulm Associates, Monroeville, PA USA; [Macchiavelli, Anthony] AtlantiCare, Atlantic City, NJ USA; [Kmetzo, James] Doylestown Hosp, Cent Bucks Cardiol VIAA, Doylestown, PA USA; [Thurm, Craig] Jamaica Hosp Med Ctr, Jamaica, NY USA; [Kayembe, Tshiswaka] Midwest Hlth Profess, Ctr Adv Med & Res, St Petersburg, FL USA; [Chandrashekhar, Yellapragada] Univ Minnesota, Minneapolis VA Med Ctr, Minneapolis, MN USA; [Bassetti, Dennis] Marquez Clin Site Partners LLC, Clin Trials Florida LLC, Bassetti Med Res Inc, Sebring, FL USA; [Jaoude, Philippe] Vet Affairs Western New York Healthcare Syst Buff, Buffalo, NY USA; [Williams, Hayes] Cent Res Associates Inc, Achieve Clin Res, Elite Res Network, Birmingham, AL USA; [Dewhurst, Robert] Bay Area Cardiol Associates PA, Brandon, FL USA; [Naqvi, Syed] Univ Missouri Hlth Car, Clin Res Ctr, Columbia, MO USA; [Burr, John] Illinois Heart & Lung Res Ctr, Normal, IL USA; [Rodriguez-Cintron, William] SODEINC Inc, VA Caribbean Healthcare Syst, San Juan, PR USA; [Jeanfreau, Robert] Medpharm LLC, Benchmark Res, Metaire, LA USA; [Kosinski, Edward] Connecticut Clin Res LLC, Bridgeport, CT USA; [Ndukwu, Ikeadi] St Anthony Mem Hosp, LaPorte Cty Inst Clin Res, Effingham, IL USA; [Sotolongo, Carlos] Jacksonville Heart Ctr, Baptist Med Ctr, Baptist Heart Specialists Baptist Beaches Off, Jacksonville, FL USA; [Daboul, Nizar; Wilmer, Charles] St Lukes Hosp, Adv Med Res, Maumee, OH USA; [Simon, Peter] Vet Affairs Pittsburgh Healthcare Syst, Highland Dri, Pittsburgh, PA USA; [Tak, Tahir] Mayo Clin Hlth Syst, La Crosse, WI USA; [Rees, Christopher] Pennsylvania Hosp, Philadelphia, PA USA; [Gupta, Nishant] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA; [Lerner, Robert] Westchester Med Ctr Valhalla, Valhalla, NY USA; [Tapson, Victor] Cedars Sinai Med Ctr, Beverly Hills, CA USA; [Graffagnino, Carmelo] Duke Univ, Med Ctr, Durham, NC USA; [Reed, Robert] Univ Maryland, Baltimore, MD USA; [Alford, Chad] Mobile Heart Specialists PC, Mobile, AL USA; [Mody, Freny] Greater Angeles Healthcare Syst, Brentwood Med Res Inst, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; [Wellmon, Baxter] Biomed Res Ass, Shippensburg, PA USA; [Hamroff, Glenn] Hudson Valley Cardiol Grp Cortlandt Med Bldg, Montefiore Med Ctr, NYU Hudson Valley Cardiol, Hudson, NY USA; [Rajan, Raj] Nova Clin Res LLC, Theia Res LLC, Bradenton, FL USA; [Kaatz, Scott] Henry Ford Hosp, Detroit, MI USA	Northwell Health; Northwell Health; Icahn School of Medicine at Mount Sinai; University of Insubria; Stanford University; University of California System; University of California Davis; Intermountain Healthcare; Intermountain Medical Center; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Colorado System; University of Colorado Anschutz Medical Campus; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Imperial College London; Royal Brompton Hospital; McMaster University; McMaster University; Johnson & Johnson; Janssen Pharmaceuticals; University of Oklahoma System; University of Oklahoma Health Sciences Center; Hospital Privado - Universitario de Cordoba; Gold Coast University Hospital; Mater Health Services; Royal Perth Hospital; Royal Perth Hospital; Flinders Medical Centre; St George Hospital; St George Hospital; Medical University of Vienna; University Hospital Vienna; Konventhospital Der Barmherzigen Bruder; Republican Scientific & Practical Center Cardiology; University of Mostar; Universidade Estadual de Campinas; Universidade de Sao Paulo; Pontificia Universidade Catolica Do Rio Grande Do Sul; Fundacao Universitaria de Cardiologia; Universidade Federal de Pernambuco; Universidade de Sao Paulo; Medical University Sofia; Scarborough Hospital; Universite de Montreal; University of Ottawa; Ottawa Hospital Research Institute; University of Alberta; University of Sherbrooke; McGill University; McMaster University; Hospital Universitario San Ignacio; Fundacion Valle del Lili; Universidad del Quindio; Fundacion Cardioinfantil - Instituto de Cardiologia; Universidad de La Sabana; University of Rijeka; University of Zagreb; University of Zagreb; General University Hospital Prague; University Hospital Brno; Thomayer Hospital; University Hospital Vinohrady; General University Hospital Prague; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Ruprecht Karls University Heidelberg; Technische Universitat Dresden; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Klinikum Coburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Patras; Henry Dunant Hospital; University of Crete; University Hospital Attikon; Aristotle University of Thessaloniki; Ahepa University Hospital; Democritus University of Thrace; University of Pecs; University of Pecs; University of Pecs; Semmelweis University; University of Debrecen; University of Debrecen; University of Debrecen; University of Debrecen; Szeged University; Szeged University; Rabin Medical Center; Rambam Health Care Campus; Rabin Medical Center; Ziv Medical Center; Rambam Health Care Campus; Technion Israel Institute of Technology; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Western Galilee Hospital; Western Galilee Hospital; Bnai Zion Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Ospedale Circolo & Fondazione Macchi; ULSS 2 Marca TV; Ospedale Vittorio Veneto; ULSS 1 Dolomiti; Ospedale di Feltre; IRCCS Multimedica; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Sapienza University Rome; University Hospital Sapienza Rome; Sapienza University Rome; University Hospital Sapienza Rome; Hospital of Rimini; IRCCS Neuromed; University of Genoa; University of Genoa; IRCCS AOU San Martino IST; ULSS 8 Berica; Ospedale San Bortolo di Vicenza; University of Florence; Azienda Ospedaliero Universitaria Careggi; IRCCS INRCA; IRCCS Humanitas Research Hospital; Pauls Stradins Clinical University Hospital; Vilnius University; Klaipeda Republican Hospital; Vilnius University; Klaipeda University; Klaipeda University Hospital; Vilnius University; Jeroen Bosch Ziekenhuis; Medical Center Of Alkmaar; Rijnstate Hospital; Gelre Hospitals; Seguro Social de Salud del Peru; Silesian Center for Heart Diseases; Jagiellonian University; Collegium Medicum Jagiellonian University; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Rostov State Medical University; North-Western State Medical University named after I.I. Mechnikov; North-Western State Medical University named after I.I. Mechnikov; Sechenov First Moscow State Medical University; Pavlov First Saint Petersburg State Medical University; Krasnoyarsk State Medical University; Clinical Centre of Serbia; University of Witwatersrand; Stellenbosch University; Tygerberg Hospital; University of Cape Town; Hospital Clinico San Carlos; Hospital Universitari Son Espases; Virgen del Rocio University Hospital; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; University of Barcelona; Hospital Clinic de Barcelona; Hospital Universitario Marques de Valdecilla (HUMV); Hospital Clinic Universitari de Valencia; Hospital Universitari Son Llatzer; Universidad de la Laguna; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Hospital Universitari Vall d'Hebron; Hospital Clinico Universitario Virgen de la Arrixaca; Hospital Puerta de Hierro-Majadahonda; Hospital Universitari Vall d'Hebron; Istanbul Kartal Dr Lutfi Kirdar Training & Research Hospital; Ondokuz Mayis University; Dokuz Eylul University; Recep Tayyip Erdogan University; Ankara University; Danylo Halytsky Lviv National Medical University; Poltava State Medical University; National Academy of Medical Sciences of Ukraine; National Scientific Center M.D. Strazhesko Institute of Cardiology of the National Academy of Medical Sciences of Ukraine; National Academy of Medical Sciences of Ukraine; National Scientific Center M.D. Strazhesko Institute of Cardiology of the National Academy of Medical Sciences of Ukraine; Ministry of Education & Science of Ukraine; Sumy State University; National Academy of Medical Sciences of Ukraine; L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine; National Academy of Medical Sciences of Ukraine; I.Mechnikov Institute of Microbiology & Immunology of the National Academy of Medical Sciences of Ukraine; Kharkiv Medical Academy of Postgraduate Education; Odessa National Medical University; National Academy of Medical Sciences of Ukraine; National Scientific Center M.D. Strazhesko Institute of Cardiology of the National Academy of Medical Sciences of Ukraine; Queen Elizabeth University Hospital (QEUH); University of Dundee; Saint James's University Hospital; University of Leeds; University of Manchester; University of Chicago; Montefiore Medical Center; Northwell Health; North Shore University Hospital; Oregon Health & Science University; Hunter Holmes McGuire Veterinary Affairs Medical Center; Creighton University; Northwell Health; Jefferson University; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Westchester Medical Center; Cedars Sinai Medical Center; Duke University; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; Montefiore Medical Center; Henry Ford Health System; Henry Ford Hospital	Spyropoulos, AC (corresponding author), Northwell Hlth, Lenox Hill Hosp, 130 E 77th St, New York, NY 10075 USA.	aspyropoul@northwell.edu	Lodigiani, Corrado/AAW-1964-2020; Bereczki, Daniel/AAL-9886-2020; Halperin, Jonathan/AAJ-4721-2020; Zimmermann, Sérgio/AIE-5122-2022; Karapanayiotides, Theodoros/ABE-4423-2020; Nikolaev, Konstantin/P-4750-2017; Boldueva, Svetlana/AAH-3862-2019; Pozsonyi, Zoltán/AAD-3278-2020; Tsivgoulis, Georgios/AAD-5360-2020; Forster, Tamas/AAV-9037-2020; Zateyshchikov, Dmitry A/D-6575-2012; barba martin, raquel/GRE-9368-2022; Beyer-Westendorf, Jan/K-7569-2019; Abrahamovych, Orest/M-9818-2019; Weitz, Jeffrey/AAD-1929-2019; Jara-Palomares, Luis/A-4090-2017; Chong, Beng/AAE-2617-2019; Reis, Gilmar/I-4500-2013; Bowler, Simon/AAE-1630-2019; Ruzic, Alen/N-2117-2018; VADIKOLIAS, KONSTANTINOS/AAK-3620-2021; Köksal, Nurhan/AAG-5849-2021; Apartsin, Konstantin/ABC-5678-2020; Konstantinides, Stavros/AAL-3174-2021; Brachmann, Johannes/AAD-1499-2021; Faynyk, Andriy/G-5152-2019; Tosetto, Alberto/AAB-9320-2022; Shpagina, Lyubov/Y-7864-2018; Musiał, Jacek/U-5930-2018; Sikic, Jozica/GXG-0013-2022; nikolaishvili, Giorgi/AAX-7868-2020; Yıldız, Öznur/AAM-7271-2020; vardas, panos/ABF-7144-2020; ntsekhe, mpiko/AAI-8001-2021; Marchev, Sotir/AAH-6529-2020; Apartsin, Konstantin A/B-9179-2017; Precoma, Dalton B/D-5674-2013; STEG, Philippe Gabriel/Z-1567-2019; Maslovskyi, Valentyn/V-3896-2019; Koksal, Nurhan/AAA-3249-2022; Bustillo, Sonia Ruiz/AAC-1329-2020; Cojocaru, Cristian/ADP-1201-2022; Chong, Beng/AAM-9010-2021; Quiles, Juan/B-9663-2009; Malynovsky, Yaroslav/T-1898-2017; Zateyshchikov, Dmitry/AGN-8590-2022; Baker, Ross/AAG-5798-2021; Laganović, Mario/CAG-4680-2022; Apartsin, Konstantin/ACA-8088-2022; Grinshtein, Yury/M-4091-2014; Pojskic, Belma/AAO-9702-2021; Maslovskyi, Valentyn/GQO-9125-2022; Tosetto, Alberto/AAM-3200-2020; Antonicelli, Roberto/AAB-3233-2021; Koziolkin, Oleksandr/AAA-5382-2019; Koval, Olena/AAF-7121-2020; Andreev, Denis А/W-2390-2017; Babic, Rade/AAO-1507-2020; Tudoran, Mariana M/C-8126-2015; Akin, Ibrahim/AAF-1356-2020; Kosmacheva, Elena/AAY-4841-2020; dursun, adile berna/GXM-6812-2022; Middeldorp, Saskia/ABI-8197-2020; Vyshnyvetskyy, Ivan/AAP-5012-2020; Ripoll-Vera, Tomas/AAT-3535-2021; Prozesky, Hans Walter/ABE-6956-2020; Shvarts, Yury Григорьевич/AAB-4929-2022; Segovia-Cubero, Javier/AAB-7345-2021; Repin, Alexey/J-6150-2017; Serik, Serhii/T-3897-2018; Barbarash, Olga/A-4834-2017; Lopez Meseguer, Manuel/D-6177-2018; Cuervas-Mons, Valentin/C-8504-2017	Lodigiani, Corrado/0000-0002-9152-9385; Halperin, Jonathan/0000-0002-8318-5471; Nikolaev, Konstantin/0000-0003-4601-6203; Boldueva, Svetlana/0000-0002-1898-084X; Tsivgoulis, Georgios/0000-0002-0640-3797; Zateyshchikov, Dmitry A/0000-0001-7065-2045; barba martin, raquel/0000-0002-1408-1441; Beyer-Westendorf, Jan/0000-0002-6983-9993; Abrahamovych, Orest/0000-0001-6862-6809; Weitz, Jeffrey/0000-0002-1092-7550; Jara-Palomares, Luis/0000-0002-4125-3376; Reis, Gilmar/0000-0002-4847-1034; Ruzic, Alen/0000-0001-5031-2975; VADIKOLIAS, KONSTANTINOS/0000-0003-0484-369X; Apartsin, Konstantin/0000-0003-0577-9001; Konstantinides, Stavros/0000-0001-6359-7279; Shpagina, Lyubov/0000-0003-0871-7551; Musiał, Jacek/0000-0002-8994-0036; Yıldız, Öznur/0000-0002-5379-6829; ntsekhe, mpiko/0000-0002-0851-7675; Marchev, Sotir/0000-0001-9250-510X; Apartsin, Konstantin A/0000-0003-0577-9001; Maslovskyi, Valentyn/0000-0001-5184-1799; Bustillo, Sonia Ruiz/0000-0002-6074-914X; Cojocaru, Cristian/0000-0001-9933-8965; Quiles, Juan/0000-0002-3458-6260; Malynovsky, Yaroslav/0000-0002-9118-1104; Zateyshchikov, Dmitry/0000-0001-7065-2045; Baker, Ross/0000-0002-2728-6788; Laganović, Mario/0000-0002-0240-4178; Apartsin, Konstantin/0000-0003-0577-9001; Grinshtein, Yury/0000-0001-8847-235X; Pojskic, Belma/0000-0002-5374-990X; Maslovskyi, Valentyn/0000-0001-5184-1799; Tosetto, Alberto/0000-0002-0119-5204; Antonicelli, Roberto/0000-0002-5921-1828; Koziolkin, Oleksandr/0000-0001-9878-5798; Andreev, Denis А/0000-0002-0276-7374; Babic, Rade/0000-0002-1674-9732; Tudoran, Mariana M/0000-0001-8989-5899; Middeldorp, Saskia/0000-0002-1006-6420; Vyshnyvetskyy, Ivan/0000-0001-7228-3052; Prozesky, Hans Walter/0000-0001-9715-3449; Shvarts, Yury Григорьевич/0000-0002-5205-7311; RIPOLL-VERA, TOMAS/0000-0001-9222-325X; Albers, Gregory/0000-0003-0263-4632; Giorgi-Pierfranceschi, Matteo/0000-0002-7988-9652; Apostolovic, Svetlana/0000-0001-9015-297X; Sala-Llinas, Ernest/0000-0002-6499-1638; Torbicki, Adam/0000-0003-3475-8832; Gallus, Alexander/0000-0001-7347-9989; Ramacciotti, Eduardo/0000-0002-5735-1333; Karapanayiotides, Theodoros/0000-0002-2357-7967; Repin, Alexey/0000-0001-7123-0645; Khorana, Alok/0000-0002-9509-0998; Kosior, Dariusz/0000-0002-7821-4442; Serik, Serhii/0000-0001-6257-3566; Csanyi, Attila/0000-0002-2368-3751; Khalafallah, Alhossain/0000-0002-2399-3311; Zolotaikina, Viktoriia/0000-0002-5265-4861; Barbarash, Olga/0000-0002-4642-3610; Godlevska, Olga/0000-0001-7473-9711; Lopez Meseguer, Manuel/0000-0003-2650-9238; Gomez-Mesa, Juan Esteban/0000-0002-6635-6224; Gregorio, Tiago/0000-0002-0131-9430; Sanchez Martinez, Rosario/0000-0003-0408-3029; Kosmacheva, Elena/0000-0001-8600-0199; Gazmuri, Raul J./0000-0002-3848-7227; Kopitovic, Ivan/0000-0003-4733-0093; Cuervas-Mons, Valentin/0000-0003-3086-9463	Janssen Research and Development; Daiichi Sankyo; Portola; Boehringer Ingelheim; Janssen; Bayer; BMS Pfizer; Aspen; Sanofi; University of Cincinnati and Spectrum Health; Pfizer; ATLAS Group (Colorado Prevention Center); Johnson Johnson; Ortho-McNeil-Janssen; Bayer/Janssen; Merck; Amgen	Janssen Research and Development; Daiichi Sankyo(Daiichi Sankyo Company Limited); Portola; Boehringer Ingelheim(Boehringer Ingelheim); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Bayer(Bayer AG); BMS Pfizer(Pfizer); Aspen; Sanofi; University of Cincinnati and Spectrum Health; Pfizer(Pfizer); ATLAS Group (Colorado Prevention Center); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Ortho-McNeil-Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Bayer/Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech IncBayer AG); Merck(Merck & Company); Amgen(Amgen)	Supported by Janssen Research and Development.r Dr. Spyropoulos reports receiving advisory board fees from Daiichi Sankyo and Portola, grant support, consulting fees, and advisory board fees from Boehringer Ingelheim and Janssen, consulting fees and advisory board fees from Bayer, and a stipend from ATLAS Group (Colorado Prevention Center); Dr. Ageno, receiving grant support and advisory board fees from Bayer and BMS Pfizer and advisory board fees from Portola, Daiichi Sankyo, Aspen, Boehringer Ingelheim, and Sanofi; Dr. Albers, receiving consulting fees from Bayer; Dr. Elliott, receiving fees for serving on a steering committee from Bayer and lecture fees from the University of Cincinnati and Spectrum Health; Dr. Halperin, receiving consulting fees from Boehringer Ingelheim, Daiichi Sankyo, Pfizer, ATLAS Group (Colorado Prevention Center), Johnson & Johnson, and Ortho-McNeil-Janssen; Dr. Hiatt, receiving grant support from Janssen and Bayer; Dr. Steg, receiving grant support and fees for serving on a steering committee from Bayer/Janssen, grant support and lecture fees from Merck, grant support, consulting fees, lecture fees, and fees for serving as cochair of the ODYSSEY outcomes trial and the SCORED trial from Sanofi, grant support and fees for serving as chair of the CLARIFY registry from Servier, consulting fees and fees for serving on the executive steering committee for the REDUCE IT trial from Amarin, consulting fees and lecture fees from Amgen, consulting fees, lecture fees, and fees for critical event committee work from Bristol-Myers Squibb, fees for serving on the executive steering committee of the REDUAL PCI trial from Boehringer Ingelheim, fees for critical event committee work from Pfizer, consulting fees and fees for serving on the executive steering committee for the PARADISE MI trial from Novartis, consulting fees from Regeneron and Lilly, and consulting fees and fees for serving as cochair of the THEMIS trial from AstraZeneca; Dr. Weitz, receiving consulting fees and honoraria from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Ionis, Janssen, Merck, Novartis, Pfizer and Portola; Dr. Suh and Dr. Barnathan, being employed by Janssen Research and Development and owning stock in Johnson & Johnson; Dr. Spiro, being employed by and owning shares in Bayer U.S.; and Dr. Raskob, receiving consulting fees from Bayer, BMS, Boehringer Ingelheim, Eli Lilly, Portola, and Novartis and consulting fees and honoraria from Daiichi Sankyo and Pfizer. No other potential conflict of interest relevant to this article was reported.	Cohen AT, 2016, NEW ENGL J MED, V375, P534, DOI 10.1056/NEJMoa1601747; Cohen AT, 2013, NEW ENGL J MED, V368, P513, DOI 10.1056/NEJMoa1111096; Cohen AT, 2005, THROMB HAEMOSTASIS, V94, P750, DOI 10.1160/TH05-06-0385; Gardlund B, 1996, LANCET, V347, P1357; Gibson C Michael, 2017, TH Open, V1, pe56, DOI 10.1055/s-0037-1603929; Goldhaber SZ, 2011, NEW ENGL J MED, V365, P2167, DOI 10.1056/NEJMoa1110899; Hull RD, 2013, CLIN APPL THROMB-HEM, V19, P357, DOI 10.1177/1076029613481105; Hull RD, 2010, ANN INTERN MED, V153, P8, DOI 10.7326/0003-4819-153-1-201007060-00004; Kahn Susan R, 2012, Chest, V141, pe195S, DOI 10.1378/chest.11-2296; Kakkar AK, 2011, NEW ENGL J MED, V365, P2463, DOI 10.1056/NEJMoa1111288; Lutz J, 2014, NEPHROL DIAL TRANSPL, V29, P29, DOI 10.1093/ndt/gft209; Mahan CE, 2014, THROMB HAEMOSTASIS, V112, P692, DOI 10.1160/TH14-03-0239; Mahan CE, 2013, THROMB RES, V132, P520, DOI 10.1016/j.thromres.2013.08.013; Raskob GE, 2016, THROMB HAEMOSTASIS, V115, P1240, DOI 10.1160/TH15-09-0756; Rosenberg D, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001152; Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x; Spyropoulos AC, 2011, CHEST, V140, P706, DOI 10.1378/chest.10-1944; Wattanakit K, 2008, J AM SOC NEPHROL, V19, P135, DOI 10.1681/ASN.2007030308	18	141	147	4	42	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 20	2018	379	12					1118	1127		10.1056/NEJMoa1805090	http://dx.doi.org/10.1056/NEJMoa1805090			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU1KV	30145946	Green Published			2023-01-03	WOS:000445020900006
J	Straus, S; Watt, J				Straus, Sharon; Watt, Jennifer			Aerobic and strength training did not improve cognitive function in mild to moderate dementia	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Straus, Sharon; Watt, Jennifer] Univ Toronto, Toronto, ON, Canada	University of Toronto	Straus, S (corresponding author), Univ Toronto, Toronto, ON, Canada.		Watt, Jennifer/AFS-9124-2022					Brown D, 2015, PHYSIOTHERAPY, V101, P126, DOI 10.1016/j.physio.2015.01.002; Firbes D, 2015, COCHRANE DB SYST REV, V4; Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6; Tricco AC, 2017, JAMA-J AM MED ASSOC, V318, P1687, DOI 10.1001/jama.2017.15006	4	0	0	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 18	2018	169	6					JC34	JC34		10.7326/ACPJC-2018-169-6-034	http://dx.doi.org/10.7326/ACPJC-2018-169-6-034			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GT7CZ	30242407				2023-01-03	WOS:000444679800010
J	Driesen, BEJM; Van Riet, BHG; Verkerk, L; Bonjer, HJ; Merten, H; Nanayakkara, PWB				Driesen, Babiche E. J. M.; Van Riet, Bauke H. G.; Verkerk, Lisa; Bonjer, H. Jaap; Merten, Hanneke; Nanayakkara, Prabath W. B.			Long length of stay at the emergency department is mostly caused by organisational factors outside the influence of the emergency department: A root cause analysis	PLOS ONE			English	Article							PATIENT SAFETY; INTERNATIONAL CLASSIFICATION; COMPLETION TIMES; WEAKEST LINK; CARE; RISK; COORDINATION; NETHERLANDS; MANAGEMENT; FRAMEWORK	Background Emergency department (ED) crowding is common and associated with increased costs and negative patient outcomes. The aim of this study was to conduct an in-depth analysis to identify the root causes of an ED length of stay (ED-LOS) of more than six hours. Methods An observational retrospective record review study was conducted to analyse the causes for ED-LOS of more than six hours during a one-week period in an academic hospital in the Netherlands. Basic administrative data were collected for all visiting patients. A root cause analysis was conducted using the PRISMA-method for patients with an ED-LOS > 6 hours, excluding children and critical care room presentations. Results 568 patients visited the ED during the selected week (January 2017). Eighty-four patients (15%) had an ED-LOS > 6 hours and a PRISMA-analysis was performed in 74 (88%) of these patients. 269 root causes were identified, 216 (76%) of which were organisational and 53 (22%) patient or disease related. 207 (94%) of the organisational factors were outside the influence of the ED. Descriptive statistics showed a mean number of 2,5 consultations, 59% hospital admissions or transfers and a mean age of 57 years in the ED-LOS > 6 hours group. For the total group, there was a mean number of 1,9 consultations, 29% hospital admissions or transfers and a mean age of 43 years. Conclusions This study showed that the root causes for an increased ED-LOS were mostly organisational and beyond the control of the ED. These results confirm that interventions addressing the complete acute care chain are needed in order to reduce ED-LOS and crowding in ED's.	[Driesen, Babiche E. J. M.] Vrije Univ Amsterdam Med Ctr, Dept Emergency Med, Amsterdam, Netherlands; [Van Riet, Bauke H. G.] Vrije Univ Amsterdam, Sch Med Sci, Amsterdam, Netherlands; [Van Riet, Bauke H. G.; Verkerk, Lisa; Nanayakkara, Prabath W. B.] Vrije Univ Amsterdam Med Ctr, Dept Internal Med, Sect Acute Med, Amsterdam, Netherlands; [Bonjer, H. Jaap] Vrije Univ Amsterdam Med Ctr, Dept Surg, Amsterdam, Netherlands; [Merten, Hanneke; Nanayakkara, Prabath W. B.] Vrije Univ Amsterdam Med Ctr, Dept Publ & Occupat Hlth, Amsterdam Publ Hlth Res Inst, Amsterdam, Netherlands; [Merten, Hanneke; Nanayakkara, Prabath W. B.] Vrije Univ Amsterdam Med Ctr, Acute Care Network North West, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Nanayakkara, PWB (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Internal Med, Sect Acute Med, Amsterdam, Netherlands.; Nanayakkara, PWB (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Publ & Occupat Hlth, Amsterdam Publ Hlth Res Inst, Amsterdam, Netherlands.; Nanayakkara, PWB (corresponding author), Vrije Univ Amsterdam Med Ctr, Acute Care Network North West, Amsterdam, Netherlands.	p.nanayakkara@vumc.nl		Nanayakkara, Prabath WB/0000-0002-1555-3682				American College of Emergency Physicians, 2006, Ann Emerg Med, V47, P585; Anneveld M, 2013, INT J EMERG MED, V6, DOI 10.1186/1865-1380-6-21; Balakrishnan Tharmmambal, 2017, Acute Med, V16, P170; Bernstein SL, 2009, ACAD EMERG MED, V16, P1, DOI 10.1111/j.1553-2712.2008.00295.x; Brouns SHA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173387; Byrne Declan, 2018, Acute Med, V17, P18; Cooksley T, 2017, SUPPORT CARE CANCER, V25, P3, DOI 10.1007/s00520-016-3470-1; Di Somma S, 2015, INTERN EMERG MED, V10, P171, DOI 10.1007/s11739-014-1154-8; Fluitman KS, 2016, EUR J INTERN MED, V30, P18, DOI 10.1016/j.ejim.2015.12.021; Goslings C, 2016, COMMUNICATION   0519; Henneman PL, 2010, J EMERG MED, V39, P105, DOI 10.1016/j.jemermed.2008.08.018; Jo S, 2015, AM J EMERG MED, V33, P1725, DOI 10.1016/j.ajem.2015.08.004; Leendertse AJ, 2008, ARCH INTERN MED, V168, P1890, DOI 10.1001/archinternmed.2008.3; Miro A O, 1999, EUR J EMERG MED, V6, P7; Palmisano P, 2014, INT J BIOMETEOROL, V58, P1513, DOI 10.1007/s00484-013-0755-7; Pines JM, 2011, ACAD EMERG MED, V18, P1358, DOI 10.1111/j.1553-2712.2011.01235.x; RASMUSSEN J, 1983, IEEE T SYST MAN CYB, V13, P257, DOI 10.1109/TSMC.1983.6313160; Reason J, 2000, WESTERN J MED, V172, P393, DOI 10.1136/ewjm.172.6.393; Reason J., 1997, MANAGING RISKS ORG A, P251; Richardson D., 2006, MED J AUSTRALIA, V6, P6; Richardson DB, 2017, EMERG MED AUSTRALAS, V29, P415, DOI 10.1111/1742-6723.12771; Rombach S M, 2018, Acute Med, V17, P62; Runciman WB, 2006, QUAL SAF HEALTH CARE, V15, pI82, DOI 10.1136/qshc.2005.017467; Runciman W, 2009, INT J QUAL HEALTH C, V21, P18, DOI 10.1093/intqhc/mzn057; Schaaf van der TW, 2005, PRISMA MED BRIEF DES; Sherman H, 2009, INT J QUAL HEALTH C, V21, P2, DOI 10.1093/intqhc/mzn054; Smits M, 2009, INT J QUAL HEALTH C, V21, P292, DOI 10.1093/intqhc/mzp023; Sun BC, 2000, ANN EMERG MED, V35, P426, DOI 10.1067/mem.2000.104195; van der Linden C, 2013, INT J EMERG MED, V6, DOI 10.1186/1865-1380-6-41; van der Linden MC, 2019, EUR J EMERG MED, V26, P47, DOI 10.1097/MEJ.0000000000000487; van Ierland Y, 2011, FAM PRACT, V28, P334, DOI 10.1093/fampra/cmq097; van Vuuren W, 1997, DEV INCIDENT ANAL TO, DOI 10.1519/8706&reprep1&typepdf; Vegting IL, 2015, NETH J MED, V73, P331; Vegting IL, 2011, NETH J MED, V69, P392; Verelst S, 2015, J EMERG MED, V49, P949, DOI 10.1016/j.jemermed.2015.05.034; World Health Organization Influenza Laboratory Surveillance Information by the Global Influenza Surveillance and Response System (GISRS), 2017, NUMB SPEC POS INFL S	36	25	25	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2018	13	9							e0202751	10.1371/journal.pone.0202751	http://dx.doi.org/10.1371/journal.pone.0202751			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GT7EG	30216348	Green Submitted, Green Published, gold			2023-01-03	WOS:000444683700009
J	Shen, X; Zhao, B				Shen, Xian; Zhao, Bin			Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OPEN-LABEL; PREDICTIVE BIOMARKERS; CELL CARCINOMA; NIVOLUMAB; DOCETAXEL; MULTICENTER; PEMBROLIZUMAB; ATEZOLIZUMAB; BLOCKADE; MELANOMA	OBJECTIVE To evaluate the relative efficacy of programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitors versus conventional drugs in patients with cancer that were PD-L1 positive and PD-L1 negative. DESIGN Meta-analysis of randomised controlled trials. DATA SOURCES PubMed, Embase, Cochrane database, and conference abstracts presented at the American Society of Clinical Oncology and European Society of Medical Oncology up to March 2018. REVIEW METHODS Studies of PD-1 or PD-L1 inhibitors (avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab) that had available hazard ratios for death based on PD-L1 positivity or negativity were included. The threshold for PD-L1 positivity or negativity was that PD-L1 stained cell accounted for 1% of tumour cells, or tumour and immune cells, assayed by immunohistochemistry staining methods. RESULTS 4174 patients with advanced or metastatic cancers from eight randomised controlled trials were included in this study. Compared with conventional agents, PD-1 or PD-L1 inhibitors were associated with significantly prolonged overall survival in both patients that were PD-L1 positive (n=2254, hazard ratio 0.66, 95% confidence interval 0.59 to 0.74) and PD-L1 negative (1920, 0.80, 0.71 to 0.90). However, the efficacies of PD-1 or PD-L1 blockade treatment in patients that were PD-L1 positive and PD-L1 negative were significantly different (P=0.02 for interaction). Additionally, in both patients that were PD-L1 positive and PD-L1 negative, the long term clinical benefits from PD-1 or PD-L1 blockade were observed consistently across interventional agent, cancer histotype, method of randomisation stratification, type of immunohistochemical scoring system, drug target, type of control group, and median follow-up time. CONCLUSIONS PD-1 or PD-L1 blockade therapy is a preferable treatment option over conventional therapy for both patients that are PD-L1 positive and PD-L1 negative. This finding suggests that PD-L1 expression status alone is insufficient in determining which patients should be offered PD-1 or PD-L1 blockade therapy.	[Zhao, Bin] Wenzhou Med Univ, Affiliated Hosp 2, Ctr Precis Med, 109 Xueyuan West Rd, Wenzhou 325027, Peoples R China; Wenzhou Med Univ, Yuying Childrens Hosp, 109 Xueyuan West Rd, Wenzhou 325027, Peoples R China	Wenzhou Medical University; Wenzhou Medical University	Zhao, B (corresponding author), Wenzhou Med Univ, Affiliated Hosp 2, Ctr Precis Med, 109 Xueyuan West Rd, Wenzhou 325027, Peoples R China.	doctorbinzhao@126.com						Anagnostou V, 2017, CANCER DISCOV, V7, P264, DOI 10.1158/2159-8290.CD-16-0828; Baxi S, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k793; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Blank CU, 2016, SCIENCE, V352, P658, DOI 10.1126/science.aaf2834; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Buttner R, 2017, J CLIN ONCOL, V35, P3867, DOI 10.1200/JCO.2017.74.7642; Dolled-Filhart M, 2016, ARCH PATHOL LAB MED, V140, P1243, DOI 10.5858/arpa.2015-0542-OA; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gibney GT, 2016, LANCET ONCOL, V17, pE542, DOI 10.1016/S1470-2045(16)30406-5; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Joseph RW, 2017, UROL ONCOL-SEMIN ORI, V35, P142, DOI 10.1016/j.urolonc.2017.01.017; Khagi Y, 2017, CANCER METAST REV, V36, P179, DOI 10.1007/s10555-016-9652-y; Lee CK, 2017, J THORAC ONCOL, V12, P403, DOI 10.1016/j.jtho.2016.10.007; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Matsushita H, 2016, CANCER IMMUNOL RES, V4, P463, DOI 10.1158/2326-6066.CIR-15-0225; Melosky B, 2018, CANCER TREAT REV, V65, P65, DOI 10.1016/j.ctrv.2018.02.005; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Schachter J, 2017, LANCET, V390, P1853, DOI 10.1016/S0140-6736(17)31601-X; Schuette W, 2005, J CLIN ONCOL, V23, P8389, DOI 10.1200/JCO.2005.02.3739; Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095; Socinski MA, 2018, J THORAC ONCOL, V13, P165, DOI 10.1016/j.jtho.2017.11.111; Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014; Takada K, 2018, CLIN LUNG CANCER, V19, P120, DOI 10.1016/j.cllc.2017.10.014; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Wang JS, 2017, J MANAG CARE SPEC PH, V23, P158, DOI 10.18553/jmcp.2017.23.2.184; Xu-Monette ZY, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01597; Youngnak P, 2003, BIOCHEM BIOPH RES CO, V307, P672, DOI 10.1016/S0006-291X(03)01257-9; Yousefi H, 2017, EXPERT REV CLIN IMMU, V13, P1001, DOI 10.1080/1744666X.2017.1366315	39	237	247	7	52	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 10	2018	362								k3529	10.1136/bmj.k3529	http://dx.doi.org/10.1136/bmj.k3529			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GU1JC	30201790	hybrid, Green Published			2023-01-03	WOS:000445015400002
J	Opgenorth, D; Stelfox, HT; Gilfoyle, E; Gibney, RTN; Meier, M; Boucher, P; McKinley, D; McIntosh, CNJ; Wang, XM; Zygun, DA; Bagshaw, SM				Opgenorth, Dawn; Stelfox, Henry T.; Gilfoyle, Elaine; Gibney, R. T. Noel; Meier, Michael; Boucher, Paul; McKinley, David; McIntosh, Christiane N. Job; Wang, Xiaoming; Zygun, David A.; Bagshaw, Sean M.			Perspectives on strained intensive care unit capacity: A survey of critical care professionals	PLOS ONE			English	Article							FAMILY SATISFACTION; ICU; PERCEPTIONS; MORTALITY; TIME	Background Strained intensive care unit (ICU) capacity represents a supply-demand mismatch in ICU care. Limited data have explored health care worker (HCW) perceptions of strain. Methods Cross-sectional survey of HCW across 16 Alberta ICUs. A web-based questionnaire captured data on demographics, strain definition, and sources, impact and strategies for management. Results 658 HCW responded (33%; 95% CI, 32 +/- 36%), of which 452 were nurses (69%), 128 allied health (19%), 45 physicians (7%) and 33 administrators (5%). Participants (agreed/strongly agreed: 94%) reported that strain was best defined as a time-varying imbalance between the supply of available beds, staff and/or resources and the demand to provide high-quality care for patients who may become or who are critically ill"; while some recommended defining high-quality care", integrating safety", and families in the definition. Participants reported significant contributors to strain were: inability to discharge ICU patients due to lack of available ward beds" (97%); increases in the volume" (89%); and acuity and complexity of patients requiring ICU support" (88%). Strain was perceived to increase stress levels in health care providers" (98%); and burnout in health care providers" (96%). The highest ranked strategies were: have more consistent and better goals-of-care conversations with patients/families outside of ICU" (95%); and increase non-acute care beds" (92%). Interpretation Strain is perceived as common. HCW believe precipitants represent a mix of patient-related and operational factors. Strain is thought to have negative implications for quality of care, HCW well-being and workplace environment. Most indicated strategies outside" of ICU settings were priorities for managing strain.	[Opgenorth, Dawn; Gibney, R. T. Noel; Meier, Michael; McKinley, David; Zygun, David A.; Bagshaw, Sean M.] Univ Alberta, Fac Med & Dent, Dept Crit Care Med, Edmonton, AB, Canada; [Stelfox, Henry T.; Boucher, Paul] Univ Calgary, Cumming Sch Med, Dept Crit Care Med, Calgary, AB, Canada; [Stelfox, Henry T.; Gilfoyle, Elaine; Meier, Michael; Boucher, Paul; McIntosh, Christiane N. Job; Zygun, David A.; Bagshaw, Sean M.] Alberta Hlth Serv, Crit Care Strateg Clin Network, Edmonton, AB, Canada; [Stelfox, Henry T.] Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada; [Gilfoyle, Elaine] Univ Calgary, Cumming Sch Med, Dept Pediat, Sect Crit Care, Calgary, AB, Canada; [Wang, Xiaoming] Alberta Hlth Serv, Analyt DIMR, Res Facilitat, Edmonton, AB, Canada	University of Alberta; University of Calgary; Alberta Health Services (AHS); University of Calgary; University of Calgary; Alberta Health Services (AHS)	Bagshaw, SM (corresponding author), Univ Alberta, Fac Med & Dent, Dept Crit Care Med, Edmonton, AB, Canada.; Bagshaw, SM (corresponding author), Alberta Hlth Serv, Crit Care Strateg Clin Network, Edmonton, AB, Canada.	bagshaw@ualberta.ca		Opgenorth, Dawn/0000-0003-3571-3871; Stelfox, Henry/0000-0003-1231-1490	Alberta Innovates - Health Solutions [AIHS PRIHS 201300476]; Canada Research Chair in Critical Care Nephrology; AI Population Health Investigator Award; CIHR Embedded Clinician Researcher Award	Alberta Innovates - Health Solutions; Canada Research Chair in Critical Care Nephrology; AI Population Health Investigator Award; CIHR Embedded Clinician Researcher Award	This work was supported by a grant from Alberta Innovates - Health Solutions (AIHS PRIHS 201300476) received by Dr. Sean M Bagshaw. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Dr. Bagshaw is supported by a Canada Research Chair in Critical Care Nephrology. Dr. Stelfox is supported by an AI Population Health Investigator Award and CIHR Embedded Clinician Researcher Award.	Bagshaw SM, 2017, CRIT CARE MED, V45, pE347, DOI 10.1097/CCM.0000000000002093; Brown SES, 2014, AM J RESP CRIT CARE, V190, P831, DOI 10.1164/rccm.201406-1127LE; Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372; Chrusch CA, 2016, CAN RESPIR J, V2016, DOI 10.1155/2016/2516765; Daud-Gallotti RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052342; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; Dhillon NK, 2017, JAMA SURG, V152, P1015, DOI 10.1001/jamasurg.2017.2165; Dodek PM, 2016, J CRIT CARE, V31, P178, DOI 10.1016/j.jcrc.2015.10.011; Fowler RA, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0852-6; Gabler NB, 2013, AM J RESP CRIT CARE, V188, P800, DOI 10.1164/rccm.201304-0622OC; Gardner Jane K, 2007, Nephrol Nurs J, V34, P271; Gardner JK, 2007, NEPHROL NURS J, V34, P282; Garland A, 2013, AM J CRIT CARE, V22, P390, DOI 10.4037/ajcc2013973; Hefter Y, 2016, CRIT CARE MED, V44, P1482, DOI 10.1097/CCM.0000000000001719; Heyland DK, 2013, JAMA INTERN MED, V173, P778, DOI 10.1001/jamainternmed.2013.180; Heyland DK, 2001, J CRIT CARE, V16, P142, DOI 10.1053/jcrc.2001.30163; Holodinsky JK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145408; Hua M, 2016, INTENSIVE CARE MED; Johnson-Coyle Leah, 2016, Can J Crit Care Nurs, V27, P27; Kerlin Meeta Prasad, 2014, Ann Am Thorac Soc, V11, P167, DOI 10.1513/AnnalsATS.201306-141OC; Lane D, 2013, CRIT CARE MED, V41, P2015, DOI 10.1097/CCM.0b013e31828a435f; Levin PD, 2003, J CRIT CARE, V18, P206, DOI 10.1016/j.jcrc.2003.10.003; Morrison A L, 2001, Aust Crit Care, V14, P116, DOI 10.1016/S1036-7314(01)80028-X; Neuraz A, 2015, CRIT CARE MED, V43, P1587, DOI 10.1097/CCM.0000000000001015; Rewa OG, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-1975-3; Stelfox HT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140141; van Mol MMC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136955; Wagner J, 2013, ANN INTERN MED, V159, P447, DOI 10.7326/0003-4819-159-7-201310010-00004; Wall RJ, 2007, CHEST, V132, P1425, DOI 10.1378/chest.07-0419; Wall RJ, 2007, CRIT CARE MED, V35, P271, DOI 10.1097/01.CCM.0000251122.15053.50; Weissman GE, 2015, J CRIT CARE, V30, P1303, DOI 10.1016/j.jcrc.2015.08.015; Whitehead PB, 2015, J NURS SCHOLARSHIP, V47, P117, DOI 10.1111/jnu.12115; You JJ, 2015, JAMA INTERN MED, V175, P549, DOI 10.1001/jamainternmed.2014.7732	33	18	19	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2018	13	8							e0201524	10.1371/journal.pone.0201524	http://dx.doi.org/10.1371/journal.pone.0201524			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GR3NR	30133479	Green Submitted, Green Published, gold			2023-01-03	WOS:000442500400023
